The DT N
lunar JJ 1_i
stent NN 1_i
characteristics NNS N
and CC N
clinical JJ N
results NNS N
. . N

One CD N
of IN N
the DT N
frequent JJ N
long-term JJ N
complications NNS N
after IN N
stent JJ 1_i
implantation NN 1_i
is VBZ N
restenosis JJ N
due JJ N
to TO N
the DT N
building NN N
up IN N
of IN N
a DT N
neointima NN N
within IN N
the DT N
artery NN N
, , N
as RB N
well RB N
as IN N
endovascular JJ N
hyperplasia NN N
( ( N
tissue VB N
growth NN N
) ) N
. . N

The DT N
interesting JJ N
feature NN N
of IN N
the DT N
Lunar NNP 1_i
stent NN 1_i
from IN 1_i
Inflow NNP 1_i
Dynamics NNP 1_i
is VBZ N
that IN N
it PRP N
is VBZ N
coated VBN N
with IN N
a DT N
layer NN N
of IN N
iridium NN N
oxide NN N
. . N

The DT N
iridium NN 1_i
oxide IN 1_i
coating NN N
is VBZ N
believed VBN N
to TO N
reduce VB N
restenosis NN 1_o
by IN N
decreasing VBG N
the DT N
inflammatory JJ 1_o
response NN 1_o
to TO N
the DT N
stent NN N
via IN N
its PRP$ N
antioxidant JJ N
action NN N
. . N

The DT N
MOONLIGHT NNP 1_p
( ( 1_p
Multicenter NNP 1_p
Objective NNP 1_p
ObservatioNal NNP 1_p
Lunar NNP 1_i
Iridiumoxide NNP 1_i
intimal JJ 1_p
GrowtH NNP 1_p
Trial NNP 1_p
) ) 1_p
study NN 1_p
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
immediate JJ N
outcome NN N
and CC N
long-term JJ N
angiographic JJ N
success NN N
after IN N
implantation NN 1_i
of IN 1_i
Lunar NNP 1_i
stents NNS 1_i
. . 1_i

Between IN 1_p
March NNP 1_p
2001 CD 1_p
and CC 1_p
November NNP 1_p
2001 CD 1_p
, , 1_p
87 CD 1_p
patients NNS 1_p
with IN 1_p
99 CD 1_p
lesions NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
this DT 1_p
study NN 1_p
and CC N
were VBD N
treated VBN N
with IN N
12 CD N
and CC N
16 CD N
mm NNS N
long JJ N
iridium-oxide JJ 1_i
coated VBN 1_i
Lunar NNP 1_i
stents NNS 1_i
. . 1_i

Delivery NN N
of IN N
the DT N
Lunar NNP 1_i
stent NN 1_i
was VBD N
successful JJ N
in IN N
most JJS N
lesions NNS N
and CC N
the DT N
optimal JJ N
radiopacity NN N
facilitated VBN N
optimal JJ N
stent NN 1_o
positioning VBG 1_o
with IN N
optimal JJ N
immediate JJ N
clinical JJ N
and CC N
angiographic JJ N
results NNS N
is VBZ N
an DT N
unselected JJ N
patient NN N
and CC N
lesion NN N
population NN N
. . N

Preliminary JJ N
clinical JJ N
and CC N
angiographic JJ N
follow-up JJ N
show NN N
a DT N
low JJ N
rate NN 1_o
of IN 1_o
cardiac JJ 1_o
events NNS 1_o
at IN N
6 CD N
months NNS N
( ( N
16.1 CD N
% NN N
MACE NNP N
) ) N
and CC N
a DT N
moderate JJ N
hyperplastic JJ 1_o
response NN 1_o
. . 1_o

One-trial JJ 1_o
learning VBG 1_o
with IN 1_p
control NN 1_p
of IN 1_p
item-difficulty NN 1_i
. . 1_i

Aspirin NNP 1_i
in IN N
patients NNS 1_p
undergoing JJ 1_p
noncardiac JJ 1_p
surgery NN 1_p
. . 1_p

BACKGROUND NNP N
There EX N
is VBZ N
substantial JJ N
variability NN N
in IN N
the DT N
perioperative JJ N
administration NN N
of IN N
aspirin NNS 1_i
in IN N
patients NNS 1_p
undergoing JJ 1_p
noncardiac JJ 1_p
surgery NN 1_p
, , N
both DT N
among IN N
patients NNS 1_p
who WP 1_p
are VBP 1_p
already RB 1_p
on IN 1_p
an DT 1_p
aspirin JJ 1_i
regimen NNS 1_p
and CC 1_p
among IN 1_p
those DT 1_p
who WP 1_p
are VBP 1_p
not RB 1_p
. . 1_p

METHODS NNP N
Using VBG N
a DT N
2-by-2 JJ N
factorial JJ N
trial NN N
design NN N
, , N
we PRP N
randomly VBP N
assigned VBD N
10,010 CD 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
preparing VBG 1_p
to TO 1_p
undergo VB 1_p
noncardiac JJ 1_p
surgery NN 1_p
and CC 1_p
were VBD 1_p
at IN 1_p
risk NN 1_p
for IN 1_p
vascular JJ 1_p
complications NNS 1_p
to TO N
receive VB N
aspirin NN 1_i
or CC 1_i
placebo NN 1_i
and CC 1_i
clonidine NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

The DT N
results NNS N
of IN N
the DT N
aspirin JJ 1_i
trial NN N
are VBP N
reported VBN N
here RB N
. . N

The DT N
patients NNS N
were VBD N
stratified VBN N
according VBG N
to TO N
whether IN N
they PRP N
had VBD N
not RB N
been VBN N
taking VBG N
aspirin NN 1_i
before IN N
the DT N
study NN N
( ( N
initiation NN N
stratum NN N
, , N
with IN N
5628 CD N
patients NNS N
) ) N
or CC N
they PRP N
were VBD N
already RB N
on IN N
an DT N
aspirin JJ 1_i
regimen NNS N
( ( N
continuation NN N
stratum NN N
, , N
with IN N
4382 CD N
patients NNS N
) ) N
. . N

Patients NNS N
started VBD N
taking VBG N
aspirin NN 1_i
( ( N
at IN N
a DT N
dose NN N
of IN N
200 CD N
mg NN N
) ) N
or CC N
placebo VB 1_i
just RB N
before RB N
surgery NN N
and CC N
continued VBD N
it PRP N
daily RB N
( ( N
at IN N
a DT N
dose NN N
of IN N
100 CD N
mg NNS N
) ) N
for IN N
30 CD N
days NNS N
in IN N
the DT N
initiation NN N
stratum NN N
and CC N
for IN N
7 CD N
days NNS N
in IN N
the DT N
continuation NN N
stratum NN N
, , N
after IN N
which WDT N
patients NNS N
resumed VBD N
their PRP$ N
regular JJ N
aspirin JJ 1_i
regimen NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
composite JJ 1_o
of IN 1_o
death NN 1_o
or CC 1_o
nonfatal JJ 1_o
myocardial JJ 1_o
infarction NN 1_o
at IN 1_o
30 CD 1_o
days NNS 1_o
. . 1_o

RESULTS VB N
The DT N
primary JJ 1_o
outcome NN 1_o
occurred VBD N
in IN N
351 CD N
of IN N
4998 CD N
patients NNS N
( ( N
7.0 CD N
% NN N
) ) N
in IN N
the DT N
aspirin NN 1_i
group NN N
and CC N
in IN N
355 CD N
of IN N
5012 CD N
patients NNS N
( ( N
7.1 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
hazard JJ N
ratio NN N
in IN N
the DT N
aspirin NN N
group NN N
, , N
0.99 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.86 CD N
to TO N
1.15 CD N
; : N
P=0.92 NNP N
) ) N
. . N

Major JJ 1_o
bleeding NN 1_o
was VBD N
more RBR N
common JJ N
in IN N
the DT N
aspirin NN N
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
230 CD N
patients NNS N
[ JJ N
4.6 CD N
% NN N
] NNP N
vs. IN N
188 CD N
patients NNS N
[ JJ N
3.8 CD N
% NN N
] NN N
; : N
hazard CC N
ratio NN N
, , N
1.23 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01 CD N
, , N
to TO N
1.49 CD N
; : N
P=0.04 NNP N
) ) N
. . N

The DT N
primary JJ N
and CC N
secondary JJ N
outcome NN N
results NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
aspirin NN 1_i
strata NNS N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
aspirin NN 1_i
before IN N
surgery NN N
and CC N
throughout IN N
the DT N
early JJ N
postsurgical JJ N
period NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
rate NN 1_o
of IN 1_o
a DT 1_o
composite NN 1_o
of IN 1_o
death NN 1_o
or CC 1_o
nonfatal JJ 1_o
myocardial JJ 1_o
infarction NN 1_o
but CC N
increased VBD N
the DT N
risk NN 1_o
of IN 1_o
major JJ 1_o
bleeding NN 1_o
. . 1_o

( ( N
Funded VBN N
by IN N
the DT N
Canadian NNP N
Institutes NNPS N
of IN N
Health NNP N
Research NNP N
and CC N
others NNS N
; : N
POISE-2 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT01082874 NNP N
. . N

) ) N
. . N

The DT N
effect NN N
of IN N
Cys NNP 1_i
LT1 NNP 1_i
receptor NN 1_i
blockade NN 1_i
on IN N
airway NN 1_p
responses NNS 1_p
to TO 1_p
allergen VB 1_p
. . 1_p

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
potent JJ N
experimental JJ N
leukotriene NN 1_i
receptor NN 1_i
antagonist NN 1_i
, , 1_i
MK-571 NNP 1_i
, , N
on IN N
airway NN 1_p
responses NNS 1_p
to TO 1_p
inhaled VB 1_p
allergen NN 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ 1_i
, , N
crossover JJ N
trial NN N
. . N

SETTING NNP N
Clinical NNP N
research NN N
center NN N
. . N

SUBJECTS NNP N
Eight NNP 1_p
male NN 1_p
volunteers NNS 1_p
with IN 1_p
allergic JJ 1_p
asthma NN 1_p
. . 1_p

INTERVENTIONS NNP N
An DT N
intravenous JJ N
loading NN N
dose NN N
was VBD N
followed VBN N
by IN N
an DT N
8-hour JJ 1_i
infusion NN 1_i
of IN 1_i
MK-571 NNP 1_i
or CC 1_i
placebo NN 1_i
, , N
with IN N
a DT N
7- JJ N
to TO N
14-day JJ N
washout NN N
between IN N
treatments NNS N
. . N

Allergen NNP N
challenge NN N
was VBD N
performed VBN N
after IN N
the DT N
loading NN N
dose NN N
and CC N
a DT N
histamine NN 1_i
challenge NN N
was VBD N
performed VBN N
before IN N
and CC N
24 CD N
hours NNS N
after IN N
allergen NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Forced NNP 1_o
expiratory JJ 1_o
volume NN 1_o
in IN N
1 CD N
second NN N
was VBD N
measured VBN N
serially RB N
. . N

MK-571 NNP 1_i
provided VBD N
about IN N
50 CD N
% NN N
protection NN N
during IN N
maximum JJ N
early JJ N
and CC N
late JJ N
responses NNS N
compared VBN N
with IN N
placebo NN 1_i
( ( N
p=0.005 NN N
) ) N
, , N
but CC N
airway RB 1_o
obstruction NN 1_o
persisted VBD N
8-24 CD N
hours NNS N
after IN N
allergen NN N
on IN N
both DT N
treatment NN N
days NNS N
. . N

Airway NNP 1_o
responsiveness NN 1_o
to TO 1_o
histamine VB 1_o
was VBD N
not RB N
significantly RB N
attenuated VBN N
at IN N
24 CD N
hours NNS N
. . N

CONCLUSION NNP N
Blocking NNP N
Cys NNP N
LT1 NNP N
receptors NNS N
for IN N
8 CD N
hours NNS N
attenuated VBD N
the DT N
early JJ N
and CC N
late JJ N
responses NNS N
but CC N
did VBD N
not RB N
interrupt VB N
the DT N
cascade NN N
of IN N
events NNS N
leading VBG N
to TO N
subsequent JJ N
allergen-induced JJ N
airway NN N
obstruction NN N
and CC N
hyperreactivity NN N
. . N

Intraperitoneal NNP 1_o
distribution NN 1_o
imaging VBG 1_i
prior RB N
to TO N
chromic VB N
phosphate NN N
( ( N
P-32 NNP N
) ) N
therapy NN N
in IN N
ovarian JJ 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

This DT N
study NN N
addressed VBD N
the DT N
technique NN N
of IN N
intraperitoneal JJ 1_i
distribution NN 1_i
imaging NN 1_i
( ( 1_i
IDI NNP 1_i
) ) 1_i
. . 1_i

A DT N
literature NN N
search NN N
( ( N
MEDLINE NNP N
database NN N
) ) N
revealed VBD N
wide JJ N
variations NNS N
in IN N
IDI NNP 1_i
techniques NNS N
without IN N
a DT N
basis NN N
for IN N
comparison NN N
. . N

From IN N
April NNP N
1990 CD N
to TO N
September NNP N
1992 CD N
, , N
the DT N
authors NNS N
studied VBD N
8 CD 1_p
patients NNS 1_p
( ( 1_p
age NN 1_p
43-65 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
ovarian JJ 1_p
cancer NN 1_p
. . 1_p

A DT N
total NN N
of IN N
1000 CD N
ml NN N
of IN N
normal JJ 1_i
saline NN 1_i
and CC 1_i
1 CD 1_i
mCi NN 1_i
of IN 1_i
Tc-99m NNP 1_i
SC NNP 1_i
was VBD N
infused VBN N
intraperitoneally RB N
for IN N
IDI NNP 1_i
. . 1_i

In IN N
one CD N
patient NN N
loculation NN 1_o
was VBD N
observed VBN N
, , N
but CC N
only RB N
250 CD N
ml NNS N
of IN N
normal JJ 1_i
saline NN 1_i
was VBD N
infused VBN N
with IN N
Tc-99m NNP 1_i
SC NNP 1_i
. . 1_i

A NNP N
repeat NN N
study NN N
using VBG N
our PRP$ N
standard NN N
technique NN N
rendered VBD N
free JJ 1_o
intraperitoneal NN 1_o
distribution NN 1_o
in IN N
this DT N
patient NN N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
other JJ N
seven CD N
cases NNS N
. . N

Some DT N
investigators NNS N
recommend VBP N
low JJ N
volumes NNS N
, , N
but CC N
in IN N
our PRP$ N
experience NN N
this DT N
produced VBD N
the DT N
finding NN N
of IN N
pseudoloculation NN 1_o
, , N
which WDT N
could MD N
change VB N
treatment NN N
inappropriately RB N
. . N

Although IN N
the DT N
number NN N
of IN N
patients NNS N
studied VBN N
at IN N
our PRP$ N
institution NN N
was VBD N
small JJ N
, , N
administration NN N
of IN N
1 CD N
liter NN N
intraperitoneally RB N
provided VBD N
consistent JJ N
IDI NNP 1_o
results NNS N
. . N

Immunogenicity NN 1_o
and CC N
reactogenicity NN 1_o
of IN N
a DT N
group NN N
C NNP N
meningococcal JJ N
conjugate NN N
vaccine NN N
compared VBN N
with IN N
a DT N
group NN N
A+C NNP N
meningococcal JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS 1_p
in IN N
a DT N
randomised JJ N
observer-blind NN N
controlled VBN N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
immunogenicity NN 1_o
and CC N
reactogenicity NN 1_o
of IN N
a DT N
group NN 1_i
C NNP 1_i
meningococcal JJ 1_i
conjugate NN 1_i
vaccine NN 1_i
( ( 1_i
MenC NNP 1_i
) ) 1_i
compared VBN 1_i
with IN 1_i
a DT 1_i
group NN 1_i
A+C NNP 1_i
meningococcal JJ 1_i
polysaccharide NN 1_i
vaccine NN 1_i
( ( 1_i
MenPS NNP 1_i
) ) 1_i
in IN N
healthy JJ 1_p
adolescents NNS 1_p
. . 1_p

Subjects NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
MenC NNP 1_i
( ( N
n=92 NN N
) ) N
or CC N
MenPS NNP 1_i
( ( N
n=90 NN N
) ) N
. . N

Group NNP N
C NNP N
meningococcal JJ 1_o
IgG NNP 1_o
antibody NN 1_o
concentrations NNS 1_o
and CC 1_o
bactericidal JJ 1_o
titres NNS 1_o
were VBD N
higher JJR N
in IN N
the DT N
MenC NNP N
group NN N
than IN N
the DT N
MenPS NNP N
group NN N
at IN N
1 CD N
month NN N
( ( N
22.8 CD N
U/ml NNP N
vs NN N
4.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
87 CD N
vs NN N
20 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
and CC N
12 CD N
months NNS N
( ( N
6.1 CD N
U/ml NNP N
vs NN N
3.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
81.3 CD N
vs NN N
20.2 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

No DT N
differences NNS N
in IN N
post NN 1_o
immunisation NN 1_o
reaction NN 1_o
rates NNS 1_o
were VBD N
noted VBN N
between IN N
the DT N
two CD N
vaccinated VBD N
groups NNS N
. . N

This DT N
study NN N
demonstrated VBD N
the DT N
safety NN N
and CC N
enhanced JJ N
immunogenicity NN 1_o
of IN N
the DT N
candidate NN N
meningococcal JJ N
conjugate NN N
vaccine NN N
as IN N
compared VBN N
with IN N
the DT N
licensed JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS 1_p
. . 1_p

Computer-Assisted JJ 1_i
Face NNP 1_i
Processing NNP 1_i
Instruction NNP 1_i
Improves VBZ N
Emotion NNP 1_o
Recognition NNP 1_o
, , 1_o
Mentalizing NNP 1_o
, , 1_o
and CC 1_o
Social NNP 1_o
Skills NNP 1_o
in IN N
Students NNP 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

This DT N
study NN N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
a DT N
computer-based JJ 1_i
social JJ 1_i
skills NNS 1_i
intervention NN 1_i
called VBN 1_i
FaceSay NNP 1_i
was VBD N
associated VBN N
with IN N
improvements NNS N
in IN N
affect JJ 1_o
recognition NN 1_o
, , 1_o
mentalizing NN 1_o
, , 1_o
and CC 1_o
social JJ 1_o
skills NNS 1_o
of IN N
school-aged JJ 1_p
children NNS 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorder NNP 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

FaceSay NNP 1_i
offers VBZ N
students NNS 1_p
simulated JJ N
practice NN N
with IN N
eye NN 1_o
gaze NN 1_o
, , 1_o
joint JJ 1_o
attention NN 1_o
, , 1_o
and CC 1_o
facial JJ 1_o
recognition NN 1_o
skills NNS 1_o
. . 1_o

This DT N
randomized VBD N
control NN N
trial NN N
included VBD N
school-aged JJ 1_p
children NNS 1_p
meeting VBG 1_p
educational JJ 1_p
criteria NNS 1_p
for IN 1_p
autism NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
31 CD 1_p
) ) 1_p
. . 1_p

Results NNP N
demonstrated VBD N
that IN N
participants NNS N
who WP N
received VBD N
the DT N
intervention NN N
improved VBD N
their PRP$ N
affect JJ 1_o
recognition NN 1_o
and CC 1_o
mentalizing NN 1_o
skills NNS 1_o
, , 1_o
as RB 1_o
well RB 1_o
as IN 1_o
their PRP$ 1_o
social JJ 1_o
skills NNS 1_o
. . 1_o

These DT N
findings NNS N
suggest VBP N
that IN N
, , N
by IN N
targeting VBG N
face-processing JJ N
skills NNS N
, , N
computer-based JJ N
interventions NNS N
may MD N
produce VB N
changes NNS N
in IN N
broader JJR 1_o
cognitive NN 1_o
and CC 1_o
social-skills NNS 1_o
domains NNS 1_o
in IN N
a DT N
cost- JJ 1_o
and CC 1_o
time-efficient JJ 1_o
manner NN 1_o
. . 1_o

Prospective JJ N
evaluation NN N
of IN N
the DT N
macrolide NN 1_i
antibiotic JJ 1_i
dirithromycin NN 1_i
for IN N
the DT N
treatment NN N
of IN N
Helicobacter NNP 1_p
pylori NN 1_p
. . 1_p

BACKGROUND NNP N
Macrolide NNP 1_i
antibiotics NNS 1_i
are VBP N
active JJ N
in IN N
vitro NN N
and CC N
in IN N
vivo NN N
against IN N
Helicobacter NNP 1_p
pylori NN 1_p
. . 1_p

We PRP N
assessed VBD N
a DT N
newer JJR N
macrolide NN 1_i
, , 1_i
dirithromycin NN 1_i
, , N
for IN N
the DT N
treatment NN N
of IN N
H. NNP N
pylori FW N
in IN N
two CD N
separate JJ N
studies NNS N
. . N

METHODS NNP N
Volunteers NNPS 1_p
with IN 1_p
H. NNP 1_p
pylori FW 1_p
infection NN 1_p
( ( 1_p
by IN 1_p
13C-urea JJ 1_p
breath NN 1_p
test NN 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
2-week JJ N
treatment NN N
regimens NNS N
. . N

Study NNP N
1 CD N
: : N
dirithromycin NN 1_i
500 CD 1_i
mg NN 1_i
q.d.s. NN 1_i
, , N
dirithromycin VBZ 1_i
500 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
omeprazole JJ 1_i
40 CD 1_i
mg JJ 1_i
q.d.s. NN 1_i
, , N
or CC 1_i
dirithromycin VB 1_i
500 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
metronidazole JJ 1_i
500 CD 1_i
mg NN 1_i
t.d.s NN 1_i
. . 1_i

Study CC N
2 CD N
: : N
dirithromycin NN 1_i
500 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
omeprazole JJ 1_i
20 CD 1_i
mg NN 1_i
b.d. NN 1_i
, , N
dirithromycin NN 1_i
1000 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
omeprazole JJ 1_i
20 CD 1_i
mg NN 1_i
b.d. NN 1_i
, , N
or CC 1_i
amoxycillin RB 1_i
500 CD 1_i
mg NN 1_i
q.d.s NN 1_i
. . 1_i

plus CC 1_i
omepirazole JJ 1_i
20 CD 1_i
mg NN 1_i
b.d NN 1_i
. . 1_i

Four CD N
weeks NNS N
after IN N
the DT N
completion NN N
of IN N
therapy NN N
a DT N
repeat NN N
13C-urea JJ N
breath NN N
test NN N
was VBD N
done VBN N
to TO N
assess VB N
for IN N
cure NN N
. . N

RESULTS NNP N
No NNP N
patient NN N
taking VBG N
dirithromycin JJ 1_i
alone RB 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
6 CD 1_p
) ) 1_p
or CC N
in IN N
combination NN N
with IN N
omeprazole JJ 1_i
( ( N
n JJ N
= NNP N
26 CD N
) ) N
achieved VBD N
cure NN 1_o
of IN 1_o
their PRP$ 1_o
infection NN 1_o
. . 1_o

Eradication NN 1_o
of IN 1_o
H. NNP 1_o
pylori NN 1_o
was VBD N
seen VBN N
in IN N
one CD N
of IN N
seven CD N
patients NNS N
taking VBG N
dirithromycin JJ 1_i
plus CC N
metronidazole JJ 1_i
. . 1_i

Five CD N
of IN N
10 CD N
patients NNS N
taking VBG N
omeprazole-amoxycillin JJ 1_i
dual JJ N
therapy NN N
had VBD N
their PRP$ N
H. NNP 1_o
pylori NN 1_o
infection NN 1_o
cured VBD 1_o
( ( N
P NNP N
= VBZ N
0.0007 CD N
vs. NN N
patients NNS N
taking VBG N
dirithromycin JJ 1_i
plus CC N
omeprazole JJ 1_i
) ) 1_i
. . N

Eleven NNP N
( ( N
47 CD N
% NN N
) ) N
of IN N
32 CD N
patients NNS N
taking VBG N
dirithromycin JJ 1_i
alone RB N
or CC N
combined VBN N
with IN N
omeprazole JJ 1_i
reported VBD 1_o
side-effects NNS 1_o
, , N
but CC N
only RB N
two CD N
( ( N
6 CD N
% NN N
) ) N
stopped VBD N
therapy NN N
prematurely RB N
as IN N
a DT N
result NN N
of IN N
side-effects NNS 1_o
. . 1_o

CONCLUSION NNP N
No NNP N
subject JJ N
taking VBG N
dirithromycin NN 1_i
alone RB N
or CC N
in IN N
combination NN N
with IN N
omeprazole NN 1_i
had VBD N
their PRP$ N
H. NNP N
pylori NN N
infection NN N
cured VBD 1_o
. . 1_o

Dirithromycin NNP 1_i
, , N
in IN N
the DT N
regimen NNS N
used VBN N
, , N
shows VBZ N
little JJ N
promise NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
H. NNP 1_p
pylori JJ 1_p
infection NN 1_p
. . 1_p

The DT N
efficacy NN 1_o
of IN N
intramammary JJ 1_i
tilmicosin NN 1_i
at IN N
drying-off NN N
, , N
and CC N
other JJ N
risk NN N
factors NNS N
for IN N
the DT N
prevention NN N
of IN N
new JJ N
intramammary JJ N
infections NNS N
during IN N
the DT N
dry JJ N
period NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
an DT N
intramammary JJ 1_i
infusion NN 1_i
, , 1_i
containing VBG 1_i
tilmicosin NN 1_i
phosphate NN 1_i
, , N
to TO N
an DT N
infusion NN 1_i
of IN 1_i
a DT 1_i
negative JJ 1_i
control NN 1_i
intramammary JJ 1_i
placebo NN 1_i
for IN N
preventing VBG N
new JJ N
intramammary JJ 1_o
infections NNS 1_o
( ( 1_o
IMI NNP 1_o
) ) 1_o
during IN N
the DT N
dry JJ N
period NN N
. . N

Cows NNS 1_p
were VBD 1_p
enrolled VBN 1_p
from IN 1_p
24 CD 1_p
dairy NN 1_p
herds NNS 1_p
from IN 1_p
three CD 1_p
geographical JJ 1_p
regions NNS 1_p
of IN 1_p
Canada NNP 1_p
. . 1_p

Data NNP 1_p
from IN 1_p
248 CD 1_p
cows NNS 1_p
and CC 1_p
938 CD 1_p
bacteriologically RB 1_p
negative JJ 1_p
quarters NNS 1_p
at IN 1_p
drying-off NN 1_p
are VBP 1_p
summarized VBN 1_p
. . 1_p

Overall JJ N
, , N
the DT N
rate NN 1_o
of IN 1_o
new JJ 1_o
IMI NNP 1_o
during IN N
the DT N
dry JJ N
period NN N
was VBD N
16.7 CD N
% NN N
of IN N
quarters NNS N
. . N

The DT N
new JJ 1_o
infection NN 1_o
rates NNS 1_o
for IN N
quarters NNS N
that WDT N
received VBD N
intramammary JJ 1_i
tilmicosin NNS 1_i
compared VBN N
with IN N
the DT N
intramammary JJ 1_i
placebo NN 1_i
were VBD N
14.4 CD N
and CC N
19.4 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
majority NN N
of IN N
new JJ 1_o
IMI NNP 1_o
was VBD N
caused VBN N
by IN N
coagulase-negative JJ N
staphylococci NN N
( ( N
49 CD N
% NN N
) ) N
and CC N
environmental JJ N
streptococcal JJ N
organisms NNS N
( ( N
26.8 CD N
% NN N
) ) N
. . N

The DT N
probability NN N
for IN N
quarters NNS N
to TO N
develop VB N
new JJ 1_o
IMI NNP 1_o
in IN N
the DT N
dry JJ N
period NN N
was VBD N
significantly RB N
increased VBN N
when WRB N
cows NNS N
had VBD N
higher JJR N
milk NN N
production NN N
before IN N
drying-off NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
when WRB N
cows NNS N
had VBD N
longer RBR N
dry JJ N
periods NNS N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
when WRB N
dry JJ N
cows NNS N
were VBD N
housed VBN N
in IN N
tie-stall JJ N
barns NNS N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Higher JJR N
parity NN N
cows NNS N
and CC N
those DT N
that WDT N
had VBD N
a DT N
linear JJ 1_o
score NN 1_o
somatic JJ 1_o
cell NN 1_o
count NN 1_o
( ( 1_o
SCC NNP 1_o
) ) 1_o
above IN N
4 CD N
on IN N
the DT N
last JJ N
DHI NNP N
test NN N
were VBD N
also RB N
at IN N
increased VBN N
risk NN 1_o
for IN 1_o
new JJ 1_o
IMI NNP 1_o
( ( N
P NNP N
< NNP N
0.10 CD N
) ) N
. . N

Administration NN N
of IN N
intramammary JJ 1_i
tilmicosin NN 1_i
appears VBZ N
to TO N
be VB N
an DT N
efficacious JJ N
therapy NN N
for IN N
prevention NN 1_o
of IN 1_o
new JJ 1_o
IMI NNP 1_o
; : 1_o
however RB N
, , N
there EX N
is VBZ N
currently RB N
no DT N
approved VBD N
intramammary JJ N
formulation NN N
of IN N
this DT N
product NN N
available JJ N
. . N

Use NNP N
of IN N
blanket NN N
dry JJ N
cow NN N
antibiotic JJ N
therapy NN N
compared VBN N
to TO N
selective VB N
dry JJ N
cow NN N
therapy NN N
, , N
as RB N
well RB N
as IN N
the DT N
importance NN N
of IN N
identifying VBG N
risk NN N
factors NNS N
and CC N
managing VBG N
the DT N
environment NN N
of IN N
dry JJ N
cows NNS N
are VBP N
discussed VBN N
. . N

Atorvastatin NNP 1_i
and CC 1_i
quinapril JJ 1_i
inhibit NN N
blood NN N
coagulation NN N
in IN N
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
following VBG N
28 CD N
days NNS N
of IN N
therapy NN N
. . N

BACKGROUND IN N
We PRP N
evaluated VBD N
the DT N
antithrombotic JJ N
effects NNS N
of IN N
statins NNS 1_i
and CC N
angiotensin-converting JJ 1_i
enzyme NN 1_i
inhibitor NN 1_i
( ( 1_i
ACEI NNP 1_i
) ) 1_i
drugs NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
( ( 1_p
CAD NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
Blood NNP N
coagulation NN N
at IN N
the DT N
site NN N
of IN N
microvascular JJ N
injury NN N
was VBD N
assessed VBN N
in IN N
26 CD 1_p
males NNS 1_p
with IN 1_p
CAD NNP 1_p
before IN 1_p
and CC 1_p
after IN 1_p
treatment NN 1_p
with IN 1_p
quinapril NN 1_i
( ( 1_p
10 CD 1_p
mg RB 1_p
day-1 NN 1_p
; : 1_p
n=13 CC 1_p
) ) 1_p
or CC 1_p
atorvastatin NN 1_i
( ( 1_p
40 CD 1_p
mg RB 1_p
day-1 NN 1_p
; : 1_p
n=13 CC 1_p
) ) 1_p
for IN 1_p
4 CD 1_p
weeks NNS 1_p
and CC 1_p
an DT 1_p
additional JJ 1_p
4 CD 1_p
weeks NNS 1_p
of IN 1_p
combined JJ 1_p
therapy NN 1_p
( ( N
quinapril+atorvastatin NN N
) ) N
. . N

Rates NNS 1_o
of IN 1_o
prothrombin NN 1_o
and CC 1_o
factor NN 1_o
V NNP 1_o
activation NN 1_o
( ( 1_o
FVa NNP 1_o
) ) 1_o
, , 1_o
fibrinogen NN 1_o
( ( 1_o
Fbg NNP 1_o
) ) 1_o
cleavage NN 1_o
and CC 1_o
FVa NNP 1_o
inactivation NN 1_o
showed VBD N
that IN N
both DT N
quinapril NNS N
and CC N
atorvastatin NN N
decreased VBD N
the DT N
rates NNS N
of IN N
: : N
formation NN 1_o
of IN 1_o
thrombin JJ 1_o
B-chain NNP 1_o
( ( N
by IN N
30.6 CD N
% NN N
, , N
P=0.007 NNP N
; : N
and CC N
by IN N
34.3 CD N
% NN N
, , N
P=0.003 NNP N
) ) N
, , N
formation NN 1_o
of IN 1_o
thrombin-antithrombin NN 1_o
complexes NNS 1_o
( ( N
by IN N
30.4 CD N
% NN N
, , N
P=0.0002 NNP N
; : N
and CC N
by IN N
40 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
FV NNP 1_o
activation NN 1_o
( ( N
by IN N
19.1 CD N
% NN N
, , N
P=0.03 NNP N
; : N
and CC N
by IN N
21.8 CD N
% NN N
, , N
P=0.005 NNP N
) ) N
and CC N
Fbg NNP 1_o
depletion NN 1_o
( ( N
by IN N
29.2 CD N
% NN N
, , N
P=0.004 NNP N
; : N
and CC N
by IN N
32.7 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
. . N

Atorvastatin NNP N
alone RB N
accelerated VBD N
FVa NNP 1_o
inactivation NN 1_o
( ( N
P=0.005 NNP N
) ) N
. . N

A DT N
further JJ N
4 CD N
weeks NNS N
of IN N
combined JJ N
therapy NN N
enhanced VBD N
most RBS N
anticoagulant JJ 1_o
effects NNS 1_o
only RB N
when WRB N
atorvastatin NN N
was VBD N
added VBN N
to TO N
quinapril VB N
. . N

CONCLUSIONS NNP N
In IN N
CAD NNP 1_p
patients NNS 1_p
, , N
atorvastatin NN N
and CC N
quinapril NN N
slowed VBD N
blood NN N
clotting NN N
at IN N
the DT N
site NN N
of IN N
microvascular JJ N
injury NN N
after IN N
28 CD N
days NNS N
of IN N
therapy NN N
. . N

Addition NN N
of IN N
atorvastatin NN 1_i
to TO N
quinapril VB 1_i
, , N
but CC N
not RB N
quinapril VB 1_i
to TO N
the DT N
statin NN 1_i
, , N
enhanced VBD N
the DT N
anticoagulant JJ N
effects NNS N
. . N

Our PRP$ N
findings NNS N
might MD N
help VB N
explain VB N
the DT N
reduced JJ N
risk NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
stroke NN N
in IN N
patients NNS N
treated VBN N
with IN N
statins NNS 1_i
and/or VBP N
ACEIs NNP N
and CC N
the DT N
lack NN N
of IN N
clinical JJ N
benefits NNS N
from IN N
ACEI NNP N
added VBD N
to TO N
prior VB N
statin JJ N
therapy NN N
in IN N
patients NNS N
at IN N
cardiovascular JJ N
risk NN N
. . N

Contingency NNP 1_i
management NN 1_i
for IN N
the DT N
treatment NN N
of IN N
antipsychotic-induced JJ N
weight JJ 1_o
gain NN 1_o
: : 1_o
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
Weight NNP N
gain NN N
is VBZ N
common JJ N
for IN N
individuals NNS 1_p
with IN 1_p
serious JJ 1_p
mental JJ 1_p
illness NN 1_p
( ( 1_p
SMI NNP 1_p
) ) 1_p
receiving VBG 1_p
antipsychotic JJ 1_p
drug NN 1_p
therapy NN 1_p
. . 1_p

Contingency NNP 1_i
management NN 1_i
( ( 1_i
CM NNP 1_i
) ) 1_i
is VBZ N
a DT N
behavioral JJ N
intervention NN N
that IN N
rewards NNS N
positive JJ N
performance NN N
and CC N
has VBZ N
demonstrated VBN N
effectiveness NN N
in IN N
reducing VBG N
drug NN N
use NN N
in IN N
SMI NNP N
populations NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
feasibility NN N
of IN N
using VBG N
CM NNP 1_i
to TO N
promote VB N
weight JJ N
loss NN N
in IN N
individuals NNS 1_p
with IN 1_p
SMI NNP 1_p
over IN 1_p
8 CD 1_p
weeks NNS 1_p
. . 1_p

METHOD NNP N
30 CD 1_p
individuals NNS 1_p
( ( 1_p
BMI NNP 1_p
≥ VBZ 1_p
28 CD 1_p
kg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
i NN 1_i
) ) 1_i
The DT 1_i
combination NN 1_i
of IN 1_i
a DT 1_i
standardized JJ 1_i
lifestyle NN 1_i
modification NN 1_i
( ( 1_i
LM NNP 1_i
) ) 1_i
program NN 1_i
for IN 1_i
individuals NNS 1_i
with IN 1_i
SMI NNP 1_i
and CC 1_i
payment NN 1_i
for IN 1_i
group NN 1_i
attendance NN 1_i
( ( 1_i
CM NNP 1_i
( ( 1_i
attendance NN 1_i
) ) 1_i
) ) 1_i
, , 1_i
ii NN 1_i
) ) 1_i
The DT 1_i
combination NN 1_i
of IN 1_i
LM NNP 1_i
and CC 1_i
payment NN 1_i
for IN 1_i
weight JJ 1_i
loss NN 1_i
( ( 1_i
CM NNP 1_i
( ( 1_i
weight NN 1_i
) ) 1_i
) ) 1_i
, , 1_i
and CC 1_i
iii NN 1_i
) ) 1_i
waitlist NN 1_i
control NN 1_i
( ( 1_i
CON NNP 1_i
) ) 1_i
. . N

After IN N
the DT N
waitlist JJ N
period NN N
, , N
those DT N
participants NNS N
joined VBD N
a DT 1_i
LM NNP 1_i
group NN 1_i
and CC 1_i
received VBD 1_i
payment NN 1_i
for IN 1_i
behavioral JJ 1_i
change NN 1_i
( ( 1_i
CM NNP 1_i
( ( 1_i
behavior NN 1_i
) ) 1_i
) ) 1_i
. . N

RESULTS JJ N
Subjects NNPS N
in IN N
the DT N
CM NNP N
( ( N
attendance NN N
) ) N
and CC N
in IN N
the DT N
CM NNP N
( ( N
weight NN N
) ) N
group NN N
lost VBD N
a DT 1_o
mean NN 1_o
of IN N
1.16 CD N
kg NNS N
and CC N
1.23 CD N
kg NN N
, , N
respectively RB N
, , N
while IN N
subjects NNS N
in IN N
the DT N
CON NNP 1_o
gained VBD 1_o
a DT N
mean NN N
of IN N
0.68 CD N
kg NNS N
. . N

Subjects NNS N
receiving VBG N
CM NNP N
( ( N
behavior NN N
) ) N
, , N
lost VBD N
a DT N
mean NN N
of IN N
2.54 CD N
kg NNS N
, , N
which WDT N
was VBD N
a DT N
significant JJ 1_o
weight NN 1_o
loss NN 1_o
compared VBN N
to TO N
the DT N
control NN N
period NN N
. . N

CONCLUSION NNP 1_i
LM NNP 1_i
supplemented VBD 1_i
with IN 1_i
CM NNP 1_i
may MD N
facilitate VB 1_o
weight NN 1_o
loss NN 1_o
in IN 1_p
patients NNS 1_p
taking VBG 1_p
antipsychotic JJ 1_p
medications NNS 1_p
; : 1_p
financial JJ N
reimbursement NN N
for IN N
behavioral JJ N
change NN N
may MD N
be VB N
particularly RB N
effective JJ N
in IN N
this DT N
population NN N
. . N

Adjvant NNP 1_i
treatment NN 1_i
of IN N
tongue NN 1_p
and CC 1_p
floor NN 1_p
of IN 1_p
the DT 1_p
mouth NN 1_p
cancers NNS 1_p
. . 1_p

Since IN 1_p
January NNP 1_p
1974 CD 1_p
, , 1_p
95 CD 1_p
patients NNS 1_p
with IN 1_p
anterior JJ 1_p
tongue NN 1_p
and CC 1_p
floor NN 1_p
of IN 1_p
the DT 1_p
mouth NN 1_p
cancers NNS 1_p
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

After IN N
stratification NN N
according VBG N
to TO N
staging VBG N
and CC N
initial JJ N
treatment NN N
, , N
one-third NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
received VBD 1_p
chemotherapy NN 1_i
for IN 1_i
2 CD 1_i
years NNS 1_i
( ( 1_i
methotrexate VB 1_i
400 CD 1_i
mg NN 1_i
followed VBN 1_i
by IN 1_i
citrovorum NN 1_i
factor NN 1_i
100 CD 1_i
mg NN 1_i
+ NNP 1_i
bleomycin VBZ 1_i
60 CD 1_i
mg/week NN 1_i
, , 1_i
during IN 1_i
the DT 1_i
first JJ 1_i
15 CD 1_i
weeks NNS 1_i
) ) 1_i
, , 1_i
one-third JJ 1_i
of IN 1_i
the DT 1_i
patients NNS 1_i
received VBD 1_i
immunotherapy JJ 1_i
with IN 1_i
weekly JJ 1_i
C. NNP 1_i
parvum NN 1_i
injections NNS 1_i
during IN 1_i
2 CD 1_i
years NNS 1_i
, , 1_i
while IN 1_i
the DT 1_i
remaining VBG 1_i
third NN 1_i
did VBD 1_i
not RB 1_i
receive VB 1_i
any DT 1_i
treatment NN 1_i
. . 1_i

If IN N
adjuvant JJ N
treatment NN N
seems VBZ N
to TO N
delay VB 1_o
recurrence NN 1_o
it PRP N
did VBD N
not RB N
significantly RB N
decrease VB N
the DT N
recurrence NN 1_o
rate NN 1_o
. . 1_o

Survival NN 1_o
is VBZ N
also RB N
not RB N
signigicantly RB N
modified VBN N
by IN N
adjuvant JJ 1_i
treatment NN N
and CC N
was VBD N
better JJR N
for IN N
patients NNS N
with IN N
small JJ N
tumors NNS N
. . N

Patients NNS 1_p
who WP 1_p
previously RB 1_p
received VBD 1_p
radiotherapy NN 1_i
did VBD N
not RB N
benefit VB N
from IN N
adjuvant JJ 1_i
therapy NN 1_i
. . 1_i

Differences NNS N
in IN N
vision NN N
between IN N
clinic JJ N
and CC N
home NN N
and CC N
the DT N
effect NN N
of IN N
lighting VBG N
in IN N
older JJR 1_p
adults NNS 1_p
with IN 1_p
and CC 1_p
without IN 1_p
glaucoma NN 1_p
. . 1_p

IMPORTANCE JJ N
Patients NNS N
often RB N
report VBP N
greater JJR N
visual JJ N
difficulties NNS N
at IN N
home NN N
than IN N
expected VBN N
from IN N
vision NN N
testing VBG N
in IN N
the DT N
clinic NN N
. . N

Such JJ N
discordance NN N
may MD N
be VB N
owing VBG N
to TO N
worse VB N
vision NN N
in IN N
the DT N
home NN N
than IN N
measured VBN N
in IN N
clinic NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
vision NN 1_o
measured VBN N
between IN N
the DT N
clinic NN N
and CC N
home NN N
and CC N
evaluate JJ N
factors NNS N
, , N
including VBG N
lighting NN N
, , N
associated VBN N
with IN N
these DT N
differences NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
cross-sectional JJ N
study NN N
conducted VBN 1_p
from IN 1_p
2005-2009 CD 1_p
involved JJ 1_p
126 CD 1_p
patients NNS 1_p
with IN 1_p
glaucoma NN 1_p
and CC 1_p
49 CD 1_p
without IN 1_p
glaucoma NN 1_p
recruited VBN 1_p
from IN 1_p
the DT 1_p
Glaucoma NNP 1_p
and CC 1_p
Comprehensive NNP 1_p
Eye NNP 1_p
Clinics NNP 1_p
at IN 1_p
Washington NNP 1_p
University NNP 1_p
, , 1_p
St NNP 1_p
Louis NNP 1_p
, , 1_p
Missouri NNP 1_p
. . 1_p

Patients NNPS N
underwent JJ N
clinic JJ N
and CC N
home NN N
visits NNS N
, , N
were VBD N
aged VBN 1_p
55 CD 1_p
to TO 1_p
90 CD 1_p
years NNS 1_p
, , N
were VBD N
consecutively RB N
recruited VBN N
, , N
and CC N
met VBD N
inclusion NN N
criteria NNS N
for IN N
this DT N
study NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
166 CD 1_p
eligible JJ 1_p
patients NNS 1_p
refused VBD 1_p
participation NN 1_p
. . 1_p

EXPOSURE NNP N
Participants NNPS 1_i
underwent JJ 1_i
clinic NN 1_i
and CC 1_i
home NN 1_i
visits NNS 1_i
randomized VBN N
to TO N
order NN N
of IN N
completion NN N
. . N

At IN 1_i
each DT 1_i
visit NN 1_i
, , 1_i
masked VBN 1_i
and CC 1_i
certified VBN 1_i
examiners NNS 1_i
measured VBD 1_i
binocular JJ 1_o
distance NN 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
DVA NNP 1_o
) ) 1_o
with IN 1_o
a DT 1_o
nonbacklit JJ 1_o
chart NN 1_o
, , 1_o
near IN 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
NVA NNP 1_o
) ) 1_o
, , 1_o
contrast JJ 1_o
sensitivity NN 1_o
( ( 1_o
CS NNP 1_o
) ) 1_o
, , 1_o
CS NNP 1_o
with IN 1_o
glare NN 1_o
, , 1_o
and CC 1_o
lighting VBG 1_o
. . 1_o

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Differences NNP 1_o
in IN 1_o
vision NN 1_o
between IN 1_o
the DT 1_o
clinic NN 1_o
and CC 1_o
home NN 1_o
. . 1_o

RESULTS VB N
The DT N
mean JJ N
scores NNS N
for IN N
all DT 1_o
vision NN 1_o
tests NNS 1_o
were VBD 1_o
significantly RB 1_o
better RBR 1_o
in IN N
the DT N
clinic NN N
than IN N
home NN N
for IN N
participants NNS N
with IN N
and CC N
without IN N
glaucoma NN N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
matched-pair JJ N
t NN N
tests NNS N
) ) N
. . N

For IN N
DVA NNP N
, , N
29 CD N
% NN N
of IN N
participants NNS N
with IN N
glaucoma NN N
read VBP 1_o
2 CD 1_o
or CC 1_o
more JJR 1_o
lines NNS 1_o
better RBR 1_o
in IN N
the DT N
clinic NN N
than IN N
home NN N
and CC N
39 CD N
% NN N
with IN N
advanced JJ N
glaucoma NN N
read VBD N
3 CD N
or CC N
more JJR N
lines NNS N
better RBR N
. . N

For IN N
the DT N
entire JJ N
sample NN N
, , N
21 CD N
% NN N
of IN N
participants NNS N
read VBP 1_o
2 CD 1_o
or CC 1_o
more JJR 1_o
lines NNS 1_o
better RBR N
in IN N
the DT N
clinic NN N
than IN N
home NN N
for IN N
NVA NNP N
and CC N
49 CD N
% NN N
read JJ N
2 CD N
or CC N
more JJR N
triplets NNS N
better RBR N
in IN N
the DT N
clinic NN N
for IN N
CS NNP N
with IN N
glare NN N
. . N

Lighting NNP N
was VBD N
the DT N
most RBS N
significant JJ N
factor NN N
associated VBN N
with IN N
differences NNS N
in IN N
vision NN N
between IN N
the DT N
clinic NN N
and CC N
home NN N
for IN N
DVA NNP 1_o
, , 1_o
NVA NNP 1_o
, , 1_o
and CC 1_o
CS NNP 1_o
with IN N
glare NN N
testing VBG N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
multiple JJ N
regression NN N
model NN N
) ) N
. . N

Median JJ 1_o
home NN 1_o
lighting NN 1_o
was VBD N
4.3 CD N
times NNS N
and CC N
2.8 CD N
times NNS N
lower JJR N
than IN N
clinic JJ N
lighting NN N
in IN N
areas NNS N
tested VBN N
for IN N
DVA NNP N
and CC N
NVA NNP N
, , N
respectively RB N
. . N

Home NNP 1_o
lighting NN 1_o
was VBD N
below IN N
that DT N
recommended VBD N
in IN N
85 CD N
% NN N
or CC N
greater JJR N
of IN N
participants NNS N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
Vision NNP 1_o
measured VBD N
in IN N
the DT N
clinic NN N
is VBZ N
generally RB N
better JJR N
than IN N
vision NN N
measured VBN N
at IN N
home NN N
, , N
with IN N
differences NNS N
mainly RB N
owing VBG N
to TO N
poor JJ N
home NN N
lighting NN N
. . N

Knowledge NNP N
that IN N
vision NN N
discrepancies NNS N
between IN N
patient JJ N
report NN N
and CC N
clinical JJ N
testing NN N
may MD N
be VB N
owing VBG N
to TO N
home NN N
lighting NN N
may MD N
initiate VB N
clinician-patient JJ N
discussions NNS N
to TO N
optimize VB N
home NN N
lighting NN N
and CC N
improve VB N
the DT N
vision NN N
of IN N
older JJR 1_p
adults NNS 1_p
in IN N
their PRP$ N
homes NNS N
. . N

Acute NNP 1_o
and CC 1_o
late JJ 1_o
toxicity NN 1_o
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
conventional JJ 1_i
versus NN N
hypofractionated VBD 1_i
three-dimensional JJ 1_i
conformal JJ 1_i
radiotherapy NN 1_i
for IN N
prostate NN 1_p
cancer NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
compare VB N
the DT N
toxicity NN N
between IN N
hypofractionation NN 1_i
vs. FW 1_i
conventional JJ 1_i
fractionation NN 1_i
schedules NNS N
in IN N
patients NNS 1_p
with IN 1_p
high-risk JJ 1_p
prostate NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP 1_p
January NNP 1_p
2003 CD 1_p
and CC 1_p
December NNP 1_p
2007 CD 1_p
, , 1_p
168 CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
hypofractionated VBN 1_i
( ( N
62 CD N
Gy NNP N
in IN N
20 CD N
fractions NNS N
within IN N
5 CD N
weeks NNS N
, , N
4 CD N
fractions/wk NN N
) ) N
or CC 1_i
conventionally RB 1_i
fractionated VBN 1_i
( ( N
80 CD N
Gy NNP N
in IN N
40 CD N
fractions NNS N
within IN N
8 CD N
weeks NNS N
) ) N
three-dimensional JJ 1_i
conformal JJ 1_i
radiotherapy NN 1_i
to TO N
the DT N
prostate NN N
and CC N
seminal JJ N
vesicles NNS N
. . N

All DT 1_p
patients NNS 1_p
had VBD 1_p
undergone RP 1_p
a DT 1_p
9-month JJ 1_p
course NN 1_p
of IN 1_p
total JJ 1_p
androgen NN 1_p
deprivation NN 1_p
, , 1_p
with IN 1_p
radiotherapy NN 1_p
starting VBG 1_p
2 CD 1_p
months NNS 1_p
after IN 1_p
initiation NN 1_p
of IN 1_p
the DT 1_p
total JJ 1_p
androgen NN 1_p
deprivation NN 1_p
. . 1_p

RESULTS VB N
The DT N
median JJ N
follow-up NN N
was VBD N
32 CD N
and CC N
35 CD N
months NNS N
in IN N
the DT N
hypofractionation NN N
and CC N
conventional JJ N
fractionation NN N
arms NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
patients NNS N
developing VBG N
acute JJ N
toxicity NN N
, , N
no DT N
difference NN N
between IN N
the DT N
two CD N
fractionation NN N
groups NNS N
was VBD N
found VBN N
in IN N
either DT N
severity NN 1_o
or CC 1_o
duration NN 1_o
of IN 1_o
gastrointestinal JJ 1_o
or CC 1_o
genitourinary JJ 1_o
toxicity NN 1_o
. . 1_o

Also RB N
, , N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
incidence NN N
and CC N
severity NN 1_o
of IN 1_o
late JJ 1_o
gastrointestinal NN 1_o
and CC 1_o
genitourinary JJ 1_o
toxicity NN 1_o
between IN N
the DT N
two CD N
treatment NN N
schedules NNS N
, , N
with IN N
a DT N
3-year JJ N
rate NN N
of IN N
Grade NNP N
2 CD N
or CC N
greater JJR N
toxicity NN N
of IN N
17 CD N
% NN N
and CC N
16 CD N
% NN N
for IN N
the DT N
hypofractionation NN N
arm NN N
and CC N
14 CD N
% NN N
and CC N
11 CD N
% NN N
for IN N
the DT N
conventional JJ N
fractionation NN N
arm NN N
, , N
respectively RB N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
acute NN 1_o
and CC 1_o
late JJ 1_o
gastrointestinal JJ 1_o
toxicity NN 1_o
was VBD N
found VBN N
only RB N
in IN N
the DT N
conventional JJ N
fractionation NN N
group NN N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
the DT N
hypofractionation NN 1_i
regimen NNS N
used VBN N
in IN N
our PRP$ N
study NN N
is VBZ N
safe JJ N
, , N
with IN N
only RB N
a DT N
slight NN N
, , N
nonsignificant JJ N
increase NN N
in IN N
tolerable JJ 1_o
and CC 1_o
temporary JJ 1_o
acute NN 1_o
toxicity NN 1_o
compared VBN N
with IN N
the DT N
conventional JJ N
fractionation NN N
schedule NN N
. . N

The DT N
severity NN N
and CC N
frequency NN N
of IN N
late JJ N
complications NNS N
was VBD N
equivalent JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Positive JJ N
impact NN N
of IN N
crisis NN 1_i
resource NN 1_i
management NN 1_i
training NN 1_i
on IN N
no-flow JJ N
time NN N
and CC N
team NN N
member NN N
verbalisations NNS N
during IN N
simulated JJ 1_i
cardiopulmonary JJ 1_i
resuscitation NN 1_i
: : 1_i
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
impact NN N
of IN N
video-based JJ 1_i
interactive JJ 1_i
crisis NN 1_i
resource NN 1_i
management NN 1_i
( ( 1_i
CRM NNP 1_i
) ) 1_i
training VBG 1_i
on IN N
no-flow JJ 1_o
time NN 1_o
( ( 1_o
NFT NNP 1_o
) ) 1_o
and CC N
on IN N
proportions NNS N
of IN N
team NN 1_o
member NN 1_o
verbalisations NNS 1_o
( ( 1_o
TMV NNP 1_o
) ) 1_o
during IN N
simulated VBN 1_i
cardiopulmonary JJ 1_i
resuscitation NN 1_i
( ( 1_i
CPR NNP 1_i
) ) 1_i
. . N

Further UH N
, , N
to TO N
investigate VB N
the DT N
link NN N
between IN N
team NN N
leader NN N
verbalisation NN N
accuracy NN N
and CC N
NFT NNP N
. . N

METHODS NNP N
The DT N
randomised VBN N
controlled VBD N
study NN N
was VBD N
embedded VBN N
in IN N
the DT N
obligatory NN N
advanced VBD N
life NN N
support NN N
( ( N
ALS NNP N
) ) N
course NN N
for IN N
final-year JJ 1_p
medical JJ 1_p
students NNS 1_p
. . 1_p

Students NNS 1_p
( ( 1_p
176 CD 1_p
; : 1_p
25.35±1.03 CD 1_p
years NNS 1_p
, , 1_p
63 CD 1_p
% NN 1_p
female NN 1_p
) ) 1_p
were VBD N
alphabetically RB N
assigned VBN N
to TO 1_p
44 CD 1_p
four-person JJ 1_p
teams NNS 1_p
that WDT N
were VBD N
then RB N
randomly RB N
( ( N
computer-generated JJ N
) ) N
assigned VBN N
to TO N
either DT 1_i
CRM NNP 1_i
intervention NN 1_i
( ( N
n=26 JJ N
) ) N
, , N
receiving VBG 1_i
interactive JJ 1_i
video-based JJ 1_i
CRM-training NN 1_i
, , 1_i
or CC 1_i
to TO 1_i
control VB 1_i
intervention NN 1_i
( ( 1_i
n=18 JJ 1_i
) ) 1_i
, , 1_i
receiving VBG 1_i
an DT 1_i
additional JJ 1_i
ALS-training NN 1_i
. . N

Primary JJ N
outcomes NNS N
were VBD 1_o
NFT NNP 1_o
and CC 1_o
proportions NNS 1_o
of IN 1_o
TMV NNP 1_o
, , N
which WDT N
were VBD N
subdivided VBN N
into IN N
eight CD N
categories NNS N
: : N
four CD N
team NN N
leader NN N
verbalisations NNS N
( ( N
TLV NNP N
) ) N
with IN N
different JJ N
accuracy NN N
levels NNS N
and CC N
four CD N
follower JJR N
verbalisation NN N
categories NNS N
( ( N
FV NNP N
) ) N
. . N

Measurements NNS N
were VBD N
made VBN N
of IN 1_p
all DT 1_p
groups NNS 1_p
administering VBG 1_p
simulated JJ 1_p
adult NN 1_p
CPR NNP 1_p
. . N

RESULTS NNP 1_o
NFT NNP 1_o
rates NNS 1_o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
CRM-training NNP N
group NN N
( ( N
31.4±6.1 CD N
% NN N
vs. FW N
36.3±6.6 CD N
% NN N
, , N
p=0.014 NN N
) ) N
. . N

Proportions NNS N
of IN N
all DT 1_o
TLV NNP 1_o
categories NNS N
were VBD N
higher JJR N
in IN N
the DT N
CRM-training NNP N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Differences NNS N
in IN N
FV NNP N
were VBD N
only RB N
found VBN N
for IN N
one CD N
category NN N
( ( N
unsolicited JJ N
information NN N
) ) N
( ( N
p=0.012 NN N
) ) N
. . N

The DT 1_o
highest JJS 1_o
correlation NN 1_o
with IN 1_o
NFT NNP 1_o
was VBD N
found VBN N
for IN 1_o
high JJ 1_o
accuracy NN 1_o
TLV NNP 1_o
( ( N
direct JJ N
orders NNS N
) ) N
( ( N
p=0.06 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
inclusion NN N
of IN 1_i
CRM NNP 1_i
training NN 1_i
in IN N
undergraduate JJ N
medical JJ N
education NN N
reduces NNS N
NFT NNP N
in IN 1_i
simulated JJ 1_i
CPR NNP 1_i
and CC N
improves VBZ N
TLV NNP N
proportions NNS N
during IN 1_i
simulated JJ 1_i
CPR NNP 1_i
. . N

Further NNP N
research NN N
will MD N
test VB N
how WRB N
these DT N
results NNS N
translate VBP N
into IN N
clinical JJ N
performance NN N
and CC N
patient JJ N
outcome NN N
. . N

Factors NNS N
that WDT N
influence NN N
cancer NN 1_p
patients NNS 1_p
' POS 1_p
anxiety NN 1_o
following VBG 1_p
a DT 1_p
medical JJ 1_p
consultation NN 1_p
: : 1_p
impact NN N
of IN N
a DT N
communication NN 1_i
skills VBZ 1_i
training VBG 1_i
programme NN 1_i
for IN N
physicians NNS N
. . N

BACKGROUND NNP N
No NNP N
study NN N
has VBZ N
yet RB N
assessed VBN N
the DT N
impact NN N
of IN N
physicians NNS N
' POS N
skills NNS N
acquisition NN N
after IN N
a DT N
communication NN 1_i
skills VBZ 1_i
training VBG 1_i
programme NN 1_i
on IN N
the DT N
evolution NN N
of IN N
patients NNS 1_p
' POS 1_p
anxiety NN N
following VBG N
a DT N
medical JJ N
consultation NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
impact NN N
, , N
on IN N
patients NNS N
' POS N
anxiety NN N
, , N
of IN N
a DT N
basic JJ 1_i
communication NN 1_i
skills NNS 1_i
training VBG 1_i
programme NN 1_i
( ( 1_i
BT NNP 1_i
) ) 1_i
and CC N
the DT N
same JJ N
programme NN N
consolidated VBN N
by IN N
consolidation NN 1_i
workshops NNS 1_i
( ( N
CW NNP N
) ) N
, , N
and CC N
to TO N
investigate VB N
physicians NNS N
' POS N
communication NN N
variables NNS N
associated VBN N
with IN N
patients NNS N
' POS N
anxiety NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Physicians NNP 1_p
, , 1_p
after IN 1_p
attending VBG 1_p
the DT 1_p
BT NNP 1_i
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
CW NNP 1_i
or CC N
to TO N
a DT N
waiting VBG 1_i
list NN 1_i
. . 1_i

The DT N
control NN N
group NN N
was VBD N
not RB N
a DT N
non-intervention JJ N
group NN N
. . N

Consultations NNS N
with IN N
a DT N
cancer NN N
patient NN N
were VBD N
recorded VBN N
. . N

Patients NNS N
' POS N
anxiety NN 1_o
was VBD N
assessed VBN N
with IN N
the DT N
State NNP 1_o
Trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
before IN N
and CC N
after IN N
a DT N
consultation NN N
. . N

Communication NNP 1_o
skills NNS 1_o
were VBD N
analysed VBN N
according VBG N
to TO N
the DT N
Cancer NNP N
Research NNP N
Campaign NNP N
Workshop NNP N
Evaluation NNP N
Manual NNP N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
change NN N
over IN N
time NN 1_o
and CC N
between IN N
groups NNS N
was VBD N
observed VBN N
. . N

Mixed-effects NNS N
modelling VBG N
showed VBD N
that IN N
a DT N
decrease NN N
in IN N
patients NNS 1_o
' POS 1_o
anxiety NN 1_o
was VBD N
linked VBN N
with IN N
screening JJ N
questions NNS N
( ( N
P NNP N
= NNP N
0.045 CD N
) ) N
, , N
physicians NNS 1_o
' POS 1_o
satisfaction NN 1_o
about IN N
support NN N
given VBN N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
and CC N
with IN N
patients NNS N
' POS N
distress NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

An DT N
increase NN N
in IN N
anxiety NN 1_o
was VBD N
linked VBN N
with IN N
breaking VBG N
bad JJ N
news NN N
( ( N
P NNP N
= NNP N
0.050 CD N
) ) N
and CC N
with IN N
supportive JJ N
skills NNS N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

No DT N
impact NN N
of IN N
the DT N
training NN N
programme NN N
was VBD N
observed VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
the DT N
influence NN N
of IN N
some DT N
communication NN N
skills NNS N
on IN N
the DT N
evolution NN N
of IN N
patients NNS 1_o
' POS 1_o
anxiety NN 1_o
. . 1_o

Physicians NNS 1_p
should MD N
be VB N
aware JJ N
of IN N
these DT N
influences NNS N
. . N

B-type JJ 1_i
natriuretic JJ 1_i
peptide NN 1_i
for IN N
acute JJ N
dyspnea NN N
in IN N
patients NNS 1_p
with IN 1_p
kidney JJ 1_p
disease NN 1_p
: : 1_p
insights NNS N
from IN N
a DT N
randomized JJ N
comparison NN N
. . N

BACKGROUND NNP N
B-type NNP 1_o
natriuretic JJ 1_o
peptide NN 1_o
( ( 1_o
BNP NNP 1_o
) ) 1_o
levels NNS 1_o
are VBP N
reliably RB N
elevated VBN N
in IN N
patients NNS 1_p
with IN 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
CHF NNP 1_p
) ) 1_p
and CC N
therefore RB N
helpful JJ N
in IN N
its PRP$ N
diagnosis NN N
. . N

However RB N
, , N
kidney FW N
disease NN N
results NNS N
in IN N
elevated JJ N
BNP NNP N
levels NNS N
independently RB N
of IN N
CHF NNP N
. . N

Accordingly RB N
, , N
the DT N
impact NN N
of IN N
kidney NN N
disease NN N
on IN N
the DT N
benefit NN N
of IN N
BNP NNP 1_i
testing VBG N
needs NNS N
to TO N
be VB N
scrutinized VBN N
. . N

METHODS NNP N
This DT N
study NN N
evaluated VBD N
patients NNS 1_p
with IN 1_p
and CC 1_p
without IN 1_p
kidney NN 1_p
disease NN 1_p
[ NNP 1_p
glomerular JJ 1_p
filtration NN 1_p
rate NN 1_p
( ( 1_p
GFR NNP 1_p
) ) 1_p
less JJR 1_p
than IN 1_p
60 CD 1_p
mL/min/1.73 JJ 1_p
m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
) ) 1_p
presenting VBG 1_p
with IN 1_p
acute JJ 1_p
dyspnea NN 1_p
. . 1_p

A DT N
total NN N
of IN N
452 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
( ( 1_p
240 CD 1_p
with IN 1_p
kidney NN 1_p
disease NN 1_p
and CC 1_p
212 CD 1_p
without IN 1_p
kidney NN 1_p
disease NN 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
diagnostic JJ 1_i
strategy NN 1_i
with IN 1_i
( ( 1_i
BNP NNP 1_i
group NN 1_i
) ) 1_i
or CC 1_i
without IN 1_i
( ( 1_i
control NN 1_i
group NN 1_i
) ) 1_i
the DT 1_i
use NN 1_i
of IN 1_i
BNP NNP 1_i
levels NNS 1_i
provided VBN 1_i
by IN 1_i
a DT 1_i
rapid JJ 1_i
bedside NN 1_i
assay NN 1_i
. . 1_i

RESULTS JJ N
Patients NNS 1_p
with IN 1_p
kidney JJ 1_p
disease NN 1_p
were VBD 1_p
older JJR 1_p
, , 1_p
more RBR 1_p
often RB 1_p
had VBD 1_p
CHF NNP 1_o
as IN 1_o
the DT 1_o
cause NN 1_o
of IN 1_o
acute JJ 1_o
dyspnea NN 1_o
, , 1_p
and CC 1_p
more RBR 1_p
often RB 1_p
died JJ 1_p
in-hospital JJ 1_p
or CC 1_p
within IN 1_p
30 CD 1_p
days NNS 1_p
as RB 1_p
compared VBN 1_p
to TO 1_p
patients NNS 1_p
without IN 1_p
kidney NN 1_p
disease NN 1_p
. . N

In IN N
patients NNS N
without IN N
kidney NN N
disease NN N
, , N
BNP NNP 1_i
testing VBG 1_i
significantly RB N
reduced VBN N
median JJ 1_o
time NN 1_o
to TO 1_o
discharge VB 1_o
( ( N
from IN N
9.5 CD N
days NNS N
to TO N
2.5 CD N
days NNS N
) ) N
( ( N
P= NNP N
0.003 CD N
) ) N
and CC N
total JJ 1_o
cost NN 1_o
of IN 1_o
treatment NN 1_o
( ( N
from IN N
7184 CD N
dollars NNS N
to TO N
4151 CD N
dollars NNS N
) ) N
( ( N
P= NNP N
0.004 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
in IN N
patients NNS N
with IN N
kidney NN N
disease NN N
, , N
time NN N
to TO N
discharge VB N
and CC N
total JJ N
cost NN N
of IN N
treatment NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
When WRB N
applying VBG N
BNP NNP 1_i
cut-off NN N
values NNS N
without IN N
adjustment NN N
for IN N
the DT N
presence NN N
of IN N
kidney NN N
disease NN N
, , N
the DT N
use NN N
of IN N
BNP NNP 1_o
levels NNS 1_o
does VBZ N
significantly RB N
improve VB N
the DT N
management NN N
of IN N
patients NNS N
without IN N
kidney NN N
disease NN N
, , N
but CC N
not RB N
of IN N
those DT N
with IN N
kidney JJ N
disease NN N
. . N

Effect NN N
of IN N
practice NN N
on IN N
laterality NN N
in IN N
a DT N
mental JJ 1_i
rotation NN 1_i
task NN 1_i
. . 1_i

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
practice NN 1_i
on IN 1_i
the DT 1_i
lateralization NN 1_i
of IN 1_i
mental JJ 1_i
rotation NN 1_i
skills NNS 1_i
. . 1_i

Forty-six JJ 1_p
females NNS 1_p
and CC 1_p
46 CD 1_p
males NNS 1_p
completed VBN N
four CD N
blocks NNS N
of IN N
64 CD N
trials NNS 1_i
in IN 1_i
a DT 1_i
lateralized JJ 1_i
mental JJ 1_i
rotation NN 1_i
task NN 1_i
. . 1_i

Results NNP N
revealed VBD N
a DT N
reduction NN N
in IN N
reaction NN 1_o
time NN 1_o
and CC N
error NN 1_o
rate NN 1_o
across IN N
blocks NNS N
, , N
thus RB N
demonstrating VBG N
a DT N
practice NN N
effect NN N
. . N

A DT N
shift NN N
from IN N
a DT N
right NN N
hemisphere RB N
advantage RB N
to TO N
a DT N
left NN N
hemisphere JJ N
advantage NN N
across IN N
blocks NNS N
of IN N
trials NNS N
was VBD N
also RB N
found VBN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
their PRP$ N
implication NN N
for IN N
hypotheses NNS N
linking VBG N
laterality NN N
and CC N
training NN N
. . N

Practical JJ N
implications NNS N
for IN N
laterality NN N
research NN N
are VBP N
also RB N
discussed VBN N
. . N

Negative JJ N
emotional JJ N
experiences NNS N
during IN N
navigation NN N
enhance NN N
parahippocampal JJ N
activity NN N
during IN N
recall NN N
of IN N
place NN N
information NN N
. . N

It PRP N
is VBZ N
known VBN N
that IN N
the DT N
parahippocampal JJ N
cortex NN N
is VBZ N
involved VBN N
in IN N
object-place JJ N
associations NNS N
in IN N
spatial JJ N
learning NN N
, , N
but CC N
it PRP N
remains VBZ N
unknown JJ N
whether IN N
activity NN N
within IN N
this DT N
region NN N
is VBZ N
modulated VBN N
by IN N
affective JJ N
signals NNS N
during IN N
navigation NN N
. . N

Here RB N
we PRP N
used VBD N
fMRI NN 1_i
to TO N
measure VB N
the DT N
neural JJ 1_o
consequences NNS 1_o
of IN 1_o
emotional JJ 1_o
experiences NNS 1_o
on IN 1_o
place NN 1_o
memory NN 1_o
during IN N
navigation NN N
. . N

A DT N
day NN N
before IN N
scanning VBG N
, , N
participants NNS 1_p
undertook VBP 1_p
an DT 1_p
active JJ 1_p
object NN 1_p
location NN 1_p
memory NN 1_p
task NN 1_p
within IN 1_p
a DT 1_p
virtual JJ 1_p
house NN 1_p
in IN 1_p
which WDT 1_p
each DT 1_p
room NN 1_p
was VBD 1_p
associated VBN 1_p
with IN 1_p
a DT 1_p
different JJ 1_p
schedule NN 1_p
of IN 1_p
task-irrelevant JJ 1_p
emotional JJ 1_p
events NNS 1_p
. . 1_p

The DT N
events NNS N
varied VBN N
in IN N
valence NN N
( ( N
positive JJ N
, , N
negative JJ N
, , N
or CC N
neutral JJ N
) ) N
and CC N
in IN N
their PRP$ N
rate NN N
of IN N
occurrence NN N
( ( N
intermittent JJ N
vs. FW N
constant NN N
) ) N
. . N

On IN N
a DT N
subsequent JJ N
day NN N
, , N
we PRP N
measured VBD N
neural JJ 1_o
activity NN 1_o
while IN N
participants NNS 1_p
were VBD N
shown VBN N
static JJ N
images NNS N
of IN N
the DT N
previously RB N
learned VBN N
virtual JJ N
environment NN N
, , N
now RB N
in IN N
the DT N
absence NN N
of IN N
any DT N
affective JJ N
stimuli NN N
. . N

Our PRP$ N
results NNS N
showed VBD N
that IN N
parahippocampal JJ 1_o
activity NN 1_o
was VBD N
significantly RB N
enhanced VBN N
bilaterally RB N
when WRB N
participants NNS 1_p
viewed VBD N
images NNS N
of IN N
a DT N
room NN N
in IN N
which WDT N
they PRP N
had VBD N
previously RB N
encountered VBN N
negatively RB N
arousing VBG N
events NNS N
. . N

We PRP N
conclude VBP N
that IN N
such JJ N
automatic JJ 1_o
enhancement NN 1_o
of IN 1_o
place NN 1_o
representations NNS 1_o
by IN N
aversive JJ N
emotional JJ N
events NNS N
serves VBZ N
as IN N
an DT N
important JJ N
adaptive NN N
mechanism NN N
for IN N
avoiding VBG N
future JJ N
threats NNS N
. . N

The DT N
effect NN N
of IN N
body NN N
weight JJ N
changes NNS N
and CC N
endurance NN N
training NN N
on IN N
24h CD 1_o
substrate JJ 1_o
oxidation NN 1_o
. . 1_o

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
exercise NN 1_i
training NN 1_i
and CC 1_i
dietary JJ 1_i
macronutrient NN 1_i
composition NN 1_i
on IN N
24 CD 1_o
h NN 1_o
substrate JJ 1_o
oxidation NN 1_o
in IN N
male NN 1_p
, , 1_p
obese JJ 1_p
subjects NNS 1_p
. . 1_p

DESIGN VB N
A DT N
16 CD N
month NN N
exercise NN 1_i
intervention NN 1_i
study NN N
was VBD N
executed VBN N
, , N
including VBG N
a DT N
weight JJ N
loss NN N
period NN N
with IN N
a DT N
very RB 1_i
low JJ 1_i
energy NN 1_i
diet NN 1_i
( ( 1_i
VLED NNP 1_i
) ) 1_i
for IN N
2 CD N
months NNS N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
. . N

SUBJECTS NNP N
Twelve NNP 1_p
male NN 1_p
, , 1_p
obese JJ 1_p
subjects NNS 1_p
( ( 1_p
age NN 1_p
36.3+/-5.1 CD 1_p
y NN 1_p
; : 1_p
body NN 1_p
weight VBD 1_p
94.6+/-13.9 CD 1_p
kg NN 1_p
; : 1_p
body NN 1_p
mass NN 1_p
index NN 1_p
, , 1_p
BMI NNP 1_p
30.8+/-3.0 NNP 1_p
kg/m2 NN 1_p
) ) 1_p
and CC 1_p
in IN 1_p
an DT 1_p
additional JJ 1_p
study NN 1_p
15 CD 1_p
lean JJ 1_p
, , 1_p
well-trained JJ 1_p
subjects NNS 1_p
( ( 1_p
age NN 1_p
36.2+/-7.2 CD 1_p
y NN 1_p
; : 1_p
body NN 1_p
weight VBD 1_p
72.2+/-5.9 JJ 1_p
kg NN 1_p
; : 1_p
BMI NNP 1_p
22.3+/-1.7 CD 1_p
kg/m2 NN 1_p
) ) 1_p
participated VBD 1_p
. . 1_p

MEASUREMENTS NNP N
Substrate NNP 1_o
oxidation NN 1_o
was VBD N
measured VBN N
during IN N
a DT N
standardized JJ N
36 CD N
h NN N
stay NN N
in IN N
the DT N
respiration NN N
chamber NN N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
( ( N
0 CD N
months NNS N
) ) N
, , N
and CC N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
. . N

In IN N
the DT N
respiration NN N
chamber NN N
subjects NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
a DT N
high-fat NN 1_i
( ( 1_i
Hi.F NNP 1_i
) ) 1_i
diet NN 1_i
( ( 1_i
60 CD 1_i
% NN 1_i
of IN 1_i
energy NN 1_i
( ( 1_i
En NNP 1_i
% NN 1_i
) ) 1_i
fat NN 1_i
) ) 1_i
or CC 1_i
a DT 1_i
reduced-fat JJ 1_i
( ( 1_i
Red.F NNP 1_i
) ) 1_i
diet NN 1_i
( ( 1_i
30 CD 1_i
En NNP 1_i
% NN 1_i
fat NN 1_i
) ) 1_i
. . 1_i

The DT N
well-trained JJ N
group NN N
was VBD N
measured VBN N
once RB N
in IN N
the DT N
respiration NN N
chamber NN N
for IN N
36 CD N
h NN N
according VBG N
to TO N
the DT N
same JJ N
protocol NN N
. . N

RESULTS NNP N
At IN N
any DT N
time NN N
point NN N
, , N
independent JJ N
of IN N
the DT N
diet NN N
consumed VBD N
, , N
the DT N
24 CD 1_o
h NN 1_o
carbohydrate NN 1_o
( ( 1_o
CHO NNP 1_o
) ) 1_o
balances NNS 1_o
in IN N
the DT N
chamber NN N
were VBD N
mostly RB N
negative JJ N
( ( N
means NNS N
ranging VBG N
from IN N
+31 NN N
to TO N
-98 VB N
g/d NN N
) ) N
and CC N
the DT N
fat JJ 1_o
balances NNS 1_o
mostly RB N
positive JJ N
( ( N
means NNS N
ranging VBG N
from IN N
-26 NN N
to TO N
+38 VB N
g/d NN N
) ) N
for IN N
the DT N
obese NN N
a DT N
well RB N
as IN N
for IN N
the DT N
lean JJ N
, , N
well-trained JJ N
group NN N
. . N

For IN N
both DT N
diets NNS N
an DT N
increased JJ N
shortage NN 1_o
of IN 1_o
70 CD 1_o
g NN 1_o
of IN 1_o
CHO NNP 1_o
was VBD N
found VBN N
at IN N
16 CD N
months NNS N
compared VBN N
with IN N
4 CD N
months NNS N
, , N
and CC N
an DT N
increase NN N
in IN N
fat JJ 1_o
balance NN 1_o
of IN N
33 CD N
g NN N
during IN N
the DT N
same JJ N
time NN N
period NN N
in IN N
the DT N
obese JJ N
subjects NNS N
, , N
indicating VBG N
that IN N
CHO NNP 1_o
oxidation NN 1_o
had VBD N
increased VBN N
with IN N
12 CD N
months NNS N
endurance RB N
training VBG N
. . N

In IN N
the DT N
well-trained JJ N
group NN N
the DT N
24h CD 1_o
CHO NNP 1_o
balance NN 1_o
was VBD N
even RB N
more RBR N
negative JJ N
for IN N
both DT N
types NNS N
of IN N
diet NN N
( ( N
-103 UH N
to TO N
-185 VB N
g/d NN N
for IN N
the DT N
Red.F NNP N
and CC N
Hi.F NNP N
diet NN N
, , N
respectively RB N
) ) N
under IN N
similar JJ N
conditions NNS N
compared VBN N
with IN N
the DT N
trained JJ N
obese JJ N
group NN N
. . N

CONCLUSION NNP N
The DT N
changes NNS N
in IN N
24 CD 1_o
h NN 1_o
substrate JJ 1_o
utilization NN 1_o
in IN N
the DT N
obese JJ N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
well-trained JJ N
group NN N
, , N
suggest VBP N
that IN N
endurance NN N
training NN N
increased VBD N
the DT N
reliance NN N
on IN N
carbohydrate NN 1_o
oxidation NN 1_o
and CC N
therefore RB N
did VBD N
not RB N
increase VB N
24 CD 1_o
fat JJ 1_o
oxidation NN 1_o
. . 1_o

Percutaneous JJ 1_i
coronary JJ 1_i
intervention NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
previous JJ 1_p
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
grafting NN 1_p
( ( 1_p
from IN 1_p
the DT 1_p
j-Cypher JJ 1_p
Registry NNP 1_p
) ) 1_p
. . 1_p

A DT N
paucity NN N
of IN N
data NNS N
is VBZ N
available JJ N
from IN N
large-scale JJ N
studies NNS N
evaluating VBG N
the DT N
long-term JJ N
outcomes NNS N
of IN N
percutaneous JJ 1_i
coronary JJ 1_i
intervention NN 1_i
in IN N
patients NNS 1_p
who WP 1_p
had VBD 1_p
previously RB 1_p
undergone JJ 1_p
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting NN 1_i
( ( 1_i
CABG NNP 1_i
) ) 1_i
in IN 1_p
the DT 1_p
drug-eluting JJ 1_p
stent NN 1_p
era NN 1_p
. . 1_p

Of IN N
12,812 CD 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
undergone JJ 1_p
sirolimus-eluting JJ 1_p
stent NN 1_p
implantation NN 1_p
in IN 1_p
the DT 1_p
j-Cypher JJ 1_p
registry NN 1_p
, , 1_p
919 CD 1_p
( ( 1_p
7.2 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
a DT 1_p
history NN 1_p
of IN 1_p
CABG NNP 1_p
and CC 1_p
had VBD 1_p
significantly RB 1_p
higher JJR 1_p
crude JJ 1_o
5-year JJ 1_o
mortality NN 1_o
( ( 1_p
19.9 CD 1_p
% NN 1_p
vs JJ 1_p
14.0 CD 1_p
% NN 1_p
, , 1_p
p NN 1_p
< NNP 1_p
0.001 CD 1_p
) ) 1_p
. . N

After IN N
adjusting VBG N
for IN N
confounders NNS N
, , N
the DT 1_o
excess JJ 1_o
risk NN 1_o
of IN 1_o
death NN 1_o
was VBD N
no RB N
longer RBR N
significant JJ N
( ( N
hazard JJ N
ratio NN N
0.99 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.83 CD N
to TO N
1.18 CD N
, , N
p NN N
= NNP N
0.90 CD N
) ) N
, , N
and CC N
the DT N
adjusted VBN 1_o
risk NN 1_o
of IN 1_o
target NN 1_o
lesion NN 1_o
revascularization NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN 1_p
patients NNS 1_p
with IN 1_p
previous JJ 1_p
CABG NNP 1_p
than IN N
in IN N
those DT N
without IN N
( ( N
hazard NN N
ratio NN N
1.25 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.06 CD N
to TO N
1.47 CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

Of IN N
the DT 1_p
patients NNS 1_p
with IN 1_p
previous JJ 1_p
CABG NNP 1_p
, , N
those DT N
who WP N
had VBD N
undergone JJ N
≥1 NNP N
saphenous JJ N
vein NN N
graft NN N
intervention NN N
had VBD N
significantly RB N
higher JJR 1_o
adjusted JJ 1_o
risks NNS 1_o
of IN 1_o
cardiac JJ 1_o
death NN 1_o
( ( N
hazard JJ N
ratio NN N
2.21 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.26 CD N
to TO N
3.76 CD N
, , N
p NN N
= NNP N
0.01 CD 1_o
) ) 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
( ( N
hazard JJ N
ratio NN N
2.56 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.10 CD N
to TO N
5.60 CD N
, , N
p NN N
= NNP N
0.03 CD 1_o
) ) 1_o
, , 1_o
target NN 1_o
lesion NN 1_o
revascularization NN 1_o
( ( N
hazard JJ N
ratio NN N
2.65 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.82 CD N
to TO N
3.81 CD N
, , N
p NN N
< NNP 1_o
0.001 CD 1_o
) ) 1_o
, , 1_o
and CC 1_o
definite JJ 1_o
stent NN 1_o
thrombosis NN 1_o
( ( N
hazard JJ N
ratio NN N
7.70 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.99 CD N
to TO N
29.1 CD N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
compared VBN N
with IN N
those DT N
who WP N
underwent VBP 1_i
percutaneous JJ 1_i
coronary JJ 1_i
intervention NN 1_i
only RB N
for IN N
the DT N
native JJ N
coronary JJ N
artery NN N
. . N

In IN N
conclusion NN 1_o
, , 1_o
the DT 1_o
adjusted JJ 1_o
mortality NN 1_o
was VBD N
similar JJ N
between IN N
patients NNS N
with IN N
and CC N
without IN N
previous JJ N
CABG NNP N
, , N
despite IN N
a DT N
significantly RB N
different JJ 1_o
risk NN 1_o
of IN 1_o
target NN 1_o
lesion NN 1_o
revascularization NN 1_o
. . N

Among IN 1_p
the DT 1_p
patients NNS 1_p
with IN 1_p
previous JJ 1_p
CABG NNP N
, , N
those DT N
with IN N
saphenous JJ N
vein NN N
graft NN N
intervention NN N
using VBG N
a DT N
first-generation JJ N
drug-eluting JJ N
stent NN 1_o
had VBD 1_o
worse JJR 1_o
clinical JJ 1_o
outcomes NNS 1_o
than IN N
those DT N
with IN N
a DT N
native JJ N
coronary JJ N
artery NN N
target NN N
only RB N
. . N

Migration NN 1_p
of IN 1_p
the DT 1_p
acetabular JJ 1_p
component NN 1_p
: : 1_p
effect NN 1_o
of IN 1_o
cement NN 1_o
pressurization NN 1_o
and CC 1_o
significance NN 1_o
of IN 1_o
early JJ 1_o
radiolucency NN 1_o
: : 1_o
a DT N
randomized JJ N
5-year JJ N
study NN N
using VBG N
radiostereometry NN 1_i
. . 1_i

BACKGROUND NNP N
Cementing NNP N
technique NN N
is VBZ N
a DT N
crucial JJ N
factor NN N
in IN N
prosthesis NN 1_p
fixation NN 1_p
. . 1_p

No DT N
randomized JJ N
studies NNS N
have VBP N
been VBN N
published VBN N
, , N
however RB N
, , N
comparing VBG N
the DT N
outcome NN N
of IN N
conventional JJ N
fingerpacking NN N
with IN N
the DT N
outcome NN N
of IN N
pressurization NN N
of IN N
the DT N
cement NN N
prior RB N
to TO N
cup VB N
insertion NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
randomized VBD N
50 CD 1_p
THAs NNP 1_i
to TO 1_i
either VB 1_i
fingerpacking NN 1_i
or CC 1_i
sequential JJ 1_i
pressurization NN 1_i
( ( 1_i
including VBG 1_i
individual JJ 1_i
pressurization NN 1_i
of IN 1_i
each DT 1_i
anchorage NN 1_i
hole NN 1_i
) ) 1_i
and CC 1_p
followed VBD 1_p
the DT 1_p
patients NNS 1_p
with IN 1_p
RSA NNP 1_i
for IN 1_p
5 CD 1_p
years NNS 1_p
. . 1_p

The DT N
penetration NN N
of IN N
cement NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
measured VBN N
on IN N
digital JJ N
radiographs NN N
. . N

Postoperative JJ N
radiolucent NN 1_o
lines NNS 1_o
around IN 1_o
the DT 1_o
cup NN 1_o
were VBD 1_o
correlated VBN 1_o
to TO 1_o
later RBR 1_o
RSA NNP 1_o
results NNS 1_o
. . 1_o

For IN N
clinical JJ N
evaluation NN N
, , N
we PRP N
used VBD N
SF-36 NNP N
and CC N
HHS NNP N
. . N

RESULTS VB N
The DT N
pressurized JJ N
group NN N
of IN N
THAs NNP N
was VBD N
more RBR N
stable JJ N
regarding VBG N
changes NNS N
in IN N
inclination NN N
. . N

We PRP N
found VBD N
no DT N
other JJ N
difference NN N
in IN N
the DT N
migratory NN N
behavior NN N
. . N

The DT N
cement NN N
penetration NN N
into IN N
the DT N
anchorage NN N
holes NNS N
was VBD N
deeper RBR N
with IN N
the DT N
pressurization NN N
technique NN N
than IN N
with IN N
fingerpacking NN N
. . N

For IN N
the DT N
whole JJ N
group NN N
taken VBN N
together RB N
, , N
there EX N
was VBD N
a DT N
strong JJ N
relation NN N
between IN N
the DT N
presence NN N
of IN N
radiolucent NN N
lines NNS N
as IN N
measured VBN N
on IN N
the DT N
postoperative JJ N
radiograph NN N
and CC N
later JJ N
migration NN N
observed VBN N
by IN N
RSA NNP N
at IN N
2 CD N
and CC N
5 CD N
years NNS N
. . N

INTERPRETATION NNP N
Pressurization NNP N
of IN N
the DT N
cement NN N
produced VBD N
better JJR N
cement NN N
penetration NN N
and CC N
increased VBD N
the DT N
cup NN N
stability NN N
in IN N
terms NNS N
of IN N
changes NNS N
in IN N
inclination NN N
. . N

Early JJ N
findings NNS N
of IN N
radiolucent NN N
lines NNS N
can MD N
predict VB N
later RB N
unfavorable JJ N
cup NN N
migration NN N
. . N

[ NNS N
Randomized NNP N
controlled VBD N
study NN N
of IN N
OK-432 NNP 1_i
in IN N
the DT N
treatment NN N
of IN N
cancerous JJ 1_o
pleurisy NN 1_o
] NNP 1_o
. . N

A NNP N
randomized VBD N
controlled VBN N
study NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
intrapleural JJ N
and CC N
systemic JJ N
administration NN N
of IN N
OK-432 NNP 1_i
, , 1_i
streptococcus NN 1_i
preparation NN 1_i
, , N
in IN N
patients NNS 1_p
with IN 1_p
cancerous JJ 1_p
pleurisy NN 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
53 CD 1_p
patients NNS 1_p
were VBD 1_p
accessed VBN 1_p
to TO 1_p
the DT 1_p
study NN 1_p
: : 1_p
29 CD 1_p
patients NNS 1_p
for IN 1_p
the DT 1_p
OK-432 NNP 1_i
group NN 1_p
and CC 1_p
24 CD 1_p
patients NNS 1_p
for IN 1_p
the DT 1_p
control NN 1_i
group NN 1_i
. . 1_i

Intrapleural NNP N
instillation NN N
of IN N
50 CD 1_i
mg NN 1_i
of IN 1_i
adriamycin NN 1_i
and CC 1_i
a DT 1_i
combination NN 1_i
chemotherapy NN 1_i
of IN 1_i
MFC NNP 1_i
( ( 1_i
mitomycin JJ 1_i
C NNP N
0.08 CD N
mg/kg NN N
, , N
5-FU JJ N
10 CD N
mg/kg NN N
, , N
ara-C JJ 1_i
0.8 CD N
mg/kg NN N
iv NN N
, , N
weekly RB N
) ) N
were VBD N
administered VBN N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
OK-432 NNP N
group NN N
intrapleural JJ N
instillation NN N
of IN N
2 CD N
units NNS N
of IN N
OK-432 NNP 1_i
was VBD N
administered VBN N
daily RB N
until IN N
disappearance NN N
of IN N
pleural JJ N
effusion NN N
; : N
thereafter RB N
, , N
2 CD N
to TO N
5 CD N
units NNS N
of IN N
OK-432 NNP N
were VBD N
administered VBN N
intradermally RB N
every DT N
other JJ N
day NN N
. . N

Patients NNS N
with IN N
stage NN N
III NNP N
in IN N
the DT N
OK-432 NNP N
group NN N
survived VBD 1_o
significantly RB 1_o
longer RBR 1_o
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significance NN N
between IN N
in IN N
patients NNS N
with IN N
stage JJ N
IV NNP N
of IN N
both DT N
treatment NN N
groups NNS N
. . N

Also RB N
patients NNS N
with IN N
PPD NNP N
negative JJ N
skin NN N
reaction NN N
at IN N
the DT N
time NN N
of IN N
beginning VBG N
of IN N
treatment NN N
in IN N
the DT N
OK-432 NNP N
group NN N
survived VBD N
significantly RB N
longer RBR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significance NN N
between IN N
both DT N
treatment NN N
groups NNS N
in IN N
patients NNS N
with IN N
PPD NNP N
positive JJ N
skin NN 1_o
reaction NN 1_o
at IN N
the DT N
time NN N
of IN N
beginning VBG N
of IN N
treatment NN N
. . N

Eighteen NNP N
( ( N
62 CD N
% NN N
) ) N
of IN N
29 CD N
patients NNS N
treated VBN N
with IN N
OK-432 NNP N
had VBD N
a DT N
fever NN N
, , N
but CC N
well RB N
tolerated VBN N
. . N

A DT N
randomized JJ N
surveillance NN 1_i
study NN N
of IN N
patients NNS 1_p
with IN 1_p
pedunculated JJ 1_p
and CC 1_p
small JJ 1_p
sessile NN 1_p
tubular NN 1_p
and CC 1_p
tubulovillous JJ 1_p
adenomas NN 1_p
. . 1_p

The DT N
Funen NNP N
Adenoma NNP N
Follow-up NNP N
Study NNP N
. . N

BACKGROUND NNP N
We PRP N
wanted VBD N
to TO N
assess VB N
the DT N
influence NN N
of IN N
various JJ N
surveillance NN 1_i
intervals NNS N
on IN N
the DT N
risk NN 1_o
of IN 1_o
new JJ 1_o
neoplasia NN 1_o
after IN N
removal NN N
of IN N
pedunculated JJ N
and CC N
small JJ N
sessile NN N
tubular NN N
and CC N
tubulovillous JJ N
adenomas NN N
. . N

METHODS NNP N
After IN 1_p
initial JJ 1_p
colonoscopic NN 1_p
polypectomy NN 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
surveillance VB 1_i
with IN N
either DT N
2 CD 1_i
years NNS 1_i
( ( 1_i
group NN 1_i
A NNP 1_i
) ) 1_i
or CC N
4 CD 1_i
years NNS 1_i
( ( N
group NN N
B NNP N
) ) N
between IN N
colorectal JJ N
examinations NNS N
. . N

RESULTS VB N
The DT N
cumulated JJ N
risk NN 1_o
of IN 1_o
a DT 1_o
patient NN 1_o
having VBG 1_o
new JJ 1_o
adenomas NN 1_o
was VBD N
35.0 CD N
% NN N
( ( N
28.7-41.4 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
and CC N
35.5 CD N
% NN N
( ( N
28.4-42.7 CD N
% NN N
) ) N
in IN N
group NN N
B NNP N
after IN N
48 CD N
months NNS N
. . N

The DT N
risk NN N
increased VBD N
to TO N
44.9 CD N
% NN N
( ( N
36.0-53.9 CD N
% NN N
) ) N
and CC N
60.1 CD N
% NN N
( ( N
48.5-71.7 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
after IN N
96 CD N
months NNS N
. . N

The DT N
risk NN N
of IN N
significant JJ 1_o
neoplasia NN 1_o
( ( 1_o
carcinoma NN 1_o
or CC 1_o
adenoma NN 1_o
with IN 1_o
villous JJ 1_o
structure NN 1_o
, , 1_o
severe JJ 1_o
dysplasia NN 1_o
, , 1_o
or CC 1_o
diameter NN 1_o
> VBP 1_o
10 CD 1_o
mm NN 1_o
) ) 1_o
was VBD N
5.2 CD N
% NN N
( ( N
2.3-8.1 CD N
% NN N
) ) N
and CC N
8.6 CD N
% NN N
( ( N
3.8-13.3 CD N
% NN N
) ) N
after IN N
48 CD N
months NNS N
and CC N
8.6 CD N
% NN N
( ( N
4.2-13.0 CD N
% NN N
) ) N
and CC N
17.4 CD N
% NN N
( ( N
7.6-27.2 CD N
% NN N
) ) N
after IN N
96 CD N
months NNS N
. . N

More JJR N
than IN N
one CD N
adenoma NN N
at IN N
first JJ N
examination NN N
was VBD N
associated VBN N
with IN N
higher JJR 1_o
risk NN 1_o
of IN 1_o
new JJ 1_o
adenomas NN 1_o
. . 1_o

Furthermore RB N
, , N
we PRP N
found VBD N
a DT N
tendency NN N
for IN N
age NN 1_p
above IN 1_p
60 CD 1_p
years NNS 1_p
and CC 1_p
male JJ 1_p
gender NN 1_p
to TO N
be VB N
associated VBN N
with IN N
higher JJR N
risk NN N
of IN N
new JJ N
adenomas NN 1_o
. . 1_o

More JJR N
than IN N
two CD N
adenomas NNS N
at IN N
first JJ N
examination NN N
was VBD N
the DT N
only JJ N
factor NN N
found VBD N
to TO N
be VB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN 1_o
of IN 1_o
new JJ 1_o
significant JJ 1_o
neoplasia NN 1_o
. . 1_o

One CD N
patient NN N
in IN N
group NN N
A NNP N
and CC N
two CD N
patients NNS N
in IN N
group NN N
B NNP N
developed VBD N
cancer NN 1_o
, , N
which WDT N
is VBZ N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
number NN N
expected VBN N
( ( N
3.43 CD N
) ) N
in IN N
the DT N
average JJ N
Danish JJ N
population NN N
( ( N
RR NNP N
= NNP N
0.9 CD N
, , N
0.2-2.6 NN N
) ) N
. . N

CONCLUSION NN N
After IN N
colonoscopy NN N
with IN N
removal NN N
of IN N
all DT N
polyps NNS N
, , N
colorectal JJ N
examination NN N
at IN N
4 CD N
years NNS N
resulted VBD N
in IN N
a DT N
similar JJ N
risk NN 1_o
of IN 1_o
new JJ 1_o
adenomas NNS 1_o
compared VBN N
with IN N
examinations NNS N
at IN N
2 CD N
and CC N
4 CD N
years NNS N
. . N

However RB N
, , N
new JJ N
significant JJ N
neoplasia NN 1_o
tended VBD N
to TO N
be VB N
more RBR N
frequent JJ N
when WRB N
first JJ N
surveillance NN N
was VBD N
at IN N
4 CD N
years NNS N
. . N

Extending VBG N
the DT N
surveillance NN N
to TO N
8 CD N
years NNS N
also RB N
tended VBD N
to TO N
increase VB N
the DT N
risk NN N
more RBR N
in IN N
the DT N
group NN N
being VBG N
examined VBN N
every DT N
4 CD N
years NNS N
, , N
but CC N
reduction NN N
of IN N
the DT N
number NN N
of IN N
surveillance NN N
examinations NNS N
by IN N
more JJR N
than IN N
50 CD N
% NN N
and CC N
a DT N
probable JJ N
reduction NN N
of IN N
complications NNS N
from IN N
surveillance NN N
examinations NNS N
themselves PRP N
may MD N
justify VB N
a DT N
recommendation NN N
for IN N
the DT N
longest JJS N
interval NN N
. . N

Control NN N
of IN N
the DT N
lumbar NN N
neutral JJ N
zone NN N
decreases VBZ N
low JJ 1_o
back RB 1_o
pain NN 1_o
and CC N
improves VBZ 1_o
self-evaluated JJ 1_o
work NN 1_o
ability NN 1_o
: : 1_o
a DT N
12-month JJ N
randomized NN N
controlled VBD N
study NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized NN N
controlled VBD N
study NN N
with IN N
12 CD N
months NNS N
intervention NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effectiveness NN N
of IN N
a DT N
training NN 1_i
intervention NN 1_i
with IN 1_i
emphases NNS 1_i
on IN 1_i
the DT 1_i
control NN 1_i
of IN 1_i
lumbar JJ 1_i
neutral JJ 1_i
zone NN 1_i
( ( N
NZ NNP N
) ) N
and CC N
behavior JJ 1_i
modeling NN 1_i
as IN N
secondary JJ N
prevention NN N
of IN N
low JJ 1_o
back RB 1_o
pain NN 1_o
( ( 1_o
LBP NNP 1_o
) ) 1_o
and CC 1_o
disability NN 1_o
. . 1_o

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Improving NNP N
the DT N
control NN N
of IN N
lumbar NN N
NZ NNP N
and CC N
enhancing VBG N
muscle NN N
activation NN N
patterns NNS N
ensuring VBG N
spinal JJ N
stability NN N
have VBP N
been VBN N
proposed VBN N
as IN N
means NNS N
for IN N
secondary JJ N
prevention NN N
of IN N
LBP NNP 1_o
and CC 1_o
disability NN 1_o
. . 1_o

In IN N
addition NN N
, , N
cognitive JJ 1_i
behavior NN 1_i
interventions NNS 1_i
have VBP N
been VBN N
shown VBN N
to TO N
lower VB N
the DT N
risk NN N
of IN N
recurrence NN 1_o
of IN 1_o
LBP NNP 1_o
and CC 1_o
long-term JJ 1_o
disability NN 1_o
. . 1_o

METHODS NNP N
Middle-aged JJ 1_p
working VBG 1_p
men NNS 1_p
with IN 1_p
recent JJ 1_p
LBP NNP 1_p
but CC 1_p
without IN 1_p
severe JJ 1_p
disability NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
training NN 1_i
( ( N
TG NNP N
, , N
n JJ N
= NNP N
52 CD N
) ) N
or CC N
control VB 1_i
group NN 1_i
( ( N
CG NNP N
, , N
n JJ N
= NNP N
54 CD N
) ) N
. . N

The DT N
aim NN N
was VBD N
to TO N
exercise VB N
twice RB N
a DT N
week NN N
for IN N
12 CD N
months NNS N
, , N
once RB N
guided VBN N
and CC N
once RB N
independently RB N
. . N

The DT N
outcome NN N
measures NNS N
were VBD N
the DT N
changes NNS 1_o
in IN 1_o
intensity NN 1_o
of IN 1_o
LBP NNP 1_o
, , 1_o
disability NN 1_o
, , 1_o
self-evaluated JJ 1_o
future NN 1_o
work NN 1_o
ability NN 1_o
, , 1_o
and CC 1_o
neuromuscular JJ 1_o
fitness NN 1_o
. . 1_o

RESULTS VB N
The DT N
intensity NN 1_o
of IN 1_o
LBP NNP 1_o
decreased VBD N
significantly RB N
more JJR N
( ( N
39 CD N
% NN N
) ) N
in IN N
the DT N
TG NNP N
than IN N
in IN N
CG NNP N
at IN N
12 CD N
months NNS N
. . N

The DT N
proportion NN 1_o
of IN 1_o
subjects NNS 1_o
with IN 1_o
negative JJ 1_o
expectations NNS 1_o
about IN 1_o
their PRP$ 1_o
future NN 1_o
work NN 1_o
ability NN 1_o
decreased VBN N
in IN N
both DT N
groups NNS N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
; : N
however RB N
, , N
the DT N
proportion NN N
was VBD N
significantly RB N
bigger JJR N
in IN N
TG NNP N
compared VBN N
with IN N
CG NNP N
( ( N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

There EX N
effects NNS N
on IN N
disability NN 1_o
indexes NNS 1_o
and CC 1_o
fitness NN 1_o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSIONS NNP N
Controlling NNP N
lumbar NN N
NZ NNP N
is VBZ N
a DT N
specific JJ N
form NN N
of IN N
exercise NN 1_i
and CC 1_i
daily JJ 1_i
self-care NN 1_i
with IN N
potential JJ N
for IN N
prevention NN N
of IN N
recurrent NN N
nonspecific JJ N
LBP NNP 1_p
and CC 1_p
disability NN 1_p
among IN 1_p
middle JJ 1_p
aged VBN 1_p
working VBG 1_p
men NNS 1_p
. . 1_p

Outcomes NNS 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
mellitus VBP 1_p
undergoing VBG 1_p
percutaneous JJ 1_i
coronary JJ 1_i
intervention NN 1_i
in IN 1_p
the DT 1_p
current JJ 1_p
era NN 1_p
: : 1_p
a DT N
report NN N
from IN N
the DT N
Prevention NNP N
of IN N
REStenosis NNP N
with IN N
Tranilast NNP N
and CC N
its PRP$ N
Outcomes NNP N
( ( N
PRESTO NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Diabetes NNP N
portends VBZ N
an DT N
adverse JJ N
prognosis NN N
in IN N
patients NNS 1_p
undergoing VBG 1_p
percutaneous JJ 1_i
coronary JJ 1_i
intervention NN 1_i
( ( 1_i
PCI NNP 1_i
) ) 1_i
. . 1_i

Whether PRP$ N
improvements NNS N
in IN N
current JJ N
clinical JJ N
practice NN N
( ( N
stents NNS N
, , N
IIb/IIIa NNP N
antagonists VBZ N
) ) N
have VBP N
resulted VBN N
in IN N
substantial JJ N
improvement NN N
of IN N
these DT N
outcomes NNS N
remains VBZ N
an DT N
issue NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
influence NN N
of IN N
diabetes NNS N
on IN N
9-month JJ N
outcomes NNS N
of IN N
patients NNS 1_p
undergoing VBG 1_p
PCI NNP 1_i
in IN 1_p
the DT 1_p
current JJ 1_p
era NN 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
The DT 1_p
11 CD 1_p
482 CD 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
Prevention NNP 1_i
of IN 1_i
REStenosis NNP 1_i
with IN 1_i
Tranilast NNP 1_i
and CC 1_i
its PRP$ 1_i
Outcomes NNP 1_i
( ( 1_i
PRESTO NNP 1_i
) ) 1_i
Trial NNP 1_i
were VBD N
stratified VBN N
according VBG N
to TO N
the DT N
presence NN N
( ( N
n=2694 JJ N
) ) N
or CC N
absence NN N
( ( N
n=8798 JJ N
) ) N
of IN N
diabetes NNS N
. . N

Diabetic JJ N
patients NNS N
were VBD N
older JJR N
; : N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
female JJ N
; : N
had VBD N
a DT N
higher JJR N
proportion NN N
of IN N
congestive JJ 1_o
failure NN 1_o
, , 1_o
hypertension NN 1_o
, , 1_o
prior JJ 1_o
CABG NNP 1_o
, , 1_o
and CC 1_o
unstable JJ 1_o
angina NN 1_o
; : 1_o
and CC N
had VBD N
higher JJR N
body NN 1_o
mass NN 1_o
index NN 1_o
and CC N
lower JJR N
ejection NN 1_o
fraction NN 1_o
than IN N
nondiabetic JJ N
patients NNS N
( ( N
P NNP N
< VBZ N
0.01 CD N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

The DT N
degree NN 1_o
of IN 1_o
multivessel NN 1_o
disease NN 1_o
was VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

American JJ N
College NNP N
of IN N
Cardiology/American NNP N
Heart NNP N
Association NNP N
type VBD 1_o
C NNP 1_o
lesions NNS 1_o
were VBD N
more JJR N
common JJ N
in IN N
diabetic JJ N
patients NNS N
( ( N
17 CD N
% NN N
versus IN N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Angiographic NNP 1_o
and CC 1_o
procedural JJ 1_o
success NN 1_o
rates NNS 1_o
and CC N
in-hospital JJ 1_o
events NNS 1_o
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
of IN N
death NN 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
or CC 1_o
target VB 1_o
vessel JJ 1_o
revascularization NN 1_o
( ( 1_o
TVR NNP 1_o
) ) 1_o
was VBD N
analyzed VBN N
as IN N
time-to-first JJ N
event NN N
within IN N
9 CD N
months NNS N
of IN N
the DT N
index NN N
PCI NNP 1_i
. . 1_i

After IN N
adjusting VBG N
for IN N
certain JJ N
baseline NN N
characteristics NNS N
, , N
diabetes NNS N
was VBD N
independently RB N
associated VBN N
with IN N
death NN 1_o
at IN N
9 CD N
months NNS N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
1.87 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.31 CD N
to TO N
2.68 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
with IN N
an DT N
increased VBN N
likelihood NN N
of IN N
TVR NNP 1_o
( ( N
RR NNP N
, , N
1.27 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.14 CD N
to TO N
1.42 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
composite JJ N
end NN N
point NN N
of IN N
death/myocardial JJ 1_o
infarction/TVR NN 1_o
( ( N
RR NNP N
, , N
1.26 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.13 CD N
to TO N
1.40 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
advances NNS N
in IN N
interventional JJ N
techniques NNS N
, , N
diabetes VBZ N
remains VBZ N
a DT N
significant JJ N
independent JJ N
predictor NN N
of IN N
adverse JJ N
events NNS N
in IN N
the DT N
intermediate JJ N
term NN N
after IN N
PCI NNP 1_i
. . 1_i

Mediterranean NNP 1_i
diet NN 1_i
and CC 1_i
high JJ 1_i
dietary JJ 1_i
acid NN 1_i
load NN 1_i
associated VBN N
with IN N
mixed JJ 1_i
nuts NNS 1_i
: : 1_i
effect NN 1_o
on IN N
bone NN 1_o
metabolism NN 1_o
in IN N
elderly JJ 1_p
subjects NNS 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
analyze VB N
the DT N
effect NN N
of IN N
differing VBG N
diet NN N
on IN N
the DT N
acid JJ N
load NN N
content NN N
on IN N
bone NN 1_o
metabolism NN 1_o
. . 1_o

DESIGN NNP N
Multicentric NNP N
, , N
randomized VBD N
, , N
single-blind JJ N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient JJ 1_p
clinics NNS 1_p
. . 1_p

PARTICIPANTS VB N
Two CD 1_p
hundred CD 1_p
thirty-eight JJ 1_p
elderly JJ 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
aged VBD 1_p
60 CD 1_p
to TO 1_p
80 CD 1_p
at IN 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
cardiovascular JJ 1_p
disease NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
interventional JJ N
groups NNS N
: : N
a DT N
recommended JJ 1_i
low-fat JJ 1_i
diet NN 1_i
( ( 1_i
control VB 1_i
diet JJ 1_i
group NN 1_i
) ) 1_i
, , 1_i
a DT 1_i
Mediterranean NNP 1_i
diet NN 1_i
supplemented VBD 1_i
with IN 1_i
virgin JJ 1_i
olive JJ 1_i
oil NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
Mediterranean NNP 1_i
diet NN 1_i
supplemented VBD 1_i
with IN 1_i
mixed JJ 1_i
nuts NNS 1_i
. . 1_i

MEASUREMENTS NNP N
Main NNP N
outcomes NNS N
were VBD N
12-month JJ N
changes NNS N
from IN N
baseline NN N
in IN N
bone NN 1_o
formation NN 1_o
and CC 1_o
resorption NN 1_o
markers NNS 1_o
and CC 1_o
bone NN 1_o
mass NN 1_o
measured VBD 1_o
according VBG N
to TO N
quantitative JJ N
ultrasound JJ N
scanning NN N
. . N

RESULTS VB N
The DT N
baseline NN N
data NNS N
on IN N
the DT N
anthropometric NN 1_o
, , 1_o
bone NN 1_o
densitometry NN 1_o
, , 1_o
and CC 1_o
biochemical JJ 1_o
variables NNS 1_o
did VBD N
not RB N
differ VB N
between IN N
the DT N
three CD 1_p
groups NNS 1_p
. . 1_p

Dietary NNP 1_o
potential JJ 1_o
renal JJ 1_o
acid NN 1_o
load NN 1_o
( ( 1_o
PRAL NNP 1_o
) ) 1_o
and CC 1_o
daily JJ 1_o
net NN 1_o
endogenous JJ 1_o
acid NN 1_o
production NN 1_o
( ( 1_o
NEAP NNP 1_o
) ) 1_o
at IN N
baseline NN N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

After IN N
intervention NN N
, , N
subjects NNS 1_p
allocated VBD N
to TO N
the DT N
Mediterranean NNP 1_i
diet NN 1_i
with IN 1_i
mixed JJ 1_i
nuts NNS 1_i
had VBD N
a DT N
significant JJ N
increase NN N
of IN N
PRAL NNP 1_o
and CC 1_o
NEAP NNP 1_o
. . 1_o

In IN N
comparison NN N
, , N
subjects NNS N
in IN N
the DT N
Mediterranean NNP 1_i
diet NN 1_i
with IN 1_i
nuts NNS 1_i
group NN 1_p
had VBD N
higher JJR N
parathyroid NN 1_o
hormone NN 1_o
( ( 1_o
PTH NNP 1_o
) ) 1_o
levels NNS 1_o
( ( N
2.63 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
=-1.01-6.35 NN N
, , N
P=.02 NNP N
) ) N
and CC N
a DT N
nonsignificantly RB N
higher JJR N
( ( N
0.31 CD N
, , N
95 CD N
% NN N
CI=-0.13-0.74 NNP N
, , N
P=.14 NNP N
) ) N
urine VBP 1_o
free JJ 1_o
deoxypyridoxine NN 1_o
: : 1_o
creatinine NN 1_o
ratio NN 1_o
, , N
a DT N
marker NN N
of IN N
bone NN N
resorption NN N
, , N
than IN N
the DT N
control NN N
group NN 1_p
and CC N
the DT N
Mediterranean NNP N
diet NN N
with IN N
virgin JJ N
olive JJ N
oil NN N
group NN 1_p
. . 1_p

CONCLUSION VB N
A DT N
Mediterranean NNP 1_i
dietary JJ 1_i
pattern NN 1_i
associated VBN N
with IN N
a DT N
high JJ N
dietary JJ N
acid NN N
load NN N
derived VBN N
from IN N
consumption NN N
of IN N
mixed JJ N
nuts NNS N
does VBZ N
not RB N
seem VB N
to TO N
have VB N
a DT N
much RB N
greater JJR N
effect NN N
on IN N
bone NN 1_o
metabolism NN 1_o
biomarkers NNS 1_o
, , N
with IN N
the DT N
exception NN N
of IN N
PTH NNP 1_o
levels NNS 1_o
, , N
than IN N
a DT N
Mediterranean NNP 1_i
diet NN 1_i
without IN 1_i
mixed JJ 1_i
nuts NNS 1_i
or CC 1_i
a DT 1_i
control NN 1_i
diet NN 1_i
in IN N
elderly JJ 1_p
subjects NNS 1_p
. . 1_p

Effect NN N
of IN N
a DT N
synthetic JJ 1_i
appeasing VBG 1_i
pheromone NN 1_i
on IN N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
perioperative JJ N
stress NN N
responses NNS N
in IN N
dogs NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
study VB N
the DT N
effects NNS N
of IN N
a DT N
synthetic JJ 1_i
, , 1_i
dog-appeasing JJ 1_i
pheromone NN 1_i
( ( 1_i
sDAP NN 1_i
) ) 1_i
on IN N
the DT N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
perioperative JJ N
stress NN N
responses NNS N
in IN N
dogs NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
orchiectomy NN 1_p
or CC 1_p
ovariohysterectomy NN 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

ANIMALS $ N
46 CD 1_p
dogs NNS 1_p
housed VBN 1_p
in IN 1_p
animal NN 1_p
shelters NNS 1_p
and CC 1_p
undergoing VBG 1_p
elective JJ 1_p
orchiectomy NN 1_p
or CC 1_p
ovariohysterectomy NN 1_p
. . 1_p

PROCEDURES NNP N
Intensive NNP N
care NN N
unit NN N
cages NNS N
were VBD N
sprayed VBN N
with IN N
sDAP JJ 1_i
solution NN 1_i
or CC 1_i
sham NN 1_i
treated VBN 1_i
with IN 1_i
the DT 1_i
carrier NN 1_i
used VBN 1_i
in IN 1_i
the DT 1_i
solution NN 1_i
20 CD 1_i
minutes NNS 1_i
prior RB 1_i
to TO 1_i
use VB 1_i
. . 1_i

Dogs NNS N
( ( N
n JJ N
= NN N
24 CD N
and CC N
22 CD N
in IN N
the DT N
sDAP NN 1_i
and CC N
sham JJ 1_i
treatment NN 1_i
exposure NN N
groups NNS N
, , N
respectively RB N
) ) N
were VBD N
placed VBN N
in IN N
treated JJ N
cages NNS N
for IN N
30 CD N
minutes NNS N
before IN N
and CC N
after IN N
surgery NN N
. . N

Indicators NNS N
of IN N
stress NN N
( ( N
ie NN N
, , N
alterations NNS N
in IN N
behavioral JJ 1_o
, , 1_o
neuroendocrine JJ 1_o
, , 1_o
immune JJ 1_o
, , 1_o
and CC 1_o
acute-phase JJ 1_o
responses NNS 1_o
) ) 1_o
were VBD N
evaluated VBN N
perioperatively RB N
. . N

Behavioral JJ 1_o
response NN 1_o
variables NNS 1_o
, , 1_o
salivary JJ 1_o
cortisol NN 1_o
concentration NN 1_o
, , 1_o
WBC NNP 1_o
count NN 1_o
, , 1_o
and CC 1_o
serum JJ 1_o
concentrations NNS 1_o
of IN 1_o
glucose NN 1_o
, , 1_o
prolactin NN 1_o
, , 1_o
haptoglobin NN 1_o
, , 1_o
and CC 1_o
C-reactive JJ 1_o
protein NN 1_o
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Behavioral NNP 1_o
response NN 1_o
variables NNS 1_o
and CC 1_o
serum NN 1_o
prolactin NN 1_o
concentration NN 1_o
were VBD N
influenced VBN N
by IN N
sDAP NN N
exposure NN N
. . N

Dogs NNS N
exposed VBD N
to TO N
sDAP VB N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
alertness NN 1_o
and CC 1_o
visual JJ 1_o
exploration NN 1_o
behaviors NNS 1_o
after IN N
surgery NN N
than IN N
were VBD N
dogs NNS N
exposed VBN N
to TO N
sham VB N
treatment NN N
. . N

Decreases VBZ N
in IN N
serum NN 1_o
prolactin NN 1_o
concentrations NNS 1_o
in IN N
response NN N
to TO N
perioperative JJ N
stress NN N
were VBD N
significantly RB N
smaller JJR N
in IN N
dogs NNS N
exposed VBN N
to TO N
sDAP VB N
, , N
compared VBN N
with IN N
findings NNS N
in IN N
dogs NNS N
exposed VBN N
to TO N
the DT N
sham NN N
treatment NN N
. . N

Variables NNS N
examined VBD N
to TO N
evaluate VB N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
, , N
immune JJ N
system NN N
, , N
and CC N
acute-phase JJ N
responses NNS N
were VBD N
unaffected VBN N
by IN N
treatment NN N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
sDAP NN N
appeared VBD N
to TO N
affect VB N
behavioral JJ 1_o
and CC 1_o
neuroendocrine JJ 1_o
perioperative JJ 1_o
stress NN 1_o
responses NNS 1_o
by IN N
modification NN N
of IN N
lactotropic JJ N
axis NN N
activity NN N
. . N

Use NN N
of IN N
sDAP NN 1_i
in IN N
a DT N
clinical JJ N
setting NN N
may MD N
improve VB N
the DT N
recovery NN 1_o
and CC N
welfare NN N
of IN N
dogs NNS 1_p
undergoing VBG 1_p
surgery NN 1_p
. . 1_p

Randomized VBN N
trial NN N
of IN N
a DT N
decision NN N
aid NN N
for IN N
individuals NNS 1_p
considering VBG 1_p
genetic JJ 1_p
testing NN 1_p
for IN 1_p
hereditary JJ 1_p
nonpolyposis NN 1_p
colorectal NN 1_p
cancer NN 1_p
risk NN 1_p
. . 1_p

BACKGROUND NNP N
Despite IN N
the DT N
potential JJ N
benefits NNS N
of IN N
genetic JJ N
testing VBG N
for IN N
hereditary JJ N
nonpolyposis NN N
colorectal NN N
cancer NN N
( ( N
HNPCC NNP N
) ) N
risk NN N
, , N
individuals NNS N
can MD N
find VB N
the DT N
genetic JJ N
testing VBG N
decision-making JJ N
process NN N
complicated VBN N
and CC N
challenging VBG N
. . N

The DT N
goal NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
measure VB N
the DT N
effectiveness NN 1_o
of IN 1_o
a DT 1_o
tailored JJ 1_o
decision NN 1_o
aid NN 1_o
designed VBN N
specifically RB N
to TO N
assist VB N
individuals NNS N
to TO N
make VB N
informed JJ N
decisions NNS N
regarding VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
risk NN N
. . N

METHODS NNP N
In IN N
all DT N
, , N
153 CD 1_p
individuals NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB 1_i
the DT 1_i
decision NN 1_i
aid NN 1_i
or CC 1_i
a DT 1_i
control JJ 1_i
pamphlet NN 1_i
at IN 1_i
the DT 1_i
end NN 1_i
of IN 1_i
their PRP$ 1_i
first JJ 1_i
genetic JJ 1_i
counseling NN 1_i
consultation NN 1_i
. . 1_i

Of IN N
these DT N
, , N
109 CD N
( ( N
71.2 CD N
% NN N
) ) N
completed VBD N
the DT N
first JJ N
questionnaire NN 1_o
1 CD N
week NN N
after IN N
consultation NN N
, , N
whereas IN N
95 CD N
( ( N
62.1 CD N
% NN N
) ) N
completed VBD N
the DT N
6-month JJ N
follow-up JJ 1_o
questionnaire NN 1_o
. . 1_o

RESULTS CC N
Although IN N
the DT N
decision NN N
aid NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
postdecisional JJ N
regret NN N
or CC N
actual JJ N
genetic JJ N
testing VBG N
decision NN N
, , N
the DT N
trial NN N
results NNS N
demonstrated VBD N
that IN N
participants NNS N
who WP N
received VBD N
the DT N
decision NN 1_i
aid NN 1_i
had VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
decisional JJ 1_o
conflict NN 1_o
( ( 1_o
ie JJ 1_o
, , 1_o
uncertainty NN 1_o
) ) 1_o
regarding VBG N
genetic JJ 1_o
testing NN 1_o
( ( N
chi-square JJ N
( ( N
1 CD N
) ) N
= NN N
8.97 CD N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
classified VBN N
as IN N
having VBG N
made VBN N
an DT N
informed JJ 1_o
choice NN 1_o
concerning VBG N
genetic JJ N
testing NN N
( ( N
chi-square JJ N
( ( N
1 CD N
) ) N
= NN N
4.37 CD N
; : N
P NNP N
= NNP N
.037 NNP N
) ) N
than IN N
participants NNS N
who WP N
received VBD N
a DT N
control NN 1_i
pamphlet NN 1_i
. . 1_i

Also RB N
, , N
men NNS N
who WP N
received VBD N
the DT N
decision NN 1_i
aid NN 1_i
had VBD N
significantly RB N
higher JJR 1_o
knowledge NN 1_o
levels NNS 1_o
regarding VBG N
genetic JJ N
testing NN N
compared VBN N
with IN N
men NNS 1_p
who WP N
received VBD N
the DT N
control NN 1_i
pamphlet NN 1_i
, , N
whereas JJ N
no DT N
such JJ N
differences NNS N
were VBD N
found VBN N
for IN N
women NNS 1_p
( ( N
chi-square NN N
( ( N
2 CD N
) ) N
= NN N
6.76 CD N
; : N
P NNP N
= NNP N
.034 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
decision NN 1_i
aid NN 1_i
for IN N
individuals NNS N
considering VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
is VBZ N
an DT N
effective JJ N
intervention NN N
to TO N
reduce VB N
uncertainty NN N
and CC N
assist JJ N
individuals NNS N
to TO N
make VB N
an DT N
informed JJ N
choice NN N
regarding VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
after IN N
genetic JJ N
counseling NN N
. . N

Transcranial NNP 1_i
Magnetic NNP 1_i
Stimulation NNP 1_i
to TO N
Address NNP N
Mild NNP 1_p
Cognitive NNP 1_p
Impairment NNP 1_p
in IN 1_p
the DT 1_p
Elderly JJ 1_p
: : 1_p
A DT N
Randomized NNP N
Controlled NNP N
Study NNP N
. . N

Transcranial NNP 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
TMS NNP 1_i
) ) 1_i
is VBZ N
a DT N
noninvasive JJ N
brain NN N
stimulation NN N
technique NN N
with IN N
potential JJ N
to TO N
improve VB N
memory NN N
. . N

Mild NNP 1_p
cognitive JJ 1_p
impairment NN 1_p
( ( 1_p
MCI NNP 1_p
) ) 1_p
, , N
which WDT N
still RB N
lacks VBZ N
a DT N
specific JJ N
therapy NN N
, , N
is VBZ N
a DT N
clinical JJ N
syndrome NN N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
dementia NN N
. . N

This DT N
study NN N
aims VBZ N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
high-frequency NN 1_i
repetitive JJ 1_i
TMS NNP 1_i
( ( 1_i
HF NNP 1_i
rTMS NN 1_i
) ) 1_i
on IN N
everyday JJ N
memory NN N
of IN N
the DT 1_p
elderly JJ 1_p
with IN 1_p
MCI NNP 1_p
. . 1_p

We PRP N
conducted VBD N
a DT N
double-blinded JJ N
randomized JJ N
sham-controlled JJ N
trial NN N
using VBG N
rTMS NN 1_i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
. . N

Thirty-four CD 1_p
elderly JJ 1_p
outpatients NNS 1_p
meeting VBG 1_p
Petersen NNP 1_p
's POS 1_p
MCI NNP 1_p
criteria NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB 1_i
10 CD 1_i
sessions NNS 1_i
of IN 1_i
either DT 1_i
active JJ 1_i
TMS NNP 1_i
or CC 1_i
sham NN 1_i
, , 1_i
10 CD 1_i
Hz NNP 1_i
rTMS NN 1_i
at IN 1_i
110 CD 1_i
% NN 1_i
of IN 1_i
motor NN 1_i
threshold NN 1_i
, , 1_i
2,000 CD 1_i
pulses NNS 1_i
per IN 1_i
session NN 1_i
. . 1_i

Neuropsychological JJ 1_i
assessment NN 1_i
at IN 1_i
baseline NN 1_i
, , 1_i
after IN 1_i
the DT 1_i
last JJ 1_i
session NN 1_i
( ( 1_i
10th CD 1_i
) ) 1_i
and CC 1_i
at IN 1_i
one-month JJ 1_i
follow-up NN 1_i
, , 1_i
was VBD 1_i
applied VBN 1_i
. . N

ANOVA NNP N
on IN N
the DT N
primary JJ N
efficacy NN N
measure NN N
, , N
the DT 1_o
Rivermead NNP 1_o
Behavioural NNP 1_o
Memory NNP 1_o
Test NNP 1_o
, , N
revealed VBD N
a DT N
significant JJ N
group-by-time JJ N
interaction NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
, , N
favoring VBG N
the DT N
active JJ N
group NN N
. . N

The DT N
improvement NN N
was VBD N
kept VBN N
after IN N
one CD N
month NN N
. . N

Other JJ N
neuropsychological JJ N
tests NNS N
were VBD 1_o
heterogeneous JJ 1_o
. . 1_o

rTMS NN 1_o
at IN 1_o
10 CD 1_o
Hz NNP 1_o
enhanced VBD 1_o
everyday JJ 1_o
memory NN 1_o
in IN 1_p
elderly JJ 1_p
with IN 1_p
MCI NNP N
after IN N
10 CD N
sessions NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN 1_i
rTMS NN 1_i
might MD N
be VB N
effective JJ N
as IN N
a DT N
therapy NN N
for IN N
MCI NNP N
and CC N
probably RB N
a DT N
tool NN N
to TO N
delay VB N
deterioration NN N
. . N

Human NNP 1_i
recombinant JJ 1_i
GM-CSF NNP 1_i
in IN N
allogeneic JJ N
bone NN N
marrow NN N
transplantation NN N
for IN N
leukaemia NN N
: : N
double-blind JJ N
placebo NN N
controlled VBN N
trial NN N
. . N

A DT N
double-blind NN N
randomised VBN N
trial NN N
compared VBN N
20 CD 1_p
patients NNS 1_p
with IN 1_p
leukaemia JJ 1_p
receiving VBG 1_p
human JJ 1_i
recombinant JJ 1_i
granulocyte NN 1_i
macrophage NN 1_i
colony NN 1_i
stimulating VBG 1_i
factor NN 1_i
( ( 1_i
GM NNP 1_i
CSF NNP 1_i
) ) 1_i
, , 1_p
with IN 1_p
20 CD 1_p
patients NNS 1_p
receiving VBG 1_p
placebo NN 1_i
for IN 1_i
14 CD 1_i
days NNS 1_i
after IN 1_i
allogeneic JJ 1_i
matched VBD 1_i
sibling VBG 1_i
bone NN 1_i
marrow NN 1_i
transplantation NN 1_i
. . 1_i

The DT N
median JJ 1_o
neutrophil NN 1_o
count NN 1_o
at IN N
14 CD N
days NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM NNP 1_i
CSF NNP 1_i
group NN N
( ( N
1.90 CD N
vs. FW N
0.46 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
. . N

The DT N
duration NN 1_o
of IN 1_o
hospital NN 1_o
stay NN 1_o
, , 1_o
the DT 1_o
number NN 1_o
of IN 1_o
antibiotic JJ 1_o
days NNS 1_o
, , 1_o
and CC 1_o
the DT 1_o
number NN 1_o
of IN 1_o
fever JJ 1_o
days NNS 1_o
was VBD N
the DT N
same JJ N
for IN N
both DT 1_p
patient JJ 1_p
groups NNS 1_p
. . 1_p

The DT N
lymphocyte NN 1_o
count NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM-CSF NNP 1_i
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
between IN N
days NNS N
10 CD N
and CC N
15 CD N
after IN N
transplantation NN N
. . N

The DT N
GM-CSF NNP 1_i
group NN N
had VBD N
lower JJR N
haemoglobin NN 1_o
concentrations NNS 1_o
and CC 1_o
platelets NNS 1_o
counts NNS 1_o
, , 1_o
and CC 1_o
higher JJR 1_o
plasma NN 1_o
urea JJ 1_o
creatinine NN 1_o
and CC 1_o
bilirubin NN 1_o
, , N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
GM NNP 1_i
CSF NNP 1_i
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
leukaemic JJ 1_o
relapse NN 1_o
. . 1_o

MR NNP N
imaging NN N
of IN N
pituitary JJ 1_p
region NN 1_p
lesions NNS 1_p
with IN N
gadodiamide JJ 1_i
injection NN N
. . N

Twelve CD 1_p
patients NNS 1_p
with IN 1_p
known VBN 1_p
or CC 1_p
suspected VBN 1_p
pituitary JJ 1_p
lesions NNS 1_p
underwent JJ N
MR NNP 1_i
imaging VBG 1_i
with IN N
gadodiamide JJ 1_i
injection NN 1_i
at IN N
a DT N
dose NN N
of IN N
0.1 CD N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
0.3 CD N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
mM/kg NN N
. . N

Six CD 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
were VBD N
also RB N
studied VBN N
with IN N
0.1 CD 1_i
mM/kg NNS 1_i
gadopentetate JJ 1_i
dimeglumine NN 1_i
. . 1_i

Consistent JJ N
with IN N
previous JJ N
reports NNS N
gadodiamide NN 1_i
injection NN N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ 1_o
and CC 1_o
effective JJ 1_o
contrast NN N
medium NN N
for IN N
MR NNP N
imaging NN N
of IN N
the DT N
pituitary JJ N
region NN N
. . N

No DT N
additional JJ N
diagnostic JJ N
information NN N
was VBD N
obtained VBN N
using VBG N
0.3 CD N
mM/kg JJ N
gadodiamide NN 1_i
injection NN N
compared VBN N
to TO N
0.1 CD N
mM/kg NNS N
gadopentate JJ N
dimeglumine NN N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
high JJ N
dose NN N
( ( N
0.3 CD N
mM/kg NN N
) ) N
gadodiamide NN 1_i
injection NN N
in IN N
7 CD N
patients NNS N
did VBD N
not RB N
shorten VB 1_o
the DT 1_o
T2 NNP 1_o
value NN 1_o
sufficiently RB 1_o
to TO N
overwhelm VB N
the DT N
T1 NNP 1_o
shortening NN 1_o
and CC 1_o
leave VBP 1_o
pathologic JJ 1_o
lesions NNS 1_o
hypointense VBP 1_o
compared VBN N
to TO N
precontrast VB N
studies NNS N
. . N

With IN N
the DT N
comparable JJ N
relaxivities NNS N
of IN N
gadodiamide JJ 1_i
injection NN N
and CC N
gadopentetate NN 1_i
dimeglumine NN 1_i
, , N
similarities NNS N
in IN N
results NNS N
have VBP N
to TO N
be VB N
expected VBN N
when WRB N
using VBG N
these DT N
media NNS N
for IN N
MR NNP N
image NN N
enhancement NN N
. . N

Concomitant NNP N
, , N
sequential JJ N
, , N
and CC N
hybrid JJ N
therapy NN N
for IN N
H. NNP 1_o
pylori JJ 1_o
eradication NN 1_o
: : 1_o
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Since IN N
the DT N
efficacy NN N
of IN N
the DT N
standard JJ N
triple NN N
therapies NNS N
for IN N
Helicobacter NNP 1_o
pylori NN 1_o
eradication NN 1_o
has VBZ N
decreased VBN N
, , N
novel JJ 1_i
antibiotic JJ 1_i
regimens NNS 1_i
have VBP N
been VBN N
introduced VBN N
, , N
including VBG 1_i
concomitant NN 1_i
, , 1_i
sequential JJ 1_i
, , N
and CC N
hybrid JJ 1_i
therapies NNS 1_i
. . 1_i

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
cure NN 1_o
rates NNS 1_o
achieved VBN N
by IN N
these DT N
new JJ N
therapy NN N
regimens NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN 1_p
, , 1_p
open-label JJ 1_p
, , 1_p
pilot NN 1_p
study NN 1_p
enrolling VBG 1_p
consecutive JJ 1_p
non-ulcer JJ 1_p
dyspepsia NN 1_p
patients NNS 1_p
with IN 1_p
H. NNP 1_p
pylori FW 1_p
infection NN 1_p
never RB 1_p
previously RB 1_p
treated VBN 1_p
for IN 1_p
the DT 1_p
infection NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( N
a DT N
) ) N
concomitant NN 1_i
therapy NN 1_i
: : 1_i
omeprazole JJ 1_i
20mg CD N
, , N
amoxicillin RB 1_i
1g CD N
, , N
clarithromycin VBD 1_i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ 1_i
500 CD N
mg NN N
for IN N
5 CD N
days NNS N
; : N
( ( N
b NN N
) ) N
sequential JJ 1_i
therapy NN 1_i
: : 1_i
omeprazole JJ 1_i
20mg CD N
and CC N
amoxicillin $ 1_i
1g CD N
for IN N
5 CD N
days NNS N
followed VBN N
by IN N
omeprazole JJ 1_i
20mg CD N
, , N
clarithromycin VBD 1_i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ 1_i
500 CD N
mg NN N
for IN N
5 CD N
days NNS N
; : N
( ( N
c NN N
) ) N
hybrid JJ 1_i
therapy NN 1_i
: : 1_i
omeprazole JJ 1_i
20mg CD N
, , N
and CC N
amoxicillin VBZ 1_i
1g CD N
for IN N
7 CD N
days NNS N
followed VBN N
by IN N
omeprazole JJ 1_i
20mg CD N
, , N
amoxicillin RB 1_i
1g CD N
, , N
clarithromycin VBD 1_i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ 1_i
500 CD N
mg NN N
, , N
for IN N
7 CD N
days NNS N
. . N

All DT N
drugs NNS N
were VBD N
administered VBN N
twice RB N
daily RB N
. . N

Bacterial JJ 1_o
eradication NN 1_o
was VBD N
checked VBN N
6 CD N
weeks NNS N
after IN N
treatment NN N
by IN N
using VBG N
a DT N
( ( 1_i
13 CD 1_i
) ) 1_i
C-urea NNP 1_i
breath NN 1_i
test NN 1_i
. . 1_i

A DT N
10-day JJ N
, , N
second-line JJ 1_i
therapy NN 1_i
with IN N
omeprazole JJ 1_i
20mg CD N
, , N
levofloxacin VBD 1_i
250 CD N
mg NN N
, , N
and CC N
amoxicillin RB 1_i
1g CD N
, , N
all DT N
given VBN N
twice RB N
daily RB N
, , N
was VBD N
offered VBN N
to TO N
the DT N
eradication NN N
failure NN N
patients NNS N
. . N

RESULTS NNP N
Overall NNP N
, , N
270 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
but CC 1_p
13 CD 1_p
patients NNS 1_p
early RB 1_p
interrupted VBN 1_p
treatment NN 1_p
due JJ N
to TO N
side VB N
effects NNS N
. . N

At IN N
intention-to-treat NN N
( ( N
ITT NNP N
) ) N
and CC N
per-protocol JJ N
analysis NN N
( ( N
PP NNP N
) ) N
, , N
the DT N
eradication NN 1_o
rates NNS 1_o
were VBD N
85.5 CD N
% NN N
and CC N
91.6 CD N
% NN N
with IN N
the DT N
concomitant JJ 1_i
regimen NNS 1_i
, , N
91.1 CD N
% NN N
and CC N
92.1 CD N
% NN N
with IN N
the DT N
sequential JJ 1_i
therapy NN 1_i
, , N
and CC N
80 CD N
% NN N
and CC N
85.7 CD N
% NN N
with IN N
the DT N
hybrid JJ 1_i
regimen NNS 1_i
. . 1_i

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

H. NNP 1_o
pylori JJ 1_o
infection NN 1_o
was VBD N
cured VBN 1_o
in IN N
10 CD N
( ( N
55.6 CD N
% NN N
) ) N
patients NNS N
with IN N
the DT N
second-line JJ 1_i
regimen NNS 1_i
. . 1_i

CONCLUSION NN N
In IN N
our PRP$ N
study NN N
, , N
both DT N
concomitant NN 1_i
and CC N
sequential JJ 1_i
therapy NN 1_i
, , N
but CC N
not RB N
hybrid JJ 1_i
therapy NN 1_i
, , N
reached VBN N
high JJ N
eradication NN 1_o
rates NNS 1_o
. . 1_o

The DT N
success NN 1_o
rate NN 1_o
of IN N
second-line JJ N
levofloxacin-based JJ 1_i
triple NN 1_i
therapy NN 1_i
is VBZ N
decreasing VBG N
. . N

Do VB N
cervical JJ N
cancer NN N
screening VBG N
rates NNS N
increase VBP N
in IN N
association NN N
with IN N
an DT N
intervention NN N
designed VBN N
to TO N
increase VB N
mammography NN N
usage NN N
? . N
OBJECTIVES UH N
To TO N
assess VB N
cervical JJ 1_o
cancer NN 1_o
screening VBG 1_o
behaviors NNS 1_o
among IN N
underserved JJ 1_p
women NNS 1_p
participating VBG 1_p
in IN 1_p
an DT 1_p
intervention NN 1_p
designed VBN 1_p
to TO 1_p
increase VB 1_p
mammography NN 1_p
use NN 1_p
. . 1_p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
trial NN N
of IN N
897 CD 1_p
women NNS 1_p
from IN 1_p
three CD 1_p
racial JJ 1_p
groups NNS 1_p
( ( 1_p
white JJ 1_p
, , 1_p
African JJ 1_p
American NNP 1_p
, , 1_p
Native JJ 1_p
American NNP 1_p
) ) 1_p
living NN 1_p
in IN 1_p
a DT 1_p
rural JJ 1_p
county NN 1_p
in IN 1_p
North NNP 1_p
Carolina NNP 1_p
. . 1_p

Baseline NNP N
and CC N
followup JJ N
surveys NNS N
were VBD N
completed VBN N
by IN N
815 CD 1_p
women NNS 1_p
; : 1_p
775 CD 1_p
women NNS 1_p
provided VBD 1_p
data NNS 1_p
to TO N
be VB N
included VBN N
in IN N
these DT N
analyses NNS N
. . N

The DT N
intervention NN N
group NN N
received VBD N
an DT N
educational JJ 1_i
program NN 1_i
focused VBN 1_i
on IN 1_i
mammography NN 1_i
delivered VBN 1_i
by IN 1_i
a DT 1_i
lay NN 1_i
health NN 1_i
advisor NN 1_i
, , N
and CC N
the DT N
control NN N
group NN N
received VBD N
a DT N
physician JJ 1_i
letter/brochure NN 1_i
focusing VBG 1_i
on IN 1_i
Pap NNP 1_i
tests NNS 1_i
. . 1_i

RESULTS NNP N
Women NNP N
in IN N
both CC N
the DT N
intervention NN N
( ( N
OR NNP N
1.70 CD N
; : N
1.31 CD N
, , N
2.21 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
control NN N
groups NNS N
( ( N
OR NNP N
1.38 CD N
; : N
1.04 CD N
, , N
1.82 CD N
, , N
p NN N
= NNP N
0.025 CD N
) ) N
significantly RB N
increased VBD N
cervical JJ 1_o
cancer NN 1_o
screening VBG 1_o
rates NNS 1_o
within IN N
risk NN N
appropriate JJ N
guidelines NNS N
. . N

No DT N
differences NNS N
by IN N
racial JJ N
group NN N
were VBD N
documented VBN N
. . N

Women NNP N
categorized VBD N
in IN N
the DT N
high-risk JJ N
group NN N
for IN N
developing VBG N
cervical JJ N
cancer NN N
( ( N
> $ N
2 CD N
sexual JJ N
partners NNS N
, , N
age NN N
< VBD N
18 CD N
years NNS N
at IN N
first JJ N
sexual JJ N
intercourse NN N
, , N
smoker NN N
; : N
treated VBN N
for IN N
sexually RB N
transmitted VBN N
disease NN N
[ NNP N
STD NNP N
] NNP N
or CC N
partner NN N
with IN N
treated JJ N
STD NNP N
) ) N
significantly RB N
( ( N
OR NNP N
1.88 CD N
; : N
1.54 CD N
, , N
2.28 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
increased VBD 1_o
Pap NNP 1_o
test NN 1_o
completion NN 1_o
. . 1_o

However RB N
, , N
a DT N
nonsignificant JJ 1_o
increase NN 1_o
( ( N
OR NNP N
1.25 CD N
; : N
0.87 CD N
, , N
1.79 CD N
, , N
p NN N
= NNP N
0.221 CD N
) ) N
in IN N
Pap NNP 1_o
test NN 1_o
completion NN 1_o
was VBD N
demonstrated VBN N
in IN N
women NNS N
categorized VBN N
as IN N
low JJ N
risk NN N
for IN N
cervical JJ N
cancer NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
women NNS N
in IN N
an DT N
intensive JJ 1_i
behavioral JJ 1_i
intervention NN 1_i
designed VBN 1_i
to TO 1_i
increase VB 1_i
mammography NN 1_i
use NN 1_i
may MD N
also RB N
increase VB N
Pap NNP 1_o
test JJS 1_o
completion NN 1_o
, , N
similar JJ N
to TO N
a DT N
minimal JJ N
intervention NN N
focused VBD N
only RB N
on IN N
increasing VBG N
Pap NNP 1_o
test NN 1_o
completion NN 1_o
. . 1_o

These DT N
results NNS N
have VBP N
implications NNS N
for IN N
the DT N
design NN N
and CC N
evaluation NN N
of IN N
behavioral JJ N
intervention NN N
studies NNS N
. . N

Improvement NN N
of IN N
pain NN N
related VBN N
self JJ N
management NN N
for IN N
oncologic JJ 1_p
patients NNS 1_p
through IN N
a DT N
trans JJ N
institutional JJ N
modular JJ N
nursing NN N
intervention NN N
: : N
protocol NN N
of IN N
a DT N
cluster NN N
randomized VBN N
multicenter RB N
trial NN N
. . N

BACKGROUND NNP N
Pain NNP N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
frequent JJ N
and CC N
distressing VBG N
symptoms NNS N
in IN N
cancer NN 1_p
patients NNS 1_p
. . 1_p

For IN N
the DT N
majority NN N
of IN N
the DT N
patients NNS N
, , N
sufficient JJ N
pain NN N
relief NN N
can MD N
be VB N
obtained VBN N
if IN N
adequate JJ N
treatment NN N
is VBZ N
provided VBN N
. . N

However RB N
, , N
pain NN N
remains NNS N
often RB N
undertreated VBD N
due JJ N
to TO N
institutional JJ N
, , N
health NN N
care NN N
professional JJ N
and CC N
patient JJ N
related JJ N
barriers NNS N
. . N

Patients NNS N
self JJ N
management NN N
skills NNS N
are VBP N
affected VBN N
by IN N
the DT N
patients NNS N
' POS N
knowledge NN N
, , N
activities NNS N
and CC N
attitude NN N
to TO N
pain VB N
management NN N
. . N

This DT N
trial NN N
protocol NN N
is VBZ N
aimed VBN N
to TO N
test VB N
the DT N
SCION-PAIN JJ N
program NN N
, , N
a DT N
multi NN N
modular NN N
structured VBD N
intervention NN N
to TO N
improve VB N
self NN N
management NN N
in IN N
cancer NN 1_p
patients NNS 1_p
with IN 1_p
pain NN 1_p
. . 1_p

METHODS NNP N
240 CD 1_p
patients NNS 1_p
with IN 1_p
diagnosed JJ 1_p
malignancy NN 1_p
and CC 1_p
pain NN 1_p
> VBP 1_p
3 CD 1_p
days NNS 1_p
and CC 1_p
average JJ 1_p
pain NN 1_p
> JJ 1_p
or= NN 1_p
3/10 CD 1_p
will MD 1_p
participate VB 1_p
in IN 1_p
a DT 1_p
cluster NN 1_p
randomized VBN 1_p
trial NN 1_p
on IN 1_p
18 CD 1_p
wards NNS 1_p
in IN 1_p
2 CD 1_p
German JJ 1_p
university NN 1_p
hospitals NNS 1_p
. . 1_p

Patients NNS N
from IN N
the DT N
intervention NN N
wards NNS N
will MD N
receive VB N
, , N
additionally RB N
to TO N
standard VB 1_i
pain NN 1_i
treatment NN 1_i
, , 1_i
the DT 1_i
SCION-PAIN JJ 1_i
program NN 1_i
consisting NN 1_i
of IN 1_i
3 CD 1_i
modules NNS 1_i
: : 1_i
pharmacologic NN 1_i
pain NN 1_i
management NN 1_i
, , 1_i
nonpharmacologic RB 1_i
pain JJ 1_i
management NN 1_i
and CC 1_i
discharge NN 1_i
management NN 1_i
. . 1_i

The DT N
intervention NN N
will MD N
be VB N
conducted VBN N
by IN N
specially RB N
trained JJ N
oncology NN N
nurses NNS N
and CC N
includes VBZ N
components NNS N
of IN N
patient JJ 1_i
education NN 1_i
, , 1_i
skills NNS 1_i
training NN 1_i
and CC 1_i
counseling NN 1_i
to TO 1_i
improve VB 1_i
self PRP 1_i
care VB 1_i
regarding VBG 1_i
pain JJ 1_i
management NN 1_i
beginning VBG 1_i
with IN 1_i
admission NN 1_i
followed VBN 1_i
by IN 1_i
booster NN 1_i
session NN 1_i
every DT 1_i
3rd CD 1_i
day NN 1_i
and CC 1_i
one CD 1_i
follow VBP 1_i
up RP 1_i
telephone NN 1_i
counseling NN 1_i
within IN 1_i
2 CD 1_i
to TO 1_i
3 CD 1_i
days NNS 1_i
after IN 1_i
discharge NN 1_i
. . 1_i

Patients NNS N
in IN N
the DT N
control NN N
group NN N
will MD N
receive VB N
standard NN N
care NN N
. . N

Primary JJ N
endpoint NN N
is VBZ N
the DT N
group NN 1_o
difference NN 1_o
in IN 1_o
patient NN 1_o
related JJ 1_o
barriers NNS 1_o
to TO 1_o
management NN 1_o
of IN 1_o
cancer NN 1_o
pain NN 1_o
( ( N
BQII NNP N
) ) N
, , N
7 CD N
days NNS N
after IN N
discharge NN N
. . N

Secondary JJ N
endpoints NNS N
are VBP N
: : N
pain NN 1_o
intensity NN 1_o
& CC 1_o
interference NN 1_o
, , 1_o
adherence NN 1_o
, , 1_o
coping VBG 1_o
and CC 1_o
HRQoL NNP 1_o
. . 1_o

DISCUSSION NNP N
The DT N
study NN N
will MD N
determine VB N
if IN N
the DT N
acquired VBN N
self NN N
management NN N
skills NNS N
of IN N
the DT N
patients NNS N
continue VBP N
to TO N
be VB N
used VBN N
after IN N
discharge NN N
from IN N
hospital NN N
. . N

It PRP N
is VBZ N
hypothesized VBN N
that IN N
patients NNS N
who WP N
receive VBP N
the DT N
multi NN N
modular NN N
structured VBN N
intervention NN N
will MD N
have VB N
less RBR N
patient JJ N
related JJ N
barriers NNS N
and CC N
a DT N
better JJR N
self JJ N
management NN N
of IN N
cancer NN 1_o
pain NN 1_o
. . 1_o

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials NNP N
NCT00779597 NNP N
. . N

A DT N
trial NN N
with IN N
3'-azido-2',3'-dideoxythymidine JJ 1_i
and CC N
human JJ N
interferon-α NN 1_i
in IN 1_p
cats NNS 1_p
naturally RB 1_p
infected VBN 1_p
with IN 1_p
feline JJ 1_p
leukaemia NN 1_p
virus NN 1_p
. . N

Feline NNP N
leukaemia NN N
virus NN N
( ( N
FeLV NNP N
) ) N
infection NN N
is VBZ N
still RB N
one CD N
of IN N
the DT N
leading JJ N
causes NNS N
of IN N
infection-related JJ N
deaths NNS N
in IN 1_p
domestic JJ 1_p
cats NNS 1_p
. . N

Treatment NN N
with IN N
various JJ N
drugs NNS N
has VBZ N
been VBN N
attempted VBN N
, , N
but CC N
none NN N
has VBZ N
resulted VBN N
in IN N
cure NN N
or CC N
complete JJ N
virus NN N
elimination NN N
. . 1_i

Human JJ 1_i
interferon-α2a JJ 1_i
( ( 1_i
huIFN-α2a JJ 1_i
) ) 1_i
and CC 1_i
3'-azido-2',3'-dideoxythymidine JJ 1_i
( ( 1_i
AZT NNP 1_i
) ) 1_i
have VBP N
been VBN N
proven VBN N
to TO N
decrease VB N
antigenaemia NN N
in IN N
cats NNS N
infected VBN N
experimentally RB N
with IN N
FeLV NNP N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT 1_o
efficacy NN 1_o
of IN 1_i
huIFN-α2a NN 1_i
, , N
AZT NNP N
and CC N
a DT N
combination NN N
of IN N
both DT N
drugs NNS N
in IN N
cats NNS N
infected VBN N
naturally RB N
with IN N
FeLV NNP N
in IN N
a DT N
placebo-controlled JJ N
double-blinded JJ N
trial NN 1_p
. . 1_p

Fourty-four CD 1_p
FeLV-infected JJ 1_p
cats NNS 1_p
in IN 1_p
which WDT 1_p
free JJ 1_p
FeLV NNP 1_p
p27 NN 1_p
antigen NN 1_p
was VBD 1_p
detected VBN 1_p
in IN 1_p
serum NN 1_p
by IN 1_p
enzyme-linked JJ 1_p
immunosorbent JJ 1_p
assay NN 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . N

Cats NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
treatment NN N
groups NNS N
that WDT N
received VBD N
either RB N
high JJ N
dose JJ 1_i
huIFN-α2a NN 1_i
( ( N
10 CD N
( ( N
5 CD N
) ) N
IU/kg NNP N
q24h NN N
; : N
12 CD N
cats NNS 1_i
) ) 1_i
, , N
AZT NNP N
( ( N
5 CD N
mg/kg NN N
q12h NN N
; : N
10 CD N
cats NNS N
, , N
both DT N
of IN N
these DT N
treatments NNS N
( ( N
12 CD N
cats NNS 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
( ( N
10 CD N
cats NNS N
) ) N
. . N

All DT N
cats NNS N
were VBD N
treated VBN N
for IN N
6 CD N
weeks NNS N
. . N

Clinical JJ N
variables NNS N
, , N
including VBG 1_o
stomatitis NN 1_o
, , 1_o
and CC 1_o
laboratory NN 1_o
parameters NNS 1_o
, , 1_o
such JJ 1_o
as IN 1_o
CD4 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
and CC 1_o
CD8 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
counts NNS 1_o
and CC 1_o
serum NN 1_o
FeLV NNP 1_o
p VBZ 1_o
27 CD 1_o
antigen NN 1_o
concentration NN 1_o
, , N
were VBD N
recorded VBN N
throughout IN N
the DT N
treatment NN N
period NN 1_o
. . 1_o

No DT 1_o
significant JJ 1_o
difference NN 1_o
among IN N
the DT N
groups NNS N
was VBD N
observed VBN N
during IN N
the DT N
treatment NN N
period NN N
for IN N
any DT N
of IN N
the DT N
parameters NNS N
. . N

Aside RB N
from IN 1_o
anaemia NN 1_o
in IN N
one CD N
cat NN N
treated VBN N
with IN N
AZT NNP 1_o
, , 1_o
no DT 1_o
adverse JJ 1_o
effects NNS 1_o
were VBD N
observed VBN N
. . N

It PRP N
was VBD N
not RB N
possible JJ N
to TO N
demonstrate VB 1_o
efficacy NN 1_o
of IN 1_i
huIFN-α2a NN 1_i
or CC N
AZT NNP N
alone RB N
or CC N
together RB N
in IN N
cats NNS N
infected VBN N
naturally RB N
with IN N
FeLV NNP N
when WRB N
given VBN N
according VBG N
to TO N
this DT N
regimen NNS N
for IN N
6 CD N
weeks NNS N
; : N
however RB 1_o
, , 1_o
no DT 1_o
notable JJ 1_o
side NN 1_o
effects NNS 1_o
were VBD N
detected VBN N
. . N

Working VBG N
memory NN N
and CC N
cognitive JJ N
flexibility-training NN N
for IN N
children NNS 1_p
with IN 1_p
an DT 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
People NNPS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASDs NNP 1_p
) ) 1_p
experience NN N
executive NN N
function NN N
( ( N
EF NNP N
) ) N
deficits NNS N
. . N

There EX N
is VBZ N
an DT N
urgent JJ N
need NN N
for IN N
effective JJ N
interventions NNS N
, , N
but CC N
in IN N
spite NN N
of IN N
the DT N
increasing VBG N
research NN N
focus NN N
on IN N
computerized JJ N
cognitive JJ N
training NN N
, , N
this DT N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
ASD NNP N
. . N

Hence NNP N
, , N
we PRP N
investigated VBD N
two CD N
EF NNP 1_i
training NN 1_i
conditions NNS 1_i
in IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
121 CD 1_p
, , 1_p
8-12 CD 1_p
years NNS 1_p
, , 1_p
IQ NNP 1_p
> NNP 1_p
80 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT 1_i
adaptive JJ 1_i
working JJ 1_i
memory NN 1_i
( ( 1_i
WM NNP 1_i
) ) 1_i
training NN 1_i
, , 1_i
an DT 1_i
adaptive JJ 1_i
cognitive JJ 1_i
flexibility-training NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
non-adaptive JJ 1_i
control NN 1_i
training NN 1_i
( ( 1_i
mock-training JJ 1_i
) ) 1_i
. . 1_i

Braingame NNP 1_i
Brian NNP 1_i
, , 1_i
a DT 1_i
computerized JJ 1_i
EF-training NN 1_i
with IN 1_i
game-elements NNS 1_i
, , N
was VBD N
used VBN N
. . N

Outcome JJ N
measures NNS N
( ( N
pretraining VBG N
, , N
post-training NN N
, , N
and CC N
6-week-follow-up JJ N
) ) N
were VBD N
near-transfer JJ 1_o
to TO 1_o
trained JJ 1_o
EFs NNP 1_o
, , 1_o
far-transfer NN 1_o
to TO 1_o
other JJ 1_o
EFs NNP 1_o
( ( 1_o
sustained VBN 1_o
attention NN 1_o
and CC 1_o
inhibition NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
parent NN 1_o
's POS 1_o
ratings NNS 1_o
of IN 1_o
daily JJ 1_o
life NN 1_o
EFs NNP 1_o
, , 1_o
social JJ 1_o
behavior NN 1_o
, , 1_o
attention NN 1_o
deficit NN 1_o
hyperactivity NN 1_o
disorder NN 1_o
( ( 1_o
ADHD NNP 1_o
) ) 1_o
-behavior NN 1_o
, , 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

RESULTS NNP N
Attrition-rate NNP 1_o
was VBD N
26 CD N
% NN N
. . N

Children NNP N
in IN N
all DT N
conditions NNS N
who WP N
completed VBD N
the DT N
training NN N
improved VBN N
in IN N
WM NNP 1_o
, , 1_o
cognitive JJ 1_o
flexibility NN 1_o
, , 1_o
attention NN 1_o
, , 1_o
and CC 1_o
on IN 1_o
parent NN 1_o
's POS 1_o
ratings NNS 1_o
, , 1_o
but CC 1_o
not RB 1_o
in IN 1_o
inhibition NN 1_o
. . 1_o

There EX N
were VBD N
no DT N
significant JJ N
differential JJ N
intervention NN N
effects NNS N
, , N
although IN N
children NNS N
in IN N
the DT N
WM NNP N
condition NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
on IN N
near-transfer JJ 1_o
WM NNP 1_o
and CC 1_o
ADHD-behavior NNP 1_o
, , N
and CC N
children NNS N
in IN N
the DT N
cognitive JJ N
flexibility NN N
condition NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
on IN N
near-transfer JJ 1_o
flexibility NN 1_o
. . 1_o

CONCLUSION NNP N
Although IN N
children NNS N
in IN N
the DT N
WM NNP N
condition NN N
tended VBD N
to TO N
improve VB N
more RBR N
in IN N
WM NNP 1_o
and CC 1_o
ADHD-behavior NNP 1_o
, , N
the DT N
lack NN N
of IN N
differential JJ N
improvement NN N
on IN N
most JJS N
outcome JJ N
measures NNS N
, , N
the DT N
absence NN N
of IN N
a DT N
clear JJ N
effect NN N
of IN N
the DT N
adaptive JJ N
training NN N
compared VBN N
to TO N
the DT N
mock-training NN N
, , N
and CC N
the DT N
high JJ N
attrition NN N
rate NN N
suggest VBP N
that IN N
the DT N
training NN N
in IN N
its PRP$ N
present JJ N
form NN N
is VBZ N
probably RB N
not RB N
suitable JJ N
for IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Comparison NNP N
of IN N
nicardipine NN 1_i
and CC N
propranolol NN 1_i
in IN N
the DT N
treatment NN N
of IN N
mild NN 1_p
and CC 1_p
moderate JJ 1_p
hypertension NN 1_p
. . 1_p

In IN N
a DT N
double-blind NN N
controlled VBN N
trial NN N
22 CD 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
or CC 1_p
moderate JJ 1_p
essential JJ 1_p
hypertension NN 1_p
were VBD N
treated VBN N
with IN N
nicardipine JJ 1_i
30 CD N
mg NN N
t.d.s NN N
. . N

and CC N
19 CD N
patients NNS N
with IN N
propranolol JJ 1_i
80 CD N
mg NN N
t.d.s NN N
. . N

as IN N
monotherapy NN N
for IN N
24 CD N
weeks NNS N
. . N

Blood NNP 1_o
pressure NN 1_o
in IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
trial NN N
was VBD N
equally RB N
and CC N
significantly RB N
reduced VBN N
; : N
systolic JJ N
pressure NN N
22.2 CD N
mmHg NN N
and CC N
diastolic JJ N
pressure NN N
15.5 CD N
mmHg NN N
in IN N
the DT N
supine JJ N
position NN N
, , N
and CC N
24.4 CD N
mmHg NN N
and CC N
18.4 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
standing VBG N
position NN N
in IN N
those DT N
on IN N
nicardipine NN 1_i
, , N
and CC N
by IN N
23.7 CD N
and CC N
16.2 CD N
mmHg NN N
and CC N
28.0 CD N
and CC N
19.2 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
propranolol NN 1_i
group NN N
. . N

There EX N
was VBD N
an DT N
initial JJ N
increase NN N
in IN N
heart NN 1_o
rate NN 1_o
in IN N
the DT N
nicardipine NN 1_i
group NN N
, , N
but CC N
the DT N
rise NN N
was VBD N
only RB N
moderate JJ N
( ( N
3 CD N
beats/min NN N
supine NN N
p NN N
= VBD N
0.3219 CD N
, , N
and CC N
7 CD N
beats/min NN N
standing NN N
, , N
p VBP N
= RB N
0.0203 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
24 CD N
weeks NNS N
. . N

In IN N
the DT N
propranolol NN 1_i
group NN N
heart NN 1_o
rate NN 1_o
was VBD N
reduced VBN N
markedly RB N
. . N

Adverse JJ 1_o
effects NNS 1_o
occurred VBD N
in IN N
77 CD N
% NN N
of IN N
patients NNS N
on IN N
nicardipine NN 1_i
and CC N
in IN N
63 CD N
% NN N
of IN N
those DT N
on IN N
propranolol NN 1_i
, , N
and CC N
there EX N
were VBD N
no DT N
unexpected JJ N
findings NNS N
. . N

The DT N
effects NNS N
were VBD N
mild VBN N
in IN N
both DT N
groups NNS N
and CC N
did VBD N
not RB N
lead VB N
any DT N
patient NN N
to TO N
stop VB N
medication NN N
. . N

One CD N
patient NN N
on IN N
propranolol NN 1_i
was VBD N
withdrawn VBN N
from IN N
the DT N
trial NN N
because IN N
of IN N
poor JJ N
blood NN 1_o
pressure NN 1_o
control NN 1_o
and CC 1_o
suspected VBD 1_o
angina NNS 1_o
pectoris VBP 1_o
after IN N
5 CD N
weeks NNS N
on IN N
active JJ N
medication NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
blood NN 1_o
chemistry NN 1_o
, , 1_o
including VBG 1_o
lipoprotein NN 1_o
classes NNS 1_o
. . 1_o

Overall JJ N
, , N
in IN N
comparison NN N
with IN N
propranolol NN 1_i
, , N
nicardipine NN N
was VBD N
effective JJ N
, , N
well-tolerated JJ N
and CC N
safe JJ N
to TO N
use VB N
in IN N
the DT N
monotherapy NN N
of IN N
mild NN N
or CC N
moderate JJ N
essential JJ N
hypertension NN N
. . N

Treatment NN 1_o
of IN 1_o
gastrointestinal JJ 1_o
cancer NN 1_o
: : 1_o
the DT N
Southeastern NNP 1_p
Cancer NNP 1_p
Study NNP 1_p
Group NNP 1_p
experience NN 1_p
, , 1_p
1979 CD 1_p
to TO 1_p
1983 CD 1_p
. . 1_p

The DT N
treatment NN N
of IN N
gastrointestinal JJ 1_o
cancer NN 1_o
was VBD N
studied VBN N
in IN N
20 CD N
phase NN N
I PRP N
, , N
II NNP N
, , N
and CC N
III NNP N
clinical JJ N
trials NNS N
from IN 1_p
1979 CD 1_p
to TO 1_p
1983 CD 1_p
at IN 1_p
30 CD 1_p
member NN 1_p
institutions NNS 1_p
of IN 1_p
the DT 1_p
Southeastern NNP 1_p
Cancer NNP 1_p
Study NNP 1_p
Group NNP 1_p
( ( 1_p
SECSG NNP 1_p
) ) 1_p
. . 1_p

These DT N
studies NNS N
used VBD N
both DT N
new JJ 1_i
and CC 1_i
commercially RB 1_i
available JJ 1_i
drugs NNS 1_i
, , N
as RB N
well RB N
as IN N
surgery NN 1_i
and/or NN 1_i
radiation NN 1_i
therapy NN 1_i
in IN N
1,087 CD 1_p
patients NNS 1_p
. . 1_p

No DT N
significant JJ N
benefit NN N
was VBD N
seen VBN N
from IN N
18 CD 1_i
agents NNS 1_i
, , N
and CC N
one CD N
agent NN N
is VBZ N
still RB N
under IN N
evaluation NN N
. . N

Unfortunately RB N
, , N
no DT N
recommendations NNS N
can MD N
be VB N
drawn VBN N
from IN N
these DT N
studies NNS N
that WDT N
would MD N
alter VB N
presently RB N
accepted VBN N
methods NNS N
of IN N
management NN N
. . N

Adenocarcinoma NNP N
of IN N
the DT N
gastrointestinal JJ N
tract NN N
remains VBZ N
a DT N
major JJ N
challenge NN N
to TO N
tumor VB N
biologists NNS N
and CC N
clinical JJ N
oncologists NNS N
because IN N
it PRP N
is VBZ N
generally RB N
resistant JJ N
to TO N
chemotherapy VB 1_i
and CC N
radiation NN 1_i
therapy NN 1_i
, , N
yet RB N
common JJ N
enough RB N
to TO N
represent VB N
a DT N
vital JJ N
public JJ N
health NN N
concern NN N
in IN N
America NNP 1_p
. . 1_p

Pulse NNP N
oximeter NN N
perfusion NN N
index NN N
as IN N
an DT N
early JJ N
indicator NN N
of IN N
sympathectomy NN N
after IN N
epidural JJ N
anesthesia NN N
. . N

BACKGROUND IN N
The DT N
pulse JJ N
oximeter NN N
perfusion NN N
index NN N
( ( N
PI NNP N
) ) N
has VBZ N
been VBN N
used VBN N
to TO N
indicate VB N
sympathectomy-induced JJ N
vasodilatation NN N
. . N

We PRP N
hypothesized VBD N
that IN N
pulse JJ N
oximeter NN N
PI NNP N
provides VBZ N
an DT N
earlier JJR N
and CC N
clearer JJR N
indication NN N
of IN N
sympathectomy NN N
following VBG N
epidural JJ N
anesthesia NNS N
than IN N
skin JJ N
temperature NN N
and CC N
arterial JJ N
pressure NN N
. . N

METHODS NNP N
Forty NNP 1_p
patients NNS 1_p
received VBD 1_i
lumbar JJ 1_i
epidural JJ 1_i
catheters NNS 1_i
. . 1_i

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB 1_i
either RB 1_i
10 CD 1_i
ml VBD 1_i
0.5 CD 1_i
% NN 1_i
bupivacaine NN 1_i
or CC 1_i
10 CD 1_i
ml JJ 1_i
0.25 CD 1_i
% NN 1_i
bupivacaine NN 1_i
. . 1_i

PI NNP 1_o
in IN 1_o
the DT 1_o
toe NN 1_o
, , 1_o
mean JJ 1_o
arterial JJ 1_o
pressure NN 1_o
( ( 1_o
MAP NNP 1_o
) ) 1_o
and CC 1_o
toe JJ 1_o
temperature NN 1_o
were VBD 1_i
all DT 1_i
assessed VBN 1_i
at IN 1_i
baseline NN 1_i
and CC 1_i
at IN 1_i
5 CD 1_i
, , 1_i
10 CD 1_i
and CC 1_i
20 CD 1_i
min NN 1_i
following VBG 1_i
epidural JJ 1_i
anesthesia NN 1_i
. . 1_i

The DT N
effect NN 1_o
of IN N
epidural JJ 1_i
anesthesia NN 1_i
over IN N
time NN N
was VBD N
assessed VBN N
by IN N
repeated JJ N
measures NNS 1_o
analysis NN 1_o
of IN 1_o
variance NN 1_o
. . 1_o

Additionally RB N
, , N
we PRP N
defined VBD N
clinically RB 1_o
evident JJ 1_o
sympathectomy NN 1_o
criteria NNS 1_o
( ( 1_o
a DT 1_o
100 CD 1_o
% NN 1_o
increase NN 1_o
in IN 1_o
the DT 1_o
PI NNP 1_o
, , 1_o
a DT 1_o
15 CD 1_o
% NN 1_o
decrease NN 1_o
in IN 1_o
MAP NNP 1_o
and CC 1_o
a DT 1_o
1 CD 1_o
degrees NNS 1_o
C NNP 1_o
increase NN 1_o
in IN 1_o
toe JJ 1_o
temperature NN 1_o
) ) 1_o
. . 1_o

The DT N
numbers NNS N
of IN N
patients NNS N
demonstrating VBG N
these DT N
changes NNS 1_o
for IN N
each DT N
test NN N
were VBD N
compared VBN N
using VBG N
the DT N
McNemar NNP 1_o
test NN 1_o
for IN N
each DT N
time NN N
point NN N
. . N

RESULTS NNP N
Twenty-nine JJ 1_p
subjects NNS 1_p
had VBD N
photoplethysmography NN 1_o
signals NNS 1_o
that WDT N
met VBD N
a DT N
priori JJ N
signal NN N
quality NN N
criteria NNS N
for IN N
analysis NN N
. . N

By IN N
20 CD N
min NNS N
, , N
PI NNP 1_o
increased VBN N
by IN N
326 CD N
% NN N
, , N
compared VBN N
with IN N
a DT N
10 CD N
% NN N
decrease NN N
and CC N
a DT N
3 CD N
% NN N
increase NN N
in IN N
MAP NNP 1_o
and CC 1_o
toe JJ 1_o
temperature NN 1_o
, , N
respectively RB N
. . N

For IN N
PI NNP N
15/29 CD N
, , N
26/29 CD N
and CC N
29/29 CD N
of IN N
the DT N
subjects NNS N
met VBD N
the DT N
sympathectomy NN 1_o
criteria NNS 1_o
at IN N
5 CD N
, , N
10 CD N
and CC N
20 CD N
min NN N
, , N
respectively RB N
, , N
compared VBN N
with IN N
4/29 CD N
, , N
6/29 CD N
and CC N
18/29 CD N
for IN N
MAP NNP 1_o
changes NNS N
and CC N
3/29 CD N
, , N
8/29 CD N
and CC N
14/29 CD N
for IN N
toe NN N
temperature NN 1_o
changes NNS 1_o
. . 1_o

CONCLUSIONS NNP N
PI NNP N
was VBD N
an DT N
earlier JJR N
, , N
clearer JJR N
and CC N
more RBR N
sensitive JJ N
indicator NN N
of IN N
the DT N
development NN N
of IN N
epidural-induced JJ N
sympathectomy NN N
than IN N
either DT N
skin JJ 1_o
temperature NN 1_o
or CC N
MAP NNP 1_o
. . 1_o

Parietal NNP 1_o
cell NN 1_o
density NN 1_o
in IN N
duodenal JJ 1_p
ulcer NN 1_p
patients NNS 1_p
after IN 1_p
short-term JJ 1_p
treatment NN 1_p
with IN 1_p
cimetidine NN 1_i
and CC 1_i
antacids NNS 1_i
. . 1_i

In IN N
a DT N
prospective JJ N
study NN N
, , N
20 CD 1_p
patients NNS 1_p
with IN 1_p
endoscopically RB 1_p
proven JJ 1_p
duodenal JJ 1_p
ulcers NNS 1_p
were VBD N
randomised VBN N
to TO N
be VB N
treated VBN N
with IN N
cimetidine NN 1_i
1 CD 1_i
g JJ 1_i
daily JJ 1_i
or CC 1_i
with IN 1_i
antacids NNS 1_i
350 CD 1_i
mmol JJ 1_i
daily RB 1_i
. . 1_i

The DT N
duration NN N
of IN N
treatment NN N
was VBD N
30 CD N
days NNS N
, , N
but CC N
this DT N
was VBD N
extended VBN N
to TO N
three CD N
months NNS N
in IN N
3 CD N
patients NNS N
in IN N
the DT N
cimetidine NN 1_i
group NN N
and CC N
4 CD N
patients NNS N
in IN N
the DT N
antacid NN 1_i
group NN N
. . N

A DT N
morphological JJ N
study NN N
of IN N
biopsies NNS N
taken VBN N
via IN N
a DT N
gastroscope NN N
from IN N
the DT N
corpus NN N
mucosa NN N
showed VBD N
no DT N
change NN N
in IN N
mucosal NN 1_o
height NN 1_o
, , 1_o
parietal JJ 1_o
cell NN 1_o
density NN 1_o
per IN 1_o
unit NN 1_o
volume NN 1_o
or CC 1_o
changes NNS 1_o
in IN 1_o
cellular JJ 1_o
infiltration NN 1_o
after IN N
30 CD N
and CC N
90 CD N
days NNS N
treatment NN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Neither CC N
H-2 JJ 1_i
receptor NN 1_i
blockers NNS 1_i
nor CC N
antacids NNS 1_i
alter NN N
mucosal NN 1_o
height VBD 1_o
or CC 1_o
parietal JJ 1_o
cell NN 1_o
density NN 1_o
. . 1_o

Treatment NNP N
was VBD N
not RB N
found VBN N
to TO N
induce VB N
gastritic JJ 1_o
changes NNS 1_o
in IN N
the DT N
mucosa NN N
. . N

[ IN N
The DT N
value NN N
of IN N
local JJ 1_i
administration NN 1_i
of IN 1_i
antibiotics NNS 1_i
in IN N
treatment NN 1_p
of IN 1_p
bone NN 1_p
infections NNS 1_p
] NNP 1_p
. . N

An DT N
open JJ N
, , N
controlled VBN N
, , N
randomized VBN N
clinical JJ N
investigation NN N
was VBD N
carried VBN N
out RP N
in IN N
33 CD 1_p
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
osteomyelitis NN 1_p
. . 1_p

In IN N
the DT N
first JJ N
group NN N
, , N
17 CD 1_p
patients NNS 1_p
, , 1_p
a DT 1_p
through IN 1_p
drainage NN 1_p
with IN 1_p
sterile JJ 1_i
physiologic JJ 1_i
solution NN 1_i
was VBD 1_p
applied VBN 1_p
, , 1_p
while IN 1_p
in IN 1_p
the DT 1_p
second JJ 1_p
group NN 1_p
, , 1_p
16 CD 1_p
patients NNS 1_p
, , 1_p
antibiotic JJ 1_i
was VBD 1_i
added VBN 1_i
to TO 1_i
the DT 1_i
sterile JJ 1_i
physiologic JJ 1_i
solution NN 1_i
. . 1_i

In IN N
all DT N
patients NNS N
values NNS N
of IN N
C NNP N
reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
in IN N
the DT N
blood NN N
were VBD N
examined VBN N
, , N
and CC N
later RB N
on IN N
every DT N
third JJ N
day NN N
after IN N
the DT N
operation NN N
. . N

A DT 1_o
significant JJ 1_o
difference NN 1_o
of IN 1_o
average JJ 1_o
values NNS 1_o
of IN 1_o
CRP NNP 1_o
between IN 1_o
the DT 1_o
3rd CD 1_o
and CC 1_o
21st CD 1_o
day NN 1_o
in IN 1_o
both DT 1_o
groups NNS 1_o
of IN 1_o
patients NNS 1_o
was VBD 1_o
established VBN 1_o
, , N
as RB N
well RB N
as IN N
the DT N
similarity NN 1_o
in IN 1_o
average JJ 1_o
values NNS 1_o
of IN 1_o
CRP NNP 1_o
, , N
which WDT N
points VBZ N
to TO N
the DT N
fact NN N
that IN N
the DT N
mechanical JJ N
effect NN N
of IN N
through IN N
drainage NN N
is VBZ N
dominant JJ N
, , N
speaking VBG N
about IN N
rinsing VBG N
focus NN N
of IN N
infection NN 1_o
and CC N
eliminating VBG N
necrotic JJ N
tissues NNS N
and CC N
small JJ N
sequesters NNS N
. . N

Pars NNS 1_i
plana VBP 1_i
vitrectomy NN 1_i
for IN N
diabetic JJ N
macular JJ N
edema NN N
. . N

Internal NNP 1_i
limiting VBG 1_i
membrane NN 1_i
delamination NN 1_i
vs FW N
posterior JJ 1_i
hyaloid NN 1_i
removal NN 1_i
. . 1_i

A DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Diabetes VBZ N
mellitus RB N
, , N
as RB N
well RB N
as IN N
subsequent JJ N
ocular JJ N
complications NNS N
such JJ N
as IN N
cystoid JJ N
macular JJ N
edema NN N
( ( N
CME NNP N
) ) N
, , N
are VBP N
of IN N
fundametal JJ N
socio-economic JJ N
relevance NN N
. . N

Therefore RB N
, , N
we PRP N
evaluated VBD N
the DT N
influence NN N
of IN N
internal JJ 1_i
limiting VBG 1_i
membrane NN 1_i
( ( 1_i
ILM NNP 1_i
) ) 1_i
removal NN 1_i
on IN N
longterm JJ N
morphological JJ N
and CC N
functional JJ N
outcome NN N
in IN N
patients NNS 1_p
with IN 1_p
diabetes NNS 1_p
mellitus NNS 1_p
( ( 1_p
DM NNP 1_p
) ) 1_p
type NN 1_p
2 CD 1_p
and CC 1_p
chronic JJ 1_p
CME NNP 1_p
without IN 1_p
evident JJ 1_p
vitreomacular JJ 1_p
traction NN 1_p
. . 1_p

METHOD NNP N
Forty NNP 1_p
eyes NNS 1_p
with IN 1_p
attached JJ 1_p
posterior JJ 1_p
hyaloid NN 1_p
were VBD N
included VBN N
in IN N
this DT N
prospective JJ N
trial NN N
and CC N
randomized VBN N
intraoperatively RB N
. . N

Prior NNP N
focal JJ N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
panretinal JJ N
( ( 1_i
n JJ 1_i
= NNP 1_i
25 CD 1_i
) ) 1_i
laser JJR 1_i
coagulation NN 1_i
was VBD N
permitted VBN N
. . N

Group NNP N
I PRP N
( ( N
n JJ N
= $ N
19 CD N
patients NNS 1_i
) ) 1_i
underwent JJ 1_i
surgical JJ 1_i
induction NN 1_i
of IN 1_i
posterior JJ 1_i
vitreous JJ 1_i
detachment NN 1_i
( ( N
PVD NNP N
) ) N
, , N
group NN N
II NNP N
( ( 1_i
n JJ 1_i
= $ 1_i
20 CD 1_i
patients NNS 1_i
) ) 1_i
PVD NNP 1_i
and CC 1_i
removal NN 1_i
of IN N
the DT N
ILM NNP N
. . N

Eleven NNP N
patients NNS N
with IN N
detached JJ N
posterior JJ N
hyaloid NN N
( ( N
group NN N
III NNP N
) ) N
were VBD N
not RB N
randomized VBN 1_i
, , N
and CC N
ILM NNP N
removal NN N
was VBD N
performed VBN N
. . N

One CD N
eye NN N
had VBD N
to TO N
be VB N
excluded VBN N
from IN N
further JJ N
analysis NN N
. . N

Examinations NNS 1_o
included VBD 1_o
ETDRS NNP 1_o
best-corrected JJ 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
BCVA NNP 1_o
) ) 1_o
, , 1_o
fluorescein JJ 1_o
angiography NN 1_o
( ( N
FLA NNP N
) ) N
and CC N
OCT NNP N
at IN N
baseline NN N
, , N
3 CD N
and CC N
6 CD N
months NNS N
postoperatively RB N
. . N

Main NNP N
outcome JJ 1_o
measure NN N
was VBD N
BCVA NNP N
at IN N
6 CD 1_o
months NNS 1_o
, , 1_o
secondary JJ 1_o
was VBD 1_o
foveal JJ N
thickness NN 1_o
. . 1_o

RESULTS NNP N
Mean NNP N
BCVA NNP N
over IN N
6 CD N
months NNS N
remained VBD N
unchanged JJ N
in IN N
85 CD N
% NN N
of IN N
patients NNS N
of IN N
group NN N
II NNP N
, , N
and CC N
decreased VBD N
in IN N
53 CD N
% NN N
of IN N
patients NNS N
of IN N
group NN N
I PRP N
. . N

Results NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
different JJ N
[ NNP N
group NN N
I PRP N
: : N
mean JJ N
decrease NN N
log NN N
MAR NNP N
95 CD N
% NN N
CI NNP N
( ( N
0.06 CD N
; : N
0.32 CD N
) ) N
, , N
group NN N
II NNP N
: : N
( ( N
-0.02 VBP N
; : N
0.11 CD N
) ) N
] NN N
. . N

OCT NNP N
revealed VBD N
a DT N
significantly RB N
greater JJR 1_o
reduction NN 1_o
of IN 1_o
foveal JJ N
thickness NN N
following VBG N
PVD NNP N
with IN N
ILM NNP N
removal NN N
[ NNP N
group NN N
I PRP N
: : N
mean JJ N
change NN N
: : N
95 CD N
% NN N
CI NNP N
( ( N
-208.95 NNP N
μm NNP N
; : N
-78.05 NNP N
μm NNP N
) ) N
, , N
group NN N
II NNP N
: : N
( ( 1_i
-80.90 JJ 1_i
μm NN 1_i
: : 1_i
+59.17 JJ 1_i
μm NN 1_i
) ) 1_i
] NN 1_i
. . 1_i

CONCLUSION NNP 1_i
Vitrectomy NNP 1_i
, , 1_i
PVD NNP 1_i
with IN 1_i
or CC N
without IN N
ILM NNP N
removal NN N
does VBZ 1_p
not RB 1_p
improve VB 1_p
vision NN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
DM NNP 1_p
type NN 1_p
2 CD 1_p
and CC 1_p
cystoid JJ 1_p
diabetic JJ 1_p
macular NN 1_p
edema NN 1_p
without IN 1_p
evident JJ 1_p
vitreoretinal JJ N
traction NN N
. . N

ILM NNP N
delamination NN N
shows VBZ N
improved JJ N
morphological JJ N
results NNS N
, , N
and CC N
appears VBZ 1_p
to TO 1_p
be VB 1_p
beneficial JJ 1_p
in IN 1_p
eyes NNS N
with IN N
preexisting VBG N
PVD NNP N
. . N

Everolimus NNP 1_i
for IN N
subependymal JJ N
giant NN N
cell NN N
astrocytoma NN N
in IN N
patients NNS 1_p
with IN 1_p
tuberous JJ 1_p
sclerosis NN 1_p
complex NN 1_p
: : 1_p
2-year JJ N
open-label JJ N
extension NN N
of IN N
the DT N
randomised JJ N
EXIST-1 NNP N
study NN N
. . N

BACKGROUND NNP N
In IN N
the DT N
EXIST-1 NNP N
trial NN N
, , N
initiated VBN N
on IN N
Aug NNP N
10 CD N
, , N
2009 CD N
, , N
more JJR N
than IN N
35 CD N
% NN N
of IN N
patients NNS 1_p
with IN 1_p
subependymal JJ 1_p
giant NN 1_p
cell NN 1_p
astrocytoma NN 1_p
( ( 1_p
SEGA NNP 1_p
) ) 1_p
associated VBN 1_p
with IN 1_p
tuberous JJ 1_p
sclerosis NN 1_p
complex NN 1_p
had VBD N
at IN N
least JJS N
50 CD N
% NN N
reduction NN N
in IN N
SEGA NNP N
volume NN N
after IN N
9·6 CD N
months NNS N
of IN N
treatment NN N
with IN N
everolimus NN N
. . N

In IN N
this DT N
Article NNP N
, , N
we PRP N
report VBP N
interim JJ N
data NNS 1_p
( ( 1_p
up IN 1_p
to TO 1_p
Jan NNP 1_p
11 CD 1_p
, , 1_p
2013 CD 1_p
) ) 1_p
to TO N
support VB N
longer-term JJ N
tolerability NN N
and CC N
efficacy NN N
of IN 1_i
everolimus NN 1_i
from IN N
the DT N
continuing VBG N
4-year JJ N
extension NN N
phase NN N
of IN N
EXIST-1 NNP N
. . N

METHODS NNP N
We PRP N
assessed VBD N
data NNS N
from IN N
a DT N
prospective JJ N
, , N
open-label JJ N
extension NN N
of IN N
a DT N
multicentre NN N
, , N
phase NN N
3 CD N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
in IN 1_p
patients NNS 1_p
with IN 1_p
tuberous JJ 1_p
sclerosis NN 1_p
complex NN 1_p
who WP 1_p
had VBD 1_p
SEGA NNP 1_p
that WDT 1_p
was VBD 1_p
growing VBG 1_p
and CC 1_p
needed VBN 1_p
treatment NN 1_p
. . N

In IN N
this DT N
extension NN N
study NN N
, , N
we PRP N
included VBD 1_p
all DT 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
been VBN 1_p
assigned VBN 1_i
everolimus RBR 1_i
during IN 1_p
the DT 1_p
double-blind NN 1_p
, , 1_p
randomised VBD 1_p
phase NN 1_p
of IN 1_p
the DT 1_p
trial NN 1_p
and CC 1_p
those DT 1_p
patients NNS 1_p
who WP 1_p
crossed VBD 1_p
over IN 1_p
from IN 1_p
the DT 1_i
placebo NN 1_i
group NN 1_p
to TO 1_p
receive VB 1_i
everolimus NN 1_i
during IN 1_p
the DT 1_p
randomised JJ 1_p
phase NN 1_p
or CC 1_p
at IN 1_p
the DT 1_p
start NN 1_p
of IN 1_p
the DT 1_p
extension NN 1_p
phase NN 1_p
. . N

All DT N
patients NNS N
received VBD N
oral JJ 1_i
everolimus NN 1_i
at IN N
a DT N
starting VBG N
dose NN N
of IN N
4·5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
per IN N
day NN 1_i
. . 1_i

Everolimus NNP 1_i
dose NN N
was VBD N
subsequently RB N
adjusted VBN N
subject NN N
to TO N
tolerability NN N
to TO N
attain VB 1_o
blood NN 1_o
trough IN 1_o
concentrations NNS 1_o
of IN N
5-15 JJ N
ng/mL NN N
. . N

An DT N
independent JJ N
central JJ N
radiology NN N
review NN N
team NN N
assessed VBD N
SEGA NNP N
response NN N
( ( N
at IN N
least JJS N
a DT N
50 CD N
% NN N
reduction NN N
from IN N
baseline NN N
in IN N
total JJ N
volume NN N
of IN N
all DT N
target NN N
SEGAs NNP N
; : N
the DT N
primary JJ N
endpoint NN N
) ) N
by IN N
MRI NNP N
at IN N
12 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
weeks NNS N
, , N
then RB N
every DT N
year NN N
thereafter RB N
in IN N
all DT N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
everolimus NN N
. . N

This DT N
study NN N
was VBD N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00789828 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT 1_p
original JJ 1_p
117 CD 1_p
randomly RB 1_p
assigned VBN 1_p
patients NNS 1_p
, , 1_p
111 CD 1_p
were VBD 1_p
given VBN 1_p
everolimus NNS 1_p
between IN 1_p
Aug NNP 1_p
20 CD 1_p
, , 1_p
2009 CD 1_p
, , 1_p
and CC 1_p
Jan NNP 1_p
11 CD 1_p
, , 1_p
2013 CD 1_p
( ( N
date NN N
of IN N
data NNS N
cutoff NN N
) ) N
; : N
we PRP N
included VBD N
these DT N
patients NNS N
in IN N
our PRP$ N
longer-term JJ N
analysis NN N
. . N

Median JJ N
duration NN N
of IN N
everolimus NN N
exposure NN N
was VBD N
29·3 CD N
months NNS N
( ( N
IQR NNP N
19·4-33·8 CD N
) ) N
. . N

Median JJ N
follow-up NN N
was VBD N
28·3 CD N
months NNS N
( ( N
IQR NNP N
19·3-33·0 CD N
) ) N
. . N

54 CD N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
had VBD N
a DT N
response NN N
of IN N
50 CD N
% NN N
or CC N
greater JJR N
reduction NN 1_o
in IN 1_o
SEGA NNP 1_o
volume NN N
( ( N
95 CD N
% NN N
CI NNP N
39·0-58·3 CD 1_o
) ) 1_o
, , 1_o
and CC 1_o
duration NN 1_o
of IN 1_o
response NN N
was VBD N
between IN N
2·1 CD N
and CC N
31·1 CD N
months NNS N
( ( N
median JJ N
not RB 1_o
reached VBN 1_o
) ) 1_o
. . 1_o

SEGA JJ N
volume NN N
was VBD N
reduced VBN N
by IN N
50 CD N
% NN N
or CC N
more JJR N
in IN N
39 CD N
( ( N
37 CD N
% NN N
) ) N
of IN N
105 CD N
patients NNS N
at IN N
24 CD N
weeks NNS N
, , N
48 CD N
( ( N
46 CD N
% NN N
) ) N
of IN N
104 CD N
patients NNS N
at IN N
48 CD N
weeks NNS N
, , N
36 CD N
( ( N
47 CD N
% NN N
) ) N
of IN N
76 CD N
patients NNS N
at IN N
96 CD N
weeks NNS N
, , N
and CC N
11 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
29 CD N
patients NNS N
at IN 1_o
144 CD 1_o
weeks NNS 1_o
. . 1_o

Stomatitis NNP N
( ( N
48 CD N
[ RB N
43 CD N
% NN N
] JJ N
patients NNS 1_o
) ) 1_o
and CC 1_o
mouth JJ 1_o
ulceration NN N
( ( N
33 CD N
[ RB N
30 CD N
% NN N
] JJ N
patients NNS N
) ) N
were VBD N
the DT N
most RBS N
frequent JJ N
treatment-related JJ N
adverse JJ 1_o
events NNS 1_o
; : 1_o
infections NNS N
were VBD N
the DT N
most RBS N
commonly RB N
reported VBD N
treatment-related JJ N
serious JJ N
adverse JJ N
event NN N
, , N
occurring VBG N
in IN N
15 CD N
( ( N
14 CD N
% NN N
) ) N
patients NNS N
. . N

35 CD N
( ( N
32 CD N
% NN N
) ) N
patients NNS N
reported VBD N
treatment-related JJ N
grade NN 1_o
3 CD 1_o
or CC 1_o
4 CD 1_o
adverse JJ 1_o
events NNS N
, , N
the DT N
most RBS N
common JJ N
of IN 1_o
which WDT 1_o
were VBD 1_o
stomatitis NN N
( ( 1_o
nine CD 1_o
[ RB 1_o
8 CD 1_o
% NN 1_o
] NN 1_o
) ) 1_o
and CC 1_o
pneumonia NN N
( ( N
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
. . N

18 CD N
( ( N
16 CD N
% NN N
) ) N
patients NNS 1_o
had VBD 1_o
treatment-related JJ 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS N
. . N

Six NNP N
( ( N
5 CD N
% NN N
) ) N
patients NNS N
withdrew VBD 1_o
because IN 1_o
of IN 1_o
adverse JJ 1_o
events NNS N
. . N

INTERPRETATION NNP N
These DT N
results NNS N
support VBD N
the DT N
longer-term JJ N
use NN N
of IN N
everolimus NN 1_p
in IN 1_p
patients NNS 1_p
who WP 1_p
have VBP 1_p
few JJ 1_p
treatment NN 1_p
options NNS 1_p
and CC 1_p
who WP 1_p
need VBP 1_p
continued VBN 1_p
treatment NN 1_p
for IN 1_p
tuberous JJ 1_p
sclerosis NN 1_p
complex NN N
and CC N
its PRP$ N
varied JJ N
manifestations NNS 1_o
. . 1_o

Reduction NN 1_o
or CC 1_o
stabilisation NN 1_o
of IN 1_o
tumour JJ 1_o
volume NN 1_i
with IN 1_i
everolimus NN N
will MD N
hopefully RB N
provide VB N
long-term JJ N
clinical JJ N
benefit NN N
in IN N
patients NNS N
with IN N
SEGA NNP N
. . N

FUNDING NN N
Novartis NN N
Pharmaceuticals NNP N
. . N

Estradiol NNP 1_i
and CC 1_i
the DT 1_i
addition NN 1_i
of IN 1_i
progesterone NN 1_i
increase NN N
the DT N
sensitivity NN N
to TO N
a DT N
neurosteroid NN N
in IN N
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacodynamic JJ N
response NN N
to TO N
a DT N
neuroactive JJ 1_i
steroid NN 1_i
, , 1_i
pregnanolone NN 1_i
, , N
before IN N
and CC N
during IN N
different JJ N
hormonal JJ N
settings NNS N
of IN N
postmenopausal NN 1_i
hormone NN 1_i
replacement NN 1_i
therapy NN 1_i
( ( 1_i
HRT NNP 1_i
) ) 1_i
, , N
using VBG N
natural JJ 1_i
progesterone NN 1_i
. . 1_i

A DT N
second JJ N
aim NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
response NN N
to TO N
pregnanolone NN 1_i
was VBD N
associated VBN N
with IN N
cyclicity NN N
in IN N
negative JJ 1_o
mood NN 1_o
symptoms NNS 1_o
during IN N
treatment NN N
. . N

Twenty NNP 1_p
six CD 1_p
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
climacteric JJ 1_p
symptoms NNS 1_p
were VBD 1_p
administered VBN N
HRT NNP 1_i
in IN N
a DT N
randomized JJ N
, , N
double JJ N
blinded VBN N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

The DT N
women NNS N
received VBD N
2 CD N
mg JJ N
oral JJ 1_i
estradiol NN 1_i
( ( 1_i
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
) ) 1_i
continuously RB N
during IN N
two CD N
28-day JJ N
cycles NNS N
and CC N
800 CD N
mg NN N
of IN N
vaginal JJ 1_i
progesterone NN 1_i
or CC 1_i
placebo NN 1_i
sequentially RB N
for IN N
the DT N
last JJ N
14 CD N
days NNS N
of IN N
each DT N
treatment NN N
cycle NN N
. . N

Pharmacodynamic NNP 1_o
response NN 1_o
to TO N
pregnanolone NN 1_i
was VBD N
assessed VBN N
before IN N
treatment NN N
, , N
and CC N
during IN N
the DT N
last JJ N
week NN N
of IN N
each DT N
treatment NN N
cycle NN N
, , N
by IN N
comparing VBG N
the DT N
effects NNS N
of IN N
intravenous JJ N
pregnanolone NN 1_i
( ( 1_i
3alpha-hydroxy-5beta-pregnan-20-one CD 1_i
) ) 1_i
on IN N
saccadic JJ 1_o
eye NN 1_o
velocity NN 1_o
( ( 1_o
SEV NNP 1_o
) ) 1_o
, , 1_o
saccade JJ 1_o
acceleration NN 1_o
, , 1_o
saccade JJ 1_o
latency NN 1_o
and CC 1_o
self-rated JJ 1_o
sedation NN 1_o
. . 1_o

Throughout IN N
the DT N
study NN N
daily JJ 1_o
symptom NN 1_o
rating NN 1_o
scales NNS 1_o
were VBD N
kept VBN N
. . N

According VBG N
to TO N
the DT N
daily JJ 1_o
symptom NN 1_o
rating NN 1_o
scales NNS 1_o
, , N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD 1_p
groups NNS 1_p
; : 1_p
one CD 1_p
group NN 1_p
who WP 1_p
displayed VBD 1_p
a DT 1_p
significant JJ 1_p
variance NN 1_p
in IN 1_p
negative JJ 1_o
mood NN 1_o
symptoms NNS 1_o
during IN 1_p
HRT NNP 1_i
( ( 1_p
cyclicity NN 1_p
) ) 1_p
and CC 1_p
one CD 1_p
group NN 1_p
with IN 1_p
no DT 1_p
cyclical JJ 1_p
changes NNS 1_p
in IN 1_p
negative JJ 1_o
mood NN 1_o
symptoms NNS 1_o
during IN 1_p
treatment NN 1_p
. . 1_p

During IN N
treatment NN N
with IN N
either DT N
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
alone RB 1_i
or CC 1_i
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
+progesterone CD 1_i
the DT N
response NN N
in IN N
saccadic JJ 1_o
eye NN 1_o
movement NN 1_o
parameters NNS 1_o
and CC N
in IN N
self-rated JJ 1_o
sedation NN 1_o
to TO N
pregnanolone NN N
was VBD N
enhanced VBN N
compared VBN N
to TO N
pretreatment VB N
values NNS N
. . N

The DT N
SEV NNP N
, , N
saccade JJ 1_o
acceleration NN 1_o
and CC 1_o
sedation NN 1_o
responses NNS 1_o
to TO N
pregnanolone NN 1_i
was VBD N
also RB N
increased VBN N
in IN N
women NNS N
expressing VBG N
cyclicity NN N
in IN N
negative JJ 1_o
mood NN 1_o
symptoms NNS 1_o
compared VBN N
to TO N
women NNS N
with IN N
no DT N
cyclical JJ N
changes NNS N
in IN N
negative JJ N
mood NN N
during IN N
HRT NNP 1_i
. . 1_i

In IN N
conclusion NN N
, , N
during IN N
treatment NN N
with IN N
either DT N
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
alone RB 1_i
, , 1_i
or CC 1_i
E NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
+progesterone NN 1_i
, , 1_i
pregnanolone NN 1_o
sensitivity NN 1_o
was VBD N
increased VBN N
. . N

Women NNP 1_p
expressing VBG 1_p
cyclicity NN 1_p
in IN 1_p
negative JJ 1_p
mood NN 1_p
symptoms NNS 1_p
were VBD N
more RBR N
sensitive JJ N
to TO N
pregnanolone VB 1_i
than IN N
women NNS N
without IN N
symptom JJ N
cyclicity NN N
during IN N
HRT NNP 1_i
. . 1_i

Rifampicin NNP 1_i
plus CC 1_i
isoniazid NN 1_i
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN 1_p
in IN 1_p
an DT 1_p
immigrant JJ 1_p
population NN 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
tolerance NN N
, , N
adherence NN N
and CC N
effectiveness NN N
of IN N
two CD N
approaches NNS N
for IN N
the DT N
treatment NN N
of IN N
latent JJ N
tuberculosis NN N
infection NN N
( ( N
LTBI NNP N
) ) N
: : N
6 CD N
months NNS N
of IN N
isoniazid NN 1_i
( ( 1_i
6H CD 1_i
) ) 1_i
vs. FW N
3 CD N
months NNS N
of IN N
isoniazid JJ 1_i
plus CC 1_i
rifampicin JJ 1_i
( ( 1_i
3RH CD 1_i
) ) 1_i
. . 1_i

POPULATION JJ N
Immigrants NNS 1_p
with IN 1_p
LTBI NNP 1_p
. . 1_p

METHODS NNP N
Participants NNPS N
were VBD N
enrolled VBN N
in IN N
a DT N
controlled VBN N
, , N
randomised VBD N
clinical JJ N
trial NN N
in IN 1_p
Barcelona NNP 1_p
, , 1_p
Spain NNP 1_p
, , 1_p
from IN 1_p
April NNP 1_p
2001 CD 1_p
to TO 1_p
April NNP 1_p
2005 CD 1_p
. . 1_p

Monthly JJ N
follow-up NN N
was VBD N
done VBN N
to TO N
assess VB N
tolerance NN N
, , N
side NN N
effects NNS N
and CC N
adherence NN N
. . N

Effectiveness NNP N
was VBD N
evaluated VBN N
at IN N
5 CD N
years NNS N
. . N

RESULTS NN N
In IN N
the DT N
590 CD 1_p
subjects NNS 1_p
enrolled VBN 1_p
, , N
the DT N
rate NN 1_o
of IN 1_o
adherence NN 1_o
was VBD N
greater JJR N
in IN N
the DT N
3RH CD N
than IN N
in IN N
the DT N
6H CD N
arm NN N
( ( N
72 CD N
% NN N
vs. FW N
52.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
study NN N
arms NNS N
were VBD N
observed VBN N
with IN N
respect NN N
to TO N
hepatotoxicity NN 1_o
or CC 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

Variables NNS N
associated VBN N
with IN N
non-adherence NN N
were VBD N
diagnosis VBN N
by IN N
screening VBG 1_o
( ( N
OR CC N
1.88 CD N
, , N
95 CD N
% NN N
CI NNP N
1.26-2.82 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
illegal JJ 1_o
immigration NN 1_o
status NN 1_o
( ( N
OR CC N
1.48 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01-2.15 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
unemployment NN 1_o
( ( N
OR CC N
1.91 CD N
, , N
95 CD N
% NN N
CI NNP N
1.28-2.85 CD N
, , N
P NNP N
= NNP N
0.0008 CD N
) ) N
, , N
illiteracy NN 1_o
( ( N
OR CC N
1.73 CD N
, , N
95 CD N
% NN N
CI NNP N
1.04-2.88 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
lack NN 1_o
of IN 1_o
family NN 1_o
support NN 1_o
( ( N
OR NNP N
3.7 CD N
, , N
95 CD N
% NN N
CI NNP N
2.54-5.4 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
the DT N
6-month JJ 1_o
treatment NN 1_o
regimen NNS 1_o
( ( N
OR NNP N
2.45 CD N
, , N
95 CD N
% NN N
CI NNP N
1.68-3.57 CD N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
who WP N
completed VBD N
either CC N
treatment NN N
developed VBD N
tuberculosis NN 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
3RH CD 1_i
regimen NNS 1_i
facilitates VBZ N
adherence NN N
to TO N
LTBI NNP N
treatment NN N
and CC N
offers VBZ N
a DT N
safe JJ N
, , N
well-tolerated JJ N
and CC N
effective JJ N
alternative NN N
. . N

Short-term JJ N
effect NN N
of IN N
pitavastatin NN 1_i
on IN N
the DT N
reactive JJ 1_o
hyperemic JJ 1_o
index NN 1_o
in IN N
post-menopausal JJ 1_p
women NNS 1_p
with IN 1_p
high JJ 1_p
levels NNS 1_p
in IN 1_p
serum JJ 1_p
LDL-cholesterol NNP 1_p
. . 1_p

The DT N
REFLO-STEMI NNP N
trial NN N
comparing VBG N
intracoronary JJ 1_i
adenosine NN 1_i
, , 1_i
sodium NN 1_i
nitroprusside RB 1_i
and CC 1_i
standard JJ 1_i
therapy NN 1_i
for IN N
the DT N
attenuation NN N
of IN N
infarct JJ N
size NN N
and CC N
microvascular JJ N
obstruction NN N
during IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Microvascular NNP N
obstruction NN N
( ( N
MVO NNP N
) ) N
secondary JJ N
to TO N
ischaemic-reperfusion JJ N
injury NN N
is VBZ N
an DT N
important JJ N
but CC N
underappreciated JJ N
determinant NN N
of IN N
short- JJ N
and CC N
longer-term JJ N
outcome NN N
following VBG N
percutaneous JJ 1_i
coronary JJ 1_i
intervention NN 1_i
( ( 1_i
PCI NNP 1_i
) ) 1_i
treatment NN N
of IN N
ST-elevation NNP N
myocardial JJ N
infarction NN N
( ( N
STEMI NNP N
) ) N
. . N

Several JJ N
small JJ N
studies NNS N
have VBP N
demonstrated VBN N
a DT N
reduction NN N
in IN N
the DT N
degree NN N
of IN N
MVO NNP 1_o
utilising VBG N
a DT N
variety NN N
of IN N
vasoactive JJ 1_i
agents NNS 1_i
, , 1_i
with IN 1_i
adenosine NN 1_i
and CC 1_i
sodium NN 1_i
nitroprusside NN 1_i
( ( 1_i
SNP NNP 1_i
) ) 1_i
being VBG N
most JJS N
evaluated VBN N
. . N

However RB N
, , N
the DT N
evidence NN N
base NN N
remains VBZ N
weak JJ N
as IN N
the DT N
trials NNS N
have VBP N
had VBN N
variable JJ N
endpoints NNS N
, , N
differing VBG N
drug NN N
doses NNS N
and CC N
delivery NN N
. . N

As IN N
such JJ N
, , N
the DT N
results NNS N
regarding VBG N
benefit NN N
are VBP N
conflicting VBG N
. . N

METHODS NNP N
The DT N
REperfusion NNP N
Facilitated NNP N
by IN N
LOcal NNP 1_i
adjunctive JJ 1_i
therapy NN 1_i
in IN 1_i
STEMI NNP 1_i
( ( 1_i
REFLO-STEMI NNP 1_i
) ) 1_i
trial NN N
is VBZ N
a DT N
multicentre NN N
, , N
prospective JJ N
, , N
randomised VBD N
, , N
controlled VBD N
, , N
open JJ N
label NN N
, , N
study NN N
with IN N
blinded JJ N
endpoint NN N
analysis NN N
: : N
Patients NNS 1_p
presenting VBG 1_p
within IN 1_p
6 CD 1_p
h NN 1_p
of IN 1_p
onset NN 1_p
of IN 1_p
STEMI NNP 1_p
and CC 1_p
undergoing JJ 1_p
planned VBN 1_p
primary JJ 1_p
PCI NNP 1_p
( ( 1_p
P-PCI NNP 1_p
) ) 1_p
with IN 1_p
TIMI NNP 1_p
0/1 CD 1_p
flow NN 1_p
in IN 1_p
the DT 1_p
infarct-related JJ 1_p
artery NN 1_p
( ( 1_p
IRA NNP 1_p
) ) 1_p
and CC 1_p
no DT 1_p
significant JJ 1_p
bystander NN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
on IN 1_p
angiography NN 1_i
, , 1_p
are VBP 1_p
randomised VBN 1_p
into IN 1_p
one CD 1_p
of IN 1_p
three CD 1_p
groups NNS 1_p
: : 1_p
PCI NNP 1_p
with IN 1_p
adjunctive JJ 1_p
pharmacotherapy NN 1_p
( ( 1_p
intracoronary JJ 1_p
adenosine NN 1_p
or CC 1_p
SNP NNP 1_p
) ) 1_p
or CC 1_p
control NN 1_p
( ( 1_p
standard JJ 1_p
PCI NNP 1_p
) ) 1_p
. . 1_p

All DT 1_p
receive VBP 1_p
Bivalirudin NNP 1_i
anticoagulation NN 1_i
and CC 1_i
thrombus JJ 1_i
aspiration NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
is VBZ N
infarct JJ 1_o
size NN 1_o
( ( 1_o
IS NNP 1_o
) ) 1_o
( ( N
determined VBN N
as IN N
a DT N
percentage NN N
of IN N
total JJ N
left VBD N
ventricular JJ N
mass NN N
) ) N
measured VBN N
by IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
CMRI NNP N
) ) N
undertaken VBP N
at IN N
48 CD N
to TO N
72 CD N
h NNS N
post JJ N
P-PCI NNP N
. . N

Secondary NNP N
outcome NN N
measures NNS N
include VBP N
MVO NNP 1_o
( ( 1_o
hypoenhancement NN 1_o
within IN 1_o
infarct JJ 1_o
core NN 1_o
) ) 1_o
on IN 1_o
CMRI NNP 1_o
, , 1_o
angiographic JJ 1_o
markers NNS 1_o
of IN 1_o
microvascular JJ 1_o
perfusion NN 1_o
and CC 1_o
MACE NNP 1_o
during IN N
1-month JJ N
follow-up NN N
. . N

The DT N
study NN N
aims VBZ N
to TO N
recruit VB N
240 CD 1_p
patients NNS 1_p
( ( 1_p
powered VBN 1_p
at IN 1_p
80 CD 1_p
% NN 1_p
to TO 1_p
detect VB 1_p
a DT 1_p
5 CD 1_p
% NN 1_p
absolute JJ 1_p
reduction NN 1_p
in IN 1_p
IS NNP 1_p
) ) 1_p
. . 1_p

DISCUSSION VB N
The DT N
REFLO-STEMI NNP N
study NN N
has VBZ N
been VBN N
designed VBN N
to TO N
address VB N
the DT N
weaknesses NNS N
of IN N
previous JJ N
trials NNS N
, , N
which WDT N
have VBP N
collectively RB N
failed VBN N
to TO N
demonstrate VB N
whether IN N
adjunctive JJ 1_i
pharmacotherapy NN 1_i
with IN N
adenosine JJ N
and/or NN N
SNP NNP N
can MD N
reduce VB N
measures NNS N
of IN N
myocardial JJ N
injury NN N
( ( N
infarct JJ N
size NN N
and CC N
MVO NNP N
) ) N
and CC N
improve VB N
clinical JJ N
outcome NN N
, , N
despite IN N
good JJ N
basic JJ N
evidence NN N
that IN N
they PRP N
have VBP N
the DT N
potential JJ N
to TO N
attenuate VB N
this DT N
process NN N
. . N

The DT N
REFLO-STEMI NNP N
study NN N
will MD N
be VB N
the DT N
most RBS N
scientifically RB N
robust JJ N
trial NN N
to TO N
date NN N
evaluating VBG N
whether IN N
adjunctive JJ 1_i
therapy NN 1_i
( ( 1_i
intracoronary JJ 1_i
adenosine NN 1_i
or CC 1_i
SNP NNP 1_i
following VBG 1_i
thrombus JJ 1_i
aspiration NN 1_i
) ) 1_i
reduces VBZ N
CMRI NNP 1_o
measured VBN N
IS NNP 1_o
and CC 1_o
MVO NNP 1_o
in IN N
patients NNS N
undergoing VBG N
P-PCI NNP N
within IN N
6 CD N
h NN N
of IN N
onset NN N
of IN N
STEMI NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
Trial NNP N
registered VBD N
20th CD N
November NNP N
2012 CD N
: : N
ClinicalTrials.gov NNP N
Identifier NNP N
NCT01747174 NNP N
. . N

Gender NNP 1_p
differences NNS 1_p
in IN N
response NN N
to TO N
nicotine VB 1_i
replacement NN 1_i
therapy NN 1_i
: : 1_i
objective JJ N
and CC N
subjective JJ N
indexes NNS N
of IN N
tobacco NN 1_p
withdrawal NN 1_p
. . 1_p

K. NNP N
A. NN N
Perkins NNP N
( ( N
1996 CD N
) ) N
recently RB N
proposed VBD N
that IN N
nicotine JJ 1_i
reinforcement NN 1_i
controls NNS 1_p
smoking VBG 1_p
to TO 1_p
a DT 1_p
greater JJR 1_p
degree NN 1_p
among IN 1_p
men NNS 1_p
than IN 1_p
women NNS 1_p
and CC N
that DT N
consequently RB N
, , N
nicotine JJ 1_i
replacement NN 1_i
therapy NN 1_i
( ( 1_i
NRT NNP 1_i
) ) 1_i
during IN N
smoking VBG N
cessation NN N
should MD N
benefit VB N
men NNS N
more JJR N
than IN N
women NNS N
. . N

The DT N
authors NNS N
tested VBD N
this DT N
hypothesis NN N
. . N

Polysomnographic JJ N
measures NNS N
of IN N
sleep NN 1_o
and CC 1_o
self-report NN 1_o
indexes NNS 1_o
of IN N
tobacco NN N
withdrawal NN N
were VBD N
collected VBN N
pre- JJ N
and CC N
postcessation NN N
from IN N
an DT N
active JJ 1_p
nicotine NN 1_i
patch NN 1_i
group NN 1_p
and CC 1_p
a DT 1_p
placebo NN 1_i
patch NN 1_i
group NN 1_p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
( ( 1_p
N NNP 1_p
= NNP 1_p
34 CD 1_p
) ) 1_p
. . 1_p

Objective JJ N
sleep JJ N
parameters NNS N
supported VBD N
Perkins NNP N
's POS N
hypothesis NN N
and CC N
indicated VBD N
that IN N
among IN N
women NNS N
, , N
NRT NNP 1_i
may MD N
be VB N
less RBR N
effective JJ N
at IN N
suppressing VBG 1_o
certain JJ 1_o
withdrawal NN 1_o
responses NNS 1_o
compared VBN N
with IN N
men NNS N
and CC N
may MD 1_o
produce VB 1_o
some DT 1_o
iatrogenic JJ 1_o
effects NNS 1_o
. . 1_o

Valid NNP N
and CC N
reliable JJ N
self-report JJ N
measures NNS N
of IN N
withdrawal NN 1_o
did VBD 1_o
not RB 1_o
reveal VB 1_o
gender NN 1_o
differences NNS 1_o
in IN 1_o
response NN 1_o
to TO 1_o
NRT NNP 1_o
. . 1_o

Custom NNP N
tray JJ N
application NN N
of IN N
peroxide JJ 1_i
gel NN 1_i
as IN N
an DT N
adjunct NN N
to TO N
scaling NN 1_i
and CC 1_i
root NN 1_i
planing NN 1_i
in IN N
the DT N
treatment NN 1_p
of IN 1_p
periodontitis NN 1_p
: : 1_p
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
after IN N
six CD N
months NNS N
. . N

OBJECTIVE NNP N
Scaling NNP 1_i
and CC 1_i
root NN 1_i
planing NN 1_i
( ( 1_i
SRP NNP 1_i
) ) 1_i
is VBZ N
the DT N
primary JJ N
non-surgical JJ N
treatment NN N
for IN N
periodontitis NN N
, , N
but CC N
its PRP$ N
effectiveness NN N
is VBZ N
limited VBN N
. . N

Consequently RB N
, , N
various JJ N
adjunctive JJ N
therapies NNS N
have VBP N
been VBN N
investigated VBN N
to TO N
improve VB N
clinical JJ N
outcome NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
clinical JJ N
effects NNS N
of IN N
one CD N
SRP NNP 1_i
procedure NN N
alone RB N
or CC N
combined VBN N
with IN N
local JJ N
administration NN N
of IN N
hydrogen NN 1_i
peroxide NN 1_i
gel NN 1_i
using VBG N
customized JJ N
trays NNS N
for IN N
the DT N
treatment NN N
of IN N
subjects NNS 1_p
with IN 1_p
chronic JJ 1_p
periodontitis NN 1_p
over IN N
a DT N
period NN N
of IN N
six CD N
months NNS N
. . N

METHODS NNP N
An DT N
examiner-blind JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
30 CD 1_p
subjects NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
advanced JJ 1_p
periodontitis NN 1_p
who WP N
were VBD N
randomized VBN N
to TO N
SRP VB 1_i
alone RB N
or CC N
SRP NNP 1_i
combined VBN 1_i
with IN N
prescription NN N
custom-tray JJ N
application NN N
( ( N
Perio NNP N
Tray NNP N
) ) N
of IN N
1.7 CD 1_i
% NN 1_i
hydrogen NN 1_i
peroxide NN 1_i
gel NN 1_i
( ( 1_i
Perio NNP 1_i
Gel NNP 1_i
) ) 1_i
for IN N
a DT N
period NN N
of IN N
three CD N
months NNS N
, , N
then RB N
extended VBD N
to TO N
six CD N
months NNS N
. . N

Following VBG N
impressions NNS N
for IN N
the DT N
test NN N
group NN N
, , N
all DT N
subjects NNS N
brushed VBN 1_i
twice RB 1_i
daily RB 1_i
with IN 1_i
a DT 1_i
regular JJ 1_i
dentifrice NN 1_i
and CC 1_i
toothbrush NN 1_i
for IN N
a DT N
four-week JJ N
acclimation NN N
phase NN N
to TO N
standardize VB N
oral JJ N
conditions NNS N
( ( N
while IN N
trays NNS N
were VBD N
fabricated VBN N
) ) N
prior RB N
to TO N
initiating VBG N
the DT N
treatment NN N
phase NN N
. . N

SRP NNP 1_i
was VBD N
performed VBN N
three CD N
weeks NNS N
after IN N
baseline NN N
, , N
and CC N
clinical JJ N
assessments NNS N
, , N
i.e. FW N
, , N
pocket NN 1_o
probing VBG 1_o
depth NN 1_o
( ( 1_o
PPD NNP 1_o
) ) 1_o
and CC 1_o
bleeding VBG 1_o
index NN 1_o
( ( 1_o
BI NNP 1_o
) ) 1_o
, , N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
13 CD N
, , N
and CC N
26 CD N
weeks NNS N
of IN N
peroxide JJ 1_i
gel NN 1_i
applications NNS N
. . N

Clinical JJ N
variables NNS N
were VBD N
compared VBN N
by IN N
ANCOVA NNP N
and CC N
paired VBD N
t-tests NNS N
after IN N
each DT N
treatment NN N
interval NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
13 CD 1_p
test NN 1_p
and CC 1_p
15 CD 1_p
control NN 1_p
subjects NNS 1_p
completed VBD N
the DT N
original JJ N
three-month JJ N
trial NN N
, , N
of IN N
whom WP N
10 CD N
test NN N
and CC N
13 CD N
control NN N
subjects NNS N
finished VBD N
the DT N
three-month JJ N
extension NN N
. . N

After IN N
two CD N
weeks NNS N
of IN N
peroxide NN 1_i
gel NN 1_i
use NN N
prior RB N
to TO N
SRP NNP 1_i
, , N
mean JJ 1_o
PPD NNP 1_o
for IN N
the DT N
test NN N
group NN N
significantly RB N
decreased VBN N
from IN N
baseline NN N
by IN N
0.21 CD N
mm NNS N
and CC N
mean JJ 1_o
BI NNP 1_o
significantly RB N
dropped VBD N
by IN N
0.14 CD N
; : N
clinical JJ N
parameters NNS N
for IN N
the DT N
control NN N
group NN N
were VBD N
unchanged JJ N
. . N

Two CD N
weeks NNS N
following VBG N
SRP NNP 1_i
, , N
mean JJ 1_o
PPD NNP 1_o
significantly RB N
decreased VBD N
from IN N
baseline NN N
by IN N
0.65 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.17 CD N
mm NN N
for IN N
the DT N
control NN N
; : N
mean CC N
BI NNP N
significantly RB N
dropped VBD N
by IN N
0.17 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.05 CD N
for IN N
the DT N
control NN N
. . N

Ten CD N
weeks NNS N
following VBG N
SRP NNP 1_i
, , N
mean JJ 1_o
PPD NNP 1_o
decreases NNS N
were VBD N
0.77 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.13 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
mean JJ 1_o
BI NNP 1_o
reductions NNS N
were VBD N
0.14 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
control NN N
. . N

For IN N
subjects NNS N
who WP N
completed VBD N
the DT N
three-month JJ N
extension NN N
( ( N
i.e. JJ N
, , N
23 CD N
weeks NNS N
post-SRP NN N
) ) N
, , N
mean JJ 1_o
PPD NNP 1_o
decreases NNS N
were VBD N
0.72 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.13 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
mean JJ 1_o
BI NNP 1_o
reductions NNS N
were VBD N
0.05 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.01 CD N
for IN N
the DT N
control NN N
. . N

Analysis NN N
of IN N
deeper JJR N
pockets NNS N
( ( N
i.e. NN N
, , N
> VBZ N
5 CD N
mm NN N
at IN N
baseline NN N
) ) N
showed VBD N
the DT N
same JJ N
relationship NN N
for IN N
PPD NNP N
, , N
but CC N
with IN N
larger JJR N
differences NNS N
between IN N
groups NNS N
. . N

For IN N
example NN N
, , N
after IN N
two CD N
weeks NNS N
of IN N
peroxide NN 1_i
gel NN 1_i
use NN N
prior RB N
to TO N
SRP NNP 1_i
, , N
mean JJ 1_o
PPD NNP 1_o
decreased VBN N
by IN N
0.48 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
compared VBN N
to TO N
0.04 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

Two CD N
weeks NNS N
after IN N
SRP NNP 1_i
, , N
mean JJ 1_o
PPD NNP 1_o
decreased VBD N
from IN N
baseline NN N
by IN N
1.40 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.60 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
10 CD N
weeks NNS N
after IN N
SRP NNP N
by IN N
1.57 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.58 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

After IN N
the DT N
extension NN N
( ( N
i.e. JJ N
, , N
23 CD N
weeks NNS N
post-SRP NN N
) ) N
, , N
mean JJ 1_o
PPD NNP 1_o
changed VBD N
from IN N
baseline NN N
by IN N
1.50 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.55 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

With IN N
the DT N
exception NN N
of IN N
BI NNP N
at IN N
23 CD N
weeks NNS N
post-SRP JJ N
, , N
all DT N
reductions NNS N
cited VBN N
above IN N
for IN N
the DT N
test NN N
group NN N
were VBD N
statistically RB N
significantly RB N
different JJ N
from IN N
the DT N
control NN N
group NN N
for IN N
both DT N
PPD NNP N
and CC N
BI NNP N
for IN N
all DT N
comparisons NNS N
. . N

CONCLUSION NN N
When WRB N
compared VBN N
with IN N
SRP NNP 1_i
alone RB N
, , N
clinical JJ N
improvements NNS N
in IN N
PPD NNP N
( ( N
e.g. NN N
, , N
-1.0 NNP N
mm NN N
for IN N
pockets NNS N
> VBP N
5 CD N
mm NN N
at IN N
baseline NN N
) ) N
were VBD N
maintained VBN N
for IN N
up IN N
to TO N
six CD N
months NNS N
after IN N
SRP NNP 1_i
with IN N
adjunctive JJ N
use NN N
of IN N
1.7 CD N
% NN N
hydrogen NN 1_i
peroxide NN 1_i
gel NN 1_i
, , N
locally RB N
administered VBN N
using VBG N
prescription NN N
customized VBD N
trays NNS N
in IN N
the DT N
treatment NN N
of IN N
subjects NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
advanced JJ 1_p
periodontitis NN 1_p
. . 1_p

A DT N
comparative JJ N
study NN N
of IN N
caudal JJ 1_i
bupivacaine NN 1_i
and CC 1_i
midazolam-bupivacaine JJ 1_i
mixture NN 1_i
for IN N
post-operative JJ N
analgesia NN N
in IN N
children NNS 1_p
undergoing VBG 1_p
genitourinary JJ 1_p
surgery NN 1_p
. . 1_p

OBJECTIVE CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
caudal JJ 1_i
midazolam-bupivacaine JJ 1_i
combination NN 1_i
in IN N
providing VBG N
post-operative JJ N
pain NN N
relief NN N
in IN N
children NNS 1_p
undergoing VBG 1_p
genitourinary JJ 1_p
surgery NN 1_p
and CC N
to TO N
study VB N
the DT N
occurrence NN N
of IN N
adverse JJ N
effects NNS N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Thirty NNP 1_p
children NNS 1_p
, , 1_p
aged VBD 1_p
2 CD 1_p
to TO 1_p
8 CD 1_p
years NNS 1_p
, , 1_p
scheduled VBN 1_p
for IN 1_p
genitourinary JJ 1_p
surgery NN 1_p
were VBD N
allocated VBN N
randomly RB N
to TO N
receive VB N
either RB N
0.25 CD N
% NN N
bupivacaine NN 1_i
0.5 CD N
ml/kg NN N
( ( N
group NN N
B NNP N
; : N
n CC N
= VB N
15 CD N
) ) N
or CC N
0.25 CD N
% NN N
bupivacaine NN 1_i
0.5 CD 1_i
ml/kg NN 1_i
with IN 1_i
50 CD 1_i
microg/kg NNS 1_i
midazolam NN 1_i
( ( N
group NN N
BM NNP N
; : N
n CC N
= VB N
15 CD N
) ) N
by IN N
the DT N
caudal JJ N
route NN N
immediately RB N
after IN N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

Heart NNP 1_o
rate NN 1_o
, , 1_o
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
and CC 1_o
oxygen NN 1_o
saturation NN 1_o
were VBD N
monitored VBN N
throughout IN N
the DT N
study NN N
period NN N
. . N

Postoperative JJ 1_o
pain NN 1_o
was VBD N
assessed VBN N
at IN N
regular JJ N
intervals NNS N
for IN N
12 CD N
hours NNS N
using VBG N
an DT N
objective JJ N
pain NN 1_o
score NN 1_o
. . 1_o

Analgesia NNP 1_o
was VBD N
supplemented VBN N
whenever IN N
the DT N
pain NN 1_o
score NN 1_o
was VBD N
> JJ N
or CC N
= JJ N
4 CD N
. . N

Duration NN 1_o
of IN 1_o
analgesia NN 1_o
, , N
as RB N
well RB N
as IN N
the DT N
requirement NN N
of IN N
additional JJ N
analgesics NNS N
, , N
were VBD N
noted VBN N
. . N

RESULTS NNP N
Lowest NNP N
pain NN 1_o
scores NNS 1_o
were VBD N
observed VBN N
with IN N
the DT N
addition NN N
of IN N
midazolam NN 1_i
to TO 1_i
caudal VB 1_i
bupivacaine NN 1_i
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Duration NN 1_o
of IN 1_o
analgesia NN 1_o
was VBD N
longer RBR N
in IN N
group NN N
BM NNP N
( ( N
11 CD N
+/- JJ N
0.5 CD N
h NN N
) ) N
as IN N
compared VBN N
to TO N
group NN N
B NNP N
( ( N
7.4 CD N
+/- JJ N
2.1 CD N
hours NNS N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Fewer JJR N
children NNS N
( ( N
26.6 CD N
% NN N
) ) N
required VBD N
additional JJ 1_o
analgesia NN 1_o
in IN N
the DT N
combination NN N
group NN N
whereas VBZ N
in IN N
group NN N
B NNP N
, , N
60 CD N
% NN N
of IN N
the DT N
children NNS N
received VBD N
analgesic JJ 1_o
supplements NNS 1_o
within IN N
6 CD N
hours NNS N
after IN N
surgery NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
heart NN 1_o
rate NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
and CC 1_o
oxygen NN 1_o
saturation NN 1_o
in IN N
both DT N
groups NNS N
. . N

We PRP N
observed VBD N
no DT N
untoward JJ 1_o
event NN 1_o
in IN N
either DT N
of IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
Caudal NNP 1_i
administration NN 1_i
of IN 1_i
bupivacaine-midazolam JJ 1_i
mixture NN 1_i
prolongs NNS N
post-operative JJ N
analgesia NNS N
compared VBN N
to TO N
bupivacaine VB 1_i
alone RB N
without IN N
causing VBG N
any DT N
adverse JJ N
effects NNS N
. . N

Effects NNS N
of IN N
glucagon-like JJ 1_i
peptide-1 JJ 1_i
( ( 1_i
7-36 JJ 1_i
) ) 1_i
amide NN 1_i
on IN N
motility NN 1_o
and CC 1_o
sensation NN 1_o
of IN 1_o
the DT 1_o
proximal JJ 1_o
stomach NN 1_o
in IN 1_p
humans NNS 1_p
. . 1_p

BACKGROUND NNP N
Glucagon-like JJ 1_i
peptide-1 NN 1_i
( ( 1_i
7-36 JJ 1_i
) ) 1_i
amide NN 1_i
( ( 1_i
GLP-1 NNP 1_i
) ) 1_i
retards NNS N
gastric JJ 1_o
emptying NN 1_o
, , 1_o
reduces NNS 1_o
food NN 1_o
intake NN 1_o
, , 1_o
and CC 1_o
inhibits VBZ 1_o
antroduodenal JJ 1_o
and CC 1_o
stimulates VBZ 1_o
pyloric JJ 1_o
motility NN 1_o
. . 1_o

AIMS NNP N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
synthetic JJ 1_i
GLP-1 NNP 1_i
on IN N
fundus NN 1_o
tone NN 1_o
and CC 1_o
volume NN 1_o
waves NNS 1_o
, , 1_o
gastric JJ 1_o
compliance NN 1_o
, , 1_o
and CC 1_o
perception NN 1_o
of IN 1_o
gastric JJ 1_o
distension NN 1_o
. . 1_o

SUBJECTS NNP N
Eleven NNP 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
. . 1_p

METHODS NNP N
Background NNP N
infusions NNS N
were VBD N
saline JJ 1_i
, , 1_i
or CC 1_i
GLP-1 NNP 1_i
at IN N
0.3 CD N
or CC N
0.9 CD N
pmol/ JJ N
kg/min NN N
on IN N
separate JJ N
days NNS N
in IN N
random JJ N
order NN N
. . N

Interdigestive JJ 1_o
fundus NN 1_o
motility NN 1_o
was VBD N
recorded VBN N
by IN N
barostat NN N
( ( N
maximum JJ N
capacity NN N
of IN N
intragastric JJ N
bag NN N
1200 CD N
ml NN N
) ) N
during IN N
basal NN N
and CC N
peptide JJ N
periods NNS N
of IN N
60 CD N
minutes NNS N
each DT N
. . N

Thereafter RB N
stepwise JJ N
isobaric JJ N
distensions NNS N
were VBD N
performed VBN N
with IN N
ongoing JJ N
peptide NN N
infusion NN N
, , N
and CC N
gastric JJ 1_o
sensation NN 1_o
was VBD N
scored VBN N
. . N

RESULTS NNP N
Low NNP N
and CC N
high JJ N
loads NNS N
of IN N
GLP-1 NNP 1_i
induced JJ N
physiological JJ 1_o
and CC 1_o
supraphysiological JJ 1_o
plasma NN 1_o
immunoreactivities NNS 1_o
, , N
respectively RB N
. . N

GLP-1 NNP 1_i
dose NN N
dependently RB N
diminished VBD N
fundus JJ 1_o
tone NN 1_o
( ( N
162.9 CD N
( ( N
15.0 CD N
) ) N
and CC N
259.5 CD N
( ( N
17.2 CD N
) ) N
v NN N
121.1 CD N
( ( N
6.0 CD N
) ) N
ml NN N
with IN N
saline NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

It PRP N
greatly RB N
reduced VBD N
volume NN 1_o
waves NNS 1_o
and CC 1_o
total JJ 1_o
volume NN 1_o
displaced VBN 1_o
by IN N
these DT N
events NNS N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Gastric NNP 1_o
compliance NN 1_o
derived VBD N
from IN N
isobaric JJ N
distension NN N
rose VBD N
in IN N
a DT N
dose NN N
related JJ N
manner NN N
( ( N
42.6 CD N
( ( N
5.5 CD N
) ) N
and CC N
63.6 CD N
( ( N
7.7 CD N
) ) N
v NN N
27.0 CD N
( ( N
3.5 CD N
) ) N
ml/mm NN N
Hg NNP N
; : N
p=0.0004 NN N
) ) N
with IN N
a DT N
concomitant JJ N
reduction NN N
of IN N
the DT N
pressure NN 1_o
at IN N
half JJ N
maximum JJ N
bag NN N
volume NN N
( ( N
6.4 CD N
( ( N
0.4 CD N
) ) N
and CC N
5.5 CD N
( ( N
0.4 CD N
) ) N
v NN N
7.2 CD N
( ( N
0.1 CD N
) ) N
mm NN N
Hg NNP N
; : N
p VBZ N
< $ N
0.0001 CD N
) ) N
. . N

GLP-1 NNP 1_i
did VBD N
not RB N
change VB N
perception NN N
of IN N
isobaric JJ 1_o
distension NN 1_o
but CC N
reduced VBD N
the DT N
perception NN 1_o
score RB 1_o
related VBN N
to TO N
corresponding VBG N
bag NN N
volume NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSIONS NNP N
GLP-1 NNP 1_i
is VBZ N
a DT N
candidate JJ N
physiological JJ N
inhibitory NN N
regulator NN N
of IN N
fundus JJ 1_o
motility NN 1_o
. . 1_o

It PRP N
allows VBZ N
the DT N
stomach NN N
to TO N
afford VB N
a DT N
larger JJR N
volume NN N
without IN N
increase NN 1_o
in IN 1_o
sensation NN 1_o
. . 1_o

Comparison NNP N
of IN N
hand-sewn NN 1_i
and CC N
stapled VBD 1_i
esophagogastric JJ 1_i
anastomosis NN 1_i
after IN N
esophageal JJ N
resection NN N
for IN N
cancer NN N
: : N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
hand-sewn JJ 1_i
and CC N
stapled JJ 1_i
methods NNS N
in IN N
esophagogastric JJ 1_i
anastomosis NN 1_i
. . 1_i

SUMMARY NNP N
BACKGROUND NNP N
DATA NNP N
After IN N
esophageal JJ N
resection NN N
for IN N
cancer NN N
, , N
the DT N
relative JJ N
merits NNS N
of IN N
the DT N
hand-sewn NN N
and CC N
the DT N
stapled JJ N
methods NNS N
of IN N
esophagogastric JJ N
anastomosis NN N
, , N
especially RB N
regarding VBG N
leakage NN 1_o
and CC 1_o
stricture NN 1_o
rates NNS 1_o
, , N
have VBP N
not RB N
adequately RB N
been VBN N
studied VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
undertaken VBN N
in IN N
122 CD 1_p
patients NNS 1_p
with IN 1_p
squamous JJ 1_p
cell NN 1_p
cancer NN 1_p
of IN 1_p
the DT 1_p
thoracic NN 1_p
esophagus NN 1_p
who WP 1_p
underwent VBD 1_p
a DT 1_p
Lewis-Tanner JJ 1_i
esophagectomy NN 1_i
. . 1_i

Patients NNS 1_p
were VBD 1_p
stratified VBN N
according VBG 1_p
to TO 1_p
esophageal VB 1_p
size NN 1_p
, , 1_p
based VBN 1_p
on IN 1_p
the DT 1_p
diameter NN 1_p
of IN 1_p
the DT 1_p
divided VBN 1_p
esophagus NN 1_p
( ( N
< CD N
or CC N
> VB N
or CC N
= VB N
30 CD N
mm NN N
) ) N
and CC N
then RB N
were VBD N
randomized VBN N
to TO N
have VB N
either CC N
a DT N
hand-sewn NN 1_i
or CC 1_i
a DT 1_i
stapled JJ 1_i
anastomosis NN 1_i
. . 1_i

RESULTS VB N
The DT N
mean JJ 1_o
total NN 1_o
operating VBG 1_o
times NNS 1_o
( ( N
standard JJ N
error NN N
of IN N
the DT N
mean NN N
) ) N
when WRB N
the DT N
hand-sewn NN N
and CC N
the DT N
stapled JJ N
methods NNS N
were VBD N
used VBN N
were VBD N
214 CD N
( ( N
4 CD N
) ) N
minutes NNS N
and CC N
217 CD N
( ( N
3.4 CD N
) ) N
minutes NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
not RB N
significant JJ N
[ NNP N
NS NNP N
] NNP N
) ) N
. . N

The DT N
respective NN N
in IN N
vivo NN 1_o
proximal JJ 1_o
resection NN 1_o
margins NNS 1_o
( ( N
standard JJ N
error NN N
of IN N
the DT N
mean NN N
) ) N
were VBD N
8 CD N
( ( N
0.4 CD N
) ) N
cm NN N
and CC N
7.6 CD N
( ( N
0.4 CD N
) ) N
cm NN N
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

Leakage VB 1_o
rates NNS 1_o
were VBD N
1.6 CD N
% NN N
and CC N
4.9 CD N
% NN N
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

Excluding VBG N
hospital JJ 1_o
deaths NNS 1_o
, , N
patients NNS N
with IN N
leakage NN 1_o
or CC 1_o
anastomotic JJ 1_o
recurrence NN 1_o
, , N
and CC N
those DT N
who WP N
received VBD N
radiation NN N
therapy NN N
to TO N
histologically RB N
infiltrated JJ N
resection NN N
margin NN N
, , N
anastomotic JJ 1_o
stricture NN 1_o
was VBD N
found VBN N
in IN N
5 CD N
( ( N
9.1 CD N
% NN N
) ) N
of IN N
55 CD N
patients NNS N
in IN N
the DT N
hand-sewn JJ N
group NN N
and CC N
20 CD N
( ( N
40 CD N
% NN N
) ) N
of IN N
50 CD N
in IN N
the DT N
stapler NN N
group NN N
( ( N
p JJ N
= NNP N
0.0003 CD N
) ) N
. . N

The DT N
difference NN 1_o
in IN 1_o
stricture NN 1_o
rates NNS 1_o
was VBD N
significant JJ N
in IN N
small JJ N
as RB N
well RB N
as IN N
large JJ N
esophagi NN N
. . N

Anastomotic JJ 1_o
recurrence NN 1_o
developed VBD N
in IN N
only RB N
one CD N
patient NN N
in IN N
each DT N
group NN N
. . N

CONCLUSIONS VB N
The DT N
authors NNS N
conclude VBP N
that IN N
both DT N
methods NNS N
were VBD N
safe JJ 1_o
, , N
but CC N
the DT N
stapled JJ N
technique NN N
resulted VBD N
in IN N
more RBR N
stricture JJ 1_o
formation NN 1_o
. . 1_o

Osteosarcoma NN N
: : N
the DT N
addition NN N
of IN N
muramyl NN 1_i
tripeptide NN 1_i
to TO N
chemotherapy VB N
improves NNS N
overall JJ 1_o
survival NN 1_o
-- : 1_o
a DT 1_o
report NN N
from IN N
the DT N
Children NNP 1_p
's POS 1_p
Oncology NNP 1_p
Group NNP 1_p
. . 1_p

PURPOSE NNP N
To TO N
compare VB N
three-drug JJ N
chemotherapy NN N
with IN N
cisplatin NN 1_i
, , 1_i
doxorubicin NN 1_i
, , 1_i
and CC 1_i
methotrexate NN 1_i
with IN N
four-drug JJ 1_i
chemotherapy NN 1_i
with IN 1_i
cisplatin NN 1_i
, , 1_i
doxorubicin NN 1_i
, , 1_i
methotrexate NN 1_i
, , 1_i
and CC 1_i
ifosfamide NN 1_i
for IN N
the DT N
treatment NN N
of IN N
osteosarcoma NN N
. . N

To TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
muramyl NN 1_i
tripeptide NN 1_i
( ( 1_i
MTP NNP 1_i
) ) 1_i
to TO N
chemotherapy VB N
enhances NNS N
event-free JJ 1_o
survival NN 1_o
( ( 1_o
EFS NNP 1_o
) ) 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
in IN N
newly RB N
diagnosed VBN N
patients NNS N
with IN N
osteosarcoma NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Six NNP 1_p
hundred VBD 1_p
sixty-two JJ 1_p
patients NNS 1_p
with IN 1_p
osteosarcoma NN 1_p
without IN 1_p
clinically RB 1_p
detectable JJ 1_p
metastatic JJ 1_p
disease NN 1_p
and CC 1_p
whose WP$ 1_p
disease NN 1_p
was VBD 1_p
considered VBN 1_p
resectable JJ 1_p
received VBD 1_p
one CD 1_p
of IN 1_p
four CD 1_p
prospectively RB 1_p
randomized JJ 1_p
treatments NNS 1_p
. . 1_p

All DT N
patients NNS N
received VBD N
identical JJ N
cumulative JJ N
doses NNS N
of IN N
cisplatin NN 1_i
, , 1_i
doxorubicin NN 1_i
, , 1_i
and CC 1_i
methotrexate NN 1_i
and CC N
underwent JJ N
definitive JJ N
surgical JJ N
resection NN N
of IN N
primary JJ N
tumor NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
or CC N
not RB N
to TO N
receive VB 1_i
ifosfamide JJ 1_i
and/or NN 1_i
MTP NNP 1_i
in IN N
a DT N
2 CD N
x NN N
2 CD N
factorial JJ N
design NN N
. . N

The DT N
primary JJ N
end NN N
points NNS N
for IN N
analysis NN N
were VBD N
EFS NNP 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
. . 1_o

RESULTS NNP N
In IN N
the DT N
current JJ N
analysis NN N
, , N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
interaction NN N
, , N
and CC N
we PRP N
were VBD N
able JJ N
to TO N
examine VB N
each DT N
intervention NN N
separately RB N
. . N

The DT N
chemotherapy NN N
regimens VBZ N
resulted VBN N
in IN N
similar JJ N
EFS NNP 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
. . 1_o

There EX N
was VBD N
a DT N
trend NN N
toward IN N
better JJR N
EFS NN 1_o
with IN N
the DT N
addition NN N
of IN N
MTP NNP N
( ( N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

The DT N
addition NN N
of IN N
MTP NNP N
to TO N
chemotherapy VB N
improved JJ N
6-year JJ 1_o
overall JJ 1_o
survival NN 1_o
from IN N
70 CD N
% NN N
to TO N
78 CD N
% NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

The DT N
hazard NN 1_o
ratio NN 1_o
for IN 1_o
overall JJ 1_o
survival NN 1_o
with IN N
the DT N
addition NN N
of IN N
MTP NNP N
was VBD N
0.71 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.52 CD N
to TO N
0.96 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
ifosfamide NN N
to TO N
cisplatin VB N
, , N
doxorubicin NN N
, , N
and CC N
methotrexate NN N
did VBD N
not RB N
enhance VB N
EFS NNP 1_o
or CC N
overall JJ 1_o
survival NN 1_o
for IN N
patients NNS N
with IN N
osteosarcoma NN N
. . N

The DT N
addition NN N
of IN N
MTP NNP N
to TO N
chemotherapy VB N
resulted VBN N
in IN N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
overall JJ 1_o
survival NN 1_o
and CC N
a DT N
trend NN N
toward IN N
better JJR N
EFS NNP 1_o
. . 1_o

Single-dose JJ N
tranexamic JJ 1_i
acid NN 1_i
reduces NNS N
postoperative VBP 1_o
bleeding NN 1_o
after IN N
coronary JJ 1_i
surgery NN 1_i
in IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
aspirin NN 1_i
until IN 1_p
surgery NN 1_p
. . 1_p

UNLABELLED NNP N
Tranexamic NNP 1_i
acid NN 1_i
reduces NNS N
postoperative VBP N
bleeding NN N
after IN N
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting VBG 1_i
. . 1_i

We PRP N
evaluated VBD N
the DT N
effects NNS 1_o
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ 1_i
acid NN 1_i
given VBN N
immediately RB N
before IN N
cardiopulmonary JJ 1_i
bypass NN 1_i
( ( 1_i
CPB NNP 1_i
) ) 1_i
in IN 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
aspirin NN 1_i
until IN 1_p
the DT 1_p
day NN 1_p
before IN 1_p
surgery NN 1_p
. . 1_p

The DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ 1_i
, , N
parallel-group JJ N
trial NN N
. . N

Eighty JJ 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
and CC 1_p
divided VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
: : 1_p
one CD 1_p
group NN 1_p
received VBD 1_p
tranexamic JJ 1_i
acid NN 1_i
30 CD 1_i
mg/kg NN 1_i
, , 1_i
and CC 1_i
one CD 1_i
group NN 1_i
received VBD 1_i
placebo NN 1_i
( ( 1_i
0.9 CD 1_i
% NN 1_i
NaCl NNP 1_i
) ) 1_i
as IN 1_i
a DT 1_i
bolus JJ 1_i
injection NN 1_i
before IN 1_i
CPB NNP 1_i
. . 1_i

Postoperative NNP 1_o
blood NN 1_o
loss NN 1_o
was VBD N
recorded VBN N
for IN N
16 CD N
h. JJ N
Transfusions NNS 1_o
of IN 1_o
blood NN 1_o
products NNS 1_o
were VBD N
recorded VBN N
for IN N
the DT N
whole JJ N
hospital NN N
stay NN N
. . N

Transfusions NNS N
of IN N
packed JJ N
red JJ N
cells NNS N
were VBD N
given VBN N
when WRB N
the DT N
hematocrit NN 1_o
value NN 1_o
was VBD N
less JJR N
than IN N
20 CD N
% NN N
during IN N
CPB NNP N
and CC N
less JJR N
than IN N
25 CD N
% NN N
after IN N
surgery NN N
. . N

The DT 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
tranexamic JJ 1_i
acid NN 1_i
group NN 1_p
had VBD N
significantly RB N
less RBR N
postoperative JJ 1_o
bleeding NN 1_o
compared VBN N
with IN N
the DT 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
placebo NN 1_i
group NN 1_p
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
) ) N
( ( N
475 CD N
[ RB N
274 CD N
] JJ N
mL NN N
versus NN N
713 CD N
[ NN N
243 CD N
] NNP N
mL NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

An DT N
effective JJ N
inhibition NN 1_o
of IN 1_o
fibrinolysis NN 1_o
was VBD N
found VBN N
in IN N
patients NNS 1_p
receiving VBG 1_p
tranexamic JJ 1_i
acid NN 1_i
. . 1_i

Tranexamic NNP 1_i
acid NN 1_i
reduces NNS N
postoperative VBP 1_o
bleeding NN 1_o
in IN N
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting VBG 1_i
patients NNS N
treated VBN N
with IN N
aspirin NN N
until IN N
the DT N
day NN N
before IN N
surgery NN N
. . N

IMPLICATIONS NNP N
Continuation NNP N
of IN N
aspirin JJ 1_i
medication NN N
until IN N
the DT N
day NN N
before IN N
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting NN 1_i
may MD N
increase VB N
postoperative JJ 1_o
bleeding NN 1_o
. . 1_o

The DT N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
tranexamic JJ 1_i
acid NN 1_i
( ( N
30 CD N
mg/kg NN N
) ) N
immediately RB N
before IN N
cardiopulmonary JJ N
bypass NN N
significantly RB N
reduced VBD N
postoperative JJ 1_o
bleeding NN 1_o
and CC N
inhibited JJ N
fibrinolysis NN 1_o
in IN N
these DT N
patients NNS N
. . N

A DT N
comparison NN N
of IN N
acupuncture NN 1_i
with IN N
advice NN 1_i
and CC 1_i
exercises NNS 1_i
on IN N
the DT N
symptomatic JJ 1_o
treatment NN 1_o
of IN N
osteoarthritis NN 1_p
of IN 1_p
the DT 1_p
hip NN 1_p
-- : 1_p
a DT 1_p
randomised JJ N
controlled VBN N
trial NN N
. . N

Acupuncture NN 1_i
is VBZ N
becoming VBG N
a DT N
common JJ N
technique NN N
within IN N
the DT N
physiotherapy NN N
profession NN N
as IN N
a DT N
treatment NN N
modality NN N
for IN N
pain NN 1_o
relief NN 1_o
; : 1_o
however RB N
, , N
few JJ N
randomised VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
undertaken VBN N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
acupuncture NN 1_i
, , N
particularly RB N
in IN N
the DT N
treatment NN N
of IN N
osteoarthritis NN 1_p
( ( 1_p
OA NNP 1_p
) ) 1_p
of IN 1_p
the DT 1_p
hip NN 1_p
. . 1_p

Therefore RB N
, , N
a DT N
randomised JJ N
trial NN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
acupuncture NN 1_i
with IN N
advice NN N
and CC N
exercises NNS 1_i
on IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
OA NNP 1_p
of IN 1_p
the DT 1_p
hip NN 1_p
was VBD N
carried VBN N
out RP N
. . N

Thirty-two JJ 1_p
patients NNS 1_p
awaiting VBG 1_p
a DT 1_p
total JJ 1_p
hip NN 1_p
arthroplasty NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
, , N
( ( N
A DT N
) ) N
, , N
to TO N
have VB N
six CD 1_i
sessions NNS 1_i
of IN 1_i
acupuncture NN 1_i
each DT N
lasting VBG N
up RP N
to TO N
25 CD N
minutes NNS N
, , N
or CC N
the DT N
control NN N
group NN N
, , N
( ( N
B NNP N
) ) N
, , N
to TO N
be VB N
given VBN N
advice NN 1_i
and CC 1_i
exercises NNS 1_i
for IN N
their PRP$ N
hip NN N
over IN N
a DT N
six CD N
week NN N
period NN N
. . N

Group NNP 1_p
A NNP 1_p
consisted VBD 1_p
of IN 1_p
three CD 1_p
men NNS 1_p
and CC 1_p
13 CD 1_p
women NNS 1_p
, , 1_p
and CC 1_p
group NN 1_p
B NNP 1_p
consisted VBD 1_p
of IN 1_p
four CD 1_p
men NNS 1_p
and CC 1_p
eight CD 1_p
women NNS 1_p
. . 1_p

The DT N
average JJ 1_p
age NN 1_p
in IN 1_p
group NN 1_p
A NNP 1_p
was VBD 1_p
66 CD 1_p
years NNS 1_p
and CC 1_p
in IN 1_p
group NN 1_p
B NNP 1_p
it PRP 1_p
was VBD 1_p
68 CD 1_p
years NNS 1_p
. . 1_p

Patients NNS N
were VBD N
assessed VBN N
for IN N
pain NN N
and CC N
functional JJ N
ability NN N
, , N
using VBG N
a DT N
modified JJ N
version NN N
of IN N
the DT N
WOMAC NNP 1_o
questionnaire NN 1_o
, , N
pre-treatment JJ N
, , N
immediately RB N
post-treatment JJ N
and CC N
at IN N
eight CD N
weeks NNS N
post-treatment JJ N
. . N

The DT N
pre-treatment JJ N
WOMAC NNP 1_o
scores NNS 1_o
in IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
( ( N
p=0.85 NN N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
group NN N
A NNP N
( ( N
decrease NN N
in IN N
WOMAC NNP 1_o
score NN 1_o
) ) 1_o
immediately RB N
post-treatment JJ N
( ( N
p=0.002 NN N
) ) N
and CC N
this DT N
was VBD N
maintained VBN N
at IN N
the DT N
eight-week JJ N
follow-up NN N
( ( N
p=0.03 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
group NN N
B NNP N
. . N

When WRB N
the DT N
changes NNS N
in IN N
WOMAC NNP 1_o
scores NNS 1_o
were VBD N
compared VBN N
between IN N
groups NNS N
, , N
a DT N
significantly RB N
greater JJR N
improvement NN N
was VBD N
found VBN N
between IN N
pre-treatment JJ N
and CC N
immediately RB N
post-treatment JJ N
in IN N
group NN N
A NNP N
, , N
compared VBN N
with IN N
group NN N
B NNP N
( ( N
p=0.02 NN N
) ) N
. . N

The DT N
changes NNS N
between IN N
pre-treatment NN N
and CC N
the DT N
eight-week JJ N
follow-up NN N
also RB N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
group NN N
A NNP N
compared VBN N
with IN N
group NN N
B NNP N
( ( N
p=0.03 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
this DT N
trial NN N
supports VBZ N
the DT N
hypothesis NN N
that IN N
acupuncture NN 1_i
is VBZ N
more RBR N
effective JJ 1_o
than IN N
advice NN N
and CC N
exercises NNS N
in IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
OA NNP N
of IN N
the DT N
hip NN N
. . N

Adult NNP 1_p
height NN 1_p
in IN 1_p
short JJ 1_p
children NNS 1_p
born VBN 1_p
SGA NNP 1_p
treated VBD 1_p
with IN 1_p
growth NN 1_i
hormone NN 1_i
and CC 1_i
gonadotropin NN 1_i
releasing VBG 1_i
hormone NN 1_i
analog NN 1_i
: : 1_i
results NNS N
of IN N
a DT N
randomized JJ N
, , N
dose-response JJ N
GH NNP 1_i
trial NN N
. . N

CONTEXT NNP N
GH NNP 1_i
treatment NN 1_i
is VBZ N
effective JJ N
in IN N
improving VBG N
height NN N
in IN N
short JJ 1_p
children NNS 1_p
born VBP 1_p
small JJ 1_p
for IN 1_p
gestational JJ 1_p
age NN 1_p
( ( 1_p
SGA NNP 1_p
) ) 1_p
. . 1_p

GH NNP 1_i
is VBZ N
thought VBN N
to TO N
have VB N
limited VBN N
effect NN N
when WRB N
started VBD N
during IN N
adolescence NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
GH NNP 1_i
treatment NN 1_i
efficacy NN 1_o
in IN N
short JJ N
SGA NNP N
children NNS N
when WRB N
treatment NN N
was VBD N
started VBN N
during IN N
adolescence NN N
; : N
to TO N
assess VB N
whether IN N
GH NNP 1_i
2 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
· NN N
d NN N
during IN N
puberty JJ N
improves NNS 1_o
adult VBP 1_o
height NN 1_o
( ( 1_o
AH NNP 1_o
) ) 1_o
compared VBN N
with IN N
1 CD N
mg/m NNS N
( ( N
2 CD N
) ) N
· NN N
d NN N
; : N
and CC N
to TO N
assess VB N
whether IN N
an DT N
additional JJ N
2-yr JJ N
postponement NN N
of IN N
puberty NN N
by IN 1_i
GnRH NNP 1_i
analog NN 1_i
( ( 1_i
GnRHa NNP 1_i
) ) 1_i
improves VBZ N
AH NNP N
in IN N
children NNS N
who WP N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
( ( N
< JJ N
140 CD N
cm NN N
) ) N
, , N
with IN N
a DT N
poor JJ N
AH NNP N
expectation NN 1_p
. . N

PATIENTS NNP N
AND CC N
DESIGN NNP N
In IN N
this DT N
longitudinal JJ N
, , N
randomized VBN N
, , N
dose-response JJ N
GH NNP N
trial NN N
, , N
we PRP N
included VBD 1_p
121 CD 1_p
short JJ 1_p
SGA NNP 1_p
children NNS 1_p
( ( 1_p
60 CD 1_p
boys NNS 1_p
) ) 1_p
at IN 1_p
least JJS 1_p
8 CD 1_p
yr NN 1_p
of IN 1_p
age NN 1_p
. . N

We PRP N
performed VBD 1_p
intention-to-treat JJ 1_p
analyses NNS 1_p
on IN 1_p
all DT 1_p
children NNS 1_p
and CC 1_p
uncensored JJ 1_p
case NN 1_p
analyses VBZ 1_p
on IN 1_p
84 CD 1_p
children NNS 1_p
who WP 1_p
reached VBD 1_p
AH NNP 1_p
. . N

Besides NNP N
, , N
we PRP N
evaluated VBD 1_o
growth NN 1_o
during IN N
2 CD N
yr NNS N
of IN 1_i
combined JJ 1_i
GH/GnRHa NNP 1_i
and CC 1_i
subsequent JJ 1_i
GH NNP 1_i
treatment NN 1_i
until IN N
AH NNP N
in IN N
a DT N
subgroup NN N
of IN N
40 CD N
pubertal JJ N
children NNS N
with IN N
a DT N
height NN N
of IN N
less JJR N
than IN N
140 CD N
cm NN N
at IN N
the DT N
start NN N
. . N

RESULTS NNP 1_p
Short NNP 1_p
SGA NNP 1_p
children NNS 1_p
started VBD N
treatment NN N
at IN N
a DT N
median JJ N
age NN N
of IN N
11.2 CD N
yr NNS N
, , N
when WRB N
46 CD N
% NN N
had VBD N
already RB N
started VBN N
puberty NN 1_o
. . 1_o

Median JJ 1_o
height NN 1_o
increased VBD N
from IN N
-2.9 NN N
at IN N
start NN N
to TO N
-1.7 VB N
sd NN N
score NN N
( ( N
SDS NNP N
) ) N
at IN N
AH NNP N
( ( N
P NNP N
< NNP N
0.001 CD 1_i
) ) 1_i
. . 1_i

Treatment NN 1_i
with IN 1_i
GH NNP 1_i
2 CD N
vs. FW N
1 CD N
mg/m NN N
( ( N
2 CD N
) ) N
· NN N
d NN N
during IN N
puberty NN N
resulted VBD N
in IN N
significantly RB N
better JJR 1_o
AH NNP N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
also RB N
after IN N
correction NN N
for IN N
gender NN N
, , N
age NN N
at IN N
start NN N
, , N
height VBD N
SDS NNP N
at IN N
start NN N
, , N
treatment NN N
years NNS N
before IN N
puberty NN N
, , N
and CC N
target VB N
height JJ N
SDS NNP 1_o
. . 1_o

AH NNP N
was VBD N
similar JJ N
in IN N
children NNS N
who WP N
started VBD N
puberty NN N
at IN N
less JJR N
than IN N
140 CD N
cm NN N
and CC N
received VBD 1_i
GH/GnRHa NNP 1_i
, , N
compared VBN N
with IN N
children NNS N
who WP N
started VBD N
puberty NN N
greater JJR N
than IN N
140 CD N
cm NN N
and CC N
received VBD 1_i
GH NNP 1_i
only RB 1_i
( ( N
P NNP N
= NNP N
0.795 CD N
) ) N
. . N

CONCLUSION NN N
When WRB N
started VBN N
in IN N
adolescence NN 1_i
, , 1_i
GH NNP 1_i
treatment NN 1_i
significantly RB N
improves VBZ 1_o
AH NNP N
in IN 1_p
short JJ 1_p
SGA NNP 1_p
children NNS 1_p
, , 1_p
particularly RB 1_p
with IN 1_i
GH NNP 1_p
2 CD 1_p
mg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
· NN 1_p
d NN 1_p
during IN 1_p
puberty NN 1_p
. . N

When WRB N
SGA NNP N
children NNS N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
, , N
they PRP N
can MD N
benefit VB N
from IN N
combined JJ 1_i
GH/GnRHa NNP 1_i
treatment NN 1_i
. . N

Low-dose JJ N
clonidine NN 1_i
administration NN N
in IN N
the DT N
treatment NN N
of IN N
mild NN 1_p
or CC 1_p
moderate JJ 1_p
essential JJ 1_p
hypertension NN 1_p
: : 1_p
results NNS N
from IN N
a DT N
double-blind JJ N
placebo-controlled JJ 1_i
study NN N
( ( N
Clobass NNP N
) ) N
. . N

The DT N
Clobass NNP N
Study NNP N
Group NNP N
. . N

Five CD 1_p
hundred JJ 1_p
and CC 1_p
fifty-nine JJ 1_p
hypertensive JJ 1_p
outpatients NNS 1_p
with IN 1_p
diastolic JJ 1_p
blood NN 1_p
pressure NN 1_p
between IN 1_p
95 CD 1_p
and CC 1_p
110 CD 1_p
mmHg NN 1_p
participated VBN N
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ 1_i
, , N
multicenter NN N
study NN N
. . N

Eligible JJ N
subjects NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
clonidine NN 1_i
( ( N
75 CD N
micrograms NNS N
twice RB N
daily RB N
) ) N
or CC N
a DT N
placebo NN 1_i
. . 1_i

After IN N
4 CD N
weeks NNS N
, , N
'responders NNS N
' POS N
to TO N
treatment NN N
( ( 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
reduced VBD N
to TO N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
90 CD N
mmHg NNS N
or CC N
by IN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
10 CD N
mmHg NNS N
) ) N
were VBD N
kept VBN N
on IN N
monotherapy NN 1_i
and CC N
checked VBN N
at IN N
4-weekly JJ N
intervals NNS N
for IN N
another DT N
3 CD N
months NNS N
. . N

Non-responders NNS N
were VBD N
given VBN N
15 CD N
mg JJ N
chlorthalidone NN 1_i
and CC N
were VBD N
also RB N
checked VBN N
for IN N
a DT N
further JJ N
3 CD N
months NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
month NN N
, , N
54.2 CD N
% NN N
of IN N
the DT N
subjects NNS N
were VBD N
responders NNS N
to TO N
clonidine VB 1_i
and CC N
41.5 CD N
% NN N
were VBD N
responders NNS N
to TO N
the DT N
placebo NN 1_i
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
for IN N
both DT N
groups NNS N
) ) N
. . N

Of IN N
the DT N
remaining VBG N
patients NNS N
, , N
69.0 CD N
% NN N
became VBD N
responders NNS N
to TO N
clonidine VB 1_i
plus CC N
chlorthalidone VB 1_i
, , N
whereas IN N
only RB N
34.7 CD N
% NN N
were VBD N
responders NNS N
to TO N
placebo VB 1_i
plus CC N
chlorthalidone NN 1_i
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
for IN N
both DT N
groups NNS N
) ) N
. . N

Withdrawals NNS N
from IN N
the DT N
study NN N
because IN N
of IN N
excessive JJ 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
levels NNS 1_o
were VBD N
about RB N
eight CD N
times NNS N
less RBR N
frequent JJ N
among IN N
the DT N
subjects NNS N
treated VBN N
with IN N
clonidine NN 1_i
, , N
either CC N
alone RB N
or CC N
with IN N
chlorthalidone NN 1_i
. . 1_i

Dry NNP 1_o
mouth NN 1_o
was VBD N
twice RB N
as RB N
frequent JJ N
in IN N
the DT N
clonidine-treated JJ 1_i
patients NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
all DT N
side NN 1_o
effects NNS 1_o
or CC N
the DT N
number NN 1_o
of IN 1_o
withdrawals NNS 1_o
from IN N
the DT N
study NN N
because IN N
of IN N
side NN N
effects NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

We PRP N
conclude VBP N
that IN N
low-dose JJ N
clonidine NN 1_i
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
mild NN N
or CC N
moderate JJ N
hypertension NN N
. . N

Clonidine-related JJ 1_i
side NN N
effects NNS N
are VBP N
still RB N
evident JJ N
, , N
but CC N
the DT N
overall JJ N
tolerance NN N
profile NN N
for IN N
this DT N
reduced JJ N
dosage NN N
of IN N
the DT N
drug NN N
appears VBZ N
to TO N
be VB N
favorable JJ N
. . N

Combining VBG N
afferent JJ 1_i
stimulation NN 1_i
and CC 1_i
mirror NN 1_i
therapy NN 1_i
for IN N
rehabilitating VBG N
motor NN 1_o
function NN 1_o
, , 1_o
motor NN 1_o
control NN 1_o
, , 1_o
ambulation NN 1_o
, , 1_o
and CC 1_o
daily JJ 1_o
functions NNS 1_o
after IN 1_o
stroke NN 1_o
. . 1_o

BACKGROUND NNP N
Mirror NNP 1_i
therapy NN 1_i
( ( 1_i
MT NNP 1_i
) ) 1_i
and CC 1_i
mesh JJ 1_i
glove NN 1_i
( ( 1_i
MG NNP 1_i
) ) 1_i
afferent NN 1_i
stimulation NN 1_i
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
motor NN N
impairment NN N
after IN N
stroke NN N
. . N

A DT N
hybrid JJ N
intervention NN N
of IN N
MT NNP 1_i
combined VBD 1_i
with IN 1_i
MG NNP 1_i
( ( 1_i
MT NNP 1_i
+ NNP 1_i
MG NNP 1_i
) ) 1_i
may MD N
broaden VB N
aspects NNS N
of IN N
treatment NN N
benefits NNS N
. . N

OBJECTIVE NNP N
To TO N
demonstrate VB N
the DT N
comparative JJ N
effects NNS N
of IN N
MG NNP 1_i
+ NNP 1_i
MT NNP 1_i
, , 1_i
MT NNP 1_i
, , N
and CC N
a DT N
control NN 1_i
treatment NN 1_i
( ( 1_i
CT NNP 1_i
) ) 1_i
on IN N
the DT N
outcomes NNS N
of IN N
motor NN N
impairments NNS N
, , N
manual JJ N
dexterity NN N
, , N
ambulation NN N
function NN N
, , N
motor NN N
control NN N
, , N
and CC N
daily JJ N
function NN N
. . N

METHODS NNP N
Forty-three JJ 1_p
chronic JJ 1_p
stroke NN 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
upper JJ 1_p
extremity NN 1_p
impairment NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
MT NNP 1_i
+ NNP 1_i
MG NNP 1_i
, , 1_i
MT NNP 1_i
, , N
or CC N
CT NNP 1_i
for IN N
1.5 CD N
hours/day NN N
, , N
5 CD N
days/week NN N
for IN N
4 CD N
weeks NNS N
. . N

Outcome NNP N
measures NNS N
were VBD N
the DT N
Fugl-Meyer NNP 1_o
Assessment NNP 1_o
( ( 1_o
FMA NNP 1_o
) ) 1_o
and CC 1_o
muscle NN 1_o
tone NN 1_o
measured VBN 1_o
by IN 1_o
Myoton-3 NNP 1_o
for IN 1_o
motor NN 1_o
impairment NN 1_o
and CC N
the DT N
Box NNP 1_o
and CC 1_o
Block NNP 1_o
Test NNP 1_o
( ( 1_o
BBT NNP 1_o
) ) 1_o
and CC N
10-Meter JJ 1_o
Walk NNP 1_o
Test NNP 1_o
( ( 1_o
10 CD 1_o
MWT NNP 1_o
) ) 1_o
for IN N
motor NN N
function NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
kinematic JJ 1_o
parameters NNS 1_o
for IN 1_o
motor NN 1_o
control NN 1_o
and CC N
the DT N
Motor NNP 1_o
Activity NNP 1_o
Log NNP 1_o
and CC N
ABILHAND NNP 1_o
Questionnaire NNP 1_o
for IN 1_o
daily JJ 1_o
function NN 1_o
. . 1_o

RESULTS NNP N
FMA NNP 1_o
total JJ 1_o
scores NNS 1_o
were VBD N
significantly RB N
higher JJR N
and CC N
synergistic JJ 1_o
shoulder NN 1_o
abduction NN 1_o
during IN 1_o
reach NN 1_o
was VBD N
less RBR N
in IN N
the DT N
MT NNP 1_i
+ NNP 1_i
MG NNP 1_i
and CC N
MT NNP 1_i
groups NNS N
compared VBN N
with IN N
the DT N
CT NNP 1_i
group NN N
. . N

Performance NN N
on IN N
the DT N
BBT NNP 1_o
and CC N
the DT N
10 CD 1_o
MWT NNP 1_o
( ( N
velocity NN N
and CC N
stride JJ N
length NN N
in IN N
self-paced JJ N
task NN N
and CC N
velocity NN N
in IN N
as-quickly-as-possible JJ N
task NN N
) ) N
were VBD N
improved VBN N
after IN N
MT NNP 1_i
+ NNP 1_i
MG NNP 1_i
compared VBN N
with IN N
MT NNP 1_i
. . 1_i

CONCLUSIONS NNP N
MT NNP 1_i
+ NNP 1_i
MG NNP 1_i
improved VBD N
manual JJ 1_o
dexterity NN 1_o
and CC 1_o
ambulation NN 1_o
. . 1_o

MT NNP 1_i
+ NNP 1_i
MG NNP 1_i
and CC N
MT NNP 1_i
reduced VBD N
motor NN 1_o
impairment NN 1_o
and CC 1_o
synergistic JJ 1_o
shoulder NN 1_o
abduction NN 1_o
more JJR N
than IN N
CT. NNP 1_i
Future NNP N
studies NNS N
may MD N
integrate VB N
functional JJ N
task NN N
practice NN N
into IN N
treatments NNS N
to TO N
enhance VB N
functional JJ N
outcomes NNS N
in IN N
patients NNS N
with IN N
various JJ N
levels NNS N
of IN N
motor NN N
severity NN N
. . N

The DT N
long-term JJ N
effects NNS N
of IN N
MG NNP 1_i
+ NNP 1_i
MT NNP 1_i
remain VBP N
to TO N
be VB N
evaluated VBN N
. . N

There EX N
is VBZ N
no DT N
sweet JJ N
escape NN N
from IN N
social JJ N
pain NN N
: : N
glucose NN N
does VBZ N
not RB N
attenuate VB N
the DT N
effects NNS 1_p
of IN 1_p
ostracism NN 1_p
. . 1_p

Ostracism NN N
causes VBZ N
social JJ N
pain NN N
and CC N
is VBZ N
known VBN N
to TO N
activate VB N
regions NNS N
of IN N
the DT N
brain NN N
that WDT N
are VBP N
involved VBN N
in IN N
the DT N
representation NN N
of IN N
physical JJ N
pain NN N
. . N

Previous JJ N
research NN N
has VBZ N
observed VBN N
that IN N
acetominophen NN 1_i
( ( N
a DT N
common JJ N
pain NN N
reliever NN N
) ) N
can MD N
reduce VB N
the DT N
pain NN N
of IN N
exclusion NN N
. . N

The DT N
taste NN N
and CC N
consumption NN N
of IN N
glucose NN N
can MD N
also RB N
relieve VB N
physical JJ N
pain NN N
, , N
and CC N
the DT N
purpose NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
examine VB N
whether IN N
it PRP N
might MD N
also RB N
reduce VB N
the DT N
negative JJ 1_o
emotional JJ 1_o
effects NNS 1_o
of IN 1_o
ostracism NN 1_o
. . 1_o

In IN N
an DT N
appropriately RB N
powered JJ N
experiment NN N
, , N
participants NNS 1_p
were VBD 1_p
given VBN 1_p
25g CD 1_i
of IN 1_i
glucose NN 1_i
or CC 1_i
a DT 1_i
sucralose JJ 1_i
placebo NN 1_i
before IN 1_p
being VBG 1_p
ostracized VBN 1_p
while IN 1_p
playing VBG 1_p
Cyberball NNP 1_p
. . 1_p

Strong NNP N
effects NNS N
of IN N
ostracism NN N
were VBD N
observed VBN N
, , N
however RB N
, , N
there EX N
was VBD N
no DT N
effect NN N
of IN N
glucose NN 1_o
on IN N
immediate JJ 1_o
or CC 1_o
delayed VBN 1_o
self-reported JJ 1_o
needs NNS 1_o
or CC 1_o
mood NN 1_o
. . 1_o

These DT N
results NNS N
are VBP N
discussed VBN N
in IN N
reference NN N
to TO N
the DT N
possibility NN N
that IN N
social JJ N
pain NN N
is VBZ N
unlike IN N
physical JJ N
pain NN N
since IN N
the DT N
latter NN N
is VBZ N
affected VBN N
by IN N
glucose NN N
, , N
which WDT N
is VBZ N
believed VBN N
to TO N
lessen VB N
pain NN N
by IN N
increasing VBG N
endogenous JJ N
opioid NN N
activity NN N
. . N

Dissociation NN N
between IN N
cortical JJ N
activation NN N
and CC N
cognitive JJ N
performance NN N
under IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
in IN N
chronic JJ N
hypotension NN N
. . N

The DT N
present JJ N
study NN N
explored VBD N
the DT N
impact NN N
of IN N
pharmacological JJ 1_i
blood NN 1_i
pressure NN 1_i
elevation NN 1_i
on IN N
cortical JJ N
activation NN N
and CC N
reaction NN N
time NN N
in IN N
chronic JJ 1_p
hypotension NN 1_p
. . 1_p

Effects NNS N
of IN N
the DT N
sympathomimetic JJ 1_i
etilefrine NN 1_i
were VBD N
investigated VBN N
in IN N
50 CD 1_p
hypotensive JJ 1_p
persons NNS 1_p
based VBN N
on IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ 1_i
double JJ N
blind NN N
design NN N
. . N

As IN N
an DT N
indicator NN N
of IN N
cortical JJ N
excitability NN N
, , N
the DT N
contingent NN N
negative JJ N
variation NN N
( ( N
CNV NNP N
) ) N
, , N
induced VBN N
by IN N
a DT N
constant JJ N
foreperiod NN N
reaction NN N
time NN N
task NN N
, , N
was VBD N
assessed VBN N
at IN N
frontal JJ N
( ( N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
Cz NNP N
, , N
C4 NNP N
) ) N
scalp NN N
sites NNS N
. . N

Etilefrine NNP 1_i
provoked VBD N
a DT N
decrease NN N
in IN N
the DT N
frontal NN 1_o
and CC 1_o
central JJ 1_o
CNV NNP 1_o
. . 1_o

In IN N
contrast NN N
, , N
shorter JJR N
reaction NN 1_o
times NNS 1_o
were VBD N
observed JJ N
following JJ N
drug NN N
administration NN N
. . N

The DT N
degree NN 1_o
of IN N
pharmacologically RB N
induced VBN 1_o
blood NN 1_o
pressure NN 1_o
elevation NN 1_o
was VBD N
correlated VBN N
to TO N
CNV NNP N
attrition NN N
as RB N
well RB N
as IN N
to TO N
performance NN N
enhancement NN N
. . N

Inhibitory JJ N
effects NNS N
of IN N
baroreceptor NN N
activation NN N
on IN N
cortical JJ N
excitability NN N
and CC N
enhanced VBD N
cerebral JJ N
blood NN N
flow NN N
are VBP N
considered VBN N
to TO N
be VB N
involved VBN N
in IN N
mediating VBG N
the DT N
effects NNS N
of IN N
blood NN 1_o
pressure NN 1_o
elevation NN 1_o
on IN N
cerebral JJ N
functioning NN N
. . N

Implications NNS N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ 1_o
hypotension NN 1_o
are VBP N
discussed VBN N
. . N

Social JJ N
robots NNS N
as IN N
embedded JJ N
reinforcers NNS N
of IN N
social JJ 1_p
behavior NN 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

In IN N
this DT N
study NN N
we PRP N
examined VBD N
the DT N
social JJ N
behaviors NNS N
of IN N
4- JJ 1_p
to TO 1_p
12-year-old JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
; : 1_p
N NNP 1_p
= NNP 1_p
24 CD 1_p
) ) 1_p
during IN N
three CD N
tradic JJ N
interactions NNS N
with IN N
an DT 1_i
adult NN 1_i
confederate NN 1_i
and CC 1_i
an DT 1_i
interaction NN 1_i
partner NN 1_i
, , N
where WRB N
the DT N
interaction NN N
partner NN N
varied VBD N
randomly RB N
among IN N
( ( 1_i
1 CD 1_i
) ) 1_i
another DT 1_i
adult NN 1_i
human NN 1_i
, , 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
a DT 1_i
touchscreen JJ 1_i
computer NN 1_i
game NN 1_i
, , 1_i
and CC 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
a DT 1_i
social JJ 1_i
dinosaur NN 1_i
robot NN 1_i
. . N

Children NNP N
spoke VBD N
more RBR N
in IN N
general JJ N
, , N
and CC N
directed VBD N
more JJR N
speech NN N
to TO N
the DT N
adult NN N
confederate NN N
, , N
when WRB N
the DT N
interaction NN N
partner NN N
was VBD N
a DT N
robot NN N
, , N
as IN N
compared VBN N
to TO N
a DT N
human NN N
or CC N
computer NN N
game NN N
interaction NN N
partner NN N
. . N

Children NNP N
spoke VBD N
as RB N
much JJ N
to TO N
the DT N
robot NN N
as IN N
to TO N
the DT N
adult NN N
interaction NN N
partner NN N
. . N

This DT N
study NN N
provides VBZ N
the DT N
largest JJS N
demonstration NN N
of IN N
social JJ N
human-robot JJ N
interaction NN N
in IN N
children NNS N
with IN N
autism NN N
to TO N
date NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
social JJ N
robots NNS N
may MD N
be VB N
developed VBN N
into IN N
useful JJ N
tools NNS N
for IN N
social JJ N
skills NNS N
and CC N
communication NN N
therapies NNS N
, , N
specifically RB N
by IN N
embedding VBG N
social JJ N
interaction NN N
into IN N
intrinsic JJ N
reinforcers NNS N
and CC N
motivators NNS N
. . N

Modest JJS N
visceral JJ N
fat NN 1_i
gain NN 1_i
causes VBZ N
endothelial JJ 1_p
dysfunction NN 1_p
in IN 1_p
healthy JJ 1_p
humans NNS 1_p
. . 1_p

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
fat JJ N
gain NN N
and CC N
its PRP$ N
distribution NN N
on IN N
endothelial JJ 1_o
function NN 1_o
in IN 1_p
lean JJ 1_p
healthy JJ 1_p
humans NNS 1_p
. . 1_p

BACKGROUND NNP N
Endothelial NNP 1_o
dysfunction NN 1_o
has VBZ N
been VBN N
identified VBN N
as IN N
an DT N
independent JJ N
predictor NN N
of IN N
cardiovascular JJ N
events NNS N
. . N

Whether NNP N
fat JJ 1_i
gain NN 1_i
impairs NNS N
endothelial JJ 1_o
function NN 1_o
is VBZ N
unknown JJ N
. . N

METHODS VB N
A DT N
randomized NN N
controlled VBD N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
fat JJ 1_i
gain NN 1_i
on IN N
endothelial JJ N
function NN N
. . N

Forty-three JJ 1_p
normal-weight JJ 1_p
healthy JJ 1_p
volunteers NNS 1_p
were VBD 1_p
recruited VBN 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
29 CD 1_p
years NNS 1_p
; : 1_p
18 CD 1_p
women NNS 1_p
) ) 1_p
. . 1_p

Subjects NNS 1_p
were VBD N
assigned VBN N
to TO N
gain VB 1_i
weight NN 1_i
( ( N
approximately RB N
4 CD N
kg NNS N
) ) N
( ( N
n=35 JJ N
) ) N
or CC N
to TO N
maintain VB 1_i
weight NN 1_i
( ( N
n=8 JJ N
) ) N
. . N

Endothelial JJ 1_o
function NN 1_o
( ( 1_o
brachial JJ 1_o
artery NN 1_o
flow-mediated JJ 1_o
dilation NN 1_o
[ NNP 1_o
FMD NNP 1_o
] NNP 1_o
) ) 1_o
was VBD N
measured VBN N
at IN N
baseline NN N
, , N
after IN N
fat JJ N
gain NN N
( ( N
8 CD N
weeks NNS N
) ) N
, , N
and CC N
after IN N
weight JJ N
loss NN N
( ( N
16 CD N
weeks NNS N
) ) N
for IN N
fat JJ N
gainers NNS N
and CC N
at IN N
baseline NN N
and CC N
follow-up NN N
( ( N
8 CD N
weeks NNS N
) ) N
for IN N
weight NN N
maintainers NNS N
. . N

Body NNP N
composition NN N
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
and CC N
abdominal JJ N
computed JJ N
tomographic JJ N
scans NNS N
. . N

RESULTS NNP N
After IN N
an DT N
average JJ N
weight JJ N
gain NN N
of IN N
4.1 CD N
kg NN N
, , N
fat JJ N
gainers NNS N
significantly RB N
increased VBD N
their PRP$ N
total JJ 1_o
, , 1_o
visceral JJ 1_o
, , 1_o
and CC 1_o
subcutaneous JJ 1_o
fat NN 1_o
. . 1_o

Blood NNP 1_o
pressure NN 1_o
and CC 1_o
overnight JJ 1_o
polysomnography NN 1_o
did VBD N
not RB N
change NN N
after IN N
fat JJ N
gain NN N
or CC N
loss NN N
. . N

FMD NNP 1_o
remained VBD N
unchanged JJ N
in IN N
weight JJ N
maintainers NNS N
. . N

FMD NNP 1_o
decreased VBD N
in IN N
fat JJ N
gainers NNS N
( ( N
9.1+/-3 CD N
% NN N
vs. FW N
7.8+/-3.2 CD N
% NN N
, , N
p=0.003 NN N
) ) N
but CC N
recovered VBD N
to TO N
baseline VB N
when WRB N
subjects NNS N
shed VBD N
the DT N
gained JJ N
weight NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
the DT N
decrease NN N
in IN N
FMD NNP 1_o
and CC N
the DT N
increase NN N
in IN N
visceral JJ 1_o
fat JJ 1_o
gain NN 1_o
( ( N
rho=-0.42 JJ N
, , N
p=0.004 NN N
) ) N
, , N
but CC N
not RB N
with IN N
subcutaneous JJ 1_o
fat JJ 1_o
gain NN 1_o
( ( N
rho=-0.22 JJ N
, , N
p=0.15 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
normal-weight JJ 1_p
healthy JJ 1_p
young JJ 1_p
subjects NNS 1_p
, , N
modest JJ N
fat JJ 1_i
gain NN 1_i
results NNS N
in IN N
impaired JJ N
endothelial JJ 1_o
function NN 1_o
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
changes NNS N
in IN N
blood NN 1_o
pressure NN 1_o
. . 1_o

Endothelial JJ 1_o
function NN 1_o
recovers NNS N
after IN N
weight JJ N
loss NN N
. . N

Increased VBN N
visceral JJ 1_o
rather RB 1_o
than IN 1_o
subcutaneous JJ 1_o
fat JJ 1_o
predicts NNS N
endothelial JJ 1_o
dysfunction NN 1_o
. . 1_o

( ( N
Fat JJ N
Gain NNP N
and CC N
Cardiovascular NNP N
Disease NNP N
Mechanisms NNP N
; : N
NCT00589498 NNP N
) ) N
. . N

Decreased VBN N
expression NN 1_o
of IN 1_o
Yes-associated JJ 1_o
protein NN 1_o
is VBZ N
associated VBN N
with IN N
outcome NN N
in IN N
the DT N
luminal NN 1_p
A NNP 1_p
breast NN 1_p
cancer NN 1_p
subgroup NN 1_p
and CC N
with IN N
an DT N
impaired JJ N
tamoxifen NN 1_i
response NN N
. . N

BACKGROUND NNP N
Yes-associated JJ 1_o
protein NN 1_o
( ( 1_o
YAP1 NNP 1_o
) ) 1_o
is VBZ N
frequently RB N
reported VBN N
to TO N
function NN N
as IN N
an DT N
oncogene NN N
in IN N
many JJ N
types NNS N
of IN N
cancer NN N
, , N
but CC N
in IN N
breast JJ N
cancer NN N
results NNS N
remain VBP N
controversial JJ N
. . N

We PRP N
set VBD N
out RP N
to TO N
clarify VB N
the DT N
role NN N
of IN N
YAP1 NNP 1_o
in IN N
breast NN N
cancer NN N
by IN N
examining VBG N
gene NN N
and CC N
protein JJ N
expression NN N
in IN N
subgroups NNS N
of IN N
patient JJ N
material NN N
and CC N
by IN N
downregulating VBG N
YAP1 NNP N
in IN N
vitro NN N
and CC N
studying VBG N
its PRP$ N
role NN N
in IN N
response NN N
to TO N
the DT N
widely RB N
used VBN N
anti-estrogen NN N
tamoxifen NN 1_i
. . 1_i

METHODS NNP N
YAP1 NNP 1_o
protein NN 1_o
intensity NN 1_o
was VBD N
scored VBN N
as IN N
absent NN N
, , N
weak JJ N
, , N
intermediate JJ N
or CC N
strong JJ N
in IN N
two CD 1_p
primary JJ 1_p
breast NN 1_p
cancer NN 1_p
cohorts NNS 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
144 CD 1_p
and CC 1_p
n JJ 1_p
= NNP 1_p
564 CD 1_p
) ) 1_p
and CC 1_p
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
YAP1 NNP 1_o
was VBD 1_p
evaluated VBN 1_p
in IN 1_p
a DT 1_p
gene NN 1_p
expression NN 1_p
dataset NN 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
1107 CD 1_p
) ) 1_p
. . N

Recurrence-free JJ 1_o
survival NN 1_o
was VBD N
analysed VBN N
using VBG N
the DT N
log-rank JJ N
test NN N
and CC N
Cox NNP N
multivariate VBP N
analysis NN N
was VBD N
used VBN N
to TO N
test VB N
for IN N
independence NN N
. . N

WST-1 JJ 1_i
assay NN 1_i
was VBD N
employed VBN N
to TO N
measure VB N
cell NN 1_o
viability NN 1_o
and CC N
a DT N
luciferase NN 1_o
ERE NNP 1_o
( ( N
estrogen JJ N
responsive JJ N
element NN N
) ) N
construct NN N
was VBD N
used VBN N
to TO N
study VB N
the DT N
effect NN N
of IN N
tamoxifen NN 1_i
, , N
following VBG N
downregulation NN N
of IN N
YAP1 NNP N
using VBG N
siRNAs NN N
. . N

RESULTS NNP N
In IN N
the DT N
ER+ NNP 1_p
( ( 1_p
Estrogen NNP 1_p
Receptor NNP 1_p
α NNP 1_p
positive JJ 1_p
) ) 1_p
subgroup NN 1_p
of IN N
the DT N
randomised JJ N
cohort NN N
, , N
YAP1 NNP 1_o
expression NN 1_o
was VBD N
inversely RB N
correlated VBN N
to TO N
histological JJ N
grade NN N
and CC N
proliferation NN N
( ( N
p JJ N
= NN N
0.001 CD N
and CC N
p VB N
= JJ N
0.016 CD N
, , N
respectively RB N
) ) N
whereas NNS N
in IN N
the DT 1_p
ER- NNP 1_p
( ( 1_p
Estrogen NNP 1_p
Receptor NNP 1_p
α NNP 1_p
negative JJ 1_p
) ) 1_p
subgroup NN 1_o
YAP1 NNP 1_o
expression NN 1_o
correlated VBD N
positively RB N
to TO N
proliferation NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
. . N

Notably RB N
, , N
low JJ 1_o
YAP1 NNP 1_o
mRNA NN 1_o
was VBD N
independently RB N
associated VBN N
with IN N
decreased JJ 1_o
recurrence-free JJ 1_o
survival NN 1_o
in IN N
the DT N
gene NN N
expression NN N
dataset NN N
, , N
specifically RB N
for IN N
the DT N
luminal JJ N
A NNP N
subgroup NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
which WDT N
includes VBZ N
low JJ N
proliferating VBG N
tumours NN N
of IN N
lower JJR N
grade NN N
, , N
usually RB N
associated VBN N
with IN N
a DT N
good JJ N
prognosis NN N
. . N

This DT N
subgroup NN N
specificity NN N
led VBD N
us PRP N
to TO N
hypothesize VB N
that IN 1_o
YAP1 NNP 1_o
may MD N
be VB N
important JJ N
for IN N
response NN N
to TO N
endocrine VB N
therapies NNS N
, , N
such JJ N
as IN 1_i
tamoxifen NN 1_i
, , N
extensively RB N
used VBN N
for IN N
luminal JJ N
A NNP N
breast NN N
cancers NNS N
. . N

In IN N
a DT 1_i
tamoxifen NN 1_i
randomised VBN N
patient JJ N
material NN N
, , N
absent JJ 1_o
YAP1 NNP 1_o
protein NN 1_o
expression NN 1_o
was VBD N
associated VBN N
with IN N
impaired JJ 1_o
tamoxifen NN 1_o
response NN 1_o
which WDT N
was VBD N
significant JJ N
upon IN N
interaction NN N
analysis NN N
( ( N
p JJ N
= NNP N
0.042 CD N
) ) N
. . N

YAP1 CC N
downregulation NN N
resulted VBD N
in IN N
increased JJ 1_o
progesterone NN 1_o
receptor NN 1_o
( ( 1_o
PgR NNP 1_o
) ) 1_o
expression NN 1_o
and CC N
a DT N
delayed NN N
and CC N
weaker JJR 1_i
tamoxifen NN 1_i
in IN N
support NN N
of IN N
the DT N
clinical JJ N
data NNS N
. . N

CONCLUSIONS NNP N
Decreased VBD 1_o
YAP1 NNP 1_o
expression NN 1_o
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
for IN N
recurrence NN N
in IN N
the DT N
less RBR N
aggressive JJ 1_p
luminal NN 1_p
A NNP 1_p
breast NN 1_p
cancer NN 1_p
subgroup NN 1_p
, , N
likely RB N
due JJ N
to TO N
the DT N
decreased VBN 1_i
tamoxifen NN 1_i
sensitivity NN N
conferred VBN N
by IN N
YAP1 NNP N
downregulation NN N
. . N

Improved NNP N
local JJ N
control NN N
of IN N
invasive JJ N
bladder NN N
cancer NN N
by IN N
concurrent NN 1_i
cisplatin NN 1_i
and CC 1_i
preoperative NN 1_i
or CC 1_i
definitive JJ 1_i
radiation NN 1_i
. . 1_i

The DT N
National NNP N
Cancer NNP N
Institute NNP N
of IN N
Canada NNP N
Clinical NNP N
Trials NNP N
Group NNP N
. . N

PURPOSE NNP N
A NNP N
prospective JJ N
randomized VBN N
trial NN N
was VBD N
conducted VBN N
to TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
concurrent NN 1_i
cisplatin NN 1_i
to TO 1_i
preoperative VB 1_i
or CC 1_i
definitive JJ 1_i
radiation NN 1_i
therapy NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
muscle-invasive JJ 1_p
bladder NN 1_p
cancer NN 1_p
improved VBD 1_p
local JJ 1_o
control NN 1_o
or CC 1_o
survival NN 1_o
. . 1_o

PATIENTS NNP N
AND CC N
METHODS NNP N
Ninety-nine NNP 1_p
eligible JJ 1_p
patients NNS 1_p
with IN 1_p
T2 NNP 1_p
to TO 1_p
T4b NNP 1_p
transitional JJ 1_p
cell NN 1_p
bladder NN 1_p
cancer NN 1_p
participated VBD 1_p
, , 1_p
64 CD 1_p
% NN 1_p
with IN 1_p
cT3b NN 1_p
or CC 1_p
cT4 NN 1_p
. . 1_p

Patients NNS N
and CC N
their PRP$ N
physicians NNS N
selected VBN N
either RB N
definitive JJ N
radiotherapy NN 1_i
or CC 1_i
precystectomy JJ 1_i
radiotherapy NN 1_i
; : 1_i
patients NNS N
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
receive VB N
intravenous JJ 1_i
cisplatin NNS 1_i
100 CD N
mg/m2 NNS N
at IN N
2-week JJ N
intervals NNS N
for IN N
three CD N
cycles NNS N
concurrent VBP 1_i
with IN 1_i
pelvic JJ 1_i
radiation NN 1_i
, , N
or CC N
to TO N
receive VB 1_i
radiation NN 1_i
without IN 1_i
chemotherapy NN 1_i
. . 1_i

Patients NNS N
were VBD N
stratified VBN N
by IN N
clinical JJ N
tumor NN N
stage NN N
and CC N
by IN N
radiation NN N
plan NN N
. . N

The DT N
median JJ N
follow-up JJ N
duration NN N
is VBZ N
6.5 CD N
years NNS N
. . N

RESULTS VB N
The DT N
occurrence NN 1_o
of IN 1_o
distant JJ 1_o
metastases NNS 1_o
was VBD N
the DT N
same JJ N
in IN N
both DT N
study NN N
arms NNS N
. . N

However RB N
, , N
25 CD N
of IN N
48 CD N
control NN N
patients NNS N
have VBP N
had VBD N
a DT N
first JJ 1_o
recurrence NN 1_o
in IN N
the DT N
pelvis NN N
, , N
compared VBN N
with IN N
15 CD N
of IN N
51 CD N
cisplatin-treated JJ 1_i
patients NNS N
( ( N
P NNP N
= NNP N
.036 NNP N
) ) N
. . N

The DT N
pelvic JJ 1_o
relapse NN 1_o
rate NN 1_o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
significantly RB N
reduced VBN N
by IN N
concurrent NN 1_i
cisplatin NN 1_i
( ( N
P NNP N
= NNP N
.038 NNP N
, , N
log-rank JJ N
test NN N
) ) N
and CC N
this DT N
effect NN N
was VBD N
preserved VBN N
in IN N
a DT N
stepwise NN N
Cox NNP N
regression NN N
model NN N
of IN N
prognostic JJ N
factors NNS N
( ( N
hazards NNS N
ratio NN N
, , N
0.50 CD N
; : N
90 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.29 CD N
to TO N
0.86 CD N
; : N
P NNP N
= NNP N
.036 NNP N
) ) N
. . N

The DT N
hazard NN 1_o
reduction NN 1_o
was VBD N
similar JJ N
for IN N
both DT N
radiation NN N
plans NNS N
. . N

Pretreatment NNP N
leukocytosis NN N
and CC N
high JJ N
clinical JJ N
stage NN N
were VBD N
independent JJ N
adverse JJ N
factors NNS N
in IN N
a DT N
Cox NNP N
model NN N
of IN N
overall JJ 1_o
survival NN 1_o
, , N
but CC N
the DT N
effect NN 1_o
of IN N
cisplatin NN 1_i
was VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Concurrent NNP 1_i
cisplatin NN 1_i
may MD N
improve VB N
pelvic NNS 1_o
control NN 1_o
of IN N
locally RB N
advanced JJ N
bladder NN N
cancer NN N
with IN N
preoperative JJ 1_i
or CC 1_i
definitive JJ 1_i
radiation NN 1_i
, , N
but CC N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
improve VB N
overall JJ 1_o
survival NN 1_o
. . 1_o

The DT N
use NN N
of IN N
concurrent NN 1_i
cisplatin NN 1_i
had VBD N
no DT N
detectable JJ N
effect NN 1_o
on IN N
distant JJ N
metastases NNS N
. . N

Colonoscopic NNP N
miss JJ N
rates NNS N
of IN N
adenomas NN 1_p
determined VBN N
by IN N
back-to-back JJ N
colonoscopies NNS N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
miss JJ N
rate NN N
of IN N
colonoscopy NN N
for IN N
neoplasms NN N
is VBZ N
poorly RB N
understood JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
miss JJ N
rate NN N
of IN N
colonoscopy NN 1_i
by IN N
same JJ N
day NN N
back-to-back JJ N
colonoscopy NN N
. . N

METHODS NNP N
Two CD N
consecutive JJ N
same JJ N
day NN N
colonoscopies NNS 1_i
were VBD N
performed VBN N
in IN N
183 CD 1_p
patients NNS 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB N
the DT N
second JJ 1_i
colonoscopy NN 1_i
by IN N
the DT N
same JJ 1_i
or CC 1_i
a DT 1_i
different JJ 1_i
endoscopist NN 1_i
and CC 1_i
in IN 1_i
the DT 1_i
same JJ 1_i
or CC 1_i
different JJ 1_i
position NN 1_i
. . 1_i

RESULTS VB N
The DT N
overall JJ 1_o
miss NN 1_o
rate NN 1_o
for IN 1_o
adenomas NN 1_o
was VBD N
24 CD N
% NN N
, , N
27 CD N
% NN N
for IN N
adenomas JJ N
< NN N
or CC N
= $ N
5 CD N
mm NN N
, , N
13 CD N
% NN N
for IN N
adenomas JJ N
6-9 JJ N
mm NN N
, , N
and CC N
6 CD N
% NN N
for IN N
adenomas JJ N
> NN N
or CC N
= $ N
1 CD N
cm NN N
. . N

Patients NNS 1_p
with IN 1_p
two CD 1_p
or CC 1_p
more JJR 1_p
adenomas NNS 1_p
at IN N
the DT N
first JJ N
examination NN N
were VBD N
more RBR N
likely JJ N
than IN N
patients NNS 1_p
with IN 1_p
no DT 1_p
or CC 1_p
one CD 1_p
adenoma NN 1_p
detected VBN N
at IN N
the DT N
first JJ N
examination NN N
to TO N
have VB N
one CD N
or CC N
more JJR N
adenomas NNS 1_o
at IN N
the DT N
second JJ N
examination NN N
( ( N
odds NNS N
ratio NN N
, , N
3.3 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.69-6.46 JJ N
) ) N
. . N

Right JJ N
colon NN N
adenomas NNS N
were VBD N
missed VBN 1_o
more RBR N
often RB N
( ( N
27 CD N
% NN N
) ) N
than IN N
left VBN N
colon NN N
adenomas NN N
( ( N
21 CD N
% NN N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

There EX N
was VBD N
evidence NN N
of IN N
variation NN 1_o
in IN 1_o
sensitivity NN 1_o
between IN N
endoscopists NNS N
, , N
but CC N
significant JJ N
miss JJ 1_o
rates NNS 1_o
for IN 1_o
small JJ N
adenomas NNS N
were VBD N
found VBN N
among IN N
essentially RB N
all DT N
endoscopists NNS N
. . N

CONCLUSIONS NNP N
Using NNP N
current JJ N
colonoscopic NN 1_i
technology NN 1_i
, , N
there EX N
are VBP N
significant JJ N
miss JJ 1_o
rates NNS 1_o
for IN N
adenomas JJ N
< $ N
1 CD N
cm NN N
even RB N
with IN N
meticulous JJ N
colonoscopy NN N
. . N

Miss JJ 1_o
rates NNS 1_o
are VBP N
low JJ N
for IN N
adenomas NN N
> NN N
or CC N
= $ N
1 CD N
cm NN N
. . N

The DT N
results NNS N
suggest VBP N
the DT N
need NN N
for IN N
improvements NNS N
in IN N
colonoscopic NN N
technology NN N
. . N

Fusidic NNP N
acid VBZ N
prophylaxis NN N
before IN 1_p
cataract JJ 1_p
surgery NN 1_p
: : 1_p
patient JJ 1_p
self-administration NN 1_p
. . 1_p

In IN N
a DT N
placebo-controlled JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
the DT N
authors NNS N
evaluated VBD N
the DT N
efficacy NN N
of IN N
patient-administered JJ N
1 CD N
% NN N
fusidic JJ 1_i
acid RB 1_i
viscous JJ 1_i
eye NN 1_i
drops NNS 1_i
in IN N
clearing VBG N
the DT N
commonest JJS N
organisms JJ N
causing VBG N
pseudophakic NN N
endophthalmitis NN N
( ( N
Staphylococcus NNP N
epidermidis RB N
and CC N
aureus RB N
) ) N
from IN N
the DT N
lids NNS N
and CC N
conjunctivae NN N
of IN N
79 CD 1_p
patients NNS 1_p
before IN 1_p
cataract JJ 1_p
surgery NN 1_p
. . 1_p

The DT N
treatment NN N
group NN N
self-administered JJ N
fusidic JJ 1_i
acid NN 1_i
viscous JJ N
eye NN N
drops VBZ N
four CD N
times NNS N
daily RB N
for IN N
seven CD N
days NNS N
before IN N
surgery NN N
; : N
the DT N
placebo NN N
group NN N
received VBD N
inert JJ 1_i
ophthalmic JJ 1_i
drops NNS 1_i
. . 1_i

Fellow NNP N
eyes NNS N
of IN N
both DT N
groups NNS N
remained VBD N
untreated JJ N
as IN N
a DT N
natural JJ N
control NN N
. . N

Lower JJR N
fornix NN N
and CC N
lid JJ N
margin NN N
cultures NNS N
were VBD N
taken VBN N
from IN N
both DT N
eyes NNS N
before IN N
and CC N
after IN N
treatment NN N
. . N

Before IN N
treatment NN N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
organism NN 1_o
counts NNS 1_o
between IN N
the DT N
groups NNS N
. . N

After IN N
treatment NN N
, , N
eyes NNS N
receiving VBG N
fusidic JJ 1_i
acid NNS 1_i
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
free JJ N
of IN N
clinically RB N
relevant JJ N
Staphylococcus NNP N
spp NN N
. . N

than IN N
all DT N
pre-treatment JJ N
eyes NNS N
( ( N
for IN N
lids NNS N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
conjunctivae NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

A DT N
highly RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
number NN 1_o
of IN 1_o
lid JJ 1_o
margins NNS 1_o
were VBD N
rendered VBN N
'clinically RB N
clean JJ N
' '' N
( ( N
i.e. FW N
, , N
0-49 JJ N
organisms/swab NN N
) ) N
by IN N
fusidic JJ N
acid NN N
when WRB N
compared VBN N
with IN N
untreated JJ N
eyes NNS N
. . N

Treatment NNP N
also RB N
effectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
reduced VBD N
the DT N
numbers NNS 1_o
of IN 1_o
bacteria NNS 1_o
isolated VBN 1_o
from IN 1_o
conjunctivae NN 1_o
. . 1_o

This DT N
study NN N
indicates VBZ N
that IN N
there EX N
is VBZ N
a DT N
highly RB N
significant JJ N
reduction NN N
of IN N
Staphylococcus NNP N
spp NN N
. . N

( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
non-Staphylococcus JJ N
spp NN N
. . N

( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
attainment NN N
of IN N
sterile JJ N
eyes NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
at IN N
operation NN N
gained VBN N
by IN N
patient JJ N
self-administration NN N
of IN N
1 CD N
% NN N
fusidic JJ N
acid RB N
four CD N
times NNS N
daily RB N
for IN N
seven CD N
days NNS N
before IN N
surgery NN N
. . N

A DT N
comparison NN N
of IN N
human JJ N
papillomavirus NN N
testing NN N
of IN N
clinician-collected JJ 1_i
and CC 1_i
self-collected JJ 1_i
samples NNS 1_i
during IN N
follow-up JJ N
after IN N
screen-and-treat NN N
. . N

Screen-and-treat JJ N
cervical JJ N
cancer NN N
prevention NN N
programs NNS N
based VBN N
on IN N
high-risk JJ N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
testing NN N
and CC N
cryotherapy NN N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
resource-limited JJ N
settings NNS N
. . N

However RB N
, , N
because IN N
cryotherapy NN N
is VBZ N
not RB N
100 CD N
% NN N
effective JJ N
, , N
follow-up JJ N
is VBZ N
needed VBN N
after IN N
treatment NN N
to TO N
detect VB N
post-treatment JJ N
failures NNS N
. . N

We PRP N
compared VBN N
the DT N
test NN N
performances NNS N
of IN N
high-risk JJ N
HPV NNP N
testing NN N
( ( N
Hybrid JJ N
Capture NNP N
2 CD N
) ) N
using VBG N
self-collected JJ 1_i
and CC 1_i
clinician-collected JJ 1_i
samples NNS 1_i
as RB N
well RB N
as IN N
cervical JJ 1_i
cytology NN 1_i
for IN N
identifying VBG N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grades NNS N
2 CD N
or CC N
3 CD N
or CC N
invasive JJ N
cervical JJ N
cancer NN N
( ( N
CIN2+ NNP N
) ) N
among IN 1_p
women NNS 1_p
who WP 1_p
did VBD 1_p
( ( 1_p
n=812 NN 1_p
) ) 1_p
and CC 1_p
did VBD 1_p
not RB 1_p
( ( 1_p
n=1858 JJ 1_p
) ) 1_p
undergo VBP 1_p
cryotherapy NN 1_p
in IN 1_p
a DT 1_p
South JJ 1_p
African JJ 1_p
screen-and-treat JJ 1_p
trial NN 1_p
. . 1_p

At IN N
6 CD N
months NNS N
after IN N
enrolment NN N
( ( N
and CC N
after IN N
cryotherapy NN 1_i
, , N
if IN N
performed VBN N
) ) N
, , N
women NNS N
were VBD N
tested VBN N
using VBG N
all DT N
three CD N
screening VBG N
methods NNS N
and CC N
then RB N
underwent JJ N
colposcopy/biopsy NN 1_i
. . N

A DT N
predefined JJ N
subset NN N
of IN N
women NNS N
( ( N
n=1,455 NN N
) ) N
had VBD N
extended VBN N
follow-up NN N
with IN N
colposcopy/biopsy NN 1_i
at IN N
12 CD N
months NNS N
. . N

A DT N
total NN N
of IN N
33 CD N
and CC N
91 CD N
cases NNS N
of IN N
CIN2+ NNP N
were VBD N
detected VBN N
among IN N
treated JJ N
and CC N
untreated JJ N
women NNS N
, , N
respectively RB N
. . N

The DT N
sensitivity NN 1_o
of IN 1_o
HPV NNP 1_o
testing VBG 1_o
using VBG N
clinician-collected JJ 1_i
samples NNS 1_i
and CC N
cervical JJ N
cytology NN N
did VBD N
not RB N
differ VB N
by IN N
treatment NN N
status NN N
. . N

HPV NNP N
testing VBG N
of IN N
clinician-collected JJ 1_i
samples NNS 1_i
detected VBN N
the DT N
most RBS N
cases NNS N
of IN N
CIN2+ NNP 1_o
among IN N
both DT N
treated VBN N
( ( N
85 CD N
% NN N
) ) N
and CC N
untreated JJ N
( ( N
91 CD N
% NN N
) ) N
women NNS N
( ( N
p=0.31 NN N
) ) N
. . N

Cytology NNP 1_o
( ( N
at IN N
a DT N
cutoff NN N
of IN N
atypical JJ N
squamous JJ N
cells NNS N
of IN N
undetermined JJ N
significance NN N
or CC N
greater JJR N
) ) N
detected VBD N
76 CD N
% NN N
of IN N
cases NNS N
among IN N
both DT N
treated VBN N
and CC N
untreated JJ N
women NNS N
. . N

However RB N
, , N
the DT N
sensitivity NN 1_o
of IN 1_o
HPV NNP 1_o
testing VBG 1_o
using VBG N
self-collected JJ 1_i
samples NNS 1_i
was VBD N
significantly RB N
lower JJR N
among IN N
treated JJ N
versus NN N
untreated JJ N
women NNS N
( ( N
55 CD N
% NN N
vs. FW N
78 CD N
% NN N
, , N
p=0.01 NN N
) ) N
. . N

HPV NNP N
testing VBG N
using VBG N
self-collected JJ 1_i
vaginal JJ 1_i
specimens NNS 1_i
may MD N
be VB N
useful JJ N
in IN N
primary JJ N
screening NN N
but CC N
performs NNS N
poorly RB N
for IN N
detecting VBG N
post-treatment JJ 1_o
failures NNS 1_o
. . 1_o

Extra JJ 1_i
prompts NNS 1_i
versus IN N
no DT 1_i
extra JJ 1_i
prompts NNS 1_i
in IN N
self-care JJ N
training NN N
of IN N
autistic JJ 1_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
. . 1_p

A DT N
color-coded JJ 1_i
" NN 1_i
extra JJ 1_i
prompt NN 1_i
" JJ 1_i
procedure NN 1_i
was VBD 1_i
compared VBN 1_i
to TO 1_i
a DT 1_i
" JJ 1_i
no DT 1_i
extra JJ 1_i
prompt NN 1_i
" JJ 1_i
procedure NN 1_i
in IN N
teaching VBG N
autistic JJ 1_p
children NNS 1_p
and CC 1_p
adolescents VBZ 1_p
how WRB N
to TO N
lace VB N
shoes NNS N
. . N

One CD N
randomly NN N
assigned VBN N
group NN N
of IN N
10 CD 1_p
autistic JJ 1_p
subjects NNS 1_p
first RB N
learned VBD 1_i
to TO 1_i
lace VB 1_i
shoes NNS 1_i
whose WP$ 1_i
laces NNS 1_i
and CC 1_i
eyelets NNS 1_i
were VBD 1_i
color-coded JJ 1_i
red JJ 1_i
and CC 1_i
white JJ 1_i
, , 1_i
and CC 1_i
then RB 1_i
encountered VBD 1_i
the DT 1_i
no DT 1_i
extra JJ 1_i
prompt JJ 1_i
condition NN 1_i
in IN 1_i
which WDT 1_i
color NN 1_i
codes NNS 1_i
could MD 1_i
no RB 1_i
longer RB 1_i
be VB 1_i
depended VBN 1_i
upon IN 1_i
to TO 1_i
solve VB 1_i
the DT 1_i
position NN 1_i
discriminations NNS 1_i
required VBN 1_i
to TO 1_i
lace VB 1_i
properly RB 1_i
. . 1_i

In IN N
a DT N
counterbalanced JJ N
fashion NN N
, , N
the DT N
other JJ N
group NN N
of IN N
10 CD 1_p
autistic JJ 1_p
subjects NNS 1_p
reached VBN N
criterion NN N
on IN N
the DT N
non-color-coded JJ N
, , N
naturalistic JJ N
shoe NN N
before IN N
experiencing VBG N
the DT N
extra JJ N
prompt JJ N
condition NN N
. . N

Analysis NN N
of IN N
variance NN N
and CC N
post-hoc JJ N
analyses NNS N
suggest VBP N
that IN N
subjects NNS N
who WP N
first RB N
learned VBN N
under IN N
the DT N
color-coded JJ N
, , N
extra JJ N
prompt JJ N
condition NN N
encountered VBD N
significant JJ N
difficulty NN N
in IN N
transferring VBG N
their PRP$ N
newly RB N
acquired VBN N
skill NN N
to TO N
the DT N
naturalistic JJ N
, , N
non-color-coded JJ N
condition NN N
, , N
whereas JJ N
subjects NNS N
who WP N
learned VBD N
initially RB N
without IN N
the DT N
extra JJ N
prompts NNS N
had VBD N
little JJ N
difficulty NN N
with IN N
the DT N
subsequent JJ N
color-coded JJ N
condition NN N
. . N

A DT N
follow-up JJ N
procedure NN N
requiring VBG N
all DT N
subjects NNS N
to TO N
choose VB N
between IN N
the DT N
color NN N
prompt NN N
and CC N
the DT N
position NN N
cue NN N
revealed VBD N
that IN N
11 CD N
of IN N
20 CD 1_p
subjects NNS 1_p
consistently RB N
chose VBD N
the DT N
color NN N
cue NN N
, , N
even RB N
though IN N
it PRP N
resulted VBD N
in IN N
improper JJ N
lacing NN N
. . N

It PRP N
is VBZ N
recommended VBN N
that IN N
clinicians NNS N
avoid VBP N
the DT N
use NN N
of IN N
highly RB N
salient JJ N
, , N
non-criterion-related JJ N
prompts NNS N
in IN N
teaching VBG N
certain JJ N
types NNS N
of IN N
adaptive JJ N
skills NNS N
to TO N
autistic JJ 1_p
children NNS 1_p
. . 1_p

Rioprostil NNP 1_i
, , N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
, , N
in IN N
the DT N
once-daily JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
duodenal JJ 1_p
ulcer JJ 1_p
recurrence NN N
: : N
a DT N
comparison NN N
with IN N
ranitidine NN N
. . N

The DT N
efficacy NN 1_o
of IN N
Rioprostil NNP 1_i
( ( N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
) ) N
is VBZ N
compared VBN N
with IN N
that DT N
of IN N
ranitidine NN 1_i
in IN N
the DT N
recurrence NN N
prevention NN N
of IN N
duodenal JJ N
ulcer NN N
( ( N
s NN N
) ) N
. . N

Duration NN N
of IN N
treatment NN N
is VBZ N
6 CD N
months NNS N
. . N

Ninety-seven JJ 1_p
patients NNS 1_p
received VBD 1_p
rioprostil JJ 1_i
, , 1_i
600 CD 1_i
micrograms NNS 1_i
once-daily RB 1_i
orally RB 1_i
, , 1_i
and CC 1_i
110 CD 1_i
patients NNS 1_i
received JJ 1_i
ranitidine NN 1_i
, , 1_i
150 CD 1_i
mg JJ 1_i
once-daily RB 1_i
orally RB 1_i
. . 1_i

On IN N
rioprostil NN 1_i
, , N
14.9 CD N
% NN N
of IN N
patients NNS N
showed VBD N
a DT N
relapse NN 1_o
after IN N
6 CD N
months NNS N
compared VBN N
to TO N
10.1 CD N
% NN N
on IN N
ranitidine NN 1_i
. . 1_i

Diarrhoea NNP 1_o
occurred VBD N
in IN N
7 CD N
patients NNS N
on IN N
rioprostil NN 1_i
and CC N
3 CD N
patients NNS N
on IN N
ranitidine NN 1_i
. . 1_i

Rioprostil NNP 1_i
given VBN N
600 CD N
micrograms NNS N
daily RB N
in IN N
the DT N
evening NN N
is VBZ N
a DT N
highly RB N
effective JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
duodenal JJ N
ulcer NN N
relapse NN N
, , N
the DT N
efficacy NN 1_o
not RB N
being VBG N
significantly RB N
different JJ N
from IN N
ranitidine NN 1_i
150 CD N
mg NN N
. . N

Studies NNS N
on IN N
leptin NN 1_o
and CC 1_o
leptin NN 1_o
receptor NN 1_o
gene NN 1_o
expression NN 1_o
in IN N
myometrium NN 1_p
and CC 1_p
uterine JJ 1_p
myomas NN 1_p
of IN 1_p
gnRH JJ 1_i
analogue-treated JJ 1_i
women NNS 1_p
. . 1_p

AIM NNP N
To TO N
test VB N
if IN N
treatment NN N
with IN N
GnRH NNP 1_i
analogue NN 1_i
, , N
which WDT N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
myoma NN 1_o
volume NN 1_o
, , 1_o
changes NNS 1_o
expression NN 1_o
of IN 1_o
leptin NN 1_o
genes NNS 1_o
and CC 1_o
gene NN 1_o
coding VBG 1_o
leptin JJ 1_o
receptor NN 1_o
isoforms NNS 1_o
in IN N
uterine JJ N
myomas NN N
and CC N
in IN N
the DT N
surrounding NN N
unaltered JJ N
myometrium NN N
. . N

METHODS NNP N
Using VBG N
RT-PCR NNP N
, , N
expression NN N
of IN N
leptin NN N
genes NNS N
and CC N
leptin NN N
receptor NN N
genes NNS N
was VBD N
studied VBN N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
in IN N
women NNS 1_p
with IN 1_p
uterine JJ 1_p
myomas NN 1_p
, , 1_p
untreated VBD 1_p
or CC 1_p
treated VBN 1_p
with IN 1_p
GnRH NNP 1_i
analogue NN 1_i
. . 1_i

In IN N
the DT N
randomly RB N
selected VBN N
cases NNS N
presence NN N
of IN N
leptin NN N
protein NN N
and CC N
of IN N
leptin JJ N
receptor NN N
proteins NNS N
was VBD N
examined VBN N
also RB N
by IN N
Western JJ N
blotting NN N
. . N

RESULTS NNP N
Expression NNP 1_o
of IN 1_o
leptin NN 1_o
genes NNS 1_o
was VBD N
demonstrated VBN N
both DT N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
, , N
and CC N
a DT N
similar JJ N
pattern NN N
of IN N
expression NN N
was VBD N
found VBN N
for IN N
leptin JJ N
receptor NN N
isoforms NNS N
. . N

The DT N
results NNS N
of IN N
RT-PCR NNP N
were VBD N
confirmed VBN N
by IN N
Western JJ N
blotting NN N
, , N
which WDT N
documented VBD N
the DT N
identical JJ N
distribution NN N
of IN N
leptin NN 1_o
proteins NNS 1_o
and CC 1_o
leptin JJ 1_o
receptor NN 1_o
proteins NNS 1_o
in IN N
studied JJ N
tissues NNS N
. . N

Treatment NN N
with IN N
GnRH NNP 1_i
analogue NN 1_i
had VBD N
no DT N
effect NN 1_o
on IN N
the DT N
expression NN 1_o
pattern NN 1_o
of IN N
studied VBN N
genes NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
on IN N
the DT N
administration NN N
of IN N
GnRH NNP 1_i
analogue NN 1_i
to TO N
females NNS 1_p
with IN 1_p
myomas NN 1_p
suggest VBP N
that IN N
no DT N
direct JJ N
or CC N
immediate JJ N
inter-relationship JJ N
exists NNS N
between IN N
expression NN N
of IN N
leptin NN 1_o
genes NNS 1_o
in IN N
uterine JJ N
myomas NN N
on IN N
one CD N
hand NN N
and CC N
estrogen NN N
, , N
progesterone NN N
and CC N
leptin NN N
levels NNS N
in IN N
the DT N
blood NN N
on IN N
the DT N
other JJ N
. . N

Expression NN N
seems VBZ N
to TO N
be VB N
of IN N
a DT N
more RBR N
durable JJ N
nature NN N
but CC N
factors NNS N
that WDT N
induce VBP N
such JJ N
expression NN N
remain VBP N
unknown JJ N
. . N

Vaginal JJ 1_i
electrical JJ 1_i
stimulation NN 1_i
of IN 1_i
the DT 1_i
pelvic JJ 1_i
floor NN 1_i
: : 1_i
a DT N
randomized JJ N
feasibility NN N
study NN N
in IN N
urinary JJ 1_p
incontinent NN 1_p
elderly JJ 1_p
women NNS 1_p
. . 1_p

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN 1_o
of IN N
intravaginal JJ 1_i
electrical JJ 1_i
stimulation NN 1_i
( ( 1_i
ES NNP 1_i
) ) 1_i
of IN N
the DT N
pelvic JJ N
floor NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ 1_p
women NNS 1_p
, , N
and CC N
to TO N
determine VB N
whether IN N
ES NNP 1_i
of IN 1_i
the DT 1_i
pelvic JJ 1_i
floor NN 1_i
is VBZ N
a DT N
preferable JJ N
treatment NN N
for IN N
urinary JJ 1_p
incontinence NN 1_p
in IN 1_p
elderly JJ 1_p
women NNS 1_p
. . 1_p

METHODS NNP N
Postmenopausal NNP 1_p
women NNS 1_p
( ( 1_p
age NN 1_p
65 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
) ) 1_p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
and CC N
underwent JJ N
every-other-day JJ N
ES NNP 1_i
of IN 1_i
the DT 1_i
pelvic JJ 1_i
floor NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
daily JJ 1_i
Kegel NNP 1_i
exercise NN 1_i
( ( 1_i
KE NNP 1_i
) ) 1_i
program NN 1_i
. . 1_i

Objective NNP N
outcome NN N
variables NNS N
were VBD N
: : N
( ( 1_o
1 CD 1_o
) ) 1_o
Urinary JJ 1_o
leakage NN 1_o
( ( 1_o
during IN 1_o
a DT 1_o
standardized JJ 1_o
PAD NNP 1_o
test NN 1_o
) ) 1_o
, , 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
pelvic NN 1_o
muscle NN 1_o
strength NN 1_o
( ( 1_o
measured VBN 1_o
by IN 1_o
a DT 1_o
perineometer NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
( ( 1_o
3 CD 1_o
) ) 1_o
detrusor NN 1_o
instability NN 1_o
( ( 1_o
on IN 1_o
ambulant NN 1_o
urodynamic JJ 1_o
registration NN 1_o
) ) 1_o
. . 1_o

Subjective JJ N
outcome NN N
variables NNS N
were VBD N
women NNS 1_o
's POS 1_o
subjective JJ 1_o
assessment NN 1_o
of IN 1_o
change NN 1_o
in IN 1_o
urinary JJ 1_o
symptoms NNS 1_o
based VBN 1_o
on IN 1_o
the DT 1_o
PRAFAB NNP 1_o
score NN 1_o
. . 1_o

Twenty-four JJ 1_p
women NNS 1_p
treated VBN 1_p
with IN 1_p
ES NNP 1_i
and CC 1_p
11 CD 1_p
women NNS 1_p
treated VBN 1_p
with IN 1_p
Kegel NNP 1_i
exercises NNS 1_i
completed VBD N
the DT N
8-week JJ N
study NN N
program NN N
. . N

The DT N
Chi-square JJ N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
in IN N
objective JJ N
outcome NN N
variables NNS N
was VBD N
observed VBN N
in IN N
the DT N
population NN N
treated VBD N
with IN N
ES NNP 1_i
compared VBN N
with IN N
the DT N
population NN N
treated VBD N
with IN N
KE NNP 1_i
( ( N
with IN N
29.2 CD N
% NN N
vs. FW N
36.4 CD N
% NN N
of IN N
the DT N
women NNS N
showing VBG N
objective JJ N
improvement NN N
in IN N
measured JJ 1_o
urinary JJ 1_o
leakage NN 1_o
) ) 1_o
. . N

Neither CC N
was VBD N
subjective JJ N
improvement NN N
significant JJ N
, , N
with IN N
29.2 CD N
% NN N
vs. FW N
27.3 CD N
% NN N
of IN N
the DT N
women NNS N
reporting VBG N
improvement NN N
in IN N
the DT N
amount NN 1_o
of IN 1_o
urinary JJ 1_o
leakage NN 1_o
. . 1_o

CONCLUSIONS NNP N
Although IN N
the DT N
number NN N
of IN N
enrolled JJ N
women NNS N
was VBD N
very RB N
small JJ N
this DT N
study NN N
shows VBZ N
that IN N
: : N
1 CD N
. . N

Treating VBG N
elderly JJ 1_p
women NNS 1_p
with IN N
vaginal JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
has VBZ N
a DT N
high JJ N
physical JJ N
and CC N
emotional JJ N
cost NN N
for IN N
the DT N
individual NN N
. . N

2 CD N
. . N

The DT N
effectiveness NN 1_o
of IN N
ES NNP 1_i
of IN N
the DT N
pelvic JJ N
floor NN N
in IN N
urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
is VBZ N
low JJ N
. . N

3 CD N
. . N

There EX N
is VBZ N
no DT N
great JJ N
discrepancy NN N
between IN N
objective JJ N
amelioration NN N
( ( N
PAD NNP N
test NN N
) ) N
and CC N
subjective JJ N
amelioration NN N
( ( N
PRAFAB NNP N
score/quantity NN N
of IN N
urinary JJ N
leakage NN N
) ) N
, , N
if IN N
the DT N
objective JJ N
improvement NN N
is VBZ N
adequately RB N
defined VBN N
. . N

4 CD N
. . N

It PRP N
is VBZ N
not RB N
reasonable JJ N
to TO N
advise VB N
elderly JJ N
women NNS N
with IN N
urinary JJ N
incontinence NN N
to TO N
undertake VB N
this DT N
treatment NN N
procedure NN N
. . N

The DT N
effectiveness NN N
of IN N
treatment NN N
does VBZ N
not RB N
compensate VB N
for IN N
the DT N
long-lasting JJ N
and CC N
intense JJ N
treatment NN N
protocol NN N
. . N

5 CD N
. . N

We PRP N
terminated VBD N
this DT N
study NN N
because IN N
of IN N
the DT N
negative JJ N
outcome NN N
with IN N
ES NNP 1_i
. . 1_i

Dronabinol NNP 1_i
versus NN 1_i
megestrol NN 1_i
acetate VBP 1_i
versus NN 1_i
combination NN 1_i
therapy NN 1_i
for IN N
cancer-associated JJ N
anorexia NN N
: : N
a DT N
North JJ N
Central JJ N
Cancer NNP N
Treatment NNP N
Group NNP N
study NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
whether IN N
dronabinol NN 1_i
administered VBN N
alone RB N
or CC N
with IN N
megestrol JJ 1_i
acetate NN 1_i
was VBD N
more RBR N
, , N
less RBR N
, , N
or CC N
equal JJ N
in IN N
efficacy NN N
to TO N
single-agent JJ N
megestrol NN 1_i
acetate NN 1_i
for IN N
palliating VBG N
cancer-associated JJ N
anorexia NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Four NNP 1_p
hundred VBD 1_p
sixty-nine JJ 1_p
assessable JJ 1_p
advanced JJ 1_p
cancer NN 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
( ( 1_p
1 CD 1_p
) ) 1_p
oral JJ 1_p
megestrol NN 1_i
acetate VBP 1_i
800 CD 1_p
mg/d NN 1_p
liquid NN 1_i
suspension NN 1_i
plus CC 1_i
placebo NN 1_i
, , 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
oral JJ 1_p
dronabinol $ 1_i
2.5 CD 1_p
mg NN 1_p
twice RB 1_p
a DT 1_p
day NN 1_p
plus CC 1_p
placebo NN 1_i
, , 1_p
or CC 1_p
( ( 1_p
3 CD 1_p
) ) 1_p
both DT 1_i
agents NNS 1_i
. . 1_i

Eligible JJ 1_p
patients NNS 1_p
acknowledged VBD 1_p
that IN 1_p
loss NN 1_p
of IN 1_p
appetite NN 1_p
or CC 1_p
weight NN 1_p
was VBD 1_p
a DT 1_p
problem NN 1_p
and CC 1_p
reported VBD 1_p
the DT 1_p
loss NN 1_p
of IN 1_p
5 CD 1_p
pounds NNS 1_p
or CC 1_p
more JJR 1_p
during IN 1_p
2 CD 1_p
months NNS 1_p
and/or IN 1_p
a DT 1_p
daily JJ 1_p
intake NN 1_p
of IN 1_p
less JJR 1_p
than IN 1_p
20 CD 1_p
calories/kg NN 1_p
of IN 1_p
body NN 1_p
weight NN 1_p
. . 1_p

RESULTS JJ N
Groups NNP N
were VBD N
comparable JJ N
at IN N
baseline NN N
in IN N
age NN N
, , N
sex NN N
, , N
tumor NN N
type NN N
, , N
weight JJ N
loss NN N
, , N
and CC N
performance NN N
status NN N
. . N

A DT N
greater JJR N
percentage NN N
of IN N
megestrol NN 1_i
acetate-treated JJ 1_i
patients NNS 1_p
reported VBD N
appetite JJ 1_o
improvement NN 1_o
and CC 1_o
weight VBD 1_o
gain NN 1_o
compared VBN N
with IN N
dronabinol-treated JJ 1_i
patients NNS 1_p
: : 1_p
75 CD N
% NN N
versus IN N
49 CD N
% NN N
( ( N
P NNP N
=.0001 NNP N
) ) N
for IN N
appetite NN N
and CC N
11 CD N
% NN N
versus IN N
3 CD N
% NN N
( ( N
P NNP N
=.02 NNP N
) ) N
for IN N
> NN N
or CC N
= VB N
10 CD N
% NN N
baseline NN N
weight NN N
gain NN N
. . N

Combination NNP N
treatment NN N
resulted VBD N
in IN N
no DT N
significant JJ N
differences NNS 1_o
in IN 1_o
appetite NN 1_o
or CC 1_o
weight NN 1_o
compared VBN N
with IN N
megestrol NN 1_i
acetate NN 1_i
alone RB N
. . N

The DT N
Functional NNP N
Assessment NNP N
of IN N
Anorexia/Cachexia NNP N
Therapy NNP N
questionnaire NN N
, , N
which WDT N
emphasizes VBZ N
anorexia-related JJ N
questions NNS N
, , N
demonstrated VBD N
an DT N
improvement NN N
in IN N
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QOL NNP 1_o
) ) 1_o
among IN N
megestrol JJ 1_i
acetate-treated JJ 1_i
and CC 1_p
combination-treated JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
single-item JJ N
Uniscale NNP N
, , N
a DT N
global JJ N
QOL NNP 1_o
instrument NN N
, , N
found VBN N
comparable JJ N
scores NNS N
. . N

Toxicity NN 1_o
was VBD N
also RB N
comparable JJ N
, , N
with IN N
the DT N
exception NN N
of IN N
an DT N
increased JJ N
incidence NN N
of IN N
impotence NN 1_o
among IN N
men NNS 1_p
who WP 1_p
received VBD 1_p
megestrol NN 1_i
acetate NN 1_i
. . 1_i

CONCLUSION NNP N
In IN N
the DT N
doses NNS N
and CC N
schedules NNS N
we PRP N
studied VBD N
, , N
megestrol NN 1_i
acetate NN 1_i
provided VBD N
superior JJ N
anorexia JJ N
palliation NN N
among IN N
advanced JJ 1_p
cancer NN 1_p
patients NNS 1_p
compared VBN N
with IN N
dronabinol NN 1_i
alone RB N
. . N

Combination NNP N
therapy NN N
did VBD N
not RB N
appear VB N
to TO N
confer VB N
additional JJ N
benefit NN N
. . N

Benefits NNS N
of IN N
adding VBG N
fluticasone NN 1_i
propionate/salmeterol NN 1_i
to TO N
tiotropium VB 1_i
in IN N
moderate JJ 1_p
to TO 1_p
severe VB 1_p
COPD NNP 1_p
. . 1_p

BACKGROUND NNP N
Combining NNP N
maintenance NN N
medications NNS N
with IN N
different JJ N
mechanisms NNS N
of IN N
action NN N
may MD N
improve VB N
outcomes NNS N
in IN N
COPD NNP N
. . N

In IN N
this DT N
study NN N
we PRP N
evaluated VBD N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
fluticasone/salmeterol NN 1_i
( ( 1_i
FSC NNP 1_i
) ) 1_i
( ( N
250/50 CD N
mcg NN N
twice RB N
daily RB N
) ) N
when WRB N
added VBN N
to TO 1_i
tiotropium VB 1_i
( ( N
18 CD N
mcg NN N
once RB N
daily RB 1_i
) ) 1_i
( ( N
TIO NNP N
) ) N
in IN 1_p
subjects NNS 1_p
with IN 1_p
symptomatic JJ 1_p
moderate NN 1_p
to TO 1_p
severe VB 1_p
COPD NNP 1_p
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
24-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel JJ N
group NN N
, , N
multi-center NN N
study NN 1_p
. . 1_p

Subjects VBZ 1_p
40 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
with IN 1_p
cigarette NN 1_p
smoking VBG 1_p
history NN 1_p
≥10 JJ 1_p
pack-years NNS 1_p
and CC 1_p
with IN 1_p
the DT 1_p
diagnosis NN 1_p
of IN 1_p
COPD NNP 1_p
and CC 1_p
post-bronchodilator NN 1_p
FEV NNP 1_p
( ( 1_p
1 CD 1_p
) ) 1_p
≥40 NN 1_p
to TO 1_p
≤ VB 1_p
80 CD 1_p
% NN 1_p
of IN 1_p
predicted VBN 1_p
normal JJ 1_p
and CC 1_p
FEV NNP 1_p
( ( 1_p
1 CD 1_p
) ) 1_p
/FVC NN 1_p
of IN 1_p
≤0.70 NN 1_p
were VBD 1_p
enrolled VBN N
. . N

Following VBG N
a DT N
4-week JJ N
treatment NN N
with IN N
open-label JJ 1_i
TIO NNP N
18 CD N
mcg NN N
once RB N
daily JJ N
, , N
subjects NNS N
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
either VB N
the DT N
addition NN N
of IN N
FSC NNP N
250/50 CD N
DISKUS NNP N
twice RB N
daily RB N
or CC N
matching VBG N
placebo NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN 1_o
was VBD 1_o
AM NNP 1_o
pre-dose JJ 1_o
FEV NNP N
( ( N
1 CD N
) ) N
and CC N
secondary JJ N
endpoints NNS N
included VBD 1_o
other JJ 1_o
measures NNS 1_o
of IN 1_o
lung NN 1_o
function NN 1_o
, , 1_o
rescue NN 1_o
albuterol NN 1_o
use NN 1_o
, , 1_o
health NN 1_o
status NN 1_o
and CC 1_o
exacerbations NNS 1_o
. . N

RESULTS VB N
The DT N
addition NN 1_i
of IN N
FSC NNP N
to TO N
TIO NNP N
significantly RB 1_o
improved VBD 1_o
lung JJ 1_o
function NN 1_o
indices NNS 1_o
including VBG 1_o
AM NNP 1_o
pre-dose JJ 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
, , 1_o
2 CD 1_o
h NN 1_o
post-dose JJ 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
, , 1_o
AM NNP 1_o
pre-dose JJ 1_o
FVC NNP 1_o
, , 1_o
2 CD 1_o
h NN 1_o
post-dose JJ 1_o
FVC NNP 1_o
and CC 1_o
AM NNP 1_o
pre-dose JJ N
IC NNP N
compared VBN N
with IN N
TIO NNP N
alone RB N
. . N

Furthermore RB N
, , N
this DT N
combination NN N
was VBD N
superior JJ N
to TO N
TIO VB N
alone RB 1_o
in IN 1_o
reducing VBG 1_o
rescue NN 1_o
albuterol NN 1_o
use NN N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN 1_o
groups NNS 1_o
in IN 1_o
health NN 1_o
status NN 1_o
or CC 1_o
COPD NNP 1_o
exacerbations NNS 1_o
. . N

The DT N
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
events NNS N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
addition NN 1_p
of IN 1_p
FSC NNP 1_p
to TO 1_p
subjects NNS 1_p
with IN N
COPD NNP N
treated VBD N
with IN N
TIO NNP N
significantly RB 1_o
improves VBZ 1_o
lung JJ 1_o
function NN N
without IN N
increasing VBG 1_o
the DT 1_o
risk NN 1_o
of IN N
adverse JJ N
events NNS N
. . N

NCT00784550 NNP N
. . N

Using VBG N
repeated JJ N
measures NNS N
of IN N
symptom NN N
score NN N
, , N
uroflowmetry NN N
and CC N
prostate NN N
specific JJ N
antigen NN N
in IN N
the DT N
clinical JJ N
management NN N
of IN N
prostate NN 1_p
disease NN 1_p
. . 1_p

Benign NNP 1_p
Prostatic NNP 1_p
Hyperplasia NNP 1_p
Treatment NNP N
Outcomes NNP N
Study NNP N
Group NNP N
. . N

Measurements NNS 1_i
of IN 1_i
American NNP 1_o
Urological NNP 1_o
Association NNP 1_o
symptom VBD 1_o
score RB 1_o
, , 1_o
peak JJ 1_o
urine JJ 1_o
flow NN 1_o
rate NN 1_o
and CC 1_i
prostate NN 1_o
specific JJ 1_o
antigen NN 1_o
( ( 1_o
PSA NNP 1_o
) ) 1_o
are VBP 1_i
often RB 1_i
followed VBN 1_i
over RP 1_i
time NN 1_i
in IN 1_i
urological JJ 1_i
management NN 1_i
. . 1_i

However RB N
, , N
their PRP$ N
interpretation NN N
is VBZ N
confounded VBN N
by IN N
within-patient JJ N
variability NN N
due JJ N
to TO N
chance NN N
. . N

Data NNP N
from IN N
2 CD N
clinical JJ N
trials NNS N
are VBP N
used VBN N
to TO N
examine VB N
the DT N
magnitude NN N
of IN N
this DT N
variation NN N
. . N

When WRB N
these DT N
measures NNS N
are VBP N
repeated VBN N
at IN N
a DT N
short JJ N
interval NN N
variation NN N
is VBZ N
modest JJ N
and CC N
might MD N
easily RB N
be VB N
misinterpreted VBN N
as IN N
a DT N
true JJ N
change NN N
in IN N
patient JJ N
condition NN N
. . N

For IN N
example NN N
, , N
approximately RB 1_p
20 CD 1_p
% NN 1_p
of IN 1_p
patients NNS 1_p
might MD N
be VB N
expected VBN N
to TO N
have VB N
a DT N
chance NN N
increase NN N
or CC N
decrease NN N
in IN N
symptom NN N
score NN N
by IN N
at IN N
least JJS N
4.9 CD N
points NNS N
, , N
in IN N
peak JJ N
urine JJ N
flow NN N
rate NN N
by IN N
at IN N
least JJS N
4.1 CD N
ml NN N
. . N

per IN N
second NN N
or CC N
in IN N
PSA NNP N
by IN N
at IN N
least JJS N
1.6 CD N
ng./ml NN N
. . N

Clinicians NNS N
can MD N
use VB N
these DT N
data NNS N
to TO N
help VB N
interpret VB N
repeated JJ N
measures NNS N
of IN N
these DT N
variables NNS N
in IN N
patients NNS N
, , N
and CC N
can MD N
consider VB N
obtaining VBG N
paired JJ N
measurements NNS N
to TO N
decrease VB N
the DT N
effect NN N
of IN N
chance NN N
variation NN N
when WRB N
they PRP N
plan VBP N
on IN N
following VBG N
them PRP N
over IN N
time NN N
. . N

Effects NNS N
of IN N
formoterol NN 1_i
, , 1_i
salmeterol NN 1_i
or CC 1_i
oxitropium NN 1_i
bromide NN 1_i
on IN N
airway NN 1_o
responses NNS 1_o
to TO 1_o
salbutamol VB 1_o
in IN N
COPD NNP 1_p
. . 1_p

We PRP N
examined VBD N
whether IN N
a DT N
pretreatment NN N
with IN N
formoterol NN 1_i
, , 1_i
oxitropium NN 1_i
bromide NN 1_i
, , 1_i
or CC 1_i
salmeterol NN 1_i
might MD N
modify VB N
the DT N
dose-response JJ 1_o
curves NNS 1_o
to TO 1_o
inhaled VB 1_o
salbutamol NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
stable JJ 1_p
and CC 1_p
partially RB 1_p
reversible JJ 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
( ( 1_p
COPD NNP 1_p
) ) 1_p
. . 1_p

Sixteen JJ 1_p
outpatients NNS 1_p
with IN 1_p
partially RB 1_p
reversible JJ 1_p
, , 1_p
stable JJ 1_p
COPD NNP 1_p
received VBD 1_i
24 CD 1_i
microg NNS 1_i
formoterol NN 1_i
, , 1_i
50 CD 1_i
microg NN 1_i
salmeterol NN 1_i
, , 1_i
200 CD 1_i
microg NN 1_i
oxitropium NN 1_i
bromide NN 1_i
, , 1_i
or CC 1_i
placebo VB 1_i
on IN 1_i
four CD 1_i
non-consecutive JJ 1_i
days NNS 1_i
. . 1_i

Spirometric JJ 1_i
testing NN 1_i
was VBD N
performed VBN N
immediately RB N
before IN N
inhalation NN N
of IN N
treatment NN N
and CC N
after IN N
2 CD N
h. VBD N
A DT N
dose-response JJ 1_o
curve NN 1_o
to TO 1_o
inhaled VB 1_o
salbutamol NN 1_o
was VBD N
then RB N
constructed VBN 1_i
using VBG 1_i
doses NNS 1_i
of IN 1_i
100 CD 1_i
, , 1_i
100 CD 1_i
, , 1_i
200 CD 1_i
microg NN 1_i
and CC 1_i
400 CD 1_i
microg NN 1_i
-- : 1_i
that WDT 1_i
is VBZ 1_i
, , 1_i
a DT 1_i
total JJ 1_i
cumulative JJ 1_i
dose NN 1_i
of IN 1_i
800 CD 1_i
microg NN 1_i
. . 1_i

Dose JJ N
increments NNS N
were VBD N
given VBN N
at IN N
20 CD N
min NN N
intervals NNS N
with IN N
measurements NNS N
being VBG N
made VBD N
15 CD N
min NNS N
after IN N
each DT N
dose NN N
. . N

Formoterol NNP 1_i
, , 1_i
salmeterol NN 1_i
, , N
or CC N
oxitropium NN 1_i
bromide RB 1_i
elicited VBD N
a DT N
significant JJ N
increase NN N
in IN N
forced JJ 1_o
expiratory NN 1_o
volume NN 1_o
in IN 1_o
one CD 1_o
second NN 1_o
( ( 1_o
FEV1 NNP 1_o
) ) 1_o
compared VBN N
with IN N
placebo NN 1_i
( ( N
mean JJ N
differences NNS N
( ( N
L NNP N
) ) N
= VBD N
placebo $ 1_i
0.05 CD N
; : N
formoterol NN 1_i
0.34 CD N
; : N
salmeterol NN 1_i
0.27 CD N
; : N
oxitropium NN 1_i
bromide IN 1_i
0.23 CD N
) ) N
. . N

Dose-dependent JJ N
increases NNS N
in IN N
FEV1 NNP 1_o
were VBD N
seen VBN N
( ( N
mean JJ N
values NNS N
( ( N
L NNP N
) ) N
before IN N
salbutamol NN N
and CC N
after IN N
a DT N
cumulative JJ N
dose NN N
of IN N
100 CD N
, , N
200 CD N
, , N
400 CD N
, , N
and CC N
800 CD N
microg NN N
= NN N
placebo NN 1_i
: : 1_i
1.06 CD N
, , N
1.28 CD N
, , N
1.35 CD N
, , N
1.39 CD N
, , N
1.41 CD N
; : N
formoterol NN 1_i
: : 1_i
1.33 CD N
, , N
1.37 CD N
, , N
1.41 CD N
, , N
1.44 CD N
, , N
1.44 CD N
; : N
salmeterol NN 1_i
: : 1_i
1.30 CD N
, , N
1.33 CD N
, , N
1.36 CD N
, , N
1.39 CD N
, , N
1.42 CD N
; : N
oxitropium JJ 1_i
bromide NN 1_i
: : 1_i
1.27 CD N
, , N
1.34 CD N
, , N
1.37 CD N
, , N
1.41 CD N
, , N
1.40 CD N
) ) N
. . N

Statistical JJ N
analysis NN N
revealed VBD N
no DT N
significant JJ N
differences NNS N
in IN N
FEV1 NNP 1_o
and CC 1_o
forced VBD 1_o
vital JJ 1_o
capacity NN 1_o
( ( 1_o
FVC NNP 1_o
) ) 1_o
responses VBZ 1_o
to TO N
salbutamol VB N
after IN N
therapy NN N
with IN N
formoterol NN 1_i
, , 1_i
salmeterol NN 1_i
, , 1_i
or CC 1_i
oxitropium NN 1_i
bromide NN 1_i
compared VBN N
with IN N
placebo NN 1_i
. . 1_i

This DT N
study NN N
clearly RB N
shows VBZ N
that IN N
a DT N
pretreatment NN N
with IN N
a DT N
conventional JJ N
dose NN N
of IN N
formoterol NN 1_i
, , 1_i
salmeterol NN 1_i
, , 1_i
or CC 1_i
oxitropium JJ 1_i
bromide NN 1_i
does VBZ N
not RB N
preclude VB N
the DT N
possibility NN N
of IN N
inducing VBG N
a DT N
further JJ N
bronchodilation NN 1_o
with IN N
salbutamol NN 1_i
in IN N
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
partially RB 1_p
reversible JJ 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
. . 1_p

Management NN N
of IN N
unstable JJ 1_p
angina NN 1_p
at IN 1_p
rest NN 1_p
by IN N
verapamil NN 1_i
. . 1_i

A DT N
double-blind JJ N
cross-over NN N
study NN N
in IN N
coronary JJ N
care NN N
unit NN N
. . N

A NNP N
therapeutic JJ N
trial NN N
with IN N
verapamil NN 1_i
, , N
a DT N
calcium-antagonist JJ 1_i
drug NN 1_i
, , N
was VBD N
performed VBN N
in IN N
12 CD 1_p
patients NNS 1_p
admitted VBN 1_p
to TO 1_p
our PRP$ 1_p
coronary JJ 1_p
care NN 1_p
unit NN 1_p
because IN 1_p
of IN 1_p
frequent JJ 1_p
daily JJ 1_p
attacks NNS 1_p
of IN 1_p
angina NN 1_p
at IN 1_p
rest NN 1_p
attributed VBN 1_p
to TO 1_p
coronary JJ 1_p
vasospasm NN 1_p
. . 1_p

After IN N
a DT N
48-hour JJ N
run-in JJ N
period NN N
, , N
oral JJ 1_i
verapamil NN 1_i
480 CD 1_i
mg/day NN 1_i
and CC 1_i
placebo NN 1_i
were VBD N
administered VBN N
alternately RB N
during IN N
4 CD N
randomised VBD N
48-hour CD N
periods NNS N
. . N

Transient NNP 1_o
ischaemic JJ 1_o
attacks NNS 1_o
with IN 1_o
ST NNP 1_o
segment NN 1_o
elevation NN 1_o
or CC 1_o
depression NN 1_o
, , 1_o
with IN 1_o
or CC 1_o
without IN 1_o
pain NN 1_o
, , N
were VBD N
documented VBN N
by IN N
continuous JJ 1_o
electrocardiographic JJ 1_o
monitoring NN 1_o
. . 1_o

The DT N
number NN 1_o
of IN 1_o
attacks NNS 1_o
during IN N
the DT N
run-in JJ N
and CC N
2 CD N
placebo NN 1_i
periods NNS N
were VBD N
128 CD N
, , N
123 CD N
, , N
and CC N
130 CD N
, , N
respectively RB N
, , N
and CC N
31 CD N
and CC N
23 CD N
during IN N
the DT N
2 CD N
treatment NN N
periods NNS N
( ( N
P NNP N
less JJR N
than IN N
0.006 CD N
and CC N
P NNP N
less JJR N
than IN N
0.003 CD N
) ) N
. . N

This DT N
drug NN N
therefore RB N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
the DT N
management NN N
of IN N
patients NNS 1_p
with IN 1_p
frequent JJ 1_p
attacks NNS 1_o
of IN 1_o
angina NN 1_o
at IN 1_o
rest NN 1_o
. . 1_o

Growth NNP 1_o
hormone NN 1_o
( ( 1_o
GH NNP 1_o
) ) 1_o
responses VBZ 1_o
to TO N
GH-releasing NNP 1_i
hormone NN 1_i
alone RB 1_i
or CC N
combined VBN 1_i
with IN 1_i
arginine NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
adrenal JJ 1_p
incidentaloma NN 1_p
: : 1_p
evidence NN N
for IN N
enhanced JJ N
somatostatinergic JJ N
tone NN N
. . N

Spontaneous JJ N
and CC N
stimulated VBD N
GH NNP N
secretion NN N
is VBZ N
blunted VBN N
in IN N
hypercortisolemic JJ N
states NNS N
due JJ N
to TO N
increased VBN N
hypothalamic JJ N
somatostatinergic NN N
tone NN N
. . N

However RB N
, , N
no DT N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
characteristics NNS N
of IN N
GH NNP N
secretion NN N
in IN N
patients NNS 1_p
with IN 1_p
incidentally RB 1_p
discovered VBN 1_p
adrenal JJ 1_p
adenomas NN 1_p
. . 1_p

They PRP N
represent VBP N
an DT N
interesting JJ N
model NN N
for IN N
studying VBG N
GH NNP N
secretion NN N
, , N
as IN N
a DT N
slight JJ N
degree NN N
of IN N
cortisol NN N
excess NN N
may MD N
frequently RB N
be VB N
observed VBN N
in IN N
such JJ N
patients NNS 1_p
who WP 1_p
do VBP 1_p
not RB 1_p
present VB 1_p
with IN 1_p
any DT 1_p
clear JJ 1_p
Cushingoid NNP 1_p
sign NN 1_p
. . 1_p

In IN N
the DT N
present JJ N
study NN N
, , N
10 CD 1_p
patients NNS 1_p
( ( 1_p
3 CD 1_p
men NNS 1_p
and CC 1_p
7 CD 1_p
women NNS 1_p
, , 1_p
aged VBD 1_p
48-63 JJ 1_p
yr NN 1_p
) ) 1_p
with IN 1_p
an DT 1_p
adrenal JJ 1_p
mass NN 1_p
discovered VBD 1_p
serendipitously RB 1_p
underwent JJ N
, , N
on IN N
separate JJ N
occasions NNS N
, , N
a DT N
GHRH NNP 1_i
injection NN 1_i
alone RB 1_i
or CC N
combined VBN 1_i
with IN 1_i
an DT 1_i
infusion NN 1_i
of IN 1_i
the DT 1_i
functional JJ 1_i
somatostatin NN 1_i
antagonist NN 1_i
, , 1_i
arginine NN 1_i
. . 1_i

Thirteen JJ 1_p
age-matched JJ 1_p
healthy JJ 1_p
volunteers NNS 1_p
served VBD 1_p
as IN 1_p
controls NNS 1_i
. . 1_i

Briefly NNP N
, , N
arginine NN 1_i
( ( 1_i
30 CD 1_i
g NN 1_i
) ) 1_i
was VBD 1_i
infused VBN 1_i
from IN 1_i
-30 NN 1_i
to TO 1_i
0 CD 1_i
min NN 1_i
, , 1_i
and CC 1_i
GHRH NNP 1_i
( ( 1_i
100 CD 1_i
microg NN 1_i
) ) 1_i
was VBD 1_i
injected VBN 1_i
as IN 1_i
a DT 1_i
bolus NN 1_i
at IN 1_i
0 CD 1_i
min NNS 1_i
, , N
with IN N
measurement NN N
of IN N
serum NN 1_i
GH NNP 1_i
[ NNP 1_i
immunoradiometric JJ 1_i
assay NN 1_i
( ( 1_i
IRMA NNP 1_i
) ) 1_i
] VBP 1_i
every DT N
15 CD N
min NN N
for IN N
150 CD N
min NN N
. . N

Plasma NNP 1_i
IGF-I NNP 1_i
( ( 1_i
RIA NNP 1_i
after IN 1_i
acid-ethanol JJ 1_i
extraction NN 1_i
) ) 1_i
was VBD N
measured VBN N
in IN N
a DT N
morning NN N
sample NN N
. . N

The DT N
diagnosis NN N
of IN N
cortical JJ N
adenoma NN N
was VBD N
based VBN N
on IN N
computed JJ N
tomography NN N
features NNS N
and CC N
pattern NN N
of IN N
uptake NN N
on IN N
adrenal JJ N
scintigraphy NN N
. . N

Patients NNS 1_p
with IN 1_p
obesity NN 1_p
and/or NN 1_p
diabetes NNS 1_p
were VBD 1_p
excluded VBN 1_p
. . 1_p

The DT N
study NN N
design NN N
included VBD N
also RB N
an DT N
endocrine JJ N
work-up NN N
aimed VBN N
to TO N
study VB N
the DT N
hypothalamic-pituitary-adrenal JJ 1_o
axis NN 1_o
[ NNP 1_o
urinary JJ 1_o
free JJ 1_o
cortisol NN 1_o
( ( 1_o
UFC NNP 1_o
) ) 1_o
excretion NN 1_o
, , 1_o
serum NN 1_o
cortisol NN 1_o
at IN 1_o
0800 CD 1_o
h NN 1_o
, , 1_o
plasma JJ 1_o
ACTH NNP 1_o
at IN 1_o
0800 CD 1_o
h NN 1_o
, , 1_o
morning NN 1_o
cortisol NN 1_o
after IN 1_o
overnight JJ 1_o
1 CD 1_o
mg NN 1_o
dexamethasone NN 1_o
] NN 1_o
. . 1_o

Five CD N
of IN N
10 CD N
patients NNS N
showed VBD N
abnormalities NNS 1_o
of IN 1_o
the DT 1_o
hypothalamic-pituitary-adrenal JJ 1_o
axis NN 1_o
, , N
including VBG N
borderline NN 1_o
or CC 1_o
increased VBN 1_o
UFC JJ 1_o
excretion NN 1_o
in IN N
4 CD N
of IN N
them PRP N
accompanied VBN N
by IN N
blunted JJ N
ACTH NNP N
in IN N
2 CD N
cases NNS N
and CC N
failure NN N
of IN N
cortisol NN N
to TO N
suppress VB N
after IN N
dexamethasone NN N
in IN N
1 CD N
; : N
the DT N
fifth JJ N
patient NN N
displayed VBD N
low JJ N
ACTH NNP N
and CC N
resistance NN N
to TO N
dexamethasone VB N
suppression NN N
. . N

However RB N
, , N
all DT N
patients NNS N
had VBD N
a DT N
unilateral JJ N
uptake NN N
of IN N
the DT N
tracer NN N
on IN N
the DT N
side NN N
of IN N
the DT N
mass NN N
with IN N
suppression NN N
of IN N
the DT N
contralateral JJ N
normal JJ N
adrenal JJ N
gland NN N
. . N

As IN N
a DT N
group NN N
, , N
the DT N
patients NNS N
displayed VBD N
greater JJR N
UFC NNP 1_o
excretion NN 1_o
and CC 1_o
lower JJR 1_o
ACTH NNP 1_o
concentrations NNS 1_o
than IN N
the DT N
controls NNS N
. . N

GH NNP 1_o
release NN 1_o
after IN 1_o
GHRH NNP 1_o
treatment NN 1_o
was VBD N
blunted VBN N
in IN N
patients NNS 1_p
bearing VBG 1_p
adrenal JJ 1_p
incidentaloma NNS 1_p
compared VBN N
with IN N
controls NNS N
( ( N
GH NNP N
peak NN N
, , N
5.7 CD N
+/- JJ N
5.2 CD N
vs. FW N
18.0 CD N
+/- JJ N
7.0 CD N
microg/L NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
whereas JJ N
GHRH NNP 1_i
plus CC 1_i
arginine NN 1_i
was VBD N
able JJ N
to TO N
elicit VB N
a DT N
comparable JJ N
response NN N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
GH NNP N
peak NN N
, , N
33.5 CD N
+/- JJ N
20.3 CD N
vs. FW N
33.7 CD N
+/- JJ N
17.5 CD N
microg/L NN N
; : N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

The DT N
ratio NN N
between IN N
GH NNP 1_o
peaks NNS 1_o
after IN 1_o
GHRH NNP 1_o
plus CC 1_o
arginine NN 1_o
and CC 1_o
after IN 1_o
GHRH NNP 1_o
plus CC 1_o
saline NN 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
than IN N
in IN N
controls NNS N
( ( N
751 CD N
+/- JJ N
531 CD N
% NN N
vs. FW N
81 CD N
+/- JJ N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

Similar JJ N
data NNS N
were VBD N
obtained VBN N
when WRB N
comparing VBG N
GH NNP N
area NN N
under IN N
the DT N
curve NN N
after IN N
GHRH NNP N
plus CC N
saline NN N
or CC N
GHRH NNP N
plus CC N
arginine NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
summary JJ N
, , N
the DT N
present JJ N
data NNS N
suggest VBP N
that IN N
in IN N
patients NNS 1_p
with IN 1_p
incidental JJ 1_p
adrenal JJ 1_p
adenomas IN 1_p
the DT N
GH NNP 1_o
response NN 1_o
to TO N
GHRH NNP N
is VBZ N
blunted VBN N
due JJ N
to TO N
increased VBN N
somatostatinergic NN 1_o
tone NN 1_o
, , N
as IN N
it PRP N
can MD N
be VB N
restored VBN N
to TO N
normal JJ N
by IN N
pretreatment NN N
with IN N
the DT N
functional JJ N
somatostatin NN N
antagonist JJ N
arginine NN N
. . N

The DT N
blunted JJ N
GH NNP N
release NN N
to TO N
GHRH NNP N
may MD N
be VB N
an DT N
early JJ N
and CC N
long JJ N
lasting JJ N
sign NN N
of IN N
autonomous JJ N
cortisol NNS N
secretion NN N
by IN N
the DT N
adrenal JJ N
adenoma NN N
. . N

Direct JJ N
and CC N
indirect JJ N
effects NNS N
of IN N
interdental JJ 1_i
hygiene NN 1_i
in IN N
a DT N
clinical JJ N
trial NN N
. . N

Many JJ N
randomized VBD N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
in IN N
dental JJ N
research NN N
test NN N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
more JJR N
than IN N
one CD N
outcome NN N
variable NN N
. . N

Univariate NNP N
methods NNS N
, , N
such JJ N
as IN N
the DT N
t JJ N
test NN N
or CC N
analysis NN N
of IN N
covariance NN N
, , N
can MD N
not RB N
evaluate VB N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
multiple JJ N
outcomes NNS N
simultaneously RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
structural JJ 1_i
equation NN 1_i
modeling NN 1_i
( ( N
SEM NNP N
) ) N
to TO N
re-analyze VB N
a DT N
RCT NNP N
, , N
comparing VBG N
the DT N
effects NNS N
of IN N
pre-curved JJ 1_i
interdental JJ 1_i
brushes NNS 1_i
and CC 1_i
flossing VBG 1_i
on IN N
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
, , N
plaque JJ N
indices NNS N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
measured VBD N
at IN N
baseline NN N
, , N
intermediate NN N
, , N
and CC N
final JJ N
examinations NNS N
. . N

Results NNS N
of IN N
SEM NNP N
showed VBD N
that IN N
the DT N
observed JJ N
greater JJR 1_o
reduction NN 1_o
in IN 1_o
PPD NNP 1_o
and CC 1_o
BOP NNP 1_o
in IN N
persons NNS 1_p
using VBG 1_p
interdental JJ 1_p
brushing NN 1_p
than IN 1_p
in IN 1_p
those DT 1_p
flossing NN 1_p
is VBZ N
due JJ N
mainly RB N
to TO N
the DT N
greater JJR N
efficiency NN 1_o
in IN 1_o
plaque NN 1_o
removal NN 1_o
with IN N
the DT N
interdental JJ N
brushes NNS N
( ( N
indirect JJ N
effect NN N
) ) N
rather RB N
than IN N
to TO N
the DT N
compression NN N
of IN N
the DT N
interdental JJ N
papillae NN N
( ( N
direct JJ N
effect NN N
) ) N
. . N

In IN N
contrast NN N
, , N
smokers NNS 1_p
showed VBD N
less JJR N
BOP NNP 1_o
at IN N
baseline NN N
but CC N
also RB N
less RBR N
improvement NN N
in IN N
BOP NNP 1_o
through IN N
direct JJ N
effects NNS N
. . N

Response NN N
to TO N
tubular VB 1_i
airway RP 1_i
resistance NN 1_i
in IN N
normal JJ 1_p
subjects NNS 1_p
and CC 1_p
postoperative JJ 1_p
patients NNS 1_p
. . 1_p

Critically NNP 1_p
ill JJ 1_p
patients NNS 1_p
must MD N
often RB N
breathe VB N
spontaneously RB N
through IN N
an DT N
endotracheal JJ 1_i
tube NN 1_i
that WDT N
acts VBZ N
as IN N
a DT N
fixed JJ N
inspiratory NN N
and CC N
expiratory JJ N
tubular JJ N
airway NN N
resistor NN N
. . N

Although IN N
this DT N
practice NN N
is VBZ N
common JJ N
, , N
its PRP$ N
effect NN N
on IN N
the DT N
pattern NN N
of IN N
breathing NN N
is VBZ N
not RB N
known VBN N
. . N

The DT N
mean JJ N
breathing NN N
patterns NNS N
of IN N
seven CD 1_p
normal JJ 1_p
, , 1_p
healthy JJ 1_p
male NN 1_p
subjects NNS 1_p
and CC 1_p
eight CD 1_p
male NN 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
undergone JJ 1_p
upper JJ 1_p
abdominal JJ 1_p
surgery NN 1_p
2-4 JJ 1_p
days NNS 1_p
previously RB 1_p
were VBD N
studied VBN N
breathing VBG N
through IN N
a DT 1_i
mouthpiece NN 1_i
fitted VBN 1_i
in IN 1_i
random JJ 1_i
order NN 1_i
with IN 1_i
a DT 1_i
5 CD 1_i
, , 1_i
6 CD 1_i
, , 1_i
7 CD 1_i
, , 1_i
8 CD 1_i
, , 1_i
or CC 1_i
15 CD 1_i
mm NNS 1_i
diameter NN 1_i
( ( 1_i
17 CD 1_i
mm RB 1_i
long RB 1_i
) ) 1_i
resistor NN 1_i
. . 1_i

These DT N
diameters NNS N
were VBD N
selected VBN N
because IN N
they PRP N
simulate VBP N
the DT N
pressure-flow JJ N
relationships NNS N
of IN N
adult NN N
endotracheal NN N
tubes NNS N
. . N

With IN N
the DT N
15 CD N
mm NN N
aperture NN N
, , N
the DT N
patients NNS N
had VBD N
a DT N
greater JJR N
breathing NN 1_o
frequency NN 1_o
( ( 1_o
f NN 1_o
) ) 1_o
than IN N
did VBD N
the DT N
normal JJ N
subjects NNS N
( ( N
21 CD N
+/- JJ N
5 CD N
[ JJ N
SD NNP N
] NNP N
vs. IN N
14 CD N
+/- JJ N
4 CD N
breaths/min NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
as RB N
well RB N
as IN N
a DT N
smaller JJR N
mean JJ 1_o
tidal NN 1_o
volume NN 1_o
( ( 1_o
VT NNP 1_o
) ) 1_o
. . 1_o

In IN N
both DT N
groups NNS N
, , N
minute JJ 1_o
ventilation NN 1_o
( ( 1_o
VE NNP 1_o
) ) 1_o
and CC 1_o
f $ 1_o
progressively RB N
decreased VBN N
as IN N
resistance NN N
was VBD N
increased VBN N
by IN N
decreasing VBG N
the DT N
aperture NN N
size NN N
from IN N
15 CD N
to TO N
16 CD N
mm NN N
. . N

In IN N
the DT N
normal JJ N
subjects NNS N
but CC N
not RB N
the DT N
patients NNS N
, , N
VT NNP 1_o
also RB N
progressively RB N
decreased VBN N
. . N

When WRB N
the DT N
diameter NN N
was VBD N
decreased VBN N
from IN N
6 CD N
mm NNS N
to TO N
5 CD N
mm NN N
, , N
there EX N
were VBD N
increases NNS N
in IN N
VT NNP 1_o
and CC N
decreases NNS N
in IN N
f NN 1_o
that WDT N
were VBD N
more JJR N
marked VBN N
in IN N
the DT N
normal JJ N
subjects NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
changes NNS 1_o
in IN 1_o
VE NNP 1_o
were VBD N
accompanied VBN N
by IN N
decreases NNS N
in IN N
mean NN N
and CC N
peak JJ 1_o
inspiratory NN 1_o
and CC 1_o
expiratory NN 1_o
flow NN 1_o
rates NNS 1_o
. . 1_o

Throughout IN N
the DT N
study NN N
, , N
oxygen NN 1_o
consumption NN 1_o
( ( 1_o
VO2 NNP 1_o
) ) 1_o
and CC 1_o
carbon NN 1_o
dioxide NN 1_o
production NN 1_o
( ( 1_o
VCO2 NNP 1_o
) ) 1_o
did VBD N
not RB N
change VB N
. . N

This DT N
, , N
coupled VBN N
with IN N
the DT N
decreases NNS N
in IN N
VE NNP N
resulted VBD N
in IN N
decreases NNS N
in IN N
the DT N
ventilatory NN N
equivalents NNS N
to TO N
CO2 NNP N
and CC N
O2 NNP N
( ( N
VE/VCO2 NNP N
, , N
VE/VO2 NNP N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
Rationale NNP N
and CC N
design NN N
of IN N
the DT N
Folic NNP 1_i
Acid NNP 1_i
for IN N
Vascular NNP 1_o
Outcome NNP 1_o
Reduction NNP N
In IN N
Transplantation NNP N
( ( N
FAVORIT NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS 1_p
with IN 1_p
chronic JJ 1_p
kidney NN 1_p
disease NN 1_p
, , 1_p
including VBG 1_p
kidney NN 1_p
transplant NN 1_p
recipients NNS 1_p
, , N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
cardiovascular JJ 1_o
disease NN 1_o
( ( 1_o
CVD NNP 1_o
) ) 1_o
. . 1_o

In IN N
addition NN N
to TO N
the DT N
constellation NN N
of IN N
traditional JJ N
CVD NNP N
risk NN N
factors NNS N
in IN N
chronic JJ N
kidney NN N
disease NN N
, , N
elevated VBD N
total JJ 1_o
homocysteine NN 1_o
( ( 1_o
tHcy NN 1_o
) ) 1_o
is VBZ N
notably RB N
more RBR N
prevalent JJ N
among IN N
the DT N
general JJ N
population NN N
. . N

The DT 1_i
Folic NNP 1_i
Acid NNP 1_i
for IN N
Vascular NNP N
Outcome NNP N
Reduction NNP N
In IN N
Transplantation NNP N
( ( N
FAVORIT NNP N
) ) N
trial NN N
is VBZ N
designed VBN N
to TO N
evaluate VB N
whether IN N
lowering VBG N
tHcy NN 1_o
using VBG N
vitamin JJ 1_i
supplementation NN 1_i
reduces NNS N
CVD NNP 1_o
events NNS 1_o
in IN N
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
. . 1_p

METHODS NNP N
FAVORIT NNP N
is VBZ N
a DT N
multicenter JJ N
double-blind NN N
randomized VBD N
controlled JJ N
clinical JJ N
trial NN N
. . N

Participants NNS 1_p
are VBP 1_p
clinically RB 1_p
stable JJ 1_p
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
who WP 1_p
are VBP 1_p
6 CD 1_p
months NNS 1_p
or CC 1_p
longer JJR 1_p
posttransplant NN 1_p
with IN 1_p
elevated JJ 1_p
tHcy NN 1_p
. . 1_p

Patients NNS N
are VBP N
randomized VBN N
to TO N
a DT N
multivitamin NN 1_i
that WDT 1_i
includes VBZ 1_i
either CC 1_i
a DT 1_i
high-dose JJ 1_i
or CC 1_i
low-dose JJ 1_i
of IN 1_i
folic JJ 1_i
acid NN 1_i
( ( N
5 CD N
or CC N
0 CD N
mg NN N
) ) N
, , N
vitamin FW 1_i
B6 NNP 1_i
( ( N
50 CD N
or CC N
1.4 CD N
mg NN N
) ) N
, , N
and CC 1_i
vitamin NN 1_i
B12 NNP 1_i
( ( N
1000 CD N
or CC N
2 CD N
microg NN N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
is VBZ N
a DT N
composite NN 1_o
of IN 1_o
incident NN 1_o
or CC 1_o
recurrent NN 1_o
CVD NNP 1_o
outcomes RB 1_o
, , 1_o
that DT 1_o
is VBZ 1_o
, , 1_o
coronary JJ 1_o
heart NN 1_o
, , 1_o
cerebrovascular JJ 1_o
, , 1_o
or CC 1_o
abdominal JJ 1_o
aortic/lower NN 1_o
extremity NN 1_o
arterial JJ 1_o
events NNS 1_o
. . 1_o

A DT N
sample JJ N
size NN N
of IN N
4000 CD N
is VBZ N
estimated VBN N
to TO N
provide VB N
87 CD N
% NN N
power NN N
to TO N
detect VB N
a DT N
20 CD N
% NN N
treatment NN N
effect NN N
. . N

Recruitment NN 1_p
is VBZ 1_p
expected VBN 1_p
to TO 1_p
continue VB 1_p
until IN 1_p
July NNP 1_p
2006 CD 1_p
, , N
with IN N
follow-up JJ N
through IN N
June NNP N
2010 CD N
. . N

RESULTS VB N
From IN 1_p
August NNP 1_p
2002 CD 1_p
through IN 1_p
December NNP 1_p
2004 CD 1_p
, , 1_p
2234 CD 1_p
of IN 1_p
the DT 1_p
target NN 1_p
4000 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

In IN N
accordance NN N
with IN N
trial NN N
design NN N
, , N
mean NN 1_o
( ( 1_o
SD NNP 1_o
) ) 1_o
screening VBG 1_o
tHcy NN 1_o
was VBD N
elevated VBN N
( ( N
17.4 CD N
+/- JJ N
6.2 CD N
micromol/L NN N
) ) N
, , N
and CC N
mean NN 1_o
( ( 1_o
SD NNP 1_o
) ) 1_o
estimated VBD 1_o
creatinine JJ 1_o
clearance NN 1_o
was VBD N
consistent JJ N
with IN N
stable JJ N
renal JJ N
function NN N
( ( N
58.0 CD N
+/- JJ N
18.6 CD N
mL/min NN N
) ) N
. . N

Evaluating VBG N
baseline JJ N
results NNS N
to TO N
date NN N
, , N
42 CD N
% NN N
of IN N
the DT N
randomized JJ N
participants NNS N
had VBD N
a DT N
history NN 1_o
of IN 1_o
diabetes NNS 1_o
mellitus NNS 1_o
, , N
and CC N
21 CD N
% NN N
had VBD N
prevalent JJ N
CVD NNP N
. . N

CONCLUSIONS NNP N
The DT N
FAVORIT NNP N
trial NN N
is VBZ N
designed VBN N
with IN N
sufficient JJ N
power NN N
and CC N
follow-up JJ N
time NN N
to TO N
detect VB N
a DT N
clinically RB N
relevant JJ N
change NN N
in IN N
CVD NNP N
risk NN N
between IN N
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
receiving VBG N
a DT N
high JJ N
or CC N
low JJ N
tHcy-lowering JJ N
folic JJ 1_i
acid NN 1_i
multivitamin NN 1_i
. . 1_i

Preliminary JJ N
screening NN N
and CC N
baseline NN N
data NNS N
support NN N
the DT N
trial NN N
's POS N
objectives NNS N
. . N

[ JJ N
Clinical NNP N
early JJ N
phase NN N
II NNP N
study NN N
of IN N
bicalutamide NN 1_i
( ( 1_i
Casodex NNP 1_i
) ) 1_i
in IN N
patients NNS 1_p
with IN 1_p
prostatic JJ 1_p
cancer NN 1_p
] NN 1_p
. . N

To TO N
investigate VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
bicalutamide NN 1_i
( ( N
Casodex NNP N
) ) N
with IN N
its PRP$ N
clinically NN N
recommended VBD N
dose NN N
, , N
the DT N
randomized VBN N
early JJ N
phase NN N
II NNP N
study NN N
was VBD N
performed VBN N
in IN N
124 CD 1_p
patients NNS 1_p
with IN 1_p
prostatic JJ 1_p
cancer NN 1_p
( ( 1_p
stage NN 1_p
C NNP 1_p
, , 1_p
D NNP 1_p
) ) 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
given VBN N
50 CD 1_i
, , 1_i
80 CD 1_i
or CC 1_i
100 CD 1_i
mg NN 1_i
of IN 1_i
bicalutamide NN 1_i
orally RB N
once RB N
a DT N
day NN N
in IN N
fixed JJ N
doses NNS N
for IN N
12 CD N
weeks NNS N
; : N
122 CD N
patients NNS N
were VBD N
eligible JJ N
for IN N
evaluation NN N
. . N

The DT N
overall JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
50.0 CD N
% NN N
( ( N
20/40 CD N
) ) N
, , N
61.0 CD N
% NN N
( ( N
25/41 CD N
) ) N
and CC N
53.7 CD N
% NN N
( ( N
22/41 CD N
) ) N
in IN N
the DT N
50 CD N
mg NN N
, , N
80 CD N
mg NN N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
response NN 1_o
rate NN 1_o
in IN 1_o
prostate NN 1_o
lesion NN 1_o
, , 1_o
bone NN 1_o
and CC 1_o
lymph NN 1_o
node NN 1_o
metastases NNS 1_o
was VBD N
slightly RB N
higher JJR N
in IN N
the DT N
80 CD N
mg NN N
group NN N
than IN N
in IN N
the DT N
50 CD N
mg NN N
and CC N
100 CD N
mg NN N
groups NNS N
. . N

The DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
showing VBG 1_o
a DT 1_o
response NN 1_o
with IN 1_o
regard NN 1_o
to TO 1_o
serum VB 1_o
PSA NNP 1_o
( ( 1_o
CR NNP 1_o
and CC 1_o
PR NNP 1_o
) ) 1_o
was VBD N
84.2 CD N
, , N
92.7 CD N
and CC N
97.6 CD N
% NN N
in IN N
the DT N
50 CD N
, , N
80 CD N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN 1_o
of IN 1_o
adverse JJ 1_o
reactions NNS 1_o
was VBD N
65.0 CD N
, , N
61.0 CD N
and CC N
61.0 CD N
% NN N
in IN N
the DT N
50 CD N
, , N
80 CD N
and CC N
100 CD N
mg NN N
groups NNS N
, , N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT 1_o
significant JJ 1_o
difference NN 1_o
in IN N
overall JJ 1_o
safety NN 1_o
rating NN 1_o
in IN N
the DT N
three CD N
groups NNS N
. . N

Frequent JJ 1_o
adverse JJ 1_o
reactions NNS 1_o
were VBD N
gynecomastia JJ 1_o
and CC 1_o
breast NN 1_o
pain NN 1_o
. . 1_o

Only RB N
one CD N
patient NN N
in IN N
the DT N
80 CD N
mg NN N
group NN N
was VBD N
withdrawn VBN 1_o
due JJ 1_o
to TO 1_o
shortness VB 1_o
of IN 1_o
breath NN 1_o
. . 1_o

Serum NNP 1_o
concentrations NNS 1_o
of IN 1_o
LH NNP 1_o
, , 1_o
testosterone NN 1_o
and CC 1_o
estradiol NN 1_o
increased VBD 1_o
significantly RB 1_o
after IN N
treatment NN N
. . N

Bicalutamide NNP 1_i
was VBD N
concluded VBN N
to TO N
be VB N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
patients NNS 1_p
with IN 1_p
prostatic JJ 1_p
cancer NN 1_p
, , N
and CC N
its PRP$ N
recommended VBD N
dose NN N
was VBD N
80 CD N
mg NN N
once RB N
daily RB N
. . N

[ JJ N
Report NNP N
of IN N
a DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
a DT N
new JJ N
synthetic JJ N
drug NN N
, , N
parsalmide NN 1_i
, , N
in IN N
rheumatic JJ 1_p
arthropathies NNS 1_p
( ( 1_p
inflammatory NN 1_p
and CC 1_p
degenerative NN 1_p
) ) 1_p
] NN 1_p
. . N

The DT N
anti-inflammatory JJ N
, , N
analgesic JJ N
and CC N
tranquillizing JJ N
activity NN N
of IN N
a DT N
synthetic JJ N
compound NN N
called VBD N
parsalmide NN 1_i
was VBD N
investigated VBN N
in IN N
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
inflammatory NN 1_p
and CC 1_p
degenerative JJ 1_p
rheumatic JJ 1_p
arthropathies NNS 1_p
. . 1_p

The DT N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
30 CD 1_p
subjects NNS 1_p
using VBG 1_p
the DT 1_p
controlled JJ 1_p
experiment NN 1_p
technique NN 1_p
according VBG 1_p
to TO 1_p
the DT 1_p
" NN 1_p
between IN 1_p
patient JJ 1_p
" NNP 1_p
pattern NN 1_p
, , 1_p
attributing VBG 1_p
parsalmide NN 1_i
and CC 1_i
indomethacin NN 1_i
at IN 1_p
random NN 1_p
to TO 1_p
two CD 1_p
groups NNS 1_p
. . 1_p

Both DT N
preparations NNS N
were VBD N
found VBN N
to TO N
possess VB N
good JJ N
anti-inflammatory JJ 1_o
and CC 1_o
analgesic JJ 1_o
action NN 1_o
, , N
comparable JJ N
clinically RB N
and CC N
statistically RB N
. . N

Tolerance NN 1_o
was VBD N
very RB N
good JJ N
, , N
particularly RB N
at IN N
gastroenteric JJ N
level NN N
( ( N
no DT N
side NN N
and/or RB N
undesired JJ N
effects NNS N
were VBD N
observed VBN N
) ) N
and CC N
at IN N
the DT N
level NN N
of IN N
haemopoietic JJ N
, , N
renal JJ N
and CC N
hepatic JJ N
function NN N
. . N

Effect NN N
of IN N
acarbose NN 1_i
on IN N
additional JJ N
insulin NN 1_i
therapy NN 1_i
in IN N
type NN 1_p
2 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
late JJ 1_p
failure NN 1_p
of IN 1_p
sulphonylurea JJ 1_p
therapy NN 1_p
. . 1_p

AIM VB N
The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
acarbose NN 1_i
on IN N
insulin NN 1_o
requirements NNS 1_o
and CC N
glycaemic JJ 1_o
control NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
receiving VBG 1_p
exogenous JJ 1_p
insulin NN 1_i
due JJ 1_p
to TO 1_p
secondary JJ 1_p
failure NN 1_p
of IN 1_p
maximum NN 1_p
dose JJ 1_p
sulphonylurea JJ 1_p
therapy NN 1_p
. . 1_p

METHODS VB N
A DT N
single-centre JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
study NN N
was VBD N
performed VBN N
in IN N
48 CD 1_p
type NN 1_p
2 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
late-term JJ 1_p
failure NN 1_p
following VBG 1_p
at IN 1_p
least JJS 1_p
3 CD 1_p
years NNS 1_p
of IN 1_p
sulphonylurea JJ 1_i
therapy NN 1_p
requiring VBG 1_p
additional JJ 1_p
insulin NN 1_i
therapy NN 1_p
to TO 1_p
determine VB 1_p
the DT 1_p
impact NN 1_p
of IN 1_p
acarbose NN 1_i
on IN 1_p
glycaemic JJ 1_p
control NN 1_p
and CC 1_p
insulin NN 1_p
requirements NNS 1_p
. . 1_p

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
glycaemic JJ 1_o
response NN 1_o
rate NN 1_o
( ( N
responders NNS N
being VBG N
predefined VBN N
as IN N
patients NNS N
who WP N
achieve VBP N
a DT N
decrease NN N
in IN N
HbA1c NNP N
to TO N
less JJR N
than IN N
8 CD N
% NN N
or CC N
a DT N
reduction NN N
by IN N
at IN N
least JJS N
15 CD N
% NN N
as IN N
compared VBN N
to TO N
the DT N
baseline NN N
values NNS N
) ) N
and CC N
the DT N
daily JJ 1_o
insulin NN 1_o
dose NN 1_o
at IN N
6 CD N
months NNS N
. . N

Secondary JJ N
parameters NNS N
assessed VBD N
included VBN N
postprandial JJ 1_o
changes NNS 1_o
in IN 1_o
blood NN 1_o
glucose NN 1_o
, , 1_o
serum JJ 1_o
insulin NN 1_o
and CC 1_o
C-peptide NNP 1_o
during IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS CC N
There EX N
were VBD N
significantly RB N
more JJR N
responders NNS N
in IN N
the DT N
acarbose-treated JJ N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
20/24 CD N
patients NNS N
vs. FW N
10/19 CD N
patients NNS N
; : N
p VB N
< $ N
0.05 CD N
) ) N
. . N

The DT N
mean JJ 1_o
daily JJ 1_o
insulin NN 1_o
dose NN 1_o
after IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
was VBD N
16.4 CD N
+/- JJ N
10.1 CD N
IU NNP N
in IN N
the DT N
acarbose JJ 1_i
group NN N
and CC N
22.4 CD N
+/- JJ N
12.2 CD N
IU NNP N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
. . N

; : N
p JJ N
< NNP N
0.07 CD N
) ) N
. . N

Postprandial JJ 1_o
increases NNS 1_o
in IN 1_o
blood NN 1_o
glucose NN 1_o
, , 1_o
insulin NN 1_o
and CC 1_o
C-peptide NNP 1_o
were VBD N
consistently RB N
lower JJR N
in IN N
the DT N
acarbose-treated JJ N
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

For IN N
example NN N
, , N
the DT N
mean JJ 1_o
increase NN 1_o
in IN 1_o
2-h JJ 1_o
postprandial JJ 1_o
serum NN 1_o
insulin NN 1_o
remained VBD N
almost RB N
unchanged JJ N
in IN N
the DT N
acarbose JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
compared VBN N
to TO N
an DT N
increase NN N
to TO N
43 CD N
+/- JJ N
29 CD N
microU/ml NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
. . N

) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
for IN N
the DT N
placebo NN 1_i
group NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
the DT N
addition NN N
of IN N
acarbose NN 1_i
to TO N
sulphonylurea/insulin VB 1_i
combination NN 1_i
therapy NN 1_i
can MD N
improve VB N
glycaemic JJ 1_o
control NN 1_o
in IN N
type NN 1_p
2 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
. . 1_p

Acarbose NNP 1_i
may MD N
also RB N
reduce VB N
insulin NN 1_o
resistance NN 1_o
and CC 1_o
hyperinsulinaemia NN 1_o
. . 1_o

Postoperative JJ 1_p
magnesium NN 1_i
sulphate NN 1_i
infusion NN 1_i
reduces NNS N
analgesic JJ N
requirements NNS N
in IN N
spinal JJ N
anaesthesia NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Magnesium NNP 1_i
sulphate NN 1_i
infusion NN N
during IN N
general JJ N
anaesthesia NN N
reduces NNS N
anaesthetic JJ 1_o
consumption NN 1_o
and CC N
analgesic JJ 1_o
requirements NNS 1_o
. . 1_o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
postoperative JJ N
magnesium NN 1_i
infusion NN N
on IN N
duration NN 1_o
of IN 1_o
block NN 1_o
, , 1_o
sedation NN 1_o
and CC 1_o
analgesic JJ 1_o
consumption NN 1_o
after IN N
spinal JJ N
anaesthesia NN N
. . N

METHODS NNP N
Fifty NNP 1_p
ASA NNP 1_p
I-II JJ 1_p
patients NNS 1_p
were VBD N
included VBN N
in IN N
the DT N
randomized JJ N
double JJ N
blind NN N
study NN N
. . N

Spinal NNP 1_i
anaesthesia NN 1_i
was VBD 1_i
performed VBN 1_i
at IN 1_i
L3-4 NNP 1_i
or CC 1_i
L4-5 NNP 1_i
interspace NN 1_i
with IN 1_i
12.5 CD 1_i
mg NNS 1_i
0.5 CD 1_i
% NN 1_i
heavy JJ 1_i
bupivacaine NN 1_i
, , 1_i
using VBG 1_i
a DT 1_i
25 CD 1_i
G NNP 1_i
Quincke NNP 1_i
needle NN 1_i
. . 1_i

Patients NNS 1_i
received VBD 1_i
a DT 1_i
5 CD 1_i
mg NN 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
bolus NN 1_i
of IN 1_i
magnesium NN 1_i
sulphate NN 1_i
followed VBN 1_i
by IN 1_i
a DT 1_i
500 CD 1_i
mg NN 1_i
h NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
infusion NN 1_i
or CC 1_i
saline NN 1_i
in IN N
the DT N
same JJ N
volumes NNS N
for IN N
24 CD N
h. JJ N
Time NNP 1_o
to TO 1_o
first VB 1_o
pain NN 1_o
, , 1_o
analgesic JJ 1_o
request NN 1_o
, , 1_o
return NN 1_o
of IN 1_o
motor NN 1_o
function NN 1_o
, , 1_o
visual JJ 1_o
analogue NN 1_o
pain NN 1_o
and CC 1_o
sedation NN 1_o
scores NNS 1_o
were VBD N
evaluated VBN N
every DT N
4 CD N
h NN N
during IN N
the DT N
24 CD N
h JJ N
postoperative JJ N
period NN N
. . N

The DT N
t- JJ N
and CC N
U-tests NNS N
were VBD N
used VBN N
for IN N
statistical JJ N
analyses NNS N
. . N

Data NNS N
were VBD N
expressed VBN N
as IN N
mean JJ N
+/- JJ N
SD NNP N
, , N
with IN N
P NNP N
< $ N
0.05 CD N
being VBG N
considered VBN N
significant JJ N
. . N

RESULTS NNP N
Vital JJ 1_o
signs NNS 1_o
were VBD N
stable JJ N
during IN N
spinal JJ N
anaesthesia NN N
and CC N
postoperative JJ N
period NN N
. . N

When WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
time NN 1_o
to TO 1_o
analgesic VB 1_o
need NN 1_o
was VBD N
increased VBN N
and CC N
total JJ 1_o
analgesic JJ 1_o
consumption NN 1_o
was VBD N
reduced VBN N
in IN N
the DT N
magnesium NN N
group NN N
( ( N
meperidine JJ N
consumption NN N
60.0 CD N
+/- JJ N
73.1 CD N
mg NNS N
control NN N
group NN N
, , N
31.8 CD N
+/- JJ N
30.7 CD N
mg JJ N
magnesium NN N
group NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NNP N
Magnesium NNP 1_i
sulphate JJ 1_i
infusion NN N
may MD N
be VB N
used VBN N
as IN N
an DT N
adjunct NN N
for IN N
reducing VBG N
analgesic JJ 1_o
consumption NN 1_o
after IN 1_p
spinal JJ 1_p
anaesthesia NN 1_p
. . 1_p

Serotonergic NNP N
control NN N
of IN N
TSH NNP 1_o
and CC 1_o
PRL NNP 1_o
secretion NN 1_o
in IN N
obese JJ 1_p
men NNS 1_p
. . 1_p

To TO N
evaluate VB N
whether IN N
the DT N
inhibitory JJ N
control NN N
of IN N
TSH NNP 1_o
and CC 1_o
the DT 1_o
stimulatory NN 1_o
control NN 1_o
of IN 1_o
prolactin NN 1_o
( ( 1_o
PRL NNP 1_o
) ) 1_o
secretion NN 1_o
exerted VBN N
by IN N
endogenous JJ N
serotonin NN N
was VBD N
altered VBN N
in IN N
obesity NN N
, , N
22 CD 1_p
obese JJ 1_p
men NNS 1_p
and CC 1_p
10 CD 1_p
normal JJ 1_p
controls NNS 1_p
were VBD N
tested VBN 1_i
with IN 1_i
TRH NNP 1_i
( ( 1_i
200 CD 1_i
micrograms NNS 1_i
IV NNP 1_i
bolus NN 1_i
) ) 1_i
in IN 1_i
the DT 1_i
presence NN 1_i
( ( 1_i
experimental JJ 1_i
test NN 1_i
) ) 1_i
and CC 1_i
absence NN 1_i
( ( 1_i
control VB 1_i
test NN 1_i
) ) 1_i
of IN 1_i
the DT 1_i
serotonergic JJ 1_i
agonist NN 1_i
fenfluramine NN 1_i
( ( 1_i
60 CD 1_i
mg NN 1_i
PO NNP 1_i
90 CD 1_i
min NN 1_i
before IN 1_i
TRH NNP 1_i
) ) 1_i
. . 1_i

Control NNP N
and CC N
experimental JJ N
tests NNS N
were VBD N
also RB N
performed VBN N
in IN N
seven CD 1_p
male JJ 1_p
patients NNS 1_p
with IN 1_p
subclinical JJ 1_p
hypothyroidism NN 1_p
and CC N
were VBD N
repeated VBN N
in IN N
the DT N
same JJ N
obese JJ 1_p
subjects NNS 1_p
after IN 1_p
substantial JJ 1_p
weight JJ 1_p
loss NN 1_p
. . 1_p

Basal NNP 1_o
TSH NNP 1_o
levels NNS 1_o
were VBD N
similar JJ N
in IN N
control NN 1_p
and CC 1_p
obese JJ 1_p
men NNS 1_p
. . 1_p

Normal NNP 1_o
TSH NNP 1_o
responses VBZ 1_o
to TO 1_o
TRH NNP 1_o
( ( N
peak NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
14 CD N
mU/L NNS N
) ) N
were VBD N
observed VBN N
in IN N
all DT N
normal JJ N
controls NNS N
( ( N
mean JJ N
peak NN N
+/- JJ N
SE NNP N
9.8 CD N
+/- JJ N
0.6 CD N
mU/L NN N
) ) N
. . N

In IN N
contrast NN N
, , N
obese JJ 1_p
men NNS 1_p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
nine CD N
in IN N
whom WP N
the DT N
TRH-induced NNP 1_o
TSH NNP 1_o
rise NN 1_o
was VBD N
higher JJR N
than IN N
normal JJ N
( ( N
group NN N
I PRP N
: : N
mean JJ N
peak NN N
= VBD N
16.5 CD N
+/- JJ N
0.5 CD N
mU/L NN N
) ) N
and CC N
13 CD N
in IN N
whom WP N
it PRP N
was VBD N
normal JJ N
( ( N
group NN N
II NNP N
: : N
mean JJ N
peak NN N
= VBD N
10.6 CD N
+/- JJ N
0.7 CD N
mU/L NN N
) ) N
. . N

The DT N
hypothyroid JJ 1_p
men NNS 1_p
all DT N
had VBD N
elevated VBN N
basal NN 1_o
and CC 1_o
TRH-stimulated JJ 1_o
TSH NNP 1_o
levels NNS 1_o
. . 1_o

Basal NNP 1_o
PRL NNP 1_o
concentrations NNS 1_o
were VBD N
similar JJ N
in IN N
the DT N
normal JJ N
controls NNS N
and CC N
both DT N
groups NNS N
of IN N
obese JJ 1_p
subjects NNS 1_p
. . 1_p

The DT N
PRL NNP N
response NN N
to TO N
TRH NNP N
was VBD N
lower JJR N
in IN N
both DT N
group NN N
I PRP N
and CC N
group NN N
II NNP N
obese VBZ N
men NNS N
than IN N
in IN N
normal JJ N
controls NNS N
and CC N
was VBD N
similar JJ N
between IN N
group NN N
I PRP N
and CC N
group NN N
II NNP N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
Observer NNP N
variation NN N
in IN N
the DT N
assessment NN 1_o
of IN 1_o
outcome NN 1_o
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
experience NN N
from IN N
a DT N
multicenter NN N
, , N
international JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Accurate NNP N
and CC N
consistent JJ N
outcome NN 1_o
assessment NN 1_o
is VBZ N
essential JJ N
to TO N
randomized VB N
clinical JJ N
trials NNS N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
observer JJ N
variation NN N
in IN N
the DT N
assessment NN 1_o
of IN 1_o
outcome NN 1_o
in IN N
a DT N
recently RB N
completed VBN N
trial NN N
of IN N
dexanabinol NN 1_i
in IN N
head JJ 1_p
injury NN 1_p
and CC N
to TO N
consider VB N
steps NNS N
to TO N
reduce VB N
such JJ N
variation NN N
. . N

METHODS NNP N
Eight NNP 1_p
hundred VBD 1_p
sixty-one JJ 1_p
patients NNS 1_p
with IN 1_p
severe JJ 1_p
traumatic JJ 1_p
brain NN 1_p
injury NN 1_p
who WP 1_p
were VBD 1_p
admitted VBN 1_p
to TO 1_p
86 CD 1_p
centers NNS 1_p
were VBD N
included VBN N
in IN N
a DT N
multicenter NN N
, , N
placebo-controlled JJ 1_i
, , N
Phase NNP N
III NNP N
trial NN N
. . N

Outcome NNP N
was VBD N
assessed VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
postinjury NN N
using VBG N
the DT N
extended JJ 1_o
Glasgow NNP 1_o
Outcome NNP 1_o
Scale NNP 1_o
; : 1_o
standardized VBD N
assessment NN N
was VBD N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
structured JJ N
interview NN N
. . N

Before IN N
initiation NN N
of IN N
trial NN N
centers NNS N
, , N
outcome JJ 1_o
ratings NNS 1_o
were VBD N
obtained VBN N
for IN N
sample JJ N
cases NNS N
to TO N
establish VB N
initial JJ N
levels NNS N
of IN N
agreement NN N
. . N

Training NN N
sessions NNS N
in IN N
outcome JJ N
assessment NN N
were VBD N
held VBN N
, , N
and CC N
problems NNS N
in IN N
assigning VBG N
outcome NN N
were VBD N
investigated VBN N
. . N

During IN N
the DT N
trial NN N
, , N
a DT N
process NN N
of IN N
central JJ N
review NN N
was VBD N
established VBN N
to TO N
monitor VB N
performance NN N
. . N

Interobserver NNP N
variation NN N
was VBD N
analyzed VBN N
using VBG N
the DT N
kappa NN N
statistic JJ N
. . N

RESULTS NNP N
Substantial NNP 1_o
observer JJ 1_o
variation NN 1_o
was VBD N
found VBN N
in IN N
the DT N
rating NN N
of IN N
sample JJ N
cases NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.72 CD N
; : N
confidence NN N
interval NN N
, , N
0.68-0.75 JJ N
) ) N
and CC N
in IN N
assigning VBG N
outcome NN 1_o
based VBN N
on IN N
completed VBN N
structured JJ N
interviews NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.61 CD N
; : N
confidence NN N
interval NN N
, , N
0.57-0.64 JJ N
) ) N
. . N

In IN N
the DT N
early JJ N
stages NNS N
of IN N
the DT N
trial NN N
, , N
a DT N
relatively RB N
large JJ N
number NN N
of IN N
discrepancies NNS 1_o
( ( N
29-37 CD N
% NN N
) ) N
were VBD N
identified VBN N
on IN N
central JJ N
review NN N
. . N

This DT N
number NN N
declined VBD N
as IN N
the DT N
trial NN N
progressed VBD N
and CC N
coincided VBD N
with IN N
investigator NN N
training NN N
and CC N
feedback NN N
from IN N
central JJ N
review NN N
. . N

Centers NNS N
with IN N
higher JJR N
enrollment NN N
rates NNS N
showed VBD N
better JJR N
performance NN N
. . N

CONCLUSION NNP N
Observer NNP 1_o
variation NN 1_o
in IN N
outcome JJ 1_o
assessment NN 1_o
is VBZ N
a DT N
significant JJ N
problem NN N
for IN N
head NN N
injury NN N
trials NNS N
. . N

Consistency NN 1_o
can MD N
be VB N
improved VBN N
by IN N
standardizing VBG N
procedures NNS N
, , N
training VBG N
assessors NNS N
, , N
and CC N
monitoring VBG N
the DT N
quality NN N
of IN N
assessments NNS N
and CC N
providing VBG N
feedback NN N
to TO N
interviewers NNS N
. . N

A DT N
multifactorial JJ N
strategy NN N
of IN N
pain NN N
management NN N
is VBZ N
associated VBN N
with IN N
less JJR N
pain NN N
in IN N
scheduled JJ 1_p
vaccination NN 1_p
of IN N
children NNS 1_p
. . 1_p

A DT N
study NN N
realized VBN N
by IN N
family NN N
practitioners NNS N
in IN 1_p
239 CD 1_p
children NNS 1_p
aged VBN 1_p
4-12 CD 1_p
years NNS 1_p
old JJ 1_p
. . 1_p

BACKGROUND NNP N
AND CC N
AIMS NNP N
The DT N
multiplicity NN N
of IN N
vaccine JJ N
injections NNS N
during IN N
childhood NN N
leads NNS N
to TO N
iterative VB N
painful JJ N
and CC N
stressful JJ N
experiences NNS N
which WDT N
may MD N
lead VB N
in IN N
turn NN N
to TO N
anticipated VBN N
pain NN N
and CC N
then RB N
possibly RB N
to TO N
a DT N
true JJ N
needle JJ N
phobia NN N
. . N

We PRP N
aimed VBD N
at IN N
evaluating VBG N
a DT N
multifactorial JJ N
strategy NN N
of IN N
pain NN N
management NN N
combining VBG N
pharmacological JJ N
and CC N
non-pharmacological JJ N
approaches NNS N
during IN N
vaccination NN N
, , N
as IN N
compared VBN N
to TO N
usual JJ N
care NN N
, , N
in IN 1_p
4- JJ 1_p
to TO 1_p
12-year-old JJ 1_p
children NNS 1_p
. . 1_p

METHODS NNP N
In IN N
all DT N
, , N
239 CD 1_p
children NNS 1_p
were VBD 1_p
enrolled VBN 1_p
by IN 1_p
25 CD 1_p
family NN 1_p
practitioners NNS 1_p
in IN N
an DT N
open-label JJ N
study NN N
. . N

After IN N
a DT N
pseudo-randomization NN N
, , N
usual JJ 1_i
pain NN 1_i
management NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
132 CD 1_i
) ) 1_i
was VBD 1_i
compared VBN 1_i
to TO 1_i
a DT 1_i
multifactorial JJ 1_i
strategy NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
107 CD 1_i
) ) 1_i
associating VBG 1_i
preliminary JJ 1_i
application NN 1_i
of IN 1_i
an DT 1_i
anesthesic JJ 1_i
patch NN 1_i
, , 1_i
preferential JJ 1_i
use NN 1_i
of IN 1_i
specified JJ 1_i
vaccines NNS 1_i
, , 1_i
child JJ 1_i
education NN 1_i
by IN 1_i
the DT 1_i
parents NNS 1_i
and CC 1_i
the DT 1_i
doctor NN 1_i
, , 1_i
parental JJ 1_i
accompaniment NN 1_i
and CC 1_i
child JJ 1_i
distraction NN 1_i
with IN 1_i
soap NN 1_i
bubbles NNS 1_i
during IN 1_i
the DT 1_i
procedure NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
( ( N
i.e JJ N
. . N

child VB 1_o
pain NN 1_o
) ) 1_o
was VBD N
assessed VBN N
with IN N
a DT N
self-report JJ 1_o
scale NN 1_o
named VBN 1_o
visual JJ 1_o
analog NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
of IN 1_o
pain NN 1_o
. . 1_o

RESULTS VB N
A DT N
significant JJ N
decrease NN N
in IN N
pain NN 1_o
was VBD N
obtained VBN N
using VBG N
the DT N
multifactorial JJ N
strategy NN N
, , N
as IN N
assessed VBN N
by IN N
self-reported JJ N
VAS NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

This DT N
was VBD N
confirmed VBN N
by IN N
another DT N
self-report JJ N
scale NN N
( ( N
the DT N
facial NN 1_o
pain NN 1_o
scale NN 1_o
revised VBN N
: : N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
as RB N
well RB N
as IN N
with IN N
hetero-evaluations NNS N
by IN N
GPs NNP N
and CC N
parents NNS N
[ VBP 1_o
Children NNP 1_o
's POS 1_o
Hospital NNP 1_o
of IN 1_o
Eastern NNP 1_o
Ontario NNP 1_o
Pain NNP 1_o
Scale NNP 1_o
: : 1_o
P NNP N
= VBZ N
0.0007 CD N
; : N
GPs NNP N
VAS NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
parents NNS 1_o
VAS NNP 1_o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
] NN N
, , N
which WDT N
were VBD N
secondary JJ N
outcome NN N
criteria NNS N
. . N

CONCLUSIONS VB N
This DT N
multifactorial JJ N
method NN N
significantly RB N
decreases VBZ N
vaccination NN N
pain NN 1_o
in IN N
4- JJ 1_p
to TO 1_p
12-year-old JJ 1_p
children NNS 1_p
. . 1_p

This DT N
strategy NN N
could MD N
make VB N
vaccines NNS N
more RBR N
acceptable JJ N
to TO N
children NNS 1_p
and CC N
may MD N
improve VB N
child-doctor NN N
relationships NNS N
and CC N
contribute NN N
to TO N
a DT N
decrease NN N
in IN N
child JJ N
fear VBP N
about IN N
health NN N
care NN N
. . N

Randomized VBN N
, , N
double-blind JJ N
, , N
phase JJ N
III NNP N
, , N
controlled VBD N
trial NN N
comparing VBG N
levobupivacaine JJ 1_i
0.25 CD N
% NN N
, , N
ropivacaine VB 1_i
0.25 CD N
% NN N
and CC N
bupivacaine VB 1_i
0.25 CD N
% NN N
by IN N
the DT N
caudal JJ 1_p
route NN 1_p
in IN 1_p
children NNS 1_p
. . 1_p

BACKGROUND IN N
The DT N
rationale NN N
for IN N
replacing VBG N
racemic JJ 1_i
bupivacaine NN 1_i
with IN N
the DT N
s-enantiomers NNS 1_i
levobupivacaine NN 1_i
and CC N
ropivacaine NN 1_i
is VBZ N
to TO N
provide VB N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
with IN N
the DT N
same JJ N
analgesic JJ 1_o
efficacy NN 1_o
and CC N
less RBR N
postoperative JJ 1_o
motor NN 1_o
block NN 1_o
. . 1_o

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase JJ N
III NNP N
, , N
controlled VBD N
trial NN N
we PRP N
compared VBN N
the DT N
caudal JJ N
administration NN N
of IN N
levobupivacaine JJ 1_i
0.25 CD N
% NN N
and CC N
ropivacaine VB 1_i
0.25 CD N
% NN N
with IN N
bupivacaine JJ 1_i
0.25 CD N
% NN N
in IN N
children NNS 1_p
. . 1_p

METHODS NNP N
Ninety-nine JJ 1_p
ASA NNP 1_p
I-II NNP 1_p
children NNS 1_p
less JJR 1_p
than IN 1_p
10 CD 1_p
yr JJ 1_p
old JJ 1_p
scheduled VBN 1_p
for IN 1_p
elective JJ 1_p
sub-umbilical JJ 1_p
surgery NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
caudal JJ N
block NN N
with IN N
bupivacaine JJ 1_i
0.25 CD N
% NN N
, , N
ropivacaine VB 1_i
0.25 CD N
% NN N
or CC N
levobupivacaine VB 1_i
0.25 CD N
% NN N
. . N

The DT N
primary JJ N
outcome NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
clinical JJ 1_o
efficacy NN 1_o
of IN 1_o
the DT 1_o
caudal JJ 1_o
block NN 1_o
during IN 1_o
the DT 1_o
operation NN 1_o
. . 1_o

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
analgesic JJ 1_o
onset JJ 1_o
time NN 1_o
, , 1_o
pain NN 1_o
relief NN 1_o
after IN 1_o
the DT 1_o
operation NN 1_o
and CC 1_o
residual JJ 1_o
motor NN 1_o
blockade NN 1_o
. . 1_o

RESULTS VB N
The DT N
proportion NN N
of IN N
children NNS N
with IN N
effective JJ N
analgesia NN N
during IN N
the DT N
operation NN N
was VBD N
similar JJ N
among IN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
analgesic JJ N
onset NN N
time NN N
of IN N
the DT N
caudal NN N
block NN N
. . N

Bupivacaine NNP N
produced VBD N
a DT N
significant JJ N
incidence NN N
of IN N
residual JJ 1_o
motor NN 1_o
block NN 1_o
compared VBN N
with IN N
levobupivacaine NN N
or CC N
ropivacaine NN N
at IN N
wake-up NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
receiving VBG N
rescue NN N
analgesia NN N
after IN N
surgery NN N
. . N

However RB N
, , N
analgesic JJ N
block NN N
lasted VBD N
significantly RB N
longer RBR N
in IN N
patients NNS N
receiving VBG N
bupivacaine NN N
( ( N
P=0.03 NNP N
) ) N
. . N

CONCLUSION NNP N
During IN N
sub-umbilical JJ N
surgery NN N
, , N
caudal JJ N
levobupivacaine NN N
, , N
ropivacaine NN N
and CC N
bupivacaine NN N
provided VBN N
comparable JJ N
analgesic JJ 1_o
efficacy NN 1_o
. . 1_o

Bupivacaine NNP N
produced VBD N
a DT N
higher JJR N
incidence NN 1_o
of IN 1_o
residual JJ 1_o
motor NN 1_o
blockade NN 1_o
and CC N
a DT N
longer RBR N
analgesic JJ 1_o
block NN 1_o
than IN N
ropivacaine NN N
and CC N
levobupivacaine NN N
. . N

Effect NN N
of IN N
preoperative JJ N
skull NN N
block NN N
on IN N
pediatric JJ 1_p
moyamoya NN 1_p
disease NN 1_p
. . 1_p

OBJECT NNP N
Stable JJ N
hemodynamics NNS N
, , N
normocapnia NN N
, , N
and CC N
adequate JJ N
pain NN N
relief NN N
are VBP N
considered VBN N
important JJ N
factors NNS N
in IN N
the DT N
reduction NN N
of IN N
neurological JJ N
complications NNS N
in IN N
pediatric JJ 1_p
patients NNS 1_p
undergoing JJ 1_p
encephaloduroarteriomyosynangiosis NN 1_i
( ( 1_i
EDAMS NNP 1_i
) ) 1_i
operations NNS 1_p
for IN 1_p
the DT 1_p
treatment NN 1_p
of IN 1_p
moyamoya JJ 1_p
disease NN 1_p
. . 1_p

A DT N
preoperative JJ N
skull NN N
block NN N
may MD N
reduce VB N
hemodynamic JJ 1_o
fluctuations NNS 1_o
and CC 1_o
hypo- NN 1_o
or CC 1_o
hyperventilation NN 1_o
due JJ N
to TO N
emergence VB N
delirium NN N
or CC N
oversedation NN N
and CC N
provide VB N
adequate JJ N
pain NN N
relief NN N
, , N
thereby RB N
reducing VBG N
postoperative JJ 1_o
morbidity NN 1_o
. . 1_o

METHODS NNP N
Pediatric NNP 1_p
patients NNS 1_p
( ( 1_p
age NN 1_p
3-13 CD 1_p
years NNS 1_p
) ) 1_p
undergoing VBG 1_p
EDAMS NNP 1_i
surgery NN 1_i
for IN 1_p
moyamoya JJ 1_p
disease NN 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
a DT 1_p
nerve NN 1_p
block NN 1_p
( ( 1_p
NB NNP 1_p
) ) 1_p
group NN 1_p
( ( 1_p
18 CD 1_p
cases NNS 1_p
) ) 1_p
or CC 1_p
control VB 1_p
group NN 1_p
( ( 1_p
21 CD 1_p
cases NNS 1_p
) ) 1_p
. . N

The DT N
treatment NN N
group NN N
patients NNS N
received VBD N
a DT N
preoperative JJ N
NB NNP 1_i
( ( N
0.25 CD N
% NN N
5-8 JJ N
ml NN N
bupivacaine NN 1_i
mixed JJ N
with IN N
20-40 JJ N
mg NNS N
methylprednisolone NN 1_i
) ) 1_i
targeting VBG N
the DT N
supraorbital NN N
, , N
supratrochlear JJ N
, , N
auriculotemporal JJ N
, , N
and CC N
posterior JJ N
auricular JJ N
nerves NNS N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
NB NNP N
. . N

General NNP N
anesthesia NN N
with IN N
sevoflurane NN 1_i
was VBD N
induced VBN N
in IN N
both DT N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
NB NNP N
group NN N
, , N
stable JJ 1_o
hemodynamic JJ 1_o
parameters NNS 1_o
were VBD N
obtained VBN N
with IN N
a DT N
lower JJR N
sevoflurane NN N
concentration NN N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

For IN N
delirious JJ 1_o
awakening NN 1_o
, , N
the DT N
odds NNS N
ratio NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
4.9 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

Pain NNP 1_o
and CC 1_o
analgesic JJ 1_o
requirement NN 1_o
were VBD N
higher JJR N
in IN N
the DT N
control NN N
patients NNS N
than IN N
in IN N
the DT N
NB-treated JJ N
patients NNS N
during IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
stay NN N
. . N

However RB N
, , N
the DT N
arterial JJ 1_o
CO NNP 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
tension NN 1_o
in IN 1_o
the DT 1_o
postanesthesia NN 1_o
care NN 1_o
unit NN 1_o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
odds NNS 1_o
ratio NN 1_o
in IN N
the DT N
control NN N
group NN N
for IN N
the DT N
rate NN 1_o
of IN 1_o
morbidity NN 1_o
( ( 1_o
cerebral JJ 1_o
infarction NN 1_o
and CC 1_o
reversible JJ 1_o
ischemic JJ 1_o
neurological JJ 1_o
deficits NNS 1_o
) ) 1_o
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
following VBG N
the DT N
operation NN N
was VBD N
3.2 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
skull JJ N
block NN N
during IN N
EDAMS NNP N
surgery NN N
provided VBD N
easy JJ N
hemodynamic JJ 1_o
control NN 1_o
, , 1_o
calm JJ 1_o
awakening NN 1_o
, , 1_o
and CC 1_o
better JJR 1_o
pain NN 1_o
relief NN 1_o
and CC N
may MD N
be VB N
related VBN N
to TO N
the DT N
reduced VBN N
postoperative JJ 1_o
morbidity NN 1_o
. . 1_o

Lack NN N
of IN N
a DT N
pharmacokinetic JJ 1_o
interaction NN 1_o
between IN N
steady-state JJ N
roflumilast NN 1_i
and CC N
single-dose JJ N
midazolam NN 1_i
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

AIMS IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
roflumilast NN 1_i
, , N
an DT N
investigational JJ N
PDE4 NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
COPD NNP N
and CC N
asthma RB N
, , N
on IN N
the DT N
pharmacokinetics NNS 1_o
of IN 1_o
the DT 1_o
CYP3A NNP 1_o
probe NN 1_o
drug NN N
midazolam NN 1_i
and CC N
its PRP$ N
major JJ N
metabolites NNS N
. . N

METHODS NNP N
In IN N
an DT N
open JJ N
, , N
randomized VBN N
( ( N
for IN N
midazolam NN 1_i
treatment NN N
sequence NN N
) ) N
study NN N
, , N
18 CD 1_p
healthy JJ 1_p
male NN 1_p
subjects NNS 1_p
received VBD N
single JJ N
doses NNS N
of IN N
midazolam NN 1_i
( ( N
2 CD N
mg RB N
oral JJ N
and CC N
1 CD N
mg NN N
i.v. NN N
, , N
1 CD N
day NN N
apart RB N
) ) N
alone RB N
, , N
repeated VBD N
doses NNS N
of IN N
roflumilast NN 1_i
( ( N
500 CD N
microg NN N
once RB N
daily JJ N
for IN N
14 CD N
days NNS N
) ) N
alone RB N
, , N
and CC N
repeated VBD N
doses NNS N
of IN N
roflumilast NN 1_i
together RB 1_i
with IN 1_i
single JJ 1_i
doses NNS 1_i
of IN 1_i
midazolam NN 1_i
( ( N
2 CD N
mg RB N
oral JJ N
and CC N
1 CD N
mg NN N
i.v. NN N
, , N
1 CD N
day NN N
apart RB N
) ) N
. . N

RESULTS VB N
A DT N
comparison NN N
of IN N
clearance NN 1_o
and CC 1_o
peak NN 1_o
and CC 1_o
systemic JJ 1_o
exposure NN 1_o
to TO N
midazolam VB N
following VBG N
administration NN N
of IN N
roflumilast NN N
indicated JJ N
no DT N
effect NN N
of IN N
roflumilast NN N
dosed VBN N
to TO N
steady JJ N
state NN N
on IN N
the DT N
pharmacokinetics NNS 1_o
of IN 1_o
midazolam NN 1_o
. . 1_o

Point NN N
estimates NNS N
( ( N
90 CD N
% NN N
CI NNP N
) ) N
were VBD N
0.97 CD N
( ( N
0.84 CD N
, , N
1.13 CD N
) ) N
for IN N
the DT N
AUC NNP N
of IN N
i.v NN N
. . N

midazolam NN N
and CC N
0.98 CD N
( ( N
0.82 CD N
, , N
1.17 CD N
) ) N
for IN N
that DT N
of IN N
oral JJ N
midazolam NN N
with IN N
and CC N
without IN N
roflumilast NN N
. . N

CONCLUSIONS NNP N
Therapeutic NNP N
steady JJ N
state NN N
concentrations NNS N
of IN N
roflumilast NN N
and CC N
its PRP$ N
N-oxide NNP N
do NN N
not RB N
alter VB N
the DT N
disposition NN 1_o
of IN 1_o
the DT 1_o
CYP3A NNP 1_o
substrate NN 1_o
midazolam NN 1_o
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

This DT N
finding NN N
suggests VBZ N
that IN N
roflumilast NN N
is VBZ N
unlikely JJ N
to TO N
alter VB N
the DT N
clearance NN N
of IN N
drugs NNS N
that WDT N
are VBP N
metabolized VBN N
by IN N
CYP3A4 NNP N
. . N

Timing NN N
of IN N
antibiotic JJ 1_i
administration NN 1_i
in IN N
knee JJ 1_p
replacement NN 1_p
under IN 1_p
tourniquet NN 1_p
. . 1_p

Cephamandole NNP 1_o
levels NNS 1_o
in IN 1_o
serum NN 1_o
and CC 1_o
drain NN 1_o
fluid NN 1_o
were VBD N
measured VBN N
in IN N
32 CD 1_p
knee JJ 1_p
replacement NN 1_p
operations NNS 1_p
to TO N
determine VB N
the DT N
benefit NN N
of IN N
an DT N
intravenous JJ N
dose NN N
of IN N
antibiotic JJ N
at IN N
the DT N
time NN N
of IN N
tourniquet JJ N
deflation NN N
. . N

Concentrations NNS N
of IN N
cephamandole NN 1_o
in IN 1_o
drain NN 1_o
fluid NN 1_o
were VBD N
directly RB N
proportional JJ N
to TO N
the DT N
serum NN N
concentration NN N
at IN N
the DT N
time NN N
of IN N
tourniquet JJ N
release NN N
. . N

A DT N
'tourniquet-release JJ 1_i
' POS 1_i
dose NN 1_i
of IN 1_i
antibiotic JJ 1_i
increased VBD N
drain NN 1_o
fluid NN 1_o
concentration NN 1_o
threefold NN N
. . N

Tolfenamic NNP 1_i
acid NN 1_i
and CC 1_i
caffeine NN 1_i
: : 1_i
a DT N
useful JJ N
combination NN N
in IN N
migraine NN 1_o
. . 1_o

Tolfenamic NNP 1_i
acid NN 1_i
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
prostaglandin JJ N
biosynthesis NN N
, , N
which WDT N
has VBZ N
been VBN N
proved VBN N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ 1_o
migraine NN 1_o
attacks NNS 1_o
. . 1_o

The DT N
usefulness NN N
of IN N
caffeine NN 1_i
, , 1_i
metoclopramide NN 1_i
and CC 1_i
pyridoxine NN 1_i
as IN N
adjuncts NNS N
to TO N
tolfenamic VB 1_i
acid NN 1_i
was VBD N
tested VBN N
in IN N
acute JJ 1_o
migraine NN 1_o
attacks NNS 1_o
in IN 1_p
ten JJ 1_p
patients NNS 1_p
. . 1_p

A DT N
combination NN N
of IN N
tolfenamic JJ 1_i
acid NN 1_i
( ( N
200 CD N
mg NN N
) ) N
with IN N
either DT 1_i
caffeine NN 1_i
( ( N
100 CD N
mg NN N
) ) N
, , N
metoclopramide RB 1_i
( ( N
10 CD N
mg NN N
) ) N
or CC 1_i
pyridoxine NN 1_i
( ( N
300 CD N
mg NN N
) ) N
was VBD N
given VBN N
twice RB N
to TO N
each DT N
patient NN N
in IN N
random JJ N
order NN N
. . N

Thus RB N
60 CD 1_p
attacks NNS 1_p
were VBD N
treated VBN N
. . N

The DT N
tolfenamic JJ 1_i
acid-caffeine JJ 1_i
combination NN 1_i
proved VBD N
the DT N
most RBS N
effective JJ N
as IN N
judged VBN N
by IN N
duration NN 1_o
and CC 1_o
intensity NN 1_o
of IN 1_o
attacks NNS 1_o
, , 1_o
working VBG 1_o
ability NN 1_o
, , 1_o
vigilance NN 1_o
, , 1_o
and CC 1_o
overall JJ 1_o
evaluation NN 1_o
of IN 1_o
the DT 1_o
drugs NNS 1_o
by IN N
the DT N
patients NNS N
. . N

Metoclopramide NNP 1_i
was VBD N
somewhat RB N
better JJR N
than IN N
pyridoxine NN 1_i
as IN N
an DT N
additive NN N
. . N

Adjuvant JJ 1_i
therapy NN 1_i
of IN N
breast NN N
cancer NN N
: : N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
experience NN N
. . N

The DT N
Southwest NNP N
Oncology NNP N
Group NNP N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
compared VBN N
one CD N
year NN N
of IN N
adjuvant JJ 1_i
combination NN 1_i
chemotherapy NN 1_i
with IN 1_i
continuous JJ 1_i
CMFVP NNP 1_i
( ( 1_i
cyclophosphamide NN 1_i
, , 1_i
methotrexate NN 1_i
, , 1_i
5-fluorouracil JJ 1_i
, , 1_i
vincristine NN 1_i
, , 1_i
and CC 1_i
prednisone NN 1_i
) ) 1_i
to TO 1_i
two CD 1_i
years NNS 1_i
of IN 1_i
intermittent JJ 1_i
L-phenylalanine JJ 1_i
mustard NN 1_i
( ( 1_i
L-PAM NNP 1_i
) ) 1_i
in IN N
women NNS 1_p
with IN 1_p
operable JJ 1_p
breast NN 1_p
cancer NN 1_p
with IN 1_p
histologically RB 1_p
positive JJ 1_p
axillary JJ 1_p
lymph NN 1_p
nodes NNS 1_p
. . 1_p

In IN N
fully RB N
and CC N
partially RB N
evaluable JJ N
patients NNS 1_p
with IN 1_p
a DT 1_p
68-month JJ 1_p
median JJ 1_p
follow-up NN 1_p
, , N
treatment NN 1_o
failures NNS 1_o
have VBP N
occurred VBN N
in IN N
27 CD N
% NN N
of IN N
172 CD 1_p
receiving VBG 1_p
CMFVP NNP 1_i
and CC N
47 CD N
% NN N
of IN N
186 CD 1_p
women NNS 1_p
given VBN 1_p
L-PAM NNP 1_i
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

The DT N
advantage NN N
for IN N
women NNS N
receiving VBG N
CMFVP NNP 1_i
was VBD N
seen VBN N
for IN N
all DT N
subsets NNS N
regardless RB N
of IN N
menopausal NN N
status NN N
except IN N
among IN N
women NNS 1_p
who WP 1_p
were VBD 1_p
premenopausal NN 1_p
and CC N
had VBD N
1-3 JJ N
positive JJ N
nodes NNS N
. . N

Based VBN N
on IN N
this DT N
study NN N
, , N
a DT N
second JJ N
study NN N
was VBD N
implemented VBN N
using VBG N
both DT N
the DT N
estrogen-receptor NN N
( ( N
ER NNP N
) ) N
content NN N
of IN N
the DT N
primary JJ N
tumor NN N
and CC N
axillary JJ N
nodal NN N
status NN N
to TO N
select VB N
therapy NN N
. . N

Quantifying VBG N
narrative JJ 1_o
ability NN 1_o
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
a DT N
computational JJ N
linguistic JJ N
analysis NN N
of IN N
narrative JJ N
coherence NN N
. . N

Autism NNP 1_p
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
serious JJ N
difficulties NNS N
with IN N
the DT N
social JJ N
use NN N
of IN N
language NN N
, , N
along IN N
with IN N
impaired JJ N
social JJ N
functioning NN N
and CC N
ritualistic/repetitive JJ N
behaviors NNS N
( ( N
American NNP N
Psychiatric NNP N
Association NNP N
in IN N
Diagnostic NNP N
and CC N
statistical JJ N
manual NN N
of IN N
mental JJ N
disorders NNS N
: : N
DSM-5 NNP N
, , N
5th CD N
edn NN N
. . N

American NNP N
Psychiatric NNP N
Association NNP N
, , N
Arlington NNP N
, , N
2013 CD N
) ) N
. . N

While IN N
substantial JJ N
heterogeneity NN N
exists VBZ N
in IN N
symptom JJ N
expression NN N
, , N
impairments NNS N
in IN N
language NN N
discourse NN N
skills NNS N
, , N
including VBG N
narrative JJ N
( ( N
or CC N
storytelling VBG N
) ) N
, , N
are VBP N
universally RB N
observed VBN N
in IN N
autism NN N
( ( N
Tager-Flusberg NNP N
et RB N
al RB N
. . N

in IN N
Handbook NNP N
on IN N
autism NN N
and CC N
pervasive JJ N
developmental NN N
disorders NNS N
, , N
3rd CD N
edn NN N
. . N

Wiley NNP N
, , N
New NNP N
York NNP N
, , N
pp JJ N
335-364 CD N
, , N
2005 CD N
) ) N
. . N

This DT N
study NN N
applied VBD N
a DT N
computational JJ 1_i
linguistic JJ 1_i
tool NN 1_i
, , 1_i
Latent NNP 1_i
Semantic NNP 1_i
Analysis NNP 1_i
( ( 1_i
LSA NNP 1_i
) ) 1_i
, , N
to TO N
objectively RB N
characterize VB N
narrative JJ N
performance NN N
in IN N
high-functioning JJ 1_p
individuals NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
typically-developing NN 1_p
controls NNS 1_p
, , N
across IN N
two CD N
different JJ N
narrative JJ N
contexts NN N
that WDT N
differ VBP N
in IN N
the DT N
interpersonal JJ N
and CC N
cognitive JJ N
demands NNS N
placed VBN N
on IN N
the DT N
narrator NN N
. . N

Results NNS N
indicated VBD N
that IN N
high-functioning JJ 1_p
individuals NNS 1_p
with IN 1_p
autism NN 1_p
produced VBN N
narratives NNS 1_o
comparable JJ N
in IN N
semantic JJ N
content NN N
to TO N
those DT N
produced VBN N
by IN N
controls NNS N
when WRB N
narrating VBG N
from IN N
a DT N
picture NN N
book NN N
, , N
but CC N
produced VBD N
narratives NNS 1_o
diminished VBN N
in IN N
semantic JJ N
quality NN N
in IN N
a DT N
more RBR N
demanding JJ N
narrative JJ N
recall NN N
task NN N
. . N

This DT N
pattern NN N
is VBZ N
similar JJ N
to TO N
that DT N
detected VBN N
from IN N
analyses NNS N
of IN N
hand-coded JJ N
picture NN N
book NN N
narratives NNS N
in IN N
prior JJ N
research NN N
, , N
and CC N
extends VBZ N
findings NNS N
to TO N
an DT N
additional JJ N
narrative JJ N
context NN N
that WDT N
proves VBZ N
particularly RB N
challenging VBG N
for IN N
individuals NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
utility NN N
of IN N
LSA NNP N
as IN N
a DT N
quantitative JJ N
, , N
objective JJ N
, , N
and CC N
efficient JJ N
measure NN N
of IN N
narrative JJ 1_o
ability NN 1_o
. . 1_o

Nepafenac NNP 1_i
for IN N
epiretinal JJ 1_p
membrane NN 1_p
surgery NN 1_p
. . 1_p

Morphological JJ N
onset NN N
and CC N
early JJ N
diagnosis NN N
in IN N
apical JJ 1_p
hypertrophic JJ 1_p
cardiomyopathy NN 1_p
: : 1_p
a DT N
long JJ N
term NN N
analysis NN N
with IN N
nuclear JJ 1_i
magnetic JJ 1_i
resonance NN 1_i
imaging NN 1_i
. . 1_i

OBJECTIVES VB N
A DT N
long-term JJ N
follow-up NN N
study NN N
with IN N
nuclear JJ 1_i
magnetic JJ 1_i
resonance NN 1_i
( ( 1_i
NMR NNP 1_i
) ) 1_i
imaging NN 1_i
was VBD N
undertaken VBN N
to TO N
detect VB N
the DT N
morphological JJ N
onset NN N
and CC N
to TO N
establish VB N
the DT N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
( ( N
HCM NNP N
) ) N
. . N

BACKGROUND VB N
A DT N
spadelike JJ N
configuration NN N
on IN N
left JJ 1_o
ventriculogram NN 1_o
( ( 1_o
LVG NNP 1_o
) ) 1_o
is VBZ N
regarded VBN N
as IN N
a DT N
diagnostic JJ N
criterion NN N
for IN N
the DT N
classical JJ N
apical JJ N
HCM NNP N
. . N

There EX N
also RB N
exists VBZ N
a DT N
segmented JJ 1_o
hypertrophy NN 1_o
at IN 1_o
the DT 1_o
apical JJ 1_o
level NN 1_o
without IN N
indicating VBG N
the DT N
spadelike NN N
features NNS N
( ( N
a DT N
nonspade NN N
configuration NN N
) ) N
. . N

To TO N
detect VB N
the DT N
hypertrophied JJ N
myocardium NN N
of IN N
the DT N
nonspade JJ N
configuration NN N
, , N
circumferential JJ N
scrutiny NN N
of IN N
the DT N
apex NN N
is VBZ N
required VBN N
. . N

Although IN N
both DT N
configurations NNS N
can MD N
be VB N
underlying JJ N
causes NNS N
of IN N
giant JJ N
negative JJ N
T NNP N
waves NNS N
, , N
etiological JJ N
relationship NN N
between IN N
the DT N
two CD N
is VBZ N
not RB N
clarified VBN N
. . N

METHODS NNP N
The DT N
criteria NN N
for IN N
the DT N
spadelike NN N
configuration NN N
defined VBN N
on IN N
left JJ N
ventricular JJ N
short-axis JJ N
NMR NNP 1_i
images NNS 1_i
were VBD N
as IN N
follows VBZ N
: : N
( ( N
apical JJ N
maximal NN N
thickness NN N
> NN N
or CC N
= $ N
15 CD N
mm NN N
) ) N
, , N
( ( N
apical JJ N
anterior NN N
thickness NN N
over IN N
basal JJ N
anterior JJ N
thickness NN N
> NN N
or CC N
= VB N
1.3 CD N
) ) N
and CC N
( ( N
apical JJ N
posterior NN N
thickness NN N
over IN N
basal JJ N
posterior JJ N
thickness NN N
> NN N
or CC N
=1.3 NN N
) ) N
. . N

Thirteen JJ 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
predominant JJ 1_p
hypertrophy NN 1_p
( ( 1_p
> CD 1_p
or CC 1_p
= VB 1_p
15 CD 1_p
mm NN 1_p
) ) 1_p
at IN 1_p
the DT 1_p
apical JJ 1_p
level NN 1_p
without IN 1_p
the DT 1_p
spadelike NN 1_p
configuration NN 1_p
underwent JJ 1_p
NMR NNP 1_i
imaging VBG 1_i
twice RB 1_i
before RB 1_i
and CC 1_i
after IN 1_i
54+/-10 JJ 1_i
months NNS 1_i
' POS 1_i
follow-up NN 1_i
. . 1_i

RESULTS NNP N
Apical NNP 1_o
hypertrophy NN 1_o
that WDT N
had VBD N
been VBN N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
in IN N
four CD N
, , N
the DT N
anterior-lateral JJ N
wall NN N
in IN N
two CD N
, , N
and CC N
the DT N
septal-anterior JJ N
wall NN N
in IN N
one CD N
developed NN N
to TO N
become VB N
circumferential JJ 1_o
hypertrophy NN 1_o
that WDT N
fulfilled VBD N
the DT N
criteria NNS N
for IN N
the DT N
spadelike NN N
configuration NN N
after IN N
the DT N
follow-up JJ N
period NN N
. . N

CONCLUSIONS VB N
The DT N
spadelike NN N
configuration NN N
can MD N
begin VB N
with IN N
the DT N
nonspade JJ N
configuration NN N
and CC N
therefore NN N
, , N
both DT N
can MD N
constitute VB N
a DT N
single JJ N
disease NN N
entity NN N
of IN N
apical JJ N
HCM NNP N
. . N

The DT N
early JJ N
diagnosis NN N
of IN N
apical JJ 1_o
HCM NNP 1_o
can MD N
be VB N
achieved VBN N
by IN N
identifying VBG N
the DT N
hypertrophy NN 1_o
frequently RB N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
at IN N
the DT N
apical JJ N
level NN N
. . N

Effects NNS N
of IN N
self-directed JJ 1_i
stress NN 1_i
management NN 1_i
training NN 1_i
and CC 1_i
home-based JJ 1_i
exercise NN 1_i
on IN 1_i
stress NN 1_o
management NN 1_o
skills NNS 1_o
in IN N
cancer NN 1_p
patients NNS 1_p
receiving VBG 1_p
chemotherapy NN 1_p
. . 1_p

Although IN N
exercise NN N
may MD N
be VB N
used VBN N
by IN N
some DT N
to TO N
decrease VB N
distress NN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
how WRB N
it PRP N
may MD N
contribute VB N
to TO N
stress VB N
management NN N
( ( N
SM NNP N
) ) N
among IN N
patients NNS 1_p
receiving VBG 1_p
chemotherapy NN 1_p
. . 1_p

We PRP N
evaluated VBD N
whether IN N
exercise NN 1_i
separately RB 1_i
or CC 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
SM NNP 1_i
training NN 1_i
is VBZ N
effective JJ N
at IN N
increasing VBG N
perceived JJ N
ability NN N
to TO N
manage VB N
stress NN N
. . N

Patients NNS 1_p
receiving VBG 1_p
chemotherapy NN 1_i
( ( 1_p
N NNP 1_p
= NNP 1_p
391 CD 1_p
) ) 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
receive VB 1_i
usual JJ 1_i
care NN 1_i
only RB 1_i
( ( 1_i
UCO NNP 1_i
) ) 1_i
, , 1_i
SM NNP 1_i
, , 1_i
exercise NN 1_i
( ( 1_i
EX NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
stress JJ 1_i
management NN 1_i
and CC 1_i
exercise NN 1_i
( ( 1_i
SMEX NNP 1_i
) ) 1_i
. . 1_i

They PRP N
completed VBD N
the DT N
Measure NN N
of IN N
Current NNP N
Status NNP N
prior RB N
to TO N
receiving VBG N
chemotherapy NN N
and CC N
12 CD N
weeks NNS N
after IN N
the DT N
first JJ N
infusion NN N
. . N

We PRP N
hypothesized VBD N
that IN N
participants NNS N
randomized VBN N
to TO N
an DT N
intervention NN N
condition NN N
would MD N
report VB N
improvements NNS N
in IN N
relaxation NN 1_o
, , 1_o
awareness NN 1_o
of IN 1_o
tension NN 1_o
, , 1_o
getting VBG 1_o
needs NNS 1_o
met VBD 1_o
and CC 1_o
coping VBG 1_o
confidence NN 1_o
compared VBN N
with IN N
those DT N
receiving VBG N
UCO NNP N
. . N

Results NNP N
indicated VBD N
significant JJ N
group-by-time JJ N
interactions NNS N
for IN N
the DT N
following NN N
: : N
relaxation NN 1_o
( ( N
UCO NNP N
versus NN N
SM NNP N
, , N
p NN N
= NNP N
0.008 CD N
) ) N
, , N
awareness NN 1_o
of IN 1_o
tension NN 1_o
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= VBD N
0.029 CD N
and CC N
UCO NNP N
versus NN N
EX NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
getting VBG 1_o
needs NNS 1_o
met VBD 1_o
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= NNP N
0.020 CD N
) ) N
and CC N
Measure NN N
of IN N
Current NNP 1_o
Status NNP 1_o
total NN N
score NN N
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
UCO NNP N
versus NN N
EX NNP N
, , N
p NN N
= NNP N
0.016 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
group-by-time JJ N
interactions NNS N
for IN N
coping VBG 1_o
confidence NN 1_o
( ( N
p-values JJ N
> NNP N
0.05 CD N
) ) N
. . N

This DT N
study NN N
provides VBZ N
support NN N
for IN N
including VBG N
an DT N
exercise NN 1_o
component NN 1_o
in IN N
SM NNP N
interventions NNS N
for IN N
cancer NN 1_p
patients NNS 1_p
receiving VBG 1_p
chemotherapy NN 1_p
( ( N
clinicaltrials.gov JJ N
identifier NN N
: : N
NCT00740038 NNP N
) ) N
. . N

High-dose JJ 1_i
weekly JJ 1_i
fractionation NN 1_i
radiotherapy NN 1_i
in IN N
advanced JJ 1_p
cancer NN 1_p
of IN 1_p
the DT 1_p
uterine JJ 1_p
cervix NN 1_p
. . 1_p

A DT N
trial NN N
comparing VBG N
two CD 1_p
different JJ 1_p
radiotherapy NN 1_i
techniques NNS 1_p
and CC N
schedules NNS N
in IN N
the DT N
treatment NN N
of IN N
83 CD 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
cancer NN 1_p
of IN 1_p
the DT 1_p
uterine JJ 1_p
cervix NN 1_p
( ( 1_p
stage JJ 1_p
IIIB NNP 1_p
) ) 1_p
employing VBG 1_p
external JJ 1_i
irradiation NN 1_i
alone RB 1_p
is VBZ N
described VBN N
. . N

The DT N
one CD N
technique NN N
, , N
used VBD N
routinely RB N
in IN N
this DT N
department NN N
, , N
employed VBD N
a DT N
conventional JJ N
daily JJ N
fractionation NN N
schedule NN N
while IN N
the DT N
other JJ N
used VBD N
a DT N
high-dose JJ N
weekly JJ N
fractionation NN N
regimen NNS N
. . N

The DT N
techniques NNS N
are VBP N
described VBN N
. . N

The DT N
aim NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN 1_o
and CC 1_o
morbidity NN 1_o
of IN N
these DT N
two CD N
methods NNS N
of IN N
treatment NN N
. . N

Dose NNP N
distribution NN N
curves NNS N
in IN N
cross-section NN N
and CC N
midsagittal JJ N
planes NNS N
are VBP N
shown VBN N
and CC N
calculations NNS N
or CC N
equivalent JJ N
doses NNS N
at IN N
various JJ N
selected VBN N
points NNS N
using VBG N
Ellis NNP N
's POS N
nominal JJ N
single-dose JJ N
formula NN N
are VBP N
tabulated VBN N
. . N

The DT N
2-year JJ N
survival NN 1_o
figures NNS N
were VBD N
33 CD N
% NN N
for IN N
the DT N
daily JJ N
fractionation NN N
technique NN N
and CC N
22 CD N
% NN N
for IN N
the DT N
weekly JJ N
regimen NN N
. . N

Serious JJ 1_o
late JJ 1_o
complication NN 1_o
rates NNS 1_o
were VBD N
6 CD N
% NN N
for IN N
the DT N
daily JJ N
regimen NNS N
and CC N
22 CD N
% NN N
for IN N
the DT N
weekly JJ N
schedule NN N
. . N

These DT N
differences NNS N
are VBP N
not RB N
statistically RB N
significant JJ N
. . N

Late JJ 1_o
complication NN 1_o
rates NNS 1_o
in IN N
the DT N
weekly JJ N
fractionation NN N
regimen NNS N
appeared VBD N
to TO N
be VB N
lower JJR N
than IN N
figures NNS N
quoted VBN N
by IN N
other JJ N
authors NNS N
. . N

Local JJ N
control NN N
within IN N
the DT N
irradiated JJ N
volume NN N
was VBD N
better RBR N
in IN N
the DT N
group NN N
treated VBN N
by IN N
the DT N
daily JJ N
fractionation NN N
method NN N
. . N

[ JJ 1_i
Radiotherapy NNP 1_i
and/or NN 1_i
chemotherapy NN 1_i
in IN N
children NNS 1_p
with IN 1_p
primitive JJ 1_p
neuroectodermal JJ 1_p
tumor NN 1_p
( ( 1_p
PNET NNP 1_p
) ) 1_p
of IN 1_p
the DT 1_p
pineal JJ 1_p
region NN 1_p
] NN 1_p
. . N

Sociopsychological JJ N
tailoring VBG N
to TO N
address VB N
colorectal JJ N
cancer NN N
screening VBG N
disparities NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Interventions NNP 1_i
tailored VBD 1_i
to TO 1_i
sociopsychological JJ 1_i
factors NNS 1_i
associated VBN 1_i
with IN 1_i
health NN 1_i
behaviors NNS 1_i
have VBP N
promise NN N
for IN N
reducing VBG N
colorectal JJ N
cancer NN N
screening VBG N
disparities NNS N
, , N
but CC N
limited VBD N
research NN N
has VBZ N
assessed VBN N
their PRP$ N
impact NN N
in IN N
multiethnic JJ N
populations NNS N
. . N

We PRP N
examined VBD N
whether IN N
an DT N
interactive JJ 1_i
multimedia NN 1_i
computer NN 1_i
program NN 1_i
( ( 1_i
IMCP NNP 1_i
) ) 1_i
tailored VBD N
to TO N
expanded VB N
health NN N
belief NN N
model NN N
sociopsychological JJ N
factors NNS N
could MD N
promote VB N
colorectal JJ N
cancer NN N
screening NN N
in IN N
a DT N
multiethnic JJ 1_p
sample NN 1_p
. . 1_p

METHODS NNP N
We PRP N
undertook VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
, , N
comparing VBG N
an DT N
IMCP NNP 1_i
tailored VBD 1_i
to TO 1_i
colorectal JJ 1_i
cancer NN 1_i
screening VBG 1_i
self-efficacy NN 1_i
, , 1_i
knowledge NN 1_i
, , 1_i
barriers NNS 1_i
, , 1_i
readiness NN 1_i
, , 1_i
test NN 1_i
preference NN 1_i
, , 1_i
and CC 1_i
experiences NNS 1_i
with IN 1_i
a DT 1_i
nontailored JJ 1_i
informational JJ 1_i
program NN 1_i
, , N
both DT N
delivered VBN N
before IN N
office NN N
visits NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
record-documented JJ 1_o
colorectal JJ 1_o
cancer NN 1_o
screening VBG 1_o
during IN 1_o
a DT 1_o
12-month JJ 1_o
follow-up JJ 1_o
period NN 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
included VBD N
postvisit JJ 1_o
sociopsychological JJ 1_o
factor NN 1_o
status NN 1_o
and CC 1_o
discussion NN 1_o
, , 1_o
as RB 1_o
well RB 1_o
as IN 1_o
clinician JJ 1_o
recommendation NN 1_o
of IN 1_o
screening VBG 1_o
during IN 1_o
office NN 1_o
visits NNS 1_o
. . 1_o

We PRP N
enrolled VBD 1_p
1,164 CD 1_p
patients NNS 1_p
stratified VBN 1_p
by IN 1_p
ethnicity NN 1_p
and CC 1_p
language NN 1_p
( ( 1_p
49.3 CD 1_p
% NN 1_p
non-Hispanic JJ 1_p
, , 1_p
27.2 CD 1_p
% NN 1_p
Hispanic/English NNP 1_p
, , 1_p
23.4 CD 1_p
% NN 1_p
Hispanic/Spanish NNP 1_p
) ) 1_p
from IN 1_p
26 CD 1_p
offices NNS 1_p
around IN 1_p
5 CD 1_p
centers NNS 1_p
( ( 1_p
Sacramento NNP 1_p
, , 1_p
California NNP 1_p
; : 1_p
Rochester NNP 1_p
and CC 1_p
the DT 1_p
Bronx NNP 1_p
, , 1_p
New NNP 1_p
York NNP 1_p
; : 1_p
Denver NNP 1_p
, , 1_p
Colorado NNP 1_p
; : 1_p
and CC 1_p
San NNP 1_p
Antonio NNP 1_p
, , 1_p
Texas NNP 1_p
) ) 1_p
. . 1_p

RESULTS NNP N
Adjusting NNP N
for IN N
ethnicity/language NN N
, , N
study NN N
center NN N
, , N
and CC N
the DT N
previsit NN N
value NN N
of IN N
the DT N
dependent NN N
variable NN N
, , N
compared VBN N
with IN N
control NN N
patients NNS N
, , N
the DT N
IMCP NNP N
led VBD N
to TO N
significantly RB N
greater JJR N
colorectal JJ 1_o
cancer NN 1_o
screening VBG 1_o
knowledge NN 1_o
, , 1_o
self-efficacy NN 1_o
, , 1_o
readiness NN 1_o
, , 1_o
test NN 1_o
preference NN 1_o
specificity NN 1_o
, , 1_o
discussion NN 1_o
, , 1_o
and CC 1_o
recommendation NN 1_o
. . 1_o

During IN N
the DT N
followup JJ N
period NN N
, , N
132 CD N
( ( N
23 CD N
% NN N
) ) N
IMCP NNP N
and CC N
123 CD N
( ( N
22 CD N
% NN N
) ) N
control NN N
patients NNS N
received VBD N
screening VBG 1_o
( ( N
adjusted VBN N
difference NN N
= $ N
0.5 CD N
percentage NN N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
-4.3 NNP N
to TO N
5.3 CD N
) ) N
. . N

IMCP NNP 1_o
effects NNS N
did VBD N
not RB N
differ VB N
significantly RB N
by IN N
ethnicity/language NN N
. . N

CONCLUSIONS NNP N
Sociopsychological NNP N
factor NN N
tailoring NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
nontailored JJ N
information NN N
in IN N
encouraging VBG N
colorectal JJ N
cancer NN N
screening NN N
in IN N
a DT N
multiethnic JJ 1_p
sample NN 1_p
, , N
despite IN N
enhancing VBG N
sociopsychological JJ N
factors NNS N
and CC N
visit NN N
behaviors NNS N
associated VBN N
with IN N
screening NN N
. . N

The DT N
utility NN N
of IN N
sociopsychological JJ N
tailoring NN N
in IN N
addressing VBG N
screening VBG N
disparities NNS N
remains VBZ N
uncertain JJ N
. . N

Effect NN N
of IN N
CX516 NNP 1_i
, , N
an DT N
AMPA-modulating JJ 1_i
compound NN 1_i
, , N
on IN N
cognition NN 1_o
and CC 1_o
behavior NN 1_o
in IN 1_p
fragile JJ 1_p
X JJ 1_p
syndrome NN 1_p
: : 1_p
a DT N
controlled JJ N
trial NN N
. . N

A DT N
Phase NNP N
II NNP N
, , N
4-week JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
the DT N
Ampakine NNP 1_i
compound NN N
CX516 NNP 1_i
as IN N
a DT N
potential JJ N
treatment NN N
for IN N
the DT N
underlying JJ 1_p
disorder NN 1_p
in IN 1_p
fragile JJ 1_p
X NNP 1_p
syndrome NN 1_p
( ( 1_p
FXS NNP 1_p
) ) 1_p
. . 1_p

After IN N
baseline NN N
screening NN N
, , N
subjects VBZ 1_p
with IN 1_p
FXS NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
49 CD 1_p
) ) 1_p
underwent NN N
a DT N
1-week JJ 1_i
placebo NN 1_i
lead-in NN 1_i
and CC 1_i
then RB 1_i
were VBD 1_i
randomized VBN 1_i
to TO 1_i
study VB 1_i
drug NN 1_i
or CC 1_i
placebo NN 1_i
for IN 1_i
a DT 1_i
4-week JJ 1_i
period NN 1_i
. . 1_i

Cognitive JJ 1_o
and CC 1_o
behavioral JJ 1_o
outcome NN N
measures NNS N
were VBD N
administered VBN N
prior RB N
to TO N
treatment NN N
, , N
at IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
and CC N
2 CD N
weeks NNS N
posttreatment NN N
. . N

There EX N
were VBD N
minimal JJ 1_o
side NN 1_o
effects NNS 1_o
, , N
no DT N
significant JJ 1_o
changes NNS 1_o
in IN 1_o
safety NN 1_o
parameters NNS 1_o
, , N
and CC N
no DT 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
. . 1_o

There EX N
was VBD N
a DT N
12.5 CD 1_o
% NN 1_o
frequency NN 1_o
of IN N
allergic JJ 1_o
rash NN 1_o
in IN N
the DT N
CX516 NNP 1_i
group NN N
and CC N
1 CD N
subject NN N
developed VBD N
a DT N
substantial JJ 1_o
rash NN 1_o
. . 1_o

There EX N
was VBD N
also RB N
no DT N
significant JJ 1_o
improvement NN 1_o
in IN N
memory NN 1_o
, , N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
or CC N
in IN N
secondary JJ N
measures NNS N
of IN N
language NN 1_o
, , 1_o
attention/executive JJ 1_o
function NN 1_o
, , 1_o
behavior NN 1_o
, , 1_o
and CC 1_o
overall JJ 1_o
functioning NN 1_o
in IN N
CX516-treated JJ 1_i
subjects NNS N
compared VBN N
to TO N
placebo VB 1_i
. . 1_i

This DT N
study NN N
did VBD N
demonstrate VB N
that IN N
many JJ N
outcome JJ N
measures NNS 1_o
were VBD N
reproducible JJ N
in IN N
this DT N
test-retest JJ N
setting NN N
for IN N
the DT N
FXS NNP N
population NN N
, , N
yet CC N
some DT N
were VBD N
too RB N
difficult JJ N
or CC N
variable JJ N
. . N

Adult NNP 1_p
subjects VBZ 1_p
with IN 1_p
FXS NNP 1_p
were VBD N
able JJ N
to TO N
complete VB N
an DT N
intensive JJ N
clinical JJ N
trial NN N
, , N
and CC N
some DT N
valid JJ N
outcome NN N
measures NNS N
were VBD N
identified VBN N
for IN N
future JJ N
FXS NNP N
trial NN N
design NN N
. . N

Problems VBZ N
with IN N
potency NN N
of IN N
CX516 NNP 1_i
in IN N
other JJ N
studies NNS N
have VBP N
suggested VBN N
dosing NN N
may MD N
have VB N
been VBN N
inadequate JJ N
for IN N
therapeutic JJ N
effect NN N
and CC N
thus RB N
it PRP N
remains VBZ N
unclear JJ N
whether IN N
modulation NN N
of IN N
AMPA-mediated JJ N
neurotransmission NN N
is VBZ N
a DT N
viable JJ 1_o
therapeutic JJ 1_o
strategy NN 1_o
for IN N
the DT N
treatment NN N
of IN N
FXS NNP N
. . N

Acute JJ N
effects NNS N
of IN N
caffeine JJ 1_i
ingestion NN 1_i
on IN N
signal-averaged JJ 1_o
electrocardiograms NNS 1_o
. . 1_o

BACKGROUND NNP N
Although IN N
moderate JJ N
caffeine NN N
ingestion NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
arrhythmogenic JJ N
, , N
caffeine JJ N
toxicity NN N
can MD N
cause VB N
severe JJ N
cardiac JJ N
arrhythmias NN N
, , N
including VBG N
atrial JJ N
fibrillation NN N
and CC N
ventricular JJ N
tachycardia NN N
. . N

Atrial JJ N
fibrillation NN N
and CC N
ventricular JJ N
tachycardia NN N
have VBP N
been VBN N
associated VBN N
with IN N
prolongation NN 1_o
of IN 1_o
P-wave NNP 1_o
and CC 1_o
QRS NNP 1_o
complex JJ 1_o
durations NNS 1_o
on IN 1_o
signal-averaged JJ 1_o
electrocardiograms NNS 1_o
. . 1_o

This DT N
study NN N
investigated VBD N
acute JJ N
effects NNS N
of IN N
caffeine JJ N
ingestion NN N
on IN N
signal-averaged JJ 1_o
P-wave NNP 1_o
and CC 1_o
QRS NNP 1_o
complexes NNS 1_o
. . 1_o

METHODS NNP N
AND CC N
RESULTS NNP N
Signal-averaged JJ 1_o
electrocardiograms NNS 1_o
were VBD N
obtained VBN N
from IN N
12 CD 1_p
normal JJ 1_p
subjects NNS 1_p
( ( 1_p
6 CD 1_p
men NNS 1_p
, , 1_p
6 CD 1_p
women NNS 1_p
; : 1_p
ages VBZ 1_p
21 CD 1_p
to TO 1_p
26 CD 1_p
years NNS 1_p
) ) 1_p
before IN 1_p
and CC 1_p
after IN 1_p
ingestion NN 1_p
of IN 1_p
caffeine NN 1_i
( ( N
5 CD N
mg/kg NN N
body NN N
weight NN N
) ) N
or CC N
placebo NN 1_i
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
fashion NN N
. . N

Electrocardiograms NNP N
for IN N
signal JJ N
averaging NN N
were VBD N
recorded VBN N
from IN N
electrodes NNS N
left VBN N
in IN N
a DT N
constant JJ N
location NN N
. . N

After IN N
bandpass NN N
filtering NN N
( ( N
30 CD N
to TO N
300 CD N
Hz NNP N
) ) N
and CC N
amplification NN N
, , N
signals NNS N
were VBD N
sampled VBN N
over IN N
7.2 CD N
minutes NNS N
at IN N
2000 CD N
Hz NNP N
. . N

Signal-averaged JJ 1_o
P-wave NNP 1_o
and CC 1_o
QRS NNP 1_o
complex JJ 1_o
durations NNS 1_o
did VBD N
not RB N
significantly RB N
change VBP N
after IN N
placebo NN N
ingestion NN N
. . N

After IN N
caffeine JJ N
ingestion NN N
QRS NNP 1_o
duration NN 1_o
prolonged VBD N
in IN N
9 CD N
of IN N
11 CD N
subjects NNS N
at IN N
90 CD N
minutes NNS N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
= NNP N
0.8+/-0.3 JJ N
ms NN N
, , N
P NNP N
< NNP N
.02 NNP N
) ) N
and CC N
in IN N
8 CD N
of IN N
9 CD N
after IN N
3 CD N
hours NNS N
( ( N
1.1+/-0.2 JJ N
ms NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

No DT N
significant JJ N
change NN N
in IN N
P-wave NNP 1_o
duration NN 1_o
or CC 1_o
heart NN 1_o
rate NN 1_o
was VBD N
found VBN N
after IN N
caffeine JJ N
ingestion NN N
at IN N
any DT N
test NN N
interval NN N
. . N

Average JJ 1_o
caffeine JJ 1_o
level NN 1_o
in IN 1_o
saliva JJ 1_o
90 CD N
minutes NNS N
after IN N
ingestion NN N
was VBD N
6.6+/-1.6 JJ N
( ( N
SD NNP N
) ) N
microg/dL NN N
. . N

CONCLUSIONS NNP N
Although IN N
probably RB N
not RB N
arrhythmogenic JJ N
in IN N
normal JJ 1_p
subjects NNS 1_p
, , N
moderate JJ N
caffeine NN N
ingestion NN N
does VBZ N
produce VB N
a DT N
small JJ N
but CC N
statistically RB N
significant JJ N
prolongation NN N
of IN N
signal-averaged JJ 1_o
QRS NNP 1_o
complexes NNS 1_o
. . 1_o

Further JJ N
prolongation NN N
caused VBN N
by IN N
excessive JJ N
caffeine NNS N
intake VBP N
may MD N
be VB N
a DT N
factor NN N
in IN N
the DT N
genesis NN N
of IN N
arrhythmias NNS N
associated VBN N
with IN N
caffeine JJ N
toxicity NN N
. . N

Cyproheptadine NNP N
augmentation NN N
of IN N
haloperidol NN 1_i
in IN N
chronic JJ 1_p
schizophrenic JJ 1_p
patients NNS 1_p
: : 1_p
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

A DT N
6 CD N
week NN N
double-blind JJ N
placebo-controlled JJ 1_i
trial NN N
of IN N
cyproheptadine JJ 1_i
augmentation NN 1_i
of IN 1_p
ongoing VBG 1_p
haloperidol NN 1_i
treatment NN 1_p
was VBD N
conducted VBN N
in IN N
40 CD 1_p
chronic JJ 1_p
schizophrenic JJ 1_p
in-patients NNS 1_p
. . 1_p

Cyproheptadine NNP N
augmentation NN N
, , N
compared VBN N
to TO N
administration NN N
of IN N
haloperidol NN 1_i
with IN 1_i
placebo NN 1_i
, , N
did VBD N
not RB N
produce VB N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
psychotic JJ 1_o
symptoms NNS 1_o
. . 1_o

Cyproheptadine NNP N
augmentation NN N
caused VBD N
significant JJ N
reduction NN N
in IN N
the DT N
extrapyramidal NN 1_o
symptoms NNS 1_o
, , N
which WDT N
supports VBZ N
the DT N
atypical JJ N
profile NN N
of IN N
antipsychotics NNS N
. . N

As IN N
to TO N
the DT N
neuroendocrinological JJ 1_o
effect NN 1_o
, , N
cyproheptadine JJ N
augmentation NN N
did VBD N
not RB N
reduce VB N
the DT N
plasma NN 1_o
prolactin NN 1_o
level NN 1_o
but CC N
did VBD N
induce VB N
a DT N
decrease NN N
in IN N
the DT N
plasma NN 1_o
cortisol NN 1_o
level NN 1_o
. . 1_o

Although IN N
long-term JJ N
follow-up JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
the DT N
results NNS N
, , N
this DT N
study NN N
suggests VBZ N
that IN N
cyproheptadine NN N
augmentation NN N
may MD N
be VB N
effective JJ N
in IN N
treating VBG N
chronic JJ 1_o
schizophrenic JJ 1_o
patients NNS 1_o
who WP 1_p
are VBP 1_p
intolerant JJ 1_p
of IN 1_p
extrapyramidal JJ 1_o
side NN 1_o
effects NNS 1_o
of IN 1_p
conventional JJ 1_p
antipsychotics NNS 1_p
. . 1_p

Trials NNS 1_o
and CC N
tribulations NNS 1_o
in IN N
speech NN 1_i
therapy NN 1_i
. . 1_i

Preoperative NNP N
Local NNP N
Administration NNP N
of IN N
Morphine NNP 1_i
as IN N
an DT N
Add-on JJ N
Therapy NN N
in IN N
Patients NNS 1_p
Undergoing VBG 1_p
Surgical JJ 1_p
Removal NNP 1_p
of IN 1_p
an DT 1_p
Odontogenic NNP 1_p
Maxillary NNP 1_p
Cyst NNP 1_p
. . 1_p

A NNP N
Randomized NNP N
, , N
Double-Blind NNP N
Pilot NNP N
Study NNP N
. . N

AIMS NNP N
To TO N
evaluate VB N
whether IN N
a DT N
combination NN N
of IN N
locally RB N
administered VBN N
morphine NN 1_i
( ( N
1 CD N
mg NN N
) ) N
and CC N
lidocaine NN 1_i
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
analgesic JJ N
approach NN N
is VBZ N
safe JJ N
, , N
and CC N
whether IN N
it PRP N
improves VBZ N
pain JJ N
control NN N
during IN N
the DT 1_p
first JJ 1_p
24 CD 1_p
hours NNS 1_p
after IN 1_p
odontogenic JJ 1_p
maxillary JJ 1_p
cyst NN 1_p
removal NN 1_p
under IN 1_p
general JJ 1_p
anesthesia NN 1_p
compared VBN N
to TO N
local JJ N
lidocaine NN N
alone RB N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
sham-controlled JJ N
, , N
single-center JJ N
trial NN N
, , N
patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
surgical JJ 1_p
removal NN 1_p
of IN 1_p
an DT 1_p
odontogenic JJ 1_p
maxillary JJ 1_p
cyst NN 1_p
under IN 1_p
general JJ 1_p
anesthesia NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
local JJ N
injection NN N
of IN N
lidocaine JJ 1_i
solution NN 1_i
with IN 1_i
either DT 1_i
1 CD 1_i
mg NN 1_i
of IN 1_i
morphine NN 1_i
( ( 1_i
MLA NNP 1_i
group NN N
) ) N
or CC 1_i
with IN 1_i
no DT 1_i
morphine NN 1_i
( ( 1_i
LA NNP 1_i
group NN N
) ) N
. . N

Pain NNP N
management NN N
included VBD N
intravenous JJ N
acetaminophen NN 1_i
( ( N
1 CD N
g NN N
every DT N
6 CD N
hours NNS N
) ) N
in IN N
all DT N
patients NNS N
. . N

Upon IN N
request NN N
, , N
the DT N
patients NNS N
could MD N
additionally RB N
receive VB N
ketoprofen NN 1_i
( ( N
first-line JJ N
additional JJ N
analgesia NN N
) ) N
or CC 1_i
tramadol JJ 1_i
( ( N
second-line JJ N
additional JJ N
analgesia NN N
) ) N
. . N

Pain NNP N
intensity NN N
was VBD N
assessed VBN N
using VBG N
a DT N
numeric JJ N
rating NN N
scale NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
( ( 1_o
1 CD 1_o
) ) 1_o
no DT 1_o
need NN 1_o
for IN 1_o
any DT 1_o
additional JJ 1_o
analgesic JJ 1_o
therapy NN 1_o
and CC 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
time NN 1_o
to TO 1_o
the DT 1_o
first JJ 1_o
rescue NN 1_o
analgesic JJ 1_o
therapy NN 1_o
during IN 1_o
the DT 1_o
first JJ 1_o
24 CD 1_o
hours NNS 1_o
after IN 1_o
the DT 1_o
surgery NN 1_o
. . 1_o

RESULTS NNP N
Of IN N
48 CD 1_p
eligible JJ 1_p
patients NNS 1_p
, , N
24 CD N
were VBD N
allocated VBN N
to TO N
the DT N
MLA NNP N
group NN N
and CC N
24 CD N
to TO N
the DT N
LA NNP N
group NN N
. . N

The DT N
necessity NN N
of IN N
additional JJ 1_o
ketoprofen NN 1_o
therapy NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
25.0 CD N
% NN N
vs JJ N
50.0 CD N
% NN N
, , N
P=.074 NNP N
) ) N
. . N

According VBG N
to TO N
the DT N
Kaplan-Meier NNP N
analysis NN N
, , N
the DT N
probability NN N
of IN N
remaining VBG N
without IN N
additional JJ 1_o
analgesic JJ 1_o
intervention NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
MLA NNP N
group NN N
( ( N
log-rank JJ N
test NN N
, , N
P=.040 NNP N
) ) N
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
differences NNS N
in IN N
overall JJ N
and CC N
maximum JJ N
pain NN 1_o
severity NN 1_o
between IN N
the DT N
two CD N
groups NNS N
. . N

No DT N
adverse JJ 1_o
effects NNS 1_o
of IN N
morphine NN N
were VBD N
recorded VBN N
. . N

CONCLUSION NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN N
, , N
local JJ N
administration NN N
of IN N
1 CD N
mg NN N
of IN N
morphine NN 1_i
prior RB N
to TO N
the DT N
surgical JJ N
removal NN N
of IN N
an DT N
odontogenic JJ N
maxillary JJ N
cyst NN N
was VBD N
safe JJ N
, , N
but CC N
it PRP N
did VBD N
not RB N
prove VB N
to TO N
be VB N
very RB N
effective JJ N
as IN N
an DT N
add-on JJ N
therapy NN N
for IN N
postoperative JJ N
pain NN N
control NN N
. . N

Safety NN 1_o
and CC N
efficacy NN 1_o
of IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
Logiparin NNP N
) ) N
versus NN N
dextran NN N
as IN N
prophylaxis NN N
against IN N
thrombosis NN 1_o
after IN N
total JJ 1_p
hip NN 1_p
replacement NN 1_p
. . 1_p

In IN N
order NN N
to TO N
study VB N
the DT N
plasma NN N
levels NNS N
of IN N
factor NN N
XaI NNP N
and CC N
IIaI NNP N
activity NN N
an DT N
enzymatically RB 1_i
depolymerized VBN 1_i
low JJ 1_i
molecular JJ 1_i
weight NN 1_i
heparin NN 1_i
( ( 1_i
LMW-heparin NNP 1_i
; : 1_i
Logiparin NNP 1_i
) ) 1_i
was VBD N
given VBN N
s.c. NN N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

once RB N
daily JJ N
for IN N
7 CD N
days NNS N
to TO N
10 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
total JJ 1_p
hip NN 1_p
replacement NN 1_p
( ( 1_p
THR NNP 1_p
) ) 1_p
in IN N
a DT N
pilot NN N
study NN N
. . N

The DT N
XaI NN N
activity NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.24 CD N
XaI NNP N
units/ml NN N
and CC N
the DT N
IIaI NNP N
activity NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.043 CD N
IIaI NNP N
mu/ml NN N
. . N

No DT N
accumulation NN N
of IN N
the DT N
activities NNS N
were VBD N
seen VBN N
. . N

No DT N
phlebographically RB 1_o
verified VBN 1_o
thrombi NN 1_o
or CC N
any DT N
bleeding JJ 1_o
complications NNS 1_o
were VBD N
registered VBN N
. . N

From IN N
this DT N
study NN N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
given VBN N
dose NN N
of IN N
Logiparin NNP N
was VBD N
safe JJ N
with IN N
regard NN N
to TO N
bleeding VBG N
complications NNS N
. . N

Based VBN N
on IN N
these DT N
data NNS N
, , N
an DT N
open JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
was VBD N
started VBN N
. . N

In IN N
this DT N
main JJ N
study NN N
the DT N
thromboprophylactic JJ 1_o
effect NN 1_o
of IN N
the DT N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

once RB N
daily JJ N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
dextran NN N
70 CD N
in IN N
patients NNS 1_p
undergoing JJ 1_p
THR NNP 1_p
. . 1_p

100 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
. . 1_p

The DT N
over-all JJ 1_o
thrombosis NN 1_o
rate NN 1_o
was VBD N
28 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
LMW-heparin NNP N
and CC N
39 CD N
% NN N
in IN N
those DT N
given VBN N
dextran NN N
, , N
a DT N
non-significant JJ N
difference NN N
. . N

No UH N
bleeding VBG 1_o
complications NNS 1_o
, , 1_o
deaths NNS 1_o
or CC 1_o
pulmonary JJ 1_o
embolism NN 1_o
were VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Peroperative JJ 1_o
blood NN 1_o
loss NN 1_o
and CC 1_o
transfusion NN 1_o
requirements NNS 1_o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
investigated JJ N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
preventing VBG N
postoperative JJ N
thromboembolism NN N
in IN N
patients NNS 1_p
undergoing JJ 1_p
total JJ 1_p
hip NN 1_p
replacement NN 1_p
, , N
but CC N
the DT N
dosage NN N
can MD N
probably RB N
be VB N
optimized VBN N
. . N

Absolute NNP N
bioavailability NN N
of IN N
a DT N
new JJ N
high JJ N
dose NN N
methylprednisolone NN 1_i
tablet NN N
formulation NN N
. . N

This DT N
was VBD N
a DT N
single-blind JJ N
, , N
single-dose JJ N
, , N
randomized VBN N
crossover NN N
study NN N
to TO N
determine VB N
the DT N
absolute JJ 1_o
bioavailability NN 1_o
of IN N
Medrol NNP 1_i
, , N
a DT N
new JJ N
high JJ N
dose NN N
( ( N
100 CD N
mg NN N
) ) N
methylprednisolone NN 1_i
tablet NN N
product NN N
, , N
by IN N
comparing VBG N
it PRP N
with IN N
100 CD N
mg NNS N
methylprednisolone NN 1_i
from IN N
an DT N
intravenous JJ N
formulation NN N
, , N
Solu-Medrol NNP 1_i
. . 1_i

Fourteen NNP 1_p
healthy JJ 1_p
, , 1_p
non-smoking JJ 1_p
, , 1_p
Caucasian JJ 1_p
male NN 1_p
volunteers NNS 1_p
took VBD N
part NN N
. . N

On IN N
treatment NN N
days NNS N
volunteers NNS N
remained VBD N
recumbent NN N
for IN N
4 CD N
hours NNS N
after IN N
drug NN N
administration NN N
, , N
with IN N
food NN N
and CC N
fluid NN N
intake VBP N
standardized VBN N
over IN N
this DT N
period NN N
. . N

Serial JJ N
blood NN N
samples NNS N
were VBD N
drawn VBN N
over IN N
a DT N
14-hour JJ N
period NN N
after IN N
drug NN N
administration NN N
. . N

Plasma NNP 1_o
methylprednisolone NN 1_o
concentrations NNS 1_o
were VBD N
determined VBN N
by IN N
high JJ N
performance NN N
liquid NN N
chromatography NN N
. . N

The DT N
geometric JJ N
means NNS N
of IN N
AUCi.v NNP 1_o
. . 1_o

and CC 1_o
AUCtablet NNP 1_o
were VBD N
4,049 CD N
and CC N
3,334 CD N
ng.h/ml NN N
, , N
respectively RB N
. . N

The DT N
absolute JJ 1_o
bioavailability NN 1_o
of IN N
the DT N
tablet NN N
product NN N
was VBD N
82 CD N
% NN N
, , N
which WDT N
is VBZ N
in IN N
agreement NN N
with IN N
published VBN N
data NNS N
for IN N
other JJ N
oral JJ N
dosage NN N
forms NNS N
of IN N
methylprednisolone NN 1_i
. . 1_i

Volunteers NNS N
displayed VBD N
the DT N
expected VBN N
rise NN N
in IN N
peripheral JJ 1_o
blood NN 1_o
neutrophil NN 1_o
count NN 1_o
, , N
but CC N
no DT N
other JJ N
clinically RB 1_o
relevant JJ 1_o
changes NNS 1_o
in IN 1_o
hematology NN 1_o
or CC 1_o
clinical JJ 1_o
chemistry NN 1_o
were VBD N
observed VBN N
. . N

No DT N
adverse JJ 1_o
drug NN 1_o
reactions NNS 1_o
were VBD N
recorded VBN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
tablet NN N
product NN N
can MD N
be VB N
used VBN N
as IN N
a DT N
substitute NN N
for IN N
parenteral JJ N
methylprednisolone NN 1_i
in IN N
situations NNS N
requiring VBG N
high-dose JJ N
therapy NN N
. . N

Mapping VBG N
from IN N
disease-specific JJ N
measures NNS N
to TO N
health-state JJ N
utility NN N
values NNS N
in IN N
individuals NNS 1_p
with IN 1_p
migraine NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
empirical JJ N
algorithms NN N
that WDT N
estimate VBP N
health-state JJ N
utility NN N
values NNS N
from IN N
disease-specific JJ N
quality-of-life JJ N
scores NNS N
in IN N
individuals NNS 1_p
with IN 1_p
migraine NN 1_p
. . 1_p

METHODS NNP N
Data NNP N
from IN N
a DT N
cross-sectional JJ N
, , N
multicountry NN N
study NN N
were VBD N
used VBN N
. . N

Individuals NNS 1_p
with IN 1_p
episodic NN 1_p
and CC 1_p
chronic JJ 1_p
migraine NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
training NN N
or CC N
validation NN N
samples NNS N
. . N

Spearman NNP 1_o
's POS 1_o
correlation NN 1_o
coefficients NNS 1_o
between IN N
paired VBN N
EuroQol NNP 1_i
five-dimensional JJ 1_i
( ( 1_i
EQ-5D NNP 1_i
) ) 1_i
questionnaire NN 1_i
utility NN N
values NNS N
and CC N
both DT N
Headache NNP 1_o
Impact NNP 1_o
Test NNP 1_o
( ( 1_o
HIT-6 NNP 1_o
) ) 1_o
scores NNS N
and CC N
Migraine-Specific NNP 1_o
Quality-of-Life NNP 1_o
Questionnaire NNP 1_o
version NN 1_o
2.1 CD 1_o
( ( 1_o
MSQ NNP 1_o
) ) 1_o
domain NN 1_o
scores NNS 1_o
( ( N
role NN N
restrictive NN N
, , N
role NN N
preventive NN N
, , N
and CC N
emotional JJ N
function NN N
) ) N
were VBD N
examined VBN N
. . N

Regression NN N
models NNS N
were VBD N
constructed VBN N
to TO N
estimate VB N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
from IN N
the DT N
HIT-6 NNP N
score NN N
or CC N
the DT N
MSQ NNP N
domain NN N
scores NNS N
. . N

Preferred VBN N
algorithms NNS N
were VBD N
confirmed VBN N
in IN N
the DT N
validation NN N
samples NNS N
. . N

RESULTS NNP N
In IN N
episodic JJ N
migraine NN N
, , N
the DT N
preferred JJ N
HIT-6 NNP 1_i
and CC N
MSQ NNP 1_i
algorithms VBP 1_i
explained VBD N
22 CD N
% NN N
and CC N
25 CD N
% NN N
of IN N
the DT N
variance NN N
( ( N
R NNP N
( ( N
2 CD N
) ) N
) ) N
in IN N
the DT N
training NN N
samples NNS N
, , N
respectively RB N
, , N
and CC N
had VBD N
similar JJ N
prediction NN N
errors NNS N
( ( N
root JJ N
mean NN N
square JJ N
errors NNS N
of IN N
0.30 CD N
) ) N
. . N

In IN N
chronic JJ N
migraine NN N
, , N
the DT N
preferred JJ N
HIT-6 NNP 1_i
and CC 1_i
MSQ NNP 1_i
algorithms VBP 1_i
explained VBD N
36 CD N
% NN N
and CC N
45 CD N
% NN N
of IN N
the DT N
variance NN N
in IN N
the DT N
training NN N
samples NNS N
, , N
respectively RB N
, , N
and CC N
had VBD N
similar JJ N
prediction NN N
errors NNS N
( ( N
root JJ N
mean NN N
square JJ N
errors NNS N
0.31 CD N
and CC N
0.29 CD N
) ) N
. . N

In IN N
episodic JJ N
and CC N
chronic JJ N
migraine NN N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
mean NN 1_o
observed VBD 1_o
and CC 1_o
the DT 1_o
mean NN 1_o
estimated VBD 1_o
EQ-5D NNP 1_o
questionnaire NN 1_o
utility NN 1_o
values NNS 1_o
for IN N
the DT N
preferred JJ N
HIT-6 NNP 1_i
and CC N
MSQ NNP 1_i
algorithms NN N
in IN N
the DT N
validation NN N
samples NNS N
. . N

CONCLUSIONS VB N
The DT N
relationship NN N
between IN N
the DT N
EQ-5D NNP N
questionnaire NN N
and CC N
the DT N
HIT-6 NNP N
or CC N
the DT N
MSQ NNP N
is VBZ N
adequate JJ N
to TO N
use VB N
regression NN N
equations NNS N
to TO N
estimate VB N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
. . N

The DT N
preferred JJ N
HIT-6 NNP 1_i
and CC 1_i
MSQ NNP 1_i
algorithms NN N
will MD N
be VB N
useful JJ N
in IN N
estimating VBG N
health-state JJ N
utilities NNS N
in IN N
migraine NN N
trials NNS N
in IN N
which WDT N
no DT N
preference-based JJ N
measure NN N
is VBZ N
present JJ N
. . N

A DT N
comparative JJ N
trial NN N
of IN N
fixed JJ N
ratio NN N
beta-adrenoceptor NN 1_i
blocker NN 1_i
and CC 1_i
diuretic JJ 1_i
combination NN 1_i
products NNS 1_i
in IN N
moderate JJ 1_p
hypertension NN 1_p
. . 1_p

Two CD N
fixed JJ N
ratio NN N
combination NN N
tablets NNS N
, , N
10 CD N
mg NN N
pindolol NN 1_i
combined VBN 1_i
with IN 1_i
5 CD 1_i
mg NNS 1_i
clopamide NN 1_i
and CC N
100 CD N
mg NN N
metoprolol NN 1_i
combined VBN 1_i
with IN 1_i
12.5 CD 1_i
mg NNS 1_i
hydrochlorothiazide RB 1_i
, , N
were VBD N
compared VBN N
at IN N
two CD N
dose JJ N
levels NNS N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
in IN N
10 CD 1_p
previously RB 1_p
untreated JJ 1_i
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
resting VBG 1_o
blood NN 1_o
pressure NN 1_o
on IN N
the DT N
two CD N
combinations NNS N
at IN N
either DT N
dose JJ N
level NN N
. . N

Exercise NNP 1_o
systolic JJ 1_o
pressure NN 1_o
was VBD N
lower JJR N
after IN N
the DT N
pindolol/clopamide JJ 1_i
combination NN N
at IN N
low JJ N
dose NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
incidence NN 1_o
of IN 1_o
side-effects NNS 1_o
in IN N
this DT N
trial NN N
was VBD N
high JJ N
but CC N
proper JJ N
comparison NN N
of IN N
the DT N
two CD N
products NNS N
could MD N
not RB N
be VB N
made VBN N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
patients NNS N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
combination NN 1_i
products NNS 1_i
should MD N
be VB N
used VBN N
only RB N
after IN N
patients NNS N
have VBP N
failed VBN N
to TO N
respond VB N
adequately RB N
to TO N
a DT N
single JJ N
agent NN N
. . N

The DT N
clinical JJ N
and CC N
biochemical JJ N
effects NNS N
of IN N
propofol JJ 1_i
infusion NN N
with IN 1_i
and CC 1_i
without IN 1_i
EDTA NNP 1_i
for IN N
maintenance NN N
anesthesia NN N
in IN N
healthy JJ 1_p
children NNS 1_p
undergoing VBG 1_p
ambulatory NN 1_p
surgery NN 1_p
. . 1_p

UNLABELLED IN N
We PRP N
conducted VBD N
this DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
comparative JJ N
, , N
parallel-group JJ N
study NN N
to TO N
determine VB N
whether IN N
adding VBG N
EDTA NNP 1_i
to TO 1_i
propofol VB 1_i
would MD N
affect VB N
the DT N
clinical JJ N
profile NN N
, , N
calcium NN N
and CC N
magnesium NN N
homeostasis NN N
, , N
or CC N
renal JJ N
function NN N
in IN N
healthy JJ 1_p
children NNS 1_p
. . 1_p

After IN N
the DT N
induction NN 1_i
of IN 1_i
anesthesia NN 1_i
with IN 1_i
halothane NN 1_i
, , N
69 CD 1_p
ambulatory JJ 1_p
surgical JJ 1_p
patients NNS 1_p
( ( 1_p
1 CD 1_p
mo NN 1_p
to TO 1_p
< VB 1_p
17 CD 1_p
yr NNP 1_p
old JJ 1_p
) ) 1_p
, , N
received VBD 1_i
propofol NN 1_i
without IN 1_i
EDTA NNP 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
33 CD 1_i
) ) 1_i
or CC 1_i
propofol NN 1_i
with IN 1_i
EDTA NNP 1_i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
. . N

Blood NN 1_o
samples NNS 1_o
were VBD N
obtained VBN N
for IN N
the DT N
measurement NN 1_o
of IN 1_o
ionized JJ 1_o
calcium NN 1_o
, , 1_o
ionized JJ 1_o
magnesium NN 1_o
, , 1_o
and CC 1_o
laboratory JJ 1_o
indicators NNS 1_o
of IN 1_o
renal JJ 1_o
function NN 1_o
. . 1_o

Hemodynamic NNP 1_o
measurements NNS 1_o
, , 1_o
recovery NN 1_o
, , N
and CC N
adverse JJ 1_o
events NNS 1_o
were VBD N
recorded VBN N
. . N

Propofol NNP 1_i
with IN 1_i
EDTA NNP 1_i
produced VBD N
no DT N
significant JJ N
effects NNS N
on IN N
clinical JJ 1_o
efficacy NN 1_o
or CC 1_o
renal JJ 1_o
function NN 1_o
. . 1_o

Propofol NNP 1_i
and CC 1_i
propofol JJ 1_i
EDTA NNP 1_i
produced VBD N
a DT N
statistically RB N
significant JJ N
decrease NN 1_o
from IN 1_o
baseline NN 1_o
in IN 1_o
serum JJ 1_o
concentrations NNS 1_o
of IN 1_o
ionized JJ 1_o
calcium NN 1_o
and CC 1_o
magnesium NN 1_o
during IN 1_o
infusion NN 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

Hemodynamic NNP 1_o
measurements NNS 1_o
generally RB N
remained VBD N
stable JJ N
and CC N
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
. . N

Statistically NNP N
significant JJ N
changes NNS N
in IN N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
mean JJ 1_o
arterial JJ 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
were VBD N
not RB N
considered VBN N
clinically RB N
significant JJ N
. . N

Adverse JJ N
events NNS N
were VBD N
mild JJ N
or CC N
moderate JJ N
. . N

The DT N
addition NN N
of IN N
EDTA NNP 1_i
does VBZ N
not RB N
alter VB N
the DT N
clinical JJ N
profile NN N
of IN N
propofol NN N
in IN N
pediatric JJ 1_p
ambulatory JJ 1_p
surgical JJ 1_p
patients NNS 1_p
. . 1_p

With IN N
or CC N
without IN N
EDTA NNP 1_i
, , 1_i
propofol NN 1_i
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
ionized JJ 1_o
calcium NN 1_o
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

IMPLICATIONS VBZ N
The DT N
addition NN N
of IN N
EDTA NNP N
does VBZ N
not RB N
alter VB N
the DT N
clinical JJ N
profile NN N
of IN N
propofol NN N
in IN N
pediatric JJ 1_p
ambulatory JJ 1_p
surgical JJ 1_p
patients NNS 1_p
. . 1_p

With IN N
or CC N
without IN N
EDTA NNP N
, , N
propofol NN N
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
ionized JJ 1_o
calcium NN 1_o
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

A DT N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
( ( 1_i
- : 1_i
) ) 1_i
-hyoscine NN 1_i
and CC 1_i
amylobarbitone NN 1_i
sodium NN 1_i
on IN N
measurements NNS N
of IN N
post-rotational JJ 1_p
turning VBG 1_p
sensation NN 1_p
and CC 1_p
nystagmus NN 1_o
. . 1_o

Clinical JJ N
evaluation NN N
of IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
metoprolol NN 1_i
in IN N
combination NN N
with IN N
hydrochlorothiazide NN 1_i
and CC N
hydralazine NN 1_i
in IN N
an DT N
unselected JJ 1_p
hypertensive JJ 1_p
population NN 1_p
. . 1_p

One CD 1_p
hundred VBD 1_p
nineteen JJ 1_p
patients NNS 1_p
with IN 1_p
essential JJ 1_p
hypertension NN 1_p
( ( 1_p
96 CD 1_p
completing VBG 1_p
six CD 1_p
months NNS 1_p
and CC 1_p
92 CD 1_p
a DT 1_p
one CD 1_p
year NN 1_p
study NN 1_p
period NN 1_p
) ) 1_p
were VBD N
randomized VBN N
into IN N
four CD N
parallel NN N
groups NNS N
and CC N
treated VBN N
with IN N
one CD N
of IN N
four CD N
programs NNS N
: : N
200 CD 1_i
mg NN 1_i
of IN 1_i
metoprolol JJ 1_i
plus CC 1_i
placebo NN 1_i
; : 1_i
200 CD 1_i
mg NN 1_i
of IN 1_i
metoprolol NN 1_i
plus CC 1_i
25 CD 1_i
mg NN 1_i
of IN 1_i
hydrochlorothiazide NN 1_i
; : 1_i
200 CD 1_i
mg NN 1_i
of IN 1_i
metoprolol NN 1_i
plus CC 1_i
50 CD 1_i
mg NN 1_i
hydrochlorothiazide NN 1_i
, , 1_i
or CC 1_i
; : 1_i
200 CD 1_i
mg NN 1_i
metoprolol NN 1_i
plus CC 1_i
50 CD 1_i
mg NN 1_i
of IN 1_i
hydralazine NN 1_i
. . 1_i

Blood NNP 1_o
pressure NN 1_o
reduction NN 1_o
was VBD N
significant JJ N
in IN N
these DT N
all DT 1_p
groups NNS 1_p
and CC N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
blood NN N
pressure NN N
reduction NN N
among IN N
the DT N
groups NNS N
. . N

During IN N
the DT N
one CD N
year NN N
therapy IN N
the DT N
levels NNS 1_o
of IN 1_o
serum NN 1_o
bilirubin NN 1_o
, , 1_o
uric JJ 1_o
acid NN 1_o
and CC 1_o
triglycerides NNS 1_o
were VBD N
significantly RB N
increased VBN N
in IN N
all DT N
groups NNS N
but CC N
the DT N
group NN N
treated VBD N
with IN N
metoprolol NN 1_i
and CC N
hydralazine NN 1_i
. . 1_i

Serum NNP 1_o
cholesterol NN 1_o
level NN 1_o
did VBD N
not RB N
increase VB N
in IN N
any DT N
group NN N
during IN N
the DT N
one CD N
year NN N
therapy NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
combination NN N
therapy NN N
in IN N
mild NN 1_o
to TO 1_o
moderate VB 1_o
hypertension NN 1_o
should MD N
not RB N
be VB N
initiated VBN N
before IN N
individual JJ N
response NN N
to TO N
single JJ N
drug NN N
therapy NN N
is VBZ N
evaluated VBN N
. . N

Antihypertensive JJ N
drug NN N
treatment NN N
may MD N
cause VB N
some DT N
biochemical JJ N
changes NNS N
and CC N
those DT N
changes NNS N
seem VBP N
to TO N
be VB N
smallest JJS 1_p
patients NNS 1_p
treated VBN N
with IN N
combination NN N
of IN N
beta-blocker NN 1_i
and CC N
hydralazine NN 1_i
. . 1_i

Multiple JJ N
doses NNS N
of IN N
secretin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
autism NN 1_p
: : 1_p
a DT N
controlled VBN N
study NN N
. . N

UNLABELLED NNP N
Dramatic JJ N
effects NNS N
on IN N
autistic JJ 1_o
behaviour NN 1_o
after IN N
repeated VBN N
injections NNS N
of IN N
the DT N
gastrointestinal JJ N
hormone NN N
secretin NN 1_i
have VBP N
been VBN N
referred VBN N
in IN N
a DT N
number NN N
of IN N
case NN N
reports NNS N
. . N

In IN N
the DT N
absence NN N
of IN N
curative JJ N
and CC N
effective JJ N
treatments NNS N
for IN N
this DT N
disabling JJ N
condition NN N
, , N
this DT N
information NN N
has VBZ N
created VBN N
new JJ N
hope NN N
among IN N
parents NNS N
. . N

Although IN N
controlled JJ N
studies NNS N
on IN N
the DT N
effect NN N
of IN N
mainly RB N
one CD N
single JJ N
dose NN N
have VBP N
not RB N
documented VBN N
any DT N
effect NN N
, , N
many JJ N
children NNS 1_p
still RB N
continue VBP N
to TO N
receive VB N
secretin NN 1_i
. . 1_i

Six NNP 1_p
children NNS 1_p
enrolled VBD 1_p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
in IN N
which WDT N
each DT N
child NN N
was VBD N
its PRP$ N
own JJ N
control NN N
. . N

Human NNP 1_i
synthetic JJ 1_i
secretin NN 1_i
, , 1_i
mean VBP 1_i
dose JJ 1_i
3.4 CD 1_i
clinical JJ 1_i
units NNS 1_i
, , 1_i
and CC 1_i
placebo NN 1_i
were VBD 1_i
administered VBN 1_i
intravenously RB 1_i
in IN 1_i
randomized JJ 1_i
order NN 1_i
every DT 1_i
4th CD 1_i
wk NN 1_i
, , 1_i
on IN 1_i
three CD 1_i
occasions NNS 1_i
each DT 1_i
. . 1_i

The DT N
measurement JJ N
instruments NNS N
were VBD N
the DT N
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
aberrant JJ 1_o
behaviour NN 1_o
checklist NN 1_o
( ( 1_o
ABC NNP 1_o
) ) 1_o
. . 1_o

Statistically NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
placebo NN N
in IN N
3 CD N
out IN N
of IN N
6 CD N
children NNS 1_p
and CC N
for IN N
secretin NN 1_i
in IN N
one CD N
child NN N
, , N
using VBG N
parental JJ 1_o
ratings NNS 1_o
only RB 1_o
( ( 1_o
VAS NNP 1_o
scores VBZ 1_o
) ) 1_o
. . N

Differences NNS N
were VBD N
small JJ N
and CC N
lacked JJ N
clinical JJ N
significance NN N
, , N
which WDT N
was VBD N
in IN N
accordance NN N
with IN N
the DT N
overall JJ N
impression NN N
of IN N
the DT N
parents NNS N
and CC N
teachers NNS N
and CC N
visual JJ N
inspection NN N
of IN N
graphs NN N
. . N

CONCLUSION NN N
In IN N
this DT N
placebo-controlled JJ N
study NN N
, , N
multiple JJ N
doses NNS N
of IN N
secretin NN N
did VBD N
not RB N
produce VB N
any DT N
symptomatic JJ N
improvement NN N
. . N

[ RB 1_i
Accelerated NNP 1_i
postoperative JJ 1_i
radiotherapy NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
larynx NN 1_p
cancer NN 1_p
] NNP 1_p
. . N

AIM NNP N
The DT N
aim NN N
of IN N
study NN N
was VBD N
test JJ N
efficacy NN 1_o
of IN N
accelerated JJ 1_i
postoperative JJ 1_i
radiotherapy NN 1_i
-- : 1_i
concomitant JJ 1_i
boost NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
larynx NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
AND CC N
MATERIALS NNP N
The DT N
prospective JJ N
study NN N
included VBD N
112 CD 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
larynx NN 1_p
cancer NN 1_p
after IN 1_p
radical JJ 1_i
surgical JJ 1_i
treatment NN 1_i
. . 1_i

Patients NNS N
had VBD N
postoperative JJ 1_i
radiation NN 1_i
therapy NN 1_i
, , 1_i
conventional JJ 1_i
( ( 1_i
C NNP 1_i
) ) 1_i
or CC 1_i
accelerated VBN 1_i
( ( 1_i
CB NNP 1_i
) ) 1_i
. . 1_i

RESULTS VB N
The DT N
3-year JJ 1_o
overall JJ 1_o
survival NN 1_o
in IN N
CB NNP 1_i
was VBD N
59 CD N
% NN N
, , N
in IN N
C NNP N
-- : N
58 CD N
% NN N
( ( N
p JJ N
= NNP N
0.2 CD N
) ) N
, , N
3-year JJ 1_o
locoregional JJ 1_o
control NN 1_o
in IN N
CB NNP 1_i
-- : 1_i
83 CD 1_i
% NN 1_i
, , N
in IN N
C NNP N
-- : N
75 CD N
% NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
the DT N
3-year JJ 1_o
disease NN 1_o
free JJ 1_o
survival NN 1_o
was VBD N
in IN N
CB NNP 1_i
-- : 1_i
72 CD 1_i
% NN 1_i
, , N
C NNP N
-- : N
66 CD N
% NN N
( ( N
p JJ N
= NNP N
0.1 CD N
) ) N
. . N

CONCLUSION NNP N
Concomitant NNP 1_i
boost VBD 1_i
postoperative JJ 1_i
radiation NN 1_i
therapy NN 1_i
did VBD N
not RB N
improve VB N
overall JJ 1_o
survival NN 1_o
, , 1_o
loco-regional JJ 1_o
control NN 1_o
, , 1_o
disease NN 1_o
free JJ 1_o
survival NN 1_o
. . 1_o

Patients NNS 1_p
with IN 1_p
close JJ 1_p
surgical JJ 1_p
margins NNS 1_p
, , N
longer JJR N
interval NN N
between IN N
surgery NN N
and CC N
radiation NN N
, , N
high JJ N
level NN N
of IN N
hemoglobin NN N
, , N
T4 NNP N
had VBD N
benefit VBN N
from IN N
accelerated VBN 1_i
radiotherapy NN 1_i
. . 1_i

Total JJ N
intravenous JJ N
anesthesia NN N
using VBG N
remifentanil NN 1_i
in IN N
extracorporeal NN 1_i
shock NN 1_i
wave VBP 1_i
lithotripsy NN 1_i
( ( 1_i
ESWL NNP 1_i
) ) 1_i
. . 1_i

Comparison NNP N
of IN N
two CD N
dosages NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Extracorporeal NNP 1_i
Shock NNP 1_i
Wave NNP 1_i
Lithotripsy NNP 1_i
is VBZ N
usually RB N
performed VBN N
in IN N
day NN N
surgery NN N
setting NN N
, , N
consequently RB N
people NNS N
who WP N
undergo VBP N
to TO N
this DT N
procedure NN N
need VB N
a DT N
safe JJ N
and CC N
fast JJ N
recovery NN N
. . N

Conscious JJ N
sedation NN N
with IN N
remifentanil NN 1_i
can MD N
relieve VB N
from IN N
pain NN N
and CC N
keep VB N
patients NNS N
in IN N
touch JJ N
with IN N
anaesthesiologists NNS N
. . N

Few JJ N
publications NNS N
tell VBP N
about IN N
infusion NN N
rates NNS N
administered VBD N
to TO N
perform VB N
this DT N
procedure7 NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
which WDT N
is VBZ N
the DT N
most RBS N
appropriate JJ N
infusion NN N
rate NN N
. . N

METHODS CC N
Patients NNPS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
two CD 1_p
groups NNS 1_p
. . 1_p

Two CD N
different JJ N
infusion NN N
rates NNS N
were VBD N
compared VBN N
: : N
0,05 CD N
mcg/kg/min NN N
, , N
GROUP NNP N
A NNP N
( ( N
N.=114 NNP N
) ) N
, , N
vs. FW N
0.1 CD N
µg/kg/min NNP N
, , N
GROUP NNP N
B NNP N
( ( N
N.=114 NNP N
) ) N
. . N

Patients NNS 1_o
' POS 1_o
vital JJ 1_o
signs NNS 1_o
, , 1_o
additional JJ 1_o
analgesic NN 1_o
requests NNS 1_o
, , 1_o
PONV NNP 1_o
( ( 1_o
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
) ) 1_o
and CC N
other JJ N
side NN N
effects NNS N
were VBD N
registered VBN N
. . N

The DT N
deepness NN N
of IN N
sedation NN N
and CC N
patient NN N
's POS N
satisfaction NN N
were VBD N
evaluated VBN N
referring VBG N
to TO 1_o
Obsever NNP 1_o
's POS 1_o
Assessment NNP 1_o
of IN 1_o
Alertness NNP 1_o
and CC 1_o
Sedation NNP 1_o
scale NN 1_o
( ( N
O/ASS NNP N
) ) N
and CC N
using VBG N
a DT N
Likert NNP N
's POS N
scale NN N
respectively RB N
. . 1_o

Pain NNP 1_o
intensity NN 1_o
was VBD N
assessed VBN N
with IN N
a DT N
11-points NNS N
VAS NNP N
( ( N
visual JJ N
analogue NN N
scale NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
were VBD N
analyzed VBN N
using VBG N
Student NNP N
t JJ N
test NN N
for IN N
independent JJ N
variables NNS N
. . N

The DT N
χ2 JJ N
test NN N
was VBD N
used VBN N
to TO N
analyze VB N
categorical JJ N
variables NNS N
. . N

RESULTS VB N
The DT N
study NN N
enrolled VBD 1_p
228 CD 1_p
patients NNS 1_p
and CC N
assigned VBD N
them PRP N
to TO N
two CD N
groups NNS N
( ( N
N.=114 NNP N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
regarding VBG 1_o
Likert NNP 1_o
's POS 1_o
scale NN 1_o
values NNS 1_o
( ( N
P=0.20 NNP N
) ) N
, , N
additional JJ N
analgesic JJ N
request NN N
( ( N
P=0.30 NNP N
) ) N
and CC N
mean JJ 1_o
VAS NNP 1_o
values NNS 1_o
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
about IN 1_o
PONV NNP 1_o
, , 1_o
hypotension NN 1_o
, , 1_o
oxygen NN 1_o
desaturation NN 1_o
and CC 1_o
respiratory NN 1_o
depression NN 1_o
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
as IN N
a DT N
matter NN N
of IN N
fact NN N
in IN N
group NN N
A NNP N
these DT N
side NN N
effects NNS N
occurred VBD N
less RBR N
frequently RB N
. . N

The DT 1_o
fifth JJ 1_o
degree NN 1_o
of IN 1_o
O/ASS NNP 1_o
was VBD N
estimated VBN N
in IN N
about RB N
1.61±0.19 CD N
min NNS N
and CC N
2.987±0.20 CD N
min NN N
in IN N
group NN N
A NNP N
and CC N
in IN N
group NN N
B NNP N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
According VBG N
with IN N
previous JJ N
results NNS N
remifentanil VBP N
at IN N
the DT N
infusion NN N
rate NN N
of IN N
0.05 CD N
µg/kg/min NNP N
provides VBZ N
an DT N
effective JJ N
analgesia NN N
, , N
causing VBG N
a DT N
lower JJR N
incidence NN N
of IN N
side NN N
effect NN N
than IN N
0.1 CD N
µg/kg/min NN N
, , N
granting VBG N
a DT N
fast JJ N
and CC N
safe JJ N
recovery NN N
. . N

Effect NN N
of IN N
interferon NN N
gamma NN N
on IN N
infection-related JJ N
death NN N
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
injuries NNS 1_p
. . 1_p

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
interferon NN 1_i
gamma NN 1_i
in IN N
reducing VBG N
infection NN 1_o
and CC N
death NN N
in IN N
patients NNS 1_p
sustaining VBG 1_p
severe JJ 1_p
injury NN 1_p
. . 1_p

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
with IN N
observation NN N
for IN N
60 CD N
days NNS N
and CC N
until IN N
discharge NN N
for IN N
patients NNS 1_p
with IN 1_p
major JJ 1_p
infection NN 1_p
on IN 1_p
day NN 1_p
60 CD 1_p
. . 1_p

SETTING CD N
Nine JJ 1_p
university-affiliated JJ 1_p
level NN 1_p
1 CD 1_p
trauma NN 1_p
centers NNS 1_p
. . 1_p

PATIENTS VB N
Four CD 1_p
hundred JJ 1_p
sixteen JJ 1_p
patients NNS 1_p
with IN 1_p
severe JJ 1_p
injuries NNS 1_p
, , 1_p
assessed VBN 1_p
by IN 1_p
Injury NNP 1_o
Severity NNP 1_o
Score NNP 1_o
and CC 1_o
degree NN 1_o
of IN 1_o
contamination NN 1_o
. . 1_o

INTERVENTION NNP N
Recombinant NNP 1_i
human JJ 1_i
interferon NN 1_i
gamma NN 1_i
, , 1_i
100 CD 1_i
micrograms NNS 1_i
, , 1_i
was VBD 1_i
administered VBN 1_i
subcutaneously RB 1_i
once RB 1_i
daily JJ 1_i
for IN 1_i
21 CD 1_i
days NNS 1_i
( ( 1_i
or CC 1_i
until IN 1_i
patient JJ 1_i
discharge NN 1_i
if IN 1_i
prior JJ 1_i
to TO 1_i
21 CD 1_i
days NNS 1_i
) ) 1_i
as IN 1_i
an DT 1_i
adjunct NN 1_i
to TO 1_i
standard VB 1_i
antibiotic JJ 1_i
and CC 1_i
supportive JJ 1_i
therapy NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Incidence NNP 1_o
of IN 1_o
major JJ 1_o
infection NN 1_o
, , 1_o
death NN 1_o
related VBN 1_o
to TO 1_o
infection NN 1_o
, , 1_o
and CC 1_o
death NN 1_o
. . 1_o

RESULTS JJ N
Infection NN 1_o
rates NNS 1_o
were VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
; : N
however RB N
, , N
patients NNS N
treated VBD N
with IN N
interferon NN N
gamma NN N
experienced VBD N
fewer JJR N
deaths NNS 1_o
related VBN N
to TO N
infection NN 1_o
( ( N
seven CD N
[ RB N
3 CD N
% NN N
] NNP N
vs NN N
18 CD N
[ JJ N
9 CD N
% NN N
] NN N
; : N
P NNP N
= NNP N
.008 NNP N
) ) N
and CC N
fewer JJR N
overall JJ N
deaths NNS 1_o
( ( N
21 CD N
[ RB N
10 CD N
% NN N
] NNP N
vs NN N
30 CD N
[ JJ N
14 CD N
% NN N
] NN N
; : N
P NNP N
= NNP N
.17 NNP N
) ) N
. . N

While IN N
12 CD N
early JJ 1_o
deaths NNS 1_o
( ( N
days NNS N
1 CD N
through IN N
7 CD N
) ) N
occurred VBD N
in IN N
each DT N
treatment NN N
group NN N
, , N
late RB N
death NN 1_o
occurred VBD N
in IN N
18 CD N
placebo-treated JJ N
patients NNS N
and CC N
nine CD N
in IN N
interferon JJ 1_i
gamma-treated JJ 1_i
patients NNS N
. . N

The DT N
results NNS N
were VBD N
dominated VBN N
by IN N
findings NNS N
at IN N
one CD N
center NN N
, , N
which WDT N
had VBD N
the DT N
highest JJS N
enrollment NN N
and CC N
higher JJR N
infection NN N
and CC N
death NN N
rates NNS N
. . N

Statistical JJ N
analysis NN N
did VBD N
not RB N
eliminate VB N
the DT N
possibility NN N
of IN N
an DT N
unidentified JJ N
imbalance NN N
between IN N
arms NNS N
as IN N
an DT N
explanation NN N
for IN N
the DT N
results NNS N
. . N

CONCLUSION NNP N
Further NNP N
evaluation NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
validity NN N
of IN N
the DT N
observed JJ N
reduction NN N
in IN N
infection-related JJ 1_o
deaths NNS N
in IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
interferon NN 1_i
gamma NN 1_i
. . 1_i

REVIVE JJ N
Trial NN N
: : N
Retrograde JJ N
Delivery NNP N
of IN N
Autologous NNP N
Bone NNP N
Marrow NNP N
in IN N
Patients NNP 1_p
With IN 1_p
Heart NNP 1_p
Failure NNP 1_p
. . 1_p

UNLABELLED NNP N
Cell NNP 1_i
therapy NN 1_i
is VBZ N
an DT N
evolving VBG N
option NN N
for IN N
patients NNS 1_p
with IN 1_p
end-stage JJ 1_p
heart NN 1_p
failure NN 1_p
and CC 1_p
ongoing NN 1_p
symptoms NNS 1_p
despite IN 1_p
optimal JJ 1_p
medical JJ 1_p
therapy NN 1_p
. . 1_p

Our PRP$ N
goal NN N
was VBD N
to TO N
evaluate VB N
retrograde VB N
bone NN N
marrow NN N
cell NN N
delivery NN N
in IN N
patients NNS 1_p
with IN 1_p
either DT 1_p
ischemic JJ 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
IHF NNP 1_p
) ) 1_p
or CC 1_p
nonischemic JJ 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
NIHF NNP 1_p
) ) 1_p
. . 1_p

This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
, , N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
the DT N
safety NN N
and CC N
feasibility NN N
of IN N
bone NN 1_i
marrow NN 1_i
aspirate NN 1_i
concentrate NN 1_i
( ( N
BMAC NNP N
) ) N
infused VBD N
retrograde NN 1_i
into IN N
the DT N
coronary JJ N
sinus NN N
. . N

Sixty JJ 1_p
patients NNS 1_p
were VBD 1_p
stratified VBN 1_p
by IN 1_p
IHF NNP 1_p
and CC 1_p
NIHF NNP 1_p
and CC N
randomized VBN N
to TO N
receive VB N
either DT N
BMAC NNP 1_i
infusion NN 1_i
or CC N
control NN 1_i
( ( N
standard JJ N
heart NN N
failure NN N
care NN N
) ) N
in IN N
a DT N
4:1 CD N
ratio NN N
. . N

Accordingly RB N
, , N
24 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
ischemic JJ N
BMAC NNP N
group NN N
and CC N
6 CD N
to TO N
the DT N
ischemic JJ N
control NN N
group NN N
. . N

Similarly RB N
, , N
24 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
nonischemic JJ N
BMAC NNP N
group NN N
and CC N
6 CD N
to TO N
the DT N
nonischemic JJ N
control NN N
group NN N
. . N

All DT 1_p
60 CD 1_p
patients NNS 1_p
were VBD 1_p
successfully RB 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
treatment NN N
groups NNS N
received VBD N
BMAC NNP 1_i
infusion NN 1_i
without IN N
complications NNS N
. . N

The DT N
left JJ 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
in IN N
the DT N
patients NNS N
receiving VBG N
BMAC NNP N
demonstrated VBD N
significant JJ 1_o
improvement NN 1_o
compared VBN N
with IN N
baseline NN N
, , N
from IN N
25.1 CD N
% NN N
at IN N
screening VBG N
to TO N
31.1 CD N
% NN N
at IN N
12 CD N
months NNS N
( ( N
p=.007 NN N
) ) N
in IN N
the DT N
NIHF NNP N
group NN N
and CC N
from IN N
26.3 CD N
% NN N
to TO N
31.1 CD N
% NN N
in IN N
the DT N
IHF NNP N
group NN N
( ( N
p=.035 NN N
) ) N
. . N

The DT N
end-systolic JJ 1_o
diameter NN 1_o
decreased VBN 1_o
significantly RB 1_o
in IN N
the DT N
nonischemic JJ N
BMAC NNP 1_i
group NN N
from IN N
55.6 CD N
to TO N
50.9 CD N
mm NN N
( ( N
p=.020 NN N
) ) N
. . N

Retrograde NNP N
BMAC NNP N
delivery NN 1_o
is VBZ 1_o
safe JJ 1_o
. . 1_o

All DT N
patients NNS N
receiving VBG N
BMAC NNP N
experienced VBD 1_o
improvements NNS 1_o
in IN N
left JJ 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
, , N
but CC N
only RB N
those DT N
with IN N
NIHF NNP N
showed VBD N
improvements NNS 1_o
in IN N
left JJ 1_o
ventricular JJ 1_o
end-systolic JJ 1_o
diameter NN 1_o
and CC 1_o
B-type NNP 1_o
natriuretic JJ 1_o
peptide NN 1_o
. . 1_o

These DT N
results NNS N
provide VBP N
the DT N
basis NN N
for IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
in IN N
HF NNP N
patients NNS N
. . N

SIGNIFICANCE VB N
This DT N
work NN N
is VBZ N
the DT N
first JJ N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
using VBG N
high-dose JJ N
cell NN N
therapy NN N
delivered VBN N
via IN N
a DT N
retrograde JJ N
coronary JJ N
sinus NN N
infusion NN N
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

This DT N
was VBD N
a DT N
multinational JJ N
, , N
multicenter NN N
study NN N
, , N
and CC N
it PRP N
is VBZ N
novel JJ N
, , N
translatable JJ N
, , N
and CC N
scalable JJ N
. . N

On IN N
the DT N
basis NN N
of IN N
this DT N
trial NN N
and CC N
the DT N
safety NN N
of IN N
retrograde JJ N
coronary JJ N
sinus NN N
infusion NN N
, , N
there EX N
are VBP N
three CD N
other JJ N
trials NNS N
under IN N
way NN N
using VBG N
this DT N
route NN N
of IN N
delivery NN N
. . N

Cognitive JJ 1_o
performance NN 1_o
and CC N
serotonergic JJ 1_o
function NN 1_o
in IN N
users NNS 1_p
of IN 1_p
ecstasy NN 1_p
. . 1_p

RATIONALE NNP N
( ( N
+/- JJ N
) ) N
3,4-Methylenedioxymethamphetamine CD 1_i
( ( 1_i
MDMA NNP 1_i
or CC 1_i
" NNP 1_i
ecstasy VBP 1_i
" NNP 1_i
) ) 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
cause VB N
long JJ N
term NN N
damage NN N
to TO N
serotonergic VB N
cerebral JJ N
neurons NNS N
in IN N
animals NNS N
. . N

The DT N
neurotoxic JJ 1_o
effects NNS 1_o
in IN N
humans NNS 1_p
are VBP N
less JJR N
clear JJ N
and CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
functional JJ N
consequences NNS N
, , N
although IN N
some DT N
studies NNS N
suggest VBP N
memory NN N
impairment NN N
. . N

Given VBN N
the DT N
widespread JJ N
use NN N
of IN N
MDMA NNP 1_i
, , N
our PRP$ N
lack NN N
of IN N
knowledge NN N
raises NNS N
concerns NNS N
. . N

OBJECTIVE IN N
We PRP N
investigated VBD N
, , N
in IN N
humans NNS N
, , N
the DT N
relation NN N
between IN N
past JJ N
use NN N
of IN N
ecstasy NN N
and CC N
cognitive JJ N
performance NN N
as RB N
well RB N
as IN N
serotonergic JJ N
function NN N
. . N

METHODS NNP N
Two CD 1_p
groups NNS 1_p
of IN 1_p
21 CD 1_p
males NNS 1_p
with IN 1_p
moderate JJ 1_p
and CC 1_p
heavy JJ 1_p
recreational JJ 1_p
use NN 1_p
of IN 1_p
MDMA NNP 1_i
, , 1_p
respectively RB 1_p
, , 1_p
and CC 1_p
a DT 1_p
control NN 1_p
group NN 1_p
of IN 1_p
20 CD 1_p
males NNS 1_p
without IN 1_p
use NN 1_p
of IN 1_p
MDMA NNP 1_i
were VBD 1_p
compared VBN 1_p
. . 1_p

All DT N
were VBD N
from IN N
the DT N
same JJ 1_p
subculture NN 1_p
. . 1_p

Reaction NN 1_o
time NN 1_o
, , 1_o
direct JJ 1_o
recall NN 1_o
, , N
and CC N
recognition NN 1_o
were VBD N
assessed VBN N
. . N

Serotonergic NNP 1_o
function NN 1_o
was VBD N
measured VBN N
by IN N
the DT N
neuro-endocrine JJ N
response NN N
to TO N
a DT N
placebo-controlled JJ 1_i
, , N
crossover JJ N
challenge NN N
with IN N
dexfenfluramine NN 1_i
. . 1_i

RESULTS NNP N
Ecstasy NNP N
users NNS N
showed VBD N
a DT N
broad JJ N
pattern NN N
of IN N
statistically RB N
significant JJ N
, , N
but CC N
clinically RB N
small JJ 1_o
, , 1_o
impairment NN 1_o
of IN 1_o
memory NN 1_o
and CC 1_o
prolonged JJ 1_o
reaction NN 1_o
times NNS 1_o
. . 1_o

Heavy JJ N
users NNS N
were VBD N
affected JJ N
stronger JJR N
than IN N
moderate JJ N
users NNS N
. . N

Release NNP 1_o
of IN 1_o
cortisol NN 1_o
but CC N
not RB N
of IN N
prolactin NN 1_o
after IN N
dexfenfluramine JJ 1_i
administration NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
of IN N
ecstasy JJ N
users NNS N
compared VBN N
with IN N
the DT N
controls NNS N
. . N

Analyses NNS N
of IN N
covariance NN N
showed VBD N
that IN N
likely JJ N
confounding VBG N
variables NNS N
including VBG N
recent JJ N
exposure NN N
to TO N
ecstasy VB N
, , N
psychosocial JJ N
profiles NNS N
and CC N
use NN N
of IN N
other JJ N
drugs NNS N
did VBD N
not RB N
explain VB N
the DT N
differences NNS N
found VBD N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
provide VBP N
further JJ N
evidence NN N
that IN N
use NN N
of IN N
ecstasy NN N
may MD N
be VB N
associated VBN N
with IN N
impairment NN 1_o
of IN 1_o
memory NN 1_o
and CC 1_o
of IN 1_o
serotonergic JJ 1_o
function NN 1_o
. . 1_o

These DT N
findings NNS N
are VBP N
compatible JJ N
with IN N
neurotoxicity NN 1_o
of IN N
ecstasy NN N
as IN N
shown VBN N
in IN N
animals NNS N
. . N

Effect NN N
of IN N
chronic JJ 1_i
aerobic JJ 1_i
exercise NN 1_i
and CC 1_i
progressive JJ 1_i
relaxation NN 1_i
on IN N
motor NN N
performance NN N
and CC N
affect NN N
following VBG N
acute JJ N
stress NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
10-week JJ N
aerobic JJ 1_i
exercise NN 1_i
and CC 1_i
progressive JJ 1_i
relaxation NN 1_i
training VBG N
program NN N
on IN N
somatic JJ N
, , N
emotional JJ N
, , N
and CC N
behavioral JJ N
responses NNS N
to TO N
acute VB N
stress NN N
, , N
as IN N
determined VBN N
by IN N
quality NN N
of IN N
motor NN N
performance NN N
and CC N
affect NN N
, , N
were VBD N
examined VBN N
. . N

The DT N
participants NNS N
consisted VBD N
of IN N
60 CD 1_p
unfit JJ 1_p
male NN 1_p
university NN 1_p
undergraduate JJ 1_p
students NNS 1_p
with IN 1_p
no DT 1_p
previous JJ 1_p
training NN 1_p
in IN 1_p
stress JJ 1_p
management NN 1_p
who WP N
were VBD N
randomly RB N
and CC N
evenly RB N
assigned VBD N
to TO N
engage VB N
in IN N
one CD 1_i
of IN 1_i
four CD 1_i
treatments NNS 1_i
over IN 1_i
10 CD 1_i
weeks NNS 1_i
: : 1_i
( ( 1_i
a DT 1_i
) ) 1_i
moderate NN 1_i
aerobic JJ 1_i
exercise NN 1_i
, , 1_i
( ( 1_i
b NN 1_i
) ) 1_i
progressive NN 1_i
relaxation NN 1_i
, , 1_i
( ( 1_i
c NN 1_i
) ) 1_i
a DT 1_i
placebo NN 1_i
group NN 1_i
that WDT 1_i
engaged VBD 1_i
in IN 1_i
group NN 1_i
discussion NN 1_i
but CC 1_i
did VBD 1_i
experience VB 1_i
acute NN 1_i
stress NN 1_i
, , 1_i
and CC 1_i
( ( 1_i
d NN 1_i
) ) 1_i
a DT 1_i
nonintervention NN 1_i
control NN 1_i
group NN 1_i
that WDT 1_i
did VBD 1_i
not RB 1_i
experience VB 1_i
stress NN 1_i
while IN 1_i
performing VBG 1_i
the DT 1_i
motor NN 1_i
task NN 1_i
. . 1_i

Acute NNP N
stress NN N
consisted VBD N
of IN N
" NN N
losing VBG N
" NNP N
against IN N
a DT N
competitor NN N
of IN N
the DT N
opposite JJ N
sex NN N
on IN N
the DT N
criterion NN N
motor NN N
task NN N
while IN N
receiving VBG N
unpleasant JJ N
information NN N
about IN N
their PRP$ N
performance NN N
over IN N
30 CD N
preintervention NN N
and CC N
30 CD N
postintervention NN N
trials NNS N
. . N

Analyses NNS N
indicated VBD N
that IN N
aerobic JJ N
exercisers NNS N
, , N
in IN N
comparisons NNS N
with IN N
the DT N
other JJ N
groups NNS N
, , N
responded VBD N
to TO N
acute VB 1_o
stress NN 1_o
with IN N
more RBR N
positive JJ N
affect NN N
, , N
lower JJR 1_o
stressor NN 1_o
task JJ 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
reduced VBN 1_o
systolic JJ 1_o
( ( 1_o
but CC 1_o
not RB 1_o
diastolic JJ 1_o
) ) 1_o
blood NN 1_o
pressure NN 1_o
, , N
and CC N
superior JJ N
motor NN 1_o
performance NN 1_o
. . 1_o

Progressive JJ N
relaxation NN N
markedly RB N
reduced VBD N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
but CC N
did VBD N
not RB N
favorably RB N
influence JJ N
performance NN N
or CC N
affect VB N
in IN N
response NN N
to TO N
acute VB 1_o
stress NN 1_o
. . 1_o

Placebo NNP N
and CC N
control NN N
groups NNS N
were VBD N
statistically RB N
similar JJ N
on IN N
all DT N
measures NNS N
. . N

The DT N
findings NNS N
indicated VBD N
support NN N
for IN N
the DT N
use NN N
of IN N
chronic JJ N
aerobic JJ N
exercise NN N
as IN N
a DT N
strategy NN N
for IN N
improved JJ N
coping NN N
with IN N
acute JJ N
stress NN N
. . N

Improving VBG N
patient JJ 1_i
involvement NN 1_i
in IN N
chronic JJ N
disease NN N
management NN N
: : N
the DT N
views NNS N
of IN N
patients NNS N
, , N
GPs NNP N
and CC N
specialists NNS N
on IN N
a DT N
guidebook NN N
for IN N
ulcerative JJ N
colitis NN N
. . N

Patient JJ N
information NN N
, , N
shared VBN N
care NN N
and CC N
decision-making NN N
are VBP N
recognised VBN N
as IN N
beneficial JJ N
to TO N
chronic VB N
disease NN N
management NN N
. . N

As IN N
part NN N
of IN N
an DT N
RCT NNP N
, , N
opinions NNS N
of IN N
ulcerative JJ 1_p
colitis NN 1_p
patients NNS 1_p
and CC 1_p
their PRP$ 1_p
doctors NNS 1_p
were VBD N
sought VBN N
on IN N
a DT N
guidebook NN N
designed VBN N
to TO N
support VB 1_i
self-care NN 1_i
and CC N
mediate VB 1_i
doctor/patient JJ 1_i
interaction NN 1_i
during IN N
consultations NNS N
. . N

Semi-structured JJ 1_i
interviews NNS 1_i
were VBD N
conducted VBN N
with IN N
6 CD 1_p
specialists NNS 1_p
and CC 1_p
16 CD 1_p
GPs NNP 1_p
. . 1_p

Patients NNS 1_p
' POS 1_p
views NNS 1_p
were VBD 1_p
obtained VBN 1_p
from IN 1_p
written VBN 1_p
responses NNS 1_p
to TO 1_p
a DT 1_p
postal JJ 1_i
questionnaire NN 1_i
( ( 1_p
136 CD 1_p
replies NNS 1_p
) ) 1_p
. . 1_p

Inclusion NN N
of IN N
lay NN N
knowledge NN N
and CC N
clarification NN N
of IN N
treatment NN N
decision NN N
processes NNS N
increased VBD N
patients NNS N
' POS N
perception NN N
of IN N
involvement NN N
in IN N
disease NN N
management NN N
through IN N
increased VBN N
identification NN N
and CC N
awareness NN N
of IN N
others NNS N
' POS N
self-management JJ N
experiences NNS N
. . N

Doctors NNS N
focused VBD N
on IN N
the DT N
importance NN N
of IN N
improving VBG N
patients NNS N
' POS N
compliance NN N
and CC N
use NN N
of IN N
services NNS N
. . N

However RB N
, , N
the DT N
guidebook NN N
was VBD N
seldom RB N
used VBN N
as IN N
it PRP N
had VBD N
been VBN N
intended VBN N
during IN N
consultations NNS N
. . N

Patients NNS N
felt VBD N
constrained VBN N
by IN N
time NN N
limits NNS N
and CC N
consultants NNS N
did VBD N
not RB N
actively RB N
encourage VB N
guidebook NN N
use NN N
. . N

Based VBN N
on IN N
the DT N
findings NNS N
, , N
we PRP N
suggest VBP N
an DT N
approach NN N
utilising VBG 1_o
the DT 1_o
guidebook NN 1_o
to TO N
improve VB N
patient JJ 1_o
participation NN 1_o
in IN N
disease NN N
management NN N
. . N

Psychoeducational NNP 1_i
group NN 1_i
intervention NN 1_i
for IN N
wives NNS 1_p
of IN 1_p
men NNS 1_p
with IN 1_p
prostate NN 1_p
cancer NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
effects NNS N
of IN N
a DT N
6-week JJ N
psychoeducational JJ 1_i
group NN 1_i
intervention NN 1_i
on IN N
the DT N
distress NN N
, , N
coping NN N
, , N
personal JJ N
growth NN N
, , N
and CC N
marital JJ N
communication NN N
of IN N
wives NNS 1_p
of IN 1_p
men NNS 1_p
diagnosed VBN 1_p
with IN 1_p
prostate JJ 1_p
cancer NN 1_p
were VBD N
evaluated VBN N
using VBG N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
Sixty NNP 1_p
wives NNS 1_p
completed VBD N
measures NNS N
prior RB N
to TO N
random VB N
assignment NN N
to TO N
either VB N
the DT N
psychoeducational JJ 1_i
group NN 1_i
intervention NN 1_i
or CC 1_i
a DT 1_i
no-treatment JJ 1_i
control NN 1_i
group NN 1_i
, , N
and CC N
1 CD N
month NN N
after IN N
completion NN N
of IN N
the DT N
group NN N
. . N

RESULTS NNP N
No NNP N
differences NNS N
with IN N
regard NN N
to TO N
wives NNS N
' POS N
general JJ 1_o
distress NN 1_o
or CC 1_o
cancer-specific JJ 1_o
distress NN 1_o
were VBD N
noted VBN N
. . N

In IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
, , N
participants NNS N
receiving VBG N
the DT N
intervention NN N
perceived VBD N
that IN N
having VBG N
a DT N
spouse NN N
with IN N
prostate NN N
cancer NN N
had VBD N
made VBN N
positive JJ N
contributions NNS N
to TO N
their PRP$ N
lives NNS N
, , N
reported VBD N
gains NNS N
in IN N
the DT N
use NN N
of IN N
positive JJ 1_o
reappraisal NN 1_o
coping VBG 1_o
and CC N
reductions NNS N
in IN N
denial JJ 1_o
coping NN 1_o
. . 1_o

CONCLUSION NNP N
Although IN N
the DT N
psychoeducational JJ 1_i
intervention NN 1_i
did VBD N
not RB N
result VB N
in IN N
changes NNS N
in IN N
psychological JJ 1_o
distress NN 1_o
, , N
improvements NNS N
in IN N
adaptive JJ 1_o
coping NN 1_o
and CC 1_o
indicators NNS 1_o
of IN 1_o
psychological JJ 1_o
growth NN 1_o
were VBD N
found VBN N
. . N

The DT N
utility NN N
of IN N
group NN N
interventions NNS N
for IN N
spouses NNS 1_p
of IN 1_p
men NNS 1_p
with IN 1_p
prostate NN 1_p
cancer NN 1_p
is VBZ N
discussed VBN N
. . N

Use NNP N
of IN N
high-dose JJ N
cytarabine NN 1_i
to TO N
enhance VB N
cisplatin JJ 1_i
cytotoxicity-effects NNS 1_o
on IN N
the DT N
response NN N
and CC N
overall JJ N
survival NN 1_o
rates NNS 1_o
of IN N
advanced JJ 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

UNLABELLED IN N
It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
cytarabine NN 1_i
, , N
acting VBG N
by IN N
at IN N
least JJS N
two CD N
different JJ N
mechanisms NNS N
, , N
enhances VBZ N
the DT N
cytotoxic JJ N
effect NN N
of IN N
cisplatin NN 1_i
in IN N
in IN N
vitro JJ N
systems NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
open JJ N
, , N
prospective JJ N
, , N
randomised VBD N
study NN N
was VBD N
to TO N
estimate VB N
the DT N
eventual JJ N
benefits NNS N
from IN N
the DT N
inclusion NN N
of IN N
high-dose JJ N
cytarabine NN 1_i
in IN N
the DT N
cisplatin-5-fluorouracil NN 1_i
( ( 1_i
5-FU JJ 1_i
) ) 1_i
regimen NNS N
as IN N
first-line JJ 1_p
treatment NN 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
. . 1_p

The DT N
study NN N
recruited VBD N
successive JJ 1_p
patients NNS 1_p
with IN 1_p
unresectable JJ 1_p
grade NN 1_p
I/II NNP 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
who WP 1_p
were VBD 1_p
not RB 1_p
suitable JJ 1_p
for IN 1_p
irradiation NN 1_i
treatment NN 1_i
( ( 1_p
T NNP 1_p
any DT 1_p
N3 NNP 1_p
or CC 1_p
T4 NNP 1_p
N2C NNP 1_p
) ) 1_p
, , 1_p
metastatic JJ 1_p
or CC 1_p
previously RB 1_p
irradiated VBN 1_p
. . 1_p

All DT N
patients NNS N
gave VBD N
their PRP$ N
informed JJ N
consent NN N
. . N

A DT N
joint JJ N
ear NN N
, , N
nose JJ N
and CC N
throat NN N
( ( N
ENT NNP N
) ) N
oncological JJ N
committee NN N
performed VBD N
the DT N
selection NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
170 CD 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Patients NNS N
randomised VBD N
to TO N
arm VB N
A NNP N
were VBD N
given VBN N
1000 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
cytarabine NN 1_i
on IN N
day NN N
1 CD N
preceding NN N
for IN N
6 CD N
h NN N
cisplatin NN 1_i
infusion NN 1_i
, , N
30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h NN N
cisplatin NN 1_i
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
bolus JJ N
days NNS N
1-4 CD N
and CC N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h JJ N
5-FU JJ N
in IN N
a DT N
4-h JJ N
infusion NN N
on IN N
days NNS N
1-4 JJ N
. . N

Patients NNS N
in IN N
arm NN N
B NNP N
were VBD N
given VBN N
cisplatin NNS 1_i
and CC 1_i
5-FU JJ 1_i
in IN N
the DT N
same JJ N
dosage NN N
and CC N
schedule NN N
as IN N
in IN N
arm NN N
A NNP N
. . N

Additional NNP N
irradiation+/-surgery NN 1_i
was VBD N
performed VBN N
if IN N
and CC N
when WRB N
feasible JJ N
. . N

Patients NNS N
in IN N
both DT N
arms NNS N
were VBD N
well RB N
balanced VBN N
with IN N
regard NN N
to TO N
clinical JJ N
variables NNS N
. . N

The DT N
following JJ N
results NNS N
were VBD N
obtained VBN N
: : N
Arm NN N
A NN N
: : N
84 CD N
patients NNS N
were VBD N
included VBN N
, , N
74 CD N
were VBD N
evaluable JJ N
for IN N
activity NN N
; : N
RESPONSE NNP N
complete JJ 1_o
response NN 1_o
( ( 1_o
CR NNP 1_o
) ) 1_o
8 CD N
( ( N
11 CD N
% NN N
) ) N
, , N
partial JJ 1_o
response NN 1_o
( ( 1_o
PR NNP 1_o
) ) 1_o
40 CD N
( ( N
54 CD N
% NN N
) ) N
, , N
stable JJ 1_o
disease NN 1_o
( ( 1_o
SD NNP 1_o
) ) 1_o
11 CD N
( ( N
15 CD N
% NN N
) ) N
, , N
progressive JJ 1_o
disease NN 1_o
( ( N
PD NNP N
) ) N
15 CD N
( ( N
20 CD N
% NN N
) ) N
. . N

The DT N
overall JJ 1_o
response NN 1_o
rate NN 1_o
( ( 1_o
RR NNP 1_o
) ) 1_o
based VBN N
on IN N
the DT N
evaluable JJ N
patients NNS N
was VBD N
48/74 CD N
( ( N
65 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
54-75 CD N
% NN N
) ) N
; : N
The DT N
RR NNP 1_o
based VBN 1_o
on IN 1_o
an DT 1_o
intent-to-treat JJ 1_o
analysis NN 1_o
was VBD N
57 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
47-67 CD N
% NN N
; : N
Median JJ 1_o
survival NN 1_o
was VBD N
13 CD N
months NNS N
; : N
There EX N
were VBD N
50 CD N
episodes NNS N
of IN N
granulocytopenia NN 1_o
grade NN 1_o
IV NNP 1_o
and CC N
15 CD N
of IN N
febrile JJ 1_o
neutropenia NNS 1_o
per IN N
316 CD N
cycles NNS N
. . N

Arm NN N
B NN N
: : N
86 CD N
patients NNS N
were VBD N
included VBN N
, , N
80 CD N
were VBD N
evaluable JJ N
for IN N
activity NN N
; : N
RESPONSE NNP N
CR NNP 1_o
7 CD N
( ( N
9 CD N
% NN N
) ) N
, , N
PR NNP 1_o
29 CD N
( ( N
36 CD N
% NN N
) ) N
, , N
SD NNP 1_o
10 CD N
( ( N
12.5 CD N
% NN N
) ) N
, , N
PD NNP 1_o
34 CD N
( ( N
42.5 CD N
% NN N
) ) N
; : N
The DT N
overall JJ 1_o
RR NNP 1_o
based VBN N
on IN N
the DT N
evaluable JJ N
patients NNS N
was VBD N
36/80 CD N
( ( N
45 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
35-56 CD N
% NN N
) ) N
; : N
The DT N
RR NNP 1_o
based VBN 1_o
on IN 1_o
an DT 1_o
intent-to-treat JJ 1_o
analysis NN 1_o
was VBD N
42 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
32-52 CD N
% NN N
; : N
Median JJ 1_o
survival NN 1_o
was VBD N
8 CD N
months NNS N
; : N
There EX N
were VBD N
14 CD N
episodes NNS N
of IN N
granulocytopenia NN N
grade NN N
IV NNP N
and CC N
7 CD N
febrile NN N
neutropenias NNS N
per IN N
324 CD N
cycles NNS N
. . N

The DT N
RR NNP 1_o
was VBD 1_o
significantly RB 1_o
higher JJR 1_o
in IN N
arm NN N
A NNP N
( ( N
P=0.013 NNP N
) ) N
, , N
power NN N
( ( N
one-sided JJ N
) ) N
80 CD N
% NN N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
from IN N
the DT N
appropriate JJ N
subset NN N
who WP N
achieved VBD N
a DT N
clinical JJ 1_o
response NN 1_o
making VBG 1_o
additional JJ 1_o
treatment NN 1_o
feasible NN 1_o
was VBD N
higher RBR 1_o
in IN N
arm NN N
A NNP N
( ( N
P=0.00015 NNP N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
a DT 1_o
performance NN 1_o
status NN 1_o
2+3 CD 1_o
achieving VBG 1_o
a DT 1_o
response NN 1_o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Using VBG N
the DT N
Log-rank JJ N
test NN N
, , N
patients NNS N
from IN N
arm NN N
A NNP N
achieved VBD N
a DT N
significantly RB 1_o
longer RBR 1_o
survival JJ 1_o
( ( N
P=0.009 NNP N
) ) N
, , N
with IN N
the DT N
probability NN N
of IN N
survival NN 1_o
at IN 1_o
12 CD 1_o
months NNS 1_o
of IN N
0.58 CD N
for IN N
patients NNS N
in IN N
arm NN N
A NN N
and CC N
0.28 CD N
for IN N
patients NNS N
in IN N
arm NN N
B. NNP N
Grade NNP 1_o
IV NNP 1_o
granulocytopenia NN 1_o
and CC 1_o
thrombocytopenia NN 1_o
were VBD N
more RBR 1_o
frequent JJ 1_o
in IN N
arm NN N
A NN N
. . N

Due JJ N
to TO N
its PRP$ N
haematological JJ 1_o
side-effects NNS 1_o
, , N
cytarabine NN 1_i
might MD N
not RB N
be VB N
the DT N
ideal JJ N
drug NN N
to TO N
modulate VB N
the DT N
cytotoxicity NN 1_o
of IN N
cisplatin NN 1_i
. . 1_i

However RB N
, , N
other JJ N
modulators NNS N
of IN N
its PRP$ N
activity NN N
could MD N
be VB N
of IN N
interest NN N
for IN N
further JJ N
studies NNS N
in IN N
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

Causes NNS N
of IN N
variation NN N
in IN N
BCG NNP 1_i
vaccine NN 1_i
efficacy NN 1_o
: : 1_o
examining VBG N
evidence NN N
from IN N
the DT N
BCG NNP N
REVAC NNP N
cluster NN N
randomized VBD N
trial NN N
to TO N
explore VB N
the DT N
masking NN N
and CC N
the DT N
blocking NN N
hypotheses NNS N
. . N

BCG NNP N
protection NN N
varies NNS N
and CC N
in IN N
some DT N
places NNS N
( ( N
nearest JJS N
the DT N
equator NN N
) ) N
is VBZ N
low JJ N
or CC N
absent NN N
. . N

Understanding VBG N
this DT N
variation NN N
can MD N
inform VB N
the DT N
efforts NNS N
to TO N
develop VB N
new JJ N
vaccines NNS N
against IN N
tuberculosis NN N
. . N

Two CD N
main JJ N
hypotheses NNS N
are VBP N
used VBN N
to TO N
explain VB N
this DT N
variation NN N
: : N
under IN N
masking VBG N
, , N
new JJ N
vaccines NNS N
are VBP N
unlikely JJ N
to TO N
increase VB N
protection NN 1_o
; : 1_o
under IN N
blocking VBG N
new JJ N
vaccines NNS N
have VBP N
a DT N
greater JJR N
potential JJ N
to TO N
be VB N
effective JJ N
when WRB N
BCG NNP N
is VBZ N
not RB N
. . N

We PRP N
conducted VBD N
a DT N
cluster NN N
randomized VBN N
trial NN N
to TO N
explored VB N
the DT N
masking NN N
and CC N
blocking VBG N
hypotheses NNS N
by IN N
studying VBG N
BCG NNP 1_i
vaccine NN 1_i
efficacy NN N
of IN N
neonatal JJ N
vaccination NN N
and CC N
when WRB N
administered VBN N
for IN N
the DT N
first JJ N
or CC N
a DT N
second JJ N
( ( N
revaccination NN N
) ) N
time NN N
at IN N
school NN 1_p
age NN 1_p
in IN 1_p
two CD 1_p
sites NNS 1_p
( ( 1_p
Manaus NNP 1_p
close RB 1_p
and CC 1_p
Salvador NNP 1_p
further RB 1_p
south RB 1_p
from IN 1_p
the DT 1_p
equator NN 1_p
) ) 1_p
. . 1_p

Seven VBN 1_p
hundred CD 1_p
and CC 1_p
sixty VBD 1_p
three CD 1_p
state NN 1_p
schools NNS 1_p
were VBD 1_p
matched VBN 1_p
on IN 1_p
socio JJ 1_p
economic JJ 1_p
characteristics NNS 1_p
of IN 1_p
the DT 1_p
neighborhood NN 1_p
and CC 1_p
239,934 CD 1_p
children NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
vaccine VB N
( ( 1_i
BCG NNP 1_i
vaccination NN 1_i
at IN N
school NN N
age NN N
) ) N
or CC N
control VB 1_i
group NN 1_i
. . 1_i

Protection NN 1_o
by IN 1_o
first JJ 1_o
BCG NNP 1_o
vaccination NN 1_o
at IN N
school NN N
age NN N
was VBD N
high JJ N
in IN N
Salvador NNP 1_p
( ( N
34 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
7-53 CD N
% NN N
, , N
p=0.017 NN N
) ) N
but CC N
low JJ N
in IN N
Manaus NNP 1_p
( ( N
8 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
t0 VBZ N
39-40 CD N
% NN N
, , N
p=0.686 NN N
) ) N
. . N

For IN N
revaccination NN 1_o
at IN 1_o
school NN 1_o
age NN 1_o
, , N
protection NN N
was VBD N
modest JJ N
in IN N
Salvador NNP N
( ( N
19 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
3-33 CD N
% NN N
, , N
p=0.022 NN N
) ) N
and CC N
absent NN N
in IN N
Manaus NNP N
( ( N
1 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
to TO N
27-23 CD N
% NN N
, , N
p=0.932 NN N
) ) N
. . N

Vaccine NNP 1_o
efficacy NN 1_o
for IN N
neonatal JJ N
vaccination NN N
was VBD N
similar JJ N
in IN N
Salvador NNP N
( ( N
40 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
22-54 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
Manaus NNP N
( ( N
36 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
11-53 CD N
% NN N
, , N
p=0.008 NN N
) ) N
. . N

Variation NN 1_o
in IN 1_o
BCG NNP 1_o
efficacy NN 1_o
was VBD N
marked VBN N
when WRB N
vaccine NN N
was VBD N
given VBN N
at IN N
school NN N
age NN N
but CC N
absent NN N
at IN N
birth NN N
, , N
which WDT N
points VBZ N
towards NNS N
blocking VBG N
as IN N
the DT N
dominant JJ N
mechanism NN N
. . N

New NNP N
tuberculosis NN N
vaccines NNS N
that WDT N
overcome VBP N
or CC N
by IN N
pass NN N
this DT N
blocking VBG N
effect NN N
could MD N
confer VB N
protection NN N
in IN N
situations NNS N
where WRB N
BCG NNP N
is VBZ N
not RB N
protective JJ N
. . N

Failure NN N
of IN N
lithium NN 1_i
to TO N
reduce VB N
period NN N
of IN N
neutropenia NN N
during IN N
induction NN 1_i
therapy NN 1_i
of IN N
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
. . 1_p

Fifty-four CD 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
daunorubicin NN 1_i
, , 1_i
cytosine JJ 1_i
arabinoside NN 1_i
and CC 1_i
thioquanine NN 1_i
for IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ 1_i
lithium NN 1_i
carbonate NN 1_i
1200 CD 1_i
mg JJ 1_i
daily JJ 1_i
or CC 1_i
no DT 1_i
lithium NN 1_i
. . 1_i

The DT N
duration NN 1_o
of IN 1_o
neutropenia NN 1_o
( ( N
less JJR N
than IN N
0.5 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
was VBD N
similar JJ N
between IN N
controls NNS N
( ( N
median JJ N
22.5 CD N
days NNS N
) ) N
and CC N
patients NNS N
treated VBN N
with IN N
lithium NN 1_i
( ( N
median JJ N
24 CD N
days NNS N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
remissions NNS 1_o
, , 1_o
relapse-free JJ 1_o
survival NN 1_o
and CC 1_o
survival NN 1_o
were VBD N
similar JJ 1_o
for IN N
the DT N
lithium NN 1_i
treated VBD N
and CC N
control VB N
groups NNS N
of IN N
patients NNS N
. . N

There EX N
was VBD N
no DT N
apparent JJ N
clinical JJ 1_o
efficacy NN 1_o
in IN N
the DT N
use NN N
of IN N
lithium NN 1_i
to TO N
reduce VB N
the DT N
period NN N
of IN N
neutropenia NN N
in IN N
patients NNS 1_p
undergoing JJ 1_p
remission NN 1_p
induction NN 1_i
therapy NN 1_i
for IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
. . 1_p

Exploratory JJ N
Subset NNP N
Analysis NNP N
of IN N
African JJ 1_p
Americans NNPS 1_p
From IN 1_p
the DT 1_p
PointBreak NNP 1_p
Study NNP 1_p
: : 1_p
Pemetrexed-Carboplatin-Bevacizumab JJ 1_i
Followed NNP 1_i
by IN 1_i
Maintenance NNP 1_i
Pemetrexed-Bevacizumab NNP 1_i
Versus NNP N
Paclitaxel-Carboplatin-Bevacizumab NNP 1_i
Followed NNP 1_i
by IN 1_i
Maintenance NNP 1_i
Bevacizumab NNP 1_i
in IN 1_p
Patients NNP 1_p
With IN 1_p
Stage NNP 1_p
IIIB/IV NNP 1_p
Nonsquamous NNP 1_p
Non-Small-Cell NNP 1_p
Lung NNP 1_p
Cancer NNP 1_p
. . N

INTRODUCTION NNP 1_p
African JJ 1_p
Americans NNPS 1_p
have VBP 1_p
a DT 1_p
greater JJR 1_p
incidence NN 1_p
of IN 1_p
lung NN 1_p
cancer NN 1_p
than IN 1_p
whites NNS 1_p
and CC N
have VBP N
been VBN N
underrepresented VBN N
in IN N
clinical JJ N
trials NNS N
. . N

In IN N
the DT N
PointBreak NNP N
trial NN N
( ( 1_i
pemetrexed-carboplatin-bevacizumab JJ 1_i
and CC 1_i
maintenance JJ 1_i
pemetrexed-bevacizumab JJ 1_i
[ NN 1_i
PemCBev NNP 1_i
] NNP 1_i
vs. IN 1_i
paclitaxel-carboplatin-bevacizumab NN 1_i
and CC 1_i
maintenance NN 1_i
bevacizumab NN 1_i
[ NNP 1_i
PacCBev NNP 1_i
] NNP 1_i
) ) 1_i
, , N
10 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
were VBD 1_p
African JJ 1_p
American NNP 1_p
. . N

PointBreak NNP N
had VBD N
negative JJ N
findings NNS N
; : N
PemCBev NNP N
did VBD N
not RB N
demonstrate VB 1_o
superior JJ 1_o
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
PointBreak NNP N
subgroup NN 1_o
efficacy NN 1_o
and CC 1_o
safety NN 1_o
data NNS N
were VBD N
retrospectively RB N
analyzed VBN 1_p
: : 1_p
African JJ 1_p
Americans NNPS 1_p
versus VBP 1_p
whites NNS 1_p
for IN 1_i
PemCBev NNP 1_i
; : 1_i
PemCBev NNP 1_p
versus NN 1_i
PacCBev NNP 1_i
in IN 1_p
African NNP 1_p
Americans NNPS 1_p
; : 1_p
and CC 1_p
academic JJ 1_p
versus NN 1_p
community NN 1_p
settings NNS 1_p
for IN 1_p
African JJ 1_p
Americans NNPS 1_p
. . 1_o

Hazard NNP 1_o
ratios NNS 1_o
( ( 1_o
HRs NNP 1_o
) ) 1_o
and CC 1_o
P NNP 1_o
values NNS 1_o
were VBD N
derived VBN N
from IN N
a DT 1_o
multivariate NN 1_o
Cox NNP 1_o
proportional JJ N
hazards NNS N
model NN N
after IN N
adjusting VBG N
for IN N
covariates NNS N
. . N

RESULTS NNP 1_p
Of IN 1_p
939 CD 1_p
intent-to-treat NN 1_p
( ( 1_p
ITT NNP 1_p
) ) 1_p
patients NNS 1_p
, , 1_p
94 CD 1_p
were VBD 1_p
African JJ 1_p
American NNP 1_p
and CC 1_p
805 CD 1_p
were VBD 1_p
white JJ 1_p
. . 1_p

African-American JJ 1_p
enrollment NN N
was VBD N
uniform JJ N
across IN N
the DT N
study NN N
sites NNS N
( ( N
median JJ N
, , N
1 CD N
African JJ N
American NNP N
per IN N
site NN N
) ) N
. . N

In IN N
the DT N
PemCBev NNP N
arm NN N
, , N
OS NNP N
( ( N
HR NNP N
, , N
1.125 CD N
; : N
P NNP N
= NNP N
.525 NNP 1_o
) ) 1_o
, , 1_o
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
( ( N
HR NNP N
, , N
1.229 CD N
; : N
P NNP N
= NNP N
.251 NNP 1_o
) ) 1_o
, , 1_o
response NN 1_o
( ( N
P NNP N
= NNP N
.607 NNP N
) ) N
, , N
and CC 1_o
toxicity NN 1_o
profiles NNS 1_o
were VBD N
similar JJ N
in IN N
African JJ N
Americans NNPS N
versus NN N
whites NNS N
. . N

For IN N
African JJ N
Americans NNPS 1_o
, , N
OS NNP N
( ( N
HR NNP N
, , N
1.375 CD N
; : N
P NNP N
= NNP N
.209 NNP 1_o
) ) 1_o
, , N
PFS NNP N
( ( N
HR NNP N
, , N
0.902 CD N
; : N
P NNP N
= NNP N
.670 NNP N
) ) N
, , N
response NN N
( ( N
P NNP N
= NNP N
1.000 CD 1_o
) ) 1_o
, , 1_o
and CC 1_o
toxicity NN 1_o
profiles NNS 1_o
were VBD N
similar JJ N
in IN N
the DT N
PemCBev NNP N
versus NN N
PacCBev NNP N
arm NN N
. . N

For IN N
African JJ N
Americans NNPS N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
seen VBN 1_o
in IN N
OS NNP N
( ( N
HR NNP N
, , N
0.661 CD N
; : N
P NNP N
= NNP N
.191 NNP 1_o
) ) 1_o
or CC N
PFS NNP N
( ( N
HR NNP N
, , N
0.969 CD N
; : N
P NNP N
= NNP N
.915 NNP N
) ) N
in IN N
academic JJ N
versus NN N
community NN N
practice NN N
settings NNS N
. . N

CONCLUSION NNP N
In IN N
the DT N
PemCBev NNP N
arm NN N
, , N
this DT N
exploratory NN N
analysis NN N
showed VBD N
no DT N
significant JJ N
differences NNS 1_p
between IN 1_p
African JJ 1_p
Americans NNPS 1_p
and CC 1_p
whites NNS 1_o
for IN 1_o
the DT 1_o
efficacy NN 1_o
outcomes VBZ 1_o
or CC 1_o
toxicity NN 1_o
profiles NNS N
. . N

Consistent JJ N
with IN N
the DT N
ITT NNP N
population NN N
negative JJ N
trial NN N
result NN 1_p
, , 1_p
for IN 1_p
African JJ 1_p
Americans NNPS 1_p
, , N
the DT N
median JJ N
OS NNP N
was VBD N
not RB N
superior JJ N
for IN N
either DT N
arm NN 1_p
. . 1_p

For IN 1_p
African JJ 1_p
Americans NNPS 1_p
, , N
PFS NNP N
and CC N
OS NNP N
were VBD N
similar JJ N
in IN N
the DT N
academic JJ N
and CC N
community NN N
settings NNS N
. . N

Additional JJ N
outcomes NNS 1_p
data NNS 1_p
for IN 1_p
African JJ 1_p
Americans NNPS N
should MD N
be VB N
collected VBN N
in IN N
lung NN N
cancer NN N
studies NNS N
. . N

Are NNP N
prenatal JJ 1_i
ultrasound JJ 1_i
scans NNS 1_i
associated VBN N
with IN N
the DT N
autism NN 1_o
phenotype NN 1_o
? . N
Follow-up NNP N
of IN N
a DT N
randomised VBN N
controlled VBN 1_i
trial NN N
. . N

An DT N
existing VBG N
randomised VBD N
controlled VBN 1_i
trial NN N
was VBD N
used VBN N
to TO N
investigate VB N
whether IN N
multiple JJ 1_i
ultrasound JJ 1_i
scans NNS 1_i
may MD N
be VB N
associated VBN N
with IN N
the DT N
autism NN 1_o
phenotype NN 1_o
. . 1_o

From IN 1_p
2,834 CD 1_p
single JJ 1_p
pregnancies NNS 1_p
, , 1_p
1,415 CD 1_p
were VBD 1_p
selected VBN 1_p
at IN 1_p
random NN 1_p
to TO N
receive VB N
ultrasound JJ 1_i
imaging NN 1_i
and CC 1_i
continuous JJ 1_i
wave NN 1_i
Doppler NNP 1_i
flow NN 1_i
studies NNS 1_i
at IN N
five CD N
points NNS N
throughout IN N
pregnancy NN N
( ( N
Intensive NNP N
) ) N
and CC N
1,419 CD N
to TO N
receive VB N
a DT N
single JJ 1_i
imaging NN 1_i
scan NN 1_i
at IN N
18 CD N
weeks NNS N
( ( N
Regular NNP N
) ) N
, , N
with IN N
further JJ N
scans NNS N
only RB N
as RB N
indicated VBN N
on IN N
clinical JJ N
grounds NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN 1_o
of IN 1_o
Autism NNP 1_o
Spectrum NNP 1_o
Disorder NNP 1_o
between IN N
the DT N
Regular NNP N
( ( N
9/1,125 CD N
, , N
0.8 CD N
% NN N
) ) N
and CC N
Intensive NNP N
( ( N
7/1,167 CD N
, , N
0.6 CD N
% NN N
) ) N
groups NNS N
, , N
nor CC N
a DT N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
level NN 1_o
of IN 1_o
autistic-like JJ 1_o
traits NNS 1_o
in IN N
early JJ N
adulthood NN N
. . N

There EX N
is VBZ N
no DT N
clear JJ N
link NN N
between IN N
the DT N
frequency NN 1_o
and CC N
timing NN 1_o
of IN N
prenatal JJ 1_i
ultrasound JJ 1_i
scans NNS 1_i
and CC N
the DT N
autism NN 1_o
phenotype NN 1_o
. . 1_o

Effect NN N
of IN N
intestinal JJ N
production NN N
of IN N
equol NN N
on IN N
menopausal NN 1_o
symptoms NNS 1_o
in IN 1_p
women NNS 1_p
treated VBN 1_p
with IN 1_p
soy JJ 1_i
isoflavones NNS 1_i
. . 1_i

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
soy NN 1_i
isoflavones NNS 1_i
on IN N
menopausal NN N
symptoms NNS N
in IN N
women NNS 1_p
who WP 1_p
do VBP 1_p
and CC 1_p
who WP 1_p
do VBP 1_p
not RB 1_p
produce VB 1_p
equol NN 1_p
, , N
a DT N
daidzein NN N
metabolite NN N
. . N

METHOD NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
clinical JJ N
trial NN N
was VBD N
conducted VBN N
over IN N
6 CD N
months NNS N
with IN N
96 CD 1_p
healthy JJ 1_p
menopausal NN 1_p
women NNS 1_p
. . 1_p

After IN N
taking VBG N
take VB N
135 CD N
mg NN N
of IN N
isoflavones NNS 1_i
daily RB N
for IN N
1 CD N
week NN N
, , N
the DT N
women NNS N
in IN N
the DT N
study NN N
group NN N
were VBD N
assigned VBN N
to TO N
the DT N
equol-producing NN N
( ( N
EP NNP N
) ) N
or CC N
the DT N
non-EP JJ N
group NN N
according VBG N
to TO N
the DT N
presence NN N
or CC N
absence NN N
of IN N
equol NN N
in IN N
their PRP$ N
urine NN N
. . N

Menopausal NNP N
symptoms NNS N
were VBD N
evaluated VBN N
using VBG N
a DT N
modified VBN N
Kupperman NNP N
Index NNP N
. . N

RESULT NNP N
Compared NNP N
with IN N
the DT N
placebo NN 1_i
group NN N
, , N
the DT N
scores NNS N
for IN N
hot JJ 1_o
flashes NNS 1_o
and CC 1_o
excessive JJ 1_o
sweating NN 1_o
were VBD N
significantly RB N
reduced VBN N
after IN N
3 CD N
months NNS N
, , N
and CC N
the DT N
scores NNS N
for IN N
weakness NN 1_o
, , 1_o
palpitations NNS 1_o
, , 1_o
limb NN 1_o
paresthesia NN 1_o
, , 1_o
and CC 1_o
total JJ 1_o
symptoms NNS 1_o
after IN N
6 CD N
months NNS N
, , N
in IN N
the DT N
EP NNP N
group NN N
only RB N
. . N

CONCLUSIONS NNP N
Isoflavone NNP 1_i
supplementation NN 1_i
improves VBZ N
menopausal NN 1_o
symptoms NNS 1_o
only RB N
in IN N
women NNS N
with IN N
the DT N
ability NN N
to TO N
produce VB N
equol NN N
. . N

Effect NN N
of IN N
propranolol NN 1_i
on IN N
facial JJ N
scanning NN N
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
a DT N
preliminary JJ N
investigation NN N
. . N

BACKGROUND NNP N
Autism NNP 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
social JJ N
communication NN N
impairments NNS N
and CC N
restricted VBN N
, , N
repetitive JJ N
behaviors NNS N
. . N

Whereas NNP N
current JJ N
pharmacological JJ N
interventions NNS N
for IN N
ASD NNP N
focus VBP N
primarily RB N
on IN N
psychiatric JJ N
symptoms NNS N
, , N
including VBG N
agitation NN N
and CC N
obsessive JJ N
behaviors NNS N
, , N
few JJ N
agents NNS N
target VB N
core NN N
symptomatology NN N
. . N

It PRP N
has VBZ N
been VBN N
previously RB N
hypothesized VBN N
that IN N
abnormalities NNS N
in IN N
facial JJ N
scanning NN N
, , N
such JJ N
as IN N
reduced JJ N
eye NN N
contact NN N
or CC N
increased VBN N
mouth JJ N
fixation NN N
, , N
contribute NN N
to TO N
social JJ N
communication NN N
deficits NNS N
in IN N
ASD NNP N
. . N

In IN N
addition NN N
, , N
previous JJ N
reports NNS N
have VBP N
suggested VBN N
elevated JJ N
stress NN N
and CC N
anxiety NN N
in IN N
ASD NNP N
, , N
symptoms NNS N
that WDT N
are VBP N
believed VBN N
to TO N
impact VB N
facial JJ N
scanning NN N
patterns NNS N
. . N

OBJECTIVES IN N
The DT N
present JJ N
pilot NN N
study NN N
sought VBD N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
pharmacological JJ N
intervention NN N
via IN N
propranolol NN 1_i
, , N
a DT N
nonselective JJ N
β-adrenergic JJ N
antagonist NN N
and CC N
known VBN N
anxiolytic JJ N
, , N
on IN N
facial JJ N
scanning NN N
in IN N
ASD NNP N
. . N

Specifically RB N
, , N
we PRP N
wished VBD N
to TO N
determine VB N
whether IN N
there EX N
is VBZ N
an DT N
increase NN N
in IN N
eye NN N
contact NN N
and CC N
a DT N
decrease NN N
in IN N
mouth JJ N
fixation NN N
with IN N
administration NN N
of IN N
propranolol NN N
. . N

METHOD NNP 1_p
A NNP 1_p
sample NN 1_p
of IN 1_p
14 CD 1_p
participants NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
14 CD 1_p
matched VBD 1_p
controls NNS 1_p
participated VBN N
in IN N
two CD N
study NN N
sessions NNS N
in IN N
which WDT 1_i
propranolol NN 1_i
and CC 1_i
placebo NN 1_i
were VBD 1_i
administered VBN 1_i
in IN 1_i
a DT 1_i
counterbalanced JJ 1_i
, , 1_i
double-blinded JJ 1_i
manner NN 1_i
. . N

At IN N
each DT N
session NN N
, , N
ocular JJ 1_o
fixation NN 1_o
data NNS 1_o
were VBD N
collected VBN N
during IN 1_i
presentation NN 1_i
of IN 1_i
video JJ 1_i
stimuli NNS 1_i
of IN 1_i
16 CD 1_i
human JJ 1_i
faces VBZ 1_i
. . N

Fixation NNP N
time NN N
on IN N
the DT N
eye NN N
, , N
nose JJ N
, , N
and CC N
mouth JJ N
regions NNS N
of IN N
the DT N
face NN N
stimuli NN N
was VBD N
analyzed VBN N
. . N

RESULTS VB N
The DT N
baseline JJ N
fixation NN N
patterns NNS N
for IN N
the DT 1_p
ASD NNP 1_p
and CC 1_p
control NN 1_p
groups NNS 1_p
did VBD N
not RB N
significantly RB N
differ VBP N
; : N
however RB N
, , N
administration NN N
of IN N
propranolol NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN 1_o
mouth NN 1_o
fixation NN 1_o
for IN N
the DT 1_p
ASD NNP 1_p
group NN 1_p
. . N

Additionally RB N
, , N
mouth JJ 1_o
fixation NN 1_o
was VBD N
positively RB N
related VBN N
to TO N
nonverbal JJ N
communication NN N
impairment NN N
in IN N
the DT N
ASD NNP N
group NN N
. . N

CONCLUSIONS NNP N
Although IN N
eye NN N
fixation NN N
in IN N
ASD NNP N
appears VBZ N
typical JJ N
in IN N
the DT N
present JJ N
study NN N
, , N
the DT N
effect NN N
of IN N
propranolol NN N
in IN N
reducing VBG N
mouth JJ N
fixation NN N
suggests VBZ N
an DT N
important JJ N
focus NN N
for IN N
further JJ N
research NN N
. . N

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
better RBR N
characterize VB N
the DT N
relationship NN N
between IN N
stress NN N
and CC N
anxiety NN N
and CC N
facial JJ N
scanning NN N
in IN N
ASD NNP N
, , N
as RB N
well RB N
as IN N
the DT N
effects NNS N
of IN N
pharmacological JJ N
intervention NN N
. . N

Prophylactic JJ 1_p
amnioinfusion NN 1_i
in IN 1_p
pregnancies NNS 1_p
complicated VBN 1_p
by IN 1_p
oligohydramnios NNS 1_p
: : 1_p
a DT N
prospective JJ N
study NN N
. . N

Prophylactic JJ N
amnioinfusion NN 1_i
was VBD N
assessed VBN N
in IN N
term NN 1_p
and CC 1_p
post-dates NNS 1_p
pregnancies NNS 1_p
with IN 1_p
decreased JJ 1_p
amniotic JJ 1_p
fluid NN 1_p
volume NN 1_p
. . 1_p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
amnioinfusion NN 1_i
with IN 1_i
warmed JJ 1_i
saline JJ 1_i
solution NN 1_i
, , 1_i
room-temperature JJ 1_i
saline NN 1_i
, , 1_i
or CC 1_i
control NN 1_i
. . 1_i

Patients NNS 1_p
receiving VBG 1_p
prophylactic JJ 1_p
amnioinfusion NN 1_i
had VBD N
a DT N
significant JJ N
decrease NN N
in IN N
both CC N
the DT N
frequency NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
variable JJ 1_o
decelerations NNS 1_o
in IN 1_o
the DT 1_o
first JJ 1_o
stage NN 1_o
of IN 1_o
labor NN 1_o
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
and CC N
in IN N
the DT N
average JJ N
total JJ N
number NN N
of IN N
variable JJ N
decelerations NNS N
in IN N
the DT N
first JJ N
and CC N
second JJ N
stages NNS N
of IN N
labor NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
compared VBN N
with IN N
controls NNS N
. . N

There EX N
was VBD N
no DT N
observed JJ N
effect NN N
on IN N
newborn JJ 1_o
serum NN 1_o
electrolyte NN 1_o
levels NNS 1_o
with IN N
amnioinfusion NN 1_i
, , N
nor CC N
was VBD N
there EX N
any DT N
apparent JJ N
benefit NN N
of IN N
infusion NN N
of IN N
warmed JJ N
saline NN N
compared VBN N
with IN N
room-temperature JJ N
saline NN N
. . N

In IN N
contrast NN N
to TO N
premature VB N
gestations NNS N
with IN N
oligohydramnios NNS N
, , N
prophylactic JJ N
amnioinfusion NN 1_i
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
improvement NN N
in IN N
mean JJ 1_o
umbilical JJ 1_o
arterial NN 1_o
and CC 1_o
venous JJ 1_o
pH NN 1_o
or CC N
a DT N
significant JJ 1_o
decrease NN 1_o
in IN N
cesarean JJ 1_o
delivery NN 1_o
for IN 1_o
fetal JJ 1_o
distress NN 1_o
( ( N
P NNP N
= NNP N
.09 NNP N
) ) N
. . N

This DT N
is VBZ N
perhaps RB N
because IN N
the DT N
term NN N
fetus NN N
has VBZ N
an DT N
enhanced VBN N
ability NN N
to TO N
tolerate VB N
recurrent JJ N
episodes NNS N
of IN N
heart NN 1_o
rate NN 1_o
decelerations NNS 1_o
without IN N
demonstrating VBG N
the DT N
rapid JJ N
metabolic JJ N
changes NNS N
seen VBN N
in IN N
the DT N
premature NN N
fetus NN N
. . N

Effects NNS N
of IN N
captopril NN 1_i
and CC N
enalapril NN 1_i
on IN N
electroencephalogram NN 1_o
and CC 1_o
cognitive JJ 1_o
performance NN 1_o
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

OBJECTIVE NNP N
Captopril NNP 1_i
and CC N
enalapril NNS 1_i
have VBP N
been VBN N
reported VBN N
to TO N
influence VB N
cognitive JJ 1_o
functions NNS 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
in IN N
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
The DT N
effects NNS N
of IN N
captopril NN 1_i
( ( N
12.5 CD N
mg NN N
and CC N
25 CD N
mg NN N
) ) N
and CC N
enalapril $ 1_i
( ( N
5 CD N
mg NN N
and CC N
10 CD N
mg NN N
) ) N
administered VBD N
during IN N
7-day JJ N
periods NNS N
on IN N
electroencephalogram NN 1_o
( ( 1_o
EEG NNP 1_o
) ) 1_o
, , 1_o
cognitive JJ 1_o
functions NNS 1_o
, , 1_o
and CC 1_o
subjective JJ 1_o
assessments NNS 1_o
were VBD N
investigated VBN N
in IN N
healthy JJ 1_p
males NNS 1_p
. . 1_p

RESULTS NNP N
Neither NNP N
captopril NN N
nor CC N
enalapril NN N
influenced VBN N
EEG NNP 1_o
and CC 1_o
cognitive JJ 1_o
functions NNS 1_o
compared VBN N
with IN N
placebo NN N
. . N

Captopril NNP 1_i
12.5 CD N
mg NN N
decreased VBD N
subjective JJ 1_o
activity NN 1_o
compared VBN N
with IN N
placebo NN 1_i
. . 1_i

Enalapril NNP 1_i
did VBD N
not RB N
alter VB N
subjective JJ 1_o
ratings NNS 1_o
. . 1_o

Both DT N
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
were VBD N
significantly RB N
lower JJR N
after IN N
administration NN N
of IN N
captopril JJ 1_i
25 CD N
mg NN N
, , N
whereas WP N
blood NN 1_o
pressure NN 1_o
was VBD N
unaffected VBN N
by IN N
enalapril NNS 1_i
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
central JJ N
effects NNS N
of IN N
captopril NN 1_i
and CC N
enalapril NN 1_i
were VBD N
minor JJ N
and CC N
not RB N
constant JJ N
in IN N
young JJ 1_p
healthy JJ 1_p
men NNS 1_p
. . 1_p

Comparison NNP 1_o
of IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
with IN N
sequential JJ N
chemotherapy NN N
for IN N
intermediate-grade JJ 1_p
and CC 1_p
high-grade JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
in IN 1_p
first JJ 1_p
complete JJ 1_o
remission NN 1_o
: : 1_o
a DT 1_p
study NN 1_p
of IN 1_p
464 CD 1_p
patients NNS 1_p
. . 1_p

Groupe NNP N
d'Etude NN N
des NNS N
Lymphomes NNP N
de IN N
l'Adulte FW N
. . N

PURPOSE NNP N
Intensive NNP N
chemotherapy NN N
followed VBN N
by IN N
autotransplantation NN N
has VBZ N
given VBN N
promising VBG N
results NNS N
in IN N
partially RB N
responding VBG N
or CC N
sensitive JJ N
relapsed JJ N
patients NNS 1_p
with IN 1_p
aggressive JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
. . 1_p

In IN N
1987 CD N
, , N
we PRP N
designed VBD N
a DT N
randomized VBN N
study NN N
to TO N
evaluate VB N
the DT N
potential JJ N
benefit NN 1_o
of IN N
a DT N
high-dose JJ 1_i
regimen NN 1_i
containing VBG 1_i
cyclophosphamide NN 1_i
, , 1_i
carmustine NN 1_i
, , 1_i
and CC 1_i
etoposide RB 1_i
( ( 1_i
CBV NNP 1_i
) ) 1_i
followed VBN 1_i
by IN 1_i
autotransplantation NN 1_i
over IN 1_i
a DT 1_i
consolidative JJ 1_i
sequential JJ 1_i
chemotherapy NN 1_i
( ( 1_i
ifosfamide JJ 1_i
, , 1_i
etoposide RB 1_i
, , 1_i
asparaginase NN 1_i
, , 1_i
and CC 1_i
cytarabine NN 1_i
) ) 1_i
in IN N
patients NNS N
in IN N
first JJ N
complete JJ N
remission NN N
with IN N
intermediate- JJ 1_p
and CC 1_p
high-grade JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS 1_p
were VBD 1_p
younger JJR 1_p
than IN 1_p
55 CD 1_p
years NNS 1_p
and CC 1_p
had VBD 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
adverse JJ 1_p
prognostic JJ 1_p
factor NN 1_p
. . 1_p

Induction NNP N
treatment NN N
was VBD N
that IN N
of IN N
the DT N
LNH84 NNP N
protocol NN N
with IN N
an DT N
open JJ N
randomization NN N
on IN N
the DT N
anthracycline NN 1_i
. . 1_i

Patients NNS N
in IN N
complete JJ 1_o
remission NN 1_o
were VBD N
further JJ N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
consolidation NN N
procedure NN N
. . N

RESULTS NNP N
After IN N
induction NN N
treatment NN N
, , N
464 CD 1_p
patients NNS 1_p
were VBD N
assessable JJ N
for IN N
the DT N
consolidation NN N
phase NN N
. . N

With IN N
a DT N
median JJ N
follow-up JJ N
duration NN N
of IN N
28 CD N
months NNS N
, , N
the DT N
3-year JJ 1_o
disease-free JJ 1_o
survival NN 1_o
rate NN 1_o
was VBD N
52 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
45 CD N
% NN N
to TO N
59 CD N
% NN N
) ) N
in IN N
the DT N
sequential JJ N
chemotherapy NN N
arm NN N
and CC N
59 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
52 CD N
% NN N
to TO N
66 CD N
% NN N
) ) N
in IN N
the DT N
autologous JJ N
transplant NN N
arm NN N
( ( N
P NNP N
= NNP N
.46 NNP N
, , N
relative JJ N
risk NN N
= NNP N
0.90 CD N
) ) N
. . N

The DT N
3-year JJ 1_o
survival NN 1_o
rate NN 1_o
did VBD N
not RB N
differ VB N
between IN N
sequential JJ N
chemotherapy NN N
and CC N
autotransplantation NN N
, , N
at IN N
71 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
64 CD N
% NN N
to TO N
78 CD N
% NN N
) ) N
and CC N
69 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
62 CD N
% NN N
to TO N
76 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.60 NNP N
, , N
relative JJ N
risk NN N
= NNP N
1.11 CD N
) ) N
. . N

CONCLUSION NNP N
For IN N
such JJ N
a DT N
subset NN N
of IN N
patients NNS N
, , N
consolidation NN N
with IN N
the DT N
CBV NNP N
regimen NNS N
followed VBN N
by IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
is VBZ N
not RB N
superior JJ 1_o
to TO N
sequential JJ N
chemotherapy NN N
. . N

Computer-assisted JJ 1_i
instruction NN 1_i
: : 1_i
an DT N
effective JJ N
instructional JJ N
method NN N
for IN N
HIV NNP 1_o
prevention NN 1_o
education NN N
? . N
PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
of IN N
a DT N
computer-assisted JJ 1_i
instruction NN 1_i
( ( 1_i
CAI NNP 1_i
) ) 1_i
-based VBD 1_i
intervention NN 1_i
to TO N
a DT N
more RBR N
traditional JJ 1_i
lecture-based JJ 1_i
intervention NN 1_i
for IN N
influencing VBG N
psychosocial JJ N
correlates NNS N
of IN N
human JJ 1_p
immunodeficiency NN 1_p
virus NN 1_p
( ( 1_p
HIV NNP 1_p
) ) 1_p
preventive JJ N
behaviors NNS N
. . N

METHODS NNP N
Students NNPS 1_p
enrolled VBD 1_p
in IN 1_p
a DT 1_p
Human NNP 1_p
Sexuality NNP 1_p
course NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
152 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
CAI NNP 1_i
, , 1_i
Lecture NNP 1_i
, , 1_i
or CC 1_i
No DT 1_i
Intervention NNP 1_i
group NN 1_i
. . 1_i

Participants NNS N
in IN N
the DT N
CAI NNP N
group NN N
reviewed VBD N
a DT N
1-hour JJ N
long JJ N
CAI NNP 1_i
program NN 1_i
, , N
participants NNS N
in IN N
the DT N
Lecture NNP N
group NN N
were VBD N
presented VBN N
with IN N
a DT N
1-hour JJ N
long JJ N
lecture NN N
, , N
and CC N
participants NNS N
in IN N
the DT N
No NNP N
Intervention NNP N
group NN N
received VBD N
no DT N
intervention NN N
. . N

After IN N
completing VBG N
the DT N
respective JJ N
interventions NNS N
, , N
all DT N
participants NNS N
completed VBD N
the DT N
HIV NNP 1_o
questionnaire NN 1_o
, , N
which WDT N
measured VBD N
selected VBN N
Social NNP 1_o
Cognitive NNP 1_o
Theory NNP 1_o
constructs NNS N
associated VBN N
with IN N
HIV NNP 1_o
preventive JJ 1_o
behaviors NNS 1_o
. . 1_o

MANCOVA NNP N
, , N
ANCOVA NNP N
and CC N
Post NNP N
Hoc NNP N
analyses NNS N
were VBD N
utilized JJ N
to TO N
test VB N
for IN N
significant JJ N
differences NNS N
among IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS VB N
The DT N
analyses NNS N
disclosed VBD N
that IN N
, , N
compared VBN N
to TO N
participants NNS N
in IN N
the DT N
Lecture NNP N
group NN N
, , N
participants NNS N
in IN N
the DT N
CAI NNP N
group NN N
scored VBD N
significantly RB N
higher JJR N
on IN N
the DT N
scales NNS 1_o
measuring VBG 1_o
autoimmune JJ 1_o
deficiency NN 1_o
syndrome NN 1_o
( ( 1_o
AIDS NNP 1_o
) ) 1_o
knowledge NN 1_o
, , 1_o
self-evaluative JJ 1_o
outcome NN 1_o
motivation NN 1_o
, , 1_o
and CC 1_o
intention NN 1_o
to TO 1_o
practice NN 1_o
HIV NNP 1_o
preventive JJ 1_o
behaviors NNS 1_o
with IN N
current JJ N
partner NN N
. . N

In IN N
addition NN N
, , N
compared VBN N
to TO N
the DT N
No NNP N
Intervention NNP N
group NN N
, , N
the DT N
CAI NNP N
group NN N
scored VBD N
significantly RB N
higher JJR N
on IN N
the DT N
scales NNS 1_o
measuring VBG 1_o
physical JJ 1_o
outcome NN 1_o
motivation NN 1_o
and CC 1_o
social JJ 1_o
outcome NN 1_o
motivation NN 1_o
. . 1_o

CONCLUSIONS NNP N
CAI-based JJ N
programs NNS N
can MD N
be VB N
effective JJ N
for IN N
delivering VBG N
instruction NN N
on IN N
HIV NNP 1_o
prevention NN 1_o
. . 1_o

However RB N
, , N
because IN N
of IN N
certain JJ N
limitations NNS N
, , N
this DT N
type NN N
of IN N
program NN N
is VBZ N
best RB N
utilized VBN N
as IN N
part NN N
of IN N
a DT N
more RBR N
comprehensive JJ N
intervention NN N
that WDT N
uses VBZ N
several JJ N
different JJ N
delivery NN N
systems NNS N
. . N

Effect NN N
of IN N
ranitidine NN 1_i
on IN N
the DT N
disposition NN 1_o
of IN N
orally RB N
and CC N
intravenously RB N
administered VBN N
triazolam NN N
. . N

The DT N
effect NN N
of IN N
orally RB N
administered VBN N
ranitidine NN 1_i
on IN N
the DT N
pharmacokinetic JJ 1_o
properties NNS 1_o
of IN N
orally RB N
and CC N
intravenously RB N
administered VBD N
triazolam NN 1_i
was VBD N
determined VBN N
. . N

Twelve NNP 1_p
healthy JJ 1_p
males NNS 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
35 CD 1_p
years NNS 1_p
were VBD N
enrolled VBN N
in IN N
this DT N
four-way NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

Each DT N
subject NN N
received VBD N
a DT N
total NN N
of IN N
four CD N
treatments NNS N
, , N
each DT N
separated VBN N
by IN N
one CD N
week NN N
. . N

The DT N
treatments NNS N
consisted VBN N
of IN N
( ( N
1 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ 1_i
triazolam NN 1_i
tablet NN 1_i
after IN 1_i
treatment NN 1_i
with IN 1_i
ranitidine NN 1_i
; : 1_i
( ( N
2 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ 1_i
triazolam NN 1_i
tablet NN 1_i
, , 1_i
with IN 1_i
no DT 1_i
ranitidine JJ 1_i
pretreatment NN 1_i
; : 1_i
( ( N
3 CD N
) ) N
a DT N
0.25-mg JJ 1_i
intravenous JJ 1_i
dose NN 1_i
of IN 1_i
triazolam NN 1_i
after IN 1_i
treatment NN 1_i
with IN 1_i
ranitidine NN 1_i
; : 1_i
and CC N
( ( N
4 CD N
) ) N
a DT N
0.25-mg JJ 1_i
intravenous JJ 1_i
dose NN 1_i
of IN 1_i
triazolam NN 1_i
, , 1_i
with IN 1_i
no DT 1_i
ranitidine NN 1_i
pretreatment NN 1_i
. . 1_i

Ranitidine NNP 1_i
pretreatment NN N
consisted VBD N
of IN N
five CD N
150-mg JJ N
oral JJ N
doses NNS N
( ( N
as IN N
the DT N
hydrochloride NN N
salt NN N
) ) N
given VBN N
every DT N
12 CD N
hours NNS N
; : N
the DT N
last JJ N
dose NN N
was VBD N
given VBN N
two CD N
hours NNS N
before IN N
triazolam NN 1_i
was VBD N
administered VBN N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
at IN N
intervals NNS N
up RB N
to TO N
12 CD N
hours NNS N
after IN N
triazolam JJ N
treatment NN N
. . N

Serum NNP 1_o
triazolam JJ 1_o
concentrations NNS 1_o
were VBD N
measured VBN N
by IN N
modified JJ N
high-performance NN N
liquid NN N
chromatography NN N
, , N
and CC N
pharmacokinetic JJ 1_o
values NNS 1_o
were VBD N
calculated VBN N
. . N

Pretreatment NN N
with IN N
ranitidine NN 1_i
had VBD N
no DT N
effect NN N
on IN N
the DT N
disposition NN 1_o
of IN 1_o
intravenously RB 1_o
administered VBN 1_o
triazolam NN 1_o
but CC N
significantly RB N
increased VBD N
the DT N
area NN 1_o
under IN 1_o
the DT 1_o
serum JJ 1_o
drug NN 1_o
concentration-time JJ 1_o
curve NN 1_o
of IN 1_o
oral JJ 1_o
triazolam NN 1_o
. . 1_o

Ranitidine NNP 1_i
pretreatment NN N
had VBD N
no DT N
effect NN N
on IN N
triazolam NN 1_o
's POS 1_o
terminal JJ 1_o
elimination NN 1_o
rate NN 1_o
constant JJ 1_o
or CC N
on IN N
the DT N
time NN 1_o
to TO 1_o
reach VB 1_o
maximum JJ 1_o
serum JJ 1_o
triazolam NN 1_o
concentration NN 1_o
. . 1_o

Ranitidine JJ 1_i
pretreatment NN N
increased VBD N
the DT N
systemic JJ 1_o
availability NN 1_o
of IN 1_o
triazolam NN 1_o
by IN N
increasing VBG N
its PRP$ N
absorption NN 1_o
. . 1_o

Plasma NNP N
Epstein-Barr NNP N
virus NN N
DNA NNP N
predicts VBZ N
outcome VBN N
in IN N
advanced JJ 1_p
Hodgkin NNP 1_p
lymphoma NN 1_p
: : 1_p
correlative JJ N
analysis NN N
from IN N
a DT N
large JJ 1_p
North JJ 1_p
American JJ 1_p
cooperative NN 1_p
group NN 1_p
trial NN 1_p
. . 1_p

Epstein-Barr JJ N
virus NN N
( ( N
EBV NNP N
) ) N
is VBZ N
associated VBN N
with IN N
Hodgkin NNP N
lymphoma NN N
( ( N
HL NNP N
) ) N
and CC N
can MD N
be VB N
detected VBN N
by IN N
in IN N
situ JJ N
hybridization NN N
( ( N
ISH NNP N
) ) N
of IN N
viral JJ N
nucleic JJ N
acid NN N
( ( N
EBER NNP N
) ) N
in IN N
tumor NN N
cells NNS N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
plasma JJ N
EBV-DNA NNP N
could MD N
serve VB N
as IN N
a DT N
surrogate NN N
for IN N
EBER-ISH NNP 1_o
and CC N
to TO N
explore VB N
its PRP$ N
prognostic JJ N
utility NN N
in IN N
HL NNP N
. . N

Specimens NNS 1_p
from IN 1_p
the DT 1_p
Cancer NNP 1_p
Cooperative NNP 1_p
Intergroup NNP 1_p
Trial NNP 1_p
E2496 NNP 1_p
were VBD N
used VBN N
to TO N
compare VB 1_i
pretreatment JJ 1_i
plasma JJ 1_i
EBV-DNA JJ 1_i
quantification NN 1_i
with IN 1_i
EBV NNP 1_i
tumor NN 1_o
status NN 1_o
by IN 1_i
EBER-ISH NNP 1_o
. . 1_o

A NNP N
cutoff NN N
of IN N
> $ N
60 CD N
viral JJ N
copies/100 NN N
µL NNP N
plasma NN N
yielded VBD N
96 CD N
% NN N
concordance NN N
with IN 1_o
EBER-ISH NNP 1_o
. . N

Pretreatment NNP N
and CC N
month NN N
6 CD 1_p
plasma NN 1_p
specimens NNS 1_p
were VBD N
designated VBN N
EBV NNP N
( ( N
- : N
) ) N
or CC N
EBV NNP N
( ( N
+ NNP N
) ) N
by IN N
this DT N
cutoff NN N
. . N

Patients NNS N
with IN N
pretreatment JJ N
EBV NNP N
( ( N
+ NNP N
) ) N
plasma NN N
( ( N
n JJ N
= NNP N
54 CD N
) ) N
had VBD 1_o
inferior JJ 1_o
failure-free JJ 1_o
survival NN 1_o
( ( 1_o
FFS NNP 1_o
) ) 1_o
compared VBN N
with IN N
those DT N
with IN N
pretreatment JJ N
EBV NNP N
( ( N
- : N
) ) N
plasma NN N
( ( N
n JJ N
= NNP N
274 CD N
) ) N
, , N
log-rank JJ N
P NNP N
= NNP N
.009 NNP N
. . N

By IN N
contrast NN N
, , N
no DT N
difference NN N
in IN 1_o
FFS NNP 1_o
was VBD N
observed VBN N
when WRB N
patients NNS N
were VBD N
stratified VBN N
by IN 1_o
EBER-ISH NNP 1_o
. . N

Pretreatment NNP N
plasma NN N
EBV NNP N
positivity NN N
was VBD N
an DT N
independent JJ N
predictor NN N
of IN N
treatment NN N
failure NN N
on IN N
multivariate NN N
analyses NNS N
. . N

At IN N
month NN N
6 CD N
, , N
plasma NN 1_o
EBV NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
patients NNS N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
had VBD 1_o
inferior JJ 1_o
FFS NNP 1_o
compared VBN N
with IN 1_o
plasma NN 1_o
EBV NNP 1_o
( ( 1_o
- : 1_o
) ) 1_o
patients NNS N
( ( N
n JJ N
= NNP N
125 CD N
) ) N
, , N
log-rank JJ N
P NNP N
= NNP N
.007 NNP N
. . N

These DT N
results NNS N
confirm VBP N
that IN N
plasma JJ N
EBV-DNA NNP N
is VBZ N
highly RB N
concordant JJ N
with IN 1_o
EBER-ISH NNP 1_o
in IN N
HL NNP N
and CC N
suggest VBP N
that IN N
it PRP N
may MD N
have VB N
prognostic JJ N
utility NN N
both DT N
at IN N
baseline NN N
and CC N
after IN N
therapy NN N
. . N

This DT N
trial NN N
was VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00003389 NNP N
. . N

Variations NNS N
in IN N
EEG NNP 1_o
discharges NNS 1_o
predict VBP N
ADHD NNP N
severity NN N
within IN N
individual JJ 1_p
Smith-Lemli-Opitz JJ 1_p
patients NNS 1_p
. . 1_p

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
examine VB N
the DT N
prevalence NN N
of IN N
EEG NNP N
abnormalities NNS N
in IN N
Smith-Lemli-Opitz NNP 1_p
syndrome NN 1_p
( ( 1_p
SLOS NNP 1_p
) ) 1_p
as RB N
well RB N
as IN N
the DT N
relationship NN N
between IN N
interictal JJ N
epileptiform NN N
discharges NNS N
( ( N
IEDs NNP N
) ) N
and CC N
within-subject JJ N
variations NNS N
in IN N
attentional JJ N
symptom NN N
severity NN N
. . N

METHODS NNP N
In IN N
the DT N
context NN N
of IN N
a DT N
clinical JJ N
trial NN N
for IN N
SLOS NNP N
, , N
we PRP N
performed VBD N
cross-sectional JJ N
and CC N
repeated-measure JJ N
observational JJ N
studies NNS N
of IN N
the DT N
relationship NN N
between IN N
EEG NNP 1_i
findings NNS N
and CC N
cognitive/behavioral JJ N
factors NNS N
on IN N
23 CD 1_p
children NNS 1_p
( ( 1_p
aged VBN 1_p
4-17 CD 1_p
years NNS 1_p
) ) 1_p
. . 1_p

EEGs NNP 1_i
were VBD N
reviewed VBN N
for IN N
clinical JJ N
abnormalities NNS N
, , N
including VBG N
IEDs NNP N
, , N
by IN N
readers NNS N
blinded VBD N
to TO N
participants NNS N
' POS N
behavioral NN N
symptoms NNS N
. . N

Between-group JJ N
differences NNS N
in IN N
baseline JJ N
characteristics NNS N
of IN N
participants NNS N
with IN N
and CC N
without IN N
IEDs NNP N
were VBD N
analyzed VBN N
. . N

Within-subject JJ N
analyses NNS N
examined VBD N
the DT N
association NN N
between IN N
the DT N
presence NN N
of IN N
IEDs NNP N
and CC N
changes NNS N
in IN N
attention-deficit/hyperactivity NN 1_o
disorder NN 1_o
( ( 1_o
ADHD NNP 1_o
) ) 1_o
symptoms NNS 1_o
. . 1_o

RESULTS NNP N
Of IN N
85 CD N
EEGs NNP N
, , N
43 CD N
( ( N
51 CD N
% NN N
) ) N
were VBD N
abnormal JJ 1_o
, , N
predominantly RB N
because IN N
of IN N
IEDs NNP N
. . N

Only RB N
one CD N
subject NN N
had VBD N
documented VBN N
clinical JJ 1_o
seizures NNS 1_o
. . 1_o

IEDs NNP N
clustered VBD N
in IN N
13 CD 1_p
subjects NNS 1_p
( ( 1_p
57 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
whereas $ 1_p
9 CD 1_p
subjects NNS 1_p
( ( 1_p
39 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
EEGs NNP 1_p
consistently RB 1_p
free JJ 1_p
of IN 1_p
IEDs NNP 1_p
. . 1_p

While IN N
there EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
in IN N
sex NN 1_o
, , 1_o
age NN 1_o
, , 1_o
intellectual JJ 1_o
disability NN 1_o
, , 1_o
language NN 1_o
level NN 1_o
, , 1_o
or CC 1_o
baseline VB 1_o
ADHD NNP 1_o
symptoms NNS 1_o
, , 1_o
autistic JJ 1_o
symptoms NNS 1_o
tended VBD N
to TO N
be VB N
more RBR N
prevalent JJ N
in IN N
the DT N
" NNP N
IED NNP N
" NNP N
group NN N
( ( N
according VBG N
to TO N
Autism NNP 1_o
Diagnostic NNP 1_o
Observation NNP 1_o
Schedule-2 NNP 1_o
criteria NNS 1_o
) ) 1_o
. . N

Within JJ N
individuals NNS N
, , N
the DT N
presence NN N
of IN N
IEDs NNP N
on IN N
a DT N
particular JJ N
EEG NNP N
predicted VBD N
, , N
on IN N
average NN N
, , N
a DT N
27 CD N
% NN N
increase NN N
in IN N
ADHD NNP 1_o
symptom NN 1_o
severity NN 1_o
. . 1_o

CONCLUSIONS NNP N
Epileptiform NNP N
discharges NNS N
are VBP N
common JJ N
in IN N
SLOS NNP N
, , N
despite IN N
a DT N
relatively RB N
low JJ N
prevalence NN N
of IN N
epilepsy NN N
. . N

Fluctuations NNS N
in IN N
the DT N
presence NN N
of IN N
epileptiform NN N
discharges NNS N
within IN N
individual JJ N
children NNS N
with IN N
a DT N
developmental JJ N
disability NN N
syndrome NN N
may MD N
be VB N
associated VBN N
with IN N
fluctuations NNS N
in IN N
ADHD NNP N
symptomatology NN N
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
clinical JJ N
seizures NNS N
. . N

Behavioral JJ 1_o
effects NNS 1_o
of IN N
Org NNP 1_i
2766 CD 1_i
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
the DT N
adrenocorticotrophic JJ N
hormone NN N
( ( N
4-9 JJ N
) ) N
, , N
in IN N
14 CD 1_p
outpatient JJ 1_p
autistic JJ 1_p
children NNS 1_p
. . 1_p

Fourteen NNP 1_p
children NNS 1_p
( ( 1_p
12 CD 1_p
infantile NN 1_p
autism NN 1_p
full JJ 1_p
syndrome NN 1_p
present NN 1_p
, , 1_p
2 CD 1_p
atypical JJ 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
) ) 1_p
between IN 1_p
5 CD 1_p
and CC 1_p
13 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
participated VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
. . N

Each DT N
child NN N
received VBD N
20 CD 1_i
mg NNS 1_i
Org JJ 1_i
2766 CD 1_i
( ( 1_i
synthetic JJ 1_i
analog NN 1_i
of IN 1_i
ACTH NNP 1_i
4-9 JJ 1_i
) ) 1_i
/day NN 1_i
during IN 1_i
4 CD 1_i
weeks NNS 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
in IN 1_i
a DT 1_i
randomly NN 1_i
assigned VBN 1_i
sequence NN 1_i
. . 1_i

Drug JJ 1_o
effects NNS 1_o
were VBD 1_i
monitored VBN 1_i
by IN 1_i
ethological JJ 1_o
playroom NN 1_o
observation NN 1_o
and CC 1_i
by IN 1_i
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
ratings NNS 1_o
by IN 1_i
parents NNS 1_i
and CC 1_i
teachers NNS 1_i
. . 1_i

Data NNP N
of IN N
the DT N
playroom NN N
observation NN N
pointed VBD N
to TO N
an DT N
activating VBG 1_o
influence NN 1_o
of IN N
Org NNP N
2766 CD N
, , N
as IN N
revealed VBN N
by IN N
a DT N
significant JJ N
decrease NN N
of IN N
stereotypic NN 1_o
behavior NN 1_o
and CC N
significant JJ N
increases NNS N
in IN N
" JJ 1_o
change NN 1_o
toys NNS 1_o
, , 1_o
" NNP 1_o
" NNP 1_o
locomote NN 1_o
, , 1_o
" NNP 1_o
and CC 1_o
" NNP 1_o
talk NN 1_o
. . 1_o

" JJ 1_o
Checklist NNP N
ratings NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
. . N

The DT N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

Exemestane NN 1_i
for IN N
breast-cancer JJ 1_p
prevention NN 1_p
in IN 1_p
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

BACKGROUND NNP N
Tamoxifen NNP N
and CC N
raloxifene NN N
have VBP N
limited VBN N
patient JJ N
acceptance NN N
for IN N
primary JJ N
prevention NN N
of IN N
breast NN N
cancer NN N
. . N

Aromatase NNP N
inhibitors NNS N
prevent VBP N
more JJR N
contralateral JJ N
breast NN N
cancers NNS N
and CC N
cause NN N
fewer JJR N
side NN N
effects NNS N
than IN N
tamoxifen NN N
in IN N
patients NNS 1_p
with IN 1_p
early-stage JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
trial NN N
of IN N
exemestane NN 1_i
designed VBN N
to TO N
detect VB N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN N
in IN N
invasive JJ N
breast NN N
cancer NN N
, , N
eligible JJ 1_p
postmenopausal NN 1_p
women NNS 1_p
35 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
or CC 1_p
older JJR 1_p
had VBD 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
of IN 1_p
the DT 1_p
following JJ 1_p
risk NN 1_p
factors NNS 1_p
: : 1_p
60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
or CC 1_p
older JJR 1_p
; : 1_p
Gail NNP 1_p
5-year JJ 1_p
risk NN 1_p
score NN 1_p
greater JJR 1_p
than IN 1_p
1.66 CD 1_p
% NN 1_p
( ( 1_p
chances NNS 1_p
in IN 1_p
100 CD 1_p
of IN 1_p
invasive JJ 1_p
breast NN 1_p
cancer NN 1_p
developing VBG 1_p
within IN 1_p
5 CD 1_p
years NNS 1_p
) ) 1_p
; : 1_p
prior JJ 1_p
atypical JJ 1_p
ductal NN 1_p
or CC 1_p
lobular JJ 1_p
hyperplasia NN 1_p
or CC 1_p
lobular JJ 1_p
carcinoma NN 1_p
in IN 1_p
situ NN 1_p
; : 1_p
or CC 1_p
ductal JJ 1_p
carcinoma NN 1_p
in IN 1_p
situ NN 1_p
with IN 1_p
mastectomy NN 1_p
. . 1_p

Toxic NNP 1_o
effects NNS 1_o
and CC 1_o
health-related JJ 1_o
and CC 1_o
menopause-specific JJ 1_o
qualities NNS 1_o
of IN 1_o
life NN 1_o
were VBD N
measured VBN N
. . N

RESULTS VB N
A DT N
total NN 1_p
of IN 1_p
4560 CD 1_p
women NNS 1_p
for IN 1_p
whom WP 1_p
the DT 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
62.5 CD 1_p
years NNS 1_p
and CC 1_p
the DT 1_p
median JJ 1_o
Gail NNP 1_o
risk NN 1_o
score NN 1_o
was VBD 1_p
2.3 CD 1_p
% NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
exemestane NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

At IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
11 CD N
invasive JJ N
breast NN N
cancers NNS N
were VBD N
detected VBN N
in IN N
those DT N
given VBN N
exemestane NN 1_i
and CC N
in IN N
32 CD N
of IN N
those DT N
given VBN N
placebo NNS 1_i
, , N
with IN N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN 1_o
in IN 1_o
the DT 1_o
annual JJ 1_o
incidence NN 1_o
of IN 1_o
invasive JJ 1_o
breast NN 1_o
cancer NN 1_o
( ( N
0.19 CD N
% NN N
vs. FW N
0.55 CD N
% NN N
; : N
hazard CC N
ratio NN N
, , N
0.35 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.18 CD N
to TO N
0.70 CD N
; : N
P=0.002 NNP N
) ) N
. . N

The DT N
annual JJ 1_o
incidence NN 1_o
of IN 1_o
invasive JJ 1_o
plus CC 1_o
noninvasive JJ 1_o
( ( 1_o
ductal JJ 1_o
carcinoma NN 1_o
in IN 1_o
situ NN 1_o
) ) 1_o
breast NN 1_o
cancers NNS 1_o
was VBD N
0.35 CD N
% NN N
on IN N
exemestane NN N
and CC N
0.77 CD N
% NN N
on IN N
placebo NN 1_i
( ( N
hazard JJ N
ratio NN N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.79 CD N
; : N
P=0.004 NNP N
) ) N
. . N

Adverse JJ 1_o
events NNS 1_o
occurred VBD N
in IN N
88 CD N
% NN N
of IN N
the DT N
exemestane NN N
group NN N
and CC N
85 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
P=0.003 NNP N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
skeletal JJ 1_o
fractures NNS 1_o
, , 1_o
cardiovascular JJ 1_o
events NNS 1_o
, , 1_o
other JJ 1_o
cancers NNS 1_o
, , 1_o
or CC 1_o
treatment-related JJ 1_o
deaths NNS 1_o
. . 1_o

Minimal JJ N
quality-of-life JJ 1_o
differences NNS N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Exemestane NNP 1_i
significantly RB N
reduced VBD N
invasive JJ 1_p
breast NN 1_p
cancers NNS 1_p
in IN 1_p
postmenopausal JJ 1_p
women NNS 1_p
who WP 1_p
were VBD 1_p
at IN 1_p
moderately RB 1_p
increased VBN 1_p
risk NN 1_p
for IN 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

During IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
3 CD N
years NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
no DT N
serious JJ N
toxic NN N
effects NNS N
and CC N
only RB N
minimal JJ N
changes NNS N
in IN N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

( ( N
Funded VBN N
by IN N
Pfizer NNP N
and CC N
others NNS N
; : N
NCIC NNP N
CTG NNP N
MAP.3 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00083174 NNP N
. . N

) ) N
. . N

Measurement NN N
of IN N
peptidase NN 1_o
activity NN 1_o
and CC N
evaluation NN N
of IN N
effectiveness NN N
of IN N
administration NN N
of IN N
minocycline NN 1_i
for IN N
treatment NN N
of IN N
dogs NNS 1_p
with IN 1_p
periodontitis NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
determine VB N
clinical JJ 1_o
, , 1_o
enzymatic JJ 1_o
, , 1_o
and CC 1_o
microbiologic JJ 1_o
effects NNS 1_o
of IN N
controlled-release NN N
localized JJ N
administration NN N
of IN N
minocycline NN 1_i
on IN N
dogs NNS 1_p
with IN 1_p
periodontitis NN 1_p
. . 1_p

ANIMALS NNP N
Five CD 1_p
adult NN 1_p
Beagles NNS 1_p
with IN 1_p
periodontitis NN 1_p
. . 1_p

PROCEDURE NNP N
After IN N
tooth CC N
scaling VBG N
and CC N
root NN N
planing NN N
, , N
2 CD N
treatment NN N
, , N
1 CD N
placebo NN N
, , N
and CC N
1 CD N
control NN N
site NN N
were VBD N
selected VBN N
for IN N
each DT N
dog NN N
. . N

Treatment NN N
sites NNS N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
received VBD N
a DT N
periodontal JJ 1_i
formulation NN 1_i
of IN 1_i
minocycline NN 1_i
hydrochloride NN 1_i
, , 1_i
placebo NN 1_i
sites NNS N
( ( N
5 CD N
) ) N
received VBD 1_i
ointment JJ 1_i
without IN 1_i
minocycline NN 1_i
, , 1_i
and CC 1_i
control VB 1_i
sites NNS 1_i
( ( 1_i
5 CD 1_i
) ) 1_i
did VBD 1_i
not RB 1_i
receive VB 1_i
ointment NN 1_i
. . 1_i

Treatments NNS N
were VBD N
administered VBN N
4 CD N
times NNS N
at IN N
weekly JJ N
intervals NNS N
. . N

Peptidase NNP 1_o
activity NN 1_o
and CC 1_o
clinical JJ 1_o
and CC 1_o
microbiologic JJ 1_o
effects NNS 1_o
were VBD N
evaluated VBN N
and CC N
compared VBN N
among IN N
sites NNS N
for IN N
17 CD N
weeks NNS N
. . N

RESULTS NNP N
Bleeding NNP 1_o
of IN 1_o
the DT 1_o
gums NNS 1_o
on IN 1_o
probing VBG 1_o
( ( 1_o
BOP NNP 1_o
) ) 1_o
and CC 1_o
pocket NN 1_o
depth NN 1_o
( ( 1_o
PD NNP 1_o
) ) 1_o
improved VBD 1_o
at IN N
the DT N
treatment NN N
site NN N
and CC N
were VBD N
maintained VBN N
for IN N
13 CD N
weeks NNS N
after IN N
treatment NN N
. . N

However RB N
, , N
BOP NNP 1_o
and CC 1_o
PD NNP 1_o
in IN N
placebo NN N
and CC N
control VB N
sites NNS N
increased VBN N
from IN N
weeks NNS N
9 CD N
to TO N
17 CD N
Peptidase NNP 1_o
activity NN 1_o
in IN N
the DT N
periodontal JJ N
pocket NN N
decreased VBD N
noticeably RB N
from IN N
week NN N
1 CD N
to TO N
17 CD N
, , N
compared VBN N
with IN N
baseline NN N
values NNS N
for IN N
the DT N
treatment NN N
site NN N
. . N

However RB N
, , N
peptidase NN 1_o
activity NN 1_o
for IN N
placebo NN N
and CC N
control VB N
sites NNS N
increased VBN N
and CC N
were VBD N
above RB N
baseline JJ N
values NNS N
on IN N
week NN N
9 CD N
and CC N
week NN N
13 CD N
, , N
respectively RB N
. . N

Total JJ 1_o
bacterial JJ 1_o
counts NNS 1_o
decreased VBN N
by IN N
90 CD N
% NN N
for IN N
treatment NN N
sites NNS N
and CC N
remained VBD N
at IN N
that DT N
value NN N
for IN N
13 CD N
weeks NNS N
. . N

However RB N
, , N
for IN N
placebo NN N
and CC N
control NN N
sites NNS N
, , N
bacterial JJ 1_o
counts NNS 1_o
increased VBD N
and CC N
reached VBD N
the DT N
baseline NN N
value NN N
on IN N
week NN N
17 CD N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
Increased VBD 1_o
peptidase NN 1_o
activity NN 1_o
is VBZ N
correlated VBN N
with IN N
the DT N
progression NN N
of IN N
periodontitis NN 1_p
in IN 1_p
dogs NNS 1_p
. . 1_p

Treatment NN N
with IN N
minocycline NN 1_i
, , N
using VBG N
a DT N
localized VBN N
delivery NN N
system NN N
, , N
was VBD N
effective JJ N
in IN N
dogs NNS N
for IN N
at IN N
least JJS N
13 CD N
weeks NNS N
after IN N
cessation NN N
of IN N
drug NN N
administration NN N
. . N

The DT N
effect NN N
of IN N
a DT N
parent-implemented JJ 1_i
imitation NN 1_i
intervention NN 1_i
on IN N
spontaneous JJ 1_o
imitation NN 1_o
skills NNS 1_o
in IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Children NNP 1_p
with IN 1_p
autism NN 1_p
exhibit NN N
significant JJ N
deficits NNS N
in IN N
their PRP$ N
ability NN N
to TO N
spontaneously RB 1_o
imitate VB 1_o
the DT N
play NN 1_o
actions NNS 1_o
and CC 1_o
descriptive JJ 1_o
gestures NNS 1_o
of IN N
others NNS N
. . N

Reciprocal JJ 1_i
imitation NN 1_i
training NN 1_i
( ( 1_i
RIT NNP 1_i
) ) 1_i
is VBZ 1_i
a DT 1_i
naturalistic JJ 1_i
imitation NN 1_i
intervention NN 1_i
designed VBN N
to TO N
teach VB N
spontaneous JJ 1_o
imitation NN 1_o
skills NNS 1_o
during IN N
play NN N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effectiveness NN 1_o
of IN N
parent-implemented JJ N
RIT NNP 1_i
using VBG N
a DT N
multiple-baseline JJ N
design NN N
across IN N
three CD 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
their PRP$ 1_p
mothers NNS 1_p
. . 1_p

After IN N
an DT N
initial JJ N
baseline NN N
, , N
mothers NNS N
were VBD N
taught VBN N
to TO N
implement VB N
RIT NNP 1_i
techniques NNS N
with IN N
their PRP$ N
child NN N
twice RB N
a DT N
week NN N
for IN N
10 CD N
weeks NNS N
in IN N
a DT N
clinic JJ N
setting NN N
. . N

Two CD N
mothers NNS N
were VBD N
taught VBN N
to TO N
use VB N
RIT NNP 1_i
to TO N
teach VB N
object JJ N
imitation NN N
. . N

The DT N
third JJ N
mother NN N
was VBD N
taught VBN N
to TO N
use VB N
RIT NNP 1_i
to TO N
target VB N
both DT N
object JJ N
and CC N
gesture JJ N
imitation NN N
in IN N
a DT N
multiple-baseline JJ N
design NN N
across IN N
behaviors NNS N
. . N

Generalization NNP N
was VBD N
assessed VBN N
in IN N
the DT N
families NNS N
' POS N
homes NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
and CC N
a DT N
1-month JJ N
follow-up NN N
. . N

Parents NNS N
learned VBD 1_o
to TO N
use VB N
the DT N
intervention NN N
strategies NNS N
and CC N
their PRP$ N
children NNS N
exhibited VBN N
increases NNS N
in IN N
spontaneous JJ 1_o
imitation NN 1_o
. . 1_o

These DT N
findings NNS N
replicate VBP N
the DT N
results NNS N
from IN N
previous JJ N
studies NNS N
, , N
indicating VBG N
that IN N
RIT NNP N
is VBZ N
effective JJ N
for IN N
teaching VBG N
imitation NN 1_o
skills NNS 1_o
to TO N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
in IN N
a DT N
naturalistic JJ N
setting NN N
and CC N
extend VB N
the DT N
findings NNS N
to TO N
parents NNS 1_p
. . 1_p

Polycystic JJ N
ovary JJ N
syndrome NN N
and CC N
cardiovascular JJ N
risk NN N
in IN N
young JJ 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
drospirenone-ethinylestradiol NN 1_i
or CC 1_i
contraceptive JJ 1_i
vaginal JJ 1_i
ring NN 1_i
. . 1_i

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
pill NN 1_i
containing VBG 1_i
drospirenone NN 1_i
with IN 1_i
those DT 1_i
of IN 1_i
a DT 1_i
combined JJ 1_i
contraceptive JJ 1_i
vaginal JJ 1_i
ring NN 1_i
on IN 1_i
the DT N
lipid JJ N
and CC N
carbohydrate JJ N
metabolism NN N
and CC N
on IN N
the DT N
surrogate NN N
markers NNS N
of IN N
arterial JJ N
function NN N
. . N

SETTING NNP N
Bologna NNP 1_p
University NNP 1_p
School NNP 1_p
of IN 1_p
Medicine NNP 1_p
. . 1_p

PATIENT NNP N
( ( N
S NNP N
) ) N
Thirty-seven NNP 1_p
women NNS 1_p
with IN 1_p
polycystic JJ 1_p
ovary JJ 1_p
syndrome NN 1_p
( ( 1_p
PCOS NNP 1_p
) ) 1_p
were VBD N
randomly RB N
submitted VBN N
to TO N
drospirenone+ethinylestradiol VB 1_i
( ( N
group NN N
I PRP N
; : N
n=19 CC N
) ) N
or CC 1_i
combined VBN 1_i
contraceptive JJ 1_i
vaginal JJ 1_i
ring NN 1_i
( ( N
group NN N
II NNP N
; : N
n=18 CC N
) ) N
therapy NN 1_i
. . 1_i

The DT N
duration NN N
of IN N
the DT N
study NN N
was VBD N
6 CD N
months NNS N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
The DT N
effect NN N
of IN N
treatments NNS N
was VBD N
assessed VBN N
after IN N
6 CD 1_i
months NNS 1_i
of IN 1_i
therapy NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Utero-ovarian JJ 1_o
ultrasound JJ 1_o
analysis NN 1_o
and CC 1_o
color NN 1_o
Doppler NNP 1_o
evaluation NN 1_o
of IN 1_o
uterine JJ 1_o
and CC 1_o
stromal JJ 1_o
ovarian JJ 1_o
arteries NNS 1_o
. . 1_o

In IN N
addition NN N
, , N
analysis NN 1_o
of IN 1_o
brachial JJ 1_o
artery NN 1_o
flow-mediated JJ 1_o
vasodilatation NN 1_o
and CC 1_o
24-hour JJ 1_o
ambulatory NN 1_o
blood NN 1_o
pressure NN 1_o
monitoring NN 1_o
were VBD N
performed VBN N
. . N

Fasting VBG 1_o
blood NN 1_o
samples NNS 1_o
were VBD N
drawn VBN N
for IN N
testing VBG N
biochemical JJ N
and CC N
hormonal JJ N
parameters NNS N
and CC N
nitrites/nitrates NNS N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Both NNP N
treatments NNS N
improved VBD N
hirsutism NN 1_o
, , 1_o
hyperandrogenemia NN 1_o
, , 1_o
and CC 1_o
ultrasound NN 1_o
and CC 1_o
color NN 1_o
Doppler NNP 1_o
ovarian JJ 1_o
parameters NNS 1_o
. . 1_o

Both DT N
drospirenone+ethinylestradiol NN N
or CC N
contraceptive JJ N
vaginal JJ N
ring NN N
induced VBD N
a DT N
slight JJ N
but CC N
significant JJ N
increase NN N
of IN N
diurnal JJ 1_o
and CC 1_o
24-hour JJ 1_o
blood NN 1_o
pressure NN 1_o
. . 1_o

Although IN N
both DT N
therapies NNS N
worsened VBD N
the DT N
lipid JJ 1_o
profile NN 1_o
, , N
the DT N
oral JJ N
pill NN N
administration NN N
was VBD N
associated VBN N
with IN N
a DT N
more RBR N
evident JJ N
increase NN N
of IN N
circulating VBG 1_o
triglycerides NNS 1_o
. . 1_o

The DT N
6-month JJ N
treatment NN N
with IN N
the DT N
vaginal JJ N
ring NN N
significantly RB N
improved VBD N
the DT N
area NN 1_o
under IN 1_o
the DT 1_o
curve NN 1_o
for IN 1_o
glucose NN 1_o
, , 1_o
insulin NN 1_o
, , 1_o
and CC 1_o
C-peptide NNP 1_o
, , N
whereas IN N
the DT N
drospirenone+ethinylestradiol NN N
pill NN N
induced VBD N
an DT N
increase NN N
in IN N
the DT N
insulinogenic JJ 1_o
index NN 1_o
and CC N
homeostatic JJ 1_o
model NN 1_o
assessment NN 1_o
estimate NN 1_o
for IN 1_o
insulin NN 1_o
resistance NN 1_o
values NNS 1_o
. . 1_o

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Vaginal NNP N
hormonal JJ N
contraception NN N
appears VBZ N
to TO N
be VB N
preferable JJ N
to TO N
oral JJ N
ethinylestradiol NN N
+ NNP N
drospirenone NN N
administration NN N
in IN N
hyperinsulinemic JJ N
patients NNS N
with IN N
PCOS NNP N
. . N

Biventricular JJ N
pacing VBG N
improves NNS N
cardiac JJ 1_o
function NN 1_o
and CC N
prevents NNS N
further RBR N
left VBD 1_o
atrial JJ 1_o
remodeling NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
symptomatic JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
after IN 1_p
atrioventricular JJ 1_p
node JJ 1_p
ablation NN 1_p
. . 1_p

BACKGROUND NNP N
Randomized NNP N
trials NNS N
have VBP N
demonstrated VBN N
benefits NNS N
of IN N
biventricular NN 1_i
( ( 1_i
BiV NNP 1_i
) ) 1_i
pacing NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
heart NN 1_p
failure NN 1_p
, , 1_p
intraventricular JJ 1_p
conduction NN 1_p
delay NN 1_p
, , 1_p
and CC 1_p
atrial JJ 1_p
fibrillation NN 1_p
( ( 1_p
AF NNP 1_p
) ) 1_p
post-atrioventricular NN 1_p
( ( 1_p
AV NNP 1_p
) ) 1_p
node NN 1_p
ablation NN 1_p
. . 1_p

The DT N
AV NNP N
Node NNP N
Ablation NNP N
with IN N
CLS NNP N
and CC N
CRT NNP N
Pacing NNP N
Therapies NNP N
for IN N
Treatment NNP N
of IN N
AF NNP N
trial NN N
( ( N
AVAIL NNP N
CLS/CRT NNP N
) ) N
was VBD N
designed VBN N
to TO N
demonstrate VB N
superiority NN N
of IN N
BiV NNP N
pacing VBG N
in IN N
patients NNS N
with IN N
AF NNP N
after IN N
AV NNP N
node JJ N
ablation NN N
, , N
to TO N
evaluate VB N
its PRP$ N
effects NNS N
on IN N
cardiac JJ N
structure NN N
and CC N
function NN N
, , N
and CC N
to TO N
investigate VB N
additional JJ N
benefits NNS N
of IN N
Closed JJ N
Loop NNP N
Stimulation NNP N
( ( N
CLS NNP N
) ) N
( ( N
BIOTRONIK NNP N
, , N
Berlin NNP N
, , N
Germany NNP N
) ) N
. . N

METHODS JJ N
Patients NNS 1_p
with IN 1_p
refractory JJ 1_p
AF NNP 1_p
underwent NN 1_p
AV NNP 1_p
node CC 1_p
ablation NN 1_p
and CC N
were VBD N
randomized VBN N
( ( N
2:2:1 CD N
) ) N
to TO N
BiV NNP 1_i
pacing VBG 1_i
with IN 1_i
CLS NNP 1_i
, , 1_i
BiV NNP 1_i
pacing VBG 1_i
with IN 1_i
accelerometer NN 1_i
, , 1_i
or CC 1_i
right JJ 1_i
ventricular NN 1_i
( ( 1_i
RV NNP 1_i
) ) 1_i
pacing NN 1_i
. . 1_i

Echocardiography NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
, , N
with IN N
paired VBN N
data NNS N
available JJ N
for IN N
108 CD 1_p
patients NNS 1_p
. . 1_p

RESULTS VB N
The DT N
RV NNP N
pacing NN N
contributed VBD N
to TO N
significant JJ N
increase NN N
in IN N
left JJ 1_o
atrial JJ 1_o
volume NN 1_o
, , 1_o
left VBD 1_o
ventricular JJ 1_o
( ( 1_o
LV NNP 1_o
) ) 1_o
end-systolic JJ 1_o
volume NN 1_o
, , 1_o
and CC 1_o
LV NNP 1_o
mass NN 1_o
compared VBN N
to TO N
BiV NNP N
pacing NN N
. . N

Ejection NNP 1_o
fraction NN 1_o
decreased VBD N
insignificantly RB N
with IN N
RV NNP N
pacing VBG N
compared VBN N
to TO N
significant JJ N
increase NN N
with IN N
BiV NNP N
pacing VBG N
. . N

Interventricular JJ 1_o
dyssynchrony NN 1_o
significantly RB N
decreased VBN N
with IN N
BiV NNP N
compared VBN N
with IN N
RV NNP N
pacing VBG N
. . N

Closed VBN N
Loop NNP N
Stimulation NNP N
did VBD N
not RB N
result VB N
in IN N
additional JJ N
echocardiographic JJ 1_o
changes NNS 1_o
; : 1_o
heart NN 1_o
rate NN 1_o
distribution NN 1_o
was VBD N
significantly RB N
wider JJR N
with IN N
CLS NNP N
. . N

All DT N
groups NNS N
showed VBD N
significant JJ N
improvement NN N
in IN N
6-minute JJ 1_o
walk NN 1_o
distance NN 1_o
, , 1_o
quality-of-life JJ 1_o
score NN 1_o
, , 1_o
and CC 1_o
New NNP 1_o
York NNP 1_o
Heart NNP 1_o
Association NNP 1_o
class NN 1_o
. . 1_o

CONCLUSION NNP N
In IN N
conclusion NN N
, , N
RV NNP N
pacing VBG N
results NNS N
in IN N
significant JJ N
increase NN N
in IN N
left JJ 1_o
atrial JJ 1_o
volume NN 1_o
, , 1_o
LV NNP 1_o
mass NN 1_o
, , N
and CC N
worsening NN 1_o
of IN 1_o
LV NNP 1_o
contractility NN 1_o
compared VBN N
to TO N
patients NNS N
receiving VBG N
BiV NNP N
pacing VBG N
post-AV JJ N
node JJ N
ablation NN N
for IN N
refractory NN N
AF NNP N
. . N

Closed VBD N
Loop NNP N
Stimulation NNP N
was VBD N
not RB N
associated VBN N
with IN N
additional JJ N
structural JJ 1_o
changes NNS 1_o
but CC N
resulted VBD N
in IN N
significantly RB N
wider JJR 1_o
heart NN 1_o
rate NN 1_o
distribution NN 1_o
. . 1_o

Enhancing VBG N
HIV NNP N
medication NN N
adherence NN 1_o
in IN N
India NNP N
. . N

BACKGROUND NNP N
This DT N
pilot NN N
study NN N
evaluated VBD N
an DT N
intervention NN N
designed VBN N
to TO N
enhance VB N
adherence NN N
among IN N
those DT N
new JJ N
to TO N
antiretroviral JJ N
therapy NN N
. . N

METHODS NNP 1_p
Participants NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
80 CD 1_p
) ) 1_p
were VBD 1_p
recruited VBN 1_p
from IN 1_p
a DT 1_p
hospital NN 1_p
clinic NN 1_p
in IN 1_p
Chandigarh NNP 1_p
, , 1_p
India NNP 1_p
, , 1_p
and CC 1_p
randomized VBD 1_p
to TO 1_p
a DT 1_p
3-month JJ 1_i
group NN 1_i
intervention NN 1_i
or CC 1_i
individual JJ 1_i
enhanced JJ 1_i
standard NN 1_i
of IN 1_i
care NN 1_i
followed VBN 1_i
by IN 1_i
crossover NN 1_i
of IN 1_i
condition NN 1_i
and CC 1_i
assessed VBD 1_i
over IN 1_i
6 CD 1_i
months NNS 1_i
. . 1_i

Adherence NNP N
was VBD N
measured VBN N
by IN N
prescription NN 1_o
refill NN 1_o
, , 1_o
pill NN 1_o
count NN 1_o
, , 1_o
and CC 1_o
self-report NN 1_o
. . 1_o

RESULTS NNP N
At IN N
baseline NN N
, , N
56 CD N
% NN N
of IN N
group NN N
condition NN N
( ( N
immediate JJ N
intervention NN N
) ) N
and CC N
54 CD N
% NN N
of IN N
individual JJ N
condition NN N
( ( N
delayed VBN N
intervention NN N
) ) N
participants NNS N
were VBD N
nonadherent JJ N
by IN N
pill NN 1_o
count NN 1_o
and CC N
23 CD N
% NN N
of IN N
group NN N
and CC N
26 CD N
% NN N
of IN N
individual JJ N
condition NN N
participants NNS N
self-reported JJ 1_o
skipping JJ 1_o
medication NN 1_o
at IN N
least JJS N
once RB N
over IN N
the DT N
last JJ N
3 CD N
months NNS N
. . N

From IN N
the DT N
postintervention NN N
to TO N
long-term JJ N
follow-up NN N
, , N
adherence NN N
in IN N
the DT N
group NN N
condition NN N
( ( N
immediate JJ N
intervention NN N
) ) N
improved VBN N
in IN N
comparison NN N
with IN N
adherence NN N
in IN N
the DT N
individual JJ N
condition NN N
( ( N
delayed VBN N
intervention NN N
; : N
χ NNP N
( ( N
2 CD N
) ) N
= NN N
5.67 CD N
, , N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSIONS JJ N
Results NNP N
support NN N
the DT N
use NN N
of IN N
interventions NNS N
early RB N
in IN N
treatment NN N
to TO N
provide VB N
information NN N
and CC N
social JJ N
support NN N
to TO N
establish VB N
long-term JJ N
healthy JJ 1_o
adherence NN 1_o
behaviors NNS N
. . N

Treatments NNS N
of IN N
preterm JJ 1_p
premature JJ 1_p
rupture NN 1_p
of IN 1_p
the DT 1_p
membranes NNS 1_p
: : 1_p
a DT N
meta-analysis NN N
. . N

The DT N
objective NN N
of IN N
this DT N
overview NN N
was VBD N
to TO N
critically RB N
evaluate VB N
published VBN N
randomized JJ N
controlled VBN N
trials NNS N
on IN N
treatments NNS N
in IN N
preterm JJ 1_p
premature JJ 1_p
rupture NN 1_p
of IN 1_p
the DT 1_p
membranes NNS 1_p
. . 1_p

The DT N
Oxford NNP N
data NN N
base NN N
on IN N
perinatal JJ N
trials NNS N
, , N
MEDLINE NNP N
, , N
Excerpta NNP N
Medica NNP N
, , N
and CC N
Index NNP N
Medicus NNP N
were VBD N
searched VBN N
. . N

Through IN N
primary JJ N
and CC N
secondary JJ N
review NN N
with IN N
preset JJ N
inclusion NN N
criteria NNS N
, , N
two CD N
independent JJ N
judges NNS N
identified VBD N
27 CD 1_p
randomized VBN 1_p
controlled VBN 1_p
trials NNS 1_p
, , 1_p
of IN 1_p
which WDT 1_p
13 CD 1_p
met VBD 1_p
inclusion NN 1_p
criteria NNS 1_p
. . 1_p

The DT N
quality NN N
of IN N
these DT N
randomized VBN N
controlled VBD N
trials NNS N
was VBD N
scored VBN N
. . N

Five CD 1_p
randomized VBN 1_p
controlled VBN N
trials NNS N
regarding VBG N
antenatal JJ N
use NN N
of IN N
corticosteroids NNS 1_i
to TO N
prevent VB N
respiratory JJ 1_o
distress JJ 1_o
syndrome NN 1_o
could MD N
be VB N
combined VBN N
meta-analytically RB N
and CC N
showed VBD N
a DT N
reduction NN N
in IN N
respiratory NN 1_o
distress NN 1_o
syndrome NN 1_o
in IN N
the DT N
treatment NN N
group NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
no DT N
significant JJ N
reduction NN N
in IN N
respiratory NN 1_o
distress NN 1_o
syndrome NN 1_o
( ( N
p JJ N
= NNP N
0.286 CD N
) ) N
was VBD N
found VBN N
after IN N
one CD N
study NN N
, , N
with IN N
the DT N
lowest JJS N
quality NN N
score NN N
, , N
was VBD N
excluded VBN N
. . N

A DT N
significant JJ N
increase NN N
in IN N
endometritis NN 1_o
and CC N
a DT N
trend NN N
toward IN N
an DT N
increase NN N
in IN N
neonatal JJ 1_o
infections NNS 1_o
and CC 1_o
cesarean JJ 1_o
section NN 1_o
rates NNS 1_o
were VBD N
noted VBN N
with IN N
treatment NN N
. . N

Tocolysis NN 1_i
, , 1_i
prophylactic JJ 1_i
antibiotics NNS 1_i
, , N
and CC N
other JJ N
interventions NNS N
studied VBN N
were VBD N
not RB N
found VBN N
to TO N
be VB N
of IN N
proved JJ N
benefit NN N
and CC N
therefore RB N
should MD N
not RB N
be VB N
used VBN N
outside IN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

The DT N
dud JJ N
effect NN N
: : N
adding VBG 1_p
highly RB 1_p
dissimilar JJ 1_p
fillers NNS 1_p
increases VBZ 1_p
confidence NN 1_p
in IN N
lineup JJ 1_p
identifications NNS 1_p
. . 1_p

Recent JJ N
research NN N
in IN N
decision-making NN N
has VBZ N
demonstrated VBN N
the DT N
" JJ N
dud-alternative JJ N
effect NN N
" NNP N
-- : N
the DT N
tendency NN N
to TO N
become VB N
more RBR N
confident JJ N
that IN N
a DT N
chosen NN N
response NN N
option NN N
is VBZ N
correct JJ N
if IN N
it PRP N
is VBZ N
surrounded VBN N
by IN N
implausible JJ N
response NN N
options NNS N
( ( N
Windschitl NNP N
& CC N
Chambers NNP N
, , N
J NNP N
Exp NNP N
Psychol NNP N
30:198-215 CD N
, , N
2004 CD N
) ) N
. . N

This DT N
finding NN N
may MD N
be VB N
applicable JJ N
to TO N
a DT N
lineup NN N
task NN N
: : N
The DT N
presence NN N
of IN N
duds NN N
( ( N
i.e. FW N
, , N
highly RB N
dissimilar JJ N
fillers NNS N
) ) N
may MD N
increase VB N
a DT N
witness NN 1_o
's POS 1_o
confidence NN 1_o
that IN N
an DT N
identified VBN 1_p
( ( 1_p
non-dud JJ 1_p
) ) 1_p
lineup NN 1_p
member NN 1_p
is VBZ N
the DT N
criminal JJ N
. . N

Four CD 1_p
studies NNS 1_p
( ( 1_p
N NNP 1_p
= NNP N
665 CD N
) ) N
demonstrate NN N
that IN N
the DT N
mere JJ N
presence NN N
of IN N
highly RB N
dissimilar JJ N
fillers NNS N
inflates VBZ N
witnesses NNS 1_o
' POS 1_o
confidence NN 1_o
in IN N
a DT N
mistaken JJ N
identification NN N
( ( N
Studies NNP N
1-4 CD N
) ) N
, , N
provides VBZ N
evidence NN N
that IN N
this DT N
confidence NN 1_o
inflation NN 1_o
is VBZ N
due JJ N
to TO N
the DT N
duds NN N
inflating VBG N
the DT N
perceived JJ N
similarity NN N
of IN N
the DT N
other JJ N
lineup NN N
members NNS N
to TO N
the DT N
criminal NN N
( ( N
Studies NNPS N
2 CD N
, , N
3 CD N
) ) N
, , N
and CC N
delineates VBZ N
some DT N
conditions NNS N
under IN N
which WDT N
the DT N
effect NN N
holds VBZ N
( ( N
Studies NNPS N
3 CD N
, , N
4 CD N
) ) N
. . N

The DT N
addition NN N
of IN N
highly RB N
dissimilar JJ 1_i
lineup NN 1_i
members NNS 1_i
, , N
far RB N
from IN N
being VBG N
inert JJ N
, , N
as IN N
is VBZ N
often RB N
implicitly RB N
assumed VBN N
, , N
can MD N
bias VB N
witnesses NNS 1_p
' POS 1_p
confidence NN N
reports NNS N
. . N

Femoral NNP N
neck NN N
osteotomy NN N
guide NN N
for IN N
total JJ 1_p
hip NN 1_p
arthroplasty NN 1_p
. . 1_p

BACKGROUND NNP N
Total NNP 1_i
hip NN 1_i
arthroplasty NN 1_i
( ( 1_i
THA NNP 1_i
) ) 1_i
is VBZ N
a DT N
common JJ N
last-resort NN N
treatment NN N
for IN N
hip NN N
disease NN N
, , N
but CC N
postoperative JJ 1_p
patients NNS 1_p
often RB N
complain VBP N
of IN N
discrepancies NNS N
in IN N
leg JJ N
length NN N
. . N

This DT N
study NN N
introduces VBZ N
a DT N
device NN N
designed VBN N
to TO N
increase VB N
the DT N
precision NN 1_o
of IN 1_o
the DT 1_o
femoral JJ 1_o
neck NN 1_o
osteotomy NN 1_o
and CC N
reduce VB N
the DT N
incidence NN 1_o
of IN 1_o
leg JJ 1_o
length NN 1_o
discrepancy NN 1_o
. . 1_o

METHODS NNP N
Forty-eight JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
THA NNP 1_i
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
with IN N
and CC N
without IN N
the DT N
use NN N
of IN N
the DT N
femoral JJ 1_i
osteotomy NN 1_i
guide NN 1_i
. . 1_i

All DT N
operations NNS N
were VBD N
performed VBN N
through IN N
a DT N
posterolateral JJ N
approach NN N
. . N

Differences NNS 1_o
in IN 1_o
leg JJ 1_o
length NN 1_o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
the DT N
operation NN N
. . N

Measurements NNS N
were VBD N
also RB N
made VBN N
to TO N
compare VB N
the DT N
preoperative JJ 1_o
plan NN 1_o
with IN N
the DT N
actual JJ 1_o
amount NN 1_o
of IN 1_o
bone NN 1_o
removed VBN 1_o
. . 1_o

RESULTS VB N
The DT N
mean JJ 1_o
average JJ 1_o
difference NN 1_o
in IN 1_o
femoral JJ 1_o
neck NN 1_o
resection NN 1_o
height NN 1_o
was VBD N
0.84 CD N
mm NN N
when WRB N
using VBG N
the DT N
osteotomy NN N
guide NN N
and CC N
1.69 CD N
mm NN N
without IN N
the DT N
guide NN 1_o
. . 1_o

Discrepancies NNS 1_o
in IN 1_o
postoperative JJ 1_o
leg NN 1_o
length NN 1_o
were VBD N
5.45 CD N
mm NNS N
and CC N
13.37 CD N
mm NN N
in IN N
the DT N
groups NNS N
with IN N
and CC N
without IN N
the DT N
guide NN N
, , N
respectively RB N
. . N

CONCLUSION VB 1_i
The DT 1_i
femoral JJ 1_i
neck NN 1_i
osteotomy NN 1_i
guide NN 1_i
is VBZ N
an DT N
effectively RB N
auxiliary JJ N
tool NN N
for IN N
increasing VBG N
the DT 1_o
accuracy NN 1_o
of IN 1_o
bone NN 1_o
resection NN 1_o
in IN 1_p
arthroplasty JJ 1_p
using VBG 1_p
the DT 1_p
posterolateral JJ 1_p
approach NN 1_p
. . N

TRIAL NNP N
REGISTRATION NNP N
ChiCTR-OOC-15005904 NNP N
; : N
date NN N
: : N
2015-01-30 JJ N
. . N

A DT N
pilot NN N
study NN N
to TO N
improve VB N
venipuncture NN 1_o
compliance NN 1_o
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

OBJECTIVE NNP N
Medical NNP N
procedures NNS N
, , N
particularly RB N
venipuncture NN N
( ( N
the DT N
puncture NN N
of IN N
a DT N
vein NN N
especially RB N
for IN N
the DT N
withdrawal NN N
of IN N
blood NN N
) ) N
, , N
can MD N
cause VB N
serious JJ 1_o
distress NN 1_o
and CC N
behavior JJ 1_o
disturbance NN 1_o
for IN N
many JJ N
children NNS N
. . N

Noncompliance NN N
to TO N
blood VB N
draws NNS N
can MD N
have VB N
significant JJ N
ramifications NNS N
in IN N
both DT N
research NN N
and CC N
clinical JJ N
settings NNS N
. . N

The DT N
negative JJ 1_o
reactions NNS 1_o
may MD N
be VB N
exacerbated VBN N
in IN N
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Even RB N
so RB N
, , N
there EX N
has VBZ N
been VBN N
little JJ N
research NN N
into IN N
the DT N
prevalence NN N
of IN N
the DT N
problem NN N
or CC N
effective JJ N
intervention NN N
procedures NNS N
. . N

In IN N
response NN N
to TO N
these DT N
concerns NNS N
, , N
we PRP N
developed VBD N
and CC N
evaluated VBD N
the DT N
Blood NNP 1_i
Draw NNP 1_i
Intervention NNP 1_i
Program NNP 1_i
. . 1_i

The DT N
program NN N
was VBD N
designed VBN N
to TO N
be VB N
easy JJ N
to TO N
use VB N
, , N
require VB N
little JJ N
provider NN N
or CC N
family NN N
time NN N
, , N
effectively RB N
reduce VB N
negative JJ 1_o
behaviors NNS 1_o
, , N
and CC N
increase VB 1_o
blood NN 1_o
draw JJ 1_o
compliance NN 1_o
. . 1_o

METHOD NNP N
In IN N
a DT N
quasi-randomized JJ N
trial NN N
over IN N
the DT N
course NN N
of IN N
∼ JJ N
18 CD N
months NNS 1_p
, , 1_p
58 CD 1_p
of IN 1_p
210 CD 1_p
families NNS 1_p
with IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
participating VBG 1_p
in IN 1_p
a DT 1_p
larger JJR 1_p
study NN 1_p
of IN 1_p
phenotypic NN 1_p
and CC 1_p
genotypic NN 1_p
factors NNS 1_p
reported VBD 1_p
significant JJ 1_p
concerns NNS 1_p
about IN 1_p
blood NN 1_p
draws NNS 1_p
and CC 1_p
elected VBN 1_p
to TO 1_p
use VB 1_p
the DT 1_p
Blood NNP 1_p
Draw NNP 1_p
Intervention NNP 1_p
Program NNP 1_p
. . N

RESULTS NNP N
Completion NNP N
of IN N
the DT N
program NN N
increased VBD 1_o
blood NN 1_o
draw NN 1_o
compliance NN 1_o
rates NNS 1_o
from IN N
85.4 CD N
% NN N
to TO N
96.6 CD N
% NN N
( ( N
odds NNS N
ratio VBP N
= JJ N
4.80 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
= VBD N
1.12 CD N
, , N
20.59 CD N
; : N
p NN N
= NNP N
.03 NNP N
) ) N
. . N

CONCLUSION NNP N
Results NNP N
indicate VBP N
the DT N
efficacy NN N
of IN N
the DT N
program NN N
in IN N
a DT N
research NN N
setting NN N
and CC N
suggest VB N
a DT N
potential JJ N
clinical JJ N
application NN N
. . N

The DT N
current JJ N
intervention NN N
, , N
unlike IN N
many JJ N
others NNS N
for IN N
the DT N
same JJ N
or CC N
similar JJ N
difficulties NNS N
proposed VBN N
in IN N
the DT N
past NN N
, , N
was VBD N
successful JJ N
without IN N
requiring VBG N
extensive JJ N
time NN N
, , N
training NN N
, , N
or CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
providers NNS N
and CC N
parents NNS N
or CC N
their PRP$ N
children NNS N
, , N
nor CC N
did VBD N
it PRP N
require VB N
large-scale JJ N
institutional JJ N
changes NNS N
. . N

A DT N
randomized JJ N
double-blind NN N
study NN N
of IN N
atomoxetine JJ 1_i
versus NN N
placebo NN 1_i
for IN N
attention-deficit/hyperactivity NN 1_p
disorder NN 1_p
symptoms NNS 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
efficacy NN N
of IN N
atomoxetine NN 1_i
as IN N
treatment NN N
of IN N
symptoms NNS N
of IN N
attention-deficit/hyperactivity NN 1_p
disorder NN 1_p
( ( 1_p
ADHD NNP 1_p
) ) 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
has VBZ N
not RB N
been VBN N
established VBN N
. . N

METHOD NNP N
In IN N
this DT N
study NN N
, , N
97 CD 1_p
patients NNS 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
with IN 1_p
ADHD NNP 1_p
and CC 1_p
ASD NNP 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
double-blind VB N
treatment NN N
with IN N
1.2 CD N
mg/kg/day JJ N
atomoxetine NN 1_i
or CC 1_i
placebo NN 1_i
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
ADHD NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
( ( 1_o
ADHD-RS NNP 1_o
) ) 1_o
score NN 1_o
; : 1_o
secondary JJ 1_o
endpoints NNS 1_o
were VBD 1_o
the DT 1_o
Clinical JJ 1_o
Global NNP 1_o
Impression NNP 1_o
of IN 1_o
ADHD-Improvement NNP 1_o
( ( 1_o
CGI-I NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
Conners NNP 1_o
Teacher NNP 1_o
Rating VBG 1_o
Scale-Revised JJ 1_o
: : 1_o
Short JJ 1_o
Form NNP 1_o
( ( 1_o
CTRS-R JJ 1_o
: : 1_o
S NN 1_o
) ) 1_o
score NN 1_o
. . 1_o

RESULTS NNP N
Baseline NNP N
mean JJ N
ADHD-RS NNP 1_o
scores NNS N
for IN N
atomoxetine JJ 1_i
versus NN N
placebo NN 1_i
were VBD N
40.7 CD N
and CC N
38.6 CD N
; : N
after IN N
8 CD N
weeks NNS N
, , N
mixed-effect JJ N
model NN N
repeated-measure NN N
means NNS N
were VBD N
31.6 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
29.2-33.9 JJ N
) ) N
and CC N
38.3 CD N
( ( N
36.0-40.6 CD N
) ) N
, , N
respectively RB N
, , N
with IN N
a DT N
difference NN N
in IN N
least JJS N
square JJ N
means NNS N
of IN N
-6.7 NNP N
( ( N
-10.0 UH N
to TO N
-3.4 VB N
; : N
p CC N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
CTRS-R JJ 1_o
: : 1_o
S NNP 1_o
Hyperactivity NNP N
subscore NN N
also RB N
improved VBN N
significantly RB N
for IN N
atomoxetine NN 1_i
compared VBN N
with IN N
placebo NN 1_i
, , N
but CC N
not RB N
the DT N
other JJ N
CTRS-R JJ 1_o
: : 1_o
S JJ 1_o
subscores NNS N
. . N

However RB N
, , N
there EX N
were VBD N
not RB N
significantly RB N
more RBR N
patients NNS N
on IN N
atomoxetine NN 1_i
( ( N
20.9 CD N
% NN N
) ) N
who WP N
improved VBD N
much RB N
, , N
or CC N
very RB N
much JJ N
according VBG N
to TO N
the DT N
CGI-I NNP N
, , N
than IN N
on IN N
placebo NN 1_i
( ( N
8.7 CD N
% NN N
; : N
p CC N
= VB N
0.14 CD N
) ) N
. . N

Adverse JJ N
events NNS N
( ( N
mostly RB N
nausea RB 1_o
, , N
decrease NN N
in IN N
appetite NN 1_o
, , 1_o
fatigue NN 1_o
, , 1_o
and CC 1_o
early JJ 1_o
morning NN 1_o
awakening VBG 1_o
) ) 1_o
were VBD N
reported VBN N
in IN N
81.3 CD N
% NN N
of IN N
atomoxetine JJ 1_i
patients NNS N
and CC N
65.3 CD N
% NN N
of IN N
placebo NN 1_i
patients NNS N
( ( N
p JJ N
> NNP N
.1 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ 1_o
events NNS 1_o
. . 1_o

CONCLUSIONS NNP N
Atomoxetine NNP 1_i
moderately RB N
improved VBD N
ADHD NNP N
symptoms NNS N
in IN N
patients NNS N
with IN N
ASD NNP N
and CC N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

Adverse JJ N
events NNS N
in IN N
this DT N
study NN N
were VBD N
similar JJ N
to TO N
those DT N
in IN N
other JJ N
studies NNS N
with IN N
ADHD NNP 1_p
patients NNS 1_p
without IN 1_p
ASD NNP 1_p
. . 1_p

Clinical JJ N
trial NN N
registration NN N
information-A JJ N
Randomized NNP N
Double-Blind NNP N
Study NNP N
of IN N
Atomoxetine NNP 1_i
Versus NNP N
Placebo NNP 1_i
for IN N
ADHD NNP N
Symptoms NNP N
in IN N
Children NNP 1_p
with IN 1_p
ASD NNP 1_p
; : 1_p
www.clinicaltrials.gov NN N
; : N
NCT00380692 NNP N
. . N

Gemcitabine NNP 1_i
combined VBN 1_i
with IN 1_i
either DT 1_i
pemetrexed NN 1_i
or CC 1_i
paclitaxel NN 1_i
in IN 1_i
the DT N
treatment NN N
of IN N
advanced JJ 1_p
non-small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
: : 1_p
a DT N
randomized JJ N
phase NN N
II NNP N
SICOG NNP N
trial NN N
. . N

PURPOSE NNP N
To TO N
estimate VB N
the DT N
safety NN 1_o
, , 1_o
activity NN 1_o
, , 1_o
and CC 1_o
impact NN 1_o
on IN 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
a DT N
combination NN 1_i
of IN 1_i
gemcitabine NN 1_i
and CC 1_i
pemetrexed NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
locally RB 1_p
advanced JJ 1_p
or CC 1_p
metastatic JJ 1_p
non-small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
( ( 1_p
NSCLC NNP 1_p
) ) 1_p
in IN N
the DT N
context NN N
of IN N
a DT N
randomized JJ N
two-stage NN N
phase NN N
II NNP N
study NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS 1_p
in IN 1_p
stage NN 1_p
IIIB NNP 1_p
or CC 1_p
IV NNP 1_p
NSCLC NNP 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT 1_i
gemcitabine NN 1_i
1250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
, , N
and CC 1_i
pemetrexed NN 1_i
( ( N
Alimta NNP N
) ) N
500 CD N
mg/m NN N
( ( N
2 CD N
) ) N
followed VBN 1_i
by IN 1_i
gemcitabine NN 1_i
1250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
8 CD N
of IN N
a DT N
3-weekly JJ N
cycle NN N
( ( 1_i
GA NNP 1_i
arm NN N
) ) N
, , N
or CC N
paclitaxel VB 1_i
120 CD N
mg/m NN N
( ( N
2 CD N
) ) N
followed VBN 1_i
by IN 1_i
gemcitabine NN 1_i
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
both DT N
given VBN N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
of IN N
a DT N
3-weekly JJ N
cycle NN N
( ( 1_i
PG NNP 1_i
arm NN N
) ) N
. . N

RESULTS $ N
105 CD 1_p
( ( 1_p
GA NNP 1_p
arm NN 1_p
, , 1_p
51 CD 1_p
; : 1_p
PG NNP 1_p
arm NN 1_p
, , 1_p
54 CD 1_p
) ) 1_p
eligible JJ 1_p
patients NNS 1_p
( ( 1_p
stage NN 1_p
IV NNP 1_p
, , 1_p
32 CD 1_p
and CC 1_p
30 CD 1_p
, , 1_p
respectively RB 1_p
) ) 1_p
were VBD N
enrolled VBN N
into IN N
this DT N
study NN N
; : N
thereafter RB N
, , N
accrual JJ N
was VBD N
stopped VBN N
due JJ N
to TO N
first-stage JJ N
analysis NN N
. . N

The DT N
response NN 1_o
rate NN 1_o
was VBD N
20 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
10-33 CD N
% NN N
) ) N
in IN N
the DT N
GA NNP N
arm NN N
, , N
and CC N
32 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
20-46 CD N
% NN N
) ) N
in IN N
the DT N
PG NNP N
arm NN N
. . N

Median JJ 1_o
progression-free JJ 1_o
survival NN 1_o
was VBD N
5.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
3.7-6.5 JJ N
) ) N
months NNS N
in IN N
the DT N
GA NNP N
arm NN N
, , N
and CC N
8.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.9-10.7 JJ N
) ) N
months NNS N
in IN N
the DT N
PG NNP N
arm NN N
, , N
while IN N
median JJ 1_o
overall JJ 1_o
survival NN 1_o
was VBD N
10.5 CD N
( ( N
95 CD N
% NN N
CI NNP N
7.1-13.9 CD N
) ) N
, , N
and CC N
13.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.7-14.9 CD N
) ) N
months NNS N
, , N
respectively RB N
. . N

Severe NNP 1_o
neutropenia NN 1_o
( ( N
36 CD N
% NN N
vs JJ N
22 CD N
% NN N
) ) N
, , N
and CC N
febrile JJ 1_o
neutropenia NN 1_o
( ( N
14 CD N
% NN N
vs JJ N
7 CD N
% NN N
) ) N
were VBD N
more RBR N
common JJ N
with IN N
the DT N
GA NNP N
regimen NNS N
, , N
while IN N
hair JJ 1_o
loss NN 1_o
( ( N
52 CD N
% NN N
vs JJ N
16 CD N
% NN N
) ) N
and CC N
any DT 1_o
grade JJ 1_o
peripheral JJ 1_o
neuropathy NN 1_o
( ( N
31 CD N
% NN N
vs JJ N
2 CD N
% NN N
) ) N
occurred VBD N
more RBR N
frequently RB N
with IN N
PG NNP 1_i
regimen NNS 1_i
. . 1_i

Other JJ N
severe JJ 1_o
side NN 1_o
effects NNS 1_o
of IN N
GA NNP 1_i
regimen NNS 1_i
were VBD N
diarrhoea JJ 1_o
( ( N
10 CD N
% NN N
) ) N
, , N
liver RB 1_o
enzyme JJ 1_o
derangement NN 1_o
( ( N
10 CD N
% NN N
) ) N
, , N
and CC N
fatigue NN 1_o
( ( N
8 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
GA NNP N
regimen NN N
was VBD N
tolerated VBN 1_o
and CC 1_o
moderately RB 1_o
active JJ 1_o
in IN N
advanced JJ N
or CC N
metastatic JJ N
NSCLC NNP N
. . N

However RB N
, , N
this DT N
combination NN N
did VBD N
not RB N
yield VB N
any DT N
advantage NN N
in IN N
comparison NN N
with IN N
the DT N
PG NNP N
regimen NNS N
, , N
and CC N
does VBZ N
not RB N
deserve VB N
further JJ N
evaluation NN N
. . N

Effectiveness NN N
of IN N
a DT N
clinical JJ 1_i
intervention NN 1_i
in IN N
improving VBG N
pain NN N
control NN N
in IN N
outpatients NNS 1_p
with IN 1_p
cancer NN 1_p
treated VBN 1_p
by IN 1_p
radiation NN 1_i
therapy NN 1_i
. . 1_i

PURPOSE NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
multicomponent JJ 1_i
clinical JJ 1_i
intervention NN 1_i
to TO N
reduce VB N
pain NN N
in IN N
outpatients NNS 1_p
with IN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
AND CC N
MATERIALS NNP N
Sixty-four JJ 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
clinical JJ 1_i
intervention NN 1_i
including VBG N
an DT N
information NN 1_i
session NN 1_i
, , N
the DT N
use NN N
of IN N
a DT N
pain NN 1_i
diary JJ 1_i
, , N
and CC N
the DT N
possibility NN N
to TO N
contact VB 1_i
a DT 1_i
physician NN 1_i
to TO N
adjust VB N
the DT N
pain NN N
medication NN N
, , N
or CC 1_i
the DT 1_i
usual JJ 1_i
treatment NN 1_i
of IN 1_i
pain NN 1_i
by IN 1_i
the DT 1_i
staff NN 1_i
radiation NN 1_i
oncologist NN 1_i
. . 1_i

All DT N
patients NNS N
reported VBD N
their PRP$ N
average NN N
and CC N
worst JJS N
pain NN 1_o
levels NNS 1_o
at IN N
baseline NN N
and CC N
2 CD N
and CC N
3 CD N
weeks NNS N
after IN N
the DT N
start NN N
of IN N
the DT N
intervention NN N
. . N

RESULTS VB N
The DT N
study NN N
groups NNS N
were VBD N
similar JJ N
with IN N
respect NN N
to TO N
their PRP$ N
baseline NN N
characteristics NNS N
and CC N
pain NN N
levels NNS N
at IN N
randomization NN N
. . N

After IN N
3 CD N
weeks NNS N
, , N
the DT N
average NN N
and CC N
worst JJS N
pain NN N
experienced VBN N
by IN N
patients NNS N
randomized VBN N
to TO N
the DT N
clinical JJ 1_i
intervention NN 1_i
group NN 1_i
was VBD N
significantly RB N
inferior JJ N
to TO N
the DT N
average NN N
pain NN N
experienced VBN N
by IN N
patients NNS N
in IN N
the DT N
control NN 1_i
group NN N
( ( N
2.9/10 CD N
vs. FW N
4.4/10 CD N
and CC N
4.2/10 CD N
vs. FW N
5.5/10 CD N
, , N
respectively RB N
) ) N
. . N

Results CC N
showed VBD N
that IN N
the DT N
experimental JJ N
group NN N
patients NNS N
decreased VBD N
their PRP$ N
pain NN N
levels NNS N
more RBR N
than IN N
the DT N
control NN N
group NN N
patients NNS N
did VBD N
over IN N
time NN N
. . N

CONCLUSION NNP N
An DT 1_o
intervention NN 1_o
including VBG 1_o
patient JJ 1_o
education NN 1_o
, , 1_o
a DT 1_o
pain NN 1_o
diary JJ 1_o
, , 1_o
and CC 1_o
defining VBG 1_o
a DT 1_o
procedure NN 1_o
for IN 1_o
therapeutic JJ 1_o
adjustments NNS 1_o
can MD 1_o
be VB 1_o
effective JJ 1_o
to TO 1_o
improve VB 1_o
pain NN 1_o
relief NN 1_o
in IN 1_o
outpatients NNS 1_o
with IN 1_o
cancer NN 1_o
. . 1_o

Single-dose JJ 1_i
and CC 1_i
multi-dose JJ 1_i
clindamycin NN 1_i
therapy NN 1_i
fails VBZ N
to TO N
demonstrate VB N
efficacy NN N
in IN N
preventing VBG N
infectious JJ N
and CC N
inflammatory JJ N
complications NNS N
in IN N
third JJ 1_p
molar JJ 1_p
surgery NN 1_p
. . 1_p

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
single- JJ 1_i
and CC 1_i
multi-dose JJ 1_i
( ( 1_i
5-day JJ 1_i
) ) 1_i
clindamycin NN 1_i
therapy NN 1_i
for IN N
the DT N
prevention NN N
of IN N
inflammatory JJ N
complications NNS N
in IN N
patients NNS 1_p
undergoing VBG 1_p
lower JJR 1_p
third JJ 1_p
molar JJ 1_p
surgical JJ 1_p
extraction NN 1_p
with IN 1_p
bone NN 1_p
removal NN 1_p
. . 1_p

Patients NNS 1_p
who WP N
qualified VBD N
for IN N
the DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
were VBD N
randomly RB N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
single JJ 1_i
dose NN 1_i
of IN 1_i
oral JJ 1_i
clindamycin NN 1_i
administered VBN 1_i
preoperatively RB 1_i
( ( N
single-dose JJ N
group NN N
) ) N
; : N
( ( N
2 CD N
) ) N
clindamycin NN 1_i
administered VBD 1_i
preoperatively RB 1_i
with IN 1_i
continued JJ 1_i
therapy NN 1_i
for IN 1_i
5 CD 1_i
days NNS 1_i
( ( N
5-day JJ N
group NN N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
a DT N
placebo NN 1_i
group NN N
. . N

The DT N
following JJ N
parameters NNS N
were VBD N
evaluated VBN N
on IN N
the DT N
first JJ N
, , N
second JJ N
and CC N
seventh JJ N
days NNS N
postsurgery NN N
: : N
trismus NN 1_o
, , 1_o
facial JJ 1_o
swelling NN 1_o
, , 1_o
body NN 1_o
temperature NN 1_o
, , 1_o
lymphadenopathy JJ 1_o
, , 1_o
alveolar JJ 1_o
osteitis NN 1_o
and CC 1_o
subjective JJ 1_o
pain NN 1_o
sensations NNS 1_o
. . 1_o

There EX 1_p
were VBD 1_p
86 CD 1_p
patients NNS 1_p
( ( 1_p
31 CD 1_p
in IN 1_p
the DT 1_p
single-dose JJ 1_p
group NN 1_p
, , 1_p
28 CD 1_p
in IN 1_p
the DT 1_p
5-day JJ 1_p
group NN 1_p
and CC 1_p
27 CD 1_p
in IN 1_p
the DT 1_p
placebo NN 1_i
group NN 1_p
) ) 1_p
enrolled VBD 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
postoperative JJ 1_o
inflammatory JJ 1_o
complications NNS 1_o
in IN N
patients NNS N
during IN N
the DT N
first JJ N
and CC N
second JJ N
days NNS N
postsurgery NN N
. . N

A DT N
statistically RB N
significant JJ N
variation NN 1_o
in IN N
body NN 1_o
temperature NN 1_o
was VBD N
reported VBN N
on IN N
the DT N
seventh JJ N
day NN N
. . N

Analysis NN N
of IN N
the DT N
postoperative JJ 1_o
analgesic JJ 1_o
intake NN 1_o
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
examined VBN N
groups NNS N
. . N

Clindamycin NNP 1_i
applied VBD N
in IN N
a DT N
single JJ N
preoperative NN N
dose NN N
of IN N
600 CD N
mg NN N
with IN N
or CC N
without IN N
subsequent JJ N
5-day JJ N
therapy NN N
does VBZ N
not RB N
demonstrate VB N
efficacy NN 1_o
in IN N
prophylaxis NN N
for IN N
postoperative JJ N
inflammatory NN N
complications NNS N
after IN N
third JJ N
molar JJ N
surgery NN N
. . N

Therapeutic JJ N
recommendations NNS 1_o
in IN N
polycythemia NN N
vera NN N
based VBN N
on IN N
Polycythemia NNP N
Vera NNP N
Study NNP N
Group NNP N
protocols VBZ N
. . N

The DT N
PVSG NNP N
was VBD N
organized VBN N
in IN N
1967 CD N
to TO N
establish VB N
effective JJ N
diagnostic JJ N
criteria NNS N
for IN N
polycythemia NN N
vera NN N
, , N
to TO N
study VB N
the DT N
natural JJ N
history NN N
of IN N
the DT N
disease NN N
and CC N
to TO N
define VB N
the DT N
optimal JJ N
treatment NN N
. . N

Although IN N
polycythemia NN 1_p
vera NN 1_p
and CC 1_p
the DT 1_p
other JJ 1_p
myeloproliferative JJ 1_p
diseases NNS 1_p
are VBP N
relatively RB N
uncommon JJ N
, , N
the DT N
PVSG NNP N
was VBD N
able JJ N
to TO 1_p
accumulate VB 1_p
well RB 1_p
over IN 1_p
1,000 CD 1_p
patients NNS 1_p
with IN 1_p
these DT 1_p
various JJ 1_p
disorders NNS 1_p
and CC N
to TO N
study VB N
them PRP N
according VBG N
to TO N
a DT N
total NN N
of IN N
15 CD N
different JJ N
protocols NNS N
. . N

PVSG-01 NNP N
, , N
a DT N
long-term JJ N
randomized NN N
controlled VBD N
study NN N
of IN N
phlebotomy NN 1_i
alone RB 1_i
compared VBN N
with IN N
the DT N
myelosuppressive JJ 1_i
agents NNS 1_i
, , 1_i
32P CD 1_i
or CC 1_i
chlorambucil NN 1_i
supplemented VBN 1_i
by IN 1_i
phlebotomy NN 1_i
, , N
continues VBZ N
to TO N
receive VB N
follow-up JJ N
data NNS N
on IN N
93 CD N
% NN N
of IN N
surviving VBG N
patients NNS N
18 CD N
years NNS N
after IN N
initiation NN N
of IN N
the DT N
study NN N
. . N

During IN N
its PRP$ N
lifetime NN N
, , N
PVSG NNP N
has VBZ N
developed VBN N
a DT N
widely RB N
accepted VBN N
and CC N
highly RB N
effective JJ N
set NN N
of IN N
criteria NNS N
for IN N
the DT N
specific JJ N
diagnosis NN N
of IN N
polycythemia NN N
vera NN N
as RB N
well RB N
as IN N
useful JJ N
criteria NNS N
for IN N
the DT N
diagnosis NN N
of IN N
essential JJ N
thrombocythemia NN N
. . N

It PRP N
has VBZ N
gathered VBN N
an DT N
enormous JJ N
volume NN N
of IN N
data NNS N
on IN N
the DT N
natural JJ N
history NN N
of IN N
the DT N
myeloproliferative JJ N
diseases NNS N
and CC N
in IN N
particular JJ N
on IN N
the DT N
nature NN N
of IN N
the DT N
prevalent JJ N
complications NNS N
, , N
such JJ N
as IN N
thrombotic JJ N
events NNS N
and CC N
hematologic NN N
and CC N
nonhematologic JJ N
malignancies NNS N
. . N

With IN N
respect NN N
to TO N
the DT N
final JJ N
question NN N
, , N
the DT N
optimal JJ N
treatment NN N
for IN N
polycythemia NN N
vera NN N
, , N
it PRP N
is VBZ N
apparent JJ N
that IN N
the DT N
expectation NN N
of IN N
a DT N
single JJ 1_i
optimal JJ 1_i
therapy NN 1_i
that WDT N
would MD N
apply VB N
to TO N
all DT N
patients NNS N
at IN N
all DT N
ages NNS N
and CC N
stages NNS N
of IN N
the DT N
disease NN N
was VBD N
naive JJ N
. . N

Nevertheless NNP N
considerable JJ N
progress NN N
has VBZ N
been VBN N
made VBN N
. . N

Moreover RB N
, , N
the DT N
group NN N
has VBZ N
defined VBN N
more RBR N
precisely RB N
than IN N
ever RB N
before IN N
the DT N
nature NN 1_o
of IN 1_o
the DT 1_o
complications NNS 1_o
of IN N
the DT N
disease NN N
and CC N
the DT N
association NN N
of IN N
the DT N
risks NNS 1_o
of IN 1_o
specific JJ 1_o
complications NNS 1_o
with IN N
specific JJ N
forms NNS N
of IN N
therapy NN N
. . N

It PRP N
thus RB N
has VBZ N
made VBN N
it PRP N
possible JJ N
to TO N
pose VB N
the DT N
next JJ N
series NN N
of IN N
therapeutic JJ N
questions NNS N
that WDT N
must MD N
be VB N
addressed VBN N
in IN N
this DT N
disorder NN N
with IN N
a DT N
greater JJR N
degree NN N
of IN N
sophistication NN N
than IN N
was VBD N
previously RB N
possible JJ N
. . N

Aerobic NNP 1_i
and CC 1_i
strength NN 1_i
training NN 1_i
reduces NNS N
adiposity NN 1_o
in IN N
overweight JJ 1_p
Latina NNP 1_p
adolescents NNS 1_p
. . 1_p

PURPOSE NNP N
To TO N
date NN N
, , N
no DT N
study NN N
has VBZ N
examined VBN N
the DT N
synergistic JJ N
effects NNS N
of IN N
a DT N
nutrition NN 1_i
and CC N
combination NN 1_i
of IN 1_i
aerobic JJ 1_i
and CC 1_i
strength NN 1_i
training NN 1_i
( ( 1_i
CAST NNP 1_i
) ) 1_i
on IN N
both DT N
adiposity NN 1_o
and CC 1_o
metabolic JJ 1_o
parameters NNS 1_o
in IN N
overweight JJ 1_p
Latina NNP 1_p
adolescent NN 1_p
females NNS 1_p
. . 1_p

The DT N
goal NN N
was VBD N
to TO N
assess VB N
if IN N
a DT N
16-wk JJ N
nutrition NN 1_i
plus CC N
CAST NNP 1_i
pilot NN N
study NN N
had VBD N
stronger JJR N
effects NNS N
on IN N
reducing VBG N
adiposity NN 1_o
and CC N
on IN N
improving VBG N
glucose/insulin NN 1_o
indices NNS 1_o
compared VBN N
with IN N
control NN N
( ( N
C NNP N
) ) N
, , N
nutrition NN 1_i
only RB 1_i
( ( N
N NNP N
) ) N
, , N
and CC N
a DT N
nutrition NN 1_i
plus CC N
strength NN 1_i
training NN 1_i
( ( N
N NNP N
+ NNP N
ST NNP N
) ) N
groups NNS N
. . N

METHODS NNP N
In IN N
a DT N
16-wk JJ N
randomized JJ N
trial NN N
, , N
41 CD 1_p
overweight JJ 1_p
Latina NNP 1_p
girls NNS 1_p
( ( 1_p
15.2 CD 1_p
+/- JJ 1_p
1.1 CD 1_p
yr NN 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
C NNP 1_i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
N NNP 1_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
, , N
N NNP 1_i
+ NNP 1_i
ST NNP 1_i
( ( N
n JJ N
= NNP N
9 CD N
) ) N
, , N
or CC N
N NNP 1_i
+ NNP 1_i
CAST NNP 1_i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

All DT N
intervention NN N
groups NNS N
received VBD N
modified JJ 1_i
carbohydrate NN 1_i
nutrition NN 1_i
classes NNS 1_i
( ( N
once RB N
a DT N
week NN N
) ) N
, , N
whereas IN N
the DT N
N NNP 1_i
+ NNP 1_i
ST NNP 1_i
also RB N
received VBD 1_i
strength NN 1_i
training NN 1_i
( ( N
twice RB N
a DT N
week NN N
) ) N
and CC N
the DT N
N NNP 1_i
+ NNP 1_i
CAST NNP 1_i
received VBD N
a DT 1_i
combination NN 1_i
of IN 1_i
strength NN 1_i
and CC 1_i
aerobic JJ 1_i
training NN 1_i
( ( N
twice RB N
a DT N
week NN N
) ) N
. . N

The DT N
following VBG N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
intervention NN N
: : N
strength NN 1_o
by IN N
one CD N
repetition NN N
maximum NN N
, , N
physical JJ 1_o
activity NN 1_o
by IN 1_o
the DT 1_o
7-d JJ 1_o
accelerometry NN 1_o
and CC N
the DT N
3-d JJ 1_o
physical JJ 1_o
activity NN 1_o
recall NN 1_o
, , 1_o
dietary JJ 1_o
intake NN 1_o
by IN 1_o
3-d JJ 1_o
records NNS 1_o
, , 1_o
body NN 1_o
composition NN 1_o
by IN N
dual-energy JJ N
x-ray JJ N
absorptiometry NN N
( ( N
DEXA NNP N
) ) N
, , N
glucose/insulin JJ 1_o
indices NNS 1_o
by IN N
oral JJ N
glucose JJ N
tolerance NN N
test NN N
, , N
and CC N
intravenous JJ 1_o
glucose JJ 1_o
tolerance NN 1_o
test NN 1_o
with IN N
minimal JJ N
modeling NN N
. . N

Across IN N
intervention NN N
group NN N
, , N
effects NNS N
were VBD N
tested VBN N
using VBG N
ANCOVA NNP N
with IN N
post NN N
hoc NN N
pairwise NN N
comparisons NNS N
. . N

RESULTS VB N
There EX N
were VBD N
significant JJ N
overall JJ N
intervention NN N
effects NNS N
for IN N
all DT N
adiposity NN 1_o
measures NNS 1_o
( ( 1_o
weight NN 1_o
, , 1_o
body NN 1_o
mass NN 1_o
index NN 1_o
[ NNP 1_o
BMI NNP 1_o
] NNP 1_o
, , 1_o
BMI NNP 1_o
z-scores NNS 1_o
, , 1_o
and CC 1_o
DEXA NNP 1_o
total VBP 1_o
body NN 1_o
fat NN 1_o
) ) 1_o
, , N
with IN N
a DT N
decrease NN N
of IN N
3 CD N
% NN N
in IN N
the DT N
N NNP 1_i
+ NNP 1_i
CAST NNP 1_i
group NN N
compared VBN N
with IN N
a DT N
3 CD N
% NN N
increase NN N
in IN N
the DT N
N NNP 1_i
+ NNP 1_i
ST NNP 1_i
group NN N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
an DT N
intervention NN N
effect NN N
for IN N
fasting VBG 1_o
glucose NN 1_o
with IN N
the DT N
N NNP 1_i
group NN N
increasing VBG N
by IN N
3 CD N
% NN N
and CC N
the DT N
N NNP 1_i
+ NNP 1_i
CAST NNP 1_i
group NN N
decreasing VBG N
by IN N
4 CD N
% NN N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
CAST NNP 1_i
was VBD N
more RBR N
effective JJ N
than IN N
nutrition NN 1_i
alone RB N
or CC N
nutrition JJ 1_i
plus CC N
strength NN 1_i
training NN 1_i
for IN N
reducing VBG N
multiple JJ 1_o
adiposity NN 1_o
outcomes NNS 1_o
and CC 1_o
fasting VBG 1_o
glucose NN 1_o
in IN N
overweight JJ 1_p
Latina NNP 1_p
girls NNS 1_p
. . 1_p

However RB N
, , N
further JJ N
research NN N
investigating NN N
and CC N
identifying VBG N
intervention NN N
approaches NNS N
that WDT N
improve VBP N
both DT N
adiposity NN 1_o
and CC 1_o
insulin NN 1_o
indices NNS 1_o
, , N
particularly RB N
in IN N
high-risk JJ N
populations NNS N
, , N
are VBP N
warranted VBN N
. . N

Non-contrast-enhanced JJ 1_i
4D CD 1_i
MR NNP 1_i
angiography NN 1_i
with IN N
STAR NNP N
spin NN N
labeling NN N
and CC N
variable JJ N
flip NN N
angle NN N
sampling NN N
: : N
a DT N
feasibility NN N
study NN N
for IN N
the DT N
assessment NN N
of IN N
Dural NNP 1_p
Arteriovenous NNP 1_p
Fistula NNP 1_p
. . 1_p

INTRODUCTION NNP N
This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
non-contrast-enhanced JJ N
4D CD N
magnetic JJ N
resonance NN N
angiography NN N
( ( N
NCE NNP N
4D CD N
MRA NNP N
) ) N
with IN N
signal JJ N
targeting VBG N
with IN N
alternative JJ N
radiofrequency NN N
( ( N
STAR NNP N
) ) N
spin NN N
labeling NN N
and CC N
variable JJ N
flip NN N
angle NN N
( ( N
VFA NNP N
) ) N
sampling NN N
in IN N
the DT N
assessment NN N
of IN N
dural JJ 1_p
arteriovenous JJ 1_p
fistula NN 1_p
( ( 1_p
DAVF NNP 1_p
) ) 1_p
in IN 1_p
the DT 1_p
transverse NN 1_p
sinus NN 1_p
. . 1_p

METHODS NNP N
Nine NNP 1_p
patients NNS 1_p
underwent JJ 1_p
NCE NNP 1_i
4D CD 1_i
MRA NNP 1_i
for IN N
the DT N
evaluation NN N
of IN N
DAVF NNP N
in IN N
the DT N
transverse NN N
sinus NN N
at IN N
3 CD N
T. NNP N
One CD N
patient NN N
was VBD N
examined VBN N
twice RB N
, , N
once RB N
before IN N
and CC N
once RB N
after IN N
the DT N
interventional JJ N
treatment NN N
. . 1_p

All DT 1_p
patients NNS 1_p
also RB 1_p
underwent JJ 1_i
digital JJ 1_i
subtraction NN 1_i
angiography NN 1_i
( ( 1_p
DSA NNP 1_p
) ) 1_p
and/or VBD 1_i
contrast-enhanced JJ 1_i
magnetic JJ 1_i
resonance NN 1_i
angiography NN 1_i
( ( N
CEMRA NNP N
) ) N
. . N

For IN N
the DT N
acquisition NN N
of IN N
NCE NNP N
4D CD N
MRA NNP N
, , N
a DT N
STAR NNP N
spin NN N
tagging VBG N
method NN N
was VBD N
used VBN N
, , N
and CC N
a DT N
VFA NNP N
sampling NN N
was VBD N
applied VBN N
in IN N
the DT N
data NNS N
readout NN N
module NN N
instead RB N
of IN N
a DT N
constant JJ N
flip NN N
angle NN N
. . N

Two CD N
readers NNS N
evaluated VBD N
the DT N
NCE NNP N
4D CD N
MRA NNP N
data NNS N
for IN N
the DT N
diagnosis NN N
of IN N
DAVF NNP N
and CC N
its PRP$ N
type NN N
with IN N
consensus NN N
. . N

The DT N
results NNS N
were VBD N
compared VBN N
with IN N
those DT N
from IN N
DSA NNP N
and/or NN N
CEMRA NNP N
. . N

RESULTS NNP N
All NNP N
patients NNS 1_o
underwent JJ 1_o
NCE NNP 1_i
4D CD 1_i
MRA NNP 1_o
without IN 1_o
any DT 1_o
difficulty NN 1_o
. . N

Among IN 1_p
seven CD 1_p
patients NNS 1_p
with IN 1_p
patent NN 1_p
DAVFs NNP 1_p
, , N
all DT N
cases NNS N
showed VBD N
an DT 1_o
early JJ 1_o
visualization NN 1_o
of IN 1_o
the DT 1_o
transverse JJ 1_o
sinus NN 1_o
on IN 1_i
NCE NNP 1_i
4D CD 1_i
MRA NNP 1_i
. . N

Except IN N
for IN N
one CD N
case NN N
, , N
the DT N
type NN N
of IN N
DAVF NNP N
of IN 1_i
NCE NNP 1_i
4D CD 1_i
MRA NNP 1_i
was VBD N
agreed VBN N
with IN N
that DT N
of IN N
reference NN N
standard NN N
study NN N
. . 1_o

Cortical NNP 1_o
venous JJ 1_o
reflux NN 1_o
( ( 1_o
CVR NNP 1_o
) ) 1_o
was VBD N
demonstrated VBN N
in IN N
two CD N
cases NNS N
out IN N
of IN 1_p
three CD 1_p
patients NNS 1_p
with IN 1_p
CVR NNP 1_p
. . N

CONCLUSION NNP N
NCE NNP N
4D CD N
MRA NNP N
with IN N
STAR NNP N
tagging VBG N
and CC N
VFA NNP N
sampling NN N
is VBZ N
technically RB N
and CC N
clinically RB N
feasible JJ N
and CC N
represents VBZ N
a DT N
promising NN N
technique NN N
for IN N
assessment NN N
of IN N
DAVF NNP N
in IN N
the DT N
transverse NN N
sinus NN N
. . N

Further NNP N
technical JJ N
developments NNS N
should MD N
aim VB N
at IN N
improvements NNS N
of IN N
spatial JJ N
and CC N
temporal JJ N
coverage NN N
. . N

Trace NNP 1_i
element NN 1_i
supplementation NN 1_i
after IN N
major JJ 1_p
burns NNS 1_p
modulates VBZ N
antioxidant JJ N
status NN N
and CC N
clinical JJ N
course NN N
by IN N
way NN N
of IN N
increased JJ N
tissue NN 1_o
trace NN 1_o
element NN 1_o
concentrations NNS 1_o
. . 1_o

BACKGROUND NNP N
After IN N
major JJ 1_p
burns NNS 1_p
, , 1_p
patients NNS 1_p
can MD N
develop VB N
nutritional JJ 1_p
deficiencies NNS 1_p
including VBG 1_p
trace NN 1_o
element NN 1_o
( ( 1_o
TE NNP 1_o
) ) 1_o
deficiencies NNS 1_p
. . 1_p

Various JJ N
complications NNS N
, , N
such JJ N
as IN N
infections NNS N
and CC N
delayed VBN N
wound NN N
healing NN N
, , N
influence VB N
the DT N
clinical JJ N
course NN N
of IN N
such JJ N
patients NNS N
. . N

OBJECTIVES IN N
We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
large JJ N
, , N
intravenous JJ N
doses NNS N
of IN N
TE NNP 1_i
supplements NNS 1_i
on IN N
circulating NN N
and CC N
cutaneous JJ N
TE NNP N
tissue NN N
concentrations NNS N
, , N
on IN N
antioxidant JJ 1_o
status NN 1_o
, , N
and CC N
on IN N
clinical JJ 1_o
outcome NN 1_o
after IN N
major JJ 1_p
burns NNS 1_p
. . 1_p

DESIGN NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
trial NN N
in IN N
21 CD 1_p
patients NNS 1_p
aged VBD 1_p
35 CD 1_p
+/- JJ 1_p
11 CD 1_p
y NN 1_p
( ( 1_p
x JJ 1_p
+/- NNP 1_p
SD NNP 1_p
) ) 1_p
with IN 1_p
burns NNS 1_p
on IN 1_p
45 CD 1_p
+/- JJ 1_p
21 CD 1_p
% NN 1_p
of IN 1_p
their PRP$ 1_p
body NN 1_p
surface NN 1_p
area NN 1_p
. . 1_p

Intravenous JJ 1_i
copper NN 1_i
, , 1_i
selenium NN 1_i
, , 1_i
and CC 1_i
zinc NN 1_i
( ( 1_i
TE NNP 1_i
group NN 1_i
) ) 1_i
or CC 1_i
vehicle NN 1_i
( ( N
V NNP N
group NN N
) ) N
was VBD N
given VBN N
with IN N
a DT N
saline JJ N
solution NN N
for IN N
14-21 JJ N
d. NN N
Blood NNP N
and CC N
urine JJ N
samples NNS N
were VBD N
collected VBN N
until IN N
day NN N
20 CD N
, , N
and CC N
skin FW N
biopsy NN N
specimens NNS N
were VBD N
collected VBN N
on IN N
days NNS N
3 CD N
, , N
10 CD N
, , N
and CC N
20 CD N
. . N

RESULTS VB N
The DT N
age NN N
of IN N
the DT N
patients NNS N
and CC N
the DT N
severity NN N
of IN N
their PRP$ N
burns NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
. . N

Plasma NNP 1_o
TE NNP 1_o
concentrations NNS 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
TE NNP N
group NN N
. . N

In IN N
burned JJ N
areas NNS N
, , N
skin JJ 1_o
contents NNS 1_o
of IN 1_o
both DT 1_o
selenium NN 1_o
( ( N
P=0.05 NNP N
) ) N
and CC N
zinc NN 1_o
( ( N
P=0.04 NNP N
) ) N
increased VBD N
significantly RB N
by IN N
day NN N
20 CD N
. . N

Plasma NNP 1_o
and CC 1_o
tissue NN 1_o
antioxidant NN 1_o
status NN 1_o
was VBD N
improved VBN N
by IN N
supplementation NN N
. . N

The DT N
number NN 1_o
of IN 1_o
infections NNS 1_o
in IN N
the DT N
first JJ N
30 CD N
d NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TE NNP N
group NN N
( ( N
P=0.015 NNP N
) ) N
, , N
with IN N
a DT N
median JJ N
number NN N
of IN N
2 CD N
versus NN N
4 CD N
infections NNS N
per IN N
patient NN N
in IN N
the DT N
TE NNP N
and CC N
V NNP N
groups NNS N
, , N
respectively RB N
, , N
as IN N
a DT N
result NN N
of IN N
a DT N
reduction NN N
in IN N
pulmonary JJ 1_o
infections NNS N
( ( N
P=0.03 NNP N
) ) N
. . N

Wound IN 1_o
healing NN 1_o
was VBD N
improved VBN N
in IN N
the DT N
TE NNP N
group NN N
, , N
with IN N
lower JJR N
requirements NNS 1_o
for IN 1_o
regrafting VBG 1_o
( ( N
P=0.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
TE NNP 1_i
supplementation NN N
was VBD N
associated VBN N
with IN N
higher JJR N
circulating NN 1_o
plasma NN 1_o
and CC 1_o
skin JJ 1_o
tissue NN 1_o
contents NNS 1_o
of IN 1_o
selenium NN 1_o
and CC 1_o
zinc NN 1_o
and CC N
improved VBN N
antioxidant JJ 1_o
status NN 1_o
. . 1_o

These DT N
changes NNS N
were VBD N
associated VBN N
with IN N
improved JJ N
clinical JJ 1_o
outcome NN 1_o
, , 1_o
including VBG 1_o
fewer JJR 1_o
pulmonary JJ 1_o
infections NNS 1_o
and CC 1_o
better JJR 1_o
wound NN 1_o
healing NN 1_o
. . 1_o

Neuropsychological JJ N
effects NNS N
of IN N
risperidone NN 1_i
in IN N
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorders NNS 1_p
: : 1_p
a DT N
blinded JJ N
discontinuation NN N
study NN N
. . N

OBJECTIVE NNP N
Little NNP N
is VBZ N
known VBN N
about IN N
the DT N
neuropsychological JJ N
effects NNS N
of IN N
risperidone NN 1_i
in IN N
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
. . 1_p

METHOD NNP N
Twenty-four JJ 1_p
children NNS 1_p
( ( 1_p
aged VBN 1_p
5-17 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
and CC 1_p
co-morbid JJ 1_p
disruptive JJ 1_p
behavior NN 1_p
who WP 1_p
responded VBD 1_p
favorably RB 1_p
to TO 1_p
open-label JJ 1_p
treatment NN 1_p
with IN 1_p
risperidone NN 1_i
as IN 1_p
part NN 1_p
of IN 1_p
a DT 1_p
previously RB 1_p
described VBN 1_p
controlled VBN 1_p
discontinuation NN 1_p
study NN 1_p
completed VBD N
two CD 1_i
different JJ 1_i
computerized JJ 1_i
attention NN 1_i
tasks NNS 1_i
at IN 1_i
baseline NN 1_i
, , 1_i
weeks NNS 1_i
4 CD 1_i
, , 1_i
8 CD 1_i
, , 1_i
and CC 1_i
24 CD 1_i
of IN 1_i
open-label JJ 1_i
treatment NN 1_i
, , 1_i
and CC 1_i
, , 1_i
at IN 1_i
8 CD 1_i
weeks NNS 1_i
after IN 1_i
random JJ 1_i
assignment NN 1_i
to TO 1_i
either DT 1_i
placebo NN 1_i
or CC 1_i
risperidone NN 1_i
. . 1_i

The DT N
primary JJ N
efficacy NN N
measures NNS N
were VBD N
response NN 1_o
latencies NNS 1_o
to TO N
visually RB N
presented VBN N
stimuli JJ N
requiring VBG N
two CD N
different JJ N
types NNS N
of IN N
attention-controlled JJ 1_o
processing NN 1_o
, , 1_o
i.e. FW 1_o
, , N
focused VBD 1_o
and CC 1_o
divided VBD 1_o
attention NN 1_o
. . 1_o

RESULTS VB N
About IN N
half NN N
of IN N
the DT N
clinical JJ N
responders NNS N
did VBD N
not RB N
produce VB N
valid JJ 1_o
performance NN 1_o
measures NNS 1_o
. . 1_o

These DT N
could MD N
be VB N
shown VBN N
to TO N
be VB N
of IN N
younger JJR N
mental JJ N
age NN N
and CC N
less RBR N
adaptive JJ N
as IN N
measured VBN N
by IN N
the DT N
Vineland NNP 1_o
Behavior NNP 1_o
Scales NNP 1_o
. . 1_o

For IN N
the DT N
valid JJ N
task NN N
performers NNS N
divided VBD N
attention NN N
( ( 1_o
serial JJ 1_o
search NN 1_o
in IN 1_o
working VBG 1_o
memory NN 1_o
) ) 1_o
was VBD N
shown VBN N
to TO N
regress VB N
in IN N
the DT N
placebo NN N
group NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
while IN N
in IN N
the DT N
risperidone NN N
group NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
there EX N
was VBD N
further JJ N
improvement NN N
. . N

No DT N
such JJ N
group NN N
difference NN N
was VBD N
found VBN N
for IN N
focused JJ N
attention NN N
. . N

CONCLUSIONS VB N
The DT N
study NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
risperidone NN 1_i
after IN N
several JJ N
months NNS N
of IN N
treatment NN N
, , N
enhancing VBG N
divided VBN N
attention NN N
in IN N
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
. . 1_p

Acceptability NNP N
of IN N
an DT N
Electronic JJ 1_i
Self-Report JJ 1_i
Assessment NNP 1_i
Program NNP 1_i
for IN N
patients NNS 1_p
with IN 1_p
cancer NN 1_p
. . 1_p

Eliciting VBG N
symptom NN N
and CC N
quality NN N
of IN N
life NN N
information NN N
from IN N
patients NNS N
is VBZ N
an DT N
important JJ N
component NN N
of IN N
medical JJ N
and CC N
nursing NN N
care NN N
processes VBZ N
. . N

Traditionally RB N
, , N
this DT N
information NN N
has VBZ N
been VBN N
collected VBN N
with IN N
paper NN N
and CC N
pencil NN N
. . N

However RB N
, , N
this DT N
approach NN N
presents VBZ N
several JJ N
barriers NNS N
, , N
including VBG N
delays NNS N
in IN N
receiving VBG N
information NN N
, , N
difficulty NN N
in IN N
integrating VBG N
responses NNS N
with IN N
electronic JJ N
records NNS N
, , N
and CC N
the DT N
time NN N
required VBN N
to TO N
manually RB N
score VB N
questionnaires NNS N
for IN N
measurement NN N
purposes NNS N
. . N

One CD N
solution NN N
that WDT N
addresses VBZ N
many JJ N
of IN N
these DT N
barriers NNS N
is VBZ N
the DT N
adoption NN 1_i
of IN 1_i
computerized JJ 1_i
screening NN 1_i
for IN 1_i
symptom NN 1_i
and CC 1_i
quality-of-life JJ 1_i
information NN 1_i
. . 1_i

This DT N
research NN N
explored VBD N
the DT N
acceptability NN 1_o
of IN N
asking VBG N
symptom NN N
and CC N
quality-of-life JJ N
questions NNS N
using VBG 1_i
the DT 1_i
Electronic NNP 1_i
Self NNP 1_i
Report NNP 1_i
Assessment-Cancer NNP 1_i
program NN 1_i
on IN 1_i
wireless NN 1_i
laptops NNS 1_i
equipped VBN 1_i
with IN 1_i
touch-screen JJ 1_i
format NN 1_i
. . 1_i

Acceptability NNP 1_o
data NNS 1_o
were VBD N
explored VBN N
with IN N
respect NN N
to TO N
whether IN N
any DT N
differences NNS N
may MD N
be VB N
attributed VBN N
to TO N
demographics NNS N
and CC N
symptom NN N
and CC N
quality-of-life NN 1_o
levels NNS 1_o
, , N
such JJ N
as IN N
depression NN 1_o
and CC 1_o
cognitive JJ 1_o
and CC 1_o
emotional JJ 1_o
functioning NN 1_o
. . 1_o

This DT N
evaluation NN N
used VBN N
descriptive JJ N
and CC N
univariate JJ N
statistics NNS N
to TO N
examine VB N
data NNS N
from IN N
342 CD 1_p
participants NNS 1_p
from IN 1_p
the DT 1_p
ongoing JJ 1_p
ESRA-C NNP 1_i
randomized VBD 1_p
clinical JJ 1_p
trial NN 1_p
. . 1_p

Research NN 1_p
participants NNS 1_p
for IN 1_p
the DT 1_p
ESRA-C NNP 1_i
study NN 1_p
were VBD 1_p
recruited VBN 1_p
from IN 1_p
the DT 1_p
Seattle NNP 1_p
Cancer NNP 1_p
Care NNP 1_p
Alliance NNP 1_p
, , 1_p
a DT 1_p
consortium NN 1_p
among IN 1_p
the DT 1_p
University NNP 1_p
of IN 1_p
Washington NNP 1_p
Medical NNP 1_p
Center NNP 1_p
, , 1_p
Fred NNP 1_p
Hutchinson NNP 1_p
Cancer NNP 1_p
Research NNP 1_p
Center NNP 1_p
, , 1_p
and CC 1_p
Children NNP 1_p
's POS 1_p
Hospital NNP 1_p
and CC 1_p
Regional NNP 1_p
Medical NNP 1_p
Center NNP 1_p
in IN 1_p
Seattle NNP 1_p
, , 1_p
WA NNP 1_p
. . 1_p

The DT N
sample NN N
consisted VBD N
of IN N
342 CD 1_p
adult NN 1_p
participants NNS 1_p
who WP 1_p
completed VBD 1_p
both DT 1_p
baseline NN 1_p
and CC 1_p
follow-up JJ 1_p
survey NN 1_p
sessions NNS 1_p
. . 1_p

Medical NNP N
oncology NN N
represented VBD N
the DT N
largest JJS N
recruitment NN 1_p
group NN 1_p
( ( N
45.3 CD N
% NN N
) ) N
, , N
followed VBN N
by IN N
stem NN N
cell NN N
transplant NN N
( ( N
34.5 CD N
% NN N
) ) N
and CC N
radiation NN N
oncology NN N
( ( N
20.2 CD N
% NN N
) ) N
. . N

The DT N
primary JJ N
finding NN N
was VBD N
that IN N
patients NNS N
were VBD N
generally RB N
able JJ 1_o
to TO 1_o
use VB 1_o
ESRA-C JJ 1_o
quickly RB 1_o
and CC N
without IN N
difficulty NN N
in IN N
a DT N
real-world JJ N
clinical JJ N
setting NN N
and CC N
that IN N
they PRP N
were VBD N
overall JJ N
quite RB N
satisfied VBN 1_o
with IN 1_o
the DT 1_o
ESRA-C JJ 1_o
program NN 1_o
. . 1_o

Significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
several JJ N
acceptability NN 1_o
areas NNS 1_o
with IN N
respect NN N
to TO N
demographics NNS N
and CC N
quality NN N
of IN N
life NN N
measures NNS N
such JJ N
as IN N
age NN N
, , N
sex NN N
, , N
and CC N
severe JJ N
distress NN N
. . N

This DT N
analysis NN N
confirms VBZ N
that IN N
the DT N
ESRA-C NNP 1_i
application NN 1_i
for IN 1_i
collecting VBG 1_i
symptom NN 1_i
and CC 1_i
quality NN 1_i
of IN 1_i
life NN 1_i
information NN 1_i
is VBZ N
easy JJ N
for IN N
patients NNS N
to TO N
use VB N
and CC N
acceptable JJ N
across IN N
a DT N
range NN N
of IN N
user JJ N
characteristics NNS N
. . N

We PRP N
intend VBP N
to TO N
build VB N
on IN N
our PRP$ N
work NN N
by IN N
using VBG N
the DT N
survey NN N
platform NN N
in IN N
other JJ N
modalities NNS N
while IN N
ensuring VBG N
that IN N
the DT N
patient NN N
's POS N
preferences NNS N
are VBP N
considered VBN N
at IN N
all DT N
times NNS N
. . N

Lower JJR N
relapse NN N
rates NNS N
after IN N
neighbourhood JJ N
injection NN N
of IN N
Corynebacterium NNP 1_i
parvum NN 1_i
in IN N
operable JJ N
cervix NN N
carcinoma NN N
. . N

The DT N
effect NN N
of IN N
adjuvant JJ N
immunotherapy NN N
with IN N
a DT N
single JJ 1_i
neighbourhood NN 1_i
injection NN 1_i
of IN 1_i
2 CD 1_i
mg NNS 1_i
C. NNP 1_i
parvum NN 1_i
( ( 1_i
CP NNP 1_i
) ) 1_i
was VBD N
investigated VBN N
in IN N
a DT N
randomized JJ N
study NN N
involving VBG N
43 CD 1_p
patients NNS 1_p
with IN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
cervix NN 1_p
uteri NN 1_p
, , 1_p
all DT 1_p
of IN 1_p
whom WP 1_p
were VBD 1_p
treated VBN 1_p
by IN 1_p
radical JJ 1_i
surgery NN 1_i
. . 1_i

All DT 1_p
patients NNS 1_p
had VBD 1_p
carcinoma NNS 1_p
confined VBN 1_p
to TO 1_p
the DT 1_p
cervix NN 1_p
, , 1_p
the DT 1_p
upper JJ 1_p
part NN 1_p
of IN 1_p
the DT 1_p
vagina NN 1_p
or CC 1_p
the DT 1_p
parametrial JJ 1_p
region NN 1_p
. . 1_p

When WRB 1_p
the DT 1_p
malignancy NN 1_p
had VBD 1_p
spread VBN 1_p
to TO 1_p
the DT 1_p
parametrial JJ 1_p
region NN 1_p
, , 1_p
additional JJ 1_p
postoperative NN 1_i
radiotherapy NN 1_i
was VBD 1_p
given VBN 1_p
. . 1_p

22 CD 1_p
patients NNS 1_p
received VBD 1_p
immunotherapy JJ 1_i
10 CD 1_p
days NNS 1_p
before RB 1_p
surgery NN 1_p
, , 1_p
whereas IN 1_p
the DT 1_p
remaining VBG 1_p
21 CD 1_p
control NN 1_p
patients NNS 1_p
received VBD 1_p
no DT 1_i
immune JJ 1_i
stimulation NN 1_i
. . 1_i

Only RB N
minor JJ N
side NN 1_o
effects NNS 1_o
of IN N
CP NNP N
were VBD N
encountered VBN N
. . N

Follow-up NN N
shows VBZ N
a DT N
relapse NN 1_o
rate NN 1_o
of IN N
5 CD N
% NN N
in IN N
the DT N
CP NNP N
treated VBD N
group NN N
and CC N
of IN N
29 CD N
% NN N
in IN N
the DT N
controls NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

A DT N
further JJ N
15 CD 1_p
patients NNS 1_p
with IN 1_p
more RBR 1_p
advanced JJ 1_p
malignancies NNS 1_p
were VBD 1_p
added VBN 1_p
to TO 1_p
our PRP$ 1_p
studies NNS 1_p
. . 1_p

In IN N
these DT N
, , N
CP NNP 1_i
stimulation NN 1_i
had VBD N
no DT N
effect NN N
on IN N
relapse NN 1_o
rates NNS 1_o
, , N
but CC N
the DT N
relapse-free JJ 1_o
intervals NNS 1_o
were VBD N
longer RB N
after IN N
immune JJ 1_i
stimulation NN 1_i
: : 1_i
control NN N
3.5 CD N
months NNS N
( ( N
mean JJ N
) ) N
+/- JJ N
1.5 CD N
( ( N
s.d NN N
. . N

) ) N
, , N
CP NNP N
13.0 CD N
months NNS N
+/- JJ N
7.0 CD N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
peripheral JJ 1_o
T NNP 1_o
cells NNS 1_o
and CC 1_o
the DT 1_o
ability NN 1_o
to TO 1_o
become VB 1_o
sensitized JJ 1_o
to TO 1_o
DNCB NNP 1_o
were VBD N
increased VBN N
after IN N
CP NNP 1_i
stimulation NN 1_i
. . 1_i

A DT N
decrease NN N
was VBD N
found VBN N
in IN N
the DT N
number NN 1_o
of IN 1_o
blood NN 1_o
monocytes NNS 1_o
and CC 1_o
the DT 1_o
number NN 1_o
of IN 1_o
monocytes NNS 1_o
capable JJ 1_o
of IN 1_o
transforming VBG 1_o
into IN 1_o
active JJ 1_o
macrophages NNS 1_o
, , N
indicating VBG N
a DT N
possible JJ N
sequestration NN N
of IN N
these DT N
cells NNS N
in IN N
the DT N
tissues NNS N
. . N

[ JJ 1_i
Carticaine NNP 1_i
in IN N
the DT N
therapie NN N
of IN N
pain NN 1_o
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

Low JJ N
body NN N
mass NN N
index NN N
and CC N
dyslipidemia NN N
in IN N
dialysis NN 1_i
patients NNS 1_p
linked VBN N
to TO N
elevated VBN N
plasma NN N
fibroblast NN N
growth NN N
factor NN N
23 CD N
. . N

BACKGROUND NNP N
Fibroblast NNP N
growth NN N
factor NN N
23 CD N
( ( N
FGF23 NNP N
) ) N
has VBZ N
been VBN N
associated VBN N
with IN N
death NN N
in IN N
dialysis NN 1_i
patients NNS 1_p
. . 1_p

Since IN N
FGF23 NNP N
shares NNS N
structural JJ N
features NNS N
with IN N
FGF19 NNP N
subfamily RB N
members NNS N
that IN N
exert JJ N
hormonal JJ N
control NN N
of IN N
fat JJ N
mass NN N
, , N
we PRP N
hypothesized VBD N
that DT N
high JJ N
circulating NN N
FGF23 NNP N
concentrations NNS N
would MD N
be VB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
a DT N
uremic JJ N
lipid NN N
profile NN N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
conducted VBN N
among IN N
654 CD 1_p
patients NNS 1_p
receiving VBG 1_p
chronic JJ 1_p
hemodialysis NN 1_i
. . 1_i

C-terminal JJ 1_o
FGF23 NNP 1_o
concentrations NNS 1_o
were VBD 1_i
measured VBN 1_i
in IN 1_i
stored JJ 1_i
plasma NN 1_i
samples NNS 1_i
. . 1_i

Linear JJ 1_i
regression NN 1_i
was VBD 1_i
used VBN 1_i
to TO 1_i
examine VB 1_i
the DT 1_i
cross-sectional JJ 1_i
associations NNS 1_i
of IN 1_i
plasma NN 1_o
FGF23 NNP 1_o
concentrations NNS 1_o
with IN 1_o
BMI NNP 1_o
, , 1_o
total JJ 1_o
cholesterol NN 1_o
( ( 1_o
TC NNP 1_o
) ) 1_o
, , 1_o
low-density JJ 1_o
lipoprotein-cholesterol NN 1_o
( ( 1_o
LDL-C NNP 1_o
) ) 1_o
, , 1_o
high-density JJ 1_o
lipoprotein-cholesterol NN 1_o
( ( 1_o
HDL-C NNP 1_o
) ) 1_o
and CC 1_o
triglycerides NNS 1_o
. . 1_o

Cox NNP N
proportional JJ N
hazard NN N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
association NN N
between IN N
FGF23 NNP N
concentrations NNS N
and CC N
all-cause JJ N
mortality NN N
. . N

RESULTS JJ N
Participants NNS 1_p
had VBD 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
60 CD 1_p
± JJ 1_p
11 CD 1_p
years NNS 1_p
and CC 1_p
a DT 1_p
median JJ 1_p
( ( 1_p
IQR NNP 1_p
) ) 1_p
FGF23 NNP 1_p
concentration NN 1_p
of IN 1_p
4,212 CD 1_p
( ( 1_p
1,411-13,816 JJ 1_p
) ) 1_p
RU/ml NNP 1_p
. . N

An DT N
increase NN N
per IN N
SD NNP N
in IN N
log10 JJ N
FGF23 NNP N
was VBD N
associated VBN N
with IN N
lower JJR N
BMI NNP N
( ( N
β NNP N
= NNP N
-1.11 NNP N
; : N
p VBZ N
= $ N
0.008 CD N
) ) N
, , N
TC NNP N
( ( N
β NNP N
= NNP N
-6.46 NNP N
; : N
p VBZ N
= $ N
0.02 CD N
) ) N
, , N
LDL-C NNP N
( ( N
β NNP N
= NNP N
-4.73 NNP N
; : N
p VBZ N
= $ N
0.04 CD N
) ) N
and CC N
HDL-C NNP N
( ( N
β NNP N
= NNP N
-2.14 NNP N
; : N
p VBZ N
= $ N
0.03 CD N
) ) N
; : N
after IN N
adjusting VBG N
for IN N
age NN N
, , N
gender NN N
, , N
race NN N
, , N
cardiovascular JJ N
risk NN N
factors NNS N
, , N
serum NN N
albumin NN N
, , N
markers NNS N
of IN N
mineral JJ N
metabolism NN N
, , N
and CC N
use NN N
of IN N
lipid-lowering JJ N
drugs NNS N
. . N

The DT N
association NN N
of IN N
FGF23 NNP N
with IN N
death NN N
was VBD N
attenuated VBN N
after IN N
adjustment NN N
for IN N
HDL-C NNP N
( ( N
HR NNP N
of IN N
highest JJS N
quartile NN N
1.53 CD N
, , N
95 CD N
% NN N
CI NNP N
1.06-2.20 CD N
compared VBN N
to TO N
lowest VB N
quartile NN N
) ) N
. . N

CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
higher JJR N
plasma NN N
FGF23 NNP N
levels NNS N
are VBP N
associated VBN N
with IN N
lower JJR N
BMI NNP N
and CC N
dyslipidemia NN 1_i
in IN 1_i
dialysis NN 1_i
patients NNS 1_p
. . N

The DT N
association NN N
between IN N
FGF23 NNP N
and CC N
death NN N
may MD N
be VB N
mediated VBN N
through IN N
unexplored JJ N
metabolic JJ N
risk NN N
factors NNS N
unrelated VBD N
to TO N
mineral JJ N
metabolism NN N
. . N

The DT N
VA NNP 1_i
augmentation NN 1_i
and CC 1_i
switching NN 1_i
treatments NNS 1_i
for IN N
improving VBG N
depression NN N
outcomes NNS N
( ( N
VAST-D NNP N
) ) N
study NN N
: : N
Rationale NNP N
and CC N
design NN N
considerations NNS N
. . N

Because IN N
two-thirds NNS N
of IN N
patients NNS 1_p
with IN 1_p
Major JJ 1_p
Depressive NNP 1_p
Disorder NNP 1_p
do VBP N
not RB N
achieve VB N
remission NN N
with IN N
their PRP$ N
first JJ N
antidepressant NN N
, , N
we PRP N
designed VBD N
a DT N
trial NN N
of IN N
three CD N
" JJ N
next-step JJ N
" NN N
strategies NNS N
: : N
switching NN 1_i
to TO 1_i
another DT 1_i
antidepressant NN 1_i
( ( 1_i
bupropion-SR JJ 1_i
) ) 1_i
or CC N
augmenting VBG 1_i
the DT 1_i
current JJ 1_i
antidepressant NN 1_i
with IN 1_i
either DT 1_i
another DT 1_i
antidepressant NN 1_i
( ( 1_i
bupropion-SR JJ 1_i
) ) 1_i
or CC 1_i
with IN 1_i
an DT 1_i
atypical JJ 1_i
antipsychotic NN 1_i
( ( 1_i
aripiprazole JJ 1_i
) ) 1_i
. . 1_i

The DT N
study NN N
will MD N
compare VB N
12-week JJ 1_o
remission NN 1_o
rates NNS 1_o
and CC N
, , N
among IN N
those DT N
who WP N
have VBP N
at IN N
least JJS N
a DT N
partial JJ N
response NN N
, , N
relapse NN 1_o
rates NNS 1_o
for IN N
up IN N
to TO N
6 CD N
months NNS N
of IN N
additional JJ N
treatment NN N
. . N

We PRP N
review VBP N
seven CD N
key JJ N
efficacy/effectiveness JJ N
design NN N
decisions NNS N
in IN N
this DT N
mixed JJ N
" JJ N
efficacy-effectiveness JJ N
" JJ N
trial NN N
. . N

[ JJ N
Prevention NNP N
of IN N
stress NN 1_p
ulcers NNS 1_p
with IN N
synthetic JJ 1_i
depot NN 1_i
secretin NN 1_i
] NN 1_i
. . N

The DT N
pathogenesis NN N
of IN N
stress NN 1_p
ulcers NNS 1_p
is VBZ N
still RB N
far RB N
from IN N
being VBG N
understood NN N
. . N

It PRP N
is VBZ N
reported VBN N
about IN N
a DT N
synthetic JJ 1_i
secretin NN 1_i
( ( 1_i
Hoe $ 1_i
069 CD 1_i
+ NNP 1_i
depot FW 1_i
component NN 1_i
) ) 1_i
given VBN N
prophylactically RB N
to TO N
100 CD 1_p
patients NNS 1_p
postoperatively RB 1_p
. . 1_p

It PRP N
eliminated VBD 1_o
or CC 1_o
ameliorated VBD 1_o
stress JJ 1_o
ulcers NNS 1_o
. . 1_o

The DT N
result NN N
, , N
confirmed VBN N
by IN N
gastroscopy NN N
, , N
demonstrates VBZ N
the DT N
treatment NN 1_i
with IN 1_i
secretin JJ 1_i
plus CC 1_i
depot JJ 1_i
component NN 1_i
as IN N
a DT N
highly RB N
recommendable JJ N
prophylaxis NN N
in IN N
the DT N
postsurgical JJ N
intensive JJ N
care NN N
treatment NN N
. . N

Compliance NN N
with IN N
continuous JJ 1_i
passive JJ 1_i
movement NN 1_i
is VBZ N
low JJ N
after IN N
surgical JJ N
treatment NN N
of IN N
idiopathic JJ 1_p
club JJ 1_p
foot NN 1_p
in IN 1_p
infants NNS 1_p
: : 1_p
a DT N
prospective JJ N
, , N
double-blinded JJ N
clinical JJ N
study NN N
. . N

Treatment NN N
by IN N
continuous JJ 1_i
passive JJ 1_i
movement NN 1_i
at IN 1_i
home NN 1_i
is VBZ N
an DT N
alternative JJ N
to TO N
immobilisation NN N
in IN N
a DT N
cast NN N
after IN 1_p
surgery NN 1_p
for IN 1_p
club JJ 1_p
foot NN 1_p
. . 1_p

Compliance NN N
with IN N
the DT N
recommended JJ N
treatment NN N
, , N
of IN N
at IN N
least JJS N
four CD N
hours NNS N
daily RB N
, , N
is VBZ N
unknown JJ N
. . N

The DT N
duration NN N
of IN N
treatment NN N
was VBD N
measured VBN N
in IN N
24 CD 1_p
of IN 1_p
27 CD 1_p
consecutive JJ 1_p
children NNS 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
24 CD 1_p
months NNS 1_p
( ( 1_p
5 CD 1_p
to TO 1_p
75 CD 1_p
) ) 1_p
following VBG 1_p
posteromedial JJ 1_p
release NN 1_p
for IN 1_p
idiopathic JJ 1_p
club JJ 1_p
foot NN 1_p
. . 1_p

Only RB N
21 CD N
% NN N
( ( N
5 CD N
) ) N
of IN N
the DT N
children NNS N
used VBD N
the DT N
continuous JJ 1_i
passive JJ 1_i
movement NN 1_i
machine NN N
as IN N
recommended JJ N
. . N

The DT N
mean JJ N
duration NN N
of IN N
treatment NN N
at IN N
home NN N
each DT N
day NN N
was VBD N
126 CD N
minutes NNS N
( ( N
11 CD N
to TO N
496 CD N
) ) N
. . N

The DT N
mean JJ 1_o
range NN 1_o
of IN 1_o
movement NN 1_o
for IN 1_o
plantar NN 1_o
flexion NN 1_o
improved VBD 1_o
from IN 1_o
15.2 CD 1_o
degrees NNS 1_o
( ( 1_o
10.0 CD 1_o
degrees NNS 1_o
to TO 1_o
20.6 CD 1_o
degrees NNS 1_o
) ) 1_o
to TO 1_o
18.7 CD 1_o
degrees NNS 1_o
( ( 1_o
10.0 CD 1_o
degrees NNS 1_o
to TO 1_o
33.0 CD 1_o
degrees NNS 1_o
) ) 1_o
and CC 1_o
for IN 1_o
dorsiflexion NN 1_o
from IN 1_o
12.3 CD 1_o
degrees NNS 1_o
( ( 1_o
7.4 CD 1_o
degrees NNS 1_o
to TO 1_o
19.4 CD 1_o
degrees NNS 1_o
) ) 1_o
to TO 1_o
18.9 CD 1_o
degrees NNS 1_o
( ( 1_o
10.0 CD 1_o
degrees NNS 1_o
to TO 1_o
24.1 CD 1_o
degrees NNS 1_o
) ) 1_o
( ( 1_o
both DT 1_o
, , 1_o
p NN 1_o
= NNP 1_o
0.0001 CD 1_o
) ) 1_o
when WRB 1_o
the DT 1_o
first JJ 1_o
third NN 1_o
of IN 1_o
therapy NN 1_o
was VBD 1_o
compared VBN 1_o
with IN 1_o
the DT 1_o
last JJ 1_o
third JJ 1_o
. . 1_o

A DT N
low JJ N
level NN N
of IN N
patient JJ N
compliance NN N
must MD N
be VB N
considered VBN N
when WRB N
the DT N
outcome NN N
after IN N
treatment NN N
at IN N
home NN N
is VBZ N
interpreted VBN N
. . N

Improving VBG N
peer NN 1_o
engagement NN 1_o
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
on IN 1_p
the DT 1_p
school NN 1_p
playground NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
test VB N
the DT N
effects NNS N
of IN N
a DT N
psychosocial JJ 1_i
intervention NN 1_i
, , 1_i
Remaking VBG 1_i
Recess NNP 1_i
, , N
on IN N
peer NN N
engagement NN N
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

Using VBG N
a DT N
randomized VBN N
, , N
wait-list-controlled JJ N
design NN N
, , N
the DT N
intervention NN N
was VBD N
implemented VBN N
during IN N
recess NN N
at IN N
four CD 1_p
elementary JJ 1_p
schools NNS 1_p
. . 1_p

The DT N
immediate JJ 1_i
treatment NN 1_i
( ( 1_i
IT NNP 1_i
) ) 1_i
group NN 1_p
consisted VBD 1_p
of IN 1_p
13 CD 1_p
( ( 1_p
2 CD 1_p
female NN 1_p
) ) 1_p
elementary JJ 1_p
school NN 1_p
students NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
the DT 1_p
wait-list NN 1_i
( ( 1_i
WL NNP 1_i
) ) 1_i
group NN 1_i
contained VBD 1_p
11 CD 1_p
( ( 1_p
4 CD 1_p
female NN 1_p
) ) 1_p
students NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

All DT 1_p
of IN 1_p
the DT 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
were VBD N
fully RB N
included VBN N
in IN N
the DT N
general JJ N
education NN N
program NN N
. . N

Analyses VBZ N
revealed VBD N
that IN N
time NN 1_o
spent VBN 1_o
engaged VBN 1_o
with IN 1_o
peers NNS 1_o
was VBD 1_o
significantly RB 1_o
increased VBN 1_o
for IN N
the DT N
IT NNP N
group NN N
and CC N
maintained VBD N
over IN N
the DT N
follow-up JJ N
. . N

School NNP N
playground JJ N
staff NN N
in IN N
the DT N
IT NNP N
group NN N
showed VBD 1_o
increased JJ 1_o
behaviors NNS 1_o
aimed VBN 1_o
at IN 1_o
improving VBG 1_o
peer NN 1_o
engagement NN 1_o
for IN 1_o
children NNS 1_o
with IN 1_p
ASD NNP 1_p
compared VBN N
to TO N
playground VB N
staff NN N
at IN N
the DT N
WL NNP N
sites NNS N
. . N

These DT N
improvements NNS 1_o
did VBD 1_o
not RB 1_o
maintain VB 1_o
to TO N
follow-up JJ N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
low JJ N
dose NN N
, , N
brief JJ N
intervention NN N
can MD N
be VB N
beneficial JJ N
in IN N
increasing VBG N
peer NN 1_o
engagement NN 1_o
for IN 1_o
children NNS 1_o
with IN 1_o
autism NN 1_o
in IN N
inclusive JJ N
settings NNS N
, , N
but CC N
continued VBD N
support NN N
of IN N
playground JJ N
staff NN N
is VBZ N
likely JJ N
needed VBN N
. . N

Long-term JJ N
evaluation NN N
of IN N
tamsulosin NN 1_i
in IN N
benign JJ 1_p
prostatic JJ 1_p
hyperplasia NN 1_p
: : 1_p
placebo-controlled JJ 1_i
, , N
double-blind JJ N
extension NN N
of IN N
phase NN N
III NNP N
trial NN N
. . N

Tamsulosin NNP N
Investigator NNP N
Group NNP N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
tamsulosin NN 1_i
( ( N
0.4 CD N
and CC N
0.8 CD N
mg NN N
) ) N
, , N
a DT N
unique JJ N
selective JJ N
alpha1A-adrenoceptor NN N
antagonist NN N
in IN N
patients NNS 1_p
with IN 1_p
benign JJ 1_p
prostatic JJ 1_p
hyperplasia NN 1_p
( ( N
BPH NNP N
) ) N
. . N

METHODS NNP N
This DT N
trial NN N
extended VBD N
a DT N
13-week JJ N
, , N
Phase NNP N
III NNP N
multicenter NN N
placebo-controlled JJ N
, , N
double-blind JJ N
outpatient JJ N
trial NN N
for IN N
an DT N
additional JJ N
40 CD N
weeks NNS N
. . N

Of IN N
618 CD 1_p
patients NNS 1_p
, , 1_p
418 CD 1_p
( ( 1_p
68 CD 1_p
% NN 1_p
) ) 1_p
continued VBD N
into IN N
the DT N
extension NN N
phase NN N
on IN N
the DT N
same JJ N
double-blind JJ N
medication NN N
and CC N
dose NN N
. . N

The DT N
primary JJ N
efficacy NN N
parameters NNS N
were VBD N
total JJ 1_o
American NNP 1_o
Urological NNP 1_o
Association NNP 1_o
( ( 1_o
AUA NNP 1_o
) ) 1_o
symptom NN 1_o
score NN 1_o
and CC 1_o
maximum JJ 1_o
urinary JJ 1_o
flow NN 1_o
( ( 1_o
Qmax NNP 1_o
) ) 1_o
. . 1_o

RESULTS VB N
The DT N
mean JJ N
changes NNS N
in IN N
AUA NNP 1_o
symptom NN 1_o
score NN 1_o
from IN N
baseline NN N
to TO N
end VB N
point NN N
were VBD N
statistically RB N
significant JJ N
in IN N
all DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
Qmax NNP 1_o
for IN N
both DT N
tamsulosin JJ 1_i
groups NNS N
but CC N
not RB N
for IN N
the DT N
placebo NN 1_i
group NN N
. . N

The DT N
statistically RB N
significant JJ 1_o
improvements NNS 1_o
from IN N
baseline NN N
in IN N
efficacy NN N
parameters NNS N
observed VBD N
for IN N
each DT N
tamsulosin NN 1_i
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
13-week JJ N
Phase NNP N
III NNP N
trial NN N
were VBD N
maintained VBN N
during IN N
the DT N
long-term JJ N
extension NN N
phase NN N
. . N

Tamsulosin NN N
at IN N
both DT N
dosages NNS N
was VBD N
well RB N
tolerated VBN 1_o
as IN N
maintenance NN N
therapy NN N
. . N

Clinically NNP N
significant JJ N
orthostatic JJ 1_o
hypotension NN 1_o
was VBD N
not RB N
observed VBN N
. . N

Vital JJ 1_o
sign NN 1_o
changes NNS 1_o
in IN N
either DT N
hypertensive JJ N
or CC N
normotensive JJ N
patients NNS N
were VBD N
not RB N
clinically RB N
significantly RB N
different JJ N
across IN N
the DT N
three CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Tamsulosin NNP 1_i
once-daily RB N
at IN N
0.4 CD N
or CC N
0.8 CD N
mg NN N
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
target NN 1_p
BPH NNP 1_p
population NN 1_p
during IN N
long-term JJ N
use NN N
. . N

Using VBG N
a DT N
population-based JJ 1_p
cancer NN 1_p
registry NN 1_p
for IN N
recruitment NN N
in IN N
a DT N
pilot NN N
cancer NN N
control NN N
study NN N
. . N

Cancer NNP N
control NN N
investigations NNS N
in IN N
the DT N
United NNP 1_p
States NNPS 1_p
rarely RB N
use VBP N
population-based JJ 1_p
registries NNS 1_p
as IN N
a DT N
resource NN N
for IN N
recruitment NN N
. . N

A DT N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
, , N
randomized JJ N
toxicity NN N
trial NN N
of IN N
tamoxifen NN 1_i
was VBD N
conducted VBN N
among IN N
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
node JJ 1_p
negative JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

To TO N
achieve VB N
the DT N
accrual JJ N
goal NN N
of IN N
140 CD 1_p
subjects NNS 1_p
in IN 1_p
this DT 1_p
single JJ 1_p
institution NN 1_p
study NN 1_p
, , 1_p
the DT 1_p
Wisconsin NNP 1_o
Cancer NNP 1_o
Reporting NNP 1_o
System NNP 1_o
( ( 1_o
WCRS NNP 1_o
) ) 1_o
, , 1_p
a DT 1_p
population-based JJ 1_p
cancer NN 1_p
registry NN 1_p
, , 1_p
was VBD 1_p
used VBN 1_p
. . 1_p

Registry VB N
information NN N
from IN N
the DT N
last JJ N
9 CD N
years NNS N
was VBD N
used VBN N
to TO N
identify VB N
3,585 CD 1_p
women NNS 1_p
who WP 1_p
met VBD 1_p
the DT 1_p
study NN 1_p
criteria NNS 1_p
with IN 1_p
respect NN 1_p
to TO 1_p
age NN 1_p
, , 1_p
stage NN 1_p
, , 1_p
and CC 1_p
previous JJ 1_p
therapy NN 1_p
. . 1_p

The DT N
vital JJ N
status NN N
of IN N
identified JJ N
women NNS 1_p
was VBD N
confirmed VBN N
using VBG N
Wisconsin NNP N
state NN N
death NN N
records NNS N
. . N

For IN N
identified JJ N
cases NNS N
, , N
rosters NNS N
were VBD N
prepared JJ N
and CC N
sent VBD N
to TO N
the DT N
physician NN N
with IN N
a DT N
cover NN N
letter NN N
and CC N
study NN N
description NN N
. . N

The DT N
physicians NNS N
were VBD N
asked VBN N
to TO N
update VB N
the DT N
list NN N
and CC N
, , N
if IN N
appropriate JJ N
, , N
to TO N
sign VB N
letters NNS N
to TO N
potentially RB N
eligible JJ 1_p
and CC 1_p
interested JJ 1_p
women NNS 1_p
. . 1_p

Thirty-eight JJ N
percent NN N
of IN N
women NNS N
receiving VBG N
a DT N
letter NN N
and CC N
study NN N
information NN N
from IN N
their PRP$ N
physicians NNS N
contacted VBN N
the DT N
study NN N
office NN N
about IN N
participation NN N
. . N

Eighteen JJ N
months NNS N
from IN N
its PRP$ N
initiation NN N
, , N
140 CD 1_p
women NNS 1_p
were VBD 1_p
entered VBN 1_p
on IN 1_p
study NN 1_p
. . 1_p

This DT N
successful JJ N
use NN N
of IN N
a DT N
population-based JJ 1_o
cancer NN 1_o
registry NN 1_o
illustrates VBZ N
an DT N
efficient JJ 1_o
recruitment NN 1_o
method NN 1_o
which WDT N
could MD N
be VB N
modified VBN N
for IN N
other JJ N
cancer NN N
control/chemoprevention NN N
trials NNS N
. . N

Retrograde NNP N
tracing NN N
and CC N
electrophysiological JJ N
findings NNS N
of IN N
collateral NN N
sprouting NN N
after IN 1_p
end-to-side JJ 1_p
neurorrhaphy NN 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
seek VB N
more RBR N
potent JJ N
evidences NNS N
of IN N
collateral NN N
sprouting NN N
for IN N
both DT N
motor NN N
and CC N
sensory JJ N
nerve NN N
fibres NNS N
after IN 1_p
end-to-side JJ 1_p
neurorrhaphy NN 1_p
using VBG N
a DT N
modified VBN N
double-labelling NN N
retrograde NN N
tracing VBG N
method NN N
and CC N
to TO N
investigate VB N
the DT N
function NN N
of IN N
regenerated JJ N
motor NN N
axons NNS N
with IN N
electrophysiological JJ N
evaluation NN N
. . N

Four CD 1_p
groups NNS 1_p
( ( 1_p
n=4 JJ 1_p
for IN 1_p
each DT 1_p
group NN 1_p
) ) 1_p
were VBD 1_p
used VBN 1_p
: : 1_p
end-to-end JJ 1_i
coaptation NN 1_i
( ( 1_p
six CD 1_p
months NNS 1_p
postoperatively RB 1_p
) ) 1_p
, , 1_p
end-to-side JJ 1_i
coaptation NN 1_i
( ( 1_p
four CD 1_p
months NNS 1_p
and CC 1_p
six CD 1_p
months NNS 1_p
postoperatively RB 1_p
) ) 1_p
and CC 1_p
normal JJ 1_i
control NN 1_i
. . 1_i

Two CD N
fluorescent JJ 1_i
tracers NNS 1_i
( ( N
true JJ N
blue NN N
and CC N
diamidino NN N
yellow NN N
) ) N
were VBD N
applied VBN N
to TO N
the DT N
proximal JJ N
ends NNS N
of IN N
tibial JJ N
and CC N
common JJ N
peroneal NN N
nerves NNS N
, , N
respectively RB N
after IN N
four CD N
or CC N
six CD N
months NNS N
of IN N
nerve DT N
coaptation NN N
. . N

Five CD N
days NNS N
later RB N
, , N
we PRP N
only RB N
found VBD N
single-labelled JJ 1_o
motor NN 1_o
and CC 1_o
sensory JJ 1_o
neurons NNS 1_o
in IN N
the DT N
normal JJ N
and CC N
end-to-end JJ N
coaptation NN N
groups NNS N
, , N
while IN N
some DT N
dual-labelled JJ N
neurons NNS N
can MD N
be VB N
identified VBN N
in IN N
end-to-side JJ N
coaptation NN N
groups NNS N
. . N

Four CD N
months NNS N
after IN N
surgery NN N
, , N
the DT N
motor NN 1_o
nerve NN 1_o
conduction NN 1_o
velocity NN 1_o
in IN 1_o
end-to-side JJ 1_o
coaptation NN N
was VBD N
significantly RB N
slower JJR N
than IN N
in IN N
the DT N
normal JJ N
control NN N
. . N

But CC N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
sixth JJ N
month NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
end-to-side JJ 1_i
neurorrhaphy NN 1_i
can MD N
induce VB N
the DT N
functional JJ N
collateral NN N
sprouting NN N
of IN N
both DT N
motor NN N
and CC N
sensory JJ N
axons NNS N
in IN N
the DT N
peripheral JJ N
nerve NN N
. . N

Weight NNP N
and CC N
lean JJ N
body NN N
mass NN N
change NN N
with IN N
antiretroviral JJ 1_i
initiation NN 1_i
and CC N
impact NN N
on IN N
bone NN N
mineral JJ N
density NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
that IN N
initiating VBG N
different JJ N
antiretroviral JJ 1_i
therapy NN 1_i
( ( 1_i
ART NNP 1_i
) ) 1_i
regimens VBZ N
has VBZ N
on IN N
weight NN N
, , N
BMI NNP N
, , N
and CC N
lean JJ N
body NN N
mass NN N
( ( N
LBM NNP N
) ) N
and CC N
explore VB N
how WRB N
changes NNS N
in IN N
body NN N
composition NN N
are VBP N
associated VBN N
with IN N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
. . N

METHODS NNP N
A5224s NNP 1_p
was VBD 1_p
a DT 1_p
sub-study NN 1_p
of IN 1_p
A5202 NNP 1_p
, , 1_p
a DT 1_p
prospective JJ 1_p
trial NN 1_p
of IN 1_p
1857 CD 1_p
ART-naive JJ 1_p
participants NNS 1_p
randomized VBN 1_p
to TO 1_p
blinded VBN 1_i
abacavir-lamivudine NN 1_i
( ( 1_i
ABC/3TC NNP 1_i
) ) 1_i
or CC 1_i
tenofovir JJ 1_i
DF-emtricitabine NNP 1_i
( ( 1_i
TDF/FTC NNP 1_i
) ) 1_i
with IN 1_i
open-label JJ 1_i
efavirenz NN 1_i
( ( 1_i
EFV NNP 1_i
) ) 1_i
or CC 1_i
atazanavir-ritonavir JJ 1_i
( ( 1_i
ATV/r NNP 1_i
) ) 1_i
. . 1_i

All DT N
participants NNS N
underwent JJ N
dual-energy JJ 1_i
absorptiometry NN 1_i
( ( 1_i
DXA NNP 1_i
) ) 1_i
and CC 1_i
abdominal JJ 1_i
computed VBN 1_i
tomography NN 1_i
for IN 1_i
body NN 1_i
composition NN 1_i
. . 1_i

Analyses NNS N
used VBD N
two-sample JJ N
t-tests NNS N
and CC N
linear JJ N
regression NN N
. . N

RESULTS NNP N
A5224s NNP N
included VBD N
269 CD 1_p
participants NNS 1_p
: : 1_p
85 CD 1_p
% NN 1_p
men NNS 1_p
, , 1_p
47 CD 1_p
% NN 1_p
white JJ 1_p
non-Hispanic JJ 1_p
, , 1_p
median JJ 1_p
age NN 1_p
38 CD 1_p
years NNS 1_p
, , 1_p
HIV-1 NNP 1_p
RNA NNP 1_p
4.6 CD 1_p
log10 NN 1_p
copies/ml NN 1_p
, , 1_p
and CC 1_p
CD4 NNP 1_p
cell VBP 1_p
count NN 1_p
233 CD 1_p
cells/μl NN 1_p
. . N

Overall JJ N
, , N
significant JJ N
gains NNS N
occurred VBD N
in IN 1_o
weight NN 1_o
, , 1_o
BMI NNP 1_o
, , 1_o
and CC 1_o
LBM NNP 1_o
at IN N
96 CD N
weeks NNS N
post-randomization NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Assignment NN N
to TO 1_i
ATV/r NNP 1_i
( ( 1_i
vs. FW 1_i
EFV NNP 1_i
) ) 1_i
resulted VBD N
in IN N
significantly RB N
greater JJR 1_o
weight NN 1_o
( ( N
mean JJ N
difference NN N
3.35 CD N
kg NN N
) ) N
and CC 1_o
BMI NNP 1_o
gain NN 1_o
( ( N
0.88 CD N
kg/m NN N
; : N
both DT N
P=0.02 NNP N
) ) N
, , N
but CC N
not RB 1_o
LBM NNP 1_o
( ( N
0.67 CD N
kg NN N
; : N
P=0.15 NNP N
) ) N
, , N
whereas JJ N
ABC/3TC NNP N
and CC N
TDF/FTC NNP N
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
P≥0.10 NNP N
) ) N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
only RB N
lower JJR N
baseline NN 1_o
CD4 NNP 1_o
cell NN 1_o
count NN 1_o
and CC N
higher JJR 1_o
HIV-1 NNP 1_o
RNA NNP 1_o
were VBD N
associated VBN N
with IN N
greater JJR N
increase NN N
in IN 1_o
weight NN 1_o
, , 1_o
BMI NNP 1_o
, , 1_o
or CC 1_o
LBM NNP 1_o
. . N

In IN N
multivariable JJ N
analyses NNS N
, , N
increased VBD 1_o
LBM NNP 1_o
was VBD N
associated VBN N
with IN N
an DT N
increased VBN 1_o
hip NN 1_o
BMD NNP 1_o
. . N

CONCLUSION NNP N
ABC/3TC NNP N
vs. IN 1_i
TDF/FTC NNP 1_i
did VBD N
not RB N
differ VB N
in IN N
change NN N
in IN 1_o
weight NN 1_o
, , 1_o
BMI NNP 1_o
, , 1_o
or CC 1_o
LBM NNP 1_o
; : 1_o
ATV/r NNP N
vs. FW N
EFV NNP N
resulted VBD N
in IN N
greater JJR 1_o
weight NN 1_o
and CC 1_o
BMI NNP 1_o
gain NN N
but CC N
not RB 1_o
LBM NNP 1_o
. . N

A NNP N
positive JJ N
association NN N
between IN N
increased VBN N
LBM NNP N
and CC N
increased VBD N
hip NN N
BMD NNP N
should MD N
be VB N
further RB N
investigated VBN N
through IN N
prospective JJ N
interventional JJ N
studies NNS N
to TO N
verify VB N
the DT N
impact NN N
of IN N
increased JJ N
LBM NNP N
on IN N
hip NN N
BMD NNP N
. . N

Leukocyte-depleted JJ 1_i
reperfusion NN 1_i
of IN 1_p
transplanted JJ 1_p
human JJ 1_p
hearts NNS 1_p
: : 1_p
a DT N
randomized JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
. . N

Standard NNP N
methods NNS N
of IN N
myocardial JJ N
preservation NN N
for IN N
heart NN N
transplantation NN N
have VBP N
generally RB N
provided VBN N
good JJ N
results NNS 1_o
. . 1_o

Preservation NNP N
times VBZ N
beyond IN N
3 CD N
hours NNS N
, , N
however RB N
, , N
have VBP N
been VBN N
associated VBN N
with IN N
decreased JJ N
survival NN 1_o
. . 1_o

Leukocyte-mediated JJ N
reperfusion NN N
injury NN N
is VBZ N
partly RB N
responsible JJ N
for IN N
decreased JJ N
graft NN 1_o
function NN 1_o
after IN N
prolonged JJ N
graft NN N
ischemia NN N
. . N

Leukocyte-depleted JJ 1_i
reperfusion NN 1_i
has VBZ N
been VBN N
shown VBN N
experimentally RB N
to TO N
improve VB N
cardiac JJ 1_o
function NN 1_o
after IN N
cold JJ N
ischemic JJ N
arrest NN N
. . N

To TO N
determine VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
leukocyte-depleted JJ 1_i
reperfusion NN 1_i
, , N
20 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
, , 1_p
double-blind JJ 1_p
clinical JJ 1_p
trial NN 1_p
to TO 1_p
be VB 1_p
treated VBN 1_p
with IN 1_p
either DT 1_p
warm JJ 1_i
whole NN 1_i
blood NN 1_i
reperfusion NN 1_i
( ( 1_p
group NN 1_p
I PRP 1_p
; : 1_p
n CC 1_p
= VB 1_p
9 CD 1_p
) ) 1_p
or CC 1_i
warm JJ 1_i
leukocyte-depleted JJ 1_i
blood NN 1_i
reperfusion NN 1_i
( ( 1_p
group NN 1_p
II NNP 1_p
; : 1_p
n CC 1_p
= VB 1_p
11 CD 1_p
) ) 1_p
. . 1_p

Reperfusion NN 1_i
with IN 1_i
leukocyte-depleted JJ 1_i
blood NN 1_i
or CC 1_i
whole JJ 1_i
blood NN 1_i
was VBD N
carried VBN N
out IN N
for IN N
10 CD N
minutes NNS N
, , N
with IN N
enriched JJ N
cardioplegic JJ N
solution NN N
added VBD N
for IN N
the DT N
first JJ N
3 CD N
minutes NNS N
of IN N
reperfusion NN N
. . N

The DT N
mean JJ 1_o
donor NN 1_o
and CC 1_o
recipient JJ 1_o
age NN 1_o
and CC 1_o
the DT 1_o
ischemic JJ 1_o
time NN 1_o
( ( N
142 CD N
versus NN N
153 CD N
minutes NNS N
) ) N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Coronary NNP 1_o
sinus VBD 1_o
release NN 1_o
of IN 1_o
creatinine JJ 1_o
phosphokinase-MB JJ 1_o
5 CD 1_o
minutes NNS 1_o
after IN 1_o
reperfusion NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
group NN N
II NNP N
( ( N
1.65 CD N
EU/min NNP N
) ) N
than IN N
in IN N
group NN N
I PRP N
( ( N
3.83 CD N
units/min NN N
; : N
p CC N
= VB N
0.05 CD N
) ) N
. . N

Thromboxane NNP 1_o
B2 NNP 1_o
release NN 1_o
was VBD N
also RB N
significantly RB N
less JJR N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
in IN N
group NN N
II NNP N
( ( N
33.6 CD N
pg/min NN N
) ) N
than IN N
in IN N
group NN N
I PRP N
( ( N
67.0 CD N
pg/min NN N
) ) N
. . N

All DT N
hearts NNS 1_o
functioned VBD 1_o
adequately RB N
in IN N
both DT N
groups NNS N
. . N

The DT N
duration NN 1_o
of IN 1_o
inotropic JJ 1_o
support NN 1_o
was VBD N
shorter JJR N
in IN N
group NN N
II NNP N
than IN N
in IN N
group NN N
I PRP N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Postoperative JJ 1_o
hemodynamics NNS 1_o
, , 1_o
rejection NN 1_o
episodes NNS 1_o
, , 1_o
and CC 1_o
infectious JJ 1_o
complications NNS 1_o
were VBD N
also RB N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
in IN N
a DT N
mean JJ N
follow-up NN N
of IN N
9 CD N
months NNS N
. . N

Mean NNP 1_o
ejection NN 1_o
fraction NN 1_o
1 CD 1_o
month NN 1_o
after IN 1_o
operation NN 1_o
was VBD N
65 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

One CD N
early JJ N
death NN 1_o
occurred VBD N
at IN N
66 CD N
days NNS N
secondary JJ N
to TO N
infection NN N
; : N
two CD N
late JJ N
deaths NNS 1_o
occurred VBD N
in IN N
group NN N
II NNP N
, , N
both DT N
from IN N
rejection NN N
. . N

Leukocyte-depleted JJ 1_i
reperfusion NN 1_i
is VBZ N
safe JJ 1_o
and CC N
easily RB N
applied VBN N
in IN N
the DT N
operating NN N
room NN N
. . N

Furthermore CD N
, , N
leukocyte-depleted JJ N
reperfusion NN N
decreases VBZ N
biochemical JJ 1_o
evidence NN 1_o
of IN N
reperfusion NN N
injury NN N
. . N

Although IN N
not RB N
influencing VBG N
postoperative JJ N
cardiac JJ 1_o
function NN 1_o
when WRB N
the DT N
ischemic JJ N
time NN N
is VBZ N
short JJ N
, , N
less JJR N
than IN N
3 CD N
hours NNS N
, , N
leukocyte-depleted JJ N
reperfusion NN N
may MD N
prevent VB N
significant JJ N
reperfusion NN 1_o
injury NN 1_o
and CC N
improve VB N
posttransplantation NN 1_o
graft NN 1_o
function NN 1_o
when WRB N
ischemic JJ 1_o
times NNS 1_o
are VBP N
long JJ N
. . N

Safe JJ N
extension NN N
of IN N
the DT N
ischemic JJ N
time NN N
would MD N
expand VB N
the DT N
donor NN N
pool NN N
and CC N
allow VB N
for IN N
better JJR N
crossmatching NN N
. . N

Treatment NN N
of IN N
duodenal JJ 1_p
ulcer NN 1_p
with IN N
low-dose JJ 1_i
antacids NNS 1_i
. . 1_i

The DT N
aim NN N
of IN N
the DT N
present JJ N
investigation NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
a DT N
low-dose JJ 1_i
antacid NN 1_i
( ( 1_i
Maalox NNP 1_i
70 CD 1_i
, , N
280 CD N
mmol/day NN N
) ) N
with IN N
that DT N
of IN N
the DT N
H2-receptor NNP 1_i
antagonist NN 1_i
cimetidine NN 1_i
( ( 1_i
Tagamet NNP 1_i
, , N
200 CD N
mg NN N
three CD N
times NNS N
daily RB N
and CC N
400 CD N
mg/day NN N
) ) N
after IN N
14 CD N
and CC N
28 CD N
days NNS N
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ 1_p
ulcer NN 1_p
. . 1_p

The DT N
prospective JJ N
multicentre NN N
study NN N
included VBD N
171 CD 1_p
patients NNS 1_p
with IN 1_p
endoscopically RB 1_p
confirmed VBN 1_p
duodenal JJ 1_p
ulcers NNS 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
groups NNS N
with IN N
antacid JJ 1_i
containing VBG 1_i
Mg NNP 1_i
and CC 1_i
Al NNP 1_i
hydroxide NN 1_i
( ( 1_i
M NNP 1_i
) ) 1_i
( ( 1_i
4 CD 1_i
X RB N
70 CD N
mmol/day NN N
; : N
n CC N
= VB N
86 CD N
) ) N
or CC N
to TO N
the DT N
group NN N
receiving VBG N
cimetidine NN 1_i
( ( N
T NNP N
) ) N
( ( N
1000 CD N
mg/day NN N
; : N
n CC N
= VB N
85 CD N
) ) N
. . N

The DT N
two CD 1_p
treatment NN 1_p
groups NNS 1_p
were VBD N
matched VBN N
for IN N
age NN N
, , N
sex NN N
, , N
drinking NN N
and CC N
smoking NN N
habits NNS N
, , N
and CC N
drug NN N
use NN N
. . N

Endoscopic JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
14 CD N
days NNS N
later RB N
. . N

If IN N
the DT N
ulcer NN N
was VBD N
still RB N
present JJ N
at IN N
this DT N
time NN N
, , N
the DT N
second JJ N
endoscopic NN N
examination NN N
was VBD N
done VBN N
after IN N
a DT N
further JJ N
14 CD N
days NNS N
. . N

Endoscopically RB N
, , N
the DT N
ulcer NN N
had VBD N
healed VBN 1_o
at IN N
14 CD N
days NNS N
in IN N
38.8 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
in IN N
34.9 CD N
% NN N
( ( N
T NNP N
) ) N
and CC N
at IN N
28 CD N
days NNS N
in IN N
80.0 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
74.7 CD N
% NN N
( ( N
T NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
healing VBG 1_o
rate NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Complaints NNS 1_o
, , N
measured VBN N
as IN N
percentage NN N
of IN N
days NNS N
per IN N
week NN N
with IN N
upper JJ 1_o
abdominal JJ 1_o
pain NN 1_o
, , N
were VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
pain VB 1_o
relief NN 1_o
or CC 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

Treatment NN N
had VBD N
to TO N
be VB N
abandoned VBN N
in IN N
one CD N
patient NN N
receiving VBG N
antacid NN N
because IN N
of IN N
diarrhoea NN N
and CC N
in IN N
one CD N
patient NN N
receiving VBG N
cimetidine NN N
because IN N
of IN N
the DT N
absence NN N
of IN N
any DT N
response NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
Further JJ N
evaluation NN N
of IN N
docosahexaenoic JJ 1_i
acid NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
retinitis NN 1_p
pigmentosa NN 1_p
receiving VBG 1_p
vitamin IN 1_i
A NNP 1_i
treatment NN 1_p
: : 1_p
subgroup NN N
analyses NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
docosahexaenoic JJ 1_i
acid NNS 1_i
will MD N
slow VB N
the DT N
course NN N
of IN N
retinal JJ N
degeneration NN N
in IN N
subgroups NNS N
of IN N
patients NNS 1_p
with IN 1_p
retinitis NN 1_p
pigmentosa NN 1_p
who WP 1_p
are VBP 1_p
receiving VBG 1_p
vitamin IN 1_i
A NNP 1_i
. . 1_i

DESIGN NNP N
A NNP N
cohort NN N
of IN N
208 CD 1_p
patients NNS 1_p
with IN 1_p
retinitis NN 1_p
pigmentosa NN 1_p
, , 1_p
aged VBD 1_p
18 CD 1_p
to TO 1_p
55 CD 1_p
years NNS 1_p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
1200 CD N
mg NN N
of IN N
docosahexaenoic NN 1_i
acid NN 1_i
plus CC 1_i
15 CD 1_i
000 CD 1_i
IU/d NNP 1_i
of IN 1_i
vitamin NN 1_i
A NNP 1_i
given VBN 1_i
as IN 1_i
retinyl NN 1_i
palmitate NN 1_i
( ( 1_i
DHA NNP 1_i
+ VBZ 1_i
A NNP 1_i
group NN 1_i
) ) 1_i
or CC 1_i
control VB 1_i
fatty JJ 1_i
acid JJ 1_i
plus CC 1_i
15 CD 1_i
000 CD 1_i
IU/d NNP 1_i
of IN 1_i
vitamin NN 1_i
A NNP 1_i
( ( 1_i
control NN 1_i
+ VBZ 1_i
A NNP 1_i
group NN 1_i
) ) 1_i
and CC N
followed VBD N
up RB N
over IN N
4 CD N
years NNS N
. . N

Seventy NNP 1_p
percent NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
were VBD 1_p
taking VBG 1_p
vitamin NN 1_i
A NNP 1_i
, , 1_p
15 CD 1_p
000 CD 1_p
IU/d NNP 1_p
, , 1_p
prior RB 1_p
to TO 1_p
entry NN 1_p
. . 1_p

We PRP N
compared VBN N
rates NNS N
of IN N
decline NN N
in IN N
ocular JJ N
function NN N
in IN N
the DT N
DHA NNP 1_i
+ VBZ 1_i
A NNP 1_i
vs NN N
control NN 1_i
+ VBZ 1_i
A DT 1_i
groups NNS N
among IN N
the DT N
subgroups NNS N
defined VBN N
by IN N
use NN N
or CC N
nonuse NN N
of IN N
vitamin NN 1_i
A NNP 1_i
prior RB N
to TO N
entry NN N
. . N

We PRP N
also RB N
determined VBD N
whether IN N
decline NN N
in IN N
ocular JJ N
function NN N
was VBD N
related VBN N
to TO N
red JJ N
blood NN N
cell NN N
phosphatidylethanolamine NN N
docosahexaenoic NN N
acid JJ N
level NN N
, , N
dietary JJ N
omega-3 JJ N
fatty JJ N
acid NNS N
intake VBP N
, , N
or CC N
duration NN N
of IN N
vitamin NN N
A NNP N
use NN N
. . N

Main NNP N
outcome JJ N
measures NNS N
were VBD N
Humphrey NNP 1_o
Field NNP 1_o
Analyzer NNP 1_o
visual JJ 1_o
field NN 1_o
sensitivity NN 1_o
, , 1_o
30-Hz JJ 1_o
electroretinogram NN 1_o
amplitude NN 1_o
, , 1_o
and CC 1_o
visual JJ 1_o
acuity NN 1_o
. . 1_o

RESULTS NNP N
Among IN N
patients NNS N
not RB 1_i
taking VBG 1_i
vitamin RP 1_i
A DT 1_i
prior JJ N
to TO N
entry NN N
, , N
those DT N
in IN N
the DT N
DHA NNP 1_i
+ NNP 1_i
A NNP 1_i
group NN N
had VBD N
a DT N
slower JJR N
decline NN N
in IN N
field NN 1_o
sensitivity NN 1_o
and CC 1_o
electroretinogram NN 1_o
amplitude NN 1_o
than IN N
those DT N
in IN N
the DT N
control NN 1_i
+ VBZ 1_i
A NNP 1_i
group NN N
over IN N
the DT N
first JJ N
2 CD N
years NNS N
( ( N
P NNP N
=.01 NNP N
and CC N
P NNP N
=.03 NNP N
, , N
respectively RB N
) ) N
; : N
these DT N
differences NNS N
were VBD N
not RB N
observed VBN N
in IN N
years NNS N
3 CD N
and CC N
4 CD N
of IN N
follow-up JJ N
or CC N
among IN N
patients NNS N
taking VBG N
vitamin NN 1_i
A NNP 1_i
prior RB N
to TO N
entry NN N
. . N

In IN N
the DT N
entire JJ N
cohort NN N
, , N
red JJ N
blood NN N
cell NN N
phosphatidylethanolamine NN N
docosahexaenoic NN 1_i
acid IN 1_i
level NN N
was VBD N
inversely RB N
related VBN N
to TO N
rate NN N
of IN N
decline NN N
in IN N
total JJ 1_o
field NN 1_o
sensitivity NN 1_o
over IN N
4 CD N
years NNS N
( ( N
test NN N
for IN N
trend NN N
, , N
P NNP N
=.05 NNP N
) ) N
. . N

This DT N
was VBD N
particularly RB N
evident JJ N
over IN N
the DT N
first JJ N
2 CD N
years NNS N
among IN N
those DT N
not RB 1_i
on IN 1_i
vitamin NN 1_i
A NNP 1_i
prior RB N
to TO N
entry NN N
( ( N
test NN N
for IN N
trend NN N
, , N
P NNP N
=.003 NNP N
) ) N
. . N

In IN N
the DT N
entire JJ N
control NN 1_i
+ VBZ 1_i
A NNP 1_i
group NN N
, , N
dietary JJ 1_i
omega-3 JJ 1_i
fatty JJ 1_i
acid NNS 1_i
intake NN N
was VBD N
inversely RB N
related VBN N
to TO N
loss NN N
of IN N
total JJ 1_o
field NN 1_o
sensitivity NN 1_o
over IN N
4 CD N
years NNS N
( ( N
intake VB N
, , N
< VB N
0.20 CD N
vs JJ N
> NN N
or CC N
=0.20 JJ N
g/d NN N
; : N
P NNP N
=.02 NNP N
) ) N
. . N

The DT N
duration NN 1_o
of IN 1_o
vitamin NN 1_o
A DT 1_o
supplementation NN 1_o
prior RB N
to TO N
entry NN N
was VBD N
inversely RB N
related VBN N
to TO N
rate NN N
of IN N
decline NN N
in IN N
electroretinogram JJ N
amplitude NN N
( ( N
P NNP N
=.008 NNP N
) ) N
. . N

CONCLUSIONS NNP N
For IN N
patients NNS 1_p
with IN 1_p
retinitis NN 1_p
pigmentosa NN 1_p
beginning VBG N
vitamin IN 1_i
A NNP 1_i
therapy NN 1_i
, , N
addition NN N
of IN N
docosahexaenoic NN 1_i
acid NN 1_i
, , N
1200 CD N
mg/d NN N
, , N
slowed VBD N
the DT N
course NN N
of IN N
disease NN N
for IN N
2 CD N
years NNS N
. . N

Among IN N
patients NNS 1_p
on IN 1_p
vitamin NN 1_i
A NN 1_i
for IN 1_p
at IN 1_p
least JJS 1_p
2 CD 1_p
years NNS 1_p
, , N
a DT N
diet JJ N
rich JJ N
in IN N
omega-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
( ( N
> CD N
or CC N
=0.20 VB N
g/d NN N
) ) N
slowed VBD N
the DT N
decline NN N
in IN N
visual JJ N
field NN N
sensitivity NN N
. . N

A DT N
controlled VBN N
study NN N
of IN N
the DT N
effect NN 1_o
of IN N
indomethacin NN 1_i
in IN N
uremic JJ 1_o
pericarditis NN 1_o
. . 1_o

To TO N
determine VB N
the DT N
impact NN N
of IN N
indomethacin NN 1_i
on IN N
the DT N
course NN N
of IN N
uremic JJ N
pericarditis NN N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
double JJ N
blind NN N
study NN N
in IN N
which WDT N
24 CD 1_p
patients NNS 1_p
with IN 1_p
endstage NN 1_p
chronic JJ 1_p
renal JJ 1_p
failure NN 1_p
and CC 1_p
pericarditis NN 1_p
randomly RB 1_p
received VBD 1_p
indomethacin JJ 1_i
, , 1_p
25 CD 1_p
mg NN 1_p
four CD 1_p
times NNS 1_p
daily RB 1_p
, , 1_p
( ( 1_p
11 CD 1_p
patients NNS 1_p
) ) 1_p
or CC 1_p
a DT 1_p
placebo NN 1_i
( ( 1_p
13 CD 1_p
patients NNS 1_p
) ) 1_p
for IN N
a DT N
3-week JJ N
period NN N
. . N

All DT N
patients NNS 1_p
received VBN 1_p
peritoneal JJ 1_p
or CC 1_p
hemodialysis NN 1_p
treatment NN 1_p
concurrently RB 1_p
with IN N
the DT N
study NN N
drug NN N
. . N

In IN N
contrast NN N
to TO N
the DT N
placebo NN 1_i
, , 1_i
indomethacin NN 1_i
produced VBD N
an DT N
immediate JJ N
and CC N
sustained JJ N
reduction NN 1_o
of IN 1_o
fever NN 1_o
in IN N
all DT N
but CC N
one CD N
patient NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
indomethacin NN 1_i
had VBD N
no DT N
effect NN N
on IN N
the DT N
duration NN 1_o
of IN 1_o
chest NN 1_o
pain NN 1_o
( ( N
mean JJ N
days NNS N
+/- JJ N
SE NNP N
: : N
placebo NN 1_i
1.4 CD N
+/- JJ N
0.6 CD N
, , N
indomethacin JJ 1_i
5.5 CD N
+/- JJ N
3.3 CD N
) ) N
, , N
duration NN N
of IN N
pericardial JJ 1_o
friction NN 1_o
rub NN 1_o
( ( N
placebo JJ N
10.3 CD N
+/- JJ N
1.7 CD N
, , N
indomethacin JJ 1_i
16.0 CD N
+/- JJ N
3.8 CD N
) ) N
, , N
or CC N
on IN N
the DT N
amount NN N
of IN N
pericardial JJ 1_o
effusion NN 1_o
. . 1_o

Further NNP N
, , N
indomethacin NN N
did VBD N
not RB N
diminish VB N
the DT N
need NN 1_o
for IN 1_o
invasive JJ 1_o
surgical JJ 1_o
procedures NNS 1_o
for IN 1_o
relief NN 1_o
of IN 1_o
tamponade NN 1_o
( ( N
three CD N
of IN N
13 CD N
placebo NN N
patients NNS N
, , N
two CD N
of IN N
11 CD N
indomethacin JJ N
patients NNS N
) ) N
or CC N
result NN N
in IN N
decreased JJ N
mortality NN 1_o
rate NN 1_o
. . 1_o

Death NNP 1_o
( ( N
not RB N
due RB N
to TO N
pericarditis NN N
) ) N
occurred VBD N
in IN N
two CD N
patients NNS N
treated VBN N
with IN N
indomethacin NN N
and CC N
one CD N
patient NN N
who WP N
received VBD N
the DT N
placebo NN 1_i
. . 1_i

In IN N
our PRP$ N
patients NNS N
pericarditis VBP N
encompassed VBD N
a DT N
wide JJ N
spectrum NN N
ranging VBG N
from IN N
a DT N
mild JJ 1_o
illness NN 1_o
of IN 1_o
several JJ 1_o
days NNS 1_o
duration NN 1_o
to TO N
a DT N
painful JJ 1_o
and CC 1_o
debilitating JJ 1_o
disease NN 1_o
lasting JJ 1_o
weeks NNS 1_o
and CC N
requiring VBG N
surgical JJ 1_o
intervention NN 1_o
. . 1_o

Although IN N
the DT N
size NN N
of IN N
our PRP$ N
population NN N
prohibits VBZ N
definitive JJ N
conclusions NNS N
, , N
it PRP N
would MD N
appear VB N
that IN N
, , N
except IN N
for IN N
fever NN N
, , N
the DT N
manifestations NNS N
and CC N
natural JJ N
history NN N
of IN N
this DT N
illness NN 1_o
are VBP N
unaffected VBN N
by IN N
indomethacin NN 1_i
. . 1_i

Pilot NNP N
randomized VBD N
controlled VBN N
trial NN N
of IN N
Reciprocal NNP 1_i
Imitation NNP 1_i
Training NNP 1_i
for IN N
teaching VBG N
elicited VBN N
and CC N
spontaneous JJ 1_o
imitation NN 1_o
to TO N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Children NNP 1_p
with IN 1_p
autism NN 1_p
exhibit NN N
significant JJ N
deficits NNS N
in IN N
imitation NN 1_o
skills NNS 1_o
. . 1_o

Reciprocal JJ 1_i
Imitation NNP 1_i
Training NNP 1_i
( ( 1_i
RIT NNP 1_i
) ) 1_i
, , N
a DT N
naturalistic JJ N
imitation NN N
intervention NN N
, , N
was VBD N
developed VBN N
to TO N
teach VB N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
to TO N
imitate VB N
during IN N
play NN N
. . N

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
of IN N
RIT NNP N
on IN N
elicited VBN N
and CC N
spontaneous JJ N
imitation NN 1_o
skills NNS 1_o
in IN N
21 CD 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Results NNP N
found VBD N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB 1_o
more RBR 1_o
gains NNS 1_o
in IN N
elicited JJ 1_o
and CC 1_o
spontaneous JJ 1_o
imitation NN 1_o
, , N
replicating VBG N
previous JJ N
single-subject JJ N
design NN N
studies NNS N
. . N

Number NNP 1_o
of IN 1_o
spontaneous JJ 1_o
play NN 1_o
acts NNS 1_o
at IN N
pre-treatment NN N
was VBD N
related VBN N
to TO N
improvements NNS N
in IN N
imitation NN 1_o
during IN N
the DT N
intervention NN N
, , N
suggesting VBG N
that IN N
children NNS N
with IN N
a DT N
greater JJR N
play NN N
repertoire NN N
make VBP N
greater JJR N
gains NNS N
during IN N
RIT NNP N
. . N

Effect NN N
of IN N
beta-blocking NN N
drugs NNS N
on IN N
beta-cell NN N
function NN N
and CC N
insulin NN N
sensitivity NN N
in IN N
hypertensive JJ 1_p
non-diabetic JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
effects NNS N
of IN N
two CD N
beta-blocking JJ N
drugs NNS N
on IN N
endogenous JJ N
insulin NN N
secretion NN N
and CC N
insulin NN N
sensitivity NN N
were VBD N
investigated VBN N
in IN N
a DT N
double-blind JJ N
cross-over NN N
study NN N
in IN N
13 CD 1_p
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
each DT N
of IN N
three CD N
2-week JJ N
treatment NN N
periods NNS N
with IN N
propranolol JJ 1_i
80 CD 1_i
mg NN 1_i
b.i.d. NN 1_i
, , N
atenolol RB 1_i
50 CD 1_i
mg NN 1_i
b.i.d NN 1_i
. . 1_i

and CC 1_i
placebo JJ 1_i
b.i.d NN 1_i
. . 1_i

Endogenous JJ N
insulin NN N
secretion NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
serum JJ N
insulin NN N
and CC N
C-peptide NNP N
before IN N
and CC N
6 CD N
min NN N
after IN N
iv JJ N
administration NN N
of IN N
glucagon NN N
; : N
insulin JJ N
sensitivity NN N
was VBD N
determined VBN N
by IN N
measuring VBG N
insulin NN N
binding VBG N
to TO N
erythrocytes NNS N
, , N
and CC N
as IN N
the DT N
glucose JJ N
disappearance NN N
rate NN N
( ( N
KITT NNP N
) ) N
after IN N
i.v NN N
. . N

insulin NN N
. . N

Fasting VBG N
concentrations NNS N
of IN N
serum JJ N
free JJ N
fatty NN N
acids NNS N
( ( N
S-FFA NNP N
) ) N
and CC N
plasma JJ N
gastric JJ N
inhibitory NN N
polypeptide NN N
( ( N
P-GIP NNP N
) ) N
were VBD N
also RB N
recorded VBN N
during IN N
the DT N
three CD N
study NN N
periods NNS N
. . N

Both DT N
propranolol NN 1_i
and CC N
atenolol NN 1_i
reduced VBD N
blood NN 1_o
pressure NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
S-FFA NNP 1_o
concentrations NNS 1_o
compared VBN N
to TO N
placebo VB 1_i
, , N
and CC N
all DT N
patients NNS N
showed VBD N
measurable JJ N
plasma JJ N
concentrations NNS N
of IN N
propranolol NN N
and CC N
atenolol NN N
. . N

The DT N
results NNS N
can MD N
be VB N
considered VBN N
representative JJ N
, , N
therefore RB N
, , N
of IN N
clinical JJ 1_o
beta-blockade NN 1_o
. . 1_o

The DT N
two CD N
drugs NNS N
did VBD N
not RB N
significantly RB N
influence VB N
the DT N
fasting NN 1_o
blood NN 1_o
glucose JJ 1_o
level NN 1_o
. . 1_o

There EX N
was VBD N
an DT N
increase NN N
in IN N
fasting VBG 1_o
and CC 1_o
glucagon-stimulated JJ 1_o
serum NN 1_o
C-peptide NNP 1_o
concentration NN 1_o
during IN N
propranolol JJ N
therapy NN N
compared VBN N
with IN N
placebo NN N
( ( N
p JJ N
= NN N
0.037 CD N
and CC N
p VB N
= JJ N
0.030 CD N
, , N
respectively RB N
) ) N
, , N
although IN N
this DT N
was VBD N
not RB N
reflected VBN N
by IN N
a DT N
significant JJ N
change NN N
in IN N
serum JJ 1_o
insulin NN 1_o
. . 1_o

Propranolol NNP 1_i
and CC N
atenolol RB N
did VBD N
not RB N
significantly RB N
influence JJ N
insulin NN 1_o
binding NN 1_o
to TO 1_o
erythrocytes NNS 1_o
, , N
but CC N
they PRP N
clearly RB N
reduced VBD N
the DT N
glucose JJ 1_o
disappearance NN 1_o
rate NN 1_o
KITT NNP 1_o
was VBD N
compared VBN N
to TO N
placebo VB N
( ( N
p JJ N
= NN N
0.0036 CD N
and CC N
p VB N
= NNP N
0.0003 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

The DT N
findings NNS N
support VBP N
the DT N
view NN N
that IN N
beta-blocking JJ N
drugs NNS N
can MD N
influence VB N
glucose JJ 1_o
metabolism NN 1_o
by IN N
mechanisms NNS N
other JJ N
than IN N
inhibition NN N
of IN N
endogenous JJ 1_o
insulin NN 1_o
secretion NN 1_o
. . 1_o

Double-blind NNP N
, , N
placebo-controlled JJ 1_i
study NN N
of IN N
amantadine JJ 1_i
hydrochloride NN 1_i
in IN N
the DT N
treatment NN N
of IN N
children NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
amantadine JJ 1_i
hydrochloride NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
treatment NN N
for IN N
behavioral JJ 1_o
disturbances NNS 1_o
-- : 1_o
for IN 1_o
example NN N
, , N
hyperactivity NN 1_o
and CC 1_o
irritability NN 1_o
-- : 1_o
in IN 1_o
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

METHOD NNP N
Thirty-nine JJ 1_p
subjects NNS 1_p
( ( 1_p
intent NN 1_p
to TO 1_p
treat VB 1_p
; : 1_p
5-19 CD 1_p
years NNS 1_p
old JJ 1_p
; : 1_p
IQ NNP 1_p
> NNP 1_p
35 CD 1_p
) ) 1_p
had VBD 1_p
autism NN 1_p
diagnosed VBN 1_p
according VBG 1_p
to TO 1_p
DSM-IV NNP 1_p
and CC 1_p
ICD-10 NNP 1_p
criteria NNS 1_p
using VBG 1_p
the DT 1_p
Autism NNP 1_p
Diagnostic NNP 1_p
Interview-Revised JJ 1_p
and CC 1_p
the DT 1_p
Autism NNP 1_p
Diagnostic NNP 1_p
Observation NNP 1_p
Schedule-Generic NNP 1_p
. . 1_p

The DT N
Aberrant JJ 1_o
Behavior NNP 1_o
Checklist-Community NNP 1_o
Version NNP 1_o
( ( 1_o
ABC-CV NNP 1_o
) ) 1_o
and CC 1_o
Clinical JJ 1_o
Global NNP 1_o
Impressions NNP 1_o
( ( 1_o
CGI NNP 1_o
) ) 1_o
scale NN N
were VBD N
used VBN N
as IN N
outcome JJ N
variables NNS N
. . N

After IN N
a DT N
1-week JJ N
, , N
single-blind JJ N
placebo NN N
run-in NN N
, , N
patients NNS N
received VBD N
a DT N
single JJ 1_i
daily JJ 1_i
dose NN 1_i
of IN 1_i
amantadine NN 1_i
( ( 1_i
2.5 CD 1_i
mg/kg NNS 1_i
per IN 1_i
day NN 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
for IN 1_i
the DT 1_i
next JJ 1_i
week NN 1_i
, , 1_i
and CC 1_i
then RB 1_i
bid VB 1_i
dosing VBG 1_i
( ( 1_i
5.0 CD 1_i
mg/kg NNS 1_i
per IN 1_i
day NN 1_i
) ) 1_i
for IN 1_i
the DT 1_i
subsequent JJ 1_i
3 CD 1_i
weeks NNS 1_i
. . 1_i

RESULTS VB N
When WRB N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
parent-rated JJ 1_o
ABC-CV NNP 1_o
ratings NNS 1_o
of IN 1_o
irritability NN 1_o
and CC 1_o
hyperactivity NN 1_o
, , N
the DT N
mean JJ N
placebo NN N
response NN N
rate NN N
was VBD N
37 CD N
% NN N
versus NN N
amantadine NN N
at IN N
47 CD N
% NN N
( ( N
not RB N
significant JJ N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
amantadine-treated JJ 1_i
group NN N
there EX N
were VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
absolute JJ N
changes NNS N
in IN N
clinician-rated JJ N
ABC-CVs NNP 1_o
for IN 1_o
hyperactivity NN 1_o
( ( N
amantadine JJ N
-6.4 NNP N
versus NN N
placebo NN N
-2.1 NNP N
; : N
p CC N
= NNP N
.046 NNP N
) ) N
and CC N
inappropriate JJ 1_o
speech NN 1_o
( ( N
-1.9 JJ N
versus NN N
0.4 CD N
; : N
p NN N
= NNP N
.008 NNP N
) ) N
. . N

CGI NNP 1_o
scale JJ 1_o
ratings NNS 1_o
were VBD N
higher JJR N
in IN N
the DT N
amantadine NN N
group NN N
: : N
53 CD N
% NN N
improved JJ N
versus NN N
25 CD N
% NN N
( ( N
p JJ N
= NNP N
.076 NNP N
) ) N
. . N

Amantadine NNP 1_i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS NNP N
Parents NNPS N
did VBD N
not RB N
report VB N
statistically RB N
significant JJ N
behavioral JJ 1_o
change NN 1_o
with IN N
amantadine NN N
. . N

However RB N
, , N
clinician-rated JJ 1_o
improvements NNS 1_o
in IN 1_o
behavioral JJ 1_o
ratings NNS 1_o
following VBG N
treatment NN N
with IN N
amantadine JJ 1_i
suggest VBP N
that IN N
further JJ N
studies NNS N
with IN N
this DT N
or CC N
other JJ N
drugs NNS N
acting VBG N
on IN N
the DT N
glutamatergic NN N
system NN N
are VBP N
warranted VBN N
. . N

The DT N
design NN N
of IN N
these DT N
and CC N
similar JJ N
drug NN N
trials NNS N
in IN N
children NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
must MD N
take VB N
into IN N
account NN N
the DT N
possibility NN N
of IN N
a DT N
large JJ N
placebo NN N
response NN N
. . N

Pelvic JJ N
lymphocysts NNS N
following VBG N
retroperitoneal JJ N
lymphadenectomy NN N
: : N
retroperitoneal NN 1_i
partial JJ 1_i
" NNP 1_i
no-closure NN 1_i
" NN 1_i
for IN N
ovarian JJ N
and CC N
endometrial JJ N
cancers NNS N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Pelvic NNP N
lymphocysts NNS N
have VBP N
been VBN N
reported VBN N
mainly RB N
following VBG N
pelvic JJ N
lymphadenectomy NN N
for IN N
cervical JJ N
cancer NN N
. . N

We PRP N
attempted VBD N
to TO N
assess VB N
whether IN N
retroperitoneal JJ 1_i
partial JJ 1_i
" NN 1_i
no-closure JJ 1_i
" NN 1_i
reduces VBZ N
the DT N
incidence NN N
of IN N
lymphocyst JJ 1_o
formation NN 1_o
following VBG N
retroperitoneal JJ N
lymphadenectomy NN N
. . N

METHODS NNP N
Sixty-one JJ 1_p
patients NNS 1_p
with IN 1_p
ovarian JJ 1_p
cancer NN 1_p
or CC 1_p
endometrial JJ 1_p
cancer NN 1_p
who WP 1_p
underwent JJ 1_p
retroperitoneal NN 1_p
lymph NN 1_p
node JJ 1_p
resection NN 1_p
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
a DT N
retroperitoneal JJ 1_i
partial JJ 1_i
" NN 1_i
no-closure JJ 1_i
" NNP 1_i
group NN 1_i
or CC 1_i
a DT 1_i
" JJ 1_i
closure NN 1_i
" NNP 1_i
group NN 1_i
. . 1_i

The DT N
incidence NN N
of IN N
lymphocysts NNS 1_o
in IN N
the DT N
two CD N
groups NNS N
as IN N
determined JJ N
using VBG N
ultrasonography NN N
was VBD N
compared VBN N
. . N

RESULTS JJ N
Lymphocysts NNS 1_o
appeared VBD N
in IN N
23/61 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
in IN N
total JJ N
. . N

In IN N
the DT N
" JJ N
closure NN N
" NNP N
group NN N
, , N
the DT N
incidence NN N
was VBD N
52 CD N
% NN N
( ( N
16/31 CD N
) ) N
, , N
but CC N
in IN N
the DT N
" JJ N
no-closure JJ N
" NN N
group NN N
it PRP N
was VBD N
only RB N
23 CD N
% NN N
( ( N
7/30 CD N
) ) N
; : N
the DT N
incidence NN N
in IN N
the DT N
" JJ N
no-closure JJ N
" NN N
group NN N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ 1_o
fever NN 1_o
was VBD N
17 CD N
% NN N
( ( N
5/30 CD N
) ) N
in IN N
the DT N
" JJ N
no-closure JJ N
" NN N
group NN N
, , N
which WDT N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
" JJ N
closure NN N
" NNP N
group NN N
( ( N
42 CD N
% NN N
, , N
13/31 CD N
) ) N
, , N
but CC N
not RB N
significantly RB N
so RB N
( ( N
P NNP N
< NNP N
0.1 CD N
) ) N
. . N

No DT N
patients NNS N
in IN N
the DT N
" JJ N
no-closure JJ N
" NNP N
group NN N
required VBD N
surgical JJ N
procedures NNS N
such JJ N
as IN N
needle JJ N
aspiration NN N
or CC N
cyst NN N
drainage NN N
. . N

CONCLUSIONS NNP N
Retroperitoneal NNP 1_i
partial JJ 1_i
" NNP 1_i
no-closure NN 1_i
" NN 1_i
appears VBZ N
to TO N
be VB N
a DT N
useful JJ N
procedure NN N
for IN N
reducing VBG N
the DT N
incidence NN N
of IN N
pelvic JJ 1_o
lymphocysts NNS 1_o
associated VBN N
with IN N
retroperitoneal JJ 1_i
lymphadenectomy NN 1_i
. . 1_i

Monitoring VBG N
tumour NN N
cells NNS N
in IN N
the DT N
peripheral JJ N
blood NN N
of IN N
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Flow NNP 1_i
cytometry NN 1_i
was VBD N
used VBN N
to TO N
enumerate VB N
tumour JJ N
cells NNS N
in IN N
longitudinal JJ N
studies NNS N
of IN N
peripheral JJ N
blood NN N
from IN N
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
( ( 1_p
SCLC NNP 1_p
) ) 1_p
patients NNS 1_p
, , N
together RB N
with IN N
magnetic JJ N
bead NN N
selection NN N
to TO N
isolate VB N
and CC N
identify VB N
these DT N
cells NNS N
. . N

As IN N
part NN N
of IN N
a DT N
trial NN N
, , N
11 CD 1_p
patients NNS 1_p
received VBD 1_p
either RB 1_p
standard JJ 1_p
( ( 1_p
four CD 1_p
weekly RB 1_p
) ) 1_p
chemotherapy NN 1_i
with IN 1_i
ifosfamide NN 1_i
, , 1_i
carboplatin NN 1_i
, , 1_i
and CC 1_i
etoposide RB 1_i
( ( 1_i
ICE NNP 1_i
) ) 1_i
or CC 1_i
accelerated VBN 1_i
( ( 1_i
two CD 1_i
weekly RB 1_i
) ) 1_i
ICE NNP 1_i
with IN 1_i
filgrastim NN 1_i
( ( 1_i
granulocyte JJ 1_i
colony-stimulating NN 1_i
factor NN 1_i
[ IN 1_i
G-CSF NNP 1_i
] NNP 1_i
) ) 1_i
and CC 1_i
autologous JJ 1_i
stem NN 1_i
cell NN 1_i
support NN 1_i
. . 1_i

METHODS NNP N
Fresh NNP N
venous JJ N
blood NN N
was VBD N
taken VBN N
throughout IN N
treatment NN N
and CC N
follow-up NN N
. . N

Aliquots NNS N
were VBD N
stained VBN N
with IN N
a DT N
" JJ N
tumour-specific JJ N
" NN N
antibody NN N
against IN N
epithelial JJ N
tissue NN N
( ( N
Ber NNP N
EP4 NNP N
) ) N
, , N
verified VBD N
as IN N
a DT N
good JJ N
marker NN N
of IN N
SCLC NNP N
cells NNS N
by IN N
immunohistochemistry NN N
. . N

Matched NNP N
samples NNS N
labelled VBD N
with IN N
Ber NNP N
EP4 NNP N
were VBD N
separated VBN N
magnetically RB N
by IN N
adding VBG N
a DT N
secondary JJ N
bead-antibody NN N
conjugate NN N
for IN N
confirmation NN N
of IN N
tumour NN N
cell NN N
identity NN N
. . N

RESULTS NNP N
Circulating NNP 1_o
tumour JJ 1_o
cells NNS 1_o
were VBD N
detected VBN N
and CC N
monitored VBN N
throughout IN N
treatment NN N
periods NNS N
. . N

An DT N
initial JJ 1_o
rise NN 1_o
in IN 1_o
circulating VBG 1_o
cells NNS 1_o
after IN 1_o
the DT 1_o
first JJ 1_o
cycle NN 1_o
was VBD N
followed VBN N
by IN N
a DT N
fall NN N
in IN N
both DT N
treatment NN N
arms NNS N
to TO N
baseline NN N
levels NNS N
set VBN N
by IN N
normal JJ N
controls NNS N
. . N

This DT N
was VBD N
achieved VBN N
by IN N
week NN N
12 CD N
in IN N
the DT N
accelerated JJ N
treatment NN N
arm NN N
and CC N
by IN N
week NN N
24 CD N
in IN N
the DT N
standard JJ N
arm NN N
. . N

CONCLUSIONS NNP N
Flow NNP N
cytometry NN N
and CC N
magnetic JJ N
bead NN N
isolation NN N
can MD N
be VB N
used VBN N
to TO N
identify VB N
changes NNS N
in IN N
numbers NNS N
of IN N
circulating VBG N
tumour JJ N
cells NNS N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN 1_i
for IN N
SCLC NNP N
and CC N
thereafter RB N
during IN N
follow-up JJ N
periods NNS N
. . N

Absence NN N
of IN N
tumour JJ N
cells NNS N
may MD N
indicate VB N
a DT N
more RBR N
favourable JJ N
patient NN N
group NN N
who WP N
would MD N
benefit VB N
from IN N
a DT N
more RBR N
intense JJ N
course NN N
of IN N
treatment NN N
. . N

N-butyl JJ N
cyanoacrylate NN N
embolization NN N
of IN N
cerebral JJ N
arteriovenous JJ N
malformations NNS N
: : N
results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multi-center JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Liquid NNP N
N-butyl NNP N
cyanoacrylate NN N
( ( N
n-BCA JJ N
) ) N
use NN N
for IN N
the DT N
treatment NN N
of IN N
arteriovenous JJ N
malformations NNS N
( ( N
AVM NNP N
) ) N
in IN N
the DT N
brain NN N
has VBZ N
become VBN N
part NN N
of IN N
medical JJ N
practice NN N
. . N

However RB N
, , N
no DT N
study NN N
has VBZ N
led VBN N
to TO N
the DT N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
's POS N
approval NN N
of IN N
n-BCA JJ N
for IN N
intravascular JJ N
use NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
verify VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
an DT N
n-BCA/Tantalum JJ N
Powder/Ethiodized NNP N
Oil NNP N
mixture NN N
, , N
compared VBN N
with IN N
conventional JJ N
treatment NN N
( ( N
Trufill NNP N
polyvinyl VBZ N
alcohol NN N
[ NNP N
PVA NNP N
] NNP N
) ) N
for IN N
preoperative JJ N
embolization NN N
of IN N
cerebral JJ N
AVM NNP N
. . N

METHODS NNP N
Between NNP 1_p
October NNP 1_p
15 CD 1_p
, , 1_p
1996 CD 1_p
, , 1_p
and CC 1_p
March NNP 1_p
24 CD 1_p
, , 1_p
1999 CD 1_p
, , 1_p
104 CD 1_p
patients NNS 1_p
at IN 1_p
13 CD 1_p
centers NNS 1_p
were VBD 1_p
prospectively RB 1_p
randomized VBN 1_p
to TO N
undergo VB N
embolization NN 1_i
using VBG 1_i
an DT 1_i
n-BCA/Tantalum JJ 1_i
Powder/Ethiodol NNP 1_i
mixture NN 1_i
or CC 1_i
Trufill NNP 1_i
PVA NNP 1_i
. . 1_i

The DT N
pre-embolization NN N
therapy NN N
goals NNS N
were VBD N
determined VBN N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
pedicles NNS N
to TO N
be VB N
embolized VBN N
and CC N
the DT N
percent NN N
of IN N
nidus JJ N
reduction NN N
expected VBN N
. . N

Embolization NN N
results NNS N
were VBD N
evaluated VBN N
by IN N
a DT N
central JJ N
laboratory NN N
. . N

Subsequent JJ N
surgical JJ N
resection NN N
data NNS N
were VBD N
recorded VBN N
. . N

Safety NNP N
evaluation NN N
data NNS N
included VBD N
recording VBG N
device NN 1_o
complications NNS 1_o
, , 1_o
procedure NN 1_o
complications NNS 1_o
, , 1_o
and CC 1_o
intracranial JJ 1_o
events/overall NN 1_o
neurologic JJ 1_o
outcomes NNS 1_o
, , N
which WDT N
could MD N
be VB N
either CC N
device-related JJ N
, , N
procedure-related JJ N
, , N
or CC N
both DT N
. . N

RESULTS VB N
The DT N
reduction NN N
of IN N
AVM NNP 1_o
dimensions NNS 1_o
( ( N
79.4 CD N
% NN N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
86.9 CD N
% NN N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
and CC N
the DT N
mean JJ 1_o
number NN 1_o
of IN 1_o
vessels NNS 1_o
embolized VBN 1_o
( ( N
2.2 CD N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
2.1 CD N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Coils NNS N
were VBD N
used VBN N
more RBR N
commonly RB N
with IN N
PVA NNP N
embolization NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

No UH N
differences NNS N
were VBD N
detected VBN N
in IN N
surgical JJ 1_o
resection NN 1_o
time NN 1_o
, , 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
required VBD 1_o
transfusion NN 1_o
, , 1_o
volume NN 1_o
and CC 1_o
number NN 1_o
of IN 1_o
transfusion NN 1_o
units NNS 1_o
, , 1_o
or CC 1_o
type NN 1_o
and CC 1_o
volume NN 1_o
of IN 1_o
fluid JJ 1_o
replacement NN 1_o
. . 1_o

Glasgow NNP 1_o
Outcome NNP 1_o
Scale NNP 1_o
scores NNS 1_o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
before IN N
treatment NN N
, , N
after IN N
embolization NN N
, , N
or CC N
after IN N
resection NN N
. . N

Two CD N
of IN N
42 CD N
patients NNS N
who WP N
underwent JJ N
resection NN N
and CC N
had VBD N
been VBN N
treated VBN N
with IN N
n-BCA JJ N
experienced JJ N
post-resection NN 1_o
hematoma NN 1_o
, , N
compared VBN N
with IN N
eight CD N
of IN N
45 CD N
patients NNS N
who WP N
underwent JJ N
resection NN N
and CC N
had VBD N
been VBN N
treated VBN N
with IN N
PVA NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
showed VBD N
that IN N
n-BCA JJ N
is VBZ N
equivalent JJ N
to TO N
PVA NNP N
as IN N
a DT N
preoperative JJ N
embolic JJ N
agent NN N
for IN N
treatment NN N
of IN N
cerebral JJ 1_p
AVM NNP 1_p
as IN N
determined VBN N
by IN N
percent NN N
of IN N
nidus JJ N
reduction NN N
and CC N
number NN N
of IN N
feeding VBG N
pedicles NNS N
embolized VBN N
. . N

Randomized VBN N
controlled JJ N
trial NN N
for IN N
early JJ 1_i
intervention NN 1_i
for IN N
autism NN N
: : N
a DT N
pilot NN N
study NN N
of IN N
the DT N
Autism NNP 1_i
1-2-3 JJ 1_i
Project NNP 1_i
. . 1_i

We PRP N
piloted VBD N
a DT N
2-week JJ N
" JJ 1_i
Autism-1-2-3 NNP 1_i
" NNP 1_i
early JJ 1_i
intervention NN 1_i
for IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
their PRP$ 1_p
parents NNS 1_p
immediately RB N
after IN N
diagnosis NN N
that WDT N
targeted VBD N
at IN N
( ( 1_i
1 CD 1_i
) ) 1_i
eye NN 1_i
contact NN 1_i
, , 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
gesture NN 1_i
and CC 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
vocalization/words NNS 1_i
. . 1_i

Seventeen JJ 1_p
children NNS 1_p
were VBD 1_p
randomized VBN 1_p
into IN 1_p
the DT 1_p
Intervention NNP 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
9 CD 1_p
) ) 1_p
and CC 1_p
Control NNP 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
8 CD 1_p
) ) 1_p
groups NNS 1_p
. . 1_p

Outcome NNP N
measures NNS N
included VBD N
the DT N
Autism NNP 1_o
Diagnostic NNP 1_o
Observation NNP 1_o
Schedule NNP 1_o
, , 1_o
Ritvo-Freeman NNP 1_o
Real NNP 1_o
Life NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
, , 1_o
Symbolic NNP 1_o
Play NNP 1_o
Test NNP 1_o
, , 1_o
and CC 1_o
Parenting NNP 1_o
Stress NNP 1_o
Index NNP 1_o
. . 1_o

Children NNP 1_p
with IN 1_p
autism NN 1_p
improved VBN N
in IN N
language/communication NN 1_o
, , 1_o
reciprocal JJ 1_o
social JJ 1_o
interaction NN 1_o
, , 1_o
and CC 1_o
symbolic JJ 1_o
play NN 1_o
. . 1_o

Parents NNS N
perceived VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
children NNS 1_o
's POS 1_o
language NN 1_o
, , 1_o
social JJ 1_o
interaction NN 1_o
, , 1_o
and CC 1_o
their PRP$ 1_o
own JJ 1_o
stress NN 1_o
level NN 1_o
. . 1_o

This DT N
intervention NN N
can MD N
serve VB N
as IN N
short-term JJ N
training NN 1_i
on IN 1_i
communication NN 1_i
and CC 1_i
social JJ 1_i
interaction NN 1_i
for IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
reduce VB N
the DT N
stress NN N
of IN N
their PRP$ N
parents NNS N
during IN N
the DT N
long JJ N
waiting NN N
time NN N
for IN N
public JJ N
health NN N
services NNS N
. . N

Effects NNS N
of IN N
pindolol NN 1_i
and CC 1_i
clopamide NN 1_i
on IN N
blood NN 1_o
lipids NNS 1_o
in IN N
arterial JJ 1_p
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
effects NNS N
of IN N
clopamide NN 1_i
, , 1_i
pindolol NN 1_i
and CC 1_i
its PRP$ 1_i
combination NN 1_i
on IN 1_i
plasma JJ 1_i
lipids NNS 1_i
in IN N
49 CD 1_p
hypertensive JJ 1_p
patients NNS 1_p
( ( 1_p
WHO NNP 1_p
I-II NNP 1_p
) ) 1_p
, , 1_p
divided VBD 1_p
into IN 1_p
three CD 1_p
parallel JJ 1_p
randomized VBN 1_p
groups NNS 1_p
, , 1_p
were VBD 1_p
studied VBN 1_p
over IN 1_p
a DT 1_p
6 CD 1_p
months NNS 1_p
period NN 1_p
. . 1_p

Total JJ 1_o
cholesterol NN 1_o
, , 1_o
triglycerides NNS 1_o
, , 1_o
HDL NNP 1_o
and CC 1_o
LDL NNP 1_o
cholesterol NN 1_o
fractions NNS 1_o
were VBD N
determined VBN N
twice RB N
during IN N
an DT N
initial JJ N
4-week JJ N
washout NN N
phase NN N
, , N
and CC N
after IN N
a DT N
1- JJ N
, , N
3- JJ N
and CC N
6-month JJ N
active JJ N
hypotensive JJ N
drug NN N
phase NN N
. . N

Patients NNS N
were VBD N
instructed VBN N
to TO N
maintain VB N
their PRP$ N
usual JJ N
dietary JJ N
habits NNS N
. . N

Daily JJ N
drug NN N
doses NNS N
were VBD N
adjusted VBN N
progressively RB N
to TO N
attain VB N
optimal JJ N
hypotensive JJ N
effects NNS N
. . N

In IN N
the DT N
clopamide NN N
monotherapy NN N
group NN N
, , N
total JJ 1_o
cholesterol NN 1_o
increased VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
; : N
triglycerides NNS 1_o
and CC N
LDL NNP 1_o
showed VBD N
a DT N
tendency NN N
to TO N
increase VB N
while IN N
for IN N
HDL NNP 1_o
a DT N
tendency NN N
to TO N
decrease VB N
was VBD N
observed VBN N
. . N

In IN N
the DT N
pindolol NN N
monotherapy NN N
group NN N
, , N
a DT N
significant JJ N
reduction NN N
of IN N
triglycerides NNS 1_o
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
a DT N
significant JJ N
increase NN N
of IN N
HDL NNP 1_o
cholesterol NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
were VBD N
recorded VBN N
. . N

No DT N
significant JJ N
changes NNS N
in IN N
total JJ 1_o
cholesterol NN 1_o
or CC 1_o
LDL NNP 1_o
fraction NN 1_o
were VBD N
observed VBN N
. . N

Combined VBN N
pindolol-clopamide JJ N
therapy NN N
decreased VBD N
total JJ 1_o
triglycerides NNS 1_o
( ( 1_o
NS NNP 1_o
) ) 1_o
, , N
increased VBD N
HDL NNP 1_o
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
did VBD N
not RB N
influence VB N
total JJ 1_o
cholesterol NN 1_o
and CC 1_o
LDL NNP 1_o
fraction NN 1_o
. . 1_o

It PRP N
is VBZ N
concluded VBN N
that IN N
pindolol NN N
does VBZ N
not RB N
negatively RB N
influence VB N
blood NN 1_o
lipids NNS 1_o
as IN N
the DT N
thiazide-type JJ N
diuretic JJ N
clopamide NN N
does VBZ N
, , N
and CC N
that IN N
when WRB N
both DT N
drugs NNS N
are VBP N
used VBN N
together RB N
, , N
the DT N
beta-blocker NN N
can MD N
probably RB N
counterbalance VB N
the DT N
diuretic-induced JJ N
negative JJ N
effects NNS N
on IN N
blood NN 1_o
lipids NNS 1_o
. . 1_o

Accordingly RB N
, , N
it PRP N
is VBZ N
suggested VBN N
that IN N
pindolol NN N
could MD N
be VB N
a DT N
more RBR N
favorable JJ N
beta-blocker JJ N
drug NN N
to TO N
be VB N
used VBN N
on IN N
hypertensive JJ 1_p
subjects NNS 1_p
with IN 1_p
metabolic JJ 1_p
coronary JJ 1_p
risk NN 1_p
factors NNS 1_p
. . 1_p

Changes NNS N
in IN N
heart NN 1_o
rate NN 1_o
and CC 1_o
forearm NN 1_o
blood NN 1_o
flow NN 1_o
following VBG N
intravenous JJ N
boluses NNS N
of IN N
isoprenaline NN 1_i
in IN N
the DT N
presence NN N
of IN N
practolol NN N
and CC N
propranolol NN N
. . N

1 CD N
Increases NNS N
in IN N
heart NN 1_o
rate NN 1_o
and CC 1_o
forearm NN 1_o
blood NN 1_o
flow NN 1_o
following VBG N
graded VBD N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline JJ 1_i
sulphate NN 1_i
, , N
were VBD N
measured VBN N
in IN N
a DT N
double-blind NN N
randomised VBN N
study NN N
of IN N
six CD 1_p
subjects NNS 1_p
who WP 1_p
received VBD 1_p
either DT 1_p
placebo NN 1_i
, , 1_i
practolol VBP 1_i
50 CD 1_i
mg NN 1_i
, , 1_i
practolol VBP 1_i
200 CD 1_i
mg NN 1_i
, , 1_i
propranolol VBP 1_i
10 CD 1_i
mg NN 1_i
or CC 1_i
propranolol VB 1_i
40 CD 1_i
mg. NN 1_i
2 CD N
Dose NNP N
related JJ N
increases NNS N
in IN N
forearm NN 1_o
blood NN 1_o
flow NN 1_o
were VBD N
produced VBN N
by IN N
the DT N
graded JJ N
boluses NNS N
of IN N
isoprenaline JJ 1_i
sulphate NN 1_i
. . 1_i

3 CD N
Practolol NNP 1_i
50 CD N
mg NN N
attenuated VBD N
the DT N
heart NN 1_o
rate NN 1_o
response NN 1_o
to TO N
isoprenaline VB N
but CC N
did VBD N
not RB N
significantly RB N
affect VB N
the DT N
changes NNS N
in IN N
forearm NN 1_o
blood NN 1_o
flow NN 1_o
. . 1_o

Practolol CC 1_i
200 CD N
mg NN N
further RB N
attenuated VBD N
the DT N
heart NN 1_o
rate NN 1_o
responses NNS 1_o
but CC N
also RB N
decreased VBD N
the DT N
forearm NN 1_o
blood NN 1_o
flow NN 1_o
responses NNS 1_o
. . 1_o

4 CD N
Propranolol NNP 1_i
10 CD N
mg NN N
and CC N
propranolol NN N
40 CD N
mg NN N
significantly RB N
attenuated VBD N
both DT N
the DT N
heart NN 1_o
rate NN 1_o
and CC 1_o
forearm NN 1_o
blood NN 1_o
flow NN 1_o
responses NNS 1_o
. . 1_o

The DT N
effect NN N
on IN N
forearm NN 1_o
blood NN 1_o
flow NN 1_o
tended VBD N
to TO N
be VB N
greater JJR N
than IN N
the DT N
effect NN N
on IN N
heart NN 1_o
rate NN 1_o
. . 1_o

5 CD N
Practolol NNP 1_i
200 CD N
mg NN N
had VBD N
the DT N
same JJ N
effect NN N
on IN N
heart NN 1_o
rate NN 1_o
responses NNS 1_o
as IN N
propranolol NN 1_i
10 CD N
mg NN N
but CC N
a DT N
significantly RB N
smaller JJR N
effect NN N
on IN N
the DT N
forearm NN 1_o
blood NN 1_o
flow NN 1_o
responses NNS 1_o
. . 1_o

6 CD N
The DT N
measurement NN N
of IN N
forearm NN 1_o
blood NN 1_o
flow NN 1_o
following VBG N
intravenous JJ N
bolus JJ N
injections NNS N
of IN N
isoprenaline NN N
provides VBZ N
useful JJ N
information NN N
about IN N
the DT N
beta NN N
2-adrenoceptor JJ N
antagonism NN N
of IN N
propranolol NN 1_i
and CC N
practolol NN 1_i
. . N

However RB N
, , N
application NN N
of IN N
the DT N
technique NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
magnitude NN N
of IN N
the DT N
heart NN 1_o
rate NN 1_o
response NN N
and CC N
by IN N
the DT N
short-lived JJ N
nature NN N
of IN N
the DT N
increase NN N
in IN N
forearm JJ 1_o
blood NN 1_o
flow NN 1_o
. . 1_o

Are NNP N
postural JJ 1_o
responses NNS 1_o
to TO N
backward VB N
and CC N
forward VB N
perturbations NNS N
processed VBN N
by IN N
different JJ N
neural JJ N
circuits NNS N
? . N
Startle NNP N
pathways VBZ N
may MD N
contribute VB N
to TO N
rapid JJ N
accomplishment NN N
of IN N
postural JJ N
stability NN N
. . N

Here RB N
we PRP N
investigate VBP N
the DT N
possible JJ N
influence NN N
of IN N
a DT N
startling JJ 1_i
auditory NN 1_i
stimulus NN 1_i
( ( 1_i
SAS NNP 1_i
) ) 1_i
on IN N
postural JJ 1_o
responses NNS 1_o
. . 1_o

We PRP N
formulated VBD N
four CD N
specific JJ N
questions NNS N
: : N
( ( N
1 CD N
) ) N
can MD N
a DT N
concurrent JJ N
SAS NNP N
shorten VBD N
the DT N
onset NN N
of IN N
automatic JJ N
postural JJ N
responses NNS N
? . N
; : N
and CC N
if IN N
so RB N
( ( N
2 CD N
) ) N
is VBZ N
this DT N
effect NN N
different JJ N
for IN N
forward RB N
versus FW N
backward NN N
perturbations NNS N
? . N
; : N
( ( N
3 CD N
) ) N
does VBZ N
this DT N
effect NN N
depend NN N
on IN N
prior JJ N
knowledge NN N
of IN N
the DT N
perturbation NN N
direction NN N
? . N
; : N
and CC N
( ( N
4 CD N
) ) N
is VBZ N
this DT N
effect NN N
different JJ N
for IN N
low- JJ N
and CC N
high-magnitude JJ N
perturbations NNS N
? . N
Balance NNP N
was VBD N
perturbed VBN N
in IN N
11 CD 1_p
healthy JJ 1_p
participants NNS 1_p
by IN 1_p
a DT 1_p
movable JJ 1_p
platform NN 1_p
that IN 1_p
suddenly RB 1_p
translated VBN 1_p
forward RB 1_p
or CC 1_p
backward RB 1_p
. . 1_p

Each DT N
participant NN N
received VBD N
160 CD N
perturbations NNS 1_i
, , N
25 CD N
% NN N
of IN N
which WDT N
were VBD N
combined VBN N
with IN N
a DT N
SAS NNP 1_i
. . 1_i

We PRP N
varied VBD N
the DT N
direction NN N
and CC N
magnitude NN N
of IN N
the DT N
perturbations NNS N
, , N
as RB N
well RB N
as IN N
the DT N
prior JJ N
knowledge NN N
of IN N
perturbation NN N
direction NN N
. . N

Perturbation NN N
trials NNS N
were VBD N
interspersed VBN N
with IN N
SAS-only JJ 1_i
trials NNS N
. . N

The DT N
SAS NNP 1_i
accelerated VBD N
and CC N
strengthened VBD N
postural JJ 1_o
responses NNS 1_o
with IN N
clear JJ N
functional JJ N
benefits NNS N
( ( N
better JJR N
balance NN N
control NN N
) ) N
, , N
but CC N
this DT N
was VBD N
only RB N
true JJ N
for IN N
responses NNS N
that WDT N
protected VBD N
against IN N
falling VBG N
backwards NNS N
( ( N
i.e NN N
. . N

in IN N
tibialis JJ N
anterior JJ N
and CC N
rectus JJ N
femoris NN N
) ) N
. . N

These DT N
muscles NNS N
also RB N
demonstrated VBD N
the DT N
most RBS N
common JJ N
SAS-triggered JJ 1_o
responses NNS 1_o
without IN N
perturbation NN N
. . N

Increasing VBG N
the DT N
perturbation NN N
magnitude NN N
accelerated VBD N
postural JJ 1_o
responses NNS 1_o
, , N
but CC N
again RB N
with IN N
a DT N
larger JJR N
acceleration NN N
for IN N
backward JJ N
perturbations NNS N
. . N

We PRP N
conclude VBP N
that IN N
postural JJ N
responses NNS N
to TO N
backward VB N
and CC N
forward VB N
perturbations NNS N
may MD N
be VB N
processed VBN N
by IN N
different JJ N
neural JJ N
circuits NNS N
, , N
with IN N
influence NN N
of IN N
startle NN N
pathways NNS N
on IN N
postural JJ N
responses NNS N
to TO N
backward VB N
perturbations NNS N
. . N

These DT N
findings NNS N
give VBP N
directions NNS N
for IN N
future JJ N
studies NNS N
investigating VBG N
whether IN N
deficits NNS N
in IN N
startle JJ N
pathways NNS N
may MD N
explain VB N
the DT N
prominent JJ N
backward NN N
instability NN N
seen VBN N
in IN N
patients NNS 1_p
with IN 1_p
Parkinson NNP 1_p
's POS 1_p
disease NN 1_p
and CC 1_p
progressive JJ 1_p
supranuclear NN 1_p
palsy NN 1_p
. . 1_p

Chloroprocaine NNP 1_i
and CC 1_i
lidocaine JJ 1_i
decrease NN N
hospital NN N
stay NN N
and CC N
admission NN N
rate NN N
after IN N
outpatient JJ 1_p
epidural JJ 1_p
anesthesia NN 1_p
. . 1_p

Lumbar NNP 1_i
epidural JJ 1_i
anesthesia NN 1_i
with IN 1_i
20 CD 1_i
ml NN 1_i
of IN 1_i
either DT 1_i
3 CD 1_i
% NN 1_i
2-chloroprocaine JJ 1_i
( ( 1_i
C NNP 1_i
) ) 1_i
, , 1_i
1.5 CD 1_i
% NN 1_i
lidocaine NN 1_i
( ( 1_i
L NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
1.5 CD 1_i
% NN 1_i
mepivacaine NN 1_i
( ( 1_i
M NNP 1_i
) ) 1_i
with IN 1_i
epinephrine NN 1_i
was VBD N
studied VBN N
in IN N
84 CD 1_p
outpatients NNS 1_p
undergoing JJ 1_p
surgery NN 1_p
( ( 1_p
extracorporeal JJ 1_p
shock NN 1_p
wave NN 1_p
lithotripsy NN 1_p
( ( 1_p
ESWL NNP 1_p
] NNP 1_p
. . 1_p

The DT N
average JJ 1_o
duration NN 1_o
of IN 1_o
the DT 1_o
procedure NN 1_o
was VBD N
31.9 CD N
minutes NNS N
. . N

The DT N
total JJ 1_o
duration NN 1_o
of IN 1_o
sensory JJ 1_o
anesthesia NN 1_o
was VBD N
133 CD N
+/- JJ N
28 CD N
minutes NNS N
( ( N
C NNP N
) ) N
, , N
182 CD N
+/- JJ N
38 CD N
( ( N
L NNP N
) ) N
, , N
and CC N
247 CD N
+/- JJ N
42 CD N
( ( N
M NNP N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Times NNS 1_o
to TO 1_o
discharge VB 1_o
were VBD N
269 CD N
+/- JJ N
62 CD N
minutes NNS N
( ( N
C NNP N
) ) N
, , N
284 CD N
+/- JJ N
62 CD N
( ( N
L NNP N
) ) N
, , N
and CC N
357 CD N
+/- JJ N
71 CD N
( ( N
M NNP N
) ) N
. . N

The DT N
time NN 1_o
to TO 1_o
discharge VB 1_o
with IN N
M NNP N
, , N
almost RB N
six CD N
hours NNS N
, , N
was VBD N
significantly RB N
longer JJR N
than IN N
with IN N
C NNP N
or CC N
L. NNP N
There EX N
was VBD N
a DT N
trend NN N
to TO N
an DT N
increasing VBG N
rate NN N
of IN N
unplanned JJ 1_o
overnight JJ 1_o
hospital NN 1_o
admission NN 1_o
with IN N
increasing VBG N
duration NN N
of IN N
the DT N
local JJ N
anesthetic JJ N
drug NN N
employed VBN N
. . N

Continuous JJ N
epidural JJ N
anesthesia NN N
with IN N
C NNP N
, , N
L NNP N
or CC N
M NNP N
appears VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
outpatient JJ N
surgical JJ N
procedures NNS N
such JJ N
as IN N
ESWL NNP N
. . N

In IN N
contrast NN N
to TO N
previous JJ N
understanding NN N
, , N
mepivacaine NN N
produces VBZ N
significantly RB N
longer JJR N
anesthesia NN N
and CC N
recovery NN N
times NNS N
and CC N
may MD N
not RB N
be VB N
optimal JJ N
for IN N
outpatient JJ N
epidural JJ N
use NN N
. . N

Activation NN N
and CC N
intermuscular JJ N
coherence NN N
of IN N
distal JJ N
arm NN N
muscles NNS N
during IN N
proximal JJ N
muscle NN N
contraction NN N
. . N

In IN N
the DT N
human JJ N
upper JJ N
extremity NN N
( ( N
UE NNP N
) ) N
, , N
unintended JJ N
effects NNS N
of IN N
proximal JJ N
muscle NN N
activation NN N
on IN N
muscles NNS N
controlling VBG N
the DT N
hand NN N
could MD N
be VB N
an DT N
important JJ N
aspect NN N
of IN N
motor NN N
control NN N
due JJ N
to TO N
the DT N
necessary JJ N
coordination NN N
of IN N
distal NN N
and CC N
proximal JJ N
segments NNS N
during IN N
functional JJ N
activities NNS N
. . N

This DT N
study NN N
aimed VBD N
to TO N
elucidate VB N
the DT N
effects NNS N
of IN N
concurrent JJ N
activation NN N
of IN N
elbow NN N
muscles NNS N
on IN N
the DT N
coordination NN N
between IN N
hand NN N
muscles NNS N
performing VBG N
a DT N
grip NN N
task NN N
. . N

Eleven NNP 1_p
healthy JJ 1_p
subjects NNS 1_p
performed VBN N
precision NN 1_i
grip NN 1_i
tasks NNS 1_i
while IN 1_i
a DT 1_i
constant JJ 1_i
extension NN 1_i
or CC 1_i
flexion NN 1_i
moment NN 1_i
was VBD 1_i
applied VBN 1_i
to TO 1_i
their PRP$ 1_i
elbow NN 1_i
joints NNS 1_i
, , N
inducing VBG N
a DT N
sustained VBN N
submaximal JJ N
contraction NN N
of IN N
elbow NN N
muscles NNS N
to TO N
counter VB N
the DT N
applied JJ N
torque NN N
. . N

Activation NNP N
of IN N
four CD N
hand NN N
muscles NNS N
was VBD N
measured VBN N
during IN N
each DT N
task NN N
condition NN N
using VBG N
surface NN 1_i
electromyography NN 1_i
( ( 1_i
EMG NNP 1_i
) ) 1_i
. . 1_i

When WRB N
concurrent JJ N
activation NN N
of IN N
elbow NN N
muscles NNS N
was VBD N
induced VBN N
, , N
significant JJ N
changes NNS N
in IN N
the DT N
activation NN 1_o
levels NNS 1_o
of IN 1_o
the DT 1_o
hand NN 1_o
muscles NNS 1_o
were VBD N
observed VBN N
, , N
with IN N
greater JJR N
effects NNS N
on IN N
the DT N
extrinsic JJ N
finger NN N
extensor NN N
( ( N
23.2 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
extensor NN N
activation NN N
; : N
p CC N
= VB N
0.003 CD N
) ) N
than IN N
extrinsic JJ N
finger NN N
flexor NN N
( ( N
14.2 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
flexor JJ N
activation NN N
; : N
p CC N
= VB N
0.130 CD N
) ) N
. . N

Elbow NNP 1_o
muscle NN 1_o
activation NN 1_o
also RB N
induced VBD N
involuntary JJ N
changes NNS N
in IN N
the DT N
intrinsic JJ 1_o
thumb NN 1_o
flexor NN 1_o
activation NN 1_o
( ( N
44.6 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
extensor NN N
activation NN N
; : N
p CC N
= VB N
0.005 CD N
) ) N
. . N

EMG-EMG JJ N
coherence NN N
analyses NNS N
revealed VBD N
that IN N
elbow JJ 1_o
muscle NN 1_o
activation NN 1_o
significantly RB N
reduced VBD N
intermuscular JJ 1_o
coherence NN 1_o
between IN 1_o
distal JJ 1_o
muscle NN 1_o
pairs NNS 1_o
, , N
with IN N
its PRP$ N
greatest JJS N
effects NNS N
on IN N
coherence NN N
in IN N
the DT N
β-band NN N
( ( N
13-25 JJ N
Hz NNP N
) ) N
( ( N
average NN N
of IN N
17 CD N
% NN N
decrease NN N
under IN N
30 CD N
% NN N
elbow NN N
flexor JJ N
activation NN N
) ) N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
provide VBP N
evidence NN N
for IN N
involuntary JJ N
, , N
muscle-specific JJ N
interactions NNS N
between IN N
distal NN N
and CC N
proximal JJ N
UE NNP N
muscles NNS N
, , N
which WDT N
may MD N
contribute VB N
to TO N
UE NNP N
motor NN N
performance NN N
in IN N
health NN N
and CC N
disease NN N
. . N

Safety NN N
and CC N
efficacy NN N
of IN N
donepezil NN 1_i
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
neuropsychological JJ N
measures NNS N
. . N

OBJECTIVE NNP N
There EX N
has VBZ N
been VBN N
recent JJ N
interest NN N
in IN N
the DT N
use NN N
of IN N
cognitive JJ 1_i
enhancing VBG 1_i
drugs NNS 1_i
, , N
such JJ N
as IN N
cholinesterase NN 1_i
inhibitors NNS 1_i
, , N
as IN N
a DT N
possible JJ N
treatment NN N
for IN N
executive NN 1_o
functioning NN 1_o
( ( N
EF NNP N
) ) N
deficits NNS N
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
tolerability NN 1_o
, , 1_o
safety NN 1_o
, , 1_o
and CC 1_o
efficacy NN 1_o
of IN N
donepezil NN N
on IN N
EF NNP N
in IN N
a DT N
sample NN 1_p
of IN 1_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

METHOD NNP N
Thirty-four JJ 1_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
ASD NNP 1_p
( ( 1_p
age NN 1_p
range NN 1_p
8-17 CD 1_p
years NNS 1_p
; : 1_p
IQ NNP 1_p
> NNP 1_p
75 CD 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
in IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
of IN N
donepezil NN 1_i
( ( 1_i
doses NNS 1_i
of IN 1_i
5 CD 1_i
and CC 1_i
10 CD 1_i
mg NN 1_i
) ) 1_i
, , 1_i
followed VBN 1_i
by IN 1_i
a DT 1_i
10-week JJ 1_i
open JJ 1_i
label NN 1_i
trial NN 1_i
for IN 1_i
placebo NN 1_i
nonresponders NNS 1_i
. . N

RESULTS VB N
The DT N
effect NN N
of IN 1_i
donepezil NN 1_i
treatment NN N
on IN N
EF NNP N
was VBD N
examined VBN N
. . N

Despite IN N
improvement NN N
on IN N
a DT N
number NN N
of IN 1_o
EF NNP 1_o
measures NNS 1_o
, , N
no DT N
statistically RB N
significant JJ N
between-group JJ N
differences NNS N
were VBD N
found VBN N
( ( N
with IN N
gains NNS N
observed VBN N
for IN N
both DT N
the DT N
placebo NN N
and CC N
donepezil NN N
groups NNS N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
short-term JJ N
treatment NN N
with IN N
donepezil NN N
may MD N
have VB N
limited VBN N
impact NN N
on IN N
cognitive JJ N
functioning NN N
in IN N
ASD NNP N
. . N

Future NNP N
controlled VBD N
trials NNS N
may MD N
need VB N
to TO N
consider VB N
a DT N
longer RBR N
treatment NN N
period NN N
to TO N
detect VB N
significant JJ N
gains NNS N
on IN N
EF NNP N
measures NNS N
. . N

Correlations NNS N
between IN N
the DT N
clinical JJ 1_o
, , 1_o
histological JJ 1_o
and CC 1_o
neurophysiological JJ 1_o
examinations NNS 1_o
in IN N
patients NNS 1_p
before IN 1_p
and CC 1_p
after IN 1_p
parotid JJ 1_i
gland NN 1_i
tumor NN 1_i
surgery NN 1_i
: : 1_i
verification NN N
of IN N
facial JJ N
nerve NN N
transmission NN N
. . N

Parotid NNP N
gland NN N
tumor NN N
surgery NN N
sometimes RB N
leads VBZ N
to TO N
facial JJ N
nerve NN N
paralysis NN N
. . N

Malignant NNP N
more JJR N
than IN N
benign JJ N
tumors NNS N
determine VBP N
nerve NN N
function NN N
preoperatively RB N
, , N
while IN N
postoperative JJ N
observations NNS N
based VBN N
on IN N
clinical JJ N
, , N
histological JJ N
and CC N
neurophysiological JJ N
studies NNS N
have VBP N
not RB N
been VBN N
reported VBN N
in IN N
detail NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
evaluation NN N
and CC N
correlations NNS N
of IN N
histological JJ 1_o
properties NNS 1_o
of IN 1_o
tumor NN 1_o
( ( 1_o
its PRP$ 1_o
size NN 1_o
and CC 1_o
location NN 1_o
) ) 1_o
and CC N
clinical JJ 1_o
and CC 1_o
neurophysiological JJ 1_o
assessment NN 1_o
of IN 1_o
facial JJ 1_o
nerve NN 1_o
function NN 1_o
pre- NN 1_o
and CC 1_o
post-operatively RB 1_o
( ( N
1 CD N
and CC N
6 CD N
months NNS N
) ) N
. . N

Comparative JJ N
studies NNS N
included VBD N
17 CD 1_p
patients NNS 1_p
with IN 1_p
benign JJ 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
13 CD 1_p
) ) 1_p
and CC 1_p
malignant JJ 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
4 CD 1_p
) ) 1_p
tumors NNS 1_p
. . 1_p

Clinical JJ 1_o
assessment NN 1_o
was VBD N
based VBN N
on IN N
House-Brackmann NNP 1_o
scale NN 1_o
( ( 1_o
H-B NNP 1_o
) ) 1_o
, , 1_o
neurophysiological JJ 1_o
diagnostics NNS 1_o
included VBD 1_o
facial JJ 1_o
electroneurography NN 1_o
[ NNP 1_o
ENG NNP 1_o
, , 1_o
compound NN 1_o
muscle NN 1_o
action NN 1_o
potential NN 1_o
( ( 1_o
CMAP NNP 1_o
) ) 1_o
] NN 1_o
, , 1_o
mimetic JJ 1_o
muscle NN 1_o
electromyography NN 1_o
( ( 1_o
EMG NNP 1_o
) ) 1_o
and CC 1_o
blink-reflex JJ 1_o
examinations NNS 1_o
( ( 1_o
BR NNP 1_o
) ) 1_o
. . 1_o

Mainly RB N
grade VBD N
I PRP N
of IN N
H-B NNP 1_o
was VBD N
recorded VBN N
both DT N
pre- JJ N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
and CC N
post-operatively RB N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
small JJ 1_p
( ( 1_p
1.5-2.4 JJ 1_p
cm NN 1_p
) ) 1_p
benign NN 1_p
tumors NNS 1_p
located VBN 1_p
in IN 1_p
superficial JJ 1_p
lobes NNS 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
medium NN 1_p
size NN 1_p
( ( 1_p
2.5-3.4 JJ 1_p
cm NN 1_p
) ) 1_p
malignant NN 1_p
tumors NNS 1_p
in IN 1_p
both DT 1_p
lobes NNS 1_p
were VBD N
scored VBN N
at IN N
grade NN N
I PRP N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
and CC N
III NNP N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
pre- NN N
and CC N
mainly RB N
VI NNP N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
post-operatively RB N
. . N

CMAP NNP 1_o
amplitudes NNS 1_o
after IN N
stimulation NN N
of IN N
mandibular JJ N
marginal JJ N
branch NN N
were VBD N
reduced VBN N
at IN N
about RB N
25 CD N
% NN N
in IN N
patients NNS 1_p
with IN 1_p
benign JJ 1_p
tumors NNS 1_p
after IN N
surgery NN N
. . N

In IN N
the DT N
cases NNS N
of IN N
malignant JJ N
tumors NNS N
CMAPs NNP 1_o
were VBD N
not RB N
recorded VBN N
following VBG N
stimulation NN N
of IN N
any DT N
branch NN N
. . N

A DT N
similar JJ N
trend NN N
was VBD N
found VBN N
for IN N
BR NNP 1_o
results NNS 1_o
. . 1_o

H-B NNP 1_o
and CC 1_o
ENG NNP 1_o
results NNS N
revealed VBD N
positive JJ N
correlations NNS N
between IN N
the DT N
type NN N
of IN N
tumor NN N
and CC N
surgery NN N
with IN N
facial JJ N
nerve NN N
function NN N
. . N

Neurophysiological JJ N
studies NNS N
detected VBN N
clinically RB 1_o
silent JJ 1_o
facial JJ 1_o
nerve NN 1_o
neuropathy NN 1_o
of IN 1_o
mandibular JJ 1_o
marginal JJ 1_o
branch NN 1_o
in IN N
postoperative JJ N
period NN N
. . N

Needle NNP 1_o
EMG NNP 1_o
, , 1_o
ENG NNP 1_o
and CC 1_o
BR NNP 1_o
examinations NNS 1_o
allow VBP N
for IN N
the DT N
evaluation NN N
of IN N
face NN 1_o
muscles NNS 1_o
reinnervation NN 1_o
and CC 1_o
facial JJ 1_o
nerve NN 1_o
regeneration NN 1_o
. . 1_o

36-month JJ N
treatment NN N
experience NN N
of IN N
two CD N
doses NNS N
of IN N
leuprolide JJ 1_i
acetate JJ 1_i
3-month JJ 1_i
depot NN 1_i
for IN N
children NNS 1_p
with IN 1_p
central JJ 1_p
precocious JJ 1_p
puberty NN 1_p
. . 1_p

CONTEXT NNP N
We PRP N
have VBP N
recently RB N
demonstrated VBN N
short-term JJ N
( ( N
6-month JJ N
) ) N
efficacy NN N
and CC N
safety NN N
of IN N
leuprolide JJ 1_i
acetate JJ 1_i
3-month JJ 1_i
depot NN 1_i
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS 1_p
with IN 1_p
central JJ 1_p
precocious JJ 1_p
puberty NN 1_p
( ( 1_p
CPP NNP 1_p
) ) 1_p
. . 1_p

OBJECTIVE UH N
To TO N
assess VB N
long-term JJ 1_o
( ( N
36-month JJ N
) ) N
hypothalamic-pituitary-gonadal JJ 1_o
axis JJ 1_o
suppression NN 1_o
and CC 1_o
safety NN 1_o
of IN N
leuprolide JJ 1_i
acetate JJ 1_i
3-month JJ 1_i
depot NN 1_i
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS 1_p
with IN 1_p
CPP NNP 1_p
. . 1_p

DESIGN NNP N
Open-label NNP N
, , N
36-month JJ N
extension NN N
. . N

SETTING NNP N
Twenty NNP 1_p
pediatric JJ 1_p
endocrine NN 1_p
centers NNS 1_p
. . 1_p

PATIENTS VB N
Seventy-two JJ 1_p
children NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
8.5 CD 1_p
± NN 1_p
1.6 CD 1_p
y NN 1_p
; : 1_p
65 CD 1_p
females NNS 1_p
) ) 1_p
with IN 1_p
CPP NNP 1_p
completed VBD 1_p
and CC 1_p
showed VBD 1_o
maintenance NN 1_o
of IN 1_o
LH NNP 1_o
suppression NN 1_o
after IN 1_p
a DT 1_p
6-month JJ 1_p
lead-in NN 1_p
study NN 1_p
. . N

INTERVENTION NNP 1_i
Leuprolide NNP 1_i
acetate NN 1_i
depot NN 1_i
( ( N
11.25 CD N
or CC N
30 CD N
mg NN N
) ) N
administered VBD N
im JJ N
every DT N
3 CD N
months NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP 1_o
Peak-stimulated NNP 1_o
LH NNP 1_o
, , 1_o
estradiol NN 1_o
, , 1_o
T NNP 1_o
, , 1_o
growth NN 1_o
rate NN 1_o
, , 1_o
pubertal JJ 1_o
progression NN 1_o
, , 1_o
and CC 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
AEs NNP 1_o
) ) 1_o
. . N

RESULTS JJ N
Twenty-nine NNP N
of IN N
34 CD N
subjects NNS N
in IN N
the DT N
11.25-mg JJ N
group NN N
and CC N
36 CD N
of IN N
38 CD N
subjects NNS N
in IN N
the DT N
30-mg JJ N
group NN N
had VBD 1_o
LH NNP 1_o
values NNS 1_o
< VBP N
4 CD N
mIU/mL NNS N
after IN N
day NN N
1 CD N
at IN N
all DT N
time NN N
points NNS N
. . N

All DT N
seven CD N
subjects NNS N
who WP N
escaped VBD 1_o
LH NNP 1_o
suppression NN 1_o
at IN N
any DT N
time NN N
still RB N
maintained VBD 1_o
sex NN 1_o
steroid NN 1_o
concentrations NNS 1_o
at IN N
prepubertal JJ N
levels NNS N
and CC N
showed VBD N
no DT N
signs NNS N
of IN 1_o
pubertal JJ 1_o
progression NN 1_o
. . 1_o

AEs NNP 1_o
were VBD N
comparable JJ N
between IN N
groups NNS N
, , N
with IN 1_o
injection NN 1_o
site NN 1_o
pain NN 1_o
being VBG N
the DT N
most RBS N
common JJ N
( ( N
26.4 CD N
% NN N
overall JJ N
) ) N
. . N

No DT 1_o
AE NNP 1_o
led VBD N
to TO N
discontinuation NN N
of IN N
study JJ N
drug NN N
. . N

The DT 1_o
safety NN 1_o
profile NN 1_o
over IN N
36 CD N
months NNS N
was VBD N
comparable JJ N
to TO N
that DT N
observed VBD N
during IN N
the DT N
6-month JJ N
pivotal NN N
study NN N
. . N

CONCLUSIONS VB N
The DT N
two CD N
doses NNS N
of IN 1_i
leuprolide JJ 1_i
acetate JJ 1_i
3-month JJ 1_i
depot NN N
were VBD N
associated VBN N
with IN N
an DT 1_o
acceptable JJ 1_o
safety NN 1_o
profile NN 1_o
and CC N
provided VBD 1_o
maintenance NN 1_o
of IN 1_o
LH NNP 1_o
suppression NN 1_o
in IN N
the DT N
majority NN N
of IN N
children NNS N
with IN N
CPP NNP N
during IN N
the DT N
36 CD N
months NNS N
of IN N
the DT N
study NN N
or CC N
until IN N
readiness NN N
for IN N
puberty NN N
. . N

Immediately RB N
restored VBN N
, , N
single-tapered JJ N
implants NNS 1_i
in IN 1_p
the DT 1_p
anterior JJ 1_p
maxilla NN 1_p
: : 1_p
prosthodontic JJ N
and CC N
aesthetic JJ N
outcomes NNS N
after IN N
1 CD N
year NN N
. . N

BACKGROUND NNP N
Conventional NNP N
implant JJ N
protocols NNS N
advocate VBP N
a DT N
two-stage NN N
technique NN N
with IN N
a DT N
load-free JJ N
, , N
submerged VBD N
healing JJ N
period NN N
. . N

Recent JJ N
studies NNS N
suggest VBP N
that IN N
immediate JJ N
restoration NN N
of IN N
single JJ N
implants NNS N
may MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
prosthodontic JJ 1_o
and CC 1_o
aesthetic JJ 1_o
peri-implant JJ 1_o
mucosal NN 1_o
outcomes NNS N
of IN N
immediately RB 1_p
restored VBN 1_p
, , 1_p
Southern JJ 1_p
single-tapered JJ 1_p
implants NNS 1_i
in IN 1_p
the DT 1_p
anterior JJ 1_p
maxilla NN 1_p
after IN 1_p
1 CD 1_p
year NN 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
Participants NNP 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
: : 1_p
43.25 CD 1_p
years NNS 1_p
; : 1_p
range NN 1_p
: : 1_p
23-71 JJ 1_p
years NNS 1_p
) ) 1_p
satisfying VBG 1_p
specified VBN 1_p
inclusion NN 1_p
criteria NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
conventional JJ N
two-stage JJ 1_i
restoration NN 1_i
( ( N
control NN N
group NN N
; : N
n=14 CC N
) ) N
and CC N
immediate JJ 1_i
restoration NN 1_i
groups NNS 1_i
( ( N
test NN N
group NN N
; : N
n CC N
=14 NN N
) ) N
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

Tapered VBN N
, , N
roughened-surface JJ N
Southern JJ N
implants NNS N
were VBD N
placed VBN N
using VBG N
a DT N
standardized JJ N
technique NN N
, , N
and CC N
implant JJ N
level NN N
bone NN N
impressions NNS N
were VBD N
made VBN N
. . N

Provisional JJ N
screw-retained JJ N
crowns NNS N
, , N
out IN N
of IN N
occlusion NN N
, , N
were VBD N
placed VBN N
at IN N
second-stage NN N
surgery NN N
after IN N
26 CD N
weeks NNS N
for IN N
the DT N
conventional JJ N
restoration NN N
group NN N
, , N
and CC N
within IN N
4 CD N
hours NNS N
of IN N
implant JJ N
placement NN N
for IN N
the DT N
immediate JJ N
restoration NN N
group NN N
. . N

Both DT N
groups NNS N
had VBD N
definitive JJ N
screw-retained JJ N
metal-ceramic JJ N
crowns NNS N
placed VBN N
in IN N
occlusion NN N
8 CD N
weeks NNS N
later RB N
. . N

Peri-implant JJ 1_o
mucosal NN 1_o
response NN 1_o
and CC 1_o
papilla NN 1_o
index NN 1_o
were VBD N
recorded VBN N
4 CD N
weeks NNS N
after IN N
definitive JJ N
crown JJ N
placement NN N
to TO N
allow VB N
for IN N
mucosal JJ N
maturation NN N
and CC N
at IN N
1 CD N
year NN N
. . N

Prosthodontic NNP 1_o
and CC 1_o
aesthetic JJ 1_o
outcomes NNS N
were VBD N
assessed VBN N
using VBG N
established VBN N
criteria NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
within IN N
, , N
or CC N
between IN N
, , N
the DT N
control NN N
and CC N
test NN N
groups NNS N
for IN N
age NN 1_o
, , 1_o
gender NN 1_o
, , 1_o
bone NN 1_o
quality NN 1_o
or CC 1_o
quantity NN 1_o
, , 1_o
implant JJ 1_o
stability NN 1_o
measurements NNS 1_o
at IN 1_o
surgery NN 1_o
, , N
or CC N
implant JJ 1_o
length NN 1_o
. . 1_o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
implant JJ 1_o
success NN 1_o
rate NN 1_o
as IN N
determined VBN N
by IN N
radiographic JJ N
bone NN 1_o
loss NN 1_o
and CC N
stability NN N
tests NNS N
after IN N
1 CD N
year NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
prosthodontic JJ 1_o
maintenance NN 1_o
, , 1_o
peri-implant JJ 1_o
mucosal NN 1_o
response NN 1_o
, , 1_o
and CC 1_o
papilla NN 1_o
index NN 1_o
between IN N
the DT N
two CD N
groups NNS N
over IN N
1 CD N
year NN N
. . N

CONCLUSIONS NNP N
Tapered NNP N
, , N
roughened-surface JJ N
implants NNS N
immediately RB N
restored VBN N
with IN N
single JJ N
provisional JJ N
crowns NNS N
at IN N
surgery NN N
and CC N
definitive JJ N
crowns NNS N
8 CD N
weeks NNS N
later RB N
were VBD N
as IN N
prosthodontically RB N
and CC N
aesthetically RB N
successful JJ N
as IN N
conventionally RB N
restored VBN N
two-stage JJ N
implants NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
service NN N
. . N

Restoring VBG 1_i
single JJ N
implants NNS N
immediately RB N
with IN N
screw-retained JJ N
crowns NNS N
is VBZ N
an DT N
efficient JJ N
procedure NN N
, , N
but CC N
the DT N
short-term JJ N
outcome NN N
is VBZ N
by IN N
no DT N
means NNS N
superior VBP N
to TO N
a DT N
conventional JJ N
two-stage JJ N
approach NN N
. . N

High-pressure NN 1_i
, , 1_i
rapid-inflation NN 1_i
pneumatic JJ 1_i
compression NN 1_i
improves VBZ N
venous JJ N
hemodynamics NNS N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
and CC 1_p
patients NNS 1_p
who WP 1_p
are VBP 1_p
post-thrombotic JJ 1_p
. . 1_p

PURPOSE NNP N
Deep NNP 1_p
vein NN 1_p
thrombosis NN 1_p
( ( 1_p
DVT NNP 1_p
) ) 1_p
is VBZ N
a DT N
preventable JJ N
cause NN N
of IN N
morbidity NN 1_p
and CC 1_p
mortality NN 1_p
in IN 1_p
patients NNS 1_p
who WP 1_p
are VBP 1_p
hospitalized VBN 1_p
. . 1_p

An DT N
important JJ N
part NN N
of IN N
the DT N
mechanism NN N
of IN N
DVT NNP N
prophylaxis NN N
with IN N
intermittent JJ N
pneumatic JJ N
compression NN N
( ( N
IPC NNP N
) ) N
is VBZ N
reduced VBN N
venous JJ N
stasis NN N
with IN N
increased JJ N
velocity NN N
of IN N
venous JJ N
return NN N
. . N

The DT N
conventional JJ N
methods NNS N
of IN N
IPC NNP N
use NN N
low JJ N
pressure NN N
and CC N
slow JJ N
inflation NN N
of IN N
the DT N
air NN N
bladder NN N
on IN N
the DT N
leg NN N
to TO N
augment VB N
venous JJ N
return NN N
. . N

Recently RB N
, , N
compression NN N
devices NNS N
have VBP N
been VBN N
designed VBN N
that IN N
produce VBP N
high JJ N
pressure NN N
and CC N
rapid JJ N
inflation NN N
of IN N
air NN N
cuffs NNS N
on IN N
the DT N
plantar NN N
plexus NN N
of IN N
the DT N
foot NN N
and CC N
the DT N
calf NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
venous JJ N
velocity NN N
response NN N
to TO N
high-pressure NN N
, , N
rapid-inflation NN N
compression NN N
devices NNS N
versus VBP N
standard JJ N
, , N
low-pressure JJ N
, , N
slow-inflation JJ N
compression NN N
devices NNS N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
and CC 1_p
patients NNS 1_p
with IN 1_p
severe JJ 1_p
post-thrombotic JJ 1_p
venous JJ 1_p
disease NN 1_p
. . 1_p

METHOD NNP N
Twenty-two NNP 1_p
lower JJR 1_p
extremities NNS 1_p
from IN 1_p
healthy JJ 1_p
volunteers NNS 1_p
and CC 1_p
11 CD 1_p
lower JJR 1_p
extremities NNS 1_p
from IN 1_p
patients NNS 1_p
with IN 1_p
class NN 1_p
4 CD 1_p
to TO 1_p
class NN 1_p
6 CD 1_p
post-thrombotic JJ 1_p
chronic JJ 1_p
venous JJ 1_p
insufficiency NN 1_p
were VBD 1_p
studied VBN 1_p
. . 1_p

With IN N
duplex JJ 1_i
ultrasound NN 1_i
scanning NN 1_i
( ( N
ATL-Ultramark NNP N
9 CD N
, , N
Advanced NNP N
Tech NNP N
Laboratory NNP N
, , N
Bothell NNP N
, , N
Wash NNP N
) ) N
, , N
acute JJ N
DVT NNP N
was VBD N
excluded VBN N
before IN N
subject JJ N
evaluation NN N
. . N

Venous JJ N
velocities NNS N
were VBD N
monitored VBN N
after IN N
the DT N
application NN N
of IN N
each DT N
of IN N
five CD N
IPC NNP N
devices NNS N
, , N
with IN N
all PDT N
the DT N
patients NNS N
in IN N
the DT N
supine JJ N
position NN N
. . N

Three CD 1_i
high-pressure NN 1_i
, , 1_i
rapid-compression NN 1_i
devices NNS 1_i
and CC 1_i
two CD 1_i
standard NN 1_i
, , 1_i
low-pressure JJ 1_i
, , 1_i
slow-inflation JJ 1_i
compression NN 1_i
devices NNS 1_i
were VBD N
applied VBN N
in IN N
a DT N
random JJ N
sequence NN N
. . N

Maximal NNP N
venous JJ N
velocities NNS N
were VBD N
obtained VBN N
at IN N
the DT N
common JJ N
femoral JJ N
vein NN N
and CC N
the DT N
popliteal NN N
vein NN N
for IN N
all PDT N
the DT N
devices NNS N
and CC N
were VBD N
recorded VBN N
as IN N
the DT N
mean JJ N
peak JJ N
velocity NN N
of IN N
three CD N
compression NN N
cycles NNS N
and CC N
compared VBN N
with IN N
baseline NN N
velocities NNS N
. . N

RESULTS VB N
The DT N
baseline NN N
venous JJ N
velocities NNS N
were VBD N
higher JJR N
in IN N
the DT N
femoral JJ N
veins NNS N
than IN N
in IN N
the DT N
popliteal NN N
veins NNS N
in IN N
both DT N
the DT N
volunteers NNS N
and CC N
the DT N
post-thrombotic JJ N
subjects NNS N
. . N

Standard NNP 1_o
and CC 1_o
high-pressure NN 1_o
, , 1_o
rapid-inflation NN 1_o
compression NN 1_o
significantly RB N
increased VBD N
the DT N
popliteal NN 1_o
and CC 1_o
femoral JJ 1_o
vein NN 1_o
velocities NNS 1_o
in IN N
healthy JJ N
and CC N
post-thrombotic JJ N
subjects NNS N
. . N

High-pressure NN N
, , N
rapid-inflation NN N
compression NN N
produced VBD N
significantly RB N
higher JJR N
maximal JJ 1_o
venous JJ 1_o
velocities NNS 1_o
in IN 1_o
the DT 1_o
popliteal NN 1_o
and CC 1_o
femoral JJ 1_o
veins NNS 1_o
in IN N
both DT N
healthy JJ N
volunteers NNS N
and CC N
patients NNS N
who WP N
were VBD N
post-thrombotic JJ N
as IN N
compared VBN N
with IN N
standard JJ N
compression NN N
. . N

Compared VBN N
with IN N
the DT N
healthy JJ N
volunteers NNS N
, , N
the DT N
patients NNS N
who WP N
were VBD N
post-thrombotic JJ N
had VBD N
a DT N
significantly RB N
attenuated VBN N
velocity NN 1_o
response NN 1_o
at IN N
both DT N
the DT N
popliteal NN N
and CC N
the DT N
femoral JJ N
vein NN N
levels NNS N
. . N

CONCLUSION NNP N
High-pressure NNP N
, , N
rapid-inflation NN N
pneumatic JJ N
compression NN N
increases NNS N
popliteal NN 1_o
and CC 1_o
femoral JJ 1_o
vein NN 1_o
velocity NN 1_o
as IN N
compared VBN N
with IN N
standard JJ N
, , N
low-pressure JJ N
, , N
slow-inflation JJ N
pneumatic JJ N
compression NN N
. . N

Patients NNS 1_p
with IN 1_p
post-thrombotic JJ 1_p
venous JJ 1_p
disease NN 1_p
have VBP N
a DT N
compromised JJ N
hemodynamic JJ N
response NN N
to TO N
all DT N
IPC NNP N
devices NNS N
. . N

However RB N
, , N
an DT N
increased VBN N
velocity NN N
response NN N
to TO N
the DT N
high-pressure NN N
, , N
rapid-inflation NN N
compression NN N
device NN N
is VBZ N
preserved VBN N
. . N

High-pressure NN N
, , N
rapid-inflation NN N
pneumatic JJ N
compression NN N
may MD N
offer VB N
additional JJ N
protection NN N
from IN N
thrombotic JJ N
complications NNS N
on IN N
the DT N
basis NN N
of IN N
an DT N
improved JJ N
hemodynamic JJ 1_o
response NN 1_o
, , N
both DT N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
and CC 1_p
in IN 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
post-thrombotic JJ 1_p
. . 1_p

Information NNP 1_i
source NN 1_i
affects VBZ N
peers NNS N
' POS N
initial JJ N
attitudes NNS N
toward IN N
autism NN 1_o
. . 1_o

Authors NNS N
examined VBD N
the DT N
effects NNS N
of IN N
information NN N
source NN N
on IN N
peers NNS N
' POS N
cognitive NN 1_o
and CC 1_o
behavioral JJ 1_o
attitudes NNS 1_o
toward IN N
an DT N
unfamiliar JJ 1_p
child NN 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Children NNP 1_p
( ( 1_p
N=296 NNP 1_p
; : 1_p
M NNP 1_p
age=10.21 IN 1_p
years NNS 1_p
) ) 1_p
received VBD N
information NN N
about IN N
an DT N
unfamiliar JJ 1_p
child NN 1_p
with IN 1_p
autism NN 1_p
from IN N
one CD N
of IN N
the DT N
following JJ N
sources NNS N
: : N
( ( N
a DT N
) ) N
videotape NN 1_i
, , N
( ( N
b NN N
) ) N
teacher NN 1_i
, , N
( ( N
c NN N
) ) N
hypothetical JJ 1_i
mother NN 1_i
, , N
( ( N
d NN N
) ) N
hypothetical JJ 1_i
father NN 1_i
, , N
or CC N
( ( N
e NN N
) ) N
hypothetical JJ 1_i
" NNP 1_i
doctor NN 1_i
. . 1_i

" JJ 1_i
Interactive JJ N
effects NNS N
between IN N
source NN N
, , N
and CC N
sex NN N
and CC N
grade NN N
were VBD N
found VBN N
for IN N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
. . N

Fifth-graders NNS 1_p
reported VBD N
more RBR N
favorable JJ N
cognitive JJ 1_o
and CC 1_o
behavioral JJ 1_o
attitudes NNS 1_o
when WRB N
information NN N
was VBD N
provided VBN N
by IN N
extra-familial JJ N
sources NNS N
( ( N
i.e. NN N
, , N
" NNP N
doctor NN N
" NN N
) ) N
versus NN N
parent NN N
sources NNS N
. . N

Mother NNP N
yielded VBD N
more RBR 1_o
persuasive JJ 1_o
effects NNS 1_o
on IN 1_o
behavioral JJ 1_o
attitudes NNS 1_o
for IN N
third-graders NNS N
versus JJ N
fifth-graders NNS N
. . N

Attitudes NNS N
toward IN N
autism NN N
differ VBP N
depending VBG N
on IN N
who WP N
provides VBZ N
information NN N
about IN N
the DT N
disability NN N
. . N

Persuasion NNP N
theory NN N
appears VBZ N
useful JJ N
to TO N
guide VB N
evaluation NN N
of IN N
educational JJ N
interventions NNS N
to TO N
improve VB N
attitudes NNS 1_o
towards IN 1_o
autism NN 1_o
. . 1_o

Implications NNS N
of IN N
the DT N
findings NNS N
, , N
study NN N
limitations NNS N
, , N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

Predictive JJ N
and CC N
prognostic JJ N
roles NNS N
of IN N
BRAF NNP 1_p
mutation NN 1_p
in IN 1_p
stage NN 1_p
III NNP 1_p
colon NN 1_p
cancer NN 1_p
: : 1_p
results NNS N
from IN N
intergroup JJ N
trial NN N
CALGB NNP N
89803 CD N
. . N

PURPOSE NNP N
Alterations NNPS N
in IN N
the DT N
RAS-RAF-MAP2K NNP N
( ( N
MEK NNP N
) ) N
-MAPK VBP N
signaling VBG N
pathway NN N
are VBP N
major JJ N
drivers NNS N
in IN N
colorectal JJ 1_p
carcinogenesis NN 1_p
. . 1_p

In IN N
colorectal JJ N
cancer NN N
, , N
BRAF NNP N
mutation NN N
is VBZ N
associated VBN N
with IN N
microsatellite JJ N
instability NN N
( ( N
MSI NNP N
) ) N
, , N
and CC N
typically RB N
predicts VBZ N
inferior JJ N
prognosis NN N
. . N

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
BRAF NNP N
mutation NN N
on IN N
survival NN N
and CC N
treatment NN N
efficacy NN N
in IN N
patients NNS 1_p
with IN 1_p
stage NN 1_p
III NNP 1_p
colon NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
We PRP N
assessed VBD N
status NN 1_i
of IN 1_i
BRAF NNP 1_i
c.1799T NN 1_i
> VBZ 1_i
A NNP 1_i
( ( 1_i
p.V600E NN 1_i
) ) 1_i
mutation NN 1_i
and CC 1_i
MSI NNP 1_i
in IN N
506 CD 1_p
stage NN 1_p
III NNP 1_p
colon NN 1_p
cancer NN 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
adjuvant NN 1_p
chemotherapy NN 1_i
trial NN 1_i
[ NNP 1_i
5-fluorouracil CD 1_i
and CC 1_i
leucovorin NN 1_i
( ( 1_i
FU/LV NNP 1_i
) ) 1_i
vs. FW 1_i
irinotecan JJ 1_i
( ( 1_i
CPT11 NNP 1_i
) ) 1_i
, , 1_i
FU NNP 1_i
and CC 1_i
LV NNP 1_i
( ( 1_i
IFL NNP 1_i
) ) 1_i
; : 1_i
CALGB $ N
89803 CD N
] NNP N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
model NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
prognostic JJ N
role NN N
of IN N
BRAF NNP N
mutation NN N
, , N
adjusting VBG N
for IN N
clinical JJ N
features NNS N
, , N
adjuvant JJ N
chemotherapy NN 1_i
arm NN N
, , N
and CC N
MSI NNP N
status NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
431 CD N
BRAF NNP N
wild-type JJ N
patients NNS N
, , N
75 CD 1_p
BRAF-mutated JJ 1_p
patients NNS 1_p
experienced VBD N
significantly RB N
worse JJR N
overall JJ 1_o
survival NN 1_o
[ NNP 1_o
OS NNP 1_o
; : 1_o
log-rank JJ N
P NNP N
= NNP N
0.015 CD N
; : N
multivariate NN N
HR NNP N
= NNP N
1.66 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.05-2.63 JJ N
] NN N
. . N

By IN N
assessing VBG N
combined JJ N
status NN N
of IN N
BRAF NNP N
and CC N
MSI NNP N
, , N
it PRP N
seemed VBD N
that IN N
BRAF-mutated NNP N
MSS NNP N
( ( N
microsatellite JJ N
stable NN N
) ) N
tumor NN N
was VBD N
an DT N
unfavorable JJ N
subtype NN N
, , N
whereas JJ N
BRAF NNP N
wild-type JJ N
MSI-high NNP N
tumor NN N
was VBD N
a DT N
favorable JJ N
subtype NN N
, , N
and CC N
BRAF-mutated JJ N
MSI-high JJ N
tumor NN N
and CC N
BRAF NNP N
wild-type JJ N
MSS NNP N
tumor NN N
were VBD N
intermediate JJ N
subtypes NNS N
. . N

Among IN N
patients NNS N
with IN N
BRAF-mutated JJ N
tumors NNS N
, , N
a DT N
nonsignificant JJ N
trend NN N
toward IN N
improved JJ N
OS NNP 1_o
was VBD N
observed VBN N
for IN N
IFL NNP 1_i
versus NN N
FU/LV NNP 1_i
arm NN N
( ( N
multivariate JJ N
HR NNP N
= NNP N
0.52 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.25-1.10 NN N
) ) N
. . N

Among IN N
patients NNS N
with IN N
BRAF NNP N
wild-type JJ N
cancer NN N
, , N
IFL NNP 1_i
conferred VBD N
no DT N
suggestion NN N
of IN N
benefit NN N
beyond IN N
FU/LV NNP 1_i
alone RB N
( ( N
multivariate JJ N
HR NNP N
= NNP N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.72-1.46 NN N
) ) N
. . N

CONCLUSIONS NNP N
BRAF NNP N
mutation NN N
is VBZ N
associated VBN N
with IN N
inferior JJ N
survival NN 1_o
in IN N
stage NN 1_p
III NNP 1_p
colon NN 1_p
cancer NN 1_p
. . 1_p

Additional JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
whether IN N
there EX N
is VBZ N
any DT N
predictive JJ N
role NN N
of IN N
BRAF NNP N
mutation NN N
for IN N
irinotecan-based JJ 1_i
therapy NN 1_i
. . 1_i

Greater NNP N
knowledge NN 1_o
gain NN 1_o
with IN N
structured VBN 1_i
than IN N
student-directed JJ 1_i
learning NN 1_i
in IN N
Child NNP 1_p
Health NNP 1_p
: : 1_p
cluster NN N
randomized VBD N
trial NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
detect VB N
a DT N
difference NN N
in IN N
knowledge NN 1_o
gain NN 1_o
between IN N
students NNS 1_p
receiving VBG 1_p
structured JJ 1_i
versus NN 1_i
student-directed JJ 1_i
learning NN 1_i
for IN 1_p
the DT 1_p
two-week JJ 1_p
Child NNP 1_p
Health NNP 1_p
outpatient NN 1_p
module NN 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
138 CD 1_p
phase NN 1_p
3 CD 1_p
( ( 1_p
year NN 1_p
4 CD 1_p
) ) 1_p
medical JJ 1_p
students NNS 1_p
in IN 1_p
10 CD 1_p
two-week JJ 1_p
paediatric JJ 1_p
outpatient NN 1_p
blocks NNS 1_p
at IN 1_p
the DT 1_p
Department NNP 1_p
of IN 1_p
Child NNP 1_p
Health NNP 1_p
, , 1_p
University NNP 1_p
of IN 1_p
Dundee NNP 1_p
, , 1_p
Scotland NNP 1_p
, , N
were VBD N
randomized VBN N
to TO N
student-directed JJ 1_i
or CC 1_i
structured VBN 1_i
learning NN 1_i
between IN N
January NNP N
and CC N
December NNP N
2002 CD N
. . N

Pre- JJ 1_o
and CC 1_o
post-course JJ 1_o
tests NNS 1_o
were VBD N
administered VBN N
at IN N
the DT N
start NN N
and CC N
the DT N
end NN N
of IN N
the DT N
attachment NN N
; : N
129 CD 1_p
students NNS 1_p
sat VBD 1_p
both DT 1_p
tests NNS 1_p
. . 1_p

Results NNS N
are VBP N
presented VBN N
as IN N
mean JJ N
scores NNS N
with IN N
standard JJ N
deviations NNS N
or CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
in IN N
parentheses NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
gain NN 1_o
in IN 1_o
knowledge NN 1_o
of IN N
the DT N
Child NNP N
Health NNP N
core NN N
curriculum NN N
that WDT N
is VBZ N
covered VBN N
in IN N
the DT N
outpatient JJ N
setting NN N
. . N

Although IN N
pre-course JJ 1_o
scores NNS 1_o
were VBD N
similar JJ N
( ( N
student-directed JJ N
25.3 CD N
( ( N
7.3 CD N
) ) N
; : N
structured VBN N
24.8 CD N
( ( N
7.5 CD N
) ) N
) ) N
the DT N
structured JJ N
approach NN N
resulted VBD N
in IN N
higher JJR N
post-course NN 1_o
scores NNS 1_o
in IN N
comparison NN N
with IN N
the DT N
student-directed JJ N
approach NN N
( ( N
student-directed JJ N
41.8 CD N
( ( N
9.4 CD N
) ) N
; : N
structured VBN N
53.8 CD N
( ( N
8.8 CD N
) ) N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

Knowledge NNP 1_o
gain NN 1_o
showed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
learning NN N
approaches NNS N
( ( N
student-directed JJ N
16.5 CD N
( ( N
3.7 CD N
) ) N
; : N
structured VBN N
29.1 CD N
( ( N
3.8 CD N
) ) N
, , N
difference NN N
= VBD N
12.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.3 CD N
to TO N
13.9 CD N
) ) N
) ) N
. . N

Low JJ N
pre-course JJ 1_o
scores NNS 1_o
or CC N
gender VB N
did VBD N
not RB N
affect VB N
knowledge NN 1_o
gain NN 1_o
. . 1_o

In IN N
the DT N
Child NNP N
Health NNP N
outpatient NN N
setting NN N
, , N
the DT N
'traditional NNP N
' POS N
structured JJ N
approach NN N
led VBD N
to TO N
significantly RB N
greater JJR N
knowledge NN 1_o
gain NN 1_o
in IN N
comparison NN N
with IN N
the DT N
'novel NNP N
' POS N
student-directed JJ N
approach NN N
. . N

The DT N
findings NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
careful JJ N
evaluation NN N
of IN N
novel JJ N
medical JJ N
education NN N
strategies NNS N
before IN N
their PRP$ N
implementation NN N
in IN N
medical JJ N
schools NNS N
, , N
and CC N
the DT N
need NN N
for IN N
further JJ N
research NN N
to TO N
define VB N
the DT N
effective JJ N
methods NNS N
for IN N
delivering VBG N
medical JJ N
education NN N
in IN N
Child NNP N
Health NNP N
. . N

Comparison NNP N
of IN N
neodymium-doped JJ 1_i
yttrium NN 1_i
aluminum NN 1_i
garnet NN 1_i
laser NN 1_i
treatment NN 1_i
with IN N
cold JJ 1_i
knife NN 1_i
endoscopic NN 1_i
incision NN 1_i
of IN N
urethral JJ N
strictures NNS N
in IN N
male JJ 1_p
patients NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN 1_o
of IN N
visual JJ 1_i
laser NN 1_i
ablation NN 1_i
treatment NN 1_i
with IN 1_i
neodymium-doped JJ 1_i
yttrium NN 1_i
aluminum NN 1_i
garnet NN 1_i
( ( 1_i
Nd NNP 1_i
: : 1_i
YAG NN 1_i
) ) 1_i
laser NN N
in IN 1_p
male JJ 1_p
patients NNS 1_p
with IN 1_p
urethral JJ 1_p
strictures NNS 1_p
and CC N
to TO N
compare VB N
the DT N
effects NNS N
with IN N
those DT N
obtained VBN N
in IN N
patients NNS N
treated VBN N
with IN N
Sachse NNP N
's POS N
optical JJ N
urethrotomy NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty NNP 1_p
patients NNS 1_p
aged VBD 1_p
22 CD 1_p
to TO 1_p
83 CD 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
61.8 CD 1_p
) ) 1_p
with IN 1_p
primary JJ 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
26 CD 1_p
, , 1_p
52 CD 1_p
% NN 1_p
) ) 1_p
and CC 1_p
recurrent NN 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
24 CD 1_p
, , 1_p
48 CD 1_p
% NN 1_p
) ) 1_p
urethral JJ 1_p
strictures VBZ 1_p
0.3 CD 1_p
to TO 1_p
2.4 CD 1_p
cm NNS 1_p
long RB 1_p
qualified VBD 1_p
for IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
30 CD N
men NNS N
treated VBD N
using VBG N
visual JJ 1_i
laser NN 1_i
ablation NN 1_i
of IN 1_i
urethral JJ 1_i
strictures NNS 1_i
( ( 1_i
VLASU NNP 1_i
) ) 1_i
with IN 1_i
Nd NNP 1_i
: : 1_i
YAGlaser NN 1_i
and CC N
20 CD N
men NNS N
treated VBN N
by IN N
correction NN 1_i
of IN 1_i
urethral JJ 1_i
strictures NNS 1_i
using VBG 1_i
Sachse NNP 1_i
's POS 1_i
optical JJ 1_i
urethrotomy NN 1_i
. . 1_i

RESULTS VB N
At IN N
12-month JJ N
follow-up NN N
, , N
seven CD N
( ( N
35 CD N
% NN N
) ) N
patients NNS N
who WP N
underwent JJ N
optical JJ 1_i
urethrotomy NN 1_i
and CC N
21 CD N
( ( N
70 CD N
% NN N
) ) N
in IN N
the DT N
VLASU NNP 1_i
group NN N
did VBD N
not RB N
require VB N
repetition NN 1_o
of IN 1_o
the DT 1_o
procedure NN 1_o
. . 1_o

The DT N
choice NN N
of IN N
VLASU NNP 1_i
as IN N
a DT N
method NN N
of IN N
treatment NN N
significantly RB N
decreased VBD 1_o
the DT 1_o
probability NN 1_o
of IN 1_o
therapeutic JJ 1_o
failure NN 1_o
and CC 1_o
recurrence NN 1_o
of IN 1_o
urethral JJ 1_o
strictures NNS 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSION NNP N
VLASU NNP 1_i
can MD N
be VB N
used VBN N
as IN N
a DT N
method NN N
of IN N
treatment NN N
of IN N
this DT N
disorder NN N
. . N

It PRP N
is VBZ N
an DT N
effective JJ N
, , N
modern JJ N
, , N
low-invasive JJ N
, , N
and CC N
repeatable JJ N
technique NN N
and CC N
is VBZ N
technically RB N
simple JJ N
and CC N
easy JJ N
to TO N
master NN N
. . N

It PRP N
can MD N
be VB N
used VBN N
in IN N
cases NNS N
in IN N
which WDT N
introduction NN N
of IN N
a DT N
22 CD N
Char NNP N
optical JJ N
urethrotome NN N
into IN N
the DT N
stricture NN N
site NN N
is VBZ N
impossible JJ N
, , N
as RB N
well RB N
as IN N
for IN N
treatment NN N
of IN N
multiple JJ N
strictures NNS N
during IN N
one CD N
procedure NN N
. . N

Oral NNP N
ondansetron NN 1_i
in IN N
the DT N
prevention NN 1_o
of IN 1_o
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
. . 1_o

The DT N
effect NN N
of IN N
three CD N
times NNS N
daily JJ N
oral JJ N
ondansetron NN N
in IN N
preventing VBG N
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
was VBD N
investigated VBN N
in IN N
two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
multi-centre JJ N
studies NNS N
. . N

The DT N
first JJ N
study NN N
compared VBN N
ondansetron RB 1_i
1 CD 1_i
, , 1_i
8 CD 1_i
and CC 1_i
16 CD 1_i
mg NN 1_i
to TO N
placebo VB 1_i
, , N
and CC N
the DT N
second JJ N
study NN N
compared VBN N
8 CD 1_i
mg JJ 1_i
ondansetron NN 1_i
to TO 1_i
placebo VB 1_i
. . 1_i

Both DT N
studies NNS N
included VBD N
ASA NNP 1_p
Class NNP 1_p
I-III NNP 1_p
female JJ 1_p
patients NNS 1_p
about IN 1_p
to TO 1_p
undergo VB 1_p
major JJ 1_p
abdominal JJ 1_p
gynaecological JJ 1_p
surgery NN 1_p
or CC 1_p
vaginal JJ 1_p
hysterectomy NN 1_p
. . 1_p

In IN N
the DT N
first JJ N
study NN N
, , N
the DT N
8 CD 1_i
and CC 1_i
16 CD 1_i
mg NN 1_i
ondansetron NN 1_i
groups NNS 1_i
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN 1_o
of IN 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
in IN N
the DT N
0-24 JJ N
h JJ N
period NN N
following VBG N
recovery NN N
from IN N
anaesthesia NN N
than IN N
the DT N
placebo NN 1_i
group NN N
. . N

Ondansetron NNP 1_i
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
was VBD N
also RB N
significantly RB N
better JJR N
than IN N
placebo NN N
in IN N
the DT N
second JJ N
study NN N
. . N

Side-effects NNS 1_o
mainly RB N
consisted VBD N
of IN N
constipation NN 1_o
, , 1_o
headache NN 1_o
, , 1_o
and CC 1_o
asymptomatic JJ 1_o
elevation NN 1_o
of IN 1_o
liver NN 1_o
enzymes NNS 1_o
. . 1_o

The DT N
incidence NN N
of IN N
side-effects NNS 1_o
was VBD N
similar JJ N
in IN N
ondansetron- JJ N
and CC N
placebo-treated JJ N
patients NNS N
. . N

There EX N
appeared VBD N
to TO N
be VB N
no DT N
clinically RB 1_o
important JJ 1_o
benefit NN 1_o
of IN N
the DT N
16 CD N
mg NN N
three CD N
times NNS N
daily JJ N
ondansetron VBP 1_i
regimen NNS N
over IN N
the DT N
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
dose VBP N
, , N
therefore RB N
8 CD N
mg NN N
three CD N
times NNS N
daily RB N
is VBZ N
recommended VBN N
as IN N
the DT N
optimal JJ 1_o
oral JJ 1_o
dose NN 1_o
in IN N
the DT N
prevention NN N
of IN N
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
. . 1_o

[ NN 1_i
Simvastatin NNP 1_i
versus NN 1_i
gemfibrozil NN 1_i
in IN N
the DT N
treatment NN N
of IN N
primary JJ 1_p
hypercholesterolemia NN 1_p
in IN 1_p
hypertensive JJ 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
hydrochlorothiazide JJ 1_i
] NN 1_i
. . N

Recent JJ N
pharmacological JJ N
studies NNS N
confirmed VBD N
the DT N
role NN N
of IN N
hypercholesterolemia NN N
in IN N
the DT N
pathogenesis NN N
of IN N
coronary JJ N
atherosclerosis NN N
. . N

A DT N
10 CD N
% NN N
reduction NN N
in IN N
cholesterol NN N
levels NNS N
can MD N
reduce VB N
the DT N
risk NN N
of IN N
coronary JJ N
heart NN N
disease NN N
by IN N
15 CD N
% NN N
. . N

However RB N
many JJ N
hypercholesterolemic JJ 1_p
patients NNS 1_p
often RB N
suffer VBP N
from IN N
arterial JJ N
hypertension NN N
and CC N
drugs NNS N
such JJ N
as IN N
thiazide JJ 1_i
diuretics NNS 1_i
cause VBP N
an DT N
imbalance NN N
in IN N
lipid JJ N
metabolism NN N
. . N

The DT N
efficacy NN 1_o
and CC 1_o
the DT 1_o
tolerability NN 1_o
of IN N
simvastatin NN 1_i
( ( N
a DT N
inhibitor NN N
of IN N
HGM-CoA NNP N
reductase NN N
) ) N
with IN N
that DT N
of IN N
gemfibrozil NN 1_i
( ( N
a DT N
fibric NN N
acid NN N
derivative NN N
, , N
which WDT N
can MD N
reduce VB N
the DT N
VLDL NNP N
level NN N
) ) N
were VBD N
compared VBN N
in IN N
a DT N
placebo-controlled JJ 1_i
study NN N
in IN N
2 CD N
groups NNS N
of IN N
patients NNS 1_p
with IN 1_p
primary JJ 1_p
hypercholesterolemia NN 1_p
and CC 1_p
mild-to-moderate JJ 1_p
essential JJ 1_p
hypertension NN 1_p
treated VBN 1_p
with IN 1_p
hydrochlorothiazide NN 1_p
. . 1_p

After IN 1_p
10 CD 1_p
weeks NNS 1_p
standard JJ 1_i
hypolipidemic JJ 1_i
diet NN 1_i
and CC 1_i
hydrochlorothiazide NN 1_i
( ( 1_p
25 CD 1_p
mg RB 1_p
od NN 1_p
) ) 1_p
therapy NN 1_p
, , 1_p
30 CD 1_p
patients NNS 1_p
whose WP$ 1_p
cholesterol NN 1_o
levels NNS 1_o
were VBD 1_p
still RB 1_p
greater JJR 1_p
than IN 1_p
or CC 1_p
equal JJ 1_p
to TO 1_p
250 CD 1_p
mg/100 NNS 1_p
ml NN 1_p
and CC 1_p
whose WP$ 1_p
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_p
was VBD 1_p
less JJR 1_p
than IN 1_p
95 CD 1_p
mmHg NNS 1_p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
simvastatin NN 1_i
, , N
20 CD N
mg NN N
od NN N
, , N
gemfibrozil NN 1_i
, , N
600 CD N
mg NN N
bid NN N
or CC 1_i
placebo NN 1_i
, , N
while IN N
continuing VBG N
dietetic JJ N
and CC N
diuretic JJ N
treatment NN N
. . N

After IN N
24 CD N
weeks NNS N
treatment NN N
, , N
simvastatin NN 1_i
induced VBD N
a DT N
37 CD N
% NN N
reduction NN N
in IN N
cholesterol NN 1_o
plasma NN 1_o
levels NNS 1_o
, , N
a DT N
9 CD N
% NN N
increase NN N
of IN N
HDL NNP 1_o
and CC N
a DT N
16 CD N
% NN N
reduction NN N
of IN N
LDL NNP 1_o
. . 1_o

APO-A1 NNP 1_o
showed VBD N
a DT N
4 CD N
% NN N
increase NN N
, , N
while IN N
APO-B NNP N
showed VBD N
a DT N
3 CD N
% NN N
reduction NN N
. . N

Gemfibrozil NNP 1_i
induced VBD N
a DT N
20 CD N
% NN N
reduction NN N
in IN N
plasma NN 1_o
triglycerides NNS 1_o
and CC N
a DT N
13 CD N
% NN N
decrease NN N
in IN N
plasma NN 1_o
cholesterol NN 1_o
, , N
with IN N
a DT N
significant JJ N
19 CD N
% NN N
increase NN N
in IN N
HDL NNP 1_o
and CC N
a DT N
11 CD N
% NN N
reduction NN N
in IN N
LDL NNP 1_o
. . 1_o

No NNP N
significant JJ N
variations NNS N
in IN N
any DT N
of IN N
the DT N
lipid JJ N
parameters NNS N
monitored VBD N
were VBD N
observed VBN N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

Treatment NN N
with IN N
simvastatin NN 1_i
or CC N
gemfibrozil NN 1_i
in IN N
hypertensive JJ N
patients NNS N
in IN N
hydrochlorothiazide JJ 1_i
monotherapy NN N
can MD N
reduce VB N
total JJ 1_o
cholesterol NN 1_o
and CC 1_o
LDL-cholesterol NNP 1_o
plasma NN 1_o
levels NNS 1_o
, , N
while IN N
significantly RB N
increasing VBG N
HDL NNP 1_o
plasma NN 1_o
levels NNS 1_o
compared VBN N
to TO N
placebo VB N
. . N

Simvastatin NNP 1_i
, , N
however RB N
, , N
resulted VBD N
more RBR N
efficient JJ N
than IN N
gemfibrozil NN 1_i
on IN N
total JJ 1_o
cholesterol NN 1_o
or CC 1_o
cholesterol NN 1_o
fractions NNS 1_o
. . 1_o

Stepwise NNP 1_i
hook NN 1_i
extension NN 1_i
technique NN 1_i
for IN N
radiofrequency NN N
ablation NN N
therapy NN N
of IN N
hepatocellular JJ 1_p
carcinoma NN 1_p
. . 1_p

OBJECTIVE CC N
Our PRP$ N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
stepwise NN 1_i
hook NN 1_i
extension NN 1_i
technique NN 1_i
for IN 1_i
radiofrequency NN 1_i
ablation NN 1_i
( ( 1_i
RFA NNP 1_i
) ) 1_i
therapy NN 1_i
of IN N
hepatocellular JJ 1_p
carcinoma NN 1_p
in IN N
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

METHOD NNP N
Twenty NNP 1_p
patients NNS 1_p
with IN 1_p
hepatocellular JJ 1_p
carcinoma NN 1_p
measuring VBG 1_p
< $ 1_p
25 CD 1_p
mm NN 1_p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
equal JJ N
groups NNS N
. . N

RFA NNP 1_i
was VBD N
applied VBN N
using VBG N
our PRP$ N
new JJ N
stepwise NN 1_i
hook NN 1_i
extension NN 1_i
technique NN 1_i
in IN N
patients NNS N
of IN N
group NN N
1 CD N
, , N
and CC N
the DT N
full JJ 1_i
extension NN 1_i
method NN 1_i
in IN N
group NN N
2 CD N
. . N

The DT N
10-hook JJ 1_i
electrode NN 1_i
of IN 1_i
LeVeen NNP 1_i
needle NN 1_i
was VBD N
deployed VBN N
in IN N
four CD N
steps NNS N
to TO N
full JJ N
extension NN N
during IN N
ablation NN N
in IN N
group NN N
1 CD N
, , N
and CC N
full JJ N
extension NN N
at IN N
start NN N
of IN N
treatment NN N
in IN N
group NN N
2 CD N
. . N

RESULTS VB N
Roll-off NNP 1_o
was VBD N
achieved VBN N
in IN N
all DT N
10 CD N
patients NNS N
of IN N
group NN N
1 CD N
, , N
indicative NN N
of IN N
sufficient JJ N
tumor NN N
coagulation NN N
, , N
but CC N
only RB N
in IN N
3 CD N
of IN N
10 CD N
patients NNS N
of IN N
group NN N
2 CD N
. . N

The DT N
median JJ 1_o
time NN 1_o
to TO 1_o
completion NN 1_o
of IN 1_o
treatment NN 1_o
was VBD N
6 CD N
min NN N
and CC N
55 CD N
s NN N
( ( N
range VB N
3 CD N
min NN N
to TO N
14 CD N
min NNS N
and CC N
3 CD N
s NN N
) ) N
and CC N
15 CD N
min NN N
( ( N
6-15 JJ N
min NN N
) ) N
, , N
respectively RB N
. . N

The DT N
total JJ 1_o
power NN 1_o
output NN 1_o
used VBN N
for IN N
RF NNP N
was VBD N
lower JJR N
in IN N
group NN N
1 CD N
than IN N
in IN N
group NN N
2 CD N
( ( N
median JJ N
271 CD N
vs. FW N
1,045 CD N
W.m NNP N
) ) N
. . N

The DT N
diameters NNS 1_o
of IN 1_o
RFA-induced JJ 1_o
lesions NNS 1_o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
( ( N
group NN N
1 CD N
: : N
27 CD N
, , N
range NN N
23-37 JJ N
mm NN N
; : N
group NN N
2 CD N
: : N
23 CD N
, , N
0-42 JJ N
mm NN N
) ) N
. . N

CONCLUSIONS NNP N
Application NNP N
of IN N
RFA NNP N
using VBG N
stepwise NN N
hook NN N
extension NN N
technique NN N
is VBZ N
superior JJ N
to TO N
the DT N
full JJ N
extension NN N
method NN N
since IN N
it PRP N
produces VBZ N
the DT N
same JJ 1_o
therapeutic JJ 1_o
effects NNS 1_o
within IN N
a DT N
short JJ N
period NN N
using VBG N
a DT N
lower JJR N
energy NN N
. . N

Tradeoffs NNS N
and CC N
theory NN N
: : N
the DT N
double-mediation NN 1_i
model NN 1_i
. . 1_i

Most JJS N
theories NNS N
of IN N
decision NN N
making VBG N
suggest VBP N
that IN N
, , N
when WRB N
options NNS N
imply VBP N
tradeoffs NNS N
between IN N
their PRP$ N
attributes NNS N
, , N
conflict NN N
increases NNS N
as IN N
tradeoff NN N
size NN N
increases NNS N
, , N
because IN N
greater JJR N
sacrifices NNS N
are VBP N
to TO N
be VB N
incurred VBN N
in IN N
choosing VBG N
one CD N
option NN N
instead RB N
of IN N
another DT N
. . N

An DT N
alternative JJ N
view NN N
is VBZ N
that IN N
conflict NN N
decreases NNS N
as IN N
tradeoff NN N
size NN N
increases NNS N
, , N
because IN N
stronger JJR N
arguments NNS N
can MD N
be VB N
made VBN N
for IN N
any DT N
decision NN N
. . N

The DT N
authors NNS N
propose VBP N
a DT N
unified JJ N
model NN N
, , N
the DT N
double-mediation NN 1_i
model NN 1_i
, , 1_i
which WDT 1_i
combines VBZ 1_i
the DT 1_i
mediating JJ 1_i
effects NNS 1_i
of IN 1_i
sacrifice NN 1_i
and CC 1_i
argumentation NN 1_i
. . 1_i

Our PRP$ N
model NN N
generally RB N
predicts VBZ N
an DT N
inverse JJ N
U-shaped JJ N
relation NN 1_p
between IN 1_p
tradeoff NN 1_p
size NN 1_p
and CC 1_p
conflict NN 1_p
. . 1_p

Results VB N
support NN N
this DT N
prediction NN N
. . N

Also RB 1_o
, , 1_o
when WRB 1_o
the DT 1_o
decision NN 1_o
situation NN 1_o
increases VBZ 1_o
the DT 1_o
mediating VBG 1_o
effect NN 1_o
of IN 1_o
sacrifice NN 1_o
relative NN 1_o
to TO 1_o
that DT 1_o
of IN 1_o
argumentation NN 1_o
, , 1_o
the DT 1_o
relation NN 1_o
between IN 1_o
tradeoff NN 1_o
size NN 1_o
and CC 1_o
conflict NN 1_o
changes NNS 1_o
in IN 1_o
an DT 1_o
upward JJ 1_o
direction NN 1_o
; : 1_o
conversely RB 1_o
, , 1_o
when WRB 1_o
the DT 1_o
decision NN 1_o
situation NN 1_o
increases VBZ 1_o
the DT 1_o
mediating VBG 1_o
effect NN 1_o
of IN 1_o
argumentation NN 1_o
relative NN 1_o
to TO 1_o
that DT 1_o
of IN 1_o
sacrifice NN 1_o
, , 1_o
the DT 1_o
relation NN 1_o
changes NNS 1_o
in IN 1_o
a DT 1_o
downward JJ 1_o
direction NN 1_o
. . 1_o

Results VB N
support NN N
these DT N
predictions NNS N
as RB N
well RB N
. . N

Commonalities NNS N
and CC N
differences NNS N
between IN N
our PRP$ N
model NN N
and CC N
other JJ N
formulations NNS N
are VBP N
discussed VBN N
. . N

Cardiovascular JJ 1_o
risk NN 1_o
markers NNS 1_o
during IN N
treatment NN N
with IN N
estradiol NN 1_i
and CC 1_i
trimegestone NN 1_i
or CC 1_i
dydrogesterone NN 1_i
. . N

OBJECTIVE UH N
To TO N
study VB N
cardiovascular JJ 1_o
risk NN 1_o
markers NNS 1_o
in IN N
women NNS 1_p
taking VBG 1_p
estradiol/trimegestone NN 1_i
or CC 1_i
estradiol/dydrogesterone NN 1_i
. . 1_i

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
184 CD 1_p
healthy JJ 1_p
post-menopausal JJ 1_p
women NNS 1_p
randomized VBD N
to TO N
6 CD 1_i
cycles NNS 1_i
of IN 1_i
either DT 1_i
estradiol NN 1_i
( ( 1_i
2mg CD 1_i
) ) 1_i
+trimegestone NN 1_i
( ( 1_i
0.5mg CD 1_i
) ) 1_i
( ( 1_i
T-group NNP 1_i
) ) 1_i
or CC 1_i
estradiol NN 1_i
( ( 1_i
2mg CD 1_i
) ) 1_i
+dydrogesterone NN 1_i
( ( 1_i
10mg CD 1_i
) ) 1_i
( ( 1_i
DYDR NNP 1_i
group NN 1_i
) ) 1_i
. . 1_i

Cardiovascular JJ 1_o
risk NN 1_o
markers NNS 1_o
were VBD 1_i
measured VBN 1_i
before IN 1_i
, , 1_i
after IN 1_i
cycle NN 1_i
1 CD 1_i
, , 1_i
3 CD 1_i
and CC 1_i
6 CD 1_i
and CC 1_i
at IN 1_i
4 CD 1_i
weeks NNS 1_i
post-treatment JJ 1_i
. . 1_i

RESULTS NNP N
Fibrinogen NNP 1_o
was VBD N
reduced VBN N
in IN N
both DT N
groups NNS N
but CC N
more JJR N
markedly RB N
in IN N
the DT N
DYDR NNP N
group NN N
. . N

Factor NNP 1_o
VIIc NNP 1_o
activity NN 1_o
levels NNS 1_o
decreased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
change NN N
in IN N
the DT N
T-group NNP N
. . N

Factor NNP 1_o
VII NNP 1_o
antigen NN 1_o
was VBD N
increased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
increase NN N
in IN N
the DT N
DYDR NNP N
group NN N
. . N

Factor NNP 1_o
VIIa NNP 1_o
was VBD N
increased VBN N
in IN N
the DT N
DYDR NNP N
group NN N
only RB N
. . N

Plasminogen NN 1_o
levels NNS 1_o
were VBD N
also RB N
increased VBN N
in IN N
both DT N
groups NNS N
with IN N
a DT N
greater JJR N
increase NN N
in IN N
the DT N
T-group NNP N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN N
lipid JJ 1_o
variables NNS 1_o
between IN N
the DT N
different JJ N
regimens NNS N
. . N

Changes NNS N
in IN N
total JJ 1_o
cholesterol NN 1_o
and CC 1_o
LDL NNP 1_o
cholesterol NN 1_o
were VBD N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
factor NN 1_o
VIIc NNP 1_o
in IN N
the DT N
DYDR NNP N
group NN N
and CC N
negatively RB N
with IN N
changes NNS N
in IN N
factor NN 1_o
VIIc NNP 1_o
in IN N
the DT N
T-group NNP N
. . N

Trigemestone NN N
was VBD N
associated VBN N
with IN N
a DT N
better JJR N
bleeding NN 1_o
pattern NN 1_o
. . 1_o

CONCLUSIONS NNP N
Trimegestone NNP N
was VBD N
associated VBN N
with IN N
less RBR N
procoagulant JJ 1_o
changes NNS 1_o
in IN 1_o
factor NN 1_o
VIIa NNP 1_o
and CC N
factor NN 1_o
VIIc NNP 1_o
activity NN 1_o
and CC N
larger JJR N
decrease NN N
in IN N
PAI-1 NNP 1_o
activity NN 1_o
compared VBN N
with IN N
the DT N
dydrogesterone NN N
preparation NN N
. . N

These DT N
results NNS N
reflect VBP N
less JJR N
androgenic JJ 1_o
properties NNS 1_o
of IN N
the DT N
trimegestone NN N
preparation NN N
. . N

The DT N
fibrinogen NN 1_o
level NN 1_o
and CC N
Lp NNP 1_o
( ( 1_o
a DT 1_o
) ) 1_o
were VBD N
more JJR N
decreased JJ N
during IN N
dydrogesterone NN N
treatment NN N
. . N

Further JJ N
investigation NN N
is VBZ N
required VBN N
to TO N
clarify VB N
the DT N
relative JJ N
importance NN N
of IN N
beneficial JJ N
effects NNS N
with IN N
respect NN N
to TO N
cardiovascular JJ N
risk NN N
. . N

Increased VBN N
5α-reductase JJ 1_o
type NN 1_o
2 CD 1_o
expression NN 1_o
in IN 1_p
human JJ 1_p
breast NN 1_p
carcinoma NN 1_p
following VBG 1_i
aromatase NN 1_i
inhibitor NN 1_i
therapy NN 1_i
: : 1_i
the DT N
correlation NN N
with IN 1_o
decreased JJ 1_o
tumor NN 1_o
cell NN 1_o
proliferation NN 1_o
. . N

Tumor NNP 1_o
cell NN 1_o
proliferation NN 1_o
and CC 1_o
progression NN 1_o
of IN 1_o
breast NN 1_o
cancer NN 1_o
are VBP N
influenced VBN N
by IN N
female JJ N
sex NN N
steroids NNS N
. . N

However RB N
, , N
not RB N
all DT N
breast NN N
cancer NN N
patients NNS N
respond VBP N
to TO 1_i
aromatase VB 1_i
inhibitors NNS 1_i
( ( 1_i
AI NNP 1_i
) ) 1_i
, , N
and CC N
many JJ N
patients NNS N
become VBP N
unresponsive JJ N
or CC N
relapse NN N
. . N

Recent JJ N
studies NNS N
demonstrate VBP N
that IN N
not RB N
only RB N
estrogens VBZ N
but CC N
also RB N
androgens VBZ N
may MD N
serve VB N
as IN N
regulators NNS N
of IN N
estrogen-responsive JJ N
as RB N
well RB N
as IN N
estrogen-unresponsive JJ N
human JJ N
breast NN N
cancers NNS N
. . N

However RB N
, , N
the DT N
mechanism NN N
underlying VBG N
these DT N
androgenic JJ N
actions NNS N
has VBZ N
remained VBN N
relatively RB N
unknown JJ N
. . N

Therefore RB N
, , N
in IN N
this DT N
study NN N
, , N
we PRP N
evaluated VBD N
the DT 1_o
effects NNS 1_o
of IN N
AI NNP N
upon IN N
the DT 1_o
expression NN 1_o
of IN 1_o
enzymes NNS 1_o
involved VBN 1_o
in IN 1_o
intratumoral JJ 1_o
androgen NN 1_o
production NN 1_o
including VBG 1_o
17β-hydroxysteroid JJ 1_o
dehydrogenase NN 1_o
type NN 1_o
5 CD 1_o
( ( 1_o
17βHSD5 CD 1_o
) ) 1_o
, , 1_o
5α-reductase JJ 1_o
types NNS 1_o
1 CD 1_o
and CC 1_o
2 CD 1_o
( ( 1_o
5αRed1 CD 1_o
and CC 1_o
5αRed2 CD 1_o
) ) 1_o
as RB N
well RB 1_o
as IN 1_o
androgen NN 1_o
receptor NN 1_o
( ( 1_o
AR NNP 1_o
) ) 1_o
levels NNS 1_o
and CC N
correlated VBD N
the DT N
findings NNS 1_o
with IN 1_o
therapeutic JJ 1_o
responses NNS 1_o
including VBG 1_o
Ki67 NNP 1_o
labeling VBG 1_o
index NN 1_o
( ( 1_o
Ki67 NNP 1_o
) ) 1_o
. . 1_p

Eighty-two JJ 1_p
postmenopausal NN 1_p
invasive JJ 1_p
ductal JJ 1_p
carcinoma NN 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
CAAN NNP 1_p
study NN 1_p
from IN 1_p
November NNP 1_p
2001 CD 1_p
to TO 1_p
April NNP 1_p
2004 CD N
. . N

Pre- JJ N
and CC N
post-treatment JJ N
specimens NNS N
of IN N
29 CD N
cases NNS N
were VBD N
available JJ N
for IN N
this DT N
study NN N
. . N

The DT N
status NN 1_o
of IN 1_o
17βHSD5 CD 1_o
, , 1_o
5αRed1 CD 1_o
, , 1_o
5αRed2 CD 1_o
, , N
and CC N
Ki67 NNP N
in IN N
pre- JJ N
and CC N
post-treatment JJ N
specimens NNS N
were VBD N
evaluated VBN N
. . N

The DT N
significant JJ N
increments NNS 1_o
of IN 1_o
5αRed2 CD 1_o
as RB 1_o
well RB 1_o
as IN N
AR NNP N
were VBD N
detected VBN N
in IN N
biological JJ N
response NN N
group NN 1_o
whose WP$ 1_o
Ki67 NNP N
LI NNP N
decreased VBN N
by IN N
more JJR N
than IN N
40 CD N
% NN N
of IN N
the DT N
pre-treatment JJ N
level NN N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
demonstrating VBG N
an DT N
increment NN 1_o
of IN 1_o
5αRed2 CD 1_o
and CC N
AR NNP N
in IN N
the DT N
group NN N
of IN N
the DT N
patients NNS N
associated VBN 1_o
with IN N
Ki67 NNP N
decrement NN N
following VBG N
AI NNP N
treatment NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN 1_o
increased VBD 1_o
5αRed2 CD 1_o
and CC N
AR NNP N
following VBG N
AI NNP N
treatment NN N
may MD N
partly RB N
contribute VB N
to TO N
reduce VB N
the DT N
tumor NN N
cell NN N
proliferation NN N
through IN N
increasing VBG N
intratumoral JJ N
androgen NN N
concentrations NNS N
and CC N
its PRP$ N
receptor NN N
. . N

Peripheral NNP N
intravenous JJ 1_o
line NN 1_o
survival NN 1_o
and CC N
phlebitis NN 1_o
prevention NN N
in IN N
patients NNS 1_p
receiving VBG 1_p
intravenous JJ 1_p
antibiotics NNS 1_i
: : 1_i
heparin/hydrocortisone NN N
versus IN N
in-line JJ N
filters NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
use NN N
of IN N
in-line JJ N
filtration NN N
with IN N
the DT N
addition NN N
of IN N
heparin/hydrocortisone NN 1_i
( ( N
hep/hc NN N
) ) N
to TO N
the DT N
infusate NN N
for IN N
both DT N
phlebitis NN N
prevention NN N
and CC N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
line NN N
survival NN N
in IN N
peripheral JJ N
i.v NN N
. . N

catheters NNS N
. . N

This DT N
study NN N
was VBD N
specific JJ 1_p
for IN 1_p
a DT 1_p
patient NN 1_p
group NN 1_p
receiving VBG 1_p
prolonged JJ 1_p
courses NNS 1_p
of IN 1_p
i.v NN 1_p
. . 1_p

antibiotics NNS 1_p
. . 1_p

Analysis NN N
of IN N
the DT N
two CD N
endpoints NNS N
for IN N
conventional JJ N
short JJ N
i.v NN 1_i
. . 1_i

catheters NNS 1_i
( ( N
short JJ N
lines NNS N
) ) N
versus NN N
long RB N
( ( N
30 CD N
cm NN N
) ) N
i.v NN N
. . N

catheters NNS N
( ( N
long JJ N
lines NNS N
) ) N
was VBD N
also RB N
performed VBN N
. . N

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
receiving VBG 1_p
intermittent JJ 1_p
i.v NN 1_p
. . 1_p

antibiotics NNS 1_i
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
their PRP$ N
drugs NNS N
either CC N
through IN N
an DT N
in-line JJ N
filter NN N
using VBG N
a DT N
drug-free JJ N
infusate NN N
or CC N
with IN N
no DT N
filter NN N
and CC N
an DT N
infusate NN N
containing VBG N
heparin JJ 1_i
500 CD N
units NNS N
and CC N
hydrocortisone NN 1_i
10 CD N
mg/L NN N
. . N

Infusion NN N
sites NNS N
were VBD N
assessed VBN N
daily RB N
. . N

RESULTS NNP N
Both NNP N
the DT N
hep/hc NN N
and CC N
filter NN N
groups NNS N
were VBD N
similar JJ N
in IN N
terms NNS N
of IN N
phlebitis NN 1_o
incidence NN 1_o
and CC 1_o
i.v NN 1_o
. . 1_o

line NN 1_o
survival NN 1_o
when WRB N
analyzed VBN N
separately RB N
for IN N
both DT N
short JJ N
and CC N
long JJ N
lines NNS N
. . N

Long NNP N
lines NNS N
displayed VBD N
markedly RB N
prolonged JJ N
survival NN 1_o
times NNS 1_o
and CC N
reduced JJ N
phlebitis NN 1_o
compared VBN N
with IN N
short JJ N
lines NNS N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
of IN N
i.v NN N
. . N

filters NNS N
in IN N
excluding VBG N
the DT N
large JJ N
particle NN N
load NN N
introduced VBN N
by IN N
i.v NN N
. . N

antibiotics NNS N
and CC N
hence NN N
in IN N
reducing VBG N
the DT N
subsequent JJ N
phlebitis NN N
makes VBZ N
them PRP N
a DT N
useful JJ N
alternative NN N
to TO N
the DT N
use NN N
of IN N
hep/hc NN N
. . N

The DT N
use NN N
of IN N
filters NNS N
in IN N
this DT N
patient JJ N
group NN N
may MD N
offer VB N
advantages NNS N
in IN N
terms NNS N
of IN N
ease NN N
of IN N
use NN N
and CC N
a DT N
possible JJ N
decrease NN N
in IN N
hep/hc-related JJ 1_o
problems NNS 1_o
. . N

Long JJ N
lines NNS N
offer VBP N
practical JJ N
advantages NNS N
over IN N
short JJ N
lines NNS N
for IN N
patients NNS 1_p
requiring VBG 1_p
longer JJR 1_p
term NN 1_p
i.v NN 1_p
. . 1_p

access NN 1_p
. . 1_p

Inflammatory JJ N
response NN N
in IN N
humans NNS 1_p
exposed VBN 1_p
to TO 1_p
2.0 CD 1_p
ppm NNS 1_p
nitrogen JJ 1_i
dioxide NN 1_i
. . 1_i

Nitrogen NNP 1_i
dioxide NN 1_i
( ( 1_i
NO2 NNP 1_i
) ) 1_i
is VBZ N
a DT N
common JJ N
indoor NN N
air NN N
pollutant NN N
, , N
especially RB N
in IN N
homes NNS N
with IN N
unvented JJ N
combustion NN N
appliances NNS N
. . N

Epidemiological JJ N
studies NNS N
suggest VBP N
that IN N
children NNS N
living VBG N
in IN N
homes NNS N
with IN N
unvented JJ N
heating NN N
sources NNS N
are VBP N
more JJR N
prone NN N
to TO N
respiratory NN N
infections NNS N
than IN N
children NNS N
living VBG N
in IN N
homes NNS N
with IN N
lower JJR N
levels NNS N
of IN N
NO2 NNP 1_i
. . 1_i

However RB N
, , N
experimental JJ N
studies NNS N
in IN N
which WDT N
human JJ N
volunteers NNS N
were VBD N
exposed VBN N
acutely RB N
to TO N
moderate JJ N
levels NNS N
of IN N
NO2 NNP 1_i
( ( N
0.5-2.0 JJ N
ppm NN N
) ) N
have VBP N
shown VBN N
little JJ N
evidence NN N
of IN N
lung NN N
inflammation NN N
or CC N
decreased VBN N
host NN N
resistance NN N
capacity NN N
. . N

In IN N
the DT N
study NN N
reported VBD N
here RB N
, , N
8 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
were VBD 1_p
exposed VBN 1_p
to TO 1_p
2.0 CD 1_p
ppm NN 1_p
NO2 NNP 1_i
and CC 1_p
to TO 1_p
filtered VB 1_i
air NN 1_i
for IN 1_p
4 CD 1_p
h NNS 1_p
while IN 1_p
undergoing VBG 1_i
intermittent JJ 1_i
moderate JJ 1_i
exercise NN 1_i
. . 1_i

Bronchoalveolar JJ 1_i
lavage NN 1_i
was VBD N
performed VBN N
the DT N
following JJ N
morning NN N
. . N

The DT N
lavage NN N
was VBD N
divided VBN N
into IN N
a DT N
predominantly RB N
bronchial JJ N
washing NN N
( ( N
first JJ N
20 CD N
ml NN N
of IN N
lavage NN N
; : N
BL NNP N
) ) N
and CC N
a DT N
predominantly RB N
alveolar JJ N
washing NN N
( ( N
BAL NNP N
) ) N
. . N

In IN N
the DT N
BL NNP N
, , N
NO2 NNP 1_o
exposure NN 1_o
caused VBD N
increases NNS N
in IN N
polymorphonuclear JJ 1_o
neutrophils NNS 1_o
( ( 1_o
PMNs NNP 1_o
) ) 1_o
, , 1_o
interleukin JJ 1_o
6 CD 1_o
( ( 1_o
IL-6 NNP 1_o
) ) 1_o
, , 1_o
IL-8 NNP 1_o
, , 1_o
alpha1-antitrypsin NN 1_o
, , 1_o
and CC 1_o
tissue NN 1_o
plasminogen NN 1_o
activator NN 1_o
, , N
and CC N
decreases NNS N
in IN N
epithelial JJ 1_o
cells NNS 1_o
. . 1_o

In IN N
the DT N
BAL NNP N
, , N
there EX N
were VBD N
no DT N
NO2-induced JJ N
changes NNS N
in IN N
either DT N
cell NN 1_o
numbers NNS 1_o
or CC 1_o
soluble JJ 1_o
mediators NNS 1_o
. . 1_o

On IN N
the DT N
other JJ N
hand NN N
, , N
alveolar JJ N
macrophages NNS N
from IN N
BAL NNP N
showed VBD N
a DT N
decrease NN N
in IN N
the DT N
ability NN N
to TO N
phagocytose VB 1_o
unopsonized JJ 1_o
Candida NNP 1_o
albicans NNS 1_o
and CC N
a DT N
decrease NN N
in IN N
superoxide JJ 1_o
production NN 1_o
. . 1_o

No DT N
difference NN N
in IN N
susceptibility NN 1_o
to TO 1_o
virus VB 1_o
infection NN 1_o
was VBD N
found VBN N
between IN N
the DT N
NO2- NNP 1_i
and CC N
air-exposed JJ N
macrophages NNS N
. . N

No DT N
changes NNS N
in IN N
lung NN N
function NN N
were VBD N
observed VBN N
, , N
but CC N
the DT N
aerosol JJ N
bolus JJ N
recovery NN N
technique NN N
revealed VBD N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
decrease NN N
in IN N
the DT N
fraction NN N
of IN N
aerosol NN N
recovered VBD N
following VBG N
nitrogen NN 1_i
dioxide NN 1_i
exposure NN N
, , N
which WDT N
is VBZ N
suggestive JJ N
of IN N
small JJ N
obstructive JJ N
changes NNS N
induced VBN N
by IN N
NO2 NNP 1_i
. . 1_i

Haemodynamic NNP N
profile NN N
of IN N
angiotensin NN 1_i
II NNP 1_i
antagonism NN 1_i
in IN N
essential JJ 1_p
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

1 CD N
. . N

The DT N
haemodynamic JJ N
response NN N
to TO N
antagonistic JJ 1_i
( ( N
10 CD N
microgram RB N
min-1 JJ N
kg-1 NN N
) ) N
and CC N
agonistic JJ 1_i
( ( N
40 CD N
microgram RB N
min-1 JJ N
kg-1 NN N
) ) N
doses VBZ N
of IN N
saralasin NN 1_i
was VBD N
studied VBN N
in IN N
young JJ 1_p
essential JJ 1_p
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

Blood NNP 1_o
pressure NN 1_o
behaviour NN 1_o
alone RB N
was VBD N
thought VBN N
to TO N
be VB N
inadequate JJ N
to TO N
describe VB N
the DT N
response NN N
pattern NN N
. . N

2 CD N
. . N

Pre-saralasin JJ N
setting NN N
of IN N
the DT N
renin-angiotensin JJ 1_i
axis NN 1_i
was VBD N
varied VBN N
with IN N
salt JJ N
intake NN N
( ( N
15 CD N
and CC N
290 CD N
mmol NN N
of IN N
Na+/day NNP N
) ) N
each DT N
for IN N
10 CD N
days NNS N
. . N

This DT N
failed VBD N
to TO N
influence VB N
blood NN 1_o
pressure NN 1_o
or CC 1_o
plasma NN 1_o
volume NN 1_o
. . 1_o

3 CD N
. . N

Antagonist NN N
blockade NN N
after IN N
low JJ N
salt NN N
lowered VBD N
blood NN 1_o
pressure NN 1_o
in IN N
three CD N
patients NNS N
with IN N
the DT N
highest JJS N
plasma NN N
renin NN N
values NNS N
. . N

Cardiac NNP 1_o
output NN 1_o
rose VBD N
in IN N
two CD N
of IN N
these DT N
, , N
but CC N
it PRP N
dropped VBD N
in IN N
all DT N
others NNS N
. . N

4 CD N
. . N

Decreases NNS N
in IN N
cardiac JJ 1_o
output NN 1_o
occurred VBD N
with IN N
both DT N
doses NNS N
of IN N
saralasin NN N
and CC N
even RB N
with IN N
suppression NN N
of IN N
the DT N
renin-angiotensin JJ N
axis NN N
. . N

This DT N
response NN N
is VBZ N
therefore RB N
unlikely JJ N
to TO N
be VB N
due JJ N
to TO N
removal VB N
of IN N
myocardial JJ 1_o
or CC 1_o
venous JJ 1_o
angiotensin NN 1_o
effects NNS 1_o
. . 1_o

5 CD N
. . N

The DT N
renin-angiotensin JJ N
system NN N
played VBD N
a DT N
part NN N
in IN N
maintenance NN N
of IN N
blood NN 1_o
pressure NN 1_o
only RB N
with IN N
severe JJ N
salt NN N
restriction NN N
and CC N
in IN N
a DT N
small JJ N
proportion NN N
of IN N
cases NNS N
. . N

6 CD N
. . N

No DT N
heart NN 1_o
rate NN 1_o
effect NN 1_o
was VBD N
seen VBN N
with IN N
sarcalasin NN N
. . N

7 CD N
. . N

Blood NN 1_o
pressure NN 1_o
and CC 1_o
total JJ 1_o
peripheral JJ 1_o
resistance NN 1_o
responses NNS 1_o
were VBD N
dependent JJ N
on IN N
pre- NN N
( ( N
antagonist/agonist NN N
) ) N
setting NN N
, , N
but CC N
heart NN 1_o
rate NN 1_o
and CC N
cardiac JJ 1_o
output NN 1_o
were VBD N
not RB N
influenced VBN N
by IN N
this DT N
factor NN N
. . N

Effect NN N
of IN N
total JJ N
enteral JJ N
nutrition NN N
on IN N
the DT N
short-term JJ 1_o
outcome NN 1_o
of IN N
severely RB 1_o
malnourished VBN 1_o
cirrhotics NNS 1_o
. . 1_o

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

Thirty-five JJ 1_p
severely RB 1_p
malnourished VBN 1_p
cirrhotic JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN 1_i
to TO 1_i
receive VB 1_i
either DT 1_i
enteral-tube JJ 1_i
feeding NN 1_i
as IN 1_i
the DT 1_i
sole JJ 1_i
nutritional JJ 1_i
support NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
16 CD 1_i
) ) 1_i
or CC 1_i
an DT 1_i
isocaloric JJ 1_i
, , 1_i
isonitrogenous JJ 1_i
, , 1_i
low-sodium JJ 1_i
standard JJ 1_i
oral JJ 1_i
diet NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
19 CD 1_i
) ) 1_i
. . N

Both DT 1_p
groups NNS 1_p
were VBD 1_p
homogeneous JJ 1_p
regarding VBG 1_p
age NN 1_p
, , 1_p
sex NN 1_p
distribution NN 1_p
, , 1_p
etiology NN 1_p
of IN 1_p
liver JJ 1_p
cirrhosis NN 1_p
, , 1_p
history NN 1_p
of IN 1_p
previous JJ 1_p
complications NNS 1_p
, , 1_p
clinical JJ 1_p
status NN 1_p
, , 1_p
liver RB 1_p
and CC 1_p
renal JJ 1_p
function NN 1_p
, , 1_p
modified VBD 1_p
Child NNP 1_p
's POS 1_p
score NN 1_p
, , 1_p
and CC 1_p
nutritional JJ 1_p
status NN 1_p
at IN 1_p
admission NN 1_p
. . 1_p

The DT N
enteral JJ 1_i
formula NN 1_i
diet NN 1_i
was VBD 1_i
energy NN 1_i
dense NN 1_i
, , 1_i
containing VBG 1_i
40 CD 1_i
mmol NN 1_i
Na/day NNP 1_i
, , 1_i
whole JJ 1_i
protein NN 1_i
plus CC 1_i
branched-chain JJ 1_i
amino NN 1_i
acids NNS 1_i
, , 1_i
medium- JJ 1_i
and CC 1_i
long-chain JJ 1_i
triglycerides NNS 1_i
, , 1_i
and CC 1_i
maltodextrin NN 1_i
. . 1_i

It PRP 1_i
supplied VBD 1_i
2115 CD 1_i
kcal/day NN 1_i
. . 1_i

The DT 1_i
amount NN 1_i
of IN 1_i
vitamins NNS 1_i
and CC 1_i
trace NN 1_i
elements NNS 1_i
was VBD 1_i
at IN 1_i
the DT 1_i
upper JJ 1_i
limit NN 1_i
of IN 1_i
the DT 1_i
recommended JJ 1_i
dietary JJ 1_i
allowances NNS 1_i
. . 1_i

The DT 1_i
orally RB 1_i
fed JJ 1_i
patients NNS 1_i
were VBD 1_i
encouraged VBN 1_i
to TO 1_i
eat VB 1_i
all DT 1_i
meals NNS 1_i
served VBD 1_i
. . 1_i

Total JJ 1_o
enteral JJ 1_o
nutrition NN 1_o
was VBD N
well RB N
tolerated VBN 1_o
without IN N
major JJ N
complications NNS N
. . N

Serum NNP 1_o
albumin NN 1_o
and CC 1_o
Child NNP 1_o
's POS 1_o
score NN 1_o
improved VBD N
in IN N
the DT N
enterally RB N
fed JJ N
patients NNS N
but CC N
not RB N
in IN N
controls NNS N
. . N

Mortality NNP 1_o
rate NN 1_o
while IN 1_o
in IN 1_o
the DT 1_o
hospital NN 1_o
was VBD N
lower JJR N
in IN N
patients NNS N
on IN N
enteral JJ N
feeding NN N
than IN N
in IN N
controls NNS N
( ( N
12 CD N
% NN N
vs JJ N
47 CD N
% NN N
) ) N
. . N

These DT N
results NNS N
show VBP N
that IN N
total JJ N
enteral JJ N
nutrition NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
the DT N
short-term JJ 1_o
clinical JJ 1_o
outcome NN 1_o
in IN N
severely RB 1_p
malnourished JJ 1_p
cirrhotics NNS 1_p
. . 1_p

Marginal NNP N
biotin NN N
deficiency NN N
during IN N
normal JJ 1_p
pregnancy NN 1_p
. . 1_p

BACKGROUND NNP N
Biotin NNP N
deficiency NN N
is VBZ N
teratogenic JJ N
in IN N
several JJ 1_p
mammalian JJ 1_p
species NNS 1_p
. . 1_p

Approximately RB N
50 CD N
% NN N
of IN N
pregnant JJ 1_p
women NNS 1_p
have VBP N
an DT N
abnormally RB N
increased JJ N
urinary JJ N
excretion NN N
of IN N
3-hydroxyisovaleric JJ 1_o
acid NN 1_o
( ( 1_o
3-HIA JJ 1_o
) ) 1_o
, , N
which WDT N
probably RB N
reflects VBZ N
decreased JJ N
activity NN N
of IN N
the DT N
biotin-dependent JJ N
enzyme JJ N
methylcrotonyl-CoA JJ N
carboxylase NN N
. . N

However RB N
, , N
increased VBD N
3-HIA JJ N
excretion NN N
could MD N
result VB N
from IN N
pregnancy NN N
per IN N
se NN N
( ( N
eg JJ N
, , N
from IN N
an DT N
effect NN N
of IN N
pregnancy NN N
on IN N
renal JJ N
handling NN N
of IN N
organic JJ N
acids NNS N
) ) N
. . N

OBJECTIVE IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
biotin VBZ N
supplementation NN N
significantly RB N
decreases VBZ N
3-HIA JJ N
excretion NN N
in IN N
pregnant JJ 1_p
women NNS 1_p
with IN 1_p
abnormally RB 1_p
increased VBN 1_p
3-HIA JJ 1_p
excretion NN 1_p
. . 1_p

DESIGN NNP N
Twenty-six NNP 1_p
pregnant JJ 1_p
women NNS 1_p
with IN 1_p
increased JJ 1_p
3-HIA JJ 1_p
excretion NN 1_p
were VBD 1_p
studied VBN 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
, , 1_p
placebo-controlled JJ 1_i
trial NN 1_p
; : 1_p
10 CD N
women NNS N
were VBD N
studied VBN N
during IN N
early JJ N
pregnancy NN N
( ( N
6-17 JJ N
wk NN N
gestation NN N
) ) N
and CC N
16 CD N
women NNS N
during IN N
late JJ N
pregnancy NN N
( ( N
21-37 JJ N
wk NN N
gestation NN N
) ) N
. . N

Urine JJ 1_o
samples NNS 1_o
were VBD N
collected VBN N
before IN N
and CC N
after IN N
14 CD N
d NN N
of IN N
supplementation NN N
with IN N
300 CD 1_i
microg NNS 1_i
( ( 1_i
1.2 CD 1_i
micromol NN 1_i
) ) 1_i
biotin/d NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

RESULTS NNP N
In IN N
the DT N
early-pregnancy NN N
group NN N
, , N
3-HIA JJ 1_o
excretion NN 1_o
decreased VBN N
( ( N
P NNP N
< NNP N
0.006 CD N
) ) N
by IN N
11.7 CD N
+/- JJ N
3.6 CD N
mmol/mol NN N
creatinine NN N
( ( N
mean JJ N
+/- NNP N
SEM NNP N
) ) N
in IN N
the DT N
5 CD N
women NNS N
who WP N
received VBD N
biotin NN N
supplements NNS N
, , N
whereas IN N
3-HIA JJ 1_o
excretion NN 1_o
increased VBN N
by IN N
1.6 CD N
+/- JJ N
0.6 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
5 CD N
women NNS N
who WP N
received VBD N
placebo NN N
. . N

In IN N
the DT N
late-pregnancy NN N
group NN N
, , N
3-HIA JJ 1_o
excretion NN 1_o
decreased VBN N
( ( N
P NNP N
< NNP N
0.002 CD N
) ) N
by IN N
7.1 CD N
+/- JJ N
1.2 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
8 CD N
women NNS N
who WP N
received VBD N
biotin NN N
supplements NNS N
, , N
whereas IN N
3-HIA JJ 1_o
excretion NN 1_o
increased VBN N
by IN N
0.9 CD N
+/- JJ N
1.8 CD N
mmol/mol JJ N
creatinine NN N
in IN N
the DT N
8 CD N
women NNS N
who WP N
received VBD N
placebo NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
evidence NN N
that IN N
the DT N
increased JJ N
excretion NN 1_o
of IN 1_o
3-HIA JJ 1_o
seen VBN N
frequently RB N
in IN N
normal JJ 1_p
pregnancy NN 1_p
reflects VBZ N
reduced VBN N
biotin JJ 1_o
status NN 1_o
. . 1_o

The DT N
conclusion NN N
that IN N
marginal JJ N
biotin NN N
deficiency NN N
occurs VBZ N
frequently RB N
in IN N
the DT N
first JJ N
trimester NN N
further RBR N
raises NNS N
concern NN N
about IN N
potential JJ N
human JJ N
teratogenicity NN N
. . N

Network NNP N
coordination NN N
following VBG N
discharge NN N
from IN N
psychiatric JJ 1_i
inpatient JJ 1_i
treatment NN 1_i
: : 1_i
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Inadequate NNP N
discharge NN N
planning VBG N
following VBG N
inpatient NN N
stays NNS N
is VBZ N
a DT N
major JJ N
issue NN N
in IN N
the DT N
provision NN N
of IN N
a DT N
high JJ 1_o
standard NN 1_o
of IN 1_o
care NN 1_o
for IN N
patients NNS 1_p
who WP 1_p
receive VBP 1_p
psychiatric JJ 1_i
treatment NN 1_i
. . 1_i

Studies NNS N
have VBP N
shown VBN N
that IN N
half NN N
of IN N
patients NNS 1_p
who WP 1_p
had VBD 1_p
no DT 1_p
pre-discharge JJ 1_p
contact NN 1_p
with IN 1_p
outpatient NN 1_p
services NNS 1_p
do VBP N
not RB N
keep VB N
their PRP$ N
first JJ N
outpatient JJ N
appointment NN N
. . N

Additionally RB N
, , N
discharged VBD 1_p
patients NNS 1_p
who WP 1_p
are VBP 1_p
not RB 1_p
well RB 1_p
linked VBN 1_p
to TO 1_p
their PRP$ 1_p
outpatient NN 1_p
care NN 1_p
networks NNS 1_p
are VBP N
at IN N
twice RB N
the DT N
risk NN N
of IN N
re-hospitalization NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
if IN N
the DT N
Post-Discharge NNP 1_o
Network NNP 1_o
Coordination NNP 1_o
Program NNP 1_o
at IN N
ipw NN N
has VBZ N
a DT N
demonstrably RB N
significant JJ N
impact NN N
on IN N
the DT N
frequency NN 1_o
and CC 1_o
duration NN 1_o
of IN 1_o
patient JJ 1_o
re-hospitalization NN 1_o
. . 1_o

Subjects NNS N
are VBP N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
treatment NN N
group NN N
or CC N
to TO N
the DT N
control NN N
group NN N
. . N

The DT N
treatment NN N
group NN N
participates VBZ N
in IN N
the DT N
Post-Discharge NNP 1_o
Network NNP 1_o
Coordination NNP 1_o
Program NNP 1_o
. . 1_o

The DT N
control NN N
group NN N
receives VBZ N
treatment NN 1_i
as IN 1_i
usual JJ 1_i
with IN N
no DT N
additional JJ N
social JJ N
support NN N
. . N

Further CC N
outcome JJ N
variables NNS N
include VBP N
: : N
social JJ 1_o
support NN 1_o
, , 1_o
change NN 1_o
in IN 1_o
psychiatric JJ 1_o
symptoms NNS 1_o
, , 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
and CC 1_o
independence NN 1_o
in IN 1_o
daily JJ 1_o
functioning NN 1_o
. . 1_o

METHODS/DESIGN NNP N
The DT N
study NN N
is VBZ N
conducted VBN N
as IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Subjects NNS N
are VBP N
randomly RB N
assigned VBN N
to TO N
either VB N
the DT N
control NN 1_i
group NN N
or CC N
to TO N
the DT N
treatment NN 1_i
group NN N
. . N

Computer NNP 1_i
generated VBD 1_i
block NN 1_i
randomization NN 1_i
is VBZ N
used VBN N
to TO N
assure VB N
both DT N
groups NNS N
have VBP N
the DT N
same JJ N
number NN N
of IN N
subjects NNS N
. . N

Stratified NNP 1_i
block NN 1_i
randomization NN 1_i
is VBZ N
used VBN N
for IN N
the DT N
psychiatric JJ N
diagnosis NN N
of IN N
ICD-10 NNP N
, , N
F1 NNP N
. . N

Approximately RB 1_p
160 CD 1_p
patients NNS 1_p
are VBP 1_p
recruited VBN 1_p
in IN 1_p
two CD 1_p
care NN 1_p
units NNS 1_p
at IN 1_p
Psychiatrie-Zentrum NNP 1_p
Hard NNP 1_p
Embrach NNP 1_p
and CC 1_p
two CD 1_p
care NN 1_p
units NNS 1_p
at IN 1_p
Klinik NNP 1_p
Schlosstal NNP 1_p
Winterthur NNP 1_p
. . 1_p

DISCUSSION NNP N
The DT N
proposed VBN N
post-discharge NN 1_o
network NN 1_o
coordination NN 1_o
program NN 1_o
intervenes NNS N
during IN N
the DT N
critical JJ N
post-discharge NN N
period NN N
. . N

It PRP N
focuses VBZ N
primarily RB N
on IN N
promoting VBG N
the DT N
integration NN 1_o
of IN 1_o
the DT 1_o
patients NNS 1_o
into IN 1_o
their PRP$ 1_o
social JJ 1_o
networks NNS 1_o
, , N
and CC N
additionally RB N
to TO N
coordinating VBG 1_o
outpatient JJ 1_o
care NN 1_o
and CC N
addressing VBG 1_o
concerns NNS 1_o
of IN 1_o
daily JJ 1_o
life NN 1_o
. . 1_o

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
ISRCTN58280620 NNP N
. . N

Monotherapy NNP N
of IN N
mild JJ 1_p
hypertension NN 1_o
with IN N
nifedipine NN 1_i
. . 1_i

The DT N
effectiveness NN 1_o
of IN N
nifedipine JJ 1_i
as IN N
first-line JJ N
monotherapy NN N
for IN N
mild JJ 1_p
diastolic JJ 1_o
hypertension NN 1_o
( ( 1_p
range NN 1_p
: : 1_p
95 CD 1_p
to TO 1_p
105 CD 1_p
mm NNS 1_p
Hg NNP 1_p
) ) 1_p
was VBD N
tested VBN N
in IN N
this DT N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
. . N

Fifty-six JJ 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
and CC N
, , N
after IN N
titration NN N
of IN N
the DT N
placebo NN 1_i
or CC N
active JJ 1_i
drug NN 1_i
, , N
they PRP N
were VBD N
followed VBN N
for IN N
12 CD N
weeks NNS N
. . N

Significant JJ N
declines NNS N
in IN N
the DT N
sitting VBG N
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
pressures NNS 1_o
of IN N
-19 JJ N
+/- JJ N
4 CD N
mm NN N
Hg NNP N
( ( N
standard JJ N
error NN N
) ) N
and CC N
-13 $ N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
were VBD N
observed VBN N
during IN N
this DT N
follow-up JJ N
period NN N
. . N

Overall JJ N
, , N
75 CD N
percent NN N
of IN N
patients NNS N
receiving VBG N
active JJ 1_i
drug NN 1_i
had VBD N
diastolic JJ 1_o
pressures NNS 1_o
less RBR N
than IN N
or CC N
equal JJ N
to TO N
90 CD N
mm NNS N
Hg NNP N
at IN N
the DT N
last JJ N
treatment NN N
visit NN N
. . N

Heart NNP 1_o
rate NN 1_o
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
the DT N
sitting VBG N
position NN N
during IN N
the DT N
treatment NN N
period NN N
, , N
and CC N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
75 CD N
percent NN N
) ) N
showed VBD N
a DT N
response NN N
to TO N
nifedipine JJ 1_i
doses NNS N
of IN N
10 CD N
or CC N
20 CD N
mg NNS N
orally RB N
three CD N
times NNS N
daily RB N
in IN N
the DT N
capsule NN N
form NN N
. . N

The DT N
levels NNS N
of IN N
the DT N
systolic NN 1_o
and CC 1_o
diastolic JJ 1_o
pressures NNS 1_o
at IN N
entry NN N
were VBD N
not RB N
predictive JJ N
of IN N
the DT N
dose NN N
of IN N
nifedipine NN 1_i
required VBN N
for IN N
effective JJ 1_o
blood NN 1_o
pressure NN 1_o
control NN N
. . N

Reducing VBG N
polycystic JJ 1_o
liver NN 1_o
volume NN 1_o
in IN 1_p
ADPKD NNP 1_p
: : 1_p
effects NNS N
of IN N
somatostatin NN 1_i
analogue NN 1_i
octreotide NN 1_i
. . 1_i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
No NNP N
medical JJ N
treatment NN N
is VBZ N
available JJ N
for IN N
polycystic JJ N
liver NN N
disease NN N
, , N
a DT N
frequent JJ N
manifestation NN N
of IN N
autosomal-dominant JJ 1_p
polycystic JJ 1_p
kidney NN 1_p
disease NN 1_p
( ( 1_p
ADPKD NNP 1_p
) ) 1_p
. . 1_p

In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
, , N
6 CD N
months NNS N
of IN N
octreotide NN 1_i
( ( N
40 CD N
mg NN N
every DT N
28 CD N
days NNS N
) ) N
therapy NN N
limited JJ N
kidney NN N
volume NN N
growth NN N
more RBR N
effectively RB N
than IN N
placebo NN 1_i
in IN N
12 CD 1_p
patients NNS 1_p
with IN 1_p
ADPKD NNP 1_p
. . 1_p

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
In IN N
this DT N
secondary JJ N
, , N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
above NN N
study NN N
, , N
octreotide-induced JJ 1_i
changes NNS N
in IN N
liver NN 1_o
volumes NNS 1_o
compared VBN N
with IN N
placebo NN 1_i
and CC N
the DT N
relationship NN N
between IN N
concomitant NN N
changes NNS N
in IN N
liver NN N
and CC N
kidney NN N
volumes NNS N
were VBD N
evaluated VBN N
. . N

Those DT N
analyzing VBG N
liver NN 1_o
and CC 1_o
kidney NN 1_o
volumes NNS 1_o
were VBD N
blinded VBN N
to TO N
treatment NN N
. . N

RESULTS NNP N
Liver NNP 1_o
volumes VBZ 1_o
significantly RB 1_o
decreased VBN 1_o
from IN N
1595 CD N
+/- JJ N
478 CD N
ml NN N
to TO N
1524 CD N
+/- JJ N
453 CD N
ml NN N
with IN N
octreotide JJ N
whereas IN N
they PRP N
did VBD N
not RB N
appreciably RB N
change NN N
with IN N
placebo NN 1_i
. . 1_i

Changes NNS 1_o
in IN 1_o
liver NN 1_o
volumes NNS 1_o
were VBD N
significantly RB 1_o
different JJ 1_o
between IN N
the DT N
two CD N
treatment NN N
periods NNS N
( ( N
-71 JJ N
+/- JJ N
57 CD N
ml NN N
versus NN N
+14 VBD N
+/- JJ N
85 CD N
ml NN N
) ) N
. . N

Octreotide-induced JJ 1_o
liver NN 1_o
volume NN 1_o
reduction NN 1_o
was VBD N
fully RB N
explained VBN N
by IN N
a DT N
reduction NN N
in IN N
parenchyma JJ 1_o
volume NN 1_o
from IN N
1506 CD N
+/- JJ N
431 CD N
ml NN N
to TO N
1432 CD N
+/- JJ N
403 CD N
ml NN N
. . N

Changes NNS 1_o
in IN 1_o
liver NN 1_o
volumes NNS 1_o
were VBD N
significantly RB N
correlated VBN N
with IN N
concomitant JJ N
changes NNS N
in IN N
kidney NN 1_o
volumes NNS 1_o
( ( N
r VB N
= RB N
0.67 CD N
) ) N
during IN N
octreotide NN N
but CC N
not RB N
during IN N
placebo JJ N
treatment NN N
. . N

Liver NNP 1_o
and CC 1_o
kidney NN 1_o
volume NN 1_o
changes NNS 1_o
significantly RB N
differed VBN 1_o
with IN N
both DT N
treatments NNS N
( ( 1_i
octreotide IN 1_i
: : 1_i
-71 JJ N
+/- JJ N
57 CD N
ml NN N
versus NN N
+71 VBD N
+/- JJ N
107 CD N
; : N
placebo NN 1_i
: : 1_i
+14 JJ N
+/- JJ N
85 CD N
ml NN N
versus NN N
+162 VBD N
+/- JJ N
114 CD N
) ) N
, , N
but CC N
net JJ 1_o
reductions NNS 1_o
in IN 1_o
liver NN 1_o
( ( N
-85 JJ N
+/- JJ N
103 CD N
ml NN N
) ) N
and CC N
kidney NN 1_o
( ( N
-91 JJ N
+/- JJ N
125 CD N
ml NN N
) ) N
volume NN 1_o
growth NN 1_o
on IN N
octreotide IN 1_i
versus NN N
placebo NN 1_i
were VBD N
similar JJ 1_o
. . 1_o

CONCLUSIONS NNP N
Octreotide NNP 1_i
therapy NN 1_i
reduces NNS N
liver RB 1_o
volumes NNS 1_o
in IN N
patients NNS N
with IN N
ADPKD NNP N
and CC N
is VBZ N
safe JJ N
. . N

Monitoring VBG N
acute JJ N
effects NNS N
on IN N
athletic JJ N
performance NN N
with IN N
mixed JJ N
linear JJ N
modeling NN N
. . N

UNLABELLED IN N
There EX N
is VBZ N
a DT N
need NN N
for IN N
a DT N
sophisticated JJ N
approach NN N
to TO N
track VB N
athletic JJ N
performance NN N
and CC N
to TO N
quantify VB N
factors NNS N
affecting VBG N
it PRP N
in IN N
practical JJ N
settings NNS N
. . N

PURPOSE NNP N
To TO N
demonstrate VB N
the DT N
application NN N
of IN N
mixed JJ N
linear JJ N
modeling VBG N
for IN N
monitoring VBG N
athletic JJ N
performance NN N
. . N

METHODS NNP N
Elite NNP 1_p
sprint NN 1_p
and CC 1_p
middle-distance NN 1_p
swimmers NNS 1_p
( ( 1_p
three CD 1_p
females NNS 1_p
and CC 1_p
six CD 1_p
males NNS 1_p
; : 1_p
aged VBN 1_p
21-26 JJ 1_p
yr NN 1_p
) ) 1_p
performed VBD 1_p
6-13 JJ 1_p
time NN 1_p
trials NNS 1_p
in IN 1_p
training NN 1_p
and CC 1_p
competition NN 1_p
in IN 1_p
the DT 1_p
9 CD 1_p
wk NN 1_p
before IN 1_p
and CC 1_p
including VBG 1_p
Olympic-qualifying JJ 1_p
trials NNS 1_p
, , 1_p
all DT 1_p
in IN 1_p
their PRP$ 1_p
specialty NN 1_p
event NN 1_p
. . 1_p

We PRP N
included VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
diet-controlled JJ 1_i
crossover NN 1_i
intervention NN 1_i
, , N
in IN N
which WDT N
the DT N
swimmers NNS N
consumed VBN N
caffeine NN 1_i
( ( N
5 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
body NN N
mass NN N
) ) N
or CC N
placebo NN 1_i
. . 1_i

The DT N
swimmers NNS N
also RB N
knowingly RB N
consumed VBD N
varying VBG N
doses NNS N
of IN N
caffeine NN 1_i
in IN N
some DT N
time NN N
trials NNS N
. . N

We PRP N
used VBD N
mixed JJ N
linear JJ N
modeling NN N
of IN N
log-transformed JJ N
swim JJ N
time NN N
to TO N
quantify VB N
effects NNS 1_o
on IN 1_o
performance NN 1_o
in IN N
training VBG N
versus NN N
competition NN N
, , N
in IN N
morning NN N
versus NN N
evening NN N
swims NNS N
, , N
and CC N
with IN N
use NN N
of IN N
caffeine NN N
. . N

Predictor NN N
variables NNS N
were VBD N
coded VBN N
as IN N
0 CD N
or CC N
1 CD N
to TO N
represent VB N
absence NN N
or CC N
presence NN N
, , N
respectively RB N
, , N
of IN N
each DT N
condition NN N
and CC N
were VBD N
included VBN N
as IN N
fixed JJ N
effects NNS N
. . N

The DT N
date NN N
of IN N
each DT N
performance NN N
test NN N
was VBD N
included VBN N
as IN N
a DT N
continuous JJ N
linear JJ N
fixed VBN N
effect NN N
and CC N
interacted VBN N
with IN N
the DT N
random NN N
effect NN N
for IN N
the DT N
athlete NN N
to TO N
represent VB N
individual JJ N
differences NNS N
in IN N
linear JJ N
trends NNS N
in IN N
performance NN N
. . N

RESULTS NNP N
Most JJS N
effects NNS 1_o
were VBD N
clear JJ N
, , N
owing VBG N
to TO N
the DT N
high JJ N
reliability NN N
of IN N
performance NN 1_o
times NNS 1_o
in IN 1_o
training NN 1_o
and CC 1_o
competition NN 1_o
( ( N
typical JJ N
errors NNS N
of IN N
0.9 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Performance NN 1_o
time NN 1_o
improved VBN N
linearly RB N
by IN N
0.8 CD N
% NN N
per IN N
4 CD N
wk NN N
. . N

The DT N
swimmers NNS N
performed VBD 1_o
substantially RB 1_o
better RBR 1_o
in IN N
evenings NNS N
versus JJ N
mornings NNS N
and CC N
in IN N
competition NN N
versus IN N
training NN N
. . N

A DT N
100-mg JJ N
dose NN N
of IN N
caffeine NN N
enhanced VBN N
performance NN 1_o
in IN 1_o
training NN 1_o
and CC 1_o
competition NN 1_o
by IN N
approximately RB N
1.3 CD N
% NN N
. . N

There EX N
were VBD N
substantial JJ N
but CC N
unclear JJ N
individual JJ N
responses NNS N
to TO N
training NN N
and CC N
caffeine NN N
( ( N
SD NNP N
of IN N
0.3 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Mixed NNP N
linear IN N
modeling VBG N
can MD N
be VB N
applied VBN N
successfully RB N
to TO N
monitor VB N
factors NNS N
affecting VBG N
performance NN N
in IN N
a DT N
squad NN N
of IN N
elite JJ 1_p
athletes NNS 1_p
. . 1_p

Effects NNS N
of IN N
a DT N
music NN 1_i
therapy NN 1_i
group NN 1_i
intervention NN 1_i
on IN N
enhancing VBG N
social JJ 1_o
skills NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

BACKGROUND NNP N
Research NNP N
indicates VBZ N
that IN N
music NN 1_i
therapy NN 1_i
can MD N
improve VB N
social JJ N
behaviors NNS N
and CC N
joint JJ N
attention NN N
in IN N
children NNS 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorder NNP 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
; : 1_p
however RB N
, , N
more JJR N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
interventions NNS N
for IN N
social JJ 1_o
skills NNS 1_o
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
impact NN N
of IN N
group NN N
music NN N
therapy NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
music NN 1_i
therapy NN 1_i
group NN N
intervention NN N
on IN N
eye NN 1_o
gaze NN 1_o
, , 1_o
joint JJ 1_o
attention NN 1_o
, , 1_o
and CC 1_o
communication NN 1_o
in IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

METHOD NNP N
Seventeen NNP 1_p
children NNS 1_p
, , 1_p
ages VBZ 1_p
6 CD 1_p
to TO 1_p
9 CD 1_p
, , 1_p
with IN 1_p
a DT 1_p
diagnosis NN 1_p
of IN 1_p
ASD NNP 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
the DT 1_p
music NN 1_i
therapy NN 1_i
group NN 1_i
( ( 1_i
MTG NNP 1_i
) ) 1_i
or CC 1_p
the DT 1_p
no-music JJ 1_i
social JJ 1_i
skills NNS 1_i
group NN 1_i
( ( 1_i
SSG NNP 1_i
) ) 1_i
. . 1_i

Children NNP N
participated VBD N
in IN N
ten JJ N
50-minute JJ N
group NN N
sessions NNS N
over IN N
a DT N
period NN N
of IN N
5 CD N
weeks NNS N
. . N

All DT N
group NN N
sessions NNS N
were VBD N
designed VBN N
to TO N
target VB N
social JJ N
skills NNS N
. . N

The DT N
Social NNP 1_o
Responsiveness NNP 1_o
Scale NNP 1_o
( ( 1_o
SRS NNP 1_o
) ) 1_o
, , 1_o
the DT 1_o
Autism NNP 1_o
Treatment NNP 1_o
Evaluation NNP 1_o
Checklist NNP 1_o
( ( 1_o
ATEC NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
video JJ 1_o
analysis NN 1_o
of IN 1_o
sessions NNS 1_o
were VBD N
used VBN N
to TO N
evaluate VB N
changes NNS N
in IN N
social JJ N
behavior NN N
. . N

RESULTS CC N
There EX N
were VBD N
significant JJ N
between-group JJ N
differences NNS N
for IN N
joint JJ 1_o
attention NN 1_o
with IN 1_o
peers NNS 1_o
and CC 1_o
eye NN 1_o
gaze NN 1_o
towards NNS 1_o
persons NNS 1_o
, , N
with IN N
participants NNS N
in IN N
the DT N
MTG NNP N
demonstrating NN N
greater JJR N
gains NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group NN N
differences NNS N
for IN N
initiation NN 1_o
of IN 1_o
communication NN 1_o
, , 1_o
response NN 1_o
to TO 1_o
communication NN 1_o
, , 1_o
or CC 1_o
social JJ 1_o
withdraw/behaviors NNS 1_o
. . 1_o

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
time NN N
and CC N
group NN N
for IN N
SRS NNP 1_o
scores NNS 1_o
, , N
with IN N
improvements NNS N
for IN N
the DT N
MTG NNP N
but CC N
not RB N
the DT N
SSG NNP N
. . N

Scores NNS 1_o
on IN 1_o
the DT 1_o
ATEC NNP 1_o
did VBD N
not RB N
differ VB N
over IN N
time NN N
between IN N
the DT N
MTG NNP 1_i
and CC N
SSG NNP N
. . N

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
support VB N
further JJ N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
group NN N
interventions NNS N
for IN N
social JJ 1_o
skills NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Statistical JJ N
results NNS N
demonstrate VBP N
initial JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
social JJ N
groups NNS N
to TO N
develop VB N
joint JJ 1_o
attention NN 1_o
. . 1_o

Auditory NNP 1_o
signal JJ 1_o
detection NN 1_o
in IN N
paranoid NN 1_p
and CC 1_p
nonparanoid JJ 1_p
schizophrenics NNS 1_p
. . 1_p

Double-blind NNP N
, , N
placebo-controlled JJ N
study NN N
of IN N
azelastine NN 1_i
and CC 1_i
fluticasone NN 1_i
in IN N
a DT N
single JJ N
nasal NN N
spray NN N
delivery NN N
device NN N
. . N

BACKGROUND VB N
A DT N
proof-of-concept JJ N
study NN N
suggested VBD N
that IN N
combination NN N
therapy NN N
with IN N
commercial JJ N
azelastine NN 1_i
hydrochloride NN 1_i
nasal NN N
spray NN N
and CC N
fluticasone NN 1_i
propionate NN 1_i
nasal NN N
spray NN N
significantly RB N
improved VBN N
nasal JJ 1_o
symptoms NNS 1_o
of IN 1_o
seasonal JJ 1_o
allergic JJ 1_o
rhinitis NN 1_o
compared VBN N
with IN N
either DT N
agent NN N
alone RB N
. . N

OBJECTIVE UH N
To TO N
compare VB N
an DT N
azelastine-fluticasone JJ 1_i
combination NN N
nasal NN N
spray NN N
administered VBN N
in IN N
a DT N
single-delivery JJ N
device NN N
with IN N
a DT N
commercially RB N
available JJ N
azelastine NN N
nasal NN N
spray NN N
and CC N
fluticasone NN N
nasal NN N
spray NN N
. . N

METHODS NNP N
This DT N
14-day JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
conducted VBN N
during IN N
the DT N
Texas NNP N
mountain NN N
cedar NN N
season NN N
. . N

After IN N
a DT N
5-day JJ N
placebo NN 1_i
lead-in NN N
, , N
610 CD 1_p
patients NNS 1_p
with IN 1_p
moderate-to-severe JJ 1_p
nasal NN 1_p
symptoms NNS 1_p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
( ( 1_i
1 CD 1_i
) ) 1_i
azelastine NN 1_i
nasal NN 1_i
spray NN 1_i
, , 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
fluticasone NN 1_i
nasal NN 1_i
spray NN 1_i
, , 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
combination NN 1_i
azelastine NN 1_i
and CC 1_i
fluticasone NN 1_i
nasal NN 1_i
spray NN 1_i
, , 1_i
or CC 1_i
( ( 1_i
4 CD 1_i
) ) 1_i
placebo NN 1_i
nasal JJ 1_i
spray NN 1_i
. . 1_i

All DT N
treatments NNS N
were VBD N
given VBN N
as IN N
1 CD 1_i
spray NN 1_i
per IN 1_i
nostril JJ 1_i
twice JJ 1_i
daily RB 1_i
. . 1_i

The DT N
primary JJ N
efficacy NN N
variable NN N
was VBD N
the DT N
change NN N
from IN N
baseline NN N
in IN N
the DT N
total JJ 1_o
nasal JJ 1_o
symptom NN 1_o
score NN 1_o
( ( 1_o
TNSS NNP 1_o
) ) 1_o
, , 1_o
consisting VBG 1_o
of IN 1_o
nasal JJ 1_o
congestion NN 1_o
, , 1_o
runny NN 1_o
nose RB 1_o
, , 1_o
itchy NN 1_o
nose NN 1_o
, , 1_o
and CC 1_o
sneezing VBG 1_o
. . 1_o

RESULTS NNP N
All DT N
3 CD N
active JJ N
groups NNS N
were VBD N
statistically RB N
superior JJ N
( ( N
P NNP N
< NNP N
or= NNP N
.02 NNP N
) ) N
to TO N
placebo VB N
, , N
and CC N
the DT N
combination NN N
was VBD N
statistically RB N
superior JJ N
( ( N
P NNP N
< NNP N
or= NNP N
.003 NNP N
) ) N
to TO N
either DT N
agent NN N
alone RB N
. . N

The DT N
TNSS NNP 1_o
improved VBN N
by IN N
28.4 CD N
% NN N
with IN N
combination NN N
azelastine-fluticasone NN 1_i
, , N
20.4 CD N
% NN N
with IN N
fluticasone NN 1_i
, , N
16.4 CD N
% NN N
with IN N
azelastine NN 1_i
, , N
and CC N
11.2 CD N
% NN N
with IN N
placebo NN 1_i
. . 1_i

All DT N
3 CD N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
azelastine-fluticasone NN 1_i
nasal NN N
spray NN N
provided VBD N
statistically RB N
significant JJ N
improvement NN N
in IN N
the DT N
TNSS NNP 1_o
and CC N
additive JJ N
clinical JJ N
benefit NN N
compared VBN N
with IN N
either DT N
agent NN N
alone RB N
in IN N
patients NNS 1_p
with IN 1_p
moderate-to-severe JJ 1_p
seasonal JJ 1_p
allergic JJ 1_p
rhinitis NN 1_p
. . 1_p

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00660517 NN N
. . N

Is VBZ N
successful JJ N
rehabilitation NN N
of IN N
complex JJ 1_p
regional JJ 1_p
pain NN 1_p
syndrome NN 1_p
due JJ N
to TO N
sustained JJ N
attention NN N
to TO N
the DT N
affected JJ N
limb NN N
? . N
A DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

In IN N
complex JJ N
regional JJ N
pain NN N
syndrome NN N
( ( N
CRPS1 NNP N
) ) N
initiated VBN N
by IN N
wrist JJ N
fracture NN N
, , N
a DT N
motor NN 1_i
imagery NN 1_i
program NN 1_i
( ( N
MIP NNP N
) ) N
, , N
consisting VBG N
of IN N
hand NN N
laterality NN N
recognition NN N
followed VBN N
by IN N
imagined JJ 1_i
movements NNS 1_i
and CC N
then RB N
mirror NN 1_i
movements NNS 1_i
, , N
reduces NNS N
pain VBP 1_o
and CC 1_o
disability NN 1_o
, , N
but CC N
the DT N
mechanism NN N
of IN N
effect NN N
is VBZ N
unclear JJ N
. . N

Possibilities NNS N
include VBP N
sustained JJ N
attention NN N
to TO N
the DT N
affected JJ N
limb NN N
, , N
in IN N
which WDT N
case NN N
the DT N
order NN N
of IN N
MIP NNP N
components NNS N
would MD N
not RB N
alter VB N
the DT N
effect NN N
, , N
and CC N
sequential JJ N
activation NN N
of IN N
cortical JJ N
motor NN N
networks NNS N
, , N
in IN N
which WDT N
case NN N
it PRP N
would MD N
. . N

Twenty VB 1_p
subjects NNS 1_p
with IN 1_p
chronic JJ 1_p
CRPS1 NNP 1_p
initiated VBN 1_p
by IN 1_p
wrist JJ 1_p
fracture NN 1_p
and CC 1_p
who WP 1_p
satisfied VBD 1_p
stringent JJ 1_p
inclusion NN 1_p
criteria NNS 1_p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
hand NN 1_i
laterality NN 1_i
recognition NN 1_i
, , 1_i
imagined VBD 1_i
movements NNS 1_i
, , 1_i
mirror NN 1_i
movements NNS 1_i
( ( 1_i
RecImMir NNP 1_i
, , 1_i
MIP NNP 1_i
) ) 1_i
; : 1_i
imagined VBN 1_i
movements NNS 1_i
, , 1_i
recognition NN 1_i
, , 1_i
imagined VBD 1_i
movements NNS 1_i
( ( 1_i
ImRecIm NNP 1_i
) ) 1_i
; : 1_i
recognition NN 1_i
, , 1_i
mirror NN 1_i
movements NNS 1_i
, , 1_i
recognition NN 1_i
( ( 1_i
RecMirRec NNP 1_i
) ) 1_i
. . 1_i

At IN N
6 CD N
and CC N
18 CD N
weeks NNS N
, , N
reduced VBD N
pain NN 1_o
and CC 1_o
disability NN 1_o
were VBD N
greater JJR N
for IN N
the DT N
RecImMir NNP N
group NN N
than IN N
for IN N
the DT N
other JJ N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Hand NNP N
laterality NN N
recognition NN N
imparted VBD N
a DT N
consistent JJ N
reduction NN N
in IN N
pain NN 1_o
and CC 1_o
disability NN 1_o
across IN N
groups NNS N
, , N
however RB N
, , N
this DT N
effect NN N
was VBD N
limited VBN N
in IN N
magnitude NN N
. . N

Imagined VBD N
movements NNS N
imparted VBD N
a DT N
further JJ N
reduction NN N
in IN N
pain NN 1_o
and CC 1_o
disability NN 1_o
, , N
but CC N
only RB N
if IN N
they PRP N
followed VBD N
hand NN N
laterality NN N
recognition NN N
. . N

Mirror NN N
movements NNS N
also RB N
imparted VBD N
a DT N
reduction NN N
in IN N
pain NN 1_o
and CC 1_o
disability NN 1_o
, , N
but CC N
only RB N
when WRB N
they PRP N
followed VBD N
imagined JJ N
movements NNS N
. . N

The DT N
effect NN 1_o
of IN N
the DT N
MIP NNP N
seems VBZ N
to TO N
be VB N
dependent JJ N
on IN N
the DT N
order NN N
of IN N
components NNS N
, , N
which WDT N
suggests VBZ N
that IN N
it PRP N
is VBZ N
not RB N
due JJ N
to TO N
sustained JJ N
attention NN N
to TO N
the DT N
affected JJ N
limb NN N
, , N
but CC N
is VBZ N
consistent JJ N
with IN N
sequential JJ N
activation NN N
of IN N
cortical JJ N
motor NN N
networks NNS N
. . N

Diet-Related JJ N
Colorectal NNP N
Cancer NNP N
Prevention NNP N
Beliefs NNP N
and CC N
Dietary NNP 1_i
Intakes NNP 1_i
in IN N
an DT N
Urban JJ 1_p
Minority NNP 1_p
Population NNP 1_p
. . 1_p

In IN N
the DT N
United NNP 1_p
States NNPS 1_p
, , N
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
is VBZ N
the DT N
third JJ N
leading JJ N
cause NN N
of IN N
cancer-related JJ N
death NN N
and CC N
third JJ N
most RBS N
commonly RB N
diagnosed JJ N
cancer NN N
among IN N
adults NNS N
. . N

This DT N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
diet-related JJ 1_o
beliefs NNS 1_o
for IN 1_o
colorectal JJ 1_o
cancer NN 1_o
prevention NN 1_o
and CC 1_o
dietary JJ 1_o
intake NN 1_o
among IN N
an DT N
urban JJ 1_p
, , 1_p
predominantly RB 1_p
Black NNP 1_p
population NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
169 CD 1_p
) ) 1_p
. . 1_p

More JJR N
than IN N
two-thirds NNS N
reported VBN N
diet-related JJ N
CRC NNP N
prevention NN N
beliefs NN N
. . N

Those DT N
with IN N
diet-related JJ 1_i
CRC NNP N
prevention NN N
beliefs NNS N
had VBD N
healthier JJR N
intakes NNS 1_o
for IN 1_o
dietary JJ 1_o
fiber NN 1_o
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
, , N
fruit NN 1_o
, , 1_o
vegetable NN 1_o
, , 1_o
bean NN 1_o
( ( N
p JJ N
= NNP N
.027 NNP N
) ) N
, , N
red JJ 1_o
meat NN 1_o
( ( N
p JJ N
= NNP N
.032 NNP N
) ) N
, , N
vitamin FW 1_o
C NNP 1_o
( ( N
p JJ N
= NNP N
.039 NNP N
) ) N
, , N
and CC N
cholesterol NN 1_o
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
. . N

Most JJS N
people NNS N
may MD N
already RB N
have VB N
diet-related JJ 1_i
CRC NNP 1_i
prevention NN 1_i
beliefs NN 1_i
and CC N
having VBG N
them PRP N
is VBZ N
associated VBN N
with IN N
a DT N
more RBR N
healthful JJ 1_o
dietary JJ 1_o
intake NN 1_o
. . 1_o

Prospective JJ N
, , N
blinded VBD N
exploratory JJ N
evaluation NN N
of IN N
the DT N
PlayWisely NNP 1_i
program NN 1_i
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
explore VB N
a DT N
low-cost JJ 1_i
intervention NN 1_i
that WDT N
targets VBZ N
an DT N
increasingly RB N
common JJ N
developmental JJ N
disorder NN N
. . N

The DT N
study NN N
was VBD N
a DT N
blinded JJ N
, , N
exploratory JJ N
evaluation NN N
of IN N
the DT N
PlayWisely NNP 1_i
program NN 1_i
on IN N
autism NN 1_o
symptoms NNS 1_o
and CC 1_o
essential JJ 1_o
learning NN 1_o
foundation NN 1_o
skills NNS 1_o
( ( 1_o
attention NN 1_o
, , 1_o
recognition NN 1_o
, , 1_o
and CC 1_o
memory NN 1_o
skills NNS 1_o
) ) 1_o
in IN N
children NNS 1_p
with IN 1_p
a DT 1_p
diagnosis NN 1_p
of IN 1_p
autism NN 1_p
, , 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
, , 1_p
pervasive JJ 1_p
developmental NN 1_p
disorder NN 1_p
- : 1_p
not RB 1_p
otherwise RB 1_p
specified VBN 1_p
( ( 1_p
PDD-NOS NNP 1_p
) ) 1_p
, , 1_p
and CC 1_p
Asperger NNP 1_p
syndrome VBP 1_p
( ( 1_p
AS IN 1_p
) ) 1_p
. . 1_p

Eighteen JJ 1_p
children NNS 1_p
, , 1_p
1 CD 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , N
were VBD N
evaluated VBN N
using VBG N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
, , N
Second NNP N
Edition NNP N
( ( N
CARS2 NNP N
) ) N
; : N
the DT N
PlayWisely NNP N
Interactive NNP N
Test NNP N
of IN N
Attention NNP N
, , N
Recognition NNP N
, , N
and CC N
Memory NNP N
Skills NNP N
; : N
Autism NNP N
Treatment NNP N
Evaluation NNP N
Checklist NNP N
( ( N
ATEC NNP N
) ) N
, , N
and CC N
the DT N
Modified NNP N
Checklist NNP N
for IN N
Autism NNP N
in IN N
Toddlers NNP N
( ( N
M-CHAT NNP N
) ) N
. . N

There EX N
were VBD N
significant JJ N
treatment NN N
effects NNS 1_o
for IN N
the DT N
PlayWisely NNP N
measure NN N
on IN N
the DT N
Yellow NNP N
Sets NNPS N
that WDT N
examine VBP N
recognition NN 1_o
; : 1_o
Purple NNP N
Sets VBZ N
that IN N
examine NN N
brain NN 1_o
region NN 1_o
agility NN 1_o
and CC 1_o
early JJ 1_o
memory NN 1_o
skills NNS 1_o
; : 1_o
Blue NNP N
Sets NNPS N
that WDT N
examine VBP N
phonemic JJ 1_o
awareness NN 1_o
and CC 1_o
recognition NN 1_o
; : 1_o
and CC N
for IN N
the DT N
Total NNP N
Sets NNP N
, , N
with IN N
a DT N
similar JJ N
trend NN N
toward IN N
improvement NN N
in IN N
the DT N
Green JJ N
Sets NNS N
that WDT N
examine VBP N
perception NN N
and CC N
Red NNP N
Sets NNP N
that IN N
examine JJ N
attention NN 1_o
. . 1_o

No DT N
other JJ N
measures NNS N
reached VBD N
statistical JJ N
significance NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
PlayWisely RB N
can MD N
improve VB N
recognition NN 1_o
, , 1_o
brain NN 1_o
region NN 1_o
agility NN 1_o
, , 1_o
phonemic JJ 1_o
awareness NN 1_o
, , 1_o
letter NN 1_o
recognition NN 1_o
, , 1_o
and CC 1_o
early JJ 1_o
memory NN 1_o
skills NNS 1_o
in IN N
ASD NNP N
. . N

It PRP N
was VBD N
observed VBN N
by IN N
the DT N
parents NNS N
, , N
coaches NNS N
, , N
and CC N
study NN N
investigators NNS N
that IN N
the DT N
children NNS N
who WP N
were VBD N
less JJR N
than IN N
3 CD N
years NNS N
of IN N
age NN N
showed VBD N
improvements NNS N
in IN N
autism NN 1_o
symptoms NNS 1_o
; : 1_o
however RB N
, , N
the DT N
group NN N
was VBD N
too RB N
small JJ N
to TO N
reach VB N
statistical JJ N
significance NN N
. . N

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
see VB N
if IN N
this DT N
intervention NN N
can MD N
mitigate VB N
autism NN 1_o
symptoms NNS 1_o
in IN N
very RB N
young JJ N
children NNS N
with IN N
ASD NNP N
. . N

Gene NNP N
variants NNS N
in IN N
CYP2C19 NNP N
are VBP N
associated VBN N
with IN N
altered VBN N
in IN N
vivo JJ N
bupropion NN 1_i
pharmacokinetics NNS N
but CC N
not RB N
bupropion-assisted JJ N
smoking VBG 1_p
cessation NN 1_p
outcomes NNS N
. . N

Bupropion NNP 1_i
is VBZ N
used VBN N
clinically RB N
to TO N
treat VB N
depression NN N
and CC N
to TO N
promote VB N
smoking VBG N
cessation NN N
. . N

It PRP N
is VBZ N
metabolized VBN N
by IN N
CYP2B6 NNP N
to TO N
its PRP$ N
active JJ N
metabolite JJ N
hydroxybupropion NN N
, , N
yet CC N
alterations NNS N
in IN N
CYP2B6 NNP N
activity NN N
have VBP N
little JJ N
impact NN N
on IN N
bupropion NN 1_o
plasma NN 1_o
levels NNS 1_o
. . 1_o

Furthermore RB N
, , N
less JJR N
than IN N
10 CD N
% NN N
of IN N
a DT N
bupropion NN 1_i
dose NN N
is VBZ N
excreted VBN N
as IN N
urinary JJ N
bupropion NN 1_i
and CC N
its PRP$ N
characterized JJ N
metabolites NNS N
hydroxybupropion NN N
, , N
threohydrobupropion NN N
, , N
and CC N
erythrohydrobupropion NN N
, , N
suggesting VBG N
that IN N
alternative JJ N
metabolic JJ N
pathways NNS N
may MD N
exist VB N
. . N

In IN N
vitro JJ N
data NNS N
suggested VBD N
CYP2C19 NNP N
could MD N
metabolize VB N
bupropion NN 1_i
. . 1_i

The DT N
current JJ N
study NN N
investigated VBD N
the DT N
impact NN N
of IN N
functional JJ N
CYP2C19 NNP N
genetic JJ N
variants NNS N
on IN N
bupropion NN N
pharmacokinetics NNS N
and CC N
treatment NN N
outcomes NNS N
. . N

In IN N
42 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
, , N
CYP2C19*2 NNP N
( ( N
a DT N
reduced VBN N
activity NN N
allele NN N
) ) N
was VBD N
associated VBN N
with IN N
higher JJR N
bupropion NN 1_i
area NN N
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
, , N
but CC N
similar JJ N
hydroxybupropion NN N
AUC NNP N
. . N

The DT N
mean JJ 1_o
bupropion NN 1_o
AUC NNP 1_o
was VBD N
771 CD N
versus NN N
670 CD N
hours⋅ng/ml NN N
in IN N
individuals NNS N
with IN N
and CC N
without IN N
CYP2C19*2 NNP N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CYP2C19*2 NNP N
was VBD N
also RB N
associated VBN N
with IN N
higher JJR 1_o
threohydrobupropion NN 1_o
and CC 1_o
erythrohydrobupropion NN 1_o
AUC NNP 1_o
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

Adjusting VBG N
for IN N
CYP2B6 NNP N
genotype NN N
did VBD N
not RB N
alter VB N
these DT N
associations NNS N
, , N
and CC N
CYP2C19 NNP N
variants NNS N
did VBD N
not RB N
alter VB N
the DT N
utility NN N
of IN N
the DT 1_o
hydroxybupropion/bupropion NN 1_o
ratio NN 1_o
as IN N
a DT N
measure NN N
of IN N
CYP2B6 NNP N
activity NN N
. . N

Finally RB N
, , N
in IN N
a DT N
clinical JJ N
trial NN N
of IN 1_p
540 CD 1_p
smokers NNS 1_p
, , N
CYP2C19 NNP N
genotype NN N
was VBD N
not RB N
associated VBN N
with IN N
smoking VBG 1_o
cessation NN 1_o
outcomes NNS 1_o
, , N
supporting VBG N
the DT N
hypothesis NN N
that WDT 1_i
bupropion NN 1_i
response NN N
is VBZ N
mediated VBN N
by IN 1_o
hydroxybupropion NN 1_o
, , N
which WDT N
is VBZ N
not RB N
altered VBN N
by IN N
CYP2C19 NNP N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
study NN N
reports VBZ N
the DT N
first JJ N
in IN N
vivo JJ N
evidence NN N
that IN N
reduced VBD 1_o
CYP2C19 NNP 1_o
activity NN 1_o
significantly RB N
increases VBZ N
the DT 1_o
steady-state JJ 1_o
exposure NN 1_o
to TO 1_o
bupropion NN 1_o
and CC 1_o
its PRP$ 1_o
reductive JJ 1_o
metabolites NNS 1_o
threohydrobupropion NN 1_o
and CC 1_o
erythrohydrobupropion NN 1_o
. . N

These DT N
pharmacokinetic JJ N
changes NNS N
were VBD N
not RB N
associated VBN N
with IN N
differences NNS N
in IN N
bupropion NN N
's POS N
ability NN N
to TO N
promote VB N
smoking VBG N
cessation NN N
in IN 1_p
smokers NNS 1_p
, , N
but CC N
may MD N
influence VB N
the DT 1_o
side NN 1_o
effects NNS 1_o
and CC 1_o
toxicity NN 1_o
associated VBN N
with IN 1_i
bupropion NN 1_i
. . N

[ NN N
Combined VBD N
preoperative JJ 1_i
xeloda NN 1_i
and CC 1_i
radiotherapy NN 1_i
for IN N
lower JJR 1_p
rectal NN 1_p
cancer NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
combined JJ 1_i
preoperative JJ 1_i
xeloda NN 1_i
and CC 1_i
pelvic JJ 1_i
radiotherapy NN 1_i
on IN N
locally RB 1_p
advanced VBN 1_p
lower JJR 1_p
rectal JJ 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
Sixty NNP 1_p
lower JJR 1_p
rectal JJ 1_p
cancer NN 1_p
patients NNS 1_p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

30 CD 1_p
patients NNS 1_p
( ( N
Group NNP N
A NNP N
) ) N
were VBD N
treated VBN N
with IN N
operation NN 1_i
alone RB 1_i
and CC N
30 CD N
patients NNS N
( ( N
Group NNP N
B NNP N
) ) N
were VBD N
treated VBN N
with IN N
xeloda NNP 1_i
and CC 1_i
radiotherapy NN 1_i
before IN 1_i
operation NN 1_i
. . 1_i

RESULTS VB N
The DT N
operative JJ 1_o
resection NN 1_o
, , 1_o
anal JJ 1_o
preservation NN 1_o
and CC 1_o
local JJ 1_o
recurrence NN 1_o
rates NNS 1_o
were VBD N
86.66 CD N
% NN N
, , N
33.33 CD N
% NN N
, , N
15.38 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
100 CD N
% NN N
, , N
83.33 CD N
% NN N
, , N
0 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Combined VBD 1_i
preoperative JJ 1_i
xeloda NN 1_i
and CC 1_i
radiotherapy NN 1_i
for IN N
lower JJR N
rectal NN N
cancer NN N
is VBZ N
able JJ N
to TO N
significantly RB N
improve VB N
the DT N
operative JJ N
resection NN N
, , N
anal JJ N
preservation NN N
and CC N
decrease VB N
the DT N
local JJ N
recurrence NN N
rates NNS N
. . N

The DT N
effect NN N
of IN N
polyvinylpyrrolidone-iodine NN 1_i
as IN N
an DT N
disinfectant NN 1_o
in IN N
eye NN 1_p
surgery NN 1_p
. . 1_p

105 CD 1_p
patients NNS 1_p
admitted VBN 1_p
for IN 1_p
cataract NN 1_p
surgery NN 1_p
were VBD N
treated VBN N
pre-operatively RB N
with IN N
polyvinylpyrrolidone-iodine JJ 1_i
( ( 1_i
PVP-I NNP 1_i
) ) 1_i
as IN N
a DT N
disinfectant NN N
, , N
and CC N
consecutive JJ N
bacterial JJ N
cultures NNS N
were VBD N
obtained VBN N
before IN N
initiating VBG N
surgery NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
. . N

A DT N
control NN 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
99 CD 1_p
) ) 1_p
only RB N
had VBD N
a DT N
standard JJ 1_o
disinfection NN 1_o
procedure NN 1_i
of IN N
the DT N
eye NN N
( ( N
including VBG N
instillation NN N
of IN N
Terramycin NNP 1_i
cum NN 1_i
polymyxin NN 1_i
B NNP 1_i
cream NN 1_i
in IN N
the DT N
conjunctival NN N
sac VBD N
the DT N
evening NN N
before IN N
surgery NN N
) ) N
. . N

The DT N
cultures NNS N
obtained VBN N
from IN N
the DT N
conjunctival NN N
sac NN N
of IN N
the DT N
control NN N
group NN N
principally RB N
showed VBD N
growth NN N
of IN N
Staph NNP N
. . N

albus NN N
and CC N
Staph NNP N
. . N

aureus NN N
, , N
and CC N
to TO N
a DT N
minor JJ N
degree NN N
diphtheroids NNS N
( ( N
Corynebacterium NNP N
species NNS N
) ) N
. . N

Proteus NNP N
mirabilis NN N
, , N
Escherichia NNP N
coli NN N
and CC N
micrococci NN N
. . N

There EX N
was VBD N
a DT N
significant JJ 1_o
quantitative JJ 1_o
diminished VBN 1_o
growth NN 1_o
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
of IN N
bacteria NN N
in IN N
the DT N
group NN N
of IN N
patients NNS N
treated VBN N
with IN N
PVP-I NNP 1_i
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Concerning VBG N
the DT N
growth NN N
of IN N
Staph NNP N
. . N

albus NN N
, , N
this DT N
was VBD N
reduced VBN N
to TO N
almost RB N
one CD N
third JJ N
and CC N
other JJ N
bacteria NNS N
were VBD N
almost RB N
eliminated VBN N
in IN N
the DT N
group NN N
receiving VBG N
PVP-I NNP 1_i
. . 1_i

As IN N
we PRP N
disclosed VBD N
no DT N
toxic NN 1_o
or CC 1_o
allergic JJ 1_o
reaction NN 1_o
post-operatively RB 1_o
which WDT N
could MD N
be VB N
related VBN N
to TO N
the DT N
use NN N
of IN N
PVP-I NNP 1_i
as IN N
a DT N
disinfectant NN N
, , N
this DT N
agent NN N
seems VBZ N
to TO N
constitute VB N
an DT N
effective JJ 1_o
pre-operative JJ 1_o
antimicrobial JJ 1_o
treatment NN 1_o
, , N
taking VBG N
into IN N
consideration NN N
the DT N
broad JJ N
antimicrobial JJ N
spectrum NN N
of IN N
PVP-I NNP 1_i
shown VBN N
by IN N
other JJ N
authors NNS N
. . N

An DT N
emergency NN N
clinical JJ N
pathway NN N
for IN N
stroke NN 1_p
patients NNS 1_p
-- : 1_p
results NNS 1_p
of IN N
a DT N
cluster NN N
randomised VBN N
trial NN N
( ( N
isrctn41456865 NN N
) ) N
. . N

BACKGROUND NNP N
Emergency NNP 1_i
Clinical NNP 1_i
Pathways NNP 1_i
( ( 1_i
ECP NNP 1_i
) ) 1_i
for IN N
stroke NN N
have VBP N
never RB N
been VBN N
tested VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN 1_o
of IN N
an DT N
ECP NNP 1_i
for IN N
stroke NN 1_p
patients NNS 1_p
in IN 1_p
Latium NNP 1_p
( ( 1_p
Italy NNP 1_p
) ) 1_p
emergency NN 1_p
system NN 1_p
. . 1_p

METHODS NNP N
cluster-RCT NN 1_i
designed VBN N
to TO N
compare VB N
stroke JJ 1_p
patient JJ 1_p
referrals NNS 1_p
by IN 1_p
Emergency NNP 1_i
Medical NNP 1_i
Service NNP 1_i
( ( 1_i
EMS NNP 1_i
) ) 1_i
and CC 1_p
Emergency NNP 1_p
Room NNP 1_p
( ( 1_p
ER NNP 1_p
) ) 1_p
health NN 1_p
professionals NNS 1_p
trained VBN 1_p
in IN 1_p
the DT 1_p
ECP NNP 1_i
, , 1_p
with IN 1_p
those DT 1_p
of IN 1_p
non-trained JJ 1_p
EMS NNP 1_p
and CC 1_p
ER NNP 1_p
controls NNS 1_p
. . 1_p

Primary NNP N
outcome JJ N
measure NN N
was VBD N
the DT N
proportion NN 1_o
of IN 1_o
eligible JJ 1_o
( ( 1_o
aged VBN 1_o
< NNP 1_o
/= $ 1_o
80 CD 1_o
and CC 1_o
symptom JJ 1_o
onset NN 1_o
< NNP 1_o
/= VBZ 1_o
6 CD 1_o
hours NNS 1_o
) ) 1_o
stroke VBD 1_o
patients NNS 1_o
referred VBN 1_o
to TO 1_o
a DT 1_o
stroke NN 1_o
unit NN 1_o
( ( 1_o
SU NNP 1_o
) ) 1_o
. . 1_o

Intention NN 1_o
to TO 1_o
treat VB 1_o
( ( 1_o
ITT NNP 1_o
) ) 1_o
and CC 1_o
per-protocol JJ 1_o
( ( 1_o
PP NNP 1_o
) ) 1_o
analyses NNS 1_o
were VBD N
performed VBN N
, , N
and CC N
risk NN 1_o
ratios NNS 1_o
( ( 1_o
RR NNP 1_o
) ) 1_o
adjusted VBN N
by IN N
age NN N
, , N
gender NN N
and CC N
area NN N
, , N
were VBD N
calculated VBN N
. . N

RESULTS JJ N
2656 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
intervention NN 1_p
arm NN 1_p
and CC 1_p
2239 CD 1_p
in IN 1_p
the DT 1_p
control NN 1_p
arm NN 1_p
required VBN N
assistance NN 1_o
; : 1_o
78.3 CD N
% NN N
of IN N
the DT N
former JJ N
and CC N
80.6 CD N
% NN N
of IN N
the DT N
latter NN N
were VBD N
admitted VBN 1_o
to TO 1_o
hospitals NNS 1_o
, , N
and CC N
respectively RB N
74.8 CD N
% NN N
and CC N
78.3 CD N
% NN N
were VBD N
confirmed VBN 1_o
strokes NNS 1_o
. . 1_o

Of IN N
the DT N
eligible JJ N
confirmed JJ 1_o
strokes NNS 1_o
, , N
106/434 CD N
( ( N
24.4 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
43/328 CD N
( ( N
13.1 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
were VBD N
referred VBN N
to TO N
the DT N
SU NNP 1_o
in IN N
the DT N
ITT NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
2.01 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.79-4.00 NN N
) ) N
, , N
and CC N
respectively RB N
105/243 CD N
( ( N
43.2 CD N
% NN N
) ) N
and CC N
43/311 CD N
( ( N
13.8 CD N
% NN N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
3.21 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.62-4.98 JJ N
) ) N
. . N

Of IN N
patients NNS N
suitable JJ N
for IN N
i.v NN N
. . N

thrombolysis NN N
, , N
15/175 CD N
( ( N
8.6 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
2/115 CD N
( ( N
1.7 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
received VBN N
thrombolysis NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
ITT NNP N
analysis NN N
, , N
and CC N
respectively RB N
15/99 CD N
( ( N
15.1 CD N
% NN N
) ) N
and CC N
2/107 CD N
( ( N
1.9 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
. . N

CONCLUSION NNP N
Our PRP$ N
data NNS N
suggest VBP N
potenti JJ N
efficiency NN 1_o
and CC 1_o
feasibility NN 1_o
of IN N
an DT N
ECP NNP N
. . N

The DT N
integration NN N
of IN N
EMS NNP N
and CC N
ERs NNP N
with IN N
SU NNP N
networks NNS N
for IN N
organised JJ N
acute NN N
stroke NN N
care NN N
is VBZ N
feasible JJ N
and CC N
may MD N
ameliorate VB N
the DT N
quality NN 1_o
of IN 1_o
care NN 1_o
for IN N
stroke NN 1_p
patients NNS 1_p
. . 1_p

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
( ( N
ISRCTN41456865 NNP N
) ) N
. . N

Lack NN N
of IN N
efficacy NN 1_o
of IN N
citalopram NN 1_i
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
and CC 1_p
high JJ 1_p
levels NNS 1_p
of IN 1_p
repetitive JJ 1_p
behavior NN 1_p
: : 1_p
citalopram NN 1_i
ineffective NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

CONTEXT NNP N
Selective NNP 1_i
serotonin NN 1_i
reuptake NN 1_i
inhibitors NNS 1_i
are VBP N
widely RB N
prescribed VBN N
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
citalopram JJ 1_i
hydrobromide NN 1_i
therapy NN 1_i
for IN N
repetitive JJ N
behavior NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

DESIGN NNP N
National NNP N
Institutes NNPS N
of IN N
Health-sponsored NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Six NNP 1_p
academic JJ 1_p
centers NNS 1_p
, , 1_p
including VBG 1_p
Mount NNP 1_p
Sinai NNP 1_p
School NNP 1_p
of IN 1_p
Medicine NNP 1_p
, , 1_p
North NNP 1_p
Shore-Long NNP 1_p
Island NNP 1_p
Jewish NNP 1_p
Health NNP 1_p
System NNP 1_p
, , 1_p
University NNP 1_p
of IN 1_p
North NNP 1_p
Carolina NNP 1_p
at IN 1_p
Chapel NNP 1_p
Hill NNP 1_p
, , 1_p
University NNP 1_p
of IN 1_p
California NNP 1_p
at IN 1_p
Los NNP 1_p
Angeles NNP 1_p
, , 1_p
Yale NNP 1_p
University NNP 1_p
, , 1_p
and CC 1_p
Dartmouth NNP 1_p
Medical NNP 1_p
School NNP 1_p
. . 1_p

PARTICIPANTS NNP N
One CD 1_p
hundred VBD 1_p
forty-nine JJ 1_p
volunteers NNS 1_p
5 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
old JJ 1_p
( ( 1_p
mean JJ 1_p
[ NNP 1_p
SD NNP 1_p
] NNP 1_p
age NN 1_p
, , 1_p
9.4 CD 1_p
[ NN 1_p
3.1 CD 1_p
] CD 1_p
years NNS 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
citalopram NN 1_i
( ( N
n JJ N
= NNP N
73 CD N
) ) N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Participants NNS 1_p
had VBD 1_p
autistic JJ 1_p
spectrum NN 1_p
disorders NNS 1_p
, , 1_p
Asperger NNP 1_p
disorder NN 1_p
, , 1_p
or CC 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
, , 1_p
not RB 1_p
otherwise RB 1_p
specified VBN 1_p
; : 1_p
had VBD 1_p
illness JJ 1_p
severity NN 1_p
ratings NNS 1_p
of IN 1_p
at IN 1_p
least JJS 1_p
moderate JJ 1_p
on IN 1_p
the DT 1_p
Clinical NNP 1_p
Global NNP 1_p
Impressions NNP 1_p
, , 1_p
Severity NNP 1_p
of IN 1_p
Illness NNP 1_p
Scale NNP 1_p
; : 1_p
and CC 1_p
scored VBD 1_p
at IN 1_p
least JJS 1_p
moderate JJ 1_p
on IN 1_p
compulsive JJ 1_p
behaviors NNS 1_p
measured VBN 1_p
with IN 1_p
the DT 1_p
Children NNP 1_p
's POS 1_p
Yale-Brown JJ 1_p
Obsessive NNP 1_p
Compulsive NNP 1_p
Scales NNP 1_p
modified VBD 1_p
for IN 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
. . 1_p

INTERVENTIONS NNP N
Twelve NNP N
weeks NNS N
of IN N
citalopram NN 1_i
hydrobromide NN 1_i
( ( 1_i
10 CD 1_i
mg/5 RB 1_i
mL NN 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

The DT N
mean NN N
( ( N
SD NNP N
) ) N
maximum JJ N
dosage NN N
of IN N
citalopram NN 1_i
hydrobromide NN 1_i
was VBD N
16.5 CD N
( ( N
6.5 CD N
) ) N
mg/d NN N
by IN N
mouth NN N
( ( N
maximum JJ N
, , N
20 CD N
mg/d NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Positive NNP N
response NN N
was VBD N
defined VBN N
by IN N
a DT N
score NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
Clinical NNP 1_o
Global NNP 1_o
Impressions NNP 1_o
, , 1_o
Improvement NNP 1_o
subscale NN 1_o
. . 1_o

An DT N
important JJ N
secondary JJ N
outcome NN N
was VBD N
the DT N
score NN N
on IN N
the DT N
Children NNP 1_o
's POS 1_o
Yale-Brown JJ 1_o
Obsessive NNP 1_o
Compulsive NNP 1_o
Scales NNP 1_o
modified VBD 1_o
for IN 1_o
pervasive JJ 1_o
developmental NN 1_o
disorders NNS 1_o
. . 1_o

Adverse JJ 1_o
events NNS 1_o
were VBD N
systematically RB N
elicited VBN N
using VBG N
the DT N
Safety NNP N
Monitoring NNP N
Uniform NNP N
Report NNP N
Form NNP N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN 1_o
of IN 1_o
positive JJ 1_o
response NN 1_o
on IN N
the DT N
Clinical NNP 1_o
Global NNP 1_o
Impressions NNP 1_o
, , 1_o
Improvement NNP 1_o
subscale NN 1_o
between IN N
the DT N
citalopram-treated JJ 1_i
group NN N
( ( N
32.9 CD N
% NN N
) ) N
and CC N
the DT N
placebo NN 1_i
group NN N
( ( N
34.2 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
, , N
0.96 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.61-1.51 JJ N
; : N
P NNP N
> NNP N
.99 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
score NN N
reduction NN N
on IN N
the DT N
Children NNP 1_o
's POS 1_o
Yale-Brown JJ 1_o
Obsessive NNP 1_o
Compulsive NNP 1_o
Scales NNP 1_o
modified VBD N
for IN N
pervasive JJ N
developmental JJ 1_o
disorders NNS 1_o
from IN N
baseline NN N
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
, , N
-2.0 NNP N
[ VBZ N
3.4 CD N
] NN N
points NNS N
for IN N
the DT N
citalopram-treated JJ 1_i
group NN N
and CC N
-1.9 NNP N
[ NNP N
2.5 CD N
] NN N
points NNS N
for IN N
the DT N
placebo NN 1_i
group NN N
; : N
P NNP N
= NNP N
.81 NNP N
) ) N
. . N

Citalopram NNP 1_i
use NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
adverse JJ N
events NNS N
, , N
particularly RB N
increased VBD N
energy NN 1_o
level NN 1_o
, , 1_o
impulsiveness NN 1_o
, , N
decreased VBN N
concentration NN 1_o
, , 1_o
hyperactivity NN 1_o
, , 1_o
stereotypy NN 1_o
, , 1_o
diarrhea NN 1_o
, , 1_o
insomnia NN 1_o
, , 1_o
and CC 1_o
dry JJ 1_o
skin NN 1_o
or CC 1_o
pruritus NN 1_o
. . 1_o

CONCLUSION NNP N
Results NNP N
of IN N
this DT N
trial NN N
do VBP N
not RB N
support VB N
the DT N
use NN N
of IN N
citalopram NN 1_i
for IN N
the DT N
treatment NN N
of IN N
repetitive JJ N
behavior NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Trial JJ N
Registration NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00086645 NN N
. . N

Glucosamine NNP 1_o
in IN 1_o
serum NN 1_o
of IN N
patients NNS 1_p
after IN 1_p
myocardial JJ 1_p
infarction NN 1_p
subjected VBN N
to TO N
rehabilitation VB 1_i
training NN 1_i
. . 1_i

This DT N
paper NN N
presents VBZ N
results NNS N
of IN N
3 CD N
weeks NNS N
physical JJ 1_i
training NN 1_i
on IN N
glucosamine JJ 1_o
level NN 1_o
in IN 1_o
serum NN 1_o
of IN N
male NN 1_p
patients NNS 1_p
after IN 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( 1_p
MI NNP 1_p
) ) 1_p
aged VBD 1_p
between IN 1_p
38 CD 1_p
and CC 1_p
61 CD 1_p
. . 1_p

Patients NNS N
were VBD N
randomised VBN N
in IN N
two CD N
groups NNS N
: : N
the DT 1_p
training NN 1_i
group NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
21 CD 1_p
) ) 1_p
, , 1_p
staying VBG 1_p
in IN 1_p
Cardiac NNP 1_p
Rehabilitation NNP 1_p
Department NNP 1_p
and CC 1_p
the DT 1_p
control NN 1_i
group NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
11 CD 1_i
) ) 1_i
, , 1_i
discharged VBD 1_i
home NN 1_i
for IN N
3 CD N
weeks NNS N
. . N

Each DT N
group NN N
received VBD N
identical JJ N
dietary JJ N
instructions NNS N
. . N

The DT 1_p
training NN 1_p
group NN 1_p
performed VBD N
exercises NNS 1_i
every DT 1_i
day NN 1_i
: : 1_i
on IN 1_i
bicycle NN 1_i
ergometer NN 1_i
during IN 1_i
30 CD 1_i
minutes NNS 1_i
( ( 1_i
5 CD 1_i
times NNS 1_i
a DT 1_i
week NN 1_i
) ) 1_i
, , 1_i
overall-conditioning JJ 1_i
exercises NNS 1_i
for IN 1_i
30 CD 1_i
minutes NNS 1_i
daily RB 1_i
and CC 1_i
30 CD 1_i
to TO 1_i
60 CD 1_i
minutes NNS 1_i
of IN 1_i
walking VBG 1_i
each DT 1_i
day NN 1_i
. . 1_i

Before IN 1_i
administering VBG 1_i
of IN 1_i
the DT 1_i
therapy NN 1_i
and CC 1_i
3 CD 1_i
weeks NNS 1_i
later RB 1_i
all DT 1_i
MI NNP 1_i
patients NNS 1_i
performed VBD 1_i
the DT 1_i
bicycle NN 1_i
ergometer NN 1_i
exercise NN 1_i
test NN 1_i
until IN 1_i
the DT 1_i
ventilatory NN 1_o
threshold NN 1_o
was VBD 1_i
reached VBN 1_i
. . 1_i

Before IN 1_i
that DT 1_i
test NN 1_i
and CC 1_i
3 CD 1_i
minutes NNS 1_i
after IN 1_i
its PRP$ 1_i
termination NN 1_i
capillary NN 1_i
and CC 1_i
venous JJ 1_i
blood NN 1_i
samples NNS 1_i
were VBD 1_i
drawn VBN 1_i
. . 1_i

In IN 1_i
the DT 1_i
capillary JJ 1_i
blood NN 1_i
samples NNS 1_i
indices NNS 1_o
of IN 1_o
acid-base JJ 1_o
balance NN 1_o
, , 1_o
lactate JJ 1_o
level NN 1_o
, , 1_o
and CC 1_o
glucose JJ 1_o
level NN 1_o
were VBD 1_i
determined VBN 1_i
. . 1_i

In IN N
venous JJ N
blood NN N
samples NNS N
the DT N
serum NN 1_o
levels NNS 1_o
of IN 1_o
immunoreactive JJ 1_o
insulin NN 1_o
, , 1_o
C-peptide NNP 1_o
and CC 1_o
glucosamine NN 1_o
were VBD N
determined VBN N
as RB N
well RB N
as IN N
binding NN 1_o
of IN 1_o
125I-insulin JJ 1_o
to TO 1_o
erythrocyte VB 1_o
receptors NNS 1_o
. . 1_o

Obtained VBN N
results NNS N
show VBP N
that IN N
administered JJ N
therapy NN N
increased VBD N
physical JJ 1_o
fitness NN 1_o
and CC N
decreased VBN N
of IN N
glucosamine NN 1_o
concentration NN 1_o
, , 1_o
insulinaemia NN 1_o
and CC 1_o
insulin NN 1_o
resistance NN 1_o
. . 1_o

Caphosol NNP 1_i
( ( 1_i
® NNP 1_i
) ) 1_i
mouthwash VBP 1_i
gives VBZ N
no DT N
additional JJ N
protection NN N
against IN N
oral JJ N
mucositis NN N
compared VBN N
to TO 1_i
cryotherapy VB 1_i
alone RB N
in IN 1_p
stem NN 1_p
cell NN 1_p
transplantation NN 1_p
. . N

A DT N
pilot NN N
study NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
if IN N
adding VBG 1_i
Caphosol NNP 1_i
( ( 1_i
® NNP 1_i
) ) 1_i
, , N
a DT N
mouthwash JJ N
solution NN N
, , N
to TO N
oral JJ 1_i
cryotherapy NN 1_i
( ( N
OC NNP N
) ) N
further RBR N
protects NNS N
against IN N
oral JJ N
mucositis NN N
( ( N
OM NNP N
) ) N
, , N
a DT N
toxic JJ N
painful JJ N
complication NN N
to TO N
high VB N
dose JJ N
chemotherapy NN N
. . N

METHOD NNP N
The DT N
study NN N
was VBD N
a DT N
randomised JJ N
, , N
controlled VBN N
, , N
study NN N
design NN 1_p
. . 1_p

Patients NNS 1_p
≥16 JJ 1_p
years NNS 1_p
scheduled VBN 1_p
for IN 1_p
allogeneic JJ 1_p
stem NN 1_p
cell NN 1_p
transplantation NN 1_p
were VBD 1_p
included VBN 1_p
consecutively RB N
and CC N
randomised VBD N
to TO N
experimental VB N
group NN N
receiving VBG 1_i
OC NNP 1_i
combined VBN 1_i
with IN 1_i
Caphosol NNP 1_i
( ( 1_i
® NNP 1_i
) ) 1_i
( ( N
n JJ N
= NNP N
20 CD 1_i
) ) 1_i
or CC 1_i
control VB 1_i
group NN 1_i
receiving VBG 1_i
OC NNP 1_i
only RB N
( ( N
n JJ N
= NNP N
20 CD 1_i
) ) 1_i
. . N

OC NNP N
was VBD N
given VBN N
from IN N
start NN N
to TO N
end VB N
of IN N
HDCT NNP 1_i
. . 1_i

Caphosol NNP 1_i
( ( 1_i
® NNP 1_i
) ) 1_i
, , N
from IN N
day NN N
0 CD N
to TO N
day NN N
21 CD N
. . N

RESULT VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
regarding VBG N
age NN N
or CC N
gender NN N
between IN N
the DT N
groups NNS 1_o
. . 1_o

Mucositis NNP 1_o
was VBD N
assessed VBN N
with IN 1_o
the DT 1_o
World NNP 1_o
Health NNP 1_o
Organisation NNP 1_o
( ( 1_o
WHO NNP 1_o
) ) 1_o
grading VBG 1_o
scale NN 1_o
. . 1_o

Pain NN N
was VBD N
assessed VBN N
with IN 1_o
a DT 1_o
10 CD 1_o
cm NN 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( N
VAS NNP N
) ) N
from IN N
0 CD N
= JJ N
no DT N
pain NN N
to TO N
10 CD N
= NNS N
worst RBR N
imaginable JJ N
pain NN 1_o
. . 1_o

Start NNP 1_o
and CC 1_o
duration NN 1_o
of IN 1_o
therapy NN 1_o
with IN 1_o
pain NN 1_o
relieving VBG 1_o
drugs NNS 1_o
, , 1_o
serum VBD 1_o
C-reactive JJ 1_o
protein NN 1_o
values NNS 1_o
, , 1_o
and CC 1_o
number NN 1_o
of IN 1_o
days NNS 1_o
of IN 1_o
hospitalisation NN 1_o
were VBD N
collected VBN N
from IN N
the DT N
medical JJ N
records NNS 1_o
. . 1_o

Data NNS 1_o
on IN 1_o
OM NNP 1_o
, , 1_o
oral JJ 1_o
pain NN 1_o
, , 1_o
use NN 1_o
of IN 1_o
i.v NN 1_o
. . 1_o

opioids NNS 1_o
and CC 1_o
total JJ 1_o
parenteral JJ 1_o
nutrition NN 1_o
were VBD N
collected VBN N
during IN N
22 CD N
days NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS 1_o
on IN 1_o
OM NNP 1_o
, , 1_o
oral JJ 1_o
pain NN 1_o
, , 1_o
use NN 1_o
of IN 1_o
i.v NN 1_o
. . 1_o

opioids NNS 1_o
or CC 1_o
TPN NNP N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
study NN N
showed VBD N
no DT N
additional JJ N
effect NN N
of IN N
combining VBG 1_i
Caphosol NNP 1_i
( ( 1_i
® NNP 1_i
) ) 1_i
with IN 1_i
OC NNP N
. . N

Beta-carotene NNP 1_i
in IN N
HIV NNP 1_p
infection NN 1_p
. . 1_p

beta-Carotene NN 1_i
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
an DT N
immunostimulatory JJ N
effect NN N
. . N

Recent JJ N
studies NNS N
suggest VBP N
that IN N
beta-carotene JJ 1_i
supplementation NN 1_i
can MD N
increase VB N
CD4 NNP 1_o
counts NNS 1_o
in IN N
HIV-infected JJ 1_p
patients NNS 1_p
. . 1_p

Our PRP$ N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
beta-carotene NN 1_i
in IN N
raising VBG N
CD4 NNP N
counts NNS N
in IN N
HIV-infected JJ 1_p
patients NNS 1_p
. . 1_p

Twenty-one CD 1_p
HIV-seropositive JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
beta-carotene NN 1_i
, , 1_i
180 CD 1_i
mg/day NN 1_i
or CC 1_i
placebo NN 1_i
for IN N
4 CD N
weeks NNS N
, , N
and CC N
then RB N
crossed VBD N
over IN N
to TO N
receive VB N
the DT N
alternative JJ N
treatment NN N
for IN N
the DT N
following JJ N
4 CD N
weeks NNS N
. . N

beta-Carotene NN N
resulted VBD N
in IN N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
total JJ 1_o
WBC NNP 1_o
count NN 1_o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
% NN 1_o
change NN 1_o
in IN 1_o
CD4 NNP 1_o
count NN 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
% NN 1_o
change NN 1_o
in IN 1_o
CD4/CD8 NNP 1_o
ratios NNS 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
absolute JJ 1_o
CD4 NNP 1_o
count NN 1_o
, , 1_o
absolute JJ 1_o
CD4/CD8 NNP 1_o
ratio NN 1_o
, , 1_o
and CC 1_o
total JJ 1_o
and CC 1_o
B-lymphocytes NNP 1_o
all DT N
increased VBN N
on IN N
carotene NN N
and CC N
fell VBD N
during IN N
placebo NN N
, , N
but CC N
these DT N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

No DT N
toxicity NN 1_o
was VBD N
observed VBN N
on IN N
either DT N
treatment NN N
. . N

beta-Carotene JJ N
appears VBZ N
to TO N
have VB N
an DT N
immunostimulatory JJ 1_o
effect NN 1_o
in IN N
HIV-infected JJ 1_p
patients NNS 1_p
. . 1_p

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
demonstrate VB N
whether IN N
beta-carotene NN N
has VBZ N
a DT N
role NN N
as IN N
adjunct JJ N
therapy NN N
in IN N
treatment NN N
of IN N
HIV-infected JJ 1_o
patients NNS 1_o
. . 1_o

Maternal NNP 1_i
dietary JJ 1_i
counseling NN 1_i
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
healthy JJ 1_o
eating VBG 1_o
index NN 1_o
in IN N
childhood NN 1_p
. . 1_p

Food NNP N
preferences NNS N
are VBP N
established VBN N
in IN N
early JJ N
childhood NN N
and CC N
track NN N
later RB N
in IN N
life NN N
. . N

Therefore RB N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
promote VB N
healthy JJ N
feeding NN N
practices NNS N
as RB N
early RB N
as IN N
possible JJ N
. . N

A DT N
randomized JJ N
field NN N
trial NN N
was VBD N
conducted VBN N
with IN N
500 CD 1_p
mother-child JJ 1_p
pairs NNS 1_p
from IN 1_p
a DT 1_p
low-income JJ 1_p
area NN 1_p
of IN 1_p
São NNP 1_p
Leopoldo NNP 1_p
, , 1_p
State NNP 1_p
of IN 1_p
Rio NNP 1_p
Grande NNP 1_p
do VBP 1_p
Sul NNP 1_p
, , 1_p
Brazil NNP 1_p
, , 1_p
to TO 1_p
evaluate VB 1_p
the DT 1_p
impact NN 1_p
of IN 1_p
a DT 1_i
nutritional JJ 1_i
intervention NN 1_i
in IN 1_p
the DT 1_p
first JJ 1_p
year NN 1_p
of IN 1_p
life NN 1_p
on IN 1_p
the DT 1_p
dietary JJ 1_p
quality NN 1_p
of IN 1_p
3- JJ 1_p
to TO 1_p
4-y-old JJ 1_p
children NNS 1_p
. . N

Mother-child JJ N
pairs NNS N
were VBD N
randomized VBN N
either RB N
to TO 1_i
intervention NN 1_i
and CC 1_i
control NN 1_i
groups NNS N
and CC 1_i
dietary JJ 1_i
counseling NN 1_i
was VBD N
provided VBN N
for IN N
mothers NNS N
in IN N
the DT N
intervention NN N
group NN N
during IN N
10 CD N
home NN N
visits NNS N
in IN N
the DT N
course NN N
of IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
. . N

These DT N
visits NNS N
were VBD N
carried VBN N
out RP N
by IN N
fieldworkers NNS N
who WP 1_i
counseled VBD 1_i
the DT N
mothers NNS N
about IN N
the DT N
Ten NNP N
Steps NNP N
for IN N
Healthy NNP N
Feeding VBG N
from IN N
Birth NNP N
to TO N
Two CD N
Years NNS N
of IN N
Age NNP N
, , N
based VBN N
on IN N
the DT N
WHO NNP N
guidelines NNS N
. . 1_o

Dietary JJ 1_o
intake NN 1_o
was VBD N
assessed VBN N
at IN N
3-4 JJ N
y NN N
of IN N
age NN N
for IN 1_p
345 CD 1_p
children NNS 1_p
using VBG N
two CD N
24-h JJ N
food NN N
recalls NNS N
. . 1_o

Overall JJ 1_o
diet JJ 1_o
quality NN 1_o
was VBD N
determined VBN N
by IN N
the DT N
Healthy NNP N
Eating NNP N
Index NNP N
. . N

The DT 1_o
prevalence NN 1_o
of IN 1_o
poor JJ 1_o
diet NNS 1_o
in IN N
the DT N
intervention NN N
group NN N
was VBD N
lower JJR N
compared VBN N
with IN N
the DT N
control NN N
group NN N
[ NNP N
relative NN N
risk NN N
( ( N
RR NNP N
) ) N
= VBZ N
0.30 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.13-0.71 NN N
) ) N
. . N

The DT N
number NN N
of IN N
children NNS N
who WP N
achieved VBD N
the DT 1_o
75th CD 1_o
percentile NN 1_o
for IN 1_o
the DT 1_o
vegetable JJ 1_o
and CC 1_o
fruit JJ 1_o
component NN 1_o
score NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
intervention NN N
than IN N
in IN N
control NN N
group NN N
( ( N
RR NNP N
= NNP N
1.95 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.31-2.89 JJ N
and CC N
RR NNP N
= NNP N
1.49 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.07-2.07 CD N
, , N
respectively RB N
) ) N
. . N

Such JJ N
data NNS N
provide VBP N
evidence NN N
that IN 1_i
dietary JJ 1_i
counseling NN 1_i
for IN N
mothers NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
improves VBZ N
the DT 1_o
overall JJ 1_o
dietary JJ 1_o
quality NN 1_o
of IN 1_p
children NNS 1_p
in IN 1_p
a DT 1_p
low-income JJ 1_p
population NN 1_p
. . N

Effect NN N
of IN N
glycemic JJ N
load NN N
on IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
during IN N
weight JJ N
loss NN N
. . N

High JJ N
eating JJ N
behavior JJ N
self-efficacy NN N
may MD N
contribute VB N
to TO N
successful JJ N
weight JJ N
loss NN N
. . N

Diet JJ 1_i
interventions NNS 1_i
that WDT N
maximize VBP N
eating VBG N
behavior JJ N
self-efficacy NN N
may MD N
therefore VB N
improve VB N
weight NN N
loss NN N
outcomes NNS N
. . N

However RB N
, , N
data NNS N
on IN N
the DT N
effect NN N
of IN N
diet JJ N
composition NN N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
are VBP N
sparse JJ N
. . N

To TO N
determine VB N
the DT N
effects NNS N
of IN N
dietary JJ N
glycemic JJ N
load NN N
( ( N
GL NNP N
) ) N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
during IN N
weight JJ N
loss NN N
, , N
body NN 1_o
weight NN 1_o
and CC N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
were VBD N
measured VBN N
every DT N
six CD N
months NNS N
in IN N
overweight JJ 1_p
adults NNS 1_p
participating VBG 1_p
in IN 1_p
a DT 1_p
12-mo JJ 1_p
randomized JJ 1_p
trial NN 1_p
testing VBG 1_i
energy-restricted JJ 1_i
diets NNS 1_i
differing VBG 1_i
in IN 1_i
GL NNP 1_i
. . 1_i

All DT N
food NN N
was VBD N
provided VBN N
during IN N
the DT N
first JJ N
six CD N
months NNS N
and CC N
self-selected JJ N
thereafter NN N
. . N

Total JJ 1_o
mean JJ 1_o
weight NN 1_o
loss NN 1_o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
, , N
and CC N
GL-level NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
. . 1_o

In IN N
the DT N
combined JJ N
cohort NN N
, , N
individuals NNS N
losing VBG N
the DT N
most RBS N
weight JJ N
reported VBD N
improvements NNS N
in IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
, , N
whereas IN N
those DT N
achieving VBG N
less JJR N
weight JJ 1_o
loss NN 1_o
reported VBD N
decrements NNS N
in IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
. . 1_o

Decrements NNS N
in IN N
eating VBG 1_o
behavior JJ 1_o
self-efficacy NN 1_o
were VBD N
associated VBN N
with IN N
subsequent JJ N
weight NN 1_o
regain NN N
when WRB N
diets NNS N
were VBD N
self-selected JJ N
. . N

While IN N
GL NNP N
does VBZ N
not RB N
appear VB N
to TO N
influence VB N
eating VBG N
behavior JJ N
self-efficacy NN N
, , N
lesser JJR N
amounts NNS N
of IN N
weight JJ N
loss NN N
on IN N
provided-food JJ 1_i
energy NN 1_i
restricted VBN 1_i
diets NNS 1_i
may MD N
deter VB N
successful JJ N
maintenance NN N
of IN N
weight JJ N
loss NN N
by IN N
attenuating VBG N
improvements NNS N
in IN N
eating VBG N
behavior JJ N
self-efficacy NN N
. . N

Bridge NNP 1_i
plate NN 1_i
osteosynthesis NN 1_i
using VBG 1_i
dynamic JJ 1_i
condylar JJ 1_i
screw NN 1_i
( ( 1_i
DCS NNP 1_i
) ) 1_i
or CC 1_i
retrograde VBN 1_i
intramedullary JJ 1_i
supracondylar JJ 1_i
nail NN 1_i
( ( 1_i
RIMSN NNP 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
distal JJ 1_p
femoral JJ 1_p
fractures NNS 1_p
: : 1_p
comparison NN N
of IN N
two CD N
methods NNS N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
treatment NN N
of IN N
distal JJ 1_p
femoral JJ 1_p
fractures NNS 1_p
remains VBZ N
a DT N
significant JJ N
surgical JJ N
challenge NN N
. . N

With IN N
the DT N
rigid JJ N
fixation NN N
of IN N
the DT N
distal JJ N
femoral JJ N
fractures NNS N
, , N
bone NN N
grafting NN N
is VBZ N
frequently RB N
needed VBN N
. . N

Biological JJ N
osteosynthesis NN N
using VBG N
dynamic JJ N
condylar JJ N
screw NN N
( ( N
DCS NNP N
) ) N
and CC N
retrograde JJ N
intramedullary JJ N
supracondylar NN N
nail NN N
( ( N
RIMSN NNP N
) ) N
preserve VBP N
the DT N
blood NN N
supply NN N
and CC N
limit NN N
the DT N
need NN N
for IN N
bone NN N
grafting NN N
. . N

METHODS NNP N
From IN 1_p
September NNP 1_p
2002 CD 1_p
to TO 1_p
December NNP 1_p
2004 CD 1_p
, , 1_p
68 CD 1_p
closed VBD 1_p
fractures NNS 1_p
of IN 1_p
the DT 1_p
distal JJ 1_p
femur NN 1_p
were VBD 1_p
treated VBN 1_p
by IN 1_p
bridge NN 1_i
plate NN 1_i
osteosynthesis NN 1_i
using VBG 1_i
DCS NNP 1_i
in IN 1_i
31 CD 1_i
and CC 1_i
RIMSN NNP 1_i
in IN 1_i
37 CD 1_i
. . 1_i

The DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
groups NNS N
randomly RB N
and CC N
followed VBD N
for IN N
24-36 JJ N
months NNS N
( ( N
average JJ N
: : N
30 CD N
months NNS N
) ) N
. . N

RESULTS VBN N
With IN N
respect NN N
to TO N
operation NN N
time NN N
, , N
the DT N
DCS NNP N
group NN N
presented VBD N
significantly RB N
better JJR N
results NNS N
than IN N
the DT N
RIMSN NNP N
group NN N
( ( N
p=0.000 NN N
) ) N
. . N

However RB N
, , N
the DT N
blood NN 1_o
loss NN 1_o
was VBD N
significantly RB N
more RBR N
in IN N
the DT N
DCS NNP N
group NN N
( ( N
p=0.000 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
cumulative JJ 1_o
rate NN 1_o
of IN 1_o
union NN 1_o
( ( N
p=0.855 NN N
) ) N
, , N
range NN 1_o
of IN 1_o
motion NN 1_o
of IN 1_o
the DT 1_o
knee NN 1_o
( ( N
p=0.727 NN N
) ) N
, , N
overall JJ 1_o
results NNS 1_o
( ( N
p=0.925 NN N
) ) N
and CC N
complications NNS 1_o
( ( N
p=0.927 NN N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
No NNP N
implant NN N
or CC N
surgical JJ N
technique NN N
is VBZ N
superior JJ N
to TO N
any DT N
other JJ N
under IN N
all DT N
circumstances NNS N
for IN N
distal JJ N
femoral JJ N
fracture NN N
. . N

RIMSN NNP N
is VBZ N
standard JJ N
care NN N
, , N
yet RB N
the DT N
biological JJ N
osteosynthesis NN N
using VBG N
DCS NNP N
is VBZ N
a DT N
very RB N
good JJ N
alternative NN N
for IN N
the DT N
treatment NN N
of IN N
distal JJ 1_p
femoral JJ 1_p
fractures NNS 1_p
. . 1_p

Stroke NNP N
team NN N
remote NN N
evaluation NN N
using VBG N
a DT N
digital JJ N
observation NN N
camera NN N
in IN N
Arizona NNP 1_p
: : 1_p
the DT N
initial JJ N
mayo NN N
clinic JJ N
experience NN N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Telemedicine NNP N
techniques NNS N
can MD N
be VB N
used VBN N
to TO N
address VB N
the DT N
rural-metropolitan JJ 1_p
disparity NN N
in IN N
acute JJ N
stroke NN N
care NN N
. . N

The DT N
Stroke NNP N
Team NNP N
Remote NNP N
Evaluation NNP N
Using VBG N
a DT N
Digital NNP N
Observation NNP N
Camera NNP N
( ( N
STRokE NNP N
DOC NNP N
) ) N
trial NN N
reported VBD N
more RBR N
accurate JJ N
decision NN N
making NN N
for IN N
telemedicine JJ 1_i
consultations NNS N
compared VBN N
with IN N
telephone-only JJ 1_i
and CC N
that IN N
the DT N
California-based JJ N
research NN N
network NN N
facilitated VBD N
a DT N
high JJ N
rate NN N
of IN N
thrombolysis NN N
use NN N
, , N
improved VBN N
data NNS N
collection NN N
, , N
low JJ N
risk NN N
of IN N
complications NNS N
, , N
low JJ N
technical JJ N
complications NNS N
, , N
and CC N
favorable JJ N
assessment NN N
times NNS N
. . N

The DT N
main JJ N
objective NN N
of IN N
the DT N
STRokE NNP N
DOC NNP N
Arizona NNP N
TIME NNP N
( ( N
The DT N
Initial NNP N
Mayo NNP N
Clinic NNP N
Experience NNP N
) ) N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
feasibility NN N
of IN N
establishing VBG N
, , N
de FW N
novo FW N
, , N
a DT N
single-hub JJ N
, , N
multirural JJ N
spoke VBD N
hospital JJ N
telestroke NN N
research NN N
network NN N
across IN N
a DT N
large JJ N
geographical JJ N
area NN N
in IN N
Arizona NNP N
by IN N
replicating VBG N
the DT N
STRokE NNP N
DOC NNP N
protocol NN N
. . N

METHODS NNP N
Methods NNP N
included VBD N
prospective JJ N
, , N
single-hub JJ N
, , N
2-spoke JJ N
, , N
randomized VBN N
, , N
blinded VBD N
, , N
controlled VBD N
trial NN N
of IN N
a DT N
2-way JJ N
, , N
site-independent JJ N
, , N
audiovisual JJ 1_i
telemedicine NN 1_i
system NN 1_i
designed VBN 1_i
for IN 1_i
remote JJ 1_i
examination NN 1_i
of IN N
adult NN 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
stroke NN 1_p
versus IN 1_p
telephone NN 1_i
consultation NN 1_i
to TO 1_i
assess VB 1_i
eligibility NN 1_i
for IN 1_i
treatment NN 1_i
with IN 1_p
intravenous JJ 1_i
thrombolysis NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
whether IN N
the DT N
decision NN 1_o
to TO 1_o
give VB 1_o
thrombolysis NN 1_o
was VBD 1_o
correct JJ 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
were VBD N
rate NN 1_o
of IN 1_o
thrombolytic JJ 1_o
use NN 1_o
, , 1_o
90-day JJ 1_o
functional JJ 1_o
outcomes NNS 1_o
, , 1_o
incidence NN 1_o
of IN 1_o
intracerebral JJ 1_o
hemorrhages NNS 1_o
, , 1_o
and CC 1_o
technical JJ 1_o
observations NNS 1_o
. . 1_o

RESULTS NN N
From IN 1_p
December NNP 1_p
2007 CD 1_p
to TO 1_p
October NNP 1_p
2008 CD 1_p
, , 1_p
54 CD 1_p
patients NNS 1_p
were VBD 1_p
assessed VBN 1_p
, , N
27 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
each DT N
arm NN N
. . N

Mean JJ N
National NNP N
Institutes NNPS N
of IN N
Health NNP N
Stroke NNP N
Scale NNP N
score NN N
at IN N
presentation NN N
was VBD N
7.3 CD N
( ( N
SD NNP N
6.2 CD N
) ) N
points NNS N
. . N

No DT N
consultations NNS N
were VBD N
aborted VBN N
; : N
however RB N
, , N
technical JJ 1_o
problems NNS 1_o
( ( N
74 CD N
% NN N
) ) N
were VBD N
prevalent JJ N
in IN N
the DT N
telemedicine NN N
arm NN N
. . N

Overall JJ N
, , N
the DT N
correct JJ N
treatment NN 1_o
decision NN 1_o
was VBD N
established VBN N
in IN N
87 CD N
% NN N
of IN N
the DT N
consultations NNS N
. . N

Both DT N
modalities NNS N
, , N
telephone NN N
( ( N
89 CD N
% NN N
correct NN N
) ) N
and CC N
telemedicine NN N
( ( N
85 CD N
% NN N
correct NN N
) ) N
, , N
performed VBN N
well RB N
. . N

Intravenous JJ N
thrombolytic JJ 1_i
treatment NN 1_i
was VBD N
used VBN N
in IN N
30 CD N
% NN N
of IN N
the DT N
telemedicine NN N
and CC N
telephone NN N
consultations NNS N
. . N

Good JJ N
functional JJ 1_o
outcomes NNS 1_o
at IN N
90 CD N
days NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
mortality NN 1_o
( ( N
4 CD N
% NN N
in IN N
telemedicine NN N
and CC N
11 CD N
% NN N
in IN N
telephone NN N
) ) N
or CC N
rates NNS 1_o
of IN 1_o
intracerebral JJ 1_o
hemorrhage NN 1_o
( ( N
4 CD N
% NN N
in IN N
telemedicine NN N
and CC N
0 CD N
% NN N
in IN N
telephone NN N
) ) N
. . N

CONCLUSIONS VB N
It PRP N
is VBZ N
feasible JJ N
to TO N
extend VB N
the DT N
original JJ N
STRokE NNP N
DOC NNP N
trial NN N
protocol NN N
to TO N
a DT N
new JJ N
state NN N
and CC N
establish VB N
an DT N
operational JJ N
single-hub NN N
, , N
multispoke VBD N
rural JJ N
hospital NN N
telestroke VBD N
research NN N
network NN N
in IN N
Arizona NNP N
. . N

The DT N
trial NN N
was VBD N
not RB N
designed VBN N
to TO N
have VB N
sufficient JJ N
power NN N
to TO N
detect VB N
a DT N
difference NN N
between IN N
the DT N
2 CD N
consultative JJ N
modes NNS N
: : N
telemedicine NN N
and CC N
telephone-only RB N
. . N

Whether CC N
by IN N
telemedicine NN N
or CC N
telephone NN N
consultative JJ N
modalities NNS N
, , N
there EX N
were VBD N
appropriate JJ N
treatment NN 1_o
decisions NNS 1_o
, , N
high JJ N
rates NNS N
of IN N
thrombolysis NN 1_o
use NN 1_o
, , N
improved VBN N
data NNS 1_o
collection NN 1_o
, , N
low JJ N
rates NNS 1_o
of IN 1_o
intracerebral JJ 1_o
hemorrhage NN 1_o
, , N
and CC N
equally RB N
favorable JJ N
time NN 1_o
requirements NNS 1_o
. . 1_o

The DT N
learning VBG N
curve NN N
was VBD N
steep JJ N
for IN N
the DT N
hub NN N
and CC N
spoke VBD N
personnel NNS N
of IN N
the DT N
new JJ N
telestroke NN N
network NN N
, , N
as IN N
reflected VBN N
by IN N
frequent JJ N
technical JJ N
problems NNS N
. . N

Overall NNP N
, , N
the DT N
results NNS N
support VBD N
the DT N
effectiveness NN N
of IN N
highly RB N
organized VBN N
and CC N
structured VBN N
stroke NN N
telemedicine NN N
networks NNS N
for IN N
extending VBG N
expert JJ N
stroke NN N
care NN N
into IN N
rural JJ 1_p
remote JJ 1_p
communities NNS 1_p
lacking VBG 1_p
sufficient JJ 1_p
neurological JJ 1_p
expertise NN 1_p
. . 1_p

Comparison NNP N
of IN N
sedative JJ 1_i
drugs NNS 1_i
under IN N
peribulbar NN N
or CC N
topical JJ N
anesthesia NN N
during IN N
phacoemulsification NN 1_p
. . 1_p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
To TO N
compare VB N
dexmedetomidine NN 1_i
and CC 1_i
midazolam+fentanyl JJ 1_i
sedation NN 1_i
primarily RB N
based VBN N
on IN N
patient JJ N
satisfaction NN N
during IN N
phacoemulsification NN N
under IN N
topical JJ N
and CC N
peribulbar JJ N
anesthesia NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Prospective NNP N
, , N
randomized VBN N
, , N
and CC N
double-blind NN N
study NN N
of IN N
80 CD 1_p
American JJ 1_p
Society NNP 1_p
of IN 1_p
Anesthesiology NNP 1_p
grade VBD 1_p
I-II NNP 1_p
patients NNS 1_p
who WP 1_p
underwent JJ 1_p
phacoemulsification NN 1_p
with IN 1_p
local JJ 1_p
anesthesia NN 1_p
under IN 1_p
sedation NN 1_p
. . 1_p

Patients NNS N
were VBD N
divided VBN N
into IN N
four CD 1_p
groups NNS 1_p
( ( 1_p
20 CD 1_p
patients NNS 1_p
for IN 1_p
each DT 1_p
) ) 1_p
: : 1_p
dexmedetomidine NN 1_i
and CC 1_i
topical JJ 1_i
anesthesia NN 1_i
, , 1_i
dexmedetomidine NN 1_i
and CC 1_i
peribulbar NN 1_i
anesthesia NN 1_i
, , 1_i
midazolam+fentanyl NN 1_i
and CC 1_i
topical JJ 1_i
anesthesia NN 1_i
, , N
and CC N
midazolam+fentanyl NN 1_i
and CC 1_i
peribulbar NN 1_i
anesthesia NN 1_i
. . 1_i

Patient NNP N
and CC N
surgeon JJ N
satisfaction NN N
were VBD N
determined VBN N
on IN N
a DT N
5-point JJ N
scale NN N
. . N

The DT N
pain NN N
was VBD N
determined VBN N
by IN N
verbal JJ N
pain NN N
scale NN N
intraoperatively RB N
and CC N
postoperatively RB N
. . N

Drugs NNS N
were VBD N
given VBN N
to TO N
a DT N
Ramsay NNP N
sedation NN N
scale NN N
of IN N
3 CD N
. . N

Topical JJ N
and CC N
peribulbar JJ N
anesthesia NN N
were VBD N
performed VBN N
by IN N
an DT N
ophthalmologist NN N
. . N

Hemodynamic NNP N
, , N
respiratory NN N
, , N
and CC N
intraocular JJ N
pressure NN N
monitoring NN N
was VBD N
done VBN N
. . N

Operative NNP N
and CC N
recovery NN N
times NNS N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
In IN N
the DT N
midazolam+fentanyl NN 1_i
groups NNS N
, , N
better JJR N
patient NN 1_o
and CC 1_o
surgeon JJ 1_o
satisfaction NN 1_o
scores NNS 1_o
were VBD N
obtained VBN N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
, , N
verbal JJ 1_o
pain NN 1_o
scale NN 1_o
scores NNS 1_o
were VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
patients NNS N
needed VBN N
less RBR N
postoperative JJ 1_o
analgesia NN 1_o
. . 1_o

Ramsay NNP 1_o
sedation NN 1_o
scale NN 1_o
scores NNS 1_o
were VBD N
between IN N
3 CD N
and CC N
4 CD N
in IN N
all DT N
patients NNS N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
. . N

Intraocular JJ 1_o
pressure NN 1_o
alterations NNS 1_o
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

Recovery JJ 1_o
time NN 1_o
was VBD N
longer RBR N
in IN N
the DT N
dexmedetomidine NN N
groups NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
study NN N
demonstrated VBD N
that IN N
the DT N
midazolam+fentanyl NN 1_i
combination NN 1_i
provided VBD N
high-level JJ N
patient JJ 1_o
satisfaction NN 1_o
scores NNS 1_o
, , N
low-level JJ N
pain NN 1_o
scores NNS 1_o
, , N
and CC N
shorter JJR N
recovery NN 1_o
time NN 1_o
. . 1_o

Also RB N
, , N
both DT N
of IN N
the DT N
peribulbar NN N
and CC N
topical JJ N
anesthesia NN N
procedures NNS N
showed VBD N
similar JJ N
efficiency NN N
. . N

Long-term JJ N
anticoagulant NN 1_i
treatment NN 1_i
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

The DT N
Warfarin NNP N
Re-Infarction NNP N
Study NNP N
. . N

High NNP N
levels NNS N
of IN N
fibrinogen NN N
and CC N
clotting VBG N
factor NN N
VII NNP N
are VBP N
associated VBN N
with IN N
an DT N
increased VBN 1_o
risk NN 1_o
for IN N
subsequent JJ 1_o
death NN 1_o
and CC N
cardiovascular JJ 1_o
disease NN 1_o
in IN N
apparently RB 1_p
healthy JJ 1_p
individuals NNS 1_p
. . 1_p

Furthermore RB N
, , N
pathoanatomic JJ N
studies NNS N
and CC N
coronary JJ N
angiography NN N
have VBP N
confirmed VBN N
a DT N
relationship NN 1_o
between IN 1_o
coronary JJ 1_o
thrombus NN 1_o
formation NN 1_o
and CC 1_o
acute JJ 1_o
Q-wave NNP 1_o
infarction NN 1_o
. . 1_o

Effective JJ N
antithrombotic JJ N
agents NNS N
may MD N
prevent VB N
or CC N
limit VB N
thrombus JJ 1_o
formation NN 1_o
and CC N
events NNS 1_o
related VBN 1_o
to TO 1_o
thrombosis NN 1_o
. . 1_o

The DT N
Warfarin NNP N
Re-Infarction NNP N
Study NNP N
( ( N
WARIS NNP N
) ) N
studied VBD N
the DT N
effect NN N
of IN N
warfarin NN 1_i
in IN N
survivors NNS 1_p
of IN 1_p
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

Patients NNS 1_p
aged VBD 1_p
75 CD 1_p
years NNS 1_p
or CC 1_p
less JJR 1_p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
to TO N
test VB N
whether IN N
long-term JJ N
treatment NN N
with IN N
warfarin JJ 1_i
reduces NNS N
the DT N
risk NN 1_o
of IN N
death NN 1_o
, , 1_o
reinfarction NN 1_o
, , N
and CC N
thromboembolic JJ 1_o
morbidity NN 1_o
. . 1_o

A DT 1_p
total NN 1_p
of IN 1_p
1918 CD 1_p
patients NNS 1_p
were VBD 1_p
screened VBN 1_p
for IN 1_p
participation NN 1_p
; : 1_p
1214 CD 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

The DT N
mean JJ N
follow-up NN N
was VBD N
37 CD N
months NNS N
. . N

Analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
, , N
123 CD N
( ( N
20 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 1_i
group NN N
died VBD 1_o
, , N
versus FW N
94 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
warfarin NN 1_i
group NN N
, , N
a DT N
risk NN 1_o
reduction NN 1_o
of IN N
24 CD N
% NN N
( ( N
P NNP N
= NNP N
0.026 CD N
) ) N
. . N

Considering VBG N
patients NNS N
on IN N
treatment NN N
or CC N
within IN N
28 CD N
days NNS N
after IN N
discontinuing VBG N
the DT N
test NN N
medication NN N
, , N
92 CD N
in IN N
the DT N
placebo NN N
group NN N
died VBD 1_o
, , N
as IN N
compared VBN N
with IN N
60 CD N
of IN N
the DT N
warfarin-treated JJ 1_i
patients NNS N
, , N
a DT N
risk NN 1_o
reduction NN 1_o
of IN N
35 CD N
% NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

Relapsing VBG 1_o
myocardial JJ 1_o
infarction NN 1_o
( ( 1_o
fatal JJ 1_o
and CC 1_o
nonfatal JJ 1_o
) ) 1_o
was VBD N
reduced VBN N
by IN N
43 CD N
% NN N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

The DT N
incidence NN 1_o
of IN 1_o
cerebrovascular JJ 1_o
attacks NNS 1_o
was VBD N
lower RBR N
in IN N
the DT N
warfarin NN 1_i
group NN N
( ( N
16 CD N
patients NNS N
) ) N
than IN N
the DT N
placebo NN 1_i
group NN N
( ( N
41 CD N
patients NNS N
) ) N
, , N
a DT N
highly RB N
significant JJ N
reduction NN N
of IN N
61 CD N
% NN N
( ( N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

Serious JJ 1_o
bleeding NN 1_o
occurred VBD N
in IN N
11 CD N
patients NNS N
taking VBG N
warfarin NN 1_i
, , N
an DT N
incidence NN N
of IN N
0.6 CD N
% NN N
per IN N
year NN N
. . N

In IN N
conclusion NN N
, , N
long-term JJ N
anticoagulant JJ 1_i
therapy NN 1_i
may MD N
be VB N
recommended VBN N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

Reducing VBG N
blood NN 1_o
loss NN 1_o
in IN N
simultaneous JJ 1_p
bilateral JJ 1_p
total NN 1_p
knee NN 1_p
arthroplasty NN 1_p
: : 1_p
combined VBN N
intravenous-intra-articular JJ N
tranexamic JJ 1_i
acid NN 1_i
administration NN N
. . N

A DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
We PRP N
asked VBD N
whether IN N
tranexamic JJ 1_i
acid NN 1_i
( ( 1_i
TXA NNP 1_i
) ) 1_i
administration NN N
could MD N
reduce VB N
blood NN 1_o
loss NN 1_o
and CC 1_o
blood NN 1_o
transfusion NN 1_o
requirements NNS 1_o
after IN 1_p
simultaneous JJ 1_p
bilateral JJ 1_p
total NN 1_p
knee NN 1_p
arthroplasty NN 1_p
( ( 1_p
TKA NNP 1_p
) ) 1_p
. . 1_p

This DT N
study NN N
examined VBD N
the DT N
role NN N
of IN N
a DT N
novel JJ N
method NN N
of IN N
TXA NNP N
administration NN N
in IN N
TKA NNP N
. . N

METHODS NNP N
TXA NNP 1_i
was VBD 1_i
administered VBN 1_i
as IN 1_i
a DT 1_i
bolus NN 1_i
dose NN 1_i
of IN 1_i
15 CD 1_i
mg/kg NNS 1_i
10 CD 1_i
min NN 1_i
before IN 1_i
the DT 1_i
inflation NN 1_i
of IN 1_i
the DT 1_i
tourniquet NN 1_i
on IN 1_i
the DT 1_i
first JJ 1_i
side NN 1_i
. . 1_i

This DT 1_i
was VBD 1_i
followed VBN 1_i
by IN 1_i
intra-articular JJ 1_i
administration NN 1_i
of IN 1_i
3 CD 1_i
grams NNS 1_i
at IN 1_i
10 CD 1_i
min NN 1_i
before IN 1_i
the DT 1_i
deflation NN 1_i
of IN 1_i
the DT 1_i
tourniquet NN 1_i
. . 1_i

IV NNP 1_i
infusion NN 1_i
of IN 1_i
10 CD 1_i
mg/kg/h NN 1_i
was VBD 1_i
continued VBN 1_i
for IN 1_i
3h CD 1_i
following VBG 1_i
completion NN 1_i
on IN 1_i
the DT 1_i
second JJ 1_i
side NN 1_i
. . 1_i

We PRP N
measured VBD N
volume NN 1_o
of IN 1_o
drained JJ 1_o
blood NN 1_o
48 CD 1_o
h NN 1_o
postoperatively RB 1_o
, , 1_o
decrease NN 1_o
in IN 1_o
hemoglobin NN 1_o
levels NNS 1_o
12h CD 1_o
postoperatively RB 1_o
, , 1_o
amount NN 1_o
of IN 1_o
blood NN 1_o
transfused VBN 1_o
( ( 1_o
BT NNP 1_o
) ) 1_o
, , N
and CC N
number NN 1_o
of IN 1_o
patients NNS 1_o
requiring VBG 1_o
allogenic JJ 1_o
BT NNP 1_o
. . 1_o

RESULTS NNP N
Median JJ N
postoperative JJ N
volume NN 1_o
of IN 1_o
drained JJ 1_o
blood NN 1_o
was VBD N
lower JJR N
in IN N
the DT N
group NN N
receiving VBG N
TXA NNP 1_i
( ( N
500.00 CD N
mL NN N
) ) N
than IN N
in IN N
control NN N
subjects NNS N
( ( N
900.00 CD N
mL NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
[ VBD N
95 CD N
% NN N
CI NNP N
( ( N
-525.00 NNP N
) ) N
to TO N
( ( N
-300.00 NNP N
) ) N
] NN N
. . N

The DT N
median JJ 1_o
hemoglobin NN 1_o
decrease NN 1_o
12 CD 1_o
h NN 1_o
postoperatively RB 1_o
was VBD N
lower JJR N
in IN N
patients NNS 1_p
receiving VBG N
TXA NNP N
( ( N
2.10 CD N
g/dL NN N
) ) N
than IN N
in IN N
control NN N
subjects NNS N
( ( N
3.10 CD N
g/dL NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
[ VBD N
95 CD N
% NN N
CI NNP N
( ( N
-1.60 NNP N
) ) N
to TO N
( ( N
-0.60 NNP N
) ) N
] NN N
. . N

The DT N
amount NN 1_o
of IN 1_o
BT NNP 1_o
and CC 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
requiring VBG 1_o
BT NNP 1_o
were VBD N
lower JJR N
in IN N
patients NNS N
receiving VBG N
TXA NNP N
than IN N
in IN N
control NN N
subjects NNS N
. . N

Nevertheless RB N
, , N
the DT N
number NN N
of IN N
allogeneic JJ N
units NNS N
of IN N
packed JJ 1_o
red JJ 1_o
blood NN 1_o
cells NNS 1_o
transfused VBN 1_o
in IN N
the DT N
postoperative JJ N
period NN N
was VBD N
not RB N
significantly RB N
higher RBR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
TXA NNP N
group NN N
( ( N
p=0.109 NN N
) ) N
[ VBZ N
95 CD N
% NN N
CI NNP N
( ( N
0.101 CD N
) ) N
to TO N
( ( N
0.117 CD N
) ) N
] NN N
. . N

CONCLUSIONS VB N
This DT N
prospective JJ N
randomized NN N
study NN N
showed VBD N
that IN N
during IN N
simultaneous JJ N
bilateral JJ N
TKA NNP N
, , N
TXA NNP 1_i
reduced VBD N
blood NN 1_o
loss NN 1_o
with IN N
negligible JJ N
side NN 1_o
effects NNS 1_o
. . 1_o

Intravenous JJ 1_i
hyperimmune NN 1_i
globulin NN 1_i
prophylaxis NN 1_i
against IN N
cytomegalovirus JJ N
interstitial JJ N
pneumonitis NN N
after IN N
allogenic JJ 1_i
bone NN 1_i
marrow NN 1_i
transplantation NN 1_i
. . 1_i

In IN N
an DT N
attempt NN N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
lethal JJ N
cytomegalovirus NN 1_o
( ( 1_o
CMV NNP 1_o
) ) 1_o
interstitial NN 1_o
pneumonitis NN 1_o
after IN 1_p
allogenic JJ 1_i
bone NN 1_i
marrow NN 1_i
transplantation NN 1_i
49 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
in IN 1_p
a DT 1_p
multicenter NN 1_p
controlled VBN 1_p
study NN 1_p
to TO N
receive VB N
either DT N
CMV-hyperimmune NNP 1_i
globulin NN 1_i
or CC N
a DT N
control NN 1_i
immune JJ 1_i
globulin NN 1_i
with IN 1_i
low JJ 1_i
anticytomegalovirus NN 1_i
titer NN 1_i
. . 1_i

Immune NNP 1_i
globulin NN 1_i
was VBD N
administered VBN N
intravenously RB N
6 CD N
times NNS N
with IN N
20 CD N
days NNS N
interval NN N
, , N
starting VBG N
on IN N
day NN N
7 CD N
before IN N
transplantation NN N
. . N

Patients NNS N
receiving VBG N
CMV NNP 1_i
hyperimmune NN 1_i
globulin NN 1_i
or CC N
control NN 1_i
immune JJ 1_i
globulin NNS 1_i
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
age NN N
, , N
diagnosis NN N
, , N
pretransplant JJ N
anti-CMV JJ N
titer NN N
, , N
incidence NN N
of IN N
graft-versus-host JJ N
disease NN N
and CC N
transfusions NNS N
. . N

In IN N
each DT N
group NN N
, , N
the DT N
incidence NN 1_o
of IN 1_o
histologically RB 1_o
proven VBN 1_o
CMV NNP 1_o
interstitial JJ 1_o
pneumonitis NN 1_o
during IN N
the DT N
first JJ N
110 CD N
days NNS N
post RB N
BMT NNP N
was VBD N
recorded VBN N
. . N

Six NNP 1_p
of IN 1_p
23 CD 1_p
patients NNS 1_p
in IN N
the DT N
control NN 1_i
group NN N
versus VBD N
1 CD N
of IN N
26 CD N
in IN N
the DT N
CMV NNP 1_i
hyperimmune NNP 1_i
globulin NN 1_i
group NN N
died VBD 1_o
of IN 1_o
CMV NNP 1_o
interstitial JJ 1_o
pneumonitis NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
effect NN 1_o
on IN 1_o
idiopathic JJ 1_o
pneumonitis NN 1_o
or CC 1_o
survival NN 1_o
was VBD N
observed VBN N
. . N

Effect NN N
of IN N
nimodipine JJ 1_i
upon IN N
electroencephalographic JJ 1_o
vigilance NN 1_o
in IN N
elderly JJ 1_p
persons NNS 1_p
with IN 1_p
minor JJ 1_p
impairment NN 1_p
of IN 1_p
brain NN 1_p
functions NNS 1_p
. . 1_p

10 CD 1_p
volunteers NNS 1_p
( ( 1_p
61-78 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
minor JJ 1_p
impairment NN 1_p
of IN 1_p
brain NN 1_p
function NN 1_p
were VBD N
given VBN N
placebo NNS 1_i
, , N
40 CD N
mg NN N
and CC N
60 CD N
mg NNS N
nimodipine JJ 1_i
( ( 1_i
Nimotop NNP 1_i
) ) 1_i
in IN N
single JJ N
doses NNS N
with IN N
intervals NNS N
of IN N
3 CD N
medication-free JJ N
days NNS N
between IN N
medications NNS N
under IN N
double-blind JJ N
conditions NNS N
. . N

Consecutive JJ N
2-s JJ N
epochs NN N
of IN N
a DT N
10-min JJ 1_i
EEG NN 1_i
record NN N
( ( N
resting VBG N
conditions NNS N
) ) N
of IN N
F3/C3-F4/C4-P3/01-P4/02 NNP N
were VBD N
subjected VBN N
to TO N
FFT NNP N
( ( N
Fast NNP N
Fourier NNP N
Transform NNP N
) ) N
. . N

Using VBG N
the DT N
information NN N
given VBN N
by IN N
the DT N
4 CD N
leads NNS N
for IN N
each DT N
minute NN N
of IN N
recording VBG N
the DT N
number NN 1_o
of IN 1_o
epochs NN 1_o
which WDT N
correspond NN N
to TO N
a DT N
stage NN N
A DT N
or CC N
non-A JJ N
were VBD N
determined VBN N
. . N

In IN N
order NN N
to TO N
evaluate VB N
subtle JJ N
effects NNS N
on IN N
electroencephalographic JJ N
vigilance NN N
within IN N
stage NN N
A NNP N
, , N
also RB N
the DT N
anterior-posterior JJ 1_o
and CC 1_o
left-right JJ 1_o
relations NNS 1_o
of IN 1_o
absolute JJ 1_o
alpha-power NN 1_o
were VBD N
calculated VBN N
. . N

Since IN N
previous JJ N
findings NNS N
suggested VBD N
that IN N
a DT N
nimodipine JJ N
effect NN N
can MD N
only RB N
be VB N
demonstrated VBN N
when WRB N
individual JJ N
differences NNS N
in IN N
the DT N
baseline-EEG NN 1_o
are VBP N
considered VBN N
, , N
the DT N
subjects NNS N
were VBD N
subdivided VBN N
in IN N
equal JJ N
subgroups NNS N
according VBG N
to TO N
the DT N
number NN N
of IN N
non-A JJ N
epochs NN N
under IN N
placebo NN N
. . N

The DT N
rationale NN N
for IN N
this DT N
is VBZ N
the DT N
finding NN N
that IN N
in IN N
geriatric JJ 1_p
patients NNS 1_p
two CD N
electroencephalographically RB N
distinguishable JJ N
forms NNS 1_o
of IN N
dissolution NN N
can MD N
be VB N
observed VBN N
. . N

Under IN N
both DT N
40 CD N
mg NN N
and CC N
60 CD N
mg NNS N
nimodipine VBP 1_i
the DT N
subgroup NN N
with IN N
a DT N
prevalence NN N
of IN N
non-A JJ 1_o
epochs NN 1_o
( ( N
poor JJ N
alpha-activity NN 1_o
) ) 1_o
showed VBD N
a DT N
decrease NN N
of IN N
non-A JJ 1_o
epochs NN 1_o
; : 1_o
the DT N
subgroup NN N
with IN N
a DT N
prevalence NN 1_o
of IN 1_o
A-epochs NNP 1_o
( ( 1_o
abundant JJ 1_o
alpha-activity NN 1_o
) ) 1_o
, , N
an DT N
increase NN N
. . N

Opposite JJ N
results NNS N
for IN N
the DT N
two CD N
subgroups NNS N
were VBD N
also RB N
obtained VBN N
for IN N
the DT N
left-right JJ 1_o
relations NNS 1_o
of IN 1_o
alpha-power NN 1_o
over IN N
the DT N
anterior JJ N
regions NNS N
. . N

Under IN N
40 CD N
mg NNS N
nimodipine VBP 1_i
the DT N
subgroup NN N
with IN N
poor JJ N
alpha-activity NN 1_o
showed VBD N
a DT N
shift NN 1_o
to TO 1_o
the DT 1_o
left NN 1_o
; : 1_o
the DT N
subgroup NN N
with IN N
abundant JJ N
alpha-activity NN 1_o
to TO 1_o
the DT 1_o
right NN 1_o
. . 1_o

Under IN N
60 CD N
mg NN N
nimodipine JJ 1_i
both DT N
subgroups NNS N
showed VBD N
a DT N
shift NN 1_o
to TO 1_o
the DT 1_o
left NN 1_o
. . 1_o

The DT N
results NNS N
confirm VBP N
findings NNS N
that WDT N
nimodipine VBP N
stabilizes VBZ N
electroencephalographic JJ 1_o
vigilance NN 1_o
at IN N
a DT N
medium NN N
level NN N
. . N

Moreover RB N
they PRP N
suggest VBP N
a DT N
dose JJ N
dependence NN N
of IN N
the DT N
effect NN N
, , N
i.e. FW N
, , N
at IN N
higher JJR N
doses NNS N
nimodipine VBP 1_i
seems VBZ N
to TO N
act VB N
as IN N
a DT N
sedative NN N
. . N

Buccal JJ 1_i
misoprostol NN 1_i
to TO N
decrease VB N
blood NN 1_o
loss NN 1_o
after IN 1_p
vaginal JJ 1_p
delivery NN 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
buccal JJ 1_i
misoprostol NN 1_i
to TO N
decrease VB N
bleeding NN 1_o
after IN 1_p
vaginal JJ 1_p
delivery NN 1_p
. . 1_p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS 1_p
between IN 1_p
22 CD 1_p
weeks NNS 1_p
and CC 1_p
42 CD 1_p
weeks NNS 1_p
of IN 1_p
gestation NN 1_p
with IN 1_p
anticipated JJ 1_p
vaginal JJ 1_p
delivery NN 1_p
. . 1_p

Patients NNS N
were VBD N
given VBN N
either CC N
a DT N
200-mug JJ 1_i
misoprostol NN 1_i
tablet NN 1_i
or CC 1_i
placebo NN 1_i
in IN N
the DT N
buccal JJ N
space NN N
at IN N
the DT N
time NN N
of IN N
cord NN N
clamping NN N
. . N

A DT N
continuous JJ N
dilute NN N
intravenous JJ N
oxytocin JJ 1_i
infusion NN N
was VBD N
given VBN N
to TO N
all DT N
patients NNS N
at IN N
delivery NN N
of IN N
the DT N
placenta NN N
. . N

Postpartum NNP 1_o
hemorrhage NN 1_o
was VBD N
defined VBN N
as IN N
blood NN 1_o
loss NN 1_o
exceeding VBG N
500 CD N
mL NN N
. . N

Sample NNP N
size NN N
calculations NNS N
based VBN N
on IN N
previous JJ N
studies NNS N
assumed VBD N
a DT N
13 CD N
% NN N
incidence NN N
of IN N
postpartum NN N
hemorrhage NN N
in IN N
the DT N
control NN N
group NN N
. . N

To TO N
show VB N
a DT N
statistically RB N
significant JJ N
reduction NN N
of IN N
postpartum NN N
hemorrhage NN N
a DT 1_p
total NN 1_p
of IN 1_p
1,604 CD 1_p
patients NNS 1_p
would MD 1_p
be VB 1_p
required VBN 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
848 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
and CC 1_p
756 CD 1_p
randomly RB 1_p
assigned VBN 1_p
, , 1_p
377 CD 1_p
in IN 1_p
the DT 1_p
misoprostol NN 1_i
group NN 1_p
and CC 1_p
379 CD 1_p
in IN 1_p
the DT 1_p
placebo NN 1_i
group NN 1_p
. . 1_p

Demographic NNP 1_p
, , 1_p
antepartum NN 1_p
, , 1_p
and CC 1_p
intrapartum NN 1_p
characteristics NNS 1_p
were VBD 1_p
similar JJ 1_p
between IN 1_p
the DT 1_p
groups NNS 1_p
. . 1_p

The DT N
incidence NN 1_o
of IN 1_o
postpartum NN 1_o
hemorrhage NN 1_o
, , N
3 CD N
% NN N
compared VBN N
with IN N
5 CD N
% NN N
, , N
( ( N
relative JJ N
risk NN N
0.65 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
0.33-1.29 JJ N
, , N
P NNP N
= NNP N
.22 NNP N
) ) N
, , N
mean JJ 1_o
estimated VBN 1_o
blood NN 1_o
loss NN 1_o
, , N
322 CD N
compared VBN N
with IN N
329 CD N
mL NNS N
, , N
( ( N
P NNP N
= NNP N
.45 NNP N
) ) N
, , N
and CC N
mean JJ 1_o
minutes NNS 1_o
of IN 1_o
the DT 1_o
third JJ 1_o
stage NN 1_o
of IN 1_o
labor NN 1_o
, , N
6.7 CD N
compared VBN N
with IN N
6.9 CD N
( ( N
P NNP N
= NNP N
.52 NNP N
) ) N
were VBD N
similar JJ N
between IN N
the DT N
groups NNS N
, , N
misoprostol NN 1_i
and CC N
placebo NN 1_i
, , N
respectively RB N
. . N

Hemoglobin NNP 1_o
difference NN 1_o
before IN 1_o
and CC 1_o
after IN 1_o
delivery NN 1_o
, , 1_o
need NN 1_o
for IN 1_o
second JJ 1_o
or CC 1_o
third JJ 1_o
uterotonic JJ 1_o
agent NN 1_o
, , 1_o
and CC 1_o
all DT 1_o
measured VBN 1_o
neonatal JJ 1_o
variables NNS 1_o
including VBG 1_o
birth NN 1_o
weights NNS 1_o
, , 1_o
and CC 1_o
umbilical JJ 1_o
cord NN 1_o
pH NN 1_o
were VBD N
similar JJ N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
Buccal NNP 1_i
misoprostol NN 1_i
at IN N
cord NN N
clamping NN N
is VBZ N
no DT N
more RBR N
effective JJ N
than IN N
placebo NN 1_i
in IN N
reducing VBG N
postpartum JJ 1_o
hemorrhage NN 1_o
. . 1_o

A DT N
randomized JJ N
study NN N
of IN N
fetal JJ N
abdominal JJ N
diameter NN N
and CC N
fetal JJ N
weight NN N
estimation NN N
for IN N
detection NN N
of IN N
light-for-gestation NN 1_p
infants NNS 1_p
in IN 1_p
low-risk JJ 1_p
pregnancies NNS 1_p
. . 1_p

A DT N
total NN N
of IN N
2771 CD 1_p
pregnant JJ 1_p
women NNS 1_p
with IN 1_p
gestational JJ 1_p
age NN 1_p
estimated VBN 1_p
by IN 1_p
ultrasound JJ 1_p
measurement NN 1_p
of IN 1_p
the DT 1_p
fetal JJ 1_p
biparietal JJ 1_p
diameter NN 1_p
( ( 1_p
BPD NNP 1_p
) ) 1_p
before IN 1_p
the DT 1_p
22nd CD 1_p
week NN 1_p
of IN 1_p
gestation NN 1_p
were VBD N
re-examined VBN N
by IN N
ultrasound NN 1_i
in IN 1_p
the DT 1_p
32nd CD 1_p
and CC 1_p
37th CD 1_p
week NN 1_p
of IN 1_p
pregnancy NN 1_p
at IN N
which WDT N
time NN N
the DT N
fetal JJ N
BPD NNP N
and CC N
abdominal JJ N
diameter NN N
( ( N
AD NNP N
) ) N
were VBD N
measured VBN N
. . N

An DT N
additional JJ N
examination NN N
was VBD N
performed VBN N
at IN N
34 CD N
weeks NNS N
if IN N
the DT N
fetal JJ N
weight NN N
in IN N
the DT N
32nd CD N
week NN N
was VBD N
estimated VBN N
to TO N
be VB N
less JJR N
than IN N
95 CD N
% NN N
of IN N
the DT N
expected JJ N
mean JJ N
weight NN N
. . N

Light-for-gestational JJ 1_o
age NN 1_o
( ( 1_o
LGA NNP 1_o
) ) 1_o
was VBD N
suspected VBN N
if IN N
the DT N
estimated VBN N
birth-weight NN N
was VBD N
less JJR N
than IN N
85 CD N
% NN N
of IN N
the DT N
expected JJ N
mean NN N
birthweight NN N
. . N

This DT N
applied VBD N
to TO N
186 CD 1_p
uncomplicated JJ 1_p
pregnancies NNS 1_p
in IN 1_p
which WDT 1_p
there EX 1_p
was VBD 1_p
no DT 1_p
clinical JJ 1_p
suspicion NN 1_p
of IN 1_p
poor JJ 1_o
intrauterine JJ 1_o
growth NN 1_o
. . 1_o

These DT N
pregnancies NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
treatment NN N
group NN N
( ( N
AD NNP N
and CC N
estimated VBN N
weight NN N
reported VBN N
) ) N
or CC N
to TO N
a DT N
control NN N
group NN N
( ( N
AD NNP N
and CC N
estimated VBN N
weight JJ N
withheld NN N
) ) N
. . N

Induction NN 1_o
of IN 1_o
labour NN 1_o
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
treatment NN N
group NN N
( ( N
41 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
15 CD N
% NN N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
use NN 1_o
of IN 1_o
instrumental JJ 1_o
vaginal JJ 1_o
delivery NN 1_o
or CC 1_o
caesarean JJ 1_o
section NN 1_o
. . 1_o

There EX N
was VBD N
a DT N
suggestion NN N
of IN N
marginal JJ N
benefit NN N
in IN N
terms NNS N
of IN N
neonatal JJ 1_o
morbidity NN 1_o
but CC N
this DT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Disc NNP 1_i
coablation NN 1_i
and CC 1_i
epidural JJ 1_i
injection NN 1_i
of IN 1_i
steroids NNS 1_i
: : 1_i
a DT N
comparison NN N
of IN N
strategies NNS N
in IN N
the DT N
treatment NN N
of IN N
mechanical JJ 1_p
spinal JJ 1_p
discogenic NN 1_p
pain NN 1_p
. . 1_p

In IN N
this DT N
study NN N
two CD N
strategies NNS N
in IN N
the DT N
treatment NN N
of IN N
Mechanical NNP N
Spinal NNP N
Discogenic NNP N
Pain NNP N
have VBP N
been VBN N
compared VBN N
: : N
Disc NNP 1_i
Coablation NNP 1_i
and CC 1_i
Epidural NNP 1_i
Injection NNP 1_i
of IN 1_i
Steroids NNP 1_i
. . 1_i

In IN 1_p
2003 CD 1_p
50 CD 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
one CD 1_i
or CC 1_i
two CD 1_i
epidural JJ 1_i
injections NNS 1_i
have VBP 1_p
been VBN 1_p
selected VBN 1_p
" JJ 1_p
ad NN 1_p
random NN 1_p
" NNP 1_p
and CC 1_p
50 CD 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
disc JJ 1_i
coablation NN 1_i
. . 1_i

Comparison NNP N
of IN N
the DT N
data NNS N
indicated VBD N
an DT N
improvement NN N
of IN N
average JJ 1_o
VAS NNP 1_o
when WRB N
relaxed NN N
for IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
while IN N
after IN N
slight-moderate JJ N
strain NN N
, , N
this DT N
value NN N
was VBD N
significant JJ N
only RB N
after IN N
coablation NN 1_i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Finally RB N
, , N
average JJ 1_o
VAS NNP 1_o
was VBD N
clearly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
after IN N
coablation NN N
as IN N
compared VBN N
to TO N
epidural JJ 1_i
injections NNS 1_i
. . N

Postoperative JJ N
dreaming NN N
. . N

A DT N
comparison NN N
of IN N
the DT N
incidence NN N
following VBG N
pentazocine NN 1_i
and CC N
morphine JJ 1_i
premedication NN N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ N
dreaming NN N
following VBG N
the DT N
use NN N
of IN N
morphine NN 1_i
and CC 1_i
pentazocine NN 1_i
as IN N
premedicants NNS N
in IN N
an DT N
otherwise RB N
standard JJ N
anaesthetic JJ N
sequence NN N
is VBZ N
compared VBN N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
demonstrated VBN N
between IN N
the DT N
two CD N
drugs NNS N
. . N

The DT N
causes NNS N
of IN N
psychotomimetic JJ N
problems NNS N
in IN N
the DT N
postoperative JJ N
period NN N
and CC N
the DT N
difficulty NN N
of IN N
precise JJ N
definition NN N
of IN N
hallucinations NNS N
are VBP N
discussed VBN N
. . N

Peptide NNP 1_o
T NNP 1_o
: : 1_o
negative JJ 1_o
trial NN 1_o
result NN 1_o
. . 1_o

Active JJ 1_i
treatment NN 1_i
programs NNS 1_i
for IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
: : 1_p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
observer-blinded JJ N
study NN N
. . N

Several JJ N
new JJ N
studies NNS N
have VBP N
indicated VBN N
that IN N
an DT N
active JJ N
approach NN N
to TO N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
disabling VBG 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
( ( 1_p
LBP NNP 1_p
) ) 1_p
seems VBZ N
effective JJ N
. . N

Some DT N
of IN N
these DT N
studies NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
dealing VBG N
with IN N
the DT N
patient NN N
's POS N
total JJ N
situation NN N
in IN N
comprehensive JJ N
multidisciplinary JJ N
programs NNS N
-- : N
the DT N
bio-psycho-social JJ N
model NN N
. . N

However RB N
, , N
these DT N
programs NNS N
are VBP N
expensive JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
rehabilitation NN N
outcome NN N
from IN N
three CD N
different JJ N
active JJ N
programs NNS N
in IN N
terms NNS N
of IN N
: : N
( ( 1_o
1 CD 1_o
) ) 1_o
return-to-work NN 1_o
rate NN 1_o
, , 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
days NNS 1_o
of IN 1_o
sick JJ 1_o
leave NN 1_o
, , 1_o
( ( 1_o
3 CD 1_o
) ) 1_o
health-care NN 1_o
contacts NNS 1_o
, , 1_o
( ( 1_o
4 CD 1_o
) ) 1_o
pain NN 1_o
and CC 1_o
disability NN 1_o
scores NNS 1_o
, , 1_o
and CC 1_o
( ( 1_o
5 CD 1_o
) ) 1_o
staying VBG 1_o
physically RB 1_o
active JJ 1_o
. . 1_o

The DT 1_p
subjects NNS 1_p
included VBD 1_p
132 CD 1_p
patients NNS 1_p
randomized VBN 1_p
to TO 1_p
the DT 1_p
study NN 1_p
, , 1_p
of IN 1_p
whom WP 1_p
123 CD 1_p
started VBD 1_p
one CD 1_p
of IN 1_p
the DT 1_p
treatment NN 1_p
programs NNS 1_p
. . 1_p

They PRP 1_p
had VBD 1_p
all DT 1_p
had VBN 1_p
at IN 1_p
least JJS 1_p
6 CD 1_p
months NNS 1_p
of IN 1_p
chronic JJ 1_p
LBP NNP 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
three CD N
programs NNS N
: : N
group NN N
1 CD N
-- : N
a DT N
full-time JJ 1_i
, , 1_i
intensive JJ 1_i
3-week JJ 1_i
multidisciplinary JJ 1_i
program NN 1_i
, , 1_i
including VBG 1_i
active JJ 1_i
physical JJ 1_i
and CC 1_i
ergonomic JJ 1_i
training NN 1_i
and CC 1_i
psychological JJ 1_i
pain NN 1_i
management NN 1_i
, , N
followed VBN N
by IN N
1 CD N
day NN N
weekly VB N
for IN N
the DT N
subsequent JJ N
3 CD N
weeks NNS N
; : N
group NN N
2 CD 1_i
-- : 1_i
active JJ 1_i
physical JJ 1_i
training NN 1_i
, , 1_i
twice RB 1_i
a DT 1_i
week NN 1_i
for IN 1_i
6 CD 1_i
weeks NNS 1_i
, , 1_i
for IN 1_i
a DT 1_i
total NN 1_i
of IN 1_i
24h CD 1_i
; : 1_i
group NN N
3 CD 1_i
-- : 1_i
psychological JJ 1_i
pain NN 1_i
management NN 1_i
combined VBN 1_i
with IN 1_i
active JJ 1_i
physical JJ 1_i
training NN 1_i
, , N
twice RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
also RB N
for IN N
a DT N
total NN N
of IN N
24h CD N
. . N

The DT N
results NNS N
presented VBN N
here RB N
are VBP N
based VBN N
on IN N
data NNS N
collected VBN N
4 CD N
months NNS N
following VBG N
treatment NN N
, , N
which WDT N
shows VBZ N
an DT N
86 CD N
% NN N
response NN N
rate NN N
. . N

The DT N
initial JJ N
examination NN N
and CC N
the DT N
follow-up JJ N
evaluation NN N
were VBD N
performed VBN N
by IN N
a DT N
blinded VBN N
observer NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
4 CD N
months NNS N
after IN N
treatment NN N
, , N
the DT N
intensive JJ N
multidisciplinary JJ N
program NN N
is VBZ N
superior JJ N
to TO N
the DT N
less RBR N
intensive JJ N
programs NNS N
in IN N
terms NNS N
of IN N
return-to-work NN N
rate NN N
, , N
health-care JJ N
contacts NNS N
, , N
pain NN N
and CC N
disability NN N
scores NNS N
, , N
and CC N
staying VBG N
physically RB N
active JJ N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
A DT N
single JJ N
dose NN N
of IN N
gabapentin NN 1_i
reduces NNS N
acute VBP 1_o
pain NN 1_o
and CC N
allodynia NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
herpes NNS 1_p
zoster NN 1_p
. . 1_p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
crossover NN N
study NN N
measured VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
oral JJ 1_i
gabapentin NN 1_i
( ( N
900 CD N
mg NN N
) ) N
on IN N
pain NN 1_o
and CC 1_o
allodynia NN 1_o
associated VBN 1_o
with IN 1_o
herpes NNS 1_o
zoster NN 1_o
. . 1_o

Pain NNP 1_o
severity NN 1_o
decreased VBN N
by IN N
66 CD N
% NN N
with IN N
gabapentin NN 1_i
compared VBN N
to TO N
33 CD N
% NN N
with IN N
placebo NN 1_i
. . 1_i

Reductions NNS N
in IN N
allodynia JJ 1_o
area NN 1_o
and CC 1_o
severity NN 1_o
, , 1_o
and CC 1_o
overall JJ 1_o
pain NN 1_o
relief NN 1_o
, , N
were VBD N
also RB N
greater JJR N
with IN N
gabapentin NN 1_i
. . 1_i

Injection NNP 1_i
sclerotherapy NN 1_i
versus NN 1_i
electrocoagulation NN 1_i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ 1_p
haemorrhoids NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
study VB N
the DT N
symptomatology NN N
of IN N
early JJ 1_p
hemorrhoids NNS 1_p
and CC N
to TO N
compare VB N
injection NN 1_i
sclerotherapy NN 1_i
( ( 1_i
IS NNP 1_i
) ) 1_i
with IN 1_i
electrocoagulation NN 1_i
( ( 1_i
EC NNP 1_i
) ) 1_i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ N
haemorrhoids NNS N
with IN N
respect NN N
to TO N
pain VB 1_o
during IN 1_o
the DT 1_o
procedure NN 1_o
, , 1_o
reduction NN 1_o
in IN 1_o
bleeding VBG 1_o
per IN 1_o
rectum NN 1_o
, , N
and CC N
overall JJ 1_o
patient NN 1_o
satisfaction NN 1_o
score NN 1_o
. . 1_o

METHODS NNP N
A NNP N
total NN N
of IN N
102 CD 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
in IN N
this DT N
experimental JJ N
study NN N
at IN 1_p
the DT 1_p
POF NNP 1_p
Hospital NNP 1_p
, , 1_p
Wah NNP 1_p
Cantt NNP 1_p
from IN 1_p
October NNP 1_p
2004 CD 1_p
to TO 1_p
June NNP 1_p
2005 CD 1_p
. . 1_p

A DT N
detailed JJ N
history NN N
was VBD N
taken VBN N
and CC N
proctoscopic JJ N
examination NN N
was VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
then RB N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
Lottery NNP N
method NN N
) ) N
. . N

One CD N
group NN N
was VBD N
subjected VBN N
to TO N
EC NNP N
and CC N
the DT N
other JJ N
to TO N
IS NNP N
. . N

In IN N
the DT N
EC NNP N
, , N
using VBG N
the DT N
EC NNP N
machine NN N
( ( N
Wieda NNP N
, , N
China NNP N
) ) N
, , N
direct JJ N
current JJ N
of IN N
10-20 JJ N
mA NN N
was VBD N
applied VBN N
in IN N
the DT N
submucosal JJ N
plane NN N
of IN N
each DT N
pile NN N
core NN N
for IN N
5-7 JJ N
minutes NNS N
. . N

In IN N
the DT N
IS NNP N
1-2 JJ N
ml NN N
of IN N
5 CD N
% NN N
phenol NN 1_i
in IN 1_i
almond NN 1_i
oil NN 1_i
was VBD N
injected VBN N
in IN N
the DT N
same JJ N
plane NN N
in IN N
each DT N
pile NN N
core NN N
. . N

Pain NN 1_o
during IN 1_o
the DT 1_o
procedure NN 1_o
, , 1_o
reduction NN 1_o
in IN 1_o
bleeding VBG 1_o
per IN 1_o
rectum NN 1_o
and CC 1_o
overall JJ 1_o
patient NN 1_o
satisfaction NN 1_o
, , N
were VBD N
studied VBN N
as IN N
outcome JJ N
measures NNS N
. . N

RESULTS VB N
The DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
was VBD 1_p
44 CD 1_p
years NNS 1_p
, , 1_p
86 CD 1_p
were VBD 1_p
males NNS 1_p
and CC 1_p
16 CD 1_p
were VBD 1_p
females NNS 1_p
. . 1_p

Two CD N
thirds NNS N
of IN N
the DT N
patients NNS N
were VBD N
having VBG N
symptoms NNS N
for IN N
more JJR N
than IN N
6 CD N
months NNS N
. . N

A DT N
third JJ N
of IN N
patients NNS N
had VBD N
associated VBN N
local JJ 1_o
pain NN 1_o
while IN N
another DT N
third JJ N
had VBD N
associated VBN N
mucous JJ 1_o
discharge NN 1_o
. . 1_o

Chronic JJ 1_o
constipation NN 1_o
was VBD N
present JJ N
in IN N
81 CD N
% NN N
patients NNS N
. . N

Only RB N
24.5 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
had VBD 1_p
a DT 1_p
positive JJ 1_p
family NN 1_p
history NN 1_p
of IN 1_p
haemorrhoids NNS 1_p
. . 1_p

Patients NNS N
in IN N
the DT N
electrocoagulation NN N
( ( N
EC NNP N
) ) N
group NN N
experienced VBD N
more JJR N
pain NN 1_o
during IN 1_o
the DT 1_o
procedure NN 1_o
than IN N
the DT N
injection NN N
sclerotherapy NN 1_i
( ( 1_i
IS NNP 1_i
) ) 1_i
group NN N
( ( N
P NNP N
< NNP N
0.000 CD N
) ) N
, , N
but CC N
EC NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
IS NNP N
in IN N
terms NNS N
of IN N
reducing VBG N
the DT N
bleeding NN 1_o
per IN 1_o
rectum NN 1_o
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
and CC N
also RB N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
were VBD N
fully RB 1_o
satisfied VBN 1_o
with IN N
EC NNP N
than IN N
with IN N
IS NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

CONCLUSION NNP N
EC NNP N
, , N
although IN N
more RBR N
painful JJ 1_o
, , N
is VBZ N
a DT N
safe JJ 1_o
, , N
more RBR N
effective JJ 1_o
and CC N
a DT N
highly RB 1_o
satisfying JJ 1_o
procedure NN N
for IN N
treating VBG N
early JJ N
hemorrhoids NNS N
. . N

Effects NNS N
of IN N
a DT N
long-term JJ N
vitamin NN 1_i
D NNP 1_i
and CC N
calcium NN 1_i
supplementation NN 1_i
on IN N
falls NNS 1_o
and CC 1_o
parameters NNS 1_o
of IN 1_o
muscle NN 1_o
function NN 1_o
in IN N
community-dwelling JJ 1_p
older NN 1_p
individuals NNS 1_p
. . 1_p

UNLABELLED NN N
In IN N
242 CD 1_p
community-dwelling JJ 1_p
seniors NNS 1_p
, , N
supplementation NN N
with IN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN 1_i
or CC N
1000 CD N
mg NN N
of IN N
calcium NN 1_i
plus CC 1_i
vitamin NN 1_i
D NNP 1_i
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
. . N

Additionally RB N
, , N
parameters NNS N
of IN N
muscle NN 1_o
function NN 1_o
improved VBD N
significantly RB N
. . N

INTRODUCTION NNP N
The DT N
efficacy NN N
of IN N
vitamin NN 1_i
D NNP 1_i
and CC N
calcium NN 1_i
supplementation NN N
on IN N
risk NN 1_o
of IN 1_o
falling VBG 1_o
in IN N
the DT N
elderly JJ N
is VBZ N
discussed VBN N
controversially RB N
. . N

Randomized NNP N
controlled VBD N
trials NNS N
using VBG N
falls NNS N
as IN N
primary JJ N
outcome NN N
are VBP N
needed VBN N
. . N

We PRP N
investigated VBD N
long-term JJ N
effects NNS N
of IN N
calcium NN 1_i
and CC N
vitamin NN 1_i
D NNP 1_i
on IN N
falls NNS 1_o
and CC 1_o
parameters NNS 1_o
of IN 1_o
muscle NN 1_o
function NN 1_o
in IN N
community-dwelling JJ 1_p
elderly JJ 1_p
women NNS 1_p
and CC 1_p
men NNS 1_p
. . 1_p

METHODS NNP N
Our PRP$ N
study NN N
population NN N
consisted VBD N
of IN N
242 CD 1_p
individuals NNS 1_p
recruited VBN 1_p
by IN 1_p
advertisements NNS 1_p
and CC 1_p
mailing VBG 1_p
lists NNS 1_p
( ( 1_p
mean JJ 1_p
[ NNP 1_p
+/- NN 1_p
SD NNP 1_p
] NNP 1_p
age NN 1_p
, , 1_p
77 CD 1_p
+/- JJ 1_p
4 CD 1_p
years NNS 1_p
) ) 1_p
. . 1_p

All DT 1_p
serum JJ 1_p
25-hydroxyvitamin JJ 1_p
D NNP 1_p
( ( 1_p
25 CD 1_p
[ NNP 1_p
OH NNP 1_p
] NNP 1_p
D NNP 1_p
) ) 1_p
levels NNS 1_p
were VBD 1_p
below IN 1_p
78 CD 1_p
nmol/l NN 1_p
. . 1_p

Individuals NNS N
received VBD N
in IN N
a DT N
double JJ N
blinded JJ N
fashion NN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN 1_i
or CC N
1000 CD N
mg NN N
of IN N
calcium NN 1_i
plus CC N
800 CD N
IU NNP N
of IN N
vitamin NNP 1_i
D NNP 1_i
per IN N
day NN N
over IN N
a DT N
treatment NN N
period NN N
of IN N
12 CD N
months NNS N
, , N
which WDT N
was VBD N
followed VBN N
by IN N
a DT N
treatment-free JJ N
but CC N
still RB N
blinded VBD N
observation JJ N
period NN N
of IN N
8 CD N
months NNS N
. . N

Falls NNP 1_o
were VBD N
documented VBN N
using VBG N
diaries NNS N
. . N

The DT 1_p
study NN 1_p
took VBD 1_p
place NN 1_p
in IN 1_p
Bad NNP 1_p
Pyrmont NNP 1_p
, , 1_p
Germany NNP 1_p
( ( 1_p
latitude VBP 1_p
52 CD 1_p
degrees NNS 1_p
) ) 1_p
and CC 1_p
Graz NNP 1_p
, , 1_p
Austria NNP 1_p
( ( 1_p
latitude VBP 1_p
46 CD 1_p
degrees NNS 1_p
) ) 1_p
. . 1_p

RESULTS $ N
Compared VBD N
to TO N
calcium VB N
mono NN N
, , N
supplementation NN N
with IN N
calcium NN N
plus CC N
vitamin NN 1_i
D NNP 1_i
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS 1_o
with IN 1_o
first JJ 1_o
falls NNS 1_o
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
( ( N
RR NNP N
= NNP N
0.73 CD N
; : N
CI NNP N
= NNP N
0.54-0.96 NN N
) ) N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
( ( N
RR NNP N
= NNP N
0.61 CD N
; : N
CI NNP N
= NNP N
0.34-0.76 NN N
) ) N
. . N

Concerning VBG N
secondary JJ N
endpoints NNS N
, , N
we PRP N
observed VBD N
significant JJ N
improvements NNS 1_o
in IN 1_o
quadriceps JJ 1_o
strength NN 1_o
of IN N
8 CD N
% NN N
, , N
a DT N
decrease NN N
in IN N
body NN 1_o
sway NN 1_o
of IN N
28 CD N
% NN N
, , N
and CC N
a DT N
decrease NN N
in IN N
time NN 1_o
needed VBN 1_o
to TO 1_o
perform VB 1_o
the DT 1_o
TUG NNP 1_o
test NN 1_o
of IN N
11 CD N
% NN N
. . N

DISCUSSION NNP N
Combined NNP N
calcium NN 1_i
and CC N
vitamin NN 1_i
D NNP 1_i
supplementation NN N
proved VBD N
superior JJ N
to TO N
calcium VB N
alone RB N
in IN N
reducing VBG N
the DT N
number NN 1_o
of IN 1_o
falls NNS 1_o
and CC N
improving VBG N
muscle NN 1_o
function NN 1_o
in IN N
community-dwelling JJ 1_p
older NN 1_p
individuals NNS 1_p
. . 1_p

Dose-response JJ N
characteristics NNS N
during IN N
long-term JJ N
inhalation NN N
of IN N
nitric JJ 1_i
oxide NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
acute JJ 1_p
respiratory NN 1_p
distress JJ 1_p
syndrome NN 1_p
: : 1_p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
. . N

Inhaled VBN N
nitric JJ 1_i
oxide NN 1_i
( ( 1_i
NO NNP 1_i
) ) 1_i
improves VBZ N
systemic JJ N
oxygenation NN N
( ( N
PaO2/FIO2 NNP N
) ) N
in IN N
adult NN 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
respiratory NN 1_p
distress NN 1_p
syndrome NN 1_p
( ( 1_p
ARDS NNP 1_p
) ) 1_p
. . 1_p

However RB N
, , N
individual JJ N
response NN N
varies NNS N
, , N
and CC N
previous JJ N
trials NNS N
demonstrated VBD N
no DT N
outcome NN N
benefit NN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
in IN N
40 CD 1_p
ARDS NNP 1_p
patients NNS 1_p
analyzed VBD N
dose-response JJ 1_o
( ( 1_o
DR NNP 1_o
) ) 1_o
characteristics NNS 1_o
during IN N
long-term JJ N
inhaled JJ N
NO NNP 1_i
. . 1_i

Patients NNS 1_p
were VBD 1_p
randomized VBN 1_i
for IN 1_i
conventional JJ 1_i
therapy NN 1_i
( ( 1_i
control NN 1_i
) ) 1_i
or CC 1_i
continuous JJ 1_i
treatment NN 1_i
with IN 1_i
10 CD 1_i
parts NNS 1_i
per IN 1_i
million CD 1_i
( ( 1_i
ppm NN 1_i
) ) 1_i
inhaled VBD 1_i
NO NNP 1_i
until IN 1_i
weaning VBG 1_i
was VBD 1_i
initiated VBN 1_i
. . 1_i

We PRP N
measured VBD N
DR NNP 1_o
curves NNS 1_o
of IN 1_o
PaO2/FIO2 NNP 1_o
versus IN 1_o
the DT 1_o
inhaled JJ 1_o
NO NNP 1_o
dose NN 1_o
at IN N
regular JJ N
intervals NNS N
. . N

Before IN N
treatment NN N
( ( N
Day NNP N
0 CD N
) ) N
, , N
peak JJ N
improvement NN N
in IN N
PaO2/FIO2 NNP 1_o
was VBD N
achieved VBN N
at IN N
10 CD N
ppm NN N
for IN N
both DT N
control NN N
and CC N
NO-treated JJ 1_i
patients NNS N
. . N

After IN N
4 CD N
days NNS N
, , N
the DT N
DR NNP 1_o
curve NN 1_o
of IN 1_o
the DT 1_o
NO-treated JJ 1_o
patients NNS 1_o
was VBD N
left VBN N
shifted VBN N
with IN N
a DT N
peak JJ N
response NN N
at IN N
1 CD N
ppm NN N
. . N

At IN N
higher JJR N
doses NNS N
( ( N
10 CD N
and CC N
100 CD N
ppm NN N
) ) N
, , N
oxygenation NN 1_o
deteriorated VBD 1_o
, , N
and CC N
the DT N
response NN N
to TO N
inhaled VB N
NO RB N
disappeared VBN N
in IN N
several JJ N
patients NNS N
. . N

This DT N
effect NN N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
inhaled JJ N
NO NNP N
on IN N
duration NN N
of IN N
mechanical JJ 1_o
ventilation NN 1_o
or CC 1_o
stay VB 1_o
at IN 1_o
the DT 1_o
intensive JJ 1_o
care NN 1_o
unit NN 1_o
. . 1_o

In IN N
conclusion NN N
, , N
long-term JJ N
inhaled VBD N
NO NNP N
with IN N
constant JJ N
doses NNS N
of IN N
10 CD N
ppm NNS N
leads VBZ N
to TO N
enhanced VB N
sensitivity NN N
after IN N
several JJ N
days NNS N
and CC N
does VBZ N
do VB N
not RB N
allow VB N
reduction NN N
of IN N
ventilation NN N
parameters NNS N
. . N

Hence NNP N
, , N
previous JJ N
trials NNS N
on IN N
therapy NN N
with IN N
inhaled JJ N
NO NNP N
in IN N
ARDS NNP N
should MD N
be VB N
carefully RB N
interpreted VBN N
, , N
as IN N
they PRP N
used VBD N
constant JJ N
NO NNP N
concentrations NNS N
, , N
which WDT N
may MD N
have VB N
become VBN N
overdoses NNS N
leading VBG N
to TO N
deterioration NN N
of IN N
oxygenation NN 1_o
after IN N
several JJ N
days NNS N
. . N

Acute NNP N
effect NN N
of IN N
pegvisomant NN 1_i
on IN N
cardiovascular JJ N
risk NN N
markers NNS N
in IN N
healthy JJ 1_p
men NNS 1_p
: : 1_p
implications NNS N
for IN N
the DT N
pathogenesis NN N
of IN N
atherosclerosis NN N
in IN N
GH NNP N
deficiency NN N
. . N

Cardiovascular JJ N
risk NN N
is VBZ N
increased VBN N
in IN N
GH NNP N
deficiency NN N
( ( N
GHD NNP N
) ) N
. . N

GHD NNP 1_p
adults NNS 1_p
are VBP N
frequently RB N
abdominally RB N
obese JJ N
and CC N
display JJ N
features NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

Otherwise NNP N
healthy JJ N
abdominally RB N
obese JJ N
subjects NNS N
have VBP N
low JJ N
GH NNP N
levels NNS N
and CC N
show NN N
features NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
as RB N
well RB N
. . N

We PRP N
investigated VBD N
in IN N
healthy JJ 1_p
nonobese JJ 1_p
males NNS 1_p
the DT N
effect NN N
of IN N
the DT N
GH NNP N
receptor NN N
antagonist NN N
pegvisomant NN 1_i
in IN N
different JJ N
metabolic JJ N
conditions NNS N
. . N

This DT N
is VBZ N
a DT N
model NN N
for IN N
acute JJ N
GHD NNP N
without IN N
the DT N
alterations NNS N
in IN N
body NN N
composition NN N
associated VBN N
with IN N
GHD NNP N
. . N

We PRP N
compared VBN N
the DT N
effect NN N
of IN N
pegvisomant NN 1_i
with IN N
that DT N
of IN N
placebo NN 1_i
before IN N
and CC N
after IN N
3 CD N
d NN N
of IN N
fasting VBG N
. . N

In IN N
addition NN N
, , N
we PRP N
investigated VBD N
the DT N
effect NN N
of IN N
pegvisomant JJ 1_i
under IN N
normal JJ N
, , N
i.e JJ N
. . N

fed VBN N
, , N
conditions NNS N
. . N

Three CD N
days NNS N
of IN N
fasting NN N
as RB N
well RB N
as IN N
pegvisomant JJ N
alone NN N
decreased VBD N
serum JJ 1_o
free JJ 1_o
IGF-I NN 1_o
levels NNS 1_o
( ( N
1.0 CD N
+/- JJ N
0.15 CD N
vs. FW N
0.31 CD N
+/- JJ N
0.05 CD N
ng/ml NN N
and CC N
0.86 CD N
+/- JJ N
0.23 CD N
vs. FW N
0.46 CD N
+/- JJ N
0.23 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
. . N

Fasting VBG N
in IN N
combination NN N
with IN N
pegvisomant NN N
also RB N
decreased VBD N
serum JJ 1_o
free JJ 1_o
IGF-I NN 1_o
levels NNS 1_o
( ( N
1.0 CD N
+/- JJ N
0.15 CD N
vs. FW N
0.31 CD N
+/- JJ N
0.07 CD N
ng/ml NN N
) ) N
. . N

Treatment NN N
with IN N
pegvisomant NN 1_i
had VBD N
no DT N
additional JJ N
influence NN N
on IN N
the DT N
decline NN N
of IN N
free JJ 1_o
IGF-I NNP 1_o
induced VBN N
by IN N
fasting VBG N
. . N

Pegvisomant VB N
alone RB N
had VBD N
no DT N
influence NN N
on IN N
insulin NN 1_o
sensitivity NN 1_o
. . 1_o

The DT N
increase NN N
in IN N
insulin JJ 1_o
sensitivity NN 1_o
induced VBN N
by IN N
fasting VBG N
was VBD N
comparable JJ N
to TO N
the DT N
increase NN N
in IN N
insulin JJ 1_o
sensitivity NN 1_o
induced VBN N
by IN N
fasting VBG N
combined VBN N
with IN N
pegvisomant JJ N
. . N

Among IN N
serum JJ 1_o
lipid JJ 1_o
concentrations NNS 1_o
, , N
only RB N
serum JJ 1_o
triglycerides NNS 1_o
increased VBD N
significantly RB N
as IN N
a DT N
result NN N
of IN N
pegvisomant NN N
alone NN N
( ( N
1.0 CD N
+/- JJ N
0.2 CD N
vs. FW N
1.6 CD N
+/- JJ N
0.4 CD N
mmol/liter NN N
) ) N
. . N

The DT N
changes NNS 1_o
in IN 1_o
lipid JJ 1_o
concentrations NNS 1_o
induced VBN N
by IN N
fasting VBG N
alone RB N
or CC N
pegvisomant VB N
were VBD N
not RB N
different JJ N
from IN N
those DT N
induced VBN N
by IN N
pegvisomant JJ N
alone NN N
. . N

von JJ 1_o
Willebrand NNP 1_o
factor NN 1_o
antigen NN 1_o
levels NNS 1_o
declined VBD N
significantly RB N
under IN N
the DT N
influence NN N
of IN N
pegvisomant NN N
alone NN N
( ( N
1.1 CD N
+/- JJ N
0.07 CD N
vs. FW N
0.8 CD N
+/- JJ N
0.06 CD N
U/ml NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
in IN N
different JJ N
metabolic JJ N
conditions NNS N
the DT N
GH NNP N
receptor NN N
antagonist NN N
pegvisomant NN N
induces VBZ N
no DT N
significant JJ N
acute NN N
changes NNS N
in IN N
the DT N
major JJ N
risk NN 1_o
markers NNS 1_o
for IN 1_o
cardiovascular JJ 1_o
disease NN 1_o
. . 1_o

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
secondary JJ N
metabolic NN N
changes NNS N
, , N
e.g NN N
. . N

abdominal JJ 1_o
obesity NN 1_o
or CC 1_o
inflammatory JJ 1_o
factors NNS 1_o
, , N
that WDT N
develop VBZ N
as IN N
a DT N
result NN N
of IN N
long-standing JJ N
GHD NNP N
are VBP N
of IN N
primary JJ N
importance NN N
in IN N
the DT N
pathogenesis NN N
of IN N
atherosclerosis NN N
in IN N
patients NNS N
with IN N
GHD NNP N
. . N

Comparative JJ N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
metronidazole JJ 1_i
application NN N
in IN N
adult NN 1_p
periodontitis NN 1_p
; : 1_p
12-months JJ N
results NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
application NN N
of IN N
25 CD N
% NN N
metronidazole JJ 1_i
dental JJ 1_i
gel NN 1_i
as IN N
an DT N
adjunct NN N
to TO N
scaling NN 1_i
and CC 1_i
root NN 1_i
planing NN 1_i
( ( 1_i
SRP NNP 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
adult NN 1_p
periodontitis NN 1_p
. . 1_p

Eighty NNP 1_p
teeth VBZ 1_p
in IN 1_p
18 CD 1_p
patients NNS 1_p
were VBD N
evaluated VBN N
using VBG N
a DT N
split NN N
mouth NN N
design NN N
. . N

The DT N
test NN N
teeth NN N
received VBD N
SRP NNP 1_i
and CC N
a DT N
25 CD N
% NN N
metronidazole JJ 1_i
gel NN 1_i
applied VBN N
subgingivally RB N
on IN N
days NNS N
0 CD N
and CC N
7 CD N
. . N

The DT N
control NN N
teeth VBZ N
received VBN N
SRP NNP 1_i
only RB 1_i
. . 1_i

Clinical JJ N
and CC N
microbiological JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
treatment NN N
and CC N
on IN N
weeks NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
13 CD N
, , N
26 CD N
, , N
38 CD N
and CC N
52 CD N
of IN N
the DT N
experimental JJ N
period NN N
. . N

Colony NNP N
forming VBG N
units NNS N
of IN N
Porphyromonas NNP N
gingivalis NN N
and CC N
Prevotella NNP N
intermedia VBP N
/ NNP N
Prevotella NNP N
nigrescens NNS N
were VBD N
determined VBN N
. . N

Both DT N
treatments NNS N
provided VBD N
significant JJ N
improvements NNS N
in IN N
all PDT N
the DT N
clinical JJ 1_o
and CC 1_o
microbiological JJ 1_o
parameters NNS 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

As IN N
a DT N
conclusion NN N
, , N
the DT N
present JJ N
study NN N
does VBZ 1_o
not RB 1_o
provide VB 1_o
evidence NN 1_o
in IN 1_o
favour NN 1_o
of IN 1_o
the DT 1_o
routine JJ 1_o
use NN 1_o
of IN 1_o
adjunctive JJ 1_o
metronidazole JJ 1_o
dental NN 1_o
gel NN 1_o
in IN N
the DT N
treatment NN N
of IN N
adult NN 1_o
periodontitis NN 1_o
. . 1_o

Absorption NN 1_o
of IN 1_o
intramuscular JJ 1_o
phenobarbitone NN 1_o
in IN N
children NNS 1_p
with IN 1_p
severe JJ 1_p
falciparum NN 1_p
malaria NN 1_p
. . 1_p

The DT N
absorption NN 1_o
of IN 1_o
intramuscular JJ 1_o
phenobarbitone NN 1_o
7 CD 1_i
mg.kg-1 NN 1_i
was VBD N
studied VBN N
in IN N
11 CD 1_p
Karen NNP 1_p
children NNS 1_p
aged VBD 1_p
between IN 1_p
1.7 CD 1_p
and CC 1_p
11 CD 1_p
y NN 1_p
with IN 1_p
severe JJ 1_p
falciparum NN 1_p
malaria NN 1_p
. . 1_p

Eight CD 1_p
of IN 1_p
the DT 1_p
children NNS 1_p
were VBD 1_p
comatose JJ 1_p
. . 1_p

Clinical JJ N
findings NNS N
were VBD N
compared VBN N
with IN N
those DT N
in IN N
9 CD 1_p
further JJ 1_p
children NNS 1_p
with IN 1_p
severe JJ 1_p
malaria NNS 1_p
of IN 1_p
similar JJ 1_p
age NN 1_p
range NN 1_p
( ( 1_p
four CD 1_p
of IN 1_p
whom WP 1_p
were VBD 1_p
unconscious JJ 1_p
) ) 1_p
, , N
who WP N
received VBD N
an DT N
identical JJ 1_i
placebo NN 1_i
. . 1_i

One CD N
child NN N
, , N
who WP N
had VBD N
received VBN N
placebo NN N
, , N
had VBD N
repeated VBN 1_o
convulsions NNS 1_o
and CC N
died VBD N
1 CD N
h NN N
after IN N
admission NN N
to TO N
hospital NN N
. . N

The DT N
remainder NN N
made VBD N
an DT N
uncomplicated JJ 1_o
recovery NN 1_o
. . 1_o

There EX N
were VBD N
no DT N
convulsions NNS 1_o
subsequent VBP N
to TO N
treatment NN N
, , N
although IN N
the DT N
study NN N
was VBD N
too RB N
small JJ N
to TO N
assess VB N
anticonvulsant JJ N
efficacy NN N
. . N

There EX N
was VBD N
no DT N
observable JJ N
toxicity NN 1_o
, , N
but CC N
phenobarbitone NN N
recipients NNS N
had VBD N
a DT N
significant JJ N
tendency NN N
to TO N
deepen VB N
in IN N
their PRP$ N
level NN 1_o
of IN 1_o
coma NN 1_o
or CC N
to TO N
become VB 1_o
sleepy NN 1_o
within IN N
the DT N
4 CD N
h NN N
after IN N
drug NN N
administration NN N
. . N

Phenobarbitone NNP N
was VBD N
rapidly RB N
absorbed VBN N
, , N
reaching VBG N
a DT N
mean NN N
( ( N
range NN N
) ) N
peak NN N
concentration NN N
of IN N
34.2 CD N
[ JJ N
29.3-42.6 JJ N
] JJ N
mumol.l-1 NN N
in IN N
a DT N
median NN N
( ( N
range NN N
) ) N
of IN N
4 CD N
( ( N
2.5-12 CD N
) ) N
h. NN N
These DT N
values NNS N
are VBP N
comparable JJ N
to TO N
those DT N
previously RB N
reported VBN N
in IN N
healthy JJ N
children NNS N
and CC N
in IN N
children NNS N
with IN N
febrile JJ 1_o
convulsions NNS 1_o
. . 1_o

Intramuscular NNP N
phenobarbitone NN N
is VBZ N
well RB N
absorbed VBN N
in IN N
children NNS 1_p
with IN 1_p
severe JJ 1_p
malaria NNS 1_p
; : 1_p
the DT N
optimum JJ N
prophylactic JJ N
anticonvulsant NN N
dose NN N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

[ JJ N
Structural NNP N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
induced VBN N
by IN N
topical JJ N
glaucoma NN N
medication NN N
] NNP N
. . N

PURPOSE VB N
The DT N
topical JJ 1_i
medication NN 1_i
represents VBZ N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
the DT N
primary JJ N
open JJ N
angle NN N
glaucoma NN N
. . N

The DT N
study NN N
is VBZ N
aimed VBN N
at IN N
assessing VBG N
the DT N
structural JJ N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
induced VBN N
by IN N
topical JJ 1_i
glaucoma NN 1_i
medication NN 1_i
. . 1_i

METHODS NNP N
For IN N
this DT N
purpose NN N
, , N
we PRP N
carried VBD N
out RP N
a DT N
40 CD N
weeks NNS N
, , N
prospective JJ N
, , N
experimental JJ N
, , N
epidemiological-operational JJ N
and CC N
randomized JJ N
study NN N
enrolling VBG N
18 CD 1_p
patients NNS 1_p
( ( 1_p
36 CD 1_p
eyes NNS 1_p
) ) 1_p
with IN 1_p
recently RB 1_p
primary JJ 1_p
open JJ 1_p
angle NN 1_p
glaucoma NN 1_p
. . 1_p

The DT N
eyes NNS N
were VBD N
divided VBN N
into IN N
treatment NN N
( ( 1_i
non-selective JJ 1_i
beta NN 1_i
blockers NNS 1_i
or CC 1_i
selective JJ 1_i
, , 1_i
prostaglandin JJ 1_i
analogues NNS 1_i
, , 1_i
topical JJ 1_i
carbonic JJ 1_i
anhydrase NN 1_i
inhibitors NNS 1_i
) ) 1_i
in IN N
four CD N
groups NNS N
. . N

The DT N
assessment NN N
was VBD N
performed VBN N
by IN N
comparison NN N
with IN N
control NN 1_i
group NN 1_p
( ( 1_p
4 CD 1_p
patients NNS 1_p
) ) 1_p
who WP 1_p
was VBD 1_p
instilled VBN 1_p
with IN 1_p
natural JJ 1_i
tears NNS 1_i
( ( 1_p
with IN 1_p
different JJ 1_p
preservative NN 1_p
) ) 1_p
. . 1_p

Both CC N
the DT N
cytology NN N
and CC N
the DT N
conjunctival NN N
biopsy NN N
specimens NNS N
were VBD N
investigated VBN N
by IN N
histological JJ N
exams NNS N
and CC N
immunohistochemistry NN N
using VBG N
different JJ N
monoclonal JJ N
antibodies NNS N
. . N

The DT N
study NN N
was VBD N
performed VBN N
by IN N
collaboration NN N
with IN N
The DT N
National NNP N
Institute NNP N
of IN N
Research NNP N
and CC N
Development NNP N
in IN N
Pathology NNP N
and CC N
Biomedical NNP N
Sciences- NNP N
" NNP N
V. NNP N
Babes NNP N
" NNP N
-Bucharest NNP N
. . N

RESULTS VB N
The DT N
morphometric JJ N
analysis NN N
of IN N
histological JJ N
sections NNS N
of IN N
conjunctiva NN N
showed VBD N
the DT N
following JJ N
changes NNS N
: : N
squamous JJ 1_o
metaplasia NN 1_o
( ( N
significant JJ N
increases NNS N
in IN N
the DT N
thickness NN 1_o
and CC 1_o
number NN 1_o
of IN 1_o
epithelial JJ 1_o
cell NN 1_o
layers NNS 1_o
) ) 1_o
, , 1_o
inflammation NN 1_o
( ( N
increase VB N
the DT N
number NN 1_o
of IN 1_o
lymphocytes NNS 1_o
, , 1_o
macrophages NNS 1_o
and CC 1_o
fibroblasts NNS 1_o
) ) 1_o
and CC 1_o
subconjunctival JJ 1_o
fibrosis NN 1_o
. . 1_o

According VBG N
to TO N
the DT N
type NN N
of IN N
medication NN N
, , N
we PRP N
observed VBD N
the DT N
significant JJ N
increase NN N
of IN N
subepithelial JJ 1_o
collagen NN 1_o
density NN 1_o
and CC 1_o
degenerative JJ 1_o
changes NNS 1_o
of IN 1_o
fibrocytes NNS 1_o
, , 1_o
the DT 1_o
reduction NN 1_o
of IN 1_o
extracellular JJ 1_o
matrix NN 1_o
and CC 1_o
also RB 1_o
the DT 1_o
up-regulation NN 1_o
of IN 1_o
antibodies NNS 1_o
against IN 1_o
matrix JJ 1_o
metalloproteinase NN 1_o
and CC 1_o
allergic JJ 1_o
changes NNS 1_o
. . 1_o

According VBG N
to TO N
structural JJ N
changes NNS N
, , N
the DT N
immunohistochemistry NN N
confirmed VBD N
the DT N
tendency NN N
of IN N
chronic JJ 1_o
inflammation NN 1_o
. . 1_o

CONCLUSIONS VB N
This DT N
study NN N
revealed VBD N
important JJ N
structural JJ N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN 1_o
after IN N
topical JJ 1_i
glaucoma NN 1_i
medication NN 1_i
. . 1_i

The DT N
category NN N
and CC N
the DT N
intensity NN N
of IN N
these DT N
changes NNS N
are VBP N
dependent JJ N
on IN N
the DT N
sort NN N
of IN N
therapy NN N
and CC N
the DT N
topical JJ N
treatment NN N
period NN N
. . N

The DT N
findings NNS N
showed VBD N
that IN N
benzalkonium NN 1_i
chloride NN 1_i
( ( 1_i
the DT 1_i
most RBS 1_i
common JJ 1_i
preservative NN 1_i
of IN 1_i
antiglaucoma NN 1_i
drugs NNS 1_i
) ) 1_i
is VBZ N
a DT N
major JJ N
factor NN N
for IN N
conjunctival NN N
metaplasia NN N
. . N

Two CD N
large JJ N
preoperative JJ N
doses NNS N
of IN N
erythropoietin NN 1_i
do VBP N
not RB N
reduce VB N
the DT N
systemic JJ 1_p
inflammatory NN 1_p
response NN 1_p
to TO 1_p
cardiac VB 1_p
surgery NN 1_p
. . 1_p

OBJECTIVES NNP N
Cardiac NNP N
surgery NN N
and CC N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
induce VBP N
an DT N
inflammatory JJ N
reaction NN N
that WDT N
may MD N
lead VB N
to TO N
tissue VB N
injury NN N
. . N

Experimental JJ N
studies NNS N
suggest VBP N
that IN N
recombinant JJ 1_i
human JJ 1_i
erythropoietin NN 1_i
( ( 1_i
EPO NNP 1_i
) ) 1_i
independent JJ N
of IN N
its PRP$ N
erythropoietic JJ N
effect NN N
may MD N
be VB N
used VBN N
clinically RB N
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that IN N
2 CD N
large JJ N
doses NNS N
of IN N
EPO NNP 1_i
administered VBD N
shortly RB N
before IN N
CPB NNP N
ameliorate VBP N
the DT N
systemic JJ N
inflammatory NN N
response NN N
to TO N
CPB NNP N
. . N

DESIGN NNP N
AND NNP N
SETTING NNP N
A NNP N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
and CC N
randomized JJ N
study NN N
at IN N
a DT N
single JJ N
tertiary NN N
care NN N
hospital NN N
. . N

PARTICIPANTS CC N
Patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
coronary JJ 1_p
artery NN 1_p
bypass NN 1_p
graft NN 1_p
surgery NN 1_p
with IN 1_p
CPB NNP 1_p
. . 1_p

INTERVENTIONS NNP N
EPO NNP 1_i
( ( 1_i
epoetin JJ 1_i
alfa NN 1_i
, , N
500 CD N
IU/kg NNP N
intravenously RB N
, , N
n JJ 1_p
= NNP 1_p
22 CD 1_p
) ) 1_p
or CC 1_p
placebo NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
21 CD 1_p
) ) 1_p
was VBD N
administered VBN N
12 CD N
to TO N
18 CD N
hours NNS N
preoperatively RB N
and CC N
again RB N
at IN N
the DT N
induction NN N
of IN N
anesthesia NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
CPB NNP N
in IN N
both DT N
groups NNS N
greatly RB N
increased VBD N
plasma JJ 1_o
concentrations NNS 1_o
of IN 1_o
tumor NN 1_o
necrosis NN 1_o
factor NN 1_o
alpha NN 1_o
( ( 1_o
TNF-alpha NNP 1_o
) ) 1_o
, , 1_o
interleukin FW 1_o
( ( 1_o
IL NNP 1_o
) ) 1_o
-1beta NN 1_o
, , 1_o
IL-1beta NNP 1_o
receptor NN 1_o
antagonist NN 1_o
, , 1_o
IL-6 NNP 1_o
, , 1_o
IL-10 NNP 1_o
, , 1_o
and CC 1_o
N-terminal JJ 1_o
probrain NN 1_o
natriuretic JJ 1_o
peptide NN 1_o
( ( 1_o
NT-proBNP NNP 1_o
) ) 1_o
. . 1_o

Compared VBN N
with IN N
placebo NN 1_i
, , 1_i
EPO NNP 1_i
at IN N
day NN N
3 CD N
after IN N
CPB NNP N
augmented VBD N
the DT N
TNF-alpha JJ 1_o
response NN 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
2 CD N
hours NNS N
after IN N
CPB NNP N
increased VBD N
NT-proBNP NNP 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
EPO NNP 1_i
tended VBD N
to TO N
enhance VB N
the DT N
CPB-induced JJ N
increase NN N
in IN N
IL-1beta NNP 1_o
receptor NN 1_o
antagonist NN 1_o
( ( N
p JJ N
= NNP N
0.057 CD N
) ) N
. . N

Otherwise UH N
, , N
EPO NNP 1_i
had VBD N
no DT N
effect NN N
on IN N
pro- NN 1_o
and CC 1_o
antiinflammatory NN 1_o
mediators NNS 1_o
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSIONS NNP N
Two CD N
large JJ N
doses NNS N
of IN N
EPO NNP 1_i
given VBN N
shortly RB N
before IN N
CPB NNP N
do VBP N
not RB N
reduce VB N
perioperative JJ 1_o
release NN 1_o
of IN 1_o
inflammatory JJ 1_o
cytokines NNS 1_o
. . 1_o

In IN N
contrast NN N
, , N
EPO NNP 1_i
may MD N
augment VB N
the DT N
TNF-alpha NNP N
and CC N
NT-proBNP NNP N
response NN N
. . N

Although IN N
the DT N
long-term JJ N
clinical JJ N
impact NN N
remains VBZ N
unknown JJ N
, , N
the DT N
findings NNS N
do VBP N
not RB N
support VB N
use NN N
of IN N
EPO NNP 1_i
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
in IN N
patients NNS 1_p
undergoing JJ 1_p
cardiac JJ 1_p
surgery NN 1_p
. . 1_p

Risperidone NN 1_i
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
study NN N
. . N

Some DT N
open-label JJ N
studies NNS N
suggest VBP N
that IN N
risperidone NN 1_i
can MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
certain JJ N
target NN N
symptoms NNS N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

We PRP N
aimed VBD N
to TO N
study VB N
whether IN N
the DT N
use NN N
of IN N
risperidone NN 1_i
in IN N
comparison NN N
with IN N
placebo NN 1_i
improved VBN N
functioning NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
with IN N
regard NN N
to TO N
behavior VB N
( ( N
aggressiveness NN N
, , N
hyperactivity NN N
, , N
irritability NN N
) ) N
, , N
social JJ N
and CC N
emotional JJ N
responsiveness NN N
, , N
and CC N
communication NN N
skills NNS N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
with IN N
40 CD 1_p
consecutive JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
, , 1_p
whose WP$ 1_p
ages NNS 1_p
ranged VBD 1_p
from IN 1_p
2 CD 1_p
to TO 1_p
9 CD 1_p
years NNS 1_p
, , 1_p
who WP 1_p
were VBD 1_p
receiving VBG 1_p
either CC 1_p
risperidone NN 1_i
or CC 1_i
placebo VB 1_i
given VBN 1_p
orally RB 1_p
at IN 1_p
a DT 1_p
dose NN 1_p
of IN 1_p
1 CD 1_p
mg/day NN 1_p
for IN 1_p
6 CD 1_p
months NNS 1_p
. . 1_p

Autism NN N
symptoms NNS N
were VBD N
monitored VBN N
periodically RB N
. . N

The DT N
outcome NN N
variables NNS N
were VBD N
total JJ N
scores NNS N
on IN N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
CARS NNP N
) ) N
and CC N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
( ( N
CGAS NNP N
) ) N
after IN N
6 CD N
months NNS N
. . N

Of IN N
the DT N
40 CD 1_p
children NNS 1_p
enrolled VBD 1_p
, , N
39 CD N
completed VBD N
the DT N
trial NN N
over IN N
a DT N
period NN N
of IN N
18 CD N
months NNS N
; : N
19 CD N
received VBD N
risperidone NN 1_i
, , N
and CC N
20 CD N
received VBD N
placebo NN 1_i
. . 1_i

In IN N
the DT N
risperidone NN 1_i
group NN N
, , N
12 CD N
of IN N
19 CD N
children NNS N
showed VBD N
improvement NN N
in IN N
the DT N
total JJ 1_o
Childhood NNP 1_o
Autism NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
score NN 1_o
and CC N
17 CD N
of IN N
19 CD N
children NNS N
in IN N
the DT N
Children NNP 1_o
's POS 1_o
Global NNP 1_o
Assessment NNP 1_o
Scale NNP 1_o
score NN 1_o
compared VBN N
with IN N
0 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Childhood NNP 1_o
Autism NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
score NN 1_o
and CC N
2 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Children NNP 1_o
's POS 1_o
Global NNP 1_o
Assessment NNP 1_o
Scale NNP 1_o
score NN 1_o
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
and CC N
P NNP N
= NNP N
.035 NNP N
, , N
respectively RB N
) ) N
. . N

Risperidone NNP 1_i
also RB N
improved VBD N
social JJ 1_o
responsiveness NN 1_o
and CC 1_o
nonverbal JJ 1_o
communication NN 1_o
and CC N
reduced VBD N
the DT N
symptoms NNS 1_o
of IN 1_o
hyperactivity NN 1_o
and CC 1_o
aggression NN 1_o
. . 1_o

Risperidone NN 1_i
was VBD N
associated VBN N
with IN N
increased VBN N
appetite NN 1_o
and CC 1_o
a DT 1_o
mild JJ 1_o
weight NN 1_o
gain NN 1_o
, , 1_o
mild JJ 1_o
sedation NN 1_o
in IN 1_o
20 CD 1_o
% NN 1_o
, , 1_o
and CC 1_o
transient NN 1_o
dyskinesias NN 1_o
in IN N
three CD N
children NNS N
. . N

Risperidone NN 1_i
improved VBD N
global JJ 1_o
functioning NN 1_o
and CC 1_o
social JJ 1_o
responsiveness NN 1_o
while IN N
reducing VBG 1_o
hyperactivity NN 1_o
and CC 1_o
aggression NN 1_o
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC N
was VBD N
well RB N
tolerated VBN N
. . N

Effects NNS N
of IN N
fish JJ 1_i
oil NN 1_i
supplementation NN 1_i
on IN N
markers NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
fish JJ 1_i
oil NN 1_i
affects NNS N
cardiovascular JJ 1_o
risk NN 1_o
factors NNS 1_o
during IN N
the DT N
adolescent JJ N
growth NN N
spurt NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
78 CD 1_p
boys NNS 1_p
age NN 1_p
13-15 CD 1_p
years NNS 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
body NN 1_p
fat JJ 1_p
percentage NN 1_p
of IN 1_p
30 CD 1_p
% NN 1_p
+/-9 JJ 1_p
% NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
consume VB N
fish JJ 1_i
oil NN 1_i
( ( N
providing VBG N
1.5 CD N
g NN N
of IN N
n-3 JJ N
long-chain NN 1_i
polyunsaturated VBD 1_i
fatty JJ 1_i
acid/day NN 1_i
) ) 1_i
or CC 1_i
vegetable JJ 1_i
oil NN 1_i
( ( 1_i
control NN 1_i
) ) 1_i
for IN N
16 CD N
weeks NNS N
. . N

The DT N
oils NNS N
were VBD N
included VBN N
in IN N
bread NN N
. . N

RESULTS NNP N
After IN N
the DT N
intervention NN N
, , N
the DT N
red JJ 1_o
blood NN 1_o
cell NN 1_o
( ( 1_o
RBC NNP 1_o
) ) 1_o
content NN N
of IN N
eicosapentaenoic JJ 1_o
acid NN 1_o
( ( 1_o
EPA NNP 1_o
) ) 1_o
and CC 1_o
docosahexaenoic JJ 1_o
acid NN 1_o
( ( 1_o
DHA NNP 1_o
) ) 1_o
were VBD N
1.2 CD N
% NN N
+/-0.5 JJ N
% NN N
and CC N
6.7 CD N
% NN N
+/-1.6 JJ N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
those DT N
receiving VBG N
fish JJ 1_i
oil NN 1_i
( ( 1_i
FO NNP 1_i
group NN 1_i
) ) 1_i
, , N
compared VBN N
with IN N
0.6 CD N
% NN N
+/-0.3 JJ N
% NN N
and CC N
4.1 CD N
% NN N
+/-0.9 JJ N
% NN N
in IN N
the DT N
control NN 1_i
group NN N
. . N

Systolic NNP 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
SBP NNP 1_o
) ) 1_o
was VBD N
3.8+/-1.4 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.006 NNP N
) ) N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
was VBD N
2.6+/-1.1 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
in IN N
the DT N
FO NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Plasma NNP 1_o
triacylglycerol NN 1_o
( ( 1_o
TAG NNP 1_o
) ) 1_o
concentration NN 1_o
and CC N
insulin JJ 1_o
sensitivity NN 1_o
were VBD N
unaffected VBN N
by IN N
either DT N
of IN N
the DT N
treatments NNS N
. . N

Plasma NNP 1_o
high-density NN 1_o
lipoprotein NN 1_o
( ( 1_o
HDL NNP 1_o
) ) 1_o
and CC 1_o
non-HDL JJ 1_o
cholesterol NN 1_o
were VBD N
increased VBN N
by IN N
5 CD N
% NN N
and CC N
7 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
FO NNP 1_i
group NN N
, , N
and CC N
by IN N
2 CD N
% NN N
and CC N
0 CD N
% NN N
in IN N
the DT N
control NN 1_i
group NN 1_i
( ( N
P NNP N
< NNP N
.01-.02 NN N
) ) N
. . N

The DT N
changes NNS 1_o
in IN 1_o
RBC NNP 1_o
EPA NNP 1_o
content NN 1_o
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
changes NNS 1_o
in IN 1_o
SBP NNP 1_o
and CC 1_o
DBP NNP 1_o
and CC N
directly RB N
correlated VBN N
with IN N
the DT N
increases NNS N
in IN N
HDL NNP 1_o
cholesterol NN 1_o
and CC 1_o
non-HDL JJ 1_o
cholesterol NN 1_o
concentrations NNS 1_o
. . 1_o

No DT N
association NN N
was VBD N
seen VBN N
between IN N
RBC NNP 1_o
EPA NNP 1_o
and CC 1_o
plasma VB 1_o
TAG NNP 1_o
concentration NN 1_o
or CC 1_o
insulin JJ 1_o
sensitivity NN 1_o
. . 1_o

CONCLUSION NNP N
Fish NNP 1_i
oil NN 1_i
improves VBZ N
BP NNP 1_o
in IN N
normotensive JJ 1_p
and CC 1_p
normolipidemic JJ 1_p
slightly RB 1_p
overweight JJ 1_p
adolescent NN 1_p
boys NNS 1_p
. . 1_p

Concurrent NNP 1_i
doxorubicin NN 1_i
plus CC 1_i
docetaxel NN 1_i
is VBZ N
not RB N
more RBR N
effective JJ N
than IN N
concurrent NN 1_i
doxorubicin NN 1_i
plus CC 1_i
cyclophosphamide NN 1_i
in IN N
operable JJ 1_p
breast NN 1_o
cancer NN 1_o
with IN 1_p
0 CD 1_p
to TO 1_p
3 CD 1_p
positive JJ 1_p
axillary JJ 1_p
nodes NNS 1_p
: : 1_p
North JJ N
American JJ N
Breast NNP N
Cancer NNP N
Intergroup NNP N
Trial NNP N
E NNP N
2197 CD N
. . N

PURPOSE VB N
The DT N
combination NN N
of IN N
doxorubicin NN 1_i
and CC 1_i
cyclophosphamide NN 1_i
( ( 1_i
AC NNP 1_i
) ) 1_i
is VBZ N
a DT N
standard JJ N
adjuvant JJ N
regimen NNS N
. . N

Doxorubicin NNP 1_i
and CC 1_i
docetaxel NN 1_i
( ( 1_i
AT NNP 1_i
) ) 1_i
is VBZ N
one CD N
of IN N
the DT N
most RBS N
active JJ N
cytotoxic NN N
regimens NNS N
for IN N
metastatic JJ 1_o
breast NN 1_o
cancer NN 1_o
. . 1_o

The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
whether IN N
adjuvant NN N
AT NNP N
improved VBD N
disease-free JJ N
survival NN N
compared VBN N
with IN N
AC NNP N
in IN N
operable JJ 1_p
breast NN 1_o
cancer NN 1_o
. . 1_o

PATIENTS NNP N
AND CC N
METHODS NNP N
Women NNP 1_p
with IN 1_p
invasive JJ 1_p
breast NN 1_p
cancer NN 1_p
were VBD 1_p
eligible JJ 1_p
if IN 1_p
there EX 1_p
were VBD 1_p
one CD 1_p
to TO 1_p
three CD 1_p
positive JJ 1_p
lymph NN 1_p
nodes NNS 1_p
or CC 1_p
if IN 1_p
the DT 1_p
node-negative JJ 1_p
tumor NN 1_p
was VBD 1_p
greater JJR 1_p
than IN 1_p
1 CD 1_p
cm NN 1_p
. . 1_p

Patients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
after IN 1_p
surgery NN 1_p
to TO N
receive VB N
doxorubicin NN 1_i
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC 1_i
either DT 1_i
cyclophosphamide NN 1_i
( ( N
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
AC NNP N
) ) N
or CC 1_i
docetaxel NN 1_i
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
AT NNP N
) ) N
given VBN N
every DT N
3 CD N
weeks NNS N
for IN N
four CD N
cycles NNS N
, , N
followed VBN N
by IN N
hormone NN N
therapy NN N
for IN N
patients NNS 1_p
with IN 1_p
estrogen JJ 1_p
receptor NN 1_p
( ( 1_p
ER NNP 1_p
) ) 1_p
and/or VBP 1_p
progesterone NN 1_p
receptor NN 1_p
( ( 1_p
PR NNP 1_p
) ) 1_p
-positive JJ 1_p
tumors NNS 1_p
. . 1_p

RESULTS VB N
There EX N
were VBD N
2,882 CD 1_p
eligible JJ 1_p
patients NNS 1_p
enrolled VBN 1_p
. . 1_p

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
79.5 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
disease-free JJ 1_o
survival NN 1_o
( ( N
DFS NNP N
; : N
85 CD N
% NN N
in IN N
both DT N
arms NNS N
) ) N
or CC N
overall JJ 1_o
survival NN 1_o
( ( N
91 CD N
% NN N
v JJ N
92 CD N
% NN N
) ) N
at IN N
5 CD N
years NNS N
. . N

The DT N
hazard NN 1_o
ratio NN 1_o
for IN N
AC NNP 1_i
versus NN N
AT NNP N
was VBD N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
DFS NNP N
, , N
0.86 CD N
to TO N
1.22 CD N
; : N
P NNP N
= NNP N
.78 NNP N
) ) N
. . N

In IN N
an DT N
exploratory JJ N
analysis NN N
of IN N
prespecified JJ N
stratification NN N
factors NNS N
by IN N
ER NNP N
and CC N
PR NNP N
expression NN N
there EX N
were VBD N
trends NNS N
toward IN N
improved JJ 1_o
DFS NNP 1_o
for IN N
AT NNP N
in IN N
ER/PR-negative JJ N
disease NN N
. . N

Grade VB 1_o
3 CD 1_o
neutropenia RB 1_o
associated VBN 1_o
with IN 1_o
fever NN 1_o
or CC 1_o
infection NN 1_o
occurred VBD N
more RBR N
often RB N
with IN N
AT NNP N
( ( N
26 CD N
% NN N
v JJ N
10 CD N
% NN N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NN N
AT NNP 1_i
did VBD N
not RB N
improve VB N
DFS NNP 1_o
or CC 1_o
overall JJ 1_o
survival NN 1_o
in IN N
this DT N
population NN N
, , N
and CC N
was VBD N
associated VBN N
with IN N
more JJR N
toxicity NN 1_o
. . 1_o

Application NN N
of IN N
ambulatory JJ N
blood NN N
pressure NN N
monitoring NN N
to TO N
clinical JJ N
therapeutic JJ N
decisions NNS N
in IN N
hypertension NN 1_p
. . 1_p

The DT N
antihypertensive JJ 1_o
efficacies NNS N
of IN N
lisinopril NN 1_i
and CC N
captopril NN 1_i
were VBD N
compared VBN N
using VBG N
office NN N
sphygmomanometry NN N
and CC N
24-h JJ N
ambulatory NN N
blood NN N
pressure NN N
monitoring NN N
. . N

In IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
randomly RB N
allocated VBN N
trial NN N
, , N
the DT 1_p
patients NNS 1_p
were VBD N
given VBN N
increasing VBG N
doses NNS N
of IN N
captopril NN 1_i
at IN N
25-100 JJ N
mg NN N
twice RB N
a DT N
day NN N
or CC N
lisinopril NN 1_i
at IN N
10-40 JJ N
mg NN N
once IN N
a DT N
day NN N
until IN N
a DT N
clinical JJ 1_o
response NN 1_o
was VBD N
achieved VBN N
or CC N
the DT N
highest JJS N
dose NN N
was VBD N
reached VBN N
. . N

A DT N
response NN N
was VBD N
defined VBN N
as IN N
a DT N
reduction NN 1_o
in IN 1_o
diastolic JJ 1_o
pressure NN 1_o
below IN 1_o
90 CD 1_o
mmHg NN 1_o
or CC 1_o
a DT 1_o
fall NN 1_o
of IN 1_o
at IN 1_o
least JJS 1_o
10 CD 1_o
mmHg NN 1_o
from IN 1_o
baseline NN 1_o
. . 1_o

The DT N
ambulatory NN N
monitoring NN N
showed VBD N
that IN N
lisinopril NN N
reduced VBD N
blood NN 1_o
pressure NN 1_o
from IN N
baseline NN N
to TO N
the DT N
final JJ N
value NN N
and CC N
maintained VBD 1_o
the DT 1_o
reduction NN 1_o
to TO N
a DT N
greater JJR N
degree NN N
than IN N
captopril NN 1_i
throughout IN N
24-h JJ N
periods NNS N
of IN N
observation NN N
. . N

The DT N
office NN 1_o
measurements NNS 1_o
showed VBD N
a DT N
similar JJ N
trend NN N
, , N
but CC N
the DT N
intertreatment JJ N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

No DT N
first-dose JJ 1_o
side NN 1_o
effects NNS N
were VBD N
observed VBN N
with IN N
either DT N
drug NN N
. . N

Once IN N
a DT N
day NN N
lisinopril NN 1_i
appeared VBD N
to TO N
be VB N
a DT N
more RBR N
effective JJ 1_o
antihypertensive JJ 1_i
regimen NNS 1_i
than IN N
twice RB N
a DT N
day NN N
captopril NN N
. . N

Improving VBG N
care NN 1_p
givers NNS 1_p
' POS 1_p
satisfaction NN 1_p
with IN 1_p
information NN 1_i
received VBN 1_i
during IN 1_i
hospitalization NN 1_i
. . 1_i

As IN N
competition NN N
for IN N
patient NN N
volume NN N
escalates VBZ N
among IN N
hospital JJ N
providers NNS N
, , N
administrators NNS N
must MD N
identify VB N
ways NNS N
to TO N
attract VB N
new JJ 1_p
patients NNS 1_p
and CC 1_p
maintain NN 1_p
or CC 1_p
increase VB 1_p
patient JJ 1_p
volume NN 1_p
. . 1_p

Family NNP 1_p
care NN 1_p
givers NNS 1_p
are VBP N
known VBN N
to TO N
greatly RB N
influence JJ N
individuals NNS N
' POS N
choices NNS N
in IN N
these DT N
matters NNS N
of IN N
selection NN N
of IN N
healthcare NN N
services NNS N
and CC N
providers NNS N
. . N

The DT N
results NNS N
of IN N
a DT N
successful JJ N
nurse-initiated JJ 1_i
daily JJ 1_i
phone NN 1_i
calls VBZ 1_i
program NN 1_i
, , N
designed VBN N
to TO N
improve VB N
family NN N
care NN N
giver NN N
satisfaction NN N
by IN N
enhancing VBG N
the DT N
provision NN N
of IN N
patient-specific JJ 1_i
information NN 1_i
, , N
are VBP N
presented VBN N
. . N

The DT N
components NNS 1_o
of IN 1_o
the DT 1_o
program NN 1_o
, , 1_o
associated VBN 1_o
costs NNS 1_o
, , 1_o
and CC 1_o
implications NNS 1_o
on IN 1_o
delivery NN 1_o
of IN 1_o
care NN 1_o
are VBP N
discussed VBN N
. . N

[ JJ N
Comparative NNP N
effects NNS N
of IN N
nebivolol NN 1_i
and CC 1_i
valsartan NN 1_i
on IN N
atrial JJ 1_o
electromechanical JJ 1_o
coupling NN 1_o
in IN N
newly RB 1_p
diagnosed VBN 1_p
stage NN 1_p
1 CD 1_p
hypertensive JJ 1_p
patients NNS 1_p
] VBP 1_p
. . N

OBJECTIVES NNP N
Hypertension NNP N
is VBZ N
an DT N
important JJ N
cardiovascular NN N
risk NN N
factor NN N
for IN N
the DT N
development NN N
of IN N
atrial JJ 1_o
fibrillation NN 1_o
( ( 1_o
AF NNP 1_o
) ) 1_o
. . 1_o

Increased VBN N
atrial JJ N
electromechanical JJ N
coupling NN N
time NN N
interval NN N
measured VBN N
by IN N
tissue NN N
Doppler NNP N
is VBZ N
accepted VBN N
as IN N
an DT N
important JJ N
factor NN N
for IN N
prediction NN N
of IN N
AF NNP 1_o
development NN 1_o
in IN N
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
valsartan NN 1_i
, , N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
, , N
and CC N
nebivolol RB 1_i
, , N
a DT N
beta-blocker NN N
, , N
on IN N
atrial JJ N
electromechanical JJ N
coupling NN N
in IN N
newly RB 1_p
diagnosed VBN 1_p
stage NN 1_p
1 CD 1_p
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
included VBD N
60 CD 1_p
newly RB 1_p
diagnosed VBN 1_p
stage NN 1_p
1 CD 1_p
hypertensive JJ 1_p
patients NNS 1_p
with IN 1_p
no DT 1_p
other JJ 1_p
systemic JJ 1_p
disease NN 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
nebivolol JJ 1_i
5 CD 1_i
mg NN 1_i
( ( N
30 CD N
patients NNS N
; : N
21 CD N
women NNS N
, , N
9 CD N
men NNS N
; : N
mean JJ N
age NN N
48.4 CD N
± JJ N
11.4 CD N
years NNS N
) ) N
and CC 1_i
valsartan $ 1_i
160 CD 1_i
mg NN 1_i
( ( N
30 CD N
patients NNS N
; : N
21 CD N
women NNS N
, , N
9 CD N
men NNS N
; : N
mean JJ N
age NN N
49.8 CD N
± JJ N
11.3 CD N
years NNS N
) ) N
. . N

All PDT N
the DT N
patients NNS N
underwent JJ N
tissue NN N
Doppler NNP N
echocardiographic JJ N
examination NN N
before IN N
and CC N
three CD N
months NNS N
after IN N
treatment NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
two CD N
drugs NNS N
on IN 1_o
atrial JJ 1_o
electromechanical JJ 1_o
coupling NN 1_o
. . N

RESULTS NNP 1_o
Baseline NNP 1_o
blood NN 1_o
pressures NNS 1_o
, , 1_o
electrocardiographic JJ 1_o
and CC 1_o
echocardiographic JJ 1_o
findings NNS 1_o
, , 1_o
and CC 1_o
atrial JJ 1_o
electromechanical JJ 1_o
coupling NN 1_o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Both DT N
drugs NNS N
significantly RB N
reduced VBD 1_o
blood NN 1_o
pressure NN 1_o
after IN N
treatment NN N
, , N
with IN N
similar JJ N
efficacy NN N
( ( 1_o
p JJ 1_o
> NNP 1_o
0.05 CD 1_o
) ) 1_o
. . 1_o

Atrial JJ 1_o
electromechanical JJ 1_o
coupling NN 1_o
time NN 1_o
intervals NNS 1_o
showed VBD N
significant JJ N
decreases NNS N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP 1_o
Prolonged VBD 1_o
interatrial JJ 1_o
electromechanical JJ 1_o
time NN 1_o
intervals NNS 1_o
in IN N
hypertensives NNS N
are VBP N
improved VBN N
with IN N
antihypertensive JJ N
treatment NN N
. . N

Maximal NNP 1_o
bioavailability NN 1_o
of IN 1_p
digoxin NN 1_i
from IN 1_p
tablets NNS 1_p
and CC 1_p
oral JJ 1_p
solution NN 1_p
in IN 1_p
steady JJ 1_p
state NN 1_p
. . 1_p

Comparison NNP N
has VBZ N
been VBN N
made VBN N
between IN N
the DT N
absorption NN 1_o
of IN 1_o
digoxin NN 1_o
from IN N
Lanoxin NNP 1_i
tablets NNS N
and CC N
the DT N
absorption NN N
of IN N
international JJ N
chemical NN N
reference NN N
substance NN N
digoxin NN 1_o
from IN 1_i
an DT 1_i
oral JJ 1_i
solution NN 1_i
. . 1_i

Plasma NNP 1_o
levels NNS 1_o
, , 1_o
areas NNS 1_o
under IN 1_o
24-hour JJ 1_o
plasma NN 1_o
concentration NN 1_o
curves NNS 1_o
and CC 1_o
urinary JJ 1_o
excretion NN 1_o
were VBD N
similar JJ N
by IN N
both DT N
formulations NNS N
in IN N
steady JJ N
state NN N
. . N

78 CD N
% NN N
of IN N
the DT N
digoxin NN 1_o
administered VBD N
was VBD N
absorbed VBN N
from IN N
the DT N
tablets NNS N
and CC N
76 CD N
% NN N
from IN N
the DT N
solution NN N
. . N

Rapid JJ N
dissolution NN N
in IN N
the DT N
intestinal JJ N
fluids NNS N
accounts NNS N
for IN N
the DT N
high JJ N
digoxin NN 1_o
bioavailability NN 1_o
of IN N
the DT N
tablets NNS N
. . N

Effects NNS N
of IN N
a DT N
standardized JJ 1_i
pamphlet NN 1_i
on IN N
insomnia NN 1_o
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

OBJECTIVE NNP N
Sleep NNP 1_o
difficulties NNS 1_o
are VBP N
common JJ N
reasons NNS N
why WRB 1_p
parents NNS 1_p
seek VBP 1_p
medical JJ 1_p
intervention NN 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASDs NNP 1_p
) ) 1_p
. . 1_p

We PRP N
determined VBD N
whether IN N
a DT N
pamphlet NN 1_i
alone RB N
could MD N
be VB N
used VBN N
by IN N
parents NNS N
to TO N
help VB N
their PRP$ N
child NN N
's POS N
insomnia NN 1_o
. . 1_o

METHODS NNP N
Thirty-six JJ 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
, , 1_p
ages VBZ 1_p
2 CD 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
, , 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

All DT 1_p
had VBD 1_p
prolonged VBN 1_p
sleep JJ 1_o
latency NN 1_o
confirmed VBN 1_p
by IN 1_p
actigraphy NN 1_p
showing VBG 1_p
a DT 1_p
mean JJ 1_p
sleep JJ 1_o
latency NN 1_o
of IN 1_p
30 CD 1_p
minutes NNS 1_p
or CC 1_p
more JJR 1_p
. . 1_p

Parents NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
receive VB 1_p
the DT 1_p
sleep JJ 1_i
education NN 1_i
pamphlet NN 1_i
or CC 1_i
no DT 1_i
intervention NN 1_i
. . 1_i

Children NNP N
wore VBD N
an DT N
actigraphy NN 1_i
device NN 1_i
to TO N
record VB N
baseline NN N
sleep JJ 1_o
parameters NNS 1_o
, , N
with IN N
the DT N
primary JJ N
outcome NN N
variable JJ N
being VBG N
change NN 1_o
in IN 1_o
sleep JJ 1_o
latency NN 1_o
. . 1_o

Actigraphy NNP N
data NNS N
were VBD N
collected VBN N
a DT N
second JJ N
time NN N
2 CD N
weeks NNS N
after IN N
the DT N
parent NN N
received VBD N
the DT N
randomization NN N
assignment NN N
and CC N
analyzed VBN N
by IN N
using VBG N
Student NNP N
's POS N
t JJ N
test NN N
. . N

Parents NNS N
were VBD N
also RB N
asked VBN N
a DT N
series NN N
of IN N
questions NNS N
to TO N
gather VB N
information NN N
about IN N
the DT N
pamphlet NN 1_i
and CC N
its PRP$ N
usefulness NN N
. . N

RESULTS NNP N
Although IN N
participants NNS N
randomized VBN N
to TO N
the DT N
2 CD N
arms NNS N
did VBD N
not RB N
differ VB N
statistically RB N
in IN N
age NN 1_o
, , 1_o
gender NN 1_o
, , 1_o
socioeconomic JJ 1_o
status NN 1_o
, , 1_o
total JJ 1_o
Children NNP 1_o
's POS 1_o
Sleep NNP 1_o
Habits NNP 1_o
Questionnaire NNP 1_o
score NN 1_o
, , 1_o
or CC 1_o
actigraphy NN 1_o
parameters NNS 1_o
, , N
some DT N
differences NNS N
may MD N
be VB N
large JJ N
enough RB N
to TO N
affect VB N
results NNS N
. . N

Mean JJ 1_o
change NN 1_o
in IN 1_o
sleep-onset JJ 1_o
latency NN 1_o
did VBD N
not RB N
differ VB N
between IN N
the DT N
randomized VBN N
groups NNS N
( ( 1_i
pamphlet VB 1_i
versus NN 1_i
no DT 1_i
pamphlet NN 1_i
) ) 1_i
. . 1_i

Parents NNS N
commented VBD N
that IN N
the DT N
pamphlet NN 1_i
contained VBD N
good JJ N
information NN 1_o
, , N
but CC N
indicated VBD N
that IN N
it PRP N
would MD N
have VB N
been VBN N
more RBR N
useful JJ N
to TO N
be VB N
given VBN N
specific JJ N
examples NNS N
of IN N
how WRB N
to TO N
take VB N
the DT N
information NN N
and CC N
put VB N
it PRP N
into IN N
practice NN N
. . N

CONCLUSIONS VB N
A DT N
sleep JJ 1_i
education NN 1_i
pamphlet NN 1_i
did VBD N
not RB N
appear VB N
to TO N
improve VB N
sleep JJ 1_o
latency NN 1_o
in IN 1_p
children NNS 1_p
with IN 1_p
ASDs NNP 1_p
. . 1_p

Randomized VBN N
trial NN N
comparing VBG N
induction NN 1_i
chemotherapy NN 1_i
versus NN N
induction NN 1_i
chemotherapy NN 1_i
followed VBN 1_i
by IN 1_i
maintenance NN 1_i
chemotherapy NN 1_i
in IN N
small-cell JJ 1_p
lung NN 1_p
cancer NN 1_p
. . 1_p

European JJ N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
. . N

PURPOSE NNP N
AND CC N
METHODS NNP N
The DT N
European NNP N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
( ( N
ELCWP NNP N
) ) N
performed VBD N
a DT N
randomized JJ N
trial NN N
with IN N
the DT N
primary JJ N
end NN N
point NN N
to TO N
determine VB N
if IN N
maintenance NN N
chemotherapy NN N
with IN N
12 CD N
courses NNS N
of IN N
etoposide NN 1_i
( ( N
120 CD N
mg/m2 NN N
on IN N
days NNS N
1 CD N
and CC N
3 CD N
) ) N
and CC N
vindesine NN 1_i
( ( N
3 CD N
mg/m2 NN N
on IN N
day NN N
3 CD N
) ) N
could MD N
improve VB N
progression-free JJ 1_o
survival NN 1_o
in IN N
small-cell JJ 1_p
lung NN 1_p
cancer NN 1_p
( ( 1_p
SCLC NNP 1_p
) ) 1_p
patients NNS 1_p
who WP 1_p
responded VBD 1_p
to TO 1_p
six CD 1_p
courses NNS 1_p
of IN 1_p
induction NN 1_i
chemotherapy NN 1_i
with IN 1_i
ifosfamide NN 1_i
, , 1_i
etoposide RB 1_i
, , 1_i
and CC 1_i
an DT 1_i
anthracycline NN 1_i
( ( 1_i
doxorubicin NN 1_i
or CC 1_i
epirubicin NN 1_i
) ) 1_i
. . 1_i

RESULTS NNP N
Among IN 1_p
235 CD 1_p
eligible JJ 1_p
patients NNS 1_p
initially RB 1_p
registered VBD 1_p
, , 1_p
91 CD 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
receive VB 1_p
maintenance NN 1_p
therapy NN 1_p
, , 1_p
including VBG 1_p
seven CD 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
no RB 1_p
longer RBR 1_p
responding VBG 1_p
. . 1_p

Among IN N
84 CD N
randomized JJ N
responders NNS N
, , N
progression-free JJ 1_o
survival NN 1_o
was VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
by IN N
maintenance NN N
therapy NN N
, , N
with IN N
median JJ N
durations NNS N
( ( N
maintenance NN N
v IN N
follow-up JJ N
) ) N
of IN N
25 CD N
versus NNS N
12 CD N
weeks NNS N
after IN N
the DT N
second JJ N
randomization NN N
, , N
but CC N
survival NN 1_o
was VBD N
not RB N
significantly RB N
increased VBN N
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
, , N
with IN N
median JJ N
durations NNS N
of IN N
48 CD N
and CC N
38 CD N
weeks NNS N
. . N

However RB N
, , N
in IN N
a DT N
multi-variate JJ N
analysis NN N
that WDT N
took VBD N
into IN N
account NN 1_o
disease NN 1_o
extent NN 1_o
, , 1_o
maintenance NN 1_o
therapy NN 1_o
, , 1_o
Karnofsky NNP 1_o
performance NN 1_o
status NN 1_o
( ( 1_o
PS NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
absolute JJ 1_o
dose-intensity NN 1_o
( ( 1_o
ADI NNP 1_o
) ) 1_o
of IN 1_o
anthracycline NN 1_o
given VBN N
during IN N
induction NN N
, , N
limited JJ 1_o
disease NN 1_o
( ( 1_o
LD NNP 1_o
) ) 1_o
and CC 1_o
maintenance NN 1_o
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
positive JJ N
predictors NNS N
of IN N
survival NN 1_o
. . 1_o

CONCLUSION NNP N
We PRP N
conclude VBP N
that DT N
maintenance NN N
chemotherapy NN N
in IN N
responding VBG N
patients NNS N
is VBZ N
beneficial JJ N
in IN N
SCLC NNP N
. . N

Homocysteine NNP N
Metabolism NNP N
Gene NNP N
Polymorphisms NNP N
( ( N
MTHFR NNP N
C677T NNP N
, , N
MTHFR NNP N
A1298C NNP N
, , N
MTR NNP N
A2756G NNP N
and CC N
MTRR NNP N
A66G NNP N
) ) N
Jointly RB N
Elevate VBP N
the DT N
Risk NN N
of IN N
Folate NNP N
Deficiency NNP N
. . N

Folate NNP N
deficiency NN N
is VBZ N
strongly RB N
associated VBN N
with IN N
cardiovascular JJ N
disease NN N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
the DT N
joint JJ N
effect NN N
of IN N
the DT N
methylenetetrahydrofolate NN 1_i
reductase NN 1_i
( ( 1_i
MTHFR NNP 1_i
) ) 1_i
C677T NNP 1_i
and CC 1_i
A1298C NNP 1_i
, , 1_i
methionine NN 1_i
synthase NN 1_i
( ( 1_i
MTR NNP 1_i
) ) 1_i
A2756G NNP 1_i
, , 1_i
and CC 1_i
methionine JJ 1_i
synthase NN 1_i
reductase NN 1_i
( ( 1_i
MTRR NNP 1_i
) ) 1_i
A66G NNP 1_i
polymorphisms NN N
on IN N
folate JJ 1_o
deficiency NN 1_o
in IN N
a DT 1_p
Chinese JJ 1_p
hypertensive JJ 1_p
population NN 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
480 CD 1_p
subjects NNS 1_p
aged VBN 1_p
28-75 CD 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
this DT 1_p
study NN 1_p
from IN 1_p
September NNP 1_p
2005-December JJ 1_p
2005 CD 1_p
from IN 1_p
six CD 1_p
hospitals NNS 1_p
in IN 1_p
different JJ 1_p
Chinese JJ 1_p
regions NNS 1_p
. . 1_p

Known VBN N
genotypes NNS N
were VBD N
detected VBN N
by IN N
PCR-RFLP NNP N
methods NNS N
and CC N
serum NN 1_o
folate NN 1_o
was VBD N
measured VBN N
by IN N
chemiluminescence NN N
immunoassay NN N
. . N

Our PRP$ N
results NNS N
showed VBD N
that IN N
MTHFR NNP 1_o
677TT CD 1_o
and CC 1_o
MTR NNP 1_o
2756AG CD 1_o
+ NNP 1_o
GG NNP 1_o
were VBD N
independently RB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
folate JJ 1_o
deficiency NN 1_o
( ( N
TT NNP N
vs. FW N
CC NNP N
+ NNP N
CT NNP N
, , N
p NN N
< VBD N
0.001 CD N
and CC N
AG NNP N
+ NNP N
GG NNP N
vs. FW N
AA NNP N
p NN N
= NN N
0.030 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
the DT N
MTHFR NNP 1_i
A1298C NNP 1_i
mutation NN N
may MD N
confer VB N
protection NN N
by IN N
elevating VBG N
the DT N
serum NN 1_o
folate NN 1_o
level NN 1_o
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
. . N

Furthermore NNP N
, , N
patients NNS N
carrying VBG N
two CD N
or CC N
more JJR N
risk NN N
genotypes NNS N
showed VBD N
higher JJR N
odds NNS N
of IN N
folate NN 1_o
deficiency NN 1_o
than IN N
null JJ N
risk NN N
genotype NN N
carriers NNS N
, , N
especially RB N
those DT N
carrying VBG N
four CD N
risk NN N
genotypes NNS N
. . N

These DT N
findings NNS N
were VBD N
verified VBN N
by IN N
generalized JJ N
multifactor NN N
dimensionality NN N
reduction NN N
( ( N
p JJ N
= NNP N
0.0107 CD N
) ) N
and CC N
a DT N
cumulative JJ N
effects NNS N
model NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
have VBP N
shown VBN N
that IN N
interactions NNS N
among IN N
homocysteine JJ N
metabolism NN N
gene NN N
polymorphisms JJ N
lead NN N
to TO N
dramatic JJ N
elevations NNS N
in IN N
the DT N
folate NN N
deficiency NN N
risk NN N
. . N

A DT N
controlled VBN N
study NN N
of IN N
early JJ 1_i
discharge NN 1_i
after IN 1_p
uncomplicated JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

Out IN N
of IN N
383 CD 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( 1_p
MI NNP 1_p
) ) 1_p
patients NNS 1_p
aged VBN 1_p
below IN 1_p
70 CD 1_p
years NNS 1_p
, , 1_p
252 CD 1_p
( ( 1_p
66 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
judged VBN 1_p
after IN 1_p
the DT 1_p
third JJ 1_p
day NN 1_p
in IN 1_p
hospital NN 1_p
to TO 1_p
have VB 1_p
had VBN 1_p
uncomplicated VBN 1_p
infarctions NNS 1_p
. . 1_p

These DT N
patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
two CD N
groups NNS N
, , N
one CD 1_i
of IN 1_i
which WDT 1_i
was VBD 1_i
given VBN 1_i
treatment NN 1_i
for IN 1_i
8 CD 1_i
days NNS 1_i
and CC 1_i
the DT 1_i
other JJ 1_i
for IN 1_i
15 CD 1_i
days NNS 1_i
. . 1_i

No DT N
significant JJ N
differences NNS 1_o
in IN 1_o
mortality NN 1_o
, , 1_o
morbidity NN 1_o
or CC 1_o
incapacity NN 1_o
for IN 1_o
work NN 1_o
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
. . N

The DT N
findings NNS N
thus RB N
support VBP N
previous JJ N
conclusions NNS N
that WDT N
early RB 1_i
discharge VBP 1_i
from IN N
hospital NN N
after IN N
uncomplicated JJ N
MI NNP N
is VBZ N
not RB N
associated VBN N
with IN N
greater JJR N
risk NN N
for IN N
the DT N
patient NN N
than IN N
later RB N
discharge NN N
. . N

Faux NNP 1_i
pas CC 1_i
detection NN 1_i
and CC N
intentional JJ N
action NN N
in IN N
Asperger NNP 1_p
Syndrome NNP 1_p
. . 1_p

A DT N
replication NN N
on IN N
a DT N
French JJ N
sample NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
investigated VBD N
mind NN N
reading NN N
abilities NNS N
in IN N
a DT N
group NN 1_p
of IN 1_p
adults NNS 1_p
with IN 1_p
Asperger NNP 1_p
Syndrome NNP 1_p
( ( 1_p
AS IN 1_p
) ) 1_p
by IN N
using VBG N
the DT N
faux JJ 1_i
pas NN 1_i
task NN 1_i
, , 1_i
an DT 1_i
advanced JJ 1_i
test NN 1_i
of IN 1_i
theory NN 1_i
of IN 1_i
mind NN 1_i
( ( N
Baron-Cohen NNP N
et RB N
al RB N
. . N

( ( N
1999 CD N
) ) N
. . N

Journal NNP N
of IN N
Autism NNP N
and CC N
Developmental NNP N
Disorders NNP N
, , N
29 CD N
, , N
407-418 JJ N
) ) N
. . N

The DT N
faux JJ 1_i
pas NN 1_i
is VBZ N
a DT N
particular JJ N
case NN N
of IN N
a DT N
non-intentional JJ N
action NN N
reflecting VBG N
an DT N
involuntary JJ N
socially RB N
inappropriate JJ N
behavior NN N
. . N

Here RB N
, , N
individuals NNS 1_p
with IN 1_p
AS NNP 1_p
over-detected JJ 1_p
faux NN 1_o
pas NN 1_o
stories NNS 1_o
, , N
failed VBD N
to TO N
provide VB 1_o
correct JJ 1_o
justifications NNS 1_o
of IN 1_o
the DT 1_o
speaker NN 1_o
's POS 1_o
behavior NN 1_o
and CC N
were VBD N
unaware NN N
of IN N
the DT N
mistaken JJ 1_o
belief NN 1_o
and CC 1_o
of IN 1_o
the DT 1_o
resulting JJ 1_o
emotional JJ 1_o
impact NN 1_o
, , N
whereas IN N
they PRP N
appeared VBD N
to TO N
be VB N
responsive JJ N
to TO N
social JJ N
rule NN N
violations NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
because IN N
of IN N
an DT N
impaired JJ N
theory-of-mind NN N
, , N
individuals NNS 1_p
with IN 1_p
AS NNP 1_p
may MD N
develop VB N
compensatory JJ N
cognitive JJ N
strategies NNS N
based VBN N
on IN N
overlearned JJ N
abstract JJ N
knowledge NN N
about IN N
normative JJ N
rules NNS N
. . N

Effects NNS N
of IN N
cooking NN 1_i
plant NN 1_i
oils NNS 1_i
on IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE NNP N
One-third NNP N
of IN N
the DT N
total JJ N
population NN N
seems VBZ N
to TO N
develop VB N
minor JJ N
recurrent NN 1_p
aphthous JJ 1_p
stomatitis NN 1_p
( ( 1_p
RAS NNP 1_p
) ) 1_p
during IN N
their PRP$ N
lifetime NN N
. . N

However RB N
, , N
well-controlled JJ N
dietary JJ N
intervention NN N
studies NNS N
to TO N
prevent VB N
minor JJ N
RAS NNP N
are VBP N
very RB N
rare JJ N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
prevalence NN N
of IN N
RAS NNP N
decreased VBD N
with IN N
perilla NN 1_i
oil NN 1_i
( ( N
rich JJ N
in IN N
alpha-linolenic JJ N
acid NN N
) ) N
. . N

METHODS NNP N
Thirty NNP 1_p
subjects NNS 1_p
( ( 1_p
8 CD 1_p
men NNS 1_p
and CC 1_p
22 CD 1_p
women NNS 1_p
) ) 1_p
who WP 1_p
had VBD 1_p
minor JJ 1_p
RAS NNP 1_p
at IN 1_p
least JJS 1_p
once RB 1_p
a DT 1_p
month NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
soybean JJ 1_i
oil NN 1_i
group NN 1_i
or CC 1_i
a DT 1_i
perilla JJ 1_i
oil NN 1_i
group NN 1_i
in IN 1_i
a DT 1_i
double-blind JJ 1_i
manner NN 1_i
( ( 1_i
experimental JJ 1_i
phase NN 1_i
) ) 1_i
after IN 1_i
a DT 1_i
run-in JJ 1_i
phase NN 1_i
of IN 1_i
4 CD 1_i
mo NN 1_i
during IN 1_i
which WDT 1_i
subjects NNS 1_i
used VBD 1_i
a DT 1_i
reference NN 1_i
oil NN 1_i
, , 1_i
the DT 1_i
most RBS 1_i
popular JJ 1_i
cooking NN 1_i
oil NN 1_i
in IN 1_i
Japan NNP 1_i
, , 1_i
or CC 1_i
a DT 1_i
50/50 CD 1_i
mixture NN 1_i
of IN 1_i
soybean JJ 1_i
oil NN 1_i
and CC 1_i
rapeseed NN 1_i
oil NN 1_i
. . 1_i

During IN N
the DT N
experimental JJ N
phase NN N
, , N
subjects NNS N
were VBD N
asked VBN N
to TO N
use VB N
soybean JJ N
oil NN N
or CC N
perilla NN N
oil NN N
as IN N
the DT N
sole JJ N
cooking NN N
oil NN N
for IN N
8 CD N
mo NN N
. . N

Blood NN 1_o
samples NNS 1_o
were VBD N
collected VBN N
at IN N
the DT N
start NN N
and CC N
end NN N
of IN N
the DT N
experimental JJ N
phase NN N
for IN N
fatty JJ N
acid JJ N
analysis NN N
of IN N
total JJ N
plasma NN N
phospholipid JJ N
fraction NN N
. . N

Occurrence NN 1_o
and CC 1_o
needed VBN 1_o
days NNS 1_o
for IN 1_o
healing NN 1_o
of IN 1_o
minor JJ 1_o
RAS NNP 1_o
were VBD N
recorded VBN N
during IN N
the DT N
two CD N
phases NNS N
and CC N
compared VBN N
. . N

RESULTS NNP N
alpha-Linolenic JJ 1_o
acid JJ 1_o
concentrations NNS 1_o
in IN 1_o
the DT 1_o
plasma NN 1_o
phospholipid JJ 1_o
fraction NN 1_o
increased VBD 1_o
significantly RB N
in IN N
both DT N
groups NNS N
during IN N
the DT N
experimental JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

The DT N
prevalence NN N
of IN N
minor JJ 1_o
RAS NNP 1_o
in IN 1_o
the DT 1_o
experimental JJ 1_o
phase NN 1_o
decreased VBD 1_o
significantly RB 1_o
in IN N
both DT N
groups NNS N
compared VBN N
with IN N
the DT N
run-in JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
, , N
without IN N
intergroup JJ N
differences NNS N
. . N

CONCLUSION NNP N
Perilla NNP N
oil NN N
, , N
which WDT N
is VBZ N
rich JJ N
in IN N
alpha-linolenic JJ N
acid NN N
, , N
was VBD N
not RB N
superior JJ N
to TO N
soybean VB N
oil NN N
in IN N
preventing VBG N
minor JJ N
RAS NNP N
. . N

There EX N
was VBD N
a DT N
possibility NN N
that IN N
avoiding VBG N
rapeseed VB N
oil NN N
might MD N
be VB N
beneficial JJ N
for IN N
prevention NN N
of IN N
minor JJ N
RAS NNP N
. . N

Drug NNP N
therapy NN N
of IN N
ventricular JJ 1_p
tachycardia NN 1_p
: : 1_p
a DT N
cost NN N
comparison NN N
of IN N
randomized JJ N
noninvasive JJ 1_i
and CC 1_i
invasive JJ 1_i
approaches NNS 1_i
. . 1_i

OBJECTIVE NNP N
Economic NNP 1_o
evaluation NN 1_o
of IN N
noninvasive JJ 1_i
( ( 1_i
suppression NN 1_i
of IN 1_i
ventricular JJ 1_i
arrhythmias NNS 1_i
detected VBN 1_i
by IN 1_i
ambulatory JJ 1_i
monitoring NN 1_i
) ) 1_i
and CC N
invasive JJ 1_i
( ( 1_i
suppression NN 1_i
of IN 1_i
arrhythmias NNS 1_i
induced VBN 1_i
by IN 1_i
programmed JJ 1_i
stimulation NN 1_i
) ) 1_i
approaches VBZ N
to TO N
antiarrhythmic VB N
drug NN N
selection NN N
for IN N
ventricular JJ N
tachyarrhythmias NN N
. . N

DESIGN/SETTING NNP N
Randomized NNP N
clinical JJ N
trial/tertiary-care JJ N
hospital NN N
. . N

PATIENTS NNP N
Of IN N
124 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
referred VBD 1_p
for IN 1_p
treatment NN 1_p
of IN 1_p
symptomatic JJ 1_p
ventricular NN 1_p
tachyarrhythmias NN 1_p
, , 1_p
57 CD 1_p
consenting NN 1_p
patients NNS 1_p
were VBD 1_p
eligible JJ 1_p
to TO 1_p
have VB 1_p
drug NN 1_p
therapy NN 1_p
selected VBN 1_p
by IN 1_p
either DT 1_p
noninvasive JJ 1_i
or CC 1_i
invasive JJ 1_i
approaches NNS 1_i
. . 1_i

MEASUREMENTS NNP N
Costs NNPS 1_o
of IN 1_o
initial JJ 1_o
and CC 1_o
follow-up JJ 1_o
( ( N
26 CD N
+/- JJ N
15 CD N
months NNS N
) ) N
admissions NNS N
for IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

This DT N
economic JJ 1_o
evaluation NN 1_o
also RB N
considered VBN N
relative JJ N
efficacies NNS 1_o
of IN N
the DT N
approaches NNS N
using VBG N
the DT N
primary JJ 1_o
outcome NN 1_o
variable NN 1_o
of IN N
symptomatic JJ 1_o
, , 1_o
sustained VBD 1_o
ventricular JJ 1_o
tachyarrhythmia NN 1_o
recurrence NN 1_o
( ( 1_o
including VBG 1_o
sudden JJ 1_o
death NN 1_o
) ) 1_o
. . 1_o

RESULTS NNP N
Initial JJ 1_o
hospitalization NN 1_o
for IN N
therapy NN N
selection NN N
was VBD N
less RBR N
costly JJ 1_o
by IN N
the DT N
noninvasive JJ N
approach NN N
( ( N
$ $ N
6,869 CD N
+/- JJ N
4,019 CD N
) ) N
than IN N
by IN N
the DT N
invasive JJ 1_i
approach NN 1_i
( ( N
$ $ N
13,164 CD N
+/- JJ N
6,740 CD N
) ) N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

However RB N
, , N
the DT N
noninvasive JJ 1_i
approach NN 1_i
generated VBD N
higher JJR N
follow-up JJ 1_o
hospital NN 1_o
costs NNS 1_o
( ( N
$ $ N
9,204 CD N
+/- JJ N
9,217 CD N
) ) N
than IN N
the DT N
invasive JJ N
approach NN N
( ( N
$ $ N
3,784 CD N
+/- JJ N
4,944 CD N
) ) N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

Thus RB N
, , N
total JJ 1_o
hospital NN 1_o
costs NNS 1_o
of IN N
the DT N
noninvasive JJ N
( ( N
$ $ N
16,073 CD N
+/- JJ N
9,423 CD N
) ) N
and CC N
invasive JJ N
approaches NNS N
( ( N
$ $ N
16,949 CD N
+/- JJ N
7,174 CD N
) ) N
were VBD N
equivalent JJ N
. . N

The DT N
two-year JJ 1_o
actuarial JJ 1_o
probability NN 1_o
of IN 1_o
a DT 1_o
recurrent NN 1_o
, , 1_o
sustained VBN 1_o
, , 1_o
symptomatic JJ 1_o
ventricular NN 1_o
tachyarrhythmia NN 1_o
was VBD N
greater JJR N
in IN N
noninvasive JJ 1_i
( ( N
0.50 CD N
+/- JJ N
0.10 CD N
) ) N
than IN N
in IN N
invasive JJ 1_i
( ( N
0.20 CD N
+/- JJ N
0.08 CD N
) ) N
approach NN N
patients NNS N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
lower JJR N
initial JJ 1_o
hospital NN 1_o
costs NNS 1_o
of IN N
the DT N
noninvasive JJ N
approach NN N
are VBP N
offset VBN N
by IN N
greater JJR N
follow-up NN 1_o
costs NNS 1_o
. . 1_o

Within IN N
two CD N
years NNS N
the DT N
costs NNS 1_o
of IN N
the DT N
two CD N
approaches NNS N
are VBP N
equivalent JJ N
. . N

Thus RB N
, , N
greater JJR N
antiarrhythmic JJ 1_o
efficacy NN 1_o
can MD N
be VB N
achieved VBN N
by IN N
the DT N
invasive JJ 1_i
approach NN 1_i
to TO N
drug NN N
selection NN N
without IN N
increasing VBG N
total JJ 1_o
hospital NN 1_o
costs NNS 1_o
. . 1_o

A DT N
double JJ N
blind NN N
randomized VBD N
trial NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
eprosartan NN 1_i
and CC 1_i
enalapril NN 1_i
on IN N
blood NN 1_o
pressure NN 1_o
, , 1_o
platelets NNS 1_o
, , 1_o
and CC 1_o
endothelium NN 1_o
function NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
essential JJ 1_p
hypertension NN 1_p
. . 1_p

The DT N
renin-angiotensin JJ N
system NN N
is VBZ N
the DT N
major JJ N
contributor NN N
to TO N
development NN N
of IN N
hypertension NN N
, , N
atherosclerosis NN N
, , N
and CC N
many JJ N
other JJ N
cardiovascular JJ N
diseases NNS N
. . N

Angiotensin NNP N
II NNP N
, , N
one CD N
of IN N
the DT N
main JJ N
effectors NNS N
of IN N
this DT N
system NN N
, , N
contributes VBZ N
to TO N
the DT N
pathogenesis NN N
of IN N
hypertension NN N
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
monocyte NN N
, , N
platelet NN N
, , N
and CC N
endothelium NN N
interactions NNS N
. . N

The DT N
effects NNS N
on IN N
platelet NN 1_o
and CC 1_o
endothelial JJ 1_o
function NN 1_o
, , N
either RB N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitors NNS N
or CC N
angiotensin NN N
receptor NN N
antagonists NNS N
, , N
are VBP N
still RB N
not RB N
well RB N
understood RB N
. . N

A DT N
double-blind NN N
, , N
randomized VBN N
, , N
prospective JJ N
trial NN N
of IN N
either DT N
enalapril NN 1_i
( ( N
10-20 JJ N
mg NNS N
daily RB N
) ) N
or CC N
eprosartan JJ 1_i
( ( N
400-800 JJ N
mg NNS N
daily RB N
) ) N
over IN N
a DT N
10-week JJ N
period NN N
was VBD N
conducted VBN N
in IN N
42 CD 1_p
patients NNS 1_p
( ( 1_p
27 CD 1_p
males NNS 1_p
, , 1_p
15 CD 1_p
females NNS 1_p
) ) 1_p
. . 1_p

Platelet NNP N
activation NN N
was VBD N
evaluated VBN N
by IN N
measuring VBG N
platelet NN 1_o
factor NN 1_o
4 CD 1_o
( ( 1_o
PF-4 NNP 1_o
) ) 1_o
, , 1_o
beta-thromboglobulin JJ 1_o
( ( 1_o
beta-TG JJ 1_o
) ) 1_o
, , 1_o
the DT 1_o
ratio NN 1_o
of IN 1_o
platelet NN 1_o
factor NN 1_o
4 CD 1_o
to TO 1_o
beta-thromboglobulin NN 1_o
, , 1_o
and CC 1_o
endothelial JJ 1_o
function NN 1_o
by IN 1_o
measuring VBG 1_o
total JJ 1_o
plasma JJ 1_o
nitrate NN 1_o
levels NNS 1_o
, , 1_o
von FW 1_o
Willebrand NNP 1_o
factor NN 1_o
( ( 1_o
vWF NN 1_o
) ) 1_o
levels NNS 1_o
, , 1_o
and CC 1_o
blood NN 1_o
flow NN 1_o
using VBG 1_o
venous JJ 1_o
occlusive JJ 1_o
plethysmography NN 1_o
. . 1_o

After IN N
a DT N
10-week JJ N
treatment NN N
with IN N
enalapril NN 1_i
or CC 1_i
eprosartan NN 1_i
, , N
the DT N
sitting VBG 1_o
blood NN 1_o
pressure NN 1_o
in IN N
both DT N
the DT N
enalapril NN 1_i
group NN N
( ( N
from IN N
152.2 CD N
+/- JJ N
18.7 CD N
mmHg NN N
to TO N
141.9 CD N
+/- JJ N
23.5 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
eprosartan JJ 1_i
group NN N
( ( N
from IN N
151 CD N
+/- JJ N
10.0 CD N
mmHg NN N
to TO N
142.3 CD N
+/- JJ N
12.9 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
was VBD N
significantly RB N
reduced VBN N
. . N

Significant NNP N
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
DPB NNP 1_o
) ) 1_o
reduction NN N
( ( N
from IN N
94 CD N
+/- JJ N
8.7 CD N
to TO N
84.5 CD N
+/- JJ N
9.6 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
a DT N
greater JJR N
DBP NNP 1_o
reduction NN N
response NN N
were VBD N
found VBN N
in IN N
the DT N
eprosartan NN 1_i
group NN N
( ( N
63 CD N
% NN N
in IN N
eprosartan JJ 1_i
versus NN N
25 CD N
% NN N
in IN N
enalapril NN 1_i
) ) 1_i
. . N

Additionally RB N
, , N
dose-dependent JJ N
reductions NNS N
in IN N
the DT N
indices NNS N
of IN N
platelet NN 1_o
activation NN 1_o
and CC 1_o
endothelial JJ 1_o
dysfunction NN 1_o
were VBD N
observed VBN N
in IN N
patients NNS N
administered VBN N
high JJ N
dose JJ N
treatments NNS N
of IN N
eprosartan NN 1_i
and CC 1_i
enalapril NN 1_i
, , N
and CC N
the DT N
beneficial JJ N
effects NNS N
of IN N
these DT N
agents NNS N
were VBD N
not RB N
correlated VBN N
with IN N
the DT N
reduction NN N
of IN N
blood NN 1_o
pressure NN 1_o
using VBG N
both DT N
agents NNS N
. . N

Eprosartan NNP 1_i
is VBZ N
effective JJ 1_o
and CC N
well-tolerated JJ 1_o
in IN N
the DT N
treatment NN N
of IN N
mid-to-moderate JJ N
hypertension NN N
, , N
and CC N
the DT N
DBP NNP 1_o
response NN N
reduction NN N
to TO N
eprosartin VB 1_i
was VBD N
better JJR N
than IN N
that DT N
to TO N
enalapril VB 1_i
. . 1_i

A DT N
high JJ N
dose NN N
of IN N
either DT N
eprosartan NN 1_i
or CC 1_i
enalapril VB 1_i
significantly RB N
decreased VBN N
the DT N
indices NNS N
of IN N
platelet NN 1_o
activation NN 1_o
and CC N
endothelial JJ N
dysfunction NN N
in IN N
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
benefits NNS N
of IN N
both DT N
agents NNS N
can MD N
not RB N
be VB N
explained VBN N
solely RB N
by IN N
their PRP$ N
antihypertensive JJ N
effects NNS N
and CC N
possibly RB N
may MD N
be VB N
mediated VBN N
through IN N
their PRP$ N
unique JJ N
effect NN N
on IN N
angiotensin NN N
blockade NN N
. . N

Effect NN N
of IN N
pravastatin NN 1_i
on IN N
cardiovascular JJ 1_o
events NNS 1_o
in IN N
women NNS 1_p
after IN 1_p
myocardial JJ 1_p
infarction NN 1_p
: : 1_p
the DT N
cholesterol NN N
and CC N
recurrent JJ N
events NNS N
( ( N
CARE NNP N
) ) N
trial NN N
. . N

OBJECTIVES IN N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
pravastatin NN 1_i
on IN N
recurrent NN 1_o
cardiovascular JJ 1_o
events NNS 1_o
in IN N
women NNS 1_p
with IN 1_p
average JJ 1_p
cholesterol NN 1_p
levels NNS 1_p
after IN 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( 1_p
MI NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND NNP N
Little JJ N
information NN N
is VBZ N
available JJ N
on IN N
the DT N
effectiveness NN N
of IN N
lipid JJ N
lowering VBG N
in IN N
secondary JJ N
prevention NN N
of IN N
coronary JJ 1_p
heart NN 1_p
disease NN 1_p
( ( 1_p
CHD NNP 1_p
) ) 1_p
in IN 1_p
women NNS 1_p
; : 1_p
in IN 1_p
particular JJ 1_p
, , 1_p
those DT 1_p
with IN 1_p
CHD NNP 1_p
and CC 1_p
average JJ 1_p
cholesterol NN 1_p
levels NNS 1_p
. . 1_p

METHODS NNP N
In IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
, , N
576 CD 1_p
postmenopausal NN 1_p
women NNS 1_p
, , 1_p
between IN 1_p
3 CD 1_p
and CC 1_p
20 CD 1_p
months NNS 1_p
after IN 1_p
MI NNP 1_p
, , 1_p
with IN 1_p
a DT 1_p
total JJ 1_p
cholesterol NN 1_p
level NN 1_p
< VBD 1_p
240 CD 1_p
mg/dl NN 1_p
and CC 1_p
a DT 1_p
low JJ 1_p
density NN 1_p
lipoprotein NN 1_p
cholesterol NN 1_p
level NN 1_p
115 CD 1_p
to TO 1_p
174 CD 1_p
mg/dl NNS 1_p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
pravastatin NN 1_i
40 CD 1_i
mg/day NN 1_i
or CC N
matching VBG N
placebo NN 1_i
for IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
5 CD N
years NNS N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
combined VBN 1_o
coronary JJ 1_o
events NNS 1_o
( ( 1_o
coronary JJ 1_o
death NN 1_o
, , 1_o
nonfatal JJ 1_o
MI NNP 1_o
, , 1_o
percutaneous JJ 1_o
transluminal JJ 1_o
coronary NN 1_o
angioplasty NN 1_o
[ NNP 1_o
PTCA NNP 1_o
] NNP 1_o
or CC 1_o
coronary JJ 1_o
artery NN 1_o
bypass NN 1_o
graft NN 1_o
surgery NN 1_o
[ NNP 1_o
CABG NNP 1_o
] NNP 1_o
) ) 1_o
, , 1_o
the DT 1_o
primary JJ 1_o
trial NN 1_o
end NN 1_o
point NN 1_o
( ( 1_o
coronary JJ 1_o
death NN 1_o
or CC 1_o
nonfatal JJ 1_o
MI NNP 1_o
) ) 1_o
and CC 1_o
stroke NN 1_o
. . 1_o

RESULTS NNP N
Women NNP N
treated VBD N
with IN N
pravastatin NN N
had VBD N
a DT N
risk NN 1_o
reduction NN 1_o
of IN N
43 CD N
% NN N
for IN N
the DT N
primary JJ N
end NN N
point NN N
( ( N
p JJ N
= NNP N
0.035 CD N
) ) N
, , N
46 CD N
% NN N
for IN N
combined JJ N
coronary JJ N
events NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
, , N
48 CD N
% NN N
for IN N
PTCA NNP N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
, , N
40 CD N
% NN N
for IN N
CABG NNP N
( ( N
p JJ N
= NNP N
0.14 CD N
) ) N
and CC N
56 CD N
% NN N
for IN N
stroke NN N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
. . N

The DT 1_p
3,583 CD 1_p
men NNS 1_p
in IN 1_p
the DT 1_p
CARE NNP 1_p
trial NN 1_p
also RB N
showed VBD N
a DT N
reduction NN N
in IN N
risk NN 1_o
, , N
but CC N
the DT N
magnitude NN N
tended VBD N
to TO N
be VB N
less JJR N
. . N

Pravastatin NNP 1_i
improved VBD N
plasma JJ 1_o
lipids NNS 1_o
similarly RB N
in IN N
men NNS 1_p
and CC 1_p
women NNS 1_p
. . 1_p

There EX N
were VBD N
no DT N
differences NNS N
in IN N
risk NN 1_o
of IN 1_o
coronary JJ 1_o
events NNS 1_o
in IN N
the DT N
placebo NN N
group NN N
between IN N
men NNS N
and CC N
women NNS N
. . N

Minor JJ N
differences NNS N
between IN N
men NNS N
and CC N
women NNS N
were VBD N
present JJ N
in IN N
baseline NN N
characteristics NNS N
and CC N
treatment NN N
for IN N
MI NNP N
, , N
in IN N
general JJ N
, , N
conferring VBG N
a DT N
higher JJR N
risk NN N
status NN N
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
CABG NNP 1_o
in IN N
the DT N
women NNS N
. . N

CONCLUSIONS NNP N
Pravastatin NNP 1_i
led VBD N
to TO N
significant JJ N
early JJ N
reduction NN N
of IN N
a DT N
wide JJ N
range NN N
of IN N
cardiovascular JJ 1_o
events NNS 1_o
in IN N
post-MI JJ 1_p
women NNS 1_p
with IN 1_p
average JJ 1_p
cholesterol NN 1_p
levels NNS 1_p
. . 1_p

Comments NNS N
on IN N
" NNP 1_o
Secretin NNP 1_o
and CC N
autism NN 1_o
: : 1_o
a DT N
two-part JJ N
clinical JJ N
investigation NN N
" NN N
by IN N
M.G NNP N
. . N

Chez NNP N
et CC N
al NN N
. . N

Study NNP N
protocol NN N
: : N
Rehabilitation NN 1_i
including VBG 1_i
Social NNP 1_i
and CC 1_i
Physical NNP 1_i
activity NN 1_i
and CC 1_i
Education NN 1_i
in IN N
Children NNP 1_p
and CC 1_p
Teenagers NNP 1_p
with IN 1_p
Cancer NNP 1_p
( ( N
RESPECT NNP N
) ) N
. . N

BACKGROUND NNP N
During IN N
cancer NN N
treatment NN N
children NNS 1_p
have VBP 1_p
reduced VBN 1_p
contact NN 1_p
with IN 1_p
their PRP$ 1_p
social JJ 1_p
network NN 1_p
of IN 1_p
friends NNS 1_p
, , 1_p
and CC 1_p
have VBP 1_p
limited VBN 1_p
participation NN 1_p
in IN 1_p
education NN 1_p
, , 1_p
sports NNS 1_p
, , 1_p
and CC 1_p
leisure NN 1_p
activities NNS 1_p
. . 1_p

During IN N
and CC N
following VBG N
cancer NN N
treatment NN N
, , N
children NNS 1_p
describe VBP N
school NN N
related VBN N
problems NNS N
, , N
reduced VBD N
physical JJ N
fitness NN N
, , N
and CC N
problems NNS N
related VBN N
to TO N
interaction NN N
with IN N
peers NNS N
. . N

METHODS/DESIGN NNP N
The DT N
RESPECT NNP N
study NN N
is VBZ N
a DT N
nationwide JJ 1_p
population-based JJ N
prospective NN N
, , N
controlled VBN N
, , N
mixed-methods NNS N
intervention NN N
study NN N
looking VBG N
at IN N
children NNS 1_p
aged VBN 1_p
6-18 CD 1_p
years NNS 1_p
newly RB 1_p
diagnosed VBN 1_p
with IN 1_p
cancer NN 1_p
in IN 1_p
eastern JJ 1_p
Denmark NNP 1_p
( ( 1_p
n=120 NN 1_p
) ) 1_p
and CC 1_p
a DT 1_p
matched JJ 1_p
control NN 1_p
group NN 1_p
in IN 1_p
western JJ 1_p
Denmark NNP 1_p
( ( 1_p
n=120 NN 1_p
) ) 1_p
. . 1_p

RESPECT NNP N
includes VBZ 1_p
Danish-speaking NNP 1_p
children NNS 1_p
diagnosed VBD 1_p
with IN 1_p
cancer NN 1_p
and CC 1_p
treated VBN 1_p
at IN 1_p
pediatric JJ 1_p
oncology NN 1_p
units NNS 1_p
in IN 1_p
Denmark NNP 1_p
. . 1_p

Primary JJ N
endpoints NNS N
are VBP N
the DT N
level NN 1_o
of IN 1_o
educational JJ 1_o
achievement NN 1_o
one CD 1_o
year NN 1_o
after IN 1_o
the DT 1_o
cessation NN 1_o
of IN 1_o
first-line JJ 1_o
cancer NN 1_o
therapy NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
value NN 1_o
of IN 1_o
VO2max NNP 1_o
one CD 1_o
year NN 1_o
after IN 1_o
the DT 1_o
cessation NN 1_o
of IN 1_o
first-line JJ 1_o
cancer NN 1_o
therapy NN 1_o
. . 1_o

Secondary JJ N
endpoints NNS N
are VBP N
quality NN 1_o
of IN 1_o
life NN 1_o
measured VBN 1_o
by IN 1_o
validated JJ 1_o
questionnaires NNS 1_o
and CC 1_o
interviews NNS 1_o
, , 1_o
and CC 1_o
physical JJ 1_o
performance NN 1_o
. . 1_o

RESPECT NNP N
includes VBZ N
a DT N
multimodal JJ 1_i
intervention NN 1_i
program NN 1_i
, , 1_i
including VBG 1_i
ambassador-facilitated JJ 1_i
educational JJ 1_i
, , 1_i
physical JJ 1_i
, , 1_i
and CC 1_i
social JJ 1_i
interventions NNS 1_i
. . 1_i

The DT N
educational JJ 1_i
intervention NN 1_i
includes VBZ N
an DT N
educational JJ 1_i
program NN 1_i
aimed VBN N
at IN N
the DT N
child NN 1_p
with IN 1_p
cancer NN 1_p
, , N
the DT N
child NN N
's POS N
schoolteachers NNS N
and CC N
classmates NNS N
, , N
and CC N
the DT N
child NN N
's POS N
parents NNS N
. . N

Children NNP 1_p
with IN 1_p
cancer NN 1_p
will MD N
each DT N
have VB N
two CD N
ambassadors NNS N
assigned VBD N
from IN N
their PRP$ N
class NN N
. . N

The DT N
ambassadors NNS N
visit VBP 1_i
the DT 1_i
child NN 1_i
with IN 1_i
cancer NN 1_i
at IN N
the DT N
hospital NN N
at IN N
alternating VBG N
2-week JJ N
intervals NNS N
and CC 1_i
participate VB 1_i
in IN 1_i
the DT 1_i
intervention NN 1_i
program NN 1_i
. . 1_i

The DT N
physical JJ 1_i
and CC 1_i
social JJ 1_i
intervention NN 1_i
examines VBZ N
the DT N
effect NN N
of IN N
early JJ N
, , N
structured VBN N
, , N
individualized VBN N
, , N
and CC N
continuous JJ N
physical JJ N
activity NN N
from IN N
diagnosis NN N
throughout IN N
the DT N
treatment NN N
period NN N
. . N

The DT N
patients NNS 1_p
are VBP N
tested VBN N
at IN N
diagnosis NN N
, , N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
diagnosis NN N
, , N
and CC N
one CD N
year NN N
after IN N
the DT N
cessation NN N
of IN N
treatment NN N
. . N

The DT N
study NN N
is VBZ N
powered VBN N
to TO N
quantify VB N
the DT N
impact NN N
of IN N
the DT N
combined JJ N
educational JJ 1_i
, , 1_i
physical JJ 1_i
, , 1_i
and CC 1_i
social JJ 1_i
intervention NN 1_i
programs NNS 1_i
. . 1_i

DISCUSSION NNP N
RESPECT NNP N
is VBZ N
the DT N
first JJ N
population-based JJ N
study NN N
to TO N
examine VB N
the DT N
effect NN N
of IN N
early JJ N
rehabilitation NN N
for IN N
children NNS N
with IN N
cancer NN N
, , N
and CC N
to TO N
use VB N
healthy JJ N
classmates NNS 1_i
as IN 1_i
ambassadors NNS 1_i
to TO N
facilitate VB N
the DT N
normalization NN N
of IN N
social JJ N
life NN N
in IN N
the DT N
hospital NN N
. . N

For IN N
children NNS 1_p
with IN 1_p
cancer NN 1_p
, , N
RESPECT NNP N
contributes VBZ N
to TO N
expanding VBG N
knowledge NN N
on IN N
rehabilitation NN N
that WDT N
can MD N
also RB N
facilitate VB N
rehabilitation NN N
of IN N
other JJ N
children NNS N
undergoing VBG N
hospitalization NN N
for IN N
long-term JJ N
illness NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials.gov NNP N
: : N
file NN N
. . N

NCT01772849 NNP N
and CC N
NCT01772862 NNP N
. . N

The DT N
need NN N
for IN N
chemotherapy NN 1_i
after IN N
prolonged JJ 1_p
complete JJ 1_p
remission NN 1_p
in IN 1_p
acute JJ 1_p
leukemia NN 1_p
of IN 1_p
childhood NN 1_p
. . 1_p

Two CD N
randomized JJ N
studies NNS N
demonstrate VBP N
the DT N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
dapsone NN 1_i
gel NN 1_i
, , N
5 CD N
% NN N
for IN N
the DT N
treatment NN N
of IN N
acne JJ 1_p
vulgaris NN 1_p
. . 1_p

BACKGROUND VB N
A DT N
new JJ N
aqueous JJ N
gel JJ N
formulation NN N
of IN N
dapsone NN 1_i
has VBZ N
been VBN N
developed VBN N
that IN N
allows VBZ N
clinically-effective JJ N
doses NNS N
of IN N
dapsone NN 1_i
to TO N
be VB N
administered VBN N
topically RB N
with IN N
minimal JJ N
systemic JJ N
absorption NN N
. . N

OBJECTIVES CC N
The DT N
goal NN N
of IN N
these DT N
studies NNS N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
dapsone NN 1_i
gel NN 1_i
, , N
5 CD N
% NN N
in IN N
the DT N
treatment NN N
of IN N
acne NN N
. . N

METHODS NNP N
Patients NNPS 1_p
12 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC 1_p
older JJR 1_p
with IN 1_p
acne JJ 1_p
vulgaris NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
3010 CD 1_p
) ) 1_p
participated VBN 1_p
in IN N
two CD N
identically-designed JJ N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
studies NNS N
of IN N
twice-daily JJ N
monotherapy NN 1_i
with IN 1_i
dapsone NN 1_i
gel NN 1_i
, , 1_i
5 CD 1_i
% NN 1_i
, , N
versus IN N
a DT N
vehicle NN 1_i
gel NN 1_i
. . 1_i

RESULTS NNP N
Dapsone NNP 1_i
gel-treated JJ 1_i
patients NNS N
achieved VBN N
superior JJ N
results NNS N
in IN N
terms NNS N
of IN N
the DT N
investigator NN 1_o
's POS 1_o
global JJ 1_o
acne NN 1_o
assessment NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
the DT N
mean JJ N
percentage NN N
reduction NN 1_o
in IN 1_o
inflammatory NN 1_o
, , 1_o
noninflammatory NN 1_o
, , 1_o
and CC 1_o
total JJ 1_o
lesion NN 1_o
counts NNS 1_o
( ( N
all DT N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
week NN N
12 CD N
. . N

Reductions NNS N
in IN N
inflammatory JJ 1_o
lesion NN 1_o
counts NNS 1_o
favoring VBG N
dapsone NN 1_i
gel NN 1_i
over IN N
vehicle NN N
were VBD N
apparent JJ N
as RB N
early RB N
as IN N
2 CD N
weeks NNS N
and CC N
reached VBD N
statistical JJ N
significance NN N
by IN N
4 CD N
weeks NNS N
. . N

No DT N
clinically RB N
significant JJ N
changes NNS N
in IN N
laboratory NN N
parameters NNS N
, , N
including VBG N
hemoglobin NN 1_o
, , N
even RB N
among IN N
glucose-6-phosphate JJ N
dehydrogenase-deficient JJ N
patients NNS N
, , N
were VBD N
observed VBN N
. . N

Adverse JJ 1_o
events NNS 1_o
were VBD N
comparable JJ N
between IN N
the DT N
treatment NN N
groups NNS N
and CC N
rarely RB N
led VBD N
to TO N
discontinuation NN N
. . N

LIMITATIONS NNP N
Adjunctive NNP N
topical JJ N
treatments NNS N
and CC N
their PRP$ N
impact NN N
on IN N
acne NNS N
were VBD N
not RB N
studied VBN N
in IN N
this DT N
trial NN N
. . N

CONCLUSIONS NNP N
Dapsone NNP 1_i
gel NN 1_i
, , N
5 CD N
% NN N
appears VBZ N
to TO N
be VB N
an DT N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
acne JJ 1_o
vulgaris NN 1_o
, , N
with IN N
a DT N
rapid JJ N
onset NN N
of IN N
action NN N
. . N

Antifibrinolytic JJ 1_i
therapy NN 1_i
for IN N
prevention NN N
of IN N
hemorrhage NN N
during IN N
surgery NN 1_p
of IN 1_p
the DT 1_p
thyroid JJ 1_p
gland NN 1_p
. . 1_p

The DT N
amount NN N
of IN N
fibrinolytic JJ N
activity NN N
in IN N
the DT N
thyroid JJ N
gland NN N
equals NNS N
that WDT N
of IN N
the DT N
prostate NN N
. . N

In IN N
order NN N
to TO N
examine VB N
the DT N
effect NN N
of IN N
the DT N
antifibrinolytic JJ 1_i
drug NN 1_i
tranexemic JJ 1_i
acid NN 1_i
on IN N
perioperative JJ 1_o
bleeding NN 1_o
saline NN 1_i
or CC N
tranexemic JJ 1_i
acid NN 1_i
were VBD N
given VBN N
randomized VBN N
double JJ N
blind NN N
to TO N
76 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
who WP 1_p
came VBD 1_p
for IN 1_p
scheduled VBN 1_p
thyroid NN 1_p
surgery NN 1_p
. . 1_p

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
perioperative JJ 1_o
bleeding NN 1_o
between IN N
patients NNS 1_p
in IN 1_p
the DT 1_p
treatment NN 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
39 CD 1_p
) ) 1_p
and CC 1_p
control NN 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
37 CD 1_p
) ) 1_p
. . N

The DT N
gastric JJ 1_o
emptying NN 1_o
and CC 1_o
small JJ 1_o
intestinal JJ 1_o
transit NN 1_o
after IN N
highly RB 1_p
selective JJ 1_p
vagotomy NN 1_p
without IN 1_p
drainage NN 1_p
and CC 1_p
selective JJ 1_p
vagotomy NN 1_p
with IN 1_p
pyloroplasty NN 1_p
. . 1_p

Metabolic JJ N
responses NNS N
to TO N
oral JJ 1_i
surgery NN 1_i
under IN N
local JJ 1_i
anesthesia NN 1_i
and CC N
sedation NN N
with IN N
intravenous JJ N
midazolam NNS 1_i
: : 1_i
the DT N
effects NNS N
of IN N
two CD N
different JJ N
local JJ 1_i
anesthetics NNS 1_i
. . 1_i

The DT N
effects NNS N
of IN N
epinephrine-free JJ 1_i
and CC 1_i
epinephrine-containing JJ 1_i
local JJ 1_i
anesthetic JJ 1_i
solutions NNS N
on IN N
plasma NN 1_o
potassium NN 1_o
and CC 1_o
blood NN 1_o
glucose JJ 1_o
concentrations NNS 1_o
were VBD N
investigated VBN N
in IN N
20 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
oral JJ 1_p
surgery NN 1_p
with IN 1_p
intravenous JJ 1_p
midazolam NNS 1_i
sedation NN 1_p
. . 1_p

Ten CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
4.4 CD 1_i
mL NN 1_i
of IN 1_i
2 CD 1_i
% NN 1_i
lidocaine NN 1_i
with IN 1_i
1:80,000 CD 1_i
epinephrine NN 1_i
as IN 1_i
a DT 1_i
local JJ 1_i
anesthetic NN 1_i
and CC 1_i
10 CD 1_i
were VBD 1_i
given VBN 1_i
4.4 CD 1_i
mL NN 1_i
of IN 1_i
3 CD 1_i
% NN 1_i
prilocaine NN 1_i
with IN 1_i
0.03 CD 1_i
IU/mL NNP 1_i
felypressin NN 1_i
. . 1_i

There EX N
were VBD N
significant JJ N
changes NNS N
from IN N
baseline NN N
potassium NN 1_o
and CC 1_o
glucose JJ 1_o
concentrations NNS 1_o
both DT N
within IN N
and CC N
between IN N
treatments NNS N
in IN N
the DT N
early JJ N
postinjection NN N
period NN N
. . N

The DT N
epinephrine-containing JJ N
local JJ N
anesthetic NN N
significantly RB N
reduced VBD N
the DT N
plasma NN 1_o
potassium NN 1_o
concentration NN 1_o
10 CD 1_o
min NN 1_o
after IN 1_o
injection NN 1_o
, , N
by IN N
0.16 CD N
+/- JJ N
0.20 CD N
mmol/L NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
and CC N
increased VBD N
the DT N
blood NN 1_o
glucose JJ 1_o
concentration NN 1_o
at IN N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
min NN N
( ( N
by IN N
0.46 CD N
+/- JJ N
0.37 CD N
, , N
0.63 CD N
+/- JJ N
0.45 CD N
, , N
and CC N
0.56 CD N
+/- JJ N
0.28 CD N
mmol/L NN N
, , N
respectively RB N
) ) N
. . N

Conversely RB N
, , N
plasma JJ 1_o
potassium NN 1_o
increased VBD N
and CC N
blood NN 1_o
glucose NN 1_o
decreased VBD N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
min NN N
following VBG N
the DT N
administration NN N
of IN N
the DT N
epinephrine-free JJ 1_i
solution NN 1_i
. . 1_i

At IN N
30 CD 1_o
min NN 1_o
potassium NN 1_o
was VBD N
increased VBN N
by IN N
0.24 CD N
+/- JJ N
0.16 CD N
mmol/L NN N
, , N
and CC N
glucose NN 1_o
was VBD N
decreased VBN N
by IN N
0.23 CD N
+/- JJ N
0.16 CD N
mmol/L NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
epinephrine-free JJ 1_i
and CC N
epinephrine-containing JJ 1_i
local JJ 1_i
anesthetics NNS 1_i
differ VBP N
in IN N
their PRP$ N
metabolic JJ N
effects NNS N
during IN N
oral JJ N
surgery NN N
with IN N
midazolam JJ 1_i
sedation NN 1_i
. . 1_i

A DT N
step-by-step JJ N
introduction NN N
to TO N
vegetables NNS 1_i
at IN N
the DT N
beginning NN N
of IN N
complementary JJ N
feeding NN N
. . N

The DT N
effects NNS N
of IN N
early JJ N
and CC N
repeated JJ N
exposure NN N
. . N

Breastfeeding NNP 1_p
( ( 1_p
BF NNP 1_p
) ) 1_p
is VBZ N
associated VBN N
with IN N
willingness NN N
to TO N
accept VB N
vegetables NNS N
. . N

This DT N
may MD N
be VB N
due JJ N
to TO N
the DT N
variety NN N
of IN N
flavours NNS N
delivered VBN N
via IN N
breast NN N
milk NN N
. . N

Some DT N
mothers NNS 1_p
add VBP N
vegetables NNS N
to TO N
milk VB N
during IN N
complementary JJ N
feeding NN N
( ( N
CF NNP N
) ) N
to TO N
enhance VB N
acceptance NN N
. . N

The DT N
present JJ N
study NN N
tested VBD N
a DT N
step-by-step JJ N
exposure NN N
to TO N
vegetables NNS 1_i
in IN 1_i
milk NN 1_i
then RB 1_i
rice NN 1_i
during IN N
CF NNP N
, , N
on IN N
intake NN N
and CC N
liking NN N
of IN N
vegetables NNS N
. . N

Just NNP N
before IN N
CF NNP N
, , N
enrolled VBD 1_p
mothers NNS 1_p
were VBD 1_p
randomised VBN 1_p
to TO 1_p
an DT 1_p
intervention NN 1_p
( ( 1_p
IG NNP 1_p
, , 1_p
n JJ 1_p
= VBP 1_p
18 CD 1_p
; : 1_p
6 CD 1_p
BF NNP 1_p
) ) 1_p
or CC 1_p
control VB 1_p
group NN 1_p
( ( 1_p
CG NNP 1_p
, , 1_p
n JJ 1_p
= VBP 1_p
18 CD 1_p
; : 1_p
6 CD 1_p
BF NNP 1_p
) ) 1_p
. . 1_p

IG JJ 1_p
infants NNS N
received VBD N
12 CD N
daily JJ N
exposures NNS 1_i
to TO 1_i
vegetable JJ 1_i
puree NN 1_i
added VBD 1_i
to TO N
milk VB N
( ( N
days NNS N
1-12 RB N
) ) N
, , N
then RB N
12 CD N
× NNS N
2 CD N
daily JJ N
exposures NNS 1_i
to TO 1_i
vegetable JJ 1_i
puree NN 1_i
added VBD 1_i
to TO 1_i
rice VB N
at IN N
home NN N
( ( 1_i
days NNS 1_i
13-24 RB 1_i
) ) 1_i
. . 1_i

Plain NNP 1_i
milk NN 1_i
and CC N
rice NN N
were VBD N
given VBN N
to TO N
CG NNP N
. . N

Then RB N
both DT N
received VBD N
11 CD N
daily JJ N
exposures NNS 1_i
to TO 1_i
vegetable JJ 1_i
puree NN N
. . N

Intake NNP N
was VBD N
weighed VBN N
and CC N
liking VBG N
rated VBN N
on IN N
days NNS N
25-26 JJ N
and CC N
33-35 JJ N
after IN N
the DT N
start NN N
of IN N
CF NNP N
in IN N
the DT N
laboratory NN N
, , N
supplemented VBN N
by IN N
the DT N
same JJ N
data NN N
recorded VBD N
at IN N
home NN N
. . N

Vegetables NNS N
were VBD N
rotated VBN N
daily RB N
( ( N
carrots NNS N
, , N
green JJ N
beans NNS N
, , N
spinach NN 1_o
, , 1_o
broccoli NN 1_o
) ) 1_o
. . 1_o

Intake NNP 1_o
, , 1_o
liking VBG 1_o
and CC 1_o
pace NN 1_o
of IN N
eating VBG N
were VBD N
greater JJR N
for IN N
IG NNP N
than IN 1_o
CG NNP 1_o
infants NNS 1_o
. . 1_o

Intake NNP 1_o
and CC 1_o
liking NN 1_o
of IN N
carrots NNS N
were VBD N
greater JJR N
than IN N
green JJ N
beans NNS N
. . N

However RB N
, , N
at IN N
6m CD N
then RB N
18m CD N
follow VBP N
up RB N
, , N
vegetable JJ N
( ( N
carrot JJ N
> NN N
green JJ N
beans NNS N
) ) N
but CC N
not RB N
group NN N
differences NNS 1_p
were VBD 1_p
observed VBN 1_p
. . N

Mothers NNS N
reported VBD N
appreciation NN N
of IN N
the DT N
structure NN N
and CC N
guidance NN N
of IN N
this DT N
systematic JJ N
approach NN N
. . N

Early JJ 1_i
exposure NN 1_i
to TO N
vegetables NNS N
in IN N
a DT N
step-by-step JJ N
method NN N
could MD N
be VB N
included VBN N
in IN N
CF NNP N
guidelines NNS N
and CC N
longer JJR N
term NN N
benefits NNS N
assessed VBN N
by IN N
extending VBG N
the DT N
exposure NN N
period NN N
. . N

Minimal NNP 1_i
clinically RB 1_i
important JJ 1_i
change NN 1_i
for IN N
pain NN 1_o
intensity NN 1_o
, , 1_o
functional JJ 1_o
status NN 1_o
, , N
and CC N
general JJ N
health NN 1_o
status NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
nonspecific JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
Cohort NNP N
study NN N
. . N

OBJECTIVES NNP N
To TO N
estimate VB N
the DT N
Minimal NNP 1_o
Clinically NNP 1_o
Important NNP 1_o
Change NNP 1_o
( ( 1_o
MCIC NNP 1_o
) ) 1_o
of IN N
the DT N
pain NN 1_o
intensity NN 1_o
numerical JJ 1_o
rating NN 1_o
scale NN 1_o
( ( 1_o
PI-NRS NNP 1_o
) ) 1_o
, , N
the DT N
Quebec NNP 1_o
Back NNP 1_o
Pain NNP 1_o
Disability NNP 1_o
Scale NNP 1_o
( ( 1_o
QBPDS NNP 1_o
) ) 1_o
, , N
and CC N
the DT N
Euroqol NNP 1_o
( ( 1_o
EQ NNP 1_o
) ) 1_o
in IN N
patients NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
MCIC NNP N
can MD N
provide VB N
valuable JJ N
information NN N
for IN N
researchers NNS N
, , N
healthcare NN N
providers NNS N
, , N
and CC N
policymakers NNS N
. . N

METHODS NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
with IN N
442 CD 1_p
patients NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
were VBD 1_p
used VBN 1_p
. . 1_p

The DT N
MCIC NNP 1_i
was VBD N
estimated VBN N
over IN N
a DT N
12-week JJ N
period NN N
, , N
and CC N
three CD N
different JJ N
methods NNS N
were VBD N
used VBN N
: : N
1 CD N
) ) N
mean NN N
change NN N
scores NNS N
, , N
2 CD N
) ) N
minimal NN N
detectable JJ N
change NN N
, , N
and CC N
3 CD N
) ) N
optimal VBD N
cutoff NN N
point NN N
in IN N
receiver NN N
operant JJ N
curves NNS N
. . N

The DT N
global JJ N
perceived JJ N
effect NN N
scale NN N
( ( N
GPE NNP N
) ) N
was VBD N
used VBN N
as IN N
an DT N
external JJ N
criterion NN N
. . N

The DT N
effect NN N
of IN N
initial JJ N
scores NNS N
on IN N
the DT N
MCIC NNP 1_i
was VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
The DT N
MCIC NNP 1_o
of IN N
the DT N
PI-NRS NNP N
ranged VBD N
from IN N
3.5 CD N
to TO N
4.7 CD N
points NNS N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
2.5 CD N
to TO N
4.5 CD N
points NNS N
in IN N
chronic JJ N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
. . N

The DT N
MCIC NNP 1_o
of IN 1_o
the DT 1_o
QBPDS NNP 1_o
was VBD N
estimated VBN N
between IN N
17.5 CD N
to TO N
32.9 CD N
points NNS N
and CC N
8.5 CD N
to TO N
24.6 CD N
points NNS N
for IN N
( ( 1_p
sub NN 1_p
) ) 1_p
acute NN 1_p
and CC 1_p
chronic JJ 1_p
patients NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

The DT N
MCIC NNP 1_o
for IN 1_o
the DT 1_o
EQ NNP 1_o
ranged VBD N
from IN N
0.07 CD N
to TO N
0.58 CD N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
0.09 CD N
to TO N
0.28 CD N
in IN N
patients NNS N
with IN N
chronic JJ N
low JJ N
back RB N
pain NN N
. . N

CONCLUSION NNP N
Reporting VBG N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
have VBP N
made VBN N
a DT N
MCIC NNP 1_i
adds VBZ N
to TO N
the DT N
interpretability NN N
of IN N
study NN N
results NNS N
. . N

We PRP N
present VBD N
a DT N
range NN N
of IN N
MCIC NNP 1_i
values NNS N
and CC N
advocate VB N
the DT N
choice NN N
of IN N
a DT N
single JJ N
MCIC NNP 1_i
value NN N
according VBG N
to TO N
the DT N
specific JJ N
context NN N
. . N

Central NNP N
nervous JJ N
system NN N
serotonin JJ N
function NN N
and CC N
cardiovascular JJ 1_o
responses NNS 1_o
to TO N
stress VB N
. . N

OBJECTIVE VB N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
indices NNS N
of IN N
central JJ N
nervous JJ N
system NN N
( ( N
CNS NNP N
) ) N
serotonin NN N
function NN N
on IN N
cardiovascular JJ 1_o
reactivity NN 1_o
to TO N
mental JJ N
stress NN N
. . N

METHODS NNP N
Lumbar NNP 1_i
puncture NN 1_i
was VBD N
performed VBN N
on IN N
54 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
to TO 1_p
obtain VB N
cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
for IN N
determination NN N
of IN N
5-hydroxyindoleacetic JJ N
acid NN N
( ( N
5HIAA CD N
) ) N
levels NNS N
. . N

Genotypes NNS N
were VBD N
determined VBN N
with IN N
respect NN N
to TO N
a DT N
functional JJ N
polymorphism NN N
of IN N
the DT N
serotonin NN N
transporter NN N
gene NN N
promoter NN N
region NN N
( ( N
5HTTLPR CD N
) ) N
. . N

Subjects NNS N
then RB N
underwent JJ N
mental JJ N
stress NN N
testing VBG N
. . N

RESULTS JJ N
Persons NNPS 1_p
with IN 1_p
one CD 1_p
or CC 1_p
two CD 1_p
long JJ 1_p
( ( 1_p
l NN 1_p
) ) 1_p
5HTTLPR CD 1_p
alleles NNS 1_p
had VBD N
CSF NNP 1_o
levels NNS 1_o
of IN N
the DT N
major JJ N
serotonin NN N
metabolite NN N
, , N
5HIAA CD N
, , N
that WDT N
were VBD N
50 CD N
% NN N
higher JJR N
than IN N
those DT N
of IN N
persons NNS N
with IN N
the DT N
s/s NN N
5HTTLPR CD 1_p
genotype NN 1_p
. . 1_p

Persons NNS N
with IN N
one CD N
or CC N
two CD N
l JJ N
alleles NNS N
or CC N
higher JJR N
CSF NNP 1_o
5HIAA CD 1_o
levels NNS 1_o
also RB N
exhibited VBD N
greater JJR N
blood NN 1_o
pressure NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
responses NNS 1_o
to TO N
a DT N
mental JJ N
stress NN N
protocol NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
the DT N
5HTTLPR CD N
polymorphism NN N
affects NNS N
CNS NNP N
serotonin NN N
function NN N
, , N
and CC N
they PRP N
are VBP N
consistent JJ N
with IN N
the DT N
general JJ N
hypothesis NN N
that WDT N
CNS NNP N
serotonin NN N
function NN N
is VBZ N
involved VBN N
in IN N
the DT N
regulation NN N
of IN N
potentially RB N
health-damaging JJ N
biobehavioral JJ N
characteristics NNS N
. . N

In IN N
particular JJ N
, , N
the DT N
l NN N
allele NN N
could MD N
contribute VB N
, , N
through IN N
its PRP$ N
association NN N
with IN N
increased JJ N
cardiovascular JJ 1_o
reactivity NN 1_o
to TO N
stress VB N
, , N
to TO N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

Clinically RB N
relevant JJ N
improvement NN N
of IN N
recurrence-free JJ 1_o
survival NN 1_o
with IN N
5-aminolevulinic JJ 1_i
acid NN 1_i
induced VBD N
fluorescence NN N
diagnosis NN N
in IN N
patients NNS 1_p
with IN 1_p
superficial JJ 1_p
bladder NN 1_p
tumors NNS 1_p
. . 1_p

PURPOSES NNP N
Fluorescence NNP N
diagnosis NN N
induced VBN N
by IN N
5-aminolevulinic JJ 1_i
acid NN 1_i
enables VBZ N
more RBR N
thorough JJ N
transurethral JJ N
resection NN N
of IN N
superficial JJ 1_p
bladder NN 1_p
carcinoma NNS 1_p
compared VBN N
with IN N
conventional JJ N
white JJ N
light NN N
. . N

We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
single JJ N
institution NN N
, , N
randomized VBN N
trial NN N
to TO N
investigate VB N
whether IN N
the DT N
residual JJ N
tumor NN N
rate NN N
and CC N
long-term JJ N
tumor NN N
recurrence NN N
can MD N
be VB N
decreased VBN N
by IN N
fluorescence NN 1_i
diagnosis NN 1_i
. . 1_i

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
301 CD 1_p
patients NNS 1_p
underwent JJ 1_p
transurethral JJ 1_i
resection NN 1_i
of IN 1_p
bladder NN 1_p
tumors NNS 1_p
with IN 1_p
white JJ 1_i
light NN 1_i
or CC 1_i
fluorescence NN 1_i
diagnosis NN 1_i
. . 1_i

Transurethral JJ 1_i
resection NN 1_i
was VBD N
repeated VBN N
5 CD N
to TO N
6 CD N
weeks NNS N
later RB N
to TO N
evaluate VB N
the DT N
residual JJ N
tumor NN N
rate NN N
. . N

To TO N
determine VB N
recurrence-free JJ 1_o
survival JJ 1_o
patient NN N
followup NN N
was VBD N
performed VBN N
every DT N
3 CD N
months NNS N
by IN N
white JJ 1_i
light JJ 1_i
cystoscopy NN 1_i
and CC N
urine JJ 1_i
cytology NN 1_i
. . 1_i

Recurrence-free JJ 1_o
survival NN 1_o
was VBD N
analyzed VBN N
via IN N
Kaplan-Meier NNP N
methods NNS N
and CC N
multivariable JJ N
Cox NNP N
regression NN N
analysis NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
191 CD 1_p
patients NNS 1_p
with IN 1_p
superficial JJ 1_p
bladder NN 1_p
carcinoma NN 1_p
were VBD 1_p
available JJ 1_p
for IN N
efficacy NN N
analysis NN N
. . N

The DT N
residual JJ 1_o
tumor NN 1_o
rate NN 1_o
was VBD N
25.2 CD N
% NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
versus NN N
4.5 CD N
% NN N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Median JJ N
followup NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
in IN N
103 CD N
cases NNS N
was VBD N
21.2 CD N
months NNS N
( ( N
range VB N
4 CD N
to TO N
40 CD N
) ) N
compared VBN N
with IN N
20.5 CD N
( ( N
range NN N
3 CD N
to TO N
40 CD N
) ) N
in IN N
the DT N
88 CD N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
. . N

Recurrence-free JJ 1_o
survival NN 1_o
in IN N
the DT N
fluorescence NN N
diagnosis NN N
group NN N
was VBD N
89.6 CD N
% NN N
after IN N
12 CD N
and CC N
24 CD N
months NNS N
compared VBN N
with IN N
73.8 CD N
% NN N
and CC N
65.9 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
white JJ N
light NN N
group NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

This DT N
superiority NN N
proved VBD N
to TO N
be VB N
independent JJ N
of IN N
risk NN N
group NN N
. . N

The DT N
adjusted JJ 1_o
hazard NN 1_o
ratio NN 1_o
of IN 1_o
fluorescence NN 1_o
diagnosis NN 1_o
versus IN 1_o
white JJ 1_o
light JJ 1_o
transurethral JJ 1_o
resection NN 1_o
was VBD N
0.33 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
0.16 CD N
to TO N
0.67 CD N
) ) N
. . N

CONCLUSIONS NNP N
Fluorescence NNP N
diagnosis NN N
is VBZ N
significantly RB N
superior JJ N
to TO N
conventional JJ N
white JJ N
light JJ N
transurethral JJ N
resection NN N
with IN N
respect NN N
to TO N
the DT N
residual JJ 1_o
tumor NN 1_o
rate NN 1_o
and CC 1_o
recurrence-free JJ 1_o
survival NN 1_o
. . 1_o

The DT N
differences NNS N
in IN N
recurrence-free JJ 1_o
survival NN 1_o
imply NN N
that WDT N
fluorescence NN N
diagnosis NN N
is VBZ N
a DT N
clinically RB N
relevant JJ N
procedure NN N
for IN N
decreasing VBG N
the DT N
number NN 1_o
of IN 1_o
tumor NN 1_o
recurrences NNS 1_o
. . 1_o

Children NNP 1_p
with IN 1_p
persistent JJ 1_p
conduct NN 1_p
problems NNS 1_p
who WP 1_p
dropout VBP 1_p
of IN 1_p
treatment NN 1_p
. . 1_p

Dropout NNP 1_o
of IN N
treatment NN N
is VBZ N
one CD N
of IN N
the DT N
key JJ N
issues NNS N
in IN N
outcome NN N
in IN N
a DT N
child NN 1_p
and CC 1_p
adolescent JJ 1_p
mental JJ 1_p
health NN 1_p
service NN 1_p
. . 1_p

We PRP N
report VBP N
two CD N
studies NNS N
focusing VBG N
on IN N
the DT N
treatment NN N
process NN N
and CC N
the DT N
dropout NN 1_o
rate NN 1_o
of IN 1_o
children NNS 1_o
with IN 1_p
persistent JJ 1_p
conduct NN 1_p
problems NNS 1_p
presenting VBG 1_p
to TO 1_p
a DT 1_p
community NN 1_p
mental JJ 1_p
health NN 1_p
service NN 1_p
, , N
using VBG N
a DT N
prospective JJ N
design NN N
. . N

The DT N
first JJ 1_p
study NN 1_p
included VBD 1_p
32 CD 1_p
children NNS 1_p
and CC N
used VBD N
a DT N
randomised JJ N
controlled JJ N
treatment NN N
design NN N
comparing VBG N
a DT N
CBT NNP 1_i
approach NN 1_i
with IN 1_i
conjoint JJ 1_i
family NN 1_i
therapy NN 1_i
and CC 1_i
an DT 1_i
eclectic JJ 1_i
approach NN 1_i
. . 1_i

The DT N
overall JJ 1_o
dropout NN 1_o
rate NN 1_o
was VBD N
36 CD N
% NN N
. . N

Dropout NN 1_o
occurred VBD N
significantly RB N
less RBR N
frequently RB N
in IN N
the DT N
CBT NNP 1_i
group NN N
. . N

The DT N
dropout NN N
group NN N
was VBD N
associated VBN N
with IN N
mothers NNS 1_p
who WP 1_p
were VBD 1_p
younger JJR 1_o
and CC 1_o
less RBR 1_o
educated VBN 1_o
, , N
a DT N
poorer NN 1_o
rating NN 1_o
by IN 1_o
the DT 1_o
clinicians NNS 1_o
at IN N
the DT N
last JJ N
meeting NN N
, , N
parental JJ 1_o
dissatisfaction NN 1_o
with IN 1_o
the DT 1_o
treatment NN 1_o
service NN 1_o
and CC N
perception NN 1_o
that IN 1_o
the DT 1_o
treatment NN 1_o
was VBD N
less JJR N
organised JJ N
and CC N
having VBG N
less JJR N
behavioural JJ N
tasks NNS N
. . N

In IN N
the DT N
second JJ N
study NN N
we PRP N
used VBD N
a DT N
naturalistic JJ 1_i
follow-up JJ 1_i
design NN 1_i
. . 1_i

Forty-six JJ 1_p
children NNS 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

The DT N
overall JJ 1_o
dropout NN 1_o
rate NN 1_o
was VBD N
48 CD N
% NN N
. . N

Again NNP N
, , N
the DT N
children NNS 1_p
who WP 1_p
defaulted VBD 1_p
were VBD N
rated VBN N
by IN N
clinicians NNS N
as IN N
less RBR N
likely JJ N
to TO N
have VB N
improved VBN N
and CC N
dropout NN N
was VBD N
also RB N
significantly RB N
associated VBN N
with IN N
parental JJ 1_o
perception NN 1_o
of IN 1_o
a DT 1_o
less RBR 1_o
organised JJ 1_o
treatment NN 1_o
. . 1_o

In IN N
both DT N
studies NNS N
dropout VBP 1_o
usually RB N
occurred VBN N
after IN N
assessment NN N
and CC N
at IN N
the DT N
early JJ N
phase NN N
of IN N
treatment NN N
. . N

Outcomes NNS N
and CC N
biochemical JJ N
parameters NNS N
following VBG N
cardiac JJ 1_i
surgery NN 1_i
: : 1_i
effects NNS N
of IN N
transfusion NN 1_i
of IN 1_i
residual JJ 1_i
blood NN 1_i
using VBG N
centrifugation NN 1_i
and CC 1_i
multiple-pass NN 1_i
hemoconcentration NN 1_i
. . 1_i

OBJECTIVES UH N
To TO N
determine VB N
whether IN N
or CC N
not RB N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
methods NNS 1_i
of IN 1_i
centrifugation NN 1_i
( ( 1_i
CF NNP 1_i
) ) 1_i
and CC 1_i
multiple-pass JJ 1_i
hemoconcentration NN 1_i
( ( 1_i
MPH NNP 1_i
) ) 1_i
of IN N
the DT N
residual JJ N
cardiopulmonary-bypass NN N
volume NN N
in IN N
relation NN N
to TO N
biochemical JJ N
measurements NNS N
and CC N
patient JJ N
outcomes NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBN N
, , N
and CC N
controlled VBD N
. . N

SETTING NN N
Conducted VBN N
at IN N
a DT 1_p
western JJ 1_p
Canadian JJ 1_p
tertiary NN 1_p
care NN 1_p
hospital NN 1_p
. . 1_p

PARTICIPANTS NNP N
Consisted NNP 1_p
of IN 1_p
61 CD 1_p
consecutive JJ 1_p
male NN 1_p
and CC 1_p
female JJ 1_p
patients NNS 1_p
from IN 1_p
ages NNS 1_p
40 CD 1_p
to TO 1_p
80 CD 1_p
who WP 1_p
were VBD 1_p
scheduled VBN 1_p
for IN 1_p
cardiac JJ 1_i
surgery NN 1_i
with IN 1_p
cardiopulmonary JJ 1_i
bypass NN 1_i
. . 1_i

INTERVENTIONS NNP N
Either CC N
the DT N
centrifugation NN 1_i
or CC 1_i
multiple-pass NN 1_i
hemoconcentration NN 1_i
method NN 1_i
was VBD N
used VBN N
to TO N
process VB N
the DT N
residual JJ N
blood NN N
from IN N
the DT N
cardiopulmonary JJ N
bypass NN N
circuit NN N
. . N

RESULTS VB N
The DT N
12-hour JJ 1_o
postoperative JJ 1_o
levels NNS 1_o
of IN 1_o
serum NN 1_o
hemoglobin NNS 1_o
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
the DT N
centrifugation NN 1_i
group NN N
as IN N
compared VBN N
to TO N
the DT N
multiple-pass JJ 1_i
hemoconcentration NN 1_i
group NN N
. . N

However RB N
, , N
the DT N
serum NN 1_o
levels NNS 1_o
of IN 1_o
total JJ 1_o
protein NN 1_o
and CC 1_o
albumin NN 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
multiple-pass JJ 1_i
hemoconcentration NN 1_i
group NN N
as IN N
compared VBN N
to TO N
the DT N
centrifugation NN 1_i
group NN N
. . N

Additionally RB N
, , N
after IN N
12-hours JJ N
postoperatively RB N
, , N
the DT N
serum NN 1_o
fibrinogen NN 1_o
and CC 1_o
platelet NN 1_o
counts NNS 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
multiple-pass JJ 1_i
hemoconcentration NN 1_i
group NN N
as IN N
compared VBN N
to TO N
those DT N
of IN N
the DT N
centrifugation NN 1_i
group NN N
. . N

The DT N
allogeneic JJ 1_o
product NN 1_o
transfusion NN 1_o
index NN 1_o
and CC 1_o
the DT 1_o
chest-tube JJ 1_o
blood NN 1_o
drainage NN 1_o
indices NNS 1_o
were VBD N
lower JJR 1_o
in IN N
the DT N
multiple-pass JJ 1_i
hemoconcentration NN 1_i
group NN N
as IN N
compared VBN N
to TO N
the DT N
centrifugation NN 1_i
group NN N
. . N

CONCLUSION NNP N
Although IN N
the DT N
CF NNP 1_i
method NN 1_i
provided VBD N
a DT N
product NN N
in IN N
a DT N
shorter JJR N
turnaround NN N
time NN N
, , N
with IN N
consistent JJ N
clearance NN N
of IN N
heparin NN 1_i
, , N
the DT N
MPH NNP 1_i
method NN 1_i
trended VBD N
towards NNS N
enhanced VBN 1_o
biochemical JJ 1_o
and CC 1_o
clinical JJ 1_o
patient NN 1_o
outcomes VBZ 1_o
over IN N
the DT N
12-hour JJ N
postoperative JJ N
period NN N
. . N

[ JJ N
Trial NNP N
of IN N
a DT N
calcium NN 1_i
antagonist NN 1_i
in IN N
dysmenorrhea NN 1_o
] NN 1_o
. . N

Relationship NN N
of IN N
the DT N
dose NN N
of IN N
intravenous JJ N
gammaglobulin NN 1_i
to TO N
the DT N
prevention NN N
of IN N
infections NNS N
in IN N
adults NNS 1_p
with IN 1_p
common JJ 1_p
variable JJ 1_p
immunodeficiency NN 1_p
. . 1_p

The DT N
objective NN N
was VBD N
to TO N
assess VB N
clinical JJ N
efficacy NN N
of IN N
3 CD N
dosages NNS N
of IN N
intravenous JJ 1_i
gammaglobulins NNS 1_i
to TO N
prevent VB N
infectious JJ N
episodes NNS N
in IN N
adult NN N
common JJ N
variable JJ N
immunodeficiency NN N
. . N

We PRP N
designed VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
dose-assessing JJ N
study NN N
. . N

The DT 1_p
setting NN 1_p
was VBD 1_p
at IN 1_p
University NNP 1_p
Hospital NNP 1_p
, , 1_p
Out-patient NNP 1_p
Clinic NNP 1_p
. . 1_p

Our PRP$ N
patients NNS 1_p
were VBD 1_p
twenty-one JJ 1_p
adult NN 1_p
patients NNS 1_p
with IN 1_p
common JJ 1_p
variable JJ 1_p
immunodeficiency NN 1_p
. . 1_p

The DT N
measurements NNS N
were VBD N
comparative JJ N
study NN N
of IN N
the DT N
number NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
infections NNS 1_o
using VBG N
3 CD N
various JJ N
dosages NNS N
of IN N
intravenous JJ N
gammaglobulins NNS 1_i
, , N
each DT N
given VBN N
monthly RB N
for IN N
M NNP N
least JJS N
6 CD N
months NNS N
. . N

Results NNS N
indicated VBD N
four CD N
hundred CD N
and CC N
eighty-four JJ N
infectious JJ 1_o
episodes NNS 1_o
occurred VBD N
while IN N
giving VBG N
305 CD 1_i
infusions NNS 1_i
of IN 1_i
IVIG NNP 1_i
200 CD 1_i
mg/kg NN 1_i
; : 1_i
205 CD N
infectious JJ N
episodes NNS N
while IN N
giving VBG N
170 CD 1_i
infusions NNS 1_i
of IN 1_i
400 CD 1_i
mg/kg NNS 1_i
and CC N
436 CD N
infectious JJ N
episodes NNS N
while IN N
giving VBG N
247 CD 1_i
infusions NNS 1_i
of IN 1_i
600 CD 1_i
mg/kg NN 1_i
. . 1_i

The DT N
morbidity NN 1_o
scores NNS 1_o
( ( 1_o
infection/infusion NN 1_o
) ) 1_o
were VBD N
1.59 CD N
, , N
1.21 CD N
and CC N
1.77 CD N
respectively RB N
( ( N
p JJ N
- : N
N/S NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
severity NN 1_o
of IN 1_o
infections NNS 1_o
on IN N
the DT N
above JJ N
3 CD N
dosages NNS N
, , N
and CC N
no DT N
difference NN N
in IN N
the DT N
duration NN 1_o
of IN 1_o
infection-free JJ 1_o
intervals NNS 1_o
. . 1_o

The DT N
conclusions NNS N
resulted VBD N
in IN N
no DT N
significant JJ N
differences NNS N
in IN N
morbidity NN 1_o
in IN N
adult NN N
patients NNS N
with IN N
common JJ N
variable JJ N
immunodeficiency NN N
treated VBN N
in IN N
cross-over JJ N
pattern NN N
with IN N
IVIG NNP N
200 CD N
mg/kg NN N
, , N
400 CD N
mg/kg NN N
and CC N
600 CD N
mg/kg NN N
. . N

Thus NNP N
, , N
high JJ N
dosages NNS N
of IN N
IVIG NNP N
are VBP N
not RB N
conferring VBG N
better JJR N
protection NN N
against IN N
infections NNS N
in IN N
such JJ N
patients NNS N
. . N

Potentiation NN N
of IN N
bradykinin-induced JJ N
tissue NN N
plasminogen NN N
activator NN N
release NN N
by IN N
angiotensin-converting JJ N
enzyme JJ N
inhibition NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibition NN N
on IN N
the DT N
local JJ N
stimulated VBD N
release NN N
of IN N
tissue NN N
plasminogen NN N
activator NN N
( ( N
t-PA JJ N
) ) N
from IN N
the DT N
endothelium NN N
. . N

BACKGROUND NNP N
Angiotensin-converting NNP 1_i
enzyme NN 1_i
inhibitor NN 1_i
therapy NN 1_i
may MD N
exert VB N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
endogenous JJ N
fibrinolytic JJ N
balance NN N
. . N

METHODS NNP N
Blood NNP 1_o
flow NN 1_o
and CC 1_o
plasma JJ 1_o
fibrinolytic JJ 1_o
factors NNS 1_o
were VBD N
measured VBN N
in IN N
both DT 1_p
forearms NNS 1_p
of IN 1_p
eight CD 1_p
healthy JJ 1_p
males NNS 1_p
who WP 1_p
received VBD 1_p
unilateral JJ 1_p
brachial JJ 1_p
artery NN 1_p
infusions NNS 1_p
of IN 1_p
the DT 1_p
endothelium-dependent JJ 1_i
vasodilators NNS 1_i
substance NN 1_i
P NNP 1_i
( ( 1_p
2 CD 1_p
to TO 1_p
8 CD 1_p
pmol/min NN 1_p
) ) 1_p
and CC 1_p
bradykinin NN 1_i
( ( 1_p
100 CD 1_p
to TO 1_p
1,000 CD 1_p
pmol/min NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
the DT 1_p
endothelium-independent JJ 1_i
vasodilator NN 1_i
sodium NN 1_i
nitroprusside NN 1_i
( ( 1_p
2 CD 1_p
to TO 1_p
8 CD 1_p
microg/min NN 1_p
) ) 1_p
. . 1_p

These DT N
measurements NNS N
were VBD N
performed VBN N
on IN N
each DT N
of IN N
three CD N
occasions NNS N
following VBG N
one CD N
week NN N
of IN N
matched JJ N
placebo NN 1_i
, , 1_i
quinapril RB 1_i
40 CD N
mg NN N
or CC N
losartan JJ 1_i
50 CD N
mg JJ N
daily RB N
administered VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
crossover NN N
design NN N
. . N

RESULTS NNP N
Sodium NNP N
nitroprusside RB N
, , N
substance NN N
P NNP N
and CC N
bradykinin NN N
produced VBD N
dose-dependent JJ N
increases NNS 1_o
in IN 1_o
the DT 1_o
blood NN 1_o
flow NN 1_o
of IN N
infused JJ N
forearm NN N
( ( N
analysis NN N
of IN N
variance NN N
[ NNP N
ANOVA NNP N
] NNP N
, , N
p NN N
< VBD N
0.001 CD N
for IN N
all DT N
) ) N
. . N

Although IN N
sodium JJ N
nitroprusside RB N
did VBD N
not RB N
affect VB N
plasma JJ 1_o
t-PA JJ 1_o
concentrations NNS 1_o
, , N
they PRP N
were VBD N
increased VBN N
dose-dependently RB N
in IN N
the DT N
infused JJ N
forearm NN N
by IN N
substance NN N
P NNP N
and CC N
bradykinin JJ N
infusion NN N
( ( N
ANOVA NNP N
, , N
p NN N
< VBD N
0.001 CD N
for IN N
both DT N
) ) N
. . N

Bradykinin-induced JJ N
release NN 1_o
of IN 1_o
active JJ 1_o
t-PA NN 1_o
was VBD N
more RBR N
than IN N
doubled VBD N
during IN N
treatment NN N
with IN N
quinapril NN 1_i
in IN N
comparison NN N
to TO N
placebo VB 1_i
or CC N
losartan VB 1_i
( ( N
two-way JJ N
ANOVA NNP N
: : N
p NN N
< VBZ N
0.003 CD N
for IN N
treatment NN N
group NN N
, , N
p VBP N
< $ N
0.001 CD N
for IN N
t-PA JJ N
response NN N
and CC N
p NN N
= NNP N
ns NN N
for IN N
interaction NN N
) ) N
, , N
whereas IN N
the DT N
substance NN 1_o
P NNP 1_o
response NN 1_o
was VBD 1_o
unaffected JJ 1_o
. . 1_o

CONCLUSIONS NN N
We PRP N
have VBP N
shown VBN N
a DT N
selective JJ N
and CC N
marked JJ N
augmentation NN N
of IN N
bradykinin-induced JJ N
t-PA JJ N
release NN N
during IN N
ACE NNP N
inhibition NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
beneficial JJ N
clinical JJ N
and CC N
vascular JJ N
effects NNS N
of IN N
ACE NNP N
inhibition NN N
may MD N
, , N
in IN N
part NN N
, , N
be VB N
mediated VBN N
through IN N
local JJ N
augmentation NN N
of IN N
bradykinin-induced JJ N
t-PA JJ N
release NN N
. . N

Naltrexone NN 1_i
, , N
an DT N
opiate JJ 1_i
antagonist NN 1_i
, , N
fails VBZ N
to TO N
modify VB N
motor NN 1_o
symptoms NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
Parkinson NNP 1_p
's POS 1_p
disease NN 1_p
. . 1_p

One CD N
month NN N
of IN N
adjunct JJ N
treatment NN N
with IN N
naltrexone NN 1_i
( ( N
100 CD N
mg/day NN N
) ) N
was VBD N
compared VBN N
with IN N
placebo NN 1_i
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
design NN N
in IN N
two CD 1_p
groups NNS 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
Parkinson NNP 1_p
's POS 1_p
disease NN 1_p
. . 1_p

The DT N
first JJ N
group NN N
was VBD N
composed VBN N
of IN N
10 CD 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
moderate JJ 1_p
motor NN 1_o
impairment NN 1_o
insufficiently RB 1_p
controlled VBN 1_p
by IN 1_p
monotherapy NN 1_p
with IN 1_p
bromocriptine NN 1_i
. . 1_i

The DT N
second JJ N
group NN N
was VBD N
composed VBN N
of IN N
eight CD 1_p
patients NNS 1_p
with IN 1_p
L-dopa-induced JJ 1_p
peak-dose JJ 1_p
dyskinesia NN 1_p
. . 1_p

Naltrexone CC 1_i
as IN N
compared VBN N
with IN N
placebo NN 1_i
did VBD N
not RB N
demonstrate VB N
any DT N
significant JJ N
change NN N
in IN N
motor NN 1_o
function NN 1_o
in IN N
either DT N
group NN N
. . N

These DT N
negative JJ N
clinical JJ N
results NNS N
do VBP N
not RB N
support VB N
a DT N
significant JJ N
role NN N
of IN N
endogenous JJ N
opioid JJ N
systems NNS N
in IN N
the DT N
pathophysiology NN N
of IN N
motor NN 1_o
impairment NN 1_o
in IN N
Parkinson NNP N
's POS N
disease NN N
. . N

A DT N
randomised JJ N
trial NN N
comparing VBG N
holmium NN 1_i
laser NN 1_i
enucleation NN 1_i
versus IN N
transurethral JJ 1_i
resection NN 1_i
in IN N
the DT N
treatment NN 1_p
of IN 1_p
prostates NNS 1_p
larger JJR 1_p
than IN 1_p
40 CD 1_p
grams NNS 1_p
: : 1_p
results NNS N
at IN N
2 CD N
years NNS N
. . N

OBJECTIVE NN N
To TO N
compare VB N
holmium NN 1_i
laser JJR 1_i
enucleation NN 1_i
of IN 1_i
the DT 1_i
prostate NN 1_i
( ( 1_i
HoLEP NNP 1_i
) ) 1_i
with IN N
transurethral JJ 1_i
resection NN 1_i
of IN 1_i
the DT 1_i
prostate NN 1_i
( ( 1_i
TURP NNP 1_i
) ) 1_i
for IN N
treatment NN N
of IN N
men NNS 1_p
with IN 1_p
bladder NN 1_p
outflow JJ 1_p
obstruction NN 1_p
( ( 1_p
BOO NNP 1_p
) ) 1_p
secondary VBP 1_p
to TO 1_p
benign VB 1_p
prostatic JJ 1_p
hyperplasia NN 1_p
with IN 1_p
a DT 1_p
minimum NN 1_p
of IN 1_p
24-month JJ 1_p
follow-up JJ 1_p
. . 1_p

PATIENTS NNPS N
AND CC N
METHODS NNP N
Sixty-one CD 1_p
patients NNS 1_p
were VBD N
randomised VBN N
to TO N
either DT N
HoLEP NNP 1_i
or CC N
TURP NNP 1_i
. . 1_i

All DT 1_p
patients NNS 1_p
had VBD 1_p
BOO NNP 1_p
proven RB 1_p
on IN 1_p
urodynamic JJ 1_p
studies NNS 1_p
pre-operatively RB 1_p
( ( 1_p
prostate JJ 1_p
size NN 1_p
40-200 JJ 1_p
g NN 1_p
) ) 1_p
. . 1_p

One CD N
patient NN N
died VBD N
before IN N
treatment NN N
, , N
which WDT N
left VBD N
30 CD 1_p
patients NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

Perioperative NNP 1_o
data NN 1_o
, , 1_o
as RB 1_o
well RB 1_o
as IN 1_o
symptom NN 1_o
scores NNS 1_o
, , 1_o
Quality NNP 1_o
of IN 1_o
Life NNP 1_o
( ( 1_o
QoL NNP 1_o
) ) 1_o
scores VBZ 1_o
, , 1_o
and CC 1_o
maximum JJ 1_o
urinary JJ 1_o
flow NN 1_o
rates NNS 1_o
( ( 1_o
Qmax NNP 1_o
) ) 1_o
were VBD N
obtained VBN N
at IN N
one CD N
, , N
three CD N
, , N
six,12 NN N
, , N
and CC N
24 CD N
months NNS N
. . N

Post-void JJ 1_o
residual JJ 1_o
volumes NNS 1_o
, , 1_o
transrectal JJ 1_o
ultrasound NN 1_o
( ( 1_o
TRUS NNP 1_o
) ) 1_o
volumes NNS 1_o
, , 1_o
and CC 1_o
pressure NN 1_o
flow NN 1_o
studies NNS 1_o
were VBD N
obtained VBN N
six CD N
months NNS N
post-operatively RB N
. . N

Continence NN 1_o
and CC 1_o
potency NN 1_o
data NNS 1_o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
surgical JJ N
groups NNS N
pre-operatively RB N
. . N

Mean JJ 1_o
pre-operative JJ 1_o
TRUS NNP 1_o
volume NN 1_o
was VBD N
77.8+/-5.6 JJ N
g NN N
( ( N
42-152 JJ N
) ) N
in IN N
the DT N
HoLEP NNP N
group NN N
and CC N
70.0+/-5.0 JJ N
g NN N
( ( N
46-156 JJ N
) ) N
in IN N
the DT N
TURP NNP 1_i
group NN N
. . N

Patients NNS N
in IN N
the DT N
HoLEP NNP 1_i
group NN N
had VBD N
shorter JJR N
catheter NN 1_o
times NNS 1_o
and CC N
hospital NN 1_o
stays NNS 1_o
. . 1_o

More JJR N
prostate JJ 1_o
tissue NN 1_o
was VBD N
retrieved VBN N
in IN N
the DT N
HoLEP NNP 1_i
group NN N
. . N

At IN N
six CD N
months NNS N
, , N
HoLEP NNP 1_i
was VBD N
urodynamically RB 1_o
superior JJ N
to TO N
TURP NNP 1_i
in IN N
relieving VBG N
BOO NNP N
. . N

At IN N
24 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
surgical JJ N
groups NNS N
with IN N
respect NN N
to TO N
American NNP 1_o
Urology NNP 1_o
Association NNP 1_o
scores NNS 1_o
, , 1_o
QoL NNP 1_o
scores VBZ 1_o
, , 1_o
or CC 1_o
Qmax NNP 1_o
values NNS 1_o
; : 1_o
however RB N
, , N
two CD N
patients NNS N
in IN N
the DT N
TURP NNP N
group NN N
required VBD N
re-operation NN N
. . N

CONCLUSIONS NNP N
HoLEP NNP 1_i
has VBZ N
less RBR N
perioperative JJ 1_o
morbidity NN 1_o
and CC N
produces VBZ N
superior JJ N
urodynamic JJ 1_o
outcomes NNS 1_o
than IN N
TURP NNP 1_i
, , N
when WRB N
treating VBG N
prostates NNS N
> VBP N
40 CD N
g. NN N
At IN N
24 CD N
months NNS N
of IN N
follow-up NN N
, , N
HoLEP NNP 1_i
is VBZ N
equivalent JJ N
to TO N
TURP NNP 1_i
. . 1_i

Relaxation NN 1_i
and CC 1_i
imagery NN 1_i
and CC 1_i
cognitive-behavioral JJ 1_i
training NN 1_i
reduce VB N
pain NN 1_o
during IN N
cancer NN N
treatment NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
. . N

Few NNP N
controlled VBD N
clinical JJ N
trials NNS N
of IN N
psychological JJ N
interventions NNS N
for IN N
cancer NN 1_o
pain NN 1_o
relief NN 1_o
exist NN N
in IN N
spite NN N
of IN N
frequent JJ N
support NN N
for IN N
their PRP$ N
importance NN N
as IN N
adjuncts NNS N
to TO N
medical JJ N
treatment NN N
. . N

This DT N
study NN N
compared VBN N
oral JJ N
mucositis NN N
pain NN N
levels NNS N
in IN N
4 CD 1_p
groups NNS 1_p
of IN 1_p
cancer NN 1_p
patients NNS 1_p
receiving VBG 1_p
bone NN 1_p
marrow NN 1_p
transplants NNS 1_p
( ( 1_p
BMT NNP 1_p
) ) 1_p
: : 1_p
( ( 1_p
1 CD 1_p
) ) 1_p
treatment NN 1_i
as IN 1_i
usual JJ 1_i
control NN 1_i
, , 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
therapist NN 1_i
support NN 1_i
, , 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
relaxation NN 1_i
and CC 1_i
imagery NN 1_i
training NN 1_i
, , 1_i
and CC 1_i
( ( 1_i
4 CD 1_i
) ) 1_i
training NN 1_i
in IN 1_i
a DT 1_i
package NN 1_i
of IN 1_i
cognitive-behavioral JJ 1_i
coping NN 1_i
skills NNS 1_i
which WDT 1_i
included VBD 1_i
relaxation NN 1_i
and CC 1_i
imagery NN 1_i
. . 1_i

A DT N
total NN N
of IN N
94 CD 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
which WDT 1_p
involved VBD 1_p
two CD 1_p
training NN 1_p
sessions NNS 1_p
prior RB 1_p
to TO 1_p
treatment NN 1_p
and CC 1_p
twice RB 1_p
a DT 1_p
week NN 1_p
'booster POS 1_p
' POS 1_p
sessions NNS 1_p
during IN 1_p
the DT 1_p
first JJ 1_p
5 CD 1_p
weeks NNS 1_p
of IN 1_p
treatment NN 1_p
. . 1_p

Results NNS N
confirmed VBD N
our PRP$ N
hypothesis NN N
that IN N
patients NNS N
who WP N
received VBD N
either DT N
relaxation NN N
and CC N
imagery VB N
alone RB N
or CC N
patients NNS N
who WP N
received VBD N
the DT N
package NN N
of IN N
cognitive-behavioral JJ N
coping NN N
skills NNS N
would MD N
report VB N
less JJR N
pain NN 1_o
than IN N
patients NNS N
in IN N
the DT N
other JJ N
2 CD N
groups NNS N
. . N

The DT N
hypothesis NN N
that IN N
the DT N
cognitive-behavioral JJ N
skills NNS N
package NN N
would MD N
have VB N
an DT N
additive JJ N
effect NN N
beyond IN N
relaxation NN N
and CC N
imagery NN N
alone RB N
was VBD N
not RB N
confirmed VBN N
. . N

Average JJ 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
report NN 1_o
of IN 1_o
pain NN 1_o
within IN N
the DT N
therapist JJ N
support NN N
group NN N
was VBD N
not RB N
significantly RB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.103 CD N
) ) N
nor CC N
significantly RB N
higher JJR N
than IN N
the DT N
training NN N
groups NNS N
. . N

Patient JJ N
reports NNS N
of IN N
relative JJ N
helpfulness NN N
of IN N
the DT N
interventions NNS N
for IN N
managing VBG N
pain NN 1_o
and CC 1_o
nausea NN 1_o
matched VBD N
the DT N
results NNS N
of IN N
VAS NNP N
reports NNS N
. . N

From IN N
these DT N
results NNS N
, , N
we PRP N
conclude VBP N
that DT N
relaxation NN N
and CC N
imagery NN N
training NN N
reduces NNS N
cancer NN 1_o
treatment-related JJ 1_o
pain NN 1_o
; : 1_o
adding VBG N
cognitive-behavioral JJ N
skills NNS N
to TO N
the DT N
relaxation NN N
with IN N
imagery NN N
does VBZ N
not RB N
, , N
on IN N
average NN N
, , N
further JJ N
improve VB N
pain NN 1_o
relief NN 1_o
. . 1_o

Sulfasalazine NNP 1_i
decreases VBZ N
acute JJ N
gastrointestinal JJ N
complications NNS N
due JJ N
to TO N
pelvic JJ N
radiotherapy NN N
. . N

BACKGROUND NNP N
Radiation-induced NNP N
gastrointestinal JJ N
toxicity NN N
is VBZ N
a DT N
significant JJ N
concern NN N
for IN N
patients NNS 1_p
who WP 1_p
are VBP 1_p
treated VBN 1_p
with IN 1_p
this DT 1_p
modality NN 1_p
for IN 1_p
pelvic JJ 1_p
malignancies NNS 1_p
. . 1_p

Eicosanoids NNS N
and CC N
free JJ N
radicals NNS N
are VBP N
thought VBN N
to TO N
be VB N
among IN N
the DT N
reasons NNS N
for IN N
this DT N
effect NN N
. . N

Sulfasalazine NNP 1_i
is VBZ N
an DT N
inhibitor NN N
of IN N
their PRP$ N
synthesis NN N
in IN N
the DT N
mucosa NN N
. . N

OBJECTlVE NN N
: : N
To TO N
determine VB N
whether IN N
sulfasalazine NN 1_i
can MD N
reduce VB N
the DT N
radiation-induced JJ N
acute JJ N
gastrointestinal JJ N
complications NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
, , N
31 CD 1_p
patients NNS 1_p
receiving VBG 1_p
pelvic JJ 1_p
radiotherapy NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
two CD N
sulfasalazine JJ 1_i
500-mg JJ 1_i
tablets NNS 1_i
twice JJ 1_i
daily RB 1_i
or CC 1_i
placebo VB 1_i
, , N
administered VBN N
orally RB N
from IN N
the DT N
first JJ N
day NN N
of IN N
irradiation NN N
. . N

Patients NNS N
were VBD N
evaluated JJ N
weekly JJ N
, , N
and CC N
gastrointestinal JJ 1_o
toxicities NNS 1_o
were VBD N
graded VBN N
according VBG N
to TO N
the DT N
Late JJ 1_o
Effect NNP 1_o
of IN 1_o
Normal NNP 1_o
Tissue-Subjective NNP 1_o
Objective NNP 1_o
Management NNP 1_o
Analytic NNP 1_o
( ( 1_o
LENT-SOMA NNP 1_o
) ) 1_o
toxicity NN 1_o
table NN 1_o
during IN N
pelvic JJ N
radiotherapy NN N
. . N

On IN N
the DT N
last JJ N
day NN N
of IN N
week NN N
5 CD N
, , N
the DT N
subjects NNS N
were VBD N
graded VBN N
endoscopically RB N
, , N
and CC N
biopsies NNS N
taken VBN N
from IN N
the DT N
rectum NN N
were VBD N
classified VBN N
histopathologically RB N
. . N

RESULTS NNP N
Groups NNP 1_p
did VBD 1_p
not RB 1_p
differ VB 1_p
in IN 1_p
age NN 1_p
, , 1_p
gender NN 1_p
, , 1_p
tumor NN 1_p
site NN 1_p
, , 1_p
or CC 1_p
irradiation NN 1_p
procedure NN 1_p
. . 1_p

During IN N
radiotherapy NN N
, , N
grade VBD 1_o
2 CD 1_o
or CC 1_o
higher JJR 1_o
gastrointestinal JJ 1_o
toxicity NN 1_o
occurred VBD N
in IN N
20 CD N
% NN N
( ( N
3/15 CD N
) ) N
and CC N
63 CD N
% NN N
( ( N
10/16 CD N
) ) N
of IN N
the DT N
sulfasalazine NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

This DT N
difference NN 1_o
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.017 CD N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
endoscopic NN N
and CC N
histopathologic JJ N
evaluations NNS N
. . N

CONCLUSIONS NNP N
Sulfasalazine NNP N
is VBZ N
effective JJ N
in IN N
decreasing VBG N
clinically RB N
acute JJ N
gastrointestinal JJ N
toxicities NNS N
. . N

Long-term JJ N
follow-up JJ N
with IN N
the DT 1_p
subjects NNS 1_p
will MD N
help VB N
to TO N
determine VB N
the DT N
net JJ N
effect NN N
of IN N
sulfasalazine NN N
on IN N
the DT N
radiation-induced JJ 1_p
gastrointestinal JJ 1_p
injuries NNS 1_p
. . 1_p

LEGO NNP 1_i
therapy NN 1_i
and CC N
the DT N
social JJ 1_i
use NN 1_i
of IN 1_i
language NN 1_i
programme NN 1_i
: : 1_i
an DT N
evaluation NN N
of IN N
two CD N
social JJ 1_o
skills NNS 1_o
interventions NNS N
for IN N
children NNS 1_p
with IN 1_p
high JJ 1_p
functioning VBG 1_p
autism NN 1_p
and CC 1_p
Asperger NNP 1_p
Syndrome NNP 1_p
. . 1_p

LEGO NNP 1_i
therapy NN 1_i
and CC N
the DT N
Social NNP 1_i
Use NNP 1_i
of IN 1_i
Language NNP 1_i
Programme NNP 1_i
( ( 1_i
SULP NNP 1_i
) ) 1_i
were VBD N
evaluated VBN N
as IN N
social JJ 1_i
skills NNS 1_i
interventions NNS 1_i
for IN 1_p
6-11 JJ 1_p
year NN 1_p
olds NNS 1_p
with IN 1_p
high JJ 1_p
functioning VBG 1_p
autism NN 1_p
and CC 1_p
Asperger NNP 1_p
Syndrome NNP 1_p
. . 1_p

Children NNP 1_p
were VBD N
matched VBN N
on IN N
CA NNP N
, , N
IQ NNP N
, , N
and CC N
autistic JJ N
symptoms NNS N
before IN N
being VBG N
randomly RB N
assigned VBN N
to TO N
LEGO NNP 1_i
or CC N
SULP NNP 1_i
. . 1_i

Therapy NNP N
occurred VBD N
for IN N
1 CD 1_p
h/week NN 1_p
over IN 1_p
18 CD 1_p
weeks NNS 1_p
. . 1_p

A DT N
no-intervention JJ 1_i
control NN 1_i
group NN 1_i
was VBD N
also RB N
assessed VBN N
. . N

Results NNS N
showed VBD N
that IN N
the DT N
LEGO NNP 1_i
therapy NN N
group NN N
improved VBD N
more JJR N
than IN N
the DT N
other JJ 1_p
groups NNS 1_p
on IN 1_p
autism-specific JJ 1_o
social JJ 1_o
interaction NN 1_o
scores NNS 1_o
( ( 1_o
Gilliam NNP 1_o
Autism NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
) ) 1_o
. . N

Maladaptive JJ 1_o
behaviour NN 1_o
decreased VBD N
significantly RB N
more RBR N
in IN N
the DT N
LEGO NNP 1_i
and CC 1_p
SULP NNP 1_i
groups NNS 1_p
compared VBN 1_p
to TO 1_p
the DT 1_p
control NN 1_p
group NN 1_p
. . 1_p

There EX N
was VBD N
a DT N
non-significant JJ N
trend NN N
for IN N
SULP NNP 1_i
and CC 1_p
LEGO NNP 1_i
groups NNS 1_p
to TO N
improve VB N
more JJR N
than IN N
the DT N
no-intervention JJ 1_i
group NN N
in IN N
communication NN 1_o
and CC 1_o
socialisation NN 1_o
skills NNS 1_o
. . 1_o

Mandibular JJ 1_i
advancement NN 1_i
splint NN 1_i
improves VBZ N
indices NNS N
of IN N
obstructive JJ 1_p
sleep NN 1_p
apnoea NN 1_p
and CC 1_p
snoring VBG 1_p
but CC N
side JJ N
effects NNS N
are VBP N
common JJ N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
mandibular JJ 1_i
advancement NN 1_i
splint NN 1_i
( ( 1_i
MAS NNP 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
obstructive JJ 1_o
sleep JJ 1_o
apnoea NN 1_o
syndrome NN 1_o
( ( 1_o
OSAS NNP 1_o
) ) 1_o
. . 1_o

METHODS NNP N
Nineteen NNP 1_p
patients NNS 1_p
using VBG 1_p
a DT 1_p
MAS NNP 1_i
for IN 1_p
symptomatic JJ 1_p
OSAS NNP 1_p
underwent NN 1_p
polysomnography NN 1_i
, , 1_p
with IN 1_p
MAS NNP 1_i
use NN 1_p
randomised VBD 1_p
to TO 1_p
one CD 1_p
half NN 1_p
of IN 1_p
the DT 1_p
night NN 1_p
. . 1_p

Indices NNS 1_o
of IN 1_o
snoring VBG 1_o
and CC 1_o
OSAS NNP 1_o
were VBD N
compared VBN N
. . N

Side NNP 1_o
effects NNS 1_o
, , 1_o
compliance NN 1_o
and CC 1_o
treatment NN 1_o
response NN 1_o
were VBD N
evaluated VBN N
by IN N
questionnaire NN N
. . N

RESULTS NNP N
Use NNP N
of IN N
the DT N
MAS NNP 1_i
improved VBD N
total JJ 1_o
respiratory NN 1_o
disturbance NN 1_o
index NN 1_o
( ( 1_o
RDI NNP 1_o
) ) 1_o
from IN N
22.2 CD N
+/- JJ N
19.8 CD N
( ( N
SD NNP N
) ) N
events NNS 1_o
per IN 1_o
hour NN 1_o
to TO N
16.5 CD N
+/- JJ N
21.4/hr CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
, , N
supine JJ 1_o
RDI NNP 1_o
( ( N
30.8 CD N
+/- JJ N
23.8/hr CD N
to TO N
18.8 CD N
+/- JJ N
22.1/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
arousal JJ 1_o
index NN 1_o
( ( N
25.2 CD N
+/- JJ N
18.9/hr CD N
to TO N
19.3 CD N
+/- JJ N
14.2/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
and CC N
snoring VBG 1_o
intensity NN 1_o
( ( N
52.7 CD N
+/- JJ N
4.1 CD N
to TO N
50.7 CD N
+/- JJ N
2.7 CD N
dB NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
but CC N
not RB N
total JJ 1_o
snore NN 1_o
frequency NN 1_o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Using VBG N
polysomnographic JJ N
criteria NNS N
, , N
MAS NNP 1_i
treatment NN N
was VBD N
completely RB 1_o
successful JJ 1_o
in IN N
four CD N
( ( N
21 CD N
% NN N
) ) N
patients NNS N
, , N
partially RB 1_o
successful JJ 1_o
in IN N
ten NN N
( ( N
52.6 CD N
% NN N
) ) N
and CC N
a DT N
failure NN 1_o
in IN N
five CD N
( ( N
26.3 CD N
% NN N
) ) N
. . N

Treatment NN N
over IN N
a DT N
median NN N
of IN N
6.5 CD N
weeks NNS N
( ( N
range VB N
2-48 CD N
) ) N
was VBD N
perceived VBN N
as IN N
beneficial JJ N
by IN N
ten NN N
of IN N
eleven JJ N
partners NNS N
. . N

Fifteen JJ 1_p
patients NNS 1_p
( ( 1_p
79 CD 1_p
% NN 1_p
) ) 1_p
reported VBD N
side JJ 1_o
effects NNS 1_o
, , N
9 CD N
( ( N
46 CD N
% NN N
) ) N
did VBD N
not RB N
use VB N
the DT N
device NN N
every DT N
night NN N
and CC N
four CD N
( ( N
21 CD N
% NN N
) ) N
used VBD N
the DT N
device NN N
less JJR N
than IN N
three CD N
nights NNS N
per IN N
week NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
the DT N
MAS NNP 1_i
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
indices NNS N
of IN N
OSAS NNP 1_o
and CC 1_o
snoring VBG 1_o
. . 1_o

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
patients NNS N
had VBD N
difficulty NN N
tolerating NN N
and CC N
regularly RB N
using VBG N
the DT N
device NN N
. . N

Changes NNS N
in IN N
motor NN N
cortex NN N
excitability NN N
associated VBN N
with IN N
temporal JJ 1_i
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
in IN N
tinnitus NN 1_p
: : 1_p
hints NNS N
for IN N
cross-modal JJ N
plasticity NN N
? . N
BACKGROUND NNP N
Motor NNP N
cortex VBP N
excitability NN N
was VBD N
found VBN N
to TO N
be VB N
changed VBN N
after IN N
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
rTMS NN 1_i
) ) 1_i
of IN N
the DT N
temporal JJ N
cortex NN N
highlighting VBG N
the DT N
occurrence NN N
of IN N
cross-modal JJ N
plasticity NN N
in IN N
non-invasive JJ N
brain NN N
stimulation NN N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
temporal JJ 1_i
low-frequency NN 1_i
rTMS NN 1_i
on IN N
motor NN N
cortex NN N
plasticity NN N
in IN N
a DT N
large JJ N
sample NN N
of IN N
tinnitus NN 1_p
patients NNS 1_p
. . 1_p

In IN N
116 CD 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
tinnitus NN 1_p
different JJ N
parameters NNS N
of IN N
cortical JJ N
excitability NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
ten JJ N
rTMS JJ 1_i
treatment NN N
sessions NNS N
. . N

Patients NNS N
received VBD N
one CD N
of IN N
three CD N
different JJ N
protocols NNS N
all DT N
including VBG N
1 CD 1_i
Hz NNP 1_i
rTMS NN 1_i
over IN 1_i
the DT 1_i
left JJ 1_i
temporal JJ 1_i
cortex NN 1_i
. . 1_i

Treatment NNP N
response NN N
was VBD N
defined VBN N
as IN N
improvement NN N
by IN N
at IN N
least JJS N
five CD N
points NNS N
in IN N
the DT N
tinnitus NN N
questionnaire NN N
( ( N
TQ NNP N
) ) N
. . N

Variables NNS N
of IN N
interest NN N
were VBD N
resting VBG 1_o
motor NN 1_o
threshold NN 1_o
( ( 1_o
RMT NNP 1_o
) ) 1_o
, , 1_o
short-interval JJ 1_o
intra-cortical JJ 1_o
inhibition NN 1_o
( ( 1_o
SICI NNP 1_o
) ) 1_o
, , 1_o
intracortical JJ 1_o
facilitation NN 1_o
( ( 1_o
ICF NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
cortical JJ 1_o
silent JJ 1_o
period NN 1_o
( ( 1_o
CSP NNP 1_o
) ) 1_o
. . 1_o

RESULTS NNP N
After IN N
rTMS JJ 1_i
treatment NN N
RMT NNP 1_o
was VBD 1_o
decreased VBN 1_o
by IN N
about IN N
1 CD N
% NN N
of IN N
stimulator NN N
output NN N
near-significantly RB N
in IN N
the DT N
whole JJ N
group NN N
of IN N
patients NNS N
. . N

SICI NNP 1_o
was VBD N
associated VBN N
with IN N
significant JJ N
changes NNS N
with IN N
respect NN N
to TO N
treatment NN N
response NN N
. . N

The DT N
group NN N
of IN N
treatment NN N
responders NNS N
showed VBD N
a DT N
decrease NN 1_o
of IN 1_o
SICI NNP 1_o
over IN N
the DT N
course NN N
of IN N
treatment NN N
, , N
the DT N
group NN N
of IN N
non-responders NNS N
the DT N
reverse NN N
pattern NN N
. . N

CONCLUSIONS NNP N
Minor NNP 1_o
RMT NNP 1_o
changes NNS 1_o
during IN N
rTMS NN 1_i
treatment NN N
do VBP N
not RB N
necessarily RB N
suggest VB N
the DT N
need NN N
for IN N
systematic JJ N
re-examination NN N
of IN N
the DT N
RMT NNP N
for IN N
safety NN N
and CC N
efficacy NN N
issues NNS N
. . N

Treatment NNP N
response NN N
to TO N
rTMS VB 1_i
was VBD N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
changes NNS N
in IN N
SICI NNP N
that WDT N
might MD N
reflect VB N
modulation NN N
of IN N
GABAergic NNP N
mechanisms FW N
directly RB N
or CC N
indirectly RB N
related VBN N
to TO N
rTMS VB N
treatment NN N
effects NNS N
. . N

Traumatic JJ 1_p
brain NN 1_p
injury-related JJ 1_p
attention NN 1_o
deficits NNS 1_o
: : 1_o
treatment NN N
outcomes NNS 1_o
with IN N
lisdexamfetamine JJ 1_i
dimesylate NN 1_i
( ( 1_i
Vyvanse NNP 1_i
) ) 1_i
. . 1_i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Attention NNP N
deficits NNS N
are VBP N
often RB N
among IN N
the DT N
most RBS N
persistent JJ N
and CC N
debilitating VBG N
impairments NNS N
resulting VBG N
from IN N
traumatic JJ N
brain NN N
injury NN N
( ( N
TBI NNP N
) ) N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
lisdexamfetamine JJ 1_i
dimesylate NN 1_i
( ( 1_i
Vyvanse NNP 1_i
) ) 1_i
in IN N
treating VBG N
attention NN 1_o
deficits NNS 1_o
due JJ 1_p
to TO 1_p
moderate-to-severe JJ 1_p
TBI NNP 1_p
. . 1_p

It PRP N
was VBD N
the DT N
first JJ N
study NN N
of IN N
lisdexamfetamine JJ 1_i
dimesylate NN 1_i
with IN N
this DT 1_p
population NN 1_p
and CC N
, , N
in IN N
fact NN N
, , N
was VBD N
the DT N
first JJ N
controlled VBN N
trial NN N
in IN N
this DT N
area NN N
examining VBG N
a DT N
stimulant JJ N
medication NN N
option NN N
other JJ N
than IN N
methylphenidate NN 1_i
. . 1_i

METHODS NNP N
This DT N
was VBD N
a DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
cross-over JJ N
trial NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
22 CD 1_p
rigorously RB 1_p
selected VBN 1_p
cases NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
13 CD 1_p
of IN 1_p
whom WP 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
. . 1_p

They PRP 1_p
were VBD 1_p
16-42 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
and CC 1_p
had VBD 1_p
newly RB 1_p
acquired VBN 1_p
attention NN 1_o
deficits NNS 1_o
persisting VBG 1_p
for IN 1_p
6-34 JJ 1_p
months NNS 1_p
post-injury NN 1_p
. . 1_p

They PRP 1_p
were VBD N
assessed VBN N
on IN N
a DT N
broad JJ N
range NN N
of IN N
neuropsychological JJ 1_o
and CC 1_o
behavioural JJ 1_o
measures NNS 1_o
at IN N
baseline NN N
, , N
6-weeks JJ N
and CC N
at IN N
12-weeks JJ N
. . N

RESULTS NNP N
AND CC N
CONCLUSIONS NNP N
Positive NNP N
treatment NN N
effects NNS N
were VBD N
found VBN N
involving VBG N
selective JJ N
measures NNS N
of IN N
sustained JJ 1_o
attention NN 1_o
, , 1_o
working VBG 1_o
memory NN 1_o
, , 1_o
response NN 1_o
speed NN 1_o
stability NN 1_o
and CC 1_o
endurance NN 1_o
and CC 1_o
in IN 1_o
aspects NNS 1_o
of IN 1_o
executive NN 1_o
functioning NN 1_o
. . 1_o

No DT N
major JJ N
problems NNS N
with IN N
safety NN 1_o
or CC 1_o
tolerability NN 1_o
were VBD N
observed VBN N
. . N

Some DT N
moderating VBG N
treatment NN N
effects NNS N
were VBD N
found VBN N
from IN N
a DT N
broad JJ N
range NN N
of IN N
pre-treatment JJ N
subject JJ N
characteristics NNS N
and CC N
injury NN N
variables NNS N
examined VBN N
. . N

Avenues NNS N
for IN N
further JJ N
research NN N
and CC N
treatment NN N
applications NNS N
in IN N
this DT N
area NN N
are VBP N
discussed VBN N
. . N

Comparative JJ N
speed NN N
of IN N
kill NN N
of IN N
selamectin NN 1_i
, , 1_i
imidacloprid JJ 1_i
, , 1_i
and CC 1_i
fipronil- NN 1_i
( ( 1_i
S NNP 1_i
) ) 1_i
-methoprene VBD 1_i
spot-on JJ N
formulations NNS N
against IN N
fleas NNS 1_o
on IN 1_p
cats NNS 1_p
. . 1_p

The DT N
speed NN N
of IN N
kill NN N
of IN N
selamectin NN 1_i
, , 1_i
imidacloprid JJ 1_i
, , 1_i
and CC 1_i
fipronil- NN 1_i
( ( 1_i
S NNP 1_i
) ) 1_i
-methoprene NN 1_i
against IN N
Ctenocephalides NNP N
felis JJ N
infestations NNS N
on IN N
cats NNS 1_p
for IN N
one CD N
month NN N
following VBG N
a DT N
single JJ N
treatment NN N
was VBD N
evaluated VBN N
. . N

Eighty NNP 1_p
cats NNS 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
so RB N
that IN N
there EX N
were VBD N
20 CD N
cats NNS N
in IN N
four CD N
different JJ N
treatment NN N
groups NNS N
. . N

On IN N
Days NNPS N
-2 NNP N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
, , N
and CC N
28 CD N
, , N
each DT N
cat NN N
was VBD N
infested VBN N
with IN N
100 CD N
adult NN N
C. NNP N
felis NN N
from IN N
the DT N
Kansas NNP 1_p
1 CD 1_p
flea NN 1_p
strain NN 1_p
. . 1_p

Following VBG N
initial JJ N
application NN N
only RB N
imidacloprid JJ 1_i
had VBD N
caused VBN N
a DT N
significant JJ N
reduction NN 1_o
in IN 1_o
adult NN 1_o
fleas NNS 1_o
on IN N
treated JJ N
cats NNS N
within IN N
6 CD N
hours NNS N
, , N
but CC N
by IN N
24 CD N
hours NNS N
all DT N
three CD N
formulations NNS N
had VBD N
killed VBN N
96.7 CD N
% NN N
of IN N
the DT N
fleas NNS N
. . N

At IN N
7 CD N
days NNS N
post NN N
treatment NN N
, , N
all DT N
three CD N
formulations NNS N
reduced VBD N
flea JJ 1_o
populations NNS 1_o
within IN N
6 CD N
and CC N
24 CD N
hours NNS N
by IN N
68.4 CD N
% NN N
and CC N
99.4 CD N
% NN N
, , N
respectively RB N
. . N

At IN N
21 CD N
and CC N
28 CD N
days NNS N
after IN N
treatment NN N
, , N
none NN N
of IN N
the DT N
formulations NNS N
killed VBD N
significant JJ N
numbers NNS 1_o
of IN 1_o
fleas NNS 1_o
as IN N
compared VBN N
to TO N
controls NNS N
within IN N
6 CD N
hours NNS N
of IN N
infestation NN N
. . N

At IN N
28 CD N
days NNS N
after IN N
treatment NN N
, , N
selamectin NN 1_i
, , 1_i
fipronil- JJ 1_i
( ( 1_i
S NNP 1_i
) ) 1_i
-methoprene NN 1_i
, , 1_i
and CC 1_i
imidacloprid VB 1_i
had VBD N
killed VBN N
99.0 CD N
% NN N
, , N
86.4 CD N
% NN N
, , N
and CC N
72.6 CD N
% NN N
of IN N
the DT N
fleas NNS 1_o
within IN N
48 CD N
hours NNS N
of IN N
infestation NN N
, , N
respectively RB N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
the DT N
speed NN N
of IN N
kill NN N
of IN N
residual JJ N
flea NN 1_o
products NNS 1_o
on IN N
cats NN 1_p
decreases NNS N
throughout IN N
the DT N
month NN N
following VBG N
application NN N
. . N

It PRP N
also RB N
demonstrated VBD N
that IN N
selamectin NN N
provided VBD N
the DT N
highest JJS N
level NN N
of IN N
residual JJ 1_o
activity NN 1_o
on IN N
cats NNS 1_p
against IN N
the DT N
Kansas NNP N
1 CD N
flea NN N
strain NN N
. . N

Heat-exercise JJ 1_p
performance NN 1_p
of IN 1_p
pyridostigmine-treated JJ 1_i
subjects NNS 1_p
wearing VBG 1_p
chemical NN 1_p
protective JJ 1_p
clothing NN 1_p
. . 1_p

Pyridostigmine NNP 1_i
bromide NN 1_i
is VBZ N
currently RB N
the DT N
pretreatment NN N
of IN N
choice NN N
for IN N
operation NN N
in IN N
a DT N
chemical NN N
warfare NN N
( ( N
CW NNP N
) ) N
environment NN N
. . N

Under IN N
CW NNP N
conditions NNS N
, , N
subjects NNS N
are VBP N
exposed VBN N
to TO N
thermal VB 1_p
stress NN 1_p
caused VBN 1_p
by IN 1_p
CW NNP 1_p
protective JJ 1_p
clothing NN 1_p
. . 1_p

This DT N
investigation NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
pyridostigmine JJ 1_i
affects VBZ N
various JJ N
physiological JJ N
and CC N
biophysical JJ N
parameters NNS N
of IN N
human JJ N
temperature NN N
regulation NN N
in IN N
subjects NNS N
wearing VBG N
CW NNP N
protective JJ N
clothing NN N
. . N

Pyridostigmine NNP 1_i
was VBD 1_i
administered VBN 1_i
orally RB 1_i
in IN N
a DT N
randomized JJ N
double-blind JJ N
cross-over NN N
study NN N
in IN N
four CD N
doses NNS N
of IN N
30 CD N
mg NN N
every DT N
8 CD N
h. NN N
An DT N
average NN N
of IN N
33 CD N
% NN N
whole JJ N
blood NN N
cholinesterase NN N
inhibition NN N
was VBD N
induced VBN N
in IN N
the DT N
pyridostigmine NN 1_i
treated VBD N
group NN N
4 CD N
h NN N
after IN N
ingestion NN N
of IN N
last JJ N
tablet NN N
. . N

The DT N
subjects NNS N
were VBD N
exposed VBN N
to TO N
170 CD N
min NNS N
exercise-heat JJ N
stress NN N
( ( N
Tdb NNP N
= VBZ N
33 CD N
degrees NNS N
C NNP N
; : N
rh VBZ N
= $ N
60 CD N
% NN N
) ) N
consisting NN N
of IN N
60 CD N
min NNS N
in IN N
a DT N
sitting JJ N
position NN N
and CC N
two CD N
50-min JJ N
walks NNS N
( ( N
1.39 CD N
m.s-1 NN N
, , N
5 CD N
% NN N
grade NN N
) ) N
separated VBN N
by IN N
10 CD N
min NN N
of IN N
rest NN N
. . N

Non-evaporative NNP 1_o
heat NN 1_o
exchange NN 1_o
was VBD N
significantly RB N
higher JJR N
, , N
-14.0 JJ N
and CC N
-10.6 JJ N
W.m-2 NNP N
( ( N
p NN N
less JJR N
than IN N
0.03 CD N
) ) N
, , N
for IN N
the DT N
pyridostigmine-treated JJ 1_i
subjects NNS N
. . N

No DT N
additional JJ N
differences NNS N
were VBD N
found VBN N
between IN N
treatments NNS N
in IN N
the DT N
physiological JJ N
responses NNS N
and CC N
heat NN N
balance NN N
parameters NNS N
at IN N
the DT N
end NN N
of IN N
exposure NN N
: : N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
was VBD N
( ( N
mean JJ N
+/- JJ N
S.D NNP N
. . N

) ) N
154 CD N
+/- JJ N
16 CD N
and CC N
151 CD N
+/- JJ N
24 CD N
bpm NN N
, , N
rectal JJ N
temperature NN N
( ( N
Tre NNP N
) ) N
was VBD N
39.0 CD N
+/- JJ N
0.4 CD N
and CC N
38.9 CD N
+/- JJ N
0.2 CD N
degrees NNS N
C NNP N
, , N
heat NN N
storage NN N
over IN N
the DT N
2 CD N
h NN N
of IN N
exercise NN N
was VBD N
62 CD N
+/- JJ N
15 CD N
and CC N
70 CD N
+/- JJ N
15 CD N
W.m-2 JJ N
, , N
and CC N
sweat NN N
rate NN N
was VBD N
832 CD N
+/- JJ N
185 CD N
and CC N
748 CD N
+/- JJ N
52 CD N
g.h-1 NN N
, , N
in IN N
the DT N
pyridostigmine NN N
and CC N
placebo NN N
treatments NNS N
, , N
respectively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
One-year JJ N
results NNS N
from IN N
the DT N
phase NN N
III NNP N
investigation NN 1_i
of IN 1_i
the DT 1_i
KeraVision NNP 1_i
Intacs NNP 1_i
. . 1_i

BACKGROUND NNP N
Limitations NNP N
of IN N
the DT N
surgical JJ N
correction NN N
for IN N
myopia NN 1_p
include VBP N
inaccuracy NN N
, , N
instability NN N
, , N
treatment NN N
of IN N
the DT N
central JJ N
optical JJ N
zone NN N
, , N
and CC N
lack NN N
of IN N
reversibility NN N
. . N

KeraVision NNP 1_i
Intacs NNP 1_i
offer VBP N
an DT N
alternative NN N
that WDT N
addresses VBZ N
these DT N
shortcomings NNS N
. . N

METHODS NNP N
We PRP N
present VBD N
1 CD N
year NN N
of IN N
follow-up JJ N
information NN N
on IN N
95 CD 1_p
subjects NNS 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
United NNP 1_p
States NNPS 1_p
Food NNP 1_p
and CC 1_p
Drug NNP 1_p
Administration NNP 1_p
Phase NNP 1_p
III NNP 1_p
clinical JJ 1_p
trials NNS 1_p
. . 1_p

RESULTS NNP N
At IN N
1 CD N
year NN N
, , N
99 CD 1_p
% NN 1_p
of IN 1_p
patients NNS 1_p
( ( 1_p
89 CD 1_p
of IN 1_p
90 CD 1_p
) ) 1_p
had VBD 1_p
20/40 CD 1_p
uncorrected JJ 1_p
vision NN 1_p
or CC 1_p
better JJR 1_p
. . 1_p

Ninety-two JJ N
percent NN N
of IN N
eyes NNS N
( ( N
83 CD N
of IN N
90 CD N
) ) N
were VBD N
within IN N
1.00 CD N
D NNP N
of IN N
intended VBN N
correction NN N
and CC N
76 CD N
% NN N
of IN N
eyes NNS N
( ( N
68 CD N
of IN N
90 CD N
) ) N
were VBD N
within IN N
0.50 CD N
D NNP N
of IN N
intended JJ N
correction NN N
. . N

Stability NNP 1_o
was VBD N
achieved VBN N
at IN N
3 CD N
months NNS N
, , N
with IN N
96 CD N
% NN N
of IN N
subjects NNS N
( ( N
86 CD N
of IN N
90 CD N
) ) N
having VBG N
less JJR N
than IN N
1.00 CD N
D NNP N
of IN N
change NN N
from IN N
their PRP$ N
previous JJ N
examination NN N
. . N

In IN N
a DT N
substudy NN N
, , N
89 CD N
% NN N
eyes NNS N
( ( N
58 CD N
of IN N
65 CD N
) ) N
varied VBD N
within IN N
+/- JJ N
0.50 CD N
D NNP N
over IN N
the DT N
course NN N
of IN N
a DT N
day NN N
. . N

Corneal NNP 1_o
curvature NN 1_o
changed VBD N
as IN N
predicted VBN N
, , N
resulting VBG N
in IN N
a DT N
prolate NN N
aspheric JJ N
shape NN N
within IN N
the DT N
central JJ N
optical JJ N
zone NN N
. . N

Most JJS N
complications NNS 1_o
or CC 1_o
adverse JJ 1_o
events NNS 1_o
experienced VBN N
were VBD N
managed VBN N
with IN N
additional JJ N
medication NN N
or CC N
surgical JJ N
intervention NN N
, , N
resulting VBG N
in IN N
a DT N
favorable JJ N
outcome NN N
for IN N
subjects NNS N
. . N

CONCLUSIONS NNP N
KeraVision NNP N
Intacs NNP N
are VBP N
effective JJ 1_o
, , 1_o
predictable JJ 1_o
, , 1_o
stable JJ 1_o
, , 1_o
and CC 1_o
safe JJ 1_o
. . 1_o

This DT N
additive JJ N
technique NN N
may MD N
also RB N
offer VB N
reversibility NN N
. . N

A DT N
first-in-man JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
study NN N
to TO N
evaluate VB N
the DT N
safety NN 1_o
and CC 1_o
feasibility NN 1_o
of IN N
autologous JJ 1_i
delipidated VBN 1_i
high-density NN 1_i
lipoprotein NN 1_i
plasma NN 1_i
infusions NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
coronary JJ 1_p
syndrome NN 1_p
. . 1_p

OBJECTIVES CC N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
whether IN N
serial JJ 1_i
autologous JJ 1_i
infusions NNS 1_i
of IN 1_i
selective JJ 1_i
high-density NN 1_i
lipoprotein NN 1_i
( ( 1_i
HDL NNP 1_i
) ) 1_i
delipidated VBD 1_i
plasma NN 1_i
are VBP N
feasible JJ 1_o
and CC N
well RB N
tolerated VBN 1_o
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
coronary JJ 1_p
syndrome NN 1_p
( ( 1_p
ACS NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND NNP N
Low NNP N
HDL NNP N
is VBZ N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

Plasma NNP N
selective JJ N
delipidation NN N
converts NNS N
alphaHDL VBP N
to TO N
prebeta-like JJ N
HDL NNP N
, , N
the DT N
most RBS N
effective JJ N
form NN N
of IN N
HDL NNP N
for IN N
lipid JJ N
removal NN N
from IN N
arterial JJ N
plaques NNS N
. . N

METHODS NNP N
ACS NNP 1_p
patients NNS 1_p
undergoing VBG 1_p
cardiac JJ 1_p
catheterization NN 1_p
with IN 1_p
> NNP 1_p
or=1 VBP 1_p
nonobstructive JJ 1_p
native JJ 1_p
coronary JJ 1_p
artery NN 1_p
atheroma NN 1_p
were VBD N
randomized VBN N
to TO N
either DT N
7 CD N
weekly JJ N
HDL NNP 1_i
selective NN 1_i
delipidated VBD 1_i
or CC 1_i
control VB 1_i
plasma JJ 1_i
apheresis/reinfusions NNS 1_i
. . 1_i

Patients NNS N
underwent JJ N
intravascular JJ 1_o
ultrasound NN 1_o
( ( 1_o
IVUS NNP 1_o
) ) 1_o
evaluation NN 1_o
of IN N
the DT N
target NN N
vessel NN N
during IN N
the DT N
catheterization NN N
for IN N
ACS NNP N
and CC N
up RB N
to TO N
14 CD N
days NNS N
following VBG N
the DT N
final JJ N
apheresis/reinfusion NN 1_i
session NN N
. . N

2-D JJ N
gel JJ N
electrophoresis NN N
of IN N
delipidated JJ N
plasmas NN N
established VBN N
successful JJ N
conversion NN N
of IN N
alphaHDL NN N
to TO N
prebeta-like JJ N
HDL NNP N
. . N

The DT N
trial NN N
was VBD N
complete JJ N
with IN N
28 CD 1_p
patients NNS 1_p
randomized VBN N
. . N

RESULTS NNP N
All DT N
reinfusion NN N
sessions NNS N
were VBD N
tolerated VBN 1_o
well RB N
by IN N
all DT N
patients NNS N
. . N

The DT N
levels NNS 1_o
of IN 1_o
prebeta-like JJ 1_o
HDL NNP 1_o
and CC 1_o
alphaHDL NN 1_o
in IN N
the DT N
delipidated JJ N
plasma NN N
converted VBD N
from IN N
5.6 CD N
% NN N
to TO N
79.1 CD N
% NN N
and CC N
92.8 CD N
% NN N
to TO N
20.9 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
IVUS NNP N
data NNS N
demonstrated VBD N
a DT N
numeric JJ N
trend NN N
toward IN N
regression NN N
in IN N
the DT N
total JJ N
atheroma NN 1_o
volume NN 1_o
of IN N
-12.18 JJ N
+/- JJ N
36.75 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
delipidated JJ N
group NN N
versus VBD N
an DT N
increase NN N
of IN N
total JJ 1_o
atheroma JJ 1_o
volume NN 1_o
of IN N
2.80 CD N
+/- JJ N
21.25 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.268 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN 1_p
ACS NNP 1_p
patients NNS 1_p
, , N
serial JJ N
autologous JJ N
infusions NNS N
of IN N
selective JJ 1_i
HDL NNP 1_i
delipidated VBD 1_i
plasma NNS 1_i
are VBP N
clinically RB 1_o
feasible JJ 1_o
and CC N
well RB N
tolerated VBN 1_o
. . 1_o

This DT N
therapy NN N
may MD N
offer VB N
a DT N
novel JJ N
adjunct JJ N
treatment NN N
for IN N
patients NNS 1_p
presenting VBG 1_p
with IN 1_p
ACS NNP 1_p
. . 1_p

Further NNP N
study NN N
will MD N
be VB N
needed VBN N
to TO N
determine VB N
its PRP$ N
ability NN N
to TO N
reduce VB N
clinical JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
. . 1_o

MSL-109 NNP 1_i
adjuvant JJ 1_i
therapy NN 1_i
for IN N
cytomegalovirus NN 1_p
retinitis NN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
acquired JJ 1_p
immunodeficiency NN 1_p
syndrome NN 1_p
: : 1_p
the DT N
Monoclonal NNP N
Antibody NNP N
Cytomegalovirus NNP N
Retinitis NNP N
Trial NNP N
. . N

The DT 1_p
Studies NNPS 1_p
of IN 1_p
Ocular JJ 1_p
Complications NNS 1_p
of IN 1_p
AIDS NNP 1_p
Research NNP 1_p
Group NNP 1_p
. . 1_p

AIDS NNP 1_p
Clinical JJ 1_p
Trials NNP 1_p
Group NNP 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
an DT N
intravenous JJ N
human JJ N
monoclonal NN N
antibody NN N
to TO N
cytomegalovirus VB N
( ( N
CMV NNP N
) ) N
, , N
MSL-109 NNP 1_i
, , N
as IN N
adjuvant JJ N
treatment NN N
for IN N
CMV NNP N
retinitis NN N
. . N

METHODS NNP N
Two CD 1_p
hundred VBD 1_p
nine CD 1_p
patients NNS 1_p
with IN 1_p
acquired JJ 1_p
immunodeficiency NN 1_p
syndrome NN 1_p
and CC 1_p
active JJ 1_p
CMV NNP 1_p
retinitis NN 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
multicenter NN 1_p
, , 1_p
phase NN 1_p
2/3 CD 1_p
, , 1_p
randomized VBN 1_p
, , 1_p
placebo-controlled JJ 1_i
clinical JJ 1_p
trial NN 1_p
. . 1_p

Patients NNS N
received VBD N
adjuvant JJ N
treatment NN N
with IN N
MSL-109 NNP 1_i
, , N
60 CD N
mg NN N
intravenously RB N
every DT N
2 CD N
weeks NNS N
, , N
or CC N
placebo NN 1_i
. . 1_i

Randomization NN N
was VBD N
stratified VBN N
on IN N
the DT N
basis NN N
of IN N
whether IN N
patients NNS N
had VBD N
untreated VBN N
or CC N
relapsed VBN N
retinitis NN N
. . N

Primary JJ 1_i
drug NN 1_i
therapy NN 1_i
for IN N
CMV NNP N
retinitis NN N
was VBD N
determined VBN N
by IN N
the DT N
treating NN N
physician NN N
. . N

RESULTS VB N
The DT N
rates NNS 1_o
of IN 1_o
retinitis NN 1_o
progression NN 1_o
, , N
as IN N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
, , N
were VBD N
3.04/person-year JJ N
in IN N
the DT N
MSL-109-treated NNP 1_i
group NN N
and CC N
3.05/person-year JJ N
in IN N
the DT N
placebo-treated JJ 1_i
group NN N
( ( N
P=.98 NNP N
; : N
Wald NNP N
test NN N
) ) N
; : N
the DT N
median JJ N
times NNS N
to TO N
progression NN N
were VBD N
67 CD N
days NNS N
in IN N
the DT N
MSL-109-treated NNP 1_i
group NN N
and CC N
65 CD N
days NNS N
in IN N
the DT N
placebo-treated JJ N
group NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
noted VBN N
in IN N
the DT N
rates NNS 1_o
of IN 1_o
increase NN 1_o
in IN 1_o
retinal JJ 1_o
area NN 1_o
involved VBN 1_o
by IN 1_o
CMV NNP 1_o
, , 1_o
visual JJ 1_o
field NN 1_o
loss NN 1_o
, , 1_o
or CC 1_o
visual JJ 1_o
acuity NN 1_o
outcomes NNS 1_o
. . 1_o

The DT N
mortality NN 1_o
rate NN 1_o
in IN N
the DT N
MSL-109-treated NNP 1_i
group NN N
was VBD N
0.68/person-year JJ N
, , N
and CC N
in IN N
the DT N
placebo-treated JJ 1_i
group NN N
, , N
0.31/person-year JJ N
( ( N
P=.01 NNP N
) ) N
. . N

The DT N
mortality NN 1_o
difference NN N
was VBD N
not RB N
explained VBN N
by IN N
differences NNS N
in IN N
baseline NN N
variables NNS N
or CC N
in IN N
concurrent JJ N
antiretroviral JJ N
therapy NN N
. . N

Among IN 1_p
patients NNS 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
retinitis NN 1_p
, , N
mortality NN 1_o
rates NNS 1_o
were VBD N
similar JJ N
( ( N
MSL-109 NNP N
, , N
0.41/person-year JJ N
; : N
placebo NN N
, , N
0.42/person-year JJ N
; : N
P=.95 NNP N
) ) N
, , N
whereas JJ N
among IN N
patients NNS N
with IN N
relapsed JJ N
retinitis NN N
the DT N
MSL-109-treated NNP 1_i
group NN N
had VBD N
a DT N
greater JJR N
mortality NN 1_o
rate NN 1_o
( ( 1_i
MSL-109 NNP 1_i
, , N
0.83/person-year JJ N
; : N
placebo NN 1_i
, , N
0.24/person-year JJ N
; : N
P=.003 NNP N
) ) N
. . N

However RB N
, , N
the DT N
mortality NN 1_o
rate NN 1_o
in IN N
the DT N
placebo-treated JJ 1_i
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
placebo-treated JJ N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
CMV NNP N
retinitis NN N
and CC N
lower JJR N
than IN N
that DT N
in IN N
other JJ N
trials NNS N
of IN N
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
. . N

CONCLUSIONS NNP N
Intravenous NNP N
MSL-109 NNP 1_i
, , N
60 CD N
mg NN N
every DT N
2 CD N
weeks NNS N
, , N
appeared VBD N
to TO N
be VB N
ineffective JJ 1_o
adjuvant JJ N
therapy NN N
for IN N
CMV NNP N
retinitis NN N
. . N

The DT N
mortality NN 1_o
rate NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
MSL-109-treated NNP 1_i
group NN N
, , N
but CC N
the DT N
reasons NNS N
for IN N
this DT N
difference NN N
remain NN N
uncertain JJ N
. . N

Metformin NNP 1_i
does VBZ N
not RB N
enhance VB N
ovulation NN N
induction NN N
in IN N
clomiphene NN 1_p
resistant JJ 1_p
polycystic JJ 1_p
ovary JJ 1_p
syndrome NN 1_p
in IN N
clinical JJ N
practice NN N
. . N

AIMS NNP N
To TO N
determine VB N
whether IN N
metformin NN 1_i
pretreatment NN 1_i
has VBZ N
beneficial JJ 1_o
effects NNS 1_o
in IN N
clomiphene NN 1_p
resistant JJ 1_p
infertile JJ 1_p
women NNS 1_p
with IN 1_p
polycystic JJ 1_p
ovary JJ 1_p
syndrome NN 1_p
( ( 1_p
PCOS NNP 1_p
) ) 1_p
in IN 1_p
an DT 1_p
infertility NN 1_p
clinic NN 1_p
. . 1_p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
placebo NN N
controlled VBD N
double-blind NN N
crossover NN N
study NN N
of IN N
3 CD N
months NNS N
metformin RB 1_i
( ( N
1500 CD N
mg IN N
day-1 NN 1_i
) ) 1_i
/placebo NN 1_i
, , N
followed VBN N
by IN N
3 CD N
months NNS N
metformin/placebo VBN 1_i
together RB 1_i
with IN 1_i
clomiphene NN 1_i
( ( N
50-100 JJ N
mg NN N
for IN N
5 CD N
days NNS N
) ) N
for IN N
three CD N
cycles NNS N
in IN N
clomiphene NN 1_p
resistant JJ 1_p
women NNS 1_p
with IN 1_p
PCOS NNP 1_p
. . 1_p

The DT N
primary JJ N
outcomes NNS N
were VBD N
restoration NN 1_o
of IN 1_o
spontaneous JJ 1_o
menses NNS 1_o
, , 1_o
ovulation NN 1_o
induction NN 1_o
( ( 1_o
spontaneous JJ 1_o
or CC 1_o
clomiphene NN 1_o
induced VBN 1_o
) ) 1_o
and CC 1_o
pregnancy NN 1_o
. . 1_o

Secondary JJ 1_o
endpoints NNS 1_o
were VBD N
changes NNS N
in IN N
biochemical JJ N
parameters NNS N
related VBN N
to TO N
androgens NNS N
and CC N
insulin NN N
. . N

RESULTS NNP N
Twelve NNP 1_p
women NNS 1_p
completed VBD 1_p
the DT 1_p
metformin NN 1_i
arm NN 1_p
and CC 1_p
14 CD 1_p
the DT 1_p
placebo NN 1_i
arm NN 1_p
. . 1_p

Spontaneous JJ 1_o
menstruation NN 1_o
resumed VBD N
in IN N
five CD N
metformin NNS 1_i
treated VBD N
patients NNS N
and CC N
in IN N
six CD N
placebo NN 1_i
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

No NNP N
women NNS N
given VBN N
metformin NNS N
spontaneously RB 1_o
ovulated VBD 1_o
, , N
although IN N
one CD N
patient NN N
given VBN N
placebo NN 1_i
did VBD N
, , N
P=0.30 NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
efficacy NN 1_o
of IN 1_o
clomiphene NN 1_o
between IN N
the DT N
two CD N
groups NNS N
with IN N
ovulation NN 1_o
being VBG 1_o
induced VBN 1_o
in IN N
five CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
metformin NN 1_i
treated VBN N
women NNS N
and CC N
four CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
placebo NN 1_i
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

Pregnancy NN 1_o
occurred VBD N
in IN N
three CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
women NNS N
given VBN N
metformin NNS 1_i
and CC N
two CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
women NNS N
given VBN N
placebo NNS 1_i
, , N
P=0.59 NNP N
. . N

CONCLUSIONS NNP N
Metformin NNP 1_i
is VBZ N
not RB N
always RB N
beneficial JJ N
when WRB N
given VBN N
to TO N
clomiphene VB 1_p
resistant JJ 1_p
infertile JJ 1_p
women NNS 1_p
with IN 1_p
PCOS NNP 1_p
in IN N
clinical JJ N
practice NN N
. . N

The DT N
effects NNS N
of IN N
hormone NN 1_i
replacement NN 1_i
therapy NN 1_i
on IN N
hemostatic JJ N
variables NNS N
in IN N
women NNS 1_p
with IN 1_p
angiographically RB 1_p
verified VBN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
: : 1_p
results NNS N
from IN N
the DT N
estrogen NN N
in IN N
women NNS 1_p
with IN 1_p
atherosclerosis NN 1_p
study NN 1_p
. . 1_p

Data NNP N
on IN N
the DT N
effect NN N
of IN N
hormone NN 1_i
replacement NN 1_i
therapy NN 1_i
on IN N
hemostasis NN N
are VBP N
inconsistent JJ N
, , N
and CC N
there EX N
are VBP N
few JJ N
data NNS N
in IN N
women NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
. . 1_p

In IN N
a DT N
single-center NN N
, , N
open JJ N
, , N
randomized VBN N
study NN N
, , N
118 CD 1_p
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
angiographically RB 1_p
verified VBN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
were VBD N
randomized VBN N
to TO N
hormone VB N
replacement NN N
therapy NN N
, , N
given VBN N
as IN N
long-cycle JJ 1_i
transdermal JJ 1_i
17-beta-estradiol JJ 1_i
( ( N
50 CD N
microg/24 RB N
hour NN N
) ) N
for IN N
3 CD N
months NNS N
with IN N
sequential JJ 1_i
medroxy-progesterone NN 1_i
acetate NN 1_i
for IN N
14 CD N
days NNS N
, , N
or CC N
to TO N
a DT N
control NN 1_i
group NN N
receiving VBG 1_i
no DT 1_i
therapy NN 1_i
. . 1_i

Hemostatic JJ N
parameters NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
and CC N
12 CD N
months NNS N
of IN N
therapy NN N
. . N

The DT N
coagulation NN 1_o
inhibitors NNS 1_o
antithrombin VBP 1_o
, , 1_o
protein JJ 1_o
C NNP 1_o
, , 1_o
and CC 1_o
protein NN 1_o
S NNP 1_o
, , N
but CC N
not RB N
tissue VB 1_o
factor NN 1_o
pathway NN 1_o
inhibitor NN 1_o
, , N
decreased VBN N
significantly RB N
from IN N
baseline NN N
in IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
at IN N
both DT N
3 CD N
and CC N
12 CD N
months NNS N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

The DT N
absolute NN N
decreases VBZ N
within IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
were VBD N
3 CD N
to TO N
10 CD N
% NN N
. . N

No DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
were VBD N
observed VBN N
for IN N
the DT N
coagulation NN 1_o
products NNS 1_o
prothrombin VBP 1_o
fragment JJ 1_o
1+2 CD 1_o
or CC 1_o
thrombin-antithrombin JJ 1_o
complex NN 1_o
or CC 1_o
for IN 1_o
D-dimer NNP 1_o
, , N
although IN N
there EX N
were VBD N
significant JJ N
decreases NNS N
in IN N
the DT N
levels NNS N
within IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
. . N

Levels NNP 1_o
of IN 1_o
fibrinogen NN 1_o
, , 1_o
activated VBD 1_o
factor NN 1_o
VII NNP 1_o
, , 1_o
and CC 1_o
factor NN 1_o
VII NNP 1_o
antigen NN 1_o
were VBD N
not RB N
significantly RB N
influenced VBN N
by IN N
hormone NN N
replacement NN N
therapy NN N
treatment NN N
. . N

Similarly RB N
, , N
nonsignificant JJ N
changes NNS N
were VBD N
detected VBN N
for IN N
the DT N
fibrinolytic JJ 1_o
parameters NNS 1_o
tissue VBP 1_o
plasminogen JJ 1_o
activator NN 1_o
activity NN 1_o
, , 1_o
tissue NN 1_o
plasminogen NN 1_o
activator NN 1_o
antigen NN 1_o
, , 1_o
and CC 1_o
global JJ 1_o
fibrinolytic JJ 1_o
activity NN 1_o
, , 1_o
but CC 1_o
plasminogen NN 1_o
activator NN 1_o
inhibitor NN 1_o
type VBD 1_o
1 CD 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
due JJ N
to TO N
a DT N
questionable JJ N
increase NN N
in IN N
the DT N
levels NNS N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
transdermal JJ 1_i
estradiol NNS 1_i
combined VBN 1_i
with IN 1_i
long-cycle NN 1_i
progestins NNS 1_i
was VBD N
associated VBN N
with IN N
no DT N
net JJ N
activation NN 1_o
of IN 1_o
coagulation NN 1_o
despite IN N
reduced JJ N
levels NNS N
of IN N
coagulation NN 1_o
inhibitors NNS 1_o
. . 1_o

Evaluation NN N
of IN N
asthma NN N
knowledge NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
Hungarian JJ 1_p
asthmatics NNS 1_p
. . 1_p

BACKGROUND IN N
The DT N
objective NN N
was VBD N
to TO N
develop VB N
an DT N
educational JJ 1_i
instrument NN 1_i
, , N
to TO N
assess VB N
its PRP$ N
impact NN N
as IN N
an DT N
intervention NN 1_i
instrument NN N
and CC N
to TO N
examine VB N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
. . N

METHODS $ N
119 CD 1_p
asthmatics NNS 1_p
were VBD 1_p
randomized VBN 1_p
( ( N
64 CD N
in IN N
the DT N
intervention NN 1_i
and CC N
55 CD N
in IN N
the DT N
reference NN 1_i
group NN N
) ) N
. . N

The DT N
education NN 1_i
instrument NN 1_i
was VBD N
developed VBN N
based VBN N
on IN N
the DT N
EuroPharm-Forum NNP N
Guidelines NNP N
and CC N
its PRP$ N
impact NN N
assessed VBN N
by IN N
a DT N
self-developed JJ N
questionnaire NN N
. . N

Patients NNS N
' POS N
QoL NNP N
, , N
asthma NN N
knowledge NN N
was VBD N
assessed VBN N
twice RB N
, , N
once RB N
before IN N
and CC N
after IN N
the DT N
education NN 1_i
seminar NN 1_i
, , N
education NN N
was VBD N
only RB N
provided VBN N
for IN N
the DT N
intervention NN N
group NN N
. . N

QoL NNP 1_o
was VBD N
measured VBN N
with IN N
the DT N
St NNP 1_o
George NNP 1_o
's POS 1_o
Respiratory NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
SGRQ NNP 1_o
) ) 1_o
and CC N
a DT N
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
. . N

RESULTS NNP N
We PRP N
found VBD N
significant JJ N
differences NNS N
in IN N
answers NNS N
to TO N
the DT N
asthma JJ N
questions NNS N
, , N
by IN N
40 CD N
% NN N
improvement NN N
, , N
but CC N
no DT N
changes NNS N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
inhaler-use NN N
technique NN N
, , N
we PRP N
could MD N
not RB N
find VB N
significant JJ N
changes NNS N
neither CC N
in IN N
the DT N
intervention NN N
nor CC N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
results NNS N
of IN N
the DT N
two CD N
visits NNS N
neither CC N
with IN N
the DT N
VAS NNP 1_o
nor CC N
with IN N
the DT N
SGRQ NNP 1_o
on IN N
the DT N
QoL NNP 1_o
data NN 1_o
. . 1_o

CONCLUSION NNP N
The DT N
results NNS N
indicate VBP N
that IN N
asthmatics NNS N
experience VB N
lower JJR N
QoL NNP 1_o
. . 1_o

As IN N
the DT 1_p
subjects NNS 1_p
were VBD 1_p
regularly RB 1_p
controlled VBN 1_p
asthmatics NNS 1_p
they PRP N
had VBD N
better RBR N
general JJ N
knowledge NN N
and CC N
inhaler-use NN N
technique NN N
was VBD N
expected VBN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
regularly VB N
refresh JJ N
asthma NN N
knowledge NN N
, , N
to TO N
assess VB N
patients NNS N
' POS N
self-management JJ N
plans NNS N
to TO N
achieve VB N
long-term JJ N
effectiveness NN N
of IN N
asthma JJ N
management NN N
. . N

Pilot NNP N
study NN N
of IN N
imiquimod JJ 1_i
5 CD 1_i
% NN 1_i
cream NN 1_i
as IN N
adjunctive JJ 1_i
therapy NN 1_i
to TO N
curettage VB 1_i
and CC N
electrodesiccation NN 1_i
for IN N
nodular JJ 1_p
basal NN 1_p
cell NN 1_p
carcinoma NN 1_p
. . 1_p

BACKGROUND NNP N
Curettage NNP 1_i
and CC 1_i
electrodesiccation NN 1_i
( ( 1_i
C NNP 1_i
& CC 1_i
D NNP 1_i
) ) 1_i
is VBZ N
a DT N
widely RB N
used VBN N
method NN N
to TO N
treat VB N
nodular JJ 1_p
basal NN 1_p
cell NN 1_p
carcinoma NN 1_p
( ( 1_p
BCC NNP 1_p
) ) 1_p
. . 1_p

However RB N
, , N
residual JJ N
tumor NN N
is VBZ N
present JJ N
immediately RB N
after IN N
the DT N
procedure NN N
in IN N
approximately RB N
20 CD N
to TO N
40 CD N
% NN N
of IN N
cases NNS N
. . N

Imiquimod NNP N
, , N
a DT N
topical JJ N
immune NN N
response NN N
modifier NN N
that WDT N
targets VBZ N
Toll-like NNP N
receptor NN N
7 CD N
, , N
is VBZ N
currently RB N
approved VBN N
for IN N
superficial JJ N
BCC NNP N
. . N

OBJECTIVE NNP N
In IN N
a DT N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
, , N
the DT N
administration NN N
of IN N
imiquimod NN 1_i
after IN N
C NNP N
& CC N
D NNP N
was VBD N
investigated VBN N
to TO N
determine VB N
if IN N
the DT N
combination NN N
regimen NNS N
would MD N
reduce VB N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
compared VBN N
with IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
alone RB N
in IN N
patients NNS 1_p
with IN 1_p
nodular JJ 1_p
BCC NNP 1_p
. . 1_p

METHODS NNP N
Twenty NNP 1_p
patients NNS 1_p
received VBD N
three CD N
cycles NNS N
of IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
followed VBN N
by IN N
imiquimod JJ 1_i
5 CD 1_i
% NN 1_i
or CC 1_i
vehicle NN 1_i
cream NN 1_i
once RB 1_i
daily JJ 1_i
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ 1_i
therapy NN 1_i
. . 1_i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
. . N

The DT N
secondary JJ N
end NN N
points NNS N
included VBD N
the DT N
time NN N
to TO N
heal VB N
and CC N
cosmetic JJ N
appearance NN N
. . N

RESULTS NNP N
Twenty NNP 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
the DT N
imiquimod NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
10 CD 1_p
) ) 1_p
or CC N
vehicle NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
10 CD 1_p
) ) 1_p
treatment NN N
group NN N
. . N

At IN N
8 CD N
weeks NNS N
, , N
the DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
residual JJ 1_o
tumor NN 1_o
was VBD N
substantially RB N
decreased VBN N
with IN N
imiquimod JJ 1_i
therapy NN N
( ( N
10 CD N
% NN N
) ) N
compared VBN N
with IN N
vehicle NN 1_i
( ( N
40 CD N
% NN N
) ) N
. . N

Wounds VBZ N
in IN N
the DT N
vehicle NN N
group NN N
healed VBD 1_o
more RBR N
quickly RB N
than IN N
those DT N
in IN N
the DT N
imiquimod NN N
group NN N
, , N
although IN N
by IN N
8 CD N
weeks NNS N
, , N
all DT N
excision NN N
sites NNS N
were VBD N
healed VBN N
. . N

The DT N
majority NN N
of IN N
scars NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
atrophic JJ N
and CC N
hypopigmented VBD N
, , N
whereas IN N
most JJS N
scars NNS N
in IN N
the DT N
imiquimod NN 1_i
group NN N
were VBD N
flat JJ N
and CC N
slightly RB N
pink VBP N
. . N

CONCLUSION NNP N
Imiquimod NNP 1_i
5 CD N
% NN N
cream NN N
once RB N
daily JJ N
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ N
therapy NN N
after IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
substantially RB N
reduced VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
and CC N
improved VBD N
the DT N
cosmetic JJ N
appearance NN N
compared VBN N
with IN N
C NNP 1_i
& CC 1_i
D NNP 1_i
alone RB N
. . N

These DT N
preliminary JJ N
results NNS N
suggest VBP N
that IN N
further JJ N
studies NNS N
to TO N
investigate VB N
imiquimod JJ 1_i
adjunctive JJ 1_i
therapy NN 1_i
are VBP N
warranted VBN N
. . N

Prophylactic JJ 1_i
lidocaine NN 1_i
in IN N
the DT N
early JJ N
phase NN N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
. . N

Four CD 1_p
hundred VBD 1_p
two CD 1_p
patients NNS 1_p
with IN 1_p
suspected JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
seen VBN 1_p
within IN 1_p
6 CD 1_p
hours NNS 1_p
of IN 1_p
the DT 1_p
onset NN 1_p
of IN 1_p
symptoms NNS 1_p
entered VBD N
a DT N
double-blind JJ N
randomized JJ N
trial NN N
of IN N
lidocaine NN 1_i
vs NN 1_i
placebo NN 1_i
. . 1_i

During IN N
the DT N
1 CD N
hour NN N
after IN N
administration NN N
of IN N
the DT N
drug NN N
the DT N
incidence NN 1_o
of IN 1_o
ventricular JJ 1_o
fibrillation NN 1_o
or CC 1_o
sustained VBN 1_o
ventricular JJ 1_o
tachycardia NN 1_o
among IN N
the DT N
204 CD 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
was VBD N
low JJ N
, , N
1.5 CD N
% NN N
. . N

Lidocaine NNP 1_i
, , N
given VBN N
in IN N
a DT N
300 CD N
mg NN N
dose VBD N
intramuscularly RB N
followed VBN N
by IN N
100 CD N
mg NN N
intravenously RB N
, , N
did VBD N
not RB N
prevent VB N
sustained JJ 1_o
ventricular JJ 1_o
tachycardia NN 1_o
, , N
although IN N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
warning VBG 1_o
arrhythmias NNS 1_o
between IN N
15 CD N
and CC N
45 CD N
minutes NNS N
after IN N
the DT N
administration NN N
of IN N
lidocaine NN 1_i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
average JJ 1_o
plasma JJ 1_o
lidocaine JJ 1_o
level NN 1_o
10 CD N
minutes NNS 1_o
after IN 1_o
administration NN N
for IN N
patients NNS N
without IN N
a DT N
myocardial JJ N
infarction NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
for IN N
patients NNS N
with IN N
an DT N
acute JJ N
infarction NN N
. . N

The DT N
mean JJ 1_o
plasma NN 1_o
lidocaine JJ 1_o
level NN 1_o
of IN N
patients NNS N
on IN N
beta-blocking JJ N
agents NNS N
was VBD N
no DT N
different JJ N
from IN N
that DT N
in IN N
patients NNS N
not RB N
on IN N
beta NN N
blocking VBG N
agents NNS N
. . N

During IN N
the DT N
1-hour JJ N
study NN N
period NN N
, , N
the DT N
incidence NN 1_o
of IN 1_o
central JJ 1_o
nervous JJ 1_o
system NN 1_o
side NN 1_o
effects NNS 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
lidocaine NN N
group NN N
, , N
hypotension NN 1_o
occurred VBD N
in IN N
11 CD N
patients NNS N
, , N
nine CD N
of IN N
whom WP N
had VBD N
received VBN N
lidocaine NN N
, , N
and CC N
four CD 1_p
patients NNS 1_p
died VBD 1_o
from IN N
asystole NN N
, , N
three CD N
of IN N
whom WP N
had VBD N
had VBN N
lidocaine NN 1_i
. . 1_i

We PRP N
can MD N
not RB N
advocate VB N
the DT N
administration NN N
of IN N
lidocaine JJ 1_i
prophylactically RB N
in IN N
the DT N
early JJ N
hours NNS N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
. . N

Leukotriene NNP 1_i
antagonist NN 1_i
prevents NNS N
exacerbation NN N
of IN N
asthma NN 1_p
during IN N
reduction NN N
of IN N
high-dose JJ N
inhaled JJ N
corticosteroid NN N
. . N

The DT N
Tokyo NNP N
Joshi-Idai NNP N
Asthma NNP N
Research NNP N
Group NNP N
. . N

To TO N
test VB N
whether IN N
the DT N
leukotriene JJ 1_i
antagonist JJ 1_i
ONO-1078 NNP 1_i
( ( 1_i
pranlukast NN 1_i
) ) 1_i
prevents VBZ N
asthma JJ 1_p
exacerbations NNS N
during IN N
reduction NN N
of IN N
high-dose JJ N
inhaled JJ N
corticosteroid NN 1_i
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
79 CD 1_p
asthma NN 1_p
patients NNS 1_p
requiring VBG 1_p
high JJ 1_p
doses NNS 1_p
( ( 1_p
1,500 CD 1_p
microg/d NN 1_p
or CC 1_p
more JJR 1_p
) ) 1_p
of IN 1_p
inhaled JJ 1_i
beclomethasone NN 1_i
dipropionate NN 1_i
( ( 1_i
BDI NNP 1_i
) ) 1_i
for IN 1_i
clinical JJ 1_p
control NN 1_p
( ( 1_p
duration NN 1_p
of IN 1_p
asthma NN 1_p
, , 1_p
11.0 CD 1_p
+/- JJ 1_p
3.1 CD 1_p
yr NN 1_p
; : 1_p
duration NN 1_p
of IN 1_p
BDI NNP 1_p
treatment NN 1_p
, , 1_p
0.5 CD 1_p
+/- JJ 1_p
0.3 CD 1_p
yr NN 1_p
; : 1_p
FEV1 NNP 1_p
percentage NN 1_p
of IN 1_p
predicted VBN 1_p
, , 1_p
80.7 CD 1_p
+/- JJ 1_p
2.0 CD 1_p
% NN 1_p
) ) 1_p
. . 1_p

After IN N
a DT N
2-wk JJ N
run-in JJ N
period NN N
, , N
the DT N
doses NNS N
of IN N
BDI NNP N
were VBD N
halved VBN N
, , N
while IN N
the DT N
patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
orally RB 1_i
ONO-1078 NNP 1_i
, , 1_i
450 CD 1_i
mg NN 1_i
twice RB 1_i
daily RB 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

In IN N
the DT N
placebo NN 1_i
group NN N
FEV1 NNP 1_o
decreased VBN N
by IN N
0.33 CD N
+/- JJ N
0.20 CD N
L NNP N
after IN N
6 CD N
wk NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Likewise NNP N
, , N
morning NN 1_o
and CC 1_o
evening NN 1_o
PEF NNP 1_o
decreased VBN N
by IN N
46 CD N
+/- JJ N
7 CD N
L/min NNP N
and CC N
18 CD N
+/- JJ N
6 CD N
L/min NNP N
, , N
respectively RB N
. . N

By IN N
contrast NN N
these DT N
variables NNS N
were VBD N
sustained VBN N
above IN N
baseline NN N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

The DT N
number NN 1_o
of IN 1_o
daytime NN 1_o
and CC 1_o
nighttime JJ 1_o
asthma NN 1_o
symptoms NNS 1_o
and CC 1_o
the DT 1_o
use NN 1_o
of IN 1_o
beta2-agonist NN 1_o
increased VBN N
in IN N
the DT N
placebo NN N
group NN N
, , N
whereas IN N
they PRP N
remained VBD N
unchanged JJ N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

In IN N
the DT N
placebo NN 1_i
group NN N
concentrations NNS 1_o
of IN 1_o
serum NN 1_o
eosinophil NN 1_o
cationic JJ 1_o
protein NN 1_o
and CC 1_o
exhaled VBD 1_o
nitric JJ 1_o
oxide NN 1_o
increased VBD N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.025 CD N
, , N
respectively RB N
) ) N
, , N
compared VBN N
with IN N
no DT N
change NN N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

Therefore RB N
, , N
the DT N
leukotriene JJ 1_i
antagonist JJ 1_i
ONO-1078 JJ 1_i
prevents NNS N
the DT N
asthma JJ 1_p
deterioration NN N
provoked VBN N
by IN N
a DT N
6-wk JJ N
reduction NN N
of IN N
the DT N
dose NN N
of IN N
inhaled JJ N
BDI NNP N
into IN N
half NN N
. . N

Comparison NNP N
of IN N
dual-axis JJ 1_i
rotational JJ 1_i
coronary NN 1_i
angiography NN 1_i
( ( 1_i
XPERSWING NN 1_i
) ) 1_i
versus IN N
conventional JJ 1_i
technique NN N
in IN N
routine JJ N
practice NN N
. . N

INTRODUCTION NNP N
AND NNP N
OBJECTIVES NNP N
Coronary NNP N
angiography NN 1_i
is VBZ N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
study NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

This DT N
technique NN N
requires VBZ N
several JJ N
orthogonal JJ N
projections NNS N
. . N

Rotational JJ 1_i
angiography NN 1_i
is VBZ N
a DT N
new JJ N
technique NN N
which WDT N
involves VBZ N
pre-set JJ N
rotation NN N
of IN N
the DT N
X-ray JJ N
tube NN N
around IN N
the DT N
patient NN N
and CC N
allows VBZ N
visualization NN N
of IN N
each DT N
coronary JJ N
artery NN N
in IN N
different JJ N
views NNS N
, , N
using VBG N
a DT N
single JJ N
contrast NN N
injection NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
conventional JJ 1_i
coronary JJ 1_i
angiography NN 1_i
( ( 1_i
A DT 1_i
) ) 1_i
vs FW 1_i
rotational JJ 1_i
angiography NN 1_i
( ( N
B NNP N
) ) N
, , N
focusing VBG N
on IN N
radiation NN N
dose NN N
, , N
amount NN N
of IN N
contrast NN N
administered VBN N
, , N
and CC N
total JJ N
procedure NN N
time NN N
for IN N
both DT N
diagnostic JJ N
and CC N
therapeutic JJ N
percutaneous JJ N
coronary JJ N
interventions NNS N
. . N

METHODS NNP N
Prospective NNP 1_p
study NN 1_p
of IN 1_p
104 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
coronary JJ 1_i
angiography NN 1_i
who WP 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
one CD N
of IN N
these DT N
techniques NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
amount NN 1_o
of IN 1_o
contrast NN 1_o
administered VBN 1_o
( ( N
A DT N
vs NN N
B NNP N
, , N
93.1 CD N
[ NN N
41.7 CD N
] NNP N
vs NN N
50.9 CD N
[ NN N
14.7 CD N
] NNP N
mL NN N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
and CC N
radiation NN 1_o
exposure NN 1_o
( ( N
27.6 CD N
[ RB N
11.5 CD N
] JJ N
vs NN N
18 CD N
[ NN N
6.4 CD N
] NN N
mGycm NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

A DT N
significant JJ N
increase NN N
in IN N
total JJ 1_o
procedure NN 1_o
time NN 1_o
was VBD N
noted VBN N
in IN N
the DT N
rotational JJ N
angiography NN N
arm NN N
. . N

However RB N
, , N
when WRB N
only RB N
the DT N
last JJ N
50 CD N
patients NNS N
were VBD N
analyzed VBN N
, , N
we PRP N
found VBD N
no DT N
difference NN N
in IN N
procedure NN 1_o
time NN 1_o
between IN N
the DT N
groups NNS N
, , N
probably RB N
related VBN N
to TO N
the DT N
learning VBG N
curve NN N
of IN N
the DT N
operators NNS N
. . N

Angioplasty NNP 1_o
was VBD N
performed VBN N
in IN N
29 CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
28 CD N
patients NNS N
in IN N
group NN N
B NNP N
. . N

Contrast NNP 1_o
reduction NN 1_o
was VBD N
maintained VBN N
in IN N
the DT N
rotational JJ N
angiography NN N
group NN N
compared VBN N
to TO N
the DT N
conventional JJ N
technique NN N
( ( N
A NNP N
vs NN N
B NNP N
, , N
335.1 CD N
[ NN N
192.1 CD N
] NNP N
vs NN N
238.5 CD N
[ NN N
114.4 CD N
] NNP N
mL NN N
; : N
P=.02 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
rotational JJ 1_i
angiography NN 1_i
technique NN N
leads VBZ N
to TO N
a DT N
significant JJ N
decrease NN N
in IN N
radiation NN 1_o
exposure NN 1_o
and CC N
contrast NN 1_o
dose NN 1_o
administered VBN N
for IN N
diagnostic JJ N
procedures NNS N
when WRB N
compared VBN N
to TO N
conventional JJ 1_i
coronary JJ 1_i
angiography NN 1_i
. . 1_i

In IN N
patients NNS N
who WP N
undergo VBP N
percutaneous JJ N
coronary JJ N
intervention NN N
, , N
contrast NN N
reduction NN N
remains VBZ N
significant JJ N
. . N

Comparison NNP N
of IN N
different JJ N
approaches NNS N
for IN N
assessment NN N
of IN N
HER2 NNP N
expression NN N
on IN N
protein NN N
and CC N
mRNA JJ N
level NN N
: : N
prediction NN N
of IN N
chemotherapy NN 1_i
response NN N
in IN N
the DT N
neoadjuvant JJ N
GeparTrio NNP N
trial NN N
( ( N
NCT00544765 NNP N
) ) N
. . N

Human NNP 1_i
epidermal JJ 1_i
growth NN 1_i
factor NN 1_i
receptor NN 1_i
2 CD 1_i
( ( N
HER2 NNP N
) ) N
testing NN N
is VBZ N
an DT N
essential JJ N
part NN N
of IN N
pathological JJ N
assessment NN N
in IN N
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
, , N
as IN N
HER2 NNP N
provides VBZ N
not RB N
only RB N
prognostic JJ N
but CC N
also RB N
predictive JJ N
information NN N
on IN N
response NN N
to TO N
targeted VBN N
therapy NN N
. . N

So RB N
far RB N
, , N
HER2 NNP N
test JJS N
accuracy NN N
of IN N
immunohistochemistry/in JJ N
situ-hybridization NN N
techniques NNS N
is VBZ N
still RB N
under IN N
debate NN N
, , N
and CC N
more RBR N
reliable JJ N
and CC N
robust JJ N
technologies NNS N
are VBP N
needed VBN N
. . N

To TO N
address VB N
this DT N
issue NN N
and CC N
to TO N
evaluate VB N
the DT N
predictive JJ N
value NN N
of IN N
HER2 NNP N
on IN N
chemotherapy NN 1_i
, , N
we PRP N
investigated VBD 1_p
a DT 1_p
cohort NN 1_p
of IN 1_p
278 CD 1_p
patients NNS 1_p
from IN 1_p
the DT 1_p
GeparTrio NNP 1_p
trial NN 1_p
, , N
a DT N
prospective JJ N
neoadjuvant JJ N
anthracycline/taxane-based JJ N
multicenter NN N
study NN N
. . N

In IN N
the DT N
GeparTrio NNP N
trial NN N
, , N
patients NNS N
were VBD N
not RB N
treated VBN N
with IN N
any DT N
anti-HER2 JJ 1_i
therapy NN 1_i
, , N
as IN N
this DT N
was VBD N
not RB N
standard JJ N
therapy NN N
at IN N
this DT N
time NN N
. . N

The DT N
HER2 NNP 1_o
status NN 1_o
was VBD N
analyzed VBN N
by IN N
three CD N
different JJ N
approaches NNS N
: : N
local JJ 1_i
and CC 1_i
central JJ 1_i
evaluation NN 1_i
using VBG 1_i
immunohistochemistry NN 1_i
combined VBN 1_i
with IN 1_i
in IN 1_i
situ-hybridization NN 1_i
as RB N
well RB N
as IN N
evaluation NN 1_i
of IN 1_i
HER2 NNP 1_o
mRNA FW 1_o
expression NN 1_o
using VBG 1_i
kinetic JJ 1_i
RT-PCR JJ 1_i
from IN 1_i
formalin-fixed JJ 1_i
, , 1_i
paraffin-embedded JJ 1_i
( ( 1_i
FFPE NNP 1_i
) ) 1_i
tissue NN 1_i
samples NNS 1_i
using VBG N
a DT N
predefined VBN N
cutoff NN N
. . N

HER2 NNP 1_o
overexpression/amplification NN 1_o
was VBD N
observed VBN N
in IN N
37.3 CD N
% NN N
( ( N
91/244 CD N
) ) N
and CC N
17.9 CD N
% NN N
( ( N
41/229 CD N
) ) N
of IN N
the DT N
informative JJ N
samples NNS N
in IN N
the DT N
local JJ N
and CC N
central JJ N
evaluations NNS N
, , N
respectively RB N
. . N

Positive JJ 1_o
HER2 NNP 1_o
mRNA NN 1_o
levels NNS 1_o
were VBD N
found VBN N
in IN N
19.8 CD N
% NN N
( ( N
55/278 CD N
) ) N
. . N

We PRP N
observed VBD N
a DT N
highly RB N
significant JJ N
correlation NN 1_o
between IN 1_o
central JJ 1_o
HER2 NNP 1_o
expression NN 1_o
and CC 1_o
HER2 NNP 1_o
status NN 1_o
measured VBN 1_o
by IN 1_o
kinetic JJ 1_o
RT-PCR NNP 1_o
( ( N
r VB N
= RB N
0.856 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
an DT N
overall JJ N
agreement NN N
of IN N
95.6 CD N
% NN N
( ( N
κ JJ N
statistic NN N
, , N
0.862 CD N
, , N
CI NNP N
0.77-0.94 NN N
) ) N
. . N

Further NNP N
, , N
central JJ 1_o
HER2 NNP 1_o
as RB 1_o
well RB 1_o
as IN 1_o
HER2 NNP 1_o
mRNA FW 1_o
expression NN 1_o
were VBD 1_o
predictors NNS 1_o
for IN 1_o
a DT 1_o
pathological JJ 1_o
complete JJ 1_o
response NN 1_o
after IN 1_o
neoadjuvant JJ 1_o
anthracycline/taxane-based JJ 1_o
primary JJ 1_o
chemotherapy NN 1_o
in IN N
a DT N
univariate JJ N
binary JJ N
logistic JJ N
regression NN N
analysis NN N
( ( N
OR CC N
3.29 CD N
, , N
P NNP N
= NNP N
0.002 CD N
; : N
OR CC N
2.65 CD N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

The DT 1_o
predictive JJ 1_o
value NN 1_o
could MD N
be VB N
confirmed VBN N
for IN N
the DT 1_o
central JJ 1_o
HER2 NNP 1_o
status NN 1_o
by IN N
multivariate NN N
analysis NN N
( ( N
OR CC N
3.04 CD N
, , N
P NNP N
= NNP N
0.027 CD N
) ) N
. . N

The DT 1_o
locally RB 1_o
assessed VBN 1_o
HER2 NNP 1_o
status NN 1_o
was VBD 1_o
not RB 1_o
predictive JJ 1_o
of IN 1_o
response NN 1_o
to TO 1_o
chemotherapy NN 1_o
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
standardized JJ N
methods NNS N
are VBP N
preferable JJ N
for IN N
evaluation NN N
of IN N
HER2 NNP N
status NN N
. . N

The DT N
kinetic JJ N
RT-PCR NNP N
from IN N
FFPE NNP N
tissue NN N
might MD N
be VB N
an DT N
additional JJ N
approach NN N
for IN N
assessment NN N
of IN N
this DT N
important JJ N
prognostic NN N
and CC N
predictive JJ N
parameter NN N
but CC N
has VBZ N
to TO N
be VB N
confirmed VBN N
by IN N
other JJ N
studies NNS N
. . N

Disopyramide NNP 1_i
in IN N
the DT N
treatment NN N
and CC N
prevention NN N
of IN N
arrhythmias NN 1_o
following VBG 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

Successful JJ N
production NN 1_o
of IN N
piglets NNS 1_p
derived VBN N
from IN N
expanded JJ N
blastocysts NNS N
vitrified VBD N
using VBG N
a DT N
micro NN 1_i
volume NN 1_i
air NN 1_i
cooling VBG 1_i
method NN 1_i
without IN N
direct JJ N
exposure NN N
to TO N
liquid VB N
nitrogen NN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
clarify VB N
the DT N
feasibility NN N
of IN N
newly RB N
developed VBN N
vitrification NN N
techniques NNS N
for IN N
porcine NN 1_p
embryos NN 1_p
using VBG N
the DT N
micro NN 1_i
volume NN 1_i
air NN 1_i
cooling VBG 1_i
( ( 1_i
MVAC NNP 1_i
) ) 1_i
method NN N
without IN N
direct JJ N
contact NN N
with IN N
liquid JJ N
nitrogen NN N
( ( N
LN₂ NNP N
) ) N
. . N

Expanded VBN N
blastocysts NNS N
were VBD N
vitrified VBN N
in IN N
a DT N
solution NN N
containing VBG 1_i
6 CD 1_i
M NNP 1_i
ethylene NN 1_i
glycol NN 1_i
, , 1_i
0.6 CD 1_i
M NNP 1_i
trehalose NN 1_i
and CC 1_i
2 CD 1_i
% NN 1_i
( ( 1_i
wt/vol NN 1_i
) ) 1_i
polyethylene NN 1_i
glycol NN 1_i
in IN 1_i
10 CD 1_i
% NN 1_i
HEPES-buffered JJ 1_i
PZM-5 NNP 1_i
. . N

The DT N
blastocysts NNS N
were VBD N
collected VBN N
from IN N
gilts NNS N
and CC N
vitrified VBD N
using VBG N
the DT 1_i
new JJ 1_i
device NN 1_i
( ( 1_i
MVAC NNP 1_i
) ) 1_i
or CC 1_i
a DT 1_i
Cryotop NNP 1_i
( ( 1_i
CT NNP 1_i
) ) 1_i
. . N

Blastocysts NNS N
were VBD N
stored VBN N
in IN N
LN₂ NNP N
for IN N
at IN N
least JJS N
1 CD N
month NN N
. . N

After IN N
warming VBG N
, , N
cryoprotective JJ N
agents NNS N
were VBD N
removed VBN N
using VBG N
a DT N
single JJ N
step NN 1_o
. . 1_o

Survival NN 1_o
of IN 1_o
the DT 1_o
embryos NN 1_o
was VBD N
assessed VBN N
by IN N
in IN N
vitro JJ N
culture NN N
( ( N
Experiment NNP N
1 CD N
) ) N
and CC N
by IN N
embryo NN N
transfer NN N
to TO N
recipients NNS N
( ( N
Experiment NNP N
2 CD N
) ) N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
the DT N
embryos NN N
vitrified VBN N
by IN N
the DT 1_i
MVAC NNP 1_i
or CC 1_i
CT NNP N
and CC N
fresh JJ N
embryos NN N
without IN N
vitrification NN N
( ( N
Control NNP N
) ) N
were VBD N
used VBN N
. . N

The DT 1_o
survival JJ 1_o
rates NNS 1_o
of IN 1_o
embryos NN 1_o
in IN N
the DT 1_i
MVAC NNP 1_i
, , N
CT NNP N
and CC N
Control NNP N
groups NNS N
were VBD N
88.9 CD N
% NN N
( ( N
32/36 CD N
) ) N
, , N
91.7 CD N
% NN N
( ( N
33/36 CD N
) ) N
and CC N
100 CD N
% NN N
( ( N
34/34 CD N
) ) N
, , N
respectively RB N
, , N
after IN N
48 CD N
h JJ N
culture NN N
, , N
and CC N
the DT 1_o
hatching VBG 1_o
rates NNS 1_o
of IN 1_o
embryos NN 1_o
after IN 1_o
48 CD 1_o
h JJ 1_o
incubation NN 1_o
were VBD N
69.4 CD N
% NN N
( ( N
25/36 CD N
) ) N
, , N
63.9 CD N
% NN N
( ( N
23/36 CD N
) ) N
and CC N
94.1 CD N
% NN N
( ( N
32/34 CD N
) ) N
, , N
respectively RB N
. . N

In IN N
Experiment JJ 1_p
2 CD 1_p
, , 1_p
64 CD 1_p
vitrified VBD 1_p
embryos NN 1_p
were VBD N
transferred VBN N
to TO N
5 CD N
recipient NN N
gilts NNS N
, , N
and CC 1_o
8 CD 1_o
healthy JJ 1_o
piglets NNS 1_o
were VBD N
produced VBN N
from IN N
3 CD N
recipients NNS N
in IN N
the DT 1_i
MVAC NNP 1_i
group NN N
. . N

Similarly RB 1_p
, , 1_p
66 CD 1_p
vitrified VBD 1_p
embryos NN 1_p
were VBD N
transferred VBN N
to TO N
5 CD N
recipient NN N
gilts NNS N
, , N
and CC 1_o
9 CD 1_o
healthy JJ 1_o
piglets NNS 1_o
were VBD N
produced VBN N
from IN N
2 CD N
recipients NNS N
in IN N
the DT 1_i
CT NNP N
group NN N
. . N

These DT N
results NNS N
indicated VBD N
that IN 1_p
porcine NN 1_p
expanded VBN 1_p
blastocysts NNS 1_p
can MD N
be VB N
cryopreserved VBN N
using VBG N
the DT 1_i
MVAC NNP 1_i
method NN N
without IN N
potential JJ N
pathogen NN N
contamination NN N
from IN N
LN₂ NNP N
. . N

Comparison NNP N
of IN N
40 CD N
milliliters NNS N
of IN N
0.25 CD N
% NN N
intrapleural JJ N
bupivacaine NN 1_i
with IN N
epinephrine NN 1_i
with IN N
20 CD N
milliliters NNS N
of IN N
0.5 CD N
% NN N
intrapleural JJ N
bupivacaine NN N
with IN N
epinephrine NN N
after IN N
cholecystectomy NN N
. . N

To TO N
determine VB N
the DT N
influence NN N
of IN N
the DT N
volume NN N
of IN N
local JJ N
anesthetic JJ N
injected VBN N
for IN N
intrapleural JJ N
analgesia NN N
, , N
40 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
cholecystectomy NNS 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
to TO 1_p
two CD 1_p
groups NNS 1_p
of IN 1_p
20 CD 1_p
patients NNS 1_p
each DT 1_p
. . 1_p

One CD 1_i
group NN 1_i
received VBD 1_i
40 CD 1_i
mL NN 1_i
of IN 1_i
0.25 CD 1_i
% NN 1_i
bupivacaine NN 1_i
with IN 1_i
epinephrine NN 1_i
injected VBN 1_i
intrapleurally RB 1_i
postoperatively RB 1_i
. . 1_i

The DT 1_i
other JJ 1_i
group NN 1_i
received VBD 1_i
20 CD 1_i
mL NN 1_i
of IN 1_i
0.5 CD 1_i
% NN 1_i
bupivacaine NN 1_i
with IN 1_i
epinephrine NN 1_i
. . 1_i

The DT N
onset JJ 1_o
time NN 1_o
of IN 1_o
analgesia NN 1_o
was VBD N
nearly RB N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
and CC N
within IN N
25 CD N
min NNS N
all DT N
patients NNS 1_p
were VBD N
nearly RB N
pain JJ N
free JJ N
. . N

Our PRP$ N
data NNS N
demonstrate NN N
that IN N
100 CD N
mg NN N
of IN N
bupivacaine NN N
with IN N
epinephrine JJ N
elicits NNS N
effective JJ N
analgesia NN N
after IN N
cholecystectomy NN N
. . N

There EX N
are VBP N
only RB N
minor JJ N
differences NNS N
between IN N
20 CD N
and CC N
40 CD N
mL NN N
with IN N
regard NN N
to TO N
pain VB 1_o
relief NN 1_o
. . 1_o

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
volume NN N
of IN N
local JJ N
anesthetic NN N
within IN N
the DT N
range NN N
of IN N
20-40 JJ N
mL NN N
in IN N
an DT N
adult NN N
has VBZ N
little JJ N
influence NN N
on IN N
the DT N
extent NN N
or CC N
duration NN N
of IN N
intrapleural JJ N
analgesia NN N
. . N

Leptin NNP N
levels NNS N
in IN N
protracted JJ 1_p
critical JJ 1_p
illness NN 1_p
: : 1_p
effects NNS N
of IN N
growth NN 1_i
hormone-secretagogues NNS 1_i
and CC N
thyrotropin-releasing JJ 1_i
hormone NN 1_i
. . 1_i

Prolonged NNP N
critical JJ N
illness NN N
is VBZ N
characterized VBN N
by IN N
feeding-resistant JJ N
wasting NN N
of IN N
protein NN N
, , N
whereas JJ N
reesterification NN N
, , N
instead RB N
of IN N
oxidation NN N
of IN N
fatty JJ N
acids NNS N
, , N
allows VBZ N
fat JJ N
stores NNS N
to TO N
accrue NNS N
and CC N
associate NN N
with IN N
a DT N
low-activity JJ N
status NN N
of IN N
the DT N
somatotropic NN N
and CC N
thyrotropic NN N
axis NN N
, , N
which WDT N
seems VBZ N
to TO N
be VB N
partly RB N
of IN N
hypothalamic JJ N
origin NN N
. . N

To TO N
further JJ N
unravel NN N
this DT N
paradoxical JJ N
metabolic JJ N
condition NN N
, , N
and CC N
in IN N
search NN N
of IN N
potential JJ N
therapeutic JJ N
strategies NNS N
, , N
we PRP N
measured VBD N
serum JJ N
concentrations NNS N
of IN N
leptin NN N
; : N
studied VBD N
the DT N
relationship NN N
with IN N
body NN N
mass NN N
index NN N
, , N
insulin NN N
, , N
cortisol NN N
, , N
thyroid JJ N
hormones NNS N
, , N
and CC N
somatomedins NNS N
; : N
and CC N
documented VBD N
the DT N
effects NNS N
of IN N
hypothalamic JJ N
releasing NN N
factors NNS N
, , N
in IN N
particular JJ N
, , N
GH-secretagogues NNP N
and CC N
TRH NNP N
. . N

Twenty NNP 1_p
adults NNS 1_p
, , 1_p
critically RB 1_p
ill VB 1_p
for IN 1_p
several JJ 1_p
weeks NNS 1_p
and CC 1_p
supported VBD 1_p
with IN 1_p
normocaloric JJ 1_p
, , 1_p
continuously RB 1_p
administered VBN 1_p
parenteral JJ 1_p
and/or JJ 1_p
enteral JJ 1_p
feeding NN 1_p
, , N
were VBD N
studied VBN N
for IN N
45 CD N
h. NN N
They PRP N
had VBD N
been VBN N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
three CD N
combinations NNS N
of IN N
peptide JJ N
infusions NNS N
, , N
in IN N
random JJ N
order NN N
: : N
TRH NN 1_i
( ( 1_i
one CD 1_i
day NN 1_i
) ) 1_i
and CC 1_i
placebo NN 1_i
( ( N
other JJ N
day NN N
) ) N
; : N
TRH NNP N
+ NNP N
GH-releasing NNP N
peptide NN N
( ( N
GHRP NNP N
) ) N
-2 NN N
and CC N
GHRP-2 NNP N
; : N
TRH NNP N
+ NNP N
GHRH NNP N
+ NNP N
GHRP-2 NNP N
and CC N
GHRH NNP N
+ NNP N
GHRP-2 NNP N
. . N

Peptide NNP 1_i
infusions NNS 1_i
were VBD N
started VBN N
after IN N
a DT N
1-microgram/kg JJ N
bolus NN N
at IN N
0900 CD N
h NN N
and CC N
infused VBN N
( ( N
1 CD N
microgram/kg.h NN N
) ) N
until IN N
0600 CD N
h VBD N
the DT N
next JJ N
morning NN N
. . N

Serum NNP 1_o
concentrations NNS 1_o
of IN 1_o
leptin NN 1_o
, , 1_o
insulin NN 1_o
, , 1_o
cortisol NN 1_o
, , 1_o
T4 NNP 1_o
, , 1_o
T3 NNP 1_o
, , 1_o
insulin-like JJ 1_o
growth NN 1_o
factor NN 1_o
( ( 1_o
IGF NNP 1_o
) ) 1_o
-I NN 1_o
, , 1_o
IGF-binding JJ 1_o
protein-3 NN 1_o
and CC 1_o
the DT 1_o
acid-labile JJ 1_o
subunit NN 1_o
( ( 1_o
ALS NNP 1_o
) ) 1_o
were VBD N
measured VBN N
at IN N
0900 CD N
h NN N
, , N
2100 CD N
h NN N
, , N
and CC N
0600 CD N
h NN N
on IN N
each DT N
of IN N
the DT N
2 CD N
study NN N
days NNS N
. . N

Baseline NNP 1_o
leptin NN 1_o
levels NNS 1_o
( ( N
mean JJ N
+/- JJ N
SEM NN N
: : N
12.4 CD N
+/- JJ N
2.1 CD N
micrograms/L NN N
) ) N
were VBD N
independent JJ N
of IN N
body NN N
mass NN N
index NN N
( ( N
25 CD N
+/- JJ N
1 CD N
kg/m2 NN N
) ) N
, , N
insulin NN N
( ( N
18.6 CD N
+/- JJ N
2.9 CD N
microIU/mL NN N
) ) N
, , N
cortisol NN N
( ( N
504 CD N
+/- JJ N
43 CD N
mmol/L NN N
) ) N
, , N
and CC N
thyroid JJ N
hormones NNS N
( ( N
T4 NNP N
: : N
63 CD N
+/- JJ N
5 CD N
nmol/L NN N
, , N
T3 NNP N
: : N
0.72 CD N
+/- JJ N
0.08 CD N
nmol/L NN N
) ) N
but CC N
correlated VBD N
positively RB N
with IN N
circulating VBG N
levels NNS N
of IN N
IGF-I NNP N
[ NNP N
86 CD N
+/- JJ N
6 CD N
micrograms/L NN N
, , N
determination NN N
coefficient NN N
( ( N
R2 NNP N
) ) N
= VBD N
0.25 CD N
] NN N
and CC N
ALS NNP N
( ( N
7.2 CD N
+/- JJ N
0.6 CD N
mg/L NN N
, , N
R2 NNP N
= NNP N
0.32 CD N
) ) N
. . N

Infusion NN N
of IN N
placebo NN 1_i
or CC N
TRH NNP 1_i
had VBD N
no DT N
effect NN N
on IN N
leptin NN 1_o
. . 1_o

In IN N
contrast NN N
, , N
GH-secretagogues NNP N
elevated VBD N
leptin NN 1_o
levels NNS 1_o
within IN N
12 CD N
h. JJ N
Infusion NNP N
of IN N
GHRP-2 NNP N
alone RB N
induced VBD N
a DT N
maximal JJ 1_o
leptin JJ 1_o
increase NN 1_o
of IN N
+87 NNP N
% NN N
after IN N
24 CD N
h NN N
, , N
whereas WP N
GHRH NNP N
+ VBD N
GHRP-2 NNP N
elevated VBD N
leptin NN 1_o
by IN N
up IN N
to TO N
+157 VB N
% NN N
after IN N
24 CD N
h. VBD N
The DT N
increase NN N
in IN N
leptin NN 1_o
within IN 1_o
12 CD 1_o
h NN 1_o
was VBD N
related VBN N
( ( N
R2 NNP N
= NNP N
0.58 CD N
) ) N
to TO N
the DT N
substantial JJ N
rise NN N
in IN N
insulin NN N
. . N

After IN N
45 CD N
h NN N
, , N
and CC N
having VBG N
reached VBN N
a DT N
plateau NN N
, , N
leptin NN 1_o
was VBD N
related VBN N
to TO N
the DT N
increased VBN 1_o
IGF-I NNP 1_o
( ( N
R2 NNP N
= NNP N
0.37 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
circulating VBG 1_o
leptin NN 1_o
levels NNS 1_o
during IN N
protracted JJ N
critical JJ N
illness NN N
were VBD N
linked VBN N
to TO N
the DT N
activity NN N
state NN N
of IN N
the DT N
GH/IGF-I NNP N
axis NN N
. . N

Stimulating VBG N
the DT N
GH/IGF-I NNP N
axis NN N
with IN N
GH-secretagogues NNP N
increased VBD N
leptin NN 1_o
levels NNS 1_o
within IN N
12 CD N
h. NN N
Because IN N
leptin NN N
may MD N
stimulate VB N
oxidation NN N
of IN N
fatty JJ N
acids NNS N
, , N
and CC N
because IN N
GH NNP N
, , N
IGF-I NNP N
, , N
and CC N
insulin NN N
have VBP N
a DT N
protein-sparing JJ N
effect NN N
, , N
GH-secretagogue NNP 1_i
administration NN N
may MD N
be VB N
expected VBN N
to TO N
result VB N
in IN N
increased JJ N
utilization NN N
of IN N
fat NN N
as IN N
preferential JJ N
substrate NN N
and CC N
to TO N
restore VB N
protein JJ N
content NN N
in IN N
vital JJ N
tissues NNS N
and CC N
, , N
consequently RB N
, , N
has VBZ N
potential JJ N
as IN N
a DT N
strategy NN N
to TO N
reverse VB N
the DT N
paradoxical JJ N
metabolic JJ N
condition NN N
of IN N
protracted JJ N
critical JJ N
illness NN N
. . N

Immunologic NNP 1_o
response NN 1_o
after IN N
laparoscopic NN 1_p
colon NN 1_p
cancer NN 1_p
operation NN 1_p
within IN N
an DT N
enhanced JJ N
recovery NN N
program NN N
. . N

OBJECTIVE NN N
It PRP N
has VBZ N
been VBN N
demonstrated VBN N
that IN N
colon NN N
operation NN N
combined VBN N
with IN N
fast-track NN N
( ( N
FT NNP N
) ) N
surgery NN N
and CC N
laparoscopic NN N
technique NN N
can MD N
shorten VB N
the DT N
length NN 1_o
of IN 1_o
hospital NN 1_o
stay NN 1_o
, , 1_o
accelerate JJ 1_o
recovery NN 1_o
of IN 1_o
intestinal JJ 1_o
function NN 1_o
, , 1_o
and CC 1_o
reduce VB 1_o
the DT 1_o
occurrence NN 1_o
of IN 1_o
post-operative JJ 1_o
complications NNS 1_o
. . 1_o

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
regarding VBG N
the DT N
combined JJ N
effects NNS N
of IN N
FT NNP N
colon NN N
operation NN N
and CC N
laparoscopic NN N
technique NN N
on IN N
humoral JJ 1_o
inflammatory NN 1_o
cellular JJ 1_o
immunity NN 1_o
. . 1_o

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
. . N

One CD 1_p
hundred VBD 1_p
sixty-three JJ 1_p
colon NN 1_p
cancer NN 1_p
patients NNS 1_p
underwent VBD 1_p
the DT 1_p
traditional JJ 1_i
protocol NN 1_i
and CC 1_i
open JJ 1_i
operation NN 1_i
( ( 1_p
traditional JJ 1_p
open JJ 1_p
group NN 1_p
, , 1_p
n=42 RB 1_p
) ) 1_p
, , 1_p
the DT 1_p
traditional JJ 1_i
protocol NN 1_i
and CC 1_i
laparoscopic NN 1_i
operation NN 1_i
( ( 1_p
traditional JJ 1_p
laparoscopic NN 1_p
group NN 1_p
, , 1_p
n=40 RB 1_p
) ) 1_p
, , 1_p
the DT 1_p
FT NNP 1_i
protocol NN 1_i
and CC 1_i
open JJ 1_i
operation NN 1_i
( ( 1_p
FT NNP 1_p
open JJ 1_p
group NN 1_p
, , 1_p
n=41 RB 1_p
) ) 1_p
, , 1_p
or CC 1_p
the DT 1_p
FT NNP 1_i
protocol NN 1_i
and CC 1_i
laparoscopic NN 1_i
operation NN 1_i
( ( 1_p
FT NNP 1_p
laparoscopic NN 1_p
group NN 1_p
, , 1_p
n=40 RB 1_p
) ) 1_p
. . 1_p

Blood NN N
samples NNS N
were VBD N
taken VBN N
prior RB N
to TO N
operation NN N
as RB N
well RB N
as IN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
after IN N
operation NN N
. . N

The DT N
number NN 1_o
of IN 1_o
lymphocyte JJ 1_o
subpopulations NNS 1_o
was VBD N
determined VBN N
by IN N
flow JJ N
cytometry NN N
, , N
and CC N
serum VB 1_o
interleukin-6 JJ 1_o
and CC 1_o
C-reactive JJ 1_o
protein NN 1_o
levels NNS 1_o
were VBD N
measured VBN N
. . N

Post-operative JJ 1_o
hospital NN 1_o
stay NN 1_o
, , 1_o
post-operative JJ 1_o
morbidity NN 1_o
, , 1_o
readmission NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
in-hospital JJ 1_o
mortality NN 1_o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
open JJ N
operation NN N
, , N
laparoscopic JJ N
colon NN N
operation NN N
effectively RB N
inhibited VBD N
the DT N
release NN N
of IN N
post-operative JJ 1_o
inflammatory JJ 1_o
factors NNS 1_o
and CC N
yielded VBD N
good JJ N
protection NN N
via IN N
post-operative JJ N
cell NN N
immunity NN N
. . N

FT NNP N
surgery NN N
had VBD N
a DT N
better RBR N
protective JJ N
role NN N
with IN N
respect NN N
to TO N
the DT N
post-operative JJ N
immune NN N
system NN N
compared VBN N
with IN N
traditional JJ N
peri-operative JJ N
care NN N
. . N

Inflammatory JJ 1_o
reactions NNS 1_o
, , 1_o
based VBN 1_o
on IN 1_o
interleukin-6 JJ 1_o
and CC 1_o
C-reactive JJ 1_o
protein NN 1_o
levels NNS 1_o
, , N
were VBD N
less JJR N
intense JJ N
following VBG N
FT NNP N
laparoscopic NN N
operation NN N
compared VBN N
to TO N
FT NNP N
open JJ N
operation NN N
; : N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
specific JJ 1_o
immunity NN 1_o
( ( 1_o
CD3+ NNP 1_o
and CC 1_o
CD4+ NNP 1_o
counts NNS 1_o
, , 1_o
and CC 1_o
the DT 1_o
CD4+/CD8+ NNP 1_o
ratio NN 1_o
) ) 1_o
during IN N
these DT N
two CD N
types NNS N
of IN N
surgical JJ N
procedures NNS N
. . N

Post-operative JJ 1_o
hospital NN 1_o
stay NN 1_o
in IN N
patients NNS N
randomized VBN N
to TO N
the DT N
FT NNP N
laparoscopic NN N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Post-operative JJ 1_o
complications NNS 1_o
in IN N
patients NNS N
who WP N
underwent VBP N
FT NNP N
laparoscopic NN N
treatment NN N
were VBD N
less JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
four CD N
treatment NN N
groups NNS N
regarding VBG N
readmission NN 1_o
rate NN 1_o
and CC 1_o
in-hospital JJ 1_o
mortality NN 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
laparoscopic NN N
technique NN N
and CC N
FT NNP N
surgery NN N
rehabilitation NN N
program NN N
effectively RB N
inhibited VBD N
release NN N
of IN N
post-operative JJ 1_o
inflammatory JJ 1_o
factors NNS 1_o
with IN 1_o
a DT 1_o
reduction NN 1_o
in IN 1_o
peri-operative JJ 1_o
trauma NN 1_o
and CC 1_o
stress NN 1_o
, , N
which WDT N
together RB N
played VBD N
a DT N
protective JJ N
role NN N
on IN N
the DT N
post-operative JJ N
immune NN N
system NN N
. . N

Combining VBG N
two CD N
treatment NN N
measures NNS N
during IN N
colon NN N
operation NN N
produced VBD N
better RBR N
protective JJ 1_o
effects NNS 1_o
via IN 1_o
the DT 1_o
immune JJ 1_o
system NN 1_o
. . 1_o

The DT N
beneficial JJ N
clinical JJ N
effects NNS N
support NN N
that IN N
the DT N
better-preserved JJ N
post-operative JJ N
immune NN N
system NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN 1_o
of IN 1_o
post-operative JJ 1_o
results NNS 1_o
in IN N
FT NNP 1_p
laparoscopic NN 1_p
patients NNS 1_p
. . 1_p

Effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN 1_i
treatment NN 1_p
on IN 1_p
prolactin NN 1_o
levels NNS 1_o
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
effects NNS N
of IN N
short- JJ N
and CC N
long-term JJ N
risperidone NN 1_i
treatment NN N
on IN N
serum NN N
prolactin NN N
were VBD N
assessed VBN N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

METHODS NNP N
Patients NNPS 1_p
with IN 1_p
autism NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
101 CD 1_p
, , 1_p
5-17 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
an DT N
8-week JJ N
trial NN N
of IN N
risperidone NN 1_i
or CC 1_i
placebo NN 1_i
and CC N
63 CD 1_p
then RB 1_p
took VBD 1_p
part NN 1_p
in IN 1_p
a DT 1_p
4-month JJ 1_p
open-label JJ 1_p
follow-up JJ 1_p
phase NN 1_p
. . 1_p

Serum NNP N
samples NNS N
were VBD N
obtained VBN N
at IN N
Baseline NNP N
and CC N
Week-8 NNP N
( ( N
N NNP N
= NNP N
78 CD N
) ) N
, , N
and CC N
at IN N
6-month JJ N
( ( N
N NNP N
= NNP N
43 CD N
) ) N
and CC N
22-month JJ N
( ( N
N NNP N
= NNP N
30 CD N
) ) N
follow-up NN N
. . N

Serum NNP N
prolactin NN N
was VBD N
determined VBN N
by IN N
immunoradiometric JJ N
assay NN N
; : N
dopamine JJ 1_o
type-2 JJ 1_o
receptor NN 1_o
( ( 1_o
DRD2 NNP 1_o
) ) 1_o
polymorphisms NNS 1_o
were VBD 1_o
genotyped VBN 1_o
. . 1_o

RESULTS NNP N
Baseline NNP 1_o
prolactin NN 1_o
levels NNS 1_o
were VBD N
similar JJ N
in IN N
the DT N
risperidone NN 1_i
( ( N
N NNP N
= NNP N
42 CD N
) ) N
and CC N
placebo NN 1_i
( ( N
N NNP N
= NNP N
36 CD N
) ) N
groups NNS N
( ( N
9.3 CD N
+/- JJ N
7.5 CD N
and CC N
9.3 CD N
+/- JJ N
7.6 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
risperidone NN 1_i
, , N
prolactin NN 1_o
increased VBD N
to TO N
39.0 CD N
+/- JJ N
19.2 CD N
ng/ml NN N
, , N
compared VBN N
with IN N
10.1 CD N
+/- JJ N
8.8 CD N
ng/ml NN N
for IN N
placebo NN N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN 1_o
levels NNS 1_o
were VBD N
also RB N
significantly RB N
increased VBN N
at IN N
6 CD N
months NNS N
( ( N
32.4 CD N
+/- JJ N
17.8 CD N
ng/ml NN N
; : N
N NNP N
= VBZ N
43 CD N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
and CC N
at IN N
22 CD N
months NNS N
( ( N
N NNP N
= NNP N
30 CD N
, , N
25.3 CD N
+/- JJ N
15.6 CD N
ng/ml NN N
, , N
p NN N
< NNP N
.0001 NNP N
) ) N
. . N

Prolactin NN 1_o
levels NNS 1_o
were VBD N
not RB N
associated VBN N
with IN N
adverse JJ N
effects NNS N
and CC N
DRD2 NNP N
alleles NNS N
( ( N
Taq1A NNP N
, , N
-141C NNP N
Ins/Del NNP N
, , N
C957T NNP N
) ) N
did VBD N
not RB N
significantly RB N
influence VB N
baseline NN N
levels NNS N
or CC N
risperidone-induced JJ N
increases NNS N
in IN N
prolactin NN N
. . N

CONCLUSIONS NNP N
Risperidone NNP 1_i
treatment NN N
was VBD N
associated VBN N
with IN N
two- JJ N
to TO N
four-fold JJ N
mean NN N
increases NNS N
in IN N
serum NN N
prolactin NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Although IN N
risperidone-induced JJ N
increases NNS N
tended VBD N
to TO N
diminish VB N
with IN N
time NN N
, , N
further JJ N
research NN N
on IN N
the DT N
consequences NNS N
of IN N
long-term JJ N
prolactin NN N
elevations NNS N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
is VBZ N
needed VBN N
. . N

Combination NNP N
hydrocodone NN 1_i
and CC 1_i
ibuprofen JJ 1_i
versus NN N
combination NN N
codeine NN 1_i
and CC 1_i
acetaminophen NN 1_i
for IN N
the DT N
treatment NN 1_p
of IN 1_p
chronic JJ 1_p
pain NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
combination NN N
hydrocodone NN 1_i
7.5 CD N
mg NN N
and CC N
ibuprofen $ 1_i
200 CD N
mg NN N
with IN N
that DT N
of IN N
combination NN N
codeine NN 1_i
30 CD N
mg NN N
and CC N
acetaminophen $ 1_i
300 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
pain NN N
. . N

BACKGROUND NNP N
Hydrocodone NNP 1_i
7.5 CD N
mg NN N
with IN N
ibuprofen JJ 1_i
200 CD N
mg NN N
is VBZ N
the DT N
only JJ N
approved VBD N
fixed-dose JJ N
combination NN N
analgesic IN N
containing VBG N
an DT N
opioid NN N
and CC N
ibuprofen NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
repeated-dose JJ N
, , N
active-comparator JJ N
, , N
4-week JJ N
, , N
multicenter NN N
study NN N
, , N
469 CD 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
1-tablet JJ N
( ( N
n JJ N
= NNP N
156 CD N
) ) N
or CC N
2-tablet JJ N
( ( N
n JJ N
= NNP N
153 CD N
) ) N
dose NN N
of IN N
combination NN 1_i
hydrocodone NN 1_i
7.5 CD 1_i
mg NN 1_i
and CC 1_i
ibuprofen $ 1_i
200 CD 1_i
mg NN 1_i
( ( N
HI1 NNP N
and CC N
HI2 NNP N
, , N
respectively RB N
) ) N
or CC N
a DT N
2-tablet JJ 1_i
dose NN 1_i
of IN N
combination NN N
codeine NN 1_i
30 CD 1_i
mg NN 1_i
and CC 1_i
acetaminophen $ 1_i
300 CD 1_i
mg NN 1_i
( ( N
CA NNP N
, , N
n RB N
= VBZ N
160 CD N
) ) N
, , N
the DT N
active JJ N
comparator NN N
, , N
every DT N
6 CD N
to TO N
8 CD N
hours NNS N
as IN N
needed VBN N
for IN N
pain NN N
. . N

Efficacy NN N
was VBD N
measured VBN N
through IN N
pain NN 1_o
relief NN 1_o
scores NNS 1_o
, , 1_o
number NN 1_o
of IN 1_o
daily JJ 1_o
doses NNS 1_o
of IN 1_o
study NN 1_o
medication NN 1_o
, , 1_o
number NN 1_o
of IN 1_o
daily JJ 1_o
doses NNS 1_o
of IN 1_o
supplemental JJ 1_o
analgesics NNS 1_o
, , 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
discontinued VBD 1_o
therapy NN 1_o
due JJ 1_o
to TO 1_o
an DT 1_o
unsatisfactory JJ 1_o
analgesic JJ 1_o
response NN 1_o
, , N
and CC N
global JJ N
assessment NN N
scores NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
469 CD 1_p
patients NNS 1_p
, , 1_p
255 CD 1_p
( ( 1_p
54.4 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
female JJ 1_p
and CC 1_p
214 CD 1_p
( ( 1_p
45.6 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
male JJ 1_p
. . 1_p

The DT N
mean JJ 1_p
age NN 1_p
was VBD 1_p
51.1 CD 1_p
years NNS 1_p
. . 1_p

Types NNS 1_p
of IN 1_p
chronic NN 1_p
pain NN 1_p
included VBD 1_p
back RB 1_p
( ( 1_p
214 CD 1_p
; : 1_p
45.6 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
arthritic JJ 1_p
( ( 1_p
145 CD 1_p
; : 1_p
30.9 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
other JJ 1_p
musculoskeletal NN 1_p
( ( 1_p
65 CD 1_p
; : 1_p
13.9 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
cancer NN 1_p
( ( 1_p
6 CD 1_p
; : 1_p
1.3 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
diabetic JJ 1_p
neuropathic NN 1_p
( ( 1_p
3 CD 1_p
; : 1_p
0.6 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
postherpetic JJ 1_p
neuralgic NN 1_p
( ( 1_p
5 CD 1_p
; : 1_p
1.1 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
other JJ 1_p
neurologic NN 1_p
( ( 1_p
21 CD 1_p
; : 1_p
4.5 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
other JJ 1_p
unclassified JJ 1_p
chronic JJ 1_p
pain NN 1_p
( ( 1_p
10 CD 1_p
; : 1_p
2.1 CD 1_p
% NN 1_p
) ) 1_p
. . N

During IN N
the DT N
48 CD N
hours NNS N
prior RB N
to TO N
the DT N
study NN N
, , N
351 CD N
( ( N
74.8 CD N
% NN N
) ) N
patients NNS N
had VBD N
been VBN N
treated VBN N
with IN N
opioid JJ N
or CC N
opioid-nonopioid JJ N
combination NN N
analgesics NNS N
. . N

The DT N
overall JJ 1_o
mean JJ 1_o
daily JJ 1_o
pain NN 1_o
relief NN 1_o
score NN 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.25+/-0.89 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
1.98+/-0.87 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
1.85+/-0.96 JJ N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
overall JJ 1_o
mean JJ 1_o
number NN 1_o
of IN 1_o
daily JJ 1_o
doses NNS 1_o
of IN 1_o
study NN 1_o
medication NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.94+/-0.99 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
3.23+/-0.76 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
3.26+/-0.75 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

The DT N
overall JJ 1_o
mean JJ 1_o
number NN 1_o
of IN 1_o
daily JJ 1_o
doses NNS 1_o
of IN 1_o
supplemental JJ 1_o
analgesics NNS 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
0.24+/-0.49 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
0.34+/-0.58 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
or CC N
CA NNP N
group NN N
( ( N
0.49+/-0.85 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
discontinued VBD 1_o
treatment NN 1_o
due JJ 1_o
to TO 1_o
an DT 1_o
unsatisfactory JJ 1_o
analgesic JJ 1_o
response NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2 CD N
; : N
1.3 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
CA NNP N
group NN N
( ( N
12 CD N
; : N
7.5 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

HI2 NNP N
was VBD N
more RBR N
effective JJ N
than IN N
HI1 NNP N
and CC N
CA NNP N
as IN N
measured VBN N
by IN N
pain NN 1_o
relief NN 1_o
scores NNS 1_o
for IN N
week NN N
1 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
and CC N
week NN N
3 CD N
( ( N
P NNP N
= VBZ N
0.008 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ 1_o
doses NNS 1_o
of IN 1_o
study NN 1_o
medication NN 1_o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.019 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.011 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ 1_o
doses NNS 1_o
of IN 1_o
supplemental JJ 1_o
analgesics NNS 1_o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.010 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
; : N
and CC N
global JJ 1_o
assessment NN 1_o
scores NNS 1_o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.018 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
= VBZ N
0.005 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
and CC N
week NN N
4 CD N
( ( N
P NNP N
= VBZ N
0.013 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.023 CD N
vs NN N
CA NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
HI1 NNP 1_i
and CC N
CA NNP 1_i
in IN N
any DT N
efficacy NN 1_o
variable JJ N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN 1_o
of IN 1_o
patients NNS 1_o
experiencing VBG 1_o
adverse JJ 1_o
events NNS 1_o
in IN N
the DT N
HI2 NNP N
( ( N
127 CD N
; : N
83 CD N
% NN N
) ) N
, , N
HI1 NNP 1_i
( ( N
124 CD N
; : N
79.5 CD N
% NN N
) ) N
, , N
and CC N
CA NNP 1_i
( ( N
129 CD N
; : N
80.6 CD N
% NN N
) ) N
groups NNS N
. . N

However RB N
, , N
the DT N
mean JJ 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
who WP 1_o
discontinued VBD 1_o
treatment NN 1_o
due JJ 1_o
to TO 1_o
adverse JJ 1_o
events NNS 1_o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP 1_i
group NN N
( ( N
40 CD N
; : N
26.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
HI1 NNP 1_i
group NN N
( ( N
23 CD N
; : N
14.7 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
hydrocodone NN 1_i
7.5 CD N
mg NN N
and CC 1_i
ibuprofen $ 1_i
200 CD N
mg NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
1-tablet JJ N
doses NNS N
of IN N
this DT N
combination NN N
or CC N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN 1_i
30 CD N
mg NN N
and CC 1_i
acetaminophen $ 1_i
300 CD N
mg NN N
. . N

Moreover RB N
, , N
1-tablet JJ N
doses NNS N
of IN N
combination NN 1_i
hydrocodone NN 1_i
7.5 CD 1_i
mg NN 1_i
and CC 1_i
ibuprofen $ 1_i
200 CD N
mg NN N
may MD N
be VB N
as RB N
effective JJ N
as IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN 1_i
30 CD N
mg NN N
and CC 1_i
acetaminophen $ 1_i
300 CD N
mg NN N
. . N

A DT N
pilot NN N
study NN N
of IN N
the DT N
Tele-Airway NNP 1_i
Management NNP 1_i
System NNP 1_i
in IN N
a DT N
hospital NN 1_p
emergency NN 1_p
department NN 1_p
. . 1_p

We PRP N
developed VBD N
a DT N
telemedicine NN N
system NN N
for IN N
remote JJ N
guidance NN N
of IN N
emergency NN N
airway NN N
management NN N
called VBD N
the DT N
Tele-Airway NNP 1_i
Management NNP 1_i
System NNP 1_i
( ( N
TAMS NNP N
) ) N
. . N

In IN N
a DT N
pilot NN N
study NN N
we PRP N
examined VBD N
the DT N
usefulness NN N
of IN N
the DT N
TAMS NNP 1_i
for IN N
intubations NNS N
of IN N
actual JJ N
patients NNS 1_p
in IN 1_p
a DT 1_p
hospital NN 1_p
emergency NN 1_p
department NN 1_p
. . 1_p

Twenty-five JJ 1_p
patients NNS 1_p
were VBD 1_p
allocated VBN 1_p
randomly RB 1_p
either DT 1_p
to TO 1_p
a DT 1_p
TAMS NNP 1_i
group NN 1_i
or CC 1_p
to TO 1_p
an DT 1_p
on-scene JJ 1_i
directed NN 1_i
( ( 1_i
OSD NNP 1_i
) ) 1_i
group NN 1_i
. . 1_i

A DT N
total NN N
of IN N
12 CD 1_p
were VBD 1_p
intubated VBN 1_p
using VBG N
the DT N
TAMS NNP 1_i
. . 1_i

The DT N
mean JJ 1_o
time NN 1_o
to TO 1_o
intubation NN 1_o
( ( 1_i
TAMS NNP 1_i
62 CD N
s NN N
vs. FW N
OSD NNP 1_i
56 CD N
s NN N
) ) N
and CC N
the DT N
success NN 1_o
rate NN 1_o
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
two CD N
oesophageal JJ 1_o
intubations NNS 1_o
in IN N
the DT N
TAMS NNP 1_i
group NN N
and CC N
four CD N
in IN N
the DT N
OSD NNP 1_i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
mechanical JJ 1_o
or CC 1_o
technical JJ 1_o
errors NNS 1_o
such JJ 1_o
as IN 1_o
disconnection NN 1_o
during IN N
use NN N
of IN N
the DT N
TAMS NNP 1_i
. . 1_i

The DT N
pilot NN N
study NN N
demonstrated VBD N
the DT N
feasibility NN 1_o
of IN N
the DT N
TAMS NNP N
as IN N
an DT N
alternative NN N
to TO N
OSD NNP 1_i
. . 1_i

However RB N
, , N
a DT N
larger JJR N
study NN N
will MD N
be VB N
required VBN N
to TO N
determine VB N
non-superiority NN N
or CC N
equivalence NN N
. . N

Blockade NN N
of IN N
endogenous JJ N
growth NN N
hormone-releasing VBG N
hormone NN N
receptors NNS N
dissociates VBZ N
nocturnal JJ 1_o
growth NN 1_o
hormone NN 1_o
secretion NN 1_o
and CC N
slow-wave JJ 1_o
sleep NN 1_o
. . 1_o

OBJECTIVES CC N
A NNP N
temporal JJ N
association NN N
between IN N
non-rapid JJ N
eye NN N
movement NN N
( ( N
NREM NNP N
) ) N
sleep VBP N
stages NNS N
3 CD N
and CC N
4 CD N
and CC N
nocturnal JJ N
augmentation NN N
of IN N
GH NNP N
release NN N
was VBD N
found VBN N
long RB N
ago RB N
, , N
yet RB N
the DT N
precise NN N
mechanism NN N
for IN N
this DT N
association NN N
has VBZ N
not RB N
been VBN N
identified VBN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
, , N
however RB N
that IN N
pulsatile JJ N
GHRH NNP N
administration NN N
increases VBZ N
both DT N
slow-wave JJ 1_o
sleep NN 1_o
( ( 1_o
SWS NNP 1_o
) ) 1_o
and CC N
GH NNP 1_o
. . 1_o

Based VBN N
on IN N
these DT N
data NNS N
, , N
a DT N
role NN N
for IN N
GHRH NNP N
as IN N
an DT N
inducer NN N
of IN N
SWS NNP N
was VBD N
proposed VBN N
. . N

To TO N
test VB N
this DT N
hypothesis NN N
, , N
we PRP N
have VBP N
performed VBN N
the DT N
corollary JJ N
experiment NN N
whereby WRB N
the DT N
action NN N
of IN N
endogenous JJ N
GHRH NNP N
has VBZ N
been VBN N
antagonized VBN N
. . N

DESIGN NNP N
Healthy NNP 1_p
men NNS 1_p
( ( 1_p
20-33 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
had VBD N
an DT N
infusion NN 1_i
of IN 1_i
GHRH NNP 1_i
antagonist NN 1_i
( ( 1_i
( ( 1_i
N-Ac-Tyr NNP 1_i
( ( 1_i
1 CD 1_i
) ) 1_i
, , 1_i
D-Arg NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
) ) 1_i
GHRH-29 NNP 1_i
( ( 1_i
NH NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
) ) 1_i
) ) 1_i
or CC 1_i
saline NN 1_i
for IN 1_i
a DT 1_i
12-h JJ 1_i
period NN 1_i
, , N
between IN N
2100 CD N
and CC N
0900 CD N
h. NN N
An DT N
i.v NN N
. . N

bolus NN N
of IN N
GHRH NNP 1_i
was VBD N
given VBN N
at IN N
0700 CD N
h NN N
and CC N
GH NNP N
samples NNS N
were VBD N
drawn VBN N
from IN N
0700 CD N
to TO N
0900 CD N
h NN N
to TO N
document VB N
the DT N
efficacy NN N
of IN N
GH NNP 1_o
suppression NN N
by IN N
the DT N
GHRH NNP N
antagonist NN N
. . N

METHODS NNP N
A NNP N
limited JJ N
montage NN N
sleep NN N
study NN N
was VBD N
recorded VBN N
from IN N
2300 CD N
to TO N
0700 CD N
h NN N
during IN N
each DT N
admission NN N
. . N

Plasma NNP 1_o
GH NNP 1_o
concentrations NNS 1_o
were VBD N
analyzed VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
sensitive JJ N
chemiluminometric JJ N
assay NN N
. . N

RESULTS NNP N
Effectiveness NNP 1_o
of IN N
the DT N
GHRH NNP N
antagonist NN N
was VBD N
validated VBN N
in IN N
all DT N
subjects NNS N
by IN N
demonstrating VBG N
93+/-1.8 CD N
% NN N
( ( N
P=0.012 NNP N
) ) N
suppression NN 1_o
of IN 1_o
GH NNP 1_o
response NN 1_o
to TO N
a DT N
GHRH NNP N
bolus NN N
. . N

Polysomnography NNP N
demonstrated VBD N
that IN N
the DT N
percentage NN N
of IN N
SWS NNP 1_o
was VBD N
not RB N
different JJ N
when WRB N
saline NN N
and CC N
GHRH NNP N
antagonist VBP N
nights NNS N
were VBD N
compared VBN N
( ( N
P=0.607 NNP N
) ) N
; : N
other JJ N
quantifiable JJ N
sleep JJ 1_o
parameters NNS 1_o
were VBD N
also RB N
unchanged JJ N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that DT N
endogenous JJ N
GHRH NNP N
is VBZ N
indispensable JJ N
for IN N
the DT N
nocturnal JJ N
augmentation NN N
of IN N
GH NNP N
secretion NN N
, , N
but CC N
that IN N
it PRP N
is VBZ N
unlikely JJ N
to TO N
participate VB N
in IN N
the DT N
genesis NN N
of IN N
SWS NNP N
. . N

Short-term JJ N
metabolic JJ N
effects NNS 1_o
of IN N
prednisone NN 1_i
administration NN N
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

AIMS NNP N
Supraphysiologic NNP N
glucocorticoid NN N
activity NN N
is VBZ N
well RB N
established VBN N
to TO N
cause VB N
impaired JJ N
glucose JJ 1_o
tolerance NN 1_o
and CC 1_o
insulin NN 1_o
resistance NN 1_o
, , N
yet RB N
no DT N
study NN N
has VBZ N
evaluated VBN N
dose-dependent JJ N
effects NNS N
of IN N
low-dose JJ N
prednisone NN 1_i
during IN N
short-term JJ N
oral JJ N
administration NN N
. . N

METHODS NNP N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
quantify VB N
the DT N
effects NNS N
of IN N
daily JJ N
10 CD 1_i
or CC 1_i
25 CD 1_i
mg NNS 1_i
prednisone JJ 1_i
administration NN N
for IN N
one CD N
week NN N
on IN N
insulin NN N
sensitivity NN N
by IN N
employing VBG N
a DT N
two-step JJ 1_i
hyperinsulinemic JJ 1_i
euglycemic JJ 1_i
glucose NN 1_i
clamp NN 1_i
( ( N
Step JJ N
1 CD N
: : N
insulin NN N
infusion NN N
= VBD N
20 CD N
mU/m²/min NN N
; : N
Step CC N
2 CD 1_i
: : 1_i
insulin NN 1_i
infusion NN 1_i
= VBD 1_i
80 CD 1_i
mU/m²/min NN 1_i
) ) 1_i
in IN 1_p
healthy JJ 1_p
, , 1_p
lean JJ 1_p
males NNS 1_p
. . N

The DT 1_o
amount NN 1_o
of IN 1_o
glucose NN 1_o
infused VBN 1_o
at IN 1_o
steady-state JJ 1_o
to TO N
maintain VB 1_o
stable JJ 1_o
blood NN 1_o
glucose JJ 1_o
[ $ N
90 CD N
mg/dl NN N
( ( N
4.95 CD N
mmol/l NN N
) ) N
] NN N
was VBD N
used VBN N
to TO N
calculate VB N
several JJ N
indices NNS N
of IN N
insulin NN N
sensitivity NN N
. . N

RESULTS NNP N
During IN N
Step NNP N
1 CD N
of IN N
the DT N
clamp NN 1_o
, , 1_o
whole JJ 1_o
body NN 1_o
glucose JJ 1_o
disposal NN 1_o
( ( 1_o
M NNP 1_o
) ) 1_o
was VBD N
reduced VBN N
by IN N
35 CD N
% NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
M/I NNP N
was VBD N
reduced VBN N
by IN N
29 CD N
% NN N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
for IN N
25 CD N
mg NN 1_i
prednisone NN 1_i
compared VBN N
to TO 1_i
placebo VB 1_i
. . N

No DT N
appreciable JJ N
effect NN N
of IN N
10 CD N
mg NN N
prednisone NN N
was VBD N
observed VBN N
. . N

During IN N
Step NNP N
2 CD 1_o
, , N
M NNP N
was VBD N
reduced VBN N
by IN N
33 CD N
% NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
and CC N
15 CD N
% NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
for IN N
25 CD N
and CC N
10 CD N
mg NN 1_i
prednisone NN 1_i
compared VBN N
to TO 1_i
placebo VB 1_i
; : 1_i
and CC 1_o
M/I NNP 1_o
ratio NN 1_o
was VBD N
reduced VBN N
by IN N
31 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
13 CD N
% NN N
( ( N
p JJ N
= NNP N
0.026 CD N
) ) N
, , N
respectively RB N
. . N

The DT 1_o
insulin NN 1_o
sensitivity NN 1_o
index NN 1_o
, , 1_o
Si NNP 1_o
, , N
calculated VBD N
as IN N
the DT N
quotient NN N
of IN N
augmentation NN N
of IN N
M/I NNP N
between IN N
Step NNP N
1 CD N
and CC N
2 CD N
, , N
was VBD N
reduced VBN N
by IN N
35.3 CD N
% NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
23.5 CD N
% NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
25 CD N
and CC N
10 CD N
mg NN 1_i
prednisone NN 1_i
, , N
respectively RB N
. . N

CONCLUSION NNP N
Administration NNP N
of IN N
relatively RB N
low JJ N
pharmacological JJ N
doses NNS N
of IN N
prednisone NN N
for IN N
one CD N
week NN N
impaired JJ 1_o
insulin NN 1_o
sensitivity NN 1_o
in IN N
a DT N
dose-dependent JJ N
manner NN N
in IN 1_p
healthy JJ 1_p
males NNS 1_p
. . N

These DT N
observed JJ N
changes NNS N
in IN N
insulin NN N
sensitivity NN N
are VBP N
likely JJ N
to TO N
be VB N
clinically RB N
relevant JJ N
, , N
especially RB N
in IN N
individuals NNS N
predisposed VBN N
to TO N
develop VB N
glucose JJ N
intolerance NN N
. . N

Virtual JJ 1_i
reality NN 1_i
for IN N
acute NN N
pain NN N
reduction NN N
in IN N
adolescents NNS 1_p
undergoing VBG 1_p
burn NN 1_p
wound NN 1_p
care NN 1_p
: : 1_p
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Effective NNP N
pain NN 1_i
management NN 1_i
remains VBZ N
a DT N
challenge NN N
for IN N
adolescents NNS 1_p
during IN 1_p
conscious JJ 1_p
burn NN 1_p
wound NN 1_p
care NN 1_p
procedures NNS 1_p
. . 1_p

Virtual JJ 1_i
reality NN 1_i
( ( 1_i
VR NNP 1_i
) ) 1_i
shows VBZ N
promise NN N
as IN N
a DT N
non-pharmacological JJ N
adjunct NN N
in IN N
reducing VBG N
pain NN N
. . N

AIMS VB N
This DT N
study NN N
assessed VBD N
off-the-shelf JJ 1_i
VR NNP 1_i
for IN N
( ( N
1 CD N
) ) N
its PRP$ N
effect NN N
on IN N
reducing VBG N
acute JJ N
pain NN N
intensity NN N
during IN N
adolescent JJ N
burn NN N
wound NN N
care NN N
, , N
and CC N
( ( N
2 CD N
) ) N
its PRP$ N
clinical JJ N
utility NN N
in IN N
a DT N
busy JJ N
hospital NN N
setting NN N
. . N

METHODS NNP N
Forty-one CD 1_p
adolescents NNS 1_p
( ( 1_p
11-17 CD 1_p
years NNS 1_p
) ) 1_p
participated VBD N
in IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Acute NNP N
pain NN N
outcomes NNS N
including VBG N
adolescent JJ N
self-report NN N
, , N
nursing VBG N
staff NN N
behavioral JJ N
observation NN N
, , N
caregiver NN N
observation NN N
and CC N
physiological JJ N
measures NNS N
were VBD N
collected VBN N
. . N

Length NNP N
of IN N
procedure NN N
times NNS N
and CC N
adolescent JJ N
reactions NNS N
were VBD N
also RB N
recorded VBN N
to TO N
inform VB N
clinical JJ N
utility NN N
. . N

RESULTS NNP N
Nursing JJ N
staff NN N
reported VBD N
a DT N
statistically RB N
significant JJ N
reduction NN N
in IN N
pain NN 1_o
scores NNS 1_o
during IN N
dressing VBG N
removal NN N
, , N
and CC N
significantly RB N
less JJR N
rescue JJ 1_o
doses NNS 1_o
of IN 1_o
Entonox NNP 1_o
given VBN N
to TO N
those DT N
receiving VBG N
VR NNP 1_i
, , N
compared VBN N
to TO N
those DT N
receiving VBG N
standard JJ N
distraction NN N
. . N

For IN N
all DT N
other JJ N
pain NN N
outcomes NNS N
and CC N
length NN N
of IN N
treatment NN N
, , N
there EX N
was VBD N
a DT N
trend NN N
for IN N
lower JJR N
pain NN 1_o
scores NNS 1_o
and CC 1_o
treatment NN 1_o
times NNS 1_o
for IN N
those DT N
receiving VBG N
VR NNP 1_i
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSION NNP N
Despite IN N
only RB N
minimal JJ N
pain NN N
reduction NN N
achieved VBD N
using VBG N
off-the-shelf JJ N
VR NNP 1_i
, , N
other JJ N
results NNS N
from IN N
this DT N
trial NN N
and CC N
previous JJ N
research NN N
on IN N
younger JJR N
children NNS N
with IN N
burns NNS N
suggest VBP N
a DT N
customized JJ N
, , N
adolescent JJ N
and CC N
hospital JJ N
friendly JJ N
device NN N
may MD N
be VB N
more RBR N
effective JJ N
in IN N
pain NN N
reduction NN N
. . N

Theory NN N
of IN N
Mind NNP 1_i
training NN 1_i
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_o
: : 1_o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Many JJ N
children NNS 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorders NNP 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
participate NN N
in IN N
social JJ N
skills NNS N
or CC N
Theory NN 1_i
of IN 1_i
Mind NNP 1_i
( ( 1_i
ToM NNP 1_i
) ) 1_i
treatments NNS 1_i
. . 1_i

However RB N
, , N
few JJ N
studies NNS N
have VBP N
shown VBN N
evidence NN N
for IN N
their PRP$ N
effectiveness NN N
. . N

The DT N
current JJ N
study NN N
used VBD N
a DT N
randomized JJ N
controlled JJ N
design NN N
to TO N
test VB N
the DT N
effectiveness NN 1_o
of IN N
a DT N
16-week JJ N
ToM NNP 1_i
treatment NN 1_i
in IN N
8-13 JJ 1_p
year NN 1_p
old JJ 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
normal JJ 1_p
IQs NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
40 CD 1_p
) ) 1_p
. . N

The DT N
results NNS N
showed VBD N
that IN N
, , N
compared VBN N
to TO N
controls NNS N
, , N
the DT N
treated JJ N
children NNS N
with IN N
ASD NNP 1_o
improved VBN 1_o
in IN N
their PRP$ 1_o
conceptual JJ 1_o
ToM NNP 1_o
skills NNS 1_o
, , N
but CC N
their PRP$ 1_o
elementary JJ 1_o
understanding NN 1_o
, , 1_o
self PRP 1_o
reported VBD 1_o
empathic JJ 1_o
skills NNS 1_o
or CC 1_o
parent NN 1_o
reported VBN 1_o
social JJ 1_o
behaviour NN 1_o
did VBD N
not RB N
improve VB N
. . N

Despite IN N
the DT N
effects NNS N
on IN N
conceptual JJ N
understanding NN N
, , N
the DT N
current JJ N
study NN N
does VBZ N
not RB N
indicate VB N
strong JJ N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
a DT N
ToM NNP N
treatment NN N
on IN N
the DT N
daily JJ N
life NN 1_o
mindreading VBG 1_o
skills NNS N
. . N

Histologic NNP 1_o
conversion NN 1_o
in IN N
the DT N
non-Hodgkin NN 1_p
's POS 1_p
lymphomas NN 1_p
. . 1_p

Between NNP 1_p
July NNP 1_p
1 CD 1_p
, , 1_p
1971 CD 1_p
and CC 1_p
December NNP 1_p
31 CD 1_p
, , 1_p
1978 CD 1_p
, , 1_p
150 CD 1_p
patients NNS 1_p
with IN 1_p
favorable JJ 1_p
subtypes NNS 1_p
of IN 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
[ NNP 1_p
nodular JJ 1_p
poorly RB 1_p
differentiated VBN 1_p
lymphocytic JJ 1_p
( ( 1_p
NLPD NNP 1_p
) ) 1_p
, , 1_p
nodular JJ 1_p
mixed JJ 1_p
, , 1_p
or CC 1_p
diffuse RB 1_p
well RB 1_p
differentiated VBN 1_p
lymphocytic JJ 1_p
] NNS 1_p
were VBD N
entered VBN N
into IN N
prospective JJ N
randomized VBN N
clinical JJ 1_p
trials NNS 1_p
at IN 1_p
Stanford NNP 1_p
University NNP 1_p
. . 1_p

Treatments NNS N
included VBD N
involved JJ N
field NN 1_i
, , 1_i
total JJ 1_i
lymphoid NN 1_i
, , 1_i
or CC 1_i
whole JJ 1_i
body NN 1_i
irradiation NN 1_i
, , 1_i
single JJ 1_i
alkylating VBG 1_i
agent NN 1_i
chemotherapy NN 1_i
, , 1_i
combination NN 1_i
chemotherapy NN 1_i
with IN 1_i
cyclophosphamide NN 1_i
, , 1_i
vincristine NN 1_i
and CC 1_i
prednisone NN 1_i
( ( 1_i
CVP NNP 1_i
) ) 1_i
or CC 1_i
with IN 1_i
cyclophosphamide NN 1_i
, , 1_i
vincristine NN 1_i
, , 1_i
procarbazine NN 1_i
, , 1_i
and CC 1_i
prednisone NN 1_i
( ( 1_i
C-MOPP NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
various JJ 1_i
combinations NNS 1_i
of IN 1_i
chemotherapy NN 1_i
and CC 1_i
irradiation NN 1_i
. . 1_i

The DT N
initial JJ N
complete JJ 1_o
response NN 1_o
rate NN 1_o
( ( 1_o
CR NNP 1_o
) ) 1_o
was VBD N
79 CD N
% NN N
. . N

Among IN N
patients NNS N
who WP N
achieved VBD 1_o
a DT 1_o
CR NNP 1_o
, , N
31 CD N
% NN N
later RB N
relapsed VBN 1_o
. . 1_o

There EX N
were VBD N
78 CD N
patients NNS N
who WP N
either RB N
failed VBD N
to TO N
achieve VB 1_o
a DT 1_o
CR NNP 1_o
or CC N
achieved VBD 1_o
a DT 1_o
CR NNP 1_o
and CC N
later RB N
relapsed VBN 1_o
. . 1_o

Histologic NNP 1_o
conversion NN 1_o
( ( N
change NN N
from IN N
initially RB N
favorable JJ N
to TO N
an DT N
unfavorable JJ N
subtype NN N
of IN N
non-Hodgkin NN N
's POS N
lymphoma NN N
) ) N
was VBD N
documented VBN N
in IN N
22/78 CD N
patients NNS N
( ( N
28 CD N
% NN N
) ) N
. . N

However RB N
, , N
the DT N
actuarial JJ 1_o
risk NN 1_o
for IN 1_o
conversion NN 1_o
was VBD N
actually RB N
much JJ N
greater JJR 1_o
( ( N
60 CD N
% NN N
at IN N
8 CD N
yr NN N
) ) N
. . N

The DT N
median JJ 1_o
time NN 1_o
to TO 1_o
documentation NN 1_o
of IN 1_o
conversion NN 1_o
was VBD N
51 CD N
mo NN N
. . N

The DT N
most RBS 1_o
common JJ 1_o
type NN N
of IN N
histologic JJ 1_o
conversion NN 1_o
was VBD N
from IN N
NLPD NNP N
to TO N
diffuse VB N
histiocytic JJ 1_o
lymphoma NN 1_o
. . 1_o

Documented VBN N
histologic JJ 1_o
conversion NN 1_o
was VBD N
often RB N
associated VBN N
with IN N
a DT N
more RBR N
aggressive JJ 1_o
clinical JJ 1_o
behavior NN 1_o
of IN N
the DT N
lymphoma NN N
, , N
and CC N
the DT N
median JJ 1_o
survival NN 1_o
after IN N
conversion NN 1_o
was VBD N
less JJR N
than IN N
1 CD N
yr NN N
. . N

However RB N
, , N
those DT N
patients NNS N
who WP N
achieved VBD 1_o
a DT 1_o
CR NNP 1_o
after IN N
conversion NN 1_o
had VBD N
a DT N
more RBR N
favorable JJ 1_o
outcome NN 1_o
( ( 1_o
actuarial JJ 1_o
survival NN 1_o
75 CD N
% NN N
at IN N
5 CD N
yr NN N
) ) N
. . N

No DT N
specific JJ N
risk NN 1_o
factors NNS 1_o
predictive VBP N
of IN N
histologic JJ 1_o
conversion NN 1_o
could MD N
be VB N
identified VBN N
. . N

Comparison NNP N
of IN N
meloxicam NN 1_i
and CC 1_i
a DT 1_i
glucosamine-chondroitin JJ 1_i
supplement NN 1_i
in IN N
management NN N
of IN N
feline NN 1_o
osteoarthritis NN 1_o
. . 1_o

A DT N
double-blind NN N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
prospective JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
meloxicam NN 1_i
and CC 1_i
a DT 1_i
glucosamine-chondroitin JJ 1_i
( ( 1_i
Glu-Ch NNP 1_i
) ) 1_i
supplement NN 1_i
in IN N
the DT N
management NN N
of IN N
feline NN 1_o
osteoarthritis NN 1_o
( ( 1_o
OA NNP 1_o
) ) 1_o
. . N

METHODS NNP N
Prospective NNP N
, , N
blinded VBD N
, , N
randomized VBD N
clinical JJ N
trial NN N
. . N

Cats NNPS 1_p
over IN 1_p
eight CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
clinical JJ 1_p
signs NNS 1_p
of IN 1_p
chronic JJ 1_p
OA NNP 1_p
were VBD 1_p
assigned VBN 1_p
to TO 1_p
one CD 1_p
of IN 1_p
two CD 1_p
groups NNS 1_p
and CC N
Glu-Ch NNP 1_i
or CC 1_i
meloxicam NN 1_i
was VBD N
administered VBN N
orally RB N
for IN N
70 CD N
days NNS N
, , N
followed VBN N
by IN N
a DT N
placebo NN 1_i
until IN N
day NN N
98 CD N
. . N

Cats NNPS 1_p
were VBD N
assessed VBN N
by IN N
a DT N
veterinarian NN N
on IN N
five CD N
occasions NNS N
and CC N
the DT N
owner NN N
completed VBD N
an DT N
assessment JJ N
form NN N
at IN N
the DT N
same JJ N
time NN N
. . N

RESULTS NNP N
Data NNP N
were VBD N
collected VBN N
from IN N
thirty NN N
cats NNS N
. . N

Pre-treatment JJ N
disease NN 1_o
scores NNS 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
meloxicam NN 1_i
group NN N
for IN N
owner NN 1_o
mobility NN 1_o
( ( N
p=0.01 NN N
) ) N
and CC N
veterinary JJ 1_o
lameness NN 1_o
( ( N
p=0.02 NN N
) ) N
. . N

Owner NNP 1_o
mobility NN 1_o
scores NNS 1_o
at IN N
day NN N
14 CD N
( ( N
p=0.01 NN N
) ) N
and CC N
day NN N
42 CD N
( ( N
p=0.002 NN N
) ) N
were VBD N
significantly RB N
improved VBN N
compared VBN N
to TO N
pre-treatment JJ N
scores NNS N
for IN N
the DT N
meloxicam NN 1_i
group NN N
. . N

When WRB N
meloxicam NN 1_i
and CC N
Glu-Ch NNP N
were VBD N
discontinued VBN N
and CC N
the DT N
placebo NN 1_i
commenced VBD N
, , N
a DT N
significant JJ N
proportion NN N
of IN N
the DT N
meloxicam NN 1_i
group NN N
showed VBD N
worsening NN N
of IN N
all PDT N
the DT N
owner-assessed JJ 1_o
scores NNS 1_o
between IN N
day NN N
70 CD N
and CC N
day NN N
98 CD N
, , N
when WRB N
compared VBN N
to TO N
the DT N
Glu-Ch NNP N
group NN N
( ( 1_o
mobility NN 1_o
p=0.01 NN N
; : N
activity NN 1_o
p=0.02 NN N
; : N
temperament JJ 1_o
p=0.04 NN N
; : N
lifestyle CC 1_o
p=0.01 NN N
) ) N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
meloxicam NN 1_i
resulted VBN N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
mobility NN 1_o
and CC 1_o
activity NN 1_o
levels NNS 1_o
of IN N
cats NNS 1_p
with IN N
OA NNP N
until IN N
the DT N
placebo NN 1_i
was VBD N
introduced VBN N
. . N

A DT N
greater JJR N
proportion NN N
of IN N
cats NNS N
receiving VBG N
meloxicam NN 1_i
medication NN N
showed VBD N
a DT N
significant JJ N
worsening NN N
of IN N
owner NN 1_o
assessment NN 1_o
scores VBZ 1_o
once RB N
the DT N
placed NN N
was VBD N
introduced VBN N
, , N
when WRB N
compared VBN N
to TO N
the DT N
Glu-Ch NNP N
group NN N
. . N

Effectiveness NN 1_o
of IN N
once-daily JJ 1_i
monotherapy NN 1_i
with IN N
a DT N
new JJ N
nifedipine NN N
sustained VBN N
release NN N
calcium NN N
antagonist NN N
. . N

Data NNS N
from IN N
2 CD 1_p
separate JJ 1_p
multicenter NN 1_p
, , N
double-blind JJ N
clinical JJ N
studies NNS N
following VBG N
the DT N
same JJ N
protocol NN N
, , N
except IN N
for IN N
the DT N
selection NN N
of IN N
doses NNS N
, , N
were VBD N
pooled VBN N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
fixed JJ N
doses NNS N
of IN N
a DT N
new JJ 1_i
sustained-release NN 1_i
( ( 1_i
SR NNP 1_i
) ) 1_i
formulation NN 1_i
of IN 1_i
nifedipine JJ 1_i
compared VBN N
with IN N
placebo NN 1_i
in IN N
388 CD 1_p
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
uncomplicated JJ 1_p
essential JJ 1_p
hypertension NN 1_p
. . 1_p

After IN N
a DT N
3-6 JJ N
week NN N
placebo NN N
washout IN N
period NN N
, , N
the DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
placebo NN 1_i
or CC 1_i
nifedipine JJ 1_i
SR-20 JJ N
mg NN N
( ( N
study NN N
I PRP N
only RB N
) ) N
, , N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
, , N
or CC N
150 CD N
mg NN N
( ( N
study VB N
II NNP N
only RB N
) ) N
. . N

Among IN N
the DT N
278 CD N
patients NNS N
who WP N
completed VBD N
6 CD N
weeks NNS N
of IN N
active JJ N
therapy NN N
, , N
mean JJ 1_o
supine VBP 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
reductions NNS 1_o
from IN N
pretreatment JJ N
baseline NN N
were VBD N
5.9 CD N
, , N
9.3 CD N
, , N
9.2 CD N
, , N
11.1 CD N
, , N
and CC N
13.2 CD N
mm NN N
Hg NNP N
in IN N
the DT N
placebo NN N
, , N
20- JJ N
, , N
50- JJ N
, , N
100- JJ N
, , N
and CC N
150-mg JJ N
groups NNS N
, , N
respectively RB N
. . N

The DT N
reductions NNS N
achieved VBN N
in IN N
each DT N
of IN N
the DT N
nifedipine JJ 1_i
SR NNP N
groups NNS N
were VBD N
statistically RB N
significant JJ N
versus NN N
baseline NN N
values NNS N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

All DT N
nifedipine-SR JJ N
doses NNS N
reduced VBN 1_o
supine JJ 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
significantly RB N
more RBR N
than IN N
placebo NN 1_i
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
linear JJ N
relationship NN N
between IN N
the DT N
log NN 1_o
of IN 1_o
the DT 1_o
dose NN 1_o
and CC N
the DT N
blood NN 1_o
pressure NN 1_o
reduction NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Automated VBN 1_o
ambulatory JJ 1_o
blood NN 1_o
pressure NN 1_o
recordings NNS 1_o
performed VBN N
in IN N
221 CD N
of IN N
the DT N
patients NNS N
showed VBD N
that IN N
the DT N
blood NN 1_o
pressure NN 1_o
was VBD 1_o
lowered VBN 1_o
evenly RB N
through IN N
the DT N
entire JJ N
24-hour JJ N
dosing NN N
period NN N
. . N

The DT N
doses NNS N
that WDT N
were VBD N
effective JJ N
and CC N
associated VBN N
with IN N
the DT N
fewest JJS N
adverse JJ N
reactions NNS N
were VBD N
20 CD N
mg NNS N
and CC N
50 CD N
mg NN N
once RB N
daily RB N
. . N

The DT N
effect NN N
of IN N
cessation NN N
of IN N
raloxifene NN 1_i
treatment NN N
on IN N
bone NN 1_p
turnover NN 1_p
in IN 1_p
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

There EX N
is VBZ N
evidence NN N
to TO N
suggest VB N
accelerated JJ 1_p
bone NN 1_o
loss NN 1_o
following VBG 1_p
estrogen JJ 1_p
cessation NN 1_p
. . 1_p

The DT N
effect NN N
of IN N
cessation NN N
of IN N
raloxifene NN 1_i
therapy NN N
on IN N
bone NN N
turnover NN N
is VBZ N
unknown JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
cessation NN N
of IN N
raloxifene NN 1_i
treatment NN N
on IN N
bone NN 1_o
turnover NN 1_o
and CC N
bone JJ 1_o
mineral NN 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
in IN N
postmenopausal NN 1_p
, , 1_p
osteopenic JJ 1_p
women NNS 1_p
. . 1_p

Women NNS 1_p
aged VBD 1_p
50 CD 1_p
to TO 1_p
80 CD 1_p
years NNS 1_p
received VBD N
raloxifene NN 1_i
for IN N
96 CD N
weeks NNS N
and CC N
were VBD N
then RB N
randomized VBN N
to TO N
continue VB N
raloxifene NN 1_i
( ( 1_p
group NN 1_p
1 CD 1_p
, , 1_p
n=20 NN 1_p
) ) 1_p
or CC 1_i
placebo NN 1_i
( ( 1_p
group NN 1_p
2 CD 1_p
, , 1_p
n=20 NN 1_p
) ) 1_p
for IN 1_p
a DT 1_p
further JJ 1_p
96 CD 1_p
weeks NNS 1_p
. . 1_p

A DT 1_p
third JJ 1_p
group NN 1_p
( ( 1_p
group NN 1_p
3 CD 1_p
, , 1_p
n=14 NN 1_p
) ) 1_p
received VBD 1_p
no DT 1_i
treatment NN 1_i
. . 1_i

Bone NNP 1_o
turnover NN 1_o
markers NNS 1_o
and CC 1_o
bone NN 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
were VBD N
measured VBN N
throughout IN N
the DT N
study NN N
. . N

Raloxifene NNP 1_i
treatment NN N
for IN N
96 CD N
weeks NNS N
resulted VBD N
in IN N
a DT N
decrease NN 1_o
in IN 1_o
bone NN 1_o
turnover NN 1_o
( ( N
PINP NNP N
by IN N
31 CD N
% NN N
) ) N
and CC N
an DT N
increase NN 1_o
in IN 1_o
spine JJ 1_o
BMD NNP 1_o
( ( N
by IN N
2 CD N
% NN N
) ) N
but CC N
no DT N
change NN N
in IN N
hip NN 1_o
BMD NNP 1_o
for IN N
groups NNS N
1 CD N
and CC N
2 CD N
. . N

Continuation NN N
of IN N
raloxifene NN 1_i
( ( N
group NN N
1 CD N
) ) N
maintained VBD N
these DT N
changes NNS N
. . N

Following VBG N
cessation NN N
of IN N
raloxifene NN 1_i
( ( N
group NN N
2 CD N
) ) N
, , N
bone NN 1_o
markers NNS 1_o
returned VBD N
to TO N
baseline NN N
levels NNS N
( ( N
by IN N
120 CD N
weeks NNS N
) ) N
. . N

Hip NNP 1_o
BMD NNP 1_o
was VBD N
decreased VBN N
by IN N
2 CD N
% NN N
at IN N
192 CD N
weeks NNS N
compared VBN N
to TO N
baseline VB N
. . N

Bone NNP 1_o
markers NNS 1_o
in IN N
the DT N
controls NNS N
( ( N
group NN N
3 CD N
) ) N
remained VBD N
at IN N
the DT N
upper JJ N
limit NN N
of IN N
the DT N
reference NN N
range NN N
throughout IN N
, , N
with IN N
decreases NNS N
in IN N
BMD NNP 1_o
of IN N
2.3 CD N
% NN N
( ( N
spine NN N
) ) N
and CC N
2.8 CD N
% NN N
( ( N
hip NN N
) ) N
. . N

Bone NNP 1_o
loss NN 1_o
following VBG N
cessation NN N
of IN N
raloxifene NN 1_i
therapy NN N
at IN N
96 CD N
weeks NNS N
was VBD N
greater JJR N
than IN N
in IN N
the DT N
control NN N
group NN N
, , N
suggesting VBG N
accelerated VBD 1_p
bone JJ 1_p
loss NN 1_p
. . 1_p

The DT N
beneficial JJ N
effect NN N
on IN N
bone NN 1_o
turnover NN 1_o
of IN N
96 CD N
weeks NNS N
of IN N
raloxifene NN N
was VBD N
lost VBN N
6 CD N
months NNS N
after IN N
cessation NN N
of IN N
treatment NN N
. . N

The DT N
costs NNS 1_o
and CC N
effects NNS 1_o
of IN N
a DT N
nutritional JJ 1_i
education NN 1_i
program NN 1_i
following VBG N
work-site JJ N
cholesterol NN N
screening NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
costs NNS 1_o
and CC N
impact NN 1_o
of IN N
a DT N
nutrition JJ 1_i
education NN 1_i
program NN 1_i
following VBG N
a DT N
cholesterol NN N
screening NN N
. . N

METHODS NNP N
Forty NNP 1_p
work-sites NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
educational JJ 1_i
interventions NNS 1_i
: : 1_i
a DT N
" JJ 1_i
usual JJ 1_i
" NNP 1_i
intervention NN 1_i
of IN 1_i
5 CD 1_i
minutes NNS 1_i
of IN 1_i
counseling NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
" JJ 1_i
special JJ 1_i
" NNP 1_i
intervention NN 1_i
of IN 1_i
2 CD 1_i
hours NNS 1_i
of IN 1_i
behaviorally RB 1_i
based VBN 1_i
education NN 1_i
on IN 1_i
dietary JJ 1_i
changes NNS 1_i
to TO 1_i
lower VB 1_i
serum NN 1_i
cholesterol NN 1_i
. . 1_i

Costs NNS 1_o
were VBD N
monitored VBN N
, , N
and CC N
cholesterol NN 1_o
levels NNS 1_o
were VBD N
retested VBN N
6 CD N
and CC N
12 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
total JJ 1_o
per-person JJ 1_o
cost NN 1_o
for IN N
screening VBG N
and CC N
the DT N
educational JJ N
intervention NN N
was VBD N
about IN N
$ $ N
50 CD N
. . N

Cholesterol NN 1_o
levels NNS 1_o
differed VBD N
little RB N
between IN N
the DT N
two CD N
intervention NN N
groups NNS N
6 CD N
months NNS N
after IN N
screening VBG N
, , N
but CC N
after IN N
12 CD N
months NNS N
those DT N
in IN N
the DT N
special JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
6.5 CD N
% NN N
drop NN N
in IN N
cholesterol NN 1_o
, , N
whereas IN N
those DT N
at IN N
the DT N
usual JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
drop NN N
of IN N
only RB N
3.0 CD N
% NN N
. . N

Hence NNP N
a DT N
3.5 CD N
% NN N
cholesterol NN 1_o
reduction NN 1_o
was VBD N
attributable JJ N
to TO N
the DT N
special JJ N
intervention NN N
. . N

CONCLUSIONS VB N
A NNP N
behaviorally RB 1_i
based VBN 1_i
nutrition JJ 1_i
education NN 1_i
program NN 1_i
following VBG N
cholesterol NN N
screening VBG N
can MD N
have VB N
a DT N
meaningful JJ N
impact NN N
on IN N
long-term JJ N
cholesterol NN N
levels NNS N
at IN N
a DT N
low JJ N
cost NN N
. . N

Nutrition NNP 1_i
education NN 1_i
in IN N
work-sites NNS N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
way NN N
to TO N
lower VB N
the DT N
risk NN N
of IN N
heart NN N
disease NN N
in IN N
communities NNS N
. . N

Inhibition NN N
of IN N
epidural JJ 1_o
morphine-induced JJ 1_o
pruritus NN 1_o
by IN N
intravenous JJ N
droperidol NN 1_i
. . 1_i

The DT N
effect NN N
of IN N
increasing VBG N
the DT N
doses NNS N
of IN N
morphine NN 1_i
and CC N
of IN N
droperidol NN 1_i
. . 1_i

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Because IN N
the DT N
mechanism NN N
of IN N
inhibition NN N
of IN N
epidural JJ N
morphine-induced JJ N
pruritus NN N
by IN N
droperidol NN N
is VBZ N
not RB N
clear JJ N
, , N
this DT N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
larger JJR N
doses NNS N
of IN N
droperidol NN 1_i
or CC 1_i
morphine NN 1_i
, , N
or CC N
both DT N
. . N

METHODS VB N
A DT N
double-blind NN N
study NN N
was VBD N
performed VBN N
in IN N
210 CD 1_p
ASA NNP 1_p
I PRP 1_p
or CC 1_p
II NNP 1_p
patients NNS 1_p
undergoing VBG 1_p
cesarean JJ 1_p
delivery NN 1_p
, , 1_p
who WP 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
six CD 1_p
groups NNS 1_p
. . 1_p

All DT N
patients NNS N
received VBD N
epidural JJ 1_i
anesthesia NN 1_i
with IN 1_i
0.5 CD 1_i
% NN 1_i
bupivacaine NN 1_i
containing VBG 1_i
1:200,000 CD 1_i
epinephrine NN 1_i
, , 1_i
to TO 1_i
which WDT 1_i
2 CD 1_i
mg NN 1_i
( ( N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
or CC N
4 CD N
mg NN N
( ( N
groups NNS N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
) ) N
morphine NN 1_i
sulfate NN 1_i
was VBD N
added VBN N
. . N

Just RB N
after IN N
delivery NN N
, , N
2.5 CD N
mg NN N
droperidol NN 1_i
was VBD N
given VBN N
intravenously RB N
to TO N
groups NNS N
2 CD N
and CC N
5 CD N
, , N
and CC N
5 CD N
mg NN N
was VBD N
given VBN N
to TO N
groups NNS N
3 CD N
and CC N
6 CD N
. . N

During IN N
the DT N
postoperative JJ N
period NN N
, , N
the DT N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
occurrence NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
pruritus NN 1_o
( ( N
classified VBN N
as IN N
absent NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
) ) N
or CC N
other JJ 1_o
untoward JJ 1_o
symptoms NNS 1_o
. . 1_o

The DT N
groups NNS N
were VBD N
compared VBN N
for IN N
the DT N
incidence NN 1_o
of IN 1_o
pruritus NN 1_o
by IN N
the DT N
Mann-Whitney NNP N
nonparametric JJ N
test NN N
. . N

RESULTS VB N
The DT N
incidence NN 1_o
of IN 1_o
pruritus NN 1_o
was VBD N
significantly RB N
reduced VBN N
only RB N
when WRB N
the DT N
control NN N
group NN N
. . N

( ( N
no DT N
droperidol NN 1_i
) ) 1_i
was VBD N
compared VBN N
with IN N
the DT N
group NN N
that WDT N
received VBD N
2.5 CD N
mg NN N
droperidol NN 1_i
, , N
both DT N
when WRB N
2 CD N
mg NN N
and CC N
when WRB N
4 CD N
mg NN N
morphine NN 1_i
was VBD N
used VBN N
. . N

A DT N
5-mg JJ N
dose NN N
of IN N
droperidol NN N
had VBD N
no DT N
inhibitory JJ 1_o
effect NN 1_o
. . 1_o

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
incidence NN 1_o
of IN 1_o
pruritus NN 1_o
between IN N
use NN N
of IN N
2 CD N
mg NNS N
and CC N
4 CD N
mg NN N
morphine NN 1_i
. . 1_i

Other JJ N
untoward JJ 1_o
effects NNS 1_o
of IN N
morphine NN 1_i
either DT N
could MD N
not RB N
be VB N
observed VBN N
or CC N
occurred VBN N
with IN N
an DT N
incidence NN N
unaffected VBN N
by IN N
either DT N
dose NN N
of IN N
droperidol NN 1_i
. . 1_i

CONCLUSION NNP N
Pruritus NNP 1_o
caused VBN N
by IN N
epidural JJ N
use NN N
of IN N
2 CD N
or CC N
4 CD N
mg NN N
of IN N
morphine NN 1_i
is VBZ N
inhibited VBN N
by IN N
the DT N
intravenous JJ N
use NN N
of IN N
2.5 CD N
mg NNS N
droperidol RB 1_i
but CC N
not RB N
by IN N
a DT N
larger JJR N
dose NN N
. . N

Validity NNP 1_o
and CC 1_o
reliability NN 1_o
assessment NN N
of IN N
the DT N
Siriraj NNP 1_i
Asthma NNP 1_i
Control NNP 1_i
Questionnaire NNP 1_i
. . 1_i

OBJECTIVE CC N
The DT N
present JJ N
study NN N
assessed VBD N
the DT N
validity NN 1_o
and CC N
reliability NN 1_o
of IN N
the DT N
Siriraj NNP 1_i
Asthma NNP 1_i
Control NNP 1_i
Questionnaire NNP 1_i
in IN N
Asthma NNP N
Clinic NNP N
, , N
Siriraj NNP 1_p
Hospital NNP 1_p
. . 1_p

MATERIAL NNP N
AND CC N
METHOD NNP N
The DT N
data NN N
of IN N
the DT N
questionnaire NN N
responses NNS N
and CC N
spirometric JJ N
results NNS N
from IN N
20 CD 1_p
randomized JJ 1_p
asthmatic JJ 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
clinic NN 1_p
including VBG 1_p
the DT 1_p
record NN 1_p
of IN 1_p
3 CD 1_p
visits NNS 1_p
for IN 1_p
each DT 1_p
subject NN 1_p
. . 1_p

The DT N
validation NN N
was VBD N
performed VBN N
by IN N
Kruskal-Wallis NNP 1_i
test NN 1_i
comparing VBG N
the DT N
scores NNS N
with IN N
the DT N
level NN N
of IN N
asthma NNS N
control NN N
determined VBN N
by IN N
physicians NNS N
according VBG N
to TO N
GINA NNP N
guideline NN N
. . N

Internal NNP N
consistency NN N
reliability NN N
was VBD N
analyzed VBN N
by IN N
Cronbach NNP N
's POS N
alpha NN N
. . N

RESULTS NNP N
Sixty NNP N
questionnaires VBZ N
from IN N
20 CD 1_p
patients NNS 1_p
with IN 1_p
age NN 1_p
29-73 CD 1_p
years NNS 1_p
were VBD N
analyzed VBN N
. . N

There EX N
were VBD N
40 CD N
controlled VBN N
, , N
7 CD N
partly RB N
controlled VBN N
and CC N
13 CD N
uncontrolled JJ N
visits NNS N
. . N

The DT N
scores NNS 1_o
from IN 1_o
5-items JJ 1_o
questionnaires NNS 1_o
and CC 1_o
6-items JJ 1_o
clinical JJ 1_o
score NN 1_o
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
physician-diagnosed JJ N
groups NNS N
( ( N
i.e. FW N
, , N
controlled VBD N
, , N
partly RB N
controlled VBN N
and CC N
uncontrolled JJ N
groups NNS N
) ) N
. . N

Median JJ 1_o
scores NNS 1_o
( ( 1_o
min NN 1_o
, , 1_o
max NN 1_o
) ) 1_o
were VBD N
0 CD N
( ( N
0 CD N
, , N
5 CD N
) ) N
, , N
2 CD N
( ( N
0 CD N
, , N
6 CD N
) ) N
, , N
4 CD N
( ( N
0 CD N
, , N
12 CD N
) ) N
respectively RB N
, , N
( ( N
5-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
and CC N
2 CD N
( ( N
0 CD N
, , N
7 CD N
) ) N
, , N
3 CD N
( ( N
1 CD N
, , N
7 CD N
) ) N
, , N
6 CD N
( ( N
2,15 CD N
) ) N
respectively RB N
, , N
( ( N
6-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
. . N

Internal NNP 1_o
consistency NN 1_o
reliability NN 1_o
of IN N
both DT N
5-items JJ N
questionnaire NN N
and CC N
6-items JJ N
clinical JJ N
score NN N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.829 CD N
and CC N
0.708 CD N
respectively RB N
) ) N
. . N

5-items JJ 1_o
questionnaire NN 1_o
is VBZ N
more RBR N
associated JJ N
with IN N
the DT N
physician NN N
diagnosed VBN N
group NN N
and CC N
more JJR N
consistent JJ 1_o
than IN N
6-items JJ 1_o
clinical JJ 1_o
score NN 1_o
. . 1_o

Further JJ N
analysis NN N
revealed VBD N
cutoff NN N
point NN N
at IN N
2.5 CD N
to TO N
separate VB N
uncontrolled JJ N
from IN N
controlled VBN N
or CC N
partly RB N
controlled VBN N
patient NN N
with IN N
sensitivity NN 1_o
76.9 CD N
% NN N
and CC N
specificity NN 1_o
89.4 CD N
% NN N
and CC N
cutoff NN 1_o
point NN 1_o
at IN N
1.5 CD N
to TO N
separate VB N
uncontrolled JJ N
or CC N
partly RB N
controlled VBN N
from IN N
controlled VBN N
patient NN N
with IN N
sensitivity NN 1_o
70.0 CD N
% NN N
and CC N
specificity NN 1_o
85.0 CD N
% NN N
. . N

CONCLUSION NNP N
The DT N
validity NN 1_o
and CC 1_o
reliability NN 1_o
of IN N
Siriraj NNP 1_i
Asthma NNP 1_i
Control NNP 1_i
Questionnaire NNP 1_i
is VBZ N
acceptable JJ N
and CC N
might MD N
be VB N
used VBN N
in IN N
the DT N
clinical JJ N
practice NN N
and CC N
research NN N
in IN N
Thai NNP 1_p
asthmatic JJ 1_p
patients NNS 1_p
. . 1_p

Secretin NNP 1_i
and CC N
sleep NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

The DT N
objectives NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
1 CD N
) ) N
to TO N
examine VB N
possible JJ N
effects NNS N
of IN N
secretin JJ 1_i
infusions NNS N
on IN N
sleep-wake JJ N
state NN N
organization NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
, , 1_p
and CC 1_p
2 CD 1_p
) ) 1_p
to TO 1_p
assess VB 1_p
the DT 1_p
feasibility NN 1_p
of IN 1_p
home NN 1_p
recordings NNS 1_p
using VBG 1_p
time-lapse JJ 1_p
videosomnography NN 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Participants NNS 1_p
were VBD 1_p
a DT 1_p
subset NN 1_p
of IN 1_p
subjects NNS 1_p
from IN 1_p
two CD 1_p
double JJ 1_p
blind NN 1_p
, , 1_p
placebo-control NN 1_p
, , 1_p
multi-center JJ 1_p
clinical JJ 1_p
trials NNS 1_p
. . 1_p

One CD N
trial NN N
, , N
the DT N
UC NNP N
Irvine NNP N
study NN N
, , N
assessed VBD N
the DT N
effects NNS N
of IN N
porcine NN 1_i
secretin NN 1_i
vs. FW 1_i
saline NN 1_i
infusions NNS 1_i
on IN N
children NNS N
's POS N
behavior NN 1_o
, , 1_o
language NN 1_o
and CC N
IQ NNP 1_o
. . 1_o

The DT N
UC NNP N
Davis NNP N
trial NN N
assessed VBD N
the DT N
effects NNS N
of IN N
synthetic JJ 1_i
human JJ 1_i
secretin NN 1_i
vs. FW 1_i
saline NN 1_i
infusions NNS 1_i
on IN N
behavior NN 1_o
, , 1_o
language NN 1_o
and CC N
gastrointestinal JJ 1_o
function NN 1_o
. . 1_o

The DT N
sleep NN N
study NN N
enrolled VBD 1_p
some DT 1_p
of IN 1_p
the DT 1_p
children NNS 1_p
from IN 1_p
each DT 1_p
of IN 1_p
the DT 1_p
two CD 1_p
trials NNS 1_p
to TO N
observe VB N
possible JJ N
secretin JJ N
effects NNS N
on IN N
sleep NN N
. . N

To TO N
examine VB N
sleep NN N
, , N
the DT N
UC NNP N
Irvine NNP N
trial NN N
used VBD N
the DT N
Children NNP 1_o
's POS 1_o
Sleep NNP 1_o
Habits NNP 1_o
Questionnaire NNP 1_o
and CC 1_o
daily JJ 1_o
sleep NN 1_o
diaries NNS 1_o
, , N
whereas IN N
the DT N
UC NNP N
Davis NNP N
study NN N
used VBD N
home-recorded JJ 1_o
time-lapse JJ 1_o
videosomnography NN 1_o
. . 1_o

Because IN N
of IN N
the DT N
small JJ N
sample NN N
size NN N
, , N
the DT N
results NNS N
from IN N
both DT N
trials NNS N
are VBP N
preliminary JJ N
. . N

They PRP N
suggest VBP N
that IN N
secretin NN 1_i
, , 1_i
porcine NN 1_i
or CC 1_i
synthetic JJ 1_i
, , N
does VBZ N
not RB N
improve VB N
sleep-wake NN 1_o
state NN 1_o
organization NN 1_o
dramatically RB N
. . N

Alvimopan NNP 1_i
for IN N
the DT N
management NN N
of IN N
postoperative JJ N
ileus NN N
after IN N
bowel JJ N
resection NN N
: : N
characterization NN N
of IN N
clinical JJ N
benefit NN N
by IN N
pooled JJ N
responder NN N
analysis NN N
. . N

BACKGROUND VB N
A NNP N
pooled JJ N
post NN N
hoc NN N
responder NN N
analysis NN N
was VBD N
performed VBN N
to TO N
assess VB N
the DT N
clinical JJ N
benefit NN N
of IN N
alvimopan NN 1_i
, , N
a DT N
peripherally RB N
acting VBG N
mu-opioid JJ N
receptor NN N
( ( N
PAM-OR NNP N
) ) N
antagonist NN N
, , N
for IN N
the DT N
management NN N
of IN N
postoperative JJ N
ileus NN N
after IN N
bowel NN N
resection NN N
. . N

METHODS NNP N
Adult NNP 1_p
patients NNS 1_p
who WP 1_p
underwent VBP 1_p
laparotomy NN 1_i
for IN 1_p
bowel NN 1_p
resection NN 1_p
scheduled VBN 1_p
for IN 1_p
opioid-based JJ 1_i
intravenous JJ 1_i
patient-controlled JJ 1_i
analgesia NN 1_i
received VBD 1_i
oral JJ 1_i
alvimopan NN 1_i
or CC 1_i
placebo NN 1_i
preoperatively RB 1_p
and CC 1_p
twice RB 1_p
daily RB 1_p
postoperatively RB 1_p
until IN 1_p
hospital JJ 1_p
discharge NN 1_p
or CC 1_p
for IN 1_p
7 CD 1_p
postoperative JJ 1_p
days NNS 1_p
. . 1_p

The DT N
proportion NN N
of IN N
responders NNS N
and CC N
numbers NNS N
needed VBN N
to TO N
treat VB N
( ( N
NNT NNP N
) ) N
were VBD N
examined VBN N
on IN N
postoperative JJ N
days NNS N
( ( N
POD NNP N
) ) N
3-8 CD N
for IN N
GI-2 JJ N
recovery NN N
( ( N
first JJ N
bowel NN N
movement NN N
, , N
toleration NN N
of IN N
solid JJ N
food NN N
) ) N
and CC N
hospital JJ N
discharge NN N
order NN N
( ( N
DCO NNP N
) ) N
written VBN N
. . N

RESULTS NNP N
Alvimopan NNP 1_i
significantly RB N
increased VBD N
the DT N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
GI-2 NNP 1_o
recovery NN 1_o
and CC 1_o
DCO NNP 1_o
written VBN 1_o
by IN 1_o
each DT 1_o
POD NNP 1_o
( ( N
P NNP N
< VBZ N
0.001 CD N
for IN N
all DT N
) ) N
. . N

More JJR N
patients NNS N
who WP N
received VBD N
alvimopan RB 1_i
achieved VBN N
GI-2 JJ 1_o
recovery NN 1_o
on IN 1_o
or CC 1_o
before IN 1_o
POD NNP 1_o
5 CD 1_o
( ( 1_i
alvimopan NN 1_i
, , N
80 CD N
% NN N
; : N
placebo NN 1_i
, , N
66 CD N
% NN N
) ) N
and CC N
DCO NNP N
written VBN N
before IN N
POD NNP N
7 CD N
( ( 1_i
alvimopan NN 1_i
, , N
87 CD N
% NN N
; : N
placebo NN 1_i
, , N
72 CD N
% NN N
) ) N
, , N
with IN N
corresponding JJ N
NNTs NNP N
equal JJ N
to TO N
7 CD N
. . N

CONCLUSIONS VB N
On IN N
each DT N
POD NNP N
analyzed VBD N
, , N
alvimopan VBZ N
significantly RB N
increased VBN N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
GI-2 NNP 1_o
recovery NN 1_o
and CC N
DCO NNP N
written VBN N
versus NN N
placebo NN N
and CC N
was VBD N
associated VBN N
with IN N
relatively RB N
low JJ N
NNTs NNP N
. . N

The DT N
results NNS N
of IN N
these DT N
analyses NNS N
provide VBP N
additional JJ N
characterization NN N
and CC N
support NN N
for IN N
the DT N
overall JJ N
clinical JJ N
benefit NN N
of IN N
alvimopan NN N
in IN N
patients NNS 1_p
undergoing VBG 1_p
bowel JJ 1_p
resection NN 1_p
. . 1_p

Failure NN N
of IN N
pyridoxine NN N
to TO N
suppress VB N
raised VBN 1_o
serum NN 1_o
prolactin NN 1_o
levels NNS 1_o
. . 1_o

Pyridoxine NNP N
has VBZ N
been VBN N
reported VBN N
as IN N
having VBG N
an DT N
antilactogenic JJ N
effect NN N
, , N
presumably RB N
by IN N
suppressing VBG N
prolactin JJ 1_o
secretion NN 1_o
. . 1_o

We PRP N
have VBP N
measured VBN N
serum JJ 1_o
prolactin NN 1_o
levels NNS 1_o
during IN N
pyridoxine JJ 1_i
administration NN 1_i
in IN N
two CD 1_p
groups NNS 1_p
of IN 1_p
hyperprolactinaemic JJ 1_i
subjects NNS 1_i
. . 1_i

In IN N
normal JJ 1_p
postpartum JJ 1_p
women NNS 1_p
, , N
the DT N
postdelivery NN N
fall NN N
in IN N
serum NN 1_o
prolactin NN 1_o
levels NNS 1_o
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
treated JJ N
and CC N
control JJ N
subjects NNS N
. . N

In IN N
patients NNS 1_p
with IN 1_p
chlorpromazine-induced JJ 1_p
hyperprolactinaemia NN 1_p
and CC 1_p
galactorrhoea NN 1_p
, , N
pyridoxine NN N
did VBD N
not RB N
reduce VB N
the DT N
elevated JJ N
levels NNS N
. . N

In IN 1_p
neither DT 1_p
group NN 1_p
was VBD 1_p
milk VBN 1_o
production NN 1_o
suppressed VBN 1_p
. . 1_p

Longitudinal JJ N
quality NN 1_o
of IN 1_o
life NN 1_o
study NN N
in IN N
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
gastric JJ 1_p
cancer NN 1_p
. . 1_p

Analysis NNP N
modalities NNS N
and CC N
clinical JJ N
applicability NN N
of IN N
QoL NNP 1_o
in IN N
randomized JJ N
phase NN N
II NNP N
trial NN N
in IN N
a DT N
digestive JJ N
oncology NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
longitudinal JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QoL NNP 1_o
) ) 1_o
between IN N
LV5FU2-irinotecan JJ 1_i
and CC 1_i
LV5FU2 NNP 1_i
alone RB 1_i
or CC 1_i
LV5FU2-cisplatin NNP 1_i
in IN N
a DT N
randomized JJ N
Phase NNP N
II NNP N
trial NN N
in IN N
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
gastric JJ 1_p
adenocarcinoma NN 1_p
. . 1_p

METHODS NNP N
Among IN N
134 CD 1_p
eligible JJ 1_p
patients NNS 1_p
, , N
QLQ-C30 JJ 1_o
scores NNS 1_o
were VBD N
collected VBN N
and CC N
described VBN N
at IN N
each DT N
2 CD N
monthly JJ N
follow-up JJ N
visit NN N
during IN N
6 CD N
months NNS N
. . N

The DT N
frequencies NNS 1_o
of IN 1_o
QLQ-C30 NNP 1_o
score NN 1_o
improvement NN 1_o
were VBD N
calculated VBN N
and CC N
mixed JJ N
models NNS N
for IN N
repeated JJ N
measurements NNS N
were VBD N
applied VBN N
with IN N
or CC N
without IN N
extreme JJ N
poorest JJS N
imputation NN N
for IN N
missing VBG N
scores NNS N
. . N

The DT N
" JJ 1_o
survival NN 1_o
" NN 1_o
until IN 1_o
definitive JJ 1_o
global JJ 1_o
health NN 1_o
score NN 1_o
( ( 1_o
GHS NNP 1_o
) ) 1_o
deterioration NN 1_o
was VBD N
estimated VBN N
. . N

RESULTS NNP N
At IN N
the DT N
3rd CD N
follow-up NN N
, , N
patients NNS N
with IN N
a DT N
stable JJ N
or CC N
improved VBN N
global JJ 1_o
health NN 1_o
ranged VBD N
from IN N
11 CD N
% NN N
in IN N
the DT N
LV5FU2-cisplatin JJ 1_i
arm NN N
to TO N
18 CD N
% NN N
in IN N
the DT N
LV5FU2-irinotecan JJ 1_i
arm NN N
. . N

The DT N
irinotecan-based-therapy JJ N
presented VBD N
14 CD N
to TO N
15 CD N
scores NNS N
with IN N
a DT N
better JJR N
QoL NNP 1_o
. . 1_o

The DT N
time NN 1_o
until IN 1_o
definitive JJ 1_o
GHS NNP 1_o
deterioration NN 1_o
was VBD N
globally RB N
similar JJ N
between IN N
treatment NN N
arms NNS N
. . N

CONCLUSION NN N
This DT N
study NN N
highlights VBZ N
a DT N
better JJR N
impact NN N
of IN N
LV5FU2-irinotecan JJ 1_i
and CC N
the DT N
interest NN N
of IN N
QoL NNP 1_o
assessment NN 1_o
in IN N
phase NN N
II NNP N
trials NNS N
to TO N
complement VB N
the DT N
risk-benefit JJ N
judgement NN N
. . N

The DT N
role NN N
of IN N
routinely RB N
given VBN N
hyoscine-N-butylbromide NN 1_i
in IN N
colonoscopy NN 1_p
: : 1_p
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
, , N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
Hyoscine-N-butylbromide NNP 1_i
( ( 1_i
HBB NNP 1_i
) ) 1_i
has VBZ N
been VBN N
proposed VBN N
to TO N
ease VB N
colonoscopy NN N
and CC N
improve VB N
mucosal NN N
visualization NN N
, , N
yet RB N
the DT N
results NNS N
from IN N
previous JJ N
studies NNS N
are VBP N
conflicting VBG N
. . N

In IN N
our PRP$ N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
randomized JJ N
study NN N
we PRP N
aimed VBD N
at IN N
evaluating VBG N
whether IN N
routine JJ N
administration NN N
of IN N
HBB NNP 1_i
, , N
before IN N
and CC N
during IN N
colonoscopy NN N
, , N
ease VB 1_o
the DT 1_o
procedure NN 1_o
or CC 1_o
increase VB 1_o
the DT 1_o
detection NN 1_o
rate NN 1_o
for IN 1_o
polyps NNS 1_o
. . 1_o

MATERIAL NNP N
AND CC N
METHODS NNP N
One CD 1_p
hundred VBD 1_p
fifty JJ 1_p
outpatients NNS 1_p
scheduled VBN 1_p
for IN 1_p
an DT 1_p
elective JJ 1_p
colonoscopy NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
intravenous JJ N
injections NNS N
of IN N
either DT N
10 CD N
mg JJ N
hyoscine-N-butylbromide NN 1_i
or CC 1_i
saline NN 1_i
before IN 1_i
insertion NN N
and CC N
at IN N
cecum NN N
. . N

Patient JJ 1_o
tolerance NN 1_o
and CC 1_o
technical JJ 1_o
ease NN 1_o
of IN 1_o
colonoscopy NN 1_o
were VBD N
evaluated VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
. . N

Procedure NN 1_o
times NNS 1_o
were VBD N
recorded VBN N
. . N

Number NNP 1_o
of IN 1_o
detected JJ 1_o
polyps NNS 1_o
per IN 1_o
patient NN 1_o
was VBD N
evaluated VBN N
as RB N
well RB N
. . N

Heart NNP 1_o
rate NN 1_o
was VBD N
monitored VBN N
with IN N
a DT N
pulse JJ N
oximetry NN N
. . N

RESULTS NNP N
HBB NNP 1_i
did VBD N
not RB N
improve VB N
patient NN 1_o
tolerance NN 1_o
or CC 1_o
technically RB 1_o
ease VB 1_o
the DT 1_o
procedure NN 1_o
as IN N
evaluated VBN N
by IN N
VAS NNP N
. . N

However RB N
, , N
HBB NNP 1_i
led VBD N
to TO N
faster VB N
ileal JJ 1_o
intubation NN 1_o
( ( N
1.5 CD N
vs RB N
2.0 CD N
min NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
shorter JJR N
total JJ 1_o
procedure NN 1_o
time NN 1_o
( ( N
22.0 CD N
vs RB N
24.0 CD N
min NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
HBB NNP 1_i
also RB N
needed VBD N
less RBR N
often RB N
external JJ 1_o
abdominal JJ 1_o
pressure NN 1_o
( ( N
48.6 CD N
vs RB N
66.7 CD N
% NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

HBB NNP 1_i
did VBD N
not RB N
improve VB N
polyp JJ 1_o
detection NN 1_o
rate NN 1_o
( ( N
0.89 CD N
vs NN N
0.91 CD N
, , N
p NN N
= NNP N
0.90 CD N
) ) N
. . N

HBB NNP 1_i
induced VBD N
a DT N
significant JJ N
rise NN N
in IN N
heart NN 1_o
rate NN 1_o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
more RBR N
often RB N
tachycardia NNP 1_o
( ( N
17.6 CD N
vs RB N
0 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Routine NNP N
administration NN N
of IN N
HBB NNP 1_i
before IN N
and CC N
during IN N
colonoscopy NN N
yields NNS N
only RB N
limited VBD N
improvement NN N
in IN N
the DT N
technical JJ 1_o
performance NN 1_o
of IN 1_o
the DT 1_o
examination NN 1_o
compromised VBN N
by IN N
high JJ N
incidence NN N
of IN N
tachycardia NN 1_o
. . 1_o

Vinegar NNP 1_i
intake NN N
enhances NNS N
flow-mediated JJ 1_p
vasodilatation NN 1_p
via IN N
upregulation NN N
of IN N
endothelial JJ N
nitric JJ N
oxide JJ N
synthase NN N
activity NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
acetate NN 1_i
on IN N
endothelial JJ N
nitric JJ N
oxide NN N
synthase NN N
( ( N
eNOS NN N
) ) N
in IN N
human JJ N
umbilical JJ N
vein NN N
endothelial JJ N
cells NNS N
( ( N
HUVECs NNP N
) ) N
by IN N
immunoblotting VBG N
assay NN N
and CC N
the DT N
ability NN N
of IN N
acetic JJ N
acid NN N
to TO N
upregulate VB N
flow-mediated JJ 1_p
vasodilatation NN 1_p
in IN 1_p
humans NNS 1_p
. . 1_p

In IN N
HUVECs NNP N
, , N
acetate NN N
induced VBD N
a DT N
biphasic JJ N
increase NN N
in IN N
the DT N
phosphorylated JJ N
form NN N
of IN N
eNOS NN N
. . N

The DT N
amount NN N
of IN N
phosphorylated JJ N
eNOS NN N
was VBD N
significantly RB N
increased VBN N
by IN N
exposure NN N
to TO N
200 CD 1_i
mumol/l NNS 1_i
acetate VBP 1_i
for IN 1_i
20 CD 1_i
min NN 1_i
( ( 1_i
early JJ 1_i
phase NN 1_i
) ) 1_i
and CC 1_i
for IN 1_i
4 CD 1_i
h NNS 1_i
( ( 1_i
late JJ 1_i
phase NN 1_i
) ) 1_i
. . N

The DT N
inhibitors NNS N
of IN N
cAMP-dependent JJ N
protein NN N
kinase NN N
( ( N
PKA NNP N
) ) N
and CC N
AMP-activated JJ N
protein NN N
kinase NN N
( ( N
AMPK NNP N
) ) N
blocked VBD N
acetate-induced JJ N
eNOS JJ N
phosphorylation NN N
in IN N
the DT N
early JJ N
and CC N
the DT N
late JJ N
phase NN N
respectively RB N
. . N

Furthermore NNP N
, , N
in IN N
postmenopausal JJ 1_p
women NNS 1_p
, , N
maximum JJ 1_o
forearm NN 1_o
blood NN 1_o
flow NN 1_o
( ( 1_o
FBF NNP 1_o
) ) 1_o
in IN N
response NN N
to TO N
shear VB N
stress NN N
increased VBN N
in IN N
the DT N
vinegar NN 1_p
( ( 1_i
acetic JJ 1_i
acid NN 1_i
) ) 1_i
administered VBD 1_p
group NN 1_p
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
acetic JJ N
acid-induced JJ N
eNOS NN N
phosphorylation NN N
contributes VBZ N
to TO N
upregulation NN N
of IN N
flow-mediated JJ N
vasodilatation NN N
in IN N
humans NNS N
. . N

Long-term JJ N
use NN N
of IN N
Viozan NNP 1_i
( ( 1_i
sibenadet JJ 1_i
HCl NNP 1_i
) ) 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
: : 1_p
results NNS N
of IN N
a DT N
1-year JJ N
study NN N
. . N

Viozan NNP 1_i
( ( 1_i
sibenadet JJ 1_i
HCl NNP 1_i
, , 1_i
AR-C68397AA NNP 1_i
) ) 1_i
is VBZ N
a DT N
novel JJ N
dual JJ N
D2 NNP N
dopamine NN N
receptor NN N
, , N
beta2-adrenoceptor JJ N
agonist NN N
that WDT N
has VBZ N
been VBN N
investigated VBN N
for IN N
efficacy NN N
in IN N
alleviating VBG N
the DT N
symptoms NNS N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
. . N

The DT N
slowly RB N
progressive JJ N
nature NN N
of IN N
this DT N
disease NN N
means VBZ N
that IN N
patients NNS N
will MD N
require VB N
ongoing JJ N
therapeutic JJ N
management NN N
for IN N
many JJ N
years NNS N
, , N
or CC N
even RB N
decades NNS N
. . N

With IN N
such JJ N
long-term JJ N
treatment NN N
, , N
the DT N
safety NN N
profile NN N
of IN N
new JJ N
agents NNS N
will MD N
be VB N
of IN N
paramount JJ N
importance NN N
. . N

As IN N
part NN N
of IN N
the DT N
large-scale JJ N
assessment NN N
of IN N
sibenadet NN 1_i
, , N
a DT N
12-month JJ N
safety NN N
study NN N
has VBZ N
been VBN N
conducted VBN N
. . N

Following VBG N
completion NN N
of IN N
a DT N
2-week JJ N
baseline NN N
period NN N
, , N
435 CD 1_p
adults NNS 1_p
with IN 1_p
stable JJ 1_p
, , 1_p
symptomatic JJ 1_p
, , 1_p
smoking-related JJ 1_p
COPD NNP 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
receive VB N
either RB N
500 CD 1_i
microg NN 1_i
sibenadet NN 1_i
or CC 1_i
placebo NN 1_i
delivered VBN N
via IN N
pressurized VBN N
metered VBD N
dose JJ N
inhaler NN N
( ( N
pMDI NN N
) ) N
, , N
three CD N
times NNS N
daily RB N
for IN N
52 CD N
weeks NNS N
. . N

Sibenadet NNP 1_i
therapy NN 1_i
was VBD N
generally RB N
well RB 1_o
tolerated VBN 1_o
, , N
with IN N
the DT N
only JJ N
notable JJ 1_o
differences NNS 1_o
seen VBN N
in IN N
the DT N
incidence NN 1_o
of IN 1_o
tremor NN 1_o
and CC 1_o
taste NN 1_o
of IN 1_o
treatment NN 1_o
( ( N
16.9 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
and CC N
14.5 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
in IN N
the DT N
sibenadet NN N
and CC N
placebo NN 1_i
groups NNS N
respectively RB N
) ) N
. . N

There EX N
were VBD N
a DT N
total NN N
of IN N
79 CD 1_p
patients NNS 1_p
with IN 1_p
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_p
SAEs NNP 1_p
) ) 1_p
, , 1_p
43 CD 1_p
( ( 1_p
14.8 CD 1_p
% NN 1_p
) ) 1_p
in IN 1_p
the DT 1_p
sibenadet NN 1_p
pMDI NN 1_p
group NN 1_p
and CC 1_p
36 CD 1_p
( ( 1_p
24.8 CD 1_p
% NN 1_p
) ) 1_p
in IN 1_p
the DT 1_p
placebo NN 1_i
group NN 1_i
. . 1_i

No DT N
clinically RB 1_o
significant JJ 1_o
abnormal JJ 1_o
laboratory NN 1_o
values NNS 1_o
or CC N
overall JJ 1_o
differences NNS 1_o
between IN N
treatment NN N
groups NNS N
were VBD N
noted VBN N
. . N

Similarly RB N
, , N
there EX N
were VBD N
no DT 1_o
clinically RB 1_o
significant JJ 1_o
differences NNS 1_o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
cardiac JJ 1_o
variables NNS 1_o
, , 1_o
or CC 1_o
in IN 1_o
vital JJ 1_o
signs NNS 1_o
. . 1_o

The DT N
secondary JJ 1_o
variables NNS 1_o
showed VBD N
no DT 1_o
notable JJ 1_o
differences NNS 1_o
with IN N
respect NN N
to TO N
lung NN 1_o
function NN 1_o
, , 1_o
exacerbations NNS 1_o
or CC 1_o
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

Due NNP N
to TO N
the DT N
effective JJ N
beta2-agonist NN N
properties NNS N
, , N
patients NNS N
in IN N
the DT N
sibenadet NN N
group NN N
did VBD N
, , N
however RB N
, , N
report NN N
reduced VBD 1_o
rescue JJ 1_o
medication NN 1_o
usage NN 1_o
at IN 1_o
all DT 1_o
timepoints NNS 1_o
. . 1_o

While IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
, , N
overall JJ N
, , N
sibenadet JJ N
therapy NN N
was VBD N
well RB 1_o
tolerated VBN 1_o
, , N
the DT N
lack NN 1_o
of IN 1_o
sustained JJ 1_o
benefit NN 1_o
reported VBD N
in IN N
large-scale JJ 1_o
clinical JJ 1_o
efficacy NN 1_o
studies NNS 1_o
means VBZ N
that IN N
sibenadet NN N
development NN N
will MD N
not RB N
be VB N
continued VBN N
. . N

A DT N
multicenter NN N
investigation NN N
of IN N
lorazepam NN 1_i
in IN 1_p
anxiety NN 1_o
neurosis NN 1_o
. . 1_o

Examination NN 1_o
of IN N
aggression NN 1_o
and CC N
self-injury NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
and CC 1_p
serious JJ 1_p
behavioral JJ 1_p
problems NNS 1_p
. . 1_p

This DT N
study NN N
identified VBD N
subtypes NNS N
of IN N
aggression NN N
in IN N
a DT N
sample NN N
of IN N
206 CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
who WP 1_p
participated VBD 1_p
in IN 1_p
2 CD 1_i
risperidone NN 1_i
trials NNS 1_i
. . 1_i

The DT N
narratives NNS N
were VBD N
derived VBN N
from IN N
a DT N
parent NN N
interview NN N
about IN N
each DT N
child NN N
's POS N
2 CD N
most RBS N
pressing JJ N
problems NNS N
. . N

Five CD N
subtypes NNS N
of IN N
aggression NN N
emerged VBN N
: : N
hot JJ 1_o
aggression NN 1_o
only RB 1_o
, , 1_o
cold JJ 1_o
aggression NN 1_o
only RB 1_o
, , 1_o
self-injurious JJ 1_o
behavior NN 1_o
( ( 1_o
SIB NNP 1_o
) ) 1_o
only RB 1_o
, , 1_o
aggression NN 1_o
and CC 1_o
SIB NNP 1_o
, , N
and CC N
nonaggressive JJ 1_o
. . 1_o

All DT N
groups NNS N
showed VBD N
a DT N
high JJ N
rate NN N
of IN N
positive JJ 1_o
response NN 1_o
to TO N
risperidone VB N
with IN N
no DT N
differences NNS N
across IN N
subtypes NNS N
. . N

These DT N
study NN N
findings NNS N
extend VBP N
understanding NN N
of IN N
aggression NN N
in IN N
ASD NNP N
and CC N
may MD N
be VB N
useful JJ N
to TO N
guide VB N
further RB N
study NN N
on IN N
biological JJ N
mechanisms NNS N
and CC N
individualized JJ N
treatment NN N
in IN N
ASD NNP N
. . N

Comparison NNP N
of IN N
three-year JJ N
clinical JJ 1_o
outcomes NNS 1_o
between IN N
sirolimus-versus JJ 1_i
paclitaxel-eluting JJ 1_i
stents NNS 1_i
in IN 1_p
diabetic JJ 1_p
patients NNS 1_p
: : 1_p
prospective JJ N
randomized VBN N
multicenter NN N
trial NN N
. . N

BACKGROUND NNP N
Three-year JJ N
follow-up NN N
of IN N
major JJ 1_o
adverse JJ 1_o
cardiovascular JJ 1_o
event NN 1_o
( ( 1_o
MACE NNP 1_o
) ) 1_o
( ( 1_o
death NN 1_o
, , 1_o
nonfatal JJ 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
target NN 1_o
lesion NN 1_o
revascularization NN 1_o
) ) 1_o
and CC N
the DT N
predictors NNS 1_o
of IN 1_o
MACEs NNP 1_o
in IN 1_p
diabetic JJ 1_p
patients NNS 1_p
after IN 1_p
sirolimus-eluting JJ 1_i
stent NN 1_i
( ( 1_i
SES NNP 1_i
) ) 1_i
or CC 1_i
paclitaxel-eluting JJ 1_i
stent NN 1_i
( ( 1_i
PES NNP 1_i
) ) 1_i
implantation NN 1_i
have VBP N
not RB N
been VBN N
reported VBN N
. . N

METHODS NNP N
Diabetic NNP 1_p
patients NNS 1_p
with IN 1_p
de FW 1_p
novo FW 1_p
coronary JJ 1_p
lesions NNS 1_p
( ( 1_p
169 CD 1_p
patients NNS 1_p
with IN 1_p
190 CD 1_p
lesions NNS 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
prospectively RB N
to TO N
either DT N
SES NNP 1_i
or CC 1_i
PES NNP 1_i
. . 1_i

RESULTS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
rates NNS 1_o
of IN 1_o
MACEs NNP 1_o
[ NNP N
5.9 CD N
% NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
in IN N
the DT N
SES NNP 1_i
vs. FW N
9.5 CD N
% NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
in IN N
the DT N
PES NNP 1_i
Group NNP N
, , N
P NNP N
= VBZ N
0.374 CD N
] NN N
and CC N
definite JJ 1_o
stent NN 1_o
thrombosis NN 1_o
[ VBD N
1.2 CD N
% NN N
( ( N
n JJ N
= NNP N
1 CD N
) ) N
in IN N
the DT N
SES NNP 1_i
vs. FW N
3.6 CD N
% NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
in IN N
the DT N
PES NNP 1_i
Group NNP N
, , N
P NNP N
= VBZ N
0.368 CD N
] NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
during IN N
the DT N
three-year JJ N
follow-up NN N
. . N

Multivariate NNP N
logistic JJ N
analysis NN N
showed VBD N
that IN N
insulin NN N
treatment NN N
was VBD N
the DT N
only JJ N
independent JJ 1_o
predictor NN 1_o
of IN N
MACE NNP 1_o
[ NNP N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
8.60 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
3.25-22.76 CD N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
and CC N
target NN 1_o
vessel NN 1_o
revascularization NN 1_o
( ( 1_o
TVR NNP 1_o
) ) 1_o
( ( N
OR $ N
9.50 CD N
, , N
95 CD N
% NN N
CI NNP N
3.07-29.44 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
during IN N
the DT N
three-year JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
rates NNS 1_o
of IN 1_o
MACEs NNP 1_o
, , 1_o
TVR NNP 1_o
, , 1_o
and CC 1_o
stent JJ 1_o
thrombosis NN 1_o
during IN N
the DT N
three-year JJ N
follow-up NN N
were VBD N
similar JJ N
in IN N
the DT N
SES NNP 1_i
and CC 1_i
PES NNP 1_i
Groups NNP N
. . N

Insulin NNP N
treatment NN N
was VBD N
a DT N
main JJ N
predictor NN N
of IN N
MACEs NNP 1_o
and CC 1_o
TVR NNP 1_o
during IN N
the DT N
three-year JJ N
follow-up NN N
after IN N
either DT N
SES NNP 1_i
or CC N
PES NNP 1_i
implantation NN N
. . N

Fixed-dose JJ N
combination NN N
of IN N
AR-13324 NNP 1_i
and CC 1_i
latanoprost NN 1_i
: : 1_i
a DT N
double-masked JJ N
, , N
28-day JJ N
, , N
randomised VBN N
, , N
controlled VBN N
study NN N
in IN N
patients NNS 1_p
with IN 1_p
open-angle JJ 1_p
glaucoma NN 1_p
or CC 1_p
ocular JJ 1_p
hypertension NN 1_p
. . 1_p

BACKGROUND/AIMS NNP N
To TO N
evaluate VB N
the DT N
ocular JJ N
hypotensive JJ N
efficacy NN 1_o
of IN N
fixed-dose JJ N
combinations NNS N
of IN N
the DT N
Rho NNP 1_i
kinase NN 1_i
inhibitor NN 1_i
and CC 1_i
norepinephrine JJ 1_i
transport NN 1_i
inhibitor NN 1_i
AR-13324 NNP 1_i
( ( N
0.01 CD N
% NN N
and CC N
0.02 CD N
% NN N
) ) N
and CC N
latanoprost $ 1_i
( ( N
PG324 NNP N
Ophthalmic NNP N
Solution NNP N
) ) N
relative VBP N
to TO N
the DT N
active JJ N
components NNS N
AR-13324 JJ 1_i
0.02 CD N
% NN N
and CC N
latanoprost $ N
0.005 CD N
% NN N
, , N
used VBN N
bilaterally RB N
at IN N
night NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
double-masked JJ N
, , N
randomised VBN N
, , N
parallel JJ N
comparison NN N
study NN N
in IN N
patients NNS 1_p
with IN 1_p
open-angle JJ 1_p
glaucoma NN 1_p
or CC 1_p
ocular JJ 1_p
hypertension NN 1_p
. . 1_p

After IN N
washout NN N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
one CD N
of IN N
four CD N
treatment NN N
arms NNS N
and CC N
treated VBD N
for IN N
28 CD N
days NNS N
. . N

The DT N
primary JJ N
efficacy NN N
variable NN N
was VBD 1_o
mean JJ 1_o
diurnal JJ 1_o
intraocular JJ 1_o
pressure NN 1_o
( ( 1_o
IOP NNP 1_o
) ) 1_o
at IN N
day NN N
29 CD N
. . N

RESULTS NN N
We PRP N
randomised VBD 1_p
298 CD 1_p
patients NNS 1_p
, , 1_p
of IN 1_p
whom WP 1_p
292 CD 1_p
( ( 1_p
98 CD 1_p
% NN 1_p
) ) 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
. . N

Mean NNP 1_o
unmedicated VBD 1_o
diurnal JJ 1_o
IOPs NNP 1_o
( ( N
study VB N
eye NN N
) ) N
was VBD N
25.1 CD N
, , N
25.1 CD N
, , N
26.0 CD N
and CC N
25.4 CD N
in IN N
the DT N
PG324 NNP N
0.01 CD N
% NN N
, , N
PG324 NNP N
0.02 CD N
% NN N
, , N
latanoprost NN N
and CC N
AR-13324 JJ N
0.02 CD N
% NN N
groups NNS N
, , N
respectively RB N
. . N

On IN N
day NN N
29 CD N
, , N
mean JJ 1_o
diurnal JJ 1_o
IOP NNP 1_o
decreased VBD N
to TO N
17.3 CD N
, , N
16.5 CD N
, , N
18.4 CD N
and CC N
19.1 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

For IN N
the DT N
primary JJ 1_o
efficacy NN 1_o
variable NN N
of IN 1_o
mean JJ 1_o
diurnal JJ 1_o
IOP NNP N
at IN N
day NN N
29 CD N
, , N
PG324 NNP N
0.02 CD N
% NN N
met VBD N
the DT N
criterion NN N
for IN N
statistical JJ N
superiority NN N
relative NN N
to TO N
both DT N
latanoprost FW N
and CC N
AR-13324 NNP N
0.02 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
providing VBG N
additional JJ N
IOP NNP N
lowering NN N
of IN N
1.9 CD N
and CC N
2.6 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

PG324 VB N
0.01 CD N
% NN N
also RB N
met VBD N
the DT N
criterion NN N
for IN N
superiority NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
event NN 1_o
was VBD 1_o
conjunctival JJ 1_o
hyperaemia NN 1_o
with IN N
an DT N
incidence NN N
of IN N
41 CD N
% NN N
( ( N
30/73 CD N
) ) N
, , N
40 CD N
% NN N
( ( N
29/73 CD N
) ) N
, , N
14 CD N
% NN N
( ( N
10/73 CD N
) ) N
and CC N
40 CD N
% NN N
( ( N
31/78 CD N
) ) N
in IN N
the DT N
PG324 NNP N
0.01 CD N
% NN N
, , N
PG324 NNP N
0.02 CD N
% NN N
, , N
latanoprost NN 1_i
and CC 1_i
AR-13324 JJ N
0.02 CD N
% NN N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
short-term JJ N
study NN N
, , N
the DT N
fixed-dose JJ N
combination NN 1_i
of IN 1_i
AR-13324 NNP N
0.02 CD N
% NN N
and CC N
latanoprost $ N
0.005 CD N
% NN N
in IN N
PG324 NNP N
Ophthalmic NNP N
Solution NNP N
provides VBZ N
clinically RB N
and CC N
statistically RB 1_o
superior JJ 1_o
ocular JJ 1_o
hypotensive JJ 1_o
efficacy NN N
relative JJ N
to TO N
its PRP$ N
individual JJ N
active JJ N
components NNS N
at IN N
the DT N
same JJ N
concentrations NNS N
. . 1_o

The DT 1_o
only JJ 1_o
safety NN N
finding NN N
of IN N
note NN N
was VBD N
transient JJ N
asymptomatic JJ N
conjunctival NN N
hyperaemia NN N
which WDT N
was VBD N
typically RB N
of IN N
mild JJ N
severity NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT02207491 NNP N
. . N

Effect NN N
of IN N
six-hour JJ N
exposure NN N
to TO N
nitrogen VB 1_i
dioxide NN 1_i
on IN N
early-phase JJ N
nasal JJ 1_o
response NN 1_o
to TO N
allergen VB N
challenge NN N
in IN N
patients NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
seasonal JJ 1_p
allergic JJ 1_p
rhinitis NN 1_p
. . 1_p

BACKGROUND NNP N
Recent NNP N
studies NNS N
have VBP N
suggested VBN N
that IN N
exposure NN N
to TO N
air NN N
pollutants NNS N
may MD N
enhance VB N
the DT N
airway NN N
responsiveness NN N
of IN N
susceptible JJ 1_p
individuals NNS 1_p
to TO N
inhaled VB N
allergen NN N
. . N

METHODS NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
exposure NN N
to TO N
nitrogen VB 1_i
dioxide NN 1_i
( ( 1_i
NO2 NNP 1_i
) ) 1_i
on IN N
nasal NN N
airways NNS N
resistance NN N
( ( N
NAR NNP N
) ) N
and CC N
inflammatory JJ N
mediators NNS N
in IN N
nasal JJ N
lavage NN N
fluid NN N
, , N
eight CD 1_p
subjects NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
seasonal JJ 1_p
allergic JJ 1_p
rhinitis NN 1_p
, , 1_p
who WP 1_p
were VBD 1_p
tested VBN 1_p
out IN 1_p
of IN 1_p
season NN 1_p
, , N
were VBD N
exposed VBN N
in IN N
a DT N
randomized JJ N
single-blind NN N
, , N
crossover NN N
study NN N
to TO N
either DT N
air NN 1_i
or CC N
400 CD N
ppb NNS N
NO2 NNP 1_i
for IN N
6 CD N
hours NNS N
. . N

The DT N
changes NNS 1_o
in IN 1_o
NAR NNP 1_o
and CC 1_o
eosinophil VB 1_o
cationic JJ 1_o
protein NN 1_o
( ( 1_o
ECP NNP 1_o
) ) 1_o
, , 1_o
mast RB 1_o
cell NN 1_o
tryptase NN 1_o
( ( 1_o
MCT NNP 1_o
) ) 1_o
, , 1_o
neutrophil JJ 1_o
myeloperoxidase NN 1_o
( ( 1_o
MPO NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
interleukin-8 JJ 1_o
( ( 1_o
IL-8 NNP 1_o
) ) 1_o
in IN 1_o
nasal JJ 1_o
lavage NN 1_o
fluid NN 1_o
before IN N
and CC N
after IN N
exposure NN N
were VBD N
evaluated VBN N
. . N

Another DT 1_p
group NN 1_p
of IN 1_p
eight CD 1_p
subjects NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
seasonal JJ 1_p
allergic JJ 1_p
rhinitis NN 1_p
were VBD N
also RB N
randomized VBN N
to TO N
exposure VB N
to TO N
air NN N
or CC N
400 CD N
ppb NNS N
NO2 NNP 1_i
for IN N
6 CD N
hours NNS N
and CC N
then RB N
challenged VBD N
with IN N
allergen NN N
, , N
before IN N
evaluation NN N
for IN N
changes NNS 1_o
in IN 1_o
NAR NNP 1_o
and CC 1_o
changes NNS 1_o
in IN 1_o
ECP NNP 1_o
, , 1_o
MCT NNP 1_o
, , 1_o
MPO NNP 1_o
, , 1_o
and CC 1_o
IL-8 NNP 1_o
in IN 1_o
nasal JJ 1_o
lavage NN 1_o
fluid NN 1_o
. . 1_o

RESULTS NNP N
Exposure NNP N
to TO N
air NN N
or CC N
NO2 NNP 1_i
did VBD N
not RB N
alter VB N
either CC N
NAR NNP 1_o
or CC N
the DT N
levels NNS 1_o
of IN 1_o
ECP NNP 1_o
, , 1_o
MCT NNP 1_o
, , 1_o
MPO NNP 1_o
, , 1_o
or CC 1_o
IL-8 NNP 1_o
in IN N
nasal JJ N
lavage NN N
fluid NN N
. . N

Allergen NNP N
challenge NN N
after IN N
exposure NN N
to TO N
both DT N
air NN N
and CC N
NO2 NNP 1_i
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
increased VBD N
levels NNS N
of IN N
MCT NNP 1_o
, , N
but CC N
not RB N
MPO NNP 1_o
and CC 1_o
IL-8 NNP 1_o
in IN N
the DT N
nasal JJ N
lavage NN N
fluid NN N
. . N

In IN N
addition NN N
, , N
allergen NN N
challenge NN N
after IN N
exposure NN N
to TO N
NO2 NNP 1_i
but CC N
not RB N
air NN N
, , N
significantly RB N
increased JJ N
levels NNS N
of IN N
only RB N
ECP NNP 1_o
in IN 1_o
nasal JJ 1_o
lavage NN 1_o
fluid NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
acute JJ N
exposure NN N
to TO N
NO2 NNP 1_i
at IN N
concentrations NNS N
found VBN N
at IN N
the DT N
curbside NN N
in IN N
heavy JJ N
traffic NN N
during IN N
episodes NNS N
of IN N
pollution NN N
, , N
may MD N
" VB N
prime JJ N
" NNP N
eosinophils NNS N
for IN N
subsequent JJ N
activation NN N
by IN N
allergen NN N
in IN N
individuals NNS N
with IN N
a DT N
history NN N
of IN N
seasonal JJ N
allergic JJ N
rhinitis NN N
. . N

[ JJ 1_i
Plasma NNP 1_i
separation NN 1_i
combined VBN N
with IN N
CVVHF NNP 1_i
in IN N
septic JJ 1_p
and CC 1_p
SIRS JJ 1_p
patients NNS 1_p
] VBP 1_p
. . N

In IN N
a DT N
prospective JJ N
non-randomized JJ N
trial NN N
, , N
59 CD 1_p
patients NNS 1_p
with IN 1_p
sepsis NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
43 CD 1_p
) ) 1_p
and CC 1_p
SIRS NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
16 CD 1_p
) ) 1_p
were VBD N
treated VBN N
on IN N
a DT N
surgical JJ N
intensive JJ N
care NN N
unit NN N
. . N

In IN N
22 CD 1_p
patients NNS 1_p
plasmapheresis NN 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
continuous JJ 1_i
venovenous JJ 1_i
hemofiltration NN 1_i
( ( 1_i
CVVHF NNP 1_i
) ) 1_i
was VBD N
administered VBN N
. . N

Lethality NNP 1_o
was VBD 1_o
56 CD 1_o
% NN 1_o
in IN 1_o
the DT 1_o
sepsis NN 1_o
group NN 1_o
; : 1_o
in IN 1_o
the DT 1_o
therapy NN 1_o
group NN 1_o
lethality NN 1_o
was VBD 1_o
significantly RB 1_o
lower JJR 1_o
in IN 1_o
patients NNS 1_o
with IN 1_o
plasmapheresis NN 1_o
, , 1_o
even RB 1_o
though IN 1_o
in IN 1_o
this DT 1_o
population NN 1_o
the DT 1_o
organic JJ 1_o
failure NN 1_o
rate NN 1_o
was VBD 1_o
higher JJR 1_o
. . 1_o

Finally RB N
the DT 1_o
dependency NN 1_o
of IN 1_o
lethality NN 1_o
and CC 1_o
age NN 1_o
was VBD 1_o
similar JJ 1_o
in IN 1_o
both DT 1_o
groups NNS 1_o
. . 1_o

Lethality NNP 1_o
at IN 1_o
22 CD 1_o
% NN 1_o
in IN 1_o
the DT 1_o
plasmapheresis NN 1_o
group NN 1_o
with IN 1_o
double JJ 1_o
organ JJ 1_o
failure NN 1_o
was VBD 1_o
significantly RB 1_o
lower JJR 1_o
( ( 1_o
P NNP 1_o
> NNP 1_o
0.01 CD 1_o
) ) 1_o
than IN 1_o
in IN 1_o
controls NNS 1_o
. . 1_o

Reduction NN 1_o
of IN 1_o
lethality NN 1_o
seemed VBD 1_o
to TO 1_o
be VB 1_o
as RB 1_o
high JJ 1_o
as IN 1_o
18 CD 1_o
% NN 1_o
in IN 1_o
patients NNS 1_o
with IN 1_o
sepsis NN 1_o
, , 1_o
while IN 1_o
patients NNS 1_o
with IN 1_o
SIRS NNP 1_o
did VBD 1_o
not RB 1_o
profit NN 1_o
from IN 1_o
the DT 1_o
additional JJ 1_o
therapy NN 1_o
. . 1_o

A DT N
prospective JJ N
randomized VBN N
trial NN N
in IN N
sepsis NN N
and CC N
double JJ N
organic JJ N
failure NN N
should MD N
be VB N
projected VBN N
. . N

Exposure NN N
reduced VBN N
agoraphobia NNS N
but CC N
not RB N
panic JJ N
, , N
and CC N
cognitive JJ 1_i
therapy NN 1_i
reduced VBD N
panic JJ N
but CC N
not RB N
agoraphobia RB N
. . N

Earlier JJR N
studies NNS N
showed VBD N
that IN N
cognitive JJ 1_i
therapy NN 1_i
has VBZ N
anti-panic JJ N
effects NNS N
and CC N
exposure NN N
has VBZ N
anti-agoraphobic JJ N
effects NNS N
while IN N
other JJ N
studies NNS N
suggest VBP N
that IN N
agoraphobia NN N
is VBZ N
a DT N
secondary JJ N
complication NN N
of IN N
panic JJ N
disorder NN N
. . N

It PRP N
was VBD N
therefore RB N
hypothesized VBN N
that IN N
cognitive JJ 1_i
therapy NN 1_i
not RB N
only RB N
reduces VBZ N
panic NN N
but CC N
also RB N
agoraphobia JJ N
and CC N
that IN N
it PRP N
potentiates VBZ N
the DT N
effects NNS N
of IN N
exposure NN N
in IN N
vivo NN N
. . N

Two CD 1_p
groups NNS 1_p
of IN 1_p
12 CD 1_p
severe JJ 1_p
agoraphobics NNS 1_p
were VBD 1_p
treated VBN 1_p
with IN N
4 CD N
sessions NNS N
of IN N
cognitive JJ 1_i
therapy NN 1_i
followed VBN 1_i
by IN 1_i
8 CD 1_i
sessions NNS 1_i
of IN 1_i
cognitive JJ 1_i
therapy NN 1_i
combined VBN 1_i
with IN 1_i
in IN 1_i
vivo NN 1_i
exposure NN 1_i
. . 1_i

The DT N
other JJ N
12 CD 1_p
received VBD 1_p
4 CD 1_i
sessions NNS 1_i
of IN 1_i
'associative JJ 1_i
therapy NN 1_i
' '' 1_i
, , N
a DT N
presumably RB N
inert JJ N
treatment NN N
that WDT N
controls VBZ N
for IN N
therapist NN N
attention NN N
, , N
followed VBN N
by IN N
8 CD N
sessions NNS N
of IN N
in IN N
vivo NN N
exposure NN N
that WDT N
was VBD N
framed VBN N
in IN N
common JJ N
behavioral JJ N
terms NNS N
. . N

The DT N
initial JJ N
cognitive JJ N
therapy NN N
produced VBD N
a DT N
significant JJ N
reduction NN N
in IN N
panic JJ 1_o
frequency NN 1_o
, , N
while IN N
associative JJ N
therapy NN N
did VBD N
not RB N
affect VB N
panic NN N
. . N

Neither CC N
cognitive JJ 1_i
therapy NN 1_i
alone RB N
, , N
nor CC N
associate JJ 1_i
therapy NN 1_i
alone RB N
significantly RB N
reduced VBN N
depression NN 1_o
, , 1_o
state NN 1_o
or CC 1_o
trait NN 1_o
anxiety NN 1_o
, , 1_o
self-rated JJ 1_o
agoraphobia NN 1_o
or CC 1_o
behavioral JJ 1_o
avoidance NN 1_o
. . 1_o

After IN N
adding VBG N
exposure NN N
however RB N
, , N
these DT N
parameters NNS N
were VBD N
clearly RB N
and CC N
significantly RB N
reduced VBN N
. . N

Cognitive JJ 1_i
therapy NN 1_i
did VBD N
not RB N
potentiate VB N
exposure NN N
effects NNS N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
. . N

The DT N
effects NNS N
of IN N
a DT N
multi-component JJ N
higher-functioning JJ 1_p
autism NN 1_p
anti-stigma JJ N
program NN N
on IN N
adolescent JJ 1_p
boys NNS 1_p
. . 1_p

A DT N
six-session JJ N
higher-functioning JJ 1_p
autism NN 1_p
anti-stigma JJ N
program NN N
incorporating NN N
descriptive NN N
, , N
explanatory NN N
and CC N
directive JJ N
information NN N
was VBD N
delivered VBN N
to TO N
adolescent VB 1_p
boys NNS 1_p
and CC N
the DT N
impact NN N
upon IN N
knowledge NN 1_o
, , 1_o
attitudes NNS 1_o
and CC 1_o
behavioural JJ 1_o
intentions NNS 1_o
towards NNS N
peers NNS N
with IN N
autism NN N
was VBD N
evaluated VBN N
. . N

Participants NNS 1_p
were VBD 1_p
seventh- JJ 1_p
, , 1_p
eighth- JJ 1_p
and CC 1_p
ninth-grade JJ 1_p
students NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
395 CD 1_p
) ) 1_p
from IN 1_p
regular JJ 1_p
classes NNS 1_p
in IN 1_p
a DT 1_p
mainstream JJ 1_p
school NN 1_p
. . 1_p

Two-eighth-grade JJ 1_p
classes NNS 1_p
were VBD 1_i
randomly RB 1_i
allocated VBN 1_i
to TO 1_i
the DT 1_i
intervention NN 1_i
condition NN 1_i
and CC 1_i
all DT 1_i
remaining VBG 1_i
students NNS 1_i
were VBD 1_i
either RB 1_i
allocated VBN 1_i
to TO 1_i
the DT 1_i
no-intervention JJ 1_i
peer NN 1_i
or CC 1_i
no-intervention JJ 1_i
non-peer JJ 1_i
condition NN 1_i
. . N

The DT N
anti-stigma JJ N
program NN N
improved VBD N
the DT 1_o
knowledge NN 1_o
and CC 1_o
attitudes NNS 1_o
, , N
but CC N
not RB N
the DT 1_o
behavioural JJ 1_o
intentions NNS 1_o
of IN N
participants NNS N
towards VBP N
their PRP$ N
peers NNS N
with IN N
autism NN 1_o
. . 1_o

Knowledge NNP 1_o
and CC 1_o
attitudinal JJ 1_o
changes NNS 1_o
were VBD N
maintained VBN N
at IN N
follow-up NN N
. . N

There EX N
were VBD N
no DT 1_o
spill-over JJ 1_o
effects NNS 1_o
of IN N
the DT N
program NN N
to TO N
non-targeted JJ N
students NNS N
. . N

These DT N
results NNS N
provide VBP N
some DT N
preliminary JJ N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
multi-session NN N
anti-stigma JJ N
programs NNS N
incorporating VBG N
combined VBN N
information NN N
for IN 1_p
adolescent NN 1_p
students NNS 1_p
in IN 1_p
inclusive JJ 1_p
educational JJ 1_p
environments NNS 1_p
. . N

Use NNP 1_i
of IN 1_i
an DT 1_i
Internet NNP 1_i
portal NN 1_i
to TO N
improve VB N
community-based JJ 1_p
pediatric JJ 1_p
ADHD NNP 1_p
care NN 1_p
: : 1_p
a DT N
cluster NN N
randomized VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
quality NN 1_i
improvement NN 1_i
program NN 1_i
to TO N
improve VB N
pediatricians NNS 1_p
' POS 1_p
adherence NN N
to TO N
existing VBG N
, , N
evidence-based JJ N
, , N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
practice NN N
guidelines NNS N
. . N

METHODS NNP N
Forty-nine JJ 1_p
community-based JJ 1_p
pediatricians NNS 1_p
at IN 1_p
8 CD 1_p
practices NNS 1_p
participated VBN 1_p
in IN 1_p
a DT 1_p
cluster-randomized JJ 1_p
trial NN 1_p
. . 1_p

Practices NNS N
were VBD N
matched VBN N
according VBG N
to TO N
the DT N
numbers NNS 1_p
of IN 1_p
pediatricians NNS 1_p
and CC 1_p
the DT 1_p
proportions NNS 1_p
of IN 1_p
patients NNS 1_p
receiving VBG 1_p
Medicaid NNP 1_p
. . 1_p

The DT N
medical JJ N
charts NNS N
for IN N
a DT N
random JJ N
sample NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
for IN N
each DT N
of IN N
the DT N
participating VBG N
pediatricians NNS N
were VBD N
examined VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

All DT N
practices NNS N
participated VBN N
in IN N
4 CD N
sessions NNS N
of IN N
training NN 1_i
, , 1_i
including VBG 1_i
didactic JJ 1_i
lectures NNS 1_i
and CC 1_i
office NN 1_i
flow NN 1_i
modification NN 1_i
workshops NNS 1_i
. . 1_i

Practices NNS N
were VBD N
then RB N
given VBN N
access NN N
to TO N
an DT N
ADHD NNP 1_i
Internet NNP 1_i
portal NN 1_i
that WDT N
allowed VBD N
parents NNS N
, , N
teachers NNS N
, , N
and CC N
pediatricians NNS N
to TO N
input VB N
information NN N
( ( N
eg NN N
, , N
rating NN N
scales NNS N
) ) N
about IN N
patients NNS N
, , N
after IN N
which WDT N
information NN N
was VBD N
scored VBN N
, , N
interpreted VBN N
, , N
and CC N
formatted VBN N
in IN N
a DT N
report NN N
style NN N
that WDT N
was VBD N
helpful JJ N
for IN N
assessment NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
. . N

Physicians NNPS N
evaluated VBD N
their PRP$ N
practice NN 1_o
behaviors NNS 1_o
quarterly RB N
and CC N
addressed VBD N
underperforming JJ 1_o
areas NNS 1_o
. . 1_o

RESULTS NNP N
Pediatricians NNPS N
in IN N
the DT N
intervention NN N
group NN N
, , N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN 1_i
group NN N
, , N
demonstrated VBD N
significantly RB N
higher JJR N
rates NNS N
of IN N
many JJ N
American JJ N
Academy NNP N
of IN N
Pediatrics-recommended NNP N
ADHD NNP N
care NN N
practices NNS N
, , N
including VBG N
collection NN 1_o
of IN 1_o
parent NN 1_o
( ( N
Cohen NNP N
's POS N
d NN N
= VBZ N
0.69 CD N
) ) N
and CC N
teacher $ 1_o
( ( N
d JJ N
= NNP N
0.68 CD N
) ) N
rating NN 1_o
scales NNS 1_o
for IN N
assessment NN N
of IN N
children NNS N
with IN N
ADHD NNP N
, , N
use NN N
of IN N
Diagnostic NNP N
and CC N
Statistical NNP 1_o
Manual NNP 1_o
of IN 1_o
Mental NNP 1_o
Disorders NNP 1_o
, , N
Fourth NNP N
Edition NNP N
, , N
criteria NNS N
( ( N
d VB N
= RB N
0.85 CD N
) ) N
, , N
and CC N
use NN N
of IN N
teacher NN 1_o
rating NN 1_o
scales NNS 1_o
to TO N
monitor VB N
treatment NN N
responses NNS N
( ( N
d VB N
= RB N
1.01 CD N
) ) N
. . N

CONCLUSION VB N
A DT 1_i
quality NN 1_i
improvement NN 1_i
intervention NN 1_i
that WDT N
can MD N
be VB N
widely RB N
disseminated VBN N
by IN N
using VBG N
Internet-based JJ 1_i
information NN 1_i
technology NN 1_i
significantly RB N
improved VBD N
the DT N
quality NN N
of IN N
ADHD NNP N
care NN N
in IN N
community-based JJ 1_p
pediatric JJ 1_p
settings NNS 1_p
. . 1_p

Effects NNS N
of IN N
nifedipine NN 1_i
and CC N
nitrendipine NN 1_i
on IN N
insulin NN 1_o
secretion NN 1_o
in IN N
obese JJ 1_p
patients NNS 1_p
. . 1_p

Data NNS N
on IN N
the DT N
influence NN N
of IN N
calcium NN N
antagonists NNS N
on IN N
glucose JJ 1_o
tolerance NN 1_o
and CC 1_o
insulin NN 1_o
release NN 1_o
in IN N
humans NNS N
are VBP N
conflicting VBG N
. . N

The DT N
present JJ N
double-blind NN N
, , N
double-dummy JJ N
, , N
controlled VBD N
trial NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
short-term JJ N
( ( N
7 CD N
days NNS N
) ) N
treatment NN N
with IN N
nitrendipine NN 1_i
, , 1_i
20 CD 1_i
mg NN 1_i
b.i.d NN 1_i
. . 1_i

; : 1_i
nitrendipine NN 1_i
, , 1_i
20 CD 1_i
mg NN 1_i
once RB 1_i
daily JJ 1_i
; : 1_i
or CC 1_i
placebo VB 1_i
on IN N
blood NN 1_o
glucose NN 1_o
and CC 1_o
plasma JJ 1_o
insulin NN 1_o
and CC 1_o
C-peptide JJ 1_o
response NN 1_o
to TO N
an DT N
intravenous JJ N
glucose NN N
load NN N
in IN N
mildly RB 1_p
or CC 1_p
transiently RB 1_p
hypertensive JJ 1_p
nondiabetic JJ 1_p
obese JJ 1_p
patients NNS 1_p
. . 1_p

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
fasting VBG 1_o
glucose NN 1_o
, , 1_o
insulin NN 1_o
, , 1_o
and CC 1_o
C-peptide NNP 1_o
, , 1_o
or CC 1_o
in IN 1_o
the DT 1_o
glucose JJ 1_o
disappearance NN 1_o
rate NN 1_o
and CC 1_o
in IN 1_o
any DT 1_o
of IN 1_o
the DT 1_o
parameters NNS 1_o
for IN 1_o
insulin NN 1_o
and CC 1_o
C-peptide NNP 1_o
response NN 1_o
after IN N
i.v NN N
. . N

glucose VB N
, , N
between IN N
the DT N
three CD N
groups NNS N
of IN N
patients NNS N
. . N

However RB N
, , N
a DT N
slight JJ N
decrease NN N
in IN N
early JJ 1_o
insulin NN 1_o
response NN 1_o
to TO 1_o
glucose VB 1_o
was VBD N
observed VBN N
in IN N
the DT N
nifedipine NN N
and CC N
the DT N
nitrendipine JJ N
groups NNS N
. . N

This DT N
study NN N
confirms VBZ N
that IN N
calcium NN N
antagonists NNS N
have VBP N
no DT N
clinically RB 1_o
relevant JJ 1_o
effect NN 1_o
on IN N
glucose JJ N
homeostasis NN N
even RB N
if IN N
a DT N
slight JJ N
alteration NN N
of IN N
insulin NN 1_o
release NN 1_o
after IN N
glucose JJ N
load NN N
can MD N
not RB N
be VB N
ruled VBN N
out RP N
. . N

The DT N
accuracy NN 1_o
of IN N
clinical JJ 1_o
neurosensory NN 1_o
testing VBG 1_o
for IN N
nerve JJ N
injury NN N
diagnosis NN N
. . N

PURPOSE VB N
The DT N
accuracy NN N
of IN N
the DT N
clinical JJ 1_i
neurosensory JJ 1_i
test NN 1_i
to TO N
diagnose VB N
trigeminal JJ N
nerve NN N
injuries NNS N
has VBZ N
never RB N
been VBN N
statistically RB N
evaluated VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
statistical JJ 1_o
efficacy NN 1_o
of IN 1_o
the DT 1_o
clinical JJ 1_o
neurosensory JJ 1_o
test NN 1_o
using VBG N
surgical JJ N
findings NNS N
as IN N
the DT N
" NNP N
gold NN N
" NNP N
standard NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
a DT N
correlation NN N
existed VBN N
between IN N
the DT N
sensory JJ N
impairment NN N
score NN N
obtained VBN N
by IN N
preoperative JJ N
testing NN N
and CC N
the DT N
degree NN N
of IN N
nerve NN N
injury NN N
found VBD N
at IN N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
multisite NN N
, , N
randomized VBN N
, , N
prospective JJ N
, , N
blinded VBD N
, , N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
130 CD 1_p
patients NNS 1_p
with IN 1_p
inferior JJ 1_p
alveolar JJ 1_p
nerve NN 1_p
( ( 1_p
IAN NNP 1_p
) ) 1_p
and CC 1_p
lingual JJ 1_p
nerve NN 1_p
( ( 1_p
LN NNP 1_p
) ) 1_p
injuries NNS 1_p
. . 1_p

Preoperatively RB N
, , N
patients NNS 1_i
were VBD 1_i
provided VBN 1_i
a DT 1_i
sensory JJ 1_i
impairment NN 1_i
score NN 1_i
using VBG 1_i
a DT 1_i
three-level JJ 1_i
drop-out JJ 1_i
clinical JJ 1_i
neurosensory NN 1_i
test NN 1_i
( ( 1_i
NST NNP 1_i
) ) 1_i
, , 1_i
and CC 1_i
blind IN 1_i
comparisons NNS 1_i
were VBD 1_i
made VBN 1_i
with IN 1_i
the DT 1_i
surgical JJ 1_i
findings NNS 1_i
postoperatively RB 1_i
. . 1_i

RESULTS VB N
The DT N
positive JJ 1_o
predictive NN 1_o
and CC 1_o
negative JJ 1_o
predictive NN 1_o
values NNS 1_o
for IN N
LN-injured JJ N
patients NNS N
were VBD N
95 CD N
% NN N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
positive JJ N
predictive NN N
and CC N
negative JJ N
predictive NN N
values NNS N
for IN N
IAN NNP 1_p
patients NNS 1_p
were VBD N
77 CD N
% NN N
and CC N
60 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
distribution NN N
of IN N
age NN N
, , N
duration NN N
of IN N
injury NN N
, , N
cause NN N
of IN N
injury NN N
, , N
presence NN N
of IN N
neuropathic JJ N
pain NN N
, , N
presence NN N
of IN N
trigger NN N
pain NN N
, , N
and CC N
degree NN N
of IN N
injury NN N
between IN N
the DT 1_p
IAN NNP 1_p
and CC 1_p
LN NNP 1_p
patient JJ 1_p
populations NNS 1_p
. . 1_p

There EX N
was VBD N
a DT N
statistically RB 1_o
significant JJ 1_o
positive JJ 1_o
relationship NN 1_o
found VBD 1_o
between IN 1_o
the DT 1_o
sensory JJ 1_o
impairment NN 1_o
score NN 1_o
and CC 1_o
the DT 1_o
degree NN 1_o
of IN 1_o
nerve NN 1_o
injury NN 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
NST NNP 1_i
is VBZ N
a DT N
clinically RB N
useful JJ N
method NN N
to TO N
diagnose VB N
IAN NNP N
and CC N
LN NNP N
injuries NNS N
. . N

However RB N
, , N
the DT N
NST NNP 1_i
results NNS N
are VBP N
less RBR 1_o
efficient JJ 1_o
for IN N
IAN NNP N
injuries NNS N
than IN N
LN NNP N
injuries NNS N
, , N
and CC N
have VBP N
a DT N
high JJ 1_o
incidence NN 1_o
of IN 1_o
false-positive JJ 1_o
( ( N
23 CD N
% NN N
) ) N
and CC N
false-negative JJ 1_o
( ( N
40 CD N
% NN N
) ) N
results NNS N
when WRB N
testing VBG N
patients NNS 1_p
with IN 1_p
IAN NNP 1_p
injuries NNS 1_p
. . 1_p

The DT N
different JJ N
rates NNS N
of IN N
statistical JJ 1_o
efficiency NN 1_o
between IN N
the DT N
two CD N
groups NNS N
of IN N
patients NNS N
may MD N
be VB N
attributable JJ N
to TO N
differences NNS N
in IN N
prevalence NN N
and CC N
biologic NN N
covariates NNS N
. . N

Levels NNS N
of IN N
opioid JJ 1_p
physical JJ 1_p
dependence NN 1_p
in IN 1_p
heroin NN 1_p
addicts NNS 1_p
. . 1_p

The DT N
levels NNS N
of IN N
opioid JJ N
physical JJ N
dependence NN N
in IN N
a DT N
group NN N
of IN N
long-term JJ 1_p
heroin NN 1_p
addicts NNS 1_p
were VBD N
ascertained VBN N
by IN N
measuring VBG N
the DT N
severity NN N
of IN N
the DT N
opioid JJ 1_o
withdrawal NN 1_o
syndrome NN 1_o
before IN N
and CC N
after IN N
pharmacological JJ N
challenge NN N
with IN N
either DT N
0.4 CD N
mg NN N
naloxone NN 1_i
or CC N
placebo NN 1_i
. . 1_i

Prior NNP N
to TO N
challenge VB N
, , N
patients NNS N
manifested VBD N
some DT N
subjective JJ 1_o
symptoms NNS 1_o
but CC N
few JJ N
objective JJ N
signs NNS N
of IN N
opioid JJ N
withdrawal NN N
. . N

Patients NNS 1_p
who WP 1_p
received VBD 1_p
placebo NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
18 CD 1_p
) ) 1_p
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
mean NN N
score NN N
on IN N
one CD N
of IN N
three CD N
rating NN N
scales NNS N
used VBN N
to TO N
assess VB N
opioid JJ N
withdrawal NN N
. . N

Patients NNS 1_p
who WP 1_p
received VBD 1_p
naloxone NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
58 CD 1_p
) ) 1_p
showed VBD N
significant JJ N
increases NNS N
in IN N
mean JJ N
scores NNS N
on IN N
all DT N
three CD N
rating NN N
scales NNS N
, , N
but CC N
this DT N
was VBD N
due JJ N
primarily RB N
to TO N
increases NNS N
observed VBN N
in IN N
a DT N
minority NN N
of IN N
patients NNS N
. . N

Sixty-one CD N
percent NN N
of IN N
patients NNS N
failed VBD N
to TO N
manifest VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
subjective NN 1_o
symptoms NNS 1_o
, , N
and CC N
74 CD N
% NN N
of IN N
patients NNS N
failed VBD N
to TO N
manifest VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
objective JJ 1_o
signs NNS 1_o
of IN 1_o
opioid JJ 1_o
withdrawal NN 1_o
following VBG N
naloxone JJ 1_i
administration NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
a DT N
substantial JJ N
subgroup NN N
of IN N
heroin NN N
addicts NNS N
are VBP N
able JJ N
to TO N
use VB N
opioids NNS N
regularly RB N
while IN N
maintaining VBG N
relatively RB N
low JJ N
levels NNS N
of IN N
physical JJ N
dependence NN N
. . N

Interfering VBG N
with IN N
the DT N
central JJ N
executive NN N
by IN N
means NNS N
of IN N
a DT N
random NN 1_i
interval JJ 1_i
repetition NN 1_i
task NN 1_i
. . 1_i

Four CD N
dual-task JJ N
experiments NNS N
are VBP N
reported VBN N
in IN N
which WDT N
a DT N
short-term JJ 1_i
memory NN 1_i
task NN 1_i
is VBZ N
performed VBN N
concurrently RB N
with IN N
a DT N
random NN 1_i
interval JJ 1_i
repetition NN 1_i
task NN 1_i
, , N
which WDT N
was VBD N
designed VBN N
to TO N
interfere VB N
with IN N
functions NNS N
normally RB N
attributed VBD N
to TO N
the DT N
central JJ 1_p
executive NN 1_p
in IN N
the DT N
working JJ N
memory NN N
model NN N
of IN N
Baddeley NNP N
and CC N
Hitch NNP N
( ( N
1974 CD N
) ) N
. . N

The DT N
task NN 1_i
was VBD N
found VBN N
to TO N
interfere VB N
with IN N
supra-span JJ N
serial JJ N
recall NN N
and CC N
with IN N
backward JJ 1_o
memory NN 1_o
span NN 1_o
, , N
but CC N
did VBD N
not RB N
disrupt VB N
performance NN N
on IN N
a DT N
forward-memory-span JJ 1_o
task NN 1_i
. . 1_i

The DT N
effects NNS N
were VBD N
observed VBN N
in IN N
dissociation NN N
with IN N
effects NNS N
of IN N
articulatory JJ N
suppression NN N
and CC N
matrix NN N
tapping NN N
, , N
so IN N
that IN N
the DT N
locus NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
new JJ N
task NN N
is VBZ N
not RB N
due JJ N
to TO N
the DT N
slave JJ N
systems NNS N
. . N

In IN N
addition NN N
, , N
single-task JJ 1_i
random-interval JJ 1_i
repetition NN N
performance NN N
was VBD N
sampled VBN N
and CC N
compared VBN N
to TO N
performance NN N
in IN N
the DT N
dual-task JJ 1_i
conditions NNS N
of IN N
all DT N
four CD N
experiments NNS N
. . N

Although IN N
quality NN N
of IN N
tapping VBG 1_o
performance NN 1_o
differed VBD N
between IN N
the DT N
single-task NN 1_i
and CC N
the DT N
dual-task JJ 1_i
conditions NNS N
, , N
it PRP N
was VBD N
not RB N
related VBN N
to TO N
recall VB 1_o
performance NN 1_o
. . 1_o

All PDT N
the DT N
results NNS N
are VBP N
discussed VBN N
with IN N
reference NN N
to TO N
the DT N
working VBG N
memory NN N
model NN N
. . N

An DT N
evaluation NN N
of IN N
family NN 1_i
therapy NN 1_i
in IN N
anorexia JJ 1_p
nervosa NN 1_p
and CC 1_p
bulimia NN 1_p
nervosa NN 1_p
. . 1_p

A DT N
controlled JJ N
trial NN N
comparing VBG N
family NN 1_i
therapy NN 1_i
with IN N
individual JJ N
supportive JJ N
therapy NN N
in IN N
anorexia JJ N
nervosa NN N
and CC N
bulimia NN N
nervosa NN N
was VBD N
undertaken VBN N
. . N

Eighty JJ 1_p
patients NNS 1_p
( ( 1_p
57 CD 1_p
with IN 1_p
anorexia JJ 1_p
nervosa NN 1_p
; : 1_p
23 CD 1_p
with IN 1_p
bulimia NN 1_p
nervosa NN 1_p
) ) 1_p
were VBD 1_p
first RB 1_p
admitted VBN 1_p
to TO 1_p
a DT 1_p
specialized JJ 1_p
unit NN 1_p
to TO 1_p
restore VB 1_p
their PRP$ 1_p
weight NN 1_p
to TO 1_p
normal JJ 1_p
. . 1_p

Before IN N
discharge NN N
, , N
they PRP N
were VBD N
randomly RB N
allocated VBN N
to TO N
family NN 1_i
therapy NN 1_i
or CC 1_i
the DT 1_i
control NN 1_i
treatment NN 1_i
( ( 1_i
individual JJ 1_i
supportive JJ 1_i
therapy NN 1_i
) ) 1_i
. . N

After IN N
one CD N
year NN N
of IN N
psychological JJ N
treatment NN N
, , N
they PRP N
were VBD N
reassessed VBN N
, , N
using VBG N
body NN 1_o
weight NN 1_o
, , 1_o
menstrual JJ 1_o
function NN 1_o
, , 1_o
and CC 1_o
ratings NNS 1_o
on IN 1_o
the DT 1_o
Morgan NNP 1_o
and CC 1_o
Russell NNP 1_o
scales NNS 1_o
. . 1_o

Family NNP 1_o
therapy NN 1_o
was VBD 1_o
found VBN 1_o
to TO 1_o
be VB 1_o
more RBR 1_o
effective JJ 1_o
than IN 1_o
individual JJ 1_o
therapy NN 1_o
in IN N
patients NNS 1_p
whose WP$ 1_p
illness NN 1_p
was VBD 1_p
not RB 1_p
chronic JJ 1_p
and CC 1_p
had VBD 1_p
begun VBN 1_p
before IN 1_p
the DT 1_p
age NN 1_p
of IN 1_p
19 CD 1_p
years NNS 1_p
. . 1_p

A DT N
more RBR N
tentative JJ N
finding NN N
was VBD N
the DT N
greater JJR N
value NN N
of IN N
individual JJ N
supportive JJ N
therapy NN N
in IN N
older JJR 1_p
patients NNS 1_p
. . 1_p

To TO N
our PRP$ N
knowledge NN N
, , N
this DT N
is VBZ N
the DT N
first JJ N
controlled JJ N
trial NN N
of IN N
family NN N
therapy NN N
in IN N
anorexia JJ N
nervosa NN N
and CC N
clarifies VBZ N
the DT N
specific JJ N
indications NNS N
for IN N
this DT N
treatment NN N
. . N

Safety NN N
and CC N
acceptability NN N
of IN N
cellulose JJ 1_i
sulfate NN 1_i
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN N
HIV-infected JJ 1_p
women NNS 1_p
. . 1_p

OBJECTIVES NNP N
Few JJ N
studies NNS N
of IN N
topical JJ N
microbicides NNS N
have VBP N
assessed VBN N
their PRP$ N
safety NN 1_o
in IN 1_o
HIV-infected JJ 1_o
women NNS 1_o
. . 1_o

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN 1_o
and CC 1_o
acceptability NN 1_o
of IN N
6 CD N
% NN N
cellulose JJ 1_i
sulfate NN 1_i
( ( 1_i
CS NNP 1_i
) ) 1_i
gel NN N
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN 1_p
sexually RB 1_p
abstinent JJ 1_p
and CC 1_p
active JJ 1_p
HIV-infected JJ 1_p
women NNS 1_p
. . 1_p

METHODS NNP N
Fifty-nine JJ 1_p
HIV-infected JJ 1_p
women NNS 1_p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ 1_i
study NN N
comparing VBG N
6 CD N
% NN N
CS NNP 1_i
to TO 1_i
placebo VB 1_i
gel NNS 1_i
used VBN N
for IN N
14 CD N
days NNS N
. . N

Sexually NNP 1_p
abstinent JJ 1_p
women NNS 1_p
applied VBD N
gel JJ N
once RB N
or CC N
twice JJ N
daily JJ N
and CC N
sexually RB N
active JJ N
women NNS N
used VBN N
gel JJ N
once RB N
daily JJ N
. . N

RESULTS NNP N
CS NNP N
gel NN N
was VBD N
safe JJ N
with IN N
no DT N
reported VBN N
severe RB 1_o
or CC 1_o
life-threatening JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
AE NNP 1_o
) ) 1_o
. . 1_o

Thirty-nine NNP N
( ( N
66 CD N
% NN N
) ) N
of IN N
the DT N
participants NNS N
experienced VBD N
urogenital JJ 1_o
AE NNP 1_o
judged VBD N
as IN N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
. . N

The DT N
majority NN N
( ( N
51 CD N
% NN N
) ) N
of IN N
these DT N
participants NNS N
reported VBD N
only RB N
mild JJ 1_o
events NNS 1_o
. . 1_o

Fewer JJR N
women NNS N
( ( N
62 CD N
% NN N
) ) N
who WP N
used VBD N
CS NNP N
experienced VBD N
urogenital JJ 1_o
AE NNP 1_o
than IN N
those DT N
assigned VBN N
to TO N
placebo VB 1_i
gel NN N
( ( N
70 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.59 CD N
) ) N
. . N

Eleven NNP N
( ( N
19 CD N
% NN N
) ) N
women NNS N
experienced VBD N
intermenstrual JJ 1_o
bleeding NN 1_o
judged VBD N
to TO N
be VB N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
use NN N
( ( N
four CD N
in IN N
the DT N
CS NNP N
and CC N
seven CD N
in IN N
the DT N
placebo NN N
gel NN N
group NN N
) ) N
. . N

There EX N
was VBD N
no DT N
increase NN N
in IN N
AE NNP 1_o
by IN N
frequency NN N
of IN N
gel NN N
use NN N
or CC N
sexual JJ N
activity NN N
with IN N
the DT N
exception NN N
of IN N
abdominal/pelvic NN 1_o
pain NN 1_o
which WDT N
was VBD N
noted VBN N
more RBR N
frequently RB N
with IN N
twice RB N
daily JJ N
use NN N
among IN N
sexually RB N
abstinent JJ N
women NNS N
. . N

Women NNS N
and CC N
men NNS N
found VBD N
the DT N
gel NN N
highly RB N
acceptable JJ N
. . N

CONCLUSIONS VB N
This DT N
Phase NNP N
I PRP N
study VBP N
demonstrated VBD N
that IN N
CS NNP 1_i
vaginal JJ 1_i
gel NN 1_i
was VBD N
safe JJ 1_o
, , 1_o
well RB 1_o
tolerated VBN 1_o
and CC 1_o
acceptable JJ 1_o
by IN N
HIV-infected JJ 1_p
women NNS 1_p
and CC 1_p
their PRP$ 1_p
male JJ 1_p
partners NNS 1_p
. . 1_p

Thus RB N
, , N
further JJ N
development NN N
of IN N
CS NNP N
is VBZ N
warranted VBN N
as IN N
a DT N
potential JJ N
method NN N
to TO N
prevent VB N
HIV NNP 1_o
transmission NN 1_o
and CC 1_o
acquisition NN 1_o
. . 1_o

Treatment NN N
of IN N
stable JJ 1_p
angina NN 1_p
of IN 1_p
effort NN 1_p
with IN N
verapamil NN 1_i
: : 1_i
a DT N
double-blind NN N
, , N
placebo-controlled JJ 1_i
randomized VBN N
crossover NN N
study NN N
. . N

The DT N
effects NNS N
of IN N
verapamil NN 1_i
were VBD N
assessed VBN N
in IN N
26 CD 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
exertional JJ 1_p
angina NN 1_p
pectoris NN 1_p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
crossover NN N
protocol NN N
using VBG N
serial JJ N
treadmill NN N
tests NNS N
. . N

Verapamil NNP 1_i
, , N
480 CD N
mg/day NN N
, , N
reduced VBD N
anginal JJ 1_o
frequency NN 1_o
from IN N
5.6 CD N
+/- JJ N
7.3 CD N
to TO N
2.2 CD N
+/- JJ N
3.9 CD N
attacks NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
nitroglycerin JJ 1_o
consumption NN 1_o
from IN N
3.4 CD N
+/- JJ N
4.9 CD N
to TO N
1.2 CD N
+/- JJ N
2.5 CD N
tablets NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN 1_i
. . 1_i

Treadmill NNP 1_o
time NN 1_o
increased VBD N
from IN N
6.4 CD N
+/- JJ N
2.1 CD N
minutes NNS N
during IN N
the DT N
placebo NN 1_i
phase NN N
to TO N
7.5 CD N
+/- JJ N
1.8 CD N
minutes NNS N
during IN N
the DT N
verapamil JJ 1_i
phase NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP 1_i
's POS 1_i
beneficial JJ N
effect NN N
appeared VBD N
to TO N
be VB N
related VBN N
, , N
in IN N
part NN N
, , N
to TO N
a DT N
10 CD N
% NN N
reduction NN N
of IN N
the DT N
rate-pressure JJ 1_o
product NN 1_o
at IN N
rest NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
a DT N
12 CD N
% NN N
reduction NN N
during IN N
submaximal JJ N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP 1_i
also RB N
caused VBD N
less JJR N
marked JJ N
ST-segment JJ 1_o
depressions NNS 1_o
at IN 1_o
peak NN 1_o
exercise NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
at IN N
a DT N
similar JJ N
rate-pressure NN N
product NN N
, , N
suggesting VBG N
a DT N
favorable JJ N
redistribution NN N
of IN N
coronary JJ 1_o
blood NN 1_o
flow NN 1_o
to TO N
the DT N
ischemic JJ N
zone NN N
. . N

Side JJ N
effects NNS N
from IN N
verapamil NN 1_i
were VBD N
minimal JJ N
, , N
consisting VBG N
mainly RB N
of IN N
constipation NN 1_o
( ( N
six CD N
patients NNS N
) ) N
. . N

Verapamil NNP 1_i
appears VBZ N
to TO N
be VB N
a DT N
safe JJ 1_o
and CC 1_o
effective JJ 1_o
drug NN N
for IN N
treating VBG N
angina NN 1_p
of IN N
effort NN N
. . N

A DT N
comparison NN N
of IN N
sclerotherapy NN 1_i
with IN N
staple JJ 1_i
transection NN 1_i
of IN 1_i
the DT 1_i
esophagus NN 1_i
for IN N
the DT N
emergency NN N
control NN 1_o
of IN 1_o
bleeding VBG 1_o
from IN 1_p
esophageal JJ 1_p
varices NNS 1_p
. . 1_p

We PRP N
compared VBN N
two CD N
procedures NNS N
for IN N
the DT N
emergency NN N
treatment NN N
of IN N
bleeding VBG 1_o
esophageal JJ 1_p
varices NNS 1_p
in IN 1_p
patients NNS 1_p
who WP 1_p
did VBD 1_p
not RB 1_p
respond VB 1_p
to TO 1_p
blood VB 1_p
transfusion NN 1_p
and CC 1_p
vasoactive JJ 1_p
drugs NNS 1_p
. . 1_p

We PRP N
randomly VBP N
assigned VBD N
101 CD 1_p
patients NNS 1_p
with IN 1_p
cirrhosis NN 1_p
of IN 1_p
the DT 1_p
liver NN 1_p
and CC 1_p
bleeding VBG 1_p
esophageal JJ 1_p
varices NNS 1_p
to TO N
undergo VB 1_i
either DT 1_i
emergency NN 1_i
sclerotherapy NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
50 CD 1_i
) ) 1_i
or CC 1_i
staple JJ 1_i
transection NN 1_i
of IN 1_i
the DT 1_i
esophagus NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
51 CD 1_i
) ) 1_i
. . N

Four CD N
patients NNS N
assigned VBN N
to TO N
sclerotherapy VB 1_i
and CC N
12 CD N
assigned VBN N
to TO N
staple VB N
transection NN N
did VBD N
not RB N
actually RB N
undergo VBP N
those DT N
procedures NNS N
, , N
but CC N
all DT N
analyses NNS N
were VBD N
made VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

Total JJ 1_o
mortality NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
; : N
the DT N
relative JJ 1_o
risk NN 1_o
of IN 1_o
death NN 1_o
for IN N
staple JJ N
transection NN N
as IN N
compared VBN N
with IN N
sclerotherapy NN N
was VBD N
0.88 CD N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.51 CD N
to TO N
1.54 CD N
) ) N
. . N

Mortality NN 1_o
at IN N
six CD N
weeks NNS N
was VBD N
44 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB 1_i
and CC N
35 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
. . N

Complication NN 1_o
rates NNS 1_o
were VBD N
similar JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

An DT N
interval NN 1_o
of IN 1_o
five CD 1_o
days NNS 1_o
without IN 1_o
bleeding NN 1_o
was VBD N
achieved VBN N
in IN N
88 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
and CC N
in IN N
62 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB 1_i
after IN N
a DT N
single JJ N
injection NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
82 CD N
percent NN N
after IN N
three CD N
injections NNS N
. . N

In IN N
only RB N
2 CD N
of IN N
the DT N
11 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
sclerotherapy NN 1_i
injection NN N
was VBD N
bleeding VBG 1_o
controlled VBN 1_o
for IN N
more JJR N
than IN N
five CD N
days NNS N
, , N
and CC N
9 CD N
died VBD N
. . N

We PRP N
conclude VBP N
that IN N
staple JJ N
transection NN N
of IN N
the DT N
esophagus NN N
is VBZ N
as RB 1_o
safe JJ 1_o
as IN 1_o
sclerotherapy NN 1_o
for IN N
the DT N
emergency NN 1_o
treatment NN 1_o
of IN 1_o
bleeding VBG 1_o
esophageal JJ N
varices NNS N
and CC N
that IN N
it PRP N
is VBZ N
more RBR N
effective JJ N
than IN N
a DT N
single JJ N
sclerotherapy NN 1_i
procedure NN N
. . N

We PRP N
currently RB N
recommend VBP N
surgery NN N
after IN N
two CD N
injection NN N
treatments NNS N
have VBP N
failed VBN N
. . N

Comparison NNP N
of IN N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
phonophoresis NN 1_i
and CC N
iontophoresis NN 1_i
using VBG N
dexamethasone NN 1_i
sodium NN 1_i
phosphate NN 1_i
in IN N
the DT N
management NN N
of IN N
patients NNS 1_p
with IN 1_p
knee JJ 1_p
osteoarthritis NN 1_p
. . 1_p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Many NNP N
treatment NN N
options NNS N
, , N
including VBG N
non-pharmacological JJ N
and CC N
pharmacological JJ N
measures NNS N
, , N
have VBP N
been VBN N
recommended VBN N
in IN N
the DT N
management NN N
of IN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
. . N

Among IN N
the DT N
non-pharmacological JJ N
approach NN N
is VBZ N
physiotherapy NN N
, , N
which WDT N
involves VBZ N
the DT N
use NN N
of IN N
physical JJ N
modalities NNS N
like IN N
, , N
heat NN N
therapy NN N
, , N
exercise NN N
therapy NN N
, , N
electrical JJ N
stimulation NN N
, , N
therapeutic JJ N
ultrasound NN N
, , N
iontophoresis NN N
, , N
and CC N
phonophoresis NN N
. . N

This DT N
study NN N
was VBD N
therefore RB N
designed VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
0.4 CD N
% NN N
Dexamethasone NNP 1_i
sodium NN 1_i
phosphate NN 1_i
( ( 1_i
DEX-P NNP 1_i
) ) 1_i
phonophoresis NN 1_i
( ( 1_i
PH NNP 1_i
) ) 1_i
with IN N
0.4 CD 1_i
% NN 1_i
DEX-P JJ 1_i
iontophoresis NN 1_i
( ( 1_i
ION NNP 1_i
) ) 1_i
therapy NN 1_i
in IN N
the DT N
management NN N
of IN N
patients NNS 1_p
with IN 1_p
knee JJ 1_p
joint JJ 1_p
OA NNP 1_p
. . 1_p

METHODS NNP N
Fifty NNP 1_p
patients NNS 1_p
( ( 1_p
19 CD 1_p
males NNS 1_p
and CC 1_p
31 CD 1_p
females NNS 1_p
) ) 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
53.6 CD 1_p
+/- JJ 1_p
8.9 CD 1_p
years NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
PH NNP 1_i
or CC N
ION NNP 1_i
groups NNS N
with IN N
25 CD N
patients NNS N
in IN N
each DT N
group NN N
. . N

Ultrasound NNP N
waves VBZ N
of IN N
1 CD N
MHz NNP N
frequency NN N
was VBD N
applied VBN N
for IN N
5 CD N
minutes NNS N
to TO N
the DT N
target NN N
knee NN N
, , N
so RB N
also RB N
was VBD N
the DT N
direct JJ N
current JJ N
for IN N
10 CD N
minutes NNS N
for IN N
10 CD N
sessions NNS N
treatment NN N
period NN N
. . N

Western JJ 1_o
Ontario NNP 1_o
and CC 1_o
McMaster NNP 1_o
University NNP 1_o
Osteoarthritis NNP 1_o
Index NNP 1_o
( ( 1_o
WOMAC NNP 1_o
) ) 1_o
scores VBZ 1_o
, , 1_o
20 CD 1_o
meters NNS 1_o
ambulatory JJ 1_o
time NN 1_o
, , N
and CC N
knee VB 1_o
range NN 1_o
of IN 1_o
motion NN 1_o
( ( 1_o
ROM NNP 1_o
) ) 1_o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
therapy NN N
as IN N
the DT N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
two CD N
weeks NNS N
, , N
significant JJ N
improvement NN N
in IN N
total JJ N
WOMAC NNP 1_o
scores NNS 1_o
was VBD N
observed VBN N
in IN N
15 CD N
( ( N
60 CD N
% NN N
) ) N
and CC N
16 CD N
( ( N
64 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
PH NNP N
and CC N
ION NNP N
groups NNS N
respectively RB N
, , N
indicating VBG N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
rate NN N
. . N

Twenty NNP N
( ( N
20 CD N
) ) N
metres NNS N
ambulatory JJ 1_o
time NN 1_o
and CC 1_o
knee NN 1_o
range NN 1_o
of IN 1_o
motion NN 1_o
also RB N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
yet RB N
these DT N
variables NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Both NNP N
therapeutic JJ N
modalities NNS N
were VBD N
found VBN N
to TO N
be VB N
effective JJ N
and CC N
generally RB N
well RB N
tolerated VBN N
after IN N
10 CD N
treatment NN N
sessions NNS N
. . N

DEX-P JJ 1_i
phonophoresis NN 1_i
was VBD N
not RB N
superior JJ N
to TO N
DEX-P JJ 1_i
iontophoresis NN 1_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
OA NNP 1_p
of IN 1_p
the DT 1_p
knee NN 1_p
. . 1_p

Response NNP N
prediction NN N
in IN N
metastasised JJ N
colorectal NN N
cancer NN N
using VBG N
intratumoural JJ N
thymidylate JJ N
synthase NN N
: : N
results NNS N
of IN N
a DT N
randomised JJ N
multicentre NN N
trial NN N
. . N

BACKGROUND NNP N
Molecular NNP N
markers NNS N
to TO N
predict VB N
response NN N
to TO N
5-fluorouracil JJ 1_i
( ( 1_i
FU NNP 1_i
) ) 1_i
-based VBD 1_i
treatment NN N
of IN N
recurrent NN 1_p
or CC 1_p
metastasised VBN 1_p
colorectal JJ 1_p
cancer NN 1_p
( ( 1_p
mCRC NN 1_p
) ) 1_p
are VBP N
not RB N
established VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
value NN N
of IN N
thymidylate JJ N
synthase NN N
( ( N
TS NNP N
) ) N
, , N
a DT N
key JJ N
enzyme NN N
of IN N
DNA NNP N
synthesis NN N
and CC N
target NN N
of IN N
5-FU JJ N
, , N
to TO N
predict VB 1_o
response NN 1_o
to TO N
chemotherapy NN N
of IN N
mCRC NN N
. . N

METHODS NNP N
Tumour NNP 1_p
tissue NN 1_p
was VBD 1_p
obtained VBN 1_p
from IN 1_p
168 CD 1_p
patients NNS 1_p
with IN 1_p
mCRC NN 1_p
for IN 1_p
relative JJ 1_p
thymidylate NN 1_o
synthase NN 1_o
( ( 1_o
TS NNP 1_o
) ) 1_o
mRNA NN 1_p
quantitation NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
5-FU/folinic JJ 1_i
acid NN 1_i
( ( 1_i
FA NNP 1_i
, , 1_i
FUFA NNP 1_i
) ) 1_i
alone RB 1_i
or CC 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
irinotecan JJ 1_i
5-fluorouracil/folinic JJ 1_i
acid NN 1_i
and CC 1_i
irinotecan JJ 1_i
( ( 1_i
FOLFIRI NNP 1_i
) ) 1_i
stratified VBN 1_i
by IN 1_i
TS NNP 1_i
( ( 1_i
low JJ 1_i
versus RB 1_i
high JJ 1_i
) ) 1_i
. . N

Primary JJ N
end-point NN N
was VBD N
overall JJ 1_o
response NN 1_o
to TO 1_o
first-line JJ 1_o
treatment NN 1_o
among IN N
TS NNP N
high JJ N
patients NNS N
. . N

All DT N
parties NNS N
, , N
except IN N
for IN N
the DT N
randomisation NN N
centre NN N
, , N
were VBD N
blinded VBN N
for IN N
TS NNP N
status NN N
. . N

RESULTS NNP N
Biopsies NNP N
( ( N
n=168 RB N
) ) N
were VBD N
taken VBN N
without IN N
complications NNS N
. . N

TS NN 1_o
levels NNS 1_o
were VBD N
available JJ N
for IN N
147 CD N
patients NNS N
( ( N
87.5 CD N
% NN N
) ) N
. . N

Analysing VBG N
response NN 1_o
to TO 1_o
FUFA NNP 1_o
and CC 1_o
FOLFIRI NNP 1_o
in IN N
the DT N
per NN N
protocol NN N
set VBN N
( ( N
n=119 NN N
) ) N
after IN N
un-blinding JJ N
TS NNP N
in IN N
the DT N
data NN N
base NN N
revealed VBD N
a DT N
trend NN N
to TO N
better JJR N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
( ( N
9/19 CD N
, , N
47 CD N
% NN N
) ) N
in IN N
TS NNP N
high JJ N
compared VBN N
to TO N
FUFA NNP N
( ( N
5/23 CD N
, , N
22 CD N
% NN N
, , N
p=0.077 NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
biopsies NNS N
taken VBN N
from IN N
liver JJ N
lesions NNS N
( ( N
n=91 NN N
) ) N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
and CC N
FUFA NNP N
in IN N
TS NNP N
high NN N
was VBD N
53 CD N
% NN N
( ( N
9/17 CD N
) ) N
and CC N
18 CD N
% NN N
( ( N
3/17 CD N
) ) N
, , N
respectively RB N
( ( N
p=0.035 NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
low JJ N
TS NNP N
, , N
no DT N
remarkable JJ N
difference NN N
in IN N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
and CC N
FUFA NNP N
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Taking VBG N
a DT N
pre-treatment JJ N
biopsy NN N
is VBZ N
a DT N
safe JJ N
and CC N
feasible JJ N
procedure NN N
in IN N
mCRC NN N
. . N

After IN N
validation NN N
of IN N
our PRP$ N
data NNS N
in IN N
a DT N
larger JJR N
group NN N
TS NNP N
determination NN N
may MD N
have VB N
the DT N
potential NN N
to TO N
better JJR N
help NN N
direct VB N
systemic JJ N
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
primarily RB 1_p
non-resectable JJ 1_p
mCRC NN 1_p
. . 1_p

Selected VBN N
polymorphisms NNS N
of IN N
GSTP1 NNP N
and CC N
TERT NNP N
were VBD N
associated VBN N
with IN N
glioma NN 1_p
risk NN 1_p
in IN 1_p
Han NNP 1_p
Chinese NNP 1_p
. . 1_p

BACKGROUND NNP N
Current NNP N
evidence NN N
suggests VBZ N
that IN N
a DT N
majority NN N
of IN N
the DT N
inherited JJ N
risks NNS N
play VBP N
a DT N
major JJ N
role NN N
in IN N
glioma JJ 1_p
susceptibility NN 1_p
, , N
and CC N
glioma NN N
is VBZ N
due JJ N
to TO N
the DT N
co-inheritance NN N
of IN N
multiple JJ N
low-risk JJ N
variants NNS N
. . N

These DT N
variants NNS N
can MD N
be VB N
identified VBN N
through IN N
association NN N
studies NNS N
including VBG N
such JJ N
as IN N
genome-wide JJ N
association NN N
studies NNS N
( ( N
GWAS NNP N
) ) N
, , N
which WDT N
has VBZ N
led VBN N
the DT N
glioma NN N
epidemiology NN N
researchers NNS N
to TO N
focus VB N
on IN N
identifying VBG N
potential JJ N
disease-causing JJ N
factors NNS N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
and CC N
validated VBD N
10 CD 1_p
tag NN 1_p
single JJ 1_p
nucleotide JJ 1_p
polymorphisms NN 1_p
( ( 1_p
tSNPs NN 1_p
) ) 1_p
in IN 1_p
seven CD 1_p
genes NNS 1_p
associated VBN 1_p
with IN 1_p
glioma NN 1_p
susceptibility NN 1_p
in IN 1_p
a DT 1_p
Han NNP 1_p
Chinese NNP 1_p
population NN 1_p
, , 1_p
including VBG 1_p
301 CD 1_p
glioma NN 1_p
cases NNS 1_p
and CC 1_p
302 CD 1_p
controls NNS 1_p
, , 1_p
using VBG 1_p
a DT 1_p
multiplexed JJ 1_i
single JJ 1_i
nucleotide NN 1_i
polymorphism NN 1_i
( ( 1_i
SNP NNP 1_i
) ) 1_i
MassEXTEND NNP 1_i
assay NN 1_i
. . 1_i

We PRP N
ascertained VBD N
the DT N
genotypic NN N
frequencies NNS N
for IN N
each DT N
tSNP NN N
in IN N
control NN N
subjects NNS N
were VBD N
within IN N
Hardy-Weinberg NNP N
equilibrium NN N
( ( N
HWE NNP N
) ) N
using VBG N
an DT N
exact JJ N
test NN N
, , N
and CC N
then RB N
compared VBN N
the DT N
genotype NN N
and CC N
allele JJ N
frequencies NNS N
of IN N
glioma NN N
patients NNS N
and CC N
control NN N
subjects NNS N
using VBG N
the DT N
χ2 JJ N
test NN N
. . N

We PRP N
then RB N
applied VBD N
three CD N
genetic JJ N
models NNS N
( ( N
dominant JJ N
, , N
recessive JJ N
, , N
and CC N
additive JJ N
) ) N
using VBG N
PLINK NNP N
software NN N
to TO N
assess VB N
the DT N
association NN N
of IN N
each DT N
tSNP NN N
with IN N
glioma NN N
risk NN N
. . N

RESULTS NNP N
We PRP N
identified VBD N
two CD N
tSNPs NN N
to TO N
be VB N
associated VBN N
with IN 1_o
glioma NN 1_o
susceptibility NN 1_o
( ( N
rs1695 NN N
, , N
GSTP1 NNP N
, , N
P NNP N
= NNP N
0.019 CD N
; : N
rs2853676 NN N
, , N
TERT NNP N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
which WDT N
we PRP N
confirmed VBD N
using VBG N
dominant NN N
and CC N
additive JJ N
model NN N
analyses NNS N
. . N

The DT N
genotype NN N
& CC N
ldquo NN N
; : N
GA NNP N
& CC N
rdquo NN N
; : N
for IN N
rs1695 NN N
was VBD N
recognized VBN N
to TO N
be VB N
a DT N
protective JJ N
genotype NN N
for IN 1_o
glioma NN 1_o
( ( N
OR NNP N
, , N
0.67 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.47-0.96 NNP N
; : N
P NNP N
= NNP N
0.027 CD N
) ) N
, , N
while IN N
the DT N
genotype NN N
& CC N
ldquo NN N
; : N
AG NNP N
& CC N
rdquo NN N
; : N
for IN N
rs2853676 NN N
was VBD N
shown VBN N
to TO N
be VB N
a DT N
risk NN N
genotype NN N
for IN 1_o
glioma NN 1_o
( ( N
OR NNP N
, , N
1.50 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.15 JJ N
; : N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
, , N
and CC N
those DT N
from IN N
previous JJ N
studies NNS N
, , N
suggest VBP N
potential JJ N
genetic JJ N
contributes NNS N
for IN N
GSTP1 NNP N
and CC N
TERT NNP N
in IN N
glioma NN N
development NN N
. . N

[ JJ N
Effects NNS N
of IN N
small JJ 1_i
needle-knife JJ 1_i
comprehensive JJ 1_i
therapy NN 1_i
on IN N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ 1_p
nonspecific NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
patient NN 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effect NN N
of IN N
small JJ 1_i
needle-knife JJ 1_i
comprehensive JJ 1_i
therapy NN 1_i
on IN N
pain NN 1_o
and CC 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
in IN N
the DT N
chronic JJ 1_p
nonspecific NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
patient NN 1_p
. . 1_p

METHODS NNP N
Three CD 1_p
hundred VBD 1_p
and CC 1_p
five CD 1_p
cases NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
needle-knife JJ 1_i
group NN 1_i
of IN N
153 CD N
cases NNS N
and CC N
a DT N
physiotherapy NN 1_i
group NN 1_i
of IN N
152 CD N
cases NNS N
. . N

The DT N
needle-knife JJ 1_i
group NN N
were VBD N
treated VBN N
with IN N
small JJ 1_i
needle-knife JJ 1_i
releasing NN 1_i
therapy NN 1_i
, , 1_i
blocking VBG 1_i
and CC 1_i
functional JJ 1_i
training NN 1_i
. . 1_i

The DT N
physiotherapy NN 1_i
group NN N
were VBD N
treated VBN N
with IN N
ultra-short JJ 1_i
wave NN 1_i
, , 1_i
modulated VBD 1_i
medium NN 1_i
frequency NN 1_i
current JJ 1_i
, , 1_i
massage NN 1_i
and CC 1_i
functional JJ 1_i
training NN 1_i
. . 1_i

Pain NN 1_o
was VBD N
assessed VBN N
by IN N
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
was VBD N
determined VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
pain NN 1_o
and CC 1_o
the DT 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
were VBD N
significantly RB N
improved VBN N
in IN N
the DT N
two CD N
groups NNS N
; : N
and CC N
after IN N
treatment NN N
, , N
the DT N
VAS NNP 1_o
score NN 1_o
and CC 1_o
the DT 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
were VBD N
( ( N
1.60 CD N
+/- JJ N
0.38 CD N
) ) N
points NNS N
and CC N
( ( N
65.76 CD N
+/- JJ N
15.11 CD N
) ) N
cm NN N
in IN N
the DT N
needle-knife JJ 1_i
group NN N
and CC N
( ( N
4.59 CD N
+/- JJ N
1.09 CD N
) ) N
points NNS N
and CC N
( ( N
53.74 CD N
+/- JJ N
15.13 CD N
) ) N
cm NN N
in IN N
the DT N
physiotherapy NN N
group NN N
, , N
respectively RB N
, , N
the DT N
needle-knife JJ 1_i
group NN N
being VBG N
significantly RB N
better JJR N
than IN N
the DT N
physiotherapy NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Follow-up NNP N
survey NN N
of IN N
6-36 JJ N
months NNS N
showed VBD N
that IN N
the DT N
VAS NNP 1_o
score NN 1_o
and CC 1_o
the DT 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
in IN N
the DT N
needle-knife JJ 1_i
group NN N
were VBD N
superior JJ N
to TO N
those DT N
in IN N
the DT N
physiotherapy NN 1_i
group NN N
. . N

CONCLUSION NNP N
Small NNP 1_i
needle-knife JJ 1_i
comprehensive JJ 1_i
therapy NN 1_i
can MD N
significantly RB N
improve VB N
pain NN 1_o
and CC 1_o
lumbar NN 1_o
flexion NN 1_o
range NN 1_o
in IN N
the DT N
chronic JJ 1_p
nonspecific NN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
patient NN 1_p
, , N
with IN N
a DT N
stable JJ N
long-term JJ N
therapeutic JJ N
effect NN N
. . N

[ IN N
The DT N
equipotency NN N
of IN N
ropivacaine NN 1_i
, , 1_i
bupivacaine NN 1_i
and CC N
etidocaine NN 1_i
] NN 1_i
. . N

Ropivacaine NNP 1_i
, , N
congenerate NN N
to TO N
bupivacaine VB N
and CC N
mepivacaine VB N
has VBZ N
been VBN N
widely RB N
studied VBN N
in IN N
laboratory NN N
animals NNS N
, , N
but CC N
there RB N
have VBP N
been VBN N
few JJ N
investigations NNS N
of IN N
its PRP$ N
efficacy NN N
in IN N
human JJ N
epidural JJ N
anesthesia NN N
and CC N
peripheral JJ N
nerve NN N
blocks NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
three CD N
long-acting JJ N
local JJ N
anesthetics NNS N
( ( 1_i
bupivacaine VB 1_i
0.75 CD N
% NN N
, , N
ropivacaine VB 1_i
1 CD N
% NN N
and CC N
etidocaine VB 1_i
1 CD N
% NN N
) ) N
and CC N
to TO N
try VB N
, , N
with IN N
reference NN N
to TO N
previous JJ N
studies NNS N
, , N
to TO N
make VB N
some DT N
statement NN N
about IN N
the DT N
equipotency NN N
of IN N
ropivacaine JJ 1_i
relative NN N
to TO N
bupivacaine VB 1_i
and CC N
etidocaine VB 1_i
. . 1_i

METHODS NNP N
. . N

In IN N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
, , N
epidural JJ N
anesthesia NN N
was VBD N
carried VBN N
out IN N
with IN N
20 CD N
ml NNS N
bupivacaine VBP 1_i
0.75 CD N
% NN N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
and CC N
ropivacaine VB 1_i
1 CD N
% NN N
( ( N
n JJ N
= NNP N
21 CD N
) ) N
. . N

Following VBG N
this DT N
study NN N
epidural JJ N
anesthesia NN N
was VBD N
carried VBN N
out IN N
with IN N
20 CD N
ml NNS N
etidocaine VBP 1_i
1 CD N
% NN N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
in IN N
an DT N
open JJ N
study NN N
. . N

Patients NNS 1_p
with IN 1_p
ASA NNP 1_p
I PRP 1_p
or CC 1_p
II NNP 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
were VBD 1_p
scheduled VBN 1_p
for IN 1_p
varicose JJ 1_p
vein NN 1_p
stripping VBG 1_p
. . 1_p

Male NNP 1_p
and CC 1_p
female JJ 1_p
patients NNS 1_p
aged VBN 1_p
18-70 JJ 1_p
years NNS 1_p
and CC 1_p
weighing VBG 1_p
50-100 JJ 1_p
kg NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Patients NNS N
were VBD N
all DT N
placed VBN N
in IN N
a DT N
sitting JJ N
position NN N
, , N
after IN N
which WDT N
the DT N
epidural JJ N
space NN N
was VBD N
identified VBN N
by IN N
the DT N
" JJ N
loss NN N
of IN N
resistance NN N
" NN N
technique NN N
and CC N
a DT N
midline NN N
approach NN N
, , N
at IN N
the DT N
L-3/4 JJ N
interspace NN N
. . N

Injections NNS 1_i
of IN 1_i
3 CD 1_i
ml NN 1_i
of IN 1_i
the DT 1_i
local JJ 1_i
anesthetic NN 1_i
were VBD N
given VBN N
, , N
followed VBN 1_i
by IN 1_i
the DT 1_i
remainder NN 1_i
of IN 1_i
the DT 1_i
local JJ 1_i
anesthetic NN 1_i
at IN 1_i
10 CD 1_i
ml/min NN 1_i
1 CD 1_i
min NN 1_i
later RB 1_i
. . 1_i

Following VBG N
injection NN N
patients NNS N
were VBD N
immediately RB N
positioned VBN N
supine NN N
. . N

Analgesia NNP N
was VBD N
determined VBN N
by IN N
the DT N
pin-prick JJ 1_o
method NN 1_o
and CC N
motor NN N
blockade NN N
was VBD N
assessed VBN N
according VBG N
to TO N
the DT N
Bromage NNP 1_o
scale NN 1_o
. . 1_o

Heart NNP 1_o
rate NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
were VBD N
monitored VBN N
until IN N
3 CD N
h NNS N
after IN N
injection NN N
. . N

RESULTS NNP N
. . N

The DT N
latency NN 1_o
of IN 1_o
analgesia NN 1_o
for IN N
the DT N
first JJ N
blocked VBN N
segment NN N
( ( N
T NNP N
12 CD N
for IN N
bupivacaine NN N
and CC N
ropivacaine NN N
and CC N
L-1 NNP N
for IN N
etidocaine NN N
) ) N
was VBD N
6.0 CD N
min NN N
for IN N
bupivacaine NN 1_i
0.75 CD N
, , N
5.5 CD N
min NN N
for IN N
ropivacaine JJ 1_i
1 CD N
% NN N
, , N
and CC N
5.2 CD N
min NN N
for IN N
etidocaine JJ 1_i
1 CD N
% NN N
, , N
and CC N
the DT N
highest JJS N
thoracic JJ N
dermatome NN N
( ( N
T NNP N
5 CD N
for IN N
bupivacaine NN 1_i
, , N
T NNP N
4 CD N
for IN N
ropivacaine NN 1_i
and CC N
T NNP N
7 CD N
for IN N
etidocaine NN 1_i
) ) 1_i
was VBD N
reached VBN N
after IN N
24 CD N
+/- JJ N
10 CD N
, , N
26 CD N
+/- JJ N
9 CD N
, , N
and CC N
30 CD N
+/- JJ N
18 CD N
min NN N
for IN N
bupivacaine NN 1_i
, , 1_i
ropivacaine NN 1_i
, , N
and CC N
etidocaine NN 1_i
, , N
respectively RB N
. . N

The DT N
duration NN 1_o
of IN 1_o
sensory JJ 1_o
anesthesia NN 1_o
at IN N
the DT N
T NNP N
10 CD N
dermatomal JJ N
level NN N
was VBD N
257 CD N
+/- JJ N
102 CD N
, , N
278 CD N
+/- JJ N
67 CD N
, , N
and CC N
191 CD N
+/- JJ N
86 CD N
min NN N
for IN N
bupivacaine NN 1_i
, , 1_i
ropivacaine NN 1_i
, , N
and CC N
etidocaine NN 1_i
, , N
respectively RB N
. . N

The DT N
two-segment JJ 1_o
regression NN 1_o
time NN 1_o
was VBD N
199 CD N
+/- JJ N
80 CD N
min NN N
for IN N
bupivacaine NN 1_i
, , N
201 CD N
+/- JJ N
52 CD N
min NN N
for IN N
ropivacaine NN 1_i
, , N
and CC N
174 CD N
+/- JJ N
81 CD N
min NN N
for IN N
etidocaine NN 1_i
. . 1_i

The DT N
total JJ 1_o
duration NN 1_o
of IN 1_o
sensory JJ 1_o
block NN 1_o
was VBD N
340 CD N
+/- JJ N
103 CD N
min NN N
for IN N
bupivacaine NN 1_i
, , N
428 CD N
+/- JJ N
65 CD N
min NN N
for IN N
ropivacaine NN 1_i
and CC N
223 CD N
+/- JJ N
62 CD N
min NN N
for IN N
etidocaine NN 1_i
, , N
respectively RB N
. . N

In IN N
the DT N
ropivacaine NN 1_i
and CC N
bupivacaine NN 1_i
groups NNS N
sensory JJ N
anesthesia NN N
was VBD N
considered VBN N
adequate NN N
for IN N
surgery NN N
in IN N
all DT N
cases NNS N
but CC N
one CD N
in IN N
each DT N
group NN N
; : N
in IN N
the DT N
etidocaine NN 1_i
group NN N
, , N
however RB N
60 CD N
% NN N
of IN N
the DT N
patients NNS N
showed VBD N
inadequate JJ 1_o
analgesia NN 1_o
and CC N
all PDT N
these DT N
patients NNS N
( ( N
12/20 CD N
) ) N
required VBN N
additional JJ N
analgesics NNS N
. . N

Bupivacaine NNP 1_i
achieved VBD N
an DT N
average NN N
of IN N
motor NN N
block NN N
2.1 CD N
, , N
ropivacaine NN 1_i
2.3 CD N
, , N
and CC N
etidocaine VB 1_i
2.4 CD N
. . N

CONCLUSION NNP N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
ropivacaine NN 1_i
is VBZ N
an DT N
effective JJ N
local JJ N
anesthetic JJ N
agent NN N
. . N

Its PRP$ N
potency NN N
is VBZ N
about RB N
equal JJ N
to TO N
that DT N
of IN N
bupivacaine NN 1_i
and CC N
much RB N
higher JJR N
than IN N
that DT N
of IN N
etidocaine NN 1_i
... : 1_i
Event-related JJ N
potentials NNS N
and CC N
monoamines NNS N
in IN N
autistic JJ 1_p
children NNS 1_p
on IN N
a DT N
clinical JJ N
trial NN N
of IN N
fenfluramine NN 1_i
. . 1_i

In IN N
a DT N
double JJ N
blind NN N
, , N
crossover NN N
study NN N
of IN N
the DT N
response NN N
of IN N
autistic JJ 1_p
subjects NNS 1_p
to TO N
fenfluramine VB 1_i
, , 1_i
event-related JJ 1_i
potentials NNS 1_i
( ( 1_i
ERPs NNP 1_i
) ) 1_i
were VBD N
recorded VBN N
from IN N
7 CD 1_p
subjects NNS 1_p
on IN N
an DT N
attention-demanding JJ N
auditory NN N
choice NN N
reaction NN N
time NN N
task NN N
( ( N
ACRT NNP N
) ) N
. . N

ACRT NNP N
, , N
IQ NNP N
and CC N
biochemical JJ N
measures NNS N
were VBD N
taken VBN N
after IN N
5 CD N
months NNS N
placebo NN 1_i
and CC N
5 CD N
months NNS N
fenfluramine JJ 1_i
treatment NN 1_i
. . 1_i

After IN N
fenfluramine JJ N
treatment NN N
blood NN N
serotonin NN N
levels NNS N
fell VBD N
, , N
urinary JJ N
catecholamine NN N
levels NNS N
fell VBD N
and CC N
the DT N
HVA/DA NNP N
ratio NN N
rose VBD N
. . N

IQ NNP 1_o
and CC 1_o
ACRT NNP 1_o
performance NN 1_o
improved VBD N
. . N

On IN N
the DT N
ACRT NNP 1_o
subjects NNS N
were VBD N
asked VBN N
to TO N
press VB N
a DT N
button NN N
to TO N
a DT N
rare JJ N
target NN N
( ( N
500 CD N
Hz NNP N
, , N
P NNP N
= NNP N
0.14 CD N
) ) N
and CC N
to TO N
ignore VB N
higher JJR N
pitched VBN N
rare JJ N
( ( N
2,000 CD N
Hz NNP N
, , N
P NNP N
= NNP N
0.14 CD N
) ) N
and CC N
frequent JJ N
non-targets NNS N
( ( N
1,000 CD N
Hz NNP N
) ) N
. . N

After IN N
fenfluramine JJ 1_i
treatment NN N
N1 NNP 1_o
latencies NNS 1_o
increased VBD N
. . N

The DT N
scalp JJ 1_o
distribution NN 1_o
of IN 1_o
ERP NNP 1_o
maxima NNP N
changes NNS N
slightly RB N
with IN N
treatment NN N
. . N

P3 NNP 1_o
maxima NN 1_o
elicited VBN N
by IN N
rare JJ N
non-targets NNS N
were VBD N
recorded VBN N
more RBR N
rostrally RB N
after IN N
fenfluramine JJ 1_i
treatment NN N
. . N

After IN N
rare JJ N
non-targets NNS N
N1 NNP 1_o
amplitudes NNS 1_o
at IN 1_o
Fz NNP 1_o
decreased VBD N
but CC N
P3 NNP 1_o
amplitudes NNS 1_o
at IN 1_o
Pz NNP 1_o
increased VBD N
. . N

Early JJ N
negativity NN N
after IN N
the DT N
rare JJ N
non-target JJ N
( ( N
particularly RB N
on IN N
the DT N
right JJ N
side NN N
) ) N
was VBD N
negatively RB N
correlated VBN N
with IN N
the DT N
HVA/DA NNP N
ratio NN N
. . N

Subtraction NN N
of IN N
the DT N
P3 NNP N
component NN N
elicited VBN N
in IN N
a DT N
passive JJ N
condition NN N
where WRB N
no DT N
response NN N
was VBD N
required VBN N
from IN N
the DT N
active JJ N
condition NN N
showed VBD N
that IN N
P3 NNP 1_o
positivity NN 1_o
to TO N
targets NNS N
was VBD N
halved VBN N
with IN N
treatment NN N
. . N

( ( N
In IN N
contrast NN N
Nd NNP N
increased VBD N
on IN N
fenfluramine JJ N
treatment NN N
) ) N
. . N

Overall JJ N
, , N
N1 NNP N
and CC N
P3 NNP N
components NNS N
showed VBD N
greatest JJS N
responsiveness NN N
to TO N
rare VB N
non-targets NNS N
on IN N
fenfluramine NN N
. . N

N1 NNP N
but CC N
not RB N
P3 NNP N
changes NNS N
may MD N
represent VB N
slight JJ N
improvement NN N
of IN N
attention-related JJ N
function NN N
with IN N
treatment NN N
. . N

Small JJ N
changes NNS N
in IN N
ERP NNP 1_o
latency NN 1_o
and CC 1_o
distribution NN 1_o
, , N
associated VBN N
with IN N
the DT N
neuroleptic JJ N
action NN N
of IN N
fenfluramine NN 1_i
may MD N
be VB N
partly RB N
responsible JJ N
for IN N
a DT N
mild JJ N
improvement NN N
of IN N
IQ NNP N
and CC N
ACRT NNP N
performance NN N
on IN N
medication NN N
. . N

Effect NN N
of IN N
prophylactic JJ 1_i
amiodarone NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
rheumatic JJ 1_p
valve NNS 1_p
disease NN 1_p
undergoing VBG 1_p
valve JJ 1_p
replacement NN 1_p
surgery NN 1_p
. . 1_p

The DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prophylactic JJ N
single-dose JJ N
intravenous JJ N
amiodarone NN 1_i
in IN N
patients NNS 1_p
undergoing VBG 1_p
valve JJ 1_p
replacement NN 1_p
surgery NN 1_p
. . 1_p

Maintenance NN N
of IN N
sinus NN N
rhythm NN N
is VBZ N
better JJR N
than IN N
maintenance NN N
of IN N
fixed JJ N
ventricular JJ N
rate NN N
in IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
especially RB N
in IN N
the DT N
presence NN N
of IN N
irritable JJ N
left NN N
or CC N
right JJ N
atrium NN N
because IN N
of IN N
enlargement NN N
. . N

Fifty-six JJ 1_p
patients NNS 1_p
with IN 1_p
valvular JJ 1_p
heart NN 1_p
disease NN 1_p
with IN 1_p
or CC 1_p
without IN 1_p
AF NNP 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
or CC N
the DT N
amiodarone NN 1_i
group NN 1_i
( ( N
n=28 NN N
) ) N
received VBD N
amiodarone NN 1_i
( ( N
3 CD N
mg/kg NN N
in IN N
100 CD N
ml NNS N
normal JJ N
saline NN N
) ) N
and CC N
group NN N
II NNP N
or CC N
the DT N
control NN 1_i
group NN N
received VBD N
same JJ N
volume NN N
of IN N
normal JJ 1_i
saline NN 1_i
. . 1_i

The DT N
standardized JJ N
protocol NN N
for IN N
cardiopulmonary JJ N
bypass NN N
was VBD N
maintained VBN N
for IN N
all PDT N
the DT N
patients NNS N
. . N

AF NNP 1_o
occurred VBD N
in IN N
7.14 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
, , N
and CC N
in IN N
group NN N
II NNP N
, , N
28.57 CD N
% NN N
( ( N
P=0.035 NNP N
) ) N
; : N
ventricular JJ 1_o
tachycardia/fibrillation NN 1_o
was VBD N
observed VBN N
in IN N
21.43 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
and CC N
46.43 CD N
% NN N
patients NNS N
in IN N
group NN N
II NNP N
( ( N
P=0.089 NNP N
) ) N
after IN N
release NN N
of IN N
aortic JJ N
clamp NN N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
92.86 CD N
% NN N
) ) N
maintained VBD N
sinus JJ 1_o
rhythm NN 1_o
without IN 1_o
cardioversion NN 1_o
or CC 1_o
defibrillation NN 1_o
after IN N
release NN N
of IN N
aortic JJ N
cross NN N
clamp NN N
( ( N
P=0.002 NNP N
) ) N
. . N

Defibrillation NN 1_o
or CC 1_o
cardio NN 1_o
version NN 1_o
was VBD N
needed VBN N
in IN N
7.14 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
and CC N
28.57 CD N
% NN N
patients NNS N
in IN N
group NN N
II NNP N
( ( N
P=0.078 NNP N
) ) N
. . N

A DT N
single JJ N
prophylactic JJ N
intraoperative NN N
dose NN N
of IN N
intravenous JJ N
amiodarone NN 1_i
decreased VBD N
post NN 1_o
bypass NN 1_o
arrhythmia NN 1_o
in IN N
this DT N
study NN N
in IN N
comparison NN N
to TO N
the DT N
control NN N
group NN N
. . N

Single NNP N
dose NN N
of IN N
intraoperative JJ N
amiodarone NN 1_i
may MD N
be VB N
used VBN N
to TO N
decrease VB N
postoperative JJ N
arrhythmia NN N
in IN N
open JJ N
heart NN N
surgery NN N
. . N

Quitting VBG N
a DT N
weight JJ 1_i
loss NN 1_i
program NN 1_i
is VBZ N
associated VBN N
with IN N
anhedonia NN 1_p
: : 1_p
preliminary JJ 1_p
findings NNS 1_p
of IN 1_p
the DT 1_p
Lifestyle NNP 1_p
Intervention NNP 1_p
Treatment NNP 1_p
Evaluation NNP 1_p
Study NNP 1_p
in IN 1_p
northern JJ 1_p
Finland NNP 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
examine VB N
whether IN N
a DT N
diagnosis NN N
for IN N
major JJ 1_p
depression NN 1_p
, , 1_p
chronic JJ 1_p
depression NN 1_p
or CC 1_p
specific JJ 1_p
symptoms NNS 1_p
of IN 1_p
depression NN 1_p
is VBZ N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
quitting VBG N
a DT N
weight JJ 1_i
loss NN 1_i
program NN 1_i
. . 1_i

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
involved VBD N
82 CD 1_p
overweight JJ 1_p
adults NNS 1_p
participating VBG 1_p
in IN 1_p
the DT 1_p
Lifestyle NNP 1_i
Intervention NNP 1_i
Treatment NNP 1_i
Evaluation NNP 1_i
( ( 1_p
LITE NNP 1_p
) ) 1_p
follow-up NN 1_p
study NN 1_p
at IN 1_p
Oulu NNP 1_p
University NNP 1_p
Hospital NNP 1_p
in IN 1_p
northern JJ 1_p
Finland NNP 1_p
. . 1_p

METHODS NNP N
Psychiatric NNP 1_o
diagnostic JJ 1_o
assessments NNS 1_o
were VBD N
based VBN N
on IN N
the DT N
Structured NNP N
Clinical NNP N
Interview NNP N
for IN N
DSMIV NNP 1_o
disorders NNS N
( ( N
SCID-I NNP N
) ) N
conducted VBN N
by IN N
a DT N
clinical JJ N
psychiatrist NN N
. . N

Anhedonia NNP 1_o
( ( 1_o
lack NN 1_o
of IN 1_o
pleasure NN 1_o
) ) 1_o
was VBD N
assessed VBN N
as IN N
one CD N
of IN N
the DT N
core NN N
symptoms NNS N
of IN N
major JJ N
depression NN N
and CC N
chronic JJ 1_o
depression NN N
( ( N
dysthymia NN N
) ) N
. . N

Anhedonia NNP 1_o
was VBD N
defined VBN N
to TO N
be VB N
present JJ N
if IN N
the DT N
participants NNS N
reported VBD N
having VBG N
suffered VBD N
a DT N
major JJ N
loss NN N
of IN N
interest NN N
during IN N
the DT N
previous JJ N
month NN N
. . N

RESULTS NNP N
Twenty NNP N
participants NNS N
( ( N
24.4 CD N
% NN N
) ) N
quit NN N
during IN N
the DT N
6-month JJ N
intervention NN N
period NN N
. . N

Anhedonia NNP 1_o
put VBD N
individuals NNS N
at IN N
risk NN N
of IN N
quitting VBG N
the DT N
weight JJ N
loss NN N
program NN N
( ( N
bivariate JJ N
analysis NN N
OR NNP N
3.1 CD N
, , N
95 CD N
% NN N
CI NNP N
0.8-11.6 CD N
, , N
p=0.091 NN N
, , N
multivariate JJ N
analysis NN N
OR NNP N
6.5 CD N
, , N
95 CD N
% NN N
CI NNP N
1.1-38.2 CD N
, , N
p=0.038 NN N
) ) N
. . N

However RB N
, , N
a DT N
diagnosis NN N
for IN N
major JJ 1_o
depression NN 1_o
or CC 1_o
chronic JJ 1_o
depression NN 1_o
did VBD N
not RB N
predict JJ N
quitting VBG N
. . N

CONCLUSIONS NNP N
Individual NNP N
assessments NNS N
of IN N
obesity NN N
and CC N
overweight NN N
should MD N
also RB N
include VB N
an DT N
assessment NN N
for IN N
subthreshold JJ N
depression NN N
, , N
mainly RB N
anhedonia NN N
. . N

Synthetic JJ 1_i
serum NN 1_i
substitute NN 1_i
( ( 1_i
SSS NNP 1_i
) ) 1_i
: : 1_i
a DT N
globulin-enriched JJ N
protein NN N
supplement NN N
for IN N
human JJ 1_p
embryo JJ 1_p
culture NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
an DT N
IVF NNP N
protein NN N
supplement NN N
prepared VBN N
from IN N
human JJ N
serum NN N
albumin NN N
( ( N
HSA NNP N
) ) N
and CC N
human JJ N
globulins NNS N
would MD N
retain VB N
performance NN 1_o
characteristics NNS 1_o
equivalent JJ N
to TO N
those DT N
reported VBN N
for IN N
the DT N
commercial JJ N
plasma NN N
expanders NNS N
, , N
Plasmatein NNP 1_i
( ( N
Alpha NNP N
Therapeutics NNP N
, , N
Los NNP N
Angeles NNP N
, , N
California NNP N
) ) N
and CC N
Plasmanate NNP 1_i
( ( N
Cutter NNP N
Biological NNP N
, , N
Miles NNP N
Inc. NNP N
, , N
Elkhart NNP N
, , N
Indiana NNP N
) ) N
. . N

METHODS NNP N
Pronuclear-stage JJ 1_p
human JJ 1_p
embryos NN 1_p
were VBD N
randomly RB N
divided VBN 1_i
and CC 1_i
cultured VBN 1_i
in IN 1_i
human JJ 1_i
tubal JJ 1_i
fluid NN 1_i
medium NN 1_i
( ( 1_i
HTF NNP 1_i
) ) 1_i
supplemented VBD 1_i
with IN 1_i
either DT 1_i
HSA NNP 1_i
( ( 1_i
5 CD 1_i
mg/mL NN 1_i
) ) 1_i
or CC 1_i
Plasmatein NNP 1_i
( ( 1_i
10 CD 1_i
% NN 1_i
, , 1_i
v/v NN 1_i
; : 1_i
5 CD 1_i
mg/ml NN 1_i
) ) 1_i
as IN 1_i
a DT 1_i
means NN 1_i
of IN 1_i
indirectly RB 1_i
assessing VBG 1_i
the DT 1_i
effect NN 1_i
alpha- JJ 1_i
and CC 1_i
beta-globulins NNS 1_i
have VBP 1_i
on IN 1_i
embryonic JJ 1_i
development NN 1_i
. . 1_i

Those DT N
results NNS N
coupled VBD N
with IN N
the DT N
known VBN N
composition NN N
characteristics NNS N
of IN N
Plasmatein NNP 1_i
were VBD N
used VBN N
as IN N
the DT N
starting VBG N
basis NN N
to TO N
formulate VB N
test JJ N
lots NNS N
of IN N
synthetic JJ N
serum NN N
substitute NN N
( ( N
SSS NNP N
) ) N
. . N

RESULTS NNP N
Significantly NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
more JJR N
of IN N
the DT N
human JJ N
embryos NN N
cultured VBN N
in IN N
Plasmatein NNP 1_i
supplemented VBD N
medium NN N
reached VBD N
the DT N
four-cell NN 1_o
or CC 1_o
greater JJR 1_o
stage NN 1_o
by IN N
40 CD N
hr NNS N
postinsemination NN N
than IN N
a DT N
comparable JJ N
group NN N
cultured VBD N
in IN N
HSA NNP 1_i
alone RB N
. . N

Lot NNP N
1 CD N
of IN N
SSS NNP N
, , N
formulated VBD N
with IN N
HSA NNP N
( ( N
84 CD N
% NN N
of IN N
total JJ N
protein NN N
) ) N
and CC N
human JJ N
globulins NNS N
( ( N
16 CD N
% NN N
of IN N
total JJ N
protein NN N
) ) N
and CC N
an DT N
aqueous JJ N
lipoprotein NN N
fraction NN N
derived VBN N
from IN N
human JJ N
plasma NN N
( ( N
Excyte NNP N
IV NNP N
; : N
Miles NNP N
Diagnostics NNPS N
, , N
Kankakee NNP N
, , N
Illinois NNP N
) ) N
, , N
produced VBD N
accelerated VBN N
early JJ 1_o
embryonic JJ 1_o
growth NN 1_o
relative JJ N
to TO N
control VB N
murine JJ N
embryos NNS N
grown VBN N
in IN N
the DT N
presence NN N
of IN N
Plasmatein NNP N
, , N
however RB N
, , N
the DT N
percentage NN N
of IN N
the DT N
embryos NN N
reaching VBG N
the DT N
hatched JJ N
blastocyst NN N
stage NN N
was VBD N
decreased VBN N
( ( N
45 CD N
vs RB N
100 CD N
% NN N
) ) N
. . N

Human JJ 1_p
embryos NN 1_p
from IN 1_p
seven CD 1_p
patients NNS 1_p
, , N
randomized VBN N
to TO N
HTF NNP N
medium NN N
supplemented VBD N
with IN N
Plasmatein NNP 1_i
or CC N
lot NN N
1 CD N
of IN N
SSS NNP 1_i
, , N
showed VBD N
equivalent JJ N
growth NN 1_o
at IN N
36-40 JJ N
hr NN N
postinsemination NN N
. . N

A DT N
microprecipitate NN N
developed VBN N
in IN N
media NNS N
supplemented VBN N
with IN N
lot NN N
1 CD N
after IN N
several JJ N
days NNS N
of IN N
culture NN N
. . N

The DT N
Excyte NNP 1_o
IV NNP 1_o
concentration NN 1_o
was VBD N
reduced VBN N
and CC N
, , N
ultimately RB N
, , N
eliminated VBN N
from IN N
the DT N
subsequent JJ N
and CC N
final JJ N
prototype NN N
lots NNS N
of IN N
SSS NNP N
. . N

Murine NNP 1_p
embryos JJ 1_p
grown VBN N
in IN N
the DT N
presence NN N
of IN N
lipoprotein JJ N
free JJ N
SSS NNP 1_i
showed VBD N
significantly RB N
accelerated VBN 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
0.01 CD 1_o
) ) 1_o
growth NN 1_o
at IN N
17 CD N
hr NN N
postthaw NN N
compared VBN N
to TO N
Plasmatein NNP 1_i
and CC N
all DT N
embryos NNS N
progressed VBN N
to TO N
hatching VBG 1_o
by IN N
41 CD N
hr NN N
. . N

Human NNP 1_p
embryos NN 1_p
, , N
randomized VBN N
to TO N
either DT N
Plasmatein NNP 1_i
or CC N
lot NN N
3 CD N
of IN N
SSS NNP 1_i
, , N
showed VBD N
significantly RB N
accelerated VBN 1_o
growth NN 1_o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
when WRB N
scored VBN N
at IN N
38 CD N
hr NN N
following VBG N
insemination NN N
. . N

CONCLUSION NNP N
Synthetic NNP 1_i
serum NN 1_i
substitute NN 1_i
provides VBZ N
a DT N
convient NN N
, , N
standardized JJ N
means NNS N
of IN N
adding VBG N
protein NN N
to TO N
media NNS N
used VBN N
in IN N
assisted JJ N
reproductive JJ N
technology NN N
( ( N
ART NNP N
) ) N
procedures NNS N
. . N

Caudal NNP N
analgesia NN N
for IN N
perianal JJ N
surgery NN N
. . N

A DT N
comparison NN N
between IN N
bupivacaine NN 1_i
and CC N
diamorphine NN 1_i
. . 1_i

Seventy-three JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
perianal JJ 1_p
surgery NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT 1_i
control NN 1_i
group NN 1_i
, , 1_i
a DT 1_i
group NN 1_i
who WP 1_i
received VBD 1_i
a DT 1_i
caudal JJ 1_i
injection NN 1_i
of IN 1_i
20 CD 1_i
ml NNS 1_i
bupivacaine VBP 1_i
0.5 CD 1_i
% NN 1_i
plain NN 1_i
and CC 1_i
a DT 1_i
group NN 1_i
who WP 1_i
received VBD 1_i
diamorphine JJ 1_i
2.5 CD 1_i
mg NN 1_i
in IN 1_i
10 CD 1_i
ml NNS 1_i
normal JJ 1_i
saline NN 1_i
by IN 1_i
caudal JJ 1_i
injection NN 1_i
; : 1_i
a DT 1_i
comparison NN 1_i
was VBD 1_i
then RB 1_i
made VBN 1_i
of IN 1_i
postoperative JJ 1_i
analgesia NN 1_i
requirements NNS 1_i
. . 1_i

The DT N
bupivacaine NN 1_i
group NN N
had VBD N
better JJR N
analgesia NN 1_o
than IN N
the DT N
control NN N
group NN N
for IN N
the DT N
first JJ N
8 CD N
hours NNS N
, , N
after IN N
which WDT N
there EX N
was VBD N
no DT N
difference NN N
. . N

The DT N
diamorphine NN 1_i
group NN N
had VBD N
better JJR N
analgesia NN 1_o
than IN N
the DT N
control NN N
group NN N
for IN N
the DT N
first JJ N
24 CD N
hours NNS N
postoperatively RB N
. . N

Side JJ 1_o
effects NNS 1_o
were VBD N
less RBR N
in IN N
the DT N
diamorphine NN 1_i
group NN N
than IN N
the DT N
control NN N
, , N
or CC N
the DT N
bupivacaine NN 1_i
group NN N
. . N

In IN N
particular JJ N
, , N
41 CD N
% NN N
of IN N
the DT N
bupivacaine NN 1_i
group NN N
complained VBD N
of IN N
some DT 1_o
degree NN 1_o
of IN 1_o
urinary JJ 1_o
retention NN 1_o
and CC N
one CD N
patient NN N
required VBN N
temporary JJ 1_o
catheterisation NN 1_o
. . 1_o

It PRP N
is VBZ N
concluded VBN N
that IN N
caudal JJ N
diamorphine NN 1_i
gives VBZ N
good JJ N
postoperative JJ N
analgesia NN N
for IN N
perianal JJ N
operations NNS N
, , N
particularly RB N
when WRB N
motor NN N
blockade NN N
is VBZ N
not RB N
wanted VBN N
by IN N
the DT N
surgeon NN N
. . N

The DT N
influence NN N
of IN N
adult NN 1_i
intervention NN 1_i
on IN N
infants NNS 1_o
' POS 1_o
level NN 1_o
of IN 1_o
attention NN 1_o
. . 1_o

The DT N
effects NNS N
of IN N
adult NN 1_i
intervention NN 1_i
on IN N
infants NNS N
' POS N
level NN 1_o
of IN 1_o
attention NN 1_o
to TO N
objects NNS N
were VBD N
studied VBN N
with IN N
10-month-old JJ 1_p
infants NNS 1_p
. . 1_p

After IN N
a DT N
baseline JJ N
measure NN N
of IN N
spontaneous JJ N
attention NN N
was VBD N
obtained VBN N
, , N
infants NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
( ( 1_i
low JJ 1_i
, , 1_i
medium NN 1_i
, , 1_i
high JJ 1_i
intervention NN 1_i
, , 1_i
or CC 1_i
no-intervention JJ 1_i
control NN 1_i
) ) 1_i
. . N

Level NN N
of IN N
intervention NN N
was VBD N
controlled VBN N
by IN N
systematically RB 1_i
varying VBG 1_i
the DT 1_i
manner NN 1_i
and CC 1_i
frequency NN 1_i
with IN 1_i
which WDT 1_i
objects NNS 1_i
were VBD 1_i
presented VBN 1_i
, , 1_i
the DT 1_i
extent NN 1_i
to TO 1_i
which WDT 1_i
the DT 1_i
experimenter NN 1_i
talked VBD 1_i
to TO 1_i
the DT 1_i
infant NN 1_i
, , 1_i
and CC 1_i
physical JJ 1_i
proximity NN 1_i
. . 1_i

Infant JJ N
attention NN N
was VBD N
defined VBN N
as IN N
duration NN 1_o
of IN 1_o
time NN 1_o
spent VBN 1_o
examining VBG 1_o
objects NNS 1_o
. . 1_o

The DT N
overall JJ 1_o
duration NN 1_o
of IN 1_o
infant JJ 1_o
attention NN 1_o
increased VBD N
during IN N
medium NN N
intervention NN N
when WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Baseline NNP N
attention NN N
was VBD N
then RB N
used VBN N
to TO N
separate VB N
low JJ N
and CC N
high JJ N
attenders NNS N
. . N

Low JJ N
attending VBG N
infants NNS N
attended VBD 1_o
more RBR N
in IN N
medium NN N
and CC N
high JJ N
intervention NN N
than IN N
in IN N
the DT N
low JJ N
condition NN N
, , N
while IN N
high JJ N
attending VBG N
infants NNS N
were VBD N
unaffected VBN N
by IN N
intervention NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
level NN N
of IN N
intervention NN 1_i
interacts NNS N
with IN N
the DT N
child NN 1_o
's POS 1_o
spontaneous JJ 1_o
tendency NN 1_o
to TO 1_o
focus VB 1_o
attention NN 1_o
on IN N
objects NNS N
. . N

Oral NNP N
health NN N
impacts NNS N
on IN N
daily JJ N
living NN N
related VBN N
to TO N
four CD N
different JJ N
treatment NN N
protocols NNS N
for IN N
chronic JJ 1_p
periodontitis NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
oral JJ N
health NN N
impacts NNS N
perceived VBN N
by IN N
patients NNS 1_p
submitted VBN 1_p
to TO 1_p
different JJ 1_p
treatments NNS 1_p
of IN 1_p
chronic JJ 1_p
periodontitis NN 1_p
and CC 1_p
their PRP$ 1_p
association NN 1_p
with IN 1_p
clinical JJ 1_p
parameters NNS 1_p
. . 1_p

METHODS NNP N
Sixty NNP 1_p
patients NNS 1_p
were VBD 1_p
assigned VBN 1_p
to TO N
one CD N
of IN N
the DT N
following JJ N
therapeutic JJ N
groups NNS N
: : N
control NN 1_i
, , 1_i
treated VBN 1_i
with IN 1_i
full-mouth JJ 1_i
scaling NN 1_i
and CC 1_i
root NN 1_i
planing NN 1_i
( ( 1_i
SRP NNP 1_i
) ) 1_i
; : 1_i
test $ N
1 CD N
, , N
treated VBN 1_i
with IN 1_i
SRP NNP 1_i
and CC 1_i
400 CD 1_i
mg NNS 1_i
systemically RB 1_i
administered VBN 1_i
metronidazole NN 1_i
( ( 1_i
MET NNP 1_i
) ) 1_i
three CD N
times NNS N
per IN N
day NN N
for IN N
10 CD N
days NNS N
; : N
test JJS N
2 CD N
, , N
treated VBN 1_i
with IN 1_i
SRP NNP 1_i
and CC 1_i
professional JJ 1_i
supragingival NN 1_i
plaque NN 1_i
removal NN 1_i
( ( 1_i
PP NNP 1_i
) ) 1_i
every DT N
week NN N
for IN N
3 CD N
months NNS N
; : N
and CC N
test VB N
3 CD N
, , N
treated VBN N
with IN N
SRP NNP 1_i
and CC 1_i
MET NNP 1_i
plus CC 1_i
PP NNP 1_i
. . 1_i

Clinical NNP N
periodontal JJ N
measurements NNS N
and CC N
data NNS N
regarding VBG N
patients NNS N
' POS N
oral JJ 1_o
health NN 1_o
impacts NNS 1_o
( ( 1_o
perceived VBN 1_o
impacts NNS 1_o
on IN 1_o
bleeding VBG 1_o
gums NNS 1_o
, , 1_o
gingival JJ 1_o
recession NN 1_o
, , 1_o
sensitivity NN 1_o
to TO 1_o
cold VB 1_o
, , 1_o
packing VBG 1_o
foods NNS 1_o
, , 1_o
aesthetics NNS 1_o
, , 1_o
bad JJ 1_o
breath NN 1_o
, , 1_o
and CC 1_o
tooth DT 1_o
mobility NN 1_o
) ) 1_o
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
3 CD N
months NNS N
after IN N
therapy NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
presented VBD N
significant JJ N
improvement NN N
in IN N
oral JJ 1_o
health NN 1_o
perceived VBD 1_o
impacts NNS 1_o
. . 1_o

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
of IN N
oral JJ 1_o
health NN 1_o
impacts NNS 1_o
among IN N
groups NNS N
subjected VBN N
to TO N
different JJ N
treatments NNS N
. . N

The DT N
clinical JJ N
data NNS N
of IN N
percentage NN N
of IN N
deep JJ 1_o
probing VBG 1_o
depth NN 1_o
, , 1_o
deep JJ 1_o
clinical JJ 1_o
attachment NN 1_o
level NN 1_o
, , 1_o
and CC 1_o
bleeding VBG 1_o
on IN 1_o
probing VBG 1_o
were VBD N
found VBN N
to TO N
be VB N
correlated VBN N
significantly RB N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

CONCLUSIONS NNP N
Periodontal NNP 1_i
treatment NN 1_i
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
of IN N
self-perceived JJ 1_o
impacts NNS 1_o
regardless RB N
of IN N
the DT N
non-surgical JJ N
treatment NN N
protocol NN N
employed VBN N
. . N

Most JJS N
of IN N
the DT N
clinical JJ N
data NNS N
were VBD N
associated VBN N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

Are NNP N
back RB 1_i
supports VBZ 1_i
plus CC 1_i
education NN 1_i
more RBR N
effective JJ N
than IN N
education NN 1_i
alone RB 1_i
in IN N
promoting VBG N
recovery NN 1_p
from IN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
? . N
: : N
Results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
back JJ 1_i
support NN 1_i
plus CC 1_i
education NN 1_i
versus IN N
education NN 1_i
alone RB 1_i
in IN N
promoting VBG N
recovery NN N
from IN N
a DT N
work-related JJ 1_p
low JJ 1_p
back RB 1_p
disorder NN 1_p
( ( 1_p
WR-LBD NNP 1_p
) ) 1_p
while IN N
simultaneously RB N
considering VBG N
personal JJ N
, , N
health NN N
, , N
and CC N
occupational JJ N
factors NNS N
and CC N
the DT N
impact NN N
of IN N
occupational JJ N
factors NNS N
on IN N
recovery NN N
. . N

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
No NNP N
randomized JJ N
studies NNS N
of IN N
active JJ 1_p
industrial JJ 1_p
workers NNS 1_p
with IN 1_p
low JJ 1_p
back RB 1_p
disorders NNS 1_p
exist VBP N
regarding VBG N
the DT N
effectiveness NN N
of IN N
back JJ N
supports NNS N
plus CC N
education NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
433 CD 1_p
actively RB 1_p
employed VBN 1_p
hourly RB 1_p
union NN 1_p
workers NNS 1_p
who WP 1_p
had VBD 1_p
a DT 1_p
recent JJ 1_p
diagnosis NN 1_p
of IN 1_p
a DT 1_p
WR-LBD JJ 1_p
: : 1_p
1 CD 1_p
) ) 1_p
those DT 1_p
who WP 1_p
wore VBP 1_p
a DT 1_i
specially RB 1_i
designed VBN 1_i
back RP 1_i
support NN 1_i
plus CC 1_i
received JJ 1_i
education NN 1_i
on IN 1_i
back JJ 1_i
health NN 1_i
; : 1_i
and CC 1_p
2 CD 1_p
) ) 1_p
those DT 1_p
who WP 1_p
received VBD 1_p
education NN 1_i
on IN 1_i
back JJ 1_i
health NN 1_i
only RB 1_i
. . 1_i

Demographic NNP N
, , N
health NN N
, , N
medical JJ N
, , N
and CC N
occupational JJ N
factors NNS N
were VBD N
obtained VBN N
through IN N
interview NN N
or CC N
abstraction NN N
of IN N
computer NN N
files NNS N
; : N
individual JJ N
ergonomic JJ N
exposures NNS N
were VBD N
measured VBN N
with IN N
a DT N
lumbar NN N
motion NN N
monitor NN N
. . N

Outcomes CC N
evaluated VBD N
over IN N
a DT N
12-month JJ N
period NN N
included VBD N
: : N
self-reported JJ 1_o
measures NNS 1_o
of IN 1_o
back RB 1_o
pain NN 1_o
, , 1_o
back RB 1_o
pain NN 1_o
disability NN 1_o
level NN 1_o
, , 1_o
physical JJ 1_o
health NN 1_o
, , 1_o
mental JJ 1_o
health NN 1_o
, , 1_o
and CC 1_o
administrative JJ 1_o
measures NNS 1_o
of IN 1_o
recurrence NN 1_o
, , 1_o
lost VBN 1_o
work NN 1_o
time NN 1_o
, , 1_o
and CC 1_o
medical JJ 1_o
care NN 1_o
utilization NN 1_o
. . 1_o

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
study NN N
groups NNS N
with IN N
respect NN N
to TO N
mental VB 1_o
or CC 1_o
physical JJ 1_o
health NN 1_o
, , 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
, , 1_o
back RB 1_o
pain NN 1_o
disability NN 1_o
, , 1_o
neurogenic JJ 1_o
symptoms NNS 1_o
, , 1_o
lost VBN 1_o
work NN 1_o
time NN 1_o
, , 1_o
likelihood NN 1_o
of IN 1_o
recurrence NN 1_o
of IN 1_o
an DT 1_o
episode NN 1_o
of IN 1_o
a DT 1_o
back JJ 1_o
disorder NN 1_o
, , 1_o
or CC 1_o
other JJ 1_o
administrative JJ 1_o
measures NNS 1_o
of IN 1_o
healthcare JJ 1_o
utilization NN 1_o
or CC 1_o
lost VBN 1_o
work NN 1_o
time NN 1_o
. . 1_o

However RB N
, , N
significant JJ N
decreases NNS N
in IN 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
, , 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
disability NN 1_o
, , 1_o
neurogenic JJ 1_o
symptoms NNS 1_o
, , 1_o
and CC 1_o
an DT 1_o
increase NN 1_o
in IN 1_o
physical JJ 1_o
health NN 1_o
were VBD N
observed VBN N
over IN N
the DT N
12 CD N
months NNS N
of IN N
observation NN N
in IN N
both DT N
study NN N
groups NNS N
. . N

The DT N
only JJ N
occupational JJ N
variable NN N
found VBD N
to TO N
influence VB N
was VBD N
plant NN N
group NN N
whereby WRB N
service NN N
parts NNS N
operations NNS N
workers NNS N
in IN N
the DT N
back JJ N
support NN N
plus CC N
education NN N
group NN N
experienced VBD N
a DT N
lower JJR N
likelihood NN N
of IN N
WR-LBD NNP 1_o
recurrence NN 1_o
. . 1_o

CONCLUSION NNP N
Although IN N
there EX N
was VBD N
no DT N
overall JJ N
effect NN N
on IN N
self-reported JJ N
recovery NN N
or CC N
administrative JJ N
measures NNS N
or CC N
lost VBN N
work NN N
time NN N
between IN N
the DT N
study NN N
groups NNS N
, , N
a DT N
back JJ 1_i
support NN 1_i
plus CC 1_i
health NN 1_i
education NN 1_i
may MD N
have VB N
some DT N
value NN N
in IN N
preventing VBG N
recurrent JJ N
WR-LBD NNP N
in IN N
industrial JJ 1_p
workers NNS 1_p
who WP 1_p
work VBP 1_p
in IN 1_p
psychosocial JJ 1_p
environments NNS 1_p
and CC 1_p
perform VB 1_p
manual JJ 1_p
material NN 1_p
handling VBG 1_p
tasks NNS 1_p
similar JJ 1_p
to TO 1_p
those DT 1_p
found VBN 1_p
in IN 1_p
parts NNS 1_p
distribution NN 1_p
centers NNS 1_p
. . 1_p

Lactoferrin NNP 1_i
supplementation NN 1_i
to TO N
Holstein NNP 1_p
calves NNS 1_p
during IN 1_p
the DT 1_p
preweaning NN 1_p
and CC 1_p
postweaning NN 1_p
phases NNS 1_p
. . 1_p

Sixty NNP 1_p
Holstein NNP 1_p
calves VBZ 1_p
( ( 1_p
30 CD 1_p
bulls NNS 1_p
, , 1_p
30 CD 1_p
heifers NNS 1_p
) ) 1_p
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
supplemental JJ 1_i
lactoferrin NN 1_i
on IN N
feed NN 1_o
intake NN 1_o
, , 1_o
growth NN 1_o
, , 1_o
and CC 1_o
health NN 1_o
during IN N
the DT N
preweaning NN N
and CC N
postweaning NN N
periods NNS N
. . N

One CD N
of IN N
3 CD N
levels NNS N
of IN N
lactoferrin NN 1_i
was VBD N
supplemented VBN N
from IN N
3 CD N
to TO N
56 CD N
d NN N
in IN N
either DT N
whole JJ N
milk NN N
or CC N
water NN N
to TO N
produce VB N
3 CD N
dietary JJ N
treatments NNS N
: : N
1 CD N
) ) N
0 CD N
g/d NN N
, , N
2 CD N
) ) N
0.5 CD N
g/d NN N
, , N
and CC N
3 CD N
) ) N
1 CD N
g/d NN N
. . N

Whole JJ N
milk NN N
( ( N
3.8 CD N
L/d NNP N
) ) N
containing VBG N
lactoferrin JJ 1_i
supplements NNS 1_i
was VBD N
fed VBN N
from IN N
bottles NNS N
until IN N
weaning VBG N
at IN N
35 CD N
d. NN N
From NNP N
d VBZ N
36 CD N
to TO N
56 CD N
, , N
lactoferrin JJ 1_i
supplements NNS 1_i
were VBD N
added VBN N
to TO N
water NN N
( ( N
15 CD N
to TO N
25 CD N
mL NN N
) ) N
and CC N
fed VBN N
from IN N
bottles NNS N
. . N

Lactoferrin NNP 1_i
supplementation NN 1_i
had VBD N
no DT N
effect NN N
on IN N
feed NN 1_o
intake NN 1_o
, , 1_o
body NN 1_o
weight NN 1_o
, , 1_o
average JJ 1_o
daily JJ 1_o
gain NN 1_o
, , 1_o
heart NN 1_o
girth NN 1_o
, , 1_o
body NN 1_o
temperature NN 1_o
, , 1_o
fecal JJ 1_o
scores NNS 1_o
, , 1_o
respiratory NN 1_o
scores NNS 1_o
, , 1_o
or CC 1_o
haptoglobin JJ 1_o
concentrations NNS 1_o
. . 1_o

Calves NNS 1_p
were VBD N
housed VBN N
in IN N
individual JJ N
pens NNS N
in IN N
either DT N
an DT N
open-sided JJ N
barn NN N
or CC N
hutches NNS N
. . N

Calves NNS 1_p
raised VBD 1_p
in IN 1_p
the DT 1_p
barn NN 1_p
consumed VBD N
more JJR N
calf JJ N
starter NN N
and CC N
therefore RB N
grew VBD N
better JJR N
than IN N
calves NNS N
raised VBN N
in IN N
hutches NNS N
. . N

Under IN N
the DT N
conditions NNS N
of IN N
this DT N
study NN N
, , N
lactoferrin JJ 1_i
supplementation NN 1_i
was VBD N
not RB N
beneficial JJ N
. . N

Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
elucidate VB N
the DT N
role NN N
of IN N
lactoferrin NN 1_i
, , N
and CC N
possible JJ N
benefits NNS N
during IN N
different JJ N
feeding VBG N
conditions NNS N
or CC N
milk NN N
sources NNS N
. . N

The DT N
effects NNS N
of IN N
encoding VBG N
in IN N
hypnosis NN N
and CC N
post-hypnotic JJ N
suggestion NN N
on IN N
academic JJ N
performance NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
relationship NN N
between IN N
proactive JJ 1_p
learning NN 1_p
in IN 1_p
hypnosis NN 1_i
, , 1_i
post-hypnotic JJ 1_i
suggestion NN 1_i
, , 1_p
and CC 1_p
academic JJ 1_p
performance NN 1_p
. . 1_p

Participants NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
56 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN 1_i
group NN 1_p
or CC N
a DT N
treatment NN 1_i
group NN 1_p
. . 1_p

The DT N
treatment NN N
group NN N
was VBD N
hypnotized VBN 1_i
and CC 1_i
read VB 1_i
a DT 1_i
passage NN 1_i
while IN 1_i
in IN 1_i
hypnosis NN 1_i
. . 1_i

Concurrently RB N
, , N
they PRP N
were VBD N
given VBN N
a DT N
post-hypnotic JJ 1_i
suggestion NN 1_i
, , N
which WDT N
attempted VBD N
to TO N
aid VB N
recognition NN N
and CC N
performance NN N
on IN N
a DT N
test NN N
immediately RB N
following VBG N
the DT N
hypnosis NN N
session NN N
. . N

Both DT N
groups NNS N
completed VBD N
a DT N
multiple-choice JJ N
test NN N
based VBN N
on IN N
the DT N
aforementioned JJ N
passage NN N
. . N

An DT N
analysis NN N
of IN N
covariance NN N
discerned VBD N
the DT N
effect NN 1_o
of IN 1_o
proactive JJ 1_o
learning NN 1_o
and CC N
post-hypnotic JJ 1_o
suggestion NN 1_o
on IN N
test NN 1_o
performance NN 1_o
, , N
while IN N
controlling VBG N
for IN N
the DT N
variance NN N
introduced VBN N
by IN N
scholastic JJ 1_o
aptitude NN 1_o
as IN N
measured VBN N
by IN N
the DT N
ACT NNP N
. . N

Results NNP N
indicated VBD N
that IN N
the DT N
hypnosis NN 1_i
sessions NNS N
predicted VBD N
significantly RB N
impaired JJ 1_o
test NN 1_o
performance NN 1_o
. . 1_o

Fertility NNP N
outcome NN N
after IN N
systemic JJ 1_i
methotrexate NN 1_i
and CC 1_i
laparoscopic NN 1_i
salpingostomy NN 1_i
for IN N
tubal JJ 1_p
pregnancy NN 1_p
. . 1_p

Assessment NN N
of IN N
response NN N
to TO N
induction NN N
therapy NN N
and CC N
its PRP$ N
influence NN N
on IN N
5-year JJ 1_o
failure-free JJ 1_o
survival NN 1_o
in IN 1_p
group NN 1_p
III NNP 1_p
rhabdomyosarcoma NN 1_p
: : 1_p
the DT N
Intergroup NNP N
Rhabdomyosarcoma NNP N
Study-IV NNP N
experience NN N
-- : N
a DT N
report NN N
from IN N
the DT N
Soft NNP N
Tissue NNP N
Sarcoma NNP N
Committee NNP N
of IN N
the DT N
Children NNP N
's POS N
Oncology NNP N
Group NNP N
. . N

PURPOSE NNP N
Initial NNP N
response NN N
to TO N
induction NN 1_i
chemotherapy NN 1_i
predicts VBZ N
failure-free JJ 1_o
survival NN 1_o
( ( 1_o
FFS NNP 1_o
) ) 1_o
in IN N
osteosarcoma NN 1_p
and CC 1_p
Ewing NNP 1_p
's POS 1_p
sarcoma NN 1_p
. . 1_p

For IN N
Intergroup NNP N
Rhabdomyosarcoma NNP N
Study NNP N
( ( N
IRS NNP N
) ) N
IV VBZ N
patients NNS 1_p
with IN 1_p
group NN 1_p
III NNP 1_p
rhabdomyosarcoma NN 1_p
, , N
we PRP N
assessed VBD N
whether IN N
reported VBN N
response NN N
assessed VBN N
by IN N
anatomic JJ N
imaging NN N
at IN N
week NN N
8 CD N
predicted VBD N
FFS NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
studied VBD N
444 CD 1_p
group NN 1_p
III NNP 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
induction NN 1_i
therapy NN 1_i
, , 1_p
had VBD 1_p
response NN 1_p
assessed VBN 1_p
at IN 1_p
week NN 1_p
8 CD 1_p
by IN 1_p
anatomic JJ 1_i
imaging NN 1_i
, , 1_i
and CC 1_i
continued VBD 1_i
with IN 1_i
protocol NN 1_i
therapy NN 1_i
. . 1_i

Induction NNP 1_i
chemotherapy NN 1_i
was VBD N
generally RB N
followed VBN N
by IN N
radiation NN 1_i
therapy NN 1_i
( ( 1_i
RT NNP 1_i
) ) 1_i
starting VBG N
after IN N
week NN N
9 CD N
. . N

Response NN 1_o
to TO N
induction NN N
therapy NN N
was VBD N
determined VBN N
at IN N
weeks NNS N
0 CD N
and CC N
8 CD N
. . N

Local JJ N
institutions NNS N
coded VBD N
response NN N
. . N

RESULTS JJ N
Response JJ 1_o
rate NN 1_o
for IN N
the DT N
entire JJ N
cohort NN N
at IN N
week NN N
8 CD N
was VBD N
77 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
73 CD N
% NN N
to TO N
81 CD N
% NN N
; : N
complete JJ 1_o
response NN 1_o
[ NNP 1_o
CR NNP 1_o
] NNP 1_o
, , N
21 CD N
% NN N
; : N
partial JJ 1_o
response NN 1_o
[ NNP 1_o
PR NNP 1_o
] NNP 1_o
, , N
56 CD N
% NN N
) ) N
but CC N
response NN N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP 1_o
( ( N
P NNP N
= NNP N
.57 NNP N
) ) N
. . N

Two CD N
hundred VBD N
seventy-two JJ N
patients NNS N
received VBD N
standard-timing JJ N
RT NNP N
at IN N
week NN N
9 CD N
and CC N
thus RB N
only RB N
chemotherapy NN N
during IN N
induction NN N
. . N

Response NNP 1_o
rate NN 1_o
was VBD N
81 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP 1_o
, , N
76 CD N
% NN N
to TO N
86 CD N
% NN N
; : N
CR NNP 1_o
, , N
22 CD N
% NN N
; : N
PR NNP 1_o
, , N
59 CD N
% NN N
) ) N
. . N

In IN N
these DT N
patients NNS N
, , N
response NN N
did VBD 1_o
not RB 1_o
influence VB 1_o
FFS NNP 1_o
except IN N
for IN N
those DT N
with IN N
alveolar JJ N
histology NN N
. . N

One CD N
hundred VBD N
thirty-two NN N
other JJ N
patients NNS N
received VBN N
chemotherapy NN N
and CC N
RT NNP N
during IN N
induction NN N
( ( N
up-front JJ N
RT NNP N
) ) N
. . N

Response JJ 1_o
rate NN 1_o
was VBD N
65 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP 1_o
, , N
57 CD N
% NN N
to TO N
73 CD N
% NN N
; : N
CR NNP 1_o
, , N
12 CD N
% NN N
; : N
PR NNP 1_o
, , N
53 CD N
% NN N
) ) N
, , N
but CC N
response NN N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP 1_o
( ( N
P NNP N
= NNP N
.69 NNP N
) ) N
. . N

Forty JJ N
patients NNS N
received VBD N
no DT N
RT NNP N
at IN N
all DT N
( ( N
protocol JJ N
violation NN N
) ) N
and CC N
response NN N
to TO N
induction NN N
therapy NN N
had VBD N
no DT 1_o
effect NN 1_o
on IN N
FFS NNP 1_o
. . 1_o

CONCLUSION NNP N
In IN N
IRS-IV NNP N
, , N
response NN 1_o
rate NN 1_o
to TO N
induction NN N
therapy NN N
was VBD N
77 CD N
% NN N
in IN N
group NN 1_p
III NNP 1_p
patients NNS 1_p
, , N
was VBD N
independent JJ N
of IN N
histology NN N
, , N
and CC N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP 1_o
overall JJ N
. . N

Lung NNP N
function NN N
and CC N
respiratory NN N
symptoms NNS N
in IN N
a DT N
1-year JJ N
randomized JJ N
smoking NN N
cessation NN N
trial NN N
of IN N
varenicline NN 1_i
in IN N
COPD NNP 1_p
patients NNS 1_p
. . 1_p

UNLABELLED IN N
There EX N
are VBP N
few JJ N
data NNS N
concerning VBG N
changes NNS N
in IN N
lung NN N
function NN N
and CC N
respiratory NN N
symptoms NNS N
in IN N
smokers NNS 1_p
with IN 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
( ( 1_p
COPD NNP 1_p
) ) 1_p
weeks NNS 1_p
to TO 1_p
months NNS 1_p
after IN 1_p
quitting VBG 1_p
smoking NN 1_p
. . 1_p

We PRP N
examined VBD N
serial JJ N
changes NNS N
in IN N
spirometry NN N
and CC N
Clinical NNP N
COPD NNP N
Questionnaire NNP N
( ( N
CCQ NNP N
) ) N
scores VBZ N
( ( N
measuring VBG N
respiratory NN N
symptoms NNS N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
) ) N
in IN N
COPD NNP 1_p
participants NNS 1_p
by IN 1_p
smoking VBG 1_p
status NN 1_p
during IN N
a DT N
smoking NN N
cessation NN N
trial NN N
. . N

In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
, , N
smokers NNS 1_p
with IN 1_p
mild-to-moderate JJ 1_p
COPD NNP 1_p
were VBD N
treated VBN N
with IN N
varenicline JJ 1_i
1 CD 1_i
mg NN 1_i
b.i.d NN 1_i
. . 1_i

or CC 1_i
placebo NN 1_i
for IN N
12 CD N
weeks NNS N
and CC N
followed VBD N
to TO N
Week VB N
52 CD N
. . N

Primary JJ N
endpoints NNS N
of IN N
abstinence NN 1_o
were VBD N
previously RB N
reported VBN N
. . N

Secondary JJ N
endpoints NNS N
were VBD N
mean JJ 1_o
changes NNS 1_o
from IN 1_o
baseline NN 1_o
in IN N
post-bronchodilator NN 1_o
forced VBN 1_o
expired JJ 1_o
volume NN 1_o
in IN 1_o
1 CD 1_o
s NN 1_o
( ( 1_o
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
) ) 1_o
and CC 1_o
CCQ NNP 1_o
scores NNS 1_o
. . 1_o

Change NN 1_o
from IN 1_o
baseline NN 1_o
in IN N
post-bronchodilator NN N
FEV NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
was VBD N
significantly RB N
improved VBN N
in IN N
continuous JJ N
abstainers NNS N
( ( N
121.8 CD N
mL NN N
) ) N
vs. FW N
continuous JJ N
smokers NNS N
( ( N
37.9 CD N
mL NN N
) ) N
at IN N
Week $ N
12 CD N
( ( N
P NNP N
= NNP N
0.0069 CD N
) ) N
, , N
but CC N
not RB N
at IN N
Weeks NNP N
24 CD N
or CC N
52 CD N
. . N

Mean JJ 1_o
change NN 1_o
from IN 1_o
baseline NN 1_o
at IN 1_o
Week NNP 1_o
12 CD 1_o
in IN 1_o
CCQ NNP 1_o
Total NNP 1_o
Score NNP 1_o
was VBD N
significantly RB N
better RBR N
in IN N
continuous JJ N
abstainers NNS N
( ( N
-1.04 NN N
) ) N
vs. FW N
continuous JJ N
smokers NNS N
( ( N
-0.53 NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
: : N
this DT N
improvement NN N
was VBD N
sustained VBN N
at IN N
Weeks NNP N
24 CD N
and CC N
52 CD N
. . N

In IN N
a DT N
1-year JJ N
cessation NN N
trial NN N
of IN N
smokers NNS 1_p
with IN 1_p
COPD NNP 1_p
, , N
continuous JJ 1_o
abstinence NN 1_o
compared VBN N
with IN N
continuous JJ N
smoking VBG N
significantly RB N
improved VBN N
post-bronchodilator NN 1_o
FEV NNP N
( ( N
1 CD N
) ) N
at IN N
Week $ N
12 CD N
( ( N
although IN N
the DT N
difference NN N
narrowed VBD N
subsequently RB N
) ) N
and CC N
CCQ NNP 1_o
Total NNP 1_o
Scores NNP 1_o
at IN N
Week NNP N
12 CD N
, , N
with IN N
sustained JJ N
improvement NN N
thereafter RB N
. . N

( ( N
TRIAL NNP N
REGISTRY NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
; : N
trial NN N
identifier NN N
: : N
NCT00285012 NNP N
) ) N
. . N

Using VBG N
personalized VBN 1_i
feedback NN 1_i
to TO N
reduce VB N
alcohol NN N
use NN N
among IN N
hazardous JJ 1_p
drinking VBG 1_p
college NN 1_p
students NNS 1_p
: : 1_p
the DT N
moderating VBG N
effect NN N
of IN N
alcohol-related JJ N
negative JJ N
consequences NNS N
. . N

UNLABELLED JJ N
Web-based JJ 1_i
screening NN 1_i
and CC 1_i
brief JJ 1_i
interventions NNS 1_i
that WDT N
include VBP N
personalized VBN N
feedback NN N
about IN N
their PRP$ N
alcohol NN N
use NN N
have VBP N
proven VBN N
to TO N
be VB N
particularly RB N
promising VBG N
for IN N
reducing VBG N
hazardous JJ 1_p
drinking NN 1_p
among IN 1_p
university JJ 1_p
students NNS 1_p
. . 1_p

Despite IN N
the DT N
increasing VBG N
use NN N
of IN N
these DT N
approaches NNS N
, , N
there EX N
is VBZ N
still RB N
relatively RB N
little JJ N
known VBN N
about IN N
how WRB N
the DT N
content NN N
of IN N
these DT N
interventions NNS N
may MD N
influence VB N
outcomes NNS N
and CC N
who WP N
may MD N
benefit VB N
most JJS N
from IN N
these DT N
approaches NNS N
. . N

The DT N
current JJ N
study NN N
sought VBD N
to TO N
address VB N
these DT N
issues NNS N
by IN N
examining VBG N
how WRB N
individual JJ N
differences NNS N
in IN N
alcohol NN N
consequences NNS N
influence NN N
outcomes NNS N
of IN N
a DT N
laboratory-based JJ 1_i
computerized JJ 1_i
intervention NN 1_i
. . 1_i

METHODS NNP N
One-hundred JJ 1_p
and CC 1_p
nineteen JJ 1_p
introductory NN 1_p
psychology NN 1_p
students NNS 1_p
who WP 1_p
either DT 1_p
had VBD 1_p
two CD 1_p
episodes NNS 1_p
of IN 1_p
heavy JJ 1_p
episodic JJ 1_p
drinking NN 1_p
in IN 1_p
the DT 1_p
past JJ 1_p
month NN 1_p
or CC 1_p
scored VBN 1_p
≥8 NNS 1_p
on IN 1_p
the DT 1_p
AUDIT NNP 1_p
participated VBD 1_p
in IN 1_p
this DT 1_p
randomized VBN 1_p
controlled VBD 1_p
trial NN 1_p
for IN 1_p
course NN 1_p
credit NN 1_p
. . N

Participants NNS N
were VBD N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
in IN N
this DT N
2 CD N
Intervention NNP 1_i
( ( 1_i
Alcohol NNP 1_i
Feedback NNP 1_i
vs. IN 1_i
Control NNP 1_i
) ) 1_i
×2 FW 1_i
Assessment NNP 1_i
( ( 1_i
Motivational NNP 1_i
Assessment NNP 1_i
vs. IN 1_i
No NNP 1_i
Motivational NNP 1_i
Assessment NNP 1_i
) ) 1_i
between-subjects NNS N
design NN 1_o
. . 1_o

Quantity NN 1_o
of IN 1_o
alcohol NN 1_o
consumed VBN 1_o
per IN 1_o
week NN 1_o
and CC 1_o
heavy JJ 1_o
episodic JJ 1_o
drinking VBG 1_o
one CD 1_o
month NN 1_o
later RBR 1_o
were VBD N
the DT N
primary JJ N
dependent JJ N
variables NNS N
. . N

RESULTS NNP N
Controlling VBG N
for IN N
corresponding VBG N
baseline NN 1_o
alcohol NN 1_o
measures NNS 1_o
, , N
hierarchical JJ N
linear JJ N
regression NN N
analyses NNS N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
intervention NN N
condition NN N
and CC N
baseline VB N
alcohol-related JJ N
consequences NNS N
. . N

For IN N
those DT N
who WP N
reported VBD N
more JJR N
alcohol NN N
consequences NNS N
at IN N
baseline NN N
, , N
the DT N
alcohol NN N
intervention NN N
resulted VBD N
in IN N
significantly RB N
less JJR 1_o
alcohol NN 1_o
use NN 1_o
and CC 1_o
fewer JJR 1_o
heavy JJ 1_o
drinking NN 1_o
episodes NNS 1_o
at IN N
follow-up JJ N
, , N
while IN N
no DT N
difference NN N
was VBD N
observed VBN N
between IN N
intervention NN N
conditions NNS N
for IN N
those DT N
with IN N
few JJ N
baseline NN N
consequences NNS N
. . N

Assessment NN N
did VBD N
not RB N
moderate VB N
intervention NN N
effects NNS N
. . N

DISCUSSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN 1_i
a DT 1_i
feedback-based JJ 1_i
computerized JJ 1_i
intervention NN 1_i
that WDT N
includes VBZ N
normative JJ N
information NN N
about IN 1_o
alcohol NN 1_o
use NN 1_o
and CC N
consequences NNS N
may MD N
be VB N
more RBR N
effective JJ N
for IN 1_p
hazardous JJ 1_p
drinking NN 1_p
students NNS 1_p
who WP 1_p
are VBP 1_p
experiencing VBG 1_p
higher JJR 1_p
levels NNS 1_p
of IN 1_p
alcohol-related JJ 1_p
consequences NNS 1_p
. . N

Effects NNS N
of IN N
static JJ 1_i
stretching VBG 1_i
on IN N
repeated VBN 1_o
sprint NN 1_o
and CC 1_o
change NN 1_o
of IN 1_o
direction NN 1_o
performance NN 1_o
. . 1_o

PURPOSE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
static JJ 1_i
stretching VBG 1_i
during IN N
the DT N
recovery NN N
periods NNS N
of IN N
field-based JJ N
team NN N
sports NNS N
on IN N
subsequent NN N
repeated VBN 1_o
sprint JJ 1_o
ability NN 1_o
( ( 1_o
RSA NNP 1_o
) ) 1_o
and CC 1_o
change NN 1_o
of IN 1_o
direction NN 1_o
speed NN 1_o
( ( 1_o
CODS NNP 1_o
) ) 1_o
performance NN 1_o
. . 1_o

METHODS NNP N
On IN N
four CD N
separate JJ N
occasions NNS N
, , N
12 CD 1_p
male JJ 1_p
team-sport NN 1_p
players NNS 1_p
performed VBD N
a DT N
standardized JJ N
warm-up NN N
, , N
followed VBN N
by IN N
a DT N
test NN N
of IN N
either DT N
RSA NNP 1_o
or CC N
CODS NNP 1_i
( ( N
on IN N
two CD N
occasions NNS N
each DT N
) ) N
in IN N
a DT N
counterbalanced JJ N
design NN N
. . N

Both DT N
tests NNS N
involved VBD N
three CD N
sets NNS N
of IN N
six CD 1_i
maximal JJ 1_i
sprint NN 1_i
repetitions NNS 1_i
, , 1_i
with IN 1_i
a DT 1_i
4-min JJ 1_i
recovery NN 1_i
between IN 1_i
sets NNS 1_i
. . 1_i

During IN N
the DT N
break NN N
between IN N
sets NNS N
, , N
the DT N
participants NNS 1_p
either CC N
rested VBN 1_i
( ( 1_i
control VB 1_i
[ NNP 1_i
CON NNP 1_i
] NNP 1_i
) ) 1_i
or CC N
completed VBN N
a DT N
static JJ 1_i
stretching NN 1_i
protocol NN 1_i
( ( 1_i
static JJ 1_i
stretch NN 1_i
[ NNP 1_i
SS NNP 1_i
] NNP 1_i
) ) 1_i
. . N

The DT N
RSA NNP 1_i
test NN N
involved VBN N
straight-line JJ 1_i
sprints NNS 1_i
, , N
whereas IN N
the DT N
CODS NNP 1_i
test NN N
required VBD N
a DT N
change NN N
of IN N
direction NN N
( ( N
100 CD N
degrees NNS N
) ) N
every DT N
4 CD N
m NN N
( ( N
total JJ N
of IN N
four CD N
) ) N
. . N

Mean NNP 1_o
, , 1_o
total NN 1_o
( ( 1_o
sum NN 1_o
of IN 1_o
six CD 1_o
sprints NNS 1_o
) ) 1_o
, , 1_o
first RB 1_o
, , 1_o
and CC 1_o
best JJS 1_o
sprint NN 1_o
times NNS 1_o
( ( 1_o
MST NNP 1_o
, , 1_o
TST NNP 1_o
, , 1_o
FST NNP 1_o
, , 1_o
and CC 1_o
BST NNP 1_o
, , 1_o
respectively RB 1_o
) ) 1_o
were VBD N
recorded VBN N
for IN N
each DT N
set NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
consistent JJ N
tendency NN N
for IN N
RSA NNP 1_o
times NNS 1_o
to TO N
be VB N
slower JJR N
after IN N
the DT N
static JJ 1_i
stretching NN 1_i
intervention NN 1_i
, , N
which WDT N
was VBD N
supported VBN N
by IN N
statistical JJ N
significance NN N
for IN N
three CD N
performance NN N
variables NNS N
( ( N
MST NNP N
0-5 NNP N
m NN N
set NN N
2 CD N
, , N
MST NNP N
0-20 NNP N
m NN N
set NN N
2 CD N
, , N
and CC N
TST NNP N
set VBD N
2 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
tendency NN N
was VBD N
also RB N
supported VBN N
by IN N
moderate JJ N
effect NN N
sizes NNS N
and CC N
qualitative JJ N
indications NNS N
of IN N
" NNP N
likely JJ N
" NNP N
harmful NN N
or CC N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
RSA-SS NNP 1_i
. . 1_i

Further NNP N
, , N
sprint NN 1_o
times NNS 1_o
again RB N
tended VBD N
to TO N
be VB N
slower JJR N
in IN N
the DT N
CODS-SS NNP 1_i
trial NN N
compared VBN N
with IN N
the DT N
CODS-CON NNP 1_i
across IN N
all DT N
sprint NN N
variables NNS N
, , N
with IN N
a DT N
significantly RB N
slower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
BST NNP N
recorded VBD N
for IN N
set NN N
3 CD N
after IN N
static JJ N
stretching NN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
an DT N
acute NN N
bout NN N
( ( N
4 CD N
min NN N
) ) N
of IN N
static JJ 1_i
stretching NN 1_i
of IN N
the DT N
lower JJR N
limbs NN N
during IN N
recovery NN N
periods NNS N
between IN N
efforts NNS N
may MD N
compromise VB N
RSA NNP 1_o
performance NN 1_o
but CC N
has VBZ N
less JJR N
effect NN N
on IN N
CODS NNP 1_o
performance NN 1_o
. . 1_o

A DT N
Placebo-Controlled JJ N
Trial NNP N
of IN N
Obeticholic NNP 1_i
Acid NNP 1_i
in IN N
Primary NNP 1_p
Biliary NNP 1_p
Cholangitis NNP 1_p
. . 1_p

BACKGROUND NNP N
Primary NNP 1_p
biliary JJ 1_p
cholangitis NN 1_p
( ( 1_p
formerly RB 1_p
called VBN 1_p
primary JJ 1_p
biliary JJ 1_p
cirrhosis NN 1_p
) ) 1_p
can MD N
progress VB N
to TO N
cirrhosis VB N
and CC N
death NN N
despite IN N
ursodiol JJ N
therapy NN N
. . N

Alkaline NNP N
phosphatase NN N
and CC N
bilirubin NN N
levels NNS N
correlate VBP N
with IN N
the DT N
risk NN N
of IN N
liver JJ N
transplantation NN N
or CC N
death NN N
. . N

Obeticholic NNP N
acid NN N
, , N
a DT N
farnesoid JJ N
X NNP N
receptor NN N
agonist NN N
, , N
has VBZ N
shown VBN N
potential JJ N
benefit NN N
in IN N
patients NNS N
with IN N
this DT N
disease NN N
. . N

METHODS NNP N
In IN N
this DT N
12-month JJ 1_p
, , 1_p
double-blind JJ 1_p
, , 1_p
placebo-controlled JJ 1_p
, , 1_p
phase VB 1_p
3 CD 1_p
trial NN 1_p
, , 1_p
we PRP 1_p
randomly VBP 1_p
assigned VBD 1_p
217 CD 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
an DT 1_p
inadequate JJ 1_p
response NN 1_p
to TO 1_p
ursodiol VB 1_p
or CC 1_p
who WP 1_p
found VBD 1_p
the DT 1_p
side NN 1_p
effects NNS 1_p
of IN 1_p
ursodiol JJ 1_i
unacceptable JJ 1_p
to TO N
receive VB 1_i
obeticholic JJ 1_i
acid NN 1_i
at IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
10 CD 1_i
mg NN 1_i
( ( 1_i
the DT 1_i
10-mg JJ 1_i
group NN 1_i
) ) 1_i
, , 1_i
obeticholic JJ 1_i
acid NN 1_i
at IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
5 CD 1_i
mg NN 1_i
with IN 1_i
adjustment NN 1_i
to TO 1_i
10 CD 1_i
mg NNS 1_i
if IN 1_i
applicable JJ 1_i
( ( 1_i
the DT 1_i
5-10-mg NNP 1_i
group NN 1_i
) ) 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
an DT N
alkaline JJ 1_o
phosphatase NN 1_o
level NN 1_o
of IN N
less JJR N
than IN N
1.67 CD N
times NNS N
the DT N
upper JJ N
limit NN N
of IN N
the DT N
normal JJ N
range NN N
, , N
with IN N
a DT N
reduction NN N
of IN N
at IN N
least JJS N
15 CD N
% NN N
from IN N
baseline NN N
, , N
and CC N
a DT N
normal JJ N
total JJ N
bilirubin NN 1_o
level NN 1_o
. . 1_o

RESULTS NNP N
Of IN N
216 CD 1_p
patients NNS 1_p
who WP 1_p
underwent JJ 1_p
randomization NN 1_p
and CC 1_p
received VBN 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
dose NN 1_p
of IN 1_p
obeticholic JJ 1_i
acid NN 1_i
or CC 1_p
placebo NN 1_i
, , N
93 CD N
% NN N
received VBD N
ursodiol JJ 1_i
as IN N
background NN N
therapy NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
occurred VBD N
in IN N
more RBR N
patients NNS N
in IN N
the DT N
5-10-mg JJ N
group NN N
( ( N
46 CD N
% NN N
) ) N
and CC N
the DT N
10-mg JJ N
group NN N
( ( N
47 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
10 CD N
% NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
comparisons NNS N
) ) N
. . N

Patients NNS N
in IN N
the DT N
5-10-mg JJ N
group NN N
and CC N
those DT N
in IN N
the DT N
10-mg JJ N
group NN N
had VBD N
greater JJR N
decreases NNS N
than IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
in IN N
the DT N
alkaline JJ 1_o
phosphatase NN 1_o
level NN 1_o
( ( N
least-squares JJ N
mean NN N
, , N
-113 NNP N
and CC N
-130 NNP N
U NNP N
per IN N
liter NN N
, , N
respectively RB N
, , N
vs. FW N
-14 FW N
U NNP N
per IN N
liter NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
comparisons NNS N
) ) N
and CC N
total JJ 1_o
bilirubin NN 1_o
level NN 1_o
( ( N
-0.02 JJ N
and CC N
-0.05 JJ N
mg NN N
per IN N
deciliter NN N
[ NN N
-0.3 NNP N
and CC N
-0.9 NNP N
μmol NNP N
per IN N
liter NN N
] NN N
, , N
respectively RB N
, , N
vs. FW N
0.12 CD N
mg NN N
per IN N
deciliter NN N
[ NN N
2.0 CD N
μmol NN N
per IN N
liter NN N
] NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
comparisons NNS N
) ) N
. . N

Changes NNS N
in IN 1_o
noninvasive JJ 1_o
measures NNS 1_o
of IN 1_o
liver NN 1_o
fibrosis NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
either CC N
treatment NN N
group NN N
and CC N
the DT N
placebo NN N
group NN N
at IN N
12 CD N
months NNS 1_o
. . 1_o

Pruritus NNP 1_o
was VBD N
more RBR N
common JJ N
with IN N
obeticholic JJ N
acid NNS N
than IN N
with IN N
placebo NN N
( ( N
56 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
5-10-mg JJ N
group NN N
and CC N
68 CD N
% NN N
of IN N
those DT N
in IN N
the DT N
10-mg JJ N
group NN N
vs. FW N
38 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
) ) N
. . N

The DT N
rate NN N
of IN 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
was VBD N
16 CD N
% NN N
in IN N
the DT N
5-10-mg JJ N
group NN N
, , N
11 CD N
% NN N
in IN N
the DT N
10-mg JJ N
group NN N
, , N
and CC N
4 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS NNP N
Obeticholic NNP N
acid NN N
administered VBD N
with IN 1_i
ursodiol JJ 1_i
or CC N
as IN N
monotherapy NN N
for IN N
12 CD N
months NNS N
in IN 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
biliary JJ 1_p
cholangitis NN 1_p
resulted VBD N
in IN N
decreases NNS N
from IN N
baseline NN N
in IN 1_o
alkaline JJ 1_o
phosphatase NN 1_o
and CC 1_o
total JJ 1_o
bilirubin NN 1_o
levels NNS 1_o
that WDT N
differed VBD N
significantly RB N
from IN N
the DT N
changes NNS N
observed VBN N
with IN 1_i
placebo NN 1_i
. . N

There EX N
were VBD N
more RBR N
serious JJ N
adverse JJ N
events NNS N
with IN 1_i
obeticholic JJ 1_i
acid NN 1_i
. . N

( ( N
Funded VBN N
by IN N
Intercept NNP N
Pharmaceuticals NNP N
; : N
POISE NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT01473524 NNP N
; : N
Current NNP N
Controlled VBD N
Trials NNP N
number NN N
, , N
ISRCTN89514817 NNP N
. . N

) ) N
. . N

Use NNP N
of IN N
a DT N
clay NN 1_i
modeling VBG 1_i
task NN 1_i
to TO N
reduce VB N
chocolate NN 1_o
craving NN 1_o
. . 1_o

Elaborated VBN N
Intrusion NNP N
theory NN N
( ( N
EI NNP N
theory NN N
; : N
Kavanagh NNP N
, , N
Andrade NNP N
, , N
& CC N
May NNP N
, , N
2005 CD N
) ) N
posits VBZ N
two CD N
main JJ N
cognitive JJ N
components NNS N
in IN N
craving NN 1_o
: : 1_o
associative JJ N
processes NNS N
that WDT N
lead VBP N
to TO N
intrusive VB N
thoughts NNS N
about IN N
the DT N
craved JJ N
substance NN N
or CC N
activity NN N
, , N
and CC N
elaborative JJ N
processes NNS N
supporting VBG N
mental JJ N
imagery NN N
of IN N
the DT N
substance NN N
or CC N
activity NN N
. . N

We PRP N
used VBD N
a DT N
novel JJ 1_i
visuospatial JJ 1_i
task NN 1_i
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
visual JJ N
imagery NN N
plays VBZ N
a DT N
key JJ N
role NN N
in IN N
craving VBG 1_o
. . 1_o

Experiment NN N
1 CD N
showed VBD N
that IN N
spending VBG N
10 CD N
min JJ N
constructing VBG 1_i
shapes NNS 1_i
from IN 1_i
modeling VBG 1_i
clay NN 1_i
( ( 1_i
plasticine NN 1_i
) ) 1_i
reduced VBD N
participants NNS 1_p
' POS 1_p
craving VBG 1_o
for IN 1_o
chocolate NN 1_o
compared VBN N
with IN N
spending NN N
10 CD N
min NN N
'letting VBG 1_i
your PRP$ 1_i
mind NN 1_i
wander NN 1_i
' POS 1_i
. . 1_i

Increasing VBG N
the DT N
load NN N
on IN N
verbal JJ N
working VBG N
memory NN N
using VBG N
a DT N
mental JJ N
arithmetic JJ N
task NN N
( ( N
counting VBG N
backwards NNS N
by IN N
threes NNS N
) ) N
did VBD N
not RB N
reduce VB N
craving VBG 1_o
further RB N
. . N

Experiment JJ N
2 CD N
compared VBN N
effects NNS N
on IN N
craving NN 1_o
of IN N
a DT N
simpler NN 1_i
verbal JJ 1_i
task NN 1_i
( ( 1_i
counting VBG 1_i
by IN 1_i
ones NNS 1_i
) ) 1_i
and CC 1_i
clay NN 1_i
modeling NN 1_i
. . 1_i

Clay NNP 1_i
modeling VBG 1_i
reduced VBN N
overall JJ 1_o
craving NN 1_o
strength NN 1_o
and CC N
strength NN 1_o
of IN 1_o
craving VBG 1_o
imagery NN 1_o
, , N
and CC N
reduced VBD N
the DT N
frequency NN 1_o
of IN 1_o
thoughts NNS 1_o
about IN 1_o
chocolate NN 1_o
. . 1_o

The DT N
results NNS N
are VBP N
consistent JJ N
with IN N
EI NNP N
theory NN N
, , N
showing VBG N
that IN N
craving NN 1_o
is VBZ N
reduced VBN N
by IN N
loading VBG N
the DT N
visuospatial JJ N
sketchpad NN N
of IN N
working VBG N
memory NN N
but CC N
not RB N
by IN N
loading VBG N
the DT N
phonological JJ N
loop NN N
. . N

Clay NNP 1_i
modeling VBG 1_i
might MD N
be VB N
a DT N
useful JJ N
self-help JJ N
tool NN N
to TO N
help VB N
manage VB N
craving VBG 1_o
for IN 1_p
chocolate NN 1_p
, , 1_p
snacks NNS 1_p
and CC 1_p
other JJ 1_p
foods NNS 1_p
. . 1_p

Effect NN N
of IN N
sensory JJ 1_i
stimulation NN 1_i
( ( 1_i
acupuncture NN 1_i
) ) 1_i
on IN N
sympathetic JJ N
and CC N
parasympathetic JJ N
activities NNS N
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

UNLABELLED NN N
It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
sensory JJ 1_i
stimulation NN 1_i
( ( 1_i
acupuncture NN 1_i
) ) 1_i
affects VBZ N
the DT N
cardiovascular JJ N
system NN N
via IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
. . N

Previously RB N
, , N
skin JJ 1_o
temperature NN 1_o
, , 1_o
thermography NN 1_o
, , 1_o
plethysmography NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
changes NNS N
have VBP N
been VBN N
used VBN N
in IN N
evaluation NN N
of IN N
sympathetic JJ N
nerve NN N
activity NN N
following VBG N
acupuncture NN N
. . N

By IN N
using VBG N
power NN N
spectral JJ N
analysis NN N
, , N
the DT N
low JJ N
frequency NN N
and CC N
high JJ N
frequency NN N
components NNS N
of IN N
heart NN N
rate NN N
variability NN N
can MD N
be VB N
calculated VBN N
reflecting VBG N
the DT N
sympathetic JJ N
and CC N
parasympathetic JJ N
activity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
to TO N
what WP N
extent JJ N
acupuncture NN N
applied VBN N
into IN N
the DT N
thenar JJ N
muscle NN N
and CC N
into IN N
the DT N
cavum JJ N
concha NN N
of IN N
the DT N
ear NN N
induced VBD N
changes NNS N
in IN N
the DT N
sympathetic JJ N
and/or NN N
parasympathetic JJ N
nervous JJ N
system NN N
in IN N
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
Twelve NNP 1_p
healthy JJ 1_p
volunteers NNS 1_p
, , 1_p
six CD 1_p
men NNS 1_p
and CC 1_p
six CD 1_p
women NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
34.4 CD 1_p
( ( 1_p
range VB 1_p
23-48 CD 1_p
) ) 1_p
participated VBD N
in IN N
three CD N
balanced NNS N
, , N
randomly RB N
distributed VBN N
sessions NNS N
. . N

At IN N
an DT N
individual JJ N
initial JJ N
visit NN N
the DT N
12 CD N
volunteers NNS N
were VBD N
introduced VBN N
to TO N
the DT N
needle JJ 1_i
sensation NN 1_i
by IN N
having VBG N
a DT N
needle JJ N
inserted VBN N
into IN N
the DT N
point NN N
LI NNP N
11 CD N
. . N

The DT N
needle JJ N
sensation NN N
was VBD N
evoked VBN N
and CC N
the DT N
subject NN N
was VBD N
trained VBN N
to TO N
identify VB N
the DT N
characteristic JJ N
needle JJ N
sensation NN N
. . N

The DT N
introduction NN N
was VBD N
followed VBN N
by IN N
three CD N
test NN N
sessions NNS N
. . N

SESSION VB N
A DT N
A NNP N
short JJ 1_i
acupuncture NN 1_i
needle NN 1_i
, , N
( ( N
Seirin NNP N
no DT N
3 CD N
, , N
& CC N
emptyv NN N
; : N
0.20x15 CD N
mm NN N
) ) N
was VBD N
inserted VBN N
perpendicular JJ N
into IN N
the DT N
earpoint NN N
, , N
Lu NNP N
1 CD N
, , N
in IN N
the DT N
left JJ N
inferior JJ N
hemi-conchae NN N
. . N

SESSION NNP N
B NNP N
An DT N
acupuncture NN 1_i
needle NN 1_i
( ( N
Hwato NNP N
, , N
& CC N
emptyv NN N
; : N
0.30x30 CD N
mm NN N
) ) N
was VBD N
inserted VBN N
perpendicular JJ N
into IN N
the DT N
Hegu NNP N
point NN N
( ( N
LI NNP N
4 CD N
) ) N
in IN N
the DT N
middle NN N
of IN N
the DT N
right JJ N
dorsal NN N
thenar JJ N
muscle NN N
. . N

SESSION NNP N
C NNP N
An DT N
acupuncture NN 1_i
needle NN 1_i
( ( N
Hwato NNP N
, , N
& CC N
emptyv NN N
; : N
0.30x30 CD N
mm NN N
) ) N
was VBD N
inserted VBN N
perpendicular JJ N
superficially RB N
into IN N
the DT N
skin NN N
overlying VBG N
the DT N
Hegu NNP N
point NN N
on IN N
the DT N
left JJ N
hand NN N
. . N

Results NNP N
. . N

Stimulation NNP N
of IN N
the DT N
ear NN N
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
parasympathetic JJ 1_o
activity NN 1_o
during IN N
the DT N
stimulation NN N
period NN N
of IN N
25 CD N
min NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
during IN N
the DT N
post-stimulation JJ N
period NN N
of IN N
60 CD N
min NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
either CC N
the DT N
sympathetic JJ 1_o
activity NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
or CC 1_o
heart NN 1_o
rate NN 1_o
. . 1_o

Stimulation NN N
of IN N
the DT N
thenar NN N
muscle NN N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
sympathetic JJ 1_o
and CC 1_o
the DT 1_o
parasympathetic JJ 1_o
activity NN 1_o
during IN N
the DT N
stimulation NN N
period NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
during IN N
the DT N
post-stimulation JJ N
period NN N
( ( N
P NNP N
< NNP N
0.01 CD N
and CC N
P NNP N
< NNP N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
the DT N
heart NN 1_o
rate NN 1_o
frequency NN 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
post-stimulation JJ N
period NN N
was VBD N
also RB N
demonstrated VBN N
. . N

The DT N
superficial JJ N
needle JJ N
insertion NN N
into IN N
the DT N
skin NN N
overlaying VBG N
the DT N
right JJ N
thenar NN N
muscle NN N
caused VBD N
a DT N
pronounced JJ N
balanced JJ N
increase NN N
in IN N
both CC N
the DT N
sympathetic JJ 1_o
and CC 1_o
parasympathetic JJ 1_o
activity NN 1_o
during IN N
the DT N
post NN N
stimulation NN N
period NN N
of IN N
60 CD N
min NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
while IN N
no DT N
changes NNS N
were VBD N
observed VBN N
during IN N
the DT N
stimulation NN N
period NN N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
indicated VBN N
that IN N
sensory JJ 1_i
stimulation NN 1_i
( ( 1_i
acupunctura NN 1_i
) ) 1_i
in IN N
healthy JJ 1_p
persons NNS 1_p
is VBZ N
associated VBN N
with IN N
changed JJ N
activity NN N
in IN N
the DT N
sympathetic JJ 1_o
and CC 1_o
parasympathetic JJ 1_o
nervous JJ 1_o
system NN 1_o
depending VBG N
on IN N
site NN N
of IN N
stimulation NN N
and CC N
period NN N
of IN N
observation NN N
. . N

Randomized VBN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
risedronate NN 1_i
on IN N
vertebral JJ 1_o
fractures NNS 1_o
in IN N
women NNS 1_p
with IN 1_p
established VBN 1_p
postmenopausal NN 1_p
osteoporosis NN 1_p
. . 1_p

Vertebral JJ N
Efficacy NN N
with IN N
Risedronate NNP N
Therapy NNP N
( ( N
VERT NNP N
) ) N
Study NNP N
Group NNP N
. . N

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN 1_o
risedronate NN 1_o
in IN N
the DT N
prevention NN N
of IN N
vertebral JJ N
fractures NNS N
in IN N
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
established VBN 1_p
osteoporosis NN 1_p
. . 1_p

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
80 CD 1_p
study NN 1_p
centers NNS 1_p
in IN 1_p
Europe NNP 1_p
and CC 1_p
Australia NNP 1_p
. . 1_p

Postmenopausal NNP 1_p
women NNS 1_p
( ( 1_p
n JJ 1_p
= NN 1_p
1226 CD 1_p
) ) 1_p
with IN 1_p
two CD 1_p
or CC 1_p
more JJR 1_p
prevalent JJ 1_p
vertebral JJ 1_o
fractures NNS 1_o
received VBD 1_i
risedronate JJ 1_i
2.5 CD 1_i
or CC 1_i
5 CD 1_i
mg/day NN 1_i
or CC 1_i
placebo NN 1_i
; : 1_i
all DT 1_i
subjects NNS 1_i
also RB 1_i
received VBD 1_i
elemental JJ 1_i
calcium NN 1_i
1000 CD 1_i
mg/day NN 1_i
, , 1_i
and CC 1_i
up RB 1_i
to TO 1_i
500 CD 1_i
IU/day NNP 1_i
vitamin FW 1_i
D NNP 1_i
if IN 1_i
baseline NN 1_i
levels NNS 1_i
were VBD 1_i
low JJ 1_i
. . 1_i

The DT N
study NN N
duration NN N
was VBD N
3 CD N
years NNS N
; : N
however RB N
, , N
the DT 1_i
2.5 CD 1_i
mg NN 1_i
group NN 1_i
was VBD 1_i
discontinued VBN 1_i
by IN 1_i
protocol NN 1_i
amendment NN 1_i
after IN 1_i
2 CD 1_i
years NNS 1_i
. . 1_i

Lateral JJ N
spinal JJ N
radiographs NN N
were VBD N
taken VBN N
annually RB N
for IN N
assessment NN N
of IN N
vertebral JJ 1_o
fractures NNS 1_o
, , 1_o
and CC 1_o
bone RB 1_o
mineral JJ 1_o
density NN 1_o
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
at IN N
6-month JJ N
intervals NNS N
. . N

Risedronate VB N
5 CD N
mg NN N
reduced VBD N
the DT N
risk NN N
of IN N
new JJ 1_o
vertebral JJ 1_o
fractures NNS 1_o
by IN N
49 CD N
% NN N
over IN N
3 CD N
years NNS N
compared VBN N
with IN N
control NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
significant JJ N
reduction NN N
of IN N
61 CD N
% NN N
was VBD N
seen VBN N
within IN N
the DT N
first JJ N
year NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
fracture NN 1_o
reduction NN 1_o
with IN N
risedronate NN N
2.5 CD N
mg NN N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
the DT N
5 CD N
mg NN N
group NN N
over IN N
2 CD N
years NNS N
. . N

The DT N
risk NN N
of IN N
nonvertebral JJ 1_o
fractures NNS 1_o
was VBD N
reduced VBN N
by IN N
33 CD N
% NN N
compared VBN N
with IN N
control NN N
over IN N
3 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Risedronate NNP N
significantly RB N
increased VBD N
bone JJ 1_o
mineral JJ 1_o
density NN 1_o
at IN N
the DT N
spine NN N
and CC N
hip NN N
within IN N
6 CD N
months NNS N
. . N

The DT N
adverse-event JJ N
profile NN N
of IN N
risedronate NN N
, , N
including VBG N
gastrointestinal JJ 1_o
adverse JJ 1_o
events NNS 1_o
, , N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
control NN N
. . N

Risedronate NNP N
5 CD N
mg NN N
provides VBZ N
effective JJ N
and CC N
well-tolerated JJ N
therapy NN N
for IN N
severe JJ 1_p
postmenopausal NN 1_p
osteoporosis NN 1_p
, , N
reducing VBG N
the DT N
incidence NN N
of IN N
vertebral JJ N
fractures NNS N
and CC N
improving VBG N
bone NN N
density NN N
in IN N
women NNS 1_p
with IN 1_p
established VBN 1_p
disease NN 1_p
. . 1_p

Dipyrone NN 1_i
for IN N
treatment NN N
of IN N
post-operative JJ 1_o
pain NN 1_o
. . 1_o

Treatment NN N
of IN N
peri-implantitis NN N
by IN N
the DT N
Vector NNP 1_i
system NN 1_i
. . 1_i

AIM NNP N
To TO N
compare VB N
the DT N
effectiveness NN 1_o
of IN 1_o
treatment NN 1_o
of IN N
peri-implantitis NN N
with IN N
a DT N
novel JJ N
ultrasonic JJ N
device NN N
, , N
the DT N
Vector NNP 1_i
system NN 1_i
, , N
with IN N
that DT N
of IN N
subgingival JJ N
debridement NN N
with IN N
carbon NN N
fiber NN N
curettes NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
, , N
comprising VBG N
11 CD 1_p
patients NNS 1_p
with IN 1_p
at IN 1_p
least JJS 1_p
two CD 1_p
screw JJ 1_p
type NN 1_p
implants NNS 1_p
with IN 1_p
bleeding VBG 1_o
on IN 1_o
probing VBG 1_o
( ( 1_o
BOP NNP 1_o
) ) 1_o
, , 1_o
probing VBG 1_o
pocket NN 1_o
depth NN 1_o
( ( 1_o
PPD NNP 1_o
) ) 1_o
> VBD 1_p
or CC 1_p
=5 JJ 1_p
mm NN 1_p
, , 1_p
and CC 1_p
at IN 1_p
least JJS 1_p
1.5 CD 1_p
mm JJ 1_p
radiographic JJ 1_p
bone NN 1_o
loss NN 1_o
and CC 1_p
exposed VBN 1_p
implant JJ 1_p
threads NNS 1_p
, , N
was VBD N
carried VBN N
out RP N
as IN N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

At IN N
baseline JJ N
one CD N
randomly NN N
chosen VBN N
implant JJ N
in IN N
each DT N
patient NN N
was VBD N
treated VBN N
by IN N
the DT N
Vector NNP 1_i
system NN 1_i
( ( N
test NN N
) ) N
while IN N
the DT N
other JJ N
implant NN N
( ( N
control NN N
) ) N
was VBD N
treated VBN N
by IN N
submucosal JJ N
debridement NN N
with IN N
a DT N
carbon NN 1_i
fiber NN 1_i
curette NN 1_i
. . 1_i

After IN N
3 CD N
months NNS N
, , N
the DT N
same JJ N
treatments NNS N
were VBD N
repeated VBN N
. . N

Plaque NNP 1_o
, , 1_o
BOP NNP 1_o
, , 1_o
and CC 1_o
PPD NNP 1_o
were VBD N
recorded VBN N
on IN N
all DT N
implant JJ N
surfaces NNS N
at IN N
baseline NN N
, , N
and CC N
after IN N
3 CD N
and CC N
6 CD N
months NNS N
. . N

Bone NN 1_o
levels NNS 1_o
were VBD N
recorded VBN N
on IN N
radiographs NN N
taken VBN N
prior RB N
to TO N
the DT N
start NN N
of IN N
the DT N
study NN N
, , N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Oral NNP 1_o
hygiene NN 1_o
around IN N
both DT N
test NN N
and CC N
control NN N
implants NNS N
was VBD N
improved VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
compared VBN N
with IN N
baseline NN N
. . N

At IN N
6 CD N
months NNS N
, , N
four CD N
of IN N
the DT N
Vector-treated NNP 1_i
sites NNS 1_i
, , N
and CC N
only RB N
one CD N
site NN N
treated VBN N
with IN N
curettes NNS N
, , N
had VBD N
stopped VBN N
to TO N
bleed VB 1_o
. . 1_o

In IN N
neither CC N
the DT N
test NN N
nor CC N
the DT N
control NN N
group NN N
, , N
were VBD N
there EX N
any DT N
differences NNS N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
regarding VBG N
PPD NNP 1_o
and CC 1_o
bone NN 1_o
levels NNS 1_o
. . 1_o

CONCLUSION NNP N
Although IN N
there EX N
was VBD N
a DT N
greater JJR N
reduction NN N
in IN N
the DT N
number NN 1_o
of IN 1_o
sites NNS 1_o
with IN 1_o
BOP NNP 1_o
following VBG N
treatment NN N
with IN N
the DT N
Vector NNP 1_i
system NN 1_i
than IN N
following VBG N
instrumentation NN N
with IN N
carbon NN N
fiber NN N
curettes NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
. . N

Use NNP N
of IN N
abciximab NN 1_i
prior RB N
to TO N
primary JJ 1_i
angioplasty NN 1_i
in IN N
STEMI NNP 1_p
results NNS N
in IN N
early JJ N
recanalization NN 1_o
of IN 1_o
the DT 1_o
infarct-related JJ 1_o
artery NN 1_o
and CC N
improved VBN N
myocardial JJ 1_o
tissue NN 1_o
reperfusion NN 1_o
- : N
results NNS N
of IN N
the DT N
Austrian JJ 1_p
multi-centre JJ 1_p
randomized VBN 1_p
ReoPro-BRIDGING NN 1_p
Study NNP 1_p
. . 1_p

AIMS NNP N
The DT N
aim NN N
of IN N
the DT N
ReoPro-BRIDGING JJ 1_p
Austrian JJ 1_p
multi-centre NN 1_p
study NN 1_p
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
abciximab NN 1_i
( ( 1_i
ReoPro NNP 1_i
) ) 1_i
on IN N
early JJ 1_o
reperfusion NN 1_o
in IN 1_o
ST-elevation NNP 1_o
myocardial JJ 1_o
infarction NN 1_o
prior RB N
to TO N
or CC N
during IN N
primary JJ N
percutaneous JJ 1_i
coronary JJ 1_i
angioplasty NN 1_i
( ( 1_i
pPCI NN 1_i
) ) 1_i
. . 1_i

METHODS NNP N
AND CC N
RESULTS NNP N
Fifty-five JJ 1_p
patients NNS 1_p
with IN 1_p
STEMI NNP 1_p
were VBD 1_p
randomized VBN 1_p
either RB 1_p
to TO 1_p
start VB 1_p
abciximab NN 1_i
( ( 1_p
0.25 CD 1_p
mg/kg NN 1_p
bolus NN 1_p
followed VBN 1_p
by IN 1_p
10 CD 1_p
microg/min NNS 1_p
infusion NN 1_p
) ) 1_p
during IN 1_p
the DT 1_p
organization NN 1_p
phase NN 1_p
for IN 1_p
pPCI NN 1_p
( ( 1_p
Group NNP 1_p
1 CD 1_p
, , 1_p
n=28 NN 1_p
) ) 1_p
or CC 1_p
immediately RB 1_p
before IN 1_p
pPCI NN 1_p
( ( 1_p
Group NNP 1_p
2 CD 1_p
, , 1_p
n=27 NN 1_p
) ) 1_p
. . 1_p

The DT N
time NN N
between IN N
first JJ N
bolus NN N
of IN N
abciximab NN 1_i
and CC N
first JJ N
balloon NN N
inflation NN N
of IN N
pPCI NN N
was VBD N
83+/-18 JJ N
vs JJ N
21+/-13 JJ N
min NN N
in IN N
Group NNP N
1 CD N
vs NN N
2 CD N
. . N

The DT N
pre-pPCI JJ 1_o
ST-segment JJ 1_o
resolution NN 1_o
( ( N
55+/-21.4 CD N
% NN N
vs JJ N
42.4+/-18.2 CD N
% NN N
, , N
p=0.005 NN N
) ) N
, , N
TIMI NNP 1_o
flow NN 1_o
grade VBD 1_o
3 CD 1_o
( ( N
29 CD N
% NN N
vs JJ N
7 CD N
% NN N
, , N
p=0.042 NN N
) ) N
, , N
corrected VBN N
TIMI NNP 1_o
frame NN 1_o
count NN 1_o
( ( N
58.4+/-32.7 JJ N
vs NN N
78.9+/-28.4 JJ N
frame NN N
, , N
p=0.018 NN N
) ) N
% NN 1_o
diameter JJ 1_o
stenosis NN 1_o
( ( N
76.3 CD N
/63.5-100/ JJ N
vs NN N
100 CD N
/73.5-100/ NN N
; : N
median JJ N
/interquartile NN N
range/ NN N
, , N
p=0.023 NN N
) ) N
, , N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
1 CD N
vs NN N
Group NNP N
2 CD N
. . N

Quantitative JJ N
myocardial JJ N
dye NN N
intensity NN N
measurement NN N
revealed VBD N
a DT N
significantly RB N
higher JJR N
grade NN N
of IN N
myocardial JJ 1_o
tissue NN 1_o
perfusion NN 1_o
( ( N
1 CD N
/0-9.25/ JJ N
vs NN N
0 CD N
/0-3.0/ JJ N
grey NNS N
pixel JJ N
unit NN N
, , N
p=0.048 NN N
) ) N
in IN N
Group NNP N
1 CD N
before IN N
pPCI NN N
. . N

Rapid JJ N
release NN N
of IN N
cardiac JJ 1_o
enzymes NNS 1_o
was VBD N
observed VBN N
in IN N
Group NNP N
1 CD N
as IN N
compared VBN N
with IN N
Group NNP N
2 CD N
: : N
rate NN N
of IN N
rise NN 1_o
of IN 1_o
CK NNP 1_o
was VBD N
210+/-209 JJ N
vs JJ N
97+/-95 CD N
U/l/h NNP N
( ( N
p=0.015 NN N
) ) N
. . N

QRS NNP 1_o
score RB 1_o
indicated VBD N
a DT N
smaller JJR N
infarct NN 1_o
size NN 1_o
in IN N
Group NNP N
1 CD N
( ( N
4.8+/-3.8 JJ N
vs NN N
7.6+/-3.5 CD N
, , N
p=0.011 NN N
) ) N
on IN N
day NN N
7 CD N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
abciximab NN N
in IN N
the DT N
organization NN N
phase NN N
for IN N
pPCI JJ N
results NNS N
in IN N
signs NNS 1_o
of IN 1_o
early JJ 1_o
recanalization NN 1_o
of IN 1_o
the DT 1_o
infarct-related JJ 1_o
artery NN 1_o
and CC N
a DT N
subsequent JJ N
improved VBN N
myocardial JJ 1_o
tissue NN 1_o
reperfusion NN 1_o
. . 1_o

Studies NNS N
on IN N
section NN 1_o
2D1 CD 1_o
monoclonal JJ 1_o
antibodies NNS 1_o
. . 1_o

Monoclonal JJ N
antibodies NNS N
in IN N
" NNP N
Other JJ N
Blood NNP N
Groups NNP N
" NNP N
were VBD N
tested VBN N
with IN N
random JJ 1_i
blood NN 1_i
samples NNS 1_i
collected VBN N
from IN N
the DT N
various JJ 1_p
ethnic JJ 1_p
groups NNS 1_p
in IN 1_p
KwaZulu-Natal NNP 1_p
, , 1_p
South NNP 1_p
Africa NNP 1_p
, , 1_p
and CC 1_p
with IN 1_p
samples NNS 1_p
of IN 1_p
selected VBN 1_p
red JJ 1_p
cell NN 1_p
phenotypes NNS 1_p
. . 1_p

Standard NNP 1_i
red VBD 1_i
cell NN 1_i
serological JJ 1_i
techniques NNS 1_i
were VBD N
used VBN N
. . N

Safety NN 1_o
and CC N
efficacy NN 1_o
of IN N
irinotecan JJ 1_i
plus CC 1_i
high-dose JJ 1_i
leucovorin NN 1_i
and CC N
intravenous JJ N
bolus JJ N
5-fluorouracil JJ 1_i
for IN N
metastatic JJ 1_p
colorectal JJ 1_p
cancer NN 1_p
: : 1_p
pooled VBN N
analysis NN N
of IN N
two CD N
consecutive JJ N
southern JJ 1_p
Italy NNP 1_p
cooperative JJ 1_p
oncology NN 1_p
group NN 1_p
trials NNS 1_p
. . 1_p

BACKGROUND VB N
A DT N
biweekly JJ N
regimen NN N
of IN N
irinotecan JJ 1_i
200 CD N
mg/m2 NN N
on IN N
day NN N
1 CD N
and CC N
levo-leucovorin JJ 1_i
( ( 1_i
LV NNP 1_i
) ) 1_i
250 CD N
mg/m2 JJ N
plus CC N
5-fluorouracil JJ 1_i
( ( 1_i
5-FU JJ 1_i
) ) 1_i
850 CD N
mg/m2 NN N
via IN N
intravenous JJ N
bolus NNS N
on IN N
day NN N
2 CD N
was VBD N
assessed VBN N
in IN N
2 CD N
consecutive JJ N
randomized VBN N
trials NNS N
in IN N
metastatic JJ 1_p
colorectal NN 1_p
cancer NN 1_p
( ( 1_p
CRC NNP 1_p
) ) 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Individual NNP N
data NN N
of IN N
254 CD 1_p
patients NNS 1_p
were VBD N
merged VBN N
, , N
and CC N
baseline NN N
features NNS N
potentially RB N
affecting VBG N
overall JJ 1_o
response NN 1_o
rate NN 1_o
( ( 1_o
ORR NNP 1_o
) ) 1_o
, , 1_o
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
, , 1_o
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
occurrence NN 1_o
of IN 1_o
severe JJ 1_o
toxicity NN 1_o
were VBD N
analyzed VBN N
by IN N
univariate JJ N
and CC N
multivariate JJ N
analyses NNS N
. . N

RESULTS NNP N
In IN N
the DT N
pooled JJ N
series NN N
, , N
ORR NNP 1_o
was VBD N
33 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
27 CD N
% NN N
-39 NNP N
% NN N
) ) N
. . N

Liver-only JJ N
disease NN N
( ( N
47 CD N
% NN N
vs. FW N
25 CD N
% NN N
; : N
P=0.0012 NNP N
) ) N
and CC N
absence NN N
of IN N
previous JJ N
weight JJ N
loss NN N
( ( N
38 CD N
% NN N
vs. FW N
20 CD N
% NN N
; : N
P=0.0189 NNP N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
a DT N
higher JJR N
ORR NN N
on IN N
the DT N
multivariate NN N
analysis NN N
. . N

Absence NN N
of IN N
weight JJ 1_o
loss NN 1_o
( ( N
hazard JJ N
ratio NN N
, , N
1.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.02-1.93 JJ N
; : N
P=0.0377 NNP N
) ) N
was VBD N
significantly RB N
associated VBN N
with IN N
a DT N
longer RBR N
PFS NNP N
( ( N
7.5 CD N
months NNS N
vs. IN N
6 CD N
months NNS N
) ) N
. . N

Median JJ 1_o
OS NNP 1_o
was VBD N
15.1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
13.5-16.6 JJ N
months NNS N
) ) N
. . N

Primary JJ N
surgery NN N
, , N
good JJ N
performance NN N
status NN N
( ( N
PS NNP N
) ) N
, , N
only RB N
one CD N
metastatic JJ N
site NN N
, , N
and CC N
oxaliplatin-based JJ N
second-line JJ N
treatment NN N
independently RB N
predicted VBD N
a DT N
longer RBR 1_o
OS NNP 1_o
. . 1_o

Grade VB 1_o
4 CD 1_o
neutropenia NN 1_o
was VBD N
significantly RB N
associated VBN N
with IN N
a DT N
PS NNP N
> NNP N
or=1 NN N
, , N
whereas JJ N
risk NN N
of IN N
grade NN N
> NNP N
or=3 NN N
diarrhea NN 1_o
was VBD N
directly RB N
related VBN N
to TO N
age NN N
and CC N
previous JJ N
weight NN N
loss NN N
. . N

CONCLUSION JJ N
Patients NNS N
with IN N
no DT N
weight JJ N
loss NN N
and/or NN N
preserved VBD N
PS NNP N
and CC N
with IN N
a DT N
limited JJ N
disease NN N
extent NN N
appeared VBD N
to TO N
obtain VB N
the DT N
greatest JJS N
benefit NN N
from IN N
our PRP$ N
irinotecan/5-FU/LV JJ 1_i
regimen NNS N
, , N
with IN N
acceptable JJ N
toxicity NN N
. . N

Notably RB N
, , N
the DT N
regimen NNS N
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
by IN N
elderly JJ 1_p
patients NNS 1_p
. . 1_p

This DT N
regimen NN N
may MD N
represent VB N
the DT N
rationale NN N
for IN N
assessing VBG N
the DT N
addition NN N
of IN N
novel JJ N
antiangiogenic JJ N
drugs NNS N
to TO N
the DT N
treatment NN N
of IN N
metastatic JJ N
CRC NNP N
. . N

Sustained VBN N
ventricular JJ N
arrhythmias NNS N
and CC N
mortality NN N
among IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
: : 1_p
results NNS N
from IN N
the DT N
GUSTO-III NNP N
trial NN N
. . N

BACKGROUND NNP N
In IN N
many JJ N
patients NNS N
, , N
ventricular JJ N
arrhythmias NN N
will MD N
develop VB N
early JJ N
after IN N
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

We PRP N
studied VBD N
the DT N
incidence NN N
, , N
timing NN N
, , N
and CC N
outcomes NNS N
of IN N
such JJ N
arrhythmias NNS N
in IN N
the DT N
international JJ N
Global NNP N
Utilization NNP N
of IN N
Streptokinase NNP N
and CC N
TPA NNP N
( ( N
alteplase NN N
) ) N
for IN N
Occluded NNP N
Coronary NNP N
Arteries NNP N
( ( N
GUSTO NNP N
) ) N
-III VBP N
trial NN N
. . N

METHODS NNP N
We PRP 1_i
identified VBD 1_i
independent JJ 1_i
predictors NNS 1_i
of IN 1_i
inhospital JJ 1_i
ventricular JJ 1_i
fibrillation NN 1_i
( ( 1_i
VF NNP 1_i
) ) 1_i
and CC 1_i
ventricular JJ 1_i
tachycardia NN 1_i
( ( 1_i
VT NNP 1_i
) ) 1_i
and CC 1_i
compared VBN 1_i
30-day JJ 1_i
and CC 1_i
1-year JJ 1_i
mortality NN 1_i
rates NNS 1_i
of IN 1_i
patients NNS 1_i
who WP 1_i
did VBD 1_i
( ( 1_i
n VB 1_i
= NNP 1_i
1121 CD 1_i
) ) 1_i
and CC 1_i
did VBD 1_i
not RB 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
13,921 CD 1_i
) ) 1_i
have VBP 1_i
these DT 1_i
arrhythmias NNS 1_i
during IN 1_i
the DT 1_i
index NN 1_i
hospitalization NN 1_i
. . 1_i

RESULTS NNP N
Significant NNP N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VF NNP N
were VBD N
higher JJR N
Killip NNP 1_o
class NN 1_o
, , 1_o
lower JJR 1_o
baseline NN 1_o
systolic JJ 1_o
pressure NN 1_o
, , 1_o
intravenous JJ 1_o
preenrollment NN 1_o
lidocaine NN 1_o
use NN 1_o
, , N
shorter JJR N
time NN N
to TO N
thrombolysis VB 1_o
, , N
and CC N
beta-blocker NN 1_i
use NN 1_i
< VBZ N
2 CD N
weeks NNS N
before IN N
enrollment NN N
; : N
independent JJ N
predictors NNS N
of IN N
inhospital JJ N
VT NNP N
were VBD N
lower JJR N
baseline NN 1_o
systolic JJ 1_o
pressure NN 1_o
, , 1_o
intravenous JJ 1_o
lidocaine NN 1_o
use NN N
before IN N
enrollment NN N
, , N
higher JJR N
Killip NNP N
class NN N
, , N
faster JJR N
baseline JJ 1_o
heart NN 1_o
rate NN 1_o
, , N
and CC N
advanced JJ N
age NN N
. . N

The DT N
30-day JJ 1_o
mortality NN 1_o
rate NN 1_o
was VBD N
31 CD N
% NN N
in IN N
patients NNS N
with IN N
VF NNP N
, , N
24 CD N
% NN N
in IN N
those DT N
with IN N
VT NNP N
, , N
44 CD N
% NN N
in IN N
those DT N
with IN N
both DT N
, , N
and CC N
6 CD N
% NN N
in IN N
those DT N
with IN N
neither DT N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
corresponding JJ N
1-year JJ 1_o
mortality NN 1_o
rates NNS 1_o
were VBD N
34 CD N
% NN N
, , N
29 CD N
% NN N
, , N
49 CD N
% NN N
, , N
and CC N
9 CD N
% NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
30-day JJ 1_o
and CC 1_o
1-year JJ 1_o
mortality NN 1_o
rates NNS 1_o
were VBD N
higher JJR N
for IN N
patients NNS N
with IN N
late JJ N
( ( N
> JJ N
48 CD N
hours NNS N
after IN N
enrollment NN N
) ) N
versus FW N
early JJ N
arrhythmias NN N
( ( N
< CD N
or CC N
=48 VB N
hours NNS N
after IN N
enrollment NN N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
thrombolysis NN N
, , N
inhospital JJ N
ventricular NN N
arrhythmias NNS N
are VBP N
associated VBN N
with IN N
higher JJR N
30-day JJ N
and CC N
1-year JJ N
mortality NN 1_o
rates NNS 1_o
after IN N
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
, , N
particularly RB N
when WRB N
occurring VBG N
later RB N
during IN N
the DT N
initial JJ N
hospitalization NN N
. . N

Better JJR N
therapies NNS N
are VBP N
needed VBN N
to TO N
improve VB N
outcomes NNS N
of IN N
these DT N
arrhythmias NNS N
. . N

Genetic JJ 1_i
testing VBG 1_i
for IN 1_i
BRCA1 NNP N
: : N
effects NNS N
of IN N
a DT N
randomised JJ N
study NN N
of IN N
knowledge NN N
provision NN N
on IN N
interest NN N
in IN N
testing VBG N
and CC N
long JJ N
term NN N
test NN N
uptake NN N
; : N
implications NNS N
for IN N
the DT N
NICE NNP N
guidelines NNS N
. . N

INTRODUCTION JJ N
Interest NNP N
in IN N
searching VBG N
for IN N
mutations NNS N
in IN N
BRCA1 NNP N
and CC N
BRCA2 NNP N
is VBZ N
high JJ N
. . N

Knowledge NNP N
regarding VBG N
these DT N
genes NNS N
and CC N
the DT N
advantages NNS N
and CC N
limitations NNS N
of IN N
genetic JJ N
testing NN N
is VBZ N
limited VBN N
. . N

It PRP N
is VBZ N
unknown JJ N
whether IN N
increasing VBG N
knowledge NN N
about IN N
breast NN N
cancer NN N
genetic JJ N
testing VBG N
alters NNS N
interest NN N
in IN N
testing VBG N
. . N

METHODS NNP N
Three CD 1_p
hundred VBD 1_p
and CC 1_p
seventy JJ 1_p
nine CD 1_p
women NNS 1_p
( ( 1_p
260 CD 1_p
with IN 1_p
a DT 1_p
family NN 1_p
history NN 1_p
of IN 1_p
breast NN 1_p
cancer NN 1_p
; : 1_p
119 CD 1_p
with IN 1_p
breast NN 1_p
cancer NN 1_p
) ) 1_p
from IN 1_p
The DT 1_p
Royal NNP 1_p
Marsden NNP 1_p
NHS NNP 1_p
Foundation NNP 1_p
Trust NNP 1_p
were VBD N
randomised VBN N
to TO N
receive VB 1_i
or CC 1_i
not RB 1_i
receive JJ 1_i
written VBN 1_i
educational JJ 1_i
information NN 1_i
on IN N
cancer NN N
genetics NNS N
. . N

A DT N
questionnaire NN 1_i
was VBD N
completed VBN N
assessing VBG N
interest NN 1_o
in IN 1_o
BRCA1 NNP 1_o
testing VBG 1_o
and CC N
knowledge NN N
on IN N
breast NN N
cancer NN N
genetics NNS N
and CC N
screening VBG N
. . N

Actual JJ N
uptake NN N
of IN N
BRCA1 NNP 1_o
testing NN 1_o
is VBZ N
reported VBN N
with IN N
a DT N
six CD N
year NN N
follow-up RB N
. . N

RESULTS NNP N
Eighty NNP N
nine CD N
percent NN N
of IN N
women NNS N
at IN N
risk NN N
of IN N
breast NN N
cancer NN N
and CC N
76 CD N
% NN N
of IN N
women NNS N
with IN N
breast NN N
cancer NN N
were VBD N
interested JJ N
in IN N
BRCA1 NNP 1_o
testing NN 1_o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Provision NN N
of IN N
educational JJ N
information NN N
did VBD N
not RB N
affect VB N
level NN 1_o
of IN 1_o
interest NN 1_o
. . 1_o

Knowledge NNP 1_o
about IN 1_o
breast NN 1_o
cancer NN 1_o
susceptibility NN 1_o
genes NNS 1_o
was VBD N
poor JJ N
. . N

According VBG N
to TO N
the DT N
NICE NNP N
guidelines NNS N
regarding VBG N
eligibility NN N
for IN N
BRCA1 NNP N
and CC N
BRCA2 NNP N
testing NN N
, , N
the DT N
families NNS N
of IN N
66 CD N
% NN N
of IN N
the DT N
at IN N
risk NN N
group NN N
and CC N
13 CD N
% NN N
of IN N
the DT N
women NNS N
with IN N
breast NN N
cancer NN N
would MD N
be VB N
eligible JJ N
for IN N
testing VBG N
( ( N
probability NN N
of IN N
BRCA1 NNP N
mutation NN N
> NNP N
or=20 CD N
% NN N
) ) N
. . N

Within IN N
six CD N
years NNS N
of IN N
randomisation NN N
, , N
genetic JJ 1_o
testing NN 1_o
was VBD N
actually RB N
undertaken VBN N
on IN N
12 CD N
women NNS N
, , N
only RB N
10 CD N
of IN N
whom WP N
would MD N
now RB N
be VB N
eligible JJ N
, , N
on IN N
the DT N
NICE NNP N
guidelines NNS N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
strong JJ N
interest NN N
in IN N
BRCA1 NNP N
testing VBG N
. . N

Despite IN N
considerable JJ N
ignorance NN N
of IN N
factors NNS N
affecting VBG N
the DT N
inheritance NN N
of IN N
breast NN N
cancer NN N
, , N
education NN N
neither RB N
reduced VBN N
nor CC N
increased JJ N
interest NN 1_o
to TO 1_o
undergo VB 1_o
testing VBG 1_o
. . 1_o

The DT N
NICE NNP N
guidelines NNS N
successfully RB N
triage VBP N
those DT N
with IN N
a DT N
high JJ N
breast NN N
cancer NN N
risk NN N
to TO N
be VB N
managed VBN N
in IN N
cancer NN N
genetics NNS N
clinics NNS N
. . N

Temozolomide NNP 1_i
and CC 1_i
cisplatin VB 1_i
versus NN 1_i
temozolomide NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
melanoma NN 1_p
: : 1_p
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
of IN N
the DT N
Hellenic NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
. . N

PURPOSE NNP N
Temozolomide NNP 1_i
( ( 1_i
TMZ NNP 1_i
) ) 1_i
is VBZ N
an DT N
oral JJ N
alkylating NN N
agent NN N
that WDT N
produces VBZ N
methyl JJ N
adducts NNS N
at IN N
the DT N
0.6 CD N
position NN N
of IN N
guanine NN N
. . N

The DT N
methyl NN N
adducts NNS N
are VBP N
removed VBN N
by IN N
the DT N
DNA NNP N
repair NN N
enzyme JJ N
AGAT NNP N
. . N

As IN N
demonstrated VBN N
by IN N
in IN N
vitro NN N
studies NNS N
, , N
cisplatin NN 1_i
( ( 1_i
CDDP NNP 1_i
) ) 1_i
is VBZ N
able JJ N
to TO N
down-regulate VB N
the DT N
AGAT NNP N
activity NN N
, , N
suggesting VBG N
that IN N
CDDP NNP 1_i
could MD N
enhance VB N
the DT N
antitumor NN 1_o
activity NN 1_o
of IN 1_o
TMZ NNP 1_o
. . 1_o

We PRP N
designed VBD N
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
to TO N
evaluate VB N
and CC N
compare VB N
the DT N
activity NN N
and CC N
safety NN N
profile NN N
of IN N
the DT N
combination NN 1_i
versus IN 1_i
single-agent JJ 1_i
TMZ NNP 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
melanoma NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP 1_p
January NNP 1_p
2000 CD 1_p
to TO 1_p
April NNP 1_p
2002 CD 1_p
, , 1_p
132 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
on IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Patient NNP 1_p
and CC 1_p
tumor NN 1_p
characteristics NNS 1_p
were VBD N
well RB N
balanced VBN N
between IN N
the DT N
two CD N
arms NNS N
. . N

Patients NNS 1_p
with IN 1_p
cerebral JJ 1_p
metastases NNS 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

Patients NNS N
received VBD N
TMZ NNP 1_i
200 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
/day NN 1_i
orally RB 1_i
for IN N
five CD N
consecutive JJ N
days NNS N
every DT N
4 CD N
weeks NNS N
or CC N
TMZ NNP 1_i
+ NNP 1_i
CDDP NNP 1_i
200 CD N
mg/m NN N
( ( N
2 CD N
) ) N
daily RB N
on IN N
days NNS N
1-5 CD N
and CC N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
of IN N
CDDP NNP 1_i
on IN N
day NN N
1 CD N
. . N

RESULTS NNP N
Tumor NNP 1_o
responses VBZ 1_o
( ( N
complete JJ N
and CC N
partial JJ N
responses NNS N
) ) N
were VBD N
seen VBN N
in IN N
16 CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
in IN N
arm NN N
A NN N
and CC N
19 CD N
patients NNS N
( ( N
29 CD N
% NN N
) ) N
in IN N
arm NN N
B NNP N
. . N

The DT N
median JJ 1_o
time NN 1_o
to TO 1_o
progression NN 1_o
( ( 1_o
TTP NNP 1_o
) ) 1_o
was VBD N
3.8 CD N
months NNS N
in IN N
arm NN N
A NN N
and CC N
5.8 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

The DT N
median JJ 1_o
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
was VBD N
11.5 CD N
months NNS N
in IN N
arm NN N
A NN N
and CC N
12 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

The DT N
difference NN N
between IN N
treatment NN N
arms NNS N
regarding VBG N
objective JJ 1_o
response NN 1_o
rates NNS 1_o
, , 1_o
TTP NNP 1_o
and CC 1_o
OS NNP 1_o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Toxicity NN N
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
arms NNS N
for IN N
anemia NN 1_o
, , 1_o
leukopenia NN 1_o
, , 1_o
neutropenia NN 1_o
, , 1_o
thrombocytopenia NN 1_o
, , 1_o
fatigue NN 1_o
, , 1_o
constipation NN 1_o
and CC 1_o
arthralgias/myalgias NN 1_o
. . 1_o

There EX N
was VBD N
significantly RB N
more JJR N
grade JJ 1_o
3 CD 1_o
and CC 1_o
4 CD 1_o
emesis NN 1_o
in IN N
the DT N
combination NN N
arm NN N
. . N

CONCLUSIONS NNP N
No NNP 1_o
clear JJ 1_o
benefit NN 1_o
in IN N
terms NNS N
of IN N
response NN 1_o
rates NNS 1_o
, , 1_o
median JJ 1_o
TTP NNP 1_o
or CC N
OS NNP N
was VBD N
shown VBN N
with IN N
the DT N
combination NN N
of IN N
TMZ NNP 1_i
+ NNP 1_i
CDDP NNP 1_i
. . 1_i

Additionally RB N
, , N
the DT N
combination NN N
was VBD N
associated VBN N
with IN N
higher JJR N
incidence NN N
of IN N
grade NN 1_o
3 CD 1_o
and CC 1_o
4 CD 1_o
emesis NN 1_o
. . 1_o

Cognitive JJ N
effects NNS N
of IN N
lithium NN 1_i
carbonate NN 1_i
and CC 1_i
haloperidol NN 1_i
in IN N
treatment-resistant JJ 1_p
aggressive JJ 1_p
children NNS 1_p
. . 1_p

The DT N
effects NNS N
of IN N
lithium NN 1_i
carbonate NN 1_i
and CC 1_i
haloperidol NN 1_i
on IN N
cognition NN N
were VBD N
examined VBN N
in IN N
a DT N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
study NN N
of IN N
61 CD 1_p
treatment-resistant JJ 1_p
, , 1_p
hospitalized VBN 1_p
school-aged JJ 1_p
children NNS 1_p
. . 1_p

They PRP N
all DT N
had VBD N
a DT N
DSM-III JJ N
diagnosis NN N
of IN N
conduct NN N
disorder NN N
-- : N
undersocialized JJ 1_p
, , 1_p
aggressive JJ 1_p
, , 1_p
with IN 1_p
a DT 1_p
profile NN 1_p
of IN 1_p
highly RB 1_p
explosive JJ 1_p
and CC 1_p
aggressive JJ 1_p
behavior NN 1_p
. . 1_p

Children NNP 1_p
were VBD 1_p
assessed VBN 1_p
at IN 1_p
the DT 1_p
end NN 1_p
of IN 1_p
a DT 1_p
two-week JJ 1_p
placebo-baseline JJ 1_i
period NN 1_p
and CC 1_p
again RB 1_p
after IN 1_p
four CD 1_p
weeks NNS 1_p
of IN 1_p
treatment NN 1_p
. . 1_p

Drug NNP N
effects NNS N
on IN N
cognition NN N
were VBD N
mild JJ N
. . N

Haloperidol NNP 1_i
( ( N
mean JJ N
dose NN N
, , N
2.95 CD N
mg/day NN N
) ) N
caused VBD N
significant JJ N
decreases NNS N
in IN N
Porteus NNP 1_o
Maze NNP 1_o
test NN 1_o
quotient NN 1_o
scores NNS 1_o
and CC N
a DT N
slowing NN 1_o
of IN 1_o
reaction NN 1_o
time NN 1_o
( ( 1_o
RT NNP 1_o
) ) 1_o
on IN N
a DT N
simple JJ N
RT NNP N
task NN N
. . N

Lithium JJ 1_i
carbonate NN 1_i
( ( N
mean JJ N
dose NN N
, , N
1,166 CD N
mg/day NN N
) ) N
adversely RB N
affected JJ N
qualitative JJ 1_o
scores NNS 1_o
on IN 1_o
the DT 1_o
Porteus NNP 1_o
Maze NNP 1_o
test NN 1_o
. . 1_o

No DT N
significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
the DT N
Matching NNP 1_o
Familiar NNP 1_o
Figures NNP 1_o
Test NNP 1_o
, , 1_o
short-term JJ 1_o
recognition NN 1_o
memory NN 1_o
and CC 1_o
concept NN 1_o
attainment NN 1_o
tasks NNS 1_o
, , 1_o
or CC 1_o
the DT 1_o
Stroop NNP 1_o
Test NNP 1_o
. . 1_o

Effectiveness NN N
and CC N
safety NN N
of IN N
the DT N
Levitan NNP 1_i
FPS NNP 1_i
Scope™ NNP 1_i
for IN 1_p
tracheal JJ 1_p
intubation NN 1_p
under IN 1_p
general JJ 1_p
anesthesia NN 1_p
with IN N
a DT 1_p
simulated JJ 1_p
difficult JJ 1_p
airway NN 1_p
. . N

PURPOSE NNP N
Studies NNP N
show VBP N
that IN N
the DT 1_i
Levitan NNP 1_i
FPS NNP 1_i
( ( 1_i
first JJ 1_i
pass NN 1_i
success NN 1_i
) ) 1_i
Scope™ NNP 1_i
( ( 1_i
LFS NNP 1_i
) ) 1_i
is VBZ N
analogous JJ N
to TO N
a DT N
bougie NN N
in IN N
simulated JJ N
difficult JJ N
airways NNS N
with IN N
comparable JJ N
tracheal JJ N
intubation NN N
success NN N
rates NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
with IN N
the DT N
LFS NNP N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
the DT N
Macintosh NNP N
laryngoscope NN N
utilizing VBG N
manual JJ N
in-line JJ N
stabilization NN N
( ( N
MILS NNP N
) ) N
to TO N
simulate VB N
difficult JJ N
airways NNS N
. . N

METHODS NNP 1_p
Ninety-four JJ 1_p
subjects NNS 1_p
successfully RB 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
. . N

Manual JJ N
in-line JJ N
stabilization NN N
of IN N
the DT N
cervical JJ N
spine NN N
was VBD N
applied VBN N
and CC N
the DT 1_i
initial JJ 1_i
laryngoscopy NN 1_i
was VBD N
performed VBN N
using VBG N
either CC N
the DT 1_i
Macintosh NNP 1_i
or CC 1_i
the DT 1_i
LFS NNP 1_i
in IN 1_i
conjunction NN 1_i
with IN 1_i
the DT 1_i
Macintosh NNP 1_i
. . N

Following VBG N
the DT N
initial JJ N
grading NN 1_i
, , 1_i
a DT 1_i
second JJ 1_i
laryngoscopy NN 1_i
was VBD N
repeated VBN N
using VBG N
the DT N
second JJ N
randomized JJ N
technique NN 1_o
. . 1_o

Cormack-Lehane NNP 1_o
grades NNS 1_o
, , 1_o
percentage NN 1_o
of IN 1_o
glottic JJ 1_o
opening NN 1_o
( ( 1_o
POGO NNP 1_o
) ) 1_o
scores VBZ 1_o
, , 1_o
time NN 1_o
to TO 1_o
intubate VB 1_o
, , 1_o
number NN 1_o
of IN 1_o
intubation NN 1_o
attempts NNS 1_o
, , 1_o
and CC 1_o
the DT 1_o
use NN 1_o
of IN 1_o
alternate NN 1_o
techniques NNS 1_o
were VBD N
recorded VBN N
. . N

The DT N
anesthesiologist NN N
rated VBD N
the DT N
subjective JJ N
difficulty NN N
in IN N
using VBG N
each DT N
technique NN N
with IN 1_o
a DT 1_o
numeric JJ 1_o
rating NN 1_o
scale NN 1_o
and CC 1_o
a DT 1_o
visual JJ 1_o
rating NN 1_o
scale NN 1_o
. . N

RESULTS NNP N
There EX N
was VBD 1_o
no DT 1_o
significant JJ 1_o
difference NN 1_o
in IN N
the DT 1_o
primary JJ 1_o
outcome NN 1_o
" NNP 1_o
good JJ 1_o
laryngoscopic NN 1_o
views NNS 1_o
" NNP 1_o
( ( 1_o
Cormack-Lehane NNP 1_o
grade VBD 1_o
1 CD 1_o
and CC 1_o
2 CD N
) ) N
compared VBN N
with IN 1_o
" NNP 1_o
poor JJ 1_o
laryngoscopic NN 1_o
views NNS 1_o
" NNP 1_o
( ( 1_o
Cormack-Lehane NNP 1_o
grade VBD 1_o
3 CD 1_o
and CC 1_o
4 CD N
) ) N
between IN N
the DT N
LFS NNP N
and CC N
the DT N
Macintosh NNP N
. . N

There EX N
were VBD 1_o
higher JJR 1_o
POGO NNP 1_o
scores NNS 1_o
with IN N
the DT N
LFS NNP N
compared VBN N
with IN N
the DT N
Macintosh NNP N
( ( N
80 CD N
% NN N
vs JJ N
20 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
, , N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
( ( N
< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
, , N
respectively RB N
) ) N
. . N

The DT N
incidence NN 1_o
of IN 1_o
mucosal NN 1_o
trauma NN 1_o
, , 1_o
sore RB 1_o
throat NN 1_o
, , 1_o
and CC 1_o
hemodynamic JJ 1_o
responses NNS 1_o
did VBD 1_o
not RB 1_o
differ VB 1_o
significantly RB N
between IN N
the DT N
two CD N
techniques NNS N
. . N

CONCLUSION VB N
The DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT 1_i
Macintosh NNP 1_i
laryngoscope NN 1_i
does VBZ N
not RB N
improve VB N
the DT N
efficacy NN N
or CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
in IN 1_p
a DT 1_p
simulated JJ 1_p
difficult JJ 1_p
airway NN 1_p
. . N

Is VBZ N
individual JJ 1_i
peer NN 1_i
support NN 1_i
a DT N
promising NN N
intervention NN N
for IN N
persons NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
? . N
Peer NNP 1_i
support NN 1_i
has VBZ N
been VBN N
used VBN N
effectively RB N
in IN N
a DT N
variety NN N
of IN N
patient JJ N
populations NNS N
, , N
but CC N
its PRP$ N
effectiveness NN N
in IN N
improving VBG N
outcomes NNS N
in IN N
persons NNS 1_p
with IN 1_p
chronic JJ 1_p
heart NN 1_p
failure NN 1_p
has VBZ N
not RB N
been VBN N
explored VBN N
. . N

We PRP N
trained VBD N
9 CD 1_p
persons NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
to TO 1_p
mentor VB 1_i
other JJ 1_i
heart NN 1_i
failure NN 1_i
patients NNS 1_i
and CC N
tested VBD N
the DT N
effectiveness NN N
of IN N
this DT N
approach NN N
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

A DT N
low JJ N
proportion NN N
( ( 1_p
37 CD 1_p
% NN 1_p
) ) 1_p
of IN 1_p
the DT 1_p
eligible JJ 1_p
population NN 1_p
of IN 1_p
hospitalized JJ 1_p
patients NNS 1_p
agreed VBD 1_p
to TO 1_p
participate VB 1_p
. . 1_p

At IN N
the DT N
end NN N
of IN N
the DT N
3-month JJ N
trial NN N
, , N
there EX N
was VBD N
significantly RB N
higher JJR N
heart NN 1_o
failure NN 1_o
self-care NN 1_o
in IN N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
only JJ N
difference NN N
in IN N
social JJ N
support NN N
was VBD N
a DT N
significant JJ N
decline NN N
in IN N
perceived JJ N
support NN 1_o
reciprocity NN 1_o
in IN N
the DT N
intervention NN N
group NN N
( ( N
F NNP N
= NNP N
5.94 CD N
, , N
P NNP N
= NNP N
.004 NNP N
) ) N
. . N

No DT N
significant JJ N
group NN N
differences NNS N
in IN N
heart NN 1_o
failure NN 1_o
readmissions NNS 1_o
, , 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
, , 1_o
or CC 1_o
cost NN 1_o
were VBD N
evident JJ N
at IN N
90-days CD N
, , N
although IN N
the DT N
heart NN 1_o
failure NN 1_o
readmission NN 1_o
rate NN 1_o
was VBD N
96 CD N
% NN N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
when WRB N
compared VBN N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
reasons NNS N
for IN N
low JJ 1_o
overall JJ 1_o
enrollment NN 1_o
and CC 1_o
high JJ 1_o
readmission NN 1_o
rates NNS 1_o
in IN N
the DT N
intervention NN N
group NN N
require VBP N
further JJ N
study NN N
. . N

Including VBG N
additional JJ N
self-care JJ N
education NN N
by IN N
a DT N
professional JJ N
, , N
rather RB N
than IN N
leaving VBG N
all PDT N
the DT N
education NN N
to TO N
the DT N
mentor NN N
, , N
could MD N
strengthen VB N
the DT N
peer NN N
support NN N
intervention NN N
trialed VBN N
in IN N
this DT N
study NN N
. . N

Small NNP N
group NN N
meetings NNS N
may MD N
be VB N
less JJR N
intrusive JJ N
and CC N
more RBR N
desirable JJ N
for IN N
this DT N
patient JJ N
population NN N
. . N

Reduced VBN N
mortality NN N
among IN N
children NNS 1_p
in IN 1_p
southern JJ 1_p
India NNP 1_p
receiving VBG 1_p
a DT 1_p
small JJ 1_p
weekly JJ 1_p
dose NN 1_p
of IN 1_p
vitamin NN 1_i
A NNP 1_i
. . 1_i

BACKGROUND NNP N
Clinical NNP N
vitamin VBD N
A DT N
deficiency NN N
affects VBZ N
millions NNS N
of IN N
children NNS N
worldwide IN N
, , N
and CC N
subclinical JJ N
deficiency NN N
is VBZ N
even RB N
more RBR N
common JJ N
. . N

Supplemental JJ N
vitamin NN N
A NNP N
has VBZ N
been VBN N
reported VBN N
to TO N
reduce VB N
mortality NN N
among IN N
these DT N
children NNS N
, , N
but CC N
the DT N
results NNS N
have VBP N
been VBN N
questioned VBN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
, , N
masked VBD N
clinical JJ N
trial NN N
for IN N
one CD N
year NN N
in IN 1_p
southern JJ 1_p
India NNP 1_p
involving VBG 1_p
15,419 CD 1_p
preschool-age JJ 1_p
children NNS 1_p
who WP 1_p
received VBD 1_p
either CC 1_p
8.7 CD 1_i
mumol NN 1_i
( ( 1_i
8333 CD 1_i
IU NNP 1_i
) ) 1_i
of IN 1_i
vitamin NN 1_i
A NNP 1_i
and CC 1_i
46 CD 1_i
mumol NN 1_i
( ( 1_i
20 CD 1_i
mg NN 1_i
) ) 1_i
of IN 1_i
vitamin NN 1_i
E NNP 1_i
( ( 1_i
the DT 1_i
treated VBN 1_i
group NN 1_i
) ) 1_i
or CC 1_i
vitamin JJ 1_i
E NNP 1_i
alone RB 1_i
( ( 1_i
the DT 1_i
control NN 1_i
group NN 1_i
) ) 1_i
. . N

Vitamin JJ 1_i
supplements NNS 1_i
were VBD N
delivered VBN N
weekly JJ N
by IN N
community NN N
health NN N
volunteers NNS N
who WP N
also RB N
recorded VBD N
mortality NN 1_o
and CC 1_o
morbidity NN 1_o
. . 1_o

Weekly JJ N
contact NN N
was VBD N
made VBN N
with IN N
at IN N
least JJS N
88 CD N
percent NN N
of IN N
the DT N
children NNS N
in IN N
both DT N
study NN N
groups NNS N
. . N

The DT N
base-line JJ N
characteristics NNS N
of IN N
the DT N
children NNS N
were VBD N
similar JJ N
and CC N
documented VBD N
a DT N
high JJ N
prevalence NN N
of IN N
vitamin NN N
A NNP N
deficiency NN N
and CC N
undernutrition NN N
. . N

RESULTS NNP N
One CD N
hundred VBD N
twenty-five JJ N
deaths NNS N
occurred VBD N
, , N
of IN N
which WDT N
117 CD N
were VBD N
not RB N
accidental JJ N
. . N

The DT N
risk NN 1_o
of IN 1_o
death NN 1_o
in IN N
the DT N
group NN N
treated VBD N
with IN N
vitamin NN N
A NNP N
was VBD N
less JJR N
than IN N
half NN N
that IN N
in IN N
the DT N
control NN N
group NN N
( ( N
relative JJ N
risk NN N
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.30 CD N
to TO N
0.71 CD N
) ) N
. . N

The DT N
risk NN N
was VBD N
most RBS N
reduced JJ N
among IN N
children NNS N
under IN N
3 CD N
years NNS N
of IN N
age NN N
( ( N
6 CD N
to TO N
11 CD N
months NNS N
-- : N
relative JJ N
risk NN N
, , N
0.28 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.09 CD N
to TO N
0.85 CD N
; : N
12 CD N
to TO N
35 CD N
months NNS N
-- : N
relative JJ N
risk NN N
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.26 CD N
to TO N
0.81 CD N
) ) N
and CC N
among IN N
those DT N
who WP N
were VBD N
chronically RB N
undernourished JJ N
, , N
as IN N
manifested VBN N
by IN N
stunting VBG N
( ( N
relative JJ N
risk NN N
, , N
0.11 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.03 CD N
to TO N
0.36 CD N
) ) N
. . N

The DT N
symptom-specific JJ 1_o
risk NN 1_o
of IN 1_o
mortality NN 1_o
was VBD N
significantly RB N
associated VBN N
with IN N
diarrhea NN 1_o
, , 1_o
convulsions NNS 1_o
, , 1_o
and CC 1_o
other JJ 1_o
infection-related JJ 1_o
symptoms NNS 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
regular JJ N
provision NN N
of IN N
a DT N
supplement NN N
of IN N
vitamin NN 1_i
A NNP 1_i
to TO N
children NNS N
, , N
at IN N
a DT N
level NN N
potentially RB N
obtainable JJ N
from IN N
foods NNS N
, , N
in IN N
an DT N
area NN N
where WRB N
vitamin NN N
A DT N
deficiency NN N
and CC N
under-nutrition NN N
are VBP N
documented VBN N
public JJ N
health NN N
problems NNS N
contributed VBD N
substantially RB N
to TO N
children NNS N
's POS N
survival NN N
; : N
mortality NN N
was VBD N
reduced VBN N
on IN N
average NN N
by IN N
54 CD N
percent NN N
. . N

Effectiveness NN N
and CC N
safety NN N
of IN N
inhaled JJ N
treprostinil NN 1_i
for IN N
the DT N
treatment NN N
of IN N
pulmonary JJ 1_p
arterial JJ 1_p
hypertension NN 1_p
in IN 1_p
children NNS 1_p
. . 1_p

The DT N
introduction NN N
of IN N
prostanoid NN 1_i
therapy NN 1_i
has VBZ N
revolutionized VBN N
the DT N
treatment NN N
of IN N
pulmonary JJ N
arterial JJ N
hypertension NN N
( ( N
PAH NNP N
) ) N
. . N

However RB N
, , N
continuous JJ N
intravenous JJ N
prostacyclin NN 1_i
infusion NN N
poses VBZ N
significant JJ N
risks NNS N
and CC N
challenges NNS N
, , N
particularly RB N
in IN N
children NNS 1_p
. . 1_p

Inhaled VBN N
treprostinil NN 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
efficacious JJ N
in IN N
adults NNS N
. . N

This DT N
study NN N
describes VBZ N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
inhaled JJ N
treprostinil NN 1_i
in IN N
children NNS 1_p
with IN 1_p
PAH NNP 1_p
. . 1_p

A NNP N
retrospective JJ N
analysis NN N
of IN N
29 CD 1_p
children NNS 1_p
treated VBN 1_p
with IN 1_p
inhaled JJ 1_p
treprostinil NN 1_i
for IN 1_p
≥6 JJ 1_p
weeks NNS 1_p
was VBD 1_p
performed VBN 1_p
. . N

Effects NNS N
of IN N
inhaled JJ 1_i
treprostinil NN 1_i
on IN N
exercise NN N
capacity NN N
, , N
functional JJ N
class NN N
, , N
and CC N
echocardiographic JJ N
and CC N
hemodynamic JJ N
data NNS N
were VBD N
evaluated VBN N
. . N

Adverse JJ N
events NNS N
were VBD N
documented VBN N
. . N

Patients NNS N
received VBD N
3 CD N
to TO N
9 CD N
breaths NNS N
( ( N
6 CD N
μg/breath NN N
) ) N
of IN N
inhaled VBN 1_i
treprostinil NN 1_i
4 CD N
times/day NN N
. . N

All DT N
were VBD N
receiving VBG 1_i
background NN 1_i
PAH NNP 1_i
therapy NN 1_i
; : 1_i
12 CD N
had VBD N
previously RB N
received VBN N
parenteral JJ N
prostanoid NN N
. . N

Inhaled VBD 1_i
treprostinil NN 1_i
was VBD N
discontinued VBN N
in IN 1_p
4 CD 1_p
patients NNS 1_p
because IN N
of IN N
symptoms NNS N
including VBG 1_o
cough NN 1_o
and CC 1_o
bronchospasm NN 1_o
( ( N
n JJ N
= NNP N
3 CD N
) ) N
and CC 1_o
progression NN 1_o
of IN 1_o
PAH NNP 1_o
( ( N
n JJ N
= NNP N
1 CD 1_o
) ) 1_o
. . 1_o

Mild JJ 1_o
side JJ 1_o
effects NNS 1_o
including VBG 1_o
cough NN 1_o
( ( N
n JJ N
= NNP N
9 CD N
) ) N
and CC 1_o
sore $ 1_o
throat NN 1_o
( ( N
n JJ N
= NNP N
6 CD N
) ) N
did VBD N
not RB N
require VB N
discontinuation NN N
of IN N
therapy NN 1_o
. . 1_o

World NNP 1_o
Health NNP 1_o
Organization NNP 1_o
functional JJ 1_o
class NN 1_o
improved VBN N
in IN N
19 CD N
and CC N
was VBD N
unchanged JJ N
in IN N
10 CD 1_o
; : 1_o
exercise NN 1_o
capacity NN 1_o
significantly RB N
improved VBN N
with IN N
the DT N
6-minute JJ N
walk NN N
distance NN N
, , N
improving VBG N
on IN N
follow-up NN N
from IN N
455.7 CD N
± $ N
71.5 CD N
to TO N
498 CD N
± NNS N
70 CD N
m NN N
( ( N
p JJ N
= NNP N
0.01 CD 1_o
) ) 1_o
and CC 1_o
peak JJ 1_o
oxygen NN 1_o
consumption NN 1_o
increasing VBG N
from IN N
25.5 CD N
± $ N
10.2 CD N
to TO N
27.4 CD N
± NNS N
10 CD N
( ( N
p NN N
= RB N
0.04 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
inhaled VBD N
treprostinil NN N
was VBD N
associated VBN N
with IN N
improvement NN 1_o
in IN 1_o
exercise NN 1_o
capacity NN 1_o
and CC 1_o
World NNP 1_o
Health NNP 1_o
Organization NNP 1_o
functional JJ 1_o
class NN N
when WRB N
added VBD N
to TO N
background VB N
targeted JJ 1_p
PAH NNP 1_p
therapy NN 1_p
in IN 1_p
children NNS 1_p
and CC N
had VBD N
an DT N
acceptable JJ N
safety NN N
profile NN N
. . N

Based VBN N
on IN N
these DT N
early JJ N
data NNS N
, , N
further JJ N
study NN N
of IN N
inhaled JJ 1_i
treprostinil NN 1_i
appears VBZ N
warranted VBN 1_p
in IN 1_p
pediatric JJ 1_p
patients NNS 1_p
with IN 1_p
PAH NNP N
. . N

Weighted VBN 1_i
blankets NNS 1_i
and CC N
sleep NN N
in IN N
autistic JJ 1_p
children NNS 1_p
-- : 1_p
a DT 1_p
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
weighted-blanket JJ 1_i
intervention NN 1_i
in IN N
treating VBG N
severe JJ 1_p
sleep NN 1_p
problems NNS 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
This DT N
phase NN N
III NNP N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
crossover NN N
design NN N
. . N

Participants NNS 1_p
were VBD 1_p
aged VBN 1_p
between IN 1_p
5 CD 1_p
years NNS 1_p
and CC 1_p
16 CD 1_p
years NNS 1_p
10 CD 1_p
months NNS 1_p
, , 1_p
with IN 1_p
a DT 1_p
confirmed JJ 1_p
ASD NNP 1_p
diagnosis NN 1_p
and CC 1_p
severe JJ 1_p
sleep NN 1_p
problems NNS 1_p
, , 1_p
refractory NN 1_p
to TO 1_p
community-based JJ 1_p
interventions NNS 1_p
. . 1_p

The DT N
interventions NNS N
were VBD N
either RB N
a DT N
commercially RB 1_i
available JJ 1_i
weighted JJ 1_i
blanket NN 1_i
or CC 1_i
otherwise RB 1_i
identical JJ 1_i
usual JJ 1_i
weight NN 1_i
blanket NN 1_i
( ( N
control NN N
) ) N
, , N
introduced VBN N
at IN N
bedtime NN N
; : N
each DT N
was VBD N
used VBN N
for IN N
a DT N
2-week JJ N
period NN N
before IN N
crossover NN N
to TO N
the DT N
other JJ N
blanket NN N
. . N

Primary JJ N
outcome NN N
was VBD N
total JJ 1_o
sleep JJ 1_o
time NN 1_o
( ( 1_o
TST NNP 1_o
) ) 1_o
recorded VBN N
by IN N
actigraphy NN N
over IN N
each DT N
2-week JJ N
period NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
actigraphically RB 1_o
recorded VBN 1_o
sleep-onset JJ 1_o
latency NN 1_o
, , 1_o
sleep JJ 1_o
efficiency NN 1_o
, , 1_o
assessments NNS 1_o
of IN 1_o
child NN 1_o
behavior NN 1_o
, , 1_o
family NN 1_o
functioning NN 1_o
, , 1_o
and CC 1_o
adverse JJ 1_o
events NNS 1_o
. . 1_o

Sleep NNP N
was VBD N
also RB N
measured VBN N
by IN N
using VBG N
parent-report JJ N
diaries NNS N
. . N

RESULTS NNP N
Seventy-three JJ 1_p
children NNS 1_p
were VBD 1_p
randomized VBN 1_p
and CC 1_p
analysis NN 1_p
conducted VBN 1_p
on IN 1_p
67 CD 1_p
children NNS 1_p
who WP 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

Using VBG N
objective JJ N
measures NNS N
, , N
the DT N
weighted JJ 1_i
blanket NN 1_i
, , N
compared VBN N
with IN N
the DT N
control NN 1_i
blanket NN 1_i
, , N
did VBD N
not RB N
increase VB N
TST NNP 1_o
as IN N
measured VBN N
by IN N
actigraphy NN N
and CC N
adjusted VBN N
for IN N
baseline NN N
TST NNP N
. . N

There EX N
were VBD N
no DT N
group NN N
differences NNS N
in IN N
any DT N
other JJ N
objective NN 1_o
or CC 1_o
subjective JJ 1_o
measure NN 1_o
of IN 1_o
sleep NN 1_o
, , N
including VBG N
behavioral JJ N
outcomes NNS N
. . N

On IN N
subjective JJ N
preference NN N
measures NNS N
, , N
parents NNS N
and CC N
children NNS N
favored VBD N
the DT N
weighted JJ 1_i
blanket NN 1_i
. . 1_i

CONCLUSIONS VB N
The DT N
use NN N
of IN N
a DT N
weighted JJ 1_i
blanket NN 1_i
did VBD N
not RB N
help VB N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
sleep NN N
for IN N
a DT N
longer JJR N
period NN N
of IN N
time NN N
, , N
fall VB N
asleep RB N
significantly RB N
faster RBR N
, , N
or CC N
wake VB N
less JJR N
often RB N
. . N

However RB N
, , N
the DT N
weighted JJ 1_i
blanket NN 1_i
was VBD N
favored VBN N
by IN N
children NNS N
and CC N
parents NNS N
, , N
and CC N
blankets NNS N
were VBD N
well RB 1_o
tolerated VBN 1_o
over IN N
this DT N
period NN N
. . N

A DT N
play NN 1_i
and CC 1_i
joint JJ 1_i
attention NN 1_i
intervention NN 1_i
for IN N
teachers NNS 1_p
of IN 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
pilot VB N
test VB N
a DT N
classroom-based JJ N
intervention NN N
focused VBD N
on IN N
facilitating VBG N
play NN N
and CC N
joint JJ N
attention NN N
for IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
in IN 1_p
self-contained JJ 1_p
special JJ 1_p
education NN 1_p
classrooms NNS 1_p
. . 1_p

Thirty-three JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
3 CD 1_p
and CC 1_p
6 CD 1_p
years NNS 1_p
participated VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
with IN 1_p
their PRP$ 1_p
classroom NN 1_p
teachers NNS 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
14 CD 1_p
) ) 1_p
. . 1_p

The DT N
14 CD 1_p
preschool NN 1_p
special JJ 1_p
education NN 1_p
teachers NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
symbolic NN 1_i
play NN 1_i
then RB 1_i
joint JJ 1_i
attention NN 1_i
intervention NN 1_i
, , N
( ( N
2 CD N
) ) N
joint NN 1_i
attention NN 1_i
then RB 1_i
symbolic JJ 1_i
intervention NN 1_i
, , N
and CC N
( ( N
3 CD N
) ) N
wait-list NN 1_i
control NN 1_i
period NN 1_i
then RB 1_i
further RB 1_i
randomized VBN 1_i
to TO 1_i
either DT 1_i
group NN 1_i
1 CD 1_i
or CC 1_i
group NN 1_i
2 CD 1_i
. . 1_i

In IN N
the DT N
intervention NN N
, , N
teachers NNS N
participated VBD N
in IN N
eight CD N
weekly JJ N
individualized VBN N
1-h JJ N
sessions NNS N
with IN N
a DT N
researcher NN N
that WDT N
emphasized VBD N
embedding VBG N
strategies NNS N
targeting VBG N
symbolic JJ N
play NN N
and CC N
joint JJ N
attention NN N
into IN N
their PRP$ N
everyday JJ N
classroom NN N
routines NNS N
and CC N
activities NNS N
. . N

The DT N
main JJ N
child NN N
outcome NN N
variables NNS N
of IN N
interest NN N
were VBD N
collected VBN N
through IN N
direct JJ N
classroom NN N
observations NNS N
. . N

Findings NNS N
indicate VBP N
that IN N
teachers NNS N
can MD N
implement VB N
an DT N
intervention NN 1_o
to TO 1_o
significantly RB 1_o
improve VB 1_o
joint JJ 1_o
engagement NN 1_o
of IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
in IN 1_p
their PRP$ 1_p
classrooms NNS 1_p
. . 1_p

Furthermore RB N
, , N
multilevel NN N
analyses NNS N
showed VBD N
significant JJ 1_o
increases NNS 1_o
in IN 1_o
joint JJ 1_o
attention NN 1_o
and CC 1_o
symbolic JJ 1_o
play NN 1_o
skills NNS 1_o
. . 1_o

Thus RB N
, , N
these DT N
pilot NN N
data NNS N
emphasize VBP N
the DT N
need NN N
for IN N
further JJ N
research NN N
and CC N
implementation NN N
of IN N
classroom-based JJ N
interventions NNS N
targeting VBG N
play NN 1_o
and CC 1_o
joint JJ 1_o
attention NN 1_o
skills NNS 1_o
for IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

The DT N
" NNP N
SPEM NNP N
" NNP N
( ( N
Studio NNP N
Policentrico NNP N
Elettrocateteri NNP N
Membrane NNP N
) ) N
: : N
a DT N
multicenter NN N
study NN N
on IN N
membrane NN 1_p
leads NNS 1_p
. . 1_p

SPEM NNP N
is VBZ N
a DT N
multicenter NN 1_p
randomized VBN N
double-blind NN N
study NN N
performed VBD N
to TO N
test VB N
the DT N
acute NN 1_o
and CC 1_o
chronic JJ 1_o
electrophysiological JJ 1_o
behavior NN 1_o
of IN N
three CD N
different JJ N
ventricular JJ 1_p
leads NNS 1_p
: : 1_p
( ( N
1 CD N
) ) N
an DT 1_i
ion NN 1_i
exchange NN 1_i
membrane NN 1_i
with IN 1_i
30-microgram JJ 1_i
dexamethasone NN 1_i
elution NN 1_i
in IN 1_i
a DT 1_i
contoured JJ 1_i
activated JJ 1_i
carbon NN 1_i
tip NN 1_i
lead NN 1_i
( ( N
Membrane NNP N
1400T CD N
, , N
30 CD N
patients NNS N
) ) N
; : N
( ( N
2 CD N
) ) N
the DT 1_i
same JJ 1_i
lead NN 1_i
design NN 1_i
without IN 1_i
steroid NN 1_i
( ( N
Membrane NNP N
1401T CD N
, , N
24 CD N
patients NNS N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT 1_i
same JJ 1_i
lead NN 1_i
design NN 1_i
without IN 1_i
steroid NN 1_i
or CC 1_i
membrane NN 1_i
( ( N
control NN N
group NN N
, , N
27 CD N
patients NNS N
) ) N
. . N

Twenty-three CD 1_p
of IN 1_p
the DT 1_p
81 CD 1_p
patients NNS 1_p
were VBD 1_p
women NNS 1_p
; : 1_p
the DT 1_p
mean JJ 1_p
age NN 1_p
for IN 1_p
all DT 1_p
patients NNS 1_p
was VBD 1_p
74 CD 1_p
+/- JJ 1_p
10 CD 1_p
years NNS 1_p
. . 1_p

Parameters NNS N
are VBP N
calculated VBN N
both DT N
in IN N
uni- JJ N
and CC N
bipolar JJ N
configuration NN N
at IN N
implant JJ N
and CC N
at IN N
follow-up JJ N
after IN N
1 CD N
, , N
5 CD N
, , N
15 CD N
, , N
30 CD N
, , N
90 CD N
, , N
180 CD N
, , N
and CC N
360 CD N
days NNS N
. . N

Implant JJ N
threshold NN N
( ( N
chronaxie JJ N
= $ N
0.413 CD N
+/- JJ N
0.280 CD N
ms NN N
, , N
rheobase VB N
= JJ N
0.264 CD N
+/- JJ N
0.099 CD N
V NNP N
) ) N
, , N
signal JJ N
amplitude NN N
( ( N
13.45 CD N
+/- JJ N
5.87 CD N
mV NN N
) ) N
, , N
and CC N
slew JJ N
rate NN N
( ( N
2.05 CD N
+/- JJ N
1.38 CD N
V/s NNP N
) ) N
reveal VBP N
no DT N
significant JJ N
differences NNS N
. . N

Pacing VBG 1_o
impedance NN 1_o
values NNS 1_o
both DT N
at IN N
implant NN N
( ( N
unipolar JJ N
571 CD N
+/- JJ N
165 CD N
omega NN N
; : N
bipolar JJ N
605 CD N
+/- JJ N
123 CD N
omega NN N
) ) N
and CC N
at IN N
follow-ups NNS N
( ( N
unipolar JJ N
480 CD N
+/- JJ N
72 CD N
omega NN N
; : N
bipolar JJ N
518 CD N
+/- JJ N
75 CD N
omega NN N
) ) N
are VBP N
slightly RB N
lower JJR N
in IN N
the DT N
unipolar JJ N
configuration NN N
. . N

At IN N
15 CD N
and CC N
30-day JJ N
follow-ups NNS N
, , N
control NN N
group NN N
and CC N
nonsteroid JJ N
leads VBZ N
show VB N
a DT N
higher JJR N
threshold JJ 1_o
value NN N
growth NN N
( ( N
in IN N
unipolar NN N
from IN N
0.16 CD N
+/- JJ N
0.11 CD N
to TO N
1.19 CD N
+/- JJ N
0.85 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.18 CD N
+/- JJ N
0.13 CD N
to TO N
1.24 CD N
+/- JJ N
0.88 CD N
microJ NN N
) ) N
than IN N
the DT N
membrane NN N
steroid NN N
leads VBZ N
( ( N
in IN N
unipolar NN N
from IN N
0.13 CD N
+/- JJ N
0.11 CD N
to TO N
0.70 CD N
+/- JJ N
0.39 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.23 CD N
+/- JJ N
0.32 CD N
to TO N
0.76 CD N
+/- JJ N
0.36 CD N
microJ NN N
) ) N
; : N
the DT N
threshold NN 1_o
of IN N
nonsteroid JJ N
leads NNS N
decreases NNS N
after IN N
1-3 JJ N
months NNS N
and CC N
it PRP N
settles VBZ N
at IN N
the DT N
same JJ N
threshold JJ 1_o
level NN N
of IN N
the DT N
leads NNS N
with IN N
membrane NN N
and CC N
steroid NN N
( ( N
in IN N
unipolar JJ N
0.60 CD N
+/- JJ N
0.33 CD N
microJ NN N
; : N
in IN N
bipolar JJ N
0.55 CD N
+/- JJ N
0.26 CD N
microJ NN N
) ) N
, , N
which WDT N
has VBZ N
been VBN N
stable JJ N
since IN N
the DT N
first JJ N
month NN N
. . N

The DT N
ion NN 1_i
exchange NN 1_i
membrane NN 1_i
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
chronic JJ 1_o
pacing NN 1_o
threshold NN 1_o
like IN N
acute JJ N
steroid JJ N
elution NN N
at IN N
low JJ N
doses NNS N
, , N
but CC N
membrane FW N
alone RB N
does VBZ N
not RB N
prevent VB N
an DT N
acute JJ 1_o
pacing NN 1_o
threshold JJ 1_o
increase NN N
through IN N
the DT N
first JJ N
month NN N
postimplant NN N
. . N

Vilazodone NN 1_i
lacks VBZ N
proarrhythmogenic JJ N
potential NN N
in IN N
healthy JJ 1_p
participants NNS 1_p
: : 1_p
a DT N
thorough JJ N
ECG NNP N
study NN N
. . N

OBJECTIVE NNP N
Vilazodone NNP 1_i
is VBZ N
a DT N
potent JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
and CC N
5-HT1A JJ N
receptor NN N
partial JJ N
agonist NN N
approved VBD N
for IN N
the DT N
treatment NN N
of IN N
major JJ 1_p
depressive JJ 1_p
disorder NN 1_p
( ( 1_p
MDD NNP 1_p
) ) 1_p
in IN 1_p
adults NNS 1_p
. . 1_p

The DT N
effect NN N
of IN N
clinical JJ N
and CC N
supratherapeutic JJ N
doses NNS N
of IN N
vilazodone NN 1_i
on IN N
cardiac JJ N
repolarization NN N
was VBD N
determined VBN N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

METHODS NNP N
In IN N
this DT N
Phase NNP N
1 CD N
, , N
randomized VBN N
, , N
doubleblind VB N
, , N
placebo- JJ 1_i
and CC N
active-controlled JJ N
, , N
3-arm JJ N
, , N
parallel JJ N
, , N
single-center JJ N
study NN N
, , N
healthy JJ 1_p
subjects NNS 1_p
received VBD N
placebo NN 1_i
; : 1_i
moxifloxacin CC 1_i
400 CD 1_i
mg NN 1_i
; : 1_i
or CC 1_i
vilazodone NN 1_i
( ( N
sequentially RB N
escalated VBN N
every DT N
3 CD N
days NNS N
) ) N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
80 CD N
mg/day NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time-matched JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
QT NNP 1_o
interval NN 1_o
corrected VBD 1_o
for IN 1_o
heart NN 1_o
rate NN 1_o
( ( 1_o
QTc NNP 1_o
) ) 1_o
using VBG N
an DT N
individual JJ N
correction NN N
method NN N
( ( N
QTcI NNP N
) ) N
. . N

RESULTS JJ N
Placebo-corrected JJ 1_i
time-matched JJ N
analysis NN N
of IN N
the DT N
QTcI NNP 1_o
duration NN 1_o
for IN N
the DT N
vilazodone NN 1_i
treatment NN N
effect NN N
indicated VBD N
that IN N
no DT N
vilazodone NN 1_i
dose NN N
had VBD N
an DT N
upper JJ N
bound NN N
that IN N
approached VBD N
or CC N
exceeded VBD N
10 CD N
ms NN N
, , N
demonstrating VBG N
no DT N
signal NN N
for IN N
a DT N
significant JJ N
vilazodone NN 1_i
effect NN N
on IN N
cardiac JJ 1_o
repolarization NN 1_o
. . 1_o

Vilazodone NNP 1_i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
heart NN 1_o
rate NN 1_o
, , 1_o
PR NNP 1_o
, , 1_o
or CC 1_o
QRS NNP 1_o
interval JJ 1_o
duration NN 1_o
. . 1_o

The DT N
pharmacokinetic/pharmacodynamic JJ N
model NN N
showed VBD N
that IN N
the DT N
QTcI NNP 1_o
slope NN N
for IN N
vilazodone NN 1_i
was VBD N
not RB N
different JJ N
from IN N
0.0 CD N
and CC N
that IN N
the DT N
predicted JJ N
increase NN N
from IN N
baseline NN N
in IN N
the DT N
QTc NNP 1_o
at IN 1_o
Cmax NNP 1_o
for IN N
the DT N
highest JJS N
therapeutic JJ N
dose NN N
( ( N
156 CD N
ng/ml RB N
after IN N
40 CD N
mg/day NN N
) ) N
was VBD N
< JJ N
1 CD N
ms NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ 1_o
events NNS 1_o
( ( 1_o
AEs NNP 1_o
) ) 1_o
was VBD N
higher RBR N
in IN N
the DT N
vilazodone NN 1_i
group NN N
( ( N
57.6 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
moxifloxacin NN 1_i
( ( N
37.0 CD N
% NN N
) ) N
and CC N
placebo NN 1_i
( ( N
35.6 CD N
% NN N
) ) N
groups NNS N
, , N
though IN N
AEs NNP 1_o
were VBD N
generally RB N
mild VBN N
to TO N
moderate VB N
in IN N
severity NN N
and CC N
resulted VBD N
in IN N
few JJ N
discontinuations NNS N
. . N

CONCLUSIONS NNP N
Vilazodone NNP 1_i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
cardiac JJ 1_o
repolarization NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
PR NNP 1_o
or CC 1_o
QRS NNP 1_o
interval JJ 1_o
duration NN 1_o
, , 1_o
or CC 1_o
ECG NNP 1_o
morphology NN 1_o
in IN N
healthy JJ 1_p
adult NN 1_p
participants NNS 1_p
. . 1_p

[ JJ N
Comparison NNP N
of IN N
two CD N
methods NNS N
of IN N
local JJ 1_i
anaesthesia NN 1_i
prior RB N
to TO N
transrectal VB N
ultrasound-guided JJ N
prostate NN N
biopsies NNS N
] VBP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
rectal JJ N
administration NN N
of IN N
Lidocaïne NNP 1_i
gel NN 1_i
with IN 1_i
Lidocaïne NNP 1_i
periprostatic JJ 1_i
infiltration NN 1_i
prior RB N
to TO N
transrectal VB N
ultrasound-guided JJ N
prostate NN N
biopsies NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP 1_p
Between NNP 1_p
July NNP 1_p
2002 CD 1_p
and CC 1_p
July NNP 1_p
2003 CD 1_p
, , 1_p
candidates NNS 1_p
to TO 1_p
prostate VB 1_p
biopsies NNS 1_p
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
group NN N
1 CD 1_i
, , 1_i
15 CD 1_i
ml VBD 1_i
2 CD 1_i
% NN 1_i
Lidocaïne NNP 1_i
gel NN 1_i
was VBD 1_i
administered VBN N
intra-rectally RB N
10 CD N
minutes NNS N
prior RB N
to TO N
biopsies NNS N
and CC N
patients NNS N
included VBD N
in IN N
group NN N
2 CD N
received VBD N
10 CD N
ml NN N
of IN 1_i
1 CD 1_i
% NN 1_i
Lidocaïne NNP 1_i
in IN 1_i
two CD 1_i
périprostatique JJ 1_i
equivalent JJ 1_i
injections NNS 1_i
, , N
4 CD N
minutes NNS N
prior RB N
to TO N
prostate VB N
biopsies NNS N
. . N

Pain NN N
was VBD N
assessed VBN N
with IN 1_o
a DT 1_o
Visual JJ 1_o
Analog NNP 1_o
Scale NNP 1_o
, , N
during IN N
anaesthesia NN N
( ( N
VAS NNP N
1 CD N
) ) N
, , N
during IN N
the DT N
biopsies NNS N
procedure NN N
( ( N
VAS NNP N
2 CD N
) ) N
and CC N
30 CD N
minutes NNS N
after IN N
them PRP N
( ( N
VAS NNP N
3 CD N
) ) N
. . N

RESULTS $ 1_p
308 CD 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
this DT 1_p
trial NN 1_p
with IN 1_p
156 CD 1_p
patients NNS 1_p
in IN 1_p
group NN 1_p
1 CD 1_p
and CC 1_p
152 CD 1_p
in IN 1_p
group NN 1_p
2 CD N
. . N

Group NNP N
1 CD N
experienced VBD N
statistically RB N
less JJR N
pain NN 1_o
for IN 1_o
VAS NNP 1_o
1 CD N
( ( N
0.1 CD N
versus NN N
1.4 CD N
, , N
p NN N
< NNP N
0.0001 CD 1_o
) ) 1_o
and CC 1_o
VAS $ 1_o
3 CD N
( ( N
0.8 CD N
versus NN N
1.4 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
but CC N
no DT N
significative JJ N
difference NN N
could MD N
be VB N
demonstrated VBN 1_o
for IN 1_o
VAS NNP 1_o
2 CD N
( ( N
1.8 CD N
versus IN N
2.0 CD 1_o
) ) 1_o
. . 1_o

No DT 1_o
major JJ 1_o
complication NN 1_o
was VBD N
noted VBN N
. . N

CONCLUSION NNP N
Rectal NNP N
administration NN 1_i
of IN 1_i
Lidocaïne NNP 1_i
gel NN N
and CC N
infiltration NN 1_i
of IN 1_i
Lidocaïne NNP 1_i
lead NN N
to TO N
a DT N
comparable JJ N
level NN N
of IN N
anaesthesia NN N
during IN N
prostatic JJ N
biopsies NNS N
procedure NN N
. . N

However RB 1_i
, , 1_i
the DT 1_i
Lidocaïne NNP 1_i
gel NN N
, , N
being VBG N
both DT N
safe JJ N
and CC N
simple JJ N
, , N
tends VBZ N
to TO N
maintain VB N
a DT N
better JJR N
comfort NN N
of IN N
the DT N
patient NN N
30 CD N
minutes NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
biopsies NNS N
. . N

The DT N
sequencing NN N
of IN N
chemotherapy NN 1_i
and CC N
radiation NN 1_i
therapy NN 1_i
after IN N
conservative JJ 1_p
surgery NN 1_p
for IN 1_p
early-stage JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

BACKGROUND NNP N
Patients NNPS 1_p
with IN 1_p
early-stage JJ 1_p
breast NN 1_p
cancer NN 1_p
who WP 1_p
are VBP 1_p
at IN 1_p
substantial JJ 1_p
risk NN 1_p
for IN 1_p
systemic JJ 1_p
metastases NNS 1_p
are VBP N
increasingly RB N
treated VBN N
with IN N
breast-conserving JJ 1_i
therapy NN 1_i
and CC 1_i
adjuvant JJ 1_i
chemotherapy NN 1_i
. . 1_i

However RB N
, , N
the DT N
optimal JJ N
sequencing NN N
of IN N
chemotherapy NN 1_i
and CC 1_i
radiation NN 1_i
therapy NN 1_i
is VBZ N
not RB N
clear JJ N
. . N

METHODS NNP N
Two CD 1_p
hundred VBD 1_p
forty-four JJ 1_p
patients NNS 1_p
with IN 1_p
stage NN 1_p
I PRP 1_p
or CC 1_p
II NNP 1_p
breast NN 1_p
cancer NN 1_p
who WP 1_p
were VBD 1_p
at IN 1_p
substantial JJ 1_p
risk NN 1_p
for IN 1_p
distant JJ 1_p
metastases NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
12-week JJ 1_i
course NN 1_i
of IN 1_i
chemotherapy NN 1_i
either CC 1_i
before IN 1_i
or CC 1_i
after IN 1_i
radiation NN 1_i
therapy NN 1_i
. . 1_i

All DT 1_p
had VBD 1_p
had VBN 1_p
breast-conserving JJ 1_p
surgery NN 1_p
. . 1_p

The DT N
median JJ N
length NN N
of IN N
follow-up NN N
in IN N
surviving VBG N
patients NNS N
was VBD N
58 CD N
months NNS N
( ( N
range NN N
, , N
10 CD N
to TO N
124 CD N
) ) N
. . N

RESULTS VB N
The DT N
five-year JJ 1_o
actuarial JJ 1_o
rates NNS 1_o
of IN 1_o
cancer NN 1_o
recurrence NN 1_o
at IN N
any DT N
site NN N
and CC N
of IN N
distant JJ N
metastases NNS N
in IN N
the DT N
radiotherapy-first JJ 1_i
group NN N
and CC N
the DT N
chemotherapy-first JJ 1_i
group NN N
were VBD N
38 CD N
percent NN N
and CC N
31 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.17 CD N
) ) N
and CC N
36 CD N
percent NN N
and CC N
25 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Overall JJ 1_o
survival NN 1_o
was VBD N
73 CD N
percent NN N
and CC N
81 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
five-year JJ 1_o
crude NN 1_o
rates NNS 1_o
of IN 1_o
first JJ 1_o
recurrence NN 1_o
according VBG N
to TO N
site NN N
in IN N
the DT N
radiotherapy-first JJ 1_i
and CC 1_i
chemotherapy-first JJ 1_i
groups NNS N
, , N
respectively RB N
, , N
were VBD N
5 CD N
percent NN N
and CC N
14 CD N
percent NN N
for IN N
local JJ N
recurrence NN N
and CC N
32 CD N
percent NN N
and CC N
20 CD N
percent NN N
for IN N
distant NN N
or CC N
regional JJ N
recurrence NN N
or CC N
both DT N
. . N

This DT N
difference NN N
in IN N
the DT N
pattern NN 1_o
of IN 1_o
recurrence NN 1_o
was VBD N
of IN N
borderline JJ N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
for IN N
patients NNS 1_p
ar VBP 1_p
substantial JJ 1_p
risk NN 1_p
for IN 1_p
systemic JJ 1_p
metastases NNS 1_p
, , N
it PRP N
is VBZ N
preferable JJ N
to TO N
give VB N
a DT N
12-week JJ N
course NN N
of IN N
chemotherapy NN 1_i
followed VBN N
by IN N
radiation NN 1_i
therapy NN 1_i
, , N
rather RB N
than IN N
radiation NN 1_i
therapy NN 1_i
followed VBN 1_i
by IN 1_i
chemotherapy NN 1_i
. . 1_i

Treatment NN 1_i
of IN 1_i
periodontal JJ 1_i
disease NN 1_i
and CC 1_p
the DT 1_p
risk NN 1_p
of IN 1_p
preterm JJ 1_o
birth NN 1_o
. . 1_o

The DT N
effects NNS N
of IN N
candesartan NN 1_i
on IN N
diabetes NNS 1_o
glomerulopathy NNS 1_o
: : 1_o
a DT N
double-blind NN N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
study VB N
the DT N
effects NNS N
of IN N
candesartan NN 1_i
on IN N
diabetic JJ 1_o
glomerulopathy NN 1_o
in IN N
young JJ 1_p
normoalbuminuric JJ 1_p
and CC 1_p
normotensive JJ 1_p
patients NNS 1_p
with IN 1_p
type JJ 1_p
1 CD 1_p
diabetes NNS 1_p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

In IN N
13 CD 1_p
patients NNS 1_p
aged VBN 1_p
24 CD 1_p
years NNS 1_p
at IN 1_p
baseline NN 1_p
, , N
we PRP N
evaluated VBD N
blood NN N
pressure NN N
, , N
kidney NN N
biopsies NNS N
and CC N
kidney NN N
function NN N
tests NNS N
at IN N
baseline NN N
and CC N
after IN N
5 CD N
years NNS N
of IN N
treatment NN N
. . N

Kidney NNP N
biopsies NNS N
were VBD N
examined VBN N
with IN N
light JJ N
and CC N
electron JJ N
microscopy NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
and CC N
effective JJ N
renal JJ N
plasma NN N
flow NN N
determined VBD N
with IN N
inulin NN N
and CC N
para-aminohippuric JJ N
acid NN N
clearances NNS N
. . N

Two CD N
patients NNS N
in IN N
the DT N
placebo NN 1_i
group NN N
needed VBD N
antihypertensive JJ N
treatment NN N
because IN N
they PRP N
developed VBD N
microalbuminuria NNS 1_o
and/or JJ 1_o
hypertension NN 1_o
, , N
but CC N
no DT N
patient NN N
in IN N
the DT N
candesartan NN 1_i
group NN N
did VBD N
. . N

A DT N
significant JJ N
reduction NN N
in IN N
mesangial JJ 1_o
matrix NN 1_o
volume NN 1_o
and CC 1_o
mesangial JJ 1_o
volume NN 1_o
occurred VBD N
in IN N
the DT N
candesartan NN N
group NN N
, , N
although IN N
changes NNS N
in IN N
morphological JJ 1_o
parameters NNS 1_o
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

Office NNP 1_o
blood NN 1_o
pressure NN 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
candesartan NN 1_i
group NN N
at IN N
follow-up NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
. . N

Deterioration NN N
in IN N
morphological JJ 1_o
parameters NNS 1_o
observed VBD N
in IN N
earlier JJR N
studies NNS N
of IN N
our PRP$ N
patients NNS N
did VBD N
not RB N
become VB N
worse JJR N
during IN N
treatment NN N
with IN N
candesartan NN 1_i
or CC N
placebo NN 1_i
. . 1_i

The DT N
effects NNS N
of IN N
candesartan NN 1_i
, , N
with IN N
reduction NN N
in IN N
morphological JJ 1_o
parameters NNS 1_o
and CC 1_o
lowering NN 1_o
of IN 1_o
blood NN 1_o
pressure NN 1_o
, , N
might MD N
influence VB N
future JJ N
treatment NN N
of IN N
glomerulopathy NN N
in IN N
type NN 1_p
1 CD 1_p
diabetes VBZ 1_p
patients NNS 1_p
. . 1_p

Low-dose JJ N
mifepristone NN 1_i
for IN N
uterine JJ N
leiomyomata NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
5 CD N
and CC N
10 CD N
mg NN N
of IN N
mifepristone NN 1_i
on IN N
uterine JJ 1_o
leiomyoma NN 1_o
size NN 1_o
and CC 1_o
symptoms NNS 1_o
, , N
and CC N
to TO N
measure VB N
side JJ N
effects NNS N
. . N

METHODS NNP N
Forty NNP 1_p
premenopausal JJ 1_p
women NNS 1_p
with IN 1_p
large JJ 1_p
, , 1_p
symptomatic JJ 1_p
leiomyomata NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB 1_i
either RB 1_i
5 CD 1_i
or CC 1_i
10 CD 1_i
mg NN 1_i
of IN 1_i
mifepristone JJ 1_i
daily JJ 1_i
for IN 1_i
6 CD 1_i
months NNS 1_i
in IN 1_i
an DT 1_i
open-label JJ 1_i
study NN 1_i
. . 1_i

Uterine NNP N
volume NN N
was VBD N
measured VBN N
at IN N
bimonthly JJ N
intervals NNS N
by IN N
sonography NN N
. . N

Serum NNP N
concentrations NNS N
of IN N
hemoglobin NN N
levels NNS N
, , N
follicle-stimulating JJ N
hormone NN N
, , N
and CC N
liver RB N
enzymes NNS N
were VBD N
obtained VBN N
, , N
and CC N
endometrial JJ N
samples NNS N
, , N
symptoms NNS N
, , N
and CC N
menstrual JJ N
bleeding NN N
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
Nineteen NNP 1_p
of IN 1_p
20 CD 1_p
subjects NNS 1_p
taking VBG N
5 CD N
mg NN N
and CC N
all DT N
20 CD N
subjects NNS N
taking VBG N
10 CD N
mg NN N
completed VBD N
all DT N
6 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

Mean NNP 1_o
uterine JJ 1_o
volume NN 1_o
shrank NN 1_o
by IN N
48 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
5-mg JJ N
group NN N
and CC N
49 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
10-mg JJ N
group NN N
, , N
a DT N
nonsignificant JJ N
difference NN N
. . N

Leiomyoma-related JJ 1_o
symptoms NNS 1_o
were VBD N
comparably RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

Amenorrhea NNP 1_o
occurred VBD N
in IN N
60-65 CD N
% NN N
of IN N
both DT N
groups NNS N
. . N

Hemoglobin NNP 1_o
levels NNS 1_o
increased VBN N
by IN N
2.5 CD N
g/dL NNS N
in IN N
anemic JJ N
subjects NNS N
. . N

The DT N
incidence NN N
of IN N
hot JJ 1_o
flashes NNS 1_o
increased VBD N
significantly RB N
over IN N
baseline NN N
in IN N
the DT N
10-mg JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
5-mg JJ N
group NN N
. . N

Simple NNP 1_o
endometrial JJ 1_o
hyperplasia NN 1_o
occurred VBD N
in IN N
28 CD N
% NN N
of IN N
all DT N
subjects NNS N
, , N
with IN N
no DT N
difference NN N
between IN N
groups NNS N
. . N

No DT N
atypical JJ 1_o
hyperplasia NN 1_o
was VBD N
noted VBN N
. . N

CONCLUSION NNP N
Mifepristone NNP 1_i
in IN N
doses NNS N
of IN N
5 CD N
mg NNS N
or CC N
10 CD N
mg JJ N
results NNS N
in IN N
comparable JJ N
leiomyoma NN 1_o
regression NN 1_o
, , 1_o
improvement NN 1_o
in IN 1_o
symptoms NNS 1_o
, , 1_o
and CC 1_o
few JJ 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

Further NNP N
study NN N
is VBZ N
needed VBN N
to TO N
assess VB N
the DT N
long-term JJ N
safety NN N
and CC N
efficacy NN N
of IN N
low-dose JJ N
mifepristone NN 1_i
. . 1_i

Evaluation NN N
of IN N
a DT N
new JJ N
wound NN N
closure NN N
device NN N
for IN N
linear JJ 1_p
surgical JJ 1_p
incisions NNS 1_p
: : 1_p
3M CD 1_i
Steri-Strip JJ 1_i
S NNP 1_i
Surgical NNP 1_i
Skin NNP 1_i
Closure NNP 1_i
versus IN 1_i
subcuticular JJ 1_i
closure NN 1_i
. . 1_i

BACKGROUND NNP N
Technological JJ N
innovations NNS N
are VBP N
often RB N
adopted VBN N
before IN N
scientific JJ N
comparison NN N
to TO N
an DT N
accepted JJ N
standard NN N
. . N

The DT N
authors NNS N
' POS N
study NN N
compared VBN N
suture NN N
with IN N
a DT N
new JJ 1_i
coaptive JJ 1_i
film NN 1_i
device NN 1_i
, , 1_i
3M CD 1_i
Steri-Strip JJ 1_i
S NNP 1_i
Surgical NNP 1_i
Skin NNP 1_i
Closure NNP 1_i
, , 1_i
on IN 1_i
linear JJ 1_i
incisions NNS 1_i
. . 1_i

METHODS NNP N
Patients NNPS 1_p
undergoing VBG 1_p
Wise-pattern JJ 1_p
breast NN 1_p
reduction NN 1_p
or CC 1_p
abdominal JJ 1_p
procedures NNS 1_p
had VBD N
paired VBN N
incisions NNS N
randomly RB N
assigned VBN N
to TO N
Steri-Strip NNP 1_i
S NNP 1_i
or CC 1_i
suture JJ 1_i
closure NN 1_i
. . 1_i

Key NNP N
outcome JJ N
measures NNS N
were VBD N
closure JJ 1_o
time NN 1_o
, , 1_o
patient JJ 1_o
comfort NN 1_o
, , 1_o
and CC 1_o
scar NN 1_o
quality NN 1_o
at IN N
6 CD N
months NNS N
by IN N
patients NNS N
and CC N
surgeons NNS N
using VBG N
a DT N
new JJ 1_i
scar NN 1_i
evaluation NN 1_i
tool NN 1_i
, , N
visual JJ N
assessment NN N
of IN N
linear JJ N
scars NNS N
. . N

Statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
closure NN N
techniques NNS N
were VBD N
assessed VBN N
by IN N
Wilcoxon NNP N
signed VBD N
rank JJ N
test NN N
. . N

RESULTS NNP N
Of IN 1_p
59 CD 1_p
patients NNS 1_p
, , 1_p
eight CD 1_p
were VBD 1_p
excluded VBN 1_p
from IN 1_p
randomization NN 1_p
( ( N
a DT N
surgeon NN N
judged VBN N
Steri-Strip NNP N
S NNP N
to TO N
be VB N
a DT N
nonviable JJ N
closure NN N
technique NN N
for IN N
mismatched VBN N
wound NN N
edges NNS N
) ) N
. . N

Fifty-one CD 1_p
patients NNS 1_p
( ( 1_p
breast NN 1_p
, , 1_p
n JJ 1_p
= VBP 1_p
24 CD 1_p
; : 1_p
abdomen NNS 1_p
, , 1_p
n JJ 1_p
= NNP 1_p
27 CD 1_p
) ) 1_p
were VBD N
randomized VBN N
. . N

Operative JJ 1_o
time NN 1_o
with IN N
Steri-Strip NNP 1_i
S NNP 1_i
for IN N
breast NN N
was VBD N
2.0 CD N
minutes NNS N
( ( N
SD NNP N
= NNP N
1.1 CD N
) ) N
versus NN N
suture NN 1_i
closure NN 1_i
at IN N
4.6 CD N
minutes NNS N
( ( N
SD NNP N
= NNP N
1.5 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
. . N

Similarly RB N
, , N
Steri-Strip NNP N
S NNP N
versus NN N
suture NN N
for IN N
the DT N
abdomen NNS N
was VBD N
faster RBR 1_o
( ( N
p JJ N
< VBZ N
0.001 CD N
; : N
4.9 CD N
minutes NNS N
, , N
SD NNP N
= VBZ N
2.3 CD N
versus NN N
10.1 CD N
minutes NNS N
, , N
SD NNP N
= NNP N
3.4 CD N
) ) N
. . N

Comfort NNP 1_o
scores NNS 1_o
did VBD N
not RB N
differ VB N
between IN N
closures NNS N
[ VBP N
5.8 CD N
( ( N
SD NNP N
= NNP N
2.7 CD N
) ) N
versus NN N
6.9 CD N
( ( N
SD NNP N
= NNP N
2.0 CD N
) ) N
, , N
respectively RB N
, , N
on IN N
breast NN N
( ( N
p JJ N
= NNP N
0.142 CD N
) ) N
and CC N
7.7 CD N
( ( N
SD NNP N
= NNP N
1.8 CD N
) ) N
versus NN N
7.7 CD N
( ( N
SD NNP N
= NNP N
2.3 CD N
) ) N
on IN N
abdomen NNS N
( ( N
p JJ N
= NNP N
0.903 CD N
) ) N
] NN N
. . N

Complication NN 1_o
rates NNS 1_o
did VBD N
not RB N
differ VB N
between IN N
closure NN N
types NNS N
. . N

Patients NNS 1_o
' POS 1_o
visual JJ 1_o
assessment NN 1_o
of IN 1_o
linear JJ 1_o
scars NNS 1_o
rating NN 1_o
of IN 1_o
breasts NNS 1_o
was VBD N
3.8 CD N
( ( N
SD NNP N
= NNP N
2.9 CD N
) ) N
for IN N
Steri-Strip NNP N
S NNP N
and CC N
better JJR N
at IN N
2.6 CD N
( ( N
SD NNP N
= NNP N
2.9 CD N
) ) N
for IN N
suture NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

One CD N
surgeon NN N
rated VBN N
breast IN N
Steri-Strip NNP N
S NNP N
scars VBZ N
worse JJR N
than IN N
suture NN N
scars NNS N
( ( N
4.3 CD N
versus NN N
3.7 CD N
; : N
p NN N
= VBZ N
0.014 CD N
) ) N
. . N

For IN N
abdominal JJ N
scars NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
patient NN N
or CC N
surgeon NN N
ratings NNS N
. . N

CONCLUSIONS NNP N
Steri-Strip NNP 1_i
S NNP 1_i
permits VBZ N
faster JJR N
wound IN 1_o
closure NN 1_o
than IN N
suture NN 1_i
. . 1_i

On IN N
the DT N
basis NN N
of IN N
patient JJ N
reports NNS N
of IN N
comfort NN 1_o
and CC 1_o
scar NN 1_o
quality NN 1_o
, , N
surgeons NNS N
increase VBP N
efficiency NN 1_o
and CC N
maintain VBP N
quality NN 1_o
with IN N
the DT N
use NN N
of IN N
Steri-Strip NNP N
S NNP N
on IN N
abdominal JJ N
wounds NNS N
but CC N
not RB N
on IN N
breast NN N
wounds NNS N
. . N

Dose-response JJ 1_o
and CC 1_o
concentration-response JJ 1_o
relation NN N
of IN N
rocuronium NN 1_i
infusion NN 1_i
during IN N
propofol-nitrous JJ 1_i
oxide NN 1_i
and CC N
isoflurane-nitrous JJ 1_i
oxide NN 1_i
anaesthesia NN 1_i
. . 1_i

The DT 1_o
dose-response JJ 1_o
and CC 1_o
concentration-response JJ 1_o
relation NN 1_o
of IN N
rocuronium NN 1_i
infusion NN 1_i
was VBD N
studied VBN N
in IN N
20 CD 1_p
adult NN 1_p
surgical JJ 1_p
patients NNS 1_p
during IN 1_p
propofol-nitrous JJ 1_i
oxide NN 1_i
and CC 1_i
isoflurane NN 1_i
( ( 1_i
1 CD 1_i
MAC NNP 1_i
) ) 1_i
-nitrous JJ 1_i
oxide JJ 1_i
anaesthesia NN 1_i
. . 1_i

Neuromuscular JJ N
block NN N
was VBD N
kept VBN N
constant JJ N
, , N
initially RB N
at IN N
90 CD N
% NN N
and CC N
then RB N
at IN N
50 CD N
% NN N
with IN N
a DT N
closed-loop JJ 1_i
feedback NN 1_i
controller NN 1_i
. . 1_i

At IN N
90 CD N
% NN N
block NN N
the DT N
steady-state JJ 1_o
infusion NN 1_o
of IN 1_i
rocuronium NN 1_i
was VBD N
0.55 CD N
+/- JJ N
0.16 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
corresponding JJ 1_i
concentration NN 1_o
1714 CD N
+/- JJ N
281 CD N
ng JJ N
mL-1 NN N
in IN N
patients NNS N
receiving VBG N
propofol NN 1_i
. . 1_i

At IN N
50 CD N
% NN N
block NN N
the DT N
corresponding JJ 1_o
infusion NN 1_o
rate NN 1_o
was VBD N
0.27 CD N
+/- JJ N
0.11 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
concentration NN 1_o
1077 CD N
+/- JJ N
244 CD N
ng JJ N
mL-1 NN N
, , N
respectively RB N
. . N

At IN N
50 CD N
% NN N
block NN N
isoflurane NN 1_i
reduced VBD N
the DT N
rate NN 1_o
of IN 1_o
infusion NN 1_o
by IN N
52 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
and CC N
the DT N
concentration NN 1_o
by IN N
59 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
at IN N
90 CD N
% NN N
block NN N
both CC N
the DT N
mean JJ 1_o
infusion NN 1_o
rate NN 1_o
and CC N
the DT N
concentration NN 1_o
of IN 1_o
rocuronium NN 1_o
were VBD N
reduced VBN N
by IN N
35 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

The DT N
mean JJ 1_o
rocuronium NN 1_o
clearance NN 1_o
at IN N
50 CD N
% NN N
block NN N
was VBD N
unaffected VBN N
by IN N
the DT N
type NN N
of IN N
anaesthesia NN 1_i
; : 1_i
it PRP N
was VBD N
4.1 CD N
+/- JJ N
1.6 CD N
and CC N
4.9 CD N
+/- JJ N
2.7 CD N
mL JJ N
kg-1 JJ N
min-1 NN N
in IN N
the DT N
groups NNS N
receiving VBG N
propofol NN 1_i
and CC N
isoflurane NN 1_i
anaesthesia NN 1_i
, , N
respectively RB N
. . N

We PRP N
conclude VBP N
that IN N
isoflurane NN N
reduces VBZ N
the DT N
infusion NN 1_o
requirements NNS 1_o
of IN 1_o
rocuronium NN 1_o
by IN N
changing VBG N
the DT N
pharmacodynamic JJ N
behaviour NN N
. . N

Increasing VBG N
verbal JJ N
responsiveness NN N
in IN N
parents NNS 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
a DT 1_p
pilot NN N
study NN N
. . N

Correlational NNP N
studies NNS N
have VBP N
revealed VBN N
a DT N
positive JJ N
relationship NN N
between IN N
parent NN 1_p
verbal JJ N
responsiveness NN N
and CC N
language NN N
outcomes NNS N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

We PRP N
investigated VBD N
whether IN N
parents NNS 1_p
of IN 1_p
young JJ 1_p
children NNS 1_p
on IN 1_p
the DT 1_p
autism NN 1_p
spectrum NN 1_p
could MD N
learn VB N
and CC N
implement VB N
the DT N
specific JJ N
categories NNS N
of IN N
verbal JJ N
responsiveness NN N
that WDT N
have VBP N
been VBN N
suggested VBN N
to TO N
facilitate VB N
language NN N
development NN N
. . N

Parents NNS 1_p
were VBD N
taught VBN N
to TO N
increase VB 1_i
their PRP$ 1_i
verbal JJ 1_i
responsiveness NN 1_i
in IN N
the DT N
context NN N
of IN N
a DT N
short-term JJ 1_i
language NN 1_i
intervention NN 1_i
that WDT N
included VBD N
group NN 1_i
parent NN 1_i
education NN 1_i
sessions NNS 1_i
, , N
as RB N
well RB N
as IN N
individual JJ 1_i
and CC 1_i
small-group JJ 1_i
coaching NN 1_i
sessions NNS 1_i
of IN 1_i
parent-child JJ 1_i
play NN 1_i
interactions NNS 1_i
. . 1_i

Parents NNS 1_p
in IN N
the DT N
treatment NN N
group NN N
increased VBD N
their PRP$ N
use NN N
of IN N
comments NNS N
that WDT N
: : N
described VBD N
their PRP$ N
child NN 1_o
's POS 1_o
focus NN 1_o
of IN 1_o
attention NN 1_o
; : 1_o
interpreted VBN N
or CC N
expanded VBN N
child JJ 1_o
communication NN 1_o
acts NNS 1_o
; : 1_o
and CC N
prompted VBD N
child JJ 1_o
communication NN 1_o
. . 1_o

Preliminary JJ N
treatment NN N
effects NNS N
were VBD N
also RB N
noted VBN N
in IN N
children NNS 1_o
's POS 1_o
prompted VBN 1_o
and CC 1_o
spontaneous JJ 1_o
communication NN 1_o
. . 1_o

These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
parent-mediated JJ 1_i
interventions NNS 1_i
targeting VBG N
verbal JJ 1_o
responsiveness NN 1_o
to TO N
facilitate VB N
language NN 1_o
development NN 1_o
and CC 1_o
communication NN 1_o
in IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Randomized VBN N
trial NN N
of IN N
liberal JJ 1_i
versus NN 1_i
restrictive JJ 1_i
guidelines NNS 1_i
for IN 1_i
red JJ 1_i
blood NN 1_i
cell NN 1_i
transfusion NN 1_i
in IN N
preterm JJ 1_p
infants NNS 1_p
. . 1_p

OBJECTIVE NNP N
Although IN N
many JJ N
centers NNS N
have VBP N
introduced VBN N
more RBR N
restrictive JJ N
transfusion NN N
policies NNS N
for IN N
preterm JJ 1_p
infants NNS 1_p
in IN N
recent JJ N
years NNS N
, , N
the DT N
benefits NNS N
and CC N
adverse JJ N
consequences NNS N
of IN N
allowing VBG N
lower JJR N
hematocrit NN N
levels NNS N
have VBP N
not RB N
been VBN N
systematically RB N
evaluated VBN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
restrictive JJ 1_i
guidelines NNS 1_i
for IN 1_i
red JJ 1_i
blood NN 1_i
cell NN 1_i
( ( 1_i
RBC NNP 1_i
) ) 1_i
transfusions NNS 1_i
for IN N
preterm JJ N
infants NNS N
can MD N
reduce VB N
the DT N
number NN 1_o
of IN 1_o
transfusions NNS 1_o
without IN N
adverse JJ N
consequences NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
We PRP N
enrolled VBD N
100 CD 1_p
hospitalized JJ 1_p
preterm NN 1_p
infants NNS 1_p
with IN 1_p
birth JJ 1_p
weights NNS 1_p
of IN 1_p
500 CD 1_p
to TO 1_p
1300 CD 1_p
g NN 1_p
into IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
2 CD N
levels NNS N
of IN N
hematocrit NN N
threshold NN N
for IN N
RBC NNP N
transfusion NN N
. . N

INTERVENTION NNP N
The DT N
infants NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
either VB N
the DT N
liberal- NN 1_i
or CC 1_i
the DT 1_i
restrictive-transfusion NN 1_i
group NN N
. . N

For IN N
each DT N
group NN N
, , N
transfusions NNS N
were VBD N
given VBN N
only RB N
when WRB N
the DT N
hematocrit NN N
level NN N
fell VBD N
below IN N
the DT N
assigned JJ N
value NN N
. . N

In IN N
each DT N
group NN N
, , N
the DT N
transfusion NN N
threshold NN N
levels NNS N
decreased VBN N
with IN N
improving VBG N
clinical JJ N
status NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
We PRP N
recorded VBD N
the DT N
number NN 1_o
of IN 1_o
transfusions NNS 1_o
, , 1_o
the DT 1_o
number NN 1_o
of IN 1_o
donor JJ 1_o
exposures NNS 1_o
, , 1_o
and CC 1_o
various JJ 1_o
clinical JJ 1_o
and CC 1_o
physiologic JJ 1_o
outcomes NNS 1_o
. . 1_o

RESULTS JJ N
Infants NNS N
in IN N
the DT N
liberal-transfusion NN N
group NN N
received VBD N
more JJR N
RBC JJ 1_o
transfusions NNS 1_o
( ( N
5.2 CD N
+/- JJ N
4.5 CD N
[ JJ N
mean JJ N
+/- JJ N
SD NNP N
] NNP N
vs VBD N
3.3 CD N
+/- JJ N
2.9 CD N
in IN N
the DT N
restrictive-transfusion NN 1_i
group NN N
) ) N
. . N

However RB N
, , N
the DT N
number NN 1_o
of IN 1_o
donors NNS 1_o
to TO N
whom WP N
the DT N
infants NNS N
were VBD N
exposed VBN N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
2.8 CD N
+/- JJ N
2.5 CD N
vs JJ N
2.2 CD N
+/- JJ N
2.0 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
the DT N
percentage NN 1_o
of IN 1_o
infants NNS 1_o
who WP 1_o
avoided VBD 1_o
transfusions NNS 1_o
altogether RB 1_o
( ( N
12 CD N
% NN N
in IN N
the DT N
liberal-transfusion NN N
group NN N
versus VBD N
10 CD N
% NN N
in IN N
the DT N
restrictive-transfusion NN N
group NN N
) ) N
. . N

Infants NNS N
in IN N
the DT N
restrictive-transfusion NN 1_i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
intraparenchymal JJ 1_o
brain NN 1_o
hemorrhage NN 1_o
or CC 1_o
periventricular JJ 1_o
leukomalacia NN 1_o
, , N
and CC N
they PRP N
had VBD N
more RBR 1_o
frequent JJ 1_o
episodes NNS 1_o
of IN 1_o
apnea NN 1_o
, , N
including VBG N
both DT N
mild JJ 1_o
and CC 1_o
severe JJ 1_o
episodes NNS 1_o
. . 1_o

CONCLUSIONS NNP N
Although IN N
both DT N
transfusion NN 1_i
programs NNS N
were VBD N
well RB N
tolerated VBN N
, , N
our PRP$ N
finding NN N
of IN N
more RBR N
frequent JJ N
major JJ 1_o
adverse JJ 1_o
neurologic NN 1_o
events NNS 1_o
in IN N
the DT N
restrictive JJ 1_i
RBC-transfusion NNP 1_i
group NN N
suggests VBZ N
that IN N
the DT N
practice NN N
of IN N
restrictive JJ 1_i
transfusions NNS 1_i
may MD N
be VB N
harmful JJ N
to TO N
preterm VB N
infants NNS N
. . N

Clinical JJ N
evaluation NN N
of IN N
Er NNP 1_i
, , 1_i
Cr NNP 1_i
: : 1_i
YSGG NN 1_i
and CC 1_i
GaAlAs NNP 1_i
laser NN 1_i
therapy NN 1_i
for IN N
treating VBG N
dentine JJ 1_o
hypersensitivity NN 1_o
: : 1_o
A DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
The DT N
advent NN N
of IN N
dental JJ N
lasers NNS N
has VBZ N
raised VBN N
another DT N
possible JJ N
treatment NN N
option NN N
for IN N
dentine NN 1_o
hypersensitivity NN 1_o
( ( 1_o
DH NNP 1_o
) ) 1_o
and CC N
has VBZ N
become VBN N
a DT N
research NN N
interest NN N
in IN N
the DT N
last JJ N
decades NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
randomized VBN N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
split NN N
mouth NN N
, , N
clinical JJ N
study NN N
was VBD N
to TO N
evaluate VB 1_o
and CC 1_o
compare VB 1_o
the DT N
desensitizing JJ N
effects NNS N
of IN N
erbium NN 1_i
, , 1_i
chromium-doped JJ 1_i
: : 1_i
yttrium NN 1_i
, , 1_i
scandium NN 1_i
, , 1_i
gallium NN 1_i
and CC 1_i
garnet NN 1_i
( ( 1_i
Er NNP 1_i
, , 1_i
Cr NNP 1_i
: : 1_i
YSGG NN 1_i
) ) 1_i
to TO 1_i
galium-aluminium-arsenide JJ 1_i
( ( 1_i
GaAlAs NNP 1_i
) ) 1_i
laser NN 1_i
on IN N
DH NNP N
. . N

METHODS NNP N
Fifty-one CD 1_p
patients NNS 1_p
participated VBN 1_p
in IN 1_p
this DT 1_p
study NN 1_p
for IN 1_p
a DT 1_p
total NN 1_p
of IN 1_p
174 CD 1_p
teeth NNS 1_p
. . 1_p

DH NNP 1_o
was VBD 1_o
assessed VBN 1_o
for IN N
all DT N
groups NNS N
with IN N
a DT N
visual JJ 1_o
analog NN 1_o
scale NN 1_o
. . 1_o

For IN N
each DT N
patient NN N
, , N
the DT N
teeth NNS N
were VBD N
randomized VBN N
to TO N
three CD N
groups NNS N
. . N

In IN N
the DT N
diode NN N
laser NN N
group NN N
, , N
sensitive JJ N
teeth NNS N
were VBD N
irradiated VBN 1_i
with IN 1_i
the DT 1_i
GaAlAs NNP 1_i
laser NN 1_i
at IN 1_i
8.5J/cm CD 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
energy NN 1_i
density NN 1_i
. . 1_i

In IN N
the DT N
Er NNP 1_i
, , 1_i
Cr NNP 1_i
: : 1_i
YSGG NNP 1_i
laser NN 1_i
group NN N
, , N
sensitive JJ N
teeth NNS N
were VBD N
irradiated VBN 1_i
with IN 1_i
Er NNP 1_i
, , 1_i
Cr NNP 1_i
: : 1_i
YSGG PRP$ 1_i
laser NN 1_i
in IN N
the DT N
hard JJ N
tissue NN N
mode NN N
using VBG N
a DT N
none-contact JJ N
probe NN N
at IN N
an DT N
energy NN N
level NN N
of IN N
0.25W CD N
and CC N
repetition NN N
rate NN N
of IN N
20Hz CD N
, , N
0 CD N
% NN N
water NN N
and CC N
10 CD N
% NN N
air NN N
. . N

In IN N
the DT N
control NN N
group NN N
no DT 1_i
treatment NN 1_i
was VBD N
performed VBN N
. . N

Treatment JJ N
time NN N
was VBD N
60s CD N
for IN N
GaAlAs NNP 1_i
laser NN 1_i
and CC N
30s CD N
for IN N
Er NNP 1_i
, , 1_i
Cr NNP 1_i
: : 1_i
YSGG NNP 1_i
laser NN 1_i
. . 1_i

RESULTS VB N
When WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
baseline NN N
data NNS N
, , N
in IN N
both DT N
laser NN N
groups NNS N
, , N
laser JJR 1_i
irradiation NN 1_i
provided VBD N
a DT N
desensitizing JJ 1_o
effect NN 1_o
immediately RB N
after IN N
treatment NN N
and CC N
this DT N
effect NN N
was VBD N
maintained VBN N
throughout IN N
the DT N
study NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
between IN N
Er NNP 1_i
, , 1_i
Cr NNP 1_i
: : 1_i
YSGG NN 1_i
and CC N
GaAlAs NNP 1_i
laser NN 1_i
groups NNS N
were VBD N
found VBN N
at IN N
any DT N
follow-up JJ N
examination NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
these DT N
findings NNS N
, , N
it PRP N
may MD N
be VB N
concluded VBN N
that IN N
both DT N
Er NNP 1_i
, , 1_i
Cr NNP 1_i
: : 1_i
YSGG NN 1_i
and CC 1_i
GaAlAs NNP 1_i
lasers NNS 1_i
were VBD N
effective JJ 1_o
in IN N
the DT N
treatment NN N
of IN N
DH NNP N
following VBG N
a DT N
single JJ N
application NN N
. . N

Efficacy NN N
of IN N
ebrotidine NN 1_i
and CC 1_i
ranitidine NN 1_i
combined VBN 1_i
with IN 1_i
amoxicillin NN 1_i
and CC 1_i
metronidazole NN 1_i
in IN N
the DT N
eradication NN 1_o
of IN N
Helicobacter NNP N
pylori NN N
in IN N
patients NNS 1_p
with IN 1_p
duodenal JJ 1_p
ulcer NN 1_p
. . 1_p

This DT N
double-blind NN N
, , N
randomized VBN N
, , N
phase VB N
III NNP N
clinical JJ N
trial NN N
was VBD N
carried VBN N
out RP N
in IN N
two CD 1_p
parallel JJ 1_p
groups NNS 1_p
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
ebrotidine NN 1_i
( ( 1_i
N- JJ 1_i
[ NN 1_i
( ( 1_i
E NNP 1_i
) ) 1_i
- : 1_i
[ JJ 1_i
[ JJ 1_i
2- JJ 1_i
[ NN 1_i
[ NNP 1_i
[ NNP 1_i
2- JJ 1_i
[ NNP 1_i
( ( 1_i
diaminomethylene NN 1_i
) ) 1_i
amino NN 1_i
] JJ 1_i
-4-thiazolyl NNP 1_i
] NNP 1_i
methyl NN 1_i
] NNP 1_i
thio NN 1_i
] NNP 1_i
ethyl VBZ 1_i
] NNP 1_i
amino NN 1_i
] NNP 1_i
methylene NN 1_i
] NNP 1_i
-4-bromo-benzenesulfonamide NNP 1_i
, , 1_i
CAS NNP 1_i
100981-43-9 CD 1_i
, , 1_i
FI-3542 NNP 1_i
) ) 1_i
400 CD 1_i
mg NN 1_i
and CC 1_i
ranitidine VB 1_i
300 CD 1_i
mg NN 1_i
given VBN N
in IN N
single JJ N
evening NN N
dose NN N
, , N
combined VBN 1_i
with IN 1_i
amoxicillin JJ 1_i
750 CD N
mg NN N
and CC N
metronidazole $ 1_i
500 CD N
mg NN N
three CD N
times NNS N
daily RB N
for IN N
14 CD N
days NNS N
, , N
in IN N
the DT N
eradication NN 1_o
of IN N
Helicobacter NNP N
pylori NN N
in IN N
patients NNS 1_p
with IN 1_p
duodenal JJ 1_p
ulcer NN 1_p
. . 1_p

Thirty JJ 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
, , 1_p
divided VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
of IN 1_p
15 CD 1_p
, , 1_p
to TO 1_p
whom WP 1_p
one CD 1_p
of IN 1_p
the DT 1_p
study NN 1_p
therapies NNS 1_p
was VBD 1_p
administered VBN 1_p
based VBN 1_p
on IN 1_p
a DT 1_p
randomization NN 1_p
code NN 1_p
. . 1_p

Clinical JJ N
and CC N
endoscopic JJ N
controls NNS N
were VBD N
performed VBN N
4 CD N
, , N
6 CD N
and CC N
8 CD N
weeks NNS N
after IN N
the DT N
onset NN N
of IN N
the DT N
treatment NN N
. . N

No DT N
differences NNS N
were VBD N
seen VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
demographic JJ 1_o
parameters NNS 1_o
and CC 1_o
clinical JJ 1_o
histories NNS 1_o
. . 1_o

They PRP N
were VBD N
both DT N
perfectly RB N
homogeneous JJ N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
eradication NN 1_o
of IN N
both DT N
therapies NNS N
in IN N
both DT N
the DT N
antrum NN N
and CC N
gastric JJ N
body NN N
samples NNS N
( ( N
over IN N
80 CD N
% NN N
eradication NN N
) ) N
, , N
allowing VBG N
the DT N
results NNS N
to TO N
be VB N
classified VBN N
as IN N
satisfactory NN N
. . N

Moreover RB N
, , N
perfect JJ N
control NN N
was VBD N
achieved VBN N
through IN N
the DT N
study NN N
of IN N
clinical JJ 1_o
symptoms NNS 1_o
, , N
which WDT N
even RB N
disappeared VBD N
in IN N
some DT N
cases NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
healing VBG 1_o
rate NN 1_o
of IN N
the DT N
duodenal JJ N
ulcer NN N
after IN N
four CD N
weeks NNS N
, , N
86.7 CD N
% NN N
being VBG N
achieved VBN N
for IN N
both DT N
groups NNS N
. . N

[ NN N
Using VBG N
gaviscon JJ 1_i
preparation NN 1_i
for IN N
relief NN N
of IN N
esophageal NN N
, , N
extraesophageal JJ N
syndromes NNS N
and CC N
functional JJ N
dyspepsia NN N
in IN N
elderly JJ 1_p
patients NNS 1_p
with IN 1_p
GERD NNP 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
alginate JJ N
drug NN N
Geviskon NNP 1_i
and CC N
aluminum-magnesium JJ 1_i
antacids NNS 1_i
to TO N
relieve VB N
symptoms NNS N
of IN N
esophageal NN N
, , N
extraesophageal JJ N
syndrome NN N
and CC N
functional JJ N
dyspepsia NN N
at IN N
3 CD N
and CC N
7 CD N
days NNS N
of IN N
study NN N
in IN N
patients NNS 1_p
with IN 1_p
GERD NNP 1_p
elderly RB 1_p
. . 1_p

MATERIALS NNP N
AND NNP N
METHODS NNP N
An DT N
open JJ N
, , N
longitudinal JJ N
, , N
randomized VBN N
, , N
parallel-group NN N
. . N

The DT N
study NN N
included VBD N
60 CD 1_p
patients NNS 1_p
with IN 1_p
" PDT 1_p
A DT 1_p
" JJ 1_p
degree NN 1_p
of IN 1_p
ERD NNP 1_p
, , 1_p
consistently RB 1_p
received VBN 1_p
in-patient JJ 1_p
treatment NN 1_p
in IN 1_p
the DT 1_p
Municipal NNP 1_p
KGVV NNP 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
79.0 CD 1_p
+/- JJ 1_p
6.8 CD 1_p
years NNS 1_p
. . 1_p

During IN N
the DT N
first JJ N
12 CD N
hours NNS N
of IN N
hospital NN N
stay NN N
by IN N
" NNP N
sealed VBD N
envelopes NNS N
" VB N
them PRP N
randomly RB N
divided VBD N
into IN N
equal JJ N
groups NNS N
of IN N
comparison NN N
, , N
given VBN N
3 CD N
times NNS N
a DT N
day NN N
: : N
alginate JJ 1_i
product NN 1_i
-- : 1_i
Geviskon NNP 1_i
forte VBP 1_i
dose NN 1_i
of IN 1_i
10 CD 1_i
ml NNS 1_i
and CC 1_i
aluminum-magnesium JJ 1_i
antacid JJ 1_i
drug NN 1_i
at IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
1 CD 1_i
sachet NN 1_i
. . 1_i

Assess IN N
the DT N
frequency NN 1_o
and CC N
severity NN 1_o
of IN 1_o
esophageal NN 1_o
symptoms NNS 1_o
, , 1_o
extraesophageal JJ 1_o
syndrome NN 1_o
, , 1_o
functional JJ 1_o
dyspepsia NN 1_o
at IN N
3 CD N
and CC N
7 CD N
days NNS N
of IN N
study NN N
on IN N
5-point JJ N
scale NN N
Likert NNP N
. . N

The DT N
degree NN 1_o
of IN 1_o
esophageal NN 1_o
mucosal JJ 1_o
injury NN 1_o
was VBD N
determined VBN N
during IN N
endoscopy NN N
before IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
technique NN N
of IN N
alginate NN N
compared VBN N
with IN N
antacids NNS 1_i
provided VBN N
significantly RB N
more RBR N
complete JJ N
and CC N
earlier RBR N
effect NN N
on IN N
the DT N
relief NN 1_o
of IN 1_o
heartburn NN 1_o
, , 1_o
regurgitation NN 1_o
, , 1_o
chronic JJ 1_o
cough NN 1_o
, , 1_o
sore RB 1_o
throat NN 1_o
, , 1_o
and CC 1_o
EBS NNP 1_o
. . 1_o

Only RB N
Geviskon NNP 1_i
influenced VBD N
the DT N
symptoms NNS N
of IN N
PPD NNP N
in IN N
patients NNS 1_p
with IN 1_p
GERD NNP 1_p
. . 1_p

CONCLUSION NNP N
The DT N
clinical JJ N
features NNS N
Geviskon VBP N
the DT N
frequency NN N
and CC N
timing NN N
of IN N
relief NN N
of IN N
symptoms NNS N
of IN N
esophageal NN 1_o
, , 1_o
extraesophageal JJ 1_o
syndrome NN 1_o
, , 1_o
functional JJ 1_o
dyspepsia NN 1_o
with IN 1_p
GERD NNP 1_p
in IN 1_p
the DT 1_p
older JJR 1_p
age NN 1_p
groups NNS 1_p
is VBZ N
higher JJR N
than IN N
that DT N
of IN N
antacids NNS N
. . N

Suspension NNP N
Geviskon NNP N
may MD N
be VB N
recommended VBN N
in IN N
patients NNS 1_p
with IN 1_p
middle JJ 1_p
and CC 1_p
old JJ 1_p
age NN 1_p
as IN N
an DT N
effective JJ N
and CC N
safe JJ N
symptomatic JJ N
funds NNS N
in IN N
the DT N
first JJ N
days NNS N
of IN N
exchange NN N
rate NN N
earlier RBR N
generations NNS N
of IN N
PPI NNP N
therapy NN N
, , N
as RB N
well RB N
as IN N
monotherapy NN N
-- : N
to TO N
maintain VB N
remission NN N
. . N

The DT N
effect NN N
of IN N
nebivolol JJ 1_i
treatment NN 1_i
on IN N
oxidative JJ 1_o
stress NN 1_o
and CC 1_o
antioxidant JJ 1_o
status NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
cardiac JJ 1_p
syndrome-X NN 1_p
. . 1_p

BACKGROUND NNP N
Free JJ N
radical-mediated JJ N
oxidative JJ N
stress NN N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
etiopathogenesis NN N
of IN N
several JJ N
disorders NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
nebivolol NN 1_i
on IN N
the DT N
metabolic JJ 1_o
state NN 1_o
of IN 1_o
oxidative JJ 1_o
stress NN 1_o
, , N
and CC N
antioxidant JJ N
status NN N
markers NNS N
in IN N
patients NNS 1_p
with IN 1_p
cardiac JJ 1_p
syndrome-X NN 1_p
( ( 1_p
CSX NNP 1_p
) ) 1_p
, , N
additionally RB N
, , N
to TO N
compare VB N
with IN N
the DT N
effect NN N
of IN N
metoprolol NN 1_i
treatment NN 1_i
. . 1_i

METHODS NNP N
Thirty NNP 1_p
patients NNS 1_p
, , 1_p
17 CD 1_p
female NN 1_p
and CC 1_p
13 CD 1_p
male NN 1_p
, , 1_p
with IN 1_p
CSX NNP 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Nebivolol NNP 1_i
( ( N
5 CD N
mg/day NN N
) ) N
or CC N
metoprolol NN 1_i
( ( N
50 CD N
mg/day NN N
) ) N
was VBD N
administrated VBN N
for IN N
12 CD N
weeks NNS N
. . N

Twelve VB N
hour NN N
fasting VBG N
blood NN 1_o
samples NNS 1_o
, , N
taken VBN N
at IN N
the DT N
initiation NN N
and CC N
on IN N
the DT N
third JJ N
month NN N
of IN N
therapy NN N
, , N
were VBD N
analyzed VBN N
for IN N
the DT N
levels NNS 1_o
of IN 1_o
malondialdehyde NN 1_o
( ( 1_o
MDA NNP 1_o
) ) 1_o
, , 1_o
nitrite+nitrate JJ 1_o
( ( 1_o
NOx NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
the DT 1_o
activity NN 1_o
of IN 1_o
myeloperoxidase NN 1_o
( ( 1_o
MPO NNP 1_o
) ) 1_o
, , 1_o
superoxide JJ 1_o
dismutase NN 1_o
( ( 1_o
SOD NNP 1_o
) ) 1_o
. . 1_o

No DT N
patient NN N
presented VBD N
additional JJ N
risk NN N
factors NNS N
for IN N
increased JJ N
reactive JJ N
oxygen NN N
species NNS N
levels NNS N
. . N

RESULTS NNP N
Compared VBD N
with IN N
sixteen JJ N
control NN N
participants NNS N
, , N
patients NNS N
with IN N
CSX NNP N
had VBD N
significantly RB N
higher JJR N
activity NN 1_o
of IN 1_o
MPO NNP 1_o
and CC 1_o
levels NNS 1_o
of IN 1_o
MDA NNP 1_o
, , N
but CC N
significantly RB N
lower JJR 1_o
SOD NNP 1_o
activity NN 1_o
and CC 1_o
levels NNS 1_o
of IN 1_o
NOx NNP 1_o
before IN N
treatment NN N
. . N

After IN N
treatment NN N
, , N
MPO NNP 1_o
activity NN 1_o
and CC 1_o
MDA NNP 1_o
levels NNS 1_o
were VBD N
significantly RB N
reduced VBN N
; : N
SOD NNP 1_o
activity NN 1_o
and CC 1_o
NOx NNP 1_o
levels NNS 1_o
were VBD N
significantly RB N
increased VBN N
with IN N
nebivolol NN 1_i
but CC N
remained VBD N
unchanged JJ N
with IN N
metoprolol NN 1_i
. . 1_i

CONCLUSION NN N
We PRP N
have VBP N
shown VBN N
that IN N
patients NNS 1_p
with IN 1_p
CSX NNP 1_p
who WP N
taken VBN N
nebivolol RB 1_i
have VBP N
lower JJR N
serum NN 1_o
MPO NNP 1_o
activity NN 1_o
, , 1_o
levels NNS 1_o
of IN 1_o
MDA NNP 1_o
and CC N
higher JJR N
serum NN 1_o
SOD NNP 1_o
activity NN 1_o
, , 1_o
NOx NNP 1_o
levels NNS 1_o
when WRB N
compared VBN N
with IN N
metoprolol JJ 1_i
treatment NN N
. . N

Exercise NNP N
stress JJ N
test NN N
parameters NNS N
were VBD N
also RB N
ameliorated VBN N
in IN N
patients NNS N
who WP N
had VBD N
taken VBN N
nebivolol RB 1_i
in IN N
contrast NN N
to TO N
metoprolol VB 1_i
. . 1_i

Nebivolol NNP 1_i
treatment NN N
may MD N
be VB N
a DT N
novel JJ N
treatment NN N
strategy NN N
in IN N
cases NNS N
with IN N
CSX NNP N
in IN N
the DT N
future NN N
. . N

[ JJ 1_i
Therapy NNP 1_i
of IN N
metastatic JJ 1_p
endocrine NN 1_p
tumors NNS 1_p
of IN 1_p
the DT 1_p
gastrointestinal JJ 1_p
tract NN 1_p
] NN 1_p
. . 1_p

Impact NN N
of IN N
dronedarone NN 1_i
on IN N
hospitalization NN 1_o
burden NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
: : 1_p
results NNS N
from IN N
the DT N
ATHENA NNP N
study NN N
. . N

AIMS NNP N
Cardiovascular NNP N
( ( N
CV NNP N
) ) N
hospitalization NN N
is VBZ N
a DT N
predictor NN N
of IN N
CV NNP 1_o
mortality NN 1_o
and CC N
has VBZ N
a DT N
negative JJ N
impact NN N
on IN N
patients NNS N
' POS N
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

The DT N
primary JJ N
endpoint NN N
of IN N
A NNP N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
parallel-arm JJ N
Trial NNP N
to TO N
assess VB N
the DT N
efficacy NN 1_o
of IN N
dronedarone NN 1_i
400 CD N
mg NN N
bid NN N
for IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ 1_o
Hospitalization NNP 1_o
or CC 1_o
death NN 1_o
from IN N
any DT N
cause NN N
in IN N
patiENTs NN 1_p
with IN 1_p
Atrial NNP 1_p
fibrillation/atrial JJ 1_p
flutter NN 1_p
( ( 1_p
ATHENA NNP 1_p
) ) 1_p
, , N
a DT N
composite NN N
of IN N
first JJ N
CV NNP N
hospitalization NN N
or CC N
death NN N
from IN N
any DT N
cause NN N
, , N
was VBD N
significantly RB N
reduced VBN N
by IN N
dronedarone NN 1_i
. . 1_i

This DT N
post NN N
hoc NN N
analysis NN N
evaluated VBD N
the DT N
secondary JJ N
endpoint NN N
of IN N
CV NNP 1_o
hospitalization NN 1_o
and CC N
the DT N
clinical JJ 1_o
benefit NN 1_o
of IN N
dronedarone NN 1_i
on IN N
the DT N
number NN 1_o
and CC 1_o
duration NN 1_o
of IN 1_o
CV NNP 1_o
hospitalizations NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
( ( 1_p
AF NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
ATHENA NNP N
was VBD N
a DT N
double-blind NN N
, , N
parallel JJ N
group NN N
study NN N
in IN N
4628 CD 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
paroxysmal/persistent NN 1_p
AF NNP 1_p
and CC 1_p
additional JJ 1_p
risk NN 1_p
factors NNS 1_p
, , N
treated VBN N
with IN N
placebo NN 1_i
or CC 1_i
dronedarone NN 1_i
. . 1_i

Dronedarone NNP 1_i
treatment NN N
significantly RB N
reduced VBD 1_o
the DT 1_o
risk NN 1_o
of IN 1_o
first JJ 1_o
CV NNP 1_o
hospitalization NN 1_o
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN 1_i
) ) 1_i
, , N
while IN N
the DT N
risk NN N
of IN N
first JJ N
non-CV JJ 1_o
hospitalization NN 1_o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
= NNP N
0.77 CD N
) ) N
. . N

About IN N
half NN N
of IN N
the DT N
CV NNP 1_o
hospitalizations NNS 1_o
were VBD N
AF-related JJ 1_o
, , N
with IN N
a DT N
median JJ N
duration NN N
of IN N
hospital JJ 1_o
stay NN 1_o
of IN N
four CD N
nights NNS N
. . N

The DT N
risk NN N
of IN N
any DT N
hospitalization NN N
for IN N
AF NNP N
[ NNP N
hazard NN N
ratio NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
0.626 CD N
( ( N
0.546-0.719 NN N
) ) N
] NN N
and CC N
duration NN N
of IN N
hospital NN 1_o
stay NN 1_o
were VBD N
significantly RB N
reduced VBN N
by IN N
dronedarone NN 1_i
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN 1_i
) ) 1_i
. . N

Dronedarone NNP 1_i
treatment NN N
reduced VBD 1_o
total JJ 1_o
hospitalizations NNS 1_o
for IN N
acute JJ N
coronary JJ N
syndrome NN N
( ( N
P NNP N
= NNP N
0.0105 CD N
) ) N
and CC N
the DT N
time NN N
between IN N
the DT N
first JJ 1_o
AF/atrial NNP 1_o
flutter NN 1_o
recurrence NN 1_o
and CC 1_o
CV NNP 1_o
hospitalization/death NN 1_o
( ( N
P NNP N
= NNP N
0.0048 CD N
) ) N
. . N

Hospitalization NNP 1_o
burden NN 1_o
was VBD N
significantly RB N
reduced VBN N
across IN N
all DT N
levels NNS N
of IN N
care NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Cumulative JJ N
incidence NN N
data NNS N
indicated VBD N
that IN N
the DT N
effects NNS N
of IN N
dronedarone NN 1_i
persisted VBN N
for IN N
at IN N
least JJS N
24 CD N
months NNS N
. . N

CONCLUSION NNP N
Dronedarone NNP 1_i
reduced VBD N
the DT N
risk NN N
for IN N
CV NNP 1_o
hospitalization NN 1_o
and CC N
the DT N
total JJ N
hospitalization NN 1_o
burden NN 1_o
in IN N
this DT N
patient NN N
group NN N
. . N

The DT N
trial NN N
is VBZ N
registered VBN N
under IN N
ClinicalTrials.gov NNP N
# # N
NCT NNP N
00174785 CD N
. . N

Comparison NNP N
of IN N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
esmolol NN 1_i
, , N
a DT N
short-acting JJ N
beta NN N
blocker NN N
, , N
with IN N
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
supraventricular JJ 1_p
tachyarrhythmias NN 1_p
. . 1_p

The DT N
Esmolol NNP 1_i
vs NN 1_i
Placebo NNP 1_i
Multicenter NNP N
Study NNP N
Group NNP N
. . N

The DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
esmolol NN 1_i
, , N
a DT N
short-acting JJ N
intravenous JJ N
beta-adrenergic-blocking JJ N
agent NN N
, , N
and CC N
placebo NN 1_i
were VBD N
compared VBN N
in IN N
patients NNS 1_p
with IN 1_p
supraventricular JJ 1_p
tachyarrhythmias NN 1_p
( ( 1_p
heart NN 1_p
rate NN 1_p
greater JJR 1_p
than IN 1_p
120 CD 1_p
bpm NN 1_p
) ) 1_p
in IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
partial-crossover JJ N
study NN N
. . N

Seventy-one CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
esmolol NN 1_i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
as IN N
initial JJ N
treatment NN N
. . N

Therapeutic JJ N
failures NNS N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
other JJ N
study NN N
medication NN N
. . N

Therapeutic JJ 1_o
response NN 1_o
was VBD N
defined VBN N
as IN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
20 CD N
% NN N
reduction NN N
in IN N
heart NN 1_o
rate NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
less JJR 1_o
than IN 1_o
100 CD 1_o
bpm NN 1_o
, , 1_o
or CC 1_o
conversion NN 1_o
to TO 1_o
normal JJ 1_o
sinus NN 1_o
rhythm NN 1_o
. . 1_o

The DT 1_o
therapeutic JJ 1_o
response NN 1_o
to TO N
esmolol VB 1_i
during IN N
the DT N
initial JJ N
treatment NN N
period NN N
( ( N
72 CD N
% NN N
) ) N
was VBD N
similar JJ N
to TO N
that DT N
obtained VBN N
when WRB N
esmolol NN N
was VBD N
given VBN N
as IN N
a DT N
second JJ N
agent NN N
. . N

The DT N
average JJ N
esmolol JJ N
dosage NN N
producing VBG N
a DT N
therapeutic JJ N
response NN N
was VBD N
97.5 CD N
micrograms/kg/min NN N
. . N

Four CD N
patients NNS N
( ( N
6 CD N
% NN N
) ) N
converted VBD N
to TO N
normal JJ 1_o
sinus JJ 1_o
rhythm NN 1_o
during IN N
esmolol JJ N
infusion NN N
. . N

In IN N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
, , N
therapeutic JJ 1_o
response NN 1_o
was VBD N
lost VBN N
within IN N
30 CD N
minutes NNS N
following VBG N
discontinuation NN N
of IN N
esmolol JJ 1_i
infusion NN N
, , N
a DT N
finding JJ N
indicative NN N
of IN N
rapid JJ N
reversal NN N
of IN N
beta-adrenoceptor NN N
blockade NN N
. . N

The DT N
most RBS N
prevalent JJ N
adverse JJ 1_o
effect NN 1_o
during IN N
esmolol JJ 1_i
infusion NN N
was VBD N
hypotension NN 1_o
which WDT N
occurred VBD N
in IN N
eight CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
. . N

Hypotension NN 1_o
and CC 1_o
associated VBN 1_o
symptoms NNS 1_o
resolved VBD N
within IN N
30 CD N
minutes NNS N
after IN N
discontinuation NN N
of IN N
esmolol JJ 1_i
infusion NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
short JJ N
duration NN N
of IN N
action NN N
of IN N
esmolol NN 1_i
( ( N
elimination JJ N
half-life NN N
of IN N
9.2 CD N
minutes NNS N
) ) N
. . N

Bovine NNP 1_i
carotid NN 1_i
artery NN 1_i
heterografts NNS 1_i
versus VBP 1_i
polytetrafluoroethylene JJ 1_i
grafts NNS 1_i
. . 1_i

A DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

A DT N
prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
BCAH NNP 1_i
and CC 1_i
PTFE NNP 1_i
vascular JJ 1_i
access NN 1_i
grafts NNS 1_i
resulted VBD N
in IN N
no DT N
statistically RB N
significant JJ N
difference NN N
when WRB N
analyzed VBN N
for IN N
survival JJ 1_o
rates NNS 1_o
of IN 1_o
complications NNS 1_o
, , 1_o
types NNS 1_o
of IN 1_o
complications NNS 1_o
, , 1_o
reasons NNS 1_o
for IN 1_o
failure NN 1_o
, , 1_o
and CC 1_o
clot NN 1_o
salvageability NN 1_o
. . 1_o

The DT N
results NNS N
in IN N
diabetic JJ 1_p
patients NNS 1_p
were VBD N
similar JJ N
to TO N
those DT N
in IN N
nondiabetic JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
majority NN N
of IN N
retrospective JJ N
studies NNS N
and CC N
subjective JJ N
experiences NNS N
favor VBP N
PTFE NNP 1_i
grafts NNS 1_i
over IN N
BCAHs NNP 1_i
. . N

The DT N
explanation NN N
may MD N
be VB N
part NN N
that IN N
BCAH NNP 1_i
preceded VBD N
PTFE NNP 1_i
grafts NNS 1_i
into IN N
clinical JJ N
use NN N
, , N
and CC N
inexperience NN N
in IN N
the DT N
operating NN N
room NN N
and CC N
in IN N
the DT N
dialysis NN N
unit NN N
had VBD N
an DT N
effect NN N
on IN N
BCAH NNP N
results NNS N
. . N

A DT N
review NN N
of IN N
impressions NNS N
of IN N
the DT N
graft NN N
materials NNS N
indicated VBD N
a DT N
decided JJ N
preference NN N
for IN N
PTFE NNP 1_i
grafts NNS 1_i
. . 1_i

Safety NN 1_o
of IN N
ferumoxytol NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
anemia NN 1_p
and CC 1_p
CKD NNP 1_p
. . 1_p

BACKGROUND NNP N
Iron NNP N
deficiency NN N
anemia NN N
is VBZ N
a DT N
common JJ N
complication NN N
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
kidney NN 1_p
disease NN 1_p
( ( 1_p
CKD NNP 1_p
) ) 1_p
. . 1_p

Currently NNP N
available JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
iron NN 1_i
replacement NN 1_i
therapies NNS 1_i
have VBP N
either DT N
inconvenient JJ N
regimens NNS N
of IN N
administration NN N
or CC N
adverse JJ N
event NN N
profiles NNS N
that WDT N
limit VBP N
their PRP$ N
utility NN N
in IN N
the DT N
outpatient JJ 1_p
setting NN N
. . N

Ferumoxytol NNP 1_i
is VBZ N
a DT N
novel NN N
, , N
semisynthetic JJ N
, , N
carbohydrate-coated JJ N
, , N
superparamagnetic JJ N
iron NN N
oxide NN N
nanoparticle NN N
that WDT N
is VBZ N
administered VBN N
IV NNP N
as IN N
an DT N
injection NN N
. . N

The DT N
main JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
safety NN 1_o
of IN N
ferumoxytol NN 1_i
for IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
CKD NNP 1_p
stages VBZ 1_p
1 CD 1_p
to TO 1_p
5 CD 1_p
and CC 1_p
5D CD 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
Phase NNP N
3 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
crossover NN N
, , N
multicenter NN N
study NN N
of IN N
a DT N
single JJ N
510-mg JJ N
dose NN N
of IN N
ferumoxytol JJ 1_i
versus NN 1_i
saline NN 1_i
as IN 1_i
placebo NN 1_i
. . 1_i

SETTING NNP N
& CC N
PARTICIPANTS NNP N
750 CD 1_p
patients NNS 1_p
with IN 1_p
CKD NNP 1_p
stages VBZ 1_p
1 CD 1_p
to TO 1_p
5 CD 1_p
and CC 1_p
5D CD 1_p
. . 1_p

INTERVENTION NNP N
An DT N
IV NNP 1_i
injection NN 1_i
of IN N
either CC N
17 CD N
mL NN N
of IN N
ferumoxytol NN 1_i
or CC 1_i
saline NN 1_i
placebo NN 1_i
over IN N
17 CD N
seconds NNS N
on IN N
day NN N
0 CD N
and CC N
the DT N
alternate NN N
agent NN N
on IN N
day NN N
7 CD N
. . N

OUTCOMES NNP N
& CC N
MEASUREMENTS NNP N
Descriptive NNP N
comparison NN N
of IN N
adverse JJ 1_o
events NNS 1_o
, , 1_o
laboratory NN 1_o
tests NNS 1_o
, , 1_o
and CC 1_o
vital JJ 1_o
signs NNS 1_o
. . 1_o

RESULTS NNP N
Of IN N
750 CD 1_p
randomly NNS 1_p
assigned VBD 1_p
patients NNS 1_p
with IN 1_p
CKD NNP 1_p
, , 1_p
60 CD 1_p
% NN 1_p
were VBD 1_p
not RB 1_p
on IN 1_p
dialysis NN 1_i
therapy NN 1_i
. . 1_i

713 CD 1_p
patients NNS 1_p
received VBD 1_p
ferumoxytol JJ 1_i
, , 1_p
and CC 1_p
711 CD 1_p
received VBD 1_p
placebo NN 1_i
. . 1_i

There EX N
were VBD N
420 CD 1_p
adverse JJ 1_o
events NNS 1_o
reported VBD 1_p
; : 1_p
242 CD 1_p
in IN 1_p
152 CD 1_p
patients NNS 1_p
( ( 1_p
21.3 CD 1_p
% NN 1_p
) ) 1_p
with IN 1_p
ferumoxytol NN 1_p
and CC 1_p
178 CD 1_p
in IN 1_p
119 CD 1_p
patients NNS 1_p
( ( 1_p
16.7 CD 1_p
% NN 1_p
) ) 1_p
with IN 1_p
placebo NN 1_i
. . 1_i

The DT N
incidence NN 1_o
of IN 1_o
related JJ 1_o
adverse JJ 1_o
events NNS 1_o
was VBD N
5.2 CD N
% NN N
with IN N
ferumoxytol NN 1_i
and CC N
4.5 CD N
% NN N
with IN N
placebo NN 1_i
. . 1_i

The DT N
most RBS N
common JJ N
related JJ N
adverse JJ 1_o
events NNS 1_o
after IN N
each DT N
treatment NN N
included VBD N
symptoms NNS 1_o
related VBN N
to TO N
the DT N
injection/infusion NN 1_o
site NN 1_o
, , 1_o
dizziness NN 1_o
, , 1_o
pruritus NN 1_o
, , 1_o
headache NN 1_o
, , 1_o
fatigue NN 1_o
, , 1_o
and CC 1_o
nausea NN 1_o
. . 1_o

Serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
occurred VBD N
in IN N
21 CD N
patients NNS N
( ( N
2.9 CD N
% NN N
) ) N
after IN N
ferumoxytol NN 1_i
and CC N
13 CD N
patients NNS N
( ( N
1.8 CD N
% NN N
) ) N
after IN N
placebo NN 1_i
. . 1_i

Serious JJ 1_o
related JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
observed VBN N
in IN N
1 CD N
patient NN N
( ( N
0.1 CD N
% NN N
) ) N
after IN N
each DT N
treatment NN N
. . N

There EX N
was VBD N
no DT N
meaningful JJ N
decrease NN N
in IN N
blood NN 1_o
pressure NN 1_o
after IN N
administration NN N
of IN N
ferumoxytol NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

LIMITATIONS NNP N
Follow-up NNP N
was VBD N
7 CD N
days NNS N
after IN N
each DT N
study NN N
treatment NN N
. . N

CONCLUSIONS NNP N
Ferumoxytol NNP 1_i
is VBZ N
well RB N
tolerated VBN 1_o
and CC N
has VBZ N
a DT N
safety NN 1_o
profile NN 1_o
similar JJ N
to TO N
placebo VB 1_i
in IN N
anemic JJ 1_p
patients NNS 1_p
with IN 1_p
CKD NNP 1_p
stages VBZ 1_p
1 CD 1_p
to TO 1_p
5 CD 1_p
and CC 1_p
5D CD 1_p
. . 1_p

No DT N
pain NN 1_o
relief NN 1_o
with IN N
the DT N
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
. . 1_i

The DT N
sense NN N
of IN N
body NN N
ownership NN N
can MD N
be VB N
easily RB N
disrupted VBN N
during IN N
illusions NNS N
and CC N
the DT N
most RBS N
common JJ N
illusion NN N
is VBZ N
the DT N
rubber JJ 1_i
hand NN 1_i
illusion NN 1_i
. . 1_i

An DT N
idea NN N
that WDT N
is VBZ N
rapidly RB N
gaining VBG N
popularity NN N
in IN N
clinical JJ N
pain NN N
medicine NN N
is VBZ N
that IN N
body NN 1_i
ownership NN 1_i
illusions NNS 1_i
can MD N
be VB N
used VBN N
to TO N
modify VB N
pathological JJ N
pain NN N
sensations NNS N
and CC N
induce VB N
analgesia NN N
. . N

However RB N
, , N
this DT N
idea NN N
has VBZ N
not RB N
been VBN N
empirically RB N
evaluated VBN N
. . N

Two CD N
separate JJ N
research NN N
laboratories NNS N
undertook VBP N
independent JJ N
randomized VBN N
repeated JJ N
measures NNS N
experiments NNS N
, , N
both DT N
designed VBN N
to TO N
detect VB N
an DT N
effect NN N
of IN N
the DT N
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
on IN N
experimentally RB N
induced JJ N
hand NN 1_o
pain NN 1_o
. . 1_o

In IN N
Experiment JJ N
1 CD N
, , N
16 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
rated VBD N
the DT N
pain NN 1_o
evoked VBN N
by IN N
noxious JJ 1_i
heat NN 1_i
stimuli NNS 1_i
( ( N
5 CD N
s NN N
duration NN N
; : N
interstimulus CC N
interval JJ N
25 CD N
s NN N
) ) N
of IN N
set NN N
temperatures NNS N
( ( N
47° CD N
, , N
48° CD N
and CC N
49°C CD N
) ) N
during IN N
the DT 1_i
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
or CC 1_i
during IN 1_i
a DT 1_i
control JJ 1_i
condition NN 1_i
. . N

There EX N
was VBD N
a DT N
main JJ N
effect NN N
of IN 1_o
stimulus JJ 1_o
temperature NN 1_o
on IN 1_o
pain NN 1_o
ratings NNS 1_o
, , N
but CC N
no DT 1_o
main JJ 1_o
effect NN 1_o
of IN 1_o
condition NN 1_o
( ( N
p JJ N
= NNP N
0.32 CD N
) ) N
, , N
nor CC 1_o
a DT 1_o
condition NN 1_o
x JJ 1_o
temperature NN 1_o
interaction NN 1_o
( ( N
p JJ N
= NNP N
0.31 CD 1_p
) ) 1_p
. . 1_p

In IN 1_p
Experiment JJ 1_p
2 CD 1_p
, , 1_p
20 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
underwent JJ N
quantitative JJ N
sensory NN N
testing VBG N
to TO N
determine VB 1_o
heat NN 1_o
and CC 1_o
cold JJ 1_o
pain NN 1_o
thresholds NNS 1_o
during IN N
the DT 1_i
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
or CC N
during IN N
a DT N
control JJ N
condition NN N
. . N

Secondary JJ N
analyses NNS N
involved VBN 1_o
heat NN 1_o
and CC 1_o
cold JJ 1_o
detection NN 1_o
thresholds NNS 1_o
and CC 1_o
paradoxical JJ 1_o
heat NN 1_o
sensations NNS 1_o
. . N

Again NNP N
, , N
there EX N
was VBD N
no DT 1_o
main JJ 1_o
effect NN 1_o
of IN 1_o
condition NN 1_o
on IN 1_o
heat NN 1_o
pain NN 1_o
threshold NN 1_o
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
nor CC N
on IN 1_o
cold JJ 1_o
pain NN 1_o
threshold NN 1_o
( ( N
p JJ N
= NNP N
0.65 CD N
) ) N
, , N
nor CC N
on IN N
any DT N
of IN N
the DT 1_o
secondary JJ 1_o
measures NNS 1_o
( ( N
p VB N
< $ N
0.56 CD N
for IN N
all DT N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
the DT 1_i
rubber NN 1_i
hand NN 1_i
illusion NN 1_i
does VBZ N
not RB N
induce VB 1_o
analgesia NN 1_o
. . N

Similar JJ N
compliance NN N
and CC N
effect NN N
of IN N
treatment NN N
in IN N
chronic JJ 1_p
hepatitis NN 1_p
C NNP 1_p
resulting VBG 1_p
from IN 1_p
intravenous JJ 1_i
drug NN 1_i
use NN 1_i
in IN N
comparison NN N
with IN N
other JJ N
infection NN N
causes NNS N
. . N

OBJECTIVES NNP N
There EX N
is VBZ N
some DT N
reluctance NN N
to TO N
treat VB N
intravenous JJ 1_p
drug NN 1_p
users NNS 1_p
( ( 1_p
IVDUs NNP 1_p
) ) 1_p
with IN 1_p
chronic JJ 1_p
hepatitis NN 1_p
C NNP 1_p
( ( 1_p
CHC NNP 1_p
) ) 1_p
because IN N
of IN N
presumed JJ N
lower JJR N
compliance NN N
and CC N
response NN N
to TO N
antiviral JJ 1_i
therapy NN 1_i
. . 1_i

We PRP N
intended VBD N
to TO N
evaluate VB N
the DT N
compliance NN N
and CC N
response NN N
to TO N
antiviral JJ 1_i
treatment NN 1_i
for IN 1_i
CHC NNP 1_i
in IN N
IVDUs NNP N
compared VBN N
with IN N
non-IVDUs JJ N
. . N

METHODS VB N
A DT N
retrospective JJ N
cohort NN N
study NN N
-- : N
secondary JJ N
analysis NN N
of IN N
the DT N
results NNS N
of IN N
a DT N
treatment NN 1_p
trial NN 1_p
-- : 1_p
was VBD 1_p
performed VBN 1_p
in IN 1_p
Belgium NNP 1_p
and CC 1_p
The DT 1_p
Netherlands NNP 1_p
. . 1_p

A NNP 1_p
total NN 1_p
of IN 1_p
406 CD 1_p
previously RB 1_p
untreated JJ 1_p
CHC NNP 1_p
patients NNS 1_p
, , 1_p
including VBG 1_p
98 CD 1_p
( ( 1_p
24 CD 1_p
% NN 1_p
) ) 1_p
IVDUs NNP 1_p
, , N
were VBD N
studied VBN N
for IN N
compliance NN N
( ( N
presentation NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
, , N
complete JJ N
response NN N
( ( N
alanine JJ N
aminotransferase NN N
within IN N
normal JJ N
limits NNS N
and CC N
serum NN N
hepatitis NN N
C NNP N
virus NN N
polymerase NN N
chain NN N
reaction NN N
negative JJ N
) ) N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBD N
virological JJ N
response NN N
( ( N
SVR NNP N
) ) N
. . N

RESULTS JJ N
Non-compliance NNP 1_o
( ( N
8.2 CD N
% NN N
) ) N
in IN N
IVDUs NNP N
was VBD N
not RB N
different JJ N
from IN N
non-IVDUs JJ N
( ( N
6.8 CD N
% NN N
) ) N
( ( N
relative JJ N
risk=1.20 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=0.55-2.62 NN N
) ) N
. . N

Complete JJ 1_o
response NN 1_o
after IN N
controlling VBG N
for IN N
hepatitis NN N
C NNP N
virus NN N
was VBD N
similar JJ N
( ( N
relative JJ N
risk=1.19 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=0.89-1.60 NN N
) ) N
. . N

Controlling VBG N
for IN N
treatment NN N
arm NN N
, , N
age NN N
, , N
sex NN N
, , N
presence NN N
of IN N
cirrhosis NN N
or CC N
hepatitis NN N
C NNP N
virus NN N
viral JJ N
load NN N
before IN N
treatment NN N
did VBD N
not RB N
change VB N
these DT N
results NNS N
. . N

There EX N
was VBD N
a DT N
marginally RB N
significant JJ N
difference NN N
in IN N
the DT N
sustained JJ 1_o
virological JJ 1_o
response NN 1_o
between IN N
IVDUs NNP N
( ( N
46.6 CD N
% NN N
) ) N
and CC N
non-IVDUs JJ N
( ( N
34.6 CD N
% NN N
) ) N
( ( N
relative JJ N
risk=1.35 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=1.00-1.81 NN N
) ) N
, , N
also RB N
disappearing VBG N
after IN N
adjusting VBG N
for IN N
genotype NN N
. . N

No DT N
difference NN N
in IN N
compliance NN 1_o
or CC 1_o
sustained VBN 1_o
virological JJ 1_o
response NN 1_o
was VBD N
found VBN N
between IN N
active JJ N
and CC N
non-active JJ N
IVDUs NNP N
or CC N
between IN N
IVDU NNP N
patients NNS N
in IN N
or CC N
without IN N
a DT N
methadone NN N
maintenance NN N
program NN N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
group NN N
of IN N
Benelux NNP 1_p
patients NNS 1_p
, , N
IVDUs NNP N
showed VBD N
similar JJ 1_o
compliance NN 1_o
and CC 1_o
response NN 1_o
to TO N
treatment NN N
with IN N
interferon NN N
and CC N
ribavirin NN N
compared VBN N
with IN N
other JJ N
patients NNS N
with IN N
CHC NNP N
infection NN N
. . N

Therefore RB N
, , N
it PRP N
is VBZ N
no RB N
longer RBR N
justifiable JJ N
to TO N
withhold VB N
treatment NN N
to TO N
chronic VB 1_o
hepatitis NN 1_o
C NNP 1_o
patients NNS 1_p
who WP 1_p
use VBP 1_p
intravenous JJ 1_p
drugs NNS 1_p
. . 1_p

Nateglinide NNP 1_i
reduces VBZ N
carotid JJ 1_o
intima-media JJ 1_o
thickening NN 1_o
in IN N
type NN 1_p
2 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
under IN 1_p
good JJ 1_p
glycemic JJ 1_p
control NN 1_p
. . 1_p

OBJECTIVE NNP N
Postprandial NNP N
hyperglycemia NN N
observed VBD N
in IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
mellitus NN N
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
atherosclerosis NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
strict JJ 1_i
glycemic NNS 1_i
control NN 1_i
by IN N
nateglinide NN N
on IN N
common JJ N
carotid NN 1_o
far RB 1_o
wall JJ 1_o
intima-media JJ 1_o
thickness NN 1_o
in IN N
type NN 1_p
2 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
already RB 1_p
under IN 1_p
good JJ 1_p
glycemic JJ 1_p
control NN 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
performed VBD N
an DT N
open JJ N
labeled VBN N
randomized JJ N
prospective JJ N
trial NN N
on IN N
78 CD 1_i
drug-naive JJ 1_i
type NN 1_i
2 CD 1_i
diabetic JJ 1_i
patients NNS 1_i
whose WP$ 1_i
HbA1c NNP 1_i
was VBD 1_i
less JJR 1_i
than IN 1_i
6.5 CD 1_i
% NN 1_i
. . 1_i

Thirty-eight JJ 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
nateglinide NN 1_i
( ( 1_i
270 CD 1_i
mg/dL NN 1_i
) ) 1_i
and CC 1_i
40 CD 1_i
to TO 1_i
control VB 1_i
group NN 1_i
( ( 1_i
no DT 1_i
treatment NN 1_i
) ) 1_i
. . 1_i

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
HbA1c NNP 1_o
was VBD N
observed VBN N
in IN N
the DT N
nateglinide JJ N
group NN N
, , N
whereas IN N
a DT N
significant JJ N
increase NN N
of IN N
HbA1c NNP 1_o
was VBD N
observed VBN N
in IN N
the DT N
untreated JJ N
group NN N
. . N

The DT N
carotid JJ 1_o
intima-media JJ 1_o
thickness NN 1_o
at IN N
the DT N
end NN N
of IN N
1-year JJ N
follow-up NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
nateglinide JJ N
group NN N
compared VBN N
with IN N
the DT N
untreated JJ 1_i
group NN 1_i
( ( N
-0.017+/-0.054 JJ N
mm/year VBP N
versus IN N
0.024+/-0.066 JJ N
mm/year NN N
, , N
P=0.0064 NNP N
) ) N
. . N

Whereas NNP N
nateglinide JJ N
treatment NN N
also RB N
reduced VBD N
triglyceride JJ 1_o
, , 1_o
highly-sensitive JJ 1_o
C-reactive JJ 1_o
protein NN 1_o
, , 1_o
and CC 1_o
E-selectin NNP 1_o
, , N
multiple JJ N
regression NN N
analysis NN N
identified VBN N
HbA1c NNP 1_o
as IN N
the DT N
only JJ N
significant JJ N
independent JJ N
determinant NN N
of IN N
the DT N
change NN N
in IN N
carotid JJ 1_o
intima-media JJ 1_o
thickness NN 1_o
. . 1_o

CONCLUSION NNP N
In IN N
type NN 1_p
2 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
good JJ 1_p
glycemic NNS 1_p
control NN 1_p
, , N
further JJ N
strict JJ 1_i
glycemic NNS 1_i
control NN 1_i
by IN 1_i
nateglinide JJ 1_i
results NNS N
in IN N
regression NN N
of IN N
carotid JJ 1_o
intima-media JJ 1_o
thickness NN 1_o
. . 1_o

Epinephrine-induced JJ N
panic NN N
attacks NNS N
and CC N
hyperventilation NN N
. . N

To TO N
assess VB N
the DT N
effects NNS N
of IN N
epinephrine NN 1_i
on IN N
ventilation NN N
in IN N
patients NNS 1_p
with IN 1_p
panic JJ 1_p
disorder NN 1_p
and CC 1_p
in IN 1_p
social JJ 1_p
phobics NNS 1_p
, , N
analyses NNS N
were VBD N
performed VBN N
on IN N
pooled VBN N
data NNS N
from IN N
two CD N
previous JJ N
infusion NN N
studies NNS N
. . N

Throughout IN N
the DT N
infusion NN N
, , N
changes NNS 1_o
in IN 1_o
transcutaneous JJ 1_o
PCO2 NNP 1_o
( ( 1_o
tcPCO2 NN 1_o
) ) 1_o
, , 1_o
subjective JJ 1_o
anxiety NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
were VBD N
recorded VBN N
continuously RB N
. . N

Twenty-nine JJ 1_p
patients NNS 1_p
received VBD 1_p
epinephrine JJ 1_i
, , 1_p
ten JJ 1_p
patients NNS 1_p
received VBD 1_p
placebo NN 1_i
. . 1_i

Thirteen JJ N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
had VBD N
a DT N
panic JJ N
attack NN N
during IN N
epinephrine NN 1_i
. . 1_i

The DT N
fall NN 1_o
in IN 1_o
tcPCO2 NN 1_o
and CC 1_o
the DT 1_o
cardiovascular JJ 1_o
response NN 1_o
was VBD N
greater JJR N
in IN N
panicking VBG N
patients NNS N
than IN N
patients NNS N
who WP N
did VBD N
not RB N
panic JJ N
. . N

Although IN N
the DT N
fall NN N
in IN N
tcPCO2 NN 1_o
associated VBN N
with IN N
panic NN N
was VBD N
not RB N
substantial JJ N
and CC N
did VBD N
not RB N
indicate VB N
clinically RB N
significant JJ N
acute JJ 1_o
hyperventilation NN 1_o
, , N
it PRP N
appears VBZ N
to TO N
be VB N
a DT N
sensitive JJ N
index NN N
for IN N
epinephrine-induced JJ N
panic NN N
. . N

The DT N
fall NN 1_o
in IN 1_o
tcPCO2 NN 1_o
was VBD N
predicted VBN N
rather RB N
by IN N
the DT N
frequency NN N
of IN N
occurrence NN 1_o
of IN 1_o
anxiety-related JJ 1_o
somatic NN 1_o
symptoms NNS 1_o
than IN N
by IN N
the DT N
fear NN N
of IN N
these DT N
symptoms NNS N
. . N

These DT N
findings NNS N
further RB N
reduce VB N
a DT N
role NN N
for IN N
fear NN N
of IN N
bodily JJ N
sensations NNS N
in IN N
epinephrine-induced JJ 1_i
panic NN N
attacks NNS N
and CC N
favor VBP N
a DT N
biological JJ N
sensitivity NN N
to TO N
sympathetic JJ N
stimulation NN N
. . N

Evaluation NN N
of IN N
additional JJ N
amine NN 1_i
fluoride/stannous JJ 1_i
fluoride-containing JJ 1_i
mouthrinse NN 1_i
during IN N
supportive JJ N
therapy NN N
in IN N
patients NNS 1_p
with IN 1_p
generalized JJ 1_p
aggressive JJ 1_p
periodontitis NN 1_p
. . 1_p

A DT N
randomized JJ N
, , N
crossover RB N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
. . N

OBJECTIVES CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
mouthrinse NN 1_i
containing VBG 1_i
a DT 1_i
combination NN 1_i
of IN 1_i
AmF/SnF2 NNP 1_i
in IN N
controlling VBG N
supragingival JJ N
plaque NN N
accumulation NN N
and CC N
gingival JJ N
inflammation NN N
during IN N
a DT N
12-week JJ N
period NN N
in IN N
patients NNS 1_p
affected VBN 1_p
by IN 1_p
generalized JJ 1_p
aggressive JJ 1_p
periodontitis NN 1_p
( ( 1_p
GAP NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Eighteen NNP 1_p
subjects NNS 1_p
, , 1_p
six CD 1_p
males NNS 1_p
and CC 1_p
12 CD 1_p
females NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
: : 1_p
32.2 CD 1_p
years NNS 1_p
, , 1_p
were VBD 1_p
evaluated VBN 1_p
. . 1_p

One-half NN N
of IN N
the DT N
patients NNS N
was VBD N
either RB N
prescribed VBN N
an DT N
AmF/SnF2-containing JJ 1_i
mouthrinse NN 1_i
( ( N
test JJS N
mouthrinse NN N
) ) N
or CC N
a DT N
control NN 1_i
mouthrinse NN 1_i
in IN N
addition NN N
to TO N
mechanical JJ 1_i
plaque NN 1_i
control NN 1_i
for IN N
12 CD N
weeks NNS N
. . N

After IN N
a DT N
2-week JJ N
wash-out JJ N
period NN N
, , N
the DT N
patients NNS N
received VBD N
the DT N
alternative JJ N
mouthrinse NN 1_i
. . 1_i

Before IN N
and CC N
after IN N
treatment NN N
plaque NN 1_o
index NN 1_o
( ( 1_o
PlI NNP 1_o
) ) 1_o
, , 1_o
gingival JJ 1_o
index NN 1_o
( ( 1_o
GI NNP 1_o
) ) 1_o
, , 1_o
angulated VBD 1_o
bleeding VBG 1_o
index NN 1_o
( ( 1_o
AngBI NNP 1_o
) ) 1_o
, , 1_o
tooth EX 1_o
stain NN 1_o
( ( 1_o
GMSI NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
tongue NN 1_o
stain NN 1_o
were VBD N
recorded VBN N
. . N

RESULTS JJ N
Test NNP 1_i
mouthrinse NN 1_i
resulted VBD N
in IN N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
PlI NNP 1_o
( ( N
p JJ N
= NNP N
0.029 CD N
) ) N
and CC N
GI NNP N
( ( N
p JJ N
= NNP N
0.017 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
PlI NNP 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
test NN N
compared VBN N
to TO N
control VB N
mouthrinse NN N
( ( N
p JJ N
= NNP N
0.027 CD N
) ) N
. . N

GMSI NNP 1_o
significantly RB N
increased VBD N
post-treatment NN N
for IN N
both DT N
mouthrinse NN 1_i
regimens VBZ 1_i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
a DT N
significantly RB N
higher JJR N
score NN N
being VBG N
observed VBN N
for IN N
the DT N
test NN N
compared VBN N
to TO N
control VB 1_i
mouthrinse NN 1_i
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
12-week JJ N
use NN N
of IN N
a DT N
AmF/SnF2-containing JJ 1_i
mouthrinse NN 1_i
as IN N
an DT N
adjunct NN N
to TO N
conventional JJ N
mechanical JJ N
oral JJ N
hygiene NN N
procedures NNS N
in IN N
GAP NNP 1_p
patients NNS 1_p
was VBD N
effective JJ N
in IN N
controlling VBG N
the DT N
amount NN N
of IN N
supragingival JJ N
plaque NN N
deposits NNS N
. . N

The DT N
effect NN N
of IN N
body NN N
positioning VBG N
upon IN N
maximal JJ 1_i
oxygenation NN 1_i
of IN N
patients NNS 1_p
with IN 1_p
unilateral JJ 1_p
lung NN 1_p
pathology NN 1_p
. . 1_p

A DT N
quasi-experimental JJ N
, , N
repeated-measures JJ N
cross-over NN N
design NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
body NN N
position NN N
on IN N
oxygenation NN 1_i
( ( 1_i
SaO2 NNP 1_i
) ) 1_i
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
in IN N
patients NNS 1_p
with IN 1_p
unilateral JJ 1_p
lung NN 1_p
pathology NN 1_p
was VBD N
conducted VBN N
. . N

Previous JJ N
research NN N
strongly RB N
suggests VBZ N
that IN N
positioning VBG N
with IN N
the DT N
healthy JJ N
( ( N
unaffected JJ N
) ) N
lung NN N
in IN N
the DT N
dependent JJ N
lateral NN N
( ( N
down RP N
) ) N
position NN N
is VBZ N
related VBN N
to TO N
improved VBN N
oxygenation NN N
, , N
but CC N
knowledge VBP N
about IN N
whether IN N
this DT N
effect NN N
is VBZ N
maintained VBN N
over IN N
time NN N
is VBZ N
lacking VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
positioning VBG N
with IN N
the DT N
unaffected JJ N
lung NN N
in IN N
the DT N
dependent JJ N
lateral JJ N
position NN N
related VBN N
to TO N
increased VBN N
arterial JJ N
blood NN N
saturation NN N
levels NNS N
and CC N
decreased VBD N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
? . N
( ( N
2 CD N
) ) N
What WP N
is VBZ N
the DT N
relationship NN N
between IN N
the DT N
dependent JJ N
variables NNS N
-- : N
oxygenation NN N
saturation NN N
levels NNS N
, , N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
-- : N
and CC N
the DT N
independent JJ N
variables NNS N
-- : N
body NN N
position NN N
and CC N
time NN N
in IN N
the DT N
position NN N
? . N
Thirty-nine JJ 1_p
patients NNS 1_p
with IN 1_p
unilateral JJ 1_p
lung NN 1_p
pathology NN 1_p
were VBD N
positioned VBN 1_i
on IN 1_i
their PRP$ 1_i
sides NNS 1_i
with IN 1_i
the DT 1_i
unaffected JJ 1_i
lung NN 1_i
down RP 1_i
, , 1_i
on IN 1_i
their PRP$ 1_i
sides NNS 1_i
with IN 1_i
the DT 1_i
affected JJ 1_i
lung NN 1_i
down RB 1_i
, , 1_i
and CC 1_i
also RB 1_i
in IN 1_i
semi-Fowler NN 1_i
's POS 1_i
position NN 1_i
. . 1_i

Arterial NNP 1_o
( ( 1_o
SaO2 NNP 1_o
) ) 1_o
blood NN 1_o
saturation NN 1_o
and CC 1_o
vital JJ 1_o
signs NNS 1_o
were VBD N
measured VBN N
at IN N
baseline NN N
0 CD N
, , N
15 CD N
and CC N
30 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
relationship NN N
between IN N
oxygenation NN 1_o
level NN 1_o
or CC 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
. . 1_o

Diastolic NNP 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
respiration NN 1_o
and CC 1_o
pulse NN 1_o
did VBD N
vary JJ N
significantly RB N
with IN N
position NN N
. . N

Body NNP 1_i
asymmetry NN 1_i
affects VBZ N
conjugate JJ 1_o
lateral JJ 1_o
eye NN 1_o
movement NN 1_o
. . 1_o

A. NNP N
H. NNP N
Baker NNP N
( ( N
1989 CD N
) ) N
and CC N
A. NNP N
H. NNP N
Baker NNP N
and CC N
A. NNP N
I. NNP N
Ledner NNP N
( ( N
1990 CD N
) ) N
reported VBD N
that DT N
asymmetrical JJ N
visual JJ N
stimulation NN N
affects NNS N
conjugate VBP 1_o
lateral JJ 1_o
eye NN 1_o
movement NN 1_o
( ( 1_o
CLEM NNP 1_o
) ) 1_o
. . 1_o

In IN N
the DT N
present JJ N
article NN N
, , N
the DT N
authors NNS N
explored VBD N
whether IN N
asymmetrical JJ N
body NN N
position NN N
similarly RB N
affects VBZ N
CLEM NNP N
. . N

The DT N
authors NNS 1_p
assessed VBD N
CLEMs NNP N
twice RB N
in IN N
a DT N
counterbalanced JJ N
design NN N
. . N

In IN N
the DT N
control NN 1_p
( ( 1_p
symmetric JJ 1_p
) ) 1_p
condition NN 1_p
, , N
each DT N
participant NN 1_p
sat VBD N
in IN N
a DT N
completely RB 1_i
symmetrical JJ 1_i
position NN 1_i
facing VBG N
a DT N
wall NN N
devoid NN N
of IN N
any DT N
asymmetrical JJ N
features NNS N
. . N

In IN N
the DT N
experimental NN N
( ( N
asymmetrical JJ N
) ) N
condition NN N
, , N
half PDT N
the DT N
participants NNS 1_p
rotated VBD 1_i
their PRP$ 1_i
heads NNS 1_i
68 CD 1_i
degrees NNS 1_i
clockwise RB 1_i
relative VBP 1_i
to TO 1_i
their PRP$ 1_i
bodies NNS 1_i
to TO 1_i
face VB 1_i
the DT 1_i
experimenter NN 1_i
, , 1_i
and CC 1_i
the DT 1_i
other JJ 1_i
half NN 1_i
rotated VBD 1_i
their PRP$ 1_i
heads NNS 1_i
68 CD 1_i
degrees NNS 1_i
counterclockwise NN 1_i
, , N
also RB N
to TO N
face VB N
the DT N
experimenter NN N
. . N

CLEM NNP N
was VBD N
predominantly RB N
toward IN N
the DT N
body NN N
's POS N
position NN N
in IN N
the DT N
asymmetrical JJ N
condition NN N
rather RB N
than IN N
toward IN N
the DT N
body NN N
's POS N
position NN N
in IN N
the DT N
symmetrical JJ N
condition NN N
. . N

Antihistaminics NNS 1_i
in IN N
idiopathic JJ 1_o
dystonia NN 1_o
. . 1_o

Patient JJ 1_i
navigation NN 1_i
improves VBZ N
cancer NN N
diagnostic JJ N
resolution NN N
: : N
an DT N
individually RB N
randomized JJ N
clinical JJ N
trial NN N
in IN N
an DT N
underserved JJ 1_p
population NN 1_p
. . 1_p

BACKGROUND NNP N
Barriers NNPS N
to TO N
timely JJ N
resolution NN N
of IN N
abnormal JJ N
cancer NN N
screening VBG N
tests NNS N
add VBP N
to TO N
cancer NN N
health NN N
disparities NNS N
among IN N
low-income JJ 1_p
, , 1_p
uninsured JJ 1_p
, , 1_p
and CC 1_p
minority NN 1_p
populations NNS 1_p
. . 1_p

We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
lay NN 1_i
patient NN 1_i
navigators NNS 1_i
on IN N
time NN N
to TO N
resolution NN N
and CC N
completion NN N
of IN N
follow-up JJ N
testing NN N
among IN N
patients NNS 1_p
with IN 1_p
abnormal JJ 1_p
screening VBG 1_p
tests NNS 1_p
in IN 1_p
a DT 1_p
medically RB 1_p
underserved JJ 1_p
patient JJ 1_p
population NN 1_p
. . 1_p

METHODS NNP N
Denver NNP 1_p
Health NNP 1_p
, , 1_p
the DT 1_p
safety-net JJ 1_p
health NN 1_p
care NN 1_p
system NN 1_p
serving VBG 1_p
Denver NNP 1_p
, , 1_p
is VBZ 1_p
one CD 1_p
of IN 1_p
10 CD 1_p
performance NN 1_p
sites NNS 1_p
participating VBG 1_p
in IN 1_p
the DT 1_p
Patient NNP 1_p
Navigation NNP 1_p
Research NNP 1_p
Program NNP 1_p
. . 1_p

Of IN N
993 CD 1_p
eligible JJ 1_p
subjects NNS 1_p
with IN 1_p
abnormal JJ 1_p
screening VBG 1_p
tests NNS 1_p
randomized VBD 1_p
to TO 1_p
navigation NN 1_i
and CC 1_i
no-navigation NN 1_i
( ( 1_i
control NN 1_i
) ) 1_i
arms NNS 1_p
and CC 1_p
analyzed VBD 1_p
, , 1_p
628 CD 1_p
had VBD 1_p
abnormal JJ 1_p
breast NN 1_p
screens NNS 1_p
( ( 1_p
66 CD 1_p
abnormal RB 1_p
clinical JJ 1_p
breast NN 1_p
examinations NNS 1_p
, , 1_p
304 CD 1_p
BIRADS NNP 1_p
0 CD 1_p
, , 1_p
200 CD 1_p
BIRADS NNP 1_p
3 CD 1_p
, , 1_p
58 CD 1_p
BIRADS NNP 1_p
4 CD 1_p
or CC 1_p
5 CD 1_p
) ) 1_p
whereas VBD 1_p
235 CD 1_p
had VBD 1_p
abnormal JJ 1_p
colorectal NN 1_p
and CC 1_p
130 CD 1_p
had VBD 1_p
abnormal JJ 1_p
prostate NN 1_p
screens NNS 1_p
. . 1_p

RESULTS JJ N
Time NNP 1_o
to TO 1_o
resolution NN 1_o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
navigated JJ N
group NN N
( ( N
stratified VBN N
log NN N
rank NN N
test NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Patient JJ 1_i
navigation NN 1_i
improved VBD N
diagnostic JJ 1_o
resolution NN 1_o
for IN N
patients NNS N
presenting VBG N
with IN N
mammographic JJ N
BIRADS NNP N
3 CD N
( ( N
P NNP N
= NNP N
0.0003 CD N
) ) N
and CC N
BIRADS $ N
0 CD N
( ( N
P NNP N
= NNP N
0.09 CD N
) ) N
, , N
but CC N
not RB N
BIRADS NNP N
4/5 CD N
or CC N
abnormal JJ N
breast NN N
examinations NNS N
. . N

Navigation NNP N
shortened VBD N
the DT N
time NN N
for IN N
both DT N
colorectal JJ 1_o
( ( N
P NNP N
= NNP N
0.0017 CD N
) ) N
and CC N
prostate VB 1_o
screening VBG 1_o
resolution NN 1_o
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
. . N

Participant JJ 1_p
demographics NNS 1_p
included VBD 1_p
72 CD 1_p
% NN 1_p
minority NN 1_p
, , 1_p
49 CD 1_p
% NN 1_p
with IN 1_p
annual JJ 1_p
household JJ 1_p
income NN 1_p
less JJR 1_p
than IN 1_p
$ $ 1_p
10,000 CD 1_p
, , 1_p
and CC 1_p
36 CD 1_p
% NN 1_p
uninsured JJ 1_p
. . 1_p

CONCLUSIONS NNP N
Patient NNP 1_i
navigation NN 1_i
positively RB N
impacts VBZ N
time NN N
to TO N
resolution NN 1_o
of IN N
abnormal JJ N
screening NN N
tests NNS N
for IN N
breast NN N
, , N
colorectal NN N
, , N
and CC N
prostate NN N
cancers NNS N
in IN N
a DT N
medically RB 1_p
underserved JJ 1_p
population NN 1_p
. . 1_p

IMPACT NNP N
By IN N
shortening VBG N
the DT N
time NN N
to TO N
and CC N
increasing VBG N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
diagnostic JJ N
resolution NN N
patient NN N
navigation NN N
could MD N
reduce VB N
disparities NNS N
in IN N
stage NN N
at IN N
diagnosis NN N
and CC N
improve VB N
cancer NN N
outcomes NNS N
. . N

Comparison NNP N
of IN N
arch NN N
dimension NN N
changes NNS N
in IN N
1-phase JJ N
vs JJ N
2-phase JJ N
treatment NN N
of IN N
Class NNP 1_p
II NNP 1_p
malocclusion NN 1_p
. . 1_p

INTRODUCTION NNP N
We PRP N
compared VBN N
arch JJ N
dimension NN N
changes NNS N
in IN N
1-phase JJ N
and CC N
2-phase JJ N
treatment NN N
of IN N
Class NNP 1_p
II NNP 1_p
malocclusion NN 1_p
. . 1_p

This DT N
was VBD N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
conducted VBN N
in IN N
the DT N
Department NNP 1_p
of IN 1_p
Orthodontics NNP 1_p
at IN 1_p
the DT 1_p
University NNP 1_p
of IN 1_p
Florida NNP 1_p
between IN 1_p
1990 CD 1_p
and CC 1_p
2003 CD 1_p
. . 1_p

METHODS NNP N
During IN N
phase NN N
1 CD N
treatment NN N
, , N
86 CD 1_p
subjects NNS 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
a DT 1_p
bionator NN 1_i
, , 1_p
93 CD 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
headgear/biteplane NN 1_i
, , N
and CC N
81 CD 1_p
served VBD 1_p
as IN 1_p
the DT 1_p
observation NN 1_p
group NN 1_p
. . 1_p

For IN N
phase NN N
2 CD N
, , N
all DT N
subjects NNS N
were VBD N
then RB N
treated VBN N
with IN N
full JJ 1_i
orthodontic JJ 1_i
appliances NNS 1_i
. . 1_i

Arch VBP N
dimensions NNS N
were VBD N
followed VBN N
; : N
maxillary JJ N
and CC N
mandibular JJ N
alginate NN N
impressions NNS N
were VBD N
taken VBN N
at IN N
baseline NN N
, , N
end NN N
of IN N
early JJ N
Class NNP N
II NNP N
treatment NN N
or CC N
observation NN N
, , N
beginning VBG N
of IN N
fixed JJ N
appliance NN N
treatment NN N
, , N
end NN N
of IN N
orthodontic JJ N
treatment NN N
, , N
and CC N
approximately RB N
3 CD N
years NNS N
posttreatment NN N
. . N

Alginate NNP N
impressions NNS N
were VBD N
taken VBN N
of IN N
each DT N
dental JJ N
arch NN N
at IN N
each DT N
data NN N
collection NN N
point NN N
. . N

These DT N
were VBD N
poured VBN N
in IN N
orthodontic JJ N
stone NN N
, , N
trimmed VBN N
, , N
and CC N
photocopied VBD N
from IN N
the DT N
occlusal NN N
aspect NN N
. . N

These DT N
images NNS N
were VBD N
then RB N
scanned VBN N
and CC N
measured VBN N
. . N

RESULTS NNP N
Although IN N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
were VBD N
found VBN N
in IN N
both DT N
the DT N
maxillary NN N
and CC N
mandibular JJ N
arches NNS N
after IN N
phase NN N
1 CD N
, , N
these DT N
differences NNS N
were VBD N
no RB N
longer RBR N
evident JJ N
by IN N
the DT N
end NN N
of IN N
full JJ N
orthodontic JJ N
treatment NN N
or CC N
after IN N
posttreatment JJ N
retention NN N
. . N

CONCLUSIONS NNP N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
arch NN 1_o
dimensions NNS 1_o
after IN N
1-phase JJ N
or CC N
2-phase JJ N
treatment NN N
of IN N
Class NNP N
II NNP N
malocclusion NN N
. . N

Take VB N
a DT N
walk NN N
in IN N
the DT N
park NN N
? . N
A DT N
cross-over NN N
pilot NN N
trial NN N
comparing VBG N
brisk JJ 1_i
walking VBG 1_i
in IN 1_i
two CD 1_i
different JJ 1_i
environments NNS 1_i
: : 1_i
park NN N
and CC N
urban JJ N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
differences NNS N
exist VBP N
between IN N
a DT N
30 CD 1_i
minute NN 1_i
brisk NN 1_i
walk VBP 1_i
taken VBN N
in IN N
two CD N
different JJ N
environments NNS N
in IN N
order NN N
to TO N
determine VB N
which WDT N
environment NN N
best JJS N
facilitates NNS N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
: : N
park NN N
or CC N
urban JJ N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
cross-over NN N
pilot NN N
study NN N
, , N
participants NNS 1_p
performed VBD 1_p
a DT 1_p
self-timed JJ 1_i
30 CD 1_i
minute NN 1_i
brisk NN 1_i
walk VBP 1_i
in IN 1_i
two CD 1_i
different JJ 1_i
environments NNS 1_i
, , 1_i
park NN 1_i
and CC 1_i
urban JJ 1_i
, , N
in IN N
Glasgow NNP N
, , N
Scotland NNP N
( ( N
October NNP N
2009 CD N
to TO N
January NNP N
2010 CD N
) ) N
. . N

Cadence NN 1_o
, , N
recorded VBD N
using VBG N
the DT N
activPAL™ NN N
activity NN N
monitor NN N
, , N
was VBD N
used VBN N
to TO N
measure VB N
intensity NN N
. . N

Outcome CC N
measures NNS N
were VBD 1_o
: : 1_o
mean JJ 1_o
cadence NN 1_o
; : 1_o
moderate-to-vigorous JJ 1_o
physical JJ 1_o
activity NN 1_o
time NN 1_o
accumulated VBN 1_o
in IN 1_o
bouts NNS 1_o
lasting VBG 1_o
≥ $ 1_o
10 CD 1_o
min NN 1_o
; : 1_o
number NN 1_o
of IN 1_o
walking VBG 1_o
breaks NNS 1_o
; : 1_o
and CC 1_o
duration NN 1_o
. . N

RESULTS VB N
A DT N
convenience NN N
sample NN 1_p
of IN 1_p
40 CD 1_p
healthy JJ 1_p
adults NNS 1_p
was VBD 1_p
recruited VBN 1_p
: : 1_p
16 CD 1_p
males NNS 1_p
, , 1_p
24 CD 1_p
females NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
22.9 CD 1_p
( ( 1_p
5.5 CD 1_p
) ) 1_p
years NNS 1_p
. . N

The DT 1_o
mean JJ 1_o
cadence NN 1_o
for IN 1_o
the DT 1_o
whole JJ 1_o
walk NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
park NN N
: : N
119.3 CD N
( ( N
8.3 CD N
) ) N
vs. FW N
110.9 CD N
( ( N
8.9 CD N
) ) N
steps/min NN 1_p
. . 1_p

Participants NNS 1_p
accumulated VBD N
more RBR 1_o
moderate-to-vigorous JJ 1_o
physical JJ 1_o
activity NN 1_o
in IN 1_o
≥ $ 1_o
10 CD 1_o
minute NN 1_o
bouts NNS N
during IN N
park JJ N
walks NNS N
: : N
25.5 CD N
( ( N
9.6 CD N
) ) N
[ NN N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
] VBZ N
vs. FW N
14.0 CD N
( ( N
20.3 CD N
) ) N
min NN N
. . N

There EX N
was VBD N
no DT N
difference NN 1_o
in IN 1_o
self-timed JJ 1_o
duration NN 1_o
between IN N
locations NNS N
. . N

CONCLUSION NNP N
Participants NNPS N
accumulated VBD 1_o
more RBR 1_o
moderate-to-vigorous JJ 1_o
physical JJ 1_o
activity NN 1_o
in IN N
bouts NNS N
≥ VBP N
10 CD N
min NN N
in IN N
duration NN N
on IN N
park NN N
walks NNS N
due JJ N
to TO N
the DT N
lack NN N
of IN N
interruptions NNS N
in IN N
walking VBG N
. . N

Hence NNP N
the DT N
park NN N
environment NN N
better RBR N
facilitated VBD N
the DT N
achievement NN N
of IN N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
. . N

Further JJ N
research NN N
involving VBG N
a DT N
larger JJR N
, , N
more RBR N
heterogeneous JJ N
sample NN N
is VBZ N
recommended VBN N
. . N

Endotracheal NNP 1_p
cuff NN 1_p
pressure NN 1_p
and CC 1_p
tracheal NN 1_p
mucosal NN 1_p
blood NN 1_p
flow NN 1_p
: : 1_p
endoscopic NN N
study NN N
of IN N
effects NNS N
of IN N
four CD 1_p
large JJ 1_p
volume NN 1_p
cuffs NNS 1_p
. . 1_p

Large JJ 1_i
volume NN 1_i
, , 1_i
low JJ 1_i
pressure NN 1_i
endotracheal NN 1_i
tube NN 1_i
cuffs NNS 1_i
are VBP N
claimed VBN N
to TO N
have VB N
less RBR N
deleterious JJ N
effect NN N
on IN N
tracheal NN 1_o
mucosa NN 1_o
than IN N
high JJ N
pressure NN N
, , N
low JJ N
volume NN N
cuffs NNS N
. . N

Low JJ 1_i
pressure NN 1_i
cuffs NNS 1_i
, , N
however RB N
, , N
may MD N
easily RB N
be VB N
overinflated VBN N
to TO N
yield VB N
pressures NNS N
that WDT N
will MD N
exceed VB N
capillary JJ N
perfusion NN N
pressure NN N
. . N

Various JJ N
large JJ 1_i
volume NN 1_i
cuffed VBD 1_i
endotracheal JJ 1_i
tubes NNS 1_i
were VBD N
studied VBN N
, , N
including VBG N
Portex NNP 1_i
Profile NNP 1_i
, , 1_i
Searle NNP 1_i
Sensiv NNP 1_i
, , 1_i
Mallinkrodt NNP 1_i
Hi-Lo NNP 1_i
, , N
and CC N
Lanz NNP 1_i
. . 1_i

Tracheal NNP N
mucosal NN N
blood NN N
flow NN N
in IN N
40 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
surgery NN 1_p
was VBD N
assessed VBN N
using VBG N
an DT N
endoscopic JJ 1_i
photographic JJ 1_i
technique NN 1_i
while IN 1_i
varying VBG 1_i
the DT 1_i
cuff NN 1_i
inflation NN 1_i
pressure NN 1_i
. . 1_i

It PRP N
was VBD N
found VBN N
that IN N
these DT N
cuffs NNS N
when WRB N
overpressurised VBN N
impaired JJ 1_o
mucosal NN 1_o
blood NN 1_o
flow NN 1_o
. . 1_o

This DT N
impairment NN N
of IN N
tracheal NN 1_o
mucosal NN 1_o
blood NN 1_o
flow NN 1_o
is VBZ N
an DT N
important JJ N
factor NN N
in IN N
tracheal JJ 1_o
morbidity NN 1_o
associated VBN N
with IN N
intubation NN N
. . N

Hence NN N
it PRP N
is VBZ N
recommended VBN N
that IN N
a DT N
cuff NN 1_o
inflation NN 1_o
pressure NN 1_o
of IN N
30 CD N
cm NNS N
H2O NNP N
( ( N
22 CD N
mm RB N
Hg NNP N
) ) N
should MD N
not RB N
be VB N
exceeded VBN N
. . N

Autism NNP N
Spectrum NNP N
Social NNP N
Stories NNP N
In IN N
Schools NNP N
Trial NNP N
( ( N
ASSSIST NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
feasibility NN N
randomised VBN N
controlled VBN N
trial NN N
analysing VBG N
clinical JJ 1_o
and CC 1_o
cost-effectiveness NN 1_o
of IN 1_o
Social NNP 1_o
Stories NNP 1_o
in IN N
mainstream JJ N
schools NNS N
. . N

INTRODUCTION NNP N
Current NNP N
evidence NN N
suggests VBZ N
that IN N
Social NNP 1_i
Stories NNPS 1_i
can MD N
be VB N
effective JJ N
in IN N
tackling VBG N
problem NN 1_o
behaviours NNS 1_o
exhibited VBN N
by IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

Exploring VBG N
the DT N
meaning NN N
of IN N
behaviour NN N
from IN N
a DT N
child NN N
's POS N
perspective JJ N
allows NNS N
stories NNS N
to TO N
provide VB N
social JJ N
information NN N
that WDT N
is VBZ N
tailored VBN N
to TO N
their PRP$ N
needs NNS N
. . N

Case NNP N
reports VBZ N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
have VBP N
suggested VBN N
that IN N
these DT N
stories NNS N
can MD N
lead VB N
to TO N
a DT N
number NN N
of IN N
benefits NNS N
including VBG N
improvements NNS N
in IN N
social JJ 1_o
interactions NNS 1_o
and CC 1_o
choice NN 1_o
making NN 1_o
in IN N
educational JJ N
settings NNS N
. . N

METHODS NNP N
AND CC N
ANALYSIS NNP N
The DT N
feasibility NN 1_o
of IN 1_o
clinical JJ 1_o
and CC 1_o
cost-effectiveness NN 1_o
of IN N
a DT N
Social NNP 1_i
Stories NNP 1_i
toolkit NN N
will MD N
be VB N
assessed VBN N
using VBG N
a DT N
randomised VBN N
control NN N
framework NN N
. . N

Participants NNS 1_p
( ( 1_p
n=50 NN 1_p
) ) 1_p
will MD 1_p
be VB 1_p
randomised VBN 1_p
to TO 1_p
either CC 1_p
the DT 1_p
Social NNP 1_i
Stories NNPS 1_i
intervention NN 1_i
or CC 1_i
a DT 1_i
comparator NN 1_i
group NN 1_i
where WRB 1_p
they PRP 1_p
will MD 1_p
be VB 1_p
read VBN 1_p
standard JJ 1_p
stories NNS 1_p
for IN 1_p
an DT 1_p
equivalent JJ 1_p
amount NN 1_p
of IN 1_p
time NN 1_p
. . 1_p

Statistics NNS N
will MD N
be VB N
calculated VBN N
for IN N
recruitment NN 1_o
rates NNS 1_o
, , 1_o
follow-up JJ 1_o
rates NNS 1_o
and CC 1_o
attrition NN 1_o
. . 1_o

Economic JJ N
analysis NN N
will MD N
determine VB N
appropriate JJ N
measures NNS 1_o
of IN 1_o
generic JJ 1_o
health NN 1_o
and CC 1_o
resource NN 1_o
use NN 1_o
categories NNS 1_o
for IN 1_o
cost-effectiveness JJ 1_o
analysis NN 1_o
. . 1_o

Qualitative JJ N
analysis NN N
will MD N
ascertain VB N
information NN N
on IN N
perceptions NNS N
about IN N
the DT N
feasibility NN 1_o
and CC 1_o
acceptability NN 1_o
of IN N
the DT N
intervention NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
National NNP N
Health NNP N
Service NNP N
Ethics NNP N
Approval NNP N
( ( N
NHS NNP N
; : N
ref VBZ N
11/YH/0340 CD N
) ) N
for IN N
the DT N
trial NN N
protocol NN N
has VBZ N
been VBN N
obtained VBN N
along IN N
with IN N
NHS NNP N
Research NNP N
and CC N
Development NNP N
permission NN N
from IN N
Leeds NNP N
and CC N
York NNP N
Partnership NNP N
NHS NNP N
Foundation NNP N
Trust NNP N
. . N

All DT N
adverse JJ 1_o
events NNS 1_o
will MD N
be VB N
closely RB N
monitored VBN N
, , N
documented VBN N
and CC N
reported VBN N
to TO N
the DT N
study NN N
Data NNP N
Monitoring NNP N
Ethics NNP N
Committee NNP N
. . N

At IN N
least JJS N
one CD N
article NN N
in IN N
a DT N
peer NN N
reviewed VBN N
journal NN N
will MD N
be VB N
published VBN N
and CC N
research NN N
findings NNS N
presented VBN N
at IN N
relevant JJ N
conferences NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN96286707 NNP N
. . N

Psoriasis NN 1_p
of IN 1_p
the DT 1_p
scalp NN 1_p
treated VBD N
with IN N
Grenz NNP 1_i
rays NNS 1_i
or CC N
topical JJ 1_i
corticosteroid NN 1_i
combined VBN 1_i
with IN 1_i
Grenz NNP 1_i
rays NNS 1_i
. . 1_i

A DT N
comparative JJ N
randomized VBN N
trial NN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
Grenz NNP 1_i
ray NN 1_i
therapy NN 1_i
alone RB N
compared VBN N
with IN N
Grenz NNP 1_i
rays NNS 1_i
combined VBN 1_i
with IN 1_i
a DT 1_i
topical JJ 1_i
corticosteroid NN 1_i
( ( 1_i
betamethasone JJ 1_i
dipropionate NN 1_i
) ) 1_i
in IN N
psoriasis NN N
of IN N
the DT N
scalp NN N
, , N
40 CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
4 CD 1_i
Gy NNP 1_i
of IN 1_i
Grenz NNP 1_i
rays NNS 1_i
administered VBD N
on IN N
six CD N
occasions NNS N
at IN N
intervals NNS N
of IN N
1 CD N
week NN N
and CC N
the DT N
other JJ N
group NN N
was VBD N
given VBN N
the DT N
same JJ N
Grenz NNP 1_i
ray NN 1_i
treatment NN 1_i
plus CC 1_i
topical JJ 1_i
corticosteroid NN 1_i
. . 1_i

The DT N
patients NNS N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
Grenz NNP N
ray NN N
therapy NN N
and CC N
were VBD N
followed-up NNS N
for IN N
6 CD N
months NNS N
. . N

Of IN N
the DT N
37 CD 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
16 CD N
out IN N
of IN N
19 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
Grenz NNP 1_i
ray NN 1_i
group NN N
, , N
and CC N
13 CD N
out IN N
of IN N
18 CD N
( ( N
72 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
combination NN N
group NN N
healed VBD 1_o
. . 1_o

The DT N
remission NN 1_o
time NN 1_o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Of IN N
the DT N
patients NNS 1_p
who WP 1_p
healed VBD 1_o
, , N
5 CD N
of IN N
16 CD N
patients NNS N
in IN N
the DT N
Grenz NNP 1_i
ray NN 1_i
only RB N
group NN N
and CC N
4 CD N
of IN N
13 CD N
patients NNS N
in IN N
the DT N
combination NN N
group NN N
remained VBD 1_o
healed VBN 1_o
at IN N
6 CD N
months NNS N
. . N

We PRP N
conclude VBP N
that IN N
Grenz NNP 1_i
ray NN 1_i
therapy NN 1_i
is VBZ N
a DT N
useful JJ N
treatment NN 1_o
modality NN N
for IN N
scalp JJ 1_o
psoriasis NN 1_o
, , N
but CC N
that IN N
the DT N
addition NN N
of IN N
a DT N
topical JJ N
corticosteroid NN 1_i
has VBZ N
only RB N
a DT N
minor JJ 1_o
effect NN 1_o
. . 1_o

Effects NNS N
of IN N
the DT N
Quest NNP 1_i
to TO 1_i
Lava NNP 1_i
Mountain NNP 1_i
Computer NNP 1_i
Game NNP 1_i
on IN N
Dietary NNP 1_o
and CC 1_o
Physical NNP 1_o
Activity NNP 1_o
Behaviors NNP 1_o
of IN N
Elementary NNP 1_p
School NNP 1_p
Children NNP 1_p
: : 1_p
A DT N
Pilot NNP N
Group-Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Computer-based JJ 1_i
educational JJ 1_i
games NNS 1_i
present VBP N
an DT N
opportunity NN N
for IN N
health NN N
education NN N
in IN N
school NN N
; : N
however RB N
, , N
their PRP$ N
feasibility NN N
in IN N
school NN N
settings NNS N
and CC N
effectiveness NN N
in IN N
changing VBG N
behavior NN N
are VBP N
poorly RB N
understood JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
, , N
acceptability NN N
, , N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP 1_i
to TO 1_i
Lava NNP 1_i
Mountain NNP 1_i
( ( 1_i
QTLM NNP 1_i
) ) 1_i
computer NN 1_i
game NN 1_i
on IN N
dietary JJ 1_o
behaviors NNS 1_o
, , 1_o
physical JJ 1_o
activity NN 1_o
behaviors NNS 1_o
, , 1_o
and CC 1_o
psychosocial JJ 1_o
factors NNS 1_o
among IN N
ethnically RB 1_p
diverse JJ 1_p
children NNS 1_p
in IN 1_p
Texas NNP 1_p
. . 1_p

DESIGN NNP N
Quasi-experimental JJ N
group-randomized JJ N
controlled VBN N
trial NN N
conducted VBN N
during IN N
the DT N
2012-2013 JJ 1_p
school NN 1_p
year NN 1_p
. . 1_p

PARTICIPANTS/SETTING CC N
A DT 1_p
total NN 1_p
of IN 1_p
107 CD 1_p
children NNS 1_p
in IN 1_p
fourth JJ 1_p
and CC 1_p
fifth JJ 1_p
grade NN 1_p
consented VBN 1_p
. . 1_p

There EX 1_p
was VBD 1_p
an DT 1_p
attrition NN 1_p
rate NN 1_p
of IN 1_p
8.8 CD 1_p
% NN 1_p
with IN 1_p
a DT 1_p
final JJ 1_p
sample NN 1_p
size NN 1_p
of IN 1_p
44 CD 1_p
children NNS 1_p
in IN 1_p
three CD 1_p
intervention NN 1_p
schools NNS 1_p
, , 1_p
and CC 1_p
a DT 1_p
sample NN 1_p
of IN 1_p
50 CD 1_p
children NNS 1_p
in IN 1_p
three CD 1_p
comparison NN 1_p
schools NNS 1_p
. . 1_p

Dietary NNP N
intake NN N
was VBD N
measured VBN N
using VBG N
two CD N
random JJ N
24-hour JJ N
recalls NNS N
, , N
whereas JJ N
child NN N
self-report JJ N
surveys NNS N
measured VBN N
diet JJ 1_o
, , 1_o
physical JJ 1_o
activity NN 1_o
, , 1_o
and CC 1_o
psychosocial JJ 1_o
factors NNS 1_o
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

Process NNP N
data NN N
on IN N
QTLM NNP 1_i
usability NN N
and CC N
back-end JJ N
server NN N
data NNS N
on IN N
QTLM NNP N
exposure NN N
and CC N
progress NN N
achieved VBN N
were VBD N
collected VBN N
. . N

INTERVENTION NNP N
QTLM NNP 1_i
was VBD N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
in-school NN 1_p
or CC 1_p
afterschool JJ 1_p
program NN 1_p
. . 1_p

Recommended JJ N
game NN N
exposure NN N
duration NN N
was VBD N
90 CD N
min/wk NN N
for IN N
6 CD N
weeks NNS N
. . N

STATISTICAL JJ N
ANALYSIS NNP N
Analysis NNP N
of IN N
covariance NN N
or CC N
logistic JJ N
regression NN N
models NNS N
evaluated VBN N
effects NNS N
of IN N
QTLM NNP 1_i
on IN N
diet JJ 1_o
, , 1_o
physical JJ 1_o
activity NN 1_o
, , 1_o
and CC 1_o
psychosocial JJ 1_o
factors NNS 1_o
. . 1_o

Post NNP N
hoc JJ N
exploratory NN N
analysis NN N
examined VBD N
the DT N
changes NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
outcome JJ N
variables NNS N
among IN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

Significance NN N
was VBD N
set VBN N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

RESULTS NNP N
Children NNP N
played VBD N
an DT N
average NN N
of IN N
274±110 CD N
minutes NNS N
( ( N
approximately RB N
4.6 CD N
hours NNS N
) ) N
of IN 1_i
QTLM NNP 1_i
during IN N
the DT N
6 CD N
weeks NNS N
( ( N
51 CD N
% NN N
of IN N
recommended JJ N
dosage NN N
) ) N
. . N

Compared VBN N
with IN N
the DT N
comparison NN N
group NN N
, , N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD 1_o
decreased JJ 1_o
sugar NN 1_o
consumption NN 1_o
( ( N
P=0.021 NNP N
) ) N
and CC 1_o
higher JJR 1_o
nutrition/physical JJ 1_o
activity NN 1_o
attitudes NNS 1_o
( ( N
P=0.041 NNP N
) ) N
pre- NN N
to TO N
postintervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
QTLM NNP N
on IN 1_o
physical JJ 1_o
activity NN 1_o
. . N

However RB N
, , N
post NN N
hoc NN N
analysis NN N
showed VBD N
that IN N
higher JJR 1_i
QTLM NNP 1_i
exposure NN N
and CC N
gaming VBG N
progress NN N
was VBD N
associated VBN N
with IN N
increased JJ 1_o
frequency NN 1_o
of IN 1_o
physical JJ 1_o
activity NN 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP 1_i
QTLM NNP 1_i
has VBZ N
some DT N
promising JJ N
acceptability NN N
and CC N
initial JJ N
effects NNS N
on IN 1_o
diet JJ 1_o
and CC 1_o
physical JJ 1_o
activity NN 1_o
behaviors NNS 1_o
among IN 1_p
children NNS 1_p
in IN 1_p
elementary JJ 1_p
school NN 1_p
. . N

Predictors NNS N
of IN N
incident NN 1_o
depression NN 1_o
after IN 1_p
hip NN 1_p
fracture NN 1_p
surgery NN 1_p
. . 1_p

OBJECTIVE NNP N
Depression NNP N
after IN N
hip NN 1_i
fracture NN 1_i
surgery NN 1_i
is VBZ N
prevalent JJ N
and CC N
associated VBN N
with IN N
increased JJ N
mortality NN N
rates NNS N
and CC N
impaired JJ N
functional JJ N
recovery NN N
. . N

The DT N
incidence NN N
of IN N
new-onset JJ N
depressive NN N
symptoms NNS N
in IN N
patients NNS N
initially RB N
not RB N
depressed VBN N
after IN N
hip NN 1_i
fracture NN 1_i
surgery NN 1_i
and CC N
their PRP$ N
relationship NN N
with IN N
functional JJ N
recovery NN N
is VBZ N
unknown JJ N
. . N

METHODS VB N
A DT N
cohort NN N
of IN N
139 CD 1_p
nondepressed JJ 1_p
elderly JJ 1_p
patients NNS 1_p
( ( 1_p
> JJ 1_p
60 CD 1_p
years NNS 1_p
) ) 1_p
hospitalized VBD 1_p
for IN 1_p
hip NN 1_i
fracture NN 1_i
surgery NN 1_i
were VBD N
followed VBN N
up RP N
for IN N
six CD N
months NNS N
. . N

Clinically NNP N
significant JJ N
depressive NN N
symptoms NNS N
were VBD N
defined VBN N
as IN N
a DT N
score NN N
of IN N
7 CD N
or CC N
more JJR N
on IN N
the DT N
15-item JJ 1_o
Geriatric NNP 1_o
Depression NNP 1_o
Scale NNP 1_o
. . 1_o

RESULTS VB N
The DT N
authors NNS N
found VBD N
a DT N
cumulative JJ 1_o
incidence NN 1_o
rate NN 1_o
of IN N
20.5 CD N
% NN N
adjusted VBN N
for IN N
dropouts NNS N
. . N

Multiple JJ N
Cox-regression JJ N
analyses NNS N
yielded VBD N
the DT N
presence NN N
of IN N
subthreshold JJ N
symptoms NNS N
of IN N
depression NN 1_o
, , 1_o
anxiety NN 1_o
, , 1_o
pain NN 1_o
, , 1_o
and CC 1_o
cognitive JJ 1_o
impairment NN 1_o
at IN 1_o
baseline NN 1_o
, , 1_o
the DT 1_o
premorbid NN 1_o
level NN 1_o
of IN 1_o
mobility NN 1_o
, , 1_o
and CC 1_o
a DT 1_o
history NN 1_o
of IN 1_o
( ( 1_o
treated VBN 1_o
) ) 1_o
depression NN 1_o
as IN 1_o
risk NN 1_o
factors NNS 1_o
for IN 1_o
incident JJ 1_o
depression NN 1_o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
forward NN N
, , N
conditional JJ N
procedure NN N
identified VBN N
postoperative JJ 1_o
pain NN 1_o
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
1.32 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.14-1.53 JJ N
, , N
Wald NNP N
chi NN N
( ( N
2 CD N
) ) N
= NN N
13.57 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
baseline JJ 1_o
anxiety NN 1_o
( ( N
HR NNP N
= NNP N
1.25 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.08-1.44 JJ N
, , N
Wald NNP N
chi NN N
( ( N
2 CD N
) ) N
= NN N
8.86 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
as IN N
the DT N
strongest JJS N
independent JJ N
risk NN N
factors NNS N
. . N

Incident NNP 1_o
depression NN 1_o
was VBD N
associated VBN N
with IN N
a DT N
less RBR N
favorable JJ N
outcome NN N
at IN N
3 CD N
months NNS N
follow-up RB N
. . N

CONCLUSION VB N
This DT N
exploratory NN N
study NN N
identified VBD N
two CD N
treatable JJ N
baseline NN N
characteristics NNS N
that WDT N
predicted VBD N
incident JJ 1_o
depression NN 1_o
in IN N
nondepressed JJ 1_p
patients NNS 1_p
after IN 1_p
hip-fracture JJ 1_p
surgery NN 1_p
. . 1_p

Efficacy NN 1_o
of IN N
prepackaged VBN 1_i
, , 1_i
low JJ 1_i
residual JJ 1_i
test NN 1_i
meals NNS 1_i
with IN 1_i
4L CD 1_i
polyethylene NN 1_i
glycol NN 1_i
versus IN 1_i
a DT 1_i
clear JJ 1_i
liquid NN 1_i
diet NN 1_i
with IN 1_i
4L CD 1_i
polyethylene NN 1_i
glycol NN 1_i
bowel NN 1_i
preparation NN 1_i
: : 1_i
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
A NNP N
prepackaged VBD N
low JJ N
residue JJ N
one-day JJ N
diet NN N
( ( N
breakfast NN N
, , N
lunch NN N
and CC N
dinner NN N
) ) N
has VBZ N
been VBN N
recently RB N
developed VBN N
to TO N
improve VB N
patient NN 1_o
tolerance NN 1_o
for IN 1_o
bowel NN 1_o
preparation NN 1_o
prior RB N
to TO N
colonoscopy VB N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC N
tolerability NN 1_o
of IN N
bowel NN N
preparation NN N
protocols NNS N
based VBN N
on IN N
a DT N
low JJ 1_i
residue JJ 1_i
diet NN 1_i
and CC N
4L CD 1_i
polyethylene NN 1_i
glycol NN 1_i
( ( 1_i
PEG NNP 1_i
) ) 1_i
solution NN 1_i
, , N
and CC N
to TO N
compare VB N
these DT N
new JJ N
options NNS N
with IN N
the DT N
traditional JJ 1_i
liquid NN 1_i
diet NN 1_i
and CC 1_i
the DT 1_i
PEG NNP 1_i
4L CD 1_i
lavage NN 1_i
. . 1_i

METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
214 CD 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
: : 1_p
54.1 CD 1_p
years NNS 1_p
; : 1_p
120 CD 1_p
male NN 1_p
, , 1_p
94 CD 1_p
female NN 1_p
) ) 1_p
from IN 1_p
four CD 1_p
university NN 1_p
hospitals NNS 1_p
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
clear JJ 1_i
liquid NN 1_i
diet NN 1_i
and CC 1_i
the DT 1_i
PEG NNP 1_i
4L CD 1_i
regimen NNS 1_i
( ( 1_p
106 CD 1_p
patients NNS 1_p
) ) 1_p
or CC N
the DT N
low JJ 1_i
residue JJ 1_i
test NN 1_i
meals NNS 1_i
and CC 1_i
the DT 1_i
PEG NNP 1_i
4L CD 1_i
regimen NNS 1_i
( ( 1_i
TM-PEG JJ 1_i
4L CD N
, , N
108 CD N
patients NNS N
) ) N
. . N

The DT N
colon NN 1_o
cleansing VBG 1_o
efficacy NN 1_o
of IN N
the DT N
different JJ N
preparations NNS N
was VBD N
rated VBN N
using VBG N
the DT N
Ottawa NNP 1_o
bowel NN 1_o
preparation NN 1_o
scale NN 1_o
. . 1_o

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
treatment NN N
groups NNS N
according VBG N
to TO N
the DT N
Ottawa NNP 1_o
cleansing VBG 1_o
scale JJ 1_o
findings NNS N
( ( N
PEG NNP N
4L CD N
: : N
2.97 CD N
vs IN N
TM-PEG JJ N
4L CD N
: : N
2.46 CD N
, , N
P NNP N
= NNP N
0.063 CD N
) ) N
. . N

The DT N
overall JJ 1_o
tolerability NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
TM-PEG NNP N
4L CD N
group NN N
than IN N
in IN N
the DT N
PEG NNP N
4L CD N
group NN N
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

No DT N
difference NN N
was VBD N
found VBN N
when WRB N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
with IN N
regard NN N
to TO N
adverse JJ 1_o
events NNS 1_o
( ( N
P NNP N
= NNP N
0.599 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
prepackaged JJ N
low JJ N
residue JJ N
one-day JJ N
diet NN N
provided VBD N
cleansing VBG 1_o
efficacy NN 1_o
similar JJ N
to TO N
that DT N
of IN N
a DT N
clear JJ N
liquid NN N
diet NN N
and CC N
offered VBD N
the DT N
benefit NN N
of IN N
improved JJ 1_o
tolerability NN 1_o
compared VBN N
to TO N
the DT N
conventional JJ N
PEG NNP N
4L CD N
regimen NNS N
. . N

Incidence NN 1_o
of IN 1_o
candida NN 1_o
in IN 1_p
hospital JJ 1_p
in-patients NNS 1_p
and CC N
the DT N
effects NNS N
of IN N
antibiotic JJ 1_i
therapy NN 1_i
. . 1_i

Dentists NNS N
United NNP N
to TO N
Extinguish VB N
Tobacco NNP N
( ( N
DUET NNP N
) ) N
: : N
a DT N
study NN N
protocol NN N
for IN N
a DT N
cluster NN N
randomized VBN N
, , N
controlled VBN N
trial NN N
for IN N
enhancing VBG N
implementation NN N
of IN N
clinical JJ 1_i
practice NN 1_i
guidelines NNS 1_i
for IN N
treating VBG N
tobacco NN 1_p
dependence NN 1_p
in IN 1_p
dental JJ 1_p
care NN 1_p
settings NNS 1_p
. . 1_p

BACKGROUND NNP N
Although IN N
dental JJ N
care NN N
settings NNS N
provide VBP N
an DT N
exceptional JJ N
opportunity NN N
to TO N
reach VB N
smokers NNS 1_p
and CC N
provide VB N
brief JJ N
cessation NN N
advice NN N
and CC N
treatment NN N
to TO N
reduce VB N
oral JJ N
and CC N
other JJ N
tobacco-related JJ N
health NN N
conditions NNS N
, , N
dental JJ N
care NN N
providers NNS N
demonstrate VBP N
limited JJ N
adherence NN N
to TO N
evidence-based JJ N
guidelines NNS N
for IN N
treatment NN N
of IN N
tobacco NN 1_p
use NN 1_p
and CC 1_p
dependence NN 1_p
. . 1_p

METHODS/DESIGN NNP N
Guided VBN N
by IN N
a DT N
multi-level NN N
, , N
conceptual JJ N
framework NN N
that WDT N
emphasizes VBZ N
changes NNS N
in IN N
provider NN N
beliefs NNS N
and CC N
organizational JJ N
characteristics NNS N
as IN N
drivers NNS N
of IN N
improvement NN N
in IN N
tobacco NN N
treatment NN N
delivery NN N
, , N
the DT N
current JJ N
protocol NN N
will MD N
use VB N
a DT N
cluster NN N
, , N
randomized VBN N
design NN N
and CC N
multiple JJ N
data NNS N
sources NNS N
( ( N
patient JJ N
exit NN N
interviews NNS N
, , N
provider NN N
surveys NNS N
, , N
site NN N
observations NNS N
, , N
chart JJ N
audits NN N
, , N
and CC N
semi-structured JJ N
provider NN N
interviews NNS N
) ) N
to TO N
study VB N
the DT N
process NN N
of IN N
implementing VBG N
clinical JJ N
practice NN N
guidelines NNS N
for IN N
treating VBG N
tobacco NN N
dependence NN N
in IN N
18 CD 1_p
public JJ 1_p
dental NN 1_p
care NN 1_p
clinics NNS 1_p
in IN 1_p
New NNP 1_p
York NNP 1_p
City NNP 1_p
. . 1_p

The DT N
specific JJ N
aims NNS N
of IN N
this DT N
comparative-effectiveness JJ 1_o
research NN N
trial NN N
are VBP N
to TO N
: : N
compare VB N
the DT N
effectiveness NN N
of IN N
three CD N
promising VBG N
strategies NNS N
for IN N
implementation NN N
of IN N
tobacco NN 1_i
use NN 1_i
treatment NN 1_i
guidelines-staff JJ 1_i
training NN 1_i
and CC 1_i
current JJ 1_i
best JJS 1_i
practices NNS 1_i
( ( 1_i
CBP NNP 1_i
) ) 1_i
, , 1_i
CBP NNP 1_i
+ NNP 1_i
provider NN 1_i
performance NN 1_i
feedback NN 1_i
( ( 1_i
PF NNP 1_i
) ) 1_i
, , 1_i
and CC 1_i
CBP NNP 1_i
+ NNP 1_i
PF NNP 1_i
+ NNP 1_i
provider NN 1_i
reimbursement NN 1_i
for IN 1_i
delivery NN 1_i
of IN 1_i
tobacco NN 1_i
cessation NN 1_i
treatment NN 1_i
( ( 1_i
pay-for-performance NN 1_i
, , N
or CC N
P4P NNP N
) ) N
; : N
examine JJ N
potential JJ N
theory-driven JJ N
mechanisms NNS N
hypothesized VBN N
to TO N
explain VB N
the DT N
comparative JJ N
effectiveness NN N
of IN N
three CD N
strategies NNS N
for IN N
implementation NN N
; : N
and CC N
identify VB N
baseline JJ N
organizational JJ N
factors NNS N
that WDT N
influence VBP N
the DT N
implementation NN N
of IN N
evidence-based JJ N
tobacco NN N
use NN N
treatment NN N
practices NNS N
in IN N
dental JJ N
clinics NNS N
. . N

The DT N
primary JJ 1_o
outcome NN 1_o
is VBZ 1_o
change VBN 1_o
in IN 1_o
providers NNS 1_o
' POS 1_o
tobacco NN 1_o
treatment NN 1_o
practices NNS N
and CC N
the DT N
secondary JJ N
outcomes NNS 1_o
are VBP 1_o
cost VBN 1_o
per IN 1_o
quit NN 1_o
, , 1_o
use NN 1_o
of IN 1_o
tobacco NN 1_o
cessation NN 1_o
treatments NNS 1_o
, , 1_o
quit NN 1_o
attempts NNS 1_o
, , 1_o
and CC 1_o
smoking VBG 1_o
abstinence NN N
. . N

DISCUSSION NNP N
We PRP N
hypothesize VBP N
that IN N
the DT N
value NN N
of IN N
these DT N
promising JJ N
implementation NN N
strategies NNS N
is VBZ N
additive JJ N
and CC N
that IN N
incorporating VBG N
all DT N
three CD N
strategies NNS N
( ( N
CBP NNP N
, , N
PF NNP N
, , N
and CC N
P4P NNP N
) ) N
will MD N
be VB N
superior JJ 1_i
to TO 1_i
CBP VB 1_i
alone RB 1_i
and CC 1_i
CBP NNP N
+ NNP N
PF NNP N
in IN N
improving VBG N
delivery NN N
of IN N
cessation NN N
assistance NN N
to TO N
smokers NNS N
. . N

The DT N
findings NNS N
will MD N
improve VB N
knowledge NN N
pertinent NN N
to TO N
the DT N
implementation NN N
, , N
dissemination NN N
, , N
and CC N
sustained VBD N
utilization NN N
of IN N
evidence-based JJ N
tobacco NN N
use NN N
treatment NN N
in IN N
dental JJ N
practices NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT01615237 NNP N
. . N

Effects NNS N
of IN N
saxagliptin NN 1_i
added VBN N
to TO N
sub-maximal JJ N
doses NNS N
of IN N
metformin NNS 1_i
compared VBN N
with IN N
uptitration NN N
of IN N
metformin NN 1_i
in IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
: : 1_p
the DT N
PROMPT NNP N
study NN N
. . N

OBJECTIVE CC N
The DT N
PROMPT NNP N
study NN N
compared VBN N
efficacy NN N
and CC N
tolerability NN N
of IN N
two CD N
treatment NN N
intensification NN N
strategies NNS N
: : N
adding VBG N
saxagliptin NN 1_i
or CC N
uptitrating JJ N
metformin NN 1_i
monotherapy NN 1_i
, , N
in IN N
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
( ( 1_p
T2D NNP 1_p
) ) 1_p
and CC 1_p
inadequate JJ 1_p
glycaemic NNS 1_p
control NN 1_p
on IN 1_p
a DT 1_p
sub-maximal JJ 1_p
metformin NN 1_p
dose NN 1_p
. . 1_p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
24-week JJ N
study NN N
, , N
metformin-tolerant JJ 1_p
patients NNS 1_p
with IN 1_p
T2D NNP 1_p
on IN 1_p
metformin NN 1_i
monotherapy NN 1_p
were VBD N
randomised VBN N
to TO N
receive VB N
fixed-dose JJ 1_i
metformin NN 1_i
1500 CD 1_i
mg/day NN 1_i
, , 1_i
plus CC 1_i
either DT 1_i
add-on JJ 1_i
saxagliptin NN 1_i
5 CD 1_i
mg/day NN 1_i
( ( 1_i
SAXA-MET NNP 1_i
) ) 1_i
or CC 1_i
a DT 1_i
two-step JJ 1_i
metformin NN 1_i
uptitration NN 1_i
( ( 1_i
MET-UP NNP 1_i
) ) 1_i
to TO 1_i
a DT 1_i
maximum JJ 1_i
dose NN 1_i
( ( 1_i
2500 CD 1_i
mg/day NN 1_i
) ) 1_i
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
NCT01006590 NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
: : N
absolute JJ 1_o
change NN 1_o
from IN 1_o
baseline NN 1_o
in IN 1_o
glycated JJ 1_o
haemoglobin NN 1_o
A NNP 1_o
( ( 1_o
1c CD 1_o
) ) 1_o
( ( 1_o
HbA NNP 1_o
( ( 1_o
1c CD 1_o
) ) 1_o
) ) 1_o
( ( N
Week $ N
24 CD N
) ) N
. . N

Secondary JJ N
: : N
proportion NN N
of IN N
patients NNS N
achieving VBG 1_o
a DT 1_o
therapeutic JJ 1_o
glycaemic JJ 1_o
response NN 1_o
( ( N
Week NNP N
24 CD N
) ) N
; : N
change NN N
from IN N
baseline NN 1_o
in IN 1_o
fasting VBG 1_o
plasma NN 1_o
glucose NN 1_o
( ( 1_o
Week NNP 1_o
24 CD 1_o
) ) 1_o
; : 1_o
safety NN 1_o
and CC 1_o
tolerability NN 1_o
. . N

Exploratory JJ N
analyses NNS N
comprised VBD N
three CD N
patient-related JJ N
questionnaires NNS N
, , N
including VBG N
the DT N
validated JJ N
5-dimension JJ N
Digestive NNP N
Health NNP N
Status NNP N
Index NNP N
( ( N
DHSI NNP N
) ) N
. . N

RESULTS VB 1_p
A DT 1_p
total NN 1_p
of IN 1_p
286 CD 1_p
patients NNS 1_p
were VBD N
randomised VBN N
: : N
( ( N
SAXA-MET JJ N
: : N
147 CD N
; : N
MET-UP JJ N
: : N
139 CD 1_o
) ) 1_o
. . 1_o

Baseline JJ 1_o
mean NN 1_o
( ( 1_o
SD NNP 1_o
) ) 1_o
HbA NNP 1_o
( ( 1_o
1c CD 1_o
) ) 1_o
: : 1_o
7.71 CD N
( ( N
0.85 CD N
; : N
SAXA-MET NNP N
) ) N
; : N
7.80 CD N
( ( N
0.82 CD N
; : N
MET-UP NNP 1_o
) ) 1_o
. . 1_o

Adjusted VBN 1_o
mean JJ 1_o
reductions NNS 1_o
from IN 1_o
baseline NN 1_o
in IN 1_o
HbA NNP 1_o
( ( 1_o
1c CD 1_o
) ) 1_o
( ( N
Week $ N
24 CD N
) ) N
: : N
-0.47 CD N
% NN N
( ( N
SAXA-MET NNP N
) ) N
; : N
-0.38 CD N
% NN N
( ( N
MET-UP NNP N
) ) N
; : N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
difference NN N
in IN N
treatment NN N
effect NN N
, , N
-0.10 CD N
% NN N
( ( N
-0.26 NNP N
, , N
0.07 CD N
) ) N
; : N
p CC N
= $ N
0.260 CD N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
achieving VBG 1_o
a DT 1_o
therapeutic JJ 1_o
glycaemic JJ 1_o
response NN 1_o
( ( N
HbA NNP N
( ( N
1c CD N
) ) N
< VBD N
7 CD N
% NN N
) ) N
: : N
43.8 CD N
% NN N
( ( N
34.8 CD N
, , N
49.6 CD N
) ) N
( ( N
SAXA-MET NNP N
) ) N
vs. FW N
35.0 CD N
% NN N
( ( N
29.0 CD N
, , N
43.8 CD N
) ) N
( ( N
MET-UP NNP N
) ) N
. . N

Of IN N
the DT N
five CD N
DHSI NNP N
domains NNS N
, , N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
differences NNS N
were VBD 1_o
observed VBN 1_o
for IN 1_o
diarrhoea-predominant JJ 1_o
score NN N
( ( N
+0.8 JJ N
[ NNP N
-2.5 NNP N
, , N
4.0 CD N
] NN N
vs. FW N
+7.9 NNP N
[ NNP 1_o
4.6 CD 1_o
, , 1_o
11.2 CD 1_o
] NN 1_o
) ) 1_o
and CC 1_o
dysmotility NN N
score NN N
( ( N
-0.5 JJ N
[ NNP N
-2.0 NNP N
, , N
1.0 CD N
] NN N
vs. FW N
+1.9 NNP N
[ NNP N
0.3 CD N
, , N
3.4 CD N
] NN N
) ) N
, , N
( ( N
SAXA-MET JJ N
and CC N
MET-UP NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ 1_o
event NN 1_o
was VBD N
diarrhoea NN N
: : N
6.1 CD N
% NN N
( ( N
SAXA-MET NNP N
) ) N
vs. FW N
12.2 CD N
% NN N
( ( N
MET-UP NNP N
) ) N
. . N

CONCLUSIONS NNP 1_p
In IN 1_p
metformin-tolerant JJ 1_p
patients NNS 1_p
with IN 1_p
T2D NNP 1_p
( ( 1_p
inadequately RB 1_p
controlled VBN 1_p
on IN 1_p
sub-maximal JJ 1_p
metformin NN 1_p
monotherapy NN 1_i
) ) 1_i
, , N
saxagliptin NN N
was VBD N
well RB N
tolerated VBN N
. . N

Although IN N
HbA NNP N
( ( N
1c CD N
) ) N
reduction NN N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
treatment NN N
groups NNS N
, , N
the DT N
lower JJR N
occurrence NN N
of IN N
gastrointestinal JJ N
symptoms NNS N
in IN N
the DT N
SAXA-MET NNP N
group NN N
suggests VBZ N
that IN N
saxagliptin JJ N
add-on JJ N
treatment NN N
may MD N
be VB N
a DT N
suitable JJ N
alternative JJ N
treatment NN N
strategy NN N
to TO N
metformin VB N
uptitration NN N
. . N

Carbon NNP 1_i
dioxide RB 1_i
versus VBZ N
normal JJ 1_i
saline NN 1_i
as IN N
a DT N
uterine JJ N
distension NN N
medium NN N
for IN N
diagnostic JJ N
vaginoscopic NN N
hysteroscopy NN N
in IN N
infertile JJ 1_p
patients NNS 1_p
: : 1_p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
satisfaction NN 1_o
rate NN 1_o
, , 1_o
efficacy NN 1_o
, , N
and CC N
complication NN 1_o
rate NN 1_o
of IN N
carbon NN 1_i
dioxide NN 1_i
( ( 1_i
CO NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
) ) 1_i
versus NN N
normal JJ 1_i
saline NN 1_i
as IN N
a DT N
uterine JJ N
distension NN N
medium NN N
for IN N
outpatient JJ N
diagnostic JJ N
vaginoscopic NN N
hysteroscopy NN N
in IN N
infertile JJ N
patients NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
multicenter NN N
study NN N
. . N

SETTING NNP N
Hysteroscopy NNP N
units NNS N
in IN N
two CD N
university NN N
hospitals NNS N
and CC N
in IN N
a DT N
private JJ N
center NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
One CD 1_p
hundred VBN 1_p
eighty-nine JJ 1_p
infertile JJ 1_p
women NNS 1_p
undergoing VBG 1_p
outpatient JJ 1_p
hysteroscopy NN 1_p
. . 1_p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Outpatient NNP N
hysteroscopy NN N
was VBD N
performed VBN N
with IN N
CO NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
( ( 1_i
group NN 1_i
A NNP 1_i
) ) 1_i
or CC 1_i
normal JJ 1_i
saline NN 1_i
( ( 1_i
group NN 1_i
B NNP 1_i
) ) 1_i
and CC N
with IN N
endometrial JJ 1_i
biopsy NN 1_i
when WRB N
indicated VBN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Quality NN 1_o
of IN 1_o
the DT 1_o
visualization NN 1_o
of IN 1_o
the DT 1_o
uterine JJ 1_o
cavity NN 1_o
, , 1_o
procedure NN 1_o
time NN 1_o
, , 1_o
complications NNS 1_o
, , 1_o
patient JJ 1_o
discomfort NN 1_o
, , 1_o
and CC 1_o
satisfaction NN 1_o
rate NN 1_o
. . 1_o

RESULT NNP N
( ( N
S NNP N
) ) N
Significantly NNP N
lower JJR N
abdominal NN 1_o
and CC 1_o
shoulder NN 1_o
tip NN 1_o
pain NN 1_o
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
vasovagal JJ 1_o
reactions NNS 1_o
were VBD N
observed VBN N
in IN N
group NN 1_p
B NNP 1_p
in IN N
comparison NN N
with IN N
group NN 1_p
A NNP 1_p
. . 1_p

A NNP N
higher JJR 1_o
satisfaction NN 1_o
rate NN 1_o
and CC 1_o
a DT 1_o
lower JJR 1_o
operative JJ 1_o
time NN 1_o
were VBD N
obtained VBN N
in IN N
the DT N
normal JJ N
saline NN N
group NN N
in IN N
comparison NN N
with IN N
the DT N
CO NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
group NN N
. . N

Moreover RB N
, , N
group NN N
A NNP N
required VBD N
significantly RB N
more RBR N
analgesics NNS N
after IN N
the DT N
procedure NN N
than IN N
group NN N
B NNP N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Uterine NNP N
distension NN N
with IN N
normal JJ N
saline NN N
seems VBZ N
to TO N
have VB N
less JJR N
adverse JJ N
effects NNS N
and CC N
is VBZ N
better RBR N
tolerated VBN N
by IN N
patients NNS 1_p
. . 1_p

Moreover RB N
, , N
it PRP N
allows VBZ N
operative JJ N
procedures NNS N
to TO N
be VB N
performed VBN N
with IN N
the DT N
new JJ N
bipolar JJ N
instruments NNS N
. . N

Etanercept NNP 1_i
treatment NN N
in IN N
adults NNS 1_p
with IN 1_p
established VBN 1_p
rheumatoid NN 1_p
arthritis NN 1_p
: : 1_p
7 CD N
years NNS N
of IN N
clinical JJ N
experience NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
longterm JJ N
etanercept FW 1_i
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
disease NN 1_p
modifying VBG 1_p
antirheumatic JJ 1_p
drug NN 1_p
( ( 1_p
DMARD NNP 1_p
) ) 1_p
refractory NN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
( ( 1_p
RA NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Safety NNP N
results NNS N
are VBP N
reported VBN N
for IN N
714 CD 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
etanercept RB 1_i
in IN 1_p
one CD 1_p
of IN 1_p
7 CD 1_p
initial JJ 1_p
trials NNS 1_p
or CC 1_p
a DT 1_p
longterm JJ 1_p
extension NN 1_p
. . 1_p

Efficacy NN N
results NNS N
are VBP N
reported VBN N
for IN N
581 CD 1_p
patients NNS 1_p
who WP 1_p
enrolled VBD 1_p
in IN 1_p
the DT 1_p
extension NN 1_p
. . 1_p

RESULTS NNP N
Of IN N
the DT N
714 CD 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
initial JJ 1_p
trials NNS 1_p
, , 1_p
581 CD 1_p
( ( 1_p
81 CD 1_p
% NN 1_p
) ) 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
extension NN 1_p
, , 1_p
and CC 1_p
388 CD 1_p
( ( 1_p
54 CD 1_p
% NN 1_p
) ) 1_p
patients NNS 1_p
are VBP 1_p
continuing VBG 1_p
to TO 1_p
receive VB 1_p
etanercept JJ 1_i
therapy NN 1_i
. . 1_i

The DT N
longest JJS N
individual JJ N
treatment NN N
was VBD N
8.2 CD N
years NNS N
, , N
with IN N
3139 CD N
total JJ N
patient-years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

Rates NNS 1_o
of IN 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( N
overall JJ N
rate=14.8 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
serious JJ 1_o
infections NNS 1_o
( ( N
overall JJ N
rate=4.2 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
cancer NN 1_o
( ( N
overall JJ N
rate=1.0 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
and CC 1_o
deaths NNS 1_o
( ( N
overall JJ N
rate=0.7 NN N
events/100 IN N
patient-yrs NN N
) ) N
were VBD N
stable JJ N
each DT N
year NN N
, , N
through IN N
8 CD N
years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

For IN N
356 CD 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
6 CD 1_p
years NNS 1_p
of IN 1_p
etanercept JJ 1_p
treatment NN 1_p
, , N
response NN 1_o
rates NNS 1_o
were VBD N
ACR20=73 NNP N
% NN N
, , N
ACR50=52 NNP N
% NN N
, , N
ACR70=27 NNP N
% NN N
, , N
DAS28 NNP N
CRP NNP N
good JJ N
response=52 NN N
% NN N
, , N
and CC N
DAS28 NNP N
CRP NNP N
remission=37 VBZ N
% NN N
of IN N
patients NNS N
. . N

Similar JJ N
responses NNS N
occurred VBD N
in IN N
167 CD 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
Year NNP 1_p
7 CD 1_p
. . 1_p

Doses NNS 1_o
of IN N
concomitant JJ N
methotrexate NN N
or CC N
corticosteroids NNS N
were VBD N
reduced VBN N
in IN N
many JJ N
patients NNS N
who WP N
maintained VBD N
clinical JJ N
responses NNS N
. . N

CONCLUSION VB N
The DT N
safety NN 1_o
profile NN 1_o
of IN N
etanercept NN 1_i
was VBD N
consistent JJ N
over IN N
time NN N
, , N
with IN N
rates NNS 1_o
of IN 1_o
adverse JJ 1_o
events NNS 1_o
similar JJ N
to TO N
those DT N
reported VBN N
for IN N
patients NNS 1_p
with IN 1_p
RA NNP 1_p
in IN 1_p
general JJ 1_p
. . 1_p

Durable JJ N
clinical JJ N
responses NNS N
were VBD N
observed VBN N
in IN N
some DT N
patients NNS N
for IN N
7 CD N
years NNS N
or CC N
more JJR N
. . N

The DT N
benefit-to-risk JJ N
ratio NN N
for IN N
longterm JJ N
etanercept JJ 1_i
treatment NN N
remains VBZ N
highly RB N
favorable JJ N
. . N

Afatinib NNP 1_i
versus NN N
methotrexate NN 1_i
as IN N
second-line JJ N
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
recurrent NN 1_p
or CC 1_p
metastatic JJ 1_p
squamous-cell JJ 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
progressing VBG 1_p
on IN 1_p
or CC 1_p
after IN 1_p
platinum-based JJ 1_p
therapy NN 1_p
( ( 1_p
LUX-Head NNP 1_p
& CC 1_p
Neck NNP 1_p
1 CD 1_p
) ) 1_p
: : 1_p
an DT N
open-label JJ N
, , N
randomised JJ N
phase NN N
3 CD N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS 1_p
with IN 1_p
recurrent NN 1_p
or CC 1_p
metastatic JJ 1_p
squamous-cell JJ 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
( ( 1_p
HNSCC NNP 1_p
) ) 1_p
progressing NN 1_p
after IN 1_p
first-line JJ 1_p
platinum NN 1_p
regimens NNS 1_p
have VBP N
a DT N
poor JJ N
prognosis NN N
and CC N
few JJ N
treatment NN N
options NNS N
. . N

Afatinib NNP 1_i
, , N
an DT N
irreversible JJ N
ERBB NNP N
family NN N
blocker NN N
, , N
has VBZ N
shown VBN N
efficacy NN N
in IN N
a DT N
phase NN N
2 CD N
study NN N
in IN N
this DT N
setting NN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
afatinib NNS 1_i
compared VBN N
with IN N
methotrexate NN 1_i
as IN N
second-line JJ N
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
recurrent NN 1_p
or CC 1_p
metastatic JJ 1_p
HNSCC NNP 1_p
progressing NN 1_p
on IN 1_p
or CC 1_p
after IN 1_p
platinum-based JJ 1_p
therapy NN 1_p
. . 1_p

METHODS NNP N
In IN 1_p
this DT 1_p
open-label JJ 1_p
, , 1_p
phase JJ 1_p
3 CD 1_p
, , 1_p
randomised VBD 1_p
controlled VBN 1_p
trial NN 1_p
conducted VBN 1_p
in IN 1_p
101 CD 1_p
centres NNS 1_p
in IN 1_p
19 CD 1_p
countries NNS 1_p
, , 1_p
we PRP 1_p
enrolled VBD 1_p
patients NNS 1_p
aged VBN 1_p
18 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
with IN 1_p
histologically RB 1_p
or CC 1_p
cytologically RB 1_p
confirmed VBN 1_p
HNSCC NNP 1_p
that WDT 1_p
was VBD 1_p
recurrent NN 1_p
, , 1_p
metastatic JJ 1_p
, , 1_p
or CC 1_p
both DT 1_p
who WP 1_p
had VBD 1_p
progressed VBN 1_p
on IN 1_p
or CC 1_p
after IN 1_p
first-line JJ 1_p
platinum-based JJ 1_p
therapy NN 1_p
, , 1_p
were VBD 1_p
not RB 1_p
amenable JJ 1_p
for IN 1_p
salvage NN 1_p
surgery NN 1_p
or CC 1_p
radiotherapy NN 1_p
, , 1_p
and CC 1_p
who WP 1_p
had VBD 1_p
an DT 1_p
Eastern JJ 1_p
Cooperative NNP 1_p
Oncology NNP 1_p
Group NNP 1_p
( ( 1_p
ECOG NNP 1_p
) ) 1_p
performance NN 1_p
status NN 1_p
of IN 1_p
0 CD 1_p
or CC 1_p
1 CD 1_p
. . 1_p

Previous JJ 1_p
treatment NN 1_p
with IN 1_p
more JJR 1_p
than IN 1_p
one CD 1_p
systemic JJ 1_p
regimen NN 1_p
in IN 1_p
this DT 1_p
setting NN 1_p
was VBD 1_p
not RB 1_p
allowed VBN 1_p
; : 1_p
previous JJ 1_p
treatment NN 1_p
with IN 1_p
EGFR-targeted JJ 1_i
antibody NN 1_i
therapy NN 1_i
( ( 1_i
but CC 1_i
not RB 1_i
EGFR-targeted JJ 1_i
tyrosine-kinase JJ 1_i
inhibitors NNS 1_i
) ) 1_i
was VBD 1_p
allowed VBN 1_p
. . 1_p

We PRP N
randomly VBP N
assigned VBN N
eligible JJ N
patients NNS N
in IN N
a DT N
2:1 CD N
ratio NN N
to TO N
receive VB N
oral JJ 1_i
afatinib NN 1_i
( ( 1_i
40 CD 1_i
mg/day NN 1_i
) ) 1_i
or CC 1_i
intravenous JJ 1_i
methotrexate NN 1_i
( ( 1_i
40 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
per IN 1_i
week NN 1_i
) ) 1_i
, , N
stratified VBN N
by IN N
ECOG NNP N
performance NN N
status NN N
and CC N
previous JJ N
EGFR-targeted JJ N
antibody NN N
therapy NN N
for IN N
recurrent NN N
or CC N
metastatic JJ N
disease NN N
. . N

Randomisation NN N
was VBD N
done VBN N
centrally RB N
with IN N
an DT N
interactive JJ N
voice NN N
or CC N
web-based JJ N
response NN N
system NN N
. . N

Clinicians NNPS N
and CC N
patients NNS N
were VBD N
not RB N
masked VBN N
to TO N
treatment NN N
allocation NN N
; : N
independent JJ N
review NN N
of IN N
tumour JJ N
response NN N
was VBD N
done VBN N
in IN N
a DT N
blinded JJ N
manner NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
progression-free JJ 1_o
survival NN 1_o
as IN N
assessed VBN N
by IN N
an DT N
independent JJ N
, , N
central JJ N
imaging VBG N
review NN N
committee NN N
. . N

Efficacy NN 1_o
analyses NNS 1_o
were VBD N
done VBN N
in IN N
the DT N
intention-to-treat JJ N
population NN N
and CC N
safety NN 1_o
analyses NNS 1_o
were VBD N
done VBN N
in IN N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
study JJ N
drug NN N
. . N

This DT N
ongoing JJ N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01345682 NNP N
. . N

FINDINGS NNP N
Between NNP N
Jan NNP 1_p
10 CD 1_p
, , 1_p
2012 CD 1_p
, , 1_p
and CC 1_p
Dec NNP 1_p
12 CD 1_p
, , 1_p
2013 CD 1_p
, , 1_p
we PRP 1_p
enrolled VBD 1_p
483 CD 1_p
patients NNS 1_p
and CC N
randomly RB N
assigned VBD N
322 CD N
to TO N
afatinib VB 1_i
and CC N
161 CD N
to TO N
methotrexate VB 1_i
. . 1_i

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
6·7 CD N
months NNS N
( ( N
IQR NNP N
3·1-9·0 NNP 1_o
) ) 1_o
, , 1_o
progression-free JJ 1_o
survival NN 1_o
was VBD N
longer RBR N
in IN N
the DT 1_i
afatinib NN 1_i
group NN N
than IN N
in IN N
the DT 1_i
methotrexate NN 1_i
group NN N
( ( N
median JJ N
2·6 CD N
months NNS N
[ RB N
95 CD N
% NN N
CI NNP N
2·0-2·7 CD N
] NN N
for IN N
the DT N
afatinib NN N
group NN N
vs VBD N
1·7 CD N
months NNS N
[ JJ N
1·5-2·4 JJ N
] NN N
for IN N
the DT N
methotrexate NN N
group NN N
; : N
hazard CC N
ratio VB N
[ JJ N
HR NNP N
] NNP N
0·80 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0·65-0·98 CD N
] NNP N
, , N
p=0·030 NN N
) ) N
. . N

The DT N
most RBS N
frequent JJ N
grade NN 1_o
3 CD 1_o
or CC 1_o
4 CD 1_o
drug-related JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD 1_o
rash JJ N
or CC N
acne NN N
( ( N
31 CD N
[ RB N
10 CD N
% NN N
] NN N
of IN N
320 CD N
patients NNS N
in IN N
the DT N
afatinib NN N
group NN N
vs VBD N
none NN N
of IN N
160 CD N
patients NNS N
in IN N
the DT N
methotrexate NN 1_o
group NN 1_o
) ) 1_o
, , N
diarrhoea NN N
( ( N
30 CD N
[ RB N
9 CD N
% NN N
] NN N
vs NN N
three CD 1_o
[ $ 1_o
2 CD 1_o
% NN 1_o
] NN 1_o
) ) 1_o
, , N
stomatitis NN N
( ( N
20 CD N
[ RB N
6 CD N
% NN N
] NNP N
vs NN 1_o
13 CD 1_o
[ JJ 1_o
8 CD 1_o
% NN 1_o
] NN 1_o
) ) 1_o
, , N
fatigue NN N
( ( N
18 CD N
[ RB N
6 CD N
% NN N
] JJ N
vs NN N
five CD 1_o
[ JJ 1_o
3 CD 1_o
% NN 1_o
] NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
neutropenia NN N
( ( N
1 CD N
[ NNP N
< VBD N
1 CD N
% NN N
] NNP N
vs NN 1_o
11 CD 1_o
[ JJ 1_o
7 CD 1_o
% NN 1_o
] NN 1_o
) ) 1_o
; : 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS N
occurred VBD N
in IN 1_i
44 CD 1_i
( ( 1_i
14 CD 1_i
% NN 1_i
) ) 1_i
of IN N
afatinib-treated JJ N
patients NNS N
and CC 1_i
18 CD 1_i
( ( 1_i
11 CD 1_i
% NN 1_i
) ) 1_i
of IN 1_i
methotrexate-treated JJ N
patients NNS N
. . N

INTERPRETATION NNP 1_i
Afatinib NNP N
was VBD N
associated VBN N
with IN N
significant JJ N
improvements NNS 1_o
in IN 1_o
progression-free JJ 1_o
survival NN N
and CC N
had VBD N
a DT N
manageable JJ N
safety NN N
profile NN N
. . N

These DT N
findings NNS N
provide VBP N
important JJ N
new JJ N
insights NNS N
into IN N
the DT N
treatment NN N
of IN N
this DT N
patient JJ N
population NN N
and CC N
support NN N
further JJ N
investigations NNS N
with IN N
irreversible JJ N
ERBB NNP N
family NN N
blockers NNS N
in IN N
HNSCC NNP N
. . N

FUNDING NN N
Boehringer NNP N
Ingelheim NNP N
. . N

Using VBG N
a DT N
novel NN N
wound NN N
model NN N
to TO N
investigate VB N
the DT N
healing NN 1_o
properties NNS 1_o
of IN N
products NNS N
for IN N
superficial JJ N
wounds NNS N
. . N

OBJECTIVE NNP N
To TO N
establish VB N
a DT N
new JJ N
wound NN N
model NN N
that WDT N
can MD N
induce VB N
uniform JJ N
abrasions NNS N
and CC N
use VB N
it PRP N
to TO N
assess VB N
the DT N
healing NN 1_o
properties NNS 1_o
of IN N
a DT N
range NN N
of IN N
products NNS N
commonly RB N
applied VBD N
to TO N
these DT N
wounds NNS N
. . N

METHOD NNP N
Ten NNP 1_p
healthy JJ 1_p
volunteers NNS 1_p
were VBD N
enrolled VBN N
into IN N
an DT N
open-label JJ N
, , N
randomised JJ N
, , N
intra-individual JJ N
comparison NN N
pilot NN N
study NN N
. . N

Five CD N
standardised JJ N
, , N
superficial JJ N
abrasions NNS N
were VBD N
induced VBN N
on IN N
their PRP$ N
forearms NNS N
by IN N
repeatedly RB N
scrubbing VBG N
the DT N
skin NN N
with IN N
a DT N
surgical JJ N
brush NN N
until IN N
the DT N
first JJ N
signs NNS N
of IN N
uniform JJ N
glistening NN N
and CC N
punctuate NN N
bleeding NN N
were VBD N
observed VBN N
. . N

Three CD N
products NNS N
that WDT N
promote VBP N
a DT N
moist NN N
wound NN N
environment NN N
( ( 1_i
polyurethane NN 1_i
, , 1_i
hydrocolloid NN 1_i
, , 1_i
hydrogel NN 1_i
) ) 1_i
and CC N
two CD 1_i
standard JJ 1_i
plasters NNS 1_i
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
test NN N
areas NNS N
. . N

RESULTS NNP N
Evaluation NNP 1_o
of IN 1_o
wound NN 1_o
healing VBG 1_o
on IN N
days NNS N
2 CD N
, , N
5 CD N
, , N
8 CD N
and CC N
14 CD N
+/- JJ N
1 CD N
showed VBD N
best RBS N
results NNS N
for IN N
the DT N
polyurethane NN 1_i
and CC N
hydrocolloid JJ 1_i
plasters NNS N
. . N

Visible JJ 1_o
re-epithelialisation NN 1_o
was VBD N
recorded VBN N
on IN N
days NNS N
5 CD N
and CC N
8 CD N
. . N

More JJR N
than IN N
50 CD N
% NN N
of IN N
the DT N
wound JJ 1_o
area NN 1_o
had VBD 1_o
closed VBN 1_o
. . 1_o

Video NNP N
microscope NN N
images VBZ N
support VB N
these DT N
findings NNS N
. . N

The DT N
investigator NN N
and CC N
volunteers NNS N
assessed VBD N
cosmetic JJ 1_o
outcomes NNS 1_o
on IN N
day NN N
31 CD N
+/- JJ N
2 CD N
. . N

Best JJS N
results NNS N
were VBD N
obtained VBN N
for IN N
the DT N
polyurethane NN N
and CC N
hydrocolloid NN N
products NNS N
, , N
which WDT N
had VBD N
high JJ 1_o
mean NN 1_o
scores NNS 1_o
close RB N
to TO N
the DT N
maximum NN N
of IN N
10 CD N
. . N

Histological JJ 1_o
examination NN 1_o
of IN 1_o
biopsies NNS 1_o
taken VBN N
from IN N
the DT N
abrasions NNS N
of IN N
two CD N
volunteers NNS N
showed VBD N
the DT N
dermis NN 1_o
remained VBD 1_o
intact JJ 1_o
, , N
making VBG N
the DT N
model NN N
highly RB N
suitable JJ N
for IN N
the DT N
study NN N
of IN N
superficial JJ N
wounds NNS N
. . N

CONCLUSION NNP N
Uniform NNP N
and CC N
identical JJ N
standardised VBD N
wounds NNS N
created VBN N
using VBG N
an DT N
abrasive JJ N
brush NN N
technique NN N
can MD N
be VB N
used VBN N
to TO N
reliably VB N
detect JJ N
differences NNS N
in IN N
the DT N
performance NN 1_o
of IN 1_o
plasters NNS 1_o
intended VBN N
for IN N
superficial JJ 1_p
wounds NNS 1_p
. . 1_p

In IN N
general JJ N
, , N
products NNS N
that IN N
promote VBP N
a DT N
moist NN N
wound NN N
environment NN N
produced VBD N
better JJR N
results NNS N
than IN N
those DT N
that WDT N
promote VBP N
a DT N
dry JJ N
wound NN N
environment NN N
, , N
with IN N
an DT N
earlier JJR N
onset NN N
of IN N
healing NN 1_o
and CC N
better JJR N
healing VBG 1_o
outcomes NNS 1_o
. . 1_o

Superficial NNP N
cutaneous JJ N
wounds NNS N
treated VBN N
with IN N
polyurethane NN 1_i
or CC N
hydrocolloid NN 1_i
products NNS N
demonstrated VBD N
superior JJ N
rates NNS N
of IN N
re-epithelialisation NN 1_o
and CC 1_o
overall JJ 1_o
cosmetic JJ 1_o
outcomes NNS 1_o
. . 1_o

DECLARATION NNP N
OF IN N
INTEREST NNP N
This DT N
study NN N
was VBD N
funded VBN N
by IN N
Beiersdorf NNP N
AG NNP N
. . N

Neither CC N
author NN N
has VBZ N
any DT N
interest NN N
in IN N
the DT N
sponsor NN N
's POS N
commercial JJ N
activities NNS N
. . N

Drug NN N
preference NN N
in IN N
normal JJ 1_p
volunteers NNS 1_p
: : 1_p
effects NNS N
of IN N
age NN N
and CC N
time NN N
of IN N
day NN N
. . N

These DT N
experiments NNS N
assessed VBD N
the DT N
influence NN N
of IN N
two CD N
variables NNS N
, , N
age NN N
of IN N
subjects NNS N
and CC N
time NN N
of IN N
drug NN N
administration NN N
, , N
on IN N
the DT N
reinforcing VBG N
properties NNS N
of IN N
amphetamine NN 1_i
and CC N
of IN N
diazepam NN 1_i
in IN N
normal JJ N
volunteers NNS N
. . N

Three CD 1_p
groups NNS 1_p
of IN 1_p
subjects NNS 1_p
were VBD 1_p
tested VBN 1_p
: : 1_p
i NN 1_p
) ) 1_p
a DT 1_p
group NN 1_p
of IN 1_p
40-55-year-old JJ 1_p
subjects NNS 1_p
( ( 1_p
AGE NNP 1_p
group NN 1_p
; : 1_p
N NNP 1_p
= NNP 1_p
11 CD 1_p
) ) 1_p
who WP 1_p
were VBD 1_p
tested VBN 1_p
in IN 1_p
the DT 1_p
morning NN 1_p
, , 1_p
ii NN 1_p
) ) 1_p
a DT 1_p
group NN 1_p
of IN 1_p
21-35-year-old JJ 1_p
subjects NNS 1_p
( ( 1_p
CTL NNP 1_p
group NN 1_p
; : 1_p
N NNP 1_p
= NNP 1_p
12 CD 1_p
) ) 1_p
who WP 1_p
were VBD 1_p
also RB 1_p
tested VBN 1_p
in IN 1_p
the DT 1_p
morning NN 1_p
, , 1_p
and CC 1_p
iii NN 1_p
) ) 1_p
a DT 1_p
group NN 1_p
of IN 1_p
21-35-year-olds NNS 1_p
who WP 1_p
were VBD 1_p
tested VBN 1_p
in IN 1_p
the DT 1_p
late JJ 1_p
afternoon NN 1_p
( ( 1_p
AFT NNP 1_p
group NN 1_p
; : 1_p
N NNP 1_p
= NNP 1_p
13 CD 1_p
) ) 1_p
. . 1_p

All DT N
subjects NNS N
participated VBN N
in IN N
three CD N
separate JJ N
experiments NNS N
comparing VBG N
one CD N
drug NN N
( ( N
5 CD N
mg NN N
d NN 1_i
, , 1_i
l-amphetamine JJ 1_i
, , N
5 CD N
mg NN N
diazepam NN 1_i
or CC N
10 CD N
mg NNS N
diazepam RB 1_i
) ) 1_i
to TO N
placebo VB 1_i
. . 1_i

Each DT N
experiment NN N
consisted VBN N
of IN N
nine CD N
sessions NNS N
: : N
On IN N
the DT N
first JJ N
four CD N
sessions NNS N
subjects NNS N
sampled VBD N
two CD N
color-coded JJ N
capsules NNS N
on IN N
alternate JJ N
sessions NNS N
and CC N
on IN N
the DT N
following JJ N
five CD N
sessions NNS N
they PRP N
chose VBD N
and CC N
ingested VBD N
the DT N
capsule NN N
they PRP N
preferred VBD N
. . N

Subjective JJ N
effects NNS N
of IN N
the DT N
drugs NNS N
were VBD N
monitored VBN N
using VBG N
the DT N
Profile NNP 1_o
of IN 1_o
Mood NNP 1_o
States NNPS 1_o
( ( 1_o
POMS NNP 1_o
) ) 1_o
and CC 1_o
a DT 1_o
shortened JJ 1_o
version NN 1_o
of IN 1_o
the DT 1_o
Addiction NNP 1_o
Research NNP 1_o
Center NNP 1_o
Inventory NNP 1_o
( ( 1_o
ARCI NNP 1_o
) ) 1_o
. . 1_o

Subjects NNS N
in IN N
all DT N
three CD N
groups NNS N
chose VBD N
5 CD N
mg NN N
diazepam NN 1_i
as RB N
often RB N
as IN N
placebo NNS N
but CC N
preferred JJ N
placebo NN 1_i
to TO N
10 CD N
mg NN N
diazepam NN 1_i
. . 1_i

In IN N
contrast NN N
, , N
they PRP N
chose VBD N
amphetamine NN 1_i
either CC N
as RB N
often RB N
as IN N
or CC N
more RBR N
often RB N
than IN N
placebo NNS 1_i
. . 1_i

The DT N
subjective JJ N
effects NNS N
of IN N
diazepam NN 1_i
( ( N
i.e JJ N
. . N

sedation NN N
) ) N
were VBD N
similar JJ N
across IN N
all DT N
three CD N
groups NNS N
, , N
but CC N
after IN N
amphetamine VBP N
the DT N
AGE NNP N
group NN N
showed VBD N
greater JJR N
stimulant JJ N
effects NNS N
. . N

In IN N
addition NN N
, , N
the DT N
AFT NNP N
group NN N
showed VBD N
fewer JJR N
positive JJ N
mood NN N
effects NNS N
after IN N
amphetamine NN N
than IN N
the DT N
CTL NNP N
group NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
Effects NNS N
of IN N
vacuum-compression NN 1_o
therapy NN 1_o
on IN N
healing NN N
of IN N
diabetic JJ 1_o
foot NN 1_o
ulcers NNS 1_o
: : 1_o
randomized VBN N
controlled JJ N
trial NN N
. . N

A DT N
single-blind JJ N
, , N
randomized VBN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
vacuum-compression NN 1_o
therapy NN 1_o
( ( 1_o
VCT NNP 1_o
) ) 1_o
for IN N
the DT N
healing NN N
of IN N
diabetic JJ 1_o
foot NN 1_o
ulcers NNS 1_o
. . 1_o

Eighteen NNP 1_p
diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
foot JJ 1_o
ulcers NNS 1_o
were VBD 1_p
recruited VBN 1_p
through IN 1_p
simple JJ 1_p
nonprobability NN 1_p
sampling VBG 1_p
. . 1_p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
experimental JJ N
or CC N
a DT N
control NN 1_i
group NN N
. . N

Before IN N
and CC N
after IN N
intervention NN N
, , N
the DT N
foot NN 1_o
ulcer JJ 1_o
surface NN 1_o
area NN 1_o
was VBD N
estimated VBN N
stereologically RB N
, , N
based VBN N
on IN N
Cavalieri NNP N
's POS N
principle NN N
. . N

The DT N
experimental JJ N
group NN N
was VBD N
treated VBN N
with IN N
VCT NNP 1_o
in IN 1_i
addition NN 1_i
to TO 1_i
conventional JJ 1_o
therapy NN 1_o
for IN N
10 CD N
sessions NNS N
. . N

The DT N
control NN N
group NN N
received VBD N
only RB N
conventional JJ 1_o
therapy NN 1_o
, , 1_i
including VBG 1_i
debridement NN 1_o
, , 1_o
blood NN 1_o
glucose NNS 1_o
control NN 1_o
agents NNS 1_o
, , 1_o
systemic JJ 1_o
antibiotics NNS 1_o
, , 1_o
wound IN 1_o
cleaning VBG 1_o
with IN 1_o
normal JJ 1_o
saline NN 1_o
, , 1_o
offloading VBG 1_o
( ( 1_o
pressure NN 1_o
relief NN 1_o
) ) 1_o
, , 1_i
and CC 1_i
daily RB 1_o
wound JJ 1_o
dressings NNS 1_o
. . 1_o

The DT N
mean JJ N
foot NN 1_o
ulcer JJ 1_o
surface NN 1_o
area NN 1_o
decreased VBD N
from IN N
46.88 CD N
+/- JJ N
9.28 CD N
mm NN N
( ( N
2 CD N
) ) N
to TO N
35.09 CD N
+/- JJ N
4.09 CD N
mm NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
and CC N
from IN N
46.62 CD N
+/- JJ N
10.03 CD N
mm NN N
( ( N
2 CD N
) ) N
to TO N
42.89 CD N
+/- JJ N
8.1 CD N
mm NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
the DT N
experimental JJ N
group NN N
significantly RB N
improved VBN N
in IN N
measures NNS 1_o
of IN 1_o
foot NN 1_o
ulcer JJ 1_o
surface NN 1_o
area NN 1_o
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.024 CD N
) ) N
. . N

VCT NNP 1_o
enhances VBZ N
diabetic JJ 1_o
foot NN 1_o
ulcer NN 1_o
healing VBG 1_o
when WRB N
combined VBN N
with IN N
appropriate JJ N
wound NN N
care NN N
. . N

Enhancing VBG N
implementation NN N
of IN N
tobacco NN 1_i
use NN 1_i
prevention NN 1_i
and CC 1_i
cessation NN 1_i
counselling VBG 1_i
guideline NN 1_i
among IN 1_p
dental JJ 1_p
providers NNS 1_p
: : 1_p
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Tobacco NNP N
use NN N
adversely RB N
affects VBZ N
oral JJ N
health NN N
. . N

Tobacco NNP 1_i
use NN 1_i
prevention NN 1_i
and CC 1_i
cessation NN 1_i
( ( 1_i
TUPAC NNP 1_i
) ) 1_i
counselling VBG 1_i
guidelines NNS 1_i
recommend VBP N
that IN N
healthcare NN 1_p
providers NNS 1_p
ask VBP N
about IN N
each DT N
patient NN 1_p
's POS 1_p
tobacco NN N
use NN N
, , N
assess IN N
the DT N
patient NN N
's POS N
readiness NN N
and CC N
willingness NN N
to TO N
stop VB N
, , N
document NN N
tobacco NN 1_p
use NN 1_p
habits NNS 1_p
, , N
advise VBP N
the DT N
patient NN N
to TO N
stop VB N
, , N
assist NN N
and CC N
help NN N
in IN N
quitting NN N
, , N
and CC N
arrange JJ N
monitoring NN N
of IN N
progress NN N
at IN N
follow-up JJ N
appointments NNS N
. . N

Adherence NN N
to TO N
such JJ N
guidelines NNS N
, , N
especially RB N
among IN N
dental JJ 1_p
providers NNS 1_p
, , N
is VBZ N
poor JJ N
. . N

To TO N
improve VB N
guideline NN N
implementation NN N
, , N
it PRP N
is VBZ N
essential JJ N
to TO N
understand VB N
factors NNS N
influencing VBG N
it PRP N
and CC N
find VB N
effective JJ N
ways NNS N
to TO N
influence VB N
those DT N
factors NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
protocol NN N
is VBZ N
to TO N
introduce VB N
a DT N
theory-based JJ 1_i
approach NN 1_i
to TO 1_i
diagnose VB 1_i
implementation NN 1_i
difficulties NNS 1_i
of IN 1_i
TUPAC NNP 1_i
counselling VBG 1_i
guidelines NNS 1_i
among IN 1_i
dental JJ 1_i
providers NNS 1_i
. . 1_i

METHODS NNP N
Theories NNPS 1_o
of IN 1_o
behaviour NN 1_o
change NN 1_o
have VBP N
been VBN N
used VBN N
to TO N
identify VB N
key JJ N
theoretical JJ N
domains NNS N
relevant VBP N
to TO N
the DT N
behaviours NN N
of IN N
healthcare JJ 1_p
providers NNS 1_p
involved VBN N
in IN N
implementing VBG N
clinical JJ N
guidelines NNS N
. . N

These DT N
theoretical JJ N
domains NNS N
will MD N
inform VB N
the DT N
development NN N
of IN N
a DT N
questionnaire NN 1_o
aimed VBN N
at IN N
assessing VBG N
the DT N
implementation NN N
of IN N
the DT N
TUPAC NNP 1_i
counselling VBG 1_i
guidelines NNS 1_i
among IN N
Finnish JJ 1_p
municipal JJ 1_p
dental JJ 1_p
providers NNS 1_p
. . 1_p

Specific JJ N
items NNS N
will MD N
be VB N
drawn VBN N
from IN N
the DT N
guidelines NNS N
and CC N
the DT N
literature NN N
on IN N
TUPAC NNP 1_i
studies NNS N
. . N

After IN N
identifying VBG N
potential JJ N
implementation NN N
difficulties NNS N
, , N
we PRP N
will MD N
design VB N
two CD N
interventions NNS N
using VBG N
theories NNS 1_i
of IN 1_i
behaviour JJ 1_i
change NN 1_i
to TO N
link VB N
them PRP N
with IN N
relevant JJ N
behaviour NN N
change NN N
techniques NNS N
aiming VBG N
to TO N
improve VB N
guideline NN 1_i
adherence NN 1_i
. . 1_i

For IN N
assessing VBG N
the DT N
implementation NN N
of IN N
TUPAC NNP 1_i
guidelines NNS 1_i
, , N
the DT N
electronic JJ 1_o
dental NN 1_o
record NN 1_o
audit NN 1_o
and CC N
self-reported JJ 1_o
questionnaires NNS 1_o
will MD N
be VB N
used VBN N
. . N

DISCUSSION NNP N
To TO N
improve VB N
guideline NN N
adherence NN N
, , N
the DT N
theoretical-domains NNS N
approach NN N
could MD N
provide VB N
a DT N
comprehensive JJ N
basis NN N
for IN N
assessing VBG N
implementation NN N
difficulties NNS N
, , N
as RB N
well RB N
as IN N
designing VBG N
and CC N
evaluating VBG N
interventions NNS N
. . N

After IN N
having VBG N
identified VBN N
implementation NN N
difficulties NNS N
, , N
we PRP N
will MD N
design VB N
and CC N
test VB N
two CD N
interventions NNS N
to TO N
enhance VB N
TUPAC NNP 1_i
guideline JJ 1_i
adherence NN N
. . N

Using VBG N
the DT N
cluster NN N
randomised VBD N
controlled JJ N
design NN N
, , N
we PRP N
aim VBP N
to TO N
provide VB N
further JJ N
evidence NN N
on IN N
intervention NN N
effects NNS N
, , N
as RB N
well RB N
as IN N
on IN N
the DT N
validity NN N
and CC N
feasibility NN N
of IN N
the DT N
theoretical-domain JJ N
approach NN N
. . N

The DT N
empirical JJ N
data NNS N
collected VBN N
within IN N
this DT N
trial NN N
will MD N
be VB N
useful JJ N
in IN N
testing VBG N
whether IN N
this DT N
theoretical-domain JJ 1_i
approach NN 1_i
can MD N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
implementation NN N
of IN N
TUPAC NNP 1_i
guidelines NNS 1_i
among IN N
dental JJ 1_p
providers NNS 1_p
. . 1_p

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN15427433 NNP N
. . N

Double-blind NNP N
comparison NN N
of IN N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
trandolapril JJ 1_i
2 CD N
mg NN N
and CC N
hydrochlorothiazide VB 1_i
25 CD N
mg NNS N
in IN N
patients NNS 1_p
with IN 1_p
mild-to-moderate JJ 1_p
essential JJ 1_p
hypertension NN 1_p
. . 1_p

Investigator NNP N
Study NNP N
Group NNP N
. . N

This DT N
multicenter NN N
international JJ N
trial NN N
recruited VBD N
205 CD 1_p
patients NNS 1_p
from IN 1_p
16 CD 1_p
investigators NNS 1_p
. . 1_p

After IN N
a DT N
4-week JJ N
, , N
single-blind JJ 1_i
placebo NN 1_i
run-in NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
weeks NNS N
of IN N
trandolapril JJ 1_i
2 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
hydrochlorothiazide RB 1_i
( ( 1_i
HCTZ NNP 1_i
) ) 1_i
25 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
or CC 1_i
the DT 1_i
combination NN 1_i
( ( N
69 CD N
patients NNS N
) ) N
. . N

Morning VBG 1_o
predosing VBG 1_o
supine NN 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
DBP NNP 1_o
) ) 1_o
was VBD N
the DT N
primary JJ N
efficacy NN N
measurement NN N
. . N

Intention-to-treat JJ N
analysis NN N
showed VBD N
significant JJ N
decreases NNS N
in IN N
all DT N
three CD N
groups NNS N
in IN N
mean JJ N
( ( N
+/- JJ N
SEM NNP N
) ) N
supine NN 1_o
DBP NNP 1_o
throughout IN N
the DT N
study NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
at IN N
week NN N
16 CD N
between IN N
trandolapril NN N
( ( N
-10.6 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
HCTZ NNP N
( ( N
-10.9 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
. . N

The DT N
combination NN N
gave VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
than IN N
either DT N
drug NN N
alone RB N
( ( N
-15.1 JJ N
+/- JJ N
1.13 CD N
mm NN N
Hg NNP N
) ) N
. . N

Blood NNP 1_o
pressure NN 1_o
was VBD N
normalized VBN N
in IN N
the DT N
combination NN N
group NN N
in IN N
67 CD N
% NN N
of IN N
patients NNS N
, , N
a DT N
significantly RB N
higher JJR N
proportion NN N
than IN N
either DT N
trandolapril NN N
( ( N
63 CD N
% NN N
) ) N
or CC N
HCTZ NNP N
( ( N
60 CD N
% NN N
; : N
p CC N
= VB N
0.04 CD N
) ) N
. . N

Each DT N
treatment NN N
was VBD N
well RB N
tolerated VBN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ 1_o
events NNS 1_o
was VBD N
similar JJ N
in IN N
all DT N
three CD N
groups NNS N
. . N

Trandolapril NNP N
2 CD N
mg NN N
once RB N
daily JJ N
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
agent NN N
, , N
comparable JJ N
to TO N
HCTZ NNP N
. . N

Furthermore NNP N
, , N
the DT N
combination NN N
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
shown VBN N
to TO N
enhance VB N
the DT N
antihypertensive JJ 1_o
effect NN 1_o
of IN N
the DT N
two CD N
compounds NNS N
alone RB N
. . N

Misoprostol NNP 1_i
versus NN N
oxytocin NN 1_i
for IN N
the DT N
reduction NN N
of IN N
postpartum NN 1_o
blood NN 1_o
loss NN 1_o
. . 1_o

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
400 CD N
mug NN N
of IN N
oral JJ 1_i
misoprostol NN 1_i
with IN N
5 CD N
U NNP N
of IN N
intravenous JJ 1_i
oxytocin NNS 1_i
in IN N
the DT N
reduction NN N
of IN N
postpartum NN 1_o
blood NN 1_o
loss NN 1_o
and CC N
prevention NN N
of IN N
postpartum NN N
hemorrhage NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN 1_p
conducted VBN 1_p
in IN 1_p
a DT 1_p
tertiary JJ 1_p
maternity NN 1_p
hospital NN 1_p
622 CD 1_p
women NNS 1_p
received VBD N
either RB N
400 CD N
mug NN N
of IN N
oral JJ 1_i
misoprostol NN 1_i
or CC N
5 CD N
U NNP N
of IN N
intravenous JJ 1_i
oxytocin NNS 1_i
after IN N
delivery NN N
of IN N
the DT N
anterior JJ N
shoulder NN N
or CC N
within IN N
1 CD N
min NNS N
of IN N
delivery NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
hematocrit JJ 1_o
drop NN 1_o
of IN 1_o
10 CD 1_o
% NN 1_o
or CC 1_o
greater JJR 1_o
24 CD 1_o
h NN 1_o
postpartum NN 1_o
. . 1_o

The DT N
secondary JJ N
outcomes NNS N
were VBD N
a DT N
hemoglobin JJ 1_o
drop NN 1_o
of IN 1_o
30 CD 1_o
mg/L NN 1_o
or CC 1_o
greater JJR 1_o
, , 1_o
the DT 1_o
use NN 1_o
of IN 1_o
additional JJ 1_o
oxytocin NN 1_o
, , 1_o
an DT 1_o
estimated VBN 1_o
blood NN 1_o
loss NN 1_o
greater JJR 1_o
than IN 1_o
1000 CD 1_o
mL NN 1_o
, , 1_o
manual JJ 1_o
removal NN 1_o
of IN 1_o
the DT 1_o
placenta NN 1_o
, , 1_o
a DT 1_o
blood NN 1_o
transfusion NN 1_o
, , 1_o
and CC 1_o
shivering VBG 1_o
and CC 1_o
fever NN 1_o
( ( 1_o
> JJ 1_o
or=38 NN 1_o
degrees NNS 1_o
C NNP 1_o
) ) 1_o
as IN 1_o
adverse JJ 1_o
effects NNS 1_o
of IN 1_o
misoprostol NN 1_o
. . 1_o

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
regarding VBG N
the DT N
primary JJ N
outcome NN N
( ( N
a DT N
> NN N
or=10 NN N
% NN N
hematocrit JJ 1_o
drop NN 1_o
occurred VBD N
in IN N
3.4 CD N
% NN N
and CC N
3.7 CD N
% NN N
of IN N
the DT N
participants NNS N
in IN N
the DT N
oxytocin NN 1_i
and CC N
misoprostol NN 1_i
groups NNS N
, , N
P=0.98 NNP N
) ) N
. . N

The DT N
rate NN N
of IN N
use NN 1_o
of IN 1_o
additional JJ 1_o
oxytocin NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
misoprostol NN 1_i
group NN N
( ( N
51 CD N
% NN N
versus IN N
40.5 CD N
% NN N
, , N
P=0.01 NNP N
) ) N
. . N

Shivering VBG 1_o
was VBD N
confined VBN N
to TO N
the DT N
misoprostol NN 1_i
group NN N
( ( N
6.8 CD N
% NN N
) ) N
, , N
and CC N
fever RB N
occurred VBD N
in IN N
12.5 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
misoprostol NN 1_i
group NN N
and CC N
0.3 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
oxytocin NN 1_i
group NN N
. . N

CONCLUSION NNP N
The DT N
routine JJ N
use NN N
of IN N
400 CD N
microg NN N
of IN N
oral JJ N
misoprostol NN 1_i
was VBD N
no DT N
less RBR N
effective JJ N
than IN N
5 CD N
U NNP N
of IN N
intravenous JJ N
oxytocin NNS 1_i
in IN N
reducing VBG N
blood NN 1_o
loss NN 1_o
after IN N
delivery NN N
, , N
as IN N
assessed VBN N
by IN N
change NN N
in IN N
postpartum NN N
hematocrit NN N
. . N

The DT N
adverse JJ N
effects NNS N
of IN N
misoprostol NN 1_i
were VBD N
mild JJ N
and CC N
self-limiting JJ N
. . N

Biochemical NNP N
and CC N
functional JJ N
effects NNS N
of IN N
creatine NN 1_i
phosphate NN 1_i
in IN N
cardioplegic JJ N
solution NN N
during IN N
aortic JJ 1_p
valve NN 1_p
surgery NN 1_p
-- : 1_p
a DT 1_p
clinical JJ N
study NN N
. . N

During IN N
myocardial JJ N
ischemia NN N
there EX N
is VBZ N
a DT N
drop NN 1_o
in IN 1_o
high-energy JJ 1_o
phosphates NNS 1_o
in IN N
the DT N
myocardium NN N
. . N

Cold NNP N
potassium NN N
cardioplegia NN N
decreases NNS N
but CC N
does VBZ N
not RB N
altogether RB N
prevent VB N
this DT N
reduction NN N
. . N

Supplementation NN N
of IN N
cardioplegic JJ N
solutions NNS N
with IN N
the DT N
high-energy JJ N
compound NN N
creatine NN 1_i
phosphate NN 1_i
( ( N
10 CD N
mmol/L NN N
) ) N
compared VBN N
to TO N
plain VB 1_i
cardioplegic JJ 1_i
solutions NNS 1_i
was VBD N
investigated VBN N
in IN N
this DT N
study NN N
. . N

Thirty NNP 1_p
patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
aortic JJ 1_p
valve NNS 1_p
replacement NN 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
group NN N
I PRP N
( ( 1_i
creatine VB 1_i
phosphate NN 1_i
) ) 1_i
or CC N
group NN N
II NNP N
( ( 1_i
control NN 1_i
) ) 1_i
. . N

Postoperative JJ N
hemodynamic JJ 1_o
evaluation NN 1_o
revealed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

However RB N
, , N
group NN N
I PRP N
exhibited VBD N
a DT N
tendency NN N
toward IN N
a DT N
better JJR N
stroke-work NN 1_o
index NN 1_o
( ( N
135 CD N
+/- JJ N
18 CD N
% NN N
vs. FW N
102 CD N
+/- JJ N
5 CD N
% NN N
recovery NN N
15 CD N
minutes NNS N
after IN N
bypass NN N
and CC N
145 CD N
+/- JJ N
16 CD N
% NN N
vs. FW N
119 CD N
+/- JJ N
11 CD N
% NN N
recovery NN N
105 CD N
min NN N
after IN N
bypass NN N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
5/15 CD N
) ) N
needing VBG 1_o
inotropic JJ 1_o
support NN 1_o
compared VBN N
to TO N
group NN N
II NNP N
( ( N
9/14 CD N
) ) N
. . N

The DT N
myocardial JJ 1_o
content NN 1_o
of IN 1_o
ATP NNP 1_o
and CC 1_o
creatine NN 1_o
phosphate NN 1_o
showed VBD N
no DT N
significant JJ N
differences NNS N
during IN N
ischemia NN N
and CC N
reperfusion NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
myocardial JJ N
protection NN N
during IN N
ischemia NN N
was VBD N
sufficient JJ N
to TO N
prevent VB N
significant JJ N
reductions NNS N
of IN N
myocardial JJ 1_o
ATP NNP 1_o
and CC 1_o
creatine VB 1_o
phosphate JJ 1_o
irrespective NN N
of IN N
supplementation NN N
with IN N
CP NNP N
. . N

Pathology NN N
parameters NNS N
and CC N
adjuvant JJ 1_o
tamoxifen NN 1_o
response NN 1_o
in IN N
a DT N
randomised JJ N
premenopausal NN 1_p
breast NN 1_p
cancer NN 1_p
trial NN N
. . N

BACKGROUND NNP N
Subgroups NNP N
of IN N
breast NN N
cancer NN N
that WDT N
have VBP N
an DT N
impaired JJ N
response NN N
to TO N
endocrine VB N
treatment NN N
, , N
despite IN N
hormone NN N
receptor NN N
positivity NN N
, , N
are VBP N
still RB N
poorly RB N
defined VBN N
. . N

Breast NNP N
cancer NN N
can MD N
be VB N
subdivided VBN N
according VBG N
to TO N
standard JJ N
pathological JJ N
parameters NNS N
including VBG N
histological JJ N
type NN N
, , N
grade NN N
, , N
and CC N
assessment NN N
of IN N
proliferation NN N
. . N

These DT N
parameters NNS N
are VBP N
the DT N
net JJ N
result NN N
of IN N
combinations NNS N
of IN N
genetic JJ N
alterations NNS N
effecting VBG N
tumour JJ N
behaviour NN N
and CC N
could MD N
potentially RB N
reflect VB N
subtypes NNS N
that IN N
respond NN N
differently RB N
to TO N
endocrine VB N
treatment NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
usefulness NN N
of IN N
these DT N
parameters NNS N
as IN N
predictors NNS N
of IN N
the DT N
response NN N
to TO N
tamoxifen VB 1_i
in IN N
premenopausal JJ 1_p
women NNS 1_p
with IN 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

MATERIALS/METHODS NNP N
Clinically NNP N
established VBD N
pathological JJ N
parameters NNS N
were VBD N
assessed VBN N
and CC N
related VBN N
to TO N
the DT N
tamoxifen NN 1_i
response NN N
in IN N
500 CD 1_p
available JJ 1_p
tumour NN 1_p
specimens NNS 1_p
from IN 1_p
564 CD 1_p
premenopausal NN 1_p
patients NNS 1_p
with IN 1_p
breast JJ 1_p
cancer NN 1_p
randomised VBD N
to TO N
either DT N
two CD N
years NNS N
of IN N
tamoxifen NN 1_i
or CC N
no DT 1_i
treatment NN 1_i
with IN N
14 CD N
years NNS N
of IN N
follow NN N
up RB N
. . N

Proliferation NN N
was VBD N
further RB N
evaluated VBN N
by IN N
immunohistochemical JJ N
Ki-67 NNP N
expression NN N
. . N

RESULTS NNP N
Oestrogen NNP 1_o
receptor NN 1_o
positive JJ 1_o
ductal JJ 1_o
carcinomas NN 1_o
responded VBD N
as IN N
expected VBN N
to TO N
tamoxifen VB 1_i
, , N
whereas IN N
the DT N
difference NN N
in IN N
recurrence NN 1_o
free JJ 1_o
survival NN 1_o
between IN N
control NN 1_i
and CC N
tamoxifen NN 1_i
treated VBD N
patients NNS N
was VBD N
less RBR N
apparent JJ N
in IN N
the DT N
relatively RB N
few JJ N
lobular JJ N
carcinomas NN N
. . N

For IN N
histological JJ N
grade NN N
, , N
there EX N
was VBD N
no DT N
obvious JJ N
difference NN N
in IN N
treatment NN N
response NN N
between IN N
the DT N
groups NNS N
. . N

The DT N
relation NN N
between IN N
proliferation NN N
and CC N
tamoxifen NN 1_i
response NN N
seemed VBD N
to TO N
be VB N
more RBR 1_o
complex JJ 1_o
, , 1_o
with IN 1_o
a DT 1_o
clear JJ 1_o
response NN 1_o
in IN 1_o
tumours NN 1_o
with IN 1_o
high JJ 1_o
and CC 1_o
low JJ 1_o
proliferation NN 1_o
, , N
whereas JJ N
tumours NN N
with IN N
intermediate JJ N
proliferation NN N
defined VBN N
by IN N
Ki-67 NNP N
responded VBD N
more RBR N
poorly RB 1_o
. . 1_o

CONCLUSIONS NNP N
Clinically NNP N
established VBD N
pathology NN N
parameters NNS N
seem VBP N
to TO N
mirror VB N
the DT N
endocrine NN N
treatment NN N
response NN N
and CC N
could MD N
potentially RB N
be VB N
valuable JJ N
in IN N
future JJ N
treatment NN N
decisions NNS N
for IN N
patients NNS 1_p
with IN 1_p
breast JJ 1_p
cancer NN 1_p
. . 1_p

Lactobacillus NNP 1_i
plantarum NN 1_i
CECT7315 NNP 1_i
and CC 1_i
CECT7316 NNP 1_i
stimulate VBP N
immunoglobulin NN 1_o
production NN 1_o
after IN N
influenza JJ 1_i
vaccination NN 1_i
in IN 1_p
elderly JJ 1_p
. . 1_p

OBJECTIVE IN N
The DT N
effectiveness NN N
of IN N
influenza JJ 1_i
vaccination NN 1_i
in IN N
preventing VBG N
illness NN N
is VBZ N
lower RBR N
in IN N
the DT N
elderly JJ N
; : N
this DT N
is VBZ N
why WRB N
the DT N
ability NN N
of IN N
Lactobacillus NNP 1_i
plantarum NN 1_i
CECT NNP 1_i
7315/7316 CD 1_i
to TO N
stimulate VB 1_o
the DT 1_o
response NN 1_o
to TO 1_o
influenza VB 1_o
vaccination NN 1_o
in IN 1_p
elderly JJ 1_p
was VBD N
evaluated VBN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
human JJ N
trial NN N
including VBG N
60 CD 1_p
institutionalized JJ 1_p
volunteers NNS 1_p
aged VBN 1_p
65-85 CD 1_p
years NNS 1_p
was VBD N
performed VBN N
. . N

All PDT N
the DT N
volunteers NNS N
were VBD N
vaccinated VBN N
with IN N
a DT N
trivalent JJ 1_i
influenza NN 1_i
vaccine NN 1_i
( ( 1_i
A/Wisconsin/67/2005 NNP 1_i
NYMC NNP 1_i
X-161B NNP 1_i
( ( 1_i
H3N2 NNP 1_i
) ) 1_i
, , 1_i
A/Solomon NNP 1_i
Islands/3/2006 NNP 1_i
( ( 1_i
H1N1 NNP 1_i
) ) 1_i
and CC 1_i
B/Malaysia/2506/2004 NNP 1_i
) ) 1_i
for IN N
the DT N
Spanish JJ N
vaccine NN N
campaign NN N
2006/2007 CD N
. . N

The DT N
consumption NN N
of IN N
the DT N
probiotic JJ N
began VBD N
between IN N
three CD N
and CC N
four CD N
months NNS N
after IN N
the DT N
vaccination NN N
. . N

Volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
following VBG N
groups NNS N
: : N
group NN N
A NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
9 CD N
) ) N
cfu/day NN N
of IN N
L. NNP 1_i
plantarum NN 1_i
CECT NNP 1_i
7315/7316 CD 1_i
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
, , N
group NN N
B NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
8 CD N
) ) N
cfu/day NN N
of IN N
L. NNP 1_i
plantarum NN 1_i
CECT NNP 1_i
7315/7316 CD 1_i
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
and CC N
group NN N
C NNP N
or CC N
placebo NN 1_i
( ( N
20 CD N
g NN N
powered VBN 1_i
skim JJ 1_i
milk NN 1_i
) ) 1_i
. . 1_i

The DT N
participants NNS N
consumed VBD N
the DT N
probiotic JJ N
during IN N
3 CD N
months NNS N
. . N

RESULTS VB N
The DT N
consumption NN N
of IN N
L. NNP 1_i
plantarum NN 1_i
CECT NNP 1_i
7315/7316 CD 1_i
during IN N
3 CD N
months NNS N
after IN N
influenza JJ 1_i
vaccination NN 1_i
increased VBD N
the DT N
levels NNS 1_o
of IN 1_o
influenza-specific JJ 1_o
IgA NNP 1_o
and CC 1_o
IgG NNP 1_o
antibodies NNS 1_o
. . 1_o

Moreover RB N
, , N
a DT N
trend NN N
towards IN N
an DT N
increase NN N
in IN N
influenza-specific JJ 1_o
IgM NNP 1_o
antibodies NNS 1_o
was VBD N
also RB N
observed VBN N
. . N

CONCLUSION NNP N
L. NNP 1_i
plantarum NN 1_i
CECT7315/7316 NNP 1_i
has VBZ N
an DT N
immunostimulating JJ N
effect NN N
and CC N
could MD N
be VB N
used VBN N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB 1_i
vaccination NN 1_i
in IN N
elderly JJ N
. . N

Vigorous JJ 1_i
, , 1_i
aerobic JJ 1_i
exercise NN 1_i
versus NN 1_i
general JJ 1_i
motor NN 1_i
training NN 1_i
activities NNS 1_i
: : 1_i
effects NNS N
on IN N
maladaptive JJ 1_o
and CC 1_o
stereotypic JJ 1_o
behaviors NNS 1_o
of IN N
adults NNS 1_p
with IN 1_p
both DT 1_p
autism NN 1_p
and CC 1_p
mental JJ 1_p
retardation NN 1_p
. . 1_p

Examined VBD N
the DT N
effects NNS N
of IN N
antecedent JJ 1_i
exercise NN 1_i
conditions NNS 1_i
on IN N
maladaptive NN 1_o
and CC 1_o
stereotypic NN 1_o
behaviors NNS 1_o
in IN N
6 CD 1_p
adults NNS 1_p
with IN 1_p
both DT 1_p
autism NN 1_p
and CC 1_p
moderate VB 1_p
to TO 1_p
profound VB 1_p
mental JJ 1_p
retardation NN 1_p
. . 1_p

The DT N
behaviors NNS N
were VBD N
observed VBN N
in IN N
a DT N
controlled JJ N
environment NN N
before IN N
and CC N
after IN N
2 CD N
exercise NN 1_i
and CC N
1 CD N
non-exercise JJ 1_i
conditions NNS 1_i
. . 1_i

From IN N
the DT N
original JJ N
group NN N
of IN N
6 CD 1_p
participants NNS 1_p
, , N
2 CD N
were VBD N
selected VBN N
subsequently RB N
to TO N
participate VB N
in IN N
aerobic JJ 1_i
exercise NN 1_i
immediately RB N
before IN N
performing VBG N
a DT N
community-integrated JJ N
vocational JJ N
task NN N
. . N

Only RB N
antecedent JJ 1_i
aerobic JJ 1_i
exercise NN 1_i
significantly RB N
reduced VBD N
maladaptive JJ 1_o
and CC 1_o
stereotypic JJ 1_o
behaviors NNS 1_o
in IN N
the DT N
controlled JJ N
setting NN N
. . N

Neither CC N
of IN N
the DT N
less RBR N
vigorous JJ N
antecedent JJ N
conditions NNS N
did VBD N
. . N

When WRB N
aerobic JJ 1_i
exercise NN 1_i
preceded VBD N
the DT N
vocational JJ N
task NN N
, , N
similar JJ N
reductions NNS N
were VBD N
observed VBN N
. . N

There EX N
were VBD N
individual JJ N
differences NNS N
in IN N
response NN N
to TO N
antecedent JJ 1_i
exercise NN 1_i
. . 1_i

Use NN N
of IN N
antecedent NN 1_i
aerobic JJ 1_i
exercise NN 1_i
to TO N
reduce VB N
maladaptive JJ 1_o
and CC 1_o
stereotypic JJ 1_o
behaviors NNS 1_o
of IN N
adults NNS 1_p
with IN 1_p
both DT 1_p
autism NN 1_p
and CC 1_p
mental JJ 1_p
retardation NN 1_p
is VBZ N
supported VBN N
. . N

Prolonged JJ N
effects NNS N
of IN N
a DT N
home-based JJ 1_i
intervention NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
illness NN 1_p
. . 1_p

BACKGROUND NNP N
Data NNP N
on IN N
the DT N
long-term JJ N
benefits NNS N
of IN N
nonspecific JJ N
disease NN N
management NN N
programs NNS N
are VBP N
limited JJ N
. . N

We PRP N
performed VBD N
a DT N
long-term JJ N
follow-up NN N
of IN N
a DT N
previously RB N
published VBN N
randomized VBN N
trial NN N
. . N

METHODS NNP N
We PRP N
compared VBN N
all-cause JJ 1_o
mortality NN 1_o
and CC 1_o
recurrent JJ 1_o
hospitalization NN 1_o
during IN N
median JJ N
follow-up NN N
of IN N
7.5 CD N
years NNS N
in IN N
a DT N
heterogeneous JJ 1_p
cohort NN 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
illness NN 1_p
initially RB 1_p
exposed VBD 1_p
to TO 1_p
a DT 1_p
multidisciplinary JJ 1_i
, , 1_i
home-based JJ 1_i
intervention NN 1_i
( ( 1_i
HBI NNP 1_i
) ) 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
260 CD 1_p
) ) 1_p
or CC 1_p
to TO 1_p
usual JJ 1_i
postdischarge NN 1_i
care NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
268 CD 1_p
) ) 1_p
. . 1_p

RESULTS NNP N
During IN N
follow-up JJ N
, , N
HBI NNP 1_i
had VBD N
no DT N
impact NN N
on IN N
all-cause JJ 1_o
mortality NN 1_o
( ( N
relative JJ N
risk NN N
, , N
1.04 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.80-1.35 JJ N
) ) N
or CC N
event-free JJ 1_o
survival NN 1_o
from IN 1_o
death NN 1_o
or CC 1_o
unplanned JJ 1_o
hospitalization NN 1_o
( ( N
relative JJ N
risk NN N
, , N
1.03 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.86-1.24 JJ N
) ) N
. . N

Initial JJ N
analysis NN N
suggested VBD N
that IN N
HBI NNP 1_i
had VBD N
only RB N
a DT N
marginal JJ N
impact NN N
in IN N
reducing VBG N
unplanned JJ 1_o
hospitalization NN 1_o
, , N
with IN N
677 CD N
readmissions NNS N
vs VBP N
824 CD N
for IN N
the DT N
usual JJ N
care NN N
group NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.72 CD N
+/- JJ N
0.96 CD N
vs JJ N
0.84 CD N
+/- JJ N
1.20 CD N
readmissions/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

When WRB N
accounting VBG N
for IN N
increased JJ N
hospital NN 1_o
activity NN 1_o
in IN N
HBI NNP N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
obstructive JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
during IN N
follow-up NN N
for IN N
2 CD N
years NNS N
, , N
post NN N
hoc NN N
analyses VBZ N
showed VBD N
that IN N
HBI NNP 1_i
reduced VBD N
readmissions NNS 1_o
by IN N
14 CD N
% NN N
within IN N
2 CD N
years NNS N
in IN N
patients NNS N
without IN N
this DT N
condition NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.54 CD N
+/- JJ N
0.72 CD N
vs JJ N
0.63 CD N
+/- JJ N
0.88 CD N
readmission/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
and CC N
by IN N
21 CD N
% NN N
in IN N
all DT N
surviving VBG N
patients NNS N
within IN N
3 CD N
to TO N
8 CD N
years NNS N
( ( N
mean JJ N
+/- JJ N
SD NNP N
rate NN N
, , N
0.64 CD N
+/- JJ N
1.26 CD N
vs JJ N
0.81 CD N
+/- JJ N
1.61 CD N
readmissions/patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Overall JJ N
, , N
recurrent JJ 1_o
hospital NN 1_o
costs NNS 1_o
were VBD N
significantly RB N
lower JJR N
( ( N
14 CD N
% NN N
) ) N
in IN N
the DT N
HBI NNP 1_i
group NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
823 CD N
dollars NNS N
+/- JJ N
1642 CD N
dollars NNS N
vs JJ N
960 CD N
dollars NNS N
+/- JJ N
1376 CD N
dollars NNS N
per IN N
patient NN N
per IN N
year NN N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
unique JJ N
study NN N
suggests VBZ N
that IN N
a DT N
nonspecific JJ N
HBI NNP 1_i
provides VBZ N
long-term JJ N
cost NN N
benefits NNS N
in IN N
a DT N
range NN N
of IN N
chronic JJ N
illnesses NNS N
, , N
except IN N
for IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
. . N

Pentraxin-3 NN 1_i
in IN N
chronic JJ 1_p
heart NN 1_p
failure NN 1_p
: : 1_p
the DT N
CORONA NNP N
and CC N
GISSI-HF NNP N
trials NNS N
. . N

AIMS NNP N
Pentraxin-3 NNP 1_i
( ( 1_i
PTX3 NNP 1_i
) ) 1_i
is VBZ N
a DT N
component NN N
of IN N
the DT N
humoral JJ N
arm NN N
of IN N
innate NN N
immunity NN N
which WDT N
can MD N
regulate VB N
inflammatory JJ N
processes NNS N
. . N

Since IN N
the DT N
role NN N
of IN N
inflammation NN N
in IN N
the DT N
progression NN N
of IN N
chronic JJ N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
is VBZ N
debated VBN N
, , N
we PRP N
investigated VBD N
the DT N
prognostic JJ N
value NN N
of IN N
PTX3 NNP 1_i
and CC N
the DT N
effect NN N
of IN N
a DT N
statin NN 1_i
in IN N
two CD 1_p
large JJ 1_p
populations NNS 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
HF NNP 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
Plasma NNP N
levels NNS N
of IN N
PTX3 NNP 1_i
were VBD N
measured VBN N
at IN N
randomization NN N
and CC N
after IN N
3 CD N
months NNS N
in IN N
1457 CD 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
Controlled NNP 1_p
Rosuvastatin NNP 1_p
Multinational NNP 1_p
Trial NNP 1_p
in IN 1_p
HF NNP 1_p
( ( 1_p
CORONA NNP 1_p
) ) 1_p
and CC 1_p
1233 CD 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
GISSI-Heart NNP 1_p
Failure NNP 1_p
trial NN 1_p
( ( 1_p
GISSI-HF NNP 1_p
) ) 1_p
. . 1_p

The DT N
relationships NNS N
between IN N
baseline NN 1_i
PTX3 NNP 1_i
levels NNS 1_i
or CC N
their PRP$ N
changes NNS N
over IN N
time NN N
and CC N
mortality NN N
were VBD N
evaluated VBN N
with IN N
multivariable JJ N
Cox NNP N
proportional JJ N
hazard NN N
models NNS N
including VBG N
clinical JJ N
factors NNS N
, , N
high JJ N
sensitivity NN N
C-reactive JJ N
protein NN N
( ( N
hsCRP NN N
) ) N
, , N
and CC N
N-terminal JJ N
pro JJ N
brain NN N
natriuretic JJ N
peptide NN N
( ( N
NT-proBNP NNP N
) ) N
. . N

PTX3 NNP 1_o
concentration NN 1_o
[ NN N
median JJ N
( ( N
Q1-Q3 NNP N
) ) N
= VBZ N
5.34 CD N
( ( N
3.55-7.64 CD N
) ) N
ng/mL NN N
, , N
n RB N
= JJ N
2690 CD N
] NN N
was VBD N
higher RBR N
in IN N
females NNS N
, , N
in IN N
older JJR N
patients NNS N
, , N
and CC N
those DT N
with IN N
lower JJR N
body NN N
mass NN N
index NN N
. . N

Baseline NNP 1_i
elevated VBD 1_i
PTX3 NNP 1_i
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN 1_o
of IN 1_o
all-cause JJ 1_o
mortality NN 1_o
[ $ N
759 CD N
events NNS N
, , N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
for IN N
1 CD N
SD NNP N
increase NN N
1.20 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.12-1.30 CD N
, , N
P NNP N
< VBZ N
0.0001 CD N
] NN N
, , N
cardiovascular JJ 1_o
mortality NN 1_o
( ( N
587 CD N
events NNS N
, , N
HR NNP N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
1.17-1.38 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
or CC N
hospitalization NN 1_o
for IN 1_o
worsening VBG 1_o
HF NNP 1_o
( ( N
720 CD N
events NNS N
, , N
HR NNP N
1.21 CD N
, , N
95 CD N
% NN N
CI NNP N
1.12-1.30 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
marginally RB N
improved VBN N
discrimination NN N
. . N

Three-month JJ N
changes NNS N
in IN N
PTX3 NNP N
were VBD N
associated VBN N
with IN N
fatal JJ 1_o
events NNS 1_o
after IN N
adjustment NN N
for IN N
hsCRP NN N
or CC N
NT-proBNP NNP N
. . N

Rosuvastatin NNP N
lowered VBD N
hsCRP JJ 1_o
levels NNS 1_o
but CC N
significantly RB N
raised VBD N
PTX3 NNP 1_o
. . 1_o

CONCLUSION NNP N
In IN N
two CD N
independent JJ N
clinical JJ N
trials NNS N
that WDT N
enrolled VBD N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
HF NNP 1_p
, , N
PTX3 NNP 1_i
was VBD N
consistently RB N
associated VBN N
with IN N
outcomes NNS N
. . N

The DT N
opposite JJ N
effects NNS N
of IN N
a DT N
statin NN 1_i
on IN N
hsCRP NN N
and CC N
PTX3 NNP 1_i
call VB N
for IN N
further JJ N
investigation NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00336336 NNP N
( ( N
GISSI-HF NNP N
) ) N
, , N
NCT00206310 NNP N
( ( N
CORONA NNP N
) ) N
. . N

Contribution NN N
of IN N
endogenous JJ N
bradykinin NN N
to TO N
fibrinolysis NN 1_o
, , 1_o
inflammation NN 1_o
, , 1_o
and CC 1_o
blood NN 1_o
product NN 1_o
transfusion NN 1_o
following VBG 1_p
cardiac JJ 1_p
surgery NN 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Bradykinin NNP N
increases VBZ N
during IN N
cardiopulmonary JJ 1_p
bypass NN 1_p
( ( 1_p
CPB NNP 1_p
) ) 1_p
and CC N
stimulates VBZ N
the DT N
release NN 1_o
of IN 1_o
nitric JJ 1_o
oxide NN 1_o
, , 1_o
inflammatory JJ 1_o
cytokines NNS 1_o
, , 1_o
and CC 1_o
tissue-type JJ 1_o
plasminogen NN 1_o
activator NN 1_o
( ( 1_o
t-PA JJ 1_o
) ) 1_o
, , N
acting VBG N
through IN N
its PRP$ N
B2 NNP N
receptor NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
endogenous JJ N
bradykinin NN N
contributes NNS N
to TO N
the DT N
fibrinolytic JJ 1_o
and CC 1_o
inflammatory JJ 1_o
response NN 1_o
to TO 1_o
CPB NNP 1_o
and CC 1_o
that IN 1_o
bradykinin NN 1_o
B2 NNP 1_o
receptor NN 1_o
antagonism NN 1_o
reduces VBZ 1_o
fibrinolysis NN 1_o
, , 1_o
inflammation NN 1_o
, , 1_o
and CC 1_o
subsequent JJ 1_o
transfusion NN 1_o
requirements NNS 1_o
. . 1_o

Patients NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
115 CD 1_p
) ) 1_p
were VBD N
prospectively RB N
randomized VBN N
to TO N
placebo VB 1_i
, , 1_i
ε-aminocaproic JJ 1_i
acid NN 1_i
( ( 1_i
EACA NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
HOE NNP 1_i
140 CD 1_i
, , N
a DT N
bradykinin NN N
B2 NNP N
receptor NN N
antagonist NN N
. . N

Bradykinin NNP N
B2 NNP N
receptor NN N
antagonism NN N
decreased VBD 1_o
intraoperative JJ 1_o
fibrinolytic JJ 1_o
capacity NN 1_o
as RB N
much RB N
as IN 1_i
EACA NNP 1_i
, , N
but CC N
only RB 1_i
EACA NNP 1_i
decreased VBD 1_o
D-dimer NNP 1_o
formation NN 1_o
and CC N
tended VBD N
to TO N
decrease VB 1_o
postoperative JJ 1_o
bleeding NN 1_o
. . N

Although IN 1_i
EACA NNP 1_i
and CC 1_i
HOE NNP 1_i
140 CD 1_i
decreased VBD 1_o
fibrinolysis NN 1_o
and CC 1_o
EACA NNP 1_o
attenuated VBD 1_o
blood NN 1_o
loss NN 1_o
, , N
these DT N
treatments NNS N
did VBD N
not RB N
reduce VB N
the DT N
proportion NN N
of IN N
patients NNS N
transfused VBN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
endogenous JJ N
bradykinin NN N
contributes NNS N
to TO 1_o
t-PA JJ 1_o
generation NN 1_o
in IN 1_p
patients NNS 1_p
undergoing VBG 1_p
CPB NNP 1_p
, , N
but CC N
that IN N
additional JJ N
effects NNS N
on IN 1_o
plasmin NN 1_o
generation NN 1_o
contribute NN N
to TO 1_o
decreased VBN 1_o
D-dimer NNP 1_o
concentrations NNS 1_o
during IN 1_i
EACA NNP 1_i
treatment NN N
. . N

Effect NN N
of IN N
esmolol JJ 1_i
pretreatment NN N
on IN N
EEG NNP 1_o
seizure NN 1_o
morphology NN 1_o
in IN N
RUL NNP N
ECT NNP N
. . N

Intravenous JJ N
beta-blockers NNS N
are VBP N
an DT N
effective JJ N
means NNS N
of IN N
controlling VBG N
heart NN 1_o
rate NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
during IN N
electroconvulsive JJ 1_i
therapy NN 1_i
( ( 1_i
ECT NNP 1_i
) ) 1_i
, , N
but CC N
have VBP N
been VBN N
shown VBN N
to TO N
decrease VB N
seizure NN N
duration NN N
. . N

While IN N
the DT N
importance NN N
of IN N
seizure NN N
duration NN N
to TO N
the DT N
antidepressant JJ N
response NN N
of IN N
ECT NNP N
grows VBZ N
less JJR N
certain JJ N
, , N
there EX N
is VBZ N
growing VBG N
evidence NN N
that IN N
seizure NN N
morphology NN N
predicts VBZ N
the DT N
antidepressant JJ N
effect NN N
of IN N
ECT NNP N
. . N

This DT N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
esmolol JJ 1_i
pretreatment NN N
on IN N
seizure NN 1_o
morphology NN 1_o
. . 1_o

Eighteen NNP 1_p
depressed VBD 1_p
patients NNS 1_p
( ( 1_p
6 CD 1_p
men NNS 1_p
, , 1_p
12 CD 1_p
women NNS 1_p
; : 1_p
69 CD 1_p
+/- JJ 1_p
12.8 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
received VBD 1_p
ECT NNP 1_i
with IN 1_i
and CC 1_i
without IN 1_i
esmolol JJ 1_i
pretreatment NN 1_i
in IN N
a DT N
randomized JJ N
, , N
blinded VBD N
crossover NN N
design NN N
. . N

The DT N
seizures NNS N
were VBD N
blindly RB N
rated VBN N
for IN N
duration NN 1_o
of IN 1_o
motor NN 1_o
convulsion NN 1_o
, , 1_o
duration NN 1_o
of IN 1_o
electroencephalogram NN 1_o
( ( 1_o
EEG NNP 1_o
) ) 1_o
seizure NN 1_o
, , 1_o
degree NN 1_o
of IN 1_o
seizure NN 1_o
regularity NN 1_o
, , 1_o
and CC 1_o
degree NN 1_o
of IN 1_o
postictal JJ 1_o
EEG NNP 1_o
suppression NN 1_o
. . 1_o

Esmolol NNP N
shortened VBD N
the DT N
duration NN N
of IN N
the DT N
motor NN N
convulsion NN N
and CC N
degraded VBD N
the DT N
quality NN 1_o
of IN 1_o
the DT 1_o
ictal JJ 1_o
regularity NN 1_o
. . 1_o

Routine JJ N
administration NN N
of IN N
intravenous JJ N
esmolol NN N
before IN N
ECT NNP N
may MD N
cause VB N
a DT N
decrease NN N
in IN N
ictal JJ 1_o
regularity NN 1_o
. . 1_o

Careful JJ N
consideration NN N
should MD N
be VB N
given VBN N
to TO N
the DT N
potential JJ N
benefits NNS N
of IN N
esmolol NN N
versus IN N
the DT N
deleterious JJ N
effect NN N
on IN N
the DT N
electrophysiologic JJ N
process NN N
. . N

Esmolol NN N
may MD N
still RB N
be VB N
indicated VBN N
on IN N
a DT N
case-by-case JJ N
basis NN N
for IN N
extreme JJ N
tachycardia NN N
or CC N
hypertension NN N
associated VBN N
with IN N
ECT NNP N
, , N
and CC N
presumably RB N
poses VBZ N
no DT N
problem NN N
for IN N
the DT N
therapeutic JJ N
effect NN N
of IN N
ECT NNP N
if IN N
given VBN N
after IN N
the DT N
seizure NN N
is VBZ N
over IN N
. . N

Comparison NNP N
of IN N
the DT N
effect NN N
of IN N
intra-arterial JJ 1_i
versus NN N
intravenous JJ 1_i
heparin NN 1_i
on IN N
radial JJ 1_p
artery NN 1_p
occlusion NN 1_p
after IN 1_p
transradial JJ 1_p
catheterization NN 1_p
. . 1_p

Radial JJ N
artery NN N
occlusion NN N
( ( N
RAO NNP N
) ) N
is VBZ N
an DT N
infrequent NN N
, , N
asymptomatic JJ N
, , N
complication NN N
of IN N
transradial JJ N
catheterization NN N
and CC N
probably RB N
1 CD N
of IN N
the DT N
few JJ N
. . N

Intravenous JJ N
heparin NN N
and CC N
patent NN N
hemostasis NN N
lower RBR N
its PRP$ N
incidence NN N
. . N

A DT N
possible JJ N
local JJ N
effect NN N
of IN N
intra-arterially RB N
administered VBN N
heparin NN 1_i
during IN N
transradial JJ N
procedures NNS N
has VBZ N
not RB N
been VBN N
evaluated VBN N
. . N

We PRP N
studied VBD N
500 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
randomized VBN 1_i
to TO 1_i
an DT 1_i
intravenous JJ 1_i
group NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
250 CD 1_i
) ) 1_i
, , 1_i
receiving VBG 1_i
50 CD 1_i
U/kg NNP 1_i
of IN 1_i
unfractionated JJ 1_i
heparin NN 1_i
( ( 1_i
maximal JJ 1_i
dose VBP 1_i
5,000 CD 1_i
U NNP 1_i
) ) 1_i
intravenously RB 1_i
, , 1_i
and CC 1_i
an DT 1_i
intra-arterial JJ 1_i
group NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
250 CD 1_i
) ) 1_i
receiving VBG 1_i
the DT 1_i
same JJ 1_i
dose JJ 1_i
intra-arterially RB 1_i
. . 1_i

All DT N
patients NNS N
received VBD N
a DT N
vasodilator NN 1_i
" NN 1_i
cocktail NN 1_i
" NNP 1_i
intra-arterially RB 1_i
and CC 1_i
underwent JJ 1_i
cardiac JJ 1_i
catheterization NN 1_i
using VBG 1_i
a DT 1_i
5F CD 1_i
introducer NN 1_i
sheath NN 1_i
and CC 1_i
catheters NNS 1_i
. . 1_i

The DT N
activated JJ 1_o
clotting NN 1_o
time NN 1_o
was VBD N
measured VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
. . N

All DT N
patients NNS N
received VBD N
hemostasis NN N
with IN N
a DT N
radial JJ N
compression NN N
device NN N
( ( N
TR NNP N
Band NNP N
) ) N
, , N
applied VBN N
after IN N
sheath NN N
removal NN N
, , N
for IN N
2 CD N
hours NNS N
. . N

A DT N
plethysmographic JJ 1_o
evaluation NN 1_o
for IN 1_o
RAO NNP 1_o
was VBD N
performed VBN N
at IN N
24 CD N
hours NNS N
and CC N
30 CD N
days NNS N
after IN N
the DT N
procedure NN N
. . N

Early JJ 1_o
RAO NNP 1_o
occurred VBD N
in IN N
5.6 CD N
% NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
of IN N
the DT N
intravenous JJ N
group NN N
and CC N
6 CD N
% NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
of IN N
the DT N
intra-arterial JJ N
group NN N
. . N

The DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
chi-square JJ N
= NN N
0.037 CD N
, , N
p NN N
> NNP N
0.8 CD N
) ) N
. . N

Chronic NNP 1_o
RAO NNP 1_o
occurred VBD N
in IN N
3.2 CD N
% NN N
, , N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
of IN N
the DT N
intravenous JJ N
group NN N
compared VBN N
to TO N
4 CD N
% NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
of IN N
the DT N
intra-arterial JJ N
group NN N
. . N

The DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
chi-square JJ N
= NN N
0.231 CD N
, , N
p NN N
> NNP N
0.6 CD N
) ) N
. . N

The DT N
activated JJ 1_o
clotting NN 1_o
time NN 1_o
was VBD N
211 CD N
+/- JJ N
16 CD N
seconds NNS N
in IN N
the DT N
intravenous JJ N
group NN N
and CC N
213 CD N
+/- JJ N
17 CD N
seconds NNS N
in IN N
the DT N
intra-arterial JJ N
group NN N
, , N
a DT N
statistically RB N
insignificant JJ N
difference NN N
( ( N
t JJ N
= NNP N
-1.095 NNP N
, , N
p NN N
> NNP N
0.2 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
intra-arterial JJ N
and CC N
intravenous JJ N
heparin NNS N
administration NN N
provide VBP N
comparable JJ N
efficacy NN N
in IN N
preventing VBG N
RAO NNP N
, , N
favoring VBG N
a DT N
probable JJ N
systemically RB N
mediated VBD N
mechanism NN N
of IN N
action NN N
, , N
rather RB N
than IN N
a DT N
local JJ N
effect NN N
. . N

[ JJ 1_o
Rapidity NNP 1_o
of IN 1_o
pain NN 1_o
relief NN 1_o
, , 1_o
medication NN 1_o
requirement NN 1_o
and CC 1_o
patient JJ 1_o
satisfaction NN 1_o
with IN 1_p
reflux JJ 1_p
treatment NN 1_p
in IN N
the DT N
physician NN N
's POS N
office NN N
] NN N
. . N

Treatment NN N
of IN N
gastroesophageal NN 1_o
reflux NN 1_o
disease NN 1_o
( ( 1_o
GERD NNP 1_o
) ) 1_o
with IN N
proton NN 1_o
pump NN 1_o
inhibitors NNS 1_o
was VBD N
investigated VBN N
in IN N
three CD N
controlled VBD N
prospective JJ N
, , N
randomized JJ N
open JJ N
studies NNS N
. . N

Lansoprazole NNP 1_i
, , 1_i
omeprazole JJ 1_i
MUPS NNP 1_i
and CC 1_i
esomeprazole NN 1_i
were VBD N
compared VBN N
under IN N
doctor NN N
's POS N
office NN N
conditions NNS N
. . N

The DT N
outcomes NNS N
of IN N
interest NN N
were VBD N
the DT N
rapidity NN 1_o
of IN 1_o
pain NN 1_o
relief NN 1_o
achieved VBN N
with IN N
a DT N
single JJ 1_o
dose NN 1_o
, , 1_o
effectiveness NN 1_o
and CC 1_o
patient JJ 1_o
satisfaction NN 1_o
with IN N
on IN N
demand NN N
therapy NN N
. . N

In IN N
the DT N
first JJ N
study NN N
, , N
180 CD 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
and CC 1_p
prolonged JJ 1_p
episodes NNS 1_p
of IN 1_p
reflux NN 1_p
were VBD 1_p
investigated VBN 1_p
. . 1_p

Time NN N
to TO N
pain VB 1_o
relief NN 1_o
following VBG N
a DT N
single JJ N
dose NN N
was VBD N
1.1 CD N
+/- JJ N
0.8 CD N
hours NNS N
with IN N
30 CD N
mg NNS N
lansoprazole JJ 1_i
, , N
3.0 CD N
+/- JJ N
2.5 CD N
hours NNS N
with IN N
20 CD N
mgomeprazole JJ 1_i
MUPS NNP N
and CC N
2.1 CD N
+/- JJ N
1.2 CD N
hours NNS N
with IN N
40 CD N
mg NNS N
esomeprazole JJ 1_i
. . 1_i

Studies NNS N
2 CD N
and CC N
3 CD N
were VBD N
designed VBN N
as IN N
cross-over NN N
studies NNS N
intended VBN N
to TO N
investigate VB N
drug NN 1_o
consumption NN 1_o
. . 1_o

In IN N
study NN N
2 CD N
, , N
the DT N
amount NN 1_o
of IN 1_o
lansoprazole NN 1_o
consumed VBN 1_o
was VBD N
approximately RB N
50 CD N
% NN N
less JJR N
than IN N
that DT N
of IN N
omeprazole NN 1_i
, , N
and CC N
this DT N
translated VBN N
to TO N
81 CD N
% NN N
patient JJ 1_o
satisfaction NN 1_o
with IN N
lansoprazole JJ 1_i
compared VBN N
with IN N
only RB N
9.5 CD N
% NN N
for IN N
omeprazole NN 1_i
. . 1_i

In IN N
study NN N
3 CD N
comparing VBG N
lansoprazole NN N
and CC N
esomeprazole NN 1_i
, , N
consumption NN 1_o
of IN N
the DT N
former JJ N
was VBD N
85 CD N
% NN N
that WDT N
of IN N
the DT N
latter NN N
. . N

58 CD N
% NN N
of IN N
the DT N
patients NNS N
opted VBD N
to TO N
continuetreatment VB 1_o
with IN N
lansoprazole NN 1_i
, , N
compared VBN N
with IN N
only RB N
25 CD N
% NN N
in IN N
the DT N
case NN N
of IN N
esomeprazole NN 1_i
. . N

The DT N
appreciably RB N
greater JJR N
patient JJ 1_o
satisfaction NN 1_o
with IN N
lansoprazole NN 1_i
was VBD N
due JJ N
tothe NN N
faster RBR 1_o
pain NN 1_o
relief NN 1_o
achieved VBN N
with IN N
this DT N
drug NN N
. . N

The DT N
effects NNS N
of IN N
ezetimibe/simvastatin JJ 1_i
versus NN 1_i
simvastatin NN 1_i
monotherapy NN 1_i
on IN N
platelet NN 1_o
and CC 1_o
inflammatory JJ 1_o
biomarkers NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
metabolic JJ 1_p
syndrome NN 1_p
. . 1_p

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
of IN N
15 CD 1_p
aspirin-naive JJ 1_i
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
48.8 CD 1_p
± JJ 1_p
10.2 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
the DT 1_p
metabolic JJ 1_p
syndrome NN 1_p
, , N
statin NN 1_i
monotherapy NN 1_i
( ( 1_i
simvastatin JJ 1_i
40 CD N
mg JJ N
daily RB N
) ) N
was VBD N
compared VBN N
to TO 1_i
combination VB 1_i
therapy NN 1_i
( ( 1_i
simvastatin JJ 1_i
40 CD N
mg NN 1_i
and CC 1_i
ezetimibe $ 1_i
10 CD N
mg JJ N
daily RB N
) ) N
on IN N
biomarkers NNS N
of IN 1_o
inflammation NN 1_o
and CC 1_o
platelet NN 1_o
activity NN 1_o
. . N

The DT N
addition NN N
of IN 1_i
ezetimibe NN 1_i
to TO 1_i
simvastatin VB 1_i
over RP N
a DT N
4-week JJ N
period NN N
was VBD N
associated VBN N
with IN N
reduced JJ 1_o
expression NN 1_o
of IN 1_o
CD141 NNP 1_o
( ( N
thrombomodulin NN N
; : N
p CC N
= VB N
0.02 CD N
) ) N
, , N
platelet VBP 1_o
endothelial JJ 1_o
cell NN 1_o
adhesion NN 1_o
molecule NN 1_o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC 1_o
CD51/61 NNP 1_o
( ( N
vitronectin JJ N
receptor NN N
; : N
p CC N
= VB N
0.048 CD N
) ) N
compared VBN N
to TO 1_i
statin VB 1_i
monotherapy NN 1_i
. . 1_i

Ezetimibe NNP 1_i
added VBD N
to TO N
simvastatin VB N
improves NNS 1_o
several JJ 1_o
indices NNS 1_o
of IN 1_o
platelet NN 1_o
reactivity NN 1_o
beyond IN 1_i
statin JJ 1_i
monotherapy NN 1_i
. . N

However RB N
, , N
the DT N
clinical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
await VBP N
results NNS N
of IN N
the DT N
IMPROVE-IT NNP N
trial NN N
( ( N
Improved NNP N
Reduction NNP N
of IN N
Outcomes NNP N
: : N
Vytorin NNP N
Efficacy NNP N
International NNP N
Trial NNP N
) ) N
. . N

Comparison NNP N
of IN N
fluid NN N
types NNS N
for IN N
resuscitation NN N
after IN N
acute JJ 1_o
blood NN 1_o
loss NN 1_o
in IN 1_p
mallard NN 1_p
ducks NNS 1_p
( ( 1_p
Anas NNP 1_p
platyrhynchos NN 1_p
) ) 1_p
. . 1_p

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
LD NNP N
( ( N
50 CD N
) ) N
for IN N
acute JJ 1_p
blood NN 1_p
loss NN 1_p
in IN 1_p
mallard NN 1_p
ducks NNS 1_p
( ( 1_p
Anas NNP 1_p
platyrhynchos NN 1_p
) ) 1_p
, , N
compare VBP N
the DT N
mortality NN N
rate NN N
among IN N
3 CD N
fluid JJ N
resuscitation NN N
groups NNS N
, , N
and CC N
determine VB N
the DT N
time NN N
required VBN N
for IN N
a DT N
regenerative JJ N
RBC NNP N
response NN N
. . N

DESIGN NNP N
Prospective NNP N
study NN N
. . N

SETTING NNP N
Medical NNP 1_p
College NNP 1_p
of IN 1_p
Wisconsin NNP 1_p
Research NNP 1_p
facility NN 1_p
. . 1_p

ANIMALS NNP N
Eighteen NNP 1_p
mallard NN 1_p
ducks NNS 1_p
were VBD N
included VBN N
for IN N
the DT N
LD NNP N
( ( N
50 CD N
) ) N
study NN N
and CC N
28 CD 1_p
for IN N
the DT N
fluid NN 1_i
resuscitation NN 1_i
study NN N
. . N

INTERVENTIONS NNP N
Phlebotomy NNP 1_i
was VBD N
performed VBN N
during IN N
both DT N
the DT N
LD NNP N
( ( N
50 CD N
) ) N
and CC N
fluid JJ 1_i
resuscitation NN 1_i
studies NNS N
. . N

Ducks NNS N
in IN N
the DT N
fluid NN N
resuscitation NN N
study NN N
received VBD N
a DT N
5 CD 1_i
mL/kg NN 1_i
intravenous JJ 1_i
bolus NN 1_i
of IN 1_i
crystalloids NNS 1_i
, , 1_i
hetastarch NN 1_i
( ( 1_i
HES NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
a DT 1_i
hemoglobin-based JJ 1_i
oxygen-carrying JJ 1_i
solution NN 1_i
( ( 1_i
HBOCS NNP 1_i
) ) 1_i
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
LD NNP N
( ( N
50 CD N
) ) N
for IN N
acute JJ 1_o
blood NN 1_o
loss NN 1_o
was VBD N
60 CD N
% NN N
of IN N
total JJ 1_o
blood NN 1_o
volume NN 1_o
. . 1_o

This DT N
blood NN N
volume NN N
was VBD N
removed VBN N
in IN N
the DT N
fluid NN N
resuscitation NN N
study NN N
to TO N
create VB N
a DT N
model NN N
of IN N
acute JJ N
blood NN N
loss NN N
. . N

Following VBG N
fluid JJ N
administration NN N
, , N
6 CD N
birds NNS N
in IN N
the DT N
crystalloid NN N
group NN N
( ( N
66 CD N
% NN N
) ) N
, , N
4 CD N
birds NNS N
in IN N
the DT N
HES NNP N
group NN N
( ( N
40 CD N
% NN N
) ) N
, , N
and CC N
2 CD N
birds NNS N
in IN N
the DT N
HBOCS NNP N
group NN N
( ( N
20 CD N
% NN N
) ) N
died VBD N
. . N

No NNP N
statistical JJ N
difference NN N
in IN N
mortality NN 1_o
rate NN 1_o
was VBD N
seen VBN N
among IN N
the DT N
3 CD N
fluid NN N
resuscitation NN N
groups NNS N
. . N

Relative JJ N
polychromasia NN N
evaluated VBD N
post-phlebotomy JJ N
demonstrated JJ N
regeneration NN N
starting VBG N
at IN N
24 CD N
hours NNS N
and CC N
continuing VBG N
through IN N
48 CD N
hours NNS N
. . N

CONCLUSIONS VB N
The DT N
LD NNP N
( ( N
50 CD N
) ) N
for IN N
acute JJ 1_o
blood NN 1_o
loss NN 1_o
in IN N
mallard NN 1_p
ducks NNS 1_p
was VBD N
60 CD N
% NN N
of IN N
their PRP$ N
total JJ N
blood NN N
volume NN N
. . N

Although IN N
no DT N
statistical JJ N
difference NN N
in IN N
mortality NN 1_o
rate NN 1_o
was VBD N
appreciated VBN N
among IN N
the DT N
3 CD N
fluid NN N
resuscitation NN N
groups NNS N
, , N
a DT N
trend NN N
of IN N
decreased JJ N
mortality NN 1_o
rate NN 1_o
was VBD N
observed VBN N
in IN N
the DT N
HBOCS NNP N
group NN N
. . N

An DT N
early JJ N
regenerative NN N
response NN N
was VBD N
apparent JJ N
following VBG N
acute JJ 1_o
blood NN 1_o
loss NN 1_o
. . 1_o

Teriparatide NNP N
improves VBZ N
early JJ 1_o
callus NN 1_o
formation NN 1_o
in IN N
distal JJ 1_p
radial JJ 1_p
fractures NNS 1_p
. . 1_p

BACKGROUND NNP N
Teriparatide NNP N
( ( N
parathyreoid JJ N
hormone NN N
; : N
PTH NNP N
1-34 CD N
) ) N
increases VBZ N
skeletal JJ N
mass NN N
in IN N
humans NNS N
and CC N
improves VBZ N
fracture NN N
healing VBG N
in IN N
animals NNS N
. . N

A DT N
recent JJ N
randomized JJ N
multicenter NN N
trial NN N
of IN N
nonoperated JJ 1_p
distal JJ 1_p
radial NN 1_p
fractures NNS 1_p
showed VBD N
a DT N
moderate JJ N
shortening NN N
of IN N
the DT N
time NN N
to TO N
restoration NN N
of IN N
cortical JJ N
continuity NN N
by IN N
treatment NN N
with IN N
20 CD 1_i
microg NNS 1_i
( ( 1_i
low-dose JJ 1_i
) ) 1_i
teriparatide NN 1_i
per IN 1_i
day NN 1_i
, , 1_i
but CC 1_i
not RB 1_i
with IN 1_i
40 CD 1_i
microg NNS 1_i
( ( 1_i
high-dose JJ 1_i
) ) 1_i
. . N

As IN N
radiographic JJ N
cortical JJ N
continuity NN N
appears VBZ N
late RB N
in IN N
the DT N
healing NN N
process NN N
, , N
perhaps RB N
too RB N
late JJ N
for IN N
clinical JJ N
relevance NN N
, , N
we PRP N
studied VBD N
the DT N
qualitative JJ N
appearance NN N
of IN N
the DT N
callus JJ N
5 CD N
weeks NNS N
after IN N
fracture NN N
. . N

METHODS NNP N
One CD 1_p
third NN 1_p
of IN 1_p
the DT 1_p
patients NNS 1_p
of IN 1_p
the DT 1_p
international JJ 1_p
trial NN 1_p
were VBD 1_p
treated VBN 1_p
at IN 1_p
Linköping NNP 1_p
University NNP 1_p
Hospital NNP 1_p
. . N

The DT N
multicenter NN N
trial NN N
did VBD N
not RB N
evaluate VB N
early JJ N
callus NN N
formation NN N
. . N

We PRP N
therefore RB N
made VBD N
a DT N
blinded JJ N
qualitative JJ N
scoring NN N
of IN N
the DT N
callus NN N
at IN N
5 CD N
weeks NNS N
in IN N
our PRP$ 1_p
27 CD 1_p
patients NNS 1_p
. . N

Callus NNP N
formation NN N
was VBD N
arbitrarily RB N
classified VBN N
as IN N
rich JJ N
, , N
intermediate JJ N
, , N
or CC N
poor JJ N
. . N

RESULTS NNP N
9 CD N
patients NNS N
were VBD N
classified VBN N
as IN 1_o
rich JJ 1_o
( ( N
none NN N
had VBD N
received VBN N
placebo RB N
, , N
3 CD N
low-dose JJ N
teriparatide NN N
, , N
and CC N
6 CD N
high-dose JJ N
teriparatide NN N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN 1_o
intermediate NN 1_o
( ( N
1 CD N
had VBD N
received VBN N
placebo RB N
, , N
5 CD N
low-dose JJ N
, , N
and CC N
3 CD N
high-dose JJ N
) ) N
. . N

9 CD N
patients NNS N
were VBD N
classified VBN N
as IN 1_o
poor JJ 1_o
( ( N
7 CD N
had VBD N
received VBN N
placebo RB N
, , N
1 CD N
low-dose JJ N
, , N
and CC N
1 CD N
high-dose NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

INTERPRETATION NN N
This DT N
is VBZ N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
of IN N
an DT N
outcome NN N
variable NN N
, , N
which WDT N
was VBD N
not RB N
in IN N
the DT N
official JJ N
protocol NN N
. . N

The DT N
results NNS N
must MD N
therefore RB N
be VB N
interpreted VBN N
with IN N
caution NN N
. . N

However RB N
, , N
in IN N
combination NN N
with IN N
the DT N
results NNS N
of IN N
the DT N
larger JJR N
trial NN N
, , N
the DT N
data NN N
suggest NN N
that IN N
radiographic JJ N
quality NN N
at IN N
an DT N
early JJ N
time NN N
point NN N
might MD N
be VB N
a DT N
sensitive JJ N
variable NN N
, , N
perhaps RB N
better JJR N
than IN N
time NN N
to TO N
cortical JJ N
continuity NN N
. . N

Moreover RB N
, , N
teriparatide RB 1_i
appeared VBD N
to TO N
improve VB 1_o
early JJ 1_o
callus NN 1_o
formation NN 1_o
in IN 1_p
distal JJ 1_p
radial JJ 1_p
fractures NNS 1_p
. . 1_p

Clinical JJ 1_o
pharmacology NN 1_o
of IN N
methadone NN 1_i
in IN N
dogs NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
pharmacokinetics NNS 1_o
and CC 1_o
effects NNS 1_o
of IN N
methadone NN 1_i
on IN N
behaviour NN 1_o
and CC N
plasma JJ 1_o
concentrations NNS 1_o
of IN 1_o
cortisol NN 1_o
and CC 1_o
vasopressin NN 1_o
in IN N
healthy JJ 1_p
dogs NNS 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
Randomized NNP N
, , N
cross-over NN N
, , N
experimental JJ N
trial NN N
. . N

ANIMALS NNP N
Nine NNP 1_p
adult NN 1_p
dogs NNS 1_p
( ( 1_p
beagle NN 1_p
and CC 1_p
beagle NN 1_p
cross NN 1_p
breeds NNS 1_p
) ) 1_p
, , 1_p
four CD 1_p
males NNS 1_p
and CC 1_p
five CD 1_p
females NNS 1_p
. . 1_p

METHODS NNP N
Methadone NNP 1_i
hydrochloride NN 1_i
, , N
0.4 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
was VBD N
administered VBN N
intravenously RB N
( ( N
IV NNP N
) ) N
and CC N
subcutaneously RB N
( ( N
SC NNP N
) ) N
with IN N
a DT N
crossover NN N
design NN N
. . N

Drug NNP 1_o
and CC 1_o
hormone NN 1_o
analyses NNS 1_o
in IN 1_o
plasma NN 1_o
were VBD N
performed VBN N
using VBG N
Liquid NNP 1_i
Chromatography-Electrospray NNP 1_i
Ionization-Tandem NNP 1_i
Mass NNP 1_i
Spectrometry NNP 1_i
and CC 1_i
radioimmunoassay VB 1_i
respectively RB N
. . N

Behavioural NNP 1_o
data NNS 1_o
were VBD N
collected VBN N
using VBG N
a DT N
standardized JJ N
protocol NN N
. . N

RESULTS NNP N
After IN N
IV NNP N
administration NN N
, , N
the DT N
plasma JJ 1_o
concentration NN 1_o
of IN 1_o
methadone NN 1_o
at IN N
10 CD N
minutes NNS N
was VBD N
82.1 CD N
+/- JJ N
9.2 CD N
ng JJ N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
the DT N
terminal JJ 1_o
half-life NN 1_o
was VBD N
3.9 CD N
+/- JJ N
1.0 CD N
hours NNS N
, , N
the DT N
volume NN 1_o
of IN 1_o
distribution NN 1_o
9.2 CD N
+/- JJ N
3.3 CD N
L NNP N
kg NN N
( ( N
-1 NNP N
) ) N
and CC N
plasma JJ 1_o
clearance NN 1_o
27.9 CD N
+/- JJ N
7.6 CD N
mL NNS N
minute NN N
( ( N
-1 NNP N
) ) N
kg NN N
( ( N
-1 NNP N
) ) N
. . N

After IN N
SC NNP N
administration NN N
, , N
time NN 1_o
to TO 1_o
maximal VB 1_o
plasma JJ 1_o
concentration NN 1_o
was VBD N
1.26 CD N
+/- JJ N
1.04 CD N
hours NNS N
and CC N
maximal JJ 1_o
plasma NN 1_o
concentration NN 1_o
of IN 1_o
methadone NN 1_o
was VBD N
23.9 CD N
+/- JJ N
14.4 CD N
ng JJ N
mL NN N
( ( N
-1 NNP N
) ) N
, , N
the DT N
terminal JJ 1_o
half-life NN 1_o
was VBD N
10.7 CD N
+/- JJ N
4.3 CD N
hours NNS N
and CC N
bioavailability NN 1_o
was VBD N
79 CD N
+/- JJ N
22 CD N
% NN N
. . N

Concentrations NNS 1_o
of IN 1_o
both DT 1_o
cortisol NNS 1_o
and CC 1_o
vasopressin NN 1_o
were VBD N
increased VBN N
for IN N
an DT N
hour NN N
following VBG N
IV NNP N
methadone NN 1_i
. . 1_i

The DT N
observed JJ 1_o
behavioural JJ 1_o
effects NNS 1_o
of IN N
methadone NN N
were VBD N
decreased VBN N
licking NN 1_o
and CC 1_o
swallowing NN 1_o
and CC N
an DT N
increase NN N
in IN N
whining VBG 1_o
after IN N
SC NNP N
administration NN N
. . N

The DT N
latter JJ N
finding NN N
is VBZ N
notable JJ N
as IN N
it PRP N
can MD N
be VB N
misinterpreted VBN N
as IN N
pain NN 1_o
when WRB N
methadone NN 1_i
is VBZ N
used VBN N
as IN N
an DT N
analgesic JJ N
. . N

CONCLUSION NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
When WRB N
methadone NN 1_i
was VBD N
administered VBN N
by IN N
the DT N
SC NNP N
route NN N
, , N
the DT N
half-life NN 1_o
was VBD N
longer RBR N
, , N
but CC N
the DT N
individual JJ N
variation NN 1_o
in IN 1_o
plasma JJ 1_o
concentrations NNS 1_o
was VBD N
greater JJR N
compared VBN N
with IN N
IV NNP N
administration NN N
. . N

Increased VBD N
frequency NN 1_o
of IN 1_o
whining VBG 1_o
occurred VBN N
after IN N
administration NN N
of IN N
methadone NN 1_i
and CC N
may MD N
be VB N
a DT N
drug NN N
effect NN N
and CC N
not RB N
a DT N
sign NN N
of IN N
pain NN N
. . N

Cortisol NNP 1_o
and CC 1_o
vasopressin JJ 1_o
concentrations NNS 1_o
in IN 1_o
plasma NN 1_o
may MD N
not RB N
be VB N
suitable JJ N
for IN N
evaluating VBG N
analgesia NN 1_o
after IN N
methadone NN 1_i
treatment NN N
. . N

Effectiveness NN N
of IN N
sensory JJ 1_i
integration NN 1_i
interventions NNS 1_i
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
establish VB N
a DT N
model NN N
for IN N
randomized VBN N
controlled JJ N
trial NN N
research NN N
, , N
identify VB N
appropriate JJ N
outcome NN N
measures NNS N
, , N
and CC N
address VB N
the DT N
effectiveness NN N
of IN N
sensory JJ 1_i
integration NN 1_i
( ( 1_i
SI NNP 1_i
) ) 1_i
interventions NNS N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

Children NNP 1_p
ages VBZ 1_p
6-12 NN 1_p
with IN 1_p
ASD NNP 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
fine JJ 1_i
motor NN 1_i
or CC N
SI NNP 1_i
treatment NN 1_i
group NN N
. . N

Pretests NNS N
and CC N
posttests NNS N
measured VBD N
social JJ 1_o
responsiveness NN 1_o
, , 1_o
sensory JJ 1_o
processing NN 1_o
, , 1_o
functional JJ 1_o
motor NN 1_o
skills NNS 1_o
, , 1_o
and CC 1_o
social-emotional JJ 1_o
factors NNS 1_o
. . 1_o

Results NNS N
identified VBD N
significant JJ N
positive JJ N
changes NNS N
in IN N
Goal NNP 1_o
Attainment NNP 1_o
Scaling NNP 1_o
scores NNS 1_o
for IN N
both DT N
groups NNS N
; : N
more RBR N
significant JJ N
changes NNS N
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
, , N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
autistic JJ 1_o
mannerisms NNS 1_o
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
. . N

No DT N
other JJ N
results NNS N
were VBD N
significant JJ N
. . N

The DT N
study NN N
discusses VBZ N
considerations NNS N
for IN N
designing VBG N
future JJ N
outcome NN N
studies NNS N
for IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Comparison NNP N
of IN N
the DT N
evolutional JJ 1_o
process NN 1_o
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
in IN N
different JJ N
language NN 1_i
therapeutic JJ 1_i
interventions NNS 1_i
. . 1_i

PURPOSE NNP N
To TO N
analyze VB N
and CC N
compare VB N
the DT 1_o
extension NN 1_o
and CC 1_o
the DT 1_o
speed NN 1_o
of IN 1_o
the DT 1_o
evolutional JJ 1_o
process NN 1_o
of IN N
children NNS 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorders NNP 1_p
in IN N
direct JJ 1_i
and CC 1_i
indirect JJ 1_i
interventions NNS 1_i
as IN N
opposed VBN N
to TO N
only RB N
indirect VB N
intervention NN N
. . N

METHODS NNP N
The DT N
design NN N
of IN N
this DT N
study NN N
is VBZ N
a DT N
clinical JJ N
trial NN N
. . N

The DT N
sample NN N
was VBD N
composed VBN N
of IN N
11 CD 1_p
children NNS 1_p
diagnosed VBN 1_p
with IN 1_p
Autism NNP 1_p
( ( 1_p
n=6 NN 1_p
) ) 1_p
and CC 1_p
Asperger NNP 1_p
syndrome VBP 1_p
( ( 1_p
n=5 NN 1_p
) ) 1_p
by IN 1_p
a DT 1_p
multidisciplinary JJ 1_p
team NN 1_p
, , 1_p
that WDT 1_p
attended VBD 1_p
specialized JJ 1_p
speech-language JJ 1_p
pathology NN 1_p
therapy NN 1_p
at IN 1_p
the DT 1_p
institution NN 1_p
were VBD 1_p
the DT 1_p
study NN 1_p
was VBD 1_p
carried VBN 1_p
out RP 1_p
. . 1_p

These DT N
children NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Therapy NNP 1_i
Group NNP 1_i
( ( 1_i
TG NNP 1_i
) ) 1_i
- : 1_i
composed VBN 1_i
by IN 1_i
six CD 1_i
subjects NNS 1_i
receiving VBG 1_i
both DT 1_i
direct JJ 1_i
and CC 1_i
indirect JJ 1_i
intervention NN 1_i
; : 1_i
and CC 1_i
Orientation NNP 1_i
Group NNP 1_i
( ( 1_i
OG NNP 1_i
) ) 1_i
- : 1_i
constituted VBN 1_i
by IN 1_i
five CD 1_i
subjects NNS 1_i
receiving VBG 1_i
exclusively RB 1_i
indirect JJ 1_i
intervention NN 1_i
. . 1_i

It PRP N
was VBD N
used VBN N
the DT N
Autism NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
( ( 1_o
ABC NNP 1_o
) ) 1_o
to TO 1_i
interview NN 1_i
the DT 1_i
mothers NNS 1_i
, , 1_i
and CC 1_i
the DT 1_i
Sample NNP 1_o
of IN 1_o
Vocal NNP 1_o
Behavior NNP 1_o
( ( 1_o
SVB NNP 1_o
) ) 1_o
, , 1_i
in IN 1_i
three CD 1_i
occasions NNS 1_i
: : 1_i
at IN 1_i
the DT 1_i
beginning NN 1_i
of IN 1_i
the DT 1_i
intervention NN 1_i
process NN 1_i
( ( 1_i
time NN 1_i
0 CD 1_i
) ) 1_i
, , 1_i
six CD 1_i
months NNS 1_i
later RB 1_i
( ( 1_i
time NN 1_i
1 CD 1_i
) ) 1_i
and CC 1_i
12 CD 1_i
months NNS 1_i
later RB 1_i
( ( 1_i
time NN 1_i
2 CD 1_i
) ) 1_i
. . 1_i

RESULTS VB N
It PRP N
was VBD N
observed VBN N
greater JJR N
speed NN 1_o
and CC 1_o
extension NN 1_o
in IN 1_o
the DT 1_o
evolutional JJ 1_o
process NN 1_o
of IN N
the DT N
TG NNP N
Group NNP N
, , N
both DT N
in IN N
the DT N
analysis NN N
of IN N
the DT N
Autism NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
( ( 1_o
total JJ 1_o
and CC 1_o
partial JJ 1_o
scores NNS 1_o
) ) 1_o
and CC N
the DT N
Sample NNP 1_o
of IN 1_o
Vocal NNP 1_o
Behavior NNP 1_o
, , N
especially RB N
in IN N
the DT N
item NN N
Full NNP N
Language NNP N
. . N

The DT N
performance NN N
of IN N
children NNS 1_p
with IN 1_p
Asperger NNP 1_p
syndrome NN 1_p
was VBD N
considered VBN N
more RBR N
positive JJ N
when WRB N
compared VBN N
to TO N
that DT N
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

There EX N
was VBD N
greater JJR N
evolution NN 1_o
in IN N
younger JJR N
children NNS N
and CC N
with IN N
normal JJ N
, , N
mild JJ N
, , N
and CC N
moderate JJ N
adaptive JJ 1_o
functioning NN 1_o
. . 1_o

CONCLUSION VB N
The DT N
tendency NN N
towards NNS N
better RBR N
performance NN 1_o
of IN N
the DT N
children NNS N
attending VBG N
direct JJ 1_i
and CC 1_i
indirect JJ 1_i
intervention NN 1_i
showed VBD N
that IN N
this DT N
association NN N
is VBZ N
fundamental JJ N
in IN N
the DT N
therapeutic JJ N
process NN N
of IN N
children NNS 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorders NNP 1_p
. . 1_p

Phase NNP N
III NNP N
trial NN N
comparing VBG N
whole-pelvic JJ N
versus NN N
prostate-only JJ N
radiotherapy NN 1_i
and CC N
neoadjuvant JJ 1_i
versus NN 1_i
adjuvant NN 1_i
combined VBN 1_i
androgen JJ 1_i
suppression NN 1_i
: : 1_i
Radiation NN 1_i
Therapy NNP 1_i
Oncology NNP N
Group NNP N
9413 CD N
. . N

PURPOSE VB N
This DT N
trial NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
combined VBD N
androgen DT 1_i
suppression NN 1_i
( ( 1_i
CAS NNP 1_i
) ) 1_i
and CC 1_i
whole-pelvic JJ 1_i
( ( 1_i
WP NNP 1_i
) ) 1_i
radiotherapy NN 1_i
( ( 1_i
RT NNP 1_i
) ) 1_i
followed VBN N
by IN N
a DT N
boost NN N
to TO N
the DT N
prostate NN N
improves VBZ N
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
by IN N
10 CD N
% NN N
compared VBN N
with IN N
CAS NNP N
and CC N
prostate-only RB N
( ( N
PO NNP N
) ) N
RT NNP N
. . N

This DT N
trial NN N
also RB N
tested VBD N
the DT N
hypothesis NN N
that WDT N
neoadjuvant JJ 1_i
and CC 1_i
concurrent JJ 1_i
hormonal JJ 1_i
therapy NN 1_i
( ( 1_i
NCHT NNP 1_i
) ) 1_i
improves VBZ N
PFS NNP N
compared VBN N
with IN N
adjuvant JJ 1_i
hormonal JJ 1_i
therapy NN 1_i
( ( 1_i
AHT NNP 1_i
) ) 1_i
by IN N
10 CD N
% NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Eligibility NNP 1_p
included VBD 1_p
localized JJ 1_p
prostate NN 1_p
cancer NN 1_p
with IN 1_p
an DT 1_p
elevated JJ 1_p
prostate-specific JJ 1_p
antigen NN 1_p
( ( 1_p
PSA NNP 1_p
) ) 1_p
< VBD 1_p
or CC 1_p
= $ 1_p
100 CD 1_p
ng/mL NN 1_p
and CC 1_p
an DT 1_p
estimated VBN 1_p
risk NN 1_p
of IN 1_p
lymph JJ 1_p
node NN 1_p
( ( 1_p
LN NNP 1_p
) ) 1_p
involvement NN 1_p
of IN 1_p
15 CD 1_p
% NN 1_p
. . 1_p

Between NNP 1_p
April NNP 1_p
1 CD 1_p
, , 1_p
1995 CD 1_p
, , 1_p
and CC 1_p
June NNP 1_p
1 CD 1_p
, , 1_p
1999 CD 1_p
, , 1_p
1,323 CD 1_p
patients NNS 1_p
were VBD 1_p
accrued VBN 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
WP NNP N
+ NNP N
NCHT NNP N
, , N
PO NNP N
+ NNP N
NCHT NNP N
, , N
WP NNP N
+ NNP N
AHT NNP N
, , N
or CC N
PO NNP N
+ NNP N
AHT NNP N
. . N

Failure NN 1_o
for IN 1_o
PFS NNP 1_o
was VBD N
defined VBN N
as IN N
the DT N
first JJ N
occurrence NN N
of IN N
local JJ 1_o
, , 1_o
regional JJ 1_o
, , 1_o
or CC 1_o
distant JJ 1_o
disease NN 1_o
; : 1_o
PSA NNP 1_o
failure NN 1_o
; : 1_o
or CC N
death NN 1_o
for IN N
any DT N
cause NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
59.5 CD N
months NNS N
, , N
WP NNP N
RT NNP N
was VBD N
associated VBN N
with IN N
a DT N
4-year JJ 1_o
PFS NNP 1_o
of IN N
54 CD N
% NN N
compared VBN N
with IN N
47 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
PO NNP N
RT NNP N
( ( N
P NNP N
=.022 NNP N
) ) N
. . N

Patients NNS N
treated VBD N
with IN N
NCHT NNP 1_i
experienced VBD N
a DT N
4-year JJ 1_o
PFS NNP 1_o
of IN N
52 CD N
% NN N
versus IN N
49 CD N
% NN N
for IN N
AHT NNP 1_i
( ( N
P NNP N
=.56 NNP N
) ) N
. . N

When WRB N
comparing VBG N
all DT N
four CD N
arms NNS N
, , N
there EX N
was VBD N
a DT N
progression-free JJ 1_o
difference NN 1_o
among IN N
WP NNP 1_i
RT NNP 1_i
+ NNP 1_i
NCHT NNP 1_i
, , 1_i
PO NNP 1_i
RT NNP 1_i
+ NNP 1_i
NCHT NNP 1_i
, , 1_i
WP NNP 1_i
RT NNP 1_i
+ NNP 1_i
AHT NNP 1_i
, , N
and CC N
PO NNP 1_i
RT NNP 1_i
+ NNP 1_i
AHT NNP 1_i
( ( N
60 CD N
% NN N
v JJ N
44 CD N
% NN N
v JJ N
49 CD N
% NN N
v JJ N
50 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
=.008 NNP N
) ) N
. . N

No UH N
survival JJ 1_o
advantage NN 1_o
has VBZ N
yet RB N
been VBN N
seen VBN N
. . N

CONCLUSION NNP N
WP NNP 1_i
RT NNP 1_i
+ NNP 1_i
NCHT NNP 1_i
improves VBZ N
PFS NNP 1_o
compared VBN N
with IN N
PO NNP 1_i
RT NNP 1_i
and CC N
NCHT NNP 1_i
or CC N
PO NNP 1_i
RT NNP 1_i
and CC N
AHT NNP 1_i
, , N
and CC N
compared VBN N
with IN N
WP NNP 1_i
RT NNP 1_i
+ NNP 1_i
AHT NNP 1_i
in IN N
patients NNS 1_p
with IN 1_p
a DT 1_p
risk NN 1_p
of IN 1_p
LN NNP 1_p
involvement NN 1_p
of IN 1_p
15 CD 1_p
% NN 1_p
. . 1_p

Baseline NNP N
factors NNS N
predicting VBG N
placebo NN 1_i
response NN N
to TO N
treatment NN N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
a DT N
multisite JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE VBZ N
The DT N
finding NN N
of IN N
factors NNS N
that WDT N
differentially RB N
predict VBP N
the DT N
likelihood NN N
of IN N
response NN N
to TO N
placebo VB N
over IN N
that DT N
of IN N
an DT N
active JJ N
drug NN N
could MD N
have VB N
a DT N
significant JJ N
impact NN N
on IN N
study NN N
design NN N
in IN N
this DT N
population NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
possible JJ N
nonspecific NN N
, , N
baseline JJ N
predictors NNS N
of IN N
response NN 1_o
to TO 1_o
intervention NN 1_o
in IN N
a DT N
large JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Randomized NNP N
clinical JJ N
trial NN N
of IN N
citalopram NN 1_i
hydrobromide NN 1_i
for IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
and CC 1_p
prominent JJ 1_p
repetitive JJ 1_p
behavior NN 1_p
. . 1_p

Baseline NNP N
data NN N
at IN N
study NN N
entry NN N
were VBD N
examined VBN N
with IN N
respect NN N
to TO N
final JJ N
outcome NN N
to TO N
determine VB N
if IN N
response NN N
predictors NNS N
could MD N
be VB N
identified VBN N
. . N

A DT N
total NN N
of IN N
149 CD 1_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
5 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
( ( 1_p
mean JJ 1_p
[ NNP 1_p
SD NNP 1_p
] NNP 1_p
age NN 1_p
, , 1_p
9.4 CD 1_p
[ NN 1_p
3.1 CD 1_p
] CD 1_p
years NNS 1_p
) ) 1_p
from IN 1_p
6 CD 1_p
academic JJ 1_p
centers NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
citalopram VB 1_i
( ( N
n JJ N
= NNP N
73 CD N
) ) N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Participants NNS 1_p
had VBD 1_p
autistic JJ 1_p
disorder NN 1_p
, , 1_p
Asperger NNP 1_p
syndrome NN 1_p
, , 1_p
or CC 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
, , 1_p
not RB 1_p
otherwise RB 1_p
specified VBN 1_p
; : 1_p
had VBD 1_p
illness JJ 1_p
severity NN 1_p
ratings NNS 1_p
that WDT 1_p
were VBD 1_p
moderate JJ 1_p
or CC 1_p
more JJR 1_p
than IN 1_p
moderate VB 1_p
on IN 1_p
the DT 1_p
Clinical JJ 1_p
Global NNP 1_p
Impression-Severity NNP 1_p
scale NN 1_p
; : 1_p
and CC 1_p
scored VBD 1_p
moderate JJ 1_p
or CC 1_p
more JJR 1_p
than IN 1_p
moderate VB 1_p
on IN 1_p
compulsive JJ 1_p
behaviors NNS 1_p
measured VBN 1_p
with IN 1_p
the DT 1_p
modified JJ 1_p
Children NNP 1_p
's POS 1_p
Yale-Brown JJ 1_p
Obsessive-Compulsive JJ 1_p
Scale NNP 1_p
. . 1_p

INTERVENTIONS NNP N
Twelve NNP N
weeks NNS N
of IN N
treatment NN N
with IN N
citalopram NN 1_i
( ( N
10 CD N
mg/5 RB N
mL NN N
) ) N
or CC N
placebo NN 1_i
. . 1_i

The DT N
mean NN N
( ( N
SD NNP N
) ) N
maximum VBD N
dose NN N
of IN N
citalopram NN N
was VBD N
16.5 CD N
( ( N
6.5 CD N
) ) N
mg NN N
by IN N
mouth JJ N
daily JJ N
( ( N
maximum JJ N
dose NN N
, , N
20 CD N
mg/d NN N
) ) N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
A NNP N
positive JJ N
response NN N
was VBD N
defined VBN N
as IN N
having VBG N
a DT N
score NN N
of IN N
at IN N
least JJS N
much JJ N
improved VBN N
on IN N
the DT N
Clinical JJ 1_o
Global NNP 1_o
Impression-Improvement NNP 1_o
scale NN 1_o
at IN N
week NN N
12 CD N
. . N

Baseline NNP N
measures VBZ N
included VBN N
demographic JJ N
( ( N
sex NN N
, , N
age NN N
, , N
weight NN N
, , N
and CC N
pubertal JJ N
status NN N
) ) N
, , N
clinical JJ N
, , N
and CC N
family NN N
measures NNS N
. . N

Clinical JJ N
variables NNS N
included VBD N
baseline NN N
illness NN N
severity NN N
ratings NNS N
( ( 1_o
the DT 1_o
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
, , 1_o
the DT 1_o
Child NNP 1_o
and CC 1_o
Adolescent NNP 1_o
Symptom NNP 1_o
Inventory NNP 1_o
, , 1_o
the DT 1_o
Vineland NNP 1_o
Adaptive NNP 1_o
Behavior NNP 1_o
Scales NNP 1_o
, , 1_o
the DT 1_o
Repetitive JJ 1_o
Behavior NNP 1_o
Scale-Revised JJ 1_o
, , 1_o
and CC 1_o
the DT 1_o
Children NNP 1_o
's POS 1_o
Yale-Brown JJ 1_o
Obsessive-Compulsive JJ 1_o
Scale NNP 1_o
) ) 1_o
. . N

Family JJ N
measures NNS N
included VBD N
the DT N
Caregiver NNP 1_o
Strain NNP 1_o
Questionnaire NNP 1_o
. . 1_o

RESULTS NNP N
Several JJ N
baseline JJ N
predictors NNS N
of IN N
response NN N
were VBD N
identified VBN N
, , N
and CC N
a DT N
principal JJ N
component NN N
analysis NN N
yielded VBD N
3 CD N
composite JJ N
measures NNS N
( ( 1_o
disruptive JJ 1_o
behavior NN 1_o
, , 1_o
autism/mood NN 1_o
, , 1_o
and CC 1_o
caregiver RB 1_o
strain NN 1_o
) ) 1_o
that WDT N
significantly RB N
predicted VBD N
response NN N
at IN N
week NN N
12 CD N
. . N

Specifically RB N
, , N
participants NNS N
in IN N
the DT N
placebo NN N
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
than IN N
participants NNS N
in IN N
the DT N
citalopram NN N
group NN N
to TO N
respond VB N
at IN N
week NN N
12 CD N
if IN N
they PRP N
entered VBD N
the DT N
study NN N
more RBR N
symptomatic JJ N
on IN N
each DT N
of IN N
the DT N
3 CD N
composite JJ N
measures NNS N
, , N
and CC N
they PRP N
were VBD N
at IN N
least JJS N
2 CD N
times NNS N
less RBR N
likely JJ N
to TO N
be VB N
responders NNS N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
This DT N
analysis NN N
suggests VBZ N
strategies NNS N
that WDT N
may MD N
be VB N
useful JJ N
in IN N
anticipating VBG N
and CC N
potentially RB N
mitigating VBG N
the DT N
nonspecific JJ N
response NN N
in IN N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00086645 NN N
. . N

Effect NN N
of IN N
cicloxilic JJ 1_i
acid NN 1_i
on IN N
bile NN 1_o
lipid JJ 1_o
composition NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
gallstones NNS 1_p
: : 1_p
a DT N
multicenter NN N
trial NN N
. . N

24 CD 1_p
gallstone NN 1_p
patients NNS 1_p
were VBD N
treated VBN N
with IN N
cicloxilic JJ 1_i
acid NN 1_i
, , N
an DT N
agent NN N
endowed VBN N
with IN N
choleretic JJ N
activity NN N
, , N
at IN N
the DT N
dose NN N
of IN N
240 CD N
mg/day NN N
for IN N
1 CD N
month NN N
. . N

24 CD 1_p
comparable JJ 1_p
patients NNS 1_p
on IN 1_p
placebo NN 1_i
treatment NN 1_p
acted VBD N
as IN N
controls NNS N
. . N

Bile NNP 1_o
lipid JJ 1_o
composition NN 1_o
was VBD N
determined VBN N
and CC N
the DT N
saturation NN N
index NN N
calculated VBD N
before IN N
and CC N
after IN N
treatment NN N
, , N
on IN N
samples NNS N
collected VBN N
by IN N
duodenal JJ N
siphonage NN N
after IN N
caerulein JJ N
stimulation NN N
, , N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
cicloxilic JJ N
group NN N
there EX N
was VBD N
little JJ N
or CC N
no DT N
change NN N
in IN N
bile NN 1_o
salts NNS 1_o
and CC 1_o
phospholipids NNS 1_o
, , N
whereas NNS N
biliary VBP 1_o
cholesterol NN 1_o
concentration NN 1_o
was VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
consequently RB N
the DT N
lithogenic JJ 1_o
index NN 1_o
lowered VBD N
( ( N
from IN N
1.5 CD N
to TO N
1.2 CD N
, , N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Cicloxilic JJ N
acid NN N
can MD N
have VB N
a DT N
place NN N
in IN N
gallstone NN N
disease NN N
therapy NN N
in IN N
association NN N
with IN N
the DT N
litholytic JJ N
bile NN N
acids NNS N
or CC N
in IN N
the DT N
prevention NN N
of IN N
gallstone NN 1_o
formation NN 1_o
in IN N
high-risk JJ N
populations NNS N
. . N

Barriers NNS N
to TO N
hypertension NN N
care NN N
and CC N
control NN N
in IN N
young JJ 1_p
urban JJ 1_p
black JJ 1_p
men NNS 1_p
. . 1_p

Barriers NNS N
to TO N
high JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( N
HBP NNP N
) ) N
care NN N
and CC N
control NN N
have VBP N
been VBN N
reported VBN N
in IN N
the DT N
literature NN N
for IN N
> $ N
30 CD N
years NNS N
. . N

Few JJ N
reports NNS N
on IN N
barriers NNS N
, , N
however RB N
, , N
have VBP N
focused VBN N
on IN N
the DT N
young JJ 1_p
black JJ 1_p
man NN 1_p
with IN 1_p
HBP NNP 1_p
, , N
the DT N
age/sex/race NN N
group NN N
with IN N
the DT N
highest JJS N
rates NNS N
of IN N
early JJ N
severe JJ N
and CC N
complicated JJ N
HBP NNP N
and CC N
the DT N
lowest JJS N
rates NNS N
of IN N
awareness NN N
, , N
treatment NN N
, , N
and CC N
control NN N
. . N

In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
comprehensive JJ N
care NN N
for IN N
hypertensive JJ 1_p
young JJ 1_p
urban JJ 1_p
black JJ 1_p
men NNS 1_p
, , N
factors NNS N
potentially RB N
associated VBN N
with IN N
care NN N
and CC N
control NN N
were VBD N
assessed VBN N
at IN N
baseline NN N
for IN N
the DT N
309 CD 1_p
enrolled VBD 1_p
men NNS 1_p
. . 1_p

A DT 1_p
majority NN 1_p
of IN 1_p
the DT 1_p
men NNS 1_p
encountered VBD 1_p
a DT 1_p
variety NN 1_p
of IN 1_p
barriers NNS 1_p
including VBG 1_p
economic JJ 1_p
, , 1_p
social JJ 1_p
, , 1_p
and CC 1_p
lifestyle JJ 1_p
obstacles NNS 1_p
to TO 1_p
adequate VB 1_p
BP NNP 1_p
care NN 1_p
and CC 1_p
control NN 1_p
, , 1_p
including VBG 1_p
no DT 1_o
current JJ 1_o
HBP NNP 1_o
care NN 1_o
( ( 1_p
49 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
risk NN 1_o
of IN 1_o
alcoholism NN 1_o
( ( 1_p
62 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
use NN 1_o
of IN 1_o
illicit NN 1_o
drugs NNS 1_o
( ( 1_p
45 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
social JJ 1_o
isolation NN 1_o
( ( 1_p
47 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
unemployment NN 1_o
( ( 1_p
40 CD 1_p
% NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
lack NN 1_o
of IN 1_o
health NN 1_o
insurance NN 1_o
( ( 1_p
51 CD 1_p
% NN 1_p
) ) 1_p
. . 1_p

Having VBG 1_o
health NN 1_o
insurance NN 1_o
( ( N
odds NNS N
ratio VBP N
= JJ N
7.20 CD N
, , N
P NNP N
= NNP N
.00 NNP N
) ) N
and CC N
a DT N
negative JJ 1_o
urine JJ 1_o
drug NN 1_o
screen NN 1_o
( ( N
odds NNS N
ratio VBP N
= JJ N
.56 NNP N
, , N
P NNP N
= NNP N
.04 NNP N
) ) N
were VBD N
significant JJ N
predictors NNS N
of IN N
being VBG N
in IN N
HBP NNP N
care NN N
. . N

Low JJ 1_o
alcoholism NN 1_o
risk NN 1_o
and CC 1_o
employment NN 1_o
were VBD N
identified VBN N
as IN N
significant JJ N
predictors NNS N
of IN N
compliance NN N
with IN N
HBP NNP N
medication-taking JJ N
behavior NN N
. . N

Men NNP 1_p
currently RB 1_p
using VBG 1_o
illicit JJ 1_o
drugs NNS 1_o
were VBD N
2.64 CD N
times NNS N
less RBR N
likely JJ N
to TO N
have VB N
controlled VBN 1_o
BP NNP 1_o
compared VBN N
with IN N
their PRP$ N
counterparts NNS 1_p
who WP 1_p
did VBD 1_p
not RB 1_p
use VB 1_p
illicit JJ 1_p
drugs NNS 1_p
, , N
and CC N
men NNS 1_p
currently RB 1_p
taking VBG 1_o
HBP NNP 1_o
medication NN 1_o
were VBD N
63 CD N
times NNS N
more RBR N
likely JJ N
have VBP N
controlled VBN 1_o
BP NNP 1_o
compared VBN N
with IN N
men NNS 1_p
not RB 1_p
taking VBG 1_p
HBP NNP 1_p
medication NN 1_p
. . 1_p

Comprehensive JJ 1_i
interventions NNS 1_i
are VBP N
needed VBN N
to TO N
address VB N
socioeconomic JJ N
and CC N
lifestyle JJ N
issues NNS N
as RB N
well RB N
as IN N
other JJ N
barriers NNS N
to TO N
care VB N
and CC N
treatment NN N
, , N
if IN N
HBP NNP N
care NN N
is VBZ N
to TO N
be VB N
salient JJ N
and CC N
effective JJ N
in IN N
this DT N
high JJ 1_p
risk NN 1_p
group NN 1_p
. . 1_p

Racial JJ 1_i
differences NNS 1_i
in IN 1_i
primary JJ 1_i
and CC 1_i
repeat VB 1_i
lower JJR 1_i
extremity NN 1_i
amputation NN 1_i
: : 1_i
results NNS N
from IN N
a DT N
multihospital NN 1_i
study NN 1_i
. . 1_i

OBJECTIVE CC N
African JJ 1_p
Americans NNPS 1_p
have VBP N
a DT N
much RB N
higher JJR N
risk NN 1_o
of IN 1_o
major JJ 1_o
( ( 1_o
above- JJ 1_o
or CC 1_o
below-knee NN 1_o
) ) 1_o
lower JJR 1_o
extremity NN 1_o
amputation NN 1_o
and CC N
a DT N
lower JJR 1_i
rate NN 1_o
of IN 1_o
limb-preserving JJ 1_o
vascular JJ 1_o
surgery NN 1_o
or CC 1_i
angioplasty NN 1_i
than IN N
white JJ N
patients NNS N
. . N

This DT N
article NN N
analyzes VBZ N
two CD N
potential JJ N
pathways NNS N
for IN N
racial JJ N
disparities NNS N
: : N
primary JJ N
amputation NN N
, , N
defined VBD N
as IN N
a DT N
major JJ N
amputation NN 1_i
performed VBN N
without IN N
any DT N
prior JJ N
attempt NN N
at IN N
revascularization NN 1_i
, , N
and CC N
repeat NN N
amputation NN 1_i
, , N
defined VBD N
as IN N
a DT N
major JJ N
amputation NN 1_i
subsequent NN N
to TO N
a DT N
previous JJ N
through-foot NN N
or CC N
major JJ N
amputation NN N
. . N

METHODS NNP N
Randomly NNP 1_p
selected VBD 1_p
medical JJ 1_i
records NNS 1_i
were VBD 1_i
reviewed VBN 1_i
for IN 1_i
248 CD 1_i
African JJ 1_i
American NNP 1_i
, , 1_i
30 CD 1_i
Hispanic NNP 1_i
, , 1_i
and CC 1_i
235 CD 1_i
white JJ 1_i
or CC 1_i
other-race JJ 1_i
patients NNS 1_i
undergoing VBG 1_i
above- JJ 1_i
or CC 1_i
below-knee JJ 1_i
amputation NN 1_i
between IN 1_i
1995 CD 1_i
and CC 1_i
2003 CD 1_i
at IN 1_i
three CD 1_i
Chicago NNP 1_i
teaching VBG 1_i
hospitals NNS 1_i
. . 1_i

Chronic NNP 1_i
disease NN 1_i
prevalence NN 1_i
and CC 1_i
severity NN 1_i
, , 1_i
preadmission NN 1_i
functional JJ 1_i
status NN 1_i
, , 1_i
clinical JJ 1_i
presentation NN 1_i
, , 1_i
and CC 1_i
vascular JJ 1_i
history NN 1_i
were VBD N
used VBN N
to TO N
test VB N
the DT N
risk-adjusted JJ N
effect NN N
of IN N
race NN N
and CC N
ethnicity NN N
on IN N
rates NNS 1_o
of IN 1_o
primary JJ 1_o
and CC 1_o
repeat JJ 1_o
amputation NN 1_o
. . 1_o

RESULTS NNP N
Controlling VBG N
for IN N
demographic JJ N
, , N
functional JJ N
, , N
chronic JJ N
disease NN N
, , N
and CC N
clinical JJ N
characteristics NNS N
, , N
African JJ N
American JJ N
patients NNS N
were VBD N
1.7 CD N
times NNS N
more RBR N
likely JJ N
to TO N
have VB N
undergone JJ N
both DT N
primary JJ N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
and CC N
repeat NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
amputation NN 1_i
than IN N
white JJ N
or CC N
other-race JJ N
amputees NNS N
. . N

Race NNP N
remained VBD N
a DT N
significant JJ N
independent JJ N
risk NN N
factor NN N
even RB N
after IN N
controlling VBG N
for IN N
the DT N
higher JJR N
severity NN N
of IN N
illness NN N
, , N
greater JJR N
disability NN N
, , N
and CC N
more RBR N
complex JJ N
presentation NN N
of IN N
African JJ 1_p
American JJ 1_p
amputees NNS 1_p
. . 1_p

CONCLUSIONS NNP N
Higher JJR N
rates NNS N
of IN N
primary JJ 1_o
and CC 1_o
repeat JJ 1_o
amputation NN 1_o
for IN N
African JJ N
American JJ N
patients NNS N
at IN N
study NN N
hospitals NNS N
, , N
which WDT N
all DT N
have VBP N
significant JJ N
vascular JJ N
surgery NN N
capacity NN N
and CC N
an DT N
aggressive JJ N
policy NN N
of IN N
limb NN N
salvage NN N
, , N
suggest VBP N
that IN N
these DT N
rates NNS N
may MD N
be VB N
even RB N
higher JJR N
at IN N
less JJR N
well RB N
equipped JJ N
institutions NNS N
. . N

Improving VBG N
access NN N
to TO N
primary JJ N
and CC N
preventive JJ N
care NN N
for IN N
lower-income JJ N
patients NNS N
could MD N
reduce VB N
amputation NN 1_o
rates NNS 1_o
among IN N
African JJ N
Americans NNPS N
. . N

Exploring VBG N
the DT N
social JJ 1_o
impact NN 1_o
of IN N
being VBG N
a DT N
typical JJ 1_i
peer NN 1_i
model NN 1_i
for IN N
included JJ N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

This DT N
study NN N
examined VBD N
the DT N
social JJ 1_o
impact NN 1_o
of IN N
being VBG N
a DT N
typical JJ N
peer NN N
model NN N
as IN N
part NN N
of IN N
a DT N
social JJ 1_i
skills NNS 1_i
intervention NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

Participants NNS N
were VBD N
drawn VBN N
from IN N
a DT N
randomized-controlled-treatment JJ N
trial NN N
that WDT N
examined VBD N
the DT N
effects NNS N
of IN N
targeted JJ N
interventions NNS 1_i
on IN N
the DT N
social JJ 1_o
networks NNS 1_o
of IN N
60 CD 1_p
elementary-aged JJ 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Results NNP N
demonstrated VBD N
that DT N
typical JJ N
peer NN N
models NNS N
had VBD N
higher RBR 1_o
social JJ 1_o
network NN 1_o
centrality NN 1_o
, , 1_o
received VBN 1_o
friendships NNS 1_o
, , 1_o
friendship JJ 1_o
quality NN 1_o
, , 1_o
and CC 1_o
less JJR 1_o
loneliness JJR 1_o
than IN N
non-peer JJ N
models NNS N
. . N

Peer NNP 1_i
models NNS 1_i
were VBD N
also RB N
more RBR 1_o
likely JJ 1_o
to TO N
be VB N
connected VBN N
with IN N
children NNS N
with IN N
ASD NNP N
than IN N
non-peer JJ N
models NNS N
at IN N
baseline NN N
and CC N
exit NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
typical JJ N
peers NNS N
can MD N
be VB N
socially RB N
connected VBN N
to TO N
children NNS N
with IN N
ASD NNP N
, , N
as RB N
well RB N
as IN N
other JJ N
classmates NNS N
, , N
and CC N
maintain VB N
a DT N
strong JJ 1_o
and CC 1_o
positive JJ 1_o
role NN 1_o
within IN N
the DT N
classroom NN N
. . N

Time NN N
intervals NNS N
production NN N
in IN N
tapping VBG 1_p
and CC N
oscillatory JJ 1_p
motion NN 1_p
. . 1_p

We PRP N
applied VBD N
spectral JJ 1_i
analysis NN 1_i
on IN N
series NN N
of IN N
time NN N
intervals NNS N
produced VBN N
in IN N
a DT N
synchronization-continuation JJ N
experiment NN N
. . N

In IN N
the DT N
first JJ N
condition NN N
intervals NNS N
were VBD N
produced VBN N
by IN N
finger NN 1_p
tapping NN 1_p
, , N
and CC N
in IN N
the DT N
second JJ N
by IN N
an DT N
oscillatory JJ 1_p
motion NN 1_p
of IN 1_p
the DT 1_p
hand NN 1_p
. . 1_p

Results NNS N
obtained VBD N
in IN N
tapping VBG 1_p
were VBD N
consistent JJ N
with IN N
a DT N
discrete JJ N
, , N
event-based JJ N
timing NN N
model NN N
. . N

In IN N
the DT N
oscillatory JJ 1_p
condition NN 1_p
, , N
the DT N
spectra NN N
suggested VBD N
a DT N
continuous JJ N
, , N
dynamic JJ N
timing NN N
mechanism NN N
, , N
based VBN N
on IN N
the DT N
regulation NN N
of IN N
effector NN N
stiffness NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
oscillatory JJ 1_p
character NN 1_p
of IN N
movement NN N
can MD N
offer VB N
an DT N
important JJ N
resource NN N
for IN N
timing VBG N
control NN N
. . N

The DT N
use NN N
of IN N
an DT N
event-based JJ N
timing NN N
control NN N
such JJ N
as IN N
postulated VBN N
in IN N
the DT N
Wing-Kristoffersson NNP N
model NN N
could MD N
be VB N
restricted VBN N
to TO N
a DT N
quite RB N
limited JJ N
class NN N
of IN N
rhythmic JJ N
tasks NNS N
, , N
characterized VBN N
by IN N
the DT N
concatenation NN N
of IN N
discrete JJ N
events NNS N
. . N

Video-feedback JJ 1_i
Intervention NNP 1_i
to TO N
promote VB N
Positive NNP N
Parenting NNP N
adapted VBD N
to TO N
Autism NNP N
( ( N
VIPP-AUTI NNP N
) ) N
: : N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
we PRP N
evaluated VBD N
the DT N
early JJ N
intervention NN N
program NN N
Video-feedback NNP 1_i
Intervention NNP 1_i
to TO N
promote VB N
Positive NNP 1_p
Parenting NNP 1_p
adapted VBD 1_p
to TO 1_p
Autism NNP 1_p
( ( 1_p
VIPP-AUTI NNP 1_p
) ) 1_p
with IN 1_p
78 CD 1_p
primary JJ 1_p
caregivers NNS 1_p
and CC 1_p
their PRP$ 1_p
child NN 1_p
( ( 1_p
16-61 JJ 1_p
months NNS 1_p
) ) 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorder NNP 1_p
. . 1_p

VIPP-AUTI NNP 1_i
is VBZ N
a DT N
brief JJ N
attachment-based JJ 1_i
intervention NN 1_i
program NN 1_i
, , N
focusing VBG N
on IN N
improving VBG N
parent-child JJ 1_o
interaction NN 1_o
and CC N
reducing VBG N
the DT N
child NN 1_o
's POS 1_o
individual JJ 1_o
Autism NNP 1_o
Spectrum NNP 1_o
Disorder-related NNP 1_o
symptomatology NN 1_o
in IN N
five CD N
home NN N
visits NNS N
. . N

VIPP-AUTI NNP 1_i
, , N
as IN N
compared VBN N
with IN N
usual JJ N
care NN N
, , N
demonstrated VBD N
efficacy NN 1_o
in IN N
reducing VBG N
parental JJ N
intrusiveness NN N
. . N

Moreover RB N
, , N
parents NNS N
who WP N
received VBD N
VIPP-AUTI NNP 1_i
showed VBD N
increased JJ 1_o
feelings NNS 1_o
of IN 1_o
self-efficacy NN 1_o
in IN N
child NN N
rearing NN N
. . N

No DT 1_o
significant JJ N
group NN N
differences NNS N
were VBD N
found VBN N
on IN N
other JJ N
aspects NNS N
of IN N
parent-child JJ 1_o
interaction NN 1_o
or CC 1_o
on IN 1_o
child JJ 1_o
play NN 1_o
behavior NN 1_o
. . 1_o

At IN N
3-months JJ N
follow-up NN N
, , N
intervention NN N
effects NNS N
were VBD N
found VBN N
on IN N
child-initiated JJ 1_o
joint JJ 1_o
attention NN 1_o
skills NNS 1_o
, , N
not RB N
mediated VBN N
by IN N
intervention NN N
effects NNS N
on IN N
parenting VBG N
. . N

Implementation NN N
of IN N
VIPP-AUTI NNP 1_i
in IN N
clinical JJ N
practice NN N
is VBZ N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
detailed JJ N
manual NN N
and CC N
a DT N
relatively RB N
brief JJ N
training NN N
of IN N
interveners NNS N
. . N

Plasma NNP N
antioxidant NN N
status NN N
after IN N
high-dose JJ 1_i
chemotherapy NN 1_i
: : 1_i
a DT N
randomized JJ N
trial NN N
of IN N
parenteral JJ N
nutrition NN N
in IN N
bone NN 1_p
marrow NN 1_p
transplantation NN 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Chemotherapy NNP 1_i
and CC 1_i
radiation NN 1_i
therapy NN 1_i
result NN N
in IN N
increased JJ N
free JJ N
radical JJ N
formation NN N
and CC N
depletion NN N
of IN N
tissue NN N
antioxidants NNS N
. . N

It PRP N
is VBZ N
not RB N
known VBN N
whether IN N
parenteral JJ 1_i
nutrition NN 1_i
( ( 1_i
PN NNP 1_i
) ) 1_i
administered VBD N
during IN N
bone NN 1_i
marrow NN 1_i
transplantation NN 1_i
( ( 1_i
BMT NNP 1_i
) ) 1_i
supports VBZ N
systemic JJ N
antioxidant NN N
status NN N
. . N

OBJECTIVE CC N
The DT N
aims NNS N
of IN N
the DT N
study NN N
were VBD N
to TO N
determine VB N
1 CD N
) ) N
whether IN N
high-dose JJ 1_i
chemotherapy NN 1_i
decreases VBZ N
concentrations NNS N
of IN N
major JJ N
circulating VBG N
antioxidants NNS N
in IN N
patients NNS 1_p
undergoing VBG 1_p
BMT NNP 1_i
and CC N
2 CD N
) ) N
whether IN N
administration NN N
of IN N
standard JJ N
PN NNP 1_i
maintains VBZ N
systemic JJ N
antioxidant JJ N
concentrations NNS N
compared VBN N
with IN N
PN NNP 1_i
containing VBG N
micronutrients NNS N
and CC N
minimal JJ N
lipids NNS N
alone RB N
. . N

DESIGN NNP N
Twenty-four JJ 1_p
BMT NNP 1_i
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
standard JJ 1_i
PN NNP 1_i
containing VBG 1_i
conventional JJ 1_i
amounts NNS 1_i
of IN 1_i
dextrose NN 1_i
, , 1_i
amino JJ 1_i
acids NNS 1_i
, , 1_i
micronutrients NNS 1_i
, , 1_i
and CC 1_i
lipid JJ 1_i
( ( N
120 CD N
kJ/d NN N
) ) N
or CC N
a DT N
solution NN 1_i
containing VBG 1_i
only JJ 1_i
micronutrients NNS 1_i
( ( N
identical JJ N
to TO N
those DT N
in IN N
standard JJ N
PN NNP N
) ) N
and CC N
a DT N
small JJ N
amount NN N
of IN N
lipid JJ N
( ( N
12 CD N
kJ/d NN N
) ) N
. . N

Plasma NNP 1_o
antioxidant JJ 1_o
status NN 1_o
was VBD N
measured VBN N
before IN N
conditioning VBG N
therapy NN N
and CC N
serially RB N
at IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
10 CD N
, , N
and CC N
14 CD N
after IN N
BMT NNP N
. . N

RESULTS NNP N
Plasma NNP 1_o
glutathione NN 1_o
( ( 1_o
GSH NNP 1_o
) ) 1_o
and CC 1_o
alpha- JJ 1_o
and CC 1_o
gamma-tocopherol JJ 1_o
concentrations NNS 1_o
decreased VBN N
and CC N
the DT N
GSH NNP 1_o
redox NN 1_o
state NN 1_o
became VBD N
more RBR N
oxidized JJ N
after IN N
conditioning VBG N
chemotherapy NN N
. . N

Plasma NNP 1_o
cysteine JJ 1_o
concentrations NNS 1_o
were VBD N
unchanged JJ N
, , N
whereas JJ N
cystine NN N
concentrations NNS N
increased VBD N
. . N

Plasma NNP 1_o
vitamin JJ 1_o
C NNP 1_o
and CC 1_o
zinc NNP 1_o
concentrations NNS 1_o
and CC 1_o
GSH NNP 1_o
peroxidase NN 1_o
activity NN 1_o
increased VBD N
over IN N
time NN N
. . N

Plasma VB 1_o
alpha-tocopherol JJ 1_o
concentrations NNS 1_o
were VBD N
lower JJR N
in IN N
patients NNS N
given VBN N
standard JJ N
PN NNP N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
other JJ N
plasma JJ 1_o
antioxidants NNS 1_o
between IN N
groups NNS N
. . N

CONCLUSIONS VB N
A DT N
significant JJ N
decline NN N
in IN N
GSH-glutathione NNP 1_o
disulfide NN 1_o
, , 1_o
cysteine-cystine NN 1_o
, , 1_o
and CC 1_o
vitamin FW 1_o
E NNP 1_o
status NN 1_o
occurs VBZ N
after IN N
chemotherapy NN 1_i
and CC 1_i
BMT NNP 1_i
. . 1_i

Standard NNP N
PN NNP N
does VBZ N
not RB N
improve VB N
antioxidant NN N
status NN N
compared VBN N
with IN N
administration NN N
of IN N
micronutrients NNS N
alone RB N
. . N

Further JJ N
evaluation NN N
of IN N
PN NNP N
formulations NNS N
to TO N
support VB N
patients NNS 1_p
undergoing VBG 1_p
high-dose JJ 1_i
chemotherapy NN 1_i
and CC N
BMT NNP 1_i
are VBP N
needed VBN N
. . N

Anaphylactoid JJ 1_o
reactions NNS 1_o
and CC 1_o
histamine NN 1_o
release NN 1_o
by IN N
plasma NN 1_i
substitutes NNS 1_i
: : 1_i
a DT N
randomized NN N
controlled VBN N
trial NN N
in IN 1_p
human JJ 1_p
subjects NNS 1_p
and CC 1_p
in IN 1_p
dogs NNS 1_p
[ JJ N
proceedings NNS N
] NN N
. . N

Epidural JJ 1_i
fentanyl-bupivacaine JJ 1_i
compared VBN N
with IN N
clonidine-bupivacaine NN 1_i
for IN N
analgesia NN 1_p
in IN 1_p
labour NN 1_p
. . 1_p

Alpha-adrenergic JJ N
agonists NNS N
produce VBP N
pain NN 1_o
relief NN 1_o
through IN N
an DT N
opioid JJ N
independent JJ N
mechanism NN N
and CC N
may MD N
be VB N
alternatives NNS N
to TO N
opioids NNS N
for IN N
combination NN N
with IN N
local JJ N
anaesthetics NNS N
for IN N
analgesia NN N
during IN 1_p
labour NN 1_p
. . 1_p

We PRP 1_p
studied VBD 1_p
41 CD 1_p
pregnant JJ 1_p
women NNS 1_p
. . 1_p

Epidural JJ N
block NN N
was VBD N
performed VBN N
with IN N
75 CD N
microg NNS N
clonidine NN 1_i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
50 CD 1_i
microg NNS 1_i
fentanyl NN 1_i
( ( N
n JJ N
= NNP N
21 CD N
) ) N
combined VBN 1_i
with IN 1_i
0.125 CD 1_i
% NN 1_i
bupivacaine NN 1_i
( ( N
10 CD N
mL NN N
) ) N
. . N

Maternal JJ 1_o
vital JJ 1_o
parameters NNS 1_o
were VBD N
measured VBN N
. . N

Analgesia NNP 1_o
was VBD N
evaluated VBN N
using VBG N
a DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
; : N
sedation NN 1_o
was VBD N
scored VBN N
using VBG N
a DT N
five-point JJ N
scale NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
maternal JJ 1_o
vital JJ 1_o
parameters NNS 1_o
, , 1_o
fetal JJ 1_o
heart NN 1_o
rate NN 1_o
( ( 1_o
FHR NNP 1_o
) ) 1_o
or CC 1_o
Apgar NNP 1_o
scores NNS 1_o
between IN N
the DT N
groups NNS N
. . N

Analgesia NNP 1_o
lasted VBD N
longer RBR N
in IN N
the DT N
bupivacaine-clonidine JJ 1_i
group NN N
( ( N
139.4 CD N
+/- JJ N
31 CD N
min NN N
) ) N
compared VBN N
with IN N
the DT N
bupivacaine-fentanyl JJ 1_i
group NN N
( ( N
127.9 CD N
+/- JJ N
48 CD N
min NN N
) ) N
( ( N
P NNP N
= NNP N
0.42 CD N
) ) N
. . N

Additional JJ 1_o
analgesic JJ 1_o
requirement NN 1_o
was VBD N
more RBR N
often RB N
in IN N
the DT N
fentanyl-bupivacaine JJ 1_i
group NN N
and CC N
total JJ N
bupivacaine NN N
requirement NN N
was VBD N
less RBR N
in IN N
the DT N
clonidine-bupivacaine JJ 1_i
group NN N
( ( N
22.5 CD N
+/- JJ N
12.5 CD N
mg NN N
vs. FW N
30.9 CD N
+/- JJ N
12.8 CD N
mg NN N
) ) N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

This DT N
small JJ N
study NN N
confirms VBZ N
that IN N
this DT N
combination NN N
of IN N
bupivacaine NN 1_i
and CC N
clonidine NN 1_i
provides VBZ N
satisfactory JJ 1_o
analgesia NN 1_o
for IN N
first-stage JJ N
labour NN N
, , N
and CC N
of IN N
longer JJR N
duration NN 1_o
than IN N
bupivacaine-fentanyl NN 1_i
. . 1_i

A DT N
drug NN N
interaction NN N
study NN N
between IN N
ticlopidine NN 1_i
and CC N
cyclosporin NN 1_i
in IN N
heart NN 1_p
transplant NN 1_p
recipients NNS 1_p
. . 1_p

OBJECTIVES NNP N
Previous NNP N
uncontrolled JJ N
studies NNS N
have VBP N
suggested VBN N
an DT N
interaction NN N
between IN N
ticlopidine NN 1_i
, , N
a DT N
major JJ N
antiplatelet NN N
agent NN N
, , N
and CC N
cyclosporin NN 1_i
in IN N
heart- JJ N
and CC N
kidney-transplant JJ N
recipients NNS N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
fashion NN N
, , N
the DT N
possible JJ N
interaction NN N
between IN N
cyclosporin NN 1_i
A NNP 1_i
and CC 1_i
ticlopidine NN 1_i
( ( N
250 CD N
mg NNS N
per IN N
day NN N
) ) N
and CC N
the DT N
tolerability NN N
of IN N
this DT N
combination NN N
in IN N
heart-transplant JJ 1_p
recipients NNS 1_p
. . 1_p

METHODS NNP N
Twenty NNP 1_p
heart-transplant JJ 1_p
recipients NNS 1_p
were VBD 1_p
randomised VBN 1_p
into IN 1_p
either CC 1_p
a DT 1_p
treated JJ 1_p
or CC 1_p
a DT 1_p
placebo NN 1_i
group NN 1_p
. . 1_p

Blood NN N
samples NNS N
were VBD N
drawn VBN N
for IN N
time-course JJ N
evaluation NN N
of IN N
cyclosporin NN N
blood NN N
levels NNS N
over IN N
a DT N
period NN N
of IN N
12 CD N
h NNS N
, , N
following VBG N
the DT N
morning NN N
intake NN N
of IN N
cyclosporin NN 1_i
and CC N
, , N
for IN N
platelet NN N
aggregation NN N
studies NNS N
, , N
before IN N
and CC N
after IN N
14 CD N
days NNS N
of IN N
ticlopidine JJ 1_i
administration NN N
. . N

Twenty CD N
four-hour JJ N
urine JJ N
samples NNS N
were VBD N
collected VBN N
for IN N
6-beta-hydroxycortisol JJ N
measurements NNS N
, , N
before IN N
and CC N
after IN N
14 CD N
days NNS N
of IN N
ticlopidine NN N
. . N

RESULTS NNP N
Although IN N
given VBN N
at IN N
half PDT N
the DT N
recommended JJ N
daily JJ N
dosage NN N
, , N
ticlopidine NN N
significantly RB N
reduced VBN N
platelet NN 1_o
aggregation NN 1_o
. . 1_o

Pharmacokinetic JJ N
parameters NNS N
indicate VBP N
that IN N
the DT N
bioavailability NN 1_o
of IN 1_o
cyclosporin NN 1_o
A NNP 1_o
was VBD N
not RB N
significantly RB N
modified VBN N
by IN N
ticlopidine NN 1_i
. . 1_i

However RB N
, , N
one CD 1_p
patient NN 1_p
in IN 1_p
the DT 1_p
ticlopidine NN 1_p
group NN 1_p
was VBD 1_p
withdrawn VBN 1_p
because IN 1_p
of IN 1_p
a DT 1_p
major JJ 1_p
fall NN 1_o
in IN 1_o
cyclosporin JJ 1_o
blood NN 1_o
level NN 1_o
within IN 1_p
3 CD 1_p
days NNS 1_p
of IN 1_p
treatment NN 1_p
. . 1_p

Urinary JJ 1_o
excretion NN 1_o
of IN 1_o
6-beta-hydroxycortisol NNP 1_o
was VBD N
augmented VBN N
after IN N
treatment NN N
in IN N
the DT N
ticlopidine NN 1_i
group NN N
compared VBN N
with IN N
the DT N
placebo NN 1_i
group NN N
, , N
suggesting VBG N
that IN N
induction NN N
of IN N
drug NN N
metabolism NN N
might MD N
have VB N
occurred VBN N
. . N

Data NNP N
also RB N
show VBP N
quite RB N
a DT N
large JJ N
intra-individual JJ N
variability NN N
in IN N
cyclosporin JJ 1_o
bioavailability NN 1_o
in IN N
the DT N
placebo NN 1_i
group NN N
, , N
suggesting VBG N
that IN N
poor JJ N
absorption NN N
of IN N
the DT N
drug NN N
formulation NN N
and/or IN N
poor JJ N
compliance NN N
might MD N
have VB N
contributed VBN N
to TO N
the DT N
decreased VBN N
cyclosporin NN 1_o
blood NN 1_o
levels NNS 1_o
in IN N
the DT N
patient JJ N
withdrawn NN N
from IN N
this DT N
study NN N
and CC N
in IN N
previous JJ N
uncontrolled JJ N
studies NNS N
. . N

CONCLUSION NNP N
Cyclosporin NNP 1_o
bioavailability NN 1_o
was VBD N
not RB N
clearly RB N
modified VBN N
by IN N
a DT N
half JJ N
dosage NN N
of IN N
ticlopidine NN 1_i
in IN N
this DT N
study NN N
. . N

We PRP N
, , N
however RB N
, , N
recommend VBP N
closely RB N
monitoring JJ N
cyclosporin NNS N
blood NN N
levels NNS N
when WRB N
prescribing VBG N
ticlopidine NN 1_i
. . 1_i

Further JJ N
studies NNS N
will MD N
be VB N
needed VBN N
with IN N
new JJ N
formulations NNS N
of IN N
cyclosporin NN 1_i
or CC N
when WRB N
using VBG N
the DT N
full JJ N
dosage NN N
of IN N
ticlopidine NN 1_i
. . 1_i

Improved VBN N
adherence NN 1_o
with IN N
once-daily JJ N
versus NN N
twice-daily RB N
dosing NN N
of IN N
mometasone NN 1_i
furoate NN 1_i
administered VBD N
via IN N
a DT N
dry JJ N
powder NN N
inhaler NN N
: : N
a DT N
randomized JJ N
open-label NN N
study NN N
. . N

BACKGROUND NNP N
Poor NNP N
adherence NN N
with IN N
prescribed JJ N
asthma JJ N
medication NN N
is VBZ N
a DT N
major JJ N
barrier NN N
to TO N
positive JJ N
treatment NN N
outcomes RB N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
a DT N
once-daily JJ N
administration NN N
of IN N
mometasone NN 1_i
furoate NN 1_i
administered VBD N
via IN N
a DT N
dry JJ N
powder NN N
inhaler NN N
( ( N
MF-DPI NNP N
) ) N
on IN N
treatment NN N
adherence NN N
compared VBN N
with IN N
a DT N
twice-daily JJ N
administration NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
12-week JJ N
open-label NN N
study NN N
designed VBN N
to TO N
mimic VB N
an DT N
actual JJ N
clinical JJ N
setting NN N
in IN 1_p
patients NNS 1_p
> JJ 1_p
or=12 CD 1_p
years NNS 1_p
old JJ 1_p
with IN 1_p
mild-to-moderate JJ 1_p
persistent JJ 1_p
asthma NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
MF-DPI NNP 1_i
400 CD 1_i
microg NN 1_i
once-daily RB 1_i
in IN 1_i
the DT 1_i
evening NN 1_i
or CC 1_i
MF-DPI JJ 1_i
200 CD 1_i
microg JJ 1_i
twice-daily RB 1_i
. . 1_i

Adherence NNP 1_o
was VBD N
assessed VBN N
primarily RB N
using VBG N
the DT N
number NN N
of IN N
actual JJ 1_o
administered VBN 1_o
doses NNS 1_o
reported VBN N
from IN N
the DT N
device NN N
counter NN N
divided VBN N
by IN N
the DT N
number NN N
of IN N
scheduled JJ N
doses NNS N
. . N

Self-reports NNS N
were VBD N
also RB N
used VBN N
to TO N
determine VB N
adherence NN N
. . N

Health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
healthcare JJ 1_o
resource NN 1_o
utilization NN 1_o
, , 1_o
and CC 1_o
days NNS 1_o
missed VBN 1_o
from IN 1_o
work NN 1_o
or CC 1_o
school NN 1_o
were VBD N
also RB N
reported VBN N
. . N

RESULTS JJ N
1233 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
. . 1_p

The DT N
mean JJ 1_o
adherence NN 1_o
rates NNS 1_o
, , N
as IN N
measured VBN N
by IN N
the DT N
automatic JJ N
dose NN N
counter NN N
, , N
were VBD N
significantly RB N
better JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
MF-DPI NNP N
400 CD N
microg NN N
once-daily RB N
in IN N
the DT N
evening NN N
( ( N
93.3 CD N
% NN N
) ) N
than IN N
with IN N
MF-DPI NNP N
200 CD N
microg NN N
twice-daily RB N
( ( N
89.5 CD N
% NN N
) ) N
. . N

Mean JJ 1_o
adherence NN 1_o
rates NNS 1_o
based VBN N
on IN N
self-reports NNS N
were VBD N
also RB N
significantly RB N
better RBR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
MF-DPI NNP N
400 CD N
microg NN N
QD NNP N
PM NNP N
( ( N
97.2 CD N
% NN N
) ) N
than IN N
with IN N
MF-DPI NNP N
200 CD N
microg NN N
twice-daily RB N
( ( N
95.3 CD N
% NN N
) ) N
. . N

Adherence NN 1_o
rates NNS 1_o
were VBD N
lower JJR N
in IN N
adolescents NNS N
( ( N
12-17 CD N
years NNS N
old JJ N
) ) N
. . N

Health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
improved VBN N
by IN N
20 CD N
% NN N
in IN N
patients NNS N
using VBG N
MF-DPI JJ N
once-daily RB N
in IN N
the DT N
evening NN N
and CC N
by IN N
14 CD N
% NN N
in IN N
patients NNS N
using VBG N
MF-DPI JJ N
twice-daily JJ N
. . N

Very RB N
few JJ N
( ( N
< JJ N
8 CD N
% NN N
) ) N
patients NNS N
missed JJ 1_o
work/school NN 1_o
. . 1_o

CONCLUSION NNP N
Mean NNP N
adherence NN 1_o
rates NNS 1_o
were VBD N
greater JJR N
with IN N
a DT N
once-daily JJ N
dosing VBG N
regimen NNS N
of IN N
MF-DPI NNP 1_i
than IN N
with IN N
a DT N
twice-daily JJ N
dosing NN N
regimen.This NN N
trial NN N
was VBD N
completed VBN N
prior RB N
to TO N
the DT N
ISMJE NNP N
requirements NNS N
for IN N
trial NN N
registration NN N
. . N

Pharmacokinetics NNS 1_o
of IN N
adriamycin NN 1_i
and CC N
adriamycin NN 1_i
-- : 1_i
DNA NN 1_i
complex NN 1_i
in IN N
L1210 NNP 1_p
mice NN 1_p
and CC 1_p
men NNS 1_p
. . 1_p

A DT N
sensory JJ 1_i
integration NN 1_i
therapy NN 1_i
program NN 1_i
on IN N
sensory JJ 1_p
problems NNS 1_p
for IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

The DT N
study NN N
was VBD N
planned VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
sensory JJ 1_i
integration NN 1_i
therapy NN 1_i
program NN 1_i
on IN N
sensory JJ 1_o
problems NNS 1_o
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

This DT N
study NN N
was VBD N
conducted VBN N
at IN N
the DT N
Trakya NNP 1_p
University NNP 1_p
Training NNP 1_p
and CC 1_p
Research NNP 1_p
Center NNP 1_p
for IN 1_p
Mentally NNP 1_p
and CC 1_p
Physically NNP 1_p
Handicapped NNP 1_p
Children NNP 1_p
in IN 1_p
Turkey NNP 1_p
. . 1_p

The DT N
children NNS N
were VBD N
separated VBN N
into IN N
two CD N
groups NNS N
, , N
each DT N
comprising VBG 1_p
15 CD 1_p
children NNS 1_p
between IN 1_p
7 CD 1_p
and CC 1_p
11 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
autism NN 1_p
, , 1_p
according VBG 1_p
to TO 1_p
DSM-IV NNP 1_p
criteria NNS 1_p
. . 1_p

The DT N
children NNS N
in IN N
each DT N
group NN N
were VBD N
assessed VBN N
initially RB N
on IN N
a DT N
checklist NN N
, , N
Sensory NNP N
Evaluation NNP N
Form NNP N
for IN N
Children NNP N
with IN N
Autism NNP N
, , N
developed VBD N
to TO N
evaluate VB N
sensory JJ 1_o
characteristics NNS 1_o
of IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
participants NNS N
were VBD N
assessed VBN N
again RB N
on IN N
the DT N
checklist NN N
. . N

Statistically NNP N
significant JJ N
differences NNS N
between IN N
groups NNS N
indicated VBD N
that IN N
the DT N
sensory JJ 1_i
integration NN 1_i
therapy NN 1_i
program NN 1_i
positively RB N
affected VBD N
treated JJ N
children NNS N
. . N

Chemotherapy NN N
of IN N
large JJ 1_p
bowel NN 1_p
carcinoma NN 1_i
-- : 1_i
fluorouracil NN 1_i
( ( 1_i
FU NNP 1_i
) ) 1_i
+ VBP 1_i
hydroxyurea NN 1_i
( ( 1_i
HU NNP 1_i
) ) 1_i
vs. FW 1_i
methyl-CCNU NN 1_i
, , 1_i
oncovin NN 1_i
, , 1_i
fluorouracil NN 1_i
, , 1_i
and CC 1_i
streptozotocin NN 1_i
( ( 1_i
MOF-Strep NNP 1_i
) ) 1_i
. . 1_i

An DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
of IN N
initial JJ N
chemotherapy NN N
for IN N
advanced JJ 1_p
measurable JJ 1_p
metastatic JJ 1_p
large JJ 1_p
bowel NN 1_o
carcinoma NN 1_o
, , N
the DT N
response NN 1_o
rate NN 1_o
was VBD N
6/32 CD 1_p
( ( 1_p
19 CD 1_p
% NN 1_p
) ) 1_p
for IN 1_p
FU NNP 1_p
+ NNP 1_p
HU NNP 1_p
and CC 1_p
5/32 CD 1_p
( ( 1_p
16 CD 1_p
% NN 1_p
) ) 1_p
for IN 1_p
MOF-Strep NNP 1_p
; : 1_p
the DT N
estimated JJ N
median JJ 1_o
survival NN 1_o
is VBZ N
43 CD N
weeks NNS N
for IN N
both DT N
treatments NNS N
. . N

Patients NNS N
who WP N
received VBD N
MOF-Strep NNP N
experienced VBD N
substantially RB N
greater JJR N
vomiting VBG 1_o
and CC 1_o
hematologic JJ 1_o
toxicity NN 1_o
than IN N
patients NNS 1_p
who WP 1_p
received VBD 1_p
FU NNP N
+ NNP N
HU NNP N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Comparison NNP N
of IN N
needlescopic JJ 1_i
appendectomy JJ 1_i
versus JJ 1_i
conventional JJ 1_i
laparoscopic NN 1_i
appendectomy NN 1_i
. . 1_i

A DT N
randomized JJ 1_p
controlled JJ 1_p
trial NN 1_p
. . 1_p

Children NNP 1_p
's POS 1_p
attitudes NNS 1_o
and CC 1_o
behavioral JJ 1_o
intentions NNS 1_o
toward IN 1_p
a DT 1_p
peer NN 1_p
with IN 1_p
autistic JJ 1_o
behaviors NNS 1_o
: : 1_o
does VBZ N
a DT N
brief JJ N
educational JJ 1_i
intervention NN 1_i
have VBP N
an DT N
effect NN N
? . N
This DT N
study NN N
examined VBD N
children NNS 1_p
's POS 1_p
ratings NNS 1_p
of IN 1_p
attitudes NNS 1_o
and CC 1_o
behavioral JJ 1_o
intentions NNS 1_o
toward IN 1_p
a DT 1_p
peer NN 1_p
presented VBN 1_p
with IN 1_p
or CC 1_p
without IN 1_p
autistic JJ 1_o
behaviors NNS 1_o
. . 1_o

The DT N
impact NN N
of IN N
information NN N
about IN N
autism NN N
on IN N
these DT N
ratings NNS N
was VBD N
investigated VBN N
as RB N
well RB N
as IN N
age NN N
and CC N
gender NN N
effects NNS N
. . N

Third- CD 1_p
and CC 1_p
sixth-grade JJ 1_p
children NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
233 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB 1_i
a DT 1_i
video NN 1_i
of IN 1_i
the DT 1_i
same JJ 1_i
boy NN 1_i
in IN 1_i
one CD 1_i
of IN 1_i
three CD 1_i
conditions NNS 1_i
: : 1_i
No DT 1_i
Autism NNP 1_i
, , 1_i
Autism NNP 1_i
, , 1_i
or CC 1_i
Autism/Information NNP 1_i
. . 1_i

Children NNP N
at IN N
both DT N
grade NN N
levels NNS N
showed VBD N
less RBR 1_o
positive JJ 1_o
attitudes NNS 1_o
toward IN N
the DT N
child NN N
in IN N
the DT N
two CD N
autism NN N
conditions NNS N
. . N

In IN N
rating NN N
their PRP$ N
own JJ N
behavioral JJ 1_o
intentions NNS 1_o
, , N
children NNS N
showed VBD N
no DT N
differences NNS N
between IN N
conditions NNS N
. . N

However RB N
, , N
in IN N
attributing VBG N
intentions NNS N
to TO N
their PRP$ N
classmates NNS N
, , N
older JJR N
children NNS N
and CC N
girls NNS N
gave VBD N
lower JJR 1_o
ratings NNS 1_o
to TO N
the DT N
child NN N
in IN N
the DT N
autism NN N
conditions NNS N
. . N

Information NN N
about IN N
autism NN N
did VBD N
not RB N
affect JJ N
ratings NNS N
of IN N
either DT N
attitudes NNS 1_o
or CC 1_o
behavioral JJ 1_o
intentions NNS 1_o
as IN N
ascribed NN N
to TO N
self VB N
or CC N
others NNS N
. . N

Field NNP N
trials NNS N
of IN N
a DT N
vaccine NN 1_i
against IN N
bovine NN N
mastitis NN N
. . N

1 CD N
. . N

Evaluation NN N
in IN N
heifers NNS 1_p
. . 1_p

A DT N
vaccine NN 1_i
was VBD N
developed VBN N
against IN N
bovine NN N
mastitis NN N
based VBN N
on IN N
inactivated JJ N
, , N
highly RB N
encapsulated JJ N
Staphylococcus NNP N
aureus NN N
cells NNS N
; : N
a DT N
crude NN N
extract NN N
of IN N
Staph NNP N
. . N

aureus NN N
exopolysaccharides NNS N
; : N
and CC N
inactivated VBD N
, , N
unencapsulated JJ N
Staph NNP N
, , N
aureus NN N
and CC N
Streptococcus NNP N
spp NN N
. . N

cells NNS N
. . N

This DT N
vaccine NN 1_i
was VBD N
tested VBN N
on IN N
30 CD 1_p
heifers NNS 1_p
during IN N
a DT N
7-mo JJ N
period NN N
. . N

The DT N
30 CD 1_p
heifers NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
of IN N
10 CD N
heifers NNS N
each DT N
. . N

The DT N
prepartum NN N
group NN N
received VBD N
two CD N
injections NNS N
of IN N
the DT N
vaccine NN 1_i
at IN N
8 CD N
and CC N
4 CD N
wk NN N
before IN N
calving NN N
, , N
and CC N
the DT N
postpartum NN N
group NN N
received VBD N
two CD N
injections NNS N
at IN N
1 CD N
and CC N
5 CD N
wk NN N
after IN N
calving VBG N
. . N

The DT N
control NN N
group NN N
received VBD N
two CD N
injections NNS N
of IN N
a DT N
placebo NN N
at IN N
8 CD N
and CC N
4 CD N
wk NN N
before IN N
calving VBG N
. . N

The DT N
vaccine NN 1_i
or CC N
the DT N
placebo NN 1_i
was VBD N
administered VBN N
subcutaneously RB N
in IN N
the DT N
brachiocephalicus NN N
muscle NN N
of IN N
the DT N
neck NN N
. . N

The DT N
frequencies NNS 1_o
of IN 1_o
intramammary JJ 1_o
infections NNS 1_o
caused VBN 1_o
by IN 1_o
Staph NNP 1_o
. . 1_o

aureus NN 1_o
were VBD N
reduced VBN N
from IN N
18.8 CD N
% NN N
for IN N
heifers NNS N
in IN N
the DT N
control NN N
group NN N
to TO N
6.7 CD N
and CC N
6.0 CD N
% NN N
for IN N
heifers NNS N
in IN N
the DT N
prepartum NN N
and CC N
postpartum NN N
groups NNS N
, , N
respectively RB N
. . N

This DT N
protective JJ 1_o
effect NN 1_o
was VBD N
maintained VBN N
for IN N
at IN N
least JJS N
6 CD N
mo NN N
. . N

The DT N
relative JJ 1_o
risk NN 1_o
of IN 1_o
mastitis NN 1_o
caused VBN 1_o
by IN 1_o
Staph NNP 1_o
. . 1_o

aureus NN 1_o
was VBD N
0.31 CD N
and CC N
0.28 CD N
for IN N
heifers NNS N
in IN N
the DT N
prepartum NN N
and CC N
postpartum NN N
groups NNS N
, , N
respectively RB N
, , N
compared VBN N
with IN N
that DT N
for IN N
heifers NNS N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
results NNS 1_o
of IN 1_o
the DT 1_o
trial NN 1_o
indicated VBD 1_o
the DT 1_o
effectiveness NN 1_o
of IN 1_o
the DT 1_o
vaccine NN 1_o
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
intrammammary JJ N
infections NNS N
caused VBN N
by IN N
Staph NNP N
. . N

aureus NN N
. . N

A DT N
slight JJ N
but CC N
nonsignificant JJ N
increase NN N
occurred VBD N
in IN N
fat JJ 1_o
production NN 1_o
in IN N
the DT N
milk NN N
of IN N
vaccinated JJ N
cows NNS N
. . N

The DT N
vaccine NN N
had VBD N
no DT N
observable JJ N
effect NN N
on IN N
somatic JJ N
cell NN N
count NN N
or CC N
streptococcal JJ N
infections NNS N
. . N

Cardiovascular JJ N
effects NNS N
of IN N
non-depolarizing JJ 1_i
neuromuscular JJ 1_i
blockers NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
aortic JJ 1_p
valve NN 1_p
disease NN 1_p
. . 1_p

To TO N
compare VB N
haemodynamic JJ N
responses NNS N
associated VBN N
with IN N
equipotent JJ N
doses NNS N
of IN N
neuromuscular JJ 1_i
blockers NNS 1_i
and CC N
high-dose JJ N
fentanyl NN 1_i
( ( N
50 CD N
micrograms.kg-1 NN N
) ) N
, , N
40 CD 1_p
patients NNS 1_p
with IN 1_p
aortic JJ 1_p
valve NNS 1_p
stenosis NN 1_p
( ( 1_p
AS IN 1_p
) ) 1_p
and CC 1_p
20 CD 1_p
patients NNS 1_p
with IN 1_p
aortic JJ 1_p
insufficiency NN 1_p
( ( 1_p
AI NNP 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
four CD N
study NN N
groups NNS N
to TO N
receive VB N
the DT N
following NN N
: : N
( ( N
1 CD N
) ) N
pancuronium NN 1_i
0.12 CD 1_i
mg.kg-1 NN 1_i
, , 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
vecuronium NN 1_i
0.12 CD 1_i
mg.kg-1 NN 1_i
, , 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
atracurium NN 1_i
0.4 CD 1_i
mg.kg-1 NN 1_i
, , 1_i
or CC 1_i
( ( 1_i
4 CD 1_i
) ) 1_i
pancuronium-metocurine NN 1_i
mixture NN 1_i
( ( N
0.4 CD N
mg NN N
+ VBD N
1.6 CD N
mg/ml NN N
) ) N
: : N
1 CD N
ml/10 NNS N
kg NN N
) ) N
. . N

Neuromuscular JJ 1_i
blockers NNS 1_i
were VBD N
injected VBN N
at IN N
the DT N
same JJ N
time NN N
with IN N
the DT N
fentanyl NN 1_i
; : 1_i
haemodynamics NNS N
were VBD N
recorded VBN N
with IN N
the DT N
patients NNS N
awake VBP N
( ( N
baseline NN N
) ) N
, , N
at IN N
two CD N
minutes NNS N
post-induction NN N
, , N
and CC N
at IN N
two CD N
and CC N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

In IN N
patients NNS N
with IN N
AS NNP N
, , N
pancuronium NN 1_i
increased VBD N
heart NN 1_o
rate NN 1_o
more JJR N
than IN N
vecuronium NN 1_i
or CC N
atracurium NN 1_i
; : 1_i
heart NN 1_o
rates NNS 1_o
were VBD N
also RB N
higher JJR 1_o
with IN N
the DT N
pancuronium-metocurine JJ 1_i
mixture NN 1_i
than IN N
with IN N
vecuronium NN 1_i
. . 1_i

Although IN N
there EX N
were VBD N
no DT N
ECG NNP 1_o
signs NNS 1_o
of IN 1_o
ischaemia NN 1_o
, , N
one CD N
patient NN N
given VBN N
pancuronium NN N
developed VBD N
severe JJ 1_o
hypotension NN 1_o
associated VBN 1_o
with IN 1_o
tachycardia NN 1_o
. . 1_o

Reductions NNS N
in IN N
SVR NNP 1_o
after IN N
atracurium NN N
allowed VBD N
small JJ N
but CC N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
decreases NNS N
in IN N
MAP NNP 1_o
which WDT N
were VBD N
well RB 1_o
tolerated VBN 1_o
; : 1_o
one CD N
patient NN N
, , N
however RB N
, , N
did VBD N
develop VB N
severe JJ 1_o
hypotension NN 1_o
. . 1_o

Intubation NNP N
resulted VBD N
in IN N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
increases NNS N
in IN N
MAP NNP 1_o
in IN N
the DT N
pancuronium-metocurine JJ 1_i
mixture NN N
group NN N
. . N

Vecuronium NNP 1_i
permitted VBD N
the DT N
most RBS N
stable JJ N
overall JJ 1_o
haemodynamic JJ 1_o
course NN 1_o
at IN N
all DT N
measurement JJ N
times NNS N
. . N

In IN N
contrast NN N
, , N
patients NNS N
with IN N
AI NNP N
showed VBD N
stable JJ 1_o
haemodynamics NNS 1_o
after IN N
vecuronium NN 1_i
, , 1_i
pancuronium NN 1_i
and CC N
the DT N
pancuronium-metocurine JJ 1_i
mixture NN 1_i
; : 1_i
one CD N
patient NN N
became VBD N
tachycardic JJ 1_o
following VBG N
vecuronium NN 1_i
. . 1_i

Atracurium NNP 1_i
caused VBD N
unexplained JJ N
elevations NNS 1_o
in IN 1_o
diastolic JJ 1_o
and CC 1_o
mean JJ 1_o
arterial NN 1_o
pressures NNS 1_o
which WDT N
were VBD N
significant JJ N
when WRB N
compared VBN N
to TO N
vecuronium VB 1_i
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

These DT N
results NNS N
in IN N
increases NNS N
in IN N
PCWP NNP 1_o
; : 1_o
mean JJ 1_o
PA NNP 1_o
pressures NNS 1_o
and CC 1_o
CVP NNP 1_o
were VBD N
also RB N
increased VBN 1_o
. . 1_o

These DT N
effects NNS N
of IN N
atracurium NN 1_i
inpatients NNS N
with IN N
Al NNP N
need VBP N
further JJ N
evaluation NN N
. . N

Significant JJ N
differential JJ N
effects NNS N
of IN N
omega-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
and CC N
fenofibrate NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
hypertriglyceridemia NN 1_p
. . 1_p

BACKGROUND NNP N
Omega-3 NNP 1_i
fatty JJ 1_i
acids NNS 1_i
and CC N
fenofibrate NN 1_i
are VBP N
both DT N
used VBN N
to TO N
treat VB N
patients NNS 1_p
with IN 1_p
hypertriglyceridemia NN 1_o
. . 1_o

However RB N
, , N
a DT N
head-to-head JJ N
comparison NN N
of IN N
the DT N
lipoprotein NN N
and CC N
metabolic JJ N
effects NNS N
of IN N
these DT N
two CD N
medicines NNS N
has VBZ N
not RB N
been VBN N
published VBN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
study NN N
. . N

Age NNP N
, , N
sex NN N
, , N
and CC N
body NN N
mass NN N
index NN N
were VBD N
matched VBN N
among IN N
groups NNS N
. . N

All DT N
patients NNS N
were VBD N
recommended VBN N
to TO N
maintain VB N
a DT N
low JJ N
fat NN N
diet NN N
. . N

Fifty JJ 1_p
patients NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
were VBD N
given VBN N
placebo NNS 1_i
, , 1_i
omega-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
2 CD 1_i
g NN 1_i
( ( N
most RBS N
commonly RB N
used JJ N
dosage NN N
in IN N
Korean JJ N
patients NNS N
) ) N
, , N
or CC N
fenofibrate VB 1_i
160 CD 1_i
mg NN 1_i
, , N
respectively RB N
daily JJ N
for IN N
2 CD N
months NNS N
. . N

RESULTS NNP N
Omega-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
therapy NN 1_i
decreased VBN N
triglycerides NNS 1_o
by IN N
21 CD N
% NN N
and CC N
triglycerides/HDL NN 1_o
cholesterol NN 1_o
and CC N
improved VBN N
flow-mediated JJ 1_o
dilation NN 1_o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
however RB N
, , N
did VBD N
not RB N
significantly RB N
change VBP N
insulin NN 1_o
, , 1_o
plasma VBP 1_o
adiponectin NN 1_o
levels NNS 1_o
, , 1_o
and CC 1_o
insulin NN 1_o
sensitivity NN 1_o
( ( N
determined VBN N
by IN N
QUICKI NNP N
) ) N
relative VBP N
to TO N
baseline VB N
measurements NNS N
. . N

Fenofibrate NNP 1_i
therapy NN 1_i
decreased VBD N
total JJ 1_o
cholesterol NN 1_o
, , 1_o
triglycerides NNS 1_o
by IN N
29 CD N
% NN N
, , N
and CC N
triglycerides/HDL-cholesterol NN 1_o
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
improved VBN 1_o
flow-mediated JJ 1_o
dilation NN 1_o
when WRB N
compared VBN N
with IN N
baseline NN N
. . N

When WRB N
compared VBN N
with IN N
placebo NN 1_i
and CC 1_i
omega-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
, , 1_i
fenofibrate JJ 1_i
therapy NN 1_i
decreased VBD N
non-HDL JJ 1_o
cholesterol NN 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
triglycerides/HDL $ 1_o
cholesterol NN 1_o
( ( N
P=0.016 NNP N
) ) N
while IN N
increasing VBG N
HDL NNP 1_o
cholesterol NN 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
apolipoprotein JJ 1_o
AI NNP 1_o
( ( N
P=0.001 NNP N
) ) N
. . N

Of IN N
note NN N
, , N
when WRB N
compared VBN N
with IN N
omega-3 JJ N
fatty JJ N
acids NNS N
, , N
fenofibrate JJ N
therapy NN N
decreased VBD N
fasting JJ 1_o
insulin NN 1_o
( ( N
P=0.023 NNP N
) ) N
and CC N
increased VBD N
plasma NN 1_o
adiponectin NN 1_o
( ( N
P=0.002 NNP N
) ) N
and CC N
insulin JJ 1_o
sensitivity NN 1_o
( ( N
P=0.015 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Omega-3 NNP N
fatty JJ N
acids NNS N
and CC N
fenofibrate JJ N
therapy NN N
promoted VBD N
similar JJ N
changes NNS N
in IN N
triglycerides NNS 1_o
and CC 1_o
endothelium-dependent JJ 1_o
dilation NN 1_o
. . 1_o

However RB N
, , N
fenofibrate JJ N
therapy NN N
had VBD N
substantially RB N
better JJR N
effects NNS N
on IN N
lipoprotein NN 1_o
and CC 1_o
metabolic JJ 1_o
profiles NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
hypertriglyceridemia NN 1_p
. . 1_p

Teaching VBG 1_i
children NNS 1_i
with IN 1_i
autism NN 1_i
to TO 1_i
seek VB 1_i
information NN 1_i
: : 1_i
acquisition NN N
of IN N
novel JJ N
information NN N
and CC N
generalization NN N
of IN N
responding VBG N
. . N

A DT 1_i
time NN 1_i
delay NN 1_i
procedure NN 1_i
was VBD 1_i
used VBN 1_i
to TO 1_i
teach VB 1_i
3 CD 1_i
children NNS 1_i
with IN 1_i
autism NN 1_i
to TO 1_i
ask VB 1_i
the DT 1_i
question NN 1_i
" VBD 1_i
What WP 1_i
's VBZ 1_i
that DT 1_i
? . 1_i
" NN 1_i
when WRB 1_i
novel NN 1_i
stimuli NNS 1_i
were VBD 1_i
presented VBN 1_i
during IN 1_i
an DT 1_i
instructional JJ 1_i
task NN 1_i
. . 1_i

Once IN N
the DT N
ability NN N
to TO N
ask VB N
the DT N
question NN N
was VBD N
acquired VBN N
, , N
the DT N
children NNS N
's POS N
ability NN N
to TO N
learn VB N
novel JJ N
information NN N
by IN N
asking VBG N
the DT N
question NN N
was VBD N
assessed VBN N
. . N

The DT N
children NNS N
were VBD N
then RB N
taught VBN N
to TO N
ask VB N
the DT N
question NN N
within IN N
a DT N
less RBR N
structured JJ N
context NN N
. . N

All DT N
three CD N
studies NNS N
used VBD N
a DT N
multiple JJ N
baseline NN N
across IN N
participants NNS N
. . N

Generalization NN N
was VBD N
assessed VBN N
in IN N
a DT N
different JJ N
room NN N
, , N
to TO N
a DT N
new JJ N
person NN N
, , N
and CC N
to TO N
novel VB N
stimuli NNS N
. . N

All DT N
of IN N
the DT N
children NNS 1_p
learned VBD N
to TO N
ask VB N
the DT N
question NN N
within IN N
the DT N
instructional JJ N
context NN N
, , N
while IN N
on IN N
a DT N
walk NN N
in IN N
the DT N
school NN N
building NN N
, , N
and CC N
to TO N
request VB N
information NN N
about IN N
three-dimensional JJ N
objects NNS N
. . N

The DT N
acquisition NN 1_o
of IN 1_o
novel JJ 1_o
information NN 1_o
was VBD N
consistent JJ N
for IN N
receptive JJ N
and CC N
expressive JJ N
tests NNS N
for IN N
2 CD N
of IN N
the DT N
children NNS N
, , N
with IN N
varied JJ N
results NNS N
for IN N
the DT N
3rd CD N
. . N

These DT N
studies NNS N
indicate VBP N
that IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
can MD N
be VB N
taught VBN N
to TO N
ask VB N
questions NNS N
that WDT N
lead VBP N
to TO N
the DT N
acquisition NN N
of IN N
new JJ N
information NN N
. . N

Evaluation NN N
of IN N
nonpharmacologic JJ 1_i
methods NNS 1_i
of IN 1_i
pain NN 1_i
and CC 1_i
anxiety NN 1_i
management NN 1_i
for IN N
laceration NN N
repair NN N
in IN N
the DT N
pediatric JJ N
emergency NN N
department NN N
. . N

BACKGROUND NNP N
Nonpharmacologic NNP 1_i
interventions NNS 1_i
, , 1_i
such JJ 1_i
as IN 1_i
distraction NN 1_i
, , N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
powerful JJ N
adjuncts NNS N
in IN N
reducing VBG N
pain NN N
and CC N
anxiety NN N
in IN N
children NNS 1_p
with IN 1_p
both DT 1_p
acute NN 1_p
and CC 1_p
chronic JJ 1_p
painful JJ 1_p
conditions NNS 1_p
. . 1_p

There EX N
are VBP N
no DT N
controlled JJ N
studies NNS N
evaluating VBG N
these DT N
interventions NNS N
as IN N
adjuncts NNS N
to TO N
facilitate VB N
completion NN N
of IN N
painful JJ N
procedures NNS N
in IN N
the DT N
pediatric JJ N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
. . N

OBJECTIVE IN N
We PRP N
assessed VBD N
the DT N
effectiveness NN N
of IN N
distraction NN 1_i
techniques NNS 1_i
in IN N
reducing VBG N
the DT N
sensory NN N
and CC N
affective JJ N
components NNS N
of IN N
pain NN N
among IN N
pediatric JJ 1_p
patients NNS 1_p
undergoing JJ 1_p
laceration NN 1_p
repair NN 1_p
in IN 1_p
the DT 1_p
ED NNP 1_p
. . 1_p

METHODS NNP N
Eligible JJ 1_p
children NNS 1_p
between IN 1_p
6 CD 1_p
and CC 1_p
18 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
240 CD 1_p
) ) 1_p
presenting NN 1_p
to TO 1_p
the DT 1_p
ED NNP 1_p
for IN 1_p
laceration NN 1_p
repair NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
or CC N
control NN N
arm NN N
. . N

Those DT N
assigned VBN N
to TO N
the DT N
intervention NN N
arm NN N
were VBD N
given VBN N
a DT N
choice NN N
of IN N
age-appropriate JJ 1_i
distracters NNS 1_i
during IN N
laceration NN N
repair NN N
. . N

Quantitative JJ N
measures NNS N
of IN N
pain NN 1_o
intensity NN 1_o
, , 1_o
situational JJ 1_o
anxiety NN 1_o
, , 1_o
and CC 1_o
pain NN 1_o
distress NN 1_o
( ( 1_o
as IN 1_o
perceived VBN 1_o
by IN 1_o
the DT 1_o
parent NN 1_o
) ) 1_o
were VBD N
assessed VBN N
by IN N
using VBG N
the DT N
7-point JJ 1_o
Facial NNP 1_o
Pain NNP 1_o
Scale NNP 1_o
, , 1_o
State NNP 1_o
Trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
for IN N
Children NNP N
, , N
and CC N
a DT N
visual JJ 1_o
analog NN 1_o
scale NN 1_o
, , N
respectively RB N
, , N
before IN N
and CC N
after IN N
laceration NN N
repair NN N
. . N

The DT N
State NNP 1_o
Trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
for IN N
Children NNP N
was VBD N
performed VBN N
in IN N
children NNS N
> VBP N
or CC N
= VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
mean JJ 1_o
change NN 1_o
in IN 1_o
Facial NNP 1_o
Pain NNP 1_o
Scale NNP 1_o
scores VBZ N
between IN N
the DT N
control NN N
and CC N
the DT N
intervention NN N
groups NNS N
in IN N
children NNS N
< VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

Multivariate NNP N
analysis NN N
in IN N
this DT N
same JJ N
age NN N
group NN N
showed VBD N
that IN N
the DT N
intervention NN N
was VBD N
independently RB N
associated VBN N
with IN N
a DT N
reduction NN 1_o
in IN 1_o
pain NN 1_o
distress NN 1_o
as IN N
perceived VBN N
by IN N
parents NNS N
based VBN N
on IN N
the DT N
mean JJ N
change NN N
in IN N
visual JJ N
analog NN N
scale NN N
scores NNS N
. . N

In IN N
older JJR N
children NNS N
, , N
the DT N
intervention NN N
was VBD N
independently RB N
associated VBN N
with IN N
reduction NN N
in IN N
situational JJ 1_o
anxiety NN 1_o
but CC N
not RB N
in IN N
pain NN 1_o
intensity NN 1_o
or CC 1_o
in IN 1_o
parental JJ 1_o
perception NN 1_o
of IN N
pain NN N
distress NN N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
distraction NN 1_i
techniques NNS 1_i
is VBZ N
effective JJ N
in IN N
reducing VBG N
situational JJ N
anxiety NN N
in IN N
older JJR 1_p
children NNS 1_p
and CC N
lowering VBG N
parental JJ N
perception NN N
of IN N
pain NN N
distress NN N
in IN N
younger JJR N
children NNS N
. . N

This DT N
technique NN N
may MD N
have VB N
a DT N
role NN N
in IN N
improving VBG N
the DT N
quality NN N
of IN N
management NN N
of IN N
procedural JJ N
pain NN N
in IN N
a DT N
pediatric JJ N
ED NNP N
setting NN N
. . N

Prediction NN N
of IN N
gestational JJ N
diabetes NNS N
mellitus VBP N
in IN N
the DT N
first JJ 1_p
trimester NN 1_p
, , N
comparison NN N
of IN N
fasting VBG N
plasma NN N
glucose NN N
, , N
two-step JJ N
and CC N
one-step JJ N
methods NNS N
: : N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
the DT N
diagnostic JJ 1_o
performance NN 1_o
of IN N
three CD N
methods NNS N
commonly RB N
used VBD N
for IN N
GDM NNP N
screening NN N
: : N
fasting NN 1_i
plasma NN 1_i
glucose NN 1_i
( ( 1_i
FPG NNP 1_i
) ) 1_i
, , N
two-step JJ N
50 CD N
g NN N
glucose JJ 1_i
challenge NN 1_i
test NN 1_i
( ( 1_i
GCT NNP 1_i
) ) 1_i
, , N
and CC N
75 CD 1_i
g NN 1_i
glucose JJ 1_i
tolerance NN 1_i
test NN 1_i
( ( 1_i
GTT NNP 1_i
) ) 1_i
in IN N
a DT N
randomized JJ N
study NN N
design NN N
to TO N
predict VB N
GDM NNP N
in IN N
the DT N
first JJ 1_p
trimester NN 1_p
and CC N
determine VB N
the DT N
best JJS N
approach NN N
in IN N
predicting VBG N
GDM NNP N
. . N

In IN N
a DT N
non-blind JJ N
, , N
parallel-group JJ N
prospective JJ N
randomized VBN N
controlled VBN N
study NN N
; : N
736 CD 1_p
singleton NN 1_p
pregnant JJ 1_p
women NNS 1_p
underwent JJ N
FPG NNP N
testing NN N
in IN N
the DT N
first JJ N
trimester NN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
; : N
two-step JJ 1_i
50 CD 1_i
g NN 1_i
GCT NNP 1_i
and CC 1_i
75 CD 1_i
g NN 1_i
GTT NNP 1_i
. . 1_i

GDM NNP N
diagnosis NN N
was VBD N
made VBN N
according VBG N
to TO N
Carpenter-Coustan NNP N
or CC N
ADA NNP N
( ( N
American NNP N
Diabetes NNP N
Association NNP N
) ) N
criteria NNS N
in IN N
two-step JJ N
50 CD N
g NN N
GCT NNP N
and CC N
75 CD N
g NN N
GTT NNP N
groups NNS N
, , N
respectively RB N
. . N

Subsequent JJ N
testing NN N
was VBD N
performed VBN N
by IN N
two-step JJ N
50 CD N
g NN N
GCT NNP N
at IN N
24-28 JJ N
weeks NNS N
for IN N
screen JJ N
negatives NNS N
. . N

After IN 1_p
excluding VBG 1_p
the DT 1_p
women NNS 1_p
who WP 1_p
were VBD 1_p
lost VBN 1_p
to TO 1_p
follow-up NN 1_p
or CC 1_p
withdrawn NN 1_p
as IN 1_p
a DT 1_p
result NN 1_p
of IN 1_p
pregnancy NN 1_p
loss NN 1_p
, , 1_p
486 CD 1_p
pregnant JJ 1_p
women NNS 1_p
were VBD 1_p
recruited VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
FPG NNP N
, , N
two-step JJ N
GCT NNP N
, , N
and CC N
one-step JJ N
GTT NNP N
methods NNS N
identified VBD N
GDM NNP 1_o
in IN N
25/486 CD N
( ( N
5.1 CD N
% NN N
) ) N
, , N
15/248 CD N
( ( N
6.0 CD N
% NN N
) ) N
, , N
and CC N
27/238 CD N
( ( N
11.3 CD N
% NN N
) ) N
women NNS 1_p
, , N
respectively RB N
. . N

Area NNP 1_o
under IN 1_o
ROC NNP 1_o
curves NNS 1_o
were VBD N
0.623 CD N
, , N
0.708 CD N
, , N
and CC N
0.792 CD N
, , N
respectively RB N
. . N

Sensitivities NNS 1_o
were VBD N
47.17 CD N
, , N
68.18 CD N
, , N
and CC N
87.1 CD N
% NN N
, , N
respectively RB N
. . N

Specificities NNS 1_o
were VBD N
77.37 CD N
, , N
100 CD N
, , N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

Positive JJ 1_o
predictive JJ 1_o
values NNS 1_o
were VBD N
20.33 CD N
, , N
100 CD N
, , N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

Negative JJ 1_o
predictive JJ 1_o
values NNS 1_o
were VBD N
92.29 CD N
, , N
97 CD N
, , N
and CC N
98.1 CD N
% NN N
, , N
respectively RB N
. . N

Until IN N
superior JJ N
screening VBG N
alternatives NNS N
become VBP N
available JJ N
, , N
the DT N
75 CD N
g NNS N
GTT NNP N
may MD N
be VB N
preferred VBN N
for IN N
GDM NNP N
screening NN N
in IN N
the DT N
first JJ 1_p
trimester NN 1_p
. . 1_p

A DT N
comparison NN N
of IN N
the DT N
efficacy NN N
of IN N
heparinized VBN 1_i
and CC 1_i
nonheparinized JJ 1_i
solutions NNS 1_i
for IN N
maintenance NN 1_o
of IN 1_o
perioperative JJ 1_o
radial JJ 1_o
arterial JJ 1_o
catheter NN 1_o
patency NN 1_o
and CC 1_o
subsequent JJ 1_o
occlusion NN 1_o
. . 1_o

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled VBD N
study NN N
, , N
we PRP N
compared VBN N
heparinized VBN 1_i
and CC 1_i
nonheparinized VBN 1_i
infusions NNS 1_i
for IN N
the DT N
maintenance NN 1_o
of IN 1_o
perioperative JJ 1_o
arterial JJ 1_o
catheter NN 1_o
patency NN 1_o
and CC 1_o
the DT 1_o
incidence NN 1_o
of IN 1_o
subsequent JJ 1_o
radial JJ 1_o
arterial JJ 1_o
occlusion NN 1_o
. . 1_o

Two-hundred JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN N
into IN N
2 CD 1_i
groups NNS 1_i
to TO 1_i
receive VB 1_i
heparinized VBN 1_i
( ( 1_i
group NN 1_i
H NNP 1_i
, , 1_i
n JJ 1_i
= NNP 1_i
100 CD 1_i
) ) 1_i
or CC 1_i
nonheparinized VBN 1_i
( ( 1_i
group NN 1_i
S NNP 1_i
, , 1_i
n JJ 1_i
= NNP 1_i
100 CD 1_i
) ) 1_i
flush NN 1_i
solutions NNS 1_i
. . 1_i

Radial NNP 1_o
and CC 1_o
ulnar JJ 1_o
blood NN 1_o
flows NNS 1_o
were VBD 1_i
assessed VBN 1_i
using VBG 1_i
Doppler NNP 1_o
probe NN 1_o
and CC 1_o
pulse JJ 1_o
oximetry NN 1_o
before IN 1_i
, , 1_i
just RB 1_i
after IN 1_i
, , 1_i
and CC 1_i
24 CD 1_i
h NN 1_i
after IN 1_i
decannulation NN 1_o
by IN 1_i
the DT 1_i
same JJ 1_i
investigator NN 1_i
. . 1_i

The DT 1_o
cannulation NN 1_o
site NN 1_o
was VBD N
examined VBN N
for IN N
complications NNS 1_o
such JJ 1_o
as IN 1_o
hematoma NN 1_o
, , 1_o
nerve JJ 1_o
injury NN 1_o
, , 1_o
and CC 1_o
infection NN 1_o
. . 1_o

The DT N
mean JJ N
duration NN N
of IN N
cannulations NNS 1_o
was VBD N
378 CD N
+/- JJ N
159.0 CD N
min NN N
in IN N
group NN N
H NNP N
and CC N
332 CD N
+/- JJ N
154.6 CD N
min NN N
in IN N
group NN N
S. NNP N
The DT N
mean JJ N
number NN N
of IN N
corrective JJ N
interventions NNS N
caused VBN N
by IN N
dampening VBG N
of IN N
the DT N
pressure NN N
wave NN N
( ( N
mean JJ N
number NN N
of IN N
positional JJ N
changes NNS N
[ VBP N
group NN N
S NNP N
, , N
1.5 CD N
+/- JJ N
2.0 CD N
; : N
group NN N
H NNP N
, , N
1.4 CD N
+/- JJ N
3.8 CD N
] NN N
and CC N
mean JJ N
number NN N
of IN N
manual JJ 1_o
flushes NNS 1_o
[ VBP N
group NN N
S NNP N
, , N
1.3 CD N
+/- JJ N
1.7 CD N
; : N
group NN N
H NNP N
, , N
1.2 CD N
+/- JJ N
1.2 CD N
] NN N
) ) N
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

After IN N
decannulation NN N
, , N
partial JJ 1_o
or CC 1_o
total JJ 1_o
occlusion NN 1_o
developed VBD N
in IN N
20 CD N
group NN N
H NNP N
patients NNS N
and CC N
16 CD N
group NN N
S NNP N
patients NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

The DT N
incidence NN N
of IN N
occlusion NN 1_o
was VBD N
correlated VBN N
to TO N
the DT N
presence NN 1_p
of IN 1_p
hematoma NN 1_o
at IN 1_p
the DT 1_p
puncture NN 1_p
site NN 1_p
after IN 1_p
decannulation NN 1_p
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
, , N
long JJ 1_o
duration NN 1_o
of IN 1_o
cannulation NN 1_o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
age NN 1_p
< VBP 1_p
65 CD 1_p
yr NN 1_p
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
there EX N
is VBZ N
no DT N
significant JJ N
difference NN N
between IN N
heparinized VBN 1_i
and CC 1_i
nonheparinized VBN 1_i
flush JJ 1_i
solutions NNS 1_i
for IN N
the DT N
maintenance NN 1_o
of IN 1_o
perioperative JJ 1_o
radial JJ 1_o
artery NN 1_o
catheter NN 1_o
patency NN 1_o
. . 1_o

Effects NNS N
of IN N
pyridostigmine NN 1_i
and CC N
naloxone NN 1_i
on IN N
the DT N
abnormal JJ 1_o
TSH NNP 1_o
response NN 1_o
to TO 1_o
TRH NNP 1_o
during IN 1_o
starvation NN 1_o
in IN 1_p
humans NNS 1_p
. . 1_p

BACKGROUND NNP N
Starvation NNP N
is VBZ N
associated VBN N
with IN N
a DT N
blunted JJ 1_o
TSH NNP 1_o
response NN 1_o
to TO N
thyrotropin-releasing JJ 1_o
hormone NN 1_o
( ( 1_o
TRH NNP 1_o
) ) 1_o
( ( N
peak JJ N
minus NN N
baseline NN N
< $ N
5 CD N
mIU/L NN N
) ) N
, , N
despite IN N
basal JJ N
TSH NNP N
and CC N
thyroid VB N
hormone NN N
levels NNS N
within IN N
the DT N
normal JJ N
range NN N
. . N

In IN N
light NN N
of IN N
the DT N
inhibitory JJ N
effect NN N
of IN N
somatostatin NN N
on IN N
TSH NNP N
secretion NN N
, , N
we PRP N
examined VBD N
whether IN N
this DT N
condition NN N
is VBZ N
caused VBN N
by IN N
an DT N
increased VBN N
hypothalamic NN 1_o
somatostatinergic NN 1_o
tone NN 1_o
in IN N
starving VBG 1_p
subjects NNS 1_p
. . 1_p

The DT N
possible JJ N
involvement NN 1_o
of IN 1_o
endogenous JJ 1_o
opioids NNS 1_o
in IN 1_o
the DT 1_o
mechanism NN 1_o
underlying VBG 1_o
the DT 1_o
abnormal JJ 1_o
TSH NNP 1_o
response NN 1_o
to TO 1_o
TRH NNP 1_o
was VBD N
also RB N
evaluated VBN N
. . N

METHODS NNP N
The DT N
TSH NNP 1_o
response NN 1_o
to TO 1_o
TRH NNP 1_o
( ( 1_o
25 CD 1_o
micrograms NNS 1_o
in IN 1_o
an DT 1_o
intravenous JJ 1_o
bolus NN 1_o
) ) 1_o
, , 1_o
serum JJ 1_o
total NN 1_o
and CC 1_o
free JJ 1_o
T4 NNP 1_o
and CC 1_o
T3 NNP 1_o
levels NNS 1_o
, , 1_o
and CC 1_o
24-hour JJ 1_o
urinary-free JJ 1_o
cortisol NN 1_o
levels NNS 1_o
were VBD N
measured VBN N
in IN N
28 CD 1_p
normal JJ 1_p
men NNS 1_p
( ( 1_p
age NN 1_p
27-35 CD 1_p
years NNS 1_p
) ) 1_p
within IN 1_p
10 CD 1_p
% NN 1_p
of IN 1_p
their PRP$ 1_p
ideal NN 1_p
body NN 1_p
weight NN 1_p
. . 1_p

They PRP 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
4 CD 1_p
groups NNS 1_p
of IN 1_p
7 CD 1_p
. . 1_p

In IN N
21 CD N
subjects NNS N
( ( N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
, , N
TRH NNP 1_i
tests NNS 1_i
were VBD 1_i
performed VBN 1_i
after IN 1_i
an DT 1_i
overnight NN 1_i
( ( 1_i
8 CD 1_i
hours NNS 1_i
) ) 1_i
fast RB 1_i
, , 1_i
placebo JJ 1_i
administrations NNS 1_i
( ( 1_i
control VB 1_i
test NN 1_i
) ) 1_i
, , 1_i
and CC 1_i
after IN 1_i
prolonged VBN 1_i
( ( 1_i
56 CD 1_i
hours NNS 1_i
) ) 1_i
starvation NN 1_i
. . 1_i

TRH NNP 1_o
tests NNS 1_o
after IN 1_o
prolonged JJ 1_o
starvation NN 1_o
were VBD 1_i
performed VBN 1_i
either RB 1_i
after IN 1_i
placebos NN 1_i
( ( 1_i
in IN 1_i
all DT 1_i
subjects NNS 1_i
) ) 1_i
or CC 1_i
the DT 1_i
administration NN 1_i
of IN 1_i
pyridostigmine NN 1_i
( ( 1_i
180 CD 1_i
mg NNS 1_i
orally RB 1_i
) ) 1_i
( ( 1_i
in IN 1_i
7 CD 1_i
subjects NNS 1_i
, , 1_i
group NN 1_i
1 CD 1_i
) ) 1_i
; : 1_i
naloxone NN 1_i
( ( 1_i
0.8 CD 1_i
mg NN 1_i
in IN 1_i
an DT 1_i
i.v NN 1_i
. . 1_i

bolus CC 1_i
injection NN 1_i
) ) 1_i
( ( 1_i
in IN 1_i
7 CD 1_i
subjects NNS 1_i
, , 1_i
group NN 1_i
2 CD 1_i
) ) 1_i
; : 1_i
or CC 1_i
the DT 1_i
combination NN 1_i
of IN 1_i
pyridostigmine NN 1_i
and CC 1_i
naloxone NN 1_i
( ( 1_i
in IN 1_i
7 CD 1_i
subjects NNS 1_i
, , 1_i
group NN 1_i
3 CD 1_i
) ) 1_i
. . 1_i

The DT N
remaining VBG N
7 CD N
subjects NNS N
( ( N
group NN N
4 CD N
) ) N
were VBD N
tested VBN N
at IN N
weekly JJ N
intervals NNS N
with IN N
TRH NNP 1_i
plus CC 1_i
placebo NN 1_i
, , 1_i
TRH NNP 1_i
plus CC 1_i
naloxone NN 1_i
, , 1_i
TRH NNP 1_i
plus CC 1_i
pyridostigmine NN 1_i
, , 1_i
and CC 1_i
TRH NNP 1_i
plus CC 1_i
naloxone JJ 1_i
plus CC 1_i
pyridostigmine NN 1_i
after IN N
a DT N
fasting JJ N
period NN N
of IN N
8 CD N
hours NNS N
. . N

RESULTS NNP N
In IN N
all DT N
subjects NNS N
of IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
TRH-induced NNP 1_o
TSH NNP 1_o
rise NN 1_o
was VBD N
significantly RB N
lower JJR N
after IN N
prolonged JJ N
starvation NN N
than IN N
after IN N
overnight JJ N
fast NN N
. . N

Neither CC N
pyridostigmine JJ 1_i
nor CC N
naloxone JJ 1_i
, , N
given VBN N
alone RB N
, , N
changed VBD N
the DT N
basal NN 1_o
levels NNS 1_o
of IN 1_o
TSH NNP 1_o
and CC N
the DT N
TSH NNP 1_o
response NN 1_o
to TO 1_o
TRH NNP 1_o
after IN 1_o
prolonged JJ 1_o
starvation NN 1_o
. . 1_o

In IN N
contrast NN N
, , N
the DT N
concomitant JJ N
administration NN N
of IN N
naloxone NN N
and CC N
pyridostigmine NN N
significantly RB N
enhanced VBD N
the DT N
TRH-induced NNP N
TSH NNP N
rise NN N
. . N

After IN N
overnight JJ N
fasting NN N
, , N
naloxone JJ N
administration NN N
in IN N
group NN N
4 CD N
subjects NNS N
did VBD N
not RB N
change VB N
the DT N
TSH NNP N
response NN N
to TO N
TRH NNP N
, , N
whereas JJ N
pyridostigmine VBP N
significantly RB N
enhanced VBN N
the DT N
TSH NNP N
response NN N
to TO N
TRH NNP N
. . N

When WRB N
naloxone NN N
was VBD N
given VBN N
together RB N
with IN N
pyridostigmine NN 1_i
and CC N
TRH NNP 1_i
the DT N
TSH NNP N
response NN N
was VBD N
similar JJ N
to TO N
that DT N
observed VBN N
in IN N
the DT N
TRH NNP N
plus CC N
pyridostigmine JJ N
test NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
naloxone-sensitive JJ N
endogenous JJ N
opioids NNS N
exert VBP N
an DT N
inhibitory JJ N
effect NN N
on IN N
the DT N
cholinergic JJ 1_o
stimulatory NN 1_o
control NN 1_o
of IN 1_o
TSH NNP 1_o
secretion NN 1_o
during IN N
prolonged JJ N
starvation NN N
. . N

This DT N
suggests VBZ N
that IN N
an DT N
enhanced JJ N
hypothalamic JJ N
somatostatinergic NN N
activity NN N
is VBZ N
involved VBN N
in IN N
the DT N
mechanism NN N
underlying VBG N
the DT N
reduced VBN N
TSH NNP N
response NN N
to TO N
TRH NNP N
. . N

Prospectively RB N
randomized VBN N
toxicity NN 1_o
study NN N
of IN N
high-dose JJ N
versus NN N
low-dose JJ N
treatment NN N
strategies NNS N
for IN N
lymphoblastoid JJ 1_i
interferon NN 1_i
. . 1_i

It PRP N
is VBZ N
unclear JJ N
from IN N
preliminary JJ N
laboratory NN N
studies NNS N
whether IN N
a DT N
high- NN 1_i
or CC 1_i
a DT 1_i
low-dose JJ 1_i
interferon NN 1_i
treatment NN N
strategy NN N
is VBZ N
optimal JJ N
. . N

As IN N
part NN N
of IN N
an DT N
ongoing JJ N
study NN N
of IN N
mechanisms NNS N
of IN N
interferon NN 1_i
action NN N
, , N
we PRP N
have VBP N
evaluated VBN N
toxicity NN 1_o
in IN N
a DT N
two-arm JJ N
protocol NN N
in IN N
which WDT N
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
lymphoblastoid JJ 1_i
interferon NN 1_i
by IN N
either CC N
a DT N
low-dose JJ N
treatment NN N
strategy NN N
( ( N
2 CD N
X RB N
10 CD N
( ( N
6 CD N
) ) N
units/m2 JJ N
daily JJ N
X $ N
28 CD N
days NNS N
then RB N
daily JJ N
X NNP N
5 CD N
days NNS N
every DT N
other JJ N
week NN N
by IN N
im JJ N
injection NN N
) ) N
or CC N
a DT N
high-dose JJ N
treatment NN N
strategy NN N
( ( N
5 CD N
X RB N
10 CD N
( ( N
6 CD N
) ) N
units/m2 NN N
by IN N
continuous JJ N
iv JJ N
infusion NN N
over IN N
24 CD N
hours NNS N
, , N
escalating VBG N
by IN N
5 CD N
X NNS N
10 CD N
( ( N
6 CD N
) ) N
units/m2/day NN N
as IN N
tolerated VBN N
over IN N
10 CD N
days NNS N
, , N
repeated VBD N
every DT N
28 CD N
days NNS N
) ) N
. . N

The DT N
main JJ 1_o
toxic NN 1_o
effects NNS 1_o
in IN N
both DT N
arms NNS N
were VBD N
fever RB 1_o
, , 1_o
fatigue NN 1_o
, , 1_o
and CC 1_o
anorexia RB 1_o
. . 1_o

Marked JJ N
interpatient NN N
differences NNS N
within IN N
each DT N
dose JJ N
arm NN N
were VBD N
greater JJR N
than IN N
differences NNS N
between IN N
arms NNS N
. . N

Additional JJ N
significant JJ 1_o
toxic NN 1_o
effects NNS 1_o
included VBD 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
, , 1_o
hypotension NN 1_o
, , 1_o
leukopenia NN 1_o
, , 1_o
thrombocytopenia NN 1_o
, , 1_o
and CC 1_o
evidence NN 1_o
of IN 1_o
hepatic JJ 1_o
toxicity NN 1_o
. . 1_o

Minor JJ N
changes NNS 1_o
in IN 1_o
serum NN 1_o
electrolytes NNS 1_o
were VBD N
noted VBN N
. . N

Coagulation NNP 1_o
studies NNS 1_o
were VBD N
normal JJ N
. . N

The DT N
dose-limiting JJ N
toxic NN 1_o
effect NN 1_o
for IN N
the DT N
high-dose JJ N
arm NN N
was VBD N
myelosuppression NN 1_o
. . 1_o

Median JJ N
maximum NN 1_o
tolerated VBD 1_o
dose JJ 1_o
among IN N
high-dose JJ N
strategy NN N
patients NNS N
was VBD N
18 CD N
X JJ N
10 CD N
( ( N
6 CD N
) ) N
units/m2 NN N
, , N
but CC N
there RB N
was VBD N
marked VBN N
interpatient JJ N
variation NN N
. . N

We PRP N
conclude VBP N
that IN N
both DT N
dose JJ N
schedules NNS N
were VBD N
relatively RB 1_o
well-tolerated JJ 1_o
. . 1_o

Because IN N
of IN N
individual JJ N
variation NN N
in IN N
tolerance NN 1_o
, , N
high-dose JJ N
treatment NN N
should MD N
include VB N
a DT N
dose JJ N
escalation NN N
strategy NN N
. . N

Influence NN N
of IN N
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
location NN N
on IN N
in-hospital JJ N
and CC N
late JJ N
outcome NN N
after IN N
primary JJ 1_i
percutaneous JJ 1_i
transluminal JJ 1_i
coronary NN 1_i
angioplasty NN 1_i
versus NN 1_i
tissue NN 1_i
plasminogen NN 1_i
activator NN 1_i
therapy NN 1_i
. . 1_i

In IN N
the DT N
Primary NNP N
Angioplasty NNP N
in IN N
Myocardial NNP N
Infarction NNP N
trial NN N
, , N
395 CD 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
( ( 1_p
AMI NNP 1_p
) ) 1_p
were VBD N
prospectively RB N
randomized VBN N
to TO N
tissue VB 1_i
plasminogen NN 1_i
activator NN 1_i
( ( 1_i
tPA NN 1_i
) ) 1_i
or CC 1_i
primary JJ 1_i
percutaneous JJ 1_i
transluminal JJ 1_i
coronary NN 1_i
angioplasty NN 1_i
( ( 1_i
PTCA NNP 1_i
) ) 1_i
. . 1_i

In IN N
138 CD 1_p
patients NNS 1_p
with IN 1_p
anterior JJ 1_p
wall NN 1_p
AMI NNP 1_p
, , N
in-hospital JJ 1_o
mortality NN 1_o
was VBD N
significantly RB N
reduced VBN N
by IN N
treatment NN N
with IN N
PTCA NNP N
compared VBN N
with IN N
tPA NN N
( ( N
1.4 CD N
% NN N
vs JJ N
11.9 CD N
% NN N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

PTCA NNP N
also RB N
resulted VBD N
in IN N
lower JJR N
rates NNS 1_o
of IN N
death NN 1_o
or CC 1_o
reinfarction NN 1_o
( ( N
1.4 CD N
% NN N
vs JJ N
18.0 CD N
% NN N
, , N
p NN N
= NNP N
0.0009 CD N
) ) N
, , N
recurrent JJ 1_o
myocardial JJ 1_o
ischemia NN 1_o
( ( N
11.3 CD N
% NN N
vs JJ N
28.4 CD N
% NN N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
stroke VBD 1_o
( ( N
0.0 CD N
% NN N
vs JJ N
6.0 CD N
% NN N
, , N
p NN N
= NNP N
0.037 CD N
) ) N
in IN N
anterior JJ N
wall NN N
AMI NNP N
. . N

The DT N
independent JJ N
beneficial JJ N
effect NN N
of IN N
treatment NN N
with IN N
primary JJ N
PTCA NNP N
rather RB N
than IN N
tPA VB N
in IN N
anterior JJ N
wall NN N
AMI NNP N
was VBD N
confirmed VBN N
by IN N
multivariate NN N
analysis NN N
and CC N
interaction NN N
testing NN N
. . N

The DT N
in-hospital JJ 1_o
mortality NN 1_o
of IN N
257 CD 1_p
patients NNS 1_p
with IN 1_p
nonanterior JJ 1_p
wall NN 1_p
AMI NNP 1_p
was VBD N
similar JJ N
after IN N
PTCA NNP N
and CC N
tPA NNP N
( ( N
3.2 CD N
% NN N
vs JJ N
3.8 CD N
% NN N
, , N
p NN N
= NNP N
0.82 CD N
) ) N
. . N

Compared VBN N
with IN N
tPA NN N
, , N
however RB N
, , N
primary JJ N
PTCA NNP N
resulted VBD N
in IN N
a DT N
markedly RB N
lower JJR N
rate NN N
of IN N
recurrent NN 1_o
myocardial JJ 1_o
ischemia NN 1_o
( ( N
9.7 CD N
% NN N
vs JJ N
27.8 CD N
% NN N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
, , N
fewer JJR N
unscheduled JJ 1_o
catheterization NN 1_o
and CC 1_o
revascularization NN 1_o
procedures NNS 1_o
, , N
and CC N
a DT N
shorter JJR N
hospital NN 1_o
stay NN 1_o
( ( N
7.0 CD N
vs RB N
8.6 CD N
days NNS N
, , N
p VBP N
= RB N
0.01 CD N
) ) N
in IN N
nonanterior JJ N
wall NN N
AMI NNP N
. . N

Thus NNP N
, , N
compared VBN N
with IN N
tPA NN N
, , N
primary JJ N
PTCA NNP N
in IN N
patients NNS 1_p
with IN 1_p
anterior JJ 1_p
wall NN 1_p
AMI NNP 1_p
results NNS N
in IN N
significantly RB N
improved VBN 1_o
survival NN 1_o
, , N
with IN N
lower JJR N
rates NNS 1_o
of IN 1_o
stroke NN 1_o
, , 1_o
reinfarction NN 1_o
, , 1_o
and CC 1_o
recurrent JJ 1_o
myocardial JJ 1_o
ischemia NN 1_o
. . 1_o

In IN N
nonanterior JJ N
wall NN N
AMI NNP N
, , N
treatment NN N
with IN N
PTCA NNP N
and CC N
tPA JJ N
results NNS N
in IN N
similar JJ N
early JJ N
mortality NN 1_o
, , N
although IN N
PTCA-treated JJ N
patients NNS N
have VBP N
a DT N
more RBR N
stable JJ N
hospital NN N
course NN N
characterized VBN N
by IN N
reduced JJ N
recurrent NN 1_o
ischemia NN 1_o
, , N
fewer JJR N
subsequent JJ 1_o
invasive NN 1_o
procedures NNS 1_o
, , N
and CC N
earlier RB N
discharge NN 1_o
. . 1_o

Effects NNS N
of IN N
glucocorticoids NNS 1_i
on IN N
energy NN 1_o
metabolism NN 1_o
and CC N
food NN 1_o
intake NN 1_o
in IN N
humans NNS 1_p
. . 1_p

The DT N
effect NN N
of IN N
glucocorticoid JJ 1_i
administration NN N
on IN N
energy NN 1_o
metabolism NN 1_o
and CC N
food NN 1_o
intake NN 1_o
was VBD N
studied VBN N
in IN N
20 CD 1_p
healthy JJ 1_p
, , 1_p
nondiabetic JJ 1_p
Caucasian NNP 1_p
male NN 1_p
volunteers NNS 1_p
[ VBP 1_p
27 CD 1_p
+/- JJ 1_p
5 CD 1_p
( ( 1_p
SD NNP 1_p
) ) 1_p
yr NN 1_p
, , 1_p
72 CD 1_p
+/- JJ 1_p
9 CD 1_p
kg NN 1_p
, , 1_p
20 CD 1_p
+/- JJ 1_p
7 CD 1_p
% NN 1_p
body NN 1_p
fat JJ 1_p
] NNP 1_p
randomly NN N
and CC N
blindly RB N
assigned VBD N
to TO N
glucocorticoid VB 1_i
( ( 1_i
methylprednisolone NN 1_i
, , 1_i
METH NNP 1_i
; : 1_i
n CC N
= VB N
10 CD N
) ) N
or CC N
placebo NN 1_i
( ( 1_i
PLAC NNP 1_i
; : 1_i
n CC N
= VB N
10 CD N
) ) N
treatment NN N
. . N

Each DT N
subject NN N
was VBD N
studied VBN N
twice RB N
: : N
during IN N
a DT N
weight JJ N
maintenance NN N
diet JJ N
and CC N
during IN N
ad NN N
libitum NN N
food NN N
intake NN N
. . N

Energy NNP 1_o
metabolism NN 1_o
was VBD N
measured VBN N
by IN N
indirect JJ N
calorimetry NN N
and CC N
food NN 1_o
intake NN 1_o
by IN N
an DT N
automated VBN N
food-selection NN N
system NN N
. . N

Twenty-four-hour JJ N
urinary JJ 1_o
norepinephrine NN 1_o
excretion NN 1_o
( ( N
24-h JJ N
NE NNP N
) ) N
was VBD N
used VBN N
as IN N
an DT N
estimate NN N
of IN N
sympathetic JJ 1_o
nervous JJ 1_o
system NN 1_o
activity NN 1_o
. . 1_o

During IN N
weight JJ N
maintenance NN N
, , N
METH NNP N
intravenous JJ N
infusion NN N
( ( N
125 CD N
mg/30 NNS N
min NN N
) ) N
increased VBD N
energy NN 1_o
expenditure NN 1_o
compared VBN N
with IN N
PLAC NNP N
, , N
and CC N
after IN N
4 CD N
days NNS N
of IN N
oral JJ N
therapy NN N
, , N
METH NNP N
( ( N
40 CD N
mg/day NN N
) ) N
decreased VBD N
24-h JJ 1_o
NE NNP 1_o
and CC N
increased VBD N
energy NN 1_o
expenditure NN 1_o
compared VBN N
with IN N
PLAC NNP N
. . N

During IN N
ad NN N
libitum NN N
food NN N
intake NN N
, , N
after IN N
4 CD N
days NNS N
of IN N
METH NNP N
( ( N
40 CD N
mg/day NN N
) ) N
or CC N
PLAC NNP N
oral JJ N
therapy NN N
, , N
both DT N
groups NNS N
increased VBD N
their PRP$ N
energy NN 1_o
intake NN 1_o
over IN N
weight JJ N
maintenance NN N
, , N
but CC N
the DT N
increase NN N
was VBD N
significantly RB N
larger JJR N
in IN N
the DT N
METH NNP N
group NN N
compared VBN N
with IN N
the DT N
PLAC NNP N
group NN N
( ( N
4,554 CD N
+/- JJ N
1,857 CD N
vs. FW N
2,867 CD N
+/- JJ N
846 CD N
kcal/day NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
therapeutic JJ N
doses NNS N
of IN N
glucocorticoids NNS N
induce VBP N
obesity NN N
mostly RB N
by IN N
increasing VBG N
energy NN 1_o
intake NN 1_o
, , N
an DT N
effect NN N
which WDT N
may MD N
be VB N
related VBN N
to TO N
the DT N
ability NN N
of IN N
glucocorticoids NNS N
to TO N
act VB N
directly RB N
or CC N
indirectly RB N
on IN N
the DT N
central JJ N
regulation NN N
of IN N
appetite NN N
. . N

Non-Hodgkin NNP N
's POS N
malignant JJ N
lymphomas NN N
: : N
treatment NN N
of IN N
localized JJ N
relapses NNS N
with IN N
chemo NN 1_i
+ NN 1_i
radio NN 1_i
+ NNP 1_i
BCG-therapy NNP 1_i
. . 1_i

16 CD 1_p
patients NNS 1_p
with IN 1_p
relapsing VBG 1_p
non-Hodgkin NN 1_p
's POS 1_p
malignant JJ 1_p
lymphomas NN 1_p
considered VBN 1_p
as IN 1_p
clinical JJ 1_p
stage NN 1_p
I PRP 1_p
or CC 1_p
II NNP 1_p
were VBD N
treated VBN N
by IN N
an DT N
association NN N
of IN N
chemo NN 1_i
+ NNP 1_i
radiotherapy NN 1_i
and CC 1_i
thereafter RB 1_i
by IN 1_i
maintenance NN 1_i
BCG NNP 1_i
therapy NN 1_i
. . 1_i

5 CD 1_p
of IN 1_p
them PRP 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
trial NN 1_p
and CC N
have VB N
a DT N
significantly RB N
different JJ N
disease-free JJ 1_o
survival NN 1_o
from IN N
patients NNS N
receiving VBG N
the DT N
same JJ N
treatment NN N
but CC N
without IN N
BCG NNP 1_i
. . 1_i

11 CD 1_p
were VBD 1_p
systematically RB 1_p
treated VBN 1_p
by IN 1_p
BCG NNP 1_i
and CC N
they PRP N
also RB N
have VBP N
a DT N
fairly RB N
good JJ N
disease-free JJ 1_o
survival NN 1_o
. . 1_o

Such PDT N
a DT N
treatment NN N
appears VBZ N
to TO N
be VB N
of IN N
value NN N
in IN N
treating VBG N
these DT N
patients NNS N
and CC N
even RB N
probably RB N
of IN N
curing VBG N
some DT N
of IN N
them PRP N
. . N

Emotion NNP 1_i
regulation NN 1_i
strategies NNS 1_i
that WDT N
promote VBP N
learning NN N
: : N
reappraisal NN N
enhances VBZ N
children NNS 1_o
's POS 1_o
memory NN 1_o
for IN 1_o
educational JJ 1_o
information NN 1_o
. . 1_o

The DT N
link NN N
between IN N
emotion NN 1_i
regulation NN 1_i
and CC N
academic JJ 1_o
achievement NN 1_o
is VBZ N
well RB N
documented VBN N
. . N

Less NNP N
is VBZ N
known VBN N
about IN N
specific JJ N
emotion NN 1_i
regulation NN 1_i
strategies NNS N
that WDT N
promote VBP N
learning VBG N
. . N

Six- JJ 1_p
to TO 1_p
13-year-olds NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
126 CD 1_p
) ) 1_p
viewed VBD 1_i
a DT 1_i
sad JJ 1_i
film NN 1_i
and CC 1_i
were VBD 1_i
instructed VBN 1_i
to TO 1_i
reappraise VB 1_i
the DT 1_i
importance NN 1_i
, , 1_i
reappraise VB 1_i
the DT 1_i
outcome NN 1_i
, , 1_i
or CC 1_i
ruminate VB 1_i
about IN 1_i
the DT 1_i
sad JJ 1_i
events NNS 1_i
; : 1_i
another DT 1_i
group NN 1_i
received VBD 1_i
no DT 1_i
regulation NN 1_i
instructions NNS 1_i
. . 1_i

Children NNP 1_p
viewed VBD N
an DT N
educational JJ 1_i
film NN 1_i
, , N
and CC N
memory NN N
for IN N
this DT N
was VBD N
later RB N
assessed VBN N
. . N

As IN N
predicted JJ N
, , N
reappraisal JJ N
strategies NNS N
more RBR N
effectively RB N
attenuated JJ N
children NNS 1_o
's POS 1_o
self-reported JJ 1_o
emotional JJ 1_o
processing NN 1_o
. . 1_o

Reappraisal NNP N
enhanced VBD N
memory NN 1_o
for IN 1_o
educational JJ 1_o
details NNS 1_o
relative VBP N
to TO N
no DT N
instructions NNS N
. . N

Rumination NN N
did VBD N
not RB N
lead VB N
to TO N
differences NNS N
in IN N
memory NN 1_o
from IN N
the DT N
other JJ N
instructions NNS N
. . N

Memory NNP 1_o
benefits NNS 1_o
of IN N
effective JJ N
instructions NNS N
were VBD N
pronounced VBN 1_o
for IN N
children NNS 1_p
with IN N
poorer JJR 1_o
emotion NN 1_o
regulation NN 1_o
skill NN 1_o
, , N
suggesting VBG N
the DT N
utility NN N
of IN N
reappraisal NN N
in IN N
learning VBG N
contexts NN N
. . N

Impact NN N
of IN N
antioxidants NNS 1_i
, , 1_i
zinc NN 1_i
, , 1_i
and CC 1_i
copper NN 1_i
on IN N
cognition NN 1_p
in IN 1_p
the DT 1_p
elderly JJ 1_p
: : 1_p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

Participants NNS 1_p
in IN 1_p
the DT 1_p
Age-Related JJ 1_p
Eye NNP 1_p
Disease NNP 1_p
Study NNP 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
daily JJ N
antioxidants NNS 1_i
( ( 1_i
vitamin JJ 1_i
C NNP 1_i
, , 1_i
500 CD 1_i
mg NN 1_i
; : 1_i
vitamin CC 1_i
E NNP 1_i
, , 1_i
400 CD 1_i
IU NNP 1_i
; : 1_i
beta NN 1_i
carotene NN 1_i
, , 1_i
15 CD 1_i
mg NN 1_i
) ) 1_i
, , 1_i
zinc NN 1_i
and CC 1_i
copper NN 1_i
( ( 1_i
zinc NN 1_i
, , 1_i
80 CD 1_i
mg NN 1_i
; : 1_i
cupric JJ 1_i
oxide NN 1_i
, , 1_i
2 CD 1_i
mg NN 1_i
) ) 1_i
, , 1_i
antioxidants NNS 1_i
plus CC 1_i
zinc NN 1_i
and CC 1_i
copper NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

A DT N
cognitive JJ N
battery NN N
was VBD N
administered VBN N
to TO N
2,166 CD 1_p
elderly JJ 1_p
persons NNS 1_p
after IN 1_p
a DT 1_p
median NN 1_p
of IN 1_p
6.9 CD 1_p
years NNS 1_p
of IN 1_p
treatment NN 1_p
. . 1_p

Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
any DT N
of IN N
the DT N
six CD 1_o
cognitive JJ 1_o
tests NNS 1_o
( ( N
p JJ N
> VBP N
0.05 CD N
for IN N
all DT N
) ) N
. . N

These DT N
results NNS N
do VBP N
not RB N
support VB N
a DT N
beneficial JJ 1_o
or CC 1_o
harmful JJ 1_o
effect NN 1_o
of IN 1_o
antioxidants NNS 1_o
or CC 1_o
zinc NN 1_o
and CC 1_o
copper NN 1_o
on IN N
cognition NN 1_o
in IN N
older JJR N
adults NNS N
. . N

[ JJ N
Potentiation NNP N
of IN N
the DT N
effect NN N
of IN N
non-depolarizing JJ N
muscle NN 1_p
relaxants NNS 1_p
by IN N
acylaminopenicillins NNS 1_i
. . 1_i

Studies NNS N
on IN N
the DT N
example NN N
of IN N
vecuronium NN N
] NN N
. . N

In IN N
a DT N
prospective JJ N
controlled VBN N
clinical JJ N
study NN N
interactions NNS N
between IN N
nondepolarizing VBG 1_i
muscle NN 1_i
relaxants NNS 1_i
and CC 1_i
acylaminopenicillins NNS 1_i
were VBD N
investigated VBN N
electromyographically RB N
. . N

Six CD 1_p
patients NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
received VBD N
either RB N
apalcillin JJ 1_i
, , 1_i
azlocillin NN 1_i
, , 1_i
mezlocillin NN 1_i
or CC 1_i
piperacillin NN 1_i
during IN N
the DT N
operation NN N
. . N

Muscle NNP 1_o
relaxation NN 1_o
was VBD N
maintained VBN N
using VBG N
the DT N
short JJ N
acting VBG N
nondepolarizing VBG N
relaxant JJ N
vecuronium NN N
, , N
which WDT N
shows VBZ N
no DT N
cumulative JJ N
effect NN N
within IN N
clinical JJ N
dosages NNS N
. . N

The DT N
intra-individual JJ N
comparison NN N
with IN N
the DT N
control NN N
period NN N
( ( N
100 CD N
% NN N
) ) N
showed VBD N
a DT N
significant JJ N
prolongation NN 1_o
of IN 1_o
the DT 1_o
duration NN 1_o
of IN 1_o
action NN 1_o
after IN N
a DT N
fixed JJ N
dose NN N
of IN N
vecuronium NN N
. . N

The DT N
mean JJ 1_o
increase NN 1_o
was VBD N
+26 JJ N
% NN N
following VBG N
apalcillin NN N
, , N
+46 CD N
% NN N
after IN N
piperacillin NN N
, , N
+38 CD N
% NN N
following VBG N
mezlocillin NN N
and CC N
+55 CD N
% NN N
following VBG N
azlocillin NN N
. . N

The DT N
shortest JJ 1_o
time NN 1_o
of IN N
the DT N
control NN N
periods NNS N
was VBD N
8.6 CD N
min NN N
and CC N
the DT N
maximum JJ N
time NN N
was VBD N
32.6 CD N
min NN N
. . N

We PRP N
also RB N
found VBD N
a DT N
significant JJ N
depression NN 1_o
of IN N
the DT N
EMG-response NNP 1_o
. . 1_o

No NNP N
significant JJ N
differences NNS N
could MD N
be VB N
detected VBN N
between IN N
the DT N
four CD N
antibiotics NNS N
. . N

The DT N
method NN N
described VBN N
here RB N
has VBZ N
proven VBN N
to TO N
be VB N
sensitive JJ N
enough RB N
to TO N
detect VB N
clinically RB 1_o
relevant JJ 1_o
interactions NNS 1_o
with IN N
muscle NN 1_o
relaxants NNS 1_o
. . 1_o

As IN N
a DT N
result NN N
of IN N
our PRP$ N
study NN N
, , N
caution NN N
seems VBZ N
to TO N
be VB N
necessary JJ N
if IN N
acylaminopenicillins NNS 1_i
are VBP N
administered VBN N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
. . N

A DT N
prospective JJ N
comparison NN N
of IN N
transthoracic NN 1_i
and CC 1_i
transhiatal JJ 1_i
resection NN 1_i
for IN N
esophageal JJ 1_p
carcinoma NN 1_p
in IN 1_p
Asians NNPS 1_p
. . 1_p

BACKGROUND/AIMS NNP N
Transthoracic NNP 1_i
and CC 1_i
transhiatal JJ 1_i
esophagectomy NN 1_i
are VBP N
two CD N
common JJ N
procedures NNS N
for IN N
esophageal JJ N
cancer NN N
resection NN N
. . N

Prospective JJ N
studies NNS N
comparing VBG N
the DT N
two CD N
methods NNS N
in IN 1_p
Asian JJ 1_p
people NNS 1_p
are VBP N
few JJ N
. . N

In IN N
addition NN N
, , N
the DT N
data NNS N
comparing VBG N
their PRP$ N
effects NNS N
on IN N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
are VBP N
lacking VBG N
. . N

METHODOLOGY NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
from IN N
January NNP N
2003 CD N
. . N

Patients NNS 1_p
of IN 1_p
resectable JJ 1_p
esophageal JJ 1_p
cancer NN 1_p
of IN 1_p
comparable JJ 1_p
stage NN 1_p
were VBD N
allocated VBN N
to TO N
undergo VB N
the DT N
transthoracic NN 1_i
or CC 1_i
transhiatal JJ 1_i
procedure NN 1_i
in IN N
turn NN N
. . N

They PRP 1_i
were VBD 1_i
all DT 1_i
reconstructed VBN 1_i
with IN 1_i
stomach NN 1_i
interposition NN 1_i
through IN 1_i
the DT 1_i
retrosternal JJ 1_i
route NN 1_i
. . 1_i

Discharged VBN 1_i
patients NNS 1_i
were VBD 1_i
followed-up JJ 1_i
in IN 1_i
the DT 1_i
outpatient NN 1_i
clinic NN 1_i
. . 1_i

They PRP 1_i
were VBD 1_i
questioned VBN 1_i
on IN 1_i
the DT 1_i
topics NNS 1_i
of IN 1_i
( ( 1_o
i NN 1_o
) ) 1_o
severity NN 1_o
of IN 1_o
pain NN 1_o
, , 1_o
( ( 1_o
ii NN 1_o
) ) 1_o
ease NN 1_o
of IN 1_o
swallowing NN 1_o
, , 1_o
( ( 1_o
iii NN 1_o
) ) 1_o
satisfaction NN 1_o
of IN 1_o
daily JJ 1_o
activities NNS 1_o
, , 1_o
( ( 1_o
iv NN 1_o
) ) 1_o
dependence NN 1_o
on IN 1_o
medications NNS 1_o
, , 1_o
( ( 1_o
v NN 1_o
) ) 1_o
working VBG 1_o
ability NN 1_o
, , 1_o
( ( 1_o
vi NN 1_o
) ) 1_o
fatigue NN 1_o
, , 1_o
( ( 1_o
vii NN 1_o
) ) 1_o
appetite NN 1_o
, , 1_o
( ( 1_o
viii NN 1_o
) ) 1_o
sociality NN 1_o
, , 1_o
( ( 1_o
ix NN 1_o
) ) 1_o
happiness NN 1_o
and CC 1_o
( ( 1_o
x NNP 1_o
) ) 1_o
self NN 1_o
respect NN 1_o
, , 1_i
in IN 1_i
the DT 1_i
third JJ 1_i
, , 1_i
sixth JJ 1_i
and CC 1_i
twelfth JJ 1_i
month NN 1_i
. . 1_i

Also RB N
the DT N
demographic JJ 1_o
data NNS 1_o
, , 1_o
operative JJ 1_o
results NNS 1_o
and CC 1_o
survival NN 1_o
were VBD N
recorded VBN N
. . N

RESULTS VB N
Up IN 1_p
to TO 1_p
December NNP 1_p
2006 CD 1_p
, , 1_p
eighty-seven JJ 1_p
patients NNS 1_p
of IN 1_p
stage NN 1_p
II NNP 1_p
and CC 1_p
III NNP 1_p
, , 1_p
including VBG 1_p
71 CD 1_p
patients NNS 1_p
of IN 1_p
middle JJ 1_p
third JJ 1_p
lesions NNS 1_p
and CC 1_p
16 CD 1_p
lower JJR 1_p
third JJ 1_p
lesions NNS 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

The DT N
operation NN 1_o
time NN 1_o
was VBD N
significantly RB N
longer JJR N
, , N
and CC N
the DT N
leakage NN 1_o
rate NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
transthoracic NN N
group NN N
( ( N
Student NNP N
's POS N
t-test NN N
and CC N
Fischer NNP N
's POS N
exact JJ N
test NN N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
intraoperative JJ 1_o
blood NN 1_o
loss NN 1_o
and CC 1_o
postoperative JJ 1_o
hospital NN 1_o
stay NN 1_o
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
Student NNP N
t-test NN N
) ) N
. . N

Also RB N
, , N
the DT N
Kaplan-Meier NNP 1_o
survival NN 1_o
curves NNS 1_o
of IN N
these DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
by IN N
log-rank JJ N
test NN N
( ( N
p=0.286 NN N
) ) N
. . N

The DT N
score NN N
on IN N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
transhiatal JJ N
patients NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
transthoracic NN N
patients NNS N
in IN N
the DT N
third JJ N
, , N
sixth JJ N
and CC N
twelfth JJ N
month NN N
. . N

CONCLUSIONS NNP N
Transhiatal NNP 1_i
esophagectomy NN 1_i
is VBZ N
a DT N
safe JJ N
and CC N
fast JJ N
procedure NN N
. . N

The DT N
survival NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
transthoracic JJ N
approach NN N
. . N

Its PRP$ N
leakage NN 1_o
rate NN 1_o
was VBD N
lower JJR N
and CC N
quality NN N
of IN N
life NN N
was VBD N
better RBR N
. . N

Chemotherapy NNP N
of IN N
advanced JJ 1_p
gastric JJ 1_p
carcinoma NN 1_p
( ( 1_p
stage JJ 1_p
IV NNP 1_p
) ) 1_p
: : 1_p
a DT N
randomized JJ N
study NN N
of IN N
FAM NNP 1_i
versus IN N
5-FU JJ 1_i
plus JJ 1_i
BCNU NNP 1_i
. . 1_i

Forty-six JJ 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
gastric JJ 1_p
carcinoma NN 1_p
( ( 1_p
Stage NNP 1_p
IV NNP 1_p
) ) 1_p
were VBD 1_p
evaluated VBN 1_p
in IN N
a DT N
prospective JJ N
randomized VBN N
comparison NN N
of IN N
two CD N
chemotherapy NN 1_i
regimens NNS N
( ( 1_i
FAM NNP 1_i
versus IN 1_i
5-FU JJ 1_i
plus CC 1_i
BCNU NNP 1_i
) ) 1_i
to TO N
identify VB N
therapeutic JJ N
activity NN N
. . N

Treatment NN N
groups NNS N
were VBD N
well RB N
balanced VBN N
with IN N
respect NN N
to TO N
known VBN N
prognostic JJ N
factors NNS N
. . N

Thirty-three JJ 1_p
patients NNS 1_p
had VBD 1_p
measurable JJ 1_p
disease NN 1_p
and CC 1_p
thirteen NN 1_p
had VBD 1_p
only RB 1_p
microscopic JJ 1_p
residual JJ 1_p
disease NN 1_p
in IN 1_p
the DT 1_p
resection NN 1_p
margins NNS 1_p
. . 1_p

The DT N
overall JJ 1_o
median JJ 1_o
survival NN 1_o
of IN N
the DT N
entire JJ N
group NN N
was VBD N
13.2 CD N
months NNS N
. . N

Two CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
with IN N
measurable JJ N
disease NN N
reached VBD N
complete JJ 1_o
response NN 1_o
( ( 1_o
CR NNP 1_o
) ) 1_o
, , N
1 CD N
( ( N
3 CD N
% NN N
) ) N
partial JJ 1_o
response NN 1_o
( ( 1_o
PR NNP 1_o
) ) 1_o
, , N
12 CD N
( ( N
36 CD N
% NN N
) ) N
had VBD N
stable JJ 1_o
disease NN 1_o
( ( 1_o
SD NNP 1_o
) ) 1_o
and CC N
18 CD N
( ( N
56 CD N
% NN N
) ) N
had VBD N
progressive JJ 1_o
disease NN 1_o
( ( 1_o
PD NNP 1_o
) ) 1_o
. . 1_o

The DT N
responders NNS N
had VBD N
not RB N
reached VBN N
the DT N
median JJ 1_o
survival NN 1_o
yet RB N
, , N
the DT N
patients NNS N
with IN N
SD NNP N
had VBD N
a DT N
median JJ N
survival NN 1_o
of IN N
14.7 CD N
months NNS N
and CC N
the DT N
PD NNP N
9.5 CD N
months NNS N
. . N

In IN N
the DT N
FAM NNP 1_i
arm NN N
there EX N
were VBD N
3 CD N
( ( N
18 CD N
% NN N
) ) N
responders NNS N
( ( N
2 CD N
CR NNP N
and CC N
1 CD N
PR NNP N
) ) N
, , N
7 CD N
( ( N
41 CD N
% NN N
) ) N
SD NNP N
and CC N
7 CD N
( ( N
41 CD N
% NN N
) ) N
PD NNP N
, , N
versus NN N
O NNP N
responders NNS N
, , N
5 CD N
( ( N
31 CD N
% NN N
) ) N
SD NNP N
and CC N
11 CD N
( ( N
69 CD N
% NN N
) ) N
PD NNP N
in IN N
the DT N
5-FU JJ N
plus CC N
BCNU NNP N
arm NN N
. . N

In IN N
the DT N
FAM NNP 1_i
arm NN N
the DT N
median JJ 1_o
survival NN 1_o
was VBD N
15.7 CD N
months NNS N
versus IN N
9.9 CD N
months NNS N
in IN N
the DT N
other JJ N
therapeutic JJ N
arm NN N
. . N

The DT N
statistical JJ N
analysis NN N
indicated VBD N
that IN N
survival NN N
associated VBN N
with IN N
FAM NNP 1_i
regimen NNS N
was VBD N
superior JJ N
to TO N
that DT N
reached VBN N
with IN N
the DT N
5-FU JJ 1_i
plus CC 1_i
BCNU JJ 1_i
regimen NNS N
. . N

Thirteen JJ 1_p
patients NNS 1_p
with IN N
unmeasurable JJ N
disease NN N
had VBD N
a DT N
median JJ N
survival NN 1_o
of IN N
15.9 CD N
months NNS N
. . N

Comparison NNP N
of IN N
the DT N
antihypertensive JJ 1_o
effect NN 1_o
of IN N
metipranolol NN 1_i
, , 1_i
butizide NN 1_i
and CC 1_i
torrat NN 1_i
in IN N
Kenyan NNP 1_p
Africans NNPS 1_p
. . 1_p

[ JJ N
Observation NNP N
on IN N
therapeutic JJ N
effect NN N
of IN N
picking VBG N
therapy NN N
on IN N
Graves NNP 1_p
' POS 1_p
disease NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
therapeutic JJ N
effect NN N
of IN N
picking VBG N
therapy NN N
on IN N
Graves NNP 1_p
' POS 1_p
disease NN 1_p
( ( 1_p
GD NNP 1_p
) ) 1_p
and CC N
its PRP$ N
effects NNS N
on IN N
thyroid JJ N
function NN N
. . N

METHODS NNP N
Sixty NNP 1_p
cases NNS 1_p
of IN 1_p
GD NNP 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN N
a DT N
treatment NN 1_i
group NN 1_i
( ( 1_i
pricking VBG 1_i
therapy NN 1_i
group NN 1_i
) ) 1_i
and CC 1_i
a DT 1_i
control NN 1_i
group NN 1_i
( ( 1_i
medication NN 1_i
group NN 1_i
) ) 1_i
. . 1_i

They PRP N
were VBD N
treated VBN N
respectively RB N
with IN N
pricking VBG 1_i
thyroid JJ 1_i
gland NN 1_i
high JJ 1_i
point NN 1_i
or CC 1_i
oral JJ 1_i
administration NN 1_i
of IN 1_i
tapazole NN 1_i
. . 1_i

And CC N
changes NNS N
of IN N
total JJ 1_o
triiodothyronine NN 1_o
( ( 1_o
TT3 NNP 1_o
) ) 1_o
, , 1_o
total JJ 1_o
thyroxine NN 1_o
( ( 1_o
TT4 NNP 1_o
) ) 1_o
, , 1_o
free JJ 1_o
T3 NNP 1_o
( ( 1_o
FT3 NNP 1_o
) ) 1_o
, , 1_o
free JJ 1_o
T4 NNP 1_o
( ( 1_o
FT4 NNP 1_o
) ) 1_o
, , 1_o
thyroxine JJ 1_o
receptor NN 1_o
antibody NN 1_o
( ( 1_o
TRAb NNP 1_o
) ) 1_o
, , 1_o
supersensitive JJ 1_o
thyrotropin NN 1_o
( ( 1_o
S-TSH NNP 1_o
) ) 1_o
after IN N
treatment NN N
were VBD N
investigated VBN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
93.33 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
76.67 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
with IN N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
serum NN 1_o
TT3 NNP 1_o
, , 1_o
TT4 NNP 1_o
, , 1_o
FT3 NNP 1_o
, , 1_o
FT4 NNP 1_o
and CC 1_o
S-TSH NNP 1_o
contents NNS 1_o
had VBD N
very RB N
significant JJ N
change NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
TRAb NNP N
had VBD N
very RB N
significant JJ N
change NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
no DT N
significant JJ N
change NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
decrease NN N
of IN N
TT3 NNP 1_o
, , 1_o
FT3 NNP 1_o
, , 1_o
TRAb NNP 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
no DT N
significant JJ N
difference NN N
in IN N
decrease NN N
of IN N
TT4 NNP 1_o
, , 1_o
FT4 NNP 1_o
and CC 1_o
increase NN 1_o
of IN 1_o
S-TSH NNP 1_o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Pricking VBG N
therapy NN N
has VBZ N
a DT N
definite JJ N
therapeutic JJ N
effect NN N
on IN N
Graves NNP 1_p
' POS 1_p
disease NN 1_p
, , N
which WDT N
is VBZ N
carried VBN N
out RP N
through IN N
regulating VBG N
thyroid JJ N
function NN N
. . N

Allogeneic NNP 1_i
marrow NN 1_i
transplantation NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
in IN 1_p
the DT 1_p
chronic JJ 1_p
phase NN 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
irradiation NN N
regimens NNS N
. . N

A DT N
randomized JJ N
trial NN N
was VBD N
performed VBN N
to TO N
compare VB N
two CD N
regimens NNS N
of IN N
total JJ 1_i
body NN 1_i
irradiation NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
treated VBN 1_p
by IN 1_p
allogeneic JJ 1_i
marrow NN 1_i
transplantation NN 1_i
while IN 1_p
in IN 1_p
the DT 1_p
chronic JJ 1_p
phase NN 1_p
. . 1_p

All DT N
patients NNS N
received VBD N
cyclophosphamide JJ 1_i
120 CD N
mg/kg NN N
followed VBN N
by IN N
total JJ 1_i
body NN 1_i
irradiation NN 1_i
and CC 1_i
marrow NN 1_i
from IN 1_i
HLA-identical JJ 1_i
siblings NNS 1_i
. . 1_i

Cyclosporine NNP 1_i
and CC 1_i
methotrexate NN 1_i
were VBD N
used VBN N
for IN N
prophylaxis NN N
against IN N
acute JJ N
graft-versus-host JJ N
disease NN N
. . N

Fifty-seven JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
2.0 CD N
Gy NNP N
fractions NNS N
of IN N
irradiation NN 1_i
daily NN N
for IN N
6 CD N
days NNS N
and CC N
59 CD N
were VBD N
randomized VBN N
to TO N
receive VB N
2.25 CD N
Gy NNP N
fractions NNS N
daily RB N
for IN N
7 CD N
days NNS N
. . N

The DT N
probabilities NNS 1_o
of IN 1_o
relapse NN 1_o
at IN N
4 CD N
years NNS N
were VBD N
0.25 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

The DT N
actuarial JJ 1_o
probabilities NNS 1_o
of IN 1_o
survival NN 1_o
and CC 1_o
relapse-free JJ 1_o
survival NN 1_o
at IN N
4 CD N
years NNS N
were VBD N
0.60 CD N
and CC N
0.58 CD N
among IN N
the DT N
patients NNS N
who WP N
received VBD N
12.0 CD N
Gy NNP N
compared VBN N
with IN N
0.66 CD N
and CC N
0.66 CD N
for IN N
those DT N
who WP N
received VBD N
15.75 CD N
Gy NNP N
. . N

The DT N
4-year JJ 1_o
probabilities NNS 1_o
of IN 1_o
transplant-related JJ 1_o
mortality NN 1_o
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN 1_o
of IN 1_o
moderate JJ 1_o
to TO 1_o
severe VB 1_o
acute JJ 1_o
graft-versus-host JJ 1_o
disease NN 1_o
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

The DT N
lower JJR N
relapse NN 1_o
probability NN 1_o
in IN N
the DT N
patients NNS 1_p
receiving VBG 1_p
the DT 1_p
higher JJR 1_p
dose NN 1_p
of IN 1_p
total JJ 1_i
body NN 1_i
irradiation NN 1_i
did VBD N
not RB N
result VB N
in IN N
improved JJ 1_o
survival NN 1_o
because IN N
mortality NN N
from IN N
causes VBZ N
other JJ N
than IN N
relapse NN N
was VBD N
increased VBN N
. . N

Evaluating VBG N
the DT N
acceptability NN N
and CC N
efficacy NN N
of IN N
a DT N
psycho-educational JJ 1_i
intervention NN 1_i
for IN N
coping VBG N
and CC N
symptom JJ N
management NN N
by IN N
children NNS 1_p
with IN 1_p
cancer NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
acceptability NN N
and CC N
efficacy NN N
of IN N
a DT N
psycho-educational JJ 1_i
intervention NN 1_i
designed VBN N
to TO N
improve VB N
effective JJ N
coping NN N
and CC N
reduce VB N
symptom JJ N
severity NN N
in IN N
children NNS 1_p
with IN 1_p
cancer NN 1_p
. . 1_p

BACKGROUND NNP N
Cancer NNP N
treatments VBZ N
increase VB N
survival JJ N
rates NNS N
and CC N
also RB N
cause VB N
physical JJ N
and CC N
psychological JJ N
effects NNS N
on IN N
children NNS 1_p
with IN 1_p
cancer NN 1_p
. . 1_p

A DT N
psycho-educational JJ 1_i
intervention NN 1_i
is VBZ N
used VBN N
to TO N
assist VB N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
these DT 1_p
effects NNS 1_p
and CC N
its PRP$ N
efficacy NN N
has VBZ N
been VBN N
described VBN N
in IN N
several JJ N
studies NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHODS NNP N
Participants NNPS 1_p
being VBG 1_p
treated VBN 1_p
were VBD 1_p
recruited VBN 1_p
and CC 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
two CD 1_p
groups NNS 1_p
from IN 1_p
September NNP 1_p
2011-February JJ 1_p
2013 CD 1_p
in IN 1_p
Taiwan NNP 1_p
. . 1_p

The DT N
intervention NN N
group NN N
received VBD N
a DT N
psycho-educational JJ 1_i
intervention NN 1_i
in IN 1_i
addition NN 1_i
to TO 1_i
standard VB 1_i
care NN 1_i
, , 1_i
while IN 1_i
the DT 1_i
control NN 1_i
group NN 1_i
received VBD 1_i
only RB 1_i
standard JJ 1_i
care NN 1_i
. . 1_i

Each DT N
participant NN N
was VBD N
assessed VBN N
using VBG N
a DT N
paediatric JJ N
cancer NN N
coping VBG N
scale NN N
and CC N
perceived VBD N
symptom JJ N
severity NN N
was VBD N
evaluated VBN N
at IN N
three CD N
time NN N
points NNS N
( ( N
baseline NN N
, , N
1 CD N
month NN N
and CC N
3 CD N
months NNS N
) ) N
. . N

A DT N
repeated-measures JJ N
analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
effects NNS N
of IN N
intervention NN N
. . N

Qualitative JJ N
findings NNS N
were VBD N
analysed VBN N
using VBG N
content JJ N
analysis NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
in IN N
coping VBG N
scores NNS N
was VBD N
found VBN N
between IN N
groups NNS N
, , N
but CC N
the DT N
experimental JJ N
group NN N
reported VBD N
significantly RB N
lower JJR N
scores NNS N
in IN N
gastrointestinal JJ 1_o
problems NNS 1_o
and CC 1_o
pain NN 1_o
. . 1_o

Most JJS N
symptoms NNS N
decreased VBN N
significantly RB N
over IN N
time NN N
in IN N
both DT N
groups NNS N
, , N
except IN N
for IN N
gastrointestinal JJ N
problems NNS N
. . N

The DT N
scores NNS N
in IN N
pain NN 1_o
, , 1_o
bone NN 1_o
marrow NN 1_o
suppression NN 1_o
and CC 1_o
body NN 1_o
image NN 1_o
showed VBD N
significant JJ N
interaction NN N
effects NNS N
between IN N
groups NNS N
on IN N
changes NNS N
over IN N
time NN N
. . N

Qualitative JJ N
results NNS N
reported VBD N
that IN N
participants NNS N
evaluated VBD N
the DT N
intervention NN N
positively RB N
, , N
especially RB N
about IN N
receipt NN N
of IN N
psychological JJ N
support NN N
and CC N
learnt NN N
coping VBG N
skills NNS N
. . N

CONCLUSIONS VB N
The DT N
psycho-educational JJ 1_i
intervention NN 1_i
administered VBN N
was VBD N
acceptable JJ N
for IN N
children NNS 1_p
with IN 1_p
cancer NN 1_p
and CC N
was VBD N
found VBN N
to TO N
reduce VB N
gastrointestinal JJ N
problems NNS N
and CC N
pain NN N
. . N

A DT N
comparison NN N
of IN N
high JJ 1_i
and CC 1_i
low JJ 1_i
fat NN 1_i
meals NNS 1_i
on IN N
postprandial JJ 1_p
esophageal JJ 1_p
acid NN 1_p
exposure NN 1_p
. . 1_p

Fatty NNP N
foods NNS N
have VBP N
been VBN N
identified VBN N
as IN N
precipitating VBG N
factors NNS N
in IN N
symptomatic JJ N
gastroesophageal NN 1_p
reflux NN 1_p
( ( 1_p
GER NNP 1_p
) ) 1_p
. . 1_p

A DT N
fat JJ N
meal NN N
has VBZ N
also RB N
been VBN N
found VBN N
to TO N
decrease VB N
lower JJR N
esophageal NN 1_o
sphincter NN 1_o
pressure NN 1_o
( ( 1_o
LESP NNP 1_o
) ) 1_o
in IN N
normal JJ N
subjects NNS N
. . N

We PRP N
used VBD N
the DT N
ambulatory JJ N
24-h JJ N
pH NN N
monitor NN N
to TO N
assess VB N
esophageal JJ N
acid NN N
exposure NN N
in IN N
10 CD 1_p
normal JJ 1_p
subjects NNS 1_p
and CC 1_p
10 CD 1_p
GER NNP 1_p
patients NNS 1_p
following VBG 1_p
low JJ 1_i
and CC 1_i
high JJ 1_i
fat NN 1_i
meals NNS 1_i
eaten VBP 1_i
in IN 1_i
two CD 1_i
body NN 1_i
positions NNS 1_i
. . 1_i

The DT N
meals NNS N
had VBD N
nearly RB N
identical JJ N
protein NN N
content NN N
, , N
volumes NNS N
, , N
and CC N
calories NNS N
. . N

On IN N
successive JJ N
days NNS N
, , N
patients NNS N
ingested VBD N
one CD N
of IN N
the DT N
meals NNS 1_i
twice RB N
, , N
followed VBN N
by IN N
random JJ N
assignment NN N
to TO N
3 CD N
h NN N
upright JJ 1_i
and CC 1_i
3 CD N
h NN N
recumbent JJ 1_i
position NN 1_i
. . 1_i

Acid NNP 1_o
exposure NN 1_o
for IN 1_o
each DT 1_o
hour NN 1_o
over IN N
a DT N
3-h JJ N
postprandial NN N
( ( N
PP NNP N
) ) N
period NN N
was VBD N
assessed VBN N
as IN N
the DT N
percent NN N
time NN N
pH NN N
less JJR N
than IN N
4.0 CD N
. . N

Increased VBN N
upright JJ 1_o
acid NN 1_o
exposure NN 1_o
occurred VBD N
in IN N
normals NNS N
after IN N
the DT N
high JJ N
fat NN N
( ( N
6.2 CD N
+/- JJ N
2.1 CD N
% NN N
; : N
mean JJ N
+/- JJ N
SE NNP N
) ) N
compared VBN N
with IN N
the DT N
low JJ N
fat JJ N
meal NN N
( ( N
1.5 CD N
+/- JJ N
0.5 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

GER NNP N
patients NNS N
had VBD N
greater JJR N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
acid NN 1_o
exposure NN 1_o
than IN N
normals NNS N
in IN N
all DT N
study NN N
periods NNS N
, , N
but CC N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
low JJ N
and CC N
high JJ N
fat NN N
meals NNS N
in IN N
either DT N
study NN N
position NN N
. . N

High JJ N
fat JJ N
meals NNS N
induce VBP N
upright JJ 1_o
GER NNP 1_o
in IN N
normals NNS N
, , N
but CC N
do VBP N
not RB N
significantly RB N
affect VBP N
the DT N
abnormal JJ N
amount NN N
of IN N
GER NNP N
in IN N
patients NNS N
. . N

In IN N
addition NN N
, , N
progressive JJ N
increases NNS N
in IN N
acid JJ 1_o
exposure NN 1_o
were VBD N
found VBN N
over IN N
the DT N
3 CD N
postprandial JJ N
hours NNS N
in IN N
GER NNP N
patients NNS N
in IN N
a DT N
recumbent JJ N
position NN N
. . N

The DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
prior JJ N
data NNS N
showing VBG N
decreased JJ N
LESP NNP 1_o
with IN N
a DT N
fat JJ N
meal NN N
in IN N
normals NNS N
. . N

Covariance NN 1_i
analysis NN 1_i
in IN 1_p
generalized JJ 1_p
linear JJ 1_p
measurement NN 1_p
error NN 1_p
models NNS 1_p
. . 1_p

We PRP N
summarize VBP N
some DT N
of IN N
the DT N
recent JJ N
work NN N
on IN N
the DT N
errors-in-variables NNS N
problem NN N
in IN N
generalized JJ N
linear JJ N
models NNS N
. . N

The DT N
focus NN N
is VBZ N
on IN N
covariance NN N
analysis NN N
, , N
and CC N
in IN N
particular JJ N
testing NN N
for IN N
and CC N
estimation NN N
of IN N
treatment NN N
effects NNS N
. . N

There EX N
is VBZ N
a DT N
considerable JJ N
difference NN N
between IN N
the DT N
randomized JJ N
and CC N
non-randomized JJ N
models NNS N
when WRB N
testing VBG N
for IN N
an DT N
effect NN N
. . N

In IN N
randomized JJ N
studies NNS N
, , N
simple JJ N
techniques NNS N
exist VBP N
for IN N
testing VBG N
for IN N
a DT N
treatment NN N
effect NN N
. . N

In IN N
some DT N
instances NNS N
, , N
such JJ N
as IN N
linear JJ N
and CC N
multiplicative JJ N
regression NN N
, , N
simple JJ N
methods NNS N
exist VBP N
for IN N
estimating VBG N
the DT N
treatment NN N
effect NN N
. . N

In IN N
other JJ N
examples NNS N
such JJ N
as IN N
logistic JJ N
regression NN N
, , N
estimating VBG N
a DT N
treatment NN N
effect NN N
requires VBZ N
careful JJ N
attention NN N
to TO N
measurement VB N
error NN N
. . N

In IN N
non-randomized JJ N
studies NNS N
, , N
there EX N
is VBZ N
no DT N
recourse NN N
to TO N
understanding NN N
and CC N
modelling VBG N
measurement JJ N
error NN N
. . N

In IN N
particular JJ N
ignoring VBG N
measurement JJ N
error NN N
can MD N
lead VB N
to TO N
the DT N
wrong JJ N
conclusions NNS N
, , N
for IN N
example NN N
the DT N
true JJ N
but CC N
unobserved JJ N
data NNS N
may MD N
indicate VB N
a DT N
positive JJ N
effect NN N
for IN N
treatment NN N
, , N
while IN N
the DT N
observed JJ N
data NNS N
indicate VBP N
the DT N
opposite NN N
. . N

Some DT N
of IN N
the DT N
possible JJ N
methods NNS N
are VBP N
outlined VBN N
and CC N
compared VBN N
. . N

Randomized NNP N
clinical JJ N
trial NN N
of IN N
behavioral JJ N
intervention NN N
and CC N
nutrition NN N
education NN N
to TO N
improve VB N
caloric JJ N
intake NN N
and CC N
weight NN N
in IN N
children NNS 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
, , N
Be NNP N
In IN N
CHARGE NNP N
! . N
, , N
compared VBN N
with IN N
that DT N
of IN N
a DT N
nutrition NN N
education NN N
intervention NN N
alone RB N
on IN N
caloric JJ 1_o
intake NN 1_o
and CC N
weight JJ 1_o
gain NN 1_o
in IN N
children NNS 1_p
with IN 1_p
cystic JJ 1_p
fibrosis NN 1_p
and CC 1_p
pancreatic JJ 1_p
insufficiency NN 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Cystic JJ 1_p
fibrosis NN 1_p
centers NNS 1_p
in IN 1_p
the DT 1_p
eastern JJ 1_p
, , 1_p
midwestern JJ 1_p
, , 1_p
and CC 1_p
southern JJ 1_p
United NNP 1_p
States NNPS 1_p
. . 1_p

PARTICIPANTS VB N
Seventy-nine JJ 1_p
children NNS 1_p
aged VBD 1_p
4 CD 1_p
to TO 1_p
12 CD 1_p
years NNS 1_p
below IN 1_p
the DT 1_p
40th CD 1_p
percentile NN 1_p
for IN 1_p
weight NN 1_p
for IN 1_p
age NN 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

Sixty-seven JJ N
completed VBD N
the DT N
intervention NN N
and CC N
59 CD N
completed VBD N
a DT N
24-month JJ N
follow-up JJ N
assessment NN N
. . N

INTERVENTION NNP N
Comparison NNP N
of IN N
a DT N
behavioral JJ 1_i
plus CC 1_i
nutrition JJ 1_i
education NN 1_i
intervention NN 1_i
with IN 1_i
a DT 1_i
nutrition NN 1_i
education NN 1_i
intervention NN 1_i
alone RB 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
were VBD N
changes NNS N
from IN N
pretreatment NN N
to TO N
posttreatment VB N
in IN N
caloric JJ 1_o
intake NN 1_o
and CC 1_o
weight JJ 1_o
gain NN 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
from IN N
pretreatment NN N
to TO N
posttreatment VB N
in IN N
percentage NN 1_o
of IN 1_o
the DT 1_o
estimated VBN 1_o
energy NN 1_o
requirement NN 1_o
and CC 1_o
body NN 1_o
mass NN 1_o
index NN 1_o
z VBD 1_o
score NN 1_o
. . 1_o

These DT N
outcomes NNS N
were VBD N
also RB N
examined VBN N
24 CD N
months NNS N
posttreatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
as IN N
compared VBN N
with IN N
the DT N
nutrition NN N
education NN N
intervention NN N
alone RB N
had VBD N
a DT N
statistically RB N
greater JJR N
average JJ N
increase NN N
on IN N
the DT N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
of IN N
caloric JJ 1_o
intake NN 1_o
( ( N
mean JJ N
, , N
872 CD N
vs NN N
489 CD N
cal/d NN N
, , N
respectively RB N
) ) N
, , N
percentage NN 1_o
of IN 1_o
the DT 1_o
estimated VBN 1_o
energy NN 1_o
requirement NN 1_o
( ( N
mean JJ N
, , N
148 CD N
% NN N
vs JJ N
127 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
weight JJ 1_o
gain NN 1_o
( ( N
mean JJ N
, , N
1.47 CD N
vs NN N
0.92 CD N
kg NN N
, , N
respectively RB N
) ) N
, , N
and CC N
body NN 1_o
mass NN 1_o
index NN 1_o
z NN 1_o
score NN 1_o
( ( N
0.38 CD N
vs NN N
0.18 CD N
, , N
respectively RB N
) ) N
. . N

At IN N
the DT N
24-month JJ N
follow-up NN N
, , N
children NNS N
in IN N
both DT N
conditions NNS N
maintained VBD N
an DT N
estimated VBN N
energy NN 1_o
requirement NN 1_o
of IN N
around IN N
120 CD N
% NN N
and CC N
did VBD N
not RB N
significantly RB N
differ VB N
on IN N
any DT N
outcomes NNS N
. . N

CONCLUSIONS VB N
A DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
was VBD N
more RBR N
effective JJ N
than IN N
a DT N
nutrition JJ N
education NN N
intervention NN N
alone RB N
at IN N
increasing VBG N
dietary JJ N
intake NN N
and CC N
weight NN N
over IN N
a DT N
9-week JJ N
period NN N
. . N

However RB N
, , N
across IN N
the DT N
24-month JJ N
follow-up NN N
, , N
both DT N
treatments NNS N
achieved VBD N
similar JJ N
outcomes NNS N
. . N

Trial JJ N
Registration NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00006169 NN N
. . N

Adjunctive JJ N
perampanel NN 1_i
for IN N
refractory JJ N
partial-onset JJ N
seizures NNS N
: : N
randomized VBN N
phase NN N
III NNP N
study NN N
304 CD N
. . N

OBJECTIVE NN N
To TO N
assess VB N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
8 CD N
or CC N
12 CD N
mg JJ N
perampanel NN 1_i
, , N
a DT N
noncompetitive JJ N
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic JJ N
acid NN N
( ( N
AMPA NNP N
) ) N
receptor NN N
antagonist NN N
, , N
when WRB N
added VBN N
to TO N
concomitant VB N
antiepileptic JJ N
drugs NNS N
( ( N
AEDs NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
drug-resistant JJ N
partial-onset JJ N
seizures NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
( ( N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00699972 NNP N
) ) N
. . 1_p

Patients NNS 1_p
( ( 1_p
≥12 CD 1_p
years NNS 1_p
, , 1_p
with IN 1_p
ongoing JJ 1_p
seizures NNS 1_p
despite IN 1_p
1-3 JJ 1_p
AEDs NNP 1_p
) ) 1_p
were VBD N
randomized VBN N
( ( N
1:1:1 CD N
) ) N
to TO 1_i
once-daily JJ 1_i
perampanel NN 1_i
8 CD 1_i
mg NN 1_i
, , 1_i
12 CD 1_i
mg NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
. . N

Following VBG N
baseline NN N
( ( N
6 CD N
weeks NNS N
) ) N
, , N
patients NNS N
entered VBD N
a DT N
19-week JJ N
double-blind JJ N
phase NN 1_i
: : 1_i
6-week JJ 1_i
titration NN 1_i
( ( 1_i
2 CD 1_i
mg/week NN 1_i
increments NNS 1_i
to TO 1_i
target VB 1_i
dose NN 1_i
) ) 1_i
followed VBN 1_i
by IN 1_i
a DT 1_i
13-week JJ 1_i
maintenance NN 1_i
period NN 1_i
. . N

Percent JJ N
change NN N
in IN N
seizure NN N
frequency NN N
was VBD N
the DT N
primary JJ N
endpoint NN N
; : N
50 CD N
% NN N
responder NN N
rate NN N
was VBD N
the DT N
primary JJ N
endpoint NN N
for IN N
EU NNP N
registration NN N
. . N

RESULTS NNP 1_p
Of IN 1_p
388 CD 1_p
patients NNS 1_p
randomized VBN 1_p
and CC 1_p
treated VBN 1_p
, , 1_p
387 CD 1_p
provided VBD 1_p
seizure NN 1_p
frequency NN 1_p
data NNS 1_p
. . N

Using VBG N
this DT N
intent-to-treat JJ N
population NN N
over IN N
the DT N
double-blind JJ N
phase NN N
, , N
the DT 1_o
median JJ 1_o
percent NN 1_o
change NN 1_o
in IN 1_o
seizure NN 1_o
frequency NN 1_o
was VBD N
-21.0 JJ N
% NN N
, , N
-26.3 CD N
% NN N
, , N
and CC N
-34.5 CD N
% NN N
for IN 1_i
placebo NN 1_i
and CC 1_i
perampanel NN 1_i
8 CD N
and CC N
12 CD N
mg NN N
, , N
respectively RB N
( ( N
p JJ N
= NN N
0.0261 CD N
and CC N
p VB N
= $ N
0.0158 CD N
for IN N
8 CD N
and CC N
12 CD N
mg NN N
vs NN N
placebo NN N
, , N
respectively RB N
) ) N
. . N

Fifty NNP N
percent NN N
responder NN N
rates NNS N
during IN N
the DT N
maintenance NN N
period NN N
were VBD N
26.4 CD N
% NN N
, , N
37.6 CD N
% NN N
, , N
and CC N
36.1 CD N
% NN N
, , N
respectively RB N
, , N
for IN 1_i
placebo NN 1_i
, , 1_i
perampanel VBP 1_i
8 CD N
mg NN N
, , N
and CC 1_i
perampanel $ 1_i
12 CD N
mg NN N
; : N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
for IN N
8 CD N
mg NN N
( ( N
p JJ N
= NNP N
0.0760 CD N
) ) N
or CC N
12 CD N
mg NN N
( ( N
p JJ N
= NNP N
0.0914 CD 1_p
) ) 1_p
. . 1_p

Sixty-eight NNP 1_p
( ( 1_p
17.5 CD 1_p
% NN 1_p
) ) 1_p
patients NNS 1_p
discontinued VBN 1_p
, , 1_p
including VBG 1_p
40 CD 1_p
( ( 1_p
10.3 CD 1_p
% NN 1_p
) ) 1_p
for IN 1_p
adverse JJ 1_p
events NNS 1_p
. . N

Most JJS N
frequent JJ N
treatment-emergent JJ N
adverse JJ N
events NNS N
were VBD 1_o
dizziness RB 1_o
, , 1_o
somnolence NN 1_o
, , 1_o
irritability NN 1_o
, , 1_o
headache NN 1_o
, , 1_o
fall NN 1_o
, , 1_o
and CC 1_o
ataxia RB 1_o
. . N

CONCLUSIONS VB N
This DT N
trial NN N
demonstrated VBD N
that IN N
once-daily RB N
, , N
adjunctive JJ 1_i
perampanel NN 1_i
at IN N
doses NNS N
of IN N
8 CD N
or CC N
12 CD N
mg NNS N
improved JJ 1_o
seizure NN 1_o
control NN 1_o
in IN 1_p
patients NNS 1_p
with IN 1_p
uncontrolled JJ 1_p
partial-onset NN 1_p
seizures NNS 1_p
. . N

Doses NNS N
of IN N
perampanel NN N
8 CD N
and CC N
12 CD N
mg NNS N
were VBD N
safe JJ N
, , N
and CC N
tolerability NN N
was VBD N
acceptable JJ N
. . N

CLASSIFICATION NNP N
OF IN N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
I PRP N
evidence NN N
that IN N
once-daily JJ N
8 CD N
and CC N
12 CD N
mg NN N
doses NNS N
of IN N
adjunctive JJ 1_i
perampanel NNS 1_i
are VBP N
effective JJ N
in IN N
patients NNS N
with IN N
uncontrolled JJ N
partial-onset NN N
seizures NNS N
. . N

Disopyramide-pyridostigmine JJ 1_i
interaction NN N
: : N
selective JJ N
reversal NN N
of IN N
anticholinergic NN N
symptoms NNS N
with IN N
preservation NN N
of IN N
antiarrhythmic JJ N
effect NN N
. . N

This DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo FW 1_i
crossover NN N
study NN N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
cholinesterase NN 1_i
inhibitor NN 1_i
-- : 1_i
slow-release JJ 1_i
pyridostigmine NN 1_i
( ( N
180 CD N
mg NNS N
orally RB N
every DT N
12 CD N
hours NNS N
) ) N
-- : N
on IN N
the DT N
anticholinergic NN 1_o
and CC 1_o
antiarrhythmic JJ 1_o
properties NNS 1_o
of IN N
disopyramide NN 1_i
. . 1_i

Quantitative JJ N
side NN N
effects NNS N
questionnaire VBP N
scores NNS N
were VBD N
used VBN N
to TO N
guide VB N
disopyramide JJ 1_i
administration NN N
in IN N
20 CD 1_p
men NNS 1_p
with IN 1_p
ventricular JJ 1_p
tachycardia NN 1_p
. . 1_p

Disopyramide NNP 1_i
was VBD N
given VBN N
to TO N
each DT N
patient NN 1_p
both DT 1_p
with IN 1_p
placebo NN 1_i
and CC 1_p
with IN 1_p
active JJ 1_p
pyridostigmine NN 1_i
. . 1_i

The DT N
maximal JJ N
administered VBD N
dose NN N
for IN N
each DT N
regimen NN N
was VBD N
used VBN N
in IN N
conjunction NN N
with IN N
corresponding JJ N
questionnaire NN N
scores NNS N
to TO N
calculate VB N
an DT N
index NN N
or CC N
estimate NN N
of IN N
the DT N
maximal JJ 1_o
tolerable JJ 1_o
dose NN 1_o
of IN N
disopyramide NN 1_i
. . 1_i

Additional JJ N
evaluations NNS N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
each DT N
maximal NN N
administered VBD N
dose JJ N
regimen NNS N
included VBD N
tear JJ 1_o
and CC 1_o
saliva JJ 1_o
quantitation NN 1_o
, , 1_o
24 CD 1_o
hour NN 1_o
electrocardiogram NN 1_o
( ( 1_o
ECG NNP 1_o
) ) 1_o
, , 1_o
exercise VBP 1_o
testing VBG 1_o
and CC 1_o
programmed VBD 1_o
ventricular JJ 1_o
stimulation NN 1_o
. . 1_o

Results NNS N
showed VBD N
that IN N
the DT N
maximal NN N
administered VBD N
dose NN N
of IN N
disopyramide NN 1_i
was VBD N
greater JJR N
with IN N
active JJ N
pyridostigmine NN 1_i
than IN N
with IN N
placebo NN N
: : N
295 CD N
+/- JJ N
75 CD N
versus NN N
245 CD N
+/- JJ N
100 CD N
mg NN N
every DT N
6 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
calculated JJ N
maximal NN 1_o
tolerable JJ 1_o
dose NN 1_o
was VBD N
substantially RB N
greater JJR N
in IN N
the DT N
presence NN N
of IN N
pyridostigmine NN 1_i
: : 1_i
355 CD N
+/- JJ N
90 CD N
versus NN N
260 CD N
+/- JJ N
115 CD N
mg NN N
every DT N
6 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Maximal JJ 1_o
side NN 1_o
effects NNS 1_o
questionnaire NN 1_o
scores NNS 1_o
also RB N
reflected VBD N
decreased JJ N
anticholinergic JJ 1_o
activity NN 1_o
in IN N
the DT N
presence NN N
of IN N
pyridostigmine NN 1_i
compared VBN N
with IN N
placebo NN 1_i
: : 1_i
101.9 CD N
+/- JJ N
2.2 CD N
versus NN N
104.6 CD N
+/- JJ N
2.8 CD N
, , N
respectively RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
. . N

Baseline NNP N
tear NN N
and CC N
saliva JJ N
production NN N
was VBD N
significantly RB N
reduced VBN N
during IN N
disopyramide JJ N
therapy NN N
, , N
but CC N
was VBD N
restored VBN N
toward IN N
normal JJ N
by IN N
the DT N
addition NN N
of IN N
pyridostigmine NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
[ NNS N
Randomized NNP N
clinical JJ N
trial NN N
between IN N
nutritional JJ 1_i
counselling NN 1_i
and CC N
commercial JJ N
hypocaloric NN 1_i
diet NN 1_i
in IN N
weight JJ N
loss NN N
in IN N
obese JJ 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
arthropathy JJ 1_p
] NN 1_p
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
The DT N
aim NN N
of IN N
our PRP$ N
work NN N
was VBD N
to TO N
evaluate VB N
in IN N
obese JJ 1_p
patients NNS 1_p
with IN 1_p
an DT 1_p
indication NN 1_p
of IN 1_p
replacement NN 1_p
surgery NN 1_p
for IN 1_p
degenerative JJ 1_p
osteoarthritis NN 1_p
, , N
the DT N
utility NN N
of IN N
a DT N
hypocaloric JJ N
diet NN N
with IN N
Optisource NNP 1_i
vs FW N
nutritional JJ N
counseling NN N
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
Thirty NNP 1_p
six CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
in IN N
both DT N
branches NNS N
: : N
diet JJ 1_i
I PRP 1_i
with IN 1_i
lunch NN 1_i
and CC 1_i
dinner NN 1_i
substituted VBN 1_i
by IN 1_i
two CD 1_i
Optisource NNP 1_i
( ( N
1109,3 CD N
kcal/day NN N
, , N
166,4g CD N
of IN N
carbohydrates NNS N
( ( N
60 CD N
% NN N
) ) N
, , N
63g CD N
of IN N
proteins NNS N
( ( N
23 CD N
% NN N
) ) N
, , N
21,3g CD N
of IN N
lipids NNS N
17 CD N
% NN N
) ) N
and CC N
diet JJ N
II NNP 1_i
with IN 1_i
nutritional JJ 1_i
counselling VBG 1_i
with IN 1_i
a DT 1_i
decrease NN 1_i
of IN 1_i
500 CD 1_i
cal/day NN 1_i
from IN 1_i
the DT 1_i
previous JJ 1_i
dietary JJ 1_i
intake NN 1_i
. . 1_i

Before IN N
and CC N
3 CD N
months NNS N
after IN N
treatment NN N
, , N
a DT N
nutritional JJ N
and CC N
biochemical JJ N
study NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
Nineteen JJ N
patients NNS N
were VBD N
randomized VBN N
in IN N
group NN N
I PRP N
and CC N
17 CD N
patients NNS N
in IN N
group NN N
II NNP N
. . N

19 CD N
patients NNS N
finished VBD N
the DT N
study NN N
in IN N
group NN N
I PRP N
and CC N
14 CD N
in IN N
group NN N
II NNP N
. . N

Weight NNP 1_o
loss NN 1_o
was VBD N
higher RBR N
in IN N
group NN N
I PRP N
than IN N
II NNP N
( ( N
7,7 CD N
[ RB N
4,7 CD N
] JJ N
vs NN N
3,92 CD N
[ NN N
3,32 CD N
] NNP N
kg NN N
; : N
P=.05 NNP N
) ) N
, , N
with IN N
a DT N
significant JJ N
decrease NN N
of IN N
HOMA NNP 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
in IN N
group NN N
I. NNP N
Decreases NNP N
of IN N
body NN 1_o
mass NN 1_o
index NN 1_o
( ( N
-2,9 NNP N
[ VBZ N
1,8 CD N
] NN N
vs NN N
-1,4 NNP N
[ VBZ N
0,9 CD N
] NN N
; : N
P=.05 NNP N
) ) N
, , N
fat JJ 1_o
mass NN 1_o
( ( N
-3,8 JJ N
[ $ N
3,4 CD N
] NNP N
vs NN N
-2,3 NNP N
[ VBZ N
1,7 CD N
] NN N
kg NN N
; : N
P=.0,05 NNP N
) ) N
and CC N
HOMA NNP 1_o
( ( N
-2,0 NNP N
[ VBZ N
2,2 CD N
] NN N
vs NN N
-0,4 NNP N
[ VBZ N
1,82 CD N
] NN N
; : N
P=.05 NNP N
) ) N
were VBD N
higher JJR N
in IN N
group NN N
I PRP N
than IN N
II NNP N
. . N

CONCLUSIONS NNP N
Obese JJ 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
osteoarthritis NN 1_p
treated VBN N
with IN N
a DT N
mixed JJ N
diet NN N
supplemented VBN N
with IN N
a DT N
commercial JJ 1_i
hypocaloric NN 1_i
formula NN 1_i
improved VBD N
weight NN 1_o
, , 1_o
fat JJ 1_o
mass NN 1_o
and CC 1_o
HOMA NNP 1_o
in IN N
a DT N
better JJR N
way NN N
than IN N
patients NNS N
treated VBN N
with IN N
a DT N
dietary JJ 1_i
counselling NN 1_i
alone RB N
. . N

Bitewing NNP 1_p
film NN 1_p
quality NN 1_p
: : 1_p
a DT N
clinical JJ N
comparison NN N
of IN N
the DT N
loop NN 1_i
vs. FW 1_i
holder NN 1_i
techniques NNS 1_i
. . 1_i

OBJECTIVE NNP N
To TO N
compare VB N
in IN N
vivo JJ N
bitewing NN N
film NN N
quality NN N
using VBG N
the DT N
holder NN 1_i
versus IN 1_i
the DT 1_i
paper NN 1_i
loop NN 1_i
technique NN 1_i
. . 1_i

METHOD NNP N
AND CC N
MATERIALS NNP N
Four NNP 1_p
bitewing VBG 1_p
films NNS 1_p
were VBD N
taken VBN N
from IN N
the DT N
right NN 1_p
and CC 1_p
left VBD 1_p
premolar JJ 1_p
and CC 1_p
molar JJ 1_p
regions NNS 1_p
of IN 1_p
45 CD 1_p
dental JJ 1_p
students NNS 1_p
using VBG N
both DT N
the DT N
bitewing NN 1_i
holder NN 1_i
and CC 1_i
paper NN 1_i
loop NN 1_i
techniques NNS 1_i
. . 1_i

A DT N
total NN N
of IN N
360 CD 1_p
films NNS 1_p
were VBD N
taken VBN N
and CC N
assessed VBN N
by IN N
an DT N
experienced JJ N
practitioner NN N
not RB N
apprised VBN N
of IN N
the DT N
bitewing NN 1_i
technique NN 1_i
used VBN N
. . N

Of IN N
interest NN N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
number NN N
of IN N
overlaps NNS N
and CC N
the DT N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
; : N
( ( N
2 CD N
) ) N
proper NN N
film NN N
positioning NN N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
percentage NN N
of IN N
cone NN N
cutting NN N
. . N

A DT N
Poisson NNP N
regression NN N
using VBG N
generalized VBN N
estimating VBG N
equations NNS N
( ( N
GEEs NNP N
) ) N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
difference NN N
in IN N
overlap NN N
between IN N
the DT N
two CD N
techniques NNS N
. . N

For IN N
proper JJ N
positioning NN N
and CC N
cone NN N
cutting NN N
, , N
logistic JJ N
regressions NNS N
using VBG N
GEEs NNP N
were VBD N
used VBN N
. . N

RESULTS VB N
The DT N
average JJ 1_o
number NN 1_o
of IN 1_o
horizontal JJ 1_o
overlaps NNS 1_o
for IN 1_o
the DT 1_o
loop NN 1_o
and CC 1_o
holder NN 1_o
techniques NNS 1_o
at IN N
the DT N
right JJ N
premolar NN N
, , N
right JJ N
molar NN N
, , N
left VBD N
premolar JJ N
, , N
and CC N
left VBD N
molar NN N
were VBD N
1.64 CD N
, , N
2.11 CD N
, , N
2.16 CD N
, , N
2.78 CD N
, , N
and CC N
1.64 CD N
, , N
2.00 CD N
, , N
2.00 CD N
, , N
2.18 CD N
, , N
respectively RB N
. . N

The DT N
loop NN 1_i
technique NN 1_i
was VBD N
1.11 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
overlapping VBG 1_o
than IN N
the DT N
holder NN 1_i
technique NN 1_i
. . 1_i

The DT N
highest JJS 1_o
percentage NN 1_o
of IN 1_o
teeth NNS 1_o
showing VBG 1_o
the DT 1_o
alveolar JJ 1_o
crest NN 1_o
by IN 1_o
the DT 1_o
loop NN 1_o
technique NN 1_o
was VBD N
97.8 CD N
% NN N
in IN N
the DT N
mandibular JJ N
second JJ N
premolar NN N
and CC N
first JJ N
molar NN N
. . N

With IN N
respect NN N
to TO N
film NN N
positioning NN N
, , N
the DT N
loop NN 1_i
technique NN 1_i
was VBD N
1.12 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
improper JJ 1_o
positioning NN 1_o
than IN N
the DT N
holder NN 1_i
technique NN 1_i
. . 1_i

Both DT N
techniques NNS N
demonstrated VBN N
minimal JJ 1_o
cone NN 1_o
cutting NN 1_o
( ( N
1 CD N
in IN N
the DT N
loop NN N
versus NN N
0 CD N
in IN N
the DT N
holder NN N
) ) N
. . N

CONCLUSION VB N
The DT N
quality NN N
of IN N
bitewing VBG N
films NNS N
taken VBN N
by IN N
the DT N
loop NN 1_i
and CC 1_i
holder NN 1_i
techniques NNS 1_i
was VBD N
not RB N
significantly RB N
different JJ N
. . N

A DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
of IN N
5-fluorouracil JJ 1_i
, , N
with IN N
or CC N
without IN N
human JJ 1_i
interferon-beta NN 1_i
, , N
for IN N
advanced JJ 1_p
colorectal JJ 1_p
cancer NN 1_p
. . 1_p

This DT N
study NN N
compared VBN N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
5-fluorouracil JJ 1_i
( ( 1_i
5-FU JJ 1_i
) ) 1_i
monotherapy NN 1_i
to TO N
that DT N
of IN N
5-FU JJ 1_i
combined VBN 1_i
with IN 1_i
natural JJ 1_i
human JJ 1_i
interferon-beta NN 1_i
( ( 1_i
IFN-beta NNP 1_i
) ) 1_i
in IN N
patients NNS 1_p
with IN 1_p
unresectable JJ 1_p
, , 1_p
advanced JJ 1_p
colorectal JJ 1_p
carcinoma NN 1_p
. . 1_p

Forty-nine JJ 1_p
chemotherapy-naive JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
5-FU JJ N
alone RB N
or CC N
to TO N
the DT N
combination NN N
. . N

All DT N
patients NNS N
received VBD N
750 CD N
mg NNS N
m NN N
( ( N
-2 JJ N
) ) N
day NN N
( ( N
-1 JJ N
) ) N
5-FU NN N
for IN N
5 CD N
days NNS N
by IN N
continuous JJ N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
infusion NN N
, , N
followed VBD N
after IN N
day NN N
15 CD N
by IN N
a DT N
weekly JJ N
i.v NN N
. . N

bolus NN N
of IN N
750 CD N
mg NNS N
m NN N
( ( N
-2 NNP N
) ) N
. . N

IFN-beta NNP 1_i
was VBD N
injected VBN N
intramuscularly RB N
three CD N
times NNS N
weekly RB N
at IN N
9 CD N
M NNP N
IU NNP N
. . N

Treatment NNP N
continued VBD N
for IN N
52 CD N
weeks NNS N
, , N
or CC N
until IN N
disease JJ 1_o
progression NN 1_o
or CC N
intolerable JJ 1_o
toxicity NN 1_o
. . 1_o

Clinical JJ N
endpoints NNS N
were VBD N
tumor JJ 1_o
response NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
progression NN 1_o
, , 1_o
survival NN 1_o
and CC 1_o
toxicity NN 1_o
. . 1_o

The DT N
addition NN N
of IN N
IFN-3 NNP 1_i
to TO 1_i
5-FU CD 1_i
significantly RB N
improved VBN 1_o
response NN 1_o
rate NN 1_o
( ( N
33.3 CD N
% NN N
vs JJ N
4.5 CD N
% NN N
for IN N
evaluable JJ N
patients NNS N
; : N
P NNP N
= NNP N
0.021 CD N
) ) N
, , N
time NN 1_o
to TO 1_o
progression NN 1_o
( ( N
median JJ N
7.2 CD N
vs JJ N
4.2 CD N
months NNS N
; : N
P NNP N
= NNP N
0.0435 CD N
) ) N
, , N
and CC N
survival JJ 1_o
time NN 1_o
( ( N
median JJ N
15.9 CD N
vs JJ N
7.2 CD N
months NNS N
; : N
P NNP N
= NNP N
0.038 CD N
) ) N
without IN N
significantly RB N
increasing VBG N
toxicity NN 1_o
compared VBN N
to TO N
5-FU JJ N
alone RB N
. . N

Cumulative JJ 1_o
5-FU JJ 1_o
dose NN 1_o
was VBD N
higher JJR N
with IN N
combined JJ N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
: : N
more JJR N
patients NNS N
receiving VBG N
monotherapy JJ N
discontinued VBN N
treatment NN N
because IN N
of IN N
disease NN 1_o
progression NN 1_o
. . 1_o

Fever NNP 1_o
was VBD N
more RBR N
frequent JJ N
with IN N
combined JJ N
therapy NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
; : N
there EX N
were VBD N
no DT N
other JJ N
differences NNS N
in IN N
toxicity NN 1_o
. . 1_o

The DT N
only JJ N
grade NN 1_o
IV NNP 1_o
toxicity NN 1_o
observed VBD N
was VBD N
neutropenia JJ N
( ( N
two CD N
patients NNS N
per IN N
group NN N
) ) N
. . N

A DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
has VBZ N
been VBN N
initiated VBN N
to TO N
confirm VB N
the DT N
synergy NN N
between IN N
5-FU JJ 1_i
and CC N
IFN-beta NNP 1_i
. . 1_i

Successful JJ N
face NN 1_o
recognition NN 1_o
is VBZ N
associated VBN N
with IN N
increased JJ N
prefrontal JJ N
cortex NN N
activation NN N
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

This DT N
study NN N
examines VBZ N
whether IN N
deficits NNS N
in IN N
visual JJ 1_o
information NN 1_o
processing NN 1_o
in IN N
autism-spectrum JJ 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
can MD N
be VB N
offset VBN N
by IN N
the DT N
recruitment NN N
of IN N
brain NN N
structures NNS N
involved VBN N
in IN N
selective JJ N
attention NN N
. . N

During IN N
functional JJ 1_i
MRI NNP 1_i
, , N
12 CD 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
19 CD 1_p
control NN 1_p
participants NNS 1_p
completed VBD N
a DT N
selective JJ 1_o
attention NN 1_o
one-back NN 1_i
task NN 1_i
in IN N
which WDT N
images NNS 1_i
of IN 1_i
faces VBZ 1_i
and CC 1_i
houses NNS 1_i
were VBD 1_i
superimposed VBN 1_i
. . 1_i

When WRB N
attending VBG N
to TO N
faces VBZ N
, , N
the DT N
ASD NNP N
group NN N
showed VBD N
increased VBN N
activation NN 1_o
relative NN N
to TO N
control VB N
participants NNS N
within IN N
multiple JJ N
prefrontal JJ 1_o
cortex NN 1_o
areas NNS 1_o
, , N
including VBG N
dorsolateral JJ 1_o
prefrontal JJ 1_o
cortex NN 1_o
( ( N
DLPFC NNP N
) ) N
. . N

DLPFC NNP N
activation NN N
in IN N
ASD NNP N
was VBD N
associated VBN N
with IN N
increased VBN N
response NN 1_o
times NNS 1_o
for IN 1_o
faces VBZ 1_o
. . 1_o

These DT N
data NNS N
suggest VBP N
that IN N
prefrontal JJ 1_o
cortex JJ 1_o
activation NN 1_o
may MD N
represent VB N
a DT N
compensatory NN N
mechanism NN N
for IN N
diminished JJ N
visual JJ 1_o
information NN 1_o
processing NN 1_o
abilities NNS 1_o
in IN N
ASD NNP 1_p
. . 1_p

Effects NNS N
of IN N
low-level JJ 1_i
laser NN 1_i
and CC 1_i
plyometric JJ 1_i
exercises NNS 1_i
in IN N
the DT N
treatment NN N
of IN N
lateral JJ 1_p
epicondylitis NN 1_p
. . 1_p

OBJECTIVE CC N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
a DT N
protocol NN N
of IN N
combination NN N
of IN N
laser NN 1_i
with IN 1_i
plyometric JJ 1_i
exercises NNS 1_i
and CC N
a DT N
protocol NN N
of IN N
placebo NN 1_i
laser NN 1_i
with IN 1_i
the DT 1_i
same JJ 1_i
program NN 1_i
, , N
in IN N
the DT N
treatment NN N
of IN N
tennis NN 1_p
elbow NN 1_p
. . 1_p

BACKGROUND NNP N
DATA NNP N
The DT N
use NN N
of IN N
low-level JJ 1_i
laser NN 1_i
has VBZ N
been VBN N
recommended VBN N
for IN N
the DT N
management NN N
of IN N
tennis NN 1_p
elbow NN 1_p
with IN N
contradictory JJ N
results NNS N
. . N

Also RB N
, , N
plyometric JJ 1_i
exercises NNS 1_i
was VBD N
recommended VBN N
for IN N
the DT N
treatment NN N
of IN N
the DT N
tendinopathy NN N
. . N

METHODS NNP N
Fifty NNP 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
tennis NN 1_p
elbow NN 1_p
participated VBD 1_p
in IN 1_p
the DT 1_p
study NN 1_p
and CC N
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
was VBD N
treated VBN N
with IN N
a DT N
904 CD 1_i
Ga-As NNP 1_i
laser NN 1_i
CW NNP 1_i
, , N
frequency NN N
50 CD N
Hz NNP N
, , N
intensity NN N
40 CD N
mW NN N
and CC N
energy NN N
density NN N
2.4 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
, , N
plus CC 1_i
plyometric JJ 1_i
exercises NNS 1_i
and CC N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
that WDT N
received VBD N
placebo NNS 1_i
laser RBR 1_i
plus CC 1_i
the DT 1_i
same JJ 1_i
plyometric JJ 1_i
exercises NNS 1_i
. . 1_i

During IN N
eight CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
patients NNS N
of IN N
the DT N
two CD N
groups NNS N
received VBD N
12 CD N
sessions NNS N
of IN N
laser NN 1_i
or CC 1_i
placebo NN 1_i
, , N
two CD N
sessions NNS N
per IN N
week NN N
( ( N
weeks NNS N
1-4 RB N
) ) N
and CC N
one CD N
session NN N
per IN N
week NN N
( ( N
weeks NNS N
5-8 RB N
) ) N
. . N

Pain NN 1_o
at IN 1_o
rest NN 1_o
, , 1_o
at IN 1_o
palpation NN 1_o
on IN 1_o
the DT 1_o
lateral JJ 1_o
epicondyle NN 1_o
, , 1_o
during IN 1_o
resisted VBN 1_o
wrist JJ 1_o
extension NN 1_o
, , 1_o
middle JJ 1_o
finger NN 1_o
test NN 1_o
, , N
and CC N
strength NN 1_o
testing NN 1_o
was VBD N
evaluated VBN N
using VBG N
Visual NNP 1_o
Analogue NNP 1_o
Scales NNP 1_o
. . 1_o

Also RB N
it PRP N
was VBD N
evaluated VBN N
the DT N
grip NN 1_o
strength NN 1_o
, , N
the DT N
range NN 1_o
of IN 1_o
motion NN 1_o
and CC N
weight JJ 1_o
test NN 1_o
. . 1_o

Parameters NNS N
were VBD N
determined VBN N
before IN N
the DT N
treatment NN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
eighth JJ N
week NN N
course NN N
of IN N
treatment NN N
( ( N
week NN N
8 CD N
) ) N
, , N
and CC N
eighth RB N
( ( N
week NN N
8 CD N
) ) N
after IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
the DT N
group NN N
B NNP N
, , N
the DT N
group NN N
A NNP N
had VBD N
( ( N
1 CD N
) ) N
a DT N
significant JJ N
decrease NN 1_o
of IN 1_o
pain NN 1_o
at IN 1_o
rest NN 1_o
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
following VBG N
up RP N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
a DT N
significant JJ N
decrease NN 1_o
in IN 1_o
pain NN 1_o
at IN 1_o
palpation NN 1_o
and CC 1_o
pain NN 1_o
on IN 1_o
isometric JJ 1_o
testing VBG 1_o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
3 CD N
) ) N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN 1_o
during IN 1_o
middle JJ 1_o
finger NN 1_o
test NN 1_o
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
4 CD N
) ) N
a DT N
significant JJ N
decrease NN 1_o
of IN 1_o
pain NN 1_o
during IN 1_o
grip NN 1_o
strength NN 1_o
testing VBG 1_o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
5 CD N
) ) N
a DT N
significant JJ N
increase NN 1_o
in IN 1_o
the DT 1_o
wrist NN 1_o
range NN 1_o
of IN 1_o
motion NN 1_o
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
( ( N
6 CD N
) ) N
an DT N
increase NN 1_o
in IN 1_o
grip JJ 1_o
strength NN 1_o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
( ( N
7 CD N
) ) N
a DT N
significant JJ N
increase NN 1_o
in IN 1_o
weight-test JJ 1_o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
suggested VBD N
that IN N
the DT N
combination NN 1_i
of IN 1_i
laser NN 1_i
with IN 1_i
plyometric JJ 1_i
exercises NNS 1_i
was VBD N
more RBR N
effective JJ N
treatment NN N
than IN N
placebo FW 1_i
laser NN 1_i
with IN 1_i
the DT 1_i
same JJ 1_i
plyometric JJ 1_i
exercises NNS 1_i
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
as RB N
well RB N
as IN N
at IN N
the DT N
follow-up NN N
. . N

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
establish VB N
the DT N
relative JJ N
and CC N
absolute JJ N
effectiveness NN N
of IN N
the DT N
above JJ N
protocol NN N
. . N

Functional JJ N
outcome NN N
following VBG N
intramedullary JJ 1_i
nailing NN 1_i
of IN 1_i
the DT 1_i
femur NN 1_i
: : 1_i
a DT N
prospective JJ N
randomized VBN N
comparison NN N
of IN N
piriformis NN N
fossa NN N
and CC N
greater JJR N
trochanteric JJ N
entry NN N
portals NNS N
. . N

BACKGROUND IN N
The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
prospectively RB N
compare VB N
the DT N
functional JJ N
outcome NN N
of IN N
intramedullary JJ 1_i
nailing NN 1_i
of IN 1_i
the DT 1_i
femur NN 1_i
performed VBD N
with IN N
use NN N
of IN N
a DT N
trochanteric NN N
and CC N
a DT N
piriformis NN N
fossa NN N
entry NN N
portal NN N
. . N

METHODS NNP N
One CD 1_p
hundred CD 1_p
and CC 1_p
ten JJ 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
femoral JJ 1_p
shaft NN 1_p
fracture NN 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
prospective JJ 1_p
, , 1_p
randomized VBN 1_p
study NN 1_p
. . 1_p

Fifty-four CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
Group NNP N
A NNP N
( ( 1_i
piriformis JJ 1_i
fossa NN 1_i
portal NN 1_i
) ) 1_i
and CC N
fifty-six JJ 1_p
to TO N
Group NNP N
B NNP N
( ( 1_i
trochanteric JJ 1_i
portal NN 1_i
) ) 1_i
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
( ( N
WOMAC NNP N
) ) N
Osteoarthritis NNP N
Index NNP N
hip NN N
function NN N
score NN N
, , N
pain NN N
, , N
and CC N
blinded VBD N
functional JJ N
evaluation NN N
by IN N
a DT N
physical JJ N
therapist NN N
. . N

RESULTS NNP N
Most JJS N
measures NNS N
of IN N
hip NN N
function NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
WOMAC NNP 1_o
score NN 1_o
at IN N
three CD N
, , N
six CD N
, , N
and CC N
twelve JJ N
months NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
piriformis NN N
fossa NN N
and CC N
trochanteric JJ N
nailing NN N
groups NNS N
. . N

Functional JJ N
tests NNS N
included VBD N
the DT N
chair NN N
stand VBP N
test NN N
and CC N
the DT N
timed VBN N
up RP N
and CC N
go VB N
test NN N
. . N

Patients NNS N
in IN N
Group NNP N
B NNP N
had VBD N
significantly RB N
better JJR N
scores NNS N
on IN N
the DT N
chair NN 1_o
stand VBP 1_o
test NN 1_o
( ( N
13.3 CD N
compared VBN N
with IN N
11.1 CD N
in IN N
Group NNP N
A NNP N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
at IN N
six CD N
months NNS N
postoperatively RB N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
at IN N
twelve JJ N
months NNS N
( ( N
14.0 CD N
compared VBN N
with IN N
13.6 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
on IN N
the DT N
timed VBN N
up RP N
and CC N
go VB N
test NN N
at IN N
either DT N
six CD N
or CC N
twelve VB N
months NNS N
. . N

The DT N
two CD N
groups NNS N
also RB N
did VBD N
not RB N
differ VB N
on IN N
the DT N
muscle NN 1_o
strength NN 1_o
testing VBG 1_o
. . 1_o

Intraoperative JJ N
parameters NNS N
differed VBD N
significantly RB N
between IN N
the DT N
groups NNS N
with IN N
respect NN 1_o
to TO 1_o
operative JJ 1_o
time NN 1_o
, , 1_o
fluoroscopy JJ 1_o
time NN 1_o
, , 1_o
and CC 1_o
incision NN 1_o
length NN 1_o
, , N
with IN N
the DT N
difference NN N
favoring VBG N
Group NNP N
B NNP N
for IN N
each DT N
parameter NN N
. . N

Analog NNP N
pain VBP 1_o
scale JJ 1_o
values NNS 1_o
were VBD N
similar JJ N
in IN N
Group NNP N
A NNP N
( ( N
2.49 CD N
) ) N
and CC N
Group NNP N
B NNP N
( ( N
2.15 CD N
) ) N
at IN N
twelve JJ N
months NNS N
postoperatively RB N
. . N

CONCLUSIONS JJ N
Patients NNPS N
in IN N
our PRP$ N
prospective JJ N
randomized VBN N
study NN N
who WP N
were VBD N
treated VBN N
with IN N
trochanteric JJ N
nailing VBG N
did VBD N
not RB N
differ VB N
in IN N
hip NN 1_o
function NN 1_o
at IN N
one CD N
year NN N
postoperatively RB N
compared VBN N
with IN N
patients NNS N
treated VBN N
with IN N
intramedullary JJ 1_i
nailing VBG 1_i
through IN N
the DT N
piriformis NN N
fossa NN N
. . N

The DT N
values NNS 1_o
of IN 1_o
several JJ 1_o
intraoperative JJ 1_o
parameters NNS 1_o
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
trochanteric JJ N
nailing NN N
group NN N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
functional JJ N
hip NN N
outcome NN N
of IN N
femoral JJ N
intramedullary JJ N
nailing NN N
performed VBN N
through IN N
the DT N
greater JJR N
trochanter NN N
is VBZ N
equal JJ N
to TO N
that DT N
of IN N
intramedullary JJ 1_i
nailing NN 1_i
performed VBN N
through IN N
the DT N
piriformis NN N
fossa NN N
. . N

[ JJ N
Comparison NNP N
of IN N
three CD N
analgesic JJ N
methods NNS N
for IN N
postoperative JJ 1_p
pain NN 1_p
relief NN N
and CC N
their PRP$ N
effects NNS N
on IN N
plasma JJ 1_o
interleukin-6 JJ 1_o
concentration NN 1_o
following VBG N
radical JJ 1_p
surgery NN 1_p
for IN 1_p
gastric JJ 1_p
carcinoma NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
preemptive JJ 1_i
epidural JJ 1_i
analgesia NN 1_i
combined VBN 1_i
with IN 1_i
postoperative JJ 1_i
epidural JJ 1_i
analgesia NN 1_i
, , 1_i
postoperative JJ 1_i
epidural JJ 1_i
analgesia NN 1_i
alone RB 1_i
and CC N
intravenous JJ 1_i
analgesia NN 1_i
for IN N
postoperative JJ 1_o
pain NN 1_o
relief NN 1_o
and CC N
their PRP$ N
effects NNS N
on IN N
plasma JJ 1_o
interleukin-6 JJ 1_o
( ( 1_o
IL-6 NNP 1_o
) ) 1_o
concentration NN 1_o
following VBG N
radical JJ 1_p
surgery NN 1_p
for IN 1_p
gastric JJ 1_p
carcinoma NN 1_p
. . 1_p

METHODS NNP N
Sixty-six JJ 1_p
patients NNS 1_p
with IN 1_p
gastric JJ 1_p
carcinoma NN 1_p
scheduled VBN 1_p
for IN 1_p
gastrectomy NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
, , N
namely RB N
group NN N
P NNP N
( ( N
n=22 NN N
) ) N
, , N
group NN N
E NNP N
( ( N
n=22 NN N
) ) N
and CC N
group NN N
V NNP N
( ( N
n=22 NN N
) ) N
, , N
to TO N
receive VB N
preemptive JJ 1_i
epidural JJ 1_i
analgesia NN 1_i
combined VBN 1_i
with IN 1_i
postoperative JJ 1_i
epidural JJ 1_i
analgesia NN 1_i
, , 1_i
exclusive JJ 1_i
postoperative JJ 1_i
epidural JJ 1_i
analgesia NN 1_i
, , 1_i
and CC 1_i
exclusive JJ 1_i
postoperative NN 1_i
intravenous JJ 1_i
analgesia NN 1_i
, , N
respectively RB N
. . N

Hemodynamic NNP 1_o
data NNS 1_o
were VBD N
recorded VBN N
for IN N
all PDT N
the DT N
patients NNS N
during IN N
the DT N
operation NN N
, , N
and CC N
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
was VBD N
used VBN N
to TO N
assess VB N
the DT N
pain NN 1_o
intensity NN 1_o
at IN N
4 CD N
, , N
8 CD N
, , N
16 CD N
, , N
24 CD N
, , N
48 CD N
and CC N
72 CD N
h NN N
after IN N
surgery NN N
. . N

Plasma NNP 1_o
IL-6 JJ 1_o
concentration NN 1_o
was VBD N
determined VBN N
before IN N
surgery NN N
and CC N
at IN N
24 CD N
, , N
48 CD N
, , N
72 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
changes NNS N
occurred VBD N
in IN N
the DT N
hemodynamics NNS N
during IN N
the DT N
preoperative JJ N
periods NNS N
. . N

VAS NNP 1_o
and CC 1_o
IL-6 NNP 1_o
were VBD N
lower JJR N
in IN N
group NN N
P NNP N
than IN N
in IN N
group NN N
E NNP N
and CC N
V NNP N
, , N
and CC N
group NN N
E NNP N
had VBD N
lower JJR N
measurement NN N
than IN N
group NN N
V NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Preemptive NNP N
epidural JJ N
analgesia NN N
combined VBN N
with IN N
postoperative JJ N
epidural JJ N
analgesia NN N
provides VBZ N
more RBR N
satisfactory JJ N
pain NN 1_o
relief NN 1_o
and CC N
more RBR N
effectively RB N
prevents VBZ N
IL-6 JJ 1_o
increment NN 1_o
than IN N
exclusive JJ N
epidural JJ N
analgesia NN N
or CC N
intravenous JJ N
analgesia NN N
after IN 1_p
gastrectomy NN 1_p
for IN 1_p
gastric JJ 1_p
carcinoma NN 1_p
. . 1_p

Less NNP N
tachycardia NN 1_o
in IN N
adults NNS 1_p
when WRB N
using VBG N
atropine VBP 1_i
0.9 CD N
mg NNS N
compared VBN N
with IN N
1.2 CD N
mg NNS N
plus CC N
neostigmine JJ 1_i
2.5 CD N
mg NN N
. . N

OBJECTIVE CC N
Compare NNP N
the DT N
increase NN N
in IN N
heart NN 1_o
rate NN 1_o
in IN 1_p
adults NNS 1_p
after IN N
0.9 CD N
vs. FW N
1.2 CD N
mg NN N
of IN N
atropine JJ 1_i
plus CC 1_i
neostigmine JJ 1_i
2.5 CD N
mg NN N
as IN N
the DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
reversal NN N
agent NN N
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
randomized NN N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
trial NN N
on IN N
46 CD 1_p
adults NNS 1_p
ASA NNP 1_p
I-II NNP 1_p
, , 1_p
undergoing VBG 1_p
elective JJ 1_p
gynecological NN 1_p
or CC 1_p
general JJ 1_p
surgery NN 1_p
with IN 1_p
balanced JJ 1_p
general JJ 1_p
anesthesia NN 1_p
was VBD N
performed VBN N
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
After IN N
surgery NN N
, , N
the DT N
study NN N
group NN N
received VBD N
0.9 CD 1_i
mg NN 1_i
of IN 1_i
atropine NN 1_i
, , N
while IN N
the DT N
control NN 1_i
group NN N
received VBD N
1.2 CD 1_i
mg NN 1_i
of IN 1_i
atropine NN 1_i
. . 1_i

Both DT N
groups NNS N
received VBD N
2.5 CD 1_i
mg NN 1_i
of IN 1_i
neostigmine JJ 1_i
simultaneously RB 1_i
. . 1_i

RESULTS VB N
The DT N
heart NN 1_o
rate NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
were VBD N
taken VBN N
at IN N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
, , N
9 CD N
, , N
10 CD N
, , N
15 CD N
, , N
20 CD N
, , N
25 CD N
, , N
and CC N
30 CD N
min NN N
after IN N
the DT N
injection NN N
. . N

The DT N
increase NN 1_o
in IN 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
between IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

The DT N
heart NN 1_o
rate NN 1_o
( ( N
at IN N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
min NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
study NN N
group NN N
increased VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
blood NN 1_o
pressure NN 1_o
between IN N
groups NNS N
and CC N
no DT N
side NN N
effects NNS N
occurred VBD N
. . N

CONCLUSION VB N
The DT N
authors NNS N
conclude VBP N
that IN N
0.9 CD N
mg NN N
of IN N
atropine NN 1_i
with IN N
2.5 CD N
mg NNS N
neostigmine JJ 1_i
can MD N
be VB N
safely RB N
used VBN N
as IN N
the DT N
reversal NN N
agent NN N
for IN N
a DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
, , N
particularly RB N
in IN N
patients NNS N
for IN N
whom WP N
any DT N
increase NN N
in IN N
heart NN 1_o
rate NN 1_o
would MD N
be VB N
harmful JJ N
. . N

Effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
rabeprazole JJ 1_i
20 CD N
mg NN N
and CC N
esomeprazole JJ 1_i
40 CD N
mg NN N
on IN N
24-h JJ 1_o
intragastric JJ 1_o
pH NN 1_o
in IN 1_p
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
compare VB N
antisecretory JJ N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
rabeprazole NN 1_i
and CC N
esomeprazole NN 1_i
. . 1_i

METHODS NNP N
Open NNP N
, , N
randomised VBD N
, , N
2-way JJ N
crossover NN N
, , N
clinical JJ N
pharmacology NN N
study NN N
. . N

24 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
( ( 1_p
10 CD 1_p
men NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
26.2 CD 1_p
y NN 1_p
) ) 1_p
received VBD N
a DT N
single JJ N
dose NN N
of IN N
rabeprazole JJ 1_i
20 CD 1_i
mg NN 1_i
or CC 1_i
esomeprazole JJ 1_i
40 CD 1_i
mg NN 1_i
, , N
with IN N
a DT N
14-day JJ N
'washout NN N
' POS N
. . N

Intragastric NNP 1_o
pH NN 1_o
was VBD N
recorded VBN N
continuously RB N
from IN N
24 CD N
h NN N
before IN N
to TO N
24 CD N
h NN N
after IN N
dosing VBG N
. . N

RESULTS JJ N
Mean NNP 1_o
intragastric JJ 1_o
pH NN 1_o
was VBD N
higher JJR N
after IN N
esomeprazole JJR 1_i
than IN N
rabeprazole NN 1_i
during IN N
0-5 JJ N
h NN N
after IN N
dosing VBG N
( ( N
P=0.0001 NNP N
) ) N
; : N
the DT N
reverse NN N
was VBD N
true JJ N
from IN N
14-24 JJ N
h NN N
( ( N
P=0.0002 NNP N
) ) N
. . N

Mean VB 1_o
% NN 1_o
time NN 1_o
pH JJ 1_o
> $ 1_o
3 CD 1_o
and CC 1_o
> $ 1_o
4 CD 1_o
was VBD N
greater JJR N
after IN N
esomeprazole JJR 1_i
than IN N
rabeprazole NN 1_i
during IN N
0-14 JJ N
h NN N
( ( N
P=0.041 NNP N
and CC N
0.044 CD N
) ) N
, , N
but CC N
the DT N
reverse NN N
was VBD N
true JJ N
during IN N
14-24 JJ N
h NN N
( ( N
P=0.0005 NNP N
and CC N
0.001 CD N
) ) N
. . N

In IN N
the DT N
0-24 JJ N
h NN N
interval NN N
as IN N
a DT N
whole NN N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
in IN N
mean JJ 1_o
pH NN 1_o
or CC 1_o
% NN 1_o
time NN 1_o
pH JJ 1_o
> JJ 1_o
3 CD 1_o
or CC 1_o
> $ 1_o
4 CD 1_o
. . 1_o

CONCLUSION NNP N
Single-dose JJ N
rabeprazole NN 1_i
20 CD N
mg NN N
was VBD N
as RB N
effective JJ N
as IN N
esomeprazole JJ 1_i
40 CD N
mg NN N
in IN N
increasing VBG N
intragastric JJ 1_o
pH NN 1_o
and CC N
maintaining VBG N
pH NN 1_o
> $ 1_o
3 CD 1_o
and CC 1_o
> $ 1_o
4 CD 1_o
, , N
despite IN N
the DT N
2-fold JJ N
difference NN N
in IN N
dose NN N
. . N

[ JJ N
Effects NNS N
of IN N
transcutaneous JJ 1_i
electrical JJ 1_i
stimulation NN 1_i
of IN 1_i
auricular JJ 1_i
Shenmen NNP 1_i
point NN 1_i
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ 1_p
section NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ N
section NN N
. . N

METHODS NNP N
After IN N
IRB NNP N
approval NN N
and CC N
informed JJ N
consent NN N
, , N
one CD 1_p
hundred CD 1_p
and CC 1_p
eighty VB 1_p
singleton NN 1_p
primiparas IN 1_p
undergoing VBG 1_p
elective JJ 1_p
cesarean JJ 1_p
section NN 1_p
, , 1_p
in IN 1_p
Qingdao NNP 1_p
Municipal NNP 1_p
Hospital NNP 1_p
, , 1_p
and CC 1_p
Qingdao NNP 1_p
Hiser NNP 1_p
Medical NNP 1_p
Center NNP 1_p
, , 1_p
from IN 1_p
November NNP 1_p
2011 CD 1_p
to TO 1_p
March NNP 1_p
2012 CD 1_p
, , 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
three CD N
groups NNS N
: : N
transcutaneous JJ 1_i
electrical JJ 1_i
stimulation NN 1_i
of IN 1_i
auricular JJ 1_i
Shenmen NNP 1_i
point NN 1_i
group NN 1_i
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
, , N
transcutaneous JJ 1_i
electrical JJ 1_i
stimulation NN 1_i
of IN 1_i
auricular JJ 1_i
Eye NNP 1_i
point NN 1_i
group NN 1_i
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
and CC N
control NN 1_i
group NN 1_i
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Women NNP N
of IN N
group NN N
A NNP N
received VBD N
transcutaneous JJ 1_i
electrical JJ 1_i
stimulation NN 1_i
of IN N
auricular JJ N
Shenmen NNP N
point NN N
( ( N
frequency NN N
1.5 CD N
HZ NNP N
) ) N
at IN N
the DT N
time NN N
of IN N
preoperation NN N
, , N
4 CD N
, , N
10 CD N
and CC N
22 CD N
hours NNS N
of IN N
postoperation NN N
for IN N
30 CD N
minutes NNS N
. . N

The DT N
strength NN N
was VBD N
controlled VBN N
by IN N
themselves PRP N
. . N

Women NNP N
of IN N
group NN N
B NNP N
received VBD N
stimulation NN N
of IN N
auricular JJ N
Eye NNP N
point NN N
as IN N
group NN N
A NNP N
. . N

Women NNP N
of IN N
group NN N
C NNP N
received VBD N
pressurization NN 1_i
and CC 1_i
connected VBN 1_i
line NN 1_i
were VBD 1_i
the DT 1_i
same JJ 1_i
with IN 1_i
group NN 1_i
A NNP 1_i
, , 1_i
but CC 1_i
without IN 1_i
electrical JJ 1_i
stimulation NN 1_i
. . 1_i

The DT N
following JJ N
indexes NNS N
was VBD N
observed VBN N
: : N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
for IN N
48 CD N
hours NNS N
; : N
the DT N
rate NN N
of IN N
metoclopramide NN N
; : N
the DT 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
score NN 1_o
of IN 1_o
rest NN 1_o
pain NN 1_o
, , 1_o
uterine JJ 1_o
contration NN 1_o
pain NN 1_o
and CC 1_o
dynamic JJ 1_o
pain NN 1_o
at IN 1_o
the DT 1_o
time NN 1_o
of IN 1_o
postoperation NN 1_o
for IN 1_o
6 CD 1_o
, , 1_o
12 CD 1_o
, , 1_o
24 CD 1_o
and CC 1_o
48 CD 1_o
hours NNS 1_o
( ( 1_o
T NNP 1_o
( ( 1_o
1 CD 1_o
) ) 1_o
-T NN 1_o
( ( 1_o
4 CD 1_o
) ) 1_o
) ) 1_o
; : 1_o
the DT 1_o
total JJ 1_o
number NN 1_o
and CC 1_o
effective JJ 1_o
compressions NNS 1_o
number NN 1_o
of IN 1_o
patient-controlled JJ 1_o
epidural JJ 1_o
analgesia NN 1_o
( ( 1_o
PCEA NNP 1_o
) ) 1_o
; : 1_o
the DT 1_o
dose NN 1_o
of IN 1_o
analgesia JJ 1_o
mixture NN 1_o
; : 1_o
the DT 1_o
anal JJ 1_o
exhaust JJ 1_o
time NN 1_o
; : 1_o
the DT 1_o
volume NN 1_o
of IN 1_o
postoperative JJ 1_o
bleeding NN 1_o
for IN 1_o
6 CD 1_o
hours NNS 1_o
of IN 1_o
postoperation NN 1_o
and CC 1_o
the DT 1_o
other JJ 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

RESULTS NNP N
Compared NNP N
with IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
, , N
the DT N
incidence NN 1_o
of IN 1_o
PONV NNP 1_o
, , 1_o
the DT 1_o
rate NN 1_o
of IN 1_o
metoclopramide NN 1_o
, , 1_o
the DT 1_o
VAS NNP 1_o
score NN 1_o
at IN N
the DT N
time NN N
T NNP N
( ( N
1 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
, , N
the DT N
total JJ 1_o
number NN 1_o
and CC 1_o
effective JJ 1_o
compressions NNS 1_o
number NN 1_o
of IN 1_o
PCEA NNP 1_o
, , 1_o
the DT 1_o
ratio NN 1_o
of IN 1_o
the DT 1_o
total JJ 1_o
number NN 1_o
with IN 1_o
effective JJ 1_o
compressions NNS 1_o
number NN 1_o
and CC 1_o
the DT 1_o
dose NN 1_o
of IN 1_o
analgesia JJ 1_o
mixture NN 1_o
were VBD N
decreased VBN N
in IN N
group NN N
A NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
compared VBN N
group NN N
B NNP N
with IN N
group NN N
C NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
anal JJ 1_o
exhaust NN 1_o
time NN 1_o
and CC 1_o
the DT 1_o
volume NN 1_o
of IN 1_o
postoperative JJ 1_o
bleeding NN 1_o
for IN N
6 CD N
hours NNS N
of IN N
postoperation NN N
were VBD N
no DT N
difference NN N
in IN N
the DT N
three CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

No UH N
other JJ N
side NN 1_o
effects NNS 1_o
were VBD N
observed VBN N
. . N

CONCLUSION NNP N
Transcutaneous NNP N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNS N
point NN N
can MD N
reduce VB N
the DT N
incidence NN 1_o
of IN 1_o
PONV NNP 1_o
and CC 1_o
improves VBZ 1_o
analgesia JJ 1_o
effect NN 1_o
of IN 1_o
PCEA NNP 1_o
in IN 1_o
postoperation NN 1_o
of IN 1_o
cesarean JJ 1_o
section NN 1_o
. . 1_o

The DT N
GH NNP N
response NN N
to TO N
low-dose JJ 1_i
bolus JJ 1_i
growth NN 1_i
hormone-releasing VBG 1_i
hormone NN 1_i
( ( 1_i
GHRH NNP 1_i
( ( 1_i
1-29 JJ 1_i
) ) 1_i
NH2 NNP 1_i
) ) 1_i
is VBZ N
attenuated VBN N
in IN N
patients NNS 1_p
with IN 1_p
longstanding JJ 1_p
post-irradiation NN 1_p
GH NNP 1_p
insufficiency NN 1_p
. . 1_p

OBJECTIVE NNP N
Previous JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
post-irradiation NN N
GH NNP N
insufficiency NN N
results NNS N
from IN N
a DT N
loss NN N
of IN N
GHRH NNP N
secretion NN N
, , N
since IN N
many JJ N
patients NNS N
were VBD N
able JJ N
to TO N
release VB N
GH NNP N
following VBG N
exogenous JJ N
GHRH NNP N
stimulation NN N
. . N

However RB N
, , N
supramaximal JJ 1_i
doses NNS 1_i
of IN 1_i
GHRH NNP 1_i
were VBD N
used VBN N
and CC N
the DT N
response NN N
may MD N
decline VB N
with IN N
time NN N
after IN N
radiotherapy NN 1_i
. . 1_i

We PRP N
re-evaluated VBD N
the DT N
GHRH NNP 1_i
dose-response JJ N
curve NN N
in IN N
patients NNS 1_p
post VBP 1_p
cranial JJ 1_p
irradiation NN 1_p
and CC 1_p
in IN 1_p
controls NNS 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
controlled VBD N
study NN N
. . N

METHODS NNP N
Five CD 1_p
adult NN 1_p
male NN 1_p
long-term JJ 1_p
survivors NNS 1_p
of IN 1_p
childhood NN 1_p
brain NN 1_p
tumours NNS 1_p
( ( 1_p
median JJ 1_p
age NN 1_p
21.8 CD 1_p
years NNS 1_p
( ( 1_p
18.4-26.7 JJ 1_p
) ) 1_p
; : 1_p
13.7 CD 1_p
years NNS 1_p
( ( 1_p
11.4-15.7 JJ 1_p
) ) 1_p
post-radiotherapy NN 1_p
, , 1_p
> NNP 1_p
30Gy CD 1_p
) ) 1_p
and CC 1_p
five CD 1_p
matched VBN 1_p
controls NNS 1_p
were VBD 1_p
studied VBN 1_p
. . 1_p

An DT N
intravenous JJ N
bolus NN N
of IN N
GHRH NNP 1_i
( ( 1_i
1-29 JJ 1_i
) ) 1_i
NH NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
was VBD N
administered VBN N
in IN N
doses NNS N
at IN N
the DT N
lower JJR N
( ( N
0.05 CD N
microg/kg NN N
) ) N
and CC N
upper JJ N
( ( N
0.15 CD N
microg/kg NN N
) ) N
range NN N
of IN N
the DT N
dose-response JJ N
curves NNS N
for IN N
young JJ 1_p
males NNS 1_p
, , N
as RB N
well RB N
as IN N
the DT N
standard NN N
supramaximal NN N
dose NN N
( ( N
1 CD N
. . N

0 CD N
microg/kg NN N
) ) N
. . N

GH NNP 1_o
was VBD N
measured VBN N
before IN N
stimulation NN N
, , N
every DT N
2min CD N
for IN N
the DT N
first JJ N
hour NN N
and CC N
every DT N
5min CD N
for IN N
the DT N
second JJ N
hour NN N
. . N

All DT N
studies NNS N
were VBD N
conducted VBN N
in IN N
a DT N
random JJ N
fashion NN N
. . N

RESULTS NNP N
Significantly NNP 1_o
lower JJR 1_o
peak NN 1_o
and CC 1_o
area NN 1_o
under IN 1_o
the DT 1_o
curve NN 1_o
( ( 1_o
AUC NNP 1_o
) ) 1_o
GH NNP 1_o
concentrations NNS 1_o
occurred VBD N
in IN N
the DT N
irradiated JJ N
group NN N
using VBG N
0.15 CD N
microg/kg NN N
( ( N
median JJ N
peak NN N
Irradiated NNP N
, , N
4 CD N
. . N

5mU/l CD N
vs NN N
median NN N
Controls NNP N
, , N
37.4mU/l CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
1.0 CD N
microg/kg NN N
( ( N
median JJ N
peak NN N
Irradiated NNP N
, , N
4.8mU/l CD N
vs NN N
median NN N
Controls NNP N
, , N
15.2mU/l CD N
; : N
P NNP N
< VBD N
0 CD N
. . N

05 CD N
) ) N
GHRH NNP N
( ( N
1-29 JJ N
) ) N
NH NNP N
( ( N
2 CD N
) ) N
. . N

In IN N
irradiated JJ N
subjects NNS N
there EX N
was VBD N
an DT N
incremental JJ N
rise NN 1_o
in IN 1_o
GH NNP 1_o
output NN 1_o
with IN N
increasing VBG N
doses NNS N
of IN N
GHRH NNP 1_i
( ( 1_i
1-29 JJ 1_i
) ) 1_i
NH NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
( ( 1_i
median JJ 1_i
AUC NNP N
: : N
122mU/l.min CD N
vs NN N
179mU/l.min CD N
vs NN N
268mU/l.min CD N
; : N
P=0.007 NNP N
) ) N
reflecting VBG N
altered VBN N
pituitary JJ 1_o
sensitivity NN 1_o
and CC 1_o
reduced JJ 1_o
responsiveness NN 1_o
. . 1_o

CONCLUSION VB N
The DT N
GH NNP N
response NN N
to TO N
bolus VB N
GHRH NNP 1_i
( ( 1_i
1-29 JJ 1_i
) ) 1_i
NH NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
is VBZ N
attenuated VBN N
in IN N
adult JJ 1_p
long-term JJ 1_p
survivors NNS 1_p
of IN 1_p
childhood NN 1_p
brain NN 1_p
tumours NN 1_p
. . 1_p

This DT N
may MD N
reflect VB N
direct JJ N
pituitary JJ N
damage NN N
and/or VBD N
the DT N
loss NN N
of IN N
the DT N
tropic NN N
effects NNS N
of IN N
chronic JJ N
GHRH NNP N
deficiency NN N
. . N

Thromboprophylaxis VBN N
by IN N
low-molecular-weight JJ 1_i
heparin NN 1_i
in IN N
elective JJ 1_p
hip NN 1_p
surgery NN 1_p
. . 1_p

A DT N
placebo NN 1_i
controlled VBN N
study NN N
. . N

In IN N
a DT N
double-blind NN N
, , N
randomised VBD N
study NN N
of IN N
thromboprophylaxis NN N
in IN N
patients NNS 1_p
undergoing JJ 1_p
total JJ 1_p
hip NN 1_p
replacement NN 1_p
, , N
we PRP N
compared VBN N
a DT N
low-molecular-weight JJ 1_i
heparin NN 1_i
with IN 1_i
a DT 1_i
placebo NN 1_i
. . 1_i

Of IN N
the DT N
120 CD 1_p
patients NNS 1_p
enrolled VBD 1_p
, , 1_p
112 CD 1_p
completed VBD 1_p
the DT N
trial NN N
; : N
58 CD N
in IN N
the DT N
treatment NN N
group NN N
and CC N
54 CD N
in IN N
the DT N
placebo NN N
group NN N
. . N

Nine NNP N
( ( N
16 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
and CC N
19 CD N
( ( N
35 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN 1_i
group NN N
developed VBD N
deep RB 1_o
venous JJ 1_o
thrombosis NN 1_o
, , N
diagnosed VBN N
by IN N
the DT N
125I-fibrinogen JJ N
uptake JJ N
test NN N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

Verification NN N
was VBD N
obtained VBN N
by IN N
phlebography NN N
in IN N
86 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

Prolonged JJ N
surgery NN N
increased VBD N
the DT N
risk NN 1_o
of IN 1_o
thrombosis NN 1_o
in IN N
the DT N
placebo NN N
group NN N
but CC N
not RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
significantly RB N
more JJR N
cases NNS 1_o
of IN 1_o
deep JJ 1_o
venous JJ 1_o
thrombosis NN 1_o
in IN N
the DT N
placebo NN N
group NN N
during IN N
the DT N
first JJ N
four CD N
postoperative JJ N
days NNS N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
with IN N
respect NN N
to TO N
peroperative VB 1_o
and CC 1_o
postoperative JJ 1_o
bleeding NN 1_o
. . 1_o

Low-molecular-weight JJ 1_i
heparin NN 1_i
offers NNS N
safe JJ N
and CC N
easily RB N
administered VBN N
thromboprophylaxis NN N
in IN N
total JJ N
hip NN N
replacement NN N
. . N

Early JJ N
effects NNS N
of IN N
continuous JJ N
low-dosage JJ N
all-norgestrel NN 1_i
administered VBD N
alone RB N
or CC N
with IN N
estrogen NN N
. . N

Twenty-six JJ 1_p
postmenopausal JJ 1_p
women NNS 1_p
participated VBD N
in IN N
a DT N
double-blind JJ N
trial NN N
involving VBG N
treatment NN N
according VBG N
to TO N
a DT N
Latin NNP N
square JJ N
design NN N
with IN N
either DT N
( ( N
i NN N
) ) N
dl-norgestrel NN 1_i
alone RB 1_i
( ( N
0.075 CD N
mg/day NN N
) ) N
continuously RB N
for IN N
two CD N
cycles NNS N
, , N
( ( N
ii NN N
) ) N
estradiol-17 JJ 1_i
beta NN 1_i
alone RB 1_i
( ( N
1 CD N
mg NN N
on IN N
25 CD N
of IN N
28 CD N
days NNS N
) ) N
for IN N
two CD N
cycles NNS N
, , N
or CC N
( ( N
iii NN N
) ) N
the DT N
combined JJ 1_i
hormones NNS 1_i
for IN N
six CD N
cycles NNS N
. . N

A DT N
placebo NN 1_i
control NN 1_i
cycle NN N
followed VBD N
each DT N
hormonal JJ N
treatment NN N
. . N

Plasma NNP 1_o
triglycerides NNS 1_o
decreased VBN 1_o
by IN N
an DT N
average JJ N
22 CD N
% NN N
during IN N
treatment NN N
with IN N
either DT N
dl-norgestrel JJ 1_i
alone NN N
( ( N
123 CD N
+/- JJ N
11 CD N
vs. FW N
160 CD N
+/- JJ N
10 CD N
mg/dl NN N
, , N
n JJ N
= NN N
25 CD N
, , N
P NNP N
< NNP N
0.005 CD N
) ) N
or CC N
combination NN N
therapy NN N
( ( N
126 CD N
+/- JJ N
11 CD N
vs. FW N
162 CD N
+/- JJ N
11 CD N
, , N
n RB N
= JJ N
25 CD N
, , N
P NNP N
< NNP N
0.005 CD N
) ) N
as IN N
compared VBN N
with IN N
control NN N
. . N

Plasma NNP 1_o
total JJ 1_o
cholesterol NN 1_o
fell VBD N
by IN N
5 CD N
% NN N
during IN N
two CD N
cycles NNS N
of IN N
treatment NN N
with IN N
either DT N
dl-norgestrel JJ 1_i
alone NN N
( ( N
229 CD N
+/- JJ N
11 CD N
vs. FW N
242 CD N
+/- JJ N
10 CD N
mg/dl NN N
, , N
n JJ N
= NN N
25 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
or CC N
combination NN N
therapy NN N
( ( N
233 CD N
+/- JJ N
11 CD N
vs. FW N
246 CD N
+/- JJ N
10 CD N
, , N
n RB N
= JJ N
25 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
versus NN N
placebo NN N
. . N

During IN N
the DT N
fifth NN N
and CC N
sixth JJ N
cycles NNS N
of IN N
combination NN N
therapy NN N
94 CD N
% NN N
of IN N
cycles NNS N
were VBD N
free JJ 1_o
of IN 1_o
flushing VBG 1_o
( ( N
vs. FW N
31 CD N
% NN N
for IN N
control NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
64 CD N
% NN N
of IN N
cycles NNS N
were VBD N
free JJ 1_o
of IN 1_o
spotting VBG 1_o
not RB 1_o
requiring VBG 1_o
protection NN 1_o
( ( N
control VB N
75 CD N
% NN N
) ) N
, , N
96 CD N
% NN N
of IN N
cycles NNS N
were VBD N
free JJ 1_o
of IN 1_o
vaginal JJ 1_o
bleeding NN 1_o
( ( N
control VB N
100 CD N
% NN N
) ) N
, , N
endometrial JJ N
biopsy NN N
showed VBD N
inactive JJ 1_o
endometrium NN 1_o
in IN N
nine CD N
of IN N
the DT N
10 CD N
subjects NNS N
re-biopsied JJ N
, , N
fasting VBG 1_o
blood NN 1_o
pyruvate NN 1_o
decreased VBN 1_o
by IN N
20 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
fell VBD 1_o
by IN N
4 CD N
% NN N
compared VBN N
with IN N
control NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
whereas VBP N
glucose JJ 1_o
tolerance NN 1_o
was VBD 1_o
unchanged JJ 1_o
. . 1_o

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
vasomotor NN 1_o
flushing VBG 1_o
beginning VBG N
with IN N
the DT N
third JJ N
to TO N
fourth JJ N
cycles NNS N
of IN N
combination NN N
therapy NN N
. . N

Clinical JJ N
observation NN N
on IN N
treatment NN N
of IN N
obstinate JJ 1_p
heart NN 1_p
failure NN 1_p
by IN N
supplementing VBG 1_i
qi NN 1_i
and CC 1_i
activating VBG 1_i
blood NN 1_i
flow NN 1_i
. . 1_i

Anti-Xa JJ N
effect NN 1_o
of IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN 1_i
( ( 1_i
dalteparin NN 1_i
) ) 1_i
does VBZ N
not RB N
accumulate VB N
in IN N
extended JJ N
duration NN N
therapy NN N
for IN N
venous JJ 1_p
thromboembolism NN 1_p
in IN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

Many JJ N
patients NNS 1_p
with IN 1_p
venous JJ 1_p
thromboembolism NN 1_p
are VBP N
being VBG N
treated VBN N
with IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
for IN N
extended JJ N
periods NNS N
of IN N
time NN N
. . N

It PRP N
is VBZ N
not RB N
certain JJ N
if IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
assess VB N
anti-Xa JJ 1_o
levels NNS 1_o
for IN N
extended VBN N
treatment NN N
periods NNS N
. . N

This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
assessment NN N
of IN N
anti-Xa JJ 1_o
levels NNS 1_o
in IN N
patients NNS 1_p
on IN 1_p
long-term JJ 1_p
therapy NN 1_p
for IN 1_p
acute JJ 1_p
venous JJ 1_p
thromboembolism NN 1_p
who WP 1_p
have VBP 1_p
active JJ 1_p
cancer NN 1_p
. . 1_p

Consecutive JJ 1_p
consenting VBG 1_p
patients NNS 1_p
from IN 1_p
one CD 1_p
center NN 1_p
in IN 1_p
a DT 1_p
multicenter NN 1_p
trial NN 1_p
that WDT N
compared VBN N
6 CD N
months NNS N
of IN N
low JJ N
molecular JJ N
weight NN N
heparin NN N
with IN N
oral JJ 1_i
anticoagulant JJ 1_i
therapy NN 1_i
were VBD N
treated VBN N
with IN N
therapeutic JJ N
doses NNS N
of IN N
dalteparin NN N
( ( N
200 CD N
IU NNP N
per IN N
kilogram NN N
) ) N
subcutaneously RB N
daily JJ N
. . N

Anti-Xa JJ 1_o
levels NNS 1_o
were VBD N
assessed VBN N
at IN N
the DT N
end NN N
of IN N
weeks NNS N
1 CD N
and CC N
4,4-6 JJ N
hours NNS N
after IN N
injection NN N
of IN N
dalteparin NN N
. . N

Patients NNS N
were VBD N
followed VBN N
for IN N
bleeding NN 1_o
and CC 1_o
recurrent NN 1_o
venous JJ 1_o
thromboembolism NN 1_o
. . 1_o

There EX N
were VBD N
24 CD 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
anti-Xa JJ 1_o
levels NNS 1_o
measured VBN N
at IN N
weeks NNS N
1 CD N
and CC N
4 CD N
. . N

Two CD N
other JJ N
patients NNS N
had VBD N
week NN N
1 CD N
measurements NNS N
performed VBN N
but CC N
died VBD 1_o
before IN N
the DT N
week NN N
4 CD N
sample NN N
was VBD N
collected VBN N
due JJ N
to TO N
their PRP$ N
underlying JJ N
cancer NN N
. . N

The DT N
mean JJ 1_o
anti-Xa JJ 1_o
levels NNS 1_o
at IN N
weeks NNS N
1 CD N
and CC N
4 CD N
were VBD N
1.11 CD N
and CC N
1.03 CD N
anti-Xa JJ N
units/ml NN N
respectively RB N
( ( N
P=0.13 NNP N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
for IN N
patients NNS 1_p
with IN 1_p
active JJ 1_i
cancer NN 1_i
receiving VBG 1_i
extended VBN 1_i
duration NN 1_i
therapy NN 1_i
with IN N
low JJ N
molecular JJ N
weight NN N
heparin NN 1_i
( ( 1_i
dalteparin NN 1_i
) ) 1_i
there EX N
is VBZ N
no DT N
accumulation NN 1_o
of IN 1_o
anti-Xa JJ 1_o
effect NN 1_o
over IN N
the DT N
first JJ N
month NN N
of IN N
therapy NN N
. . N

Monitoring NN N
of IN N
anti-Xa JJ 1_o
levels NNS 1_o
in IN N
this DT N
situation NN N
is VBZ N
usually RB N
not RB N
required VBN N
. . N

A DT N
randomized JJ N
prospective NN N
controlled VBN N
trial NN N
of IN N
oral JJ N
ganciclovir NN 1_i
versus IN N
oral JJ N
valacyclovir NN 1_i
for IN N
prophylaxis NN N
of IN N
cytomegalovirus NN 1_o
disease NN 1_o
after IN N
renal JJ 1_p
transplantation NN 1_p
. . 1_p

Oral NNP N
ganciclovir NN 1_i
and CC 1_i
valacyclovir NN 1_i
reduce VB N
the DT N
incidence NN N
of IN N
cytomegalovirus NN 1_o
( ( 1_o
CMV NNP 1_o
) ) 1_o
disease NN 1_o
after IN 1_p
renal JJ 1_p
transplantation NN 1_p
( ( 1_p
RTx NNP 1_p
) ) 1_p
. . 1_p

Our PRP$ N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN 1_o
, , 1_o
costs NNS 1_o
, , 1_o
and CC 1_o
safety NN 1_o
of IN N
oral JJ N
ganciclovir NN 1_i
and CC 1_i
valacyclovir NN 1_i
in IN N
the DT N
prophylaxis NN N
of IN N
CMV NNP N
disease NN N
over IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
RTx NNP N
. . N

A NNP N
total NN 1_p
of IN 1_p
38 CD 1_p
patients NNS 1_p
was VBD 1_p
randomized VBN 1_p
to TO 1_p
3-month JJ 1_p
treatment NN 1_p
with IN 1_p
either DT 1_p
oral JJ 1_i
ganciclovir NN 1_i
( ( 1_p
1 CD 1_p
g NN 1_p
t.i.d. NN 1_p
, , N
n=14 RB 1_p
, , 1_p
GAN NNP 1_p
group NN 1_p
) ) 1_p
or CC 1_p
oral JJ 1_i
valacyclovir NN 1_i
( ( 1_p
2 CD 1_p
g NN 1_p
q.i.d. NN 1_p
, , N
n=12 RB 1_p
, , 1_p
VAL NNP 1_p
group NN 1_p
) ) 1_p
. . N

A DT N
third JJ N
group NN N
( ( N
C NNP N
, , N
n=12 NN N
) ) N
received VBD N
no DT 1_i
prophylaxis NN 1_i
. . 1_i

The DT N
patients NNS N
were VBD N
monitored VBN N
by IN N
CMV-nested JJ N
PCR NNP N
in IN N
whole JJ N
blood NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
in IN N
their PRP$ N
demographic JJ N
characteristics NNS N
, , N
immunosuppressive JJ N
protocols NNS N
, , N
or CC N
donor NN N
and CC N
recipient NN N
CMV NNP N
serology NN N
. . N

Thirty-six CD N
out IN N
of IN N
38 CD N
( ( N
94.7 CD N
% NN N
) ) N
recipients NNS N
were VBD N
CMV-seropositive JJ 1_o
. . 1_o

Over IN N
the DT N
6-month JJ N
post-RTx JJ N
period NN N
, , N
there EX N
were VBD N
13 CD N
episodes NNS N
of IN N
CMV NNP 1_o
disease NN N
in IN N
eight CD N
( ( N
66.7 CD N
% NN N
) ) N
patients NNS N
of IN N
the DT N
C NNP N
group NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
GAN NNP N
and CC N
VAL NNP N
groups NNS N
( ( N
P=0.0005 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.001 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
) ) N
. . N

The DT N
incidence NN 1_o
of IN 1_o
CMV NNP 1_o
viremia NN 1_o
was VBD N
30.8 CD N
% NN N
, , N
50.0 CD N
% NN N
, , N
and CC N
91.7 CD N
% NN N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
( ( N
P=0.004 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.07 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
; : N
P=NS NNP N
, , N
GAN NNP N
vs NNP N
VAL NNP N
) ) N
. . N

Treatment JJ 1_o
failure NN 1_o
( ( 1_o
death NN 1_o
, , 1_o
graft NN 1_o
loss NN 1_o
, , 1_o
CMV NNP 1_o
disease NN 1_o
, , 1_o
or CC 1_o
withdrawal NN 1_o
from IN 1_o
study NN 1_o
) ) 1_o
occurred VBD N
in IN N
14.3 CD N
% NN N
, , N
0 CD N
% NN N
and CC N
66.7 CD N
% NN N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
( ( N
P=0.014 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.001 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
; : N
P=NS NNP N
, , N
GAN NNP N
vs NNP N
VAL NNP N
) ) N
. . N

The DT N
average JJ 1_o
CMV-associated JJ 1_o
costs NNS 1_o
per IN 1_o
patient NN 1_o
( ( N
in IN N
2001 CD N
euros NN N
) ) N
were VBD N
2,449+/-1,178 JJ N
, , N
2,485+/-581 JJ N
, , N
and CC N
4,259+/-4,616 JJ N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
. . N

Ganciclovir NNP N
and CC N
valacyclovir NN N
were VBD N
well RB 1_o
tolerated VBN 1_o
, , N
with IN N
ganciclovir JJ N
having VBG N
had VBD N
to TO N
be VB N
withdrawn VBN N
shortly RB N
in IN N
one CD N
patient NN N
only RB N
because IN N
of IN N
thrombocytopenia NN N
. . N

In IN N
conclusion NN N
, , N
oral JJ N
ganciclovir NN N
and CC N
valacyclovir NN N
are VBP N
equally RB 1_o
safe JJ 1_o
and CC 1_o
effective JJ 1_o
in IN N
the DT N
prophylaxis NN N
of IN N
CMV NNP N
disease NN N
after IN N
RTx NNP N
. . N

Both DT N
are VBP N
cost-effective JJ 1_o
and CC N
help VB N
reduce VB N
CMV-associated JJ 1_o
costs NNS 1_o
by IN N
some DT N
40 CD N
% NN N
compared VBN N
with IN N
patients NNS N
without IN N
prophylaxis NN N
. . N

Pharmacodynamic JJ N
effects NNS N
on IN N
biochemical JJ 1_o
markers NNS 1_o
of IN 1_o
bone NN 1_o
turnover NN 1_o
and CC 1_o
pharmacokinetics NNS 1_o
of IN N
the DT N
cathepsin NN 1_i
K NNP 1_i
inhibitor NN 1_i
, , 1_i
ONO-5334 NNP 1_i
, , N
in IN N
an DT N
ascending VBG N
multiple-dose NN N
, , N
phase NN N
1 CD N
study NN N
. . N

Selective JJ N
inhibitors NNS N
of IN N
cathepsin NN N
K NNP N
, , N
which WDT N
has VBZ N
a DT N
major JJ N
role NN N
in IN N
the DT N
degradation NN N
of IN N
bone NN N
collagen NN N
, , N
are VBP N
potential JJ N
new JJ N
treatments NNS N
for IN N
osteoporosis NN N
. . N

The DT N
pharmacokinetics NNS 1_o
and CC 1_o
the DT 1_o
pharmacodynamic JJ 1_o
effects NNS 1_o
on IN 1_o
biochemical JJ 1_o
markers NNS 1_o
of IN 1_o
bone NN 1_o
turnover NN 1_o
of IN N
the DT N
new JJ N
cathepsin NN 1_i
K NNP 1_i
inhibitor NN 1_i
, , 1_i
ONO-5334 NNP 1_i
, , N
were VBD N
investigated VBN N
in IN N
a DT N
multiple JJ N
ascending NN N
dose NN N
, , N
phase NN N
1 CD N
study NN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
120 CD 1_p
healthy JJ 1_p
postmenopausal NN 1_p
women NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
and CC 1_p
doses NNS 1_i
of IN 1_i
10 CD 1_i
to TO 1_i
600 CD 1_i
mg NNS 1_i
once RB 1_i
daily JJ 1_i
and CC 1_i
50 CD 1_i
and CC 1_i
300 CD 1_i
mg NN 1_i
twice RB 1_i
daily RB 1_i
were VBD 1_i
evaluated VBN 1_i
in IN 1_i
15- JJ 1_i
and CC 1_i
28-day JJ 1_i
multiple-dosing JJ 1_i
cohorts NNS 1_i
. . 1_i

Plasma NNP N
ONO-5334 NNP N
concentration NN N
reached VBD N
steady JJ N
state NN N
within IN N
2 CD N
days NNS N
. . N

Twenty-four CD N
hours NNS N
after IN N
the DT N
last JJ N
dose NN N
in IN N
the DT N
15-day JJ N
multiple-dose JJ N
cohort NN N
, , N
100 CD N
, , N
300 CD N
, , N
and CC N
600 CD N
mg NN N
once RB N
daily RB N
reduced VBN N
urinary JJ 1_o
C-terminal JJ 1_o
telopeptide NN 1_o
of IN 1_o
type NN 1_o
I PRP 1_o
collagen VBP 1_o
by IN N
a DT N
mean NN N
( ( N
± JJ N
standard NN N
deviation NN N
) ) N
44.9 CD N
% NN N
± JJ N
13.6 CD N
% NN N
, , N
84.5 CD N
% NN N
± JJ N
4.4 CD N
% NN N
, , N
and CC N
92.5 CD N
% NN N
± JJ N
1.3 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
28-day JJ N
cohort NN N
showed VBD N
similar JJ N
effects NNS N
. . N

There EX N
were VBD N
far RB N
smaller JJR N
effects NNS 1_o
on IN 1_o
bone-specific JJ 1_o
alkaline JJ 1_o
phosphatase NN 1_o
( ( 1_o
B-ALP NNP 1_o
) ) 1_o
, , 1_o
tartrate-resistant JJ 1_o
acid NN 1_o
phosphatase NN 1_o
5b CD 1_o
( ( 1_o
TRAP5b NNP 1_o
) ) 1_o
, , 1_o
or CC 1_o
osteocalcin NN 1_o
( ( 1_o
OC NNP 1_o
) ) 1_o
( ( N
measured VBN N
after IN N
28 CD N
days NNS 1_i
) ) 1_i
. . 1_i

ONO-5334 NN 1_i
was VBD N
well RB N
tolerated VBN N
up RP N
to TO N
600 CD N
mg/d NNS N
and CC N
for IN N
up RB N
to TO N
28 CD N
days NNS N
of IN N
multiple JJ N
dosing NN N
. . N

Multiple JJ N
dosing VBG N
with IN 1_i
ONO-5334 NNP 1_i
100 CD N
mg NN N
resulted VBD N
in IN N
considerable JJ N
suppression NN 1_o
of IN 1_o
bone NN 1_o
resorption NN 1_o
markers NNS 1_o
with IN N
no DT N
appreciable JJ N
effects NNS 1_o
on IN 1_o
bone NN 1_o
formation NN 1_o
markers NNS 1_o
( ( 1_o
B-ALP NNP 1_o
, , 1_o
OC NNP 1_o
) ) 1_o
or CC 1_o
osteoclast JJ 1_o
number NN 1_o
( ( 1_o
TRAP5b NNP 1_o
) ) 1_o
. . N

Dietary NNP 1_i
lignan NN 1_i
and CC 1_i
proanthocyanidin NN 1_i
consumption NN 1_i
and CC N
colorectal JJ 1_o
adenoma NN 1_o
recurrence NN 1_o
in IN N
the DT N
Polyp NNP N
Prevention NNP N
Trial NNP N
. . N

Lignans NNPS N
and CC N
proanthocyanidins NNS N
are VBP N
plant NN N
polyphenols NNS 1_i
that WDT N
have VBP N
shown VBN N
protective JJ N
properties NNS N
against IN N
colorectal JJ 1_o
neoplasms NNS 1_o
in IN 1_p
some DT 1_p
human JJ 1_p
studies NNS 1_p
. . 1_p

Using VBG N
logistic JJ N
regression NN N
, , N
we PRP N
estimated VBD N
odds NNS N
ratios NNS N
( ( N
ORs NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
to TO N
prospectively RB N
evaluate VB N
the DT N
association NN N
between IN N
lignan NN 1_i
and CC 1_i
proanthocyanidin JJ 1_i
intake NN 1_i
, , N
estimated VBN N
from IN N
databases NNS N
linked VBN N
to TO N
a DT N
food NN N
frequency NN N
questionnaire NN N
, , N
and CC N
adenoma JJ 1_o
recurrence NN 1_o
in IN N
1,859 CD 1_p
participants NNS 1_p
of IN 1_p
the DT 1_p
Polyp NNP 1_p
Prevention NNP 1_p
Trial NNP 1_p
. . 1_p

Overall NNP N
, , N
individual NN N
or CC N
total JJ N
lignans NNS N
or CC N
proanthocyanidins NNS N
were VBD N
not RB N
associated VBN N
with IN N
colorectal JJ 1_o
adenoma NN 1_o
recurrence NN 1_o
. . 1_o

However RB N
, , N
in IN N
sex-specific JJ N
analyses NNS N
, , N
total JJ N
lignan JJ N
intake NN N
was VBD N
positively RB N
associated VBN N
with IN N
any DT N
adenoma JJ 1_o
recurrence NN 1_o
in IN N
women NNS N
( ( N
highest JJS N
vs. NN N
lowest JJS N
lignan JJ N
intake NN N
quartile NN N
OR NNP N
= VBZ N
2.07 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.22-3.52 JJ N
, , N
p JJ N
trend NN N
= VBZ N
0.004 CD N
) ) N
but CC N
not RB N
in IN N
men NNS N
( ( N
p JJ N
interaction NN N
= NNP N
0.04 CD N
) ) N
. . N

To TO N
conclude VB N
, , N
dietary JJ N
lignan NN N
and CC N
proanthocyanidin NN N
consumption NN N
were VBD N
not RB N
generally RB N
related VBN N
to TO N
colorectal JJ 1_o
adenoma JJ 1_o
recurrence NN 1_o
; : 1_o
however RB N
, , N
high JJ N
lignan NNS N
intake VBP N
may MD N
increase VB N
the DT N
risk NN 1_o
of IN 1_o
adenoma JJ 1_o
recurrence NN 1_o
in IN 1_p
women NNS 1_p
. . 1_p

The DT N
effect NN N
of IN N
recent JJ 1_p
bereavement NN 1_p
on IN N
outcomes NNS N
in IN N
a DT N
primary JJ 1_o
care NN 1_o
depression NN 1_o
intervention NN N
study NN N
. . N

OBJECTIVES NNP N
Although IN N
bereavement NN N
and CC N
depression NN N
are VBP N
both DT N
common JJ N
in IN N
older JJR N
primary JJ N
care NN N
patients NNS N
, , N
the DT N
effect NN N
of IN N
bereavement NN N
on IN N
depression NN 1_o
intervention NN N
outcomes NNS N
is VBZ N
unknown JJ N
. . N

We PRP N
examined VBD N
whether IN N
standard JJ 1_i
interventions NNS 1_i
for IN N
depression NN N
in IN N
primary JJ N
care NN N
were VBD N
as IN N
effective JJ N
for IN N
bereaved VBN 1_p
as IN 1_p
for IN 1_p
non-bereaved JJ 1_p
depressed JJ 1_p
patients NNS 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Twenty CD 1_p
community-based JJ 1_p
primary JJ 1_p
care NN 1_p
practices NNS 1_p
in IN 1_p
New NNP 1_p
York NNP 1_p
City NNP 1_p
, , 1_p
greater JJR 1_p
Philadelphia NNP 1_p
, , 1_p
and CC 1_p
Pittsburgh NNP 1_p
. . 1_p

Randomization NNP N
to TO N
either DT N
intervention NN 1_i
or CC N
usual JJ 1_i
care NN 1_i
occurred VBN 1_i
by IN 1_i
practice NN 1_i
. . 1_i

PARTICIPANTS CC 1_p
Patients NNPS 1_p
aged VBD 1_p
60 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
who WP 1_p
met VBD 1_p
criteria NNS 1_p
for IN 1_p
major JJ 1_p
depression NN 1_p
or CC 1_p
clinically RB 1_p
significant JJ 1_p
minor JJ 1_p
depression NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
599 CD 1_p
) ) 1_p
. . 1_p

Patients NNS 1_p
who WP 1_p
did VBD 1_p
not RB 1_p
complete VB 1_p
the DT 1_p
bereavement JJ 1_p
measure NN 1_p
or CC 1_p
who WP 1_p
were VBD 1_p
missing VBG 1_p
4-month JJ 1_p
data NNS 1_p
were VBD 1_p
excluded VBN 1_p
( ( 1_p
final JJ 1_p
N NNP 1_p
= NNP 1_p
417 CD 1_p
) ) 1_p
. . N

INTERVENTION NNP 1_i
Study-trained JJ 1_i
depression NN 1_i
care NN 1_i
managers NNS 1_i
offered VBD 1_i
guideline-concordant JJ 1_i
recommendations NNS 1_i
to TO 1_i
primary VB 1_i
care NN 1_i
physicians NNS 1_i
at IN 1_i
intervention NN 1_i
sites NNS 1_i
and CC 1_i
assisted VBD 1_i
patients NNS 1_i
with IN 1_i
treatment NN 1_i
adherence NN 1_i
. . 1_i

Patients NNS 1_i
who WP 1_i
did VBD 1_i
not RB 1_i
wish VB 1_i
to TO 1_i
take VB 1_i
antidepressants NNS 1_i
could MD 1_i
receive VB 1_i
interpersonal JJ 1_i
psychotherapy NN 1_i
. . N

MEASUREMENTS NNP 1_o
Bereavement NNP 1_o
was VBD N
captured VBN N
using VBG N
the DT 1_o
Louisville NNP 1_o
Older NNP 1_o
Persons NNP 1_o
Events NNP 1_o
Schedule NNP 1_o
. . 1_o

Depression NNP 1_o
severity NN 1_o
was VBD N
assessed VBN N
using VBG N
the DT 1_o
24-item JJ 1_o
Hamilton NNP 1_o
Depression NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
( ( 1_o
HDRS NNP 1_o
) ) 1_o
. . N

Outcomes CC N
at IN N
4 CD N
months NNS N
were VBD 1_o
remission NN 1_o
( ( 1_o
HDRS NNP 1_o
≤7 NNP 1_o
) ) 1_o
and CC 1_o
response NN 1_o
( ( N
HDRS NNP N
reduction NN N
≥50 CD N
% NN N
from IN N
baseline NN N
) ) N
. . N

RESULTS NNP N
Logistic JJ N
regressions NNS N
indicated VBD N
that IN N
, , N
for IN N
non-bereaved JJ N
participants NNS 1_o
, , 1_o
response NN 1_o
and CC 1_o
remission NN 1_o
were VBD N
higher JJR N
in IN N
intervention NN N
than IN N
usual JJ N
care NN N
. . N

However RB N
, , N
recently RB N
bereaved VBD N
older JJR N
adults NNS N
were VBD N
less RBR N
likely JJ N
to TO N
achieve VB 1_o
response NN 1_o
or CC 1_o
remission NN 1_o
at IN N
4 CD N
months NNS N
if IN N
treated VBN N
in IN N
the DT N
intervention NN N
condition NN N
. . N

CONCLUSIONS NNP N
Standard NNP N
depression NN N
care NN N
management NN N
appears VBZ N
to TO N
be VB N
ineffective JJ N
among IN N
recently RB N
bereaved VBN N
older JJR N
primary JJ N
care NN N
patients NNS N
. . N

Greater NNP N
attention NN N
should MD N
be VB N
paid VBN N
in IN N
primary JJ N
care NN 1_p
to TO 1_p
emotional JJ 1_p
distress NN 1_p
in IN 1_p
the DT 1_p
context NN 1_p
of IN 1_p
bereavement NN 1_p
. . N

Comparison NNP N
of IN N
diclofenac JJ 1_i
sodium NN 1_i
and CC 1_i
morphine NN 1_i
sulphate NN 1_i
for IN N
postoperative JJ 1_o
analgesia NN 1_o
after IN N
day NN N
case NN N
inguinal JJ 1_p
hernia NN 1_p
surgery NN 1_p
. . 1_p

Postoperative NNP 1_o
pain NN 1_o
may MD N
be VB N
a DT N
significant JJ N
reason NN N
for IN N
delayed JJ N
discharge NN N
from IN N
hospital NN N
, , N
increased VBN N
morbidity NN N
and CC N
reduced JJ N
patient JJ N
satisfaction NN N
with IN N
ambulatory JJ 1_p
hernia NN 1_p
surgery NN 1_p
. . 1_p

This DT N
study NN N
compared VBN N
two CD N
postoperative JJ 1_p
oral JJ 1_p
analgesic NN 1_p
protocols NNS 1_p
after IN 1_p
day NN 1_p
case NN 1_p
inguinal JJ 1_p
hernia NN 1_p
repair NN 1_p
; : 1_p
30 CD 1_i
mg NN 1_i
morphine NN 1_i
sulphate NN 1_i
( ( 1_i
MST NNP 1_i
) ) 1_i
and CC N
10 CD 1_i
mg NNS 1_i
metoclopramide RB 1_i
every DT N
8 CD N
h NN N
for IN N
48 CD N
h NN N
or CC N
75 CD 1_i
mg NNS 1_i
diclofenac JJ 1_i
twice RB N
daily RB N
for IN N
48 CD N
h. PDT N
The DT N
pain NN 1_o
reported VBD 1_o
in IN N
the DT N
MST NNP 1_i
group NN N
was VBD N
significantly RB N
greater JJR N
on IN N
both DT N
the DT N
day NN N
of IN N
operation NN N
and CC N
the DT N
first JJ N
postoperative JJ N
day NN N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
Mann-Whitney NNP N
U NNP N
test NN N
) ) N
. . N

A DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
patients NNS 1_p
taking VBG 1_p
MST NNP 1_i
complained VBD N
of IN N
nausea NN 1_o
on IN N
the DT N
day NN N
of IN N
operation NN N
and CC N
on IN N
the DT N
1st CD N
postoperative JJ N
day NN N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
chi RB N
2 CD N
) ) N
. . N

The DT N
time NN 1_o
taken VBN 1_o
to TO 1_o
walk VB 1_o
, , 1_o
dress NN 1_o
and CC 1_o
leave VBP 1_o
home NN 1_o
alone RB 1_o
were VBD N
achieved VBN N
in IN N
a DT N
significantly RB N
shorter JJR N
duration NN N
in IN N
patients NNS N
taking VBG N
diclofenac NN 1_i
. . 1_i

We PRP N
conclude VBP N
that IN N
diclofenac NN 1_i
provides VBZ N
effective JJ N
analgesia NN 1_o
, , N
has VBZ N
a DT N
more RBR N
acceptable JJ N
side-effect JJ N
profile NN N
than IN N
morphine JJ 1_i
sulphate NN 1_i
and CC N
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
after IN N
ambulatory NN N
hernia NN N
surgery NN N
. . N

[ JJ 1_i
Piribedil NNP 1_i
in IN N
arterial JJ 1_o
diseases NNS 1_o
] VBP 1_o
. . N

Intravitreal NNP N
ranibizumab VBZ 1_i
versus FW N
isovolemic JJ 1_i
hemodilution NN 1_i
in IN N
the DT N
treatment NN N
of IN N
macular JJ 1_p
edema NN 1_p
secondary JJ 1_p
to TO 1_p
central JJ 1_p
retinal JJ 1_p
vein NN 1_p
occlusion NN 1_p
: : 1_p
twelve-month JJ N
results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
. . N

PURPOSE VB N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR 1_p
, , N
investigator-initiated JJ N
trial NN N
to TO N
evaluate VB N
the DT N
12-month JJ N
effectiveness NN N
of IN N
isovolemic JJ 1_i
hemodilution NN 1_i
( ( 1_i
IH NNP 1_i
) ) 1_i
with IN N
prompt JJ N
versus NN N
deferred VBD N
intravitreal JJ N
injections NNS N
( ( N
IVI NNP N
) ) N
of IN N
ranibizumab NN 1_i
0.5 CD 1_i
mg NN 1_i
for IN N
the DT N
treatment NN N
of IN N
macular JJ 1_p
edema NN 1_p
secondary JJ 1_p
to TO 1_p
early JJ 1_p
central JJ 1_p
retinal JJ 1_p
vein NN 1_p
occlusion NN 1_p
( ( 1_p
CRVO NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Eyes NNP 1_p
with IN 1_p
macular JJ 1_p
edema NNS 1_p
due JJ 1_p
to TO 1_p
CRVO NNP 1_p
having VBG 1_p
occurred VBD 1_p
not RB 1_p
more JJR 1_p
than IN 1_p
8 CD 1_p
weeks NNS 1_p
previously RB 1_p
received VBD N
either CC N
monthly JJ N
ranibizumab NN 1_i
IVI NNP 1_i
in IN N
combination NN N
with IN N
IH NNP 1_i
( ( N
group NN N
I PRP N
, , N
n RB N
= VBZ N
28 CD N
) ) N
or CC N
IH NNP 1_i
alone RB N
( ( N
group NN N
II NNP N
, , N
n JJ N
= NNP N
30 CD N
) ) N
. . N

From IN N
month NN N
2 CD N
to TO N
12 CD N
, , N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
could MD N
be VB N
treated VBN N
with IN N
monthly JJ N
intravitreal NN N
ranibizumab NN 1_i
. . 1_i

The DT N
main JJ N
outcome NN N
variables NNS N
were VBD N
gain NN 1_o
of IN 1_o
visual JJ 1_o
acuity NN 1_o
and CC 1_o
the DT 1_o
course NN 1_o
of IN 1_o
central JJ 1_o
retinal JJ 1_o
thickness NN 1_o
as IN N
measured VBN N
with IN N
optical JJ N
coherence NN N
tomography NN N
. . N

RESULTS NNP N
At IN N
12 CD N
months NNS N
, , N
eyes NNS N
in IN N
group NN N
I PRP N
on IN N
average NN N
gained VBN N
+28.1 NNP N
( ( 1_o
±19.3 NNP 1_o
) ) 1_o
letters NNS 1_o
compared VBN N
to TO N
+25.2 VB N
( ( N
±20.9 NN N
) ) N
letters NNS N
in IN N
group NN N
II NNP N
( ( N
p JJ N
= NNP N
0.326 CD N
) ) N
. . N

This DT N
result NN N
was VBD N
achieved VBN N
with IN N
significantly RB N
fewer JJR N
injections NNS N
in IN N
group NN N
II NNP N
. . N

Additionally RB N
, , N
30 CD N
% NN N
of IN N
the DT N
eyes NNS N
in IN N
group NN N
II NNP N
did VBD N
not RB N
need VB 1_i
ranibizumab JJ 1_i
IVI NNP N
during IN N
the DT N
12 CD N
months NNS N
of IN N
the DT N
trial NN N
. . N

CONCLUSION NNP 1_i
Ranibizumab NNP 1_i
IVI NNP N
in IN N
addition NN N
to TO N
IH NNP N
proved VBD N
to TO N
be VB 1_o
highly RB 1_o
effective JJ 1_o
in IN 1_o
increasing VBG 1_o
visual JJ 1_o
acuity NN 1_o
and CC 1_o
reducing VBG 1_o
macular JJ 1_o
edema NN 1_o
secondary JJ 1_o
to TO 1_o
CRVO NNP 1_o
. . N

Initial NNP N
IH NNP N
in IN N
early JJ N
CRVO NNP N
may MD N
be VB N
a DT N
first JJ N
treatment NN N
option NN N
in IN N
patients NNS N
anxious JJ N
about IN N
IVI NNP N
. . N

The DT N
effects NNS 1_o
of IN N
prophylactic JJ 1_i
management NN 1_i
and CC 1_i
therapeutics NNS 1_i
on IN N
hypertensive JJ 1_o
disease NN 1_o
in IN 1_p
pregnancy NN 1_p
: : 1_p
preliminary JJ N
studies NNS N
. . N

A DT N
controlled JJ N
prospective JJ N
evaluation NN N
of IN N
pregnancy NN N
complicated VBN N
by IN N
chronic JJ N
hypertension NN N
is VBZ N
proposed VBN N
and CC N
preliminary JJ N
data NNS N
on IN N
population NN 1_o
selection NN 1_o
and CC 1_o
pregnancy NN 1_o
outcome NN 1_o
are VBP N
presented VBN N
. . N

Sixty-three JJ 1_p
women NNS 1_p
with IN 1_p
evidence NN 1_p
of IN 1_p
underlying VBG 1_p
hypertensive JJ 1_p
disease NN 1_p
were VBD 1_p
followed VBN 1_p
prospectively RB N
throughout IN N
pregnancy NN N
. . N

Twenty-three JJ N
patients NNS N
were VBD N
followed VBN N
in IN N
a DT N
protocol NN N
of IN N
intensified JJ N
prenatal JJ N
care NN N
and CC N
randomized JJ N
assignment NN N
of IN N
antihypertensive JJ 1_i
agents NNS 1_i
: : 1_i
placebo NN 1_i
, , 1_i
hydralazine NN 1_i
, , 1_i
or CC 1_i
methyldopa NN 1_i
. . 1_i

Forty CD 1_p
patients NNS 1_p
were VBD 1_p
followed VBN 1_p
in IN 1_p
the DT 1_p
high-risk JJ 1_p
pregnancy NN 1_p
clinics NNS 1_p
at IN 1_p
Duke NNP 1_p
University NNP 1_p
. . 1_p

The DT N
incidence NN 1_o
of IN 1_o
preeclampsia NN 1_o
in IN N
the DT N
randomized JJ N
prophylactic JJ N
antihypertensive JJ N
group NN N
was VBD N
statistically RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
nonrandomized JJ N
group NN N
( ( N
8.7 CD N
versus RB N
32.5 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
other JJ N
statistically RB N
significant JJ N
differences NNS 1_o
between IN N
the DT N
groups NNS N
. . N

The DT N
63 CD 1_p
hypertensive JJ 1_p
women NNS 1_p
had VBD N
a DT N
high JJ N
incidence NN N
of IN N
diabetes NNS 1_o
mellitus NNS 1_o
diagnosed VBD N
during IN N
pregnancy NN N
( ( N
49.2 CD N
% NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
authors NNS N
' POS N
general JJ N
obstetric JJ N
population NN N
( ( N
8.1 CD N
% NN N
) ) N
. . N

Effects NNS 1_p
of IN 1_p
brain-penetrating JJ 1_i
ACE NNP 1_i
inhibitors NNS 1_i
on IN 1_p
Alzheimer NNP 1_o
disease NN 1_o
progression NN 1_o
. . 1_o

Randomised VBN N
controlled VBD N
study NN N
of IN N
clinical JJ N
outcome NN N
following VBG N
trophic JJ 1_i
feeding VBG 1_i
. . 1_i

AIMS NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
trophic JJ 1_i
feeding VBG 1_i
on IN N
clinical JJ N
outcome NN N
in IN N
ill JJ 1_p
preterm JJ 1_p
infants NNS 1_p
. . 1_p

METHODS NNP N
A DT N
randomised VBN N
, , N
controlled VBN N
, , N
prospective JJ N
study NN N
of IN N
100 CD 1_p
preterm JJ 1_p
infants NNS 1_p
, , 1_p
weighing VBG 1_p
less JJR 1_p
than IN 1_p
1750 CD 1_p
g NN 1_p
at IN 1_p
birth NN 1_p
and CC 1_p
requiring VBG 1_p
ventilatory JJ 1_p
support NN 1_p
and CC 1_p
parenteral JJ 1_p
nutrition NN 1_p
, , N
was VBD N
performed VBN N
. . N

Group NNP N
TF NNP N
( ( N
48 CD N
infants NNS N
) ) N
received VBD N
trophic JJ 1_i
feeding VBG 1_i
from IN 1_i
day NN 1_i
3 CD 1_i
( ( 1_i
0.5-1 JJ 1_i
ml/h NN 1_i
) ) 1_i
along IN 1_i
with IN 1_i
parenteral JJ 1_i
nutrition NN 1_i
until IN N
ventilatory JJ 1_i
support NN 1_i
finished VBD N
. . N

Group NNP N
C NNP N
( ( N
52 CD N
infants NNS N
) ) N
received VBD N
parenteral JJ 1_i
nutrition NN 1_i
alone RB 1_i
. . 1_i

" JJ 1_i
Nutritive JJ 1_i
" NN 1_i
milk NN 1_i
feeding NN 1_i
was VBD N
then RB N
introduced VBN N
to TO N
both DT N
groups NNS N
. . N

Clinical JJ N
outcomes NNS N
measured VBN N
included VBD N
total JJ 1_o
energy NN 1_o
intake NN 1_o
and CC 1_o
growth NN 1_o
over IN 1_o
the DT 1_o
first JJ 1_o
six CD 1_o
postnatal JJ 1_o
weeks NNS 1_o
, , 1_o
sepsis NN 1_o
incidence NN 1_o
, , 1_o
liver NN 1_o
function NN 1_o
, , 1_o
milk NN 1_o
tolerance NN 1_o
, , 1_o
duration NN 1_o
of IN 1_o
respiratory JJ 1_o
support NN 1_o
, , 1_o
duration NN 1_o
of IN 1_o
hospital NN 1_o
stay NN 1_o
and CC 1_o
complication NN 1_o
incidence NN 1_o
. . 1_o

RESULTS JJ N
Groups NNP N
were VBD N
well RB N
matched VBN N
for IN N
birthweight NN N
, , N
gestation NN N
and CC N
CRIB NNP N
scores NNS N
. . N

Infants NNS N
in IN N
group NN N
TF NNP N
had VBD N
significantly RB N
greater JJR N
energy NN 1_o
intake NN 1_o
, , N
mean JJ N
difference NN N
41.4 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
9 CD N
, , N
73.7 CD N
) ) N
kcal/kg NN N
p=0.02 NN N
; : N
weight JJ 1_o
gain NN 1_o
, , N
130 CD N
( ( N
CI NNP N
1 CD N
, , N
250 CD N
) ) N
g NN N
p NN N
= VBZ N
0.02 CD N
; : N
head NN 1_o
circumference NN 1_o
gain NN 1_o
, , N
mean JJ N
difference NN N
0.7 CD N
( ( N
CI NNP N
0.1 CD N
, , N
1.3 CD N
) ) N
cm NN N
, , N
p NN N
= VBD N
0.04 CD N
; : N
fewer JJR N
episodes NNS 1_o
of IN 1_o
culture NN 1_o
confirmed VBN 1_o
sepsis NN 1_o
, , N
mean JJ N
difference NN N
-0.7 NNP N
( ( N
-1.3 NNP N
, , N
-0.2 NNP N
) ) N
episodes VBZ N
, , N
p VB N
= JJ N
0.04 CD N
; : N
less JJR N
parenteral JJ 1_o
nutrition NN 1_o
, , N
mean JJ N
difference NN N
-11.5 NNP N
( ( N
CI NNP N
-20 NNP N
, , N
-3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0 CD N
. . N

03 CD N
; : N
tolerated VBN 1_o
full JJ 1_o
milk NN 1_o
feeds NNS 1_o
( ( N
165 CD N
ml/kg/day NN N
) ) N
earlier RBR N
, , N
mean JJ N
difference NN N
-11.2 NNP N
( ( N
CI NNP N
-19 NNP N
, , N
-3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.03 CD N
; : N
reduced VBN N
requirement NN 1_o
for IN 1_o
supplemental JJ 1_o
oxygen NN 1_o
, , N
mean JJ N
difference NN N
-22.4 NNP N
( ( N
CI-41.5 NNP N
, , N
-3.3 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.02 CD N
; : N
and CC N
were VBD N
discharged VBN 1_o
home NN 1_o
earlier RBR N
, , N
mean JJ N
difference NN N
-22.1 NNP N
( ( N
CI NNP N
-42.1 NNP N
, , N
-2.2 NNP N
) ) N
days NNS N
, , N
p VBP N
= JJ N
0.04 CD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
relative JJ N
risk NN 1_o
of IN 1_o
any DT 1_o
complication NN 1_o
. . 1_o

CONCLUSIONS NNP N
Trophic NNP 1_i
feeding VBG 1_i
improves NNS N
clinical JJ N
outcome NN N
in IN N
ill JJ 1_p
preterm JJ 1_p
infants NNS 1_p
requiring VBG 1_p
parenteral JJ 1_i
nutrition NN 1_i
. . 1_i

Modest NNP N
antihypertensive JJ N
effect NN N
of IN N
epanolol NN 1_i
, , N
a DT N
beta NN N
1-selective JJ N
receptor NN N
blocker NN N
with IN N
beta NN N
1 CD N
agonist NN N
activity NN N
: : N
an DT N
acute NN N
and CC N
long-term JJ N
hemodynamic NN N
study NN N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
and CC N
double JJ N
crossover NN N
comparison NN N
with IN N
atenolol NN N
on IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

Beta-blockers NNS N
with IN N
less JJR N
cardiodepressive JJ N
effect NN N
than IN N
traditional JJ N
nonselective JJ N
beta NN N
( ( N
1+2 CD N
) ) N
-blocking VBG N
agents NNS N
could MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
, , N
provided VBD N
the DT N
reduction NN N
in IN N
blood NN N
pressure NN N
was VBD N
satisfactory JJ N
. . N

Epanolol NNP 1_i
, , N
a DT N
selective JJ N
beta NN N
1-receptor JJ N
blocker NN N
with IN N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
, , N
induced VBD N
a DT N
fall NN N
in IN N
intraarterial JJ 1_o
pressure NN 1_o
of IN N
8 CD N
% NN N
at IN N
rest NN N
sitting VBG N
and CC N
11 CD N
% NN N
during IN N
100 CD N
W NNP N
bicycle NN N
exercise NN N
after IN N
the DT N
first JJ N
dose NN N
of IN N
200 CD N
mg NNS N
in IN N
12 CD 1_p
patients NNS 1_p
with IN 1_p
essential JJ 1_p
hypertension NN 1_p
. . 1_p

Heart NNP 1_o
rate NN 1_o
, , 1_o
stroke VBD 1_o
index NN 1_o
, , 1_o
and CC 1_o
cardiac JJ 1_o
index NN 1_o
initially RB N
fell VBD N
by IN N
14 CD N
% NN N
, , N
11 CD N
% NN N
, , N
and CC N
23 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
total JJ 1_o
peripheral JJ 1_o
resistance NN 1_o
index NN 1_o
increased VBD N
by IN N
21 CD N
% NN N
after IN N
2 CD N
hours NNS N
, , N
and CC N
then RB N
reverted VBD N
towards IN N
the DT N
pretreatment NN N
level NN N
. . N

After IN N
10 CD N
months NNS N
of IN N
epanolol JJ 1_i
treatment NN N
( ( N
mean JJ N
300 CD N
mg/day NN N
) ) N
, , N
the DT N
reduction NN 1_o
in IN N
arterial JJ 1_o
pressure NN 1_o
was VBD N
5 CD N
% NN N
at IN N
rest NN N
and CC N
10 CD N
% NN N
during IN N
exercise NN N
. . N

Cardiac NNP 1_o
index NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
were VBD N
still RB N
reduced VBN N
14-21 CD N
% NN N
, , N
while IN N
total JJ 1_o
peripheral JJ 1_o
resistance NN 1_o
was VBD N
unchanged JJ N
or CC N
slightly RB N
increased VBN N
( ( N
2-10 CD N
% NN N
) ) N
. . N

Twenty-four JJ 1_o
hour NN 1_o
ambulatory NN 1_o
blood NN 1_o
pressure NN 1_o
was VBD N
higher JJR N
on IN N
epanolol NN 1_i
( ( N
300 CD N
mg/day NN N
) ) N
than IN N
on IN N
atenolol NN 1_i
( ( N
150 CD N
mg/day NN N
) ) N
treatment NN N
( ( N
137/97 CD N
vs. FW N
128/91 CD N
mmHg NN N
) ) N
. . N

Thus RB N
, , N
the DT N
achieved VBN 1_o
blood NN 1_o
pressure NN 1_o
reduction NN 1_o
induced VBN N
by IN N
epanolol NN 1_i
was VBD N
moderate JJ N
, , N
while IN N
other JJ N
characteristics NNS N
of IN N
beta-receptor NN N
blockade NN N
, , N
in IN N
particular JJ N
, , N
the DT N
reduction NN 1_o
of IN 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
cardiac JJ 1_o
output NN 1_o
, , N
were VBD N
maintained VBN N
. . N

This DT N
suggests VBZ N
that IN N
the DT N
compound NN N
may MD N
be VB N
useful JJ N
for IN N
other JJ N
cardiovascular JJ 1_p
disorders NNS 1_p
, , N
e.g. NN N
, , N
angina JJ 1_p
pectoris NN 1_p
in IN 1_p
patients NNS 1_p
without IN 1_p
hypertension NN 1_p
or CC 1_p
cardiac JJ 1_p
arrhythmia NN 1_p
. . 1_p

Doxymycine-cyanoacrylate NNP 1_i
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
ulcers NNS N
. . N

OBJECTIVE VB N
This DT N
study NN N
addressed VBD N
the DT N
efficacy NN N
of IN N
singularly RB N
applied VBN N
topical JJ N
doxymycine NN 1_i
in IN N
the DT N
pain NN 1_o
relief NN 1_o
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
. . N

STUDY NNP N
DESIGN NNP N
Thirty-one CD 1_p
patients NNS 1_p
with IN 1_p
recurrent JJ 1_p
aphthous JJ 1_p
lesions NNS 1_p
were VBD N
examined VBN N
and CC N
divided VBN N
randomly RB N
in IN N
two CD N
groups NNS N
. . N

Experimental JJ 1_i
group NN 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
15 CD 1_i
) ) 1_i
received VBD 1_i
a DT 1_i
topical JJ 1_i
application NN 1_i
of IN 1_i
doxymycine NN 1_i
and CC 1_i
controls NNS 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
16 CD 1_i
) ) 1_i
received VBD 1_i
calcii JJ 1_i
gluconase NN 1_i
in IN 1_i
the DT 1_i
same JJ 1_i
manner NN 1_i
. . 1_i

Medications NNS 1_i
were VBD 1_i
covered VBN 1_i
by IN 1_i
isobutyl JJ 1_i
cyanoacrylate NN 1_i
( ( 1_i
Iso-Dent JJ 1_i
) ) 1_i
. . 1_i

Application NN N
was VBD N
made VBN N
only RB N
once RB N
during IN N
the DT N
recurrent NN N
aphthous JJ N
ulcer JJ N
episode NN N
. . N

RESULTS JJ N
Patients NNS 1_p
recorded VBD 1_p
their PRP$ 1_p
pain NN 1_o
level NN 1_o
on IN 1_p
a DT 1_p
visual JJ 1_p
analog NN 1_p
scale NN 1_p
for IN 1_p
10 CD 1_p
days NNS 1_p
during IN 1_p
healing VBG 1_p
. . 1_p

Pain VB 1_o
decreased VBD N
more RBR N
rapidly RB N
in IN N
the DT N
experimental JJ N
group NN N
, , N
and CC N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
pain NN 1_o
intensity NN 1_o
was VBD N
found VBN N
from IN N
the DT N
second JJ N
to TO N
the DT N
seventh JJ N
day NN N
after IN N
application NN N
of IN N
doxymycine NN 1_i
. . 1_i

CONCLUSIONS NNP N
In IN N
recurrent NN N
aphthous JJ N
ulcers NNS N
, , N
singular JJ N
treatment NN N
of IN N
topical JJ N
doxymycine-cyanoacrylate JJ 1_i
relieves VBZ N
the DT N
pain NN 1_o
intensity NN 1_o
remarkably RB N
for IN N
6 CD N
days NNS N
after IN N
a DT N
1 CD N
day NN N
latency NN N
period NN N
. . N

Topical JJ N
doxymycine NN 1_i
treatment NN N
further JJ N
exerts VBZ N
potential JJ N
to TO N
directly RB N
prevent VB N
tissue NN N
destruction NN N
and CC N
to TO N
indirectly RB N
suppress VB N
host NN N
inflammatory JJ N
reaction NN N
. . N

A DT N
high JJ N
intake NN N
of IN N
trans NNS 1_i
fatty JJ 1_i
acids NNS 1_i
has VBZ N
little JJ N
effect NN N
on IN N
markers NNS 1_o
of IN 1_o
inflammation NN 1_o
and CC 1_o
oxidative JJ 1_o
stress NN 1_o
in IN N
humans NNS 1_p
. . 1_p

Consumption NN 1_i
of IN 1_i
industrial JJ 1_i
trans NNS 1_i
fatty JJ 1_i
acids NNS 1_i
( ( 1_i
iTFA NN 1_i
) ) 1_i
increases VBZ N
LDL NNP N
cholesterol NN N
, , N
decreases VBZ N
HDL NNP N
cholesterol NN N
, , N
and CC N
is VBZ N
strongly RB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

However RB N
, , N
changes NNS N
in IN N
circulating VBG N
cholesterol NN N
can MD N
not RB N
explain VB N
the DT N
entire JJ N
effect NN N
. . N

Therefore RB N
, , N
we PRP N
studied VBD N
whether IN N
iTFA NN 1_i
and CC N
conjugated VBD 1_i
linoleic JJ 1_i
acid NN 1_i
( ( 1_i
CLA NNP 1_i
) ) 1_i
affect VBP N
markers NNS 1_o
of IN 1_o
inflammation NN 1_o
and CC 1_o
oxidative JJ 1_o
stress NN 1_o
. . 1_o

Sixty-one CD 1_p
healthy JJ 1_p
adults NNS 1_p
consumed VBD 1_p
each DT 1_p
of IN 1_p
3 CD 1_p
diets NNS 1_i
for IN 1_p
3 CD 1_p
wk NN 1_p
, , N
in IN N
random JJ N
order NN N
. . N

Diets NNS N
were VBD N
identical JJ N
except IN N
for IN N
7 CD N
% NN N
of IN N
energy NN N
provided VBN N
by IN N
oleic JJ 1_i
acid NN 1_i
( ( 1_i
control VB 1_i
diet NN 1_i
) ) 1_i
, , 1_i
iTFA JJ 1_i
, , 1_i
or CC 1_i
CLA NNP 1_i
. . 1_i

At IN N
the DT N
end NN N
of IN N
the DT N
3 CD N
wk NN N
, , N
we PRP N
measured VBD N
plasma JJ 1_o
inflammatory JJ 1_o
markers NNS 1_o
IL-6 NNP 1_o
, , 1_o
C-reactive NNP 1_o
protein NN 1_o
, , 1_o
tumor NN 1_o
necrosis NN 1_o
factor NN 1_o
receptors NNS 1_o
I PRP 1_o
and CC 1_o
II NNP 1_o
( ( 1_o
TNF-RI NNP 1_o
and CC 1_o
-RII NNP 1_o
) ) 1_o
, , 1_o
monocyte JJ 1_o
chemotactic JJ 1_o
protein-1 NN 1_o
and CC 1_o
E-selectin NNP 1_o
, , 1_o
and CC 1_o
urinary JJ 1_o
8-iso-PGF NN 1_o
( ( 1_o
2α CD 1_o
) ) 1_o
, , 1_o
a DT 1_o
marker NN 1_o
of IN 1_o
lipid JJ 1_o
peroxidation NN 1_o
. . N

Consumption NN N
of IN 1_i
iTFA NN 1_i
caused VBD N
4 CD N
% NN N
lower JJR 1_o
TNF-RI NNP 1_o
concentrations NNS 1_o
and CC N
6 CD N
% NN N
higher JJR 1_o
E-selectin JJ 1_o
concentrations NNS 1_o
compared VBN N
with IN N
oleic JJ N
acid NN N
( ( N
control NN N
) ) N
and CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
other JJ 1_o
inflammatory JJ 1_o
markers NNS 1_o
. . N

CLA NNP N
did VBD N
not RB N
significantly RB N
affect JJ 1_o
inflammatory NN 1_o
markers NNS 1_o
. . N

The DT 1_o
urine JJ 1_o
concentration NN 1_o
of IN 1_o
8-iso-PGF JJ 1_o
( ( 1_o
2α CD 1_o
) ) 1_o
[ NN N
geometric JJ N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
] NN N
was VBD N
greater JJR N
after IN N
the DT N
iTFA NN N
[ VBZ N
0.54 CD N
( ( N
0.48 CD N
, , N
0.60 CD N
) ) N
nmol/mmol FW N
creatinine NN N
] NN N
and CC N
the DT N
CLA NNP N
[ NNP N
1.2 CD N
( ( N
1.1 CD N
, , N
1.3 CD N
) ) N
nmol/mmol FW N
creatinine NN N
] NNP N
diet VBZ N
periods NNS N
than IN N
after IN N
the DT N
control NN N
period NN N
[ VBD N
0.45 CD N
( ( N
0.41 CD N
, , N
0.50 CD N
) ) N
nmol/mmol FW N
creatinine NN N
; : N
P NNP N
< VBD N
0.05 CD N
] NN N
. . N

In IN N
conclusion NN N
, , N
high JJ N
intakes NNS N
of IN 1_i
iTFA NN 1_i
and CC 1_i
CLA NNP 1_i
did VBD N
not RB N
substantially RB N
affect JJ 1_o
plasma NN 1_o
concentrations NNS 1_o
of IN 1_o
inflammatory JJ 1_o
markers NNS 1_o
, , N
but CC N
they PRP N
increased VBD N
the DT 1_o
urine JJ 1_o
8-iso-PGF JJ 1_o
( ( 1_o
2α CD 1_o
) ) 1_o
concentration NN 1_o
. . N

However RB N
, , N
it PRP N
is VBZ N
unlikely JJ N
this DT N
plays VBZ N
a DT N
major JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT 1_i
iTFA JJ 1_i
increase NN N
the DT N
risk NN N
of IN N
CVD NNP N
. . N

However RB N
, , N
more JJR N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
understand VB N
the DT N
implications NNS N
of IN N
these DT N
findings NNS N
. . N

Preliminary JJ N
evaluation NN N
of IN N
psychoeducational JJ 1_i
support NN 1_i
interventions NNS 1_i
on IN N
quality NN 1_o
of IN 1_o
life NN 1_o
in IN N
rural JJ 1_p
breast NN 1_p
cancer NN 1_p
survivors NNS 1_p
after IN 1_p
primary JJ 1_p
treatment NN 1_p
. . 1_p

Although IN N
most JJS N
cancer NN 1_p
survivors NNS 1_p
are VBP N
at IN N
risk NN N
for IN N
being VBG N
lost VBN N
in IN N
the DT N
transition NN N
from IN N
treatment NN N
to TO N
survivorship VB N
, , N
rural JJ 1_p
breast NN 1_p
cancer NN 1_p
survivors NNS 1_p
face VBP N
special JJ N
challenges NNS N
that WDT N
might MD N
place VB N
them PRP N
at IN N
particular JJ N
risk NN N
. . N

This DT N
small-scale JJ N
preliminary JJ N
study NN N
had VBD N
2 CD N
specific JJ N
aims NNS N
: : N
( ( N
aim IN N
1 CD N
) ) N
establish VB N
the DT N
feasibility NN N
of IN N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
participation VBP N
in IN N
a DT N
longitudinal JJ 1_i
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QOL NNP 1_o
) ) 1_o
intervention NN 1_i
trial NN N
and CC N
( ( N
aim VB N
2 CD N
) ) N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
Breast NNP 1_i
Cancer NNP 1_i
Education NNP 1_i
Intervention NNP 1_i
( ( 1_i
BCEI NNP 1_i
) ) 1_i
on IN N
overall JJ 1_o
QOL NNP 1_o
. . 1_o

Fifty-three JJ 1_p
rural JJ 1_p
breast NN 1_p
cancer NN 1_p
survivors NNS 1_p
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
experimental JJ N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
or CC N
a DT N
wait-control JJ N
arm NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
. . N

Participants NNS N
in IN N
the DT N
experimental JJ N
arm NN N
received VBD N
the DT N
BCEI NNP N
consisting NN N
of IN N
3 CD 1_i
face-to-face JJ 1_i
education NN 1_i
and CC 1_i
support NN 1_i
sessions NNS 1_i
and CC N
2 CD N
face-to-face NN N
and CC N
3 CD N
telephone NN 1_i
follow-up JJ 1_i
sessions NNS 1_i
, , N
along IN N
with IN N
supplemental JJ N
written VBN N
and CC N
audiotape JJ N
materials NNS N
over IN N
a DT N
6-month JJ N
period NN N
. . N

Breast NNP 1_i
Cancer NNP 1_i
Education NNP 1_i
Intervention NNP 1_i
modules NNS 1_i
and CC 1_i
interventions NNS 1_i
are VBP N
organized VBN N
within IN N
a DT N
QOL NNP N
framework NN N
. . N

To TO N
address VB N
the DT N
possible JJ N
effects NNS N
of IN N
attention NN N
, , N
wait-control JJ N
participants NNS N
received VBD N
3 CD N
face-to-face JJ N
sessions NNS N
and CC N
3 CD N
telephone NN N
sessions NNS N
during IN N
the DT N
first JJ N
6 CD N
months NNS N
of IN N
participation NN N
in IN N
the DT N
study NN N
, , N
but CC N
not RB N
the DT N
BCEI NNP 1_i
intervention NN 1_i
. . 1_i

Research NNP N
questions NNS N
addressing VBG N
aim NN N
1 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
can MD N
rural VB N
breast NN N
cancer NN N
survivors NNS N
be VB N
recruited VBN N
into IN N
a DT N
longitudinal JJ N
intervention NN N
trial NN N
, , N
and CC N
( ( N
b NN N
) ) N
can MD N
their PRP$ N
participation NN N
be VB N
retained VBN N
. . N

Research NNP N
questions NNS N
for IN N
aim NN N
2 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
do VBP N
participants NNS N
who WP N
received VBD N
the DT N
BCEI NNP N
show NN N
improvement NN N
in IN N
overall JJ 1_o
QOL NNP 1_o
, , N
and CC N
( ( N
b NN N
) ) N
is VBZ N
the DT N
QOL NNP 1_o
improvement NN 1_o
sustained VBD N
over IN N
time NN N
. . N

Data NNS N
were VBD N
analyzed VBN N
using VBG N
repeated-measures JJ N
general JJ N
linear NN N
mixed JJ N
models NNS N
. . N

Results NNS N
demonstrated VBD N
the DT N
ability NN N
to TO N
recruit VB N
and CC N
retain VB N
53 CD N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
, , N
that IN N
the DT N
experimental JJ N
arm NN N
showed VBD N
improvement NN N
in IN N
overall JJ 1_o
QOL NNP 1_o
( ( N
P NNP N
= NNP N
.013 NNP N
) ) N
, , N
and CC N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
overall JJ 1_o
QOL NNP 1_o
between IN N
the DT N
experimental JJ N
and CC N
wait-control JJ N
groups NNS N
at IN N
both DT N
months NNS N
3 CD N
and CC N
6 CD N
. . N

Thus RB N
, , N
it PRP N
appears VBZ N
that IN N
at IN N
least JJS N
some DT N
rural JJ 1_p
breast NN 1_p
cancer NN 1_p
survivors NNS 1_p
can MD N
and CC N
will MD N
participate VB N
in IN N
a DT N
larger JJR N
trial NN N
and CC N
will MD N
maintain VB N
their PRP$ N
participation NN N
and CC N
that IN N
those DT N
that WDT N
do VBP N
participate VB N
experience NN N
significant JJ N
QOL NNP 1_o
benefit NN N
. . N

Impact NN 1_o
of IN N
early JJ 1_i
mobilization NN 1_i
on IN N
glycemic JJ 1_o
control NN 1_o
and CC N
ICU-acquired NNP 1_o
weakness NN 1_o
in IN N
critically RB 1_p
ill JJ 1_p
patients NNS 1_p
who WP 1_p
are VBP 1_p
mechanically RB 1_p
ventilated VBN 1_p
. . 1_p

BACKGROUND NNP N
ICU-acquired JJ 1_o
weakness NN 1_o
( ( 1_o
ICU-AW NNP 1_o
) ) 1_o
has VBZ N
immediate JJ N
and CC N
long-term JJ N
consequences NNS N
for IN N
critically RB 1_p
ill JJ 1_p
patients NNS 1_p
. . 1_p

Strategies NNS N
for IN N
the DT N
prevention NN N
of IN N
weakness NN N
include VBP N
modification NN N
of IN N
known VBN N
risk NN N
factors NNS N
, , N
such JJ N
as IN N
hyperglycemia NN N
and CC N
immobility NN N
. . N

Intensive JJ 1_i
insulin NN 1_i
therapy NN 1_i
( ( N
IIT NNP N
) ) N
has VBZ N
been VBN N
proposed VBN N
to TO N
prevent VB N
critical JJ N
illness NN N
polyneuropathy NN N
. . N

However RB N
, , N
the DT N
effect NN N
of IN N
insulin NN N
and CC N
early JJ N
mobilization NN N
on IN N
clinically RB N
apparent JJ N
weakness NN N
is VBZ N
not RB N
well RB N
known VBN N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
secondary JJ N
analysis NN N
of IN N
all DT 1_p
patients NNS 1_p
with IN 1_p
mechanical JJ 1_p
ventilation NN 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
104 CD 1_p
) ) 1_p
previously RB 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
randomized NN 1_p
controlled VBN 1_p
trial NN 1_p
of IN 1_p
early JJ 1_p
occupational JJ 1_p
and CC 1_p
physical JJ 1_p
therapy NN 1_p
vs JJ 1_p
conventional JJ 1_p
therapy NN 1_p
, , 1_p
which WDT 1_p
evaluated VBD 1_p
the DT 1_p
end NN 1_p
point NN 1_p
of IN 1_p
functional JJ 1_o
independence NN 1_o
. . 1_o

Every NNP 1_p
patient NN 1_p
had VBD 1_p
IIT NNP 1_p
and CC 1_p
blinded VBD 1_p
muscle NN 1_p
strength NN 1_p
testing VBG 1_p
on IN 1_p
hospital NN 1_p
discharge NN 1_p
to TO N
determine VB N
the DT N
incidence NN N
of IN N
clinically RB 1_o
apparent JJ 1_o
weakness NN 1_o
. . 1_o

The DT N
effects NNS 1_o
of IN 1_o
insulin NN 1_o
dose NN 1_o
and CC N
early JJ 1_o
mobilization NN 1_o
on IN N
the DT N
incidence NN 1_o
of IN 1_o
ICU-AW NNP 1_o
were VBD N
assessed VBN N
. . N

RESULTS VB N
On IN N
logistic JJ N
regression NN N
analyses NNS N
, , N
early JJ N
mobilization NN N
and CC N
increasing VBG N
insulin NN N
dose NN N
prevented VBD N
the DT N
incidence NN 1_o
of IN 1_o
ICU-AW NNP 1_o
( ( N
OR NNP N
, , N
0.18 CD N
, , N
P NNP N
= NNP N
.001 NNP N
; : N
OR NNP N
, , N
0.001 CD N
, , N
P NNP N
= NNP N
.011 NNP N
; : N
respectively RB N
) ) N
independent JJ N
of IN N
known VBN N
risk NN N
factors NNS N
for IN N
weakness NN N
. . N

Early JJ N
mobilization NN N
also RB N
significantly RB N
reduced VBN N
insulin NN 1_o
requirements NNS 1_o
to TO N
achieve VB 1_o
similar JJ 1_o
glycemic JJ 1_o
goals NNS 1_o
as IN N
compared VBN N
with IN N
control NN N
patients NNS N
( ( N
0.07 CD N
units/kg/d RB N
vs JJ N
0.2 CD N
units/kg/d NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
duel NN N
effect NN N
of IN N
early JJ N
mobilization NN N
in IN N
reducing VBG N
clinically RB 1_o
relevant JJ 1_o
ICU-AW NNP 1_o
and CC N
promoting VBG 1_o
euglycemia JJ 1_o
suggests VBZ N
its PRP$ N
potential JJ N
usefulness NN N
as IN N
an DT N
alternative NN N
to TO N
IIT NNP N
. . N

Dose NNP N
response NN N
effect NN N
of IN N
cyclical JJ 1_i
medroxyprogesterone NN 1_i
on IN N
blood NN 1_o
pressure NN 1_o
in IN N
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

OBJECTIVE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
with IN N
placebo PDT 1_i
the DT N
dose-response JJ N
effect NN N
of IN N
cyclical JJ N
doses NNS N
of IN N
the DT N
C21 NNP 1_i
progestogen NN 1_i
, , 1_i
medroxyprogesterone NN 1_i
acetate NN 1_i
( ( N
MPA NNP N
) ) N
on IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
when WRB N
administered VBN N
to TO N
normotensive JJ 1_p
postmenopausal NN 1_p
women NNS 1_p
receiving VBG 1_p
a DT 1_p
fixed JJ 1_p
mid-range JJ 1_p
daily JJ 1_p
dose NN 1_p
of IN 1_p
conjugated JJ 1_i
equine NN 1_i
oestrogen NN 1_i
( ( 1_i
CEE NNP 1_i
) ) 1_i
. . 1_i

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty NNP 1_p
normotensive JJ 1_p
postmenopausal NN 1_p
women NNS 1_p
( ( 1_p
median JJ 1_p
age NN 1_p
53 CD 1_p
years NNS 1_p
) ) 1_p
participated VBD N
in IN N
the DT N
study NN N
which WDT N
used VBD N
a DT N
double-blind JJ N
crossover NN N
design NN N
. . N

There EX N
were VBD N
four CD 1_i
randomised VBN 1_i
treatment NN 1_i
phases NNS 1_i
, , N
each DT N
of IN N
4 CD N
weeks NNS N
duration NN N
. . N

The DT N
four CD N
blinded VBD N
treatments NNS N
were VBD N
MPA NNP 1_i
2.5 CD 1_i
mg NN 1_i
, , 1_i
MPA NNP 1_i
5 CD 1_i
mg NN 1_i
, , 1_i
MPA NNP 1_i
10 CD 1_i
mg NN 1_i
and CC 1_i
matching VBG 1_i
placebo NN 1_i
, , 1_i
taken VBN 1_i
for IN 1_i
the DT 1_i
last JJ 1_i
14 CD 1_i
days NNS 1_i
of IN 1_i
each DT 1_i
28 CD 1_i
day NN 1_i
treatment NN 1_i
cycle NN 1_i
. . 1_i

CEE NNP N
0.625 CD N
mg NN N
was VBD N
also RB N
administered VBN N
once RB N
daily JJ N
as IN N
open JJ N
labelled VBD N
tablets NNS N
to TO N
all DT N
subjects NNS N
throughout IN N
the DT N
study NN N
. . N

Clinic NNP 1_o
BP NNP 1_o
was VBD N
measured VBN N
weekly RB N
with IN N
the DT N
mean JJ N
values NNS N
of IN N
weeks NNS N
3 CD N
and CC N
4 CD N
of IN N
each DT N
phase NN N
used VBN N
for IN N
analysis NN N
. . N

Ambulatory NNP 1_o
BP NNP 1_o
was VBD N
performed VBN N
in IN N
the DT N
final JJ N
week NN N
of IN N
each DT N
phase NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
the DT N
placebo NN N
phase NN N
, , N
end NN N
of IN N
phase NN N
clinic JJ 1_o
BP NNP 1_o
was VBD N
unchanged JJ N
by IN N
any DT N
of IN N
the DT N
progestogen NN N
treatments NNS N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
decrease NN 1_o
in IN 1_o
ambulatory JJ 1_o
daytime JJ 1_o
diastolic NN 1_o
and CC 1_o
mean JJ 1_o
arterial JJ 1_o
BP NNP 1_o
with IN N
the DT N
progestogen NN N
treatments NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
a DT N
regimen NN N
of IN N
postmenopausal NN N
hormone NN N
replacement NN N
therapy NN N
with IN N
a DT N
fixed JJ N
mid-range JJ N
daily JJ N
dose NN N
of IN N
CEE NNP 1_i
combined VBD N
with IN N
a DT N
cyclical JJ N
regimen NN N
of IN N
a DT N
C21 NNP N
progestogen NN N
spanning VBG N
the DT N
current JJ N
clinical JJ N
dose NN N
range NN N
, , N
the DT N
progestogen NN 1_i
has VBZ N
either CC N
no DT N
effect NN N
or CC N
a DT N
small JJ N
dose-dependent JJ N
reduction NN N
in IN N
clinic NN 1_o
and CC 1_o
ambulatory JJ 1_o
BPs NNP 1_o
over IN N
one CD N
treatment NN N
cycle NN N
. . N

Intraoperative JJ 1_i
microscopy NN 1_i
of IN 1_p
bile NN 1_p
-- : 1_p
is VBZ 1_p
it PRP N
useful JJ N
? . N
Direct JJ 1_i
microscopy NN 1_i
of IN 1_i
the DT 1_i
bile NN 1_i
was VBD N
performed VBN N
during IN 1_p
cholecystectomy NN 1_i
in IN 1_p
111 CD 1_p
patients NNS 1_p
in IN 1_p
an DT N
attempt NN N
to TO N
identify VB N
those DT N
with IN N
a DT N
high JJ N
risk NN N
of IN N
wound JJ N
infection NN N
. . N

Bacteria NNP N
were VBD N
identified VBN N
in IN N
23 CD 1_p
patients NNS 1_p
, , 1_p
11 CD 1_p
of IN 1_p
83 CD 1_p
undergoing JJ 1_p
cholecystectomy NN 1_i
alone RB 1_p
and CC 1_p
12 CD 1_p
of IN 1_p
28 CD 1_p
undergoing JJ 1_p
exploration NN 1_p
of IN 1_p
the DT 1_p
common JJ 1_p
bile NN 1_p
duct NN 1_p
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

These DT N
23 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
to TO 1_p
an DT 1_p
antibiotic JJ 1_i
group NN 1_i
or CC 1_p
a DT 1_p
control NN 1_p
group NN 1_p
; : 1_p
there EX N
was VBD N
one CD N
wound NN N
infection NN N
in IN N
the DT N
antibiotic JJ 1_i
group NN 1_i
and CC N
two CD N
in IN N
the DT N
control NN 1_i
group NN 1_i
. . 1_i

A DT N
total NN N
of IN N
14 CD 1_p
patients NNS 1_p
developed VBD N
wound JJ 1_o
sepsis NN 1_o
. . 1_o

Infection NN 1_o
was VBD N
more RBR N
likely JJ N
if IN N
the DT N
common JJ N
bile NN N
duct NN N
was VBD N
explored VBN N
( ( N
6 CD N
of IN N
28 CD N
) ) N
rather RB N
than IN N
cholecystectomy VB 1_i
alone JJ N
( ( N
8 CD N
of IN N
83 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
poor JJ N
correlation NN N
between IN N
microscopy NN N
and CC N
culture NN N
of IN N
the DT N
bile NN N
for IN N
bacteria NNS 1_o
and CC N
there EX N
was VBD N
no DT N
increase NN N
in IN N
sepsis NN 1_o
when WRB N
bacteria NNS N
were VBD N
observed VBN N
on IN N
microscopy NN N
. . N

We PRP N
were VBD N
not RB N
able JJ N
to TO N
identify VB N
a DT N
high JJ N
risk NN N
group NN N
of IN N
patients NNS N
by IN N
intraoperative JJ 1_p
microscopy NN 1_p
of IN 1_p
bile NN 1_p
. . 1_p

Multiple NNP 1_i
risk NN 1_i
factor NN 1_i
intervention NN 1_i
reduces VBZ N
cardiovascular JJ N
risk NN N
in IN N
hypertensive JJ 1_p
patients NNS 1_p
with IN 1_p
echolucent JJ 1_p
plaques NNS 1_p
in IN 1_p
the DT 1_p
carotid NN 1_p
artery NN 1_p
. . 1_p

OBJECTIVE NNP N
In IN N
a DT N
previously RB N
published VBN N
randomized VBN N
6-year JJ N
study NN N
we PRP N
observed VBD N
that IN N
multiple JJ 1_i
risk NN 1_i
factor NN 1_i
intervention NN 1_i
reduced VBD N
cardiovascular JJ N
risk NN N
in IN N
high-risk JJ 1_p
hypertensive JJ 1_p
men NNS 1_p
, , N
and CC N
that IN N
this DT N
effect NN N
was VBD N
confined VBN N
to TO N
patients NNS 1_p
with IN 1_p
carotid JJ 1_p
artery NN 1_p
plaques NNS 1_p
. . 1_p

Hypothetically RB N
, , N
the DT N
underlying VBG N
mechanism NN N
might MD N
have VB N
been VBN N
a DT N
stabilization NN N
of IN N
echolucent NN N
, , N
instable JJ N
, , N
rupture-prone JJ N
plaques NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
plaque NN 1_o
characteristics NNS 1_o
by IN N
B-mode NNP 1_i
ultrasound NN 1_i
in IN N
the DT N
previous JJ N
intervention NN N
study NN N
, , N
and CC N
also RB N
to TO N
investigate VB N
the DT N
relationship NN N
between IN N
plaque NN 1_o
characteristics NNS 1_o
at IN N
baseline NN N
and CC N
cardiovascular JJ 1_o
events NNS 1_o
during IN N
the DT N
6-year JJ N
follow-up NN N
in IN N
the DT N
two CD N
randomization NN N
groups NNS N
. . N

METHODS NNP N
High NNP 1_i
resolution NN 1_i
B-mode NNP 1_i
ultrasound NN 1_i
was VBD N
used VBN N
to TO N
characterize VB 1_o
plaque JJ 1_o
echogenicity NN 1_o
in IN N
four CD N
subgroups NNS N
- : N
dominantly RB N
echolucent NN N
, , N
substantially RB N
echolucent JJ N
, , N
dominantly RB N
echogenic JJ N
, , N
and CC N
uniformly RB N
echogenic JJ N
. . N

RESULTS NNP N
In IN N
the DT N
usual JJ 1_i
care NN 1_i
group NN 1_i
17 CD 1_p
of IN 1_p
32 CD 1_p
( ( 1_p
53 CD 1_p
% NN 1_p
) ) 1_p
patients NNS 1_p
with IN 1_p
echolucent JJ 1_o
plaques NNS 1_o
at IN 1_p
baseline NN 1_p
suffered VBN N
from IN N
a DT N
combined VBN N
end-point NN N
( ( N
any DT N
death NN 1_o
or CC 1_o
nonfatal JJ 1_o
myocardial JJ 1_o
infarction NN 1_o
or CC 1_o
nonfatal JJ 1_o
stroke NN 1_o
) ) 1_o
during IN N
follow-up JJ N
compared VBN N
with IN N
seven CD N
of IN N
28 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
intervention NN 1_i
group NN 1_i
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

The DT N
corresponding JJ 1_o
numbers NNS 1_o
in IN N
patients NNS N
with IN N
echogenic JJ 1_o
plaques NNS 1_o
were VBD N
n JJ N
= JJ N
4/13 CD N
( ( N
31 CD N
% NN N
) ) N
and CC N
n JJ N
= NN N
4/17 CD N
( ( N
24 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
NS NNP N
) ) N
. . N

In IN N
the DT N
usual JJ 1_i
care NN 1_i
group NN 1_i
11 CD N
of IN N
33 CD N
( ( N
33 CD N
% NN N
) ) N
patients NNS N
with IN N
no DT N
plaques NNS N
suffered VBD N
from IN N
a DT N
combined JJ N
end-point NN N
during IN N
follow-up JJ N
compared VBN N
with IN N
11 CD N
of IN N
30 CD N
( ( N
37 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN 1_i
group NN 1_i
. . 1_i

CONCLUSION NNP N
Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
beneficial JJ 1_o
effect NN 1_o
of IN N
the DT N
multiple NN 1_i
risk NN 1_i
intervention NN 1_i
programme NN 1_i
was VBD N
confined VBN N
to TO N
those DT N
patients NNS N
with IN N
echolucent JJ N
plaques NNS N
. . N

The DT N
data NNS N
have VBP N
to TO N
be VB N
confirmed VBN N
with IN N
a DT N
large-scale JJ N
trial NN N
. . N

Randomized NNP N
comparison NN N
of IN N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
zotarolimus-eluting JJ 1_i
stents NNS 1_i
vs. IN N
sirolimus-eluting JJ 1_i
stents NNS 1_i
for IN N
percutaneous JJ 1_p
coronary JJ 1_p
intervention NN 1_p
in IN 1_p
chronic JJ 1_p
total JJ 1_p
occlusion NN 1_p
-- : 1_p
CAtholic NNP 1_p
Total NNP 1_p
Occlusion NNP 1_p
Study NNP 1_p
( ( 1_p
CATOS NNP 1_p
) ) 1_p
trial NN 1_p
. . 1_p

BACKGROUND NNP N
Limited NNP N
data NNS N
are VBP N
available JJ N
regarding VBG N
the DT N
direct JJ N
comparison NN N
of IN N
angiographic JJ N
and CC N
clinical JJ N
outcomes NNS N
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
with IN N
drug-eluting JJ 1_i
stents NNS 1_i
( ( N
DESs NNP N
) ) N
for IN N
chronic JJ 1_p
total JJ 1_p
occlusion NN 1_p
( ( 1_p
CTO NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
a DT N
zotarolimus-eluting JJ 1_i
stent NN 1_i
( ( 1_i
ZES NNP 1_i
; : 1_i
Endeavor NNP 1_i
Sprint® NNP 1_i
, , N
n=80 RB N
) ) N
to TO N
a DT 1_i
sirolimus-eluting JJ 1_i
stent NN 1_i
( ( 1_i
SES NNP 1_i
; : 1_i
Cypher® NNP 1_i
, , N
n=80 NN N
) ) N
in IN 1_p
patients NNS 1_p
with IN 1_p
CTO NNP 1_p
lesion NN 1_p
with IN 1_p
a DT 1_p
reference NN 1_p
vessel NN 1_p
diameter NN 1_p
≥ VBD 1_p
2.5mm CD 1_p
. . N

The DT N
primary JJ N
endpoint NN N
was VBD 1_o
in-segment JJ 1_o
binary JJ 1_o
restenosis NN 1_o
rate NN 1_o
at IN N
9-month JJ N
angiographic JJ N
follow-up NN N
. . N

Key NNP N
secondary JJ N
endpoints NNS N
included VBD 1_o
target NN 1_o
vessel NN 1_o
failure NN 1_o
( ( 1_o
TVF NNP 1_o
; : 1_o
including VBG 1_o
cardiac JJ 1_o
death NN 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
and CC 1_o
target VB 1_o
vessel JJ 1_o
revascularization NN 1_o
) ) 1_o
and CC 1_o
Academic NNP 1_o
Research NNP 1_o
Consortium-defined NNP 1_o
definite/probable JJ 1_o
stent NN 1_o
thrombosis NN 1_o
( ( 1_o
ST NNP 1_o
) ) 1_o
within IN N
12 CD N
months NNS N
. . N

The DT N
ZES NNP N
was VBD N
non-inferior JJ N
to TO N
the DT N
SES NNP N
with IN N
respect NN N
to TO N
the DT N
primary JJ N
endpoint NN 1_o
, , N
which WDT N
occurred VBD N
in IN N
14.1 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
6.0-22.2 JJ N
) ) N
and CC N
in IN N
13.7 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
5.8-21.6 JJ N
) ) N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
non-inferiority JJ N
margin NN N
, , N
15.0 CD N
% NN N
; : N
P NNP N
for IN N
non-inferiority JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group JJ N
differences NNS N
in IN N
the DT 1_o
rate NN 1_o
of IN 1_o
TVF NNP N
( ( N
10.0 CD N
% NN N
vs. FW N
17.5 CD N
% NN N
; : N
P=0.168 NNP N
) ) N
nor CC N
in IN N
the DT N
rate NN N
of IN N
ST NNP N
( ( N
0.0 CD N
% NN N
vs. FW N
1.3 CD N
% NN N
; : N
P=0.316 NNP N
) ) N
during IN N
the DT N
12-month JJ N
clinical JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
and CC N
safety NN N
of IN N
ZES NNP N
are VBP N
similar JJ N
to TO N
those DT N
of IN N
SES NNP N
and CC N
therefore VB N
it PRP N
is VBZ N
a DT N
good JJ N
treatment NN N
option NN 1_p
in IN 1_p
patients NNS 1_p
undergoing VBG 1_p
PCI NNP 1_p
for IN 1_p
CTO NNP 1_p
with IN 1_p
DESs NNP 1_p
. . N

A DT N
randomized JJ N
comparison NN N
of IN N
the DT N
Endeavor NNP 1_i
zotarolimus-eluting JJ 1_i
stent NN 1_i
versus IN 1_i
the DT 1_i
TAXUS NNP 1_i
paclitaxel-eluting JJ 1_i
stent NN 1_i
in IN N
de FW N
novo FW N
native JJ N
coronary JJ N
lesions NNS N
12-month JJ N
outcomes NNS N
from IN N
the DT N
ENDEAVOR NNP N
IV NNP N
trial NN N
. . N

OBJECTIVES CC N
The DT N
ENDEAVOR NNP N
IV NNP N
( ( N
Randomized NNP N
Comparison NNP N
of IN N
Zotarolimus-Eluting NNP 1_i
and CC N
Paclitaxel-Eluting NNP 1_i
Stents NNP 1_i
in IN N
Patients NNP N
with IN N
Coronary NNP N
Artery NNP N
Disease NNP N
) ) N
trial NN N
evaluated VBD N
the DT N
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
the DT N
zotarolimus-eluting JJ 1_i
stent NN 1_i
( ( 1_i
ZES NNP 1_i
) ) 1_i
compared VBN 1_i
with IN 1_i
the DT 1_i
paclitaxel-eluting JJ 1_i
stent NN 1_i
( ( 1_i
PES NNP 1_i
) ) 1_i
. . N

BACKGROUND NNP N
First-generation NNP N
drug-eluting NN N
stents NNS N
have VBP N
reduced VBN N
angiographic JJ N
and CC N
clinical JJ N
restenosis NN N
, , N
but CC N
long-term JJ N
safety NN N
remains VBZ N
controversial JJ N
. . N

A DT N
second-generation JJ 1_i
drug-eluting JJ 1_i
stent NN 1_i
, , N
which WDT N
delivers VBZ N
zotarolimus NN 1_i
, , N
a DT N
potent JJ N
antiproliferative JJ N
agent NN N
, , N
via IN N
a DT N
biocompatible JJ N
phosphorylcholine NN N
polymer NN N
on IN N
a DT N
cobalt JJ N
alloy NN N
thin-strut JJ N
stent NN N
has VBZ N
shown VBN N
promising JJ N
experimental JJ N
and CC N
early JJ N
clinical JJ N
results NNS N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
( ( N
1:1 CD N
) ) N
, , N
single-blind JJ N
, , N
controlled JJ N
trial NN N
comparing VBG N
outcomes NNS N
of IN N
patients NNS 1_p
with IN 1_p
single JJ 1_p
de FW 1_p
novo FW 1_p
coronary JJ 1_p
lesions NNS 1_p
treated VBN 1_p
with IN 1_p
ZES NNP 1_p
or CC 1_p
PES NNP 1_p
. . 1_p

The DT N
primary JJ 1_o
end NN 1_o
point NN 1_o
was VBD 1_o
noninferiority NN 1_o
of IN 1_o
9-month JJ 1_o
target NN 1_o
vessel JJ 1_o
failure NN 1_o
defined VBD 1_o
as IN 1_o
cardiac JJ 1_o
death NN 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
or CC 1_o
target VB 1_o
vessel JJ 1_o
revascularization NN 1_o
. . 1_o

RESULTS NNP N
Among IN N
a DT N
total NN N
of IN N
1,548 CD 1_p
patients NNS 1_p
assigned VBN 1_p
to TO 1_p
ZES NNP 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
773 CD 1_p
) ) 1_p
or CC 1_p
PES NNP 1_p
( ( N
n JJ N
= NNP N
775 CD N
) ) N
, , N
at IN N
9 CD N
months NNS N
, , N
ZES NNP N
was VBD N
noninferior JJ N
to TO N
PES VB N
with IN N
rates NNS N
of IN N
target NN 1_o
vessel JJ 1_o
failure NN 1_o
6.6 CD N
% NN N
versus IN N
7.1 CD N
% NN N
, , N
respectively RB N
( ( N
p NN N
( ( N
noninferiority NN N
) ) N
< NN N
or CC N
= VB N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
periprocedural JJ 1_o
myocardial JJ 1_o
infarctions NNS 1_o
with IN N
ZES NNP 1_i
( ( N
0.5 CD N
% NN N
vs. FW N
2.2 CD N
% NN N
; : N
p CC N
= VB N
0.007 CD N
) ) N
, , N
whereas VBP N
at IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
rates NNS N
of IN N
cardiac JJ 1_o
death NN 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
target NN 1_o
vessel NN 1_o
revascularization NN 1_o
, , 1_o
or CC 1_o
stent JJ 1_o
thrombosis NN 1_o
. . 1_o

Although IN N
incidence NN N
of IN N
8-month JJ N
binary JJ 1_o
angiographic JJ 1_o
in-segment JJ 1_o
restenosis NN 1_o
was VBD N
higher RBR N
in IN N
patients NNS N
treated VBN N
with IN N
ZES NNP 1_i
versus NN N
PES NNP N
( ( N
15.3 CD N
% NN N
vs. FW N
10.4 CD N
% NN N
; : N
p CC N
= VB N
0.284 CD N
) ) N
, , N
rates NNS N
of IN N
12-month JJ N
target NN 1_o
lesion NN 1_o
revascularization NN 1_o
were VBD N
similar JJ N
( ( N
4.5 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.228 CD N
) ) N
, , N
especially RB N
in IN N
patients NNS N
without IN N
planned JJ N
angiographic JJ N
follow-up NN N
( ( N
3.6 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.756 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
demonstrate VBP N
that IN N
ZES NNP 1_i
has VBZ N
similar JJ N
clinical JJ N
safety NN N
and CC N
efficacy NN N
compared VBN N
with IN N
PES NNP 1_i
in IN N
simple JJ N
and CC N
medium JJ N
complexity NN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

( ( N
ENDEAVOR NNP N
IV NNP N
Clinical NNP N
Trial NNP N
; : N
NCT00217269 NNP N
) ) N
. . N

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ 1_i
enzyme NN 1_i
inhibitor NN 1_i
imidapril NN 1_i
on IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

This DT N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
early JJ N
treatment NN N
with IN N
angiotensin-converting JJ 1_i
enzyme NN 1_i
( ( 1_i
ACE NNP 1_i
) ) 1_i
inhibitors NNS 1_i
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
is VBZ N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ 1_o
function NN 1_o
, , N
as RB N
well RB N
as IN N
left VBN 1_o
ventricular JJ 1_o
function NN 1_o
. . 1_o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS N
of IN N
plasma NN 1_o
plasminogen NN 1_o
activator NN 1_o
inhibitor NN 1_o
( ( 1_o
PAI NNP 1_o
) ) 1_o
activity NN 1_o
and CC N
serum JJ 1_o
ACE NNP 1_o
activity NN 1_o
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD 1_p
patients NNS 1_p
with IN 1_p
AMI NNP 1_p
within IN 1_p
12 CD 1_p
hours NNS 1_p
after IN 1_p
the DT 1_p
onset NN 1_p
of IN 1_p
the DT 1_p
symptom NN 1_p
and CC 1_p
who WP 1_p
randomly VBP 1_p
received VBN 1_p
early JJ 1_p
treatment NN 1_p
with IN 1_p
either CC 1_p
the DT 1_p
ACE NNP 1_i
inhibitor NN 1_i
imidapril NN 1_i
or CC 1_i
a DT 1_i
placebo NN 1_i
( ( 1_p
20 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
imidapril NN 1_p
group NN 1_p
and CC 1_p
20 CD 1_p
in IN 1_p
the DT 1_p
placebo NN 1_p
group NN 1_p
) ) 1_p
. . 1_p

The DT N
levels NNS 1_o
of IN 1_o
serum JJ 1_o
ACE NNP 1_o
activity NN 1_o
in IN N
the DT N
imidapril NN 1_i
group NN N
decreased VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
8 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN 1_i
, , N
and CC N
the DT N
levels NNS N
24 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
3.6 CD N
+/- JJ N
0.6 CD N
IU/L NNP N
vs VBD N
7.4 CD N
+/- JJ N
0.8 CD N
IU/L NNP N
; : N
p VBZ N
< $ N
0.001 CD N
) ) N
. . N

The DT N
plasma JJ 1_o
PAI NNP 1_o
activity NN 1_o
increased VBD N
gradually RB N
to TO N
peak VB N
levels NNS N
16 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN N
and CC N
placebo NN N
. . N

The DT N
levels NNS N
in IN N
the DT N
placebo NN N
group NN N
decreased VBD N
gradually RB N
but CC N
remained VBD N
high JJ N
during IN N
the DT N
study NN N
period NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS 1_o
of IN 1_o
PAI NNP 1_o
activity NN 1_o
in IN N
the DT N
imidapril NN 1_i
group NN N
decreased VBD N
rapidly RB N
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
. . N

The DT N
levels NNS 1_o
of IN 1_o
left JJ 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN N
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
imidapril NN 1_i
, , N
an DT N
ACE NNP N
inhibitor NN N
, , N
might MD N
be VB N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ 1_o
function NN 1_o
and CC N
left VBD 1_o
ventricular JJ 1_o
function NN 1_o
in IN N
the DT N
acute JJ N
phase NN N
of IN N
myocardial JJ N
infarction NN N
. . N

[ JJ N
Initial NNP N
nuclear JJ 1_i
magnetic JJ 1_i
resonance NN 1_i
tomography NN 1_i
results NNS N
of IN N
the DT N
treatment NN 1_p
course NN 1_p
of IN 1_p
avascular JJ 1_p
femur NNS 1_p
head VBP 1_p
necrosis NN 1_p
after IN 1_p
femoral JJ 1_p
core NN 1_p
decompression NN 1_p
] NNP 1_p
. . 1_p

The DT N
vascular JJ 1_p
femoral JJ 1_p
head NN 1_p
necrosis NN 1_p
is VBZ 1_p
a DT 1_p
serious JJ 1_p
illness NN 1_p
, , 1_p
especially RB 1_p
when WRB 1_p
appearing VBG 1_p
in IN 1_p
patients NNS 1_p
aged VBD 1_p
30 CD 1_p
to TO 1_p
50 CD 1_p
years NNS 1_p
. . 1_p

Many JJ N
etiologic JJ N
factors NNS N
cause VBP N
a DT N
femoral JJ N
head NN N
necrosis NN N
such JJ N
as IN N
, , N
for IN N
example NN N
, , N
high-dose JJ 1_p
steroids NNS 1_p
, , 1_p
abuse NN 1_p
of IN 1_p
alcohol NN 1_p
, , 1_p
defect NN 1_p
of IN 1_p
bone NN 1_p
marrow NN 1_p
and CC 1_p
trauma NN 1_p
of IN 1_p
the DT 1_p
hip NN 1_p
. . 1_p

Often VB N
the DT N
X-ray JJ N
photograph NN N
leads VBZ N
to TO N
the DT N
diagnosis NN N
in IN N
the DT N
second JJ N
stage NN N
( ( N
ARCO NNP N
1992 CD N
) ) N
or CC N
in IN N
the DT N
third JJ N
stage NN N
, , N
when WRB N
the DT N
femoral JJ N
head NN N
has VBZ N
begun VBN N
to TO N
collapse VB N
. . N

The DT N
stage NN N
IIc NNP N
and CC N
III NNP N
shows VBZ N
an DT N
evident JJ N
enhancement NN N
in IN N
contrast NN N
media NNS N
in IN N
MRI NNP 1_i
. . 1_i

Contrast NNP N
enhancement NN N
is VBZ N
demonstrated VBN N
by IN N
STIR NNP N
, , N
FATSAT NNP N
, , N
T1-weighted NNP N
and CC N
dynamic JJ N
screening NN N
sequence NN N
. . N

The DT N
characteristics NNS N
of IN N
the DT N
contrast NN N
media NNS N
enhancement VBP N
argue NN N
for IN N
an DT N
active JJ N
concomitant NN N
process NN N
of IN N
destruction NN N
and CC N
regeneration NN N
. . N

This DT N
stage NN N
has VBZ N
the DT N
best JJS N
chances NNS N
for IN N
a DT N
drug NN N
or CC N
a DT N
surgical JJ N
therapy NN N
. . N

The DT N
evaluation NN N
of IN N
the DT N
signal JJ N
intensity NN N
by IN N
the DT N
dynamic JJ 1_o
screening NN 1_o
sequence NN 1_o
is VBZ N
considered VBN N
as IN N
an DT N
objective JJ N
contribution NN N
for IN N
the DT N
staging NN 1_o
of IN 1_o
the DT 1_o
femoral JJ 1_o
head NN 1_o
necrosis NN 1_o
. . 1_o

This DT N
enables VBZ N
one CD N
to TO N
differentiate VB N
between IN 1_p
the DT 1_p
curable JJ 1_o
stage NN 1_o
IIc NNP 1_o
and CC 1_p
the DT 1_p
stage NN 1_o
III NNP 1_o
, , 1_p
showing VBG 1_p
the DT 1_p
beginning NN 1_p
of IN 1_p
breakdown NN 1_o
of IN 1_o
the DT 1_o
femoral JJ 1_o
head NN 1_o
. . 1_o

Inhibition NN N
of IN N
PCSK9 NNP N
with IN N
evolocumab NN 1_i
in IN N
homozygous JJ 1_p
familial JJ 1_p
hypercholesterolaemia NN 1_p
( ( N
TESLA NNP N
Part NNP N
B NNP N
) ) N
: : N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

BACKGROUND NNP N
Homozygous NNP 1_p
familial JJ 1_p
hypercholesterolaemia NN 1_p
is VBZ N
a DT N
rare JJ N
, , N
serious JJ N
disorder NN N
caused VBN N
by IN N
very RB N
low JJ N
or CC N
absent JJ N
plasma JJ N
clearance NN N
of IN N
LDL NNP N
, , N
substantially RB N
raised VBN N
LDL NNP N
cholesterol NN N
, , N
and CC N
accelerated VBD 1_o
development NN 1_o
of IN 1_o
cardiovascular JJ 1_o
disease NN 1_o
. . 1_o

Conventional JJ N
lipid-lowering JJ N
treatments NNS N
are VBP N
modestly RB N
effective JJ N
. . N

Evolocumab NNP 1_i
, , N
a DT N
monoclonal JJ 1_i
antibody NN 1_i
to TO N
proprotein VB 1_i
convertase NN 1_i
subtilisin/kexin NN 1_i
type NN 1_i
9 CD 1_i
( ( N
PCSK9 NNP N
) ) N
, , N
reduced VBD N
LDL NNP 1_o
cholesterol NN 1_o
by IN N
16 CD N
% NN N
in IN N
a DT N
pilot NN N
study NN N
. . N

We PRP N
now RB N
report VBP N
results NNS N
with IN N
evolocumab NN 1_i
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
phase NN N
3 CD N
trial NN N
. . N

METHODS NNP N
This DT N
randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
phase NN N
3 CD N
trial NN N
was VBD N
undertaken VBN N
at IN N
17 CD N
sites NNS N
in IN N
ten JJ 1_p
countries NNS 1_p
in IN 1_p
North NNP 1_p
America NNP 1_p
, , 1_p
Europe NNP 1_p
, , 1_p
the DT 1_p
Middle NNP 1_p
East NNP 1_p
, , 1_p
and CC 1_p
South NNP 1_p
Africa NNP 1_p
. . 1_p

50 CD 1_p
eligible JJ 1_p
patients NNS 1_p
( ( 1_p
aged VBN 1_p
≥12 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
homozygous JJ 1_p
familial JJ 1_p
hypercholesterolaemia NN 1_p
, , 1_p
on IN 1_i
stable JJ 1_i
lipid-regulating JJ 1_i
therapy NN 1_i
for IN 1_p
at IN 1_p
least JJS 1_p
4 CD 1_p
weeks NNS 1_p
, , 1_p
and CC 1_p
not RB 1_p
receiving VBG 1_p
lipoprotein JJ 1_p
apheresis NN 1_p
, , 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
by IN 1_p
a DT 1_p
computer-generated JJ 1_p
randomisation NN 1_p
sequence NN 1_p
in IN 1_p
a DT 1_p
2:1 CD 1_p
ratio NN 1_p
to TO 1_p
receive VB 1_i
subcutaneous JJ 1_i
evolocumab NNS 1_i
420 CD 1_i
mg NN 1_i
or CC 1_i
placebo NN 1_i
every DT 1_p
4 CD 1_p
weeks NNS 1_p
for IN 1_p
12 CD 1_p
weeks NNS 1_p
. . N

Randomisation NN N
was VBD N
stratified VBN N
by IN N
LDL NNP N
cholesterol NN N
at IN N
screening VBG N
( ( N
< JJ N
11 CD N
mmol/L NN N
or CC N
≥11 VB N
mmol/L NN N
) ) N
and CC N
implemented VBN N
by IN 1_i
a DT 1_i
computerised JJ 1_i
interactive JJ 1_i
voice-response NN 1_i
system NN 1_i
. . 1_p

Patients NNS 1_p
, , 1_p
study NN 1_p
personnel NNS 1_p
, , 1_p
and CC 1_p
the DT 1_p
funder NN 1_p
were VBD 1_p
masked VBN 1_p
to TO 1_p
treatment NN 1_p
and CC 1_p
to TO 1_p
the DT 1_p
efficacy NN 1_p
results NNS 1_p
by IN 1_p
the DT 1_p
central JJ 1_p
laboratory NN 1_p
not RB 1_p
returning VBG 1_p
LDL NNP 1_p
cholesterol NN 1_p
or CC 1_p
any DT 1_p
lipid JJ 1_p
results NNS 1_p
to TO 1_p
the DT 1_p
clinical JJ 1_p
sites NNS 1_p
after IN 1_p
the DT 1_p
baseline NN 1_p
visit NN 1_p
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
percentage NN N
change NN 1_o
in IN 1_o
ultracentrifugation NN 1_o
LDL NNP 1_o
cholesterol NN 1_o
from IN N
baseline NN N
at IN N
week NN N
12 CD N
compared VBN N
with IN N
placebo NN N
, , N
analysed VBN N
by IN N
intention-to-treat NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01588496 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT 1_p
50 CD 1_p
eligible JJ 1_p
patients NNS 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
the DT 1_p
two CD 1_p
treatment NN 1_p
groups NNS 1_p
, , 1_p
49 CD 1_p
actually RB 1_p
received VBD 1_p
the DT 1_p
study NN 1_p
drug NN 1_p
and CC 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
( ( 1_p
16 CD 1_p
in IN 1_p
the DT 1_i
placebo NN 1_i
group NN 1_p
and CC 1_p
33 CD 1_p
in IN 1_p
the DT 1_i
evolocumab NN 1_i
group NN 1_p
) ) 1_p
. . N

Compared VBN N
with IN 1_i
placebo NN 1_i
, , 1_i
evolocumab VBP 1_i
significantly RB N
reduced VBN 1_o
ultracentrifugation NN 1_o
LDL NNP 1_o
cholesterol NN 1_o
at IN N
12 CD N
weeks NNS N
by IN N
30·9 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-43·9 NNP N
% NN N
to TO N
-18·0 CD N
% NN N
; : N
p CC 1_o
< VB 1_o
0·0001 CD 1_o
) ) 1_o
. . 1_o

Treatment-emergent JJ 1_o
adverse JJ 1_o
events NNS N
occurred VBD N
in IN N
ten NN N
( ( N
63 CD N
% NN N
) ) N
of IN N
16 CD N
patients NNS 1_i
in IN 1_i
the DT 1_i
placebo NN N
group NN N
and CC N
12 CD N
( ( N
36 CD N
% NN N
) ) N
of IN N
33 CD 1_i
in IN 1_i
the DT 1_i
evolocumab NN 1_i
group NN N
. . N

No DT N
serious JJ N
clinical JJ N
or CC N
laboratory JJ N
adverse JJ N
events NNS N
occurred VBD N
, , N
and CC 1_o
no DT 1_o
anti-evolocumab JJ 1_o
antibody NN 1_o
development NN 1_o
was VBD N
detected VBN N
during IN N
the DT N
study NN N
. . N

INTERPRETATION NNP 1_p
In IN 1_p
patients NNS 1_p
with IN 1_p
homozygous JJ 1_p
familial JJ 1_p
hypercholesterolaemia NN 1_p
receiving VBG N
stable JJ N
background IN N
lipid-lowering JJ N
treatment NN N
and CC N
not RB N
on IN N
apheresis NN 1_i
, , 1_i
evolocumab VBZ 1_i
420 CD N
mg NN N
administered VBN N
every DT N
4 CD N
weeks NNS N
was VBD 1_o
well RB 1_o
tolerated VBN 1_o
and CC N
significantly RB N
reduced VBN 1_o
LDL NNP 1_o
cholesterol NN 1_o
compared VBN 1_i
with IN 1_i
placebo NN N
. . N

FUNDING NNP N
Amgen NNP N
Inc NNP N
. . N

Hemostatic JJ 1_o
function NN 1_o
of IN N
aspirin-treated JJ 1_i
platelets NNS N
vulnerable JJ N
to TO N
cardiopulmonary JJ N
bypass NN N
. . N

Altered NNP N
shear-induced JJ N
pathway NN N
. . N

The DT N
impaired JJ N
hemostasis NN N
of IN N
aspirin-treated JJ 1_i
patients NNS 1_p
is VBZ N
an DT N
annoying VBG N
problem NN N
during IN 1_p
and CC 1_p
after IN 1_p
cardiopulmonary JJ 1_p
bypass NN 1_p
. . 1_p

The DT N
hemostatic JJ 1_o
function NN 1_o
of IN N
platelets NNS N
comprises NNS N
two CD N
mechanisms NNS N
: : N
the DT N
shear-induced JJ N
and CC N
the DT N
cyclooxygenase NN N
pathways NNS N
. . N

Because IN N
the DT N
latter NN N
is VBZ N
inhibited VBN N
in IN N
aspirin-treated JJ 1_i
patients NNS 1_p
, , N
the DT N
hemostatic JJ N
function NN N
depends VBZ N
mainly RB N
on IN N
the DT N
former JJ N
pathway NN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
cardiopulmonary JJ N
bypass NN N
on IN N
the DT N
shear-induced JJ N
pathway NN N
, , N
a DT N
double-blind JJ N
study NN N
of IN N
preoperative JJ N
aspirin NN 1_i
treatment NN N
( ( N
325 CD N
mg NN N
) ) N
and CC N
placebo NN 1_i
was VBD N
conducted VBN N
in IN N
40 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting NN 1_i
. . 1_i

Postoperative JJ 1_o
blood NN 1_o
loss NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
aspirin-treated JJ 1_i
patients NNS 1_p
than IN N
in IN N
the DT N
placebo-treated JJ N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
shear-induced JJ 1_o
hemostasis NN 1_o
was VBD N
monitored VBN N
by IN N
the DT N
in IN N
vitro NN N
bleeding VBG N
test NN N
( ( N
Thrombostat NNP N
) ) N
, , N
which WDT N
mimics VBD N
bleeding VBG N
through IN N
an DT N
injured JJ N
arteriole NN N
. . N

The DT N
shear-induced JJ 1_o
pathway NN 1_o
of IN 1_o
aspirin-treated JJ 1_o
platelets NNS 1_o
was VBD N
not RB N
affected VBN N
before IN N
cardiopulmonary JJ N
bypass NN N
, , N
but CC N
it PRP N
was VBD N
impaired VBN N
more RBR N
during IN N
the DT N
operation NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
remained VBD N
worse JJR N
afterward NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
compared VBN N
with IN N
that DT N
of IN N
placebo-treated JJ 1_i
platelets NNS N
. . N

The DT N
inhibitory JJ N
effects NNS N
of IN N
aspirin NN 1_i
on IN N
thromboxane NN 1_o
production NN 1_o
and CC 1_o
on IN 1_o
collagen-induced JJ 1_o
platelet NN 1_o
aggregation NN 1_o
remained VBD N
throughout IN N
the DT N
operation NN N
. . N

In IN N
aspirin-treated JJ 1_i
platelets NNS N
, , N
the DT N
aggregation NN 1_o
capacity NN 1_o
induced VBN N
by IN N
adenosine JJ N
diphosphate NN N
was VBD N
inhibited VBN N
before IN N
the DT N
operation NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
showed VBD N
substantial JJ N
recovery NN N
during IN N
the DT N
operation NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
shear-induced JJ N
pathway NN N
of IN N
aspirin-treated JJ 1_i
platelets NNS N
is VBZ N
more RBR N
vulnerable JJ N
to TO N
cardiopulmonary JJ N
bypass NN N
than IN N
the DT N
pathway NN N
in IN N
normal JJ N
platelets NNS N
and CC N
causes NNS N
severe JJ N
impairment NN N
of IN N
hemostasis NN N
afterward NN N
. . N

Combined VBN 1_i
chemotherapy NN 1_i
and CC 1_i
radiotherapy NN 1_i
compared VBN N
with IN N
radiotherapy NN 1_i
alone RB 1_i
in IN N
patients NNS 1_p
with IN 1_p
cancer NN 1_p
of IN 1_p
the DT 1_p
esophagus NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
conventional JJ N
treatment NN N
with IN N
surgery NN N
and CC N
radiation NN N
for IN N
cancer NN N
of IN N
the DT N
esophagus NN N
is VBZ N
limited VBN N
. . N

The DT N
median JJ N
survival NN N
is VBZ N
less JJR N
than IN N
10 CD N
months NNS N
, , N
and CC N
less JJR N
than IN N
10 CD N
percent NN N
of IN N
patients NNS N
survive VBP N
for IN N
5 CD N
years NNS N
. . N

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
combined JJ 1_i
chemotherapy NN 1_i
and CC 1_i
radiation NN 1_i
therapy NN 1_i
may MD N
result VB N
in IN N
improved JJ N
survival NN N
. . N

METHODS NNP N
This DT N
phase NN N
III NNP N
prospective NN N
, , N
randomized VBN N
, , N
and CC N
stratified VBD N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
four CD N
courses NNS N
of IN N
combined JJ N
fluorouracil NN 1_i
( ( 1_i
1000 CD 1_i
mg NN 1_i
per IN 1_i
square JJ 1_i
meter NN 1_i
of IN 1_i
body-surface JJ 1_i
area NN 1_i
daily RB 1_i
for IN 1_i
four CD 1_i
days NNS 1_i
) ) 1_i
and CC 1_i
cisplatin NN 1_i
( ( 1_i
75 CD 1_i
mg NN 1_i
per IN 1_i
square JJ 1_i
meter NN 1_i
on IN 1_i
the DT 1_i
first JJ 1_i
day NN 1_i
) ) 1_i
plus CC 1_i
5000 CD 1_i
cGy NN 1_i
of IN 1_i
radiation NN 1_i
therapy NN 1_i
, , N
as IN N
compared VBN N
with IN N
6400 CD 1_i
cGy NN 1_i
of IN 1_i
radiation NN 1_i
therapy NN 1_i
alone RB N
, , N
in IN N
patients NNS N
with IN N
squamous-cell JJ N
carcinoma NN N
or CC N
adenocarcinoma NN N
of IN N
the DT N
thoracic NN N
esophagus NN N
. . N

The DT N
trial NN N
was VBD N
stopped VBN N
after IN N
the DT N
accumulated JJ N
results NNS N
in IN N
121 CD 1_p
patients NNS 1_p
demonstrated VBD 1_p
a DT 1_p
significant JJ 1_p
advantage NN 1_p
for IN 1_p
survival NN 1_p
in IN 1_p
the DT 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
chemotherapy NN 1_i
and CC 1_i
radiation NN 1_i
therapy NN 1_i
. . 1_i

RESULTS VB N
The DT N
median JJ 1_o
survival NN 1_o
was VBD N
8.9 CD N
months NNS N
in IN N
the DT N
radiation-treated JJ N
patients NNS N
, , N
as IN N
compared VBN N
with IN N
12.5 CD N
months NNS N
in IN N
the DT N
patients NNS N
treated VBN N
with IN N
chemotherapy NN 1_i
and CC 1_i
radiation NN 1_i
therapy NN 1_i
. . 1_i

In IN N
the DT N
former JJ N
group NN N
, , N
the DT N
survival NN 1_o
rates NNS 1_o
at IN N
12 CD N
and CC N
24 CD N
months NNS N
were VBD N
33 CD N
percent NN N
and CC N
10 CD N
percent NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
50 CD N
percent NN N
and CC N
38 CD N
percent NN N
in IN N
the DT N
patients NNS N
receiving VBG N
combined VBN 1_i
therapy NN 1_i
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Seven JJ 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
radiotherapy NN 1_i
group NN 1_p
and CC 1_p
25 CD 1_p
in IN 1_p
the DT 1_p
combined-therapy JJ 1_i
group NN 1_p
were VBD N
alive JJ 1_o
at IN N
the DT N
time NN N
of IN N
the DT N
analysis NN N
. . N

The DT N
patients NNS N
who WP N
received VBD N
combined JJ N
treatment NN N
had VBD N
fewer JJR N
local JJ 1_o
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
fewer JJR N
distant NN 1_o
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
recurrences NNS 1_o
. . 1_o

Severe NNP 1_o
and CC 1_o
life-threatening JJ 1_o
side NN 1_o
effects NNS 1_o
occurred VBD N
in IN N
44 CD N
percent NN N
and CC N
20 CD N
percent NN N
, , N
respectively RB N
, , N
of IN N
the DT N
patients NNS N
who WP N
received VBD N
combined JJ N
therapy NN N
, , N
as IN N
compared VBN N
with IN N
25 CD N
percent NN N
and CC N
3 CD N
percent NN N
of IN N
those DT N
treated VBN N
with IN N
radiation NN N
alone RB N
. . N

CONCLUSIONS NNP N
Concurrent NNP 1_i
therapy NN 1_i
with IN 1_i
cisplatin NN 1_i
and CC 1_i
fluorouracil NN 1_i
and CC 1_i
radiation NN 1_i
is VBZ N
superior JJ N
to TO N
radiation VB 1_i
therapy NN 1_i
alone RB N
in IN N
patients NNS N
with IN N
localized JJ N
carcinoma NN N
of IN N
the DT N
esophagus NN N
, , N
as IN N
measured VBN N
by IN N
control NN N
of IN N
local JJ N
tumors NNS N
, , N
distant JJ N
metastases NNS N
, , N
and CC N
survival NN N
, , N
but CC N
at IN N
the DT N
cost NN N
of IN N
increased JJ N
side NN N
effects NNS N
. . N

A DT N
double-blind JJ N
placebo NN 1_i
controlled VBD N
trial NN N
of IN N
piracetam NN 1_i
added VBN N
to TO N
risperidone VB 1_i
in IN N
patients NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
autism NN N
is VBZ N
a DT N
hypoglutamatergic JJ N
disorder NN N
. . N

Therefore RB N
, , N
it PRP N
was VBD N
of IN N
interest NN N
to TO N
assess VB N
the DT N
efficacy NN 1_o
of IN N
piracetam NN 1_i
, , N
a DT N
positive JJ N
modulator NN N
of IN N
AMPA-sensitive JJ N
glutamate NN N
receptors NNS N
in IN N
autistic JJ N
disorder NN N
. . N

About IN 1_p
40 CD 1_p
children NNS 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
three CD 1_p
and CC 1_p
11 CD 1_p
years NNS 1_p
( ( 1_p
inclusive JJ 1_p
) ) 1_p
with IN 1_p
a DT 1_p
DSM NNP 1_p
IV NNP 1_p
clinical JJ 1_p
diagnosis NN 1_p
of IN 1_p
autism NN 1_p
and CC 1_p
who WP 1_p
were VBD 1_p
outpatients NNS 1_p
from IN 1_p
a DT 1_p
specialty NN 1_p
clinic NN 1_p
for IN 1_p
children NNS 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

The DT N
children NNS 1_p
presented VBN 1_p
with IN 1_p
a DT 1_p
chief JJ 1_p
complaint NN 1_p
of IN 1_p
severely RB 1_p
disruptive JJ 1_p
symptoms NNS 1_p
related VBN 1_p
to TO 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
piracetam VB 1_i
+ NNP 1_i
risperidone NN 1_i
( ( 1_i
Group NNP 1_i
A NNP 1_i
) ) 1_i
or CC 1_i
placebo JJ 1_i
+ NN 1_i
risperidone NN 1_i
( ( N
Group NNP N
B NNP N
) ) N
for IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN 1_i
was VBD N
titrated VBN N
up RB N
to TO N
2 CD N
mg/day NN N
for IN N
children NNS N
between IN N
10 CD N
and CC N
40 CD N
kg NN N
and CC N
3 CD N
mg/day NN N
for IN N
children NNS N
weighting VBG N
above IN N
40 CD N
kg NN N
. . N

The DT N
dose NN N
of IN N
piracetam NN 1_i
was VBD N
titrated VBN N
up RB N
to TO N
800 CD N
mg/day NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist-Community NNP 1_o
( ( 1_o
ABC-C NNP 1_o
) ) 1_o
Rating VBG 1_o
Scale NNP 1_o
( ( 1_o
total JJ 1_o
score NN 1_o
) ) 1_o
. . 1_o

The DT N
ABC-C JJ 1_o
Rating NNP 1_o
Scale NNP 1_o
scores VBZ 1_o
improved VBN N
with IN N
piracetam NN N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
the DT N
between IN N
subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
5.85 CD N
, , N
d.f NN N
. . N

= CC N
1 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
changes NNS N
at IN N
the DT N
endpoint NN N
compared VBN N
with IN N
baseline NN N
were VBD N
: : N
-11.90 JJ N
+/- JJ N
3.79 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
and CC N
-5.15 JJ N
+/- JJ N
3.04 CD N
for IN N
group NN N
A NNP N
and CC N
B NNP N
respectively RB N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
on IN N
the DT N
change NN N
in IN N
scores NNS 1_o
in IN 1_o
the DT 1_o
ABC-C NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
in IN N
week NN N
10 CD N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
t JJ N
= NN N
6.017 CD N
, , N
d.f NN N
. . N

= CC N
38 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
a DT N
combination NN N
of IN N
atypical JJ N
antipsychotic JJ N
medications NNS N
and CC N
a DT N
glutamate JJ N
agent NN N
such JJ N
as IN N
piracetam NNS N
, , N
might MD N
have VB N
increase VBN N
synergistic JJ N
effects NNS N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
. . N

Long-term JJ N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
using VBG N
repetitive JJ N
education NN N
at IN N
six-month JJ N
intervals NNS N
and CC N
monitoring NN N
for IN N
adherence NN N
in IN N
heart NN 1_p
failure NN 1_p
outpatients NNS 1_p
: : 1_p
the DT N
REMADHE NNP N
trial NN N
. . N

BACKGROUND VB N
The DT N
effectiveness NN N
of IN N
heart NN N
failure NN N
disease NN N
management NN N
programs NNS N
in IN N
patients NNS 1_p
under IN 1_p
cardiologists NNS 1_p
' POS 1_p
care NN 1_p
over IN 1_p
long-term JJ 1_p
follow-up NN 1_p
is VBZ N
not RB N
established VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
a DT N
disease JJ 1_i
management NN 1_i
program NN 1_i
with IN 1_i
repetitive JJ 1_i
education NN 1_i
and CC 1_i
telephone NN 1_i
monitoring NN 1_i
on IN N
primary JJ 1_o
( ( 1_o
combined VBN 1_o
death NN 1_o
or CC 1_o
unplanned JJ 1_o
first JJ 1_o
hospitalization NN 1_o
and CC 1_o
quality-of-life JJ 1_o
changes NNS 1_o
) ) 1_o
and CC 1_o
secondary JJ 1_o
end NN 1_o
points NNS 1_o
( ( 1_o
hospitalization NN 1_o
, , 1_o
death NN 1_o
, , 1_o
and CC 1_o
adherence NN 1_o
) ) 1_o
. . 1_o

The DT N
REMADHE NNP N
[ NNP N
Repetitive NNP N
Education NNP 1_i
and CC 1_i
Monitoring NNP 1_i
for IN N
ADherence NNP N
for IN N
Heart NNP N
Failure NNP N
] NNP N
trial NN N
is VBZ N
a DT N
long-term JJ N
randomized NN N
, , N
prospective JJ N
, , N
parallel JJ N
trial NN N
designed VBN N
to TO N
compare VB N
intervention NN N
with IN N
control NN 1_i
. . 1_i

One CD 1_p
hundred VBD 1_p
seventeen JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
usual JJ 1_p
care NN 1_p
, , 1_p
and CC 1_p
233 CD 1_p
to TO 1_p
additional JJ 1_p
intervention NN 1_p
. . 1_p

The DT N
mean JJ N
follow-up NN N
was VBD N
2.47+/-1.75 CD N
years NNS N
, , N
with IN N
54 CD N
% NN N
adherence NN N
to TO N
the DT N
program NN N
. . N

In IN N
the DT N
intervention NN N
group NN N
, , N
the DT N
primary JJ N
end NN N
point NN N
composite NN 1_o
of IN 1_o
death NN 1_o
or CC 1_o
unplanned JJ 1_o
hospitalization NN 1_o
was VBD N
reduced VBN N
( ( N
hazard JJ N
ratio NN N
, , N
0.64 CD N
; : N
confidence NN N
interval NN N
, , N
0.43 CD N
to TO N
0.88 CD N
; : N
P=0.008 NNP N
) ) N
, , N
driven VBN N
by IN N
reduction NN N
in IN N
hospitalization NN 1_o
. . 1_o

The DT N
quality-of-life JJ 1_o
questionnaire NN 1_o
score NN 1_o
improved VBD N
only RB N
in IN N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
0.003 CD N
) ) N
. . N

Mortality NNP 1_o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Number NNP 1_o
of IN 1_o
hospitalizations NNS 1_o
( ( N
1.3+/-1.7 JJ N
versus NN N
0.8+/-1.3 NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
total JJ 1_o
hospital NN 1_o
days NNS 1_o
during IN 1_o
the DT 1_o
follow-up JJ 1_o
( ( N
19.9+/-51 JJ N
versus NN N
11.1+/-24 JJ N
days NNS N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
the DT N
need NN 1_o
for IN 1_o
emergency NN 1_o
visits NNS 1_o
( ( N
4.5+/-10.6 JJ N
versus NN N
1.6+/-2.4 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
were VBD N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
. . N

Beneficial JJ 1_o
effects NNS 1_o
were VBD N
homogeneous JJ N
for IN N
sex NN N
, , N
race NN N
, , N
diabetes NNS N
and CC N
no DT N
diabetes NN N
, , N
age NN N
, , N
functional JJ N
class NN N
, , N
and CC N
etiology NN N
. . N

CONCLUSIONS NNP N
For IN N
a DT N
longer RBR N
follow-up JJ N
period NN N
than IN N
in IN N
previous JJ N
studies NNS N
, , N
this DT N
heart NN N
failure NN N
disease JJ N
management NN N
program NN N
model NN N
of IN N
patients NNS 1_p
under IN 1_p
the DT 1_p
supervision NN 1_p
of IN 1_p
a DT 1_p
cardiologist NN 1_p
is VBZ N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
unplanned JJ 1_o
hospitalization NN 1_o
, , N
a DT N
reduction NN N
of IN N
total JJ 1_o
hospital NN 1_o
days NNS 1_o
, , N
and CC N
a DT N
reduced JJ N
need NN 1_o
for IN 1_o
emergency NN 1_o
care NN 1_o
, , N
as RB N
well RB N
as IN N
improved VBN 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , N
despite IN N
modest JJ N
program NN 1_o
adherence NN 1_o
over IN N
time NN N
. . N

Does VBZ N
an DT N
educational JJ 1_i
leaflet NN 1_i
improve VB N
self-reported JJ N
adherence NN 1_o
to TO N
therapy VB N
in IN N
osteoporosis NN 1_p
? . N
The DT N
OPTIMA NNP N
study NN N
. . N

INTRODUCTION NNP N
Adherence NNP 1_o
to TO N
treatment NN N
in IN N
osteoporosis NN N
remains VBZ N
poor JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
an DT N
educational JJ 1_i
leaflet NN 1_i
on IN N
adherence NN 1_o
to TO N
medication NN N
and CC N
to TO N
assess VB N
the DT N
association NN N
between IN N
adherence NN 1_o
and CC N
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
HRQOL NNP 1_o
) ) 1_o
. . N

METHODS CC N
A NNP N
naturalistic JJ N
, , N
observational JJ N
, , N
multi-center JJ 1_p
, , N
prospective JJ N
study NN N
of IN N
12 CD N
months NNS N
' POS N
follow-up NN N
was VBD N
performed VBN N
. . N

Consecutive JJ 1_p
post-menopausal JJ 1_p
women NNS 1_p
aged VBN 1_p
50 CD 1_p
years NNS 1_p
to TO 1_p
86 CD 1_p
years NNS 1_p
starting VBG 1_p
treatment NN 1_p
with IN 1_p
raloxifene NN 1_i
according VBG 1_p
to TO 1_p
daily JJ 1_p
practice NN 1_p
were VBD 1_p
enrolled VBN 1_p
from IN 1_p
126 CD 1_p
primary JJ 1_p
care NN 1_p
offices NNS 1_p
in IN 1_p
Spain NNP 1_p
. . 1_p

The DT N
women NNS 1_p
were VBD N
assigned VBN N
to TO N
two CD N
study NN N
groups NNS N
. . N

Group NNP N
A NNP N
received VBD N
an DT N
educational JJ 1_i
leaflet NN 1_i
with IN 1_i
general JJ 1_i
information NN 1_i
about IN 1_i
osteoporosis NN 1_i
; : 1_i
group NN N
B NNP N
followed VBD N
current JJ 1_i
practice NN 1_i
. . 1_i

To TO N
assess VB N
adherence NN 1_o
to TO 1_o
medication NN 1_o
and CC 1_o
HRQOL NNP 1_o
, , 1_o
the DT 1_o
Morisky NNP 1_o
test NN 1_o
and CC 1_o
the DT 1_o
EuroQoL NNP 1_o
questionnaire NN 1_o
were VBD N
administered VBN N
. . N

A DT 1_p
total NN 1_p
of IN 1_p
745 CD 1_p
post-menopausal JJ 1_p
women NNS 1_p
( ( 1_p
group NN 1_p
A NNP 1_p
, , 1_p
n=366 RB 1_p
; : 1_p
group NN 1_p
B NNP 1_p
n=379 NN 1_p
) ) 1_p
, , 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
62 CD 1_p
years NNS 1_p
, , N
were VBD N
included VBN N
. . N

RESULTS NNP N
Most JJS N
patients NNS N
in IN N
both DT N
study NN N
groups NNS N
showed VBD N
high JJ N
adherence NN 1_o
to TO N
raloxifene VB 1_i
at IN N
the DT N
3-month JJ N
visit NN N
: : N
56.3 CD N
% NN N
vs JJ N
62.7 CD N
% NN N
for IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
; : N
this DT N
proportion NN N
at IN N
the DT N
12-month JJ N
visit NN N
was VBD N
47.4 CD N
% NN N
( ( N
P=0.15 NNP N
) ) N
and CC N
52.5 CD N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
respectively RB N
. . N

At IN N
baseline NN N
, , N
" NNP 1_o
pain/discomfort NN 1_o
" NN 1_o
was VBD N
the DT N
dimension NN N
showing VBG N
the DT N
highest JJS N
percentage NN N
of IN N
women NNS N
reporting VBG N
problems NNS N
: : N
86.4 CD N
% NN N
vs JJ N
83.2 CD N
% NN N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P=0.22 NNP N
) ) N
. . N

HRQOL NNP 1_o
improved VBN N
in IN N
both DT N
groups NNS N
throughout IN N
the DT N
study NN N
, , N
with IN N
an DT N
overall JJ N
mean JJ N
increment NN N
in IN N
the DT N
EuroQoL NNP 1_o
visual JJ 1_o
analog NN 1_o
scale NN 1_o
( ( 1_o
EQ NNP 1_o
VAS NNP 1_o
) ) 1_o
of IN N
9.2 CD N
at IN N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Correlations NNS N
between IN N
adherence NN 1_o
and CC 1_o
HRQOL NNP 1_o
were VBD N
weak JJ N
. . N

After IN N
receiving VBG N
an DT N
educational JJ 1_i
leaflet NN 1_i
, , N
young JJ 1_p
post-menopausal JJ 1_p
women NNS 1_p
suffering VBG 1_p
osteoporosis NN 1_p
did VBD N
not RB N
show VB N
improvement NN N
in IN N
adherence NN 1_o
to TO 1_o
therapy VB 1_o
. . 1_o

HRQOL NNP 1_o
improved VBD N
at IN N
12-month JJ N
follow-up JJ N
under IN N
treatment NN N
. . N

CONCLUSION NNP N
No NNP N
consistent JJ N
correlation NN N
between IN N
adherence NN 1_o
and CC 1_o
HRQOL NNP 1_o
was VBD N
found VBN N
. . N

A DT N
Randomized NNP N
, , N
Placebo-Controlled JJ 1_i
Trial NNP N
Evaluating NNP N
Safety NNP N
and CC N
Immunogenicity NNP N
of IN N
the DT N
Killed NNP N
, , N
Bivalent NNP N
, , N
Whole-Cell NNP 1_i
Oral NNP 1_i
Cholera NNP 1_i
Vaccine NNP 1_i
in IN 1_p
Ethiopia NNP 1_p
. . 1_p

Killed VBN 1_i
whole-cell JJ 1_i
oral JJ 1_i
cholera NN 1_i
vaccine NN 1_i
( ( 1_i
OCV NNP 1_i
) ) 1_i
has VBZ N
been VBN N
a DT N
key JJ N
component NN N
of IN N
a DT N
comprehensive JJ N
package NN N
including VBG N
water NN N
and CC N
sanitation NN N
measures NNS N
for IN N
recent JJ N
cholera NN N
epidemics NNS N
. . N

The DT N
vaccine NN 1_i
, , N
given VBN N
in IN N
a DT N
two-dose JJ N
regimen NN N
, , N
has VBZ N
been VBN N
evaluated VBN N
in IN N
a DT 1_p
large JJ 1_p
number NN 1_p
of IN 1_p
human JJ 1_p
volunteers NNS 1_p
in IN 1_p
India NNP 1_p
, , 1_p
Vietnam NNP 1_p
, , 1_p
and CC 1_p
Bangladesh NNP 1_p
, , N
where WRB N
it PRP N
has VBZ N
demonstrated VBN N
safety NN N
, , N
immunogenicity NN N
, , N
and CC N
clinical JJ N
efficacy NN N
. . N

We PRP N
conducted VBD N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ 1_i
trial NN N
in IN 1_p
Ethiopia NNP 1_p
, , N
where WRB N
we PRP N
evaluated VBD 1_p
the DT 1_p
safety NN 1_o
and CC 1_o
immunogenicity NN 1_o
of IN 1_p
the DT 1_p
vaccine NN 1_i
in IN 1_p
216 CD 1_p
healthy JJ 1_p
adults NNS 1_p
and CC 1_p
children NNS 1_p
. . 1_p

OCV NNP 1_i
was VBD N
found VBN N
to TO N
be VB N
safe JJ 1_o
and CC 1_o
elicited VBD 1_o
a DT 1_o
robust JJ 1_o
immunological JJ 1_o
response NN 1_o
against IN 1_o
Vibrio NNP 1_o
cholerae NN 1_o
O1 NNP 1_o
, , N
with IN N
81 CD N
% NN N
adults NNS N
and CC N
77 CD N
% NN N
children NNS N
demonstrating VBG N
seroconversion NN 1_o
14 CD N
days NNS N
after IN N
the DT N
second JJ N
dose NN N
of IN N
vaccine NN N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
evaluate VB N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
vaccine NN 1_i
in IN N
a DT N
population NN 1_p
outside IN 1_p
Asia NNP 1_p
using VBG N
a DT N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
, , N
randomized JJ N
study NN N
design NN N
. . N

Nasal NNP N
oxytocin MD 1_i
for IN N
social JJ N
deficits NNS N
in IN N
childhood NN 1_p
autism NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

The DT N
last JJ N
two CD N
decades NNS N
have VBP N
witnessed VBN N
a DT N
surge NN N
in IN N
research NN N
investigating VBG N
the DT N
application NN N
of IN N
oxytocin NN N
as IN N
a DT N
method NN N
of IN N
enhancing VBG N
social JJ N
behaviour NN N
in IN N
humans NNS N
. . N

Preliminary JJ N
evidence NN N
suggests VBZ N
oxytocin NN N
may MD N
have VB N
potential NN N
as IN N
an DT N
intervention NN N
for IN N
autism NN N
. . N

We PRP N
evaluated VBD N
a DT N
5-day JJ N
'live-in NN N
' POS N
intervention NN N
using VBG N
a DT N
double-blind JJ N
randomized VBN N
control NN N
trial NN N
. . N

38 CD 1_p
male JJ 1_p
youths NNS 1_p
( ( 1_p
7-16 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
were VBD N
administered VBN N
24 CD 1_i
or CC 1_i
12 CD 1_i
international JJ 1_i
units NNS 1_i
( ( 1_i
depending VBG 1_i
on IN 1_i
weight NN 1_i
) ) 1_i
intranasal NN 1_i
placebo NN 1_i
or CC 1_i
oxytocin JJ 1_i
once RB N
daily RB N
over IN N
four CD N
consecutive JJ N
days NNS N
. . N

The DT N
oxytocin NN N
or CC N
placebo NN N
was VBD N
administered VBN N
during IN N
parent-child JJ N
interaction NN N
training NN N
sessions NNS N
. . N

Parent NN N
and CC N
child NN N
behaviours NNS N
were VBD N
assessed VBN N
using VBG N
parent NN 1_o
reports NNS 1_o
, , 1_o
clinician JJ 1_o
ratings NNS 1_o
, , 1_o
and CC 1_o
independent JJ 1_o
observations NNS 1_o
, , N
at IN N
multiple JJ N
time NN N
points NNS N
to TO N
measure VB 1_o
side-effects NNS 1_o
; : 1_o
social JJ 1_o
interaction NN 1_o
skills NNS 1_o
; : 1_o
repetitive JJ 1_o
behaviours NNS 1_o
; : 1_o
emotion NN 1_o
recognition NN 1_o
and CC 1_o
diagnostic JJ 1_o
status NN 1_o
. . 1_o

Compared VBN N
to TO N
placebo VB N
, , N
intranasal VB N
oxytocin RB N
did VBD N
not RB N
significantly RB N
improve VB N
emotion NN 1_o
recognition NN 1_o
, , 1_o
social JJ 1_o
interaction NN 1_o
skills NNS 1_o
, , 1_o
or CC 1_o
general JJ 1_o
behavioral JJ 1_o
adjustment NN 1_o
in IN N
male JJ N
youths NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
the DT N
benefits NNS N
of IN N
nasal JJ N
oxytocin NN N
for IN N
young JJ 1_p
individuals NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
may MD N
be VB N
more JJR N
circumscribed JJ N
than IN N
suggested VBN N
by IN N
previous JJ N
studies NNS N
, , N
and CC N
suggest JJS N
caution NN N
in IN N
recommending VBG N
it PRP N
as IN N
an DT N
intervention NN N
that WDT N
is VBZ N
broadly RB N
effective JJ N
. . N

Prognostic JJ N
significance NN N
of IN N
the DT N
dobutamine NN N
echocardiography NN N
test NN N
in IN N
idiopathic JJ 1_o
dilated VBN 1_o
cardiomyopathy NN 1_o
. . 1_o

Dobutamine NNP 1_i
stress NN 1_i
echo NN 1_i
provides VBZ N
potentially RB N
useful JJ 1_o
information NN 1_o
on IN N
idiopathic JJ 1_i
dilated VBN 1_i
cardiomyopathy NN 1_i
( ( 1_p
IDC NNP 1_p
) ) 1_p
. . 1_p

From IN 1_p
February NNP 1_p
1 CD 1_p
, , 1_p
1997 CD 1_p
, , 1_p
to TO 1_p
October NNP 1_p
1 CD 1_p
, , 1_p
1999 CD 1_p
, , 1_p
186 CD 1_p
patients NNS 1_p
( ( 1_p
131 CD 1_p
men NNS 1_p
and CC 1_p
55 CD 1_p
women NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
56 CD 1_p
+/- JJ 1_p
12 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
IDC NNP 1_p
, , 1_p
ejection NN 1_p
fraction NN 1_p
< VBD 1_p
35 CD 1_p
% NN 1_p
, , 1_p
and CC 1_p
angiographically RB 1_p
normal JJ 1_p
coronary JJ 1_p
arteries NNS 1_p
were VBD 1_p
studied VBN 1_p
by IN 1_p
high-dose NN 1_i
( ( 1_p
up IN 1_p
to TO 1_p
40 CD 1_p
micro/kg/min NN 1_p
) ) 1_p
dobutamine NN 1_i
echo NN 1_i
in IN 1_p
6 CD 1_p
centers NNS 1_p
, , 1_p
all DT 1_p
quality NN 1_p
controlled VBN 1_p
for IN 1_p
stress NN 1_p
echo NN 1_p
reading NN 1_p
. . 1_p

In IN N
all DT N
patients NNS N
, , N
wall JJ N
motion NN N
score NN N
index NN N
( ( N
WMSI NNP N
) ) N
( ( N
from IN N
1 CD N
= NNS N
normal JJ N
to TO N
4 CD N
= NNP N
dyskinetic NN N
in IN N
a DT N
16- JJ N
segment NN N
model NN N
of IN N
the DT N
left JJ N
ventricle NN N
) ) N
was VBD N
evaluated VBN N
by IN N
echo NN N
at IN N
baseline NN N
and CC N
peak JJ N
dobutamine NN N
. . N

One CD N
hundred VBD N
eighty-four JJ N
patients NNS N
were VBD N
followed VBN N
up RP N
( ( N
mean JJ N
15 CD N
+/- JJ N
13 CD N
months NNS N
) ) N
and CC N
only RB N
cardiac JJ 1_o
death NN 1_o
was VBD N
considered VBN N
as IN N
an DT N
end NN N
point NN N
. . N

There EX N
were VBD N
29 CD N
cardiac JJ N
deaths NNS N
. . N

Significant JJ N
parameters NNS N
for IN N
survival JJ N
prediction NN N
at IN N
univariate JJ N
analysis NN N
are VBP N
: : N
DeltaWMSI NNP N
( ( N
chi-square JJ N
20.1 CD N
; : N
p NN N
< VBZ N
0.0000 CD N
) ) N
, , N
New NNP N
York NNP N
Heart NNP N
Association NNP N
( ( N
NYHA NNP N
) ) N
class NN N
( ( N
chi-square JJ N
17.57 CD N
; : N
p NN N
< VBZ N
0.0000 CD N
) ) N
, , N
rest JJS N
ejection NN N
fraction NN N
( ( N
chi-square JJ N
10.41 CD N
; : N
p NN N
= VBZ N
0.0013 CD N
) ) N
, , N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
chi-square JJ N
8.23 CD N
; : N
p NN N
= VBZ N
0.0041 CD N
) ) N
, , N
and CC N
hypertension NN N
( ( N
chi-square JJ N
8.08 CD N
, , N
p NN N
= NNP N
0.0045 CD N
) ) N
. . N

In IN N
the DT N
multivariate NN N
stepwise NN N
analysis NN N
only RB N
DeltaWMSI NNP N
and CC N
NYHA NNP N
were VBD N
independent JJ N
predictors NNS N
of IN N
outcome NN N
( ( N
DeltaWMSI NNP N
= NNP N
hazard VBD N
ratio NN N
0.02 CD N
, , N
p NN N
< VBD N
0.0000 CD N
; : N
NYHA NNP N
class NN N
= NNP N
hazard NN N
ratio NN N
3.83 CD N
, , N
p NN N
< NNP N
0.0000 CD N
) ) N
. . N

Kaplan-Meier NNP N
survival NN N
estimates NNS N
showed VBD N
a DT N
better JJR 1_o
outcome NN 1_o
for IN N
patients NNS N
with IN N
a DT N
large JJ 1_o
inotropic NN 1_o
response NN 1_o
( ( N
DeltaWMSI NNP N
> NNP N
or CC N
=0.44 NNP N
, , N
a DT N
cutoff NN N
identified VBN N
by IN N
receiver-operating JJ N
characteristic JJ N
curves NNS N
analysis NN N
) ) N
than IN N
for IN N
those DT N
with IN N
a DT N
small JJ N
or CC N
no DT N
myocardial JJ N
inotropic NN N
response NN N
to TO N
dobutamine VB N
( ( N
93.6 CD N
% NN N
vs JJ N
69.4 CD N
% NN N
, , N
p NN N
= NNP N
0.00033 CD N
) ) N
. . N

Thus RB N
, , N
in IN N
patients NNS 1_p
with IN 1_p
IDC NNP 1_p
, , N
an DT N
extensive JJ N
contractile NN N
reserve NN N
identified VBN N
by IN N
high-dose JJ N
dobutamine NN N
stress NN N
echocardiography NN N
is VBZ N
associated VBN N
with IN N
a DT N
better JJR 1_o
survival NN 1_o
. . 1_o

Safety NN N
and CC N
pharmacology NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
ponezumab NN 1_i
in IN N
subjects NNS 1_p
with IN 1_p
mild-to-moderate JJ 1_p
Alzheimer NNP 1_p
disease NN 1_p
: : 1_p
a DT N
phase NN N
I PRP N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
, , N
double-blind JJ N
, , N
dose-escalation NN N
study NN N
. . N

OBJECTIVES NNP N
Ponezumab NNP 1_i
is VBZ N
a DT N
humanized JJ N
antiamyloid NN N
beta NN N
( ( N
Aβ NNP N
) ) N
monoclonal NN N
antibody NN N
designed VBN N
to TO N
treat VB N
Alzheimer NNP N
disease NN N
( ( N
AD NNP N
) ) N
. . N

METHODS NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
single-dose-escalation NN N
study NN N
evaluated VBD N
the DT N
safety NN N
, , N
pharmacokinetics NNS N
, , N
and CC N
pharmacodynamics NNS N
of IN N
0.1 CD N
, , N
0.3 CD N
, , N
1 CD N
, , N
3 CD N
, , N
and CC N
10 CD N
mg/kg NN 1_i
ponezumab NN 1_i
( ( N
n JJ N
= NN N
4 CD N
, , N
4 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
8 CD N
, , N
respectively RB N
) ) N
versus NN 1_i
placebo NN 1_i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
after IN N
a DT N
2-hour JJ N
intravenous JJ N
infusion NN N
in IN 1_p
subjects NNS 1_p
with IN 1_p
mild-to-moderate JJ 1_p
AD NNP 1_p
. . N

Cerebrospinal NNP N
fluid NN N
( ( N
CSF NNP N
) ) N
samples NNS N
were VBD N
obtained VBN N
from IN N
the DT N
1- JJ N
and CC N
10-mg/kg JJ N
groups NNS N
at IN N
baseline NN N
and CC N
at IN N
day NN N
29 CD N
. . N

The DT N
subjects NNS N
were VBD N
followed VBN N
for IN N
1 CD N
year NN N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
completed VBN N
the DT N
trial NN N
. . 1_i

Ponezumab NNP 1_i
was VBD N
well RB 1_o
tolerated VBN 1_o
with IN N
no DT N
drug-attributed JJ 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD 1_o
upper JJ 1_o
respiratory NN 1_o
tract NN 1_o
infection NN 1_o
, , 1_o
headache NN 1_o
, , 1_o
and CC 1_o
back RB 1_o
pain NN 1_o
, , 1_o
all DT 1_o
mild VBP 1_o
to TO 1_o
moderate VB 1_o
. . N

One CD N
subject NN N
( ( N
10 CD N
mg/kg NN N
) ) N
experienced VBD N
a DT 1_o
mild JJ 1_o
hypersensitivity NN 1_o
reaction NN 1_o
. . N

Another DT N
subject NN N
( ( N
0.1 CD N
mg/kg NN N
) ) N
demonstrated VBD 1_o
slight JJ 1_o
enlargement NN 1_o
of IN 1_o
a DT 1_o
preexisting NN 1_o
midbrain NN 1_o
lesion NN 1_o
. . 1_o

Electrocardiography NNP 1_o
and CC 1_o
laboratory NN 1_o
values NNS 1_o
( ( 1_o
including VBG 1_o
CSF NNP 1_o
) ) 1_o
were VBD N
unremarkable JJ N
. . N

No DT N
evidence NN N
of IN N
new JJ 1_o
microhemorrhage NN 1_o
, , 1_o
vasogenic JJ 1_o
edema NN 1_o
, , 1_o
or CC 1_o
meningoencephalitis NN 1_o
was VBD N
noted VBN N
. . N

Plasma NNP N
maximum JJ N
observed JJ N
concentration NN N
increased VBD N
approximately RB N
dose JJ N
proportionally RB N
, , N
and CC N
the DT 1_o
area NN 1_o
under IN 1_o
the DT 1_o
plasma JJ 1_o
concentration-time JJ 1_o
profile NN 1_o
from IN N
time NN N
zero CD N
extrapolated VBN N
to TO N
infinite VB N
time NN N
( ( N
AUC NNP N
( ( N
inf NN N
) ) N
) ) N
increased VBD N
slightly RB N
more JJR N
than IN N
dose VB N
proportionally RB N
. . 1_o

Mean JJ 1_o
terminal JJ 1_o
half-life NN 1_o
was VBD N
approximately RB N
6 CD N
weeks NNS N
. . N

Two CD N
subjects NNS N
( ( N
10 CD N
mg/kg NN N
) ) N
had VBD N
measurable JJ 1_o
CSF NNP 1_o
ponezumab NN 1_o
concentrations NNS 1_o
( ( N
~0.5 CD N
% NN N
of IN N
plasma NN N
values NNS N
) ) N
at IN N
day NN N
29 CD N
. . N

Plasma NNP N
Aβ NNP N
( ( N
1-x JJ N
) ) N
and CC N
Aβ NNP N
( ( N
1-40 JJ N
) ) N
increased VBD N
dose JJ N
dependently RB N
, , N
and CC 1_o
mean JJ 1_o
CSF NNP 1_o
Aβ NNP N
( ( N
1-x JJ N
) ) N
increased VBD N
38 CD N
% NN N
from IN N
baseline NN N
with IN N
10 CD N
mg/kg NNS N
( ( N
P NNP N
= VBZ N
0.002 CD 1_i
vs NN 1_i
placebo NN 1_i
) ) 1_i
. . N

CONCLUSIONS VB N
A DT N
2-hour JJ N
infusion NN N
of IN N
0.1 CD N
to TO N
10 CD N
mg/kg NNS 1_i
ponezumab NN 1_i
was VBD N
well RB N
tolerated VBN N
in IN N
subjects NNS N
with IN N
mild-to-moderate JJ N
AD NNP N
. . N

Plasma NNP N
pharmacokinetic JJ N
profile NN N
was VBD N
approximately RB N
linear JJ N
. . N

Plasma NNP N
Aβ NNP N
increased VBD N
with IN N
dose NN N
, , N
and CC N
CSF NNP N
Aβ NNP N
increased VBD N
at IN N
the DT N
highest JJS N
dose NN N
, , N
suggesting VBG N
that IN N
intravenous JJ 1_i
ponezumab NN 1_i
alters NNS N
central JJ N
Aβ NNP N
levels NNS N
. . N

Effect NN N
of IN N
surgical JJ 1_i
technique NN 1_i
in IN N
subtotal JJ 1_i
and CC 1_i
bilateral JJ 1_i
thyroidectomy NN 1_i
on IN N
risk NN N
of IN N
postoperative JJ N
parathyroid NN N
insufficiency NN N
development NN N
-- : N
our PRP$ N
experience NN N
. . N

One CD N
of IN N
the DT N
postoperative JJ N
complications NNS N
after IN N
strumectomy NN N
is VBZ N
hypoparathyroidism NN N
. . N

Therefore RB N
, , N
the DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
surgical JJ 1_i
technique NN 1_i
on IN N
the DT N
development NN 1_o
of IN 1_o
parathyroid JJ 1_o
gland NN 1_o
insufficiency NN 1_o
in IN 1_p
our PRP$ 1_p
group NN 1_p
of IN 1_p
patients NNS 1_p
. . 1_p

Subtotal NNP N
, , N
bilateral JJ 1_i
strumectomies NNS 1_i
were VBD N
performed VBN N
according VBG N
to TO N
Rothmund NNP N
's POS N
suggestions NNS N
. . N

Randomized NNP N
controlled VBD N
trial NN N
was VBD N
performed VBN N
in IN N
two CD 1_p
groups NNS 1_p
. . 1_p

In IN N
the DT N
first JJ 1_p
group NN 1_p
of IN 1_p
19 CD 1_p
patients NNS 1_p
, , 1_p
main JJ 1_i
trunk NN 1_i
of IN 1_i
the DT 1_i
inferior JJ 1_i
thyroid JJ 1_i
artery NN 1_i
was VBD 1_i
ligated VBN 1_i
and CC 1_p
in IN 1_p
the DT 1_p
second JJ 1_p
one CD 1_p
consisting NN 1_p
of IN 1_p
18 CD 1_p
patients NNS 1_p
, , 1_p
only RB 1_i
the DT 1_i
branches NNS 1_i
of IN 1_i
this DT 1_i
artery NN 1_i
were VBD 1_i
ligated VBN 1_i
. . 1_i

Total JJ 1_o
calcium NN 1_o
and CC 1_o
PTH NNP 1_o
levels NNS 1_o
were VBD N
evaluated VBN N
pre- JJ N
and CC N
postoperatively RB N
. . N

Based VBN N
on IN N
the DT N
biochemical JJ N
and CC N
clinical JJ N
data NNS N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
development NN 1_o
of IN 1_o
postoperative JJ 1_o
hypoparathyroidism NN 1_o
in IN N
relation NN N
to TO N
performed VB N
surgical JJ 1_i
techniques NNS 1_i
were VBD N
observed VBN N
. . N

Improvement NN N
in IN N
Patient-Reported NNP 1_p
Visual NNP 1_p
Function NNP 1_p
After IN 1_p
Ocriplasmin NNP 1_i
for IN 1_p
Vitreomacular NNP 1_p
Adhesion NNP 1_p
: : 1_p
Results NNS N
of IN N
the DT N
Microplasmin NNP 1_i
for IN 1_i
Intravitreous NNP 1_i
Injection-Traction NNP 1_i
Release NNP N
Without NNP N
Surgical NNP N
Treatment NNP N
( ( N
MIVI-TRUST NNP N
) ) N
Trials NNPS N
. . N

IMPORTANCE VB N
The DT N
impact NN N
of IN N
vitreomacular JJ 1_i
adhesion NN 1_i
( ( 1_i
VMA NNP 1_i
) ) 1_i
resolution NN N
on IN N
patient-reported JJ 1_p
visual JJ 1_p
function NN 1_p
in IN 1_p
symptomatic JJ 1_p
VMA/vitreomacular NNP 1_p
traction NN 1_p
( ( 1_p
VMT NNP 1_p
) ) 1_p
has VBZ N
not RB N
yet RB N
been VBN N
documented VBN N
, , N
to TO N
our PRP$ N
knowledge NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
impact NN N
of IN N
intravitreal JJ 1_i
ocriplasmin NNS 1_i
on IN N
patient-reported JJ N
visual JJ 1_o
function NN 1_o
using VBG N
the DT N
25-item JJ N
National NNP N
Eye NNP N
Institute NNP N
Visual NNP N
Function NNP N
Questionnaire NNP N
( ( 1_i
NEI NNP 1_i
VFQ-25 NNP 1_i
) ) 1_i
during IN N
a DT N
6-month JJ N
follow-up NN N
in IN N
patients NNS 1_p
with IN 1_p
symptomatic JJ 1_p
VMA NNP 1_p
. . 1_p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Two CD N
multicenter NN N
, , N
randomized VBN N
, , N
masked VBN N
, , N
phase VB N
3 CD N
clinical JJ N
trials NNS N
( ( N
studies NNS N
TG-MV-006 NNP N
[ NN N
between IN N
December NNP N
2008 CD N
and CC N
April NNP N
2010 CD N
] NNP N
and CC N
TG-MV-007 NNP N
[ NNP N
between IN N
December NNP N
2008 CD N
and CC N
July NNP N
2010 CD N
] NN N
) ) N
at IN N
clinic-based JJ N
centers NNS N
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Europe NNP N
. . N

A NNP 1_p
total NN 1_p
of IN 1_p
652 CD 1_p
patients NNS 1_p
with IN 1_p
symptomatic JJ 1_p
VMA/VMT NNP 1_p
, , 1_p
including VBG 1_p
when WRB 1_p
associated VBN 1_p
with IN 1_p
a DT 1_p
macular JJ 1_p
hole NN 1_p
400 CD 1_p
μm NN 1_p
or CC 1_p
smaller JJR 1_p
, , N
were VBD N
studied VBN N
. . N

Analysis NN N
was VBD N
by IN N
intent-to-treat JJ N
population NN N
and CC N
performed VBN N
in IN N
May NNP N
2013 CD N
. . N

INTERVENTIONS JJ 1_p
Patients NNS 1_p
with IN 1_p
symptomatic JJ 1_p
VMA/VMT NNP 1_p
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
or CC N
3:1 CD N
in IN N
study NN N
TG-MV-006 NNP N
and CC N
study VB N
TG-MV-007 NNP N
, , N
respectively RB N
) ) N
to TO N
receive VB N
a DT N
single JJ N
intravitreal NN N
injection NN N
of IN 1_i
ocriplasmin NN 1_i
, , N
125 CD N
μg NN N
, , N
or CC 1_i
placebo-injected JJ 1_i
vehicle NN 1_i
( ( 1_i
placebo NN 1_i
) ) 1_i
. . N

The DT 1_i
NEI NNP 1_i
VFQ-25 NNP 1_i
was VBD N
administered VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
following VBG 1_i
ocriplasmin JJ 1_i
injection NN N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP 1_o
Mean NNP 1_o
changes NNS 1_o
between IN 1_o
baseline NN 1_o
and CC 1_o
6-month JJ 1_o
follow-up JJ 1_o
NEI NNP 1_o
VFQ-25 NNP 1_o
composite JJ 1_o
and CC 1_o
subscale JJ 1_o
scores NNS 1_o
and CC N
the DT 1_o
proportion NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
a DT 1_o
clinically RB 1_o
meaningful JJ 1_o
change NN 1_o
( ( 1_o
≥5 JJ 1_o
points NNS 1_o
) ) 1_o
in IN 1_o
scores NNS 1_o
. . N

RESULTS NNP N
Across IN N
the DT N
2 CD N
studies NNS 1_p
, , 1_p
464 CD 1_p
patients NNS 1_p
received VBN 1_i
ocriplasmin JJ 1_i
and CC 1_p
188 CD 1_p
received VBD 1_i
placebo NN 1_i
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
ocriplasmin NN N
group NN N
reported VBD N
greater JJR 1_o
mean JJ 1_o
improvements NNS 1_o
from IN 1_o
baseline NN 1_o
in IN N
the DT 1_o
NEI NNP 1_o
VFQ-25 NNP 1_o
composite JJ 1_o
score NN 1_o
than IN N
the DT 1_i
placebo NN 1_i
group NN N
( ( N
mean JJ N
change NN N
, , N
3.4 CD N
vs NN N
0.7 CD N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.005 NNP N
) ) N
. . N

Improvements NNS N
were VBD N
also RB N
noted VBN 1_o
in IN 1_o
subscale JJ 1_o
scores NNS N
, , N
with IN N
the DT N
following VBG N
respective JJ N
mean JJ N
changes NNS N
for IN 1_i
the DT 1_i
ocriplasmin NN 1_i
vs NN 1_i
placebo NN N
groups NNS N
: : N
vision-related JJ N
dependency NN N
, , N
1.7 CD N
vs NN N
-2.1 NNP N
( ( N
P NNP N
= NNP N
.009 NNP N
) ) N
; : N
driving VBG N
difficulty NN N
, , N
2.7 CD N
vs NN N
-1.5 NNP N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
; : N
distance NN N
vision NN N
activities NNS N
, , N
4.1 CD N
vs NN N
0.8 CD N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
; : N
and CC N
general JJ N
vision NN N
, , N
6.1 CD N
vs NN N
2.1 CD N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

A DT N
higher JJR 1_i
proportion NN 1_i
of IN N
the DT N
ocriplasmin NN N
group NN N
had VBD N
a DT N
clinically RB N
meaningful JJ N
( ( 1_o
≥5-point JJ 1_o
) ) 1_o
improvement NN 1_o
in IN 1_o
NEI NNP 1_o
VFQ-25 NNP N
composite JJ N
score NN N
from IN N
baseline NN N
than IN N
the DT N
placebo NN N
group NN N
( ( N
36.0 CD N
% NN N
vs JJ N
27.2 CD N
% NN N
, , N
respectively RB 1_i
; : 1_i
P NNP 1_i
= NNP 1_i
.03 NNP 1_i
) ) 1_i
. . N

Fewer JJR N
ocriplasmin-treated JJ N
patients NNS N
had VBD N
a DT N
clinically RB N
meaningful JJ 1_o
worsening VBG 1_o
in IN N
their PRP$ 1_i
visual JJ 1_i
function NN N
than IN N
the DT N
placebo NN N
group NN N
( ( N
15.0 CD N
% NN N
vs JJ N
24.3 CD N
% NN N
, , N
respectively RB 1_o
; : 1_o
P NNP 1_o
= NNP 1_o
.005 NNP 1_o
) ) 1_o
. . 1_o

Changes NNS 1_o
in IN 1_o
NEI NNP 1_o
VFQ-25 NNP 1_o
composite JJ 1_o
score NN N
and CC N
various JJ 1_i
subscale JJ 1_i
scores NNS 1_i
were VBD N
observed VBN N
in IN N
ocriplasmin-treated JJ N
patients NNS N
who WP N
achieved VBD N
VMA NNP N
resolution NN N
at IN N
day NN 1_i
28 CD 1_i
. . 1_i

CONCLUSIONS NNP 1_i
AND CC N
RELEVANCE NNP N
Ocriplasmin NNP N
produces VBZ N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
patient-reported JJ 1_p
visual JJ 1_p
function NN N
in IN N
symptomatic JJ N
VMA/VMT NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifiers NNS N
: : N
NCT00781859 NNP N
and CC N
NCT00798317 NNP N
. . N

High-intensity NNP 1_i
physical JJ 1_i
training NN 1_i
in IN N
adults NNS 1_p
with IN 1_p
asthma NN 1_p
. . 1_p

A DT N
comparison NN N
between IN N
training VBG 1_i
on IN 1_i
land NN 1_i
and CC 1_i
in IN 1_i
water NN 1_i
. . 1_i

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
inactive JJ 1_p
asthmatic JJ 1_p
patients NNS 1_p
could MD N
perform VB N
high-intensity JJ 1_i
physical JJ 1_i
training NN 1_i
equally RB N
well RB N
on IN 1_i
land NN 1_i
as IN 1_i
in IN 1_i
water NN 1_i
, , N
and CC N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
these DT N
training NN N
forms NNS N
. . N

Thirty-two JJ 1_p
adults NNS 1_p
with IN 1_p
asthma NN 1_p
, , N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
underwent VBD N
a DT N
10-week JJ 1_i
supervised JJ 1_i
rehabilitation NN 1_i
program NN 1_i
with IN 1_i
emphasis NN 1_i
on IN 1_i
physical JJ 1_i
training NN 1_i
. . 1_i

All DT N
patients NNS N
, , N
irrespective JJ N
of IN N
training VBG N
form NN N
, , N
were VBD N
able JJ N
to TO N
exercise VB N
to TO N
maximal VB N
intensity NN N
( ( N
80-90 CD N
% NN N
of IN N
estimated VBN N
maximal JJ N
heart NN N
rate NN N
) ) N
. . N

No UH N
asthmatic JJ 1_o
attacks NNS 1_o
occurred VBD N
in IN N
connection NN N
with IN N
the DT N
training NN N
sessions NNS N
. . N

Respiratory NNP 1_o
variables NNS 1_o
remained VBD N
almost RB N
unchanged JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
asthma NN 1_o
symptoms NNS 1_o
declined VBD 1_o
during IN N
the DT N
rehabilitation NN N
period NN N
, , N
and CC N
the DT N
subjects NNS N
needed VBN N
less JJR N
acute JJ N
asthma NN N
care NN N
after IN N
the DT N
rehabilitation NN N
. . N

The DT N
cardiovascular JJ 1_o
condition NN 1_o
improved VBN N
significantly RB N
and CC N
similarly RB N
in IN N
the DT N
two CD N
groups NNS N
. . N

Ten CD 1_p
patients NNS 1_p
, , 1_p
5 CD 1_p
in IN 1_p
each DT 1_p
group NN 1_p
, , N
had VBD N
exercise-induced JJ 1_o
asthma NN 1_o
at IN N
the DT N
start NN N
of IN N
the DT N
rehabilitation NN N
. . N

Only RB N
3 CD N
patients NNS N
, , N
2 CD N
from IN N
the DT N
water NN N
group NN N
and CC N
1 CD N
from IN N
the DT N
land NN N
group NN N
, , N
had VBD N
exercise-induced VBN 1_o
asthma NNS 1_o
after IN N
10 CD N
weeks NNS N
. . N

We PRP N
conclude VBP N
that IN N
indoor JJ N
training NN N
, , N
either CC N
on IN N
land NN N
or CC N
in IN N
water NN N
, , N
is VBZ N
beneficial JJ N
. . N

The DT N
effects NNS 1_o
of IN N
these DT N
two CD N
training NN N
forms NNS N
are VBP N
almost RB N
equivalent JJ N
. . N

Treatment NN N
of IN N
beta-hemolytic JJ 1_p
streptococcal JJ 1_p
pharyngitis NN 1_p
with IN N
cefaclor NN 1_i
or CC 1_i
penicillin NN 1_i
. . 1_i

Efficacy NN N
and CC N
interaction NN N
with IN N
beta-lactamase-producing JJ N
organisms NNS N
in IN N
the DT N
pharynx NN N
. . N

The DT N
recommended JJ N
treatment NN N
for IN N
group NN 1_p
A NNP 1_p
beta-hemolytic JJ 1_p
streptococcal JJ 1_p
pharyngitis NN 1_p
has VBZ N
continued VBN N
to TO N
be VB N
penicillin JJ 1_i
given VBN N
in IN N
parenteral JJ N
or CC N
oral JJ N
form NN N
. . N

Treatment NNP 1_o
failures NNS 1_o
, , N
as IN N
determined VBN N
by IN N
the DT N
continued JJ N
presence NN N
of IN N
the DT N
streptococcal JJ N
organism NN N
in IN N
the DT N
pharynx NN N
, , N
however RB N
, , N
do VBP N
occur VB N
in IN N
6 CD N
% NN N
to TO N
25 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
penicillin NN N
. . N

Furthermore RB N
, , N
beta-lactamase NN N
produced VBN N
by IN N
other JJ N
bacteria NNS N
in IN N
the DT N
pharynx NN N
could MD N
potentially RB N
inactivate VB N
the DT N
penicillin NN N
, , N
resulting VBG N
in IN N
increased VBN N
treatment NN 1_o
failures NNS 1_o
or CC 1_o
infection NN 1_o
relapses NNS 1_o
. . 1_o

A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
cefaclor NN 1_i
, , N
which WDT N
is VBZ N
relatively RB N
resistant JJ N
to TO N
inactivation VB N
by IN N
beta-lactamase NN N
, , N
with IN N
penicillin NN N
for IN N
eradicating VBG N
the DT N
group NN 1_p
A DT 1_p
beta-hemolytic JJ 1_p
streptococcal JJ 1_p
organism NN 1_p
from IN 1_p
the DT 1_p
throats NNS 1_p
of IN 1_p
93 CD 1_p
patients NNS 1_p
with IN 1_p
pharyngitis NN 1_p
. . 1_p

Additionally RB N
, , N
extensive JJ N
cultures NNS N
for IN N
potential JJ N
beta-lactamase-producing JJ N
organisms NNS N
were VBD N
conducted VBN N
on IN N
37 CD 1_p
patients NNS 1_p
; : 1_p
27 CD 1_p
% NN 1_p
of IN 1_p
these DT 1_p
had VBD 1_p
one CD 1_p
or CC 1_p
more JJR 1_p
pharyngeal JJ 1_p
organisms NNS 1_p
that WDT 1_p
were VBD 1_p
producing VBG 1_p
beta-lactamase NN 1_p
. . 1_p

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
clinical JJ 1_o
responses NNS 1_o
or CC 1_o
the DT 1_o
bacteriological JJ 1_o
cure NN 1_o
rates NNS 1_o
of IN N
those DT N
treated VBN N
with IN N
cefaclor NN N
and CC N
those DT N
treated VBN N
with IN N
penicillin NN N
when WRB N
stratified VBN N
by IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
beta-lactamase-producing JJ N
organisms NNS N
. . N

The DT N
prevalence NN 1_o
of IN 1_o
beta-lactamase-producing JJ 1_o
organisms NNS 1_o
in IN 1_o
the DT 1_o
pharynx NN 1_o
, , N
however RB N
, , N
was VBD N
increased VBN N
after IN N
treatment NN N
with IN N
penicillin NN N
, , N
whereas IN N
no DT N
change NN N
was VBD N
noted VBN N
following VBG N
treatment NN 1_o
with IN 1_o
cefaclor NN 1_o
. . 1_o

[ JJ N
Clinical NNP N
diagnosis NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
after IN N
hip NN N
replacement NN N
surgery NN N
] NN N
. . N

Hip NNP N
replacement NN N
surgery NN N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
frequency NN N
of IN N
postoperative JJ N
deep JJ N
vein NN N
thrombosis NN N
. . N

This DT N
prospective JJ N
study NN N
was VBD N
performed VBN N
in IN N
order NN N
to TO N
investigate VB N
if IN N
routine JJ 1_i
bedside NN 1_i
questioning VBG 1_i
and CC 1_i
examination NN 1_i
by IN 1_i
the DT 1_i
visiting NN 1_i
doctor NN 1_i
could MD N
reveal VB N
deep JJ N
vein NN N
thrombosis NN N
in IN N
the DT N
legs NN N
of IN N
patients NNS 1_p
who WP 1_p
had VBD 1_p
received VBN 1_p
a DT 1_p
hip NN 1_p
replacement NN 1_p
. . 1_p

258 CD 1_p
patients NNS 1_p
were VBD 1_p
evaluated VBN 1_p
. . 1_p

Thromboprophylaxis NNP 1_i
( ( 1_i
dextran-70 JJ 1_i
, , 1_i
low JJ 1_i
molecular JJ 1_i
weight NN 1_i
heparin NN 1_i
and CC 1_i
graded VBD 1_i
elastic JJ 1_i
stockings NNS 1_i
) ) 1_i
was VBD N
given VBN N
during IN N
the DT N
first JJ N
week NN N
after IN N
operation NN N
. . N

Bilateral NNP 1_i
venography NN 1_i
was VBD N
performed VBN N
in IN N
all DT N
patients NNS N
on IN N
day NN N
seven CD N
after IN N
operation NN N
, , N
and CC N
showed VBD N
an DT N
overall JJ N
deep JJ N
vein NN N
thrombosis NN N
incidence NN N
of IN N
16 CD N
% NN N
. . N

The DT N
visiting NN N
doctors NNS N
had VBD N
not RB N
suspected VBN N
deep JJ N
vein NN N
thrombosis NN N
in IN N
any DT N
of IN N
the DT N
patients NNS N
. . N

This DT N
may MD N
have VB N
been VBN N
because RB N
postoperative JJ 1_o
painful NN 1_o
and CC 1_o
swollen JJ 1_o
legs NNS 1_o
effectively RB N
masked VBD N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
deep JJ N
vein NN N
thrombosis NN N
. . N

Our PRP$ N
results NNS N
show VBP N
that IN N
deep JJ 1_o
vein NN 1_o
thrombosis NN 1_o
during IN N
the DT N
first JJ N
week NN N
after IN N
hip NN N
replacement NN N
surgery NN N
can MD N
not RB N
be VB N
discovered VBN N
by IN N
clinical JJ N
diagnostics NNS N
. . N

The DT N
high JJ N
subclinical JJ N
frequency NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
indicates VBZ N
the DT N
importance NN N
of IN N
improving VBG N
thromboprophylaxis NN N
in IN N
order NN N
to TO N
further RBR N
minimise VB N
the DT N
occurrence NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
and CC N
the DT N
risk NN N
of IN N
thromboembolic JJ N
complications NNS N
. . N

Validation NN N
of IN N
an DT N
FFQ NNP N
for IN N
evaluation NN N
of IN N
EPA NNP 1_o
and CC 1_o
DHA NNP 1_o
intake VBP 1_o
. . 1_o

OBJECTIVE NNP N
To TO N
validate VB N
an DT N
FFQ NNP N
for IN N
the DT N
assessment NN N
of IN N
dietary JJ N
EPA NNP 1_o
and CC 1_o
DHA NNP 1_o
against IN N
their PRP$ N
relative JJ 1_o
concentrations NNS 1_o
in IN 1_o
red JJ 1_o
blood NN 1_o
cells NNS 1_o
( ( 1_o
RBC NNP 1_o
) ) 1_o
. . 1_o

DESIGN NNP N
Cross-sectional JJ N
analysis NN N
of IN N
baseline NN N
data NNS N
. . N

Intakes NNS N
of IN N
marine NN 1_i
food NN 1_i
products NNS 1_i
and CC N
EPA NNP 1_i
and CC N
DHA NNP 1_i
were VBD N
estimated VBN N
by IN N
FFQ NNP N
on IN N
the DT N
basis NN N
of IN N
consumption NN N
of IN N
marine NN 1_i
food NN 1_i
products NNS 1_i
in IN N
the DT N
last JJ N
month NN N
. . N

Fatty NNP N
acid JJ N
composition NN N
of IN N
RBC NNP N
membranes NNS N
was VBD N
quantified VBN N
by IN N
GC NNP N
. . N

SETTING NNP N
Saint-François JJ 1_p
d'Assise NN 1_p
Hospital NNP 1_p
, , 1_p
Québec NNP 1_p
, , 1_p
Canada NNP 1_p
. . N

SUBJECTS NNP N
A NNP N
total NN N
of IN 1_p
sixty-five JJ 1_p
middle-aged JJ 1_p
women NNS 1_p
who WP 1_p
participated VBD 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
clinical JJ 1_p
trial NN 1_p
. . N

RESULTS NNP N
Spearman NNP N
's POS N
correlation NN N
coefficient NN N
between IN 1_o
intake NN 1_o
of IN 1_o
EPA NNP 1_o
, , 1_o
DHA NNP 1_o
and CC 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
and CC N
their PRP$ N
corresponding JJ 1_o
concentration NN 1_o
in IN 1_o
RBC NNP 1_o
was VBD N
0.46 CD N
, , N
0.40 CD N
and CC N
0.42 CD N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
of IN 1_o
EPA+DHA NNP 1_o
intake NN 1_o
and CC 1_o
RBC NNP 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
concentration NN 1_o
indicated VBD N
positive JJ N
and CC N
significant JJ N
correlations NNS N
for IN N
oily RB N
fish JJ N
( ( N
beta JJ N
= NN N
0.44 CD N
, , N
95 CD N
% NN N
CI NNP N
0.16 CD N
, , N
0.72 CD N
, , N
P NNP N
= NNP N
0.0027 CD N
) ) N
, , N
total JJ N
fish NN N
( ( N
beta JJ N
= NN N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.19 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0005 CD N
) ) N
and CC 1_i
marine VB 1_i
food NN 1_i
products NNS 1_i
( ( N
beta NN N
= RB N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.20 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

No UH N
other JJ N
marine VB N
food NN N
products NNS N
significantly RB N
predicted VBD 1_o
RBC NNP 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
concentration NN 1_o
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
present JJ N
validation NN N
study NN N
was VBD N
undertaken VBN N
among IN 1_p
middle-aged JJ 1_p
women NNS 1_p
with IN 1_p
low JJ 1_p
consumption NN 1_p
of IN 1_p
marine NN 1_p
food NN 1_p
products NNS 1_p
( ( 1_p
< $ 1_p
3 CD 1_p
servings/week NN 1_p
) ) 1_p
, , N
our PRP$ N
FFQ NNP N
provided VBD N
estimates NNS N
of IN 1_o
EPA NNP 1_o
and CC 1_o
DHA NNP 1_o
intakes NNS 1_o
that WDT N
correlated VBD N
fairly RB N
well RB N
with IN N
their PRP$ 1_o
RBC NNP 1_o
concentrations NNS 1_o
. . N

However RB N
, , N
the DT N
absence NN N
of IN N
correlations NNS N
between IN 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
intakes NNS 1_o
from IN N
different JJ N
marine NN N
species NNS N
suggests VBZ N
that IN N
a DT N
minimum JJ 1_i
EPA NNP 1_i
+ NNP 1_i
DHA NNP 1_i
intake NN N
is VBZ N
necessary JJ N
to TO N
observe VB N
a DT N
relationship NN N
with IN 1_o
RBC NNP 1_o
EPA NNP 1_o
+ NNP 1_o
DHA NNP 1_o
concentrations NNS 1_o
. . N

A DT 1_p
randomized VBN 1_p
controlled JJ 1_p
trial NN 1_p
of IN 1_p
ergotamine JJ 1_i
tartrate NN 1_i
. . 1_i

Aerobic NNP 1_i
versus NN 1_i
resistance NN 1_i
training NN 1_i
effects NNS N
on IN N
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
body NN 1_o
composition NN 1_o
, , 1_o
and CC 1_o
function NN 1_o
of IN 1_o
older JJR 1_o
adults NNS 1_o
. . 1_o

This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
training VBG N
on IN N
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
HRQoL NNP 1_o
) ) 1_o
, , 1_o
body NN 1_o
composition NN 1_o
, , 1_o
and CC 1_o
function NN 1_o
in IN 1_p
older JJR 1_p
adults NNS 1_p
. . 1_p

Fifty JJ 1_p
participants NNS 1_p
were VBD 1_p
randomized VBN 1_p
into IN N
aerobic JJ 1_i
training NN 1_i
( ( N
AT NNP N
-- : N
70 CD N
% NN N
-80 CD N
% NN N
HR NNP N
reserve NN N
) ) N
, , N
resistance NN 1_i
training NN 1_i
( ( N
RT NNP N
-- : N
80 CD N
% NN N
1RM CD N
) ) N
, , N
or CC N
controls NNS 1_i
. . 1_i

They PRP N
had VBD N
HRQoL NNP 1_o
, , 1_o
body NN 1_o
composition NN 1_o
, , 1_o
and CC 1_o
function NN 1_o
assessed VBN N
before IN N
and CC N
after IN N
8 CD N
months NNS N
. . N

Training VBG N
groups NNS N
reduced VBD 1_o
body NN 1_o
fat JJ 1_o
, , 1_o
increased JJ 1_o
performance NN 1_o
in IN 1_o
the DT 1_o
stair NN 1_o
ascent NN 1_o
, , 1_o
8-ft JJ 1_o
up-and-go JJ 1_o
and CC 1_o
sit-to-stand JJ 1_o
five-times JJ 1_o
tests NNS 1_o
, , N
and CC N
improved VBD 1_o
their PRP$ 1_o
physical JJ 1_o
component NN 1_o
score NN 1_o
( ( N
PCS NNP N
; : N
p CC N
≤ NNP N
.03 NNP N
) ) N
. . N

AT NNP 1_o
increased VBD 1_o
performance NN 1_o
in IN N
the DT N
6MWT CD N
test NN N
, , N
and CC 1_o
improved VBN 1_o
general JJ 1_o
and CC 1_o
mental JJ 1_o
health NN 1_o
( ( 1_o
MH NNP 1_o
) ) 1_o
domains VBZ N
when WRB N
compared VBN N
to TO N
controls NNS N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

Finally RB N
, , N
changes NNS N
in IN N
stair NN N
ascent NN N
were VBD N
associated VBN N
with IN 1_o
changes NNS 1_o
in IN 1_o
bodily RB 1_o
pain NN 1_o
, , 1_o
MH NNP 1_o
, , 1_o
and CC 1_o
mental JJ 1_o
component NN 1_o
score NN 1_o
( ( N
p JJ N
≤ NNP N
.04 NNP N
) ) N
, , N
while IN N
changes NNS 1_o
in IN 1_o
handgrip NN 1_o
strength NN 1_o
were VBD N
associated VBN N
with IN 1_o
changes NNS 1_o
in IN 1_o
physical JJ 1_o
role NN 1_o
and CC 1_o
MH NNP N
( ( N
p JJ N
= NNP N
.03 NNP 1_i
) ) 1_i
. . 1_i

AT NNP N
and CC 1_i
RT NNP N
were VBD N
effective JJ N
interventions NNS N
for IN N
decreasing VBG 1_o
body NN 1_o
fat JJ N
and CC N
improving VBG 1_o
functionality NN 1_o
and CC N
the DT 1_o
PCS NNP 1_o
in IN 1_o
older JJR 1_o
adults NNS 1_o
. . N

Safety NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
cold-adapted JJ N
influenza NN 1_i
vaccine NN 1_i
, , 1_i
trivalent NN 1_i
, , N
in IN N
infants NNS 1_p
younger JJR 1_p
than IN 1_p
6 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

OBJECTIVE NNP N
Young NNP 1_p
children NNS 1_p
are VBP N
at IN N
high JJ N
risk NN N
for IN N
influenza-related JJ N
complications NNS N
. . N

Vaccination NN N
of IN N
close JJ N
household NN N
contacts NNS N
is VBZ N
recommended VBN N
to TO N
provide VB N
indirect JJ N
protection NN N
to TO N
children NNS 1_p
< $ 1_p
6 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

Studies NNS N
have VBP N
shown VBN N
that IN N
live JJ N
, , N
cold-adapted JJ N
influenza NN 1_i
vaccine NN 1_i
, , N
trivalent NN N
, , N
is VBZ N
efficacious JJ N
in IN N
children NNS 1_p
. . 1_p

To TO N
assess VB N
the DT N
risks NNS N
associated VBN N
with IN N
inadvertent JJ N
exposure NN N
of IN N
infants NNS N
to TO N
vaccine VB N
viruses NNS N
from IN N
vaccinated JJ N
contacts NNS N
, , N
this DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
safety NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
cold-adapted JJ N
influenza NN 1_i
vaccine NN 1_i
, , N
trivalent NN N
, , N
administered VBN N
intranasally RB N
to TO N
healthy JJ 1_p
children NNS 1_p
6 CD 1_p
to TO 1_p
< VB 1_p
24 CD 1_p
weeks NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

METHODS NNP N
Healthy NNP 1_p
infants NNS 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
< VB 1_p
16 CD 1_p
weeks NNS 1_p
and CC 1_p
16 CD 1_p
to TO 1_p
< VB 1_p
24 CD 1_p
weeks NNS 1_p
, , N
respectively RB N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
2 CD 1_i
doses NNS 1_i
of IN 1_i
influenza JJ 1_i
vaccine NN 1_i
, , 1_i
or CC 1_i
placebo VB 1_i
intranasally RB N
35 CD N
+/- JJ N
7 CD N
days NNS N
apart RB N
. . N

Reactogenicity NN N
events NNS N
were VBD N
monitored VBN N
for IN N
11 CD N
days NNS N
after IN N
each DT N
dose NN N
. . N

Other JJ N
adverse JJ N
events NNS N
were VBD N
monitored VBN N
through IN N
28 CD N
to TO N
35 CD N
days NNS N
after IN N
dose JJ N
2 CD N
. . N

RESULTS NN N
Of IN N
the DT N
infants NNS 1_p
aged VBD 1_p
6 CD 1_p
to TO 1_p
< VB 1_p
16 CD 1_p
weeks NNS 1_p
, , N
31 CD N
received VBD N
influenza JJ 1_i
vaccine NN 1_i
and CC N
28 CD N
received VBD N
placebo NN 1_i
, , N
and CC N
of IN N
those DT 1_p
aged VBN 1_p
16 CD 1_p
to TO 1_p
< VB 1_p
24 CD 1_p
weeks NNS 1_p
, , N
30 CD N
received VBD N
influenza JJ 1_i
vaccine NN 1_i
and CC N
31 CD N
received VBD N
placebo NN 1_i
. . 1_i

In IN N
the DT N
6- JJ N
to TO N
< VB N
16-week JJ N
cohort NN N
, , N
more JJR N
influenza JJ N
vaccine NN N
, , N
recipients NNS N
experienced VBD N
irritability NN 1_o
( ( N
66.7 CD N
% NN N
vs JJ N
35.7 CD N
% NN N
) ) N
and CC N
runny JJ 1_o
nose NN 1_o
or CC 1_o
nasal JJ 1_o
congestion NN 1_o
( ( N
63.3 CD N
% NN N
vs JJ N
33.3 CD N
% NN N
) ) N
after IN N
dose JJ N
1 CD N
but CC N
not RB N
dose JJ N
2 CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
increases NNS N
in IN N
any DT N
other JJ N
reactogenicity NN 1_o
events NNS 1_o
or CC 1_o
adverse JJ 1_o
events NNS 1_o
in IN N
the DT N
vaccine NN N
recipients NNS N
compared VBN N
with IN N
the DT N
placebo NN 1_i
group NN N
. . N

CONCLUSIONS NNP N
Although IN N
there EX N
was VBD N
an DT N
increase NN N
in IN N
mild JJ 1_o
reactogenicity NN 1_o
events NNS 1_o
in IN N
children NNS 1_p
6 CD 1_p
to TO 1_p
< VB 1_p
16 CD 1_p
weeks NNS 1_p
of IN 1_p
age NN 1_p
, , N
cold-adapted JJ N
influenza NN 1_i
vaccine NN 1_i
, , N
trivalent NN N
, , N
was VBD N
generally RB N
well RB N
tolerated VBN N
in IN N
infants NNS 1_p
6 CD 1_p
to TO 1_p
< VB 1_p
24 CD 1_p
weeks NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

These DT N
findings NNS N
support NN N
further JJ N
evaluation NN N
of IN N
cold-adapted JJ N
influenza NN 1_i
vaccine NN 1_i
, , N
trivalent NN N
, , N
in IN N
infants NNS 1_p
< VBP 1_p
6 CD 1_p
months NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

Effect NN 1_o
of IN N
hydrochlorothiazide NN 1_i
therapy NN 1_i
on IN N
cardiac JJ 1_o
arrhythmias NN 1_o
in IN 1_p
African-American JJ 1_p
men NNS 1_p
with IN 1_p
systemic JJ 1_p
hypertension NN 1_p
and CC 1_p
moderate VB 1_p
to TO 1_p
severe VB 1_p
left JJ 1_p
ventricular JJ 1_p
hypertrophy NN 1_p
. . 1_p

The DT N
effect NN N
of IN N
hydrochlorothiazide NN 1_i
therapy NN 1_i
on IN N
ventricular JJ 1_o
arrhythmias NN 1_o
was VBD N
studied VBN N
in IN N
45 CD 1_p
hypertensive JJ 1_p
African-American JJ 1_p
men NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
left VBN 1_p
ventricular JJ 1_p
( ( 1_p
LV NNP 1_p
) ) 1_p
hypertrophy NN 1_p
. . 1_p

After IN N
medication NN N
washout NN N
, , N
patients NNS 1_i
were VBD 1_i
treated VBN 1_i
with IN 1_i
placebo NN 1_i
followed VBN 1_i
by IN 1_i
hydrochlorothiazide NN 1_i
. . 1_i

Clinical NNP 1_o
, , 1_o
biochemical JJ 1_o
, , 1_o
and CC 1_o
48-hour JJ 1_o
ambulatory NN 1_o
electrocardiographic JJ 1_o
data NN 1_o
was VBD N
collected VBN N
after IN N
each DT N
treatment NN N
phase NN N
. . N

Signal-averaged JJ 1_o
electrocardiograms NNS 1_o
were VBD N
recorded VBN N
in IN N
a DT N
subgroup NN 1_p
of IN 1_p
24 CD 1_p
patients NNS 1_p
. . 1_p

Average JJ 1_o
LV NNP 1_o
posterior NN 1_o
wall NN 1_o
thickness NN 1_o
was VBD N
15 CD N
+/- JJ N
1.1 CD N
mm NN N
, , N
septum VBD N
16 CD N
+/- JJ N
2 CD N
mm NN N
, , N
LV NNP N
mass VBD N
420 CD N
+/- JJ N
90 CD N
g NN N
, , N
and CC N
LV NNP N
mass NNP N
index NN N
212 CD N
= NN N
51 CD N
g/m2 NN N
. . N

Systolic NNP 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
was VBD N
168 CD N
+/- JJ N
18 CD N
mm NN N
Hg NNP N
after IN N
the DT N
placebo NN N
phase NN N
and CC N
146 CD N
+/- JJ N
15 CD N
mm NN N
Hg NNP N
after IN N
hydrochlorothiazide NN N
; : N
diastolic JJ N
BP NNP N
was VBD N
103 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
and CC N
89 CD N
+/- JJ N
9 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

Serum NNP 1_o
potassium NN 1_o
decreased VBD N
significantly RB N
from IN N
4.2 CD N
+/- JJ N
0.4 CD N
mmol/L NN N
to TO N
3.7 CD N
+/- JJ N
0.6 CD N
mmol/L NN N
after IN N
hydrochlorothiazide JJ 1_i
therapy NN 1_i
. . 1_i

The DT N
average JJ N
hourly JJ N
incidence NN N
of IN N
ventricular JJ 1_o
premature NN 1_o
contractions NNS 1_o
was VBD N
22 CD N
with IN N
placebo NN 1_i
and CC N
25 CD N
with IN N
hydrochlorothiazide NN 1_i
. . 1_i

There EX N
were VBD N
3 CD N
and CC N
1 CD N
couplets NNS N
and CC N
0.2 CD N
and CC N
0.2 CD N
runs NNS N
of IN N
ventricular JJ 1_o
tachycardia NN 1_o
per IN N
patient NN N
per IN N
hour NN N
, , N
respectively RB N
. . N

Variables NNS N
of IN N
signal-averaged JJ 1_o
electrocardiography NN 1_o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
treatments NNS N
. . N

Thus RB N
, , N
in IN N
hypertensive JJ 1_p
African-American JJ 1_p
men NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
LV NNP 1_p
hypertrophy NN 1_p
, , N
hydrochlorothiazide NN 1_i
does VBZ N
not RB N
worsen VB N
ventricular JJ 1_o
arrhythmias NNS 1_o
or CC N
signal-averaged JJ 1_o
electrocardiographic JJ 1_o
variables NNS 1_o
. . 1_o

The DT N
effects NNS 1_o
of IN N
prism NN N
adaptation NN N
on IN N
egocentric JJ N
metric JJ 1_o
distance NN 1_o
estimation NN 1_o
. . 1_o

OBJECTIVE CC N
The DT N
present JJ N
experiment NN N
evaluated VBD N
whether IN N
training VBG N
involving VBG N
throwing VBG N
transferred VBN N
to TO N
metric JJ N
distance NN N
estimation NN N
( ( N
i.e. FW N
, , N
describing VBG N
in IN N
feet NNS N
and CC N
inches VBZ N
the DT N
distance NN N
between IN N
oneself NN N
and CC N
targets NNS N
) ) N
. . N

BACKGROUND NNP N
In IN N
prior JJ N
work NN N
, , N
we PRP N
found VBD N
that IN N
metric JJ N
estimation NN N
training NN N
negatively RB N
transferred VBN N
to TO N
throwing VBG N
. . N

We PRP N
explained VBD N
our PRP$ N
results NNS N
in IN N
terms NNS N
of IN N
cognitive JJ N
intrusion NN N
. . N

The DT N
present JJ N
study NN N
tested VBD N
that IN N
possibility NN N
by IN N
swapping VBG N
our PRP$ N
training NN N
and CC N
transfer NN N
tasks NNS N
. . N

METHOD NNP N
During IN N
pretesting VBG N
, , N
participants NNS 1_p
verbally RB 1_i
estimated VBD 1_i
the DT 1_i
metric JJ 1_i
distances NNS 1_i
between IN 1_p
themselves PRP 1_p
and CC 1_p
targets NNS 1_p
, , 1_p
or CC 1_p
they PRP 1_p
threw VBD 1_i
a DT 1_i
beanbag NN 1_i
to TO 1_i
targets NNS 1_i
. . 1_i

During IN N
training NN N
, , N
participants NNS 1_i
donned VBD 1_i
goggles NNS 1_i
that WDT N
distorted VBD N
their PRP$ N
vision NN N
. . N

While IN N
wearing VBG N
the DT N
goggles NNS N
, , N
they PRP N
threw VBD 1_i
a DT 1_i
beanbag NN 1_i
to TO 1_i
targets NNS 1_i
. . 1_i

Half NNP N
received VBD N
feedback RB N
. . N

During IN N
posttesting VBG N
, , N
participants NNS N
removed VBD N
the DT N
distorting NN N
goggles NNS 1_i
and CC N
completed VBD N
the DT N
same JJ N
task NN N
that IN N
they PRP N
performed VBD N
during IN N
pretesting VBG N
. . N

RESULTS VB N
The DT N
results NNS N
indicated VBD N
that IN N
the DT N
distorting NN N
goggles NNS N
degraded VBD N
throwing VBG N
at IN N
the DT N
beginning NN N
of IN N
training NN N
, , N
visual JJ N
feedback NN N
improved VBD N
throwing VBG N
during IN N
training NN N
, , N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
persisted VBN N
into IN N
the DT N
throwing VBG N
posttest NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
did VBD N
not RB N
transfer VB N
to TO N
the DT N
verbal JJ 1_o
metric JJ 1_o
estimation NN 1_o
posttest NN N
. . N

CONCLUSION NNP N
Training VBG N
involving VBG N
throwing NN 1_o
was VBD N
effective JJ 1_o
, , N
but CC N
did VBD N
not RB N
transfer VB N
to TO N
verbal VB 1_o
metric JJ 1_o
distance NN 1_o
estimation NN 1_o
. . 1_o

This DT N
supports VBZ N
our PRP$ N
argument NN N
that IN N
the DT N
negative JJ N
transfer NN N
observed VBN N
in IN N
our PRP$ N
previous JJ N
study NN N
stemmed VBD N
from IN N
cognitive JJ N
intrusion NN N
. . N

APPLICATION VB N
The DT N
present JJ N
experiment NN N
suggests VBZ N
that IN N
the DT N
creation NN N
of IN N
distance NN N
estimation NN N
training NN N
should MD N
begin VB N
with IN N
a DT N
careful JJ N
analysis NN N
of IN N
the DT N
transfer NN N
task NN N
, , N
and CC N
that DT N
distance NN N
estimation NN N
training NN N
programs NNS N
should MD N
explicitly RB N
teach VB N
trainees NNS 1_p
that IN 1_p
their PRP$ 1_p
training NN 1_p
will MD N
not RB N
generalize VB N
to TO N
all DT N
distance NN N
estimation NN N
tasks NNS N
. . N

Efficacy NN 1_o
of IN N
second JJ 1_i
versus NN N
third JJ 1_i
generation NN 1_i
oral JJ 1_i
contraceptives NNS 1_i
in IN N
the DT N
treatment NN N
of IN N
hirsutism NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
compare VB N
second JJ 1_i
versus JJ N
third JJ 1_i
generation NN 1_i
combination NN 1_i
oral JJ 1_i
contraceptives NNS 1_i
( ( 1_i
OCs NNP 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
hirsutism NN 1_p
. . 1_p

METHODS NNP N
Women NNP 1_p
with IN 1_p
hirsutism NN 1_p
, , 1_p
as IN 1_p
defined VBN 1_p
by IN 1_p
a DT 1_p
minimum JJ 1_p
Ferriman-Gallwey JJ 1_p
score NN 1_p
of IN 1_p
10 CD 1_p
, , N
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
receive VB N
an DT N
OC NNP N
containing NN N
either CC N
ethinyl JJ 1_i
estradiol/desogestrel NN 1_i
or CC N
ethinyl NN 1_i
estradiol/levonorgestrel NN 1_i
for IN N
9 CD N
months NNS N
of IN N
treatment NN N
. . N

Ferriman-Gallwey JJ 1_o
scores NNS 1_o
, , 1_o
androgen NN 1_o
levels NNS 1_o
and CC 1_o
sex NN 1_o
hormone-binding JJ 1_o
globulin NN 1_o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
for IN N
the DT N
duration NN N
of IN N
the DT N
study NN N
. . N

Hormones NNS 1_o
were VBD N
measured VBN N
in IN N
duplicate NN N
by IN N
radioimmunoassay NN N
. . N

RESULTS NNP N
Of IN N
the DT N
47 CD 1_p
women NNS 1_p
enrolled VBD 1_p
, , N
24 CD N
were VBD N
randomized VBN N
to TO N
ethinyl VB 1_i
estradiol/desogestrel NN 1_i
and CC N
23 CD N
were VBD N
randomized VBN N
to TO N
ethinyl VB 1_i
estradiol/levonorgestrel NN 1_i
. . 1_i

Mean JJ 1_o
sex NN 1_o
hormone-binding JJ 1_o
globulin NN 1_o
increased VBD N
significantly RB N
in IN N
subjects NNS N
using VBG N
the DT N
desogestrel-containing JJ 1_i
contraceptive NN 1_i
compared VBN N
with IN N
the DT N
levonorgestrel-containing JJ 1_i
contraceptive NN 1_i
. . 1_i

Ten CD N
subjects NNS N
completed VBD N
the DT N
9 CD N
months NNS N
of IN N
treatment NN N
in IN N
the DT N
levonorgestrel NN 1_i
group NN N
and CC N
11 CD N
completed VBD N
the DT N
study NN N
in IN N
the DT N
desogestrel NN 1_i
group NN N
. . N

Mean NNP 1_o
free JJ 1_o
testosterone NN 1_o
and CC 1_o
3alpha-androstanediol JJ 1_o
glucuronide NN 1_o
decreased VBD N
significantly RB N
in IN N
the DT N
group NN N
receiving VBG N
ethinyl JJ 1_i
estradiol/desogestrel NN 1_i
but CC N
not RB N
in IN N
the DT N
ethinyl NN 1_i
estradiol/levonorgestrel NN 1_i
group NN N
. . N

Mean JJ 1_o
Ferriman-Gallwey JJ 1_o
scores NNS 1_o
decreased VBN N
significantly RB N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Improvement NNP N
in IN N
mean JJ N
Ferriman-Gallwey NNP 1_o
score NN 1_o
was VBD N
35.7 CD N
+/- JJ N
38.1 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
for IN N
the DT N
ethinyl NN 1_i
estradiol/desogestrel NN 1_i
arm NN N
and CC N
33.4 CD N
+/- JJ N
27.3 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
for IN N
the DT N
ethinyl NN 1_i
estradiol/levonorgestrel NN 1_i
arm NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
found VBN N
in IN N
the DT N
improvement NN N
of IN N
Ferriman-Gallwey NNP 1_o
scores NNS 1_o
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
, , N
although IN N
the DT N
power NN N
to TO N
detect VB N
a DT N
difference NN N
was VBD N
limited VBN N
by IN N
the DT N
small JJ N
sample NN N
size NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
of IN N
hirsute JJ N
women NNS N
with IN N
third JJ 1_i
generation NN 1_i
OCs NNP 1_i
containing VBG N
desogestrel NN 1_i
results NNS N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
sex NN 1_o
hormone-binding JJ 1_o
globulin NN 1_o
and CC N
decrease NN N
in IN N
free JJ 1_o
testosterone NN 1_o
and CC 1_o
3alpha-androstanediol JJ 1_o
glucuronide NN 1_o
. . 1_o

Both DT N
second JJ 1_i
and CC 1_i
third JJ 1_i
generation NN 1_i
OCs NNP 1_i
were VBD N
clinically RB N
effective JJ N
in IN N
treating VBG N
hirsutism NN 1_p
. . 1_p

[ RB N
Long NNP N
term NN N
observation NN N
in IN N
effects NNS N
of IN N
potassium NN 1_i
and CC 1_i
calcium NN 1_i
supplementation NN 1_i
on IN N
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
and CC 1_o
sodium NN 1_o
metabolism NN 1_o
in IN N
adolescents NNS 1_p
with IN 1_p
higher JJR 1_p
blood NN 1_p
pressure NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
potassium NN 1_i
and CC 1_i
calcium NN 1_i
supplementation NN 1_i
in IN N
table JJ N
salt NN N
on IN N
reduction NN N
of IN N
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
and CC 1_o
sodium NN 1_o
metabolism NN 1_o
in IN N
adolescents NNS 1_p
with IN 1_p
higher JJR 1_p
blood NN 1_p
pressure NN 1_p
. . 1_p

METHODS CC N
A DT N
single JJ N
blind NN N
placebo-controlled JJ 1_i
trial NN N
was VBD N
carried VBN N
out RP N
for IN N
two CD N
years NNS N
in IN N
220 CD 1_p
adolescents NNS 1_p
with IN 1_p
higher JJR 1_p
blood NN 1_p
pressure NN 1_p
, , 1_p
aged VBD 1_p
18 CD 1_p
- : 1_p
22 CD 1_p
years NNS 1_p
, , 1_p
who WP 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
supplementary JJ 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
110 CD 1_p
) ) 1_p
and CC 1_p
control NN 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
110 CD 1_p
) ) 1_p
. . 1_p

Each DT 1_p
of IN 1_p
the DT 1_p
subjects NNS 1_p
in IN 1_p
the DT 1_p
supplementary JJ 1_p
group NN 1_p
and CC 1_p
their PRP$ 1_p
family NN 1_p
members NNS 1_p
was VBD N
given VBN N
10 CD 1_i
mmol NN 1_i
of IN 1_i
potassium NN 1_i
and CC 1_i
10 CD 1_i
mmol NN 1_i
of IN 1_i
calcium NN 1_i
mixed VBN 1_i
in IN 1_i
their PRP$ 1_i
table JJ 1_i
salt JJ 1_i
daily RB N
for IN N
24 CD N
months NNS N
. . N

RESULTS NNP N
Night NNP 1_o
urinary JJ 1_o
sodium NN 1_o
and CC 1_o
potassium JJ 1_o
excretion NN 1_o
increased VBD N
( ( N
urinary JJ N
Na NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
urinary JJ N
K NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
blood NN 1_o
pressure NN 1_o
lowered VBN 1_o
by IN N
5.3 CD N
mm NNS N
Hg/1.8 NNP N
mm NN N
Hg NNP N
in IN N
average NN N
from IN N
the DT N
baseline NN N
in IN N
the DT N
supplementary JJ N
group NN N
two CD N
years NNS N
after IN N
potassium NN 1_i
and CC 1_i
calcium NN 1_i
supplementation NN 1_i
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
control NN N
group NN N
increased VBN N
by IN N
( ( N
1.3/1.7 CD N
) ) N
mm NN N
Hg NNP N
. . N

CONCLUSIONS NNP N
Adequate NNP N
supplement NN 1_i
of IN 1_i
potassium NN 1_i
and CC 1_i
calcium NN 1_i
in IN N
daily JJ N
table JJ N
salt NN N
intake NN N
was VBD N
an DT N
effective JJ N
way NN N
to TO N
prevent VB N
form NN 1_o
hypertension NN 1_o
and CC N
could MD N
promote VB N
their PRP$ N
urinary JJ 1_o
sodium NN 1_o
excretion NN 1_o
and CC 1_o
reduction NN 1_o
of IN 1_o
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
in IN N
adolescents NNS 1_p
with IN 1_p
higher JJR 1_p
blood NN 1_p
pressure NN 1_p
. . 1_p

Physical JJ 1_i
activity NN 1_i
in IN N
first-degree JJ 1_p
relatives NNS 1_p
of IN 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

This DT N
study NN N
sought VBD N
to TO N
evaluate VB N
physical JJ 1_i
activity NN 1_i
in IN N
women NNS 1_p
at IN 1_p
moderate JJ 1_p
risk NN 1_p
for IN 1_p
breast NN 1_p
cancer NN 1_p
, , N
the DT N
correlates NNS N
of IN N
engaging VBG N
in IN N
regular JJ N
physical JJ 1_i
activity NN 1_i
, , N
and CC N
whether IN N
physical JJ 1_i
activity NN 1_i
relates VBZ N
to TO N
psychological JJ 1_o
well-being NN 1_o
. . 1_o

The DT N
results NNS N
revealed VBD N
that IN N
55 CD 1_p
% NN 1_p
of IN 1_p
women NNS 1_p
were VBD 1_p
regularly RB 1_p
active JJ 1_p
. . 1_p

Logistic JJ N
regression NN N
models NNS N
indicated VBD N
that IN N
positive JJ N
affect NN N
was VBD N
associated VBN N
with IN N
increased JJ N
and CC N
negative JJ N
affect NN N
was VBD N
associated VBN N
with IN N
decreased JJ N
overall JJ N
and CC N
leisure NN 1_o
activity NN 1_o
. . 1_o

Older JJR N
, , N
married VBN N
, , N
and CC N
employed JJ N
women NNS N
were VBD N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
household/occupational JJ 1_o
activity NN 1_o
, , N
whereas JJ N
women NNS N
who WP N
perceived VBD N
their PRP$ N
risk NN N
for IN N
breast NN N
cancer NN N
as IN N
high JJ N
were VBD N
less RBR N
likely JJ N
. . N

More RBR N
educated JJ N
women NNS N
and CC N
those DT N
with IN N
higher JJR N
perceived VBN N
risk NN N
were VBD N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
leisure NN 1_o
activity NN 1_o
, , N
and CC N
married JJ N
women NNS N
were VBD N
less RBR N
likely JJ N
. . N

These DT N
results NNS N
suggest VBP N
a DT N
need NN N
to TO N
increase VB 1_i
activity NN 1_i
levels NNS 1_i
in IN N
women NNS 1_p
at IN 1_p
moderate JJ 1_p
risk NN 1_p
for IN 1_p
breast NN 1_p
cancer NN 1_p
, , N
provide VBP N
variables NNS N
upon IN N
which WDT N
interventions NNS N
can MD N
be VB N
tailored VBN N
to TO N
promote VB N
activity NN N
, , N
and CC N
point NN N
to TO N
psychological JJ N
benefits NNS N
of IN N
activity NN N
in IN N
this DT N
population NN N
. . N

A DT N
controlled VBN N
crossover NN N
trial NN N
of IN N
fenfluramine NN 1_i
in IN N
autism NN 1_p
. . 1_p

We PRP N
report VBP N
a DT N
12 CD N
month NN N
double-blind JJ N
randomized VBD N
crossover JJ N
trial NN N
of IN N
fenfluramine NN 1_i
in IN N
20 CD 1_p
children NNS 1_p
with IN 1_p
the DT 1_p
syndrome NN 1_p
of IN 1_p
autism NN 1_p
. . 1_p

On IN N
active JJ N
drug NN N
most JJS N
of IN N
the DT N
children NNS 1_p
lost VBD 1_o
weight NN 1_o
and CC 1_o
blood NN 1_o
serotonin NN 1_o
levels NNS 1_o
fell VBD N
by IN N
an DT N
average NN N
of IN N
60 CD N
% NN N
. . N

There EX N
was VBD N
a DT N
fall NN N
in IN N
urinary JJ 1_o
dopamine NN 1_o
( ( 1_o
DA NNP 1_o
) ) 1_o
and CC 1_o
noradrenaline JJ 1_o
( ( 1_o
NA NNP 1_o
) ) 1_o
levels NNS 1_o
and CC 1_o
increased JJ 1_o
excretion NN 1_o
of IN 1_o
homovanillic JJ 1_o
acid NN 1_o
( ( 1_o
HVA NNP 1_o
) ) 1_o
. . 1_o

Some DT N
of IN N
the DT N
children NNS 1_p
showed VBD N
improvement NN N
in IN N
tests NNS 1_o
of IN 1_o
cognitive JJ 1_o
and CC 1_o
language NN 1_o
function NN 1_o
, , N
although IN N
the DT N
results NNS N
did VBD N
not RB N
achieve VB N
overall JJ N
statistical JJ 1_o
significance NN 1_o
. . 1_o

Event-related JJ 1_o
brain NN 1_o
potentials NNS 1_o
( ( 1_o
ERPs NNP 1_o
) ) 1_o
were VBD N
obtained VBN N
in IN N
seven CD N
subjects NNS N
on IN N
an DT N
auditory JJ N
choice NN N
reaction NN N
time NN N
task NN N
. . N

Side JJ 1_o
effects NNS 1_o
of IN N
the DT N
drug NN N
included VBD N
irritability NN 1_o
and CC 1_o
lethargy NN 1_o
. . 1_o

Fenfluramine NN N
may MD N
have VB N
a DT N
limited JJ N
place NN N
in IN N
the DT N
management NN N
of IN N
some DT N
patients NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

A DT N
randomized JJ N
trial NN N
of IN N
tailored JJ N
skin NN N
cancer NN N
prevention NN N
messages NNS N
for IN N
adults NNS 1_p
: : 1_p
Project NN N
SCAPE NNP N
. . N

OBJECTIVES NNP N
We PRP N
evaluated VBD N
the DT N
impact NN N
of IN N
a DT N
mailed VBN 1_i
, , 1_i
tailored VBN 1_i
intervention NN 1_i
on IN N
skin JJ 1_o
cancer NN 1_o
prevention NN N
and CC N
skin JJ 1_o
self-examination NN 1_o
behaviors NNS 1_o
of IN N
adults NNS 1_p
at IN 1_p
moderate JJ 1_p
and CC 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
skin JJ 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
Adults NNP 1_p
at IN 1_p
moderate NNP 1_p
and CC 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
skin JJ 1_p
cancer NN 1_p
were VBD 1_p
recruited VBN 1_p
in IN 1_p
primary JJ 1_p
health NN 1_p
care NN 1_p
settings NNS 1_p
in IN 1_p
Honolulu NNP 1_p
, , 1_p
HI NNP 1_p
, , 1_p
and CC 1_p
Long NNP 1_p
Island NNP 1_p
, , 1_p
NY NNP 1_p
. . 1_p

After IN N
completing VBG N
a DT N
baseline NN N
survey NN N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
. . N

The DT N
treatment NN N
group NN N
received VBD N
tailored JJ 1_i
materials NNS 1_i
, , 1_i
including VBG 1_i
personalized VBN 1_i
risk NN 1_i
feedback NN 1_i
, , N
and CC N
the DT N
control NN 1_i
group NN N
received VBD N
general JJ 1_i
educational JJ 1_i
materials NNS 1_i
. . 1_i

Multivariate NNP N
analyses NNS N
compared VBN N
sun JJ 1_o
protection NN 1_o
and CC N
skin VB 1_o
self-examination NN 1_o
between IN N
groups NNS N
, , N
controlling VBG N
for IN N
location NN N
, , N
risk NN N
level NN N
, , N
gender NN N
, , N
and CC N
age NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
596 CD 1_p
adults NNS 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
. . 1_p

The DT N
tailored JJ N
materials NNS N
had VBD N
a DT N
significant JJ N
effect NN N
on IN N
overall JJ 1_o
sun-protection NN 1_o
habits NNS 1_o
, , 1_o
the DT 1_o
use NN 1_o
of IN 1_o
hats NNS 1_o
, , 1_o
the DT 1_o
use NN 1_o
of IN 1_o
sunglasses NNS 1_o
, , 1_o
and CC 1_o
the DT 1_o
recency NN 1_o
of IN 1_o
skin JJ 1_o
self-examination NN 1_o
. . 1_o

Some DT N
effects NNS N
were VBD N
moderated VBN N
by IN N
location NN N
and CC N
risk NN N
level NN N
. . N

CONCLUSIONS NNP N
Tailored NNP 1_i
communications NNS 1_i
including VBG N
personalized VBN N
risk NN N
feedback NN N
can MD N
improve VB N
sun-protection NN 1_o
behaviors NNS 1_o
and CC 1_o
skin JJ 1_o
self-examination NN 1_o
among IN N
adults NNS 1_p
at IN 1_p
increased VBN 1_p
risk NN 1_p
for IN 1_p
skin JJ 1_p
cancer NN 1_p
. . 1_p

These DT N
convenient NN N
, , N
low-cost JJ N
interventions NNS N
can MD N
be VB N
implemented VBN N
in IN N
a DT N
variety NN N
of IN N
settings NNS N
and CC N
should MD N
be VB N
tested VBN N
further JJ N
to TO N
assess VB N
their PRP$ N
long-term JJ N
effectiveness NN N
. . N

Randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
Behavioral NNP 1_i
Family NNP 1_i
Systems NNP 1_i
Therapy NNP 1_i
for IN N
Diabetes NNPS 1_p
: : 1_p
maintenance NN N
and CC N
generalization NN N
of IN N
effects NNS N
on IN N
parent-adolescent JJ N
communication NN N
. . N

We PRP N
report VBP N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
revised JJ N
Behavioral NNP 1_i
Family NNP 1_i
Systems NNP 1_i
Therapy NNP 1_i
for IN 1_i
Diabetes NNP 1_i
( ( 1_i
BFST-D NNP 1_i
) ) 1_i
intervention NN 1_i
. . N

Families NNS 1_p
of IN 1_p
104 CD 1_p
adolescents NNS 1_p
with IN 1_p
diabetes NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
standard VB 1_i
care NN 1_i
( ( 1_i
SC NNP 1_i
) ) 1_i
or CC 1_i
to TO 1_i
6 CD 1_i
months NNS 1_i
of IN 1_i
an DT 1_i
educational JJ 1_i
support NN 1_i
group NN 1_i
( ( 1_i
ES NNP 1_i
) ) 1_i
or CC 1_i
BFST-D. JJ 1_i
Family NNP 1_o
communication NN 1_o
and CC 1_o
problem-solving JJ 1_o
skills NNS 1_o
were VBD N
assessed VBN N
at IN N
0 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
by IN N
independent JJ N
rating NN N
of IN N
videotaped JJ N
family NN N
problem-solving JJ N
discussions NNS N
. . N

BFST-D NNP 1_i
improved VBD N
individual JJ N
communication NN 1_o
of IN 1_o
adolescents NNS 1_o
and CC 1_o
mothers NNS 1_o
, , 1_o
but CC 1_o
not RB 1_o
fathers NNS 1_o
. . 1_o

BFST-D NNP 1_i
significantly RB N
improved VBD N
quality NN 1_o
of IN 1_o
family NN 1_o
interaction NN 1_o
compared VBN N
to TO N
SC NNP N
( ( N
10 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
and CC N
ES NNP N
( ( N
6 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
. . N

Changes NNS N
in IN N
family NN N
communication NN N
were VBD N
differentially RB N
associated VBN N
with IN N
changes NNS N
in IN N
glycemic JJ 1_o
control NN 1_o
, , 1_o
adherence NN 1_o
, , 1_o
and CC 1_o
family NN 1_o
conflict NN 1_o
. . 1_o

BFST-D NNP 1_i
improved VBD N
family NN 1_o
communication NN 1_o
and CC 1_o
problem NN 1_o
solving VBG 1_o
relative JJ N
to TO N
SC NNP N
and CC N
modestly RB N
relative JJ N
to TO N
ES NNP N
. . N

[ JJ N
Cardiac NNP N
protection NN N
is VBZ N
a DT N
clinical JJ N
evidence NN N
] NN N
. . N

AIM NNP N
Anaesthetics NNPS N
may MD N
have VB N
protective JJ N
effect NN N
against IN N
myocardial JJ N
ischemia NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
if IN N
sevoflurane JJ N
administration NN N
could MD N
exert VB N
myocardial JJ 1_o
protection NN 1_o
during IN N
following VBG N
coronary JJ N
occlusion NN N
in IN N
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
. . 1_p

METHODS NNP N
a DT N
) ) N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

b NN N
) ) N
. . N

SETTING NN N
University NNP 1_p
Hospital NNP 1_p
, , 1_p
cardiac JJ 1_p
surgical JJ 1_p
operative NN 1_p
theatre NN 1_p
. . 1_p

c NN N
) ) N
. . N

PATIENTS $ N
42 CD 1_p
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
, , 1_p
scheduled VBN 1_p
to TO 1_p
undergo VB 1_p
coronary JJ 1_p
surgery NN 1_p
. . 1_p

INCLUSION NNP 1_p
CRITERIA NNP 1_p
severe JJ 1_p
coronary JJ 1_p
stenosis NN 1_p
of IN 1_p
anterior JJ 1_p
descending VBG 1_p
coronary JJ 1_p
artery NN 1_p
; : 1_p
no DT 1_p
collateral NN 1_p
flow NN 1_p
on IN 1_p
angiography NN 1_p
; : 1_p
at IN 1_p
least JJS 1_p
two CD 1_p
normokinetic JJ 1_p
segments NNS 1_p
in IN 1_p
the DT 1_p
myocardial JJ 1_p
region NN 1_p
supplied VBN 1_p
by IN 1_p
the DT 1_p
vessel NN 1_p
being VBG 1_p
bypassed VBN 1_p
. . 1_p

PATIENTS NNS N
were VBD N
randomized VBN N
to TO 1_i
receive VB 1_i
( ( 1_i
group NN 1_i
S NNP 1_i
) ) 1_i
or CC 1_i
not RB 1_i
( ( 1_i
group NN 1_i
C NNP 1_i
) ) 1_i
sevoflurane NN 1_i
administration NN N
for IN N
15 CD N
min NN N
just RB N
before RB N
coronary JJ N
occlusion NN N
. . N

d NN N
) ) N
. . N

INTERVENTIONS NNP N
Transoesophageal NNP 1_i
Tissue NNP 1_i
Doppler NNP 1_i
echocardiographic JJ 1_i
examination NN 1_i
of IN 1_i
myocardial JJ 1_i
systolic NN 1_i
and CC 1_i
early JJ 1_i
diastolic NN 1_i
velocities NNS 1_i
in IN 1_i
both DT 1_i
groups NNS 1_i
basally RB 1_i
and CC 1_i
60 CD 1_i
s NN 1_i
after IN 1_i
coronary JJ 1_i
occlusion NN 1_i
by IN 1_i
the DT 1_i
surgeon NN 1_i
. . 1_i

e NN N
) ) N
. . N

MEASURES NNP N
systolic JJ 1_o
and CC 1_o
early JJ 1_o
diastolic JJ 1_o
velocities NNS 1_o
were VBD N
registered VBN N
by IN N
Tissue NNP N
Doppler NNP N
from IN N
a DT N
long-axis JJ N
view NN N
of IN N
the DT N
interventricular JJ N
septum NN N
or CC N
the DT N
anterior JJ N
wall NN N
of IN N
the DT N
left JJ N
ventricle NN N
. . N

RESULTS NNP N
In IN N
group NN N
C NNP N
a DT N
significant JJ N
reduction NN N
of IN N
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
intramyocardial JJ 1_o
velocities NNS 1_o
was VBD N
found VBN N
during IN N
myocardial JJ N
ischemia NN N
due JJ N
to TO N
coronary JJ N
occlusion NN N
. . N

CONCLUSION NNP N
Treatment NNP N
with IN N
sevoflurane NN N
before IN N
coronary JJ N
occlusion NN N
seem VBP N
effective JJ N
in IN N
reducing VBG N
functional JJ 1_o
myocardial JJ 1_o
impairment NN 1_o
due JJ N
to TO N
ischemia VB N
. . N

A DT N
potent JJ N
oral JJ N
P-selectin NNP 1_i
blocking NN 1_i
agent NN 1_i
improves VBZ N
microcirculatory JJ 1_o
blood NN 1_o
flow NN 1_o
and CC N
a DT N
marker NN 1_o
of IN 1_o
endothelial JJ 1_o
cell NN 1_o
injury NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
sickle JJ 1_p
cell NN 1_p
disease NN 1_p
. . 1_p

Abnormal JJ 1_o
blood NN 1_o
flow NN 1_o
accounts NNS N
for IN N
most JJS N
of IN N
the DT N
clinical JJ N
morbidity NN N
of IN N
sickle NN N
cell NN N
disease NN N
( ( N
SCD NNP N
) ) N
[ VBD N
1,2 CD N
] NNP N
. . N

Most JJS N
notably RB N
, , N
occlusion NN N
of IN N
flow NN N
in IN N
the DT N
microvasculature NN N
causes VBZ N
the DT N
acute NN N
pain NN N
crises NNS N
[ VBP N
3 CD N
] NN N
that WDT N
are VBP N
the DT N
commonest NN N
cause NN N
for IN N
patients NNS 1_p
with IN 1_p
SCD NNP 1_p
to TO 1_p
seek VB N
medical JJ N
attention NN N
[ VBD N
4 CD N
] NN N
and CC N
major JJ N
determinants NNS N
of IN N
their PRP$ N
quality NN 1_p
of IN 1_p
life NN 1_p
[ $ N
5 CD N
] NNP N
. . N

Based VBN N
on IN N
evidence NN N
that IN N
endothelial JJ N
P-selectin NNP N
is VBZ N
central JJ N
to TO N
the DT N
abnormal JJ 1_o
blood NN 1_o
flow NN 1_o
in IN 1_o
SCD NNP 1_o
we PRP N
provide VBP N
results NNS N
from IN N
four CD N
of IN N
our PRP$ N
studies NNS N
that WDT N
are VBP N
germane VBN N
to TO N
microvascular VB N
blood NN N
flow NN N
in IN N
SCD NNP N
. . N

A DT N
proof-of-principle JJ N
study NN N
established VBD N
that IN N
doses NNS N
of IN N
heparin NN 1_i
lower JJR N
than IN N
what WP N
are VBP N
used VBN N
for IN N
anticoagulation NN N
but CC N
sufficient JJ N
to TO N
block VB N
P-selectin NNP N
improved JJ N
microvascular JJ 1_o
blood NN 1_o
flow NN 1_o
inpatients NNS 1_p
with IN 1_p
SCD NNP 1_p
. . 1_p

An DT N
in IN N
vitro NN N
study NN N
showed VBD N
that IN N
Pentosan NNP 1_i
Polysulfate NNP 1_i
Sodium NNP 1_i
( ( 1_i
PPS NNP 1_i
) ) 1_i
had VBD N
greater JJR N
P-selectin JJ N
blocking NN N
activity NN N
than IN N
heparin NN N
. . N

A DT N
Phase NN N
I PRP N
clinical VBP N
study NN N
demonstrated VBD N
that IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
PPS NNP 1_i
increased VBD N
microvascular JJ 1_o
blood NN 1_o
flow NN 1_o
in IN N
patients NNS N
with IN N
SCD NNP N
. . N

A NNP N
Phase NNP N
II NNP N
clinical JJ N
study NN N
that WDT N
was VBD N
not RB N
completed VBN N
documented VBD N
that IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
PPS NNP 1_i
administered VBD N
for IN N
8 CD N
weeks NNS N
lowered VBD N
plasma JJ 1_o
levels NNS 1_o
of IN 1_o
sVCAM-1 NN 1_o
and CC N
tended VBD N
to TO N
improve VB N
microvascular JJ 1_o
blood NN 1_o
flow NN 1_o
in IN N
patients NNS N
with IN N
SCD NNP N
. . N

These DT N
data NNS N
support NN N
the DT N
concept NN N
that IN N
P-selectin NNP N
on IN N
the DT N
microvascular JJ N
endothelium NN N
is VBZ N
critical JJ N
to TO N
both DT N
acute JJ 1_o
vascular NN 1_o
occlusion NN 1_o
and CC 1_o
chronically RB 1_o
impaired JJ 1_o
microvascular JJ 1_o
blood NN 1_o
flow NN 1_o
in IN 1_o
SCD NNP 1_o
. . 1_o

They PRP N
also RB N
demonstrate VBP N
that IN N
oral JJ N
PPS NNP N
is VBZ N
beneficial JJ N
to TO N
microvascular VB N
sickle NN N
cell NN N
blood NN 1_o
flow NN 1_o
and CC N
has VBZ N
potential JJ N
as IN N
an DT N
efficacious JJ N
agent NN N
for IN N
long-term JJ N
prophylactic JJ N
therapy NN N
of IN N
SCD NNP N
. . N

Endometrial JJ 1_p
cytodiagnosis NN 1_p
using VBG N
a DT N
new JJ 1_i
softcyte NN 1_i
versus NN N
a DT 1_i
conventional JJ 1_i
endocyte NN 1_i
. . 1_i

A DT N
new JJ N
endometrial JJ N
cytologic NN N
sampling VBG N
device NN N
, , N
softcyte NN N
, , N
was VBD N
used VBN N
in IN N
cytological JJ 1_p
screening NN 1_p
for IN 1_p
endometrial JJ 1_p
cancer NN 1_p
, , N
and CC N
was VBD N
compared VBN N
with IN N
the DT N
endocyte NN 1_i
with IN N
regard NN N
to TO N
manipulability NN N
, , N
adverse JJ N
effects NNS N
( ( N
including VBG N
pain NN N
and CC N
hemorrhage NN N
) ) N
, , N
and CC N
cellular JJ N
findings NNS N
( ( N
including VBG N
the DT N
quantity NN N
of IN N
cells NNS N
collected VBN N
, , N
the DT N
success NN N
rate NN N
, , N
cell NN N
freshness NN N
, , N
and CC N
cellular JJ N
clumping NN N
) ) N
. . N

A DT N
total NN N
of IN N
315 CD 1_p
women NNS 1_p
( ( 1_p
premenopause IN 1_p
251 CD 1_p
, , 1_p
postmenopause RB 1_p
64 CD 1_p
) ) 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
two CD 1_p
groups NNS 1_p
who WP 1_p
underwent VBP 1_p
the DT 1_p
endometrial JJ 1_i
cytological JJ 1_i
screening NN 1_i
with IN 1_i
either CC 1_i
the DT 1_i
softcyte NN 1_i
or CC 1_i
the DT 1_i
endocyte NN 1_i
. . 1_i

To TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
softcyte NN 1_i
we PRP N
compared VBN N
it PRP N
with IN N
the DT N
endocyte NN 1_i
. . 1_i

Endometrial NNP N
cytology NN N
using VBG N
a DT N
softcyte NN 1_i
or CC N
an DT N
endocyte NN 1_i
achieved VBN N
high JJ N
correct JJ 1_o
diagnosis NN 1_o
rate NN 1_o
for IN 1_o
cancer NN 1_o
, , N
and CC N
both DT N
instruments NNS N
are VBP N
valuable JJ N
as IN N
endometrial JJ N
cytologic NN N
sample NN N
devices NNS N
. . N

The DT N
softcyte NN N
causes VBZ N
only RB N
mild JJ 1_o
pain NN 1_o
on IN 1_o
introduction NN 1_o
and CC 1_o
during IN 1_o
collection NN 1_o
, , N
and CC N
a DT N
large JJ N
quantity NN 1_o
of IN 1_o
cells NNS 1_o
could MD N
be VB N
harvested VBN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
softcyte NN N
is VBZ N
a DT N
useful JJ N
cytologic NN N
sampling VBG N
device NN N
in IN N
screening VBG 1_p
for IN 1_p
endometrial JJ 1_p
cancer NN 1_p
. . 1_p

Effectiveness NN 1_o
and CC 1_o
Safety NNP 1_o
of IN N
Tapentadol NNP 1_i
Prolonged NNP N
Release NNP N
( ( N
PR NNP N
) ) N
Versus NNP N
a DT N
Combination NNP 1_i
of IN 1_i
Tapentadol NNP 1_i
PR NNP 1_i
and CC 1_i
Pregabalin NNP 1_i
for IN N
the DT N
Management NNP N
of IN N
Severe NNP 1_p
, , 1_p
Chronic NNP 1_p
Low NNP 1_p
Back NNP 1_p
Pain NNP 1_p
With IN 1_p
a DT 1_p
Neuropathic JJ 1_p
Component NN 1_p
: : 1_p
A DT N
Randomized NNP N
, , N
Double-blind NNP N
, , N
Phase NNP N
3b CD N
Study NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
tapentadol NN 1_i
PR NNP 1_i
monotherapy NN N
versus NN N
tapentadol NN 1_i
PR/pregabalin NNP 1_i
combination NN N
therapy NN N
for IN N
severe JJ 1_p
, , 1_p
chronic JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
with IN 1_p
a DT 1_p
neuropathic JJ 1_p
component NN 1_p
. . 1_p

METHODS NNP N
Eligible JJ 1_p
patients NNS 1_p
had VBD 1_p
painDETECT VBN 1_p
" JJ 1_p
unclear JJ 1_p
" NN 1_p
or CC 1_p
" VB 1_p
positive JJ 1_p
" NNP 1_p
ratings NNS 1_p
and CC 1_p
average JJ 1_p
pain NN 1_p
intensity NN 1_p
≥ VBP 1_p
6 CD 1_p
( ( 1_p
11-point JJ 1_p
NRS-3 NNP 1_p
[ NNP 1_p
average JJ 1_p
3-day JJ 1_p
pain NN 1_p
intensity NN 1_p
] NN 1_p
) ) 1_p
at IN 1_p
baseline NN 1_i
. . 1_i

Patients NNS 1_i
were VBD 1_i
titrated VBN 1_i
to TO 1_i
tapentadol VB 1_i
PR NNP 1_i
300 CD 1_i
mg/day NN 1_i
over IN 1_i
3 CD 1_i
weeks NNS 1_i
. . N

Patients NNS N
with IN N
≥ JJ N
1-point JJ N
decrease NN 1_o
in IN 1_o
pain NN 1_o
intensity NN 1_o
and CC N
average JJ 1_o
pain NN 1_o
intensity NN 1_o
≥ VBP N
4 CD N
were VBD N
randomized VBN 1_i
to TO 1_i
tapentadol VB 1_i
PR NNP N
( ( 1_i
500 CD 1_i
mg/day NN 1_i
) ) 1_i
or CC 1_i
tapentadol JJ 1_i
PR NNP 1_i
( ( 1_i
300 CD 1_i
mg/day NN 1_i
) ) 1_i
/pregabalin NN 1_i
( ( N
300 CD N
mg/day NN N
) ) N
during IN N
an DT N
8-week JJ N
comparative JJ N
period NN N
. . N

RESULTS NNP N
In IN N
the DT N
per-protocol JJ N
population NN N
( ( 1_o
n JJ 1_o
= NNP 1_o
288 CD 1_o
) ) 1_o
, , 1_o
the DT 1_o
effectiveness NN 1_i
of IN 1_i
tapentadol NN N
PR NNP N
was VBD N
clinically RB N
and CC N
statistically RB 1_i
comparable JJ 1_i
to TO 1_i
tapentadol VB 1_i
PR/pregabalin NNP N
based VBN N
on IN 1_o
the DT 1_o
change NN 1_o
in IN 1_o
pain NN N
intensity NN N
from IN N
randomization NN N
to TO N
final JJ N
evaluation NN N
( ( N
LOCF NNP N
; : N
LSMD NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
, , N
-0.066 NNP N
[ NNP N
-0.57 NNP N
, , N
0.43 CD N
] NN N
; : N
P NNP N
< VBZ N
0.0001 CD N
for IN 1_o
noninferiority NN 1_o
) ) 1_o
. . 1_o

Neuropathic JJ 1_o
pain NN 1_o
and CC 1_o
quality-of-life JJ 1_o
measures NNS N
improved VBN N
significantly RB 1_o
in IN 1_o
both DT 1_o
groups NNS 1_o
. . N

Tolerability NNP N
was VBD N
good JJ N
in IN N
both DT N
groups NNS N
, , N
in IN N
line NN N
with IN N
prior JJ N
trials NNS N
in IN N
the DT N
high JJ N
dose NN N
range NN N
of IN 1_i
500 CD 1_i
mg/day NN 1_i
for IN N
tapentadol NN N
PR NNP N
monotherapy NN N
, , N
and CC N
favorable JJ N
compared VBN N
with IN N
historical JJ N
combination NN N
trials NNS N
of IN N
strong JJ N
opioids NNS N
and CC N
anticonvulsants NNS N
for IN N
combination NN N
therapy NN N
. . N

The DT N
incidence NN N
of IN 1_o
the DT 1_o
composite NN 1_o
of IN 1_o
dizziness NN 1_o
and/or NN N
somnolence NN N
was VBD N
significantly RB 1_i
lower JJR 1_i
with IN N
tapentadol JJ 1_i
PR NNP 1_i
( ( 1_i
16.9 CD 1_i
% NN 1_i
) ) 1_i
than IN 1_i
tapentadol NN 1_i
PR/pregabalin NNP N
( ( N
27.0 CD N
% NN N
; : N
P NNP 1_i
= NNP 1_i
0.0302 CD 1_i
) ) 1_i
. . 1_i

CONCLUSIONS NNP 1_i
Tapentadol NNP N
PR NNP N
500 CD N
mg NN N
is VBZ N
associated VBN 1_o
with IN 1_o
comparable JJ 1_o
improvements NNS 1_o
in IN 1_o
pain NN 1_o
intensity NN 1_o
and CC 1_o
quality-of-life JJ 1_o
measures NNS 1_i
to TO N
tapentadol VB N
PR NNP N
300 CD 1_o
mg/pregabalin NN 1_o
300 CD 1_o
mg NN 1_o
, , 1_o
with IN 1_o
improved JJ 1_o
central JJ 1_o
nervous JJ 1_o
system NN N
tolerability NN N
, , N
suggesting VBG N
that IN N
tapentadol NN N
PR NNP N
monotherapy NN N
may MD N
offer VB N
a DT N
favorable JJ 1_p
treatment NN 1_p
option NN 1_p
for IN 1_p
severe JJ 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
with IN 1_p
a DT N
neuropathic JJ N
component NN N
. . N

Tacrolimus NNP 1_i
monotherapy NN N
without IN N
steroids NNS N
after IN 1_p
liver JJ 1_p
transplantation NN 1_p
-- : 1_p
a DT 1_p
prospective JJ N
randomized VBN N
double-blinded JJ N
placebo-controlled JJ N
trial NN N
. . N

Early JJ N
steroid NN N
withdrawal NN N
after IN 1_p
liver JJ 1_p
transplantation NN 1_p
( ( 1_p
LT NNP 1_p
) ) 1_p
is VBZ N
desirable JJ N
in IN N
order NN N
to TO N
reduce VB N
steroid JJ N
side NN N
effects NNS N
. . N

Between NNP 1_p
February NNP 1_p
2000 CD 1_p
and CC 1_p
August NNP 1_p
2004 CD 1_p
, , 1_p
110 CD 1_p
patients NNS 1_p
after IN 1_p
LT NNP 1_p
were VBD N
included VBN N
in IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

Randomization NN N
was VBD N
performed VBN N
before IN N
LT NNP N
. . N

In IN N
all DT N
patients NNS N
, , N
tacrolimus NN 1_i
was VBD 1_i
used VBN 1_i
without IN 1_i
induction NN 1_i
therapy NN 1_i
. . 1_i

All DT 1_p
patients NNS 1_p
received VBD 1_p
methylprednisolon NN 1_i
for IN 1_p
14 CD 1_p
days NNS 1_p
, , N
thereafter RB N
a DT N
double-blinded JJ N
medication NN N
containing VBG N
either CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
56 CD N
) ) N
or CC N
methylprednisolon NN 1_i
( ( N
n JJ N
= NNP N
54 CD N
) ) N
for IN N
6 CD N
months NNS N
, , N
which WDT N
was VBD N
completely RB N
stopped JJ N
thereafter RB N
. . N

End NN N
points NNS N
were VBD N
patient JJ 1_o
and CC 1_o
graft NN 1_o
survival NN 1_o
, , 1_o
acute NN 1_o
and CC 1_o
chronic JJ 1_o
rejection NN 1_o
, , 1_o
and CC 1_o
incidence NN 1_o
of IN 1_o
steroid JJ 1_o
side NN 1_o
effects NNS 1_o
during IN N
the DT N
first JJ N
year NN N
after IN 1_p
LT NNP 1_p
. . 1_p

One-year JJ N
patient NN 1_o
survival NN 1_o
was VBD N
85.7 CD N
% NN N
( ( N
placebo NN N
) ) N
and CC N
88.8 CD N
% NN N
( ( N
steroid NN N
) ) N
( ( N
p JJ N
= NNP N
0.572 CD N
) ) N
. . N

Twenty-seven NNP N
( ( N
48.2 CD N
% NN N
) ) N
and CC N
19 CD N
( ( N
35.2 CD N
% NN N
) ) N
patients NNS N
experienced VBD N
acute JJ 1_o
rejection NN 1_o
( ( N
placebo JJ N
versus NN N
steroid NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.116 CD N
) ) N
. . N

Two CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
but CC N
none NN N
in IN N
the DT N
steroid NN N
group NN N
experienced VBD N
chronic JJ 1_o
rejection NN 1_o
( ( N
p JJ N
= NNP N
0.257 CD N
) ) N
. . N

The DT N
rates NNS 1_o
of IN 1_o
side JJ 1_o
effects NNS 1_o
were VBD N
( ( 1_i
placebo JJ 1_i
versus NN N
steroid NN 1_i
, , N
respectively RB N
) ) N
: : N
CMV JJ 1_o
infection NN 1_o
25 CD N
% NN N
versus IN N
33 CD N
% NN N
( ( N
p JJ N
= NNP N
0.336 CD N
) ) N
, , N
post-transplant JJ 1_o
diabetes NNS 1_o
30 CD N
% NN N
versus IN N
53 CD N
% NN N
( ( N
p JJ N
= NNP N
0.024 CD N
) ) N
, , N
hypertension VBP 1_o
39 CD N
% NN N
versus IN N
52 CD N
% NN N
( ( N
p JJ N
= NNP N
0.248 CD N
) ) N
, , N
hypercholesterolemia $ 1_o
10 CD N
% NN N
versus IN N
41 CD N
% NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
and CC N
hypertriglyceridemia $ 1_o
32 CD N
% NN N
versus IN N
54 CD N
% NN N
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
early JJ N
steroid NN N
withdrawal NN N
after IN 1_p
LT NNP 1_p
is VBZ N
feasible JJ 1_o
under IN N
tacrolimus NN 1_i
monotherapy NN N
without IN N
increased JJ N
rejection NN N
rates NNS N
and CC N
with IN N
a DT N
lower JJR 1_o
rate NN 1_o
of IN 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

In-season JJ N
effect NN N
of IN N
short-term JJ 1_i
sprint NN 1_i
and CC 1_i
power NN 1_i
training NN 1_i
programs NNS 1_i
on IN N
elite JJ 1_p
junior JJ 1_p
soccer NN 1_p
players NNS 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
2 CD N
in-season JJ N
short-term JJ 1_i
sprint NN 1_i
and CC 1_i
power NN 1_i
training NN 1_i
protocols NNS 1_i
on IN N
vertical JJ N
countermovement NN N
jump NN N
height NN N
( ( N
with IN N
or CC N
without IN N
arms NNS N
) ) N
, , N
sprint NN N
( ( N
Sprint-15m NNP N
) ) N
speed NN N
, , N
and CC N
agility NN N
( ( N
Agility-15m NNP N
) ) N
speed NN N
in IN N
male JJ 1_p
elite JJ 1_p
junior JJ 1_p
soccer NN 1_p
players NNS 1_p
. . 1_p

Twenty NNP 1_p
highly RB 1_p
trained VBD 1_p
soccer NN 1_p
players NNS 1_p
( ( 1_p
age NN 1_p
18.3 CD 1_p
+/- JJ 1_p
0.6 CD 1_p
years NNS 1_p
, , 1_p
height VBD 1_p
177 CD 1_p
+/- JJ 1_p
4 CD 1_p
cm NN 1_p
, , 1_p
body NN 1_p
mass VBD 1_p
71.4 CD 1_p
+/- JJ 1_p
6.9 CD 1_p
kg NN 1_p
, , 1_p
sum NN 1_p
skinfolds NNS 1_p
48.1 CD 1_p
+/- JJ 1_p
11.4 CD 1_p
mm NN 1_p
) ) 1_p
, , 1_p
members NNS 1_p
of IN 1_p
a DT 1_p
professional JJ 1_p
soccer NN 1_p
academy NN 1_p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
CONTRAST NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
SPRINT NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
group NN N
. . N

The DT 1_i
training NN 1_i
intervention NN 1_i
consisted VBD N
of IN N
6 CD 1_i
supervised JJ 1_i
training NN 1_i
sessions NNS 1_i
over IN N
7 CD N
weeks NNS N
, , N
targeting VBG N
the DT N
improvement NN N
of IN N
the DT N
players NNS N
' POS N
speed NN 1_o
and CC 1_o
power NN 1_o
. . 1_o

CONTRAST NNP N
protocol NN N
consisted VBD N
of IN N
alternating VBG N
heavy-light JJ N
resistance NN N
( ( N
15-50 CD N
% NN N
body NN N
mass NN N
) ) N
with IN N
soccer-specific JJ N
drills NNS N
( ( N
small-sided JJ N
games NNS N
or CC N
technical JJ N
skills NNS N
) ) N
. . N

SPRINT NNP 1_i
training NN 1_i
protocol NN 1_i
used VBN N
line NN N
30-m JJ N
sprints NNS N
( ( N
2-4 JJ N
sets NNS N
of IN N
4 CD N
x JJ N
30 CD N
m NN N
with IN N
180 CD N
and CC N
90 CD N
seconds NNS N
of IN N
recovery NN N
, , N
respectively RB N
) ) N
. . N

At IN N
baseline JJ N
no DT N
difference NN N
between IN N
physical JJ 1_o
test NN 1_o
performance NN 1_o
was VBD N
evident JJ N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

No DT N
time NN N
x VBZ N
training VBG N
group NN N
effect NN N
was VBD N
found VBN N
for IN N
any DT N
of IN N
the DT N
vertical JJ 1_o
jump NN 1_o
and CC 1_o
Agility-15m JJ 1_o
variables NNS 1_o
( ( 1_o
p JJ 1_o
> NNP N
0.05 CD N
) ) N
. . N

A DT N
time NN N
x JJ N
training VBG N
group NN N
effect NN N
was VBD N
found VBN N
for IN N
Sprint-15m JJ N
performance NN N
with IN N
the DT N
CONTRAST NNP N
group NN N
showing VBG N
significantly RB N
better JJR N
scores NNS N
than IN N
the DT N
SPRINT NNP N
group NN N
( ( N
7.23 CD N
+/- JJ N
0.18 CD N
vs. FW N
7.09 CD N
+/- JJ N
0.20 CD N
m.s NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
light NN N
of IN N
these DT N
findings NNS N
CONTRAST NNP 1_i
training NN 1_i
should MD N
be VB N
preferred VBN N
to TO N
line NN N
sprint NN N
training NN N
in IN N
the DT N
short JJ N
term NN N
in IN N
young JJ 1_p
elite JJ 1_p
soccer NN 1_p
players NNS 1_p
when WRB N
the DT N
aim NN N
is VBZ N
to TO N
improve VB N
soccer-specific JJ 1_o
sprint NN 1_o
performance NN 1_o
( ( 1_o
15 CD 1_o
m NN 1_o
) ) 1_o
during IN N
the DT N
competitive JJ N
season NN N
. . N

[ VB N
A NNP N
prospective JJ N
randomized VBN N
study NN N
of IN N
the DT N
radiotherapy NN 1_i
volume NN 1_i
for IN N
limited-stage JJ N
small JJ N
cell NN N
lung NN N
cancer NN N
: : N
a DT N
preliminary JJ N
report NN N
] NNP N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Controversies NNP N
exists VBZ N
with IN N
regard NN N
to TO N
target VB N
volumes NNS N
as RB N
far RB N
as IN N
thoracic JJ 1_i
radiotherapy NN 1_i
( ( 1_i
TRT NNP 1_i
) ) 1_i
is VBZ N
concerned VBN N
in IN N
the DT N
multimodality NN N
treatment NN N
for IN N
limited-stage NN 1_p
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
( ( 1_p
LSCLC NNP 1_p
) ) 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
prospectively RB N
compare VB N
the DT N
local JJ N
control NN N
rate NN N
, , N
toxicity NN N
profiles NNS N
, , N
and CC N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
between IN N
patients NNS N
received VBN N
different JJ 1_i
target NN 1_i
volumes NNS 1_i
irradiation VBP 1_i
after IN 1_i
induction NN 1_i
chemotherapy NN 1_i
. . 1_i

METHODS NNP N
LSCLC NNP 1_p
patients NNS 1_p
received VBD N
2 CD N
cycles NNS N
of IN N
etoposide NN 1_i
and CC 1_i
cisplatin NN 1_i
( ( 1_i
EP NNP 1_i
) ) 1_i
induction NN 1_i
chemotherapy NN 1_i
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
TRT NNP 1_i
to TO N
either VB N
the DT N
post- NN N
or CC N
pre-chemotherapy JJ N
tumor NN N
extent NN N
( ( N
GTV-T NNP N
) ) N
as IN N
study NN N
arm NN N
and CC N
control NN N
arm NN N
, , N
CTV-N NNP N
included VBD N
the DT N
positive JJ N
nodal JJ N
drainage NN N
area NN N
for IN N
both DT N
arms NNS N
. . N

One CD N
to TO N
2 CD N
weeks NNS N
after IN N
induction NN 1_i
chemotherapy NN 1_i
, , 1_i
45 CD 1_i
Gy/30 NNP 1_i
Fx/19 NNP 1_i
d NN 1_i
TRT NNP 1_i
was VBD N
administered VBN N
concurrently RB N
with IN N
the DT N
third JJ N
cycle NN N
of IN N
EP NNP 1_i
regimen NNS 1_i
. . 1_i

After IN N
that DT N
, , N
additional JJ N
3 CD N
cycles NNS N
of IN N
EP NNP 1_i
consolidation NN N
were VBD N
administered VBN N
. . N

Prophylactic JJ 1_i
cranial JJ 1_i
irradiation NN 1_i
( ( 1_i
PCI NNP 1_i
) ) 1_i
was VBD N
administered VBN N
to TO N
patients NNS N
with IN N
a DT N
complete JJ N
response NN N
. . N

RESULTS NNP N
Thirty-seven JJ 1_p
and CC 1_p
40 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
study VB 1_p
arm NN 1_p
and CC 1_p
control NN 1_p
arm NN 1_p
. . 1_p

The DT N
local JJ 1_o
recurrence NN 1_o
rates NNS 1_o
were VBD N
32.4 CD N
% NN N
and CC N
28.2 CD N
% NN N
respectively RB N
( ( N
P NNP N
= NNP N
0.80 CD N
) ) N
; : N
the DT N
isolated JJ N
nodal JJ 1_o
failure NN 1_o
( ( 1_o
INF NNP 1_o
) ) 1_o
rates NNS N
were VBD N
3.0 CD N
% NN N
and CC N
2.6 CD N
% NN N
respectively RB N
( ( N
P NNP N
= NNP N
0.91 CD N
) ) N
; : N
all DT N
INF NNP N
sites NNS N
were VBD N
in IN N
the DT N
ipsilateral JJ N
supraclavicular JJ N
fossa NN N
. . N

Medastinal NNP 1_o
N3 NNP 1_o
disease NN 1_o
was VBD N
the DT N
risk NN N
factor NN N
for IN N
INF NNP N
( ( N
P NNP N
= NNP N
0.02 CD N
, , N
OR NNP N
= VBZ N
14.13 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.47-136.13 JJ N
) ) N
. . N

During IN N
radiotherapy NN N
, , N
grade NN 1_o
I PRP 1_o
, , 1_o
II NNP 1_o
weight VBD 1_o
loss NN 1_o
was VBD N
observed VBN N
in IN N
29.4 CD N
% NN N
, , N
5.9 CD N
% NN N
and CC N
56.4 CD N
% NN N
, , N
7.7 CD N
% NN N
patients NNS N
respectively RB N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Grade VBN 1_o
0-I JJ 1_o
and CC 1_o
II-III JJ 1_o
late JJ 1_o
pulmonary JJ 1_o
injury NN 1_o
was VBD N
developed VBN N
in IN N
97.1 CD N
% NN N
, , N
2.9 CD N
% NN N
and CC N
86.4 CD N
% NN N
, , N
15.4 CD N
% NN N
patients NNS N
respectively RB N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

Median JJ 1_o
survival JJ 1_o
time NN 1_o
was VBD N
22.1 CD N
months NNS N
and CC N
26.9 CD N
months NNS N
respectively RB N
. . N

The DT N
1 CD 1_o
to TO 1_o
3-year JJ 1_o
OS NNP 1_o
were VBD N
77.9 CD N
% NN N
, , N
44.4 CD N
% NN N
, , N
37.3 CD N
% NN N
and CC N
75.8 CD N
% NN N
, , N
56.3 CD N
% NN N
, , N
41.7 CD N
% NN N
respectively RB N
( ( N
P NNP N
= NNP N
0.79 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
preliminary JJ N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that WDT N
irradiant VBP N
the DT N
post-chemotherapy JJ N
tumor NN N
extent NN N
( ( N
GTV-T NNP N
) ) N
and CC N
positive JJ N
nodal JJ N
drainage NN N
area NN N
did VBD N
not RB N
decrease VB N
local JJ N
control NN N
and CC N
overall JJ N
survival NN N
while IN N
radiation NN N
toxicity NN N
was VBD N
reduced VBN N
. . N

But CC N
the DT N
current JJ N
sample NN N
size NN N
has VBZ N
not RB N
met VBN N
designed VBN N
requirements NNS N
, , N
and CC N
further JJ N
investigation NN N
is VBZ N
warranted VBN N
before IN N
final JJ N
conclusions NNS N
could MD N
be VB N
drawn VBN N
. . N

In IN N
high JJ 1_p
risk NN 1_p
hypertensive JJ 1_p
subjects NNS 1_p
with IN 1_p
incidental JJ 1_p
and CC 1_p
unilateral JJ 1_p
renal JJ 1_p
artery NN 1_p
stenosis NN 1_p
percutaneous JJ 1_p
revascularization NN 1_p
with IN N
stent JJ N
improves NNS N
blood NN 1_o
pressure NN 1_o
control NN 1_o
but CC N
not RB N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
. . 1_o

AIM NNP N
In IN N
high-risk JJ 1_p
hypertensive JJ 1_p
subjects NNS 1_p
( ( 1_p
HTs NNP 1_p
) ) 1_p
with IN 1_p
incidental JJ 1_p
unilateral JJ 1_p
renal JJ 1_p
artery NN 1_p
stenosis NN 1_p
( ( 1_p
RAS NNP 1_p
) ) 1_p
, , N
the DT N
effectiveness NN N
of IN N
percutaneous JJ 1_i
revascularization NN 1_i
with IN 1_i
stent NN 1_i
( ( 1_i
PR-STENT NNP 1_i
) ) 1_i
on IN N
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
and CC N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
( ( 1_o
GFR NNP 1_o
) ) 1_o
is VBZ N
not RB N
established VBN N
. . N

METHODS NNP N
Eighteen NNP 1_p
HTs NNP 1_p
aged VBD 1_p
65.7 CD 1_p
± JJ 1_p
9.2 CD 1_p
years NNS 1_p
with IN 1_p
angiographically RB 1_p
diagnosed VBN 1_p
unilateral JJ 1_p
RAS NNP 1_p
( ( 1_p
≥ VB 1_p
60 CD 1_p
% NN 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
PR-STENT NNP N
( ( N
N=9 NNP N
) ) N
or CC N
to TO 1_i
NO-STENT NNP 1_i
( ( N
N=9 NNP N
) ) N
. . N

BP NNP N
( ( N
mercury NN N
sphygmomanometer NN N
) ) N
and CC N
GFR NNP N
( ( N
99mTc-DTPA JJ N
clearances NNS N
during IN N
renal JJ N
scintigraphy NN N
) ) N
were VBD N
evaluated VBN N
yearly RB N
for IN N
three CD N
years NNS N
. . N

Echo-Doppler NN N
of IN N
renal JJ N
arteries NNS N
was VBD N
performed VBN N
to TO N
verify VB N
the DT N
anatomic JJ N
patency NN N
and CC N
flow JJ N
velocities NNS N
of IN N
the DT N
reperfused JJ N
artery NN N
. . N

Analysis NN N
of IN N
variance NN N
compared VBN N
BP NNP N
and CC N
GFR NNP N
values NNS N
changes NNS N
from IN N
baseline NN N
to TO N
the DT N
follow-up NN N
; : N
differences NNS N
for IN N
continuous JJ N
variables NNS N
were VBD N
evaluated VBN N
between IN N
groups NNS N
with IN N
the DT N
Tukey NNP N
's POS N
post NN N
hoc NN N
test NN N
after IN N
adjustment NN N
for IN N
age NN N
, , N
change NN N
of IN N
BP NNP N
between IN N
baseline NN N
and CC N
at IN N
the DT N
follow-up NN N
, , N
GFR NNP N
and CC N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

RESULTS NNP 1_o
Baseline NNP 1_o
systolic JJ 1_o
BP NNP 1_o
and CC 1_o
GFR NNP 1_o
values NNS 1_o
were VBD N
not RB N
different JJ N
between IN N
groups NNS N
. . N

The DT N
significantly RB N
greater JJR 1_o
GFR NNP 1_o
increase NN 1_o
observed VBD N
in IN N
PR-STENT NNP N
than IN N
in IN N
NO-STENT NNP N
at IN N
univariate JJ N
analysis NN N
at IN N
the DT N
end NN N
of IN N
follow-up NN N
( ( N
62.5 CD N
± RB N
19.2 CD N
vs. FW N
42.24 CD N
± NN N
17.6 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
disappeared VBD N
after IN N
adjustment NN N
for IN N
confounding VBG N
factors NNS N
. . N

However RB 1_o
, , 1_o
systolic JJ 1_o
BP NNP N
remained VBD N
significantly RB N
lower JJR N
in IN N
PR-STENT NNP N
than IN N
in IN N
NO-STENT NNP N
( ( N
140.1 CD N
± RB N
4.6 CD N
vs. FW N
170.0 CD N
± NN N
8.3 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
also RB N
after IN N
adjustment NN N
for IN N
age NN N
, , N
GFR NNP N
and CC N
BMI NNP N
. . N

CONCLUSION NNP N
PR-STENT NNP N
reduces VBZ 1_o
systolic JJ 1_o
BP NNP N
without IN N
improving VBG 1_o
GFR NNP N
. . N

Due NNP N
to TO N
the DT N
strong JJ N
association NN N
between IN N
high JJ N
BP NNP N
and CC N
renal JJ N
damage NN N
, , N
this DT N
study NN N
raises VBZ N
the DT N
question NN N
on IN N
whether IN N
PR-STENT NNP N
should MD N
be VB N
performed VBN N
in IN 1_p
all DT 1_p
HTs NNP 1_p
with IN 1_p
unilateral JJ 1_p
and CC 1_p
incidental JJ 1_p
RAS NNP N
. . N

Once RB N
versus JJ N
thrice JJ N
daily JJ 1_i
gentamicin NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
serious JJ 1_p
infections NNS 1_p
. . 1_p

Aminoglycosides NNS N
are VBP N
usually RB N
given VBN N
in IN N
two CD N
or CC N
three CD N
divided VBN N
doses NNS N
. . N

A DT N
once-daily JJ N
regimen NN N
might MD N
be VB N
more RBR N
effective JJ N
and CC N
less RBR N
toxic JJ N
. . N

We PRP N
have VBP N
conducted VBN N
a DT N
randomised JJ N
trial NN N
in IN N
consecutive JJ 1_p
patients NNS 1_p
with IN 1_p
serious JJ 1_p
infections NNS 1_p
for IN 1_p
whom WP 1_p
an DT 1_p
aminoglycoside NN 1_i
seemed VBD 1_p
warranted JJ 1_p
. . 1_p

Exclusion NN 1_p
criteria NNS 1_p
were VBD 1_p
neutropenia RB 1_p
or CC 1_p
severely RB 1_p
impaired JJ 1_p
renal JJ 1_p
function NN 1_p
. . 1_p

123 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

For IN 1_p
efficacy NN 1_p
analysis NN 1_p
only RB 1_p
those DT 1_p
patients NNS 1_p
were VBD 1_p
considered VBN 1_p
in IN 1_p
whom WP 1_p
treatment NN 1_p
with IN 1_p
the DT 1_p
aminoglycoside NN 1_p
was VBD 1_p
not RB 1_p
stopped VBN 1_p
within IN 1_p
72 CD 1_p
h NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
67 CD 1_p
) ) 1_p
; : 1_p
toxicity NN 1_p
was VBD 1_p
analysed VBN 1_p
on IN 1_p
patients NNS 1_p
receiving VBG 1_p
aminoglycosides NNS 1_i
for IN 1_p
more JJR 1_p
than IN 1_p
48 CD 1_p
h NNS 1_p
and CC 1_p
not RB 1_p
using VBG 1_p
other JJ 1_p
nephrotoxic JJ 1_p
medication NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
85 CD 1_p
) ) 1_p
. . 1_p

Gentamicin $ 1_i
4 CD 1_i
mg/kg JJ 1_i
every DT 1_i
day NN 1_i
( ( 1_i
OD NNP 1_i
) ) 1_i
or CC 1_i
gentamicin $ 1_i
1.33 CD 1_i
mg/kg NN 1_i
three CD 1_i
times NNS 1_i
daily RB 1_i
( ( 1_i
MD NNP 1_i
) ) 1_i
( ( 1_i
with IN 1_i
dose-reduction NN 1_i
in IN 1_i
case NN 1_i
of IN 1_i
renal JJ 1_i
dysfunction NN 1_i
) ) 1_i
were VBD N
given VBN N
intravenously RB N
. . N

In IN N
almost RB N
all DT N
patients NNS N
intravenous JJ 1_i
amoxycillin JJ 1_i
1 CD 1_i
g NN 1_i
every DT 1_i
6 CD 1_i
h NN 1_i
was VBD N
also RB N
started VBN N
. . N

Baseline VB 1_p
characteristics NNS 1_p
were VBD 1_p
comparable JJ 1_p
in IN 1_p
both DT 1_p
arms NNS 1_p
. . 1_p

A DT N
good JJ N
clinical JJ N
response NN N
was VBD N
observed VBN N
in IN N
32/35 CD N
( ( N
91 CD N
% NN N
) ) N
of IN N
the DT N
OD NNP 1_i
and CC N
in IN N
25/32 CD N
( ( N
78 CD N
% NN N
) ) N
in IN N
the DT N
MD NNP 1_i
group NN N
( ( N
difference NN N
13 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
-6.4 CD N
% NN N
to TO N
+26.9 VB N
% NN N
) ) N
. . N

2 CD N
patients NNS N
in IN N
each DT N
group NN N
died VBD N
with IN N
uncontrolled JJ N
infection NN N
. . N

An DT N
insufficient JJ N
bacteriological JJ N
response NN N
( ( 1_o
persistent JJ 1_o
positive JJ 1_o
cultures NNS 1_o
, , 1_o
resistance NN 1_o
, , 1_o
or CC 1_o
superinfection NN 1_o
) ) 1_o
was VBD N
observed VBN N
in IN N
2 CD N
patients NNS N
with IN N
OD NNP N
and CC N
3 CD N
patients NNS N
with IN N
MD NNP N
. . N

In IN N
patients NNS N
treated VBN N
for IN N
more JJR N
than IN N
48 CD N
h JJ N
duration NN N
of IN N
therapy NN N
and CC N
mean JJ N
doses NNS N
were VBD N
7.0 CD N
days NNS N
( ( N
1590 CD N
mg NN N
) ) N
and CC N
7.4 CD N
days NNS N
( ( N
1672 CD N
mg NN N
) ) N
in IN N
OD NNP N
and CC N
MD NNP N
respectively RB N
. . N

Mean NNP 1_o
first JJ 1_o
serum NN 1_o
trough/peak NN 1_o
levels NNS 1_o
were VBD N
0.6/10.2 CD N
mg/L NNS N
and CC N
1.4/5.2 CD N
mg/L NN N
. . N

Nephrotoxicity NNP 1_o
( ( 1_o
a DT 1_o
rise NN 1_o
in IN 1_o
serum JJ 1_o
creatinine NN 1_o
of IN 1_o
45 CD 1_o
mumol/L NN 1_o
or CC 1_o
more JJR 1_o
) ) 1_o
developed VBD N
in IN N
2/40 CD N
( ( N
5 CD N
% NN N
) ) N
in IN N
OD NNP 1_i
and CC N
11/45 CD N
( ( N
24 CD N
% NN N
) ) N
in IN N
MD NNP 1_i
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
. . N

Risk NN N
factors NNS N
for IN N
nephrotoxicity NN 1_o
were VBD N
duration NN N
of IN N
therapy NN N
and CC N
baseline NN N
creatinine JJ 1_o
clearance NN 1_o
rate NN 1_o
. . 1_o

High-tone CD 1_o
audiometry NN 1_o
was VBD N
performed VBN N
when WRB N
possible JJ N
; : N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
hearing VBG 1_o
loss NN 1_o
( ( N
3/12 CD N
and CC N
3/11 CD N
) ) N
or CC N
prodromal JJ 1_o
signs NNS 1_o
of IN 1_o
ototoxicity NN 1_o
( ( N
5/12 CD N
and CC N
4/11 CD N
) ) N
. . N

A DT N
once-daily JJ 1_i
dosing VBG 1_i
regimen NNS 1_i
of IN 1_i
gentamicin NN 1_i
is VBZ N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
and CC N
is VBZ N
less RBR N
nephrotoxic JJ N
than IN N
more RBR N
frequent JJ N
dosing NN N
. . N

A DT N
randomized JJ N
placebo-controlled JJ 1_i
trial NN N
comparing VBG N
the DT N
efficacy NN N
of IN N
etoricoxib $ 1_i
30 CD N
mg NN N
and CC N
ibuprofen NN 1_i
2400 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
osteoarthritis NN 1_p
. . 1_p

OBJECTIVE IN N
We PRP N
compared VBN N
the DT N
efficacy NN N
of IN N
etoricoxib $ 1_i
30 CD N
mg NN N
to TO N
placebo VB 1_i
and CC N
ibuprofen VB 1_i
2400 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
osteoarthritis NN 1_p
( ( 1_p
OA NNP 1_p
) ) 1_p
of IN 1_p
the DT 1_p
hip NN 1_p
and CC 1_p
knee NN 1_p
. . 1_p

DESIGN NN N
In IN N
this DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo- JJ 1_i
and CC N
active-comparator-controlled JJ N
trial NN N
, , N
548 CD 1_p
patients NNS 1_p
( ( 1_p
median JJ 1_p
age NN 1_p
63 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
OA NNP 1_p
of IN 1_p
the DT 1_p
hip NN 1_p
or CC 1_p
knee NN 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
receive VB N
placebo NN 1_i
, , 1_i
etoricoxib VBZ 1_i
30 CD N
mg NN N
q.d. NN N
, , N
or CC N
ibuprofen VB 1_i
800 CD N
mg NN N
t.i.d NN N
. . N

Demonstration NN N
of IN N
etoricoxib NN 1_i
's POS 1_i
efficacy NN N
vs NN N
placebo NN 1_i
and CC N
comparison NN N
of IN N
its PRP$ N
efficacy NN N
to TO N
ibuprofen VB 1_i
were VBD N
assessed VBN N
using VBG N
three CD N
co-primary JJ N
endpoints NNS N
: : N
Western JJ 1_o
Ontario NNP 1_o
and CC 1_o
McMaster NNP 1_o
's POS 1_o
University NNP 1_o
Osteoarthritis NNP 1_o
Index NNP 1_o
( ( 1_o
WOMAC NNP 1_o
) ) 1_o
Pain NNP 1_o
Subscale NNP 1_o
( ( 1_o
WOMAC-PS NNP 1_o
) ) 1_o
; : 1_o
WOMAC NNP 1_o
Physical NNP 1_o
Function NNP 1_o
Subscale NNP 1_o
( ( 1_o
WOMAC-PFS NNP 1_o
) ) 1_o
; : 1_o
and CC 1_o
Patient NNP 1_o
Global NNP 1_o
Assessment NNP 1_o
of IN 1_o
Disease NNP 1_o
Status NNP 1_o
( ( 1_o
PGADS NNP 1_o
) ) 1_o
. . 1_o

Each DT N
primary JJ N
endpoint NN N
utilizes VBZ N
a DT N
0-100 JJ N
mm NN N
visual JJ N
analog NN N
scale NN N
. . N

To TO N
demonstrate VB N
comparable JJ N
efficacy NN N
of IN N
etoricoxib JJ 1_i
vs NN N
ibuprofen NN 1_i
, , N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
for IN N
the DT N
difference NN N
in IN N
the DT N
least JJS 1_o
squares NNS 1_o
( ( 1_o
LS NNP 1_o
) ) 1_o
mean VBP 1_o
change NN 1_o
over IN N
12 CD N
weeks NNS N
for IN N
all DT N
three CD N
co-primary JJ N
endpoints NNS N
had VBD N
to TO N
fall VB N
within IN N
+/-10 JJ N
mm NN N
. . N

Safety NNP 1_o
and CC 1_o
tolerability NN 1_o
data NNS 1_o
were VBD N
collected VBN N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
Mean NNP 1_o
baseline NN 1_o
values NNS 1_o
for IN N
the DT N
three CD N
co-primary JJ N
endpoints NNS N
ranged VBD N
from IN N
62.52 CD N
to TO N
70.14 CD N
mm NN N
. . N

Both DT N
etoricoxib JJ 1_i
and CC N
ibuprofen JJ 1_i
demonstrated VBN N
superior JJ N
( ( N
P NNP N
< NNP N
or CC N
=0.002 NNP N
) ) N
efficacy NN 1_o
for IN N
all DT N
primary JJ N
endpoints NNS N
. . N

The DT N
LS NNP N
mean NN N
( ( N
mm NN N
) ) N
changes NNS N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
over IN N
12 CD N
weeks NNS N
for IN N
etoricoxib NN 1_i
and CC N
ibuprofen NN 1_i
, , N
respectively RB N
, , N
compared VBN N
to TO N
placebo VB 1_i
were VBD N
given VBN N
as IN N
follows VBZ N
: : N
WOMAC-PS JJ 1_o
: : 1_o
-11.66 NN N
( ( N
-16.31 UH N
, , N
-7.01 NNP N
) ) N
and CC N
-7.62 NNP N
( ( N
-12.30 NNP N
, , N
-2.94 NNP N
) ) N
; : N
WOMAC-PFS JJ 1_o
: : 1_o
-10.15 NN N
( ( N
-14.74 UH N
, , N
-5.57 NNP N
) ) N
and CC N
-7.23 NNP N
( ( N
-11.85 NNP N
, , N
-2.61 NNP N
) ) N
; : N
PGADS NNP 1_o
: : 1_o
-11.65 NN N
( ( N
-16.81 UH N
, , N
-6.50 NNP N
) ) N
and CC N
-8.11 NNP N
( ( N
-13.30 NNP N
, , N
-2.92 NNP N
) ) N
. . N

The DT N
efficacy NN 1_o
of IN N
etoricoxib $ 1_i
30 CD N
mg NN N
was VBD N
comparable JJ N
to TO N
ibuprofen VB 1_i
2400 CD N
mg. NN N
All DT N
treatments NNS N
were VBD N
similarly RB N
well RB N
tolerated VBN 1_o
. . 1_o

CONCLUSION NNP N
Treatment NNP N
with IN N
etoricoxib JJ 1_i
30 CD N
mg NN N
q.d NN N
. . N

provides VBZ N
superior JJ N
efficacy NN 1_o
vs NN N
placebo NN 1_i
and CC N
comparable JJ N
clinical JJ N
efficacy NN N
vs NN N
ibuprofen NN 1_i
2400 CD N
mg NN N
( ( N
800 CD N
mg NN N
t.i.d NN N
. . N

) ) N
for IN N
the DT N
treatment NN N
of IN N
OA NNP 1_p
of IN 1_p
the DT 1_p
hip NN 1_p
and CC 1_p
knee NN 1_p
. . 1_p

Poor NNP 1_p
prognosis NN 1_p
patients NNS 1_p
with IN 1_p
inoperable JJ 1_p
locally RB 1_p
advanced JJ 1_p
NSCLC NNP 1_p
and CC 1_p
large JJ 1_p
tumors NNS 1_p
benefit VBP N
from IN N
palliative JJ 1_i
chemoradiotherapy NN 1_i
: : 1_i
a DT N
subset NN N
analysis NN N
from IN N
a DT N
randomized JJ N
clinical JJ N
phase NN N
III NNP N
trial NN N
. . N

INTRODUCTION NNP N
Poor NNP 1_p
prognosis NN 1_p
patients NNS 1_p
with IN 1_p
bulky JJ 1_p
stage NN 1_p
III NNP 1_p
locally RB 1_p
advanced VBD 1_p
non-small-cell JJ 1_p
lung NN 1_p
cancer NN 1_p
may MD N
not RB N
be VB N
offered VBN N
concurrent JJ N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
. . N

Following VBG N
a DT N
phase NN N
III NNP N
trial NN N
concerning VBG N
the DT N
effect NN 1_o
of IN N
palliative JJ N
CRT NNP 1_i
in IN N
inoperable JJ N
poor JJ 1_p
prognosis NN 1_p
patients NNS 1_p
, , N
this DT N
analysis NN N
was VBD N
performed VBN N
to TO N
explore VB N
how WRB N
tumor JJ N
size NN N
influenced VBD N
survival JJ 1_o
and CC 1_o
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
HRQOL NNP 1_o
) ) 1_o
. . 1_o

METHODS CC N
A DT 1_p
total NN 1_p
of IN 1_p
188 CD 1_p
poor JJ 1_p
prognosis NN 1_p
patients NNS 1_p
recruited VBN 1_p
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
received VBD N
four CD N
courses NNS N
intravenous JJ 1_i
carboplatin NNS 1_i
day NN 1_i
1 CD 1_i
and CC 1_i
oral JJ 1_i
vinorelbine NN 1_i
day NN 1_i
1 CD 1_i
and CC 1_i
8 CD 1_i
, , 1_i
at IN 1_i
3-week JJ 1_i
intervals NNS 1_i
. . 1_i

The DT N
experimental JJ N
arm NN N
( ( N
N NNP N
= NNP N
94 CD N
) ) N
received VBD N
radiotherapy NN 1_i
with IN 1_i
fractionation NN 1_i
42 CD 1_i
Gy/15 NNP 1_i
, , N
starting VBG N
at IN N
the DT N
second JJ N
chemotherapy NN N
course NN N
. . N

This DT N
subset NN N
study NN N
compares VBZ 1_o
outcomes NNS 1_o
in IN 1_o
patients NNS 1_o
with IN 1_o
tumors NNS 1_o
larger JJR 1_o
than IN 1_o
7 CD 1_o
cm NN 1_o
( ( 1_o
N NNP 1_o
= NNP 1_o
108 CD 1_o
) ) 1_o
versus NN 1_o
tumors NNS 1_o
7 CD 1_o
cm NN 1_o
or CC 1_o
smaller JJR 1_o
( ( 1_o
N NNP 1_o
= NNP 1_o
76 CD 1_o
) ) 1_o
. . 1_o

RESULTS NNP N
Among IN N
those DT N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NN N
, , N
the DT N
median JJ 1_o
overall JJ 1_o
survival NN 1_o
in IN N
the DT N
chemotherapy NN 1_i
versus NN N
CRT NNP 1_i
arm NN N
was VBD N
9.7 CD N
and CC N
13.4 CD N
months NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
1-year JJ 1_o
survival NN 1_o
was VBD N
33 CD N
% NN N
and CC N
56 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

Except IN N
for IN N
a DT N
temporary JJ N
decline NN N
during IN N
treatment NN N
, , N
HRQOL NNP 1_o
was VBD N
maintained VBN N
in IN N
the DT N
CRT NNP 1_i
arm NN N
, , N
regardless RB N
of IN N
tumor NN N
size NN N
. . N

Among IN N
those DT N
who WP N
did VBD N
not RB N
receive VB N
CRT NNP 1_i
, , N
patients NNS N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NN N
experienced VBD N
a DT N
gradual JJ N
decline NN N
in IN N
the DT N
HRQOL NNP 1_o
. . 1_o

The DT N
CRT NNP 1_i
group NN N
had VBD N
significantly RB 1_o
more RBR 1_o
esophagitis JJ 1_o
and CC 1_o
hospitalizations NNS 1_o
because IN N
of IN N
side NN 1_o
effects NNS 1_o
regardless RB N
of IN N
tumor NN N
size NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS 1_p
with IN 1_p
poor JJ 1_p
prognosis NN 1_p
and CC 1_p
inoperable JJ 1_p
locally RB 1_p
advanced JJ 1_p
non-small-cell JJ 1_p
lung NN 1_p
cancer NN 1_p
, , N
large JJ N
tumor NN N
size NN N
should MD N
not RB N
be VB N
considered VBN N
a DT N
negative JJ N
predictive JJ N
factor NN N
. . N

Except IN N
for IN N
performance NN N
status NN N
2 CD N
, , N
patients NNS N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NNS N
apparently RB N
benefit VBP N
from IN N
CRT NNP 1_i
. . 1_i

Elastic JJ 1_i
stable JJ 1_i
intramedullary JJ 1_i
nailing VBG 1_i
versus NN N
nonoperative JJ 1_i
treatment NN 1_i
of IN N
displaced JJ 1_p
midshaft NN 1_p
clavicular JJ 1_p
fractures-a JJ 1_p
randomized VBN N
, , N
controlled VBN N
, , N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB 1_o
elastic JJ 1_i
stable JJ 1_i
intramedullary JJ 1_i
nailing NN 1_i
( ( 1_i
ESIN NNP 1_i
) ) 1_i
with IN N
nonoperative JJ 1_i
treatment NN 1_i
of IN N
fully RB 1_p
displaced VBN 1_p
midshaft NN 1_p
clavicular NN 1_p
fractures NNS 1_p
in IN 1_p
adults NNS 1_p
. . 1_p

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Level NNP 1_p
1 CD 1_p
trauma NN 1_p
center NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Sixty NNP 1_p
patients NNS 1_p
between IN 1_p
18 CD 1_p
and CC 1_p
65 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
participated VBN 1_p
and CC 1_p
completed VBN 1_p
the DT 1_p
study NN 1_p
. . 1_p

They PRP N
were VBD N
randomized VBN N
to TO N
either DT N
operative JJ N
or CC N
nonoperative JJ N
treatment NN N
with IN N
a DT N
2-year JJ N
follow-up NN N
. . N

INTERVENTION NNP N
Thirty NNP N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
simple JJ 1_i
shoulder NN 1_i
sling NN 1_i
and CC N
30 CD N
patients NNS N
with IN N
ESIN NNP 1_i
within IN N
3 CD N
days NNS N
after IN N
trauma NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASUREMENT NNP N
Complications NNP 1_o
after IN N
operative JJ N
and CC N
nonoperative JJ N
treatments NNS N
, , N
Disabilities NNS 1_o
of IN 1_o
the DT 1_o
Arm NNP 1_o
, , 1_o
Shoulder NNP 1_o
and CC 1_o
Hand NNP 1_o
( ( 1_o
DASH NNP 1_o
) ) 1_o
score NN 1_o
and CC N
Constant JJ 1_o
Shoulder NNP 1_o
Score NNP 1_o
for IN N
outcome JJ 1_o
measurement NN 1_o
, , N
and CC N
clavicular JJ 1_o
shortening NN 1_o
. . 1_o

RESULTS NNP N
Fracture NNP 1_o
union NN 1_o
was VBD N
achieved VBN N
in IN N
all DT N
patients NNS N
in IN N
the DT N
operative JJ N
group NN N
, , N
whereas IN N
nonunion NN 1_o
was VBD N
observed VBN N
in IN N
3 CD N
of IN N
30 CD N
patients NNS N
of IN N
the DT N
nonoperative JJ N
group NN N
. . N

Two CD N
symptomatic JJ 1_o
malunions NNS 1_o
required VBN N
corrective JJ N
osteotomy NN N
in IN N
the DT N
nonoperative JJ N
group NN N
. . N

Medial NNP 1_o
nail JJ 1_o
protrusion NN 1_o
occurred VBD N
in IN N
7 CD N
cases NNS N
in IN N
the DT N
operative JJ N
group NN N
. . N

Implant JJ 1_o
failure NN 1_o
with IN 1_o
revision NN 1_o
surgery NN 1_o
was VBD N
necessary JJ N
in IN N
2 CD N
patients NNS N
after IN N
an DT N
additional JJ N
adequate NN N
trauma NN N
. . N

DASH NNP 1_o
scores NNS 1_o
were VBD N
lower JJR N
in IN N
the DT N
operative JJ N
group NN N
throughout IN N
the DT N
first JJ N
6 CD N
months NNS N
and CC N
2 CD N
years NNS N
after IN N
trauma NN N
, , N
with IN N
a DT N
significant JJ N
difference NN N
during IN N
the DT N
first JJ N
18 CD N
weeks NNS N
. . N

Constant JJ 1_o
scores NNS 1_o
were VBD N
significantly RB N
higher JJR N
after IN N
6 CD N
months NNS N
and CC N
2 CD N
years NNS N
after IN N
intramedullary JJ N
stabilization NN N
. . N

Patients NNS N
in IN N
the DT N
operative JJ N
group NN N
showed VBD N
a DT N
significant JJ N
improvement NN N
of IN N
posttraumatic JJ 1_o
clavicular JJ 1_o
shortening NN 1_o
; : 1_o
they PRP N
were VBD N
also RB N
more RBR N
satisfied JJ 1_o
with IN N
cosmetic JJ N
appearance NN N
and CC N
overall JJ 1_o
outcome NN 1_o
. . 1_o

CONCLUSIONS NNP N
ESIN NNP N
of IN N
displaced JJ N
midshaft NN N
clavicular NN N
fractures NNS N
resulted VBD N
in IN N
a DT N
lower JJR N
rate NN N
of IN N
nonunion NN 1_o
and CC N
delayed VBN 1_o
union NN 1_o
, , N
a DT N
faster JJR N
return NN 1_o
to TO 1_o
daily JJ 1_o
activities NNS 1_o
, , N
and CC N
a DT N
better JJR N
functional JJ 1_o
outcome NN 1_o
. . 1_o

Clavicular JJ 1_o
shortening NN 1_o
was VBD N
significantly RB N
lower JJR N
, , N
and CC N
overall JJ 1_o
satisfaction NN 1_o
was VBD N
higher RBR N
in IN N
the DT N
operative JJ N
group NN N
. . N

Enamel NNP N
and CC N
dentin VB N
bond NN N
strength NN N
following VBG N
gaseous JJ 1_i
ozone NN 1_i
application NN 1_i
. . 1_i

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
gaseous JJ 1_i
ozone NN 1_i
application NN 1_i
on IN N
enamel NN N
and CC N
dentin VB N
bond NN N
strength NN N
produced VBN N
by IN N
two CD N
self-etching JJ N
adhesive JJ N
systems NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
shear JJ N
bond NN N
strength NN N
test NN N
was VBD N
conducted VBN N
to TO N
assess VB N
adhesion NN N
on IN N
enamel NN N
( ( N
protocol JJ N
1 CD N
) ) N
, , N
while IN N
the DT N
microtensile JJ N
bond NN N
strength NN N
test NN N
was VBD N
performed VBN N
on IN N
dentin NN N
( ( N
protocol JJ N
2 CD N
) ) N
. . N

Protocol $ N
1 CD N
: : N
96 CD 1_p
bovine NN 1_p
incisors NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
, , N
and CC N
enamel JJ N
surfaces NNS N
were VBD N
bonded VBN N
in IN N
accordance NN N
with IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( 1_i
1E CD 1_i
) ) 1_i
ozone NN 1_i
+ NN 1_i
Clearfil NNP 1_i
Protect NNP 1_i
Bond NNP 1_i
; : 1_i
( ( 1_i
2E CD 1_i
) ) 1_i
Clearfil NNP 1_i
Protect NNP 1_i
Bond NNP 1_i
( ( 1_i
control NN 1_i
) ) 1_i
; : 1_i
( ( 1_i
3E CD 1_i
) ) 1_i
ozone NN 1_i
+ JJ 1_i
Xeno NNP 1_i
III NNP 1_i
; : 1_i
( ( 1_i
4E CD 1_i
) ) 1_i
Xeno NN 1_i
III NNP 1_i
( ( 1_i
control NN 1_i
) ) 1_i
. . 1_i

Ozone NNP 1_i
gas NN 1_i
was VBD N
applied VBN N
for IN N
80 CD N
s. JJ N
Shear NNP N
bond NN N
strength NN N
was VBD N
measured VBN N
with IN N
a DT N
universal JJ N
testing NN N
machine NN N
. . N

Protocol CC N
2 CD N
: : N
40 CD 1_p
noncarious JJ 1_p
human JJ 1_p
molars NNS 1_p
were VBD N
selected VBN N
. . N

Middle/deep NNP N
dentin NN N
was VBD N
exposed VBN N
and CC N
bonded VBN N
in IN N
accordance NN N
with IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( 1_i
1D CD 1_i
) ) 1_i
ozone+Clearfil NN 1_i
Protect NNP 1_i
Bond NNP 1_i
; : 1_i
( ( 1_i
2D CD 1_i
) ) 1_i
Clearfil NNP 1_i
Protect NNP 1_i
Bond NNP 1_i
( ( 1_i
control NN 1_i
) ) 1_i
; : 1_i
( ( 1_i
3D CD 1_i
) ) 1_i
ozone+Xeno NN 1_i
III NNP 1_i
( ( 1_i
4D CD 1_i
) ) 1_i
Xeno NN 1_i
III NNP 1_i
( ( 1_i
control NN 1_i
) ) 1_i
. . 1_i

Four-mm-thick JJ N
buildups NNS N
were VBD N
built VBN N
on IN N
the DT N
adhesives NNS N
, , N
then RB N
specimens NNS N
were VBD N
sectioned VBN N
in IN N
accordance NN N
with IN N
the DT N
nontrimming NN N
technique NN N
. . N

Specimens NNS N
were VBD N
stressed VBN N
until IN N
failure NN N
occurred VBD N
, , N
and CC N
failure NN N
modes NNS N
were VBD N
analyzed VBN N
. . N

Shear JJ 1_o
bond NN 1_o
and CC 1_o
microtensile NN 1_o
bond NN 1_o
strength NN 1_o
data NNS 1_o
were VBD N
analyzed VBN N
using VBG N
two-way JJ N
ANOVA NNP N
and CC N
Tukey NNP N
's POS N
post-hoc JJ N
test NN N
. . N

RESULTS NNP N
No NNP N
statistical JJ N
differences NNS N
were VBD N
found VBN N
between IN N
ozone NN N
treated VBN N
specimens NNS N
and CC N
controls NNS N
, , N
neither CC N
on IN N
enamel JJ 1_o
nor CC N
on IN N
dentin JJ 1_o
irrespective NN N
of IN N
the DT N
tested JJ N
adhesive NN N
. . N

Clearfil NNP N
Protect NNP N
Bond NNP N
showed VBD N
higher JJR N
bond NN 1_o
strength NN 1_o
to TO N
enamel VB N
than IN N
Xeno NNP 1_i
III NNP 1_i
, , N
irrespective NN N
of IN N
the DT N
ozone NN 1_i
treatment NN 1_i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
ozone NN 1_i
gas NN 1_i
to TO N
disinfect VB N
the DT N
cavity NN N
before IN N
placing VBG N
a DT N
restoration NN N
had VBD N
no DT N
influence NN N
on IN N
immediate JJ N
enamel NN N
and CC N
dentin VB N
bond NN N
strength NN N
. . N

Determining VBG N
the DT N
trough-to-peak JJ 1_o
ratio NN 1_o
in IN N
parallel-group JJ N
trials NNS N
. . N

Systolic JJ N
Hypertension NNP N
in IN N
Europe NNP N
( ( N
SYST-EUR NNP N
) ) N
Trial NNP N
Investigators NNP N
. . N

We PRP N
explored VBD N
how WRB N
in IN N
parallel-group JJ N
trials NNS N
interindividual JJ N
variability NN N
, , N
correction NN N
for IN N
placebo NN N
effects NNS N
, , N
and CC N
smoothing NN N
of IN N
blood NN N
pressure NN N
profiles NNS N
can MD N
be VB N
handled VBN N
in IN N
measuring VBG N
the DT N
trough-to-peak JJ 1_o
ratio NN 1_o
in IN N
244 CD 1_p
individuals NNS 1_p
with IN 1_p
isolated JJ 1_p
systolic JJ 1_p
hypertension NN 1_p
( ( 1_p
> CD 1_p
or CC 1_p
= $ 1_p
60 CD 1_p
years NNS 1_p
) ) 1_p
enrolled VBD 1_p
in IN 1_p
the DT 1_p
placebo-controlled JJ 1_p
Systolic NNP 1_p
Hypertension NNP 1_p
in IN 1_p
europe JJ 1_p
Trial NNP 1_p
. . 1_p

Net JJ N
treatment NN N
effects NNS N
were VBD N
computed VBN N
by IN N
subtracting VBG N
the DT N
mean JJ N
changes NNS N
from IN N
baseline NN N
during IN N
placebo NN N
( ( N
n JJ N
= NNP N
133 CD N
) ) N
from IN N
those DT N
during IN N
active JJ N
treatment NN N
( ( N
n JJ N
= NNP N
111 CD N
) ) N
. . N

At IN 1_p
entry NN 1_p
, , 1_p
systolic/diastolic JJ 1_o
pressures NNS 1_o
averaged VBD 1_p
176/86 CD 1_p
mm NN 1_p
Hg NNP 1_p
in IN 1_p
the DT 1_p
clinic NN 1_p
and CC 1_p
149/80 CD 1_p
mm NN 1_p
Hg NNP 1_p
on IN 1_p
24-hour JJ 1_p
ambulatory JJ 1_p
monitoring NN 1_p
. . 1_p

With IN N
corrections NNS N
applied VBN N
for IN N
baseline NN N
and CC N
placebo NN N
, , N
nitrendipine NN 1_i
( ( 1_i
10 CD 1_i
to TO 1_i
40 CD 1_i
mg/d NN 1_i
) ) 1_i
, , 1_i
with IN 1_i
the DT 1_i
possible JJ 1_i
addition NN 1_i
of IN 1_i
enalapril NN 1_i
( ( 1_i
5 CD 1_i
to TO 1_i
20 CD 1_i
mg/d NN 1_i
) ) 1_i
and/or NN 1_i
hydrochlorothiazide NN 1_i
( ( 1_i
12.5 CD 1_i
to TO 1_i
25 CD 1_i
mg/d NN 1_i
) ) 1_i
, , 1_i
reduced VBN 1_i
( ( 1_i
P NNP 1_i
< NNP 1_i
.001 NNP 1_i
) ) 1_i
these DT 1_i
blood NN 1_o
pressure NN 1_o
values NNS 1_o
by IN 1_i
16.6/7.3 CD 1_i
and CC 1_i
9.8/4.7 CD 1_i
mm NN 1_i
Hg NNP 1_i
, , 1_i
respectively RB 1_i
. . 1_i

The DT N
net JJ 1_o
trough-to-peak JJ 1_o
ratios NNS 1_o
were VBD N
first RB N
determined VBN N
from IN N
blood NN 1_o
pressure NN 1_o
profiles NNS 1_o
( ( 1_i
12 CD 1_i
hours NNS 1_i
) ) 1_i
with IN 1_i
1-hour JJ 1_i
precision NN 1_i
, , 1_i
synchronized VBN 1_i
by IN 1_i
the DT 1_i
morning NN 1_i
and CC 1_i
evening NN 1_i
doses NNS 1_i
of IN 1_i
the DT 1_i
double-blind JJ 1_i
medication NN 1_i
. . 1_i

According VBG N
to TO N
the DT N
usual JJ N
approach NN N
, , N
disregarding VBG N
interindividual JJ N
variability NN N
, , N
the DT N
systolic/diastolic JJ 1_o
net JJ 1_o
trough-to-peak JJ 1_o
ratios NNS 1_o
were VBD N
0.46/0.40 CD N
in IN N
the DT N
morning NN N
and CC N
0.77/0.99 CD N
in IN N
the DT N
evening NN N
. . N

In IN N
individual JJ N
subjects NNS N
, , N
the DT N
baseline-adjusted JJ 1_o
trough-to-peak JJ 1_o
ratios NNS 1_o
were VBD N
nonnormally RB N
distributed VBN N
. . N

We PRP N
therefore VBP N
used VBD N
a DT N
nonparametric JJ N
technique NN N
to TO N
calculate VB N
the DT N
net JJ 1_o
trough-to-peak JJ 1_o
ratios NNS 1_o
from IN N
the DT N
results NNS N
in IN N
individual JJ N
subjects NNS N
. . N

In IN N
the DT N
morning NN N
, , N
these DT N
ratios NNS N
averaged VBD N
0.25 CD N
systolic NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.09 CD N
to TO N
0.41 CD N
) ) N
and CC N
0.15 CD N
diastolic NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.00 CD N
to TO N
0.31 CD N
) ) N
and CC N
in IN N
the DT N
evening NN N
, , N
0.19 CD N
and CC N
0.36 CD N
( ( N
95 CD N
% NN N
confidence NN N
intervals NNS N
, , N
0.00 CD N
to TO N
0.38 CD N
and CC N
0.14 CD N
to TO N
0.56 CD N
) ) N
, , N
respectively RB N
. . N

When WRB N
the DT N
blood NN 1_o
pressure NN 1_o
profiles NNS 1_o
were VBD N
smoothed VBN N
by IN N
substituting VBG N
the DT N
1-hour JJ N
averages NNS N
by IN N
moving VBG N
or CC N
fixed VBN N
2-hour JJ N
averages NNS N
or CC N
by IN N
Fourier NNP N
modeling NN N
, , N
the DT N
trough-to-peak JJ 1_o
ratios NNS 1_o
remained VBD N
unchanged JJ N
after IN N
the DT N
morning NN N
dose NN N
( ( N
0.20/0.13 CD N
, , N
0.20/0.14 CD N
, , N
and CC N
0.16/0.21 CD N
, , N
respectively RB N
) ) N
but CC N
tended VBD N
to TO N
increase VB N
in IN N
the DT N
evening NN N
( ( N
0.32/0.38 CD N
, , N
0.28/0.40 CD N
, , N
and CC N
0.48/0.49 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
parallel-group JJ N
analysis NN N
proposed VBN N
makes VBZ N
it PRP N
possible JJ N
for IN N
one CD N
to TO N
correct VB N
the DT N
trough-to-peak JJ 1_o
ratio NN 1_o
for IN N
baseline NN N
as RB N
well RB N
as IN N
placebo NN N
, , N
to TO N
account VB N
for IN N
interindividual JJ N
variability NN N
, , N
and CC N
to TO N
calculate VB N
a DT N
confidence NN N
interval NN N
for IN N
the DT N
net JJ N
trough-to-peak JJ 1_o
ratio NN 1_o
. . 1_o

Accounting NN N
for IN N
interindividual JJ N
variability NN N
reduces VBZ N
the DT N
trough-to-peak JJ 1_o
ratio NN 1_o
. . 1_o

Smoothing VBG N
affects VBZ N
the DT N
individualized JJ N
net JJ N
trough-to-peak JJ 1_o
ratios NNS 1_o
in IN N
an DT N
unpredictable JJ N
way NN N
and CC N
should MD N
therefore RB N
be VB N
avoided VBN N
. . N

A DT N
comparison NN N
of IN N
the DT N
upper JJ 1_i
lip NN 1_i
bite JJ 1_i
test NN 1_i
( ( 1_i
a DT 1_i
simple JJ 1_i
new JJ 1_i
technique NN 1_i
) ) 1_i
with IN 1_i
modified VBN 1_i
Mallampati NNP 1_i
classification NN 1_i
in IN N
predicting VBG N
difficulty NN N
in IN N
endotracheal JJ 1_o
intubation NN 1_o
: : 1_o
a DT N
prospective JJ N
blinded VBN N
study NN N
. . N

We PRP N
explored VBD N
the DT N
possibility NN N
that IN N
a DT N
simple JJ N
and CC N
single JJ N
test NN N
could MD N
replace VB N
the DT N
modified JJ N
Mallampati NNP 1_o
score NN 1_o
for IN N
either CC N
a DT N
difficult JJ N
or CC N
an DT N
unaccomplished JJ N
tracheal NN 1_o
intubation NN 1_o
in IN N
an DT N
impending JJ 1_o
hypoxic NN 1_o
patient NN 1_p
. . 1_p

Three CD 1_p
hundred VBD 1_p
adult NN 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
this DT 1_p
study NN 1_p
. . 1_p

They PRP N
were VBD N
subjected VBN N
to TO N
the DT N
following JJ N
assessments NNS N
: : N
1 CD N
) ) N
oropharyngeal NN 1_i
class NN 1_i
according VBG 1_i
to TO 1_i
the DT 1_i
modified VBN 1_i
Mallampati NNP 1_i
criteria NNS 1_i
; : 1_i
2 CD N
) ) N
the DT 1_i
new JJ 1_i
, , 1_i
upper JJ 1_i
lip NN 1_i
bite IN 1_i
criteria-class NN 1_i
I PRP 1_i
= VBP 1_i
lower JJR 1_i
incisors NNS 1_i
can MD 1_i
bite VB 1_i
the DT 1_i
upper JJ 1_i
lip NN 1_i
above IN 1_i
the DT 1_i
vermilion NN 1_i
line NN 1_i
, , 1_i
class NN 1_i
II NNP 1_i
= NNP 1_i
lower JJR 1_i
incisors NNS 1_i
can MD 1_i
bite VB 1_i
the DT 1_i
upper JJ 1_i
lip NN 1_i
below IN 1_i
the DT 1_i
vermilion NN 1_i
line NN 1_i
, , 1_i
and CC 1_i
class NN 1_i
III NNP 1_i
= NNP 1_i
lower JJR 1_i
incisors NNS 1_i
can MD 1_i
not RB 1_i
bite VB 1_i
the DT 1_i
upper JJ 1_i
lip NN 1_i
; : 1_i
and CC 1_i
3 CD N
) ) N
laryngeal NN 1_i
view NN 1_i
grading VBG 1_i
according VBG 1_i
to TO 1_i
Cormack NNP 1_o
's POS 1_o
criteria NNS 1_o
. . 1_o

The DT N
incidence NN 1_o
of IN 1_o
difficult JJ 1_o
intubation NN 1_o
was VBD N
5.7 CD N
% NN N
. . N

The DT 1_i
upper JJ 1_o
lip NN 1_o
bite NN 1_o
test NN 1_o
showed VBD N
significantly RB N
higher JJR N
specificity NN 1_o
and CC 1_o
accuracy NN 1_o
than IN N
the DT N
modified JJ 1_i
Mallampati NNP 1_o
test NN 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Comparisons NNS N
of IN N
sensitivity NN 1_o
, , 1_o
positive JJ 1_o
and CC 1_o
negative JJ 1_o
predictive NN 1_o
values NNS 1_o
, , N
between IN N
the DT N
two CD N
tests NNS N
, , N
however RB N
, , N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
upper JJ N
lip NN N
bite JJ N
test NN N
is VBZ N
an DT N
acceptable JJ N
option NN N
for IN N
predicting VBG N
difficult JJ 1_p
intubation NN 1_p
as IN N
a DT N
simple NN N
, , N
single JJ N
test NN N
. . N

Brief JJ N
report NN N
: : N
effect NN N
of IN N
a DT N
focused JJ 1_i
imitation NN 1_i
intervention NN 1_i
on IN N
social JJ 1_o
functioning NN 1_o
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Imitation NNP N
is VBZ N
an DT N
early JJ N
skill NN N
thought VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
social JJ N
development NN N
, , N
leading VBG N
some DT N
to TO N
suggest VB N
that IN N
teaching VBG N
imitation NN N
to TO N
children NNS 1_p
with IN 1_p
autism NN 1_p
should MD N
lead VB N
to TO N
improvements NNS N
in IN N
social JJ 1_o
functioning NN 1_o
. . 1_o

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
focused JJ 1_i
imitation NN 1_i
intervention NN 1_i
on IN N
initiation NN N
of IN N
joint JJ 1_o
attention NN 1_o
and CC 1_o
social-emotional JJ 1_o
functioning NN 1_o
in IN N
27 CD 1_p
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Results NNS N
indicated VBD N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB N
more RBR N
gains NNS N
in IN N
joint JJ 1_o
attention NN 1_o
initiations NNS 1_o
at IN N
post-treatment JJ N
and CC N
follow-up JJ N
and CC N
social-emotional JJ 1_o
functioning NN 1_o
at IN N
follow-up NN N
than IN N
the DT N
control NN N
group NN N
. . N

Although IN N
gains NNS 1_o
in IN 1_o
social JJ 1_o
functioning NN 1_o
were VBD N
associated VBN N
with IN N
treatment NN N
, , N
a DT N
mediation NN N
analysis NN N
did VBD N
not RB N
support VB N
imitation NN 1_i
as IN N
the DT N
mechanism NN N
of IN N
action NN N
. . N

These DT N
findings NNS N
suggest VBP N
the DT N
intervention NN N
improves VBZ N
social JJ 1_o
functioning NN 1_o
in IN 1_o
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

The DT N
effects NNS N
of IN N
moderate JJ 1_i
to TO 1_i
vigorous JJ 1_o
aerobic JJ 1_i
exercise NN 1_i
on IN N
the DT N
sleep JJ 1_p
need NN 1_p
of IN 1_p
sedentary JJ 1_p
young JJ 1_p
adults NNS 1_p
. . 1_p

Exercise NN 1_i
has VBZ N
been VBN N
recommended VBN N
for IN N
enhancing VBG N
sleep NN N
; : N
a DT N
claim NN N
linked VBN N
to TO N
the DT N
belief NN N
that IN N
sleep VBP N
need MD N
- : N
defined VBN N
by IN N
sleep JJ N
duration NN N
and CC N
depth NN N
- : N
is VBZ N
increased VBN N
post-exercise NN N
to TO N
allow VB N
tissue NN N
recovery NN N
. . N

Objective JJ N
studies NNS N
investigating VBG N
exercise-sleep JJ N
responses NNS N
have VBP N
produced VBN N
mixed JJ N
outcomes NNS N
, , N
and CC N
the DT N
disparity NN N
in IN N
results NNS N
between IN N
studies NNS N
may MD N
be VB N
due JJ N
to TO N
differences NNS N
in IN N
individual JJ N
characteristics NNS N
and/or VBP N
exercise NN 1_i
protocol NN N
, , N
emphasising VBG N
the DT N
importance NN N
of IN N
carefully RB N
controlled VBN N
trials NNS N
. . N

We PRP N
investigated VBD N
the DT N
role NN N
of IN N
exercise NN 1_i
on IN N
the DT N
sleep JJ N
need NN N
of IN N
sedentary JJ 1_p
adults NNS 1_p
, , N
after IN N
controlling VBG N
for IN N
exercise NN N
mode NN N
, , N
timing NN N
and CC N
duration NN N
. . N

Twelve NNP 1_p
healthy JJ 1_p
volunteers NNS 1_p
( ( 1_p
25.2 CD 1_p
± RB 1_p
4.0 CD 1_p
years NNS 1_p
, , 1_p
9 CD 1_p
females NNS 1_p
, , 1_p
[ NNP 1_p
Vdot NNP 1_p
] NNP 1_p
O NNP 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
max NN 1_p
35.4 CD 1_p
± NN 1_p
8.8 CD 1_p
ml· NN 1_p
kg NN 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
· VBP 1_p
min NN 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
) ) 1_p
were VBD N
randomised VBN 1_i
to TO 1_i
no-exercise NN 1_i
or CC 1_i
to TO 1_i
a DT 1_i
bout NN 1_i
of IN 1_i
treadmill NN 1_i
exercise NN 1_i
at IN N
45 CD N
% NN N
, , N
55 CD N
% NN N
, , N
65 CD N
% NN N
or CC N
75 CD N
% NN N
[ JJ N
Vdot NNP N
] NNP N
O NNP N
( ( N
2 CD N
) ) N
max NN N
in IN N
a DT N
crossover NN N
design NN N
. . N

Sleep VB 1_i
on IN 1_i
no-exercise NN 1_i
and CC 1_i
exercise NN 1_i
nights NNS N
were VBD N
assessed VBN 1_i
by IN 1_i
polysomnography NN 1_i
. . N

Participants NNS N
spent VBD N
a DT N
greater JJR N
proportion NN 1_o
of IN 1_o
sleep NN 1_o
in IN 1_o
light JJ 1_o
sleep NN 1_o
( ( N
stage NN N
1 CD N
+ JJ N
stage NN N
2 CD N
) ) N
after IN 1_i
exercise NN 1_i
at IN N
both DT N
65 CD N
% NN N
and CC N
75 CD N
% NN N
[ JJ N
Vdot NNP N
] NNP N
O NNP N
( ( N
2 CD N
) ) N
max NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
the DT 1_i
no-exercise JJ 1_i
condition NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
of IN N
a DT N
reduced JJ N
proportion NN 1_o
of IN 1_o
rapid JJ 1_o
eye NN 1_o
movement NN 1_o
sleep JJ 1_o
with IN 1_o
increased JJ 1_o
exercise NN 1_o
intensity NN 1_o
( ( N
P NNP N
= NNP N
0.067 CD N
) ) N
. . N

No UH N
other JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
any DT N
other JJ N
sleep JJ N
variables NNS N
. . N

Two CD N
findings NNS N
emerged VBD N
: : N
vigorous JJ 1_i
exercise NN 1_i
did VBD N
not RB N
increase VB 1_o
sleep JJ 1_o
need NN 1_o
; : 1_o
however RB N
, , N
this DT N
level NN 1_i
of IN 1_i
exercise NN 1_i
increased VBN 1_o
light JJ 1_o
sleep NN 1_o
. . N

Adjusting VBG N
intraocular JJ N
pressure NN N
for IN N
central JJ N
corneal JJ N
thickness NN N
does VBZ N
not RB N
improve VB N
prediction NN N
models NNS N
for IN N
primary JJ N
open-angle JJ N
glaucoma NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
if IN N
the DT N
accuracy NN N
of IN N
the DT N
baseline NN N
prediction NN N
model NN N
for IN N
the DT N
development NN N
of IN N
primary JJ N
open-angle JJ N
glaucoma NN N
( ( N
POAG NNP N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
ocular JJ 1_p
hypertension NN 1_p
can MD N
be VB N
improved VBN N
by IN N
correcting VBG N
intraocular JJ 1_i
pressure NN 1_i
( ( 1_i
IOP NNP 1_i
) ) 1_i
for IN 1_i
central JJ 1_i
corneal NN 1_i
thickness NN 1_i
( ( 1_i
CCT NNP 1_i
) ) 1_i
. . 1_i

DESIGN NNP N
Reanalysis NNP N
of IN N
the DT N
baseline NN 1_i
prediction NN 1_i
model NN 1_i
for IN N
the DT N
development NN N
of IN N
POAG NNP N
from IN N
the DT N
Ocular NNP N
Hypertension NNP N
Treatment NNP N
Study NNP N
( ( N
OHTS NNP N
) ) N
substituting VBG N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
using VBG N
5 CD N
different JJ N
correction NN N
formulae NN N
for IN N
unadjusted JJ N
IOP NNP N
. . N

PARTICIPANTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
1433 CD 1_p
of IN 1_p
1636 CD 1_p
participants NNS 1_p
randomized VBN 1_p
to TO 1_p
OHTS NNP 1_p
who WP 1_p
had VBD 1_p
complete JJ 1_p
baseline NN 1_p
data NNS 1_p
for IN 1_p
factors NNS 1_p
in IN 1_p
the DT 1_p
prediction NN 1_p
model NN 1_p
: : 1_p
age NN 1_p
, , 1_p
IOP NNP 1_p
, , 1_p
CCT NNP 1_p
, , 1_p
vertical JJ 1_p
cup-to-disc NN 1_p
ratio NN 1_p
( ( 1_p
VCDR NNP 1_p
) ) 1_p
, , 1_p
and CC 1_p
pattern JJ 1_p
standard JJ 1_p
deviation NN 1_p
( ( 1_p
PSD NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Reanalysis NNP N
of IN N
the DT N
prediction NN 1_i
model NN 1_i
for IN N
the DT N
risk NN N
of IN N
developing VBG N
POAG NNP N
using VBG N
the DT N
same JJ N
baseline NN N
variables NNS N
( ( N
age NN N
, , N
IOP NNP N
, , N
CCT NNP N
, , N
VCDR NNP N
, , N
and CC N
PSD NNP N
) ) N
except IN N
that DT N
IOP NNP N
was VBD N
adjusted VBN N
for IN N
CCT NNP N
using VBG N
correction NN N
formulae NN N
. . N

A DT N
separate JJ N
Cox NNP N
proportional NN N
hazards NNS N
model NN N
was VBD N
run VBN N
using VBG N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
by IN N
each DT N
of IN N
the DT N
5 CD N
formulae NN N
published VBN N
to TO N
date NN N
. . N

Models NNS N
were VBD N
run VBN N
including VBG N
and CC N
excluding VBG N
CCT NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Predictive NNP 1_o
accuracy NN 1_o
of IN 1_o
each DT 1_o
Cox NNP 1_o
proportional JJ 1_o
hazards NNS 1_o
model NN 1_o
was VBD N
assessed VBN N
using VBG N
the DT 1_o
c-statistic JJ 1_o
and CC 1_o
calibration JJ 1_o
chi-square NN 1_o
. . 1_o

RESULTS NNP N
C-statistics NNPS N
for IN N
prediction NN N
models NNS N
that IN N
used VBD N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
by IN N
various JJ N
formulas NNS N
ranged VBD N
from IN N
0.75 CD N
to TO N
0.77 CD N
, , N
no DT N
better JJR N
than IN N
the DT N
original JJ N
prediction NN N
model NN N
( ( N
0.77 CD N
) ) N
that WDT N
did VBD N
not RB N
adjust VB N
IOP NNP N
for IN N
CCT NNP N
. . N

Calibration NNP N
chi-square NN N
was VBD N
acceptable JJ N
for IN N
all DT N
models NNS N
. . N

Baseline NNP 1_o
IOP NNP 1_o
, , N
whether IN N
adjusted VBN N
for IN N
CCT NNP N
or CC N
not RB N
, , N
was VBD N
statistically RB N
significant JJ N
in IN N
all DT N
models NNS N
including VBG N
those DT N
with IN N
CCT NNP N
in IN N
the DT N
same JJ N
model NN N
. . N

The DT N
CCT NNP 1_o
was VBD N
statistically RB N
significant JJ N
in IN N
all DT N
models NNS N
including VBG N
those DT N
with IN N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
in IN N
the DT N
same JJ N
model NN N
. . N

CONCLUSIONS VB N
The DT N
calculation NN N
of IN N
individual JJ N
risk NN N
for IN N
developing VBG N
POAG NNP N
in IN N
ocular JJ 1_p
hypertensive JJ 1_p
individuals NNS 1_p
is VBZ N
simpler JJR N
and CC N
equally RB N
accurate JJ N
using VBG N
IOP NNP N
and CC N
CCT NNP N
as IN N
measured VBN N
, , N
rather RB N
than IN N
applying VBG N
an DT N
adjustment NN N
formula NN N
to TO N
correct VB N
IOP NNP N
for IN N
CCT NNP N
. . N

Changes NNS N
in IN N
sleep JJ N
quality NN N
, , N
but CC N
not RB N
hormones VB N
predict JJ N
time NN N
to TO N
postpartum VB N
depression NN N
recurrence NN N
. . N

BACKGROUND NNP N
Poor NNP N
sleep JJ N
quality NN N
, , N
dysregulation NN N
of IN N
hormones NNS N
and CC N
increased VBD N
inflammatory JJ N
cytokines NNS N
are VBP N
all DT N
associated VBN N
with IN N
the DT N
risk NN N
for IN N
postpartum NN N
major JJ N
depression NN N
( ( N
PPMD NNP N
) ) N
. . N

We PRP N
evaluated VBD N
change NN N
over IN N
time NN N
in IN N
sleep JJ 1_o
quality NN 1_o
and CC N
hormones NNS 1_o
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum RB N
, , N
as RB N
well RB N
as IN N
a DT N
single JJ N
cytokine NN N
measure NN N
, , N
and CC N
their PRP$ N
association NN N
with IN N
PPMD NNP N
recurrence NN N
. . N

METHODS JJ N
Participants NNS 1_p
were VBD 1_p
pregnant JJ 1_p
women NNS 1_p
( ( 1_p
N=56 NNP 1_p
) ) 1_p
, , 1_p
with IN 1_p
past JJ 1_p
histories NNS 1_p
of IN 1_p
MDD/PPMD NNP 1_p
but CC 1_p
not RB 1_p
depressed VBN 1_p
in IN 1_p
their PRP$ 1_p
current JJ 1_p
pregnancy NN 1_p
. . 1_p

The DT N
Pittsburgh NNP 1_o
Sleep NNP 1_o
Quality NNP 1_o
Index NNP 1_o
( ( 1_i
PSQI NNP 1_i
) ) 1_i
and CC N
blood NN 1_i
samples NNS 1_i
were VBD 1_i
collected VBN 1_i
8 CD N
times NNS N
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum NN N
. . N

Estradiol NNP 1_o
, , 1_o
prolactin NN 1_o
and CC 1_o
cortisol NN 1_o
, , 1_o
and CC 1_o
a DT 1_o
single JJ 1_o
measure NN 1_o
of IN 1_o
IL-6 NNP 1_o
were VBD N
assayed VBN N
. . N

Recurrence NN N
was VBD N
determined VBN N
by IN N
two CD N
consecutive JJ N
21-item JJ 1_o
Hamilton NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
for IN 1_o
Depression NNP 1_o
( ( 1_o
HRSD NNP 1_o
) ) 1_o
scores≥15 NN 1_o
and CC 1_o
clinician JJ 1_o
interview NN 1_o
. . N

RESULTS NNP N
In IN N
the DT N
analyses NNS N
of IN N
time NN N
to TO 1_o
PPMD NNP 1_o
recurrence NN 1_o
, , 1_o
poor JJ 1_o
sleep JJ 1_o
quality NN 1_o
, , N
but CC N
none NN N
of IN N
the DT N
hormones NNS N
, , N
was VBD N
associated VBN N
with IN 1_o
PPMD NNP 1_o
recurrence NN 1_o
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
after IN N
controlling VBG N
for IN N
medication NN N
assignment NN N
. . N

With IN N
every DT N
one CD N
point NN N
increase NN N
in IN N
PSQI NNP N
scores NNS N
across IN N
time NN N
, , N
a DT N
woman NN N
's POS N
risk NN N
for IN N
recurrence NN N
increased VBN N
by IN N
approximately RB N
25 CD N
% NN N
There EX N
was VBD N
no DT N
significant JJ N
association NN N
between IN 1_o
PSQI NNP 1_o
scores NNS N
and CC 1_o
IL-6 NNP 1_o
concentrations NNS N
in IN N
early JJ N
postpartum NN N
( ( N
χ NNP N
( ( N
2 CD N
) ) N
=0.98 NN N
, , N
p=.32 NN N
) ) N
. . N

CONCLUSIONS NNP N
Poor NNP N
sleep VBP N
quality NN N
across IN N
the DT N
first JJ N
17 CD N
weeks NNS N
post-delivery JJ N
increases NNS N
the DT N
risk NN N
for IN N
recurrent JJ N
PPMD NNP N
among IN 1_p
women NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
MDD NNP 1_p
. . N

Changes NNS N
in IN N
the DT N
hormonal JJ N
milieu NN N
were VBD N
not RB N
associated VBN N
with IN N
recurrence NN N
. . N

Further JJ N
exploration NN N
of IN N
the DT N
degree NN N
to TO N
which WDT N
poor JJ N
sleep NN N
contributes NNS N
to TO N
hormonal JJ N
and CC N
cytokine JJ N
dysregulation NN N
and CC N
how WRB N
they PRP N
are VBP N
involved VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
PPMD NNP N
is VBZ N
warranted VBN N
. . N

Safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
oral JJ N
DMSA NNP 1_i
therapy NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
part NN N
B NNP N
- : N
behavioral JJ N
results NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
oral JJ 1_i
dimercapto NN 1_i
succinic JJ 1_i
acid NN 1_i
( ( 1_i
DMSA NNP 1_i
) ) 1_i
therapy NN 1_i
on IN N
the DT N
behavioural JJ N
symptoms NNS N
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
ages VBZ 1_p
3-8 JJ 1_p
years NNS 1_p
. . 1_p

METHODS NNP N
Phase NNP 1_p
1 CD 1_p
involved VBD 1_p
65 CD 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
who WP 1_p
received VBD 1_p
one CD 1_p
round NN 1_p
of IN 1_p
DMSA NNP 1_p
( ( 1_p
3 CD 1_p
days NNS 1_p
) ) 1_p
. . 1_p

Participants NNS 1_p
who WP 1_p
had VBD 1_p
high JJ 1_p
urinary JJ 1_p
excretion NN 1_p
of IN 1_p
toxic JJ 1_p
metals NNS 1_p
were VBD 1_p
selected VBN 1_p
to TO 1_p
continue VB 1_p
on IN 1_p
to TO 1_p
phase VB 1_p
2 CD 1_p
. . 1_p

In IN N
phase NN 1_p
2 CD 1_p
, , 1_p
49 CD 1_p
participants NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
in IN 1_p
a DT 1_p
double-blind JJ 1_p
design NN 1_p
to TO 1_p
receive VB 1_p
an DT 1_p
additional JJ 1_p
6 CD 1_i
rounds NNS 1_i
of IN 1_i
either DT 1_i
DMSA NNP 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

RESULTS VB N
The DT N
groups NNS N
receiving VBG N
one CD N
round NN N
and CC N
seven CD N
rounds NNS N
of IN N
DMSA NNP 1_i
had VBD N
significant JJ N
improvements NNS N
on IN N
all PDT N
the DT N
assessment JJ N
measures NNS N
. . N

For IN N
the DT N
seven CD N
round NN N
group NN N
, , N
the DT N
degree NN N
of IN N
improvement NN 1_o
on IN N
the DT N
assessment NN 1_o
measures NNS 1_o
could MD N
be VB N
partially RB N
explained VBN N
by IN N
a DT N
regression NN N
analysis NN N
based VBN N
on IN N
excretion NN 1_o
of IN 1_o
toxic JJ 1_o
metals NNS 1_o
and CC 1_o
changes NNS 1_o
in IN 1_o
glutathione NN 1_o
( ( N
adjusted VBN N
R2 NNP N
of IN N
0.28-0.75 NNP N
, , N
p NN N
< VBD N
0.02 CD N
in IN N
all DT N
cases NNS N
) ) N
. . N

One CD N
round NN N
of IN N
DMSA NNP N
had VBD N
nearly RB N
the DT N
same JJ N
benefit NN N
as IN N
seven CD N
rounds NNS N
. . N

The DT N
assessment JJ N
measures NNS N
correlated VBN N
reasonably RB N
with IN N
one CD N
another DT N
at IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
( ( N
r JJ N
= NNP N
0.60-0.87 NN N
) ) N
and CC N
even RB N
better JJR N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
r JJ N
= NNP N
0.63-0.94 NN N
) ) N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
both DT N
one CD N
and CC N
seven CD N
rounds NNS N
of IN N
DMSA NNP 1_i
therapy NN N
seems VBZ N
to TO N
be VB N
reasonably RB N
safe JJ 1_o
in IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
who WP 1_p
have VBP 1_p
high JJ 1_p
urinary JJ 1_p
excretion NN 1_p
of IN 1_p
toxic JJ 1_p
metals NNS 1_p
, , N
and CC N
possibly RB N
helpful JJ N
in IN N
reducing VBG N
some DT N
of IN N
the DT N
symptoms NNS N
of IN N
autism NN N
in IN N
those DT N
children NNS N
. . N

Randomized VBN N
Phase NNP N
II NNP N
trial NN N
assessing VBG N
estramustine NN 1_i
and CC 1_i
vinblastine JJ 1_i
combination NN 1_i
chemotherapy NN 1_i
vs JJ 1_i
estramustine NN 1_i
alone RB 1_i
in IN N
patients NNS 1_p
with IN 1_p
progressive JJ 1_p
hormone-escaped JJ 1_p
metastatic JJ 1_p
prostate NN 1_p
cancer NN 1_p
. . 1_p

Based VBN N
on IN N
the DT N
results NNS N
of IN N
combined JJ N
data NNS N
from IN N
three CD N
North JJ N
American JJ N
Phase NNP N
II NNP N
studies NNS N
, , N
a DT N
randomised JJ N
Phase NNP N
II NNP N
study NN N
in IN N
the DT N
same JJ N
patient JJ N
population NN N
was VBD N
performed VBN N
, , N
using VBG N
combination NN N
chemotherapy NN 1_i
with IN 1_i
estramustine JJ 1_i
phosphate NN 1_i
( ( 1_i
EMP NNP 1_i
) ) 1_i
and CC 1_i
vinblastine NN 1_i
( ( 1_i
VBL NNP 1_i
) ) 1_i
in IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
patients NNS N
. . N

In IN N
all DT N
, , N
92 CD 1_p
patients NNS 1_p
were VBD 1_p
randomised VBN 1_p
into IN 1_p
a DT 1_p
Phase NNP 1_p
II NNP 1_p
study NN 1_p
of IN N
oral JJ 1_i
EMP NNP 1_i
( ( 1_i
10 CD 1_i
mg NNS 1_i
kg JJ 1_i
day NN 1_i
continuously RB 1_i
) ) 1_i
or CC 1_i
oral JJ 1_i
EMP NNP 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
intravenous JJ 1_i
VBL NNP 1_i
( ( N
4 CD N
mg NN N
m NN N
( ( N
2 CD N
) ) N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
followed VBN N
by IN N
2 CD N
weeks NNS N
rest NN N
) ) N
. . N

The DT N
end NN N
points NNS N
were VBD N
toxicity NN 1_o
and CC 1_o
PSA NNP 1_o
response NN 1_o
in IN N
both DT N
groups NNS N
, , N
with IN N
the DT N
option NN N
to TO N
continue VB N
the DT N
trial NN N
as IN N
a DT N
Phase NNP N
III NNP N
study NN N
with IN N
time NN 1_o
to TO 1_o
progression NN 1_o
and CC N
survival NN 1_o
as IN N
end NN N
points NNS N
, , N
if IN N
sufficient JJ N
responses NNS N
were VBD N
observed VBN N
. . N

Toxicity NNP 1_o
was VBD N
unexpectedly RB N
high JJ N
in IN N
both DT N
treatment NN N
arms NNS N
and CC N
led VBD N
to TO N
treatment NN N
withdrawal NN N
or CC N
refusal NN N
in IN N
49 CD N
% NN N
of IN N
all DT N
patients NNS N
, , N
predominantly RB N
already RB N
during IN N
the DT N
first JJ N
treatment NN N
cycle NN N
. . N

The DT N
mean JJ 1_o
treatment NN 1_o
duration NN 1_o
was VBD N
10 CD N
and CC N
14 CD N
weeks NNS N
, , N
median JJ 1_o
time NN 1_o
to TO 1_o
PSA NNP 1_o
progression NN 1_o
was VBD N
27.2 CD N
and CC N
30.8 CD N
weeks NNS N
, , N
median JJ 1_o
survival NN 1_o
time NN 1_o
was VBD N
44 CD N
and CC N
50.9 CD N
weeks NNS N
, , N
and CC N
PSA NNP 1_o
response NN 1_o
rate NN 1_o
was VBD N
only RB N
24.6 CD N
and CC N
28.9 CD N
% NN N
in IN N
the DT N
EMP/VBL NNP 1_i
and CC N
EMP NNP 1_i
arms NNS N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
PSA NNP 1_o
response NN 1_o
and CC 1_o
survival NN 1_o
. . 1_o

While IN N
the DT N
PSA NNP 1_o
response NN 1_o
in IN N
the DT N
patients NNS N
tested VBD N
was VBD N
less JJR N
than IN N
half NN N
that WDT N
recorded VBD N
in IN N
the DT N
North JJ N
American JJ N
studies NNS N
, , N
the DT N
toxicity NN 1_o
of IN 1_o
EMP NNP 1_o
monotherapy NN 1_o
or CC N
in IN N
combination NN N
with IN N
VBL NNP 1_i
was VBD N
much RB N
higher JJR N
than IN N
expected VBN N
. . N

Further NNP N
research NN N
on IN N
more RBR N
effective JJ 1_o
and CC N
less RBR N
toxic JJ 1_o
treatment NN N
strategies NNS N
for IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
is VBZ N
mandatory JJ N
. . N

Effect NN N
of IN N
pravastatin NN 1_i
on IN N
kidney NN 1_o
function NN 1_o
and CC 1_o
urinary JJ 1_o
protein NN 1_o
excretion NN 1_o
in IN N
autosomal JJ 1_p
dominant JJ 1_p
polycystic JJ 1_p
kidney NN 1_p
disease NN 1_p
. . 1_p

OBJECTIVE NNP N
Autosomal NNP 1_p
dominant JJ 1_p
polycystic JJ 1_p
kidney NN 1_p
disease NN 1_p
( ( 1_p
ADPKD NNP 1_p
) ) 1_p
is VBZ N
progressive JJ N
, , N
resulting VBG N
in IN N
end-stage NN 1_p
kidney NN 1_p
failure NN 1_p
in IN 1_p
most JJS 1_p
patients NNS 1_p
. . 1_p

Experimental NNP N
and CC N
clinical JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
statins NNS 1_i
may MD N
slow VB N
the DT N
progression NN 1_o
of IN 1_o
chronic JJ 1_o
kidney NN 1_o
disease NN 1_o
in IN N
general JJ N
and CC N
ADPKD NNP N
specifically RB N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBD N
open-label JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
pravastatin NN 1_i
20 CD N
mg NN N
on IN N
kidney NN N
function NN N
and CC N
urinary JJ N
protein NN N
excretion NN N
in IN N
patients NNS 1_p
with IN 1_p
ADPKD NNP 1_p
. . 1_p

Sixty CD 1_p
patients NNS 1_p
were VBD 1_p
initially RB 1_p
recruited VBN 1_p
but CC 1_p
49 CD 1_p
of IN 1_p
these DT 1_p
received VBN 1_p
either RB 1_p
pravastatin JJ 1_i
20 CD 1_p
mg NN 1_p
or CC 1_p
no DT 1_i
treatment NN 1_i
for IN 1_p
2 CD 1_p
years NNS 1_p
. . 1_p

Trial JJ N
visits NNS N
were VBD N
conducted VBN N
every DT N
3 CD N
months NNS N
, , N
assessing VBG N
kidney NN 1_o
function NN 1_o
by IN N
estimated VBN N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
and CC 1_o
24 CD 1_o
h NN 1_o
urine JJ 1_o
creatinine NN 1_o
clearance NN 1_o
and CC 1_o
urinary JJ 1_o
protein NN 1_o
excretion NN 1_o
. . 1_o

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
changes NNS 1_o
in IN N
markers NNS 1_o
of IN 1_o
kidney NN 1_o
function NN 1_o
or CC 1_o
urinary JJ 1_o
protein NN 1_o
excretion NN 1_o
between IN N
groups NNS N
over IN N
the DT N
2 CD N
years NNS N
despite IN N
a DT N
significant JJ N
fall NN N
in IN N
total JJ 1_o
serum NN 1_o
cholesterol NN 1_o
in IN N
pravastatin-treated JJ 1_i
patients NNS N
( ( N
p JJ N
= NNP N
0.029 CD N
) ) N
. . N

CONCLUSION VB N
This DT N
trial NN N
found VBD N
that IN N
taking VBG N
20 CD N
mg NN N
pravastatin NN 1_i
for IN N
2 CD N
years NNS N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
kidney NN 1_o
function NN 1_o
or CC 1_o
urinary JJ 1_o
protein NN 1_o
excretion NN 1_o
in IN N
patients NNS N
with IN N
ADPKD NNP N
. . N

The DT N
lack NN N
of IN N
statistical JJ N
power NN N
limits VBZ N
the DT N
external JJ N
validity NN N
of IN N
these DT N
findings NNS N
. . N

A NNP N
larger JJR N
, , N
longer JJR N
duration NN N
study NN N
using VBG N
a DT N
higher JJR N
dose NN N
of IN N
a DT N
more RBR N
potent JJ N
statin NN N
is VBZ N
required VBN N
. . N

[ JJ 1_i
Radiotherapy NNP 1_i
of IN N
malignant JJ 1_p
brain NN 1_p
gliomas NN 1_p
using VBG N
teniposide JJ 1_i
] NNP 1_i
. . N

Efficacy NN 1_o
of IN N
radiochemotherapy NN 1_i
of IN N
malignantly-converted JJ 1_p
brain NN 1_p
gliomas NN 1_p
using VBG N
teniposide NN 1_i
was VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

Combined VBN N
use NN N
of IN N
cytostatics NNS 1_i
and CC 1_i
irradiation NN 1_i
appeared VBD N
safe JJ N
, , N
tolerable JJ N
and CC N
significantly RB N
more RBR N
effective JJ N
than IN N
radiotherapy RB 1_i
alone RB 1_i
as IN N
assessed VBN N
by IN N
local JJ 1_o
control NN 1_o
of IN 1_o
tumor NN 1_o
and CC 1_o
survival NN 1_o
. . 1_o

[ JJ N
Randomized NNP N
control NN N
study NN N
of IN N
high-dose JJ N
metoclopramide NN 1_i
in IN N
the DT N
prevention NN N
of IN N
CDDP-induced NNP 1_o
emesis NN 1_o
] NN 1_o
. . N

The DT N
effect NN N
of IN N
high-dose JJ 1_i
metoclopramide NN 1_i
( ( 1_i
2 CD 1_i
mg/kg NN 1_i
, , 1_i
4 CD 1_i
times NNS 1_i
every DT 1_i
2 CD 1_i
hours NNS 1_i
) ) 1_i
on IN N
the DT N
emesis NN 1_o
of IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
CDDP NNP 1_p
( ( 1_p
80 CD 1_p
mg/m2 NN 1_p
) ) 1_p
was VBD N
examined VBN N
by IN N
randomized VBN N
control NN N
trial NN N
. . N

The DT N
above JJ N
metoclopramide NN 1_i
regimen NNS N
significantly RB N
suppressed VBD 1_o
the DT 1_o
frequency NN 1_o
of IN 1_o
vomiting VBG 1_o
on IN N
the DT N
day NN N
of IN N
CDDP NNP N
administration NN N
. . N

The DT N
duration NN N
of IN N
nausea NN 1_o
and CC 1_o
anorexia NN 1_o
after IN N
CDDP NNP N
treatment NN N
was VBD N
also RB N
shortened VBN N
by IN N
high-dose JJ N
metoclopramide JJ 1_i
administration NN N
. . N

Enhanced NNP 1_i
small JJ 1_i
group NN 1_i
instruction NN 1_i
using VBG 1_i
choral JJ 1_i
responding NN 1_i
and CC 1_i
student NN 1_i
interaction NN 1_i
for IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
developmental JJ 1_p
disabilities NNS 1_p
. . 1_p

The DT N
use NN N
of IN N
effective JJ 1_i
instructional JJ 1_i
strategies NNS 1_i
in IN N
small JJ N
groups NNS N
was VBD N
investigated VBN N
to TO N
determine VB N
learning JJ N
effects NNS N
for IN N
24 CD 1_p
elementary JJ 1_p
age NN 1_p
students NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
developmental JJ 1_p
disabilities NNS 1_p
. . 1_p

Effective JJ N
strategies NNS N
included VBD N
( ( N
a DT N
) ) N
the DT 1_i
use NN 1_i
of IN 1_i
choral JJ 1_i
responding NN 1_i
; : 1_i
( ( N
b NN N
) ) N
the DT 1_i
use NN 1_i
of IN 1_i
student-to-student JJ 1_i
responding NN 1_i
; : 1_i
( ( N
c NN N
) ) N
the DT 1_i
rotation NN 1_i
of IN 1_i
materials NNS 1_i
every DT 1_i
5 CD 1_i
minutes NNS 1_i
during IN 1_i
the DT 1_i
30-minute JJ 1_i
group NN 1_i
while IN 1_i
teaching VBG 1_i
2 CD 1_i
to TO 1_i
3 CD 1_i
concepts NNS 1_i
; : 1_i
and CC 1_i
( ( N
d NN N
) ) N
the DT 1_i
use NN 1_i
of IN 1_i
random NN 1_i
, , 1_i
unpredictable JJ 1_i
trials NNS 1_i
for IN 1_i
student NN 1_i
responding VBG 1_i
. . 1_i

Thirty-minute JJ N
language NN N
groups NNS N
were VBD N
targeted VBN N
to TO N
teach VB N
receptive JJ N
and CC N
expressive JJ N
skills NNS N
using VBG N
pictures NNS N
and CC N
common JJ N
objects NNS N
across IN N
five CD N
categories NNS N
( ( N
e.g. NN N
, , N
household NN N
items NNS N
, , N
foods NNS N
) ) N
. . N

Results JJ N
showed VBD N
increased JJ 1_o
opportunities NNS 1_o
to TO 1_o
respond VB 1_o
, , 1_o
increased JJ 1_o
levels NNS 1_o
of IN 1_o
responding VBG 1_o
and CC 1_o
academic JJ 1_o
engagement NN 1_o
, , 1_o
higher JJR 1_o
gains NNS 1_o
on IN 1_o
weekly JJ 1_o
criterion-referenced JJ 1_o
pre- NN 1_o
and CC 1_o
posttests NNS 1_o
, , 1_o
and CC 1_o
decreased VBD 1_o
passive JJ 1_o
and CC 1_o
inappropriate JJ 1_o
student NN 1_o
behavior NN 1_o
during IN N
interventions NNS N
. . N

Socio-demographic JJ N
, , N
anthropometric JJ N
, , N
and CC N
psychosocial JJ N
predictors NNS N
of IN N
attrition NN N
across IN N
behavioral JJ N
weight-loss JJ N
trials NNS N
. . N

Preventing VBG N
attrition NN N
is VBZ N
a DT N
major JJ N
concern NN N
in IN N
behavioral JJ N
weight JJ N
loss NN N
intervention NN N
studies NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
analysis NN N
was VBD N
to TO N
identify VB N
baseline NN N
and CC N
six-month JJ N
predictors NNS N
associated VBN N
with IN N
participant JJ N
attrition NN N
across IN N
three CD N
independent JJ N
clinical JJ N
trials NNS N
of IN N
behavioral JJ N
weight JJ N
loss NN N
interventions NNS N
( ( 1_i
PREFER NNP 1_i
, , 1_i
SELF NNP 1_i
, , N
and CC N
SMART NNP 1_i
) ) 1_i
that WDT N
were VBD N
conducted VBN N
over IN N
10 CD N
years NNS N
. . N

Baseline NNP 1_i
measures VBZ 1_i
included VBN 1_i
body NN 1_o
mass NN 1_o
index NN 1_o
, , 1_o
Barriers NNP 1_o
to TO 1_o
Healthy NNP 1_o
Eating NNP 1_o
, , 1_o
Beck NNP 1_o
Depression NNP 1_o
Inventory-II NNP 1_o
( ( 1_o
BDI NNP 1_o
) ) 1_o
, , 1_o
Hunger NNP 1_o
Satiety NNP 1_o
Scale NNP 1_o
( ( 1_o
HSS NNP 1_o
) ) 1_o
, , 1_o
Binge NNP 1_o
Eating NNP 1_o
Scale NNP 1_o
( ( 1_o
BES NNP 1_o
) ) 1_o
, , 1_o
Medical NNP 1_o
Outcome NNP 1_o
Study NNP 1_o
Short NNP 1_o
Form NNP 1_o
( ( 1_o
MOS NNP 1_o
SF-36 NNP 1_o
v2 NN 1_o
) ) 1_o
and CC 1_o
Weight NNP 1_o
Efficacy NNP 1_o
Lifestyle NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
WEL NNP 1_o
) ) 1_o
. . 1_o

We PRP N
also RB N
examined VBD N
early JJ 1_o
weight NN 1_o
loss NN 1_o
and CC 1_o
attendance NN 1_o
at IN 1_i
group NN 1_i
sessions NNS 1_i
during IN 1_i
the DT 1_i
first JJ 1_i
6 CD 1_i
months NNS 1_i
. . 1_i

Attrition NNP 1_o
was VBD N
recorded VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
trials NNS N
. . N

Participants NNS 1_p
included VBD 1_p
504 CD 1_p
overweight NN 1_p
and CC 1_p
obese JJ 1_p
adults NNS 1_p
seeking VBG 1_p
weight JJ 1_p
loss NN 1_p
treatment NN 1_p
. . 1_p

The DT N
sample NN 1_p
was VBD 1_p
84.92 CD 1_p
% NN 1_p
female NN 1_p
and CC 1_p
73.61 CD 1_p
% NN 1_p
white JJ 1_p
, , 1_p
with IN 1_p
a DT 1_p
mean NN 1_p
( ( 1_p
± NNP 1_p
SD NNP 1_p
) ) 1_p
age NN 1_p
of IN 1_p
47.35 CD 1_p
± JJ 1_p
9.75 CD 1_p
years NNS 1_p
. . N

After IN N
controlling VBG N
for IN N
the DT N
specific JJ N
trial NN N
, , N
for IN N
every DT N
one CD N
unit NN N
increase NN N
in IN 1_o
BMI NNP 1_o
, , N
the DT N
odds NNS N
of IN N
attrition NN N
increased VBN N
by IN N
11 CD N
% NN N
. . N

For IN N
every DT N
year NN 1_o
increase NN 1_o
in IN 1_o
education NN 1_o
, , N
the DT N
odds NNS N
of IN N
attrition NN N
decreased VBN N
by IN N
10 CD N
% NN N
. . N

Additional JJ N
predictors NNS N
of IN N
attrition NN N
included VBD 1_p
previous JJ 1_p
attempts NNS 1_p
to TO 1_p
lose VB 1_p
50-79 JJ 1_p
lbs NN 1_p
, , 1_p
age NN 1_p
, , 1_p
not RB 1_p
possessing VBG 1_o
health NN 1_o
insurance NN 1_o
, , 1_o
and CC 1_o
BES NNP 1_o
, , 1_o
BDI NNP 1_o
, , 1_o
and CC 1_o
HSS NNP 1_o
scores NNS 1_o
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
odds NNS N
of IN 1_o
attrition NN 1_o
increased VBN N
by IN N
10 CD N
% NN N
with IN N
reduced JJ N
group NN N
session NN N
attendance NN N
. . N

There EX N
was VBD N
also RB N
an DT N
interaction NN N
between IN N
percent NN N
weight NN N
change NN N
and CC N
trial NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
of IN N
the DT N
three CD N
trials NNS N
showed VBD N
education NN N
, , N
age NN N
, , N
BMI NNP N
, , N
and CC N
BES NNP N
scores NNS N
were VBD N
independently RB N
associated VBN N
with IN N
attrition NN N
( ( N
ps JJ N
≤ NNP N
.01 NNP N
) ) N
. . N

These DT N
findings NNS N
may MD N
inform VB N
the DT N
development NN N
of IN N
more JJR N
robust JJ N
strategies NNS N
for IN N
reducing VBG N
attrition NN N
. . N

The DT N
effectiveness NN N
of IN N
Picture NNP 1_i
Exchange NNP 1_i
Communication NNP 1_i
System NNP 1_i
( ( 1_i
PECS NNP 1_i
) ) 1_i
training NN 1_i
for IN N
teachers NNS 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
a DT N
pragmatic JJ N
, , N
group NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
expert JJ N
training NN N
and CC N
consultancy NN N
for IN N
teachers NNS 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
in IN N
the DT N
use NN N
of IN N
the DT N
Picture NNP 1_i
Exchange NNP 1_i
Communication NNP 1_i
System NNP 1_i
( ( 1_i
PECS NNP 1_i
) ) 1_i
. . 1_i

METHOD NNP N
DESIGN NNP N
Group NNP N
randomised VBD N
, , N
controlled VBN N
trial NN N
( ( N
3 CD N
groups NNS N
: : N
immediate JJ N
treatment NN N
, , N
delayed VBN N
treatment NN N
, , N
no DT N
treatment NN N
) ) N
. . N

PARTICIPANTS $ N
84 CD 1_p
elementary JJ 1_p
school NN 1_p
children NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
6.8 CD 1_p
years NNS 1_p
. . 1_p

TREATMENT VB N
A DT 1_i
2-day JJ 1_i
PECS NNP 1_i
workshop NN 1_i
for IN 1_i
teachers NNS 1_i
plus CC 1_i
6 CD 1_i
half-day JJ 1_i
, , 1_i
school-based JJ 1_i
training NN 1_i
sessions NNS 1_i
with IN 1_i
expert JJ 1_i
consultants NNS 1_i
over IN 1_i
5 CD 1_i
months NNS 1_i
. . 1_i

OUTCOME NNP N
MEASURES NNP N
Rates NNPS N
of IN N
: : N
communicative JJ 1_o
initiations NNS 1_o
, , 1_o
use NN 1_o
of IN 1_o
PECS NNP 1_o
, , 1_o
and CC 1_o
speech NN 1_o
in IN 1_o
the DT 1_o
classroom NN 1_o
; : 1_o
Autism NNP 1_o
Diagnostic NNP 1_o
Observation NNP 1_o
Schedule-Generic NNP 1_o
( ( 1_o
ADOS-G NNP 1_o
) ) 1_o
domain NN 1_o
scores NNS 1_o
for IN 1_o
Communication NNP 1_o
and CC 1_o
Reciprocal NNP 1_o
Social NNP 1_o
Interaction NNP 1_o
; : 1_o
scores NNS 1_o
on IN 1_o
formal JJ 1_o
language NN 1_o
tests NNS 1_o
. . 1_o

RESULTS NNP N
Controlling VBG N
for IN N
baseline NN N
age NN N
, , N
developmental JJ 1_o
quotient NN 1_o
( ( 1_o
DQ NNP 1_o
) ) 1_o
and CC 1_o
language NN 1_o
; : 1_o
rates NNS 1_o
of IN 1_o
initiations NNS 1_o
and CC 1_o
PECS NNP 1_o
usage NN 1_o
increased VBD N
significantly RB N
immediately RB N
post-treatment JJ N
( ( N
Odds NNP N
Ratio NNP N
( ( N
OR NNP N
) ) N
of IN N
being VBG N
in IN N
a DT N
higher JJR N
ordinal JJ N
rate NN N
category NN N
2.72 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
1.22-6.09 JJ N
, , N
p JJ N
< NNP N
.05 NNP N
and CC N
OR NNP N
3.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.75-8.68 CD N
) ) N
, , N
p JJ N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
. . N

There EX N
were VBD N
no DT N
increases NNS N
in IN N
frequency NN 1_o
of IN 1_o
speech NN 1_o
, , 1_o
or CC 1_o
improvements NNS 1_o
in IN 1_o
ADOS-G NNP 1_o
ratings NNS 1_o
or CC 1_o
language NN 1_o
test NN 1_o
scores NNS 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
results NNS N
indicate VBP N
modest JJ N
effectiveness NN N
of IN N
PECS NNP 1_i
teacher NN 1_i
training/consultancy NN 1_i
. . 1_i

Rates NNS N
of IN N
pupils NNS N
' POS N
initiations NNS N
and CC N
use NN N
of IN N
symbols NNS N
in IN N
the DT N
classroom NN N
increased VBD N
, , N
although IN N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
improvement NN N
in IN N
other JJ N
areas NNS N
of IN N
communication NN N
. . N

TREATMENT NNP N
effects NNS N
were VBD N
not RB N
maintained VBN N
once RB N
active JJ N
intervention NN N
ceased VBD N
. . N

Regression NN N
of IN N
left JJ N
ventricular JJ N
hypertrophy NN N
after IN N
stentless JJ 1_i
versus JJ N
conventional JJ 1_i
aortic JJ 1_i
valve NN 1_i
replacement NN 1_i
. . 1_i

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
regression NN N
of IN N
left JJ N
ventricular JJ N
hypertrophy NN N
after IN N
randomization NN N
to TO N
conventional JJ 1_i
biological JJ 1_i
versus NN 1_i
stentless NN 1_i
aortic JJ 1_i
valve NN 1_i
replacement NN 1_i
. . 1_i

Stentless NNP 1_i
( ( 1_p
Freestyle NNP 1_p
, , 1_p
Toronto NNP 1_p
, , 1_p
n RB 1_p
= VBZ 1_p
106 CD 1_p
) ) 1_p
or CC 1_p
conventional JJ 1_i
biological JJ 1_i
aortic JJ 1_i
valves NNS 1_i
( ( 1_p
Carpentier-Edwards NNP 1_p
, , 1_p
n JJ 1_p
= NNP 1_p
74 CD 1_p
) ) 1_p
were VBD 1_p
evaluated VBN 1_p
prospectively RB N
. . N

Preoperatively RB N
there EX N
were VBD N
no DT N
differences NNS N
with IN N
regard NN N
to TO N
aortic JJ 1_o
valve NN 1_o
pathology NN 1_o
, , 1_o
left VBD 1_o
ventricular JJ 1_o
function NN 1_o
, , 1_o
and CC 1_o
pressure NN 1_o
gradients NNS 1_o
between IN N
the DT N
two CD N
patient NN N
groups NNS N
. . N

The DT N
patient NN 1_o
annulus NN 1_o
index NN 1_o
( ( N
13.55 CD N
vs. FW N
13.46 CD N
mm NN N
; : N
NS NNP N
) ) N
measured VBD N
intraoperatively RB N
was VBD N
used VBN N
as IN N
baseline NN N
for IN N
further JJ N
comparison NN N
. . N

Postoperatively RB N
, , N
left VBD 1_o
ventricular JJ 1_o
mass NN 1_o
index NN 1_o
was VBD N
213+/-77 JJ N
g/m2 NN N
( ( N
stentless NN N
) ) N
compared VBN N
with IN N
202+/-72 JJ N
( ( N
conventional JJ N
group NN N
) ) N
g/m2 NN N
( ( N
NS NNP N
) ) N
, , N
whereas RB N
after IN N
6 CD N
months NNS N
it PRP N
was VBD N
141+/-41 JJ N
g/m2 NN N
in IN N
the DT N
stentless NN N
and CC N
170+/-43 JJ N
g/m2 NN N
in IN N
the DT N
conventional JJ N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Regression NN 1_o
of IN 1_o
left JJ 1_o
ventricular JJ 1_o
hypertrophy NN 1_o
occurs VBZ N
in IN N
all DT N
patients NNS 1_p
after IN 1_p
aortic JJ 1_p
valve NN 1_p
replacement NN 1_p
. . 1_p

Nevertheless NNP N
, , N
the DT N
use NN N
of IN N
stentless NN 1_i
bioprostheses NNS 1_i
leads VBZ N
to TO N
a DT N
significant JJ N
enhancement NN N
, , N
which WDT N
may MD N
result VB N
in IN N
a DT N
reduction NN N
of IN N
the DT N
cardiac NN N
risk NN N
profile NN N
for IN N
the DT N
patient NN N
. . N

Trimetazidine NN 1_i
: : 1_i
a DT N
new JJ N
concept NN N
in IN N
the DT N
treatment NN N
of IN N
angina NN N
. . N

Comparison NNP N
with IN N
propranolol NN 1_i
in IN N
patients NNS N
with IN N
stable JJ 1_p
angina NN 1_p
. . 1_p

Trimetazidine JJ N
European JJ N
Multicenter NNP N
Study NNP N
Group NNP N
. . N

1 CD N
. . N

Trimetazidine NN 1_i
has VBZ N
a DT N
direct JJ N
anti-ischaemic JJ 1_o
effect NN 1_o
on IN N
the DT N
myocardium NN N
without IN N
altering VBG N
the DT N
rate NN 1_o
x JJ 1_o
pressure NN 1_o
product NN 1_o
or CC N
coronary JJ 1_o
blood NN 1_o
flow NN 1_o
. . 1_o

2 CD N
. . N

The DT N
effects NNS N
of IN N
trimetazidine NN 1_i
( ( N
20 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
propranolol NN 1_i
( ( N
40 CD N
mg NN N
three CD N
times NNS N
daily RB N
) ) N
in IN N
a DT N
double-blind JJ N
parallel NN N
group NN N
multicentre VBD N
study NN N
in IN N
149 CD 1_p
men NNS 1_p
with IN 1_p
stable JJ 1_p
angina NN 1_p
. . 1_p

3 CD N
. . N

Reproducibility NN N
of IN N
exercise NN N
performance NN N
was VBD N
verified VBN N
during IN N
a DT N
3 CD N
week NN N
run-in JJ N
placebo NN N
washout IN N
period NN N
. . N

All DT N
patients NNS N
had VBD N
> JJ N
1 CD N
mm JJ N
ST-depression NN N
on IN N
exercise NN N
test NN N
. . N

4 CD N
. . N

After IN N
3 CD N
months NNS N
, , N
similar JJ N
anti-anginal JJ 1_o
efficacy NN 1_o
was VBD N
observed VBN N
between IN N
the DT N
trimetazidine NN 1_i
( ( N
n JJ N
= NNP N
71 CD N
) ) N
and CC N
propranolol NN 1_i
( ( N
n JJ N
= NNP N
78 CD N
) ) N
groups NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
trimetazidine NN 1_i
and CC N
propranolol NN 1_i
as IN N
regards NNS N
anginal JJ 1_o
attack NN 1_o
rate NN 1_o
per IN 1_o
week NN 1_o
( ( N
mean JJ N
difference NN N
P-TMZ NN N
: : N
2 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
-4.4 NN N
, , N
0.5 CD N
) ) N
and CC N
exercise NN 1_o
duration NN 1_o
( ( N
mean JJ N
difference NN N
P-TMZ NN N
: : N
0 CD N
s NN N
; : N
95 CD N
% NN N
CI NNP N
: : N
-33 NN N
, , N
34 CD N
) ) N
or CC N
time NN N
to TO N
1 CD N
mm NNS N
ST NNP 1_o
segment NN 1_o
depression NN 1_o
( ( N
mean JJ N
difference NN N
P-TMZ NN N
: : N
13 CD N
s NN N
; : N
95 CD N
% NN N
CI NNP N
: : N
-24 NN N
, , N
51 CD N
) ) N
. . N

Heart NNP 1_o
rate NN 1_o
and CC 1_o
rate NN 1_o
x JJ 1_o
pressure NN 1_o
product NN 1_o
at IN 1_o
rest NN 1_o
and CC N
at IN N
peak JJ N
exercise NN N
remained VBD N
unchanged JJ N
in IN N
the DT N
trimetazidine NN 1_i
group NN N
but CC N
significantly RB N
decreased VBN N
with IN N
propranolol NN 1_i
( ( N
P NNP N
< VBZ N
0.001 CD N
in IN N
all DT N
cases NNS N
) ) N
. . N

With IN N
both DT N
drugs NNS N
there EX N
was VBD N
a DT N
trend NN N
to TO N
decreased VBN N
ischaemic JJ 1_o
episodes NNS 1_o
in IN N
the DT N
46 CD N
% NN N
patients NNS N
who WP N
experienced VBD N
ambulatory JJ N
ischaemia NN N
on IN N
Holter NNP N
monitoring NN N
. . N

Six CD N
patients NNS N
stopped VBD N
trimetazidine NN 1_i
and CC N
12 CD N
propranolol NN 1_i
. . 1_i

Of IN N
these DT N
, , N
five CD N
in IN N
each DT N
group NN N
were VBD N
withdrawn VBN 1_o
because IN N
of IN N
deterioration NN N
in IN N
cardiovascular JJ N
status NN N
. . N

5 CD N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
trimetazidine NN N
and CC N
propranolol NN N
at IN N
the DT N
doses NNS N
studied VBN N
have VBP N
similar JJ N
efficacy NN N
in IN N
patients NNS N
with IN N
stable JJ N
angina JJ N
pectoris NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
A DT N
randomised JJ N
controlled VBN N
comparison NN N
between IN N
stimulating VBG 1_i
and CC 1_i
standard JJ 1_i
catheters NNS 1_i
for IN N
lumbar NN 1_o
plexus NN 1_o
block NN 1_o
. . 1_o

The DT N
aim NN N
of IN N
this DT N
randomised VBN N
, , N
prospective JJ N
, , N
blinded VBD N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
stimulating JJ 1_i
catheters NNS 1_i
can MD N
decrease VB N
the DT N
minimum JJ 1_o
effective JJ 1_o
anaesthetic JJ 1_o
volume NN 1_o
in IN N
50 CD N
% NN N
of IN N
patients NNS 1_p
during IN 1_p
lumbar JJ 1_p
plexus NN 1_p
block NN 1_p
using VBG N
mepivacaine JJ 1_i
1.5 CD N
% NN N
compared VBN N
with IN N
standard JJ 1_i
catheters NNS 1_i
. . 1_i

Fifty-eight JJ 1_p
patients NNS 1_p
of IN 1_p
ASA NNP 1_p
physical JJ 1_p
status NN 1_p
1-3 CD 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
to TO 1_p
receive VB 1_p
a DT 1_p
lumbar NN 1_i
plexus NN 1_i
block NN 1_i
via IN 1_i
a DT 1_i
stimulating NN 1_i
or CC 1_i
standard JJ 1_i
catheter NN 1_i
, , 1_p
with IN 1_p
29 CD 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

The DT N
first JJ N
dose NN N
was VBD N
30 CD N
ml NN N
and CC N
subsequent JJ N
doses NNS N
were VBD N
determined VBN N
using VBG N
the DT N
up-and-down JJ N
staircase NN N
method NN N
. . N

The DT N
minimum JJ N
effective JJ 1_o
anaesthetic JJ 1_o
volume50 NN 1_o
was VBD N
12.2 CD N
ml NN N
( ( N
95 CD N
% NN N
CI NNP N
7.3-17.1 NNP N
ml NN N
) ) N
using VBG N
the DT N
stimulating NN N
catheter NN N
and CC N
24.8 CD N
ml NN N
( ( N
95 CD N
% NN N
CI NNP N
23.2-27.5 CD N
ml NN N
) ) N
with IN N
the DT N
standard JJ N
catheter NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Complete JJ 1_o
lumbar NN 1_o
plexus NN 1_o
block NN 1_o
was VBD N
achieved VBN N
with IN N
the DT N
initial JJ N
dose NN N
of IN N
mepivacaine NN N
in IN N
29 CD N
( ( N
100 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
stimulating JJ N
catheter NN N
group NN N
and CC N
20 CD N
( ( N
69 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
standard JJ N
catheter NN N
group NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
use NN N
of IN N
a DT N
stimulating JJ N
catheter NN N
halves VBZ N
the DT N
minimum JJ N
effective JJ N
anaesthetic JJ N
volume50 NN N
of IN N
mepivacaine JJ N
1.5 CD N
% NN N
while IN N
increasing VBG N
the DT N
success NN 1_o
rate NN 1_o
in IN N
patients NNS N
receiving VBG N
continuous JJ N
lumbar NN N
plexus NN N
block NN N
. . N

[ JJ N
Supplementary NNP N
treatment NN N
with IN N
Esberitox NNP 1_i
of IN N
female JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
curative JJ 1_i
adjuvant JJ 1_i
irradiation NN 1_i
following VBG 1_p
breast NN 1_p
cancer NN 1_p
] NNP 1_p
. . N

1 CD N
. . N

The DT N
study NN N
was VBD N
supposed VBN N
to TO N
investigate VB N
a DT N
possible JJ N
prevention NN 1_o
or CC 1_o
reduction NN 1_o
of IN 1_o
the DT 1_o
toxicity NN 1_o
of IN N
radiotherapy NN 1_i
by IN N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP 1_i
. . 1_i

This DT N
question NN N
arose VBD N
when WRB N
performing VBG N
an DT N
investigation NN N
about IN N
the DT N
effect NN N
of IN N
Esberitox NNP 1_i
in IN N
a DT N
combined JJ N
chemo-radiotherapy NN N
. . N

Whereas IN N
the DT N
latter JJ N
induces NNS N
above IN N
all PDT N
a DT N
systemic JJ N
damage NN N
to TO N
the DT N
hemopoietic JJ N
system NN N
, , N
radiotherapy NN N
is VBZ N
a DT N
regional JJ N
noxa NN N
. . N

2 CD N
. . N

The DT N
present JJ N
prospective JJ N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
with IN N
50 CD 1_p
patients NNS 1_p
submitted VBN 1_p
to TO 1_p
curative VB 1_i
adjuvant JJ 1_i
irradiation NN 1_i
following VBG 1_p
surgery NN 1_p
for IN 1_p
mammary JJ 1_p
carcinoma NN 1_p
. . 1_p

The DT N
radiotherapy NN 1_i
was VBD N
performed VBN N
in IN N
the DT N
same JJ N
way NN N
in IN N
all DT N
patients NNS 1_p
with IN 1_p
irradiations NNS 1_p
of IN 1_p
the DT 1_p
thoracic NN 1_p
wall NN 1_p
and CC 1_p
the DT 1_p
regional JJ 1_p
lymph NN 1_p
nodes NNS 1_p
. . 1_p

Two CD N
groups NNS N
were VBD N
built VBN N
by IN N
randomization NN N
. . N

The DT N
study NN N
group NN N
received VBD N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP 1_i
, , N
the DT N
control NN 1_i
group NN 1_i
did VBD 1_i
not RB 1_i
receive VB 1_i
an DT 1_i
additional JJ 1_i
treatment NN 1_i
. . 1_i

3 CD N
. . N

As IN N
a DT N
result NN N
, , N
no DT N
protective JJ N
influence NN N
of IN N
Esberitox NNP N
could MD N
be VB N
demonstrated VBN N
. . N

The DT N
parameters NNS N
investigated VBN N
were VBD N
the DT N
peripheral JJ 1_o
blood NN 1_o
count NN 1_o
( ( 1_o
leucocytes NNS 1_o
, , 1_o
granulocytes NNS 1_o
, , 1_o
lymphocytes NNS 1_o
, , 1_o
monocytes NNS 1_o
, , 1_o
thrombocytes NNS 1_o
, , 1_o
hemoglobin NN 1_o
, , 1_o
hematocrit NN 1_o
) ) 1_o
and CC 1_o
the DT 1_o
incidence NN 1_o
of IN 1_o
infections NNS 1_o
. . 1_o

4 CD N
. . N

This DT N
result NN N
diverging VBG N
from IN N
literature NN N
is VBZ N
discussed VBN N
. . N

It PRP N
is VBZ N
probably RB N
affected VBN N
by IN N
volume NN N
and CC N
extension NN N
of IN N
the DT N
injury NN N
induced VBN N
by IN N
a DT N
hematotoxic NN N
noxa NN N
and CC N
furthermore NN N
by IN N
the DT N
ability NN N
of IN N
regeneration NN N
. . N

If IN N
this DT N
ability NN N
is VBZ N
exhausted VBN N
, , N
the DT N
protective JJ N
effect NN N
of IN N
Esberitox NNP N
can MD N
act VB N
no DT N
longer JJR N
. . N

Therefore VB N
the DT N
essential JJ N
factor NN N
seems VBZ N
to TO N
be VB N
the DT N
duration NN N
of IN N
exposure NN N
to TO N
the DT N
noxa NN N
. . N

Esberitox NNP N
was VBD N
effective JJ N
in IN N
case NN N
of IN N
a DT N
short JJ N
toxicity NN N
, , N
it PRP N
was VBD N
ineffective JJ N
in IN N
case NN N
of IN N
prolonged JJ N
toxicity NN N
, , N
if IN N
the DT N
treatment NN N
continuity NN N
( ( N
noxa JJ N
) ) N
was VBD N
not RB N
broken VBN N
up RP N
by IN N
some DT N
regeneration NN N
intervals NNS N
. . N

The DT N
radiotherapy NN 1_i
studied VBN N
in IN N
this DT N
trial NN N
had VBD N
a DT N
duration NN N
of IN N
50 CD N
days NNS N
, , N
and CC N
its PRP$ N
effect NN N
was VBD N
that IN N
of IN N
a DT N
longterm JJ N
injury NN N
. . N

Rationale NNP N
and CC N
design NN N
of IN N
the DT N
Clinical NNP N
Evaluation NNP N
of IN N
Magnetic NNP 1_i
Resonance NNP 1_i
Imaging NNP 1_i
in IN N
Coronary NNP N
heart NN N
disease NN N
2 CD N
trial NN N
( ( N
CE-MARC NNP N
2 CD N
) ) N
: : N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
randomized VBN N
trial NN N
of IN N
diagnostic JJ N
strategies NNS N
in IN N
suspected JJ 1_p
coronary JJ 1_p
heart NN 1_p
disease NN 1_p
. . 1_p

BACKGROUND VB N
A DT N
number NN N
of IN N
investigative JJ N
strategies NNS N
exist VBP N
for IN N
the DT N
diagnosis NN N
of IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
. . N

Despite IN N
the DT N
widespread JJ N
availability NN N
of IN N
noninvasive JJ N
imaging NN N
, , N
invasive JJ 1_i
angiography NN 1_i
is VBZ N
commonly RB N
used VBN N
early RB N
in IN N
the DT N
diagnostic JJ N
pathway NN N
. . N

Consequently RB N
, , N
approximately RB N
60 CD N
% NN N
of IN N
angiograms JJ N
reveal VBP N
no DT N
evidence NN N
of IN N
obstructive JJ N
coronary JJ N
disease NN N
. . N

Reducing VBG N
unnecessary JJ N
angiography NN N
has VBZ N
potential JJ N
financial JJ N
savings NNS N
and CC N
avoids NNS N
exposing VBG N
the DT N
patient NN N
to TO N
unnecessary JJ N
risk NN N
. . N

There EX N
are VBP N
no DT N
large-scale JJ N
comparative JJ N
effectiveness NN N
trials NNS N
of IN N
the DT N
different JJ N
diagnostic JJ N
strategies NNS N
recommended VBD N
in IN N
international JJ N
guidelines NNS N
and CC N
none NN N
that WDT N
have VBP N
evaluated VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
cardiovascular JJ N
magnetic JJ N
resonance NN N
. . N

TRIAL NNP N
DESIGN NNP N
CE-MARC NNP N
2 CD N
is VBZ N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
3-arm JJ N
parallel NN N
group NN N
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
patients NNS 1_p
with IN 1_p
suspected JJ 1_p
CHD NNP 1_p
( ( 1_p
pretest JJS 1_p
likelihood RB 1_p
10 CD 1_p
% NN 1_p
-90 NNP 1_p
% NN 1_p
) ) 1_p
requiring VBG 1_p
further JJ 1_p
investigation NN 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
1,200 CD 1_p
patients NNS 1_p
will MD 1_p
be VB 1_p
randomized VBN 1_p
on IN N
a DT N
2:2:1 JJ N
basis NN N
to TO N
receive VB N
3.0-T JJ 1_i
cardiovascular JJ 1_i
magnetic JJ 1_i
resonance-guided JJ 1_i
care NN 1_i
, , 1_i
single-photon JJ 1_i
emission NN 1_i
computed VBD 1_i
tomography-guided JJ 1_i
care NN 1_i
( ( N
according VBG N
to TO N
American NNP N
College NNP N
of IN N
Cardiology/American NNP N
Heart NNP N
Association NNP N
appropriate-use IN N
criteria NNS N
) ) N
, , N
or CC 1_i
National NNP 1_i
Institute NNP 1_i
for IN 1_i
Health NNP 1_i
and CC 1_i
Care NNP 1_i
Excellence NNP 1_i
guidelines-based JJ 1_i
management NN 1_i
. . 1_i

The DT N
primary JJ N
( ( N
efficacy NN N
) ) N
end NN N
point NN N
is VBZ N
the DT N
occurrence NN 1_o
of IN 1_o
unnecessary JJ 1_o
angiography NN 1_o
as IN N
defined VBN N
by IN N
a DT N
normal JJ N
( ( N
> JJ N
0.8 CD N
) ) N
invasive JJ 1_o
fractional JJ 1_o
flow NN 1_o
reserve NN 1_o
. . 1_o

Safety NN 1_o
of IN N
each DT N
strategy NN N
will MD N
be VB N
assessed VBN N
by IN N
3-year JJ N
major JJ N
adverse JJ N
cardiovascular JJ N
event NN N
rates NNS N
. . N

Cost-effectiveness JJ 1_o
and CC 1_o
health-related JJ 1_o
quality-of-life JJ 1_o
measures NNS 1_o
will MD N
be VB N
performed VBN N
. . N

CONCLUSIONS VB N
The DT N
CE-MARC NNP N
2 CD N
trial NN N
will MD N
provide VB N
comparative JJ N
efficacy NN N
and CC N
safety NN N
evidence NN N
for IN N
3 CD N
different JJ N
strategies NNS N
of IN N
investigating VBG N
patients NNS 1_p
with IN 1_p
suspected JJ 1_p
CHD NNP 1_p
, , N
with IN N
the DT N
intension NN N
of IN N
reducing VBG N
unnecessary JJ N
invasive JJ N
angiography NN N
rates NNS N
. . N

Evaluation NN N
of IN N
these DT N
management NN N
strategies NNS N
has VBZ N
the DT N
potential NN N
to TO N
improve VB N
patient NN N
care NN N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
the DT N
cost-effectiveness NN N
of IN N
CHD NNP N
investigation NN N
. . N

Clinical JJ N
effects NNS N
of IN N
nanocrystalline JJ 1_i
hydroxyapatite JJ 1_i
paste NN 1_i
in IN N
the DT N
treatment NN N
of IN N
intrabony JJ N
periodontal JJ N
defects NNS N
: : N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
clinical JJ N
outcomes NNS N
of IN N
papilla NN N
preservation NN N
flap NN N
surgery NN N
with IN N
or CC N
without IN N
the DT N
application NN N
of IN N
a DT N
novel JJ N
nanocrystalline NN 1_i
hydroxyapatite NN 1_i
( ( 1_i
nano-HA JJ 1_i
) ) 1_i
bone NN 1_i
graft NN 1_i
substitute NN 1_i
. . 1_i

Fourteen JJ 1_p
patients NNS 1_p
with IN 1_p
paired JJ 1_p
intrabony NN 1_p
periodontal JJ 1_p
defects NNS 1_p
of IN 1_p
≥ $ 1_p
4 CD 1_p
mm NN 1_p
participated VBN 1_p
in IN N
this DT N
split-mouth JJ N
design NN N
study NN N
. . N

The DT N
defects NNS N
in IN N
each DT N
subject NN N
were VBD 1_i
randomly RB 1_i
selected VBN 1_i
to TO 1_i
receive VB 1_i
nano-HA JJ 1_i
paste NN 1_i
in IN 1_i
conjunction NN 1_i
with IN 1_i
papilla NN 1_i
preservation NN 1_i
flaps NNS 1_i
or CC 1_i
papilla NN 1_i
preservation NN 1_i
flaps NNS 1_i
alone RB 1_o
. . 1_o

Probing VBG 1_o
bone NN 1_o
levels NNS 1_o
( ( 1_o
PBL NNP 1_o
) ) 1_o
from IN 1_i
a DT 1_i
customized JJ 1_i
acrylic JJ 1_i
stent NN 1_i
and CC 1_o
probing VBG 1_o
pocket NN 1_o
depths NNS 1_o
( ( 1_o
PPD NNP 1_o
) ) 1_o
were VBD 1_i
measured VBN 1_i
at IN 1_i
baseline NN 1_i
and CC 1_i
again RB 1_i
6 CD 1_i
months NNS 1_i
following VBG 1_i
surgery NN 1_i
. . N

No DT N
differences NNS N
in IN N
any DT N
of IN N
the DT N
investigated JJ N
parameters NNS N
were VBD N
observed VBN N
at IN N
baseline NN N
between IN N
the DT N
two CD N
groups NNS 1_o
. . 1_o

Healing NNP 1_o
was VBD N
uneventful JJ N
in IN N
all DT N
patients NNS N
. . N

Both DT N
treatments NNS N
resulted VBD N
in IN N
significant JJ N
improvements NNS N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
6 CD N
months NNS N
after IN N
therapy NN N
, , N
the DT N
sites NNS N
treated VBD N
with IN 1_i
nano-HA JJ 1_i
paste NN 1_i
showed VBD N
a DT N
reduction NN N
in IN 1_o
mean JJ 1_o
PPD NNP 1_o
from IN N
8.3 CD N
± $ N
1.2 CD N
to TO N
4.0 CD N
± NNS N
1.1 CD N
mm NNS N
and CC N
a DT N
gain NN 1_o
in IN 1_o
PBL NNP N
of IN N
4.3 CD N
± JJ N
1.4 CD N
mm NN N
, , N
whereas NNS N
in IN N
the DT N
control NN N
group NN N
, , N
the DT N
mean NN 1_o
PPD NNP N
changed VBD N
from IN N
7.9 CD N
± $ N
1.2 CD N
mm NN N
to TO N
5.0 CD N
± NNS N
1.2 CD N
mm NNS 1_o
and CC 1_o
PBL NNP N
gain NN N
was VBD N
2.6 CD N
± JJ N
1.4 CD N
mm NN N
. . N

Results NNP N
demonstrated VBD N
statistically RB N
greater JJR 1_o
PPD NNP 1_o
reduction NN 1_o
and CC 1_o
PBL NNP 1_o
gain NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
test NN N
group NN N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
after IN N
6 CD N
months NNS N
, , N
the DT N
treatment NN N
of IN N
intrabony JJ N
periodontal JJ N
defects NNS N
with IN N
a DT N
nano-HA JJ N
paste NN N
leads VBZ N
to TO N
significantly RB N
improved VBN N
clinical JJ N
outcomes NNS N
when WRB N
compared VBN 1_i
with IN 1_i
papilla NN 1_i
preservation NN 1_i
flap NN 1_i
surgery NN N
alone RB N
. . N

Practice NNP N
makes VBZ N
improvement NN N
: : N
how WRB N
adults NNS 1_p
with IN 1_p
autism NN 1_p
out-perform JJ N
others NNS N
in IN N
a DT N
naturalistic JJ N
visual JJ N
search NN N
task NN N
. . N

People NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
often RB N
exhibit JJ N
superior JJ N
performance NN N
in IN N
visual JJ N
search NN N
compared VBN N
to TO N
others NNS N
. . N

However RB N
, , N
most JJS N
studies NNS N
demonstrating VBG N
this DT N
advantage NN N
have VBP N
employed VBN N
simple JJ N
, , N
uncluttered JJ N
images NNS N
with IN N
fully RB N
visible JJ N
targets NNS N
. . N

We PRP N
compare VBP N
the DT N
performance NN N
of IN N
high-functioning JJ 1_p
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC N
matched VBN 1_p
controls NNS 1_p
on IN N
a DT N
naturalistic JJ 1_i
luggage NN 1_i
screening VBG 1_i
task NN 1_i
. . 1_i

Although IN N
the DT N
two CD N
groups NNS N
were VBD N
equally RB N
accurate JJ N
in IN N
detecting VBG N
targets NNS N
, , N
the DT N
ASD NNP 1_p
adults NNS 1_p
improve VBP N
in IN N
their PRP$ N
correct JJ 1_o
elimination NN 1_o
of IN 1_o
target-absent NN 1_o
bags NNS N
faster RBR N
than IN N
controls NNS N
. . N

This DT N
feature NN N
of IN N
their PRP$ N
behavior NN N
is VBZ N
extremely RB N
important JJ N
for IN N
many JJ N
real-world JJ N
monitoring NN N
tasks NNS N
that WDT N
require VBP N
sustained JJ N
attention NN N
for IN N
long JJ N
time NN N
periods NNS N
. . N

Further JJ N
analyses NNS N
suggest VBP N
that IN N
this DT N
improvement NN N
is VBZ N
attributable JJ N
neither RB N
to TO N
the DT N
motor NN N
speed NN N
nor CC N
to TO N
the DT N
level NN N
of IN N
intelligence NN N
of IN N
the DT N
adults NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

These DT N
findings NNS N
may MD N
have VB N
possible JJ N
implications NNS N
for IN N
employment NN N
opportunities NNS N
of IN N
adult NN 1_p
individuals NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Reduction NN N
of IN N
isoflurane NN N
MAC NNP N
by IN N
fentanyl NN 1_i
or CC N
remifentanil NN 1_i
in IN N
rats NNS 1_p
. . 1_p

OBJECTIVE IN N
The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
three CD N
different JJ N
infusion NN N
rates NNS N
of IN N
fentanyl NN 1_i
and CC 1_i
remifentanil NN 1_i
on IN N
the DT N
minimum JJ N
alveolar JJ N
concentration NN N
( ( N
MAC NNP N
) ) N
of IN N
isoflurane NN N
in IN N
the DT N
rat NN 1_p
. . 1_p

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
cardiovascular NN N
and CC N
respiratory JJ N
effects NNS N
of IN N
the DT N
two CD N
opioid JJ N
drugs NNS N
. . N

ANIMAL NNP N
POPULATION NNP N
Thirty-seven NNP 1_p
male NN 1_p
Wistar NNP 1_p
rats NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
six CD N
treatment NN N
groups NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
For IN N
all DT N
treatment NN N
groups NNS N
anaesthesia NN N
was VBD N
induced VBN N
with IN N
5 CD N
% NN N
isoflurane NN 1_i
in IN 1_i
oxygen NN 1_i
using VBG N
an DT N
induction NN N
chamber NN N
. . N

A DT N
14-gauge JJ N
catheter NN N
was VBD N
used VBN N
for IN N
endotracheal JJ N
intubation NN N
, , N
and CC N
anaesthesia NN N
was VBD N
maintained VBN N
with IN N
isoflurane NN N
delivered VBN N
in IN N
oxygen NN N
via IN N
a DT N
T-piece NNP N
breathing NN N
system NN N
. . N

A DT N
baseline JJ N
determination NN N
of IN N
the DT N
minimum JJ N
alveolar JJ N
concentration NN N
of IN N
isoflurane NN N
( ( N
MACISO NNP N
) ) N
was VBD N
made VBN N
for IN N
each DT N
animal NN N
. . N

Fentanyl NNP 1_i
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
or CC N
remifentanil NN 1_i
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
were VBD N
infused VBN N
intravenously RB N
into IN N
a DT N
previously RB N
cannulated VBN N
tail NN N
vein NN N
. . N

Thirty NNP N
minutes NNS N
after IN N
the DT N
infusion NN N
started VBD N
, , N
a DT N
second JJ N
MACISO NNP N
( ( N
MACISO+drug NNP N
) ) N
was VBD N
determined VBN N
. . N

The DT N
carotid NN N
artery NN N
was VBD N
cannulated VBN N
to TO N
monitor VB N
the DT N
arterial JJ 1_o
pressure NN 1_o
and CC N
to TO N
take VB N
samples NNS N
for IN N
arterial JJ 1_o
gas NN 1_o
measurements NNS 1_o
. . 1_o

Cardiovascular NNP 1_o
( ( 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
arterial JJ 1_o
pressure NN 1_o
) ) 1_o
and CC 1_o
respiratory NN 1_o
( ( 1_o
respiratory JJ 1_o
rate NN 1_o
and CC 1_o
presence/absence NN 1_o
of IN 1_o
apnoea NN 1_o
) ) 1_o
effects NNS 1_o
after IN N
opioid JJ N
infusion NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS NNP N
Fentanyl NNP 1_i
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
and CC N
remifentanil NN 1_i
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
similarly RB N
reduced VBN N
isoflurane NN N
MAC NNP N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
: : N
by IN N
10 CD N
% NN N
at IN N
lower JJR N
doses NNS N
, , N
25 CD N
% NN N
at IN N
medium NN N
doses NNS N
and CC N
by IN N
60 CD N
% NN N
at IN N
higher JJR N
doses NNS N
of IN N
both DT N
the DT N
drugs NNS N
. . N

Both DT N
opioids NNS N
reduced VBD N
the DT N
respiratory NN N
rate NN N
in IN N
a DT N
similar JJ N
way NN N
for IN N
all DT N
doses NNS N
tested VBN N
. . N

No DT N
episodes NNS N
of IN N
apnoea NN N
were VBD N
recorded VBN N
in IN N
the DT N
remifentanil NN 1_i
groups NNS N
, , N
while IN N
administration NN N
of IN N
fentanyl NN N
resulted VBN N
in IN N
apnoea NN N
in IN N
three CD N
animals NNS N
( ( N
one CD N
at IN N
each DT N
dose JJ N
level NN N
) ) N
. . N

The DT N
effects NNS N
on IN N
the DT N
cardiovascular JJ N
system NN N
were VBD N
similar JJ N
with IN N
both DT N
drugs NNS N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
the DT N
intraoperative JJ N
use NN N
of IN N
remifentanil NN 1_i
in IN N
the DT N
rat NN N
reduces VBZ N
the DT N
MAC NNP N
of IN N
isoflurane NN N
, , N
and CC N
that IN N
this DT N
anaesthetic JJ N
sparing NN N
effect NN N
is VBZ N
dose-dependent JJ N
and CC N
similar JJ N
to TO N
that DT N
produced VBN N
by IN N
fentanyl NN N
at IN N
the DT N
doses NNS N
tested VBN N
. . N

CLINICAL JJ N
RELEVANCE NNP N
The DT N
use NN N
of IN N
remifentanil NN 1_i
during IN N
inhalant JJ N
anaesthesia NN N
in IN N
the DT N
rat NN N
can MD N
be VB N
considered VBN N
an DT N
intravenous JJ N
alternative NN N
to TO N
fentanyl VB 1_i
, , N
providing VBG N
similar JJ N
reduction NN N
in IN N
isoflurane NN N
requirements NNS N
. . N

Due NNP N
to TO N
its PRP$ N
rapid JJ N
offset NN N
, , N
it PRP N
is VBZ N
recommended VBN N
that IN N
alternative JJ N
pain NN N
relief NN N
be VB N
instituted VBN N
before IN N
it PRP N
is VBZ N
discontinued VBN N
. . N

Management NN 1_p
of IN 1_p
the DT 1_p
thyroid JJ 1_p
isthmus NN 1_p
in IN 1_p
tracheostomy NN 1_i
: : 1_i
a DT 1_p
prospective JJ 1_p
and CC 1_p
retrospective JJ 1_p
study NN 1_p
. . 1_p

The DT N
thyroid JJ N
isthmus NN N
is VBZ N
often RB N
encountered VBN N
while IN N
a DT N
tracheostomy NN 1_i
is VBZ N
being VBG N
performed VBN N
. . N

This DT N
study NN N
details NNS N
retrospective JJ N
and CC N
prospective JJ N
comparison NN N
of IN N
electrocautery JJ 1_i
division NN 1_i
of IN 1_i
the DT 1_i
isthmus NN 1_i
with IN N
older JJR N
techniques NNS N
. . N

In IN N
this DT N
study NN N
, , N
electrocautery DT 1_i
division NN 1_i
of IN 1_i
the DT 1_i
thyroid JJ 1_o
isthmus NN 1_o
during IN N
tracheostomy NN N
is VBZ N
faster RBR 1_o
and CC 1_o
as RB 1_o
safe JJ 1_o
as IN N
other JJ N
techniques NNS N
with IN N
respect NN N
to TO N
blood NN 1_o
loss NN 1_o
, , 1_o
perioperative JJ 1_o
complications NNS 1_o
, , 1_o
and CC 1_o
airway RB 1_o
outcome NN 1_o
. . 1_o

Can MD N
HMG NNP 1_i
Co-A NNP 1_i
reductase NN 1_i
inhibitors NNS 1_i
( ( 1_i
" JJ 1_i
statins NNS 1_i
" VBP 1_i
) ) 1_i
slow VB N
the DT N
progression NN N
of IN N
age-related JJ 1_p
macular JJ 1_p
degeneration NN 1_p
? . N
The DT N
age-related JJ N
maculopathy NN N
statin NN N
study NN N
( ( N
ARMSS NNP N
) ) N
. . N

Age-related JJ 1_p
macular JJ 1_p
degeneration NN 1_p
( ( 1_p
AMD NNP 1_p
) ) 1_p
is VBZ N
responsible JJ N
for IN N
the DT N
majority NN N
of IN N
visual JJ N
impairment NN N
in IN N
the DT N
Western JJ N
world NN N
. . N

The DT N
role NN N
of IN N
cholesterol-lowering JJ N
medications NNS N
, , N
HMG NNP 1_i
Co-A NNP 1_i
reductase NN 1_i
inhibitors NNS 1_i
or CC 1_i
statins NNS 1_i
, , N
in IN N
reducing VBG N
the DT N
risk NN N
of IN N
AMD NNP N
or CC N
of IN N
delaying VBG N
its PRP$ N
progression NN N
has VBZ N
not RB N
been VBN N
fully RB N
investigated VBN N
. . N

A DT N
3-year JJ N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
of IN N
40 CD 1_i
mg NN 1_i
simvastatin NN 1_i
per IN 1_i
day NN 1_i
compared VBN 1_i
to TO 1_i
placebo VB 1_i
in IN N
subjects NNS 1_p
at IN 1_p
high JJ 1_p
risk NN 1_p
of IN 1_p
AMD NNP 1_p
progression NN 1_p
is VBZ N
described VBN N
. . N

This DT N
paper NN N
outlines VBZ N
the DT N
primary JJ N
aims NNS N
of IN N
the DT N
Age-Related NNP N
Maculopathy NNP N
Statin NNP N
Study NNP N
( ( N
ARMSS NNP N
) ) N
, , N
and CC N
the DT N
methodology NN N
involved VBN N
. . N

Standardized NNP N
clinical JJ N
grading NN N
of IN N
macular JJ N
photographs NN N
and CC N
comparison NN N
of IN N
serial JJ N
macular JJ N
digital NN N
photographs NN N
, , N
using VBG N
the DT N
International NNP N
grading NN N
scheme NN N
, , N
form VB N
the DT N
basis NN N
for IN N
assessment NN N
of IN N
primary JJ N
study NN N
outcomes NNS N
. . N

In IN N
addition NN N
, , N
macular JJ N
function NN N
is VBZ N
assessed VBN N
at IN N
each DT N
visit NN N
with IN N
detailed JJ N
psychophysical JJ N
measurements NNS N
of IN N
rod NN N
and CC N
cone NN N
function NN N
. . N

Information NN N
collected VBN N
in IN N
this DT N
study NN N
will MD N
assist VB N
in IN N
the DT N
assessment NN N
of IN N
the DT N
potential JJ N
value NN N
of IN N
HMG NNP 1_i
Co-A NNP 1_i
reductase NN 1_i
inhibitors NNS 1_i
( ( 1_i
statins NNS 1_i
) ) 1_i
in IN N
reducing VBG N
the DT N
risk NN N
of IN N
AMD NNP N
progression NN N
. . N

Maternal JJ N
breast-milk NN N
and CC N
intestinal JJ N
bifidobacteria NNS N
guide VBP N
the DT N
compositional JJ N
development NN N
of IN N
the DT N
Bifidobacterium NNP N
microbiota NN N
in IN N
infants NNS 1_p
at IN 1_p
risk NN 1_p
of IN 1_p
allergic JJ 1_p
disease NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
sources NNS N
and CC N
the DT N
impact NN N
of IN N
maternal JJ N
bacteria NNS N
on IN N
the DT N
initial JJ N
inoculum NN N
of IN N
the DT N
intestinal JJ N
microflora NN N
of IN N
newborn JJ N
infants NNS N
remain VBP N
elusive JJ N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
association NN N
between IN N
maternal JJ N
breast-milk NN N
and CC N
fecal JJ N
bifidobacteria NN N
and CC N
infants NNS N
' POS N
fecal JJ N
bifidobacteria NN N
. . N

METHODS NNP N
Sixty-one JJ 1_p
mother-infant JJ 1_p
pairs NNS 1_p
were VBD 1_p
included VBN 1_p
, , 1_p
special JJ 1_p
emphasis NN 1_p
being VBG 1_p
placed VBN 1_p
on IN 1_p
the DT 1_p
maternal JJ 1_p
allergic NN 1_p
status NN 1_p
. . 1_p

Bifidobacteria NNP 1_o
were VBD 1_o
analysed VBN 1_o
by IN 1_i
a DT 1_i
direct JJ 1_i
PCR NNP 1_i
method NN 1_i
in IN 1_i
fecal JJ 1_i
samples NNS 1_i
from IN 1_i
mothers NNS 1_i
at IN N
30-35 JJ N
weeks NNS N
of IN N
gestation NN N
and CC N
from IN N
infants NNS N
at IN N
1 CD N
month NN N
of IN N
age NN N
and CC N
from IN N
breast-milk JJ 1_i
samples NNS 1_i
1 CD 1_i
month NN 1_i
post-partum NN 1_i
. . 1_i

RESULTS NNP N
Fecal NNP N
Bifidobacterium NNP N
adolescentis NN N
and CC N
Bifidobacterium NNP N
bifidum NN N
colonization NN N
frequencies NNS N
and CC N
counts NNS N
among IN N
mother-infant JJ N
pairs NNS N
correlated VBN N
significantly RB N
( ( N
P=0.005 NNP N
and CC N
0.02 CD N
for IN N
frequencies NNS N
, , N
respectively RB N
, , N
and CC N
P=0.002 NNP N
and CC N
0.01 CD N
for IN N
counts NNS N
, , N
respectively RB N
) ) N
. . N

Only JJ N
infants NNS 1_p
of IN 1_p
allergic NN 1_p
, , 1_p
atopic NN 1_p
mothers NNS 1_p
were VBD N
colonized VBN N
with IN N
B. NNP N
adolescentis NN N
. . N

Each DT N
of IN N
the DT N
breast-milk NN N
samples NNS N
contained VBN N
bifidobacteria NNS N
[ NNP N
median JJ N
1.4 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial JJ N
cells/mL NN N
; : N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
48.7-3.8 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
] NN N
. . N

Bifidobacterium NNP 1_o
longum NN 1_o
was VBD N
the DT N
most RBS N
frequently RB N
detected VBN N
species NNS N
in IN N
breast-milk NN N
. . N

Allergic NNP 1_p
mothers NNS 1_p
had VBD N
significantly RB N
lower JJR N
amounts NNS N
of IN N
bifidobacteria NN 1_o
in IN N
breast-milk NN N
compared VBN N
with IN N
non-allergic JJ N
mothers NNS N
[ VBP N
median JJ N
1.3 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
IQR NNP N
22.4-3.0 CD N
x NNP N
10 CD N
( ( N
3 CD N
) ) N
) ) N
vs. FW N
5.6 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
1.8 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
-1.8 NN N
x $ N
10 CD N
( ( N
4 CD N
) ) N
) ) N
, , N
respectively RB N
, , N
( ( N
P=0.004 NNP N
) ) N
] NN N
, , N
and CC N
their PRP$ N
infants NNS N
had VBD N
concurrently RB N
lower JJR N
counts NNS N
of IN N
bifidobacteria NN 1_o
in IN 1_o
feces NNS 1_o
[ VBP N
3.9 CD N
x JJ N
10 CD N
( ( N
8 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
IQR NNP N
6.5 CD N
x NN N
10 CD N
( ( N
6 CD N
) ) N
-1.5 NN N
x $ N
10 CD N
( ( N
9 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
allergic JJ N
mothers NNS N
, , N
vs. FW N
2.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
8 CD N
) ) N
-3.2 NN N
x $ N
10 CD N
( ( N
10 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
non-allergic JJ N
mothers NNS N
, , N
P=0.013 NNP N
] NNP N
. . N

CONCLUSIONS NNP N
Breast-milk NNP N
contains VBZ N
significant JJ N
numbers NNS N
of IN N
bifidobacteria NN N
and CC N
the DT N
maternal JJ N
allergic NN N
status NN N
further RBR N
deranges VBZ N
the DT N
counts NNS N
of IN N
bifidobacteria NN N
in IN N
breast-milk NN N
. . N

Maternal NNP N
fecal JJ N
and CC N
breast-milk JJ N
bifidobacterial JJ N
counts NNS N
impacted VBN N
on IN N
the DT N
infants NNS N
' POS N
fecal JJ N
Bifidobacterium NN N
levels NNS N
. . N

Breast-milk NNP N
bacteria NN N
should MD N
thus RB N
be VB N
considered VBN N
an DT N
important JJ N
source NN N
of IN N
bacteria NNS N
in IN N
the DT N
establishment NN N
of IN N
infantile JJ N
intestinal JJ N
microbiota NN N
. . N

Isradipine NNP 1_i
, , N
raised VBD N
glycosylated VBN N
haemoglobin NN N
, , N
and CC N
risk NN 1_p
of IN 1_p
cardiovascular JJ 1_o
events NNS 1_o
. . 1_o

Intestinal JJ N
absorption NN N
of IN N
dietary JJ N
fat NN N
in IN N
patients NNS 1_p
with IN 1_p
multiple JJ 1_p
sclerosis NN 1_p
. . 1_p

Fat NNP 1_o
absorption NN 1_o
was VBD N
studied VBN N
in IN N
24 CD 1_p
patients NNS 1_p
with IN 1_p
clinically RB 1_p
definite JJ 1_p
multiple JJ 1_p
sclerosis NN 1_p
and CC 1_p
in IN 1_p
36 CD 1_p
healthy JJ 1_p
control NN 1_i
subjects NNS 1_p
. . 1_p

Beta-carotene NNP 1_o
and CC 1_o
vitamin VB 1_o
A NNP 1_o
in IN 1_o
their PRP$ 1_o
plasma NN 1_o
were VBD 1_i
also RB 1_i
measured VBN 1_i
. . 1_i

This DT N
double-blind JJ N
and CC N
randomized VBN N
study NN N
showed VBD N
no DT N
differences NNS N
between IN N
these DT N
two CD N
populations NNS N
with IN N
regard NN N
to TO N
the DT N
three CD N
parameters NNS N
. . N

We PRP N
did VBD N
not RB N
find VB N
evidence NN N
for IN N
fat JJ N
malabsorption NN N
in IN N
multiple JJ N
sclerosis NN N
. . N

Comparison NNP N
of IN N
the DT N
potassium- JJ 1_o
retaining NN 1_o
effects NNS 1_o
of IN N
amiloride NN 1_i
and CC 1_i
spironolactone NN 1_i
in IN N
hypertensive JJ 1_p
patients NNS 1_p
with IN 1_p
thiazide-induced JJ 1_p
hypokalaemia NN 1_p
. . 1_p

Impact NN N
of IN N
the DT N
quantity NN 1_o
and CC 1_o
flavonoid JJ 1_o
content NN 1_o
of IN N
fruits NNS 1_i
and CC 1_i
vegetables NNS 1_i
on IN N
markers NNS N
of IN N
intake NN N
in IN N
adults NNS 1_p
with IN 1_p
an DT 1_p
increased VBN 1_p
risk NN 1_p
of IN 1_p
cardiovascular JJ 1_p
disease NN 1_p
: : 1_p
the DT N
FLAVURS NNP N
trial NN N
. . N

PURPOSE NNP N
Limited NNP N
robust NN N
randomised VBD N
controlled VBN N
trials NNS N
investigating VBG N
fruit NN 1_o
and CC 1_o
vegetable JJ 1_o
( ( 1_o
F NNP 1_o
& CC 1_o
V NNP 1_o
) ) 1_o
intake VBP 1_o
in IN N
people NNS 1_p
at IN 1_p
risk NN 1_p
of IN 1_p
cardiovascular JJ 1_p
disease NN 1_p
( ( 1_p
CVD NNP 1_p
) ) 1_p
exist VBP N
. . N

We PRP N
aimed VBD N
to TO N
design VB N
and CC N
validate VB N
a DT N
dietary JJ 1_i
strategy NN 1_i
of IN 1_i
increasing VBG 1_i
flavonoid-rich JJ 1_i
versus NN 1_i
flavonoid-poor JJ 1_i
F NNP 1_o
& CC 1_o
V NNP 1_o
consumption NN 1_o
on IN N
nutrient JJ N
biomarker NN N
profile NN N
. . N

METHODS NNP N
A NNP N
parallel NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
dose-response JJ N
dietary JJ N
intervention NN N
study NN N
. . N

Participants NNS 1_p
with IN 1_p
a DT 1_p
CVD NNP 1_p
relative JJ 1_p
risk NN 1_p
of IN 1_p
1.5 CD 1_p
assessed VBN 1_p
by IN 1_p
risk NN 1_p
scores NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
3 CD N
groups NNS N
: : N
habitual JJ 1_i
( ( 1_i
control NN 1_i
, , 1_i
CT NNP 1_i
) ) 1_i
, , 1_i
high-flavonoid JJ 1_i
( ( 1_i
HF NNP 1_i
) ) 1_i
or CC 1_i
low-flavonoid JJ 1_i
( ( 1_i
LF NNP 1_i
) ) 1_i
diets NNS 1_i
. . 1_i

While IN N
the DT N
CT NNP N
group NN N
( ( N
n JJ N
= NNP N
57 CD N
) ) N
consumed VBD N
their PRP$ N
habitual JJ N
diet NN N
throughout IN N
, , N
the DT N
HF NNP N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
and CC N
LF NNP N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
groups NNS N
sequentially RB N
increased VBD N
their PRP$ N
daily JJ N
F NNP N
& CC N
V NNP N
intake NN N
by IN N
an DT N
additional JJ N
2 CD N
, , N
4 CD N
and CC N
6 CD N
portions NNS N
for IN N
6-week JJ N
periods NNS N
during IN N
the DT N
18-week JJ N
study NN N
. . N

RESULTS NNP N
Compliance NNP N
to TO N
target VB N
numbers NNS N
and CC N
types NNS N
of IN N
F NNP N
& CC N
V NNP N
was VBD N
broadly RB N
met VBN N
and CC N
verified VBN N
by IN N
dietary JJ N
records NNS N
, , N
and CC N
plasma NN 1_o
and CC 1_o
urinary JJ 1_o
biomarkers NNS 1_o
. . 1_o

Mean NNP N
( ( N
± NNP N
SEM NNP N
) ) N
number NN N
of IN 1_o
F NNP 1_o
& CC 1_o
V NNP 1_o
portions/day NN 1_o
consumed VBN N
by IN N
the DT N
HF NNP N
and CC N
LF NNP N
groups NNS N
at IN N
baseline NN N
( ( N
3.8 CD N
± RB N
0.3 CD N
and CC N
3.4 CD N
± NNS N
0.3 CD N
) ) N
, , N
6 CD N
weeks NNS N
( ( N
6.3 CD N
± RB N
0.4 CD N
and CC N
5.8 CD N
± NNS N
0.3 CD N
) ) N
, , N
12 CD N
weeks NNS N
( ( N
7.0 CD N
± RB N
0.3 CD N
and CC N
6.8 CD N
± NNS N
0.3 CD N
) ) N
and CC N
18 CD N
weeks NNS N
( ( N
7.6 CD N
± RB N
0.4 CD N
and CC N
8.1 CD N
± NNS N
0.4 CD N
) ) N
, , N
respectively RB N
, , N
was VBD N
similar JJ N
at IN N
baseline NN N
yet RB N
higher JJR N
than IN N
the DT N
CT NNP N
group NN N
( ( N
3.9 CD N
± RB N
0.3 CD N
, , N
4.3 CD N
± NN N
0.3 CD N
, , N
4.6 CD N
± NN N
0.4 CD N
, , N
4.5 CD N
± $ N
0.3 CD N
) ) N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ 1_o
increase NN 1_o
in IN 1_o
dietary JJ 1_o
and CC 1_o
urinary JJ 1_o
flavonoids NNS N
in IN N
the DT N
HF NNP N
group NN N
, , N
with IN N
no DT N
change NN N
in IN N
other JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

Significantly RB 1_o
higher JJR 1_o
dietary JJ 1_o
intakes NNS 1_o
of IN N
folate NN N
( ( 1_o
P NNP 1_o
= NNP 1_o
0.035 CD 1_o
) ) 1_o
, , 1_o
non-starch JJ 1_o
polysaccharides NNS 1_o
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
vitamin FW N
C NNP N
( ( N
P NNP N
= NNP 1_o
0.0001 CD 1_o
) ) 1_o
and CC 1_o
carotenoids NNS N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
were VBD N
observed VBN N
in IN N
both DT N
intervention NN N
groups NNS N
compared VBN N
with IN N
CT NNP N
, , N
which WDT N
were VBD N
broadly RB N
supported VBN N
by IN N
nutrient JJ N
biomarker NN N
analysis NN N
. . N

CONCLUSIONS VB N
The DT N
success NN N
of IN 1_o
improving VBG 1_o
nutrient JJ 1_o
profile NN N
by IN N
active JJ N
encouragement NN 1_o
of IN 1_o
F NNP N
& CC N
V NNP N
intake NN N
in IN N
an DT N
intervention NN N
study NN N
implies VBZ N
the DT N
need NN N
for IN N
a DT N
more RBR N
hands-on JJ N
public JJ N
health NN N
approach NN N
. . N

Cardiac NNP N
and CC N
haemodynamic JJ N
measurements NNS N
in IN N
hypertensive JJ 1_p
pregnancy NN 1_p
. . 1_p

1 CD N
. . N

Haemodynamic NNP N
and CC N
left VBD N
ventricular JJ N
variables NNS N
were VBD N
determined VBN N
by IN N
M-mode NNP N
echocardiography NN N
in IN N
21 CD 1_p
normotensive JJ 1_p
and CC 1_p
36 CD 1_p
hypertensive JJ 1_p
patients NNS 1_p
during IN 1_p
the DT 1_p
last JJ 1_p
trimester NN 1_p
of IN 1_p
pregnancy NN 1_p
. . 1_p

2 CD N
. . N

Blood NNP 1_o
pressure NN 1_o
of IN N
hypertensive JJ 1_p
patients NNS 1_p
was VBD N
lowered VBN N
by IN N
bed NN N
rest NN N
only RB N
, , N
or CC N
by IN N
oxprenolol JJ 1_i
or CC 1_i
methyldopa NN 1_i
, , N
but CC N
remained VBD N
elevated VBN N
. . N

3 CD N
. . N

Cardiac NNP 1_o
output NN 1_o
was VBD N
raised VBN N
in IN N
the DT N
last JJ N
trimester NN N
of IN N
pregnancy NN N
in IN N
both DT N
normotensive JJ 1_p
and CC 1_p
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

4 CD N
. . N

Left VBN 1_o
ventricular JJ 1_o
mass NN 1_o
was VBD N
increased VBN N
in IN N
normal JJ N
pregnancy NN N
, , N
but CC N
displayed VBD N
an DT N
exaggerated JJ N
increase NN N
in IN N
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

5 CD N
. . N

Total JJ 1_o
peripheral JJ 1_o
resistance NN 1_o
was VBD N
inappropriately RB N
elevated VBN N
in IN N
hypertensive JJ N
pregnancy NN N
, , N
except IN N
in IN N
the DT N
oxprenolol-treated JJ N
group NN N
. . N

6 CD N
. . N

There EX N
ws VBZ N
no DT N
reduction NN N
in IN N
heart NN 1_o
rate NN 1_o
or CC 1_o
cardiac JJ 1_o
output NN 1_o
in IN N
the DT N
group NN N
treated VBD N
with IN N
beta-adrenoreceptor NN 1_i
blocking VBG 1_i
agents NNS 1_i
. . 1_i

These DT N
factors NNS N
, , N
in IN N
combination NN N
with IN N
normal JJ N
peripheral JJ N
resistance NN N
, , N
may MD N
contribute VB N
to TO N
the DT N
improvement NN N
in IN N
foetal JJ 1_o
outcome NN 1_o
described VBN N
in IN N
maternal JJ N
hypertension NN N
of IN N
pregnancy NN N
treated VBN N
with IN N
oxprenolol NN 1_i
. . 1_i

Evaluation NN 1_o
of IN N
a DT N
device NN 1_i
to TO 1_i
facilitate VB 1_i
female JJ 1_i
urethral JJ 1_i
catheterization NN 1_i
. . 1_i

Urethral JJ 1_i
catheterization NN 1_i
is VBZ 1_i
a DT N
skilled JJ N
procedure NN N
that WDT N
nurses VBZ 1_p
in IN 1_p
hospital JJ 1_p
settings NNS 1_p
perform VBP N
routinely RB N
. . N

The DT N
opening NN N
of IN N
the DT N
female JJ N
urethra NN N
is VBZ N
located VBN N
within IN N
the DT N
vulvar NN N
vestibule NN N
, , N
making VBG N
insertion NN N
of IN N
urinary JJ N
catheters NNS N
into IN N
females NNS 1_p
a DT N
greater JJR N
technical JJ N
challenge NN N
than IN N
in IN N
males NNS N
. . N

Researchers NNS N
evaluated VBD N
whether IN N
a DT N
new JJ N
device NN N
might MD N
decrease VB N
the DT N
time NN 1_o
required VBN 1_o
for IN 1_o
catheter NN 1_o
insertion NN 1_o
, , 1_o
increase VB 1_o
the DT 1_o
likelihood NN 1_o
of IN 1_o
inserting VBG 1_o
the DT 1_o
catheter NN 1_o
on IN 1_o
the DT 1_o
first JJ 1_o
attempt NN 1_o
( ( 1_o
improved VBN 1_o
accuracy NN 1_o
) ) 1_o
, , N
and CC N
reduce VB 1_o
patient JJ 1_o
discomfort NN 1_o
. . 1_o

Comments NNS N
about IN N
the DT N
device NN N
from IN N
both DT N
patients NNS N
and CC N
nurses NNS N
also RB N
are VBP N
reported VBN N
. . N

[ IN N
The DT N
comparation NN 1_o
of IN 1_o
the DT 1_o
efficacy NN 1_o
of IN 1_o
surgical JJ 1_o
treatment NN 1_o
for IN N
lung NN 1_p
cancer NN 1_p
by IN N
minimally RB 1_i
invasive JJ 1_i
thoracoscopic NN 1_i
and CC N
by IN N
traditional JJ 1_i
thoracotomy NN 1_i
] NNP 1_i
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
clinical JJ N
effects NNS N
of IN N
lung NN N
cancer NN N
, , N
75 CD 1_p
patients NNS 1_p
with IN 1_p
lung NN 1_p
cancer NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD 1_i
groups NNS 1_i
, , 1_i
observation NN 1_i
group NN 1_i
underwent JJ 1_i
minimally RB 1_i
invasive JJ 1_i
thoracic NN 1_i
surgery NN 1_i
38 CD 1_i
cases NNS 1_i
and CC 1_i
the DT 1_i
control NN 1_i
group NN 1_i
underwent JJ 1_i
conventional JJ 1_i
thoracotomy NN 1_i
37 CD 1_i
cases NNS 1_i
. . 1_i

RESULTS NNP N
Observation NNP N
group NN N
was VBD N
significantly RB N
reduced VBN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
in IN N
blood NN 1_o
loss NN 1_o
, , 1_o
postoperative JJ 1_o
pleural JJ 1_o
fluid NN 1_o
drainage NN 1_o
, , 1_o
postoperative JJ 1_o
hospital NN 1_o
stay NN 1_o
, , N
the DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

While IN N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
in IN N
the DT N
number NN N
of IN N
lymph JJ 1_o
node JJ 1_o
dissection NN 1_o
, , 1_o
operative JJ 1_o
time NN 1_o
and CC 1_o
postoperative JJ 1_o
chest NN 1_o
tube NN 1_o
drainage NN 1_o
time NN 1_o
. . 1_o

National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
's POS N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
. . N

The DT N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
is VBZ N
the DT N
largest JJS N
breast NN N
cancer NN N
prevention NN N
study NN N
ever RB N
undertaken RB N
. . N

Administered VBN N
by IN N
the DT N
National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
, , N
it PRP N
is VBZ N
the DT N
first JJ N
trial NN N
seeking VBG N
to TO N
demonstrate VB N
whether IN N
a DT N
drug NN N
, , N
tamoxifen NN 1_i
, , N
can MD N
prevent VB 1_p
breast NN 1_p
cancer NN 1_p
in IN 1_p
high-risk JJ 1_p
women NNS 1_p
. . 1_p

The DT N
objectives NNS N
of IN N
this DT N
trial NN N
are VBP N
to TO N
determine VB N
whether IN N
tamoxifen NN 1_i
is VBZ N
effective JJ N
in IN N
1 CD N
) ) N
reducing VBG 1_o
the DT 1_o
incidence NN 1_o
of IN 1_o
invasive JJ 1_o
breast NN 1_o
cancer NN 1_o
, , 1_o
2 CD 1_o
) ) 1_o
reducing VBG 1_o
breast NN 1_o
cancer NN 1_o
mortality NN 1_o
, , 1_o
3 CD 1_o
) ) 1_o
reducing VBG 1_o
deaths NNS 1_o
from IN 1_o
cardiovascular JJ 1_o
disease NN 1_o
, , 1_o
and CC 1_o
4 CD 1_o
) ) 1_o
reducing VBG 1_o
bone NN 1_o
fractures NNS 1_o
. . 1_o

In IN N
addition NN N
, , N
the DT N
study NN N
will MD N
evaluate VB N
side NN 1_o
effects NNS 1_o
, , 1_o
toxicity NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
all DT N
study NN N
participants NNS N
. . N

Vascular JJ N
pedicle NN N
width NN N
in IN N
acute JJ 1_p
lung JJ 1_p
injury NN 1_p
: : 1_p
correlation NN N
with IN N
intravascular JJ N
pressures NNS N
and CC N
ability NN N
to TO N
discriminate VB N
fluid NN N
status NN N
. . N

INTRODUCTION NNP N
Conservative NNP 1_i
fluid NN 1_i
management NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
lung NN 1_p
injury NN 1_p
( ( 1_p
ALI NNP 1_p
) ) 1_p
increases VBZ N
time NN N
alive JJ N
and CC N
free JJ N
from IN N
mechanical JJ 1_i
ventilation NN 1_i
. . 1_i

Vascular JJ 1_o
pedicle NN 1_o
width NN 1_o
( ( 1_o
VPW NNP 1_o
) ) 1_o
is VBZ N
a DT N
non-invasive JJ N
measurement NN N
of IN N
intravascular JJ N
volume NN N
status NN N
. . N

The DT N
VPW NNP N
was VBD N
studied VBN N
in IN N
ALI NNP 1_p
patients NNS 1_p
to TO N
determine VB N
the DT N
correlation NN N
between IN N
VPW NNP N
and CC N
intravascular JJ N
pressure NN N
measurements NNS N
and CC N
whether IN N
VPW NNP N
could MD N
predict VB N
fluid JJ N
status NN N
. . N

METHODS NNP N
This DT N
retrospective JJ N
cohort NN N
study NN N
involved VBD N
152 CD 1_p
patients NNS 1_p
with IN 1_p
ALI NNP 1_p
enrolled VBD 1_p
in IN 1_p
the DT 1_p
Fluid NNP 1_p
and CC 1_p
Catheter NNP 1_p
Treatment NNP 1_p
Trial NNP 1_p
( ( 1_p
FACTT NNP 1_p
) ) 1_p
from IN 1_p
five CD 1_p
NHLBI NNP 1_p
ARDS NNP 1_p
( ( 1_p
Acute NNP 1_p
Respiratory NNP 1_p
Distress NNP 1_p
Syndrome NNP 1_p
) ) 1_p
Network NNP 1_p
sites NNS 1_p
. . 1_p

VPW NNP 1_o
and CC 1_o
central JJ 1_o
venous JJ 1_o
pressure NN 1_o
( ( 1_o
CVP NNP 1_o
) ) 1_o
or CC 1_o
pulmonary JJ 1_o
artery NN 1_o
occlusion NN 1_o
pressure NN 1_o
( ( 1_o
PAOP NNP 1_o
) ) 1_o
from IN N
the DT N
first JJ N
four CD N
study NN N
days NNS N
were VBD N
correlated VBN N
. . N

The DT N
relationships NNS 1_o
between IN 1_o
VPW NNP 1_o
, , 1_o
positive JJ 1_o
end-expiratory JJ 1_o
pressure NN 1_o
( ( 1_o
PEEP NNP 1_o
) ) 1_o
, , 1_o
cumulative JJ 1_o
fluid NN 1_o
balance NN 1_o
, , 1_o
and CC 1_o
PAOP NNP 1_o
were VBD N
also RB N
evaluated VBN N
. . N

Receiver NNP N
operator NN N
characteristic NN N
( ( N
ROC NNP N
) ) N
curves NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
ability NN N
of IN N
VPW NNP 1_o
to TO N
detect VB N
PAOP NNP N
< NNP N
8 CD N
mmHg NN N
and CC N
PAOP NNP N
≥ NNP N
18 CD N
mm NN N
Hg NNP N
. . N

RESULTS VB N
A DT N
total NN N
of IN 1_p
71 CD 1_p
and CC 1_p
152 CD 1_p
patients NNS 1_p
provided VBD N
118 CD N
and CC N
276 CD N
paired VBN N
VPW/PAOP NNP N
and CC N
VPW/CVP NNP N
measurements NNS N
, , N
respectively RB N
. . N

VPW NNP N
correlated VBD N
with IN N
PAOP NNP N
( ( N
r VB N
= RB N
0.41 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
less RBR N
well RB N
with IN N
CVP NNP N
( ( N
r VB N
= RB N
0.21 CD N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
linear JJ N
regression NN N
, , N
VPW NNP N
correlated VBD N
with IN 1_o
PAOP NNP 1_o
1.5-fold JJ N
better JJR N
than IN N
cumulative JJ N
fluid NN N
balance NN N
and CC N
2.5-fold JJ N
better JJR N
than IN N
PEEP NNP N
. . N

VPW NNP N
discriminated VBD N
achievement NN N
of IN 1_o
PAOP NNP 1_o
< NNP N
8 CD N
mm NN N
Hg NNP N
( ( N
AUC NNP N
= NNP N
0.73 CD N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
with IN 1_o
VPW NNP 1_o
≤67 NNP N
mm VBD N
demonstrating VBG N
71 CD N
% NN N
sensitivity NN N
( ( N
95 CD N
% NN N
CI NNP N
30 CD N
to TO N
95 CD N
% NN N
) ) N
and CC N
68 CD N
% NN N
specificity NN N
( ( N
95 CD N
% NN N
CI NNP N
59 CD N
to TO N
75 CD N
% NN N
) ) N
. . N

For IN N
discriminating VBG N
a DT N
hydrostatic JJ N
component NN N
of IN N
the DT N
edema NN N
( ( N
that WDT N
is VBZ N
, , N
PAOP NNP N
≥ VBZ N
18 CD N
mm NN 1_o
Hg NNP 1_o
) ) 1_o
, , N
VPW NNP N
≥ VBZ N
72 CD N
mm NN N
demonstrated VBD N
61.4 CD N
% NN N
sensitivity NN N
( ( N
95 CD N
% NN N
CI NNP N
47 CD N
to TO N
74 CD N
% NN N
) ) N
and CC N
61 CD N
% NN N
specificity NN N
( ( N
49 CD N
to TO N
71 CD N
% NN N
) ) N
( ( N
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
0.69 CD N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
VPW NNP N
correlates VBZ N
with IN N
PAOP NNP N
better JJR N
than IN 1_p
CVP NNP 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
ALI NNP N
. . N

Due NNP N
to TO N
its PRP$ N
only JJ N
moderate JJ N
sensitivity NN N
and CC N
specificity NN N
, , N
the DT N
ability NN N
of IN N
VPW NNP N
to TO N
discriminate VB N
fluid NN N
status NN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
lung NN 1_p
injury NN N
is VBZ N
limited JJ N
and CC N
should MD N
only RB N
be VB N
considered VBN N
when WRB N
intravascular JJ N
pressures NNS N
are VBP N
unavailable JJ N
. . N

Primary JJ 1_i
deep JJ 1_i
sclerectomy NN 1_i
versus IN N
primary JJ 1_i
deep JJ 1_i
sclerectomy NN 1_i
with IN 1_i
the DT 1_i
use NN 1_i
of IN 1_i
mitomycin NN 1_i
C NNP 1_i
in IN N
primary JJ 1_p
open-angle JJ 1_p
glaucoma NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
prospectively RB N
study VB N
and CC N
compare VB N
the DT N
effectiveness NN 1_o
and CC N
the DT N
safety NN 1_o
of IN N
primary JJ N
deep JJ N
sclerectomy NN N
with IN N
and CC N
without IN N
the DT N
use NN N
of IN N
mitomycin NN N
C NNP N
in IN N
eyes NNS 1_p
with IN 1_p
open-angle JJ 1_p
glaucoma NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
90 CD 1_p
eyes NNS 1_p
of IN 1_p
90 CD 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
open-angle JJ 1_p
glaucoma NN 1_p
or CC 1_p
pseudoexfoliative JJ 1_p
glaucoma NN 1_p
underwent JJ 1_p
deep JJ 1_p
sclerectomy NN 1_p
. . 1_p

Patients NNS N
were VBD N
enrolled VBN N
consecutively RB N
and CC N
assigned VBD N
randomly RB N
to TO N
undergo VB N
deep JJ 1_i
sclerectomy NN 1_i
without IN 1_i
the DT 1_i
use NN 1_i
of IN 1_i
mitomycin NN 1_i
C NNP 1_i
( ( 1_i
DS NNP 1_i
group NN 1_i
) ) 1_i
and CC 1_i
deep JJ 1_i
sclerectomy NN 1_i
with IN 1_i
the DT 1_i
application NN 1_i
of IN 1_i
mitomycin NN 1_i
C NNP 1_i
( ( 1_i
DSMMC NNP 1_i
group NN 1_i
) ) 1_i
in IN N
a DT N
concentration NN N
of IN N
0.2 CD N
mg/mL NN N
for IN N
2.5 CD N
minutes NNS N
, , N
before IN N
the DT N
superficial JJ N
scleral JJ N
flap NN N
formation NN N
. . N

RESULTS VB N
The DT N
intraocular JJ 1_o
pressure NN 1_o
was VBD N
significantly RB N
decreased VBN N
by IN N
7.13 CD N
mm NNS N
Hg NNP N
or CC N
27.59 CD N
% NN N
in IN N
the DT N
DS NNP N
group NN N
and CC N
by IN N
11.68 CD N
mm NNS N
Hg NNP N
or CC N
42.25 CD N
% NN N
in IN N
the DT N
DSMMC NNP N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
. . N

The DT N
intraocular JJ 1_o
pressure NN 1_o
reduction NN 1_o
in IN N
the DT N
DSMMC NNP N
group NN N
was VBD N
statistically RB N
significant JJ N
when WRB N
compared VBN N
with IN N
that DT N
in IN N
the DT N
DS NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
complete JJ N
( ( N
IOP NNP N
< VBZ N
22 CD N
mm NN N
Hg NNP N
without IN N
medication NN N
) ) N
and CC N
qualified VBN N
( ( N
IOP NNP N
< VBZ N
22 CD N
mm NN N
Hg NNP N
with IN N
or CC N
without IN N
medication NN N
) ) N
success NN 1_o
rates NNS 1_o
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
were VBD N
42.5 CD N
% NN N
and CC N
72.5 CD N
% NN N
in IN N
the DT N
DS NNP N
group NN N
and CC N
50 CD N
% NN N
and CC N
95 CD N
% NN N
in IN N
the DT N
DSMMC NNP N
group NN N
. . N

The DT N
qualified JJ 1_o
success NN 1_o
rate NN 1_o
in IN N
the DT N
DSMMC NNP N
group NN N
was VBD N
statistically RB N
significant JJ N
when WRB N
compared VBN N
with IN N
that DT N
in IN N
the DT N
DS NNP N
group NN N
. . N

Differences NNS N
in IN N
complications NNS N
( ( 1_o
choroidal JJ 1_o
detachment NN 1_o
, , 1_o
hyphema NN 1_o
, , 1_o
leakage NN 1_o
) ) 1_o
seen VBN N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
statistically RB N
nonsignificant JJ N
. . N

A DT N
hemorrhagic JJ 1_o
detachment NN 1_o
of IN 1_o
the DT 1_o
Descemet NNP 1_o
membrane NN 1_o
was VBD N
observed VBN N
in IN N
one CD N
eye NN N
in IN N
the DT N
DSMMC NNP N
group NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
intraoperative JJ N
mitomycin NN N
C NNP N
during IN N
deep JJ N
sclerectomy NN N
significantly RB N
reduced VBD N
the DT N
postoperative JJ N
IOP NNP N
and CC N
increased VBD N
the DT N
success NN N
rate NN N
of IN N
the DT N
procedure NN N
. . N

Effects NNS N
of IN N
sensory-level JJ N
high-volt NN N
pulsed VBD N
electrical JJ N
current JJ N
ondelayed-onset JJ 1_o
muscle NN 1_o
soreness NN 1_o
. . 1_o

Ten CD 1_p
healthy JJ 1_p
males NNS 1_p
and CC 1_p
ten VB 1_p
healthy JJ 1_p
females NNS 1_p
aged VBD 1_p
21.5 CD 1_p
+/- JJ 1_p
3.2 CD 1_p
years NNS 1_p
( ( 1_p
mean JJ 1_p
+/- NNP 1_p
s NN 1_p
) ) 1_p
participated VBD 1_p
in IN 1_p
the DT 1_p
study NN 1_p
, , N
which WDT N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
sensory JJ 1_i
level-high JJ 1_i
volt NN 1_i
pulsed VBD 1_i
electrical JJ 1_i
current JJ 1_i
( ( 1_i
HVPC NNP 1_i
) ) 1_i
on IN N
delayed-onset JJ 1_o
muscle NN 1_o
soreness NN 1_o
( ( 1_o
DOMS NNP 1_o
) ) 1_o
. . 1_o

Arm NNP N
discomfort NN N
, , N
elbow JJ N
extension NN N
range NN N
of IN N
motion NN N
and CC N
isometric JJ N
elbow NN N
flexion NN N
strength NN N
were VBD N
obtained VBN N
as IN N
baseline NN N
measurements NNS N
. . N

Delayed-onset NNP 1_o
muscle NN 1_o
soreness NN 1_o
was VBD N
induced VBN N
in IN N
the DT N
participants NNS N
' POS N
dominant NN N
or CC N
non-dominant JJ N
arm NN N
using VBG N
two CD N
sets NNS N
of IN N
20 CD N
maximal JJ N
eccentric JJ N
elbow NN N
flexion NN N
contractions NNS N
. . N

After IN N
the DT N
induction NN N
of IN N
DOMS NNP 1_o
, , N
the DT N
participants NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
experimental JJ 1_i
condition NN 1_i
( ( 1_i
HVPC NNP 1_i
) ) 1_i
or CC N
a DT N
placebo JJ 1_i
condition NN N
. . N

The DT N
experimental JJ N
condition NN N
consisted VBD N
of IN N
20 CD N
min NN N
of IN N
HVPC NNP 1_i
immediately RB N
after IN N
the DT N
induction NN N
of IN N
DOMS NNP 1_o
, , N
and CC N
20 CD N
min NN N
every DT N
24 CD N
h NN N
for IN N
three CD N
consecutive JJ N
days NNS N
thereafter RB N
. . N

The DT N
participants NNS N
in IN N
the DT N
placebo NN 1_i
condition NN N
received VBD N
an DT N
intervention NN N
similar JJ N
in IN N
design NN N
; : N
however RB N
, , N
no DT N
electrical JJ N
current JJ N
was VBD N
administered VBN N
. . N

Baseline JJ 1_o
measurements NNS 1_o
were VBD N
reevaluated VBN N
at IN N
24 CD N
, , N
48 CD N
, , N
72 CD N
and CC N
96 CD N
h NN N
after IN N
the DT N
induction NN N
of IN N
DOMS NNP 1_o
. . 1_o

Three CD N
weeks NNS N
later RB N
, , N
the DT N
participants NNS N
returned VBD N
and CC N
the DT N
protocol NN N
was VBD N
repeated VBN N
on IN N
the DT N
contralateral JJ N
limb NN N
, , N
using VBG N
the DT N
opposite JJ N
intervention NN N
( ( 1_i
HVPC NNP 1_i
or CC 1_i
placebo NN 1_i
) ) 1_i
. . N

Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
revealed VBD N
a DT N
significant JJ N
increase NN N
in IN N
overall JJ 1_o
arm NN 1_o
discomfort NN 1_o
, , N
decrease NN N
in IN N
elbow JJ 1_o
extension NN 1_o
and CC N
decrease NN N
in IN N
isometric JJ 1_o
strength NN 1_o
for IN N
both DT 1_o
conditions NNS 1_o
over IN N
time NN N
. . N

No DT 1_o
significant JJ 1_o
main JJ 1_o
effect NN 1_o
of IN 1_o
treatment NN 1_o
, , 1_o
or CC 1_o
time-by-treatment JJ 1_o
interaction NN 1_o
, , N
was VBD N
found VBN N
for IN N
the DT N
HVPC NNP 1_i
condition NN N
when WRB N
compared VBN N
with IN N
the DT N
placebo NN 1_i
condition NN N
for IN N
any DT N
variable JJ N
. . N

Sensory-level JJ N
HVPC NNP N
, , N
as IN N
utilized VBN N
in IN N
our PRP$ N
application NN N
, , N
was VBD N
ineffective JJ N
in IN N
reducing VBG N
the DT N
measured JJ N
variables NNS N
associated VBN N
with IN N
DOMS NNP 1_o
. . 1_o

Brief JJ N
acceptance-based JJ 1_i
intervention NN 1_i
for IN N
increasing VBG N
intake JJ 1_o
attendance NN 1_o
at IN 1_p
a DT 1_p
community NN 1_p
mental JJ 1_p
health NN 1_p
center NN 1_p
. . 1_p

Intake VB N
no-show JJ N
rates NNS N
for IN N
psychotherapy NN N
vary NN N
from IN N
20 CD N
% NN N
to TO N
57 CD N
% NN N
( ( N
Swenson NNP N
& CC N
Pekarik NNP N
, , N
1988 CD N
) ) N
, , N
and CC N
experiential JJ N
avoidance NN N
may MD N
be VB N
related VBN N
to TO N
failure NN N
to TO N
attend VB N
intake JJ N
sessions NNS N
. . N

This DT N
pilot NN N
study NN N
attempted VBD N
to TO N
increase VB N
intake VB N
attendance NN N
at IN 1_p
a DT 1_p
community NN 1_p
mental JJ 1_p
health NN 1_p
center NN 1_p
by IN N
employing VBG N
a DT N
brief JJ N
experiential JJ N
acceptance-based JJ N
intervention NN N
. . N

Those DT 1_p
who WP 1_p
scheduled VBD 1_p
intakes NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
groups NNS N
: : N
orientation NN 1_i
letter NN 1_i
or CC 1_i
acceptance-enhanced JJ 1_i
orientation NN 1_i
letter NN 1_i
; : 1_i
rates NNS N
from IN N
these DT N
conditions NNS N
were VBD N
compared VBN N
with IN N
a DT N
retrospective JJ N
comparison NN N
control NN N
group NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
by IN N
way NN N
of IN N
an DT N
online JJ N
random NN N
number NN N
generator NN N
. . N

Persons NNS N
assigned VBD N
to TO N
the DT N
orientation NN N
group NN N
did VBD N
not RB N
have VB N
a DT N
higher JJR N
show NN 1_o
rate NN 1_o
than IN N
persons NNS N
within IN N
the DT N
control NN 1_i
group NN N
( ( N
∼48 CD N
% NN N
compared VBN N
with IN N
∼52 NNP N
% NN N
) ) N
. . N

Persons NNS N
assigned VBD N
to TO N
the DT 1_i
acceptance NN 1_i
group NN N
did VBD N
have VB N
higher JJR 1_o
show NN 1_o
rates NNS 1_o
than IN N
persons NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
∼67 CD N
% NN N
compared VBN N
with IN N
∼48 NNP N
% NN N
and CC N
∼52 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
however RB N
this DT N
difference NN N
was VBD N
nonsignificant JJ N
. . N

Results VB N
suggest JJS N
that DT N
brief JJ N
acceptance-based JJ N
interventions NNS N
should MD N
be VB N
further JJ N
studied VBN N
for IN N
their PRP$ N
potential JJ N
value NN N
in IN N
maximizing VBG N
client NN N
attendance NN N
. . N

Conventional JJ 1_i
in IN 1_i
vitro JJ 1_i
fertilization NN 1_i
versus IN N
intracytoplasmic JJ 1_i
sperm JJ 1_i
injection NN 1_i
in IN 1_p
patients NNS 1_p
with IN 1_p
borderline JJ 1_p
semen NNS 1_p
: : 1_p
a DT N
randomized JJ N
study NN N
using VBG N
sibling VBG N
oocytes NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
patients NNS 1_p
with IN 1_p
borderline JJ 1_p
semen NNS 1_p
should MD N
be VB N
treated VBN N
with IN N
conventional JJ 1_i
IVF NNP 1_i
or CC N
intracytoplasmic JJ 1_i
sperm JJ 1_i
injection NN 1_i
( ( 1_i
ICSI NNP 1_i
) ) 1_i
. . 1_i

DESIGN NNP N
Randomized NNP N
study NN N
. . N

SETTING VB N
A DT 1_p
university NN 1_p
medical JJ 1_p
center NN 1_p
in IN 1_p
The DT 1_p
Netherlands NNP 1_p
. . 1_p

PATIENT NNP N
( ( N
S NNP N
) ) N
One CD 1_p
hundred VBN 1_p
six CD 1_p
couples NNS 1_p
with IN 1_p
borderline JJ 1_p
semen NNS 1_p
who WP 1_p
were VBD 1_p
undergoing VBG 1_p
IVF NNP 1_i
and CC 1_p
ICSI NNP 1_i
on IN 1_p
sibling VBG 1_p
oocytes NNS 1_p
. . 1_p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Performing VBG N
IVF NNP 1_i
and CC 1_i
ICSI NNP 1_i
on IN N
sibling VBG N
oocytes NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Fertilization NNP 1_o
and CC 1_o
pregnancy NN 1_o
rates NNS 1_o
. . 1_o

RESULT NNP N
( ( N
S NNP N
) ) N
One CD N
thousand CD N
five CD N
hundred VBN N
eighteen NN N
oocytes NNS N
were VBD N
collected VBN N
in IN N
106 CD N
oocyte JJ N
retrievals NNS N
: : N
849 CD N
oocytes NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
ICSI NNP N
, , N
of IN N
which WDT N
761 CD N
were VBD N
microinjected VBN 1_i
, , N
and CC N
669 CD N
oocytes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
IVF NNP 1_i
. . 1_i

In IN N
26 CD N
of IN N
the DT N
106 CD N
patients NNS N
, , N
there EX N
was VBD N
fertilization NN N
only RB N
after IN N
ICSI NNP 1_i
and CC N
not RB N
after IN N
IVF NNP 1_i
( ( N
IVF- NNP N
group NN N
) ) N
. . N

The DT N
fertilization NN 1_o
rate NN 1_o
was VBD N
51 CD N
% NN N
( ( N
92/182 CD N
oocytes NNS N
) ) N
. . N

In IN 1_p
78 CD 1_p
patients NNS 1_p
, , N
there EX N
was VBD N
fertilization NN N
after IN N
both DT N
IVF NNP 1_i
and CC N
ICSI NNP 1_i
( ( N
IVF+ NNP N
group NN N
) ) N
; : N
the DT N
fertilization NN N
rate NN N
was VBD N
51 CD N
% NN N
for IN N
both DT N
the DT N
IVF- NNP 1_i
and CC N
ICSI-treated NNP 1_i
oocytes NNS N
( ( N
271/528 CD N
oocytes NNS N
and CC N
334/658 CD N
oocytes NNS N
, , N
respectively RB N
) ) N
. . N

In IN N
2 CD 1_p
patients NNS 1_p
, , N
there EX N
was VBD N
no DT N
fertilization NN N
after IN N
either DT N
IVF NNP 1_i
( ( N
0/6 CD N
oocytes NNS N
) ) N
or CC N
ICSI NNP 1_i
( ( N
0/9 CD N
oocytes NNS N
) ) N
. . N

Patients NNS 1_p
of IN 1_p
the DT 1_p
IVF+ NNP 1_p
group NN N
had VBD N
a DT N
higher JJR N
total JJ 1_o
motile JJ 1_o
sperm NN 1_o
count NN 1_o
after IN N
preparation NN N
than IN N
did VBD N
those DT N
of IN N
the DT N
IVF- NNP 1_p
group NN 1_p
. . 1_p

More JJR N
high-quality JJ 1_o
embryos NN 1_o
were VBD N
obtained VBN N
after IN N
ICSI NNP 1_i
in IN N
patients NNS N
of IN N
the DT N
IVF+ NNP 1_i
group NN N
. . N

In IN N
101 CD 1_p
patients NNS 1_p
, , N
embryo FW 1_o
transfer NN 1_o
was VBD N
performed VBN N
: : N
26 CD N
in IN N
the DT N
IVF- NNP 1_i
group NN N
and CC N
75 CD N
in IN N
the DT N
IVF+ NNP 1_i
group NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
with IN N
regard NN N
to TO N
pregnancy VB 1_o
rates NNS 1_o
between IN N
those DT N
two CD N
groups NNS N
: : N
pregnancy NN N
rates NNS N
were VBD N
54 CD N
% NN N
in IN N
the DT N
IVF- NNP 1_i
group NN N
and CC N
48 CD N
% NN N
in IN N
the DT N
IVF+ NNP 1_i
group NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Performing VBG N
ICSI NNP 1_i
on IN N
at IN N
least JJS N
some DT N
of IN N
the DT N
oocytes NNS N
will MD N
avoid VB N
unnecessary JJ N
fertilization NN 1_o
failure NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
borderline JJ 1_p
semen NNS 1_p
: : 1_p
in IN N
this DT N
study NN N
, , N
26 CD N
of IN N
104 CD N
cycles NNS N
( ( N
25 CD N
% NN N
) ) N
were VBD N
rescued VBN N
by IN N
ICSI NNP 1_i
. . 1_i

Absence NN 1_o
of IN 1_o
cervical JJ 1_o
radiation NN 1_o
myelitis NN 1_o
after IN N
hyperfractionated VBN 1_i
radiation NN 1_i
therapy NN 1_i
with IN N
and CC N
without IN N
concurrent JJ 1_i
chemotherapy NN 1_i
for IN N
locally RB 1_p
advanced JJ 1_p
, , 1_p
unresectable JJ 1_p
, , 1_p
nonmetastatic JJ 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
risk NN 1_o
of IN 1_o
developing VBG 1_o
radiation NN 1_o
myelitis NN 1_o
after IN N
a DT N
cervical JJ N
spinal NN N
cord NN N
dose NN N
of IN N
50.6 CD N
Gy NNP 1_i
given VBN N
via IN N
1.1 CD N
Gy NNP N
b.i.d NN N
. . N

fractionation NN N
during IN N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
of IN N
hyperfractionated JJ 1_i
radiation NN 1_i
therapy NN 1_i
( ( 1_i
HFX NNP 1_i
RT NNP 1_i
) ) 1_i
to TO N
a DT N
total JJ N
dose NN N
of IN N
77 CD N
Gy NNP 1_i
given VBN N
in IN N
70 CD N
fractions NNS N
of IN N
1.1 CD N
Gy NNP N
b.i.d. NN N
, , N
with IN N
and CC N
without IN N
concurrent JJ N
low-dose JJ N
, , N
daily JJ N
cisplatin NN 1_i
( ( 1_i
CDDP NNP 1_i
) ) 1_i
for IN N
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
. . 1_p

METHODS NNP N
Of IN N
130 CD 1_p
patients NNS 1_p
with IN 1_p
locally RB 1_p
advanced VBN 1_p
, , 1_p
unresectable JJ 1_p
, , 1_p
nonmetastatic JJ 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
( ( 1_p
SCC NNP 1_p
H NNP 1_p
& CC 1_p
N NNP 1_p
) ) 1_p
who WP N
entered VBD N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
, , N
101 CD N
patients NNS N
received VBD N
50.6 CD 1_i
Gy NNP 1_i
to TO 1_i
a DT N
portion NN N
of IN N
their PRP$ N
spinal JJ N
cord NN N
and CC N
survived VBD N
> NNS N
1 CD N
year NN N
following VBG N
the DT N
beginning NN N
of IN N
therapy NN N
. . N

Forty-five JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
HFX NNP 1_i
RT NNP 1_i
alone RB N
and CC N
fifty-six JJ N
patients NNS N
also RB N
received VBD N
CDDP NNP 1_i
. . 1_i

RESULTS NNP N
None NN N
of IN N
these DT N
101 CD N
patients NNS N
developed VBD N
cervical JJ 1_o
radiation NN 1_o
myelitis NN 1_o
. . 1_o

Therefore RB N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
potentially RB 1_o
contributing VBG 1_o
factors NNS 1_o
on IN N
the DT N
occurrence NN 1_o
of IN 1_o
radiation NN 1_o
myelitis NN 1_o
, , N
such JJ N
as IN N
interfraction NN 1_o
interval NN 1_o
, , 1_o
cord NN 1_o
length NN 1_o
, , 1_o
and CC 1_o
administration NN 1_o
of IN 1_o
concurrent JJ 1_o
CDDP NNP 1_o
. . 1_o

CONCLUSIONS NNP N
Given NNP N
the DT N
increasing VBG N
number NN N
of IN N
studies NNS N
with IN N
both DT N
altered VBN N
fractionated VBN N
regimens NNS N
and CC N
concurrent JJ N
radio-chemotherapy NN 1_i
in IN N
SCC NNP N
H NNP N
& CC N
N NNP N
, , N
new JJ N
studies NNS N
with IN N
more JJR N
patients NNS N
are VBP N
needed VBN N
to TO N
gain VB N
better JJR N
insight NN N
into IN N
the DT N
risks NNS 1_o
of IN 1_o
developing VBG 1_o
cervical JJ 1_o
radiation NN 1_o
myelitis NN 1_o
. . 1_o

Cost-effectiveness NN 1_o
of IN N
collaborative JJ 1_i
care NN 1_i
including VBG 1_i
PST NNP 1_i
and CC 1_i
an DT 1_i
antidepressant JJ 1_i
treatment NN 1_i
algorithm NN 1_i
for IN N
the DT N
treatment NN N
of IN N
major JJ 1_p
depressive JJ 1_p
disorder NN 1_p
in IN N
primary JJ N
care NN N
; : N
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Depressive NNP 1_p
disorder NN 1_p
is VBZ N
currently RB N
one CD N
of IN N
the DT N
most RBS N
burdensome JJ N
disorders NNS N
worldwide VBP N
. . N

Evidence-based JJ N
treatments NNS N
for IN N
depressive JJ 1_p
disorder NN 1_p
are VBP N
already RB N
available JJ N
, , N
but CC N
these DT N
are VBP N
used VBN N
insufficiently RB N
, , N
and CC N
with IN N
less JJR N
positive JJ N
results NNS N
than IN N
possible JJ N
. . N

Earlier RBR N
research NN N
in IN N
the DT N
USA NNP N
has VBZ N
shown VBN N
good JJ N
results NNS N
in IN N
the DT N
treatment NN N
of IN N
depressive JJ 1_p
disorder NN 1_p
based VBN N
on IN N
a DT N
collaborative JJ 1_i
care NN 1_i
approach NN 1_i
with IN 1_i
Problem NNP 1_o
Solving NNP 1_o
Treatment NNP 1_o
and CC 1_i
an DT 1_i
antidepressant JJ 1_i
treatment NN 1_i
algorithm NN 1_i
, , N
and CC N
research NN N
in IN N
the DT N
UK NNP N
has VBZ N
also RB N
shown VBN N
good JJ N
results NNS N
with IN N
Problem NNP 1_i
Solving VBG 1_i
Treatment NNP 1_i
. . 1_i

These DT N
treatment NN N
strategies NNS N
may MD N
also RB N
work VB N
very RB N
well RB N
in IN N
the DT N
Netherlands NNP N
too RB N
, , N
even RB N
though IN N
health NN N
care NN N
systems NNS N
differ VBP N
between IN N
countries NNS N
. . N

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
two-armed JJ N
randomised JJ N
clinical JJ N
trial NN N
, , N
with IN N
randomization NN N
on IN N
patient-level NN N
. . N

The DT N
aim NN N
of IN N
the DT N
trial NN N
is VBZ N
to TO N
evaluate VB N
the DT N
treatment NN 1_o
of IN N
depressive JJ N
disorder NN N
in IN N
primary JJ 1_p
care NN 1_p
in IN 1_p
the DT 1_p
Netherlands NNP 1_p
by IN N
means NNS N
of IN N
an DT N
adapted JJ 1_i
collaborative NN 1_i
care NN 1_i
framework NN 1_i
, , 1_i
including VBG 1_i
contracting NN 1_i
and CC 1_i
adherence-improving JJ 1_i
strategies NNS 1_i
, , 1_i
combined VBN 1_i
with IN 1_i
Problem NNP 1_i
Solving NNP 1_i
Treatment NNP 1_i
and CC 1_i
antidepressant JJ 1_i
medication NN 1_i
according VBG 1_i
to TO 1_i
a DT 1_i
treatment NN 1_i
algorithm NN 1_i
. . 1_i

Forty NNP 1_p
general JJ 1_p
practices NNS 1_p
will MD N
be VB N
randomised VBN 1_i
to TO 1_i
either CC 1_i
the DT 1_i
intervention NN 1_i
group NN 1_i
or CC 1_i
the DT 1_i
control NN 1_i
group NN 1_i
. . 1_i

Included VBN N
will MD N
be VB N
patients NNS 1_p
who WP 1_p
are VBP 1_p
diagnosed VBN 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe JJ 1_p
depression NN 1_p
, , 1_p
based VBN 1_p
on IN 1_p
DSM-IV NNP 1_p
criteria NNS 1_p
, , 1_p
and CC 1_p
stratified VBD 1_p
according VBG 1_p
to TO 1_p
comorbid VB 1_p
chronic JJ 1_p
physical JJ 1_p
illness NN 1_p
. . 1_p

Patients NNS 1_i
in IN 1_i
the DT 1_i
intervention NN 1_i
group NN 1_i
will MD 1_i
receive VB 1_i
treatment NN 1_i
based VBN 1_i
on IN 1_i
the DT 1_i
collaborative JJ 1_i
care NN 1_i
approach NN 1_i
, , 1_i
and CC 1_i
patients NNS 1_i
in IN 1_i
the DT 1_i
control NN 1_i
group NN 1_i
will MD 1_i
receive VB 1_i
care NN 1_i
as IN 1_i
usual JJ 1_i
. . 1_i

Baseline NN 1_i
measurements NNS 1_i
and CC 1_i
follow VB 1_i
up RP 1_i
measures NNS 1_i
( ( 1_i
3 CD 1_i
, , 1_i
6 CD 1_i
, , 1_i
9 CD 1_i
and CC 1_i
12 CD 1_i
months NNS 1_i
) ) 1_i
are VBP 1_i
assessed VBN 1_i
using VBG 1_i
questionnaires NNS 1_i
and CC 1_i
an DT 1_i
interview NN 1_i
. . 1_i

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
severity NN 1_o
of IN 1_o
depressive JJ 1_o
symptoms NNS 1_o
, , 1_o
according VBG 1_o
to TO 1_o
the DT 1_o
PHQ9 NNP 1_o
. . 1_o

Secondary NNP N
outcome NN N
measures NNS N
are VBP N
remission NN 1_o
as IN 1_o
measured VBN 1_o
with IN 1_o
the DT 1_o
PHQ9 NNP 1_o
and CC 1_o
the DT 1_o
IDS-SR NNP 1_o
, , 1_o
and CC 1_o
cost-effectiveness NN 1_o
measured VBN 1_o
with IN 1_o
the DT 1_o
TiC-P NNP 1_o
, , 1_o
the DT 1_o
EQ-5D NNP 1_o
and CC 1_o
the DT 1_o
SF-36 NNP 1_o
. . 1_o

DISCUSSION NNP N
In IN N
this DT N
study NN N
, , N
an DT N
American JJ N
model NN N
to TO N
enhance VB N
care NN N
for IN N
patients NNS 1_p
with IN 1_p
a DT 1_p
depressive JJ 1_p
disorder NN 1_p
, , N
the DT N
collaborative JJ 1_i
care NN 1_i
model NN 1_i
, , N
will MD N
be VB N
evaluated VBN N
for IN N
effectiveness NN N
in IN N
the DT N
primary JJ N
care NN N
setting VBG N
. . N

If IN N
effective JJ N
across IN N
the DT N
Atlantic NNP N
and CC N
across IN N
different JJ N
health NN N
care NN N
systems NNS N
, , N
it PRP N
is VBZ N
also RB N
likely JJ N
to TO N
be VB N
an DT N
effective JJ N
strategy NN N
to TO N
implement VB N
in IN N
the DT N
treatment NN N
of IN N
major JJ 1_p
depressive JJ 1_p
disorder NN 1_p
in IN N
the DT N
Netherlands NNP N
. . N

Long-term JJ N
follow-up NN N
of IN N
three CD N
randomized JJ N
trials NNS N
comparing VBG N
idarubicin NN 1_i
and CC 1_i
daunorubicin NN 1_i
as IN N
induction NN N
therapies NNS N
for IN N
patients NNS 1_p
with IN 1_p
untreated JJ 1_p
acute NN 1_p
myeloid NN 1_p
leukemia NN 1_p
. . 1_p

BACKGROUND NNP N
Most NNP N
clinical JJ N
trials NNS N
for IN N
acute NN N
leukemia NN N
have VBP N
reported VBN N
results NNS N
after IN N
2-3 JJ N
years NNS N
of IN N
follow-up NN N
. . N

Comparisons NNS N
between IN N
the DT N
original JJ N
data NNS N
and CC N
longer-term JJ N
follow-up JJ N
data NNS N
may MD N
be VB N
of IN N
interest NN N
, , N
particularly RB N
with IN N
regard NN N
to TO N
promising VBG N
new JJ N
therapies NNS N
. . N

METHODS NNP N
In IN 1_p
1996 CD 1_p
, , 1_p
survival NN 1_p
data NNS 1_p
were VBD 1_p
updated VBN 1_p
from IN 1_p
three CD 1_p
prospective JJ 1_p
, , 1_p
randomized JJ 1_p
comparisons NNS 1_p
of IN 1_p
idarubicin NN 1_i
and CC 1_i
daunorubicin NN 1_i
that WDT 1_p
began VBD 1_p
in IN 1_p
1984 CD 1_p
and CC 1_p
1985 CD 1_p
. . 1_p

These DT 1_p
were VBD 1_p
trials NNS 1_p
of IN 1_p
the DT 1_p
Memorial NNP 1_p
Sloan-Kettering NNP 1_p
Cancer NNP 1_p
Center NNP 1_p
( ( 1_p
MSKCC NNP 1_p
) ) 1_p
, , 1_p
the DT 1_p
U.S. NNP 1_p
Multicenter NNP 1_p
Study NNP 1_p
Group NNP 1_p
, , 1_p
and CC 1_p
the DT 1_p
Southeastern NNP 1_p
Cancer NNP 1_p
Study NNP 1_p
Group NNP 1_p
( ( 1_p
SEG NNP 1_p
) ) 1_p
. . 1_p

The DT N
original JJ N
results NNS N
of IN N
these DT N
trials NNS N
were VBD N
reported VBN N
in IN N
1991 CD N
and CC N
1992 CD N
. . N

RESULTS VB N
The DT N
original JJ N
results NNS N
of IN N
the DT N
SEG NNP N
trial NN N
demonstrated VBD N
no DT N
significant JJ 1_o
difference NN 1_o
between IN 1_o
idarubicin NN 1_o
and CC 1_o
daunorubicin NN 1_o
. . 1_o

The DT N
updated JJ N
survival NN 1_o
analysis NN 1_o
showed VBD N
similar JJ N
results NNS N
. . N

The DT N
MSKCC NNP N
trial NN N
revealed VBD N
a DT N
significant JJ N
advantage NN 1_o
of IN 1_o
idarubicin NNS 1_o
compared VBN N
with IN N
daunorubicin NN N
in IN N
both CC N
the DT N
original JJ N
and CC N
the DT N
updated JJ N
analyses NNS N
. . N

The DT N
U.S. NNP N
Multicenter NNP N
trial NN N
found VBD N
a DT N
significant JJ N
difference NN N
favoring VBG N
idarubicin NN N
in IN N
the DT N
original JJ N
analysis NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
in IN N
the DT N
updated JJ N
analysis NN N
. . N

CONCLUSIONS VB N
It PRP N
is VBZ N
essential JJ N
that IN N
the DT N
median JJ N
length NN N
of IN N
follow-up JJ N
be VB N
clearly RB N
stated VBN N
in IN N
any DT N
clinical JJ N
trial NN N
. . N

When WRB N
the DT N
results NNS N
obtained VBD N
with IN N
a DT N
particularly RB N
promising JJ N
new JJ N
drug NN N
or CC N
procedure NN N
are VBP N
presented VBN N
early RB N
in IN N
the DT N
course NN N
of IN N
study NN N
( ( N
within IN N
1-2 CD N
years NNS N
) ) N
, , N
the DT N
investigators NNS N
should MD N
strongly RB N
consider VB N
a DT N
repeat NN N
evaluation NN N
after IN N
an DT N
additional JJ N
3-5 CD N
years NNS N
of IN N
follow-up NN N
. . N

The DT N
neural JJ N
correlates NNS N
of IN N
semantic JJ N
richness NN N
: : N
evidence NN N
from IN N
an DT N
fMRI NN N
study NN N
of IN N
word NN N
learning NN N
. . N

We PRP N
investigated VBD N
the DT N
neural JJ N
correlates NNS N
of IN N
concrete JJ N
nouns NNS N
with IN N
either DT N
many JJ N
or CC N
few JJ N
semantic JJ N
features NNS N
. . N

A DT N
group NN 1_p
of IN 1_p
21 CD 1_p
participants NNS 1_p
underwent JJ 1_p
two CD 1_p
days NNS 1_p
of IN 1_p
training NN 1_i
and CC 1_p
were VBD 1_p
then RB 1_p
asked VBN 1_p
to TO 1_p
categorize VB 1_p
40 CD 1_p
newly RB 1_p
learned VBN 1_p
words NNS 1_p
and CC 1_p
a DT 1_p
set NN 1_p
of IN 1_p
matched NNS 1_i
familiar JJ 1_i
words NNS 1_i
as IN 1_i
living NN 1_i
or CC 1_i
nonliving NN 1_i
in IN 1_i
an DT 1_i
MRI NNP 1_i
scanner NN 1_i
. . 1_i

Our PRP$ N
results NNS N
showed VBD N
that IN N
the DT N
most RBS 1_o
reliable JJ 1_o
effects NNS 1_o
of IN 1_o
semantic JJ 1_o
richness NN 1_o
were VBD N
located VBN 1_o
in IN 1_o
the DT 1_o
left NN 1_o
angular JJ 1_o
gyrus NN 1_o
( ( 1_o
AG NNP 1_o
) ) 1_o
and CC 1_o
middle JJ 1_o
temporal JJ 1_o
gyrus NN 1_o
( ( 1_o
MTG NNP 1_o
) ) 1_o
, , N
where WRB N
activation NN 1_o
was VBD N
higher JJR N
for IN N
semantically RB N
rich JJ N
than IN N
poor JJ N
words NNS N
. . N

Other JJ N
areas NNS N
showing VBG N
the DT N
same JJ N
pattern NN N
included VBD N
bilateral JJ N
precuneus NN N
and CC N
posterior JJ N
cingulate NN N
gyrus NN N
. . N

Our PRP$ N
findings NNS N
support VBP N
the DT N
view NN N
that IN N
AG NNP N
and CC N
anterior JJ N
MTG NNP N
, , N
as IN N
part NN N
of IN N
the DT N
multimodal NN N
network NN N
, , N
play VB N
a DT N
significant JJ N
role NN N
in IN N
representing VBG N
and CC N
integrating VBG 1_o
semantic JJ 1_o
features NNS 1_o
from IN N
different JJ N
input NN N
modalities NNS N
. . N

We PRP N
propose VBP N
that DT N
activation NN N
in IN N
bilateral JJ N
precuneus NN N
and CC N
posterior JJ N
cingulate NN N
gyrus NN N
reflects VBZ N
interplay NN N
between IN N
AG NNP N
and CC N
episodic JJ N
memory NN N
systems NNS N
during IN N
semantic JJ N
retrieval NN N
. . N

Minimally RB N
invasive JJ N
treatment NN N
combined VBN N
with IN N
cytokine-induced JJ 1_i
killer NN 1_i
cells NNS 1_i
therapy VBP 1_i
lower JJR N
the DT N
short-term JJ N
recurrence NN N
rates NNS N
of IN N
hepatocellular JJ 1_p
carcinomas NN 1_p
. . 1_p

The DT N
recurrence NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
after IN N
minimally RB N
invasive JJ N
therapy NN N
is VBZ N
frequent JJ N
. . N

Adoptive JJ 1_i
immunotherapy NN 1_i
is VBZ N
thought VBN N
to TO N
be VB N
an DT N
effective JJ N
method NN N
to TO N
lower JJR N
recurrence NN N
and CC N
metastasis NN N
rates NNS N
of IN N
malignant JJ N
tumors NNS N
. . N

Therefore RB N
, , N
85 CD 1_p
HCC NNP 1_p
patients NNS 1_p
after IN 1_p
transcatheter JJ 1_i
arterial JJ 1_i
chemoembolization NN 1_i
and CC 1_p
radiofrequency NN 1_i
ablation NN 1_i
therapy NN 1_i
were VBD 1_p
randomized VBN 1_p
to TO 1_p
immunotherapy VB 1_i
group NN 1_p
and CC 1_p
no DT 1_i
adjuvant JJ 1_i
therapy NN 1_i
group NN 1_p
. . 1_p

Autologous JJ 1_i
cytokine-induced JJ 1_i
killer NN 1_i
( ( 1_i
CIK NNP 1_i
) ) 1_i
cells NNS 1_i
were VBD 1_i
transfused VBN 1_i
via IN N
hepatic JJ N
artery NN N
to TO N
the DT N
patients NNS N
. . N

The DT N
alteration NN N
of IN N
levels NNS N
of IN N
lymphocyte JJ N
subsets NNS N
in IN N
peripheral JJ N
blood NN N
of IN N
patients NNS N
was VBD N
examined VBN N
by IN N
flow JJ N
cytometry NN N
. . N

All DT 1_p
patients NNS 1_p
were VBD 1_p
screened VBN 1_p
by IN 1_p
computed JJ 1_p
tomography NN 1_p
every DT 1_p
2 CD 1_p
months NNS 1_p
to TO 1_p
observe VB 1_p
the DT 1_p
tumor NN 1_p
recurrent NN 1_p
conditions NNS 1_p
. . 1_p

After IN N
CIK NNP 1_i
cell NN 1_i
infusions NNS N
, , N
the DT N
percentages NNS 1_o
of IN 1_o
CD3+ NNP 1_o
, , 1_o
CD4+ NNP 1_o
, , 1_o
CD56+ NNP 1_o
, , 1_o
CD3+CD56+ NNP 1_o
cells NNS 1_o
, , 1_o
and CC 1_o
CD4+/CD8+ NNP 1_o
ratio VBP 1_o
increased VBN N
from IN N
68.6+/-11.0 CD N
% NN N
, , N
31.1+/-9.0 CD N
% NN N
, , N
15.6+/-7.9 CD N
% NN N
, , N
5.2+/-3.1 CD N
% NN N
, , N
and CC N
1.1+/-0.5 JJ N
to TO N
70.7+/-10.1 CD N
% NN N
, , N
33.5+/-8.0 CD N
% NN N
, , N
18.4+/-9.4 CD N
% NN N
, , N
5.9+/-2.8 CD N
% NN N
, , N
and CC N
1.3+/-0.7 JJ N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
whereas IN N
the DT N
percentage NN 1_o
of IN 1_o
CD8 NNP 1_o
cells NNS 1_o
decreased VBN N
from IN N
31.1+/-7.8 CD N
% NN N
to TO N
28.6+/-8.3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
1-year JJ 1_o
and CC 1_o
18-month JJ 1_o
recurrence NN 1_o
rates NNS 1_o
of IN 1_o
the DT 1_o
study NN 1_o
group NN 1_o
were VBD N
8.9 CD N
% NN N
and CC N
15.6 CD N
% NN N
, , N
compared VBN N
with IN N
30.0 CD N
% NN N
and CC N
40.0 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
both DT N
P NNP N
value NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
CIK NNP 1_i
cell NN 1_i
transfusion NN 1_i
is VBZ N
an DT N
effective JJ N
treatment NN N
. . N

It PRP N
can MD N
boost VB N
the DT N
immunologic JJ N
function NN N
in IN N
HCC NNP 1_p
patients NNS 1_p
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
the DT N
recurrence NN N
rate NN N
of IN N
HCC NNP N
. . N

[ JJ 1_i
Mitomycin NNP 1_i
C NNP 1_i
plus CC 1_i
HCFU NNP 1_i
adjuvant VBP N
chemotherapy NN N
for IN N
noncuratively RB N
resected VBN N
cases NNS N
of IN N
colorectal JJ N
carcinoma NN N
. . N

( ( N
Second JJ N
report NN N
) ) N
: : N
5-year JJ N
survival NN N
rate NN N
. . N

Cooperative NNP N
Study NNP N
Group NNP N
of IN N
Kyushu NNP N
and CC N
Chugoku NNP N
for IN N
HCFU NNP N
Adjuvant NNP N
Chemotherapy NNP N
] NNP N
. . N

In IN N
order NN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
adjuvant JJ 1_i
chemotherapy NN 1_i
employing VBG N
mitomycin JJ 1_i
C NNP 1_i
( ( 1_i
MMC NNP 1_i
) ) 1_i
and CC 1_i
carmofur NN 1_i
( ( 1_i
HCFU NNP 1_i
) ) 1_i
for IN 1_p
patients NNS 1_p
with IN 1_p
noncuratively RB 1_p
resected VBN 1_p
colorectal JJ 1_p
carcinoma NN 1_p
, , N
a DT N
cooperative JJ N
study NN N
was VBD N
performed VBN N
by IN N
54 CD 1_p
institutions NNS 1_p
in IN 1_p
the DT 1_p
Kyushu NNP 1_p
and CC 1_p
Chugoku NNP 1_p
areas NNS 1_p
of IN 1_p
Japan NNP 1_p
. . 1_p

The DT 1_p
criteria NNS 1_p
for IN 1_p
patient JJ 1_p
selection NN 1_p
were VBD 1_p
as IN 1_p
follows VBZ 1_p
: : 1_p
1 CD 1_p
) ) 1_p
Age NNP 1_p
of IN 1_p
75 CD 1_p
years NNS 1_p
or CC 1_p
less JJR 1_p
and CC 1_p
not RB 1_p
accompanied VBN 1_p
by IN 1_p
any DT 1_p
serious JJ 1_p
disease NN 1_p
. . 1_p

2 CD 1_p
) ) 1_p
Macroscopic NNP 1_p
diagnosis NN 1_p
as IN 1_p
being VBG 1_p
noncuratively RB 1_p
resected VBN 1_p
on IN 1_p
completion NN 1_p
of IN 1_p
the DT 1_p
surgical JJ 1_p
procedure NN 1_p
. . 1_p

3 CD 1_p
) ) 1_p
Definitive JJ 1_p
diagnosis NN 1_p
of IN 1_p
colorectal JJ 1_p
carcinomas NN 1_p
, , 1_p
histologically RB 1_p
. . 1_p

4 CD 1_p
) ) 1_p
No DT 1_p
synchronous JJ 1_p
or CC 1_p
metachronous JJ 1_p
double JJ 1_p
cancer NN 1_p
. . 1_p

The DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
consisted VBN N
of IN N
two CD N
groups NNS N
. . N

In IN N
Group NNP N
A NNP N
, , N
the DT N
MMC NNP 1_i
group NN 1_p
received VBD N
bolus RB N
intravenous JJ N
injections NNS N
of IN N
20 CD N
mg NNS N
MMC NNP 1_i
on IN N
the DT N
day NN N
of IN N
operation NN N
and CC N
10 CD N
mg NN N
the DT N
next JJ N
day NN N
, , N
followed VBN N
by IN N
10 CD N
mg NNS N
every DT N
4 CD N
weeks NNS N
until IN N
a DT N
total NN N
of IN N
100 CD N
mg NNS N
had VBD N
been VBN N
administered VBN N
. . N

In IN N
Group NNP N
B NNP N
, , N
the DT N
MMC NNP 1_i
+ NNP 1_i
HCFU NNP 1_i
group NN 1_i
received VBD N
the DT N
same JJ N
treatment NN N
in IN N
Group NNP N
A NNP N
, , N
but CC N
with IN N
the DT N
addition NN N
of IN N
600 CD N
mg/day NN N
of IN N
HCFU NNP 1_i
from IN N
the DT N
second JJ N
week NN N
, , N
orally RB N
for IN N
at IN N
least JJS N
one CD N
year NN N
. . N

Concerning VBG N
the DT N
69-month JJ 1_o
survival NN 1_o
rate NN 1_o
, , N
a DT N
better JJR N
result NN N
was VBD N
observed VBN N
in IN N
the DT N
MMC NNP 1_i
+ NNP 1_i
HCFU NNP 1_i
group NN N
than IN N
in IN N
the DT N
MMC NNP 1_i
only RB 1_i
group NN N
( ( N
generalized VBN N
Wilcoxon NNP N
test NN N
: : N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Significantly RB N
better JJR N
survival NN 1_o
rates NNS 1_o
were VBD N
obtained VBN N
in IN N
those DT N
cases NNS N
with IN N
disseminating VBG N
peritoneal JJ N
metastasis NN N
, , N
hepatic JJ N
metastasis NN N
and CC N
stage NN N
V NNP N
cancer NN N
in IN N
the DT N
MMC NNP 1_i
+ NNP 1_i
HCFU NNP 1_i
group NN N
as IN N
when WRB N
compared VBN N
with IN N
the DT N
MMC NNP 1_i
only RB N
group NN N
. . N

No DT 1_o
significant JJ 1_o
side NN 1_o
effects NNS 1_o
due JJ N
to TO N
the DT N
combined JJ N
administration NN N
of IN N
HCFU NNP 1_i
were VBD N
recognized VBN N
. . N

The DT N
combined JJ N
administration NN N
of IN N
MMC NNP 1_i
and CC N
HCFU NNP 1_i
was VBD N
suggested VBN N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
adjuvant NN N
chemotherapy NN N
for IN N
noncuratively RB N
resected VBN N
cases NNS N
of IN N
colorectal JJ N
carcinoma NN N
. . N

Evaluation NN N
of IN N
a DT N
preventive JJ 1_i
intervention NN 1_i
for IN N
child JJ 1_p
anxiety NN 1_p
in IN N
two CD N
randomized JJ N
attention-control JJ N
school NN N
trials NNS N
. . N

The DT N
present JJ N
research NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive-behavioral JJ 1_o
therapy NN 1_o
( ( 1_i
CBT NNP 1_i
) ) 1_i
based VBN 1_i
intervention NN 1_i
program NN 1_i
, , 1_i
FRIENDS NNP 1_i
, , N
for IN 1_p
children NNS 1_p
from IN 1_p
grades NNS 1_p
4 CD 1_p
to TO 1_p
6 CD 1_p
, , 1_p
using VBG 1_p
random JJ 1_p
assignment NN 1_p
at IN 1_p
the DT 1_p
school-level NN 1_p
and CC N
an DT N
attention-control JJ N
design NN N
in IN N
two CD N
longitudinal JJ N
studies NNS N
. . N

The DT N
first JJ N
study NN N
targeted VBD N
children NNS 1_p
with IN 1_p
anxiety NN 1_o
symptoms NNS 1_o
( ( 1_p
N=191 NNP 1_p
, , 1_p
mean JJ 1_p
age=10.1 NN 1_p
) ) 1_p
as IN 1_p
screened VBN 1_p
with IN 1_p
self NN 1_p
, , 1_p
parent NN 1_p
, , 1_p
and CC 1_p
teacher-reports NNS 1_p
; : 1_p
the DT 1_p
second JJ 1_p
study NN 1_p
took VBD 1_p
a DT 1_p
universal JJ 1_p
approach NN 1_p
with IN 1_p
full JJ 1_p
classrooms NNS 1_p
of IN 1_p
children NNS 1_p
participating VBG 1_p
( ( 1_p
N=253 NNP 1_p
, , 1_p
mean JJ 1_p
age=9.8 NN 1_p
) ) 1_p
. . 1_p

The DT N
results NNS N
showed VBD N
no DT N
intervention NN N
effect NN N
in IN N
both DT N
studies NNS N
, , N
with IN 1_o
children NNS 1_o
's POS 1_o
anxiety NN 1_o
symptoms NNS 1_o
decreasing VBG N
over IN N
time NN N
regardless NN N
of IN N
whether IN N
they PRP N
were VBD N
in IN N
the DT 1_i
story-reading NN 1_i
( ( N
attention NN N
control NN N
) ) N
or CC 1_i
FRIENDS JJ 1_i
condition NN N
. . N

The DT N
findings NNS N
also RB N
indicated VBD N
that IN N
girls NNS N
reported VBD N
a DT N
higher JJR 1_o
level NN 1_o
of IN 1_o
anxiety NN 1_o
than IN N
boys NNS N
and CC N
children NNS N
in IN N
higher JJR N
grades NNS N
reported VBD N
lower JJR 1_o
anxiety NN 1_o
relative NN N
to TO N
younger JJR N
children NNS N
in IN N
both DT N
studies NNS N
. . N

In IN N
addition NN N
, , N
similar JJ N
patterns NNS N
were VBD N
found VBN N
using VBG N
a DT N
subgroup NN N
of IN 1_p
children NNS 1_p
with IN 1_o
high-anxiety NN 1_o
symptoms NNS 1_o
from IN N
both DT N
studies NNS N
. . N

[ IN N
The DT N
effects NNS N
of IN N
mexicor NN 1_i
on IN N
thrombocyte JJ 1_o
aggregation NN 1_o
, , 1_o
blood NN 1_o
viscosity NN 1_o
, , 1_o
hemodynamics NNS 1_o
, , N
and CC N
the DT N
clinical JJ N
course NN N
of IN N
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
] NNP 1_p
. . N

The DT N
authors NNS N
analyze VBP N
their PRP$ N
experience NN N
in IN N
the DT N
application NN N
of IN N
mexicor NN 1_i
, , 1_i
a DT 1_i
Russian JJ 1_i
cytoprotector NN 1_i
, , N
in IN N
50patients CD 1_p
with IN 1_p
chronic JJ 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
( ( 1_p
CAD NNP 1_p
) ) 1_p
and CC 1_p
51 CD 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
coronary JJ 1_p
syndrome NN 1_p
. . 1_p

In IN N
additional JJ N
to TO N
cytoprotective JJ N
action NN N
, , N
the DT N
use NN N
of IN N
mexidor NN 1_i
in IN N
complex JJ N
therapy NN N
of IN N
CAD NNP N
lowers VBZ N
the DT N
functional JJ 1_o
activity NN 1_o
of IN 1_o
thrombocytes NNS 1_o
, , N
eliminates VBZ N
high JJ 1_o
blood NN 1_o
viscosity NN 1_o
syndrome NN 1_o
, , N
and CC N
lowers NNS N
low JJ 1_o
density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
level NN 1_o
. . 1_o

These DT N
favorable JJ N
changes NNS N
in IN N
hemorheological JJ N
parameters NNS N
improves VBZ N
myocardial JJ 1_o
perfusion NN 1_o
, , N
lowers VBZ N
the DT N
strength NN 1_o
and CC 1_o
frequency NN 1_o
of IN 1_o
coronary JJ 1_o
pain NN 1_o
attacks NNS 1_o
, , N
retards NNS N
postinfarction NN 1_o
left VBD 1_o
ventricular JJ 1_o
remodeling NN 1_o
, , N
and CC N
increases VBZ N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_p
various JJ 1_p
CAD NNP 1_p
forms NNS 1_p
. . 1_p

Influence NN 1_o
of IN N
ibopamine NN 1_i
on IN N
heart NN 1_o
rate NN 1_o
and CC 1_o
arrhythmic JJ 1_o
pattern NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

A DT N
double-blind JJ N
multicentre NN N
study NN N
. . N

Ibopamine NNP 1_i
is VBZ N
a DT N
dopaminergic NN N
and CC N
adrenergic JJ N
receptor NN N
agonist NN N
, , N
which WDT N
is VBZ N
active JJ N
in IN N
the DT N
treatment NN N
of IN N
congestive JJ N
heart NN N
failure NN N
. . N

Since IN N
the DT N
long-term JJ N
prognosis NN N
for IN N
patients NNS 1_p
with IN 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
remains VBZ N
very RB N
poor JJ N
and CC N
the DT N
incidence NN N
of IN N
arrhythmic JJ N
death NN N
is VBZ N
high JJ N
, , N
every DT N
new JJ N
drug NN N
to TO N
be VB N
employed VBN N
against IN N
this DT N
disease NN N
should MD N
be VB N
thoroughly RB N
tested VBN N
in IN N
order NN N
to TO N
rule VB N
out RP N
any DT N
possible JJ N
arrhythmogenic JJ 1_o
action NN 1_o
. . 1_o

This DT N
multicentre NN N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effect NN 1_o
of IN N
ibopamine NN 1_i
versus NN N
placebo NN 1_i
in IN N
double-blind JJ N
conditions NNS N
on IN N
heart NN 1_o
rate NN 1_o
, , 1_o
rhythm NN 1_o
and CC 1_o
electrical JJ 1_o
safety NN 1_o
. . 1_o

Ibopamine NNP 1_i
was VBD 1_i
employed VBN 1_i
at IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
100 CD 1_i
mg NN 1_i
t.i.d NN 1_i
. . 1_i

in IN 1_i
97 CD 1_i
patients NNS 1_i
( ( 1_i
aged VBN 1_i
31-83 CD 1_i
years NNS 1_i
) ) 1_i
belonging VBG 1_i
to TO 1_i
NYHA NNP 1_i
class NN 1_i
II NNP 1_i
and CC 1_i
III NNP 1_i
with IN 1_i
congestive JJ 1_i
heart NN 1_i
failure NN 1_i
of IN 1_i
different JJ 1_i
aetiology NN 1_i
, , 1_i
but CC 1_i
without IN 1_i
any DT 1_i
complex JJ 1_i
ventricular NN 1_i
arrhythmias NN 1_i
in IN 1_i
basal NN 1_i
conditions NNS 1_i
( ( 1_i
couplets NNS 1_i
with IN 1_i
R'-R NNP 1_i
" NNP 1_i
less JJR 1_i
than IN 1_i
or CC 1_i
equal JJ 1_i
to TO 1_i
400 CD 1_i
msec NNS 1_i
, , 1_i
ventricular JJ 1_i
tachycardia NN 1_i
, , 1_i
R NNP 1_i
on IN 1_i
T NNP 1_i
phenomena NN 1_i
) ) 1_i
. . 1_p

Using VBG N
a DT N
random JJ N
cross-over NN N
design NN N
the DT N
patients NNS N
were VBD N
submitted VBN N
to TO N
48 CD N
hr NN N
. . N

Holter NNP 1_o
recordings NNS 1_o
in IN 1_i
basal NN 1_i
conditions NNS 1_i
and CC 1_i
following VBG 1_i
7 CD 1_i
days NNS 1_i
of IN 1_i
ibopamine NN 1_i
and CC 1_i
placebo NN 1_i
treatment NN 1_i
. . 1_i

No DT N
influence NN N
on IN N
heart NN 1_o
rhythm NN 1_o
was VBD N
noted VBN N
. . N

No DT N
significant JJ N
variations NNS N
in IN N
maximum JJ 1_o
heart NN 1_o
rate NN 1_o
( ( N
ibopamine JJ N
117.7 CD N
+/- JJ N
20.9 CD N
; : N
placebo NN N
118.1 CD N
+/- JJ N
20.7 CD N
) ) N
, , N
medium JJ 1_o
heart NN 1_o
rate NN 1_o
( ( N
ibopamine JJ N
71.8 CD N
+/- JJ N
10.2 CD N
; : N
placebo NN N
72.6 CD N
+/- JJ N
10.1 CD N
) ) N
or CC N
minimum JJ 1_o
heart NN 1_o
rate NN 1_o
( ( N
ibopamine JJ N
55.3 CD N
+/- JJ N
11.7 CD N
; : N
placebo NN N
54.6 CD N
+/- JJ N
10.6 CD N
) ) N
were VBD N
observed VBN N
. . N

The DT N
mean JJ N
number/hr NN N
. . N

of IN N
ectopic JJ 1_o
supraventricular JJ 1_o
beats NNS 1_o
was VBD N
26.1 CD N
+/- JJ N
61.9 CD N
after IN N
ibopamine NN N
and CC N
21.7 CD N
+/- JJ N
35.8 CD N
after IN N
placebo NN N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
. . N

The DT N
complexity NN N
of IN N
ectopic NN 1_o
supraventricular JJ 1_o
beats NNS 1_o
did VBD N
not RB N
change NN N
. . N

The DT N
mean JJ N
number/hr NN N
. . N

of IN N
ectopic JJ 1_o
ventricular JJ 1_o
beats NNS 1_o
was VBD N
31.1 CD N
+/- JJ N
52.5 CD N
after IN N
ibopamine NN N
and CC N
30.4 CD N
+/- JJ N
57.8 CD N
after IN N
placebo NN N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
. . N

Neither CC N
the DT N
distribution NN N
of IN N
the DT N
patients NNS N
among IN N
Lown JJ 1_o
classification NN 1_o
nor CC 1_o
the DT 1_o
Final NNP 1_o
Score NN 1_o
of IN 1_o
the DT 1_o
Italian JJ 1_o
Lown NNP 1_o
Classification NNP 1_o
( ( N
26.1 CD N
+/- JJ N
18.0 CD N
and CC N
26.6 CD N
+/- JJ N
17.9 CD N
in IN N
the DT N
1st CD N
and CC N
2nd CD N
day NN N
of IN N
monitoring NN N
after IN N
ibopamine NN N
and CC N
25.7 CD N
+/- JJ N
18.6 CD N
and CC N
25.7 CD N
+/- JJ N
18.8 CD N
after IN N
placebo NN N
; : N
p CC N
= NNP N
ns NN N
) ) N
showed VBD N
any DT N
difference NN N
between IN N
active JJ N
treatment NN N
and CC N
placebo NN N
. . N

Similar JJ N
results NNS N
were VBD N
achieved VBN N
when WRB N
the DT N
patients NNS N
were VBD N
sub-divided JJ N
into IN N
subgroups NNS N
according VBG N
to TO N
sequences NNS N
of IN N
treatment NN N
( ( N
basal NN N
-- : N
-- : N
ibopamine NN N
-- : N
-- : N
placebo NN N
and CC N
basal NN N
-- : N
-- : N
placebo NN N
-- : N
-- : N
ibopamine NN N
) ) N
, , N
NYHA NNP N
class NN N
II NNP N
or CC N
III NNP N
, , N
aetiology NN N
of IN N
congestive JJ N
heart NN N
failure NN N
( ( N
dilatative JJ N
cardiomyopathy NN N
, , N
ischemic JJ N
cardiomyopathy NN N
and CC N
other JJ N
aetiologies NNS N
) ) N
, , N
associated VBN N
treatment NN N
with IN N
digitalis NN N
or CC N
diuretics NNS N
and CC N
the DT N
number NN N
and CC N
complexity NN N
of IN N
base NN N
ectopic NN N
ventricular JJ N
beats NNS N
. . N

None NN N
of IN N
the DT N
patients NNS N
experienced VBD N
sustained JJ N
ventricular JJ N
tachycardia NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
Comparison NNP N
of IN N
a DT N
biopsychosocial JJ 1_i
therapy NN 1_i
( ( 1_i
BT NNP 1_i
) ) 1_i
with IN 1_i
a DT 1_i
conventional JJ 1_i
biomedical JJ 1_i
therapy NN 1_i
( ( 1_i
MT NNP 1_i
) ) 1_i
of IN N
subacute NN 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
in IN N
the DT N
first JJ N
episode NN N
of IN N
sick JJ N
leave NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

This DT N
randomized VBD N
controlled JJ N
clinical JJ N
trial NN N
compares VBZ N
the DT N
effectiveness NN N
of IN N
a DT N
biopsychosocial JJ 1_i
treatment NN 1_i
with IN 1_i
a DT 1_i
solely JJ 1_i
conventional JJ 1_i
biomedical JJ 1_i
therapy NN 1_i
in IN N
patients NNS N
with IN N
subacute JJ 1_o
low JJ 1_o
back RB 1_o
pain NN 1_o
using VBG N
parameters NNS N
for IN N
pain NN N
intensity NN N
, , N
functional JJ N
status NN N
, , N
depressive JJ N
dysfunction NN N
and CC N
work NN N
performance NN N
. . N

Sixty-four JJ 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
first-time JJ 1_p
sick NN 1_p
leave VBP 1_p
between IN 1_p
3 CD 1_p
and CC 1_p
12 CD 1_p
weeks NNS 1_p
due JJ 1_p
to TO 1_p
low VB 1_p
back RB 1_p
pain NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
conventional JJ 1_i
biomedical JJ 1_i
therapy NN 1_i
( ( N
MT NNP N
; : N
n=33 CC N
) ) N
group NN N
, , N
or CC N
a DT N
biopsychosocial JJ 1_i
therapy NN 1_i
( ( N
BT NNP N
; : N
n=31 CC N
) ) N
group NN N
including VBG N
a DT N
psychotherapeutic JJ N
module NN N
; : N
both DT N
in IN N
accordance NN N
with IN N
a DT N
standardized JJ N
3 CD N
weeks NNS N
inpatient JJ N
treatment NN N
. . N

Pain NNP 1_o
intensity NN 1_o
, , 1_o
functional JJ 1_o
back RB 1_o
capacity NN 1_o
, , 1_o
clinical JJ 1_o
parameters NNS 1_o
and CC 1_o
depressive JJ 1_o
dysfunction NN 1_o
revealed VBD N
significant JJ N
improvement NN N
in IN N
both DT N
treatment NN N
groups NNS N
at IN N
end NN N
of IN N
3 CD N
weeks NNS N
therapy NN N
( ( N
T1 NNP N
) ) N
. . N

However RB N
, , N
at IN N
6 CD N
months NNS N
( ( N
T2 NNP N
) ) N
, , N
analysis NN N
revealed VBD N
significant JJ N
better JJR N
results NNS N
for IN N
nearly RB N
all DT N
parameters NNS N
in IN N
the DT N
BT NNP N
group NN N
that WDT N
showed VBD N
further JJ N
improvement NN N
from IN N
T1 NNP 1_o
to TO 1_o
T2 NNP 1_o
, , N
whereas IN N
the DT N
values NNS N
in IN N
the DT N
MT NNP N
group NN N
deteriorated VBD N
from IN N
T1 NNP N
back RB N
to TO N
the DT N
baseline NN N
values NNS N
. . N

During IN N
the DT N
2-year JJ N
period NN N
after IN N
therapy NN N
, , N
10 CD N
% NN N
in IN N
MT NNP N
and CC N
59 CD N
% NN N
in IN N
BT NNP N
required VBD N
no DT N
further JJ N
sick NN 1_o
leave VBP 1_o
due JJ N
to TO N
low VB 1_o
back RB 1_o
pain NN 1_o
. . 1_o

The DT N
results NNS N
of IN N
the DT N
study NN N
indicate VBP N
that IN N
a DT N
psychotherapeutic JJ N
element NN N
in IN N
the DT N
treatment NN N
of IN N
low JJ 1_o
back RB 1_o
pain NN 1_o
appears VBZ N
to TO N
positively RB N
influence VB N
pain NN 1_o
, , 1_o
functional JJ 1_o
status NN 1_o
and CC 1_o
work NN 1_o
performance NN 1_o
when WRB N
conducted VBN N
at IN N
an DT N
early JJ N
stage NN N
of IN N
chronification NN N
and CC N
helps VBZ N
in IN N
the DT N
achievement NN N
of IN N
a DT N
better JJR N
outcome NN N
. . N

Behavior NNP N
in IN N
children NNS 1_p
with IN 1_p
Down NNP 1_p
syndrome NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
highlight VB N
the DT N
differences NNS N
in IN N
behaviors NNS N
in IN N
children NNS 1_p
with IN 1_p
diagnosis NN 1_p
of IN 1_p
Down NNP 1_p
syndrome NN 1_p
. . 1_p

METHOD NNP N
Eight NNP 1_p
children NNS 1_p
with IN 1_p
Down NNP 1_p
syndrome NN 1_p
who WP 1_p
displayed VBD 1_p
autistic JJ 1_p
features NNS 1_p
were VBD 1_p
compared VBN 1_p
with IN 1_p
eight CD 1_p
Down NNP 1_p
syndrome NN 1_p
children NNS 1_p
without IN 1_p
autistic JJ 1_p
features NNS 1_p
. . 1_p

These DT N
children NNS N
were VBD N
randomly RB N
selected VBN N
and CC N
were VBD N
matched VBN N
for IN N
age NN N
and CC N
level NN N
of IN N
retardation NN N
. . N

Standardized JJ 1_i
Psychological JJ 1_i
tests NNS 1_i
were VBD N
administered VBN N
to TO N
tap VB N
the DT N
behavioral JJ N
differences NNS N
. . N

Mann-Whitney NNP 1_o
U NNP 1_o
test NN 1_o
was VBD N
used VBN N
for IN N
significance NN N
of IN N
difference NN N
between IN N
both CC N
the DT N
groups NNS N
. . N

RESULTS NNP N
Down NNP N
syndrome JJ N
children NNS N
without IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
had VBD N
better JJR N
communication NN 1_o
and CC 1_o
socialization NN 1_o
skills NNS 1_o
than IN N
children NNS N
with IN N
Down NNP N
syndrome NN N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
. . N

Down NNP N
syndrome JJ N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
displayed VBD N
more RBR 1_o
restricted JJ 1_o
repetitive NN 1_o
and CC 1_o
stereotyped VBD 1_o
patterns NNS 1_o
of IN 1_o
behaviors NNS 1_o
, , 1_o
interests NNS 1_o
and CC 1_o
activities NNS 1_o
. . 1_o

CONCLUSION NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
manifests VBZ N
as IN N
a DT N
distinct JJ N
behavioral JJ 1_o
phenomenon NN 1_o
in IN N
Down NNP N
syndrome NN N
. . N

Hence NN N
it PRP N
is VBZ N
important JJ N
for IN N
professionals NNS N
to TO N
consider VB N
the DT N
possibility NN N
of IN N
a DT N
dual JJ N
diagnosis NN N
which WDT N
will MD N
entitle VB N
the DT N
child NN N
to TO N
a DT N
more JJR N
specialized JJ N
and CC N
effective JJ N
educational JJ N
and CC N
intervention NN N
services NNS N
. . N

Prevention NN N
of IN N
coronary JJ 1_p
spasm NN 1_p
by IN N
nicorandil NNS 1_i
: : 1_i
comparison NN N
with IN N
nifedipine NN 1_i
. . 1_i

The DT N
efficacy NN N
of IN N
nicorandil NN 1_i
was VBD N
compared VBN N
with IN N
that DT N
of IN N
nifedipine NN 1_i
in IN N
13 CD 1_p
patients NNS 1_p
with IN 1_p
vasospastic JJ 1_p
angina NNS 1_p
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
, , N
crossover NN N
study NN N
. . N

All DT 1_p
patients NNS 1_p
had VBD 1_p
a DT 1_p
coronary JJ 1_p
spasm NN 1_p
during IN 1_p
coronary JJ 1_p
arteriography NN 1_p
, , 1_p
either CC 1_p
spontaneously RB 1_p
or CC 1_p
ergometrine-induced JJ 1_p
. . 1_p

During IN N
two CD N
consecutive JJ N
periods NNS N
of IN N
2 CD N
days NNS N
, , N
patients NNS N
received VBD N
active JJ 1_i
drugs NNS 1_i
or CC N
placebo NN 1_i
in IN N
a DT N
randomized JJ N
order NN N
. . N

Each DT N
patient NN N
received VBD N
single JJ N
oral JJ N
doses NNS N
of IN N
30 CD N
mg NN N
nicorandil NN 1_i
, , N
10 CD N
mg NN N
nifedipine NN 1_i
, , N
and CC N
, , N
on IN N
2 CD N
days NNS N
, , N
a DT N
placebo NN 1_i
. . 1_i

One CD N
hour NN N
after IN N
drug NN N
intake NN N
, , N
patients NNS N
underwent VBD N
an DT N
ergometrine JJ N
test NN N
with IN N
increasing VBG N
doses NNS N
of IN N
Methergin NNP 1_i
( ( 1_i
ergometrine NN 1_i
) ) 1_i
( ( N
0.05 CD N
, , N
0.10 CD N
, , N
0.20 CD N
, , N
and CC N
0.40 CD N
mg NN N
every DT N
5 CD N
min NN N
) ) N
. . N

After IN N
placebo NN 1_i
, , N
the DT N
tests NNS N
always RB N
were VBD N
positive JJ N
, , N
and CC N
the DT N
ECG NNP 1_o
changes NNS 1_o
occurred VBD N
at IN N
the DT N
same JJ N
+/- JJ N
1 CD N
dose NN N
of IN N
ergometrine NN 1_i
in IN N
10 CD N
cases NNS N
, , N
showing VBG N
good JJ 1_o
reproducibility NN 1_o
. . 1_o

After IN N
nicorandil NN 1_i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
nine CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
lower JJR N
dose NN N
of IN N
ergometrine NN 1_i
in IN N
three CD N
and CC N
one CD N
patient NN N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0034 CD N
vs. FW N
placebo NN 1_i
) ) 1_i
. . N

After IN N
nifedipine NN 1_i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
five CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
the DT N
same JJ N
dose NN N
of IN N
ergometrine NN 1_i
in IN N
four CD N
and CC N
four CD N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0039 CD N
vs. FW N
placebo NN 1_i
) ) 1_i
. . N

Nifedipine NNP 1_i
( ( N
10 CD N
mg NN N
) ) N
and CC N
nicorandil $ N
( ( N
30 CD N
mg NN N
) ) N
were VBD N
equally RB N
effective JJ N
in IN N
eight CD N
patients NNS N
; : N
in IN N
the DT N
remaining VBG N
five CD N
patients NNS N
, , N
nicorandil NNS 1_i
had VBD N
better JJR N
results NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Nicorandil NNP 1_i
( ( N
30 CD N
mg NN N
) ) N
prevents VBZ N
ergometrine-induced JJ 1_o
coronary JJ 1_o
spasm NN 1_o
. . 1_o

This DT N
compound NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS 1_p
with IN 1_p
vasospastic JJ 1_o
angina NN 1_o
. . 1_o

Effect NN N
of IN N
macronutrient JJ 1_i
composition NN N
of IN N
the DT N
diet NN N
on IN N
the DT N
regulation NN 1_o
of IN 1_o
lipolysis NN 1_o
in IN 1_o
adipose JJ 1_o
tissue NN 1_o
at IN N
rest NN N
and CC N
during IN N
exercise NN N
: : N
microdialysis NN N
study NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
elucidate VB N
, , N
using VBG N
a DT N
microdialysis NN N
technique NN N
, , N
whether IN N
modifications NNS N
in IN N
the DT N
proportion NN N
of IN N
fat NN 1_i
in IN 1_i
the DT 1_i
diet JJ 1_i
influence NN N
lipid JJ 1_o
mobilization NN 1_o
from IN N
adipose JJ N
tissue NN N
in IN N
situ NN N
. . N

Nine NNP 1_p
healthy JJ 1_p
volunteers NNS 1_p
( ( 1_p
age NN 1_p
, , 1_p
23.4 CD 1_p
+/- JJ 1_p
0.2 CD 1_p
years NNS 1_p
; : 1_p
body NN 1_p
mas VBZ 1_p
index NN 1_p
[ NNP 1_p
BMI NNP 1_p
] NNP 1_p
, , 1_p
23.5 CD 1_p
+/- JJ 1_p
1.6 CD 1_p
kg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
) ) 1_p
were VBD N
fed VBN N
, , N
in IN N
random JJ N
order NN N
, , N
with IN N
a DT N
high-fat JJ 1_i
diet NN 1_i
( ( 1_i
HFD NNP 1_i
) ) 1_i
( ( 1_i
65 CD 1_i
% NN 1_i
of IN 1_i
energy NN 1_i
content NN 1_i
fat NN 1_i
, , 1_i
15 CD 1_i
% NN 1_i
protein NN 1_i
, , 1_i
20 CD 1_i
% NN 1_i
carbohydrate NN 1_i
) ) 1_i
or CC 1_i
a DT 1_i
high-carbohydrate JJ 1_i
diet NN 1_i
( ( 1_i
HCD NNP 1_i
) ) 1_i
( ( 1_i
70 CD 1_i
% NN 1_i
carbohydrate NN 1_i
, , 1_i
15 CD 1_i
% NN 1_i
protein NN 1_i
, , 1_i
15 CD 1_i
% NN 1_i
fat NN 1_i
) ) 1_i
for IN 1_i
5 CD 1_i
days NNS 1_i
, , 1_i
with IN 1_i
a DT 1_i
washout JJ 1_i
period NN 1_i
of IN 1_i
10 CD 1_i
days NNS 1_i
between IN 1_i
the DT 1_i
diets NNS 1_i
. . 1_i

Subjects NNS N
were VBD N
studied VBN N
in IN N
the DT N
fasting NN N
state NN N
on IN N
the DT N
morning NN N
following VBG N
days NNS N
4 CD N
and CC N
5 CD N
of IN N
each DT N
diet NN N
. . N

We PRP N
measured VBD N
the DT N
concentration NN 1_o
of IN 1_o
extracellular JJ 1_o
glycerol NN 1_o
( ( 1_o
EGC NNP 1_o
) ) 1_o
in IN 1_o
adipose JJ 1_o
tissue NN 1_o
in IN N
response NN N
to TO N
( ( N
1 CD N
) ) N
pharmacologic NN N
stimulation NN N
with IN N
isoprenaline NN 1_i
( ( N
1 CD N
and CC N
10 CD N
micromol/L NN N
) ) N
in IN N
situ NN N
, , N
( ( N
2 CD N
) ) N
stimulation NN N
with IN N
intravenous JJ N
infusion NN N
of IN N
epinephrine NN 1_i
( ( N
0.0375 CD N
microg/min/kg NN N
body NN N
weight NN N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
submaximal NN N
aerobic JJ 1_i
exercise NN 1_i
( ( N
50 CD N
% NN N
V*O2max NNP N
, , N
60-minute JJ N
duration NN N
) ) N
. . N

No DT N
effect NN N
of IN N
the DT N
diet JJ 1_o
composition NN 1_o
was VBD N
found VBN N
in IN N
the DT N
increases NNS 1_o
of IN 1_o
EGC NNP 1_o
in IN N
response NN N
to TO N
isoprenaline VB N
( ( N
area NN N
under IN N
the DT N
curve NN N
[ NNP N
AUC NNP N
] NN N
: : N
HFD NNP N
, , N
1,534 CD N
+/- JJ N
370 CD N
micromol/90 NN N
min NN N
; : N
HCD NNP N
, , N
1,108 CD N
+/- JJ N
465 CD N
micromol/90 NN N
min NN N
; : N
not RB N
significant JJ N
[ NNP N
NS NNP N
] NNP N
) ) N
or CC N
epinephrine JJ 1_o
stimulations NNS 1_o
( ( N
AUC NNP N
: : N
HFD NNP N
, , N
190 CD N
+/- JJ N
92 CD N
micromol/30 NN N
min NN N
; : N
HCD NNP N
, , N
251 CD N
+/- JJ N
298 CD N
micromol/30 NN N
min NN N
; : N
NS NNP N
) ) N
. . N

The DT N
exercise-induced JJ 1_o
increase NN 1_o
in IN 1_o
EGC NNP 1_o
was VBD 1_o
higher RBR 1_o
during IN N
the DT N
HFD NNP N
( ( N
AUC NNP N
: : N
HFD NNP N
, , N
1,641 CD N
+/- JJ N
181 CD N
micromol/60 NN N
min NN N
; : N
HCD NNP N
, , N
963 CD N
+/- JJ N
156 CD N
micromol/60 NN N
min NN N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR 1_o
exercise-induced JJ 1_o
response NN 1_o
of IN N
norepinephrine NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
epinephrine NN N
( ( N
P NNP N
=.056 NNP N
) ) N
and CC N
lower JJR N
insulinemia NN 1_o
during IN N
exercise NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
macronutrient JJ N
composition NN N
of IN N
diet NN N
does VBZ N
not RB N
affect VB N
the DT N
beta-adrenergic JJ 1_o
responsiveness NN 1_o
of IN 1_o
adipose JJ 1_o
tissue NN 1_o
to TO N
catecholamine VB N
action NN N
at IN N
rest NN N
. . N

During IN N
exercise NN N
, , N
the DT N
HFD NNP 1_i
promotes VBZ N
higher JJR 1_o
lipolysis NN 1_o
in IN 1_o
adipose JJ 1_o
tissue NN 1_o
and CC N
this DT N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
catecholamine NN N
response NN N
and CC N
lower JJR N
insulinemia NN N
. . N

Effect NN N
of IN N
clinical JJ 1_i
pharmacy NN 1_i
services NNS 1_i
on IN N
the DT N
blood NN 1_o
pressure NN 1_o
of IN N
African-American JJ 1_p
renal JJ 1_p
transplant NN 1_p
patients NNS 1_p
. . 1_p

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
African-American JJ 1_p
renal JJ 1_p
transplant NN 1_p
patients NNS 1_p
who WP N
received VBD N
direct JJ N
patient NN N
care NN N
from IN N
a DT N
clinical JJ 1_i
pharmacist NN 1_i
had VBD N
better RBR N
blood NN 1_o
pressure NN 1_o
control NN 1_o
compared VBN N
to TO N
African-American JJ 1_p
renal JJ 1_p
transplant NN 1_p
patients NNS 1_p
who WP 1_p
did VBD 1_p
not RB 1_p
have VB 1_p
clinical JJ 1_p
pharmacy NN 1_p
services NNS 1_p
. . 1_p

METHODS NNP N
Renal NNP 1_p
transplant NN 1_p
patients NNS 1_p
were VBD N
prospectively RB N
randomized VBN N
into IN N
an DT N
intervention NN N
group NN N
or CC N
a DT N
control NN N
group NN N
. . N

Patients NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD 1_i
clinical JJ 1_i
pharmacy NN 1_i
services NNS 1_i
that WDT 1_i
included VBD 1_i
a DT 1_i
clinical JJ 1_i
pharmacist NN 1_i
performing VBG 1_i
patient JJ 1_i
medication NN 1_i
reviews NNS 1_i
, , 1_i
with IN 1_i
emphasis NN 1_i
on IN 1_i
preventing VBG 1_i
or CC 1_i
resolving VBG 1_i
medication-related JJ 1_i
problems NNS 1_i
and CC 1_i
providing VBG 1_i
medication NN 1_i
recommendations NNS 1_i
. . 1_i

Patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD 1_i
routine JJ 1_i
clinic NN 1_i
services NNS 1_i
, , 1_i
but CC 1_i
had VBD 1_i
no DT 1_i
clinical JJ 1_i
pharmacist NN 1_i
interaction NN 1_i
. . 1_i

Analysis NN N
was VBD N
performed VBN N
to TO N
detect VB N
differences NNS N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
in IN N
baseline NN 1_o
and CC 1_o
quarterly JJ 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
SBP NNP 1_o
) ) 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
DBP NNP 1_o
) ) 1_o
for IN N
one CD N
year NN N
post-study NN N
enrollment NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
intervention NN N
( ( 1_p
N NNP 1_p
= NNP 1_p
13 CD 1_p
) ) 1_p
and CC N
control NN N
( ( 1_p
N NNP 1_p
= NNP 1_p
10 CD 1_p
) ) 1_p
groups NNS N
in IN N
baseline NN N
blood NN 1_o
pressures NNS 1_o
or CC N
in IN N
the DT N
percentage NN N
of IN N
hypertensive JJ N
patients NNS N
. . N

Significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
SBP NNP 1_o
and CC 1_o
DBP NNP 1_o
from IN N
baseline NN N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
were VBD N
observed VBN N
at IN N
the DT N
second JJ N
, , N
third JJ N
, , N
and CC N
fourth JJ N
quarters NNS N
of IN N
the DT N
study NN N
, , N
favoring VBG N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Mean NNP 1_o
SBP NNP 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
at IN N
the DT N
second JJ N
( ( N
137.8 CD N
+/- JJ N
15.0 CD N
vs JJ N
168.9 CD N
+/- JJ N
15.3 CD N
) ) N
, , N
third JJ N
( ( N
135.9 CD N
+/- JJ N
11.7 CD N
vs JJ N
164.6 CD N
+/- JJ N
20.1 CD N
) ) N
, , N
and CC N
fourth JJ N
( ( N
145.3 CD N
+/- JJ N
16.8 CD N
vs JJ N
175.8 CD N
+/- JJ N
33.9 CD N
) ) N
quarters NNS N
of IN N
the DT N
study NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Mean NNP 1_o
DBP NNP 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
at IN N
the DT N
second JJ N
( ( N
76.0 CD N
+/- JJ N
11.8 CD N
vs JJ N
84.9 CD N
+/- JJ N
6.1 CD N
) ) N
and CC N
fourth JJ N
( ( N
77.0 CD N
+/- JJ N
10.2 CD N
vs JJ N
91.8 CD N
+/- JJ N
12.0 CD N
) ) N
quarters NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Direct NNP N
patient NN N
care NN N
services NNS N
provided VBN N
by IN N
a DT N
clinical JJ N
pharmacist NN N
, , N
in IN N
addition NN N
to TO N
routine VB N
clinical JJ N
services NNS N
, , N
have VBP N
a DT N
positive JJ N
effect NN N
on IN N
the DT N
blood NN 1_o
pressure NN 1_o
of IN N
African-American JJ 1_p
renal JJ 1_p
transplant NN 1_p
patients NNS 1_p
. . 1_p

A DT N
multidisciplinary JJ N
team NN N
that WDT N
includes VBZ N
a DT N
clinical JJ N
pharmacist NN N
is VBZ N
beneficial JJ N
to TO N
patient VB N
care NN N
. . N

Pharmacokinetic JJ N
and CC N
safety NN N
evaluation NN N
of IN N
high-dose JJ N
combinations NNS N
of IN N
fosamprenavir NN N
and CC N
ritonavir NN N
. . N

High-dose JJ N
combinations NNS N
of IN N
fosamprenavir NN 1_i
( ( 1_i
FPV NNP 1_i
) ) 1_i
and CC 1_i
ritonavir NN 1_i
( ( 1_i
RTV NNP 1_i
) ) 1_i
were VBD N
evaluated VBN N
in IN N
healthy JJ 1_p
adult NN 1_p
subjects NNS 1_p
in IN N
order NN N
to TO N
select VB N
doses NNS N
for IN N
further JJ N
study NN N
in IN N
multiple JJ 1_p
protease NN 1_p
inhibitor NN 1_p
( ( 1_p
PI NNP 1_p
) ) 1_p
-experienced VBD 1_p
patients NNS 1_p
infected VBN 1_p
with IN 1_p
human JJ 1_p
immunodeficiency NN 1_p
virus NN 1_p
type NN 1_p
1 CD 1_p
. . 1_p

Two CD N
high-dose JJ N
regimens NNS N
, , N
FPV NNP 1_i
1,400 CD N
mg NN N
twice RB N
a DT N
day NN N
( ( N
BID NNP N
) ) N
plus CC N
RTV $ 1_i
100 CD N
mg NN N
BID NNP N
and CC N
FPV NNP 1_i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP 1_i
200 CD N
mg NN N
BID NNP N
, , N
were VBD N
planned VBN N
to TO N
be VB N
compared VBN N
to TO N
the DT N
approved JJ N
regimen NNS N
, , N
FPV NNP 1_i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP 1_i
100 CD N
mg NN N
BID NNP N
, , N
in IN N
a DT N
randomized JJ N
three-period NN N
crossover NN N
study NN N
. . N

Forty-two NNP 1_p
healthy JJ 1_p
adult NN 1_p
subjects NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , N
and CC N
39 CD N
subjects NNS N
completed VBN N
period NN N
1 CD N
. . N

Due JJ N
to TO N
marked VB N
hepatic JJ N
transaminase NN N
elevations NNS N
, , N
predominantly RB N
with IN N
FPV NNP 1_i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP 1_i
200 CD N
mg NN N
BID NNP N
, , N
the DT N
study NN N
was VBD N
terminated VBN N
prematurely RB N
. . N

For IN N
FPV NNP 1_i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP 1_i
100 CD N
mg NN N
BID NNP N
, , N
the DT N
values NNS 1_o
for IN 1_o
plasma NN 1_o
amprenavir NN 1_o
( ( 1_o
APV NNP 1_o
) ) 1_o
area NN 1_o
under IN 1_o
the DT 1_o
concentration-time JJ 1_o
profile NN 1_o
over IN 1_o
the DT 1_o
dosing VBG 1_o
interval NN 1_o
( ( 1_o
tau NN 1_o
) ) 1_o
at IN 1_o
steady JJ 1_o
state NN 1_o
[ NNS N
AUC NNP N
( ( N
0-tau JJ N
) ) N
] NN N
, , N
maximum JJ 1_o
concentration NN 1_o
of IN 1_o
drug NN 1_o
in IN 1_o
plasma NN 1_o
( ( 1_o
C NNP 1_o
( ( 1_o
max NN 1_o
) ) 1_o
) ) 1_o
, , 1_o
and CC 1_o
plasma JJ 1_o
concentration NN 1_o
at IN 1_o
the DT 1_o
end NN 1_o
of IN 1_o
tau NN 1_o
at IN 1_o
steady JJ 1_o
state NN 1_o
( ( 1_o
C NNP 1_o
( ( 1_o
tau NN 1_o
) ) 1_o
) ) 1_o
were VBD N
54 CD N
, , N
81 CD N
, , N
and CC N
26 CD N
% NN N
higher JJR N
, , N
respectively RB N
, , N
and CC N
the DT N
values NNS 1_o
for IN 1_o
plasma NN 1_o
RTV NNP 1_o
AUC NNP 1_o
( ( 1_o
0-tau JJ 1_o
) ) 1_o
, , 1_o
C NNP 1_o
( ( 1_o
max NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
C NNP 1_o
( ( 1_o
tau NN 1_o
) ) 1_o
were VBD N
49 CD N
% NN N
higher JJR N
, , N
71 CD N
% NN N
higher JJR N
, , N
and CC N
11 CD N
% NN N
lower JJR N
, , N
respectively RB N
, , N
than IN N
those DT N
for IN N
FPV NNP 1_i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP N
100 CD N
mg NN N
BID NNP N
. . N

For IN N
FPV NNP 1_i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP N
200 CD N
mg NN N
BID NNP N
, , N
the DT N
values NNS 1_o
for IN 1_o
plasma NN 1_o
APV NNP 1_o
AUC NNP 1_o
( ( 1_o
0-tau JJ 1_o
) ) 1_o
, , 1_o
C NNP 1_o
( ( 1_o
max NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
C NNP 1_o
( ( 1_o
tau NN 1_o
) ) 1_o
were VBD N
26 CD N
, , N
48 CD N
, , N
and CC N
32 CD N
% NN N
higher JJR N
, , N
respectively RB N
, , N
and CC N
the DT N
values NNS N
for IN N
plasma NN 1_o
RTV NNP 1_o
AUC NNP 1_o
( ( 1_o
0-tau JJ 1_o
) ) 1_o
, , 1_o
C NNP 1_o
( ( 1_o
max NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
C NNP 1_o
( ( 1_o
tau NN 1_o
) ) 1_o
increased VBD N
4.15-fold JJ N
, , N
4.17-fold JJ N
, , N
and CC N
3.99-fold JJ N
, , N
respectively RB N
, , N
compared VBN N
to TO N
those DT N
for IN N
FPV NNP 1_i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP 1_i
100 CD N
mg NN N
BID NNP N
. . N

FPV NNP 1_i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP 1_i
200 CD N
mg NN N
BID NNP N
is VBZ N
not RB N
recommended VBN N
due JJ N
to TO N
an DT N
increased VBN N
rate NN 1_o
of IN 1_o
marked VBN 1_o
hepatic JJ 1_o
transaminase NN 1_o
elevations NNS 1_o
and CC N
lack NN 1_o
of IN 1_o
pharmacokinetic JJ 1_o
advantage NN 1_o
. . 1_o

FPV NNP 1_i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP 1_i
100 CD N
mg NN N
BID NNP N
is VBZ N
currently RB N
under IN N
clinical JJ N
evaluation NN N
in IN N
multiple JJ N
PI-experienced JJ N
patients NNS N
. . N

The DT N
effects NNS N
of IN N
haloperidol NN 1_i
on IN N
discrimination NN 1_o
learning NN 1_o
and CC 1_o
behavioral JJ 1_o
symptoms NNS 1_o
in IN N
autistic JJ 1_p
children NNS 1_p
. . 1_p

This DT N
double-blind JJ N
and CC N
placebo-controlled JJ 1_i
clinical JJ N
trial NN N
in IN N
autistic JJ 1_p
children NNS 1_p
had VBD N
three CD N
objectives NNS N
: : N
( ( N
a DT N
) ) N
to TO N
replicate VB N
earlier JJR N
findings NNS N
that IN N
haloperidol JJ 1_i
administration NN N
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
of IN N
behavioral JJ 1_o
symptoms NNS 1_o
; : 1_o
( ( N
b NN N
) ) N
to TO N
further JJ N
assess NN N
its PRP$ N
safety NN 1_o
when WRB N
given VBN N
on IN N
a DT N
short-term JJ N
basis NN N
; : N
and CC N
( ( N
c NN N
) ) N
to TO N
assess VB N
whether IN N
it PRP N
has VBZ N
an DT N
effect NN 1_o
on IN 1_o
discrimination NN 1_o
learning NN 1_o
. . 1_o

Forty-five JJ 1_p
children NNS 1_p
, , 1_p
2.02 CD 1_p
to TO 1_p
7.58 CD 1_p
years NNS 1_p
old JJ 1_p
( ( 1_p
M NNP 1_p
= NNP 1_p
4.49 CD 1_p
) ) 1_p
, , N
completed VBD N
this DT N
crossover NN N
design NN N
, , N
with IN N
random JJ N
assignment NN N
to TO N
treatment NN N
sequences NNS N
. . N

Haloperidol NNP 1_i
was VBD N
shown VBN N
to TO N
be VB N
a DT N
powerful JJ N
therapeutic JJ N
agent NN N
when WRB N
administered VBN N
for IN N
4 CD N
weeks NNS N
and CC N
free JJ N
of IN N
side JJ 1_o
effects NNS 1_o
; : 1_o
at IN N
doses NNS N
ranging VBG N
from IN N
0.25 CD N
to TO N
4.0 CD N
mg/day NN N
( ( N
M NNP N
= NNP N
0.844 CD N
) ) N
, , N
there EX N
was VBD N
a DT N
clinically RB N
and CC N
statistically RB N
significant JJ N
reduction NN N
of IN N
a DT N
variety NN 1_o
of IN 1_o
symptoms NNS 1_o
. . 1_o

Under IN N
the DT N
given VBN N
conditions NNS N
, , N
the DT N
children NNS N
failed VBD N
to TO N
learn VB N
on IN N
either DT N
haloperidol NN 1_i
or CC N
placebo NN 1_i
. . 1_i

Bronchodilator NNP 1_i
treatment NN 1_i
in IN N
asthma NN 1_p
and CC 1_p
bronchitis NN 1_p
. . 1_p

Effects NNS N
of IN N
an DT N
Internet-based JJ 1_i
intervention NN 1_i
on IN N
plasma NNS 1_o
glucose JJ 1_o
levels NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
. . 1_p

This DT N
study NN N
applied VBD N
a DT N
12-week JJ 1_i
educational JJ 1_i
intervention NN 1_i
that WDT N
used VBD N
both DT 1_i
the DT 1_i
cellular JJ 1_i
phone NN 1_i
and CC 1_i
the DT 1_i
Internet NNP 1_i
to TO 1_i
send VB 1_i
short JJ 1_i
message NN 1_i
service NN 1_i
. . 1_i

Forty-two NNP 1_p
diabetic JJ 1_p
patients NNS 1_p
were VBD N
asked VBN N
to TO N
access NN 1_i
a DT 1_i
Web NNP 1_i
site NN 1_i
by IN 1_i
using VBG 1_i
a DT 1_i
cellular JJ 1_i
phone NN 1_i
or CC 1_i
wire NN 1_i
Internet NNP 1_i
and CC 1_i
input VB 1_i
their PRP$ 1_i
blood NN 1_o
glucose NN 1_o
levels NNS 1_o
every DT 1_i
day NN 1_i
. . 1_i

Patients NNS N
were VBD N
sent VBN N
the DT N
optimal JJ 1_i
recommendations NNS 1_i
by IN N
both DT N
the DT N
cellular JJ N
phone NN N
and CC N
the DT N
Internet NNP N
. . N

After IN N
12 CD N
weeks NNS N
, , N
the DT N
patients NNS N
had VBD N
a DT N
mean JJ N
decrease NN N
of IN N
28.6 CD N
mg/dL NNS N
in IN N
fasting VBG 1_o
plasma NN 1_o
glucose NN 1_o
and CC N
78.4 CD N
mg/dL NN N
in IN N
2-hour JJ 1_o
postprandial JJ 1_o
blood NN 1_o
sugar NN 1_o
levels NNS 1_o
and CC N
a DT N
mean JJ N
increase NN N
in IN N
the DT N
care NN 1_o
satisfaction NN 1_o
score NN 1_o
. . 1_o

Use NNP N
of IN N
granulocyte-macrophage JJ 1_i
colony-stimulating JJ 1_i
factor NN 1_i
and CC N
erythropoietin NN 1_i
in IN N
combination NN N
after IN 1_p
autologous JJ 1_i
marrow NN 1_i
transplantation NN 1_i
. . 1_i

The DT N
toxicities NNS N
and CC N
possible JJ N
utility NN N
of IN N
the DT N
combination NN 1_i
of IN 1_i
recombinant JJ 1_i
human JJ 1_i
granulocyte-macrophage NN 1_i
colony-stimulating NN 1_i
factor NN 1_i
( ( 1_i
rhGM-CSF NN 1_i
) ) 1_i
and CC 1_i
recombinant JJ 1_i
human JJ 1_i
erythropoietin NN 1_i
( ( 1_i
rHuEPO NN 1_i
) ) 1_i
given VBN N
after IN N
autologous JJ 1_i
BMT NNP 1_i
were VBD N
evaluated VBN N
in IN N
this DT N
pilot NN N
trial NN N
. . N

Eighteen JJ 1_p
patients NNS 1_p
received VBD N
the DT N
combination NN N
and CC N
were VBD N
compared VBN N
with IN N
six CD 1_i
concurrent NN 1_i
control NN 1_i
and CC 1_i
65 CD 1_i
historical JJ 1_i
control NN 1_i
patients NNS 1_i
treated VBN 1_i
with IN 1_i
rhGM-CSF JJ 1_i
alone NN 1_i
. . 1_i

Patients NNS N
treated VBD N
with IN N
the DT N
combination NN N
tended VBD N
to TO N
have VB N
more RBR N
rapid JJ N
recovery NN 1_o
to TO N
an DT N
absolute JJ 1_o
neutrophil NN 1_o
count NN 1_o
of IN N
500 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/l NN N
( ( N
median JJ N
= NN N
12.5 CD N
vs NN N
18 CD N
days NNS N
for IN N
concurrent NN N
and CC N
19 CD N
days NNS N
for IN N
historical JJ N
control NN N
patients NNS N
) ) N
. . N

There EX N
was VBD N
no DT N
apparent JJ N
impact NN N
on IN N
red JJ 1_o
cell NN 1_o
transfusion NN 1_o
requirements NNS 1_o
, , 1_o
platelet JJ 1_o
recovery NN 1_o
or CC 1_o
duration NN 1_o
of IN 1_o
hospitalization NN 1_o
. . 1_o

Patients NNS N
treated VBD N
in IN N
the DT N
current JJ N
study NN N
with IN N
rhGM-CSF JJ N
plus CC N
either CC N
rHuEPO NN N
or CC N
with IN N
placebo NN N
had VBD N
a DT N
higher JJR N
incidence NN 1_o
of IN 1_o
rash NN 1_o
than IN N
seen VBN N
in IN N
our PRP$ N
historical JJ N
experience NN N
using VBG N
rhGM-CSF NN N
. . N

This DT N
difference NN N
may MD N
reflect VB N
changes NNS N
in IN N
the DT N
source NN N
of IN N
rhGM-CSF NN N
or CC N
in IN N
the DT N
infusion NN N
schedule NN N
. . N

Erythropoietin NN N
can MD N
be VB N
combined VBN N
safely RB N
with IN N
rhGM-CSF NN N
after IN N
autologous JJ N
transplantation NN N
. . N

Larger NNP N
controlled VBD N
trials NNS N
will MD N
be VB N
necessary JJ N
to TO N
detect VB N
possible JJ N
therapeutic JJ N
effects NNS N
. . N

A DT N
comparative JJ N
study NN N
of IN N
ofloxacin NN 1_i
and CC N
amoxycillin/clavulanate NN 1_i
in IN N
hospitalized JJ 1_p
patients NNS 1_p
with IN 1_p
lower JJR 1_o
respiratory NN 1_o
tract JJ 1_o
infections NNS 1_o
. . 1_o

We PRP N
conducted VBD N
an DT N
open JJ N
randomized VBN N
trial NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
parenteral JJ N
and CC N
oral JJ N
ofloxacin NN 1_i
with IN N
that DT N
of IN N
amoxycillin/clavulanate NN 1_i
. . 1_i

A DT N
total NN N
of IN N
121 CD 1_p
patients NNS 1_p
was VBD 1_p
studied VBN 1_p
; : 1_p
92 CD 1_p
were VBD 1_p
clinically RB 1_p
evaluable JJ 1_p
. . 1_p

Of IN N
these DT N
, , N
59 CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
ofloxacin NN 1_i
and CC 1_p
33 CD 1_p
with IN 1_p
the DT 1_p
comparator NN 1_p
drug NN 1_p
. . 1_p

Patients NNS N
were VBD N
given VBN N
the DT N
drugs NNS N
intravenously RB N
for IN N
a DT N
minimum NN N
of IN N
three CD N
days NNS N
followed VBN N
by IN N
oral JJ N
preparations NNS N
for IN N
the DT N
next JJ N
seven CD N
to TO N
ten VB N
days NNS N
. . N

Ofloxacin NNP 1_i
was VBD N
usually RB N
administered VBN N
as IN N
a DT N
200 CD N
mg NN N
dose NN N
bd NN N
. . N

In IN N
the DT N
ofloxacin NN 1_i
treated VBN N
group NN N
all DT N
patients NNS N
showed VBD N
clinical JJ 1_o
improvement NN 1_o
. . 1_o

In IN N
the DT N
comparator NN N
group NN N
94 CD N
% NN N
improved VBN N
clinically RB N
( ( N
either CC N
a DT N
complete JJ N
or CC N
partial JJ N
response NN N
) ) N
, , N
while IN N
6 CD N
% NN N
were VBD N
clinical JJ N
failures NNS N
. . N

Of IN N
the DT N
bacteriologically RB N
evaluable JJ N
patients NNS N
19 CD N
of IN N
20 CD N
showed VBD N
a DT N
satisfactory JJ 1_o
bacteriological JJ 1_o
response NN 1_o
in IN N
the DT N
ofloxacin NN N
treated VBD N
group NN N
, , N
while IN N
in IN N
the DT N
comparator NN N
group NN N
the DT N
bacteriological JJ N
response NN N
was VBD N
judged VBN N
satisfactory NN N
in IN N
14 CD N
of IN N
17 CD N
patients NNS N
. . N

A DT N
small JJ N
proportion NN N
of IN N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
treated VBD N
with IN N
ofloxacin NN 1_i
suffered VBD N
mild JJ 1_o
adverse JJ 1_o
effects NNS 1_o
( ( 1_o
nausea NN 1_o
, , 1_o
vomiting VBG 1_o
, , 1_o
headache NN 1_o
, , 1_o
hypotension NN 1_o
and CC 1_o
rash NN 1_o
) ) 1_o
. . 1_o

On IN N
the DT N
whole NN N
, , N
ofloxacin NN N
was VBD N
well RB N
tolerated VBN 1_o
by IN N
our PRP$ N
patients NNS N
. . N

The DT N
two CD N
deaths NNS 1_o
that IN N
occurred VBD N
were VBD N
in IN N
the DT N
comparator NN N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
ofloxacin NN 1_i
in IN N
both DT N
oral JJ N
and CC N
parenteral JJ N
forms NNS N
is VBZ N
an DT N
effective JJ 1_o
and CC 1_o
safe JJ 1_o
drug NN N
in IN N
the DT N
treatment NN N
of IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

Endoscopic NNP 1_i
sphincterotomy NN 1_i
by IN N
using VBG N
pure-cut JJ 1_i
electrosurgical JJ 1_i
current JJ 1_i
and CC N
the DT N
risk NN N
of IN N
post-ERCP JJ 1_p
pancreatitis NN 1_p
: : 1_p
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND VB N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
pure-cut JJ N
electrosurgical JJ N
current JJ N
for IN N
endoscopic JJ N
sphincterotomy NN 1_i
may MD N
reduce VB N
the DT N
risk NN N
of IN N
post-ERCP JJ 1_p
pancreatitis NN 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
pure-cut JJ 1_i
current JJ 1_i
reduces VBZ N
the DT N
risk NN N
of IN N
pancreatitis NN 1_o
compared VBN N
with IN N
blend JJ N
current JJ N
. . N

METHODS NN N
Patients NNPS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
sphincterotomy NN 1_i
over IN 1_i
a DT 1_i
non-conductive JJ 1_i
guidewire NN 1_i
with IN 1_i
30 CD 1_i
W/sec NNP 1_i
pure-cut JJ 1_i
current JJ 1_i
or CC 1_i
30 CD 1_i
W/sec JJ 1_i
blend-2 JJ 1_i
current JJ 1_i
by IN 1_i
a DT 1_i
blinded JJ 1_i
endoscopist NN 1_i
. . 1_i

Serum NNP N
amylase NN N
and CC N
lipase NN N
levels NNS N
were VBD N
determined VBN N
1 CD N
day NN N
before IN N
and CC N
within IN N
24 CD N
hours NNS N
after IN N
ERCP NNP N
. . N

Post-ERCP NNP 1_o
pancreatitis NN 1_o
was VBD N
the DT N
primary JJ N
outcome NN N
of IN N
interest NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
as IN N
follows VBZ N
: : N
severity NN 1_o
of IN 1_o
immediate JJ 1_o
bleeding NN 1_o
, , 1_o
as IN 1_o
graded VBN 1_o
by IN 1_o
a DT 1_o
3-point JJ 1_o
scale NN 1_o
from IN 1_o
1 CD 1_o
( ( 1_o
no DT 1_o
bleeding NN 1_o
) ) 1_o
to TO 1_o
3 CD 1_o
( ( 1_o
injection NN 1_o
or CC 1_o
balloon NN 1_o
tamponade JJ 1_o
therapy NN 1_o
required VBN 1_o
to TO 1_o
stop VB 1_o
bleeding NN 1_o
) ) 1_o
and CC 1_o
evidence NN 1_o
of IN 1_o
delayed JJ 1_o
bleeding VBG 1_o
24 CD 1_o
hours NNS 1_o
after IN 1_o
ERCP NNP 1_o
. . 1_o

Analyses NNS N
were VBD N
performed VBN N
in IN N
intention-to-treat JJ N
fashion NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
246 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
( ( 1_p
116 CD 1_p
pure-cut JJ 1_p
current JJ 1_p
, , 1_p
130 CD 1_p
blend NN 1_p
current JJ 1_p
) ) 1_p
. . 1_p

There EX N
were VBD N
no DT N
differences NNS N
in IN N
baseline NN N
characteristics NNS N
between IN N
the DT N
groups NNS N
. . N

The DT N
overall JJ N
frequency NN N
of IN N
post-ERCP JJ 1_o
pancreatitis NN 1_o
was VBD N
6.9 CD N
% NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
in IN N
frequency NN N
between IN N
treatment NN N
arms NNS N
( ( N
pure JJ N
cut NN N
, , N
7.8 CD N
% NN N
vs. FW N
blend NN N
, , N
6.1 CD N
% NN N
; : N
p CC N
= VB N
0.62 CD N
) ) N
. . N

The DT N
difference NN N
in IN N
rates NNS N
of IN N
pancreatitis NN 1_o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
1.7 CD N
% NN N
: : N
95 CD N
% NN N
CI NNP N
[ NNP N
-4.8 NNP N
% NN N
, , N
8.2 CD N
% NN N
] NN N
. . N

Six CD N
patients NNS N
( ( N
2.4 CD N
% NN N
) ) N
had VBD N
delayed VBN 1_o
bleeding NN 1_o
after IN N
ERCP NNP N
, , N
of IN N
which WDT N
two CD N
required VBD N
transfusion NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
minor JJ 1_o
bleeding NN 1_o
episodes NNS 1_o
( ( N
grade VB N
2 CD N
) ) N
in IN N
the DT N
pure-cut JJ N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Delayed NNP 1_o
episodes IN 1_o
of IN 1_o
bleeding VBG 1_o
were VBD N
equal JJ N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
in IN N
each DT N
arm NN N
. . N

CONCLUSIONS VB N
The DT N
type NN N
of IN N
current JJ 1_i
used VBN N
when WRB N
performing VBG N
endoscopic RB 1_i
sphincterotomy NN 1_i
does VBZ N
not RB N
appear VB N
to TO N
alter VB N
the DT N
risk NN N
of IN N
post-ERCP JJ N
pancreatitis NN N
. . N

The DT N
selection NN N
of IN N
electrosurgical JJ 1_i
current JJ 1_i
for IN N
biliary JJ N
endoscopic NN 1_i
sphincterotomy NN 1_i
should MD N
be VB N
based VBN N
on IN N
endoscopist JJ N
preference NN N
. . N

Psychological JJ 1_i
adjustment NN 1_i
and CC 1_i
levels NNS 1_i
of IN 1_i
self NN 1_i
esteem NN 1_i
in IN N
children NNS 1_p
with IN 1_p
visual-motor JJ 1_p
integration NN 1_p
difficulties NNS 1_p
influences VBZ N
the DT N
results NNS N
of IN N
a DT N
randomized VBN N
intervention NN N
trial NN N
. . N

This DT N
study NN N
evaluates VBZ N
how WRB N
much JJ N
the DT N
effects NNS N
of IN N
intervention NN N
programs NNS N
are VBP N
influenced VBN N
by IN N
pre-existing JJ 1_p
psychological JJ 1_p
adjustment NN 1_p
and CC 1_p
self-esteem JJ 1_p
levels NNS 1_p
in IN 1_p
kindergarten NN 1_p
and CC 1_p
first JJ 1_p
grade NN 1_p
children NNS 1_p
with IN 1_p
poor JJ 1_p
visual-motor JJ 1_p
integration NN 1_p
skills NNS 1_p
, , 1_p
from IN 1_p
low JJ 1_p
socioeconomic JJ 1_p
backgrounds NNS 1_p
. . 1_p

One CD 1_p
hundred CD 1_p
and CC 1_p
sixteen JJ 1_p
mainstream NN 1_p
kindergarten NN 1_p
and CC 1_p
first-grade JJ 1_p
children NNS 1_p
, , 1_p
from IN 1_p
low JJ 1_p
socioeconomic JJ 1_p
backgrounds NNS 1_p
, , 1_p
scoring VBG 1_p
below IN 1_p
the DT 1_p
25th CD 1_p
percentile NN 1_p
on IN 1_p
a DT 1_p
measure NN 1_p
of IN 1_p
visual-motor NN 1_p
integration NN 1_p
( ( 1_p
VMI NNP 1_p
) ) 1_p
were VBD 1_p
recruited VBN 1_p
and CC N
randomly RB N
divided VBN N
into IN N
two CD N
parallel JJ N
intervention NN N
groups NNS N
. . N

One CD N
intervention NN N
group NN N
received VBD N
directive JJ 1_i
visual-motor NN 1_i
intervention NN 1_i
( ( 1_i
DVMI NNP 1_i
) ) 1_i
, , N
while IN N
the DT N
second JJ N
intervention NN N
group NN N
received VBD N
a DT N
non-directive JJ 1_i
supportive JJ 1_i
intervention NN 1_i
( ( 1_i
NDSI NNP 1_i
) ) 1_i
. . 1_i

Tests NNS N
were VBD N
administered VBN N
to TO N
evaluate VB N
visual-motor JJ N
integration NN N
skills VBZ N
outcome NN N
. . N

Children NNP N
with IN N
higher JJR N
baseline NN N
measures NNS N
of IN N
psychological JJ N
adjustment NN N
and CC N
self-esteem NN N
responded VBD N
better RBR N
in IN N
NDSI NNP 1_i
while IN N
children NNS N
with IN N
lower JJR N
baseline NN N
performance NN N
on IN N
psychological JJ N
adjustment NN N
and CC N
self-esteem NN N
responded VBD N
better RBR N
in IN N
DVMI NNP 1_i
. . 1_i

This DT N
study NN N
suggests VBZ N
that IN N
children NNS N
from IN N
low JJ N
socioeconomic JJ N
backgrounds NNS N
with IN N
low JJ N
VMI NNP N
performance NN N
scores NNS N
will MD N
benefit VB N
more RBR N
from IN N
intervention NN N
programs NNS N
if IN N
clinicians NNS N
choose VBP N
the DT N
type NN N
of IN N
intervention NN N
according VBG N
to TO N
baseline VB N
psychological JJ N
adjustment NN N
and CC N
self-esteem JJ N
measures NNS N
. . N

A DT N
Comparison NNP N
of IN N
Outcomes NNP N
Following NNP N
Laparoscopic NNP 1_i
and CC 1_i
Open NNP 1_i
Hysterectomy NNP 1_i
With IN N
or CC N
Without IN N
Lymphadenectomy NNP N
for IN N
Presumed NNP 1_p
Early-Stage NNP 1_p
Endometrial NNP 1_p
Cancer NNP 1_p
: : 1_p
Results NNS N
From IN N
the DT N
Medical NNP N
Research NNP N
Council NNP N
ASTEC NNP N
Trial NNP N
. . N

OBJECTIVES NNP N
Laparoscopic NNP 1_i
hysterectomy NN 1_i
( ( 1_i
LH NNP 1_i
) ) 1_i
is VBZ N
increasingly RB N
used VBN N
for IN N
the DT N
management NN N
of IN N
endometrial JJ N
malignancy NN N
. . N

Its PRP$ N
benefits NNS N
may MD N
be VB N
particularly RB N
pronounced VBN N
as IN N
these DT N
women NNS 1_p
are VBP 1_p
more RBR 1_p
likely JJ 1_p
to TO 1_p
be VB 1_p
older JJR 1_p
or CC 1_p
obese JJ 1_p
. . 1_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
outcomes NNS N
for IN N
LH NNP N
are VBP N
comparable JJ N
to TO N
the DT N
open JJ N
hysterectomy NN N
( ( N
OH NNP N
) ) N
. . N

DESIGN NN N
This DT N
was VBD N
a DT N
prospective JJ N
cohort NN N
study NN N
nested VBD N
within IN N
the DT N
multicenter NN N
ASTEC NNP N
( ( N
A NNP N
Study NNP N
in IN N
the DT N
Treatment NNP N
of IN N
Endometrial NNP N
Cancer NNP N
) ) N
randomized VBD N
controlled VBN N
trial NN N
( ( N
1998-2005 JJ N
) ) N
. . N

POPULATION NNP N
Women NNP 1_p
with IN 1_p
presumed JJ 1_p
early JJ 1_p
endometrial JJ 1_p
cancer NN 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

METHODS NNP N
Laparoscopic NNP 1_i
hysterectomy NN 1_i
was VBD N
compared VBN N
with IN N
OH NNP 1_i
with IN 1_i
or CC 1_i
without IN 1_i
systematic JJ 1_i
lymphadenectomy NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Overall NNP 1_o
survival NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
first JJ 1_o
recurrence NN 1_o
, , 1_o
complication NN 1_o
rates NNS 1_o
, , 1_o
and CC 1_o
surgical JJ 1_o
outcomes NNS 1_o
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
Of IN N
1408 CD 1_p
women NNS 1_p
, , 1_p
1309 CD 1_p
( ( 1_p
93 CD 1_p
% NN 1_p
) ) 1_p
received VBD 1_p
OH NNP 1_p
, , N
and CC N
99 CD 1_p
( ( 1_p
7 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
LH NNP 1_p
. . 1_p

LH NNP N
was VBD N
associated VBN N
with IN N
longer RBR N
operating VBG 1_o
time NN 1_o
( ( N
median JJ N
, , N
LH NNP 1_i
105 CD N
minutes NNS N
[ VBP N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
, , N
60-150 JJ N
] NNP N
vs NN N
OH NNP 1_i
80 CD N
minutes NNS N
[ JJ N
IQR NNP N
, , N
60-95 JJ N
] NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
50 CD N
% NN N
shorter JJR N
hospital NN 1_o
stay NN 1_o
( ( N
median JJ N
, , N
LH NNP N
4 CD N
days NNS N
[ NNP N
IQR NNP N
, , N
3-5 JJ N
] NNP N
vs NN N
OH NNP 1_i
6 CD N
days NNS N
[ NNP N
IQR NNP N
, , N
5-7 JJ N
] NN N
) ) N
. . N

The DT N
number NN 1_o
of IN 1_o
harvested JJ 1_o
lymph NN 1_o
nodes NNS 1_o
was VBD N
similar JJ N
( ( N
median JJ N
, , N
LH NNP 1_i
13 CD N
[ NNP N
IQR NNP N
, , N
10-16 JJ N
] NNP N
vs NN N
OH NNP 1_i
12 CD N
[ NNP N
IQR NNP N
, , N
11-13 JJ N
] NN N
; : N
P NNP N
= NNP N
0.67 CD N
) ) N
. . N

LH NNP 1_i
had VBD N
fewer JJR N
intraoperative JJ 1_o
and CC 1_o
postoperative JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( N
9 CD N
% NN N
difference NN N
, , N
LH NNP N
21 CD N
% NN N
vs NN N
OH NNP N
30 CD N
% NN N
; : N
borderline JJ N
significance NN N
; : N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

The DT N
rate NN 1_o
of IN 1_o
conversion NN 1_o
to TO 1_o
laparotomy VB 1_o
for IN N
the DT N
LH NNP 1_i
group NN N
was VBD N
high JJ N
( ( N
27 CD N
% NN N
) ) N
. . N

The DT N
median JJ N
follow-up NN N
was VBD N
37 CD N
months NNS N
. . N

After IN N
adjusting VBG N
for IN N
significant JJ N
prognostic JJ N
factors NNS N
, , N
the DT N
hazard NN 1_o
ratio NN 1_o
for IN 1_o
overall JJ 1_o
survival NN 1_o
in IN N
those DT N
who WP N
underwent VBP N
LH NNP 1_i
compared VBN N
with IN N
those DT N
who WP N
underwent VBP N
OH NNP 1_i
was VBD N
0.67 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.31-1.43 NN N
) ) N
( ( N
P NNP N
= NNP N
0.30 CD N
) ) N
. . N

CONCLUSIONS NNP N
Laparoscopic NNP 1_i
hysterectomy NN 1_i
for IN N
early JJ N
endometrial JJ N
cancer NN N
is VBZ N
safe JJ N
. . N

Although IN N
it PRP N
requires VBZ N
longer JJR N
operating VBG 1_o
time NN 1_o
it PRP N
is VBZ N
associated VBN N
with IN N
shorter JJR N
hospital NN 1_o
stay NN 1_o
and CC N
favorable JJ N
morbidity NN 1_o
profile NN 1_o
. . 1_o

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
assess VB N
the DT N
long-term JJ 1_o
safety NN 1_o
. . 1_o

Psychophysiological JJ 1_o
outcome NN N
of IN N
behavioral JJ 1_i
and CC 1_i
pharmacological JJ 1_i
treatments NNS 1_i
of IN 1_i
agoraphobia NN 1_i
. . 1_i

Playing VBG N
on IN N
the DT N
typewriter NN N
, , N
typing VBG N
on IN N
the DT N
piano NN N
: : N
manipulation NN N
knowledge NN N
of IN N
objects NNS N
. . N

Two CD N
experiments NNS N
investigated VBD N
sensory/motor-based JJ 1_o
functional JJ 1_o
knowledge NN 1_o
of IN 1_p
man-made JJ 1_p
objects NNS 1_p
: : 1_p
manipulation NN N
features NNS N
associated VBN N
with IN N
the DT N
actual JJ N
usage NN N
of IN N
objects NNS N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
a DT N
series NN N
of IN N
prime-target JJ N
pairs NNS N
was VBD N
presented VBN N
auditorily RB N
, , N
and CC N
participants NNS 1_p
were VBD N
asked VBN N
to TO N
make VB N
a DT N
lexical JJ 1_i
decision NN 1_i
on IN N
the DT N
target NN N
word NN N
. . N

Participants NNS 1_p
made VBD N
a DT N
significantly RB N
faster JJR N
decision NN 1_o
about IN N
the DT N
target NN 1_i
word NN 1_i
( ( N
e.g NN N
. . N

'typewriter CC N
' POS N
) ) N
following VBG N
a DT N
related JJ N
prime NN N
that WDT N
shared VBD N
manipulation NN N
features NNS N
with IN N
the DT N
target NN N
( ( N
e.g JJ N
. . N

'piano CC N
' POS N
) ) N
than IN N
an DT N
unrelated JJ N
prime NN N
( ( N
e.g NN N
. . N

'blanket CC N
' POS N
) ) N
. . N

In IN N
Experiment JJ N
2 CD N
, , N
participants NNS 1_p
' POS 1_p
eye NN N
movements NNS N
were VBD N
monitored VBN N
when WRB N
they PRP N
viewed VBD N
a DT N
visual JJ 1_i
display NN 1_i
on IN 1_i
a DT 1_i
computer NN 1_i
screen NN 1_i
while IN 1_i
listening VBG 1_i
to TO 1_i
a DT 1_i
concurrent JJ 1_i
auditory NN 1_i
input NN 1_i
. . 1_i

Participants NNS 1_p
were VBD N
instructed VBN N
to TO N
simply RB N
identify VB N
the DT N
auditory NN N
input NN N
and CC N
touch VB N
the DT N
corresponding JJ N
object NN N
on IN N
the DT N
computer NN N
display NN N
. . N

Participants NNS 1_p
fixated VBD 1_o
an DT N
object JJ N
picture NN N
( ( N
e.g JJ N
. . N

" JJ N
typewriter NN N
" NN N
) ) N
related VBN N
to TO N
a DT N
target NN N
word NN N
( ( N
e.g NN N
. . N

'piano CC N
' POS N
) ) N
significantly RB N
more RBR N
often RB N
than IN N
an DT N
unrelated JJ N
object JJ N
picture NN N
( ( N
e.g JJ N
. . N

" JJ N
bucket NN N
" NN N
) ) N
as RB N
well RB N
as IN N
a DT N
visually RB N
matched VBN N
control NN N
( ( N
e.g JJ N
. . N

" VB N
couch JJ N
" NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
two CD N
experiments NNS N
suggest VBP N
that IN N
manipulation NN 1_o
knowledge NN 1_o
of IN 1_o
words NNS 1_o
is VBZ N
retrieved VBN N
without IN N
conscious JJ N
effort NN N
and CC N
that DT N
manipulation NN 1_o
knowledge NN 1_o
constitutes VBZ N
a DT N
part NN N
of IN N
the DT N
lexical-semantic JJ N
representation NN N
of IN N
objects NNS N
. . N

Low JJ 1_i
intensity NN 1_i
physical JJ 1_i
training NN 1_i
in IN N
older JJR 1_p
subjects NNS 1_p
. . 1_p

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
low JJ 1_i
intensity NN 1_i
general JJ 1_i
training NN 1_i
program NN 1_i
( ( N
< JJ N
50 CD N
% NN N
of IN N
heart NN N
rate NN N
reserve NN N
) ) N
on IN N
physical JJ N
fitness NN N
of IN N
healthy JJ 1_p
older JJR 1_p
subjects NNS 1_p
, , N
by IN N
comparing VBG N
maximal JJ N
and CC N
submaximal JJ N
indices NNS N
of IN N
training NN N
response NN N
. . N

METHODS NNP N
Twenty-two JJ 1_p
volunteers NNS 1_p
over IN 1_p
60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
participated VBN N
in IN N
the DT N
present JJ N
study NN N
. . N

The DT N
sample NN N
was VBD N
randomly RB N
divided VBN N
in IN N
an DT 1_p
experimental JJ 1_p
group NN 1_p
of IN 1_p
13 CD 1_p
older JJR 1_p
subjects NNS 1_p
( ( 1_p
3 CD 1_p
men NNS 1_p
and CC 1_p
10 CD 1_p
women NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
63.5 CD 1_p
+/- JJ 1_p
3 CD 1_p
years NNS 1_p
) ) 1_p
while IN 1_p
the DT 1_p
remaining VBG 1_p
9 CD 1_p
subjects NNS 1_p
( ( 1_p
3 CD 1_p
men NNS 1_p
and CC 1_p
6 CD 1_p
women NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
64.2 CD 1_p
+/- JJ 1_p
4 CD 1_p
years NNS 1_p
) ) 1_p
served VBD 1_p
as IN 1_p
inactive JJ 1_i
control NN 1_i
group NN 1_i
. . 1_i

After IN N
medical JJ N
screening VBG N
all DT N
participants NNS N
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
12 CD N
weeks NNS N
in IN N
which WDT N
the DT N
experimental JJ N
subjects NNS N
underwent VBD N
a DT N
low JJ 1_i
intensity NN 1_i
training NN 1_i
. . 1_i

Each DT N
subjects-either JJ N
inactive JJ N
or CC N
active-performed JJ N
two CD 1_i
treadmill NN 1_i
tests NNS 1_i
at IN N
two-days JJ N
interval NN N
, , N
to TO N
measure VB N
maximal JJ N
and CC N
submaximal JJ N
responses NNS N
to TO N
exercise VB N
, , N
respectively RB N
. . N

Heart NNP N
rate NN N
( ( N
HR NNP N
) ) N
, , N
oxygen JJ 1_o
uptake NN 1_o
( ( 1_o
VO2 NNP 1_o
) ) 1_o
and CC N
pulmonary JJ 1_o
ventilation NN 1_o
( ( 1_o
VE NNP 1_o
) ) 1_o
were VBD N
measured VBN N
using VBG N
a DT N
telemetric JJ N
apparatus NN N
. . N

RESULTS VB N
The DT N
major JJ N
finding NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
significant JJ N
improvement NN N
in IN N
submaximal JJ 1_o
response NN 1_o
to TO 1_o
exercise NN 1_o
of IN 1_o
experimental JJ 1_o
subjects NNS 1_o
, , N
expressed VBN N
by IN N
the DT N
reduction NN N
in IN N
HR NNP 1_o
, , 1_o
VO2 NNP 1_o
VE NNP 1_o
while IN 1_o
VO2 NNP 1_o
max NN 1_o
did VBD N
not RB N
change NN N
. . N

CONCLUSIONS NNP N
Thus NNP N
, , N
it PRP N
appears VBZ N
that IN N
a DT N
low JJ N
intensity NN N
general JJ N
training NN N
similar JJ N
to TO N
that DT N
followed VBN N
in IN N
the DT N
present JJ N
study NN N
may MD N
represent VB N
a DT N
good JJ N
means NN N
to TO N
improve VB N
physical JJ 1_o
fitness NN 1_o
in IN N
healthy JJ 1_p
elderly JJ 1_p
people NNS 1_p
. . 1_p

Similarly RB N
, , N
this DT N
study NN N
supports VBZ N
the DT N
effectiveness NN N
of IN N
evaluation NN N
tests NNS N
based VBN N
on IN N
submaximal JJ 1_o
responses NNS 1_o
to TO N
exercise VB N
in IN N
this DT N
population NN N
. . N

Absence NN N
of IN N
analgesic JJ N
effect NN N
of IN N
intravenous JJ N
melatonin JJ 1_i
administration NN N
during IN N
daytime NN N
after IN N
laparoscopic JJ N
cholecystectomy NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
whether IN N
melatonin NN 1_i
administered VBN N
intraoperatively RB N
reduced VBN N
pain NN 1_o
following VBG 1_p
laparoscopic JJ 1_p
cholecystectomy NN 1_p
. . 1_p

DESIGN NNP N
Randomized NNP N
, , N
placebo-controlled JJ N
, , N
double-blinded JJ N
study NN N
. . N

SETTING CD N
Two CD 1_p
surgical JJ 1_p
departments NNS 1_p
in IN 1_p
Copenhagen NNP 1_p
. . 1_p

PATIENTS NNP N
44 CD 1_p
women NNS 1_p
between IN 1_p
18 CD 1_p
and CC 1_p
70 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , 1_p
who WP 1_p
were VBD 1_p
surgical JJ 1_p
candidates NNS 1_p
for IN 1_p
laparoscopic JJ 1_p
cholecystectomy NN 1_p
. . 1_p

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
anesthetized VBN 1_i
by IN 1_i
a DT 1_i
standard JJ 1_i
protocol NN 1_i
and CC 1_i
received VBD 1_i
a DT 1_i
standard JJ 1_i
multimodal NN 1_i
postoperative JJ 1_i
analgesic JJ 1_i
regimen NNS 1_i
. . 1_i

Patients NNS 1_p
undergoing VBG 1_p
surgery NN 1_p
were VBD 1_p
admitted VBN 1_p
on IN 1_p
the DT 1_p
day NN 1_p
of IN 1_p
surgery NN 1_p
and CC 1_p
were VBD 1_p
discharged VBN 1_p
the DT 1_p
day NN 1_p
after IN 1_p
surgery NN 1_p
. . 1_p

Ten CD 1_i
mg NN 1_i
of IN 1_i
intravenous JJ 1_i
( ( 1_i
IV NNP 1_i
) ) 1_i
melatonin NN 1_i
or CC 1_i
placebo NN 1_i
were VBD N
administered VBN N
at IN N
the DT N
time NN N
of IN N
surgical JJ N
incision NN N
. . N

MEASUREMENTS NNP N
Pain NNP 1_o
was VBD N
assessed VBN N
by IN N
a DT N
set NN N
of IN N
questionnaires NNS N
documenting VBG N
" NN N
pain NN N
at IN N
rest NN N
" NN N
using VBG N
a DT N
visual JJ 1_o
analog NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
. . N

The DT N
use NN N
of IN N
rescue NN N
medication NN N
was VBD N
recorded VBN N
. . N

Sleep JJ 1_o
quality NN 1_o
and CC 1_o
general JJ 1_o
well-being NN 1_o
were VBD N
measured VBN N
on IN N
separate JJ N
VAS NNP 1_o
scales NNS 1_o
. . 1_o

Sleepiness NNP 1_o
was VBD N
assessed VBN N
by IN N
the DT N
Karolinska NNP N
Sleepiness NNP N
Scale NNP N
. . N

MAIN NNP N
RESULTS NNP N
Forty-four JJ 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
and CC 1_p
randomized VBN 1_p
to TO 1_p
the DT 1_p
study NN 1_p
. . 1_p

Three CD 1_p
patients NNS 1_p
did VBD 1_p
not RB 1_p
complete VB 1_p
the DT 1_p
study NN 1_p
. . 1_p

No DT N
differences NNS N
in IN N
VAS NNP 1_o
pain NN 1_o
scores NNS 1_o
, , 1_o
sleep VBP 1_o
quality NN 1_o
, , 1_o
general JJ 1_o
well-being NN 1_o
, , 1_o
or CC 1_o
sleepiness NN 1_o
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

The DT N
use NN N
of IN N
postoperative JJ N
rescue NN N
medication NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
10mg CD N
of IN N
IV NNP N
melatonin NN 1_i
administered VBD N
during IN N
laparoscopic JJ N
cholecystectomy NN N
did VBD N
not RB N
affect VB N
postoperative JJ 1_o
pain NN 1_o
or CC 1_o
use NN 1_o
of IN 1_o
analgesic JJ 1_o
medication NN 1_o
. . 1_o

Differential JJ 1_o
inhibition NN 1_o
of IN 1_o
bronchoconstriction NN 1_o
by IN N
the DT N
calcium NN 1_i
channel NN 1_i
blockers NNS 1_i
, , 1_i
verapamil NN 1_i
and CC 1_i
nifedipine NN 1_i
. . 1_i

Recent JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
the DT N
calcium NN 1_i
channel NN 1_i
blocking VBG 1_i
agents NNS 1_i
can MD N
inhibit VB N
experimentally RB 1_o
induced JJ 1_o
bronchoconstriction NN 1_o
in IN N
asthmatics NNS 1_p
, , N
but CC N
their PRP$ N
protective JJ N
action NN N
has VBZ N
been VBN N
variable JJ N
. . N

To TO N
clarify VB N
the DT N
influence NN N
of IN N
stimulus NN N
intensity NN N
and CC N
choice NN N
of IN N
calcium NN N
blocker NN N
on IN N
these DT N
reported VBN N
differences NNS N
in IN N
outcome NN N
, , N
we PRP N
performed VBD N
noncumulative JJ N
thermal JJ N
stimulus-response JJ N
curves NNS N
using VBG N
isocapnic JJ N
hyperventilation NN N
of IN N
cold JJ N
air NN N
in IN N
8 CD 1_p
asthmatics NNS 1_p
. . 1_p

Subjects NNS 1_p
received VBD N
pretreatment JJ N
with IN N
orally RB N
administered VBN N
nifedipine NN 1_i
( ( N
20 CD N
mg NN N
) ) N
, , N
intravenously RB N
administered VBN N
verapamil NN 1_i
( ( N
10 CD N
mg NN N
bolus NN N
followed VBN N
by IN N
a DT N
continuous JJ N
infusion NN N
) ) N
, , N
or CC N
appropriate JJ N
placebos NNS 1_i
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
fashion NN N
. . N

Verapamil NNP N
afforded VBD N
no DT N
consistent JJ N
protection NN N
against IN N
the DT N
thermal JJ N
challenges NNS N
, , N
whereas NNS N
nifedipine VBP N
significantly RB N
blunted VBN N
the DT N
bronchoconstrictor NN 1_o
response NN 1_o
to TO 1_o
stimuli NNS 1_o
of IN 1_o
low JJ 1_o
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
middle JJ 1_o
( ( N
p NN N
less JJR N
than IN N
0.03 CD N
) ) N
intensity NN N
. . N

At IN N
the DT N
highest JJS N
thermal JJ N
burden NN N
, , N
the DT N
effect NN 1_o
of IN 1_o
nifedipine NN 1_o
was VBD N
inconsistent JJ N
and CC N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
placebo NN 1_i
. . 1_i

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
protection NN 1_o
from IN 1_o
bronchoconstriction NN 1_o
afforded VBN N
by IN N
the DT N
calcium NN 1_i
channel NN 1_i
blockers NNS 1_i
depends VBZ N
on IN N
the DT N
choice NN N
of IN N
agent NN N
and CC N
the DT N
intensity NN N
of IN N
the DT N
bronchoconstricting NN N
stimulus NN N
, , N
and CC N
they PRP N
raise VBP N
the DT N
possibility NN N
that IN N
the DT N
contribution NN N
of IN N
transmembrane NN N
calcium NN N
ion NN N
influx NN N
to TO N
the DT N
pathogenesis NN N
of IN N
bronchoconstriction NN N
may MD N
vary VB N
according VBG N
to TO N
stimulus JJ N
intensity NN N
. . N

A DT N
randomized JJ N
trial NN N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
verbal JJ 1_i
and CC 1_i
pictorial JJ 1_i
naturalistic JJ 1_i
communication NN 1_i
strategies NNS 1_i
on IN N
spoken JJ N
language NN N
for IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Presently RB N
there EX N
is VBZ N
no DT N
consensus NN N
on IN N
the DT N
specific JJ N
behavioral JJ N
treatment NN N
of IN N
choice NN N
for IN N
targeting VBG N
language NN N
in IN N
young JJ 1_p
nonverbal JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

This DT N
randomized JJ N
clinical JJ N
trial NN N
compared VBN N
the DT N
effectiveness NN N
of IN N
a DT 1_i
verbally-based JJ 1_i
intervention NN 1_i
, , 1_i
Pivotal NNP 1_i
Response NNP 1_i
Training NNP 1_i
( ( 1_i
PRT NNP 1_i
) ) 1_i
to TO 1_i
a DT 1_i
pictorially-based JJ 1_i
behavioral JJ 1_i
intervention NN 1_i
, , 1_i
the DT 1_i
Picture NNP 1_i
Exchange NNP 1_i
Communication NNP 1_i
System NNP 1_i
( ( 1_i
PECS NNP 1_i
) ) 1_i
on IN 1_i
the DT 1_i
acquisition NN 1_i
of IN 1_i
spoken JJ 1_i
language NN 1_i
by IN N
young JJ 1_p
( ( 1_p
2-4 JJ 1_p
years NNS 1_p
) ) 1_p
, , 1_p
nonverbal JJ 1_p
or CC 1_p
minimally RB 1_p
verbal JJ 1_p
( ( 1_p
≤9 JJ 1_p
words NNS 1_p
) ) 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Thirty-nine JJ 1_p
children NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT 1_i
PRT NNP 1_i
or CC 1_i
PECS NNP 1_i
condition NN N
. . N

Participants NNS N
received VBD N
on IN N
average JJ N
247 CD N
h NN N
of IN N
intervention NN N
across IN N
23 CD N
weeks NNS N
. . N

Dependent JJ N
measures NNS N
included VBD 1_o
overall JJ 1_o
communication NN 1_o
, , 1_o
expressive JJ 1_o
vocabulary NN 1_o
, , 1_o
pictorial JJ 1_o
communication NN 1_o
and CC 1_o
parent NN 1_o
satisfaction NN 1_o
. . N

Children NNP N
in IN N
both DT N
intervention NN N
groups NNS N
demonstrated VBD N
increases NNS 1_o
in IN 1_o
spoken JJ 1_o
language NN 1_o
skills NNS 1_o
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
conditions NNS N
. . N

Seventy-eight JJ N
percent NN N
of IN N
all DT N
children NNS N
exited VBD N
the DT N
program NN N
with IN N
more JJR N
than IN 1_o
10 CD 1_o
functional JJ 1_o
words NNS 1_o
. . N

Parents NNS N
were VBD N
very RB N
satisfied JJ N
with IN N
both DT N
programs NNS N
but CC N
indicated VBD 1_i
PECS NNP N
was VBD N
more RBR N
difficult JJ N
to TO N
implement VB N
. . N

Efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
a DT N
very-low-protein JJ 1_i
diet NN 1_i
when WRB N
postponing VBG 1_p
dialysis NN 1_p
in IN 1_p
the DT 1_p
elderly JJ 1_p
: : 1_p
a DT N
prospective JJ N
randomized VBN N
multicenter NN N
controlled VBN N
study NN N
. . N

BACKGROUND NNP N
A NNP N
supplemented VBD 1_i
very-low-protein JJ 1_i
diet NN 1_i
( ( 1_i
sVLPD NN 1_i
) ) 1_i
seems VBZ N
to TO N
be VB N
safe JJ 1_o
when WRB N
postponing VBG N
dialysis NN N
therapy NN N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
multicenter NN N
randomized VBD N
controlled VBN N
study NN N
designed VBN N
to TO N
assess VB N
the DT N
noninferiority NN N
of IN N
diet JJ 1_i
versus JJ N
dialysis NN 1_i
in IN N
1-year JJ N
mortality NN N
assessed VBN N
by IN N
using VBG N
intention-to-treat JJ 1_i
and CC N
per-protocol JJ N
analysis NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
Italian JJ 1_p
uremic JJ 1_p
patients NNS 1_p
without IN 1_p
diabetes NNS 1_p
older JJR 1_p
than IN 1_p
70 CD 1_p
years NNS 1_p
with IN 1_p
glomerular JJ 1_p
filtration NN 1_p
rate NN 1_p
of IN 1_p
5 CD 1_p
to TO 1_p
7 CD 1_p
mL/min NN 1_p
( ( 1_p
0.08 CD 1_p
to TO 1_p
0.12 CD 1_p
mL/s NN 1_p
) ) 1_p
. . 1_p

INTERVENTION NNP N
Randomization NNP N
to TO N
an DT N
sVLPD NN 1_i
( ( 1_i
diet JJ 1_i
group NN 1_i
) ) 1_i
or CC N
dialysis NN 1_i
. . 1_i

The DT N
sVLPD NN 1_i
is VBZ N
a DT N
vegan JJ N
diet NN N
( ( N
35 CD N
kcal NN N
; : N
proteins NNS N
, , N
0.3 CD N
g/kg NN N
body NN N
weight VBD N
daily RB N
) ) N
supplemented VBD N
with IN N
keto-analogues NNS N
, , N
amino JJ N
acids NNS N
, , N
and CC N
vitamins NNS N
. . N

Patients NNS N
following VBG N
an DT N
sVLPD NN 1_i
started VBD N
dialysis NN 1_i
therapy NN 1_i
in IN N
the DT N
case NN N
of IN N
malnutrition NN N
, , N
intractable JJ N
fluid NN N
overload NN N
, , N
hyperkalemia NN N
, , N
or CC N
appearance NN N
of IN N
uremic JJ N
symptoms NNS N
. . N

OUTCOMES NNP N
& CC N
MEASUREMENTS NNP N
Mortality NNP 1_o
, , 1_o
hospitalization NN 1_o
, , 1_o
and CC 1_o
metabolic JJ 1_o
markers NNS 1_o
. . 1_o

RESULTS VB N
56 CD 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
each DT N
group NN N
, , N
median JJ N
follow-up NN N
was VBD N
26.5 CD N
months NNS N
( ( N
interquartile JJ N
range NN N
, , N
40 CD N
) ) N
, , N
and CC N
patients NNS N
in IN N
the DT N
diet JJ 1_i
group NN 1_i
spent VBD N
a DT N
median NN N
of IN N
10.7 CD N
months NNS N
( ( N
interquartile JJ N
range NN N
, , N
11 CD N
) ) N
following VBG N
an DT N
sVLPD NN 1_i
. . 1_i

Forty CD N
patients NNS N
in IN N
the DT N
diet JJ N
group NN N
started VBD N
dialysis NN 1_i
treatment NN 1_i
because IN N
of IN N
either DT N
fluid JJ 1_o
overload NN 1_o
or CC 1_o
hyperkalemia NN 1_o
. . 1_o

There EX N
were VBD N
31 CD N
deaths NNS N
( ( N
55 CD N
% NN N
) ) N
in IN N
the DT N
dialysis NN 1_i
group NN 1_i
and CC N
28 CD N
deaths NNS 1_o
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
diet JJ 1_i
group NN 1_i
. . 1_i

One-year JJ 1_o
observed JJ 1_o
survival NN 1_o
rates NNS 1_o
at IN N
intention NN N
to TO N
treat VB N
were VBD N
83.7 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
74.5 CD N
to TO N
94.0 CD N
) ) N
in IN N
the DT N
dialysis NN 1_i
group NN N
versus VBD N
87.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
78.9 CD N
to TO N
96.5 CD N
) ) N
in IN N
the DT N
diet JJ 1_i
group NN N
( ( N
log-rank JJ N
test NN N
for IN N
noninferiority NN N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
for IN N
superiority NN N
, , N
P NNP N
= NNP N
0.6 CD N
) ) N
: : N
the DT N
difference NN N
in IN N
survival NN 1_o
was VBD N
-3.6 JJ N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-17 NNP N
to TO N
+10 VB N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

The DT 1_o
hazard NN 1_o
ratio NN 1_o
for IN 1_o
hospitalization NN 1_o
was VBD N
1.50 CD N
for IN N
the DT N
dialysis NN 1_i
group NN 1_i
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.11 CD N
to TO N
2.01 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

LIMITATIONS VB N
The DT N
unblinded JJ N
nature NN N
of IN N
the DT N
study NN N
, , N
exclusion NN N
of IN N
patients NNS N
with IN N
diabetes NNS N
, , N
and CC N
incomplete JJ N
enrollment NN N
. . N

CONCLUSION NNP N
An DT N
sVLPD NN 1_i
was VBD N
effective JJ 1_o
and CC 1_o
safe JJ 1_o
when WRB N
postponing VBG N
dialysis NN N
treatment NN N
in IN N
elderly JJ 1_p
patients NNS 1_p
without IN 1_p
diabetes NNS 1_p
. . 1_p

Therapy NNP 1_o
effect NN 1_o
of IN N
either CC N
paclitaxel NN 1_i
or CC 1_i
cyclophosphamide JJ 1_i
combination NN 1_i
treatment NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
epithelial JJ 1_p
ovarian JJ 1_p
cancer NN 1_p
and CC 1_p
relation NN 1_p
to TO 1_p
TP53 NNP 1_p
gene NN 1_p
status NN 1_p
. . 1_p

Cell NNP N
death NN N
after IN N
treatment NN N
with IN N
chemotherapy NN 1_i
is VBZ N
exerted VBN N
by IN N
activation NN N
of IN N
apoptosis NN N
, , N
and CC N
the DT N
p53 NN N
protein NN N
has VBZ N
been VBN N
shown VBN N
to TO N
actively RB N
participate VB N
in IN N
this DT N
process NN N
. . N

This DT N
recent JJ N
focus NN N
on IN N
TP53 NNP 1_o
status NN 1_o
as IN N
a DT N
possible JJ N
determinant NN N
of IN N
cancer NN N
therapy NN N
response NN N
has VBZ N
raised VBN N
the DT N
question NN N
of IN N
whether IN N
or CC N
not RB N
mutations NNS N
in IN N
the DT N
TP53 NNP N
gene NN N
have VBP N
an DT N
influence NN N
on IN N
paclitaxel NN 1_i
therapy NN 1_i
. . 1_i

The DT N
TP53 NNP 1_o
status NN 1_o
has VBZ N
been VBN N
analysed VBN N
at IN N
the DT N
DNA NNP N
level NN N
in IN N
tumours NNS N
from IN N
45 CD 1_p
ovarian JJ 1_p
cancer NN 1_p
patients NNS 1_p
randomized VBN 1_p
to TO 1_p
treatment NN 1_p
with IN N
paclitaxel NN 1_i
and CC 1_i
cisplatin NN 1_i
or CC 1_i
cyclophosphamide NN 1_i
and CC 1_i
cisplatin NN 1_i
. . 1_i

Therapy NNP 1_o
response NN 1_o
was VBD N
obtained VBN N
for IN N
38 CD 1_p
patients NNS 1_p
with IN 1_p
clinically RB 1_p
evaluable JJ 1_p
disease NN 1_p
after IN 1_p
initial JJ 1_p
surgery NN 1_p
. . 1_p

The DT N
positive JJ 1_o
response NN 1_o
rate NN 1_o
to TO N
the DT N
paclitaxel/cisplatin NN 1_i
therapy NN 1_i
was VBD N
85 CD N
% NN N
vs JJ N
61 CD N
% NN N
for IN N
the DT N
patients NNS N
who WP N
received VBD N
the DT N
cyclophosphamide/cisplatin JJ 1_i
regimen NNS N
. . N

A DT N
significant JJ N
difference NN N
in IN N
relapse-free JJ 1_o
survival NN 1_o
in IN N
favour NN N
of IN N
paclitaxel/cisplatin NN 1_i
chemotherapy NN 1_i
was VBD N
found VBN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

A DT N
total NN N
of IN N
33 CD N
tumour NN N
samples NNS N
( ( N
73 CD N
% NN N
) ) N
had VBD N
detectable JJ N
sequence NN 1_o
alterations NNS 1_o
in IN 1_o
the DT 1_o
TP53 NNP 1_o
gene NN 1_o
. . 1_o

When WRB N
relapse-free JJ 1_o
survival NN 1_o
was VBD N
estimated VBN N
for IN N
all DT N
patients NNS N
with IN N
TP53 NNP 1_o
alterations NNS 1_o
in IN N
their PRP$ N
tumours NNS N
, , N
a DT N
significant JJ N
better RBR N
outcome NN N
for IN N
the DT N
paclitaxel/cisplatin NN 1_i
group NN N
was VBD N
found VBN N
compared VBN N
with IN N
the DT N
patient NN N
group NN N
receiving VBG N
cyclophosphamide NN 1_i
and CC N
cisplatin NN 1_i
therapy NN 1_i
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

We PRP N
did VBD N
not RB N
observe VB N
an DT N
association NN N
between IN N
TP53 NNP 1_o
tumour NN 1_o
status NN 1_o
and CC N
prognosis NN 1_o
for IN N
patients NNS N
who WP N
received VBD N
paclitaxel/cisplatin JJ 1_i
combination NN N
treatment NN N
, , N
indicating VBG N
that IN N
the DT N
effect NN N
of IN N
this DT N
therapy NN N
is VBZ N
not RB N
influenced VBN N
by IN N
this DT N
parameter NN N
. . N

Endovascular JJ N
aneurysm NN N
repair NN N
and CC N
outcome NN N
in IN N
patients NNS 1_p
unfit JJ 1_p
for IN 1_p
open JJ 1_p
repair NN 1_p
of IN 1_p
abdominal JJ 1_p
aortic JJ 1_p
aneurysm NN 1_p
( ( 1_p
EVAR NNP 1_p
trial NN 1_p
2 CD 1_p
) ) 1_p
: : 1_p
randomised VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Endovascular NNP 1_i
aneurysm NN 1_i
repair NN 1_i
( ( 1_i
EVAR NNP 1_i
) ) 1_i
to TO N
exclude VB N
abdominal JJ N
aortic JJ N
aneurysm NN N
( ( N
AAA NNP N
) ) N
was VBD N
introduced VBN N
for IN N
patients NNS 1_p
of IN 1_p
poor JJ 1_p
health NN 1_p
status NN 1_p
considered VBN 1_p
unfit NN 1_p
for IN 1_p
major JJ 1_p
surgery NN 1_p
. . 1_p

We PRP N
instigated VBD N
EVAR NNP N
trial NN N
2 CD N
to TO N
identify VB N
whether IN N
EVAR NNP N
improves VBZ N
survival JJ 1_o
compared VBN N
with IN N
no DT N
intervention NN N
in IN N
patients NNS 1_p
unfit JJ 1_p
for IN 1_p
open JJ 1_p
repair NN 1_p
of IN 1_p
aortic JJ 1_p
aneurysm NN 1_p
. . 1_p

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
338 CD 1_p
patients NNS 1_p
aged VBN 1_p
60 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
who WP 1_p
had VBD 1_p
aneurysms NNS 1_p
of IN 1_p
at IN 1_p
least JJS 1_p
5.5 CD 1_p
cm NN 1_p
in IN 1_p
diameter NN 1_p
and CC 1_p
who WP 1_p
had VBD 1_p
been VBN 1_p
referred VBN 1_p
to TO 1_p
one CD 1_p
of IN 1_p
31 CD 1_p
hospitals NNS 1_p
in IN 1_p
the DT 1_p
UK NNP 1_p
. . 1_p

We PRP N
assigned VBD N
patients NNS N
to TO N
receive VB N
either DT N
EVAR NNP 1_i
( ( N
n=166 NN N
) ) N
or CC 1_i
no DT 1_i
intervention NN 1_i
( ( N
n=172 JJ N
) ) N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
all-cause JJ 1_o
mortality NN 1_o
, , N
with IN N
secondary JJ N
endpoints NNS N
of IN N
aneurysm-related JJ 1_o
mortality NN 1_o
, , 1_o
health-related JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
HRQL NNP 1_o
) ) 1_o
, , 1_o
postoperative JJ 1_o
complications NNS 1_o
, , 1_o
and CC 1_o
hospital NN 1_o
costs NNS 1_o
. . 1_o

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
197 CD 1_p
patients NNS 1_p
underwent JJ N
aneurysm JJ 1_i
repair NN 1_i
( ( N
47 CD N
assigned VBN N
no DT N
intervention NN N
) ) N
and CC N
80 CD N
% NN N
of IN N
patients NNS N
adhered VBN N
to TO N
protocol VB N
. . N

The DT N
30-day JJ 1_o
operative JJ 1_o
mortality NN 1_o
in IN 1_o
the DT 1_o
EVAR NNP 1_o
group NN 1_o
was VBD N
9 CD N
% NN N
( ( N
13 CD N
of IN N
150 CD N
, , N
95 CD N
% NN N
CI NNP N
5-15 CD N
) ) N
and CC N
the DT N
no DT N
intervention NN N
group NN N
had VBD N
a DT N
rupture NN N
rate NN N
of IN N
9.0 CD N
per IN N
100 CD N
person NN N
years NNS N
( ( N
95 CD N
% NN N
CI NNP N
6.0-13.5 CD N
) ) N
. . N

By IN N
end NN N
of IN N
follow JJ N
up IN N
142 CD N
patients NNS N
had VBD N
died VBN 1_o
, , N
42 CD N
of IN N
aneurysm-related JJ N
factors NNS N
; : N
overall JJ 1_o
mortality NN 1_o
after IN N
4 CD N
years NNS N
was VBD N
64 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
EVAR NNP N
group NN N
and CC N
the DT N
no DT N
intervention NN N
group NN N
for IN N
all-cause JJ 1_o
mortality NN 1_o
( ( N
hazard JJ N
ratio NN N
1.21 CD N
, , N
95 CD N
% NN N
CI NNP N
0.87-1.69 CD N
, , N
p=0.25 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
aneurysm-related JJ 1_o
mortality NN 1_o
. . 1_o

The DT N
mean JJ 1_o
hospital NN 1_o
costs NNS 1_o
per IN 1_o
patient NN 1_o
over IN 1_o
4 CD 1_o
years NNS 1_o
were VBD N
UK NNP N
pound NN N
sterling NN N
13,632 CD N
in IN N
the DT N
EVAR NNP N
group NN N
and CC N
pound NN N
sterling NN N
4983 CD N
in IN N
the DT N
no DT N
intervention NN N
group NN N
( ( N
mean JJ N
difference NN N
pound NN N
sterling NN N
8649 CD N
, , N
SE NNP N
1248 CD N
) ) N
, , N
with IN N
no DT N
difference NN N
in IN N
HRQL NNP N
scores NNS N
. . N

INTERPRETATION NNP N
EVAR NNP N
had VBD N
a DT N
considerable JJ N
30-day JJ 1_o
operative JJ 1_o
mortality NN 1_o
in IN N
patients NNS N
already RB N
unfit JJ N
for IN N
open JJ N
repair NN N
of IN N
their PRP$ N
aneurysm NN N
. . N

EVAR NNP 1_i
did VBD N
not RB N
improve VB N
survival NN N
over IN N
no DT N
intervention NN N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
need NN N
for IN N
continued JJ N
surveillance NN N
and CC N
reinterventions NNS N
, , N
at IN N
substantially RB N
increased VBN N
cost NN N
. . N

Ongoing VBG N
follow-up NN N
and CC N
improved JJ N
fitness NN N
of IN N
these DT N
patients NNS N
is VBZ N
a DT N
priority NN N
. . N

Similar JJ N
MPA NNP N
exposure NN N
on IN N
modified JJ N
release NN N
and CC N
regular JJ 1_p
tacrolimus NN 1_p
. . 1_p

Concomitant JJ N
immunosuppression NN N
may MD N
affect VB N
the DT N
mycophenolate NN 1_o
mofetil NN 1_o
exposure NN N
. . N

Astellas NNP N
developed VBD N
a DT N
once-daily JJ N
modified JJ N
release NN N
formulation NN N
of IN N
tacrolimus NN 1_i
( ( N
TacMR NNP N
) ) N
with IN N
the DT N
potential JJ N
to TO N
reduce VB N
the DT N
likelihood NN N
of IN N
nonadherence NN 1_o
. . 1_o

It PRP N
is VBZ N
unknown JJ N
whether IN N
mycophenolic JJ 1_i
acid NN 1_i
( ( 1_i
MPA NNP 1_i
) ) 1_i
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
differs NNS N
between IN N
the DT N
2 CD N
tacrolimus NN N
( ( N
Tac NNP N
) ) N
formulations NNS N
. . N

In IN N
a DT N
2-by-2 JJ N
crossover NN N
design NN N
, , N
20 CD 1_p
stable JJ 1_p
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
on IN 1_p
twice-daily JJ 1_p
Tac NNP 1_p
either CC N
continued VBD N
their PRP$ N
usual JJ N
Tac NNP 1_i
therapy NN 1_i
( ( N
n JJ N
= NN N
10 CD N
, , N
group NN N
1 CD N
) ) N
or CC 1_i
switched VBN 1_i
to TO 1_i
TacMR NNP 1_i
for IN 1_i
a DT N
12-week JJ N
period NN N
( ( N
n JJ N
= NN N
10 CD N
, , N
group NN N
2 CD N
) ) N
, , N
after IN N
which WDT N
the DT N
patients NNS N
crossed VBD N
over IN N
to TO N
the DT N
other JJ N
formulation NN N
for IN N
another DT N
12-week JJ N
period NN N
. . N

Pharmacokinetic JJ N
profiles NNS N
using VBG N
limited JJ N
sampling NN N
strategies NNS N
were VBD N
obtained VBN N
before IN N
randomization NN N
( ( N
visit IN N
1 CD N
) ) N
, , N
and CC N
at IN N
12 CD N
( ( N
visit VB N
2 CD N
) ) N
and CC N
24 CD N
weeks NNS N
( ( N
visit IN N
3 CD N
) ) N
at IN N
steady JJ N
state NN N
. . N

MPA NNP N
AUC NNP N
was VBD N
calculated VBN N
using VBG N
the DT N
Pawinski NNP N
formula NN N
. . N

When WRB N
analyzing VBG N
visits NNS N
on IN N
Tac NNP 1_o
, , 1_o
TacMR NNP 1_o
, , 1_o
and CC 1_o
back RB 1_o
on IN 1_o
Tac NNP 1_o
combined VBD 1_o
, , 1_o
the DT 1_o
MPA NNP 1_o
AUC NNP 1_o
for IN 1_p
all DT 1_p
20 CD 1_p
patients NNS 1_p
at IN 1_p
baseline NN 1_p
was VBD 1_p
42.24 CD 1_p
( ( 1_p
16.98 CD 1_p
) ) 1_p
, , 1_p
37.18 CD 1_p
( ( 1_p
13.75 CD 1_p
) ) 1_p
, , 1_p
and CC 1_p
40.09 CD 1_p
( ( 1_p
16.69 CD 1_p
) ) 1_p
mg·h·L NN 1_p
( ( 1_p
-1 NNP 1_p
) ) 1_p
, , N
respectively RB N
, , N
which WDT N
was VBD N
not RB N
statistically RB N
significant JJ N
using VBG N
repeated VBN N
measures NNS N
( ( N
P NNP N
= NNP N
0.1327 CD N
, , N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.1109 CD N
) ) N
. . N

We PRP N
conclude VBP N
that IN 1_o
MPA NNP 1_o
pharmacokinetic JJ 1_o
profiles NNS 1_o
are VBP N
not RB N
altered VBN N
when WRB N
converting VBG N
patients NNS N
from IN N
Tac NNP N
to TO N
TacMR NNP N
. . N

Effect NN N
of IN N
simultaneous JJ N
didanosine JJ 1_i
administration NN N
on IN N
itraconazole JJ 1_o
absorption NN 1_o
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

STUDY NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
simultaneously RB N
administered VBN N
didanosine NN 1_i
( ( 1_i
ddI NN 1_i
) ) 1_i
on IN N
the DT N
absorption NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
itraconazole NN 1_i
. . 1_i

DESIGN NNP N
Randomized NNP N
, , N
crossover NN N
, , N
unblinded JJ N
single-dose JJ N
pharmacokinetic JJ N
study NN N
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

Comparisons NNS N
of IN N
itraconazole JJ 1_i
alone NN 1_i
and CC N
itraconazole JJ 1_i
with IN 1_i
simultaneous JJ 1_i
ddI NNS 1_i
were VBD N
performed VBN N
on IN N
days NNS N
1 CD N
and CC N
15 CD N
. . N

SETTING VB N
A DT 1_p
university NN 1_p
medical JJ 1_p
center NN 1_p
. . 1_p

PATIENTS VB N
Seven NNP 1_p
healthy JJ 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
. . 1_p

Six NNP 1_p
subjects NNS 1_p
( ( 1_p
86 CD 1_p
% NN 1_p
) ) 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
; : 1_p
one CD 1_p
was VBD 1_p
removed VBN 1_p
due JJ 1_p
to TO 1_p
the DT 1_p
development NN 1_p
of IN 1_p
a DT 1_p
rash NN 1_p
. . 1_p

INTERVENTIONS NNP N
Volunteers NNPS N
received VBD N
a DT N
single JJ 1_i
200-mg JJ 1_i
oral JJ 1_i
dose NN 1_i
of IN 1_i
itraconazole NN 1_i
or CC 1_i
itraconazole NN 1_i
with IN 1_i
concomitant JJ 1_i
oral JJ 1_i
ddI NN 1_i
300 CD 1_i
mg NN 1_i
( ( 1_i
two CD 1_i
150-mg JJ 1_i
tablets NNS 1_i
) ) 1_i
dispersed VBD N
in IN N
240 CD N
ml JJ N
water NN N
. . N

Each DT N
regimen NN N
was VBD N
separated VBN N
by IN N
a DT N
2-week JJ N
washout NN N
period NN N
. . N

Serum NNP N
samples NNS N
were VBD N
obtained VBN N
frequently RB N
for IN N
12 CD N
hours NNS N
after IN N
the DT N
dose NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Concentrations NNP N
of IN N
itraconazole NN 1_i
were VBD N
determined VBN N
using VBG N
a DT N
microbiologic JJ N
assay NN N
. . N

Individual JJ N
concentrations NNS N
in IN N
serum JJ 1_o
versus NN 1_o
time NN 1_o
data NNS 1_o
were VBD N
evaluated VBN N
by IN N
linear JJ N
regression NN N
analysis NN N
. . N

Peak NNP 1_o
serum JJ 1_o
concentration NN 1_o
and CC 1_o
time NN 1_o
to TO 1_o
peak VB 1_o
were VBD N
determined VBN N
by IN N
visual JJ N
inspection NN N
of IN N
each DT N
individual NN N
's POS N
serum JJ N
concentration-time JJ N
curve NN N
. . N

A DT N
mean JJ 1_o
+/- JJ 1_o
SD NNP 1_o
peak NN 1_o
serum NN 1_o
itraconazole JJ 1_o
concentration NN 1_o
of IN N
0.90 CD N
+/- JJ N
0.30 CD N
micrograms/ml NN N
was VBD N
observed VBN N
at IN N
3.0 CD N
+/- JJ N
0.7 CD N
hours NNS N
when WRB N
itraconazole NN N
was VBD N
administered VBN N
alone RB N
, , N
compared VBN N
with IN N
undetectable JJ N
levels NNS N
in IN N
all DT N
patients NNS N
during IN N
therapy NN N
with IN N
ddI NN N
. . N

CONCLUSIONS NNP N
Simultaneous NNP N
oral JJ 1_i
administration NN 1_i
of IN 1_i
ddI NNS 1_i
significantly RB N
decreases VBZ N
absorption NN 1_o
of IN 1_o
itraconazole NN 1_o
. . 1_o

These DT N
drugs NNS N
should MD N
not RB N
be VB N
administered VBN N
concurrently RB N
. . N

The DT N
effect NN N
of IN N
prophylactic JJ 1_i
calcium NN 1_i
and CC 1_i
magnesium NN 1_i
infusions NNS 1_i
on IN N
the DT N
incidence NN N
of IN N
neurotoxicity NN N
and CC N
clinical JJ N
outcome NN N
of IN N
oxaliplatin-based JJ N
systemic JJ N
treatment NN N
in IN N
advanced JJ 1_p
colorectal JJ 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Peripheral NNP N
sensory JJ N
neurotoxicity NN N
is VBZ N
a DT N
frequent JJ N
and CC N
potentially RB N
debilitating JJ N
side NN N
effect NN N
of IN N
oxaliplatin NN N
treatment NN N
. . N

Calcium NN N
and CC N
magnesium NN N
( ( N
Ca/Mg NNP N
) ) N
infusions NNS N
are VBP N
frequently RB N
used VBN N
to TO N
prevent VB N
this DT N
toxicity NN N
. . N

However RB N
, , N
concerns NNS N
about IN N
a DT N
negative JJ N
impact NN N
of IN N
Ca/Mg NNP N
infusions NNS N
on IN N
outcome NN N
have VBP N
been VBN N
raised VBN N
. . N

We PRP N
retrospectively RB N
assessed VBD N
the DT N
effect NN N
of IN N
Ca/Mg NNP N
infusions NNS N
on IN N
the DT N
incidence NN 1_o
of IN 1_o
neurotoxicity NN 1_o
and CC N
on IN N
clinical JJ 1_o
outcome NN 1_o
in IN N
advanced JJ 1_p
colorectal JJ 1_p
cancer NN 1_p
( ( 1_p
ACC NNP 1_p
) ) 1_p
patients NNS 1_p
treated VBN 1_p
in IN 1_p
the DT 1_p
phase NN 1_p
III NNP 1_p
CAIRO2 NNP 1_p
study NN 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
Seven NNP 1_p
hundred VBD 1_p
and CC 1_p
fifty JJ 1_p
five CD 1_p
previously RB 1_p
untreated JJ 1_p
ACC NNP 1_p
patients NNS 1_p
were VBD N
randomised VBN N
between IN N
treatment NN 1_i
with IN 1_i
capecitabine NN 1_i
, , 1_i
oxaliplatin NN 1_i
and CC 1_i
bevacizumab NN 1_i
or CC 1_i
the DT 1_i
same JJ 1_i
combination NN 1_i
with IN 1_i
the DT 1_i
addition NN 1_i
of IN 1_i
cetuximab NN 1_i
. . 1_i

Patients NNS N
were VBD N
retrospectively RB N
divided VBN N
into IN N
two CD 1_i
groups NNS 1_i
: : 1_i
patients NNS 1_i
in IN 1_i
the DT 1_i
Ca/Mg NNP 1_i
( ( 1_i
+ NNP 1_i
) ) 1_i
group NN 1_i
received VBD 1_i
Ca/Mg NNP 1_i
at IN 1_i
least JJS 1_i
during IN 1_i
their PRP$ 1_i
first JJ 1_i
treatment NN 1_i
cycle NN 1_i
, , 1_i
and CC 1_i
patients NNS 1_i
in IN 1_i
the DT 1_i
Ca/Mg NNP 1_i
( ( 1_i
- : 1_i
) ) 1_i
group NN 1_i
did VBD 1_i
not RB 1_i
. . 1_i

RESULTS VB N
Seven NNP 1_p
hundred CD 1_p
and CC 1_p
thirty VB 1_p
two CD 1_p
patients NNS 1_p
were VBD 1_p
evaluable JJ 1_p
for IN N
this DT N
analysis NN N
. . N

The DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
group NN N
consisted VBD N
of IN N
551 CD N
patients NNS N
, , N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
consisted VBD N
of IN N
181 CD N
patients NNS N
. . N

The DT N
incidence NN N
of IN N
all DT 1_o
grade JJ 1_o
neurotoxicity NN 1_o
in IN N
the DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
group NN N
and CC N
the DT N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
was VBD N
85 CD N
% NN N
and CC N
92 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
the DT N
incidence NN N
of IN N
grade NN N
≥ $ N
2 CD 1_o
neurotoxicity NN 1_o
was VBD N
40 CD N
% NN N
and CC N
45 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.22 CD N
) ) N
. . N

The DT 1_o
median JJ 1_o
PFS NNP 1_o
in IN N
the DT N
Ca/Mg NNP N
( ( N
+ NNP N
) ) N
versus NN N
Ca/Mg NNP N
( ( N
- : N
) ) N
group NN N
was VBD N
10.1 CD N
versus NN N
10.7 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.92 CD N
) ) N
, , N
the DT N
median JJ N
OS NNP N
was VBD N
19.8 CD N
versus NN N
20.7 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
, , N
and CC N
the DT N
response NN N
rate NN N
was VBD N
43.1 CD N
% NN N
versus IN N
50 CD N
% NN N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
largest JJS N
retrospective JJ N
analysis NN N
to TO N
date NN N
we PRP N
observed VBD N
that IN N
Ca/Mg NNP N
infusions NNS N
significantly RB N
reduced VBD N
all DT N
grade JJ N
oxaliplatin-related JJ N
neurotoxicity NN 1_i
. . 1_i

Ca/Mg NNP 1_i
infusions NNS 1_i
did VBD N
not RB N
affect VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
treatment NN N
. . N

A DT 1_p
randomized JJ 1_p
trial NN 1_p
in IN 1_p
simultaneous JJ 1_p
pancreas-kidney JJ 1_i
transplantation NN 1_i
: : 1_i
portal JJ 1_i
versus NN 1_i
systemic JJ 1_o
venous JJ 1_o
drainage NN 1_o
of IN 1_i
the DT 1_i
pancreas NN 1_i
allograft NN 1_i
. . 1_i

An DT N
analysis NN N
of IN N
the DT N
mortality NN N
effect NN N
in IN N
a DT N
breast NN 1_i
cancer NN 1_i
screening VBG 1_i
study NN N
. . N

In IN N
order NN N
to TO N
better JJR N
understand VB N
the DT N
effect NN N
of IN N
breast NN 1_p
cancer NN 1_p
screening VBG N
on IN N
mortality NN N
, , N
we PRP N
use VBP N
the DT N
theory NN N
of IN N
competing VBG N
risks NNS N
to TO N
analyse VB N
deaths NNS N
from IN N
the DT N
long-term JJ 1_p
follow-up NN 1_p
of IN 1_p
the DT 1_p
HIP NNP 1_i
breast NN 1_i
cancer NN 1_i
screening VBG 1_i
trial NN 1_i
. . 1_i

We PRP N
conclude VBP N
that IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
of IN N
the DT N
breast NN 1_p
cancer NN 1_p
cases NNS 1_p
detected VBD N
early RB N
as IN N
a DT N
result NN N
of IN N
screening VBG 1_i
realized VBN N
a DT N
benefit NN N
in IN N
terms NNS N
of IN N
elimination NN N
of IN N
the DT N
risk NN N
of IN N
breast NN 1_o
cancer NN 1_o
mortality NN 1_o
. . 1_o

Breast NNP 1_i
cancer NN 1_i
screening VBG 1_i
appears VBZ N
not RB N
to TO N
affect VB N
the DT N
rate NN 1_o
of IN 1_o
mortality NN 1_o
from IN N
causes NNS N
of IN N
death NN N
other JJ N
than IN N
breast JJ N
cancer NN N
. . N

Methodologically RB N
, , N
we PRP N
demonstrate VBP N
the DT N
importance NN N
of IN N
analysing VBG N
mortality NN N
separately RB N
for IN N
the DT N
breast NN 1_p
cancer NN 1_p
cases NNS N
as RB N
well RB N
as IN N
for IN N
the DT N
entire JJ 1_p
population NN 1_p
in IN N
a DT N
trial NN N
. . N

Effect NN N
of IN N
shearing VBG 1_i
on IN N
water NN 1_o
turnover NN 1_o
and CC 1_o
thermobiological JJ 1_o
variables NNS 1_o
in IN N
German JJ 1_p
Blackhead NNP 1_p
mutton NN 1_p
sheep NN 1_p
. . 1_p

Current JJ N
equations NNS N
for IN N
estimating VBG N
water NN N
requirements NNS N
in IN N
sheep JJ N
do VBP N
not RB N
differentiate VB N
between IN N
shorn JJ 1_p
and CC 1_p
unshorn JJ 1_p
sheep NN 1_p
. . 1_p

Furthermore RB N
, , N
the DT N
effect NN N
of IN N
shearing VBG N
on IN N
thermoregulative JJ 1_o
responses NNS 1_o
in IN N
sheep NN N
has VBZ N
not RB N
been VBN N
adequately RB N
studied VBN N
under IN N
temperate JJ 1_p
environmental JJ 1_p
conditions NNS 1_p
. . 1_p

Therefore RB N
, , N
the DT N
present JJ N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
wool NN N
coverage NN N
on IN N
water NN 1_o
turnover NN 1_o
in IN N
relation NN N
to TO N
thermoregulation NN N
in IN N
sheep NN N
by IN N
using VBG N
the DT N
deuterium NN N
dilution NN N
technique NN N
to TO N
predict VB N
total JJ N
water NN N
intake NN N
before IN N
and CC N
after IN N
shearing VBG 1_i
. . 1_i

Physiological JJ N
responses NNS N
, , N
such JJ N
as IN N
water NN 1_o
turnover NN 1_o
, , 1_o
surface NN 1_o
temperature NN 1_o
, , 1_o
and CC 1_o
rectal JJ 1_o
temperature NN 1_o
, , 1_o
as RB 1_o
well RB 1_o
as IN 1_o
drinking VBG 1_o
behavior NN 1_o
of IN 1_o
sheep NN 1_o
were VBD N
also RB N
evaluated VBN N
. . N

Fourteen NNP 1_p
nonlactating JJ 1_p
German JJ 1_p
Blackhead NNP 1_p
mutton NN 1_p
ewes NN 1_p
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT 1_i
control NN 1_i
group NN 1_i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
that WDT N
was VBD N
already RB 1_i
shorn VBN 1_i
, , 1_i
and CC 1_i
a DT 1_i
treatment NN 1_i
group NN 1_i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
that WDT N
was VBD N
left VBN 1_i
unshorn JJ 1_i
( ( N
wool JJ N
length NN N
: : N
10.6 CD N
± $ N
1.2 CD N
cm NN N
) ) N
. . 1_o

Individual NNP 1_o
feed NN 1_o
and CC 1_o
water NN 1_o
intakes NNS 1_o
were VBD N
recorded VBN N
throughout IN N
the DT N
experiment NN N
( ( N
d JJ N
1 CD N
to TO N
71 CD N
) ) N
. . N

Two CD N
weeks NNS N
after IN N
measurements NNS N
commenced VBD N
( ( N
d JJ N
15 CD N
) ) N
, , N
treatment NN N
sheep NN N
were VBD N
shorn VBN N
. . 1_o

Water NNP 1_o
intake NN 1_o
was VBD N
estimated VBN N
twice RB N
for IN N
2 CD N
consecutive JJ N
weeks NNS N
by IN N
using VBG N
deuterium JJ N
dilution NN N
techniques NNS N
( ( N
d VB N
1 CD N
to TO N
15 CD N
and CC N
d VB N
57 CD N
to TO N
71 CD N
) ) N
. . 1_o

Ambient JJ 1_o
temperature NN 1_o
( ( 1_o
T NNP 1_o
( ( 1_o
a DT 1_o
) ) 1_o
) ) 1_o
, , 1_o
relative JJ 1_o
humidity NN 1_o
, , 1_o
and CC 1_o
respiratory JJ 1_o
rate NN 1_o
were VBD N
measured VBN N
daily RB N
, , N
whereas JJ 1_o
BW NNP 1_o
, , 1_o
rectal NN 1_o
and CC 1_o
animal JJ 1_o
surface NN 1_o
temperatures NNS 1_o
( ( N
using VBG N
infrared VBN N
thermography NN N
) ) N
, , N
and CC 1_o
wool JJ 1_o
length NN 1_o
were VBD N
measured VBN N
weekly RB N
. . N

In IN N
the DT N
first JJ N
2 CD N
wk NN N
, , N
when WRB N
treatment NN N
sheep NN N
were VBD N
unshorn JJ N
, , N
treatment NN N
and CC N
control NN N
ewes NN N
differed VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN 1_o
DMI NNP 1_o
( ( N
52 CD N
± RB N
4 CD N
vs. FW N
59 CD N
± $ N
4 CD N
g·kg NN 1_o
( ( 1_o
-0.75 NNP 1_o
) ) 1_o
·d NN 1_o
( ( 1_o
-1 NNP 1_o
) ) 1_o
) ) 1_o
, , 1_o
water NN 1_o
intake NN 1_o
( ( N
165 CD N
± RB N
17 CD N
vs. FW N
134 CD N
± $ N
18 CD N
g·kg NN 1_o
( ( 1_o
-0.75 NNP 1_o
) ) 1_o
·d NN 1_o
( ( 1_o
-1 NNP 1_o
) ) 1_o
) ) 1_o
, , 1_o
respiratory JJ 1_o
rate NN N
( ( N
66 CD N
± RB N
5 CD N
vs. FW N
31 CD N
± $ N
4 CD N
breath/min NN 1_o
) ) 1_o
, , 1_o
rectal JJ 1_o
temperature NN 1_o
( ( N
39.3 CD N
± RB N
0.2 CD N
vs. FW N
38.8 CD N
± $ 1_o
0.1°C CD 1_o
) ) 1_o
, , 1_o
and CC 1_o
surface NN 1_o
temperatures NNS N
( ( N
body JJ N
side NN N
: : N
19.3 CD N
± $ N
0.3 CD N
vs. FW N
24.5 CD N
± $ N
0.6°C CD N
; : N
leg NN N
: : N
25.8 CD N
± $ N
2.4 CD N
vs. FW N
27.4 CD N
± $ N
1.6°C CD N
) ) N
. . N

However RB N
, , N
after IN N
shearing VBG N
, , N
these DT N
differences NNS N
partly RB N
disappeared VBD 1_o
. . 1_o

The DT 1_o
same JJ 1_o
trend NN 1_o
in IN N
water NN N
intake NN N
between IN N
groups NNS N
was VBD N
confirmed VBN N
using VBG N
the DT N
isotope NN N
dilution NN N
technique NN N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
relationship NN 1_o
between IN 1_o
T NNP 1_o
( ( 1_o
a DT 1_o
) ) 1_o
and CC 1_o
water NN 1_o
intake NN 1_o
, , 1_o
respiratory NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
body NN 1_o
surface NN 1_o
temperatures NNS N
. . N

Even RB N
under IN N
temperate NN N
conditions NNS N
( ( N
T NNP N
( ( N
a DT N
) ) N
< $ N
28°C CD N
) ) N
, , N
shearing VBG N
significantly RB 1_o
reduced VBN 1_o
core NN 1_o
body NN 1_o
temperature NN 1_o
, , 1_o
water NN 1_o
intake NN 1_o
, , N
and CC 1_p
respiratory NN 1_p
rate NN 1_p
in IN 1_p
German JJ 1_p
Blackhead NNP 1_p
mutton NN N
sheep NN 1_o
, , 1_o
thus RB 1_o
indicating VBG 1_o
heat NN 1_p
stress NN 1_p
in IN N
fleeced JJ N
animals NNS N
, , N
which WDT N
should MD N
be VB N
considered VBN N
when WRB N
determining VBG N
the DT N
optimal JJ N
shearing NN N
time NN N
in IN N
sheep NN N
as RB N
well RB N
as IN N
when WRB N
estimating VBG N
water NN N
requirements NNS N
. . N

Effect NN N
of IN N
Orlistat NNP 1_i
in IN N
obese JJ 1_p
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

Heart NNP N
failure NN N
is VBZ N
the DT N
leading VBG N
cause NN N
of IN N
hospitalization NN N
. . N

Obesity NNP N
is VBZ N
increasingly RB N
common JJ N
and CC N
is VBZ N
a DT N
major JJ N
public JJ N
health NN N
problem NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
whether IN N
obese JJ 1_p
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
can MD N
benefit VB N
from IN N
losing VBG N
weight NN N
via IN N
an DT N
orlistat-assisted JJ 1_i
diet NN 1_i
. . 1_i

This DT N
randomized JJ N
clinical JJ N
trial NN N
included VBD N
obese JJ 1_p
patients NNS 1_p
with IN 1_p
ejection NN 1_p
fractions NNS 1_p
< VBP 1_p
or CC 1_p
=40 CD 1_p
% NN 1_p
. . 1_p

Orlistat NNP 1_i
and CC 1_i
diet JJ 1_i
counseling NN 1_i
were VBD 1_i
compared VBN 1_i
with IN 1_i
diet JJ 1_i
counseling VBG 1_i
alone RB 1_i
. . 1_i

Twenty-one JJ 1_p
consecutive JJ 1_p
obese JJ 1_p
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

Significant JJ N
improvement NN N
in IN N
6-minute JJ 1_o
walk NN 1_o
test NN 1_o
( ( N
45.8 CD N
m NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
5.2-86.4 JJ N
m NN N
; : N
p=0.031 NN N
) ) N
, , N
functional JJ 1_o
class NN 1_o
( ( N
-0.6+/-0.5 UH N
, , N
p=0.014 NN N
) ) N
, , N
weight JJ 1_o
loss NN 1_o
( ( N
-8.55 JJ N
kg NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-13.0 NN N
to TO N
-4.1 VB N
kg NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
and CC N
also RB N
significant JJ N
decreases NNS N
in IN N
total JJ 1_o
cholesterol NN 1_o
( ( N
p=0.017 NN N
) ) N
, , N
low-density JJ 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
( ( N
p=0.03 NN N
) ) N
, , N
and CC N
triglycerides NNS 1_o
( ( N
p=0.036 NN N
) ) N
were VBD N
observed VBN N
in IN N
the DT N
orlistat NN N
group NN N
. . N

Orlistat CC 1_i
can MD N
promote VB N
significant JJ N
weight JJ 1_o
loss NN 1_o
and CC 1_o
symptoms NNS 1_o
of IN 1_o
relief NN 1_o
in IN N
obese JJ N
patients NNS N
with IN N
heart NN N
failure NN N
, , N
as IN N
measured VBN N
by IN N
6-minute JJ N
walk NN N
test NN N
and CC N
functional JJ N
capacity NN N
. . N

The DT N
lipid JJ N
profile NN N
improved VBN N
. . N

Orlistat NNP 1_i
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

The DT N
effect NN N
of IN N
risedronate NN 1_i
treatment NN N
on IN N
serum NN N
cytokines NNS N
in IN N
postmenopausal JJ 1_p
osteoporosis NN 1_p
: : 1_p
a DT N
6-month JJ N
randomized NN N
and CC N
controlled VBD N
study NN N
. . N

There EX N
is VBZ N
much JJ N
evidence NN N
suggesting VBG N
that IN N
the DT N
decline NN N
in IN N
ovarian JJ N
function NN N
after IN N
menopause NN N
is VBZ N
associated VBN N
with IN N
spontaneous JJ N
increases NNS N
in IN N
proinflammatory JJ N
cytokines NNS N
. . N

Treatment NN N
with IN N
risedronate NN 1_i
is VBZ N
accompanied VBN N
by IN N
significant JJ N
changes NNS N
in IN N
bone NN N
turnover NN N
and CC N
bone JJ N
mineral JJ N
density NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
risedronate NN 1_i
treatment NN N
on IN N
the DT N
level NN N
of IN N
serum JJ N
cytokines NNS N
including VBG N
receptor NN N
activator NN N
of IN N
nuclear JJ N
factor-kappaB JJ N
ligand NN N
( ( N
RANKL NNP N
) ) N
and CC N
osteoprotegerin $ N
among IN N
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
osteoporosis NN 1_p
. . 1_p

The DT N
study NN N
group NN N
consisted VBD N
of IN N
61 CD 1_p
postmenopausal JJ 1_p
women NNS 1_p
with IN 1_p
osteoporosis NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
divided VBN N
in IN N
two CD N
groups NNS N
: : N
In IN N
group NN N
1 CD N
( ( N
n JJ N
= NNP N
41 CD N
) ) N
postmenopausal NN N
women NNS N
received VBD N
oral JJ 1_i
risedronate NN 1_i
( ( N
35 CD N
mg/week NN N
) ) N
, , N
calcium NN 1_i
( ( N
1,000 CD N
mg/day NN N
) ) N
, , N
and CC N
vitamin NN 1_i
D NNP 1_i
( ( N
400 CD N
IU/day NNP N
) ) N
for IN N
12 CD N
months NNS N
. . N

In IN N
group NN N
2 CD N
( ( N
control NN N
group NN N
; : N
n CC N
= VB N
20 CD N
) ) N
patients NNS N
received VBD N
only RB N
oral JJ 1_i
calcium NN 1_i
( ( N
1,000 CD N
mg/day NN N
) ) N
and CC N
vitamin $ 1_i
D NNP 1_i
( ( N
400 CD N
IU/day NNP N
) ) N
. . N

Bone NNP 1_o
mineral JJ 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
of IN 1_o
lumbar NN 1_o
spine NN 1_o
( ( 1_o
L1-L4 NNP 1_o
) ) 1_o
and CC 1_o
proximal JJ 1_o
femur NN 1_o
were VBD N
determined VBN N
using VBG N
dual JJ N
X-ray JJ N
absorptiometry NN N
at IN N
baseline NN N
and CC N
after IN N
one CD N
year NN N
. . N

Venous NNP 1_o
blood NN 1_o
samples NNS 1_o
were VBD N
obtained VBN N
for IN N
determination NN N
of IN N
serum JJ 1_o
cytokines NNS 1_o
including VBG 1_o
interleukin-1beta JJ 1_o
( ( 1_o
IL-1beta NNP 1_o
) ) 1_o
, , 1_o
tumor JJ 1_o
necrosis NN 1_o
factor-alpha NN 1_o
( ( 1_o
TNF-alpha NNP 1_o
) ) 1_o
, , 1_o
RANKL NNP 1_o
, , 1_o
osteoprotegerin NN 1_o
, , 1_o
and CC 1_o
markers NNS 1_o
of IN 1_o
bone NN 1_o
formation NN 1_o
and CC 1_o
resorption NN 1_o
. . 1_o

Levels NNP 1_o
of IN 1_o
serum NN 1_o
cytokines NNS 1_o
were VBD N
measured VBN N
before IN N
therapy NN N
and CC N
after IN N
three CD N
and CC N
6 CD N
months NNS N
. . N

Markers NNS 1_o
of IN 1_o
bone NN 1_o
metabolism NN 1_o
were VBD N
studied VBN N
before IN N
therapy NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

In IN N
group NN N
1 CD N
( ( N
risedronate VB N
plus CC N
calcium/vitamin VB N
D-treated JJ N
patients NNS N
) ) N
, , N
serum JJ 1_o
levels NNS 1_o
of IN 1_o
RANKL NNP 1_o
and CC 1_o
IL-1beta NNP 1_o
significantly RB 1_o
decreased VBD 1_o
and CC N
the DT N
level NN 1_o
of IN 1_o
osteoprotegerin JJ 1_o
significantly RB 1_o
increased VBN 1_o
after IN N
three CD N
and CC N
6 CD N
months NNS N
, , N
but CC N
no DT N
significant JJ 1_o
difference NN 1_o
was VBD 1_o
found VBN 1_o
in IN 1_o
TNF-alpha NNP 1_o
level NN 1_o
. . 1_o

In IN N
group NN N
2 CD N
, , N
however RB N
, , N
the DT N
level NN 1_o
of IN 1_o
serum JJ 1_o
cytokines NNS 1_o
did VBD N
not RB N
change NN N
after IN N
three CD N
and CC N
6 CD N
months NNS N
. . N

In IN N
cases NNS N
of IN N
bone NN 1_o
turnover NN 1_o
, , 1_o
both DT 1_o
markers NNS 1_o
of IN 1_o
bone NN 1_o
resorption NN 1_o
and CC 1_o
formation NN 1_o
significantly RB 1_o
decreased VBN 1_o
after IN N
6 CD N
months NNS N
in IN N
group NN N
1 CD N
. . N

In IN N
conclusion NN N
risedronate NN N
could MD N
improve VB N
osteoporosis NN N
by IN N
increasing VBG N
osteoprotegerin NN N
and CC N
reducing VBG N
RANKL NNP N
and CC N
IL-1beta NNP N
. . N

Effects NNS N
of IN N
nitric JJ 1_i
oxide JJ 1_i
synthase NN 1_i
inhibition NN 1_i
on IN N
cutaneous JJ 1_o
vasodilation NN 1_o
in IN N
response NN N
to TO N
acupuncture VB 1_i
stimulation NN N
in IN N
humans NNS 1_p
. . 1_p

OBJECTIVES IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
elucidate VB N
the DT N
mechanism NN N
of IN N
cutaneous JJ N
vasodilation NN N
following VBG N
acupuncture NN N
stimulation NN N
by IN N
investigating VBG N
the DT N
roles NNS N
of IN N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
and CC N
axon $ N
reflex JJ N
vasodilation NN N
. . N

METHODS NNP N
The DT N
subjects NNS N
were VBD N
17 CD 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
. . 1_p

The DT N
role NN N
of IN N
NO NNP N
was VBD N
investigated VBN N
by IN N
administering VBG N
N NNP 1_i
( ( 1_i
G NNP 1_i
) ) 1_i
-nitro-l-arginine VBP 1_i
methyl JJ 1_i
ester NN 1_i
hydrochloride NN 1_i
( ( 1_i
L-NAME NNP 1_i
, , N
20 CD N
mM NN N
) ) N
, , N
an DT N
NO NNP 1_i
synthase NN 1_i
inhibitor NN 1_i
or CC N
Ringer NNP 1_i
's POS 1_i
solution NN 1_i
( ( N
control VB N
site NN N
) ) N
, , N
via IN N
intradermal JJ N
microdialysis NN N
( ( N
protocol JJ N
1 CD N
; : N
n=7 NN N
) ) N
. . N

The DT N
role NN N
of IN N
axon JJ N
reflex JJ N
vasodilation NN N
by IN N
local JJ N
sensory NN N
neurones NNS N
was VBD N
investigated VBN N
by IN N
comparing VBG N
vasodilation NN N
at IN N
sites NNS N
treated VBN N
with IN N
'eutectic JJ 1_i
mixture NN 1_i
of IN 1_i
local JJ 1_i
anaesthetics NNS 1_i
' POS 1_i
( ( 1_i
EMLA NNP 1_i
) ) 1_i
cream NN N
( ( N
2.5 CD N
% NN N
lidocaine NN 1_i
and CC N
2.5 CD N
% NN N
prilocaine NN 1_i
) ) 1_i
with IN N
untreated JJ N
sites NNS N
( ( N
control VB N
site NN N
) ) N
( ( N
protocol JJ N
2 CD N
; : N
n=10 NN N
) ) N
. . N

After IN N
5 CD N
min NN N
of IN N
baseline NN N
recording NN N
, , N
acupuncture NN 1_i
was VBD N
applied VBN N
to TO N
PC4 NNP N
and CC N
a DT N
control NN N
site NN N
in IN N
proximity NN N
to TO N
PC4 NNP N
for IN N
10 CD N
min NNS N
and CC N
scanning NN N
was VBD N
performed VBN N
for IN N
60 CD N
min NN N
after IN N
acupuncture JJ N
stimulation NN N
. . N

Skin NNP 1_o
blood NN 1_o
flow NN 1_o
( ( 1_o
SkBF NNP 1_o
) ) 1_o
was VBD N
evaluated VBN N
by IN N
laser NN N
Doppler NNP 1_o
perfusion NN 1_o
imaging VBG 1_o
. . 1_o

Cutaneous JJ 1_o
vascular JJ 1_o
conductance NN 1_o
( ( 1_o
CVC NNP 1_o
) ) 1_o
was VBD N
calculated VBN N
from IN N
the DT N
ratio NN N
of IN N
SkBF NNP N
to TO N
mean VB N
arterial JJ N
blood NN N
pressure NN N
. . N

RESULTS NNP N
In IN N
the DT N
first JJ N
protocol NN N
, , N
sites NNS N
administered VBD N
L-NAME NNP N
showed VBD N
significant JJ N
reductions NNS N
in IN N
CVC NNP 1_o
responses NNS 1_o
following VBG N
acupuncture NN N
stimulation NN N
compared VBN N
to TO N
control VB N
sites NNS N
( ( N
administered VBN N
Ringer NNP 1_i
's POS 1_i
solution NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
second JJ N
protocol NN N
, , N
changes NNS 1_o
in IN 1_o
CVC NNP 1_o
responses NNS 1_o
after IN N
acupuncture JJ N
stimulation NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
treated VBN N
sites NNS N
with IN N
EMLA NNP 1_i
cream NN N
and CC N
untreated JJ N
sites NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
cutaneous JJ N
vasodilation NN N
in IN N
response NN N
to TO N
acupuncture VB N
stimulation NN N
may MD N
not RB N
occur VB N
through IN N
an DT N
axon JJ N
reflex NN N
as IN N
previously RB N
reported VBN N
. . N

Rather NNP N
, , N
NO NNP N
mechanisms NN N
appear VBP N
to TO N
contribute VB N
to TO N
the DT N
vasodilator NN N
response NN N
. . N

Intense JJ 1_p
androgen-deprivation NN 1_i
therapy NN 1_i
with IN 1_i
abiraterone NN 1_i
acetate NN 1_i
plus CC 1_i
leuprolide JJ 1_i
acetate NN 1_i
in IN 1_p
patients NNS 1_p
with IN 1_p
localized JJ 1_p
high-risk JJ 1_p
prostate NN 1_p
cancer NN 1_p
: : 1_p
results NNS 1_p
of IN 1_p
a DT 1_p
randomized JJ 1_p
phase NN 1_p
II NNP 1_p
neoadjuvant NN 1_p
study NN 1_p
. . 1_p

PURPOSE NNP N
Cure NNP N
rates NNS N
for IN N
localized JJ N
high-risk JJ N
prostate NN N
cancers NNS N
( ( N
PCa NNP N
) ) N
and CC N
some DT N
intermediate-risk JJ N
PCa NNP N
are VBP N
frequently RB N
suboptimal JJ N
with IN N
local JJ N
therapy NN N
. . N

Outcomes CC N
are VBP N
improved VBN N
by IN N
concomitant JJ N
androgen-deprivation NN N
therapy NN N
( ( N
ADT NNP N
) ) N
with IN N
radiation NN N
therapy NN N
, , N
but CC N
not RB N
by IN N
concomitant JJ N
ADT NNP N
with IN N
surgery NN N
. . N

Luteinizing VBG N
hormone-releasing JJ N
hormone NN N
agonist NN N
( ( N
LHRHa NNP N
; : N
leuprolide JJ N
acetate NN N
) ) N
does VBZ N
not RB N
reduce VB N
serum NN 1_o
androgens NNS 1_o
as RB N
effectively RB N
as IN N
abiraterone NN N
acetate NN N
( ( N
AA NNP N
) ) N
, , N
a DT N
prodrug NN N
of IN N
abiraterone NN N
, , N
a DT N
CYP17 NNP N
inhibitor NN N
that IN N
lowers VBZ N
serum VBP N
testosterone NN N
( ( N
< JJ N
1 CD N
ng/dL NN N
) ) N
and CC N
improves VBZ N
survival NN N
in IN N
metastatic JJ N
PCa NNP N
. . N

The DT N
possibility NN N
that IN N
greater JJR N
androgen NN N
suppression NN N
in IN N
patients NNS N
with IN N
localized JJ N
high-risk JJ N
PCa NNP N
will MD N
result VB N
in IN N
improved JJ N
clinical JJ N
outcomes NNS N
makes VBZ N
paramount VBP N
the DT N
reassessment NN N
of IN N
neoadjuvant JJ N
ADT NNP N
with IN N
more RBR N
robust JJ N
androgen NN N
suppression NN N
. . N

PATIENTS NNP 1_p
AND CC 1_p
METHODS NNP 1_p
A NNP 1_p
neoadjuvant JJ 1_p
randomized VBN 1_p
phase NN 1_p
II NNP 1_p
trial NN 1_p
of IN 1_p
LHRHa NNP 1_i
with IN 1_i
AA NNP 1_i
was VBD 1_p
conducted VBN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
localized JJ 1_p
high-risk JJ 1_p
PCa NNP 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
58 CD 1_p
) ) 1_p
. . 1_p

For IN 1_p
the DT 1_p
first JJ 1_p
12 CD 1_p
weeks NNS 1_p
, , 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
LHRHa NNP 1_i
versus NN 1_i
LHRHa NNP 1_i
plus CC 1_i
AA NNP 1_i
. . 1_i

After IN 1_p
a DT 1_p
research NN 1_p
prostate NN 1_p
biopsy NN 1_p
, , 1_p
all DT 1_p
patients NNS 1_p
received VBD 1_p
12 CD 1_p
additional JJ 1_p
weeks NNS 1_p
of IN 1_p
LHRHa NNP 1_i
plus CC 1_i
AA NNP 1_i
followed VBN 1_i
by IN 1_i
prostatectomy NN 1_i
. . 1_i

RESULTS VB N
The DT N
levels NNS 1_o
of IN 1_o
intraprostatic JJ 1_o
androgens NNS 1_o
from IN N
12-week JJ N
prostate NN N
biopsies NNS N
, , N
including VBG N
the DT N
primary JJ 1_o
end NN 1_o
point NN 1_o
( ( 1_o
dihydrotestosterone/testosterone NN 1_o
) ) 1_o
, , N
were VBD N
significantly RB N
lower JJR N
( ( N
dehydroepiandrosterone NN N
, , N
Δ NNP N
( ( N
4 CD N
) ) N
-androstene-3,17-dione NN N
, , N
dihydrotestosterone NN N
, , N
all DT N
P NNP N
< NNP N
.001 NNP N
; : N
testosterone NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
with IN N
LHRHa NNP N
plus CC N
AA NNP N
compared VBN N
with IN N
LHRHa NNP N
alone RB N
. . N

Prostatectomy NNP N
pathologic JJ N
staging NN N
demonstrated VBD N
a DT N
low JJ 1_o
incidence NN 1_o
of IN 1_o
complete JJ 1_o
responses NNS 1_o
and CC N
minimal JJ 1_o
residual JJ 1_o
disease NN 1_o
, , N
with IN N
residual JJ N
T3- NNP N
or CC N
lymph JJ N
node-positive JJ N
disease NN N
in IN N
the DT N
majority NN N
. . N

CONCLUSION NNP 1_i
LHRHa NNP 1_i
plus CC 1_i
AA NNP 1_i
treatment NN N
suppresses NNS 1_o
tissue VBP 1_o
androgens VBZ 1_o
more RBR N
effectively RB N
than IN 1_i
LHRHa NNP 1_i
alone RB 1_i
. . N

Intensive JJ N
intratumoral JJ 1_o
androgen NN 1_o
suppression NN 1_o
with IN 1_i
LHRHa NNP 1_i
plus CC 1_i
AA NNP 1_i
before IN N
prostatectomy NN N
for IN N
localized JJ N
high-risk JJ N
PCa NNP N
may MD N
reduce VB N
tumor NN N
burden NN N
. . N

Development NNP N
of IN N
an DT N
adaptive JJ 1_i
low-pass NN 1_i
filtered VBD 1_i
speech JJ 1_i
test NN 1_i
for IN N
the DT N
identification NN N
of IN N
auditory NN 1_o
processing NN 1_o
disorders NNS 1_o
. . 1_o

OBJECTIVE CC N
One CD N
type NN N
of IN N
test NN N
commonly RB N
used VBD N
to TO N
examine VB N
auditory JJ 1_p
processing NN 1_p
disorders NNS 1_p
( ( 1_p
APD NNP 1_p
) ) 1_p
is VBZ N
the DT N
low-pass NN 1_i
filtered VBD 1_i
speech JJ 1_i
test NN 1_i
( ( N
LPFST NNP N
) ) N
, , N
of IN N
which WDT N
there EX N
are VBP N
various JJ N
versions NNS N
. . N

In IN N
LPFSTs NNP N
, , N
a DT N
monaural JJ N
, , N
low-redundancy JJ N
speech NN N
sample NN N
is VBZ N
distorted VBN N
by IN N
using VBG N
filtering VBG N
to TO N
modify VB N
its PRP$ N
frequency NN N
content NN N
. . N

Due JJ N
to TO N
the DT N
richness NN N
of IN N
the DT N
neural JJ N
pathways NNS N
in IN N
the DT N
auditory NN N
system NN N
and CC N
the DT N
redundancy NN N
of IN N
acoustic JJ N
information NN N
in IN N
spoken JJ N
language NN N
, , N
a DT N
normal JJ N
listener NN N
is VBZ N
able JJ N
to TO N
recognize VB N
speech NN N
even RB N
when WRB N
parts NNS N
of IN N
the DT N
signal NN N
are VBP N
missing VBG N
, , N
whereas IN N
this DT N
ability NN N
is VBZ N
often RB N
impaired VBN N
in IN N
listeners NNS 1_p
with IN 1_p
APD NNP 1_p
. . 1_p

One CD N
limitation NN N
of IN N
the DT N
various JJ N
versions NNS N
of IN N
the DT N
LPFST NNP 1_i
is VBZ N
that IN N
they PRP N
are VBP N
carried VBN N
out IN N
using VBG N
a DT N
constant JJ N
level NN N
of IN N
low-pass JJ N
filtering NN N
( ( N
e.g NN N
. . N

a DT N
fixed JJ N
1kHz CD N
corner NN N
frequency NN N
) ) N
which WDT N
makes VBZ N
them PRP N
prone VB N
to TO N
ceiling NN N
and CC N
floor NN N
effects NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
counter VB N
these DT N
effects NNS N
by IN N
modifying VBG N
the DT N
LPFST NNP N
using VBG N
a DT N
computer-based JJ N
adaptive JJ N
procedure NN N
, , N
and CC N
to TO N
evaluate VB N
the DT N
performance NN N
of IN N
normal-hearing JJ 1_p
participants NNS 1_p
of IN 1_p
varying VBG 1_p
ages NNS 1_p
on IN N
the DT N
test NN N
. . N

METHODS NNP N
In IN N
this DT N
preliminary JJ N
study NN N
, , N
33 CD 1_p
adults NNS 1_p
and CC 1_p
30 CD 1_p
children NNS 1_p
( ( 1_p
aged VBN 1_p
8-11 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
no DT 1_p
known JJ 1_p
history NN 1_p
of IN 1_p
listening VBG 1_p
difficulties NNS 1_p
were VBD N
tested VBN N
. . N

The DT 1_i
University NNP 1_i
of IN 1_i
Canterbury NNP 1_i
Adaptive NNP 1_i
Speech NNP 1_i
Test NNP 1_i
( ( 1_i
UCAST NNP 1_i
) ) 1_i
platform NN 1_i
was VBD 1_i
used VBN 1_i
to TO 1_i
administer VB 1_i
a DT 1_i
four-alternative JJ 1_i
forced-choice JJ 1_i
adaptive JJ 1_i
test NN 1_i
that WDT 1_i
altered VBD 1_i
a DT 1_i
low-pass JJ 1_i
filter NN 1_i
( ( 1_i
LPF NNP 1_i
) ) 1_i
to TO 1_i
track VB 1_i
the DT 1_i
corner NN 1_i
frequency NN 1_i
at IN 1_i
which WDT 1_i
participants NNS 1_i
correctly RB 1_i
identified VBN 1_i
a DT 1_i
certain JJ 1_i
percentage NN 1_i
of IN 1_i
the DT 1_i
word NN 1_i
stimuli NN 1_i
. . 1_i

RESULTS NNP N
Findings NNP N
on IN N
the DT N
University NNP 1_o
of IN 1_o
Canterbury NNP 1_o
Adaptive NNP 1_o
Speech NNP 1_o
Test-Filtered NNP 1_o
Words NNP 1_o
( ( 1_o
UCAST-FW NNP 1_o
) ) 1_o
indicated VBD N
a DT N
significant JJ 1_o
maturational JJ 1_o
effect NN 1_o
. . 1_o

Adult NN 1_p
participants NNS 1_p
performed VBD N
significantly RB N
better RBR N
on IN N
the DT N
UCAST-FW NNP 1_o
in IN N
comparison NN N
to TO N
the DT N
child NN 1_p
participants NNS 1_p
. . 1_p

The DT N
UCAST-FW JJ 1_i
test NN N
was VBD N
reliable JJ N
over IN N
repeated JJ N
administrations NNS N
. . N

CONCLUSIONS NNP N
An DT N
adaptive JJ N
low-pass NN N
filtered VBD N
speech JJ N
test NN N
such JJ N
as IN N
the DT N
UCAST-FW NNP 1_o
is VBZ N
sensitive JJ N
to TO N
maturational JJ 1_o
changes NNS 1_o
in IN 1_o
auditory NN 1_o
processing NN 1_o
ability NN 1_o
. . 1_o

Pharmacist NNP 1_i
directed VBD 1_i
home NN 1_i
medication NN 1_i
reviews NNS N
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
heart NN 1_p
failure NN 1_p
: : 1_p
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Chronic NNP 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
CHF NNP 1_p
) ) 1_p
accounts NNS N
for IN N
significant JJ N
morbidity NN N
, , N
mortality NN N
and CC N
health NN N
expenditure NN N
. . N

Furthermore NNP N
, , N
patients NNS 1_p
with IN 1_p
CHF NNP 1_p
are VBP N
often RB N
on IN N
numerous JJ N
pharmacological JJ N
agents NNS N
for IN N
their PRP$ N
comorbidities NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
pharmacist NN N
directed VBD N
home NN 1_i
medication NN 1_i
review NN N
intervention NN N
had VBD N
positive JJ N
effects NNS N
on IN N
CHF NNP 1_p
patient NN 1_p
outcomes NNS N
. . N

METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
120 CD 1_p
patients NNS 1_p
hospitalised VBN 1_p
for IN 1_p
CHF NNP 1_p
were VBD N
randomised VBN N
to TO N
receive VB N
a DT N
pharmacist NN 1_i
directed VBD 1_i
post-discharge JJ 1_i
home NN 1_i
medication NN 1_i
review NN 1_i
( ( N
n JJ N
= NN N
64 CD N
, , N
53.3 CD N
% NN N
) ) N
or CC N
standard JJ 1_i
care NN 1_i
( ( N
n JJ N
= NN N
56 CD N
, , N
46.7 CD N
% NN N
) ) N
. . N

Participants NNS N
were VBD N
followed VBN N
for IN N
6 CD N
months NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
death NN N
, , N
CHF NNP 1_o
hospitalisation NN 1_o
and CC N
length NN N
of IN N
hospital NN N
stay NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
between IN N
group NN N
differences NNS N
in IN N
mortality NN 1_o
( ( N
hazard JJ N
ratio NN N
= VBD N
1.41 CD N
, , N
0.50 CD N
to TO N
3.97 CD N
; : N
P NNP N
= NNP N
0.514 CD N
) ) N
or CC N
CHF NNP 1_o
hospitalizations NNS 1_o
( ( N
incidence NN N
rate NN N
ratio NN N
[ NNP N
IRR NNP N
] NNP N
= VBD N
1.74 CD N
95 CD N
% NN N
CI NNP N
: : N
0.85-3.60 JJ N
P NNP N
= NNP N
0.131 CD N
) ) N
over IN N
the DT N
6 CD N
month NN N
follow-up JJ N
period NN N
. . N

Days NNS 1_o
of IN 1_o
hospital NN 1_o
stay NN 1_o
for IN 1_o
CHF NNP 1_o
exacerbations NNS 1_o
in IN N
the DT N
6 CD N
month NN N
follow-up NN N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
intervention NN N
group NN N
( ( N
IRR NNP N
= NNP N
2.34 CD N
95 CD N
% NN N
CI NNP N
: : N
1.80-3.05 JJ N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

CONCLUSIONS NNP N
Post-discharge NNP N
pharmacy NN 1_i
directed VBD 1_i
home NN 1_i
medication NN 1_i
review NN 1_i
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
on IN N
mortality NN N
and CC N
health NN N
care NN N
utilisation NN N
above IN N
that DT N
achieved VBD N
with IN N
standard JJ N
care NN N
. . N

The DT N
post-acute JJ N
management NN N
of IN N
CHF NNP N
must MD N
be VB N
a DT N
collaborative JJ N
multi-disciplinary JJ N
effort NN N
by IN N
the DT N
health NN N
care NN N
team NN N
as IN N
it PRP N
is VBZ N
the DT N
additive JJ N
effect NN N
of IN N
interventions NNS N
that WDT N
are VBP N
most RBS N
effective JJ N
. . N

Assessing VBG N
drug NN N
use NN N
prevalence NN N
in IN N
the DT N
workplace NN N
: : N
a DT N
comparison NN N
of IN N
self-report JJ N
methods NNS N
and CC N
urinalysis NN N
. . N

A DT 1_p
random JJ 1_p
sample NN 1_p
of IN 1_p
800 CD 1_p
employees NNS 1_p
of IN 1_p
a DT 1_p
steel NN 1_p
manufacturing VBG 1_p
company NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
self-report JJ 1_i
methods NNS 1_i
of IN N
assessing VBG N
illicit JJ 1_i
drug NN 1_i
use NN 1_i
: : 1_i
1 CD 1_i
) ) 1_i
Individual NNP 1_i
interview NN 1_i
in IN 1_i
the DT 1_i
workplace NN 1_i
, , 1_i
2 CD 1_i
) ) 1_i
group-administered JJ 1_i
questionnaire NN 1_i
in IN 1_i
the DT 1_i
workplace NN 1_i
, , 1_i
3 CD 1_i
) ) 1_i
telephone NN 1_i
interview NN 1_i
, , 1_i
and CC 1_i
4 CD 1_i
) ) 1_i
individual JJ 1_i
interview NN 1_i
off IN 1_i
the DT 1_i
worksite NN 1_i
. . 1_i

All DT 1_p
621 CD 1_p
subjects NNS 1_p
participating VBG 1_p
in IN 1_p
the DT 1_p
research NN 1_p
were VBD 1_p
also RB 1_p
tested VBN 1_p
by IN 1_p
urinalysis NN 1_p
. . 1_p

Rates NNS 1_o
of IN 1_o
drug NN 1_o
use IN 1_o
self-report NN 1_o
were VBD N
highest JJS N
in IN N
the DT N
workplace NN N
interview NN N
condition NN N
and CC N
lowest JJS N
in IN N
the DT N
overall JJ N
group NN N
questionnaire NN N
condition NN N
. . N

Although IN N
the DT N
overall JJ 1_o
prevalence NN 1_o
rates NNS 1_o
produced VBN N
by IN N
self-reports NNS N
and CC N
urinalysis NN N
were VBD N
similar JJ N
, , N
there EX N
was VBD N
little JJ N
concordance NN N
between IN N
urinalysis NN 1_o
positives NNS 1_o
and CC N
self-report JJ 1_o
positives NNS 1_o
. . 1_o

The DT N
results NNS N
indicated VBD N
that IN N
self-reports NNS N
and CC N
urinalysis NN N
are VBP N
complementary JJ N
methods NNS N
of IN N
drug NN 1_o
use NN 1_o
assessment NN 1_o
, , N
and CC N
are VBP N
best JJS N
used VBN N
in IN N
combination NN N
. . N

Torasemide NNP 1_i
versus NN N
furosemide NN 1_i
in IN N
cirrhosis NN 1_p
: : 1_p
a DT N
long-term JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
effects NNS N
of IN N
long-term JJ N
therapy NN N
( ( N
70 CD N
days NNS N
) ) N
with IN N
torasemide NN 1_i
( ( N
20 CD N
mg/day NN N
) ) N
, , N
a DT N
new JJ N
loop NN N
diuretic JJ N
, , N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
furosemide NN 1_i
( ( N
50 CD N
mg/day NN N
) ) N
in IN N
a DT N
randomized JJ N
double-blind JJ N
trial NN N
. . N

Both DT N
drugs NNS N
were VBD N
administered VBN N
in IN N
association NN N
with IN N
spironolactone NN 1_i
( ( N
200 CD N
mg/day NN N
) ) N
in IN N
28 CD 1_p
nonazotemic JJ 1_p
cirrhotic JJ 1_p
patients NNS 1_p
with IN 1_p
controlled JJ 1_p
ascites NNS 1_p
. . 1_p

The DT N
treatments NNS N
did VBD N
not RB N
modify VB N
creatinine JJ 1_o
clearance NN 1_o
and CC N
exhibited VBD N
a DT N
similar JJ N
effect NN N
on IN N
body NN 1_o
weight NN 1_o
, , 1_o
urinary JJ 1_o
volume NN 1_o
, , N
and CC N
fractional JJ 1_o
excretion NN 1_o
of IN 1_o
uric JJ 1_o
acid NN 1_o
, , 1_o
sodium NN 1_o
, , 1_o
and CC 1_o
chloride NN 1_o
. . 1_o

The DT N
effect NN N
of IN N
torasemide NN 1_i
on IN N
fractional JJ 1_o
potassium NN 1_o
excretion NN 1_o
was VBD N
lower JJR N
than IN N
that DT N
of IN N
furosemide NN 1_i
. . 1_i

Torasemide VB 1_i
showed VBD N
higher JJR N
sparing VBG 1_o
effect NN 1_o
than IN N
furosemide NN 1_i
on IN N
calcium NN 1_o
, , 1_o
inorganic JJ 1_o
phosphate NN 1_o
, , 1_o
and CC 1_o
magnesium NN 1_o
excretion NN 1_o
and CC N
stronger JJR N
action NN N
on IN N
free JJ 1_o
water NN 1_o
clearance NN 1_o
. . 1_o

No DT N
changes NNS N
in IN N
serum NN 1_o
parameters NNS 1_o
were VBD N
induced VBN N
by IN N
either DT N
treatment NN N
. . N

Two CD N
episodes NNS N
of IN N
hepatic JJ 1_o
encephalopathy NN 1_o
occurred VBD N
in IN N
the DT N
torasemide NN 1_i
group NN N
. . N

In IN N
view NN N
of IN N
its PRP$ N
effects NNS 1_o
on IN 1_o
sodium NN 1_o
and CC 1_o
water NN 1_o
excretion NN 1_o
and CC N
on IN 1_o
other JJ 1_o
urinary JJ 1_o
parameters NNS 1_o
, , N
torasemide NN 1_i
can MD N
represent VB N
an DT N
alternative JJ N
tool NN N
for IN N
the DT N
long-term JJ N
treatment NN N
of IN N
ascites NNS 1_p
. . 1_p

Remifentanil NNP N
with IN N
morphine JJ N
transitional JJ N
analgesia NN N
shortens VBZ N
neurological JJ 1_o
recovery NN 1_o
compared VBN N
to TO N
fentanyl VB N
for IN N
supratentorial JJ N
craniotomy NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
recovery NN 1_o
profiles NNS 1_o
, , 1_o
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
remifentanil NN N
and CC N
morphine NN N
for IN N
transitional JJ N
analgesia NN N
with IN N
fentanyl NN N
in IN N
patients NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
craniotomy NN 1_p
for IN 1_p
supratentorial JJ 1_p
mass NN 1_p
lesions NNS 1_p
. . 1_p

METHODS NNP N
Ninety-one JJ 1_p
patients NNS 1_p
were VBD N
enrolled VBN N
in IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
study NN N
. . N

Anesthesia NNP 1_i
was VBD 1_i
induced VBN 1_i
with IN 1_i
thiopental JJ 1_i
and CC 1_i
remifentanil NN 1_i
( ( 1_i
1.0 CD 1_i
micro NN 1_i
g NN 1_i
x NNP 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
bolus NN 1_i
and CC 1_i
a DT 1_i
1 CD 1_i
micro NN 1_i
g NN 1_i
x NNP 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
x VBP 1_i
min NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
infusion NN 1_i
) ) 1_i
or CC 1_i
fentanyl NN 1_i
( ( 1_i
1 CD 1_i
micro NN 1_i
g NN 1_i
x NNP 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
bolus NN 1_i
and CC 1_i
a DT 1_i
1.0 CD 1_i
micro NN 1_i
g NN 1_i
x NNP 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
x VBP 1_i
min NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
infusion NN 1_i
) ) 1_i
. . 1_i

The DT 1_i
opioid JJ 1_i
infusion NN 1_i
continued VBD 1_i
until IN 1_i
the DT 1_i
level NN 1_i
of IN 1_i
anesthesia NN 1_i
was VBD 1_i
deemed VBN 1_i
appropriate JJ 1_i
for IN 1_i
intubation NN 1_i
. . 1_i

Anesthesia NNP 1_i
was VBD 1_i
maintained VBN 1_i
with IN 1_i
N NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
O/O NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
, , 1_i
isoflurane $ 1_i
0.5 CD 1_i
MAC NNP 1_i
and CC 1_i
remifentanil VB 1_i
0.2 CD 1_i
micro NN 1_i
g NN 1_i
x NNP 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
x VBP 1_i
min NN 1_i
( ( 1_i
-1 JJ 1_i
) ) 1_i
or CC 1_i
fentanyl $ 1_i
0.04 CD 1_i
micro NN 1_i
g NN 1_i
x NNP 1_i
kg NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
x VBP 1_i
min NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
. . 1_i

At IN 1_i
bone NN 1_i
flap NN 1_i
replacement NN 1_i
, , 1_i
either DT 1_i
morphine NN 1_i
0.08 CD 1_i
mg NN 1_i
x NN 1_i
kg NN 1_i
( ( 1_i
-1 NN 1_i
) ) 1_i
( ( 1_i
remifentanil JJ 1_i
group NN 1_i
) ) 1_i
or CC 1_i
saline NN 1_i
( ( 1_i
fentanyl JJ 1_i
group NN 1_i
) ) 1_i
was VBD 1_i
given VBN 1_i
. . 1_i

RESULTS NNP N
Systolic NNP 1_o
blood NN 1_o
pressure NN 1_o
was VBD N
greater JJR N
in IN N
those DT N
receiving VBG N
fentanyl NN N
during IN N
induction NN N
( ( N
145.6 CD N
+/-17.5 JJ N
mmHg NN N
vs NN N
128.8 CD N
+/-18.3 JJ N
mmHg NN N
; : N
P NNP N
= NNP N
0.006 CD N
) ) N
and CC N
intubation NN N
( ( N
126.9 CD N
+/-17.1 JJ N
vs NN N
110.9 CD N
+/-16.5 JJ N
mmHg NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Median JJ 1_o
time NN 1_o
to TO 1_o
tracheal VB 1_o
extubation NN 1_o
was VBD N
similar JJ N
but CC N
less RBR N
variable JJ N
in IN N
the DT N
remifentanil NN N
group NN N
( ( N
remifentanil JJ N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
2-44 JJ N
min NN N
; : N
fentanyl CC N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
1-732 JJ N
min NN N
) ) N
. . N

The DT N
fentanyl JJ N
patients NNS N
required VBD N
a DT N
longer JJR N
time NN 1_o
to TO 1_o
achieve VB 1_o
the DT 1_o
first JJ 1_o
normal JJ 1_o
neurological JJ 1_o
score NN 1_o
( ( N
fentanyl JJ N
= $ N
38.0 CD N
min NN N
; : N
remifentanil CC N
= $ N
26.0 CD N
min NN N
; : N
P NNP N
= NNP N
0.035 CD N
) ) N
. . N

Both CC N
the DT N
anesthesiologists NNS N
and CC N
the DT N
recovery NN N
room NN N
nurses NNS N
rated VBD N
remifentanil JJ N
better RBR N
with IN N
respect NN N
to TO N
level NN 1_o
of IN 1_o
consciousness NN 1_o
. . 1_o

Analgesics NNS 1_o
were VBD N
required VBN N
earlier RBR N
in IN N
patients NNS N
receiving VBG N
remifentanil NN N
; : N
median JJ N
time NN N
0.5 CD N
vs NN N
1.08 CD N
hr NN N
, , N
P NNP N
< VBZ N
0.001 CD N
. . N

CONCLUSIONS NNP N
Remifentanil NNP N
is VBZ N
a DT N
suitable JJ N
alternative NN N
to TO N
fentanyl VB N
in IN N
supratentorial JJ N
craniotomy NN N
. . N

Time NN 1_o
to TO 1_o
preoperative VB 1_o
neurological JJ 1_o
recovery NN 1_o
is VBZ N
faster RBR N
and CC N
morphine VB N
provides VBZ N
some DT N
transitional JJ 1_o
analgesia NN 1_o
without IN N
compromising VBG N
the DT N
quality NN 1_o
of IN 1_o
recovery NN 1_o
. . 1_o

Differences NNS N
in IN N
quality NN 1_o
of IN 1_o
life NN 1_o
outcomes NNS N
among IN N
depressed JJ 1_p
spinal JJ 1_p
cord NN 1_p
injury NN 1_p
trial NN 1_p
participants NNS 1_p
. . 1_p

OBJECTIVE NN N
To TO N
assess VB N
the DT N
role NN N
that WDT N
treatment NN N
response NN N
plays VBZ N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
an DT N
antidepressant JJ 1_i
among IN N
people NNS 1_p
with IN 1_p
spinal JJ 1_p
cord NN 1_p
injury NN 1_p
( ( 1_p
SCI NNP 1_p
) ) 1_p
diagnosed VBD 1_p
with IN 1_p
major JJ 1_p
depressive JJ 1_p
disorder NN 1_p
( ( 1_p
MDD NNP 1_p
) ) 1_p
in IN N
explaining VBG N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
, , N
assessed VBD N
both DT N
globally RB N
as IN N
life NN N
satisfaction NN N
and CC N
in IN N
terms NNS N
of IN N
physical JJ N
and CC N
mental JJ N
health-related JJ N
QOL NNP N
. . N

DESIGN NNP N
Multivariable JJ N
analyses NNS N
were VBD N
conducted VBN N
, , N
controlling VBG N
for IN N
demographic JJ N
, , N
neurologic JJ N
, , N
and CC N
participatory JJ N
factors NNS N
and CC N
perceived VBD N
functional JJ N
limitations NNS N
. . N

SETTING NN N
Rehabilitation NN N
centers NNS N
. . N

PARTICIPANTS NNS N
Of IN 1_p
the DT 1_p
133 CD 1_p
persons NNS 1_p
who WP 1_p
were VBD 1_p
randomized VBN 1_p
into IN 1_p
the DT 1_p
Project NN 1_i
to TO 1_i
Improve VB 1_i
Symptoms NNP 1_i
and CC 1_i
Mood NNP 1_i
after IN 1_p
Spinal NNP 1_p
Cord NNP 1_p
Injury NNP 1_p
randomized VBD 1_p
controlled VBN 1_p
trial NN 1_p
, , 1_p
124 CD 1_p
participated VBN 1_p
in IN 1_p
this DT 1_p
study NN 1_p
. . 1_p

All DT 1_p
participants NNS 1_p
were VBD 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
18 CD 1_p
and CC 1_p
64 CD 1_p
years NNS 1_p
, , 1_p
at IN 1_p
least JJS 1_p
1 CD 1_p
month NN 1_p
post-SCI NN 1_p
, , 1_p
met VBD 1_p
the DT 1_p
Diagnostic NNP 1_p
and CC 1_p
Statistical NNP 1_p
Manual NNP 1_p
of IN 1_p
Mental NNP 1_p
Disorders NNP 1_p
, , 1_p
4th CD 1_p
edition NN 1_p
, , 1_p
criteria NNS 1_p
for IN 1_p
MDD NNP 1_p
, , 1_p
and CC 1_p
completed VBD 1_p
the DT 1_p
core NN 1_p
measures NNS 1_p
used VBN 1_p
in IN 1_p
this DT 1_p
study NN 1_p
. . 1_p

INTERVENTIONS NNP N
Not RB N
applicable JJ N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT 1_o
Satisfaction NNP 1_o
with IN 1_o
Life NNP 1_o
Scale NNP 1_o
and CC 1_o
the DT 1_o
physical JJ 1_o
and CC 1_o
mental JJ 1_o
component NN 1_o
summary JJ 1_o
scores NNS 1_o
of IN 1_o
the DT 1_o
Medical NNP 1_o
Outcomes NNP 1_o
Study NNP 1_o
12-Item JJ 1_o
Short-Form NNP 1_o
Health NNP 1_o
Survey NNP 1_o
. . 1_o

RESULTS NNP N
Reduction NNP 1_o
in IN 1_o
depressive JJ 1_o
symptoms NNS 1_o
over IN N
the DT N
course NN N
of IN N
a DT N
12-week JJ N
trial NN N
was VBD N
predictive JJ N
of IN N
increased JJ N
QOL NNP 1_o
, , 1_o
which WDT 1_o
was VBD 1_o
measured VBN 1_o
as IN 1_o
life NN 1_o
satisfaction NN 1_o
and CC 1_o
mental JJ 1_o
well-being NN 1_o
, , N
within IN N
the DT N
context NN N
of IN N
other JJ N
explanatory JJ N
factors NNS N
. . N

However RB N
, , N
reduction NN 1_o
in IN 1_o
symptoms NNS 1_o
did VBD N
not RB N
explain VB N
differences NNS N
in IN N
physical JJ N
well-being NN N
among IN N
those DT N
with IN N
MDD NNP N
. . N

Perceived NNP 1_o
functional JJ 1_o
disability NN 1_o
explained VBD N
all DT N
3 CD N
indices NNS N
of IN N
QOL NNP N
. . N

CONCLUSIONS NNP N
Greater NNP N
recognition NN N
has VBZ N
been VBN N
given VBN N
to TO N
QOL NNP N
outcomes RB N
as IN N
endpoints NNS N
of IN N
clinical JJ N
trials NNS N
because IN N
these DT N
often RB N
reflect VBP N
participants NNS 1_p
' POS 1_p
reported VBN N
outcomes NNS N
. . N

Our PRP$ N
findings NNS N
support VB N
the DT N
association NN N
of IN N
QOL NNP N
to TO N
the DT N
reduction NN N
of IN N
depression NN N
symptoms NNS N
among IN N
trial NN 1_p
participants NNS 1_p
. . 1_p

This DT N
association NN N
differs VBZ N
depending VBG N
on IN N
how WRB N
QOL NNP N
is VBZ N
defined VBN N
and CC N
measured VBN N
, , N
with IN N
stronger JJR N
relations NNS N
observed VBN N
with IN N
life NN N
satisfaction NN N
and CC N
mental JJ N
well-being NN N
among IN N
those DT N
diagnosed VBN N
with IN N
MDD NNP N
. . N

The DT N
lack NN N
of IN N
association NN N
between IN N
depression NN N
and CC N
physical JJ N
well-being NN N
may MD N
be VB N
explained VBN N
by IN N
participants NNS 1_p
' POS 1_p
subjective JJ N
interpretation NN N
of IN N
physical JJ N
well-being NN N
after IN N
SCI NNP N
and CC N
their PRP$ N
expectations NNS N
and CC N
perceptions NNS N
of IN N
improved JJ N
physical JJ N
health-related JJ N
QOL NNP N
based VBN N
on IN N
the DT N
use NN N
of IN N
assistive JJ N
technology NN N
. . N

Consistent JJ N
with IN N
our PRP$ N
findings NNS N
, , N
pain NN N
is VBZ N
likely JJ N
to TO N
play VB N
a DT N
role NN N
in IN N
decreasing VBG N
physical JJ N
QOL NNP N
among IN N
those DT 1_p
with IN 1_p
incomplete JJ 1_p
injuries NNS 1_p
. . 1_p

Practicing VBG N
caution NN N
is VBZ N
suggested VBN N
in IN N
using VBG N
physical JJ N
well-being NN N
as IN N
an DT N
endpoint NN N
in IN N
trials NNS N
among IN N
people NNS 1_p
with IN 1_p
SCI NNP 1_p
. . 1_p

Oat NNP 1_i
ingestion NN 1_i
reduces VBZ N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
in IN N
patients NNS 1_p
with IN 1_p
mild JJ 1_p
or CC 1_p
borderline JJ 1_p
hypertension NN 1_p
: : 1_p
a DT N
pilot NN N
trial NN N
. . N

OBJECTIVES IN N
We PRP N
assessed VBD N
the DT N
short-term JJ N
antihypertensive JJ N
effects NNS N
of IN N
soluble JJ 1_i
fiber-rich JJ 1_i
whole JJ 1_i
oat NN 1_i
cereals NNS 1_i
when WRB N
added VBN N
to TO N
a DT N
standard JJ N
American JJ N
diet NN N
. . N

In IN N
addition NN N
, , N
multiple JJ N
assessments NNS N
of IN N
insulin NN N
sensitivity NN N
were VBD N
conducted VBN N
. . N

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
parallel-group JJ N
pilot NN N
study NN N
designed VBN N
to TO N
compare VB N
an DT N
oat NN 1_i
cereal NN 1_i
group NN 1_i
( ( 1_i
standardized VBN 1_i
to TO 1_i
5.52 CD 1_i
g/day JJ 1_i
beta-glucan JJ 1_i
) ) 1_i
to TO 1_i
a DT 1_i
low-fiber JJ 1_i
cereal NN 1_i
control NN 1_i
group NN 1_i
( ( 1_i
less JJR 1_i
than IN 1_i
1.0 CD 1_i
g/day JJ 1_i
total JJ 1_i
fiber NN 1_i
) ) 1_i
over IN 1_i
6 CD 1_i
weeks NNS 1_i
. . 1_i

POPULATION VB N
A DT 1_p
total NN 1_p
of IN 1_p
18 CD 1_p
hypertensive JJ 1_p
and CC 1_p
hyperinsulinemic JJ 1_p
( ( 1_p
= JJ 1_p
10 CD 1_p
U/mL NNP 1_p
or CC 1_p
more JJR 1_p
) ) 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
. . 1_p

OUTCOMES NNP N
MEASURED NNP N
Primary NNP N
study NN N
outcomes NNS N
were VBD N
changes NNS N
in IN N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
SBP NNP 1_o
) ) 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
DBP NNP 1_o
) ) 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
included VBD N
blood NN 1_o
lipid NN 1_o
, , 1_o
fasting VBG 1_o
glucose NN 1_o
, , 1_o
and CC 1_o
insulin NN 1_o
levels NNS 1_o
and CC 1_o
side NN 1_o
effects NNS 1_o
related VBN 1_o
to TO 1_o
elevated VBN 1_o
blood NN 1_o
pressure NN 1_o
and CC 1_o
increased VBD 1_o
dietary JJ 1_o
fiber NN 1_o
intake NN 1_o
. . 1_o

RESULTS VB N
The DT N
oat NN N
cereal NN N
group NN N
experienced VBD N
a DT N
7.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
SBP NNP 1_o
( ( N
P NNP N
& CC N
lt.01 NN N
) ) N
and CC N
a DT N
5.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
DBP NNP 1_o
( ( N
P NNP N
& CC N
lt.02 NN N
) ) N
, , N
while IN N
there EX N
was VBD N
virtually RB N
no DT N
change NN N
in IN N
either DT N
SBP NNP N
or CC N
DBP NNP N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
oat NN N
cereal NN N
group NN N
, , N
a DT N
trend NN N
was VBD N
observed VBN N
for IN N
a DT N
lower JJR N
total JJ 1_o
insulin NN 1_o
response NN 1_o
to TO N
a DT N
glucose JJ N
load NN N
, , N
suggesting VBG N
improved VBN N
insulin JJ N
sensitivity NN N
. . N

However RB N
, , N
this DT N
could MD N
not RB N
be VB N
confirmed VBN N
using VBG N
estimates NNS N
from IN N
the DT N
Bergman NNP N
Minimal NNP N
Model NNP N
, , N
perhaps RB N
because IN N
of IN N
our PRP$ N
small JJ N
sample NN N
size NN N
. . N

The DT N
oats NNS N
group NN N
experienced VBD N
a DT N
significant JJ N
reduction NN N
in IN N
both DT N
total JJ 1_o
cholesterol NN 1_o
( ( N
9 CD N
% NN N
) ) N
and CC N
low-density JJ 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
( ( N
14 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
oat NN 1_i
cereals NNS 1_i
to TO N
the DT N
normal JJ N
diet NN N
of IN N
patients NNS 1_p
with IN 1_p
hypertension NN 1_p
significantly RB N
reduces VBZ N
both DT N
SBP NNP 1_o
and CC 1_o
DBP NNP 1_o
. . 1_o

Soluble JJ 1_i
fiber-rich JJ 1_i
whole JJ 1_i
oats NNS 1_i
may MD N
be VB N
an DT N
effective JJ N
dietary JJ N
therapy NN N
in IN N
the DT N
prevention NN N
and CC N
adjunct JJ N
treatment NN N
of IN N
hypertension NN N
. . N

Polydioxanone NNP 1_i
sternal JJ 1_i
sutures NNS 1_i
for IN N
prevention NN N
of IN N
sternal JJ N
dehiscence NN N
. . N

BACKGROUND NNP N
Sternal NNP 1_o
dehiscence NN 1_o
and CC 1_o
wound NN 1_o
instability NN 1_o
are VBP N
troublesome JJ N
complications NNS N
following VBG N
median JJ N
sternotomy NN N
. . N

Classic JJ N
sternal JJ N
approximation NN N
with IN N
stainless JJ N
steel NN N
wires NNS N
may MD N
not RB N
be VB N
the DT N
ideal JJ N
approach NN N
in IN N
patients NNS N
predisposed VBN N
to TO N
these DT N
complications NNS N
. . N

We PRP N
tested VBD N
the DT N
efficacy NN 1_o
of IN N
polydioxanone NN 1_i
( ( 1_i
PDS NNP 1_i
) ) 1_i
suture NN 1_i
in IN N
sternal JJ 1_o
closure NN 1_o
and CC N
in IN N
prevention NN N
of IN N
complications NNS 1_o
in IN N
comparison NN N
to TO N
steel NN N
wires NNS N
in IN N
high-risk JJ 1_p
individuals NNS 1_p
. . 1_p

METHODS NNP N
Three CD 1_p
hundred VBD 1_p
sixty-six JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
cardiac JJ 1_p
surgery NN 1_p
with IN 1_p
full JJ 1_p
median JJ 1_p
sternotomy NN 1_p
and CC 1_p
having VBG 1_p
body NN 1_p
surface JJ 1_p
area NN 1_p
( ( 1_p
BSA NNP 1_p
) ) 1_p
less JJR 1_p
than IN 1_p
1.5 CD 1_p
m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
PDS NNP 1_i
( ( N
n JJ N
= NNP N
181 CD N
) ) N
or CC N
stainless JJ 1_i
steel NN 1_i
( ( N
SS NNP N
, , N
n JJ N
= NNP N
185 CD N
) ) N
sternal JJ N
approximation NN N
. . N

The DT N
study NN N
was VBD N
focused VBN N
on IN N
aseptic JJ N
sternal JJ N
complications NNS N
, , N
namely RB N
bone JJ 1_o
dehiscence NN 1_o
and CC 1_o
superficial JJ 1_o
wound NN 1_o
instability NN 1_o
. . 1_o

RESULTS NNP N
Both NNP N
bone VBD 1_o
dehiscence NN 1_o
and CC 1_o
superficial JJ 1_o
wound NN 1_o
instability NN 1_o
were VBD N
less JJR N
frequent JJ N
in IN N
the DT N
PDS NNP 1_i
Group NNP N
( ( N
4 CD N
and CC N
3 CD N
cases NNS N
in IN N
the DT N
SS NNP N
Group NNP N
, , N
respectively RB N
, , N
vs. IN N
no DT N
cases NNS N
in IN N
the DT N
PDS NNP N
Group NNP N
) ) N
. . N

Cox NNP 1_o
proportional JJ 1_o
hazards NNS 1_o
regression NN 1_o
model NN N
in IN N
the DT N
whole NN N
study NN N
population NN N
identified VBN N
female JJ 1_o
sex NN 1_o
, , 1_o
chronic JJ 1_o
renal JJ 1_o
insufficiency NN 1_o
, , 1_o
diabetes VBZ 1_o
, , 1_o
advanced JJ 1_o
age NN 1_o
, , 1_o
lower JJR 1_o
sternal JJ 1_o
thickness NN 1_o
, , 1_o
osteoporosis NN 1_o
, , 1_o
corticosteroid JJ 1_o
therapy NN 1_o
, , 1_o
and CC 1_o
prolonged VBD 1_o
CPB NNP 1_o
or CC 1_o
ventilation NN 1_o
times NNS 1_o
as IN N
predisposing VBG N
factors NNS N
to TO N
any DT N
of IN N
the DT N
two CD N
studied VBD N
sternal JJ N
complications NNS N
. . N

DISCUSSION NNP N
Data NNP N
suggest NN N
that IN N
PDS NNP 1_i
suture NN N
can MD N
protect VB N
against IN N
development NN N
of IN N
aseptic JJ 1_o
sternal JJ 1_o
complications NNS 1_o
following VBG 1_p
median JJ 1_p
sternotomy NN 1_p
in IN 1_p
high-risk JJ 1_p
patients NNS 1_p
with IN 1_p
little JJ 1_p
body NN 1_p
mass NN 1_p
. . 1_p

The DT N
adoption NN N
of IN N
PDS NNP 1_i
in IN N
other JJ N
subsets NNS N
of IN N
patients NNS N
, , N
i.e. FW N
, , N
obese JJ N
individuals NNS N
, , N
is VBZ N
to TO N
be VB N
questioned VBN N
. . N

Tailored NNP 1_i
, , 1_i
iterative JJ 1_i
, , 1_i
printed JJ 1_i
dietary JJ 1_i
feedback NN 1_i
is VBZ N
as RB N
effective JJ N
as IN N
group NN N
education NN N
in IN N
improving VBG N
dietary JJ N
behaviours NNS N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
control NN N
trial NN N
in IN N
middle-aged JJ 1_p
adults NNS 1_p
with IN 1_p
cardiovascular JJ 1_p
risk NN 1_p
factors NNS 1_p
. . 1_p

BACKGROUND NNP N
Tailored NNP N
nutrition NN N
interventions NNS N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
non-tailored JJ N
materials NNS N
in IN N
changing VBG N
dietary JJ N
behaviours NNS N
, , N
particularly RB N
fat JJ N
intake NN N
and CC N
fruit NN N
and CC N
vegetable JJ N
intake NN N
. . N

But CC N
further JJ N
research NN N
examining VBG N
efficacy NN N
of IN N
tailored JJ N
nutrition NN N
education NN N
in IN N
comparison NN N
to TO N
other JJ N
nutrition JJ N
education NN N
methods NNS N
and CC N
across IN N
a DT N
wider NN N
range NN N
of IN N
dietary JJ N
behaviours NNS N
is VBZ N
needed VBN N
. . N

The DT 1_p
Stages NNPS 1_p
to TO 1_p
Healthy NNP 1_p
Eating NNP 1_p
Patterns NNP 1_p
Study NNP 1_p
( ( 1_p
STEPs NNP 1_p
) ) 1_p
was VBD N
an DT N
intervention NN N
study NN N
, , N
in IN N
middle-aged JJ 1_p
adults NNS 1_p
with IN 1_p
cardiovascular JJ 1_p
risk NN 1_p
factors NNS 1_p
, , N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
delivered VBN N
by IN N
mail NN N
in IN N
improving VBG N
short-term JJ N
dietary JJ N
behaviour NN N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat NN N
, , N
fruit NN N
, , N
vegetable JJ N
and CC N
grain NN N
and CC N
cereal NN N
intake NN N
. . N

METHODS NNP N
STEPs NNP N
was VBD N
a DT N
3-month JJ N
randomised VBN N
controlled VBN N
trial NN N
with IN N
a DT N
pre NN N
and CC N
post-test JJ N
design NN N
. . N

There EX N
were VBD N
three CD N
experimental JJ N
conditions NNS N
: : N
1 CD N
) ) N
tailored VBN 1_i
, , 1_i
iterative JJ 1_i
, , 1_i
printed JJ 1_i
dietary JJ 1_i
feedback NN 1_i
( ( 1_i
TF NNP 1_i
) ) 1_i
with IN N
three CD N
instalments NNS N
mail-delivered JJ N
over IN N
a DT N
3-month JJ N
period NN N
that WDT N
were VBD N
re-tailored VBN N
to TO N
most RBS N
recent JJ N
assessment NN N
of IN N
dietary JJ N
intake NN N
, , N
intention NN N
to TO N
change VB N
and CC N
assessment NN N
of IN N
self-adequacy NN N
of IN N
dietary JJ N
intake NN N
. . N

Tailoring VBG N
for IN N
dietary JJ N
intake NN N
was VBD N
performed VBN N
on IN N
data NNS N
from IN N
a DT N
validated JJ N
63-item JJ N
combination NN N
FFQ NNP N
designed VBN N
for IN N
the DT N
purpose JJ N
2 CD N
) ) N
small JJ N
group NN N
nutrition NN 1_i
education NN 1_i
sessions NNS 1_i
( ( N
GE NNP N
) ) N
: : N
consisting NN N
of IN N
two CD N
90-minute JJ N
dietitian-led JJ N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
and CC N
3 CD N
) ) N
and CC N
a DT N
wait-listed JJ N
control NN N
( ( N
C NNP N
) ) N
group NN N
who WP N
completed VBD N
the DT N
dietary JJ 1_i
measures NNS 1_i
and CC 1_i
socio-demographic JJ 1_i
questionnaires NNS 1_i
at IN N
baseline NN N
and CC N
3-months JJ N
later NN N
. . N

Dietary NNP N
outcome NN N
measures NNS N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ 1_o
fat JJ 1_o
intake NN 1_o
( ( 1_o
g NN 1_o
) ) 1_o
, , N
and CC N
the DT N
intake NN 1_o
of IN 1_o
fruit NN 1_o
( ( 1_o
serves NNS 1_o
) ) 1_o
, , 1_o
vegetables NNS 1_o
( ( 1_o
serves NNS 1_o
) ) 1_o
, , 1_o
grain NN 1_o
and CC 1_o
cereals NNS 1_o
as IN N
total JJ 1_o
and CC 1_o
wholegrain NN 1_o
( ( 1_o
serves NNS 1_o
) ) 1_o
were VBD N
collected VBN N
using VBG N
7-day JJ N
estimated VBN N
dietary JJ N
records NNS N
. . N

Descriptive JJ N
statistics NNS N
, , N
paired VBD N
t-tests NNS N
and CC N
general JJ N
linear JJ N
models NNS N
adjusted VBN N
for IN N
baseline NN N
dietary JJ N
intake NN N
, , N
age NN N
and CC N
gender NN N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
different JJ N
nutrition NN N
interventions NNS N
. . N

RESULTS VB N
The DT N
TF NNP 1_i
group NN N
reported VBD N
a DT N
significantly RB N
greater JJR N
increase NN N
in IN N
fruit JJ 1_o
intake NN 1_o
( ( N
0.3 CD N
serves/d NN N
P NNP N
= NNP N
0.031 CD N
) ) N
in IN N
comparison NN N
to TO N
GE NNP N
and CC N
the DT N
C NNP N
group NN N
. . N

All DT N
three CD N
intervention NN N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
total JJ 1_o
saturated JJ 1_o
fat JJ 1_o
intake NN 1_o
. . 1_o

GE NNP N
also RB N
had VBD N
a DT N
within-group JJ N
increase NN N
in IN N
mean JJ 1_o
vegetable JJ 1_o
intake NN 1_o
after IN N
3 CD N
months NNS N
, , N
but CC N
this DT N
increase NN N
was VBD N
not RB N
different JJ N
from IN N
changes NNS N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
was VBD N
more RBR N
effective JJ N
than IN N
small JJ N
group NN N
nutrition NN N
education NN N
in IN N
improving VBG N
the DT N
short-term JJ N
fruit NN N
intake VB N
behaviour NN N
, , N
and CC N
as IN N
effective JJ N
in IN N
improving VBG N
saturated VBN N
fat JJ N
intake NN N
of IN N
middle-aged JJ 1_p
adults NNS 1_p
with IN 1_p
cardiovascular JJ 1_p
risk NN 1_p
factors NNS 1_p
. . 1_p

This DT N
showed VBD N
that IN N
a DT N
low-level JJ N
dietary JJ N
intervention NN N
could MD N
achieve VB N
modest JJ N
dietary JJ N
behaviour NN N
changes NNS N
that WDT N
are VBP N
of IN N
public JJ N
health NN N
significance NN N
. . N

Brief JJ N
Report NNP N
: : N
social JJ 1_o
disability NN 1_o
in IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
results NNS N
from IN N
Research NNP 1_p
Units NNP 1_p
on IN 1_p
Pediatric NNP 1_p
Psychopharmacology NNP 1_p
( ( 1_p
RUPP NNP 1_p
) ) 1_p
Autism NNP 1_p
Network NNP 1_p
trials NNS 1_p
. . 1_p

There EX N
is VBZ N
growing VBG N
interest NN N
in IN N
measuring VBG N
social JJ 1_o
disability NN 1_o
as IN N
a DT N
core NN N
element NN N
of IN N
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
in IN N
medication NN N
trials NNS N
. . N

We PRP N
conducted VBD N
a DT N
secondary JJ N
analysis NN N
on IN N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
Social NNP 1_o
Withdrawal NNP 1_o
subscale JJ 1_o
using VBG N
data NNS 1_p
from IN 1_p
two CD 1_p
federally-funded JJ 1_p
, , 1_p
multi-site JJ 1_p
, , 1_p
randomized JJ 1_p
trials NNS 1_p
with IN 1_p
risperidone NN 1_i
. . 1_i

Study NNP 1_p
1 CD 1_p
included VBD 1_p
52 CD 1_p
subjects NNS 1_p
assigned VBN 1_p
to TO 1_p
placebo VB 1_i
and CC 1_p
49 CD 1_p
subjects NNS 1_p
to TO 1_p
risperidone VB 1_i
under IN 1_p
double-blind JJ 1_p
conditions NNS 1_p
. . 1_p

Study NNP 1_p
2 CD 1_p
included VBD 1_p
49 CD 1_p
subjects NNS 1_p
assigned VBN 1_p
to TO 1_p
risperidone VB 1_i
only RB 1_i
and CC 1_p
75 CD 1_p
subjects NNS 1_p
assigned VBN 1_p
to TO 1_p
risperidone VB 1_i
plus JJ 1_i
parent NN 1_i
training NN 1_i
. . 1_i

After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
all DT N
active JJ N
treatments NNS N
were VBD N
superior JJ N
to TO N
placebo VB N
( ( N
effect NN N
sizes VBZ N
ranging VBG N
from IN N
0.42 CD N
to TO N
0.65 CD N
) ) N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
the DT N
Social NNP N
Withdrawal NNP N
subscale NN N
may MD N
be VB N
a DT N
useful JJ N
measure NN N
of IN N
social JJ 1_o
disability NN 1_o
in IN N
acute JJ N
treatment NN N
trials NNS N
. . N

[ JJ N
Effectiveness NNP N
of IN N
morphine NN 1_i
by IN N
periarticular JJ N
injections NNS N
after IN N
shoulder NN 1_p
arthroscopy NN 1_p
] NNP 1_p
. . N

Peripheral NNP N
opioid JJ N
receptors NNS N
have VBP N
been VBN N
found VBN N
in IN N
inflamed JJ N
synovia NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
intra-articularly JJ N
administered JJ N
morphine NN 1_i
after IN N
arthroscopic NN N
knee NN N
surgery NN N
has VBZ N
been VBN N
proven RB N
. . N

There EX N
is VBZ N
controversy NN N
about IN N
efficacy NN N
of IN N
intraarticular JJ N
morphine NN 1_i
after IN N
shoulder NN N
arthroscopy NN N
. . N

Thirty-two JJ 1_p
patients NNS 1_p
with IN 1_p
impingement JJ 1_p
syndrome JJ 1_p
underwent JJ 1_p
subacromial JJ 1_p
decompression NN 1_p
in IN 1_p
the DT 1_p
course NN 1_p
of IN 1_p
arthroscopic JJ 1_i
shoulder NN 1_i
surgery NN 1_i
. . 1_i

At IN N
the DT N
end NN N
of IN N
the DT N
operation NN 1_i
morphine NN 1_i
( ( 1_i
5 CD 1_i
mg NN 1_i
) ) 1_i
or CC 1_i
saline NN 1_i
was VBD N
injected VBN N
periarticularly RB N
. . N

Pain NNP 1_o
intensity NN 1_o
( ( 1_o
rest NN 1_o
and CC 1_o
passive JJ 1_o
mobilisation NN 1_o
) ) 1_o
was VBD N
recorded VBN N
after IN N
recovery NN N
and CC N
after IN N
1,2,4 CD N
, , N
and CC N
24 CD N
hours NNS N
( ( N
Numeric NNP N
Rating NNP N
Scale NNP N
) ) N
; : N
the DT N
use NN 1_o
of IN 1_o
rescue NN 1_o
medication NN 1_o
( ( 1_o
piritramide JJ 1_o
by IN 1_o
patient NN 1_o
controlled VBN 1_o
analgesia NN 1_o
) ) 1_o
was VBD N
noted VBN N
. . N

No DT N
relevant JJ N
pain NN 1_o
reduction NN 1_o
was VBD N
apparent JJ N
in IN N
the DT N
morphine NN N
group NN N
. . N

Piritramide NNP 1_o
consumption NN 1_o
was VBD N
identical JJ N
in IN N
both DT N
groups NNS N
( ( N
19.7 CD N
+/- JJ N
16 CD N
mg NN N
vs. FW N
19.8 CD N
+/- JJ N
19 CD N
mg NN N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
periarticularly RB N
administered VBN N
morphine NN 1_i
in IN N
arthroscopic JJ N
subacromial JJ N
decompression NN N
in IN N
the DT N
dosage NN N
applied VBN N
in IN N
this DT N
study NN N
does VBZ N
exert VB N
no DT N
relevant JJ N
analgesic JJ 1_o
effect NN 1_o
. . 1_o

This DT N
is VBZ N
possibly RB N
due JJ N
to TO N
the DT N
fact NN N
that IN N
either DT N
subacromial JJ N
tissue NN N
, , N
despite IN N
of IN N
chronic JJ N
inflammation NN N
, , N
does VBZ N
not RB N
show VB N
the DT N
same JJ N
reagibility NN N
as IN N
synovia NN N
or CC N
it PRP N
is VBZ N
a DT N
problem NN N
of IN N
the DT N
nearly RB N
complete JJ N
resection NN N
of IN N
the DT N
subacromial JJ N
bursa NN N
. . N

Azathioprine NNP 1_i
and CC N
the DT N
treatment NN N
of IN N
chronic JJ 1_p
inflammatory NN 1_p
bowel NN 1_p
disease NN 1_p
. . 1_p

Effect NN N
of IN N
ibuprofen NN 1_i
on IN N
cyclooxygenase NN 1_o
and CC 1_o
nitric JJ 1_o
oxide JJ 1_o
synthase NN 1_o
of IN 1_o
gastric JJ 1_o
mucosa NN 1_o
: : 1_o
correlation NN N
with IN N
endoscopic JJ 1_o
lesions NNS 1_o
and CC 1_o
adverse JJ 1_o
reactions NNS 1_o
. . 1_o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ibuprofen NN 1_i
on IN N
gastric JJ 1_o
mucosa NN 1_o
and CC 1_o
enzymes NNS 1_o
involved VBN 1_o
in IN 1_o
gastroprotection NN 1_o
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

Twenty-four JJ 1_p
Helicobacter NNP 1_p
pylori-negative JJ 1_p
subjects NNS 1_p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
ibuprofen NN 1_i
or CC 1_i
ibuprofen-arginate NN 1_i
( ( N
each DT N
600 CD N
mg/6 NN N
hr NN N
during IN N
3 CD N
days NNS N
) ) N
. . N

Endoscopies NNS 1_i
were VBD N
performed VBN N
1 CD N
week NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Biopsies NNS N
were VBD N
taken VBN N
from IN N
the DT N
gastric JJ N
antrum NN N
and CC N
corpus NN N
for IN N
determination NN N
of IN N
prostaglandin NN N
E2 NNP N
( ( N
PGE2 NNP N
) ) N
by IN N
ELISA NNP 1_i
and CC N
cyclooxygenase NN N
( ( N
COX-1 JJ N
and CC N
COX-2 NNP N
) ) N
and CC N
nitric JJ N
oxide NN N
synthase NN N
( ( N
eNOS JJ N
and CC N
iNOS NN N
) ) N
by IN N
western JJ N
blot NN N
. . N

All DT N
subjects NNS N
had VBD N
at IN N
least JJS N
one CD N
gastric JJ N
lesion NN N
except IN N
for IN N
two CD N
individuals NNS N
taking VBG N
ibuprofen-arginate NN N
. . N

Ibuprofen-arginate NNP N
caused VBD N
a DT N
lower JJR N
rate NN N
of IN N
clinical JJ 1_o
adverse JJ 1_o
reactions NNS 1_o
than IN N
ibuprofen NN N
. . N

Subjects NNS N
with IN N
gastric JJ 1_o
lesions NNS 1_o
or CC N
adverse JJ N
reactions NNS N
had VBD N
lower JJR N
PGE2 NNP N
levels NNS N
. . N

COX-1 NNP 1_o
, , 1_o
COX-2 NNP 1_o
, , 1_o
eNOS NN 1_o
, , 1_o
and CC 1_o
iNOS NNS 1_o
were VBD N
detectable JJ N
in IN N
all DT N
subjects NNS N
. . N

The DT N
constitutive JJ N
enzymes NNS N
( ( N
COX-1 NNP N
and CC N
eNOS NN N
) ) N
did VBD N
not RB N
change VB N
after IN N
treatment NN N
. . N

COX-2 NNP N
was VBD N
higher RBR N
in IN N
corpus NN N
than IN N
antrum NN N
and CC N
it PRP N
increased VBD N
after IN N
ibuprofen JJ N
treatment NN N
. . N

iNOS NN N
tended VBD N
to TO N
increase VB N
mildly RB N
in IN N
the DT N
corpus NN N
in IN N
subjects NNS N
with IN N
adverse JJ N
reactions NNS N
or CC N
endoscopic JJ N
lesions NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
ibuprofen NN N
and CC N
ibuprofen-arginate NN N
in IN N
PGE2 NNP N
, , N
or CC N
enzymes NNS N
. . N

The DT N
effects NNS N
of IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-oil NN N
distillers NNS 1_i
dried VBD 1_i
grains NNS 1_i
with IN 1_i
solubles NNS 1_i
on IN N
growth NN 1_o
performance NN 1_o
, , 1_o
nutrient JJ 1_o
digestibility NN 1_o
, , 1_o
and CC 1_o
fat JJ 1_o
quality NN 1_o
in IN N
finishing VBG 1_p
pigs NNS 1_p
. . 1_p

A DT 1_p
total NN 1_p
of IN 1_p
1,480 CD 1_p
pigs NNS 1_p
were VBD N
used VBN N
in IN N
3 CD N
experiments NNS N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
corn NN 1_i
distillers NNS 1_i
dried VBD 1_i
grains NNS 1_i
with IN 1_i
solubles NNS 1_i
( ( 1_i
DDGS NNP 1_i
) ) 1_i
varying VBG N
in IN N
oil NN N
content NN N
on IN N
growth NN 1_o
performance NN 1_o
, , 1_o
carcass NN 1_o
traits NNS 1_o
, , 1_o
and CC 1_o
nutrient JJ 1_o
digestibility NN 1_o
in IN N
finishing VBG 1_p
pigs NNS 1_p
. . 1_p

In IN N
Exp NNP N
. . N

1 CD N
, , N
1,198 CD 1_p
pigs NNS 1_p
( ( 1_p
PIC NNP 1_p
Line NNP 1_p
337 CD 1_p
× NN 1_p
1050 CD 1_p
; : 1_p
initially RB 1_p
46.1 CD 1_p
kg NNS 1_p
) ) 1_p
were VBD N
allotted VBN N
to TO N
a DT 1_i
corn-soybean JJ 1_i
meal-based JJ 1_i
diet NN 1_i
or CC 1_i
diets NNS 1_i
with IN 1_i
20 CD 1_i
or CC 1_i
40 CD 1_i
% NN 1_i
of IN 1_i
a DT 1_i
5.4 CD 1_i
% NN 1_i
oil NN 1_i
DDGS NNP 1_i
( ( N
29.5 CD N
% NN N
CP NNP N
, , N
8.9 CD N
% NN N
ADF NNP N
, , N
and CC N
21.8 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
or CC N
a DT N
9.6 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
29.6 CD N
% NN N
CP NNP N
, , N
15.3 CD N
% NN N
ADF NNP N
, , N
and CC N
28.6 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
. . N

From IN N
d JJ N
0 CD N
to TO N
82 CD N
, , N
ADG NNP N
was VBD N
unaffected VBN N
by IN N
DDGS NNP N
source NN N
or CC N
level NN N
. . N

However RB N
, , N
increasing VBG N
5.4 CD N
% NN N
oil NN 1_i
DDGS NNP 1_i
decreased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
G NN N
: : N
F NNP N
, , N
whereas JJ N
G NNP N
: : N
F NN N
did VBD N
not RB N
change VB N
among IN N
pigs NNS N
fed VBP N
9.6 CD N
% NN N
oil NN 1_i
DDGS NNP 1_i
( ( N
DDGS NNP N
source NN N
× NNP N
level NN N
interaction NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Regardless NNP N
of IN N
DDGS NNP N
source NN N
, , N
carcass NN N
yield NN N
and CC N
HCW NNP N
decreased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.04 CD N
) ) N
with IN N
increasing VBG N
DDGS NNP N
. . N

Increasing VBG N
DDGS NNP N
increased VBD 1_o
jowl NN 1_o
iodine NN 1_o
value NN 1_o
( ( 1_o
IV NNP 1_o
) ) 1_o
, , N
but CC N
the DT N
magnitude NN N
was VBD N
greater JJR N
in IN N
pigs NNS N
fed VBP N
the DT N
9.6 CD N
% NN N
oil NN N
DDGS NNP N
compared VBN N
with IN N
those DT N
fed JJ N
5.4 CD N
% NN N
oil NN 1_i
DDGS NNP 1_i
( ( N
DDGS NNP N
source NN N
× NNP N
level NN N
interaction NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
Exp NNP N
. . N

2 CD 1_p
, , 1_p
270 CD 1_p
pigs NNS 1_p
( ( 1_p
PIC NNP 1_p
Line NNP 1_p
327 CD 1_p
× NN 1_p
1050 CD 1_p
; : 1_p
initially RB 1_p
46.5 CD 1_p
kg NNS N
) ) N
were VBD N
allotted VBN 1_i
a DT 1_i
corn-soybean JJ 1_i
meal-based JJ 1_i
diet NN 1_i
or CC N
diets NNS N
with IN N
20 CD N
or CC N
40 CD N
% NN N
of IN N
a DT N
9.4 CD N
% NN N
oil NN 1_i
DDGS NNP 1_i
( ( 1_i
29.4 CD 1_i
% NN 1_i
CP NNP N
, , N
19.6 CD 1_i
% NN 1_i
ADF NNP N
, , N
and CC N
34.5 CD 1_i
% NN 1_i
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
or CC N
a DT N
12.1 CD 1_i
% NN 1_i
oil NN 1_i
DDGS NNP 1_i
( ( N
28.5 CD N
% NN N
CP NNP N
, , N
17.6 CD N
% NN N
ADF NNP N
, , N
and CC N
31.4 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
. . N

From IN N
d JJ N
0 CD N
to TO N
75 CD 1_o
, , N
ADG NNP N
increased VBD N
and CC N
then RB N
decreased VBD N
for IN N
pigs NNS N
fed VBN N
9.4 CD N
% NN N
oil NN N
DDGS NNP N
but CC N
was VBD N
unchanged JJ N
for IN N
pigs NNS N
fed VBN N
12.1 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
quadratic JJ N
interaction NN N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

Increasing VBG 1_i
DDGS NNP 1_i
increased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.01 CD 1_o
) ) 1_o
jowl NN 1_o
IV NNP N
and CC N
tended VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.07 CD N
) ) N
to TO N
increase VB 1_o
G NNP N
: : N
F. NNP N
Regardless NNP N
of IN N
source NN 1_o
, , 1_o
HCW NNP 1_o
and CC 1_o
carcass JJ 1_o
yield NN 1_o
decreased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
DDGS NNP N
increased VBD N
. . N

In IN N
Exp NNP N
. . N

3 CD N
, , N
nutrient JJ N
digestibility NN N
of IN N
the DT 1_i
4 CD 1_i
DDGS NNP 1_i
sources NNS N
was VBD N
determined VBN N
using VBG N
pigs NNS N
fed VBN N
either RB N
a DT N
corn-based JJ N
basal NN N
diet NN N
( ( N
96.6 CD N
% NN N
corn NN N
and CC N
3.4 CD N
% NN N
vitamins NNS N
and CC N
minerals NNS N
) ) N
or CC 1_i
a DT 1_i
DDGS NNP 1_i
diet NN N
with IN N
50 CD N
% NN N
basal NN N
diet JJ N
and CC N
50 CD 1_i
% NN 1_i
DDGS NNP 1_i
. . N

On IN N
an DT N
as-fed JJ N
basis NN N
, , N
corn NN N
contained VBD N
3,871 CD N
and CC N
3,515 CD N
kcal/kg NN N
GE NNP N
and CC N
DE NNP N
, , N
respectively RB N
. . N

The DT N
5.4 CD N
, , N
9.6 CD N
, , N
9.4 CD N
, , N
and CC N
12.1 CD N
% NN N
oil NN 1_i
DDGS NNP 1_i
contained VBD N
4,347 CD N
, , N
4,648 CD N
, , N
4,723 CD N
, , N
and CC N
4,904 CD N
kcal/kg NN N
( ( N
as-fed JJ N
basis NN N
) ) N
GE NNP N
and CC N
3,417 CD N
, , N
3,690 CD N
, , N
3,838 CD N
, , N
and CC N
3,734 CD N
kcal/kg NN N
DE NNP N
, , N
respectively RB N
( ( N
as-fed JJ N
basis NN N
) ) N
. . N

Stepwise NNP N
regression NN N
indicated VBD N
that IN N
the DT N
oil NN N
( ( N
ether CC N
extract NN N
) ) N
content NN N
was VBD N
the DT N
only JJ N
significant JJ N
variable NN N
to TO N
explain VB N
differences NNS N
in IN N
energy NN N
content NN N
. . N

The DT N
equations NNS N
generated VBD N
to TO N
predict VB N
DE NNP N
and CC N
NE NNP N
as IN N
a DT N
function NN N
of IN N
oil NN N
content NN N
on IN N
an DT N
as-fed JJ N
basis NN N
were VBD N
DE NNP N
( ( N
kcal/kg NN N
) ) N
= VBZ N
62.347 CD N
× NN N
ether CC N
extract NN N
( ( N
% NN N
) ) N
+ VBZ N
3,058.13 CD N
( ( N
n JJ N
= NN N
5 CD N
, , N
adjusted VBN N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.41 CD N
) ) N
and CC N
NE NNP N
( ( N
kcal/kg NN N
) ) N
= VBZ N
115.011 CD N
× NN N
ether CC N
extract NN N
( ( N
% NN N
) ) N
+ VBZ N
1,501.01 CD N
( ( N
n JJ N
= NN N
5 CD N
, , N
adjusted VBN N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.86 CD N
) ) N
. . N

Comparison NNP 1_p
of IN 1_p
nasal JJ 1_o
deposition NN 1_o
and CC 1_o
clearance NN 1_o
of IN 1_o
aerosol NN 1_o
generated VBN N
by IN N
nebulizer NN 1_i
and CC 1_i
an DT 1_i
aqueous JJ 1_i
spray NN 1_i
pump NN 1_i
. . 1_i

Clonidine JJ 1_o
clearance NN 1_o
matures NNS N
rapidly RB N
during IN N
the DT N
early JJ N
postnatal JJ N
period NN N
: : N
a DT N
population NN N
pharmacokinetic JJ N
analysis NN N
in IN N
newborns NNS 1_p
with IN 1_p
neonatal JJ 1_p
abstinence NN 1_p
syndrome NN 1_p
. . 1_p

The DT N
population NN N
pharmacokinetic NN 1_o
( ( 1_o
PK NNP 1_o
) ) 1_o
profile NN 1_o
of IN N
oral JJ 1_i
clonidine NN 1_i
was VBD N
characterized VBN N
in IN N
newborns NNS 1_p
with IN 1_p
neonatal JJ 1_p
abstinence NN 1_p
syndrome NN 1_p
, , N
and CC N
significant JJ N
covariates NNS N
affecting VBG N
its PRP$ N
PK NNP N
parameters NNS N
were VBD N
identified VBN N
. . N

Plasma NNP 1_o
clonidine JJ 1_o
concentration NN 1_o
data NNS 1_o
were VBD N
obtained VBN N
from IN N
a DT N
clinical JJ N
trial NN N
in IN N
which WDT N
36 CD 1_p
newborns NNS 1_p
, , 1_p
aged VBD 1_p
1 CD 1_p
to TO 1_p
25 CD 1_p
days NNS 1_p
( ( 1_p
postnatal JJ 1_p
age NN 1_p
, , 1_p
PNA NNP 1_p
) ) 1_p
and CC 1_p
weighing VBG 1_p
2.1 CD 1_p
to TO 1_p
3.9 CD 1_p
kg NNS 1_p
, , N
were VBD N
enrolled VBN N
to TO N
take VB N
multiple JJ N
oral JJ N
doses NNS N
of IN N
clonidine NN N
. . N

The DT N
population NN N
PK NNP 1_o
model NN 1_o
of IN 1_o
clonidine NN 1_o
was VBD N
developed VBN N
by IN N
NONMEM NNP N
, , N
and CC N
significant JJ N
covariates NNS N
were VBD N
identified VBN N
, , N
followed VBN N
by IN N
nonparametric JJ N
bootstraps NNS N
( ( N
2000 CD N
replicates NNS N
) ) N
and CC N
simulation NN N
experiments NNS N
. . N

A DT N
1-compartment JJ N
open JJ N
linear NN N
PK NNP N
model NN N
was VBD N
chosen VBN N
to TO N
describe VB N
plasma JJ 1_o
concentrations NNS 1_o
of IN 1_o
clonidine NN 1_o
, , N
and CC N
body NN 1_o
weight NN 1_o
and CC 1_o
PNA NNP 1_o
were VBD N
significant JJ N
covariates NNS N
for IN N
apparent JJ 1_o
clearance NN 1_o
( ( N
CL/F NNP N
) ) N
as IN N
follows VBZ N
: : N
CL/F NNP N
( ( N
L/h NNP N
) ) N
= VBD N
15.2 CD N
× NNP N
[ NNP N
body NN N
weight NN N
( ( N
kg NN N
) ) N
/70 NN N
] NNP N
( ( N
0.75 CD N
) ) N
× NN N
[ JJ N
PNA NNP N
( ( N
day NN N
) ) N
( ( N
0.441 CD N
) ) N
/ NN N
( ( N
4.06 CD N
( ( N
0.441 CD N
) ) N
+ NN N
PNA NNP N
( ( N
day NN N
) ) N
( ( N
0.441 CD N
) ) N
) ) N
] NN N
. . N

Furthermore NNP 1_o
, , 1_o
CL/F NNP 1_o
of IN 1_o
clonidine NN 1_o
increased VBN N
rapidly RB N
with IN N
PNA NNP N
during IN N
the DT N
first JJ N
month NN N
of IN N
life NN N
after IN N
body NN N
weight NN N
was VBD N
adjusted VBN N
. . N

Any DT N
optimal JJ N
dosage NN N
regimen NNS N
for IN 1_i
clonidine NN 1_i
in IN N
term NN N
neonates NNS N
should MD N
be VB N
based VBN N
on IN N
infant NN N
's POS N
age NN N
and CC N
body NN N
weight NN N
, , N
and CC N
1.5 CD N
µg/kg NN N
every DT N
4 CD N
hours NNS N
is VBZ N
proposed VBN N
starting VBG N
the DT N
second JJ N
week NN N
of IN N
life NN N
based VBN N
on IN N
the DT N
simulation NN N
results NNS N
. . N

Differences NNS N
in IN N
reach NN 1_o
and CC 1_o
attrition NN 1_o
between IN 1_o
Web-based JJ 1_o
and CC 1_o
print-delivered JJ 1_o
tailored JJ 1_o
interventions NNS 1_o
among IN N
adults NNS 1_p
over IN 1_p
50 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
: : 1_p
clustered VBN N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
Internet NNP N
has VBZ N
the DT N
potential JJ N
to TO N
provide VB N
large JJ N
populations NNS N
with IN N
individual JJ N
health NN N
promotion NN N
advice NN N
at IN N
a DT N
relatively RB N
low JJ N
cost NN N
. . N

Despite IN N
the DT N
high JJ N
rates NNS N
of IN N
Internet NNP N
access NN N
, , N
actual JJ N
reach NN N
by IN N
Web-based JJ N
interventions NNS N
is VBZ N
often RB N
disappointingly RB N
low JJ N
, , N
and CC N
differences NNS N
in IN N
use NN N
between IN N
demographic JJ N
subgroups NNS N
are VBP N
present JJ N
. . N

Furthermore RB N
, , N
Web-based JJ N
interventions NNS N
often RB N
have VBP N
to TO N
deal VB N
with IN N
high JJ N
rates NNS N
of IN N
attrition NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
aims VBZ N
to TO N
assess VB N
user JJ 1_o
characteristics NNS 1_o
related VBN 1_o
to TO 1_o
participation NN 1_o
and CC 1_o
attrition NN 1_o
when WRB N
comparing VBG N
Web-based JJ 1_i
and CC 1_i
print-delivered JJ 1_i
tailored JJ 1_i
interventions NNS 1_i
containing VBG N
similar JJ N
content NN N
and CC N
thereby RB N
to TO N
provide VB N
recommendations NNS N
in IN N
choosing VBG N
the DT N
appropriate JJ N
delivery NN N
mode NN N
for IN N
a DT N
particular JJ N
target NN N
audience NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
the DT N
distribution NN N
of IN N
a DT N
Web-based JJ 1_i
and CC 1_i
a DT 1_i
print-delivered JJ 1_i
version NN 1_i
of IN 1_i
the DT 1_i
Active NNP 1_i
Plus NNP 1_i
intervention NN 1_i
in IN N
a DT N
clustered JJ N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

Participants NNS 1_p
were VBD 1_p
recruited VBN 1_p
via IN 1_p
direct JJ 1_p
mailing NN 1_p
within IN 1_p
the DT 1_p
participating VBG 1_p
Municipal NNP 1_p
Health NNP 1_p
Council NNP 1_p
regions NNS 1_p
and CC 1_p
randomized VBN 1_p
to TO 1_p
the DT 1_p
printed VBN 1_i
or CC 1_i
Web-based VBN 1_i
intervention NN 1_i
by IN 1_p
their PRP$ 1_p
region NN 1_p
. . 1_p

Based VBN N
on IN N
the DT N
answers NNS N
given VBN N
in IN N
a DT N
prior JJ N
assessment NN N
, , N
participants NNS N
received VBD N
tailored JJ N
advice NN N
on IN N
3 CD N
occasions NNS N
: : N
( ( N
1 CD N
) ) N
within IN N
2 CD N
weeks NNS N
after IN N
the DT N
baseline NN N
, , N
( ( N
2 CD N
) ) N
2 CD N
months NNS N
after IN N
the DT N
baseline NN N
, , N
and CC N
( ( N
3 CD N
) ) N
within IN N
4 CD N
months NNS N
after IN N
the DT N
baseline NN N
( ( N
based VBN N
on IN N
a DT N
second JJ N
assessment NN N
at IN N
3 CD N
months NNS N
) ) N
. . N

The DT N
baseline NN N
( ( N
printed VBN N
or CC N
Web-based VBN N
) ) N
results NNS N
were VBD N
analyzed JJ N
using VBG N
ANOVA NNP N
and CC N
chi-square JJ N
tests NNS N
to TO N
establish VB N
the DT N
differences NNS N
in IN N
user JJ N
characteristics NNS N
between IN N
both DT N
intervention NN N
groups NNS N
. . N

We PRP N
used VBD N
logistic JJ N
regression NN N
analyses NNS N
to TO N
study VB N
the DT N
interaction NN N
between IN N
the DT N
user NN 1_o
characteristics NNS 1_o
and CC N
the DT N
delivery NN N
mode NN N
in IN N
the DT N
prediction NN N
of IN N
dropout NN 1_o
rate NN 1_o
within IN N
the DT N
intervention NN N
period NN N
. . N

RESULTS VB N
The DT N
printed JJ N
intervention NN N
resulted VBD N
in IN N
a DT N
higher JJR 1_o
participation NN 1_o
rate NN 1_o
( ( N
19 CD N
% NN N
) ) N
than IN N
the DT N
Web-based JJ N
intervention NN N
( ( N
12 CD N
% NN N
) ) N
. . N

Participants NNS N
of IN N
the DT N
Web-based JJ N
intervention NN N
were VBD N
significantly RB N
younger JJR N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
more RBR N
often RB N
men NNS N
( ( N
P=.01 NNP N
) ) N
, , N
had VBD N
a DT N
higher JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
( ( N
P=.001 NNP N
) ) N
and CC N
a DT N
lower JJR N
intention NN N
to TO N
be VB N
physically RB N
active JJ N
( ( N
P=.03 NNP N
) ) N
than IN N
participants NNS N
of IN N
the DT N
printed VBN N
intervention NN N
. . N

The DT N
dropout NN 1_o
rate NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
Web-based JJ N
intervention NN N
group NN N
( ( N
53 CD N
% NN N
) ) N
compared VBN N
to TO N
the DT N
print-delivered JJ N
intervention NN N
( ( N
39 CD N
% NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

A DT N
low JJ N
intention NN 1_o
to TO 1_o
be VB 1_o
physically RB 1_o
active JJ 1_o
was VBD N
a DT N
strong JJ N
predictor NN N
for IN N
dropout NN 1_o
within IN N
both DT N
delivery NN N
modes FW N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
difference NN N
in IN N
dropout NN 1_o
rate NN 1_o
between IN N
the DT N
Web-based JJ N
and CC N
the DT N
printed JJ N
intervention NN N
was VBD N
not RB N
explained VBN N
by IN N
user JJ N
characteristics NNS N
. . N

CONCLUSIONS VB N
The DT N
reach NN N
of IN N
the DT N
same JJ N
tailored JJ 1_o
physical JJ 1_o
activity NN 1_o
( ( 1_o
PA NNP 1_o
) ) 1_o
intervention NN N
in IN N
a DT N
printed JJ N
or CC N
Web-based JJ N
delivery NN N
mode NN N
differed VBD N
between IN N
sociodemographic JJ N
subgroups NNS N
of IN N
participants NNS N
over IN N
50 CD N
years NNS N
of IN N
age NN N
. . N

Although IN N
the DT N
reach NN N
of IN N
the DT N
Web-based JJ N
intervention NN N
is VBZ N
lower JJR N
, , N
Web-based JJ N
interventions NNS N
can MD N
be VB N
a DT N
good JJ N
channel NN N
to TO N
reach VB N
high-risk JJ N
populations NNS N
( ( N
lower JJR N
PA NNP N
intention NN N
and CC N
higher JJR N
BMI NNP N
) ) N
. . N

While IN N
the DT N
dropout NN 1_o
rate NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
Web-based JJ N
intervention NN N
group NN N
, , N
no DT N
specific JJ N
user NN N
characteristics NNS N
explained VBD N
the DT N
difference NN N
in IN N
dropout NN 1_o
rates NNS 1_o
between IN N
the DT N
delivery NN N
modes NN N
. . N

More JJR N
research NN N
is VBZ N
needed VBN N
to TO N
determine VB N
what WP N
caused VBD N
the DT N
high JJ N
rate NN 1_o
of IN 1_o
dropout NN 1_o
in IN N
the DT N
Web-based JJ N
intervention NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
( ( N
NTR NNP N
) ) N
: : N
2297 CD N
: : N
http NN N
: : N
//www.trialregister.nl/trialreg/admin/rctview.asp NN N
? . N
TC=2297 NNP N
( ( N
Archived VBN N
by IN N
WebCite NNP N
at IN N
http NN N
: : N
//www.webcitation.org/65TkwoESp NN N
) ) N
. . N

A DT N
phase NN N
II NNP N
, , N
randomized VBD N
, , N
multicenter NN N
study NN N
evaluating VBG N
the DT N
combination NN N
of IN N
lapatinib NN N
and CC N
vinorelbine NN N
in IN N
women NNS 1_p
with IN 1_p
ErbB2 NNP 1_p
overexpressing VBG 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

Lapatinib NNP N
is VBZ N
approved VBN N
in IN N
combination NN N
with IN N
capecitabine NN N
for IN N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
human JJ 1_p
epidermal JJ 1_p
growth NN 1_p
factor NN 1_p
receptor NN 1_p
2 CD 1_p
( ( 1_p
HER2 NNP 1_p
) ) 1_p
-positive VBP 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
( ( 1_p
MBC NNP 1_p
) ) 1_p
who WP N
have VBP N
progressed VBN N
on IN N
prior JJ N
trastuzumab NN N
in IN N
the DT N
metastatic JJ N
setting NN N
. . N

Vinorelbine NNP N
is VBZ N
an DT N
important JJ N
chemotherapy NN N
option NN N
for IN N
MBC NNP N
. . N

We PRP N
evaluated VBD N
efficacy NN N
and CC N
safety NN N
of IN N
lapatinib JJ N
plus CC N
vinorelbine JJ N
, , N
compared VBN N
with IN N
lapatinib JJ N
plus CC N
capecitabine JJ N
, , N
in IN N
women NNS 1_p
with IN 1_p
HER2-positive JJ 1_p
MBC NNP 1_p
. . 1_p

In IN 1_p
this DT 1_p
open-label JJ 1_p
, , 1_p
multicenter NN 1_p
, , 1_p
phase NN 1_p
II NNP 1_p
study NN 1_p
, , 1_p
eligible JJ 1_p
patients NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
112 CD 1_p
) ) 1_p
were VBD N
randomized VBN N
2:1 CD N
to TO N
lapatinib VB 1_i
plus JJ 1_i
vinorelbine NN 1_i
[ NNP 1_i
( ( 1_i
N NNP 1_i
= NNP 1_i
75 CD 1_i
) ) 1_i
1,250 CD 1_i
mg NN 1_i
orally RB 1_i
once RB 1_i
daily JJ 1_i
( ( 1_i
QD NNP 1_i
) ) 1_i
continuously RB 1_i
plus CC 1_i
20 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
/day NN 1_i
intravenously RB 1_i
] VBZ 1_i
or CC 1_i
lapatinib JJ 1_i
plus CC 1_i
capecitabine JJ 1_i
[ NNP 1_i
( ( 1_i
N NNP 1_i
= NNP 1_i
37 CD 1_i
) ) 1_i
1,250 CD 1_i
mg NN 1_i
orally RB 1_i
QD NNP 1_i
continuously RB 1_i
plus CC 1_i
2,000 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
/day NN 1_i
orally RB 1_i
, , 1_i
2 CD 1_i
doses NNS 1_i
] RB 1_i
. . 1_i

The DT N
primary JJ N
endpoint NN N
was VBD N
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
. . 1_o

Other JJ N
endpoints NNS N
included VBD N
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
and CC 1_o
safety NN 1_o
. . 1_o

Patients NNS N
progressing VBG N
within IN N
the DT N
study NN N
were VBD N
given VBN N
the DT N
option NN N
of IN N
crossover NN N
to TO N
the DT N
other JJ N
treatment NN N
arm NN N
; : N
time NN N
to TO N
second JJ N
progression NN N
was VBD N
an DT N
exploratory JJ N
endpoint NN N
. . N

Patient JJ 1_o
demographics NNS 1_o
, , 1_o
stratification NN 1_o
, , 1_o
and CC 1_o
prognostic JJ 1_o
factors NNS 1_o
were VBD N
well RB N
balanced VBN N
between IN N
treatments NNS N
. . N

Median JJ 1_o
PFS NNP 1_o
in IN N
both DT N
arms NNS N
was VBD N
6.2 CD N
months NNS N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
4.2 CD N
, , N
8.8 CD N
( ( N
lapatinib JJ N
plus CC N
vinorelbine JJ N
) ) N
; : N
4.4 CD N
, , N
8.3 CD N
( ( N
lapatinib JJ N
plus CC N
capecitabine NN N
) ) N
] NN N
. . N

Median JJ 1_o
OS NNP 1_o
on IN N
lapatinib JJ N
plus CC N
vinorelbine NN N
was VBD N
24.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
16.4 CD N
, , N
NE NNP N
) ) N
and CC N
19.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
16.4 CD N
, , N
27.2 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
capecitabine NN N
. . N

In IN N
total JJ N
, , N
42 CD N
patients NNS N
opted VBN N
to TO N
cross VB N
over RP N
; : N
median JJ N
PFS NNP N
was VBD N
3.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
1.7 CD N
, , N
5.1 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
vinorelbine NN N
and CC N
4.0 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
2.1 CD N
, , N
5.8 CD N
) ) N
on IN N
lapatinib NN N
plus CC N
capecitabine NN N
. . N

Lapatinib NNP N
plus CC N
vinorelbine NN N
offers NNS N
an DT N
effective JJ N
treatment NN N
option NN N
for IN N
patients NNS 1_p
with IN 1_p
HER2-overexpressing NNP 1_p
MBC NNP 1_p
, , N
having VBG N
displayed VBN N
comparable JJ N
efficacy NN N
and CC N
tolerability NN N
rates NNS N
to TO N
lapatinib VB N
plus JJ N
capecitabine NN N
. . N

Effects NNS N
of IN N
ATP NNP 1_i
infusion NN 1_i
on IN N
glucose JJ N
turnover NN N
and CC N
gluconeogenesis NN N
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
non-small-cell JJ 1_p
lung NN 1_p
cancer NN 1_p
. . 1_p

Cancer NNP N
cachexia NN N
is VBZ N
associated VBN N
with IN N
elevated JJ N
lipolysis NN N
, , N
proteolysis NN N
and CC N
gluconeogenesis NN N
. . N

ATP NNP 1_i
infusion NN N
has VBZ N
been VBN N
found VBN N
to TO N
significantly RB N
inhibit VB N
loss NN N
of IN N
body NN N
weight NN N
, , N
fat JJ N
mass NN N
and CC N
fat-free JJ N
mass NN N
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
lung NN 1_p
cancer NN 1_p
. . 1_p

The DT N
present JJ N
study NN N
was VBD N
aimed VBN N
at IN N
exploring VBG N
the DT N
effects NNS N
of IN N
ATP NNP 1_i
on IN N
whole-body NN N
glucose NN N
turnover NN N
, , N
alanine JJ N
turnover NN N
and CC N
gluconeogenesis NN N
from IN N
alanine NN N
. . N

Twelve CD 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
non-small-cell JJ 1_p
lung NN 1_p
cancer NN 1_p
( ( 1_p
NSCLC NNP 1_p
) ) 1_p
were VBD N
studied VBN N
1 CD N
week NN N
before RB N
and CC N
during IN N
22-24 JJ N
h NN N
of IN N
continuous JJ 1_i
ATP NNP 1_i
infusion NN 1_i
. . 1_i

After IN N
an DT N
overnight JJ N
fast NN N
, , N
turnover NN N
rates NNS N
of IN N
glucose NN N
and CC N
alanine NN N
, , N
and CC N
gluconeogenesis NN N
from IN N
alanine NN N
, , N
were VBD N
determined VBN N
using VBG N
primed VBN N
constant JJ N
infusions NNS N
of IN N
¿6 NN 1_i
, , 1_i
6- JJ 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
H NNP 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
ğlucose NN 1_i
and CC 1_i
¿3- NN 1_i
( ( 1_i
13 CD 1_i
) ) 1_i
Călanine NNP 1_i
. . 1_p

Thirteen NNP 1_p
NSCLC NNP 1_p
patients NNS 1_p
and CC 1_p
eleven RB 1_p
healthy JJ 1_p
subjects NNS 1_p
were VBD N
studied VBN N
as IN N
control NN N
groups NNS N
without IN N
ATP NNP N
infusion NN N
. . N

During IN N
high-dose JJ 1_i
ATP NNP N
infusion NN N
( ( N
75 CD N
microg.min NN 1_o
( ( 1_o
-1 NNP 1_o
) ) 1_o
.kg NNP 1_o
( ( 1_o
-1 NNP 1_o
) ) 1_o
) ) 1_o
, , 1_o
glucose JJ 1_o
turnover NN 1_o
was VBD N
0.62+/-0.07 JJ N
mmol.h NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NNP N
) ) N
, , N
compared VBN N
with IN N
0 CD N
. . N

44+/-0.13 JJ N
mmol.h NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NN N
) ) N
at IN N
baseline NN N
( ( N
P=0.04 NNP N
) ) N
. . N

For IN 1_o
gluconeogenesis NN 1_o
a DT N
similar JJ N
, , N
but CC N
non-significant JJ N
, , N
trend NN N
was VBD N
observed VBN N
¿baseline JJ N
, , N
0.30+/-0.16 JJ N
mmol.h NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NNP N
) ) N
; : N
during IN N
ATP NNP N
, , N
0.37+/-0.13 JJ N
mmol.h NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NNP N
) ) N
( ( N
P=0.08 NNP N
) ) N
. . N

At IN N
lower JJR 1_i
ATP NNP N
doses NNS N
( ( N
37-50 JJ N
microg NN N
. . N

min NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NNP N
) ) N
) ) N
these DT N
effects NNS N
were VBD N
not RB N
detected VBN N
. . N

The DT N
relative JJ 1_o
increase NN 1_o
in IN 1_o
glucose JJ 1_o
turnover NN 1_o
during IN 1_o
ATP NNP 1_o
infusion NN 1_o
compared VBN N
with IN N
baseline NN N
showed VBD N
a DT N
significant JJ N
correlation NN N
with IN 1_i
the DT 1_i
ATP NNP N
dose NN N
( ( N
r=0.58 NN N
, , N
P=0.02 NNP 1_o
) ) 1_o
. . 1_o

No DT 1_o
change NN 1_o
in IN 1_o
alanine NN 1_o
turnover NN 1_o
was VBD N
observed VBN N
at IN 1_i
any DT 1_i
ATP NNP N
dose NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
an DT N
increase NN 1_o
in IN 1_o
glucose JJ 1_o
turnover NN 1_o
during IN N
high-dose JJ N
ATP NNP N
infusion NN N
compared VBN N
with IN N
baseline NN N
levels NNS N
. . N

During IN N
high-dose JJ 1_i
ATP NNP N
infusion NN 1_o
, , 1_o
glucose JJ 1_o
turnover NN 1_o
was VBD N
similar JJ N
to TO N
that DT N
during IN N
low-dose JJ N
ATP NNP N
infusion NN N
and CC N
to TO N
that DT N
in IN N
control NN N
NSCLC NNP N
patients NNS N
. . N

Between NNP 1_i
ATP NNP N
infusions NNS N
, , N
however RB 1_o
, , 1_o
glucose JJ 1_o
turnover NN 1_o
in IN N
patients NNS N
treated VBN N
with IN N
high-dose JJ N
ATP NNP N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
low-dose JJ N
and CC N
control VB N
NSCLC NNP N
patients NNS N
( ( N
P=0.04 NNP N
and CC N
P=0.03 NNP N
respectively RB N
) ) N
, , N
and CC N
similar JJ N
to TO N
that DT N
in IN N
healthy JJ N
subjects NNS N
. . N

This DT N
would MD N
suggest VB N
that IN N
repeated JJ N
high-dose JJ 1_i
ATP NNP N
infusions NNS N
may MD N
inhibit VB N
glucose JJ N
turnover NN N
between IN N
infusion NN N
periods NNS N
. . N

Antinuclear JJ 1_o
antibodies NNS 1_o
with IN N
enalapril NN 1_i
. . 1_i

Treatment NN N
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
a DT N
caregiver-based JJ 1_i
intervention NN 1_i
program NN 1_i
in IN N
community NN 1_p
day-care NN 1_p
centers NNS 1_p
. . 1_p

This DT N
study NN N
reports VBZ N
on IN N
the DT N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
that WDT N
evaluated VBD N
a DT N
caregiver-based JJ 1_i
intervention NN 1_i
program NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
in IN 1_p
community NN 1_p
day-care NN 1_p
centers NNS 1_p
. . 1_p

Thirty-five JJ 1_p
preschool NN 1_p
children NNS 1_p
with IN 1_p
a DT 1_p
DSM NNP 1_p
III-R NNP 1_p
diagnosis NN 1_p
of IN 1_p
autism NN 1_p
or CC 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
were VBD N
randomized VBN N
to TO N
an DT N
experimental JJ N
or CC N
control NN N
group NN N
. . N

Children NNP N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
enrolled VBN N
in IN N
day NN N
care NN N
and CC N
their PRP$ N
parents NNS 1_i
and CC 1_i
child NN 1_i
care NN 1_i
workers NNS 1_i
received VBD 1_i
a DT 1_i
12-week JJ 1_i
intervention NN 1_i
consisting NN 1_i
of IN 1_i
lectures NNS 1_i
and CC 1_i
on-site JJ 1_i
consultations NNS 1_i
to TO 1_i
day-care JJ 1_i
centers NNS 1_i
. . 1_i

In IN N
addition NN N
, , N
supportive JJ N
work NN N
was VBD N
undertaken VBN N
with IN N
families NNS N
. . N

Control NNP N
subjects VBZ N
received VBN N
day NN 1_i
care VB 1_i
alone RB 1_i
. . 1_i

In IN N
the DT N
experimental JJ N
group NN N
, , N
there EX N
were VBD N
greater JJR N
gains NNS N
in IN N
language NN 1_o
abilities NNS 1_o
, , N
significant JJ N
increases NNS N
in IN N
caregivers NNS 1_o
' POS 1_o
knowledge NN 1_o
about IN 1_o
autism NN 1_o
, , N
greater JJR N
perception NN 1_o
of IN 1_o
control NN 1_o
on IN 1_o
the DT 1_o
part NN 1_o
of IN 1_o
mothers NNS 1_o
, , N
and CC N
greater JJR N
parent NN 1_o
satisfaction NN 1_o
. . 1_o

We PRP N
conclude VBP N
that IN N
this DT N
research NN N
design NN N
demonstrated VBD N
that IN N
the DT N
intervention NN N
was VBD N
significantly RB N
superior JJ N
to TO N
day NN N
care VB N
alone RB N
. . N

Multicenter NNP N
trial NN N
of IN N
cryotherapy NN 1_i
for IN N
retinopathy NN 1_p
of IN 1_p
prematurity NN 1_p
: : 1_p
preliminary JJ N
results NNS N
. . N

Cryotherapy NNP 1_i
for IN N
Retinopathy NNP N
of IN N
Prematurity NNP N
Cooperative NNP N
Group NNP N
. . N

We PRP N
report VBP N
the DT N
preliminary JJ N
3-month JJ N
outcome NN N
of IN N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
cryotherapy NN 1_i
for IN 1_i
treatment NN 1_i
of IN 1_i
retinopathy NN 1_i
of IN 1_i
prematurity NN 1_i
( ( N
ROP NNP N
) ) N
. . N

Transscleral JJ 1_i
cryotherapy NN 1_i
to TO N
the DT N
avascular JJ N
retina NN N
was VBD N
applied VBN N
to TO N
one CD 1_p
randomly NN 1_p
selected VBN 1_p
eye NN 1_p
when WRB N
there EX N
was VBD N
threshold JJ N
disease NN N
( ( N
defined VBN N
as IN N
five CD N
or CC N
more JJR N
contiguous JJ N
or CC N
eight CD N
cumulative JJ N
30 CD N
degree JJ N
sectors NNS N
[ VBP N
clock NN N
hours NNS N
] CD N
of IN N
stage NN N
3 CD N
ROP NNP N
in IN N
zone CD N
1 CD N
or CC N
2 CD N
in IN N
the DT N
presence NN N
of IN N
" NNP N
plus CC N
" NNP N
disease NN N
) ) N
. . N

An DT N
unfavorable JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
posterior JJ 1_o
retinal JJ 1_o
detachment NN 1_o
, , 1_o
retinal JJ 1_o
fold NN 1_o
involving VBG 1_o
the DT 1_o
macula NN 1_o
, , 1_o
or CC 1_o
retrolental JJ 1_o
tissue NN 1_o
. . 1_o

At IN N
this DT N
writing NN N
, , N
172 CD 1_p
infants NNS 1_p
had VBD 1_p
been VBN 1_p
examined VBN 1_p
3 CD 1_p
months NNS 1_p
after IN 1_p
randomization NN 1_p
. . 1_p

An DT N
unfavorable JJ 1_o
outcome NN 1_o
was VBD N
significantly RB N
less JJR N
frequent JJ N
in IN N
the DT N
eyes NNS N
undergoing VBG N
cryotherapy NN 1_i
( ( N
21.8 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
untreated JJ N
eyes NNS N
( ( N
43 CD N
% NN N
) ) N
. . N

While IN N
the DT N
surgery NN N
was VBD N
stressful JJ N
, , N
no DT N
unexpected JJ 1_o
complications NNS 1_o
occurred VBD N
during IN N
or CC N
following VBG N
treatment NN N
. . N

These DT N
data NNS N
support NN N
the DT N
efficacy NN 1_o
of IN N
cryotherapy NN 1_i
in IN N
reducing VBG N
by IN N
approximately RB N
one CD N
half PDT N
the DT N
risk NN N
of IN N
unfavorable JJ N
retinal JJ N
outcome NN N
from IN N
threshold JJ N
ROP NNP N
. . N

Effects NNS N
of IN N
iron NN 1_i
supplements NNS 1_i
and CC N
perinatal JJ N
factors NNS N
on IN N
fetal JJ N
hemoglobin NN N
disappearance NN N
in IN N
LBW NNP 1_p
infants NNS 1_p
. . 1_p

BACKGROUND IN N
The DT N
homeostatic JJ N
mechanisms NN N
of IN N
iron NN N
metabolism NN N
and CC N
erythropoiesis NN N
in IN N
infants NNS N
are VBP N
unclear JJ N
. . N

Infants NNS N
synthesize VB N
both DT N
fetal JJ N
hemoglobin NN N
( ( N
HbF NNP N
) ) N
and CC N
adult NN N
hemoglobin NN N
( ( N
HbA NNP N
) ) N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
how WRB N
the DT N
hemoglobin NN N
switch NN N
is VBZ N
regulated VBN N
. . N

We PRP N
hypothesized VBD N
that IN N
iron NN N
supplements NNS N
to TO N
infants NNS N
affect VB N
the DT N
disappearance NN N
of IN N
HbF NNP N
. . N

METHODS NNP N
We PRP N
randomized VBD N
285 CD 1_p
low-birth-weight JJ 1_p
infants NNS 1_p
( ( 1_p
2,000-2,500 JJ 1_p
g NN 1_p
) ) 1_p
into IN N
three CD N
intervention NN N
groups NNS 1_i
receiving VBG 1_i
0 CD 1_i
, , 1_i
1 CD 1_i
, , 1_i
or CC 1_i
2 CD 1_i
mg/kg/d NN 1_i
of IN 1_i
iron NN 1_i
supplements NNS 1_i
from IN 1_i
6 CD 1_i
wk NN 1_i
to TO 1_i
6 CD 1_i
mo NN 1_i
of IN 1_i
age NN N
. . N

In IN N
the DT N
present JJ N
secondary JJ N
analysis NN 1_i
, , 1_i
we PRP 1_i
analyzed VBD 1_o
iron NN 1_o
status NN 1_o
, , 1_o
total JJ 1_o
hemoglobin NN 1_o
( ( 1_o
Hb NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
HbF NNP 1_i
fraction NN 1_i
at IN N
6 CD N
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
at IN N
6 CD N
mo NN N
and CC N
calculated VBD N
absolute JJ N
levels NNS N
of IN N
HbF NNP N
. . N

RESULTS NNP N
We PRP N
observed VBD N
dose-dependent JJ N
increased JJ N
levels NNS 1_o
of IN N
Hb NNP N
in IN N
iron-supplemented JJ N
groups NNS N
at IN N
6 CD N
mo NN N
of IN N
age NN N
. . N

However RB 1_o
, , 1_o
for IN 1_o
absolute JJ 1_o
HbF NNP 1_o
concentration NN 1_o
, , N
there EX N
was VBD N
no DT N
similar JJ N
effect NN N
of IN N
intervention NN 1_o
. . 1_o

Mean NNP 1_o
( ( N
SD NNP N
) ) N
HbF NNP N
was VBD N
81.2 CD N
( ( N
16.8 CD N
) ) N
, , N
37.0 CD N
( ( N
13.8 CD N
) ) N
, , N
and CC N
8.1 CD N
( ( N
5.6 CD N
) ) N
g/l NN N
at IN N
6 CD N
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
6 CD N
mo NN N
, , N
respectively RB N
, , N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

In IN N
linear JJ N
regression NN N
analyses NNS N
, , N
postconceptional JJ N
age NN N
turned VBD N
out RP N
as IN N
the DT N
major JJ N
predictor NN N
of IN N
HbF NNP N
, , N
independent JJ N
of IN N
gestational JJ N
age NN N
at IN N
birth NN N
. . N

CONCLUSION NNP N
Our PRP$ N
hypothesis NN N
was VBD N
rejected VBN N
. . N

Instead RB N
, , N
we PRP N
confirmed VBD N
a DT N
close JJ N
correlation NN N
to TO N
postconceptional JJ N
age NN N
, , N
supporting VBG N
a DT N
genetically RB N
programmed VBN N
switch NN N
, , N
insensitive JJ N
to TO N
most JJS N
environmental JJ N
factors NNS N
including VBG N
birth NN N
. . N

Community-based JJ 1_i
treatment NN 1_i
for IN N
opioid JJ 1_p
dependent JJ 1_p
offenders NNS 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Primary NNP 1_i
care NN 1_i
opioid JJ 1_i
substitution NN 1_i
treatment NN 1_i
( ( 1_i
OST NNP 1_i
) ) 1_i
has VBZ N
not RB N
been VBN N
compared VBN N
to TO N
program-based JJ N
OST NNP 1_i
for IN N
community-supervised JJ 1_p
offenders NNS 1_p
. . 1_p

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
project NN N
was VBD N
to TO N
compare VB N
primary JJ N
care NN N
to TO N
specialist VB N
supervised JJ N
OST NNP N
for IN N
opioid JJ N
dependent JJ N
offenders NNS N
in IN N
terms NNS N
of IN N
substance NN 1_o
use NN 1_o
and CC N
HIV NNP 1_o
risk NN 1_o
outcomes NNS 1_o
. . 1_o

METHODS NNP N
This DT N
project NN N
randomly RB N
assigned VBD N
15 CD 1_p
jail NN 1_p
diversion NN 1_p
participants NNS 1_p
to TO N
either DT N
: : N
( ( N
i NN N
) ) N
primary NN 1_i
care NN 1_i
buprenorphine NN 1_i
OST NNP 1_i
, , 1_i
( ( 1_i
ii NN 1_i
) ) 1_i
specialist NN 1_i
facility NN 1_i
buprenorphine NN 1_i
OST NNP 1_i
, , 1_i
or CC 1_i
( ( 1_i
iii JJ 1_i
) ) 1_i
specialist NN 1_i
facility NN 1_i
methadone NN 1_i
OST NNP 1_i
. . 1_i

Participation NNP N
lasted VBD N
13.5 CD N
months NNS N
( ( N
12-month JJ N
active JJ N
treatment NN N
plus CC N
a DT N
post-participation JJ N
visit NN N
) ) N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
endorsed VBN N
0 CD N
days NNS N
of IN N
opioid JJ N
use NN N
in IN N
the DT N
previous JJ N
14 CD N
at IN N
follow-up NN N
. . N

Specialty NNP N
care NN N
reduced VBD N
HIV NNP 1_o
risk NN 1_o
( ( 1_o
Risk NNP 1_o
Assessment NNP 1_o
Battery NNP 1_o
composite JJ 1_o
score NN 1_o
) ) 1_o
over IN N
6 CD N
months NNS N
( ( N
-.24 JJ N
± NNP N
.17 NNP N
) ) N
compared VBN N
to TO N
primary VB N
care NN N
( ( N
.02 JJ N
± NNP N
.14 NNP N
; : N
p CC N
= NNP N
.032 NNP N
) ) N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
primary NN 1_i
care NN 1_i
OST NNP N
feasibility NN N
for IN N
a DT N
community-supervised JJ N
offender NN N
sample NN N
. . N

Specialist NNP N
care NN N
may MD N
facilitate VB N
improvements NNS N
in IN N
secondary JJ N
outcomes NNS N
, , N
such JJ 1_o
as IN 1_o
HIV NNP 1_o
risk NN 1_o
behaviors NNS 1_o
. . N

SCIENTIFIC NNP N
SIGNIFICANCE NNP N
Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
( ( N
i NN N
) ) N
the DT N
role NN N
of IN N
primary JJ N
care NN N
in IN N
addicted VBN N
offender NN N
management NN N
, , N
and CC N
( ( N
ii NN N
) ) N
the DT N
matching NN N
of IN N
offenders NNS N
, , N
based VBN N
upon IN N
history NN N
and CC N
co-morbidity NN N
, , N
to TO N
care VB N
coordination NN N
conditions NNS N
. . N

Comparison NNP N
of IN N
the DT N
hypotensive JJ N
effects NNS N
of IN N
bendrofluazide NN 1_i
, , 1_i
bumetanide NN 1_i
and CC 1_i
xipamide NNP 1_i
. . 1_i

A NNP N
randomized JJ N
, , N
triple JJ N
crossover NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
24 CD 1_p
elderly JJ 1_p
patients NNS 1_p
requiring VBG 1_p
chronic JJ 1_i
diuretic JJ 1_i
therapy NN 1_i
to TO N
assess VB N
the DT N
different JJ N
hypotensive JJ N
effects NNS N
of IN N
a DT N
fixed JJ N
daily JJ 1_i
dose NN 1_i
of IN 1_i
5 CD 1_i
mg NNS 1_i
bendrofluazide RB 1_i
, , 1_i
1 CD 1_i
mg NN 1_i
bumetanide NN 1_i
and CC 1_i
40 CD 1_i
mg NN 1_i
xipamide NN 1_i
. . 1_i

Each DT N
treatment NN N
was VBD N
given VBN N
for IN N
3 CD N
months NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
no DT N
significant JJ N
weight NN 1_o
change NN 1_o
took VBD N
place NN N
during IN N
the DT N
study NN N
period NN N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
a DT N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
decrease NN N
compared VBN N
to TO N
baseline VB 1_o
values NNS 1_o
both DT 1_o
in IN 1_o
systolic NN 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
during IN N
the DT N
xipamide JJ N
period NN N
and CC N
a DT N
decrease NN N
in IN N
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
when WRB N
taking VBG N
bumetanide NN 1_i
. . 1_i

Only RB N
minor JJ 1_o
side-effects NNS 1_o
were VBD N
reported VBN N
. . N

Population NNP N
pharmacokinetic/pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
DPP-4 NNP 1_i
inhibitor NN 1_i
linagliptin NN 1_i
in IN N
Japanese JJ 1_p
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
mellitus RB 1_p
. . 1_p

OBJECTIVES NNP N
Linagliptin NNP 1_i
is VBZ N
a DT N
novel JJ N
, , N
highly RB N
selective JJ N
and CC N
long JJ N
acting VBG N
DPP-4 NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
type NN N
2 CD N
diabetes NNS N
mellitus FW N
( ( N
T2DM NNP N
) ) N
. . N

Linagliptin JJ 1_i
exhibits VBZ N
non-linear JJ N
pharmacokinetics NNS N
( ( N
PK NNP N
) ) N
due JJ N
to TO N
saturable JJ N
binding NN N
to TO N
plasma VB N
and CC N
tissue VB N
DPP-4 NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
characterize VB N
the DT N
PK NNP N
and CC N
PK/DPP-4 NNP N
inhibition NN N
relationship NN N
of IN N
linagliptin NN 1_i
in IN N
Japanese JJ 1_p
patients NNS 1_p
with IN 1_p
T2DM NNP 1_p
using VBG N
a DT N
population NN N
PK/DPP-4 NNP N
model NN N
and CC N
to TO N
support VB N
the DT N
rationale NN N
for IN N
the DT N
therapeutic JJ N
dose NN N
in IN N
Japanese JJ N
patients NNS N
by IN N
simulation NN N
. . N

METHODS NNP N
Linagliptin NNP 1_i
plasma NN N
concentration NN N
and CC N
DPP-4 NNP N
inhibition NN N
measurements NNS N
from IN N
a DT N
placebo-controlled JJ 1_i
, , N
parallel JJ N
group NN N
multiple NN N
( ( N
28 CD N
days NNS N
) ) N
dose VBP N
trial NN N
that WDT N
included VBD N
36 CD 1_p
T2DM NNP 1_p
patients NNS 1_p
( ( 1_p
18 CD 1_p
patients NNS 1_p
each DT 1_p
in IN 1_p
2.5 CD 1_p
mg NN 1_p
and CC 1_p
10 CD 1_p
mg NNS 1_p
dose JJ 1_p
group NN 1_p
) ) 1_p
were VBD N
used VBN N
for IN N
analysis NN N
. . N

Modeling NNP N
was VBD N
performed VBN N
using VBG N
FOCE NNP N
INTERACTION NNP N
estimation NN N
method NN N
implemented VBN N
in IN N
NONMEM NNP N
V. NNP N
The DT N
linagliptin JJ N
plasma JJ N
concentration- NN N
and CC N
DPP-4 NNP N
inhibition- JJ N
time NN N
profiles NNS N
were VBD N
simulated VBN N
for IN N
Japanese JJ N
patients NNS N
receiving VBG N
5 CD N
mg JJ N
linagliptin NN 1_i
once RB N
daily JJ N
by IN N
the DT N
model NN N
established VBN N
. . N

RESULTS NNP N
Nonlinear NNP N
PK NNP N
of IN N
linagliptin NN N
in IN N
T2DM NNP N
patients NNS N
were VBD N
well RB N
described VBN N
by IN N
a DT N
2-compartment JJ N
model NN N
assuming VBG N
concentration-dependent JJ N
binding NN N
to TO N
DPP-4 NNP N
in IN N
the DT N
central JJ N
and CC N
peripheral JJ N
compartment NN N
. . N

Plasma NNP 1_o
DPP-4 NNP 1_o
inhibition NN 1_o
was VBD N
integrated VBN N
in IN N
the DT N
model NN N
by IN N
relating VBG N
the DT N
model-predicted JJ N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin JJ 1_i
linearly JJ N
to TO N
DPP-4 JJ N
inhibition NN N
. . N

The DT N
simulation NN N
predicted VBD N
that IN N
for IN N
the DT N
5 CD N
mg NN N
dose NN N
group NN N
the DT N
trough JJ N
DPP-4 JJ 1_o
inhibition NN 1_o
at IN N
steady-state NN N
was VBD N
84.2 CD N
% NN N
, , N
which WDT N
is VBZ N
higher JJR N
than IN N
the DT N
target NN N
inhibition NN N
( ( N
≥80 CD N
% NN N
) ) N
for IN N
an DT N
effective JJ N
dose NN N
of IN N
DPP-4 NNP N
inhibitor NN N
. . N

In IN N
2.5 CD N
mg NNS N
dose JJ N
group NN 1_o
, , 1_o
steady-state JJ 1_o
DPP-4 NNP 1_o
inhibition NN 1_o
of IN N
> $ N
80 CD N
% NN N
was VBD N
not RB N
maintained VBN N
over IN N
24 CD N
hours NNS N
( ( N
observed VBN N
and CC N
simulated VBN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
nonlinear JJ N
PK NNP N
of IN 1_i
linagliptin NN 1_i
and CC N
its PRP$ N
plasma JJ N
DPP-4 JJ N
inhibition NN N
in IN N
patients NNS N
were VBD N
well RB N
characterized VBN N
by IN N
a DT N
target-mediated JJ N
drug NN N
disposition NN N
model NN N
relating VBG N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin NN N
to TO N
DPP-4 NNP N
inhibition NN N
. . N

Simulations NNS N
of IN N
plasma JJ N
DPP-4 NNP N
inhibition NN N
suggest VBP N
that IN N
5 CD N
mg NNS 1_i
linagliptin JJ 1_i
once RB N
daily JJ N
is VBZ N
an DT N
appropriate JJ N
therapeutic JJ N
dose NN N
for IN N
Japanese JJ N
patients NNS N
with IN N
T2DM NNP N
. . N

Anemia NNP N
and CC N
associated VBN N
clinical JJ N
outcomes NNS N
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
due JJ 1_p
to TO 1_p
reduced VB 1_p
left JJ 1_p
ventricular JJ 1_p
systolic JJ 1_p
function NN 1_p
. . 1_p

BACKGROUND NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
decreased JJ N
functional JJ N
capacity NN N
, , N
reduced VBD N
quality NN N
of IN N
life NN N
, , N
and CC N
worsened VBD N
outcomes NNS N
among IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
HF NNP 1_p
) ) 1_p
due JJ 1_p
to TO 1_p
reduced VB 1_p
left JJ 1_p
ventricular JJ 1_p
ejection NN 1_p
fraction NN 1_p
( ( 1_p
HFREF NNP 1_p
) ) 1_p
. . 1_p

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
independent JJ N
effect NN N
of IN N
anemia NN N
on IN N
clinical JJ N
outcomes NNS N
among IN N
those DT 1_p
with IN 1_p
HFREF NNP 1_p
. . 1_p

HYPOTHESIS NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
cardiovascular JJ N
events NNS N
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

METHODS PDT N
The DT N
HF-ACTION NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
exercise NN 1_i
therapy NN 1_i
vs NN 1_i
usual JJ 1_i
care NN 1_i
in IN N
2331 CD 1_p
patients NNS 1_p
with IN 1_p
HFREF NNP 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
New NNP 1_p
York NNP 1_p
Heart NNP 1_p
Association NNP 1_p
class NN 1_p
II NNP 1_p
to TO 1_p
IV NNP 1_p
HF NNP 1_p
and CC 1_p
left VBD 1_p
ventricular JJ 1_p
ejection NN 1_p
fractions NNS 1_p
of IN 1_p
≤ JJ 1_p
35 CD 1_p
% NN 1_p
were VBD 1_p
recruited VBN 1_o
. . 1_o

Hemoglobin NNP 1_o
( ( 1_o
Hb NNP 1_o
) ) 1_o
was VBD N
measured VBN N
up RB N
to TO N
1 CD N
year NN N
prior RB N
to TO N
entry NN N
and CC N
was VBD N
stratified VBN N
by IN N
quintile NN 1_o
. . 1_o

Anemia NNP 1_o
was VBD N
defined VBN N
as IN 1_p
baseline NN 1_p
Hb NNP 1_p
< VBZ 1_p
13 CD 1_p
g/dL NN 1_p
and CC 1_p
< $ 1_p
12 CD 1_p
g/dL NN 1_p
in IN 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
, , N
respectively RB 1_o
. . 1_o

Hemoglobin NNP 1_o
was VBD N
assessed VBN N
in IN N
2 CD N
models NNS N
: : N
a DT N
global JJ N
prediction NN N
model NN N
that WDT N
had VBD N
been VBN N
previously RB N
developed VBN N
, , N
and CC N
a DT N
modified JJ N
model NN N
including VBG N
variables NNS N
associated VBN N
with IN N
anemia NN N
and CC N
the DT N
studied JJ N
outcomes NNS N
. . N

RESULTS NNP 1_o
Hemoglobin NNP 1_o
was VBD N
available JJ N
at IN N
baseline NN N
in IN 1_p
1763 CD 1_p
subjects NNS 1_p
( ( 1_p
76 CD 1_p
% NN 1_p
of IN 1_p
total JJ 1_p
study NN 1_p
population NN 1_p
) ) 1_p
; : 1_p
their PRP$ 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
59.0 CD 1_p
years NNS 1_p
, , 1_p
73 CD 1_p
% NN 1_p
were VBD 1_p
male JJ 1_p
, , 1_p
and CC 1_p
62 CD 1_p
% NN 1_p
were VBD 1_p
Caucasian JJ 1_p
. . N

The DT N
prevalence NN N
of IN N
anemia NN N
was VBD N
515/1763 CD N
( ( N
29 CD N
% NN N
) ) N
. . N

Older JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
African JJ N
American NNP N
race NN N
, , N
diabetes VBZ N
, , N
hypertension NN N
, , N
and CC N
lower JJR N
estimated VBN N
glomerular JJ N
filtration NN N
rates NNS N
were VBD N
all DT N
more RBR N
frequent JJ N
in IN N
lower JJR N
Hb NNP N
quintiles NNS N
. . N

Over IN N
a DT N
median JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
the DT N
primary JJ N
outcome NN N
of IN 1_o
all-cause JJ 1_o
mortality NN 1_o
or CC 1_o
all-cause JJ 1_o
hospitalization NN 1_o
occurred VBD N
in IN N
78 CD N
% NN N
of IN N
those DT N
with IN N
anemia NN N
and CC N
64 CD N
% NN N
in IN N
those DT N
without IN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
secondary JJ N
outcomes NNS N
of IN 1_o
all-cause JJ 1_o
mortality NN 1_o
alone RB 1_o
, , 1_o
cardiovascular JJ 1_o
( ( 1_o
CV NNP 1_o
) ) 1_o
mortality NN 1_o
or CC 1_o
CV NNP 1_o
hospitalization NN 1_o
, , 1_o
and CC 1_o
CV NNP 1_o
mortality NN 1_o
or CC 1_o
HF NNP 1_o
hospitalization NN 1_o
occurred VBD N
in IN N
23 CD N
% NN N
vs JJ N
15 CD N
% NN N
, , N
67 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
and CC N
44 CD N
vs NNS N
29 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD 1_o
) ) 1_o
. . 1_o

Heart NNP 1_o
failure NN 1_o
hospitalizations NNS 1_o
occurred VBD N
in IN N
36 CD N
% NN N
vs JJ N
22 CD N
% NN N
, , N
and CC 1_o
urgent JJ 1_o
outpatient NN 1_o
visits NNS 1_o
for IN 1_o
HF NNP 1_o
exacerbations NNS 1_o
occurred VBD N
in IN N
67 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
the DT N
global JJ N
model NN N
, , N
there EX N
was VBD N
an DT N
association NN N
observed VBD N
for IN N
anemia NN N
and CC 1_o
all-cause JJ 1_o
mortality NN 1_o
or CC 1_o
hospitalization NN 1_o
( ( N
adjusted VBN N
hazard RB N
ratio JJ N
[ NNP N
HR NNP N
] NN N
: : N
1.15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.01-1.32 JJ N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
but CC N
other JJ N
outcomes NNS N
were VBD N
not RB N
significant JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

In IN N
the DT N
modified JJ N
model NN N
, , N
the DT N
adjusted JJ 1_o
HR NNP 1_o
for IN N
anemia NN N
and CC N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ N
mortality NN N
or CC N
all-cause JJ N
hospitalization NN N
was VBD N
1.25 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.10-1.42 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
independent JJ N
associations NNS N
between IN 1_o
anemia NN 1_o
and CC 1_o
all-cause JJ 1_o
death NN 1_o
( ( N
HR NNP N
: : N
1.11 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.87-1.42 JJ N
, , N
P NNP N
= NNP N
0.38 CD 1_o
) ) 1_o
, , 1_o
CV NNP 1_o
death NN 1_o
or CC 1_o
CV NNP 1_o
hospitalization NN 1_o
( ( N
HR NNP N
: : N
1.16 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.33 JJ N
, , N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
and CC N
CV NNP N
death NN N
and CC 1_o
HF NNP 1_o
hospitalization NN 1_o
( ( N
HR NNP N
: : N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.06-1.51 JJ N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSIONS NNP N
Anemia NNP N
modestly RB N
is VBZ N
associated VBN N
with IN N
increased JJ N
rates NNS N
of IN N
death NN N
, , N
hospitalization NN N
, , N
and CC N
HF NNP N
exacerbation NN N
in IN 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
HFREF NNP 1_p
. . N

After IN N
adjusting VBG N
for IN N
other JJ N
important JJ N
covariates NNS N
, , N
anemia NN N
is VBZ N
independently RB N
associated VBN N
with IN N
an DT N
excess JJ N
hazard NN N
for IN N
all-cause JJ N
mortality NN N
and CC N
all-cause JJ N
hospitalization NN N
. . N

Anemia NNP N
is VBZ N
also RB N
associated VBN N
with IN N
combinations NNS N
of IN N
CV NNP N
death NN N
and CC N
CV/HF NNP N
hospitalizations NNS N
as IN N
composite JJ N
endpoints NNS N
. . N

Effects NNS N
of IN N
levosimendan JJ 1_i
versus FW N
dobutamine NN 1_i
on IN N
inflammatory NN N
and CC N
apoptotic JJ N
pathways NNS N
in IN N
acutely RB 1_p
decompensated VBN 1_p
chronic JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

A DT N
single JJ N
levosimendan NN 1_i
administration NN N
has VBZ N
recently RB N
been VBN N
shown VBN N
to TO N
result VB N
in IN N
clinical JJ N
and CC N
hemodynamic JJ N
improvement NN N
in IN N
patients NNS 1_p
with IN 1_p
decompensated JJ 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
HF NNP 1_p
) ) 1_p
, , 1_p
but CC 1_p
without IN 1_p
survival JJ 1_p
benefits NNS 1_p
. . 1_p

In IN N
this DT N
study NN N
, , N
the DT N
effects NNS N
of IN N
levosimendan NN 1_i
and CC N
dobutamine NN 1_i
on IN N
plasma NN N
levels NNS N
of IN N
proinflammatory NN N
and CC N
proapoptotic JJ N
mediators NNS N
in IN N
decompensated JJ N
HF NNP N
were VBD N
compared VBN N
and CC N
correlated VBN N
with IN N
the DT N
concomitant JJ N
effects NNS N
on IN N
cardiac JJ N
function NN N
and CC N
prognosis NN N
. . N

Sixty-nine JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
received VB N
24-hour JJ N
intravenous JJ N
infusions NNS N
of IN N
levosimendan NN 1_i
( ( N
n JJ N
= NNP N
23 CD N
) ) N
, , N
dobutamine NN 1_i
( ( N
n JJ N
= NNP N
23 CD N
) ) N
, , N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
23 CD N
) ) N
. . N

Echocardiographic NNP 1_o
, , 1_o
hemodynamic JJ 1_o
, , 1_o
and CC 1_o
biochemical JJ 1_o
assessments NNS 1_o
were VBD N
performed VBN N
at IN N
baseline NN N
, , N
immediately RB N
after IN N
treatment NN N
, , N
and CC N
48 CD N
hours NNS N
later RB N
. . N

Patients NNS N
were VBD N
subsequently RB N
followed VBN N
for IN N
4 CD N
months NNS N
for IN N
disease NN N
progression NN N
. . N

End-systolic JJ 1_o
wall NN 1_o
stress NN 1_o
, , 1_o
the DT 1_o
left NN 1_o
ventricular JJ 1_o
ejection NN 1_o
fraction NN 1_o
, , 1_o
pulmonary JJ 1_o
capillary JJ 1_o
wedge NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
cardiac JJ 1_o
index NN 1_o
were VBD N
significantly RB N
improved VBN N
in IN N
the DT N
levosimendan NN N
group NN N
but CC N
remained VBD N
practically RB N
unaffected VBN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Plasma NNP 1_o
N-terminal-pro-B-type JJ 1_o
natriuretic JJ 1_o
peptide NN 1_o
, , 1_o
tumor NN 1_o
necrosis NN 1_o
factor-alpha NN 1_o
, , 1_o
and CC 1_o
soluble JJ 1_o
Fas NNP 1_o
ligand NN 1_o
levels NNS 1_o
were VBD N
significantly RB N
decreased VBN N
only RB N
in IN N
the DT N
levosimendan NN 1_i
group NN N
( ( N
from IN N
1,900 CD N
+/- JJ N
223 CD N
to TO N
1,378 CD N
+/- JJ N
170 CD N
pg/ml NN N
, , N
13.4 CD N
+/- JJ N
1.0 CD N
to TO N
12.3 CD N
+/- JJ N
1.2 CD N
pg/ml NN N
, , N
and CC N
68.2 CD N
+/- JJ N
3.7 CD N
to TO N
59.8 CD N
+/- JJ N
3.6 CD N
pg/ml NN N
, , N
respectively RB N
; : N
p VB N
< $ N
0.05 CD N
for IN N
all DT N
) ) N
; : N
interleukin-6 NN 1_o
was VBD N
also RB N
borderline JJ N
reduced VBN N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

Levosimendan-induced JJ 1_o
reduction NN 1_o
in IN 1_o
end-systolic JJ 1_o
wall NN 1_o
stress NN 1_o
was VBD N
significantly RB N
correlated VBN N
with IN N
respective JJ N
decreases NNS N
in IN N
N-terminal-pro-B-type NNP 1_o
natriuretic JJ 1_o
peptide NN 1_o
( ( N
r JJ N
= NN N
0.671 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
, , N
tumor JJ 1_o
necrosis NN 1_o
factor-alpha NN 1_o
( ( N
r JJ N
= NN N
0.586 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
, , N
soluble JJ 1_o
Fas NNP 1_o
( ( N
r VB N
= RB N
0.441 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
soluble JJ 1_o
Fas NNP 1_o
ligand NN 1_o
( ( N
r JJ N
= NN N
0.614 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Event-free JJ 1_o
survival NN 1_o
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
levosimendan NN 1_i
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
superiority NN N
of IN N
levosimendan NN 1_i
over IN N
dobutamine NN 1_i
in IN N
improving VBG N
central JJ 1_o
hemodynamics NNS 1_o
and CC N
left VBD 1_o
ventricular JJ 1_o
performance NN 1_o
in IN N
decompensated JJ 1_p
HF NNP 1_p
seems VBZ N
to TO N
be VB N
related VBN N
to TO N
its PRP$ N
anti-inflammatory JJ N
and CC N
antiapoptotic JJ N
effects NNS N
. . N

Two-year JJ N
prospective JJ N
clinical JJ N
comparison NN N
of IN N
immediate JJ 1_i
replacement NN 1_i
vs. FW 1_i
immediate JJ 1_i
restoration NN 1_i
of IN 1_i
single JJ 1_i
tooth NN 1_i
in IN 1_p
the DT 1_p
esthetic JJ 1_p
zone NN 1_p
. . 1_p

AIM NNP N
To TO N
compare VB N
the DT N
immediate JJ N
restoration NN N
of IN N
single JJ 1_i
implants NNS 1_i
in IN N
the DT N
esthetic JJ N
zones NNS N
performed VBN N
on IN N
implants NNS N
placed VBN N
immediately RB N
after IN N
tooth JJ N
extraction NN N
or CC N
8 CD N
weeks NNS N
later RB N
( ( N
immediate JJ N
replacement NN 1_i
vs. FW N
immediate JJ N
restoration NN 1_i
) ) 1_i
. . N

METHODS NNP N
Sixteen JJ 1_p
patients NNS 1_p
( ( 1_p
10 CD 1_p
women NNS 1_p
and CC 1_p
6 CD 1_p
men NNS 1_p
) ) 1_p
with IN 1_p
a DT 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
35 CD 1_p
years NNS 1_p
( ( 1_p
ranging VBG 1_p
from IN 1_p
21 CD 1_p
to TO 1_p
49 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
were VBD 1_p
treated VBN 1_p
from IN 1_p
2004 CD 1_p
to TO 1_p
2005 CD 1_p
for IN 1_p
single-tooth JJ 1_p
replacement NN 1_p
in IN 1_p
the DT 1_p
upper JJ 1_p
arch NN 1_p
. . 1_p

The DT 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN N
two CD N
groups NNS N
: : N
in IN N
the DT N
test NN N
group NN N
patients NNS N
received VBD N
implants NNS 1_i
placed VBN 1_i
and CC 1_i
restored VBN 1_i
( ( N
non-occlusal JJ N
loading NN N
) ) N
at IN N
the DT N
time NN N
of IN N
tooth JJ N
extraction NN N
; : N
in IN N
the DT N
control NN N
group NN N
implants NNS 1_i
were VBD 1_i
placed VBN 1_i
8 CD N
weeks NNS N
after IN 1_i
tooth DT 1_i
extraction NN 1_i
and CC 1_i
immediately RB 1_i
restored VBN 1_i
. . 1_i

All PDT 1_p
the DT 1_p
patients NNS 1_p
received VBD 1_p
tapered JJ 1_i
effect NN 1_i
( ( 1_i
TE NNP 1_i
) ) 1_i
implants NNS 1_i
from IN 1_p
the DT 1_p
Straumann NNP 1_p
Dental NNP 1_p
Implant NNP 1_p
System NNP 1_p
. . 1_p

The DT N
following JJ N
parameters NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
moment NN N
of IN N
provisional JJ N
restoration NN N
( ( N
within IN N
48 CD N
h NN N
after IN N
implant JJ N
placement NN N
) ) N
and CC N
at IN N
the DT N
2 CD N
years NNS N
follow-up JJ N
visit NN N
: : N
marginal JJ 1_o
bone NN 1_o
resorption NN 1_o
, , 1_o
papilla NN 1_o
index NN 1_o
, , 1_o
position NN 1_o
of IN 1_o
the DT 1_o
mucosal NN 1_o
margin NN 1_o
. . 1_o

The DT N
implant JJ 1_o
stability NN 1_o
quotient NN 1_o
was VBD N
measured VBN N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
and CC N
at IN N
the DT N
moment NN N
of IN N
the DT N
delivery NN N
of IN N
the DT N
definitive JJ N
restoration NN N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
studied JJ N
parameters NNS N
between IN N
the DT N
test NN N
and CC N
the DT N
control NN N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
implant JJ 1_o
stability NN 1_o
quotient NN 1_o
values NNS 1_o
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
but CC N
were VBD N
no DT N
more RBR N
significant JJ N
at IN N
the DT N
loading NN N
of IN N
the DT N
definitive JJ N
restoration NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
suggest VBP N
that IN N
immediate JJ N
replacement NN N
without IN N
functional JJ N
loading NN N
may MD N
be VB N
considered VBN N
a DT N
valuable JJ N
therapeutic JJ N
option NN N
for IN N
selected VBN N
cases NNS N
of IN N
single-tooth JJ 1_i
replacement NN 1_i
in IN N
the DT N
esthetic JJ N
area NN N
when WRB N
TE NNP N
implants NNS N
are VBP N
used VBN N
. . N

Implant JJ 1_o
stability NN 1_o
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
is VBZ N
slightly RB N
inferior JJ N
in IN N
the DT N
immediate JJ N
replacement NN N
group NN N
, , N
but CC N
it PRP N
does VBZ N
not RB N
affect VB N
the DT N
treatment NN N
result NN N
. . N

Tinidazole NNP 1_i
and CC 1_i
metronidazole NN 1_i
in IN N
hepatic JJ 1_p
amoebiasis NN 1_p
. . 1_p

The DT N
efficacy NN N
of IN N
metronidazole NN 1_i
and CC N
tinidazole NN 1_i
has VBZ N
been VBN N
compared VBN N
in IN N
31 CD 1_p
patients NNS 1_p
with IN 1_p
hepatic JJ 1_p
amoebiasis NN 1_p
. . 1_p

Only RB 1_p
those DT 1_p
with IN 1_p
unequivocal JJ 1_p
clinical JJ 1_p
, , 1_p
radiological JJ 1_p
and CC 1_p
laboratory JJ 1_p
evidence NN 1_p
of IN 1_p
hepatic JJ 1_p
amoebiasis NN 1_p
were VBD N
included VBN N
; : N
diagnostic JJ N
and CC N
therapeutic JJ N
aspiration NN N
was VBD N
performed VBN N
where WRB N
necessary JJ N
. . N

15 CD 1_p
patients NNS 1_p
received VBN 1_p
metronidazole JJ 1_i
and CC 1_i
16 CD 1_i
tinidazole NN 1_i
, , 1_p
in IN 1_p
random JJ 1_p
order NN 1_p
. . 1_p

The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
. . N

Both DT N
drugs NNS N
were VBD N
given VBN N
orally RB N
in IN N
a DT N
single JJ N
daily JJ N
dose NN N
of IN N
2g CD N
for IN N
a DT N
minimum NN N
of IN N
3 CD N
days NNS N
, , N
with IN N
treatment NN N
extended VBN N
if IN N
considered VBN N
clinically RB N
advisable JJ N
. . N

12 CD N
of IN N
15 CD N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
were VBD N
cured VBN 1_o
with IN N
metronidazole JJ 1_i
given VBN N
for IN N
an DT N
average JJ N
period NN N
of IN N
7 CD N
days NNS N
( ( N
range VB N
4 CD N
to TO N
14 CD N
days NNS N
) ) N
. . N

15 CD N
of IN N
16 CD N
patients NNS N
( ( N
93.8 CD N
% NN N
) ) N
given VBN N
tinidazole NNS 1_i
were VBD N
cured VBN 1_o
and CC N
the DT N
mean JJ 1_o
duration NN 1_o
of IN 1_o
treatment NN 1_o
was VBD N
4 CD N
days NNS N
( ( N
range VB N
3 CD N
to TO N
6 CD N
days NNS N
) ) N
. . N

There EX N
were VBD N
fewer JJR 1_o
side-effects NNS 1_o
with IN N
tinidazole NN 1_i
. . 1_i

In IN N
this DT N
study NN N
of IN N
hepatic JJ 1_p
amoebiasis NN 1_p
in IN 1_p
Bangladesh NNP 1_p
, , N
tinidazole NN N
was VBD N
found VBN N
to TO N
be VB N
superior JJ N
to TO N
metronidazole VB 1_i
in IN N
overall JJ 1_o
efficacy NN 1_o
because IN N
a DT N
shorter JJR N
course NN N
of IN N
treatment NN N
was VBD N
necessary JJ N
and CC N
it PRP N
caused VBD N
fewer JJR N
side-effects NNS 1_o
. . 1_o

Intravenous JJ 1_i
flecainide NN 1_i
versus NN 1_i
verapamil NN 1_i
for IN N
acute JJ N
conversion NN N
of IN N
paroxysmal JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
or CC 1_p
flutter NN 1_p
to TO 1_p
sinus VB 1_p
rhythm NN 1_p
. . 1_p

In IN N
a DT N
single-blind JJ N
randomized NN N
study NN N
, , N
the DT N
efficacy NN 1_o
of IN N
intravenous JJ 1_i
flecainide NN 1_i
( ( N
2 CD N
mg/kg/10 NN N
minutes NNS N
) ) N
versus VBP 1_i
verapamil NN 1_i
( ( N
10 CD N
mg/1 RB N
minute NN N
) ) N
was VBD N
assessed VBN N
in IN N
40 CD 1_p
patients NNS 1_p
with IN 1_p
paroxysmal JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
( ( 1_p
AF NNP 1_p
) ) 1_p
or CC 1_p
atrial JJ 1_p
flutter NN 1_p
( ( 1_p
AFI NNP 1_p
) ) 1_p
. . 1_p

The DT N
treatment NN N
was VBD N
considered VBN N
successful JJ N
if IN N
sinus JJ 1_o
rhythm NN 1_o
occurred VBD N
within IN N
1 CD N
hour NN N
. . N

Of IN N
20 CD 1_p
patients NNS 1_p
receiving VBG 1_p
flecainide RB 1_i
, , 1_p
14 CD 1_p
of IN 1_p
17 CD 1_p
( ( 1_p
82 CD 1_p
% NN 1_p
) ) 1_p
with IN 1_p
AF NNP 1_p
converted VBD 1_p
to TO 1_p
sinus VB 1_p
rhythm NN 1_p
, , 1_p
but CC 1_p
in IN 1_p
3 CD 1_p
patients NNS 1_p
with IN 1_p
AFI NNP 1_p
flecainide NN 1_i
failed VBD 1_p
. . 1_p

All DT N
patients NNS N
treated VBN N
with IN N
verapamil NN 1_i
( ( N
17 CD N
AF NNP N
, , N
3 CD N
AFI NNP N
) ) N
showed VBD N
lower JJR 1_o
ventricular NN 1_o
rates NNS 1_o
after IN N
1 CD N
hour NN N
; : N
however RB N
, , N
only RB N
1 CD N
( ( N
6 CD N
% NN N
) ) N
with IN N
AF NNP N
converted VBD N
to TO N
sinus VB N
rhythm NN N
and CC N
1 CD N
( ( N
6 CD N
% NN N
) ) N
converted VBD N
to TO N
AFI NNP N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
convert VB N
to TO N
sinus VB N
rhythm NN N
after IN N
treatment NN N
with IN N
verapamil NNS 1_i
were VBD N
treated VBN N
with IN N
flecainide NN 1_i
and CC N
observed VBD N
for IN N
another DT N
hour NN N
. . N

After IN N
the DT N
change NN N
to TO N
flecainide VB N
, , N
9 CD N
of IN N
15 CD N
patients NNS N
( ( N
60 CD N
% NN N
) ) N
with IN N
AF NNP N
still RB N
converted VBD 1_o
. . 1_o

Thus NNP N
, , N
23 CD N
of IN N
32 CD N
patients NNS N
( ( N
72 CD N
% NN N
) ) N
with IN N
AF NNP N
and CC N
none NN N
of IN N
7 CD N
with IN N
AFI NNP N
converted VBD N
to TO N
sinus VB 1_o
rhythm NN 1_o
after IN N
treatment NN N
with IN N
flecainide NN N
. . N

Conversion NN 1_o
to TO 1_o
sinus VB 1_o
rhythm NN 1_o
was VBD N
achieved VBN N
in IN N
19 CD N
of IN N
22 CD N
patients NNS N
( ( N
86 CD N
% NN N
) ) N
when WRB N
AF NNP N
lasted VBD N
less JJR N
than IN N
24 CD N
hours NNS N
and CC N
in IN N
4 CD N
of IN N
10 CD N
( ( N
40 CD N
% NN N
) ) N
when WRB N
the DT N
arrhythmia NN N
lasted VBD N
greater JJR N
than IN N
24 CD N
hours NNS N
. . N

Transient JJ 1_o
adverse JJ 1_o
effects NNS 1_o
were VBD N
noted VBN N
in IN N
10 CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
after IN N
flecainide NN N
. . N

In IN N
summary JJ N
, , N
flecainide EX 1_i
is VBZ N
an DT N
effective JJ 1_o
and CC 1_o
safe JJ 1_o
drug NN 1_o
for IN N
conversion NN N
of IN N
paroxysmal JJ N
AF NNP N
to TO N
sinus VB N
rhythm NN N
, , N
but CC N
ineffective JJ N
for IN N
AFI NNP 1_o
. . 1_o

Verapamil NNP 1_i
appears VBZ N
to TO N
be VB N
of IN N
no DT N
use NN N
for IN N
conversion NN 1_o
of IN 1_o
AF NNP 1_o
or CC 1_o
AFI NNP 1_o
to TO N
sinus VB N
rhythm NN N
. . N

Matching VBG N
doses NNS N
of IN N
distraction NN N
with IN N
child NN 1_p
risk NN 1_p
for IN 1_p
distress NN 1_p
during IN N
a DT N
medical JJ N
procedure NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Parents NNPS N
often RB N
want VBP N
to TO N
provide VB N
support NN N
to TO N
their PRP$ N
children NNS N
during IN N
medical JJ N
procedures NNS N
, , N
but CC N
not RB N
all DT N
parents NNS N
are VBP N
effective JJ N
in IN N
providing VBG N
distraction NN N
after IN N
brief JJ N
training NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
three CD N
doses NNS 1_i
of IN 1_i
distraction NN 1_i
intervention NN 1_i
for IN N
children NNS 1_p
at IN 1_p
high JJ 1_p
and CC 1_p
medium NN 1_p
risk NN 1_p
for IN 1_p
procedure-related JJ 1_p
distress NN 1_p
. . 1_p

METHODS NNP N
Children NNP 1_p
undergoing VBG 1_p
scheduled VBN 1_p
intravenous JJ 1_p
insertions NNS 1_p
for IN 1_p
diagnostic JJ 1_p
or CC 1_p
treatment NN 1_p
purposes NNS 1_p
and CC 1_p
their PRP$ 1_p
parents NNS 1_p
participated VBN 1_p
. . 1_p

A DT N
computerized JJ N
application NN N
, , N
Children NNP N
, , N
Parents NNP N
and CC N
Distraction NNP N
, , N
was VBD N
used VBN N
to TO N
predict VB N
distress NN N
risk NN N
. . N

Doses NNS 1_i
of IN 1_i
intervention NN 1_i
were VBD N
basic JJ N
( ( 1_i
parents NNS 1_i
trained VBN 1_i
on IN 1_i
providing VBG 1_i
distraction NN 1_i
) ) 1_i
, , N
enhanced VBN N
( ( 1_i
basic JJ 1_i
training NN 1_i
plus CC 1_i
tailored JJ 1_i
instructions NNS 1_i
, , 1_i
environmental JJ 1_i
modifications NNS 1_i
, , 1_i
and CC 1_i
support NN 1_i
and CC 1_i
guidance NN 1_i
from IN 1_i
the DT 1_i
research NN 1_i
assistant NN 1_i
) ) 1_i
, , N
and CC N
professional JJ N
( ( 1_i
a DT 1_i
trained VBN 1_i
research NN 1_i
assistant NN 1_i
provided VBD 1_i
distraction NN 1_i
) ) 1_i
. . N

Outcome JJ N
measures NNS N
were VBD N
Observational NNP 1_o
Scale NNP 1_o
of IN 1_o
Behavioral NNP 1_o
Distress-Revised JJ 1_o
for IN 1_o
behavioral JJ 1_o
distress NN 1_o
, , 1_o
Oucher NNP 1_o
for IN 1_o
self-reported JJ 1_o
pain NN 1_o
, , 1_o
parent JJ 1_o
report NN 1_o
of IN 1_o
child JJ 1_o
distress NN 1_o
, , 1_o
and CC 1_o
salivary JJ 1_o
cortisol NN 1_o
for IN 1_o
physiological JJ 1_o
distress NN 1_o
. . 1_o

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
574 CD 1_p
children NNS 1_p
, , 1_p
ages VBZ 1_p
4-10 JJ 1_p
, , 1_p
and CC 1_p
their PRP$ 1_p
parents NNS 1_p
participated VBN 1_p
. . 1_p

The DT N
Children NNP N
, , N
Parents NNP N
and CC N
Distraction NNP N
predicted VBD N
that IN N
the DT N
risk NN 1_o
for IN 1_o
distress NN 1_o
was VBD N
high JJ N
for IN N
156 CD N
children NNS N
, , N
medium NN N
for IN N
372 CD N
, , N
and CC N
low JJ N
for IN N
46 CD N
. . N

Children NNP N
predicted VBD N
to TO N
have VB N
higher JJR N
risk NN N
for IN N
distress NN N
displayed VBD N
more RBR N
behavioral JJ 1_o
distress NN 1_o
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

Children NNP N
in IN N
the DT N
medium-risk JJ N
group NN N
who WP N
had VBD N
the DT N
professional JJ N
intervention NN N
displayed VBD N
significantly RB N
less RBR N
behavioral JJ 1_o
distress NN 1_o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Children NNP N
in IN N
the DT N
high-risk JJ N
group NN N
tended VBD N
to TO N
have VB N
less JJR N
behavioral JJ N
distress NN N
when WRB N
receiving VBG N
the DT N
professional JJ N
intervention NN N
( ( N
p JJ N
= NNP N
.07 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
for IN N
self-report NN 1_o
of IN 1_o
pain NN 1_o
, , 1_o
parent JJ 1_o
report NN 1_o
of IN 1_o
distress NN 1_o
, , 1_o
or CC 1_o
cortisol NN 1_o
levels NNS 1_o
. . 1_o

DISCUSSION NNP N
Some DT N
parents NNS N
may MD N
need VB N
additional JJ N
training NN N
in IN N
providing VBG N
distraction NN N
to TO N
their PRP$ N
children NNS N
during IN N
procedures NNS N
, , N
and CC N
some DT N
children NNS 1_p
at IN 1_p
medium NN 1_p
and CC 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
distress NN 1_p
may MD N
need VB N
professional JJ N
support NN N
. . N

Parents NNS N
should MD N
be VB N
asked VBN N
about IN N
their PRP$ N
preferences NNS N
in IN N
acting VBG N
as IN N
the DT N
distraction NN N
coach NN N
and CC N
, , N
if IN N
willing JJ N
, , N
be VB N
provided VBN N
as IN N
much JJ N
training NN N
and CC N
support NN N
as IN N
possible JJ N
in IN N
the DT N
clinical JJ N
situation NN N
. . N

Processing VBG N
familiar JJ N
and CC N
unfamiliar JJ N
auditory NN N
stimuli NN N
during IN 1_p
general JJ 1_p
anesthesia NN 1_p
. . 1_p

We PRP N
tested VBD N
memory NN N
priming NN N
for IN N
auditory JJ 1_i
stimuli NNS 1_i
presented VBN N
during IN N
general JJ 1_i
propofol-sufentanil JJ 1_i
anesthesia NN 1_i
in IN 1_p
58 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
day-case JJ 1_i
arthroscopic NN 1_i
surgery NN 1_i
. . 1_i

Stimuli NNP 1_i
were VBD 1_i
presented VBN 1_i
via IN 1_i
headphones NNS 1_i
and CC 1_i
consisted VBN 1_i
of IN 1_i
common JJ 1_i
facts NNS 1_i
( ( 1_p
Group NNP 1_p
A NNP 1_p
, , 1_p
29 CD 1_p
patients NNS 1_p
) ) 1_p
, , N
or CC 1_i
familiar JJ 1_i
or CC 1_i
unfamiliar JJ 1_i
full JJ 1_i
names NNS 1_i
of IN 1_i
fictitious JJ 1_i
people NNS 1_i
( ( 1_p
GRoup NNP 1_p
B NNP 1_p
, , 1_p
29 CD 1_p
patients NNS 1_p
) ) 1_p
. . 1_p

Group NNP N
A NNP N
was VBD N
expected VBN N
to TO N
give VB N
more JJR N
correct JJ N
answers NNS N
to TO N
questions NNS N
about IN N
the DT N
common JJ N
facts NNS N
than IN N
Group NNP N
B NNP N
, , N
when WRB N
tested VBN N
postoperatively RB N
, , N
and CC N
Group NNP N
B NNP N
to TO N
attribute VB N
more JJR N
fame NN N
to TO N
presented VBN N
names NNS N
than IN N
Group NNP N
A NNP N
( ( N
famous JJ N
names RB N
test NN N
) ) N
. . N

Because IN N
the DT N
process NN N
for IN N
learning VBG N
new JJ N
or CC N
unfamiliar JJ N
stimuli NNS N
( ( N
elaboration NN N
) ) N
in IN N
particular JJ N
may MD N
be VB N
impaired VBN N
under IN 1_p
general JJ 1_p
anesthesia NN 1_p
, , N
more JJR N
memory NN N
priming NN N
was VBD N
expected VBN N
for IN N
familiar JJ N
than IN N
for IN N
unfamiliar JJ N
material NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
demonstrated VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
performance NN 1_o
on IN 1_o
common JJ 1_o
facts NNS 1_o
or CC N
in IN 1_o
fame NN 1_o
attributed VBN N
to TO N
the DT N
names NNS N
. . N

The DT N
amount NN 1_o
of IN 1_o
memory NN 1_o
priming NN 1_o
, , N
however RB N
, , N
was VBD N
positively RB 1_o
related VBN 1_o
to TO 1_o
one CD 1_o
of IN 1_o
two CD 1_o
measures NNS 1_o
of IN N
preoperative JJ 1_o
anxiety NN 1_o
. . 1_o

Adequacy NN N
of IN N
vitamin NN 1_i
B6 NNP 1_i
supplementation NN 1_i
during IN N
pregnancy NN 1_p
: : 1_p
a DT N
prospective JJ N
study NN N
. . N

This DT N
prospective JJ N
study NN N
assesses VBZ N
the DT N
effect NN N
of IN N
2.5 CD 1_i
, , 1_i
4 CD 1_i
, , 1_i
and CC 1_i
10 CD 1_i
mg NN 1_i
of IN 1_i
pyridoxine JJ 1_i
supplementation NN 1_i
during IN 1_i
pregnancy NN 1_i
on IN 1_i
maternal JJ 1_o
and CC 1_o
fetal JJ 1_o
plasma NN 1_o
levels NNS 1_o
of IN 1_o
pyridoxal NN 1_o
5'-phosphate JJ 1_o
( ( 1_o
PLP NNP 1_o
) ) 1_o
and CC N
on IN N
the DT N
degree NN 1_o
of IN 1_o
coenzyme NN 1_o
saturation NN 1_o
( ( 1_o
activation JJ 1_o
factor NN 1_o
) ) 1_o
of IN 1_o
aspartate NN 1_o
aminotransferase NN 1_o
and CC 1_o
alanine JJ 1_o
aminotransferase NN 1_o
( ( 1_o
alphaEGOT JJ 1_o
and CC 1_o
alphaEGPT NN 1_o
) ) 1_o
in IN 1_o
maternal JJ 1_o
erythrocytes NNS 1_o
. . 1_o

More JJR N
than IN N
4 CD 1_i
mg NN 1_i
of IN 1_i
pyridoxine JJ 1_i
supplementation NN 1_i
daily RB 1_i
was VBD N
required VBN N
for IN N
most JJS N
pregnancies NNS N
to TO N
maintain VB N
maternal JJ 1_o
plasma NN 1_o
PLP NNP 1_o
levels NNS 1_o
within IN N
the DT N
range NN N
observed VBD N
during IN N
the DT N
first JJ N
trimester NN N
and CC N
in IN N
the DT N
nonpregnant JJ N
state NN N
. . N

The DT N
plasma NN 1_o
PLP NNP 1_o
concentrations NNS 1_o
in IN 1_o
maternal JJ 1_o
and CC 1_o
cord JJ 1_o
blood NN 1_o
were VBD N
highly RB N
correlated VBN N
and CC N
indicated VBD N
a DT N
dependence NN N
of IN N
fetal JJ N
vitamin NN N
B6 NNP N
nutrition NN N
on IN N
maternal JJ N
circulating NN N
PLP NNP N
. . N

Measurements NNS 1_o
of IN 1_o
alphaEGOT NN 1_o
and CC 1_o
alphaEGPT NN 1_o
were VBD N
not RB N
as RB N
reproducible JJ N
as IN N
plasma JJ 1_o
PLP NNP 1_o
assays NNS 1_o
and CC N
were VBD N
less RBR N
sensitive JJ N
and CC N
quantitative JJ N
indicators NNS N
. . N

In IN N
the DT N
majority NN N
of IN N
subjects NNS N
, , N
the DT N
changes NNS 1_o
in IN 1_o
alphaEGOT NN 1_o
and CC 1_o
alphaEGPT NN 1_o
with IN N
time NN N
correlated VBN N
poorly RB N
with IN N
the DT N
changes NNS N
in IN N
plasma NN 1_o
PLP NNP 1_o
. . 1_o

However RB N
, , N
when WRB N
the DT N
data NNS N
were VBD N
analyzed VBN N
without IN N
regard NN N
for IN N
their PRP$ N
dependence NN N
on IN N
time NN N
, , N
they PRP N
demonstrated VBD N
a DT N
negative JJ N
, , N
linear JJ N
correlation NN N
between IN N
alphaEGOT NN 1_o
and CC N
log NN N
plasma NN 1_o
PLP NNP 1_o
and CC N
between IN N
alphaEGPT NN 1_o
and CC 1_o
log NN 1_o
plasma NN 1_o
PLP NNP 1_o
for IN N
the DT N
group NN N
on IN N
2.5 CD N
mg NN N
of IN N
pyridoxine NN 1_i
and CC N
for IN N
all PDT N
the DT N
subjects NNS N
combined VBN N
. . N

Finally RB N
, , N
the DT N
dietary NN N
records NNS N
showed VBD N
that IN N
most JJS N
of IN N
the DT N
subjects NNS N
consumed VBD N
less JJR N
than IN N
2 CD N
mg NN N
of IN N
vitamin JJ 1_i
B6 NNP 1_i
daily RB N
from IN N
their PRP$ N
food NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
current JJ N
Recommended NNP N
Dietary NNP N
Allowance NNP N
for IN N
vitamin NN 1_i
B6 NNP 1_i
during IN N
pregnancy NN N
( ( N
2.5 CD N
mg NN N
) ) N
is VBZ N
too RB N
low JJ N
and CC N
that DT N
supplementation NN N
of IN N
this DT N
vitamin NN N
in IN N
an DT N
amount NN N
more JJR N
than IN N
4 CD N
mg JJ N
daily JJ N
is VBZ N
recommended VBN N
. . N

Early JJ N
withdrawal NN N
of IN N
calcineurin NN 1_i
inhibitors NNS 1_i
and CC 1_i
everolimus JJ 1_i
monotherapy NN 1_i
in IN N
de FW 1_p
novo FW 1_p
liver NN 1_p
transplant NN 1_p
recipients VBZ 1_p
preserves VBZ N
renal JJ N
function NN N
. . N

We PRP N
designed VBD N
a DT N
randomized JJ N
trial NN N
to TO N
assess VB N
whether IN N
the DT N
early JJ 1_i
withdrawal NN 1_i
of IN 1_i
cyclosporine NN 1_i
( ( 1_i
CsA NNP 1_i
) ) 1_i
followed VBN 1_i
by IN 1_i
the DT 1_i
initiation NN 1_i
of IN 1_i
everolimus NN 1_i
( ( 1_i
Evr NNP 1_i
) ) 1_i
monotherapy NN 1_i
in IN N
de FW 1_p
novo FW 1_p
liver FW 1_p
transplantation NN 1_p
( ( 1_p
LT NNP 1_p
) ) 1_p
patients NNS 1_p
would MD N
result VB N
in IN N
superior JJ N
renal JJ N
function NN N
compared VBN N
to TO N
a DT N
CsA-based JJ N
immunosuppression NN N
protocol NN N
. . N

All DT N
patients NNS N
were VBD N
treated VBN N
with IN N
CsA NNP 1_i
for IN N
the DT N
first JJ N
10 CD N
days NNS N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
Evr NNP 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
CsA NNP 1_i
up RB N
to TO N
day NN N
30 CD N
, , N
then RB N
either DT N
continued VBN N
on IN N
Evr NNP 1_i
monotherapy NN 1_i
( ( 1_i
Evr NNP 1_i
group NN 1_i
) ) 1_i
or CC N
maintained VBN N
on IN N
CsA NNP 1_i
with/without NN 1_i
mycophenolate NN 1_i
mofetil NN 1_i
( ( 1_i
CsA NNP 1_i
group NN 1_i
) ) 1_i
in IN N
case NN N
of IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
. . N

Seventy-eight JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
( ( 1_i
Evr NNP 1_i
n RB N
= VBZ N
52 CD N
; : N
CsA NNP 1_i
n VBD N
= NNP N
26 CD N
) ) N
. . N

The DT N
1-year JJ 1_o
freedom NN 1_o
from IN 1_o
efficacy NN 1_o
failure NN 1_o
in IN N
Evr NNP 1_i
group NN N
was VBD N
75 CD N
% NN N
versus IN N
69.2 CD N
% NN N
in IN N
CsA NNP 1_i
group NN N
, , N
p VBP N
= JJ N
0.36 CD N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
patient JJ 1_o
survival NN 1_o
between IN N
the DT N
two CD N
groups NNS N
. . N

Mean NNP 1_o
modification NN 1_o
of IN 1_o
diet NN 1_o
in IN 1_o
renal JJ 1_o
disease NN 1_o
( ( 1_o
MDRD NNP 1_o
) ) 1_o
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
Evr NNP 1_i
group NN N
at IN N
12 CD N
months NNS N
( ( N
87.7 CD N
± RB N
26.1 CD N
vs. FW N
59.9 CD N
± $ N
12.6 CD N
mL/min NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

The DT 1_o
incidence NN 1_o
of IN 1_o
CKD NNP 1_o
stage NN 1_o
≥ VBD 1_o
3 CD N
( ( N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
< $ N
60 CD N
mL/min NN N
) ) N
was VBD N
higher RBR N
in IN N
the DT 1_i
CsA NNP N
group NN N
at IN N
1 CD N
year NN N
( ( N
52.2 CD N
% NN N
vs. FW N
15.4 CD N
% NN N
, , N
p NN N
= NNP N
0.005 CD N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
early JJ N
withdrawal NN 1_i
of IN 1_i
CsA NNP N
followed VBN 1_i
by IN 1_i
Evr NNP 1_i
monotherapy NN 1_i
in IN 1_p
de FW 1_p
novo FW 1_p
LT NNP 1_p
patients NNS 1_p
is VBZ N
associated VBN N
with IN N
an DT N
improvement NN N
in IN N
renal JJ N
function NN N
, , N
with IN N
a DT N
similar JJ N
incidence NN N
of IN N
rejection NN N
and CC N
major JJ N
complications NNS N
. . N

Households NNS 1_p
with IN 1_p
young JJ 1_p
children NNS 1_p
and CC 1_p
use NN 1_p
of IN 1_p
freely RB 1_p
distributed VBN 1_p
bednets NNS 1_i
in IN 1_p
rural JJ 1_p
Madagascar NNP 1_p
. . 1_p

BACKGROUND NNP N
Malaria NNP N
infections NNS N
are VBP N
the DT N
leading VBG N
cause NN N
of IN N
death NN N
for IN N
children NNS 1_p
in IN 1_p
Madagascar NNP 1_p
. . 1_p

Insecticide-treated JJ 1_i
bednets NNS 1_i
offer VBP N
effective JJ N
prevention NN N
, , N
but CC N
it PRP N
is VBZ N
unclear JJ N
how WRB N
well RB N
free JJ 1_i
bednet NN 1_i
distribution NN 1_i
programs NNS 1_i
reach VBP N
young JJ 1_p
children NNS 1_p
. . 1_p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
secondary JJ N
analysis NN N
of IN N
a DT N
free JJ 1_i
bednet NN 1_i
distribution NN 1_i
program NN 1_i
in IN 1_p
Madagascar NNP 1_p
from IN 1_p
2007-2008 JJ 1_p
. . 1_p

Interviews NNS 1_i
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

Principal JJ N
components NNS N
analysis NN N
was VBD N
used VBN N
to TO N
construct VB N
a DT N
wealth NN N
and CC N
malaria NNS N
knowledge VBP N
index NN N
. . N

Coverage NNP N
efficiency NN N
was VBD N
calculated VBN N
as IN N
coverage NN 1_i
of IN 1_i
children NNS 1_i
per IN 1_i
bednet NN 1_i
owned VBN 1_i
. . 1_i

Univariable JJ N
and CC N
multivariable JJ N
regressions NNS N
were VBD N
used VBN N
to TO N
determine VB N
predictors NNS N
of IN N
bednet NN 1_i
use NN N
. . N

RESULTS NNP N
Bednet NNP 1_o
use NN 1_o
, , N
among IN N
the DT N
560 CD 1_p
households NNS 1_p
in IN 1_p
the DT 1_p
study NN 1_p
, , N
increased VBD N
from IN N
6 CD N
to TO N
91 CD N
% NN N
after IN N
6 CD N
months NNS N
. . N

Coverage NNP 1_o
efficiency NN 1_o
increased VBD N
from IN N
1.29 CD N
to TO N
1.56 CD N
children NNS N
covered VBN N
per IN N
bednet NN N
owned VBN N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
having VBG N
a DT N
child NN 1_p
under IN 1_p
5 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
was VBD N
the DT N
only JJ N
variable NN N
associated VBN N
with IN N
bednet NN N
use NN N
( ( N
OR CC N
9.10 CD N
; : N
p=0.001 NN N
) ) N
, , N
yielding VBG N
a DT N
99 CD N
% NN N
likelihood NN N
of IN N
using VBG N
a DT N
bednet NN N
( ( N
95 CD N
% NN N
CI NNP N
96.4 CD N
to TO N
99.9 CD N
% NN N
) ) N
versus VBZ N
82 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
72.2 CD N
to TO N
88.4 CD N
% NN N
) ) N
in IN N
households NNS N
without IN N
young JJ N
children NNS N
. . N

CONCLUSION VB N
This DT N
free JJ 1_i
bednet NN 1_i
distribution NN 1_i
program NN 1_i
achieved VBN N
high JJ N
levels NNS N
of IN N
adherence NN N
after IN N
6 CD N
months NNS N
. . N

Household NNP N
presence NN N
of IN N
children NNS 1_p
was VBD N
associated VBN N
with IN N
bednet NN N
use NN N
, , N
but CC N
not RB N
household JJ N
income NN N
or CC N
education NN N
, , N
suggesting VBG N
that IN N
distribution NN N
to TO N
priority NN N
groups NNS N
may MD N
help VB N
overcome VB N
traditional JJ N
barriers NNS N
to TO N
adoption NN N
in IN N
some DT N
settings NNS N
. . N

The DT N
effect NN 1_o
of IN N
iron NN 1_i
in IN N
formula NN N
milk NN N
after IN N
6 CD N
months NNS N
of IN N
age NN N
. . N

Ninety NNP 1_p
two CD 1_p
normal JJ 1_p
birthweight JJ 1_p
infants NNS 1_p
aged VBD 1_p
6 CD 1_p
months NNS 1_p
entered VBD N
a DT N
double JJ N
blind NN N
controlled VBD N
trial NN N
which WDT N
compared VBN N
a DT N
follow NN N
on IN N
formula NN 1_i
milk NN 1_i
with IN 1_i
no DT 1_i
added JJ 1_i
iron NN 1_i
against IN 1_i
the DT 1_i
same JJ 1_i
formula NN 1_i
milk NN 1_i
containing VBG 1_i
1.2 CD 1_i
mg NN 1_i
of IN 1_i
iron NN 1_i
per IN 1_i
100 CD 1_i
ml NN 1_i
. . 1_i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
social JJ N
class NN N
or CC N
demographic JJ N
characteristics NNS N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
or CC N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
completing VBG N
the DT N
trial NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
quantity NN 1_o
of IN 1_o
milk NN 1_o
taken VBN 1_o
but CC N
the DT N
amounts NNS N
taken VBN N
lessened VBD N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
mean VB 1_o
haemoglobin NN 1_o
and CC 1_o
median JJ 1_o
serum NN 1_o
ferritin NN 1_o
at IN N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
15 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

Very RB N
few JJ N
infants NNS N
developed VBD N
iron NN 1_o
deficiency NN 1_o
anaemia NN 1_o
in IN N
either CC N
group NN N
but CC N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
serum NN 1_o
ferritin NN 1_o
levels NNS 1_o
to TO N
fall VB N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
iron NN 1_i
added VBD N
to TO N
follow VB N
on IN N
milk NN N
was VBD N
not RB N
an DT N
important JJ N
source NN N
of IN N
dietary JJ N
iron NN 1_i
in IN N
the DT N
infants NNS N
studied VBN N
. . N

Mexiletine NNP 1_i
for IN N
treatment NN N
of IN N
chronic JJ N
painful JJ N
diabetic JJ N
neuropathy NN N
. . N

Sixteen NNP 1_p
of IN 1_p
nineteen JJ 1_p
patients NNS 1_p
completed VBD 1_p
a DT 1_p
randomised JJ 1_p
double-blind NN 1_p
crossover NN 1_p
trial NN 1_p
to TO 1_p
assess VB 1_p
the DT 1_p
effect NN 1_p
of IN 1_p
oral JJ 1_i
mexiletine NN 1_i
( ( 1_i
10 CD 1_i
mg/kg NNS 1_i
bodyweight JJ 1_i
daily RB 1_i
) ) 1_i
on IN 1_i
the DT 1_i
symptoms NNS 1_i
and CC 1_i
signs NNS 1_i
of IN 1_i
chronic JJ 1_i
painful JJ 1_i
diabetic JJ 1_i
neuropathy NN 1_i
. . 1_i

The DT 1_p
median JJ 1_p
age NN 1_p
of IN 1_p
the DT 1_p
sixteen JJ 1_p
patients NNS 1_p
was VBD 1_p
50 CD 1_p
years NNS 1_p
( ( 1_p
range VB 1_p
30-64 NNP 1_p
) ) 1_p
. . 1_p

Assessment NN N
with IN N
a DT N
five-item JJ 1_o
clinical JJ 1_o
symptom NN 1_o
scale NN 1_o
showed VBD N
significant JJ N
improvement NN N
during IN N
the DT N
mexiletine NN N
phase NN N
compared VBN N
with IN N
the DT N
placebo NN 1_i
phase NN N
. . N

Pain NN 1_o
was VBD N
reduced VBN N
during IN N
mexiletine NN 1_i
but CC N
not RB N
during IN N
placebo NN 1_i
, , N
as IN N
assessed VBN N
by IN N
a DT N
visual JJ N
analogue NN N
rating NN N
scale NN N
. . N

Mexiletine NNP 1_i
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
tendon NN 1_o
reflexes NNS 1_o
, , 1_o
vibration NN 1_o
threshold NN 1_o
levels NNS 1_o
, , 1_o
beat-to-beat JJ 1_o
variation NN 1_o
in IN 1_o
heart NN 1_o
rate NN 1_o
during IN 1_o
deep JJ 1_o
breathing NN 1_o
, , 1_o
and CC 1_o
postural JJ 1_o
blood NN 1_o
pressure NN 1_o
response NN 1_o
. . 1_o

Mild JJ 1_o
side-effects NNS 1_o
were VBD N
seen VBN N
in IN N
three CD N
of IN N
the DT N
sixteen JJ N
patients NNS N
during IN N
mexiletine JJ N
treatment NN N
. . N

Effect NN N
of IN N
protein NN 1_i
ingestion NN 1_i
on IN N
the DT N
glucose JJ 1_o
appearance NN 1_o
rate NN 1_o
in IN N
people NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
. . 1_p

Amino NNP N
acids NNS N
derived VBD N
from IN N
ingested VBN N
protein NN N
are VBP N
potential JJ N
substrates NNS N
for IN N
gluconeogenesis NN N
. . N

However RB N
, , N
several JJ N
laboratories NNS N
have VBP N
reported VBN N
that IN N
protein JJ N
ingestion NN N
does VBZ N
not RB N
result VB N
in IN N
an DT N
increase NN N
in IN N
the DT N
circulating NN 1_o
glucose JJ 1_o
concentration NN 1_o
in IN N
people NNS N
with IN N
or CC N
without IN N
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
. . 1_p

The DT N
reason NN N
for IN N
this DT N
has VBZ N
remained VBN N
unclear JJ N
. . N

In IN N
people NNS N
without IN N
diabetes NNS N
it PRP N
seems VBZ N
to TO N
be VB N
due JJ N
to TO N
less RBR N
glucose JJ N
being VBG N
produced VBN N
and CC N
entering VBG N
the DT N
circulation NN N
than IN N
the DT N
calculated JJ N
theoretical JJ N
amount NN N
. . N

Therefore RB N
, , N
we PRP N
were VBD N
interested JJ N
in IN N
determining VBG N
whether IN N
this DT N
also RB N
was VBD N
the DT N
case NN N
in IN N
people NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
. . 1_p

Ten CD 1_p
male JJ 1_p
subjects NNS 1_p
with IN 1_p
untreated JJ 1_p
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
were VBD N
given VBN N
, , N
in IN N
random JJ N
sequence NN N
, , N
50 CD 1_i
g NN 1_i
protein NN 1_i
in IN 1_i
the DT 1_i
form NN 1_i
of IN 1_i
very RB 1_i
lean JJ 1_i
beef NN 1_i
or CC 1_i
only RB 1_i
water NN 1_i
at IN 1_i
0800 CD 1_i
h NN 1_i
and CC 1_i
studied VBN 1_i
over IN 1_i
the DT 1_i
subsequent JJ 1_i
8 CD 1_i
h. NN 1_i
Protein NNP 1_i
ingestion NN N
resulted VBD N
in IN N
an DT N
increase NN N
in IN N
circulating VBG 1_o
insulin NN 1_o
, , 1_o
C-peptide NNP 1_o
, , 1_o
glucagon NN 1_o
, , 1_o
alpha NN 1_o
amino NN 1_o
and CC 1_o
urea JJ 1_o
nitrogen NN 1_o
, , 1_o
and CC 1_o
triglycerides NNS 1_o
; : 1_o
a DT 1_o
decrease NN 1_o
in IN 1_o
nonesterified JJ 1_o
fatty JJ 1_o
acids NNS 1_o
; : 1_o
and CC 1_o
a DT 1_o
modest JJ 1_o
increase NN 1_o
in IN 1_o
respiratory JJ 1_o
quotient NN 1_o
. . 1_o

The DT N
total JJ N
amount NN N
of IN N
protein NN 1_o
deaminated VBN 1_o
and CC 1_o
the DT 1_o
amino NN 1_o
groups NNS 1_o
incorporated VBD 1_o
into IN 1_o
urea NN 1_o
was VBD N
calculated VBN N
to TO N
be VB N
approximately RB N
20-23 JJ N
g. VBP N
The DT N
net JJ N
amount NN N
of IN N
glucose NN 1_o
estimated VBN N
to TO N
be VB N
produced VBN N
, , N
based VBN N
on IN N
the DT N
quantity NN 1_o
of IN 1_o
amino JJ 1_o
acids NNS 1_o
deaminated VBD 1_o
, , N
was VBD N
approximately RB N
11-13 JJ N
g. NN N
However RB N
, , N
the DT N
amount NN 1_o
of IN 1_o
glucose JJ 1_o
appearing VBG 1_o
in IN 1_o
the DT 1_o
circulation NN 1_o
was VBD N
only RB N
approximately RB N
2 CD N
g. VBD N
The DT N
peripheral JJ 1_o
plasma NN 1_o
glucose JJ 1_o
concentration NN 1_o
decreased VBN N
by IN N
approximately RB N
1 CD N
mM NNS N
after IN N
ingestion NN N
of IN N
either DT N
protein NN N
or CC N
water NN N
, , N
confirming VBG N
that IN N
ingested JJ N
protein NN N
does VBZ N
not RB N
result VB N
in IN N
a DT N
net JJ N
increase NN N
in IN N
glucose JJ 1_o
concentration NN 1_o
, , N
and CC N
results NNS N
in IN N
only RB N
a DT N
modest JJ N
increase NN N
in IN N
the DT N
rate NN 1_o
of IN 1_o
glucose JJ 1_o
disappearance NN 1_o
. . 1_o

Treatment NN N
of IN N
severe JJ N
aplastic JJ N
anemia NN N
with IN N
antilymphocyte JJ 1_i
globulin NN 1_i
, , 1_i
cyclosporine NN 1_i
and CC 1_i
two CD 1_i
different JJ 1_i
granulocyte NNS 1_i
colony-stimulating JJ 1_i
factor NN 1_i
regimens NNS 1_i
: : 1_i
a DT N
GITMO NNP N
prospective JJ N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
In IN N
a DT N
previous JJ N
study NN N
we PRP N
showed VBD N
that IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
aplastic JJ 1_p
anemia NN 1_p
( ( 1_p
SAA NNP 1_p
) ) 1_p
treated VBD 1_i
with IN 1_i
anti-lymphocyte JJ 1_i
globulin NN 1_i
( ( 1_i
ALG NNP 1_i
) ) 1_i
, , 1_i
cyclosporin NN 1_i
( ( 1_i
CyA NNP 1_i
) ) 1_i
and CC 1_i
granulocyte JJ 1_i
colony-stimulating JJ 1_i
factor NN 1_i
( ( 1_i
G-CSF NNP 1_i
) ) 1_i
5 CD 1_i
micro NN 1_i
g/kg/day NN 1_i
had VBD N
an DT N
encouraging JJ N
outcome NN 1_o
. . 1_o

However RB N
, , N
failure NN 1_o
to TO 1_o
respond VB 1_o
, , 1_o
delayed JJ 1_o
responses NNS 1_o
, , 1_o
partial JJ 1_o
responses NNS 1_o
, , 1_o
relapses NNS 1_o
and CC N
early JJ 1_o
deaths NNS 1_o
remain VBP N
significant JJ N
problems NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
test VB N
whether IN N
a DT N
higher JJR 1_i
dose NN 1_i
of IN 1_i
G-CSF NNP 1_i
( ( 1_i
10 CD 1_i
micro NNS 1_i
g/kg/day NN 1_i
) ) 1_i
would MD N
reduce VB 1_o
these DT 1_o
complications NNS 1_o
. . 1_o

DESIGN NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN 1_p
prospective JJ 1_p
trial NN 1_p
in IN 1_p
77 CD 1_p
SAA NNP 1_p
patients NNS 1_p
treated VBD 1_p
with IN 1_p
horse NN 1_i
ALG NNP 1_i
( ( 1_i
15 CD 1_i
mg/kg/day RB 1_i
day1-5 NN 1_i
) ) 1_i
and CC 1_i
CyA NNP 1_i
( ( 1_i
5 CD 1_i
mg/kg/day RB 1_i
day NN 1_i
1-180 JJ 1_i
) ) 1_i
. . 1_i

Patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO N
receive VB 1_i
G-CSF NNP 1_i
5 CD 1_i
micro NN 1_i
g/kg/day NN 1_i
( ( 1_i
n=38 JJ 1_i
, , 1_i
group NN 1_i
A NNP 1_i
) ) 1_i
or CC 1_i
10 CD 1_i
micro NNS 1_i
g/kg/day NN 1_i
( ( 1_i
n=39 JJ 1_i
, , 1_i
group NN 1_i
B NNP 1_i
) ) 1_i
from IN 1_i
day NN 1_i
+1 CD 1_i
to TO 1_i
day NN 1_i
+30 NNP 1_i
. . 1_i

All DT 1_i
patients NNS 1_i
then RB 1_i
received VBD 1_i
G-CSF NNP 1_i
5 CD 1_i
micro NN 1_i
g/kg/day NN 1_i
from IN 1_i
day NN 1_i
+31 CD 1_i
to TO 1_i
day NN 1_i
+90 NNP 1_i
. . 1_i

The DT N
primary JJ N
end NN N
point NN N
of IN N
this DT N
study NN N
was VBD N
response NN 1_o
at IN N
day NN N
+120 NNP N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
early JJ 1_o
deaths NNS 1_o
, , 1_o
blood NN 1_o
counts NNS 1_o
at IN N
day NN N
+120 NNP N
, , N
and CC N
survival NN 1_o
. . 1_o

RESULTS NNP N
At IN N
day NN N
+120 JJ N
responses NNS 1_o
were VBD N
classified VBN N
as IN N
absent NN 1_o
, , 1_o
partial JJ 1_o
, , N
and CC N
complete JJ 1_o
in IN N
12 CD N
, , N
22 CD N
, , N
and CC N
4 CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
in IN N
23 CD N
, , N
7 CD N
, , N
and CC N
9 CD N
patients NNS N
in IN N
group NN N
B NNP N
( ( N
p=0.001 NN N
) ) N
. . N

At IN N
last JJ N
follow-up JJ N
these DT N
figures NNS N
were VBD N
respectively RB N
9 CD N
, , N
12 CD N
, , N
and CC N
17 CD N
vs NN N
19 CD N
, , N
2 CD N
, , N
and CC N
18 CD N
( ( N
p=0.004 NN N
) ) N
. . N

Thirteen JJ 1_p
patients NNS 1_p
( ( 1_p
5 CD 1_p
in IN 1_p
group NN 1_p
A NNP 1_p
and CC 1_p
8 CD 1_p
in IN 1_p
group NN 1_p
B NNP 1_p
) ) 1_p
died VBD 1_o
before IN N
day NN N
120 CD N
( ( N
p=0.3 NN N
) ) N
. . N

Median JJ N
peripheral JJ 1_o
blood NN 1_o
counts NNS 1_o
on IN N
day NN N
120 CD N
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
: : N
Hb NNP N
10.5 CD N
and CC N
9.5 CD N
g/dL NN N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
p=0.6 NN N
) ) N
, , N
Neutrophil NNP 1_o
counts VBZ 1_o
were VBD N
2.4 CD N
vs NNS N
1.9x10 CD N
( ( N
9 CD N
) ) N
/L NN N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
( ( N
p=0.4 NN N
) ) N
and CC N
platelet NN 1_o
counts NNS 1_o
were VBD N
, , N
respectively RB N
, , N
42 CD N
vs NN N
36x10 CD N
( ( N
9 CD N
) ) N
/L NN N
( ( N
p=0.3 NN N
) ) N
. . N

The DT N
actuarial JJ 1_o
survival NN 1_o
at IN N
4 CD N
years NNS N
is VBZ N
72 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
67 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p=0.3 NN N
) ) N
. . N

INTERPRETATION NNP N
AND CC N
CONCLUSIONS NNP N
Increasing VBG N
the DT N
dose NN N
of IN N
G-CSF NNP 1_i
does VBZ N
not RB N
appear VB N
to TO N
reduce VB 1_o
early JJ 1_o
deaths NNS 1_o
, , N
does VBZ N
not RB N
improve VB N
peripheral JJ 1_o
blood NN 1_o
counts NNS 1_o
nor CC N
survival NN 1_o
, , N
and CC N
may MD N
reduce VB N
the DT N
response NN 1_o
rate NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
SAA NNP 1_p
receiving VBG 1_p
ALG NNP 1_i
and CC 1_i
CyA NNP 1_i
. . 1_i

Are NNP N
oral JJ N
cathartics NNS N
of IN N
value NN N
in IN N
optimizing VBG N
the DT N
gallium NN N
scan JJ N
? . N
Concise NNP N
communication NN N
. . N

The DT N
normal JJ N
intestinal JJ N
secretion NN N
of IN N
9-15 CD N
% NN N
of IN N
an DT N
administered VBN N
dose NN N
of IN N
gallium-67 NN 1_i
may MD N
prevent VB N
early JJ N
detection NN N
of IN N
intra-abdominal JJ N
disease NN N
. . N

We PRP 1_p
randomized VBD 1_p
50 CD 1_p
patients NNS 1_p
to TO N
receive VB N
either DT N
no DT 1_i
bowel NN 1_i
preparation NN 1_i
or CC 1_i
30 CD 1_i
cc NN 1_i
of IN 1_i
milk NN 1_i
of IN 1_i
magnesia JJ 1_i
plus CC 1_i
5 CD 1_i
cc NN 1_i
of IN 1_i
cascara NN 1_i
. . 1_i

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN 1_o
with IN 1_o
which WDT 1_o
gallium NN 1_o
interfered VBD 1_o
with IN 1_o
readings NNS 1_o
or CC 1_o
time NN 1_o
to TO 1_o
complete VB 1_o
the DT 1_o
study NN 1_o
. . 1_o

Effect NN N
of IN N
device-guided JJ 1_i
breathing NN 1_i
exercises NNS 1_i
on IN N
blood NN 1_o
pressure NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
hypertension NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NNP N
Hypertension NNP N
is VBZ N
a DT N
chronic JJ N
disorder NN N
with IN N
a DT N
high JJ N
prevalence NN N
worldwide NN N
. . N

Despite IN N
considerable JJ N
efforts NNS N
, , N
it PRP N
is VBZ N
sometimes RB N
hard JJ N
to TO N
reach VB N
treatment NN N
goals NNS N
for IN N
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
with IN N
classical JJ N
treatment NN N
options NNS N
. . N

Reducing VBG N
breathing VBG N
frequency NN N
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
method NN N
to TO N
reduce VB N
BP NNP 1_o
. . 1_o

METHODS NNP N
A NNP N
randomized JJ N
, , N
single-blind JJ N
, , N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
in IN N
30 CD 1_p
non-diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
hypertension NN 1_p
over IN N
a DT N
period NN N
of IN N
9 CD N
weeks NNS N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
device NN 1_i
that WDT 1_i
helps VBZ 1_i
to TO 1_i
slow VB 1_o
breathing NN 1_o
( ( 1_i
Resperate NNP 1_i
) ) 1_i
on IN N
BP NNP 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QoL NNP 1_o
) ) 1_o
. . 1_o

The DT N
control NN N
group NN N
listened VBD 1_i
to TO 1_i
music NN 1_i
and CC 1_i
used VBN 1_i
no DT 1_i
other JJ 1_i
therapeutic JJ 1_i
device NN 1_i
. . 1_i

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
change NN N
in IN N
BP NNP 1_o
between IN N
intervention NN N
and CC N
control NN N
; : N
BP NNP 1_o
-4.2 NNP N
mmHg NN N
( ( N
95 CD N
% NN N
CI NNP N
-12.4 NNP N
to TO N
3.9 CD N
) ) N
/-2.6 NN N
mmHg NN N
( ( N
95 CD N
% NN N
CI NNP N
-8.4 NNP N
to TO N
3.3 CD N
) ) N
. . N

This DT N
result NN N
did VBD N
not RB N
alter VB N
in IN N
post NN N
hoc NN N
analyses NNS N
, , N
when WRB N
patients NNS N
not RB N
achieving VBG N
target NN 1_o
breathing NN 1_o
frequency NN 1_o
( ( N
< JJ N
10 CD N
breaths/min NN N
) ) N
or CC N
non-compliant JJ N
patients NNS N
were VBD N
excluded VBN N
. . N

QoL NNP 1_o
did VBD N
not RB N
change VB N
over IN N
time NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
no DT N
effect NN N
of IN N
the DT N
Resperate NNP N
on IN N
BP NNP 1_o
or CC N
QoL NNP 1_o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
at IN N
this DT N
moment NN N
, , N
this DT N
device NN N
has VBZ N
no DT N
added VBN N
value NN N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
. . N

Vaginal NNP 1_o
pH NN 1_o
and CC 1_o
microflora NN 1_o
related VBN N
to TO N
yeast VB 1_p
infections NNS 1_p
and CC 1_p
treatment NN 1_p
. . 1_p

The DT N
relationship NN N
between IN N
vaginal JJ 1_o
pH NN 1_o
, , 1_o
microflora NN 1_o
, , N
and CC N
yeast JJS 1_p
infection NN 1_p
was VBD 1_p
investigated VBN 1_p
in IN 1_p
93 CD 1_p
women NNS 1_p
randomly RB 1_p
treated VBN 1_p
with IN 1_p
either DT 1_p
nystatin NN 1_i
or CC 1_i
miconazole JJ 1_i
pessaries NNS 1_i
and CC 1_i
cream NN 1_i
for IN 1_p
two CD 1_p
weeks NNS 1_p
. . 1_p

The DT N
vaginal JJ 1_o
pH NN 1_o
was VBD N
measured VBN N
in IN N
a DT N
control NN 1_p
group NN 1_p
of IN 1_p
48 CD 1_p
women NNS 1_p
. . 1_p

In IN N
the DT N
study NN N
group NN N
, , N
37 CD N
patients NNS N
defaulted VBD N
, , N
39 CD N
were VBD N
cured VBN N
, , N
and CC N
17 CD N
required JJ N
treatment NN N
during IN N
the DT N
six-month JJ N
follow-up JJ N
period NN N
. . N

In IN N
both DT N
study NN N
and CC N
control NN N
groups NNS N
before IN N
and CC N
after IN N
treatment NN N
the DT N
mean JJ 1_o
vaginal JJ 1_o
pH NN 1_o
was VBD N
in IN N
the DT N
range NN N
of IN N
4.3-4.6 JJ N
. . N

Lactobacilli NNP 1_o
were VBD N
plentiful JJ N
in IN N
78 CD N
( ( N
91 CD N
% NN N
) ) N
out IN N
of IN N
86 CD N
patients NNS N
and CC N
shows VBZ N
that IN N
lactobacilli NN N
and CC N
yeasts NNS N
commonly RB N
coexist VBP N
. . N

The DT N
influence NN N
of IN N
other JJ N
organisms NNS N
appeared VBD N
to TO N
be VB N
negligible JJ N
. . N

The DT N
trial NN N
showed VBD N
that IN N
nystatin NN N
and CC N
micromazole NN N
were VBD N
equallly RB N
effective JJ 1_o
in IN N
the DT N
treatment NN N
of IN N
vaginal JJ 1_p
yeast NN 1_p
infection NN 1_p
and CC N
that IN N
the DT N
broad-spectrum JJ N
activity NN N
of IN N
micronazole NN 1_i
offered VBN N
no DT N
advantage NN N
in IN N
this DT N
condition NN N
. . N

Neck NNP 1_i
circumference NN 1_i
and CC 1_p
early JJ 1_p
stage NN 1_p
atherosclerosis NN 1_p
: : 1_p
the DT N
cardiometabolic NN N
risk NN N
in IN N
Chinese NNP N
( ( N
CRC NNP N
) ) N
study NN N
. . N

BACKGROUND NNP N
Neck NNP N
circumference NN N
( ( N
NC NNP N
) ) N
has VBZ N
been VBN N
previously RB N
related VBN N
to TO N
cardiometabolic JJ N
risk NN N
factors NNS N
. . N

In IN N
this DT N
study NN N
we PRP N
examined VBD N
the DT N
association NN N
between IN N
NC NNP 1_p
and CC 1_p
early JJ 1_p
stage NN 1_p
atherosclerosis NN 1_p
in IN 1_p
Chinese JJ 1_p
adults NNS 1_p
. . 1_p

METHODS NNP N
The DT N
study NN 1_i
samples NNS 1_i
were VBD 1_i
from IN 1_i
a DT 1_i
community-based JJ 1_i
health NN 1_i
examination NN 1_i
survey NN 1_i
in IN N
central JJ 1_p
China NNP 1_p
. . 1_p

In IN 1_p
total JJ 1_p
2,318 CD 1_p
men NNS 1_p
and CC 1_p
women NNS 1_p
( ( 1_p
18-64 JJ 1_p
y NN 1_p
) ) 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
final JJ 1_p
analyses NNS 1_p
. . 1_p

Carotid NNP 1_o
radial JJ 1_o
pulse NN 1_o
wave NN 1_o
velocity NN 1_o
( ( 1_o
crPWV NN 1_o
) ) 1_o
, , 1_o
carotid JJ 1_o
femoral JJ 1_o
PWV NNP 1_o
( ( 1_o
cfPWV NN 1_o
) ) 1_o
, , 1_o
carotid JJ 1_o
artery NN 1_o
dorsalis NN 1_o
pedis NN 1_o
PWV NNP 1_o
( ( 1_o
cdPWV NN 1_o
) ) 1_o
and CC 1_o
NC NNP 1_o
were VBD 1_i
measured VBN 1_i
. . 1_i

RESULTS NNP N
After IN N
adjustment NN N
for IN N
age NN N
, , N
sex NN N
, , N
lipids NNS N
, , N
glucose NN N
, , N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
high JJ N
NC NNP N
was VBD N
significantly RB N
associated VBN N
with IN N
an DT N
increasing VBG N
trend NN 1_o
of IN N
cfPWV NN 1_o
, , 1_o
cdPWV NN 1_o
and CC 1_o
crPWV NN 1_o
( ( N
P NNP N
= NNP N
0.001 CD N
, , N
0.049 CD N
, , N
and CC N
0.038 CD N
; : N
respectively RB N
) ) N
. . N

In IN N
addition NN N
, , N
we PRP N
found VBD N
significant JJ N
interaction NN N
between IN N
hypertension NN 1_o
status NN 1_o
and CC 1_o
NC NNP 1_o
level NN 1_o
in IN N
relation NN N
to TO N
cfPWV VB N
, , N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
BMI NNP N
, , N
fasting VBG N
glucose NN N
, , N
lipids NNS N
and CC N
heart NN N
rate NN N
( ( N
P NNP N
for IN N
interaction NN N
= NNP N
0.034 CD N
) ) N
. . N

The DT N
associations NNS N
between IN N
NC NNP N
and CC N
cfPWV NN N
were VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
among IN N
those DT N
with IN N
hypertension NN N
, , N
but CC N
not RB N
significant JJ N
among IN N
those DT N
without IN N
hypertension NN N
. . N

CONCLUSIONS VB N
Our PRP$ N
data NNS N
showed VBD N
that IN N
high JJ N
NC NNP N
was VBD N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN 1_p
of IN 1_p
early JJ 1_p
stage NN 1_p
atherosclerosis NN 1_p
in IN 1_p
Chinese JJ 1_p
adults NNS N
, , N
independent JJ N
of IN N
other JJ N
metabolic JJ N
risk NN N
factors NNS N
. . N

Hypertension NN N
might MD N
modify VB N
the DT N
association NN N
between IN N
NC NNP N
and CC N
cfPWV NN N
. . N

Intrathecal JJ N
lentivirus-mediated JJ N
transfer NN N
of IN N
interleukin-10 JJ 1_i
attenuates NNS N
chronic JJ 1_o
constriction NN 1_o
injury-induced JJ 1_o
neuropathic JJ 1_o
pain NN 1_o
through IN N
modulation NN N
of IN N
spinal JJ N
high-mobility NN N
group NN N
box VBZ N
1 CD N
in IN N
rats NNS 1_p
. . 1_p

BACKGROUND NNP N
Neuropathic NNP N
pain NN N
is VBZ N
a DT N
complex JJ N
state NN N
of IN N
chronic JJ N
pain NN N
that WDT N
is VBZ N
usually RB N
accompanied VBN N
by IN N
peripheral JJ N
and CC N
central JJ N
nervous JJ N
system NN N
damage NN N
or CC N
dysfunction NN N
. . N

Previous JJ N
studies NNS N
have VBP N
indicated VBN N
that DT N
neuroinflammation NN N
in IN N
the DT N
spinal JJ N
cord NN N
is VBZ N
an DT N
important JJ N
contributor NN N
to TO N
neuropathological JJ N
and CC N
behavioral JJ N
abnormalities NNS N
. . N

A DT N
series NN N
of IN N
early JJ N
inflammatory NN N
markers NNS N
, , N
such JJ N
as IN N
IL-1 NNP N
, , N
TNF-α NNP N
, , N
and CC N
IFN-γ NNP N
, , N
and CC N
advanced VBD N
inflammatory JJ N
markers NNS N
, , N
such JJ N
as IN N
high-mobility NN N
group NN N
box VBZ N
1 CD N
( ( N
HMGB1 NNP N
) ) N
, , N
are VBP N
involved VBN N
in IN N
neuroinflammation NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized NN N
, , N
double JJ N
blind NN N
, , N
controlled VBD 1_p
animal JJ 1_p
trial NN N
. . N

OBJECTIVE NN N
In IN N
this DT N
study NN N
, , N
a DT 1_i
lentivirus NN 1_i
delivering VBG 1_i
human JJ 1_i
IL-10 NNP 1_i
( ( 1_i
LV/hIL-10 NNP 1_i
) ) 1_i
was VBD N
administered VBN N
intrathecally RB N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
IL-10 NNP N
on IN 1_o
allodynia NN 1_o
and CC 1_o
hyperalgesia NN 1_o
in IN N
a DT N
chronic JJ N
constriction NN N
injury-induced JJ N
( ( 1_p
CCI NNP 1_p
) ) 1_p
rat VBP 1_p
model NN 1_p
of IN N
neuropathic JJ N
pain NN N
. . N

METHODS NNP 1_p
Sprague-Dawley NNP 1_p
rats NNS 1_p
weighting VBG 1_p
260 CD 1_p
- : 1_p
320 CD 1_p
g NN N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
. . N

Group NNP N
Sham NNP N
( ( N
Sham NNP N
) ) N
, , N
Group NNP 1_i
CCI±Normal NNP 1_i
Saline NNP 1_i
( ( 1_i
NS NNP 1_i
) ) 1_i
, , 1_i
Group NNP 1_i
CCI±LV/hIL-10 NNP 1_i
( ( 1_i
LV/hIL-10 NNP 1_i
) ) 1_i
, , N
and CC N
Group NNP 1_i
CCI±LV/control NNP 1_i
( ( 1_i
vector NN 1_i
) ) 1_i
. . 1_p

Rats NNPS N
in IN N
each DT N
group NN N
were VBD N
intrathecally RB N
delivered VBN N
with IN 1_i
NS NNP 1_i
, , 1_i
LV/control NNP 1_i
, , 1_i
or CC 1_i
recombinant JJ 1_i
vector NN 1_i
LV/hIL-10 NNP 1_i
in IN N
a DT N
total JJ N
volume NN N
of IN N
10 CD 1_o
μl NN 1_o
. . 1_o

Paw NNP 1_o
withdrawal VBD 1_o
mechanical JJ 1_o
thresholds NNS 1_o
( ( 1_o
PWMT NNP 1_o
) ) 1_o
and CC 1_o
paw $ 1_o
withdrawal NN 1_o
thermal JJ 1_o
latency NN 1_o
PWTL NNP N
were VBD N
measured VBN N
one CD N
day NN N
before IN N
CCI NNP N
( ( N
baseline NN N
) ) N
and CC N
0 CD N
, , N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
and CC N
28 CD N
days NNS N
after IN N
intrathecal JJ N
administration NN N
. . N

Cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
samples NNS N
were VBD N
collected VBN N
during IN N
surgical JJ N
plane NN N
anesthesia NN N
and CC N
the DT N
collected JJ N
CSF NNP N
samples NNS N
were VBD N
used VBN N
to TO N
assay VB N
for IN N
human JJ N
IL-10 NNP N
, , N
rat VBZ N
IL-1β NNP N
, , N
rat VBZ N
IL-6 NNP N
, , N
and CC N
rat VB N
TNF-α JJ N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( 1_p
ELISA NNP 1_p
) ) 1_p
. . 1_p

Animals NNS 1_p
were VBD 1_p
sacrificed VBN 1_p
and CC 1_p
the DT 1_p
L4-5 NNP 1_p
lumbar NN 1_p
segment NN 1_p
of IN 1_p
the DT 1_p
spinal JJ 1_p
cord NN 1_p
was VBD 1_p
removed VBN 1_p
for IN 1_p
determination NN 1_p
of IN 1_p
green JJ 1_p
fluorescent NN 1_p
protein NN 1_p
( ( 1_p
GFP NNP 1_p
) ) 1_p
expression NN 1_p
. . N

Immunohistochemical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
anti JJ N
HMGB1 NNP N
antibodies NNS N
and CC N
the DT N
expression NN N
of IN N
HMGB1 NNP N
protein NN N
in IN N
the DT N
spinal JJ N
cord NN N
was VBD N
determined VBN N
by IN N
western JJ N
blot NN N
analysis NN N
after IN N
intrathecal JJ N
delivery NN N
( ( N
n JJ N
= RB N
8 CD N
each DT N
) ) N
. . N

RESULTS VB N
The DT N
results NNS N
show VBP 1_i
that DT 1_i
intrathecal JJ 1_i
LV/hIL-10 NNP 1_i
reverses NNS 1_o
enhanced VBD 1_o
pain NN 1_o
states NNS N
. . N

Moreover RB N
, , N
the DT N
increased VBN 1_o
level NN 1_o
of IN 1_o
HMGB1 NNP N
exhibited VBD 1_o
in IN 1_o
a DT 1_o
late JJ 1_o
stage NN 1_o
of IN N
CCI NNP N
was VBD N
inhibited VBN N
by IN N
exogenous JJ N
overexpression NN N
of IN N
hIL-10 NN N
in IN N
the DT N
CCI NNP 1_o
model NN 1_o
. . 1_o

Expression NN 1_o
of IN 1_o
HMGB1 NNP 1_o
, , 1_o
RAGE NNP 1_o
, , 1_o
and CC 1_o
pAkt NNS N
were VBD N
lower JJR N
in IN N
CCI-induced NNP N
rats NNS N
treated VBD N
with IN N
LV/hIL-10 NNP N
than IN N
in IN N
those DT N
treated VBN N
with IN N
LV/control NNP N
( ( N
vector NN N
) ) N
or CC N
saline NN N
( ( N
NS NNP N
) ) N
. . N

Our PRP$ N
results NNS N
showed VBD 1_o
that IN 1_o
IL-10 NNP N
inhibits VBZ 1_o
activation NN 1_o
of IN 1_o
the DT 1_o
inflammatory JJ 1_o
HMGB1-RAGE NNP 1_o
pathway NN N
in IN N
the DT N
CCI NNP N
rat NN N
model NN N
. . N

LIMITATIONS NNP N
Further NNP N
experimental JJ N
investigations NNS N
are VBP N
needed VBN N
to TO N
clarify VB N
the DT N
specific JJ N
biological JJ N
roles NNS N
played VBN N
by IN N
HMGB1 NNP N
in IN N
IL-10-mediated NNP N
regulation NN 1_o
of IN 1_o
neuropathic JJ 1_o
pain NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicate VBP N
that DT N
intrathecal JJ N
lentiviral-mediated JJ N
transfer NN 1_i
of IN 1_i
IL-10 NNP N
attenuates VBZ 1_o
CCI-induced NNP 1_o
neuropathic JJ 1_o
pain NN 1_p
in IN N
rats NNS N
. . N

The DT N
anti-thermal JJ N
hyperalgesia NN N
and CC N
anti-mechanical JJ N
allodynia NN N
may MD N
be VB N
partly RB N
attributable JJ N
to TO N
the DT N
decreased JJ N
expression NN N
of IN N
HMGB1 NNP N
and CC N
inhibition NN N
of IN N
HMGB1-RAGE NNP N
pathway NN N
. . N

Randomized VBN N
Controlled JJ N
Trial NNP N
of IN N
Mind NNP 1_i
Reading NNP 1_i
and CC N
In IN 1_i
Vivo NNP 1_i
Rehearsal NNP 1_i
for IN N
High-Functioning NNP 1_p
Children NNP 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

This DT N
randomized VBD N
controlled JJ N
trial NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
a DT N
computer NN 1_i
software NN 1_i
( ( 1_i
i.e. FW 1_i
, , N
Mind NNP 1_i
Reading NNP 1_i
) ) 1_i
and CC 1_i
in IN 1_i
vivo JJ 1_i
rehearsal NN 1_i
treatment NN 1_i
on IN N
the DT N
emotion NN 1_o
decoding NN 1_o
and CC 1_o
encoding VBG 1_o
skills NNS 1_o
, , 1_o
autism NN 1_o
symptoms NNS 1_o
, , 1_o
and CC 1_o
social JJ 1_o
skills NNS 1_o
of IN N
43 CD 1_p
children NNS 1_p
, , 1_p
ages VBZ 1_p
7-12 CD 1_p
years NNS 1_p
with IN 1_p
high-functioning JJ 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
HFASD NNP 1_p
) ) 1_p
. . N

Children NNP N
in IN N
treatment NN N
( ( N
n JJ N
= NNP N
22 CD N
) ) N
received VBD N
the DT 1_i
manualized VBN 1_i
protocol NN 1_i
over IN N
12 CD N
weeks NNS N
. . N

Primary JJ N
analyses NNS N
indicated VBD 1_o
significantly RB 1_o
better JJR 1_o
posttest JJS 1_o
performance NN 1_o
for IN N
the DT 1_i
treatment NN 1_i
group NN 1_i
( ( 1_i
compared VBN 1_i
to TO 1_i
controls NNS 1_o
) ) 1_o
on IN 1_o
3 CD 1_o
of IN 1_o
the DT 1_o
4 CD 1_o
measures NNS 1_o
of IN 1_o
emotion NN 1_o
decoding NN 1_o
and CC 1_o
encoding NN 1_o
and CC N
these DT N
were VBD N
maintained VBN N
at IN N
5-week JJ N
follow-up NN N
. . N

Analyses NNS N
of IN N
secondary JJ N
measures NNS N
favored VBD N
the DT 1_i
treatment NN 1_i
group NN 1_i
for IN N
1 CD N
of IN N
the DT N
2 CD N
measures NNS N
; : N
specifically RB 1_o
, , 1_o
ASD NNP 1_o
symptoms NNS 1_o
were VBD N
significantly RB 1_o
lower JJR 1_o
at IN N
posttest NN N
and CC N
follow-up NN N
. . N

Femoral NNP N
vein NN N
delivery NN N
of IN N
contrast NN N
medium NN N
enhances VBZ N
transthoracic JJ 1_o
echocardiographic JJ 1_o
detection NN 1_o
of IN N
patent NN 1_o
foramen NNS 1_o
ovale VBP 1_o
. . 1_o

OBJECTIVES IN N
We PRP N
postulated VBD N
that IN N
femoral JJ N
vein JJ N
delivery NN N
of IN N
contrast NN N
medium NN N
because IN N
of IN N
streaming NN N
, , N
might MD N
enhance VB N
precordial JJ 1_o
echocardiographic JJ 1_o
detection NN 1_o
of IN N
patent NN N
foramen NNS N
ovale VBP N
. . N

BACKGROUND NNP N
Although IN N
precordial JJ N
contrast NN N
echocardiography NN N
is VBZ N
widely RB N
used VBN N
to TO N
diagnose VB N
patent JJ N
foramen NNS N
ovale RB N
, , N
this DT N
method NN N
is VBZ N
limited VBN N
by IN N
poor JJ N
sensitivity NN N
. . N

Previous JJ N
investigators NNS N
have VBP N
demonstrated VBN N
enhanced JJ N
detection NN N
of IN N
atrial JJ 1_o
defects NNS 1_o
by IN N
the DT N
dye-dilution NN N
technique NN N
after IN N
delivery NN N
of IN N
contrast NN N
medium NN N
into IN N
the DT N
inferior NN N
rather RB N
than IN N
the DT N
superior JJ N
vena NN N
cava NN N
. . N

METHODS NNP N
Transthoracic NNP 1_i
contrast NN 1_i
examinations NNS 1_i
were VBD N
performed VBN N
in IN N
a DT N
randomly RB N
selected VBN N
group NN N
of IN N
70 CD 1_p
patients NNS 1_p
( ( 1_p
without IN 1_p
previous JJ 1_p
history NN 1_p
of IN 1_p
cerebral JJ 1_p
or CC 1_p
systemic JJ 1_p
embolus NN 1_p
) ) 1_p
undergoing VBG 1_p
cardiac JJ 1_p
catheterization NN 1_p
. . 1_p

Paired VBN N
contrast NN 1_i
agent NN 1_i
injections NNS 1_i
( ( 1_i
10 CD 1_i
ml NN 1_i
dextrose NN 1_i
in IN 1_i
water/0.25 NN 1_i
ml NNP 1_i
air NN 1_i
) ) 1_i
were VBD N
administered VBN N
from IN N
an DT N
upper JJ N
extremity NN N
vein NN N
and CC N
femoral JJ N
vein NN N
in IN N
each DT N
patient NN N
during IN N
spontaneous JJ N
respiration NN N
, , N
cough NN N
and CC N
Valsalva NNP N
maneuvers NNS N
. . N

Studies NNS N
were VBD N
interpreted VBN N
by IN N
an DT N
experienced JJ N
echocardiographer NN N
unaware NN N
of IN N
the DT N
sequence NN N
and CC N
site NN N
of IN N
injections NNS N
. . N

Positive JJ N
studies NNS N
were VBD N
semiquantitatively RB N
graded VBN N
from IN N
+1 NNP N
( ( N
minimal JJ N
left VBD N
ventricular JJ N
opacification NN N
) ) N
to TO N
+4 VB N
( ( N
intense JJ N
left VBD N
ventricular JJ N
opacification NN N
) ) N
. . N

Catheterization NN 1_o
and CC 1_o
echocardiographic JJ 1_o
assessment NN 1_o
of IN 1_o
patent NN 1_o
foramen NNS 1_o
ovale VBP 1_o
were VBD N
compared VBN N
in IN N
21 CD N
subjects NNS N
. . N

RESULTS NNP N
Patent NNP 1_o
foramen NNS 1_o
ovale NN 1_o
was VBD N
detected VBN N
significantly RB N
more RBR N
often RB N
during IN N
femoral JJ N
vein NNS N
versus VBP N
upper JJ N
extremity NN N
contrast NN N
delivery NN N
( ( N
23 CD N
of IN N
70 CD N
patients NNS N
[ JJ N
prevalence RB N
33 CD N
% NN N
] NNP N
vs. IN N
9 CD N
of IN N
70 CD N
patients NNS N
[ JJ N
prevalence RB N
13 CD N
% NN N
] NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
intensity NN 1_o
of IN 1_o
left JJ 1_o
ventricular JJ 1_o
opacification NN 1_o
was VBD N
also RB N
greater JJR N
during IN N
femoral JJ N
vein NNS N
contrast NN N
injection NN N
. . N

Precordial JJ N
echocardiography NN N
combined VBN N
with IN N
femoral JJ N
contrast NN N
delivery NN N
was VBD N
significantly RB N
more RBR N
sensitive JJ 1_o
than IN N
cardiac JJ N
catheterization NN N
for IN N
assessment NN 1_o
of IN 1_o
patent NN 1_o
foramen NNS 1_o
ovale VBP 1_o
( ( N
8 CD N
of IN N
21 CD N
patients NNS N
vs. FW N
2 CD N
of IN N
21 CD N
patients NNS N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Femoral NNP 1_i
vein NNP 1_i
contrast NN 1_i
delivery NN 1_i
significantly RB N
enhances VBZ N
the DT N
ability NN 1_o
of IN 1_o
precordial JJ 1_o
contrast NN 1_o
echocardiography NN 1_o
to TO 1_o
diagnose VB 1_o
patent JJ 1_o
foramen NNS 1_o
ovale VBP 1_o
. . 1_o

Physiologic NNP N
patency NN N
of IN N
the DT N
foramen NNS N
ovale VBP N
is VBZ N
more RBR N
common JJ N
( ( N
prevalence JJ N
33 CD N
% NN N
) ) N
than IN N
previously RB N
documented VBN N
. . N

Treatment NN 1_p
of IN 1_p
renal JJ 1_o
failure NN 1_o
associated VBN 1_p
with IN 1_p
multiple JJ 1_p
myeloma NN 1_p
. . 1_p

Plasmapheresis NN N
, , N
hemodialysis NN N
, , N
and CC N
chemotherapy NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
the DT N
efficacy NN N
of IN N
plasmapheresis NN N
in IN N
preventing VBG N
irreversible JJ 1_o
renal JJ 1_o
failure NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
multiple JJ 1_p
myeloma NN 1_p
and CC N
to TO N
study VB N
the DT N
renal JJ N
biopsy NN N
tissues NNS N
from IN N
such JJ N
patients NNS N
. . N

Twenty-one CD 1_p
patients NNS 1_p
with IN 1_p
active JJ 1_p
myeloma NN 1_p
and CC 1_p
progressive JJ 1_p
renal JJ 1_p
failure NN 1_p
were VBD N
randomized VBN 1_i
to TO 1_i
one CD 1_i
of IN 1_i
two CD 1_i
groups NNS 1_i
: : 1_i
group NN 1_i
1 CD 1_i
, , 1_i
forced VBN 1_i
diuresis NN 1_i
and CC 1_i
chemotherapy NN 1_i
( ( 1_i
10 CD 1_i
patients NNS 1_i
) ) 1_i
, , 1_i
and CC 1_i
group NN 1_i
2 CD 1_i
, , 1_i
forced VBN 1_i
diuresis NN 1_i
, , 1_i
chemotherapy NN 1_i
, , 1_i
and CC 1_i
plasmapheresis NN 1_i
( ( 1_i
11 CD 1_i
patients NNS 1_i
) ) 1_i
. . 1_i

Plasmapheresis NN N
and CC N
chemotherapy NN N
lowered VBD N
the DT N
serum NN 1_o
myeloma NN 1_o
protein IN 1_o
value NN 1_o
much RB N
more RBR N
rapidly RB N
than IN N
chemotherapy VB N
alone JJ N
. . N

Of IN 1_p
5 CD 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
oliguric JJ 1_p
and CC 1_p
undergoing JJ 1_p
dialysis NN 1_p
at IN 1_p
presentation NN 1_p
, , N
only RB N
3 CD N
who WP N
were VBD N
treated VBN N
by IN N
plasmapheresis NN N
recovered VBN N
. . N

Of IN 1_p
16 CD 1_p
polyuric JJ 1_p
patients NNS 1_p
, , N
5 CD N
in IN N
group NN N
1 CD N
and CC N
7 CD N
in IN N
group NN N
2 CD N
showed VBD N
improvement NN N
in IN N
renal JJ 1_o
function NN 1_o
. . 1_o

The DT N
main JJ N
factor NN N
that WDT N
determined VBD N
irreversibility NN N
of IN N
renal JJ N
failure NN N
was VBD N
the DT N
severity NN N
of IN N
myeloma NN N
cast NN N
formation NN N
. . N

Nasotracheal JJ 1_i
intubation NN 1_i
under IN 1_i
curve-tipped JJ 1_i
suction NN 1_i
catheter NN 1_i
guidance NN N
reduces NNS N
epistaxis VBP 1_p
. . 1_p

BACKGROUND NNP N
Nasotracheal NNP 1_i
intubation NN 1_i
( ( 1_i
NTI NNP 1_i
) ) 1_i
has VBZ N
greater JJR N
potential JJ N
for IN N
trauma NN N
of IN N
nasopharyngeal NN N
mucosa NN N
than IN N
orotracheal JJ N
intubation NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
success NN 1_o
rate NN 1_o
of IN N
NTI NNP N
and CC N
frequency NN N
of IN N
nasal JJ N
bleeding VBG N
using VBG N
a DT N
curve-tipped JJ 1_i
suction NN 1_i
catheter NN 1_i
( ( 1_i
CTSC NNP 1_i
) ) 1_i
to TO 1_i
guide VB N
nasotracheal JJ N
tube JJ N
advancement NN N
. . N

METHODS NNP N
Subjects NNPS 1_p
comprised VBD 1_p
131 CD 1_p
adult NN 1_p
patients NNS 1_p
who WP 1_p
under-went JJ 1_p
NTI NNP 1_i
. . 1_i

Subjects NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
: : 1_p
a DT 1_p
) ) 1_p
NTI NNP 1_i
under IN 1_i
CTSC NNP 1_i
guidance NN 1_i
( ( 1_i
G NNP 1_i
[ NNP 1_i
+ NNP 1_i
] NNP 1_i
group NN 1_i
) ) 1_i
. . N

The DT N
CTSC NNP N
( ( N
14 CD N
Fr NNP N
) ) N
was VBD N
first RB N
inserted VBN N
through IN N
the DT N
tracheal NN N
tube NN N
, , N
with IN N
the DT N
tip NN N
of IN N
the DT N
CTSC NNP N
emerging VBG N
from IN N
the DT N
distal JJ N
end NN N
of IN N
the DT N
tube NN N
. . N

The DT N
curved JJ N
tip NN N
was VBD N
directed VBN N
ventrally RB N
. . N

Both DT N
tracheal JJ N
tube NN N
and CC N
CTSC NNP N
were VBD N
advanced VBN N
together RB N
through IN N
the DT N
nasopharynx NN N
; : N
b NN N
) ) N
NTI NN 1_i
without IN 1_i
CTSC NNP 1_i
guidance NN 1_i
( ( N
G NNP N
[ NNP N
- : N
] NN N
group NN N
) ) N
. . N

The DT N
tracheal NN N
tube NN N
was VBD N
advanced VBN N
into IN N
the DT N
nasal JJ N
cavity NN N
and CC N
passed VBD N
into IN N
the DT N
pharynx NN N
without IN N
CTSC NNP N
guidance NN N
. . N

The DT N
time NN 1_o
required VBN 1_o
to TO 1_o
pass VB 1_o
the DT 1_o
endotracheal NN 1_o
tube NN 1_o
through IN 1_o
the DT 1_o
nasal JJ 1_o
cavity NN 1_o
( ( 1_o
nasal JJ 1_o
passage NN 1_o
time NN 1_o
) ) 1_o
, , 1_o
success NN 1_o
rate NN 1_o
of IN 1_o
nasal JJ 1_o
passage NN 1_o
with IN 1_o
nasotracheal JJ 1_o
tube NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
incidence NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
nasal JJ 1_o
bleeding VBG 1_o
were VBD N
compared VBN N
. . N

RESULTS NNP N
Success NNP 1_o
rate NN 1_o
for IN 1_o
nasal JJ 1_o
passage NN 1_o
was VBD N
100 CD N
% NN N
in IN N
the DT N
G NNP N
( ( N
+ NNP N
) ) N
group NN N
( ( N
62/62 CD N
) ) N
and CC N
82.6 CD N
% NN N
in IN N
the DT N
G NNP N
( ( N
- : N
) ) N
group NN N
( ( N
57/69 CD N
; : N
P NNP N
= NNP N
0.0006 CD N
) ) N
. . N

Frequency NN 1_o
of IN 1_o
nasal JJ 1_o
bleeding NN 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
G NNP N
( ( N
+ NNP N
) ) N
group NN N
( ( N
21/62 CD N
, , N
33.9 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
G NNP N
( ( N
- : N
) ) N
group NN N
( ( N
37/69 CD N
, , N
53.6 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

Severity NN 1_o
of IN 1_o
nasal JJ 1_o
bleeding NN 1_o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
G NNP N
( ( N
+ NNP N
) ) N
group NN N
than IN N
in IN N
the DT N
G NNP N
( ( N
- : N
) ) N
group NN N
( ( N
P NNP N
= NNP N
0.030 CD N
) ) N
. . N

CONCLUSIONS NNP N
Nasotracheal NNP 1_i
intubation NN 1_i
under IN 1_i
CTSC NNP 1_i
guidance NN 1_i
increases VBZ N
the DT N
success NN 1_o
rate NN 1_o
of IN N
airway NN N
instrumentation NN N
, , N
and CC N
also RB N
reduces VBZ N
the DT N
incidence NN 1_o
and CC 1_o
severity NN 1_o
of IN N
epistaxis NN 1_p
. . 1_p

Penetration NN 1_o
and CC 1_o
accumulation NN 1_o
of IN N
moxifloxacin NN 1_i
in IN N
uterine JJ N
tissue NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
moxifloxacin NN 1_i
penetrates VBZ N
the DT N
uterine JJ N
tissue NN N
and CC N
accumulates NNS N
at IN N
levels NNS N
sufficient JJ N
to TO N
eradicate VB 1_o
the DT 1_o
major JJ 1_o
pathogens NNS 1_o
causing VBG N
pelvic JJ 1_p
inflammatory JJ 1_p
disease NN 1_p
( ( 1_p
PID NNP 1_p
) ) 1_p
. . 1_p

METHOD NNP N
In IN N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
open-label JJ N
, , N
parallel-group JJ N
study NN N
we PRP N
determined VBD N
the DT N
concentration NN N
of IN N
moxifloxacin NN N
in IN N
plasma NN N
and CC N
uterine JJ N
tissue NN N
after IN N
a DT N
single JJ N
, , N
400-mg JJ 1_i
intravenous JJ 1_i
dose NN 1_i
of IN 1_i
moxifloxacin NN 1_i
. . 1_i

Study NN N
participants NNS N
were VBD N
randomized VBN N
for IN N
time NN N
of IN N
tissue NN N
sampling NN N
, , N
which WDT N
was VBD N
performed VBN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
7 CD N
, , N
or CC N
24 CD N
hours NNS N
following VBG N
the DT N
moxifloxacin JJ 1_i
infusion NN N
. . N

RESULTS NNP N
Of IN N
43 CD 1_p
participants NNS 1_p
, , 1_p
40 CD 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
tissue VB 1_p
sampling VBG 1_p
. . 1_p

Moxifloxacin NNP 1_o
accumulated VBD 1_o
in IN 1_o
uterine JJ 1_o
tissue NN 1_o
and CC 1_o
concentrations NNS 1_o
were VBD N
highest JJS N
1 CD N
hour NN N
after IN N
infusion NN N
in IN N
both DT N
plasma NN N
and CC N
tissue NN N
. . N

Tissue NN 1_o
to TO 1_o
plasma VB 1_o
ratios NNS 1_o
remained VBD N
between IN N
1.7 CD N
and CC N
2.1 CD N
for IN N
24 CD N
hours NNS N
. . N

Moxifloxacin NNP N
was VBD N
found VBN N
to TO N
be VB N
safe JJ 1_o
and CC 1_o
well RB 1_o
tolerated VBN 1_o
. . 1_o

CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ 1_o
tissue NN 1_o
concentrations NNS 1_o
of IN N
moxifloxacin NN N
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP 1_p
. . 1_p

The DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN 1_i
and CC 1_i
isoflurane NN 1_i
after IN N
premedication NN N
of IN N
healthy JJ 1_p
dogs NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
surgery NN 1_p
. . 1_p

Sevoflurane NNP 1_i
and CC 1_i
isoflurane NN 1_i
are VBP N
commonly RB N
used VBN N
in IN N
veterinary JJ N
anesthesia NN N
. . N

The DT N
objective NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN 1_i
and CC 1_i
isoflurane NN 1_i
via IN N
direct JJ N
arterial JJ N
blood NN N
pressure NN N
measurements NNS N
and CC N
the DT N
lithium NN N
dilution NN N
cardiac NN N
output NN N
( ( N
LDCO NNP N
) ) N
on IN N
premedicated VBN 1_p
healthy JJ 1_p
dogs NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
tibial JJ 1_p
plateau NN 1_p
leveling VBG 1_p
osteotomy NN 1_p
( ( 1_p
TPLO NNP 1_p
) ) 1_p
. . 1_p

Nineteen JJ 1_p
client-owned JJ 1_p
dogs NNS 1_p
were VBD N
included VBN N
. . N

All DT N
dogs NNS N
were VBD N
premedicated VBN N
with IN N
hydromorphone NN 1_i
( ( N
0.05 CD N
mg/kg NN N
IV NNP N
and CC N
glycopyrrolate VB 1_i
0.01 CD N
mg/kg NNS N
subcutaneously RB N
) ) N
. . N

Ten CD 1_p
dogs NNS 1_p
were VBD 1_p
anesthetized VBN 1_p
with IN 1_p
sevoflurane NN 1_i
and CC 1_p
nine CD 1_p
dogs NNS 1_p
were VBD 1_p
anesthetized VBN 1_p
with IN 1_p
isoflurane NN 1_i
. . 1_i

Eighteen JJ N
dogs NNS N
were VBD N
instrumented VBN N
with IN N
a DT N
dorsal NN N
pedal JJ N
arterial JJ N
catheter NN N
, , N
and CC N
one CD N
dog NN N
had VBD N
a DT N
femoral JJ N
arterial JJ N
catheter NN N
. . N

All DT N
dogs NNS N
had VBD N
continuous JJ N
, , N
direct JJ 1_o
systolic NN 1_o
( ( 1_o
SAP NNP 1_o
) ) 1_o
, , 1_o
diastolic JJ 1_o
( ( 1_o
DAP NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
mean JJ 1_o
arterial NN 1_o
( ( 1_o
MAP NNP 1_o
) ) 1_o
blood NN 1_o
pressure NN 1_o
readings NNS 1_o
as RB N
well RB N
as IN N
heart NN 1_o
rate NN 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
, , 1_o
cardiac JJ 1_o
output NN 1_o
( ( 1_o
CO NNP 1_o
) ) 1_o
, , 1_o
cardiac JJ 1_o
index NN 1_o
( ( 1_o
CI NNP 1_o
) ) 1_o
, , 1_o
systemic JJ 1_o
vascular NN 1_o
resistance NN 1_o
( ( 1_o
SVR NNP 1_o
) ) 1_o
, , 1_o
systemic JJ 1_o
vascular NN 1_o
resistance NN 1_o
index NN 1_o
( ( 1_o
SVRI NNP 1_o
) ) 1_o
, , 1_o
stroke VBD 1_o
volume NN 1_o
variation NN 1_o
( ( 1_o
SVV NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
pulse JJ 1_o
pressure NN 1_o
variation NN 1_o
( ( 1_o
PPV NNP 1_o
) ) 1_o
recorded VBD N
q $ N
5 CD N
min NN N
during IN N
the DT N
surgical JJ N
procedure NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
difference NN N
in IN N
all DT N
parameters NNS N
between IN N
the DT N
sevoflurane NN 1_i
and CC N
isoflurane NN 1_i
treatment NN N
groups NNS N
. . N

Both DT N
sevoflurane NN 1_i
and CC N
isoflurane NN 1_i
inhalant JJ N
anesthetics NNS N
appear VBP N
to TO N
have VB N
similar JJ N
hemodynamic JJ N
effects NNS N
when WRB N
used VBN N
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
anesthetic JJ N
protocol NN N
in IN N
premedicated VBN 1_p
healthy JJ 1_p
dogs NNS 1_p
undergoing VBG 1_p
an DT 1_p
elective JJ 1_p
surgical JJ 1_p
procedure NN 1_p
. . 1_p

The DT N
treatment NN N
of IN N
localized JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
in IN 1_p
children NNS 1_p
: : 1_p
a DT N
report NN N
from IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
. . N

Investigators NNS N
of IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
entered VBD N
73 CD 1_p
children NNS 1_p
with IN 1_p
previously RB 1_p
untreated VBN 1_p
localized JJ 1_p
non-Hodgkin NN 1_p
's POS 1_p
lymphoma NN 1_p
on IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
systemic JJ N
treatment NN N
with IN N
either DT N
a DT N
four-drug JJ N
program NN N
( ( 1_i
cyclophosphamide NN 1_i
, , 1_i
vincristine NN 1_i
, , 1_i
methotrexate NN 1_i
, , 1_i
prednisone NN 1_i
[ NNP 1_i
COMP NNP 1_i
] NNP 1_i
) ) 1_i
or CC N
a DT N
10-drug JJ 1_i
( ( 1_i
LSA2-L2 NNP 1_i
modified VBN 1_i
) ) 1_i
program NN N
of IN N
18 CD N
months NNS N
duration NN N
. . N

All DT N
patients NNS N
received VBD N
central JJ 1_i
nervous JJ 1_i
system NN 1_i
prophylaxis NN 1_i
with IN 1_i
intrathecal JJ 1_i
methotrexate NN 1_i
and CC N
most JJS N
received JJ N
local JJ 1_i
or CC 1_i
regional JJ 1_i
radiation NN 1_i
treatment NN 1_i
. . 1_i

The DT N
three-year JJ 1_o
relapse-free JJ 1_o
survival NN 1_o
rate NN 1_o
for IN N
all DT N
patients NNS N
( ( N
N NNP N
= NNP N
73 CD N
) ) N
was VBD N
84 CD N
% NN N
; : N
for IN N
COMP NNP N
( ( N
N NNP N
= NNP N
42 CD N
) ) N
was VBD N
85 CD N
% NN N
, , N
and CC N
for IN N
LSA2-L2 NNP N
( ( N
N NNP N
= NNP N
31 CD N
) ) N
was VBD N
84 CD N
% NN N
. . N

Of IN N
the DT N
12 CD N
patients NNS N
who WP N
suffered VBD N
adverse JJ 1_o
events NNS 1_o
eight CD N
relapsed VBN 1_o
and CC N
four CD N
died NN 1_o
of IN 1_o
toxicity NN 1_o
. . 1_o

Histopathology NNP N
was VBD N
reviewed VBN N
centrally RB N
. . N

Of IN N
32 CD N
patients NNS N
with IN N
nonlymphoblastic JJ N
disease NN N
treated VBD N
with IN N
COMP NNP 1_i
only RB N
one CD N
relapsed VBD 1_o
. . 1_o

Of IN N
26 CD N
patients NNS N
treated VBN N
with IN N
LSA2-L2 NNP 1_i
, , N
four CD N
relapsed VBN 1_o
. . 1_o

Patients NNS N
with IN N
localized JJ 1_o
lymphoblastic JJ 1_o
disease NN 1_o
were VBD N
uncommon JJ N
. . N

None NN N
of IN N
three CD N
patients NNS N
treated VBN N
with IN N
LSA2-L2 NNP 1_i
relapsed VBD N
compared VBN N
with IN N
three CD N
of IN N
nine CD N
treated VBN N
with IN N
COMP NNP N
. . N

COMP NNP 1_i
is VBZ N
an DT N
excellent JJ N
treatment NN N
for IN N
patients NNS N
with IN N
localized JJ N
disease NN N
of IN N
nonlymphoblastic JJ N
type NN N
, , N
but CC N
the DT N
relative JJ N
value NN N
of IN N
the DT N
two CD N
regimens NNS N
for IN N
patients NNS N
with IN N
localized JJ N
lymphoblastic JJ N
disease NN N
is VBZ N
uncertain JJ N
. . N

Enhancing VBG N
the DT N
application NN N
and CC N
evaluation NN N
of IN N
a DT N
discrete JJ 1_i
trial NN 1_i
intervention NN 1_i
package NN 1_i
for IN N
eliciting VBG N
first JJ N
words NNS N
in IN N
preverbal JJ 1_p
preschoolers NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

This DT N
study NN N
evaluates VBZ N
the DT N
effectiveness NN N
of IN N
an DT N
intervention NN N
package NN N
including VBG N
a DT N
discrete JJ 1_i
trial NN 1_i
program NN 1_i
( ( 1_i
Rapid NNP 1_i
Motor NNP 1_i
Imitation NNP 1_i
Antecedent NNP 1_i
Training NNP 1_i
( ( N
Tsiouri NNP N
and CC N
Greer NNP N
, , N
J NNP N
Behav NNP N
Educat NNP N
12:185-206 CD N
, , N
2003 CD N
) ) N
combined VBN 1_i
with IN 1_i
parent NN 1_i
education NN 1_i
for IN 1_i
eliciting VBG N
first JJ N
words NNS N
in IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
who WP 1_p
had VBD 1_p
little JJ 1_p
or CC 1_p
no DT 1_p
spoken JJ 1_p
language NN 1_p
. . 1_p

Evaluation NN N
of IN N
the DT N
approach NN N
includes VBZ N
specific JJ N
intervention NN N
targets NNS N
and CC N
functional JJ 1_o
spoken JJ 1_o
language NN 1_o
outcomes NNS 1_o
( ( 1_o
Tager-Flusberg NNP 1_o
et FW 1_o
al. NN 1_o
, , N
J NNP 1_o
Speech NNP 1_o
Lang NNP 1_o
Hear NNP 1_o
Res NNP 1_o
52:643-652 CD 1_o
, , 1_o
2009 CD 1_o
) ) 1_o
. . 1_o

Results VB N
suggest JJS N
that IN N
RMIA NNP N
, , N
with IN N
parent NN N
training NN N
, , N
catalyzes VBZ N
development NN N
of IN N
verbal JJ 1_o
imitation NN 1_o
and CC 1_o
production NN 1_o
for IN N
some DT N
children NNS N
. . N

Three CD 1_p
of IN 1_p
five CD 1_p
participants NNS 1_p
acquired VBD N
word NN 1_o
production NN 1_o
within IN N
the DT N
DTT NNP N
framework NN N
and CC N
achieved VBD N
milestones NNS N
of IN N
early JJ 1_o
functional JJ 1_o
spoken NN 1_o
language NN 1_o
use NN 1_o
( ( N
Tager-Flusberg NNP N
et FW N
al. NN N
, , N
J NNP N
Speech NNP N
Lang NNP N
Hear NNP N
Res NNP N
52:643-652 CD N
, , N
2009 CD N
) ) N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
for IN N
understanding VBG N
the DT N
role NN N
of IN N
discrete JJ N
trial NN N
approaches NNS N
to TO N
language NN N
intervention NN N
are VBP N
discussed VBN N
. . N

Efficacy NN N
of IN N
bepotastine NN 1_i
besilate NN 1_i
ophthalmic JJ 1_i
solution NN 1_i
1.5 CD N
% NN N
for IN N
seasonal JJ 1_o
allergic JJ 1_o
conjunctivitis NN 1_o
: : 1_o
a DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
, , N
natural JJ N
exposure NN N
, , N
clinical JJ N
trial NN N
. . N

Allergic NNP N
conjunctivitis NN N
( ( N
AC NNP N
) ) N
affects VBZ N
an DT N
estimated JJ N
20 CD N
% NN N
of IN N
the DT N
population NN N
in IN N
the DT N
Western JJ N
world NN N
, , N
with IN N
a DT N
large JJ N
fraction NN N
suffering VBG N
due JJ N
to TO N
seasonal JJ N
or CC N
perennial JJ N
allergen NN N
exposures NNS N
. . N

Bepotastine NNP 1_i
besilate NN 1_i
ophthalmic JJ 1_i
solution NN 1_i
( ( 1_i
BBOS NNP 1_i
) ) 1_i
1.5 CD N
% NN N
, , N
a DT N
dual-acting JJ 1_i
histamine NN 1_i
( ( N
H NNP N
( ( N
1 CD N
) ) N
) ) N
receptor NN N
antagonist NN N
and CC N
mast NN N
cell NN N
stabilizer NN N
, , N
is VBZ N
indicated VBN N
for IN N
itching VBG N
associated VBN N
with IN N
AC NNP N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
BBOS NNP N
1.5 CD N
% NN N
for IN N
reducing VBG N
ocular JJ 1_p
itching NN 1_p
associated VBN 1_p
with IN 1_p
AC NNP 1_p
in IN 1_p
subjects NNS 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
natural JJ 1_p
exposure NN 1_p
trial NN 1_p
. . 1_p

Eligible JJ 1_p
subjects NNS 1_p
in IN N
a DT N
multicenter NN N
, , N
double-masked JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ 1_i
, , N
natural JJ N
exposure NN N
clinical JJ N
trial NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
BBOS NNP 1_i
1.5 CD N
% NN N
or CC 1_i
placebo NN 1_i
eyedrops NNS 1_i
on IN N
a DT N
1:1 CD N
basis NN N
and CC N
instilled VBD N
1 CD N
drop NN N
of IN N
the DT N
test NN N
agent NN N
into IN N
both DT N
eyes NNS N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
instantaneous JJ N
and CC N
reflective JJ 1_o
ocular JJ 1_o
itching NN 1_o
scores NNS 1_o
at IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
based VBN N
on IN N
subject-assessed JJ N
severity NN N
of IN N
instantaneous JJ N
and CC N
reflective JJ N
itching NN N
. . N

Subject-reported JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
AEs NNP 1_o
) ) 1_o
were VBD N
also RB N
recorded VBN N
for IN N
safety NN N
. . N

Treatment NN N
with IN N
BBOS NNP N
1.5 CD N
% NN N
significantly RB N
reduced VBN N
instantaneous JJ 1_o
and CC 1_o
reflective JJ 1_o
ocular JJ 1_o
itching NN 1_o
scores NNS 1_o
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN N
over IN N
the DT N
2-week JJ N
study NN N
period NN N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.005 CD N
, , N
respectively RB N
) ) N
. . N

BBOS $ N
1.5 CD N
% NN N
was VBD N
well RB N
tolerated VBN 1_o
, , 1_o
and CC 1_o
AEs NNP 1_o
were VBD N
generally RB N
transient JJ N
and CC N
mild JJ N
. . N

This DT N
clinical JJ N
study NN N
indicates VBZ N
BBOS NNP N
1.5 CD N
% NN N
effectively RB 1_o
and CC 1_o
safely RB 1_o
treated VBD 1_o
ocular JJ 1_o
itching NN 1_o
in IN N
a DT N
natural JJ N
exposure NN N
allergy NN N
study NN N
and CC N
is VBZ N
a DT N
useful JJ N
treatment NN N
option NN N
for IN N
the DT N
management NN N
of IN N
ocular JJ N
itching NN N
associated VBN N
with IN N
AC NNP N
. . N

( ( N
ClinicalTrials.gov NNP N
identifier VBZ N
number NN N
: : N
NCT01174823 NNP N
. . N

) ) N
Double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
secretin NN 1_i
: : 1_i
effects NNS N
on IN N
aberrant JJ 1_o
behavior NN 1_o
in IN 1_o
children NNS 1_o
with IN 1_o
autism NN 1_o
. . 1_o

Secretin NNP 1_i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
treatment NN N
alternative NN N
for IN N
autistic JJ 1_o
spectrum NN 1_o
disorders NNS 1_o
, , N
but CC N
empirical JJ N
support NN N
is VBZ N
lacking VBG N
. . N

A DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
synthetic JJ 1_i
human JJ 1_i
secretin NN 1_i
on IN N
aberrant JJ 1_o
behavior NN 1_o
. . 1_o

Parent NN 1_p
and CC 1_p
teacher NN 1_p
data NNS 1_p
from IN 1_p
the DT 1_p
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
for IN N
eight CD 1_p
male JJ 1_p
children NNS 1_p
were VBD N
analyzed VBN N
for IN N
reliable JJ N
change NN N
in IN N
a DT N
clinical JJ N
replication NN N
series NN N
. . N

By IN N
parent NN N
and CC N
teacher NN N
report NN N
, , N
the DT N
majority NN N
of IN N
change NN N
occurred VBD N
either CC N
on IN N
the DT N
placebo NN 1_i
trial NN N
or CC N
reflected VBN N
deterioration NN N
subsequent NN N
to TO N
secretin VB 1_i
infusion NN N
. . N

Repeated-measures JJ N
multivariate JJ N
analysis NN N
of IN N
variance NN N
results NNS N
were VBD N
similar JJ N
. . N

Results NNS N
are VBP N
consistent JJ N
with IN N
other JJ N
studies NNS N
, , N
suggesting VBG N
that IN N
secretin NN 1_i
may MD N
not RB N
be VB N
an DT N
effective JJ N
treatment NN N
option NN N
. . N

Transdermal NNP 1_i
nitroglycerin NN 1_i
in IN N
angina JJ 1_p
pectoris NN 1_p
: : 1_p
efficacy NN N
of IN N
intermittent JJ N
application NN N
. . N

Continuous JJ N
application NN N
of IN N
transdermal JJ 1_i
nitroglycerin JJ 1_i
appears VBZ N
to TO N
result VB N
in IN N
tolerance NN 1_o
to TO 1_o
the DT 1_o
antianginal JJ 1_o
effect NN 1_o
. . 1_o

In IN N
a DT N
double-blind NN N
study NN N
the DT N
effects NNS N
of IN N
continuous JJ N
( ( N
24 CD N
h/day NN N
) ) N
and CC N
intermittent NN N
( ( N
16 CD N
h/day NN N
) ) N
application NN N
of IN N
transdermal JJ 1_i
nitroglycerin NN 1_i
in IN 1_i
a DT N
dosage NN N
of IN N
10 CD N
mg/day NN N
were VBD N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
placebo NN 1_i
in IN N
12 CD 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
stable JJ 1_p
angina NN 1_p
receiving VBG 1_p
treatment NN 1_p
with IN 1_p
beta-adrenergic JJ 1_i
blocking NN 1_i
or CC 1_i
calcium NN 1_i
channel NNS 1_i
blocking VBG 1_i
agents NNS 1_i
. . 1_i

Exercise NN 1_o
performance NN 1_o
was VBD N
assessed VBN N
2 CD N
to TO N
4 CD N
hours NNS N
after IN N
initial JJ N
application NN N
and CC N
after IN N
1 CD N
week NN N
of IN N
each DT N
treatment NN N
given VBN N
in IN N
random JJ N
order NN N
with IN N
a DT N
3 CD N
day NN N
interval NN N
between IN N
treatments NNS N
. . N

Exercise NN 1_o
time NN 1_o
to TO 1_o
onset VB 1_o
of IN 1_o
angina NN 1_o
, , 1_o
total JJ 1_o
exercise NN 1_o
duration NN 1_o
and CC 1_o
time NN 1_o
to TO 1_o
1 CD 1_o
mm NNS 1_o
ST NNP 1_o
segment NN 1_o
depression NN 1_o
were VBD N
all DT N
significantly RB N
increased VBN N
after IN N
initial JJ N
application NN N
during IN N
the DT N
continuous JJ N
and CC N
intermittent JJ N
treatment NN N
periods NNS N
. . N

These DT N
increases NNS N
were VBD N
maintained VBN N
after IN N
1 CD N
week NN N
of IN N
intermittent NN N
but CC N
not RB N
continuous JJ N
treatment NN N
. . N

Thus VB N
the DT N
benefit NN N
of IN N
initial JJ N
application NN N
of IN N
transdermal JJ 1_i
nitroglycerin NN 1_i
is VBZ N
maintained VBN N
with IN N
intermittent JJ N
treatment NN N
and CC N
a DT N
daily JJ N
nitrate-free JJ N
interval NN N
, , N
whereas JJ N
tolerance NN 1_o
to TO 1_o
antianginal JJ 1_o
effect NN 1_o
occurs VBZ N
with IN N
continuous JJ N
treatment NN N
. . N

Aloe NNP 1_i
vera NN 1_i
gel NN 1_i
and CC N
cesarean NN 1_o
wound NN 1_o
healing NN 1_o
; : 1_o
a DT N
randomized VBN N
controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Failure NNP N
in IN N
complete JJ N
healing NN 1_o
of IN N
the DT N
wound NN N
is VBZ N
one CD N
of IN N
the DT N
probable JJ N
complications NNS N
of IN N
cesarean NN N
. . N

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
dressing VBG N
with IN N
aloe JJ 1_i
vera NN 1_i
gel NN 1_i
in IN N
healing NN 1_o
of IN 1_o
cesarean JJ 1_o
wound NN 1_o
. . 1_o

METHODS NNP N
This DT N
prospective JJ N
randomized VBN N
double-blind JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
90 CD 1_p
women NNS 1_p
who WP 1_p
had VBD 1_p
undergone JJ 1_p
cesarean JJ 1_p
operation NN 1_p
in IN 1_p
Amir-al-Momenin NNP 1_p
hospital NN 1_p
( ( 1_p
Gerash NNP 1_p
, , 1_p
Iran NNP 1_p
) ) 1_p
. . 1_p

The DT N
participants NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
each DT 1_p
containing VBG 1_p
45 CD 1_p
patients NNS 1_p
. . 1_p

In IN N
one CD N
group NN N
, , N
the DT N
wound NN N
was VBD N
dressed VBN 1_i
with IN 1_i
aloe JJ 1_i
vera NN 1_i
gel NN 1_i
, , N
while IN N
simple JJ 1_i
dressing NN 1_i
was VBD N
used VBN N
in IN N
the DT N
control NN N
group NN N
. . N

Wound IN 1_o
healing NN 1_o
was VBD N
assessed VBN N
24 CD N
hours NNS N
and CC N
8 CD N
days NNS N
after IN N
the DT N
cesarean JJ N
operation NN N
using VBG N
REEDA NNP 1_o
scale NN 1_o
. . 1_o

The DT N
data NNS N
were VBD N
analyzed VBN N
through IN N
Chi-square NNP N
and CC N
t-test JJ N
. . N

RESULTS VB N
The DT 1_p
participants NNS 1_p
' POS 1_p
mean JJ 1_p
age NN 1_p
was VBD 1_p
27.56±4.20 CD 1_p
in IN 1_p
the DT 1_p
aloe NN 1_p
vera NN 1_p
group NN 1_p
and CC 1_p
26.62±4.88 CD 1_p
in IN 1_p
the DT 1_p
control NN 1_p
group NN 1_p
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

However RB N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
concerning VBG 1_o
body NN 1_o
mass NN 1_o
index NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
and CC 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
the DT 1_o
wound NN 1_o
healing VBG 1_o
score RB 1_o
24 CD 1_o
hours NNS 1_o
after IN 1_o
the DT 1_o
operation NN 1_o
( ( N
P=0.003 NNP N
) ) N
. . N

After IN N
8 CD N
days NNS N
, , N
however RB N
, , N
the DT N
difference NN N
in IN N
the DT 1_o
wound NN 1_o
healing VBG 1_o
score NN 1_o
was VBD N
not RB N
significant JJ N
( ( N
P=0.283 NNP N
) ) N
. . N

Overall JJ N
, , N
45 CD N
participants NNS N
in IN N
the DT N
aloe NN N
vera NN N
group NN N
and CC N
35 CD N
ones NNS N
in IN N
the DT N
control NN N
group NN N
had VBD N
obtained VBN N
a DT N
zero CD N
score NN N
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

These DT N
measures NNS N
were VBD N
respectively RB N
obtained VBN N
as IN N
42 CD N
and CC N
41eight CD N
days NNS N
after IN N
the DT N
operation NN N
. . N

CONCLUSION NNP N
According VBG N
to TO N
the DT N
findings NNS N
of IN N
this DT N
study NN N
, , N
the DT 1_p
women NNS 1_p
are VBP N
recommended VBN N
to TO N
be VB N
informed VBN N
regarding VBG N
the DT N
positive JJ 1_o
effects NNS 1_o
of IN N
dressing VBG N
with IN 1_i
aloe JJ 1_i
vera NN 1_i
gel NN N
. . N

Dose-response JJ 1_p
relationship NN 1_p
of IN 1_p
sertindole NN 1_i
and CC 1_i
haloperidol NN 1_i
using VBG 1_p
the DT 1_p
pharmacopsychometric JJ 1_p
triangle NN 1_p
. . 1_p

OBJECTIVE NNP N
Renewed NNP N
insight VBD N
into IN N
dose-related JJ N
effects NNS N
of IN N
sertindole NN 1_i
and CC 1_i
haloperidol NN 1_i
was VBD N
sought VBN N
by IN N
re-analysing NN N
published VBN N
data NNS N
for IN N
antipsychotic JJ N
effect NN N
, , N
extrapyramidal JJ N
effect NN N
, , N
and CC N
patient JJ N
wellbeing VBG N
- : N
i.e. NN N
, , N
the DT N
important JJ N
pharmacopsychometric JJ N
triangle NN N
domains NNS N
. . N

METHOD NNP N
Selected NNP 1_p
Positive NNP 1_p
and CC 1_p
Negative NNP 1_p
Syndrome NNP 1_p
Scale NNP 1_p
( ( 1_p
PANSS NNP 1_p
) ) 1_p
subscales NNS 1_p
and CC 1_p
the DT 1_p
Simpson-Angus JJ 1_p
scale NN 1_p
were VBD N
tested VBN N
for IN N
validity NN N
. . N

Standardized JJ N
effect NN N
sizes VBZ N
[ NNP N
last JJ N
observation NN N
carried VBD N
forward RB N
( ( N
LOCF NNP N
) ) N
] NN N
at IN N
endpoint NN N
were VBD N
calculated VBN N
. . N

RESULTS VB N
The DT N
scales NNS N
were VBD N
found VBN N
to TO N
be VB N
valid JJ N
instruments NNS N
. . N

The DT N
PANSS NNP N
( ( N
11 CD N
) ) N
psychotic JJ N
subscale NN N
showed VBD N
clinically RB N
significant JJ N
effect NN 1_o
sizes NNS 1_o
for IN N
all DT N
doses NNS N
of IN N
sertindole NN 1_i
( ( N
12 CD N
, , N
20 CD N
, , N
and CC N
24 CD N
mg NN N
) ) N
and CC N
haloperidol NN 1_i
( ( N
4 CD N
, , N
8 CD N
, , N
and CC N
16 CD N
mg NN N
) ) N
. . N

Extrapyramidal JJ 1_o
effects NNS 1_o
were VBD N
evident JJ N
for IN N
all DT N
doses NNS N
of IN N
haloperidol NN 1_i
, , N
but CC N
absent NN N
for IN N
the DT N
lower JJR N
doses NNS N
of IN N
sertindole NN 1_i
. . 1_i

The DT N
PANSS NNP N
( ( N
6 CD N
) ) N
depression NN N
subscale NN N
, , N
a DT N
proxy JJ N
measure NN N
of IN N
quality NN 1_o
of IN 1_o
life NN 1_o
, , N
showed VBD N
a DT N
clinically RB N
significant JJ N
effect NN N
for IN N
sertindole JJ 1_i
20 CD N
mg NN N
and CC N
no DT N
effect NN N
for IN N
haloperidol NN 1_i
. . 1_i

CONCLUSION VB N
This DT N
re-analysis NN N
confirmed VBD N
the DT N
antipsychotic JJ N
effect NN N
and CC N
absence NN N
of IN N
extrapyramidal JJ N
effects NNS N
for IN N
sertindole NN 1_i
and CC N
, , N
in IN N
addition NN N
, , N
showed VBD N
a DT N
clinically RB N
significant JJ N
antidepressant JJ N
effect NN N
. . N

A DT N
profile NN N
for IN N
bipolar JJ N
states NNS N
emerged VBD N
. . N

A DT N
web-based JJ 1_i
approach NN 1_i
to TO N
address VB N
cardiovascular JJ 1_o
risks NNS 1_o
in IN 1_p
managers NNS 1_p
: : 1_p
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
examine VB N
whether IN N
a DT N
Web-based JJ 1_i
health NN 1_i
and CC 1_i
leadership NN 1_i
development NN 1_i
program NN 1_i
-- : 1_i
designed VBN 1_i
specifically RB N
for IN N
managers NNS 1_p
-- : 1_p
was VBD 1_p
associated VBN N
with IN N
changes NNS N
in IN N
self-reported JJ 1_o
and CC 1_o
biometric JJ 1_o
indicators NNS 1_o
of IN 1_o
cardiovascular JJ 1_o
disease NN 1_o
within IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
control NN N
trial NN N
. . N

METHODS VB N
A DT N
total NN N
of IN N
145 CD 1_p
managers NNS 1_p
from IN 1_p
8 CD 1_p
organizations NNS 1_p
participated VBN N
in IN N
a DT N
6-month JJ 1_i
Internet-based JJ 1_i
program NN 1_i
or CC 1_i
a DT 1_i
control JJ 1_i
condition NN 1_i
. . 1_i

They PRP N
completed VBD N
pre- NN N
and CC N
posttest NN N
assessments NNS N
that WDT N
included VBD N
both DT N
self-reported JJ 1_o
attitudes NNS 1_o
( ( 1_o
on IN 1_o
diet NN 1_o
, , 1_o
exercise NN 1_o
, , 1_o
and CC 1_o
mental JJ 1_o
health NN 1_o
) ) 1_o
and CC N
biometric JJ 1_o
measures NNS 1_o
( ( 1_o
eg NN 1_o
, , 1_o
body NN 1_o
weight NN 1_o
, , 1_o
waist JJ 1_o
circumference NN 1_o
) ) 1_o
. . 1_o

RESULTS VB N
The DT N
intervention NN 1_i
was VBD N
associated VBN N
with IN N
improvements NNS N
in IN N
dietary JJ 1_o
attitudes NNS 1_o
, , 1_o
dietary JJ 1_o
self-efficacy NN 1_o
, , 1_o
and CC 1_o
exercise NN 1_o
, , 1_o
and CC 1_o
reductions NNS 1_o
in IN 1_o
distress NN 1_o
symptoms NNS 1_o
. . 1_o

Women NNS N
in IN N
the DT N
program NN N
reduced VBD N
their PRP$ N
waist NN 1_o
circumference NN 1_o
significantly RB N
more RBR N
than IN N
controls NNS N
. . N

CONCLUSIONS VB N
The DT N
program NN N
showed VBD N
promise NN N
for IN N
reducing VBG N
cardiovascular JJ 1_o
disease NN 1_o
risk NN 1_o
factors NNS 1_o
. . 1_o

Similar JJ N
results NNS N
across IN N
diverse JJ N
organizations NNS N
suggest VBP N
the DT N
program NN N
may MD N
be VB N
useful JJ N
across IN N
industry NN N
types NNS N
. . N

Citalopram NNP 1_i
for IN N
post-stroke JJ N
pathological JJ N
crying NN N
. . N

Post-stroke NNP N
pathological JJ N
crying NN N
is VBZ N
a DT N
distressing VBG N
condition NN N
in IN N
which WDT N
episodes VBZ N
occur VBP N
in IN N
response NN N
to TO N
minor VB N
stimuli NNS N
without IN N
associated VBN N
mood NN N
changes NNS N
. . N

There EX N
is VBZ N
preliminary JJ N
evidence NN N
of IN N
disturbed JJ N
serotoninergic JJ N
neurotransmission NN N
in IN N
such JJ N
cases NNS N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
the DT N
selective JJ 1_o
serotonin NN 1_o
reuptake NN 1_o
inhibitor NN 1_o
citalopram NN 1_o
on IN N
uncontrolled JJ 1_o
crying NN 1_o
in IN N
stroke NN 1_p
patients NNS 1_p
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

16 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
( ( 1_p
median JJ 1_p
age NN 1_p
58.5 CD 1_p
years NNS 1_p
, , 1_p
range VB 1_p
40-83 JJ 1_p
) ) 1_p
entered VBD N
the DT N
9-week JJ 1_i
study NN 1_i
a DT 1_i
median NN 1_i
of IN 1_i
168 CD 1_i
days NNS 1_i
( ( 1_i
range VB 1_i
6-913 NNP 1_i
) ) 1_i
post NN 1_i
stroke NN 1_i
and CC 1_i
were VBD 1_i
treated VBN 1_i
with IN 1_i
citalopram JJ 1_i
10-20 JJ 1_i
mg NNS 1_i
daily RB 1_i
for IN 1_i
3 CD 1_i
weeks NNS 1_i
. . 1_i

Crying VBG 1_o
history NN 1_o
was VBD 1_i
determined VBN 1_i
from IN 1_i
semistructured VBN 1_i
interviews NNS 1_i
and CC 1_i
from IN 1_i
diaries NNS 1_i
kept VBN 1_i
by IN 1_i
the DT 1_i
patients NNS 1_i
. . 1_i

Psychiatric NNP 1_o
assessment NN 1_o
was VBD N
made VBN N
with IN N
the DT N
Hamilton NNP 1_o
depression NN 1_o
scale NN 1_o
( ( N
HDS NNP N
) ) N
, , N
and CC N
unwanted JJ 1_o
effects NNS 1_o
were VBD N
measured VBN N
with IN N
the DT N
UKU NNP 1_o
side-effect JJ 1_o
scale NN 1_o
. . 1_o

In IN N
13 CD 1_p
patients NNS 1_p
in IN 1_p
whom WP 1_p
frequency NN 1_o
of IN 1_o
crying NN 1_o
could MD N
be VB N
assessed VBN N
, , N
the DT N
number NN 1_o
of IN 1_o
daily JJ 1_o
crying VBG 1_o
episodes NNS 1_o
decreased VBN N
by IN N
at IN N
least JJS N
50 CD N
% NN N
in IN N
all DT N
cases NNS N
during IN N
citalopram JJ N
treatment NN N
vs NN N
2 CD N
patients NNS N
during IN N
placebo JJ N
treatment NN N
( ( N
p JJ N
< NN N
0.005 CD N
, , N
McNemar NNP N
's POS N
test NN N
) ) N
, , N
the DT N
effect NN N
being VBG N
rapid JJ N
( ( N
1-3 JJ N
days NNS N
) ) N
and CC N
pronounced VBN N
in IN N
11 CD N
( ( N
73 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
a DT N
concomitant JJ N
significant JJ N
decrease NN 1_o
in IN 1_o
depression NN 1_o
rating NN 1_o
from IN N
HDS NNP N
8.9 CD N
to TO N
5.3 CD N
( ( N
p NN N
< VBZ N
0.005 CD N
, , N
Wilcoxon NNP N
's POS N
test NN N
) ) N
. . N

Citalopram NNP N
was VBD N
well RB N
tolerated VBN N
, , N
the DT N
few JJ N
side-effects NNS N
being VBG N
mild JJ N
and CC N
transient JJ N
. . N

We PRP N
conclude VBP N
that IN N
serotoninergic JJ N
neurotransmission NN N
plays VBZ N
an DT N
important JJ N
part NN N
in IN N
post-stroke JJ N
pathological JJ N
crying NN N
and CC N
that DT N
citalopram NN 1_i
is VBZ N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
. . N

Delayed VBN 1_p
perceptual JJ 1_p
awareness NN 1_p
in IN N
rapid JJ 1_p
perceptual JJ 1_p
decisions NNS 1_p
. . 1_p

The DT N
flourishing NN N
of IN N
studies NNS N
on IN N
the DT N
neural JJ N
correlates NNS N
of IN N
decision-making JJ N
calls NNS N
for IN N
an DT N
appraisal NN N
of IN N
the DT N
relation NN N
between IN N
perceptual JJ N
decisions NNS N
and CC N
conscious JJ N
perception NN N
. . N

By IN N
exploiting VBG N
the DT N
long JJ 1_i
integration NN 1_i
time NN 1_i
of IN 1_i
noisy JJ 1_i
motion NN 1_i
stimuli NN 1_i
, , 1_i
and CC 1_i
by IN 1_i
forcing VBG 1_i
human JJ 1_i
observers NNS 1_i
to TO 1_i
make VB 1_i
difficult JJ 1_i
speeded VBN 1_i
decisions NNS 1_i
-- : 1_i
sometimes RB 1_i
a DT 1_i
blind JJ 1_i
guess NN 1_i
-- : 1_i
about IN 1_i
stimulus JJ 1_i
direction NN 1_i
, , N
we PRP N
traced VBD N
the DT N
temporal JJ N
buildup NN N
of IN N
motion NN N
discrimination NN N
capability NN N
and CC N
perceptual JJ N
awareness NN N
, , N
as IN N
assessed VBN N
trial NN N
by IN N
trial NN N
through IN N
direct JJ N
rating NN N
. . N

We PRP N
found VBD N
that IN N
both DT N
increased VBN N
gradually RB N
with IN N
motion NN 1_o
coherence NN 1_o
and CC 1_o
viewing NN 1_o
time NN 1_o
, , N
but CC N
discrimination NN 1_o
was VBD 1_o
systematically RB 1_o
leading JJ 1_o
awareness NN 1_o
, , 1_o
reaching VBG 1_o
a DT 1_o
plateau NN 1_o
much RB 1_o
earlier RBR 1_o
. . 1_o

Sensitivity NNP 1_o
and CC 1_o
criterion NN 1_o
changes NNS 1_o
contributed VBD N
jointly RB N
to TO N
the DT N
slow JJ 1_o
buildup NN 1_o
of IN 1_o
perceptual JJ 1_o
awareness NN 1_o
. . 1_o

It PRP N
made VBD N
no DT 1_o
difference NN 1_o
whether IN N
motion NN 1_o
discrimination NN 1_o
was VBD N
accomplished VBN N
by IN N
saccades NNS 1_o
or CC 1_o
verbal JJ 1_o
responses NNS 1_o
. . 1_o

These DT N
findings NNS N
suggest VBP N
that IN N
perceptual JJ 1_o
awareness NN 1_o
emerges VBZ 1_o
on IN 1_o
the DT 1_o
top NN 1_o
of IN 1_o
a DT 1_o
developing NN 1_o
or CC 1_o
even RB 1_o
mature VBP 1_o
perceptual JJ 1_o
decision NN 1_o
. . 1_o

We PRP N
argue VBP N
that IN N
the DT N
middle JJ N
temporal JJ N
( ( N
MT NNP N
) ) N
cortical JJ N
region NN N
does VBZ N
not RB N
confer VB N
us PRP N
the DT N
full JJ 1_o
phenomenic JJ 1_o
depth NN 1_o
of IN 1_o
motion NN 1_o
perception NN 1_o
, , N
although IN N
it PRP N
may MD N
represent VB N
a DT N
precursor NN 1_o
stage NN 1_o
in IN 1_o
building VBG 1_o
our PRP$ 1_o
subjective JJ 1_o
sense NN 1_o
of IN 1_o
visual JJ 1_o
motion NN 1_o
. . 1_o

Clinical JJ N
trial NN N
of IN N
tooth NN 1_o
whitening VBG 1_o
with IN N
6 CD N
% NN N
hydrogen NN 1_i
peroxide IN 1_i
whitening VBG 1_i
strips NNS 1_i
and CC N
two CD N
whitening NN 1_i
dentifrices NNS 1_i
. . 1_i

PURPOSE NNP N
To TO N
compare VB N
tooth JJ 1_o
whitening VBG 1_o
with IN N
6 CD N
% NN N
hydrogen NN 1_i
peroxide IN 1_i
whitening VBG 1_i
strips NNS 1_i
and CC N
two CD N
whitening VBG 1_i
dentifrices NNS 1_i
in IN N
a DT N
12-week JJ N
randomized NN N
controlled VBD N
trial NN N
at IN N
a DT N
Belgian JJ 1_p
dental JJ 1_p
school NN 1_p
. . 1_p

METHODS NNP N
After IN N
informed JJ N
consent NN N
, , N
46 CD 1_p
healthy JJ 1_p
adults NNS 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO N
one CD N
of IN N
three CD N
strip NN 1_i
+ NNP N
dentifrice NN 1_i
treatment NN N
groups NNS N
. . N

Subjects NNS N
received VBD N
either RB N
6 CD 1_i
% NN 1_i
hydrogen NN 1_i
peroxide IN 1_i
whitening VBG 1_i
strips NNS 1_i
( ( 1_i
Crest NNP 1_i
Whitestrips NNP 1_i
) ) 1_i
and CC 1_i
an DT 1_i
anticavity NN 1_i
toothpaste NN 1_i
( ( N
Crest NNP N
Cavity NNP N
Protection NNP N
) ) N
, , N
placebo JJ 1_i
strips NNS 1_i
and CC 1_i
a DT 1_i
sodium NN 1_i
fluoride NN 1_i
( ( 1_i
NaF NNP 1_i
) ) 1_i
whitening VBG 1_i
dentifrice NN 1_i
( ( N
Mentadent NNP N
Whitening NNP N
Toothpaste NNP N
) ) N
or CC N
placebo VBN 1_i
strips NNS 1_i
and CC 1_i
a DT 1_i
sodium NN 1_i
monofluorophosphate NN 1_i
( ( 1_i
MFP NNP 1_i
) ) 1_i
whitening VBG 1_i
dentifrice NN 1_i
( ( N
Rembrandt NNP N
Low NNP N
Abrasion NNP N
Whitening NNP N
Toothpaste NNP N
) ) N
. . N

Strip NNP 1_i
use NN 1_i
( ( 1_i
peroxide NN 1_i
or CC 1_i
placebo NN 1_i
) ) 1_i
was VBD N
for IN N
30 CD N
minutes NNS N
, , N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
while IN N
dentifrice NN N
use NN N
was VBD N
at IN N
least JJS N
twice JJ N
daily RB N
for IN N
12 CD N
weeks NNS N
. . N

Efficacy NN 1_o
was VBD N
measured VBN N
from IN N
standardized JJ N
digital JJ N
images NNS N
of IN N
the DT N
maxillary JJ N
facial JJ N
tooth NN N
surfaces NNS N
, , N
while IN N
safety NN N
was VBD N
evaluated VBN N
from IN N
oral JJ N
examination NN N
and CC N
interview NN N
. . N

Treatments NNS N
were VBD N
compared VBN N
after IN N
2 CD N
weeks NNS N
( ( N
strip NN N
use NN N
) ) N
and CC N
12 CD N
weeks NNS N
( ( N
dentifrice NN N
use NN N
) ) N
using VBG N
analysis NN N
of IN N
covariance NN N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
completed VBN N
the DT N
12-week JJ N
evaluation NN N
. . N

Adjusting VBG N
for IN N
baseline NN N
and CC N
age NN N
, , N
the DT N
peroxide JJ N
strip NN N
group NN N
had VBD N
-2.45 NNP N
Deltab* NNP N
, , N
2.39 CD N
DeltaL* NNP N
, , N
and CC N
-0.96 JJ N
Deltaa* NNP N
at IN N
Week NNP N
2 CD N
. . N

Between-group JJ N
comparisons NNS N
demonstrated VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
reductions NNS N
in IN N
yellowness NN 1_o
and CC 1_o
redness NN 1_o
, , N
and CC N
increased VBD N
brightness NN 1_o
favoring VBG 1_o
the DT N
peroxide JJ N
strip NN N
group NN N
. . N

The DT N
peroxide JJ 1_i
strip NN 1_i
group NN 1_i
demonstrated VBD N
95 CD N
% NN N
+ NNP N
color NN 1_o
retention NN 1_o
( ( N
Deltab* NNP N
& CC N
DeltaL* NNP N
) ) N
at IN N
Week NNP N
12 CD N
, , N
differing VBG N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
versus NN N
either DT N
of IN N
the DT N
continuously NN N
used VBN N
whitening NN 1_i
dentifrices NNS 1_i
. . 1_i

There EX N
were VBD N
no DT N
significant JJ N
( ( N
P NNP N
> NNP N
0.18 CD N
) ) N
differences NNS N
between IN N
the DT N
whitening VBG N
dentifrice NN N
groups NNS N
at IN N
any DT N
timepoints NNS N
. . N

All DT N
treatments NNS N
were VBD N
well-tolerated JJ 1_o
, , N
with IN N
minor JJ 1_o
tooth DT 1_o
sensitivity NN 1_o
and CC N
oral JJ 1_o
irritation NN 1_o
representing VBG N
the DT N
most RBS N
common JJ N
findings NNS N
. . N

Risperidone NNP 1_i
improves VBZ N
behavioral JJ 1_o
symptoms NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

Subgroup NNP N
analysis NN N
of IN N
children NNS 1_p
( ( 1_p
5-12 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
autism NN 1_p
enrolled VBN N
in IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
of IN N
risperidone NN 1_i
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

The DT N
primary JJ N
efficacy NN N
measure NN N
was VBD N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist-Irritability NNP 1_o
( ( 1_o
ABC-I NNP 1_o
) ) 1_o
subscale NN 1_o
. . 1_o

Data NNS N
were VBD N
available JJ N
for IN N
55 CD 1_p
children NNS 1_p
given VBN N
risperidone NN 1_i
( ( N
n=27 JJ N
) ) N
or CC N
placebo NN 1_i
( ( N
n=28 JJ N
) ) N
; : N
mean JJ N
baseline NN N
ABC-I NNP N
( ( N
+/- JJ N
SD NNP N
) ) N
was VBD N
20.6 CD N
( ( N
8.1 CD N
) ) N
and CC N
21.6 CD N
( ( N
10.2 CD N
) ) N
. . N

Risperidone NNP 1_i
[ JJ N
mean NN N
dose NN N
( ( N
+/- JJ N
SD NNP N
) ) N
: : N
1.37 CD N
mg/day NN N
( ( N
0.7 CD N
) ) N
] NN N
resulted VBD N
in IN N
significantly RB N
greater JJR N
reduction NN N
from IN N
baseline NN N
to TO N
endpoint VB N
in IN N
ABC-I NNP 1_o
versus NN N
placebo NN 1_i
[ JJ N
mean JJ N
change NN N
( ( N
+/- JJ N
SD NNP N
) ) N
: : N
-13.4 NN N
( ( N
1.5 CD N
) ) N
vs. FW N
-7.2 NNP N
( ( N
1.4 CD N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
ES=-0.7 JJ N
] NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
effect NN N
with IN N
risperidone NN 1_i
was VBD N
somnolence NN 1_o
( ( N
74 CD N
% NN N
vs. FW N
7 CD N
% NN N
with IN N
placebo NN 1_i
) ) 1_i
. . N

Risperidone CD 1_i
treatment NN N
was VBD N
well RB N
tolerated VBN 1_o
and CC N
significantly RB N
improved VBN N
behavioral JJ 1_o
problems NNS 1_o
associated VBN N
with IN N
autism NN N
. . N

Atypical JJ 1_i
social JJ 1_i
modulation NN 1_i
of IN N
imitation NN N
in IN N
autism NN 1_p
spectrum NN 1_p
conditions NNS 1_p
. . 1_p

Appropriate NNP N
modulation NN 1_i
of IN 1_i
imitation NN 1_i
according VBG N
to TO N
social JJ N
context NN N
is VBZ N
important JJ N
for IN N
successful JJ N
social JJ N
interaction NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
subliminally RB N
primed VBD N
high-functioning JJ 1_p
adults NNS 1_p
with IN 1_p
ASC NNP 1_p
and CC 1_p
age- JJ 1_p
and CC 1_p
IQ-matched JJ 1_p
controls NNS 1_p
with IN 1_p
either DT 1_p
a DT 1_p
pro- JJ 1_p
or CC 1_p
non- JJ 1_p
social JJ 1_p
attitude NN 1_p
. . 1_p

Following VBG N
priming NN N
, , N
an DT N
automatic JJ N
imitation NN N
paradigm NN N
was VBD N
used VBN N
to TO N
acquire VB N
an DT N
index NN 1_o
of IN 1_o
imitation NN 1_o
. . 1_o

Whereas NNP N
imitation NN 1_o
levels NNS 1_o
were VBD N
higher JJR N
for IN N
pro-socially RB N
primed JJ N
relative JJ N
to TO N
non-socially RB N
primed VBN N
control NN 1_p
participants NNS 1_p
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
pro- JJ N
and CC N
non- JJ N
socially RB N
primed JJ N
individuals NNS 1_p
with IN 1_p
ASC NNP 1_p
. . 1_p

We PRP N
conclude VBP N
that IN N
high-functioning JJ 1_p
adults NNS 1_p
with IN 1_p
ASC NNP 1_p
demonstrate VB N
atypical JJ 1_o
social JJ 1_o
modulation NN 1_o
of IN 1_o
imitation NN 1_o
. . 1_o

Given VBN N
the DT N
importance NN N
of IN N
imitation NN 1_i
in IN 1_i
social JJ 1_i
interaction NN 1_i
we PRP N
speculate VBP N
that IN N
difficulties NNS N
with IN N
the DT N
modulation NN N
of IN N
imitation NN N
may MD N
contribute VB N
to TO N
the DT N
social JJ N
problems NNS N
characteristic JJ N
of IN N
ASC NNP 1_p
. . 1_p

Effects NNS N
of IN N
iron NN 1_i
on IN N
the DT N
pharmacokinetics NNS 1_o
of IN 1_o
paracetamol NN 1_o
in IN 1_o
saliva NN 1_o
. . 1_o

Paracetamol NNP 1_i
has VBZ N
been VBN N
reported VBN N
to TO N
chelate VB N
with IN N
iron NN 1_i
. . 1_i

It PRP N
was VBD N
found VBN N
that IN N
no DT N
in IN 1_o
vitro JJ 1_o
reaction NN 1_o
between IN N
ferrous JJ N
ion NN N
and CC N
paracetamol NN N
. . N

Other JJ N
studies NNS N
found VBD N
that IN N
there EX N
is VBZ N
an DT N
aerobic JJ N
( ( N
in IN N
the DT N
gastrointestinal JJ N
tract NN N
) ) N
oxidation NN N
of IN N
ferrous JJ N
ion NN N
to TO N
ferric VB N
ion NN N
caused VBN N
in IN N
iron-paracetamol NN N
in IN N
vivo JJ N
reactions NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
iron NN N
interacts NNS N
with IN N
paracetamol NN N
and CC N
reduces NNS N
paracetamol JJ 1_o
absorption NN 1_o
. . 1_o

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
study NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
in IN 1_o
vivo JJ 1_o
interaction NN 1_o
of IN 1_o
paracetamol NN 1_o
and CC 1_o
ferrous JJ 1_o
ion NN 1_o
. . 1_o

Paracetamol NNP 1_i
( ( N
1.0 CD N
g NN N
) ) N
was VBD N
co-ignested JJ N
alone RB 1_i
or CC 1_i
with IN N
( ( 1_i
300 CD 1_i
mg NN 1_i
) ) 1_i
ferrous JJ 1_i
sulphate NN 1_i
by IN N
ten JJ 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
, , N
using VBG N
saliva JJ N
drug NN N
levels NNS N
as IN N
a DT N
parameter NN N
. . N

Concomitant NNP N
administration NN N
of IN N
ferrous JJ 1_i
sulphate NN 1_i
and CC 1_i
paracetamol NN 1_i
, , N
decreased VBN N
AUC8 NNP 1_o
from IN N
42.88 CD N
+/- JJ N
3.8-34.25 JJ N
+/- JJ N
2.8 CD N
microg NN N
h NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
Cmax NNP 1_o
from IN N
18.75 CD N
+/- JJ N
1.9 CD N
to TO N
15.9 CD N
+/- JJ N
1.7 CD N
microg NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
while IN N
no DT N
change NN N
in IN N
tmax NN N
( ( N
p JJ N
= NNP N
0.5 CD N
) ) N
was VBD N
originated VBN N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
paracetamol NN 1_o
pharmacokinetic JJ 1_o
parameter NN 1_o
oral JJ 1_o
clearance NN 1_o
( ( 1_o
C1/F NNP 1_o
) ) 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
and CC N
slightly RB N
increased VBN N
in IN N
volume NN 1_o
of IN 1_o
distribution NN 1_o
( ( N
V NNP N
( ( N
d NN N
) ) N
/F NN N
) ) N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Co-administration NN N
of IN N
iron NN 1_i
and CC 1_i
paracetamol JJ 1_i
results NNS N
in IN N
decreased JJ 1_o
paracetamol NN 1_o
absorption NN 1_o
due JJ N
to TO N
an DT N
interaction NN N
between IN N
iron NN N
and CC N
paracetamol NN N
. . N

[ JJ N
Clinical NNP N
effect NN N
of IN N
transcatheter NN 1_i
arterial JJ 1_i
chemoembolization NN 1_i
combined VBN N
with IN N
high JJ 1_i
intensity NN 1_i
focused VBD 1_i
ultrasound JJ 1_i
ablation NN 1_i
in IN N
treatment NN N
of IN N
large JJ 1_p
hepatocellular JJ 1_p
carcinoma NN 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
clinical JJ N
effect NN N
of IN N
transcatheter NN 1_i
arterial JJ 1_i
chemoembolization NN 1_i
( ( 1_i
TACE NNP 1_i
) ) 1_i
combined VBN N
with IN N
high JJ 1_i
intensity NN 1_i
focused VBN 1_i
ultrasound NN 1_i
( ( 1_i
HIFU NNP 1_i
) ) 1_i
ablation NN N
in IN N
treatment NN N
of IN N
large JJ N
hepatocellular JJ 1_p
carcinoma NN 1_p
( ( 1_p
HCC NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Sixty-eight JJ 1_p
patients NNS 1_p
with IN 1_p
unresectable JJ 1_p
HCC NNP 1_p
were VBD N
randomized VBN N
into IN N
2 CD 1_i
age NN 1_i
, , 1_i
tumor NN 1_i
size NN 1_i
, , 1_i
TNM NNP 1_i
stages VBZ 1_i
, , 1_i
and CC 1_i
liver JJ 1_i
function NN 1_i
grade-matched JJ 1_i
groups NNS 1_i
: : 1_i
TACE NNP 1_i
group NN 1_i
( ( 1_i
n=30 RB 1_i
) ) 1_i
undergoing VBG 1_i
TACE NNP 1_i
and CC 1_i
TACE+HIFU NNP 1_i
group NN 1_i
( ( 1_i
n=38 RB 1_i
) ) 1_i
undergoing VBG 1_i
2-3 JJ 1_i
weeks NNS 1_i
after IN 1_i
TACE NNP 1_i
. . 1_i

A NNP N
total NN N
of IN N
88 CD N
tumors NNS N
( ( N
9.3+/-3.2 CD N
) ) N
( ( N
5.0-14.5 JJ N
) ) N
cm NN N
in IN N
diameter NN N
were VBD N
detected VBN N
, , N
and CC N
the DT N
largest JJS N
tumor NN N
in IN N
a DT N
specific JJ N
patients NNS 1_p
with IN 1_p
multiple JJ 1_p
lesions NNS 1_p
was VBD N
selected VBN N
for IN N
observation NN N
. . N

Follow-up NNP N
was VBD N
conducted VBN N
for IN N
( ( N
13+/-7 JJ N
) ) N
( ( N
3-24 JJ N
) ) N
months NNS N
to TO N
observe VB N
the DT N
necrosis NN 1_o
of IN 1_o
tumor NN 1_o
, , 1_o
size NN 1_o
of IN 1_o
tumor NN 1_o
, , 1_o
local JJ 1_o
recurrence NN 1_o
, , N
and CC N
survival NN 1_o
of IN 1_o
patient NN 1_o
. . 1_o

RESULTS VB N
The DT N
clinical JJ 1_o
symptom JJ 1_o
remission NN 1_o
rate NN 1_o
was VBD N
90.6 CD N
% NN N
( ( N
29/32 CD N
) ) N
in IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
and CC N
70.8 CD N
% NN N
( ( N
28/38 CD N
) ) N
in IN N
the DT N
TACE NNP N
group NN N
. . N

The DT N
tumor NN 1_o
necrosis NN 1_o
and CC 1_o
minification NN 1_o
rates NNS 1_o
of IN N
the DT N
TACE+HIFU NNP 1_i
and CC N
TACE NNP 1_i
groups NNS N
were VBD N
73.7 CD N
% NN N
and CC N
68.4 CD N
% NN N
respectively RB N
, , N
both DT N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
TACE NNP 1_i
group NN N
( ( N
26.7 CD N
% NN N
and CC N
33.3 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
tumor NN 1_o
local JJ 1_o
recurrence NN 1_o
rate NN 1_o
of IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
was VBD N
21.1 CD N
% NN N
, , N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
the DT N
TACE NNP 1_i
group NN N
( ( N
33.3 CD N
% NN N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
median JJ 1_o
survival NN 1_o
duration NN 1_o
of IN N
the DT N
TACE+HIFU NNP 1_i
group NN N
was VBD N
18 CD N
months NNS N
, , N
significantly RB N
longer JJR N
than IN N
that DT N
of IN N
the DT N
TACE NNP 1_i
group NN N
( ( N
10 CD N
months NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
the DT N
TACE NNP 1_i
therapy NN N
alone RB N
, , N
the DT N
combination NN N
therapy NN N
improves VBZ N
the DT N
tumor NN 1_o
necrosis NN 1_o
rate NN 1_o
and CC N
prolongs VBZ N
the DT N
patients NNS 1_o
' POS 1_o
survival JJ 1_o
duration NN 1_o
. . 1_o

[ JJ N
Management NNP N
of IN N
the DT N
perineal NN N
wounds NNS N
after IN N
abdominoperineal JJ N
resection NN N
: : N
simple JJ 1_i
drainage NN 1_i
only RB N
or CC N
with IN N
continuous JJ 1_i
irrigation NN 1_i
? . N
] NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
presacral JJ 1_i
irrigation NN 1_i
and CC N
simple JJ 1_i
drainage NN 1_i
on IN N
the DT N
perineal NN N
wound NN N
healing NN N
in IN N
patients NNS 1_p
after IN 1_p
abdominoperineal JJ 1_i
resection NN 1_i
( ( 1_i
APR NNP 1_i
) ) 1_i
. . 1_i

METHODS NNP N
From IN N
October NNP N
2004 CD N
to TO N
August NNP N
2009 CD N
, , N
patients NNS 1_p
with IN 1_p
rectal JJ 1_p
cancer NN 1_p
, , 1_p
ulcerative JJ 1_p
colitis NN 1_p
or CC 1_p
rectal JJ 1_p
gastrointestinal JJ 1_p
stromal JJ 1_p
tumor NN 1_p
, , 1_p
who WP 1_p
underwent JJ 1_p
APR NNP 1_i
or CC 1_i
proctocolectomy NN 1_i
, , N
were VBD N
randomized VBN N
into IN N
two CD N
arms NNS N
: : N
simple JJ 1_i
drainage NN 1_i
group NN N
( ( N
n JJ N
= NNP N
37 CD N
) ) N
and CC N
continuous JJ 1_i
irrigation NN 1_i
( ( N
n JJ N
= NNP N
37 CD N
) ) N
. . N

Patients NNS N
randomized VBD N
to TO N
arm VB N
B NNP N
received VBD N
simple JJ 1_i
drainage NN 1_i
only RB N
to TO N
presacral JJ N
space NN N
; : N
while IN N
those DT N
patients NNS N
in IN N
arm NN N
A NNP N
received VBD N
continuous JJ 1_i
irrigation NN 1_i
in IN N
addition NN N
to TO N
simple JJ N
drainage NN N
. . N

Perineal NNP N
wound IN N
healing NN N
was VBD N
taken VBN N
as IN N
endpoint NN N
of IN N
this DT N
study NN N
. . N

Major JJ N
complication NN N
was VBD N
defined VBN N
as IN N
wound JJ 1_o
dehiscence NN 1_o
or CC 1_o
wound NN 1_o
infection NN 1_o
that IN 1_o
the DT 1_o
perineal NN 1_o
wound NN 1_o
should MD 1_o
be VB 1_o
reopened VBN 1_o
for IN 1_o
drainage NN 1_o
. . 1_o

Minor JJ N
complication NN N
was VBD N
defined VBN N
as IN N
delayed JJ 1_o
healing VBG 1_o
wound NN 1_o
with IN 1_o
seroma NN 1_o
or CC 1_o
hematoma NN 1_o
. . 1_o

RESULTS VB N
A DT N
total NN N
of IN N
74 CD 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
present JJ 1_p
study NN 1_p
, , N
with IN N
37 CD N
patients NNS N
in IN N
each DT N
arm NN N
, , N
and CC N
there EX N
were VBD N
12 CD N
cases NNS N
and CC N
10 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ N
radiation NN N
therapy NN N
, , N
respectively RB N
. . N

In IN N
the DT N
arm NN N
A NNP N
, , N
2 CD N
patients NNS N
developed VBD N
major JJ N
complications NNS N
, , N
3 CD N
patients NNS N
incurred VBN N
with IN N
minor JJ N
complications NNS N
and CC N
32 CD N
patients NNS N
got VBD N
primary JJ N
healing NN 1_o
of IN N
the DT N
perineal NN N
wounds NNS N
. . N

In IN N
arm NN N
B NNP N
, , N
8 CD N
patients NNS N
suffered VBD N
major JJ N
complications NNS N
, , N
3 CD N
patients NNS N
incurred VBN N
with IN N
minor JJ N
complications NNS N
and CC N
26 CD N
patients NNS N
got VBD N
primary JJ N
healing NN N
of IN N
the DT N
perineal NN N
wounds VBZ N
. . N

The DT N
incidence NN 1_o
of IN 1_o
major JJ 1_o
complication NN 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
arm NN N
A NNP N
( ( N
5.4 CD N
% NN N
vs.21.6 NN N
% NN N
, , N
P NNP N
= NNP N
0.042 CD N
) ) N
. . N

Patients NNS N
received VBD N
preoperative JJ N
radiation NN N
therapy NN N
had VBD N
significantly RB N
higher JJR N
rate NN 1_o
of IN 1_o
minor JJ 1_o
complications NNS 1_o
than IN N
patients NNS N
underwent JJ N
surgery NN N
only RB N
( ( N
18.2 CD N
% NN N
vs. FW N
3.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

CONCLUSIONS NNP N
Simple NNP 1_i
drainage NN 1_i
with IN 1_i
continuous JJ 1_i
irrigation NN 1_i
of IN 1_i
the DT 1_i
presacral JJ 1_i
space NN 1_i
, , N
in IN N
patients NNS N
with IN N
abdominoperineal JJ N
resection NN N
or CC N
proctocolectomy NN N
, , N
could MD N
significantly RB N
lower VB N
the DT N
incidence NN N
of IN N
major JJ N
complication NN N
and CC N
improve VB N
wound NN N
healing VBG N
for IN N
perineal NN N
wound NN N
when WRB N
compared VBN N
with IN N
simple JJ N
drainage NN N
only RB N
. . N

Preoperative JJ N
radiation NN N
therapy NN N
tends VBZ N
to TO N
increase VB N
the DT N
incidence NN N
of IN N
minor JJ N
complications NNS N
. . N

Salmeterol NNP 1_i
versus VBZ N
slow-release JJ N
theophylline NN 1_i
combined VBN N
with IN N
ketotifen NN 1_i
in IN N
nocturnal JJ 1_p
asthma NN 1_p
: : 1_p
a DT N
multicentre JJ 1_p
trial NN N
. . N

French JJ 1_p
Multicentre NNP 1_p
Study NNP 1_p
Group NNP 1_p
. . 1_p

We PRP N
wished VBD N
to TO N
assess VB N
the DT N
efficacy NN 1_o
of IN N
inhaled JJ N
salmeterol NN 1_i
( ( N
SML NNP N
; : N
50 CD N
micrograms NNS N
b.i.d RB N
. . N

) ) N
compared VBN N
to TO N
a DT N
combination NN N
of IN N
slow-release JJ N
theophylline NN 1_i
and CC 1_i
ketotifen NN 1_i
p.o NN N
. . N

( ( N
TK NNP N
; : N
T NNP N
300 CD N
mg+K NN N
1 CD N
mg NN N
b.i.d NN N
. . N

) ) N
for IN N
the DT N
treatment NN N
of IN N
nocturnal JJ N
asthma NN N
. . N

Ninety NNP 1_p
six CD 1_p
patients NNS 1_p
with IN 1_p
nocturnal JJ 1_p
asthma NN 1_p
, , 1_p
( ( 1_p
forced JJ 1_p
expiratory NN 1_p
volume NN 1_p
in IN 1_p
one CD 1_p
second NN 1_p
( ( 1_p
FEV1 NNP 1_p
) ) 1_p
60-90 CD 1_p
% NN 1_p
of IN 1_p
predicted JJ 1_p
value NN 1_p
, , 1_p
reversibility NN 1_p
> NN 1_p
or CC 1_p
= VB 1_p
15 CD 1_p
% NN 1_p
, , 1_p
at IN 1_p
least JJS 1_p
two CD 1_p
nocturnal JJ 1_p
awakenings NNS 1_p
per IN 1_p
week NN 1_p
) ) 1_p
were VBD N
eligible JJ N
for IN N
a DT N
multicentre NN 1_p
, , N
double-blind JJ N
, , N
double-dummy JJ N
cross-over NN N
study NN N
( ( N
14-day JJ N
run-in NN N
, , N
two CD N
successive JJ N
28-day JJ N
treatment NN N
periods NNS N
) ) N
. . N

Efficacy NN 1_o
was VBD 1_o
assessed VBN 1_o
as IN 1_o
success/failure NN 1_o
, , 1_o
success NN 1_o
being VBG N
defined VBN N
as IN N
the DT N
complete JJ N
disappearance NN N
of IN N
nocturnal JJ N
symptoms/awakening NN N
during IN N
the DT N
last JJ N
week NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

There EX N
was VBD N
a DT N
statistically RB 1_o
significant JJ 1_o
difference NN 1_o
between IN N
SML NNP N
and CC N
TK NNP N
for IN N
this DT N
criterion NN N
: : N
46 CD N
% NN N
and CC N
39 CD N
% NN N
success NN N
with IN N
SML NNP N
during IN N
periods NNS N
I PRP N
( ( N
first JJ N
28-day JJ N
period NN N
) ) N
and CC N
II NNP N
( ( N
following VBG N
the DT N
cross-over NN N
) ) N
, , N
compared VBN N
to TO N
only RB N
15 CD N
% NN N
and CC N
26 CD N
% NN N
with IN N
TK NNP N
, , N
respectively RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

SML NNP N
was VBD N
also RB N
significantly RB N
better RBR N
for IN N
the DT N
other JJ 1_o
criteria NNS 1_o
( ( 1_o
lung NN 1_o
function NN 1_o
, , 1_o
rescue NN 1_o
salbutamol NNS 1_o
intake VBP 1_o
during IN 1_o
day NN 1_o
and CC 1_o
night NN 1_o
) ) 1_o
. . 1_o

Side-effects NNS 1_o
were VBD N
five CD N
times NNS N
less RBR N
frequent JJ N
in IN N
SML-treated JJ N
patients NNS N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
. . N

Efficacy NN 1_o
and CC 1_o
tolerance NN 1_o
of IN N
SML NNP N
were VBD N
obviously RB N
far RB N
better JJR N
than IN N
those DT N
of IN N
TK NNP N
in IN N
patients NNS 1_p
with IN 1_p
nocturnal JJ 1_p
asthma NN 1_p
. . 1_p

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
or CC 1_p
atrial JJ 1_p
flutter NN 1_p
. . 1_p

BACKGROUND NNP N
Diltiazem NNP 1_i
, , N
a DT N
calcium NN N
channel NN N
blocker NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
in IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
and/or IN 1_p
atrial JJ 1_p
flutter NN 1_p
. . 1_p

However RB N
, , N
there EX N
have VBP N
been VBN N
no DT N
pharmacokinetic/pharmacodynamic JJ N
studies NNS N
of IN N
diltiazem NN N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ 1_i
diltiazem NNS 1_i
were VBD N
determined VBN N
in IN N
32 CD 1_p
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
or CC 1_p
atrial JJ 1_p
flutter NN 1_p
( ( 1_p
mean JJ 1_p
+/- NN 1_p
SD NNP 1_p
age NN 1_p
, , 1_p
66 CD 1_p
+/- JJ 1_p
7 CD 1_p
years NNS 1_p
; : 1_p
mean VB 1_p
baseline JJ 1_p
heart NN 1_p
rate NN 1_p
, , 1_p
131 CD 1_p
+/- JJ 1_p
10 CD 1_p
beats NNS 1_p
per IN 1_p
minute NN 1_p
) ) 1_p
after IN 1_p
20 CD 1_p
mg NN 1_p
or CC 1_p
20 CD 1_p
mg NN 1_p
followed VBN 1_p
by IN 1_p
25-mg JJ 1_p
bolus NN 1_p
doses NNS 1_p
and CC 1_p
a DT 1_p
10 CD 1_p
and CC 1_p
15 CD 1_p
mg/hr NN 1_p
infusion NN 1_p
for IN 1_p
24 CD 1_p
hours NNS 1_p
. . N

After IN N
the DT N
10 CD N
and CC N
15 CD N
mg/hr JJ N
infusions NNS N
of IN N
diltiazem NN 1_i
, , N
mean JJ N
+/- JJ N
SD NNP N
elimination NN N
half-life NN N
was VBD N
6.8 CD N
+/- JJ N
1.8 CD N
and CC N
6.9 CD N
+/- JJ N
1.5 CD N
hours NNS N
, , N
volume NN N
of IN N
distribution NN N
was VBD N
411 CD N
+/- JJ N
151.8 CD N
and CC N
299 CD N
+/- JJ N
70.8 CD N
I PRP N
, , N
and CC N
systemic JJ N
clearance NN N
was VBD N
42 CD N
+/- JJ N
12.4 CD N
and CC N
31 CD N
+/- JJ N
8.3 CD N
l/hr NN N
, , N
respectively RB N
. . N

Percentages NNS 1_o
of IN 1_o
the DT 1_o
plasma JJ 1_o
concentrations NNS 1_o
of IN 1_o
the DT 1_o
principal JJ 1_o
metabolites NNS 1_o
desacetyldiltiazem NNS 1_o
and CC 1_o
N-desmethyldiltiazem NNP 1_o
to TO 1_o
diltiazem VB 1_o
were VBD N
< JJ N
15 CD N
% NN N
and CC N
< $ N
10 CD N
% NN N
, , N
respectively RB N
. . N

Thirty NNP 1_p
of IN 1_p
32 CD 1_p
patients NNS 1_p
maintained VBD N
response NN N
throughout IN N
the DT N
24-hour JJ N
infusion NN N
of IN N
diltiazem NN N
. . N

Using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
pharmacodynamic JJ N
model NN N
, , N
a DT N
strong JJ N
relation NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
0.78 CD N
+/- JJ N
0.2 CD N
) ) N
was VBD N
observed VBN N
between IN N
plasma NN 1_o
diltiazem NN 1_o
concentration NN 1_o
and CC 1_o
percent JJ 1_o
heart NN 1_o
rate NN 1_o
reduction NN 1_o
. . 1_o

Mean JJ 1_o
+/- JJ 1_o
SD NNP 1_o
Emax NNP 1_o
( ( N
maximum JJ N
percent NN N
reduction NN N
in IN N
heart NN N
rate NN N
from IN N
baseline NN N
) ) N
and CC N
EC50 NNP 1_o
( ( N
plasma JJ N
diltiazem NN N
concentration NN N
that WDT N
achieves VBZ N
half DT N
Emax NNP N
) ) N
were VBD N
52 CD N
+/- JJ N
17 CD N
% NN N
and CC N
110 CD N
+/- JJ N
84 CD N
ng/ml NN N
, , N
respectively RB N
. . N

The DT N
model NN N
predicts VBZ N
that IN N
mean JJ N
plasma NN 1_o
diltiazem NN 1_o
concentration NN 1_o
of IN N
79 CD N
, , N
172 CD N
, , N
and CC N
294 CD N
ng/ml NNS N
are VBP N
required VBN N
to TO N
produce VB N
a DT N
20 CD N
% NN N
, , N
30 CD N
% NN N
, , N
and CC N
40 CD N
% NN N
reduction NN N
in IN N
heart NN 1_o
rate NN 1_o
, , N
respectively RB N
. . N

A DT N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent NN N
change NN N
in IN N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
SBP NNP 1_o
) ) 1_o
or CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
DBP NNP 1_o
) ) 1_o
from IN N
baseline NN N
was VBD N
not RB N
observed VBN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
SBP/DBP NNP N
: : N
0.35 CD N
+/- JJ N
0.24/0.36 CD N
+/- JJ N
0.2 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
untoward JJ N
side NN N
effects NNS N
observed VBN N
. . N

CONCLUSIONS NNP N
First NNP N
, , N
the DT N
pharmacokinetics NNS N
of IN N
diltiazem NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
or CC 1_p
atrial JJ 1_p
flutter NN 1_p
is VBZ N
nonlinear JJ N
with IN N
an DT N
apparent JJ N
dose-dependent JJ N
decrease NN N
in IN N
systemic JJ N
clearance NN N
with IN N
increasing VBG N
infusion NN N
rate NN N
. . N

Second NNP N
, , N
using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
model NN N
, , N
there EX N
is VBZ N
a DT N
strong JJ N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent JJ N
heart NN N
rate NN N
reduction NN N
. . N

Third NNP N
, , N
the DT N
plasma JJ N
concentrations NNS N
of IN N
the DT N
principal JJ N
metabolites NNS N
desacetyldiltiazem NNS N
and CC N
N-desmethyldiltiazem NNP N
are VBP N
low JJ N
and CC N
are VBP N
not RB N
expected VBN N
to TO N
contribute VB N
significantly RB N
to TO N
the DT N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS N
in IN N
these DT N
patients NNS N
. . N

Gradual NNP N
withdrawal NN N
of IN N
diazepam NN 1_i
after IN N
long-term JJ N
therapy NN N
. . N

41 CD 1_p
outpatients NNS 1_p
who WP 1_p
were VBD 1_p
long-term JJ 1_p
consumers NNS 1_p
of IN 1_p
diazepam NN 1_i
in IN 1_p
therapeutic JJ 1_p
dosage NN 1_p
were VBD 1_p
gradually RB 1_p
withdrawn VBN 1_p
from IN 1_p
the DT 1_p
drug NN 1_p
over IN 1_p
3 CD 1_p
months NNS 1_p
by IN 1_p
stepwise NN 1_p
reduction NN 1_p
. . 1_p

In IN N
a DT N
double-blind JJ N
procedure NN N
half PDT N
the DT N
patients NNS N
began VBD N
withdrawal JJ N
immediately RB N
and CC N
half NN N
after IN N
8 CD N
weeks NNS N
. . N

Of IN N
36 CD 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
treatment NN 1_p
, , N
16 CD N
( ( N
44.4 CD N
% NN N
) ) N
experienced VBD N
true JJ 1_o
withdrawal NN 1_o
phenomena NN 1_o
on IN N
reducing VBG N
their PRP$ N
drugs NNS N
, , N
but CC N
8 CD N
other JJ N
patients NNS N
had VBD N
pseudo-withdrawal JJ 1_o
reactions NNS 1_o
at IN N
a DT N
time NN N
when WRB N
their PRP$ N
drug NN N
treatment NN N
was VBD N
unchanged JJ N
. . N

The DT N
pseudo-withdrawal JJ 1_o
reactions NNS 1_o
consisted VBD N
of IN N
an DT N
increase NN N
in IN N
anxiety NN 1_o
symptoms NNS 1_o
only RB N
, , N
whereas NNS N
true JJ 1_o
withdrawal NN 1_o
symptoms NNS 1_o
also RB N
included VBD N
perceptual JJ 1_o
changes NNS 1_o
and CC 1_o
psychotic JJ 1_o
symptoms NNS 1_o
. . 1_o

Examination NN N
of IN N
pharmacological JJ N
and CC N
clinical JJ N
predictors NNS N
of IN N
withdrawal NN 1_o
phenomena NN 1_o
and CC N
later RB N
relapse NN 1_o
showed VBD N
that IN N
personality NN N
factors NNS N
were VBD N
the DT N
most RBS N
important JJ N
, , N
patients NNS N
with IN N
passive-dependent JJ N
traits NNS N
having VBG N
a DT N
significantly RB N
greater JJR N
prevalence NN N
of IN N
withdrawal NN 1_o
reactions NNS 1_o
. . 1_o

Learning VBG N
about IN N
the DT N
equal JJ N
sign NN N
: : N
does VBZ N
comparing VBG N
with IN N
inequality NN N
symbols NNS N
help VB N
? . N
This DT 1_i
study NN 1_i
investigated VBD 1_i
whether IN 1_i
instruction NN 1_i
that WDT 1_i
involves VBZ 1_i
comparing VBG 1_i
the DT 1_i
equal JJ 1_i
sign NN 1_i
with IN 1_i
other JJ 1_i
relational JJ 1_i
symbols NNS 1_i
is VBZ 1_i
more RBR 1_i
effective JJ 1_i
at IN 1_i
imparting VBG 1_i
a DT 1_i
relational JJ 1_o
interpretation NN 1_o
of IN 1_o
the DT 1_o
equal JJ 1_o
sign NN 1_o
than IN 1_i
instruction NN 1_i
about IN 1_i
the DT 1_i
equal JJ 1_i
sign NN 1_i
alone RB 1_i
. . 1_i

Third- JJ 1_i
and CC 1_i
fourth-grade JJ 1_i
students NNS 1_i
in IN 1_i
a DT 1_i
comparing NN 1_i
symbols NNS 1_i
group NN 1_i
learned VBD 1_i
about IN 1_i
the DT 1_i
greater JJR 1_i
than IN 1_i
, , 1_i
less JJR 1_i
than IN 1_i
, , 1_i
and CC 1_i
equal JJ 1_i
signs NNS 1_i
and CC 1_i
had VBD 1_i
the DT 1_i
opportunity NN 1_i
to TO 1_i
compare VB 1_i
the DT 1_i
inequality NN 1_i
symbols VBZ 1_i
with IN 1_i
the DT 1_i
equal JJ 1_i
sign NN 1_i
. . 1_i

Students NNS 1_i
in IN 1_i
an DT 1_i
equal JJ 1_i
sign NN 1_i
group NN 1_i
learned VBD 1_i
about IN 1_i
the DT 1_i
equal JJ 1_i
sign NN 1_i
only RB 1_i
. . 1_i

A NNP 1_i
third JJ 1_i
group NN 1_i
of IN 1_i
students NNS 1_i
served VBD 1_i
as IN 1_i
a DT 1_i
control NN 1_i
group NN 1_i
. . 1_i

Three CD N
aspects NNS N
of IN N
students NNS N
' POS N
knowledge NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
lesson NN N
: : N
( ( N
a DT N
) ) N
conceptual JJ 1_o
understanding NN 1_o
of IN 1_o
the DT 1_o
equal JJ 1_o
sign NN 1_o
, , N
( ( N
b NN N
) ) N
equation NN 1_o
encoding NN 1_o
, , N
and CC N
( ( N
c NN N
) ) N
problem NN 1_o
solving VBG 1_o
. . 1_o

Students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
showed VBD N
greater JJR N
gains NNS N
in IN N
conceptual JJ 1_o
understanding NN 1_o
from IN N
pretest NN N
to TO N
posttest VB N
than IN N
students NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
and CC N
students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
also RB N
scored VBD N
higher JJR N
on IN N
a DT N
posttest NN 1_o
that WDT 1_o
assessed VBD 1_o
knowledge NN 1_o
about IN 1_o
inequality NN 1_o
symbols NNS 1_o
and CC 1_o
inequality NN 1_o
problem NN 1_o
solving VBG 1_o
. . 1_o

Thus RB N
, , N
they PRP N
learned VBD N
about IN N
three CD N
symbols NNS N
in IN N
the DT N
same JJ N
amount NN N
of IN N
time NN N
as IN N
other JJ N
students NNS N
learned VBD N
about IN N
the DT N
equal JJ N
sign NN N
alone RB N
or CC N
not RB N
at IN N
all DT N
. . N

Therefore NNP N
, , N
an DT N
instructional JJ N
approach NN N
involving VBG N
comparison NN N
can MD N
be VB N
an DT N
effective JJ N
tool NN N
for IN N
learning VBG N
about IN N
concepts NNS N
in IN N
mathematics NNS N
. . N

A DT N
chinese JJ N
mind-body NN N
exercise NN N
improves VBZ N
self-control NN 1_o
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Self-control JJ 1_o
problems NNS N
commonly RB N
manifest VBP N
as IN N
temper NN N
outbursts NNS N
and CC N
repetitive/rigid/impulsive JJ N
behaviors NNS N
, , N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
, , N
which WDT N
often RB N
contributes VBZ N
to TO N
learning VBG N
difficulties NNS N
and CC N
caregiver NN N
burden NN N
. . N

The DT N
present JJ N
study NN N
aims NNS N
to TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
traditional JJ 1_i
Chinese JJ 1_i
Chan-based JJ 1_i
mind-body NN 1_i
exercise NN 1_i
, , 1_i
Nei NNP 1_i
Yang NNP 1_i
Gong NNP 1_i
, , N
with IN N
that DT N
of IN N
the DT N
conventional JJ 1_i
Progressive NNP 1_i
Muscle NNP 1_i
Relaxation NNP 1_i
( ( 1_i
PMR NNP 1_i
) ) 1_i
technique NN 1_i
in IN N
enhancing VBG N
the DT N
self-control NN 1_o
of IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Forty-six NNP 1_p
age- JJ 1_p
and CC 1_p
IQ-matched JJ 1_p
ASD NNP 1_p
children NNS 1_p
were VBD N
randomly RB 1_i
assigned VBN 1_i
to TO 1_i
receive VB 1_i
group NN 1_i
training NN 1_i
in IN 1_i
Nei NNP 1_i
Yang NNP 1_i
Gong NNP 1_i
( ( 1_i
experimental JJ 1_i
group NN 1_i
) ) 1_i
or CC 1_i
PMR NNP 1_i
( ( 1_i
control VB 1_i
group NN 1_i
) ) 1_i
twice RB 1_i
per IN 1_i
week NN 1_i
for IN 1_i
four CD 1_i
weeks NNS 1_i
. . 1_i

The DT N
participants NNS N
' POS N
self-control NN N
was VBD N
measured VBN 1_i
by IN 1_i
three CD 1_i
neuropsychological JJ 1_o
tests NNS 1_o
and CC 1_i
parental JJ 1_o
rating NN 1_o
on IN 1_o
standardized JJ 1_o
questionnaires NNS 1_o
, , 1_i
and CC 1_i
the DT 1_i
underlying JJ 1_i
neural JJ 1_i
mechanism NN 1_i
was VBD 1_i
assessed VBN 1_i
by IN 1_i
the DT 1_i
participants NNS 1_i
' POS 1_i
brain NN 1_i
EEG NNP 1_i
activity NN 1_i
during IN 1_i
an DT 1_i
inhibitory-control JJ 1_i
task NN 1_i
before IN 1_i
and CC 1_i
after IN 1_i
intervention NN 1_i
. . 1_i

The DT N
results NNS N
show VBP N
that IN N
the DT N
experimental JJ N
group NN N
demonstrated VBD N
significantly RB N
greater JJR N
improvement NN 1_o
in IN 1_o
self-control NN 1_o
than IN N
the DT N
control NN N
group NN N
, , N
which WDT N
concurs VBZ N
with IN N
the DT N
parental JJ N
reports NNS N
of IN N
reduced VBN N
autistic JJ 1_o
symptoms NNS 1_o
and CC N
increased VBD N
control NN 1_o
of IN 1_o
temper NN 1_o
and CC 1_o
behaviors NNS 1_o
. . 1_o

In IN N
addition NN N
, , N
the DT N
experimental JJ N
group NN N
showed VBD N
enhanced JJ 1_o
EEG NNP 1_o
activity NN 1_o
in IN N
the DT N
anterior JJ N
cingulate NN N
cortex NN N
, , N
a DT N
region NN N
that WDT N
mediates VBZ N
self-control NN N
, , N
whereas IN N
the DT N
PMR NNP N
group NN N
did VBD N
not RB N
. . N

The DT N
present JJ N
findings NNS N
support VBP N
the DT N
potential JJ N
application NN N
of IN N
Chinese JJ N
Chan-based JJ 1_i
mind-body NN 1_i
exercises NNS 1_i
as IN N
a DT N
form NN N
of IN N
neuropsychological JJ N
rehabilitation NN N
for IN N
patients NNS 1_p
with IN 1_p
self-control JJ 1_o
problems NNS 1_p
. . 1_p

Chinese JJ N
Clinical JJ N
Trial NNP N
Registry NNP N
; : N
Registration NNP N
No NNP N
. . N

: : N
ChiCTR-TRC-12002561 JJ N
; : N
URL NNP N
: : N
www.chictr.org NN N
. . N

Laryngeal JJ N
preservation NN N
with IN N
induction NN 1_i
chemotherapy NN 1_i
for IN N
hypopharyngeal NN 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
: : 1_p
10-year JJ N
results NNS N
of IN N
EORTC NNP N
trial NN N
24891 CD N
. . N

BACKGROUND NNP N
We PRP N
report VBP N
the DT N
10-year JJ N
results NNS N
of IN N
the DT N
EORTC NNP N
trial NN N
24891 CD N
comparing VBG N
a DT N
larynx-preservation JJ 1_i
approach NN 1_i
to TO 1_p
immediate VB 1_i
surgery NN 1_i
in IN 1_p
hypopharynx NN 1_p
and CC 1_p
lateral JJ 1_p
epilarynx NN 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
. . 1_p

MATERIAL NNP N
AND CC N
METHODS NNP N
Two CD 1_p
hundred CD 1_p
and CC 1_p
two CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
surgical JJ N
approach NN N
( ( 1_i
total JJ 1_i
laryngectomy NN 1_i
with IN 1_i
partial JJ 1_i
pharyngectomy NN 1_i
and CC 1_i
neck NN 1_i
dissection NN 1_i
, , 1_i
followed VBN 1_i
by IN 1_i
irradiation NN 1_i
) ) 1_i
or CC 1_i
to TO 1_i
the DT 1_i
chemotherapy NN 1_i
arm NN 1_i
up IN 1_i
to TO 1_i
three CD 1_i
cycles NNS 1_i
of IN 1_i
induction NN 1_i
chemotherapy NN 1_i
( ( 1_i
cisplatin JJ 1_i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
+ CD N
5-FU JJ N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1-5 JJ N
) ) N
followed VBD N
for IN N
complete JJ N
responders NNS N
by IN N
irradiation NN 1_i
and CC N
otherwise RB N
by IN N
conventional JJ 1_i
treatment NN 1_i
. . 1_i

The DT N
end NN N
points NNS N
were VBD N
overall JJ 1_o
survival JJ 1_o
[ NN N
OS NNP N
, , N
noninferiority NN N
: : N
hazard NN N
ratio NN N
( ( N
preservation/surgery NN N
) ) N
≤ VBZ N
1.428 CD N
, , N
one-sided JJ N
α NNP N
= NNP N
0.05 CD 1_o
] NNP 1_o
, , 1_o
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
and CC 1_o
survival JJ 1_o
with IN 1_o
a DT 1_o
functional JJ 1_o
larynx NN 1_o
( ( 1_o
SFL NNP 1_o
) ) 1_o
. . N

RESULTS NNP N
At IN N
a DT N
median JJ N
follow-up NN N
of IN N
10.5 CD N
years NNS N
on IN 1_p
194 CD 1_p
eligible JJ 1_p
patients NNS 1_o
, , 1_o
disease JJ 1_o
evolution NN 1_o
was VBD N
seen VBN N
in IN N
54 CD N
and CC N
49 CD N
patients NNS N
in IN N
the DT N
surgery NN N
and CC N
chemotherapy NN N
arm NN N
, , N
respectively RB N
, , N
and CC N
81 CD N
and CC N
83 CD N
patients NNS N
had VBD N
died VBN N
. . N

The DT 1_o
10-year JJ 1_o
OS NNP 1_o
rate NN 1_o
was VBD N
13.8 CD N
% NN N
in IN N
the DT N
surgery NN N
arm NN N
and CC N
13.1 CD N
% NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
. . N

The DT 1_o
10-year JJ 1_o
PFS NNP 1_o
rates NNS 1_o
were VBD N
8.5 CD N
% NN N
and CC N
10.8 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
the DT N
chemotherapy NN N
arm NN N
, , N
the DT 1_o
10-year JJ 1_o
SFL NNP 1_o
rate NN 1_o
was VBD N
8.7 CD N
% NN N
. . N

CONCLUSION NNP N
This DT N
strategy NN N
did VBD N
not RB N
compromise VB 1_o
disease NN 1_o
control NN 1_o
or CC 1_o
survival NN 1_o
( ( N
that IN N
remained VBD N
poor JJ N
) ) N
and CC N
allowed VBD N
more JJR N
than IN N
half NN N
of IN N
the DT N
survivors NNS N
to TO N
retain VB N
their PRP$ N
larynx NN N
. . N

[ JJ N
Effect NNP N
of IN N
zengjing VBG 1_i
no DT 1_i
. . 1_i

1 CD 1_i
capsule NN 1_i
on IN N
morphology NN 1_o
and CC 1_o
motility NN 1_o
of IN 1_o
sperm NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
oligospermia JJ 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Zengjing VBG 1_i
Capsule NNP 1_i
No NNP 1_i
. . 1_i

1 CD 1_i
( ( 1_i
ZJC1 NNP 1_i
) ) 1_i
on IN N
morphology NN N
and CC N
motility NN N
of IN N
sperm NN N
in IN N
patients NNS 1_p
with IN 1_p
oligospermia NN 1_p
( ( 1_p
OSM NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Seventy-two JJ 1_p
OSM NNP 1_p
patients NNS 1_p
were VBD N
assigned VBN N
to TO N
2 CD N
groups NNS N
by IN N
a DT N
randomizing JJ N
digital NN N
table NN N
, , N
the DT N
treated VBN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
they PRP N
were VBD N
treated VBN N
respectively RB N
by IN N
ZJC1 NNP 1_i
and CC N
Wuzi NNP 1_i
Yanzong NNP 1_i
Pill NNP 1_i
( ( N
WYP NNP N
) ) N
. . N

The DT N
changes NNS 1_o
of IN 1_o
density NN 1_o
, , 1_o
motility NN 1_o
and CC 1_o
morphology NN 1_o
of IN 1_o
sperm NN 1_o
in IN N
patients NNS N
before IN N
and CC N
after IN N
3-month JJ N
treatment NN N
were VBD N
examined VBN N
using VBG N
computerized JJ N
WLJY-9000 CD N
colour JJ N
semen NNS 1_o
analysis NN 1_o
system NN 1_o
with IN N
refined JJ N
Papanicolaou NNP N
's POS N
stain NN N
. . N

RESULTS VB N
The DT N
density NN 1_o
, , 1_o
motility NN 1_o
and CC 1_o
morphology NN 1_o
of IN 1_o
sperm NN 1_o
were VBD N
improved VBN N
and CC N
sperm JJ 1_o
deformity NN 1_o
rate NN 1_o
was VBD N
significantly RB N
decreased VBN N
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
the DT N
effects NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
better JJR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
ZJC1 NNP 1_i
can MD N
enhance VB N
the DT N
density NN 1_o
and CC 1_o
motility NN 1_o
of IN 1_o
sperm NN 1_o
and CC N
reduce VB N
the DT N
sperm JJ 1_o
deformity NN 1_o
rate NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
OSM NNP 1_p
. . 1_p

[ JJ N
Results NNP N
of IN N
three-year JJ N
clinical JJ N
study NN N
of IN N
prostamol NN 1_i
uno JJ 1_i
efficacy NN 1_o
and CC N
safety NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
initial JJ 1_p
symptoms NNS 1_p
of IN 1_p
prostatic JJ 1_p
adenoma NN 1_p
and CC 1_p
risk NN 1_p
of IN 1_p
its PRP$ 1_p
progression NN 1_p
] NN 1_p
. . N

Prostamol NNP 1_i
Uno NNP 1_i
( ( 1_i
PU NNP 1_i
) ) 1_i
efficacy NN 1_o
and CC N
safety NN 1_o
were VBD N
studied VBN N
in IN N
a DT N
multicenter NN 1_p
, , 1_p
open-population NN 1_p
, , N
randomized VBN N
and CC N
comparative JJ N
trial NN N
. . N

PU NNP 1_i
was VBD N
given VBN N
in IN N
a DT N
single JJ N
daily JJ N
dose VB N
320 CD N
mg NN N
for IN N
36 CD N
months NNS N
to TO N
50 CD 1_p
patients NNS 1_p
with IN 1_p
initial JJ 1_p
symptoms NNS 1_p
of IN 1_p
prostatic JJ 1_p
adenoma NN 1_p
( ( 1_p
PA NNP 1_p
) ) 1_p
in IN 1_p
comparison NN 1_p
with IN 1_p
50 CD 1_p
matched JJ 1_p
controls NNS 1_p
. . 1_p

The DT N
trial NN N
evaluated VBD N
PU NNP 1_i
action NN N
on IN N
the DT N
symptoms NNS 1_o
progression NN 1_o
and CC N
quality NN 1_o
of IN 1_o
life NN 1_o
with IN N
application NN N
of IN N
questionnaires NNS 1_o
IPSS NNP 1_o
and CC 1_o
QoL NNP 1_o
( ( 1_o
BS NNP 1_o
) ) 1_o
. . 1_o

It PRP N
was VBD N
found VBN N
that IN N
PU NNP N
treatment NN N
relieved VBD N
PA NNP 1_o
symptoms NNS 1_o
by IN N
IPSS NNP N
, , N
while IN N
these DT N
symptoms NNS N
progressed VBD N
in IN N
the DT N
controls NNS N
. . N

QoL NNP 1_o
improved VBD N
in IN N
the DT N
study NN N
group NN N
and CC N
deteriorated VBN N
in IN N
the DT N
control NN N
one CD N
. . N

Administration NN N
of IN N
PU NNP N
significantly RB N
increased VBD N
urinary JJ 1_o
flow NN 1_o
rate NN 1_o
though IN N
in IN N
the DT N
controls NNS N
urinary JJ 1_o
flow NN 1_o
rate NN 1_o
decreased VBN N
, , N
size NN 1_o
of IN 1_o
the DT 1_o
prostate NN 1_o
diminished VBD N
and CC N
increased VBD N
, , N
respectively RB N
. . N

Changes NNS N
in IN N
the DT N
PSA NNP 1_o
were VBD N
not RB N
seen VBN N
and CC N
were VBD N
insignificant JJ N
, , N
respectively RB N
. . N

The DT N
results NNS N
of IN N
the DT N
study NN N
say VBP N
that IN N
prostamol NN N
Uno NNP N
in IN N
a DT N
dose JJ N
320 CD N
mg/day NN N
can MD N
prevent VB N
PA NNP N
progression NN N
without IN N
side JJ 1_o
effects NNS 1_o
. . 1_o

The DT N
effect NN N
of IN N
endoscopic NN 1_i
fundoplication NN 1_i
and CC 1_i
proton NN 1_i
pump NN 1_i
inhibitors NNS 1_i
on IN N
baseline NN 1_o
impedance NN 1_o
and CC 1_o
heartburn NN N
severity NN 1_o
in IN N
GERD NNP 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Antireflux NNP N
therapy NN N
may MD N
lead VB N
to TO N
recovery NN N
of IN N
impaired JJ N
mucosal NN N
integrity NN N
in IN N
gastro-esophageal JJ 1_p
reflux NN 1_p
disease NN 1_p
( ( 1_p
GERD NNP 1_p
) ) 1_p
patients NNS 1_p
as IN N
reflected VBN N
by IN N
an DT N
increase NN 1_o
in IN 1_o
baseline JJ 1_o
impedance NN 1_o
. . 1_o

The DT N
study NN N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
endoscopic NN 1_i
fundoplication NN 1_i
and CC 1_i
proton NN 1_i
pump NN 1_i
inhibitor NN 1_i
( ( 1_i
PPI NNP 1_i
) ) 1_i
PPI NNP 1_i
therapy NN 1_i
on IN N
baseline NN 1_o
impedance NN 1_o
and CC 1_o
heartburn NN 1_o
severity NN 1_o
in IN N
GERD NNP 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
Forty-seven JJ 1_p
GERD NNP 1_p
patients NNS 1_p
randomized VBD 1_p
to TO 1_p
endoscopic VB 1_i
fundoplication NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
32 CD 1_p
) ) 1_p
or CC 1_i
PPI NNP 1_i
therapy NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
15 CD 1_p
) ) 1_p
, , 1_p
and CC 1_p
29 CD 1_p
healthy JJ 1_p
controls NNS 1_p
were VBD 1_p
included VBN 1_p
. . N

Before IN N
randomization NN N
and CC N
6 CD N
months NNS N
after IN 1_i
treatment NN 1_o
, , 1_o
baseline NN 1_o
impedance NN 1_o
was VBD 1_i
obtained VBN 1_i
during IN 1_i
24-h JJ 1_i
pH-impedance NN 1_i
monitoring NN 1_o
. . 1_o

Heartburn NNP 1_o
severity NN 1_o
was VBD 1_o
evaluated VBN 1_o
using VBG 1_o
the DT 1_o
GERD-HRQL NNP 1_o
questionnaire NN 1_o
. . N

KEY NNP N
RESULTS NNP N
Before IN N
treatment NN 1_o
, , 1_o
baseline NN 1_o
impedance NN 1_o
in IN 1_p
GERD NNP 1_p
patients NNS 1_p
was VBD N
lower JJR N
than IN 1_p
in IN 1_p
healthy JJ 1_p
controls NNS 1_p
( ( N
p VB N
< RB N
0.001 CD N
) ) N
. . N

Antireflux NNP N
therapy NN N
increased VBD 1_o
baseline JJ 1_o
impedance NN 1_o
( ( N
from IN N
1498 CD N
[ JJ N
IQR NNP N
951-2472 CD N
] NN N
to TO N
2393 CD N
[ NNP N
IQR NNP N
1353-3027 JJ N
] NNP N
Ω NNP N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
, , N
however RB N
it PRP N
only RB 1_o
led VBD 1_o
to TO 1_o
a DT 1_o
partial JJ 1_o
recovery NN N
when WRB N
compared VBN N
to TO N
healthy JJ N
controls NNS N
( ( N
2393 CD N
[ NNP N
IQR NNP N
1353-3027 JJ N
] NNP N
vs NN N
2983 CD N
[ NNP N
2335-3810 JJ N
] NNP N
Ω NNP N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
effect NN N
of IN N
both DT N
treatment NN N
options NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
despite IN N
the DT N
increased JJ 1_o
number NN 1_o
of IN 1_o
non-acid JJ 1_o
reflux NN 1_i
events NNS 1_i
in IN N
the DT 1_o
PPI NNP 1_o
group NN 1_o
. . 1_o

No DT N
correlation NN N
was VBD 1_o
found VBN 1_o
between IN 1_o
baseline NN 1_o
impedance NN 1_o
and CC 1_o
GERD NNP N
symptoms NNS N
before IN N
or CC N
after IN N
treatment NN N
. . N

CONCLUSIONS NNP N
& CC N
INFERENCES NNP N
Reduction NNP N
in IN N
acid NN 1_i
reflux NN 1_i
by IN 1_i
endoscopic JJ 1_i
fundoplication NN 1_i
or CC N
PPI NNP N
therapy VBP N
leads VBZ N
to TO N
an DT 1_o
increase NN 1_o
in IN 1_o
baseline JJ 1_o
impedance NN 1_p
in IN 1_p
GERD NNP N
patients NNS N
, , N
likely RB N
to TO N
reflect VB N
recovery NN N
of IN N
mucosal NN N
integrity NN N
. . N

The DT N
impact NN N
of IN N
non-acid JJ N
reflux NN N
events NNS N
on IN N
esophageal NN N
mucosal NN N
integrity NN N
may MD N
be VB N
limited VBN N
as IN N
no DT N
difference NN N
in IN N
the DT 1_o
increase NN 1_o
in IN 1_o
baseline JJ 1_o
impedance NN N
was VBD N
observed VBN N
after IN N
both DT N
treatment NN N
options NNS N
. . N

The DT N
lack NN N
of IN N
association NN 1_o
between IN 1_o
impedance NN 1_o
baseline NN 1_o
and CC 1_o
heartburn NN 1_o
severity NN N
indicates VBZ N
that IN N
other JJ N
factors NNS N
may MD N
contribute VB N
to TO N
heartburn VB N
perception NN N
in IN N
GERD NNP N
. . N

Pilot NNP N
comparison NN N
between IN N
potassium NN 1_i
titanyl NN 1_i
phosphate NN 1_i
laser NN 1_i
and CC 1_i
bipolar JJ 1_i
radiofrequency NN 1_i
in IN N
paediatric JJ 1_p
tonsillectomy NN 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
advantages NNS N
and CC N
disadvantages NNS N
of IN N
potassium NN 1_i
titanyl NN 1_i
phosphate NN 1_i
laser NN 1_i
with IN 1_i
those DT 1_i
of IN 1_i
bipolar JJ 1_i
radiofrequency NN 1_i
techniques NNS 1_i
, , N
in IN N
paediatric JJ 1_o
tonsillectomy NN 1_o
. . 1_o

STUDY NNP N
DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
clinical JJ N
study NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP 1_p
July NNP 1_p
2004 CD 1_p
to TO 1_p
April NNP 1_p
2006 CD 1_p
, , 1_p
80 CD 1_p
patients NNS 1_p
aged VBN 1_p
between IN 1_p
10 CD 1_p
and CC 1_p
15 CD 1_p
years NNS 1_p
, , 1_p
with IN 1_p
tonsillectomy NN 1_i
planned VBN 1_p
for IN 1_p
chronic JJ 1_p
tonsillitis NN 1_p
, , 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Children NNP N
were VBD N
prospectively RB N
randomised VBN N
into IN N
two CD N
equal JJ N
groups NNS N
: : N
potassium NN 1_i
titanyl NN 1_i
phosphate NN 1_i
laser NN 1_i
tonsillectomy NN 1_i
and CC 1_i
bipolar JJ 1_i
radiofrequency NN 1_i
tonsillectomy NN 1_i
. . 1_i

Operative JJ N
time NN N
and CC N
intra-operative JJ N
blood NN N
loss NN N
were VBD N
recorded VBN N
. . N

Patients NNS N
were VBD N
scheduled VBN N
for IN N
follow VB N
up RP N
during IN N
the DT N
first JJ N
, , N
second JJ N
and CC N
fourth JJ N
post-operative JJ N
weeks NNS N
. . N

They PRP N
were VBD N
asked VBN N
to TO N
record VB N
their PRP$ N
pain NN N
and CC N
discomfort NN N
on IN N
a DT N
standardised JJ N
visual JJ N
analogue NN N
scale NN N
, , N
from IN N
zero CD N
( ( N
no DT N
pain NN N
) ) N
to TO N
10 CD N
( ( N
severe JJ N
pain NN N
) ) N
. . N

Post-operative JJ N
complications NNS N
were VBD N
also RB N
recorded VBN N
and CC N
managed VBN N
. . N

RESULTS VB N
The DT N
potassium NN 1_i
titanyl NN 1_i
phosphate VBP 1_i
laser NN 1_i
group NN 1_i
showed VBD N
a DT N
slightly RB N
longer RBR 1_o
operative JJ 1_o
time NN 1_o
( ( N
mean JJ N
12 CD N
minutes NNS N
) ) N
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
mean JJ N
10 CD N
minutes NNS N
) ) N
. . N

Intra-operative JJ 1_o
blood NN 1_o
loss NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
potassium NN 1_i
titanyl NN 1_i
phosphate VBP 1_i
laser NN 1_i
group NN N
( ( N
mean JJ N
21 CD N
cm3 NN N
) ) N
than IN N
in IN N
the DT N
bipolar JJ 1_i
radiofrequency NN 1_i
group NN 1_i
( ( N
mean JJ N
30 CD N
cm3 NN N
) ) N
. . N

In IN N
the DT N
first JJ N
week NN N
, , N
post-operative JJ 1_o
pain NN 1_o
scores NNS 1_o
were VBD N
less RBR N
in IN N
the DT N
potassium NN 1_i
titanyl NN 1_i
phosphate VBP 1_i
laser NN 1_i
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
7.5 CD N
and CC N
8.5 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
second JJ N
week NN N
pain NN 1_o
scores NNS 1_o
increased VBD N
more RBR N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
8.5 CD N
and CC N
6 CD N
, , N
respectively RB N
) ) N
. . N

In IN N
the DT N
fourth JJ N
week NN N
, , N
both DT N
groups NNS N
showed VBD N
equal JJ N
and CC N
nearly RB N
normal JJ N
pain NN 1_o
scores NNS 1_o
. . 1_o

No DT N
case NN N
of IN N
reactionary JJ 1_o
post-tonsillectomy JJ 1_o
haemorrhage NN 1_o
was VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Only RB N
one CD N
case NN N
of IN N
secondary JJ 1_o
post-tonsillectomy JJ 1_o
haemorrhage NN 1_o
was VBD N
recorded VBN N
, , N
in IN N
the DT N
potassium NN N
titanyl NN N
phosphate VBP N
laser NN N
group NN N
( ( N
2.5 CD N
per IN N
cent NN N
) ) N
, , N
managed VBD N
conservatively RB N
. . N

CONCLUSION NNP N
Both NNP N
the DT N
potassium NN 1_i
titanyl NN 1_i
phosphate NN 1_i
and CC 1_i
the DT 1_i
bipolar JJ 1_i
radiofrequency NN 1_i
techniques NNS 1_i
were VBD N
safe JJ 1_o
and CC 1_o
easy JJ 1_o
to TO 1_o
use VB 1_o
for IN N
tonsillectomy NN 1_o
, , N
with IN N
reduced VBN N
operative JJ 1_o
time NN 1_o
, , 1_o
blood NN 1_o
loss NN 1_o
and CC 1_o
complication NN 1_o
rates NNS 1_o
and CC N
better JJR N
post-operative JJ N
general JJ N
patient NN N
condition NN N
. . N

Potassium NNP 1_i
titanyl JJ 1_i
phosphate NN 1_i
laser NN 1_i
resulted VBD N
in IN N
reduced JJ N
operative JJ 1_o
bleeding NN 1_o
and CC 1_o
immediate JJ 1_o
post-operative JJ 1_o
pain NN 1_o
, , N
compared VBN N
with IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

However RB N
, , N
potassium NN 1_i
titanyl NN 1_i
phosphate VBP 1_i
laser NN 1_i
required VBN N
slightly RB N
more RBR N
operative JJ 1_o
time NN 1_o
and CC N
caused VBD N
more JJR N
late JJ 1_o
post-operative JJ 1_o
pain NN 1_o
than IN N
the DT N
bipolar JJ N
radiofrequency NN N
technique NN N
. . N

The DT N
low JJ N
rate NN N
of IN N
recorded VBN N
complications NNS N
showed VBD N
that IN N
both DT N
techniques NNS N
cause VBP N
little JJ N
damage NN N
to TO N
the DT N
tonsillar JJ N
bed NN N
during IN N
dissection NN N
, , N
thus RB N
minimising VBG N
complications NNS N
. . N

Tacrolimus/sirolimus NNP 1_i
vs NN 1_i
tacrolimus/methotrexate NN 1_i
as IN N
GVHD NNP N
prophylaxis NN N
after IN 1_p
matched VBN 1_p
, , N
related VBN N
donor NN 1_p
allogeneic NN 1_p
HCT NNP 1_p
. . 1_p

Grades NNP N
2-4 JJ N
acute JJ N
graft-versus-host JJ N
disease NN N
( ( N
GVHD NNP N
) ) N
occurs VBZ N
in IN N
approximately RB N
35 CD N
% NN N
of IN N
matched VBN 1_p
, , 1_p
related VBN 1_p
donor NN 1_p
( ( 1_p
MRD NNP 1_p
) ) 1_p
allogeneic VBZ 1_p
hematopoietic JJ 1_p
cell NN 1_p
transplantation NN 1_p
( ( 1_p
HCT NNP 1_p
) ) 1_p
recipients NNS 1_p
. . 1_p

We PRP N
sought VBD N
to TO N
determine VB N
if IN N
the DT N
combination NN N
of IN N
tacrolimus NN 1_i
and CC 1_i
sirolimus NN 1_i
( ( 1_i
Tac/Sir NNP 1_i
) ) 1_i
was VBD N
more RBR N
effective JJ N
than IN N
tacrolimus NN 1_i
and CC 1_i
methotrexate NN 1_i
( ( 1_i
Tac/Mtx NNP 1_i
) ) 1_i
in IN N
preventing VBG N
acute JJ N
GVHD NNP N
and CC N
early JJ N
mortality NN N
after IN N
allogeneic JJ N
MRD NNP N
HCT NNP N
in IN N
a DT N
phase NN N
3 CD N
, , N
multicenter JJR N
trial NN N
. . N

The DT N
primary JJ 1_o
end NN 1_o
point NN 1_o
of IN N
the DT N
trial NN N
was VBD N
to TO N
compare VB N
114-day JJ 1_o
grades NNS 1_o
2-4 JJ 1_o
acute JJ 1_o
GVHD-free NNP 1_o
survival NN 1_o
using VBG N
an DT N
intention-to-treat JJ N
analysis NN N
of IN N
304 CD 1_p
randomized JJ 1_p
subjects NNS 1_p
. . 1_p

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
probability NN N
of IN N
day NN N
114 CD N
grades NNS N
2-4 JJ N
acute JJ N
GVHD-free JJ N
survival NN N
( ( N
67 CD N
% NN N
vs JJ N
62 CD N
% NN N
, , N
P NNP N
= NNP N
.38 NNP N
) ) N
. . N

Grades NNP 1_o
2-4 JJ 1_o
GVHD NNP 1_o
was VBD N
similar JJ N
in IN N
the DT N
Tac/Sir NNP N
and CC N
Tac/Mtx NNP N
arms NNS N
( ( N
26 CD N
% NN N
vs JJ N
34 CD N
% NN N
, , N
P NNP N
= NNP N
.48 NNP N
) ) N
. . N

Neutrophil NNP 1_o
and CC 1_o
platelet VB 1_o
engraftment NN 1_o
were VBD N
more RBR N
rapid JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
14 CD N
vs RB N
16 CD N
days NNS N
, , N
P NNP N
< NNP N
.001 NNP N
; : N
16 CD N
vs IN N
19 CD N
days NNS N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Oropharyngeal NNP 1_o
mucositis NN 1_o
was VBD N
less RBR N
severe JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
peak JJ N
Oral NNP 1_o
Mucositis NNP 1_o
Assessment NNP 1_o
Scale NNP 1_o
score VBD 1_o
0.70 CD N
vs NN N
0.96 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
but CC N
otherwise RB N
toxicity NN 1_o
was VBD N
similar JJ N
. . N

Chronic NNP 1_o
GVHD NNP 1_o
, , 1_o
relapse-free JJ 1_o
survival NN 1_o
, , 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
at IN 1_o
2 CD 1_o
years NNS 1_o
were VBD N
no DT N
different JJ N
between IN N
study NN N
arms NNS N
( ( N
53 CD N
% NN N
vs JJ N
45 CD N
% NN N
, , N
P NNP N
= NNP N
.06 NNP N
; : N
53 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
P NNP N
= NNP N
.77 NNP N
; : N
and CC N
59 CD N
% NN N
vs JJ N
63 CD N
% NN N
, , N
P NNP N
= NNP N
.36 NNP N
) ) N
. . N

Based VBN N
on IN N
similar JJ N
long-term JJ N
outcomes NNS N
, , N
more RBR N
rapid JJ N
engraftment NN N
, , N
and CC N
less JJR N
oropharyngeal JJ N
mucositis NN N
, , N
the DT N
combination NN N
of IN N
Tac/Sir NNP N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
to TO N
Tac/Mtx NNP N
after IN 1_p
MRD NNP 1_p
HCT NNP 1_p
. . 1_p

This DT N
study NN N
was VBD N
funded VBN N
by IN N
the DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
and CC N
the DT N
National NNP N
Cancer NNP N
Institute NNP N
; : N
and CC N
the DT N
trial NN N
was VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00406393 NNP N
. . N

[ RB N
Clinical NNP N
study NN N
of IN N
feiyanqing VBG 1_i
rectum NN 1_i
condensed VBD 1_i
liquid NN 1_i
in IN N
treating VBG N
36 CD N
cases NNS N
of IN N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanism NN N
of IN N
Feiyangqin NNP 1_i
Rectum NNP 1_i
Condensed VBD 1_i
Liquid NNP 1_i
( ( 1_i
FRCL NNP 1_i
) ) 1_i
in IN N
treating VBG N
children NNS 1_p
syncytial JJ 1_p
viral JJ 1_p
pneumonia NN 1_p
. . 1_p

Methods NNS N
Seventy-two JJ 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
two CD 1_p
groups NNS 1_p
, , 1_p
the DT 1_p
36 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
treated JJ 1_p
group NN 1_p
were VBD 1_p
treated VBN 1_p
with IN 1_p
FRCL NNP 1_i
, , 1_p
and CC 1_p
the DT 1_p
other JJ 1_p
36 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
control NN 1_p
group NN 1_p
simply RB 1_p
treated VBD 1_p
with IN 1_p
Western JJ 1_i
medicine NN 1_i
. . 1_i

Efficacy NN 1_o
of IN N
treatment NN N
on IN N
clinical JJ N
condition NN N
and CC N
some DT N
immune JJ 1_o
function NN 1_o
( ( 1_o
IgA NNP 1_o
, , 1_o
IgG NNP 1_o
, , 1_o
CD3 NNP 1_o
, , 1_o
CD4 NNP 1_o
) ) 1_o
were VBD N
observed VBN N
. . N

RESULTS NNP N
In IN N
the DT N
treated JJ N
group NN N
, , N
28 CD N
patients NNS N
were VBD N
cured VBN 1_o
( ( N
77.8 CD N
% NN N
) ) N
, , N
treatment NN N
was VBD N
markedly RB N
effective JJ N
in IN N
4 CD N
patients NNS N
( ( N
11.1 CD N
% NN N
) ) N
, , N
effective JJ N
in IN N
2 CD N
( ( N
5.5 CD N
% NN N
) ) N
and CC N
ineffective JJ N
in IN N
2 CD N
( ( N
5.6 CD N
% NN N
) ) N
, , N
with IN N
the DT N
total JJ 1_o
effective JJ 1_o
rate NN 1_o
of IN N
94.4 CD N
% NN N
. . N

The DT N
corresponding JJ N
number NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
20 CD N
( ( N
55.6 CD N
% NN N
) ) N
, , N
7 CD N
( ( N
19.4 CD N
% NN N
) ) N
, , N
6 CD N
( ( N
16.7 CD N
% NN N
) ) N
, , N
3 CD N
( ( N
8.3 CD N
% NN N
) ) N
and CC N
91.7 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
cure NN 1_o
rate NN 1_o
in IN N
the DT N
treated JJ N
group NN N
was VBD N
obviously RB N
superior JJ N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

FRCL NNP 1_i
could MD N
improve VB N
serum NN 1_o
IgA NNP 1_o
, , 1_o
IgG NNP 1_o
, , 1_o
CD3 NNP 1_o
, , 1_o
CD4 NNP 1_o
, , 1_o
and CC 1_o
CD4/CD8 NNP 1_o
, , 1_o
lower JJR 1_o
serum NN 1_o
IgE NNP 1_o
, , N
these DT N
indexes NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
significantly RB N
different JJ N
to TO N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
FRCL NNP 1_i
had VBD N
the DT N
action NN N
in IN N
treating VBG N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
without IN N
any DT N
adverse JJ N
reaction NN N
, , N
one CD N
of IN N
its PRP$ N
mechanisms NNS N
might MD N
be VB N
related VBN N
to TO N
its PRP$ N
regulation NN N
on IN N
immune JJ N
function NN N
. . N

Efficacy NN 1_o
of IN N
azithromycin NN 1_i
for IN N
the DT N
treatment NN N
of IN N
feline JJ 1_p
chlamydophilosis NN 1_p
. . 1_p

The DT N
current JJ N
recommended VBD N
treatment NN N
for IN N
feline JJ 1_p
chlamydophilosis NN 1_p
involves VBZ N
daily RB N
oral JJ N
administration NN N
of IN N
antimicrobials NNS 1_i
to TO N
all DT N
cats NNS 1_p
within IN 1_p
an DT 1_p
affected JJ 1_p
group NN 1_p
for IN N
a DT N
prolonged JJ N
period NN N
of IN N
time NN N
( ( N
4-6 JJ N
weeks NNS N
) ) N
. . N

Not RB N
surprisingly RB N
, , N
owner NN N
compliance NN N
can MD N
be VB N
poor JJ N
resulting VBG N
in IN N
apparent JJ N
treatment NN N
failure NN N
. . N

Recent JJ N
anecdotal JJ N
evidence NN N
, , N
supported VBN N
by IN N
its PRP$ N
efficacy NN 1_o
in IN N
the DT N
treatment NN N
of IN N
Chlamydia NNP N
trachomatis NN N
infection NN N
in IN N
humans NNS N
, , N
has VBZ N
suggested VBN N
that IN N
azithromycin NN 1_i
may MD N
offer VB N
an DT N
alternative JJ N
by IN N
allowing VBG N
less JJR N
frequent JJ N
dosing NN N
for IN N
a DT N
shorter JJR N
duration NN N
. . N

A DT N
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
of IN N
azithromycin NN 1_i
for IN N
the DT N
treatment NN N
of IN N
chlamydia NN 1_p
( ( 1_p
Chlamydophila NNP 1_p
felis RB 1_p
) ) 1_p
infection NN 1_p
in IN 1_p
cats NNS 1_p
. . 1_p

Whilst NNP N
azithromycin NN 1_i
, , N
given VBN N
at IN N
10-15 JJ N
mg/kg NNS N
daily RB N
for IN N
3 CD N
days NNS N
and CC N
then RB N
twice RB N
weekly RB N
, , N
provided VBD N
a DT N
similar JJ 1_o
, , 1_o
rapid JJ 1_o
resolution NN 1_o
of IN 1_o
clinical JJ 1_o
signs NNS 1_o
and CC 1_o
negative JJ 1_o
isolation NN 1_o
scores NNS 1_o
as IN N
doxycycline NN 1_i
, , N
C NNP N
felis NN N
was VBD N
re-isolated VBN N
in IN N
four CD N
out IN N
of IN N
the DT N
five CD 1_p
cats NNS 1_p
treated VBN 1_p
. . 1_p

Furthermore NNP N
, , N
even RB N
daily JJ N
administration NN N
of IN N
azithromycin NN 1_i
to TO N
chronically RB N
infected JJ N
cats NNS N
was VBD N
ineffective JJ 1_o
in IN 1_o
clearing VBG 1_o
infection NN 1_o
. . 1_o

The DT N
azithromycin NN N
protocols NNS N
used VBN N
here RB N
were VBD N
therefore RB N
found VBN N
to TO N
be VB N
unsuccessful JJ 1_o
in IN 1_o
eliminating VBG 1_o
the DT 1_o
carriage NN 1_o
of IN 1_o
this DT 1_o
strain NN 1_o
of IN 1_o
C NNP 1_o
felis NN 1_o
. . 1_o

Is VBZ N
chronic JJ 1_i
sildenafil NN 1_i
therapy NN 1_i
safe JJ N
and CC N
clinically RB N
beneficial JJ N
in IN N
patients NNS 1_p
with IN 1_p
systolic JJ 1_p
heart NN 1_p
failure NN 1_p
? . N
Sildenafil NNP 1_i
is VBZ N
a DT N
selective JJ N
phosphodiesterase-5 JJ N
inhibitor NN N
and CC N
causes VBZ N
vasodilatation NN N
, , N
particularly RB N
in IN N
pulmonary JJ N
circulation NN N
. . N

Since IN N
left JJ 1_p
heart NN 1_p
failure NN 1_p
may MD N
be VB N
associated VBN N
with IN N
pulmonary JJ N
hypertension NN N
" VBZ N
out IN N
of IN N
proportion NN N
to TO N
left VB N
heart NN N
disease NN N
, , N
" NNP N
sildenafil NN 1_i
may MD N
have VB N
beneficial JJ N
effect NN N
in IN N
such JJ N
patients NNS N
. . N

The DT N
present JJ N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
12-week JJ N
, , N
single-center JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
sildenafil NN 1_i
on IN N
mean JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( N
primary JJ N
endpoint NN N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
left JJ 1_p
systolic JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

Secondary JJ N
endpoints NNS N
included VBD N
exercise NN 1_o
capacity NN 1_o
assessed VBN N
by IN N
6-minute JJ 1_o
walk NN 1_o
test NN 1_o
. . 1_o

A DT N
total NN N
of IN N
106 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
1:1 CD 1_p
to TO 1_p
sildenafil VB 1_i
( ( 1_p
n=53 NN 1_p
) ) 1_p
or CC 1_p
placebo NN 1_i
( ( 1_p
n=53 JJ 1_p
) ) 1_p
. . 1_p

Patients NNS 1_p
received VBD 1_p
sildenafil JJ 1_i
25 CD 1_p
mg NN 1_p
twice RB 1_p
a DT 1_p
day NN 1_p
or CC 1_p
matching VBG 1_p
placebo NN 1_i
for IN 1_p
the DT 1_p
first JJ 1_p
2 CD 1_p
weeks NNS 1_p
and CC 1_p
50 CD 1_p
mg NN 1_p
3 CD 1_p
times NNS 1_p
a DT 1_p
week NN 1_p
for IN 1_p
the DT 1_p
remainder NN 1_p
of IN 1_p
the DT 1_p
trial NN 1_p
. . 1_p

The DT N
placebo-corrected JJ N
effect NN N
on IN N
mean JJ 1_o
blood NN 1_o
pressure NN 1_o
was VBD N
1.16 CD N
mm NN N
Hg NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-1.6 VBP N
to TO N
5.1 CD N
, , N
P NNP N
> NNP N
.05 NNP N
) ) N
, , N
demonstrating VBG N
that IN N
sildenafil NN N
did VBD N
not RB N
decrease VB N
mean JJ 1_o
blood NN 1_o
pressure NN 1_o
. . 1_o

Compared VBN N
with IN N
placebo NN N
, , N
sildenafil NN 1_i
increased VBD N
the DT N
6-minute JJ 1_o
walk NN 1_o
test NN 1_o
by IN N
a DT N
nonsignificant JJ N
treatment NN N
effect NN N
of IN N
14 CD N
m NN N
( ( N
P=.67 NNP N
) ) N
. . N

Adverse JJ 1_o
effects NNS 1_o
occurred VBD N
in IN N
a DT N
comparable JJ N
proportion NN N
of IN N
patients NNS N
taking VBG N
sildenafil JJ 1_i
and CC N
placebo NN N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
needed VBN N
to TO N
discontinue VB N
therapy NN N
. . N

Sildenafil NNP N
is VBZ N
well RB N
tolerated VBN 1_o
in IN N
left JJ 1_p
heart NN 1_p
failure NN 1_p
patients NNS 1_p
and CC N
does VBZ N
not RB N
decrease VB N
blood NN 1_o
pressure NN 1_o
. . 1_o

It PRP N
can MD N
be VB N
safely RB N
added VBN N
to TO N
standard VB N
heart NN N
failure NN N
therapy NN N
. . N

Preliminary JJ N
examination NN N
of IN N
a DT N
cartoon-based JJ 1_i
hostile JJ 1_o
attributional NN 1_o
bias NN 1_o
measure NN 1_o
for IN N
urban JJ 1_p
African JJ 1_p
American JJ 1_p
boys NNS 1_p
. . 1_p

The DT N
current JJ N
study NN N
illustrates VBZ N
how WRB N
researchers NNS N
developed VBD N
and CC N
validated VBD N
a DT N
cartoon-based JJ 1_i
adaptation NN 1_i
of IN N
a DT N
written VBN N
hostile JJ 1_o
attributional JJ 1_o
bias NN 1_o
measure NN 1_o
for IN N
a DT N
sample NN 1_p
of IN 1_p
urban JJ 1_p
, , 1_p
low-income JJ 1_p
, , 1_p
African JJ 1_p
American NNP 1_p
boys NN 1_p
. . 1_p

A DT N
series NN N
of IN N
studies NNS N
were VBD N
conducted VBN N
to TO N
develop VB N
cartoon NN N
illustrations NNS N
to TO N
accompany VB N
a DT N
standard JJ 1_o
written VBN 1_o
hostile JJ 1_o
attributional JJ 1_o
bias NN 1_o
vignette NN 1_o
measure NN 1_o
( ( N
Study NNP N
1 CD N
) ) N
, , N
to TO N
determine VB N
initial JJ N
psychometric JJ 1_o
properties NNS 1_o
( ( N
Study NNP N
2 CD N
) ) N
and CC N
acceptability NN 1_o
( ( N
Study NNP N
3 CD N
) ) N
, , N
and CC N
to TO N
conduct VB N
a DT N
test-retest JJ 1_o
reliability NN 1_o
trial NN N
of IN N
the DT N
adapted JJ N
measure NN N
in IN N
a DT N
separate JJ N
sample NN N
( ( N
Study NNP N
4 CD N
) ) N
. . N

These DT N
studies NNS N
utilize VBP N
a DT N
participatory JJ N
action NN N
research NN N
approach NN N
to TO N
measurement VB N
design NN N
and CC N
adaptation NN N
, , N
and CC N
suggest VBP N
that IN N
collaborations NNS N
between IN N
researchers NNS N
and CC N
key JJ N
school NN N
stakeholders NNS N
can MD N
lead VB N
to TO N
measures NNS N
that WDT N
are VBP N
psychometrically RB N
strong JJ N
, , N
developmentally RB N
appropriate JJ N
, , N
and CC N
culturally RB N
sensitive JJ N
. . N

In IN N
addition NN N
, , N
the DT N
cartoon-based JJ 1_i
hostile JJ 1_o
attributional NN 1_o
bias NN 1_o
measure NN 1_o
appears VBZ N
to TO N
have VB N
promise NN N
as IN N
an DT N
assessment NN N
and/or NN N
outcome NN N
measure NN N
for IN N
aggression NN N
and CC N
bullying VBG N
prevention NN N
programs NNS N
conducted VBN N
with IN N
urban JJ 1_p
African JJ 1_p
American JJ 1_p
boys NNS 1_p
. . 1_p

Thrombus NNP N
aspiration NN N
reduces NNS N
microvascular JJ 1_o
obstruction NN 1_o
after IN N
primary JJ 1_p
coronary JJ 1_p
intervention NN 1_p
: : 1_p
a DT N
myocardial JJ N
contrast NN N
echocardiography NN N
substudy NN N
of IN N
the DT N
REMEDIA NNP N
Trial NNP N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
clarify VB N
the DT N
role NN N
of IN N
microembolization NN N
in IN N
the DT N
genesis NN N
of IN N
microvascular JJ 1_o
obstruction NN 1_o
( ( 1_o
MO NNP 1_o
) ) 1_o
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

BACKGROUND NNP N
Fifty NNP 1_p
consecutive JJ 1_p
patients NNS 1_p
entered VBD 1_p
the DT 1_p
myocardial JJ 1_p
contrast NN 1_p
echocardiography NN 1_p
( ( 1_p
MCE NNP 1_p
) ) 1_p
substudy NN 1_p
of IN 1_p
the DT 1_p
REMEDIA NNP 1_p
( ( 1_p
Randomized NNP 1_p
Evaluation NNP 1_p
of IN 1_p
the DT 1_p
Effect NNP 1_p
of IN 1_p
Mechanical NNP 1_p
Reduction NNP 1_p
of IN 1_p
Distal NNP 1_p
Embolization NNP 1_p
by IN 1_p
Thrombus NNP 1_p
Aspiration NNP 1_p
in IN 1_p
Primary NNP 1_p
and CC 1_p
Rescue NNP 1_p
Angioplasty NNP 1_p
) ) 1_p
trial NN 1_p
, , N
which WDT N
defined VBD N
the DT N
role NN N
of IN N
a DT N
new JJ N
thrombus-aspirating JJ N
device NN N
in IN N
preventing VBG N
distal JJ N
microembolization NN 1_o
after IN N
PCI NNP N
. . N

METHODS NNP N
A NNP N
total NN 1_p
of IN 1_p
25 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
be VB 1_p
pretreated VBN 1_p
with IN 1_p
thrombus JJ 1_i
aspiration NN 1_i
before IN 1_i
PCI NNP 1_i
of IN 1_i
the DT 1_i
culprit NN 1_i
lesion NN 1_i
and CC 1_i
25 CD 1_p
received JJ 1_p
standard JJ 1_i
PCI NNP 1_i
. . 1_i

At IN N
24 CD N
h NN N
, , N
1 CD N
week NN N
, , N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
, , N
MCE NNP N
was VBD N
performed VBN N
by IN N
Sonovue NNP N
, , N
and CC N
real-time JJ N
imaging NN N
was VBD N
performed VBN N
by IN N
contrast NN N
pulse JJ N
sequencing VBG N
technology NN N
. . N

Regional NNP 1_o
wall NN 1_o
motion NN 1_o
score NN 1_o
index NN 1_o
( ( 1_o
WMSI NNP 1_o
) ) 1_o
, , 1_o
contrast RB 1_o
score NN 1_o
index NN 1_o
( ( 1_o
CSI NNP 1_o
) ) 1_o
, , 1_o
endocardial JJ 1_o
length NN 1_o
of IN 1_o
wall NN 1_o
motion NN 1_o
abnormality NN 1_o
( ( 1_o
WML NNP 1_o
) ) 1_o
and CC 1_o
contrast NN 1_o
defect NN 1_o
( ( 1_o
CDL NNP 1_o
) ) 1_o
, , 1_o
end-diastolic JJ 1_o
and CC 1_o
end-systolic JJ 1_o
left NN 1_o
ventricular NN 1_o
( ( 1_o
LV NNP 1_o
) ) 1_o
volumes NNS 1_o
, , 1_o
and CC 1_o
ejection NN 1_o
fraction NN 1_o
were VBD N
calculated VBN N
. . N

RESULTS NNP N
At IN N
each DT N
time NN N
point NN N
, , N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
thrombus-aspiration NN N
filter NN N
device NN N
, , N
WMSI NNP 1_o
, , 1_o
CSI NNP 1_o
, , 1_o
WML NNP 1_o
, , 1_o
and CC 1_o
CDL NNP 1_o
were VBD N
significantly RB N
lower JJR N
and CC N
ejection NN 1_o
fraction NN 1_o
higher JJR N
( ( N
p JJ N
< $ N
0.05 CD N
vs. FW N
control NN N
patients NNS N
) ) N
, , N
whereas JJ N
LV NNP 1_o
volumes NNS 1_o
were VBD N
slightly RB N
but CC N
not RB N
significantly RB N
smaller JJR N
compared VBN N
with IN N
control NN N
patients NNS N
. . N

In IN N
the DT N
overall JJ N
study NN N
population NN N
, , N
the DT N
extent NN 1_o
of IN 1_o
MO NNP 1_o
significantly RB N
correlated VBD N
with IN N
temporal JJ N
changes NNS N
in IN N
LV NNP 1_o
volumes NNS 1_o
. . 1_o

CONCLUSIONS NNP N
Thrombus NNP N
aspiration NN N
used VBN N
at IN N
the DT N
time NN N
of IN N
PCI NNP N
significantly RB N
reduces VBZ N
the DT N
extent NN 1_o
of IN 1_o
MO NNP 1_o
and CC N
myocardial JJ 1_o
dysfunction NN 1_o
, , N
although IN N
it PRP N
does VBZ N
not RB N
have VB N
a DT N
significant JJ N
favorable JJ N
effect NN N
in IN N
preventing VBG N
LV NNP 1_o
remodeling VBG 1_o
. . 1_o

Thus RB N
, , N
the DT N
beneficial JJ N
effect NN N
of IN N
thrombus NN N
aspiration NN N
occurs VBZ N
at IN N
the DT N
microvascular JJ N
level NN N
, , N
but CC N
additional JJ N
mechanisms NN N
may MD N
play VB N
a DT N
role NN N
in IN N
influencing VBG N
the DT N
final JJ N
extent NN N
of IN N
MO NNP 1_o
, , N
which WDT N
strictly RB N
correlates VBZ N
with IN N
post-infarct JJ N
LV NNP 1_o
remodeling NN 1_o
. . 1_o

Afatinib NNP 1_i
versus NN N
cisplatin-based JJ 1_i
chemotherapy NN 1_i
for IN 1_p
EGFR NNP 1_p
mutation-positive JJ 1_p
lung NN 1_p
adenocarcinoma NN 1_p
( ( 1_p
LUX-Lung JJ 1_p
3 CD 1_p
and CC 1_p
LUX-Lung NNP 1_p
6 CD 1_p
) ) 1_p
: : 1_p
analysis NN N
of IN N
overall JJ 1_o
survival NN 1_o
data NNS N
from IN N
two CD N
randomised VBD N
, , N
phase NN N
3 CD N
trials NNS N
. . N

BACKGROUND IN N
We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
afatinib NN 1_i
on IN N
overall JJ 1_o
survival NN 1_o
of IN N
patients NNS 1_p
with IN 1_p
EGFR NNP 1_p
mutation-positive JJ 1_p
lung NN 1_p
adenocarcinoma NN 1_p
through IN N
an DT N
analysis NN N
of IN N
data NNS N
from IN N
two CD N
open-label JJ N
, , N
randomised VBN N
, , N
phase VB N
3 CD N
trials NNS N
. . N

METHODS NNP N
Previously RB 1_p
untreated VBD 1_p
patients NNS 1_p
with IN 1_p
EGFR NNP 1_p
mutation-positive JJ 1_p
stage NN 1_p
IIIB NNP 1_p
or CC 1_p
IV NNP 1_p
lung NN 1_p
adenocarcinoma NN 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
LUX-Lung NNP 1_i
3 CD 1_i
( ( 1_p
n=345 NN 1_p
) ) 1_p
and CC 1_p
LUX-Lung JJ 1_i
6 CD 1_i
( ( 1_p
n=364 NN 1_p
) ) 1_p
. . 1_p

These DT N
patients NNS N
were VBD N
randomly RB 1_i
assigned VBN 1_i
in IN 1_i
a DT 1_i
2:1 CD 1_i
ratio NN 1_i
to TO 1_i
receive VB 1_i
afatinib NN 1_i
or CC 1_i
chemotherapy NN 1_i
( ( 1_i
pemetrexed-cisplatin JJ 1_i
[ NNP 1_i
LUX-Lung NNP 1_i
3 CD 1_i
] NN 1_i
or CC 1_i
gemcitabine-cisplatin JJ 1_i
[ JJ 1_i
LUX-Lung NNP 1_i
6 CD 1_i
] NN 1_i
) ) 1_i
, , 1_i
stratified VBN 1_i
by IN 1_i
EGFR NNP 1_i
mutation NN 1_i
( ( 1_i
exon JJ 1_i
19 CD 1_i
deletion NN 1_i
[ NNP 1_i
del19 NN 1_i
] NNP 1_i
, , 1_i
Leu858Arg NNP 1_i
, , 1_i
or CC 1_i
other JJ 1_i
) ) 1_i
and CC 1_i
ethnic JJ 1_i
origin NN 1_i
( ( 1_i
LUX-Lung NNP 1_i
3 CD 1_i
only RB 1_i
) ) 1_i
. . 1_i

We PRP N
planned VBD N
analyses NNS N
of IN N
mature NN N
overall JJ N
survival NN N
data NNS N
in IN N
the DT N
intention-to-treat JJ N
population NN 1_p
after IN N
209 CD N
( ( N
LUX-Lung NNP N
3 CD N
) ) N
and CC N
237 CD N
( ( N
LUX-Lung NNP N
6 CD N
) ) N
deaths NNS N
. . N

These DT N
ongoing JJ N
studies NNS N
are VBP N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
numbers NNS N
NCT00949650 NNP N
and CC N
NCT01121393 NNP N
. . N

FINDINGS NNP N
Median JJ N
follow-up NN N
in IN N
LUX-Lung NNP N
3 CD N
was VBD N
41 CD N
months NNS N
( ( N
IQR NNP N
35-44 NNP N
) ) N
; : N
213 CD N
( ( N
62 CD N
% NN N
) ) N
of IN N
345 CD 1_p
patients NNS 1_p
had VBD N
died VBN N
. . N

Median JJ N
follow-up NN N
in IN N
LUX-Lung NNP N
6 CD N
was VBD N
33 CD N
months NNS N
( ( N
IQR NNP N
31-37 NNP N
) ) N
; : N
246 CD N
( ( N
68 CD N
% NN N
) ) N
of IN N
364 CD N
patients NNS N
had VBD N
died VBN N
. . N

In IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ 1_o
survival NN 1_o
was VBD N
28.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
24.6-33.6 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
and CC N
28.2 CD N
months NNS N
( ( N
20.7-33.2 JJ N
) ) N
in IN N
the DT N
pemetrexed-cisplatin JJ N
group NN N
( ( N
HR NNP N
0.88 CD N
, , N
95 CD N
% NN N
CI NNP N
0.66-1.17 CD N
, , N
p=0.39 NN N
) ) N
. . N

In IN N
LUX-Lung NNP N
6 CD N
, , N
median JJ N
overall JJ 1_o
survival NN 1_o
was VBD N
23.1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
20.4-27.3 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
and CC N
23.5 CD N
months NNS N
( ( N
18.0-25.6 JJ N
) ) N
in IN N
the DT N
gemcitabine-cisplatin JJ N
group NN N
( ( N
HR NNP N
0.93 CD N
, , N
95 CD N
% NN N
CI NNP N
0.72-1.22 CD N
, , N
p=0.61 NN N
) ) N
. . N

However RB N
, , N
in IN N
preplanned JJ N
analyses NNS N
, , N
overall JJ 1_o
survival NN 1_o
was VBD N
significantly RB N
longer JJR N
for IN N
patients NNS N
with IN N
del19-positive JJ N
tumours NNS N
in IN N
the DT N
afatinib NN N
group NN N
than IN N
in IN N
the DT N
chemotherapy NN N
group NN N
in IN N
both DT N
trials NNS N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ 1_o
survival NN 1_o
was VBD N
33.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
26.8-41.5 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
21.1 CD N
months NNS N
( ( N
16.3-30.7 JJ N
) ) N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
HR NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
0.36-0.79 CD N
, , N
p=0.0015 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
31.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
24.2-35.3 CD N
) ) N
versus NN N
18.4 CD N
months NNS N
( ( N
14.6-25.6 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
0.64 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.94 CD N
, , N
p=0.023 NN N
) ) N
. . N

By IN N
contrast NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
by IN N
treatment NN N
group NN N
for IN N
patients NNS 1_p
with IN 1_p
EGFR NNP 1_p
Leu858Arg-positive JJ N
tumours NNS N
in IN N
either DT N
trial NN N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ 1_o
survival NN 1_o
was VBD N
27.6 CD N
months NNS N
( ( N
19.8-41.7 JJ N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
40.3 CD N
months NNS N
( ( N
24.3-not JJ N
estimable NN N
) ) N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
HR NNP N
1.30 CD N
, , N
95 CD N
% NN N
CI NNP N
0.80-2.11 CD N
, , N
p=0.29 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
19.6 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
17.0-22.1 CD N
) ) N
versus NN N
24.3 CD N
months NNS N
( ( N
19.0-27.0 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
1.22 CD N
, , N
95 CD N
% NN N
CI NNP N
0.81-1.83 CD N
, , N
p=0.34 NN N
) ) N
. . N

In IN N
both DT N
trials NNS N
, , N
the DT N
most RBS N
common JJ N
afatinib-related JJ N
grade JJ 1_o
3-4 JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
rash JJ 1_o
or CC 1_o
acne NN 1_o
( ( N
37 CD N
[ RB N
16 CD N
% NN N
] NN N
of IN N
229 CD 1_p
patients NNS 1_p
in IN 1_p
LUX-Lung NNP 1_p
3 CD 1_p
and CC N
35 CD N
[ JJ N
15 CD N
% NN N
] NN N
of IN N
239 CD 1_p
patients NNS 1_p
in IN 1_p
LUX-Lung NNP 1_p
6 CD N
) ) N
, , N
diarrhoea NN 1_o
( ( N
33 CD N
[ RB N
14 CD N
% NN N
] NN N
and CC N
13 CD N
[ JJ N
5 CD N
% NN N
] NN N
) ) N
, , N
paronychia FW 1_o
( ( N
26 CD N
[ RB N
11 CD N
% NN N
] NN N
in IN N
LUX-Lung NNP N
3 CD N
only RB N
) ) N
, , N
and CC N
stomatitis NN 1_o
or CC 1_o
mucositis NN 1_o
( ( N
13 CD N
[ RB N
5 CD N
% NN N
] NN N
in IN N
LUX-Lung NNP N
6 CD N
only RB N
) ) N
. . N

In IN N
LUX-Lung NNP N
3 CD N
, , N
neutropenia NN 1_o
( ( N
20 CD N
[ RB N
18 CD N
% NN N
] NN N
of IN N
111 CD N
patients NNS N
) ) N
, , N
fatigue NN 1_o
( ( N
14 CD N
[ RB N
13 CD N
% NN N
] NN N
) ) N
and CC N
leucopenia $ 1_o
( ( N
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
were VBD N
the DT N
most RBS N
common JJ N
chemotherapy-related JJ N
grade JJ N
3-4 JJ N
adverse JJ N
events NNS N
, , N
while IN N
in IN N
LUX-Lung NNP N
6 CD N
, , N
the DT N
most RBS N
common JJ N
chemotherapy-related JJ N
grade JJ 1_o
3-4 JJ 1_o
adverse JJ 1_o
events NNS 1_o
were VBD N
neutropenia RB 1_o
( ( N
30 CD N
[ RB N
27 CD N
% NN N
] NN N
of IN N
113 CD N
patients NNS N
) ) N
, , N
vomiting VBG 1_o
( ( N
22 CD N
[ RB N
19 CD N
% NN N
] NN N
) ) N
, , N
and CC N
leucopenia NN 1_o
( ( N
17 CD N
[ RB N
15 CD N
% NN N
] NN N
) ) N
. . N

INTERPRETATION NNP N
Although IN N
afatinib NN N
did VBD N
not RB N
improve VB N
overall JJ N
survival NN N
in IN N
the DT N
whole JJ N
population NN N
of IN N
either DT N
trial NN N
, , N
overall JJ N
survival NN N
was VBD N
improved VBN N
with IN N
the DT N
drug NN N
for IN N
patients NNS 1_p
with IN 1_p
del19 JJ 1_p
EGFR NNP 1_p
mutations NNS 1_p
. . 1_p

The DT N
absence NN N
of IN N
an DT N
effect NN N
in IN N
patients NNS 1_p
with IN 1_p
Leu858Arg NNP 1_p
EGFR NNP 1_p
mutations NNS 1_p
suggests VBZ N
that IN N
EGFR NNP N
del19-positive JJ N
disease NN N
might MD N
be VB N
distinct JJ N
from IN N
Leu858Arg-positive JJ N
disease NN N
and CC N
that IN N
these DT N
subgroups NNS N
should MD N
be VB N
analysed VBN N
separately RB N
in IN N
future JJ N
trials NNS N
. . N

FUNDING NN N
Boehringer NNP N
Ingelheim NNP N
. . N

Hunter NNP N
DBT NNP N
project NN N
: : N
randomized VBN N
controlled VBD N
trial NN N
of IN N
dialectical JJ 1_i
behaviour NN 1_i
therapy NN 1_i
in IN N
women NNS 1_p
with IN 1_p
borderline JJ 1_p
personality NN 1_p
disorder NN 1_p
. . 1_p

OBJECTIVE JJ N
Deliberate NNP N
self-harm NN N
( ( N
DSH NNP N
) ) N
, , N
general JJ N
hospital NN N
admission NN N
and CC N
psychiatric JJ N
hospital NN N
admission NN N
are VBP N
common JJ N
in IN N
women NNS 1_p
meeting VBG 1_p
criteria NNS 1_p
for IN 1_p
borderline NN 1_p
personality NN 1_p
disorder NN 1_p
( ( 1_p
BPD NNP 1_p
) ) 1_p
. . 1_p

Dialectical JJ 1_i
behaviour NN 1_i
therapy NN 1_i
( ( 1_i
DBT NNP 1_i
) ) 1_i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
DSH NNP N
and CC N
hospitalization NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
73 CD 1_p
female JJ 1_p
subjects NNS 1_p
meeting VBG 1_p
criteria NNS 1_p
for IN 1_p
BPD NNP 1_p
was VBD N
carried VBN N
out RP N
with IN N
intention-to-treat JJ N
analyses NNS N
and CC N
per-protocol JJ N
analyses NNS N
. . N

The DT N
intervention NN N
was VBD N
DBT NNP 1_i
and CC N
the DT N
control NN N
condition NN N
was VBD N
treatment NN 1_i
as IN 1_i
usual JJ 1_i
plus CC 1_i
waiting JJ 1_i
list NN 1_i
for IN 1_i
DBT NNP 1_i
( ( 1_i
TAU+WL NNP 1_i
) ) 1_i
, , N
with IN N
outcomes NNS N
measured VBN N
after IN N
6 CD N
months NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
differences NNS N
in IN N
proportions NNS 1_o
and CC 1_o
event NN 1_o
rates NNS 1_o
of IN 1_o
: : 1_o
any DT 1_o
DSH NNP 1_o
; : 1_o
general JJ 1_o
hospital NN 1_o
admission NN 1_o
for IN 1_o
DSH NNP 1_o
and CC 1_o
any DT 1_o
psychiatric JJ 1_o
admission NN 1_o
; : 1_o
and CC 1_o
mean VB 1_o
difference NN 1_o
in IN 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
for IN 1_o
any DT 1_o
hospitalization NN 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
were VBD N
disability NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
measures NNS 1_o
. . 1_o

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
DSH NNP 1_o
and CC 1_o
hospitalizations NNS 1_o
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS 1_o
in IN N
DSH NNP 1_o
, , 1_o
hospital JJ 1_o
admissions NNS 1_o
or CC 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
in IN N
hospital NN N
between IN N
groups NNS N
. . N

Disability NNP 1_o
( ( 1_o
days NNS 1_o
spent VBN 1_o
in IN 1_o
bed NN 1_o
) ) 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
Physical NNP 1_o
, , 1_o
Psychological NNP 1_o
and CC 1_o
Environmental NNP 1_o
domains NNS 1_o
) ) 1_o
were VBD N
significantly RB N
improved VBN N
for IN N
the DT N
DBT NNP N
group NN N
. . N

CONCLUSION NNP N
DBT NNP 1_i
produced VBD N
non-significant JJ N
reductions NNS N
in IN N
DSH NNP 1_o
and CC N
hospitalization NN N
when WRB N
compared VBN N
to TO N
the DT N
TAU+WL NNP N
control NN N
, , N
due JJ N
in IN N
part NN N
to TO N
the DT N
lower JJR N
than IN N
expected VBN N
rates NNS N
of IN N
hospitalization NN N
in IN N
the DT N
control NN N
condition NN N
. . N

Nevertheless NNP N
, , N
DBT NNP 1_i
showed VBD N
significant JJ N
benefits NNS N
for IN N
the DT N
secondary JJ N
outcomes NNS N
of IN N
improved JJ N
disability NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
scores NNS 1_o
, , N
a DT N
clinically RB N
useful JJ N
result NN N
that WDT N
is VBZ N
also RB N
in IN N
keeping VBG N
with IN N
the DT N
theoretical JJ N
constructs NNS N
of IN N
the DT N
benefits NNS N
of IN N
DBT NNP 1_i
. . 1_i

Dietary NNP N
patterns NNS N
differ VBP N
between IN N
urban JJ 1_p
and CC 1_p
rural JJ 1_p
older JJR 1_p
, , 1_p
long-term JJ 1_p
survivors NNS 1_p
of IN 1_p
breast NN 1_p
, , 1_p
prostate NN 1_p
, , 1_p
and CC 1_p
colorectal JJ 1_p
cancer NN 1_p
and CC N
are VBP N
associated VBN N
with IN N
body NN N
mass NN N
index NN N
. . N

BACKGROUND NNP N
Older NNP 1_p
adult NN 1_p
cancer NN 1_p
survivors NNS 1_p
are VBP N
at IN N
greater JJR N
risk NN N
of IN N
cancer NN 1_o
recurrence NN 1_o
and CC N
other JJ N
comorbidities NNS 1_o
that WDT N
can MD N
be VB N
prevented VBN N
through IN N
improved VBN N
diet JJ N
and CC N
weight JJ N
management NN N
. . N

The DT N
tertiary JJ N
prevention NN N
needs NNS N
of IN N
rural-dwelling JJ N
survivors NNS N
can MD N
be VB N
even RB N
greater JJR N
, , N
yet RB N
little JJ N
is VBZ N
known VBN N
about IN N
rural JJ N
and CC N
urban JJ N
differences NNS N
in IN N
lifestyle JJ N
factors NNS N
among IN N
this DT N
high-risk JJ N
population NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB 1_i
dietary JJ 1_i
patterns NNS 1_i
of IN N
urban JJ 1_p
and CC 1_p
rural JJ 1_p
cancer NN 1_p
survivors NNS 1_p
and CC N
to TO N
examine VB N
associations NNS N
of IN N
dietary JJ 1_o
patterns NNS 1_o
with IN N
body NN 1_o
mass NN 1_o
index NN 1_o
( ( 1_o
BMI NNP 1_o
) ) 1_o
. . 1_o

DESIGN VB N
A DT N
secondary JJ N
analysis NN N
was VBD N
performed VBN N
of IN N
baseline NN N
data NNS N
from IN N
the DT N
Reach NNP 1_o
Out NNP 1_o
to TO 1_o
Enhance VB 1_o
Wellness NNP 1_o
( ( N
RENEW NNP N
) ) N
trial NN N
, , N
a DT N
diet JJ 1_i
and CC 1_i
exercise JJ 1_i
intervention NN 1_i
among IN N
overweight JJ N
, , N
long-term JJ N
( ( N
≥5 CD N
years NNS N
) ) N
, , N
older JJR N
survivors NNS N
of IN N
colorectal NN N
, , N
breast NN N
, , N
and CC N
prostate NN N
cancer NN 1_p
. . 1_p

Survivors NNS 1_p
in IN 1_p
the DT 1_p
present JJ 1_p
analysis NN 1_p
( ( 1_p
n=729 JJ 1_p
) ) 1_p
underwent JJ 1_i
two CD 1_i
45- JJ 1_i
to TO 1_i
60-minute JJ 1_i
telephone NN 1_i
surveys NNS 1_i
, , 1_i
which WDT 1_i
included VBD 1_i
two CD 1_i
24-hour JJ 1_i
dietary JJ 1_i
recalls NNS 1_i
. . 1_i

Principal JJ 1_i
components NNS 1_i
analysis NN 1_i
and CC 1_i
multivariable JJ 1_i
general JJ 1_i
linear JJ 1_i
models NNS 1_i
were VBD N
used VBN N
to TO N
derive VB 1_o
dietary JJ 1_o
patterns NNS 1_o
and CC N
to TO N
evaluate VB N
associations NNS N
between IN 1_o
dietary JJ 1_o
patterns NNS 1_o
and CC 1_o
BMI NNP 1_o
, , N
respectively RB N
. . N

RESULTS VB N
Principal JJ N
components NNS N
analysis NN N
identified VBD N
three CD 1_o
primary JJ 1_o
dietary JJ 1_o
patterns NNS 1_o
among IN N
rural JJ N
dwellers NNS N
( ( N
high JJ N
sweets NNS N
and CC N
starches NNS N
, , N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
, , N
and CC N
mixed JJ N
) ) N
and CC N
three CD N
among IN N
urban JJ N
dwellers NNS N
( ( N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
, , N
high JJ N
meat NN N
and CC N
refined VBD N
grains NNS N
, , N
and CC N
high JJ N
sugar-sweetened JJ N
beverages NNS N
) ) N
. . N

Among IN 1_p
rural JJ 1_p
survivors NNS 1_p
, , N
greater JJR N
adherence NN N
to TO N
the DT N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
pattern NN N
was VBD N
positively RB N
associated VBN N
with IN N
lower JJR 1_o
BMI NNP 1_o
( ( N
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
, , N
whereas IN N
higher JJR N
scores NNS N
on IN N
the DT N
mixed JJ N
pattern NN N
was VBD N
associated VBN N
with IN N
greater JJR 1_o
BMI NNP 1_o
( ( N
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
. . N

Greater NNP N
adherence NN N
to TO N
the DT N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
pattern VBP N
among IN N
urban JJ N
survivors NNS N
was VBD N
inversely RB N
associated VBN N
with IN 1_o
BMI NNP 1_o
( ( N
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Urban NNP N
and CC N
rural JJ N
differences NNS N
in IN N
dietary JJ N
intake NN N
behavior NN N
should MD N
be VB N
considered VBN N
in IN N
designing VBG N
public JJ N
health NN N
interventions NNS N
among IN N
the DT 1_o
increasing VBG 1_o
population NN 1_o
of IN N
older JJR N
cancer NN N
survivors NNS N
. . N

In IN N
addition NN N
, , N
targeting VBG N
overall JJ N
dietary JJ N
patterns NNS N
might MD N
be VB N
one CD N
approach NN N
to TO N
help VB N
reduce VB N
the DT N
burden NN N
of IN N
obesity NN N
among IN N
this DT N
population NN N
. . N

American NNP N
College NNP N
of IN N
Cardiology/European NNP N
Society NNP N
of IN N
Cardiology NNP N
International NNP N
Study NNP N
of IN N
Angiographic NNP N
Data NNP N
Compression NNP N
Phase NNP N
I PRP N
: : N
The DT N
effect NN N
of IN N
lossy JJ N
data NNS 1_i
compression NN 1_i
on IN N
recognition NN N
of IN N
diagnostic JJ N
features NNS N
in IN N
digital JJ 1_i
coronary JJ 1_i
angiography NN 1_i
. . 1_i

OBJECTIVES CC N
This DT N
study NN N
intended VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
varying VBG N
degrees NNS N
of IN N
lossy JJ 1_i
Joint NNP 1_i
Photographic NNP 1_o
Experts NNP 1_i
Group NNP 1_i
( ( 1_i
JPEG NNP 1_i
) ) 1_i
compression NN 1_i
on IN N
detection NN 1_o
of IN 1_o
coronary JJ 1_o
angiographic JJ 1_o
features NNS 1_o
. . 1_o

BACKGROUND NNP N
Compression NNP N
of IN N
digital JJ N
coronary JJ N
angiograms NNS N
facilitates VBZ N
playback NN N
of IN N
images NNS N
and CC N
decreases VBZ N
cost NN N
. . N

There EX N
are VBP N
little JJ N
data NNS N
on IN N
the DT N
effect NN N
of IN N
compression NN N
on IN N
the DT N
accuracy NN N
of IN N
coronary JJ N
angiography NN N
. . N

METHODS NNP N
At IN 1_p
six CD 1_p
centers NNS 1_p
, , 1_p
71 CD 1_p
angiographers NNS 1_p
each DT 1_p
reviewed VBD 1_p
a DT 1_p
set NN 1_p
of IN 1_p
100 CD 1_p
angiographic JJ 1_p
sequences NNS 1_p
. . 1_p

The DT 1_p
100 CD 1_p
sequences NNS 1_p
were VBD 1_p
divided VBN 1_p
into IN 1_p
four CD 1_p
, , 1_p
25-sequence JJ 1_p
subsets NNS 1_p
. . 1_p

Each DT N
subset NN N
of IN N
25 CD N
was VBD N
displayed VBN N
either CC N
as IN N
original JJ N
images NNS N
or CC N
at IN N
one CD N
of IN N
three CD N
compression NN N
ratios NNS N
( ( N
CRs NNP N
) ) N
( ( N
6:1 CD N
, , N
10:1 CD N
or CC N
16:1 CD N
) ) N
. . N

The DT N
effect NN 1_o
of IN 1_o
lossy JJ 1_o
compression NN 1_o
on IN 1_o
the DT 1_o
sensitivity NN 1_o
and CC 1_o
specificity NN 1_o
for IN 1_o
detection NN 1_o
of IN 1_o
diagnostic JJ 1_o
features NNS 1_o
was VBD N
determined VBN N
. . N

The DT N
effect NN 1_o
of IN 1_o
compression NN 1_o
on IN 1_o
subjective JJ 1_o
measures NNS 1_o
of IN 1_o
image NN 1_o
quality NN 1_o
graded VBN 1_o
by IN 1_o
the DT 1_o
angiographers NNS 1_o
was VBD N
also RB N
examined VBN N
. . N

RESULTS NNP N
Lossy NNP 1_o
compression NN 1_o
at IN N
a DT N
ratio NN N
of IN N
16:1 CD N
decreased VBD N
the DT N
sensitivity NN N
for IN N
the DT N
detection NN N
of IN N
diagnostic JJ N
features NNS N
( ( N
76 CD N
% NN N
vs. FW N
80 CD N
% NN N
p NN N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
largest JJS N
effect NN N
was VBD N
in IN N
the DT N
detection NN 1_o
of IN 1_o
calcification NN 1_o
( ( N
52 CD N
% NN N
vs. FW N
63 CD N
% NN N
at IN N
16:1 CD N
compression NN N
vs. FW N
original JJ N
images NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
. . N

Subjective JJ N
indicators NNS N
of IN N
image NN N
quality NN N
indicated VBD N
a DT N
reduction NN N
in IN N
confidence NN 1_o
in IN 1_o
interpretation NN 1_o
at IN N
CRs NNP N
of IN N
10:1 CD N
and CC N
16:1 CD N
. . N

CONCLUSIONS NN N
With IN N
increased JJ N
ratios NNS N
of IN N
lossy JJ N
compression NN N
, , N
a DT N
degradation NN N
of IN N
digital JJ N
coronary JJ N
angiograms NNS N
occurs VBZ N
that IN N
results NNS N
in IN N
decreased JJ 1_o
diagnostic JJ 1_o
accuracy NN 1_o
. . 1_o

The DT 1_o
sensitivity NN 1_o
for IN 1_o
detection NN 1_o
of IN 1_o
common JJ 1_o
diagnostic JJ 1_o
features NNS 1_o
was VBD N
decreased VBN N
, , N
and CC N
subjective JJ N
assessment NN N
of IN N
image NN N
quality NN N
was VBD N
impaired VBN N
. . N

Caution NN N
is VBZ N
warranted VBN N
in IN N
the DT N
interpretation NN N
of IN N
coronary JJ 1_i
angiograms NNS 1_i
that WDT N
have VBP N
been VBN N
subjected VBN N
to TO N
lossy VB N
JPEG NNP 1_i
compression NN 1_i
beyond IN N
a DT N
ratio NN N
of IN N
6:1 CD N
. . N

Thiabendazole NN 1_i
for IN N
the DT N
prophylaxis NN N
of IN N
strongyloidiasis NN N
in IN N
immunosuppressed JJ 1_p
patients NNS 1_p
with IN 1_p
hematological JJ 1_p
diseases NNS 1_p
: : 1_p
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ 1_i
study NN N
. . N

[ JJ N
Effects NNS N
of IN N
early JJ N
acupuncture NN 1_i
on IN N
motor NN N
function NN N
of IN N
the DT N
limb NN N
in IN N
the DT N
severe JJ 1_p
head NN 1_p
injury NN 1_p
patients NNS 1_p
] VBP 1_p
. . N

UNLABELLED NNP N
OBJECTIVE NNP N
; : N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
early JJ 1_i
acupuncture NN 1_i
on IN N
motor NN N
function NN N
of IN N
the DT N
limb NN N
in IN N
the DT N
severe JJ 1_p
head NN 1_p
injury NN 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
Ninety-six JJ 1_p
patients NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
observation NN N
group NN N
and CC N
a DT N
control NN N
group NN N
, , N
48 CD 1_p
cases NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

The DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
by IN N
routine JJ 1_i
treatment NN 1_i
of IN 1_i
neurosurgical JJ 1_i
operation NN 1_i
and CC 1_i
drug NN 1_i
treatment NN 1_i
( ( 1_i
Mannitol NNP 1_i
, , 1_i
Citioline NNP 1_i
Sodium NNP 1_i
, , 1_i
Cefeazidime NNP 1_i
, , 1_i
etc. NN 1_i
) ) 1_i
. . 1_i

While IN N
the DT N
patient NN N
in IN N
the DT N
observation NN N
group NN N
were VBD N
treated VBN N
by IN N
the DT N
routine JJ 1_i
treatment NN 1_i
and CC 1_i
acupuncture NN 1_i
treatment NN 1_i
48 CD 1_i
h NN 1_i
( ( 1_i
-1 NNP 1_i
) ) 1_i
week NN 1_i
after IN N
operation NN N
in IN N
different JJ N
stages NNS N
with IN N
different JJ N
acupoints NNS N
selected VBN N
when WRB N
the DT N
situation NN N
was VBD N
stable JJ N
. . N

The DT N
selected VBN 1_i
main JJ 1_i
points NNS 1_i
were VBD 1_i
Neiguan NNP 1_i
( ( 1_i
PC NNP 1_i
6 CD 1_i
) ) 1_i
, , 1_i
Qu-chi NNP 1_i
( ( 1_i
LI NNP 1_i
11 CD 1_i
) ) 1_i
, , 1_i
Waiguan NNP 1_i
( ( 1_i
TE NNP 1_i
5 CD 1_i
) ) 1_i
, , 1_i
Hegu NNP 1_i
( ( 1_i
LI NNP 1_i
4 CD 1_i
) ) 1_i
, , 1_i
Binao NNP 1_i
( ( 1_i
LI NNP 1_i
14 CD 1_i
) ) 1_i
, , 1_i
Jianyu NNP 1_i
( ( 1_i
LI NNP 1_i
15 CD 1_i
) ) 1_i
, , 1_i
Fengshi NNP 1_i
( ( 1_i
GB NNP 1_i
31 CD 1_i
) ) 1_i
, , 1_i
Xuehai NNP 1_i
( ( 1_i
SP NNP 1_i
10 CD 1_i
) ) 1_i
, , 1_i
Yinlingquan NNP 1_i
( ( 1_i
SP NNP 1_i
9 CD 1_i
) ) 1_i
, , 1_i
Sanyinjiao NNP 1_i
( ( 1_i
SP NNP 1_i
6 CD 1_i
) ) 1_i
, , 1_i
Taichong NNP 1_i
( ( 1_i
LR NNP 1_i
3 CD 1_i
) ) 1_i
, , 1_i
etc.. VBZ 1_i
The DT N
limb NN 1_o
motor NN 1_o
function NN 1_o
was VBD N
evaluated VBN N
with IN N
Fugl-Meyer NNP 1_o
Assessment NNP 1_o
( ( 1_o
FMA NNP 1_o
) ) 1_o
scale NN 1_o
before IN N
treatment NN N
and CC N
after IN N
10-week JJ N
treatment NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
FMA NNP 1_o
score NN 1_o
in IN N
the DT N
two CD N
groups NNS N
after IN N
the DT N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
comparison NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
the DT N
treatment NN N
showed VBD N
that IN N
the DT N
improvement NN 1_o
of IN 1_o
FMA NNP 1_o
score NN 1_o
in IN N
the DT N
observation NN N
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Early JJ N
acupuncture NN 1_i
can MD N
improve VB N
the DT N
limb NN N
motor NN N
function NN N
in IN N
the DT N
severe JJ 1_p
head NN 1_p
injury NN 1_p
patients NNS 1_p
. . 1_p

Efficacy NN N
of IN N
TeachTown NNP N
: : N
Basics NNS 1_i
computer-assisted JJ 1_i
intervention NN 1_i
for IN N
the DT N
Intensive NNP N
Comprehensive NNP N
Autism NNP N
Program NNP N
in IN N
Los NNP N
Angeles NNP N
Unified NNP N
School NNP N
District NNP N
. . N

Computer NNP 1_i
Assisted NNP 1_i
Instruction NNP 1_i
( ( 1_i
CAI NNP 1_i
) ) 1_i
has VBZ N
shown VBN N
increased VBN N
popularity NN N
recently RB N
and CC N
there EX N
are VBP N
many JJ N
studies NNS N
showing VBG N
promise NN N
for IN N
this DT N
approach NN N
for IN N
children NNS 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorders NNP 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

However RB N
, , N
there EX N
are VBP N
no DT N
between-subject JJ N
studies NNS N
to TO N
date NN N
assessing VBG N
the DT N
efficacy NN N
of IN N
CAI NNP 1_i
with IN N
this DT N
population NN N
. . N

In IN N
this DT N
study NN N
, , N
47 CD 1_p
preschool NN 1_p
and CC 1_p
K-1 JJ 1_p
students NNS 1_p
in IN 1_p
ASD NNP 1_p
classrooms NNS 1_p
participated VBD 1_p
from IN 1_p
Los NNP 1_p
Angeles NNP 1_p
Unified NNP 1_p
School NNP 1_p
District NNP 1_p
. . 1_p

TeachTown NN 1_i
: : 1_i
Basics NNS 1_i
, , 1_i
a DT 1_i
CAI NNP 1_i
program NN 1_i
which WDT 1_i
also RB 1_i
includes VBZ 1_i
supplementary JJ 1_i
off-computer NN 1_i
activities NNS 1_i
, , N
was VBD N
implemented VBN N
over IN N
3 CD N
months NNS N
for IN N
approximately RB N
20 CD N
minutes NNS N
per IN N
day NN N
on IN N
the DT N
computer NN 1_i
and CC N
20 CD 1_i
minutes NNS 1_i
per IN 1_i
day NN 1_i
in IN 1_i
supplementary JJ 1_i
TeachTown NN 1_i
: : 1_i
Basics JJ 1_i
activities NNS 1_i
. . 1_i

Compared VBN N
to TO N
the DT N
students NNS N
in IN N
the DT N
control NN N
group NN N
, , N
the DT N
TeachTown NNP N
: : N
Basics NNS N
students NNS N
showed VBD N
more RBR N
improvement NN N
overall JJ 1_o
on IN 1_o
language NN 1_o
and CC 1_o
cognitive JJ 1_o
outcome NN 1_o
measures NNS 1_o
. . 1_o

In IN N
addition NN N
, , N
students NNS N
who WP N
used VBD N
TeachTown NNP N
: : N
Basics NNS N
demonstrated VBD N
significant JJ N
progress NN 1_o
overall NN 1_o
in IN 1_o
the DT 1_o
software NN 1_o
and CC N
those DT N
students NNS N
who WP N
used VBD N
the DT N
program NN N
for IN N
more JJR N
time NN N
demonstrated VBD 1_o
larger JJR 1_o
gains NNS 1_o
within IN 1_o
the DT 1_o
software NN 1_o
and CC 1_o
in IN 1_o
outcome JJ 1_o
measures NNS 1_o
. . 1_o

Although IN N
not RB N
conclusive JJ N
, , N
these DT N
findings NNS N
offer VBP N
possibilities NNS N
for IN N
the DT N
use NN N
of IN N
CAI NNP 1_i
for IN N
remediating VBG N
many JJ N
deficits NNS N
for IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
other JJ 1_p
special JJ 1_p
needs NNS 1_p
. . 1_p

In IN N
addition NN N
, , N
CAI NNP 1_i
may MD N
offer VB N
solutions NNS N
to TO N
schools NNS N
and CC N
parents NNS N
with IN N
insufficient JJ N
funds NNS N
for IN N
more RBR N
expensive JJ N
treatments NNS N
. . N

Comparison NNP N
of IN N
the DT N
in IN 1_o
vitro NN 1_o
and CC 1_o
in IN 1_o
vivo JJ 1_o
release NN 1_o
of IN 1_o
digoxin NN 1_o
from IN N
four CD N
different JJ N
soft JJ N
gelatin NN N
capsule NN 1_i
formulations NNS 1_i
. . 1_i

A DT N
blinded JJ N
, , N
four-treatment JJ N
crossover NN N
study NN N
in IN N
16 CD 1_p
normal JJ 1_p
adult NN 1_p
male NN 1_p
volunteers NNS 1_p
compared VBN N
plasma JJ N
concentrations NNS N
and CC N
urinary JJ 1_o
excretion NN 1_o
of IN 1_o
digoxin NN 1_o
, , N
measured VBN N
by IN N
radioimmunoassay NN N
, , N
after IN N
oral JJ N
administration NN N
of IN N
soft JJ 1_i
gelatin NN 1_i
capsule NN 1_i
formulations NNS 1_i
of IN 1_i
digoxin NN 1_i
. . 1_i

Four CD N
0.4-mg JJ N
formulations NNS 1_i
with IN 1_i
different JJ 1_i
in IN 1_i
vitro JJ 1_i
" NNP 1_i
burst NN 1_i
times NNS 1_i
" NNP 1_i
and CC N
dissolution NN 1_i
rates NNS 1_i
were VBD N
administered VBN N
, , N
with IN N
2-week JJ N
intervals NNS N
between IN N
treatments NNS N
. . N

The DT N
two CD N
capsules NNS N
with IN N
lowest JJS N
in IN N
vitro NN N
burst NN N
times NNS N
( ( N
2.9 CD N
and CC N
16 CD N
min NN N
) ) N
gave VBD N
comparable JJ N
in IN N
vivo JJ N
results NNS N
. . N

The DT N
other JJ N
two CD N
capsules NNS N
, , N
with IN N
in IN N
vitro NN N
burst NN N
times NNS N
of IN N
62 CD N
and CC N
229 CD N
min NN N
, , N
produced VBD N
significant JJ N
delays NNS N
in IN N
digoxin NN N
absorption NN N
. . N

In IN N
vitro-in JJ N
vivo NN N
correlations NNS N
were VBD N
obtained VBN N
by IN N
comparing VBG N
the DT N
logarithm NN N
of IN N
the DT N
in IN N
vitro JJ N
burst NN N
time NN N
with IN N
time NN N
to TO N
peak VB 1_o
plasma JJ 1_o
level NN 1_o
and CC N
the DT N
time NN N
to TO N
the DT N
first JJ N
measurable JJ N
plasma NN 1_o
level NN 1_o
( ( N
> CD N
or CC N
= VB N
0 CD N
. . N

05 CD N
ng/ml NN N
) ) N
. . N

Also RB N
, , N
the DT N
mean JJ N
time NN N
to TO N
peak VB 1_o
plasma JJ 1_o
level NN 1_o
correlated VBN N
with IN N
the DT N
logarithm NN N
of IN N
the DT N
time NN N
required VBN N
to TO N
release VB N
either RB N
50 CD N
% NN N
or CC N
85 CD N
% NN N
of IN N
the DT N
digoxin NN N
in IN N
vitro NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
the DT N
amount NN N
of IN N
digoxin NN 1_i
absorbed VBN N
from IN N
each DT N
capsule NN N
as IN N
determined VBN N
by IN N
urinary JJ N
excretion NN N
or CC N
AUC0-infinity NN N
. . N

[ JJ 1_o
Efficacy NNP 1_o
and CC 1_o
immune JJ 1_o
memory NN 1_o
of IN N
plasma-derived JJ 1_i
hepatitis NN 1_i
B NNP 1_i
vaccine NN 1_i
11 CD 1_p
years NNS 1_p
after IN 1_p
primary JJ 1_p
immunization NN 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
long-term JJ 1_o
efficacy NN 1_o
of IN N
hepatitis NN 1_i
B NNP 1_i
vaccine NN 1_i
10 CD 1_p
years NNS 1_p
after IN 1_p
primary JJ 1_p
immunization NN 1_p
to TO N
provide VB N
scientific JJ N
basis NN N
for IN N
the DT N
time NN N
of IN N
revaccination NN N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
strictly RB N
designed VBN N
with IN N
randomization NN N
, , N
double-blinding NN N
, , N
and CC N
placebo-controlled JJ 1_i
method NN N
to TO N
observe VB N
the DT 1_p
efficacy NN 1_o
and CC 1_o
immune JJ 1_o
memory NN 1_o
11 CD 1_p
years NNS 1_p
following VBG 1_p
hepatitis NN 1_i
B NNP 1_i
vaccination NN 1_i
. . 1_i

RESULTS NNP N
Immunogenicity NNP 1_o
and CC 1_o
protective JJ 1_o
rate NN 1_o
of IN 1_o
vaccine NN 1_o
were VBD N
still RB N
kept VBN N
well RB N
11 CD N
years NNS N
after IN N
immunization NN N
with IN N
a DT N
protective JJ 1_o
rate NN 1_o
against IN N
HBV NNP N
infection NN 1_o
of IN N
73.5 CD N
% NN N
. . N

But CC N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
HBV NNP 1_o
infection NN 1_o
rates NNS 1_o
between IN N
vaccine NN 1_p
group NN 1_p
and CC 1_p
placebo-controlled JJ 1_p
group NN 1_p
( ( N
7.89 CD N
% NN N
vs. FW N
13.25 CD N
% NN N
, , N
P NNP N
> NNP N
0.1 CD N
) ) N
nine CD N
to TO N
11 CD N
years NNS N
following VBG N
immunization NN N
. . N

There EX N
still RB N
existed VBD N
immune JJ 1_o
memory NN 1_o
11 CD N
years NNS N
after IN N
immunization NN N
, , N
but CC N
it PRP N
was VBD N
significantly RB N
weaker JJR N
than IN N
that DT N
within IN N
the DT N
first JJ N
10 CD N
years NNS N
after IN N
immunization NN N
. . N

CONCLUSION VB N
The DT N
efficacy NN 1_o
of IN N
the DT N
vaccine NN 1_o
had VBD N
begun VBN N
to TO N
drop VB N
11 CD N
years NNS N
after IN N
immunization NN N
, , N
which WDT N
should MD N
be VB N
followed VBN N
up RP N
further RBR N
to TO N
reach VB N
a DT N
clear JJ N
conclusion NN N
. . N

Corticosteroid-induced JJ N
osteopenia NN 1_o
and CC 1_o
vitamin NN 1_o
D NNP 1_o
metabolism NN 1_o
. . 1_o

Effect NNP N
of IN N
vitamin NN 1_i
D2 NNP 1_i
, , 1_i
calcium NN 1_i
phosphate NN 1_i
and CC N
sodium NN 1_i
fluoride JJ 1_i
administration NN N
. . N

Thirty-one CD 1_p
patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
long-term JJ 1_p
( ( 1_p
24 CD 1_p
weeks NNS 1_p
) ) 1_p
treatment NN 1_p
with IN 1_p
prednisone NN 1_i
in IN 1_p
comparatively RB 1_p
high JJ 1_p
doses NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
further JJ N
treatment NN N
groups NNS N
. . N

Group NNP 1_i
A NNP 1_i
received VBD 1_i
prednisone JJ 1_i
plus CC 1_i
'triple-treatment JJ 1_i
' '' 1_i
( ( 1_i
vitamin FW 1_i
D2 NNP 1_i
45000 CD 1_i
iu NN 1_i
twice RB 1_i
weekly RB 1_i
, , 1_i
sodium JJ 1_i
fluoride RB 1_i
50 CD 1_i
mg NNS 1_i
and CC 1_i
calcium NN 1_i
phosphate VBP 1_i
4.5 CD 1_i
g JJ 1_i
daily RB 1_i
) ) 1_i
, , 1_i
group NN 1_i
B NNP 1_i
received VBD 1_i
only RB 1_i
prednisone NN 1_i
. . 1_i

The DT N
study NN N
was VBD N
undertaken VBN N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prednisone- NN 1_i
and CC N
triple-treatment JJ 1_i
upon IN N
bone JJ 1_o
mineral NN 1_o
content NN 1_o
( ( 1_o
BMC NNP 1_o
) ) 1_o
and CC 1_o
vitamin $ 1_o
D NNP 1_o
metabolism NN 1_o
. . 1_o

The DT N
groups NNS N
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
and CC N
prednisone NN N
dose NN N
. . N

BMC NNP 1_o
fell VBD N
rapidly RB N
and CC N
similarly RB N
in IN N
both DT N
groups NNS N
, , N
demonstrating VBG N
that IN N
the DT N
triple-treatment NN N
has VBZ N
no DT N
preventive JJ N
effect NN N
on IN N
corticosteroid NN N
induced VBN N
osteopenia NN N
. . N

Serum NNP 1_o
concentrations NNS 1_o
of IN 1_o
25OHD2 CD 1_o
, , 1_o
25OHD3 CD 1_o
and CC 1_o
1,25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
2D CD 1_o
were VBD N
unchanged JJ N
in IN N
group NN N
B NNP N
( ( N
without IN N
triple-treatment NN N
) ) N
, , N
whereas RB N
in IN N
group NN N
A NNP N
25OHD2 CD 1_o
increased VBD N
enormously RB N
, , N
25OHD3 CD 1_o
was VBD N
suppressed VBN N
possibly RB N
by IN N
substrate NN N
competition NN N
for IN N
hydroxylation NN N
in IN N
the DT N
liver NN N
and CC N
1,25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
2D CD 1_o
was VBD N
halved VBN N
. . N

The DT N
suppression NN N
of IN N
1,25 CD 1_o
( ( 1_o
OH NNP 1_o
) ) 1_o
2D CD 1_o
may MD N
be VB N
an DT N
effect NN N
of IN N
raised VBD N
25OHD2 CD N
alone RB N
, , N
or CC N
in IN N
combination NN N
with IN N
corticosteroid JJ N
excess NN N
. . N

Emerging VBG N
treatment NN 1_o
of IN N
acute JJ 1_o
coronary JJ 1_o
syndromes NNS 1_o
with IN N
platelet NN 1_i
glycoprotein NN 1_i
IIB/IIIA NNP 1_i
inhibitors NNS 1_i
. . 1_i

Osteopontin NNP 1_i
is VBZ N
a DT N
prognostic JJ N
factor NN N
for IN N
survival NN 1_o
of IN N
acute JJ 1_p
myeloid JJ 1_p
leukemia NN 1_p
patients NNS 1_p
. . 1_p

Osteopontin NNP 1_o
( ( 1_o
OPN NNP 1_o
) ) 1_o
is VBZ N
a DT N
glycoprotein NN N
that WDT N
is VBZ N
secreted VBN N
by IN N
osteoblasts NNS N
and CC N
hematopoietic JJ N
cells NNS N
. . N

OPN NNP 1_i
suppresses VBZ N
the DT N
proliferation NN N
of IN N
hematopoietic JJ N
stem NN N
cells NNS N
in IN N
vitro NN N
and CC N
may MD N
regulate VB N
the DT N
hematopoietic JJ N
stem NN N
cell NN N
pool NN N
. . N

Increased VBN N
serum NN N
OPN NNP N
concentrations NNS N
occur VBP N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
, , N
multiple JJ N
myeloma NN N
, , N
and CC N
acute JJ N
myeloid NN N
leukemia NN N
( ( N
AML NNP N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
analyzed VBD N
the DT N
prognostic JJ N
impact NN N
of IN N
OPN NNP N
in IN N
AML NNP N
by IN N
investigating VBG N
the DT N
expression NN 1_o
and CC 1_o
relevance NN 1_o
of IN 1_o
OPN NNP 1_o
in IN N
newly RB 1_p
diagnosed VBN 1_p
AML NNP 1_p
patients NNS 1_p
from IN 1_p
2 CD 1_p
large JJ 1_p
study NN 1_p
groups NNS 1_p
( ( 1_p
the DT 1_p
German JJ 1_p
AML NNP 1_p
Cooperative NNP 1_p
Group NNP 1_p
and CC 1_p
the DT 1_p
Dutch-Belgian JJ 1_p
Hematology NNP 1_p
Oncology NNP 1_p
Cooperative NNP 1_p
group NN 1_p
) ) 1_p
. . 1_p

IHC NNP 1_o
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
ELISAs NNP 1_o
of IN 1_o
blood/BM NN 1_o
sera NN 1_o
( ( N
n JJ N
= NNP N
41 CD N
) ) N
, , N
and CC N
microarray NN 1_o
data NNS 1_o
for IN 1_o
mRNA NN 1_o
levels NNS 1_o
( ( N
n JJ N
= NNP N
261 CD N
) ) N
were VBD N
performed VBN N
. . N

Expression NN 1_o
of IN 1_o
OPN NNP 1_o
protein NN 1_o
was VBD N
increased VBN N
in IN N
AML NNP N
patients NNS N
both DT N
in IN N
BM NNP N
blasts NNS N
( ( 1_i
IHC NNP 1_i
) ) 1_i
and CC N
in IN N
BM NNP N
serum NN N
( ( 1_i
ELISA NNP 1_i
) ) 1_i
compared VBN N
with IN N
healthy JJ N
controls NNS N
. . N

Patients NNS N
expressing VBG N
high JJ N
levels NNS 1_o
of IN 1_o
OPN NNP 1_o
within IN 1_o
the DT 1_o
BM NNP 1_o
( ( N
IHC NNP N
) ) N
experienced VBD N
shortened VBN N
overall JJ 1_o
survival NN 1_o
( ( N
OS NNP N
; : N
P NNP N
= NNP N
.025 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
identified VBD N
karyotype NN 1_o
, , 1_o
blast JJ 1_o
clearance NN 1_o
( ( N
day NN N
16 CD N
) ) N
, , N
and CC N
the DT N
level NN 1_o
of IN 1_o
OPN NNP 1_o
expression NN 1_o
as IN N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
OS NNP 1_o
. . 1_o

This DT N
prompted VBD N
us PRP N
to TO N
analyze VB N
microarray NN N
data NNS N
from IN N
261 CD 1_p
patients NNS 1_p
from IN 1_p
a DT 1_p
third JJ 1_p
cohort NN 1_p
. . 1_p

The DT N
analysis NN N
confirmed VBD N
OPN NNP N
as IN N
a DT N
prognostic JJ N
marker NN N
. . N

In IN N
summary JJ N
, , N
high JJ N
OPN NNP 1_o
mRNA NN 1_o
expression NN 1_o
indicated VBD N
decreased JJ N
event-free JJ 1_o
survival NN 1_o
( ( N
P NNP N
= NNP N
.0002 NNP N
) ) N
and CC N
OS NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

The DT N
prognostic JJ N
role NN N
of IN N
OPN NNP 1_i
was VBD N
most RBS N
prominent JJ N
in IN N
intermediate-risk JJ N
AML NNP N
. . N

These DT N
data NNS N
provide VBP N
evidence NN N
that IN N
OPN NNP 1_o
expression NN 1_o
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
AML NNP N
. . N

Intranasal NNP N
oxytocin PRP 1_i
improves VBZ N
emotion NN 1_o
recognition NN 1_o
for IN N
youth NN 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

BACKGROUND VB N
A NNP N
diagnostic JJ N
hallmark NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
is VBZ N
a DT N
qualitative JJ N
impairment NN N
in IN N
social JJ N
communication NN N
and CC N
interaction NN N
. . N

Deficits NNS N
in IN N
the DT N
ability NN N
to TO N
recognize VB N
the DT N
emotions NNS N
of IN N
others NNS N
are VBP N
believed VBN N
to TO N
contribute VB N
to TO N
this DT N
. . N

There EX N
is VBZ N
currently RB N
no DT N
effective JJ N
treatment NN N
for IN N
these DT N
problems NNS N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
design NN N
, , N
we PRP N
administered VBD N
oxytocin RP 1_i
nasal JJ 1_i
spray NN 1_i
( ( N
18 CD N
or CC N
24 CD N
IU NNPS N
) ) N
or CC N
a DT N
placebo NN 1_i
to TO N
16 CD 1_p
male NN 1_p
youth NN 1_p
aged VBD 1_p
12 CD 1_p
to TO 1_p
19 CD 1_p
who WP 1_p
were VBD 1_p
diagnosed VBN 1_p
with IN 1_p
Autistic NNP 1_p
or CC 1_p
Asperger NNP 1_p
's POS 1_p
Disorder NNP 1_p
. . 1_p

Participants NNS 1_p
then RB N
completed VBD N
the DT N
Reading VBG 1_o
the DT 1_o
Mind NNP 1_o
in IN 1_o
the DT 1_o
Eyes NNP 1_o
Task NNP 1_o
, , N
a DT N
widely RB N
used VBN N
and CC N
reliable JJ N
test NN N
of IN N
emotion NN 1_o
recognition NN 1_o
. . 1_o

RESULTS NNP N
In IN N
comparison NN N
with IN N
placebo NN 1_i
, , 1_i
oxytocin JJ 1_i
administration NN N
improved VBD N
performance NN 1_o
on IN 1_o
the DT 1_o
Reading VBG 1_o
the DT 1_o
Mind NNP 1_o
in IN 1_o
the DT 1_o
Eyes NNP 1_o
Task NNP 1_o
. . 1_o

This DT N
effect NN N
was VBD N
also RB N
shown VBN N
when WRB N
analysis NN N
was VBD N
restricted VBN N
to TO N
the DT N
younger JJR 1_p
participants NNS 1_p
aged VBD 1_p
12 CD 1_p
to TO 1_p
15 CD 1_p
who WP N
received VBD N
the DT N
lower JJR N
dose NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
the DT N
first JJ N
evidence NN N
that IN N
oxytocin JJ N
nasal NN N
spray NN N
improves VBZ N
emotion NN 1_o
recognition NN 1_o
in IN N
young JJ 1_p
people NNS 1_p
diagnosed VBN 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

Findings NNS N
suggest VBP N
the DT N
potential NN N
of IN N
earlier JJR N
intervention NN N
and CC N
further JJ N
evaluation NN N
of IN N
oxytocin JJ 1_i
nasal JJ N
spray NN N
as IN N
a DT N
treatment NN N
to TO N
improve VB N
social JJ N
communication NN N
and CC N
interaction NN N
in IN N
young JJ 1_p
people NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

Evaluation NN N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
the DT N
ophthalmic JJ 1_i
insert NN 1_i
Mydriasert NNP 1_i
in IN N
patients NNS 1_p
undergoing JJ 1_p
retinal JJ 1_p
angiography NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
verify VB N
the DT N
efficacy NN N
to TO N
obtain VB N
mydriasis NN N
and CC N
cardiovascular JJ N
safety NN N
of IN N
Mydriasert NNP 1_i
( ( 1_i
ophthalmic JJ 1_i
insert NN 1_i
containing VBG 1_i
tropicamide NN 1_i
and CC 1_i
phenylephrine NN 1_i
) ) 1_i
in IN N
diabetic JJ 1_p
and CC 1_p
nondiabetic JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
retinal JJ 1_p
angiography NN 1_p
by IN 1_p
comparing VBG 1_p
it PRP 1_p
with IN 1_p
usually RB 1_p
administered VBN 1_p
eyedrops NNS 1_p
( ( 1_i
tropicamide VB 1_i
1 CD 1_i
% NN 1_i
and CC 1_i
phenylephrine VB 1_i
10 CD 1_i
% NN 1_i
) ) 1_i
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

A DT N
total NN 1_p
of IN 1_p
154 CD 1_p
eyes NNS 1_p
of IN 1_p
77 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
2 CD 1_p
groups NNS 1_p
: : 1_p
group NN N
1 CD N
consisted VBD N
of IN N
78 CD N
eyes NNS N
, , N
group NN N
2 CD N
consisted VBD N
of IN N
76 CD N
eyes NNS N
, , N
and CC N
the DT N
patients NNS N
were VBD N
monitored VBN N
for IN N
pupillary JJ N
dilation NN N
, , N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
and CC N
possible JJ N
adverse JJ N
effects NNS N
at IN N
0 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
minutes NNS N
. . N

RESULTS NNP N
No NNP N
severe JJ 1_o
adverse JJ 1_o
effects NNS 1_o
were VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

In IN N
the DT N
entire JJ N
sample NN N
studied VBD N
, , N
the DT N
mean JJ 1_o
pupillary JJ 1_o
diameter NN 1_o
was VBD N
greater JJR N
in IN N
the DT N
eyedrops NNS N
group NN N
after IN N
20 CD N
and CC N
40 CD N
minutes NNS N
, , N
while IN N
mydriasis NN 1_o
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
after IN N
60 CD N
minutes NNS N
. . N

The DT N
diabetic JJ 1_p
patients NNS 1_p
treated VBN N
with IN N
Mydriasert NNP 1_i
had VBD N
less JJR N
mydriasis NN 1_o
than IN N
those DT N
treated VBN N
with IN N
eyedrops NNS N
after IN N
20 CD N
and CC N
40 CD N
minutes NNS N
, , N
and CC N
diabetic JJ N
patients NNS N
showed VBD N
less JJR N
mydriasis NN N
than IN N
the DT N
nondiabetic JJ N
patients NNS N
after IN N
60 CD N
and CC N
90 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
between-group JJ N
difference NN N
in IN N
mean JJ 1_o
heart NN 1_o
rate NN 1_o
or CC 1_o
systolic NN 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
at IN N
any DT N
of IN N
the DT N
time NN N
points NNS N
. . N

CONCLUSIONS NNP N
Mydriasert NNP 1_i
assures VBZ N
an DT N
adequate JJ N
degree NN N
of IN N
mydriasis NN N
for IN N
retinal JJ N
angiography NN N
in IN N
both DT N
diabetic JJ 1_p
and CC 1_p
nondiabetic JJ 1_p
patients NNS 1_p
. . 1_p

There EX N
are VBP N
no DT N
differences NNS N
in IN N
efficacy NN N
or CC N
safety NN N
between IN N
the DT N
insert NN N
and CC N
the DT N
usually RB N
administered VBN N
eyedrops NNS N
, , N
but CC N
the DT N
low JJ N
total JJ N
drug NN N
dose NN N
administered VBN N
with IN N
the DT N
insert NN N
reduces VBZ N
the DT N
risk NN N
of IN N
cardiovascular JJ N
side NN N
effects NNS N
. . N

Effects NNS N
of IN N
aerobic JJ 1_i
exercise NN 1_i
on IN N
cognition NN N
and CC N
hippocampal JJ N
volume NN N
in IN N
Alzheimer NNP 1_p
's POS 1_p
disease NN 1_p
: : 1_p
study NN N
protocol NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
The DT N
FIT-AD NNP N
trial NN N
) ) N
. . N

BACKGROUND NNP N
Alzheimer NNP 1_p
's POS 1_p
disease NN 1_p
, , N
a DT N
global JJ N
public JJ N
health NN N
issue NN N
, , N
accounts NNS N
for IN N
60 CD N
to TO N
80 CD N
% NN N
of IN N
all DT N
dementias NNS N
. . N

Alzheimer NNP N
's POS N
disease NN N
primarily RB N
causes VBZ N
cognitive JJ N
impairment NN N
and CC N
drugs NNS N
have VBP N
only RB N
modest JJ N
short-term JJ N
effects NNS N
, , N
highlighting VBG N
a DT N
pressing VBG N
need NN N
to TO N
develop VB N
effective JJ N
interventions NNS N
. . N

Aerobic NNP 1_i
exercise NN 1_i
holds VBZ N
promise NN N
for IN N
treating VBG N
cognitive JJ N
impairment NN N
in IN N
Alzheimer NNP 1_p
's POS 1_p
disease NN 1_p
through IN N
biologically RB N
sound JJ N
mechanisms NNS N
. . N

Nonetheless RB N
, , N
aerobic JJ 1_i
exercise NN 1_i
studies NNS N
in IN N
Alzheimer NNP N
's POS N
disease NN N
are VBP N
limited VBN N
with IN N
mixed JJ N
findings NNS N
. . N

METHODS/DESIGN NNP N
This DT N
pilot NN N
randomized VBD N
controlled VBN N
trial NN N
will MD N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
6-month JJ N
, , N
individualized JJ N
, , N
moderate-intensity JJ 1_i
cycling NN 1_i
intervention NN 1_i
( ( N
20 CD N
to TO N
50 CD N
minutes NNS N
per IN N
session NN N
, , N
3 CD N
times NNS N
a DT N
week NN N
) ) N
on IN N
cognition NN N
and CC N
hippocampal JJ N
volume NN N
in IN N
community-dwelling JJ 1_p
older NN 1_p
adults NNS 1_p
with IN 1_p
mild-to-moderate JJ 1_p
Alzheimer NNP 1_p
's POS 1_p
disease NN 1_p
. . 1_p

The DT N
specific JJ N
aims NNS N
are VBP N
to TO N
: : N
1 CD N
) ) N
determine VB N
the DT N
immediate JJ N
effect NN N
of IN N
the DT N
cycling NN N
intervention NN N
on IN N
cognition NN 1_o
in IN N
Alzheimer NNP N
's POS N
disease NN N
; : N
2 CD N
) ) N
examine NN N
if IN N
the DT N
cycling NN N
intervention NN N
slows VBZ N
cognitive JJ 1_o
decline NN 1_o
in IN N
Alzheimer NNP N
's POS N
disease NN N
from IN N
baseline NN N
to TO N
12 CD N
months NNS N
; : N
and CC N
3 CD N
) ) N
assess IN N
the DT N
effect NN N
of IN N
aerobic JJ 1_i
exercise NN 1_i
on IN N
hippocampal JJ N
volume NN N
over IN N
12 CD N
months NNS N
. . N

Ninety NNP 1_p
subjects NNS 1_p
will MD 1_p
be VB 1_p
randomized VBN 1_p
on IN N
a DT N
2:1 CD N
allocation NN N
ratio NN N
to TO N
cycling NN 1_i
or CC N
attention NN N
control NN N
( ( 1_i
low-intensity JJ 1_i
stretching NN 1_i
) ) 1_i
and CC N
followed VBN N
for IN N
another DT N
6 CD N
months NNS N
. . N

Allocations NNS N
will MD N
be VB N
concealed VBN N
to TO N
all DT N
investigators NNS N
and CC N
outcome JJ N
assessors NNS N
will MD N
be VB N
blinded VBN N
to TO N
group NN N
assignments NNS N
and CC N
previous JJ N
data NNS N
. . N

Cognition NN N
will MD N
be VB N
measured VBN N
by IN N
the DT N
Alzheimer NNP 1_o
's POS 1_o
disease NN 1_o
Assessment NNP 1_o
Scale-Cognition NN 1_o
at IN N
baseline NN N
before IN N
randomization NN N
and CC N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

Hippocampal NNP 1_o
volume NN 1_o
will MD N
be VB N
measured VBN N
by IN N
magnetic JJ N
resonance NN N
imaging NN N
at IN N
baseline NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
. . N

The DT N
sample JJ 1_p
size NN 1_p
of IN 1_p
90 CD 1_p
will MD N
give VB N
80 CD N
% NN N
power NN N
to TO N
detect VB N
a DT N
2.5-point JJ N
difference NN N
in IN N
within-group JJ N
changes NNS N
in IN N
the DT N
Alzheimer NNP 1_o
's POS 1_o
disease NN 1_o
Assessment NNP 1_o
Scale-Cognition NN 1_o
at IN N
6 CD N
months NNS N
for IN N
the DT N
cycling NN N
group NN N
. . N

DISCUSSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
will MD N
address VB N
the DT N
critical JJ N
gap NN N
of IN N
exercise NN 1_o
efficacy NN 1_o
in IN N
Alzheimer NNP N
's POS N
disease NN N
and CC N
use NN N
of IN N
magnetic JJ N
resonance NN N
imaging NN N
as IN N
an DT N
outcome NN N
measure NN N
in IN N
clinical JJ N
trials NNS N
. . N

This DT N
study NN N
will MD N
provide VB N
a DT N
potential JJ N
treatment NN N
that WDT N
may MD N
increase VB N
physical JJ 1_o
function NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
and CC N
curb VB N
the DT N
prohibitive JJ 1_o
costs NNS 1_o
for IN N
the DT N
growing VBG N
dementia JJ N
population NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Primary NNP N
registration NN N
: : N
( ( N
NCT01954550 NNP N
; : N
date NN N
of IN N
registration NN N
: : N
20 CD N
September NNP N
2013 CD N
) ) N
. . N

Secondary JJ N
registration NN N
: : N
( ( N
NCT01954550 NNP N
; : N
date NN N
of IN N
registration NN N
: : N
1 CD N
October NNP N
2013 CD N
) ) N
. . N

A DT N
Randomized NNP N
Double NNP N
Blind NNP N
Clinical NNP N
Trial NNP N
on IN N
a DT N
Sabgh NNP 1_i
Formulation NNP 1_i
for IN N
Patients NNPS 1_p
With IN 1_p
Vitiligo NNP 1_p
. . 1_p

BACKGROUND NNP N
The DT N
cosmetic JJ N
problem NN N
that WDT N
vitiligo VBZ 1_i
produces VBZ N
affects NNS 1_p
patients NNS 1_p
psychologically RB 1_p
. . 1_p

Many JJ N
patients NNS 1_p
with IN 1_p
vitiligo NNS 1_p
are VBP N
suggested VBN N
to TO N
cover VB N
their PRP$ N
white JJ N
skin NN N
patches NNS N
with IN N
cosmetic JJ N
products NNS N
. . N

There EX N
are VBP N
formulations NNS N
in IN N
traditional JJ N
Iranian JJ N
pharmacy NN N
to TO N
color VB N
these DT N
white JJ N
skin NN N
patches NNS N
. . N

In IN N
this DT N
study NN N
, , N
one CD N
of IN N
these DT N
formulations NNS 1_i
was VBD N
compared VBN N
with IN N
a DT N
cosmetic JJ 1_i
formulation NN 1_i
. . 1_i

METHODS NNP N
Two CD 1_p
groups NNS 1_p
of IN 1_p
patients NNS 1_p
were VBD 1_p
selected VBN 1_p
. . 1_p

One CD N
group NN N
used VBD N
a DT N
marketed JJ 1_i
formulation NN 1_i
and CC N
other JJ N
group NN N
used VBD N
a DT N
traditional JJ 1_i
Iranian JJ 1_i
Pharmacy NNP 1_i
formulation NN 1_i
. . 1_i

The DT N
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
the DT N
patients NNS N
was VBD N
compared VBN N
based VBN N
on IN N
the DT N
Dermatology NNP N
Life NNP N
Quality NNP N
Index NNP N
Questionnaire NNP N
. . N

RESULTS NNP N
Both NNP N
interventions NNS N
were VBD N
associated VBN N
with IN N
statistically RB N
improved VBN N
Dermatology NNP 1_o
Life NNP 1_o
Quality NNP 1_o
Index NNP 1_o
scores VBZ 1_o
over IN N
the DT N
8-week JJ N
intervention NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
although IN N
the DT N
difference NN N
between IN N
the DT N
2 CD N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.436 NNP N
) ) N
. . N

CONCLUSION NNP N
Traditional NNP 1_i
Iranian JJ 1_i
Pharmacy NNP 1_i
formulation NN N
is VBZ N
effective JJ N
in IN N
increasing VBG N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
in IN N
vitiligo JJ N
patients NNS N
. . N

[ JJ N
Usage NN N
of IN N
titanoreine NN 1_i
after IN N
procedure NN 1_p
for IN 1_p
prolapse NN 1_p
and CC 1_p
hemorrhoids NNS 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
titanoreine NN 1_i
on IN N
early JJ N
postoperative NN N
symptoms NNS N
after IN N
procedure NN N
for IN N
prolapse NN N
and CC N
hemorrhoids NNS N
( ( N
PPH NNP N
) ) N
. . N

METHODS NNP N
From IN 1_p
November NNP 1_p
2002 CD 1_p
to TO 1_p
July NNP 1_p
2003 CD 1_p
, , 1_p
80 CD 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
PPH NNP 1_p
were VBD N
randomly RB N
divided VBN N
in IN N
to TO N
titanoreine VB 1_i
group NN N
( ( N
n=42 CC N
) ) N
and CC N
control VB 1_i
group NN 1_i
without IN 1_i
titanoreine NN 1_i
( ( N
n=38 JJ N
) ) N
. . N

Symptom JJ 1_o
relief NN 1_o
was VBD N
recorded VBN N
24 CD N
hours NNS N
, , N
6 CD N
days NNS N
and CC N
12 CD N
days NNS N
after IN N
PPH NNP N
, , N
urine JJ 1_o
retention NN 1_o
24h CD N
after IN N
PPH NNP N
, , N
first RB 1_o
stool JJ 1_o
time NN 1_o
, , 1_o
wound IN 1_o
healing VBG 1_o
time NN 1_o
, , 1_o
mean JJ 1_o
hospital NN 1_o
stay NN 1_o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
The DT N
score NN 1_o
of IN 1_o
symptom NN 1_o
was VBD N
lower JJR N
in IN N
titanoreine NN 1_i
group NN N
( ( N
4.4 CD N
) ) N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
6.1 CD N
) ) N
24 CD N
hours NNS N
after IN N
PPH NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
significant JJ N
difference NN N
in IN N
symptom NN 1_o
grade NN 1_o
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
6 CD N
days NNS N
and CC N
12 CD N
days NNS N
after IN N
PPH NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Decrements NNS 1_o
of IN 1_o
symptom NN 1_o
grade NN 1_o
were VBD N
lower JJR N
in IN N
titanoreine NN 1_i
group NN N
than IN N
those DT N
of IN N
control NN N
group NN N
at IN N
any DT N
point NN N
after IN N
PPH NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
urine JJ 1_o
retention NN 1_o
rate NN 1_o
and CC 1_o
mean JJ 1_o
hospital NN 1_o
stay NN 1_o
between IN N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Titanoreine NNP 1_i
can MD N
effectively RB N
relieve VB 1_o
the DT N
early JJ N
postoperative NN N
symptoms NNS N
after IN N
PPH NNP N
. . N

Comparison NNP N
of IN N
single-dose JJ N
oral JJ N
granisetron NN 1_i
versus NN N
intravenous JJ N
ondansetron NN 1_i
in IN N
the DT N
prevention NN N
of IN N
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
induced VBN 1_o
by IN 1_o
moderately RB 1_o
emetogenic JJ 1_o
chemotherapy NN 1_o
: : 1_o
a DT N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
parallel NN N
study NN N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effectiveness NN N
and CC N
safety NN N
of IN N
single-dose JJ N
oral JJ N
granisetron NN 1_i
were VBD N
compared VBN N
with IN N
intravenous JJ N
( ( N
I.V NNP N
. . N

) ) N
ondansetron NN 1_i
in IN N
chemotherapy-naive JJ 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
moderately RB 1_i
emetogenic JJ 1_i
chemotherapy NN 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
parallel-group NN 1_p
study NN 1_p
, , 1_p
patients NNS 1_p
naive VBP 1_p
to TO 1_p
emetogenic VB 1_i
chemotherapy NN 1_i
( ( 1_p
N NNP 1_p
= NNP 1_p
1,085 CD 1_p
) ) 1_p
who WP 1_p
were VBD 1_p
scheduled VBN 1_p
to TO 1_p
receive VB 1_p
cyclophosphamide- NN 1_i
( ( 1_i
500 CD 1_i
to TO 1_i
1,200 CD 1_i
mg/m2 NN 1_i
) ) 1_i
or CC 1_i
carboplatin NN 1_i
( ( 1_p
> CD 1_p
or CC 1_p
= VB 1_p
300 CD 1_p
mg/m2 NN 1_p
) ) 1_p
based VBN 1_p
chemotherapy NN 1_p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
granisetron NN 1_i
( ( N
n JJ N
= NNP N
542 CD N
) ) N
or CC N
I.V NNP N
. . N

ondansetron NN 1_i
( ( N
n JJ N
= NNP N
543 CD N
) ) N
. . N

Efficacy NN N
assessments NNS N
included VBD N
the DT N
proportion NN N
of IN N
patients NNS N
in IN N
each DT N
treatment NN 1_i
group NN 1_i
with IN N
total JJ N
control NN 1_i
over IN N
the DT N
24 CD N
and CC N
48 CD N
hours NNS N
following VBG N
chemotherapy NN 1_i
initiation NN N
, , N
as RB N
well RB N
as IN N
incidence NN N
and CC N
severity NN N
of IN N
nausea NN 1_o
and CC 1_o
emesis NN 1_o
and CC N
use NN N
of IN N
antiemetic JJ N
rescue NN N
medication NN N
. . N

Prophylactic JJ 1_i
corticosteroids NNS 1_i
were VBD 1_i
allowed VBN 1_i
. . 1_i

Safety NNP N
assessment NN N
was VBD N
based VBN N
on IN N
patients NNS N
' POS N
reports NNS N
of IN N
adverse JJ N
experiences NNS N
. . N

RESULTS NNP N
Approximately RB N
80 CD N
% NN N
of IN N
patients NNS N
received VBN N
prophylactic JJ 1_i
corticosteroids NNS 1_i
. . 1_i

Single-dose JJ N
oral JJ N
granisetron NN 1_i
( ( N
2 CD N
mg NN N
) ) N
and CC N
I.V NNP N
. . N

ondansetron NN 1_i
( ( N
32 CD N
mg NN N
) ) N
resulted VBD N
in IN N
equivalent JJ N
levels NNS N
of IN N
total JJ 1_o
emetic JJ 1_o
control NN 1_o
during IN N
the DT N
first JJ N
48 CD N
hours NNS N
after IN N
chemotherapy NN 1_i
. . 1_i

The DT N
proportion NN 1_o
of IN 1_o
nausea- JJ 1_o
and CC 1_o
emesis-free JJ 1_o
patients NNS 1_o
at IN N
24 CD N
and CC N
48 CD N
hours NNS N
were VBD N
also RB N
approximately RB N
equivalent JJ N
. . N

The DT N
most RBS N
commonly RB N
reported VBD N
adverse JJ N
experiences NNS N
were VBD N
headache NN 1_o
, , 1_o
asthenia NN 1_o
, , 1_o
and CC 1_o
constipation NN 1_o
. . 1_o

More JJR N
patients NNS N
who WP N
received VBD N
ondonsetron JJR 1_i
than IN N
granisetron NN 1_i
reported VBN N
dizziness NN 1_o
( ( N
9.6 CD N
% NN N
v JJ N
5.4 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.011 NNP N
) ) N
and CC N
abnormal JJ 1_o
vision NN 1_o
( ( N
4.2 CD N
% NN N
v JJ N
0.6 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
granisetron NN 1_i
( ( N
2 CD N
mg NN N
) ) N
resulted VBD N
in IN N
equivalent JJ N
levels NNS N
of IN N
antiemetic JJ 1_o
protection NN 1_o
as IN N
I.V NNP N
. . N

ondansetron NN 1_i
( ( N
32 CD N
mg NN N
) ) N
. . N

Both DT N
agents NNS N
were VBD N
well RB N
tolerated VBN N
, , N
although IN N
more JJR N
dizziness NN 1_o
and CC 1_o
abnormal JJ 1_o
vision NN 1_o
were VBD N
reported VBN N
with IN N
ondansetron NN 1_i
. . 1_i

Because IN N
the DT N
two CD N
antiemetic JJ N
regimens NNS N
exhibited VBD N
equivalent JJ N
efficacies NNS N
, , N
additional JJ N
factors NNS N
such JJ N
as IN N
convenience NN N
and CC N
cost NN N
of IN N
therapy NN N
should MD N
be VB N
considered VBN N
. . N

The DT N
effect NN N
of IN N
inhaled JJ N
leukotriene NN 1_i
D4 NNP 1_i
and CC N
methacholine VB 1_i
on IN N
sputum NN 1_o
cell NN 1_o
differentials NNS 1_o
in IN N
asthma NN 1_p
. . 1_p

The DT N
cysteinyl JJ 1_i
leukotriene NN 1_i
LTE4 NNP 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
induce VB N
airway RP 1_o
eosinophilia NNS 1_o
in IN N
asthmatics NNS N
in IN N
vivo NN N
. . N

This DT N
phenomenon NN N
has VBZ N
not RB N
yet RB N
been VBN N
reported VBN N
for IN N
LTD4 NNP N
. . N

Hence NNP N
, , N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
inhaled JJ N
LTD4 NNP 1_i
and CC N
a DT N
control NN N
bronchoconstrictor NN N
agent NN N
, , N
methacholine NN N
, , N
on IN N
cell NN 1_o
differentials NNS 1_o
in IN N
hypertonic JJ N
saline-induced JJ N
whole JJ N
sputum NN N
samples NNS N
of IN N
12 CD 1_p
nonsmoking VBG 1_p
atopic NN 1_p
asthmatic JJ 1_p
subjects NNS 1_p
( ( 1_p
three CD 1_p
women NNS 1_p
, , 1_p
nine CD 1_p
men NNS 1_p
; : 1_p
21 CD 1_p
to TO 1_p
29 CD 1_p
yr NN 1_p
of IN 1_p
age NN 1_p
; : 1_p
FEV1 NNP 1_p
, , 1_p
74 CD 1_p
to TO 1_p
120 CD 1_p
% NN 1_p
pred VBD 1_p
; : 1_p
PC20FEV1 NNP 1_p
methacholine VBP 1_p
< $ 1_p
9.6 CD 1_p
mg/ml NN 1_p
) ) 1_p
. . N

The DT N
study NN N
had VBD N
a DT N
cross-over JJ N
, , N
placebo-controlled JJ N
design NN N
consisting NN N
of IN N
4 CD N
d NN N
separated VBN N
by IN N
> NN N
or CC N
= $ N
1 CD N
wk NN N
. . N

On IN N
each DT N
randomized VBN N
study NN N
day NN N
, , N
the DT N
subjects NNS N
inhaled VBD N
five CD N
serial JJ N
doses NNS N
of IN N
either DT N
LTD4 NNP 1_i
( ( N
mean JJ N
cumulative JJ N
concentration NN N
: : N
95.7 CD N
microM NN N
) ) N
or CC N
methacholine NN 1_i
( ( N
mean JJ N
cumulative JJ N
concentration NN N
: : N
542 CD N
mM NN N
) ) N
or CC N
five CD N
doses NNS N
of IN N
their PRP$ N
respective JJ N
diluents NNS N
( ( 1_i
PBS/ethanol NNP 1_i
or CC N
PBS NNP N
) ) N
. . N

The DT N
airway JJ 1_o
response NN 1_o
was VBD N
measured VBN N
by IN N
FEV1 NNP N
, , N
followed VBN N
by IN N
sputum JJ N
induction NN N
with IN N
4.5 CD N
% NN N
NaCl NNP N
, , N
4 CD N
h NN N
postchallenge NN N
. . N

Inflammatory NNP N
cells NNS N
( ( N
> CD N
or CC N
= VB N
250 CD N
) ) N
were VBD N
counted VBN N
twice RB N
on IN N
coded JJ N
cytospins NNS N
and CC N
expressed VBD N
as IN N
percentages NNS N
of IN N
nonsquamous JJ N
cells NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
maximal JJ 1_o
percent NN 1_o
fall NN 1_o
in IN 1_o
FEV1 NNP 1_o
from IN 1_o
baseline NN 1_o
between IN N
LTD4 NNP N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
, , N
49.5 CD N
+/- JJ N
4.4 CD N
% NN N
fall NN N
) ) N
and CC N
methacholine NN N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
, , N
55.9 CD N
+/- JJ N
3.4 CD N
% NN N
fall NN N
) ) N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
. . N

LTD4 NNP N
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
percentage NN 1_o
of IN 1_o
sputum NN 1_o
eosinophils NNS 1_o
as IN N
compared VBN N
with IN N
its PRP$ N
diluent NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
26.6 CD N
+/- JJ N
21.3 CD N
% NN N
and CC N
10.2 CD N
+/- JJ N
8.8 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.025 CD N
) ) N
, , N
whereas VBZ N
a DT N
similar JJ N
trend NN N
for IN N
methacholine NN N
failed VBD N
to TO N
reach VB N
significance NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
19.1 CD N
+/- JJ N
22.9 CD N
% NN N
and CC N
7.8 CD N
+/- JJ N
5.8 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.11 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
changes NNS N
in IN N
the DT N
percentage NN 1_o
of IN 1_o
sputum NN 1_o
eosinophils NNS 1_o
between IN 1_o
LTD4 NNP 1_o
and CC 1_o
methacholine NN 1_o
( ( N
mean JJ N
difference NN N
+/- JJ N
SD NNP N
, , N
7.5 CD N
+/- JJ N
12.5 CD N
% NN N
eosinophils NNS N
; : N
p VB N
= $ N
0.09 CD N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
LTD4 NNP N
induces NNS N
eosinophilia VBP 1_o
in IN 1_o
sputum NN 1_o
of IN N
asthmatic JJ N
subjects NNS N
4 CD N
h NN N
after IN N
inhalation NN N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
LTD4 NNP N
recruits VBZ N
eosinophils NNS 1_o
into IN N
the DT N
airways NNS N
of IN N
asthmatics NNS N
in IN N
vivo NN N
, , N
possibly RB N
by IN N
virtue NN N
of IN N
direct JJ N
or CC N
indirect JJ N
chemotactic JJ N
properties NNS N
, , N
whereas IN N
an DT N
additional JJ N
effect NN N
of IN N
vigourous JJ 1_o
airway NN 1_o
narrowing VBG 1_o
per IN N
se NN N
can MD N
not RB N
be VB N
excluded VBN N
. . N

The DT N
effects NNS N
of IN N
a DT N
24-h JJ N
psychological JJ 1_i
training NN 1_i
program NN 1_i
on IN N
attitudes NNS 1_o
, , 1_o
communication NN 1_o
skills NNS 1_o
and CC 1_o
occupational JJ 1_o
stress NN 1_o
in IN N
oncology NN N
: : N
a DT N
randomised JJ N
study NN N
. . N

The DT N
usefulness NN N
of IN N
psychological JJ 1_i
training NN 1_i
programs NNS 1_i
( ( 1_i
P.T.P NNP 1_i
. . 1_i

) ) 1_i
in IN N
health NN N
care NN N
settings NNS N
devoted VBN N
to TO N
cancer NN N
care NN N
is VBZ N
beginning VBG N
to TO N
be VB N
recognised VBN N
but CC N
their PRP$ N
content NN N
, , N
form NN N
and CC N
effectiveness VB N
need NN N
further JJ N
investigation NN N
. . N

Seventy-two JJ 1_p
oncology NN 1_p
nurses NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
24-h JJ 1_i
P.T.P NNP 1_i
. . 1_i

or CC 1_i
to TO 1_i
a DT 1_i
waiting VBG 1_i
list NN 1_i
period NN 1_i
. . 1_i

Attitudes NNS 1_o
were VBD N
assessed VBN 1_i
by IN 1_i
a DT 1_i
semantic JJ 1_o
differential NN 1_o
questionnaire NN 1_o
, , 1_o
occupational JJ 1_o
stress NN 1_o
was VBD 1_i
assessed VBN 1_i
by IN 1_i
the DT 1_o
Nursing NNP 1_o
Stress NNP 1_o
Scale NNP 1_o
and CC 1_i
communication NN 1_o
skills NNS 1_o
were VBD 1_i
assessed VBN 1_i
by IN 1_i
standardised JJ 1_o
videotaped VBD 1_o
role-playing NN 1_o
exercises NNS 1_o
. . 1_o

These DT N
were VBD N
used VBN N
to TO N
compare VB N
trained JJ N
( ( N
T.S NNP N
. . N

) ) N
and CC N
control NN N
subjects NNS N
( ( N
C.S. NNP N
) ) N
. . N

The DT N
results NNS N
show VBP N
a DT N
significant JJ N
training NN N
effect NN N
on IN N
attitudes NNS 1_o
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
especially RB N
on IN N
those DT N
related VBN N
to TO N
self VB 1_o
concept NN 1_o
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
and CC N
on IN N
the DT N
level NN 1_o
of IN 1_o
occupational JJ 1_o
stress NN 1_o
related VBN N
to TO N
inadequate VB N
preparation NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Limited VBN N
changes NNS N
were VBD N
found VBN N
regarding VBG N
post-training JJ N
communication NN N
skills NNS N
. . N

T.S NNP N
. . N

were VBD N
significantly RB N
more RBR N
in IN N
control NN N
of IN N
the DT N
interview NN N
than IN N
C.S NNP N
. . N

( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
24-h JJ N
P.T.P NNP 1_i
. . 1_i

assessed VBN N
here RB N
are VBP N
effective JJ N
. . N

The DT N
data NN N
also RB N
demonstrate VBP N
the DT N
need NN N
to TO N
consolidate VB N
the DT N
skills NNS N
acquired VBN N
by IN N
regular JJ N
post-training JJ N
sessions NNS N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
comparison NN N
of IN N
the DT N
analgesic JJ 1_o
efficacy NN 1_o
, , 1_o
onset NN 1_o
of IN 1_o
action NN 1_o
, , N
and CC N
tolerability NN 1_o
of IN N
ibuprofen JJ 1_i
arginate NN 1_i
and CC N
ibuprofen NN 1_i
in IN N
postoperative JJ 1_p
dental NN 1_p
pain NN 1_p
. . 1_p

BACKGROUND NNP N
Because IN N
of IN N
its PRP$ N
enhanced JJ N
pharmacokinetic JJ 1_o
characteristics NNS 1_o
, , N
ibuprofen JJ 1_i
arginate NN 1_i
might MD N
be VB N
expected VBN N
to TO N
provide VB N
faster JJR N
pain NN 1_o
relief NN 1_o
than IN N
standard JJ 1_i
ibuprofen JJ 1_i
formulations NNS N
in IN N
patients NNS 1_p
experiencing VBG 1_p
acute JJ 1_p
pain NN 1_p
. . 1_p

OBJECTIVE CC N
This DT N
study NN N
assessed VBD N
the DT N
analgesic JJ 1_o
efficacy NN 1_o
, , 1_o
speed NN 1_o
of IN 1_o
onset NN 1_o
, , 1_o
and CC 1_o
tolerability NN 1_o
of IN N
ibuprofen JJ N
arginate NN N
compared VBN N
with IN N
a DT N
commercially RB N
available JJ N
form NN N
of IN N
ibuprofen NN N
in IN N
patients NNS 1_p
with IN 1_p
postoperative JJ 1_p
dental NN 1_p
pain NN 1_p
. . 1_p

METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
ibuprofen JJ 1_i
arginate NN 1_i
200 CD 1_i
or CC 1_i
400 CD 1_i
mg NN 1_i
, , 1_i
ibuprofen JJ 1_i
200 CD 1_i
or CC 1_i
400 CD 1_i
mg NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
in IN N
this DT N
multicenter NN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
parallel-group JJ N
trial NN N
. . N

Patients NNS N
were VBD N
observed VBN N
for IN N
6 CD N
hours NNS N
after IN N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
study NN N
medication NN N
. . N

A DT N
repeated-dose JJ N
, , N
open-label JJ N
phase NN N
followed VBD N
. . N

Pain NNP 1_o
intensity NN 1_o
and CC 1_o
pain NN 1_o
relief NN 1_o
were VBD N
measured VBN N
using VBG N
traditional JJ N
verbal JJ 1_o
descriptor NN 1_o
scales NNS 1_o
; : 1_o
onset VBN 1_o
of IN 1_o
analgesia NN 1_o
was VBD N
assessed VBN N
using VBG N
2 CD N
stopwatches NNS N
to TO N
measure VB N
the DT N
time NN 1_o
to TO 1_o
achievement NN 1_o
of IN 1_o
specific JJ 1_o
pain NN 1_o
relief NN 1_o
criteria NNS N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
498 CD 1_p
patients NNS 1_p
( ( 1_p
219 CD 1_p
men NNS 1_p
, , 1_p
279 CD 1_p
women NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
21.5 CD 1_p
years NNS 1_p
) ) 1_p
participated VBD 1_p
in IN 1_p
this DT 1_p
study NN 1_p
. . 1_p

Baseline NNP 1_o
pain NN 1_o
was VBD N
moderate JJ N
in IN N
388 CD N
patients NNS N
( ( N
78 CD N
% NN N
) ) N
and CC N
severe JJ N
in IN N
110 CD N
patients NNS N
( ( N
22 CD N
% NN N
) ) N
. . N

Meaningful JJ N
pain NN 1_o
relief NN 1_o
was VBD N
reached VBN N
after IN N
a DT N
median NN N
of IN N
29 CD N
and CC N
28 CD N
minutes NNS N
with IN N
ibuprofen JJ 1_i
arginate NN 1_i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
and CC N
after IN N
52 CD N
and CC N
44 CD N
minutes NNS N
with IN N
ibuprofen JJ 1_i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
( ( N
all DT N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
percentages NNS N
of IN N
patients NNS N
who WP N
achieved VBD N
meaningful JJ N
pain NN 1_o
relief NN 1_o
within IN N
the DT N
first JJ N
hour NN N
after IN N
treatment NN N
were VBD N
77.6 CD N
% NN N
and CC N
83.7 CD N
% NN N
for IN N
ibuprofen JJ 1_i
arginate NN 1_i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
61.0 CD N
% NN N
and CC N
63.0 CD N
% NN N
for IN N
ibuprofen JJ 1_i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
and CC N
39.8 CD N
% NN N
for IN N
placebo NN N
. . N

The DT N
differences NNS N
between IN N
ibuprofen JJ N
arginate NN N
and CC N
ibuprofen NN N
were VBD N
statistically RB N
significant JJ N
( ( N
both DT N
doses NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Significantly RB N
greater JJR N
numbers NNS N
of IN N
patients NNS N
achieved VBN N
meaningful JJ N
pain NN 1_o
relief NN 1_o
with IN N
ibuprofen JJ 1_i
arginate NN 1_i
400 CD N
mg NN N
compared VBN N
with IN N
placebo NN 1_i
from IN N
20 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
and CC N
with IN N
ibuprofen JJ N
arginate NN N
200 CD N
mg NN N
from IN N
30 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
a DT N
greater JJR N
number NN N
of IN N
patients NNS N
achieved VBN N
meaningful JJ N
pain NN 1_o
relief NN 1_o
with IN N
ibuprofen JJ 1_i
400 CD N
mg NN N
from IN N
45 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
; : N
with IN N
ibuprofen NN N
200 CD N
mg. NN N
the DT N
corresponding JJ N
interval NN N
was VBD N
from IN N
I PRP N
through IN N
6 CD N
hours NNS N
. . N

After IN N
the DT N
first JJ N
hour NN N
, , N
pain NN 1_o
reduction NN 1_o
was VBD N
similar JJ N
for IN N
the DT N
similar JJ N
doses NNS N
of IN N
the DT N
2 CD N
ibuprofen JJ 1_i
preparations NNS N
. . N

Median JJ 1_o
remedication NN 1_o
times NNS 1_o
with IN N
both DT N
doses NNS N
of IN N
ibuprofen JJ 1_i
arginate NN 1_i
were VBD N
similar JJ N
to TO N
those DT N
with IN N
both DT N
doses NNS N
of IN N
ibuprofen NN N
, , N
ranging VBG N
from IN N
4.0 CD N
to TO N
5.2 CD N
hours NNS N
. . N

Adverse-event JJ 1_o
profiles NNS 1_o
were VBD N
similar JJ N
between IN N
the DT N
2 CD N
active JJ N
medications NNS N
. . N

CONCLUSIONS NNP N
Ibuprofen NNP 1_i
arginate NN 1_i
was VBD N
effective JJ N
in IN N
this DT N
population NN N
of IN N
patients NNS N
experiencing VBG N
moderate JJ N
to TO N
severe VB N
pain NN N
after IN N
surgical JJ N
extraction NN N
of IN N
> NN N
or CC N
= $ N
1 CD N
impacted JJ N
third JJ N
molar NN N
, , N
with IN N
16 CD N
to TO N
24 CD N
minutes NNS N
' POS N
faster NN N
time NN N
to TO N
meaningful VB N
pain NN 1_o
relief NN 1_o
than IN N
with IN N
ibuprofen NN N
. . N

The DT N
2 CD N
formulations NNS N
had VBD N
similar JJ N
tolerability NN 1_o
profiles NNS 1_o
. . 1_o

Prediction NN N
of IN N
the DT N
infarct-related JJ N
artery NN N
in IN N
acute JJ N
myocardial JJ N
infarction NN N
by IN N
a DT N
scoring NN N
system NN N
using VBG N
summary JJ 1_i
ST-segment JJ 1_i
and CC 1_i
T-wave JJ 1_i
changes NNS 1_i
. . 1_i

We PRP N
developed VBD N
a DT N
scoring NN N
system NN N
to TO N
predict VB N
the DT N
artery NN N
responsible JJ N
for IN N
an DT N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
using VBG N
ST-segment JJ 1_i
and CC 1_i
T-wave JJ 1_i
changes NNS 1_i
on IN 1_i
the DT 1_i
initial JJ 1_i
electrocardiogram NN 1_i
( ( 1_i
ECG NNP 1_i
) ) 1_i
using VBG N
data NNS N
from IN N
228 CD 1_p
patients NNS 1_p
( ( 1_p
development NN 1_p
set VBN 1_p
) ) 1_p
with IN 1_p
symptoms NNS 1_p
compatible JJ 1_p
with IN 1_p
AMI NNP 1_p
and CC 1_p
tested VBN 1_p
in IN 1_p
a DT 1_p
similar JJ 1_p
group NN 1_p
of IN 1_p
223 CD 1_p
patients NNS 1_p
( ( 1_p
test NN 1_p
set VBN 1_p
) ) 1_p
from IN 1_p
the DT 1_p
Thrombolysis NNP 1_p
and CC 1_p
Angioplasty NNP 1_p
in IN 1_p
Myocardial NNP 1_p
Infarction NNP 1_p
( ( 1_p
TAMI-5 NNP 1_p
) ) 1_p
Trial NNP 1_p
. . 1_p

Using VBG N
stepwise JJ N
logistic JJ N
regression NN N
we PRP N
were VBD N
able JJ N
to TO N
accurately RB N
predict VB N
the DT N
left NN N
anterior JJ N
descending NN N
( ( N
LAD NNP N
) ) N
, , N
right JJ N
, , N
or CC N
left VBD N
circumflex NN N
( ( N
LC NNP N
) ) N
coronary JJ N
artery NN N
as IN N
the DT N
infarct-related JJ N
artery NN N
using VBG N
2 CD N
variables NNS N
: : N
( ( N
1 CD N
) ) N
the DT N
summation NN N
of IN N
the DT N
ST-segment JJ N
elevation NN N
in IN N
leads VBZ N
V1 NNP N
to TO N
V4 NNP N
; : N
and CC N
( ( N
2 CD N
) ) N
the DT N
summation NN N
of IN N
the DT N
T-wave NNP N
negativity NN N
in IN N
leads NNS N
I PRP N
, , N
aVL RB N
, , N
and CC N
V5 NNP N
. . N

In IN N
the DT N
development NN N
set NN N
, , N
these DT N
2 CD N
variables NNS N
demonstrated VBD N
respective JJ N
sensitivity NN 1_o
and CC 1_o
specificity NN 1_o
of IN N
98 CD N
% NN N
and CC N
90 CD N
% NN N
for IN N
LAD NNP N
lesions NNS N
, , N
82 CD N
% NN N
and CC N
85 CD N
% NN N
for IN N
right JJ N
narrowings NNS N
, , N
and CC N
82 CD N
% NN N
and CC N
84 CD N
% NN N
for IN N
LC NNP N
narrowings NNS N
. . N

In IN N
the DT N
test NN N
set NN N
, , N
the DT N
sensitivity NN 1_o
and CC 1_o
specificity NN 1_o
were VBD N
97 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
LAD NNP N
lesions NNS N
, , N
85 CD N
% NN N
and CC N
86 CD N
% NN N
for IN N
right JJ N
lesions NNS N
, , N
and CC N
73 CD N
% NN N
and CC N
60 CD N
% NN N
for IN N
LC NNP 1_o
coronary JJ 1_o
artery NN 1_o
lesions NNS 1_o
. . 1_o

Information NNP N
easily RB N
obtained VBD N
on IN N
the DT N
ECG NNP N
can MD N
accurately RB N
predict VB N
the DT N
likelihood NN N
of IN N
the DT N
LAD NNP N
, , N
right RB N
, , N
or CC N
LC NNP N
artery RB N
as IN N
the DT N
infarct-related JJ N
artery NN N
. . N

This DT N
may MD N
be VB N
useful JJ N
in IN N
the DT N
decision NN N
to TO N
administer VB N
thrombolytic JJ N
treatment NN N
. . N

Risperidone-induced JJ N
prolactin NN 1_o
elevation NN 1_o
in IN N
a DT N
prospective JJ N
study NN N
of IN N
children NNS 1_p
, , 1_p
adolescents NNS 1_p
, , 1_p
and CC 1_p
adults NNS 1_p
with IN 1_p
mental JJ 1_p
retardation NN 1_p
and CC 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
. . 1_p

OBJECTIVE NNP N
Risperidone NNP N
is VBZ N
widely RB N
prescribed VBN N
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS 1_p
, , 1_p
adolescents NNS 1_p
, , 1_p
and CC 1_p
adults NNS 1_p
with IN 1_p
mental JJ 1_p
retardation NN 1_p
( ( 1_p
MR NNP 1_p
) ) 1_p
and CC 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
( ( 1_p
PDD NNP 1_p
) ) 1_p
. . 1_p

Risperidone NNP N
elevates VBZ N
prolactin RB 1_o
more JJR N
than IN N
other JJ N
atypical JJ N
antipsychotic JJ N
medications NNS N
. . N

Females NNS N
may MD N
show VB N
greater JJR N
prolactin NN 1_o
elevation NN 1_o
than IN N
males NNS N
. . N

METHOD NNP N
In IN N
this DT N
relatively RB N
long-term JJ N
study NN N
of IN N
risperidone NN 1_i
efficacy NN 1_o
and CC 1_o
safety NN 1_o
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS 1_p
, , 1_p
adolescents NNS 1_p
, , 1_p
and CC 1_p
adults NNS 1_p
with IN 1_p
MR NNP 1_p
and CC 1_p
PDDs NNP 1_p
, , N
serum NN 1_o
prolactin NN 1_o
was VBD N
measured VBN N
in IN N
a DT N
21-subject JJ 1_p
subset NN 1_p
during IN 1_p
the DT 1_p
course NN 1_p
of IN 1_p
a DT 1_p
double-blind JJ 1_p
, , 1_p
placebo-controlled JJ 1_i
trial NN 1_p
. . 1_p

Prolactin NNP 1_o
was VBD N
measured VBN N
in IN N
ng/mL NN N
at IN N
baseline NN N
, , N
once RB N
during IN N
acute JJ N
treatment NN N
, , N
and CC N
once RB N
during IN N
maintenance NN N
. . N

RESULTS NNP N
In IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
( ( 1_p
n=10 NN 1_p
) ) 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
12.5 CD 1_p
years NNS 1_p
, , N
prolactin NN 1_o
increased VBD N
from IN N
mean JJ N
13.2+/-8.6 CD N
at IN N
baseline NN N
to TO N
31.0+/-11.6 JJ N
acutely RB N
and CC N
remained VBD N
elevated VBN N
at IN N
37.9+/-10.4 JJ N
in IN N
maintenance NN N
. . N

In IN N
adults NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
of IN 1_p
35.3 CD 1_p
years NNS 1_p
, , N
prolactin NN 1_o
increased VBD N
more JJR N
markedly RB N
from IN N
11.6+/-7.4 JJ N
baseline NN N
( ( N
n=11 JJ N
) ) N
to TO N
93.3+/-54.2 CD N
acutely RB N
but CC N
decreased VBD N
to TO N
67.8+/-62.9 JJ N
in IN N
maintenance NN N
( ( N
n=7 JJ N
) ) N
. . N

Prolactin NNP 1_o
remained VBD N
significantly RB N
elevated VBN N
above IN N
normal JJ N
in IN N
all DT N
subjects NNS N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
. . N

Mean NNP 1_o
prolactin NN 1_o
of IN N
adult NN N
females NNS N
, , N
while IN N
similar JJ N
to TO N
that DT N
of IN N
adult NN N
males NNS N
at IN N
baseline NN N
, , N
was VBD N
2.2 CD N
times NNS N
male JJ N
levels NNS N
acutely RB N
and CC N
3.7 CD N
times NNS N
greater JJR N
in IN N
maintenance NN N
. . N

CONCLUSION NN N
In IN N
this DT N
small JJ N
subset NN N
, , N
mean JJ 1_o
prolactin NN 1_o
elevation NN 1_o
persisted VBD N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
. . N

In IN N
adults NNS N
, , N
females NNS N
showed VBD N
significantly RB N
greater JJR N
elevations NNS N
than IN N
males NNS N
. . N

Mechanical JJ N
sensitivity NN N
of IN N
the DT N
human JJ 1_p
conjunctiva NN 1_p
. . 1_p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
map VB N
the DT N
sensitivity NN N
of IN N
the DT N
marginal JJ N
and CC N
other JJ N
conjunctival NN N
regions NNS N
and CC N
to TO N
investigate VB N
changes NNS N
in IN N
the DT N
sensitivity NN N
of IN N
these DT N
regions NNS N
when WRB N
determined VBN N
in IN N
the DT N
morning NN N
and CC N
evening NN N
. . N

METHODS NNP N
Thirty-five JJ 1_p
healthy JJ 1_p
, , 1_p
noncontact JJ 1_p
lens VBZ 1_p
wearers NNS 1_p
( ( 1_p
20 CD 1_p
female NN 1_p
, , 1_p
15 CD 1_p
male NN 1_p
; : 1_p
age NN 1_p
27.7 CD 1_p
± JJ 1_p
7.3 CD 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_i

Mechanical JJ 1_i
sensitivity NN 1_i
was VBD 1_i
measured VBN 1_i
at IN 1_i
8 CD 1_i
locations NNS 1_i
on IN 1_i
the DT 1_i
ocular JJ 1_i
surface NN 1_i
and CC 1_i
adnexa NN 1_i
( ( 1_i
cornea NN 1_i
, , 1_i
marginal JJ 1_i
, , 1_i
bulbar NN 1_i
, , 1_i
and CC 1_i
tarsal VB 1_i
conjunctiva NN 1_i
) ) 1_i
using VBG 1_i
a DT 1_i
Cochet-Bonnet JJ 1_i
esthesiometer NN 1_i
( ( 1_i
0.12-mm JJ 1_i
diameter NN 1_i
filament NN 1_i
) ) 1_i
. . N

A DT N
subgroup NN N
of IN N
11 CD N
subjects NNS N
( ( N
6 CD N
female NN N
, , N
5 CD N
male NN N
; : N
age NN N
28.9 CD N
± JJ N
9.9 CD N
years NNS N
) ) N
returned VBD N
after IN N
12 CD N
hours NNS N
when WRB N
this DT N
protocol NN N
was VBD N
repeated VBN N
. . N

RESULTS VB N
The DT N
cornea NN N
was VBD N
found VBN N
to TO N
be VB N
the DT 1_o
most RBS 1_o
sensitive JJ 1_o
region NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT 1_o
marginal JJ 1_o
conjunctiva NN 1_o
showed VBD 1_o
greater JJR 1_o
sensitivity NN 1_o
than IN N
did VBD N
the DT N
bulbar NN N
and CC N
tarsal NN N
conjunctiva NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT 1_o
temporal JJ 1_o
marginal JJ 1_o
conjunctiva NN 1_o
was VBD 1_o
more RBR 1_o
sensitive JJ 1_o
than IN N
the DT N
central JJ N
marginal JJ N
conjunctiva NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
difference NN N
in IN 1_o
marginal JJ 1_o
conjunctival NN 1_o
sensitivity NN 1_o
was VBD N
found VBN N
between IN N
upper JJ N
and CC N
lower JJR N
eyelids NNS N
( ( N
all DT N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT 1_o
upper JJ 1_o
tarsal NN 1_o
conjunctiva NN 1_o
was VBD 1_o
more RBR 1_o
sensitive JJ 1_o
than IN N
the DT N
lower JJR N
tarsal NN N
conjunctiva NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT 1_o
sensitivity NN 1_o
determined VBN N
in IN N
the DT N
morning NN N
and CC N
the DT N
evening NN N
for IN N
any DT N
of IN N
the DT N
locations NNS N
investigated VBN N
( ( N
Bonferroni NNP N
adjusted VBN N
, , N
P NNP N
> NNP N
0.006 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
work NN N
has VBZ N
demonstrated VBN N
that IN N
the DT 1_o
marginal JJ 1_o
conjunctiva NN 1_o
was VBD 1_o
the DT 1_o
most RBS 1_o
sensitive JJ 1_o
of IN N
all PDT N
the DT N
conjunctival NN N
regions NNS N
and CC N
that IN N
this DT N
does VBZ N
not RB N
alter VB N
over IN N
the DT N
course NN N
of IN N
the DT N
day NN N
. . N

Microbial JJ N
protein NN N
synthesis NN N
, , N
nitrogen JJ N
capture NN N
efficiency NN N
and CC N
nutrient JJ N
utilisation NN N
in IN N
sheep JJ 1_p
fed NN 1_p
on IN 1_p
finger NN 1_i
millet NN 1_i
straw NN 1_i
( ( 1_i
Eleucine NNP 1_i
coracana NN 1_i
) ) 1_i
-based VBD 1_i
diet JJ 1_p
with IN N
different JJ N
rumen-degradable JJ N
nitrogen NN N
levels NNS N
. . N

BACKGROUND NNP N
Microbial NNP N
protein NN N
synthesised VBD N
in IN N
the DT N
rumen NNS N
is VBZ N
a DT N
very RB N
important JJ N
protein NN N
source NN N
for IN N
ruminants NNS N
. . N

It PRP N
is VBZ N
essential JJ N
to TO N
provide VB N
an DT N
adequate JJ N
amount NN N
of IN N
rumen-degradable JJ N
nitrogen NN N
( ( N
RDN NNP N
) ) N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
in IN N
the DT N
rumen NNS N
on IN N
straw-based JJ N
diets NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
RDN NNP N
requirement NN N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
( ( N
MPS NNP N
) ) N
, , N
nitrogen JJ N
capture NN N
efficiency NN N
( ( N
NCE NNP N
) ) N
and CC N
nutrient JJ N
utilisation NN N
in IN N
Nellore NNP 1_p
rams NNS 1_p
fed VBP 1_p
on IN 1_p
a DT 1_p
finger NN 1_i
millet NN 1_i
straw NN 1_i
( ( 1_i
FMS NNP 1_i
) ) 1_i
-based VBD 1_i
diet JJ 1_i
. . 1_i

RESULTS VB N
Thirty-six JJ 1_p
Nellore NNP 1_p
sheep NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
of IN N
nine CD N
animals NNS N
each DT N
using VBG N
a DT N
balanced VBN N
, , N
completely RB N
randomised JJ N
design NN N
. . N

The DT N
animals NNS N
in IN N
group NN N
1 CD N
( ( N
RDN0 NNP N
) ) N
were VBD N
fed VBN N
with IN N
ad NN 1_i
libitum NN 1_i
FMS NNP 1_i
. . 1_i

Those DT N
in IN N
groups NNS N
2 CD N
, , N
3 CD N
and CC N
4 CD N
( ( N
RDN1 NNP N
, , N
RDN2 NNP N
and CC N
RDN3 NNP N
) ) N
were VBD N
supplemented VBN N
with IN N
groundnut NNS 1_i
cake VBP 1_i
to TO N
provide VB N
RDN NNP 1_o
levels NNS 1_o
of IN N
14 CD N
, , N
18 CD N
and CC N
23 CD N
g NN N
RDN NNP N
kg⁻¹ NNP N
digestible JJ N
organic JJ N
matter NN N
intake NN N
( ( N
DOMI NNP N
) ) N
or CC N
21 CD N
, , N
27 CD N
and CC N
35 CD N
g NN N
RDN NNP N
kg⁻¹ NNP N
digestible JJ N
organic JJ N
matter NN N
apparently RB N
digested VBN N
in IN N
the DT N
rumen NNS N
( ( N
DOMR NNP N
) ) N
respectively RB N
along IN 1_i
with IN 1_o
FMS NNP 1_o
. . 1_o

The DT 1_o
digestibility NN 1_o
coefficients NNS 1_o
of IN 1_o
all DT 1_o
nutrients NNS 1_o
and CC 1_o
MPS NNP 1_o
increased VBD 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
quadratically RB N
with IN N
increasing VBG 1_o
level NN 1_o
of IN 1_o
RDN NNP 1_o
supplementation NN 1_o
. . 1_o

NCE NNP 1_o
decreased VBD 1_o
linearly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
the DT N
level NN 1_o
of IN 1_o
RDN NNP 1_o
increased VBD 1_o
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
12 CD N
g NNS N
RDN NNP N
kg⁻¹ VBP N
DOMI NNP N
or CC N
19 CD N
g NNS N
RDN NNP N
kg⁻¹ VBD N
DOMR NNP N
may MD N
be VB N
adequate JJ N
for IN N
optimum JJ N
MPS NNP N
, , N
NCE NNP N
and CC N
digestibility NN N
of IN N
nutrients NNS 1_p
in IN 1_p
sheep JJ 1_i
fed NN 1_i
on IN 1_i
an DT 1_i
FMS-based JJ 1_i
diet NN N
. . N

The DT N
effect NN N
of IN N
vitamin JJ 1_i
A-fortified NNP 1_i
coconut NN 1_i
cooking VBG 1_i
oil NN 1_i
on IN N
the DT N
serum NN 1_o
retinol JJ 1_o
concentration NN 1_o
of IN 1_p
Filipino NNP 1_p
children NNS 1_p
4-7 CD 1_p
years NNS 1_p
old JJ 1_p
. . 1_p

A DT N
6-month JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
among IN N
542 CD 1_p
Filipino NNP 1_p
children NNS 1_p
aged VBD 1_p
4 CD 1_p
to TO 1_p
7 CD 1_p
years NNS 1_p
to TO N
determine VB N
the DT N
effect NN N
of IN N
vitamin JJ 1_i
A-fortified NNP 1_i
coconut NN 1_i
cooking VBG 1_i
oil NN 1_i
intake NN N
on IN N
their PRP$ N
vitamin NN N
A DT N
status NN N
and CC N
to TO N
identify VB N
factors NNS N
that WDT N
influence NN N
this DT N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
vitamin JJ 1_i
A-fortified JJ 1_i
cooking NN 1_i
oil NN 1_i
ration NN N
; : N
to TO N
Control-1 NNP N
group NN N
with IN N
unfortified JJ 1_i
cooking NN 1_i
oil NN 1_i
ration NN 1_i
; : 1_i
and CC N
to TO N
Control-2 NNP N
group NN N
without IN 1_i
cooking VBG 1_i
oil NN 1_i
ration NN 1_i
. . 1_i

In IN N
all DT N
groups NNS N
, , N
children NNS N
's POS N
serum NN N
retinol NN 1_o
concentration NN 1_o
improved VBN N
. . N

Relative JJ N
change NN N
in IN N
serum NN 1_o
retinol NN 1_o
concentration NN 1_o
was VBD N
significantly RB N
higher JJR N
among IN N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
one-third NN N
of IN N
total JJ N
vitamin FW N
A DT N
intake NN N
coming VBG N
from IN N
vitamin JJ 1_i
A-fortified JJ 1_i
cooking NN 1_i
oil NN 1_i
intake NN N
, , N
than IN N
in IN N
the DT N
Control NNP N
groups NNS N
, , N
with IN N
more JJR N
than IN N
half NN N
of IN N
intake NN N
from IN N
other JJ N
vitamin JJ N
A-rich JJ N
foods NNS N
. . N

Determinants NNS N
of IN N
post-intervention NN N
serum NN N
retinol NN N
concentration NN N
included VBD N
baseline JJ N
serum NN N
retinol NN N
concentration NN N
, , N
caregiver NN N
's POS N
education NN N
, , N
receipt NN N
of IN N
high-dose JJ N
vitamin NN N
A NNP N
capsule NN N
, , N
interaction NN N
between IN N
consumption NN N
of IN N
vitamin JJ N
A-fortified JJ N
cooking NN N
oil NN N
and CC N
of IN N
other JJ N
vitamin JJ N
A-rich NNP N
foods NNS N
, , N
and CC N
between IN N
households NNS N
purchasing VBG N
cooking JJ N
oil NN N
and CC N
food NN N
expenditure NN N
. . N

Intake NNP N
of IN N
vitamin JJ 1_i
A-fortified JJ 1_i
cooking NN 1_i
oil NN 1_i
combined VBN N
with IN N
vitamin JJ N
A-rich NNP N
foods NNS N
was VBD N
necessary JJ N
to TO N
increase VB N
serum NN 1_o
retinol JJ 1_o
concentration NN 1_o
. . 1_o

It PRP N
is VBZ N
recommended VBN N
to TO N
vigorously RB N
promote VB N
the DT N
consumption NN N
of IN N
vitamin JJ 1_i
A-fortified JJ 1_i
cooking NN 1_i
oil NN 1_i
together RB N
with IN N
other JJ N
vitamin JJ N
A-rich JJ N
sources NNS N
to TO N
sustain VB N
the DT N
prevention NN 1_o
and CC N
control NN 1_o
of IN N
vitamin FW N
A DT N
deficiency NN 1_o
. . 1_o

Controlled VBN N
trial NN N
of IN N
induction NN N
of IN N
labor NN 1_o
by IN N
vaginal JJ N
suppositories NNS 1_i
containing VBG N
prostaglandin NN 1_i
E2 NNP 1_i
. . 1_i

A NNP N
group NN N
of IN N
84 CD 1_p
women NNS 1_p
at IN 1_p
39-43 JJ 1_p
weeks NNS 1_p
of IN 1_p
pregnancy NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
blind JJ N
trial NN N
of IN N
induction NN N
of IN N
labor NN 1_o
with IN N
vaginal JJ N
suppositories NNS 1_i
containing VBG N
inert JJ 1_i
material NN 1_i
or CC N
either CC N
0.2 CD N
mg NN N
or CC N
0.4 CD N
mg NN N
of IN N
prostaglandin NN 1_i
E2 NNP 1_i
. . 1_i

The DT N
suppositories NNS N
were VBD N
self-administered JJ N
every DT N
two CD N
hours NNS N
during IN N
waking VBG N
hours NNS N
on IN N
two CD N
successive JJ N
days NNS N
until IN N
labor NN N
started VBD N
or CC N
15 CD N
had VBD N
been VBN N
used VBN N
. . N

Side-effects NNS N
were VBD N
absent JJ N
. . N

Labor NN 1_o
was VBD 1_o
established VBN 1_o
within IN N
48 CD N
hr NN N
of IN N
insertion NN N
of IN N
the DT N
first JJ N
suppository NN N
in IN N
9.3 CD N
% NN N
of IN N
control NN N
patients NNS N
, , N
65.4 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
0.2 CD N
mg NNS N
PGE2 NNP 1_i
and CC N
85.7 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
0.4 CD N
mg NNS N
PGE2 NNP 1_i
. . 1_i

The DT N
mean JJ 1_o
Apgar NNP 1_o
scores NNS 1_o
in IN N
the DT N
three CD N
groups NNS N
were VBD N
the DT N
same JJ N
. . N

The DT N
mean JJ 1_o
total NN 1_o
dose NN 1_o
of IN 1_o
PGE2 NNP 1_o
were VBD N
2.0 CD N
mg NN N
( ( N
0.2 CD N
mg NNS N
group NN N
) ) N
and CC N
2.3 CD N
mg NN N
( ( N
0.4 CD N
mg NNS N
group NN N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
vaginal JJ 1_o
PGE2 NNP 1_o
is VBZ N
an DT N
effective JJ N
and CC N
acceptable JJ N
method NN 1_o
of IN 1_o
inducing VBG 1_o
labor NN 1_o
at IN 1_o
term NN 1_o
. . 1_o

Does VBZ N
an DT N
in-season JJ 1_i
detraining NN 1_i
period NN N
affect VBP N
the DT N
shoulder NN N
rotator NN N
cuff NN N
strength NN N
and CC N
balance NN N
of IN N
young JJ 1_p
swimmers NNS 1_p
? . N
Imbalance NN N
in IN N
shoulder NN N
rotator NN N
muscles NNS N
is VBZ N
a DT N
well-documented JJ N
problem NN N
in IN N
swimmers NNS 1_p
, , N
and CC N
it PRP N
is VBZ N
important JJ N
to TO N
implement VB N
land-based JJ N
strength NN N
training NN N
programs NNS N
. . N

Meanwhile RB N
, , N
the DT N
effects NNS N
of IN N
a DT N
detraining JJ N
period NN N
on IN N
swimmers NNS N
' POS N
shoulder NN N
rotator NN N
muscles NNS N
are VBP N
unknown JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
effects NNS N
of IN N
a DT N
strength NN 1_i
training NN 1_i
program NN 1_i
and CC 1_i
detraining VBG 1_i
on IN N
the DT N
strength NN N
and CC N
balance NN N
of IN N
shoulder NN N
rotator NN N
cuff NN N
muscles NNS N
in IN N
young JJ 1_p
swimmers NNS 1_p
, , N
despite IN N
the DT N
continuity NN N
of IN N
usual JJ N
water NN N
training NN N
. . N

An DT 1_p
experimental JJ 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
20 CD 1_p
) ) 1_p
and CC 1_p
a DT 1_p
control NN 1_p
group NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
20 CD 1_p
) ) 1_p
of IN 1_p
young JJ 1_p
male NN 1_p
swimmers NNS 1_p
with IN 1_p
the DT 1_p
same JJ 1_p
characteristics NNS 1_p
( ( 1_p
age NN 1_p
, , 1_p
body NN 1_p
mass NN 1_p
, , 1_p
height NN 1_p
, , 1_p
training NN 1_p
volume NN 1_p
, , 1_p
and CC 1_p
maturational JJ 1_p
state NN 1_p
) ) 1_p
were VBD 1_p
evaluated VBN 1_p
. . 1_p

In IN N
both DT N
groups NNS N
, , N
the DT N
peak NN 1_o
torques NNS 1_o
of IN 1_o
shoulder NN 1_o
internal JJ 1_o
( ( 1_o
IR NNP 1_o
) ) 1_o
and CC 1_o
external JJ 1_o
( ( 1_o
ER NNP 1_o
) ) 1_o
rotators NNS 1_o
were VBD N
assessed VBN N
during IN N
preseason NN N
, , N
midseason NN N
( ( N
16 CD N
weeks NNS N
) ) N
, , N
and CC N
postseason NN N
( ( N
32 CD N
weeks NNS N
) ) N
. . N

The DT N
experimental JJ N
group NN N
underwent VBD N
a DT N
strength NN 1_i
training VBG 1_i
regimen NNS 1_i
from IN N
baseline NN N
to TO N
16 CD N
weeks NNS N
and CC N
a DT N
detraining JJ 1_i
period NN N
from IN N
16 CD N
to TO N
32 CD N
weeks NNS N
. . N

Concentric JJ N
action NN N
at IN N
60°·s-1 JJ N
and CC N
180°·s-1 JJ N
was VBD N
measured VBN N
using VBG N
an DT N
isokinetic JJ N
dynamometer NN N
. . N

The DT 1_o
ER/IR NNP 1_o
strength NN 1_o
ratios NNS 1_o
were VBD N
obtained VBN N
. . N

At IN N
60°·s-1 JJ N
, , N
there EX N
were VBD N
significant JJ 1_o
increments NNS 1_o
in IN 1_o
IR NNP 1_o
strength NN 1_o
and CC 1_o
the DT 1_o
ER/IR NNP 1_o
ratio NN N
in IN N
both DT N
shoulders NNS N
. . N

This DT N
trend NN N
was VBD N
the DT N
same JJ N
throughout IN N
the DT N
competitive JJ N
season NN N
. . N

The DT N
tendency NN N
was VBD N
the DT N
same JJ N
at IN N
180°·s-1 JJ N
because IN N
training VBG N
effects NNS N
were VBD N
noted VBN N
primarily RB 1_o
in IN 1_o
IR NNP 1_o
and CC 1_o
ER/IR NNP 1_o
ratios NNS N
. . N

Moreover RB N
, , N
the DT N
absence NN N
of IN N
land-based JJ N
strength NN N
training NN N
, , N
from IN N
16 CD N
to TO N
32 CD N
weeks NNS N
, , N
revealed VBD 1_o
a DT 1_o
reduction NN 1_o
in IN 1_o
the DT 1_o
ER/IR NNP 1_o
ratio NN 1_o
values NNS N
in IN N
both DT N
shoulders NNS N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
young JJ N
swimmers NNS N
' POS N
coaches NNS N
should MD 1_i
use VB 1_i
dry-land JJ 1_i
strength NN 1_i
training NN 1_i
protocols NNS 1_i
, , N
and CC N
that IN N
it PRP N
is VBZ N
recommended VBN N
that IN N
these DT N
should MD N
be VB N
conducted VBN N
on IN N
a DT N
regular JJ N
basis NN N
( ( N
during IN N
the DT N
whole JJ N
season NN N
) ) N
. . N

Combined VBN 1_i
typhoid JJ 1_i
fever NN 1_i
and CC 1_i
hepatitis VB 1_i
A DT 1_i
vaccine NN 1_i
: : 1_i
comparison NN N
of IN N
immunogenicity NN 1_o
and CC 1_o
safety NN 1_o
to TO N
concomitant VB N
monovalent JJ N
vaccine NN N
over IN N
3 CD N
years NNS N
. . N

BACKGROUND IN N
The DT N
safety NN 1_o
and CC 1_o
immunogenicity NN 1_o
of IN N
Viatim NNP 1_i
, , N
a DT N
combined JJ 1_i
hepatitis NN 1_i
A NNP 1_i
( ( 1_i
HA NNP 1_i
) ) 1_i
and CC 1_i
typhoid JJ 1_i
fever NN 1_i
( ( 1_i
Vi NNP 1_i
) ) 1_i
vaccine NN 1_i
, , N
were VBD N
compared VBN N
with IN N
the DT N
monovalent JJ 1_i
component NN 1_i
vaccines VBZ 1_i
up IN N
to TO N
and CC N
1 CD N
month NN N
after IN N
a DT N
booster NN N
dose NN N
at IN N
3 CD N
years NNS N
. . N

METHODS NNP N
Healthy NNP 1_p
, , 1_p
adult NN 1_p
volunteers NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
Viatim NNP 1_i
( ( 1_p
group NN 1_p
A NNP 1_p
, , 1_p
n JJ 1_p
= NNP 1_p
179 CD 1_p
) ) 1_p
or CC N
separate JJ 1_i
HA NNP 1_i
and CC 1_i
Vi NNP 1_i
vaccines NNS 1_i
( ( 1_p
group NN 1_p
B NNP 1_p
, , 1_p
n JJ 1_p
= NNP 1_p
181 CD 1_p
) ) 1_p
; : 1_p
subgroups NNS N
were VBD N
boosted VBN N
after IN N
3 CD N
years NNS N
with IN N
Viatim NNP 1_i
( ( 1_p
groups NNS 1_p
C NNP 1_p
and CC 1_p
D NNP 1_p
, , 1_p
n JJ 1_p
= NN 1_p
56 CD 1_p
and CC 1_p
46 CD 1_p
, , 1_p
respectively RB 1_p
) ) 1_p
. . 1_p

Local JJ N
and CC N
systemic JJ N
reactions NNS N
were VBD N
recorded VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
. . N

Seroconversion NN 1_o
and CC 1_o
seroprotection NN 1_o
rates NNS 1_o
and CC 1_o
geometric JJ 1_o
mean NN 1_o
antibody NN 1_o
concentrations NNS 1_o
were VBD N
measured VBN N
at IN N
14 CD N
and CC N
28 CD N
days NNS N
, , N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
years NNS N
postvaccination NN N
, , N
and CC N
28 CD N
days NNS N
after IN N
the DT N
booster NN N
dose NN N
. . N

RESULTS NNP N
Local NNP 1_o
and CC 1_o
systemic JJ 1_o
safety NN 1_o
profiles NNS 1_o
were VBD N
equivalent JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Immediate NNP 1_o
local JJ 1_o
reactions NNS 1_o
were VBD N
infrequent JJ N
( ( N
1 CD N
in IN N
group NN N
A NNP N
and CC N
2 CD N
in IN N
group NN N
B NNP N
) ) N
. . N

Local JJ 1_o
reactions NNS 1_o
, , 1_o
consisting VBG 1_o
mostly RB 1_o
of IN 1_o
mild NN 1_o
or CC 1_o
moderate JJ 1_o
pain NN 1_o
, , N
were VBD N
least JJS N
frequent JJ N
with IN N
monovalent JJ N
HA NNP N
. . N

Antibody NNP 1_o
concentrations NNS 1_o
to TO N
both DT N
antigens NNS N
were VBD N
similar JJ N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
in IN N
which WDT N
HA NNP 1_o
seroprotection NN 1_o
rates NNS 1_o
( ( N
> CD N
or CC N
= VB N
20 CD N
mIU/mL NN N
) ) N
were VBD N
respectively RB N
, , N
98.7 CD N
% NN N
and CC N
100 CD N
% NN N
at IN N
day NN N
28 CD N
, , N
and CC N
99.1 CD N
% NN N
and CC N
99.0 CD N
% NN N
after IN N
3 CD N
years NNS N
, , N
achieving VBG N
100 CD N
% NN N
after IN N
the DT N
booster NN N
. . N

Vi NNP 1_o
seroprotection NN 1_o
rates NNS 1_o
( ( N
> CD N
or CC N
= VB N
1 CD N
microg/mL NN N
) ) N
of IN N
85.2 CD N
% NN N
and CC N
84.9 CD N
% NN N
after IN N
28 CD N
days NNS N
fell VBD N
to TO N
32.1 CD N
% NN N
and CC N
35.6 CD N
% NN N
after IN N
3 CD N
years NNS N
, , N
increasing VBG N
to TO N
67.3 CD N
% NN N
and CC N
69.8 CD N
% NN N
after IN N
the DT N
booster NN N
dose NN N
. . N

CONCLUSIONS VB N
The DT N
combined JJ 1_i
HA/Vi NNP 1_i
vaccine NN 1_i
, , 1_i
Viatim NNP 1_i
, , N
had VBD N
equivalent JJ N
tolerability NN 1_o
and CC 1_o
safety NN 1_o
and CC 1_o
was VBD 1_o
as IN 1_o
rapidly RB 1_o
immunogenic JJ 1_o
as IN N
its PRP$ N
component NN N
monovalent NN N
vaccines NNS N
when WRB N
given VBN N
concurrently RB N
. . N

A DT N
booster NN N
dose NN N
after IN N
3 CD N
years NNS N
significantly RB N
increased VBD N
antibody NN 1_o
levels NNS 1_o
with IN N
some DT N
evidence NN N
of IN N
relative JJ N
hyporesponsiveness NN 1_o
of IN 1_o
the DT 1_o
typhoid JJ 1_o
response NN 1_o
. . 1_o

Bevacizumab-augmented JJ 1_i
retinal JJ 1_i
laser NN 1_i
photocoagulation NN 1_i
in IN N
proliferative JJ 1_p
diabetic JJ 1_p
retinopathy NN 1_p
: : 1_p
a DT N
randomized JJ N
double-masked JJ N
clinical JJ N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
additional JJ N
therapeutic JJ N
effect NN N
of IN N
single JJ N
intravitreal NN 1_i
bevacizumab NN 1_i
injection NN 1_i
on IN N
standard JJ 1_i
laser NN 1_i
treatment NN 1_i
in IN N
the DT N
management NN N
of IN N
proliferative JJ N
diabetic JJ N
retinopathy NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
, , N
fellow-eye JJ N
sham NN N
controlled VBD N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
80 CD 1_p
eyes NNS 1_p
of IN 1_p
40 CD 1_p
high-risk JJ 1_p
characteristic JJ 1_p
proliferative JJ 1_p
diabetic JJ 1_p
retinopathy NN 1_p
type NN 1_p
II NNP 1_p
diabetics NNS 1_p
. . 1_p

All DT N
cases NNS N
received VBN N
standard JJ N
laser NN 1_i
treatment NN 1_i
according VBG N
to TO N
Early NNP N
Treatment NNP N
Diabetic NNP N
Retinopathy NNP N
Study NNP N
protocol NN N
. . N

Avastin-assigned JJ N
eyes NNS N
received VBD N
1.25 CD 1_i
mg NNS 1_i
intravitreal JJ 1_i
bevacizumab NN 1_i
( ( N
Genentech NNP N
Inc. NNP N
, , N
San NNP N
Francisco NNP N
, , N
CA NNP N
) ) N
on IN N
the DT N
first JJ N
session NN N
of IN N
their PRP$ N
laser NN N
treatments NNS N
. . N

Fluorescein NNP 1_i
angiography NN 1_i
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
weeks NNS N
6 CD N
and CC N
16 CD N
, , N
and CC N
proliferative JJ N
diabetic JJ N
retinopathy NN N
regression NN N
was VBD N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
. . N

RESULTS VB N
The DT 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
52 CD 1_p
years NNS 1_p
( ( 1_p
range NN 1_p
: : 1_p
39-68 JJ 1_p
) ) 1_p
and CC 1_p
30 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
participants NNS 1_p
were VBD 1_p
male JJ 1_p
. . 1_p

All DT N
patients NNS N
were VBD N
followed VBN N
for IN N
16 CD N
weeks NNS N
. . N

A DT N
total NN N
of IN N
87.5 CD N
% NN N
of IN N
Avastin-injected JJ N
eyes NNS N
and CC N
25 CD N
% NN N
of IN N
sham NN N
group NN N
showed VBD N
complete JJ 1_o
regression NN 1_o
at IN N
week NN N
6 CD N
of IN N
follow-up NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

However RB N
, , N
at IN N
week NN N
16 CD N
, , N
PDR NNP 1_o
recurred VBD N
in IN N
a DT N
sizable JJ N
number NN N
of IN N
the DT N
Avastin-treated JJ N
eyes NNS N
, , N
and CC N
the DT N
complete JJ 1_o
regression NN 1_o
rate NN 1_o
in IN N
the DT N
two CD N
groups NNS N
became VBD N
identical JJ N
( ( N
25 CD N
% NN N
; : N
p=1.000 NN N
) ) N
; : N
partial JJ N
regression NN N
rates NNS N
were VBD N
70 CD N
% NN N
vs JJ N
65 CD N
% NN N
. . N

In IN N
the DT N
subgroup NN N
of IN N
Avastin-treated JJ 1_i
eyes NNS N
, , N
multivariate NN N
analysis NN N
identified VBN N
hemoglobin JJ N
A1c NNP N
as IN N
the DT N
strongest JJS N
predictor NN N
of IN N
proliferative JJ 1_o
diabetic JJ 1_o
retinopathy NN 1_o
recurrence NN 1_o
( ( N
p=0.033 NN N
) ) N
. . N

CONCLUSIONS NNP N
Intravitreal NNP N
bevacizumab NN 1_i
remarkably RB N
augmented VBD N
the DT N
short-term JJ N
response NN N
to TO N
scatter VB N
panretinal JJ N
laser NN N
photocoagulation NN N
in IN N
high-risk JJ N
characteristic JJ N
proliferative JJ N
diabetic JJ N
retinopathy NN N
but CC N
the DT N
effect NN N
was VBD N
short-lived JJ N
, , N
as IN N
many JJ N
of IN N
the DT N
eyes NNS N
showed VBD N
rapid JJ 1_o
recurrence NN 1_o
. . 1_o

Alternative JJ N
dosing NN N
( ( N
multiple JJ N
and/or NN N
periodic JJ N
intravitreal NN N
Avastin NNP 1_i
injections NNS N
) ) N
is VBZ N
recommended VBN N
for IN N
further JJ N
evaluation NN N
. . N

A DT N
randomised JJ N
open JJ N
multicentre NN N
comparative JJ N
trial NN N
of IN N
lamotrigine NN 1_i
and CC 1_i
carbamazepine NN 1_i
as IN N
monotherapy NN N
in IN N
patients NNS 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
or CC 1_p
recurrent JJ 1_p
epilepsy NN 1_p
. . 1_p

The DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
lamotrigine NN 1_i
and CC 1_i
carbamazepine NN 1_i
as IN N
monotherapy NN N
in IN N
patients NNS 1_p
with IN 1_p
untreated JJ 1_p
, , 1_p
newly RB 1_p
diagnosed VBN 1_p
or CC 1_p
recurrent JJ 1_p
partial JJ 1_p
and/or NN 1_p
generalised VBD 1_p
tonic-clonic JJ 1_p
seizures NNS 1_p
, , N
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
, , N
open JJ N
, , N
multicentre JJ N
study NN N
. . N

Patients NNS N
received VBD N
24 CD N
weeks NNS N
' POS N
treatment NN N
with IN N
oral JJ 1_i
lamotrigine NN 1_i
100 CD 1_i
mg NN 1_i
( ( 1_i
LTG NNP 1_i
100 CD 1_i
, , 1_i
n RB 1_i
= VBZ 1_i
115 CD 1_i
) ) 1_i
or CC 1_i
200 CD 1_i
mg NN 1_i
( ( 1_i
LTG NNP 1_i
200 CD 1_i
, , 1_i
n RB 1_i
= VBZ 1_i
111 CD 1_i
) ) 1_i
or CC 1_i
carbamazepine $ 1_i
600 CD 1_i
mg NN 1_i
( ( 1_i
CBZ NNP 1_i
600 CD N
, , N
n RB N
= VBZ N
117 CD N
) ) N
. . N

Efficacy NN 1_o
measurements NNS 1_o
were VBD N
comparable JJ N
between IN N
the DT N
three CD N
treatment NN N
groups NNS N
, , N
although IN N
the DT N
higher JJR N
lamotrigine NN 1_i
dose NN N
was VBD N
possibly RB N
most RBS N
effective JJ N
, , N
with IN N
60.4 CD N
% NN N
completing VBG N
seizure NN N
free JJ N
compared VBN N
with IN N
51.3 CD N
% NN N
( ( N
LTG NNP N
100 CD N
) ) N
and CC N
54.7 CD N
% NN N
( ( N
CBZ NNP N
600 CD N
) ) N
. . N

Both DT N
dosage NN N
regimens NNS N
of IN N
lamotrigine NN 1_i
were VBD N
well RB N
tolerated VBN 1_o
. . 1_o

More JJR N
patients NNS 1_p
on IN 1_p
CBZ NNP 1_i
600 CD 1_p
reported VBD N
adverse JJ 1_o
experiences NNS 1_o
, , N
66 CD N
% NN N
versus IN N
53 CD N
% NN N
( ( 1_i
LTG NNP 1_i
100 CD N
) ) N
and CC N
58 CD N
% NN N
( ( 1_i
LTG NNP 1_i
200 CD N
) ) N
, , N
and CC N
of IN N
these DT N
a DT N
greater JJR N
proportion NN N
were VBD N
attributed VBN N
to TO N
CBZ NNP 1_i
600 CD N
treatment NN N
, , N
53 CD N
% NN N
versus IN N
23 CD N
% NN N
( ( N
LTG NNP N
100 CD N
) ) N
and CC N
28 CD N
% NN N
( ( N
LTG NNP N
200 CD N
) ) N
. . N

Similarly RB N
, , N
a DT N
greater JJR N
proportion NN N
of IN N
the DT N
CBZ NNP 1_i
600 CD N
group NN N
required VBD N
a DT N
change NN N
in IN N
dose NN N
, , N
47 CD N
% NN N
versus IN N
20 CD N
% NN N
( ( 1_i
LTG NNP 1_i
100 CD N
) ) N
and CC N
17 CD N
% NN N
( ( 1_i
LTG NNP 1_i
200 CD N
) ) N
or CC N
withdrew $ N
completely RB N
due JJ N
to TO N
adverse JJ 1_o
experiences NNS 1_o
, , N
10.3 CD N
% NN N
versus IN N
4.3 CD N
% NN N
( ( 1_i
LTG NNP 1_i
100 CD N
) ) N
and CC N
4.5 CD N
% NN N
( ( 1_i
LTG NNP 1_i
200 CD N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ 1_o
experience NN 1_o
leading VBG N
to TO N
withdrawal VB N
was VBD N
rash NN 1_o
, , N
with IN N
approximately RB N
double JJ N
the DT N
proportion NN N
of IN N
reports NNS N
occurring VBG N
in IN N
patients NNS N
on IN N
CBZ NNP 1_i
600 CD N
( ( N
5.1 CD N
% NN N
) ) N
compared VBN N
with IN N
lamotrigine NN 1_i
( ( N
1.7 CD N
% NN N
on IN N
LTG NNP 1_i
100 CD N
and CC N
2.7 CD N
% NN N
on IN N
LTG NNP 1_i
200 CD N
) ) N
. . N

Overall JJ N
lamotrigine NN 1_i
appeared VBD N
equally RB N
effective JJ N
but CC N
better RB N
tolerated VBD N
compared VBN N
with IN N
carbamazepine NN 1_i
. . 1_i

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
of IN N
two CD N
doses NNS N
of IN N
pemetrexed JJ 1_i
as IN N
first-line JJ N
chemotherapy NN N
for IN N
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

PURPOSE NNP N
Pemetrexed NNP 1_i
has VBZ N
shown VBN N
varied JJ N
response NN N
rates NNS N
in IN N
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
two CD N
doses NNS N
of IN N
pemetrexed NN 1_i
in IN N
a DT N
homogeneous JJ N
population NN N
. . N

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
identify VB N
molecular JJ N
biomarkers NNS N
correlating VBG N
with IN N
response NN 1_o
and CC 1_o
toxicity NN 1_o
. . 1_o

EXPERIMENTAL NNP N
DESIGN NNP N
Patients NNPS 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
or CC 1_p
locally RB 1_p
recurrent JJ 1_p
breast NN 1_p
cancer NN 1_p
received VBD N
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( 1_i
P600 NNP 1_i
arm NN N
) ) N
or CC N
900 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( 1_i
P900 NNP 1_i
arm NN N
) ) N
of IN N
pemetrexed NN 1_i
on IN N
day NN N
1 CD N
of IN N
a DT N
21-day JJ N
cycle NN N
. . N

All DT N
patients NNS N
received VBD N
folic JJ 1_i
acid NN 1_i
and CC 1_i
vitamin NN 1_i
B NNP 1_i
( ( 1_i
12 CD 1_i
) ) 1_i
supplementation NN 1_i
. . 1_i

RESULTS VB N
The DT 1_p
P600 NNP 1_p
( ( 1_p
47 CD 1_p
patients NNS 1_p
) ) 1_p
and CC 1_p
P900 NNP 1_p
( ( 1_p
45 CD 1_p
patients NNS 1_p
) ) 1_p
arms NNS N
had VBD N
response NN 1_o
rates NNS 1_o
of IN N
17.0 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
7.7-30.8 CD N
% NN N
) ) N
and CC N
15.6 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
6.5-29.5 CD N
% NN N
) ) N
with IN N
approximately RB N
50 CD N
% NN N
stable JJ N
disease NN N
per IN N
arm NN N
, , N
median JJ 1_o
progression-free JJ 1_o
survival NN 1_o
of IN N
4.2 CD N
and CC N
4.1 CD N
months NNS N
, , N
and CC N
median JJ 1_o
times NNS 1_o
to TO 1_o
tumor VB 1_o
progression NN 1_o
of IN N
4.2 CD N
and CC N
4.6 CD N
months NNS N
, , N
respectively RB N
. . N

Both DT N
arms NNS N
exhibited VBD N
minimal JJ 1_o
toxicity NN 1_o
( ( N
grade JJ N
3/4 CD N
neutropenia JJ 1_o
< RB N
20 CD N
% NN N
, , N
leukopenia NN 1_o
< VBD N
9 CD N
% NN N
, , N
and CC N
other JJ 1_o
toxicities NNS 1_o
< VBP N
5 CD N
% NN N
) ) N
. . N

Tumor NN N
samples NNS N
from IN N
49 CD N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
expression NN N
levels NNS N
of IN N
12 CD N
pemetrexed-related JJ 1_i
genes NNS N
. . N

Folylpolyglutamate NNP N
synthetase NN N
and CC N
thymidine JJ N
phosphorylase NN N
correlated VBN N
with IN N
efficacy NN 1_o
. . 1_o

Best JJS 1_o
response NN 1_o
rates NNS 1_o
and CC 1_o
median JJ 1_o
time NN 1_o
to TO 1_o
tumor VB 1_o
progression NN 1_o
for IN N
high JJ N
versus NN N
low JJ N
thymidine NN N
phosphorylase NN N
expression NN N
were VBD N
27.6 CD N
% NN N
versus IN N
6.3 CD N
% NN N
( ( N
P NNP N
= NNP N
0.023 CD N
) ) N
and CC N
5.4 CD N
versus NN N
1.9 CD N
months NNS N
( ( N
P NNP N
= NNP N
0.076 CD N
) ) N
, , N
and CC N
for IN N
folylpolyglutamate JJ N
synthetase NN N
were VBD N
37.5 CD N
% NN N
versus IN N
10.0 CD N
% NN N
( ( N
P NNP N
= NNP N
0.115 CD N
) ) N
and CC N
8.6 CD N
versus NN N
3.0 CD N
months NNS N
( ( N
P NNP N
= NNP N
0.019 CD N
) ) N
, , N
respectively RB N
. . N

gamma-Glutamyl JJ N
hydrolase NN N
expression NN N
correlated VBN N
with IN N
grade JJ 1_o
3/4 CD 1_o
toxicities NNS 1_o
: : 1_o
78.6 CD N
% NN N
for IN N
high JJ N
versus NN N
27.3 CD N
% NN N
for IN N
low JJ N
gamma-glutamyl JJ N
hydrolase NN N
( ( N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
two CD N
pemetrexed JJ 1_i
doses NNS N
yielded VBD N
similar JJ N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
profiles NNS N
. . N

Exploratory NNP N
biomarker NN N
analysis NN N
identified VBN N
efficacy NN 1_o
and CC 1_o
toxicity NN 1_o
correlations NNS N
and CC N
warrants NNS N
further JJ N
evaluation NN N
. . N

Fat NNP N
embolism NN N
prophylaxis NN N
with IN N
corticosteroids NNS 1_i
. . 1_i

A DT N
prospective JJ N
study NN N
in IN N
high-risk JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
efficacy NN 1_o
of IN N
corticosteroid JJ 1_i
treatment NN N
in IN N
the DT N
prophylaxis NN N
of IN N
the DT N
fat JJ 1_o
embolism NN 1_o
syndrome NN 1_o
was VBD N
evaluated VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
of IN N
high-risk JJ 1_p
patients NNS 1_p
with IN 1_p
long-bone JJ 1_p
fractures NNS 1_p
. . 1_p

Using VBG N
a DT N
set NN N
of IN N
objective JJ N
diagnostic JJ N
criteria NNS N
, , N
we PRP N
saw VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
the DT N
syndrome NN 1_o
between IN N
corticosteroid- NN 1_i
( ( 1_p
0 CD 1_p
of IN 1_p
21 CD 1_p
) ) 1_p
and CC 1_p
placebo-treated JJ 1_i
patients NNS 1_p
( ( 1_p
9 CD 1_p
of IN 1_p
41 CD 1_p
) ) 1_p
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
complications NNS N
related VBN N
to TO N
corticosteroid VB 1_i
treatment NN N
. . N

No DT N
routine JJ N
laboratory NN N
or CC N
physical JJ N
findings NNS N
reliably RB N
predicted VBD N
the DT N
development NN 1_o
of IN 1_o
the DT 1_o
fat JJ 1_o
embolism NN 1_o
syndrome NN 1_o
except IN N
petechial JJ 1_o
rash NN 1_o
, , N
which WDT N
occurred VBD N
only RB N
in IN N
5 CD N
placebo-treated JJ N
patients NNS N
who WP N
developed VBD N
the DT N
syndrome NN N
. . N

Complement JJ 1_o
activation NN 1_o
was VBD N
present JJ N
in IN N
all DT N
patients NNS N
studied VBN N
who WP N
had VBD N
the DT N
syndrome NN N
( ( N
5 CD N
of IN N
27 CD N
) ) N
but CC N
also RB N
in IN N
many JJ N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
our PRP$ N
diagnostic JJ N
criteria NNS N
, , N
suggesting VBG N
a DT N
multifactorial JJ N
cause NN N
. . N

These DT N
data NNS N
support NN N
the DT N
prophylactic JJ N
value NN N
of IN N
corticosteroid JJ 1_i
treatment NN N
in IN N
patients NNS 1_p
at IN 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
the DT 1_p
fat JJ 1_o
embolism NN 1_o
syndrome NN 1_o
, , N
particularly RB N
if IN N
several JJ N
unfavorable JJ N
predictors NNS N
are VBP N
present JJ N
. . N

Chemoradiotherapy NN N
with IN N
concurrent JJ 1_i
gemcitabine NN 1_i
and CC 1_i
cisplatin NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
sequential JJ 1_i
chemotherapy NN 1_i
with IN 1_i
gemcitabine/cisplatin JJ 1_i
vs NNS N
chemoradiotherapy NN 1_i
with IN 1_i
concurrent JJ 1_i
5-fluorouracil JJ 1_i
in IN N
patients NNS 1_p
with IN 1_p
locally RB 1_p
advanced JJ 1_p
pancreatic JJ 1_p
cancer NN 1_p
-- : 1_p
a DT 1_p
multi-centre JJ 1_p
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

BACKGROUND NNP N
No NNP N
standard NN N
treatment NN N
for IN N
locally RB 1_p
advanced JJ 1_p
pancreatic JJ 1_p
cancer NN 1_p
( ( 1_p
LAPC NNP 1_p
) ) 1_p
is VBZ N
defined VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Within NNP N
a DT N
multi-centre JJ N
, , N
randomised JJ N
phase NN N
II NNP N
trial NN N
, , N
95 CD 1_p
patients NNS 1_p
with IN 1_p
LAPC NNP 1_p
were VBD N
assigned VBN N
to TO N
three CD N
different JJ N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
regimens VBZ N
: : N
patients NNS N
received VBD N
conventionally RB N
fractionated VBN N
radiotherapy NN 1_i
of IN N
50 CD N
Gy NNP N
and CC N
were VBD N
randomised VBN N
to TO N
concurrent VB N
5-fluorouracil NNP 1_i
( ( N
350 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
per IN N
day NN N
on IN N
each DT N
day NN N
of IN N
radiotherapy NN 1_i
, , N
RT-5-FU NNP N
arm NN N
) ) N
, , N
concurrent JJ 1_i
gemcitabine NN 1_i
( ( N
300 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
, , N
and CC N
cisplatin NN 1_i
( ( N
30 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
on IN N
days NNS N
1 CD N
, , N
8 CD N
, , N
22 CD N
, , N
and CC N
29 CD N
( ( N
RT-GC NNP N
arm NN N
) ) N
, , N
or CC N
the DT N
same JJ 1_i
concurrent NN 1_i
treatment NN 1_i
followed VBN 1_i
by IN 1_i
sequential JJ 1_i
full-dose JJ 1_i
gemcitabine NN 1_i
( ( N
1000 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
and CC N
cisplatin NN 1_i
( ( N
50 CD N
mg NN N
m NN N
( ( N
-2 NNP N
) ) N
) ) N
every DT N
2 CD N
weeks NNS N
( ( N
RT-GC+GC NNP N
arm NN N
) ) N
. . N

Primary JJ N
end NN N
point NN N
was VBD N
the DT N
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
rate NN 1_o
after IN 1_o
9 CD 1_o
months NNS 1_o
. . 1_o

RESULTS VB N
The DT N
9-month JJ 1_o
OS NNP 1_o
rate NN 1_o
was VBD N
58 CD N
% NN N
in IN N
the DT N
RT-5-FU NNP N
arm NN N
, , N
52 CD N
% NN N
in IN N
the DT N
RT-GC NNP N
arm NN N
, , N
and CC N
45 CD N
% NN N
in IN N
the DT N
RT-GC+GC JJ N
arm NN N
. . N

Corresponding VBG N
median JJ 1_o
survival NN 1_o
times NNS 1_o
were VBD N
9.6 CD N
, , N
9.3 CD N
, , N
and CC N
7.3 CD N
months NNS N
( ( N
P=0.61 NNP N
) ) N
respectively RB N
. . N

The DT N
intent-to-treat JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
19 CD N
, , N
22 CD N
, , N
and CC N
13 CD N
% NN N
respectively RB N
. . N

Median JJ 1_o
progression-free JJ 1_o
survival NN 1_o
was VBD N
estimated VBN N
with IN N
4.0 CD N
, , N
5.6 CD N
, , N
and CC N
6.0 CD N
months NNS N
( ( N
P=0.21 NNP N
) ) N
. . N

Grade $ 1_o
3/4 CD 1_o
haematological JJ 1_o
toxicities NNS 1_o
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
two CD N
GC-containing JJ N
arms NNS N
, , N
no DT N
grade NN 1_o
3/4 CD 1_o
febrile NN 1_o
neutropaenia NN 1_o
was VBD N
observed VBN N
. . N

CONCLUSION NNP N
None NN N
of IN N
the DT N
three CD N
CRT NNP N
regimens NNS N
tested VBD N
met VBD N
the DT N
investigators NNS N
' POS N
definition NN N
for IN N
efficacy NN N
; : N
the DT N
median JJ N
OS NNP N
was VBD N
similar JJ N
to TO N
those DT N
previously RB N
reported VBN N
with IN N
gemcitabine NN N
alone RB N
in IN N
LAPC NNP N
. . N

Comparison NNP N
of IN N
endotracheal NN 1_i
and CC 1_i
peripheral JJ 1_i
intravenous JJ 1_i
adrenaline NN 1_i
in IN N
cardiac JJ 1_p
arrest NN 1_p
. . 1_p

Is VBZ N
the DT N
endotracheal JJ N
route NN N
reliable NN N
? . N
Twelve CD 1_p
patients NNS 1_p
presenting VBG 1_p
to TO 1_p
an DT 1_p
accident NN 1_p
and CC 1_p
emergency NN 1_p
department NN 1_p
in IN 1_p
asystolic JJ 1_p
cardiac JJ 1_p
arrest NN 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
to TO 1_p
treatment NN 1_p
with IN 1_p
endotracheal JJ 1_i
adrenaline NN 1_i
( ( 1_p
five CD 1_p
patients NNS 1_p
) ) 1_p
or CC 1_p
peripheral JJ 1_i
intravenous JJ 1_i
adrenaline NN 1_i
( ( 1_p
seven CD 1_p
patients NNS 1_p
) ) 1_p
. . 1_p

Femoral-artery JJ N
blood NN N
samples NNS N
were VBD N
taken VBN N
for IN N
assay NN N
of IN N
adrenaline NN 1_i
and CC 1_i
noradrenaline NN 1_i
. . 1_i

After IN N
intravenous JJ N
adrenaline NN 1_i
there EX N
was VBD N
a DT N
good JJ N
clinical JJ 1_o
and CC 1_o
biochemical JJ 1_o
response NN 1_o
, , N
but CC N
after IN N
endotracheal JJ N
adrenaline NN N
there EX N
was VBD N
no DT 1_o
change NN 1_o
in IN 1_o
serum JJ 1_o
adrenaline NN 1_o
and CC N
no DT 1_o
measurable JJ 1_o
clinical JJ 1_o
response NN 1_o
. . 1_o

The DT N
endotracheal JJ N
route NN N
of IN N
adrenaline JJ 1_i
administration NN N
is VBZ N
not RB N
reliable JJ N
in IN N
out-of-hospital JJ N
cardiac JJ N
arrest NN N
. . N

Short- JJ N
and CC N
long-term JJ N
results NNS N
after IN N
thrombolytic JJ 1_i
treatment NN 1_i
of IN N
deep JJ N
venous JJ N
thrombosis NN N
. . N

OBJECTIVES CC N
The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
short- JJ N
and CC N
long-term JJ N
efficacy NN N
of IN N
different JJ N
thrombolytic JJ 1_i
therapy NN 1_i
regimens NNS N
in IN N
patients NNS 1_p
with IN 1_p
leg NN 1_p
or CC 1_p
pelvic JJ 1_p
deep JJ 1_p
venous JJ 1_p
thrombosis NN 1_p
( ( 1_p
DVT NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND VB N
It PRP N
is VBZ N
unclear JJ N
whether IN N
locoregional JJ N
or CC N
systemic JJ N
thrombolysis NN N
is VBZ N
superior JJ N
in IN N
treating VBG N
acute JJ N
leg NN N
DVT NNP N
or CC N
even RB N
whether IN N
lysis NN N
is VBZ N
more RBR N
effective JJ N
than IN N
anticoagulation NN N
therapy NN N
in IN N
preventing VBG N
postthrombotic JJ N
syndrome NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
250 CD 1_p
patients NNS 1_p
averaging VBG 1_p
40 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
with IN 1_p
acute JJ 1_p
DVT NNP 1_p
were VBD N
randomized VBN N
into IN N
five CD N
groups NNS N
to TO N
receive VB N
full JJ 1_i
heparinization NN 1_i
( ( 1_i
1,000 CD 1_i
IU/h NNP 1_i
) ) 1_i
and CC 1_i
compression NN 1_i
treatment NN 1_i
, , 1_i
with IN 1_i
four CD 1_i
groups NNS 1_i
also RB 1_i
administered VBD 1_i
locoregional JJ 1_i
tissue NN 1_i
plasminogen NN 1_i
activator NN 1_i
( ( 1_i
20 CD 1_i
mg/day NN 1_i
) ) 1_i
or CC 1_i
urokinase JJ 1_i
( ( 1_i
100,000 CD 1_i
IU/day NNP 1_i
) ) 1_i
or CC 1_i
systemic JJ 1_i
streptokinase NN 1_i
( ( 1_i
3,000,000 CD 1_i
IU NNP 1_i
daily RB 1_i
) ) 1_i
or CC 1_i
urokinase JJ 1_i
( ( 1_i
5,000,000 CD 1_i
IU NNP 1_i
daily RB 1_i
) ) 1_i
. . N

All DT N
groups NNS N
then RB N
received VBD N
anticoagulation NN 1_i
and CC 1_i
compression NN 1_i
treatment NN 1_i
for IN 1_i
one CD 1_i
year NN 1_i
. . 1_i

Primary NNP N
efficacy NN N
criteria NNS N
included VBD N
the DT N
change NN N
after IN N
one CD N
year NN N
in IN N
the DT N
number NN N
of IN N
closed JJ 1_o
vein NN 1_o
segments NNS 1_o
and CC N
the DT N
occurrence NN N
of IN N
postthrombotic JJ N
syndrome NN N
. . N

RESULTS NNP N
Systemic NNP 1_i
thrombolytic JJ 1_i
therapy NN 1_i
significantly RB N
reduced VBD N
the DT N
number NN N
of IN N
closed JJ 1_o
vein NN 1_o
segments NNS 1_o
after IN N
12 CD N
months NNS N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
DVT NNP 1_p
compared VBN N
with IN N
conventional JJ N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Postthrombotic JJ 1_o
syndrome NN 1_o
also RB N
occurred VBD N
with IN N
less JJR N
frequency NN N
in IN N
systemically RB N
treated JJ N
patients NNS N
versus NN N
controls NNS N
( ( N
p VB N
< RB N
0.001 CD N
) ) N
. . N

High-dose JJ N
thrombolysis NN N
led VBD N
to TO N
better RBR N
rates NNS N
of IN N
complete JJ 1_o
recanalization NN 1_o
after IN N
seven CD N
days NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
than IN N
locoregional JJ N
lysis NN N
. . N

However RB N
, , N
12 CD 1_p
patients NNS 1_p
receiving VBG 1_p
thrombolysis NN 1_p
( ( N
9 CD N
systemic NN N
, , N
3 CD N
local JJ N
) ) N
suffered VBD N
major JJ 1_o
bleeding NN 1_o
complications NNS 1_o
; : 1_o
9 CD 1_p
patients NNS 1_p
on IN 1_p
systemic JJ 1_p
treatment NN 1_p
developed VBD N
pulmonary JJ 1_o
emboli NN 1_o
. . 1_o

CONCLUSIONS NNP N
Systemic NNP 1_i
thrombolytic JJ 1_i
treatment NN 1_i
for IN N
acute JJ N
DVT NNP N
achieved VBD N
a DT N
significantly RB N
better JJR N
short- NN N
and CC N
long-term JJ N
clinical JJ N
outcome NN N
than IN N
conventional JJ N
heparin/anticoagulation NN N
therapy NN N
but CC N
at IN N
the DT N
expense NN N
of IN N
a DT N
serious JJ N
increase NN N
in IN N
major JJ N
bleeding NN N
and CC N
pulmonary JJ N
emboli NN N
. . N

Given VBN N
the DT N
inherent JJ N
risks NNS N
for IN N
such JJ N
serious JJ N
complications NNS N
, , N
systemic JJ N
thrombolysis NN N
, , N
although IN N
effective JJ N
, , N
should MD N
be VB N
used VBN N
selectively RB N
in IN N
limb-threatening JJ N
thrombotic JJ N
situations NNS N
. . N

Effect NN N
of IN N
age NN N
and CC N
activity NN N
on IN N
knee NN 1_o
joint JJ 1_o
proprioception NN 1_o
. . 1_o

Falls NNP N
lead JJ N
to TO N
significant JJ N
morbidity NN 1_o
and CC 1_o
mortality NN 1_o
in IN N
persons NNS 1_p
older JJR 1_p
than IN 1_p
65 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

Impaired NNP N
proprioception NN N
may MD N
be VB N
a DT N
contributing JJ N
factor NN N
to TO N
falls NNS N
, , N
and CC N
this DT N
may MD N
be VB N
influenced VBN N
by IN N
the DT N
level NN N
of IN N
habitual JJ N
physical JJ N
activity NN N
. . N

The DT N
primary JJ N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
knee NNS 1_p
joint JJ 1_p
proprioception NN 1_p
among IN 1_p
young JJ 1_p
volunteers NNS 1_p
and CC 1_p
active JJ 1_p
and CC 1_p
sedentary JJ 1_p
elderly JJ 1_p
volunteers NNS 1_p
. . 1_p

Knee NNP 1_o
joint JJ 1_o
proprioception NN 1_o
was VBD N
measured VBN N
through IN N
reproduction NN N
of IN N
static JJ N
knee NN N
angles NNS N
using VBG N
a DT N
Penny NNP 1_i
and CC 1_i
Giles NNP 1_i
electrogoniometer RB 1_i
. . 1_i

The DT N
secondary JJ N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
test VB N
the DT N
reproducibility NN 1_o
of IN 1_o
the DT 1_o
Penny NNP 1_o
and CC 1_o
Giles NNP 1_o
electrogoniometer RB 1_o
in IN N
measuring VBG 1_o
static JJ 1_o
knee NN 1_o
angles NNS 1_o
. . 1_o

Sixteen NNP 1_p
young JJ 1_p
subjects NNS 1_p
( ( 1_p
age NN 1_p
range NN 1_p
, , 1_p
19-27 JJ 1_p
years NNS 1_p
) ) 1_p
and CC 1_p
24 CD 1_p
elderly JJ 1_p
subjects NNS 1_p
( ( 1_p
age NN 1_p
range NN 1_p
, , 1_p
60-86 JJ 1_p
years NNS 1_p
) ) 1_p
participated VBD 1_p
. . 1_p

Subjects NNS 1_p
were VBD 1_p
given VBN 1_p
a DT 1_p
screening VBG 1_p
history NN 1_p
and CC 1_p
physical JJ 1_p
examination NN 1_p
to TO 1_p
exclude VB 1_p
neuromuscular JJ 1_p
or CC 1_p
vestibular JJ 1_p
disorders NNS 1_p
or CC 1_p
lower JJR 1_p
limb NN 1_p
injuries NNS 1_p
. . 1_p

Knee NNP 1_o
joint JJ 1_o
proprioception NN 1_o
was VBD N
measured VBN N
two CD N
times NNS N
during IN N
one CD N
week NN N
. . N

The DT N
elderly JJ N
group NN N
was VBD N
separated VBN N
into IN N
active JJ N
and CC N
sedentary JJ N
subgroups NNS N
based VBN N
on IN N
their PRP$ N
level NN N
of IN N
activity NN N
during IN N
the DT N
past JJ N
year NN N
. . N

The DT N
electrogoniometer NN N
was VBD N
placed VBN N
laterally RB N
across IN N
the DT N
dominant JJ N
knee NN N
joint NN N
. . N

From IN N
the DT N
prone NN N
position NN N
each DT N
subject NN N
attained VBD N
one CD N
of IN N
ten NN N
randomly NNS N
predetermined VBD N
knee JJ N
joint JJ N
angles NNS N
from IN N
10 CD N
degrees NNS N
to TO N
60 CD N
degrees NNS N
. . N

The DT N
subject NN N
then RB N
returned VBD N
to TO N
the DT N
starting VBG N
position NN N
and CC N
reproduced VBD N
the DT N
test NN N
angle NN N
. . N

The DT N
absolute JJ 1_o
angular JJ 1_o
error NN 1_o
( ( N
the DT N
absolute NN N
difference NN N
between IN N
the DT N
test NN N
angle NN N
and CC N
subject JJ N
perceived VBN N
angle NN N
of IN N
knee JJ N
flexion NN N
) ) N
was VBD N
determined VBN N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
control NN N
visits NNS N
for IN N
all DT N
subjects NNS N
( ( N
r VB N
= RB N
0.88 CD N
) ) N
, , N
and CC N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
young JJ N
( ( N
mean JJ N
, , N
2.01 CD N
+/- JJ N
0.46 CD N
degrees NNS N
) ) N
and CC N
active-fold JJ N
( ( N
mean JJ N
, , N
3.12 CD N
+/- JJ N
1.12 CD N
degrees NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
young JJ N
and CC N
sedentary-old JJ N
( ( N
mean JJ N
, , N
4.58 CD N
+/- JJ N
1.93 CD N
degrees NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
active-old JJ N
and CC N
sedentary-old JJ N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
. . N

These DT N
findings NNS N
demonstrate VBP N
that IN N
the DT N
Penny NNP N
and CC N
Giles NNP N
electrogoniometer NN N
is VBZ N
a DT N
reproducible JJ N
device NN N
for IN N
measuring VBG N
knee NN N
joint NN N
angles NNS N
in IN N
both DT N
young JJ N
and CC N
elderly JJ N
subjects NNS N
. . N

Furthermore RB N
, , N
we PRP N
found VBD N
that IN N
proprioception NN 1_o
is VBZ N
diminished VBN N
with IN N
age NN N
and CC N
that IN N
regular JJ N
activity NN N
may MD N
attenuate VB N
this DT N
decline NN N
. . N

One CD N
strategy NN N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
poor JJ N
proprioception NN 1_o
and CC N
fall NN N
with IN N
ageing NN N
may MD N
be VB N
regular JJ N
exercise NN N
. . N

Virtual JJ 1_i
reality NN 1_i
job NN 1_i
interview NN 1_i
training NN 1_i
in IN N
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

The DT N
feasibility NN N
and CC N
efficacy NN N
of IN N
virtual JJ 1_i
reality NN 1_i
job NN 1_i
interview NN 1_i
training NN 1_i
( ( 1_i
VR-JIT NNP 1_i
) ) 1_i
was VBD N
assessed VBN N
in IN N
a DT N
single-blinded JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
VR-JIT NNP 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
16 CD 1_p
) ) 1_p
or CC 1_p
treatment-as-usual JJ 1_i
( ( 1_i
TAU NNP 1_i
) ) 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
10 CD 1_p
) ) 1_p
groups NNS 1_p
. . 1_p

VR-JIT NNP 1_i
consisted VBD 1_i
of IN 1_i
simulated JJ 1_i
job NN 1_i
interviews NNS 1_i
with IN 1_i
a DT 1_i
virtual JJ 1_i
character NN 1_i
and CC 1_i
didactic JJ 1_i
training NN 1_i
. . 1_i

Participants NNS N
attended VBD N
90 CD N
% NN N
of IN N
laboratory-based JJ N
training NN N
sessions NNS N
, , N
found VBD N
VR-JIT NNP 1_i
easy JJ 1_o
to TO 1_o
use VB 1_o
and CC N
enjoyable JJ 1_o
, , N
and CC N
they PRP N
felt VBD N
prepared VBN 1_o
for IN 1_o
future JJ 1_o
interviews NNS 1_o
. . 1_o

VR-JIT JJ 1_i
participants NNS 1_p
had VBD N
greater JJR 1_o
improvement NN 1_o
during IN 1_o
live JJ 1_o
standardized JJ 1_o
job NN 1_o
interview NN 1_o
role-play NN 1_o
performances NNS 1_o
than IN N
TAU NNP 1_i
participants NNS 1_p
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

A DT N
similar JJ N
pattern NN N
was VBD N
observed VBN N
for IN N
self-reported JJ 1_o
self-confidence NN 1_o
at IN N
a DT N
trend NN N
level NN N
( ( N
p JJ N
= NNP N
0.060 CD N
) ) N
. . N

VR-JIT JJ 1_o
simulation NN 1_o
performance NN 1_o
scores NNS 1_o
increased VBD N
over IN N
time NN N
( ( N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.83 CD N
) ) N
. . N

Results JJ N
indicate JJ N
preliminary JJ N
support NN N
for IN N
the DT N
feasibility NN 1_o
and CC N
efficacy NN 1_o
of IN N
VR-JIT NNP 1_i
, , N
which WDT N
can MD N
be VB N
administered VBN N
using VBG N
computer NN N
software NN N
or CC N
via IN N
the DT N
internet NN N
. . N

A DT N
field NN N
trial NN N
of IN N
production NN N
and CC N
financial JJ N
consequences NNS N
of IN N
helminthosis NN N
control NN N
in IN N
sheep JJ 1_p
production NN 1_p
in IN 1_p
Ethiopia NNP 1_p
. . 1_p

We PRP N
used VBD N
a DT N
partial-budget JJ N
analysis NN N
to TO N
evaluate VB N
profitability NN 1_o
of IN N
different JJ 1_i
management NN 1_i
strategies NNS 1_i
of IN 1_i
three CD 1_i
genotypes NNS 1_i
of IN 1_i
sheep NN 1_i
in IN 1_p
a DT 1_p
2 CD 1_p
x NN 1_p
2 CD 1_p
x JJ 1_p
3 CD 1_p
factorial JJ 1_p
experiment NN 1_p
conducted VBN 1_p
at IN 1_p
Debre NNP 1_p
Berhan NNP 1_p
research NN 1_p
station NN 1_p
in IN 1_p
the DT 1_p
central JJ 1_p
highlands NNS 1_p
of IN 1_p
Ethiopia NNP 1_p
. . 1_p

This DT N
involved JJ N
two CD 1_i
anthelmintic-treatment JJ 1_i
levels NNS 1_i
( ( 1_i
treated VBN 1_i
vs. IN 1_i
non-treated JJ 1_i
) ) 1_i
, , 1_i
two CD 1_i
supplementary JJ 1_i
nutrition NN 1_i
levels NNS 1_i
( ( 1_i
protein-energy JJ 1_i
supplementation NN 1_i
yes/no NN 1_i
) ) 1_i
and CC 1_i
three CD 1_i
genotypes NNS 1_i
: : 1_i
indigenous JJ 1_i
Menz NNP 1_i
( ( 1_p
n=40 NN 1_p
) ) 1_p
, , 1_p
50 CD 1_p
% NN 1_p
Awassi NNP 1_i
x NNP 1_i
50 CD 1_p
% NN 1_p
Menz NNP 1_i
crosses VBZ 1_i
( ( 1_p
n=38 NN 1_p
) ) 1_p
and CC 1_p
75 CD 1_p
% NN 1_p
Awassi NNP 1_p
x NNP 1_p
25 CD 1_p
% NN 1_p
Menz NNP 1_p
crosses VBZ 1_p
( ( 1_p
n=31 JJ 1_p
) ) 1_p
. . 1_p

All DT N
sheep JJ 1_p
were VBD N
exposed VBN N
to TO N
natural JJ 1_i
sub-clinical JJ 1_i
helminthosis NN 1_i
challenge NN 1_i
. . 1_i

Supplemented VBN N
sheep NN N
were VBD N
offered VBN N
a DT N
concentrate JJ 1_i
mix JJ 1_i
daily RB 1_i
on IN N
an DT N
individual JJ N
basis NN N
. . N

Anthelmintic-treated JJ 1_i
sheep NN 1_i
were VBD 1_i
drenched VBN 1_i
with IN 1_i
fenbendazole NN 1_i
against IN 1_i
nematodes NNS 1_i
and CC 1_i
with IN 1_i
triclabendazole NN 1_i
against IN 1_i
trematodes NNS 1_i
. . 1_i

Data NNS N
were VBD N
collected VBN N
during IN N
the DT N
experimental JJ N
period NN N
( ( N
for IN N
10 CD N
months NNS N
from IN N
approximately RB N
1 CD N
year NN N
of IN N
age NN N
) ) N
on IN N
feed NN 1_o
intake NN 1_o
, , 1_o
live JJ 1_o
weight NN 1_o
, , 1_o
eggs FW 1_o
per IN 1_o
gram NN 1_o
( ( 1_o
EPG NNP 1_o
) ) 1_o
of IN 1_o
faeces NNS 1_o
, , 1_o
packed-cell JJ 1_o
volume NN 1_o
( ( 1_o
PCV NNP 1_o
) ) 1_o
, , 1_o
wool JJ 1_o
weight NN 1_o
, , 1_o
and CC 1_o
adult-worm JJ 1_o
burden NN 1_o
. . 1_o

Actual JJ N
market NN 1_o
input NN 1_o
and CC 1_o
output NN 1_o
prices NNS 1_o
were VBD N
recorded VBN N
. . N

Supplemented VBN N
sheep NN N
had VBD N
significantly RB N
higher JJR N
marginal JJ 1_o
profit NN 1_o
( ( 1_o
MP NNP 1_o
) ) 1_o
per IN N
sheep NN N
than IN N
non-supplemented JJ N
sheep NN N
( ( N
ETB NNP N
33 CD N
vs. IN N
4 CD N
) ) N
. . N

Likewise NNP N
, , N
anthelmintic JJ N
treated VBD N
sheep NN N
performed VBN 1_o
significantly RB N
better RBR N
than IN N
their PRP$ N
non-treated JJ N
contemporaries NNS N
( ( N
MP=ETB NNP N
28 CD N
vs. IN N
8 CD N
) ) N
. . N

The DT N
75 CD N
% NN N
Awassi NNP N
crosses NNS N
were VBD N
least RBS N
profitable JJ 1_o
. . 1_o

[ JJ 1_p
Obstetrical NNP 1_p
analgesia NN 1_p
with IN N
tramadol JJ 1_i
] NN 1_i
. . N

Parenteral JJ N
analgesia NN N
with IN N
Tramal NNP 1_i
was VBD N
performed VBN N
in IN N
23 CD 1_p
normal JJ 1_p
deliveries NNS 1_p
. . 1_p

The DT N
results NNS N
were VBD N
compared VBN N
with IN N
a DT N
group NN 1_p
of IN 1_p
normal JJ 1_p
deliveries NNS 1_p
in IN 1_p
which WDT 1_p
analgesia NN 1_o
was VBD 1_p
achieved VBN 1_p
with IN 1_p
pethidine NN 1_i
. . 1_i

Both DT N
medicaments NNS N
excerted VBD N
an DT N
identical JJ 1_o
analgetic JJ 1_o
efficiency NN 1_o
. . 1_o

No DT N
adverse JJ 1_o
side NN 1_o
effects NNS 1_o
were VBD N
observed VBN N
with IN N
Tramal NNP 1_i
concerning VBG N
the DT N
follow-up NN N
of IN N
labour NN N
or CC N
the DT N
newborn JJ N
. . N

Tramal JJ 1_i
can MD N
be VB N
recommended VBN N
for IN N
obstetrical JJ 1_o
analgesia NN 1_o
since IN N
it PRP N
does VBZ N
not RB N
excert VB N
inhibitory JJ 1_o
effects NNS 1_o
upon IN N
the DT N
respiratory NN N
center NN N
. . N

Patient JJ 1_o
satisfaction NN 1_o
with IN N
nutrition NN N
services NNS N
amongst JJ N
cancer NN 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
autologous JJ 1_p
stem NN 1_p
cell NN 1_p
transplantation NN 1_p
: : 1_p
a DT N
comparison NN N
of IN N
usual JJ 1_i
and CC N
extended JJ 1_i
care NN 1_i
. . 1_i

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
patient JJ N
satisfaction NN N
with IN N
clinical JJ N
nutrition NN 1_i
services NNS 1_i
delivered VBN N
by IN N
an DT N
accredited JJ N
practicing NN N
dietitian JJ N
amongst NN N
cancer NN 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
autologous JJ 1_p
stem NN 1_p
cell NN 1_p
transplantation NN 1_p
that WDT N
was VBD N
provided VBN N
with IN N
usual JJ 1_i
and CC N
extended VBD 1_i
care NN 1_i
at IN N
100 CD N
days NNS N
post-transplantation NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
randomised VBN N
to TO N
receive VB 1_i
usual JJ 1_i
nutrition NN 1_i
care NN 1_i
or CC 1_i
extended VBN 1_i
nutrition NN 1_i
care NN 1_i
during IN N
the DT N
course NN N
of IN N
their PRP$ N
stem NN N
cell NN N
transplantation NN N
. . N

After IN N
hospital JJ N
discharge NN N
, , N
usual JJ 1_i
care NN 1_i
patients NNS 1_i
received VBD 1_i
no DT 1_i
further JJ 1_i
nutrition NN 1_i
support NN 1_i
, , 1_i
whereas RB 1_i
extended VBN 1_i
care NN 1_i
patients NNS 1_i
received VBD 1_i
telephone NN 1_i
dietary JJ 1_i
counselling NN 1_i
from IN 1_i
the DT 1_i
same JJ 1_i
dietitian NN 1_i
for IN 1_i
up IN 1_i
to TO 1_i
100 CD 1_i
days NNS 1_i
post-transplantation NN 1_i
. . N

The DT N
patient JJ N
satisfaction NN N
with IN N
clinical JJ N
nutrition NN N
service NN N
questionnaire NN N
was VBD N
completed VBN N
anonymously RB N
at IN N
100 CD N
days NNS N
post-transplantation NN N
. . N

Group NNP N
comparisons NNS N
were VBD N
made VBN N
using VBG N
independent JJ N
t-tests NNS N
. . N

RESULTS NNP 1_p
Thirty-seven JJ 1_p
patients NNS 1_p
consented VBN 1_p
to TO 1_p
participate VB 1_p
in IN 1_p
the DT 1_p
study NN 1_p
( ( 1_p
54 CD 1_p
% NN 1_p
male NN 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
58.7 CD 1_p
± JJ 1_p
9.5 CD 1_p
years NNS 1_p
; : 1_p
median JJ 1_p
body NN 1_p
mass NN 1_p
index NN 1_p
26.8 CD 1_p
kg NN 1_p
m NN 1_p
( ( 1_p
-2 NNP 1_p
) ) 1_p
, , 1_p
range VBP 1_p
16.4-47.6 JJ 1_p
kg NN 1_p
m NN 1_p
( ( 1_p
-2 NNP 1_p
) ) 1_p
) ) 1_p
; : 1_p
33 CD 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
and CC 1_p
28 CD 1_p
patients NNS 1_p
returned VBD 1_p
the DT 1_p
questionnaire NN 1_p
( ( 1_p
response NN 1_p
rate NN 1_o
= VBD 1_o
85 CD 1_o
% NN 1_o
) ) 1_o
. . 1_o

All DT 1_o
components NNS 1_o
of IN 1_o
the DT 1_o
questionnaire NN 1_o
were VBD N
rated VBN N
highly RB N
by IN N
both DT N
groups NNS N
; : N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Although IN N
not RB N
statistically RB N
significant JJ N
, , N
extended VBD N
care NN N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
three CD N
telephone NN 1_o
calls VBZ N
rated VBN N
a DT N
higher JJR 1_o
overall JJ 1_o
satisfaction NN N
compared VBN N
to TO N
those DT N
who WP N
received VBD N
less JJR N
calls NNS N
; : N
this DT N
difference NN N
was VBD N
clinically RB N
important JJ N
( ( N
score JJ N
difference NN 1_p
= NNP 1_p
0.56 CD 1_p
) ) 1_p
. . 1_p

CONCLUSIONS NNP 1_p
Cancer NNP 1_p
patients NNS 1_p
treated VBD 1_p
with IN 1_p
autologous JJ 1_p
stem NN 1_p
cell NN 1_p
transplantation NN N
were VBD 1_i
satisfied VBN 1_i
with IN 1_i
usual JJ 1_i
and CC 1_i
extended JJ 1_i
nutrition NN 1_i
care NN 1_i
. . 1_p

Extended NNP 1_p
care NN N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
three CD N
telephone NN N
calls VBZ N
after IN N
hospital NN N
discharge NN N
were VBD N
more JJR N
satisfied JJ N
than IN N
those DT N
with IN N
less JJR N
frequent JJ N
intervention NN N
. . N

Further JJ N
exploration NN N
regarding VBG N
the DT N
frequency NN N
and CC N
intensity NN N
of IN N
nutrition NN N
service NN N
is VBZ N
required VBN N
. . N

Comparison NNP N
with IN N
computed JJ 1_i
tomography NN 1_i
of IN N
two CD N
ultrasound JJ N
devices NNS N
for IN N
diagnosis NN N
of IN N
abdominal JJ 1_p
aortic JJ 1_p
aneurysm NN 1_p
. . 1_p

Screening VBG N
for IN N
abdominal JJ 1_p
aortic JJ 1_p
aneurysms NNS 1_p
( ( 1_p
AAAs NNP 1_p
) ) 1_p
in IN 1_p
patients NNS 1_p
at IN 1_p
risk NN 1_p
will MD N
become VB N
more RBR N
cost JJ N
effective JJ N
if IN N
a DT N
simple NN N
, , N
inexpensive JJ N
, , N
and CC N
reliable JJ N
ultrasound JJ N
device NN N
is VBZ N
available JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
2-dimensional JJ N
, , N
handheld JJ 1_i
ultrasound JJ 1_i
device NN 1_i
and CC N
a DT N
newly RB N
developed VBN N
ultrasound JJ 1_i
volume NN 1_i
scanner NN 1_i
( ( N
based VBN N
on IN N
bladder NN N
scan JJ N
technology NN N
) ) N
with IN N
computed VBN 1_i
tomography NN 1_i
( ( 1_i
CT NNP 1_i
) ) 1_i
for IN N
diagnosing VBG N
AAA NNP N
. . N

A NNP N
total NN N
of IN N
146 CD 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
69 CD 1_p
+/- JJ 1_p
10 CD 1_p
years NNS 1_p
; : 1_p
127 CD 1_p
men NNS 1_p
) ) 1_p
were VBD N
screened VBN N
for IN N
the DT N
presence NN N
of IN N
AAAs NNP N
( ( N
diameter NN N
> VBZ N
3 CD N
cm NN N
) ) N
using VBG N
CT. NNP N
All NNP N
patients NNS N
were VBD N
examined VBN N
with IN N
the DT N
handheld NN N
ultrasound JJ N
device NN N
and CC N
the DT N
volume NN N
scanner NN N
. . N

Maximal JJ 1_o
diameters NNS 1_o
and CC 1_o
volumes NNS 1_o
were VBD N
used VBN N
for IN N
the DT N
analyses NNS N
. . N

AAAs NNP N
were VBD N
diagnosed VBN N
by IN N
CT NNP 1_i
in IN N
116 CD N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
. . N

The DT N
absolute JJ 1_o
difference NN 1_o
of IN 1_o
aortic JJ 1_o
diameter NN 1_o
between IN N
ultrasound NN 1_i
and CC N
CT NNP 1_i
was VBD N
< JJ N
5 CD N
mm NN N
in IN N
88 CD N
% NN N
of IN N
patients NNS N
. . N

Limits NNS N
of IN N
agreement NN N
between IN N
ultrasound NN N
and CC N
CT NNP 1_i
( ( N
-6.6 NNP N
to TO N
9.4 CD N
mm NN N
) ) N
exceeded VBD N
the DT N
limits NNS N
of IN N
clinical JJ N
acceptability NN N
( ( N
+/-5 JJ N
mm NN N
) ) N
. . N

An DT N
excellent JJ N
correlation NN 1_o
between IN N
ultrasound NN 1_i
and CC N
CT NNP 1_i
was VBD N
observed VBN N
( ( N
r JJ N
= NNP N
0.98 CD N
) ) N
. . N

The DT N
correlation NN 1_o
coefficient NN 1_o
between IN N
the DT N
volume NN N
scanner NN N
and CC N
CT NNP 1_i
was VBD N
0.86 CD N
, , N
with IN N
agreement NN N
of IN N
90 CD N
% NN N
and CC N
kappa JJ N
value NN N
of IN N
0.73 CD N
. . N

Using VBG N
an DT N
optimal JJ 1_o
cut-off NN 1_o
value NN 1_o
of IN N
> $ N
56 CD N
ml NN N
, , N
defined VBN N
by IN N
receiver-operating JJ 1_o
characteristic JJ 1_o
curve NN 1_o
analysis NN 1_o
, , 1_o
sensitivity NN 1_o
, , 1_o
specificity NN 1_o
, , 1_o
and CC 1_o
the DT 1_o
positive JJ 1_o
and CC 1_o
negative JJ 1_o
predictive JJ 1_o
values NNS 1_o
of IN N
the DT N
volume NN N
scanner NN N
for IN N
detecting VBG N
AAA NNP N
were VBD N
90 CD N
% NN N
, , N
90 CD N
% NN N
, , N
97 CD N
% NN N
, , N
and CC N
71 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
conclusion NN N
, , N
this DT N
study NN N
shows VBZ N
that IN N
a DT N
2-dimensional JJ N
, , N
handheld JJ N
ultrasound JJ N
device NN N
and CC N
a DT N
newly RB N
developed VBN N
ultrasound JJ N
volume NN N
scanner NN N
can MD N
effectively RB N
identify VB N
patients NNS 1_p
with IN 1_p
AAAs NNP 1_p
confirmed VBN 1_p
by IN 1_p
CT NNP 1_p
. . 1_p

Characterization NN N
of IN N
early JJ 1_p
thermal JJ 1_p
burns NNS 1_p
and CC N
the DT N
effects NNS N
of IN N
hyperbaric JJ 1_i
oxygen NN 1_i
treatment NN 1_i
: : 1_i
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
Studies NNP N
investigating VBG N
hyperbaric JJ 1_i
oxygen NN 1_i
treatment NN 1_i
( ( 1_i
HBOT NNP 1_i
) ) 1_i
to TO N
improve VB N
outcome NN N
in IN N
burns NNS N
have VBP N
been VBN N
inconclusive JJ N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
characterize VB N
early JJ 1_p
thermal NN 1_p
burns NNS 1_p
injury NN 1_p
in IN 1_p
adult NN 1_p
patients NNS 1_p
with IN 1_p
< JJ 1_p
40 CD 1_p
% NN 1_p
total JJ 1_p
body NN 1_p
surface NN 1_p
area NN 1_p
( ( 1_p
TBSA NNP 1_p
) ) 1_p
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
HBOT NNP 1_i
administered VBD N
within IN N
24 CD N
h NN N
to TO N
48 CD N
h NN N
of IN N
a DT N
burn JJ N
injury NN N
. . N

METHODS NNP N
Seventeen JJ 1_p
subjects NNS 1_p
were VBD 1_p
randomized VBN 1_p
into IN 1_p
control NN 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
9 CD 1_p
) ) 1_p
and CC 1_p
HBOT NNP 1_i
treatment NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
8 CD 1_p
) ) 1_p
arms NNS 1_p
. . 1_p

Burn NNP 1_o
depth NN 1_o
, , N
measured VBN N
by IN N
laser NN N
Doppler NNP 1_i
imaging NN 1_i
( ( N
LDI NNP N
) ) N
and CC N
histologically RB N
, , N
white JJ 1_o
blood NN 1_o
cell NN 1_o
( ( 1_o
WBC NNP 1_o
) ) 1_o
count NN 1_o
and CC N
plasma JJ 1_o
cytokine NN 1_o
inflammatory NN 1_o
markers NNS 1_o
were VBD N
assessed VBN N
at IN N
24 CD N
h NN N
( ( N
pre JJ N
HBOT NNP N
) ) N
and CC N
48 CD N
h NN N
( ( N
post VB N
HBOT NNP N
) ) N
post NN N
burn NN N
, , N
as IN N
were VBD N
immunohistochemistry NN N
and CC N
microbiology NN N
of IN N
burns NNS N
tissue NN N
samples NNS N
at IN N
48 CD N
h NN N
post NN N
burn NN N
. . N

RESULTS NNP N
WBC NNP 1_o
count NN 1_o
and CC 1_o
serum NN 1_o
interleukin NN 1_o
( ( 1_o
IL NNP 1_o
) ) 1_o
-1β NN 1_o
, , 1_o
IL-4 NNP 1_o
, , 1_o
IL-6 NNP 1_o
, , 1_o
IL-10 NNP 1_o
and CC 1_o
interferon-γ NNS 1_o
were VBD N
significantly RB N
elevated VBN N
24 CD N
h NN N
after IN N
burn NN N
, , N
but CC N
no DT N
significant JJ N
changes NNS N
in IN N
any DT N
of IN N
these DT N
parameters NNS N
were VBD N
found VBN N
with IN N
HBOT NNP N
. . N

HBOT NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN 1_o
burn NN 1_o
depth NN 1_o
. . N

Two CD 1_i
HBOT NNP 1_i
patients NNS 1_p
and CC 1_p
four CD 1_p
control NN 1_p
patients NNS 1_p
developed VBD 1_o
positive JJ 1_o
bacterial JJ 1_o
cultures NNS 1_o
. . N

CONCLUSIONS NNP N
Slower JJR N
than IN N
anticipated VBN N
recruitment NN N
resulted VBD N
in IN N
considerably RB N
fewer JJR N
patients NNS N
than IN N
planned VBN N
being VBG N
studied VBN 1_o
. . 1_o

Inflammatory JJ 1_o
markers NNS 1_o
were VBD N
significantly RB N
increased VBN N
at IN N
24 CD N
h NN N
in IN N
patients NNS N
with IN N
< JJ N
40 CD N
% NN N
TBSA NNP N
burn NN N
. . N

Early JJ 1_i
HBOT NNP 1_i
had VBD N
no DT N
apparent JJ N
effects NNS N
on IN N
any DT N
of IN N
the DT N
parameters NNS N
measured VBN N
in IN N
this DT N
small JJ N
pilot NN N
study NN 1_i
. . 1_i

HBOT NNP 1_i
may MD N
possibly RB N
have VB N
a DT N
broad-spectrum JJ N
antimicrobial JJ N
effect NN N
worthy NN N
of IN N
further JJ N
study NN N
. . N

We PRP N
report VBP N
our PRP$ N
methodology NN N
in IN N
detail NN N
as IN N
a DT N
possible JJ N
model NN N
for IN N
future JJ N
burns NNS N
studies NNS N
. . N

Perception NN N
of IN N
social JJ 1_o
interactions NNS 1_o
in IN N
depressed JJ 1_p
psychiatric JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
prognostic JJ N
value NN N
of IN N
testicular JJ 1_i
biopsy NN 1_i
in IN N
childhood NN 1_p
acute NN 1_p
lymphoblastic JJ 1_p
leukemia NN 1_p
: : 1_p
a DT N
report NN N
from IN N
the DT N
Childrens NNP N
Cancer NNP N
Study NNP N
Group NNP N
. . N

One CD N
of IN N
the DT N
objectives NNS N
of IN N
Childrens NNP N
Cancer NNP N
Study NNP N
Group NNP N
( ( N
CCSG NNP N
) ) N
study NN N
141 CD N
( ( N
CCG-141 NNP N
) ) N
was VBD N
to TO N
determine VB N
the DT N
frequency NN 1_o
of IN N
occult NN 1_o
testicular JJ 1_o
leukemia NN 1_o
( ( 1_o
TL NNP 1_o
) ) 1_o
after IN N
3 CD N
years NNS N
of IN N
disease-free JJ 1_o
survival NN 1_o
( ( 1_o
DFS NNP 1_o
) ) 1_o
and CC N
to TO N
retreat VB N
boys NNS 1_p
with IN 1_p
occult NN 1_p
TL NNP 1_p
to TO N
prolong VB N
their PRP$ N
subsequent JJ N
DFS NNP N
. . N

Of IN N
the DT N
494 CD 1_p
boys NNS 1_p
entered VBD 1_p
on IN 1_p
study NN 1_p
, , N
255 CD N
( ( N
51.6 CD N
% NN N
) ) N
were VBD N
in IN N
complete JJ N
continuous JJ N
remission NN N
( ( N
CCR NNP N
) ) N
3 CD N
years NNS N
after IN N
entering VBG N
remission NN N
and CC N
an DT N
additional JJ N
eight CD N
were VBD N
in IN N
CCR NNP N
3 CD N
years NNS N
after IN N
localized JJ N
extramedullary JJ N
relapse NN N
and CC N
retreatment NN N
; : N
263 CD 1_p
boys NNS 1_p
were VBD 1_p
eligible JJ 1_p
for IN 1_p
testicular JJ 1_i
biopsy NN 1_i
. . 1_i

Elective JJ 1_p
testicular JJ 1_i
biopsy NN 1_i
was VBD 1_p
performed VBN 1_p
on IN 1_p
235 CD 1_p
( ( 1_p
89.4 CD 1_p
% NN 1_p
) ) 1_p
boys VBZ 1_p
. . 1_p

Of IN N
the DT N
204 CD N
( ( N
86.8 CD N
% NN N
) ) N
boys VBZ N
with IN N
negative JJ N
biopsies NNS N
, , N
175 CD N
( ( N
85.8 CD N
% NN N
) ) N
remained VBD N
in IN N
CCR NNP N
10 CD N
to TO N
12 CD N
years NNS N
after IN N
diagnosis NN N
and CC N
25 CD N
( ( N
12.3 CD N
% NN N
) ) N
relapsed VBD N
, , N
11 CD N
( ( N
44 CD N
% NN N
) ) N
of IN N
whom WP N
died VBD N
. . N

Isolated NNP N
overt JJ N
TL NNP N
occurred VBD N
in IN N
four CD N
( ( N
2.0 CD N
% NN N
) ) N
and CC N
all DT N
remained VBN N
in IN N
CCR NNP N
22+ CD N
to TO N
60+ CD N
months NNS N
after IN N
re-treatment JJ N
. . N

Of IN N
the DT N
26 CD N
boys NNS N
with IN N
occult NN N
TL NNP N
, , N
16 CD N
( ( N
62 CD N
% NN N
) ) N
remained VBD N
in IN N
CCR NNP N
. . N

Ten NNP N
( ( N
38 CD N
% NN N
) ) N
relapsed VBD 1_o
despite IN N
local JJ 1_i
testicular JJ 1_i
irradiation NN 1_i
and CC N
systemic JJ 1_i
re-treatment NN 1_i
; : 1_i
six CD N
of IN N
the DT N
10 CD N
died VBD 1_o
. . 1_o

Of IN N
the DT N
26 CD N
boys NNS N
who WP N
did VBD N
not RB N
undergo JJ N
biopsy NN 1_i
, , N
21 CD N
( ( N
80.8 CD N
% NN N
) ) N
remained VBD N
in IN N
CCR NNP N
; : N
two CD N
( ( N
7.7 CD N
% NN N
) ) N
developed VBD 1_o
isolated JJ 1_o
overt JJ 1_o
TL NNP 1_o
. . 1_o

DFS NNP 1_o
after IN 1_o
testicular JJ 1_o
biopsy NN 1_o
was VBD N
significantly RB 1_o
better RBR 1_o
in IN N
boys NNS N
without IN N
occult NN N
TL NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Occult NNP N
TL NNP N
after IN N
3 CD N
years NNS N
of IN N
CCR NNP N
represents VBZ N
aggressive JJ N
minimal-residual JJ N
disease NN N
and CC N
carries VBZ N
a DT N
worse JJR N
prognosis NN N
than IN N
absence NN N
of IN N
TL NNP N
. . N

Initial NNP N
treatment NN N
should MD N
be VB N
directed VBN N
at IN N
obviating VBG N
occult NN N
and CC N
overt JJ N
testicular JJ N
relapse NN N
. . N

Conventional JJ N
therapy NN N
as IN N
used VBN N
in IN N
this DT N
study NN N
was VBD N
suboptimal JJ N
in IN N
preventing VBG N
subsequent JJ 1_o
bone NN 1_o
marrow NN 1_o
( ( 1_o
BM NNP 1_o
) ) 1_o
relapse NN 1_o
and CC 1_o
death NN 1_o
. . 1_o

If IN N
occult JJ N
TR NNP N
is VBZ N
identified VBN N
during IN N
or CC N
at IN N
the DT N
end NN N
of IN N
planned JJ N
therapy NN N
, , N
a DT N
higher JJR 1_o
salvage NN 1_o
rate NN 1_o
may MD N
require VB N
intensified JJ N
alternate JJ N
therapy NN N
. . N

As IN N
such JJ N
, , N
testicular JJ 1_i
biopsies NNS 1_i
may MD N
be VB N
clinically RB N
useful JJ N
. . N

Further JJ N
investigation NN N
is VBZ N
limited VBN N
by IN N
the DT N
relative JJ N
rarity NN N
of IN N
, , N
and CC N
the DT N
lack NN N
of IN N
identifying VBG N
features NNS N
in IN N
boys NNS N
with IN N
occult NN N
TL NNP N
. . N

[ IN 1_p
The DT 1_p
use NN 1_p
of IN 1_p
cephalosporins NNS 1_i
in IN 1_p
hospital NN 1_p
practice NN 1_p
] NN 1_p
. . N

Bevacizumab NNP 1_i
compared VBN N
with IN N
macular JJ 1_i
laser NN 1_i
grid JJ 1_i
photocoagulation NN 1_i
for IN N
cystoid JJ 1_p
macular JJ 1_p
edema NN 1_p
in IN 1_p
branch JJ 1_p
retinal JJ 1_p
vein NN 1_p
occlusion NN 1_p
. . 1_p

INTRODUCTION NNP N
To TO N
evaluate VB N
the DT N
outcome NN N
of IN N
cystoid JJ N
macular JJ N
edema NN N
treated VBN N
with IN N
intravitreal JJ 1_i
injections NNS 1_i
of IN 1_i
bevacizumab NN 1_i
and CC 1_i
macular JJ 1_i
grid NN 1_i
laser NN 1_i
photocoagulation NN 1_i
( ( 1_i
GLP NNP 1_i
) ) 1_i
, , N
in IN N
patients NNS 1_p
with IN 1_p
perfused JJ 1_p
branch NN 1_p
retinal JJ 1_p
vein NN 1_p
occlusion NN 1_p
. . 1_p

METHODS NNP N
Thirty NNP 1_p
eyes NNS 1_p
of IN 1_p
30 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
with IN 1_p
cystoid JJ 1_p
macular JJ 1_p
edema NN 1_p
secondary JJ 1_p
to TO 1_p
nonischemic JJ 1_p
branch NN 1_p
retinal JJ 1_p
vein NN 1_p
occlusion NN 1_p
were VBD 1_p
assigned VBN 1_p
to TO N
either DT N
GLP NNP 1_i
group NN 1_i
or CC N
to TO N
intravitreal VB 1_i
bevacizumab NN 1_i
( ( 1_i
IB NNP 1_i
) ) 1_i
group NN N
. . N

Complete NNP 1_o
ophthalmologic JJ 1_o
examinations NNS 1_o
were VBD N
performed VBN N
just RB N
before IN N
GLP NNP 1_i
and CC N
IB NNP 1_i
injection NN N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
treatment NN N
. . N

Changes NNS N
in IN N
logarithm NN 1_o
of IN 1_o
minimum JJ 1_o
angle NN 1_o
of IN 1_o
resolution NN 1_o
( ( 1_o
logMAR JJ 1_o
) ) 1_o
best-corrected JJ 1_o
visual JJ 1_o
acuity NN 1_o
( ( 1_o
BCVA NNP 1_o
) ) 1_o
, , 1_o
central JJ 1_o
macular JJ 1_o
thickness NN 1_o
( ( 1_o
CMT NNP 1_o
) ) 1_o
shown VBN 1_o
by IN 1_o
optical JJ 1_o
coherence NN 1_o
tomography-3 NN 1_o
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Baseline NNP 1_o
BCVA NNP 1_o
( ( 1_o
logMAR NN 1_o
) ) 1_o
and CC 1_o
CMT NNP 1_o
were VBD N
, , N
respectively RB N
, , N
0.89 CD N
+/- JJ N
0.13 CD N
and CC N
650 CD N
+/- JJ N
140 CD N
microm NN N
for IN N
the DT N
GLP NNP 1_i
group NN N
, , N
0.87 CD N
+/- JJ N
0.16 CD N
and CC N
690 CD N
+/- JJ N
120 CD N
microm NN N
for IN N
the DT N
IB NNP 1_i
group NN N
. . N

After IN N
the DT N
treatment NN N
, , N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
in IN N
the DT N
GLP NNP 1_i
group NN N
, , N
BCVA NNP 1_o
had VBD N
improved VBN N
by IN N
0.19 CD N
, , N
0.22 CD N
, , N
0.21 CD N
, , N
and CC N
0.20 CD N
logMAR NN N
, , N
CMT NNP 1_o
had VBD N
decreased VBN N
by IN N
40 CD N
% NN N
, , N
41.3 CD N
% NN N
, , N
40.5 CD N
% NN N
, , N
and CC N
42 CD N
% NN N
. . N

In IN N
the DT N
IB NNP 1_i
group NN N
, , N
BCVA NNP 1_o
had VBD N
improved VBN N
by IN N
0.31 CD N
, , N
0.32 CD N
, , N
0.30 CD N
, , N
and CC N
0.31 CD N
logMAR NN 1_o
and CC N
CMT NNP 1_o
had VBD N
decreased VBN N
by IN N
59.5 CD N
% NN N
, , N
59 CD N
% NN N
, , N
60 CD N
% NN N
, , N
and CC N
60.3 CD N
% NN N
. . N

The DT N
group NN N
receiving VBG N
bevacizumab NN 1_i
had VBD N
better JJR N
BCVA NNP 1_o
and CC N
lower JJR N
CMT NNP 1_o
values NNS N
at IN N
all DT N
time NN N
points NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Intravitreal NNP N
bevacizumab NN 1_i
injection NN N
improves VBZ N
BCVA NNP 1_o
and CC N
reduces NNS N
CMT NNP 1_o
more JJR N
than IN N
GLP NNP N
. . N

Intravitreal NNP N
bevacizumab JJ 1_i
injection NN N
was VBD N
well RB N
tolerated VBN N
and CC N
could MD N
be VB N
used VBN N
as IN N
primary JJ N
treatment NN N
in IN N
patients NNS N
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
perfused VBN N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
. . N

Systematic JJ 1_i
approach NN 1_i
to TO N
benign VB 1_p
paroxysmal JJ 1_p
positional JJ 1_p
vertigo NN 1_p
in IN 1_p
the DT 1_p
elderly JJ 1_p
. . 1_p

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
a DT N
management NN N
approach NN N
that WDT N
combines VBZ N
the DT N
canalith NN 1_i
repositioning VBG 1_i
maneuver NN 1_i
( ( 1_i
CRM NNP 1_i
) ) 1_i
and CC 1_i
vestibular JJ 1_i
rehabilitation NN 1_i
( ( 1_i
VR NNP 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
benign JJ 1_p
positional JJ 1_p
paroxysmal NN 1_p
vertigo NN 1_p
( ( 1_p
BPPV NNP 1_p
) ) 1_p
in IN 1_p
elderly JJ 1_p
persons NNS 1_p
. . 1_p

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
Forty-seven JJ 1_p
patients NNS 1_p
( ( 1_p
> JJ 1_p
/=70 CD 1_p
years NNS 1_p
old JJ 1_p
) ) 1_p
with IN 1_p
the DT 1_p
diagnosis NN 1_p
of IN 1_p
unilateral JJ 1_p
posterior JJ 1_p
semicircular JJ 1_p
canal NN 1_p
BPPV NNP 1_p
formed VBD N
the DT N
study NN N
population NN N
. . N

This DT N
study NN N
has VBZ N
2 CD N
parts NNS N
. . N

In IN N
the DT N
first JJ N
part NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
groups NNS N
: : N
the DT 1_i
CRM NNP 1_i
and CC 1_i
avoidance NN 1_i
( ( 1_i
no DT 1_i
treatment NN 1_i
) ) 1_i
. . 1_i

Patients NNS N
were VBD N
evaluated VBN N
1 CD N
month NN N
after IN N
the DT N
first JJ N
visit NN N
. . N

Those DT N
patients NNS N
not RB N
responding VBG N
to TO N
treatment NN N
were VBD N
enrolled VBN N
in IN N
the DT N
second JJ N
part NN N
of IN N
the DT N
study NN N
, , N
treated VBN N
with IN N
an DT 1_i
individualized JJ 1_i
combination NN 1_i
of IN 1_i
CRM NNP 1_i
and CC 1_i
VR NNP 1_i
, , N
and CC N
then RB N
reevaluated VBD N
3 CD N
months NNS N
later RB N
. . N

RESULTS NNP N
Statistically NNP N
significant JJ N
improvement NN 1_o
of IN 1_o
vertigo NN 1_o
and CC 1_o
provoked VBD 1_o
nystagmus NNS 1_o
in IN N
64 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
CRM NNP N
group NN N
compared VBN N
with IN N
the DT N
no-treatment JJ N
group NN N
. . N

After IN N
the DT N
addition NN N
of IN N
VR NNP 1_o
, , N
77 CD N
% NN N
of IN N
all DT N
patients NNS N
improved VBN N
. . N

CONCLUSION VB N
A DT N
combination NN N
of IN N
CRM NNP N
and CC N
VR NNP N
improves VBZ N
BPPV NNP 1_o
in IN 1_p
the DT 1_p
elderly JJ 1_p
. . 1_p

SIGNIFICANCE NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
although IN N
CRM NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
no DT N
treatment NN N
, , N
VR NNP N
can MD N
be VB N
added VBN N
to TO N
improve VB N
the DT N
results NNS N
in IN N
the DT N
treatment NN N
of IN N
BPPV NNP N
. . N

Intratunnel NNP 1_i
versus NN 1_i
extratunnel RB 1_i
autologous JJ 1_i
hamstring VBG 1_i
double-bundle JJ 1_i
graft NN 1_i
for IN N
anterior JJ 1_p
cruciate NN 1_p
ligament JJ 1_p
reconstruction NN 1_p
: : 1_p
a DT N
comparison NN N
of IN N
2 CD N
femoral JJ N
fixation NN N
procedures NNS N
. . N

BACKGROUND NNP N
Anatomic NNP N
double-bundle JJ N
anterior JJ 1_p
cruciate NN 1_p
ligament NN 1_p
( ( 1_p
ACL NNP 1_p
) ) 1_p
reconstruction NN N
provides VBZ N
excellent JJ N
results NNS N
for IN N
restoring VBG 1_o
normal JJ 1_o
kinematics NNS 1_o
to TO 1_o
the DT 1_o
knee NN 1_o
. . 1_o

Nevertheless RB N
, , N
strong JJ N
evidence NN N
supporting VBG N
an DT N
ideal NN N
method NN N
for IN N
fixation NN N
of IN N
the DT N
ACL NNP N
graft NN N
is VBZ N
lacking VBG N
. . N

HYPOTHESIS NNP N
Intratunnel NNP 1_i
femoral JJ 1_i
fixation NN 1_i
of IN 1_i
the DT 1_i
ACL NNP 1_i
graft NN 1_i
via IN 1_i
a DT 1_i
cross-pin JJ 1_i
fixation NN 1_i
technique NN 1_i
would MD N
provide VB N
better JJR N
clinical JJ N
and CC N
objective JJ N
results NNS N
than IN N
the DT N
extratunnel JJ 1_i
femoral JJ 1_i
fixation NN 1_i
with IN 1_i
cortical JJ 1_i
buttons NNS 1_i
. . 1_i

STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
; : N
Level NNP N
of IN N
evidence NN N
, , N
2 CD N
. . N

METHODS NNP N
Seventy NNP 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
unilateral JJ 1_p
ACL-deficient JJ 1_p
knee NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
femoral JJ N
fixation NN N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
35 CD N
patients NNS N
) ) N
was VBD N
fixed VBN 1_i
with IN 1_i
2 CD 1_i
bioabsorbable JJ 1_i
Rigidfix NNP 1_i
pins NNS 1_i
, , 1_i
1 CD 1_i
cross-pin NN 1_i
per IN 1_i
bundle NN 1_i
, , 1_i
while IN 1_i
group NN 1_i
B NNP 1_i
( ( 1_i
35 CD 1_i
patients NNS 1_i
) ) 1_i
was VBD 1_i
secured VBN 1_i
with IN 1_i
1 CD 1_i
EndoButton NNP 1_i
cortical JJ 1_i
button NN 1_i
per IN 1_i
bundle NN 1_i
. . 1_i

All DT N
femoral JJ N
tunnels NNS N
were VBD N
created VBN N
via IN N
an DT N
anteromedial JJ N
portal NN N
, , N
and CC N
a DT N
bioabsorbable JJ N
Biointrafix NNP N
interference NN N
screw NN N
was VBD N
used VBN N
for IN N
tibial JJ N
fixation NN N
for IN N
both DT N
groups NNS N
. . N

The DT N
evaluation NN N
of IN N
the DT N
patients NNS N
was VBD N
performed VBN N
by IN N
history NN N
details NNS N
, , N
clinical JJ N
examination NN N
findings NNS N
, , N
measurement NN N
of IN N
the DT N
joint JJ N
laxity NN N
by IN N
KT-1000 NNP 1_i
arthrometer NN 1_i
, , N
and CC N
use NN N
of IN N
validated JJ N
patient JJ N
outcome NN N
questionnaires NNS N
. . N

Statistical JJ N
analysis NN N
was VBD N
carried VBN N
out RP N
with IN N
Fisher NNP N
exact JJ N
and CC N
Mann-Whitney NNP N
U NNP N
tests NNS N
, , N
with IN N
P NNP N
< NNP N
.05 NNP N
considered VBD N
the DT N
cutoff NN N
level NN N
of IN N
significance NN N
. . N

RESULTS NNP N
At IN N
a DT N
mean JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
34 CD 1_p
and CC 1_p
32 CD 1_p
patients NNS 1_p
of IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
, , N
were VBD N
available JJ N
for IN N
evaluation NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
regarding VBG N
the DT N
subjective NN N
and CC N
objective JJ N
outcomes NNS N
, , N
except IN N
for IN N
KT-1000 NNP N
arthrometer NN N
values NNS N
. . N

The DT N
median JJ 1_o
KT-1000 NNP 1_o
value NN 1_o
of IN N
patients NNS N
in IN N
the DT N
cross-pin JJ N
fixation NN N
group NN N
was VBD N
1.30 CD N
mm NNS N
, , N
while IN N
the DT N
median JJ N
value NN N
in IN N
the DT N
cortical JJ 1_i
button NN 1_i
fixation NN 1_i
group NN N
was VBD N
1.95 CD N
mm NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Four CD N
patients NNS N
with IN N
ACL NNP N
grafts NNS N
that WDT N
were VBD N
fixed VBN N
with IN N
cortical JJ 1_i
buttons NNS 1_i
demonstrated VBD N
failure NN N
of IN N
stability NN 1_o
via IN 1_o
the DT 1_o
instrumented JJ 1_o
knee NN 1_o
laxity NN 1_o
testing NN 1_o
, , N
while IN N
patients NNS N
from IN N
the DT N
other JJ N
group NN N
had VBD N
no DT N
failures NNS N
. . N

CONCLUSION NNP N
Intratunnel NNP 1_i
femoral JJ 1_i
fixation NN 1_i
of IN 1_i
the DT 1_i
double-bundle JJ 1_i
ACL NNP 1_i
graft NN 1_i
from IN N
the DT N
cross-pin JJ N
fixation NN N
technique NN N
provided VBD N
better RBR N
instrumented JJ N
knee NN 1_o
laxity NN 1_o
results NNS N
than IN N
did VBD N
the DT N
extratunnel NN 1_i
femoral JJ 1_i
fixation NN 1_i
with IN 1_i
cortical JJ 1_i
buttons NNS 1_i
. . 1_i

Future NNP N
larger JJR N
studies NNS N
comparing VBG N
these DT N
2 CD N
techniques NNS N
should MD N
be VB N
conducted VBN N
to TO N
ensure VB N
the DT N
availability NN N
of IN N
stronger JJR N
evidence NN N
supporting VBG N
the DT N
findings NNS N
of IN N
this DT N
study NN N
. . N

[ JJ 1_i
Treatment NNP 1_i
of IN 1_i
the DT 1_i
hyperkinetic JJ 1_i
response NN 1_i
to TO 1_i
exercise NN 1_i
after IN 1_p
myocardial JJ 1_p
infarct NN 1_p
. . 1_p

Results NNS N
of IN N
a DT N
randomized JJ N
ergometric NN N
study NN N
] NNP N
. . N

Catheter NNP 1_i
ablation NN 1_i
of IN 1_i
stable JJ 1_i
ventricular JJ 1_i
tachycardia NN 1_i
before IN 1_p
defibrillator NN 1_i
implantation NN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
heart NN 1_p
disease NN 1_p
( ( 1_p
VTACH NNP 1_p
) ) 1_p
: : 1_p
a DT N
multicentre NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
In IN N
patients NNS 1_p
with IN 1_p
ventricular JJ 1_p
tachycardia NN 1_p
( ( 1_p
VT NNP 1_p
) ) 1_p
and CC 1_p
a DT 1_p
history NN 1_p
of IN 1_p
myocardial JJ 1_p
infarction NN 1_p
, , N
intervention NN N
with IN N
an DT N
implantable JJ 1_i
cardioverter NN 1_i
defibrillator NN 1_i
( ( 1_i
ICD NNP 1_i
) ) 1_i
can MD N
prevent VB N
sudden JJ N
cardiac JJ N
death NN N
and CC N
thereby RB N
reduce VB N
total JJ N
mortality NN N
. . N

However RB N
, , N
ICD NNP N
shocks NNS N
are VBP N
painful JJ N
and CC N
do VBP N
not RB N
provide VB N
complete JJ N
protection NN N
against IN N
sudden JJ N
cardiac JJ N
death NN N
. . N

We PRP N
assessed VBD N
the DT N
potential JJ N
benefit NN N
of IN N
catheter NN 1_i
ablation NN 1_i
before IN N
implantation NN N
of IN N
a DT N
cardioverter NN N
defibrillator NN N
. . N

METHODS NNP N
The DT 1_p
Ventricular NNP 1_p
Tachycardia NNP 1_p
Ablation NNP 1_p
in IN 1_p
Coronary NNP 1_p
Heart NNP 1_p
Disease NNP 1_p
( ( 1_p
VTACH NNP 1_p
) ) 1_p
study NN 1_p
was VBD 1_p
a DT 1_p
prospective JJ 1_p
, , 1_p
open JJ 1_p
, , 1_p
randomised VBD 1_p
controlled VBN 1_p
trial NN 1_p
, , 1_p
undertaken VBN 1_p
in IN 1_p
16 CD 1_p
centres NNS 1_p
in IN 1_p
four CD 1_p
European JJ 1_p
countries NNS 1_p
. . 1_p

Patients NNS 1_p
aged VBN 1_p
18-80 CD 1_p
years NNS 1_p
were VBD 1_p
eligible JJ 1_p
for IN 1_p
enrolment NN 1_p
if IN 1_p
they PRP 1_p
had VBD 1_p
stable JJ 1_p
VT NNP 1_p
, , 1_p
previous JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
, , 1_p
and CC 1_p
reduced VBD 1_p
left-ventricular JJ 1_p
ejection NN 1_p
fraction NN 1_p
( ( 1_p
LVEF NNP 1_p
; : 1_p
< NNP 1_p
or=50 IN 1_p
% NN 1_p
) ) 1_p
. . 1_p

110 CD 1_p
patients NNS 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
in IN 1_p
a DT 1_p
1:1 CD 1_p
ratio NN 1_p
to TO N
receive VB 1_i
catheter NN 1_i
ablation NN 1_i
and CC 1_i
an DT 1_i
ICD NNP 1_i
( ( 1_i
ablation NN 1_i
group NN 1_i
, , 1_i
n=54 RB 1_i
) ) 1_i
or CC 1_i
ICD NNP 1_i
alone RB 1_i
( ( 1_i
control NN 1_i
group NN 1_i
, , 1_i
n=56 RB 1_i
) ) 1_i
. . 1_i

Randomisation NN N
was VBD N
done VBN N
by IN N
computer-generated JJ N
randomly NNS N
permuted VBN N
blocks NNS N
and CC N
stratified VBN N
by IN N
centre NN N
and CC N
LVEF NNP N
( ( N
< JJ N
or=30 CD N
% NN N
or CC N
> VB N
30 CD N
% NN N
) ) N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
at IN N
least JJS N
1 CD N
year NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time NN 1_o
to TO 1_o
first JJ 1_o
recurrence NN 1_o
of IN 1_o
VT NNP 1_o
or CC 1_o
ventricular JJ 1_o
fibrillation NN 1_o
( ( 1_o
VF NNP 1_o
) ) 1_o
. . 1_o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
( ( N
ITT NNP N
) ) N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00919373 NNP N
. . N

FINDINGS NNP N
107 CD 1_p
patients NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
ITT NNP 1_p
population NN 1_p
( ( 1_i
ablation NN 1_i
group NN 1_i
, , 1_p
n=52 RB 1_p
; : 1_p
control NN 1_i
group NN 1_p
, , 1_p
n=55 RB 1_p
) ) 1_p
. . 1_p

Two CD N
patients NNS N
( ( N
one CD N
in IN N
each DT N
group NN N
) ) N
withdrew VBD N
consent NN N
immediately RB N
after IN N
randomisation NN N
without IN N
any DT N
follow-up JJ N
data NNS N
and CC N
one CD N
patient NN N
( ( N
ablation NN N
group NN N
) ) N
was VBD N
excluded VBN N
because IN N
of IN N
a DT N
protocol NN N
violaton NN N
. . N

Mean JJ N
follow-up NN N
was VBD N
22.5 CD N
months NNS N
( ( N
SD NNP N
9.0 CD N
) ) N
. . N

Time NN 1_o
to TO 1_o
recurrence NN 1_o
of IN 1_o
VT NNP 1_o
or CC 1_o
VF NNP 1_o
was VBD N
longer RBR N
in IN N
the DT N
ablation NN 1_i
group NN 1_i
( ( N
median JJ N
18.6 CD N
months NNS N
[ NNP N
lower JJR N
quartile NN N
2.4 CD N
, , N
upper JJ N
quartile NN N
not RB N
determinable JJ N
] NN N
) ) N
than IN N
in IN N
the DT N
control NN 1_i
group NN 1_i
( ( N
5.9 CD N
months NNS N
[ JJ N
IQR NNP N
0.8-26.7 NNP N
] NNP N
) ) N
. . N

At IN N
2 CD N
years NNS N
, , N
estimates NNS N
for IN N
survival JJ 1_o
free JJ N
from IN N
VT NNP 1_o
or CC 1_o
VF NNP 1_o
were VBD N
47 CD N
% NN N
in IN N
the DT N
ablation NN 1_i
group NN 1_i
and CC N
29 CD N
% NN N
in IN N
the DT N
control NN 1_i
group NN 1_i
( ( N
hazard JJ N
ratio NN N
0.61 CD N
; : N
95 CD N
% NN N
CI NNP N
0.37-0.99 CD N
; : N
p=0.045 NN N
) ) N
. . N

Complications NNS N
related VBN N
to TO N
the DT N
ablation NN N
procedure NN N
occurred VBD N
in IN N
two CD N
patients NNS N
; : N
no DT 1_o
deaths NNS 1_o
occurred VBD N
within IN N
30 CD N
days NNS N
after IN N
ablation NN N
. . N

15 CD N
device-related JJ N
complications NNS N
requiring VBG N
surgical JJ N
intervention NN N
occurred VBD N
in IN N
13 CD N
patients NNS N
( ( 1_i
ablation NN 1_i
group NN 1_i
, , N
four CD N
; : N
control NN 1_i
group NN 1_i
, , N
nine CD N
) ) N
. . N

Nine JJ 1_p
patients NNS 1_p
died VBD 1_o
during IN 1_p
the DT 1_p
study NN 1_p
( ( 1_i
ablation NN 1_i
group NN 1_p
, , 1_p
five CD 1_p
; : 1_p
control NN 1_i
group NN 1_p
, , 1_p
four CD 1_p
) ) 1_p
. . 1_p

INTERPRETATION NNP N
Prophylactic NNP 1_i
VT NNP 1_i
ablation NN 1_i
before IN N
defibrillator NN 1_i
implantation NN 1_i
seemed VBD N
to TO N
prolong VB N
time NN N
to TO N
recurrence NN N
of IN N
VT NNP N
in IN N
patients NNS 1_p
with IN 1_p
stable JJ 1_p
VT NNP 1_p
, , 1_p
previous JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
, , 1_p
and CC 1_p
reduced VBD 1_p
LVEF NNP 1_p
. . 1_p

Prophylactic NNP 1_i
catheter NN 1_i
ablation NN 1_i
should MD N
therefore RB N
be VB N
considered VBN N
before IN N
implantation NN N
of IN N
a DT N
cardioverter NN 1_i
defibrillator NN 1_i
in IN N
such JJ N
patients NNS N
. . N

FUNDING NNP N
St NNP N
Jude NNP N
Medical NNP N
. . N

Comparison NNP N
of IN N
four CD N
continuously RB N
administered VBN N
progestogen NN 1_i
plus CC 1_i
oestradiol JJ 1_i
combinations NNS N
for IN N
climacteric JJ 1_o
complaints NNS 1_o
. . 1_o

Sixty NNP 1_p
women NNS 1_p
with IN 1_p
climacteric JJ 1_p
complaints NNS 1_p
who WP 1_p
had VBD 1_p
not RB 1_p
menstruated VBN 1_p
for IN 1_p
at IN 1_p
least JJS 1_p
1 CD 1_p
year NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
one CD N
of IN N
four CD N
hormonal JJ N
replacement NN N
regimens NNS N
. . N

All DT N
four CD N
formulations NNS N
were VBD N
administered VBN N
daily RB N
and CC N
continuously RB N
and CC N
each DT N
contained VBD N
2 CD N
mg NN N
of IN N
micronized JJ 1_i
oestradiol-17 JJ 1_i
beta NN 1_i
in IN 1_i
combination NN 1_i
with IN 1_i
either DT 1_i
norethisterone NN 1_i
acetate NN 1_i
1 CD 1_i
mg NN 1_i
( ( N
group NN N
A NNP N
) ) N
or CC N
0.5 CD N
mg NN N
( ( N
group NN N
B NNP N
) ) N
or CC 1_i
megestrol VB 1_i
acetate JJ 1_i
5 CD 1_i
mg NN 1_i
( ( N
group NN N
C NNP N
) ) N
or CC N
2.5 CD N
mg NN N
( ( N
group NN N
D NNP N
) ) N
. . N

The DT N
clinical JJ 1_o
efficacy NN 1_o
was VBD N
the DT N
same JJ N
although IN N
the DT N
alleviation NN N
of IN N
vasomotor NN 1_o
symptoms NNS 1_o
was VBD N
somewhat RB N
slower JJR N
in IN N
those DT N
women NNS N
receiving VBG N
preparation NN N
A NNP N
. . N

The DT N
endometrium NN 1_o
was VBD N
atrophied VBN N
in IN N
nearly RB N
all DT N
biopsies NNS 1_o
. . 1_o

Irregular JJ 1_o
uterine JJ 1_o
bleeding NN 1_o
was VBD N
almost RB N
entirely RB N
confined VBN N
to TO N
the DT N
earlier JJR N
phase NN N
of IN N
the DT N
study NN N
and CC N
was VBD N
substantially RB N
less JJR N
with IN N
the DT N
formulation NN N
containing VBG N
1 CD N
mg JJ N
norethisterone NN 1_i
acetate NN 1_i
. . 1_i

It PRP N
is VBZ N
concluded VBN N
that IN N
a DT N
continuous JJ N
oestradiol-progestogen JJ 1_i
combination NN 1_i
can MD N
be VB N
used VBN N
for IN N
long-term JJ N
treatment NN N
of IN N
climacteric JJ 1_o
complaints NNS 1_o
in IN 1_p
postmenopausal JJ 1_p
women NNS 1_p
and CC N
that IN N
after IN N
4 CD N
months NNS N
the DT N
clinical JJ 1_o
efficacy NN 1_o
is VBZ N
the DT N
same JJ N
irrespective NN N
of IN N
the DT N
type NN N
and CC N
dose NN N
of IN N
progestogen NN 1_i
administered VBN N
. . N

The DT N
effects NNS N
of IN N
amantadine NN 1_i
vs. FW 1_i
trihexyphenidyl NN 1_i
on IN N
memory NN 1_o
in IN N
elderly JJ 1_p
normal JJ 1_p
volunteers NNS 1_p
. . 1_p

[ JJ 1_o
Optimization NNP 1_o
of IN N
the DT N
postoperative JJ N
period NN N
in IN N
children NNS 1_p
after IN 1_p
adenotonsillectomy JJ 1_i
] NN 1_i
. . N

Reducing VBG N
Sitting VBG N
Time NNP N
After IN N
Stroke NNP N
: : N
A DT N
Phase NNP N
II NNP N
Safety NNP N
and CC N
Feasibility NNP N
Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

OBJECTIVE NNP N
To TO N
test VB N
the DT N
safety NN N
, , N
feasibility NN N
, , N
and CC N
effectiveness NN N
of IN N
reducing VBG 1_i
sitting VBG 1_i
time NN 1_i
in IN 1_i
stroke NN 1_i
survivors NNS 1_i
. . 1_i

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
with IN N
attention-matched JJ N
controls NNS N
and CC N
blinded VBD N
assessments NNS N
. . N

SETTING NNP N
Community NNP N
. . N

PARTICIPANTS NNP N
Stroke NNP 1_p
survivors NNS 1_p
( ( 1_p
N=35 NNP 1_p
; : 1_p
22 CD 1_p
men NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
66.9±12.7y CD 1_p
) ) 1_p
. . 1_p

INTERVENTIONS NNP 1_i
Four CD 1_i
counseling NN 1_i
sessions NNS 1_i
over IN N
7 CD N
weeks NNS N
with IN N
a DT N
message NN N
of IN 1_i
sit NN 1_i
less CC 1_i
and CC 1_i
move VB 1_i
more JJR 1_i
( ( 1_i
intervention NN 1_i
group NN 1_i
) ) 1_i
or CC 1_i
calcium NN 1_i
for IN 1_i
bone NN 1_i
health NN 1_i
( ( N
attention-matched JJ N
control NN N
group NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Measures NNP N
included VBD 1_o
safety NN 1_o
( ( 1_o
adverse JJ 1_o
events NNS 1_o
, , 1_o
increases NNS 1_o
in IN 1_o
pain NN 1_o
, , 1_o
spasticity NN 1_o
, , 1_o
or CC 1_o
fatigue NN 1_o
) ) 1_o
and CC 1_o
feasibility NN 1_o
( ( 1_o
adherence NN 1_o
to TO 1_o
trial NN 1_o
protocol NN 1_o
) ) 1_o
. . N

Secondary JJ N
measures NNS N
included VBD 1_o
time NN 1_o
spent VBN 1_o
sitting VBG 1_o
( ( 1_o
including VBG 1_o
in IN 1_o
prolonged JJ 1_o
bouts NNS 1_o
≥30min NN 1_o
) ) 1_o
, , 1_o
standing VBG 1_o
, , 1_o
and CC 1_o
stepping VBG 1_o
as IN 1_o
measured VBN 1_o
by IN 1_o
the DT 1_o
thigh-worn JJ 1_o
inclinometer NN 1_o
( ( N
7d CD N
, , N
24h/d CD N
protocol NN N
) ) N
and CC 1_o
time NN 1_o
spent VBN 1_o
in IN 1_o
physical JJ 1_o
activity NN 1_o
of IN N
at IN N
least JJS N
moderate JJ N
intensity NN N
as IN N
measured VBN N
by IN N
a DT N
triaxial JJ N
accelerometer NN N
. . N

The DT 1_o
Multimedia NNP 1_o
Activity NNP 1_o
Recall NNP 1_o
for IN 1_o
Children NNP 1_o
and CC 1_o
Adults NNP 1_o
was VBD N
used VBN N
to TO N
describe VB N
changes NNS N
in IN N
use NN N
of IN N
time NN N
. . N

RESULTS VB 1_p
Thirty-three JJ 1_p
participants NNS 1_p
completed VBD 1_p
the DT N
full JJ N
protocol NN N
. . N

Four CD N
participants NNS N
reported VBD 1_o
falls NNS 1_o
during IN N
the DT N
intervention NN N
period NN N
with IN N
no DT N
other JJ 1_o
adverse JJ 1_o
events NNS 1_o
. . N

From IN N
a DT N
baseline JJ N
average NN N
of IN N
640.7±99.6min/d CD 1_o
, , 1_o
daily RB 1_o
sitting VBG 1_o
time NN 1_o
reduced VBN N
on IN N
average NN N
by IN N
30±50.6min/d CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
5.8-54.6 JJ N
) ) N
in IN N
the DT N
intervention NN N
group NN N
and CC N
40.4±92.5min/d CD N
in IN 1_i
the DT 1_i
control NN 1_i
group NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
13.0-93.8 JJ N
) ) N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
also RB N
reduced VBD N
their PRP$ 1_o
time NN 1_o
spent VBN 1_o
in IN 1_o
prolonged JJ 1_o
sitting NN 1_o
bouts NNS N
( ( N
≥30min NN N
) ) N
and CC N
increased JJ 1_o
time NN 1_o
spent VBN 1_o
standing NN 1_o
and CC 1_o
stepping NN 1_o
. . N

CONCLUSIONS NNP N
Our PRP$ N
protocol NN N
was VBD N
both DT N
safe JJ N
and CC N
feasible JJ N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
spent VBD N
less JJR N
time NN N
sitting VBG N
and CC N
more JJR N
time NN N
standing NN N
and CC N
stepping VBG N
postintervention NN N
, , N
but CC N
outcomes NNS N
were VBD N
not RB N
superior JJ N
for IN N
intervention NN 1_p
participants NNS 1_p
. . N

Attention NN N
matching NN N
is VBZ N
desirable JJ N
in IN N
clinical JJ N
trials NNS N
and CC N
may MD N
have VB N
contributed VBN N
to TO N
the DT N
positive JJ N
outcomes NNS N
for IN N
control NN 1_p
participants NNS 1_p
. . N

Cyclosporine NNP 1_i
inhibition NN N
of IN N
P-glycoprotein NNP N
in IN N
chronic JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
blast NN 1_p
phase NN 1_p
. . 1_p

Chronic NNP N
myeloid NN N
leukemia NN N
blast NN N
phase NN N
( ( N
CML-BP NNP N
) ) N
cells NNS N
commonly RB N
express VBP N
the DT N
multidrug NN N
transporter NN N
, , N
P-glycoprotein NNP N
( ( N
Pgp NNP N
) ) N
. . N

To TO N
determine VB N
whether IN N
Pgp NNP N
inhibition NN N
improves VBZ N
treatment NN N
outcome NN N
in IN N
CML-BP NNP N
, , N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
performed VBD N
a DT N
randomized VBN 1_i
, , 1_i
controlled VBN 1_i
trial NN 1_i
testing VBG 1_i
the DT 1_i
benefit NN 1_i
of IN 1_i
the DT 1_i
Pgp NNP 1_i
modulator NN 1_i
, , 1_i
cyclosporin VB 1_i
A NNP 1_i
( ( 1_i
CsA NNP 1_i
) ) 1_i
. . 1_i

Seventy-three JJ 1_p
eligible JJ 1_p
patients NNS 1_p
were VBD N
assigned VBN 1_i
to TO 1_i
treatment NN 1_i
with IN 1_i
cytarabine NN 1_i
and CC 1_i
infusional JJ 1_i
daunorubicin NN 1_i
with IN 1_i
or CC 1_i
without IN 1_i
intravenous JJ 1_i
CsA NNP 1_i
. . 1_i

Treatment NN N
with IN N
CsA NNP N
yielded VBD N
no DT 1_o
improvement NN 1_o
in IN N
treatment NN N
outcome NN N
as IN N
measured VBN N
by IN N
the DT N
frequency NN 1_o
of IN 1_o
induction NN 1_o
resistance NN 1_o
( ( N
68 CD N
% NN N
vs JJ N
53 CD N
% NN N
) ) N
, , N
rate NN 1_o
of IN 1_o
complete JJ 1_o
remission NN 1_o
or CC 1_o
restored VBN 1_o
chronic JJ 1_o
phase NN 1_o
( ( N
CR/CP NNP N
, , N
8 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
, , N
and CC N
survival NN 1_o
( ( N
3 CD N
vs RB N
5 CD N
months NNS N
) ) N
. . N

Blast NNP 1_o
expression NN 1_o
of IN 1_o
Pgp NNP 1_o
( ( N
63 CD N
% NN N
) ) N
and CC N
LRP NNP 1_o
( ( N
71 CD N
% NN N
) ) N
was VBD N
common JJ N
, , N
whereas IN N
only RB N
Pgp NNP N
adversely RB N
impacted VBD N
the DT N
rate NN 1_o
of IN 1_o
CR/CP NNP 1_o
( ( N
P NNP N
=.025 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
Pgp NNP N
has VBZ N
prognostic JJ N
relevance NN N
in IN N
CML-BP NNP N
but CC N
that IN N
the DT N
modulation NN N
of IN N
Pgp NNP N
function NN N
with IN N
CsA NNP N
as IN N
applied VBN N
in IN N
this DT N
trial NN N
is VBZ N
ineffective JJ N
. . N

Scent NN N
and CC N
mood NN N
state NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
water NN 1_i
, , 1_i
lavender NN 1_i
, , 1_i
or CC 1_i
rosemary JJ 1_i
scent NN 1_i
on IN N
physiology NN 1_o
and CC 1_o
mood NN 1_o
state NN 1_o
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

The DT 1_p
nonsmoking JJ 1_p
participants NNS 1_p
, , 1_p
ages VBZ 1_p
18-30 CD 1_p
years NNS 1_p
, , 1_p
included VBD 1_p
42 CD 1_p
women NNS 1_p
and CC 1_p
31 CD 1_p
men NNS 1_p
who WP 1_p
reported VBD 1_p
demographic JJ 1_p
information NN 1_p
and CC 1_p
measures NNS 1_p
of IN 1_p
external JJ 1_p
temperature NN 1_p
and CC 1_p
heart NN 1_p
rate NN 1_p
were VBD 1_p
taken VBN 1_p
prior RB 1_p
to TO 1_p
introduction NN 1_p
of IN 1_p
an DT 1_p
anxiety-eliciting JJ 1_i
task NN 1_i
and CC 1_p
exposure NN 1_p
to TO 1_p
lavender VB 1_i
, , 1_i
rosemary JJ 1_i
, , 1_i
or CC 1_i
water NN 1_i
scents NNS 1_i
. . 1_i

Following VBG N
the DT N
task NN N
, , N
participants NNS N
completed VBD N
the DT N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
to TO N
assess VB N
mood NN 1_o
, , 1_o
and CC 1_o
temperature NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
were VBD N
reassessed VBN N
. . N

Participants NNS N
rated VBD N
the DT N
pleasantness NN N
of IN N
the DT N
scent NN N
received VBD N
. . N

When WRB N
pleasantness JJ N
ratings NNS N
of IN N
scent NN N
were VBD N
covaried VBN N
, , N
physiological JJ 1_o
changes NNS 1_o
in IN 1_o
temperature NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
did VBD N
not RB N
differ VB N
based VBN N
on IN N
scent NN N
exposure NN N
, , N
but CC N
mood VBD 1_o
ratings NNS 1_o
differed VBN N
by IN N
scent JJ N
condition NN N
. . N

Participants NNS N
in IN N
the DT N
rosemary JJ N
condition NN N
scored VBD N
higher JJR N
on IN N
measures NNS N
of IN N
tension-anxiety NN 1_o
and CC 1_o
confusion-bewilderment JJ 1_o
relative NN N
to TO N
the DT N
lavender NN N
and CC N
control NN N
conditions NNS N
. . N

The DT N
lavender NN N
and CC N
control NN N
conditions NNS N
showed VBD N
higher JJR N
mean JJ 1_o
vigor-activity NN 1_o
ratings NNS 1_o
relative VBP N
to TO N
the DT N
rosemary JJ N
group NN N
, , N
while IN N
both DT N
rosemary JJ N
and CC N
lavender JJ N
scents NNS N
were VBD N
associated VBN N
with IN N
lower JJR N
mean NN 1_o
ratings NNS 1_o
on IN 1_o
the DT 1_o
fatigue-inertia JJ 1_o
subscale NN 1_o
, , N
relative JJ N
to TO N
the DT N
control NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
, , N
when WRB N
individual JJ N
perception NN N
of IN N
scent JJ N
pleasantness NN N
is VBZ N
controlled VBN N
, , N
scent NN N
has VBZ N
the DT N
potential JJ N
to TO N
moderate VB N
different JJ N
aspects NNS N
of IN N
mood NN N
following VBG N
an DT N
anxiety-provoking JJ N
task NN N
. . N

Prospective JJ N
randomised VBD 1_p
multicentre JJ 1_p
trial NN 1_p
with IN 1_p
the DT 1_p
birth NN 1_i
trainer NN 1_i
EPI-NO NNP 1_i
for IN N
the DT N
prevention NN N
of IN N
perineal JJ 1_o
trauma NN 1_o
. . 1_o

BACKGROUND NNP N
In IN N
several JJ N
non-randomised JJ N
trials NNS N
training VBG N
with IN N
EPI-NO NNP 1_i
increased VBD N
the DT N
rate NN N
of IN N
intact JJ N
perineum NN N
and CC N
decreased JJ N
episiotomy NN N
rates NNS N
, , N
shortened VBD N
the DT N
second JJ N
stage NN N
of IN N
labour NN N
and CC N
lowered VBN N
use NN N
of IN N
pain NN N
killers NNS N
. . N

AIMS NNP N
To TO N
verify VB N
the DT N
preliminary JJ N
results NNS N
with IN N
EPI-NO NNP 1_i
in IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
. . N

METHODS NNP N
Randomised VBD 1_p
, , 1_p
single-blind JJ 1_p
multicentre NN 1_p
trial NN 1_p
in IN 1_p
four CD 1_p
university NN 1_p
hospitals NNS 1_p
in IN 1_p
Germany NNP 1_p
including VBG 1_p
276 CD 1_p
primigravidae NN 1_p
. . 1_p

RESULTS NNP N
After IN N
training VBG N
with IN N
EPI-NO NNP 1_i
we PRP N
observed VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
incidence NN 1_o
of IN 1_o
intact JJ 1_o
perineum NN 1_o
( ( N
37.4 CD N
% NN N
vs JJ N
25.7 CD N
% NN N
; : N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
a DT N
tendency NN N
towards NNS N
lower JJR 1_o
episiotomy NN 1_o
rates NNS 1_o
( ( N
41.9 CD N
% NN N
vs JJ N
50.5 CD N
% NN N
; : N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD 1_p
groups NNS 1_p
regarding VBG N
incidence NN 1_o
of IN 1_o
perineal NN 1_o
tears NNS 1_o
, , 1_o
duration NN 1_o
of IN 1_o
second JJ 1_o
stage NN 1_o
of IN 1_o
labour NN 1_o
, , 1_o
use NN 1_o
of IN 1_o
pain NN 1_o
relief NN 1_o
and CC 1_o
rate NN 1_o
of IN 1_o
vaginal JJ 1_o
infection NN 1_o
. . 1_o

CONCLUSIONS NNP N
Training VBG N
with IN N
EPI-NO NNP 1_i
increases NNS N
significantly RB N
the DT N
likelihood NN N
of IN N
having VBG 1_o
an DT 1_o
intact JJ 1_o
perineum NN 1_o
and CC 1_o
reduces VBZ 1_o
the DT 1_o
episiotomy NN 1_o
rate NN 1_o
. . 1_o

Clinical JJ N
impact NN N
of IN N
leak JJ N
compensation NN N
during IN N
non-invasive JJ N
ventilation NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
leak JJ N
compensation NN N
capabilities NNS N
during IN N
pressure- JJ 1_i
and CC 1_i
volume-limited JJ 1_i
non-invasive JJ 1_i
positive-pressure NN 1_i
ventilation NN 1_i
( ( 1_i
NPPV NNP 1_i
) ) 1_i
in IN N
COPD NNP N
patients NNS N
. . N

METHODS NNP N
Fourteen NNP 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
hypercapnic JJ 1_p
COPD NN 1_p
who WP 1_p
were VBD 1_p
receiving VBG 1_p
long-term JJ 1_p
NPPV NNP 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

For IN N
both DT N
modes NNS N
of IN N
NPPV NNP N
, , N
a DT N
full JJ 1_i
face NN 1_i
mask NN 1_i
and CC 1_i
an DT 1_i
artificial JJ 1_i
leak NN 1_i
in IN 1_i
the DT 1_i
ventilatory NN 1_i
circuit NN 1_i
were VBD N
used VBN N
at IN N
three CD N
different JJ N
settings NNS N
, , N
and CC N
applied VBD N
during IN N
daytime JJ N
NPPV NNP N
, , N
either RB 1_i
without IN 1_i
leakage NN 1_i
( ( 1_i
setting VBG 1_i
I PRP 1_i
) ) 1_i
, , 1_i
with IN 1_i
leakage NN 1_i
during IN 1_i
inspiration NN 1_i
only RB 1_i
( ( 1_i
setting VBG 1_i
II NNP 1_i
) ) 1_i
, , 1_i
and CC 1_i
with IN 1_i
leakage NN 1_i
during IN 1_i
inspiration NN 1_i
and CC 1_i
expiration NN 1_i
( ( 1_i
setting VBG 1_i
III NNP 1_i
) ) 1_i
. . 1_i

Ventilation NNP 1_o
pattern NN 1_o
was VBD N
pneumotachy-graphically RB N
recorded VBN N
. . N

RESULTS NNP N
NPPV NNP N
was VBD N
feasible JJ N
with IN N
negligible JJ N
leak NN 1_o
volumes NNS 1_o
, , N
indicating VBG N
optimal JJ N
mask NN N
fitting VBG N
during IN N
the DT N
daytime NN N
( ( N
setting VBG N
I PRP N
) ) N
. . N

In IN N
the DT N
presence NN N
of IN N
leakage NN 1_o
( ( N
settings NNS N
II NNP N
and CC N
III NNP N
) ) N
, , N
the DT N
attempt NN N
to TO N
compensate VB N
for IN N
leak NN N
was VBD N
only RB N
evident JJ N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
since IN N
inspiratory NN 1_o
volumes NNS 1_o
delivered VBN 1_o
by IN 1_o
the DT 1_o
ventilator NN 1_o
increased VBD N
from IN N
726+/-129 NNP N
( ( N
setting VBG N
I PRP N
) ) N
to TO N
1104+/-164 JJ N
( ( N
setting VBG N
II NNP N
) ) N
, , N
and CC N
to TO N
1257+/-166 JJ N
( ( N
setting VBG N
III NNP N
) ) N
ml NN N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
respectively RB N
( ( N
all DT N
p VBP N
< $ N
0.001 CD N
) ) N
; : N
however RB N
, , N
they PRP N
remained VBD N
stable JJ N
during IN N
volume-limited JJ N
NPPV NNP N
. . N

Leak NNP N
compensation NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
leakage-induced JJ 1_o
dyspnea NN 1_o
. . 1_o

However RB N
, , N
83 CD N
% NN N
/87 CD N
% NN N
( ( N
setting VBG N
II/III NNP N
) ) N
of IN N
the DT N
additionally-delivered JJ N
inspiratory NN N
volume NN N
during IN N
pressure-limited JJ N
NPPV NNP N
was VBD N
also RB N
lost VBN N
via IN N
leakage NN N
. . N

Expiratory JJ 1_o
volume NN 1_o
was VBD N
higher RBR N
in IN N
setting VBG N
II NNP N
compared VBN N
to TO N
setting VBG N
III NNP N
( ( N
both DT N
p VBP N
< $ N
0.001 CD N
) ) N
, , N
indicating VBG N
the DT N
presence NN N
of IN N
significant JJ N
expiratory JJ N
leakage NN N
. . N

CONCLUSIONS VB N
The DT N
attempt NN N
at IN N
leak JJ N
compensation NN N
largely RB N
feeds VBZ N
the DT N
leakage NN N
itself PRP N
and CC N
only RB N
results NNS N
in IN N
a DT N
marginal JJ N
increase NN N
of IN N
tidal JJ N
volume NN N
. . N

However RB N
, , N
pressure-limited JJ N
-- : N
but CC N
not RB N
volume-limited JJ N
-- : N
NPPV JJ N
results NNS N
in IN N
a DT N
clinically-important JJ N
leak JJ N
compensation NN N
in IN N
vivo NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html JJ N
Identifier NNP N
: : N
UKF001272 NN N
. . N

A DT N
randomized VBN N
, , N
phase VB N
II NNP N
study NN N
of IN N
afatinib JJ N
versus NN N
cetuximab NN N
in IN N
metastatic JJ 1_p
or CC 1_p
recurrent JJ 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
. . 1_p

BACKGROUND NNP N
Afatinib NNP N
is VBZ N
an DT N
oral JJ N
, , N
irreversible JJ N
ErbB NNP N
family NN N
blocker NN N
that WDT N
has VBZ N
shown VBN N
activity NN N
in IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
( ( N
EGFR NNP N
) ) N
-mutated VBD N
lung NN N
cancer NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
agent NN N
would MD N
have VB N
greater JJR N
antitumor NN 1_o
activity NN 1_o
compared VBN N
with IN N
cetuximab NN N
in IN N
recurrent NN 1_p
or CC 1_p
metastatic JJ 1_p
( ( 1_p
R/M NNP 1_p
) ) 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
( ( 1_p
HNSCC NNP 1_p
) ) 1_p
patients NNS 1_p
, , 1_p
whose WP$ 1_p
disease NN 1_p
has VBZ 1_p
progressed VBN 1_p
after IN 1_p
platinum-containing JJ 1_p
therapy NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
An DT N
open-label JJ N
, , N
randomized VBN N
, , N
phase VB N
II NNP N
trial NN N
was VBD N
conducted VBN N
in IN N
43 CD 1_p
centers NNS 1_p
; : 1_p
124 CD 1_p
patients NNS 1_p
were VBD N
randomized VBN 1_i
( ( 1_i
1 CD 1_i
: : 1_i
1 CD 1_i
) ) 1_i
to TO 1_i
either DT 1_i
afatinib NN 1_i
( ( 1_i
50 CD 1_i
mg/day NN 1_i
) ) 1_i
or CC 1_i
cetuximab NN 1_i
( ( 1_i
250 CD 1_i
mg/m NN 1_i
( ( 1_i
2 CD 1_i
) ) 1_i
/week NN 1_i
) ) 1_i
until IN 1_i
disease JJ 1_i
progression NN 1_i
or CC 1_i
intolerable JJ 1_i
adverse JJ 1_i
events NNS 1_i
( ( 1_i
AEs NNP 1_i
) ) 1_i
( ( 1_i
stage NN 1_i
I PRP 1_i
) ) 1_i
, , 1_i
with IN 1_i
optional JJ 1_i
crossover NN 1_i
( ( 1_i
stage JJ 1_i
II NNP 1_i
) ) 1_i
. . 1_i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
tumor JJ 1_o
shrinkage NN 1_o
before IN 1_o
crossover NN 1_o
assessed VBN 1_o
by IN 1_o
investigator NN 1_o
( ( 1_o
IR NNP 1_o
) ) 1_o
and CC 1_o
independent JJ 1_o
central JJ 1_o
review NN 1_o
( ( 1_o
ICR NNP 1_o
) ) 1_o
. . 1_o

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
121 CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
( ( 1_p
61 CD 1_p
afatinib NN 1_p
, , 1_p
60 CD 1_p
cetuximab NN 1_p
) ) 1_p
and CC 1_p
68 CD 1_p
crossed VBN 1_p
over IN 1_p
to TO 1_p
stage VB 1_p
II NNP 1_p
( ( 1_p
32 CD 1_p
and CC 1_p
36 CD 1_p
respectively RB 1_p
) ) 1_p
. . 1_p

In IN N
stage NN N
I PRP N
, , N
mean JJ 1_o
tumor NN 1_o
shrinkage NN 1_o
by IN 1_o
IR/ICR NNP 1_o
was VBD N
10.4 CD N
% NN N
/16.6 CD N
% NN N
with IN N
afatinib NN N
and CC N
5.4 CD N
% NN N
/10.1 CD N
% NN N
with IN N
cetuximab NN N
( ( N
P NNP N
= NNP N
0.46/0.30 CD N
) ) N
. . N

Objective JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
16.1 CD N
% NN N
/8.1 CD N
% NN N
with IN N
afatinib NN N
and CC N
6.5 CD N
% NN N
/9.7 CD N
% NN N
with IN N
cetuximab NN N
( ( N
IR/ICR NNP N
) ) N
. . N

Comparable JJ 1_o
disease NN 1_o
control NN 1_o
rates NNS 1_o
were VBD N
observed VBN N
with IN N
afatinib NN N
( ( N
50 CD N
% NN N
) ) N
and CC N
cetuximab NN N
( ( N
56.5 CD N
% NN N
) ) N
by IN N
IR NNP N
; : N
similar JJ N
results NNS N
were VBD N
seen VBN N
by IN N
ICR NNP N
. . N

Most JJS N
common JJ N
grade NN N
≥3 JJ 1_o
drug-related JJ 1_o
AEs NNP 1_o
( ( N
DRAEs NNP N
) ) N
were VBD 1_o
rash/acne VBN 1_o
( ( N
18 CD N
% NN N
versus IN N
8.3 CD 1_o
% NN 1_o
) ) 1_o
, , 1_o
diarrhea NN 1_o
( ( N
14.8 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
, , N
and CC 1_o
stomatitis/mucositis NN 1_o
( ( N
11.5 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
with IN N
afatinib NN N
and CC N
cetuximab NN N
, , N
respectively RB N
. . N

Patients NNS N
with IN 1_o
DRAEs NNP 1_o
leading VBG 1_o
to TO 1_o
treatment NN 1_o
discontinuation NN 1_o
were VBD N
23 CD N
% NN N
with IN N
afatinib NN N
and CC N
5 CD N
% NN N
with IN N
cetuximab NN N
. . N

In IN N
stage NN N
II NNP 1_o
, , 1_o
disease VB 1_o
control NN 1_o
rate NN 1_o
( ( 1_o
IR/ICR NNP 1_o
) ) 1_o
was VBD N
38.9 CD N
% NN N
/33.3 CD N
% NN N
with IN N
afatinib NN N
and CC N
18.8 CD N
% NN N
/18.8 CD N
% NN N
with IN N
cetuximab NN N
. . N

CONCLUSION NNP N
Afatinib NNP N
showed VBD 1_o
antitumor JJ 1_o
activity NN 1_o
comparable JJ N
to TO N
cetuximab VB N
in IN 1_p
R/M NNP 1_p
HNSCC NNP 1_p
in IN N
this DT N
exploratory JJ N
phase NN N
II NNP N
trial NN N
, , N
although IN N
more JJR N
patients NNS N
on IN N
afatinib JJ N
discontinued VBN N
treatment NN N
due JJ N
to TO N
AEs NNP N
. . N

Sequential NNP N
EGFR/ErbB NNP N
treatment NN N
with IN N
afatinib NN N
and CC N
cetuximab NN N
provided VBD N
sustained JJ 1_o
clinical JJ 1_o
benefit NN 1_o
in IN N
patients NNS N
after IN N
crossover NN N
, , N
suggesting VBG N
a DT N
lack NN N
of IN N
cross-resistance NN N
. . N

An DT N
analysis NN N
of IN N
the DT N
radiation NN N
related VBN N
morbidity NN 1_o
observed VBN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
neutron NN 1_i
therapy NN 1_i
for IN N
bladder NN 1_p
cancer NN 1_p
. . 1_p

This DT N
report NN N
is VBZ N
an DT N
analysis NN N
of IN N
the DT N
morbidity NN 1_o
in IN 1_p
the DT 1_p
bladder NN 1_p
and CC N
bowel NN N
observed VBN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
d NN 1_i
( ( 1_i
15 CD 1_i
) ) 1_i
+Be NN 1_i
neutrons NNS 1_i
versus VBP N
megavoltage NN 1_i
photons NNS 1_i
in IN N
the DT N
treatment NN N
of IN N
bladder NN N
cancer NN N
. . N

Acute JJ 1_o
reactions NNS 1_o
in IN N
the DT N
bladder NN N
and CC N
bowel NN N
were VBD N
significantly RB N
worse JJR N
after IN N
photon NN 1_i
therapy NN 1_i
. . 1_i

Of IN N
the DT N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
photons NNS 1_i
45.7 CD N
% NN N
had VBD N
severe JJ N
reactions NNS 1_o
in IN 1_o
the DT 1_o
bladder NN 1_o
compared VBN N
with IN N
10.6 CD N
% NN N
after IN N
neutron JJ 1_i
therapy NN 1_i
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Severe NNP 1_o
acute JJ 1_o
bowel NN 1_o
reactions NNS 1_o
were VBD N
observed VBN N
in IN N
8.5 CD N
% NN N
of IN N
the DT N
patients NNS N
after IN N
photon NN 1_i
therapy NN 1_i
compared VBN N
with IN N
3.8 CD N
% NN N
after IN N
neutron JJ 1_i
therapy NN 1_i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Late JJ 1_o
reactions NNS 1_o
were VBD N
significantly RB N
worse JJR N
after IN N
neutrons NNS 1_i
. . 1_i

Severe NNP 1_o
late JJ 1_o
reactions NNS 1_o
in IN 1_o
the DT 1_o
bladder NN 1_o
were VBD N
seen VBN N
in IN N
58.5 CD N
% NN N
of IN N
patients NNS N
after IN N
neutron JJ 1_i
therapy NN 1_i
and CC N
in IN N
40.5 CD N
% NN N
after IN N
photon NN 1_i
therapy NN 1_i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

In IN N
the DT N
bowel NN N
they PRP N
were VBD N
observed VBN N
in IN N
53.3 CD N
% NN N
of IN N
patients NNS N
after IN N
neutron JJ 1_i
therapy NN 1_i
compared VBN N
with IN N
8 CD N
% NN N
after IN N
photon NN 1_i
therapy NN 1_i
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
disparity NN 1_o
in IN 1_o
the DT 1_o
degree NN 1_o
of IN 1_o
early JJ 1_o
and CC 1_o
late JJ 1_o
complications NNS 1_o
makes VBZ N
assessment NN N
of IN N
RBE NNP 1_o
values NNS 1_o
difficult JJ N
. . N

It PRP N
is VBZ N
estimated VBN N
that IN N
for IN N
bladder NN 1_o
morbidity NN 1_o
the DT N
RBE NNP 1_o
value NN 1_o
, , N
for IN N
photon NN N
dose JJ N
fractions NNS N
of IN N
2.75 CD N
Gy NNP N
, , N
is VBZ N
less JJR N
than IN N
3.3 CD N
for IN N
early JJ N
reactions NNS N
and CC N
equal JJ N
to TO N
3.4 CD N
for IN N
late JJ N
effects NNS N
. . N

The DT N
respective JJ N
RBE NNP 1_o
values NNS 1_o
for IN N
early RB N
and CC N
late JJ N
effects NNS N
in IN N
the DT N
bowel NN N
are VBP N
less JJR N
than IN N
3.4 CD N
and CC N
3.8 CD N
. . N

Acute JJ N
effects NNS N
of IN N
static JJ 1_i
active JJ 1_i
or CC 1_i
dynamic JJ 1_i
active JJ 1_i
stretching VBG 1_i
on IN N
eccentric-exercise-induced JJ 1_o
hamstring NN 1_o
muscle NN 1_o
damage NN 1_o
. . 1_o

OBJECTIVES UH N
To TO N
examine VB N
whether IN N
an DT N
acute NN N
bout NN N
of IN N
active JJ 1_i
or CC 1_i
dynamic JJ 1_i
hamstring-stretching JJ 1_i
exercises NNS 1_i
would MD N
reduce VB N
the DT N
amount NN N
of IN N
muscle NN N
damage NN N
observed VBD N
after IN N
a DT N
strenuous JJ N
eccentric JJ N
task NN N
and CC N
to TO N
determine VB N
whether IN N
the DT N
stretching NN N
protocols VBZ N
elicit JJ N
similar JJ N
responses NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

METHODS NNP N
Thirty-six NNP 1_p
young JJ 1_p
male NN 1_p
students NNS 1_p
performed VBD 1_p
5 CD 1_p
min NN 1_p
of IN 1_p
jogging NN 1_i
as IN 1_p
a DT 1_p
warm-up JJ 1_p
and CC 1_p
were VBD 1_p
allocated VBN 1_p
to TO 1_p
1 CD 1_p
of IN 1_p
3 CD 1_p
groups NNS 1_p
: : 1_p
3 CD 1_i
min NN 1_i
of IN 1_i
static JJ 1_i
active JJ 1_i
stretching NN 1_i
( ( 1_i
SAS NNP 1_i
) ) 1_i
, , 1_i
3 CD 1_i
min NN 1_i
of IN 1_i
dynamic JJ 1_i
active JJ 1_i
stretching NN 1_i
( ( 1_i
DAS NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
control NN 1_i
( ( 1_i
CON NNP 1_i
) ) 1_i
. . 1_i

All DT N
subjects NNS 1_p
performed VBN 1_p
eccentric JJ 1_i
exercise NN 1_i
immediately RB 1_p
after IN 1_p
stretching VBG 1_p
. . 1_p

Heart NNP N
rate NN N
, , N
core NN N
temperature NN N
, , N
maximal JJ N
voluntary JJ N
isometric JJ N
contraction NN N
, , N
passive JJ N
hip NN N
flexion NN N
, , N
passive JJ N
hamstring NN N
stiffness NN N
( ( N
PHS NNP N
) ) N
, , N
plasma JJ N
creatine JJ N
kinase NN N
activity NN N
, , N
and CC N
myoglobin NNS N
were VBD N
recorded VBN N
at IN N
prestretching NN N
, , N
at IN N
poststretching NN N
, , N
and CC N
every DT N
day NN N
after IN N
the DT N
eccentric JJ N
exercises NNS N
for IN N
5 CD N
d. NN N
RESULTS NNP N
After IN N
stretching VBG 1_i
, , N
the DT N
change NN 1_o
in IN 1_o
hip NN 1_o
flexion NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
SAS NNP 1_i
( ( N
5° CD N
) ) N
and CC 1_i
DAS NNP 1_i
( ( N
10.8° CD N
) ) N
groups NNS N
than IN N
in IN N
the DT 1_i
CON NNP 1_i
( ( N
-4.1° NNP N
) ) N
group NN N
. . N

The DT N
change NN N
in IN 1_o
PHS NNP 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT 1_i
DAS NNP 1_i
( ( N
5.6 CD N
% NN N
) ) N
group NN N
than IN N
in IN N
the DT 1_i
CON NNP 1_i
( ( N
-5.7 NNP N
% NN N
) ) N
and CC N
SAS NNP N
( ( N
-6.7 NNP N
% NN N
) ) N
groups NNS N
. . N

Furthermore NNP 1_o
, , 1_o
changes NNS 1_o
in IN 1_o
muscle-damage NN 1_o
markers NNS 1_o
were VBD N
smaller JJR N
in IN N
the DT 1_i
SAS NNP 1_i
group NN N
than IN N
in IN N
the DT 1_i
DAS NNP 1_i
and CC 1_i
CON NNP 1_i
groups NNS N
. . N

CONCLUSIONS NNP N
Prior NNP N
active JJ N
stretching NN N
could MD N
be VB N
useful JJ N
for IN N
attenuating VBG N
the DT N
symptoms NNS N
of IN N
muscle NN N
damage NN N
after IN N
eccentric JJ N
exercise NN 1_i
. . 1_i

SAS NNP 1_i
is VBZ N
recommended VBN N
over RP 1_i
DAS NNP 1_i
as IN N
a DT N
stretching VBG N
protocol NN N
in IN N
terms NNS N
of IN N
strength NN N
, , N
hamstring VBG N
range NN N
of IN N
motion NN N
, , N
and CC N
damage NN N
markers NNS N
. . N

Comparison NNP N
of IN N
quality NN 1_o
of IN 1_o
life NN 1_o
, , 1_o
work NN 1_o
productivity NN 1_o
and CC N
medical JJ 1_o
resource NN 1_o
utilization NN 1_o
of IN N
peginterferon NN 1_i
alpha NN 1_i
2a CD 1_i
vs IN N
the DT N
combination NN N
of IN N
interferon NN 1_i
alpha NN 1_i
2b CD 1_i
plus CC 1_i
ribavirin VB 1_i
as IN N
initial JJ N
treatment NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
The DT N
on-treatment JJ N
impact NN N
of IN N
interferon-based JJ N
therapies NNS N
on IN N
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QOL NNP 1_o
) ) 1_o
, , 1_o
work NN 1_o
productivity NN 1_o
, , 1_o
and CC 1_o
medical JJ 1_o
resource NN 1_o
utilization NN 1_o
has VBZ N
not RB N
been VBN N
systematically RB N
studied VBN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
peginterferon NN 1_i
alpha NN 1_i
( ( 1_i
pegIFNalpha NN 1_i
) ) 1_i
2a CD 1_i
monotherapy NN 1_i
and CC N
the DT N
combination NN 1_i
of IN 1_i
interferon NN 1_i
alpha NN 1_i
( ( 1_i
IFNalpha NNP 1_i
) ) 1_i
2b CD 1_i
plus CC 1_i
ribavirin NN 1_i
( ( 1_i
RBV NNP 1_i
) ) 1_i
on IN N
health-related JJ 1_o
QOL NNP 1_o
, , 1_o
work NN 1_o
productivity NN 1_o
and CC 1_o
resource NN 1_o
utilization NN 1_o
. . 1_o

A DT N
total NN N
of IN N
412 CD 1_p
patients NNS 1_p
with IN 1_p
hepatitis NN 1_p
C NNP 1_p
infection NN 1_p
were VBD N
randomized VBN N
to TO N
open-label JJ 1_i
treatment NN 1_i
with IN 1_i
either DT 1_i
pegIFNalpha NN 1_i
2a CD 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
206 CD 1_i
) ) 1_i
or CC 1_i
IFNalpha $ 1_i
2b/RBV CD 1_i
( ( 1_i
n JJ 1_i
= NNP 1_i
206 CD 1_i
) ) 1_i
. . 1_i

PegIFNalpha $ 1_i
2a CD 1_i
was VBD N
administered VBN N
subcutaneously RB N
at IN N
a DT N
dose NN N
of IN N
180 CD N
microg NN N
once RB N
weekly JJ N
for IN N
48 CD N
weeks NNS N
; : N
and CC N
IFNalpha $ 1_i
2b/RBV CD 1_i
at IN N
doses NNS N
of IN N
3 CD N
MU NNP N
thrice JJ N
weekly RB N
subcutaneously RB N
and CC N
1000-1200 JJ N
mg/day NN N
orally RB N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
SF-36 NNP 1_o
Health NNP 1_o
Survey NNP 1_o
Questionnaire NNP 1_o
and CC 1_o
additional JJ 1_o
generic NN 1_o
and CC 1_o
specific JJ 1_o
scales NNS 1_o
. . 1_o

During IN N
treatment NN N
, , N
for IN N
all DT N
SF-36 NNP N
summary NN N
and CC N
Hepatitis NNP 1_o
Quality NNP 1_o
of IN 1_o
Life NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
HQLQ NNP 1_o
) ) 1_o
-specific NN 1_o
scales NNS 1_o
, , N
the DT N
pegIFNalpha NN 1_i
2a CD 1_i
group NN N
experienced VBD N
less JJR N
impairment JJ N
than IN N
did VBD N
the DT N
IFNalpha NNP 1_i
2b/RBV CD 1_i
patients NNS N
. . N

The DT N
between-treatment JJ N
differences NNS N
were VBD N
significant JJ N
for IN N
many JJ N
of IN N
the DT N
scores NNS N
particularly RB N
in IN N
the DT N
first JJ N
24 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Across IN N
all DT N
measures NNS N
of IN N
work NN N
functioning NN N
and CC N
productivity NN N
at IN N
each DT N
visit NN N
, , N
patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB 1_i
2a CD 1_i
treatment NN N
showed VBD N
less RBR N
impairment JJ 1_o
relative NN N
to TO N
the DT N
group NN N
treated VBD N
with IN N
IFNalpha NNP 1_i
2b/RBV CD 1_i
. . 1_i

Hence NNP N
treatment NN N
with IN N
pegIFNalpha JJ 1_i
2a CD 1_i
relative JJ N
to TO N
IFNalpha NNP 1_i
2b/RBV CD 1_i
minimizes VBZ N
the DT N
adverse JJ N
impact NN N
of IN N
therapy NN N
on IN N
health-related JJ 1_o
QOL NNP 1_o
. . 1_o

Patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB 1_i
2a CD 1_i
had VBD N
improved VBN N
work NN 1_o
productivity NN 1_o
, , 1_o
less JJR 1_o
activity NN 1_o
impairment NN 1_o
, , 1_o
decreased VBD 1_o
need NN 1_o
for IN 1_o
prescription NN 1_o
drugs NNS 1_o
to TO 1_o
treat VB 1_o
adverse JJ 1_o
effects NNS 1_o
, , 1_o
and CC 1_o
better JJR 1_o
adherence NN 1_o
to TO 1_o
therapy NN 1_o
. . 1_o

Reduced VBN N
albuminuria NNS N
with IN N
sarpogrelate NN 1_i
is VBZ N
accompanied VBN N
by IN N
a DT N
decrease NN N
in IN N
monocyte JJ N
chemoattractant JJ N
protein-1 NN N
levels NNS N
in IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
. . 1_p

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Sarpogrelate NNP 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
albuminuria NNS N
in IN N
diabetic JJ N
nephropathy NN N
. . N

For IN N
examination NN N
of IN N
whether IN N
this DT N
is VBZ N
based VBN N
on IN N
the DT N
same JJ N
mechanisms NN N
as IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
or CC N
thiazolidinedione NN 1_i
, , N
effects NNS N
of IN N
sarpogrelate NN 1_i
on IN N
atherosclerotic JJ N
inflammatory NN N
molecules NNS N
and CC N
their PRP$ N
relations NNS N
to TO N
albuminuria NNS N
in IN N
patients NNS 1_p
who WP 1_p
had VBD 1_p
diabetes NNS 1_p
and CC 1_p
had VBD 1_p
already RB 1_p
been VBN 1_p
treated VBN 1_p
with IN 1_p
angiotensin NN 1_i
II NNP 1_i
receptor NN 1_i
blockers NNS 1_i
and CC 1_p
with IN 1_p
or CC 1_p
without IN 1_p
thiazolidinedione NN 1_i
were VBD N
examined VBN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Forty NNP 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
diabetes NNS 1_p
with IN 1_p
nephropathy JJ 1_p
and CC 1_p
arteriosclerosis NN 1_p
obliterans NNS 1_p
and CC 1_p
had VBD 1_p
already RB 1_p
been VBN 1_p
treated VBN 1_p
with IN 1_p
angiotensin NN 1_i
II NNP 1_i
receptor NN 1_i
blocker NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
40 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
sarpogrelate VB 1_i
( ( N
300 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
or CC N
aspirin JJ 1_i
group NN 1_i
( ( N
100 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
. . N

Plasma NNP 1_o
monocyte JJ 1_o
chemoattractant JJ 1_o
protein-1 NN 1_o
and CC 1_o
urinary JJ 1_o
albumin-to-creatinine JJ 1_o
ratio NN 1_o
and CC 1_o
monocyte NN 1_o
chemoattractant JJ 1_o
protein-1 NN 1_o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
16 CD N
wk NN N
after IN N
administration NN N
. . N

RESULTS NNP N
Only RB N
the DT N
sarpogrelate NN 1_i
group NN N
showed VBD N
increases NNS N
in IN N
plasma NN 1_o
adiponectin NN 1_o
and CC N
decreases NNS N
in IN N
both DT N
plasma NN 1_o
and CC 1_o
urinary JJ 1_o
monocyte NN 1_o
chemoattractant JJ 1_o
protein-1 JJ 1_o
and CC 1_o
albumin-to-creatinine JJ 1_o
ratio NN 1_o
levels NNS 1_o
. . 1_o

Moreover RB N
, , N
percentage NN 1_o
change NN 1_o
of IN 1_o
monocyte NN 1_o
chemoattractant JJ 1_o
protein-1 JJ 1_o
level NN 1_o
correlated VBD N
positively RB N
to TO N
that DT N
of IN N
albumin-to-creatinine JJ N
ratio NN N
. . N

Even RB N
when WRB N
the DT N
sarpogrelate NN 1_i
group NN N
was VBD N
further RB N
divided VBN N
into IN N
two CD N
groups NNS N
with IN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
without IN N
thiazolidinedione NN 1_i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
changes NNS N
in IN N
monocyte NN 1_o
chemoattractant JJ 1_o
protein-1 JJ 1_o
or CC 1_o
albumin-to-creatinine JJ 1_o
ratio NN 1_o
did VBD N
not RB N
differ VB N
. . N

CONCLUSIONS NNP N
Sarpogrelate NNP 1_i
can MD N
reduce VB N
albuminuria NNS N
and CC N
plasma NN N
and CC N
urinary JJ N
monocyte NN N
chemoattractant JJ N
protein-1 JJ N
levels NNS N
while IN N
increasing VBG N
plasma NN N
adiponectin NN N
in IN N
diabetic JJ N
nephropathy NN N
. . N

These DT N
effects NNS N
seem VBP N
to TO N
be VB N
mediated VBN N
via IN N
mechanisms NNS N
that WDT N
are VBP N
different JJ N
from IN N
those DT N
of IN N
angiotensin JJ 1_i
II NNP 1_i
receptor NN 1_i
blocker NN 1_i
or CC N
thiazolidinedione NN 1_i
. . 1_i

A DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
of IN N
nefazodone NN 1_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
hospitalized VBN 1_p
for IN 1_p
major JJ 1_p
depression NN 1_p
. . 1_p

BACKGROUND IN N
There EX N
are VBP N
few JJ N
published VBN N
placebo-controlled JJ 1_i
clinical JJ N
trials NNS N
demonstrating VBG N
the DT N
efficacy NN N
of IN N
the DT N
newer NN N
antidepressants NNS N
in IN N
markedly RB 1_p
or CC 1_p
severely RB 1_p
depressed JJ 1_p
hospitalized JJ 1_p
patients NNS 1_p
. . 1_p

This DT N
study NN N
demonstrates VBZ N
the DT N
efficacy NN N
of IN N
nefazodone NN 1_i
compared VBN N
with IN N
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
hospitalized VBN 1_p
for IN 1_p
major JJ 1_p
depression NN 1_p
. . 1_p

METHOD NNP N
Nefazodone NNP 1_i
and CC 1_i
placebo VB 1_i
treatment NN 1_i
were VBD N
compared VBN N
in IN N
a DT N
6-week JJ N
trial NN N
of IN N
120 CD 1_p
patients NNS 1_p
hospitalized VBN 1_p
for IN 1_p
DSM-III-R NNP 1_p
diagnosed VBD 1_p
major JJ 1_p
depression NN 1_p
( ( 1_p
without IN 1_p
psychosis NN 1_p
) ) 1_p
at IN N
2 CD N
study NN N
centers NNS N
. . N

Efficacy NN N
was VBD N
evaluated VBN N
using VBG N
standard JJ 1_o
psychiatric NN 1_o
rating NN 1_o
scales NNS 1_o
, , N
and CC N
patients NNS N
were VBD N
monitored VBN N
for IN N
safety NN N
. . N

RESULTS NNP N
Nefazodone NNP N
treatment NN N
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
of IN N
the DT N
17-item JJ 1_o
Hamilton NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
for IN 1_o
Depression NNP 1_o
( ( N
HAM-D-17 NNP N
) ) N
total NN N
score NN N
compared VBN N
with IN N
placebo NN 1_i
from IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
treatment NN N
week NN N
through IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
-12.2 NNP N
nefazodone RB 1_i
vs. FW N
-7.7 NNP N
placebo NN 1_i
) ) 1_i
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
, , N
significantly RB N
more RBR N
nefazodone-treated JJ 1_i
patients NNS N
( ( N
50 CD N
% NN N
) ) N
than IN N
placebo-treated JJ 1_i
patients NNS N
( ( N
29 CD N
% NN N
) ) N
had VBD N
responded VBN N
, , N
as IN N
indicated VBN N
by IN N
their PRP$ N
Clinical JJ 1_o
Global NNP 1_o
Impressions-Improvement NN 1_o
score NN 1_o
( ( N
p JJ N
= NNP N
.021 NNP N
) ) N
or CC N
by IN N
a DT N
> NN N
or CC N
= VB N
50 CD N
% NN N
reduction NN N
in IN N
their PRP$ N
HAM-D-17 JJ 1_o
scores NNS 1_o
( ( N
p VB N
= NNP N
.017 NNP N
) ) N
. . N

Significantly RB N
more RBR N
patients NNS N
treated VBN N
with IN N
nefazodone NN 1_i
( ( N
36 CD N
% NN N
) ) N
than IN N
placebo-treated JJ 1_i
patients NNS N
( ( N
14 CD N
% NN N
) ) N
had VBD N
a DT N
HAM-D-17 NNP 1_o
score NN 1_o
< NN N
or CC N
= VB N
10 CD N
at IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
p JJ N
= NNP N
.004 NNP N
) ) N
. . N

Significant JJ N
treatment NN N
differences NNS N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
in IN N
favor NN N
of IN N
nefazodone NN N
were VBD N
also RB N
seen VBN N
in IN N
the DT N
Montgomery-Asberg NNP 1_o
Depression NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
; : 1_o
the DT 1_o
HAM-D NNP 1_o
retardation NN 1_o
, , 1_o
anxiety NN 1_o
, , 1_o
and CC 1_o
sleep JJ 1_o
disturbance NN 1_o
factors NNS 1_o
; : 1_o
and CC 1_o
HAM-D NNP 1_o
item NN 1_o
1 CD 1_o
( ( N
depressed JJ N
mood NN N
) ) N
. . N

Patients NNS 1_p
with IN 1_p
dysthymia NN 1_o
in IN 1_p
addition NN 1_p
to TO 1_p
major JJ 1_o
depression NN 1_o
also RB N
showed VBD N
significant JJ N
improvement NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
when WRB N
treated VBN N
with IN N
nefazodone NN N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
response NN N
rates NNS N
seen VBN N
as RB N
early RB N
as IN N
week NN N
2 CD N
and CC N
through IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
. . N

The DT N
mean JJ 1_o
nefazodone NN 1_o
dose NN 1_o
was VBD N
491 CD N
mg/day NN N
at IN N
the DT N
end NN N
of IN N
week NN N
2 CD N
and CC N
503 CD N
mg/day NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

Nefazodone NN N
was VBD N
well RB 1_o
tolerated VBN 1_o
, , N
and CC N
the DT N
number NN N
of IN N
patients NNS N
discontinuing VBG N
owing VBG N
to TO N
adverse JJ 1_o
events NNS 1_o
was VBD N
small JJ N
, , N
with IN N
no DT N
significant JJ N
safety NN N
issues NNS N
noted VBN N
in IN N
either DT N
treatment NN N
group NN N
. . N

Fewer JJR N
nefazodone-treated JJ 1_i
than IN N
placebo-treated JJ 1_i
patients NNS N
discontinued VBN N
owing VBG N
to TO N
lack VB N
of IN N
efficacy NN 1_o
. . 1_o

CONCLUSION NNP N
Nefazodone NNP 1_i
was VBD N
superior JJ N
to TO N
placebo VB N
in IN N
the DT N
treatment NN N
of IN N
marked VBN 1_p
to TO 1_p
severe VB 1_p
major JJ 1_p
depression NN 1_p
in IN 1_p
patients NNS 1_p
requiring VBG 1_p
hospitalization NN 1_p
. . 1_p

The DT N
clinical JJ N
benefit NN N
of IN N
nefazodone NN 1_i
was VBD N
evident JJ N
as RB N
early RB N
as IN N
the DT N
first JJ N
week NN N
of IN N
treatment NN N
as IN N
judged VBN N
by IN N
several JJ N
measures NNS N
of IN N
efficacy NN N
, , N
with IN N
significant JJ N
differences NNS N
from IN N
placebo NN N
sustained VBN N
throughout IN N
the DT N
trial NN N
. . N

Radiation-induced JJ N
brachial JJ N
plexopathy NN N
: : N
neurological JJ N
follow-up NN N
in IN N
161 CD 1_p
recurrence-free JJ 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
assess VB 1_o
the DT 1_o
incidence NN 1_o
and CC 1_o
clinical JJ 1_o
manifestations NNS 1_o
of IN N
radiation-induced JJ N
brachial JJ N
plexopathy NN N
in IN N
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
, , 1_p
treated VBD 1_p
according VBG 1_p
to TO 1_p
the DT 1_p
Danish JJ 1_p
Breast NNP 1_p
Cancer NNP 1_p
Cooperative NNP 1_p
Group NNP 1_p
protocols VBZ 1_p
. . 1_p

METHODS NNP N
AND CC N
MATERIALS NNP N
One NNP 1_p
hundred CD 1_p
and CC 1_p
sixty-one JJ 1_p
recurrence-free JJ 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
were VBD 1_p
examined VBN 1_p
for IN 1_p
radiation-induced JJ 1_p
brachial JJ 1_p
plexopathy NN 1_p
after IN 1_p
a DT 1_p
median JJ 1_p
follow-up JJ 1_p
period NN 1_p
of IN 1_p
50 CD 1_p
months NNS 1_p
( ( 1_p
13-99 JJ 1_p
months NNS 1_p
) ) 1_p
. . 1_p

After IN N
total JJ N
mastectomy NN N
and CC N
axillary JJ N
node NN N
sampling NN N
, , N
high-risk JJ 1_p
patients NNS 1_p
were VBD N
randomized VBN N
to TO N
adjuvant VB 1_i
therapy NN 1_i
. . 1_i

One CD N
hundred VBD N
twenty-eight JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
postoperative JJ 1_i
radiotherapy NN 1_i
with IN 1_i
50 CD 1_i
Gy NNP 1_i
in IN N
25 CD N
daily JJ N
fractions NNS N
over IN N
5 CD N
weeks NNS N
. . N

In IN N
addition NN N
, , N
82 CD N
of IN N
these DT N
patients NNS N
received VBD N
cytotoxic JJ 1_i
therapy NN 1_i
( ( 1_i
cyclophosphamide NN 1_i
, , 1_i
methotrexate NN 1_i
, , 1_i
and CC 1_i
5-fluorouracil JJ 1_i
) ) 1_i
and CC N
46 CD N
received VBD N
tamoxifen NN 1_i
. . 1_i

RESULTS NNP N
Five CD N
percent NN N
and CC N
9 CD N
% NN N
of IN N
the DT N
patients NNS N
receiving VBG N
radiotherapy NN N
had VBD N
disabling NN 1_o
and CC 1_o
mild JJ 1_o
radiation-induced JJ 1_o
brachial NN 1_o
plexopathy NN 1_o
, , N
respectively RB N
. . N

Radiation-induced JJ 1_o
brachial JJ 1_o
plexopathy NN 1_o
was VBD N
more RBR N
frequent JJ N
in IN N
patients NNS N
receiving VBG N
cytotoxic JJ N
therapy NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
in IN N
younger JJR N
patients NNS N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
clinical JJ N
manifestations NNS N
were VBD N
paraesthesia JJ 1_o
( ( N
100 CD N
% NN N
) ) N
, , N
hypaesthesia NN 1_o
( ( N
74 CD N
% NN N
) ) N
, , N
weakness NN 1_o
( ( N
58 CD N
% NN N
) ) N
, , N
decreased VBN 1_o
muscle NN 1_o
stretch NN 1_o
reflexes NNS 1_o
( ( N
47 CD N
% NN N
) ) N
, , N
and CC N
pain NN 1_o
( ( N
47 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
brachial JJ N
plexus NN N
is VBZ N
more RBR N
vulnerable JJ N
to TO N
large JJ N
fraction NN N
size NN N
. . N

Fractions NNS N
of IN N
2 CD N
Gy NNP N
or CC N
less JJR N
are VBP N
advisable JJ N
. . N

Cytotoxic NNP 1_i
therapy NN 1_i
adds VBZ N
to TO N
the DT N
damaging JJ N
effect NN N
of IN N
radiotherapy NN N
. . N

Peripheral JJ N
nerves NNS N
in IN N
younger JJR 1_p
patients NNS 1_p
seems VBZ N
more RBR N
vulnerable JJ N
. . N

Radiation-induced JJ N
brachial JJ N
plexopathy NN N
occurs VBZ N
mainly RB N
as IN N
diffuse NN N
damage NN N
to TO N
the DT N
brachial JJ N
plexus NN N
. . N

Non-verbal JJ 1_i
communication NN 1_i
of IN 1_i
compassion NN 1_i
: : 1_i
measuring NN N
psychophysiologic JJ N
effects NNS N
. . N

BACKGROUND NNP N
Calm NNP N
, , N
compassionate NN N
clinicians NNS N
comfort VBP N
others NNS N
. . N

To TO N
evaluate VB N
the DT N
direct JJ N
psychophysiologic JJ N
benefits NNS N
of IN N
non-verbal JJ 1_i
communication NN 1_i
of IN 1_i
compassion NN 1_i
( ( 1_i
NVCC NNP 1_i
) ) 1_i
, , N
it PRP N
is VBZ N
important JJ N
to TO N
minimize VB N
the DT N
effect NN N
of IN N
subjects NNS N
' POS N
expectation NN N
. . N

This DT N
preliminary JJ N
study NN N
was VBD N
designed VBN N
to TO N
a DT N
) ) N
test NN N
the DT N
feasibility NN N
of IN N
two CD N
strategies NNS N
for IN N
maintaining VBG N
subject JJ N
blinding VBG N
to TO N
non-verbal JJ 1_i
communication NN 1_i
of IN 1_i
compassion NN 1_i
( ( 1_i
NVCC NNP 1_i
) ) 1_i
, , N
and CC N
b NN N
) ) N
determine NN N
whether IN N
blinded JJ N
subjects NNS N
would MD N
experience VB N
psychophysiologic JJ N
effects NNS N
from IN N
NVCC NNP N
. . N

METHODS NNP N
Subjects NNPS 1_p
were VBD 1_p
healthy JJ 1_p
volunteers NNS 1_p
who WP 1_p
were VBD 1_p
told VBN 1_p
the DT 1_p
study NN 1_p
was VBD 1_p
evaluating VBG 1_p
the DT 1_p
effect NN 1_p
of IN 1_p
time NN 1_p
and CC 1_p
touch NN 1_p
on IN 1_p
the DT 1_p
autonomic JJ 1_p
nervous JJ 1_p
system NN 1_p
. . 1_p

The DT 1_p
practitioner NN 1_p
had VBD 1_p
more JJR 1_p
than IN 1_p
10 CD 1_p
years NNS 1_p
' POS 1_p
experience NN 1_p
with IN 1_p
loving-kindness JJ 1_i
meditation NN 1_i
( ( 1_p
LKM NNP 1_p
) ) 1_p
, , 1_p
a DT 1_p
form NN 1_p
of IN 1_p
NVCC NNP 1_i
. . 1_i

Subjects NNS N
completed VBD N
10-point JJ 1_o
visual JJ 1_o
analog NN 1_o
scales NNS 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
for IN 1_o
stress NN 1_o
, , 1_o
relaxation NN 1_o
, , 1_o
and CC 1_o
peacefulness NN 1_o
before IN N
and CC N
after IN N
LKM NNP N
. . N

To TO N
assess VB N
physiologic JJ 1_o
effects NNS 1_o
, , N
practitioners NNS N
and CC N
subjects NNS N
wore VBP N
cardiorespiratory JJ 1_o
monitors NNS 1_o
to TO 1_o
assess VB 1_o
respiratory JJ 1_o
rate NN 1_o
( ( 1_o
RR NNP 1_o
) ) 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
variability NN 1_o
( ( 1_o
HRV NNP 1_o
) ) 1_o
throughout IN N
the DT N
4 CD N
10-minute JJ N
study NN N
periods NNS N
: : N
Baseline NNP N
( ( N
both DT N
practitioner NN 1_i
and CC 1_i
subjects NNS 1_i
read VBP 1_i
neutral JJ 1_i
material NN 1_i
) ) 1_i
; : 1_i
non-tactile-LKM JJ N
( ( 1_i
subjects NNS 1_i
read VBP 1_i
while IN 1_i
the DT 1_i
practitioner NN 1_i
practiced VBD 1_i
LKM NNP 1_i
while IN 1_i
pretending VBG 1_i
to TO 1_i
read VB 1_i
) ) 1_i
; : 1_i
tactile-LKM JJ N
( ( 1_i
subjects NNS 1_i
rested VBN 1_i
while IN 1_i
the DT 1_i
practitioner NN 1_i
practiced VBD 1_i
LKM NNP 1_i
while IN 1_i
lightly RB 1_i
touching VBG 1_i
the DT 1_i
subject NN 1_i
on IN 1_i
arms NNS 1_i
, , 1_i
shoulders NNS 1_i
, , 1_i
hands NNS 1_i
, , 1_i
feet NNS 1_i
, , 1_i
and CC 1_i
legs NNS 1_i
) ) 1_i
; : 1_i
Post-Intervention JJ N
Rest NNP N
( ( 1_i
subjects NNS 1_i
rested VBN 1_i
; : 1_i
the DT 1_i
practitioner NN 1_i
read NN 1_i
) ) 1_i
. . N

To TO N
assess VB N
blinding NN N
, , N
subjects NNS N
were VBD N
asked VBN N
after IN N
the DT N
interventions NNS N
what WP N
the DT N
practitioner NN N
was VBD N
doing VBG N
during IN N
each DT N
period NN N
( ( N
reading NN N
, , N
touch NN N
, , N
or CC N
something NN N
else RB N
) ) N
. . N

RESULTS JJ N
Subjects NNPS 1_p
' POS 1_p
mean JJ 1_p
age NN 1_p
was VBD 1_p
43.6 CD 1_p
years NNS 1_p
; : 1_p
all DT 1_p
were VBD 1_p
women NNS 1_p
. . 1_p

Blinding NNP N
was VBD N
maintained VBN N
and CC N
the DT N
practitioner NN N
was VBD N
able JJ N
to TO N
maintain VB N
meditation NN 1_o
for IN N
both DT N
tactile JJ N
and CC N
non-tactile JJ N
LKM NNP N
interventions NNS N
as IN N
reflected VBN N
in IN N
significantly RB N
reduced VBN N
RR NNP 1_o
. . 1_o

Despite IN N
blinding NN N
, , N
subjects NNS N
' POS N
VAS NNP 1_o
scores NNS 1_o
improved VBN N
from IN N
baseline NN N
to TO N
post-intervention NN N
for IN N
stress NN 1_o
( ( N
5.5 CD N
vs. FW N
2.2 CD N
) ) N
, , N
relaxation NN 1_o
( ( N
3.8 CD N
vs. FW N
8.8 CD N
) ) N
and CC N
peacefulness NN 1_o
( ( N
3.8 CD N
vs. FW N
9.0 CD N
, , N
P NNP N
< VBZ N
0.05 CD N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

Subjects NNS N
also RB N
had VBD N
significant JJ N
reductions NNS N
in IN N
RR NNP 1_o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
improved VBN 1_o
HRV NNP 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
both DT N
tactile JJ N
and CC N
non-tactile JJ N
LKM NNP N
. . N

CONCLUSION NNP N
It PRP N
is VBZ N
possible JJ N
to TO N
test VB N
the DT N
effects NNS N
of IN N
LKM NNP N
with IN N
tactile JJ N
and CC N
non-tactile JJ N
blinding NN N
strategies NNS N
; : N
even RB N
with IN N
blinding VBG N
in IN N
this DT N
small JJ N
preliminary JJ N
study NN N
, , N
subjects NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
well-being NN N
which WDT N
were VBD N
reflected VBN N
in IN N
objective JJ N
physiologic JJ N
measures NNS N
of IN N
autonomic JJ N
activity NN N
. . N

Extending VBG N
compassion NN N
is VBZ N
not RB N
only RB N
good JJ N
care NN N
; : N
it PRP N
may MD N
also RB N
be VB N
good JJ N
medicine NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
US NNP N
National NNP N
ClinicalTrials.gov NNP N
registration NN N
number NN N
, , N
NCT01428674 NNP N
. . N

Evaluation NN N
of IN N
reducing VBG N
postoperative JJ 1_o
hip NN 1_o
precautions NNS 1_o
in IN N
total JJ 1_p
hip JJ 1_p
replacement NN 1_p
: : 1_p
a DT 1_p
randomized JJ 1_p
prospective JJ 1_p
study NN 1_p
. . 1_p

Currently NNP N
, , N
many JJ N
rehabilitation NN N
protocols NNS N
for IN N
total JJ N
hip NN N
replacements NNS N
( ( N
THRs NNP N
) ) N
include VBP N
activity NN N
restrictions NNS N
to TO N
prevent VB N
postoperative JJ N
dislocation NN N
. . N

There EX N
is VBZ N
increasing VBG N
demand NN N
for IN N
more RBR N
efficient JJ N
and CC N
safe JJ N
rehabilitation NN N
protocols NNS N
. . N

This DT N
randomized JJ N
prospective JJ N
study NN N
evaluates VBZ N
the DT N
need NN N
for IN N
hip NN N
restrictions NNS N
following VBG N
a DT N
modified JJ N
anterolateral JJ N
procedure NN N
. . N

From IN 1_p
2004 CD 1_p
to TO 1_p
2008 CD 1_p
, , 1_p
81 CD 1_p
patients NNS 1_p
seeking VBG 1_p
elective JJ 1_p
THRs NNP 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
into IN 1_p
a DT 1_p
standard JJ 1_p
rehabilitation NN 1_p
group NN 1_p
or CC 1_p
an DT 1_p
early JJ 1_p
rehabilitation NN 1_p
group NN 1_p
. . 1_p

The DT N
standard JJ 1_p
group NN 1_p
included VBD 1_p
restrictions NNS 1_i
to TO 1_i
avoid VB 1_i
hip NN 1_i
flexion NN 1_i
> VBD 1_i
90 CD 1_i
degrees NNS 1_i
and CC 1_i
avoidance NN 1_i
of IN 1_i
riding VBG 1_i
in IN 1_i
a DT 1_i
car NN 1_i
for IN 1_i
the DT 1_i
first JJ 1_i
postoperative JJ 1_i
month NN 1_i
. . 1_i

The DT 1_p
early JJ 1_p
group NN 1_p
had VBD 1_p
no DT 1_i
flexion NN 1_i
or CC 1_i
car NN 1_i
riding NN 1_i
restrictions NNS 1_i
. . 1_i

Forty-three JJ 1_p
patients NNS 1_p
were VBD 1_p
in IN 1_p
the DT 1_p
standard JJ 1_p
group NN 1_p
and CC 1_p
38 CD 1_p
patients NNS 1_p
were VBD 1_p
in IN 1_p
the DT 1_p
early JJ 1_p
group NN 1_p
. . 1_p

There EX N
were VBD N
no DT 1_p
significant JJ 1_p
demographic JJ 1_p
differences NNS 1_p
between IN 1_p
the DT 1_p
2 CD 1_p
groups NNS 1_p
. . 1_p

All DT N
patients NNS N
completed VBD N
the DT N
Short JJ N
Form NNP N
12-question JJ N
Health NNP N
Survey NNP N
and CC N
Harris NNP N
Hip NNP N
Score NNP N
preoperatively RB N
and CC N
at IN N
4 CD N
weeks NNS N
, , N
1 CD N
month NN N
, , N
3 CD N
months NNS N
, , N
and CC N
1 CD N
year NN N
postoperatively RB N
. . N

The DT N
time-points NNS 1_o
at IN 1_o
which WDT 1_o
the DT 1_o
patient NN 1_o
first RB 1_o
drove VBD 1_o
and CC 1_o
ambulated VBD 1_o
with IN N
a DT N
cane NN N
, , N
without IN N
a DT N
cane NN N
, , N
and CC N
without IN N
a DT N
limp NN N
were VBD N
also RB N
collected VBN N
. . N

No DT N
incidents NNS N
of IN N
dislocation NN 1_o
occurred VBD N
. . N

Patients NNS N
in IN N
the DT N
early JJ N
group NN N
were VBD N
faster JJR N
to TO N
ambulate VB 1_o
with IN 1_o
only RB 1_o
a DT 1_o
cane NN 1_o
( ( N
P=.03 NNP N
) ) N
, , N
without IN 1_o
a DT 1_o
cane NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
without IN 1_o
a DT 1_o
limp NN 1_o
( ( N
P=.003 NNP N
) ) N
. . N

They PRP N
also RB N
drove VBD 1_o
earlier RBR N
( ( N
P=.02 NNP N
) ) N
. . N

Pace NN 1_o
of IN 1_o
recovery NN 1_o
was VBD N
the DT N
only JJ N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
early JJ 1_i
rehabilitation NN 1_i
protocol NN 1_i
increases VBZ N
the DT N
pace NN 1_o
of IN 1_o
recovery NN 1_o
compared VBN N
to TO N
a DT N
pathway NN N
with IN N
hip NN N
precautions NNS N
without IN N
increasing VBG 1_o
complications NNS 1_o
. . 1_o

Postoperative JJ N
sleep NN 1_p
disturbances NNS 1_p
after IN N
zolpidem NN 1_i
treatment NN N
in IN N
fast-track JJ N
hip NN N
and CC N
knee VB N
replacement NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
Previous NNP N
studies NNS N
have VBP N
demonstrated VBN N
pronounced JJ N
reduction NN 1_o
of IN 1_o
REM NNP 1_o
sleep NN 1_o
on IN N
the DT N
first JJ N
nights NNS N
following VBG N
major JJ N
surgery NN N
which WDT N
may MD N
influence VB N
pain NN 1_o
, , 1_o
analgesic JJ 1_o
use NN 1_o
, , N
and CC N
recovery NN 1_o
. . 1_o

This DT N
placebo-controlled JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
set VBN N
out RP N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
zolpidem NN 1_i
on IN N
sleep JJ N
architecture NN N
in IN N
an DT N
elderly JJ 1_p
population NN 1_p
undergoing VBG 1_p
fast-track JJ 1_p
total JJ 1_p
hip NN 1_p
and CC 1_p
knee NN 1_p
arthroplasty NN 1_p
( ( 1_p
THA/TKA NNP 1_p
) ) 1_p
with IN 1_p
length NN 1_p
of IN 1_p
stay NN 1_p
< IN 1_p
3 CD 1_p
days NNS 1_p
. . 1_p

METHODS NNP N
Twenty NNP 1_p
patients NNS 1_p
( ( 1_p
≥ JJ 1_p
60 CD 1_p
years NNS 1_p
) ) 1_p
undergoing VBG 1_p
THA NNP 1_p
or CC 1_p
TKA NNP 1_p
in IN 1_p
a DT 1_p
standardized JJ 1_p
setup NN 1_p
with IN 1_p
spinal JJ 1_p
anesthesia NN 1_p
and CC 1_p
multimodal JJ 1_p
opioid-sparing JJ 1_p
postoperative JJ 1_p
analgesia NN 1_p
were VBD 1_p
included VBN 1_o
. . 1_o

Polysomnography NNP 1_o
measures NNS 1_o
were VBD N
performed VBN N
for IN N
2 CD N
nights NNS N
, , N
1 CD N
night NN N
at IN N
home NN N
prior RB N
to TO N
surgery NN N
and CC N
on IN N
the DT N
first JJ N
night NN N
after IN N
surgery NN N
, , N
when WRB N
the DT N
patient NN N
received VBD 1_i
placebo NN 1_i
or CC 1_i
zolpidem NN 1_i
10 CD 1_i
mg. NN 1_o
Analgesic NNP 1_o
use NN 1_o
, , 1_o
pain NN 1_o
levels NNS 1_o
, , 1_o
and CC 1_o
subjective JJ 1_o
measures NNS 1_o
of IN 1_o
fatigue NN 1_o
and CC 1_o
sleep JJ 1_o
quality NN 1_o
were VBD N
recorded VBN N
. . N

Analysis NN N
of IN N
sleep JJ N
data NN N
was VBD N
performed VBN N
according VBG N
to TO N
the DT 1_o
American JJ 1_o
Academy NNP 1_o
of IN 1_o
Sleep NNP 1_o
Medicine NNP 1_o
manual JJ 1_o
. . N

RESULTS NNP N
Objective JJ N
sleep JJ N
data NNS N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
any DT N
of IN N
the DT N
sleep JJ N
stages NNS N
. . N

However RB 1_o
, , 1_o
subjective JJ 1_o
data NNS 1_o
on IN 1_o
sleep JJ 1_o
quality NN 1_o
and CC 1_o
fatigue NN 1_o
showed VBD N
significantly RB N
less JJR 1_o
fatigue NN 1_o
and CC N
better JJR 1_o
sleep NN 1_o
quality NN 1_o
in IN N
the DT 1_i
zolpidem NN 1_i
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
reduced VBD N
objectively RB 1_o
recorded JJ 1_o
number NN 1_o
of IN 1_o
arousals NNS 1_o
( ( N
p JJ N
= NNP N
0.004 CD 1_o
) ) 1_o
. . 1_o

Levels NNP 1_o
of IN 1_o
pain NN 1_o
and CC 1_o
opioid NN 1_o
use NN 1_o
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
objective JJ N
data NNS N
did VBD N
not RB N
support VB N
the DT N
primary JJ N
hypothesis NN N
that WDT N
one CD N
night NN N
's POS N
treatment NN N
with IN 1_i
zolpidem NN 1_i
would MD N
significantly RB N
improve VB N
sleep JJ N
architecture NN N
following VBG N
major JJ N
surgery NN N
, , N
although IN N
there EX N
was VBD N
improved JJ 1_o
feeling NN 1_o
of IN 1_o
sleep JJ 1_o
quality NN 1_o
and CC 1_o
fatigue NN 1_o
associated VBN N
with IN N
fewer JJR N
postoperative JJ N
arousals NNS N
. . N

CITATION NNP N
Krenk NNP N
L NNP N
; : N
Jennum NNP N
P NNP N
; : N
Kehlet NNP N
H. NNP N
Postoperative NNP N
sleep NN N
disturbances NNS N
after IN N
zolpidem NN N
treatment NN N
in IN N
fast-track JJ N
hip NN N
and CC N
knee VB N
replacement NN N
. . N

Randomised VBN N
multicentre JJ N
trial NN N
of IN N
circular JJ 1_i
stapling NN 1_i
devices NNS 1_i
. . 1_i

PURPOSE NNP N
In IN N
a DT N
register NN N
study NN N
, , N
the DT N
risk NN N
of IN N
anastomotic JJ 1_o
leakage NN 1_o
correlated VBD N
to TO N
the DT N
choice NN N
of IN N
circular JJ 1_i
stapling VBG 1_i
device NN 1_i
with IN N
a DT N
4 CD N
% NN N
difference NN N
between IN N
the DT N
two CD N
brands NNS N
used VBN N
. . N

Based VBN N
on IN N
those DT N
data NNS N
, , N
a DT N
randomised JJ N
multicentre NN N
study NN N
was VBD N
started VBN N
to TO N
explore VB N
the DT N
risk NN N
of IN N
an DT N
anastomotic JJ 1_o
leakage NN 1_o
based VBN N
upon IN N
the DT N
surgical JJ 1_i
device NN 1_i
. . 1_i

METHODS NNP N
Patients NNPS 1_p
above IN 1_p
18 CD 1_p
years NNS 1_p
with IN 1_p
a DT 1_p
rectal JJ 1_p
cancer NN 1_p
, , 1_p
able JJ 1_p
to TO 1_p
give VB 1_p
informed JJ 1_p
consent NN 1_p
, , 1_p
and CC 1_p
scheduled VBD 1_p
for IN 1_p
an DT 1_p
anterior JJ 1_p
resection NN 1_p
were VBD 1_p
eligible JJ 1_p
for IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

Perioperative JJ N
randomisation NN N
was VBD N
to TO N
Ethicon™ NNP 1_i
PROXIMATE™ NNP 1_i
ILS™ NNP 1_i
or CC 1_i
Autosuture™ NNP 1_i
Premium NNP 1_i
Plus NNP 1_o
CEEA™ NNP 1_o
. . 1_o

Anastomotic JJ 1_o
leakage NN N
was VBD N
defined VBN 1_o
as IN 1_o
a DT 1_o
clinically RB 1_o
manifest JJS 1_o
leak NN 1_p
. . 1_p

RESULTS NNP 1_p
Five CD 1_p
hundred VBD 1_p
twenty-nine NN 1_p
patients NNS 1_p
were VBD 1_p
randomised VBN 1_p
( ( 1_o
58 CD 1_o
% NN 1_o
male NN 1_o
) ) 1_o
. . N

A DT N
leak NN N
occurred VBD N
in IN N
8.3 CD N
% NN N
. . N

The DT N
anastomoses NNS N
created VBN 1_i
by IN 1_i
PROXIMATE™ NNP 1_o
ILS™ NNP N
leaked VBD N
in IN N
25/265 CD N
( ( N
9.4 CD N
% NN N
) ) N
anastomoses VBZ 1_i
, , 1_i
and CC 1_i
the DT 1_i
Premium NNP 1_i
Plus NNP N
CEEA™ NNP N
leaked VBD N
in IN N
19/260 CD N
( ( N
7.3 CD N
% NN N
) ) N
, , N
p JJ N
= NNP N
.419 NNP N
. . N

CONCLUSION NNP N
No DT 1_o
difference NN 1_o
in IN N
the DT N
leak NN N
rate NN N
could MD N
be VB N
revealed VBN N
. . N

Several JJ N
centres NNS N
replaced VBD N
one CD N
of IN N
the DT N
staplers NNS N
by IN N
a DT N
new JJ N
product NN N
, , N
and CC N
the DT N
study NN N
was VBD N
ended VBN N
before IN N
the DT N
stipulated JJ N
number NN N
of IN N
patients NNS N
was VBD N
reached VBN N
. . N

In IN N
the DT N
future NN N
, , N
surgical JJ N
devices NNS 1_o
may MD 1_o
have VB 1_o
to TO 1_o
prove VB N
superiority NN N
in IN N
randomised JJ N
trials NNS N
or CC N
be VB N
monitored VBN N
in IN N
quality NN N
registers NNS N
before IN N
they PRP N
can MD N
be VB N
introduced VBN N
into IN N
day NN N
to TO N
day NN N
surgical JJ N
practice NN N
. . N

The DT N
study NN N
was VBD N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
: : N
NCT00399009 NN N
. . N

Effectiveness NN N
of IN N
education NN N
for IN N
gastric JJ 1_p
cancer NN 1_p
patients NNS 1_p
: : 1_p
a DT N
controlled JJ N
prospective JJ N
trial NN N
comparing VBG N
interactive JJ 1_i
vs. FW 1_i
lecture-based JJ 1_i
programs NNS 1_i
. . 1_i

OBJECTIVE CC N
Although IN N
patient JJ 1_i
education NN 1_i
may MD N
enhance VB N
knowledge NN N
, , N
coping VBG N
with IN N
illness NN N
, , N
and CC N
quality NN N
of IN N
life NN N
among IN N
cancer NN 1_p
patients NNS 1_p
, , N
it PRP N
is VBZ N
uncertain JJ N
which WDT N
didactic JJ N
method NN N
is VBZ N
most RBS N
effective JJ N
. . N

We PRP N
compared VBN N
the DT N
impact NN N
of IN N
an DT N
interactive JJ 1_i
, , 1_i
patient-oriented JJ 1_i
group NN 1_i
program NN 1_i
to TO 1_i
a DT 1_i
lecture-based JJ 1_i
, , 1_i
information-only JJ 1_i
program NN 1_i
in IN N
gastric JJ 1_p
cancer NN 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
controlled JJ N
trial NN N
, , N
121 CD 1_p
gastric JJ 1_p
cancer NN 1_p
patients NNS 1_p
attending VBG 1_p
inpatient JJ 1_p
rehabilitation NN 1_p
after IN 1_p
surgical JJ 1_p
treatment NN 1_p
received VBD N
either CC N
the DT N
interactive JJ 1_i
intervention NN 1_i
or CC 1_i
lectures VBZ 1_i
providing VBG 1_i
information NN 1_i
. . 1_i

The DT N
outcomes NNS N
were VBD N
patients NNS 1_o
' POS 1_o
disease-related JJ 1_o
knowledge NN 1_o
, , 1_o
active JJ 1_o
coping VBG 1_o
with IN 1_o
illness NN 1_o
, , 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QoL NNP 1_o
) ) 1_o
at IN N
the DT N
end NN N
of IN N
their PRP$ N
stay NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
thereafter RB N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
improved VBD 1_o
their PRP$ 1_o
knowledge NN 1_o
and CC 1_o
QoL NNP 1_o
during IN 1_o
rehabilitation NN 1_o
; : 1_o
however RB N
, , N
knowledge NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
interactive JJ N
group NN N
compared VBN N
to TO N
the DT N
lecture NN N
group NN N
. . N

This DT N
difference NN N
was VBD N
maintained VBN N
at IN N
the DT N
6- JJ N
and CC N
12-months JJ N
follow-ups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
interactive JJ N
group NN N
proved VBD N
superior JJ N
to TO N
the DT N
lecture NN N
group NN N
regarding VBG N
active JJ 1_o
coping NN 1_o
with IN 1_o
illness NN 1_o
and CC N
QoL NNP 1_o
at IN N
the DT N
end NN N
of IN N
rehabilitation NN N
, , N
but CC N
not RB N
during IN N
follow-up JJ N
. . N

CONCLUSIONS VB N
A DT N
structured JJ N
, , N
interactive JJ N
patient JJ N
education NN N
program NN N
proved VBD N
superior JJ N
to TO N
lecture-based JJ N
provision NN N
of IN N
information NN N
in IN N
regards NNS N
to TO N
short-term JJ N
and CC N
long-term JJ N
knowledge NN N
as RB N
well RB N
as IN N
short-term JJ N
coping NN N
and CC N
QoL NNP N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
In IN N
gastric JJ N
cancer NN N
patients NNS N
, , N
interactive JJ 1_i
patient NN 1_i
education NN 1_i
seems VBZ N
preferable JJ N
over IN N
lectures NNS N
. . N

Abdominoperineal NNP 1_i
resection NN 1_i
and CC N
anterior JJ 1_i
resection NN 1_i
in IN N
the DT N
treatment NN N
of IN N
rectal JJ 1_p
cancer NN 1_p
: : 1_p
results NNS N
in IN N
relation NN N
to TO N
adjuvant VB 1_i
preoperative JJ 1_i
radiotherapy NN 1_i
. . 1_i

The DT N
outcome NN N
of IN N
patients NNS 1_p
with IN 1_p
rectal JJ 1_p
cancer NN 1_p
treated VBN 1_p
by IN 1_p
abdominoperineal NN 1_i
or CC 1_i
anterior JJ 1_i
resection NN 1_i
, , 1_i
with IN 1_i
or CC 1_i
without IN 1_i
preoperative JJ 1_i
radiotherapy NN 1_i
, , N
was VBD N
assessed VBN N
to TO N
detect VB N
any DT N
differences NNS N
attributable JJ N
to TO N
the DT N
operative JJ N
method NN N
and CC N
interactions NNS N
between IN N
radiotherapy NN N
and CC N
type NN N
of IN N
surgery NN N
. . N

The DT N
study NN N
was VBD N
based VBN N
on IN N
1292 CD 1_p
patients NNS 1_p
included VBN 1_p
in IN 1_p
two CD 1_p
consecutive JJ 1_p
controlled VBN 1_p
randomized JJ 1_p
trials NNS 1_p
of IN 1_p
preoperative JJ 1_i
radiotherapy NN 1_i
in IN 1_p
operable JJ 1_p
rectal JJ 1_p
carcinoma NN 1_p
. . 1_p

The DT N
outcome NN N
was VBD N
not RB N
related VBN N
to TO N
surgical JJ N
method NN N
. . N

Radiotherapy NNP N
increased VBD N
postoperative JJ 1_o
mortality NN 1_o
and CC 1_o
complications NNS 1_o
and CC N
reduced JJ N
local JJ 1_o
and CC 1_o
distant JJ 1_o
recurrence NN 1_o
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
overall JJ 1_o
survival NN 1_o
. . 1_o

Effects NNS N
of IN N
radiotherapy NN 1_i
were VBD N
similar JJ N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
surgery NN N
, , N
except IN N
that IN N
the DT N
increase NN N
in IN N
postoperative JJ 1_o
mortality NN 1_o
in IN N
irradiated JJ N
patients NNS N
was VBD N
greater JJR N
in IN N
those DT N
treated VBN N
with IN N
abdominoperineal JJ N
resection NN N
. . N

Sphincter-saving JJ 1_i
procedures NNS 1_i
appear VBP N
to TO N
have VB N
no DT N
adverse JJ N
effects NNS N
on IN N
outcome NN N
of IN N
rectal JJ 1_p
cancer NN 1_p
, , N
but CC N
the DT N
optimum JJ N
use NN N
of IN N
radiotherapy NN N
is VBZ N
still RB N
to TO N
be VB N
defined VBN N
. . N

Preventing VBG N
paclitaxel-induced JJ 1_o
peripheral JJ 1_o
neuropathy NN 1_o
: : 1_o
a DT N
phase NN N
II NNP N
trial NN N
of IN N
vitamin NN 1_i
E NNP 1_i
supplementation NN 1_i
. . 1_i

A DT N
randomized JJ N
, , N
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
assess VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
vitamin NN 1_i
E NNP 1_i
supplementation NN 1_i
for IN N
prophylaxis NN N
against IN N
paclitaxel-induced JJ 1_o
peripheral JJ 1_o
neuropathy NN 1_o
( ( 1_o
PIPN NNP 1_o
) ) 1_o
. . 1_o

Thirty-two JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
six CD 1_p
courses NNS 1_p
of IN 1_p
paclitaxel-based JJ 1_i
chemotherapy NN 1_i
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
chemotherapy NN 1_i
with IN 1_i
vitamin NN 1_i
E NNP 1_i
( ( N
300 CD N
mg NN N
twice RB N
a DT N
day NN N
, , N
Group NNP N
I PRP N
) ) N
or CC N
chemotherapy NN 1_i
without IN 1_i
vitamin NN 1_i
E NNP 1_i
supplementation NN 1_i
( ( N
Group NNP N
II NNP N
) ) N
. . N

A DT N
detailed JJ 1_o
neurological JJ 1_o
examination NN 1_o
and CC 1_o
electrophysiological JJ 1_o
study NN 1_o
was VBD N
performed VBN N
during IN N
and CC N
3 CD N
months NNS N
after IN N
chemotherapy NN 1_i
. . 1_i

The DT N
severity NN 1_o
of IN 1_o
PIPN NNP 1_o
was VBD 1_o
summarized VBN 1_o
by IN 1_o
means NNS 1_o
of IN 1_o
a DT 1_o
modified JJ 1_o
Peripheral NNP 1_o
Neuropathy NNP 1_o
( ( 1_o
PNP NNP 1_o
) ) 1_o
score NN 1_o
. . 1_o

The DT N
incidence NN 1_o
of IN 1_o
neurotoxicity NN 1_o
differed VBN N
significantly RB N
between IN N
groups NNS N
, , N
occurring VBG N
in IN N
3/16 CD N
( ( N
18.7 CD N
% NN N
) ) N
patients NNS N
assigned VBN N
to TO N
the DT N
vitamin NN 1_i
E NNP 1_i
supplementation NN 1_i
group NN N
and CC N
in IN N
10/16 CD N
( ( N
62.5 CD N
% NN N
) ) N
controls VBZ N
( ( N
P=0.03 NNP N
) ) N
. . N

The DT N
relative JJ 1_o
risk NN 1_o
( ( 1_o
RR NNP 1_o
) ) 1_o
of IN 1_o
developing VBG 1_o
PIPN NNP 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
controls NNS N
than IN N
in IN N
vitamin JJ 1_i
E NNP 1_i
group NN N
patients NNS N
( ( N
RR=0.3 NNP N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
=0.1-0.9 NN N
) ) N
. . N

Mean JJ 1_o
PNP NNP 1_o
scores NNS 1_o
were VBD N
2.25+/-5.1 CD N
( ( N
range VB N
0-15 NNP N
) ) N
for IN N
patients NNS N
in IN N
Group NNP N
I PRP N
and CC N
11+/-11.63 JJ N
( ( N
range VB N
0-32 NN N
) ) N
for IN N
those DT N
in IN N
Group NNP N
II NNP N
( ( N
P=0.01 NNP N
) ) N
. . N

Vitamin NNP 1_i
E NNP 1_i
supplementation NN 1_i
was VBD N
well RB N
tolerated VBN 1_o
and CC N
showed VBD N
an DT N
excellent JJ N
safety NN 1_o
profile NN 1_o
. . 1_o

This DT N
study NN N
shows VBZ N
that IN N
vitamin NN 1_i
E NNP 1_i
effectively RB N
and CC N
safely RB N
protects VBZ N
patients NNS 1_p
with IN 1_p
cancer NN 1_p
from IN N
the DT N
occurrence NN 1_o
of IN 1_o
paclitaxel-induced JJ 1_o
peripheral JJ 1_o
nerve NN 1_o
damage NN 1_o
. . 1_o

A DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
is VBZ N
needed VBN N
to TO N
confirm VB N
these DT N
results NNS N
. . N

Effects NNS N
of IN N
Thai NNP N
traditional JJ N
massage NN N
on IN N
autistic JJ 1_p
children NNS 1_p
's POS 1_p
behavior NN 1_p
. . 1_p

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
access NN N
whether IN N
there EX N
were VBD N
any DT N
therapeutic JJ N
effects NNS N
of IN N
Thai NNP 1_i
Traditional NNP 1_i
Massage NNP 1_i
( ( 1_i
TTM NNP 1_i
) ) 1_i
on IN N
major JJ N
behavioral JJ 1_p
and CC 1_p
emotional JJ 1_p
disturbances NNS 1_p
in IN 1_p
Thai NNP 1_p
autistic JJ 1_p
children NNS 1_p
. . 1_p

DESIGN NN N
This DT N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
study NN N
. . N

SETTINGS/LOCATION NNP N
The DT 1_p
study NN 1_p
was VBD 1_p
conducted VBN 1_p
at IN 1_p
the DT 1_p
Rehabilitation NNP 1_p
Centre NNP 1_p
of IN 1_p
the DT 1_p
Thai NNP 1_p
Red NNP 1_p
Cross NNP 1_p
Society NNP 1_p
. . 1_p

SUBJECTS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
60 CD 1_p
autistic JJ 1_p
children NNS 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
of IN 1_p
3 CD 1_p
and CC 1_p
10 CD 1_p
completed VBD 1_p
this DT 1_p
study NN 1_p
. . 1_p

INTERVENTIONS NNP N
Standard NNP 1_i
sensory JJ 1_i
integration NN 1_i
therapy NN 1_i
( ( 1_i
SI NNP 1_i
) ) 1_i
was VBD N
compared VBN N
to TO N
the DT N
SI NNP N
with IN N
TTM NNP 1_i
treatments NNS N
. . N

OUTCOME NNP N
MEASURES NNP N
Parents NNP N
and CC N
teachers NNS N
assessed VBD N
major JJ 1_o
behavior NN 1_o
disturbances NNS 1_o
using VBG N
the DT N
Conners NNPS 1_o
' POS 1_o
Rating VBG 1_o
Scales NNS 1_o
at IN N
0 CD N
and CC N
8 CD N
weeks NNS N
. . N

Sleep JJ 1_o
Diary NNP 1_o
( ( 1_o
SD NNP 1_o
) ) 1_o
, , N
recorded VBN N
by IN N
the DT N
parents NNS N
, , N
assessed VBD N
the DT N
patient NN N
's POS N
sleeping NN N
patterns NNS N
every DT N
week NN N
. . N

RESULTS NNP N
Sixty NNP 1_p
( ( 1_p
60 CD 1_p
) ) 1_p
autistic JJ 1_p
children NNS 1_p
, , 1_p
mean JJ 1_p
age NN 1_p
4.67 CD 1_p
+/- JJ 1_p
1.82 CD 1_p
, , 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

No DT N
statistical JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
demographic JJ N
and CC N
baseline JJ N
data NN N
among IN N
both DT N
groups NNS N
. . N

From IN N
both CC N
the DT N
Conners NNPS 1_o
' POS 1_o
Teacher NNP 1_o
Questionnaire NNP 1_o
and CC 1_o
SD NNP 1_o
, , N
statistical JJ N
improvement NN N
was VBD N
detected VBN N
for IN N
conduct NN 1_o
problem NN 1_o
, , 1_o
hyperactivity NN 1_o
, , 1_o
inattention-passivity NN 1_o
, , 1_o
hyperactivity NN 1_o
index NN 1_o
, , 1_o
and CC 1_o
sleeping VBG 1_o
behavior NN 1_o
. . 1_o

However RB N
, , N
results NNS N
from IN N
the DT N
Conners NNP 1_o
' POS 1_o
Parent NNP 1_o
Questionnaire NNP 1_o
revealed VBD N
an DT N
improvement NN N
only RB N
for IN N
anxiety NN 1_o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
massage NN N
group NN N
, , N
whereas IN N
when WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
conduct NN 1_o
problem NN 1_o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
anxiety NN 1_o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
was VBD N
found VBN N
. . N

Results NNS N
indicated VBD N
that IN N
TTM NNP N
may MD N
have VB N
a DT N
positive JJ N
effect NN N
in IN N
improving VBG N
stereotypical JJ 1_o
behaviors NNS 1_o
in IN N
autistic JJ N
children NNS N
. . N

CONCLUSIONS NNP N
Over IN N
a DT N
period NN N
of IN N
8 CD N
weeks NNS N
, , N
our PRP$ N
findings NNS N
suggested VBD N
that IN N
TTM NNP N
could MD N
be VB N
used VBN N
as IN N
a DT N
complementary JJ N
therapy NN N
for IN N
autistic JJ N
children NNS N
in IN N
Thailand NNP 1_p
. . 1_p

Is VBZ N
periprostatic JJ N
local JJ N
anesthesia NN 1_i
for IN N
transrectal JJ 1_p
ultrasound NN 1_p
guided VBD 1_p
prostate NN 1_p
biopsy NN 1_p
associated VBN N
with IN N
increased JJ N
infectious JJ 1_o
or CC 1_o
hemorrhagic JJ 1_o
complications NNS 1_o
? . N
A DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

PURPOSE NNP N
Periprostatic NNP N
local JJ N
anesthesia NN N
for IN N
prostate NN N
biopsy NN N
requires VBZ N
2 CD N
or CC N
more JJR N
extra JJ N
needle JJ N
punctures NNS N
and CC N
injection NN N
of IN N
the DT N
local JJ N
anesthetic NN N
through IN N
the DT N
highly RB N
colonized JJ N
rectum NN N
. . N

To TO N
our PRP$ N
knowledge NN N
we PRP N
report VBP N
the DT N
first JJ N
prospective JJ N
randomized VBN N
trial NN N
to TO N
assess VB N
the DT N
infectious JJ 1_o
or CC 1_o
hemorrhagic JJ 1_o
complications NNS 1_o
associated VBN N
with IN N
this DT N
method NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
100 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
with IN 1_p
sterile JJ 1_p
urine JJ 1_p
cultures NNS 1_p
underwent JJ 1_p
transrectal JJ 1_i
ultrasound NN 1_i
guided VBD 1_i
prostate NN 1_i
biopsy NN 1_i
. . 1_i

They PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
periprostatic JJ 1_i
nerve NN 1_i
block NN 1_i
or CC 1_i
no DT 1_i
anesthesia NN 1_i
. . 1_i

Patients NNS 1_i
were VBD 1_i
evaluated VBN 1_i
for IN 1_i
the DT 1_i
amount NN 1_o
of IN 1_o
rectal NN 1_o
and CC 1_o
urethral JJ 1_o
bleeding NN 1_o
, , 1_i
and CC 1_i
symptoms NNS 1_i
and CC 1_i
signs NNS 1_i
of IN 1_i
infection NN 1_o
after IN 1_o
biopsy NN 1_o
. . 1_o

RESULTS VB N
The DT N
amount NN 1_o
of IN 1_o
urethral JJ 1_o
bleeding NN 1_o
was VBD N
slight JJ N
and CC N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Rectal JJ 1_o
bleeding NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
patients NNS N
who WP N
received VBD N
anesthesia NN N
. . N

High JJ 1_o
fever NN 1_o
( ( N
greater JJR N
than IN N
37.8C CD N
) ) N
was VBD N
more RBR N
frequent JJ N
in IN N
the DT N
nerve NN N
block NN N
group NN N
and CC N
2 CD N
patients NNS N
in IN N
this DT N
group NN N
required VBD N
rehospitalization NN N
. . N

Bacteriuria NNP 1_o
in IN 1_o
post-biopsy JJ 1_o
urine JJ 1_o
cultures NNS 1_o
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
anesthesia NN N
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
periprostatic JJ N
local JJ N
anesthesia NN 1_i
for IN N
prostate JJ N
biopsy NN N
does VBZ N
not RB N
increase VB N
the DT N
risk NN N
of IN N
urethral JJ 1_o
bleeding NN 1_o
. . 1_o

It PRP N
is VBZ N
associated VBN N
with IN N
a DT N
decreased JJ N
incidence NN N
of IN N
rectal JJ 1_o
bleeding NN 1_o
, , N
presumably RB N
due JJ N
to TO N
decreased JJ N
patient NN N
discomfort NN N
. . N

The DT N
incidence NN N
of IN N
bacteriuria NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
anesthesia NN N
group NN N
. . N

High NNP 1_o
fever NN 1_o
and CC 1_o
hospitalization NN 1_o
due JJ N
to TO N
infectious JJ N
complications NNS N
were VBD N
also RB N
more RBR N
common JJ N
in IN N
the DT N
local JJ N
anesthesia NN N
group NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
. . N

Prospective JJ N
randomized JJ N
trials NNS N
seem VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimum JJ N
antibiotic JJ N
prophylaxis NN N
regimen NNS N
in IN N
patients NNS N
undergoing VBG N
biopsy NN N
with IN N
a DT N
periprostatic JJ N
nerve NN N
block NN N
. . N

Cisplatin NNP 1_i
, , 1_i
epirubicin NN 1_i
, , 1_i
leucovorin NN 1_i
and CC 1_i
5-fluorouracil JJ 1_i
( ( 1_i
PELF NNP 1_i
) ) 1_i
is VBZ N
more RBR N
active JJ N
than IN N
5-fluorouracil JJ 1_i
, , 1_i
doxorubicin JJ 1_i
and CC 1_i
methotrexate NN 1_i
( ( 1_i
FAMTX NNP 1_i
) ) 1_i
in IN N
advanced JJ 1_p
gastric JJ 1_p
carcinoma NN 1_p
. . 1_p

BACKGROUND NNP N
5-Fluorouracil JJ 1_i
( ( 1_i
5-FU JJ 1_i
) ) 1_i
, , 1_i
doxorubicin NN 1_i
and CC 1_i
methotrexate NN 1_i
( ( 1_i
FAMTX NNP 1_i
) ) 1_i
and CC 1_i
cisplatin NN 1_i
, , 1_i
epirubicin NN 1_i
, , 1_i
leucovorin NN 1_i
and CC 1_i
5-FU JJ 1_i
( ( 1_i
PELF NNP 1_i
) ) 1_i
have VBP N
both DT N
been VBN N
reported VBN N
to TO N
be VB N
superior JJ N
to TO N
the DT N
combination NN N
5-FU JJ N
, , N
doxorubicin JJ N
and CC N
mitomycin JJ N
C NNP N
( ( N
FAM NNP N
) ) N
in IN N
advanced JJ 1_p
gastric JJ 1_p
carcinoma NN 1_p
. . N

On IN N
the DT N
basis NN N
of IN N
the DT N
presence NN N
and CC N
dose JJ N
intensity NN N
of IN N
the DT N
included JJ N
agents NNS N
, , N
we PRP N
hypothesised VBD N
that IN N
PELF NNP N
would MD N
be VB N
superior JJ N
to TO N
FAMTX NNP 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
Two CD 1_p
hundred VBD 1_p
patients NNS 1_p
with IN 1_p
untreated JJ 1_p
advanced JJ 1_p
gastric JJ 1_p
carcinoma NN 1_p
were VBD N
randomised VBN N
to TO N
receive VB N
PELF NNP 1_i
or CC 1_i
FAMTX NNP 1_i
for IN N
a DT N
maximum NN N
of IN N
six CD N
cycles NNS N
or CC N
until IN N
disease JJ N
progression NN N
. . N

RESULTS VB N
The DT N
complete JJ 1_o
response NN 1_o
( ( 1_o
CR NNP 1_o
) ) 1_o
rates NNS 1_o
to TO N
PELF NNP N
and CC N
FAMTX NNP 1_i
were VBD N
, , N
respectively RB N
, , N
13 CD N
% NN N
[ JJ N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
6 CD N
% NN N
to TO N
20 CD N
% NN N
] NN N
and CC N
2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
0 CD N
% NN N
to TO N
5 CD N
% NN N
; : N
P NNP N
= NNP N
0.003 CD N
) ) N
, , N
and CC N
the DT N
objective JJ 1_o
response NN 1_o
rates NNS 1_o
[ VBP N
CR NNP N
plus CC N
partial JJ 1_o
response NN 1_o
( ( N
PR NNP N
) ) N
rates NNS N
] VBP N
39 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
29 CD N
% NN N
to TO N
49 CD N
% NN N
) ) N
and CC N
22 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
13 CD N
% NN N
to TO N
30 CD N
% NN N
; : N
P NNP N
= NNP N
0.009 CD N
) ) N
, , N
thus RB N
significantly RB N
favouring VBG N
the DT N
PELF NNP N
combination NN N
. . N

The DT N
survival NN 1_o
rates NNS 1_o
after IN N
12 CD N
months NNS N
( ( N
30.8 CD N
% NN N
versus IN N
22.4 CD N
% NN N
) ) N
and CC N
24 CD N
months NNS N
( ( N
15.7 CD N
% NN N
versus IN N
9.5 CD N
% NN N
) ) N
were VBD N
also RB N
higher JJR N
among IN N
patients NNS N
receiving VBG N
PELF NNP N
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

The DT N
toxicities NNS 1_o
were VBD N
qualitatively RB N
different JJ N
but CC N
quantitatively RB N
similar JJ N
. . N

Both DT N
regimens VBZ N
seem VBP N
to TO N
be VB N
feasible JJ N
provided VBN N
that IN N
careful JJ N
patient JJ N
monitoring NN N
is VBZ N
assured VBN N
. . N

CONCLUSIONS NNP N
PELF NNP 1_i
is VBZ N
significantly RB N
more RBR N
active JJ N
than IN N
FAMTX NNP 1_i
and CC N
deserves VBZ N
further JJ N
research NN N
in IN N
the DT N
adjuvant JJ N
setting NN N
. . N

Clinical JJ N
and CC N
microbial JJ N
evaluation NN N
of IN N
a DT N
histatin-containing JJ 1_i
mouthrinse NN 1_i
in IN N
humans NNS 1_p
with IN 1_p
experimental JJ 1_p
gingivitis NN 1_p
. . 1_p

OBJECTIVE NNP N
P-113 NNP 1_i
, , 1_i
a DT 1_i
12 CD 1_i
amino NN 1_i
acid JJ 1_i
histatin-based JJ 1_i
peptide NN 1_i
, , N
was VBD N
evaluated VBN N
in IN N
a DT N
mouthrinse NN 1_i
formulation NN 1_i
for IN N
safety NN N
, , N
prevention NN N
of IN N
the DT N
development NN N
of IN N
experimental JJ N
gingivitis NN N
, , N
and CC N
for IN N
its PRP$ N
effects NNS N
on IN N
periodontal JJ N
flora NN N
. . N

METHOD NNP N
159 CD 1_p
periodontally RB 1_p
healthy JJ 1_p
subjects NNS 1_p
abstained VBN 1_p
from IN 1_p
oral JJ 1_p
hygiene NN 1_p
procedures NNS 1_p
and CC N
self-administered JJ 1_i
either DT 1_i
0.005 CD 1_i
% NN 1_i
, , 1_i
0.01 CD 1_i
% NN 1_i
, , 1_i
0.05 CD 1_i
% NN 1_i
P-113 NNP 1_i
or CC 1_i
placebo NN 1_i
mouthrinse NN 1_i
formulations NNS 1_i
twice RB 1_i
daily RB 1_i
over IN 1_i
a DT 1_i
four CD 1_i
week NN 1_i
treatment NN 1_i
period NN 1_i
. . 1_i

During IN N
this DT N
time NN N
, , N
the DT N
safety NN 1_o
, , 1_o
anti-plaque JJ 1_o
, , 1_o
and CC 1_o
anti-gingivitis JJ 1_o
effects NNS 1_o
of IN N
P-113 NNP N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
plaque NN 1_o
( ( N
p=0.046 NN N
) ) N
and CC N
a DT N
reduction NN 1_o
in IN 1_o
gingivitis NN 1_o
( ( N
p=0.086 NN N
) ) N
for IN N
subjects NNS N
using VBG N
0.01 CD N
% NN N
P-113 JJ 1_i
mouthrinse NN 1_i
. . 1_i

Significantly RB N
more RBR N
subjects NNS N
in IN N
the DT N
0.01 CD N
% NN N
and CC N
0.05 CD N
% NN N
treatment NN N
groups NNS N
showed VBD N
a DT N
small JJ N
increase NN N
in IN N
plaque JJ 1_o
index NN N
of IN N
< $ N
0.25 CD N
as IN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Similar JJ N
trends NNS N
were VBD N
noted VBN N
for IN N
changes NNS N
in IN N
the DT N
% NN N
of IN N
sites NNS N
with IN N
bleeding VBG 1_o
on IN 1_o
probing VBG 1_o
in IN N
the DT N
0.01 CD N
% NN N
P-113 NNP 1_i
group NN N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
adverse JJ 1_o
events NNS 1_o
, , N
and CC N
there EX N
were VBD N
no DT N
adverse JJ N
shifts NNS 1_o
in IN 1_o
supragingival JJ 1_o
microflora NN 1_o
during IN N
the DT N
study NN N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
P-113 NNP 1_i
mouthrinse NN 1_i
is VBZ N
safe JJ N
and CC N
reduces NNS N
plaque NN 1_o
, , 1_o
gingivitis NN 1_o
and CC 1_o
gingival NN 1_o
bleeding NN 1_o
in IN 1_p
the DT 1_p
human JJ 1_p
experimental JJ 1_p
gingivitis NN 1_p
model NN 1_p
. . 1_p

The DT N
evaluation NN N
of IN N
pulmonary JJ N
hypertension NN N
using VBG N
right JJ 1_i
ventricular JJ 1_i
myocardial JJ 1_i
isovolumic JJ 1_i
relaxation NN 1_i
time NN 1_i
. . 1_i

Right JJ N
ventricular NN N
( ( N
RV NNP N
) ) N
blood VBD N
pool-derived JJ N
isovolumic JJ N
relaxation NN N
time NN N
( ( N
IVRT NNP N
) ) N
correlates VBZ N
well RB N
with IN N
systolic JJ N
pulmonary JJ N
arterial JJ N
pressure NN N
( ( N
PAP NNP N
) ) N
. . N

However RB N
, , N
because IN N
of IN N
complex JJ N
parameter NN N
derivation NN N
, , N
the DT N
method NN N
is VBZ N
rarely RB N
used VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
validate VB N
the DT N
measurement NN N
of IN N
myocardial JJ N
velocity NN N
imaging-derived JJ N
RV NNP 1_i
IVRT NNP 1_i
( ( 1_i
IVRT NNP 1_i
' POS 1_i
) ) 1_i
against IN N
invasively RB 1_i
measured VBN 1_i
PAP NNP 1_i
. . 1_i

Transthoracic NNP 1_i
echocardiography NN 1_i
with IN 1_i
myocardial JJ 1_i
velocity NN 1_i
imaging NN 1_i
and CC 1_i
right JJ 1_i
heart NN 1_i
catheterization NN 1_i
were VBD N
performed VBN N
in IN N
33 CD 1_p
patients NNS 1_p
with IN 1_p
pulmonary JJ 1_p
hypertension NN 1_p
. . 1_p

Blood NNP 1_o
pool NN 1_o
IVRT NNP 1_o
and CC 1_o
myocardial JJ 1_o
IVRTs NNP 1_o
for IN 1_o
the DT 1_o
tricuspid JJ 1_o
valve NN 1_o
annulus NN 1_o
ring NN 1_o
, , 1_o
basal NN 1_o
and CC 1_o
apical JJ 1_o
RV NNP 1_o
free JJ 1_o
wall NN 1_o
segments NNS 1_o
were VBD N
measured VBN N
and CC N
compared VBN N
with IN N
data NNS N
from IN N
33 CD 1_p
age- JJ 1_p
and CC 1_p
sex-matched JJ 1_p
control NN 1_p
subjects NNS 1_p
. . 1_p

Measured VBN 1_o
IVRTs NNP 1_o
were VBD N
significantly RB 1_o
longer RBR 1_o
in IN N
patients NNS N
with IN N
pulmonary JJ N
hypertension NN N
than IN N
in IN N
control NN N
subjects NNS N
. . N

The DT N
strongest JJS N
correlation NN N
( ( N
R NNP N
= NNP N
0.74 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
was VBD N
found VBN N
between IN N
systolic JJ 1_o
PAP NNP 1_o
and CC 1_o
the DT 1_o
heart NN 1_o
rate-corrected JJ 1_o
IVRT NNP 1_o
' POS 1_o
derived VBN N
from IN N
the DT N
basal NN N
RV NNP N
free JJ N
wall NN N
segment NN N
. . N

The DT N
basal NN 1_o
segment NN 1_o
IVRT NNP 1_o
' POS 1_o
corrected VBN N
for IN N
heart NN 1_o
rate NN 1_o
correlates NNS N
well RB N
with IN N
the DT N
invasive JJ N
PAP NNP N
measurement NN N
and CC N
, , N
therefore RB N
, , N
can MD N
be VB N
used VBN N
to TO N
predict VB N
systolic JJ 1_o
PAP NNP 1_o
. . 1_o

It PRP N
can MD N
even RB N
be VB N
considered VBN N
as IN N
an DT N
alternative NN N
to TO N
tricuspid VB N
regurgitation-derived JJ N
PAP NNP N
systolic NN N
when WRB N
tricuspid JJ N
regurgitation NN N
is VBZ N
nonrecordable JJ N
. . N

A DT N
proposed VBN N
method NN N
to TO N
derive VB N
systolic JJ N
PAP NNP N
should MD N
be VB N
used VBN N
while IN N
screening VBG N
the DT N
patients NNS N
at IN N
risk NN N
for IN N
pulmonary JJ N
hypertension NN N
, , N
monitoring VBG N
the DT N
disease NN N
progression NN N
and CC N
the DT N
effect NN N
of IN N
treatment NN N
. . N

Age-related JJ 1_o
response NN 1_o
to TO N
two CD N
Haemophilus NNP 1_i
influenzae NN 1_i
type NN 1_i
b NN 1_i
vaccines NNS 1_i
. . 1_i

Two CD N
types NNS N
of IN N
Hib NNP 1_i
vaccines NNS 1_i
were VBD N
compared VBN N
for IN N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
in IN N
71 CD 1_p
normal JJ 1_p
children NNS 1_p
in IN 1_p
three CD 1_p
age NN 1_p
groups NNS 1_p
: : 1_p
36 CD 1_p
to TO 1_p
72 CD 1_p
months NNS 1_p
, , 1_p
15 CD 1_p
to TO 1_p
18 CD 1_p
months NNS 1_p
, , 1_p
and CC 1_p
6 CD 1_p
to TO 1_p
8 CD 1_p
months NNS 1_p
. . 1_p

One CD N
vaccine NN N
contained VBD N
the DT N
Hib-specific NNP 1_i
capsular JJ 1_i
polysaccharide NN 1_i
, , 1_i
PRP NNP 1_i
; : 1_i
the DT N
second JJ N
vaccine NN N
contained VBN 1_i
PRP NNP 1_i
combined VBN N
with IN N
pertussis NN 1_i
vaccine NN 1_i
, , 1_i
PRP-P. NNP 1_i
A NNP N
third JJ N
vaccine NN N
, , N
DTP NNP 1_i
, , N
was VBD N
administered VBN N
to TO N
a DT N
control NN 1_i
group NN N
for IN N
each DT N
age NN N
. . N

Anti-PRP NNP 1_o
antibody NN 1_o
levels NNS 1_o
were VBD N
greater JJR N
after IN N
vaccination NN N
with IN N
PRP-P NNP N
than IN N
after IN N
PRP NNP N
in IN N
all DT N
three CD 1_p
age NN 1_p
groups NNS 1_p
. . 1_p

Immunoresponsiveness NN 1_o
to TO N
both DT N
vaccines NNS N
increased VBD 1_o
with IN N
age NN N
. . N

A DT N
lower JJR 1_o
incidence NN 1_o
of IN 1_o
side NN 1_o
effects NNS 1_o
was VBD N
seen VBN N
with IN N
both DT N
PRP NNP 1_i
( ( N
15 CD N
% NN N
) ) N
and CC N
PRP-P NNP 1_i
( ( N
20 CD N
% NN N
) ) N
than IN N
with IN N
DTP NNP N
( ( N
56 CD N
% NN N
) ) N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
PRP-P NNP 1_i
is VBZ N
both DT N
well RB 1_o
tolerated VBN 1_o
clinically RB 1_o
and CC 1_o
has VBZ 1_o
greater JJR 1_o
immunogenicity NN 1_o
than IN N
PRP NNP N
. . N

Predictors NNS N
of IN N
mental JJ N
health NN N
problems NNS N
and CC N
negative JJ N
caregiving NN N
experiences NNS N
in IN N
carers NNS 1_p
of IN 1_p
adolescents NNS 1_p
with IN 1_p
bulimia NN 1_p
nervosa NN 1_p
. . 1_p

OBJECTIVE CC N
This DT N
exploratory NN N
study NN N
focuses VBZ N
on IN N
the DT N
mental JJ 1_i
health NN 1_i
( ( 1_i
MH NNP 1_i
) ) 1_i
and CC 1_i
caregiving VBG 1_i
experience NN 1_i
of IN 1_i
carers NNS 1_i
of IN 1_i
adolescents NNS 1_i
with IN 1_p
Bulimia NNP 1_p
Nervosa NNP 1_p
( ( 1_p
BN NNP 1_p
) ) 1_p
/Eating VBG 1_p
Disorder NNP 1_p
not RB 1_p
otherwise RB 1_p
specified VBN 1_p
( ( 1_p
EDNOS NNP 1_p
) ) 1_p
, , N
aiming VBG N
to TO N
determine VB N
: : N
levels NNS N
of IN N
MH NNP N
problems NNS N
in IN N
carers NNS N
and CC N
if IN N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
predicts NNS N
carer VBP N
MH NNP N
status NN N
and CC N
which WDT N
factors NNS N
predict VBP N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
. . N

METHOD NNP N
Hundred NNP 1_p
and CC 1_p
twelve VB 1_p
carers NNS 1_p
and CC 1_p
68 CD 1_p
adolescents NNS 1_p
with IN 1_p
BN/EDNOS NNP 1_p
completed VBD 1_p
self-report JJ 1_i
measures NNS 1_i
( ( 1_i
General NNP 1_i
Health NNP 1_i
Questionnaire NNP 1_i
, , 1_i
Experience NNP 1_i
of IN 1_i
Caregiving NNP 1_i
Inventory NNP 1_i
, , 1_i
Level NNP 1_i
of IN 1_i
Expressed JJ 1_i
Emotion NNP 1_i
, , 1_i
Self-report NNP 1_i
Family NNP 1_i
Inventory NNP 1_i
, , 1_i
Inventory NNP 1_i
of IN 1_i
Interpersonal NNP 1_i
Problems NNP 1_i
) ) 1_i
. . 1_i

RESULTS NNP N
Over IN N
half NN N
of IN N
the DT N
carers NNS N
reported VBD N
some DT N
MH NNP 1_o
problems NNS 1_o
and CC N
a DT N
minority NN N
( ( N
5.4 CD N
% NN N
) ) N
were VBD N
experiencing VBG N
considerable JJ N
difficulties NNS N
. . N

A DT 1_o
negative JJ 1_o
experience NN 1_o
of IN 1_o
caregiving VBG 1_o
predicted VBN N
carer NN N
MH NNP N
status NN N
. . N

Higher JJR 1_o
weekly JJ 1_o
contact NN 1_o
hours NNS 1_o
and CC 1_o
patient JJ 1_o
ratings NNS 1_o
of IN 1_o
expressed VBN 1_o
emotion NN 1_o
( ( 1_o
EE NNP 1_o
) ) 1_o
predicted VBD N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
. . N

CONCLUSIONS NNP N
Interventions NNPS 1_i
focusing VBG 1_i
on IN 1_i
reducing VBG 1_i
EE NNP 1_o
and CC 1_i
contact NN 1_o
hours NNS 1_o
could MD N
prove VB N
beneficial JJ N
for IN N
both DT N
patient NN 1_p
and CC N
caregiver NN 1_p
outcomes NNS N
. . N

Granulocyte-macrophage JJ 1_i
colony-stimulating JJ 1_i
factor NN 1_i
as IN N
immunomodulating VBG N
factor NN N
together RB N
with IN N
influenza JJ 1_i
vaccination NN 1_i
in IN N
stem NN 1_p
cell NN 1_p
transplant NN 1_p
patients NNS 1_p
. . 1_p

The DT N
effect NN N
of IN N
granulocyte-macrophage JJ 1_i
colony-stimulating JJ 1_i
factor NN 1_i
( ( 1_i
GM-CSF NNP 1_i
) ) 1_i
on IN N
the DT N
serological JJ 1_o
response NN 1_o
at IN N
influenza JJ 1_i
vaccination NN 1_i
was VBD N
studied VBN N
in IN N
117 CD 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
undergone JJ 1_p
stem NN 1_p
cell NN 1_p
transplantation NN 1_p
( ( 1_p
SCT NNP 1_p
) ) 1_p
. . 1_p

The DT N
vaccine NN 1_o
response NN 1_o
was VBD N
evaluated VBN N
as IN N
significant JJ N
increases NNS N
in IN N
levels NNS 1_o
of IN 1_o
influenza JJ 1_o
hemagglutination-inhibition NN 1_o
( ( 1_o
HAI NNP 1_o
) ) 1_o
antibodies NNS 1_o
and CC N
of IN N
IgG NNP 1_o
antibodies NNS 1_o
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
antibody NN 1_o
response NN 1_o
to TO N
either DT N
influenza VB N
A NNP N
or CC N
B NNP N
in IN N
64 CD N
patients NNS N
who WP N
received VBD N
GM-CSF NNP 1_i
at IN N
vaccination NN N
, , N
compared VBN N
with IN N
the DT N
53 NNS N
who WP N
did VBD N
not RB N
. . N

In IN N
the DT N
subgroup NN 1_p
of IN 1_p
allogeneic JJ 1_p
SCT NNP 1_p
patients NNS 1_p
, , N
HAI NNP N
showed VBD N
that IN N
the DT N
response NN 1_o
rate NN 1_o
to TO N
the DT N
influenza NN 1_o
B NNP 1_o
vaccine NN 1_o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

ELISA NN 1_o
showed VBD N
that IN N
autologous JJ 1_p
SCT NNP 1_p
patients NNS 1_p
with IN 1_p
breast JJ 1_p
cancer NN 1_p
who WP N
received VBD N
GM-CSF NNP N
had VBD N
a DT N
better JJR N
response NN 1_o
to TO N
influenza VB 1_o
A NNP 1_o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
B NNP 1_o
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

At IN N
early JJ N
vaccination NN N
, , N
4-12 JJ N
months NNS N
after IN N
stem NN N
cell NN N
transplantation NN N
, , N
these DT N
responses NNS N
were VBD N
more RBR N
pronounced JJ N
. . N

GM-CSF JJ 1_i
appears VBZ N
to TO N
improve VB N
the DT N
response NN 1_o
to TO 1_o
influenza VB 1_o
vaccination NN 1_o
in IN N
some DT N
groups NNS N
of IN N
SCT NNP 1_p
patients NNS 1_p
, , N
but CC N
only RB N
to TO N
a DT N
limited JJ N
extent NN N
. . N

The DT N
long-term JJ N
effects NNS N
of IN N
auditory JJ 1_i
training NN 1_i
on IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Eighty NNP 1_p
children NNS 1_p
, , 1_p
3-17 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , 1_p
with IN 1_p
autism NN 1_p
or CC 1_p
Asperger NNP 1_p
syndrome NN 1_p
and CC 1_p
mild NN 1_p
to TO 1_p
severe VB 1_p
distress NN 1_p
in IN 1_p
the DT 1_p
presence NN 1_p
of IN 1_p
some DT 1_p
sounds NNS 1_p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
. . N

The DT N
experimental JJ N
group NN N
received VBD N
auditory JJ 1_i
training NN 1_i
and CC 1_i
the DT 1_i
control NN 1_i
group NN 1_i
listened VBD 1_i
to TO 1_i
the DT 1_i
same JJ 1_i
unmodified JJ 1_i
music NN 1_i
under IN 1_i
the DT 1_i
same JJ 1_i
conditions NNS 1_i
. . 1_i

Significant JJ N
improvements NNS N
in IN N
behavior NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
autism NN 1_o
were VBD N
maintained VBN N
for IN N
12 CD N
months NNS N
by IN N
both DT N
groups NNS N
. . N

Informal NNP N
data NN N
suggested VBD N
that IN N
a DT N
range NN 1_o
of IN 1_o
abnormal JJ 1_o
responses NNS 1_o
to TO N
sound VB 1_o
and CC 1_o
other JJ 1_o
sensory JJ 1_o
abnormalities NNS 1_o
may MD N
also RB N
have VB N
improved VBN N
. . N

Verbal NNP 1_o
and CC 1_o
performance NN 1_o
IQ NNP 1_o
increased VBD N
significantly RB N
3 CD N
to TO N
12 CD N
months NNS N
after IN N
interventions NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
some DT N
aspect NN N
of IN N
both DT N
auditory JJ 1_i
training NN 1_i
and CC 1_i
listening VBG 1_i
to TO N
selected VBN N
unmodified JJ N
music NN N
may MD N
have VB N
a DT N
beneficial JJ 1_o
effect NN 1_o
on IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
and CC 1_p
sound JJ 1_p
sensitivity NN 1_p
, , N
and CC N
indicate VBP N
a DT N
need NN N
for IN N
further JJ N
research NN N
into IN N
the DT N
effects NNS N
that WDT N
led VBD N
to TO N
these DT N
changes NNS N
and CC N
the DT N
mechanisms NNS N
involved VBN N
in IN N
the DT N
sensory JJ N
abnormalities NNS N
commonly RB N
associated VBN N
with IN N
autism NN N
. . N

A DT N
double-blind NN N
, , N
randomized VBN N
trial NN N
of IN N
deep JJ 1_i
repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
rTMS NN 1_i
) ) 1_i
for IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

BACKGROUND NNP N
Biomedical NNP N
treatment NN N
options NNS N
for IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
are VBP N
extremely RB N
limited JJ N
. . N

Repetitive JJ 1_i
transcranial JJ 1_i
magnetic JJ 1_i
stimulation NN 1_i
( ( 1_i
rTMS NN 1_i
) ) 1_i
is VBZ N
a DT N
safe JJ N
and CC N
efficacious JJ N
technique NN N
when WRB N
targeting VBG N
specific JJ N
areas NNS N
of IN N
cortical JJ N
dysfunction NN N
in IN N
major JJ N
depressive JJ N
disorder NN N
, , N
and CC N
a DT N
similar JJ N
approach NN N
could MD N
yield VB N
therapeutic JJ N
benefits NNS N
in IN N
ASD NNP N
, , N
if IN N
applied VBN N
to TO N
relevant VB N
cortical JJ N
regions NNS N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
whether IN N
deep JJ N
rTMS NN 1_i
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
improves VBZ N
social JJ N
relating NN N
in IN N
ASD NNP 1_o
. . 1_o

METHODS NNP N
28 CD 1_p
adults NNS 1_p
diagnosed VBN 1_p
with IN 1_p
either DT 1_p
autistic JJ 1_p
disorder NN 1_p
( ( 1_p
high-functioning JJ 1_p
) ) 1_p
or CC 1_p
Asperger NNP 1_p
's POS 1_p
disorder NN 1_p
completed VBD 1_p
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
design NN N
with IN N
2 CD N
weeks NNS N
of IN N
daily JJ N
weekday JJ N
treatment NN N
. . N

This DT N
involved JJ N
deep JJ 1_i
rTMS NN 1_i
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
( ( N
5 CD N
Hz NNP N
, , N
10-s JJ N
train NN N
duration NN N
, , N
20-s JJ N
inter-train JJ N
interval NN N
) ) N
for IN N
15 CD N
min NN N
( ( N
1500 CD N
pulses VBZ N
per IN N
session NN N
) ) N
using VBG N
a DT N
HAUT-Coil NNP N
. . N

The DT N
sham NN N
rTMS NN 1_i
coil NN N
was VBD N
encased VBN N
in IN N
the DT N
same JJ N
helmet NN N
of IN N
the DT N
active JJ N
deep JJ N
rTMS NN 1_i
coil NN N
, , N
but CC N
no DT N
effective JJ N
field NN N
was VBD N
delivered VBN N
into IN N
the DT N
brain NN N
. . N

Assessments NNS N
were VBD N
conducted VBN N
before IN N
, , N
after IN N
, , N
and CC N
one CD N
month NN N
following VBG N
treatment NN N
. . N

RESULTS JJ N
Participants NNS N
in IN N
the DT N
active JJ N
condition NN N
showed VBD N
a DT N
near JJ N
significant JJ N
reduction NN N
in IN N
self-reported JJ 1_o
social JJ 1_o
relating NN 1_o
symptoms NNS 1_o
from IN N
pre-treatment JJ N
to TO N
one CD N
month NN N
follow-up NN N
, , N
and CC N
a DT N
significant JJ N
reduction NN N
in IN N
social JJ 1_o
relating NN 1_o
symptoms NNS 1_o
( ( N
relative JJ N
to TO N
sham VB N
participants NNS N
) ) N
for IN N
both DT N
post-treatment JJ N
assessments NNS N
. . N

Those DT N
in IN N
the DT N
active JJ N
condition NN N
also RB N
showed VBD N
a DT N
reduction NN N
in IN N
self-oriented JJ 1_o
anxiety NN 1_o
during IN N
difficult JJ N
and CC N
emotional JJ N
social JJ N
situations NNS N
from IN N
pre-treatment NN N
to TO N
one CD N
month NN N
follow-up NN N
. . N

There EX N
were VBD N
no DT N
changes NNS N
for IN N
those DT N
in IN N
the DT N
sham JJ N
condition NN N
. . N

CONCLUSION NNP N
Deep NNP N
rTMS NN N
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
yielded VBD N
a DT N
reduction NN N
in IN N
social JJ N
relating NN N
impairment NN N
and CC N
socially-related JJ N
anxiety NN N
. . N

Further NNP N
research NN N
in IN N
this DT N
area NN N
should MD N
employ VB N
extended VBD N
rTMS NN N
protocols NNS N
that WDT N
approximate VBP N
those DT N
used VBN N
in IN N
depression NN N
in IN N
an DT N
attempt NN N
to TO N
replicate VB N
and CC N
amplify VB N
the DT N
clinical JJ N
response NN N
. . N

Basal NNP 1_p
cell NN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
face NN 1_p
: : 1_p
surgery NN 1_i
or CC 1_i
radiotherapy NN 1_i
? . N
Results NNS N
of IN N
a DT N
randomized JJ N
study NN N
. . N

Impact NN N
of IN N
pentoxifylline NN 1_i
on IN N
platelet NN 1_o
function NN 1_o
profiles NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
type JJ 1_p
2 CD 1_p
diabetes NNS 1_p
mellitus NN 1_p
and CC 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
on IN 1_p
dual JJ 1_p
antiplatelet NN 1_p
therapy NN 1_p
with IN 1_p
aspirin NN 1_p
and CC 1_p
clopidogrel NN 1_p
. . 1_p

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
the DT N
phosphodiesterase NN 1_i
( ( 1_i
PDE NNP 1_i
) ) 1_i
inhibitor NN 1_i
pentoxifylline NN 1_i
on IN N
platelet NN 1_o
function NN 1_o
profiles NNS 1_o
in IN N
patients NNS 1_p
receiving VBG 1_p
dual JJ 1_p
antiplatelet NN 1_p
therapy NN 1_p
( ( 1_p
DAPT NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND NNP N
Previous NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
, , N
in IN N
patients NNS N
receiving VBG N
DAPT NNP N
, , N
the DT N
adjunctive JJ N
use NN N
of IN N
a DT N
PDE NNP 1_i
inhibitor NN 1_i
enhances NNS N
platelet NN 1_o
inhibition NN 1_o
, , N
particularly RB N
in IN N
those DT N
presenting VBG N
with IN N
diabetes NNS N
mellitus NNS N
( ( N
DM NNP N
) ) N
. . N

However RB N
, , N
the DT N
pharmacodynamic NN N
( ( N
PD NNP N
) ) N
effects NNS N
of IN N
the DT N
PDE NNP 1_i
inhibitor NN 1_i
pentoxifylline NN 1_i
on IN N
platelet NN 1_o
function NN 1_o
profiles NNS 1_o
in IN N
DM NNP N
patients NNS N
receiving VBG N
DAPT NNP N
are VBP N
unknown JJ N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel JJ N
design NN N
study NN N
conducted VBN N
in IN N
DM NNP 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
receiving VBG 1_p
DAPT NNP 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB 1_i
assigned VBN 1_i
to TO 1_i
either DT 1_i
pentoxifylline NN 1_i
400 CD 1_i
mg NN 1_i
or CC 1_i
placebo NN 1_i
3 CD 1_i
times NNS 1_i
daily RB 1_i
for IN 1_i
14 CD 1_i
days NNS 1_i
. . 1_i

The DT N
PD NNP N
effects NNS N
were VBD N
assessed VBN N
by IN N
vasodilator-stimulated JJ 1_o
phosphoprotein NN 1_o
phosphorylation NN 1_o
assay NN 1_o
, , 1_o
light JJ 1_o
transmittance NN 1_o
aggregometry NN 1_o
, , 1_o
VerifyNow NNP 1_o
P2Y12 NNP 1_o
assay NN 1_o
( ( 1_o
Accumetric NNP 1_o
, , 1_o
Inc. NNP 1_o
, , N
San NNP 1_o
Diego NNP 1_o
, , 1_o
California NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
multiple JJ 1_o
electrode NN 1_o
aggregometry NN 1_o
at IN N
baseline NN N
and CC N
14 CD N
days NNS N
. . N

The DT N
PD NNP N
effects NNS N
were VBD N
also RB N
assessed VBN N
according VBG N
the DT N
presence NN N
or CC N
absence NN N
of IN N
high JJ 1_o
on-treatment JJ 1_o
platelet NN 1_o
reactivity NN 1_o
status NN 1_o
. . 1_o

RESULTS VB N
A DT N
total NN N
of IN N
40 CD 1_p
patients NNS 1_p
were VBD N
available JJ N
for IN N
analysis NN N
. . N

At IN N
14 CD N
days NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
P2Y NNP 1_o
( ( 1_o
12 CD 1_o
) ) 1_o
reactivity NN 1_o
index NN 1_o
as IN N
assessed VBN N
by IN N
vasodilator-stimulated JJ 1_o
phosphoprotein NN 1_o
phosphorylation NN 1_o
between IN N
treatment NN N
groups NNS N
( ( N
primary JJ N
endpoint NN N
; : N
p CC N
= VB N
0.93 CD N
) ) N
. . N

Intra-group JJ N
comparisons NNS N
also RB N
failed VBD N
to TO N
show VB N
any DT N
differences NNS N
between IN N
baseline NN N
and CC N
14-day JJ 1_o
P2Y NNP 1_o
( ( 1_o
12 CD 1_o
) ) 1_o
reactivity NN 1_o
index NN 1_o
assessment NN 1_o
in IN N
the DT N
placebo NN 1_i
and CC N
pentoxifylline NN 1_i
arms NNS N
( ( N
p JJ N
= NNP N
0.61 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
inter- JJ N
and CC N
intra-group JJ N
differences NNS N
in IN N
all DT N
other JJ N
PD NNP 1_o
measures NNS 1_o
. . 1_o

The DT N
PD NNP N
effects NNS N
did VBD N
not RB N
vary JJ N
according VBG N
the DT N
presence NN N
or CC N
absence NN N
of IN N
high JJ N
on-treatment JJ N
platelet NN N
reactivity NN N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
treatment NN N
with IN N
pentoxifylline NN 1_i
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ N
platelet NN 1_o
inhibitory NN 1_o
effects NNS 1_o
in IN N
DM NNP 1_p
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
receiving VBG 1_p
DAPT NNP 1_p
. . 1_p

Pegylated VBN 1_i
feline JJ 1_i
granulocyte NN 1_i
colony-stimulating JJ 1_i
factor NN 1_i
increases NNS N
neutrophil JJ N
levels NNS N
in IN N
cats NNS 1_p
. . 1_p

Neutropenia NNP N
can MD N
often RB N
be VB N
corrected VBN N
by IN N
treatment NN N
with IN N
granulocyte-colony JJ 1_i
stimulating VBG 1_i
factor NN 1_i
( ( 1_i
G-CSF NNP 1_i
) ) 1_i
and CC N
off-label JJ 1_i
use NN 1_i
of IN 1_i
commercial JJ 1_i
human JJ 1_i
G-CSF NNP 1_i
( ( 1_i
HuG-CSF NNP 1_i
) ) 1_i
is VBZ N
a DT N
commonly RB N
used VBN N
treatment NN N
for IN N
neutropenic JJ 1_p
animals NNS 1_p
. . 1_p

However RB N
, , N
long-term JJ N
HuG-CSF NNP 1_i
treatment NN 1_i
can MD N
be VB N
associated VBN N
with IN N
adverse JJ 1_o
effects NNS 1_o
, , N
including VBG N
neutropenia NN 1_o
. . 1_o

Here RB N
, , N
feline NN N
( ( N
Fe NNP N
) ) N
G-CSF NNP N
was VBD N
produced VBN N
in IN N
Pichia NNP N
pastoris NN N
, , N
pegylated VBN N
( ( N
Peg NNP N
) ) N
FeG-CSF NNP N
and CC N
tested VBN N
in IN N
cats NNS N
. . N

A DT N
randomized JJ N
controlled JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
of IN N
PegFeG-CSF NNP 1_i
compared VBN N
to TO N
FeG-CSF NNP 1_i
or CC 1_i
HuG-CSF NNP 1_i
in IN N
FIV-infected NNP 1_p
( ( 1_p
n=14 NN 1_p
) ) 1_p
, , 1_p
FIV-uninfected JJ 1_p
healthy JJ 1_p
cats NNS 1_p
( ( 1_p
n=19 NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
in IN 1_p
HuG-CSF-induced NNP 1_p
neutropenic JJ 1_p
cats NNS 1_p
( ( 1_p
n=4 NN 1_p
) ) 1_p
. . 1_p

Daily JJ N
FeG-CSF NNP 1_i
doses NNS N
induced VBD N
higher JJR 1_o
neutrophil NN 1_o
production NN 1_o
than IN N
HuG-CSF NNP 1_i
after IN N
the DT N
second JJ N
week NN N
of IN N
treatment NN N
( ( N
P NNP N
⩽ NNP N
0.002 CD N
) ) N
. . N

Weekly JJ N
doses NNS N
of IN 1_i
PegFeG-CSF NNP 1_o
induced VBD 1_o
higher JJR 1_o
neutrophil JJ 1_o
counts NNS 1_o
and CC N
showed VBD 1_o
greater JJR 1_o
sustained VBN 1_o
activity NN 1_o
than IN N
weekly JJ N
doses NNS N
of IN 1_i
FeG-CSF NNP 1_i
. . 1_i

PegFeG-CSF NNP 1_i
provided VBD N
the DT N
most RBS N
therapeutic JJ N
and CC N
sustainable JJ 1_o
neutrophil JJ 1_o
production NN 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT 1_p
FIV-uninfected JJ 1_p
and CC 1_p
FIV-infected JJ 1_p
cats NNS 1_p
, , N
without IN N
the DT N
development NN N
of IN 1_o
neutralizing VBG 1_o
antibodies NNS 1_o
. . N

Conversely RB N
, , N
all DT 1_i
HuG-CSF-treated JJ 1_i
cats NNS 1_p
developed VBD 1_o
neutralizing VBG 1_o
antibodies NNS 1_o
, , N
suggesting VBG N
cross-reactive JJ N
antibodies NNS N
to TO N
endogenous JJ N
G-CSF NNP N
in IN N
a DT N
majority NN N
of IN N
the DT N
cases NNS N
with IN N
severe JJ N
neutropenia NN N
. . N

Strikingly RB N
, , N
when WRB 1_i
PegFeG-CSF NNP 1_i
was VBD N
used VBN N
to TO N
rescue VB N
cats NNS N
with IN 1_i
HuG-CSF-induced NNP 1_o
neutropenia NN 1_o
, , N
clinically RB N
normal JJ 1_o
neutrophil JJ 1_o
numbers NNS 1_o
returned VBN N
. . N

Thus RB 1_i
, , 1_i
PegFeG-CSF NNP 1_i
appears VBZ N
to TO N
be VB N
a DT N
superior JJ N
treatment NN N
for IN N
neutropenia NN N
in IN 1_p
feline JJ 1_p
patients NNS 1_p
. . N

Oxidized VBN 1_i
Regenerated VBD 1_i
Cellulose NNP 1_i
Reduces NNPS N
the DT N
Amount NNP N
of IN N
Fluid NNP N
Drainage NNP N
after IN N
Liver NNP N
Resection NNP N
: : N
A DT N
Randomized NNP N
Prospective NNP N
Clinical NNP N
Trial NNP N
. . N

BACKGROUND/AIMS NNP N
Oxidized NNP 1_i
regenerated VBD 1_i
cellulose NN 1_i
( ( 1_i
ORC NNP 1_i
) ) 1_i
has VBZ N
been VBN N
registered VBN N
as IN N
adjuncts NNS N
to TO N
stimulate VB N
hemostasis NN N
in IN N
liver NN N
surgery NN N
. . N

However RB N
, , N
most JJS N
previous JJ N
studies NNS N
were VBD N
primarily RB N
designed VBN N
to TO N
study VB N
the DT N
intra-operative JJ N
hemostatic JJ N
efficacy NN N
, , N
and CC N
the DT N
effect NN N
on IN N
prophylactic JJ N
application NN N
was VBD N
never RB N
studied VBN N
as IN N
a DT N
primary JJ N
endpoint NN N
. . N

This DT N
randomized JJ N
prospective JJ N
clinical JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
whether IN N
ORC NNP 1_i
is VBZ N
safe JJ N
and CC N
effective JJ N
when WRB N
used VBN N
as IN N
a DT N
prophylactic JJ N
agent NN N
covering VBG N
the DT N
raw JJ N
cut NN N
surface NN N
during IN 1_p
the DT 1_p
hepatectomy NN 1_p
to TO N
reduce VB N
the DT N
volume NN N
and CC N
duration NN N
of IN N
drainage NN N
. . N

METHODOLOGY NNP N
Between NNP 1_p
June NNP 1_p
2011 CD 1_p
and CC 1_p
August NNP 1_p
2012 CD 1_p
, , 1_p
a DT 1_p
total NN 1_p
of IN 1_p
40 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
major JJ 1_p
hepatectomy NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
ORC NNP 1_i
or CC 1_i
control NN 1_i
groups NNS 1_i
( ( N
20 CD N
in IN N
each DT N
group NN N
) ) N
. . N

Patient JJ 1_o
characteristics NNS 1_o
, , 1_o
resection-related JJ 1_o
factors NNS 1_o
, , 1_o
debit NN 1_o
of IN 1_o
drainage NN 1_o
and CC 1_o
postoperative JJ 1_o
complications NNS 1_o
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS VB N
The DT 1_p
two CD 1_p
groups NNS 1_p
were VBD 1_p
comparable JJ 1_p
in IN 1_p
terms NNS 1_p
of IN 1_p
demographics NNS 1_o
, , 1_o
indications NNS 1_o
for IN 1_o
surgery NN 1_o
, , 1_o
extent NN 1_o
of IN 1_o
hepatectomy NN 1_o
, , 1_o
and CC 1_o
intraoperative JJ 1_o
blood NN 1_o
loss NN 1_o
. . 1_o

The DT N
amount NN 1_o
of IN 1_o
drainage NN 1_o
after IN 1_o
operation NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
ORC NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
406.9 CD N
± RB N
308.1 CD N
vs. FW N
627.0 CD N
± $ N
301.6 CD N
ml NN N
, , N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

CONCLUSIONS NNP N
Application NNP N
of IN 1_i
ORC NNP 1_i
covering VBG N
the DT N
raw JJ N
cut NN N
surface NN N
during IN N
the DT N
hepatectomy NN N
can MD N
significantly RB N
decrease VB N
the DT N
amount NN N
of IN N
drainage NN N
. . N

Recurrent NNP N
ulcer NN N
after IN N
successful JJ N
treatment NN N
with IN N
cimetidine NN 1_i
or CC N
antacid NN 1_i
. . 1_i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
rates NNS N
of IN N
duodenal JJ N
ulcer NN N
healing NN N
and CC N
recurrence NN N
after IN N
treatment NN N
with IN N
cimetidine NN 1_i
or CC 1_i
antacid NN 1_i
. . 1_i

Patients NNS 1_p
with IN 1_p
endoscopically RB 1_p
documented VBN 1_p
duodenal JJ 1_p
ulcer NN 1_p
received VBD N
cimetidine NN 1_i
, , N
1200 CD N
mg NN N
daily RB N
, , N
or CC 1_i
Mylanta NNP 1_i
II NNP 1_i
, , N
7 CD N
oz JJ N
daily RB N
, , N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
. . N

For IN N
the DT N
69 CD 1_p
patients NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
who WP N
completed VBD N
the DT N
healing VBG N
phase NN N
of IN N
the DT N
trial NN N
, , N
endoscopic JJ N
ulcer NN N
healing NN N
was VBD N
almost RB N
identical JJ N
. . N

At IN N
2 CD N
, , N
4 CD N
, , N
and CC N
6 CD N
wk NN N
, , N
the DT N
cumulative JJ N
percent NN N
healed VBD N
on IN N
antacid NN 1_i
was VBD N
33 CD N
% NN N
, , N
64 CD N
% NN N
, , N
and CC N
80 CD N
% NN N
, , N
and CC N
on IN N
cimetidine NN 1_i
it PRP N
was VBD N
25 CD N
% NN N
, , N
62 CD N
% NN N
, , N
and CC N
86 CD N
% NN N
. . N

The DT N
114 CD 1_p
patients NNS 1_p
with IN 1_p
healed JJ 1_p
ulcer NN 1_p
were VBD N
observed VBN N
on IN N
no DT N
therapy NN N
and CC N
underwent JJ N
additional JJ N
endoscopy NN N
to TO N
detect VB N
recurrences NNS N
when WRB N
symptomatic JJ N
or CC N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
mo NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
frequency NN 1_o
of IN 1_o
recurrences NNS 1_o
between IN N
treatments NNS N
. . N

At IN N
3 CD N
and CC N
6 CD N
mo NN N
, , N
the DT N
cumulative JJ 1_o
percentages NNS 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
recurrence NN 1_o
were VBD N
29 CD N
% NN N
and CC N
56 CD N
% NN N
after IN N
antacid JJ 1_i
therapy NN 1_i
and CC N
36 CD N
% NN N
and CC N
55 CD N
% NN N
after IN N
cimetidine JJ 1_i
therapy NN 1_i
. . 1_i

Some DT N
patient JJ N
variables NNS N
were VBD N
associated VBN N
with IN N
delayed JJ 1_o
ulcer NN 1_o
healing NN 1_o
or CC 1_o
ulcer JJ 1_o
recurrence NN 1_o
. . 1_o

These DT N
included VBD N
sex NN N
, , N
pain NN N
frequency NN N
, , N
smoking NN N
, , N
disease NN N
duration NN N
, , N
and CC N
acid JJ N
secretion NN N
. . N

Relation NN N
of IN N
improvement NN N
in IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
with IN N
atorvastatin NN 1_i
to TO N
reductions NNS N
in IN N
hospitalizations NNS N
for IN N
heart NN N
failure NN N
( ( N
from IN N
the DT N
Treating NNP 1_p
to TO 1_p
New NNP 1_p
Targets NNP 1_p
[ NNP 1_p
TNT NNP 1_p
] NNP 1_p
study NN 1_p
) ) 1_p
. . N

Impaired NNP N
kidney NN N
function NN N
often RB N
accompanies VBZ N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
and CC N
is VBZ N
associated VBN N
with IN N
a DT N
worse JJR N
prognosis NN N
. . N

This DT N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
Treating NNP 1_p
to TO 1_p
New NNP 1_p
Targets NNP 1_p
( ( 1_p
TNT NNP 1_p
) ) 1_p
trial NN 1_p
examined VBD N
whether IN N
the DT N
observed JJ N
decrease NN N
in IN N
HF NNP N
hospitalizations NNS N
with IN N
high- JJ N
compared VBN N
to TO N
low-dose JJ N
atorvastatin NN 1_i
could MD N
be VB N
related VBN N
to TO N
improvements NNS N
in IN N
kidney NN N
function NN N
. . N

Of IN N
10,001 CD 1_p
TNT NNP 1_p
participants NNS 1_p
, , 1_p
9,376 CD 1_p
had VBD 1_p
estimated VBN 1_p
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
( ( 1_o
eGFR NN 1_o
) ) 1_o
measurements NNS 1_p
at IN 1_p
baseline NN 1_p
and CC 1_p
1 CD 1_p
year NN 1_p
and CC 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
this DT 1_p
analysis NN 1_p
. . 1_p

The DT N
association NN N
of IN N
change NN N
in IN N
year-1 JJ N
eGFR NN N
and CC N
subsequent JJ N
HF NNP N
hospitalization NN N
was VBD N
examined VBN N
using VBG N
Cox NNP N
regression NN N
models NNS N
. . N

In IN N
total JJ N
218 CD N
participants NNS N
developed VBD N
subsequent JJ N
HF NNP N
hospitalization NN N
. . N

Little JJ N
change NN N
in IN N
eGFR NN 1_o
occurred VBD N
over IN N
1 CD N
year NN N
in IN N
the DT N
atorvastatin JJ N
10-mg JJ N
group NN N
, , N
whereas IN N
eGFR NN 1_o
improved VBN N
in IN N
the DT N
80-mg JJ N
group NN N
by IN N
1.48 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
1.29 CD N
to TO N
1.67 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Subsequent JJ N
HF NNP N
was VBD N
preceded VBN N
by IN N
a DT N
decrease NN N
in IN N
eGFR NN 1_o
over IN N
1 CD N
year NN N
compared VBN N
to TO N
modest JJ N
improvement NN N
in IN N
those DT N
without IN N
subsequent JJ N
HF NNP N
( ( N
-0.09 NNP N
± VBZ N
7.89 CD N
vs NN N
0.81 CD N
± NN N
6.90 CD N
ml/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
= NNP N
0.0015 CD N
) ) N
. . N

After IN N
adjusting VBG N
for IN 1_o
baseline NN 1_o
eGFR NN 1_o
, , N
each DT N
5-ml/min/1.73 JJ N
m NN N
( ( N
2 CD N
) ) N
increase NN N
in IN 1_o
eGFR NN 1_o
at IN N
1 CD N
year NN N
was VBD N
associated VBN N
with IN N
a DT N
lower JJR N
risk NN N
of IN N
subsequent JJ N
HF NNP N
hospitalization NN N
( ( N
hazard JJ N
ratio NN N
0.85 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.77 CD N
to TO N
0.94 CD N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
. . N

This DT N
relation NN N
was VBD N
independent JJ N
of IN N
treatment NN N
effect NN N
or CC N
change NN N
in IN 1_o
low-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
level NN N
at IN N
1 CD N
year NN N
. . N

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
high- JJ N
compared VBN N
to TO N
low-dose JJ N
atorvastatin NN N
was VBD N
associated VBN N
with IN N
improvement NN N
in IN 1_o
eGFR NN 1_o
at IN N
1 CD N
year NN N
, , N
which WDT N
was VBD N
related VBN N
to TO N
a DT N
decrease NN N
in IN 1_o
subsequent JJ 1_o
HF NNP 1_o
hospitalization NN 1_o
. . N

This DT N
suggests VBZ N
that WDT N
improvement NN N
in IN 1_o
kidney NN 1_o
function NN 1_o
may MD N
be VB N
related VBN N
to TO N
the DT N
beneficial JJ N
effect NN N
of IN N
high-dose JJ N
atorvastatin NN N
on IN N
HF NNP N
hospitalization NN N
. . N

Moclobemide NNP 1_i
, , 1_i
imipramine NN 1_i
and CC 1_i
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
major JJ 1_p
depression NN 1_o
. . 1_o

Moclobemide NNP 1_i
was VBD N
compared VBN N
with IN N
imipramine NN 1_i
and CC N
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
major JJ N
depressive JJ N
episodes NNS N
in IN N
75 CD 1_p
outpatients NNS 1_p
. . 1_p

The DT N
dosage NN N
of IN N
moclobemide NN 1_i
( ( 1_i
25 CD 1_i
patients NNS 1_i
) ) 1_i
was VBD 1_i
300 CD 1_i
mg JJ 1_i
daily RB 1_i
for IN 1_i
the DT 1_i
first JJ 1_i
5 CD 1_i
days NNS 1_i
, , 1_i
after IN 1_i
which WDT 1_i
it PRP 1_i
could MD 1_i
be VB 1_i
increased VBN 1_i
to TO 1_i
600 CD 1_i
mg. NNS 1_i
Imipramine NNP 1_i
( ( 1_i
25 CD 1_i
patients NNS 1_i
) ) 1_i
was VBD 1_i
given VBN 1_i
in IN 1_i
a DT 1_i
dosage NN 1_i
starting VBG 1_i
with IN 1_i
33 CD 1_i
mg NNS 1_i
and CC 1_i
gradually RB 1_i
increased VBD 1_i
to TO 1_i
100 CD 1_i
mg/day NN 1_i
in IN 1_i
the DT 1_i
first JJ 1_i
5 CD 1_i
days NNS 1_i
, , N
after IN N
which WDT N
it PRP N
could MD N
be VB N
further RB N
increased VBN N
; : N
25 CD 1_p
patients NNS 1_p
received VBD N
placebo NN 1_i
. . 1_i

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
as IN N
measured VBN N
by IN N
the DT N
Hamilton NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
for IN 1_o
Depression NNP 1_o
, , N
the DT N
overall JJ 1_o
assessment NN 1_o
of IN 1_o
efficacy NN 1_o
and CC N
the DT N
Zung NNP 1_o
Self-rating NNP 1_o
Scale NNP 1_o
, , N
and CC N
clearly RB N
superior JJ N
to TO N
placebo VB N
; : N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
active JJ N
drugs NNS N
. . N

Moclobemide NNP 1_i
was VBD N
better RBR 1_o
tolerated VBN 1_o
than IN N
imipramine NN 1_i
, , N
and CC N
was VBD N
almost RB N
comparable JJ N
to TO N
placebo VB N
in IN N
this DT N
respect NN N
. . N

Comparison NNP N
of IN N
enoxaparin NN 1_i
and CC 1_i
standard JJ 1_i
heparin NN 1_i
in IN N
gynaecologic JJ 1_p
oncologic JJ 1_p
surgery NN 1_p
: : 1_p
a DT N
randomised JJ N
prospective JJ N
double-blind NN N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
haemorrhagic JJ N
complications NNS N
and CC N
efficacy NN N
of IN N
enoxaparin NN 1_i
, , N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMWH NNP N
) ) N
, , N
and CC N
conventional JJ N
standard NN 1_i
heparin NN 1_i
( ( 1_i
SH NNP 1_i
) ) 1_i
in IN N
gynaecological JJ 1_p
oncologic NN 1_p
surgery NN 1_p
. . 1_p

MATERIALS NNP N
METHODS NNP N
A NNP N
double JJ N
blind NN N
, , N
randomised VBD N
trial NN N
was VBD N
performed VBN N
on IN N
102 CD 1_p
consecutive JJ 1_p
women NNS 1_p
undergoing VBG 1_p
gynaecologic JJ 1_p
cancer NN 1_p
surgery NN 1_p
with IN 1_p
pelvic NN 1_p
and CC 1_p
paraaortic JJ 1_p
lymphadenectomy NN 1_p
. . 1_p

The DT N
women NNS N
were VBD N
separated VBN N
into IN N
those DT N
who WP N
were VBD N
given VBN N
2,500 CD 1_i
IU NNP 1_i
enoxaparin NN 1_i
once RB 1_i
daily JJ 1_i
and CC 1_i
SH NNP 1_i
in IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
5,000 CD 1_i
IU NNP 1_i
three CD 1_i
times NNS 1_i
daily RB 1_i
. . 1_i

The DT N
groups NNS N
were VBD N
analysed VBN N
for IN N
intraoperative JJ N
blood NN N
loss NN N
, , N
drainage NN N
, , N
transfusion NN N
requirements NNS N
, , N
perioperative JJ N
haemoglobin NN N
decrease NN N
, , N
wound NN N
haematoma NN N
, , N
and CC N
clinical JJ N
deep NN N
venous JJ N
thrombosis NN N
. . N

RESULTS VB N
The DT 1_p
two CD 1_p
groups NNS 1_p
were VBD 1_p
well RB 1_p
matched VBN 1_p
for IN 1_p
age NN 1_p
, , 1_p
weight NN 1_p
, , 1_p
and CC 1_p
other JJ 1_p
factors NNS 1_p
, , N
which WDT N
could MD N
predispose VB N
to TO N
the DT N
development NN 1_o
of IN 1_o
deep JJ 1_o
venous JJ 1_o
thrombosis NN 1_o
( ( 1_o
DVT NNP 1_o
) ) 1_o
and CC 1_o
haemorrhage NN 1_o
. . 1_o

No DT N
patient NN N
developed VBD N
clinical JJ 1_o
significant JJ 1_o
DVT NNP 1_o
, , 1_o
wound NN 1_o
haematoma NN 1_o
or CC 1_o
intra-abdominal JJ 1_o
bleeding NN 1_o
. . 1_o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
bleeding VBG 1_o
complications NNS 1_o
between IN N
the DT N
two CD N
regimens NNS N
. . N

The DT N
antiFXa JJ 1_o
level NN 1_o
in IN N
the DT N
plasma NN N
was VBD N
correlated VBN N
strongly RB N
with IN N
patient JJ N
weight NN N
. . N

CONCLUSIONS VB N
A NNP N
dose NN N
of IN N
2,500 CD N
IU NNP N
enoxaparin/day NN 1_i
does VBZ N
not RB N
cause VB N
more RBR N
bleeding JJ N
complications NNS N
than IN N
SH NNP N
5,000 CD N
IU NNP N
three CD N
times NNS N
daily RB N
when WRB N
used VBN N
to TO N
prevent VB N
thrombosis NN N
. . N

However RB N
, , N
the DT N
dose NN N
of IN N
enoxaparin NN N
must MD N
be VB N
adjusted VBN N
to TO N
the DT N
patient NN N
's POS N
weight NN N
. . N

The DT N
management NN N
of IN N
dermoid JJ 1_p
cysts NNS 1_p
-- : 1_p
a DT 1_p
comparative JJ N
study NN N
of IN N
laparoscopy NN 1_i
and CC N
laparotomy NN 1_i
. . 1_i

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
compare VB N
laparoscopy NN 1_i
with IN N
laparotomy NN 1_i
for IN N
the DT N
removal NN N
of IN N
ovarian JJ 1_p
dermoid NN 1_p
cysts NNS 1_p
. . 1_p

Thirty-eight JJ 1_p
women NNS 1_p
with IN 1_p
benign JJ 1_p
ovarian JJ 1_p
dermoid NN 1_p
cyst NN 1_p
were VBD N
allocated VBN N
for IN N
either DT N
laparoscopy NN 1_i
( ( N
18 CD N
patients NNS N
) ) N
or CC N
laparotomy NN 1_i
( ( N
20 CD N
patients NNS N
) ) N
. . N

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
for IN N
operative JJ N
and CC N
hospitalization NN N
times NNS N
and CC N
postoperative JJ N
course NN N
. . N

Operating NN 1_o
time NN 1_o
was VBD N
longer RB N
( ( N
93.6 CD N
+/- JJ N
23.8 CD N
min NN N
) ) N
and CC N
hospitalization NN 1_o
time NN 1_o
significantly RB N
shorter JJR N
( ( N
22.4 CD N
+/- JJ N
6.6 CD N
h NN N
) ) N
in IN N
the DT N
laparoscopy NN N
group NN N
. . N

No DT N
complications NNS 1_o
were VBD N
reported VBN N
in IN N
either DT N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
operative JJ 1_i
laparoscopy NN 1_i
is VBZ N
a DT N
safe JJ 1_o
procedure NN N
for IN N
the DT N
removal NN N
of IN N
dermoid JJ 1_p
ovarian JJ 1_p
cysts NNS 1_p
and CC N
is VBZ N
as RB N
effective JJ 1_o
as IN N
laparotomy NN 1_i
. . 1_i

Green JJ 1_i
banana-supplemented JJ 1_i
diet NN 1_i
in IN N
the DT N
home NN N
management NN N
of IN N
acute NN 1_o
and CC 1_o
prolonged JJ 1_o
diarrhoea NN 1_o
in IN 1_o
children NNS 1_o
: : 1_o
a DT 1_p
community-based JJ 1_p
trial NN 1_p
in IN 1_p
rural JJ 1_p
Bangladesh NNP 1_p
. . 1_p

SUMMARY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
green JJ 1_i
banana NN 1_i
in IN N
the DT N
home NN N
management NN N
of IN N
acute NN 1_o
( ( 1_p
< JJ 1_p
7 CD 1_p
days NNS 1_p
) ) 1_p
or CC 1_p
prolonged VBN 1_o
( ( 1_p
≥ JJ 1_p
7 CD 1_p
days NNS 1_o
) ) 1_o
diarrhoea VBP 1_o
at IN N
the DT N
community NN N
level NN N
. . N

METHODS NNP N
A NNP N
cluster NN N
randomized VBD N
field NN N
trial NN N
was VBD N
conducted VBN N
among IN 1_p
2968 CD 1_p
Bangladeshi NNP 1_p
rural JJ 1_p
children NNS 1_p
6-36 JJ 1_p
months NNS 1_p
old JJ 1_p
. . N

Wards NNP N
( ( N
villages NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
a DT 1_i
standard JJ 1_i
care NN 1_i
group NN 1_i
or CC 1_i
a DT 1_i
standard JJ 1_i
care NN 1_i
plus CC 1_i
green JJ 1_i
banana NN 1_i
group NN 1_i
where WRB N
mothers NNS N
were VBD N
instructed VBN N
to TO N
add VB 1_i
cooked JJ 1_i
green JJ 1_i
banana NN 1_i
to TO N
the DT N
diets NNS N
of IN 1_p
diarrhoeal JJ 1_p
children NNS 1_p
. . N

Through IN N
a DT N
village-based JJ N
surveillance NN N
system NN 1_o
, , 1_o
diarrhoeal JJ 1_o
morbidity NN 1_o
data NNS 1_o
( ( 1_o
severity NN 1_o
, , 1_o
duration NN 1_o
, , 1_o
compliance NN 1_o
) ) 1_o
were VBD N
collected VBN N
for IN N
14 CD N
days NNS N
. . N

Treatment JJ N
effects NNS N
were VBD N
determined VBN N
by IN N
analysing VBG 1_o
cumulative JJ 1_o
probability NN 1_o
of IN 1_o
cure NN 1_o
by IN N
testing VBG 1_o
Cox NNP 1_o
proportional JJ 1_o
hazards NNS 1_o
models NNS 1_o
and CC 1_o
relative JJ 1_o
risk NN 1_o
( ( N
RR NNP N
) ) N
. . N

RESULTS VB N
The DT 1_o
cumulative JJ 1_o
probability NN 1_o
of IN 1_o
cure NN 1_o
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
different JJ N
in IN N
children NNS N
receiving VBG N
GB NNP N
for IN N
both DT 1_o
acute JJ 1_o
[ NNP N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
= VBZ N
0.63 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.56-0.67 NN N
) ) N
] NN N
and CC 1_o
prolonged VBD 1_o
diarrhoea NNS 1_o
[ NNP N
HR NNP N
= VBZ N
0.38 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.26-0.59 NN N
) ) N
] NN N
. . N

The DT 1_o
recovery NN 1_o
rates NNS 1_o
of IN 1_o
children NNS 1_o
with IN 1_o
acute JJ 1_o
diarrhoea NN 1_o
receiving VBG N
GB NNP N
( ( N
vs. FW N
control NN N
) ) N
were VBD N
significantly RB N
more JJR N
by IN N
day NN N
3 CD N
: : N
79.9 CD N
% NN N
vs NN N
. . N

53.3 CD N
% NN N
[ NN N
( ( N
RR NNP N
) ) N
= VBD N
0.47 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.41-0.55 JJ N
] NN N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
day NN N
7 CD N
: : N
96.6 CD N
% NN N
vs NN N
. . N

89.1 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.32 CD N
; : N
0.22-0.46 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Children NNP N
with IN N
prolonged JJ N
diarrhoea NN N
receiving VBG 1_i
green JJ 1_i
banana NN 1_i
had VBD N
significantly RB N
higher JJR 1_o
recovery NN 1_o
rates NNS 1_o
by IN N
day NN N
10 CD N
: : N
79.8 CD N
% NN N
vs NN N
. . N

51.9 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.42 CD N
; : N
0.23-0.73 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
day NN N
14 CD N
: : N
93.6 CD N
% NN N
vs NN N
. . N

67.2 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.22 CD N
; : N
0.08-0.54 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
A DT 1_i
green JJ 1_i
banana-supplemented JJ 1_i
diet NN 1_o
hastened VBD 1_o
recovery NN 1_o
of IN 1_p
acute NN 1_p
and CC 1_p
prolonged VBD 1_p
childhood NN 1_p
diarrhoea NN 1_p
managed VBD N
at IN N
home NN N
in IN N
rural JJ N
Bangladesh NNP N
. . N

DTkid NN N
: : N
interactive JJ N
simulation NN N
software NN N
for IN N
training VBG N
tutors NNS 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Discrete-trial JJ 1_i
training NN 1_i
( ( N
DTT NNP N
) ) N
relies VBZ N
critically RB N
on IN N
implementation NN N
by IN N
trained JJ 1_p
tutors NNS 1_p
. . 1_p

We PRP N
report VBP N
three CD N
experiments NNS N
carried VBD N
out RP N
in IN N
the DT N
development NN N
of IN N
" NNP N
DTkid NNP N
" NNP N
-- : N
interactive JJ N
computer NN N
simulation NN N
software NN N
that WDT N
presents VBZ N
" JJ N
SIMon NNP N
" NNP N
, , N
a DT N
realistic JJ N
virtual JJ N
child NN N
with IN N
whom WP N
novice JJ N
tutors NNS N
can MD N
learn VB N
and CC N
practise VB N
DTT NNP N
techniques NNS N
. . N

Experiments NNS N
1 CD N
and CC N
2 CD N
exposed JJ N
groups NNS N
of IN N
participants NNS N
either DT N
to TO N
DTkid NNP 1_i
training NN 1_i
or CC 1_i
to TO 1_i
a DT 1_i
control NN 1_i
task NN 1_i
. . 1_i

Participants NNS N
in IN N
the DT N
former JJ N
groups NNS N
demonstrated VBD N
significantly RB N
greater JJR N
procedural JJ 1_o
and CC 1_o
declarative JJ 1_o
knowledge NN 1_o
of IN 1_o
DTT NNP 1_o
. . 1_o

Experiment NNP N
3 CD N
confirmed VBD N
this DT N
finding NN N
, , N
further JJ N
demonstrating NN N
that IN N
observation NN N
of IN N
DTkid NNP 1_i
training NN 1_i
trials NNS 1_i
alone RB N
was VBD N
sufficient JJ N
to TO N
enhance VB N
participants NNS N
' POS N
declarative NN 1_o
and CC 1_o
procedural JJ 1_o
knowledge NN 1_o
of IN N
DTT NNP N
. . N

Results NNP N
indicate VBP N
that IN N
DTkid NNP N
offers VBZ N
the DT N
potential NN N
for IN N
an DT N
effective JJ N
means NNS N
of IN N
teaching VBG N
DTT NNP N
skills NNS N
to TO N
novice JJ 1_p
tutors NNS 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Methylphenidate NNP 1_i
and/or VBZ N
a DT N
nursing NN 1_i
telephone NN 1_i
intervention NN 1_i
for IN N
fatigue NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
cancer NN 1_p
: : 1_p
a DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
, , N
phase JJ N
II NNP N
trial NN N
. . N

PURPOSE VB N
Cancer-related-fatigue NNP 1_o
( ( 1_o
CRF NNP 1_o
) ) 1_o
is VBZ N
common JJ N
in IN N
advanced JJ 1_p
cancer NN 1_p
. . 1_p

The DT N
primary JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
methylphenidate NN 1_i
( ( 1_i
MP NNP 1_i
) ) 1_i
with IN N
those DT N
of IN N
placebo NN 1_i
( ( N
PL NNP N
) ) N
on IN N
CRF NNP N
as IN N
measured VBN N
using VBG N
the DT N
Functional NNP 1_o
Assessment NNP 1_o
of IN 1_o
Chronic NNP 1_o
Illness NNP 1_o
Therapy-Fatigue NNP 1_o
( ( 1_o
FACIT-F NNP 1_o
) ) 1_o
fatigue NN N
subscale NN N
. . N

The DT N
effect NN N
of IN N
a DT N
combined JJ N
intervention NN N
including VBG N
MP NNP N
plus CC N
a DT N
nursing NN 1_i
telephone NN 1_i
intervention NN 1_i
( ( 1_i
NTI NNP 1_i
) ) 1_i
was VBD N
also RB N
assessed VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP 1_p
with IN 1_p
advanced JJ 1_p
cancer NN 1_p
with IN 1_p
a DT 1_p
fatigue NN 1_p
score NN 1_p
of IN 1_p
≥ $ 1_p
4 CD 1_p
out IN 1_p
of IN 1_p
10 CD 1_p
on IN 1_p
the DT 1_p
Edmonton NNP 1_p
Symptom NNP 1_p
Assessment NNP 1_p
Scale NNP 1_p
( ( 1_p
ESAS NNP 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
four CD N
groups NNS N
: : N
MP+NTI NNP N
, , N
PL+NTI NNP N
, , N
MP NNP N
+ NNP 1_i
control NN 1_i
telephone NN 1_i
intervention NN 1_i
( ( N
CTI NNP N
) ) N
, , N
and CC N
PL+CTI NNP 1_i
. . 1_i

Methylphenidate NNP 1_i
dose NN N
was VBD N
5 CD N
mg NN N
every DT N
2 CD N
hours NNS N
as IN N
needed VBN N
up IN N
to TO N
20 CD N
mg NNS N
per IN N
day NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT 1_o
median JJ 1_o
difference NN 1_o
in IN 1_o
FACIT-F NNP 1_o
fatigue NN 1_o
at IN N
day NN N
15 CD N
. . N

Secondary JJ N
outcomes NNS N
included VBD 1_o
anxiety NN 1_o
, , 1_o
depression NN 1_o
, , 1_o
and CC 1_o
sleep RB 1_o
. . N

RESULTS VB 1_p
One CD 1_p
hundred JJ 1_p
forty-one JJ 1_p
patients NNS 1_p
were VBD 1_p
evaluable JJ 1_o
. . 1_o

Median JJ 1_o
FACIT-F NNP 1_o
fatigue NN 1_o
scores NNS 1_o
improved VBN N
from IN N
baseline NN N
to TO N
day NN N
15 CD N
in IN N
all DT N
groups NNS N
: : N
MP+NTI NNP N
( ( N
median JJ N
score NN N
, , N
4.5 CD N
; : N
P NNP N
= NNP N
.005 NNP N
) ) N
, , N
PL+NTI NNP N
( ( N
median JJ N
score NN N
, , N
8.0 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
MP+CTI NNP N
( ( N
median JJ N
score NN N
, , N
7.0 CD N
; : N
P NNP N
= NNP N
.004 NNP N
) ) N
, , N
and CC N
PL+CTI NNP N
( ( N
median JJ N
score NN N
, , N
5.0 CD N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
median JJ N
improvement NN N
in IN 1_o
FACIT-F NNP 1_o
fatigue NN 1_o
between IN N
the DT N
MP NNP N
and CC N
PL NNP N
groups NNS N
( ( N
5.5 CD N
v NN N
6.0 CD N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.69 NNP N
) ) N
and CC N
among IN N
all DT N
four CD N
groups NNS N
( ( N
P NNP N
= NNP N
.16 NNP 1_o
) ) 1_o
. . 1_o

Fatigue NNP 1_o
( ( N
P NNP N
< NNP N
.001 NNP 1_o
) ) 1_o
, , 1_o
nausea NN 1_o
( ( N
P NNP N
= NNP N
.01 NNP 1_o
) ) 1_o
, , 1_o
depression NN 1_o
( ( N
P NNP N
= NNP N
.02 NNP 1_o
) ) 1_o
, , 1_o
anxiety NN 1_o
( ( N
P NNP N
= NNP N
.01 NNP 1_o
) ) 1_o
, , 1_o
drowsiness NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP 1_o
) ) 1_o
, , 1_o
appetite RB 1_o
( ( N
P NNP N
= NNP N
.009 NNP 1_o
) ) 1_o
, , 1_o
sleep JJ 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC 1_o
feeling NN 1_o
of IN 1_o
well-being NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
as IN N
measured VBN N
by IN N
the DT N
ESAS NNP N
, , N
significantly RB N
improved VBN N
in IN N
patients NNS N
who WP N
received VBD N
NTI NNP 1_o
. . 1_o

Grade NNP 1_o
≥ VBD 1_o
3 CD 1_o
adverse JJ 1_o
events NNS 1_o
did VBD N
not RB N
differ VB N
between IN N
MP NNP N
and CC N
PL NNP N
( ( N
40 CD N
of IN N
93 CD N
patients NNS N
v JJ N
29 CD N
of IN N
97 CD N
patients NNS N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.06 NNP N
) ) N
. . N

CONCLUSION NNP N
MP NNP N
and CC N
NTI NNP N
alone RB N
or CC N
combined VBN N
were VBD N
not RB N
superior JJ 1_i
to TO 1_i
placebo VB 1_i
in IN N
improving VBG 1_o
CRF NNP N
. . N

Clinical JJ N
benefits NNS N
of IN N
concurrent JJ N
capecitabine NN 1_i
and CC 1_i
cisplatin NN 1_i
versus NN N
concurrent NN 1_i
cisplatin NN 1_i
and CC 1_i
5-flurouracil JJ 1_i
in IN N
locally RB 1_p
advanced JJ 1_p
squamous JJ 1_p
cell NN 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
. . 1_p

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
concurrent JJ N
capecitabine NN 1_i
and CC 1_i
cisplatin NN 1_i
over IN N
concurrent JJ 1_i
cisplatin NN 1_i
and CC 1_i
5-flurouracil JJ 1_i
( ( 1_i
5-FU JJ 1_i
) ) 1_i
in IN N
locally RB 1_p
advanced JJ 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
. . 1_p

One CD 1_p
hundred CD 1_p
and CC 1_p
fifty-three JJ 1_p
patients NNS 1_p
( ( 1_p
all DT 1_p
of IN 1_p
whom WP 1_p
had VBD 1_p
stage NN 1_p
III NNP 1_p
or CC 1_p
IV NNP 1_p
unresectable JJ 1_p
disease NN 1_p
with IN 1_p
no DT 1_p
distant JJ 1_p
metastases NNS 1_p
and CC 1_p
who WP 1_p
had VBD 1_p
received VBN 1_p
two CD 1_p
cycles NNS 1_p
of IN 1_p
taxol NN 1_i
and CC 1_i
cisplatin NN 1_i
chemotherapy NN 1_i
) ) 1_i
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
concurrent NN 1_i
cisplatin NN 1_i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
and CC N
2 CD N
) ) N
and CC 1_i
5-FU JJ 1_i
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
from IN N
the DT N
first JJ N
day NN N
of IN N
radiotherapy NN N
at IN N
an DT N
interval NN N
of IN N
3 CD N
weeks NNS N
( ( N
Arm NNP N
I PRP N
) ) N
or CC N
cisplatin NN 1_i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
and CC N
2 CD N
) ) N
and CC N
capecitabine NN 1_i
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
two CD N
divided JJ N
doses NNS N
from IN N
day NN N
1-14 CD N
) ) N
from IN N
the DT N
first JJ N
day NN N
of IN N
radiotherapy NN N
at IN N
a DT N
3-week JJ N
interval NN N
( ( N
Arm NNP N
II NNP N
) ) N
. . N

Results CC N
showed VBD N
that IN N
patients NNS N
in IN N
Arm NNP N
II NNP N
had VBD N
a DT N
significantly RB N
better RBR 1_o
rate NN 1_o
of IN 1_o
complete JJ 1_o
response NN 1_o
, , 1_o
fewer JJR 1_o
nodes NNS 1_o
, , 1_o
and CC 1_o
better JJR 1_o
overall JJ 1_o
response NN 1_o
compared VBN N
to TO N
those DT N
in IN N
Arm NNP N
I PRP N
. . N

The DT N
two CD N
groups NNS N
had VBD N
a DT N
similar JJ N
3-year JJ 1_o
disease-free JJ 1_o
survival NN 1_o
, , 1_o
progression NN 1_o
free JJ 1_o
survival NN 1_o
, , 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
, , N
i.e NN N
. . N

they PRP N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

Variables NNS N
indicating VBG N
the DT N
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

Patients NNS N
in IN N
Arm NNP N
II NNP N
had VBD N
a DT N
significantly RB N
higher JJR N
quality NN 1_o
of IN 1_o
life NN 1_o
compared VBN N
to TO N
those DT N
in IN N
Arm NNP N
I PRP N
. . N

The DT N
two CD N
groups NNS N
had VBD N
similar JJ N
treatment-related JJ N
acute NN 1_o
and CC 1_o
late JJ 1_o
toxicity NN 1_o
, , N
i.e NN N
. . N

they PRP N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

These DT N
results NNS N
have VBP N
thoroughly RB N
substantiated VBN N
the DT N
contention NN N
that WDT N
concurrent JJ N
chemoradiation NN N
with IN N
capecitabine NN 1_i
and CC 1_i
cisplatin NN 1_i
may MD N
be VB N
regarded VBN N
as IN N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
the DT N
patients NNS 1_p
with IN 1_p
locally RB 1_p
advanced VBN 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
. . 1_p

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
guided JJ 1_i
self-help NN 1_i
for IN N
improving VBG N
the DT N
experience NN 1_o
of IN 1_o
caring VBG 1_o
for IN 1_o
carers NNS 1_o
of IN 1_p
clients NNS 1_p
with IN 1_p
depression NN 1_p
. . 1_p

AIM NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive JJ 1_i
behaviour NN 1_i
therapy NN 1_i
guided VBD 1_i
self-help JJ 1_i
manual JJ 1_i
for IN N
enhancing VBG N
the DT N
experience NN 1_o
of IN 1_o
caregiving NN 1_o
of IN 1_o
family NN 1_o
carers NNS 1_o
of IN 1_p
individuals NNS 1_p
with IN 1_p
depression NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
prevalence NN N
of IN N
depression NN N
is VBZ N
increasing VBG N
markedly RB N
in IN N
Thailand NNP 1_p
. . 1_p

While IN N
primary JJ 1_p
carers NNS 1_p
give VBP N
most JJS N
of IN N
the DT N
support NN N
for IN N
individuals NNS N
with IN N
depression NN N
, , N
they PRP N
receive VBP N
little JJ N
support NN N
from IN N
mental JJ N
health NN N
services NNS N
in IN N
this DT N
critical JJ N
role NN N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHOD NNP N
Carers NNPS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
guided VBN 1_i
self-help NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
27 CD 1_p
) ) 1_p
, , 1_p
while IN 1_p
the DT 1_p
control NN 1_i
group NN 1_i
received VBD 1_i
standard JJ 1_i
information NN 1_i
and CC 1_i
support NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
27 CD 1_p
) ) 1_p
. . 1_p

Both DT N
groups NNS N
also RB N
received VBD N
a DT N
short JJ 1_i
weekly JJ 1_i
telephone NN 1_i
call NN 1_i
. . 1_i

Participants NNS N
were VBD N
assessed VBN N
at IN N
three CD N
time NN N
points NNS N
; : N
the DT N
outcome NN N
measure NN N
was VBD N
the DT N
Experience NN N
of IN N
Caregiving NNP 1_i
Inventory NNP 1_i
. . 1_i

A NNP N
doubly RB N
multivariate JJ N
analysis NN N
of IN N
variance NN N
( ( N
anova JJ N
) ) N
procedure NN N
, , N
including VBG N
between-group JJ N
and CC N
within-group JJ N
factors NNS N
, , N
was VBD N
implemented VBN N
. . N

Fieldwork NNP N
was VBD N
from IN N
October NNP N
2007-May JJ N
2008 CD N
. . N

RESULTS VB N
Fifty-four JJ 1_p
carers NNS 1_p
completed VBD N
the DT N
study NN N
and CC N
intent-to-treat JJ N
analyses NNS N
were VBD N
undertaken VBN N
. . N

The DT N
findings NNS N
showed VBD N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
total JJ 1_o
negative JJ 1_o
experience NN 1_o
of IN 1_o
caring NN 1_o
, , N
from IN N
baseline NN N
to TO N
post-treatment NN N
, , N
in IN N
the DT N
intervention NN N
group NN N
recipients NNS N
of IN N
the DT N
manual JJ N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
treatment NN N
effects NNS N
were VBD N
maintained VBN N
at IN N
one-month JJ N
follow-up NN N
. . N

Similarly RB N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
total JJ 1_o
positive JJ 1_o
experience NN 1_o
of IN 1_o
caring NN 1_o
occurred VBD N
, , N
from IN N
baseline NN N
to TO N
post-treatment NN N
, , N
in IN N
the DT N
intervention NN N
group NN N
in IN N
contrast NN N
with IN N
the DT N
control NN N
group NN N
and CC N
these DT N
outcomes NNS N
were VBD N
sustained VBN N
at IN N
one-month JJ N
follow-up NN N
. . N

CONCLUSION NNP N
Guided VBD 1_i
self-help NN 1_i
strengthen NN N
carers NNS 1_p
' POS 1_p
positive JJ N
and CC N
reduces VBZ N
their PRP$ N
negative JJ N
, , N
experience NN 1_o
of IN 1_o
caring NN 1_o
. . 1_o

The DT N
study NN N
contributes VBZ N
to TO N
the DT N
limited JJ N
evidence NN N
base NN N
about IN N
this DT N
approach NN N
in IN N
a DT N
developing JJ N
country NN 1_p
such JJ 1_p
as IN 1_p
Thailand NNP 1_p
. . 1_p

Effect NN 1_o
of IN N
antacids NNS 1_i
on IN 1_p
intragastric JJ 1_o
pH NN 1_o
in IN 1_p
healthy JJ 1_p
subjects NNS 1_p
and CC 1_p
duodenal JJ 1_p
ulcer NN 1_p
patients NNS 1_p
. . 1_p

Influence NN N
of IN N
the DT N
size NN N
of IN N
the DT N
antacid NN 1_i
dose NN 1_i
and CC N
of IN N
anticholinergics NNS 1_i
. . 1_i

Different JJ 1_i
doses NNS 1_i
of IN 1_i
two CD 1_i
liquid JJ 1_i
antacids NNS 1_i
, , 1_i
alone RB 1_i
and CC 1_i
combined VBN 1_i
with IN 1_i
an DT 1_i
anticholinergic JJ 1_i
agent NN 1_i
, , N
were VBD N
studied VBN N
with IN N
respect NN N
to TO N
the DT N
duration NN 1_o
of IN 1_o
antacid JJ 1_o
action NN 1_o
. . 1_o

The DT N
studies NNS N
were VBD N
performed VBN N
in IN 1_p
healthy JJ 1_p
subjects NNS 1_p
with IN 1_p
MAO NNP 1_p
less JJR 1_p
than IN 1_p
30 CD 1_p
mmol/h NN 1_p
and CC 1_p
in IN 1_p
duodenal JJ 1_p
ulcer NN 1_p
patients NNS 1_p
with IN 1_p
MAO NNP 1_p
greater JJR 1_p
than IN 1_p
35 CD 1_p
mmol/h NN 1_p
. . 1_p

Gastric NNP 1_o
pH NN 1_o
was VBD 1_o
recorded VBN 1_o
using VBG 1_o
radiotelemetric JJ 1_o
technique NN 1_o
( ( 1_o
Heidelberg NNP 1_o
capsule NN 1_o
) ) 1_o
. . 1_o

In IN N
the DT N
healthy JJ 1_p
subjects NNS 1_p
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
duration NN 1_o
of IN 1_o
action NN 1_o
with IN N
the DT N
different JJ N
doses NNS N
but CC N
in IN N
duodenal JJ 1_p
ulcer NN 1_p
patients NNS 1_p
a DT N
tenfold JJ N
increase NN N
of IN N
the DT N
antacid NN 1_i
dose NN N
resulted VBD N
in IN N
a DT N
doubling NN N
of IN N
the DT N
duration NN 1_o
of IN 1_o
action NN 1_o
. . 1_o

Combined VBN N
treatment NN N
with IN N
an DT N
anticholinergic NN 1_i
and CC N
antacids NNS 1_i
enhanced VBD N
the DT N
antacid NN 1_o
effects NNS 1_o
in IN N
both DT N
groups NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
an DT N
antacid NN N
dose NN N
should MD N
be VB N
so RB N
great JJ N
that IN N
it PRP N
binds VBZ N
secreted JJ N
acid NN N
before IN N
the DT N
dose NN N
leaves VBZ N
the DT N
stomach NN N
. . N

Further JJ N
increase NN N
of IN N
the DT N
dose NN N
will MD N
not RB N
increase VB N
the DT N
duration NN 1_o
. . 1_o

Concomitant NNP N
use NN N
of IN N
an DT N
anticholinergic JJ 1_i
agent NN 1_i
increases VBZ N
the DT N
duration NN 1_o
of IN 1_o
antacid JJ 1_o
action NN 1_o
. . 1_o

Dexamethasone NNP 1_i
versus NN 1_i
prednisone NN 1_i
and CC N
daily JJ N
oral JJ N
versus NN N
weekly RB N
intravenous JJ 1_i
mercaptopurine NN 1_i
for IN N
patients NNS 1_p
with IN 1_p
standard-risk JJ 1_p
acute JJ 1_p
lymphoblastic JJ 1_p
leukemia NN 1_p
: : 1_p
a DT N
report NN N
from IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Group NNP N
. . N

Conventional NNP 1_i
therapy NN 1_i
for IN N
childhood NN 1_p
acute NN 1_p
lymphoblastic JJ 1_p
leukemia NN 1_p
( ( 1_p
ALL DT 1_p
) ) 1_p
includes VBZ N
prednisone NN 1_i
and CC 1_i
oral JJ 1_i
6-mercaptopurine JJ 1_i
. . 1_i

Prior JJ N
observations NNS N
suggested VBD N
potential JJ N
advantages NNS N
for IN N
dexamethasone NN 1_i
over IN 1_i
prednisone NN 1_i
and CC 1_i
for IN 1_i
intravenous JJ 1_i
( ( 1_i
IV NNP 1_i
) ) 1_i
over IN 1_i
oral JJ 1_i
6-mercaptopurine CD 1_i
, , N
which WDT N
remain VBP N
to TO N
be VB N
validated VBN N
. . N

We PRP N
report VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
more JJR 1_p
than IN 1_p
1000 CD 1_p
subjects NNS 1_p
that WDT N
examined VBD N
the DT N
efficacy NN 1_o
of IN N
dexamethasone NN 1_i
and CC 1_i
IV NNP 1_i
6-mercaptopurine JJ 1_i
. . 1_i

Children NNP 1_p
with IN 1_p
National NNP 1_p
Cancer NNP 1_p
Institute NNP 1_p
standard-risk NN 1_p
ALL NNP 1_p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
2 CD N
x NN N
2 CD N
factorial JJ N
design NN N
to TO N
receive VB N
dexamethasone NN 1_i
( ( N
6 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
for IN N
28 CD N
days NNS N
in IN N
induction NN N
, , N
plus CC 1_i
taper NN 1_i
, , N
compared VBN N
with IN N
prednisone NN 1_i
( ( N
40 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
. . N

The DT N
second JJ N
randomized JJ N
assignment NN N
was VBD N
for IN N
daily JJ N
oral JJ N
or CC N
weekly JJ N
IV NNP 1_i
6-mercaptopurine NN 1_i
during IN N
consolidation NN N
. . N

During IN N
maintenance NN N
, , N
5 CD N
days NNS N
of IN N
the DT N
randomized JJ N
steroid NN N
was VBD N
given VBN N
monthly RB N
, , N
at IN N
the DT N
same JJ N
dose NN N
, , N
and CC N
all DT N
patients NNS N
received VBD N
daily JJ N
oral JJ 1_i
6-mercaptopurine JJ 1_i
. . 1_i

During IN N
delayed JJ N
intensification NN N
, , N
all DT N
patients NNS N
received VBD N
a DT N
dexamethasone JJ 1_i
dosage NN N
of IN N
10 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
for IN N
21 CD N
days NNS N
, , N
with IN 1_i
taper NN 1_i
. . 1_i

Intrathecal NNP 1_i
( ( 1_i
IT NNP 1_i
) ) 1_i
methotrexate NN 1_i
was VBD N
the DT N
sole JJ N
central JJ N
nervous JJ N
system-directed JJ N
therapy NN N
. . N

Patients NNS N
randomly RB N
assigned VBN N
to TO N
receive VB N
dexamethasone NN 1_i
had VBD N
a DT N
6-year JJ 1_o
isolated JJ 1_o
central JJ 1_o
nervous JJ 1_o
system-relapse JJ 1_o
rate NN 1_o
of IN N
3.7 CD N
% NN N
+/- JJ N
0.8 CD N
% NN N
, , N
compared VBN N
with IN N
7.1 CD N
% NN N
+/- JJ N
1.1 CD N
% NN N
for IN N
prednisone NN 1_i
( ( N
P NNP N
=.01 NNP N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
trend NN N
toward IN N
fewer JJR N
isolated JJ 1_o
bone NN 1_o
marrow NN 1_o
relapses VBZ 1_o
with IN N
dexamethasone NN 1_i
. . 1_i

The DT N
6-year JJ 1_o
event-free JJ 1_o
survival NN 1_o
( ( 1_o
EFS NNP 1_o
) ) 1_o
was VBD N
85 CD N
% NN N
+/- JJ N
2 CD N
% NN N
for IN N
dexamethasone NN 1_i
and CC N
77 CD N
% NN N
+/- JJ N
2 CD N
% NN N
for IN N
prednisone NN 1_i
( ( N
P NNP N
=.002 NNP N
) ) N
. . N

EFS NNP N
was VBD N
similar JJ N
with IN N
oral JJ 1_i
or CC 1_i
IV JJ 1_i
6-mercaptopurine JJ 1_i
; : 1_i
however RB N
, , N
patients NNS N
assigned VBD N
to TO N
IV NNP 1_i
6-mercaptopurine JJ 1_i
had VBD N
decreased VBN N
survival NN 1_o
after IN 1_o
relapse NN 1_o
. . 1_o

Effects NNS N
of IN N
maternal JJ N
and CC N
dietary JJ 1_i
selenium NN 1_i
( ( 1_i
Se-enriched NNP 1_i
yeast NN 1_i
) ) 1_i
on IN N
the DT N
expression NN 1_p
of IN 1_p
p34 NN 1_p
( ( 1_p
cdc2 NN 1_p
) ) 1_p
and CC 1_p
CyclinB1 NNP 1_p
of IN 1_p
germ JJ 1_p
cells NNS 1_p
of IN 1_p
their PRP$ 1_p
offspring NN 1_p
in IN 1_p
goats NNS 1_p
. . 1_p

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
selenium NN 1_i
on IN N
the DT N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
( ( N
two CD N
components NNS N
of IN N
MPF NNP N
regulating VBG N
cell NN N
cycle NN N
) ) N
of IN N
germ JJ N
cells NNS N
of IN N
their PRP$ N
offspring NN N
in IN N
goats NNS 1_p
. . 1_p

A DT N
herd NN 1_p
of IN 1_p
119 CD 1_p
Taihang NNP 1_p
Black NNP 1_p
Goats NNP 1_p
, , N
which WDT N
was VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
treatments NNS N
, , N
received VBD N
experimental JJ 1_i
diet JJ 1_i
with IN 1_i
different JJ 1_i
Se NNP 1_i
levels NNS 1_i
( ( N
from IN N
Se-enriched NNP N
yeast NN N
) ) N
for IN N
174d CD N
. . N

The DT N
four CD N
treatments NNS N
, , N
fed VBN N
with IN N
a DT N
basal NN N
diet JJ N
, , N
were VBD N
supplemented VBN N
with IN N
0 CD N
( ( N
control NN N
) ) N
, , N
0.5 CD N
, , N
2 CD N
and CC N
4 CD N
mgkg⁻¹ NN N
DM NNP N
Se NNP N
. . N

Testis NN N
samples NNS N
were VBD N
collected VBN N
from IN N
the DT 1_p
young JJ 1_p
male NN 1_p
goats NNS 1_p
of IN N
each DT N
treatment NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
30d CD N
after IN N
weaning VBG N
) ) N
for IN N
mRNA NN N
expression NN N
using VBG N
real-time JJ 1_i
PCR NNP 1_i
and CC N
for IN N
protein JJ N
expression NN N
by IN N
immunohistochemistry NN N
assay NN N
. . N

Results NNP N
show VBP N
that IN N
a DT N
significant JJ N
decrease NN N
was VBD N
observed VBN N
in IN 1_o
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
p34 NN 1_o
( ( 1_o
cdc2 NN 1_o
) ) 1_o
and CC 1_o
CyclinB1 NNP 1_o
in IN 1_o
the DT 1_o
testis NN 1_o
of IN 1_o
Se-deficient NNP 1_o
( ( N
Group NNP N
1 CD N
) ) N
and CC N
Se-excess NNP N
( ( N
Group NNP N
4 CD N
) ) N
animals NNS N
compared VBN N
with IN N
that DT N
in IN N
Groups NNP N
2 CD N
and CC N
3 CD N
. . N

However RB N
, , N
no DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN 1_o
mRNA JJ 1_o
expression NN 1_o
of IN 1_o
p34 NN 1_o
( ( 1_o
cdc2 NN 1_o
) ) 1_o
between IN N
Se-deficient NNP N
( ( N
Group NNP N
1 CD N
) ) N
and CC N
Se-excess NNP N
( ( N
Group NNP N
4 CD N
) ) N
. . N

Also RB N
the DT N
immunohistochemistry NN N
assay NN N
detected VBD N
similar JJ N
results NNS N
of IN 1_o
protein JJ 1_o
expression NN 1_o
of IN N
these DT N
two CD N
genes NNS N
. . N

These DT N
results NNS N
suggest VBP N
, , N
that DT N
maternal JJ N
and CC N
dietary JJ N
Se-induced NNP N
oxidative JJ N
stress NN N
can MD N
modulate VB N
the DT 1_o
mRNA NN 1_o
and CC 1_o
protein JJ 1_o
expression NN 1_o
of IN N
the DT N
cell NN N
cycle NN N
related VBN N
genes NNS N
( ( N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
) ) N
in IN N
the DT N
testis NN N
of IN N
their PRP$ N
offspring NN N
. . N

In IN N
addition NN N
, , N
Se NNP N
deficiency NN N
and CC N
Se NNP N
excess NN N
could MD N
prevent VB N
the DT N
completion NN N
of IN N
the DT N
cell NN N
cycle NN N
. . N

The DT N
effects NNS 1_o
of IN N
improvisational JJ 1_i
music NN 1_i
therapy NN 1_i
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
autistic JJ 1_p
children NNS 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS 1_o
of IN N
improvisational JJ 1_i
music NN 1_i
therapy NN 1_i
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
pre-school JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

It PRP N
was VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
employing VBG N
a DT N
single JJ N
subject NN N
comparison NN N
design NN N
in IN N
two CD N
different JJ N
conditions NNS N
, , N
improvisational JJ 1_i
music NN 1_i
therapy NN 1_i
and CC 1_i
play NN 1_i
sessions NNS 1_i
with IN 1_i
toys NNS 1_i
, , N
and CC N
using VBG N
standardized JJ N
tools NNS N
and CC N
DVD NNP N
analysis NN N
of IN N
sessions NNS N
to TO N
evaluate VB N
behavioral JJ N
changes NNS N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

The DT N
overall JJ 1_o
results NNS 1_o
indicated VBD N
that IN N
improvisational JJ N
music NN N
therapy NN N
was VBD N
more RBR 1_o
effective JJ 1_o
at IN N
facilitating VBG 1_o
joint JJ 1_o
attention NN 1_o
behaviors NNS 1_o
and CC 1_o
non-verbal JJ 1_o
social JJ 1_o
communication NN 1_o
skills NNS 1_o
in IN N
children NNS N
than IN N
play NN N
. . N

Session NN N
analysis NN N
showed VBD N
significantly RB 1_o
more RBR 1_o
and CC 1_o
lengthier JJR 1_o
events NNS 1_o
of IN 1_o
eye NN 1_o
contact NN 1_o
and CC 1_o
turn-taking NN 1_o
in IN N
improvisational JJ 1_i
music NN 1_i
therapy NN 1_i
than IN N
play NN N
sessions NNS N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
further RBR N
. . N

Phonophoresis NNP 1_i
versus NN N
topical JJ N
application NN N
of IN N
ketoprofen NN 1_i
: : 1_i
comparison NN N
between IN N
tissue NN N
and CC N
plasma NN N
levels NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Over IN N
the DT N
last JJ N
few JJ N
decades NNS N
, , N
application NN N
of IN N
ultrasound NN N
has VBZ N
been VBN N
attempted VBN N
to TO N
enhance VB N
transdermal JJ N
transport NN N
of IN N
several JJ N
drugs NNS N
, , N
a DT N
method NN N
referred VBD N
to TO N
as IN N
" JJ N
phonophoresis NN N
. . N

" VB N
The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
the DT N
influence NN N
of IN N
ultrasound NN N
on IN N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
in IN N
humans NNS N
and CC N
to TO N
compare VB N
the DT N
concentrations NNS N
found VBD N
after IN N
continuous JJ N
and CC N
pulsed JJ N
application NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Twenty-six NNP 1_p
patients NNS 1_p
with IN 1_p
knee NN 1_p
disorders NNS 1_p
requiring VBG 1_p
arthroscopy NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

Just NNP N
before IN N
surgery NN N
, , N
phonophoresis NN 1_i
of IN 1_i
a DT 1_i
ketoprofen NN 1_i
gel NN 1_i
( ( N
Fastum NNP N
gel NN N
) ) N
was VBD N
given VBN N
to TO N
group NN N
A NNP N
using VBG N
continuous JJ 1_i
ultrasound NN 1_i
( ( N
1 CD N
MHz NNP N
, , N
1.5 CD N
W/cm2 NNP N
, , N
for IN N
5 CD N
minutes NNS N
) ) N
. . N

Group NNP N
B NNP N
received VBD N
the DT N
same JJ N
treatment NN N
but CC N
with IN N
pulsed JJ 1_i
ultrasound NN 1_i
( ( N
100 CD N
Hz NNP N
, , N
20 CD N
% NN N
duty NN N
cycle NN N
) ) N
. . N

Group NNP N
C NNP N
received VBD N
5 CD N
minutes NNS N
of IN N
sham NN 1_i
ultrasound NN 1_i
with IN 1_i
the DT 1_i
ketoprofen NN 1_i
gel NN 1_i
. . 1_i

The DT N
ultrasound JJ N
head NN N
was VBD N
moved VBN N
over IN N
a DT N
10-cm2 JJ N
area NN N
using VBG N
small JJ N
, , N
continuous JJ N
, , N
circular JJ N
movements NNS N
. . N

Biopsies NNS N
of IN N
adipose JJ N
tissue NN N
and CC N
synovial JJ N
tissue NN N
were VBD N
taken VBN N
during IN N
surgery NN N
to TO N
evaluate VB 1_o
the DT 1_o
local JJ 1_o
penetration NN 1_o
of IN 1_o
the DT 1_o
drug NN 1_o
. . 1_o

Blood NN N
samples NNS N
also RB N
were VBD N
collected VBN N
to TO N
determine VB 1_o
whether IN 1_o
ketoprofen NN 1_o
entered VBD 1_o
the DT 1_o
systemic JJ 1_o
circulation NN 1_o
. . 1_o

RESULTS VB N
The DT N
concentration NN 1_o
of IN 1_o
ketoprofen NN 1_o
in IN N
plasma NN N
was VBD N
negligible JJ N
in IN N
all DT N
3 CD N
groups NNS N
. . N

The DT N
concentration NN 1_o
of IN 1_o
ketoprofen NN 1_o
in IN N
synovial JJ N
tissue NN N
differed VBD N
from IN N
that IN N
in IN N
fat JJ N
tissue NN N
. . N

A DT N
difference NN N
in IN N
concentration NN 1_o
of IN 1_o
ketoprofen NN 1_o
in IN N
synovial JJ N
tissue NN N
was VBD N
found VBN N
between IN N
group NN N
C NNP N
and CC N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

The DT N
concentration NN 1_o
of IN 1_o
ketoprofen NN 1_o
in IN 1_o
fat JJ 1_o
tissue NN 1_o
and CC 1_o
synovial JJ 1_o
tissue NN 1_o
was VBD N
consistently RB N
higher JJR N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

DISCUSSION NNP N
AND CC N
CONCLUSION NNP N
This DT N
study NN N
confirms VBZ N
that IN N
phonophoresis NN N
of IN N
ketoprofen NN N
allows VBZ N
the DT N
attainment NN N
of IN N
higher JJR N
local JJ N
concentrations NNS N
, , N
whereas JJ N
systemic JJ N
exposure NN N
is VBZ N
lower JJR N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
, , N
in IN N
contrast NN N
to TO N
sham VB N
phonopheresis NN N
, , N
ultrasound NN N
can MD N
increase VB N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
. . N

Cervical JJ N
spine NN N
motion NN N
: : N
a DT N
fluoroscopic NN N
comparison NN N
during IN N
intubation NN 1_p
with IN N
lighted JJ N
stylet NN N
, , N
GlideScope NNP N
, , N
and CC N
Macintosh NNP N
laryngoscope NN N
. . N

The DT N
question NN N
of IN N
which WDT N
is VBZ N
the DT N
optimum JJ N
technique NN N
to TO N
intubate VB N
the DT N
trachea NN N
in IN N
a DT N
patient NN 1_p
who WP 1_p
may MD 1_p
have VB 1_p
a DT 1_p
cervical JJ 1_p
( ( 1_p
C NNP 1_p
) ) 1_p
-spine VBP 1_p
injury NN 1_p
remains VBZ N
unresolved JJ N
. . N

We PRP N
compared VBN N
, , N
using VBG N
fluoroscopic JJ N
video NN N
, , N
C-spine JJ 1_o
motion NN 1_o
during IN N
intubation NN N
for IN N
Macintosh NNP N
3 CD N
blade NN N
, , N
GlideScope NNP N
, , N
and CC N
Intubating NNP N
Lighted NNP N
Stylet NNP N
, , N
popularly RB N
known VBN N
as IN N
the DT N
Lightwand NNP N
or CC N
Trachlight NNP N
. . N

Thirty-six NNP 1_p
healthy JJ 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
to TO 1_p
participate VB 1_p
in IN 1_p
a DT 1_p
crossover JJ 1_p
trial NN 1_p
of IN N
either DT N
Lightwand NNP 1_i
or CC 1_i
GlideScope NNP 1_i
to TO 1_i
Macintosh NNP 1_i
laryngoscopy NN 1_i
, , 1_i
with IN 1_i
in-line JJ 1_i
stabilization NN 1_i
. . 1_i

C-spine JJ 1_o
motion NN 1_o
was VBD N
examined VBN N
at IN N
the DT N
Occiput-C1 NNP N
junction NN N
, , N
C1-2 NNP N
junction NN N
, , N
C2-5 NNP N
motion NN N
segment NN N
, , N
and CC N
C5-thoracic NNP N
motion NN N
segment NN N
during IN N
manual JJ 1_i
ventilation NN 1_i
via IN 1_i
bag-mask NN 1_i
, , 1_i
laryngoscopy NN 1_i
, , 1_i
and CC 1_i
intubation NN 1_i
. . 1_i

Time NN 1_o
to TO N
intubate VB N
was VBD N
also RB N
measured VBN N
. . N

C-spine JJ 1_o
motion NN 1_o
during IN 1_o
bag-mask JJ 1_o
ventilation NN 1_o
was VBD N
82 CD N
% NN N
less JJR N
at IN N
the DT N
four CD N
motion NN N
segments NNS N
studied VBD N
than IN N
during IN N
Macintosh NNP N
laryngoscopy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

C-spine JJ 1_o
motion NN 1_o
using VBG 1_o
the DT 1_o
Lightwand NNP 1_o
was VBD N
less JJR N
than IN N
during IN N
Macintosh NNP N
laryngoscopy NN N
, , N
averaging VBG N
57 CD N
% NN N
less JJR N
at IN N
the DT N
four CD N
motion NN N
segments NNS N
studied VBN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
time NN 1_o
to TO 1_o
intubate VB 1_o
between IN N
the DT N
Lightwand NNP N
and CC N
the DT N
Macintosh NNP N
blade NN N
. . N

C-spine JJ 1_o
motion NN 1_o
was VBD N
reduced VBN N
50 CD N
% NN N
at IN N
the DT N
C2-5 NNP N
segment NN N
using VBG N
the DT N
GlideScope NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
but CC N
unchanged JJ N
at IN N
the DT N
other JJ N
segments NNS N
. . N

Laryngoscopy NNP N
with IN N
GlideScope NNP N
took VBD N
62 CD N
% NN N
longer JJR 1_o
than IN N
with IN N
the DT N
Macintosh NNP N
blade NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Thus RB N
, , N
the DT N
Lightwand NNP N
( ( N
Intubating NNP N
Lighted NNP N
Stylet NNP N
) ) N
is VBZ N
associated VBN N
with IN N
reduced JJ N
C-spine JJ 1_o
movement NN 1_o
during IN N
endotracheal JJ N
intubation NN N
compared VBN N
with IN N
the DT N
Macintosh NNP N
laryngoscope NN N
. . N

A DT N
program NN N
of IN N
screening VBG N
and CC N
prompting VBG N
improves NNS N
short-term JJ N
physician JJ N
counseling NN N
of IN N
dependent NN 1_p
and CC 1_p
nondependent JJ 1_p
harmful JJ 1_p
drinkers NNS 1_p
. . 1_p

BACKGROUND NNP N
Physicians NNPS N
in IN N
the DT N
general JJ N
medical JJ N
setting VBG N
commonly RB N
encounter RB N
but CC N
rarely RB N
counsel NN N
patients NNS 1_p
with IN 1_p
dependent JJ 1_p
or CC 1_p
harmful JJ 1_p
drinking NN 1_p
behaviors NNS 1_p
. . 1_p

We PRP N
tested VBD N
whether IN N
providing VBG N
physicians NNS N
with IN N
their PRP$ N
patients NNS N
' POS N
results NNS N
on IN N
the DT N
alcohol NN N
module NN N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
would MD N
prompt VB N
them PRP N
to TO N
counsel NN N
these DT N
patients NNS N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBN N
83 CD 1_p
first- JJ 1_p
, , 1_p
second- JJ 1_p
, , 1_p
and CC 1_p
third-year JJ 1_p
medical JJ 1_p
residents NNS 1_p
to TO 1_p
receive VB 1_i
or CC 1_i
not RB 1_i
to TO 1_i
receive VB 1_i
diagnostic JJ 1_i
information NN 1_i
and CC 1_i
counseling VBG 1_i
directives NNS 1_i
on IN 1_i
214 CD 1_p
patients NNS 1_p
who WP 1_p
reported VBD 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
symptom NN 1_p
of IN 1_p
alcohol NN 1_p
impairment NN 1_p
as IN 1_p
defined VBN 1_p
in IN 1_p
the DT 1_p
Diagnostic NNP 1_p
and CC 1_p
Statistical NNP 1_p
Manual NNP 1_p
of IN 1_p
Mental NNP 1_p
Disorders NNP 1_p
, , 1_p
Third NNP 1_p
Edition NNP 1_p
. . 1_p

Using VBG N
binary JJ 1_i
logistic JJ 1_i
regression NN 1_i
, , N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
specific JJ N
covariables NNS N
on IN N
rates NNS N
of IN N
physician JJ N
counseling NN N
. . N

These DT N
variables NNS N
included VBD N
physician JJ N
information NN N
status NN N
, , N
patient JJ N
gender NN N
, , N
and CC N
drinking VBG N
disorder NN N
severity NN N
and CC N
recency NN N
. . N

We PRP N
also RB N
examined VBD N
the DT N
effect NN N
of IN N
physician JJ N
prompting VBG N
on IN N
counseling NN N
of IN N
female JJ 1_p
patients NNS 1_p
, , 1_p
patients NNS 1_p
with IN 1_p
inactive JJ 1_p
disorders NNS 1_p
, , 1_p
and CC 1_p
nondependent NN 1_p
but CC 1_p
harmful JJ 1_p
drinkers NNS 1_p
. . 1_p

We PRP N
determined VBD N
counseling VBG N
by IN N
post-visit JJ N
patient JJ N
interviews NNS N
. . N

RESULTS NNP N
Physician JJ 1_o
prompting NN 1_o
, , 1_o
dependent JJ 1_o
drinking NN 1_o
, , 1_o
and CC 1_o
recent JJ 1_o
disorder NN 1_o
activity NN 1_o
were VBD N
significant JJ N
correlates NNS N
of IN N
physician JJ N
counseling NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
while IN N
male JJ N
gender NN N
was VBD N
a DT N
marginally RB N
significant JJ N
correlate NN N
( ( N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

Informed VBN N
physicians NNS N
counseled VBD N
female JJ N
patients NNS N
, , N
harmful JJ N
but CC N
nondependent JJ N
drinkers NNS N
, , N
and CC N
patients NNS N
with IN N
inactive JJ N
disorders NNS N
more RBR N
often RB N
than IN N
their PRP$ N
uninformed JJ N
colleagues NNS N
, , N
although IN N
only RB N
the DT N
last JJ N
variable JJ N
achieved VBD N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Providing VBG N
physicians NNS N
with IN N
the DT N
results NNS N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
resulted VBD N
in IN N
short-term JJ N
improvement NN N
in IN N
their PRP$ N
rates NNS N
of IN N
counseling VBG N
patients NNS N
with IN N
a DT N
history NN N
of IN N
dependent NN N
or CC N
nondependent NN N
but CC N
harmful JJ N
drinking NN N
. . N

Further NNP N
research NN N
is VBZ N
necessary JJ N
to TO N
determine VB N
long-term JJ N
gains NNS N
in IN N
rates NNS N
of IN N
physician JJ 1_i
counseling NN 1_i
and CC 1_i
improvements NNS 1_i
in IN N
the DT N
course NN N
of IN N
these DT N
patients NNS N
. . N

Enhancing VBG N
the DT N
experience NN 1_p
of IN 1_p
carers NNS 1_p
in IN 1_p
the DT 1_p
chemotherapy NN 1_p
outpatient JJ 1_p
setting NN 1_p
: : 1_p
an DT N
exploratory NN N
randomised VBD N
controlled VBN N
trial NN N
to TO N
test VB N
impact NN N
, , N
acceptability NN N
and CC N
feasibility NN N
of IN N
a DT N
complex JJ 1_i
intervention NN 1_i
co-designed VBN N
by IN N
carers NNS 1_p
and CC 1_p
staff NN 1_p
. . 1_p

PURPOSE NNP N
Supporting VBG N
someone NN N
through IN N
chemotherapy NN N
can MD N
be VB N
emotionally RB N
and CC N
physically RB N
demanding VBG N
. . N

However RB N
, , N
research NN N
has VBZ N
yet RB N
to TO N
establish VB N
the DT N
type NN N
of IN N
support NN N
carers NNS N
require VBP N
or CC N
the DT N
best JJS N
way NN N
to TO N
provide VB N
this DT N
. . N

This DT N
study NN N
tested VBD N
the DT N
feasibility NN N
and CC N
acceptability NN N
of IN N
a DT N
complex JJ N
intervention NN N
for IN N
carers NNS 1_p
that WDT 1_p
was VBD 1_p
co-designed VBN 1_p
by IN 1_p
staff NN 1_p
and CC 1_p
carers NNS 1_p
of IN 1_p
patients NNS 1_p
starting VBG 1_p
chemotherapy NN 1_i
. . 1_i

METHODS NNP N
Forty-seven JJ 1_p
carers NNS 1_p
were VBD 1_p
recruited VBN 1_p
, , 1_p
randomised VBN 1_p
between IN 1_p
the DT 1_p
intervention NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
24 CD 1_p
) ) 1_p
and CC 1_p
control NN 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
23 CD 1_p
) ) 1_p
groups NNS 1_p
. . 1_p

A DT N
questionnaire NN 1_i
was VBD N
completed VBN N
pre- JJ N
and CC N
post-intervention JJ N
measuring NN N
knowledge NN N
of IN N
chemotherapy NN 1_o
and CC N
its PRP$ N
side NN N
effects NNS N
, , N
experience NN N
of IN N
care NN N
, , N
satisfaction NN N
with IN N
outpatient NN N
services NNS N
, , N
coping VBG N
and CC N
emotional JJ N
wellbeing NN N
. . N

The DT N
intervention NN 1_p
process NN 1_p
was VBD N
evaluated VBN N
by IN N
carers NNS N
and CC N
healthcare NN N
professionals NNS N
( ( N
HCPs NNP N
) ) N
in IN N
focus NN 1_p
groups NNS 1_p
. . 1_p

RESULTS NNP N
Recruitment NNP N
to TO N
the DT N
study NN N
was VBD N
unproblematic JJ N
and CC N
attrition NN N
from IN N
it PRP N
was VBD N
low JJ N
, , N
suggesting VBG N
the DT N
intervention NN N
and CC N
study NN N
processes NNS N
were VBD N
acceptable JJ N
to TO N
patients NNS N
and CC N
carers NNS N
. . N

Carers NNS N
in IN N
receipt NN N
of IN N
the DT N
'Take NNP N
Care NNP N
' POS N
intervention NN N
reported VBD N
statistically RB N
significantly RB N
better RBR N
understanding NN N
of IN N
symptoms NNS N
and CC N
side JJ N
effects NNS N
and CC N
their PRP$ N
information NN N
needs VBZ N
being VBG N
more RBR N
frequently RB N
met VBN N
than IN N
carers NNS N
in IN N
the DT N
control NN N
. . N

Confidence NN N
in IN N
coping VBG N
improved VBN N
between IN N
baseline NN N
and CC N
follow-up NN N
for IN N
the DT N
intervention NN N
group NN N
and CC N
declined VBD N
for IN N
the DT N
control NN N
although IN N
differences NNS N
were VBD N
insufficient JJ N
to TO N
achieve VB N
statistical JJ N
significance NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
' POS N
emotional JJ N
wellbeing NN N
. . N

HCP NNP N
and CC N
carer NN N
focus NN N
groups NNS N
confirmed VBD N
the DT N
feasibility NN 1_o
and CC 1_o
acceptability NN 1_o
of IN N
the DT N
intervention NN N
. . N

CONCLUSIONS VB N
The DT N
'Take NNP N
Care NNP N
' POS N
intervention NN N
proved VBD N
acceptable JJ N
to TO N
carers NNS 1_p
and CC 1_p
HCPs NNP 1_p
and CC N
demonstrates VBZ N
considerable JJ N
promise NN N
and CC N
utility NN N
in IN N
practice NN N
. . N

Study NNP N
findings NNS N
support VBP N
the DT N
conduct NN N
of IN N
a DT N
fully RB N
powered VBN N
RCT NNP N
to TO N
determine VB N
the DT N
intervention NN N
's POS N
effectiveness NN N
and CC N
cost-effectiveness NN N
. . N

Are NNP N
brand-name JJ N
and CC N
generic JJ 1_i
warfarin NN 1_i
interchangeable JJ N
? . N
Multiple JJ N
n-of-1 JJ N
randomized NN N
, , N
crossover NN N
trials NNS N
. . N

BACKGROUND NNP N
Warfarin NNP 1_i
is VBZ N
a DT N
commonly RB N
used VBN N
anticoagulant NN N
in IN N
North NNP N
America NNP N
. . N

Several JJ N
generic JJ N
formulations NNS N
have VBP N
been VBN N
approved VBN N
, , N
raising VBG N
concern NN N
over IN N
the DT N
safety NN 1_o
and CC N
efficacy NN 1_o
of IN N
these DT N
products NNS N
compared VBN N
with IN N
brand-name JJ N
Coumadin NNP 1_i
. . 1_i

OBJECTIVE NNP N
To TO N
ensure VB N
that IN N
generic JJ N
warfarin NN N
products NNS N
can MD N
be VB N
safely RB N
interchanged VBN N
with IN N
Coumadin NNP N
. . N

METHODS NNP N
Multiple NNP N
n-of-1 JJ N
randomized NN N
, , N
double-blind NN N
, , N
crossover NN N
trials NNS N
switched VBD N
outpatients NNS 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
7 CD 1_p
) ) 1_p
between IN N
a DT N
generic JJ 1_i
warfarin NN 1_i
formulation NN 1_i
( ( 1_i
Apo-warfarin NNP 1_i
) ) 1_i
and CC 1_i
Coumadin NNP 1_i
over IN 1_i
30 CD 1_i
weeks NNS 1_i
. . 1_i

Study NNP 1_p
patients NNS 1_p
took VBD 1_p
each DT 1_p
drug NN 1_p
for IN 1_p
five CD 1_p
3-week JJ 1_p
periods NNS 1_p
, , 1_p
with IN 1_p
international JJ 1_o
normalized VBN 1_o
ratio NN 1_o
( ( 1_o
INR NNP 1_o
) ) 1_o
measurements VBZ 1_p
taken VBN 1_p
twice RB 1_p
per IN 1_p
period NN 1_p
. . 1_p

Inter- JJ N
and CC N
intrapatient JJ N
differences NNS N
between IN N
generic JJ N
warfarin NN 1_i
and CC N
Coumadin NNP 1_i
were VBD N
compared VBN N
, , N
and CC N
overall JJ N
study NN N
patient NN N
results NNS N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
a DT N
Coumadin NNP N
control NN N
group NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
warfarin NN N
products NNS N
in IN N
terms NNS N
of IN N
mean JJ 1_o
INR NNP 1_o
results NNS 1_o
or CC N
number NN 1_o
of IN 1_o
dosage JJ 1_o
adjustments NNS 1_o
required VBN 1_o
. . 1_o

There EX N
also RB N
was VBD N
no DT N
difference NN N
in IN N
INR NNP 1_o
variation NN 1_o
based VBN N
on IN N
warfarin JJ N
formulation NN N
( ( N
p JJ N
> NNP N
0.69 CD N
) ) N
, , N
nor CC N
was VBD N
a DT N
patient NN N
and CC N
warfarin JJ N
interaction NN N
found VBD N
( ( N
p JJ N
> NNP N
0.81 CD N
) ) N
. . N

The DT N
INR NNP 1_o
results NNS 1_o
were VBD N
not RB N
influenced VBN N
by IN N
whether IN N
patients NNS N
were VBD N
maintained VBN N
on IN N
Coumadin NNP N
only RB N
( ( N
control VB N
group NN N
) ) N
or CC N
interchanged VBN N
between IN N
Coumadin NNP 1_i
and CC N
generic JJ 1_i
warfarin NN 1_i
( ( N
p JJ N
= NNP N
0.98 CD N
) ) N
. . N

CONCLUSIONS VB N
It PRP N
appears VBZ N
that IN N
patients NNS N
can MD N
safely RB 1_o
and CC 1_o
effectively RB 1_o
switch VB 1_o
between IN N
generic JJ N
warfarin NN 1_i
and CC N
Coumadin NNP 1_i
. . 1_i

Risperidone NN 1_i
and CC N
adaptive JJ 1_o
behavior NN 1_o
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
impact NN N
of IN N
risperidone NN 1_i
on IN N
adaptive JJ 1_o
behavior NN 1_o
in IN N
children NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
who WP 1_p
have VBP 1_p
serious JJ 1_p
behavior NN 1_p
problems NNS 1_p
and CC N
to TO N
examine VB N
different JJ N
methods NNS N
of IN N
scoring VBG N
the DT N
Vineland NNP N
Adaptive NNP N
Behavior NNP N
Scales NNP N
to TO N
measure VB N
change NN N
. . N

METHOD NNP N
Forty-eight JJ 1_p
children NNS 1_p
( ( 1_p
5 CD 1_p
years NNS 1_p
to TO 1_p
16 CD 1_p
years NNS 1_p
, , 1_p
5 CD 1_p
months NNS 1_p
) ) 1_p
who WP 1_p
showed VBD 1_p
behavioral JJ 1_p
improvement NN 1_o
during IN 1_p
acute JJ 1_p
treatment NN 1_p
with IN 1_p
risperidone NN 1_i
were VBD 1_i
followed VBN 1_i
for IN 1_i
6 CD 1_i
months NNS 1_i
and CC N
assessed VBN N
with IN N
the DT N
Vineland NNP N
Scales NNP N
. . N

RESULTS NNP N
Raw NNP 1_o
scores VBZ 1_o
, , 1_o
age-equivalents NNS 1_o
, , 1_o
and CC 1_o
special JJ 1_o
norm NN 1_o
percentile NN 1_o
scores VBZ 1_o
all DT N
showed VBD N
significant JJ N
increases NNS N
in IN N
adaptive JJ 1_o
behavior NN 1_o
in IN 1_o
the DT 1_o
areas NNS 1_o
of IN 1_o
communication NN 1_o
, , 1_o
daily JJ 1_o
living NN 1_o
skills NNS 1_o
, , 1_o
and CC 1_o
socialization NN 1_o
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

During IN N
a DT N
period NN N
of IN N
6 CD N
to TO N
8 CD N
months NNS N
, , N
children NNS N
gained VBD N
an DT N
average NN N
of IN N
7.8 CD N
age-equivalent JJ N
months NNS N
in IN N
the DT N
area NN 1_o
of IN 1_o
socialization NN 1_o
, , N
a DT N
> JJ N
6 CD N
% NN N
improvement NN N
beyond IN N
what WP N
would MD N
be VB N
expected VBN N
based VBN N
on IN N
baseline JJ N
growth NN N
rates NNS N
. . N

CONCLUSIONS NNP N
Although IN N
limited VBN N
by IN N
the DT N
absence NN N
of IN N
a DT N
control NN N
group NN N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
risperidone NN N
may MD N
improve VB N
adaptive JJ 1_o
skills NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
accompanied VBN N
by IN N
serious JJ N
behavioral JJ N
problems NNS N
. . N

Vineland NNP N
age-equivalent JJ N
scores NNS N
appear VBP N
to TO N
be VB N
most RBS N
useful JJ N
in IN N
assessing VBG N
change NN N
with IN N
treatment NN N
over IN N
time NN N
. . N

Simplified NNP 1_i
subjective JJ 1_i
workload NN 1_i
assessment NN 1_i
technique NN 1_i
. . 1_i

Although IN N
the DT N
subjective JJ 1_o
workload NN 1_o
assessment NN 1_o
technique NN 1_o
( ( 1_i
SWAT NNP 1_i
) ) 1_i
has VBZ N
been VBN N
widely RB N
used VBN N
, , N
it PRP N
has VBZ N
two CD N
main JJ N
problems NNS N
: : N
it PRP N
is VBZ N
not RB N
very RB N
sensitive JJ N
for IN N
low JJ N
mental JJ N
workloads NNS N
and CC N
it PRP N
requires VBZ N
a DT N
time-consuming JJ N
card NN N
sorting VBG N
pretask JJ N
procedure NN N
. . N

In IN N
this DT N
study NN N
are VBP N
presented VBN N
five CD 1_i
variations NNS 1_i
of IN 1_i
SWAT NNP 1_i
in IN N
an DT N
effort NN N
to TO N
overcome VB N
the DT N
limitations NNS N
. . N

Four CD N
of IN N
the DT N
variants NNS N
used VBD N
the DT N
continuous JJ 1_i
SWAT NNP 1_i
subscales NNS 1_i
while IN N
one CD N
used VBD N
the DT N
discrete JJ 1_i
SWAT NNP 1_i
subscale NN 1_i
. . 1_i

Fifteen JJ 1_p
subjects NNS 1_p
participated VBN 1_p
in IN 1_p
the DT 1_p
experiment NN 1_p
. . 1_p

The DT N
scales NNS N
were VBD N
compared VBN N
with IN N
the DT N
original JJ N
SWAT NNP 1_i
scale NN N
in IN N
terms NNS N
of IN N
sensitivity NN 1_o
and CC N
pretask NN N
procedure NN N
completion NN N
time NN N
when WRB N
performing VBG N
arithmetic JJ N
tasks NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
all DT N
four CD N
variants NNS N
are VBP N
more RBR N
sensitive JJ 1_o
than IN N
the DT N
conventional JJ 1_o
SWAT NNP 1_o
scale NN 1_o
and CC N
that IN N
the DT N
pairwise NN N
comparison NN N
procedure NN N
takes VBZ N
significantly RB N
less JJR N
pretask JJ 1_o
completion NN 1_o
time NN 1_o
compared VBN N
with IN N
the DT N
original JJ 1_i
SWAT NNP 1_i
scale NN 1_i
. . 1_i

Thus RB N
, , N
the DT N
conventional JJ 1_i
pretask JJ 1_i
procedure NN 1_i
can MD N
be VB N
replaced VBN N
by IN N
a DT N
simple JJ N
unweighted JJ N
averaging VBG N
to TO N
yield VB N
a DT N
scale NN N
of IN N
high JJ N
sensitivity NN N
. . N

Investigations NNS N
into IN N
the DT N
potential JJ N
effects NNS N
of IN N
multiple JJ N
dose JJ N
ketorolac NN N
on IN N
the DT N
pharmacokinetics NNS 1_o
and CC 1_o
pharmacodynamics NNS 1_o
of IN 1_o
racemic JJ 1_o
warfarin NN 1_o
. . 1_o

1 CD N
. . N

The DT N
potential JJ N
interaction NN N
between IN N
racemic JJ 1_i
warfarin NN 1_i
given VBN N
as IN N
a DT N
25 CD 1_i
mg NN 1_i
single JJ 1_i
oral JJ 1_i
dose NN 1_i
and CC 1_i
chronically RB 1_i
administered VBD 1_i
ketorolac NN 1_i
was VBD N
studied VBN N
in IN N
12 CD 1_p
young JJ 1_p
healthy JJ 1_p
male NN 1_p
volunteers NNS 1_p
. . 1_p

2 CD N
. . N

Ketorolac NNP 1_i
produced VBD N
no DT 1_o
major JJ 1_o
change NN 1_o
in IN 1_o
the DT 1_o
pharmacokinetics NNS 1_o
of IN 1_o
( ( 1_o
R NNP 1_o
) ) 1_o
- : 1_o
or CC 1_o
( ( 1_o
S NNP 1_o
) ) 1_o
-warfarin NN 1_o
. . 1_o

3 CD N
. . N

Ketorolac NNP 1_i
did VBD 1_o
not RB 1_o
alter VB 1_o
the DT 1_o
pharmacodynamic JJ 1_o
profile NN 1_o
of IN 1_o
racemic JJ 1_o
warfarin NN 1_o
. . 1_o

4 CD N
. . N

Ketorolac NNP 1_i
increased VBD 1_o
template VB 1_o
bleeding NN 1_o
time NN 1_o
by IN N
a DT N
factor NN N
of IN N
1.35 CD N
as IN N
compared VBN N
with IN N
placebo NN N
. . N

5 CD N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
the DT N
ketorolac-warfarin JJ N
interaction NN N
is VBZ N
unlikely JJ N
to TO N
be VB N
of IN N
major JJ N
clinical JJ N
significance NN N
; : N
however RB N
, , N
combined VBN N
use NN N
of IN N
ketorolac NN 1_i
and CC N
warfarin NN 1_i
in IN N
patients NNS N
should MD N
be VB N
undertaken VBN N
with IN N
due JJ N
caution NN N
and CC N
appropriate JJ N
monitoring NN N
. . N

The DT N
effect NN N
of IN N
a DT N
culture-specific JJ 1_i
education NN 1_i
program NN 1_i
to TO 1_i
promote VB 1_i
breastfeeding NN 1_i
among IN 1_p
Vietnamese JJ 1_p
women NNS 1_p
in IN 1_p
Sydney NNP 1_p
. . 1_p

The DT N
rate NN N
of IN N
breastfeeding VBG N
among IN N
immigrant JJ 1_p
Vietnamese JJ 1_p
women NNS 1_p
in IN 1_p
Western JJ 1_p
countries NNS 1_p
is VBZ N
low JJ N
compared VBN N
to TO N
those DT N
in IN N
Vietnam NNP N
. . N

To TO N
counteract VB N
this DT N
trend NN N
, , N
a DT N
language NN 1_i
and CC 1_i
culture NN 1_i
specific JJ 1_i
education NN 1_i
program NN N
was VBD N
developed VBN N
. . N

An DT N
experimental JJ N
design NN N
was VBD N
used VBN N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
this DT N
program NN N
. . N

The DT 1_p
sample NN 1_p
consisted VBD 1_p
of IN 1_p
182 CD 1_p
prenatal JJ 1_p
Vietnamese JJ 1_p
women NNS 1_p
. . 1_p

Data NNP N
collection NN N
included VBD N
questionnaires NNS N
and CC N
interviews NNS N
. . N

Results NNS N
suggested VBD N
that IN N
the DT N
education NN N
program NN N
had VBD N
significant JJ N
effects NNS N
on IN N
knowledge NN 1_o
, , 1_o
attitudes NNS 1_o
, , 1_o
planned VBD 1_o
and CC 1_o
actual JJ 1_o
behaviour NN 1_o
towards NNS 1_o
breastfeeding VBG 1_o
. . 1_o

However RB N
, , N
the DT N
effect NN N
did VBD N
not RB N
sustain VB N
until IN N
6 CD N
months NNS N
postpartum NN N
. . N

Implications NNS N
for IN N
nursing NN N
practice NN N
and CC N
further JJ N
research NN N
are VBP N
discussed VBN N
. . N

Confidential JJ 1_i
registration NN 1_i
in IN N
health NN N
services NNS N
: : N
randomised VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Human NNP N
rights NNS N
legislation NN N
safeguards VBZ N
the DT N
privacy NN N
and CC N
dignity NN N
of IN N
patients NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
in IN N
terms NNS N
of IN N
patient NN N
assessed VBN N
privacy NN N
of IN N
confidential JJ 1_i
registration NN 1_i
. . 1_i

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Emergency NNP 1_p
Department NNP 1_p
, , 1_p
University NNP 1_p
Hospital NNP 1_p
of IN 1_p
Wales NNP 1_p
. . 1_p

PARTICIPANTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
302 CD 1_p
patients NNS 1_p
aged VBN 1_p
over IN 1_p
15 CD 1_p
years NNS 1_p
. . 1_p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Binary NNP 1_i
choices NNS 1_i
and CC N
ordinal JJ 1_i
visual JJ 1_i
analogue NN 1_i
scores NNS N
from IN N
a DT N
validated JJ 1_i
questionnaire NN 1_i
on IN 1_i
self NN 1_i
reported VBN 1_i
measures NNS 1_i
: : 1_i
patient NN 1_o
ability NN 1_o
and CC 1_o
preference NN 1_o
to TO 1_o
speak VB 1_o
to TO 1_o
receptionists NNS 1_o
and CC 1_o
disclose VB 1_o
confidential JJ 1_o
information NN 1_o
without IN 1_o
being VBG 1_o
overhead JJ 1_o
and CC 1_o
concern NN 1_o
about IN 1_o
disclosure NN 1_o
of IN 1_o
items NNS 1_o
of IN 1_o
confidential JJ 1_o
personal JJ 1_o
information NN 1_o
. . 1_o

RESULTS NNP N
Patients NNPS N
who WP N
registered VBD N
in IN N
a DT N
screened JJ 1_i
area NN 1_i
felt VBD N
significantly RB N
more RBR N
able JJ N
to TO N
tell VB 1_o
receptionists NNS 1_o
things NNS 1_o
they PRP 1_o
did VBD 1_o
not RB 1_o
want VB 1_o
others NNS 1_o
to TO 1_o
hear VB 1_o
. . 1_o

Control NNP N
patients NNS N
were VBD N
significantly RB N
more RBR N
concerned JJ N
than IN N
intervention NN N
patients NNS N
that WDT N
others NNS 1_o
heard VBP 1_o
their PRP$ 1_o
name NN 1_o
, , 1_o
address NN 1_o
, , 1_o
date NN 1_o
of IN 1_o
birth NN 1_o
, , 1_o
reason NN 1_o
for IN 1_o
emergency NN 1_o
department NN 1_o
attendance NN 1_o
, , 1_o
and CC 1_o
telephone NN 1_o
number NN 1_o
, , 1_o
but CC 1_o
not RB 1_o
their PRP$ 1_o
marital JJ 1_o
status NN 1_o
. . 1_o

Overall NNP N
, , N
intervention NN N
patients NNS N
were VBD N
less RBR N
concerned JJ N
about IN N
disclosure NN 1_o
of IN 1_o
information NN 1_o
and CC N
that IN N
they PRP N
had VBD N
been VBN N
overheard RB N
. . N

CONCLUSIONS NNP N
Patients NNPS N
value NN N
privacy NN N
when WRB N
they PRP N
register VBP N
and CC N
are VBP N
concerned VBN N
if IN N
others NNS N
can MD N
hear VB N
them PRP N
tell VB N
receptionists NNS N
who WP N
they PRP N
are VBP N
, , N
how WRB N
to TO N
contact VB N
them PRP N
, , N
and CC N
why WRB N
they PRP N
are VBP N
there RB N
. . N

Confidential JJ 1_i
registration NN 1_i
should MD N
be VB N
instituted VBN N
in IN N
health NN N
services NNS N
. . N

Confidential JJ 1_i
registration NN 1_i
increased VBD N
patient JJ N
privacy NN N
and CC N
should MD N
be VB N
instituted VBN N
in IN N
health NN N
services NNS N
. . N

Impact NN N
of IN N
disease NN N
severity NN N
on IN N
outcome NN N
of IN N
antiviral JJ 1_i
therapy NN 1_i
for IN N
chronic JJ 1_p
hepatitis NN 1_p
C NNP 1_p
: : 1_p
Lessons NNS N
from IN N
the DT N
HALT-C NNP N
trial NN N
. . N

In IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
hepatitis NN 1_p
C NNP 1_p
, , 1_p
advanced VBD 1_p
fibrosis NN 1_p
and CC 1_p
cirrhosis NN 1_p
are VBP 1_p
associated VBN 1_p
with IN 1_p
lower JJR 1_p
rates NNS 1_p
of IN 1_p
sustained JJ 1_o
virologic JJ 1_o
response NN 1_o
( ( 1_o
SVR NNP 1_o
) ) 1_o
to TO 1_p
interferon VB 1_p
( ( 1_p
IFN NNP 1_p
) ) 1_p
-based VBD 1_p
therapy NN 1_p
. . 1_p

In IN N
this DT N
study NN N
, , N
we PRP N
assessed VBD N
virologic JJ 1_o
response NN 1_o
to TO N
retreatment VB N
with IN N
peginterferon JJ 1_i
alfa-2a JJ 1_i
and CC 1_i
ribavirin NN 1_i
( ( 1_i
RBV NNP 1_i
) ) 1_i
, , N
as IN N
a DT N
function NN N
of IN N
the DT N
baseline NN N
fibrosis NN N
score NN N
( ( N
Ishak NNP N
staging VBG N
) ) N
and CC N
platelet NN N
count NN N
, , N
in IN N
1,046 CD 1_p
patients NNS 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
Hepatitis NNP 1_p
C NNP 1_p
Antiviral NNP 1_p
Long-term NNP 1_p
Treatment NNP 1_p
against IN 1_p
Cirrhosis NNP 1_p
( ( 1_p
HALT-C NNP 1_p
) ) 1_p
Trial NNP 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
had VBD 1_p
failed VBN 1_p
prior RB 1_p
treatment NN 1_p
with IN 1_p
IFN NNP 1_i
or CC 1_p
peginterferon VB 1_i
+/- JJ 1_i
RBV NNP 1_i
and CC 1_p
had VBD 1_p
Ishak NNP 1_p
fibrosis NN 1_p
scores VBZ 1_p
> CD 1_p
or CC 1_p
= VB 1_p
3 CD 1_p
. . 1_p

Four CD 1_p
groups NNS 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
increasingly RB 1_p
severe JJ 1_p
liver NN 1_p
disease NN 1_p
were VBD 1_p
compared VBN 1_p
: : 1_p
( ( N
A DT N
) ) N
bridging NN N
fibrosis NN N
( ( N
Ishak NNP N
3 CD N
and CC N
4 CD N
) ) N
with IN N
platelet NN N
counts NNS N
> VBP N
125,000/mm3 CD N
( ( N
n JJ N
= NNP N
559 CD N
) ) N
; : N
( ( N
B NNP N
) ) N
bridging VBG N
fibrosis NN N
with IN N
platelet NN N
counts NNS N
< VBP N
or CC N
=125,000/mm3 NNP N
( ( N
n JJ N
= NNP N
96 CD N
) ) N
; : N
( ( N
C NNP N
) ) N
cirrhosis NN N
( ( N
Ishak NNP N
5 CD N
and CC N
6 CD N
) ) N
with IN N
platelet NN N
counts NNS N
> VBP N
125,000/mm3 CD N
( ( N
n JJ N
= NNP N
198 CD N
) ) N
; : N
and CC N
( ( N
D NNP N
) ) N
cirrhosis NN N
with IN N
platelet NN N
counts NNS N
< VBP N
or CC N
=125,000/mm3 NNP N
( ( N
n JJ N
= NNP N
193 CD N
) ) N
. . N

SVR JJ 1_o
rates NNS 1_o
were VBD N
23 CD N
% NN N
, , N
17 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
9 CD N
% NN N
in IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
C NNP N
, , N
and CC N
D NNP N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
.0001 NNP N
for IN N
trend NN N
) ) N
. . N

Reduction NN 1_o
in IN 1_o
SVR NNP 1_o
as IN N
a DT N
function NN N
of IN N
increasingly RB N
severe JJ N
disease NN N
was VBD N
independent JJ N
of IN N
age NN N
, , N
percent JJ N
African JJ N
American NNP N
, , N
HCV NNP N
genotype NN N
, , N
HCV NNP N
level NN N
, , N
and CC N
type NN N
of IN N
prior JJ N
therapy NN N
. . N

Dose NNP N
reduction NN N
lowered VBD N
SVR NNP 1_o
frequencies NNS 1_o
, , N
but CC N
to TO N
a DT N
lesser JJR N
extent NN N
than IN N
disease NN N
severity NN N
. . N

By IN N
logistic JJ N
regression NN N
, , N
cirrhosis NN 1_o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
was VBD N
the DT N
major JJ N
determinant NN N
that WDT N
impaired VBD N
virologic JJ 1_o
response NN 1_o
, , N
independent JJ N
of IN N
dose JJ N
reduction NN N
or CC N
platelet NN N
count NN N
. . N

In IN N
conclusion NN N
, , N
disease NN N
severity NN N
is VBZ N
a DT N
major JJ N
independent JJ N
determinant NN N
of IN N
rate NN 1_o
of IN 1_o
SVR NNP 1_o
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
chronic JJ 1_p
hepatitis NN 1_p
C. NNP 1_p
New NNP N
strategies NNS N
are VBP N
needed VBN N
to TO N
optimize VB N
antiviral JJ N
therapy NN N
in IN N
these DT N
" JJ 1_p
difficult-to-cure NN 1_p
" NN 1_p
patients NNS 1_p
. . 1_p

The DT N
FLT3ITD NNP 1_i
mRNA NN 1_i
level NN 1_i
has VBZ N
a DT N
high JJ N
prognostic JJ N
impact NN N
in IN N
NPM1 NNP 1_p
mutated VBD 1_p
, , 1_p
but CC 1_p
not RB 1_p
in IN 1_p
NPM1 NNP 1_p
unmutated VBD 1_p
, , 1_p
AML NNP 1_p
with IN 1_p
a DT 1_p
normal JJ 1_p
karyotype NN 1_p
. . 1_p

The DT N
impact NN N
of IN N
a DT N
FLT3-internal JJ N
tandem NN N
duplication NN N
( ( N
FLT3ITD NNP N
) ) N
on IN N
prognosis NN N
of IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
( ( 1_p
AML NNP 1_p
) ) 1_p
is VBZ N
dependent JJ N
on IN N
the DT N
ratio NN N
of IN N
mutated VBN N
to TO N
wild-type JJ N
allele NN N
. . N

In IN N
648 CD 1_p
normal JJ 1_p
karyotype NN 1_p
( ( 1_p
NK NNP 1_p
) ) 1_p
AML NNP 1_p
patients NNS 1_p
, , N
we PRP N
found VBD N
a DT N
significant JJ N
independent JJ N
effect NN N
of IN N
the DT N
quantitative JJ 1_o
FLT3ITD NNP 1_o
mRNA NN 1_o
level NN 1_o
-- : 1_o
measured VBN 1_o
as IN N
( ( 1_i
FLT3ITD/wtFLT3 NNP 1_i
) ) 1_i
/ NN 1_i
( ( 1_i
FLT3ITD/wtFLT3+1 NNP 1_i
) ) 1_i
-- : 1_i
on IN 1_i
outcome NN N
. . N

Moreover RB N
, , N
this DT N
effect NN N
was VBD N
clearly RB N
seen VBN N
in IN N
329 CD 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
mutated VBN 1_p
NPM1 NNP 1_p
gene NN 1_p
( ( 1_p
NPM1+ NNP 1_p
) ) 1_p
, , N
but CC N
not RB N
in IN N
319 CD 1_p
patients NNS 1_p
without IN 1_p
a DT 1_p
NPM1 NNP 1_p
mutation NN 1_p
( ( 1_p
wtNPM1 NN 1_p
) ) 1_p
. . 1_p

In IN N
a DT N
multivariate NN N
Cox NNP N
regression NN N
model NN N
, , N
the DT N
quantitative JJ N
FLT3ITD NNP 1_i
mRNA NN N
level NN N
showed VBD N
an DT N
independent JJ N
prognostic JJ N
impact NN N
on IN N
overall JJ 1_o
survival NN 1_o
( ( N
OS NNP N
) ) N
and CC N
relapse-free JJ 1_o
survival NN 1_o
( ( N
RFS NNP N
) ) N
only RB N
in IN N
the DT N
NPM1+ NNP 1_p
subgroup NN 1_p
( ( N
OS NNP N
: : N
hazard NN N
ratio NN N
, , N
5.9 CD N
; : N
[ CC N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
3.1-11.2 JJ N
] NN N
; : N
RFS NNP N
: : N
hazard NN N
ratio NN N
, , N
7.5 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
3.4-16.5 JJ N
] NN N
) ) N
. . N

The DT N
FLT3ITD NNP 1_i
mRNA MD N
level VB N
contributes NNS N
to TO N
relapse VB N
risk NN N
stratification NN N
and CC N
might MD N
help VB N
to TO N
guide VB N
postremission NN N
therapy NN N
in IN N
NPM1-mutated JJ 1_p
AML NNP 1_p
. . 1_p

Association NNP N
of IN N
chronic JJ 1_i
kidney NN 1_i
disease NN 1_i
with IN 1_p
outcomes NNS 1_p
in IN 1_p
chronic JJ 1_o
heart NN 1_o
failure NN 1_o
: : 1_o
a DT N
propensity-matched JJ N
study NN N
. . N

BACKGROUND NNP N
Chronic NNP 1_i
kidney NN 1_i
disease NN 1_i
( ( 1_i
CKD NNP 1_i
) ) 1_i
is VBZ N
associated VBN N
with IN N
increased JJ N
mortality NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_i
failure NN 1_i
( ( 1_i
HF NNP 1_i
) ) 1_i
. . 1_i

However RB N
, , N
its PRP$ N
association NN N
with IN N
hospitalization NN N
in IN N
HF NNP 1_p
patients NNS 1_p
has VBZ N
not RB N
been VBN N
well RB N
studied VBN N
. . N

METHODS NNP N
Of IN 1_p
7788 CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
Digitalis NNP 1_p
Investigation NNP 1_p
Group NNP 1_p
trial NN 1_p
, , 1_p
3527 CD 1_p
had VBD 1_p
CKD NNP 1_p
, , 1_p
defined VBN 1_p
by IN 1_p
an DT 1_p
estimated VBN 1_p
glomerular JJ 1_p
filtration NN 1_p
rate NN 1_p
( ( 1_p
GFR NNP 1_p
) ) 1_p
< VBD 1_p
60 CD 1_p
ml/min/1.73 NNS 1_p
m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
body NN 1_p
surface JJ 1_p
area NN 1_p
( ( 1_p
BSA NNP 1_p
) ) 1_p
. . 1_p

Propensity NN N
scores NNS N
for IN N
CKD NNP 1_i
were VBD N
calculated VBN N
using VBG N
a DT N
multivariable JJ 1_i
logistic JJ 1_i
regression NN 1_i
model NN 1_i
and CC N
used VBN N
to TO N
match VB N
2399 CD N
pairs NNS N
of IN N
patients NNS 1_i
with IN 1_i
and CC 1_i
without IN 1_i
CKD NNP 1_i
. . 1_i

Matched NNP 1_i
Cox NNP 1_i
regression NN 1_i
analyses NNS 1_i
were VBD N
used VBN N
to TO N
estimate VB N
association NN N
of IN N
CKD NNP 1_i
with IN N
outcomes NNS N
. . N

RESULTS NNP N
All-cause NNP 1_o
hospitalization NN 1_o
occurred VBD N
in IN N
1636 CD N
( ( N
rate NN N
, , N
4233/10,000 CD N
person-years NNS N
) ) N
and CC N
1587 CD N
( ( N
rate NN N
, , N
3733/10,000 CD N
person-years NNS N
) ) N
patients NNS N
respectively RB N
, , N
with IN 1_i
and CC 1_i
without IN 1_i
CKD NNP 1_i
( ( N
matched VBN N
hazard RB N
ratio JJ N
[ NNP N
HR NNP N
] NNP N
for IN N
CKD NNP N
, , N
1.18 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.08-1.29 JJ N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Matched VBN 1_o
HR NNP 1_o
for IN 1_o
cardiovascular JJ 1_o
and CC 1_o
HF NNP 1_o
hospitalization NN 1_o
were VBD N
respectively RB N
1.17 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.06-1.28 JJ N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
and CC N
1.28 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.13-1.45 JJ N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Compared VBN N
to TO N
GFR NNP N
> NNP N
or=60 MD N
ml/min/1.73 VB N
m NN N
( ( N
2 CD N
) ) N
BSA NNP N
, , N
HR NNP 1_o
for IN 1_o
all-cause JJ 1_o
hospitalization NN 1_o
for IN 1_o
GFR NNP 1_o
45-59 CD N
and CC N
< $ N
45 CD N
ml/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
BSA NNP N
were VBD N
respectively RB N
1.04 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.94-1.16 NNP N
; : N
P NNP N
= NNP N
0.422 CD N
) ) N
and CC N
1.58 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.34-1.87 JJ N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Similarly RB N
, , N
HR NNP 1_o
for IN 1_o
all-cause JJ 1_o
death NN 1_o
for IN 1_o
GFR NNP 1_o
45-59 CD 1_o
and CC 1_o
< $ 1_o
45 CD 1_o
ml/min/1.73 NN 1_o
m NN 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
BSA NNP 1_o
were VBD N
respectively RB N
1.03 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.90-1.18 NNP N
; : N
P NNP N
= NNP N
0.651 CD N
) ) N
and CC N
1.70 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.40-2.07 JJ N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Matched VBN 1_o
HR NNP 1_o
for IN 1_o
death NN 1_o
due JJ 1_o
to TO 1_o
cardiovascular JJ 1_o
causes NNS 1_o
and CC 1_o
progressive JJ 1_o
HF NNP 1_o
were VBD N
respectively RB N
1.24 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.09-1.40 JJ N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
1.42 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.16-1.72 JJ N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
CKD NNP 1_i
was VBD N
associated VBN N
with IN N
increased JJ N
mortality NN 1_o
and CC 1_o
hospitalization NN 1_o
in IN N
ambulatory JJ 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
HF NNP 1_p
, , N
which WDT N
increased VBD N
progressively RB N
with IN N
worsening VBG N
kidney NN 1_o
function NN 1_o
. . 1_o

Randomized VBN N
trial NN N
of IN N
recombinant JJ 1_i
alpha JJ 1_i
2b-interferon JJ 1_i
with IN 1_i
or CC 1_i
without IN 1_i
indomethacin NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
malignant JJ 1_p
melanoma NN 1_p
. . 1_p

alpha-Interferon NN 1_i
has VBZ N
antitumor VBN N
activity NN N
in IN N
a DT N
variety NN N
of IN N
malignancies NNS N
but CC N
is VBZ N
frequently RB N
associated VBN N
with IN N
unacceptable JJ N
toxic JJ 1_o
side-effects NNS 1_o
. . 1_o

The DT N
routine JJ N
use NN N
of IN N
agents NNS N
potentially RB N
capable JJ N
of IN N
reducing VBG N
these DT N
side-effects NNS N
has VBZ N
not RB N
been VBN N
recommended VBN N
out IN N
of IN N
concern NN N
for IN N
possible JJ N
reductions NNS N
in IN N
the DT N
therapeutic JJ N
activity NN N
of IN N
interferon NN N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
alpha-interferon JJ N
given VBN N
with IN N
or CC N
without IN N
indomethacin JJ 1_i
to TO N
patients NNS 1_p
with IN 1_p
malignant JJ 1_p
melanoma NN 1_p
to TO N
determine VB N
what WP N
effect NN N
, , N
if IN N
any DT N
, , N
indomethacin NN 1_i
might MD N
have VB N
on IN N
the DT N
toxic NN 1_o
, , 1_o
immunomodulatory NN 1_o
, , 1_o
and CC 1_o
therapeutic JJ 1_o
properties NNS 1_o
of IN N
interferon NN N
in IN N
this DT N
disease NN N
. . N

53 CD 1_p
patients NNS 1_p
were VBD 1_p
stratified VBN 1_p
according VBG 1_p
to TO 1_p
performance NN 1_p
status NN 1_p
and CC N
randomized VBN N
to TO N
receive VB N
alpha JJ 1_i
2b-interferon CD 1_i
, , N
20 CD N
million CD N
units NNS N
per IN N
m2 NN N
i.v. NN N
, , N
5 CD N
days NNS N
per IN N
week NN N
for IN N
4 CD N
weeks NNS N
followed VBN N
by IN N
10 CD N
million CD N
units NNS N
per IN N
m2 NN N
s.c. NN N
three CD N
times NNS N
per IN N
week NN N
, , N
either RB N
with IN N
or CC N
without IN N
indomethacin NN 1_i
, , N
25 CD N
mg NN N
orally RB N
three CD N
times NNS N
a DT N
day NN N
. . N

The DT N
overall JJ 1_o
major JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
13 CD N
% NN N
( ( N
three CD N
complete JJ N
responders NNS N
and CC N
three CD N
partial JJ N
responders NNS N
among IN N
47 CD N
evaluable JJ N
patients NNS N
) ) N
and CC N
was VBD N
the DT N
same JJ N
on IN N
both DT N
arms NNS N
. . N

The DT N
mean JJ 1_o
maximal JJ 1_o
temperature NN 1_o
elevation NN 1_o
induced VBN N
by IN N
interferon NN N
was VBD N
significantly RB N
reduced VBN N
( ( N
from IN N
102.1 CD N
to TO N
100.7 CD N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
by IN N
indomethacin NN 1_i
, , N
but CC N
the DT N
incidence NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
interferon-related JJ 1_o
fatigue NN 1_o
, , 1_o
reduction NN 1_o
in IN 1_o
performance NN 1_o
status NN 1_o
, , 1_o
headache NN 1_o
, , 1_o
depression NN 1_o
, , 1_o
confusion NN 1_o
, , 1_o
elevations NNS 1_o
in IN 1_o
liver JJ 1_o
function NN 1_o
tests NNS 1_o
, , 1_o
and CC 1_o
myelosuppression NN 1_o
were VBD N
no DT N
different JJ N
in IN N
either DT N
arm NN N
of IN N
the DT N
study NN N
. . N

Indomethacin NNP 1_i
did VBD N
not RB N
reduce VB N
the DT N
frequency NN 1_o
of IN 1_o
dose JJ 1_o
reductions NNS 1_o
for IN 1_o
toxic JJ 1_o
side-effects NNS 1_o
and CC N
did VBD N
not RB N
permit VB N
the DT N
administration NN 1_o
of IN 1_o
higher JJR 1_o
interferon NN 1_o
doses NNS 1_o
. . 1_o

Peripheral NNP 1_o
blood VBD 1_o
natural JJ 1_o
killer NN 1_o
activity NN 1_o
was VBD N
significantly RB N
enhanced VBN N
in IN N
patients NNS N
during IN N
maintenance NN N
therapy NN N
whether IN N
or CC N
not RB N
they PRP N
received VBD N
indomethacin NN N
. . N

Indomethacin NNP 1_i
appeared VBD N
to TO N
inhibit VB N
augmentation NN 1_o
of IN 1_o
natural JJ 1_o
killer NN 1_o
activity NN 1_o
during IN N
high JJ N
dose JJ N
induction NN N
therapy NN N
. . N

Immunological JJ 1_o
changes NNS 1_o
did VBD N
not RB N
correlate VB N
with IN N
response NN N
status NN N
. . N

We PRP N
conclude VBP N
that IN N
indomethacin NN N
can MD N
reduce VB N
the DT N
fever NN 1_o
associated VBN N
with IN N
interferon NN N
therapy NN N
in IN N
patients NNS 1_p
with IN 1_p
malignant JJ 1_p
melanoma NN 1_p
without IN N
interfering VBG N
with IN N
its PRP$ N
therapeutic JJ 1_o
or CC 1_o
chronic JJ 1_o
immunomodulatory NN 1_o
activities NNS 1_o
. . 1_o

Since IN N
fever NN 1_o
is VBZ N
rarely RB N
the DT N
dose-limiting JJ N
toxicity NN N
of IN N
interferon NN N
, , N
indomethacin NN 1_i
is VBZ N
of IN N
marginal JJ N
benefit NN N
to TO N
patients NNS 1_p
with IN 1_p
malignant JJ 1_p
melanoma NN 1_p
receiving VBG N
interferon NN N
at IN N
the DT N
doses NNS N
outlined VBN N
in IN N
this DT N
study NN N
. . N

A DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
of IN N
intravenous JJ 1_i
immunoglobulin NN 1_i
therapy NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
fatigue NN 1_p
syndrome NN 1_p
. . 1_p

PURPOSE VB N
The DT N
chronic JJ N
fatigue NN N
syndrome NN N
( ( N
CFS NNP N
) ) N
is VBZ N
characterized VBN N
by IN N
profound NN N
fatigue NN N
, , N
neuropsychiatric JJ N
dysfunction NN N
, , N
and CC N
frequent JJ N
abnormalities NNS N
in IN N
cell-mediated JJ N
immunity NN N
. . N

No DT N
effective JJ N
therapy NN N
is VBZ N
known VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty-nine NNP 1_p
patients NNS 1_p
( ( 1_p
40 CD 1_p
with IN 1_p
abnormal JJ 1_p
cell-mediated JJ 1_p
immunity NN 1_p
) ) 1_p
participated VBD 1_p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
high-dose JJ N
intravenously RB 1_i
administered VBN 1_i
immunoglobulin NN 1_i
G. NNP 1_i
The DT N
patients NNS N
received VBD N
three CD N
intravenous JJ N
infusions NNS N
of IN N
a DT N
placebo JJ 1_i
solution NN 1_i
or CC 1_i
immunoglobulin NN 1_i
at IN N
a DT N
dose NN N
of IN N
2 CD N
g/kg/month NN N
. . N

Assessment NN N
of IN N
the DT N
severity NN N
of IN N
symptoms NNS N
and CC N
associated JJ N
disability NN N
, , N
both DT N
before IN N
and CC N
after IN N
treatment NN N
, , N
was VBD N
completed VBN N
at IN N
detailed JJ N
interviews NNS N
by IN N
a DT N
physician NN N
and CC N
psychiatrist NN N
, , N
who WP N
were VBD N
unaware NN N
of IN N
the DT N
treatment NN N
status NN N
. . N

In IN N
addition NN N
, , N
any DT N
change NN N
in IN N
physical JJ N
symptoms NNS N
and CC N
functional JJ N
capacity NN N
was VBD N
recorded VBN N
using VBG N
visual JJ N
analogue NN N
scales NNS N
, , N
while IN N
changes NNS N
in IN N
psychologic JJ N
morbidity NN N
were VBD N
assessed VBN N
using VBG N
patient-rated JJ N
indices NNS N
of IN N
depression NN N
. . N

Cell-mediated JJ N
immunity NN N
was VBD N
evaluated VBN N
by IN N
T-cell NNP N
subset NN N
analysis NN N
, , N
delayed-type JJ N
hypersensitivity NN N
skin NN N
testing NN N
, , N
and CC N
lymphocyte JJ N
transformation NN N
with IN N
phytohemagglutinin NN N
. . N

RESULTS NNP N
At IN N
the DT N
interview NN N
conducted VBN N
by IN N
the DT N
physician JJ N
3 CD N
months NNS N
after IN N
the DT N
final JJ N
infusion NN N
, , N
10 CD N
of IN N
23 CD N
( ( N
43 CD N
% NN N
) ) N
immunoglobulin NN N
recipients NNS N
and CC N
three CD N
of IN N
the DT N
26 CD N
( ( N
12 CD N
% NN N
) ) N
placebo NN N
recipients NNS N
were VBD N
assessed VBN N
as IN N
having VBG N
responded VBN N
with IN N
a DT N
substantial JJ 1_o
reduction NN 1_o
in IN 1_o
their PRP$ 1_o
symptoms NNS 1_o
and CC 1_o
recommencement NN 1_o
of IN 1_o
work NN 1_o
, , 1_o
leisure NN 1_o
, , 1_o
and CC 1_o
social JJ 1_o
activities NNS 1_o
. . 1_o

The DT N
patients NNS N
designated VBN N
as IN N
having VBG N
responded VBN N
had VBD N
improvement NN N
in IN N
physical JJ N
, , N
psychologic JJ N
, , N
and CC N
immunologic JJ N
measures NNS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
for IN N
each DT N
) ) N
. . N

CONCLUSION NNP N
Immunomodulatory NNP 1_i
treatment NN 1_i
with IN N
immunoglobulin NN 1_i
is VBZ N
effective JJ 1_o
in IN 1_o
a DT 1_o
significant JJ 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
with IN 1_o
CFS NNP 1_o
, , N
a DT N
finding NN N
that WDT N
supports VBZ N
the DT N
concept NN N
that IN N
an DT N
immunologic JJ N
disturbance NN N
may MD N
be VB N
important JJ N
in IN N
the DT N
pathogenesis NN N
of IN N
this DT N
disorder NN N
. . N

Recombinant JJ 1_i
human JJ 1_i
granulocyte NN 1_i
and CC 1_i
granulocyte-macrophage JJ 1_i
colony-stimulating JJ 1_i
factor NN 1_i
( ( 1_i
G-CSF NNP 1_i
and CC 1_i
GM-CSF NNP 1_i
) ) 1_i
administered VBD N
following VBG N
cytotoxic NN 1_i
chemotherapy NNS 1_i
have VBP N
a DT N
similar JJ N
ability NN N
to TO N
mobilize VB N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
. . N

The DT N
availability NN N
of IN N
hematopoietic JJ N
growth NN N
factors NNS N
has VBZ N
greatly RB N
facilitated VBN N
the DT N
mobilization NN 1_o
and CC 1_o
collection NN 1_o
of IN 1_o
peripheral JJ 1_o
blood NN 1_o
stem NN 1_o
cells NNS 1_o
( ( 1_o
PBSC NNP 1_o
) ) 1_o
. . 1_o

It PRP N
was VBD N
the DT N
aim NN N
of IN N
this DT N
double-blind NN N
study NN N
to TO N
compare VB N
the DT N
PBSC-mobilizing NNP N
efficacy NN N
of IN N
recombinant JJ 1_i
human JJ 1_i
G-CSF NNP 1_i
and CC N
GM-CSF NNP 1_i
when WRB N
administered VBN N
post-chemotherapy NN 1_i
. . 1_i

Twenty-six JJ 1_p
patients NNS 1_p
with IN 1_p
relapsed JJ 1_p
Hodgkin NNP 1_p
's POS 1_p
disease NN 1_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Their PRP$ 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
31 CD 1_p
years NNS 1_p
( ( 1_p
range NN 1_p
, , 1_p
22-59 JJ 1_p
) ) 1_p
and CC 1_p
14 CD 1_p
patients NNS 1_p
were VBD 1_p
males NNS 1_p
and CC 1_p
12 CD 1_p
were VBD 1_p
females NNS 1_p
. . 1_p

Patients NNS 1_p
were VBD 1_p
pretreated VBN 1_p
with IN 1_p
a DT 1_p
median NN 1_p
of IN 1_p
eight CD 1_p
cycles NNS 1_p
of IN 1_p
cytotoxic NN 1_i
chemotherapy NN 1_i
, , 1_p
while IN 1_p
18 CD 1_p
patients NNS 1_p
had VBD 1_p
undergone JJ 1_p
extended JJ 1_p
field NN 1_p
irradiation NN 1_p
. . 1_p

The DT N
patients NNS N
received VBD N
dexamethasone RB 1_i
24 CD 1_i
mg JJ 1_i
days NNS 1_i
1-7 CD 1_i
, , 1_i
melphalan FW 1_i
30 CD 1_i
mg/m2 NNS 1_i
day NN 1_i
3 CD 1_i
, , 1_i
BCNU NNP 1_i
60 CD 1_i
mg/m2 NN 1_i
day NN 1_i
3 CD 1_i
, , 1_i
etoposide RB 1_i
75 CD 1_i
mg/m2 JJ 1_i
days NNS 1_i
4-7 CD 1_i
, , 1_i
Ara-C NNP 1_i
100 CD 1_i
mg/m2 NN 1_i
twice RB 1_i
daily JJ 1_i
days NNS 1_i
4-7 JJ 1_i
( ( 1_i
Dexa-BEAM NNP 1_i
) ) 1_i
. . N

Twelve CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB 1_i
5/microg/kg/day CD 1_i
G-CSF NNP 1_i
and CC N
14 CD N
patients NNS N
to TO N
receive VB N
5 CD 1_i
microg/kg/day JJ 1_i
GM-CSF NNP 1_i
, , N
both DT N
administered VBN N
subcutaneously RB N
starting VBG N
on IN N
day NN N
1 CD N
after IN N
the DT N
end NN N
of IN N
Dexa-BEAM NNP 1_i
. . 1_i

Primary JJ N
endpoints NNS N
of IN N
the DT N
study NN N
were VBD N
the DT N
number NN 1_o
of IN 1_o
CD34+ NNP 1_o
cells NNS 1_o
harvested VBD 1_o
per IN 1_o
kg NN 1_o
body NN 1_o
weight VBD 1_o
on IN 1_o
the DT 1_o
occasion NN 1_o
of IN 1_o
six CD 1_o
consecutive JJ 1_o
leukaphereses NNS 1_o
and CC N
the DT N
time NN 1_o
needed VBN 1_o
for IN 1_o
hematological JJ 1_o
reconstitution NN 1_o
following VBG 1_o
autografting VBG 1_o
. . 1_o

Twenty-one CD N
patients NNS N
completed VBN N
PBSC NNP N
collection NN N
, , N
and CC N
six CD N
patients NNS N
of IN N
the DT N
G-CSF NNP N
group NN N
and CC N
nine CD N
of IN N
the DT N
GM-CSF NNP N
group NN N
were VBD N
autografted VBN N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
with IN N
respect NN N
to TO N
the DT N
median JJ 1_o
yield NN 1_o
of IN 1_o
CFU-GM NNP 1_o
and CC 1_o
CD34+ NNP 1_o
cells NNS 1_o
: : 1_o
32.5 CD N
x $ N
10 CD N
( ( N
4 CD N
) ) N
/kg NN N
vs $ N
31.3 CD N
x $ N
10 CD N
( ( N
4 CD N
) ) N
/kg CD N
CFU-GM NNP N
, , N
and CC N
7.6 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
vs $ N
5.6 CD N
x $ N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
CD34+ NNP N
cells NNS N
, , N
for IN N
G-CSF NNP 1_o
and CC 1_o
GM-CSF NNP 1_o
, , N
respectively RB N
( ( N
U NNP N
test NN N
, , N
P= NNP N
0.837 CD N
and CC N
0.696 CD N
) ) N
. . N

High-dose JJ N
chemotherapy NN N
consisted VBN N
of IN N
cyclophosphamide NN 1_i
1.7 CD N
g/m2 JJ N
days NNS N
1-4 CD N
, , N
BCNU NNP 1_i
150 CD N
mg/m2 NN N
days NNS N
1-4 CD N
, , N
etoposide RB 1_i
400 CD N
mg/m2 JJ N
days NNS N
1-4 JJ N
. . N

All DT N
patients NNS N
transplanted VBN N
with IN N
more JJR N
than IN N
5 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
CD34+ NNP N
cells/kg NN N
had VBD N
a DT N
rapid JJ N
platelet NN 1_o
recovery NN 1_o
( ( N
20 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
between IN N
6 CD N
and CC N
11 CD N
days NNS N
and CC N
neutrophil JJ 1_o
recovery NN 1_o
( ( N
0.5 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
/1 NN N
) ) N
between IN N
9 CD N
and CC N
16 CD N
days NNS N
, , N
while IN N
patients NNS N
transplanted VBN N
with IN N
less JJR N
than IN N
5 CD N
x JJ N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
had VBD N
a DT N
delayed VBN 1_o
reconstitution NN 1_o
, , N
regardless RB N
of IN N
the DT N
kind NN N
of IN N
growth NN N
factor NN N
used VBN N
for IN N
PBSC NNP N
mobilization NN N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
data NNS N
indicate VBP N
that IN N
in IN N
patients NNS 1_p
with IN 1_p
Hodgkin NNP 1_p
's POS 1_p
disease NN 1_p
G-CSF NNP N
and CC N
GM-CSF NNP N
given VBN N
after IN N
salvage NN N
chemotherapy NN N
appear VBP N
to TO N
be VB N
not RB N
different JJ N
in IN N
their PRP$ N
ability NN 1_o
to TO 1_o
mobilize VB 1_o
PBSC NNP 1_o
resulting VBG N
in IN N
a DT N
similar JJ N
time NN 1_o
needed VBN 1_o
for IN 1_o
hematological JJ 1_o
reconstitution NN 1_o
when WRB N
autografted VBD N
following VBG N
high-dose JJ N
therapy NN N
. . N

Eberconazole JJ 1_i
1 CD N
% NN N
cream NN N
is VBZ N
an DT N
effective JJ 1_o
and CC 1_o
safe JJ 1_o
alternative NN N
for IN N
dermatophytosis NN N
treatment NN N
: : N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
comparative JJ N
trial NN N
with IN N
miconazole JJ 1_i
2 CD N
% NN N
cream NN N
. . N

BACKGROUND NNP N
Eberconazole NNP 1_i
is VBZ N
a DT N
topical JJ N
, , N
broad-spectrum JJ N
imidazole NN N
derivative NN N
, , N
effective JJ N
in IN N
dermatophytoses NNS N
, , N
candidiasis NN N
, , N
and CC N
pityriasis NN N
treatment NN N
. . N

In IN N
previous JJ N
trials NNS N
, , N
it PRP N
showed VBD N
a DT N
higher JJR N
efficacy NN N
than IN N
clotrimazole NN N
in IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
eberconazole JJ 1_i
1 CD N
% NN N
cream NN N
compared VBN N
with IN N
miconazole JJ 1_i
2 CD N
% NN N
cream NN N
in IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
trial NN N
was VBD N
performed VBN N
in IN N
653 CD 1_p
patients NNS 1_p
with IN 1_p
dermatophytoses NNS 1_p
, , N
randomized VBN N
to TO N
eberconazole VB 1_i
1 CD N
% NN N
cream NN N
every DT N
12 CD N
h NN N
or CC N
miconazole VB 1_i
2 CD N
% NN N
cream NN N
every DT N
12 CD N
h NN N
for IN N
4 CD N
weeks NNS N
. . N

Treatment NNP 1_o
efficacy NN 1_o
was VBD N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
the DT N
percentage NN N
of IN N
effective JJ N
response NN N
after IN N
4 CD N
weeks NNS N
through IN N
mycologic NN N
and CC N
clinical JJ N
assessment NN N
. . N

RESULTS NNP N
Of IN N
the DT N
653 CD 1_p
patients NNS 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
trial NN 1_p
, , N
360 CD N
produced VBD N
positive JJ N
baseline NN N
mycologic NN N
cultures NNS N
and CC N
were VBD N
included VBN N
in IN N
the DT N
efficacy NN N
assessment NN N
. . N

Clinical JJ N
efficacy NN N
was VBD N
shown VBN N
in IN N
76.1 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
eberconazole JJ N
and CC N
in IN N
75.0 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
miconazole NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ 1_o
events NNS 1_o
related VBN N
to TO N
treatment NN N
was VBD N
0.91 CD N
% NN N
for IN N
eberconazole NN N
and CC N
0.92 CD N
% NN N
for IN N
miconazole NN N
, , N
none NN N
being VBG N
serious JJ N
, , N
and CC N
all DT N
being VBG N
local JJ N
and CC N
transient NN N
. . N

CONCLUSIONS NNP N
Eberconazole NNP N
1 CD N
% NN N
cream NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
fungal JJ N
infections NNS N
produced VBN N
by IN N
dermatophytes NNS N
, , N
with IN N
a DT N
good JJ N
safety NN 1_o
and CC 1_o
tolerability NN 1_o
profile NN N
, , N
and CC N
can MD N
be VB N
considered VBN N
a DT N
good JJ N
alternative NN N
for IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

Tegaserod NNP 1_i
, , 1_i
a DT 1_i
5-hydroxytryptamine JJ 1_i
type NN 1_i
4 CD 1_i
receptor NN 1_i
partial JJ 1_i
agonist NN 1_i
, , N
is VBZ N
devoid JJ N
of IN N
electrocardiographic JJ 1_o
effects NNS 1_o
. . 1_o

OBJECTIVES NNP N
Certain NNP N
GI NNP 1_i
prokinetic JJ 1_i
agents NNS 1_i
have VBP N
been VBN N
shown VBN N
to TO N
affect VB N
cardiac JJ N
repolarization NN N
, , N
which WDT N
may MD N
be VB N
associated VBN N
with IN N
life-threatening JJ N
arrhythmias NNS N
. . N

The DT N
selective JJ 1_i
5-hydroxytryptamine JJ 1_i
type NN 1_i
4 CD 1_i
receptor NN 1_i
partial JJ 1_i
agonist NN 1_i
tegaserod NN 1_i
is VBZ N
a DT N
novel JJ N
promotile NN N
agent NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
functional JJ N
motility NN N
disorders NNS N
such JJ N
as IN N
irritable JJ N
bowel NN N
syndrome NN N
( ( N
IBS NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
cardiac JJ 1_o
safety NN 1_o
profile NN 1_o
of IN N
tegaserod NN 1_i
through IN N
analysis NN N
of IN N
electrocardiographic JJ N
data NNS N
from IN N
clinical JJ N
studies NNS N
conducted VBN N
in IN N
patients NNS 1_p
with IN 1_p
IBS NNP 1_p
and CC 1_p
a DT 1_p
study NN 1_p
conducted VBN 1_p
in IN 1_p
healthy JJ 1_p
male JJ 1_p
subjects NNS 1_p
. . 1_p

METHODS NNP N
In IN N
three CD N
randomized NNS N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
clinical JJ N
studies NNS N
, , N
2516 CD 1_p
IBS NNP 1_p
patients NNS 1_p
with IN 1_p
symptoms NNS 1_p
of IN 1_p
abdominal JJ 1_p
pain NN 1_p
and CC 1_p
constipation NN 1_p
received VBD N
tegaserod JJ 1_i
2 CD N
or CC N
6 CD N
mg JJ N
b.i.d NN N
. . N

( ( N
n JJ N
= NN N
1679 CD N
) ) N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
837 CD N
) ) N
for IN N
12 CD N
wk NN N
. . N

In IN 1_p
an DT 1_p
additional JJ 1_p
study NN 1_p
, , 1_p
36 CD 1_p
healthy JJ 1_p
male NN 1_p
subjects NNS 1_p
received VBD 1_p
iv NN 1_p
. . 1_p

single JJ 1_p
doses NNS 1_p
of IN 1_p
tegaserod NN 1_i
( ( 1_p
0.8 CD 1_p
mg NN 1_p
to TO 1_p
20 CD 1_p
mg NN 1_p
) ) 1_p
or CC 1_i
placebo NN 1_i
. . 1_i

Standard NNP N
12-lead JJ N
electrocardiograms NNS N
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
during IN N
treatment NN N
. . N

Baseline NNP N
values NNS N
were VBD N
compared VBN N
with IN N
data NNS N
collected VBN N
during IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS VB N
The DT N
proportion NN N
of IN N
patients NNS N
with IN N
prolongation NN 1_o
of IN 1_o
the DT 1_o
QTc NNP 1_o
interval NN 1_o
was VBD N
the DT N
same JJ N
for IN N
placebo NN N
and CC N
tegaserod NN N
, , N
as IN N
was VBD N
the DT N
frequency NN 1_o
of IN 1_o
overall JJ 1_o
electrocardiographic JJ 1_o
abnormalities NNS 1_o
. . 1_o

No DT N
ventricular NN 1_o
or CC 1_o
supraventricular JJ 1_o
tachycardia NN 1_o
was VBD N
observed VBN N
. . N

Comparable JJ N
electrocardiographic JJ 1_o
results NNS 1_o
were VBD N
obtained VBN N
during IN N
placebo NN N
and CC N
tegaserod NN N
treatment NN N
. . N

In IN N
healthy JJ 1_p
volunteers NNS 1_p
, , N
tegaserod NN N
at IN N
i.v NN N
. . N

doses NNS N
resulting VBG N
in IN N
plasma NN 1_o
concentrations NNS 1_o
up IN N
to TO N
100 CD N
times NNS N
those DT N
measured VBN N
after IN N
therapeutic JJ N
doses NNS N
( ( N
6 CD N
mg NN N
b.i.d NN N
. . N

) ) N
did VBD N
not RB N
influence VB N
electrocardiographic JJ N
parameters NNS N
. . N

CONCLUSIONS NNP N
Tegaserod NNP N
is VBZ N
devoid JJ N
of IN N
electrocardiographic JJ 1_o
effects NNS 1_o
and CC N
is VBZ N
not RB N
expected VBN N
to TO N
adversely RB N
influence VB N
cardiac JJ 1_o
function NN 1_o
. . 1_o

These DT N
data NNS N
confirm VBP N
preclinical JJ N
findings NNS N
. . N

[ VB N
A DT N
clinical JJ N
trial NN N
of IN N
ultrasound-guided JJ 1_i
facet NNS 1_i
joint JJ 1_i
block NN 1_i
in IN N
the DT N
lumbar NN N
spine NN N
to TO N
treat VB N
facet JJ 1_p
joint NN 1_p
related VBD 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
feasibility NN N
and CC N
clinical JJ N
efficacy NN N
of IN N
ultrasound-guided JJ 1_i
facet NNS 1_i
joint JJ 1_i
injection NN 1_i
and CC N
nerve NN 1_i
block NN 1_i
in IN 1_i
lumbar NN 1_i
facet NN 1_i
joint NN 1_i
for IN N
the DT N
treatment NN N
of IN N
facet-joint NN 1_p
related VBN 1_p
low JJ 1_p
back RB 1_p
pain NN 1_p
. . 1_p

METHODS NNP N
20 CD 1_p
patients NNS 1_p
with IN 1_p
facet-joint JJ 1_p
pain NN 1_p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
received VBD N
block RB 1_i
blindly RB 1_i
( ( 1_i
B NNP 1_i
group NN 1_i
) ) 1_i
or CC 1_i
guided VBN 1_i
by IN 1_i
ultrasound NN 1_i
( ( 1_i
US NNP 1_i
group NN 1_i
) ) 1_i
respectively RB 1_i
. . 1_i

The DT N
location NN N
of IN N
needle JJ N
tip NN N
was VBD N
confirmed VBN N
by IN N
CT NNP N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
accuracy NN N
was VBD N
computed VBN N
afterwards NNS N
. . N

VAS NNP 1_o
score NN 1_o
, , 1_o
puncture NN 1_o
time NN 1_o
and CC 1_o
one-time JJ 1_o
puncture NN 1_o
success NN 1_o
rate NN 1_o
( ( N
% NN N
) ) N
were VBD N
recorded VBN N
. . N

VAS NNP 1_o
scores NNS 1_o
and CC 1_o
pain VB 1_o
remission NN 1_o
rates NNS 1_o
in IN N
both DT N
groups NNS N
were VBD N
recorded VBN N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
, , N
6 CD N
weeks NNS N
after IN N
the DT N
block NN N
. . N

RESULTS VB N
The DT N
VAS NNP 1_o
scores NNS 1_o
were VBD N
3.3 CD N
+/- JJ N
0.4 CD N
in IN N
US NNP N
group NN N
and CC N
1.2 CD N
+/- JJ N
0.3 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
puncture NN 1_o
time NN 1_o
was VBD N
( ( N
206 CD N
+/- JJ N
27 CD N
) ) N
s NN N
in IN N
US NNP N
group NN N
while IN N
( ( N
397 CD N
+/- JJ N
31 CD N
) ) N
s NN N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
37 CD N
facet JJ 1_i
joint NN 1_i
blocks NNS 1_i
guided VBN 1_i
by IN 1_i
ultrasound NN 1_i
, , N
in IN N
which WDT N
32 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
. . N

The DT N
success NN 1_o
rate NN 1_o
is VBZ N
86.5 CD N
% NN N
. . N

There EX N
were VBD N
35 CD N
facet JJ 1_i
joint NN 1_i
blocks NNS 1_i
blindly RB 1_i
, , N
in IN N
which WDT N
11 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
. . N

The DT N
success NN 1_o
rate NN 1_o
is VBZ N
31.4 CD N
% NN N
. . N

The DT N
difference NN N
of IN N
one-time JJ 1_o
puncture NN 1_o
success NN 1_o
rate NN 1_o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
significant JJ 1_o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Differences NNS N
of IN N
VAS NNP 1_o
and CC 1_o
pain VB 1_o
remission NN 1_o
rate NN 1_o
at IN N
half PDT N
an DT N
hour NN N
after IN N
facet JJ N
joint JJ N
injection NN N
between IN N
B NNP N
group NN N
and CC N
US NNP N
group NN N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
8 CD N
, , N
9 CD N
, , N
9 CD N
, , N
and CC N
9 CD N
patients NNS N
in IN N
US NNP N
group NN N
obtaining VBG N
a DT N
reduction NN 1_o
in IN N
VAS NNP 1_o
scores NNS 1_o
> VBP N
or CC N
= VBP N
3 CD N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
and CC N
6 CD N
weeks NNS N
after IN N
the DT N
procedure NN N
respectively RB N
, , N
while IN N
the DT N
numbers NNS N
of IN N
such JJ N
patients NNS N
were VBD N
5 CD N
, , N
6 CD N
, , N
5 CD N
, , N
5 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

After IN N
6 CD N
weeks NNS N
of IN N
follow-up NN N
, , N
the DT N
overall JJ 1_o
remission NN 1_o
rates NNS 1_o
were VBD N
( ( N
72.3 CD N
+/- JJ N
14.0 CD N
) ) N
% NN N
in IN N
US NNP N
group NN N
, , N
and CC N
( ( N
56.7 CD N
+/- JJ N
11.0 CD N
) ) N
% NN N
in IN N
B NNP N
group NN N
, , N
there EX N
was VBD N
no DT 1_o
significant JJ 1_o
difference NN 1_o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
ultrasound-guided JJ 1_i
lumbar NN 1_i
facet NN 1_i
joint JJ 1_i
injection NN 1_i
technique NN 1_i
had VBD N
a DT N
high JJ N
feasibility NN N
and CC N
accuracy NN N
, , N
and CC N
had VBD N
better RBR N
clinical JJ N
efficacy NN N
than IN N
block NN 1_i
blindly RB 1_i
. . 1_i

Evaluation NN N
of IN N
an DT N
intervention NN N
to TO N
change VB N
benzodiazepine-prescribing JJ 1_i
behavior NN N
in IN N
a DT N
prepaid NN N
group NN N
practice NN N
setting VBG N
. . N

To TO N
determine VB N
the DT N
effect NN N
of IN N
two CD N
levels NNS N
of IN N
educational JJ 1_i
intervention NN 1_i
on IN 1_i
benzodiazepine-prescribing JJ 1_i
behavior NN 1_i
in IN N
an DT N
elderly JJ 1_p
population NN 1_p
in IN N
a DT N
controlled JJ N
prepaid NN N
group NN N
practice NN N
( ( N
PPGP NNP N
) ) N
setting NN N
, , N
we PRP N
designed VBD N
a DT N
prospective JJ N
controlled VBN N
trial NN N
, , N
with IN N
six-month JJ N
follow-up NN N
. . N

Our PRP$ N
setting NN 1_p
was VBD 1_p
a DT 1_p
270,000 CD 1_p
member NN 1_p
group-model JJ 1_p
PPGP NNP 1_p
in IN 1_p
Colorado NNP 1_p
, , 1_p
from IN 1_p
1990 CD 1_p
to TO 1_p
1991 CD 1_p
. . 1_p

Participants NNS 1_p
included VBD 1_p
91 CD 1_p
physicians NNS 1_p
, , 1_p
62 CD 1_p
men NNS 1_p
and CC 1_p
29 CD 1_p
women NNS 1_p
; : 1_p
median JJ 1_p
age NN 1_p
was VBD 1_p
38.7 CD 1_p
years NNS 1_p
. . 1_p

Group NNP N
1 CD N
received VBD N
a DT N
one-on-one JJ 1_i
educational JJ 1_i
presentation NN 1_i
by IN 1_i
a DT 1_i
clinical JJ 1_i
pharmacist NN 1_i
, , 1_i
written VBN 1_i
educational JJ 1_i
materials NNS 1_i
, , 1_i
a DT 1_i
brief JJ 1_i
follow-up JJ 1_i
visit NN 1_i
, , 1_i
and CC 1_i
feedback NN 1_i
with IN 1_i
recommendations NNS 1_i
. . 1_i

Group NNP N
2 CD N
received VBD N
only RB N
a DT N
face-to-face JJ 1_i
presentation NN 1_i
, , 1_i
given VBN 1_i
to TO 1_i
departmental VB 1_i
groups NNS 1_i
, , 1_i
as RB 1_i
well RB 1_i
as IN 1_i
the DT 1_i
same JJ 1_i
written VBN 1_i
educational JJ 1_i
materials NNS 1_i
used VBN 1_i
in IN 1_i
group NN 1_i
1 CD 1_i
. . 1_i

Controls NNP N
received VBD N
no DT 1_i
intervention NN 1_i
. . 1_i

Our PRP$ N
primary JJ N
outcome JJ N
measure NN N
was VBD N
the DT N
benzodiazepine NN 1_o
" NNP 1_o
on/off IN 1_o
" NNP 1_o
status NN 1_o
of IN 1_o
the DT 1_o
elderly JJ 1_o
PPGP NNP 1_o
members NNS 1_o
. . 1_o

The DT N
secondary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
median JJ 1_o
change NN 1_o
( ( 1_o
preintervention NN 1_o
minus IN 1_o
postintervention NN 1_o
) ) 1_o
in IN 1_o
a DT 1_o
standardized JJ 1_o
amount NN 1_o
of IN 1_o
benzodiazepines NNS 1_o
prescribed VBN 1_o
per IN 1_o
physician NN 1_o
. . 1_o

Logistic JJ N
regression NN N
analysis NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
effect NN N
on IN N
postintervention NN N
benzodiazepine NN 1_o
on/off NN 1_o
status NN 1_o
between IN N
study NN N
groups NNS N
, , N
when WRB N
controlling VBG N
for IN N
preintervention NN N
on/off NN N
status NN N
, , N
PPGP-member NNP N
age NN N
, , N
PPGP-member NNP N
gender NN N
, , N
and CC N
all DT N
possible JJ N
interactions NNS N
. . N

Analysis NN N
of IN N
variance NN N
failed VBD N
to TO N
demonstrate VB N
an DT N
effect NN N
of IN N
either DT N
intervention NN N
on IN N
the DT N
median JJ 1_o
change NN 1_o
in IN 1_o
standardized JJ 1_o
amount NN 1_o
of IN 1_o
benzodiazepines NNS 1_o
prescribed VBN N
per IN N
physician NN N
, , N
with IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
controls NNS N
yielding VBG N
values NNS N
of IN N
-278 NN N
( ( N
range NN N
: : N
-4,137 NN N
, , N
2,844 CD N
) ) N
, , N
-330 NNP N
( ( N
-1,531 NNP N
, , N
1,358 CD N
) ) N
, , N
and CC N
-541 NNP N
( ( N
range NN N
: : N
-3,716 NN N
, , N
2,185 CD N
) ) N
, , N
respectively RB N
. . N

We PRP N
conclude VBP N
that IN N
strategies NNS N
effective JJ N
in IN N
changing VBG N
physician JJ N
prescribing VBG N
behavior NN N
in IN N
other JJ N
settings NNS N
may MD N
not RB N
be VB N
effective JJ N
in IN N
a DT N
PPGP NNP N
setting VBG N
with IN N
benzodiazepines NNS 1_i
in IN N
the DT N
elderly JJ N
as IN N
the DT N
target NN N
for IN N
change NN N
. . N

A DT N
randomized JJ N
, , N
placebo-controlled JJ 1_i
phase NN N
2 CD N
study NN N
of IN N
ganitumab NN 1_i
or CC 1_i
conatumumab NN 1_i
in IN N
combination NN N
with IN N
FOLFIRI NNP N
for IN N
second-line JJ N
treatment NN N
of IN N
mutant JJ N
KRAS NNP N
metastatic JJ N
colorectal NN N
cancer NN N
. . N

BACKGROUND NNP N
Targeted VBD N
agents NNS N
presently RB N
available JJ N
for IN N
mutant JJ N
KRAS NNP N
metastatic JJ N
colorectal NN N
cancer NN N
( ( N
mCRC NN N
) ) N
are VBP N
bevacizumab JJ 1_i
and CC N
aflibercept JJ 1_i
. . 1_i

We PRP N
evaluated VBD N
the DT N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
conatumumab NN 1_i
( ( N
an DT N
agonistic JJ N
monoclonal NN N
antibody NN N
against IN N
human JJ N
death NN N
receptor NN N
5 CD N
) ) N
and CC N
ganitumab NN 1_i
( ( N
a DT N
monoclonal NN N
antibody NN N
against IN N
the DT N
type NN N
1 CD N
insulin-like JJ N
growth NN N
factor NN N
receptor NN N
) ) N
combined VBN N
with IN N
standard JJ N
FOLFIRI NNP N
chemotherapy NN N
as IN N
a DT N
second-line JJ N
treatment NN N
in IN N
patients NNS N
with IN N
mutant JJ N
KRAS NNP N
mCRC NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS 1_p
with IN 1_p
mutant JJ 1_p
KRAS NNP 1_p
metastatic JJ 1_p
adenocarcinoma NN 1_p
of IN 1_p
the DT 1_p
colon NN 1_p
or CC 1_p
rectum VB 1_p
refractory NN 1_p
to TO 1_p
fluoropyrimidine- JJ 1_i
and CC 1_i
oxaliplatin-based JJ 1_i
chemotherapy NN 1_i
were VBD N
randomized VBN N
1 CD N
: : N
1 CD N
: : N
1 CD N
to TO N
receive VB N
intravenous JJ 1_i
FOLFIRI NNP 1_i
plus CC 1_i
conatumumab JJ 1_i
10 CD 1_i
mg/kg NN 1_i
( ( 1_i
Arm NNP 1_i
A NNP 1_i
) ) 1_i
, , 1_i
ganitumab $ 1_i
12 CD 1_i
mg/kg NN 1_i
( ( 1_i
Arm NNP 1_i
B NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
( ( N
Arm NNP N
C NNP N
) ) N
Q2W NNP N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
progression-free JJ 1_o
survival NN 1_o
( ( 1_o
PFS NNP 1_o
) ) 1_o
. . 1_o

RESULTS NNP N
In IN N
total JJ N
, , N
155 CD 1_p
patients NNS 1_p
were VBD 1_p
randomized VBN 1_p
. . 1_p

Median JJ 1_o
PFS NNP 1_o
in IN N
Arms NNP N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
was VBD N
6.5 CD N
months NNS N
( ( N
HR NNP N
, , N
0.69 CD N
; : N
P NNP N
= NNP N
0.147 CD N
) ) N
, , N
4.5 CD N
months NNS N
( ( N
HR NNP N
, , N
1.01 CD N
; : N
P NNP N
= NNP N
0.998 CD N
) ) N
, , N
and CC N
4.6 CD N
months NNS N
, , N
respectively RB N
; : N
median JJ 1_o
overall JJ 1_o
survival NN 1_o
was VBD N
12.3 CD N
months NNS N
( ( N
HR NNP N
, , N
0.89 CD N
; : N
P NNP N
= NNP N
0.650 CD N
) ) N
, , N
12.4 CD N
months NNS N
( ( N
HR NNP N
, , N
1.27 CD N
; : N
P NNP N
= NNP N
0.357 CD N
) ) N
, , N
and CC N
12.0 CD N
months NNS N
; : N
and CC N
objective JJ 1_o
response NN 1_o
rate NN 1_o
was VBD N
14 CD N
% NN N
, , N
8 CD N
% NN N
, , N
and CC N
2 CD N
% NN N
. . N

The DT N
most RBS N
common JJ N
grade NN N
≥3 JJ 1_o
adverse JJ 1_o
events NNS 1_o
in IN N
Arms NNP N
A/B/C NNP N
included VBD 1_o
neutropenia NN 1_o
( ( N
30 CD N
% NN N
/25 CD N
% NN N
/18 NNP N
% NN N
) ) N
and CC 1_o
diarrhea NN 1_o
( ( N
18 CD N
% NN N
/2 CD N
% NN N
/10 NNP N
% NN N
) ) N
. . N

CONCLUSIONS NNP 1_i
Conatumumab NNP 1_i
, , N
but CC N
not RB 1_i
ganitumab VB 1_i
, , 1_i
plus CC 1_i
FOLFIRI NNP 1_i
was VBD N
associated VBN N
with IN N
a DT N
trend NN N
toward IN 1_o
improved JJ 1_o
PFS NNP 1_o
. . N

Both NNP N
combinations NNS N
had VBD 1_o
acceptable JJ 1_o
toxicity NN 1_o
. . N

Pharmacokinetics NNS N
and CC N
follicular JJ N
dynamics NNS N
of IN N
corifollitropin NN 1_i
alfa NN 1_i
versus NN 1_i
recombinant JJ 1_i
FSH NNP 1_i
during IN N
ovarian JJ 1_p
stimulation NN 1_p
for IN 1_p
IVF NNP 1_p
. . 1_p

A NNP N
single JJ N
injection NN N
of IN N
corifollitropin NN 1_i
alfa NN 1_i
can MD N
replace VB N
seven CD N
daily JJ N
injections NNS N
of IN N
recombinant JJ 1_i
FSH NNP 1_i
( ( 1_i
rFSH NN 1_i
) ) 1_i
using VBG N
a DT N
gonadotrophin-releasing JJ N
hormone NN N
antagonist NN N
protocol NN N
in IN N
ovarian JJ N
stimulation NN N
prior RB 1_p
to TO 1_p
IVF NNP 1_p
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
. . N

This DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
assessed VBD N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
150μg CD 1_i
corifollitropin NN 1_i
alfa NN 1_i
versus IN 1_i
daily JJ 1_i
200IU CD 1_i
rFSH NN 1_i
in IN 1_p
1509 CD 1_p
patients NNS 1_p
. . N

Comparative JJ N
analyses NNS N
were VBD N
performed VBN N
on IN 1_o
serum JJ 1_o
concentrations NNS 1_o
of IN 1_o
FSH NNP 1_o
immunoreactivity NN 1_o
( ( N
pharmacokinetics NNS N
) ) N
, , N
and CC N
the DT 1_o
number NN 1_o
and CC 1_o
size NN 1_o
of IN 1_o
growing VBG 1_o
follicles NNS 1_o
, , 1_o
and CC 1_o
inhibin NN 1_o
B NNP 1_o
and CC 1_o
oestradiol JJ 1_o
concentrations NNS 1_o
as IN N
biomarkers NNS N
of IN N
ovarian JJ N
response NN N
( ( N
pharmacodynamics NNS N
) ) N
. . N

The DT 1_o
rate NN 1_o
of IN 1_o
follicular JJ 1_o
development NN 1_o
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

By IN N
stimulation NN N
day NN N
8 CD N
, , N
33 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
corifollitropin NN N
alfa NN N
reached VBD N
the DT N
criterion NN N
for IN N
human JJ N
chorionic NN N
gonadotrophin NN N
( ( N
HCG NNP N
) ) N
injection NN N
. . N

The DT 1_o
number NN 1_o
of IN 1_o
follicles NNS 1_o
⩾11mm NNP 1_o
was VBD N
slightly RB N
higher JJR N
after IN 1_i
corifollitropin NN 1_i
alfa NN 1_i
compared VBN N
with IN N
daily JJ N
rFSH NN N
at IN N
stimulation NN N
day NN N
8 CD N
( ( N
difference NN N
, , N
1.2 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.5-1.8 NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
on IN N
the DT N
day NN N
of IN N
HCG NNP N
injection NN N
( ( N
difference NN N
, , N
2.1 CD N
; : N
95 CD N
% NN N
CI NNP N
1.4-2.8 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT 1_o
rise NN 1_o
of IN 1_o
inhibin NN 1_o
B NNP 1_o
and CC 1_o
oestradiol JJ 1_o
concentrations NNS 1_o
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Although IN N
the DT N
pharmacokinetics NNS N
of IN 1_i
corifollitropin NN 1_i
alfa NN 1_i
and CC 1_i
rFSH NN 1_i
are VBP N
quite RB N
different JJ N
their PRP$ N
pharmacodynamic JJ N
profiles NNS N
at IN N
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

A DT N
single JJ N
injection NN N
of IN 1_i
corifollitropin NN 1_i
alfa NN 1_i
can MD N
replace VB N
seven CD N
daily JJ N
injections NNS N
of IN 1_i
recombinant JJ 1_i
FSH NNP 1_i
( ( 1_i
rFSH NN 1_i
) ) 1_i
using VBG N
a DT N
gonadotrophin-releasing JJ N
hormone NN N
antagonist NN N
protocol NN N
in IN N
ovarian JJ N
stimulation NN N
prior RB N
to TO N
IVF NNP N
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN 1_i
corifollitropin NN 1_i
alfa JJ 1_i
versus JJ 1_i
daily JJ 1_i
rFSH NN 1_i
. . N

A DT N
total NN N
of IN 1_p
1509 CD 1_p
patients NNS 1_p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind NN N
, , N
controlled VBN N
trial NN N
to TO N
either VB N
a DT N
single JJ N
injection NN N
of IN N
150μg CD 1_i
corifollitropin NN 1_i
alfa NN 1_i
or CC N
to TO N
daily JJ N
injections NNS N
of IN N
200IU CD 1_i
rFSH NN 1_i
for IN N
the DT N
first JJ N
7 CD N
days NNS N
of IN N
ovarian JJ N
stimulation NN 1_o
. . 1_o

Serum NNP 1_o
levels NNS 1_o
of IN 1_o
FSH NNP 1_o
immunoreactivity NN 1_o
were VBD N
analysed VBN N
( ( N
pharmacokinetic JJ N
analysis NN N
) ) N
, , N
together RB N
with IN N
the DT 1_o
number NN 1_o
and CC 1_o
size NN 1_o
of IN 1_o
growing VBG 1_o
follicles NNS 1_o
and CC 1_o
serum NN 1_o
inhibin NN 1_o
B NNP N
and CC 1_o
oestradiol JJ 1_o
concentrations NNS 1_o
as IN N
biomarkers NNS N
of IN N
the DT N
ovarian JJ N
response NN N
( ( N
pharmacodynamic JJ N
analysis NN 1_o
) ) 1_o
. . 1_o

Serum NNP 1_o
FSH NNP 1_o
immunoreactivity NN 1_o
levels NNS 1_o
were VBD N
higher JJR N
up RB N
to TO N
stimulation VB N
day NN N
5 CD N
for IN 1_i
corifollitropin NN 1_i
alfa NN 1_i
compared VBN N
with IN N
the DT N
daily JJ 1_i
rFSH NN 1_i
regimen NNS N
but CC N
were VBD N
similar JJ N
from IN N
day NN N
8 CD N
onwards NNS N
, , N
when WRB N
patients NNS N
started VBD N
rFSH RB N
if IN N
the DT N
criteria NN N
for IN N
human JJ N
chorionic NN N
gonadotrophin NN N
were VBD N
not RB N
yet RB N
reached VBN 1_i
. . 1_i

Corifollitropin NNP 1_i
alfa JJ 1_i
treatment NN N
resulted VBD N
in IN 1_o
a DT 1_o
similar JJ 1_o
growth NN 1_o
rate NN 1_o
of IN 1_o
follicles NNS 1_o
though IN N
a DT N
slightly RB 1_o
higher JJR 1_o
number NN 1_o
of IN 1_o
follicles NNS 1_o
were VBD N
recruited VBN N
compared VBN N
with IN N
daily JJ N
rFSH NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
pharmacokinetics NNS 1_i
of IN 1_i
corifollitropin NN 1_i
alfa NN 1_i
and CC 1_i
rFSH NN 1_i
are VBP N
quite RB N
different JJ N
but CC N
their PRP$ N
induced JJ 1_o
pharmacodynamic JJ 1_o
effects NNS 1_o
at IN N
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

A DT N
prospective JJ N
randomized NN N
study NN N
concerning VBG N
the DT N
point NN N
A NNP N
dose NN N
in IN N
high-dose JJ 1_i
rate NN 1_i
intracavitary JJ 1_i
therapy NN 1_i
for IN N
carcinoma NN 1_p
of IN 1_p
the DT 1_p
uterine JJ 1_p
cervix NN 1_p
. . 1_p

The DT N
final JJ N
results NNS N
. . N

PURPOSE NNP N
High-dose JJ 1_i
rate NN 1_i
( ( 1_i
HDR NNP 1_i
) ) 1_i
remote VBP 1_i
afterloading VBG 1_i
intracavitary JJ 1_i
therapy NN 1_i
has VBZ N
been VBN N
recognized VBN N
as IN N
an DT N
effective JJ N
and CC N
safe JJ N
treatment NN N
modality NN N
for IN N
carcinoma NN 1_p
of IN 1_p
the DT 1_p
uterine JJ 1_p
cervix NN 1_p
. . 1_p

Since IN N
1983 CD N
, , N
a DT N
prospective JJ N
randomized NN N
study NN N
was VBD N
started VBN N
in IN N
order NN N
to TO N
investigate VB N
the DT N
more RBR N
advantageous JJ N
treatment NN N
schedule NN N
with IN N
keeping VBG N
the DT N
local JJ N
control NN N
rate NN N
. . N

This DT N
paper NN N
reports VBZ N
the DT N
final JJ N
results NNS N
in IN N
terms NNS N
of IN N
survival NN N
, , N
local JJ N
control NN N
and CC N
complications NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP 1_p
January NNP 1_p
1983 CD 1_p
and CC 1_p
February NNP 1_p
1989 CD 1_p
, , 1_p
a DT 1_p
total NN 1_p
of IN 1_p
165 CD 1_p
patients NNS 1_p
with IN 1_p
carcinoma NN 1_p
of IN 1_p
the DT 1_p
uterine JJ 1_p
cervix NN 1_p
was VBD 1_p
entered VBN 1_p
in IN 1_p
a DT 1_p
prospective JJ 1_p
randomized NN 1_p
study NN 1_p
concerning VBG 1_p
the DT 1_p
point NN 1_p
A NNP 1_p
dose NN 1_i
of IN 1_i
HDR NNP 1_i
therapy NN 1_i
( ( 1_i
6 CD 1_i
Gy/fraction NNP 1_i
vs FW 1_i
7.5 CD 1_i
Gy/fraction NNP 1_i
) ) 1_i
and CC 1_i
external JJ 1_i
irradiation NN 1_i
dose NN 1_i
at IN 1_i
Department NNP 1_i
of IN 1_i
Radiation NNP 1_i
Therapy NNP 1_i
, , 1_p
The DT 1_p
Center NNP 1_p
for IN 1_p
Adult NNP 1_p
Diseases NNP 1_p
, , 1_p
Osaka NNP 1_p
. . 1_p

UICC NNP 1_p
[ VBD 1_p
20 CD 1_p
] JJ 1_p
stage NN 1_p
distribution NN 1_p
of IN 1_p
patients NNS 1_p
was VBD 1_p
as IN 1_p
follows VBZ 1_p
: : 1_p
stage NN 1_p
IA NNP 1_p
= NNP 1_p
4 CD 1_p
, , 1_p
stage NN 1_p
IB NNP 1_p
= NNP 1_p
33 CD 1_p
, , 1_p
stage NN 1_p
IIA NNP 1_p
= NNP 1_p
18 CD 1_p
, , 1_p
stage NN 1_p
IIB NNP 1_p
= NNP 1_p
38 CD 1_p
, , 1_p
stage NN 1_p
III NNP 1_p
= NNP 1_p
57 CD 1_p
, , 1_p
stage NN 1_p
IV NNP 1_p
= VBZ 1_p
15 CD 1_p
. . 1_p

RESULTS VB N
Overall JJ N
5-year JJ 1_o
cause NN 1_o
specific JJ 1_o
survivals NNS 1_o
were VBD N
as IN N
follows VBZ N
: : N
stage NN N
IA NNP N
= VBZ N
100 CD N
% NN N
, , N
stage NN N
IB NNP N
= VBZ N
96 CD N
% NN N
, , N
stage NN N
IIA NNP N
= VBZ N
92 CD N
% NN N
, , N
stage NN N
IIB NNP N
= VBZ N
79 CD N
% NN N
, , N
stage NN N
III NNP N
= VBZ N
57 CD N
% NN N
, , N
stage NN N
IV NNP N
= VBZ N
27 CD N
% NN N
. . N

In IN N
each DT N
stage NN N
, , N
5-year JJ 1_o
survival NN 1_o
rates NNS 1_o
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
were VBD N
100 CD N
% NN N
, , N
93 CD N
% NN N
in IN N
stage NN N
I PRP N
, , N
82 CD N
% NN N
and CC N
85 CD N
% NN N
in IN N
stage NN N
II NNP N
, , N
62 CD N
% NN N
and CC N
52 CD N
% NN N
in IN N
stage NN N
II NNP N
and CC N
22 CD N
% NN N
and CC N
31 CD N
% NN N
in IN N
stage NN N
IV NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
among IN N
these DT N
survival JJ N
curves NNS N
in IN N
each DT N
stage NN N
. . N

Five-year JJ 1_o
local JJ 1_o
failure NN 1_o
rates NNS 1_o
were VBD N
16 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
16 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.9096 CD N
) ) N
, , N
and CC N
corresponding VBG N
distant JJ N
failure NN N
rates NNS N
were VBD N
23 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
19 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p JJ N
= NNP N
0.2955 CD N
) ) N
. . N

Moderate-to-severe JJ 1_o
complications NNS 1_o
requiring VBG N
treatment NN N
( ( N
Kottmeier NNP N
's POS N
grade NN N
2 CD N
or CC N
more JJR N
) ) N
were VBD N
noted VBN N
in IN N
6 CD N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
and CC N
6 CD N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
group NN N
B NNP N
. . N

All DT N
of IN N
the DT N
bladder NN 1_o
and CC 1_o
rectal JJ 1_o
complications NNS 1_o
needed VBD N
medical JJ N
treatment NN N
( ( N
Kottmeier NNP N
's POS N
grade NN N
2 CD N
) ) N
. . N

Severe JJ 1_o
complications NNS 1_o
receiving VBG N
surgery NN N
were VBD N
noted VBN N
in IN N
4 CD N
patients NNS N
( ( N
A DT N
: : N
1 CD N
; : N
B NNP N
: : N
3 CD N
) ) N
, , N
i.e. FW N
, , N
small JJ N
intestine NN N
3 CD N
and CC N
sigmoid JJ N
colon NN N
1 CD N
patient NN N
. . N

Another DT N
1 CD N
patient NN N
( ( N
A DT N
) ) N
was VBD N
dead JJ 1_o
of IN N
ileus NN N
. . N

CONCLUSIONS NNP N
There EX N
were VBD N
no DT N
statistically RB 1_o
significant JJ 1_o
differences NNS 1_o
between IN 1_o
2 CD 1_o
treatment NN 1_o
schedules NNS 1_o
in IN 1_o
survival NN 1_o
rates NNS 1_o
, , 1_o
failure NN 1_o
patterns NNS 1_o
and CC 1_o
complications NNS 1_o
rates NNS 1_o
. . 1_o

This DT N
fact NN N
suggests VBZ N
that IN N
small JJ N
number NN N
of IN N
fractions NNS N
( ( N
7.5 CD N
Gy/fraction NNP N
) ) N
may MD N
be VB N
advantageous JJ N
because IN N
of IN N
short JJ N
duration NN N
and CC N
a DT N
low JJ N
load NN N
of IN N
treatment NN N
. . N

Chronic NNP N
fatigue NN N
syndrome NN N
versus NN N
neuroendocrineimmune JJ N
dysfunction NN N
syndrome NN 1_i
: : 1_i
differential JJ 1_i
attributions NNS 1_i
. . 1_i

Since IN N
1988 CD N
, , N
when WRB N
the DT N
term NN N
chronic JJ N
fatigue NN N
syndrome NN N
( ( N
CFS NNP N
) ) N
was VBD N
coined VBN N
, , N
considerable JJ N
discussion NN N
has VBZ N
occurred VBN N
about IN N
stigma NN N
associated VBN N
with IN N
this DT N
diagnostic JJ N
term NN N
. . N

In IN N
particular JJ N
, , N
patients NNS 1_p
with IN 1_p
CFS NNP 1_p
have VBP N
felt VBN N
that IN N
this DT N
term NN N
trivializes VBZ N
the DT N
serious JJ N
nature NN N
of IN N
this DT N
disorder NN N
. . N

A DT N
Name NN N
Change NNP N
Work NNP N
group NN N
, , N
appointed VBN N
by IN N
the DT N
CFS NNP N
Coordinating NNP N
Committee NNP N
, , N
developed VBD N
an DT N
umbrella JJ N
term NN N
: : N
chronic JJ N
neuroendocrineimmune JJ N
dysfunction NN N
syndrome NN N
( ( N
CNDS NNP N
) ) N
, , N
and CC N
proposed VBD N
that IN N
there EX N
would MD N
be VB N
sub-types JJ N
under IN N
this DT N
term NN N
, , N
one CD N
being VBG N
CFS NNP N
. . N

The DT N
present JJ N
study NN N
examined VBD N
attributions NNS 1_o
of IN N
this DT N
new JJ N
umbrella JJ N
term NN N
when WRB N
compared VBN N
with IN N
CFS NNP N
. . N

Nurses NNS 1_i
and CC 1_i
physician JJ 1_i
assistants NNS 1_i
( ( 1_i
PAs NNP 1_i
) ) 1_i
were VBD 1_i
presented VBN 1_i
a DT 1_i
case NN 1_i
study NN 1_i
of IN 1_i
a DT 1_i
patient NN 1_i
with IN 1_i
symptoms NNS 1_i
of IN 1_i
CFS NNP 1_i
. . 1_i

They PRP N
were VBD N
told VBN N
that IN N
the DT N
patient NN 1_p
had VBD 1_p
either CC 1_p
" NNP 1_p
chronic JJ 1_p
fatigue NN 1_p
syndrome NN 1_p
, , 1_p
" NNP 1_p
" NNP 1_p
chronic JJ 1_p
neuroendocrineimmune JJ 1_p
dysfunction NN 1_p
syndrome NN 1_p
, , 1_p
" '' 1_p
or CC 1_p
" VB 1_p
chronic JJ 1_p
neuroendocrineimmune JJ 1_p
dysfunction NN 1_p
syndrome NN 1_p
, , N
which WDT N
had VBD N
formerly RB N
been VBN N
called VBN N
chronic JJ N
fatigue NN N
syndrome NN N
. . N

" VB N
The DT N
different JJ N
terms NNS N
led VBD N
to TO N
different JJ N
attributions NNS N
, , N
with IN N
PA NNP N
respondents NNS N
rating NN N
the DT N
" NNP N
CNDS NNP N
" NNP N
label NN N
as IN N
more RBR N
severe JJ N
. . N

Results VB N
suggest VBP N
that IN N
a DT N
more RBR N
medical JJ 1_o
sounding VBG 1_o
term NN 1_o
( ( 1_i
CNDS NNP 1_i
) ) 1_i
may MD N
lead VB N
to TO N
attributions NNS 1_o
that IN N
this DT N
syndrome NN N
is VBZ N
a DT N
more RBR 1_o
serious JJ 1_o
, , 1_o
disabling VBG 1_o
illness NN 1_o
. . 1_o

The DT N
policy NN N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

[ JJ N
Platelet NNP N
serotonin NN N
in IN N
infantile JJ 1_p
autism NN 1_p
. . 1_p

Cross-over JJ N
effects NNS N
of IN N
a DT N
dopamine JJ 1_i
agonist NN 1_i
and CC 1_i
an DT 1_i
antagonist JJ 1_i
] NN 1_i
. . N

In IN N
infantile JJ 1_p
autism NN 1_p
, , N
the DT N
serotoninergic NN N
( ( N
5-HT JJ N
) ) N
hypothesis NN N
is VBZ N
corroborated VBN N
by IN N
biological JJ N
dosages NNS N
and CC N
therapeutic JJ N
effects NNS N
of IN N
fenfluramine NN 1_i
which WDT N
decrease NN N
blood NN N
serotonin NN N
. . N

However RB N
other JJ N
drugs NNS N
, , N
such JJ N
as IN N
dopaminergic JJ 1_i
agonists NNS 1_i
or CC N
antagonists NNS 1_i
, , N
have VBP N
therapeutic JJ N
effects NNS N
. . N

Therefore RB N
, , N
we PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
two CD N
dopaminergic NN 1_i
( ( 1_i
DA NNP 1_i
) ) 1_i
drugs NNS 1_i
have VBP N
a DT N
similar JJ N
5-HT JJ N
effect NN N
underlying VBG N
the DT N
therapeutic JJ N
efficiency NN N
. . N

We PRP N
evaluated VBD N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
and CC N
cross-over JJ N
study NN N
, , N
the DT N
effects NNS N
of IN N
a DT N
DA NNP 1_i
agonist NN 1_i
( ( 1_i
bromocriptine NN 1_i
) ) 1_i
and CC 1_i
a DT 1_i
DA NNP 1_i
antagonist NN 1_i
( ( 1_i
amisulpride RB 1_i
) ) 1_i
on IN N
platelet NN N
5-HT JJ N
in IN N
infantile JJ 1_p
autism NN 1_p
. . 1_p

The DT N
prolactinemia NN N
, , N
reflecting VBG N
the DT N
DA NNP N
action NN N
, , N
has VBZ N
been VBN N
also RB N
measured VBN N
. . N

Nine NNP 1_p
children NNS 1_p
, , 1_p
aged VBN 1_p
from IN 1_p
4 CD 1_p
to TO 1_p
13 CD 1_p
years NNS 1_p
, , 1_p
according VBG 1_p
to TO 1_p
the DT 1_p
DSM NNP 1_p
III NNP 1_p
for IN 1_p
infantile JJ 1_p
autism NN 1_p
, , N
received VBD N
either DT N
drug NN N
in IN N
a DT N
random JJ N
order NN N
during IN N
four CD N
weeks NNS N
with IN N
an DT N
in-between JJ N
placebo NN 1_i
period NN N
of IN N
six CD N
weeks NNS N
. . N

The DT N
dosages NNS N
of IN N
platelet NN 1_i
5-HT JJ 1_i
and CC 1_i
serum JJ 1_i
prolactin NN 1_i
were VBD N
carried VBN N
out RP N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
every DT N
phase NN N
of IN N
treatment NN N
( ( N
active JJ N
or CC N
placebo NN 1_i
) ) 1_i
with IN N
radioenzymology NN N
and CC N
radioimmunoassay VB N
methods NNS N
respectively RB N
. . N

The DT N
principal JJ N
results NNS N
on IN N
serum JJ 1_o
prolactin NN 1_o
show NN N
neither DT N
order NN 1_o
x NNP 1_o
treatment NN 1_o
interaction NN 1_o
, , N
nor CC N
order NN N
effect NN N
but CC N
a DT N
significant JJ N
treatment NN 1_o
effect NN 1_o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
: : N
amisulpride NN 1_i
increases VBZ 1_o
serum JJ 1_o
prolactin NN 1_o
whereas NNS N
bromocriptine VBP 1_o
decreases VBZ 1_o
according VBG N
to TO N
the DT N
usual JJ N
data NN N
. . N

About IN N
platelet NN 1_o
5-HT JJ 1_o
, , N
there EX N
is VBZ N
neither DT N
order NN N
x NNP N
treatment NN N
interaction NN N
, , N
nor CC N
treatment NN N
effect NN N
but CC N
a DT N
significant JJ N
order NN 1_o
effect NN 1_o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Both DT N
drugs NNS N
increase VBP 1_o
platelet NN 1_o
5-HT JJ 1_o
in IN N
the DT N
first JJ N
phase NN N
of IN N
treatment NN N
. . N

This DT N
order NN N
effect NN N
could MD N
be VB N
explained VBN N
by IN N
a DT N
remanent JJ N
effect NN N
of IN N
amisulpride NN N
after IN N
6 CD N
wash-out JJ N
weeks NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
risperidone NN 1_i
in IN N
adults NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
and CC 1_p
other JJ 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
. . 1_p

BACKGROUND NNP N
Neurobiological NNP N
research NN N
has VBZ N
implicated VBN N
the DT N
dopamine NN N
and CC N
serotonin JJ N
systems NNS N
in IN N
the DT N
pathogenesis NN N
of IN N
autism NN 1_p
. . 1_p

Open-label JJ N
reports NNS N
suggest VBP N
that IN N
the DT N
serotonin2A-dopamine JJ 1_i
D2 NNP 1_i
antagonist NN 1_i
risperidone NN 1_i
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
reducing VBG N
the DT N
interfering NN N
symptoms NNS N
of IN N
patients NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

METHODS NNP N
Thirty-one CD 1_p
adults NNS 1_p
( ( 1_p
age NN 1_p
[ VBZ 1_p
mean+/-SD JJ 1_p
] NNP 1_p
, , 1_p
28.1+/-7.3 JJ 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
( ( 1_p
n=17 JJ 1_p
) ) 1_p
or CC 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
not RB 1_p
otherwise RB 1_p
specified VBN 1_p
( ( 1_p
n=14 JJ 1_p
) ) 1_p
participated VBD 1_p
in IN 1_p
a DT 1_p
12-week JJ 1_p
double-blind NN 1_p
, , 1_p
placebo-controlled JJ 1_i
trial NN 1_p
of IN 1_p
risperidone NN 1_i
. . 1_i

Patients NNS N
treated VBD N
with IN N
placebo NN N
subsequently RB N
received VBD N
a DT N
12-week JJ N
open-label JJ N
trial NN N
of IN N
risperidone NN 1_i
. . 1_i

RESULTS NNP N
For IN N
persons NNS N
completing VBG N
the DT N
study NN N
, , N
8 CD N
( ( N
57 CD N
% NN N
) ) N
of IN N
14 CD N
patients NNS N
treated VBN N
with IN N
risperidone NN 1_i
were VBD N
categorized VBN N
as IN N
responders NNS N
( ( N
daily JJ N
dose VB N
[ JJ N
mean+/-SD JJ N
] NN N
, , N
2.9+/-1.4 JJ N
mg NN N
) ) N
compared VBN N
with IN N
none NN N
of IN N
16 CD N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

Risperidone NN 1_i
was VBD N
superior JJ N
to TO N
placebo VB 1_i
in IN N
reducing VBG N
repetitive JJ 1_o
behavior NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
aggression NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
anxiety NN 1_o
or CC 1_o
nervousness NN 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
.02 NNP 1_o
) ) 1_o
, , 1_o
depression NN 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
.03 NNP 1_o
) ) 1_o
, , 1_o
irritability NN 1_o
( ( 1_o
P NNP 1_o
< NNP 1_o
.01 NNP 1_o
) ) 1_o
, , N
and CC N
the DT N
overall JJ 1_o
behavioral JJ 1_o
symptoms NNS 1_o
of IN 1_o
autism NN 1_o
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Objective NNP N
, , N
measurable JJ N
change NN N
in IN N
social JJ 1_o
behavior NN 1_o
and CC 1_o
language NN 1_o
did VBD N
not RB N
occur VB N
. . N

Nine NNP N
( ( N
60 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
who WP N
received VBD N
treatment NN N
with IN N
open-label JJ N
risperidone NN N
following VBG N
the DT N
double-blind JJ N
placebo NN 1_i
phase NN N
responded VBD N
. . N

Other JJ N
than IN N
mild JJ 1_o
, , 1_o
transient JJ 1_o
sedation NN 1_o
, , N
risperidone NN N
was VBD N
well RB N
tolerated VBN 1_o
, , N
with IN N
no DT N
evidence NN N
of IN N
extrapyramidal JJ 1_o
effects NNS 1_o
, , 1_o
cardiac JJ 1_o
events NNS 1_o
, , 1_o
or CC 1_o
seizures NNS 1_o
. . 1_o

CONCLUSION NNP N
Risperidone NNP 1_i
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN 1_i
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
symptoms NNS N
of IN N
autism NN 1_p
in IN 1_p
adults NNS 1_p
. . 1_p

Group-based JJ N
HIV NNP 1_i
risk NN 1_i
reduction NN 1_i
intervention NN 1_i
for IN N
adolescent JJ 1_p
girls NNS 1_p
: : 1_p
evidence NN N
of IN N
feasibility NN N
and CC N
efficacy NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
( ( N
a DT N
) ) N
to TO N
assess VB N
the DT N
feasibility NN 1_o
of IN N
a DT N
community-based JJ 1_i
, , 1_i
small JJ 1_i
group NN 1_i
HIV NNP 1_i
risk NN 1_i
reduction NN 1_i
intervention NN 1_i
with IN N
adolescent JJ 1_p
girls NNS 1_p
, , N
and CC N
( ( N
b NN N
) ) N
to TO N
obtain VB N
preliminary JJ N
evidence NN N
of IN N
the DT N
efficacy NN 1_o
of IN N
this DT N
theoretically-guided JJ 1_i
intervention NN 1_i
using VBG N
a DT N
controlled JJ N
design NN N
. . N

The DT N
feasibility NN N
of IN N
the DT N
intervention NN N
was VBD N
demonstrated VBN N
by IN N
successfully RB N
implementing VBG N
it PRP N
with IN N
33 CD 1_p
sexually-active JJ 1_p
, , 1_p
single JJ 1_p
girls NNS 1_p
. . 1_p

Preliminary JJ N
evidence NN N
of IN N
the DT N
efficacy NN N
of IN N
the DT N
intervention NN N
was VBD N
obtained VBN N
using VBG N
a DT N
randomized JJ N
trial NN N
with IN N
62 CD 1_p
sexually-active JJ 1_p
, , 1_p
single JJ 1_p
girls NNS 1_p
. . 1_p

Data NNS N
obtained VBD N
at IN N
a DT N
3-month JJ N
follow-up JJ N
assessment NN N
showed VBD N
that IN N
girls NNS 1_p
who WP N
received VBD N
the DT N
HIV-related JJ 1_i
intervention NN 1_i
improved VBD 1_o
their PRP$ 1_o
HIV-related JJ 1_o
knowledge NN 1_o
and CC N
enhanced VBD N
their PRP$ N
motivation NN 1_o
for IN 1_o
risk NN 1_o
reduction NN 1_o
compared VBN N
to TO N
girls NNS N
who WP N
received VBD N
a DT N
control NN 1_i
( ( 1_i
health NN 1_i
promotion NN 1_i
) ) 1_i
intervention NN 1_i
. . 1_i

Effect JJ 1_o
sizes VBZ N
suggest VBP N
that IN N
the DT N
HIV NNP 1_i
intervention NN 1_i
also RB N
reduced VBD 1_o
several JJ 1_o
risk NN 1_o
behaviors NNS 1_o
( ( 1_o
e.g. NN 1_o
, , N
vaginal JJ 1_o
sex NN 1_o
without IN 1_o
a DT 1_o
condom NN 1_o
, , 1_o
giving VBG 1_o
oral JJ 1_o
sex NN 1_o
, , 1_o
and CC 1_o
alcohol NN 1_o
and CC 1_o
drug NN 1_o
use NN 1_o
before IN 1_o
sex NN 1_o
) ) 1_o
. . N

Challenges VBZ N
to TO N
implementation NN N
and CC N
suggestions NNS N
for IN N
intervention NN N
enhancement NN N
are VBP N
discussed VBN N
. . N

Exercise NN N
echocardiography NN N
demonstrates VBZ N
biventricular JJ N
systolic JJ N
dysfunction NN N
and CC N
reveals NNS N
decreased VBD N
left VBD N
ventricular JJ N
contractile NN N
reserve NN N
in IN N
children NNS 1_p
after IN 1_p
tetralogy NN 1_p
of IN 1_p
Fallot NNP 1_p
repair NN 1_p
. . 1_p

BACKGROUND NNP N
Long-term NNP N
biventricular JJ N
systolic JJ N
performance NN N
is VBZ N
a DT N
key JJ N
determinant NN N
of IN N
clinical JJ N
outcomes NNS N
late RB N
after IN N
tetralogy NN 1_i
of IN 1_i
Fallot NNP 1_i
( ( 1_i
TOF NNP 1_i
) ) 1_i
repair NN 1_i
. . 1_i

A DT N
need NN N
exists VBZ N
for IN N
early JJ N
indices NNS N
of IN N
both DT N
left FW N
ventricular NN N
( ( N
LV NNP N
) ) N
and CC N
right JJ N
ventricular NN N
( ( N
RV NNP N
) ) N
compromise NN N
in IN N
this DT N
population NN N
. . N

METHODS NNP N
Twenty-nine JJ 1_p
children NNS 1_p
( ( 1_p
age NN 1_p
range NN 1_p
, , 1_p
5-18 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
repaired VBN 1_p
TOF NNP 1_p
and CC 1_p
44 CD 1_p
healthy JJ 1_p
controls NNS 1_p
were VBD N
prospectively RB N
evaluated VBN N
. . N

M-mode NNP 1_i
and CC 1_i
tissue NN 1_i
Doppler NNP 1_i
data NNS 1_i
were VBD N
obtained VBN N
for IN N
each DT N
ventricle NN N
and CC N
the DT N
RV NNP N
outflow JJ N
tract NN N
at IN N
rest NN N
and CC N
during IN N
semisupine JJ 1_i
bicycle NN 1_i
exercise NN 1_i
. . 1_i

By IN N
making VBG N
measurements NNS N
of IN N
myocardial JJ N
acceleration NN N
during IN N
isovolumic JJ N
contraction NN N
during IN N
exercise NN N
, , N
at IN N
increasing VBG N
heart NN N
rates NNS N
, , N
LV NNP N
force-frequency NN N
curves NNS N
were VBD N
constructed VBN N
. . N

Patients NNS N
also RB N
underwent JJ N
cardiac JJ 1_i
magnetic JJ 1_i
resonance NN 1_i
imaging NN 1_i
, , 1_i
cardiopulmonary JJ 1_i
exercise NN 1_i
testing NN 1_i
, , 1_i
and CC 1_i
measurement NN 1_i
of IN 1_i
serum JJ 1_i
neurohormonal JJ 1_i
markers NNS 1_i
. . 1_i

RESULTS NNP N
Children NNP 1_p
with IN 1_p
repaired VBN 1_p
TOF NNP 1_p
had VBD N
dilated VBN N
right JJ N
ventricles NNS N
( ( N
RV NNP N
end-diastolic JJ N
volume NN N
index NN N
= VBD N
153 CD N
± JJ N
37.3 CD N
mL/m NN N
( ( N
2 CD N
) ) N
) ) N
but CC N
normal JJ N
ejection NN N
fractions NNS N
as IN N
measured VBN N
on IN N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
LV NNP N
ejection NN N
fraction NN N
= VBD N
59.3 CD N
± JJ N
6.2 CD N
% NN N
, , N
RV NNP N
ejection NN N
fraction NN N
= VBD N
50.2 CD N
± JJ N
8.5 CD N
% NN N
) ) N
and CC 1_o
normal JJ 1_o
serum JJ 1_o
neurohormonal JJ 1_o
markers NNS 1_o
. . N

Detailed VBN N
resting VBG N
echocardiography NN N
detected VBD 1_o
abnormal JJ 1_o
ventricular JJ 1_o
function NN 1_o
, , N
worst RB N
in IN N
the DT N
right JJ N
ventricle NN N
and CC N
RV NNP N
outflow IN N
tract NN N
. . N

Exercise NN N
exacerbated VBD N
these DT N
findings NNS N
and CC N
provoked VBD N
significant JJ N
decline NN N
in IN 1_o
LV NNP 1_o
indices NNS 1_o
. . N

The DT 1_o
LV NNP 1_o
force-frequency NN 1_o
curves NNS 1_o
of IN N
patients NNS N
were VBD N
attenuated VBN N
, , N
with IN N
an DT N
early JJ N
plateau NN N
and CC N
inadequate JJ N
increase NN N
of IN N
isovolumic JJ N
contraction NN N
. . N

Correlations NNS N
were VBD N
seen VBN N
between IN N
peak JJ N
exercise NN N
LV NNP N
isovolumic JJ N
contraction NN N
and CC N
percentage NN N
predicted VBD 1_o
peak JJ 1_o
oxygen NN 1_o
uptake NN 1_o
( ( N
r JJ N
= NN N
0.51 CD N
, , N
P NNP N
= NNP N
.02 NNP 1_o
) ) 1_o
, , 1_o
LV NNP 1_o
and CC 1_o
RV NNP 1_o
ejection NN 1_o
fractions NNS 1_o
( ( N
r VB N
= RB N
0.41 CD N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
and CC 1_o
RV NNP 1_o
and CC 1_o
LV NNP 1_o
long-axis JJ 1_o
fractional JJ 1_o
shortening NN 1_o
( ( N
r JJ N
= NN N
0.44 CD N
, , N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
postsurgical JJ N
pathophysiology NN N
of IN N
TOF NNP N
begins VBZ N
early JJ N
after IN N
repair NN N
. . N

At IN N
a DT N
time NN N
when WRB N
clinically RB N
well RB N
and CC N
while IN N
routine JJ N
indices NNS N
of IN N
heart NN N
function NN N
remain VBP N
normal JJ 1_p
, , 1_p
children NNS 1_p
with IN 1_p
repaired JJ 1_p
TOF NNP 1_p
exhibit NN 1_p
RV NNP 1_p
dilatation NN 1_p
and CC 1_p
subtle NN 1_p
, , N
interlinked VBD N
biventricular JJ N
abnormalities NNS N
on IN N
resting VBG N
echocardiography NN 1_i
. . 1_i

Exercise NN 1_i
echocardiography NN N
provides VBZ N
additional JJ N
information NN N
and CC N
reveals NNS N
abnormal JJ N
LV NNP N
excitation-contractile NN N
coupling VBG N
that WDT N
may MD N
be VB N
linked VBN N
to TO N
impaired JJ N
exercise NN N
capacity NN N
. . N

Outcome NN N
of IN N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
in IN N
disseminated JJ 1_p
small JJ 1_p
noncleaved-cell JJ 1_p
lymphoma NN 1_p
and CC 1_p
B-cell NNP 1_p
leukemia NN 1_p
: : 1_p
a DT N
Children NNP 1_p
's POS 1_p
Cancer NNP 1_p
Group NNP 1_p
study NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
initial JJ N
CNS NNP N
involvement NN N
on IN N
outcome NN N
and CC N
patterns NNS N
of IN N
failure NN N
in IN N
patients NNS 1_p
with IN 1_p
disseminated JJ 1_p
small JJ 1_p
noncleaved-cell JJ 1_p
lymphoma NN 1_p
and CC 1_p
B-cell NNP 1_p
leukemia NN 1_p
who WP 1_p
were VBD 1_p
treated VBN 1_p
in IN 1_p
four CD 1_i
successive JJ 1_i
Children NNP 1_i
's POS 1_i
Cancer NNP 1_i
Group NNP 1_i
trials NNS 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
Of IN N
462 CD 1_p
patients NNS 1_p
with IN 1_p
disseminated JJ 1_p
disease NN 1_p
, , 1_p
49 CD 1_p
( ( 1_p
10.6 CD 1_p
% NN 1_p
) ) 1_p
had VBD 1_p
CNS NNP 1_p
disease NN 1_p
at IN 1_p
diagnosis NN 1_p
( ( 1_p
CNS+ NNP 1_p
) ) 1_p
. . 1_p

CNS NNP N
disease NN N
included VBD N
meningeal JJ N
disease NN N
or CC N
CNS NNP N
parenchymal JJ N
masses NNS N
with IN N
or CC N
without IN N
cranial JJ N
neuropathies NNS N
( ( N
CSF+/Mass NNP N
; : N
CNPs NNP N
) ) N
in IN N
36 CD N
patients NNS N
and CC N
isolated JJ N
CNPs NNP N
in IN N
13 CD N
. . N

Of IN 1_p
the DT 1_p
CNS+ NNP 1_p
patients NNS 1_p
, , 1_p
28 CD 1_p
had VBD 1_p
M2 NNP 1_p
( ( 1_p
5 CD 1_p
% NN 1_p
to TO 1_p
25 CD 1_p
% NN 1_p
blasts NNS 1_p
) ) 1_p
or CC 1_p
M3 NNP 1_p
( ( 1_p
> VB 1_p
25 CD 1_p
% NN 1_p
blasts NNS 1_p
) ) 1_p
bone NN 1_p
marrow JJ 1_p
involvement NN 1_p
. . 1_p

All DT 1_p
patients NNS 1_p
received VBD 1_p
protocol-based JJ 1_i
systemic JJ 1_i
and CC 1_i
intrathecal JJ 1_i
chemotherapy NN 1_i
. . 1_i

Thirty-six JJ N
patients NNS N
also RB N
received VBD N
CNS NNP 1_i
irradiation NN 1_i
. . 1_i

RESULTS NNP N
Relapses NNPS 1_o
occurred VBD N
in IN N
21 CD N
( ( N
43 CD N
% NN N
) ) N
of IN N
49 CD N
patients NNS N
, , N
predominantly RB N
in IN N
the DT N
CNS NNP N
( ( N
71 CD N
% NN N
) ) N
and CC N
bone NN N
marrow NN N
( ( N
52 CD N
% NN N
) ) N
. . N

The DT N
3-year JJ 1_o
event-free JJ 1_o
survival NN 1_o
+/- JJ N
SE NNP N
for IN N
all DT N
patients NNS N
with IN N
CNS+ NNP N
disease NN N
was VBD N
45 CD N
% NN N
+/- JJ N
7 CD N
% NN N
. . N

Patients NNS N
with IN N
CSF+/Mass NNP N
had VBD N
a DT N
nominally RB N
higher JJR 1_o
treatment NN 1_o
failure NN 1_o
rate NN 1_o
compared VBN N
with IN N
patients NNS N
with IN N
CNS- NNP N
after IN N
adjusting VBG N
for IN N
marrow NN N
status NN N
and CC N
lactate VB N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
diagnosis NN N
, , N
with IN N
a DT N
relative JJ 1_o
failure NN 1_o
rate NN 1_o
( ( 1_o
RFR NNP 1_o
) ) 1_o
of IN N
1.52 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.88 CD N
to TO N
2.6 CD N
; : N
P NNP N
=.15 NNP N
) ) N
. . N

In IN N
comparison NN N
, , N
the DT N
RFRs NNP 1_o
for IN N
patients NNS N
with IN N
M2 NNP N
or CC N
M3 NNP N
marrow NN N
and CC N
for IN N
those DT N
with IN N
LDH NNP N
levels NNS N
greater JJR N
than IN N
500 CD N
IU/L NNP N
after IN N
adjusting VBG N
for IN N
CNS NNP 1_o
disease NN 1_o
were VBD N
1.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
2.0 CD N
; : N
P NNP N
=.029 NNP N
) ) N
and CC N
2.2 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.5 CD N
to TO N
3.0 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
RFR NNP 1_o
for IN N
patients NNS N
with IN N
isolated JJ 1_o
CNPs NNP 1_o
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.36 CD N
to TO N
2.1 CD N
; : N
P NNP N
=.76 NNP N
) ) N
. . N

CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
, , N
with IN N
the DT N
treatments NNS N
used VBN N
during IN N
the DT N
period NN N
covered VBN N
by IN N
these DT N
studies NNS N
, , N
the DT N
presence NN N
of IN N
CSF+/Mass NNP N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
was VBD N
associated VBN N
with IN N
a DT N
nominally RB 1_o
worse JJR 1_o
outcome JJ 1_o
independent JJ N
of IN N
initial JJ N
bone NN N
marrow NN N
status NN N
and CC N
LDH NNP N
level NN N
, , N
but CC N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Prophylactic JJ 1_i
training NN 1_i
for IN N
the DT N
prevention NN N
of IN N
radiotherapy-induced JJ N
trismus NN N
- : N
a DT N
randomised JJ N
study NN N
. . N

BACKGROUND NNP N
Radiotherapy-induced JJ N
trismus NN N
( ( N
RTIT NNP N
) ) N
is VBZ N
a DT N
debilitating VBG N
condition NN N
without IN N
any DT N
proven JJ N
effective JJ N
treatment NN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
effectiveness NN 1_o
of IN N
prophylactic JJ 1_i
training NN 1_i
to TO N
prevent VB N
RTIT NNP N
during IN N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN 1_p
RT NNP 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
head NN 1_p
and CC 1_p
neck NN 1_p
cancer NN 1_p
( ( 1_p
HNC NNP 1_p
) ) 1_p
, , N
also RB N
investigating VBG N
the DT N
incidence NN N
of IN N
RTIT NNP N
. . N

METHODS NNP N
Sixty-six JJ 1_p
consecutive JJ 1_p
patients NNS 1_p
from IN 1_p
two CD 1_p
RT NNP 1_p
clinics NNS 1_p
in IN 1_p
Sweden NNP 1_p
were VBD N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
: : N
training NN 1_i
with IN 1_i
TheraBite NNP 1_i
( ( 1_i
® NNP 1_i
) ) 1_i
Jaw NNP 1_i
Motion NNP 1_i
Rehabilitation NNP 1_i
System NNP 1_i
( ( 1_i
™ NNP 1_i
) ) 1_i
or CC 1_i
a DT 1_i
control NN 1_i
group NN 1_o
. . 1_o

Maximum NNP 1_o
interincisal JJ 1_o
openings NNS 1_o
( ( 1_o
MIO NNP 1_o
) ) 1_o
were VBD 1_o
recorded VBN N
at IN N
baseline NN N
and CC N
once RB N
a DT N
week NN N
during IN N
treatment NN N
, , N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

Training NNP N
frequency NN N
was VBD N
recorded VBN N
by IN N
patients NNS N
in IN N
a DT N
log NN N
book NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN 1_o
MIO NNP 1_o
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
at IN N
any DT N
of IN N
the DT N
measurement NN N
points NNS N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
maintained VBD N
their PRP$ N
normal JJ N
variation NN N
in IN 1_o
MIO NNP 1_o
at IN N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

A NNP N
small JJ N
group NN N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
had VBD N
a DT N
17 CD N
% NN N
mean JJ N
decrease NN N
in IN 1_o
MIO NNP 1_o
by IN N
week NN N
6 CD N
compared VBN N
to TO N
baseline VB N
and CC N
improved VB N
their PRP$ 1_o
MIO NNP 1_o
by IN N
using VBG N
the DT N
training NN N
programme NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
mean JJ N
difference NN N
in IN 1_o
MIO NNP 1_o
from IN N
baseline NN N
to TO N
week NN N
6 CD N
( ( N
3 CD N
mm NN N
, , N
p NN N
= NNP N
0.018 CD N
) ) N
, , N
and CC N
month NN N
6 CD N
( ( N
2.7 CD N
mm NN N
, , N
p NN N
= NNP N
0.040 CD N
) ) N
, , N
for IN N
patients NNS N
receiving VBG N
3D CD N
conformal JJ N
radiotherapy NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN 1_o
MIO NNP 1_o
between IN N
patients NNS N
treated VBN N
with IN N
RT NNP N
and CC N
concurrent JJ N
chemotherapy NN N
compared VBN N
to TO N
patients NNS N
with IN N
RT NNP N
only RB N
at IN N
12 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.033 CD N
) ) N
. . N

CONCLUSIONS JJ 1_p
Patients NNS 1_p
with IN 1_p
HNC NNP 1_p
undergoing VBG 1_p
high JJ 1_p
dose NN 1_p
RT NNP N
do VBP N
not RB N
need VB N
to TO N
be VB N
burdened VBN N
with IN N
an DT N
intense JJ N
prophylactic JJ N
training NN N
programme NN N
during IN N
RT NNP N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP 1_o
. . 1_o

MIO NNP 1_o
measurements NNS N
during IN N
RT NNP N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
are VBP N
recommended VBN N
to TO N
identify VB N
a DT N
small JJ N
risk NN N
group NN N
who WP N
are VBP N
an DT N
exception NN N
and CC N
may MD N
need VB 1_i
a DT 1_i
training NN 1_i
programme NN 1_i
. . N

Long JJ N
term NN N
response NN N
to TO N
therapy NN N
of IN N
chronic JJ 1_p
anti-HBe-positive JJ 1_p
hepatitis NN 1_p
B NNP 1_p
is VBZ N
poor JJ N
independent JJ N
of IN N
type NN N
and CC N
schedule NN N
of IN N
interferon NN N
. . N

OBJECTIVE CC N
The DT N
response NN 1_o
rate NN 1_o
to TO 1_o
alpha VB 1_o
interferon NN 1_o
( ( 1_o
IFN NNP 1_o
) ) 1_o
of IN N
chronic JJ N
anti-HBe-positive JJ N
hepatitis NN N
B NNP N
is VBZ N
variable JJ N
. . N

We PRP N
studied VBD N
whether IN N
type NN N
, , N
dose NN N
, , N
and CC N
schedule NN N
of IN N
IFN NNP 1_i
, , N
and CC N
type NN N
and CC N
frequency NN N
of IN N
posttreatment NN N
monitoring NN N
, , N
influence VB N
the DT N
response NN N
rate NN N
. . N

METHODS NNP N
Seventy-two JJ 1_p
consecutive JJ 1_p
anti-HBe-positive JJ 1_p
chronic NN 1_p
hepatitis NN 1_p
B NNP 1_p
patients NNS 1_p
( ( 1_p
59 CD 1_p
male NN 1_p
and CC 1_p
13 CD 1_p
female NN 1_p
, , 1_p
median JJ 1_p
age NN 1_p
41 CD 1_p
yr NN 1_p
) ) 1_p
stratified VBN 1_p
by IN 1_p
sex NN 1_p
and CC 1_p
histology NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
arms NNS N
. . N

Twenty-seven JJ N
patients NNS N
( ( N
A DT N
) ) N
received VBD N
10 CD N
million CD N
units NNS N
alpha-N1 JJ 1_i
IFN NNP 1_i
i.m NN 1_i
. . 1_i

t.w NN N
. . N

for IN N
24 CD N
wk NN N
( ( N
total JJ N
dose NN N
: : N
720 CD N
million CD N
units NNS N
) ) N
; : N
21 CD N
( ( N
B NNP N
) ) N
received VBD N
9 CD N
million CD N
units NNS N
alpha-2a JJ 1_i
IFN NNP 1_i
i.m NN 1_i
. . 1_i

t.w NN N
. . N

for IN N
4 CD N
wk NN N
, , N
followed VBN N
by IN N
18 CD N
million CD N
units NNS N
for IN N
12 CD N
wk NN N
and CC N
9 CD N
million CD N
units NNS N
for IN N
8 CD N
wk NN N
( ( N
972 CD N
million CD N
units NNS N
) ) N
; : N
24 CD N
( ( N
C NNP N
) ) N
received VBD N
2 CD 1_i
alpha-2a JJ 1_i
IFN NNP 1_i
courses NNS 1_i
( ( N
9 CD N
million CD N
units NNS N
i.m RB N
. . N

t.w NN N
. . N

for IN N
16 CD N
and CC N
12 CD N
wk NN N
separated VBN N
by IN N
a DT N
6-month JJ N
interval NN N
[ $ N
756 CD N
million CD N
units NNS N
] NNP N
) ) N
. . N

Primary JJ N
response NN N
was VBD N
defined VBN N
by IN N
normal JJ 1_o
ALT NNP 1_o
and CC 1_o
serum VB 1_o
HBV-DNA NNP 1_o
levels NNS 1_o
below IN N
10 CD N
pg/ml NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBN N
response NN N
by IN N
normal JJ 1_o
ALT NNP 1_o
( ( N
tested VBN N
monthly RB N
) ) N
, , N
undetectable JJ 1_o
HBV-DNA NN 1_o
and CC N
IgM NNP N
anti-HBc NN N
( ( N
< JJ N
7 CD N
I.U NNP N
. . N

Paul NNP N
Ehrlich NNP N
Institute NNP N
) ) N
( ( N
tested VBN N
every DT N
3 CD N
months NNS N
) ) N
during IN N
the DT N
posttreatment JJ N
follow-up NN N
. . N

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
12 CD N
, , N
8 CD N
, , N
and CC N
13 CD N
patients NNS N
from IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
, , N
respectively RB N
, , N
were VBD N
responders NNS N
. . N

At IN N
the DT N
18-month JJ N
follow-up JJ N
, , N
two CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
only RB N
one CD N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
maintained VBD N
the DT N
response NN 1_o
. . 1_o

Overall NNP N
, , N
after IN N
34 CD N
months NNS N
( ( N
median JJ N
posttreatment NN N
follow-up NN N
) ) N
, , N
three CD N
patients NNS N
were VBD N
long JJ N
term NN N
responders NNS N
, , N
whereas NNS N
three CD N
showed VBD N
a DT N
sustained VBN N
remission NN 1_o
after IN N
relapse NN N
. . N

CONCLUSIONS VB N
The DT N
rate NN 1_o
of IN 1_o
long JJ 1_o
term NN 1_o
response NN 1_o
to TO N
interferon VB N
of IN N
anti-HBe-positive JJ N
chronic JJ N
hepatitis NN N
B NNP N
is VBZ N
poor JJ N
, , N
independent JJ N
of IN N
IFN NNP N
type NN N
, , N
dose VB N
, , N
or CC N
schedule NN N
; : N
the DT N
more RBR N
stringent JJ N
the DT N
monitoring NN N
, , N
the DT N
higher JJR N
the DT N
relapse NN N
rate NN N
. . N

[ JJ 1_o
Sentinel NNP 1_o
lymph NN 1_o
node NN 1_o
detection NN 1_o
in IN N
colorectal JJ N
cancer NN N
: : N
importance NN N
, , N
techniques NNS N
and CC N
results NNS N
] NNP N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
Considering NNP N
that IN N
lymph VBD N
node DT N
status NN N
is VBZ N
a DT N
key JJ N
factor NN N
in IN N
colorectal JJ N
cancer NN N
staging NN N
, , N
and CC N
the DT N
main JJ N
determinant NN N
for IN N
adjuvant JJ 1_i
therapy NN 1_i
of IN N
colorectal JJ N
cancer NN N
being VBG N
this DT N
therapy NN N
, , N
responsible JJ N
for IN N
a DT N
significant JJ N
increase NN N
in IN N
colorectal JJ N
cancer NN N
patients NNS N
survival JJ N
, , N
the DT N
staging VBG N
methods NNS N
should MD N
be VB N
the DT N
most RBS N
accurate JJ N
possible JJ N
in IN N
order NN N
to TO N
offer VB N
this DT N
individuals NNS N
the DT N
opportunity NN N
to TO N
be VB N
adequate JJ N
treated VBN N
in IN N
order NN N
to TO N
achieve VB N
the DT N
best JJS N
survival NN N
possible JJ N
. . N

Sentinel NNP N
lymph NN N
node NN N
study NN N
is VBZ N
progressively RB N
being VBG N
popularized VBN N
as IN N
a DT N
method NN N
that WDT N
increases VBZ N
sensibility NN 1_o
in IN 1_o
detect JJ 1_o
positive JJ 1_o
nodes NNS 1_o
to TO N
reveal VB N
a DT N
more RBR N
accurate JJ N
stage NN 1_o
and CC 1_o
prognosis NN 1_o
in IN N
colorectal JJ N
cancer NN N
patients NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Thirty NNP 1_p
one CD 1_p
colorectal NN 1_p
cancer NN 1_p
patients NNS 1_p
were VBD N
prospectively RB N
studied VBN N
and CC N
sentinel JJ N
lymph NN N
node NN N
was VBD N
identified VBN N
in IN N
100 CD N
% NN N
of IN N
the DT N
cases NNS N
utilizing VBG 1_i
either CC 1_i
patent JJ 1_i
blue NN 1_i
alone RB 1_i
, , 1_i
or CC 1_i
in IN 1_i
association NN 1_i
with IN 1_i
radiotracer NN 1_i
based VBN 1_i
on IN 1_i
technetium NN 1_i
99m CD 1_i
colloid JJ 1_i
solution NN 1_i
in IN 1_i
a DT 1_i
randomized JJ 1_i
fashion NN 1_i
. . 1_i

RESULTS VB N
The DT N
mean JJ 1_o
number NN 1_o
of IN 1_o
sentinel NNS 1_o
nodes NNS 1_o
per IN 1_o
patient NN 1_o
was VBD N
1.96 CD N
ranging VBG N
from IN N
1 CD N
to TO N
3 CD N
nodes NNS N
. . N

With IN N
the DT N
addition NN N
of IN N
transoperative JJ 1_o
lympho-scintigraphy NN 1_o
five CD N
extra JJ 1_o
sentinel NN 1_o
nodes NNS 1_o
, , N
not RB N
identified VBN N
by IN N
the DT N
blue JJ N
dye NN N
alone RB N
, , N
were VBD N
identified VBN N
and CC N
considered VBN N
for IN N
histopathology NN N
study NN N
. . N

In IN N
four CD N
cases NNS N
( ( N
12.9 CD N
% NN N
) ) N
the DT N
sentinel NN N
lymph NN N
node NN N
was VBD N
the DT N
only JJ N
site NN N
of IN N
metastasis NN N
, , N
all DT N
of IN N
them PRP N
being VBG N
detected VBN N
by IN N
association NN 1_o
of IN 1_o
hematoxylin NN 1_o
and CC 1_o
eosin NN 1_o
and CC 1_o
immunohistochemical JJ 1_o
examination NN 1_o
. . 1_o

CONCLUSION NNP N
Sentinel NNP N
lymph NN N
node NN N
detection NN N
and CC N
analysis NN N
is VBZ N
feasible JJ 1_o
, , N
technique NN N
is VBZ N
relatively RB N
simple JJ 1_o
and CC N
is VBZ N
able JJ N
to TO N
produce VB 1_o
upstage NN 1_o
in IN N
colorectal JJ N
cancer NN N
. . N

Blue NNP 1_i
staining VBG 1_i
and CC 1_i
radio NN 1_i
guided VBN 1_i
techniques NNS 1_i
are VBP N
both DT N
safe JJ 1_o
and CC N
their PRP$ N
superposition NN N
has VBZ N
shown VBN N
good JJ N
results NNS N
in IN N
terms NNS N
of IN N
increase NN N
accuracy NN 1_o
in IN N
our PRP$ N
experience NN N
. . N

There EX N
was VBD N
no DT N
aberrant JJ N
lymph NN 1_o
drainage NN 1_o
that WDT N
would MD N
alter VB N
resection NN N
margins NNS N
in IN N
patients NNS N
studied VBN N
. . N

Upstaging VBG 1_o
rate NN 1_o
, , N
identifying VBG N
potential JJ N
candidates NNS N
for IN N
adjuvant JJ 1_i
therapy NN 1_i
was VBD N
12.9 CD N
% NN N
( ( N
4/31 CD N
) ) N
. . N

To TO N
this DT N
individuals NNS N
chemotherapy NN 1_i
could MD N
be VB N
a DT N
chance NN N
to TO N
increase VB N
their PRP$ N
global JJ N
survival NN N
. . N

Performance NN N
of IN N
a DT N
modified VBN 1_i
starch NN 1_i
hydrophilic NN 1_i
matrix NN 1_i
for IN 1_i
the DT 1_i
sustained JJ 1_i
release NN 1_i
of IN 1_i
theophylline NN 1_i
in IN N
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

Two CD N
experimental JJ N
formulations NNS N
of IN N
theophylline NN 1_i
with IN 1_i
a DT 1_i
hydrophilic JJ 1_i
starch NN 1_i
matrix NN 1_i
were VBD N
evaluated VBN N
for IN N
their PRP$ N
sustained-release JJ N
characteristics NNS N
after IN N
single JJ N
administration NN N
in IN N
healthy JJ 1_p
human JJ 1_p
volunteers NNS 1_p
. . 1_p

Theo-dur NN 1_i
was VBD N
chosen VBN N
as IN N
a DT N
reference NN N
sustained-release JJ N
formulation NN N
. . N

In IN N
a DT N
first JJ N
study NN N
, , N
the DT N
extent NN N
of IN N
absorption NN N
was VBD N
similar JJ N
for IN N
a DT N
syrup NN N
, , N
for IN N
Theo-dur NNP 1_i
, , N
and CC N
for IN N
the DT N
experimental JJ N
formulation NN N
of IN N
theophylline NN 1_i
with IN 1_i
70 CD 1_i
% NN 1_i
drum-dried JJ 1_i
corn NN 1_i
starch NN 1_i
as IN 1_i
the DT 1_i
sustained-release JJ 1_i
agent NN 1_i
( ( 1_i
DDCS-70 NNP 1_i
) ) 1_i
. . N

The DT N
maximal JJ 1_o
plasma NN 1_o
concentration NN 1_o
( ( 1_o
Cmax NNP 1_o
) ) 1_o
was VBD N
significantly RB N
lower JJR N
, , N
and CC N
the DT N
time NN 1_o
to TO 1_o
reach VB 1_o
Cmax NNP 1_o
as RB N
well RB N
as IN N
the DT N
time NN N
span NN N
during IN N
which WDT N
the DT N
plasma NN 1_o
concentration NN 1_o
was VBD N
at IN N
least JJS N
75 CD N
% NN N
of IN N
the DT N
Cmax NNP N
were VBD N
significantly RB N
higher JJR N
for IN N
Theo-dur NNP N
than IN N
for IN N
the DT N
DDCS-70 NNP N
formulation NN N
. . N

A DT N
sustained-release JJ N
profile NN N
, , N
as IN N
for IN N
Theo-dur NNP 1_i
, , N
was VBD N
not RB N
reached VBN N
for IN N
DDCS-70 NNP N
. . N

In IN N
a DT N
second JJ N
study NN N
the DT N
influence NN N
of IN N
the DT N
starch NN N
: : N
drug NN N
ratio NN N
on IN N
the DT N
bioavailability NN N
was VBD N
investigated VBN N
. . N

The DT N
decrease NN N
in IN N
starch NN N
content NN N
from IN N
70 CD N
to TO N
50 CD N
% NN N
of IN N
the DT N
formulation NN N
did VBD N
not RB N
improve VB N
the DT N
plasma NN 1_o
concentration-time JJ 1_o
profile NN N
towards NNS N
a DT N
sustained-release JJ N
profile NN N
. . N

Evaluation NN N
of IN N
masking VBG N
study NN N
participants NNS 1_p
to TO N
intravitreal VB N
injections NNS N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
success NN 1_o
of IN N
masking VBG N
study NN N
participants NNS 1_p
to TO N
treatment NN N
allocation NN N
using VBG N
sham JJ 1_i
intravitreal JJ 1_i
injections NNS 1_i
. . 1_i

METHODS NNP N
Eyes NNP 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
sham NN 1_i
injections NNS 1_i
plus CC 1_i
prompt JJ 1_i
laser NN 1_i
, , 1_i
intravitreal JJ 1_i
ranibizumab NN 1_i
injections NNS 1_i
plus CC 1_i
prompt JJ 1_i
laser NN 1_i
, , 1_i
intravitreal JJ 1_i
ranibizumab NN 1_i
injections NNS 1_i
plus CC 1_i
deferred JJ 1_i
laser NN 1_i
, , 1_i
or CC 1_i
intravitreal VB 1_i
triamcinolone JJ 1_i
acetonide JJ 1_i
injections NNS 1_i
plus CC 1_i
prompt NN 1_i
laser NN 1_i
up RB N
to TO N
every DT N
16 CD N
weeks NNS N
with IN N
sham JJ N
injections NNS N
intermittently RB N
. . N

All DT 1_p
eyes NNS 1_p
could MD N
receive VB N
treatment NN N
or CC N
sham NN N
as RB N
often RB N
as IN N
every DT N
4 CD N
weeks NNS N
. . N

Participants NNS 1_p
with IN 1_p
2 CD 1_p
study NN 1_p
eyes NNS 1_p
had VBD N
1 CD N
eye NN N
randomized VBN N
to TO N
sham VB 1_i
plus JJ 1_i
prompt JJ 1_i
laser NN 1_i
and CC N
1 CD N
eye NN N
randomized VBN N
to TO N
a DT N
real JJ 1_i
injection NN 1_i
group NN N
. . N

Sham NNP N
injections NNS N
were VBD N
performed VBN N
by IN N
pressing VBG N
the DT N
syringe NN N
hub NN N
against IN N
the DT N
conjunctiva NN N
to TO N
mimic VB N
a DT N
real JJ N
injection NN N
. . N

Laser NNP 1_i
treatment NN 1_i
was VBD N
not RB N
masked VBN N
. . N

At IN N
the DT N
1-year JJ N
visit NN N
, , N
participants NNS N
were VBD N
asked VBN N
if IN N
they PRP N
believed VBD N
that IN N
the DT N
injections NNS N
received VBD N
during IN N
the DT N
study NN N
were VBD N
real JJ N
, , N
sham NN 1_i
, , N
or CC N
sometimes RB 1_i
real JJ 1_i
and CC 1_i
sometimes RB 1_i
sham JJ 1_i
. . 1_i

RESULTS NNP N
Among IN N
423 CD 1_p
participants NNS 1_p
with IN 1_p
1 CD 1_p
study NN 1_p
eye NN 1_p
, , N
the DT N
correct JJ 1_o
assignment NN 1_o
was VBD N
stated VBN N
by IN N
9.9 CD N
% NN N
of IN N
the DT N
sham NN 1_i
plus CC 1_i
prompt JJ 1_i
laser NN 1_i
group NN N
, , N
88.0 CD N
% NN N
of IN N
the DT N
ranibizumab NN 1_i
plus CC 1_i
prompt JJ 1_i
laser NN 1_i
group NN N
, , N
89.6 CD N
% NN N
of IN N
the DT N
unmasked JJ N
ranibizumab NN 1_i
plus CC 1_i
deferred JJ 1_i
laser NN 1_i
group NN N
, , N
and CC N
44.0 CD N
% NN N
of IN N
the DT N
triamcinolone NN 1_i
plus CC 1_i
prompt JJ 1_i
laser NN 1_i
group NN N
. . N

Among IN N
112 CD 1_p
participants NNS 1_p
with IN 1_p
2 CD 1_p
study NN 1_p
eyes NNS 1_p
, , N
the DT N
correct JJ 1_o
assignment NN 1_o
was VBD N
stated VBN N
for IN N
24.1 CD N
% NN N
of IN N
the DT N
sham NN N
plus CC N
prompt JJ N
laser NN N
eyes NNS N
. . N

CONCLUSIONS NNP N
Successful NNP 1_o
masking NN 1_o
of IN N
an DT N
intravitreal JJ N
injection NN N
can MD N
be VB N
accomplished VBN N
when WRB N
a DT N
sham NN 1_i
injection NN 1_i
procedure NN N
carefully RB N
mimics VBZ N
a DT N
real JJ 1_i
injection NN 1_i
procedure NN N
. . N

Masking VBG 1_o
seems VBZ N
less RBR N
successful JJ 1_o
when WRB N
one CD N
eye NN N
is VBZ N
receiving VBG N
a DT N
real JJ N
injection NN N
and CC N
the DT N
other JJ N
eye NN N
is VBZ N
receiving VBG N
a DT N
sham JJ N
injection NN N
or CC N
when WRB N
an DT N
individual JJ N
eye NN N
receives VBZ N
both DT N
real JJ N
and CC N
sham JJ N
injections NNS N
. . N

Intramedullary NNP 1_i
repair NN 1_i
device NN N
against IN N
volar JJ N
plating NN N
in IN N
the DT N
reconstruction NN N
of IN N
extra-articular JJ N
and CC N
simple JJ N
articular JJ N
distal JJ N
radius NN N
fractures NNS N
; : N
a DT N
randomized VBN N
pilot NN N
study NN N
. . N

PURPOSE VB N
This DT N
prospective JJ N
randomized NN N
pilot NN N
study NN N
reports VBZ N
our PRP$ N
institutional JJ N
experience NN N
and CC N
early JJ N
results NNS N
using VBG N
Sonoma NNP N
Wrx NNP N
( ( N
Sonoma NNP N
Orthopedic NNP N
Products NNPS N
, , N
Santa NNP N
Rosa NNP N
, , N
CA NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
extra-articular JJ N
and CC N
simple JJ N
intra-articular JJ N
distal JJ N
radius NN N
fractures NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
64 CD 1_p
patients NNS 1_p
, , 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

They PRP 1_p
were VBD 1_p
considered VBN 1_p
eligible JJ 1_p
if IN 1_p
they PRP 1_p
had VBD 1_p
; : 1_p
unstable JJ 1_p
extra-articular JJ 1_p
distal JJ 1_p
radius NN 1_p
fractures NNS 1_p
and CC 1_p
simple JJ 1_p
intra-articular JJ 1_p
distal JJ 1_p
radius NN 1_p
fractures NNS 1_p
suitable JJ 1_p
for IN 1_p
closed JJ 1_p
reduction NN 1_p
( ( 1_p
AO NNP 1_p
types NNS 1_p
; : 1_p
A2.2 NNP 1_p
, , 1_p
A2.3 NNP 1_p
, , 1_p
A3.1 NNP 1_p
C2.1 NNP 1_p
, , 1_p
C2.2 NNP 1_p
) ) 1_p
. . 1_p

Patients NNS 1_p
in IN 1_p
group NN 1_p
I PRP N
received VBD N
intramedullary JJ 1_i
fixation NN 1_i
using VBG 1_i
the DT 1_i
Sonoma NNP 1_i
Wrx NNP 1_i
device NN 1_i
and CC N
patients NNS N
in IN N
group NN N
II NNP N
received VBD N
standard JJ 1_i
volar JJ 1_i
locking VBG 1_i
plate NN 1_i
fixation NN 1_i
. . 1_i

Radiographic JJ N
criteria NNS N
of IN N
acceptable JJ N
healing NN N
were VBD N
used VBN N
for IN N
evaluation NN N
. . N

RESULTS NNP N
Two CD N
groups NNS N
were VBD N
similar JJ N
in IN N
terms NNS N
of IN N
baseline NN N
characteristics NNS N
. . N

Mean JJ 1_o
time NN 1_o
of IN 1_o
operation NN 1_o
was VBD N
significantly RB N
shorter JJR N
in IN N
Group NNP 1_p
1 CD 1_p
vs. NN N
in IN N
group NN 1_p
2 CD 1_p
( ( N
36.81 CD N
± RB N
7.11 CD N
vs. FW N
48.97 CD N
± $ N
5.9 CD N
minutes NNS N
, , N
p VBP 1_o
= RB 1_o
0.001 CD 1_o
) ) 1_o
. . 1_o

Time NN 1_o
to TO 1_o
healing NN 1_o
of IN 1_o
the DT N
fracture NN N
was VBD N
not RB N
different JJ N
between IN N
two CD N
groups NNS N
( ( N
5.45 CD N
± RB N
1.09 CD N
vs. FW N
5.70 CD N
± $ N
1.04 CD N
weeks NNS N
for IN N
Group NNP N
1 CD N
vs. FW N
2 CD N
, , N
respectively RB 1_o
p JJ 1_o
= NNP 1_o
0.36 CD 1_o
) ) 1_o
. . N

Overall JJ N
complications NNS 1_p
occurred VBD 1_p
in IN N
9 CD N
patients NNS N
in IN N
group NN 1_p
1 CD 1_p
and CC 1_p
in IN N
15 CD N
patients NNS N
in IN N
group NN N
2 CD N
( ( N
p NN N
= RB N
0.17 CD N
) ) N
. . 1_p

Follow-up NN 1_p
was VBD N
completed VBN N
in IN N
all DT N
patients NNS N
with IN N
a DT N
median JJ N
time NN 1_p
of IN 1_p
12 CD 1_p
months NNS 1_p
and CC N
13 CD N
months NNS N
in IN N
group NN N
1 CD N
and CC N
2 CD N
, , N
respectively RB 1_o
. . 1_o

On IN 1_o
radiographic JJ 1_o
evaluation NN 1_o
radial JJ 1_o
inclination NN 1_o
, , N
radial JJ N
height NN N
and CC N
volar JJ N
tilt NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
group NN N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN 1_o
two CD 1_o
groups NNS 1_o
in IN 1_o
regard NN 1_o
to TO N
wrist VB N
rotational JJ N
degrees NNS N
measured VBN N
in IN N
last JJ 1_i
follow-up JJ 1_i
visit NN 1_i
. . N

CONCLUSION NNP N
Sonoma NNP N
Wrx NNP N
Device NNP N
is VBZ N
reliable JJ N
and CC N
effective JJ N
in IN N
terms NNS N
of IN N
achieving VBG N
satisfactory JJ N
outcomes NNS N
in IN N
treatment NN N
of IN N
distal JJ N
radius NN N
fractures NNS N
. . N

It PRP N
may MD N
be VB N
reasonable JJ N
to TO N
use VB N
this DT N
device NN N
to TO N
prevent VB N
complications NNS N
that WDT N
are VBP N
related VBN N
to TO N
extensive JJ N
soft JJ N
tissue NN N
dissection NN N
. . N

Improving VBG N
the DT N
immunogenicity NN 1_o
of IN N
pneumococcal JJ N
conjugate NN N
vaccine NN N
in IN N
HIV-infected NNP 1_p
adults NNS 1_p
with IN 1_p
a DT 1_p
toll-like JJ 1_p
receptor NN 1_p
9 CD 1_p
agonist NN 1_p
adjuvant NN 1_p
: : 1_p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Persons NNP 1_p
infected VBD 1_p
with IN 1_p
human JJ 1_p
immunodeficiency NN 1_p
virus NN 1_p
( ( 1_p
HIV NNP 1_p
) ) 1_p
are VBP N
often RB N
hyporesponsive JJ N
to TO N
immunization NN N
, , N
including VBG N
pneumococcal JJ N
vaccines NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
adding VBG N
CPG NNP N
7909 CD N
, , N
a DT N
toll-like JJ N
receptor NN N
9 CD N
( ( N
TLR9 NNP N
) ) N
agonist NN N
and CC N
vaccine NN N
adjuvant NN N
, , N
to TO N
7-valent JJ N
pneumococcal JJ N
conjugate NN N
vaccine NN N
( ( N
7vPnC CD N
) ) N
would MD N
increase VB N
its PRP$ N
immunogenicity NN N
in IN N
HIV-infected NNP 1_p
adults NNS 1_p
. . 1_p

METHODS NNP N
We PRP N
performed VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
phase VB N
1b/2a CD N
trial NN N
randomizing VBG N
HIV-positive JJ 1_p
patients NNS 1_p
to TO N
receive VB N
double JJ N
doses NNS N
of IN N
7vPnC CD 1_i
( ( 1_i
Prevnar NNP 1_i
) ) 1_i
at IN N
0 CD N
and CC N
3 CD N
months NNS N
and CC N
1 CD N
dose NN N
of IN N
23-valent JJ 1_i
pneumococcal JJ 1_i
polysaccharide NN 1_i
vaccine NN 1_i
( ( 1_i
PPV-23 NNP 1_i
; : 1_i
Pneumo NNP 1_i
Novum NNP 1_i
) ) 1_i
at IN N
9 CD N
months NNS N
, , N
with IN N
experimental JJ N
patients NNS N
receiving VBG N
1 CD N
mg NN N
of IN N
CPG NNP 1_i
7909 CD 1_i
added VBD N
to TO N
each DT N
of IN N
their PRP$ N
3 CD N
vaccine NN N
doses NNS N
; : N
control NN N
patients NNS N
had VBD N
phosphate-buffered JJ 1_i
saline NN 1_i
added VBN N
instead RB N
. . N

Immunogenicity NNP 1_o
and CC 1_o
safety NN 1_o
were VBD N
evaluated VBN N
for IN N
up RB N
to TO N
10 CD N
months NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN 1_o
of IN 1_o
vaccine NN 1_o
high JJ 1_o
responders NNS 1_o
at IN 1_o
9 CD 1_o
months NNS 1_o
, , N
defined VBD N
as IN N
a DT N
2-fold JJ N
increase NN N
in IN N
IgG NNP N
levels NNS N
to TO N
> VB N
or CC N
= VB N
1 CD N
microg/mL NN N
for IN N
at IN N
least JJS N
5 CD N
of IN N
7 CD N
of IN N
the DT N
7vPnC CD N
serotypes NNS N
. . N

RESULTS NNP N
Ninety-seven JJ 1_p
participants NNS 1_p
were VBD 1_p
included VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
proportion NN 1_o
of IN 1_o
vaccine NN 1_o
high JJ 1_o
responders NNS 1_o
was VBD N
higher RBR N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
48 CD N
) ) N
than IN N
among IN N
controls NNS N
( ( N
n JJ N
= VBZ N
49 CD N
; : N
48.8 CD N
% NN N
vs JJ N
25.0 CD N
% NN N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
at IN N
9 CD N
months NNS N
. . N

Greater NNP N
proportions NNS 1_o
of IN 1_o
high JJ 1_o
responders NNS 1_o
were VBD N
also RB N
observed VBN N
at IN N
3 CD N
( ( N
51.1 CD N
% NN N
vs JJ N
39.6 CD N
% NN N
; : N
P NNP N
= NNP N
.26 NNP N
) ) N
, , N
4 CD N
( ( N
77.3 CD N
% NN N
vs JJ N
56.3 CD N
% NN N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
and CC N
10 CD N
months NNS N
( ( N
87.8 CD N
% NN N
vs JJ N
51.1 CD N
% NN N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Mild NNP 1_o
systemic JJ 1_o
and CC 1_o
injection NN 1_o
site NN 1_o
reactions NNS 1_o
to TO N
7vPnC CD 1_i
were VBD N
more JJR N
common JJ N
in IN N
the DT N
experimental JJ N
group NN N
than IN N
the DT N
control NN N
group NN N
( ( N
100 CD N
% NN N
vs JJ N
81.3 CD N
% NN N
; : N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

CPG JJ N
7909 CD N
did VBD N
not RB N
increase VB N
non-7vPnC JJ 1_o
IgG NNP 1_o
levels NNS 1_o
after IN N
PPV-23 NNP 1_i
immunization NN N
. . N

No DT N
adverse JJ N
effects NNS N
on IN N
CD4 NNP 1_o
( ( 1_o
+ NNP 1_o
) ) 1_o
cell NN 1_o
count NN 1_o
or CC 1_o
organ JJ 1_o
functions NNS 1_o
occurred VBD N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
a DT N
TLR9 NNP 1_i
agonist NN N
to TO N
7vPnC CD 1_i
significantly RB N
enhanced VBD N
the DT N
proportion NN N
of IN N
vaccine NN 1_o
high JJ 1_o
responders NNS 1_o
. . 1_o

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00562939 NNP N
. . N

Pregnancy NNP N
outcome NN N
and CC N
glycemic JJ 1_o
control NN 1_o
in IN N
women NNS 1_p
with IN 1_p
type JJ 1_p
1 CD 1_p
diabetes NNS 1_p
: : 1_p
a DT N
retrospective JJ N
comparison NN N
between IN N
CSII NNP 1_i
and CC N
MDI NNP 1_i
treatment NN N
. . N

AIM NNP N
Present NNP N
study NN N
was VBD N
aimed VBN N
to TO N
evaluate VB N
glycemic JJ 1_o
control NN 1_o
and CC 1_o
maternal-fetal JJ 1_o
outcome NN 1_o
in IN 1_p
pregnant JJ 1_p
type NN 1_p
1 CD 1_p
diabetic JJ 1_p
patient NN 1_p
treated VBN N
with IN N
continuous JJ 1_i
subcutaneous JJ 1_i
insulin NN 1_i
infusion NN 1_i
( ( 1_i
CSII NNP 1_i
) ) 1_i
or CC 1_i
multiple JJ 1_i
daily JJ 1_i
injections NNS 1_i
of IN 1_i
insulin NN 1_i
( ( 1_i
MDI NNP 1_i
) ) 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP 1_p
retrospective JJ 1_p
observational NN 1_p
study NN 1_p
included VBD 1_p
thirty-four JJ 1_p
pregnant JJ 1_p
type NN 1_p
1 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
. . 1_p

Patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
group NN N
, , N
CSII NNP 1_i
treated VBD 1_i
group NN 1_i
( ( 1_p
n=14 CC 1_p
) ) 1_p
and CC 1_i
MDI NNP 1_i
treated VBD 1_i
group NN 1_i
( ( 1_p
n=20 RB 1_p
) ) 1_p
. . 1_p

The DT N
HbA1c NNP N
level NN N
and CC N
maternal-fetal JJ N
outcome NN N
were VBD N
evaluated VBN N
in IN N
both DT N
the DT N
treatment NN N
group NN N
. . N

Outcome NNP N
parameters NNS N
such JJ N
as IN N
glycemic JJ 1_o
control NN 1_o
( ( 1_o
HbA1c NNP 1_o
) ) 1_o
, , 1_o
hypoglycemic JJ 1_o
events NNS 1_o
, , 1_o
time NN 1_o
and CC 1_o
mode NN 1_o
of IN 1_o
delivery NN 1_o
and CC 1_o
labor NN 1_o
results NNS 1_o
( ( 1_o
abortion NN 1_o
, , 1_o
premature NN 1_o
labor NN 1_o
, , 1_o
perinatal JJ 1_o
mortality NN 1_o
, , 1_o
neonatal JJ 1_o
weight NN 1_o
, , 1_o
Apgar NNP 1_o
score NN 1_o
, , 1_o
neonatal JJ 1_o
hypoglycaemia NN 1_o
, , 1_o
presence NN 1_o
of IN 1_o
congenital JJ 1_o
abnormalities NNS 1_o
) ) 1_o
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Pregnancy NNP 1_o
outcome NN 1_o
and CC 1_o
glycemic JJ 1_o
control NN 1_o
in IN N
pregnant JJ N
type NN N
1 CD N
diabetic JJ N
patients NNS N
treated VBN N
with IN N
CSII NNP N
and CC N
MDI NNP N
were VBD N
evaluated VBN N
and CC N
compared VBN N
. . N

Two CD N
groups NNS N
were VBD N
compared VBN N
for IN N
their PRP$ N
epidemiological JJ N
parameters NNS N
, , N
although IN N
patients NNS N
on IN N
CSII NNP N
treatment NN N
had VBD N
longer JJR 1_o
duration NN 1_o
of IN 1_o
diabetes NNS 1_o
compared VBN N
to TO N
MDI NNP N
treated VBD N
group NN N
. . N

Reduction NN 1_o
in IN 1_o
HbA1c NNP 1_o
level NN 1_o
was VBD N
higher RBR N
in IN N
CSII NNP N
treated VBD N
patients NNS N
at IN N
first JJ N
( ( N
CSII NNP N
: : N
0.9 CD N
% NN N
vs JJ N
MDI NNP N
: : N
0.46 CD N
% NN N
) ) N
, , N
second JJ N
( ( N
CSII NNP N
: : N
1.58 CD N
% NN N
vs JJ N
MDI NNP N
: : N
0.78 CD N
% NN N
) ) N
and CC N
third JJ N
trimester NN N
( ( N
CSII NNP N
: : N
1.74 CD N
% NN N
vs JJ N
MDI NNP N
: : N
1.09 CD N
% NN N
) ) N
of IN N
pregnancy NN N
compared VBN N
to TO N
MDI NNP N
treated VBD N
patients NNS N
. . N

Duration NNP 1_o
of IN 1_o
pregnancy NN 1_o
and CC 1_o
new JJ 1_o
born VBN 1_o
baby NN 1_o
weight NN 1_o
were VBD N
founded VBN N
similar JJ N
in IN N
both DT N
group NN N
. . N

Moreover RB N
, , N
the DT N
rate NN 1_o
of IN 1_o
abortion NN 1_o
, , 1_o
preterm JJ 1_o
labor NN 1_o
, , 1_o
cesarean JJ 1_o
section NN 1_o
and CC 1_o
hypoglycemia NN 1_o
in IN 1_o
new JJ 1_o
born NNS 1_o
were VBD N
founded VBN N
less RBR N
in IN N
CSII NNP N
treated VBD N
group NN N
compared VBN N
to TO N
MDI NNP N
treated VBN N
group NN N
and CC N
Apgar NNP 1_o
score NN 1_o
was VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
CSII NNP N
treated VBD N
group NN N
compared VBN N
to TO N
MDI NNP N
treated VBD N
group NN N
. . N

CONCLUSION NNP N
Results NNP N
of IN N
present JJ N
study NN N
revealed VBD N
that IN N
the DT N
CSII NNP N
gives VBZ N
better JJR N
glycemic JJ N
control NN N
and CC N
pregnancy NN N
outcome NN N
in IN N
pregnant JJ 1_p
type NN 1_p
1 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
compared VBN N
to TO N
MDI NNP N
treatment NN N
. . N

CSII NNP N
also RB N
decreases VBZ N
the DT N
daily JJ N
insulin NN N
requirement NN N
compared VBN N
MDI NNP N
. . N

Quadratus NNP N
lumborum NN 1_i
block NN 1_i
for IN N
postoperative NN 1_o
pain NN 1_o
after IN 1_p
caesarean JJ 1_i
section NN 1_i
: : 1_i
A DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Effective NNP N
postoperative JJ N
analgesia NN N
after IN N
caesarean JJ 1_i
section NN N
is VBZ N
important JJ N
because IN N
it PRP N
enables VBZ N
early JJ N
ambulation NN N
and CC N
facilitates VBZ N
breast-feeding NN N
. . N

Several JJ N
case NN N
reports NNS N
have VBP N
shown VBN N
that IN N
local JJ 1_i
anaesthetic JJ 1_i
injection NN 1_i
around IN N
the DT N
quadratus NN N
lumborum NN N
muscle NN N
is VBZ N
effective JJ N
in IN N
providing VBG N
pain NN N
relief NN N
after IN N
various JJ N
abdominal JJ N
operations NNS N
and CC N
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
pain NN 1_p
. . 1_p

The DT N
quadratus NN 1_i
lumborum NN 1_i
block NN 1_i
( ( N
QLB NNP N
) ) N
is VBZ N
performed VBN N
in IN N
close JJ N
proximity NN N
to TO N
the DT N
surface NN N
and CC N
uses VBZ N
a DT N
fascial JJ N
compartment NN N
path NN N
to TO N
extend VB N
the DT N
distribution NN N
of IN N
local JJ N
anaesthesia NN N
into IN N
the DT N
posterior JJ N
abdominal JJ N
wall NN N
and CC N
paravertebral JJ N
space NN N
. . N

This DT N
central JJ N
effect NN N
can MD N
be VB N
of IN N
vital JJ N
importance NN N
when WRB N
managing VBG N
the DT N
visceral JJ 1_o
pain NN 1_o
after IN 1_p
caesarean JJ 1_p
section NN 1_p
. . 1_p

OBJECTIVE IN N
We PRP N
hypothesised VBD N
that IN N
the DT N
QLB NNP N
after IN N
caesarean JJ 1_p
section NN 1_p
can MD N
provide VB N
adequate JJ N
pain NN N
relief NN N
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
approach NN N
. . N

DESIGN NNP N
Double-blind NNP N
, , N
randomised VBD N
and CC N
controlled VBD N
clinical JJ N
trial NN N
. . N

SETTING VB N
A DT 1_p
single JJ 1_p
centre NN 1_p
between IN 1_p
June NNP 1_p
2014 CD 1_p
and CC 1_p
December NNP 1_p
2014 CD 1_p
. . 1_p

PATIENTS VB N
Fifty JJ 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
American JJ 1_p
Society NNP 1_p
of IN 1_p
Anesthesiologists NNP 1_p
physical JJ 1_p
status NN 1_p
1 CD 1_p
or CC 1_p
2 CD 1_p
, , 1_p
with IN 1_p
normal JJ 1_p
singleton NN 1_p
pregnancies NNS 1_p
with IN 1_p
a DT 1_p
gestation NN 1_p
of IN 1_p
at IN 1_p
least JJS 1_p
37 CD 1_p
weeks NNS 1_p
, , 1_p
and CC 1_p
scheduled VBN 1_p
for IN 1_p
elective JJ 1_p
caesarean JJ 1_p
section NN 1_p
under IN 1_p
spinal JJ 1_p
anaesthesia NN 1_p
, , N
were VBD N
enrolled VBN N
into IN N
the DT N
study NN N
. . N

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
QLB NNP 1_i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
with IN N
0.125 CD 1_i
% NN 1_i
bupivacaine NN 1_i
0.2 CD N
ml NN N
kg⁻¹ NN N
( ( 1_i
Group NNP 1_i
1 CD 1_i
) ) 1_i
or CC N
a DT N
QLB NNP N
( ( 1_i
n JJ 1_i
= NNP 1_i
25 CD 1_i
) ) 1_i
with IN 1_i
0.9 CD 1_i
% NN 1_i
Normal NNP N
saline NN N
0.2 CD N
ml NN N
kg⁻¹ NN N
( ( N
Group NNP N
2 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
for IN 1_o
the DT 1_o
study NN 1_o
was VBD 1_o
the DT 1_o
morphine NN 1_o
demands NNS 1_o
and CC 1_o
doses NNS 1_o
delivered VBN 1_o
by IN 1_o
a DT 1_o
patient-controlled JJ 1_o
analgesia NN N
system NN N
at IN N
predetermined VBN N
intervals NNS N
( ( N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
12 CD N
, , N
24 CD N
and CC N
48 CD N
h NN N
) ) N
after IN N
surgery NN N
. . N

The DT N
secondary JJ 1_o
endpoints NNS 1_o
were VBD 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
for IN 1_o
pain NN 1_o
at IN 1_o
rest NN 1_o
and CC 1_o
on IN 1_o
movement NN 1_o
( ( 1_o
dynamic JJ 1_o
) ) 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
pruritus NN 1_o
, , 1_o
itching NN 1_o
, , 1_o
nausea NN 1_o
, , N
vomiting VBG N
and CC N
sedation NN N
. . N

RESULTS VB N
The DT N
patients NNS N
who WP N
received VBD N
local JJ N
anaesthetic NN N
used VBN 1_o
significantly RB 1_o
less RBR N
morphine JJ N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
at IN N
6 CD N
and CC N
12 CD N
h NN N
, , N
but CC N
not RB N
at IN N
24 CD N
and CC N
48 CD N
hours NNS N
after IN N
caesarean JJ N
section NN N
. . N

The DT N
local JJ N
anaesthetic JJ 1_o
group NN 1_o
had VBD 1_o
significantly RB N
less JJR N
morphine JJ N
demand NN N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
6 CD N
, , N
12 CD N
, , N
24 CD N
and CC N
48 CD 1_o
h NN 1_o
after IN N
caesarean JJ N
section NN N
. . N

The DT N
VAS NNP N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
local JJ N
anaesthetic NN N
group NN N
than IN N
the DT N
control NN N
group NN N
, , N
including VBG N
VAS NNP N
for IN N
pain NN N
at IN N
rest NN N
at IN N
all DT N
times NNS N
except IN N
24 CD N
h NN N
after IN N
caesarean JJ N
section NN N
, , N
and CC N
VAS NNP N
for IN N
pain NN N
on IN N
movement NN N
( ( N
dynamic JJ N
) ) N
at IN 1_p
all DT 1_p
times NNS 1_p
. . 1_p

CONCLUSION VB 1_p
The DT N
QLB NNP N
after IN N
caesarean JJ N
section NN N
was VBD N
effective JJ N
and CC N
provided VBD N
satisfactory JJ N
analgesia NN N
in IN N
combination NN N
with IN N
a DT N
typical JJ N
postoperative JJ N
analgesic JJ N
regimen NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT02328378 NNP N
. . N

Group NNP 1_i
cognitive JJ 1_i
behavioural JJ 1_i
therapy NN 1_i
and CC 1_i
group NN 1_i
recreational JJ 1_i
activity NN 1_i
for IN N
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
a DT N
preliminary JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Although IN N
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
are VBP N
an DT N
increasingly RB N
identified VBN N
patient JJ N
population NN N
, , N
few JJ N
treatment NN N
options NNS N
are VBP N
available JJ N
. . N

This DT N
preliminary JJ N
randomized NN N
controlled VBD N
open JJ N
trial NN N
with IN N
a DT N
parallel JJ N
design NN N
developed VBD N
two CD N
group NN N
interventions NNS N
for IN N
adults NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
and CC 1_p
intelligence NN 1_p
within IN 1_p
the DT 1_p
normal JJ 1_p
range NN 1_p
: : 1_p
cognitive JJ 1_i
behavioural JJ 1_i
therapy NN 1_i
and CC 1_i
recreational JJ 1_i
activity NN 1_i
. . 1_i

Both DT N
interventions NNS N
comprised VBD N
36 CD N
weekly JJ N
3-h JJ N
sessions NNS N
led VBN N
by IN N
two CD N
therapists NNS N
in IN N
groups NNS 1_p
of IN 1_p
6-8 JJ 1_p
patients NNS 1_p
. . 1_p

A DT N
total NN N
of IN N
68 CD 1_p
psychiatric JJ 1_p
patients NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
participated VBD N
in IN N
the DT N
study NN N
. . N

Outcome NNP N
measures NNS N
were VBD N
Quality NNP 1_o
of IN 1_o
Life NNP 1_o
Inventory NNP 1_o
, , 1_o
Sense NNP 1_o
of IN 1_o
Coherence NNP 1_o
Scale NNP 1_o
, , 1_o
Rosenberg NNP 1_o
Self-Esteem NNP 1_o
Scale NNP 1_o
and CC 1_o
an DT 1_o
exploratory JJ 1_o
analysis NN 1_o
on IN 1_o
measures NNS 1_o
of IN 1_o
psychiatric JJ 1_o
health NN 1_o
. . 1_o

Participants NNS N
in IN N
both DT N
treatment NN N
conditions NNS N
reported VBD N
an DT N
increased JJ N
quality NN 1_o
of IN 1_o
life NN 1_o
at IN N
post-treatment JJ N
( ( N
d JJ N
= NN N
0.39 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
with IN N
no DT N
difference NN N
between IN N
interventions NNS N
. . N

No DT N
amelioration NN N
of IN N
psychiatric JJ 1_o
symptoms NNS 1_o
was VBD N
observed VBN N
. . N

The DT N
dropout NN 1_o
rate NN 1_o
was VBD N
lower JJR N
with IN N
cognitive JJ 1_i
behavioural JJ 1_i
therapy NN 1_i
than IN N
with IN N
recreational JJ N
activity NN N
, , N
and CC N
participants NNS N
in IN N
cognitive JJ 1_i
behavioural JJ 1_i
therapy NN 1_i
rated VBN N
themselves PRP N
as IN N
more RBR N
generally RB N
improved VBN N
, , N
as RB N
well RB N
as IN N
more JJR N
improved JJ N
regarding VBG N
expression NN N
of IN N
needs NNS N
and CC N
understanding NN N
of IN N
difficulties NNS N
. . N

Both DT N
interventions NNS N
appear VBP N
to TO N
be VB N
promising JJ N
treatment NN N
options NNS N
for IN N
adults NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

The DT N
interventions NNS N
' POS N
similar JJ N
efficacy NN 1_o
may MD N
be VB N
due JJ N
to TO N
the DT N
common JJ N
elements NNS N
, , N
structure NN N
and CC N
group NN N
setting NN N
. . N

Cognitive JJ 1_i
behavioural JJ 1_i
therapy NN 1_i
may MD N
be VB N
additionally RB N
beneficial JJ N
in IN N
terms NNS N
of IN N
increasing VBG N
specific JJ N
skills NNS N
and CC N
minimizing VBG N
dropout NN N
. . N

A DT N
double-blind JJ N
comparison NN N
of IN N
clomipramine NN 1_i
, , 1_i
desipramine NN 1_i
, , 1_i
and CC 1_i
placebo NN 1_i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ 1_p
disorder NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
clomipramine NN 1_i
hydrochloride NN 1_i
, , N
a DT N
serotonin JJ N
reuptake NN N
blocker NN N
with IN N
unique JJ N
anti-obsessional JJ N
properties NNS N
, , N
is VBZ N
differentially RB N
effective JJ N
for IN N
obsessive-compulsive JJ N
and CC N
stereotyped VBD N
motor NN N
behaviors NNS N
in IN N
autistic JJ N
disorder NN N
compared VBN N
with IN N
placebo NN 1_i
and CC N
with IN N
the DT N
noradrenergic JJ 1_i
tricyclic JJ 1_i
antidepressant NN 1_i
agent NN 1_i
, , 1_i
desipramine JJ 1_i
hydrochloride NN 1_i
. . 1_i

DESIGN NNP N
Following VBG N
a DT N
2-week JJ N
, , N
single-blind JJ N
placebo NN 1_i
washout IN N
phase NN N
, , N
12 CD 1_p
autistic JJ 1_p
subjects NNS 1_p
completed VBD N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
comparison NN N
of IN N
clomipramine NN 1_i
and CC 1_i
placebo NN 1_i
, , N
and CC N
12 CD 1_p
different JJ 1_p
subjects NNS 1_p
completed VBD N
a DT N
similar JJ N
comparison NN N
of IN N
clomipramine NN 1_i
and CC N
desipramine NN 1_i
. . 1_i

SETTING CC N
Outpatient JJ N
clinic NN N
. . N

PATIENTS VB N
A DT 1_p
referral JJ 1_p
sample NN 1_p
of IN 1_p
30 CD 1_p
male NN 1_p
and CC 1_p
female JJ 1_p
autistic JJ 1_p
patients NNS 1_p
were VBD 1_p
enrolled VBN 1_p
, , 1_p
and CC 1_p
24 CD 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

MEASURES NNP N
Key NNP N
outcome NN N
measures NNS N
were VBD N
the DT N
Autism NNP 1_o
Relevant NNP 1_o
Subscale NNP 1_o
of IN 1_o
the DT 1_o
Children NNP 1_o
's POS 1_o
Psychiatric NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
, , 1_o
the DT 1_o
Modified NNP 1_o
Comprehensive NNP 1_o
Psychopathological NNP 1_o
Rating NNP 1_o
Scale-Obsessive-Compulsive JJ 1_o
Disorder NNP 1_o
Subscale NNP 1_o
, , 1_o
and CC 1_o
the DT 1_o
Clinical NNP 1_o
Global NNP 1_o
Impressions NNP 1_o
Scale NNP 1_o
. . 1_o

RESULTS NNP N
Clomipramine NNP 1_i
was VBD N
superior JJ N
to TO N
both DT N
placebo NN N
and CC N
desipramine NN N
on IN N
ratings NNS N
of IN N
autistic JJ 1_o
symptoms NNS 1_o
( ( 1_o
including VBG 1_o
stereotypies NNS 1_o
) ) 1_o
, , 1_o
anger NN 1_o
, , 1_o
and CC 1_o
compulsive JJ 1_o
, , 1_o
ritualized JJ 1_o
behaviors NNS 1_o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
with IN N
no DT N
differences NNS N
between IN N
desipramine NN 1_i
and CC N
placebo NN 1_i
. . 1_i

Clomipramine NNP 1_i
was VBD N
equal JJ N
to TO N
desipramine VB 1_i
and CC N
both DT N
tricyclic JJ N
agents NNS N
were VBD N
superior JJ N
to TO N
placebo VB N
for IN N
amelioration NN N
of IN N
hyperactivity NN 1_o
. . 1_o

CONCLUSION NNP N
Biological NNP N
links NNS N
between IN N
compulsions NNS N
and CC N
stereotyped VBD N
, , N
repetitive JJ N
behaviors NNS N
in IN N
autistic JJ 1_p
disorder NN 1_p
should MD N
be VB N
explored VBN N
. . N

Effects NNS N
of IN N
prelinguistic JJ 1_i
milieu NN 1_i
teaching NN 1_i
and CC 1_i
parent NN 1_i
responsivity NN 1_i
education NN 1_i
on IN N
dyads NNS 1_o
involving VBG 1_o
children NNS 1_o
with IN 1_o
intellectual JJ 1_o
disabilities NNS 1_o
. . 1_o

This DT N
study NN N
tested VBD N
the DT N
effect NN N
of IN N
a DT N
method NN N
of IN N
facilitating VBG 1_i
prelinguistic JJ 1_i
communication NN 1_i
on IN N
parents NNS 1_o
' POS 1_o
responsivity NN 1_o
and CC 1_o
children NNS 1_o
's POS 1_o
communication NN 1_o
and CC 1_o
productive JJ 1_o
language NN 1_o
development NN 1_o
. . 1_o

The DT N
method NN N
involved VBN N
Responsivity NNP 1_i
education NN 1_i
for IN 1_i
the DT 1_i
parents NNS 1_i
and CC 1_p
Prelinguistic NNP 1_i
Milieu NNP 1_i
Teaching NNP 1_i
for IN 1_i
the DT 1_i
children NNS 1_i
( ( 1_i
RPMT NNP 1_i
) ) 1_i
. . 1_i

Thirty-nine JJ 1_p
prelinguistic JJ 1_p
toddlers NNS 1_p
with IN 1_p
intellectual JJ 1_p
disabilities NNS 1_p
and CC 1_p
their PRP$ 1_p
primary JJ 1_p
caregivers NNS 1_p
participated VBD 1_p
in IN 1_p
this DT 1_p
study NN 1_p
. . 1_p

Parent-child JJ N
pairs NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
RPMT NNP 1_i
group NN N
or CC N
a DT N
control NN 1_i
group NN 1_i
. . 1_i

Communication NNP 1_o
and CC 1_o
language NN 1_o
were VBD N
assessed VBN N
at IN N
study NN N
entry NN N
and CC N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
later RB N
. . N

RPMT NNP 1_i
facilitated VBD N
parental JJ 1_o
responsivity NN 1_o
in IN N
the DT N
posttreatment JJ N
period NN N
. . N

The DT N
effect NN N
of IN N
RPMT NNP 1_i
on IN N
growth NN 1_o
rate NN 1_o
of IN 1_o
child-initiated JJ 1_o
comments NNS 1_o
( ( N
i.e. NN N
, , N
the DT N
most RBS N
common JJ N
type NN N
of IN N
initiating VBG N
joint JJ N
attention NN N
) ) N
varied VBN N
by IN N
pretreatment JJ N
measures NNS N
of IN N
that DT N
variable JJ N
. . N

The DT N
effect NN N
of IN N
RPMT NNP 1_i
on IN N
growth NN 1_o
rate NN 1_o
of IN 1_o
child-initiated JJ 1_o
requests NNS 1_o
( ( N
i.e. NN N
, , N
the DT N
most RBS N
common JJ N
type NN N
of IN N
initiating VBG N
behavior JJ N
regulation NN N
) ) N
varied VBN N
by IN N
presence NN N
or CC N
absence NN N
of IN N
Down NNP N
syndrome NN N
. . N

Finally RB N
, , N
the DT N
effect NN N
of IN N
RPMT NNP 1_i
on IN N
growth NN 1_o
of IN 1_o
productive JJ 1_o
language NN 1_o
varied VBN N
by IN N
pretreatment JJ N
frequency NN N
of IN N
canonical JJ N
vocal JJ N
communication NN N
. . N

Recommended VBN N
alterations NNS N
in IN N
PMT NNP 1_i
and CC N
implications NNS N
for IN N
defining VBG N
which WDT N
nonspeaking VBG N
children NNS N
are VBP N
appropriate JJ N
for IN N
prelinguistic JJ N
goals NNS N
and CC N
treatment NN N
were VBD N
discussed VBN N
. . N

Early RB 1_i
versus NN 1_i
late JJ 1_i
replacement NN 1_i
of IN 1_i
autotransfused JJ 1_i
blood NN 1_i
in IN N
elective JJ 1_p
spinal JJ 1_i
surgery NN 1_i
. . 1_i

A DT N
prospective JJ N
randomized NN N
study NN N
. . N

The DT N
use NN N
of IN N
autologous JJ 1_i
blood NN 1_i
is VBZ N
a DT N
well RB N
established VBN N
and CC N
extremely RB N
popular JJ N
technique NN N
to TO N
decrease VB N
the DT N
necessity NN N
for IN N
homologous JJ N
transfusions NNS N
and CC N
the DT N
attendant JJ N
risks NNS N
of IN N
hepatitis NN N
, , N
HIV NNP N
, , N
and CC N
HTLV NNP N
-- : N
I/II NNP N
infections NNS N
. . N

The DT N
most RBS N
beneficial JJ N
timing NN N
for IN N
autologous JJ 1_i
reinfusion NN N
of IN N
predonated JJ N
blood NN N
remains VBZ N
unknown JJ N
. . N

The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
optimal JJ N
timing NN N
of IN N
autologous JJ 1_i
blood NN 1_i
reinfusion NN 1_i
in IN 1_i
elective JJ 1_i
spinal JJ 1_i
surgery NN 1_i
. . 1_i

Fifty-seven JJ 1_p
patients NNS 1_p
were VBD N
prospectively RB N
individually RB N
randomly RB N
allocated VBN N
into IN N
early JJ 1_i
versus NN 1_i
delayed VBN 1_i
reinfusion NN 1_i
groups NNS 1_i
prior RB N
to TO N
undergoing VBG 1_p
elective JJ 1_i
spinal JJ 1_i
surgery NN 1_i
by IN N
a DT N
single JJ N
surgeon NN N
. . N

Three CD N
surgical JJ N
subgroups NNS N
were VBD N
entered VBN N
into IN N
the DT N
study NN N
: : N
anterior/posterior NN 1_p
( ( 1_p
A/P NNP 1_p
) ) 1_p
spinal JJ 1_p
fusion NN 1_p
patients NNS 1_p
, , 1_p
posterior JJ 1_p
thoracolumbar NN 1_p
scoliosis NN 1_p
fusion NN 1_p
patients NNS 1_p
( ( 1_p
PSF NNP 1_p
) ) 1_p
, , 1_p
and CC 1_p
degenerative JJ 1_p
posterior JJ 1_p
lumbar NN 1_p
fusion NN 1_p
patients NNS 1_p
( ( 1_p
LF NNP 1_p
) ) 1_p
. . N

Randomization NN N
was VBD N
successful JJ N
in IN N
that DT N
three CD N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
male NN N
to TO N
female VB N
ratio NN N
, , N
age NN N
, , N
preoperative JJ N
hemoglobin NN N
, , N
or CC N
number NN N
of IN N
units NNS N
predonated VBN N
between IN N
the DT N
early JJ 1_i
and CC 1_i
delayed JJ 1_i
reinfusion NN 1_i
groups NNS 1_i
. . 1_i

Likewise NNP N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
details NNS N
of IN N
the DT N
operative JJ N
procedure NN N
when WRB N
compared VBN N
as IN N
a DT N
group NN N
for IN N
the DT N
early JJ N
versus NN N
delayed VBN N
reinfusion NN N
groups NNS N
. . N

A DT N
significant JJ N
increase NN N
in IN N
the DT N
postoperative JJ N
day NN 1_o
# # 1_o
1 CD 1_o
, , 1_o
2 CD 1_o
and CC 1_o
3 CD 1_o
hemoglobin NN 1_o
was VBD N
seen VBN N
in IN N
the DT N
early JJ 1_i
reinfusion NN 1_i
group NN 1_i
, , N
while IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
seen VBN N
in IN N
the DT N
postoperative JJ N
day NN N
# # N
7 CD N
hemoglobin NN N
between IN N
the DT N
early JJ 1_i
versus NN 1_i
delayed VBN 1_i
reinfusion NN 1_i
group NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
surgical JJ N
grouping NN N
on IN N
these DT N
significant JJ N
comparisons NNS N
. . N

Earlier RBR N
patient JJ 1_o
mobilization NN 1_o
was VBD N
also RB N
seen VBN N
in IN N
the DT N
early JJ 1_i
reinfusion NN 1_i
groups NNS N
for IN N
the DT N
A/P NNP N
and CC N
PSF NNP N
groups NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
patients NNS N
' POS N
subjective JJ N
evaluation NN N
of IN N
satisfaction NN N
and CC N
discomfort NN N
between IN N
the DT N
early JJ N
or CC N
delayed VBN N
reinfusion NN N
groups NNS N
as IN N
determined VBN N
by IN N
blinded VBN N
interview NN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
5 CD N
, , N
and CC N
7 CD N
postoperatively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
Soluble JJ 1_i
intercellular JJ 1_i
adhesion NN 1_i
molecule-1 NN 1_i
in IN N
primary JJ 1_p
biliary JJ 1_p
cirrhosis NN 1_p
: : 1_p
effect NN N
of IN N
ursodeoxycholic JJ 1_i
acid NN 1_i
and CC N
immunosuppressive JJ 1_i
therapy NN 1_i
. . 1_i

OBJECTIVES NNP N
Soluble JJ 1_i
intercellular JJ 1_i
adhesion NN 1_i
molecule-1 NN 1_i
( ( 1_i
sICAM-1 JJ 1_i
) ) 1_i
is VBZ N
thought VBN N
to TO N
be VB N
released VBN N
by IN N
a DT N
variety NN N
of IN N
cells NNS N
at IN N
sites NNS N
of IN N
inflammation NN N
, , N
and CC N
their PRP$ N
serum NN N
levels NNS N
have VBP N
been VBN N
used VBN N
as IN N
markers NNS N
of IN N
inflammatory NN N
and CC N
immune JJ N
activity NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
therapy NN N
with IN N
ursodeoxycholic JJ 1_i
acid NN 1_i
alone RB 1_i
and CC N
in IN N
combination NN N
with IN N
azathioprine NN 1_i
and CC 1_i
prednisone NN 1_i
on IN N
serum JJ 1_o
sICAM-1 JJ 1_o
levels NNS 1_o
in IN N
primary JJ N
biliary JJ N
cirrhosis NN N
. . N

DESIGN/METHODS NNP N
Twenty-four JJ 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
biliary JJ 1_p
cirrhosis NN 1_p
and CC 1_p
17 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
were VBD 1_p
studied VBN 1_p
. . 1_p

Primary JJ 1_p
biliary JJ 1_p
cirrhosis NN 1_p
patients NNS 1_p
received VBD N
ursodeoxycholic JJ 1_i
acid NN 1_i
for IN N
12 CD N
months NNS N
and CC N
were VBD N
then RB N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
receive VB N
prednisone NN 1_i
and CC 1_i
azathioprine NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
in IN 1_i
addition NN 1_i
to TO 1_i
ursodeoxycholic JJ 1_i
acid NN 1_i
. . 1_i

RESULTS NNP N
sICAM-1 JJ 1_o
levels NNS 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
primary JJ 1_p
biliary JJ 1_p
cirrhosis NN 1_p
patients NNS 1_p
than IN N
healthy JJ 1_p
subjects NNS 1_p
and CC N
fell VBD N
by IN N
a DT N
median NN N
of IN N
20 CD N
% NN N
after IN N
12 CD N
months NNS N
' POS N
therapy NN N
with IN N
ursodeoxycholic JJ 1_i
acid NN 1_i
( ( N
P NNP N
< NNP N
0.0004 CD N
) ) N
. . N

Addition NN N
of IN N
azathioprine NN 1_i
and CC 1_i
prednisone NN 1_i
to TO N
ursodeoxycholic JJ 1_i
acid NN 1_i
resulted VBD N
in IN N
a DT N
further JJ N
reduction NN N
of IN N
sICAM-1 JJ 1_o
levels NNS 1_o
by IN N
a DT N
median NN N
of IN N
25 CD N
% NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Reductions NNPS N
in IN N
sICAM-1 JJ 1_o
were VBD N
accompanied VBN N
by IN N
improvement NN N
in IN N
liver JJ 1_o
function NN 1_o
tests NNS 1_o
but CC N
not RB N
in IN N
the DT N
lymphocyte JJ 1_o
activation NN 1_o
marker NN 1_o
, , 1_o
soluble JJ 1_o
interleukin-2 JJ 1_o
receptor NN 1_o
. . 1_o

CONCLUSION NNP N
sICAM-1 JJ 1_o
levels NNS 1_o
in IN N
primary JJ N
biliary JJ N
cirrhosis NN N
are VBP N
reduced VBN N
by IN N
ursodeoxycholic JJ 1_i
acid NN 1_i
. . 1_i

Further JJ N
reductions NNS N
were VBD N
achieved VBN N
by IN N
adding VBG N
prednisone NN 1_i
and CC 1_i
azathioprine NN 1_i
. . 1_i

These DT N
reductions NNS N
probably RB N
reflect VBP N
an DT N
improvement NN N
in IN N
hepatobiliary JJ 1_o
excretion NN 1_o
and CC N
a DT N
reduction NN 1_o
in IN 1_o
cellular JJ 1_o
production NN 1_o
of IN 1_o
sICAM-1 NN 1_o
. . 1_o

Efficacy NN N
of IN N
physiotherapy JJ 1_i
management NN 1_i
of IN N
knee NN 1_p
joint JJ 1_p
osteoarthritis NN 1_p
: : 1_p
a DT N
randomised JJ N
, , N
double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
a DT N
multimodal JJ 1_i
physiotherapy NN 1_i
programme NN 1_i
including VBG 1_i
taping VBG 1_i
, , 1_i
exercises NNS 1_i
, , 1_i
and CC 1_i
massage NN 1_i
is VBZ N
effective JJ N
for IN N
knee NN 1_p
osteoarthritis NN 1_p
, , N
and CC N
if IN N
benefits NNS N
can MD N
be VB N
maintained VBN N
with IN N
self JJ N
management NN N
. . N

METHODS NNP N
Randomised VBD N
, , N
double JJ N
blind NN N
, , N
placebo NN 1_i
controlled VBD N
trial NN N
; : N
140 CD 1_p
community NN 1_p
volunteers NNS 1_p
with IN 1_p
knee NN 1_p
osteoarthritis NN 1_p
participated VBD 1_p
and CC 1_p
119 CD 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
. . 1_p

Physiotherapy NNP 1_i
and CC 1_i
placebo JJ 1_i
interventions NNS N
were VBD N
applied VBN N
by IN N
10 CD N
physiotherapists NNS N
in IN N
private JJ N
practices NNS N
for IN N
12 CD N
weeks NNS N
. . N

Physiotherapy NNP 1_i
included VBD 1_i
exercise NN 1_i
, , 1_i
massage NN 1_i
, , 1_i
taping VBG 1_i
, , 1_i
and CC 1_i
mobilisation NN 1_i
, , 1_i
followed VBN 1_i
by IN 1_i
12 CD 1_i
weeks NNS 1_i
of IN 1_i
self JJ 1_i
management NN 1_i
. . 1_i

Placebo NNP 1_i
was VBD N
sham VBN 1_i
ultrasound JJ 1_i
and CC 1_i
light JJ 1_i
application NN 1_i
of IN 1_i
a DT 1_i
non-therapeutic JJ 1_i
gel NN 1_i
, , 1_i
followed VBN 1_i
by IN 1_i
no DT 1_i
treatment NN 1_i
. . 1_i

Primary JJ N
outcomes NNS N
were VBD N
pain RB 1_o
measured VBN 1_o
by IN 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
and CC 1_o
patient JJ 1_o
global JJ 1_o
change NN 1_o
. . 1_o

Secondary JJ N
measures NNS N
included VBD N
WOMAC NNP 1_o
, , 1_o
knee NN 1_o
pain NN 1_o
scale NN 1_o
, , 1_o
SF-36 NNP 1_o
, , 1_o
assessment NN 1_o
of IN 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
index NN 1_o
, , 1_o
quadriceps JJ 1_o
strength NN 1_o
, , 1_o
and CC 1_o
balance NN 1_o
test NN 1_o
. . 1_o

RESULTS NNP N
Using VBG N
an DT N
intention NN N
to TO N
treat VB N
analysis NN N
, , N
physiotherapy NN 1_p
and CC 1_p
placebo NN 1_p
groups NNS 1_p
showed VBD N
similar JJ N
pain NN 1_o
reductions NNS 1_o
at IN N
12 CD N
weeks NNS N
: : N
-2.2 NN N
cm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-2.6 NNP N
to TO N
-1.7 VB N
) ) N
and CC N
-2.0 $ N
cm NN N
( ( N
-2.5 UH N
to TO N
-1.5 VB N
) ) N
, , N
respectively RB N
. . N

At IN N
24 CD N
weeks NNS N
, , N
pain NN 1_o
remained VBD 1_o
reduced VBN 1_o
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
: : N
-2.1 NN N
( ( N
-2.6 UH N
to TO N
-1.6 VB N
) ) N
and CC N
-1.6 NNP N
( ( N
-2.2 UH N
to TO N
-1.0 VB N
) ) N
, , N
respectively RB N
. . N

Global JJ 1_o
improvement NN 1_o
was VBD N
reported VBN N
by IN N
70 CD N
% NN N
of IN N
physiotherapy NN N
participants NNS N
( ( N
51/73 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
59 CD N
% NN N
( ( N
43/73 CD N
) ) N
at IN N
24 CD N
weeks NNS N
. . N

Similarly RB N
, , N
global JJ 1_o
improvement NN 1_o
was VBD N
reported VBN N
by IN N
72 CD N
% NN N
of IN N
placebo NN N
participants NNS N
( ( N
48/67 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
49 CD N
% NN N
( ( N
33/67 CD N
) ) N
at IN N
24 CD N
weeks NNS N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
physiotherapy NN 1_i
programme NN 1_i
tested VBN N
in IN N
this DT N
trial NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
regular JJ N
contact NN N
with IN N
a DT N
therapist NN N
at IN N
reducing VBG N
pain NN N
and CC N
disability NN N
. . N

Effects NNS N
of IN N
a DT N
low-salt JJ 1_i
diet NN 1_i
and CC N
of IN N
acute JJ 1_i
salt NN 1_i
loading VBG 1_i
on IN N
blood NN 1_o
pressure NN 1_o
and CC N
intralymphocytic JJ 1_o
sodium NN 1_o
concentration NN 1_o
in IN N
young JJ 1_p
subjects NNS 1_p
with IN 1_p
borderline JJ 1_p
hypertension NN 1_p
. . 1_p

1 CD N
. . N

Three CD 1_p
groups NNS 1_p
of IN 1_p
young JJ 1_p
patients NNS 1_p
with IN 1_p
borderline JJ 1_p
hypertension NN 1_p
were VBD N
studied VBN N
for IN N
a DT N
12 CD N
months NNS N
period NN N
. . N

The DT N
first JJ N
was VBD N
on IN N
a DT N
free JJ 1_i
sodium NN 1_i
diet NN 1_i
while IN N
the DT N
second JJ N
was VBD N
on IN N
a DT N
low-salt JJ 1_i
diet NN 1_i
. . 1_i

The DT N
third JJ N
group NN N
of IN N
patients NNS N
underwent JJ N
acute JJ 1_i
salt NN 1_i
loading VBG 1_i
. . 1_i

2 CD N
. . N

After IN N
12 CD N
months NNS N
the DT N
group NN N
on IN N
free JJ 1_i
diet NN 1_i
showed VBD N
a DT N
significant JJ N
increase NN N
of IN N
intralymphocytic JJ 1_o
sodium NN 1_o
but CC N
no DT N
change NN N
in IN N
blood NN 1_o
pressure NN 1_o
was VBD N
noted VBN N
. . N

Five CD N
patients NNS N
who WP N
were VBD N
re-checked JJ N
after IN N
24 CD N
months NNS N
also RB N
had VBD N
a DT N
significant JJ N
increase NN N
in IN N
blood NN 1_o
pressure NN 1_o
. . 1_o

3 CD N
. . N

Patients NNS N
treated VBD N
with IN N
a DT N
low-salt JJ 1_i
diet NN 1_i
showed VBD N
a DT N
significant JJ N
decrease NN N
of IN N
both DT N
intralymphocytic JJ 1_o
sodium NN 1_o
concentration NN 1_o
and CC 1_o
blood NN 1_o
pressure NN 1_o
. . 1_o

4 CD N
. . N

After IN N
acute JJ N
salt NN N
loading NN N
, , N
borderline JJ N
subjects NNS N
with IN N
high JJ N
intralymphocytic JJ N
sodium NN N
showed VBD N
a DT N
significant JJ N
greater JJR N
natriuresis NN 1_o
whereas RBR N
intralymphocytic JJ 1_o
sodium NN 1_o
increased VBD N
only RB N
in IN N
those DT N
subjects NNS N
in IN N
whom WP N
it PRP N
was VBD N
initially RB N
normal JJ N
. . N

Placebo-controlled JJ N
study NN N
of IN N
oral JJ 1_i
enoximone NN 1_i
in IN N
congestive JJ N
heart NN N
failure NN N
with IN N
initial JJ 1_o
and CC 1_o
final JJ 1_o
intravenous JJ 1_o
hemodynamic JJ 1_o
evaluation NN 1_o
. . 1_o

Seventeen JJ 1_p
patients NNS 1_p
with IN 1_p
stable JJ 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
class NN 1_p
II NNP 1_p
and CC 1_p
III NNP 1_p
New NNP 1_p
York NNP 1_p
Heart NNP 1_p
Association NNP 1_p
) ) 1_p
received VBD N
intravenous JJ N
and CC N
oral JJ N
enoximone NN 1_i
in IN N
a DT N
2-part JJ N
study NN N
. . N

Hemodynamic NNP 1_o
data NNS 1_o
were VBD N
first RB N
obtained VBN N
after IN N
intravenous JJ 1_i
administration NN 1_i
of IN 1_i
0.75 CD 1_i
mg/kg NN 1_i
of IN 1_i
enoximone NN 1_i
; : 1_i
data NNS 1_i
were VBD 1_i
again RB 1_i
obtained VBN 1_i
after IN 1_i
12 CD 1_i
weeks NNS 1_i
of IN 1_i
therapy NN 1_i
with IN 1_i
either DT 1_i
oral JJ 1_i
enoximone NN 1_i
( ( 1_i
150 CD 1_i
mg RB 1_i
3 CD 1_i
times NNS 1_i
daily RB 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ 1_i
enoximone NN 1_i
were VBD N
also RB N
studied VBN N
in IN N
a DT N
12-week JJ N
, , N
double-blind JJ N
randomized JJ N
format NN N
. . N

In IN N
the DT N
intravenous JJ N
study NN N
, , N
enoximone NN 1_i
was VBD 1_i
delivered VBN 1_i
over IN 1_i
5 CD 1_i
minutes NNS 1_i
and CC 1_i
hemodynamic JJ 1_i
data NNS 1_i
were VBD 1_i
measured VBN 1_i
for IN 1_i
up RB 1_i
to TO 1_i
12 CD 1_i
hours NNS 1_i
after IN 1_i
. . 1_i

Cardiac NNP 1_o
index NN 1_o
increased VBD N
2.76 CD N
+/- JJ N
0.63 CD N
to TO N
3.42 CD N
+/- JJ N
0.72 CD N
liters/min/m2 NN N
) ) N
, , N
pulmonary JJ 1_o
wedge NN 1_o
pressure NN 1_o
decreased VBN N
( ( N
19.5 CD N
+/- JJ N
8.8 CD N
to TO N
14.6 CD N
+/- JJ N
8.0 CD N
mm NN N
Hg NNP N
) ) N
as IN N
did VBD N
mean VB 1_o
arterial JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( N
101 CD N
+/- JJ N
14.8 CD N
to TO N
85 CD N
+/- JJ N
13.7 CD N
mm NN N
Hg NNP N
) ) N
and CC N
systemic JJ 1_o
vascular NN 1_o
resistance NN 1_o
( ( N
1,880 CD N
+/- JJ N
573 CD N
to TO N
1,254 CD N
+/- JJ N
383 CD N
dynes NNS N
s RB N
cm-5 NN N
) ) N
. . N

Heart NNP 1_o
rate NN 1_o
increased VBD N
slightly RB N
( ( N
82 CD N
+/- JJ N
17 CD N
to TO N
86 CD N
+/- JJ N
14 CD N
beats/min NN N
) ) N
. . N

All PDT N
these DT N
changes NNS N
were VBD N
maximal JJ N
1 CD N
to TO N
2 CD N
hours NNS N
after IN N
infusion NN N
and CC N
lasted VBD N
8 CD N
hours NNS N
at IN N
least JJS N
. . N

Patients NNS N
were VBD N
then RB N
randomized VBN N
double-blind NN N
to TO N
oral JJ N
treatment NN N
. . N

Baseline NNP N
values VBZ N
showed VBD N
that IN N
the DT N
7 CD N
patients NNS N
who WP N
received VBD N
placebo NN 1_i
had VBD N
more RBR N
severe JJ N
CHF NNP 1_o
. . 1_o

Therefore NNP N
, , N
comparison NN N
might MD N
be VB N
biased VBN N
. . N

Patient NNP N
overall JJ N
assessment NN N
showed VBD N
a DT N
continuous JJ N
benefit NN N
in IN N
both DT N
groups NNS N
. . N

Ejection NNP N
fraction NN N
improved VBD N
from IN N
30.1 CD N
+/- JJ N
6.8 CD N
% NN N
to TO N
33.9 CD N
+/- JJ N
9.9 CD N
% NN N
in IN N
the DT N
enoximone NN N
group NN N
while IN N
it PRP N
remained VBD N
unchanged JJ N
with IN N
placebo NN N
( ( N
23.4 CD N
+/- JJ N
6.5 CD N
% NN N
to TO N
23.4 CD N
+/- JJ N
1.5 CD N
% NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
[ JJ N
Clinical NNP N
observation NN N
on IN N
acupuncture NN 1_i
combined VBN N
with IN N
Yizhi NNP 1_i
Jiannao NNP 1_i
granules NNS 1_i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
clinical JJ N
therapeutic JJ 1_o
effect NN 1_o
of IN N
acupuncture NN 1_i
combined VBN N
with IN N
Yizhi NNP 1_i
Jiannao NNP 1_i
Granules NNP 1_i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
and CC N
its PRP$ N
effects NNS N
on IN N
intelligence NN 1_o
, , 1_o
daily JJ 1_o
life NN 1_o
and CC 1_o
social JJ 1_o
activity NN 1_o
ability NN 1_o
. . 1_o

METHODS NNP N
Eighty-four JJ 1_p
cases NNS 1_p
were VBD 1_p
randomly RB 1_p
divided VBN 1_p
into IN 1_p
3 CD 1_p
groups NNS 1_p
, , 1_p
28 CD 1_p
cases NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

The DT N
combined JJ N
acupuncture NN 1_i
and CC N
medication NN N
group NN N
was VBD N
treated VBN N
with IN N
acupuncture NN 1_i
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Dazhui NNP N
( ( N
GV NNP N
14 CD N
) ) N
, , N
Guanyuan NNP N
( ( N
CV NNP N
4 CD N
) ) N
, , N
etc FW N
. . N

and CC N
oral JJ N
administration NN N
of IN N
Yizhi NNP 1_i
Jiannao NNP 1_i
Granules NNP 1_i
; : 1_i
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
treated VBN N
with IN N
Yizhi NNP 1_i
Jiannao NNP 1_i
Granules NNP 1_i
, , N
and CC N
the DT N
western JJ 1_i
medicine NN 1_i
group NN 1_i
with IN N
oral JJ N
administration NN N
of IN N
Aricept NNP 1_i
. . 1_i

The DT N
scores NNS 1_o
for IN 1_o
the DT 1_o
Mini-Mental JJ 1_o
State NNP 1_o
Examination NNP 1_o
( ( 1_o
MMSE NNP 1_o
) ) 1_o
, , 1_o
Ability NNP 1_o
of IN 1_o
Daily NNP 1_o
Life NNP 1_o
( ( 1_o
ADL NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
therapeutic JJ 1_o
effects NNS 1_o
were VBD N
assessed VBN N
and CC N
compared VBN N
before IN N
treatment NN N
and CC N
after IN N
treatment NN N
for IN N
12 CD N
weeks NNS N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
scores NNS N
for IN N
MMSE NNP 1_o
and CC 1_o
ADL NNP 1_o
were VBD N
improved VBN N
in IN N
the DT N
combined JJ 1_i
acupuncture NN 1_i
and CC 1_i
medication NN 1_i
group NN N
, , N
the DT N
Chinese JJ 1_i
herb NN 1_i
group NN N
and CC N
the DT N
western JJ 1_i
medicine NN 1_i
group NN N
, , N
which WDT N
were VBD N
better RBR N
in IN N
the DT N
combined JJ N
acupuncture NN 1_i
and CC 1_i
medication NN 1_i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
total JJ 1_o
effective JJ 1_o
rate NN 1_o
of IN N
85.7 CD N
% NN N
in IN N
the DT N
combined JJ 1_i
acupuncture NN 1_i
and CC 1_i
medication NN 1_i
group NN N
was VBD N
better JJR N
than IN N
71.4 CD N
% NN N
in IN N
the DT N
Chinese JJ N
herb NN N
group NN N
and CC N
67.9 CD N
% NN N
in IN N
the DT N
western JJ N
medicine NN N
group NN N
. . N

CONCLUSION NNP N
Acupuncture NNP 1_i
combined VBN 1_i
with IN 1_i
Yizhi NNP 1_i
Jiannao NNP 1_i
Granules NNP 1_i
has VBZ N
a DT N
significant JJ N
therapeutic JJ 1_o
effect NN 1_o
on IN N
Alzheimer NNP N
's POS N
disease NN N
, , N
which WDT N
is VBZ N
better JJR N
than IN N
that DT N
of IN N
Yizhi NNP 1_i
Jiannao NNP 1_i
Granules NNP 1_i
or CC N
Aricept NNP 1_i
. . 1_i

Entomological JJ N
determinants NNS N
of IN N
insecticide-treated JJ N
bed JJ N
net JJ N
effectiveness NN 1_o
in IN N
Western JJ 1_p
Myanmar NNP 1_p
. . 1_p

BACKGROUND NNP N
In IN N
a DT N
large JJ N
cluster NN N
randomized VBD N
control JJ N
trial NN N
of IN N
insecticide-treated JJ 1_i
bed NN 1_i
nets NNS 1_i
( ( 1_i
ITN NNP 1_i
) ) 1_i
in IN N
Western JJ 1_p
Myanmar NNP 1_p
the DT N
malaria NN N
protective JJ 1_o
effect NN 1_o
of IN N
ITN NNP 1_i
was VBD N
found VBN N
to TO N
be VB N
highly RB N
variable JJ N
and CC N
, , N
in IN N
aggregate NN N
, , N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

A DT N
coincident JJ N
entomological JJ N
investigation NN N
measured VBD N
malaria NNS 1_o
vector NN 1_o
abundance NN 1_o
and CC 1_o
biting VBG 1_o
behaviour NN 1_o
and CC N
the DT N
human JJ 1_o
population NN 1_o
sleeping VBG 1_o
habits NNS 1_o
, , N
factors NNS N
relevant VBP N
to TO N
ITN NNP 1_i
effectiveness NN 1_o
. . 1_o

METHODS NNP N
Entomological JJ N
surveys NNS N
were VBD N
carried VBN N
out RP N
using VBG N
different JJ N
catching VBG N
methods NNS N
to TO N
identify VB N
potential JJ 1_o
malaria NNS 1_o
vector NN 1_o
species NNS 1_o
and CC N
characterise VB N
their PRP$ N
biting NN 1_o
habits NNS 1_o
. . 1_o

The DT N
salivary JJ 1_i
glands NNS 1_i
were VBD 1_i
dissected VBN 1_i
from IN N
all DT N
female JJ N
anophelines NNS N
caught VBD N
to TO N
identify VB N
sporozoites NNS N
by IN N
microscopy NN 1_i
. . 1_i

FINDINGS NNP N
Between NNP N
1995 CD N
and CC N
2000 CD N
a DT N
total NN N
of IN N
4,824 CD 1_p
female JJ 1_p
anopheline NN 1_p
mosquitoes NNS 1_p
were VBD N
caught VBN N
with IN N
various JJ N
catching VBG N
methods NNS N
. . N

A DT N
total NN N
of IN N
916 CD 1_p
person NN 1_p
nights NNS 1_p
yielded VBD 1_p
3,009 CD 1_p
female JJ 1_p
anopheline NN 1_p
mosquitoes NNS 1_p
between IN 1_p
6 CD 1_p
pm NNS 1_p
and CC 1_p
6 CD 1_p
am VBP 1_p
. . 1_p

Except IN N
for IN N
Anopheles NNP N
annularis NN N
, , N
which WDT N
showed VBD N
no DT N
apparent JJ N
preference NN 1_o
( ( N
51 CD N
% NN N
outdoor JJ N
biting NN N
) ) N
, , N
all DT N
major JJ N
species NNS N
showed VBD N
a DT N
strong JJ N
preference NN 1_o
for IN N
outdoor JJ 1_o
biting NN 1_o
; : 1_o
Anopheles NNP N
epiroticus FW N
( ( N
79 CD N
% NN N
) ) N
, , N
Anopheles NNP N
subpictus NN N
( ( N
72 CD N
% NN N
) ) N
, , N
Anopheles NNP N
maculatus NNP N
( ( N
92 CD N
% NN N
) ) N
, , N
Anopheles NNP N
aconitus NN N
( ( N
85 CD N
% NN N
) ) N
and CC N
Anopheles NNP N
vagus NNP N
( ( N
72 CD N
% NN N
) ) N
. . N

Most JJS N
human JJ 1_o
biting NN 1_o
occurred VBD N
in IN N
the DT N
early JJ N
evening NN N
with IN N
the DT N
peak NN 1_o
biting VBG 1_o
time NN 1_o
between IN N
6 CD N
pm NNS N
and CC N
7 CD N
pm NN N
( ( N
35 CD N
% NN N
) ) N
. . N

Overall JJ N
51 CD N
% NN N
( ( N
1447/2837 CD N
) ) N
of IN N
all DT N
bites NNS 1_o
recorded VBN 1_o
were VBD N
between IN N
6 CD N
pm NNS N
and CC N
8 CD N
pm NN N
. . N

A DT 1_p
large JJ 1_p
proportion NN 1_o
of IN 1_o
children NNS 1_o
were VBD N
not RB N
sleeping VBG 1_o
under IN N
an DT N
ITN NNP 1_i
during IN N
peak NN 1_o
biting VBG 1_o
times NNS 1_o
. . 1_o

Only RB N
one CD N
An DT N
. . N

annularis NN N
mosquito NN N
( ( N
0.02 CD N
% NN N
) ) N
had VBD N
malaria VBN 1_o
sporozoites NNS 1_o
identified VBN N
in IN N
the DT N
salivary JJ N
glands NNS N
. . N

CONCLUSIONS NNP N
Peak NNP 1_o
vector NN 1_o
biting NN 1_o
occurred VBD N
early RB N
in IN N
the DT N
evening NN N
and CC N
mainly RB N
occurred VBD N
outdoors NNS 1_o
. . 1_o

The DT N
limited JJ N
efficacy NN 1_o
of IN N
ITN NNP 1_i
in IN N
this DT N
area NN N
of IN N
Western JJ 1_p
Myanmar NNP 1_p
may MD N
be VB N
explained VBN N
by IN N
the DT N
biting VBG N
behaviour NN N
of IN N
the DT N
prevalent NN N
Anopheles NNP N
mosquito NN N
vectors NNS N
in IN N
this DT N
area NN N
. . N

Effects NNS N
of IN N
risperidone NN 1_i
and CC 1_i
parent NN 1_i
training NN 1_i
on IN N
adaptive JJ N
functioning NN N
in IN N
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
and CC 1_p
serious JJ 1_p
behavioral JJ 1_p
problems NNS 1_p
. . 1_p

OBJECTIVE NNP N
Children NNP 1_p
with IN 1_p
Pervasive NNP 1_p
Developmental NNP 1_p
Disorders NNP 1_p
( ( 1_p
PDDs NNP 1_p
) ) 1_p
have VBP N
social JJ N
interaction NN N
deficits NNS N
, , N
delayed VBN N
communication NN N
, , N
and CC N
repetitive JJ N
behaviors NNS N
as RB N
well RB N
as IN N
impairments NNS N
in IN N
adaptive JJ N
functioning NN N
. . N

Many JJ N
children NNS N
actually RB N
show VBP N
a DT N
decline NN N
in IN N
adaptive JJ N
skills NNS N
compared VBN N
with IN N
age NN N
mates NNS N
over IN N
time NN N
. . N

METHOD VB N
This DT N
24-week JJ N
, , N
three-site JJ N
, , N
controlled VBD N
clinical JJ N
trial NN N
randomized VBD N
124 CD 1_p
children NNS 1_p
( ( 1_p
4 CD 1_p
through IN 1_p
13 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
with IN 1_p
PDDs NNP 1_p
and CC 1_p
serious JJ 1_p
behavioral JJ 1_p
problems NNS 1_p
to TO 1_p
medication VB 1_i
alone RB 1_i
( ( 1_p
MED NNP 1_p
; : 1_p
n CC 1_p
= $ 1_p
49 CD 1_p
; : 1_p
risperidone NN 1_i
0.5 CD 1_p
to TO 1_p
3.5 CD 1_p
mg/day NN 1_p
; : 1_p
if IN N
ineffective JJ N
, , N
switch VB N
to TO N
aripiprazole VB 1_i
was VBD N
permitted VBN N
) ) N
or CC N
a DT N
combination NN 1_i
of IN 1_i
medication NN 1_i
plus CC 1_i
parent NN 1_i
training NN 1_i
( ( 1_i
PT NNP 1_i
) ) 1_i
( ( N
COMB NNP N
; : N
n CC N
= VB N
75 CD N
) ) N
. . N

Parents NNS 1_p
of IN 1_p
children NNS 1_p
in IN 1_p
COMB NNP 1_p
received VBD 1_p
an DT 1_p
average NN 1_p
of IN 1_p
11.4 CD 1_p
PT NNP 1_i
sessions NNS 1_i
. . 1_i

Standard NNP N
scores NNS N
and CC N
Age-Equivalent JJ N
scores NNS N
on IN N
Vineland NNP N
Adaptive NNP N
Behavior NNP N
Scales NNP N
were VBD N
the DT N
outcome NN N
measures NNS N
of IN N
primary JJ N
interest NN N
. . N

RESULTS NNP N
Seventeen JJ 1_p
subjects NNS 1_p
did VBD 1_p
not RB 1_p
have VB 1_p
a DT 1_p
post-randomization NN 1_p
Vineland NNP 1_p
assessment NN 1_p
. . 1_p

Thus RB N
, , N
we PRP N
used VBD N
a DT N
mixed JJ N
model NN N
with IN N
outcome NN N
conditioned VBN N
on IN N
the DT N
baseline NN N
Vineland NNP N
scores VBZ N
. . N

Both DT N
groups NNS N
showed VBD N
improvement NN N
over IN N
the DT N
24-week JJ N
trial NN N
on IN N
all DT N
Vineland NNP N
domains NNS N
. . N

Compared VBN N
with IN N
MED NNP N
, , N
Vineland NNP 1_o
Socialization NNP 1_o
and CC 1_o
Adaptive NNP 1_o
Composite NNP 1_o
Standard NNP 1_o
scores VBZ 1_o
showed VBD N
greater JJR N
improvement NN N
in IN N
the DT N
COMB NNP N
group NN N
( ( N
p JJ N
= NNP N
.01 NNP N
and CC N
.05 NNP N
, , N
and CC N
effect NN N
sizes NNS N
= VBP N
0.35 CD N
and CC N
0.22 CD N
, , N
respectively RB N
) ) N
. . N

On IN N
Age NNP N
Equivalent NNP N
scores NNS N
, , N
Socialization NNP 1_o
and CC 1_o
Communication NNP 1_o
domains NNS 1_o
showed VBD N
greater JJR N
improvement NN N
in IN N
COMB NNP N
versus NN N
MED NNP N
( ( N
p JJ N
= NNP N
.03 NNP N
and CC N
0.05 CD N
, , N
and CC N
effect NN N
sizes NNS N
= VBP N
0.33 CD N
and CC N
0.14 CD N
, , N
respectively RB N
) ) N
. . N

Using VBG N
logistic JJ N
regression NN N
, , N
children NNS N
in IN N
the DT N
COMB NNP N
group NN N
were VBD N
twice RB N
as RB N
likely JJ N
to TO N
make VB N
at IN N
least JJS N
6 CD N
months NNS N
' POS N
gain NN N
( ( N
equal JJ N
to TO N
the DT N
passage NN N
of IN N
time NN N
) ) N
in IN N
the DT N
Vineland NNP 1_o
Communication NNP 1_o
Age NNP 1_o
Equivalent NNP 1_o
score NN 1_o
compared VBN N
with IN N
MED NNP N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
. . N

After IN N
controlling VBG N
for IN N
IQ NNP N
, , N
this DT N
difference NN N
was VBD N
no RB N
longer RBR N
significant JJ N
. . N

CONCLUSION NNP N
Reduction NNP N
of IN N
serious JJ N
maladaptive JJ N
behavior NN N
promotes NNS N
improvement NN N
in IN N
adaptive JJ N
behavior NN N
. . N

Medication NNP 1_i
plus CC 1_i
PT NNP 1_i
shows VBZ N
modest JJ N
additional JJ N
benefit NN N
over IN N
medication NN 1_i
alone RB 1_i
. . 1_i

Clinical JJ N
trial NN N
registration NN N
information-RUPP JJ N
PI NNP N
PDD NNP N
: : N
Drug NN N
and CC N
Behavioral NNP N
Therapy NNP N
for IN N
Children NNP 1_p
With IN 1_p
Pervasive NNP 1_p
Developmental NNP 1_p
Disorders NNP 1_p
; : 1_p
http NN N
: : N
//www.clinicaltrials.gov NN N
; : N
NCT00080145 NNP N
. . N

Trachoma NNP N
prevalence NN N
and CC N
associated VBN N
risk NN N
factors NNS N
in IN N
the DT 1_p
gambia NN 1_p
and CC 1_p
Tanzania NNP 1_p
: : 1_p
baseline NN N
results NNS N
of IN N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Blinding NNP N
trachoma NN N
, , N
caused VBN N
by IN N
ocular JJ N
infection NN N
with IN N
Chlamydia NNP N
trachomatis NN N
, , N
is VBZ N
targeted VBN N
for IN N
global JJ N
elimination NN N
by IN N
2020 CD N
. . N

Knowledge NNP N
of IN N
risk NN N
factors NNS N
can MD N
help VB N
target VB N
control JJ N
interventions NNS N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
As IN N
part NN N
of IN N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
, , N
we PRP N
assessed VBD 1_o
the DT 1_o
baseline NN 1_o
prevalence NN 1_o
of IN 1_o
, , 1_o
and CC 1_o
risk NN 1_o
factors NNS 1_o
for IN 1_o
, , N
active JJ N
trachoma NN 1_o
and CC N
ocular JJ 1_o
C. NNP 1_o
trachomatis NN 1_o
infection NN 1_o
in IN N
randomly RB 1_p
selected VBN 1_p
children NNS 1_p
aged VBN 1_p
0-5 CD 1_p
years NNS 1_p
from IN 1_p
48 CD 1_p
Gambian JJ 1_p
and CC 1_p
36 CD 1_p
Tanzanian JJ 1_p
communities NNS 1_p
. . 1_p

Both DT 1_i
children NNS 1_i
's POS 1_i
eyes NNS 1_i
were VBD 1_i
examined VBN 1_i
according VBG N
to TO N
the DT N
World NNP 1_o
Health NNP 1_o
Organization NNP 1_o
( ( 1_o
WHO NNP 1_o
) ) 1_o
simplified VBD 1_o
grading VBG 1_o
system NN 1_o
, , N
and CC N
an DT 1_i
ocular JJ 1_o
swab NN 1_o
was VBD 1_i
taken VBN 1_i
from IN 1_i
each DT 1_i
child NN 1_i
's POS 1_i
right JJ 1_i
eye NN 1_i
and CC 1_i
processed VBN 1_i
by IN 1_i
Amplicor NNP 1_o
polymerase NN 1_o
chain NN 1_o
reaction NN 1_o
to TO 1_i
test VB 1_i
for IN 1_i
the DT 1_i
presence NN 1_i
of IN 1_i
C. NNP 1_i
trachomatis NN 1_i
DNA NNP 1_i
. . 1_i

Prevalence NN N
of IN N
active JJ N
trachoma NN N
was VBD N
6.7 CD N
% NN N
( ( N
335/5033 CD N
) ) N
in IN N
The DT 1_p
Gambia NNP 1_p
and CC N
32.3 CD N
% NN N
( ( N
1008/3122 CD N
) ) N
in IN N
Tanzania NNP 1_p
. . 1_p

The DT N
countries NNS N
' POS N
corresponding VBG N
Amplicor NNP 1_o
positive JJ 1_o
prevalences NNS 1_o
were VBD N
0.8 CD N
% NN N
and CC N
21.9 CD N
% NN N
. . N

After IN N
adjustment NN N
, , N
risk NN N
factors NNS N
for IN N
follicular JJ N
trachoma NN N
( ( N
TF NNP N
) ) N
in IN N
both DT N
countries NNS N
were VBD N
ocular JJ 1_o
or CC 1_o
nasal JJ 1_o
discharge NN 1_o
, , N
a DT N
low JJ 1_o
level NN 1_o
of IN 1_o
household NN 1_o
head NN 1_o
education NN 1_o
, , N
and CC N
being VBG N
aged VBN 1_o
≥ $ 1_o
1 CD 1_o
year NN 1_o
. . N

Additional NNP N
risk NN N
factors NNS N
in IN 1_p
Tanzania NNP 1_p
were VBD 1_o
flies NNS 1_o
on IN 1_o
the DT 1_o
child NN 1_o
's POS 1_o
face NN 1_o
, , 1_o
being VBG 1_o
Amplicor NNP 1_o
positive JJ 1_o
, , 1_o
and CC 1_o
crowding NN 1_o
( ( N
the DT N
number NN N
of IN N
children NNS N
per IN N
household NN N
) ) N
. . N

The DT N
risk NN N
factors NNS N
for IN N
being VBG 1_o
Amplicor NNP 1_o
positive JJ 1_o
in IN 1_p
Tanzania NNP 1_p
were VBD N
similar JJ N
to TO N
those DT N
for IN N
TF NNP N
, , N
with IN N
the DT N
exclusion NN N
of IN N
flies NNS N
and CC N
crowding VBG N
. . N

In IN 1_p
The DT 1_p
Gambia NNP 1_p
, , N
only RB 1_o
ocular JJ 1_o
discharge NN 1_o
was VBD N
associated VBN N
with IN N
being VBG 1_o
Amplicor NNP 1_o
positive JJ 1_o
. . N

CONCLUSIONS/SIGNIFICANCE NNP N
These DT N
results NNS N
indicate VBP N
that IN N
although IN N
the DT N
prevalence NN N
of IN N
active JJ N
trachoma NN N
and CC 1_o
Amplicor NNP 1_o
positives NNS 1_o
were VBD N
very RB N
different JJ N
between IN N
the DT N
two CD N
countries NNS N
, , N
the DT N
risk NN N
factors NNS N
for IN N
active JJ N
trachoma NN N
were VBD N
similar JJ N
but CC N
those DT N
for IN N
being VBG 1_o
Amplicor NNP 1_o
positive JJ 1_o
were VBD N
different JJ N
. . N

The DT N
lack NN N
of IN N
an DT N
association NN N
between IN N
being VBG N
Amplicor NNP N
positive JJ N
and CC N
TF NNP N
in IN 1_p
The DT 1_p
Gambia NNP 1_p
highlights VBZ N
the DT N
poor JJ N
correlation NN N
between IN N
the DT N
presence NN N
of IN 1_o
trachoma JJ 1_o
clinical JJ 1_o
signs NNS 1_o
and CC 1_o
evidence NN 1_o
of IN 1_o
C. NNP 1_o
trachomatis NN 1_o
infection NN 1_o
in IN N
this DT N
setting NN N
. . N

Only RB 1_o
ocular JJ 1_o
discharge NN 1_o
was VBD N
associated VBN N
with IN N
evidence NN N
of IN N
C. NNP N
trachomatis NN N
DNA NN N
in IN 1_p
The DT 1_p
Gambia NNP 1_p
, , N
suggesting VBG N
that IN N
at IN N
this DT N
low JJ N
endemicity NN N
, , N
this DT N
may MD N
be VB N
the DT N
most RBS N
important JJ N
risk NN N
factor NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00792922 NNP N
. . N

Influence NN N
of IN N
occlusal JJ N
access NN N
on IN N
demineralized JJ 1_o
dentin NN 1_o
removal NN 1_o
in IN N
the DT N
atraumatic JJ 1_i
restorative JJ 1_i
treatment NN 1_i
( ( 1_i
ART NNP 1_i
) ) 1_i
approach NN N
. . N

PURPOSE NNP N
To TO N
verify VB N
the DT N
influence NN N
of IN N
cavity NN N
access NN N
diameter NN N
on IN N
demineralized JJ 1_o
dentin NN 1_o
removal NN 1_o
in IN N
the DT N
ART NNP 1_i
approach NN N
. . N

METHODS $ N
40 CD 1_p
non-carious JJ 1_p
human JJ 1_p
premolars NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
. . N

The DT N
occlusal JJ N
surface NN N
was VBD N
ground NN N
flat JJ N
and CC N
the DT N
teeth NNS N
were VBD N
sectioned VBN N
mesio-distally RB N
. . N

The DT N
hemi-sections NNS N
were VBD N
reassembled VBN N
and CC N
occlusal JJ N
access NN N
preparations NNS N
were VBD N
carried VBN N
out RP N
using VBG N
ball-shaped JJ N
diamonds NNS N
. . N

The DT N
resulting VBG N
size NN N
of IN N
the DT N
occlusal NN N
opening NN N
was VBD N
1.0 CD N
mm NN N
, , N
1.4 CD N
mm NN N
, , N
1.6 CD N
mm NN N
and CC N
1.8 CD N
mm NN N
for IN N
Groups NNP N
A NNP N
, , N
B NNP N
, , N
C NNP N
, , N
and CC N
D NNP N
, , N
respectively RB N
. . N

Standardized VBN N
artificial JJ N
carious JJ N
lesions NNS N
were VBD N
created VBN N
and CC N
demineralized VBN N
dentin NN N
was VBD N
excavated VBN 1_i
. . 1_i

After IN N
excavation NN N
, , N
the DT N
cavities NNS N
were VBD N
analyzed VBN N
using VBG N
: : N
( ( N
a DT N
) ) N
the DT 1_o
tactile NN 1_o
method NN 1_o
, , N
( ( N
b NN N
) ) N
caries-detection NN 1_o
dye NN 1_o
to TO 1_o
stain VB 1_o
demineralized JJ 1_o
dentin NN 1_o
, , N
as IN N
proposed VBN N
by IN N
Smales NNP N
& CC N
Fang NNP N
, , N
and CC N
( ( N
c NN N
) ) N
Demineralized NNP 1_o
Tissue NNP 1_o
Removal NNP 1_o
index NN 1_o
, , N
as IN N
proposed VBN N
in IN N
this DT N
study NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
Fisher NNP N
, , N
Spearman NNP N
correlation NN N
coefficient NN N
, , N
kappa NN N
, , N
Kruskal-Wallis NNP N
and CC N
Miller NNP N
tests NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
three CD N
methods NNS N
of IN N
evaluation NN N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
Groups NNP N
A NNP N
vs. NN N
B NNP N
, , N
and CC N
C NNP N
vs. FW N
D NNP N
, , N
while IN N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
Groups NNP N
A NNP N
vs. FW N
C NNP N
, , N
A NNP N
vs. NN N
D NNP N
, , N
B NNP N
vs. FW N
C NNP N
and CC N
B NNP N
vs. FW N
D. NNP N
Based VBD N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
, , N
the DT N
size NN N
of IN N
occlusal JJ N
access NN N
significantly RB N
affected VBD N
the DT N
efficacy NN 1_o
of IN N
demineralized JJ 1_o
tissue NN 1_o
removal NN 1_o
. . 1_o

[ JJ N
PLACE NNP N
REMAXOL NNP 1_i
AS IN N
A NNP N
HEPATOPROTECTOR NNP N
IN NNP N
INTENSIVE NNP N
THERAPY NNP N
OF NNP N
PERVASIVE NNP 1_p
PERITONITIS NNP 1_p
] NNP 1_p
. . N

UNLABELLED NNP N
PERPOSE NNP N
OF NNP N
RESEARCH NNP N
: : N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
Remaxol NNP 1_i
in IN N
patients NNS 1_p
with IN 1_p
pervasive JJ 1_p
peritonitis NN 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
assessed VBD N
the DT N
effectiveness NN N
of IN N
a DT N
balanced JJ N
infusion NN N
of IN N
the DT N
drug NN 1_i
( ( 1_i
Remaxol NNP 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
44 CD 1_p
patients NNS 1_p
agedfrom RB 1_p
18 CD 1_p
to TO 1_p
50 CD 1_p
years NNS 1_p
. . 1_p

Patients NNS N
were VBD N
devided VBN N
into IN N
2 CD N
groups NNS N
by IN N
the DT N
method NN N
of IN N
envelopes NNS N
. . N

All DT N
patients NNS N
received VBD N
a DT N
comprehensive JJ N
differential JJ N
therapy NN N
: : N
21 CD 1_p
patient NN 1_p
1 CD 1_p
group NN 1_p
consisting VBG N
of IN N
infusion NN 1_i
therapy NN 1_i
in IN N
the DT N
postoperative JJ N
period NN N
received VBD N
Remaxol NNP 1_i
at IN 1_i
a DT 1_i
dose NN 1_i
of IN 1_i
800 CD 1_i
mg/day NN 1_i
for IN N
7 CD N
days NNS N
. . N

RESULTS VB N
the DT N
comporative JJ N
assessment NN N
of IN N
indicators NNS 1_o
of IN 1_o
systemic JJ 1_o
hemodinamics NNS 1_o
, , 1_o
oxygen NN 1_o
transport NN 1_o
, , 1_o
asid JJ 1_o
base NN 1_o
status NN 1_o
, , 1_o
glucose RB 1_o
, , 1_o
lactose JJ 1_o
and CC 1_o
free JJ 1_o
radical JJ 1_o
oxydation NN 1_o
. . 1_o

Patients NNS N
on IN N
the DT N
first JJ N
background NN N
was VBD N
used VBN N
Remaxol NNP 1_i
have VBP N
experiensed VBN N
a DT N
more RBR N
rapid JJ 1_o
relief NN 1_o
of IN 1_o
metabolic JJ 1_o
disorders NNS 1_o
, , 1_o
endotoxemia NN 1_o
and CC 1_o
hepatic JJ 1_o
dysfunction NN 1_o
compared VBN 1_o
with IN N
the DT N
indices NNS N
of IN N
the DT N
2 CD N
group NN N
patients NNS N
. . N

Noted VBN N
earlier JJR N
stabilization NN N
of IN N
rudicators NNS N
of IN N
systemic JJ 1_o
hemodynamics NNS 1_o
and CC 1_o
oxygen NN 1_o
transport NN 1_o
. . 1_o

This DT N
has VBZ N
reduced VBN N
the DT N
duration NN 1_o
of IN 1_o
respiratory NN 1_o
and CC 1_o
vasopressor NN 1_o
suppot NN 1_o
, , N
early JJ N
start NN N
ofparenteral JJ N
intreduction NN N
in IN N
case NN N
the DT N
power NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
this DT N
study NN N
shows VBZ N
that IN N
use NN N
of IN N
the DT N
drug NN N
for IN N
the DT N
purpose NN N
of IN N
relief NN N
Remaxol NNP 1_i
hepatic JJ N
dysfunction NN N
and CC N
prevention NN N
of IN N
drug NN N
liver NN N
toxicity NN N
in IN N
conditions NNS N
ofperitonitis VBP N
, , N
after IN N
48 CD N
hours NNS N
of IN N
operation NN N
, , N
provides VBZ N
a DT N
positive JJ N
dynamics NNS N
and CC N
stabilization NN N
ofparameters NNS N
of IN N
central JJ N
hemodynamics NNS N
, , N
contributing VBG N
to TO N
the DT N
abolition NN N
of IN N
vasopressor NN N
support NN N
, , N
and CC N
contributes VBZ N
to TO N
the DT N
effective JJ N
utilization NN N
of IN N
oxygen NN N
, , N
while IN N
providing VBG N
antioxidant JJ N
effect NN N
. . N

Oscillatory NN 1_p
potentials NNS 1_p
, , 1_p
retinopathy NN 1_p
, , 1_p
and CC 1_p
long-term JJ 1_p
glucose NN 1_p
control NN 1_p
in IN 1_p
insulin-dependent JJ 1_p
diabetes NNS 1_p
. . 1_p

The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess JJ N
effects NNS N
of IN N
long-term JJ 1_i
lowering NN 1_i
of IN 1_i
glucosylated JJ 1_o
hemoglobin NN 1_o
( ( 1_i
HbA1 NNP 1_i
% NN 1_i
) ) 1_i
on IN N
neurosensory JJ N
function NN N
in IN N
insulin-dependent JJ 1_p
diabetes NNS 1_p
. . 1_p

Individual NNP 1_i
( ( 1_i
OP-1 NNP 1_i
, , 1_i
OP-2 NNP 1_i
, , 1_i
OP-3 NNP 1_i
) ) 1_i
and CC 1_i
summed VBN 1_i
( ( 1_i
OP-sum NNP 1_i
) ) 1_i
amplitudes NNS 1_i
of IN 1_i
oscillatory JJ 1_i
potentials NNS 1_i
( ( 1_i
OPs NNP 1_i
) ) 1_i
of IN 1_i
electroretinography NN 1_i
were VBD 1_i
recorded VBN 1_i
at IN N
study JJ N
start NN N
and CC N
7-years NNS N
later RB N
in IN N
45 CD 1_p
patients NNS 1_p
( ( N
the DT N
Oslo NNP 1_p
study NN N
) ) N
. . N

As IN N
an DT N
overall JJ N
7-year JJ N
change NN N
, , N
amplitudes NNS 1_o
of IN 1_o
OP-2 NNP 1_o
, , 1_o
OP-3 NNP 1_o
and CC 1_o
OP-sum NNP 1_o
were VBD 1_o
reduced VBN 1_o
( ( N
p JJ N
< NNP N
0.0001-0.01 NN N
) ) N
, , N
retinopathy JJ 1_o
worsened VBD 1_o
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
intraocular JJ 1_o
pressure NN 1_o
decreased VBN 1_o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
increased VBD 1_o
( ( N
p JJ N
< NNP N
0.0002 CD N
) ) N
, , N
and CC N
glycemic JJ 1_o
control NN 1_o
improved VBN N
from IN N
HbA1 NNP N
of IN N
11.2 CD N
+/- JJ N
2.2 CD N
% NN N
at IN N
study JJ N
start NN N
to TO N
a DT N
7-year JJ N
cumulative JJ N
mean NN N
of IN N
9.5 CD N
+/- JJ N
1.5 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
did VBD N
not RB N
identify VB N
any DT N
independent JJ N
relations NNS N
between IN N
change NN N
in IN N
OP-1 NNP 1_o
, , 1_o
OP-2 NNP 1_o
, , 1_o
OP-3 NNP 1_o
, , 1_o
OP-sum NNP 1_o
and CC N
change NN 1_o
in IN 1_o
glycemic JJ 1_o
control NN 1_o
or CC 1_o
background NN 1_o
variables NNS 1_o
, , N
including VBG N
change NN N
in IN N
age NN N
and CC N
duration NN N
of IN N
diabetes NNS N
. . N

However RB N
, , N
cross-sectional JJ N
observations NNS N
at IN N
7 CD N
years NNS N
showed VBD N
negative JJ N
correlations NNS N
between IN N
all DT N
OPs NNP 1_o
and CC N
age NN N
( ( N
p JJ N
< NNP N
0.0001-0.003 NN N
) ) N
, , N
and CC N
between IN N
OP-3 NNP 1_o
and CC 1_o
duration NN 1_o
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
counts NNS 1_o
of IN 1_o
microaneurysms NNS 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
various JJ N
clinical JJ N
background NN N
variables NNS N
may MD N
influence VB N
individual JJ N
and CC N
summed VBD N
amplitudes NNS N
of IN N
OPs NNP N
differently RB N
. . N

Reduced NNP 1_o
neurosensory JJ 1_o
retinal JJ 1_o
function NN 1_o
( ( 1_o
OPs NNP 1_o
) ) 1_o
seemed VBD N
to TO N
appear VB N
after IN N
7-years NNS N
, , N
independently RB N
of IN N
vascular JJ 1_o
defects NNS 1_o
of IN 1_o
retinopathy JJ 1_o
and CC N
long-term JJ 1_o
improvement NN 1_o
in IN 1_o
glucose JJ 1_o
control NN 1_o
. . 1_o

Instant JJ 1_i
Recess® NNP 1_i
: : 1_i
a DT N
practical JJ N
tool NN N
for IN N
increasing VBG 1_o
physical JJ 1_o
activity NN 1_o
during IN N
the DT N
school NN N
day NN N
. . N

BACKGROUND NNP N
An DT N
increased JJ N
prevalence NN N
of IN 1_p
overweight/obesity NN 1_p
among IN 1_p
children NNS 1_p
has VBZ N
led VBN N
to TO N
school NN N
district NN N
level NN N
policies NNS N
to TO N
increase VB 1_o
physical JJ 1_o
activity NN 1_o
( ( 1_o
PA NNP 1_o
) ) 1_o
among IN 1_p
elementary JJ 1_p
school NN 1_p
students NNS 1_p
. . N

Interventions NNS N
are VBP N
needed VBN N
that IN N
increase NN N
activity NN N
levels NNS N
without IN N
sacrificing VBG N
time NN N
spent VBN N
in IN N
academics NNS N
. . N

OBJECTIVES IN N
We PRP N
evaluated VBD N
a DT 1_i
policy NN 1_i
implementation NN 1_i
intervention NN 1_i
for IN N
to TO N
increase VB N
in-school JJ 1_i
PA NNP 1_i
in IN 1_p
elementary JJ 1_p
schools NNS 1_p
in IN 1_p
Forsyth NNP 1_p
County NNP 1_p
, , 1_p
North NNP 1_p
Carolina NNP 1_p
, , N
in IN N
a DT N
randomized JJ N
study NN N
with IN N
a DT N
delayed JJ N
intervention NN N
control NN N
group NN N
. . N

METHODS NNP 1_p
The DT 1_p
study NN 1_p
included VBD 1_p
third- JJ 1_p
through IN 1_p
fifth-grade JJ 1_p
classrooms NNS 1_p
in IN 1_p
eight CD 1_p
elementary JJ 1_p
schools NNS 1_p
. . 1_i

Instant NNP 1_i
Recess® NNP 1_i
was VBD N
used VBN N
to TO N
introduce VB N
10-minute JJ 1_i
PA NNP 1_i
breaks NNS 1_i
in IN N
classrooms NNS N
on IN N
schedules NNS N
determined VBN N
by IN N
teachers NNS N
. . N

Direct JJ N
observation NN N
was VBD N
used VBN N
to TO N
measure VB 1_o
activity NN 1_o
levels NNS 1_o
, , 1_o
other JJ 1_o
student NN 1_o
behaviors NNS 1_o
, , 1_o
and CC 1_o
teacher NN 1_o
behaviors NNS 1_o
related VBN N
to TO N
PA NNP N
in IN N
the DT N
classrooms NNS N
. . N

RESULTS NNP N
Twenty-eight JJ N
visits NNS N
to TO N
schools NNS N
were VBD N
made VBN N
during IN N
the DT N
spring NN N
and CC N
fall NN N
semesters NNS N
of IN N
2009 CD N
. . N

At IN N
baseline JJ N
11 CD N
% NN N
to TO N
44 CD N
% NN N
of IN N
intervention NN N
and CC N
control NN N
schools NNS N
were VBD N
engaged VBN N
in IN N
classroom-based JJ 1_i
PA. NNP 1_o
PA NNP 1_o
increased VBD N
from IN N
baseline NN N
to TO N
spring VB N
follow-up NN N
in IN N
intervention NN N
schools NNS N
and CC N
was VBD N
maintained VBN N
the DT N
following VBG N
fall NN N
. . N

Control NNP N
schools NNS N
decreased VBD 1_o
PA NNP 1_o
from IN N
baseline NN N
to TO N
spring NN N
and CC N
increased VBD 1_o
PA NNP 1_o
once RB N
they PRP N
began VBD N
the DT N
intervention NN N
. . N

Students NNS N
in IN N
classrooms NNS N
engaged VBN N
in IN N
Instant NNP N
Recess NNP N
exhibited VBD 1_o
statistically RB 1_o
significant JJ 1_o
increases NNS 1_o
in IN 1_o
light NN 1_o
( ( 1_o
51 CD 1_o
% NN 1_o
) ) 1_o
and CC 1_o
moderate-intensity NN 1_o
( ( 1_o
16 CD 1_o
% NN 1_o
) ) 1_o
PA NNP 1_o
and CC 1_o
increases NNS 1_o
in IN 1_o
time NN 1_o
spent VBN 1_o
in IN 1_o
on-task JJ 1_o
behavior NN 1_o
( ( N
11 CD N
% NN N
) ) N
. . N

Control NNP N
schools NNS N
experienced VBD N
similar JJ N
benefits NNS N
after IN N
they PRP N
began VBD N
implementing VBG N
Instant NNP N
Recess NNP N
. . N

CONCLUSIONS NNP N
Instant NNP N
Recess NNP N
is VBZ N
useful JJ N
for IN 1_o
increasing VBG 1_o
PA NNP 1_o
and CC 1_o
improving VBG 1_o
behavior NN 1_o
among IN 1_p
elementary JJ 1_p
school NN 1_p
children NNS 1_p
. . N

Additional NNP N
research NN N
may MD N
be VB N
needed VBN N
to TO N
understand VB N
how WRB N
to TO N
create VB N
policies NNS N
supporting VBG N
classroom NN N
activity NN N
breaks NNS N
and CC N
how WRB N
to TO N
assess VB N
policy NN N
adherence NN N
. . N

The DT N
Effects NNPS N
of IN N
Naltrexone NNP 1_i
on IN N
Subjective NNP N
Response NNP N
to TO N
Methamphetamine NNP 1_i
in IN N
a DT N
Clinical JJ 1_p
Sample NN 1_p
: : 1_p
a DT N
Double-Blind NNP N
, , N
Placebo-Controlled NNP N
Laboratory NNP N
Study NNP N
. . N

Methamphetamine NNP 1_i
( ( 1_p
MA NNP 1_p
) ) 1_p
use NN 1_p
disorder NN 1_p
is VBZ N
a DT N
serious JJ N
psychiatric JJ N
condition NN N
for IN N
which WDT N
there EX N
are VBP N
no DT N
FDA-approved JJ N
medications NNS N
. . N

Naltrexone NNP 1_i
( ( N
NTX NNP N
) ) N
is VBZ N
an DT N
opioid JJ N
receptor NN N
antagonist NN N
with IN N
demonstrated JJ N
efficacy NN N
, , N
albeit IN N
moderate JJ N
, , N
for IN N
the DT N
treatment NN N
of IN N
alcoholism NN N
and CC N
opioid JJ N
dependence NN N
. . N

Preclinical NNP N
and CC N
clinical JJ N
studies NNS N
suggest VBP N
that IN N
NTX NNP N
may MD N
be VB N
useful JJ N
for IN N
the DT N
treatment NN N
of IN N
MA NNP N
use NN N
disorder NN N
. . N

To TO N
inform VB N
treatment NN N
development NN N
, , N
we PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
, , N
placebo-controlled JJ N
human JJ N
laboratory NN N
study NN N
of IN N
NTX NNP N
. . N

Non-treatment-seeking JJ 1_p
individuals NNS 1_p
meeting VBG 1_p
DSM-IV NNP 1_p
criteria NNS 1_p
for IN 1_p
MA NNP 1_p
abuse NN 1_p
or CC 1_p
dependence NN 1_p
( ( 1_p
n=30 NN 1_p
) ) 1_p
completed VBD 1_p
two CD 1_p
separate JJ 1_p
5-day JJ 1_p
inpatient NN 1_p
stays NNS 1_p
. . 1_p

During IN N
each DT N
admission NN N
, , N
participants NNS N
completed VBD N
testing VBG N
sessions NNS N
comprised VBN N
of IN N
MA NNP 1_i
cue-reactivity NN N
and CC N
intravenous JJ 1_i
MA NNP 1_i
administration NN 1_i
( ( 1_i
30 CD 1_i
mg NN 1_i
) ) 1_i
after IN 1_i
receiving VBG 1_i
oral JJ 1_i
NTX NNP 1_i
( ( 1_i
50 CD 1_i
mg NN 1_i
) ) 1_i
or CC 1_i
placebo NN 1_i
for IN N
4 CD N
days NNS N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
NTX NNP N
would MD N
( ( N
a DT N
) ) N
attenuate NN N
cue-induced JJ N
MA NNP N
craving NN N
, , N
and CC N
( ( N
b NN N
) ) N
reduce VB N
subjective JJ N
responses NNS N
to TO N
MA NNP N
administration NN N
. . N

Results NNP N
largely RB N
supported VBD N
the DT N
study NN N
hypotheses NNS N
such JJ N
that IN N
( ( N
a DT N
) ) N
NTX NNP N
significantly RB N
blunted VBD N
cue-induced JJ N
craving NN N
for IN N
MA NNP N
and CC N
( ( N
b NN N
) ) N
attenuated VBD N
several JJ N
of IN N
the DT N
hedonic JJ N
subjective JJ N
effects NNS N
of IN N
MA NNP N
, , N
including VBG N
craving NN N
, , N
during IN N
controlled VBN N
MA NNP N
administration NN N
and CC N
as IN N
compared VBN N
with IN 1_i
placebo NN 1_i
. . N

NTX NNP N
decreased VBD N
overall JJ 1_o
subjective JJ 1_o
ratings NNS 1_o
of IN 1_o
'crave JJ 1_o
drug NN 1_o
, , 1_o
' '' 1_o
'stimulated VBN 1_o
, , 1_o
' '' 1_o
and CC 1_o
'would MD 1_o
like VB 1_o
drug NN 1_o
access NN 1_o
, , N
' '' N
decreased VBD N
the DT N
the DT N
post-MA JJ N
administration NN N
timecourse NN 1_o
of IN 1_o
'anxious JJ 1_o
' POS 1_o
and CC N
increased VBD 1_o
ratings NNS 1_o
of IN 1_o
'bad JJ 1_o
drug NN 1_o
effects NNS 1_o
, , N
' '' N
as IN N
compared VBN N
with IN 1_i
placebo NN 1_i
. . N

These DT N
findings NNS N
support VBP N
a DT N
potential JJ N
mechanism NN N
of IN N
action NN N
by IN N
showing VBG N
that IN N
NTX NNP N
reduced VBD 1_o
cue-induced JJ 1_o
craving NN 1_o
and CC 1_o
subjective JJ 1_o
responses NNS 1_o
to TO 1_o
MA NNP N
. . N

This DT N
is VBZ N
consistent JJ N
with IN N
positive JJ N
treatment NN N
studies NNS 1_i
of IN 1_i
NTX NNP N
for IN 1_i
amphetamine JJ 1_i
dependence NN N
, , N
as RB N
well RB N
as IN N
ongoing VBG N
clinical JJ N
trials NNS N
for IN N
MA NNP N
. . N

The DT N
study NN N
of IN N
inhibiting VBG N
systematic JJ N
inflammatory JJ N
response NN N
syndrome NN N
by IN N
applying VBG N
xenogenic JJ 1_i
( ( 1_i
porcine NN 1_i
) ) 1_i
acellular NN 1_i
dermal JJ 1_i
matrix NN 1_i
on IN N
second-degree JJ 1_p
burns NNS 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
influence NN N
of IN N
xenogenic NNP 1_i
( ( 1_i
porcine NN 1_i
) ) 1_i
acellular NN 1_i
dermal JJ 1_i
matrix NN 1_i
on IN N
the DT N
systematic JJ N
inflammatory JJ N
reaction NN N
syndrome NN N
( ( N
SIRS NNP N
) ) N
, , N
and CC N
the DT N
reaction NN N
of IN N
burn NN 1_p
patients NNS 1_p
to TO N
tissue VB N
damage NN N
upon IN N
application NN N
to TO N
second-degree JJ 1_p
burn NN 1_p
wounds NNS 1_p
. . 1_p

METHOD NNP N
Seventy-two JJ 1_p
cases NNS 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
acute JJ 1_p
second-degree JJ 1_p
burns NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
. . 1_p

According VBG N
to TO N
the DT N
total JJ N
burn NN N
surface NN N
area NN N
( ( N
TBSA NNP N
) ) N
and CC N
the DT N
treatment NN N
methods NNS N
, , N
we PRP N
randomly RB N
divided VBD N
the DT N
patients NNS N
into IN N
four CD N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
treatment NN N
group NN N
) ) N
: : N
patients NNS 1_p
with IN 1_p
less JJR 1_p
than IN 1_p
30 CD 1_p
% NN 1_p
TBSA NNP 1_p
covered VBD 1_p
with IN 1_p
xenogenic JJ 1_i
acellular JJ 1_i
dermal NN 1_i
matrix NN 1_i
. . 1_i

Group NNP N
B NNP N
( ( N
control VB N
group NN N
) ) N
: : N
patients NNS 1_p
with IN 1_p
less JJR 1_p
than IN 1_p
30 CD 1_p
% NN 1_p
TBSA NNP 1_p
covered VBD 1_p
with IN 1_p
betadine JJ 1_i
ointment NN 1_i
gauzes NNS 1_i
. . 1_i

Group NNP N
C NNP N
( ( N
treatment NN N
group NN N
) ) N
: : N
patients NNS 1_p
with IN 1_p
more JJR 1_p
than IN 1_p
30 CD 1_p
% NN 1_p
TBSA NNP 1_p
covered VBD 1_p
with IN 1_p
porcine JJ 1_i
acellular JJ 1_i
dermal NN 1_i
matrix NN 1_i
. . 1_i

Group NNP N
D NNP N
( ( N
control VB N
group NN N
) ) N
: : N
patients NNS 1_p
with IN 1_p
more JJR 1_p
than IN 1_p
30 CD 1_p
% NN 1_p
TBSA NNP 1_p
covered VBD 1_p
with IN 1_p
betadine JJ 1_i
ointment NN 1_i
gauzes NNS 1_i
. . 1_i

Serum NNP N
level NN N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
was VBD N
measured VBN N
by IN N
single JJ N
radial JJ N
immunodiffusion NN N
method NN N
on IN N
1 CD N
, , N
4 CD N
, , N
7 CD N
and CC N
14 CD N
days NNS N
postburn VBP N
. . N

RESULTS VB N
The DT N
serum JJ 1_o
level NN 1_o
of IN 1_o
CRP NNP 1_o
in IN N
group NN N
A NNP N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
on IN N
days NNS N
4 CD N
, , N
7 CD N
and CC N
14 CD N
. . N

The DT N
serum JJ 1_o
level NN 1_o
of IN 1_o
CRP NNP 1_o
in IN N
group NN N
C NNP N
increased VBD N
slowly RB N
, , N
descended VBD N
quickly RB N
and CC N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
in IN N
group NN N
D NNP N
on IN N
days NNS N
4 CD N
, , N
7 CD N
and CC N
14 CD N
. . N

CONCLUSION VB N
The DT N
application NN N
of IN N
xenogenic NNP 1_i
( ( 1_i
porcine NN 1_i
) ) 1_i
acellular NN 1_i
dermal JJ 1_i
matrix NN 1_i
on IN N
second-degree JJ 1_p
burn NN 1_p
wound NN 1_p
can MD N
decrease VB N
serum JJ 1_o
level NN 1_o
of IN 1_o
CRP NNP 1_o
of IN N
the DT N
patients NNS N
, , N
which WDT N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
SIRS NNP N
and CC N
sepsis NN N
incidence NN N
. . N

The DT N
tension-free JJ 1_i
hernioplasty NN 1_i
in IN N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
tension-free JJ 1_i
hernioplasty NN 1_i
as IN N
introduced VBN N
by IN N
Lichtenstein NNP N
has VBZ N
gained VBN N
increasing VBG N
acceptance NN N
during IN N
the DT N
last JJ N
decade NN N
although IN N
the DT N
technique NN N
has VBZ N
not RB N
been VBN N
evaluated VBN N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

METHODS NNP N
This DT N
randomized VBN N
study NN N
compares VBZ N
the DT N
2-year JJ N
follow-up JJ N
results NNS N
after IN N
102 CD 1_p
tension-free JJ 1_i
hernioplasties NNS 1_i
with IN 1_i
implantation NN 1_i
of IN 1_i
a DT 1_i
prolene NN 1_i
mesh NN 1_i
in IN 1_i
all DT 1_i
groin NN 1_i
hernias VBD 1_i
to TO 1_p
53 CD 1_p
Cooper NNP 1_i
ligament NN 1_i
repairs NNS 1_i
in IN 1_i
direct JJ 1_i
hernias NN 1_i
and CC 1_p
53 CD 1_p
abdominal JJ 1_i
ring NN 1_i
repairs NNS 1_i
in IN 1_i
indirect JJ 1_i
hernias NN 1_i
. . 1_i

RESULTS NNP N
After IN N
tension-free JJ 1_i
repairs NNS 1_i
five CD N
hernias NNS 1_o
recurred VBN 1_o
( ( N
5 CD N
% NN N
) ) N
, , N
and CC N
after IN N
either DT N
Cooper NNP 1_i
ligament NN 1_i
or CC 1_i
abdominal JJ 1_i
ring NN 1_i
repair NN 1_i
, , N
16 CD N
recurrences NNS 1_o
were VBD N
found VBN N
( ( N
15 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

No UH N
indirect JJ 1_o
hernias NN 1_o
recurred VBD 1_o
after IN N
a DT N
tension-free JJ 1_i
repair NN 1_i
; : 1_i
2 CD N
recurred VBD N
after IN N
abdominal JJ 1_i
ring NN 1_i
repair NN 1_i
( ( N
4 CD N
% NN N
; : N
NS NNP N
) ) N
. . N

The DT N
recurrence NN 1_o
rate NN 1_o
after IN 1_o
tension-free JJ 1_o
repairs NNS 1_o
for IN 1_o
primary JJ 1_o
direct JJ 1_o
inguinal JJ 1_o
hernias NN 1_o
was VBD N
7 CD N
% NN N
as IN N
compared VBN N
with IN N
30 CD N
% NN N
after IN N
Cooper NNP 1_i
ligament NN 1_i
repair NN 1_i
( ( N
P NNP N
= NNP N
0.0081 CD N
) ) N
. . N

No DT N
difference NN N
in IN N
complication NN 1_o
rate NN 1_o
between IN N
the DT N
tested JJ N
methods NNS N
was VBD N
found VBN N
. . N

CONCLUSION JJ N
Recurrence NNP 1_o
rate NN 1_o
is VBZ N
reduced VBN N
to TO N
one-third JJ N
after IN N
tension-free JJ 1_i
herniotomies NNS 1_i
as IN N
compared VBN N
with IN N
the DT N
conventionel NN 1_i
herniotomies NNS 1_i
without IN N
increase NN N
in IN N
complication NN 1_o
rate NN 1_o
. . 1_o

Anthropometric JJ N
indices NNS N
of IN N
Gambian JJ 1_p
children NNS 1_p
after IN N
one CD N
or CC N
three CD N
annual JJ N
rounds NNS N
of IN N
mass JJ 1_i
drug NN 1_i
administration NN 1_i
with IN N
azithromycin NN 1_i
for IN N
trachoma NN 1_p
control NN N
. . N

BACKGROUND NNP N
Mass NNP N
drug NN N
administration NN N
( ( N
MDA NNP N
) ) N
with IN N
azithromycin NN 1_i
, , N
carried VBD N
out RP N
for IN N
the DT N
control NN N
of IN N
blinding VBG N
trachoma NN N
, , N
has VBZ N
been VBN N
linked VBN N
to TO N
reduced VBN N
mortality NN N
in IN N
children NNS 1_p
. . 1_p

While IN N
the DT N
mechanism NN N
behind IN N
this DT N
reduction NN N
is VBZ N
unclear JJ N
, , N
it PRP N
may MD N
be VB N
due JJ N
, , N
in IN N
part NN N
, , N
to TO N
improved VBN N
nutritional JJ N
status NN N
via IN N
a DT N
potential JJ N
reduction NN N
in IN N
the DT N
community NN N
burden NN N
of IN N
infectious JJ N
disease NN N
. . N

To TO N
determine VB N
whether IN N
MDA NNP 1_i
with IN 1_i
azithromycin JJ 1_i
improves NNS N
anthropometric JJ N
indices NNS N
at IN N
the DT N
community NN N
level NN N
, , N
we PRP N
measured VBD N
the DT N
heights NNS 1_o
and CC 1_o
weights NNS 1_o
of IN N
children NNS 1_p
aged VBN 1_p
1 CD 1_p
to TO 1_p
4 CD 1_p
years NNS 1_p
in IN 1_p
communities NNS 1_p
where WRB 1_p
one CD 1_p
( ( 1_p
single JJ 1_p
MDA NNP 1_p
arm NN 1_p
) ) 1_p
or CC 1_p
three CD 1_p
annual JJ 1_p
rounds NNS 1_p
( ( 1_p
annual JJ 1_p
MDA NNP 1_p
arm NN 1_p
) ) 1_p
of IN 1_p
azithromycin NN 1_i
had VBD N
been VBN N
distributed VBN N
. . N

METHODS NNP N
Data NNP N
collection NN N
took VBD N
place NN N
three CD N
years NNS N
after IN N
treatment NN N
in IN N
the DT N
single JJ N
MDA NNP N
arm NN N
and CC N
one CD N
year NN N
after IN N
the DT N
final JJ N
round NN N
of IN N
treatment NN N
in IN N
the DT N
annual JJ N
MDA NNP N
arm NN N
. . N

Mean JJ 1_o
height-for-age NN 1_o
, , 1_o
weight-for-age NN 1_o
and CC 1_o
weight-for-height JJ 1_o
z NN 1_o
scores NNS 1_o
were VBD N
compared VBN N
between IN N
treatment NN N
arms NNS N
. . N

RESULTS NNP N
No NNP N
significant JJ 1_o
differences NNS 1_o
in IN N
mean JJ 1_o
height-for-age NN 1_o
, , 1_o
weight-for-age NN 1_o
or CC 1_o
weight-for-height JJ 1_o
z NN 1_o
scores NNS 1_o
were VBD N
found VBN N
between IN N
the DT N
annual JJ N
MDA NNP N
and CC N
single JJ N
MDA NNP N
arms NNS N
, , N
nor CC N
was VBD N
there EX N
a DT N
significant JJ 1_o
reduction NN 1_o
in IN N
prevalence NN 1_o
of IN 1_o
stunting NN 1_o
, , 1_o
wasting VBG 1_o
or CC 1_o
underweight JJ 1_o
between IN N
arms NNS N
. . N

CONCLUSIONS VB N
Our PRP$ N
data NNS N
do VBP N
not RB N
provide VB N
evidence NN N
that IN N
community NN N
MDA NNP 1_i
with IN 1_i
azithromycin NN 1_i
improved VBN N
anthropometric JJ 1_o
outcomes NNS 1_o
of IN N
children NNS 1_p
in IN 1_p
The DT 1_p
Gambia NNP 1_p
. . 1_p

This DT N
may MD N
suggest VB N
reductions NNS N
in IN N
mortality NN N
associated VBN N
with IN N
azithromycin JJ 1_i
MDA NNP 1_i
are VBP N
due JJ N
to TO N
a DT N
mechanism NN N
other JJ N
than IN N
improved JJ N
nutritional JJ N
status NN N
. . N

Aftermath NN N
of IN N
a DT N
clinical JJ N
trial NN N
: : N
evaluating VBG N
the DT N
sustainability NN N
of IN N
a DT N
medical JJ 1_i
device NN 1_i
intervention NN 1_i
in IN 1_p
Ghana NNP 1_p
. . 1_p

A NNP N
randomized VBD N
controlled VBN N
trial NN N
recently RB N
demonstrated VBD N
that IN N
continuous JJ 1_i
positive JJ 1_i
airway NN 1_i
pressure NN 1_i
( ( 1_p
CPAP NNP 1_p
) ) 1_p
effectively RB 1_p
decreases VBZ 1_p
respiratory JJ 1_o
rate NN 1_o
in IN 1_p
children NNS 1_p
presenting VBG 1_p
to TO 1_p
Ghanaian NNP 1_p
district NN 1_p
hospitals NNS 1_p
with IN 1_p
respiratory NN 1_p
distress NN 1_p
. . 1_p

A DT N
follow-up JJ N
study NN N
16 CD N
months NNS N
later RB N
evaluated VBD N
the DT N
extent NN N
to TO N
which WDT N
the DT N
skills NNS N
and CC N
equipment NN N
necessary JJ N
for IN N
CPAP NNP N
use NN N
have VBP N
been VBN N
maintained VBN N
. . N

Seven NNP N
of IN N
eight CD N
CPAP NNP N
machines NNS N
were VBD N
functional JJ N
, , N
but CC N
five CD N
of IN N
eight CD N
oxygen NN N
concentrators NNS N
and CC N
three CD N
of IN N
four CD N
electric JJ N
generators NNS N
were VBD N
non-functional JJ N
. . N

Nurses NNS 1_p
trained VBN 1_p
by IN 1_p
US NNP 1_p
study NN 1_p
personnel NNS 1_p
( ( 1_p
first-generation NN 1_p
) ) 1_p
and CC 1_p
nurses NNS 1_p
trained VBN 1_p
by IN 1_p
Ghanaian JJ 1_p
nurses NNS 1_p
after IN 1_p
the DT 1_p
study NN 1_p
( ( 1_p
second-generation NN 1_p
) ) 1_p
were VBD 1_p
evaluated VBN 1_p
on IN 1_p
CPAP NNP 1_p
knowledge NN 1_p
and CC 1_p
skills NNS 1_p
. . 1_p

Twenty-eight JJ 1_p
nurses NNS 1_p
participated VBN 1_p
in IN 1_p
the DT 1_p
study NN 1_p
, , 1_p
9 CD 1_p
first-generation NN 1_p
and CC 1_p
19 CD 1_p
second-generation NN 1_p
. . 1_p

First-generation NN N
trainees NNS N
scored VBD N
significantly RB N
higher JJR N
than IN N
second-generation NN N
trainees NNS N
on IN N
both DT N
skills NNS 1_o
and CC 1_o
knowledge NN 1_o
assessments NNS 1_o
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Appropriate NNP N
technical JJ N
support NN N
and CC N
training NN N
must MD N
be VB N
ensured VBN N
to TO N
address VB N
equipment NN N
maintenance NN N
. . N

Protocolization NN N
of IN N
the DT N
training NN N
program NN N
, , N
in IN N
conjunction NN N
with IN N
skills NNS 1_o
and CC 1_o
knowledge NN 1_o
assessment NN N
, , N
may MD N
improve VB N
acquisition NN 1_o
and CC 1_o
retention NN 1_o
among IN N
second- JJ N
and CC N
future-generation JJ N
trainees NNS N
. . N

Randomized VBN N
trial NN N
of IN N
angiotensin JJ 1_i
II-receptor NNP 1_i
blocker NN 1_i
vs. FW N
dihydropiridine NN 1_i
calcium NN 1_i
channel NN 1_i
blocker NN 1_i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ 1_p
atrial JJ 1_p
fibrillation NN 1_p
with IN 1_p
hypertension NN 1_p
( ( N
J-RHYTHM NNP N
II NNP N
study NN N
) ) N
. . N

AIMS NNP N
Atrial NNP N
fibrillation NN N
( ( N
AF NNP N
) ) N
is VBZ N
a DT N
common JJ N
arrhythmia NN N
frequently RB N
associated VBN N
with IN N
hypertension NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
lowering VBG N
blood NN N
pressure NN N
by IN N
angiotensin JJ 1_i
II-receptor NNP 1_i
blockers NNS 1_i
( ( 1_i
ARB NNP 1_i
) ) 1_i
has VBZ N
more JJR N
beneficial JJ N
effects NNS N
than IN N
by IN N
conventional JJ 1_i
calcium NN 1_i
channel NN 1_i
blockers NNS 1_i
( ( 1_i
CCB NNP 1_i
) ) 1_i
on IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
with IN N
hypertension NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
Japanese JJ 1_p
Rhythm NNP 1_p
Management NNP 1_p
Trial NNP 1_p
II NNP 1_p
for IN 1_p
Atrial NNP 1_p
Fibrillation NNP 1_p
( ( 1_p
J-RHYTHM NNP 1_p
II NNP 1_p
study NN 1_p
) ) 1_p
is VBZ N
an DT N
open-label JJ N
randomized JJ N
comparison NN N
between IN N
an DT N
ARB NNP 1_i
( ( 1_i
candesartan NN 1_i
) ) 1_i
and CC N
a DT N
CCB NNP 1_i
( ( 1_i
amlodipine NN 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ N
AF NNP N
associated VBN N
with IN N
hypertension NN N
. . N

Using VBG N
daily JJ N
transtelephonic JJ 1_i
monitoring NN 1_i
, , N
we PRP N
examined VBD N
asymptomatic JJ N
and CC N
symptomatic JJ N
paroxysmal NN 1_o
AF NNP 1_o
episodes VBZ N
during IN N
a DT N
maximum JJ N
1 CD N
year NN N
treatment NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
difference NN 1_o
in IN 1_o
AF NNP 1_o
frequency NN 1_o
between IN N
the DT N
pre-treatment JJ N
period NN N
and CC N
the DT N
final JJ N
month NN N
of IN N
the DT N
follow-up NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
included VBD N
cardiovascular JJ 1_o
events NNS 1_o
, , 1_o
development NN 1_o
of IN 1_o
persistent JJ 1_o
AF NNP 1_o
, , 1_o
left VBD 1_o
atrial JJ 1_o
dimension NN 1_o
, , 1_o
and CC 1_o
quality-of-life NN 1_o
( ( 1_o
QOL NNP 1_o
) ) 1_o
. . 1_o

The DT 1_p
study NN 1_p
enrolled VBD 1_p
318 CD 1_p
patients NNS 1_p
( ( 1_p
66 CD 1_p
years NNS 1_p
, , 1_p
male/female JJ 1_p
219/99 CD 1_p
, , 1_p
158 CD 1_p
in IN 1_p
the DT 1_p
ARB NNP 1_i
group NN 1_p
and CC 1_p
160 CD 1_p
in IN 1_p
the DT 1_p
CCB NNP 1_i
group NN 1_p
) ) 1_p
treated VBD 1_p
at IN 1_p
48 CD 1_p
sites NNS 1_p
throughout IN 1_p
Japan NNP 1_p
. . 1_p

At IN 1_p
baseline NN 1_p
, , 1_p
the DT 1_p
frequency NN 1_o
of IN 1_o
AF NNP 1_o
episodes NNS 1_o
( ( 1_p
days/month NN 1_p
) ) 1_p
was VBD 1_p
3.8 CD 1_p
± JJ 1_p
5.0 CD 1_p
in IN 1_p
the DT 1_p
ARB NNP 1_p
group NN 1_p
vs. FW 1_p
4.8 CD 1_p
± $ 1_p
6.3 CD 1_p
in IN 1_p
the DT 1_p
CCB NNP 1_p
group NN 1_p
( ( N
not RB N
significant JJ N
) ) N
. . N

During IN N
the DT N
follow-up JJ 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
CCB NNP N
group NN N
than IN N
in IN N
the DT N
ARB NNP N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT 1_o
AF NNP 1_o
frequency NN 1_o
decreased VBD N
similarly RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
endpoint NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT 1_o
development NN 1_o
of IN 1_o
persistent JJ 1_o
AF NNP 1_o
, , 1_o
changes NNS 1_o
in IN 1_o
left JJ 1_o
atrial JJ 1_o
dimension NN 1_o
, , 1_o
occurrence NN 1_o
of IN 1_o
cardiovascular JJ 1_o
events NNS 1_o
, , 1_o
or CC 1_o
changes NNS 1_o
in IN 1_o
QOL NNP 1_o
. . N

CONCLUSIONS NNP N
In IN 1_p
patients NNS 1_p
with IN 1_p
paroxysmal JJ 1_p
AF NNP 1_p
and CC 1_p
hypertension NN 1_p
, , N
treatment NN N
of IN N
hypertension NN N
by IN 1_i
candesartan NN 1_i
did VBD N
not RB N
have VB N
an DT N
advantage NN N
over RP 1_i
amlodipine NN 1_i
in IN N
the DT N
reduction NN N
in IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
( ( N
umin JJ N
CTR NNP N
C000000427 NNP N
) ) N
. . N

Simvastatin JJ 1_i
blunts NNS N
endotoxin-induced JJ N
tissue NN N
factor NN N
in IN N
vivo NN N
. . N

BACKGROUND NNP N
Beyond NNP N
lipid JJ N
lowering NN N
, , N
various JJ N
antiinflammatory NN N
properties NNS N
have VBP N
been VBN N
ascribed VBN N
to TO N
statins NNS N
. . N

Moreover RB N
, , N
in IN N
vitro JJ N
studies NNS N
have VBP N
suggested VBN N
the DT N
presence NN N
of IN N
anticoagulant JJ N
effects NNS N
of IN N
3-hydroxy-3-methylglutaryl JJ N
coenzyme NN N
A NNP N
reductase NN N
inhibitors NNS N
, , N
as IN N
lipopolysaccharide NN N
( ( N
LPS NNP N
) ) N
-induced VBD N
monocyte JJ N
tissue NN N
factor NN N
( ( N
TF NNP N
) ) N
was VBD N
suppressed VBN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examined VBD N
the DT N
role NN N
of IN N
statins NNS 1_i
in IN N
experimental JJ N
endotoxemia NN 1_p
on IN N
inflammatory NN N
and CC N
procoagulant JJ N
responses NNS N
in IN N
vivo NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ 1_i
, , N
parallel-group JJ N
study NN N
, , N
20 CD 1_p
healthy JJ 1_p
, , 1_p
male JJ 1_p
subjects NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
simvastatin NN 1_i
( ( N
80 CD N
mg/d NN N
) ) N
or CC 1_i
placebo NN 1_i
for IN N
4 CD N
days NNS N
before RB N
intravenous JJ N
administration NN N
of IN N
LPS NNP N
( ( N
20 CD N
IU/kg NNP N
IV NNP N
) ) N
. . N

Plasma JJ 1_o
high-sensitive JJ 1_o
C-reactive JJ 1_o
protein NN 1_o
( ( 1_o
hsCRP NN 1_o
) ) 1_o
, , 1_o
monocyte JJ 1_o
chemoattractant NN 1_o
protein NN 1_o
( ( 1_o
MCP-1 NNP 1_o
) ) 1_o
, , 1_o
sCD40L UH 1_o
, , 1_o
sCD40 JJ 1_o
, , 1_o
and CC 1_o
prothrombin JJ 1_o
fragment NN 1_o
F1+2 NNP 1_o
( ( 1_o
F1.2 NNP 1_o
) ) 1_o
were VBD N
determined VBN N
by IN N
ELISAs NNP N
at IN N
baseline NN N
and CC N
at IN N
4 CD N
and CC N
8 CD N
hours NNS N
after IN N
LPS NNP N
administration NN N
. . N

Monocyte NNP 1_o
TF NNP 1_o
expression NN 1_o
and CC 1_o
monocyte-platelet NN 1_o
aggregates NNS 1_o
were VBD N
measured VBN N
by IN N
whole-blood NN N
flow NN N
cytometry NN N
over IN N
the DT N
same JJ N
time NN N
course NN N
. . N

The DT N
increases NNS N
in IN N
hsCRP NN 1_o
and CC 1_o
MCP-1 NNP 1_o
, , N
both DT N
known JJ N
inducers NNS N
of IN N
TF NNP N
, , N
were VBD N
significantly RB N
suppressed VBN N
by IN N
statin NN N
treatment NN N
after IN N
LPS NNP N
challenge NN N
. . N

Statin NNP 1_i
premedication NN N
blunted VBD N
the DT N
increase NN N
of IN N
monocyte JJ 1_o
TF NNP 1_o
expression NN 1_o
in IN N
response NN N
to TO N
LPS NNP N
. . N

In IN N
parallel JJ N
, , N
endotoxin-induced JJ N
formation NN 1_o
of IN 1_o
F1.2 NNP 1_o
was VBD N
significantly RB N
reduced VBN N
by IN N
simvastatin NN 1_i
after IN N
4 CD N
and CC N
8 CD N
hours NNS N
. . N

LPS NNP N
infusion NN N
affected VBD N
neither CC N
the DT N
formation NN 1_o
and CC 1_o
activation NN 1_o
of IN 1_o
monocyte-platelet NN 1_o
aggregates NNS 1_o
nor CC N
plasma JJ 1_o
levels NNS 1_o
of IN 1_o
sCD40 NN 1_o
and CC 1_o
sCD40L NN 1_o
. . 1_o

CONCLUSIONS NNP N
Simvastatin NNP 1_i
suppresses VBZ N
the DT N
inflammatory JJ 1_o
response NN 1_o
to TO 1_o
endotoxin VB 1_o
and CC N
blunts NNS N
monocyte VBP 1_o
TF NNP 1_o
expression NN 1_o
but CC N
does VBZ N
not RB N
affect VB N
platelet NN 1_o
activation NN 1_o
. . 1_o

The DT N
effect NN N
of IN N
liquid NN 1_i
fibre NN 1_i
on IN N
feeding VBG 1_o
behaviour NN 1_o
. . 1_o

The DT N
KRAS-variant NNP N
and CC N
miRNA JJ N
expression NN N
in IN N
RTOG NNP N
endometrial JJ 1_p
cancer NN 1_p
clinical JJ N
trials NNS N
9708 CD N
and CC N
9905 CD N
. . N

OBJECTIVE VB N
To TO N
explore VB N
the DT N
association NN N
of IN N
a DT N
functional JJ N
germline NN N
variant NN N
in IN N
the DT N
3'-UTR CD N
of IN N
KRAS NNP N
with IN N
endometrial JJ N
cancer NN N
risk NN N
, , N
as RB N
well RB N
as IN N
the DT N
association NN N
of IN N
microRNA NN N
( ( N
miRNA NN N
) ) N
signatures NNS N
and CC N
the DT N
KRAS-variant NNP N
with IN N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
outcomes NNS N
in IN N
two CD N
prospective JJ N
RTOG NNP N
endometrial JJ N
cancer NN N
trials NNS N
. . N

METHODS/MATERIALS NNP N
The DT N
association NN N
of IN N
the DT N
KRAS-variant NNP N
with IN N
endometrial JJ N
cancer NN N
risk NN N
was VBD N
evaluated VBN N
by IN N
case-control JJ N
analysis NN N
of IN N
467 CD 1_p
women NNS 1_p
with IN 1_p
type JJ 1_p
1 CD 1_p
or CC 1_p
2 CD 1_p
endometrial JJ 1_p
cancer NN 1_p
and CC 1_p
582 CD 1_p
age-matched JJ 1_p
controls NNS 1_p
. . 1_p

miRNA NN N
and CC N
DNA NNP N
were VBD N
isolated VBN N
for IN N
expression NN N
profiling NN N
and CC N
genotyping VBG N
from IN N
tumor NN 1_p
specimens NNS 1_p
of IN 1_p
46 CD 1_p
women NNS 1_p
with IN 1_p
type JJ 1_p
1 CD 1_p
endometrial JJ 1_p
cancer NN 1_p
enrolled VBN 1_p
in IN 1_p
RTOG NNP 1_p
trials NNS 1_p
9708 CD 1_p
and CC 1_p
9905. CD 1_p
miRNA JJ N
expression NN N
levels NNS N
and CC N
KRAS-variant NNP N
genotype NN N
were VBD N
correlated VBN N
with IN N
patient NN N
and CC N
tumor NN N
characteristics NNS N
, , N
and CC N
survival JJ N
outcomes NNS N
were VBD N
evaluated VBN N
by IN N
variant JJ N
allele JJ N
type NN N
. . N

RESULTS VB N
The DT N
KRAS-variant NNP N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
overall JJ 1_o
endometrial JJ 1_o
cancer NN 1_o
risk NN 1_o
( ( N
14 CD N
% NN N
controls NNS N
and CC N
17 CD N
% NN N
type NN N
1 CD N
cancers NNS N
) ) N
, , N
although IN N
was VBD N
enriched VBN N
in IN N
type NN N
2 CD N
endometrial JJ N
cancers NNS N
( ( N
24 CD N
% NN N
, , N
p NN N
= NNP N
0.2 CD N
) ) N
. . N

In IN N
the DT N
combined JJ N
analysis NN N
of IN N
RTOG NNP N
9708/9905 CD 1_o
, , 1_o
miRNA FW 1_o
expression NN 1_o
differed VBN N
by IN N
age NN N
, , N
presence NN N
of IN N
lymphovascular JJ N
invasion NN N
and CC N
KRAS-variant JJ N
status NN 1_o
. . 1_o

Overall JJ 1_o
survival JJ 1_o
rates NNS 1_o
at IN N
3 CD N
years NNS N
for IN 1_p
patients NNS 1_p
with IN 1_p
the DT 1_p
variant NN 1_p
and CC 1_p
wild-type JJ 1_p
alleles NNS 1_p
were VBD N
100 CD N
% NN N
and CC N
77 CD N
% NN N
( ( N
HR NNP N
0.3 CD N
, , N
p NN N
= NNP N
0.24 CD N
) ) N
, , N
respectively RB N
, , N
favoring VBG N
the DT N
variant NN N
. . N

CONCLUSIONS VB N
The DT N
KRAS-variant NNP N
may MD N
be VB N
a DT N
genetic JJ N
marker NN N
of IN N
risk NN N
for IN N
type NN N
2 CD N
endometrial JJ N
cancers NNS N
. . N

In IN N
addition NN N
, , N
tumor NN N
miRNA NN N
expression NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
patient JJ N
age NN N
, , N
lymphovascular JJ N
invasion NN N
and CC N
the DT N
KRAS-variant NNP N
, , N
supporting VBG N
the DT N
hypothesis NN N
that WDT N
altered VBD N
tumor NN N
biology NN N
can MD N
be VB N
measured VBN N
by IN N
miRNA JJ N
expression NN N
, , N
and CC N
that IN N
the DT N
KRAS-variant NNP N
likely JJ N
impacts NNS N
endometrial JJ N
tumor NN N
biology NN N
. . N

Assessment NN N
of IN N
radiotherapy NN 1_i
combined VBN 1_i
with IN 1_i
adjuvant JJ 1_i
chemotherapy NN 1_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
nasopharyngeal JJ 1_p
carcinoma NN 1_p
: : 1_p
a DT N
prospective JJ N
study NN N
. . N

PURPOSE NNP N
To TO N
explore VB N
the DT N
clinical JJ N
efficacy NN 1_o
of IN N
radiotherapy NN 1_i
combined VBN 1_i
with IN 1_i
concurrent JJ 1_i
combination NN 1_i
chemotherapy NN 1_i
in IN N
the DT N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
nasopharyngeal JJ 1_p
carcinoma NN 1_p
( ( 1_p
NPC NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Two CD 1_p
hundred VBD 1_p
patients NNS 1_p
with IN 1_p
stage NN 1_p
III/IV NNP 1_p
NPC NNP 1_p
were VBD 1_p
randomly RB 1_p
allocated VBN 1_p
into IN N
the DT N
treatment NN 1_p
group NN 1_p
( ( 1_p
N=100 NNP 1_p
) ) 1_p
and CC 1_p
the DT 1_p
control NN 1_p
group NN 1_p
( ( 1_p
N=100 NNP 1_p
) ) 1_p
. . 1_p

Patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
conventional JJ 1_i
fractionated JJ 1_i
radiotherapy NN 1_i
, , N
while IN N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
received VBD N
conventional JJ 1_i
fractionated JJ 1_i
radiotherapy NN 1_i
combined VBN 1_i
with IN 1_i
concurrent JJ 1_i
combination NN 1_i
chemotherapy NN 1_i
with IN 1_i
cisplatin NN 1_i
and CC 1_i
5-fluorouracil JJ 1_i
( ( 1_i
5-FU JJ 1_i
) ) 1_i
. . 1_i

Short-term JJ 1_o
efficacy NN 1_o
, , 1_o
radiotherapy NN 1_o
toxicity NN 1_o
, , 1_o
shortand VB 1_o
long-term JJ 1_o
survival NN 1_o
were VBD N
compared VBN N
. . N

RESULTS VB N
The DT N
short-term JJ 1_o
response NN 1_o
rate NN 1_o
of IN N
the DT N
treatment NN N
group NN N
was VBD N
96 CD N
% NN N
, , N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
87 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
local JJ 1_o
radiation NN 1_o
toxicity NN 1_o
of IN N
the DT N
treatment NN N
group NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
group NN N
p VBD N
> NNP N
0.05 CD N
) ) N
, , N
but CC N
the DT N
hematological JJ 1_o
and CC 1_o
gastrointestinal JJ 1_o
toxicities NNS 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
treatment NN N
group NN N
p VBD N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
1- JJ N
, , N
3- JJ N
and CC N
5-year JJ N
overall JJ 1_o
survival NN 1_o
rates NNS 1_o
were VBD N
87 CD N
, , N
80 CD N
, , N
and CC N
76 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
treatment NN N
group NN N
and CC N
74 CD N
, , N
64 CD N
, , N
and CC N
51 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN N
group NN N
, , N
significantly RB N
favoring VBG N
the DT N
treatment NN N
group NN N
p VBD N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Radiotherapy NNP 1_i
with IN 1_i
concurrent JJ 1_i
combination NN 1_i
chemotherapy NN 1_i
can MD N
improve VB N
the DT N
prognosis NN 1_o
of IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
NPC NNP 1_p
but CC N
at IN N
the DT N
cost NN N
of IN N
significant JJ N
toxicity NN 1_o
. . 1_o

Inhibition NN N
of IN N
histamine-induced JJ 1_i
skin NN N
wheal NN N
and CC N
flare NN N
after IN N
5 CD N
days NNS N
of IN N
mizolastine NN 1_i
. . 1_i

Mizolastine NNP 1_i
is VBZ N
a DT N
new JJ N
, , N
nonsedating JJ N
antihistamine NN N
providing VBG N
satisfactory JJ N
symptomatic JJ N
relief NN 1_o
in IN 1_o
allergic JJ 1_o
rhinitis NN 1_o
and CC 1_o
urticaria NN 1_o
. . 1_o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
inhibition NN N
of IN N
wheal NN N
and CC N
flare NN N
formation NN N
after IN N
2-mu JJ N
g NN N
intradermal JJ N
histamine NN N
injections NNS N
as IN N
a DT N
measure NN N
of IN N
the DT N
antihistamine JJ N
effect NN N
of IN N
repeated JJ N
doses NNS N
of IN N
mizolastine NN N
. . N

Eight CD 1_p
volunteers NNS 1_p
were VBD 1_p
enrolled VBN 1_p
in IN N
this DT N
four-arm JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
randomized VBN N
study NN N
. . N

Three CD N
dose JJ N
levels NNS N
of IN N
once-daily JJ 1_i
mizolastine NN 1_i
( ( N
5 CD N
mg NN N
, , N
10 CD N
mg NN N
, , N
and CC N
15 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
placebo NN 1_i
during IN N
5-day JJ N
dose JJ N
periods NNS N
. . N

Histamine NN 1_i
tests NNS 1_i
were VBD N
performed VBN N
before IN N
drug NN N
intake NN N
on IN N
days NNS N
1 CD N
and CC N
5 CD N
, , N
and CC N
then RB N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
, , N
10 CD N
, , N
12 CD N
, , N
14 CD N
, , N
and CC N
24 CD N
hours NNS N
after IN N
drug NN N
intake NN N
on IN N
day NN N
5 CD N
. . N

All DT N
3 CD N
doses NNS N
of IN N
mizolastine NN 1_i
were VBD N
more RBR 1_o
effective JJ 1_o
than IN N
placebo NN 1_i
in IN N
suppressing VBG N
wheal NN 1_o
and CC 1_o
flare NN 1_o
reactions NNS 1_o
, , N
and CC N
the DT N
antihistamine NN 1_o
activity NN 1_o
was VBD N
highest JJS N
at IN N
both DT N
the DT N
10- JJ N
and CC N
15-mg JJ N
dose NN N
levels NNS N
. . N

The DT N
effect NN 1_o
on IN 1_o
the DT 1_o
flare JJ 1_o
reaction NN 1_o
appeared VBD N
within IN N
1 CD N
hour NN N
, , N
reached VBD N
a DT N
maximum JJ N
effect NN N
4 CD N
hours NNS N
after IN N
administration NN N
, , N
and CC N
persisted VBD N
for IN N
as RB N
long RB N
as IN N
24 CD N
hours NNS N
. . N

The DT N
relative JJ N
changes NNS 1_o
in IN N
wheal NN N
and CC N
flare JJ N
areas NNS N
were VBD N
correlated VBN N
with IN N
mizolastine NN 1_i
trough IN N
plasma NN N
levels NNS N
on IN N
day NN N
5 CD N
. . N

Safety NN 1_o
was VBD N
satisfactory JJ N
in IN N
all DT N
groups NNS N
. . N

This DT N
study NN N
confirms VBZ N
that IN N
mizolastine NN 1_i
is VBZ N
a DT N
rapid JJ N
and CC N
potent JJ N
antihistamine NN 1_o
; : 1_o
and CC N
its PRP$ N
long-lasting JJ N
effectiveness NN N
indicates VBZ N
that IN N
a DT N
once-daily JJ N
regimen NN N
is VBZ N
acceptable JJ N
for IN N
clinical JJ N
use NN N
. . N

Effect NN N
of IN N
a DT N
nutrition NN 1_i
intervention NN 1_i
during IN N
early JJ N
childhood NN N
on IN N
economic JJ 1_o
productivity NN 1_o
in IN N
Guatemalan NNP 1_p
adults NNS 1_p
. . 1_p

BACKGROUND NNP N
Substantial NNP N
, , N
but CC N
indirect JJ N
, , N
evidence NN N
suggests VBZ N
that IN N
improving VBG N
nutrition NN N
in IN N
early JJ N
childhood NN N
in IN N
developing VBG N
countries NNS N
is VBZ N
a DT N
long-term JJ N
economic JJ N
investment NN N
. . N

We PRP N
investigated VBD N
the DT N
direct JJ N
effect NN N
of IN N
a DT N
nutrition NN 1_i
intervention NN 1_i
in IN N
early JJ N
childhood NN N
on IN N
adult JJ N
economic JJ N
productivity NN N
. . N

METHODS NNP N
We PRP N
obtained VBD N
economic JJ N
data NNS N
from IN N
1424 CD 1_p
Guatemalan NNP 1_p
individuals NNS 1_p
( ( 1_p
aged VBN 1_p
25-42 CD 1_p
years NNS 1_p
) ) 1_p
between IN 1_p
2002 CD 1_p
and CC 1_p
2004 CD 1_p
. . 1_p

They PRP N
accounted VBD 1_p
for IN 1_p
60 CD 1_p
% NN 1_p
of IN 1_p
the DT 1_p
2392 CD 1_p
children NNS 1_p
( ( 1_p
aged VBN 1_p
0-7 CD 1_p
years NNS 1_p
) ) 1_p
who WP 1_p
had VBD 1_p
been VBN 1_p
enrolled VBN 1_p
in IN 1_p
a DT 1_p
nutrition NN 1_i
intervention NN 1_i
study NN 1_p
during IN 1_p
1969-77 JJ 1_p
. . 1_p

In IN N
this DT N
initial JJ N
study NN N
, , N
two CD N
villages NNS N
were VBD N
randomly RB N
assigned VBN N
a DT N
nutritious JJ 1_i
supplement NN 1_i
( ( 1_i
atole JJ 1_i
) ) 1_i
for IN 1_i
all DT 1_i
children NNS 1_i
and CC 1_i
two CD 1_i
villages NNS 1_i
a DT 1_i
less RBR 1_i
nutritious JJ 1_i
one CD 1_i
( ( 1_i
fresco NN 1_i
) ) 1_i
. . 1_i

We PRP N
estimated VBD N
annual JJ N
income NN N
, , N
hours NNS N
worked VBD N
, , N
and CC N
average JJ N
hourly JJ N
wages NNS N
from IN N
all DT N
economic JJ N
activities NNS N
. . N

We PRP N
used VBD N
linear JJ N
regression NN N
models NNS N
, , N
adjusting VBG N
for IN N
potentially RB N
confounding VBG N
factors NNS N
, , N
to TO N
assess VB N
the DT N
relation NN N
between IN N
economic JJ N
variables NNS N
and CC N
exposure NN N
to TO N
atole VB 1_i
or CC N
fresco VB 1_i
at IN N
specific JJ N
ages NNS N
between IN N
birth NN N
and CC N
7 CD N
years NNS N
. . N

FINDINGS NNP N
Exposure NN N
to TO N
atole VB 1_i
before IN N
, , N
but CC N
not RB N
after IN N
, , N
age NN N
3 CD N
years NNS N
was VBD N
associated VBN N
with IN N
higher JJR N
hourly NN 1_o
wages NNS 1_o
, , N
but CC N
only RB N
for IN N
men NNS N
. . N

For IN N
exposure NN N
to TO N
atole VB N
from IN N
0 CD N
to TO N
2 CD N
years NNS N
, , N
the DT N
increase NN N
was VBD N
US NNP N
$ $ N
0.67 CD N
per IN N
hour NN N
( ( N
95 CD N
% NN N
CI NNP N
0.16-1.17 NN N
) ) N
, , N
which WDT N
meant VBD N
a DT N
46 CD N
% NN N
increase NN N
in IN N
average JJ N
wages NNS N
. . N

There EX N
was VBD N
a DT N
non-significant JJ N
tendency NN 1_o
for IN 1_o
hours NNS 1_o
worked VBN 1_o
to TO N
be VB N
reduced VBN N
and CC N
for IN N
annual JJ 1_o
incomes NNS 1_o
to TO N
be VB N
greater JJR N
for IN N
those DT N
exposed VBN N
to TO N
atole VB 1_i
from IN N
0 CD N
to TO N
2 CD N
years NNS N
. . N

INTERPRETATION NNP N
Improving VBG N
nutrition NN N
in IN N
early JJ N
childhood NN N
led VBD N
to TO N
substantial JJ 1_o
increases NNS 1_o
in IN 1_o
wage NN 1_o
rates NNS 1_o
for IN N
men NNS N
, , N
which WDT N
suggests VBZ N
that IN N
investments NNS N
in IN N
early JJ N
childhood NN N
nutrition NN N
can MD N
be VB N
long-term JJ N
drivers NNS N
of IN N
economic JJ N
growth NN N
. . N

Pulsed VBN 1_i
electromagnetic JJ 1_i
fields NNS 1_i
for IN N
postmenopausal NN 1_p
osteoporosis NN 1_p
and CC 1_p
concomitant JJ 1_p
lumbar NN 1_p
osteoarthritis NN 1_p
in IN 1_p
southwest JJ 1_p
China NNP 1_p
using VBG N
proximal JJ 1_o
femur NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
as IN N
the DT N
primary JJ N
endpoint NN N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Osteoporosis NNP N
( ( N
OP NNP N
) ) N
and CC N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
are VBP N
prevalent JJ N
skeletal JJ N
disorders NNS N
among IN N
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

Coexistence NN N
is VBZ N
common JJ N
especially RB N
that IN N
of IN N
postmenopausal NN N
osteoporosis NN N
( ( N
PMO NNP N
) ) N
and CC N
lumbar $ N
OA NNP N
. . N

An DT N
hypothesis NN N
has VBZ N
been VBN N
raised VBN N
that IN N
OP NNP N
and CC N
OA NNP N
might MD N
share NN N
the DT N
same JJ N
pathogenic JJ N
mechanism NN N
, , N
and CC N
pulsed VBD 1_i
electromagnetic JJ 1_i
fields NNS 1_i
( ( 1_i
PEMFs NNP 1_i
) ) 1_i
were VBD N
reported VBN N
to TO N
have VB N
anti-osteoporosis NN N
and CC N
anti-osteoarthritis NN N
properties NNS N
, , N
but CC N
this DT N
suggestion NN N
was VBD N
based VBN N
primarily RB N
on IN N
biomarker NN N
data NNS N
. . N

Therefore NNP N
, , N
whether IN N
these DT N
two CD N
effects NNS N
could MD N
take VB N
place NN N
simultaneously RB N
has VBZ N
not RB N
yet RB N
been VBN N
investigated VBN N
. . N

This DT N
randomized VBD N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
is VBZ N
designed VBN N
to TO N
explore VB N
the DT N
effect NN N
of IN N
PEMFs NNP 1_i
for IN N
PMO NNP N
and CC N
concomitant JJ N
lumbar NN N
OA NNP N
. . N

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
include VB N
PMO NNP 1_p
patients NNS 1_p
( ( 1_p
postmenopausal JJ 1_p
women NNS 1_p
; : 1_p
aged VBN 1_p
between IN 1_p
50 CD 1_p
and CC 1_p
70 CD 1_p
years NNS 1_p
; : 1_p
have VBP 1_p
been VBN 1_p
postmenopausal VBN 1_p
for IN 1_p
at IN 1_p
least JJS 1_p
5 CD 1_p
years NNS 1_p
and CC 1_p
diagnosed VBD 1_p
with IN 1_p
OP NNP 1_p
using VBG 1_p
proximal JJ 1_p
femur JJ 1_p
T-score NN 1_p
) ) 1_p
with IN 1_p
concomitant JJ 1_p
lumbar NN 1_p
OA NNP 1_p
( ( 1_p
patients NNS 1_p
with IN 1_p
confounding VBG 1_p
disorders NNS 1_p
like IN 1_p
diabetes NNS 1_p
, , 1_p
hypertension NN 1_p
, , 1_p
hyperlipidemia NN 1_p
, , 1_p
and CC 1_p
previous JJ 1_p
fracture NN 1_p
history NN 1_p
, , 1_p
etcetera NN 1_p
, , 1_p
will MD 1_p
be VB 1_p
excluded VBN 1_p
) ) 1_p
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
two CD N
arms NNS N
: : N
PEMFs NNP 1_i
group NN N
and CC N
sham NN 1_i
PEMFs NNP 1_i
group NN 1_i
. . 1_i

There EX N
will MD N
be VB N
25 CD 1_p
participants NNS 1_p
in IN 1_p
each DT 1_p
arm NN 1_p
( ( 1_p
50 CD 1_p
in IN 1_p
total JJ 1_p
) ) 1_p
and CC N
the DT N
outcome NN N
assessment NN N
, , N
including VBG N
the DT N
primary JJ N
endpoint NN N
( ( 1_o
proximal JJ 1_o
femur NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
) ) 1_o
, , N
will MD N
be VB N
performed VBN N
at IN N
5 CD N
weeks NNS N
, , N
3 CD N
months NNS N
and CC N
6 CD N
months NNS N
after IN N
enrollment NN N
. . N

DISCUSSION NNP N
PMO NNP N
and CC N
lumbar NN N
OA NNP N
are VBP N
prominent JJ N
public JJ N
health NN N
problem NN N
, , N
especially RB N
for IN N
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

We PRP N
hope VBP N
this DT N
RCT NNP N
will MD N
provide VB N
scientific JJ N
evidence NN N
to TO N
primary JJ N
care NN N
of IN N
the DT N
postmenopausal JJ N
women NNS N
regarding VBG N
the DT N
use NN N
of IN N
these DT N
nonpharmaceutical JJ N
, , N
noninvasive JJ N
modalities NNS N
, , N
PEMFs NNP 1_i
, , N
in IN N
managing VBG N
PMO NNP N
and CC N
lumbar NN N
OA NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
Chinese NNP N
Clinical NNP N
Trial NNP N
Registry NNP N
: : N
ChiCTR-TRC-14005156 NNP N
( ( N
28 CD N
August NNP N
2014 CD N
) ) N
. . N

Sunlight JJ 1_i
exposure NN 1_i
or CC 1_i
vitamin NN 1_i
D NNP 1_i
supplementation NN 1_i
for IN N
vitamin JJ 1_p
D-deficient JJ 1_p
non-western JJ 1_p
immigrants NNS 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

UNLABELLED NNP N
Vitamin NNP 1_i
D NNP 1_i
deficiency NN N
is VBZ N
very RB N
common JJ N
in IN N
non-western JJ 1_p
immigrants NNS 1_p
. . 1_p

In IN N
this DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
vitamin NN 1_i
D NNP 1_i
800 CD N
IU/day NNP N
or CC N
100,000 CD N
IU/3 JJ N
months NNS N
were VBD N
compared VBN N
with IN N
advised JJ 1_i
sunlight NN 1_i
exposure NN 1_i
. . 1_i

Vitamin NNP 1_i
D NNP 1_i
supplementation NN 1_i
was VBD N
more RBR N
effective JJ N
than IN N
advised JJ 1_i
sunlight JJ 1_i
exposure NN 1_i
in IN N
improving VBG N
vitamin NN N
D NNP N
status NN N
and CC N
lowering VBG N
parathyroid JJ N
hormone NN N
levels NNS N
. . N

INTRODUCTION NNP N
Vitamin NNP N
D NNP N
deficiency NN N
( ( N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
< VBD N
25 CD N
nmol/l NN N
) ) N
is VBZ N
common JJ N
among IN N
non-western JJ N
immigrants NNS N
. . N

It PRP N
can MD N
be VB N
treated VBN N
with IN 1_i
vitamin NN 1_i
D NNP 1_i
supplementation NN 1_i
or CC 1_i
sunlight JJ 1_i
exposure NN 1_i
. . N

METHODS NNP N
To TO N
determine VB N
whether IN N
the DT N
effect NN 1_i
of IN 1_i
vitamin NN 1_i
D NNP 1_i
( ( 1_i
3 CD 1_i
) ) 1_i
supplementation NN 1_i
( ( 1_i
daily JJ 1_i
800 CD 1_i
IU NNP 1_i
or CC 1_i
100,000 CD 1_i
IU/3 NNP 1_i
months NNS 1_i
) ) 1_i
or CC 1_i
sunlight JJ 1_i
exposure NN 1_i
advice NN 1_i
is VBZ N
similar JJ N
with IN N
regard NN N
to TO N
serum VB N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
parathyroid VB N
hormone NN N
( ( N
PTH NNP N
) ) N
concentrations NNS N
. . N

Randomized NNP N
clinical JJ N
trial NN 1_p
in IN 1_p
11 CD 1_p
general JJ 1_p
practices NNS 1_p
in IN 1_p
The DT 1_p
Netherlands NNP 1_p
. . 1_p

Non-western JJ 1_p
immigrants NNS 1_p
, , 1_p
aged VBN 1_p
18-65 CD 1_p
years NNS 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
232 CD 1_p
) ) 1_p
and CC 1_p
serum $ 1_p
25 CD 1_p
( ( 1_p
OH NNP 1_p
) ) 1_p
D NNP 1_p
< $ 1_p
25 CD 1_p
nmol/l NN N
were VBD N
randomly RB N
assigned VBN 1_i
to TO 1_i
supplementation NN 1_i
( ( N
daily JJ N
800 CD N
IU NNP N
or CC N
100,000 CD N
IU/3 NNP 1_i
months NNS 1_i
) ) 1_i
or CC 1_i
advice NN 1_i
for IN 1_i
sunlight JJ 1_i
exposure NN N
for IN N
6 CD N
months NNS N
( ( 1_o
March-September NNP 1_o
) ) 1_o
. . 1_o

Blood NN 1_o
samples NNS N
were VBD N
collected VBN N
at IN N
baseline NN N
, , N
during IN N
treatment NN N
( ( N
3 CD N
months NNS N
, , N
6 CD N
months NNS N
) ) N
, , N
and CC N
at IN N
follow-up JJ N
( ( N
12 CD N
months NNS N
) ) N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
multilevel JJ N
regression NN N
modelling NN N
. . N

RESULTS VB N
The DT N
intention-to-treat JJ N
analysis NN 1_p
included VBD 1_p
211 CD 1_o
persons NNS 1_o
. . 1_o

Baseline NNP 1_o
serum NN 1_o
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
was VBD N
22.5 CD N
± JJ N
11.1 CD N
nmol/l NN N
. . 1_o

After IN 1_o
6 CD 1_o
months NNS 1_o
, , 1_o
mean VBP 1_o
serum JJ N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
increased VBD N
to TO N
53 CD N
nmol/l NNS N
with IN N
800 CD N
IU/day NNP N
, , N
to TO N
50.5 CD N
nmol/l NNS N
with IN N
100,000 CD N
IU/3 NNP N
months NNS N
, , N
and CC N
to TO N
29.1 CD 1_i
nmol/l NNS 1_i
with IN 1_i
advised JJ 1_i
sunlight NN 1_i
exposure NN 1_i
( ( 1_i
supplementation NN 1_i
vs FW N
sunshine NN 1_o
p NN 1_o
< NNP 1_o
0.001 CD 1_o
) ) 1_o
. . N

Serum NNP N
PTH NNP N
decreased VBD N
significantly RB N
in IN N
all DT N
groups NNS N
after IN N
3 CD 1_i
months NNS 1_i
, , 1_i
more RBR 1_i
in IN 1_i
the DT N
supplementation NN 1_i
groups NNS 1_i
than IN 1_i
in IN 1_i
the DT N
advised JJ N
sunlight NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
effect NN N
on IN N
physical JJ N
performance NN N
and CC N
functional JJ 1_i
limitations NNS 1_i
. . 1_i

CONCLUSION NNP 1_i
Vitamin NNP 1_i
D NNP N
supplementation NN 1_i
is VBZ 1_i
more RBR 1_i
effective JJ 1_i
than IN 1_i
advised JJ 1_i
sunlight JJ N
exposure NN N
for IN N
treating VBG 1_p
vitamin NN 1_p
D NNP 1_p
deficiency NN 1_p
in IN 1_p
non-western JJ N
immigrants NNS N
. . N

Unexpected JJ N
random NN N
urinary JJ N
protein NN N
: : N
creatinine NN N
ratio VBZ N
results-limitations NNS N
of IN N
the DT N
pyrocatechol NN 1_i
violet-dye JJ 1_i
method NN 1_i
. . 1_i

BACKGROUND NNP N
For IN N
clinicians NNS N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
rely VB N
on IN N
accurate JJ N
laboratory NN N
results NNS N
for IN N
patient JJ N
care NN N
and CC N
optimal JJ N
use NN N
of IN N
health NN N
care NN N
resources NNS N
. . N

We PRP N
sought VBD N
to TO N
explore VB N
our PRP$ N
observations NNS N
that IN N
urine JJ N
protein NN N
: : N
creatinine JJ N
ratios NNS N
( ( N
PrCr NNP N
) ) N
≥30 NN N
mg/mmol NN N
are VBP N
seen VBN N
not RB N
infrequently RB N
associated VBN N
with IN N
normal JJ N
pregnancy NN N
outcome NN N
. . N

METHODS NNP N
Urine NNP N
samples NNS N
were VBD N
collected VBN N
prospectively RB N
from IN 1_p
160 CD 1_p
pregnant JJ 1_p
women NNS 1_p
attending VBG 1_p
high-risk JJ 1_p
maternity NN 1_p
clinics NNS 1_p
at IN 1_p
a DT 1_p
tertiary JJ 1_p
care NN 1_p
facility NN 1_p
. . N

Urinary NNP N
protein NN N
was VBD N
measured VBN N
using VBG 1_i
a DT 1_i
pyrocatechol NN 1_i
violet NN 1_i
assay NN 1_i
and CC N
urinary JJ N
creatinine NN N
by IN N
an DT 1_i
enzymatic JJ 1_i
method NN 1_i
on IN 1_i
Vitros NNP 1_i
analysers NNS 1_i
. . N

Maternal/perinatal JJ N
outcomes NNS N
were VBD N
abstracted VBN N
from IN N
hospital NN N
records NNS N
. . N

RESULTS VB N
91/233 CD N
( ( N
39.1 CD N
% NN N
) ) N
samples NNS N
had VBD N
a DT N
PrCr NNP N
≥30 NNP N
mg/mmol NN N
, , N
especially RB N
when WRB N
urinary JJ N
creatinine NN N
concentration NN N
was VBD N
< JJ N
3 CD N
mM NN N
( ( N
94.1 CD N
% NN N
) ) N
vs. FW N
≥3 FW N
mM NN N
( ( N
16.4 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

When WRB N
using VBG N
the DT N
last JJ N
sample NN N
before IN N
delivery NN N
, , N
47/160 CD N
( ( N
29.4 CD N
% NN N
) ) N
had VBD N
a DT N
PrCr NNP N
≥30 NNP N
mg/mmol NN N
in IN N
diluted JJ N
urine NN N
vs. IN N
only RB N
17/160 CD N
( ( N
15.4 CD N
% NN N
) ) N
in IN N
more RBR N
concentrated JJ N
urine NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
; : N
PrCr NNP N
positive JJ N
results NNS N
were VBD N
also RB N
more RBR N
frequent JJ N
among IN N
the DT N
32 CD N
( ( N
20.0 CD N
% NN N
) ) N
women NNS N
with IN N
known VBN N
normal JJ N
pregnancy NN N
outcome NN N
( ( N
90.9 CD N
% NN N
vs. FW N
0 CD N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Using VBG N
the DT N
same JJ N
analyser NN N
, , N
0.12 CD N
g/L NN N
urinary JJ N
protein NN N
was VBD N
'detected VBN N
' '' N
in IN N
deionised JJ N
water NN N
. . N

Re-analysis NN N
of IN N
data NNS N
from IN N
two CD N
cohorts NNS N
revealed VBD N
substantially RB N
less JJR N
inflation NN N
of IN N
PrCr NNP N
in IN N
dilute NN N
urine NN N
using VBG N
a DT N
pyrogallol NN N
red JJ N
assay NN N
. . N

CONCLUSIONS NNP N
Random NNP N
urinary JJ N
PrCr NNP N
was VBD N
overestimated VBN N
in IN N
dilute NN N
urine NN N
when WRB 1_i
tested VBN 1_i
using VBG 1_i
a DT 1_i
common JJ 1_i
pyrocatechol NN 1_i
violet NN N
dye-based JJ N
method NN N
. . N

This DT N
effect NN N
was VBD N
reduced VBN N
in IN N
cohorts NNS N
when WRB N
pyrogallol NN N
red VBD N
assays NNS N
were VBD N
used VBN N
. . N

False JJ N
positive JJ N
results NNS N
can MD N
impact VB N
on IN N
diagnosis NN N
and CC N
patient JJ N
care NN N
. . N

This DT N
highlights VBZ N
the DT N
need NN N
for IN N
both DT N
clinical JJ N
and CC N
laboratory JJ N
quality NN N
improvement NN N
projects NNS N
and CC N
standardization NN N
of IN N
laboratory NN N
protein NN N
measurement NN N
. . N

A DT N
randomized VBN N
study NN N
comparing VBG N
the DT N
use NN N
of IN N
the DT N
Ligaclip NNP 1_i
with IN N
bipolar JJ N
energy NN N
to TO N
prevent VB N
lymphocele NN N
during IN N
laparoscopic JJ 1_p
pelvic JJ 1_p
lymphadenectomy NN 1_p
for IN 1_p
gynecologic JJ 1_p
cancer NN 1_p
. . 1_p

OBJECTIVE CC N
This DT N
prospective JJ N
randomized NN N
pilot NN N
study NN N
compared VBN N
the DT N
use NN N
of IN N
the DT N
Ligaclip NNP N
( ( N
Ethicon NNP N
Endo-Surgery NNP N
, , N
Cincinnati NNP N
, , N
OH NNP N
) ) N
with IN N
bipolar JJ N
coagulation NN N
in IN N
preventing VBG N
lymphoceles NNS N
after IN N
laparoscopic NN N
pelvic JJ N
lymphadenectomy NN N
for IN N
gynecologic JJ N
cancer NN N
. . N

STUDY NNP N
DESIGN NNP N
Thirty NNP 1_p
patients NNS 1_p
with IN 1_p
gynecologic JJ 1_p
malignancy NN 1_p
, , 1_p
who WP 1_p
had VBD 1_p
laparoscopic VBN 1_p
pelvic JJ 1_p
lymphadenectomy NN 1_p
were VBD N
randomly RB N
assigned VBN N
for IN N
lymphadenectomy NN 1_i
in IN 1_i
1 CD 1_i
side NN 1_i
of IN 1_i
the DT 1_i
pelvis NN 1_i
using VBG 1_i
the DT 1_i
Ligaclip NNP 1_i
, , N
whereas RB N
, , N
in IN N
the DT N
other JJ N
side NN N
, , N
the DT N
bipolar JJ 1_i
coagulation NN 1_i
to TO 1_i
seal VB 1_i
lymphatic JJ 1_i
vessels NNS 1_i
was VBD N
used VBN N
. . N

RESULTS NNP N
At IN N
ultrasound JJ N
examination NN N
, , N
we PRP N
detected VBD N
lymphocele NNS 1_o
in IN 1_p
10 CD 1_p
patients NNS 1_p
( ( N
33 CD N
% NN N
) ) N
. . N

Lymphocele NNP 1_o
developed VBD N
in IN N
9 CD N
( ( N
30 CD N
% NN N
) ) N
patients NNS N
on IN N
the DT N
side NN N
where WRB N
laparoscopic NN N
pelvic JJ N
lymphadenectomy NN N
was VBD N
perfomed VBN N
using VBG N
bipolar JJ N
coagulation NN N
, , N
and CC N
in IN N
1 CD N
( ( N
3.3 CD N
% NN N
) ) N
patient NN N
on IN N
the DT N
side NN N
where WRB N
laparoscopic NN N
pelvic JJ N
lymphadenectomy NN N
was VBD N
performed VBN N
using VBG N
the DT N
Ligaclip NNP N
. . N

Univariate NNP N
analysis NN N
revealed VBD N
that IN N
the DT N
Ligaclip NNP N
's POS N
use NN N
compared VBN N
with IN N
electrocoagulation NN N
in IN N
the DT N
laparoscopic NN N
pelvic JJ N
lymphadenectomy NN N
is VBZ N
an DT N
independent JJ N
predictive JJ N
factor NN N
for IN N
development NN 1_o
of IN 1_o
lymphocele NN 1_o
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
study NN N
demonstrates VBZ N
that IN N
the DT N
use NN N
of IN N
the DT N
Ligaclip NNP N
to TO N
close VB N
lymphatic JJ N
vessels NNS N
may MD N
reduce VB N
the DT N
incidence NN 1_o
of IN 1_o
lymphoceles NNS 1_o
in IN N
patients NNS 1_p
undergoing VBG 1_p
laparoscopic JJ 1_p
pelvic JJ 1_p
lymphadenectomy NN 1_p
. . 1_p

A DT N
multicenter NN N
study NN N
on IN N
the DT N
use NN N
of IN N
pulsed JJ 1_i
low-intensity NN 1_i
direct JJ 1_i
current JJ 1_i
for IN N
healing VBG N
chronic JJ 1_o
stage NN 1_o
II NNP 1_o
and CC 1_o
stage NN 1_o
III NNP 1_o
decubitus NN 1_o
ulcers NNS 1_o
. . 1_o

BACKGROUND NNP N
AND CC N
DESIGN NNP N
Pulsed VBD 1_i
low-intensity NN 1_i
direct JJ 1_i
current JJ 1_i
( ( 1_i
300 CD 1_i
to TO 1_i
600 CD 1_i
microA NN 1_i
) ) 1_i
has VBZ N
been VBN N
used VBN N
in IN N
a DT N
double-blind JJ N
placebo NN N
multicenter NN N
study NN N
in IN N
the DT N
treatment NN N
of IN N
stage NN 1_o
II NNP 1_o
and CC 1_o
stage NN 1_o
III NNP 1_o
chronic JJ 1_o
decubitus NN 1_o
ulcers NNS 1_o
. . 1_o

RESULTS NNP N
Seventy-four JJ 1_p
ulcers NNS 1_p
were VBD 1_p
treated VBN 1_p
in IN 1_p
four CD 1_p
centers NNS 1_p
. . 1_p

Forty-three JJ 1_p
patients NNS 1_p
were VBD 1_p
selected VBN 1_p
for IN 1_p
the DT 1_p
experimental JJ 1_p
group NN 1_p
, , 1_p
and CC 1_p
31 CD 1_p
control NN 1_p
subjects NNS 1_p
used VBD 1_p
the DT 1_p
sham JJ 1_i
instrument NN 1_i
( ( 1_i
placebo JJ 1_i
group NN 1_i
) ) 1_i
. . 1_i

In IN N
the DT N
treated JJ N
group NN N
, , N
25 CD N
ulcers NNS N
( ( N
58 CD N
% NN N
) ) N
healed VBD N
in IN N
8 CD N
weeks NNS N
, , N
whereas NNS N
in IN N
the DT N
placebo NN N
group NN N
, , N
only RB N
one CD N
ulcer NN N
( ( N
3 CD N
% NN N
) ) N
healed VBN N
and CC N
most JJS N
ulcers NNS 1_o
increased VBD N
in IN N
size NN N
. . N

Statistical JJ N
analysis NN N
, , N
based VBN N
on IN N
surface NN N
area NN N
and CC N
ulcer JJ 1_o
depth NN N
before IN N
and CC N
after IN N
treatment NN N
, , N
showed VBD N
that IN N
low-intensity NN 1_i
direct JJ 1_i
current JJ 1_i
had VBD N
a DT N
significant JJ N
influence NN N
on IN N
the DT N
healing NN 1_o
rates NNS 1_o
for IN N
these DT N
ulcers NNS N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Experiments NNS N
with IN N
guinea NN N
pigs NNS N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
showed VBD N
that IN N
pulsed VBD 1_i
low-intensity NN 1_i
direct JJ 1_i
current JJ 1_i
caused VBD N
a DT N
rapid JJ 1_o
calcium NN 1_o
flux NN 1_o
in IN N
the DT N
epidermis NN N
. . N

CONCLUSIONS NNP N
Pulsed VBD 1_i
low-intensity NN 1_i
direct JJ 1_i
current JJ 1_i
represents VBZ N
a DT N
useful JJ N
approach NN N
for IN N
the DT N
treatment NN N
of IN N
stage NN 1_o
II NNP 1_o
and CC 1_o
stage NN 1_o
III NNP 1_o
chronic JJ 1_o
decubitus NN 1_o
ulcers NNS 1_o
by IN N
increasing VBG N
the DT N
healing NN N
rate NN N
. . N

The DT N
growth NN N
of IN N
fibroblasts NNS N
and CC N
keratinocytes NNS N
may MD N
be VB N
enhanced VBN N
by IN N
pulsed JJ 1_i
low-intensity NN 1_i
direct JJ 1_i
current JJ 1_i
due JJ N
to TO N
changes NNS N
in IN N
calcium NN 1_o
homeostasis NN 1_o
. . 1_o

Can MD N
acupuncture VB 1_i
ease VB N
the DT N
symptoms NNS 1_o
of IN 1_o
menopause NN 1_o
? . N
In IN N
a DT N
randomized JJ N
, , N
2-group JJ N
clinical JJ N
study NN N
, , N
acupuncture NN 1_i
was VBD N
used VBN N
for IN N
the DT N
relief NN N
of IN N
menopausal NN 1_o
hot JJ 1_o
flushes NNS 1_o
, , 1_o
sleep JJ 1_o
disturbances NNS 1_o
, , 1_o
and CC 1_o
mood NN 1_o
changes NNS 1_o
. . 1_o

The DT N
experimental JJ N
acupuncture NN 1_i
treatment NN N
consisted VBD N
of IN N
specific JJ N
acupuncture NN 1_i
body NN N
points NNS N
related VBN N
to TO N
menopausal VB 1_o
symptoms NNS 1_o
. . N

The DT N
comparison JJ N
acupuncture NN 1_i
treatment NN N
consisted VBN N
of IN N
a DT N
treatment NN N
designated VBN N
as IN N
a DT N
general JJ N
tonic NN N
specifically RB N
designed VBN N
to TO N
benefit VB N
the DT N
flow NN N
of IN N
Ch'i NNP N
( ( N
energy NN N
) ) N
. . N

Results NNS N
from IN N
the DT N
experimental JJ 1_p
acupuncture NN 1_i
treatment NN 1_p
group NN 1_p
showed VBD N
a DT N
decrease NN N
in IN N
mean JJ 1_o
monthly JJ 1_o
hot JJ 1_o
flush NN 1_o
severity NN 1_o
for IN N
site-specific JJ N
acupuncture NN N
. . N

The DT N
comparison JJ N
acupuncture NN 1_i
treatment NN 1_p
group NN 1_p
had VBD N
no DT N
significant JJ N
change NN 1_o
in IN 1_o
severity NN 1_o
from IN N
baseline NN N
over IN N
the DT N
treatment NN N
phase NN N
. . N

Sleep JJ 1_o
disturbances NNS 1_o
in IN N
the DT N
experimental JJ 1_p
acupuncture NN 1_i
treatment NN 1_p
group NN 1_p
declined VBD N
over IN N
the DT N
study NN N
. . N

Mood NNP 1_o
changes NNS 1_o
in IN N
both DT N
the DT N
experimental JJ 1_p
acupuncture NN 1_i
treatment NN 1_p
group NN 1_p
and CC 1_p
the DT 1_p
comparison NN 1_p
acupuncture NN 1_p
treatment NN 1_p
group NN 1_p
showed VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
and CC N
the DT N
third JJ N
month NN N
of IN N
the DT N
study NN N
. . N

Acupuncture NNP 1_i
using VBG N
menopausal-specific JJ N
sites NNS N
holds VBZ N
promise NN N
for IN N
nonhormonal JJ N
relief NN 1_o
of IN 1_o
hot JJ 1_o
flushes NNS 1_o
and CC 1_o
sleep JJ 1_o
disturbances NNS 1_o
. . 1_o

Randomized NNP N
clinical JJ N
trial NN N
comparing VBG N
laparoscopic NN 1_i
and CC N
open JJ 1_i
surgery NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
rectal JJ 1_p
cancer NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
laparoscopic NN 1_i
treatment NN 1_i
of IN N
rectal JJ N
cancer NN N
is VBZ N
controversial JJ N
. . N

This DT N
study NN N
compared VBN N
surgical JJ N
outcomes NNS N
after IN N
laparoscopic NN 1_i
and CC N
open JJ N
approaches NNS N
for IN N
mid NN 1_p
and CC 1_p
low JJ 1_p
rectal NN 1_p
cancers NNS 1_p
. . 1_p

METHODS NNP N
Some DT 1_p
204 CD 1_p
patients NNS 1_p
with IN 1_p
mid NNS 1_p
and CC 1_p
low JJ 1_p
rectal NN 1_p
adenocarcinomas NN 1_p
were VBD 1_p
allocated VBN 1_p
randomly RB 1_p
to TO 1_p
open VB 1_i
( ( 1_p
103 CD 1_p
) ) 1_p
or CC 1_i
laparoscopic NN 1_i
( ( 1_i
101 CD 1_i
) ) 1_i
surgery NN 1_i
. . 1_i

The DT N
surgical JJ N
team NN N
was VBD N
the DT N
same JJ N
for IN N
both DT N
procedures NNS N
. . N

Most JJS 1_p
patients NNS 1_p
had VBD 1_p
stage NN 1_p
II NNP 1_p
or CC 1_p
III NNP 1_p
disease NN 1_p
, , N
and CC N
received VBD N
neoadjuvant JJ 1_i
therapy NN 1_i
with IN N
oral JJ 1_i
capecitabine NN 1_i
and CC 1_i
50-54 JJ 1_i
Gy NNP 1_i
external JJ 1_i
beam NN 1_i
radiotherapy NN 1_i
. . 1_i

RESULTS NNP N
Sphincter-preserving JJ 1_i
surgery NN 1_i
was VBD N
performed VBN N
in IN N
78.6 CD N
and CC N
76.2 CD N
per IN N
cent NN N
of IN N
patients NNS N
in IN N
the DT N
open JJ 1_i
and CC N
laparoscopic JJ N
groups NNS N
respectively RB N
. . N

Blood NNP 1_o
loss NN 1_o
was VBD N
significantly RB N
greater JJR N
for IN N
open JJ 1_i
surgery NN 1_i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
operating VBG 1_o
time NN 1_o
was VBD N
significantly RB N
greater JJR N
for IN N
laparoscopic NN 1_i
surgery NN 1_i
( ( N
P NNP N
= NNP N
0.020 CD N
) ) N
, , N
and CC N
return NN N
to TO N
diet VB N
and CC N
hospital VB 1_o
stay NN 1_o
were VBD N
longer JJR N
for IN N
open JJ 1_i
surgery NN 1_i
. . 1_i

Complication NN 1_o
rates NNS 1_o
, , 1_o
and CC 1_o
involvement NN 1_o
of IN 1_o
circumferential JJ 1_o
and CC 1_o
radial JJ 1_o
margins NNS 1_o
were VBD N
similar JJ N
for IN N
both DT N
procedures NNS N
, , N
but CC N
the DT N
number NN N
of IN N
isolated JJ N
lymph NN N
nodes NNS N
was VBD N
greater JJR N
in IN N
the DT N
laparoscopic NN 1_i
group NN N
( ( N
mean JJ N
13.63 CD N
versus NN N
11.57 CD N
; : N
P NNP N
= NNP N
0.026 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
local JJ 1_o
recurrence NN 1_o
, , 1_o
disease-free JJ 1_o
or CC 1_o
overall JJ 1_o
survival NN 1_o
. . 1_o

CONCLUSION NNP N
Laparoscopic NNP 1_i
surgery NN 1_i
for IN N
rectal JJ N
cancer NN N
has VBZ N
a DT N
similar JJ N
complication NN N
rate NN N
to TO N
open VB 1_i
surgery NN 1_i
, , N
with IN N
less JJR N
blood NN 1_o
loss NN 1_o
, , N
rapid JJ N
intestinal JJ 1_o
recovery NN 1_o
, , N
shorter JJR N
hospital NN 1_o
stay NN 1_o
, , N
and CC N
no DT N
compromise NN N
of IN N
oncological JJ 1_o
outcomes NNS 1_o
. . 1_o

A DT N
randomised JJ N
trial NN N
evaluating VBG N
pain NN 1_o
and CC 1_o
bleeding NN 1_o
after IN 1_p
a DT 1_p
first JJ 1_p
trimester NN 1_p
miscarriage NN 1_p
treated VBD 1_p
surgically RB 1_p
or CC 1_p
medically RB 1_p
. . 1_p

Miscarriage NN N
treated VBD N
surgically RB 1_i
and CC 1_i
medically RB 1_i
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
evaluating VBG N
pain NN 1_o
and CC 1_o
bleeding NN 1_o
. . 1_o

Surgery NN N
is VBZ N
associated VBN N
with IN N
less JJR 1_o
pain NN 1_o
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
and CC N
vaginal JJ 1_o
bleeding NN 1_o
( ( N
duration NN N
and CC N
severity NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
than IN N
medical JJ N
treatment NN N
, , N
fewer JJR 1_o
daily JJ 1_o
hospital NN 1_o
attendances NNS 1_o
( ( N
2.5 CD N
compared VBN N
with IN N
three CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
but CC N
a DT N
greater JJR N
drop NN N
in IN N
haemoglobin JJ N
concentration NN N
( ( N
difference NN N
, , N
1 CD N
g/dl NN N
; : N
CI95 NNP N
% NN N
= NNP N
0.3-1.6 NN N
) ) N
. . N

Naltrexone NN 1_i
and CC N
communication NN N
skills NNS N
in IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
naltrexone NN 1_i
on IN N
communication NN N
skills NNS N
of IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

METHOD NNP N
Twenty-four JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
, , 1_p
3.0 CD 1_p
to TO 1_p
8.3 CD 1_p
years NNS 1_p
old JJ 1_p
( ( 1_p
mean JJ 1_p
5.1 CD 1_p
) ) 1_p
who WP 1_p
were VBD 1_p
living VBG 1_p
at IN 1_p
home NN 1_p
and CC 1_p
attending VBG 1_p
appropriate JJ 1_p
school NN 1_p
programs NNS 1_p
, , N
participated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
trial NN N
. . N

Naltrexone NNP 1_i
, , 1_i
1.0 CD 1_i
mg/kg NN 1_i
, , 1_i
or CC 1_i
placebo NN 1_i
was VBD 1_i
administered VBN 1_i
daily RB 1_i
for IN 1_i
2 CD 1_i
weeks NNS 1_i
. . 1_i

Communication NN N
was VBD N
evaluated VBN N
from IN N
videotaped JJ 1_i
samples NNS 1_i
of IN 1_i
seminaturalistic JJ 1_i
parent-child JJ 1_i
interaction NN 1_i
. . 1_i

Child NN N
and CC N
parent NN N
language NN N
were VBD N
assessed VBN N
using VBG N
similar JJ N
measures NNS N
. . N

RESULTS NNP N
In IN N
this DT N
heterogeneous JJ N
sample NN N
, , N
the DT N
median JJ 1_o
number NN 1_o
of IN 1_o
words NNS 1_o
the DT 1_o
child NN 1_o
produced VBN 1_o
on IN N
placebo NN N
was VBD N
9.5 CD N
( ( N
range VB N
0-124 NN N
) ) N
. . N

The DT N
median JJ 1_o
proportion NN 1_o
of IN 1_o
utterances NNS 1_o
with IN 1_o
echolalia NN 1_o
was VBD N
0.16 CD N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
naltrexone NN 1_i
and CC N
placebo NN 1_i
conditions NNS N
in IN N
any DT N
of IN N
the DT N
measures NNS N
of IN N
children NNS 1_o
or CC 1_o
parents NNS 1_o
' POS 1_o
communication NN 1_o
. . 1_o

Significant JJ N
correlations NNS N
were VBD N
found VBN N
between IN N
the DT N
child NN 1_o
's POS 1_o
number NN 1_o
of IN 1_o
words NNS 1_o
and CC 1_o
developmental JJ 1_o
quotient NN 1_o
( ( N
Spearman NNP N
rho VBZ N
= JJ N
0.58 CD N
, , N
p NN N
= NNP N
.003 NNP N
) ) N
and CC N
between IN N
the DT N
child NN N
's POS N
and CC N
parent NN N
's POS N
number NN N
of IN N
words NNS N
( ( N
rho VB N
= RB N
0.55 CD N
, , N
p NN N
= NNP N
.005 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Previous NNP N
studies NNS N
showed VBD N
that IN N
naltrexone NN 1_i
was VBD N
associated VBN N
with IN N
modest JJ N
reduction NN N
in IN N
hyperactivity NN N
and CC N
restlessness NN N
in IN N
this DT N
group NN N
of IN N
children NNS N
with IN N
autism NN N
. . N

In IN N
this DT N
short-term JJ N
study NN N
, , N
the DT N
medication NN N
did VBD N
not RB N
lead VB N
to TO N
improvement NN N
in IN N
communication NN N
, , N
a DT N
core NN N
deficit NN N
of IN N
autism NN N
. . N

Double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
pentoxifylline NN 1_i
added VBN 1_i
to TO 1_i
risperidone VB 1_i
: : 1_i
effects NNS N
on IN N
aberrant JJ 1_o
behavior NN 1_o
in IN 1_o
children NNS 1_o
with IN 1_o
autism NN 1_o
. . 1_o

BACKGROUND IN N
There EX N
are VBP N
several JJ N
lines NNS N
of IN N
evidence NN N
to TO N
indicate VB N
that IN N
the DT N
immune NN N
system NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
pathophysiology NN N
of IN N
autism NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
access NN N
the DT N
effects NNS N
of IN N
pentoxifylline NN 1_i
plus CC 1_i
risperidone NN 1_i
in IN N
the DT N
treatment NN 1_o
of IN 1_o
autistic JJ 1_o
disorder NN 1_o
. . 1_o

METHODS NNP N
Forty NNP 1_p
children NNS 1_p
between IN 1_p
the DT 1_p
ages NNS 1_p
4 CD 1_p
and CC 1_p
12 CD 1_p
years NNS 1_p
with IN 1_p
a DT 1_p
DSM NNP 1_p
IV-TR NNP 1_p
clinical JJ 1_p
diagnosis NN 1_p
of IN 1_p
autism NN 1_p
were VBD 1_p
recruited VBN 1_p
. . 1_p

The DT 1_p
children NNS 1_p
presented VBN 1_p
with IN 1_p
a DT 1_p
chief JJ 1_p
complaint NN 1_p
of IN 1_p
severely RB 1_p
disruptive JJ 1_p
symptoms NNS 1_p
related VBN 1_p
to TO 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
pentoxifylline+risperidone VB 1_i
or CC 1_i
placebo+risperidone VB 1_i
for IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN 1_i
was VBD N
titrated VBN N
up RB N
to TO N
3 CD N
mg/day NN N
, , N
pentoxifylline NN 1_i
was VBD N
titrated VBN N
to TO N
600 CD N
mg/day NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist-Community NNP 1_o
( ( 1_o
ABC-C NNP 1_o
) ) 1_o
. . 1_o

RESULTS VB N
The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD N
pentoxifylline NN 1_i
had VBD N
greater JJR N
reduction NN N
in IN N
ABC-C NNP 1_o
subscale NN 1_o
scores NNS 1_o
for IN 1_o
Irritability NNP 1_o
, , 1_o
Lethargy/Social NNP 1_o
Withdrawal NNP 1_o
, , 1_o
Stereotypic NNP 1_o
Behavior NNP 1_o
, , 1_o
Hyperactivity/Noncompliance NNP 1_o
and CC 1_o
Inappropriate NNP 1_o
Speech NNP 1_o
. . 1_o

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
combination NN 1_i
of IN 1_i
atypical JJ 1_i
antipsychotic JJ 1_i
medications NNS 1_i
and CC 1_i
pentoxifylline NN 1_i
might MD N
have VB N
synergistic JJ N
effects NNS N
in IN N
treatment NN N
of IN N
behavioral JJ 1_o
problems NNS 1_o
of IN 1_o
children NNS 1_o
with IN 1_o
autism NN 1_o
. . 1_o

No DT N
effect NN N
of IN N
beta-carotene JJ 1_i
supplementation NN 1_i
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
to TO N
in IN 1_o
vitro JJ 1_o
oxidation NN 1_o
among IN 1_p
hypercholesterolaemic JJ 1_p
, , 1_p
postmenopausal JJ 1_p
women NNS 1_p
. . 1_p

The DT N
effect NN N
of IN N
beta-carotene NN 1_i
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
to TO N
oxidative JJ N
modification NN N
was VBD N
investigated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
placebo-controlled JJ N
study NN N
. . N

Hypercholesterolaemic NNP 1_p
, , 1_p
postmenopausal JJ 1_p
women NNS 1_p
were VBD N
given VBN N
30 CD 1_i
mg JJ 1_i
beta-carotene JJ 1_i
per IN 1_i
day NN 1_i
( ( N
n JJ N
= $ N
15 CD N
subjects NNS N
) ) N
or CC N
placebo JJ 1_i
capsules NNS 1_i
( ( N
n JJ N
= $ N
15 CD N
subjects NNS N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

They PRP N
were VBD N
instructed VBN N
to TO N
follow VB N
the DT N
American NNP N
Heart NNP N
Association NNP N
Step NNP N
One NNP N
diet NN N
. . N

LDL NNP N
, , N
isolated VBD N
before IN N
and CC N
after IN N
treatment NN N
was VBD N
subjected VBN N
to TO N
copper-catalysed JJ N
lipid JJ N
peroxidation NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
LDL NNP 1_o
from IN 1_o
the DT 1_o
beta-carotene NN 1_o
and CC N
placebo NN 1_i
groups NNS N
, , N
as IN N
assessed VBN N
by IN N
measuring VBG N
the DT N
lag NN 1_o
time NN 1_o
for IN 1_o
formation NN 1_o
of IN 1_o
conjugated JJ 1_o
dienes NNS 1_o
; : 1_o
the DT N
rate NN 1_o
of IN 1_o
formation NN 1_o
and CC 1_o
the DT 1_o
amount NN 1_o
of IN 1_o
conjugated VBN 1_o
dienes NNS 1_o
formed VBN 1_o
; : 1_o
the DT N
amount NN 1_o
of IN 1_o
lipid JJ 1_o
peroxides NNS 1_o
generated VBD 1_o
; : 1_o
and CC N
the DT N
relative JJ N
electrophoretic JJ 1_o
mobility NN 1_o
, , N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
. . N

Dietary JJ N
records NNS N
showed VBD N
that IN N
the DT N
subjects NNS N
were VBD N
consuming VBG N
similar JJ N
amounts NNS N
and CC N
types NNS N
of IN N
fat NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
lipid JJ 1_o
composition NN 1_o
and CC 1_o
fatty JJ 1_o
acid JJ 1_o
pattern NN 1_o
of IN 1_o
LDL NNP 1_o
from IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
results NNS N
indicated VBD N
that IN N
supplementation NN N
with IN N
beta-carotene JJ 1_i
in IN N
non-smoking JJ 1_p
, , 1_p
hypercholesterolaemic JJ 1_p
, , 1_p
postmenopausal JJ 1_p
women NNS 1_p
had VBD N
no DT N
protective JJ 1_o
effect NN 1_o
on IN N
the DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
copper-catalysed JJ N
modification NN N
in IN N
vitro NN N
. . N

Effect NN N
of IN N
nitric-oxide-generating JJ 1_i
system NN 1_i
on IN N
microcirculatory NN 1_o
blood NN 1_o
flow NN 1_o
in IN N
skin NN N
of IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
Raynaud NNP 1_p
's POS 1_p
syndrome NN 1_p
: : 1_p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS 1_p
with IN 1_p
Raynaud NNP 1_p
's POS 1_p
syndrome NN 1_p
have VBP N
abnormal JJ N
digital JJ N
vasoconstriction NN N
, , N
which WDT N
may MD N
be VB N
secondary JJ N
to TO N
impaired JJ N
synthesis NN N
of IN N
, , N
or CC N
impaired JJ N
sensitivity NN N
to TO N
, , N
nitric JJ N
oxide NN N
. . N

We PRP N
studied VBD N
the DT N
effect NN N
on IN N
microcirculation NN N
of IN N
a DT N
nitric-oxide-generating JJ 1_i
system NN 1_i
applied VBN N
topically RB N
to TO N
the DT N
finger NN N
and CC N
forearm NN N
of IN N
healthy JJ 1_p
volunteers NNS 1_p
and CC 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
Raynaud NNP 1_p
's POS 1_p
syndrome NN 1_p
. . 1_p

METHODS NNP N
We PRP N
did VBD N
a DT N
single-blind NN N
, , N
randomised VBN N
, , N
placebo NN N
controlled VBD N
, , N
cross-over NN N
study NN N
of IN N
the DT N
microcirculatory NN 1_o
response NN 1_o
to TO N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxidegenerating JJ 1_i
gel NN 1_i
in IN N
20 CD 1_p
patients NNS 1_p
with IN 1_p
severe JJ 1_p
Raynaud NNP 1_p
's POS 1_p
syndrome NN 1_p
, , 1_p
and CC 1_p
ten RB 1_p
healthy JJ 1_p
volunteers NNS 1_p
. . 1_p

We PRP 1_i
prepared VBD 1_i
the DT 1_i
nitric-oxide-generating JJ 1_i
system NN 1_i
by IN 1_i
mixing VBG 1_i
a DT 1_i
solution NN 1_i
of IN 1_i
KY NNP 1_i
jelly RB 1_i
and CC 1_i
sodium JJ 1_i
nitrite NN 1_i
( ( 1_i
5 CD 1_i
% NN 1_i
weight/volume NN 1_i
) ) 1_i
, , 1_i
with IN 1_i
a DT 1_i
solution NN 1_i
of IN 1_i
KY NNP 1_i
jelly RB 1_i
and CC 1_i
ascorbic JJ 1_i
acid NN 1_i
( ( 1_i
5 CD 1_i
% NN 1_i
weight/volume NN 1_i
) ) 1_i
. . N

About IN 1_i
0.5 CD 1_i
mL NNS 1_i
of IN 1_i
each DT 1_i
solution NN 1_i
was VBD 1_i
separately RB 1_i
applied VBN 1_i
to TO 1_i
the DT 1_i
skin NN 1_i
of IN 1_i
the DT 1_i
forearm NN 1_i
( ( 1_i
3 CD 1_i
cm2 NN 1_i
) ) 1_i
, , 1_i
and CC 1_i
then RB 1_i
mixed JJ 1_i
with IN 1_i
a DT 1_i
sterile JJ 1_i
cotton NN 1_i
bud NN 1_i
. . 1_i

A DT 1_i
similar JJ 1_i
procedure NN 1_i
was VBD 1_i
done VBN 1_i
simultaneously RB 1_i
on IN 1_i
the DT 1_i
other JJ 1_i
arm NN 1_i
with IN 1_i
KY NNP 1_i
jelly RB 1_i
only RB 1_i
( ( 1_i
placebo NN 1_i
) ) 1_i
. . N

The DT N
procedure NN N
was VBD N
then RB N
repeated VBN N
on IN N
the DT N
finger NN N
pulps VBZ N
. . N

Changes NNS 1_o
in IN 1_o
skin JJ 1_o
microcirculatory NN 1_o
volume NN 1_o
and CC 1_o
flux NN 1_o
were VBD N
measured VBN N
bilaterally RB N
by IN N
infrared JJ N
photoplethysmography NN N
and CC N
laser NN N
doppler NN N
fluxmetry NN N
, , N
respectively RB N
. . N

FINDINGS NNP N
In IN N
the DT N
forearm NN N
, , N
blood NN 1_o
flow NN 1_o
increased VBD N
significantly RB N
after IN N
application NN N
of IN N
the DT N
active JJ N
gel NN N
both DT N
in IN N
patients NNS N
with IN N
Raynaud NNP N
's POS N
syndrome NN N
( ( N
microcirculatory JJ N
volume NN N
from IN N
mean JJ N
area NN N
under IN N
the DT N
curve NN N
98 CD N
[ NNP N
SE NNP N
14 CD N
] NN N
to TO N
1024 CD N
[ NN N
130 CD N
] NN N
; : N
microcirculatory JJ N
flux NN N
from IN N
5060 CD N
[ $ N
462 CD N
] NN N
to TO N
74,800 CD N
[ NN N
3940 CD N
] NN N
) ) N
and CC N
in IN N
healthy JJ N
controls NNS N
( ( N
volume NN N
from IN N
85 CD N
[ $ N
19 CD N
] NN N
to TO N
1020 CD N
[ NN N
60 CD N
] NN N
; : N
flux NN N
from IN N
4420 CD N
[ $ N
435 CD N
] NN N
to TO N
84,500 CD N
[ NN N
7000 CD N
] NN N
) ) N
. . N

In IN N
the DT N
fingers NNS N
, , N
although IN N
baseline NN 1_o
blood NN 1_o
flow NN 1_o
was VBD N
lower JJR N
in IN N
patients NNS N
than IN N
in IN N
controls NNS N
, , N
both DT N
groups NNS N
showed VBD N
increases NNS N
with IN N
application NN N
of IN N
active JJ N
gel NN N
( ( N
volume NN N
from IN N
1100 CD N
[ $ N
194 CD N
] NN N
to TO N
3280 CD N
[ NN N
672 CD N
] NN N
and CC N
2380 CD N
[ NN N
441 CD N
] NN N
to TO N
6160 CD N
[ NN N
1160 CD N
] NN N
, , N
respectively RB N
; : N
flux NN 1_o
from IN N
33,400 CD N
[ JJ N
4200 CD N
] NN N
to TO N
108,000 CD N
[ NNS N
13,600 CD N
] NNS N
and CC N
52,000 CD N
[ NN N
8950 CD N
] NN N
to TO N
185,000 CD N
[ NNS N
19,500 CD N
] NN N
) ) N
. . N

Increases VBZ N
in IN N
blood NN 1_o
flow NN 1_o
with IN N
placebo JJ N
gel NNS N
were VBD N
not RB N
significant JJ N
. . N

No DT N
adverse JJ N
effects NNS N
were VBD N
reported VBN N
. . N

INTERPRETATION NNP N
In IN N
primary JJ 1_p
Raynaud NNP 1_p
's POS 1_p
syndrome NN 1_p
, , N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxide-generating JJ 1_i
system NN 1_i
can MD N
stimulate VB N
an DT N
increase NN N
in IN N
both DT N
microcirculatory JJ 1_o
volume NN 1_o
and CC 1_o
flux NN 1_o
. . 1_o

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
cognitive JJ 1_i
behavioural JJ 1_i
intervention NN 1_i
for IN N
anger JJ N
management NN N
in IN N
children NNS 1_p
diagnosed VBN 1_p
with IN 1_p
Asperger NNP 1_p
syndrome NN 1_p
. . 1_p

The DT N
purpose NN N
of IN N
the DT N
study NN N
described VBD N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive JJ N
behavioural JJ N
intervention NN N
for IN N
anger JJ N
management NN N
with IN N
children NNS 1_p
diagnosed VBN 1_p
with IN 1_p
Asperger NNP 1_p
syndrome NN 1_p
. . 1_p

Forty-five JJ 1_p
children NNS 1_p
and CC 1_p
their PRP$ 1_p
parents NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
intervention NN 1_i
or CC N
wait-list JJ 1_i
control NN 1_i
conditions NNS 1_i
. . 1_i

Children NNP N
in IN N
the DT N
intervention NN N
participated VBD N
in IN N
six CD 1_i
2-h JJ 1_i
weekly JJ 1_i
sessions NNS 1_i
while IN N
parents NNS N
participated VBN N
in IN N
a DT N
larger JJR N
parent NN N
group NN N
. . N

Parent NN N
reports NNS N
indicated VBD N
a DT N
significant JJ N
decrease NN N
in IN N
episodes NNS 1_o
of IN 1_o
anger NN 1_o
following VBG N
intervention NN N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
their PRP$ N
own JJ N
confidence NN 1_o
in IN N
managing VBG 1_o
anger NN 1_o
in IN 1_o
their PRP$ 1_o
child NN 1_o
. . 1_o

Qualitative JJ N
information NN N
gathered VBN N
from IN N
parents NNS N
and CC N
teachers NNS N
indicated VBD N
some DT N
generalization NN N
of IN N
strategies NNS N
learned VBN N
in IN N
the DT N
clinic JJ N
setting NN N
to TO N
both DT N
home NN N
and CC N
school NN N
settings NNS N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
also RB N
discussed VBN N
. . N

The DT N
effect NN N
of IN N
modified VBN 1_i
eggs NNS 1_i
and CC 1_i
an DT 1_i
egg-yolk NN 1_i
based VBN 1_i
beverage NN 1_i
on IN 1_p
serum NN 1_o
lutein NN 1_o
and CC 1_o
zeaxanthin JJ 1_o
concentrations NNS 1_o
and CC N
macular JJ N
pigment NN N
optical JJ N
density NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

UNLABELLED CC N
Increasing VBG N
evidence NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
lutein NN N
and CC N
zeaxanthin NN N
on IN N
the DT N
progression NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
lutein NN 1_i
or CC 1_i
zeaxanthin NN 1_i
enriched VBN 1_i
eggs NNS 1_i
or CC 1_i
a DT 1_i
lutein JJ 1_i
enriched VBN 1_i
egg-yolk NN 1_i
based VBN 1_i
buttermilk NN 1_i
beverage NN 1_i
on IN N
serum NN 1_o
lutein NN 1_o
and CC 1_o
zeaxanthin JJ 1_o
concentrations NNS 1_o
and CC N
macular JJ N
pigment NN N
levels NNS N
. . N

Naturally RB 1_i
enriched VBN 1_i
eggs NNS 1_i
were VBD N
made VBN N
by IN N
increasing VBG N
the DT N
levels NNS N
of IN N
the DT N
xanthophylls NNP N
lutein NN N
and CC N
zeaxanthin NN 1_i
in IN N
the DT N
feed NN N
given VBN N
to TO N
laying VBG N
hens NNS N
. . N

One CD 1_p
hundred VBD 1_p
healthy JJ 1_p
volunteers NNS 1_p
were VBD 1_p
recruited VBN 1_p
and CC 1_p
randomized VBN 1_p
into IN 1_p
5 CD 1_p
groups NNS 1_p
for IN 1_p
90 CD 1_p
days NNS 1_p
. . 1_p

Group NNP N
one CD N
added VBD N
one CD 1_i
normal JJ 1_i
egg NN 1_i
to TO 1_i
their PRP$ 1_i
daily JJ 1_i
diet NNS 1_i
and CC N
group NN 1_i
two CD 1_i
received VBD 1_i
a DT 1_i
lutein NN 1_i
enriched VBD 1_i
egg-yolk NN 1_i
based VBN 1_i
beverage NN 1_i
. . 1_i

Group NNP N
three CD N
added VBD N
one CD 1_i
lutein NN 1_i
enriched VBD 1_i
egg NN 1_i
and CC N
group NN 1_i
four CD 1_i
one CD 1_i
zeaxanthin NN 1_i
enriched VBD 1_i
egg NN 1_i
to TO 1_i
their PRP$ 1_i
diet JJ 1_i
. . 1_i

Group NNP N
five CD N
was VBD N
the DT N
control NN 1_i
group NN 1_i
and CC 1_i
individuals NNS 1_i
in IN 1_i
this DT 1_i
group NN 1_i
did VBD 1_i
not RB 1_i
modify VB 1_i
their PRP$ 1_i
daily JJ 1_i
diet NN 1_i
. . 1_i

Serum NNP 1_o
lutein NN 1_o
and CC 1_o
zeaxanthin JJ 1_o
concentrations NNS 1_o
and CC N
macular JJ 1_o
pigment NN 1_o
densities NNS 1_o
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
day NN N
45 CD N
and CC N
day NN N
90 CD N
. . N

Macular JJ 1_o
pigment NN 1_o
density NN 1_o
was VBD N
measured VBN N
by IN N
heterochromatic JJ N
flicker NN N
photometry NN N
. . N

Serum NNP 1_o
lutein JJ 1_o
concentration NN 1_o
in IN N
the DT N
lutein NN N
enriched VBD N
egg NN N
and CC N
egg NN N
yolk-based JJ N
beverage NN N
groups NNS N
increased VBD N
significantly RB N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
76 CD N
% NN N
and CC N
77 CD N
% NN N
) ) N
. . N

A DT N
strong JJ N
increase NN N
in IN N
the DT N
serum NN 1_o
zeaxanthin NN 1_o
concentration NN 1_o
was VBD N
observed VBN N
in IN N
individuals NNS N
receiving VBG N
zeaxanthin NN 1_i
enriched VBN 1_i
eggs NNS 1_i
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
430 CD N
% NN N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
in IN N
macular JJ 1_o
pigment NN 1_o
density NN 1_o
in IN N
the DT N
various JJ N
groups NNS N
tested VBN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
daily JJ N
consumption NN N
of IN N
lutein NN 1_i
or CC 1_i
zeaxanthin NN 1_i
enriched VBN 1_i
egg NN 1_i
yolks NNS 1_i
as RB N
well RB N
as IN N
an DT N
egg NN 1_i
yolk-based JJ 1_i
beverage NN 1_i
show NN N
increases VBZ N
in IN N
serum NN 1_o
lutein NN 1_o
and CC 1_o
zeaxanthin NN 1_o
levels NNS 1_o
that WDT N
are VBP N
comparable JJ N
with IN N
a DT N
daily JJ N
use NN N
of IN N
5 CD N
mg NN N
supplements NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00527553 NNP N
. . N

Flow-cytometric JJ N
studies NNS N
with IN N
eleutherococcus JJ 1_i
senticosus NN 1_i
extract NN 1_i
as IN N
an DT N
immunomodulatory NN N
agent NN N
. . N

A DT N
placebo-controlled JJ 1_i
study NN N
of IN N
the DT N
effect NN N
of IN N
an DT N
Eleutherococcus NNP 1_i
senticosus NN 1_i
extract NN 1_i
( ( 1_i
Eleukokk NNP 1_i
) ) 1_i
on IN N
the DT N
immune NN 1_p
system NN 1_p
was VBD N
performed VBN N
with IN N
36 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
utilising VBG 1_p
quantitative JJ 1_p
multi-parameter NN 1_p
flow NN 1_p
cytometry NN 1_p
with IN 1_p
monoclonal JJ 1_p
antibodies NNS 1_p
directed VBN 1_p
against IN 1_p
specific JJ 1_p
surface NN 1_p
markers NNS 1_p
of IN 1_p
human JJ 1_p
lymphocyte JJ 1_p
subsets NNS 1_p
. . 1_p

Volunteers NNS N
in IN N
the DT N
verum NN N
group NN N
received VBD N
10 CD N
ml NN N
of IN N
an DT N
ethanolic JJ 1_i
( ( 1_i
vincamine JJ 1_i
free JJ 1_i
) ) 1_i
eleutherococcus VBP 1_i
senticosus JJ 1_i
preparation NN 1_i
, , N
3 CD N
times NNS N
daily RB N
for IN N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
placebo NN 1_i
, , 1_i
the DT 1_i
eleutherococcus NN 1_i
extract NN 1_i
was VBD 1_i
substituted VBN 1_i
by IN 1_i
additional JJ 1_i
wine NN 1_i
, , 1_i
resulting VBG 1_i
in IN 1_i
identical JJ 1_i
final JJ 1_i
concentrations NNS 1_i
of IN 1_i
ethanol NN 1_i
in IN 1_i
both DT 1_i
preparations NNS 1_i
. . 1_i

The DT N
purpose NN N
of IN N
the DT N
double-blind NN N
study NN N
was VBD N
the DT N
demonstration NN N
of IN N
possible JJ N
effects NNS N
on IN N
the DT N
cellular JJ 1_o
immune NN 1_o
status NN 1_o
, , N
as IN N
determined VBN N
by IN N
quantitative JJ 1_o
flow NN 1_o
cytometry NN 1_o
. . 1_o

The DT N
most RBS N
salient JJ N
feature NN N
in IN N
the DT N
verum NN N
group NN N
was VBD N
a DT N
drastic JJ N
increase NN N
in IN N
the DT N
absolute JJ 1_o
number NN 1_o
of IN 1_o
immunocompetent JJ 1_o
cells NNS 1_o
, , N
with IN N
an DT N
especially RB N
pronounced JJ N
effect NN N
on IN N
T NNP 1_o
lymphocytes NNS 1_o
, , N
predominantly RB N
of IN N
the DT N
helper/inducer NN 1_o
type NN 1_o
, , N
but CC N
also RB N
on IN N
cytotoxic NN 1_o
and CC 1_o
natural JJ 1_o
killer NN 1_o
cells NNS 1_o
. . 1_o

In IN N
addition NN N
, , N
a DT N
general JJ N
enhancement NN N
of IN N
the DT N
activation NN 1_o
state NN 1_o
of IN 1_o
T NNP 1_o
lymphocytes NNS 1_o
was VBD N
observed VBN N
. . N

No DT N
side NN 1_o
effects NNS 1_o
were VBD N
observed VBN N
during IN N
the DT N
trial NN N
or CC N
afterwards NNS N
( ( N
observation NN N
period NN N
6 CD N
months NNS N
) ) N
. . N

Effects NNS N
of IN N
piracetam NN 1_i
on IN N
regional JJ N
cerebral JJ 1_o
blood NN 1_o
flow NN 1_o
and CC 1_o
mental JJ 1_o
functions NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
organic JJ 1_p
dementia NN 1_p
. . 1_p

The DT N
effects NNS N
of IN N
piracetam NN 1_i
( ( N
Nootropil NNP N
, , N
UCB6215 NNP N
) ) N
on IN N
mental JJ 1_o
functions NNS 1_o
and CC 1_o
on IN 1_o
regional JJ 1_o
cerebral JJ 1_o
blood NN 1_o
flow NN 1_o
( ( 1_o
rCBF NN 1_o
) ) 1_o
were VBD N
investigated VBN N
in IN N
eight CD 1_p
patients NNS 1_p
in IN 1_p
the DT 1_p
presenile JJ 1_p
age NN 1_p
who WP 1_p
displayed VBD 1_p
symptoms NNS 1_p
of IN 1_p
moderate JJ 1_p
dementia NN 1_p
. . 1_p

The DT N
double-blind JJ N
crossover NN N
design NN N
included VBD N
nine CD N
measurement NN N
occasions NNS N
, , N
each DT N
involving VBG N
rCBF NN 1_o
measurement NN 1_o
by IN N
the DT N
133-Xe JJ 1_i
inhalation NN 1_i
method NN 1_i
, , N
ratings NNS N
of IN N
symptoms NNS N
of IN N
dementia NN N
, , N
personality NN N
changes NNS N
, , N
and CC N
side NN N
effects NNS N
, , N
and CC N
a DT N
psychometric JJ N
investigation NN N
. . N

Three CD N
investigations NNS N
were VBD N
included VBN N
in IN N
each DT N
of IN N
three CD N
treatment NN N
periods NNS N
. . N

The DT N
first JJ N
investigation NN N
in IN N
a DT N
period NN N
was VBD N
made VBN N
without IN N
medication NN N
. . N

Then RB N
either DT N
placebo NN 1_i
or CC 1_i
piracetam VB 1_i
4.8 CD N
g/day NN N
or CC N
9.6 CD N
g/day NN N
was VBD N
given VBN N
during IN N
four CD N
weeks NNS N
with IN N
measurements NNS N
after IN N
2 CD N
weekks NN N
and CC N
4 CD N
weeks NNS N
. . N

There EX N
were VBD N
intervals NNS N
of IN N
4 CD N
weeks NNS N
without IN N
medication NN N
between IN N
the DT N
treatment NN N
periods NNS N
. . N

Piracetam NNP 1_i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
either CC N
mental JJ 1_o
functions NNS 1_o
or CC 1_o
rCBF NN 1_o
. . 1_o

Using VBG N
the DT N
virtual JJ 1_i
reality-cognitive JJ 1_i
rehabilitation NN 1_i
approach NN N
to TO N
improve VB N
contextual JJ 1_o
processing NN 1_o
in IN 1_o
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

BACKGROUND NNP N
This DT N
pilot NN N
study NN N
investigated VBD N
the DT N
efficacy NN N
of IN N
a DT N
novel JJ 1_i
virtual JJ 1_i
reality-cognitive JJ 1_i
rehabilitation NN 1_i
( ( 1_i
VR-CR NNP 1_i
) ) 1_i
intervention NN 1_i
to TO N
improve VB N
contextual JJ 1_o
processing NN 1_o
of IN N
objects NNS N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Previous JJ N
research NN N
supports VBZ N
that IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
show NN N
deficits NNS N
in IN N
contextual JJ 1_o
processing NN 1_o
, , N
as RB N
well RB N
as IN N
deficits NNS N
in IN N
its PRP$ N
elementary JJ N
components NNS N
: : N
abstraction NN 1_o
and CC 1_o
cognitive JJ 1_o
flexibility NN 1_o
. . 1_o

METHODS NNP N
Four CD 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
participated VBN N
in IN N
a DT N
multiple-baseline JJ N
, , N
single-subject JJ N
study NN N
. . N

The DT N
children NNS 1_p
were VBD N
taught JJ N
how WRB N
to TO N
see VB N
objects NNS N
in IN N
context NN N
by IN N
reinforcing VBG N
attention NN N
to TO N
pivotal JJ N
contextual JJ N
information NN N
. . N

RESULTS NNP N
All NNP N
children NNS 1_p
demonstrated VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
contextual JJ 1_o
processing NN 1_o
and CC 1_o
cognitive JJ 1_o
flexibility NN 1_o
. . 1_o

Mixed JJ N
results NNS N
were VBD N
found VBN N
on IN N
the DT N
control NN N
test NN N
and CC N
changes NNS N
in IN N
context-related JJ 1_o
behaviours NNS 1_o
. . 1_o

CONCLUSIONS NNP N
Larger-scale JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
and CC N
usability NN N
in IN N
comprehensive JJ N
educational JJ N
programs NNS N
. . N

Cost NNP 1_o
effectiveness NN 1_o
of IN 1_o
treatment NN 1_o
with IN 1_o
percutaneous JJ 1_o
Kirschner NNP 1_o
wires VBZ 1_o
versus IN 1_i
volar JJ 1_i
locking VBG 1_i
plate NN 1_i
for IN N
adult NN 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
dorsally RB 1_p
displaced JJ 1_p
fracture NN 1_p
of IN 1_p
the DT 1_p
distal JJ 1_p
radius NN 1_p
: : 1_p
analysis NN N
from IN N
the DT N
DRAFFT NNP N
trial NN N
. . N

We PRP N
present VBD N
an DT N
economic JJ N
evaluation NN N
using VBG N
data NNS N
from IN N
the DT N
Distal NNP N
Radius NNP N
Acute NNP N
Fracture NNP N
Fixation NNP N
Trial NNP N
( ( N
DRAFFT NNP N
) ) N
to TO N
compare VB N
the DT N
relative JJ N
cost NN N
effectiveness NN N
of IN N
percutaneous JJ 1_i
Kirschner NNP 1_i
wire NN 1_i
( ( 1_i
K-wire NNP 1_i
) ) 1_i
fixation NN 1_i
and CC 1_i
volar JJ 1_i
locking-plate JJ 1_i
fixation NN 1_i
for IN N
patients NNS 1_p
with IN 1_p
dorsally-displaced JJ 1_p
fractures NNS 1_p
of IN 1_p
the DT 1_p
distal JJ 1_p
radius NN 1_p
. . 1_p

The DT N
cost NN N
effectiveness NN N
analysis NN N
( ( 1_o
cost NN 1_o
per IN 1_o
quality-adjusted JJ 1_o
life NN 1_o
year NN 1_o
; : 1_o
QALY NNP 1_o
) ) 1_o
was VBD N
derived VBN N
from IN N
a DT N
multi-centre JJ N
, , N
two-arm JJ N
, , N
parallel JJ N
group NN N
, , N
assessor-blind NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
which WDT N
took VBD N
place NN N
in IN N
18 CD 1_p
trauma NN 1_p
centres NNS 1_p
in IN 1_p
the DT 1_p
United NNP 1_p
Kingdom NNP 1_p
. . 1_p

Data NNP 1_p
from IN 1_p
460 CD 1_p
patients NNS 1_p
were VBD 1_p
available JJ 1_p
for IN 1_p
analysis NN 1_p
, , N
which WDT N
includes VBZ N
both CC N
a DT N
National NNP N
Health NNP N
Service NNP N
cost NN N
perspective NN N
including VBG N
costs NNS 1_o
of IN 1_o
surgery NN 1_o
, , 1_o
implants NNS 1_o
and CC N
healthcare NN 1_o
resource NN 1_o
use NN 1_o
over IN N
a DT N
12-month JJ N
period NN N
after IN N
surgery NN N
, , N
and CC N
a DT N
societal JJ N
perspective NN N
, , N
which WDT N
includes VBZ N
the DT N
cost NN 1_o
of IN 1_o
time NN 1_o
off IN 1_o
work NN 1_o
and CC N
the DT N
need NN N
for IN N
additional JJ 1_o
private JJ 1_o
care NN 1_o
. . 1_o

There EX N
was VBD N
only RB N
a DT N
small JJ N
difference NN N
in IN N
QALYs NNP 1_o
gained VBD N
for IN N
patients NNS 1_p
treated VBN 1_p
with IN 1_p
locking-plate JJ 1_i
fixation NN 1_i
over IN 1_p
those DT 1_p
treated VBN 1_p
with IN 1_p
K-wires NNP 1_i
. . 1_i

At IN N
a DT N
mean JJ N
additional JJ N
cost NN N
of IN N
£714 NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
588 CD N
to TO N
865 CD N
) ) N
per IN N
patient NN N
, , N
locking-plate JJ N
fixation NN N
presented VBD N
an DT 1_o
incremental JJ 1_o
cost NN 1_o
effectiveness NN 1_o
ratio NN 1_o
( ( 1_o
ICER NNP 1_o
) ) 1_o
of IN N
£89,322 NN N
per IN N
QALY NNP N
within IN N
the DT N
first JJ N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

Sensitivity NN N
analyses NNS N
were VBD N
undertaken VBN N
to TO N
assess VB N
the DT 1_o
ICER NNP 1_o
of IN 1_i
locking-plate JJ 1_i
fixation NN 1_i
compared VBN N
with IN 1_i
K-wires NNP 1_i
. . N

These DT N
were VBD N
greater JJR N
than IN N
£30,000 NN N
. . N

Compared VBN N
with IN 1_i
locking-plate JJ 1_i
fixation NN 1_i
, , 1_i
K-wire NNP 1_i
fixation NN N
is VBZ N
a DT N
'cost JJ N
saving NN N
' '' N
intervention NN N
, , N
with IN N
similar JJ N
health NN N
benefits NNS N
. . N

The DT N
effect NN N
of IN N
prophylactic JJ 1_i
fentanyl NN 1_i
on IN N
shivering VBG 1_o
in IN 1_o
elective JJ 1_o
caesarean JJ 1_o
section NN 1_o
under IN 1_p
epidural JJ 1_p
analgesia NN 1_p
. . 1_p

The DT N
aims NNS N
of IN N
this DT N
randomised VBN N
double-blind NN N
study NN N
were VBD N
to TO N
investigate VB N
whether IN N
25 CD N
micrograms NNS N
of IN N
fentanyl NN 1_i
administered VBN N
prophylactically RB N
by IN N
the DT N
epidural JJ N
route NN N
would MD N
influence VB N
the DT N
incidence NN 1_o
of IN 1_o
shivering VBG 1_o
in IN N
parturients NNS 1_p
who WP 1_p
underwent VBP 1_p
elective JJ 1_p
Caesarean JJ 1_p
section NN 1_p
under IN 1_p
epidural JJ 1_p
analgesia NN 1_p
and CC N
whether IN N
it PRP N
would MD N
affect VB N
the DT N
axillary JJ 1_o
and CC 1_o
calf JJ 1_o
temperatures NNS 1_o
. . 1_o

There EX N
was VBD N
a DT N
50 CD N
% NN N
reduction NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
in IN N
the DT N
overall JJ N
incidence NN 1_o
of IN 1_o
shivering VBG 1_o
in IN N
patients NNS 1_p
who WP N
received VBD N
fentanyl NN 1_i
and CC N
there EX N
was VBD N
some DT N
evidence NN N
to TO N
suggest VB N
that IN N
low-dose JJ N
epidural JJ N
fentanyl NN N
might MD N
reduce VB N
shivering VBG 1_o
by IN N
an DT N
influence NN N
on IN N
thermoregulation NN 1_o
. . 1_o

Evidence NN N
of IN N
radiographic JJ 1_o
benefit NN 1_o
of IN N
treatment NN N
with IN N
infliximab JJ 1_i
plus JJ 1_i
methotrexate NN 1_i
in IN N
rheumatoid JJ 1_p
arthritis NN 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
no DT 1_p
clinical JJ 1_p
improvement NN 1_p
: : 1_p
a DT N
detailed JJ N
subanalysis NN N
of IN N
data NNS N
from IN N
the DT N
anti-tumor JJ N
necrosis NN N
factor NN N
trial NN N
in IN N
rheumatoid JJ N
arthritis NN N
with IN N
concomitant JJ N
therapy NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB 1_o
the DT 1_o
relationship NN 1_o
between IN N
inflammation NN N
and CC N
joint JJ N
destruction NN N
in IN N
rheumatoid JJ 1_p
arthritis NN 1_p
( ( 1_p
RA NNP 1_p
) ) 1_p
patients NNS 1_p
who WP 1_p
have VBP 1_p
not RB 1_p
responded VBN 1_p
clinically RB 1_p
to TO 1_p
treatment NN 1_p
. . 1_p

METHODS NNP N
Changes NNP N
from IN N
baseline NN N
to TO N
week NN N
54 CD N
in IN N
clinical JJ 1_o
variables NNS 1_o
and CC 1_o
measures NNS 1_o
of IN 1_o
radiographic JJ 1_o
progression NN 1_o
were VBD N
compared VBN N
between IN N
patients NNS N
who WP N
received VBD N
infliximab NN 1_i
( ( N
3 CD N
mg/kg NN N
or CC N
10 CD N
mg/kg NN N
every DT N
4 CD N
or CC N
8 CD N
weeks NNS N
) ) N
plus CC N
methotrexate NN 1_i
( ( 1_i
MTX NNP 1_i
) ) 1_i
and CC N
those DT N
who WP N
received VBD N
MTX NNP 1_i
plus CC 1_i
placebo NN 1_i
in IN N
the DT N
Anti-Tumor NNP N
Necrosis NNP N
Factor NNP N
Trial NNP N
in IN N
RA NNP N
with IN N
Concomitant NNP N
Therapy NNP N
trial NN N
. . N

RESULTS NN N
At IN N
week NN N
54 CD N
, , N
patients NNS 1_p
who WP N
did VBD N
not RB N
show VB N
20 CD N
% NN N
improvement NN 1_o
by IN 1_o
American NNP 1_o
College NNP 1_o
of IN 1_o
Rheumatology NNP 1_o
criteria NNS 1_o
( ( N
ACR20 NNP N
nonresponders NNS N
) ) N
while IN N
receiving VBG N
infliximab JJ 1_i
plus CC 1_i
MTX NNP 1_i
exhibited VBD N
mild JJ N
but CC N
statistically RB N
significant JJ N
improvement NN N
in IN N
clinical JJ N
variables NNS N
, , N
including VBG N
the DT N
28-joint JJ 1_o
Disease NNP 1_o
Activity NNP 1_o
Score NNP 1_o
( ( 1_o
DAS28 NNP 1_o
) ) 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
tender NN 1_o
joint NN 1_o
count NN 1_o
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
, , N
swollen JJ 1_o
joint NN 1_o
count NN 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
C-reactive JJ 1_o
protein NN 1_o
( ( 1_o
CRP NNP 1_o
) ) 1_o
level NN 1_o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Whereas IN N
the DT N
clinical JJ N
and CC N
CRP NNP N
changes NNS N
among IN N
ACR20 NNP N
nonresponders NNS N
to TO N
infliximab VB 1_i
plus JJ 1_i
MTX NNP 1_i
were VBD N
small JJ N
and CC N
much JJ N
lower JJR N
than IN N
among IN N
ACR20 NNP N
responders NNS N
to TO N
this DT N
treatment NN N
, , N
radiographic JJ 1_o
progression NN 1_o
among IN N
ACR20 NNP N
nonresponders NNS N
to TO N
infliximab VB 1_i
plus JJ 1_i
MTX NNP 1_i
was VBD N
significantly RB N
inhibited VBN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
ACR20 NNP N
nonresponders NNS N
to TO N
MTX NNP N
plus CC N
placebo NN N
. . N

Radiographic JJ N
progression NN N
was VBD N
much RB N
greater JJR N
in IN N
patients NNS N
receiving VBG N
MTX NNP 1_i
plus CC 1_i
placebo NN 1_i
than IN N
in IN N
patients NNS N
receiving VBG N
infliximab JJ N
plus CC N
MTX NNP N
, , N
irrespective NN N
of IN N
ACR NNP 1_o
response NN 1_o
status NN 1_o
( ( 1_o
mean JJ 1_o
change NN 1_o
in IN 1_o
modified JJ 1_o
Sharp/van NNP 1_o
der NN 1_o
Heijde NNP 1_o
score VBD 1_o
6.0 CD N
in IN N
ACR20 NNP N
responders NNS N
and CC N
7.2 CD N
in IN N
ACR20 NNP N
nonresponders NNS N
in IN N
the DT N
MTX NNP 1_i
plus CC N
placebo-treated JJ N
group NN N
, , N
versus VBZ N
0.1 CD N
in IN N
ACR20 NNP N
responders NNS N
and CC N
1.2 CD N
in IN N
ACR20 NNP N
nonresponders NNS N
in IN N
the DT N
infliximab JJ 1_i
plus CC 1_i
MTX-treated JJ 1_i
group NN N
) ) N
. . N

Furthermore UH N
, , N
among IN N
patients NNS N
who WP N
were VBD N
ACR20 NNP N
nonresponders NNS N
through IN N
week NN N
54 CD N
, , N
patients NNS N
who WP N
were VBD N
DAS NNP N
nonresponders NNS N
at IN N
weeks NNS N
30 CD N
and CC N
54 CD N
, , N
and CC N
patients NNS N
without IN N
any DT N
improvement NN N
in IN N
individual JJ N
clinical JJ N
variables NNS N
, , N
those DT N
receiving VBG N
infliximab JJ 1_i
plus CC 1_i
MTX NNP 1_i
still RB N
demonstrated VBD N
inhibition NN N
of IN N
structural JJ N
damage NN N
that WDT N
was VBD N
statistically RB N
significant JJ N
compared VBN N
with IN N
inhibition NN N
in IN N
patients NNS N
who WP N
received VBD N
MTX NNP 1_i
plus CC 1_i
placebo NN 1_i
( ( N
P NNP N
< VBZ N
0.05 CD N
to TO N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Even RB N
in IN N
patients NNS 1_p
without IN N
clinical JJ 1_o
improvement NN 1_o
, , N
treatment NN N
with IN N
infliximab JJ 1_i
plus CC 1_i
MTX NNP 1_i
provided VBD N
significant JJ N
benefit NN N
with IN N
regard NN N
to TO N
the DT N
destructive JJ N
process NN N
, , N
suggesting VBG N
that IN N
in IN N
such JJ N
patients NNS N
these DT N
2 CD N
measures NNS N
of IN N
disease NN N
are VBP N
dissociated VBN N
. . N

Randomized NNP N
clinical JJ N
trial NN N
of IN N
cutting VBG 1_i
balloon NN 1_i
angioplasty JJ 1_i
versus NN N
high-pressure NN 1_i
balloon NN 1_i
angioplasty NN 1_i
in IN N
hemodialysis NN 1_p
arteriovenous JJ 1_p
fistula NN 1_p
stenoses VBZ 1_p
resistant JJ 1_p
to TO 1_p
conventional JJ 1_p
balloon NN 1_p
angioplasty NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
cutting VBG 1_i
balloon NN 1_i
angioplasty NN 1_i
( ( 1_i
CBA NNP 1_i
) ) 1_i
versus IN 1_i
high-pressure NN 1_i
balloon NN 1_i
angioplasty NN 1_i
( ( 1_i
HPBA NNP 1_i
) ) 1_i
for IN N
the DT N
treatment NN N
of IN N
hemodialysis NN 1_p
autogenous JJ 1_p
fistula NN 1_p
stenoses VBZ 1_p
resistant JJ 1_p
to TO 1_p
conventional JJ 1_p
percutaneous JJ 1_p
transluminal JJ 1_p
angioplasty NN 1_p
( ( 1_p
PTA NNP 1_p
) ) 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
patients NNS 1_p
with IN 1_p
dysfunctional JJ 1_p
, , 1_p
stenotic JJ 1_p
hemodialysis NN 1_p
arteriovenous JJ 1_p
fistulas NNS 1_p
( ( 1_p
AVFs NNP 1_p
) ) 1_p
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
CBA NNP 1_i
or CC N
HPBA NNP 1_i
if IN N
conventional JJ N
PTA NNP N
had VBD N
suboptimal JJ N
results NNS N
( ( N
ie JJ N
, , N
residual JJ N
stenosis NN N
> VBD N
30 CD N
% NN N
) ) N
. . N

A DT N
total NN 1_p
of IN 1_p
516 CD 1_p
patients NNS 1_p
consented VBN 1_p
to TO 1_p
participate VB 1_p
in IN 1_p
the DT 1_p
study NN 1_p
from IN 1_p
October NNP 1_p
2008 CD 1_p
to TO 1_p
September NNP 1_p
2011 CD 1_p
, , 1_p
85 CD 1_p
% NN 1_p
of IN 1_p
whom WP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
439 CD 1_p
) ) 1_p
had VBD 1_p
technically RB 1_p
successful JJ 1_p
conventional JJ 1_p
PTA NNP 1_p
. . 1_p

The DT N
remaining VBG N
71 CD 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
, , 1_p
60 CD 1_p
y NN 1_p
; : 1_p
49 CD 1_p
men NNS 1_p
) ) 1_p
with IN 1_p
suboptimal JJ 1_p
PTA NNP 1_p
results NNS 1_p
were VBD N
eventually RB N
randomized VBN N
: : N
36 CD N
to TO N
the DT N
CBA NNP 1_i
arm NN N
and CC N
35 CD N
to TO N
the DT N
HPBA NNP N
arm NN N
. . N

Primary JJ N
and CC N
secondary JJ N
target NN N
lesion NN N
patencies NNS N
were VBD N
determined VBN N
by IN N
Kaplan-Meier NNP N
analysis NN N
. . N

RESULTS NNP N
Clinical JJ 1_o
success NN 1_o
rates NNS 1_o
were VBD N
100 CD N
% NN N
in IN N
both DT N
arms NNS N
. . N

Primary JJ 1_o
target NN 1_o
lesion NN 1_o
patency NN 1_o
rates NNS 1_o
at IN N
6 CD N
months NNS N
were VBD N
66.4 CD N
% NN N
and CC N
39.9 CD N
% NN N
for IN N
CBA NNP 1_i
and CC N
HPBA NNP 1_i
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Secondary JJ 1_o
target NN 1_o
lesion NN 1_o
patency NN 1_o
rates NNS 1_o
at IN N
6 CD N
months NNS N
were VBD N
96.5 CD N
% NN N
for IN N
CBA NNP 1_i
and CC N
80.0 CD N
% NN N
for IN N
HPBA NNP 1_i
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

There EX N
was VBD N
a DT N
single JJ N
major JJ 1_o
complication NN 1_o
of IN N
venous JJ 1_o
perforation NN 1_o
following VBG N
CBA NNP 1_i
. . 1_i

The DT N
30-day JJ 1_o
mortality NN 1_o
rate NN 1_o
was VBD N
1.4 CD N
% NN N
, , N
with IN N
one CD N
non-procedure-related JJ N
death NN N
in IN N
the DT N
HPBA NNP 1_i
group NN N
. . N

CONCLUSIONS NNP N
Primary NNP N
and CC N
secondary JJ N
target NN N
lesion NN N
patency NN N
rates NNS N
of IN N
CBA NNP 1_i
were VBD N
statistically RB N
superior JJ N
to TO N
those DT N
of IN N
HPBA NNP 1_i
following VBG N
suboptimal JJ N
conventional JJ N
PTA NNP N
. . N

For IN N
AVF NNP N
stenoses VBZ N
resistant JJ N
to TO N
conventional JJ N
PTA NNP N
, , N
CBA NNP 1_i
may MD N
be VB N
a DT N
better JJR N
second-line JJ N
treatment NN N
given VBN N
its PRP$ N
superior JJ N
patency NN N
rates NNS N
. . N

Phenobarbital JJ 1_i
compared VBN N
with IN N
phenytoin NN 1_i
for IN N
the DT N
treatment NN N
of IN N
neonatal JJ 1_p
seizures NNS 1_p
. . 1_p

BACKGROUND NNP N
Seizures NNP N
occur VBP N
in IN N
1 CD N
to TO N
2 CD N
percent NN N
of IN N
neonates NNS 1_p
admitted VBN 1_p
to TO 1_p
an DT 1_p
intensive JJ 1_p
care NN 1_p
unit NN 1_p
. . 1_p

The DT N
treatment NN N
is VBZ N
usually RB N
with IN N
either DT N
phenobarbital NN 1_i
or CC N
phenytoin NN 1_i
, , N
but CC N
the DT N
efficacy NN 1_o
of IN N
the DT N
two CD N
drugs NNS N
has VBZ N
not RB N
been VBN N
compared VBN N
directly RB N
. . N

METHODS NNP N
From IN N
1990 CD N
to TO N
1995 CD N
, , N
we PRP N
studied VBD N
59 CD 1_p
neonates NNS 1_p
with IN 1_p
seizures NNS 1_p
that WDT 1_p
were VBD 1_p
confirmed VBN 1_p
by IN 1_p
electroencephalography NN 1_p
. . 1_p

The DT N
neonates NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
phenobarbital NN 1_i
or CC N
phenytoin NN 1_i
intravenously RB N
, , N
at IN N
doses NNS N
sufficient JJ N
to TO N
achieve VB N
free JJ N
plasma NN N
concentrations NNS N
of IN N
25 CD N
microg NNS N
per IN N
milliliter NN N
for IN N
phenobarbital NN N
and CC N
3 CD N
microg NNS N
per IN N
milliliter NN N
for IN N
phenytoin NN N
. . N

Neonates NNS N
whose WP$ N
seizures NNS N
were VBD N
not RB N
controlled VBN N
by IN N
the DT N
assigned JJ N
drug NN N
were VBD N
then RB N
treated VBN N
with IN N
both DT N
drugs NNS N
. . N

Seizure NN 1_o
control NN 1_o
was VBD N
assessed VBN N
by IN N
electroencephalographic JJ N
criteria NNS N
. . N

RESULTS NNP N
Seizures NNPS 1_o
were VBD N
controlled VBN N
in IN N
13 CD N
of IN N
the DT N
30 CD 1_p
neonates NNS 1_p
assigned VBN 1_p
to TO 1_p
receive VB 1_p
phenobarbital NN 1_p
( ( N
43 CD N
percent NN N
) ) N
and CC N
13 CD N
of IN N
the DT N
29 CD 1_p
neonates NNS 1_p
assigned VBN 1_p
to TO 1_p
receive VB 1_p
phenytoin NN 1_p
( ( N
45 CD N
percent NN N
; : N
P=1.00 NNP N
) ) N
. . N

When WRB N
combined JJ N
treatment NN N
is VBZ N
considered VBN N
, , N
seizure NN 1_o
control NN 1_o
was VBD N
achieved VBN N
in IN N
17 CD N
( ( N
57 CD N
percent NN N
) ) N
of IN N
the DT N
neonates NNS N
assigned VBD N
to TO N
receive VB N
phenobarbital NN N
first RB N
and CC N
18 CD N
( ( N
62 CD N
percent NN N
) ) N
of IN N
those DT N
assigned VBN N
to TO N
receive VB N
phenytoin NN N
first RB N
( ( N
P=0.67 NNP N
) ) N
. . N

The DT N
severity NN 1_o
of IN 1_o
the DT 1_o
seizures NNS 1_o
was VBD N
a DT N
stronger JJR N
predictor NN N
of IN N
the DT N
success NN N
of IN N
treatment NN N
than IN N
was VBD N
the DT N
assigned JJ N
agent NN N
. . N

Neonates VBZ N
with IN N
mild JJ 1_o
seizures NNS 1_o
or CC N
with IN N
seizures NNS 1_o
that WDT N
were VBD N
decreasing VBG N
in IN N
severity NN 1_o
before IN N
treatment NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
seizures NNS 1_o
end VBP 1_o
, , N
regardless RB N
of IN N
the DT N
treatment NN N
assignment NN N
. . N

CONCLUSIONS NNP N
Phenobarbital NNP 1_i
and CC N
phenytoin NN 1_i
are VBP N
equally RB N
but CC N
incompletely RB N
effective JJ N
as IN N
anticonvulsants NNS 1_o
in IN N
neonates NNS 1_p
. . 1_p

With IN N
either DT N
drug NN N
given VBN N
alone RB N
, , N
the DT N
seizures NNS 1_o
were VBD N
controlled VBN 1_o
in IN N
fewer JJR N
than IN N
half NN N
of IN N
the DT N
neonates NNS N
. . N

Efficacy NN 1_o
of IN N
a DT N
tobacco NN 1_i
quitline NN 1_i
among IN N
adult JJ 1_p
cancer NN 1_p
survivors NNS 1_p
. . 1_p

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
the DT N
study NN N
( ( 1_p
conducted VBN 1_p
2010-2013 CD 1_p
) ) 1_p
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
two CD N
common JJ N
types NNS N
of IN N
tobacco NN 1_i
quitlines NNS 1_i
in IN N
adult NN 1_p
cancer NN 1_p
survivors NNS 1_p
who WP 1_p
regularly RB 1_p
smoked VBD 1_p
cigarettes NNS 1_p
. . 1_p

METHOD NNP N
Adult NNP 1_p
onset VBD 1_p
cancer NN 1_p
survivors NNS 1_p
in IN 1_p
Memphis NNP 1_p
, , 1_p
Tennessee NNP 1_p
( ( 1_p
n=427 UH 1_p
, , 1_p
67 CD 1_p
% NN 1_p
female NN 1_p
, , 1_p
60 CD 1_p
% NN 1_p
Caucasian JJ 1_p
) ) 1_p
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
Proactive NNP 1_i
( ( 1_i
i.e. FW 1_i
, , N
counselor-initiated JJ 1_i
calls NNS 1_i
) ) 1_i
or CC N
Reactive NNP 1_i
( ( N
i.e. FW N
, , N
participant-initiated JJ 1_i
calls NNS 1_i
) ) 1_i
quitline NN N
. . N

Both DT N
conditions NNS N
also RB N
received VBD N
nicotine JJ 1_i
replacement NN 1_i
therapy NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
was VBD N
biochemically-verified JJ N
( ( N
i.e. FW N
, , N
salivary JJ N
cotinine NN N
) ) N
smoking NN 1_o
cessation NN 1_o
. . 1_o

RESULTS NNP N
While IN N
12-month JJ N
self-reported JJ N
abstinence NN N
was VBD N
consistent JJ N
with IN N
other JJ N
published VBN N
studies NNS N
of IN N
smoking VBG 1_o
cessation NN 1_o
( ( N
22 CD N
% NN N
and CC N
26 CD N
% NN N
point NN N
prevalence NN N
abstinence NN N
for IN N
Proactive NNP N
and CC N
Reactive NNP N
conditions NNS N
, , N
respectively RB N
) ) N
, , N
48 CD N
% NN N
of IN N
participants NNS N
who WP N
were VBD N
tested VBN N
for IN N
cotinine NN N
failed VBD N
biochemical JJ N
verification NN N
, , N
indicating VBG N
a DT N
considerable JJ N
falsification NN N
of IN N
self-reported JJ 1_o
cessation NN 1_o
. . 1_o

Adjusted VBN 1_o
cessation NN 1_o
rates NNS 1_o
were VBD N
less JJR N
than IN N
5 CD N
% NN N
in IN N
both DT N
intervention NN N
conditions NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
are VBP N
consistent JJ N
with IN N
other JJ N
studies NNS N
indicating VBG N
that IN N
traditional JJ 1_o
smoking NN 1_o
cessation NN 1_o
interventions NNS 1_o
are VBP N
ineffective JJ N
among IN N
cancer NN N
survivors NNS N
. . N

Moreover RB N
, , N
self-reports NNS 1_o
of IN 1_o
cessation NN 1_o
were VBD N
unreliable JJ N
in IN N
cancer NN N
survivors NNS N
participating VBG N
in IN N
a DT N
quitline NN 1_i
intervention NN 1_i
, , N
indicating VBG N
that IN N
future JJ N
studies NNS N
should MD N
include VB N
biochemical JJ N
verification NN N
. . N

Given VBN N
the DT N
importance NN N
of IN N
smoking VBG N
cessation NN N
among IN N
cancer NN 1_p
survivors NNS 1_p
and CC N
low JJ N
cessation NN 1_o
rates NNS 1_o
in IN N
the DT N
current JJ N
study NN N
, , N
it PRP N
may MD N
be VB N
necessary JJ N
to TO N
design VB N
alternative JJ N
interventions NNS N
for IN N
this DT N
population NN N
. . N

ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00827866 NNP N
. . N

Transcutaneous JJ 1_i
electrical JJ 1_i
nerve NN 1_i
stimulation NN 1_i
for IN N
postoperative JJ 1_p
pain NN 1_p
relief NN 1_p
after IN 1_p
total JJ 1_p
knee NN 1_p
arthroplasty NN 1_p
. . 1_p

Transcutaneous JJ 1_i
electrical JJ 1_i
nerve NN 1_i
stimulation NN 1_i
( ( 1_i
TENS NNP 1_i
) ) 1_i
has VBZ N
been VBN N
used VBN N
to TO N
treat VB N
chronic JJ N
pain NN N
syndromes NNS N
and CC N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
of IN N
some DT N
utility NN N
in IN N
the DT N
treatment NN N
of IN N
postsurgical JJ N
pain NN N
. . N

A DT N
randomized JJ N
, , N
blinded VBD N
, , N
placebo-controlled JJ 1_i
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
utility NN N
of IN N
TENS NNP N
after IN N
total JJ 1_p
knee NN 1_p
arthroplasty NN 1_p
. . 1_p

Patients NNS 1_p
were VBD 1_p
randomly RB 1_p
enrolled VBN 1_p
into IN 1_p
patient-controlled JJ 1_i
anesthesia NN 1_i
( ( 1_i
PCA NNP 1_i
) ) 1_i
alone RB 1_i
, , 1_i
PCA NNP 1_i
plus CC 1_i
TENS NNP 1_i
, , 1_i
or CC 1_i
PCA NNP 1_i
plus CC 1_i
sham JJ 1_i
TENS NNP 1_i
. . 1_i

The DT N
cumulative JJ 1_o
dose NN 1_o
of IN 1_o
morphine NN 1_o
by IN N
PCA NNP N
for IN N
each DT N
group NN N
was VBD N
used VBN N
as IN N
the DT N
end-point NN N
of IN N
the DT N
study NN N
. . N

There EX N
was VBD N
no DT 1_o
significant JJ 1_o
reduction NN 1_o
in IN 1_o
the DT 1_o
requirement NN 1_o
for IN 1_o
patient-controlled JJ 1_o
analgesia NN 1_o
with IN N
or CC N
without IN N
TENS NNP N
. . N

We PRP N
conclude VBP N
that IN N
there EX N
is VBZ N
no DT N
utility NN N
for IN N
TENS NNP N
in IN N
the DT N
postoperative JJ N
management NN N
of IN N
pain NN N
after IN N
knee NN N
arthroplasty NN N
. . N

The DT N
interobserver JJ N
variability NN N
of IN N
digital JJ 1_i
rectal JJ 1_i
examination NN 1_i
in IN N
a DT N
large JJ N
randomized JJ N
trial NN N
for IN N
the DT N
screening NN N
of IN N
prostate NN N
cancer NN N
. . N

BACKGROUND NNP N
To TO N
analyze VB N
to TO N
what WP N
extent VB N
the DT N
percentage NN N
of IN N
suspicious JJ N
digital JJ 1_i
rectal JJ 1_i
examination NN 1_i
( ( 1_i
DRE NNP 1_i
) ) 1_i
findings NNS N
vary VBP N
between IN N
examiners NNS N
and CC N
to TO 1_p
what WP 1_p
extent VB 1_p
the DT 1_p
percentage NN 1_p
of IN 1_p
prostate NN 1_p
cancers NNS 1_p
( ( 1_p
PCs NNS 1_p
) ) 1_p
detected VBN 1_p
in IN 1_p
men NNS 1_p
with IN 1_p
these DT 1_p
suspicious JJ 1_p
findings NNS 1_p
varies NNS 1_p
between IN 1_p
examiners NNS 1_p
. . 1_p

METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
of IN N
the DT N
European NNP N
Randomized NNP N
study NN N
of IN N
Screening VBG N
for IN N
PC NN N
( ( N
ERSPC NNP N
) ) N
Rotterdam NNP N
, , N
7,280 CD 1_p
men NNS 1_p
underwent VBD 1_p
a DT 1_p
PSA-determination NN 1_i
and CC 1_i
DRE NNP 1_i
of IN 1_i
whom WP 1_i
2,102 CD 1_i
underwent JJ 1_i
prostate NN 1_i
biopsy NN 1_i
( ( 1_p
biopsy JJ 1_p
indication NN 1_p
PSA NNP 1_p
> NNP 1_p
or CC 1_p
= $ 1_p
4.0 CD 1_p
ng/ml JJ 1_p
and/or RB 1_p
suspicious JJ 1_p
DRE NNP 1_p
and/or NN 1_p
TRUS NNP 1_p
) ) 1_p
. . 1_p

Descriptive JJ 1_o
statistics NNS 1_o
of IN 1_o
DRE-outcome NNP 1_o
per IN 1_o
PSA-range NNP 1_o
were VBD N
used VBN N
to TO N
determine VB N
the DT N
observer JJ N
variability NN N
of IN N
six CD N
examiners NNS N
. . N

Because IN N
this DT N
analysis NN N
did VBD N
not RB N
correct VB N
properly RB N
for IN N
other JJ N
predictors NNS N
of IN N
a DT N
suspicious JJ 1_o
DRE NNP 1_o
( ( 1_o
PSA-level NNP 1_o
, , 1_o
biopsy NN 1_o
indication NN 1_o
, , 1_o
TRUS-outcome NNP 1_o
, , 1_o
prostate NN 1_o
volume NN 1_o
and CC 1_o
age NN 1_o
) ) 1_o
, , N
a DT N
logistic JJ N
regression NN N
analysis NN N
controlling VBG N
for IN N
these DT N
explanatory JJ N
variables NNS N
was VBD N
performed VBN N
as RB N
well RB N
. . N

RESULTS NNP N
In IN N
2,102 CD 1_p
men NNS 1_p
biopsied VBD 1_p
, , 1_p
443 CD 1_p
PCs NNS 1_p
were VBD 1_p
detected VBN 1_p
( ( 1_p
PPV NNP 1_p
= RB 1_p
21 CD 1_p
% NN 1_p
) ) 1_p
. . N

For IN N
all DT N
PSA NNP 1_o
levels NNS 1_o
the DT N
percentage NN 1_o
suspicious JJ 1_o
DRE NNP 1_o
varied VBD N
between IN N
examiners NNS N
from IN N
4 CD N
% NN N
to TO N
28 CD N
% NN N
and CC N
percentage NN 1_o
PC NN 1_o
detected VBN N
in IN N
men NNS 1_p
with IN 1_p
a DT 1_p
suspicious JJ 1_p
DRE NNP 1_p
varied VBD N
from IN N
18 CD N
% NN N
to TO N
36 CD N
% NN N
. . N

Logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
three CD N
of IN N
six CD N
examiners NNS N
considered VBN N
DRE NNP 1_o
significantly RB N
more RBR N
often RB N
abnormal JJ N
than IN N
others NNS N
( ( N
ORs NNP N
3.48 CD N
, , N
2.80 CD N
, , N
2.47 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
all DT N
examiners NNS N
the DT N
odds NNS N
to TO N
have VB N
PC NN 1_o
was VBD N
statistically RB N
significantly RB N
higher JJR N
in IN N
case NN N
of IN N
a DT N
suspicious JJ 1_o
DRE NNP 1_o
( ( N
ORs NNP N
2.21-5.96 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
increased VBD N
chance NN N
to TO N
find VB N
PC NN 1_o
was VBD N
not RB N
significantly RB N
observer-dependent JJ N
. . N

CONCLUSIONS NNP N
Three CD N
of IN N
six CD N
examiners NNS N
considered VBN N
DRE NNP 1_o
significantly RB N
more RBR N
often RB N
suspicious JJ N
than IN N
the DT N
others NNS N
. . N

However RB N
, , N
under IN N
equal JJ N
circumstances NNS N
a DT N
suspicious JJ N
DRE NNP 1_o
executed VBN N
by IN N
each DT N
examiner NN N
increased VBD N
the DT N
chance NN N
of IN N
the DT N
presence NN N
of IN N
PC NNP 1_o
similarly RB N
. . N

Left NNP 1_i
ventricular JJ 1_i
mass NN 1_i
regression NN 1_i
in IN N
elderly JJ 1_p
hypertensives NNS 1_p
. . 1_p

It PRP N
is VBZ N
now RB N
recognized VBN N
that IN N
left VBD N
ventricular JJ N
hypertrophy NN N
( ( N
LVH NNP N
) ) N
, , N
often RB N
associated VBN N
with IN N
hypertension NN N
, , N
is VBZ N
itself PRP N
a DT N
risk NN N
factor NN N
for IN N
coronary JJ N
disease NN N
in IN N
the DT N
elderly JJ N
. . N

Although IN N
many JJ N
agents NNS N
are VBP N
capable JJ N
of IN N
controlling VBG N
blood NN N
pressure NN N
, , N
the DT N
ability NN N
of IN N
these DT N
agents NNS N
to TO N
induce VB N
regression NN N
of IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
mass NN N
, , N
and CC N
the DT N
effect NN N
of IN N
regression NN N
on IN N
diastolic JJ N
relaxation NN N
and CC N
contractile NN N
indices NNS N
in IN N
the DT N
elderly JJ N
are VBP N
less RBR N
well RB N
known VBN N
. . N

Our PRP$ N
study NN N
compared VBN N
the DT N
ability NN N
of IN N
the DT N
calcium NN 1_i
blocker NN 1_i
, , 1_i
verapamil NN 1_i
, , 1_i
and CC 1_i
the DT 1_i
beta-blocker NN 1_i
, , 1_i
atenolol NN 1_i
, , N
to TO N
both DT N
control VB N
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
and CC N
to TO N
induce VB N
regression NN 1_o
of IN 1_o
LV NNP 1_o
mass NN 1_o
in IN N
older JJR N
hypertensives NNS N
. . N

In IN N
addition NN N
, , N
the DT N
influence NN N
of IN N
regression NN N
on IN N
resting VBG N
diastolic JJ N
filling NN N
and CC N
on IN N
cardiac JJ N
output NN N
and CC N
ejection NN N
fraction NN N
during IN N
rest NN N
and CC N
mild VB N
upright JJ N
bicycle NN N
exercise NN N
were VBD N
determined VBN N
. . N

Forty-two JJ 1_p
hypertensives NNS 1_p
60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
or CC 1_p
above NN 1_p
, , 1_p
without IN 1_p
evidence NN 1_p
of IN 1_p
ischemic JJ 1_p
disease NN 1_p
underwent JJ N
2-D JJ 1_i
echocardiographic JJ 1_i
evaluation NN 1_i
of IN N
LV NNP N
mass NN N
and CC N
gated VBD N
blood NN N
pool NN N
scan JJ N
determination NN N
of IN N
early JJ N
diastolic JJ N
filling NN N
, , N
cardiac JJ N
output NN N
and CC N
ejection NN N
fraction NN N
. . N

They PRP N
were VBD N
then RB N
randomized VBN N
to TO N
receive VB N
verapamil NN 1_i
or CC N
atenolol NN 1_i
during IN N
a DT N
four-week JJ N
titration NN N
period NN N
so RB N
as IN N
to TO N
achieve VB N
a DT N
BP NNP 1_o
of IN N
less JJR N
than IN N
160/90 CD N
mm JJ N
Hg NNP N
. . N

If IN N
BP NNP 1_o
was VBD N
not RB N
controlled VBN N
with IN N
either DT N
agent NN N
, , N
chlorthalidone NN N
was VBD N
added VBN N
. . N

Individuals NNS N
whose WP$ N
BP NNP 1_o
was VBD N
controlled VBN N
continued VBN N
on IN N
the DT N
protocol NN N
for IN N
six CD N
months NNS N
. . N

At IN N
that DT N
time NN N
, , N
the DT N
echocardiographic JJ N
and CC N
gated VBD N
blood NN N
pool NN N
studies NNS N
were VBD N
repeated VBN N
both DT N
on IN N
and CC N
after IN N
subsequent JJ N
withdrawal NN N
of IN N
the DT N
study NN N
medications NNS N
. . N

Twenty-one CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
verapamil NN 1_i
and CC N
21 CD N
patients NNS N
to TO N
receive VB N
atenolol NN 1_i
. . 1_i

Blood NNP N
pressure NN N
control NN N
was VBD N
achieved VBN N
with IN N
verapamil NN N
alone RB N
in IN N
18 CD N
patients NNS N
, , N
but CC N
with IN N
atenolol JJ N
alone RB N
in IN N
only RB N
8 CD N
patients NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
Safety NN 1_o
of IN N
the DT N
combination NN 1_i
of IN 1_i
valsartan NN 1_i
and CC 1_i
benazepril NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
renal JJ 1_p
disease NN 1_p
. . 1_p

European JJ N
Group NNP N
for IN N
the DT N
Investigation NNP N
of IN N
Valsartan NNP 1_i
in IN N
Chronic NNP N
Renal NNP N
Disease NNP N
. . N

OBJECTIVE NNP N
Several JJ N
experimental JJ N
and CC N
clinical JJ N
studies NNS N
indicate VBP N
that IN N
the DT N
renin NN N
system NN N
may MD N
play VB N
a DT N
pivotal JJ N
role NN N
in IN N
progressing VBG N
renal JJ N
disease NN N
. . N

The DT N
combination NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
could MD N
provide VB N
a DT N
higher JJR N
degree NN N
of IN N
blockade NN N
of IN N
the DT N
renin-angiotensin NN N
system NN N
than IN N
either DT N
agent JJ N
alone RB N
. . N

Such JJ N
enhanced JJ N
suppression NN N
might MD N
be VB N
of IN N
benefit NN N
for IN N
patients NNS 1_p
exhibiting VBG 1_p
a DT 1_p
progressive JJ 1_p
decline NN 1_p
in IN 1_p
renal JJ 1_p
function NN 1_p
because IN 1_p
of IN 1_p
chronic JJ 1_p
renal JJ 1_p
disease NN 1_p
. . 1_p

METHODS NNP N
A NNP N
pilot NN N
multinational NN N
, , N
multicentre NN N
, , N
randomized VBN N
, , N
active-controlled JJ N
, , N
parallel JJ N
group NN N
open-label JJ N
study NN N
has VBZ N
been VBN N
conducted VBN N
in IN N
a DT N
group NN 1_p
of IN 1_p
patients NNS 1_p
with IN 1_p
progressive JJ 1_p
chronic JJ 1_p
renal JJ 1_p
failure NN 1_p
( ( 1_p
creatinine JJ 1_p
clearance NN 1_p
20-45 JJ 1_p
ml/min NN 1_p
) ) 1_p
either CC 1_p
with IN 1_p
or CC 1_p
without IN 1_p
proteinuria NNS 1_p
and CC 1_p
hypertension NN 1_p
. . 1_p

The DT N
primary JJ N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
the DT N
combination NN 1_i
of IN 1_i
valsartan NN 1_i
and CC 1_i
benazepril NN 1_i
. . 1_i

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
valsartan JJ 1_i
160 CD 1_i
mg NN 1_i
once RB N
daily JJ N
( ( 1_p
n JJ 1_p
= NNP 1_p
22 CD 1_p
) ) 1_p
; : 1_p
group NN N
2 CD N
received VBD N
valsartan JJ 1_i
80 CD 1_i
mg NN 1_i
once RB 1_i
daily JJ 1_i
plus CC 1_i
benazepril JJ 1_i
5 CD 1_i
or CC 1_i
10 CD 1_i
mg NNS 1_i
once RB 1_i
daily JJ 1_i
( ( 1_p
n JJ 1_p
= NNP 1_p
42 CD 1_p
) ) 1_p
; : 1_p
group NN N
3 CD N
received VBD N
valsartan JJ 1_i
160 CD 1_i
mg NN 1_i
once RB N
daily JJ N
plus CC 1_i
benazepril JJ 1_i
5 CD 1_i
or CC 1_i
10 CD 1_i
mg NNS 1_i
once RB N
daily JJ N
( ( 1_p
n JJ 1_p
= NNP 1_p
44 CD 1_p
) ) 1_p
. . N

The DT N
study NN N
lasted VBD N
for IN N
5 CD N
weeks NNS N
, , N
and CC N
in IN N
groups NNS N
2 CD N
and CC N
3 CD N
benazepril NN N
was VBD N
added VBN N
on IN N
top NN N
of IN N
valsartan NN N
after IN N
the DT N
first JJ N
week NN N
of IN N
therapy NN N
with IN N
the DT N
angiotensin NN N
receptor NN N
blocker NN N
. . N

RESULTS NNP N
Serum NNP 1_o
creatinine NN 1_o
increased VBN N
in IN N
all DT N
three CD N
groups NNS N
( ( N
mean JJ N
change NN N
within IN N
a DT N
group NN N
: : N
11 CD N
micromol/l NN N
in IN N
group NN N
1 CD N
, , N
P= NNP N
0.045 CD N
; : N
9 CD N
micromol/l NN N
in IN N
group NN N
2 CD N
, , N
P= NNP N
0.030 CD N
; : N
15 CD N
micromol/l NN N
in IN N
group NN N
3 CD N
, , N
P= NNP N
0.0006 CD N
) ) N
. . N

Serum NNP 1_o
potassium NN 1_o
also RB N
increased VBN N
in IN N
all DT N
three CD N
groups NNS N
of IN N
patients NNS N
( ( N
mean JJ N
change NN N
within IN N
a DT N
group NN N
: : N
0.28 CD N
mmol/l NN N
in IN N
group NN N
1 CD N
, , N
P= NNP N
0.28 CD N
; : N
0.48 CD N
mmol/l NN N
in IN N
group NN N
2 CD N
, , N
P= NNP N
0.0008 CD N
; : N
0.36 CD N
mmol/l NN N
in IN N
group NN N
3 CD N
, , N
P= NNP N
0.02 CD N
) ) N
. . N

After IN N
5 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
largest JJS N
decrease NN N
in IN N
blood NN 1_o
pressure NN 1_o
was VBD N
observed VBN N
in IN N
group NN N
3 CD N
( ( N
the DT N
mean NN N
change NN N
from IN N
baseline NN N
in IN N
seated VBN 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
SDBP NNP 1_o
) ) 1_o
and CC N
seated VBN 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
SSBP NNP 1_o
) ) 1_o
, , N
respectively RB N
, , N
were VBD N
: : N
-2.0 NN N
and CC N
-11.5 NNP N
mmHg NN N
in IN N
group NN N
1 CD N
; : N
-7.6 NNS N
and CC N
-15.4 NNP N
mmHg NN N
in IN N
group NN N
2 CD N
; : N
-12.6 NNS N
and CC N
-21.6 NNP N
mmHg NN N
in IN N
group NN N
3 CD N
) ) N
. . N

In IN N
addition NN N
, , N
both DT N
combination NN N
treatments NNS N
resulted VBD N
in IN N
the DT N
reduction NN N
of IN N
proteinuria NN 1_o
. . 1_o

The DT N
total JJ 1_o
number NN 1_o
of IN 1_o
patients NNS 1_o
with IN N
adverse JJ 1_o
experiences NNS 1_o
were VBD N
10 CD N
( ( N
45.5 CD N
% NN N
) ) N
, , N
14 CD N
( ( N
33.3 CD N
% NN N
) ) N
and CC N
11 CD N
( ( N
25 CD N
% NN N
) ) N
in IN N
groups NNS N
1,2 CD N
and CC N
3 CD N
, , N
respectively RB N
. . N

In IN N
six CD N
patients NNS N
( ( N
5.6 CD N
% NN N
) ) N
therapy NN N
was VBD N
discontinued VBN N
as IN N
a DT N
result NN N
of IN N
adverse JJ 1_o
experiences NNS 1_o
. . 1_o

Only RB N
one CD N
patient NN N
in IN N
each DT N
of IN N
the DT N
combined JJ N
therapy NN N
groups NNS N
withdrew VBD N
from IN N
the DT N
study NN N
because IN N
of IN N
hyperkalaemia NN 1_o
and CC N
no DT N
patients NNS N
were VBD N
forced VBN N
to TO N
withdraw VB N
because IN N
of IN N
an DT N
increase NN N
in IN N
serum JJ 1_o
creatinine NN 1_o
, , 1_o
acute JJ 1_o
renal JJ 1_o
failure NN 1_o
or CC 1_o
hospitalization NN 1_o
. . 1_o

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
short-term JJ N
combination NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
is VBZ N
safe JJ 1_o
and CC N
well RB 1_o
tolerated VBN 1_o
in IN N
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
chronic JJ 1_p
renal JJ 1_p
failure NN 1_p
. . 1_p

A DT N
comparison NN N
of IN N
antiarrhythmic-drug JJ 1_i
therapy NN 1_i
with IN 1_i
implantable JJ 1_i
defibrillators NNS 1_i
in IN N
patients NNS 1_p
resuscitated VBN 1_p
from IN 1_p
near-fatal JJ 1_p
ventricular JJ 1_p
arrhythmias NN 1_p
. . 1_p

The DT N
Antiarrhythmics NNPS 1_i
versus NN N
Implantable JJ 1_i
Defibrillators NNS 1_i
( ( N
AVID NNP N
) ) N
Investigators NNPS N
. . N

BACKGROUND NNP N
Patients NNPS N
who WP N
survive VBP N
life-threatening JJ N
ventricular JJ N
arrhythmias NNS N
are VBP N
at IN N
risk NN N
for IN N
recurrent NN N
arrhythmias NN N
. . N

They PRP N
can MD N
be VB N
treated VBN N
with IN N
either DT N
an DT N
implantable JJ 1_i
cardioverter-defibrillator NN 1_i
or CC N
antiarrhythmic JJ 1_i
drugs NNS 1_i
, , N
but CC N
the DT N
relative JJ N
efficacy NN N
of IN N
these DT N
two CD N
treatment NN N
strategies NNS N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
To TO N
address VB N
this DT N
issue NN N
, , N
we PRP N
conducted VBD N
a DT N
randomized JJ N
comparison NN N
of IN N
these DT N
two CD N
treatment NN N
strategies NNS N
in IN N
patients NNS 1_p
who WP 1_p
had VBD 1_p
been VBN 1_p
resuscitated VBN 1_p
from IN 1_p
near-fatal JJ 1_p
ventricular JJ 1_p
fibrillation NN 1_p
or CC 1_p
who WP 1_p
had VBD 1_p
undergone JJ 1_p
cardioversion NN 1_p
from IN 1_p
sustained VBN 1_p
ventricular JJ 1_p
tachycardia NN 1_p
. . 1_p

Patients NNS 1_p
with IN 1_p
ventricular JJ 1_p
tachycardia NN 1_p
also RB 1_p
had VBD 1_p
either CC 1_p
syncope NN 1_p
or CC 1_p
other JJ 1_p
serious JJ 1_p
cardiac NN 1_p
symptoms NNS 1_p
, , 1_p
along IN 1_p
with IN 1_p
a DT 1_p
left JJ 1_p
ventricular JJ 1_p
ejection NN 1_p
fraction NN 1_p
of IN 1_p
0.40 CD 1_p
or CC 1_p
less JJR 1_p
. . 1_p

One CD N
group NN N
of IN N
patients NNS N
was VBD N
treated VBN N
with IN N
implantation NN 1_i
of IN 1_i
a DT 1_i
cardioverter-defibrillator NN 1_i
; : 1_i
the DT N
other JJ N
received JJ N
class NN 1_i
III NNP 1_i
antiarrhythmic JJ 1_i
drugs NNS 1_i
, , 1_i
primarily RB 1_i
amiodarone NN 1_i
at IN N
empirically RB N
determined VBN N
doses NNS N
. . N

Fifty-six NNP N
clinical JJ N
centers NNS N
screened VBD N
all DT N
patients NNS N
who WP N
presented VBD N
with IN N
ventricular JJ N
tachycardia NN N
or CC N
ventricular JJ N
fibrillation NN N
during IN N
a DT N
period NN N
of IN N
nearly RB N
four CD N
years NNS N
. . N

Of IN 1_p
1016 CD 1_p
patients NNS 1_p
( ( 1_p
45 CD 1_p
percent NN 1_p
of IN 1_p
whom WP 1_p
had VBD 1_p
ventricular JJ 1_p
fibrillation NN 1_p
, , 1_p
and CC 1_p
55 CD 1_p
percent NN 1_p
ventricular JJ 1_p
tachycardia NN 1_p
) ) 1_p
, , 1_p
507 CD 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
to TO 1_p
treatment NN 1_p
with IN 1_p
implantable JJ 1_i
cardioverter-defibrillators NNS 1_i
and CC 1_p
509 CD 1_p
to TO 1_p
antiarrhythmic-drug JJ 1_i
therapy NN 1_i
. . 1_i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ 1_o
mortality NN 1_o
. . 1_o

RESULTS NNP N
Follow-up NNP N
was VBD N
complete JJ N
for IN N
1013 CD N
patients NNS N
( ( N
99.7 CD N
percent NN N
) ) N
. . N

Overall JJ N
survival NN 1_o
was VBD N
greater JJR N
with IN N
the DT N
implantable JJ 1_i
defibrillator NN 1_i
, , N
with IN N
unadjusted JJ N
estimates NNS N
of IN N
89.3 CD N
percent NN N
, , N
as IN N
compared VBN N
with IN N
82.3 CD N
percent NN N
in IN N
the DT N
antiarrhythmic-drug JJ 1_i
group NN N
at IN N
one CD N
year NN N
, , N
81.6 CD N
percent NN N
versus NN N
74.7 CD N
percent NN N
at IN N
two CD N
years NNS N
, , N
and CC N
75.4 CD N
percent NN N
versus NN N
64.1 CD N
percent NN N
at IN N
three CD N
years NNS N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
corresponding JJ N
reductions NNS N
in IN N
mortality NN 1_o
( ( N
with IN N
95 CD N
percent NN N
confidence NN N
limits NNS N
) ) N
with IN N
the DT N
implantable JJ 1_i
defibrillator NN 1_i
were VBD N
39+/-20 JJ N
percent NN N
, , N
27+/-21 JJ N
percent NN N
, , N
and CC N
31+/-21 JJ N
percent NN N
CONCLUSIONS NNP N
Among IN N
survivors NNS 1_p
of IN 1_p
ventricular JJ 1_p
fibrillation NN 1_p
or CC 1_p
sustained VBN 1_p
ventricular JJ 1_p
tachycardia NN 1_p
causing VBG 1_p
severe JJ 1_p
symptoms NNS 1_p
, , N
the DT N
implantable JJ 1_i
cardioverter-defibrillator NN 1_i
is VBZ N
superior JJ N
to TO N
antiarrhythmic VB 1_i
drugs NNS 1_i
for IN N
increasing VBG N
overall JJ N
survival NN N
. . N

Brain NNP 1_o
activity NN 1_o
correlates VBZ 1_p
differentially RB 1_p
with IN 1_p
increasing VBG 1_p
temporal JJ 1_p
complexity NN 1_p
of IN 1_p
rhythms NN 1_p
during IN 1_p
initialisation NN 1_p
, , 1_p
synchronisation NN 1_p
, , 1_p
and CC 1_p
continuation NN 1_p
phases NNS 1_p
of IN 1_p
paced JJ 1_i
finger NN 1_i
tapping VBG 1_i
. . 1_i

Activity NN 1_o
in IN 1_o
parts NNS 1_o
of IN 1_o
the DT 1_o
human JJ 1_o
motor NN 1_o
system NN 1_o
has VBZ N
been VBN N
shown VBN N
to TO N
correlate VB N
with IN N
the DT N
complexity NN N
of IN N
performed JJ N
motor NN N
sequences NNS N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
limbs NNS N
moved VBN N
, , N
number NN N
of IN N
movements NNS N
, , N
and CC N
number NN N
of IN N
trajectories NNS N
. . N

Here RB N
, , N
we PRP N
searched VBD N
for IN N
activity NN N
correlating VBG N
with IN N
temporal JJ N
complexity NN N
, , N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
different JJ N
intervals NNS N
produced VBN N
in IN N
the DT N
sequence NN N
, , N
using VBG N
an DT N
overlearned JJ N
tapping NN N
task NN N
. . N

Our PRP$ N
task NN N
was VBD N
divided VBN N
into IN N
three CD N
phases NNS N
: : N
movement NN 1_i
selection NN 1_i
and CC 1_i
initiation NN 1_i
( ( 1_i
initiate NN 1_i
) ) 1_i
, , 1_i
synchronisation NN 1_i
of IN 1_i
finger NN 1_i
tapping VBG 1_i
with IN 1_i
an DT 1_i
external JJ 1_i
auditory NN 1_i
cue NN 1_i
( ( 1_i
synchronise NN 1_i
) ) 1_i
, , N
and CC N
continued VBD 1_i
tapping VBG 1_i
in IN 1_i
absence NN 1_i
of IN 1_i
the DT 1_i
auditory JJ 1_i
pacer NN 1_i
( ( N
continue NN N
) ) N
. . N

Comparisons NNS N
between IN N
synchronisation NN N
and CC N
continuation NN N
showed VBD N
a DT N
pattern NN N
in IN N
keeping VBG N
with IN N
prior JJ N
neuroimaging VBG N
studies NNS N
of IN N
paced JJ N
finger NN N
tapping VBG N
. . N

Thus RB N
, , N
activation NN 1_o
of IN 1_o
bilateral JJ 1_o
SMA NNP 1_o
and CC 1_o
basal NN 1_o
ganglia NN 1_o
was VBD N
greater JJR N
in IN N
continuation NN 1_i
tapping VBG N
than IN N
in IN N
synchronisation NN 1_i
tapping NN N
. . N

Parametric JJ N
analysis NN N
revealed VBD N
activity NN 1_o
correlating VBG 1_o
with IN 1_o
temporal JJ 1_o
complexity NN 1_o
during IN 1_o
initiate NN 1_o
in IN 1_o
bilateral JJ 1_o
supplementary JJ 1_o
and CC 1_o
pre-supplementary JJ 1_o
motor NN 1_o
cortex NN 1_o
( ( 1_o
SMA NNP 1_o
and CC 1_o
preSMA NN 1_o
) ) 1_o
, , 1_o
rostral JJ 1_o
dorsal NN 1_o
premotor NN 1_o
cortex NN 1_o
( ( 1_o
PMC NNP 1_o
) ) 1_o
, , 1_o
basal JJ 1_o
ganglia NN 1_o
, , 1_o
and CC 1_o
dorsolateral JJ 1_o
prefrontal NN 1_o
cortex NN 1_o
( ( 1_o
DLPFC NNP 1_o
) ) 1_o
, , 1_o
among IN 1_o
other JJ 1_o
areas NNS 1_o
. . 1_o

During IN N
synchronise NN N
, , N
correlated VBD 1_o
activity NN 1_o
was VBD N
observed VBN N
in IN N
bilateral JJ N
SMA NNP N
, , N
more RBR N
caudal JJ N
dorsal NN N
and CC N
ventral JJ N
PMC NNP N
, , N
right JJ N
DLPFC NNP N
and CC N
right JJ N
primary NN N
motor NN N
cortex NN N
. . N

No DT N
correlated JJ N
activity NN N
was VBD N
observed VBN N
during IN N
continue NN N
at IN N
P NNP N
< $ N
0.01 CD N
( ( N
corrected VBN N
, , N
cluster JJR N
level NN N
) ) N
, , N
though RB N
left VBD N
angular JJ N
gyrus NN N
was VBD N
active JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
preSMA NN 1_o
and CC 1_o
rostral JJ 1_o
dorsal NN 1_o
PMC NNP 1_o
activities NNS 1_o
during IN N
initiate NN N
may MD N
be VB N
associated VBN N
with IN N
selection NN 1_o
of IN 1_o
timing VBG 1_o
parameters NNS 1_o
, , N
while IN N
activation NN N
in IN N
centromedial JJ N
prefrontal JJ N
cortex NN N
during IN N
both DT N
initiate JJ N
and CC N
synchronise NN N
may MD N
be VB N
associated VBN N
with IN N
temporal JJ 1_o
error NN 1_o
monitoring NN 1_o
or CC 1_o
correction NN 1_o
. . 1_o

The DT N
absence NN N
of IN N
activity NN 1_o
significantly RB 1_o
correlated VBN 1_o
with IN 1_o
temporal JJ 1_o
complexity NN 1_o
during IN N
continue JJ N
suggests NNS N
that IN N
, , N
once RB N
an DT N
overlearned VBN N
timed JJ N
movement NN N
sequence NN N
has VBZ N
been VBN N
selected VBN N
and CC N
initiated VBN N
, , N
there EX N
is VBZ N
no DT N
further JJ N
adjustment NN N
of IN N
the DT N
timing NN N
control NN N
processes VBZ N
related VBN N
to TO N
its PRP$ N
continued JJ N
production NN N
in IN N
absence NN N
of IN N
external JJ N
cues NNS N
. . N

Pelvic NNP 1_i
lymphadenectomy NN 1_i
for IN N
cervical JJ 1_p
carcinoma NN 1_p
: : 1_p
laparotomy JJ 1_i
extraperitoneal NN 1_i
, , 1_i
transperitoneal NN 1_i
or CC 1_i
laparoscopic NN 1_i
approach NN N
? . N
A DT N
randomized JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
transperitoneal NN 1_i
, , 1_i
extraperitoneal NN 1_i
and CC 1_i
laparoscopic NN 1_i
pelvic JJ 1_i
lymphadenectomy NN 1_i
in IN N
terms NNS N
of IN N
feasibility NN 1_o
and CC 1_o
morbidity NN 1_o
in IN N
patients NNS 1_p
affected VBN 1_p
by IN 1_p
cervical JJ 1_p
cancer NN 1_p
undergoing VBG 1_p
radical JJ 1_i
hysterectomy NN 1_i
. . 1_i

METHODS NNP N
Consecutive JJ 1_p
patients NNS 1_p
affected VBN 1_p
by IN 1_p
stage NN 1_p
IB-IIB JJ 1_p
cervical JJ 1_p
carcinoma NN 1_p
scheduled VBN 1_p
for IN 1_p
radical JJ 1_i
surgery NN 1_i
entered VBD N
the DT N
study NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
transperitoneal VB 1_i
( ( 1_i
TPL NNP 1_i
) ) 1_i
, , 1_i
extraperitoneal FW 1_i
( ( 1_i
EPL NNP 1_i
) ) 1_i
or CC 1_i
laparoscopic JJ 1_i
pelvic JJ 1_i
lymphadenectomy NN 1_i
( ( 1_i
LPL NNP 1_i
) ) 1_i
. . 1_i

All DT 1_p
patients NNS 1_p
underwent JJ 1_p
classical JJ 1_i
radical JJ 1_i
hysterectomy NN 1_i
. . 1_i

Perioperative JJ N
data NNS N
were VBD N
recorded VBN N
. . N

Follow VB N
up RP N
examinations NNS 1_o
were VBD N
performed VBN N
at IN N
the DT N
15th CD N
, , N
30th CD N
and CC N
60th CD N
day NN N
after IN N
surgery NN N
. . N

RESULTS CC N
168 CD 1_p
patients NNS 1_p
entered VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

The DT N
mean JJ 1_o
operative JJ 1_o
times NNS 1_o
were VBD N
: : N
63+/-7.6 JJ N
, , N
54+/-6.7 JJ N
and CC N
75+/-8.4 JJ N
min NN N
( ( 1_i
TPL NNP 1_i
vs RB N
EPL NNP 1_i
P NNP N
< NNP N
0.001 CD N
; : N
EPL NNP N
vs FW N
LPL NNP N
P NNP N
< NNP N
0.001 CD N
; : N
TPL NNP 1_i
vs FW N
LPL NNP 1_i
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
TPL NNP 1_i
, , 1_i
EPL NNP 1_i
and CC N
LPL NNP 1_i
respectively RB N
. . N

The DT N
feasibility NN 1_o
of IN 1_o
the DT 1_o
procedures NNS 1_o
, , N
analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
, , N
was VBD N
96 CD N
% NN N
, , N
93 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
TPL NNP 1_i
, , 1_i
EPL NNP 1_i
and CC 1_i
LPL NNP 1_i
group NN 1_i
respectively RB N
( ( N
P=ns NNP N
) ) N
. . N

The DT N
average JJ 1_o
hospitalizations NNS 1_o
were VBD N
: : N
5.6+/-0.9 JJ N
, , N
3.2+/-0.4 JJ N
and CC N
3.1+/-0.3 JJ N
days NNS N
( ( 1_i
TPL NNP 1_i
vs RB N
EPL NNP 1_i
P NNP N
< NNP N
0.001 CD N
; : N
TPL NNP 1_i
vs FW N
LPL NNP 1_i
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
TPL NNP 1_i
, , 1_i
EPL NNP 1_i
and CC N
LPL NNP 1_i
respectively RB N
. . N

CONCLUSIONS NNP N
EPL NNP 1_i
and CC N
LPL NNP 1_i
are VBP N
as IN N
feasible JJ 1_o
and CC N
effective JJ 1_o
as IN N
TPL NNP 1_i
and CC N
can MD N
be VB N
adequately RB N
performed VBN N
with IN N
a DT N
reasonable JJ N
complication NN N
rate NN N
. . N

LPL NNP 1_i
showed VBD N
a DT N
statistically RB N
significant JJ N
longer RBR N
operative JJ 1_o
time NN 1_o
. . 1_o

However RB N
, , N
both DT N
EPL NNP 1_i
and CC N
LPL NNP 1_i
can MD N
minimize VB N
some DT N
postoperative JJ N
complications NNS N
reducing VBG N
length NN 1_o
of IN 1_o
stay NN 1_o
. . 1_o

A DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
St. NNP N
John NNP N
's POS N
wort NN N
for IN N
smoking VBG 1_o
cessation NN 1_o
. . 1_o

INTRODUCTION NNP N
St. NNP N
John NNP 1_i
's POS 1_i
wort NN 1_i
( ( 1_i
SJW NNP 1_i
) ) 1_i
is VBZ N
a DT N
widely RB N
used VBN N
herbal JJ N
supplement NN N
. . N

The DT N
predominant JJ N
mechanism NN N
( ( N
s PRP N
) ) N
accounting NN N
for IN N
the DT N
activity NN N
of IN N
SJW NNP 1_i
in IN N
vivo NN N
are VBP N
, , N
however RB N
, , N
unclear JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
SJW NNP 1_i
for IN N
smoking VBG 1_o
cessation NN 1_o
. . 1_o

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
blinded VBN N
, , N
placebo-controlled JJ N
, , N
three-arm JJ N
, , N
dose-ranging JJ N
clinical JJ N
trial NN N
. . N

A DT N
total NN N
of IN N
118 CD 1_p
subjects NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
SJW NNP 1_i
300 CD 1_i
mg NN 1_i
, , 1_i
600 CD 1_i
mg NN 1_i
, , 1_i
or CC 1_i
a DT 1_i
matching JJ 1_i
placebo NN 1_i
tablet NN 1_i
3 CD 1_i
times NNS 1_i
a DT 1_i
day NN 1_i
combined VBN 1_i
with IN 1_i
a DT 1_i
behavioral JJ 1_i
intervention NN 1_i
for IN 1_i
12 CD 1_i
weeks NNS 1_i
. . 1_i

Self-reported JJ N
smoking NN 1_o
abstinence NN 1_o
was VBD N
biochemically RB N
confirmed VBN N
with IN N
expired JJ 1_o
air NN 1_o
carbon NN 1_o
monoxide NN 1_o
. . 1_o

RESULTS NNP N
Mean NNP 1_p
age NN 1_p
of IN 1_p
the DT 1_p
study NN 1_p
participants NNS 1_p
was VBD 1_p
37.6 CD 1_p
+/- JJ 1_p
12.4 CD 1_p
years NNS 1_p
; : 1_p
they PRP 1_p
smoked VBD 1_p
an DT 1_p
average NN 1_p
of IN 1_p
20.0 CD 1_p
+/- JJ 1_p
6.6 CD 1_p
cigarettes NNS 1_p
per IN 1_p
day NN 1_p
for IN 1_p
20 CD 1_p
+/- JJ 1_p
12.1 CD 1_p
years NNS 1_p
. . 1_p

The DT 1_p
study NN 1_p
dropout NN 1_p
rate NN 1_p
was VBD 1_p
high JJ 1_p
( ( 1_p
43 CD 1_p
% NN 1_p
) ) 1_p
. . 1_p

By IN N
intention-to-treat JJ N
analysis NN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
abstinence NN 1_o
rates NNS N
at IN N
12 CD N
and CC N
24 CD N
weeks NNS N
between IN N
SJW NNP N
dose VBP N
groups NNS N
and CC N
placebo NN N
. . N

SJW NNP 1_i
did VBD N
not RB N
attenuate VB N
withdrawal NN 1_o
symptoms NNS 1_o
among IN N
abstinent JJ N
subjects NNS N
. . N

Abstinence NN 1_o
rates NNS 1_o
did VBD N
not RB N
differ VB N
by IN N
study NN N
group NN N
among IN N
subjects NNS N
who WP N
took VBD N
at IN N
least JJS N
75 CD N
% NN N
of IN N
their PRP$ N
study NN N
medication NN N
. . N

No DT N
significant JJ N
side-effects NNS N
were VBD N
noted VBN N
with IN N
SJW NNP 1_i
. . 1_i

CONCLUSIONS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
SJW NNP 1_i
did VBD N
not RB N
increase VB N
smoking VBG N
abstinence JJ 1_o
rates NNS N
. . N

Our PRP$ N
data NNS N
, , N
in IN N
combination NN N
with IN N
data NNS N
from IN N
other JJ N
studies NNS N
, , N
suggest VBP N
that IN N
SJW NNP N
has VBZ N
little JJ N
role NN N
in IN N
the DT N
treatment NN N
of IN N
tobacco NN 1_p
dependence NN 1_p
. . 1_p

Classification NN N
of IN N
motor NN 1_o
imagery NN 1_o
performance NN 1_o
in IN N
acute JJ 1_p
stroke NN 1_p
. . 1_p

OBJECTIVE NNP N
Effective NNP 1_o
motor NN 1_o
imagery NN 1_o
performance NN 1_o
, , N
seen VBN N
as IN N
strong JJ N
suppression NN N
of IN N
the DT N
sensorimotor NN N
rhythm NN N
, , N
is VBZ N
the DT N
key JJ N
element NN N
in IN N
motor NN 1_i
imagery NN 1_i
therapy NN 1_i
. . 1_i

Therefore RB N
, , N
optimization NN N
of IN N
methods NNS N
to TO N
classify VB N
whether IN N
the DT N
subject NN N
is VBZ N
performing VBG N
the DT N
imagery NN N
task NN N
is VBZ N
a DT N
prerequisite NN N
. . N

An DT N
optimal JJ N
classification NN N
method NN N
should MD N
have VB N
high JJ N
performance NN N
accuracy NN N
and CC N
use VB N
a DT N
small JJ N
number NN N
of IN N
channels NNS N
. . N

We PRP N
investigated VBD N
the DT N
additional JJ N
benefit NN N
of IN N
the DT N
common JJ N
spatial JJ N
pattern NN N
filtering NN N
( ( N
CSP NNP N
) ) N
to TO N
a DT N
linear JJ N
discriminant JJ N
analysis NN N
( ( N
LDA NNP N
) ) N
classifier NN N
, , N
for IN N
different JJ N
channel NN N
configurations NNS N
. . N

METHODS NNP N
Ten NNP 1_p
hemispheric JJ 1_p
acute NN 1_p
stroke NN 1_p
patients NNS 1_p
and CC 1_p
11 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

EEGs NNP 1_i
were VBD N
recorded VBN N
using VBG N
60 CD N
channels NNS N
. . N

The DT N
classifier NN N
was VBD N
trained VBN N
with IN N
a DT N
motor NN N
execution NN N
task NN N
. . N

For IN N
both DT N
healthy JJ N
controls NNS N
and CC N
patients NNS N
, , N
analysis NN N
of IN N
recordings NNS N
was VBD N
initially RB N
limited VBN N
to TO N
3 CD N
and CC N
11 CD N
electrodes NNS N
recording VBG N
from IN N
the DT N
motor NN N
cortex JJ N
area NN N
, , N
and CC N
later RB N
repeated VBD N
using VBG N
45 CD N
electrodes NNS N
. . N

RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
on IN N
the DT N
addition NN N
of IN N
CSP NNP N
to TO N
LDA NNP 1_o
was VBD N
found VBN N
( ( N
in IN N
both DT N
cases NNS N
, , N
the DT N
area NN 1_o
under IN 1_o
the DT 1_o
receiving NN 1_o
operating VBG 1_o
characteristic JJ 1_o
( ( 1_o
AU-ROC NNP 1_o
) ) 1_o
≈ VBZ N
0.70 CD N
( ( N
acceptable JJ N
) ) N
) ) N
. . N

We PRP N
then RB N
repeated VBD N
the DT N
LDA+CSP NNP N
method NN N
on IN N
recordings NNS N
of IN N
45 CD N
electrodes NNS N
, , N
since IN N
the DT N
use NN N
of IN N
imagery JJ N
neuronal JJ N
circuits NNS N
may MD N
well RB N
extend VB N
beyond IN N
the DT N
motor NN N
area NN 1_o
. . 1_o

AU-ROC NNP 1_o
rose VBD N
to TO N
0.90 CD N
, , N
but CC N
no DT 1_o
virtual JJ 1_o
'most POS 1_o
responsible JJ 1_o
' '' 1_o
electrode NN 1_o
was VBD N
observed VBN N
. . N

Finally RB N
, , N
in IN 1_p
mild-to-moderate JJ 1_p
stroke NN 1_p
patients NNS 1_p
we PRP N
could MD N
successfully RB N
use VB N
the DT 1_o
EEG NNP 1_o
data NNS 1_o
recorded VBD N
from IN N
the DT N
healthy JJ N
hemisphere NN N
to TO N
train VB N
the DT N
classifier NN N
( ( N
AU-ROC NNP N
≈ NNP N
0.70 CD N
) ) N
. . N

SIGNIFICANCE NNP N
Including VBG N
only RB N
the DT N
channels NNS N
on IN N
the DT N
unaffected JJ N
motor NN N
cortex NN N
is VBZ N
sufficient JJ N
to TO N
train VB N
a DT N
classifier NN N
. . N

Cross-over JJ N
trial NN N
of IN N
intensive JJ N
monotherapy NN N
with IN N
atorvastatin NN 1_i
and CC N
combined VBN N
therapy NN N
with IN N
atorvastatin NN 1_i
and CC N
colestimide NN 1_i
for IN N
Japanese JJ 1_p
familial JJ 1_p
hypercholesterolemia NN 1_p
. . 1_p

BACKGROUND NNP N
In IN N
familial JJ 1_p
hypercholesterolemia NN 1_p
( ( 1_p
FH NNP 1_p
) ) 1_p
, , N
low-density JJ 1_o
lipoprotein-cholesterol NN 1_o
( ( 1_o
LDL-C NNP 1_o
) ) 1_o
-lowering VBG 1_o
therapy NN N
is VBZ N
important JJ N
to TO N
avoid VB N
predisposition NN N
to TO N
coronary JJ N
artery NN N
disease NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
advantages NNS N
of IN N
combined JJ N
therapy NN N
with IN N
atorvastatin NN 1_i
and CC N
colestimide NN 1_i
vs NN N
intensive JJ N
monotherapy NN N
with IN N
atorvastatin NN 1_i
. . 1_i

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
trial NN N
used VBD N
a DT N
randomized JJ N
cross-over NN N
design NN N
consisting VBG N
of IN N
2 CD N
16-week JJ N
periods NNS N
of IN N
open-label JJ N
drug NN N
therapy NN N
. . N

Among IN N
the DT N
24 CD 1_p
initial JJ 1_p
patients NNS 1_p
, , 1_p
17 CD 1_p
heterozygous JJ 1_p
FH NNP 1_p
patients NNS 1_p
( ( 1_p
age NN 1_p
: : 1_p
54.1 CD 1_p
years NNS 1_p
; : 1_p
5 CD 1_p
males NNS 1_p
) ) 1_p
were VBD N
enrolled VBN N
after IN 1_i
20 CD 1_i
mg/day JJ 1_i
atorvastatin RB 1_i
failed VBD 1_i
to TO 1_i
achieve VB 1_i
their PRP$ 1_i
target NN 1_i
level NN 1_i
. . 1_i

The DT N
patients NNS N
received VBD N
20 CD N
mg/day JJ N
atorvastatin NN 1_i
and CC N
3 CD N
g/day JJ N
colestimide NN 1_i
or CC N
40 CD N
mg/day JJ N
atorvastatin NN 1_i
. . 1_i

Fifteen JJ 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
trial NN 1_p
and CC N
their PRP$ N
LDL-C JJ 1_o
reduced VBN N
from IN N
5.07 CD N
+/- JJ N
1.10 CD N
mmol/L NN N
to TO N
3.76 CD N
+/- JJ N
0.90 CD N
mmol/L NN N
with IN N
the DT N
combined JJ N
therapy NN N
and CC N
to TO N
3.81 CD N
+/- JJ N
0.50 CD N
mmol/L NN N
with IN N
the DT N
intensive JJ N
monotherapy NN N
. . N

Although IN N
the DT N
2 CD N
therapies NNS N
showed VBD N
comparable JJ N
mean JJ N
effects NNS N
for IN N
decreasing VBG N
LDL-C NNP 1_o
, , N
similar JJ N
adverse JJ N
reaction NN N
and CC N
cost NN N
, , N
each DT N
therapy NN N
was VBD N
predominantly RB N
more RBR N
effective JJ N
in IN N
some DT N
patients NNS N
than IN N
in IN N
others NNS N
. . N

The DT N
triglyceride NN 1_o
and CC 1_o
high-density NN 1_o
lipoprotein NNS 1_o
cholesterol NN 1_o
levels NNS 1_o
were VBD N
similar JJ N
in IN N
both DT N
therapies NNS N
. . N

CONCLUSIONS NNP N
To TO N
achieve VB N
the DT N
therapeutic JJ N
target NN N
of IN N
LDL-C NNP 1_o
level NN N
for IN N
refractory NN N
FH NNP N
, , N
the DT N
LDL-C-lowering JJ N
therapy NN N
selected VBN N
can MD N
be VB N
either RB N
intensive JJ N
monotherapy NN N
or CC N
combined VBN N
therapy NN N
as IN N
the DT N
next JJ N
to TO N
standard VB N
statin NN N
therapy NN N
. . N

Effect NN N
of IN N
finasteride JJ 1_i
treatment NN N
on IN N
suburethral JJ N
prostatic JJ N
microvessel NN N
density NN N
in IN N
patients NNS 1_p
with IN 1_p
hematuria NNS 1_p
related VBN 1_p
to TO 1_p
benign VB 1_p
prostate JJ 1_p
hyperplasia NN 1_p
. . 1_p

INTRODUCTION NNP N
In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
short-term JJ N
finasteride JJ 1_i
treatment NN N
on IN N
microvessel NN N
density NN N
( ( N
MVD NNP N
) ) N
which WDT N
is VBZ N
an DT N
indicator NN N
of IN N
prostatic JJ N
angiogenesis NN N
in IN N
patients NNS 1_p
with IN 1_p
hematuria NNS 1_p
secondary JJ 1_p
to TO 1_p
benign VB 1_p
prostatic JJ 1_p
hyperplasia NN 1_p
( ( 1_p
BPH NNP 1_p
) ) 1_p
. . 1_p

MATERIALS NNP N
AND NNP N
METHODS NNP N
30 CD 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
candidates NNS 1_p
for IN 1_p
BPH NNP 1_p
surgery NN 1_p
were VBD N
prospectively RB N
included VBN N
in IN N
the DT N
study NN N
. . N

All DT 1_p
patients NNS 1_p
had VBD 1_p
history NN 1_p
of IN 1_p
gross JJ 1_p
hematuria NN 1_p
and CC 1_p
evaluated VBN 1_p
by IN 1_p
ultrasonography NN 1_p
and CC 1_p
cystoscopy NN 1_p
. . 1_p

The DT N
patients NNS N
were VBD N
randomized VBN N
two CD N
groups NNS N
before IN N
surgery NN N
. . N

The DT N
treatment NN N
group NN N
consisted VBD N
of IN N
13 CD N
patients NNS N
who WP N
were VBD N
given VBN N
5 CD 1_i
mg JJ 1_i
finasteride JJ 1_i
daily NN 1_i
for IN N
4 CD N
weeks NNS N
before RB N
surgery NN N
. . N

The DT N
control NN N
group NN N
consisted VBD N
of IN N
17 CD N
patients NNS N
who WP N
did VBD 1_i
not RB 1_i
receive VB 1_i
finasteride NN 1_i
before IN N
surgery NN N
. . N

During IN N
surgery NN N
, , N
resected VBN N
suburethral JJ N
and CC N
hyperplastic JJ N
prostate NN N
specimens NNS N
were VBD N
sent VBN N
for IN N
histopathologic JJ N
MVD NNP N
determination NN N
separately RB N
. . N

RESULTS NNP N
Mean NNP 1_o
MVD NNP 1_o
in IN 1_o
the DT 1_o
suburethral JJ 1_o
portion NN 1_o
of IN 1_o
prostate NN 1_o
was VBD 1_o
significantly RB 1_o
lower JJR 1_o
in IN N
patients NNS N
treated VBN N
with IN N
finasteride NN N
when WRB N
compared VBN N
with IN N
controls NNS N
( ( N
9.08 CD N
+/- JJ N
5.6 CD N
and CC N
13.94 CD N
+/- JJ N
5.90 CD N
, , N
respectively RB N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Mean NNP 1_o
MVD NNP 1_o
for IN 1_o
the DT 1_o
hyperplastic JJ 1_o
portion NN 1_o
of IN 1_o
prostate NN 1_o
was VBD N
similar JJ N
for IN N
the DT N
finasteride NN N
and CC N
control NN N
groups NNS N
( ( N
14.21 CD N
+/- JJ N
7.10 CD N
and CC N
19.75 CD N
+/- JJ N
9.73 CD N
, , N
respectively RB N
, , N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
potential JJ N
role NN N
of IN N
finasteride NN N
on IN N
hematuria NNS N
related VBN N
to TO N
BPH NNP N
may MD N
be VB N
the DT N
suppressive JJ N
effect NN N
on IN N
MVD NNP 1_o
in IN N
the DT N
suburethral JJ N
tissue NN N
of IN N
prostate NN N
. . N

Hepatic JJ N
cytoprotective JJ N
effect NN N
of IN N
ischemic JJ 1_i
and CC 1_i
anesthetic JJ 1_i
preconditioning NN 1_i
before IN N
liver JJ N
resection NN N
when WRB N
using VBG N
intermittent JJ N
vascular JJ N
inflow JJ N
occlusion NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Ischemic NNP 1_i
preconditioning NN 1_i
( ( 1_i
IPC NNP 1_i
) ) 1_i
and CC N
anesthetic JJ 1_i
preconditioning NN 1_i
( ( 1_i
APC NNP 1_i
) ) 1_i
have VBP N
been VBN N
reported VBN N
to TO N
attenuate VB N
ischemia-reperfusion NN N
( ( N
IR NNP N
) ) N
injury NN N
after IN N
liver JJ N
resection NN N
under IN N
continuous JJ N
inflow JJ N
occlusion NN N
. . N

This DT N
study NN N
evaluates VBZ N
whether IN N
these DT N
strategies NNS N
enhance VBP N
hepatic JJ N
protection NN N
of IN N
remnant JJ N
liver NN N
against IN N
IR NNP N
after IN N
liver JJ 1_p
resection NN 1_p
with IN 1_p
intermittent JJ 1_i
clamping NN 1_i
( ( 1_i
INT NNP 1_i
) ) 1_i
. . 1_i

METHODS CC N
A DT 1_p
total NN 1_p
of IN 1_p
106 CD 1_p
patients NNS 1_p
without IN 1_p
underlying VBG 1_p
liver NN 1_p
disease NN 1_p
and CC 1_p
submitted VBN 1_p
to TO 1_p
liver VB 1_p
resection NN 1_p
using VBG 1_p
INT NNP 1_p
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
: : N
IPC NNP 1_i
( ( 1_i
10 CD 1_i
minutes NNS 1_i
of IN 1_i
inflow JJ 1_i
occlusion NN 1_i
followed VBN 1_i
by IN 1_i
10 CD 1_i
minutes NNS 1_i
of IN 1_i
reperfusion NN 1_i
before IN 1_i
liver JJ 1_i
transection NN 1_i
) ) 1_i
, , 1_i
APC NNP 1_i
( ( 1_i
sevoflurane JJ 1_i
administration NN 1_i
for IN 1_i
20 CD 1_i
minutes NNS 1_i
before IN 1_i
liver JJ 1_i
transection NN 1_i
) ) 1_i
, , 1_i
and CC 1_i
INT NNP 1_i
( ( 1_i
no DT 1_i
preconditioning NN 1_i
) ) 1_i
. . 1_i

Patients NNS N
were VBD N
also RB N
stratified VBN N
according VBG N
to TO N
the DT N
extent NN N
of IN N
the DT N
hepatectomy NN N
. . N

Cytoprotection NN 1_o
was VBD N
evaluated VBN N
by IN N
comparing VBG 1_o
hepatocyte NN 1_o
and CC 1_o
endothelial JJ 1_o
dysfunction NN 1_o
markers NNS 1_o
, , 1_o
apoptosis NN 1_o
, , 1_o
histologic JJ 1_o
lesions NNS 1_o
, , 1_o
and CC 1_o
postoperative JJ 1_o
outcome NN 1_o
. . 1_o

RESULTS NNP N
No NNP N
differences NNS N
were VBD N
observed VBN N
in IN N
preoperative JJ 1_o
chemotherapy NN 1_o
and CC 1_o
steatosis NN 1_o
, , 1_o
total JJ 1_o
warm JJ 1_o
ischemia NN 1_o
time NN 1_o
, , 1_o
operative JJ 1_o
time NN 1_o
, , 1_o
or CC 1_o
blood NN 1_o
loss NN 1_o
. . 1_o

Kinetics NNS 1_o
of IN 1_o
transaminases NNS 1_o
( ( N
aspartate JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.137 NNP N
; : N
alanine JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.616 NNP N
) ) N
, , N
bilirubin FW 1_o
( ( N
P NNP N
= NNP N
.980 NNP N
) ) N
, , N
and CC N
hyaluronic JJ 1_o
acid NN 1_o
increase NN N
( ( N
P NNP N
= NNP N
.514 NNP N
) ) N
revealed VBD N
no DT N
differences NNS N
. . N

Significant JJ 1_o
apoptosis NN 1_o
was VBD N
present JJ N
in IN N
40 CD N
% NN N
of IN N
patients NNS N
, , N
mild-to-moderate JJ 1_o
leukocyte NN 1_o
infiltration NN 1_o
and CC 1_o
steatosis NN 1_o
in IN N
45 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
mild VB 1_o
sinusoidal JJ 1_o
congestion NN 1_o
in IN N
65 CD N
% NN N
, , N
with IN N
a DT N
similar JJ N
distribution NN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

When WRB N
patients NNS N
were VBD N
stratified VBN N
by IN N
major JJ N
versus NN N
minor JJ N
resections NNS N
, , N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
variables NNS N
studied VBN N
. . N

Postoperative JJ N
clinical JJ N
outcomes NNS N
were VBD N
also RB N
similar JJ N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
these DT N
protocols NNS 1_i
of IN 1_i
IPC NNP 1_i
and CC 1_i
APC NNP 1_i
used VBD N
in IN N
this DT N
study NN N
do VBP N
not RB N
provide VB N
better JJR N
cytoprotection NN N
from IN N
IR NNP N
when WRB N
INT NNP 1_i
is VBZ N
used VBN N
. . N

The DT N
influence NN N
of IN N
amiloride NN 1_i
on IN N
the DT N
therapeutic JJ N
and CC N
metabolic JJ N
effects NNS N
of IN N
carbenoxolone NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
gastric JJ 1_p
ulcer NN 1_p
. . 1_p

A DT N
double-blind NN N
controlled VBN N
trial NN N
. . N

Patients NNS 1_p
with IN 1_p
benign JJ 1_p
gastric JJ 1_p
ulcer NN 1_p
were VBD N
treated VBN N
for IN N
four CD N
weeks NNS N
with IN N
carbenoxolone NN 1_i
sodium NN 1_i
as IN 1_i
Biogastrone NNP 1_i
tablets VBZ 1_i
100 CD 1_i
mg NN 1_i
three CD 1_i
times NNS 1_i
a DT 1_i
day NN 1_i
, , N
and CC N
if IN N
the DT N
ulcers NNS N
were VBD N
not RB N
healed VBN N
at IN N
4 CD N
weeks NNS N
treatment NN N
was VBD N
continued VBN N
for IN N
a DT N
further JJ N
4 CD N
weeks NNS N
. . N

Fifty NNP 1_p
two CD 1_p
patients NNS 1_p
entered VBD 1_p
the DT 1_p
trial NN 1_p
, , 1_p
and CC 1_p
12 CD 1_p
were VBD 1_p
withdrawn VBN 1_p
. . 1_p

In IN N
17 CD N
patients NNS N
who WP N
were VBD N
randomly RB N
allotted VBN N
double-blind JJ N
additional JJ N
dummy NN 1_i
tablets NNS 1_i
16 CD N
of IN N
their PRP$ N
ulcer NN N
healed VBD N
completely RB N
endoscopically RB N
, , N
whereas NNS N
of IN N
the DT N
23 CD N
patients NNS N
given VBN N
additional JJ N
amiloride NN 1_i
5 CD N
mg NN N
three CD N
times NNS N
a DT N
day NN N
only RB N
14 CD N
ulcers NNS N
healed VBD N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
ulcer JJ N
healing NN N
. . N

The DT N
clinical JJ N
( ( 1_o
weight JJ 1_o
gain NN 1_o
and CC 1_o
oedema NN 1_o
) ) 1_o
and CC N
metabolic JJ N
( ( 1_o
hypertension NN 1_o
, , 1_o
hypokalaemia NN 1_o
and CC 1_o
hypernatraemia NN 1_o
) ) 1_o
side-effects NNS N
were VBD N
reduced VBN N
by IN N
the DT N
active JJ N
amiloride NN 1_i
therapy NN N
, , N
but CC N
serum VBP 1_o
carbenoxolone NN 1_o
levels NNS 1_o
were VBD N
not RB N
affected VBN N
. . N

Thus VB N
the DT N
potassium-retaining JJ N
diuretic JJ N
amiloride NN 1_i
, , N
like IN N
the DT N
aldosterone NN N
antagonist NN N
spironolactone NN 1_i
, , N
markedly RB N
reduces VBZ N
both CC N
the DT N
ulcer-healing JJ 1_o
and CC N
the DT N
metabolic JJ 1_o
side-effects NNS 1_o
of IN N
carbenoxolone NN N
sodium NN N
, , N
and CC N
should MD N
not RB N
be VB N
used VBN N
together RB N
with IN N
it PRP N
in IN N
the DT N
treatment NN N
of IN N
peptic JJ 1_p
ulcer NN 1_p
. . 1_p

Isometric JJ 1_i
contractions NNS 1_i
reduce VB N
plantar NN 1_o
flexor NN 1_o
moment NN 1_o
, , 1_o
Achilles NNP 1_o
tendon VBZ 1_o
stiffness NN 1_o
, , 1_o
and CC 1_o
neuromuscular JJ 1_o
activity NN 1_o
but CC N
remove VB N
the DT N
subsequent JJ N
effects NNS N
of IN N
stretch NN N
. . N

The DT N
effects NNS N
of IN N
isometric JJ 1_i
contractions NNS 1_i
and CC N
passive JJ 1_i
stretching NN 1_i
on IN 1_i
muscle-tendon JJ 1_i
mechanics NNS 1_i
and CC 1_i
muscle NN 1_i
activity NN 1_i
were VBD N
studied VBN N
in IN N
16 CD 1_p
healthy JJ 1_p
human JJ 1_p
volunteers NNS 1_p
. . 1_p

First NNP N
, , N
peak NN 1_i
concentric NN 1_i
and CC 1_i
passive JJ 1_i
ankle NN 1_i
joint JJ 1_i
moment NN 1_i
data NNS 1_i
were VBD 1_i
recorded VBN 1_i
on IN 1_i
an DT 1_i
isokinetic JJ 1_i
dynamometer NN 1_i
with IN 1_i
electromyographic JJ 1_i
monitoring NN 1_i
of IN 1_i
the DT 1_i
triceps NNS 1_i
surae VBP 1_i
; : 1_i
real-time JJ 1_i
motion NN 1_i
analysis NN 1_i
of IN 1_i
the DT 1_i
lower JJR 1_i
leg NN 1_i
and CC 1_i
ultrasound JJ 1_i
imaging NN 1_i
of IN 1_i
the DT 1_i
Achilles-medial JJ 1_i
gastrocnemius NN 1_i
muscle-tendon JJ 1_i
junction NN 1_i
were VBD 1_i
simultaneously RB 1_i
conducted VBN 1_i
. . 1_i

Second NNP N
, , N
the DT N
subjects NNS N
performed VBD N
six CD 1_i
8-s JJ 1_i
maximal JJ 1_i
voluntary JJ 1_i
isometric JJ 1_i
contractions NNS 1_i
( ( 1_i
MVICs NNP 1_i
) ) 1_i
before IN 1_i
repeating VBG 1_i
the DT 1_i
passive NN 1_i
and CC 1_i
active JJ 1_i
trials NNS 1_i
. . 1_i

Although IN N
there EX N
was VBD N
no DT N
decrease NN N
in IN N
isometric JJ 1_o
joint JJ 1_o
moment NN 1_o
after IN N
MVICs NNP N
, , N
peak NN 1_o
concentric JJ 1_o
moment NN 1_o
was VBD N
significantly RB N
reduced VBN N
( ( N
11.5 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

This DT N
was VBD N
accompanied VBN N
by IN N
, , N
and CC N
correlated VBN N
with IN N
( ( N
r NN N
= VBZ N
0.90 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
significant JJ N
reductions NNS N
in IN N
peak JJ 1_o
triceps NNS 1_o
surae VBP 1_o
electromyographic JJ 1_o
amplitude NN 1_o
( ( N
21.0 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Achilles NNP 1_o
tendon VBZ 1_o
stiffness NN 1_o
( ( N
10.9 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
passive JJ 1_o
joint NN 1_o
moment NN 1_o
( ( N
4.9 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
were VBD N
also RB N
significantly RB N
reduced VBN N
. . N

Third NNP N
, , N
the DT N
subjects NNS N
performed VBD N
three CD N
60-s JJ N
static JJ 1_i
plantar NN 1_i
flexor NN 1_i
stretches NNS 1_i
before IN N
being VBG N
retested VBN N
2 CD N
and CC N
30 CD N
min NN N
after IN N
stretch NN N
. . N

The DT N
stretch NN N
protocol NN N
caused VBD N
no DT N
significant JJ N
change NN N
in IN N
any DT N
measure NN N
. . N

At IN N
30 CD N
min NN N
after IN N
stretching VBG N
, , N
significant JJ N
recovery NN N
in IN N
concentric JJ 1_o
moment NN 1_o
and CC 1_o
muscle NN 1_o
activity NN 1_o
was VBD N
detected VBN N
at IN N
dorsiflexed JJ N
joint JJ N
angles NNS N
, , N
while IN N
Achilles NNP 1_o
tendon CC 1_o
stiffness NN 1_o
and CC 1_o
passive JJ 1_o
joint JJ 1_o
moment NN 1_o
remained VBD N
significantly RB N
reduced VBN N
. . N

These DT N
data NNS N
show VBP N
that IN N
the DT N
performance NN N
of IN N
MVICs NNP N
interrupts VBP N
the DT N
normal JJ N
stretch-induced JJ N
losses NNS N
in IN N
active JJ N
and CC N
passive JJ N
plantar NN N
flexor NN N
joint JJ N
moment NN N
and CC N
neuromuscular JJ N
activity NN N
, , N
largely RB N
because IN N
concentric JJ N
strength NN N
and CC N
tendon NN N
properties NNS N
were VBD N
already RB N
affected VBN N
. . N

Importantly RB N
, , N
the DT N
decrease NN N
in IN N
Achilles NNP 1_o
tendon NN 1_o
stiffness NN 1_o
remained VBD N
30 CD N
min NN N
later RB N
, , N
which WDT N
may MD N
be VB N
an DT N
important JJ N
etiological JJ N
factor NN N
for IN N
muscle-tendon JJ N
strain NN N
injury NN N
risk NN N
. . N

Does NNP N
surface VB N
preparation NN N
alter NN N
ALA NNP 1_o
uptake NN 1_o
in IN N
superficial JJ N
non-melanoma JJ 1_p
skin NN 1_p
cancer NN 1_p
in IN N
vivo NN N
? . N
BACKGROUND/PURPOSE NNP N
Photodynamic NNP N
therapy NN N
( ( N
PDT NNP N
) ) N
using VBG N
aminolaevulinic JJ 1_i
acid NN 1_i
( ( 1_i
ALA NNP 1_i
) ) 1_i
is VBZ N
widely RB N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
non-melanoma JJ 1_p
skin NN 1_p
cancer NN 1_p
. . 1_p

Surface NNP 1_i
preparation NN 1_i
of IN N
the DT N
lesion NN N
is VBZ N
commonly RB N
performed VBN N
before IN N
application NN N
of IN N
ALA NNP N
but CC N
the DT N
extent NN N
of IN N
the DT N
preparation NN N
varies NNS N
from IN N
centre NN N
to TO N
centre VB N
and CC N
there EX N
has VBZ N
been VBN N
no DT N
study NN N
of IN N
its PRP$ N
effects NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
surface NN 1_i
preparation NN 1_i
on IN N
the DT N
local JJ N
uptake NN 1_o
of IN 1_o
ALA NNP 1_o
by IN N
recording VBG N
fluorescence NN N
from IN N
accumulated VBN N
protoporphyrin NN N
IX NNP N
( ( N
PPIX NNP N
) ) N
. . N

METHODS PDT N
The DT N
study NN N
was VBD N
performed VBN N
on IN N
16 CD 1_p
lesions NNS 1_p
, , 1_p
either RB 1_p
superficial JJ 1_p
basal NN 1_p
cell NN 1_p
carcinoma NN 1_p
( ( 1_p
BCC NNP 1_p
) ) 1_p
or CC 1_p
Bowen NNP 1_p
's POS 1_p
disease NN 1_p
( ( 1_p
BD NNP 1_p
) ) 1_p
. . 1_p

Each DT N
half NN N
of IN N
the DT N
lesion NN N
was VBD N
randomly RB N
assigned VBN N
to TO N
( ( 1_i
a DT 1_i
) ) 1_i
no DT 1_i
surface NN 1_i
preparation NN 1_i
or CC 1_i
( ( 1_i
b NN 1_i
) ) 1_i
surface NN 1_i
preparation NN 1_i
( ( 1_i
randomly RB 1_i
allocated VBN 1_i
to TO 1_i
gentle VB 1_i
curettage NN 1_i
or CC 1_i
abrasion NN 1_i
with IN 1_i
a DT 1_i
spatula NN 1_i
) ) 1_i
. . N

ALA NNP N
was VBD N
left VBN N
for IN N
4 CD N
h NN N
( ( N
BCC NNP N
) ) N
or CC N
6 CD N
h NN N
( ( N
BD NNP N
) ) N
. . N

PPIX NNP 1_o
fluorescence NN 1_o
was VBD N
measured VBN N
using VBG N
an DT N
excitation NN N
wavelength NN N
of IN N
405+/-5 JJ N
nm NN N
and CC N
emission NN N
spectrum NN N
recorded VBD N
using VBG N
a DT N
photodiode JJ 1_i
array NN 1_i
. . 1_i

Spectra NNP N
were VBD N
measured VBN N
( ( N
a DT N
) ) N
before IN N
and CC N
( ( N
b NN N
) ) N
after IN N
surface NN N
preparation NN N
, , N
( ( N
c NN N
) ) N
immediately RB N
before IN N
and CC N
( ( N
d NN N
) ) N
after IN N
laser NN 1_i
irradiation NN 1_i
at IN N
630 CD N
nm NNS N
. . N

RESULTS VB N
The DT N
ratio NN 1_o
of IN 1_o
fluorescence NN 1_o
after IN 1_o
incubation NN 1_o
to TO N
that DT N
before IN N
incubation NN N
was VBD N
6.1+/-1.2 JJ N
in IN N
the DT N
non-prepared JJ N
section NN N
. . N

This DT N
increased VBD N
slightly RB N
but CC N
not RB N
significantly RB N
to TO N
6.8 CD N
+/-1.8 NN N
in IN N
the DT N
prepared JJ N
section NN N
( ( N
P NNP N
< NNP N
0.1 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
curettage NN 1_o
and CC 1_o
abrasion NN 1_o
. . 1_o

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
outcome NN 1_o
after IN N
PDT NNP N
. . N

CONCLUSIONS NNP N
The DT N
clinical JJ N
assessment NN N
agrees VBZ N
with IN N
the DT N
fluorescence NN N
data NNS N
as IN N
no DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
between IN N
prepared JJ N
and CC N
unprepared JJ N
halves NNS N
of IN N
the DT N
lesion NN N
12 CD N
months NNS N
after IN N
PDT NNP N
. . N

Overall VB N
our PRP$ N
data NNS N
seem VBP N
to TO N
suggest VB N
that DT N
for IN N
most JJS N
BCC NNP N
and CC N
BD NNP N
lesions NNS N
, , N
surface NN N
preparation NN N
did VBD N
not RB N
increase VB N
ALA NNP 1_o
uptake JJ 1_o
. . 1_o

Video NNP N
rating NN N
analysis NN N
of IN N
effect NN N
of IN N
maprotiline NN N
in IN N
patients NNS 1_p
with IN 1_p
dementia NN 1_p
and CC 1_p
depression NN 1_p
. . 1_p

In IN N
patients NNS 1_p
with IN 1_p
dementia NN 1_p
and CC 1_p
mild JJ 1_p
depression NN 1_p
( ( 1_p
DSM-III-R NNP 1_p
290.21 CD 1_p
) ) 1_p
, , N
the DT N
effect NN N
of IN N
low JJ N
doses NNS N
of IN N
the DT N
antidepressant JJ N
maprotiline NN 1_i
( ( N
up IN N
to TO N
75 CD N
mg/d NN N
) ) N
was VBD N
examined VBN N
. . N

The DT N
main JJ N
parameter NN N
was VBD N
a DT N
video NN N
rating NN N
of IN N
global JJ N
impression NN N
. . N

The DT N
Mini-Mental JJ 1_o
State NNP 1_o
Examination NNP 1_o
( ( 1_i
MMS NNP 1_i
) ) 1_i
and CC N
the DT N
Geriatric NNP 1_o
Depression NNP 1_o
Scale NNP 1_o
( ( 1_i
GDS NNP 1_i
) ) 1_i
were VBD N
applied VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
maprotiline NN N
on IN N
cognitive JJ N
and CC N
depressive JJ N
symptoms NNS N
. . N

The DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
was VBD N
of IN N
eight CD N
weeks NNS N
' POS N
duration NN N
and CC N
included VBD N
127 CD 1_p
patients NNS 1_p
, , N
randomized VBN N
in IN N
two CD N
groups NNS N
. . N

The DT N
antidepressant JJ N
effect NN N
of IN N
maprotiline NN 1_i
was VBD N
reflected VBN N
in IN N
the DT N
GDS NNP N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
no DT N
indication NN N
of IN N
an DT N
effect NN N
of IN N
maprotiline NN N
on IN N
cognitive JJ 1_o
performance NN 1_o
. . 1_o

The DT N
global JJ N
impression NN N
, , N
evaluated VBN N
by IN N
video NN N
rating NN N
, , N
gave VBD N
no DT N
indication NN N
as IN N
to TO N
a DT N
beneficial JJ N
effect NN N
of IN N
the DT N
treatment NN N
. . N

- : N
The DT N
video NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
interrater NN N
reliability NN 1_o
. . 1_o

The DT N
discrepancy NN N
between IN N
the DT N
results NNS N
of IN N
the DT N
video NN N
rating NN N
and CC N
the DT N
GDS NNP N
is VBZ N
discussed VBN N
. . N

- : N
The DT N
results NNS N
confirm VBP N
similar JJ N
findings NNS N
of IN N
other JJ N
authors NNS N
; : N
i.e. NN N
, , N
that IN N
a DT N
sedating VBG N
antidepressant NN N
with IN N
some DT N
anticholinergic JJ N
effects NNS N
can MD N
not RB N
be VB N
expected VBN N
to TO N
improve VB N
cognitive JJ 1_o
functions NNS 1_o
despite IN N
its PRP$ N
antidepressant JJ N
effect NN N
. . N

The DT N
main JJ N
interest NN N
of IN N
this DT N
study NN N
, , N
however RB N
, , N
lies VBZ N
in IN N
its PRP$ N
methodology NN N
( ( N
video JJ N
analysis NN N
) ) N
. . N

[ JJ 1_i
New NNP 1_i
therapeutic JJ 1_i
approaches NNS 1_i
in IN N
irritable JJ 1_p
bowel NN 1_p
syndrome NN 1_p
] NN 1_p
. . N

Modifying VBG 1_o
the DT 1_o
Type NN 1_o
A DT 1_o
coronary-prone JJ 1_o
behavior NN 1_o
pattern NN 1_o
. . 1_o

Functional JJ N
modification NN 1_p
of IN 1_p
agonist-antagonist JJ 1_p
electromyographic JJ 1_p
activity NN 1_p
for IN 1_p
rapid JJ 1_p
movement NN 1_p
inhibition NN 1_p
. . 1_p

Subjects NNS 1_p
made VBD 1_p
a DT 1_p
fast JJ 1_p
elbow NN 1_p
extension NN 1_p
movement NN 1_p
to TO 1_p
designated VBN 1_p
target NN 1_p
in IN 1_p
response NN 1_p
to TO 1_p
a DT 1_p
go JJ 1_i
signal NN 1_i
. . 1_i

In IN N
45 CD N
% NN N
of IN N
trials NNS N
a DT N
stop JJ N
signal NN N
was VBD N
presented VBN N
after IN N
the DT N
go JJ N
signal NN N
, , N
to TO N
which WDT N
subjects NNS N
were VBD N
asked VBN N
to TO N
stop VB N
the DT N
movement NN N
as RB N
rapidly RB N
as IN N
possible JJ N
. . N

The DT 1_i
interstimulus JJ 1_i
interval NN 1_i
( ( 1_i
ISI NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
time NN 1_i
interval NN 1_i
between IN 1_i
the DT 1_i
go NN 1_i
and CC 1_i
stop NN 1_i
signals NNS 1_i
, , N
was VBD N
randomly RB N
varied VBN N
between IN N
0 CD N
and CC N
200 CD N
ms. NN N
Electromyographic NNP 1_o
( ( 1_o
EMG NNP 1_o
) ) 1_o
activity NN 1_o
was VBD 1_i
recorded VBN 1_i
from IN 1_i
biceps NNS 1_i
brachii NNS 1_i
and CC 1_i
triceps NNS 1_i
brachii NN 1_i
. . 1_i

Subjects NNS N
could MD N
sometimes RB N
completely RB N
inhibit JJ N
initiation NN N
of IN N
the DT N
movements NNS N
when WRB N
the DT N
ISI NNP N
was VBD N
0 CD N
ms NN N
, , N
but CC N
could MD N
rarely RB N
do VB N
so RB N
when WRB N
the DT N
ISI NNP N
exceeded VBD N
100 CD N
ms. NN N
For IN N
responses NNS N
that WDT N
were VBD N
initiated VBN N
but CC N
stopped VBN N
on IN N
the DT N
way NN N
, , N
the DT N
amplitude NN 1_o
of IN 1_o
the DT 1_o
movement NN 1_o
decreased VBD N
linearly RB N
as IN N
the DT N
time NN N
interval NN N
( ( N
=modification JJ N
time NN N
) ) N
from IN N
the DT N
stop JJ N
signal NN N
to TO N
EMG NNP N
onset NN N
increased VBD N
. . N

The DT N
peak JJ 1_o
velocity NN 1_o
increased VBD N
linearly RB N
as IN N
the DT N
movement NN N
amplitude NN N
increased VBD N
. . N

This DT N
tendency NN N
was VBD N
similar JJ N
to TO N
those DT N
previously RB N
reported VBN N
in IN N
step-tracking JJ N
movements NNS N
with IN N
various JJ N
amplitudes NNS N
. . N

In IN N
spite NN N
of IN N
the DT N
similarity NN N
in IN N
the DT N
kinematics NNS N
of IN N
the DT N
movement NN N
, , N
the DT N
EMG NNP 1_o
pattern NN 1_o
was VBD N
different JJ N
from IN N
that DT N
of IN N
step-tracking JJ 1_o
movement NN 1_o
. . 1_o

While IN N
the DT N
initial JJ 1_o
agonist NN 1_o
burst NN 1_o
( ( 1_o
AG1 NNP 1_o
) ) 1_o
decreased VBD N
linearly RB N
after IN N
the DT N
modification NN N
time NN N
exceeded VBD N
100 CD N
ms NN N
, , N
the DT N
antagonist NN 1_o
burst NN 1_o
( ( 1_o
ANT NNP 1_o
) ) 1_o
increased VBD N
compared VBN N
with IN N
the DT N
go JJ N
trial NN N
for IN N
the DT N
modification NN N
time NN N
from IN N
0 CD N
to TO N
200 CD N
ms NNS N
and CC N
decreased VBN N
after IN N
the DT N
modification NN N
time NN N
exceeded VBD N
300 CD N
ms NN N
. . N

This DT N
change NN N
of IN N
activation NN N
is VBZ N
analogous JJ N
to TO N
functional JJ N
modification NN N
of IN N
middle-latency NN N
reflex NN N
EMG NNP 1_o
response NN 1_o
to TO N
load VB N
, , N
or CC N
cutaneous JJ N
perturbation NN N
. . N

In IN N
conclusion NN N
, , N
it PRP N
is VBZ N
suggested VBN N
that IN N
adaptive JJ N
mechanisms NNS N
, , N
which WDT N
would MD N
functionally RB N
modify VB N
the DT N
reflex NN N
responses NNS N
, , N
are VBP N
also RB N
continuously RB N
working VBG N
during IN N
voluntary JJ N
movements NNS N
in IN N
response NN N
to TO N
sudden JJ N
changes NNS N
in IN N
environmental JJ N
information NN N
. . N

Sublingual JJ N
administration NN N
of IN N
micronized JJ 1_i
estradiol NN 1_i
and CC 1_i
progesterone NN 1_i
, , N
with IN N
and CC N
without IN N
micronized VBN 1_i
testosterone NN 1_i
: : 1_i
effect NN N
on IN N
biochemical JJ 1_p
markers NNS 1_p
of IN 1_p
bone NN 1_o
metabolism NN 1_p
and CC 1_o
bone JJ 1_o
mineral JJ 1_o
density NN 1_o
. . 1_o

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
the DT N
relative JJ N
efficacy NN N
of IN N
the DT N
sublingual JJ N
administration NN N
of IN N
micronized JJ 1_i
estradiol NN 1_i
( ( 1_i
E2 NNP 1_i
) ) 1_i
, , 1_i
progesterone NN 1_i
( ( 1_i
P4 NNP 1_i
) ) 1_i
, , 1_i
and CC 1_i
testosterone NN 1_i
( ( 1_i
T NNP 1_i
) ) 1_i
on IN N
bone NN 1_p
mineral JJ 1_p
density NN 1_p
and CC 1_p
biochemical JJ 1_p
markers NNS 1_p
of IN 1_p
bone NN 1_p
metabolism NN 1_p
. . 1_p

DESIGN NN N
In IN N
this DT N
double-blind NN N
, , N
prospective JJ N
study NN N
, , N
postmenopausal JJ 1_p
women NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD 1_p
treatment NN 1_p
groups NNS 1_p
: : 1_p
hysterectomized VBN 1_p
women NNS 1_p
were VBD N
assigned VBN N
to TO N
either DT N
1 CD N
) ) N
micronized VBN 1_i
E2 NNP 1_i
( ( N
0.5 CD N
mg NN N
) ) N
or CC N
2 CD N
) ) N
micronized VBN 1_i
E2 NNP 1_i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN 1_i
T NNP 1_i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

Women NNS 1_p
with IN 1_p
intact JJ 1_p
uteri NNS 1_p
were VBD N
assigned VBN N
to TO N
either DT N
3 CD N
) ) N
micronized VBN 1_i
E2 NNP 1_i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN 1_i
P4 NNP 1_i
( ( N
100 CD N
mg NN N
) ) N
or CC N
4 CD N
) ) N
micronized VBN 1_i
E2 NNP 1_i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ 1_i
micronized VBN 1_i
P4 NNP 1_i
( ( N
100 CD N
mcg NN N
) ) N
+ VBZ 1_i
micronized VBN 1_i
T NNP 1_i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

For IN N
the DT N
purpose NN N
of IN N
this DT N
study NN N
, , N
the DT N
four CD N
treatment NN N
groups NNS N
were VBD N
combined VBN N
into IN N
two CD N
groups NNS N
for IN N
all DT N
comparisons NNS N
. . N

The DT N
E2 NNP 1_i
and CC N
E2+P4 NNP 1_i
groups NNS N
were VBD N
combined VBN N
into IN N
the DT N
HRT NNP 1_p
alone RB 1_p
group NN 1_p
( ( 1_p
n=30 NN 1_p
) ) 1_p
, , N
and CC N
the DT N
E2+T NNP 1_i
and CC N
E2+P4+T NNP 1_i
groups NNS N
were VBD N
combined VBN N
into IN N
the DT N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
group NN 1_p
( ( 1_p
n=27 RB 1_p
) ) 1_p
. . 1_p

Hormones NNPS N
were VBD N
administered VBN N
sublingually RB N
as IN N
a DT N
single JJ N
tablet NN N
twice RB N
a DT N
day NN N
for IN N
12 CD N
months NNS N
. . N

Bone NNP 1_o
mineral JJ 1_o
density NN 1_o
was VBD N
measured VBN N
in IN N
the DT N
anterior-posterior JJ N
lumbar NN N
spine NN N
and CC N
total JJ N
left JJ N
hip NN N
via IN N
dual JJ N
energy NN N
x-ray JJ N
absorptiometry NN N
. . N

Bone NNP 1_o
metabolism NN 1_o
was VBD N
assessed VBN N
via IN N
serum JJ N
bone-specific JJ N
alkaline NN N
phosphatase NN N
and CC N
urinary JJ N
deoxypyridinoline NN N
and CC N
cross-linked JJ N
N-telopeptide NNP N
of IN N
type NN N
I PRP N
collagen VBP N
, , N
both DT N
normalized VBN N
to TO N
creatinine VB N
. . N

Data NNP N
were VBD N
analyzed VBN N
via IN N
a DT N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
and CC N
a DT N
Student NN N
's POS N
t JJ N
test NN N
( ( N
alpha=0.05 NN N
) ) N
. . N

RESULTS VB N
The DT 1_p
subjects NNS 1_p
were VBD 1_p
of IN 1_p
similar JJ 1_p
age NN 1_p
( ( 1_p
54.0 CD 1_p
+/- JJ 1_p
0.8 CD 1_p
years NNS 1_p
) ) 1_p
, , 1_p
height VBD 1_p
( ( 1_p
64.0 CD 1_p
+/- JJ 1_p
0.3 CD 1_p
in IN 1_p
) ) 1_p
, , 1_p
weight VBD 1_p
( ( 1_p
157.6 CD 1_p
+/- JJ 1_p
4.2 CD 1_p
lb NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
had VBD 1_p
similar JJ 1_p
baseline NN 1_p
follicle-stimulating NN 1_p
hormone NN 1_p
( ( 1_p
66.4 CD 1_p
+/- JJ 1_p
3.2 CD 1_p
mIU/L NN 1_p
) ) 1_p
, , 1_p
E2 NNP 1_p
( ( 1_p
26.4 CD 1_p
+/- JJ 1_p
1.5 CD 1_p
pg/ml NN 1_p
) ) 1_p
, , 1_p
P4 NNP 1_p
( ( 1_p
0.3 CD 1_p
+/- JJ 1_p
0.1 CD 1_p
ng/ml NN 1_p
) ) 1_p
, , 1_p
total JJ 1_p
T NNP 1_p
( ( 1_p
19.0 CD 1_p
+/- JJ 1_p
1.5 CD 1_p
ng/dL NN 1_p
) ) 1_p
, , 1_p
and CC 1_p
bioavailable JJ 1_p
T NNP 1_p
( ( 1_p
3.7 CD 1_p
+/- JJ 1_p
0.3 CD 1_p
ng/dL NN 1_p
) ) 1_p
levels NNS 1_p
. . 1_p

During IN N
therapy NN N
, , N
serum NN N
levels NNS N
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
each DT N
hormone NN N
. . N

Bone NNP 1_o
mineral JJ 1_o
density NN 1_o
and CC 1_o
bone NN 1_o
markers NNS 1_o
at IN N
baseline NN N
were VBD N
similar JJ N
for IN N
each DT N
treatment NN N
group NN N
. . N

Bone-specific JJ 1_o
alkaline JJ 1_o
phosphatase NN 1_o
decreased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
-14.3 JJ N
+/- JJ N
4.1 CD N
% NN N
in IN N
the DT N
HRT NNP 1_i
alone RB N
group NN N
and CC N
by IN N
-8.2 NNP N
+/- JJ N
4.6 CD N
% NN N
in IN N
the DT N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
group NN N
. . N

Deoxypyridinoline NNP N
levels NNS 1_o
decreased VBN N
significantly RB N
in IN N
the DT N
HRT NNP 1_i
alone RB 1_i
and CC N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
groups NNS N
, , N
- : N
14.4 CD N
+/- JJ N
6.8 CD N
% NN N
and CC N
-26.9 JJ N
+/- JJ N
7.6 CD N
% NN N
, , N
respectively RB N
. . N

Significant JJ N
reductions NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
cross-linked JJ 1_o
N-telopeptide NNP 1_o
of IN 1_o
type NN 1_o
I PRP 1_o
collagen VBP 1_o
were VBD N
also RB N
observed VBN N
in IN N
both DT N
groups NNS N
, , N
-24.4 VBD N
+/- JJ N
6.5 CD N
% NN N
and CC N
-39.5 JJ N
+/- JJ N
8.6 CD N
% NN N
, , N
respectively RB N
. . N

Bone NNP 1_o
mineral JJ 1_o
density NN 1_o
in IN 1_o
the DT 1_o
lumbar NN 1_o
spine NN 1_o
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
+2.2 JJ N
+/- JJ N
0.5 CD N
% NN N
the DT N
HRT NNP 1_i
alone RB 1_i
group NN N
and CC N
by IN N
+ JJ N
1.8 CD N
+/- JJ N
0.6 CD N
% NN N
in IN N
the DT N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
group NN N
. . N

Total JJ 1_o
hip NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
was VBD N
maintained VBN N
in IN N
the DT N
HRT NNP 1_i
alone RB 1_i
group NN N
( ( N
+0.4 JJ N
+/- JJ N
0.4 CD N
% NN N
) ) N
and CC N
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
HRT NNP 1_i
+ NNP 1_i
T NNP 1_i
group NN N
( ( N
+ JJ N
1.8 CD N
+/- JJ N
0.5 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Sublingual NNP N
micronized VBD N
HRT NNP 1_i
favorably RB N
decreases VBZ N
serum NN 1_o
and CC 1_o
urine JJ 1_o
markers NNS 1_o
of IN 1_o
bone NN 1_o
metabolism NN 1_o
, , N
prevents VBZ N
bone JJ 1_o
loss NN 1_o
, , N
and CC N
results NNS N
in IN N
a DT N
slight JJ N
increase NN N
in IN N
spine NN 1_o
and CC 1_o
hip NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
. . 1_o

Although IN N
the DT N
addition NN N
of IN N
testosterone NN N
to TO N
HRT NNP 1_i
for IN N
1 CD N
year NN N
did VBD N
not RB N
result VB N
in IN N
added JJ N
benefit NN N
to TO N
the DT N
spine NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
, , N
it PRP N
did VBD N
result VB N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
hip NN 1_o
bone NN 1_o
mineral JJ 1_o
density NN 1_o
. . 1_o

Longer JJR N
duration NN N
of IN N
therapy NN N
may MD N
have VB N
further JJR N
improved VBN N
these DT N
outcomes NNS N
. . N

The DT N
cognitive NN 1_o
, , 1_o
subjective JJ 1_o
, , 1_o
and CC 1_o
physical JJ 1_o
effects NNS 1_o
of IN N
a DT N
ginkgo NN 1_i
biloba/panax NN 1_i
ginseng NN 1_i
combination NN 1_i
in IN N
healthy JJ 1_p
volunteers NNS 1_p
with IN 1_p
neurasthenic JJ 1_p
complaints NNS 1_p
. . 1_p

We PRP N
evaluated VBD N
the DT N
effects NNS 1_o
of IN N
a DT N
Ginkgo NNP 1_i
biloba/ginseng NN 1_i
combination NN 1_i
on IN N
cognitive JJ 1_o
function NN 1_o
in IN N
this DT N
90-day JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
parallel-group JJ N
study NN N
. . N

Sixty-four CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
( ( 1_p
aged VBN 1_p
40 CD 1_p
to TO 1_p
65 CD 1_p
years NNS 1_p
) ) 1_p
, , 1_p
selected VBN 1_p
on IN 1_p
the DT 1_p
basis NN 1_p
of IN 1_p
fulfilling VBG 1_p
the DT 1_p
ICD-10 NNP 1_p
F48.0 NNP 1_p
criteria NNS 1_p
for IN 1_p
neurasthenia NN 1_p
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
four CD N
equal JJ N
dosing NN N
groups NNS N
, , N
receiving VBG N
80 CD N
, , N
160 CD N
, , N
or CC N
320 CD N
mg NN N
of IN N
the DT N
combination NN N
b.i.d NN N
. . N

or CC N
placebo NN 1_i
. . 1_i

Assessments NNS N
were VBD N
performed VBN N
on IN N
the DT N
day NN N
before IN N
dosing NN N
, , N
and CC N
again RB N
at IN N
Days NNP N
1 CD N
, , N
30 CD N
, , N
and CC N
90 CD N
at IN N
1 CD N
hour NN N
after IN N
the DT N
morning NN N
dose NN N
and CC N
1 CD N
hour NN N
after IN N
the DT N
afternoon NN N
dose NN N
. . N

The DT N
assessments NNS N
included VBD N
the DT N
Cognitive NNP 1_o
Drug NNP 1_o
Research NNP 1_o
( ( 1_o
CDR NNP 1_o
) ) 1_o
computerized VBD 1_o
assessment NN 1_o
system NN 1_o
, , 1_o
the DT 1_o
Vienna NNP 1_o
Determination NNP 1_o
Unit NNP 1_o
, , 1_o
cycle NN 1_o
ergometry NN 1_o
, , 1_o
and CC 1_o
various JJ 1_o
questionnaires NNS 1_o
. . 1_o

The DT N
treatments NNS N
were VBD N
well RB 1_o
tolerated VBN 1_o
by IN N
all DT N
volunteers NNS N
. . N

On IN N
Day NNP N
90 CD N
at IN N
1 CD N
hour NN N
post NN N
morning NN N
dosing NN N
, , N
dose-related JJ 1_o
improvements NNS 1_o
were VBD N
seen VBN N
on IN N
the DT N
CDR NNP N
tests NNS N
, , N
the DT N
320 CD N
mg NN N
dose NN N
being VBG N
significantly RB N
superior JJ N
to TO N
placebo VB 1_i
. . 1_i

These DT N
effects NNS N
, , N
however RB N
, , N
were VBD N
reversed VBN N
1 CD N
hour NN N
after IN N
the DT N
afternoon NN N
dose NN N
, , N
possibly RB N
suggesting VBG N
that IN N
a DT N
longer JJR N
inter-dosing JJ N
interval NN N
would MD N
be VB N
preferable JJ N
. . N

The DT N
80-mg JJ N
dose NN N
produced VBD N
a DT N
significant JJ N
benefit NN N
on IN N
the DT N
ergometry NN 1_o
assessment NN 1_o
of IN 1_o
heart NN 1_o
rate NN 1_o
at IN N
maximum JJ N
load NN N
. . N

There EX N
were VBD N
also RB N
several JJ N
supporting VBG N
changes NNS N
from IN N
other JJ N
assessments NNS N
, , N
including VBG N
an DT N
advantage NN N
of IN N
320 CD N
mg NN N
over IN N
placebo NN 1_i
on IN N
the DT N
global JJ N
score NN N
from IN N
the DT N
Symptom NNP N
Checklist-90-revised JJ N
( ( N
SCL-90-R NNP N
) ) N
at IN N
Day NNP N
90 CD N
. . N

Prognostic JJ N
interaction NN N
between IN N
expression NN 1_o
of IN 1_o
p53 NN 1_o
and CC N
estrogen NN N
receptor NN N
in IN N
patients NNS 1_p
with IN 1_p
node-negative JJ 1_p
breast NN 1_p
cancer NN 1_p
: : 1_p
results NNS N
from IN N
IBCSG NNP N
Trials NNP N
VIII NNP N
and CC N
IX NNP N
. . N

INTRODUCTION NNP N
The DT N
prognostic JJ N
significance NN N
of IN N
p53 NN N
protein NN N
expression NN N
in IN N
early JJ N
breast NN N
cancer NN N
remains VBZ N
uncertain JJ N
, , N
with IN N
some DT N
but CC N
not RB N
all DT N
studies NNS N
finding VBG N
an DT N
association NN N
with IN N
poorer JJR 1_o
outcomes NNS 1_o
. . 1_o

Estrogen NNP 1_o
receptor NN 1_o
( ( 1_o
ER NNP 1_o
) ) 1_o
expression NN 1_o
is VBZ N
both DT N
a DT N
positive JJ N
prognostic JJ N
marker NN N
and CC N
predictive NN N
of IN N
response NN 1_o
to TO 1_o
endocrine VB 1_o
therapies NNS 1_o
. . 1_o

The DT N
relationship NN N
between IN N
these DT N
biomarkers NNS N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
We PRP N
constructed VBD N
tissue NN N
microarrays NNS N
( ( N
TMAs NNP N
) ) N
from IN N
available JJ N
pathological JJ N
material NN N
from IN N
1113 CD 1_p
patients NNS 1_p
participating VBG 1_p
in IN N
two CD N
randomized JJ N
clinical JJ N
trials NNS N
comparing VBG N
endocrine JJ 1_i
therapy NN 1_i
alone RB 1_i
versus JJ 1_i
chemo-endocrine JJ 1_i
therapy NN 1_i
in IN 1_i
node-negative JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

Expression NN 1_o
of IN 1_o
p53 NN 1_o
defined VBN N
as IN N
> JJ N
10 CD N
% NN N
positive JJ N
nuclei NN N
was VBD N
analyzed VBN N
together RB N
with IN N
prior JJ N
immunohistochemical JJ N
assays NNS N
of IN N
ER NNP N
performed VBD N
at IN N
central JJ N
pathological JJ N
review NN N
of IN N
whole JJ N
tumor NN N
sections NNS N
. . N

RESULTS NNP N
ER NNP 1_o
was VBD N
present JJ N
( ( N
i.e JJ N
. . N

> VB N
1 CD N
% NN N
positive JJ N
tumor NN N
cell NN N
nuclei NN N
) ) N
in IN N
80.1 CD N
% NN N
( ( N
880/1092 CD N
) ) N
. . N

p53 NN 1_o
expression NN 1_o
was VBD N
significantly RB N
more RBR N
frequent JJ N
when WRB N
ER NNP N
was VBD N
absent JJ N
, , N
125/212 CD N
( ( N
59 CD N
% NN N
) ) N
than IN N
when WRB N
ER NNP N
was VBD N
present JJ N
, , N
171/880 CD N
( ( N
19 CD N
% NN N
) ) N
, , N
p JJ N
< NN N
0.0001 CD N
. . N

A DT N
significant JJ N
qualitative JJ N
interaction NN N
was VBD N
observed VBN N
such JJ N
that IN N
p53 NN 1_o
expression NN 1_o
was VBD N
associated VBN N
with IN N
better JJR N
disease-free NN 1_o
survival NN 1_o
( ( 1_o
DFS NNP 1_o
) ) 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
among IN N
patients NNS N
whose WP$ N
tumors NNS N
did VBD N
not RB N
express VB N
ER NNP N
, , N
but CC N
worse JJR N
DFS NNP 1_o
and CC N
OS NNP 1_o
among IN N
patients NNS N
whose WP$ N
tumors NNS N
expressed VBD N
ER NNP N
. . N

The DT N
interaction NN N
remained VBD N
significant JJ N
after IN N
allowance NN N
for IN N
pathologic JJ N
variables NNS N
, , N
and CC N
treatment NN N
. . N

Similar JJ N
effects NNS N
were VBD N
seen VBN N
when WRB N
luminal JJ N
and CC N
non-luminal JJ N
intrinsic JJ N
subtypes NNS N
were VBD N
compared VBN N
. . N

CONCLUSIONS NNP N
Interpretation NNP N
of IN N
the DT N
prognostic JJ N
significance NN N
of IN N
p53 NN 1_o
expression NN 1_o
requires VBZ N
knowledge NN N
of IN N
concurrent JJ N
expression NN 1_o
of IN 1_o
ER NNP 1_o
. . 1_o

The DT N
reason NN N
for IN N
the DT N
interaction NN N
between IN N
p53 NN N
and CC N
ER NNP N
is VBZ N
unknown JJ N
but CC N
may MD N
reflect VB N
qualitatively RB N
different JJ N
p53 NN 1_o
mutations NNS 1_o
underlying VBG N
the DT N
p53 NN 1_o
expression NN 1_o
in IN N
tumors NNS N
with IN N
or CC N
without IN N
ER NNP N
expression NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ACTRN12607000037404 NNP N
( ( N
Trial NNP N
VIII NNP N
) ) N
and CC N
ACTRN12607000029493 NNP N
( ( N
Trial NNP N
IX NNP N
) ) N
. . N

A DT N
stable JJ 1_i
prostacyclin NN 1_i
analogue NN 1_i
( ( 1_i
iloprost NN 1_i
) ) 1_i
in IN N
the DT N
treatment NN N
of IN N
ischaemic JJ 1_p
ulcers NNS 1_p
of IN 1_p
the DT 1_p
lower JJR 1_p
limb NN 1_p
. . 1_p

A DT N
Scandinavian-Polish JJ 1_p
placebo NN 1_i
controlled VBN 1_p
, , 1_p
randomised VBN 1_p
multicenter NN 1_p
study NN 1_p
. . 1_p

The DT N
clinical JJ 1_o
efficacy NN 1_o
of IN N
the DT N
prostacyclin NN 1_i
analogue NN 1_i
iloprost NN 1_i
was VBD N
studied VBN N
during IN N
a DT N
2 CD N
week NN N
treatment NN N
and CC N
6 CD N
month NN N
follow-up JJ N
period NN N
in IN N
103 CD 1_p
patients NNS 1_p
with IN 1_p
ischaemic JJ 1_p
ulcers NNS 1_p
who WP 1_p
were VBD 1_p
randomised VBN 1_p
to TO 1_p
receive VB 1_p
active JJ 1_i
treatment NN 1_i
or CC 1_i
placebo NN 1_i
. . 1_i

Responders NNS N
were VBD N
defined VBN N
as IN N
those DT N
patients NNS N
who WP N
achieved VBD N
healing NN N
of IN N
at IN N
least JJS N
one CD N
third NN N
of IN N
the DT N
ulcer JJ N
area NN N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
overall JJ N
responder NN 1_o
rate NN 1_o
was VBD N
41.3 CD N
% NN N
, , N
compared VBN N
with IN N
25 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.086 CD N
) ) N
. . N

Side JJ N
effects NNS N
including VBG N
flushing NN 1_o
and CC 1_o
headache NN 1_o
, , N
were VBD N
common JJ N
. . N

The DT N
study NN N
population NN N
had VBD N
a DT N
mortality NN 1_o
of IN N
23 CD N
% NN N
during IN N
the DT N
6 CD N
month NN N
period NN N
, , N
the DT N
amputation NN 1_o
rate NN 1_o
was VBD N
43.5 CD N
% NN N
for IN N
iloprost NN 1_i
and CC N
50 CD N
% NN N
for IN N
placebo NN 1_i
treated VBN N
patients NNS N
. . N

In IN N
this DT N
severely RB N
diseased JJ N
population NN N
of IN N
patients NNS N
a DT N
treatment NN N
period NN N
limited VBD N
to TO N
2 CD N
weeks NNS N
did VBD N
not RB N
sufficiently RB N
improve VB N
ulcer NN 1_o
healing NN 1_o
. . 1_o

Prazosin NNP 1_i
versus NN 1_i
captopril NN 1_i
as IN N
initial JJ N
therapy NN N
. . N

Effect VB N
on IN N
hypertension NN 1_o
and CC 1_o
lipid JJ 1_o
levels NNS 1_o
. . 1_o

A DT N
randomized JJ N
, , N
parallel JJ N
group NN N
study NN N
evaluated VBD N
the DT N
safety NN 1_o
, , 1_o
efficacy NN 1_o
, , 1_o
and CC 1_o
effect NN 1_o
of IN N
the DT N
alpha NN N
blocking VBG N
agent JJ N
prazosin NN 1_i
and CC N
the DT N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitor NN N
captopril NN 1_i
on IN N
serum NN N
lipid JJ N
levels NNS N
in IN N
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
hypertension NN 1_p
. . 1_p

Baseline JJ N
evaluations NNS N
were VBD N
performed VBN N
on IN N
31 CD 1_p
patients NNS 1_p
after IN 1_p
a DT 1_p
four-week JJ 1_p
placebo NN 1_p
washout IN 1_p
period NN 1_p
. . 1_p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
prazosin NN 1_i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
captopril NN 1_i
( ( N
n JJ N
= NNP N
16 CD N
) ) N
. . N

Daily JJ N
doses NNS N
were VBD N
titrated VBN N
as IN N
follows VBZ N
: : N
for IN N
prazosin NN 1_i
, , N
1 CD N
mg NN N
two CD N
times NNS N
daily RB N
to TO N
maximum VB N
of IN N
20 CD N
mg NNS N
per IN N
day NN N
; : N
for IN N
captopril NN 1_i
, , N
25 CD N
mg NN N
three CD N
times NNS N
daily RB N
to TO N
a DT N
maximum NN N
of IN N
450 CD N
mg NNS N
per IN N
day NN N
. . N

If IN N
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
was VBD N
not RB N
adequately RB N
controlled VBN N
( ( N
less JJR N
than IN N
85 CD N
mm JJ N
Hg NNP N
) ) N
after IN N
four CD N
weeks NNS N
of IN N
monotherapy NN N
, , N
1 CD N
mg NN N
of IN N
polythiazide NN 1_i
was VBD N
added VBN N
to TO N
the DT N
daily JJ N
regimen NNS N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
drug NN N
groups NNS N
for IN N
the DT N
measured JJ N
variables NNS N
in IN N
either CC N
the DT N
parallel NN N
or CC N
crossover JJ N
phase NN N
of IN N
the DT N
study NN N
. . N

Five CD N
of IN N
15 CD N
prazosin-treated JJ 1_i
patients NNS N
and CC N
six CD N
of IN N
16 CD N
captopril-treated JJ N
patients NNS N
required VBD N
the DT N
addition NN N
of IN N
thiazide NN 1_i
to TO N
achieve VB N
blood NN 1_o
pressure NN 1_o
control NN 1_o
. . 1_o

Effects NNS N
of IN N
bench JJ 1_i
step NN 1_i
exercise NN 1_i
intervention NN 1_i
on IN N
work NN 1_o
ability NN 1_o
in IN N
terms NNS N
of IN N
cardiovascular JJ 1_o
risk NN N
factors NNS N
and CC N
oxidative JJ N
stress NN N
: : N
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

Work NNP 1_o
ability NN 1_o
is VBZ N
partly RB N
determined VBN N
by IN N
physical JJ N
and CC N
mental JJ N
fitness NN N
. . N

Bench JJ 1_i
step NN 1_i
exercise NN 1_i
can MD N
be VB N
practiced VBN N
anywhere RB N
at IN N
any DT N
time NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
bench JJ 1_i
step NN 1_i
exercise NN 1_i
on IN N
work NN 1_o
ability NN 1_o
by IN N
examining VBG N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
oxidative JJ N
stress NN N
. . N

Thirteen NNP 1_p
volunteers NNS 1_p
working VBG 1_p
in IN 1_p
a DT 1_p
warehousing NN 1_p
industry NN 1_p
comprised VBD 1_p
the DT 1_p
bench JJ 1_i
step NN 1_i
exercise NN 1_i
group NN 1_p
( ( 1_p
n=7 CC 1_p
) ) 1_p
and CC 1_p
the DT 1_p
control NN 1_p
group NN 1_p
( ( 1_p
n=6 RB 1_p
) ) 1_p
. . 1_p

The DT N
participants NNS N
in IN N
the DT N
step NN 1_i
exercise NN 1_i
group NN N
were VBD N
encouraged VBN N
to TO N
practice NN N
the DT N
step NN 1_i
exercise NN 1_i
at IN N
home NN N
for IN N
16 CD N
weeks NNS N
. . N

The DT N
step NN 1_i
exercise NN 1_i
improved VBD N
glucose JJ 1_o
metabolism NN 1_o
and CC 1_o
antioxidative JJ 1_o
capacity NN 1_o
and CC N
increased VBD N
work NN 1_o
ability NN 1_o
by IN 1_o
reducing VBG 1_o
absences NNS 1_o
from IN 1_o
work NN 1_o
and CC 1_o
improving VBG 1_o
the DT 1_o
prognosis NN 1_o
of IN 1_o
work NN 1_o
ability NN 1_o
. . 1_o

The DT N
improvement NN N
in IN N
work NN 1_o
ability NN 1_o
was VBD N
related VBN N
to TO N
a DT N
reduction NN N
in IN N
oxidative JJ 1_o
stress NN 1_o
. . 1_o

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
bench JJ 1_i
step NN 1_i
exercise NN 1_i
may MD N
improve VB N
work NN 1_o
ability NN 1_o
by IN N
reducing VBG N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
oxidative JJ N
stress NN N
. . N

S-phase JJ 1_i
kinase-associated JJ 1_i
protein NN 1_i
2 CD N
expression NN N
in IN N
laryngeal JJ 1_p
squamous JJ 1_p
cell NN 1_p
carcinomas NN 1_p
and CC N
its PRP$ N
prognostic JJ N
implications NNS N
. . N

The DT N
F-box JJ N
protein JJ N
S-phase JJ 1_i
kinase-associated JJ 1_i
protein NN 1_i
2 CD N
( ( 1_i
Skp2 NNP 1_i
) ) 1_i
positively RB N
regulates VBZ N
the DT N
G1-S JJ N
transition NN N
by IN N
controlling VBG N
the DT N
stability NN N
of IN N
several JJ N
G1 NNP N
regulators NNS N
, , N
such JJ N
as IN N
the DT N
cell NN N
cycle NN N
inhibitor NN N
p27kip1 NN N
. . N

However RB N
, , N
the DT N
clinical JJ N
significance NN N
of IN N
Skp2 NNP 1_i
in IN N
patients NNS 1_p
with IN 1_p
laryngeal JJ 1_p
squamous JJ 1_p
cell NN 1_p
carcinoma NN 1_p
( ( 1_p
LSCC NNP 1_p
) ) 1_p
remains VBZ N
unknown JJ N
. . N

In IN N
this DT N
study NN N
, , N
a DT N
potential JJ N
distribution NN N
of IN N
Skp2 NNP 1_i
in IN N
LSCC NNP N
and CC N
its PRP$ N
clinical JJ N
implications NNS N
was VBD N
investigated VBN N
by IN N
an DT N
immunohistochemical JJ 1_i
study NN 1_i
. . 1_i

Overall NNP N
, , N
Skp2 NNP 1_o
overexpression NN 1_o
was VBD N
observed VBN N
in IN N
36.7 CD 1_p
% NN 1_p
( ( 1_p
37 CD 1_p
of IN 1_p
102 CD 1_p
) ) 1_p
patients NNS 1_p
and CC N
was VBD N
significantly RB N
associated VBN N
with IN N
lymph JJ N
node JJ N
metastasis NN N
( ( N
p=0.002 NN N
) ) N
and CC N
was VBD N
inversely RB N
associated VBN N
with IN N
p27kip1 JJ N
expression NN N
( ( N
p=0.026 NN N
) ) N
. . N

Survival JJ 1_o
analysis NN 1_o
using VBG N
the DT N
Kaplan-Meier NNP N
method NN N
showed VBD N
that IN N
Skp2 NNP 1_i
overexpression NN N
was VBD N
significantly RB N
associated VBN N
with IN N
shorter JJR N
disease-free NN 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
( ( N
p=0.0051 NN N
and CC N
p=0.0002 NN N
, , N
respectively RB N
) ) N
. . N

When WRB N
Skp2 NNP 1_o
expression NN 1_o
and CC 1_o
p27kip1 JJ 1_o
expression NN 1_o
were VBD N
combined VBN N
, , N
patients NNS N
with IN N
both DT N
Skp2 NNP 1_i
overexpression NN N
and CC N
reduced JJ N
expression NN 1_o
of IN 1_o
p27kip1 NN 1_o
revealed VBN N
poorest JJS 1_o
disease-free JJ 1_o
and CC N
overall JJ 1_o
survival NN 1_o
as IN N
compared VBN N
to TO N
the DT N
other JJ N
cases NNS N
( ( N
p=0.0017 NN N
and CC N
p NN N
< NN N
0.0001 CD N
, , N
respectively RB N
) ) N
. . N

Additionally RB N
, , N
in IN N
early JJ N
stage NN N
( ( N
I PRP N
, , N
II NNP N
) ) N
cases NNS N
, , N
Skp2 NNP 1_i
expression NN N
was VBD N
also RB N
revealed VBN N
to TO N
possess VB N
a DT N
significant JJ N
prognostic JJ N
factor NN N
in IN N
overall JJ 1_o
survival NN 1_o
( ( 1_o
p=0.0234 NN 1_o
) ) 1_o
, , N
but CC N
not RB N
in IN N
disease-free JJ 1_o
survival NN 1_o
( ( N
p=0.2055 NN N
) ) N
. . N

By IN N
multivariate NN N
analysis NN N
using VBG N
the DT N
Cox NNP 1_o
proportional JJ 1_o
hazards NNS 1_o
model NN 1_o
, , 1_o
tumor NN 1_o
grade NN 1_o
, , 1_o
tumor NN 1_o
size NN 1_o
, , 1_o
clinical JJ 1_o
stage NN 1_o
and CC 1_o
Skp2 NNP 1_o
expression NN 1_o
were VBD N
independent JJ N
prognostic JJ N
factors NNS N
both DT N
in IN N
disease-free JJ 1_o
and CC 1_o
overall JJ 1_o
survival NN 1_o
. . 1_o

These DT N
findings NNS N
indicated VBD N
that IN N
Skp2 NNP 1_o
expression NN 1_o
was VBD N
closely RB N
associated VBN N
with IN N
tumor NN N
progression NN N
and CC N
represented VBD N
an DT N
independent JJ N
marker NN N
for IN N
prognosis NN N
of IN N
LSCC NNP N
. . N

ACE NNP 1_i
inhibitors NNS 1_i
or CC 1_i
AT-1 JJ 1_i
antagonists NNS 1_i
- : N
which WDT N
is VBZ N
OPTIMAAL NNP N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
? . N
OPTIMAAL NNP N
( ( N
Optimal NNP N
Trial NNP N
in IN N
Myocardial NNP N
Infarction NNP N
with IN N
the DT N
Angiotensin NNP N
II NNP N
Antagonist NNP N
Losartan NNP N
) ) N
is VBZ N
the DT N
first JJ N
major JJ N
study NN N
to TO N
compare VB N
an DT N
angiotensin NN 1_i
II NNP 1_i
Type NNP 1_i
1 CD 1_i
antagonist NN 1_i
losartan NN 1_i
( ( N
Cozaar NNP N
trade NN N
mark NN N
, , N
Merck NNP N
) ) N
with IN N
an DT N
ACE NNP N
inhibitor NN N
captonpril NN 1_i
( ( N
Capoten NNP N
trade NN N
mark NN N
, , N
Elan NNP N
) ) N
after IN 1_p
myocardial JJ 1_p
infarction NN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
left JJ 1_p
ventricular JJ 1_p
dysfunction NN 1_p
. . 1_p

Patients NNS 1_p
were VBD N
assigned VBN N
to TO N
a DT N
target NN N
dose NN N
of IN N
losartan JJ 1_i
50 CD N
mg/day NN N
and CC N
captopril NN 1_i
50 CD N
mg NN N
t.i.d. NN N
, , N
as IN N
tolerated VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
all-cause JJ 1_o
mortality NN 1_o
and CC N
there EX N
were VBD N
499 CD N
( ( N
18 CD N
% NN N
) ) N
and CC N
447 CD N
( ( N
16 CD N
% NN N
) ) N
deaths NNS 1_o
in IN N
the DT N
losartan NN 1_i
and CC 1_i
captopril NN 1_i
group NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
significantly RB N
more JJR N
cardiovascular JJ 1_o
deaths NNS 1_o
with IN N
losartan NN N
( ( N
420 CD N
, , N
15 CD N
% NN N
) ) N
than IN N
with IN N
captopril NN 1_i
( ( N
363 CD N
, , N
13 CD N
% NN N
; : N
p CC N
= VB N
0.03 CD N
) ) N
. . N

Losartan NNP 1_i
was VBD N
better RBR N
tolerated VBN 1_o
than IN N
captopril NN 1_i
with IN N
fewer JJR N
patients NNS 1_o
discontinuing VBG 1_o
medication NN 1_o
( ( N
17 CD N
versus RB N
23 CD N
% NN N
for IN N
losartan NN 1_i
and CC N
captopril NN 1_i
, , N
respectively RB N
) ) N
. . N

In IN N
conclusion NN N
, , N
if IN N
tolerated VBN N
, , N
captopril NN 1_i
should MD N
remain VB N
the DT N
preferred JJ N
treatment NN N
for IN N
patients NNS 1_p
after IN N
complicated VBN N
acute JJ 1_o
myocardial JJ 1_o
infarction NN 1_o
. . 1_o

The DT N
effect NN N
of IN N
valaciclovir NN 1_i
on IN N
cytomegalovirus NN 1_o
viremia NN 1_o
and CC N
viruria NN N
detected VBN N
by IN N
polymerase NN N
chain NN N
reaction NN N
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
human JJ 1_p
immunodeficiency NN 1_p
virus NN 1_p
disease NN 1_p
. . 1_p

AIDS NNP N
Clinical JJ N
Trials NNP N
Group NNP N
Protocol NNP N
204/Glaxo CD N
Wellcome NNP N
123-014 JJ N
International NNP N
CMV NNP N
Prophylaxis NNP N
Study NNP N
Group NNP N
. . N

Samples NNP N
of IN N
blood NN N
and CC N
urine NN N
were VBD N
collected VBN N
at IN N
baseline NN N
, , N
week NN N
4 CD N
, , N
and CC N
week NN N
8 CD N
and CC N
then RB N
every DT N
8 CD N
weeks NNS N
from IN N
310 CD 1_p
patients NNS 1_p
entering VBG 1_p
a DT 1_p
controlled JJ 1_p
trial NN 1_p
of IN 1_p
prophylaxis NN 1_i
with IN 1_p
valaciclovir JJ 1_i
versus NN 1_i
acyclovir NN 1_i
. . 1_i

Samples NNS N
were VBD N
tested VBN N
under IN N
code NN N
by IN N
polymerase NN 1_i
chain NN 1_i
reaction NN 1_i
( ( N
PCR NNP N
) ) N
in IN N
one CD N
laboratory NN N
. . N

The DT N
median JJ N
number NN 1_o
of IN 1_o
samples NNS 1_o
collected VBN N
from IN N
each DT N
patient NN N
was VBD N
5 CD N
for IN N
blood NN N
( ( N
range NN N
, , N
0-15 NN N
) ) N
and CC N
5 CD N
for IN N
urine NN N
( ( N
range NN N
, , N
0-15 NN N
) ) N
. . N

Both DT N
baseline JJ N
PCR NNP 1_o
viremia NN 1_o
and CC 1_o
PCR NNP 1_o
viruria NNS 1_o
were VBD N
significantly RB N
associated VBN N
with IN N
future JJ N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
disease NN N
( ( N
P NNP N
= NNP N
.002 NNP N
and CC N
P NNP N
= NNP N
.02 NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
greatest JJS N
effect NN N
of IN N
valaciclovir NN 1_i
on IN N
CMV NNP 1_o
disease NN N
was VBD N
seen VBN N
in IN N
patients NNS N
who WP N
were VBD N
PCR-positive NNP N
in IN N
blood NN N
at IN N
baseline NN N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
, , N
although IN N
a DT N
significant JJ N
effect NN N
was VBD N
also RB N
seen VBN N
in IN N
those DT N
who WP N
were VBD N
PCR-negative NNP N
in IN N
urine NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Thus RB N
, , N
PCR NNP 1_o
viremia NNP 1_o
provides VBZ N
prognostic JJ N
information NN N
about IN N
CMV NNP N
disease NN N
in IN N
AIDS NNP N
patients NNS N
, , N
and CC N
valaciclovir NN 1_i
showed VBD N
activity NN N
as IN N
both DT N
a DT N
preemptive NN N
and CC N
prophylactic JJ N
agent NN N
. . N

Randomized VBN N
crossover NN N
study NN N
comparing VBG N
efficacy NN 1_o
of IN N
transnasal NN 1_i
endoscopy NN 1_i
with IN 1_i
that DT 1_i
of IN 1_i
standard JJ 1_i
endoscopy NN 1_i
to TO N
detect VB N
Barrett NNP N
's POS N
esophagus NN N
. . N

BACKGROUND NNP N
Unsedated VBD 1_i
transnasal JJ 1_i
endoscopy NN 1_i
( ( 1_i
TNE NNP 1_i
) ) 1_i
may MD N
be VB N
safer JJR N
and CC N
less RBR N
expensive JJ N
than IN N
standard JJ 1_i
endoscopy NN 1_i
( ( 1_i
SE NNP 1_i
) ) 1_i
for IN N
detecting VBG N
Barrett NNP 1_p
's POS 1_p
esophagus NN 1_p
( ( 1_p
BE NNP 1_p
) ) 1_p
. . 1_p

Emerging VBG N
technologies NNS N
require VBP N
robust JJ N
evaluation NN N
before IN N
routine JJ N
use NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
sensitivity NN 1_o
, , 1_o
specificity NN 1_o
, , 1_o
and CC 1_o
acceptability NN 1_o
of IN N
TNE NNP 1_i
in IN N
diagnosing VBG N
BE NNP N
compared VBN N
with IN N
those DT N
of IN N
SE NNP 1_i
. . 1_i

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
crossover NN N
study NN N
. . N

SETTING NNP N
Single NNP N
, , N
tertiary-care JJ N
referral JJ N
center NN N
. . N

PATIENTS VB N
This DT N
study NN N
enrolled VBD N
consecutive JJ 1_p
patients NNS 1_p
with IN 1_p
BE NNP 1_p
or CC 1_p
those DT 1_p
referred VBN 1_p
for IN 1_p
diagnostic JJ 1_p
assessment NN 1_p
. . 1_p

INTERVENTION NNP N
All NNP N
patients NNS N
underwent JJ N
TNE NNP 1_i
followed VBN N
by IN N
SE NNP 1_i
or CC N
the DT N
reverse NN N
. . N

Spielberger NNP 1_o
State-Trait JJ 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
short-form JJ 1_o
questionnaires NNS 1_o
, , 1_o
a DT 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
, , N
and CC N
a DT N
single JJ 1_o
question NN 1_o
addressing VBG 1_o
preference NN 1_o
for IN 1_o
endoscopy NN 1_o
type NN 1_o
were VBD N
administered VBN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASUREMENTS NNP N
Diagnostic NNP 1_o
accuracy NN 1_o
and CC 1_o
tolerability NN 1_o
of IN N
TNE NNP 1_i
were VBD N
compared VBN N
with IN N
those DT N
of IN N
SE NNP 1_i
. . 1_i

RESULTS NNP N
Of IN N
95 CD 1_p
patients NNS 1_p
randomized VBN 1_p
, , 1_p
82 CD 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

We PRP N
correctly RB N
diagnosed VBD N
48 CD N
of IN N
49 CD N
BE NNP N
cases NNS N
by IN N
TNE NNP 1_i
for IN N
endoscopic JJ N
findings NNS N
of IN N
columnar NN N
lined VBN N
esophagus NNS N
compared VBN N
with IN N
the DT N
criterion NN N
standard NN N
, , N
SE NNP 1_i
, , N
giving VBG N
a DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
0.98 CD N
and CC N
1.00 CD N
, , N
respectively RB N
. . N

The DT N
BE NNP 1_o
median JJ 1_o
length NN 1_o
was VBD N
3 CD N
cm NN N
( ( N
interquartile JJ N
range NN N
[ NNP N
IQR NNP N
] NNP N
1-5 JJ N
cm NN N
) ) N
with IN N
SE NNP N
and CC N
3 CD N
cm NN N
( ( N
IQR NNP N
2-4 CD N
cm NN N
) ) N
with IN N
TNE NNP 1_i
, , N
giving VBG N
high JJ N
correlations NNS N
between IN N
the DT N
two CD N
modalities NNS N
( ( N
R NNP N
( ( N
2 CD N
) ) N
= NN N
0.97 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
sensitivity NN 1_o
and CC 1_o
specificity NN 1_o
for IN N
detecting VBG N
intestinal JJ N
metaplasia NN N
by IN N
TNE NNP N
compared VBN N
with IN N
those DT N
by IN N
SE NNP N
was VBD N
0.91 CD N
and CC N
1.00 CD N
, , N
respectively RB N
. . N

The DT N
mean NN N
( ( N
± JJ N
standard NN N
deviation NN 1_o
) ) 1_o
post-endoscopy NN 1_o
Spielberger NNP 1_o
State-Trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
short-form JJ 1_o
score NN 1_o
for IN 1_i
TNE NNP 1_i
( ( N
30.0 CD N
± RB N
1.10 CD N
standard JJ N
error NN N
of IN N
the DT N
mean JJ N
[ NNP N
SEM NNP N
] NNP N
) ) N
was VBD N
lower JJR N
than IN N
that DT N
for IN 1_i
SE NNP 1_i
( ( N
30.7 CD N
± RB N
1.29 CD N
SEM NNP N
) ) N
, , N
( ( N
P NNP N
= NNP N
.054 NNP N
) ) N
. . N

The DT 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
scores NNS 1_o
were VBD N
no DT N
different JJ N
( ( N
P NNP N
= NNP N
.07 NNP N
) ) N
. . N

The DT N
majority NN N
of IN N
patients NNS N
( ( N
59 CD N
% NN N
) ) N
expressed VBD N
a DT N
preference NN N
for IN 1_i
TNE NNP 1_i
. . N

LIMITATIONS NNP N
This DT N
is VBZ N
a DT N
small JJ N
study NN N
, , N
with IN N
limited JJ N
generalizability NN N
, , N
a DT N
high JJ N
prevalence NN N
of IN 1_p
patients NNS 1_p
with IN 1_p
BE NNP N
, , N
differential JJ N
drop-out NN N
between IN N
the DT N
two CD N
procedures NNS N
, , N
and CC N
use NN N
of IN N
sedation NN N
. . N

CONCLUSION NNP N
TNE NNP N
is VBZ N
an DT N
accurate JJ N
and CC N
well-tolerated JJ N
method NN N
for IN N
diagnosing VBG N
BE NNP N
compared VBN N
with IN 1_i
SE NNP 1_i
. . 1_i

TNE NNP 1_i
warrants NNS N
further JJ N
evaluation NN N
as IN N
a DT N
screening NN N
tool NN N
for IN N
BE NNP N
. . N

Efficacy NN 1_o
and CC 1_o
safety NN 1_o
of IN N
sildenafil NN 1_i
in IN N
Asian JJ 1_p
males NNS 1_p
with IN 1_p
erectile JJ 1_p
dysfunction NN 1_p
and CC 1_p
cardiovascular JJ 1_p
risk NN 1_p
. . 1_p

OBJECTIVE NNP N
Assess NNP N
the DT N
effectiveness NN N
of IN N
sildenafil NN 1_i
in IN N
Asian JJ 1_p
males NNS 1_p
with IN 1_p
erectile JJ 1_p
dysfunction NN 1_p
( ( 1_p
ED NNP 1_p
) ) 1_p
and CC 1_p
one CD 1_p
or CC 1_p
more JJR 1_p
of IN 1_p
the DT 1_p
co-morbidities NNS 1_p
, , 1_p
mild-to-moderate JJ 1_p
hypertension NN 1_p
, , 1_p
dyslipidemia NN 1_p
, , 1_p
and CC 1_p
diabetes NNS 1_p
. . 1_p

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
six-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ 1_i
, , N
multicenter NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
Thailand NNP N
, , N
Malaysia NNP N
and CC N
Singapore NNP N
. . N

One CD 1_p
hundred CD 1_p
and CC 1_p
fifty VB 1_p
five CD 1_p
male JJ 1_p
subjects NNS 1_p
were VBD N
randomized VBN N
( ( N
2:1 CD N
) ) N
to TO N
sildenafil VB 1_i
( ( N
n JJ N
= NNP N
104 CD N
) ) N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
51 CD N
) ) N
. . N

Sildenafil NNP 1_i
was VBD N
started VBN N
at IN N
50 CD N
mg NN N
and CC N
increased VBD N
( ( N
100 CD N
mg NN N
) ) N
or CC N
decreased VBN N
( ( N
25 CD N
mg NN N
) ) N
at IN N
week NN N
2 CD N
if IN N
necessary JJ N
. . N

RESULTS VB N
On IN N
the DT N
primary JJ N
efficacy NN N
endpoint NN N
, , N
sildenafil-treated JJ 1_i
subjects NNS N
had VBD N
significantly RB N
better JJR N
scores NNS 1_o
on IN N
the DT N
International NNP 1_o
Index NNP 1_o
of IN 1_o
Erectile NNP 1_o
Function NNP 1_o
( ( 1_o
IIEF NNP 1_o
) ) 1_o
questions NNS 1_o
3 CD 1_o
and CC 1_o
4 CD 1_o
than IN N
placebo NN N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
both DT N
questions NNS N
) ) N
. . N

When WRB N
accumulated VBN N
into IN N
IIEF NNP N
domains NNS N
, , N
all DT N
five CD N
domains NNS N
were VBD N
significant JJ N
in IN N
favor NN N
of IN N
sildenafil NN N
. . N

In IN N
addition NN N
, , N
sildenafil-treated JJ 1_i
subjects NNS N
were VBD N
more RBR N
satisfied JJ 1_o
with IN N
treatment NN N
and CC N
had VBD N
a DT N
higher JJR N
intercourse JJ 1_o
success NN 1_o
rate NN 1_o
. . 1_o

The DT N
majority NN N
of IN N
adverse JJ N
events NNS N
were VBD N
mild VBN N
in IN N
severity NN 1_o
; : 1_o
the DT N
most RBS N
commonly RB N
reported VBD N
treatment-related JJ N
events NNS N
were VBD N
dizziness NN 1_o
( ( N
7.7 CD N
% NN N
) ) N
and CC N
tinnitus NN 1_o
( ( N
2.9 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Sildenafil NNP N
( ( N
25 CD N
, , N
50 CD N
, , N
and CC N
100 CD N
mg NN N
) ) N
was VBD N
found VBN N
to TO N
be VB N
an DT N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
ED NNP N
in IN N
the DT N
present JJ N
study NN N
population NN N
of IN N
Thai NNP N
, , N
Malaysian NNP N
, , N
and CC N
Singaporean NNP N
males NNS N
who WP N
also RB N
had VBD N
increased VBN N
cardiovascular JJ N
risk NN N
Effect NN N
of IN N
two CD N
monophasic JJ 1_i
oral JJ 1_i
contraceptives NNS 1_i
containing VBG 1_i
gestodene NN 1_i
or CC 1_i
desogestrel NN 1_i
on IN N
serum NN N
lipoprotein NN N
lipid JJ N
levels NNS N
. . N

Forty-nine NNP 1_p
healthy JJ 1_p
women NNS 1_p
aged VBN 1_p
20-35 JJ 1_p
years NNS 1_p
who WP 1_p
had VBD 1_p
not RB 1_p
been VBN 1_p
pregnant JJ 1_p
or CC 1_p
using VBG 1_p
an DT 1_p
oral JJ 1_i
contraceptive NN 1_i
( ( 1_i
OC NNP 1_i
) ) 1_i
for IN 1_p
the DT 1_p
previous JJ 1_p
3 CD 1_p
months NNS 1_p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
one CD N
group NN N
taking VBG N
an DT N
OC NNP 1_i
containing VBG N
75 CD N
micrograms NNS N
gestodene NN 1_i
( ( 1_i
GTD NNP 1_i
) ) 1_i
and CC N
30 CD N
micrograms NNS N
ethinyl VBP 1_i
estradiol NN 1_i
( ( 1_i
EE NNP 1_i
) ) 1_i
, , N
and CC N
the DT N
other JJ N
group NN N
using VBG N
an DT N
OC NNP 1_i
with IN N
150 CD N
micrograms NNS N
desogestrel NN 1_i
( ( 1_i
DSG NNP 1_i
) ) 1_i
and CC N
30 CD N
micrograms NNS N
EE NNP 1_i
. . 1_i

Fasting VBG 1_o
blood NN 1_o
samples NNS 1_o
were VBD N
taken VBN N
before RB N
treatment NN N
, , N
and CC N
after IN N
cycles NNS N
3 CD N
and CC N
6 CD N
, , N
between IN N
the DT N
18th CD N
and CC N
the DT N
22nd CD N
day NN N
of IN N
the DT N
cycle NN N
. . N

Blood NNP 1_o
lipoprotein JJ 1_o
lipid JJ 1_o
levels NNS 1_o
were VBD N
measured VBN N
. . N

Serum NNP 1_o
total JJ 1_o
cholesterol NN 1_o
did VBD 1_o
not RB 1_o
change VB 1_o
significantly RB N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
in IN N
the DT N
first JJ N
three CD N
cycles NNS N
, , N
serum JJ 1_o
triglyceride NN 1_o
increased VBN 1_o
by IN N
46 CD N
% NN N
and CC N
40 CD N
% NN N
and CC N
HDL-cholesterol NNP 1_o
by IN 1_o
14 CD 1_o
% NN 1_o
and CC N
8 CD 1_o
% NN 1_o
in IN 1_o
the DT 1_o
GTD NNP 1_o
and CC 1_o
DSG NNP 1_o
groups NNS N
, , N
respectively RB N
. . N

The DT N
serum NN 1_o
LDL NNP 1_o
level NN 1_o
decreased VBN 1_o
by IN N
6.2 CD N
% NN N
and CC N
11.8 CD N
% NN N
, , N
respectively RB N
. . N

Between VB N
the DT N
third JJ N
and CC N
sixth JJ N
cycle NN N
, , N
no DT 1_o
further JJ 1_o
significant JJ 1_o
changes NNS 1_o
were VBD N
observed VBN N
, , N
nor CC N
did VBD N
these DT N
changes NNS N
differ VBP N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
both DT N
OC NNP 1_i
preparations NNS N
exerted VBD N
small JJ 1_o
and CC 1_o
probably RB 1_o
favorable JJ 1_o
effects NNS 1_o
on IN 1_o
serum NN 1_o
lipoprotein NN 1_o
lipid JJ 1_o
levels NNS 1_o
. . 1_o

[ JJ N
Effect NNP N
of IN N
zero-balanced JJ 1_i
ultrafiltration NN 1_i
and CC 1_i
modified VBN 1_i
ultrafiltration NN 1_i
on IN N
pulmonary JJ N
function NN N
after IN 1_p
cardiac JJ 1_p
surgery NN 1_p
in IN 1_p
infants NNS 1_p
] NNP 1_p
. . N

OBJECTIVE NNP N
To TO N
determine VB N
the DT N
protective JJ N
effect NN N
of IN N
zero-balanced JJ 1_i
ultrafiltration NN 1_i
and CC 1_i
modified VBN 1_i
ultrafiltration NN 1_i
on IN N
infants NNS 1_p
' POS 1_p
pulmonary JJ 1_p
function NN 1_p
after IN 1_p
cardiac JJ 1_p
surgery NN 1_p
. . 1_p

METHODS NNP N
Sixty NNP 1_p
infants NNS 1_p
with IN 1_p
congenital JJ 1_p
heart NN 1_p
diseases NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD 1_i
groups NNS 1_i
: : 1_i
a DT 1_i
zero-balanced JJ 1_i
ultrafiltration NN 1_i
group NN 1_i
( ( 1_i
Z NNP 1_i
group NN 1_i
) ) 1_i
, , 1_i
a DT 1_i
modified JJ 1_i
ultrafiltration NN 1_i
group NN 1_i
( ( 1_i
M NNP 1_i
group NN 1_i
) ) 1_i
and CC 1_i
a DT 1_i
zero-balanced JJ 1_i
ultrafiltration NN 1_i
with IN 1_i
modified JJ 1_i
ultrafiltration NN 1_i
group NN 1_i
( ( 1_i
Z+M NNP 1_i
group NN 1_i
) ) 1_i
. . N

Oxygenation NNP 1_o
index NN 1_o
( ( 1_o
OI NNP 1_o
) ) 1_o
, , 1_o
difference NN 1_o
of IN 1_o
alveoli-arterial JJ 1_o
oxygen NN 1_o
pressure NN 1_o
( ( 1_o
P NNP 1_o
( ( 1_o
A-α NNP 1_o
) ) 1_o
O2 NNP 1_o
) ) 1_o
, , 1_o
static JJ 1_o
lung NN 1_o
compliance NN 1_o
( ( 1_o
Cstat NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
airway RB 1_o
resistance NN 1_o
( ( 1_o
Raw NNP 1_o
) ) 1_o
were VBD 1_o
measured VBN 1_o
before IN 1_i
caridopulmonary JJ 1_i
bypass NN 1_i
( ( 1_i
CPB NNP 1_i
, , 1_i
T1 NNP 1_i
) ) 1_i
, , 1_i
20 CD 1_i
minutes NNS 1_i
after IN 1_i
the DT 1_i
CPB NNP 1_i
( ( 1_i
T2 NNP 1_i
) ) 1_i
, , 1_i
2 CD 1_i
h NN 1_i
after IN 1_i
the DT 1_i
operation NN 1_i
( ( 1_i
T3 NNP 1_i
) ) 1_i
, , 1_i
6 CD 1_i
h NN 1_i
after IN 1_i
the DT 1_i
operation NN 1_i
( ( 1_i
T4 NNP 1_i
) ) 1_i
and CC 1_i
12 CD 1_i
h NN 1_i
after IN 1_i
the DT 1_i
operation NN 1_i
( ( 1_i
T5 NNP 1_i
) ) 1_i
. . N

The DT 1_o
time NN 1_o
of IN 1_o
mechanical JJ 1_o
ventilation NN 1_o
was VBD N
also RB N
monitored VBN N
. . N

RESULTS NNP N
After IN N
the DT 1_o
CPB NNP 1_o
, , 1_o
OI NNP 1_o
and CC 1_o
Cstat NNP 1_o
in IN N
all DT N
groups NNS N
decreased VBD N
significantly RB N
, , N
while IN 1_o
Raw NNP 1_o
and CC 1_o
P NNP 1_o
( ( 1_o
A-α NNP 1_o
) ) 1_o
O2 NNP 1_o
increased VBD N
significantly RB N
. . N

At IN 1_o
T3 NNP 1_o
, , 1_o
T4 NNP 1_o
and CC 1_o
T5 NNP 1_o
, , 1_o
OI NNP 1_o
and CC 1_o
Cstat NNP 1_o
in IN N
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( 1_o
P NNP 1_o
< NNP 1_o
0.05 CD 1_o
) ) 1_o
, , 1_o
Raw NNP 1_o
and CC 1_o
P NNP 1_o
( ( 1_o
A-α NNP 1_o
) ) 1_o
O2 NNP 1_o
in IN N
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT 1_o
ventilation NN 1_o
time NN 1_o
in IN N
the DT N
Z+M NNP N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP 1_i
Zero-balanced JJ 1_i
ultrafiltration NN 1_i
and CC 1_i
modified JJ 1_i
ultrafiltration NN 1_i
can MD N
effectively RB N
promote VB N
the DT N
pulmonary JJ N
function NN N
after IN N
cardiac JJ N
surgery NN N
in IN N
infants NNS N
. . N

Sex NN 1_o
risk NN 1_o
behavior NN 1_o
among IN N
adolescent JJ 1_p
and CC 1_p
young JJ 1_p
adult NN 1_p
children NNS 1_p
of IN 1_p
opiate JJ 1_p
addicts NNS 1_p
: : 1_p
outcomes NNS N
from IN N
the DT N
focus NN N
on IN N
families NNS N
prevention VBP N
trial NN N
and CC N
an DT N
examination NN N
of IN N
childhood NN N
and CC N
concurrent JJ N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
. . N

This DT N
study NN N
reports VBZ N
on IN N
rates NNS 1_o
and CC 1_o
predictors NNS 1_o
of IN 1_o
sex NN 1_o
risk NN 1_o
behavior NN 1_o
among IN N
a DT N
sample NN N
of IN N
adolescent NN 1_p
and CC 1_p
young JJ 1_p
adult NN 1_p
children NNS 1_p
of IN 1_p
parents NNS 1_p
enrolled VBN 1_p
in IN 1_p
methadone NN 1_i
treatment NN 1_p
for IN 1_p
opiate JJ 1_p
addiction NN 1_p
. . 1_p

Data NNS 1_p
are VBP 1_p
from IN 1_p
151 CD 1_p
participants NNS 1_p
( ( 1_p
80 CD 1_p
males NNS 1_p
, , 1_p
71 CD 1_p
females NNS 1_p
) ) 1_p
in IN 1_p
the DT 1_p
Focus NNP 1_p
on IN 1_p
Families NNP 1_p
( ( 1_p
FOF NNP 1_p
) ) 1_p
project NN 1_p
, , 1_p
a DT 1_p
randomized JJ 1_p
trial NN 1_p
of IN 1_p
a DT 1_p
family NN 1_i
intervention NN 1_i
and CC 1_p
a DT 1_p
study NN 1_p
of IN 1_p
the DT 1_p
development NN 1_p
of IN 1_p
at-risk JJ 1_p
children NNS 1_p
. . 1_p

The DT 1_p
study NN 1_p
participants NNS 1_p
are VBP 1_p
children NNS 1_p
of IN 1_p
parents NNS 1_p
enrolled VBN 1_p
in IN 1_p
methadone NN 1_i
treatment NN 1_i
between IN 1_p
1990 CD 1_p
and CC 1_p
1993 CD 1_p
. . 1_p

Participants NNS 1_p
were VBD 1_p
interviewed VBN 1_p
in IN 1_p
2005 CD 1_p
when WRB 1_p
they PRP 1_p
ranged VBD 1_p
in IN 1_p
age NN 1_p
from IN 1_p
15 CD 1_p
to TO 1_p
29 CD 1_p
years NNS 1_p
. . 1_p

In IN N
the DT N
year NN N
prior RB N
to TO N
the DT N
follow-up NN N
, , N
79 CD N
% NN N
of IN N
the DT N
males NNS N
and CC N
83 CD N
% NN N
of IN N
females NNS N
were VBD N
sexually RB N
active JJ N
, , N
26 CD N
% NN N
of IN N
males NNS N
and CC N
10 CD N
% NN N
of IN N
females NNS N
had VBD N
more JJR N
than IN N
one CD N
partner NN N
in IN N
the DT N
prior JJ N
year NN N
, , N
and CC N
34 CD N
% NN N
of IN N
males NNS N
and CC N
24 CD N
% NN N
of IN N
females NNS N
reported VBN N
having VBG N
sex NN N
outside IN N
of IN N
a DT N
committed JJ N
relationship NN N
. . N

Twenty-four CD N
percent NN N
of IN N
males NNS N
and CC N
17 CD N
% NN N
of IN N
females NNS N
met VBD N
criteria NNS N
for IN N
high-risk JJ 1_o
sexual JJ 1_o
behavior NN 1_o
, , N
reporting VBG N
casual JJ N
or CC N
multiple JJ N
partners NNS N
in IN N
the DT N
prior JJ N
year NN N
and CC N
inconsistent NN N
condom NN N
use NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN 1_i
and CC N
control NN 1_i
conditions NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
any DT N
measure NN N
of IN N
sex NN 1_o
risk NN 1_o
behavior NN 1_o
examined VBN N
. . N

None NN N
of IN N
the DT N
measures NNS N
of IN N
parent NN N
behavior NN N
and CC N
family NN N
processes NNS N
derived VBN N
from IN N
data NNS N
at IN N
baseline NN N
of IN N
the DT N
FOF NNP N
study NN N
predicted VBD N
whether IN N
participants NNS N
engaged VBN N
in IN N
high-risk JJ 1_o
sex NN 1_o
. . 1_o

Among IN N
measures NNS N
derived VBN N
from IN N
data NNS N
collected VBN N
at IN N
long-term JJ N
follow-up NN N
, , N
however RB N
, , N
having VBG N
ever RB N
met VBN N
criteria NNS N
for IN N
substance NN N
abuse NN N
or CC N
dependence NN N
predicted VBN N
greater JJR N
likelihood NN N
of IN N
high-risk JJ 1_o
sexual JJ 1_o
behavior NN 1_o
, , N
and CC N
being VBG N
married VBD N
or CC N
being VBG N
in IN N
a DT N
romantic JJ N
relationship NN N
was VBD N
associated VBN N
with IN N
lower JJR N
likelihood NN N
of IN N
high-risk JJ 1_o
sexual JJ 1_o
behavior NN 1_o
. . 1_o

The DT N
findings NNS N
point NN N
to TO N
the DT N
important JJ N
role NN N
of IN N
committed JJ N
relationships NNS N
in IN N
regulating VBG N
sex NN 1_o
risk NN 1_o
behavior NN 1_o
among IN N
this DT N
population NN N
, , N
as RB N
well RB N
as IN N
heightened VBN N
levels NNS N
of IN N
sex NN 1_o
risk NN 1_o
behavior NN 1_o
associated VBN N
with IN N
substance NN N
abuse NN N
or CC N
dependence NN N
. . N

Lack NN N
of IN N
benefit NN N
of IN N
an DT N
active JJ 1_i
pectoral JJ 1_i
pulse NN 1_i
generator NN 1_i
on IN N
atrial JJ N
defibrillation NN N
thresholds NNS N
. . N

INTRODUCTION NNP N
Atrial NNP N
defibrillation NN N
can MD N
be VB N
achieved VBN N
with IN N
standard JJ N
implantable JJ N
cardioverter NN N
defibrillator NN N
leads VBZ N
, , N
which WDT N
has VBZ N
led VBN N
to TO N
the DT N
development NN N
of IN N
combined JJ N
atrial JJ N
and CC N
ventricular JJ N
devices NNS N
. . N

For IN N
ventricular JJ N
defibrillation NN N
, , N
use NN N
of IN N
an DT N
active JJ 1_i
pectoral JJ 1_i
electrode NN 1_i
( ( 1_i
active JJ 1_i
can MD 1_i
) ) 1_i
in IN N
the DT N
shocking VBG N
pathway RB N
markedly RB N
reduces VBZ N
defibrillation NN N
thresholds NNS N
( ( N
DFTs NNP N
) ) N
. . N

However RB N
, , N
the DT N
effect NN N
of IN N
an DT N
active JJ 1_i
pectoral NN 1_i
can MD 1_i
on IN N
atrial JJ N
defibrillation NN N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
paired VBD N
comparison NN 1_i
of IN 1_i
two CD 1_i
shock NN 1_i
configurations NNS 1_i
on IN N
atrial JJ 1_p
DFTs NNP 1_p
in IN 1_p
33 CD 1_p
patients NNS 1_p
. . 1_p

The DT N
lead NN N
system NN N
evaluated VBD N
was VBD N
a DT N
dual-coil JJ 1_i
transvenous JJ 1_i
defibrillation NN 1_i
lead NN 1_i
with IN 1_i
a DT 1_i
left JJ 1_i
pectoral JJ 1_i
pulse NN 1_i
generator NN 1_i
emulator NN 1_i
. . N

Shocks NNS N
were VBD N
delivered VBN N
either RB N
between IN N
the DT N
right JJ 1_i
ventricular NN 1_i
coil NN 1_i
and CC 1_i
proximal JJ 1_i
atrial JJ 1_i
coil NN 1_i
( ( 1_i
lead JJ 1_i
) ) 1_i
or CC 1_i
between IN 1_i
the DT 1_i
right JJ 1_i
ventricular NN 1_i
coil NN 1_i
and CC 1_i
an DT 1_i
active JJ 1_i
can MD 1_i
in IN 1_i
common JJ 1_i
with IN 1_i
the DT 1_i
atrial JJ 1_i
coil NN 1_i
( ( N
active JJ N
can MD N
) ) N
. . N

Delivered VBN 1_o
energy NN 1_o
at IN 1_o
DFT NNP 1_o
was VBD N
4.2 CD N
+/- JJ N
4.1 CD N
J NNP N
in IN N
the DT N
lead NN N
configuration NN N
and CC N
5.0 CD N
+/- JJ N
3.7 CD N
J NNP N
in IN N
the DT N
active JJ 1_i
can MD 1_i
configuration NN N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Peak NNP 1_o
current JJ 1_o
was VBD N
32 CD N
% NN N
higher JJR N
with IN N
an DT N
active JJ 1_i
can MD 1_i
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas JJ N
shock NN 1_o
impedance NN 1_o
was VBD N
18 CD N
% NN N
lower JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Moreover RB N
, , N
a DT N
low JJ 1_o
threshold NN 1_o
( ( N
< CD N
or CC N
= VB N
3 CD N
J NNP N
) ) N
was VBD N
observed VBN N
in IN N
61 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
lead JJ N
configuration NN N
but CC N
in IN N
only RB N
36 CD N
% NN N
in IN N
the DT N
active JJ 1_i
can MD 1_i
configuration NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT 1_o
clinical JJ 1_o
predictors NNS 1_o
of IN N
the DT N
atrial JJ N
DFT NNP N
. . N

CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
low JJ N
atrial JJ N
DFTs NN N
can MD N
be VB N
achieved VBN N
using VBG N
a DT N
transvenous JJ N
ventricular JJ N
defibrillation NN N
lead NN N
. . N

Because IN N
no DT N
benefit NN N
was VBD N
observed VBN N
with IN N
the DT N
use NN N
of IN N
an DT N
active JJ 1_i
pectoral JJ 1_i
electrode NN 1_i
for IN N
atrial JJ N
defibrillation NN N
, , N
programmable JJ N
shock NN N
vectors NNS N
may MD N
be VB N
useful JJ N
for IN N
dual-chamber JJ N
implantable JJ N
cardioverter NN N
defibrillators NNS N
. . N

Effects NNS N
of IN N
losartan NN 1_i
and CC 1_i
enalapril NN 1_i
on IN N
high-sensitivity NN N
C-reactive JJ N
protein NN N
and CC N
total JJ N
antioxidant NN N
in IN N
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
with IN 1_p
Renin-Angiotensin NNP 1_p
system NN 1_p
polymorphisms NN 1_p
. . 1_p

BACKGROUND NNP N
As IN N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
activity NN N
may MD N
affect VB N
the DT N
severity NN N
of IN N
oxidative JJ N
stress NN N
and CC N
inflammatory NN N
markers NNS N
, , N
we PRP N
assessed VBD N
the DT N
effects NNS N
of IN N
enalapril NN 1_i
( ( 1_i
E NNP 1_i
) ) 1_i
and/or NN 1_i
losartan NN 1_i
( ( N
L NNP N
) ) N
on IN N
these DT N
markers NNS N
in IN N
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
with IN 1_p
RAS NNP 1_p
polymorphisms NNS 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
After IN N
determination NN N
by IN N
PCR NNP N
of IN N
RAS NNP N
genotypes NNS N
, , N
consisting VBG N
of IN N
the DT N
angiotensin-converting JJ N
enzymes NNS N
( ( N
ACE NNP N
I/D NNP N
) ) N
, , N
angiotensinogens VBZ N
( ( N
AGT NNP N
M235T NNP N
) ) N
and CC N
angiotensin $ N
II NNP N
type NN N
1 CD N
receptors NNS N
( ( N
ATR1 NNP N
A1166C NNP N
) ) N
, , N
76 CD 1_p
recipients NNS 1_p
were VBD 1_p
recruited VBN 1_p
randomly RB 1_p
and CC N
assigned VBD N
4 CD N
groups NNS N
. . N

The DT N
first JJ N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
and CC N
second JJ N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
groups NNS N
were VBD N
treated VBN N
with IN N
E NNP 1_i
( ( N
E NNP N
( ( N
+ NNP N
) ) N
: : N
10 CD N
mg/d NN N
) ) N
and CC N
L NNP 1_i
( ( N
L NNP N
( ( N
+ NNP N
) ) N
: : N
50 CD N
mg/d NN N
) ) N
alone RB N
, , N
respectively RB N
. . N

The DT N
third JJ N
positive JJ N
control NN N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
received VBD N
E NNP 1_i
+ NNP 1_i
L NNP 1_i
( ( N
E NNP N
( ( N
+ NNP N
) ) N
L NNP N
( ( N
+ NNP N
) ) N
: : N
10 CD N
mg/d NN N
+ VBD N
50 CD N
mg/d NN N
) ) N
and CC N
the DT N
fourth JJ N
negative JJ N
control NN N
group NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
received VBD N
no DT N
medication NN N
( ( N
E NNP N
( ( N
- : N
) ) N
: : N
L NNP N
( ( N
- : N
) ) N
) ) N
. . N

High-sensitivity JJ N
C-reactive JJ N
protein NN N
( ( N
hs-CRP JJ N
) ) N
and CC N
total JJ N
antioxidant NN N
( ( N
TA NNP N
) ) N
inflammatory NN N
and CC N
antioxidative JJ N
markers NNS N
were VBD N
measured VBN N
after IN N
2 CD N
months NNS N
. . N

After IN N
a DT N
2-week JJ N
washout NN N
period NN N
, , N
the DT N
E NNP N
( ( N
+ NNP N
) ) N
group NN N
was VBD N
changed VBN N
to TO N
L NNP N
( ( N
+ NNP N
) ) N
and CC N
vice NN N
versa NN N
in IN N
a DT N
crossover NN N
design NN N
. . N

They PRP N
were VBD N
followed VBN N
for IN N
another DT N
8 CD N
weeks NNS N
before IN N
retesting VBG N
hs-CRP NN N
and CC N
TA NNP N
. . N

A NNP N
value NN N
of IN N
P NNP N
< NNP N
or CC N
= NNP N
.05 NNP N
was VBD N
considered VBN N
significant JJ N
. . N

RESULTS NNP N
After IN N
2 CD N
and CC N
4 CD N
months NNS N
of IN N
treatment NN N
with IN N
the DT N
drug NN N
regimen NNS N
, , N
hs-CRP JJ 1_o
and CC 1_o
TA NNP 1_o
levels NNS 1_o
were VBD N
significantly RB N
decreased VBN N
and CC N
consequently RB N
increased VBN N
among IN N
the DT N
E NNP 1_i
( ( 1_i
+ NNP 1_i
) ) 1_i
L NNP 1_i
( ( 1_i
+ NNP 1_i
) ) 1_i
, , 1_i
L NNP 1_i
( ( 1_i
+ NNP 1_i
) ) 1_i
and CC N
E NNP 1_i
( ( 1_i
+ NNP 1_i
) ) 1_i
groups NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

On IN N
analyzing VBG N
the DT N
relationship NN N
between IN N
RAS NNP N
polymorphisms NNS N
and CC N
baseline VB N
hs-CRP NN N
or CC N
TA NNP N
levels NNS N
, , N
CC NNP N
genotype NN N
of IN N
ATR1 NNP N
showed VBD N
lower JJR N
hs-CRP NN 1_o
levels NNS 1_o
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
RAS NNP N
polymorphisms NN N
predicted VBD N
the DT N
antioxidant JJ 1_o
and CC 1_o
anti-inflammatory JJ 1_o
response NN 1_o
rates NNS 1_o
to TO 1_o
the DT 1_o
drugs NNS 1_o
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Although IN N
hs-CRP NN 1_o
was VBD N
lower JJR N
in IN N
the DT N
CC NNP N
genotype NN N
patients NNS N
of IN N
ATR1 NNP N
polymorphisms FW N
E NNP N
and/or NN N
L NNP N
reduced VBD N
hs-CRP JJ N
and CC N
increased JJ N
TA NNP N
regardless NN N
of IN N
the DT N
RAS NNP N
genotype NN N
. . N

Nicotinic JJ 1_i
acid NN 1_i
as IN N
therapy NN N
for IN N
dyslipidemia NN N
in IN N
non-insulin-dependent JJ 1_p
diabetes NNS 1_p
mellitus NN 1_p
. . 1_p

Recently RB N
, , N
nicotinic JJ 1_i
acid NN 1_i
has VBZ N
been VBN N
recommended VBN N
as IN N
a DT N
first-line JJ N
hypolipidemic JJ N
drug NN N
. . N

To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
nicotinic JJ N
acid NN N
in IN N
dyslipidemic JJ 1_p
patients NNS 1_p
with IN 1_p
non-insulin-dependent JJ 1_p
diabetes NNS 1_p
mellitus VBP 1_p
, , 1_p
13 CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
in IN 1_p
a DT 1_p
randomized JJ 1_p
crossover NN 1_p
trial NN 1_p
. . 1_p

Patients NNS N
received VBD N
either RB N
nicotinic JJ 1_i
acid NN 1_i
( ( N
1.5 CD N
g NN N
three CD N
times NNS N
daily RB N
) ) N
or CC N
no DT 1_i
therapy NN 1_i
( ( N
control JJ N
period NN N
) ) N
for IN N
8 CD N
weeks NNS N
each DT N
. . N

Compared VBN N
with IN N
the DT N
control NN N
period NN N
, , N
nicotinic JJ 1_i
acid NN 1_i
therapy NN N
reduced VBD N
the DT N
plasma NN 1_o
total JJ 1_o
cholesterol NN 1_o
level NN 1_o
by IN N
24 CD N
% NN N
, , N
plasma JJ 1_o
triglyceride IN 1_o
level NN 1_o
by IN N
45 CD N
% NN N
, , N
very-low-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
level NN 1_o
by IN N
58 CD N
% NN N
, , N
and CC N
low-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
level NN 1_o
by IN N
15 CD N
% NN N
, , N
and CC N
it PRP N
increased VBD N
the DT N
high-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
level NN 1_o
by IN N
34 CD N
% NN N
. . N

However RB N
, , N
nicotinic JJ 1_i
acid NN 1_i
therapy NN N
resulted VBD N
in IN N
the DT N
deterioration NN 1_o
of IN 1_o
glycemic JJ 1_o
control NN 1_o
, , N
as IN N
evidenced VBN N
by IN N
a DT N
16 CD N
% NN N
increase NN N
in IN N
mean JJ 1_o
plasma NN 1_o
glucose JJ 1_o
concentrations NNS 1_o
, , N
a DT N
21 CD N
% NN N
increase NN N
in IN N
glycosylated JJ 1_o
hemoglobin NN 1_o
levels NNS 1_o
, , N
and CC N
the DT N
induction NN N
of IN N
marked JJ 1_o
glycosuria NN 1_o
in IN N
some DT N
patients NNS N
. . N

Furthermore NNP N
, , N
a DT N
consistent JJ N
increase NN N
in IN N
plasma JJ 1_o
uric JJ 1_o
acid NN 1_o
levels NNS 1_o
was VBD N
observed VBN N
. . N

Therefore RB N
, , N
despite IN N
improvement NN N
in IN N
lipid JJ 1_o
and CC 1_o
lipoprotein JJ 1_o
concentrations NNS 1_o
, , N
because IN N
of IN N
worsening VBG N
hyperglycemia NN 1_o
and CC N
the DT N
development NN N
of IN N
hyperuricemia NN 1_o
, , N
nicotinic JJ N
acid NN N
must MD N
be VB N
used VBN N
with IN N
caution NN N
in IN N
patients NNS 1_p
with IN N
non-insulin-dependent JJ N
diabetes NNS N
mellitus VBP N
with IN N
dyslipidemia NN N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
drug NN N
not RB N
be VB N
used VBN N
as IN N
a DT N
first-line JJ N
hypolipidemic JJ N
drug NN N
in IN N
patients NNS 1_p
with IN 1_p
non-insulin-dependent JJ 1_p
diabetes NNS 1_p
mellitus NN 1_p
. . 1_p

A DT N
parent-mediated JJ 1_i
intervention NN 1_i
that WDT N
targets VBZ N
responsive JJ N
parental JJ N
behaviors NNS N
increases VBZ N
attachment JJ 1_o
behaviors NNS 1_o
in IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
: : 1_p
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

The DT N
current JJ N
study NN N
is VBZ N
a DT N
randomized JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
Focused JJ 1_i
Playtime NNP 1_i
Intervention NNP 1_i
( ( 1_i
FPI NNP 1_i
) ) 1_i
in IN N
a DT N
sample NN N
of IN N
70 CD 1_p
children NNS 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorder NNP 1_p
. . 1_p

This DT N
parent-mediated JJ N
intervention NN N
has VBZ N
previously RB N
been VBN N
shown VBN N
to TO N
significantly RB N
increase VB N
responsive JJ N
parental JJ N
communication NN N
( ( N
Siller NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
43:540-555 CD N
, , N
2013a CD N
) ) N
. . N

The DT N
current JJ N
analyses NNS N
focus VBP N
on IN N
children NNS N
's POS N
attachment NN 1_o
related VBN 1_o
outcomes NNS 1_o
. . 1_o

Results NNS N
revealed VBD N
that IN N
children NNS N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
FPI NNP 1_i
showed VBD N
bigger JJR N
increases NNS N
in IN N
attachment-related JJ 1_o
behaviors NNS 1_o
, , N
compared VBN N
to TO N
children NNS N
assigned VBN N
to TO N
the DT N
control NN N
condition NN N
. . N

Significant JJ N
treatment NN N
effects NNS N
of IN N
FPI NNP 1_i
were VBD N
found VBN N
for IN N
both DT N
an DT N
observational JJ N
measure NN N
of IN N
attachment-related JJ 1_o
behaviors NNS 1_o
elicited VBD N
during IN N
a DT N
brief JJ N
separation-reunion JJ N
episode NN N
and CC N
a DT N
questionnaire JJ N
measure NN N
evaluating VBG N
parental JJ 1_o
perceptions NNS 1_o
of IN 1_o
child JJ 1_o
attachment NN 1_o
. . 1_o

The DT N
theoretical JJ N
and CC N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

Safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
chimpanzee JJ 1_i
adenovirus-vectored JJ 1_i
Ebola NNP 1_i
vaccine NN 1_i
in IN N
healthy JJ 1_p
adults NNS 1_p
: : 1_p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
dose-finding JJ N
, , N
phase VB N
1/2a CD N
study NN N
. . N

BACKGROUND NNP N
The DT N
ongoing JJ N
Ebola NNP N
outbreak NN N
led VBD N
to TO N
accelerated VBN N
efforts NNS N
to TO N
test VB N
vaccine NN N
candidates NNS N
. . N

On IN N
the DT N
basis NN N
of IN N
a DT N
request NN N
by IN N
WHO NNP N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
monovalent NN 1_i
, , 1_i
recombinant NN 1_i
, , 1_i
chimpanzee JJ 1_i
adenovirus JJ 1_i
type-3 JJ 1_i
vector-based JJ 1_i
Ebola NNP 1_i
Zaire NNP 1_i
vaccine NN 1_i
( ( 1_i
ChAd3-EBO-Z NNP 1_i
) ) 1_i
. . 1_i

METHODS NNP N
We PRP N
did VBD N
this DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
, , N
dose-finding JJ N
, , N
phase VB N
1/2a CD N
trial NN N
at IN N
the DT N
Centre NNP 1_p
Hospitalier NNP 1_p
Universitaire NNP 1_p
Vaudois NNP 1_p
, , 1_p
Lausanne NNP 1_p
, , 1_p
Switzerland NNP 1_p
. . 1_p

Participants NNS 1_p
( ( 1_p
aged VBN 1_p
18-65 CD 1_p
years NNS 1_p
) ) 1_p
were VBD 1_p
randomly RB 1_p
assigned VBN 1_p
( ( N
2:2:1 CD N
) ) N
, , N
via IN N
two CD N
computer-generated JJ N
randomisation NN N
lists NNS N
for IN N
individuals NNS 1_p
potentially RB 1_p
deployed VBN 1_p
in IN 1_p
endemic JJ 1_p
areas NNS 1_p
and CC 1_p
those DT 1_p
not RB 1_p
deployed VBN 1_p
, , N
to TO N
receive VB N
a DT N
single JJ N
intramuscular NN N
dose NN N
of IN N
high-dose JJ 1_i
vaccine NN 1_i
( ( N
5 CD N
× RB N
10 CD N
( ( N
10 CD N
) ) N
viral JJ N
particles NNS 1_i
) ) 1_i
, , 1_i
low-dose JJ 1_i
vaccine NN 1_i
( ( N
2·5 CD N
× RB N
10 CD N
( ( N
10 CD N
) ) N
viral JJ N
particles NNS 1_i
) ) 1_i
, , N
or CC N
placebo NN N
. . N

Deployed VBN N
participants NNS N
were VBD N
allocated VBN N
to TO N
only RB N
the DT N
vaccine NN N
groups NNS N
. . N

Group NNP N
allocation NN N
was VBD N
concealed VBN N
from IN N
non-deployed JJ N
participants NNS N
, , N
investigators NNS N
, , N
and CC N
outcome JJ N
assessors NNS N
. . N

The DT N
safety NN N
evaluation NN N
was VBD N
not RB N
masked VBN N
for IN N
potentially RB N
deployed JJ N
participants NNS N
, , N
who WP N
were VBD N
therefore RB N
not RB N
included VBN N
in IN N
the DT N
safety NN N
analysis NN N
for IN N
comparison NN N
between IN N
the DT N
vaccine NN N
doses NNS N
and CC N
placebo NN N
, , N
but CC N
were VBD N
pooled VBN N
with IN N
the DT N
non-deployed JJ N
group NN N
to TO N
compare VB N
immunogenicity NN N
. . N

The DT N
main JJ N
objectives NNS N
were VBD N
safety NN N
and CC N
immunogenicity NN N
of IN N
ChAd3-EBO-Z NNP N
. . N

We PRP N
did VBD N
analysis NN N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT02289027 NNP 1_p
. . 1_p

FINDINGS NNP 1_p
Between NNP 1_p
Oct NNP 1_p
24 CD 1_p
, , 1_p
2014 CD 1_p
, , 1_p
and CC 1_p
June NNP 1_p
22 CD 1_p
, , 1_p
2015 CD 1_p
, , 1_p
we PRP 1_p
randomly VBP 1_p
assigned VBN 1_p
120 CD 1_p
participants NNS 1_p
, , 1_p
of IN 1_p
whom WP 1_p
18 CD 1_p
( ( 1_p
15 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
potentially RB 1_p
deployed VBN 1_p
and CC 1_p
102 CD 1_p
( ( 1_p
85 CD 1_p
% NN 1_p
) ) 1_p
were VBD 1_p
non-deployed JJ 1_p
, , 1_p
to TO 1_p
receive VB 1_p
high-dose JJ 1_p
vaccine NN 1_p
( ( 1_p
n=49 JJ 1_p
) ) 1_p
, , 1_p
low-dose JJ 1_p
vaccine NN 1_p
( ( 1_p
n=51 JJ 1_p
) ) 1_p
, , 1_p
or CC 1_p
placebo NN 1_p
( ( N
n=20 JJ N
) ) N
. . N

Participants NNS N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

No DT N
vaccine-related JJ 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS N
were VBD N
reported VBN N
. . N

We PRP 1_o
recorded VBD 1_o
local JJ 1_o
adverse JJ 1_o
events NNS N
in IN N
30 CD N
( ( N
75 CD N
% NN N
) ) N
of IN N
40 CD N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
33 CD N
( ( N
79 CD N
% NN N
) ) N
of IN N
42 CD N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
five CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
20 CD N
participants NNS N
in IN N
the DT N
placebo NN 1_o
group NN 1_o
. . 1_o

Fatigue NNP 1_o
or CC N
malaise NN N
was VBD N
the DT N
most RBS N
common JJ N
systemic JJ N
adverse JJ N
event NN N
, , N
reported VBD N
in IN N
25 CD N
( ( N
62 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
25 CD N
( ( N
60 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
five CD N
( ( N
25 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
placebo NN N
group NN N
, , N
followed VBN N
by IN N
headache NN N
, , N
reported VBD N
in IN N
23 CD N
( ( N
57 CD N
% NN N
) ) N
, , N
25 CD N
( ( N
60 CD N
% NN N
) ) N
, , N
and CC N
three CD N
( ( N
15 CD N
% NN N
) ) N
participants NNS N
, , N
respectively RB 1_o
. . N

Fever NNP N
occurred VBD N
24 CD N
h NN N
after IN N
injection NN N
in IN N
12 CD N
( ( N
30 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
and CC N
11 CD N
( ( N
26 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
versus IN N
one CD N
( ( N
5 CD N
% NN N
) ) N
participant NN N
in IN N
the DT N
placebo NN 1_o
group NN 1_o
. . 1_o

Geometric NNP 1_o
mean JJ 1_o
concentrations NNS 1_o
of IN 1_o
IgG NNP 1_o
antibodies NNS 1_o
against IN 1_o
Ebola NNP 1_o
glycoprotein NN 1_o
peaked VBD N
on IN N
day NN N
28 CD N
at IN N
51 CD N
μg/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
41·1-63·3 CD N
) ) N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
44·9 CD N
μg/mL NN N
( ( N
25·8-56·3 JJ N
) ) N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
5·2 CD N
μg/mL NN N
( ( N
3·5-7·6 JJ N
) ) N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
respective JJ N
response NN N
rates NNS N
of IN N
96 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
85·7-99·5 CD N
) ) N
, , N
96 CD N
% NN N
( ( 1_o
86·5-99·5 JJ 1_o
) ) 1_o
, , 1_o
and CC 1_o
5 CD 1_o
% NN 1_o
( ( 1_o
0·1-24·9 JJ 1_o
) ) 1_o
. . 1_o

Geometric JJ 1_o
mean JJ N
concentrations NNS N
decreased VBN N
by IN N
day NN N
180 CD N
to TO N
25·5 CD N
μg/mL NNS N
( ( N
95 CD N
% NN N
CI NNP N
20·6-31·5 CD N
) ) N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
22·1 CD N
μg/mL NN N
( ( N
19·3-28·6 JJ N
) ) N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
3·2 CD N
μg/mL NN N
( ( N
2·4-4·9 JJ N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

28 CD N
( ( N
57 CD N
% NN N
) ) N
participants NNS N
given VBN N
high-dose JJ N
vaccine NN N
and CC N
31 CD N
( ( N
61 CD N
% NN N
) ) N
participants NNS 1_o
given VBN 1_o
low-dose JJ 1_o
vaccine NN 1_o
developed VBD 1_o
glycoprotein-specific JJ 1_o
CD4 NNP N
cell NN N
responses NNS N
, , N
and CC N
33 CD N
( ( N
67 CD N
% NN N
) ) N
and CC N
35 CD N
( ( N
69 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
developed VBD N
CD8 NNP N
responses NNS 1_o
. . N

INTERPRETATION NNP 1_o
ChAd3-EBO-Z NNP N
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
, , N
although IN N
mild NN N
to TO N
moderate VB N
systemic JJ N
adverse JJ N
events NNS N
were VBD N
common JJ N
. . N

A DT N
single JJ N
dose NN N
was VBD N
immunogenic JJ N
in IN N
almost RB N
all DT N
vaccine NN N
recipients NNS N
. . N

Antibody NN N
responses NNS N
were VBD N
still RB N
significantly RB N
present JJ N
at IN N
6 CD N
months NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
doses NNS N
for IN N
safety NN N
and CC N
immunogenicity NN N
outcomes RB N
. . N

This DT N
acceptable JJ N
safety NN N
profile NN N
provides VBZ N
a DT N
reliable JJ N
basis NN N
to TO N
proceed VB N
with IN N
phase NN N
2 CD N
and CC N
phase VB N
3 CD N
efficacy NN N
trials NNS N
in IN N
Africa NNP N
. . N

FUNDING NN N
Swiss JJ N
State NNP N
Secretariat NNP N
for IN N
Education NNP N
, , N
Research NNP N
and CC N
Innovation NNP N
( ( N
SERI NNP N
) ) N
, , N
through IN N
the DT N
EU NNP N
Horizon NNP N
2020 CD N
Research NNP N
and CC N
Innovation NNP N
Programme NNP N
. . N

